FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Tie, M
   Qin, M
   Song, QJ
   Qi, Y
AF Tie Ming
   Qin Ming
   Song Qijiao
   Qi Ye
TI Why does the behavior of local government leaders in low-carbon city
   pilots influence policy innovation?
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Policy innovation; Low-carbon city pilots; Leaders' behavior; Local
   government
ID CHINA; EXPERIMENTATION; HIERARCHY; REFORM; PATH
AB Through its low-carbon city pilot program, China aims to combine national targets with local initiatives to advance low-carbon transformation and encourage policy innovations. Based on survey data collected from the low-carbon pilot cities, this paper aims to explore the impacts of the behavior of local government leadership on policy innovations from the three dimensions of leadership position, leadership participation, and leadership attention as well as the heterogeneous impacts of leaders' behavior on policy innovations at different levels of carbon emissions intensity. This paper used the Heckman selection model to empirically analyze the factors influencing policy innovations. The results show that under circumstances with weak incentives and weak constraints, the behaviors of local leaders in low-carbon pilot cities had a positive impact on policy innovations. Specifically, the local leader at the very top of the hierarchy responsible for the pilot leadership group had a significant impact on policy innovations. Departmental-level cadres who participated exchange seminars, which refer to conducting low-carbon tests, had positive impacts on policy innovations. Nevertheless, if the local government implemented a low-carbon related strategic plan, this also had a positive effect. With the increase in carbon emissions intensity, local leaders faced pressures to reduce carbon emissions, so that the effect of the leaders' behaviors in promoting policy innovation was greater as well.
C1 [Tie Ming; Qin Ming; Qi Ye] Tsinghua Univ, Sch Publ Policy & Management, Beijing 100084, Peoples R China.
   [Tie Ming] Beijing Informat Sci & Technol Univ, Sch Publ Adm & Commun, Beijing 100192, Peoples R China.
   [Song Qijiao; Qi Ye] Hong Kong Univ Sci & Technol, Div Publ Policy, Kowloon, Clear Water Bay, Hong Kong, Peoples R China.
   [Song Qijiao; Qi Ye] Hong Kong Univ Sci & Technol, Inst Publ Policy, Kowloon, Clear Water Bay, Hong Kong, Peoples R China.
RP Song, QJ (reprint author), Hong Kong Univ Sci & Technol, Div Publ Policy, Kowloon, Clear Water Bay, Hong Kong, Peoples R China.; Song, QJ (reprint author), Hong Kong Univ Sci & Technol, Inst Publ Policy, Kowloon, Clear Water Bay, Hong Kong, Peoples R China.
EM alliswellthu@gmail.com
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2018M631511]
FX This research is supported by China Postdoctoral Science Foundation
   (Grant No. 2018M631511). Comments and suggestions from two anonymous
   reviewers are also gratefully acknowledged. The authors also would like
   to express the deep appreciation to Dr. Tong WU from Chinese Academy of
   Sciences for his careful reading of earlier versions of this study.
CR [Anonymous], 2010, NOTICE NATL DEV REFO
   Bryman A, 1993, LEADERSHIP QUART, V4, P289, DOI DOI 10.1016/1048-9843(93)90036-S
   Chen X.L., 2009, PUBLIC ADM J, V3, P1
   Cheng JH, 2019, J CLEAN PROD, V231, P1158, DOI 10.1016/j.jclepro.2019.05.327
   Chetty R, 2009, AM ECON REV, V99, P1145, DOI 10.1257/aer.99.4.1145
   Cheung P.T.Y, 1998, PROVINCIAL STRATEGIE
   Chien SS, 2018, POLIT GEOGR, V62, P58, DOI 10.1016/j.polgeo.2017.10.001
   EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552
   Ekvall G., 1991, SCAND J MANAG, V7, P17, DOI DOI 10.1016/0956-5221(91)90024-U
   He SQ, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-23
   HECKMAN JJ, 1976, ANN ECON SOC MEAS, V5, P475
   Heilmann S, 2008, STUD COMP INT DEV, V43, P1, DOI 10.1007/s12116-007-9014-4
   Hooijberg R, 1996, HUM RELAT, V49, P917, DOI 10.1177/001872679604900703
   Hou J, 2016, ENERG POLICY, V88, P204, DOI 10.1016/j.enpol.2015.10.016
   HOUSE RJ, 1971, ADMIN SCI QUART, V16, P321, DOI 10.2307/2391905
   Huang H, 2014, CHIN PUBLIC ADM REV, V3, P26
   Jin HH, 2005, J PUBLIC ECON, V89, P1719, DOI 10.1016/j.jpubeco.2004.11.008
   Kingdon J. W., 1995, AGENDAS ALTERNATIVES
   Li S, 2016, J PUBLIC ADM, V5, P45
   Liu W, 2015, CHINESE PUBLIC ADM, V5, P113
   Lu XB, 2014, AM POLIT SCI REV, V108, P706, DOI 10.1017/S0003055414000252
   Mei C, 2015, J PUBLIC ADM, V3, P8
   Qi Y, 2014, ENVIRON POLICY GOV, V24, DOI 10.1002/eet.1640
   Rawski TG, 1995, CHINA QUART, P1150
   Rogers E, 1983, DIFFUSION INNOVATION
   Tsai WH, 2014, CHINA QUART, V218, P339, DOI 10.1017/S0305741014000630
   WALKER JL, 1969, AM POLIT SCI REV, V63, P880, DOI 10.2307/1954434
   Wang H, 2009, SHEHUIXUE YANJIU, V2, P61
   Wei N, 2001, CHIN PUBLIC ADM REV, V7, P22
   Wooldridge J. M., 2012, INTRO ECONOMETRICS M
   Xu L, 2018, RESOUR CONSERV RECY, V129, P219, DOI 10.1016/j.resconrec.2017.10.028
   Yang H, 2013, CHINESE PUBLIC ADM, V6, P12
   Yu JL, 2010, RESOUR CONSERV RECY, V54, P991, DOI 10.1016/j.resconrec.2010.02.006
   Yuan C, 2017, J PUBLIC MANAG, V1, P27
   Zhang Jun, 2007, EC RES J, V3, P4
   Zhao H, 2016, CHINA INT J, V14, P107
   Zhou BK, 2013, ORTHOGONAL POLARIZATION IN LASERS: PHYSICAL PHENOMENA AND ENGINEERING APPLICATIONS, P83
   Zhou L, 2008, LOCAL GOVT TRANSITIO
   Zhou XG, 2013, CHINA J, V70, P120, DOI 10.1086/671335
   Zhou Xueguang, 2008, SHEHUIXUE YANJIU, V6, P1
   Zhu Y, 2014, SOCIOL STUD CHILD YO, V3, P56
   Zhu Y, 2016, SOCIOL STUD CHILD YO, V5, P88
   Zhu YP, 2012, AUST J PUBL ADMIN, V71, P191, DOI 10.1111/j.1467-8500.2012.00768.x
   陈雪峰, 2008, [管理世界, Management World], P126
NR 44
TC 1
Z9 1
U1 17
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JAN
PY 2020
VL 152
AR UNSP 104483
DI 10.1016/j.resconrec.2019.104483
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JN4KI
UT WOS:000496867700021
OA Bronze
DA 2020-05-12
ER

PT J
AU Villalba, L
   Donalisio, RS
   Basualdo, NEC
   Noriega, RB
AF Villalba, Luciano
   Santiago Donalisio, Ruben
   Cisneros Basualdo, Nicolas Eloy
   Banda Noriega, Roxana
TI Household solid waste characterization in Tandil (Argentina):
   Socioeconomic, institutional, temporal and cultural aspects influencing
   waste quantity and composition
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Municipal solid waste; Household waste composition; Mass loss;
   Generation rate; Door-to-door characterization; Developing countries
ID GENERATION; MANAGEMENT; QUANTIFICATION; METHODOLOGY
AB Household waste generation and composition information is a fundamental input for waste management policy design. In developing countries (DC), however, budget constraints make some characterization methodologies inadequate. Following a methodology specially designed for DC, we performed the first door-to-door municipal solid waste (MSW) characterization in Tandil, a city of 130,000 inhabitants. We stratified households into three socioeconomic status (High, Medium and Low SES) using Geographical Information Systems and census data and performed three one-week sampling campaigns over a year. Results indicate that the generation rate of waste produced in households is 0,401 kg/person/day, less than 50% of the waste arriving at the local landfill. We analysed the normality of data associated with generation rates per category of waste (in kg/person/year) through Shapiro-Wilks tests and Q-Q plots, finding that most of them were normally distributed. Using these categories, we compared strata using ANOVA and Tukey tests, finding that strata waste compositions were similar. We registered a high mass loss during picking analysis -more than 3''/o in autumn and more than 5% in late spring-, which may be related to organic matter humidity evaporation. We compared daily average mass losses with daily average working-hour temperatures, finding a coefficient of determination r(2) of 0,7. Finally, we analyse the consumption of yerba mate -a typical South American habit- as an important source of organic waste and waste moisture content in Argentina.
C1 [Villalba, Luciano; Santiago Donalisio, Ruben; Cisneros Basualdo, Nicolas Eloy; Banda Noriega, Roxana] Natl Univ Ctr Buenos Aires Prov, Environm Studies & Res Ctr, RA-7000 Tandil, Argentina.
   [Villalba, Luciano] Univ Lausanne, Inst Earth Surface Dynam, CH-1015 Lausanne, Switzerland.
   [Santiago Donalisio, Ruben] Natl Council Sci & Technol Res CONICET, Buenos Aires, DF, Argentina.
   [Cisneros Basualdo, Nicolas Eloy; Banda Noriega, Roxana] Commiss Sci Res Prov Buenos Aires CIC, Buenos Aires, DF, Argentina.
RP Villalba, L (reprint author), Natl Univ Ctr Buenos Aires Prov, Environm Studies & Res Ctr, RA-7000 Tandil, Argentina.
EM luciano.villalba@fio.unicen.edu.ar
OI Villalba, Luciano/0000-0002-6937-3783
FU University Polices Office of the Argentinian Education Ministry
FX This study was part of the project "Analisis del Cooperativismo y la
   Economia Social y Solidaria en la Gestion de los RSU de Tandil", funded
   by the University Polices Office of the Argentinian Education Ministry.
   We thank students and researchers who worked in the characterization
   phase of this study, and the Environmental Office of Tandil that
   facilitated us the workplace.
CR ARS, 2012, ESTR NAC GEST INT RE
   ASTM, 2016, TEST METH DET COMP U, DOI [10.1520/D5231-92R16, DOI 10.1520/D5231-92R16]
   Baccini P, 2012, METABOLISM OF THE ANTHROPOSPHERE: ANALYSIS, EVALUATION, DESIGN, 2ND EDITION, P1
   Bernache-Perez G, 2001, WASTE MANAGE RES, V19, P413, DOI 10.1177/0734242X0101900506
   BRUNNER PH, 1986, WASTE MANAGE RES, V4, P147, DOI 10.1177/0734242X8600400116
   Buenrostro O., 2003, Revista Internacional de Contaminacion Ambiental, V19, P161
   Buenrostro O, 2001, RESOUR CONSERV RECY, V32, P29, DOI 10.1016/S0921-3449(00)00094-X
   Byamba B, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9060896
   Cantanhede A., 2005, P WCC 2005, P1
   CEAMSE, 2016, URB SOL WAST CHAR TR
   Christensen T., 2011, SOLID WASTE TECHNOLO
   Dangi MB, 2013, HABITAT INT, V40, P65, DOI 10.1016/j.habitatint.2013.02.005
   Dangi MB, 2011, J ENVIRON MANAGE, V92, P240, DOI 10.1016/j.jenvman.2010.09.005
   Dangi MB, 2008, WASTE MANAGE RES, V26, P493, DOI 10.1177/0734242X07085755
   Edjabou ME, 2017, WASTE MANAGE, V69, P13, DOI 10.1016/j.wasman.2017.08.036
   Edjabou ME, 2015, WASTE MANAGE, V36, P12, DOI 10.1016/j.wasman.2014.11.009
   Edwin A.M, 2012, CENSO NACL POBLACI B
   European Commission, 2004, METH AN SOL WAST SWA
   Flintoff F, 1980, MANAGEMENT SOLID WAS
   Franklin and Associates, 1999, EPA530 FRANKL ASS MU
   Giorgi N.F., 2015, SURVEY QUALITY URBAN
   Gomez G, 2008, WASTE MANAGE, V28, P2465, DOI 10.1016/j.wasman.2007.10.023
   Gullon B, 2018, IND CROP PROD, V113, P398, DOI 10.1016/j.indcrop.2018.01.064
   Inostroza L, 2013, J ENVIRON MANAGE, V115, P87, DOI 10.1016/j.jenvman.2012.11.007
   INYM, 2018, INF SECT YERB EST
   IRAM, 2003, ENV QUAL SOIL QUAL D
   Kaza S., 2018, URBAN DEV SERIES
   Khan D, 2016, WASTE MANAGE, V49, P15, DOI 10.1016/j.wasman.2016.01.019
   Lagerkvist A., 2011, SOLID WASTE TECHNOLO, P63
   Lebersorger S, 2011, WASTE MANAGE, V31, P1924, DOI 10.1016/j.wasman.2011.05.023
   Lisa D, 2008, WASTE MANAGE, V28, P1100, DOI 10.1016/j.wasman.2007.08.014
   Mbande C, 2003, J S AFR INST CIV ENG, V45, P2
   Miezah K, 2015, WASTE MANAGE, V46, P15, DOI 10.1016/j.wasman.2015.09.009
   Ojeda-Benitez S, 2008, RESOUR CONSERV RECY, V52, P992, DOI 10.1016/j.resconrec.2008.03.004
   ONU Medio Ambiente, 2018, LAC2195PA ONU MED AM
   Parizeau K, 2006, RESOUR CONSERV RECY, V49, P110, DOI 10.1016/j.resconrec.2006.03.006
   Ramos A, 2013, REV GEOGRAFICA DIGIT, P1
   Reinhart D.R., 1996, METHODOLOGY CONDUCTI
   ROJAS C., 2013, J GEOGRAPHIC INFORM, V5, P222, DOI DOI 10.4236/JGIS.2013.53021
   Sahimaa O, 2015, WASTE MANAGE, V46, P3, DOI 10.1016/j.wasman.2015.08.032
   Sakurai K, 1983, MUNICIPAL SOLID WAST
   Scheinberg A., 2010, SOLID WASTE MANAGEME
   Schneider Friedrich, 2010, International Economic Journal, V24, P443
   Tchobanoglous G., 1982, SERIE AMBIENTE RECUR
   US EPA, 2006, EPA530R06011 MUN IND
   Xu LL, 2016, J MATER CYCLES WASTE, V18, P377, DOI 10.1007/s10163-014-0340-0
NR 46
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JAN
PY 2020
VL 152
AR UNSP 104530
DI 10.1016/j.resconrec.2019.104530
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JN4KI
UT WOS:000496867700023
OA Bronze
DA 2020-05-12
ER

PT J
AU Wang, XL
   Wei, YW
   Shao, QL
AF Wang, Xiaoling
   Wei, Yawen
   Shao, Qinglong
TI Decomposing the decoupling of CO2 emissions and economic growth in
   China's iron and steel industry
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Carbon emissions; China's iron and steel (IS) industry; Tapio decoupling
   model; Grey Verhulst model
ID CARBON EMISSIONS; SUPPLY CHAIN; ENERGY; REDUCTION; CONSUMPTION;
   PREDICTION; FOOTPRINT; POLICIES; MODELS; SECTOR
AB Building a low-carbon industry is essential for the development of a sustainable economy. To study the relationship between carbon emissions and economic growth of China's iron and steel (IS) industry, this paper first measures the decoupling relationship between carbon emissions and added value of the IS industry from 2001 to 2016 based on the Tapio decoupling model. The causal-chain decomposition model is then used to decompose the decoupling index into different factors. Results show that carbon emissions and economic growth of the IS industry have mostly weak decoupling. For the influencing factors, decoupling elasticities of emission reduction and value creation exert negative impacts on overall decoupling, and the former one plays a bigger role. Decoupling elasticities of energy electricity and industrial electrification positively improve the total decoupling, but the effect is not stable yet and needs to be further enhanced. Finally, the grey Verhulst model is used to predict the decoupling state by the end of 2025. Forecasting results show that industry will still be in a weak decoupling, but the decoupling state will get better over time. Corresponding policy suggestions are posited based on the empirical findings to facilitate the green and low-carbon development of the IS industry.
C1 [Wang, Xiaoling; Wei, Yawen] Univ Sci & Technol Beijing, Sch Econ & Management, Beijing 100083, Peoples R China.
   [Shao, Qinglong] Shenzhen Univ, China Ctr Special Econ Zone Res, Shenzhen 518060, Guangdong, Peoples R China.
RP Shao, QL (reprint author), Shenzhen Univ, China Ctr Special Econ Zone Res, Shenzhen 518060, Guangdong, Peoples R China.
EM wangxiaoling@ustb.edu.cn; shao.qinglong@szu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71704010, 71771024, 71673022, 71903131]; Humanities
   and Social Science project of Ministry of Education of China
   [17YJC630163]; Social Science Research Foundation of Beijing
   [17JDGLA010, 18JDYJB021]; National Social Science Foundation of China
   [18CGL008]; China Postdoctoral Science FoundationChina Postdoctoral
   Science Foundation [2019M653047]
FX The authors are grateful for the support provided by the National
   Natural Science Foundation of China (71704010, 71771024, 71673022, and
   71903131), the Humanities and Social Science project of Ministry of
   Education of China (17YJC630163), the Social Science Research Foundation
   of Beijing (17JDGLA010 and 18JDYJB021), National Social Science
   Foundation of China (18CGL008), and the China Postdoctoral Science
   Foundation (2019M653047).
CR An RY, 2018, APPL ENERG, V226, P862, DOI 10.1016/j.apenergy.2018.06.044
   Cai F, 2018, CHINA WORLD ECON, V26, P1, DOI 10.1111/cwe.12234
   Chen AP, 2019, CHINA ECON REV, V58, DOI 10.1016/j.chieco.2018.07.009
   Cheng A.H., 2011, CHINA POPUL RESOUR E, V21, P41
   Deng J., 2002, INTRO GREY THEORY
   DENG JL, 1982, SYST CONTROL LETT, V1, P288, DOI 10.1016/S0167-6911(82)80025-X
   Du G, 2018, J CLEAN PROD, V184, P1102, DOI 10.1016/j.jclepro.2018.02.304
   Du P, 2018, RENEW ENERG, V122, P533, DOI 10.1016/j.renene.2018.01.113
   Fan FY, 2017, INT J SUSTAIN TRANSP, V11, P764, DOI 10.1080/15568318.2017.1317887
   Feng Z., 2015, E CHINA EC MANAG, V29, P50
   Gardas BB, 2018, J CLEAN PROD, V199, P47, DOI 10.1016/j.jclepro.2018.07.153
   GOSWAMI G, 2017, [No title captured], V33, P139, DOI DOI 10.1093/JLEO/EWW015
   Guo C., 2018, J BEIJING U TECHNOL, V18, P1
   Han XY, 2018, ENVIRON PROG SUSTAIN, V37, P1696, DOI 10.1002/ep.12857
   Hasanbeigi A, 2014, J CLEAN PROD, V65, P108, DOI 10.1016/j.jclepro.2013.09.047
   Hashem-Nazari M, 2017, J BUS ECON MANAG, V18, P676, DOI 10.3846/16111699.2017.1337045
   He YX, 2018, IET GENER TRANSM DIS, V12, P3375, DOI 10.1049/iet-gtd.2017.1493
   Hu XM, 2016, MATH PROBL ENG, V2016, DOI 10.1155/2016/9786107
   Javed SA, 2018, SCIENTOMETRICS, V115, P395, DOI 10.1007/s11192-017-2586-5
   Kaya Y., 1989, IPCC EN IND SUBGR RE
   Lechtenbohmer S, 2016, ENERGY, V115, P1623, DOI 10.1016/j.energy.2016.07.110
   Li C, 2017, POL J ENVIRON STUD, V26, P2619, DOI 10.15244/pjoes/70479
   Li P, 2019, ENERGIES, V12, DOI 10.3390/en12020236
   LI RR, 2017, SUSTAINABILITY-BASEL, V9, DOI DOI 10.3390/SU9061013
   [李坦 Li Tan], 2019, [生态学报, Acta Ecologica Sinica], V39, P1735
   Li YN, 2019, J CLEAN PROD, V210, P25, DOI 10.1016/j.jclepro.2018.10.249
   Li Z, 2010, STAT DECIS, V11, P108, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]
   Li Z. M., 2010, EC MANAGEMENT, V24, P41
   Liu C L, 2017, MATH PRACTICE THEORY, V47, P177
   Liu QC, 2015, MATH PROBL ENG, DOI 10.1155/2015/268286
   Liu S., 2013, P INT C MACH LEARN C, P14
   Maddaloni A, 2015, APPL THERM ENG, V91, P638, DOI 10.1016/j.applthermaleng.2015.08.051
   MEE, 2019, OP PROM IMPL ULTR EM
   Meenal R, 2018, RENEW ENERG, V121, P324, DOI 10.1016/j.renene.2017.12.005
   Miao X, 2015, ENVIRON POLLUT, V196, P473, DOI 10.1016/j.envpol.2014.11.010
   Ning YD, 2017, NAT HAZARDS, V87, P867, DOI 10.1007/s11069-017-2798-2
   NSB, 2017, CHIN IR STEEL IND YB
   Peng JY, 2018, RESOUR CONSERV RECY, V129, P392, DOI 10.1016/j.resconrec.2016.09.019
   Polat G, 2014, INT J MIN MET MATER, V21, P748, DOI 10.1007/s12613-014-0967-9
   Porzio GF, 2013, APPL ENERG, V112, P818, DOI 10.1016/j.apenergy.2013.05.005
   Puripat C, 2018, ADV METEOROL, V2018, DOI 10.1155/2018/7169130
   Purwanto H, 2018, IOP CONF SER-MAT SCI, V342, DOI 10.1088/1757-899X/342/1/012054
   Quader MA, 2016, RENEW SUST ENERG REV, V55, P537, DOI 10.1016/j.rser.2015.10.101
   Reddy KR, 2019, REV ENVIRON SCI BIO, V18, P127, DOI 10.1007/s11157-018-09490-w
   Shang W, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8050468
   Tang DC, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8101018
   Wan U, 2017, SCI TECHNOL MANAG RE, DOI [10.3969/j.issn.1000-7695.2017.03.037, DOI 10.3969/J.ISSN.1000-7695.2017.03.037]
   Wang HX, 2017, RESOUR CONSERV RECY, V124, P98, DOI 10.1016/j.resconrec.2017.04.011
   Wang Q. M, 2013, E CHINA EC MANAGEMEN, V27, P54
   Wang XL, 2016, RENEW SUST ENERG REV, V57, P1496, DOI 10.1016/j.rser.2015.12.131
   Wang XL, 2019, SCI TOTAL ENVIRON, V660, P1346, DOI 10.1016/j.scitotenv.2019.01.094
   Wang YF, 2017, RESOUR CONSERV RECY, V117, P66, DOI 10.1016/j.resconrec.2015.07.007
   Wang ZX, 2019, J CLEAN PROD, V207, P214, DOI 10.1016/j.jclepro.2018.10.010
   Wang ZX, 2018, ENERGY, V154, P522, DOI 10.1016/j.energy.2018.04.155
   Wei PB, 2017, POL J ENVIRON STUD, V26, P2307, DOI 10.15244/pjoes/70175
   Wu WQ, 2019, RENEW ENERG, V140, P70, DOI 10.1016/j.renene.2019.03.006
   Wu Y, 2019, SCI TOTAL ENVIRON, V656, P576, DOI 10.1016/j.scitotenv.2018.11.384
   Wu Y, 2018, ENVIRON IMPACT ASSES, V71, P60, DOI 10.1016/j.eiar.2018.04.001
   Xie PJ, 2019, J CLEAN PROD, V211, P598, DOI 10.1016/j.jclepro.2018.11.212
   Xuan D, 2019, WATER RESOUR HYDROPO, V50, P40
   Yin L., 2019, COAL TECHNOL, V38, P48, DOI [10.13301/j.cnki.ct.2019.01.016, DOI 10.13301/J.CNKI.CT.2019.01.016]
   Yu Yao, 2011, 2011 Fourth International Joint Conference on Computational Sciences and Optimization (CSO), P1168, DOI 10.1109/CSO.2011.99
   Zhang D, 2018, ENERGIES, V11, DOI 10.3390/en11010018
   Zhang HJ, 2016, APPL ENERG, V162, P1505, DOI 10.1016/j.apenergy.2015.08.124
   Zhang Q., 1995, J DAQING PET I, V19, P108, DOI [10.1192/bjp.111.479.1009-a, DOI 10.1192/BJP.111.479.1009-A]
   Zhang SQ, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10051340
   Zhang ZL, 2015, RESOUR CONSERV RECY, V101, P182, DOI 10.1016/j.resconrec.2015.05.018
   Zhao Yangyang, 2013, J FINANCE EC THEORY, P40
   Zhou JG, 2017, POL J ENVIRON STUD, V26, P2407, DOI 10.15244/pjoes/69103
   Zhou KL, 2016, RENEW SUST ENERG REV, V61, P319, DOI 10.1016/j.rser.2016.04.009
NR 70
TC 2
Z9 2
U1 48
U2 48
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JAN
PY 2020
VL 152
AR UNSP 104509
DI 10.1016/j.resconrec.2019.104509
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JN4KI
UT WOS:000496867700019
OA Bronze
DA 2020-05-12
ER

PT J
AU Yadav, S
   Singh, SP
AF Yadav, Sachin
   Singh, Surya Prakash
TI Blockchain critical success factors for sustainable supply chain
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Blockchain; Supply chain; PCA; Fuzzy; DEMATEL
ID MANAGEMENT-PRACTICES; ADOPTION; TECHNOLOGY; STANDARDS; BARRIERS;
   NETWORK; MODEL
AB Way back the development of Blockchain (BC) technology, Traditional supply chain (TSC) failed to meet the demand of customer of reasonable price with high quality. The current trend is the time to integrate and to make the existing system smarter, automated and sustainable. Researchers are working on the integration of information and communication technology with the supply chain (SC) and continuously endeavor to achieve an efficient SC. This paper is an attempt to study the use of BC technology and a try to develop efficient sustainable supply chain management (SSCM) rather than the inefficient design of supply chain management (SCM). Important variables related to BC are identified from the literature after going through discussion with academician and industry experts. These variables are further analyzed and modeled using Principal Component Analysis (PCA), Fuzzy-Decision making trial and evaluation laboratory (DEMATEL). PCA is applied to form the principal factor from these identified variables based on possible correlation. Although, the application of Fuzzy-DEMATEL is adopted to identify major causes that help to achieve sustainable supply chain (SSC) after integration of BC technology. The proposed integrated (incorporated) approach of PCA and Fuzzy-DEMATEL found six major causes namely Data safety and Decentralization, Accessibility, Laws and Policy, Documentation, Data management, and Quality. This study is revolving around the integrated approach of two streams namely BC-related Information technology and SC from Operations. This research represents the significant role of causes, which leads to the integration of BC with the SC resulting in achieving sustainability. BC technology is still in their nuance stage and this study will motivate researcher and industrial practitioners to achieve a more efficient and effective goal in SC practices to achieve sustainability.
C1 [Yadav, Sachin; Singh, Surya Prakash] Indian Inst Technol Delhi, Dept Management Studies, New Delhi 110016, India.
RP Singh, SP (reprint author), Indian Inst Technol Delhi, Dept Management Studies, New Delhi 110016, India.
EM sprsingh@dms.iitd.ac.in
RI SINGH, SURYA PRAKASH/O-4087-2014
OI SINGH, SURYA PRAKASH/0000-0002-3867-6845
FU UGC IndiaUniversity Grants Commission, India [RP03411G]; UKIERI
   [RP03411G]
FX The research reported in the paper is a part of Research Project
   (RP03411G) funded by UGC India and UKIERI.
CR Abeyratne Saveen A, 2016, BLOCKCHAIN READY MAN
   Ahram T, 2017, 2017 IEEE TECHNOLOGY & ENGINEERING MANAGEMENT SOCIETY CONFERENCE (TEMSCON), P137, DOI 10.1109/TEMSCON.2017.7998367
   Anjum A, 2017, IEEE CLOUD COMPUT, V4, P84
   Azaria A, 2016, PROCEEDINGS 2016 2ND INTERNATIONAL CONFERENCE ON OPEN AND BIG DATA - OBD 2016, P25, DOI 10.1109/OBD.2016.11
   Banerjee A, 2018, ADV COMPUT, V111, P69, DOI 10.1016/bs.adcom.2018.03.007
   Bartling S, 2016, IMPACT SOCIAL SCI BL
   Bashir I., 2017, MASTERING BLOCKCHAIN
   Benchoufi M, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2035-z
   Bhatia MS, 2018, RESOUR CONSERV RECY, V136, P79, DOI 10.1016/j.resconrec.2018.03.021
   Bitfury Group, 2015, SMART CONTR BITC BLO
   Bogart S., 2015, BLOCKCHAIN REPORT WE
   Castillo Md, 2017, LACK BLOCKCHAIN TALE
   Catalini C., 2016, SOME SIMPLE EC BLOCK
   Chaudhary A, 2019, ARCH PHYSIOL BIOCHEM, DOI 10.1080/13813455.2019.1669056
   Chopra A, 2018, 2018 INTERNATIONAL CONFERENCE ON AUTOMATION AND COMPUTATIONAL ENGINEERING (ICACE), P216, DOI 10.1109/ICACE.2018.8686928
   Christidis K, 2016, IEEE ACCESS, V4, P2292, DOI 10.1109/ACCESS.2016.2566339
   CONNOR T, 2001, STILL WAITING NIKE D
   Dai J, 2017, J INF SYST, V31, P5, DOI 10.2308/isys-51804
   De Filippi P., 2018, ARXIV180102507
   De Filippi P.D.F., 2018, BLOCKCHAIN LAW RULE
   Drugs C.C, 2004, REP FOOD DRUG ADM
   Elder SD, 2013, J RURAL STUD, V32, P264, DOI 10.1016/j.jrurstud.2013.07.009
   Fawcett S.E, 2007, SUPPLY CHAIN MANAGEM
   Finch P, 2004, SUPPLY CHAIN MANAG, V9, P183, DOI 10.1108/13598540410527079
   Foroglou G., 2015, 12 STUD C MAN SCI TE
   Foster S.T, 2007, MANAGING QUALITY INT, P256
   Gatteschi V, 2018, IT PROF, V20, P62, DOI 10.1109/MITP.2018.021921652
   Gunasekaran A, 2004, INT J PROD ECON, V87, P333, DOI 10.1016/j.ijpe.2003.08.003
   Tzeng GH, 2007, EXPERT SYST APPL, V32, P1028, DOI 10.1016/j.eswa.2006.02.004
   Haber S.A., 1992, U.S. Patent, Patent No. [5,136,646, 5136646]
   Halldorsson A, 2010, INT J PHYS DISTR LOG, V40, P5, DOI 10.1108/09600031011018019
   Islam MS, 2018, RESOUR CONSERV RECY, V131, P134, DOI 10.1016/j.resconrec.2017.12.015
   JACKSON JE, 1973, TECHNOMETRICS, V15, P601, DOI 10.2307/1266866
   Khatwani G., 2015, GLOB J FLEX SYST MAN, V16, P97, DOI DOI 10.1007/S40171-014-0087-4
   King S., 2012, PPCOIN PEER TO PEER
   Koch B, 2016, E INVOICING E BILLIN
   Korpela K., 2017, P 50 HAW INT C SYST
   Kosba A, 2016, P IEEE S SECUR PRIV, P839, DOI 10.1109/SP.2016.55
   Kshetri N, 2018, INT J INFORM MANAGE, V39, P80, DOI 10.1016/j.ijinfomgt.2017.12.005
   Kumar A, 2018, RESOUR CONSERV RECY, V131, P101, DOI 10.1016/j.resconrec.2017.12.024
   Kumar R, 2018, J CLEAN PROD
   Lamba K, 2018, INT J LOGIST MANAG, V29, P629, DOI 10.1108/IJLM-07-2017-0183
   Lansiti M, 2017, HARVARD BUS REV, V95, P119
   Liang XP, 2017, IEEE ACM INT SYMP, P468, DOI 10.1109/CCGRID.2017.8
   Lin KP, 2018, RESOUR CONSERV RECY, V128, P134, DOI 10.1016/j.resconrec.2016.11.017
   Lucena P., 2018, ARXIV180307877
   Lundqvist T, 2017, 2017 GLOBAL INTERNET OF THINGS SUMMIT (GIOTS 2017), P261
   Luthra S, 2018, RESOUR CONSERV RECY, V138, P194, DOI 10.1016/j.resconrec.2018.07.005
   Luthra S, 2017, RESOUR CONSERV RECY, V125, P198, DOI 10.1016/j.resconrec.2017.02.018
   Mackey TK, 2017, EXPERT OPIN DRUG SAF, V16, P587, DOI 10.1080/14740338.2017.1313227
   Madavi D, 2019, COMPREHENSIVE STUDY
   Mangla S. K, 2019, RESOUR CONSERV RECY, V142, P277, DOI DOI 10.1016/J.RESCONREC.2018.11.014
   Mathivathanan D, 2018, RESOUR CONSERV RECY, V128, P284, DOI 10.1016/j.resconrec.2017.01.003
   Michal J, 2018, JOURNAL
   Mishra S, 2019, MANAGE DECIS, V57, P811, DOI 10.1108/MD-05-2018-0565
   Moore M, 2012, TELEGRAPH, P11
   Nakamoto S., 2008, BITCOIN PEER TO PEER
   Niranjanamurthy M., 2018, CLUSTER COMPUT, P1, DOI DOI 10.1007/S10586-018-2387-5#
   Nugent T., 2016, F1000RESEARCH, V5
   Olnes S., 2017, BLOCKCHAIN GOVT BENE
   Opricovic S, 2003, INT J UNCERTAIN FUZZ, V11, P635, DOI 10.1142/S0218488503002387
   Peters G, 2015, J FINAN PERSPECTIVES, V3
   Popper N, 2017, NY TIMES, P4
   Price R, 2015, THIS LONDON STARTUP
   Punter A., 2013, SUPPLY CHAIN FAILURE
   Queiroz MM, 2019, INT J INFORM MANAGE, V46, P70, DOI 10.1016/j.ijinfomgt.2018.11.021
   Rajput S, 2018, MANAGEMENT DECISION
   Raju R, 2017, INT C POWER ELECT DR, P1, DOI 10.1109/PEDS.2017.8289295
   Rayes A, 2017, RIVER PUBLISHER SERI, P49
   Saberi S, 2018, RESOUR CONSERV RECY, V130, P80, DOI 10.1016/j.resconrec.2017.11.020
   Scherer M., 2017, PERFORMANCE SCALABIL
   Shafagh H., 2017, P 2017 CLOUD COMP SE, P45, DOI DOI 10.1145/3140649.3140656
   Smetana S, 2018, RESOUR CONSERV RECY, V133, P229, DOI 10.1016/j.resconrec.2018.02.020
   Steiner J., 2015, BLOCKCHAIN SOLUTION
   Sullivan S, 1999, ENT, V4, P3
   Swan Melanie, 2015, BLOCKCHAIN BLUEPRINT
   Vecchio P.D, 2019, RESOUR CONSERV RECY, V2, DOI 10.1016/j.rcrx.2019.100009
   Wang YK, 2016, 2016 IEEE/CSAA INTERNATIONAL CONFERENCE ON AIRCRAFT UTILITY SYSTEMS (AUS), P1, DOI 10.1109/AUS.2016.7748011
   Weber I, 2016, LECT NOTES COMPUT SC, V9850, P329, DOI 10.1007/978-3-319-45348-4_19
   WERBACH K. D., 2018, BERKELEY TECHNOLOGY, V33, P487, DOI DOI 10.15779/
   Wust K, 2018, 2018 CRYPTO VALLEY CONFERENCE ON BLOCKCHAIN TECHNOLOGY (CVCBT), P45, DOI 10.1109/CVCBT.2018.00011
   Zhang CH, 2018, APPL ENERG, V220, P1, DOI 10.1016/j.apenergy.2018.03.010
   Zhu HS, 2016, FINANC INNOV, V2, DOI 10.1186/s40854-016-0044-7
   Zyskind G, 2015, 2015 IEEE SECURITY AND PRIVACY WORKSHOPS (SPW), P180, DOI 10.1109/SPW.2015.27
NR 84
TC 3
Z9 3
U1 98
U2 98
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JAN
PY 2020
VL 152
AR UNSP 104505
DI 10.1016/j.resconrec.2019.104505
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JN4KI
UT WOS:000496867700017
OA Bronze
DA 2020-05-12
ER

PT J
AU Yuan, Y
   Yellishetty, M
   Mudd, GM
   Munoz, MA
   Northey, SA
   Werner, TT
AF Yuan, Ye
   Yellishetty, Mohan
   Mudd, Gavin M.
   Munoz, Mario A.
   Northey, Stephen A.
   Werner, Tim T.
TI Toward dynamic evaluations of materials criticality: A systems framework
   applied to platinum
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Platinum; Resources; Supply risk; Criticality; Complex systems
ID AVAILABILITY; METALS
AB A criticality assessment framework is introduced to quantitatively evaluate mineral supply-risk drivers, end-user vulnerabilities, market-dynamic indicators, and their interconnections in a time-dependent manner. Using this framework, we analyzed the criticality of platinum from 1975 to 2015, considering major regional end users (Europe, North America, Japan, and China) and producers (South Africa and Russia). Our analysis demonstrates that (1) The global supply risk of platinum is strongly influenced by South Africa's socio-political status and its dominance over global supply and reserves; (2) Production from South Africa is directly affected by the level of social progress in the region, while price is indirectly affected; (3) Platinum prices are more closely associated with production from South Africa than those from North America and Russia; (4) These prices are more connected with consumption in North America than in other regions; (5) Europe is more vulnerable to supply restrictions than North America, Japan, and China in the context of economic importance, consumption and import reliance. Our methodology shows that a detailed, dynamic understanding of constraints, drivers and trends in material supply risks and vulnerabilities can be achieved, although this requires annual reporting of data that can be challenging to compile. As such, there remain challenges in replicating the assessments demonstrated here for other potentially critical metals.
C1 [Yuan, Ye; Yellishetty, Mohan; Northey, Stephen A.] Monash Univ, Dept Civil Engn, Clayton, Vic, Australia.
   [Mudd, Gavin M.] RMIT Univ, Dept Environm Engn, Melbourne, Vic, Australia.
   [Munoz, Mario A.] Univ Melbourne, Sch Comp & Informat Syst, Melbourne, Vic, Australia.
   [Werner, Tim T.] Univ Melbourne, Sch Geog, Melbourne, Vic, Australia.
RP Yuan, Y (reprint author), Monash Univ, 38 Coll Walk, Clayton, Vic 3800, Australia.
EM ye.yuan@monash.edu
RI Munoz, Mario A./J-3176-2013
OI Munoz, Mario A./0000-0002-7254-2808; Mudd, Gavin/0000-0001-7115-1330;
   Yellishetty, Mohan/0000-0003-2921-200X; Northey,
   Stephen/0000-0001-9001-8842
CR Alonso E., 2007, MAT AVAILABILITY SUP
   Alonso E., 2008, INT PREC MET I 32 AN
   Alonso E, 2007, ENVIRON SCI TECHNOL, V41, P6649, DOI 10.1021/es070159c
   Alonso E, 2012, ENVIRON SCI TECHNOL, V46, P12986, DOI 10.1021/es301110e
   AngloAmereican, 2015, ANN REPORT, P276
   Aquarius, 2015, AQ PLAT LTD ANN REP, P140
   Bauer D., 2010, CRITICAL MAT STRATEG
   BGS, 2015, RISK LIST 2015
   BGS, 2012, RISK LIST 2012
   Brown TJ, 2012, WORLD MINERAL PRODUC
   Cairncross E, 2015, NEW SOLUT, V25, P513, DOI 10.1177/1048291115622027
   Courtrot A.-A., 1838, RECHERCHES PRINCIPES
   Day M., 2014, STRIKE FEARS PUSH PL, pC4
   EU, 2014, REP CRIT RAW MAT EU
   EU, 2010, CRITICAL RAW MAT EU
   G Gunn, 2014, CRITICAL METALS HDB
   Graedel TE, 2015, P NATL ACAD SCI USA, V112, P6295, DOI 10.1073/pnas.1312752110
   Graedel TE, 2015, P NATL ACAD SCI USA, V112, P4257, DOI 10.1073/pnas.1500415112
   Graedel TE, 2012, ENVIRON SCI TECHNOL, V46, P1063, DOI 10.1021/es203534z
   Harvey RG, 2016, EXTRACT IND SOC, V3, P832, DOI 10.1016/j.exis.2016.04.008
   Implants, 2015, IMPL INT ANN REP IMP, P74
   Kaufmann D.K., 1996, WORLDWIDE GOVERNANCE
   Knoeri C, 2013, SCI TOTAL ENVIRON, V461, P808, DOI 10.1016/j.scitotenv.2013.02.001
   Lonmin, 2015, LONM ANN REP ACC, P96
   Matthey J., 1975, PGM MARKET REPORT OH
   McMahon F.C., 2011, M FRASER I ANN SURVE
   Mudd GM, 2018, SCI TOTAL ENVIRON, V622, P614, DOI 10.1016/j.scitotenv.2017.11.350
   Mudd GM, 2012, ORE GEOL REV, V46, P106, DOI 10.1016/j.oregeorev.2012.02.005
   Mudd GM, 2012, PLATIN MET REV, V56, P2, DOI 10.1595/147106711X614713
   Nassar N., 2015, THESIS
   NRC National Research Council, 2008, MIN CRIT MIN US EC
   Ross F.M.S.A.D., 1990, IND MARK STRUCT, P70
   Rudnick, 2003, TREATISE GEOCHEMISTR, V3, P1, DOI DOI 10.1016/B0-08-043751-6/03016-4
   SCHERER FM, 1996, IND STRUCTURE STRATE
   Sverdrup HU, 2016, RESOUR CONSERV RECY, V114, P130, DOI 10.1016/j.resconrec.2016.07.011
   Tilton J.E., 2010, BORROWED TIME ASSESS
   U. S. Department of Energy (DOE), 2010, CRITICAL MAT STRATEG
   UN, 1990, HUMAN DEV REPORTS
   USGS, 1975, MIN YB US GEOL SURV
   [USGS (USGS) USGS], 1975, MINERAL COMMODITY SU
   von Stackelberg H., 1952, THEORY MARKET EC
   Yuan Y., 2019, J IND ECOL
NR 42
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JAN
PY 2020
VL 152
AR UNSP 104532
DI 10.1016/j.resconrec.2019.104532
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JN4KI
UT WOS:000496867700026
OA Bronze
DA 2020-05-12
ER

PT J
AU Zambrano-Monserrate, MA
   Ruano, MA
AF Zambrano-Monserrate, Manuel A.
   Alejandra Ruano, Maria
TI Do you need a bag? Analyzing the consumption behavior of plastic bags of
   households in Ecuador
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Disposable plastic bags; Cloth bags; Probit model; Ecuador
ID WASTE; PERCEPTIONS; TAX
AB Disposable plastic bags are one of the most used items by families worldwide, however, their excessive use and lack of re-use culture, have made them one of the most polluting materials on the planet. Disposable plastic bags can take up to 200 years to degrade, and their impact on the environment is reflected in the destruction of nature (landscape), alteration of marine ecosystems, and effect on human health. Understanding the behavior of households regarding the use of this type of material is key to undertake actions that lead to a reduction in their use. Therefore, this research aims to analyze the sociodemographic, economic, housing, social participation, and environmental perception factors that influence the decisions of households in using disposable plastic bags or reusable items, when shopping. It was found that homes, where the head of the household are women, are more likely to use non-plastic bags when shopping. In addition, heads of households with more education are more likely to use cloth bags or reusable materials than less educated ones. Furthermore, when the head of the household willingly participates in social organizations, the probability of using plastic bags decreases. It was also found that the urban population is more likely to use plastic bags than the rural population. Furthermore, families from the Andean region show better pro-environment behavior. Finally, public policies are recommended according to the main findings.
C1 [Zambrano-Monserrate, Manuel A.] Univ Espiritu Santo, Guayaquil, Ecuador.
   [Alejandra Ruano, Maria] ESPOL, Fac Ciencias Sociales & Humanist, Escuela Super Politecn Litoral, Campus Gustavo Galindo Km 30-5 Via Perimetral, Guayaquil, Ecuador.
RP Zambrano-Monserrate, MA (reprint author), Univ Espiritu Santo, Guayaquil, Ecuador.
EM manuelandreszambrano@gmail.com
OI Zambrano-Monserrate, Manuel A./0000-0002-0025-7901; Ruano, Maria
   Alejandra/0000-0001-6455-1686
CR Adane L., 2011, J TOXICOL ENV HLTH S, V3, P234
   Afroz R, 2017, ENVIRON SCI POLLUT R, V24, P2304, DOI 10.1007/s11356-016-7942-0
   Akil AM, 2015, PROCD SOC BEHV, V202, P124, DOI 10.1016/j.sbspro.2015.08.215
   Alam O, 2018, RESOUR CONSERV RECY, V132, P121, DOI 10.1016/j.resconrec.2018.01.037
   Borrelle SB, 2017, P NATL ACAD SCI USA, V114, P9994, DOI 10.1073/pnas.1714450114
   Braun YA, 2015, GENDER SOC, V29, P863, DOI 10.1177/0891243215602101
   Convery F, 2007, ENVIRON RESOUR ECON, V38, P1, DOI 10.1007/s10640-006-9059-2
   Dikgang J, 2012, S AFR J ECON, V80, P123, DOI 10.1111/j.1813-6982.2011.01289.x
   Elgaaied-Gambier L, 2016, J BUS ETHICS, V135, P683, DOI 10.1007/s10551-014-2491-2
   Ellis S., 2005, PLASTIC GROCERY BAGS, P1
   Gujarati D.N., 2009, BASIC ECONOMETRICS
   Hamad K, 2018, PROG POLYM SCI, V85, P83, DOI 10.1016/j.progpolymsci.2018.07.001
   Haward M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03104-3
   Heidbreder LM, 2019, SCI TOTAL ENVIRON, V668, P1077, DOI 10.1016/j.scitotenv.2019.02.437
   INEC, 2014, MET DIS MUESTR ENC N
   INEC, 2017, INF AMB HOG 2017
   Jezewska-Zychowicz M., 2015, J AGRIBUSINESS RURAL, V3, P447
   Knoblauch D, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10061994
   Kurisu KH, 2011, WASTE MANAGE, V31, P1441, DOI 10.1016/j.wasman.2011.03.008
   Madigele PK, 2017, CHIN J POPUL RESOUR, V15, P255, DOI 10.1080/10042857.2017.1369243
   MAE, 2018, EC ONU MED AMB LANZ
   MAE, 2014, POL GEST INT PLAST E
   MAE, 2015, DIA INT LIBR FUND PL
   Martinho G, 2017, WASTE MANAGE, V61, P3, DOI 10.1016/j.wasman.2017.01.023
   Nielsen TD, 2019, WASTE MANAGE, V87, P428, DOI 10.1016/j.wasman.2019.02.025
   Nkwachukwu OI, 2013, INT J IND CHEM, V4, DOI 10.1186/2228-5547-4-34
   O'Brien J, 2019, WASTE MANAGE, V84, P320, DOI 10.1016/j.wasman.2018.11.051
   Ohtomo S, 2014, RESOUR CONSERV RECY, V84, P57, DOI 10.1016/j.resconrec.2013.12.014
   Padilla AJ, 2018, WASTE MANAGE, V74, P16, DOI 10.1016/j.wasman.2017.11.052
   Quaglione D, 2017, ENERG POLICY, V108, P503, DOI 10.1016/j.enpol.2017.06.030
   Ritch E, 2009, INT J CONSUM STUD, V33, P168, DOI 10.1111/j.1470-6431.2009.00749.x
   Rucktum V., 2016, ABAC ODI J VISION AC, V3, P162
   Ryan PG, 1996, S AFR J SCI, V92, P163
   Sharp A, 2010, J CONSUM BEHAV, V9, P470, DOI 10.1002/cb.335
   Synthia I. J., 2015, J DEV AREAS, V49, P183, DOI [10.1353/jda.2015.0062, DOI 10.1353/JDA.2015.0062]
   UN, 2018, MARK ENV DAY
   UN, 2019, COMPR MUND RED PLAST
   UNEP, 2018, GAL FIGHT RIS TID PL
   Wagner TP, 2017, WASTE MANAGE, V70, P3, DOI 10.1016/j.wasman.2017.09.003
   WECF, 2004, DANG HLTH EFF HOM BU
   WEFORUM, 2018, CHIL IS 1 COUNTR AM
   Zen IS, 2014, HABITAT INT, V42, P83, DOI 10.1016/j.habitatint.2013.10.010
NR 42
TC 1
Z9 1
U1 22
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JAN
PY 2020
VL 152
AR UNSP 104489
DI 10.1016/j.resconrec.2019.104489
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JN4KI
UT WOS:000496867700014
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhang, A
   Zhong, RY
   Farooque, M
   Kang, K
   Venkatesh, VG
AF Zhang, Abraham
   Zhong, Ray Y.
   Farooque, Muhammad
   Kang, Kai
   Venkatesh, V. G.
TI Blockchain-based life cycle assessment: An implementation framework and
   system architecture
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Blockchain; Life cycle assessment; Supply chain sustainability;
   Environmental sustainability; Operational excellence
ID SUPPLY CHAIN MANAGEMENT; CIRCULAR ECONOMY; IMPACT ASSESSMENT; WASTE
   MANAGEMENT; ASSESSMENT LCA; TECHNOLOGY; ENERGY; SUSTAINABILITY;
   INTERNET; THINGS
AB Life cycle assessment (LCA) is widely used for assessing the environmental impacts of a product or service. Collecting reliable data is a major challenge in LCA due to the complexities involved in the tracking and quantifying inputs and outputs at multiple supply chain stages. Blockchain technology offers an ideal solution to overcome the challenge in sustainable supply chain management. Its use in combination with intemet-of-things (loT) and big data analytics and visualization can help organizations achieve operational excellence in conducting LCA for improving supply chain sustainability. This research develops a framework to guide the implementation of Blockchain-based LCA. It proposes a system architecture that integrates the use of Blockchain, loT, and big data analytics and visualization. The proposed implementation framework and system architecture were validated by practitioners who were experienced with Blockchain applications. The research also analyzes system implementation costs and discusses potential issues and solutions, as well as managerial and policy implications.
C1 [Zhang, Abraham; Farooque, Muhammad] Auckland Univ Technol, AUT Univ, Business Sch, Private Bag 92006, Auckland 1142, New Zealand.
   [Zhang, Abraham] Excelsia Coll, Lumen Res Inst, 69-71 Waterloo Rd, Macquarie Pk, NSW 2113, Australia.
   [Zhang, Abraham] Indiana Wesleyan Univ, 69-71 Waterloo Rd, Macquarie Pk, NSW 2113, Australia.
   [Zhong, Ray Y.; Kang, Kai] Univ Hong Kong, Dept Ind & Mfg Syst Engn, Hong Kong, Peoples R China.
   [Farooque, Muhammad] Sukkur IBA Univ, Sukkur, Pakistan.
   [Venkatesh, V. G.] Ecole Management Normandie, 30 Rue Richelieu, F-76087 Le Havre, France.
RP Zhang, A (reprint author), Auckland Univ Technol, AUT Univ, Business Sch, Private Bag 92006, Auckland 1142, New Zealand.
EM abraham.zhang@aut.ac.nz
RI Zhang, Abraham/AAA-7214-2019
OI Zhang, Abraham/0000-0002-3804-6392; Kang, Kai/0000-0002-3142-5883;
   Farooque, Muhammad/0000-0001-6875-2784
CR Adams R, 2017, STRATEG CHANG, V26, P417, DOI 10.1002/jsc.2141
   Al-Saqaf W., 2017, J CYBER POLICY, V2, P338, DOI DOI 10.1080/23738871.2017.1400084
   Amendola S, 2014, IEEE INTERNET THINGS, V1, P144, DOI 10.1109/JIOT.2014.2313981
   Aryal A., 2018, SUPPLY CHAIN MANAG I
   Asdrubali F, 2015, RENEW SUST ENERG REV, V42, P1113, DOI 10.1016/j.rser.2014.10.082
   Atzori L, 2010, COMPUT NETW, V54, P2787, DOI 10.1016/j.comnet.2010.05.010
   Bahga A., 2016, J SOFTW ENG APPL, V9, P533, DOI DOI 10.4236/jsea.2016.910036
   Baitz M, 2013, INT J LIFE CYCLE ASS, V18, P5, DOI 10.1007/s11367-012-0476-x
   Balaguera A, 2018, RESOUR CONSERV RECY, V132, P37, DOI 10.1016/j.resconrec.2018.01.003
   Bauer C, 2015, APPL ENERG, V157, P871, DOI 10.1016/j.apenergy.2015.01.019
   Beck R, 2017, BUS INFORM SYST ENG+, V59, P381, DOI 10.1007/s12599-017-0505-1
   Buyle M, 2013, RENEW SUST ENERG REV, V26, P379, DOI 10.1016/j.rser.2013.05.001
   Cai HM, 2014, IEEE T IND INFORM, V10, P1558, DOI 10.1109/TII.2014.2306391
   Cai YF, 2016, FINANC INNOV, V2, DOI 10.1186/s40854-016-0039-4
   Cerutti AK, 2014, J CLEAN PROD, V73, P125, DOI 10.1016/j.jclepro.2013.09.017
   Chau CK, 2015, APPL ENERG, V143, P395, DOI 10.1016/j.apenergy.2015.01.023
   Christensen TH, 2007, WASTE MANAGE RES, V25, P257, DOI 10.1177/0734242X07079184
   Christidis K, 2016, IEEE ACCESS, V4, P2292, DOI 10.1109/ACCESS.2016.2566339
   Ciroth A, 2004, INT J LIFE CYCLE ASS, V9, P216, DOI 10.1007/BF02978597
   Cooper JS, 2013, INT J LIFE CYCLE ASS, V18, P185, DOI 10.1007/s11367-012-0454-3
   Corcelli F, 2019, RESOUR CONSERV RECY, V144, P321, DOI 10.1016/j.resconrec.2019.01.040
   de Leon DC, 2017, ASIA PAC J INNOV ENT, V11, P286, DOI 10.1108/APJIE-12-2017-034
   EC (European Commission), 2012, INT REFERENCE LIFE C
   EC (European Commission), 2015, BETT REG TOOLB
   Eccles RG, 2014, MANAGE SCI, V60, P2835, DOI 10.1287/mnsc.2014.1984
   Egilmez G, 2014, RESOUR CONSERV RECY, V82, P8, DOI 10.1016/j.resconrec.2013.10.008
   Emem M, 2018, UAE LAUNCHES BLOCKCH
   Farooque M, 2017, P 15 ANZAM OP SUPPL, P9
   Farooque M, 2019, SUPPLY CHAIN MANAG, V24, P677, DOI 10.1108/SCM-10-2018-0345
   Farooque M, 2019, J CLEAN PROD, V228, P882, DOI 10.1016/j.jclepro.2019.04.303
   Fenves S., 2003, MASTER PRODUCT MODEL, P20899
   Fenves S.J., 2001, CORE PRODUCT MODEL R
   Flammer C, 2013, ACAD MANAGE J, V56, P758, DOI 10.5465/amj.2011.0744
   Francisco K., 2018, LOGISTICS, V2, P1, DOI [10.3390/logistics2010002, DOI 10.3390/logistics2010002]
   Franz P. H., 2012, VALUE DRIVEN BUSINES
   Fu BL, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10041105
   futurethinkers.org, 2017, 7 WAYS BLOCKCH CAN S
   Galletti A, 2013, BIG DATA ANAL ARE PE, P53
   Gbededo MA, 2018, J CLEAN PROD, V184, P1002, DOI 10.1016/j.jclepro.2018.02.310
   Genovese A, 2017, OMEGA-INT J MANAGE S, V66, P344, DOI 10.1016/j.omega.2015.05.015
   Goedkoop M, 2001, ECOINDICATOR 99 DAMA, V36A
   Grewal D, 2018, J MARKET EDUC, V40, P85, DOI 10.1177/0273475318755838
   Guinee J., 2017, INTRO LIFE CYCLE ASS, V4, P15, DOI [10.1007/978-3-319-29791-0_2, DOI 10.1007/978-3-319-29791-0_2]
   Guinee JB, 2011, ENVIRON SCI TECHNOL, V45, P90, DOI 10.1021/es101316v
   Guinee JB, 2009, INT J LIFE CYCLE ASS, V14, P328, DOI 10.1007/s11367-009-0080-x
   Hollberg A, 2016, INT J LIFE CYCLE ASS, V21, P943, DOI 10.1007/s11367-016-1065-1
   Hospido A, 2010, INT J LIFE CYCLE ASS, V15, P44, DOI 10.1007/s11367-009-0130-4
   Hutchins MJ, 2008, J CLEAN PROD, V16, P1688, DOI 10.1016/j.jclepro.2008.06.001
   Hyperledger, 2018, WALM BROUGHT UNPR TR
   Igos E, 2019, INT J LIFE CYCLE ASS, V24, P794, DOI 10.1007/s11367-018-1477-1
   Ikhlayel M, 2018, J CLEAN PROD, V170, P119, DOI 10.1016/j.jclepro.2017.09.137
   Jakhar SK, 2018, RESOUR CONSERV RECY, V139, P262, DOI 10.1016/j.resconrec.2018.08.019
   Jensen AA European Environment Agency, 1998, LIFE CYCLE ASSESSMEN
   Jolliet O, 2005, INT J LIFE CYCLE ASS, V10, P447, DOI 10.1065/lca2005.11.006
   Khaqqi KN, 2018, APPL ENERG, V209, P8, DOI 10.1016/j.apenergy.2017.10.070
   Khoo HH, 2019, RESOUR CONSERV RECY, V145, P67, DOI 10.1016/j.resconrec.2019.02.010
   Kouhizadeh M, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10103652
   Kumar A, 2017, RESOUR CONSERV RECY, V122, P32, DOI 10.1016/j.resconrec.2017.01.018
   Lake A, 2015, INT J PROD RES, V53, P6495, DOI 10.1080/00207543.2014.951092
   Lansiti M, 2017, HARVARD BUS REV, V95, P119
   Levasseur A, 2016, ECOL INDIC, V71, P163, DOI 10.1016/j.ecolind.2016.06.049
   Li Z, 2019, IEEE T IND INFORM, V15, P3642, DOI 10.1109/TII.2019.2900987
   Li Z, 2018, ROBOT CIM-INT MANUF, V54, P133, DOI 10.1016/j.rcim.2018.05.011
   Li Z, 2018, IND MANAGE DATA SYST, V118, P303, DOI 10.1108/IMDS-04-2017-0142
   Luo H, 2015, J INTELL MANUF, V26, P169, DOI 10.1007/s10845-013-0771-9
   Luo H, 2012, INT J PROD RES, V50, P1457, DOI 10.1080/00207543.2011.560620
   Luthra S, 2018, RESOUR CONSERV RECY, V138, P194, DOI 10.1016/j.resconrec.2018.07.005
   Mangla S. K, 2019, RESOUR CONSERV RECY, V142, P277, DOI DOI 10.1016/J.RESCONREC.2018.11.014
   Mangla SK, 2018, PROD PLAN CONTROL, V29, P551, DOI 10.1080/09537287.2018.1449265
   Marsal-Llacuna ML, 2018, TECHNOL FORECAST SOC, V128, P226, DOI 10.1016/j.techfore.2017.12.005
   Matos S, 2007, J OPER MANAG, V25, P1083, DOI 10.1016/j.jom.2007.01.013
   Mougayar W., 2016, BUSINESS BLOCKCHAIN
   Muralikrishna IV, 2017, ENVIRONMENTAL MANAGEMENT: SCIENCE AND ENGINEERING FOR INDUSTRY, P57, DOI 10.1016/B978-0-12-811989-1.00005-1
   Nakamoto S., 2008, BITCOIN PEER TO PEER
   Nasir MHA, 2017, INT J PROD ECON, V183, P443, DOI 10.1016/j.ijpe.2016.06.008
   Niero M, 2016, RESOUR CONSERV RECY, V114, P18, DOI 10.1016/j.resconrec.2016.06.023
   Niero M, 2016, J CLEAN PROD, V126, P352, DOI 10.1016/j.jclepro.2016.02.122
   Norgate TE, 2007, J CLEAN PROD, V15, P838, DOI 10.1016/j.jclepro.2006.06.018
   Notarnicola B, 2017, J CLEAN PROD, V140, P399, DOI 10.1016/j.jclepro.2016.06.071
   Panarello A, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18082575
   Perez-Lopez P, 2014, J CLEAN PROD, V64, P323, DOI 10.1016/j.jclepro.2013.07.028
   Puthal D, 2018, IEEE CONSUM ELECTR M, V7, P18, DOI 10.1109/MCE.2017.2776459
   Queiroz M.M., 2019, SUPPLY CHAIN MANAG I
   Rebitzer G, 2004, ENVIRON INT, V30, P701, DOI 10.1016/j.envint.2003.11.005
   Roy P, 2009, J FOOD ENG, V90, P1, DOI 10.1016/j.jfoodeng.2008.06.016
   Saberi S, 2019, INT J PROD RES, V57, P2117, DOI 10.1080/00207543.2018.1533261
   Schroeder P, 2018, RESOUR CONSERV RECY, V136, P77, DOI 10.1016/j.resconrec.2018.04.003
   Scientific Applications International Corporation, 2006, LIF CYCL ASS PRINC P
   Scott B, 2017, STRATEG CHANG, V26, P423, DOI 10.1002/jsc.2142
   Sikorski JJ, 2017, APPL ENERG, V195, P234, DOI 10.1016/j.apenergy.2017.03.039
   Song ML, 2018, ANN OPER RES, V270, P459, DOI 10.1007/s10479-016-2158-8
   Sudarsan R, 2005, COMPUT AIDED DESIGN, V37, P1399, DOI 10.1016/j.cad.2005.02.010
   Swan Melanie, 2015, BLOCKCHAIN BLUEPRINT
   Tama BA, 2017, 2017 INTERNATIONAL CONFERENCE ON ELECTRICAL ENGINEERING AND COMPUTER SCIENCE (ICECOS), P109, DOI 10.1109/ICECOS.2017.8167115
   Tao F, 2014, IEEE T IND INFORM, V10, P1547, DOI 10.1109/TII.2014.2306397
   Tao F, 2014, IEEE T IND INFORM, V10, P1252, DOI 10.1109/TII.2014.2306771
   Tapscott D, 2017, MIT SLOAN MANAGE REV, V58, P10
   Treiblmaier H, 2018, SUPPLY CHAIN MANAG, V23, P545, DOI 10.1108/SCM-01-2018-0029
   UNEP (United Nations Environment Programme), 2012, GLOB CHEM OUTL SYNTH
   Viriyasitavat W, 2018, J INTELL MANUF, P1, DOI [DOI 10.1007/S10845-018-1422-Y, 10.1007/s10845-018-1422-y]
   von Bahr B, 2004, J CLEAN PROD, V12, P369, DOI 10.1016/S0959-6526(02)00197-X
   von Gleich A, 2008, J CLEAN PROD, V16, P899, DOI 10.1016/j.jclepro.2007.04.017
   Wang F., 2003, P 2003 ASME DES ENG
   Wang YK, 2016, 2016 IEEE/CSAA INTERNATIONAL CONFERENCE ON AIRCRAFT UTILITY SYSTEMS (AUS), P1, DOI 10.1109/AUS.2016.7748011
   Wang YL, 2019, SUPPLY CHAIN MANAG, V24, P62, DOI 10.1108/SCM-03-2018-0148
   WEIDEMA B, 2004, DANISH ENV PROT AGEN, V70, P1
   White GRT, 2017, STRATEG CHANG, V26, P439, DOI 10.1002/jsc.2144
   Yay ASE, 2015, J CLEAN PROD, V94, P284, DOI 10.1016/j.jclepro.2015.01.089
   Yuan Y, 2018, IEEE T SYST MAN CY-S, V48, P1421, DOI 10.1109/TSMC.2018.2854904
   Yue X, 2016, J MED SYST, V40, DOI 10.1007/s10916-016-0574-6
   Zhang A, 2019, J CLEAN PROD, V240, DOI 10.1016/j.jclepro.2019.118198
   Zhang A, 2016, INT J OPER PROD MAN, V36, P1625, DOI 10.1108/IJOPM-02-2015-0093
   Zhang A, 2013, INT J PROD ECON, V146, P48, DOI 10.1016/j.ijpe.2012.12.008
   Zhong RY, 2015, INT J PROD ECON, V165, P260, DOI 10.1016/j.ijpe.2015.02.014
   Zhong RY, 2014, J INTELL MANUF, V25, P825, DOI 10.1007/s10845-012-0721-y
   Zuo Y, 2018, INT J COMPUT INTEG M, V31, P337, DOI 10.1080/0951192X.2017.1285429
NR 116
TC 0
Z9 0
U1 64
U2 64
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JAN
PY 2020
VL 152
AR UNSP 104512
DI 10.1016/j.resconrec.2019.104512
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JN4KI
UT WOS:000496867700010
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhang, DY
   Cao, YS
   Wang, YJ
   Ding, GY
AF Zhang, Deyuan
   Cao, Yushu
   Wang, Yingjie
   Ding, Guoyu
TI Operational effectiveness of funding for waste electrical and electronic
   equipment disposal in China: An analysis based on game theory
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Extended producer responsibility; WEEE disposal funding; Dual
   dismantling system; Game theory model
ID EXTENDED PRODUCER RESPONSIBILITY; WEEE
AB This paper analyzes the characteristics of waste electrical and electronic equipment (WEEE) market in China and the findings are as follows: WEEE are still seen as valuable goods, and a recovery and recycling system is thus in place naturally in China like in many other developing countries. A game theory model is therefore built here to find out how effective funding is for this recovery and recycling system. Analysis of this model reveals: (1) Some dismantling enterprises (formal dismantling enterprises) are in this funding system, while others (informal ones) are not, thus forming a dual WEEE dismantling system, after the funding system was launched; (2) To ensure effectiveness of the funding system, the funding provided for formal enterprises for each piece of WEEE they handle, after deducting the incremental cost incurred for environmental compliance, must exceed the difference between the unit selling prices of the dismantled devices at formal and informal dismantling enterprises. This difference is RMB 70.2, RMB 67.9, RMB 22.2, RMB 79.4 and RMB 68.3 respectively for televisions, refrigerators, washing machines, air conditioners and computers; (3) When the funding system was launched, WEEE recovery enterprises would raise WEEE prices to seek profit and this would channel part of the funding into the recovery segment of the market.
C1 [Zhang, Deyuan] Beijing Jiaotong Univ, Sch Econ & Management, Beijing 100044, Peoples R China.
   [Zhang, Deyuan] Natl Dev & Reform Commiss, Inst Econ Syst & Management, Beijing 100035, Peoples R China.
   [Cao, Yushu] China Assoc Construct Enterprise Management, Beijing 100038, Peoples R China.
   [Wang, Yingjie] Univ Chinese Acad Sci, Sch Econ & Management, Beijing 100190, Peoples R China.
   [Ding, Guoyu] Beijing Jiaotong Univ, Sch Civil Engn, Beijing 100044, Peoples R China.
   [Ding, Guoyu] Beijing Key Lab Aqueous Typ Pollutants Control &, Beijing 100044, Peoples R China.
RP Ding, GY (reprint author), Beijing Jiaotong Univ, Sch Civil Engn, Beijing 100044, Peoples R China.; Ding, GY (reprint author), Beijing Key Lab Aqueous Typ Pollutants Control &, Beijing 100044, Peoples R China.
EM gyding@bjtu.edu.cn
FU National Solid Waste Resources Science and Technology Fund Support
   Project [2018YFC1902705]
FX This work is supported by National Solid Waste Resources Science and
   Technology Fund Support Project (Grant No. 2018YFC1902705).
CR AEHA (General Consortium Corporation of Household Electrical Appliances Association), 2019, SIM MACH REC BENCHM
   [Anonymous], 2017, CHIN HOM APPL ERS I
   China Resources Recycling Association, 2015, COMP STUD REC SYST W
   Cucchiella F, 2015, RENEW SUST ENERG REV, V51, P263, DOI 10.1016/j.rser.2015.06.010
   Gao Y, 2016, J SYST MANAGE, V4, P726
   [顾一帆 Gu Yifan], 2017, [中国人口·资源与环境, China Population Resources and Environment], V27, P46
   Gu YF, 2017, J CLEAN PROD, V164, P347, DOI 10.1016/j.jclepro.2017.06.168
   Lindhqvist T, 2000, THESIS, P53
   Liu R, 2019, GANSU SCI TECHNOL, V48, P63
   Milovantseva N, 2015, RESOUR CONSERV RECY, V102, P170, DOI 10.1016/j.resconrec.2015.07.027
   Ministry of Ecology and Environment of People's Republic of China, 2019, LIST WEEE DISM ENT
   Parajuly K, 2017, RESOUR CONSERV RECY, V123, P85, DOI 10.1016/j.resconrec.2016.08.004
   Pu Yu, 2012, CONT EC JPN, V1, P69
   Qiao Q, 2009, EXTENDED PRODUCER RE, P32
   Ren M, 2009, SYST ENG, V4, P116
   Shan M, 2016, ECOL ECON, V32, P32
   Tang S, 2009, RES EC MANAG, V9, P118
   Wang JF, 2018, RESOUR CONSERV RECY, V130, P44, DOI 10.1016/j.resconrec.2017.11.016
   [吴怡 WU Yi], 2008, [中国工业经济, China Industrial Economy], P32
   Xu J., 2005, VENTURE CAPITAL HIGH, V11, P48
   Yan H, 2016, CHINA RESOUR COMPR U, V34, P38
   Yla-Mella J, 2014, RESOUR CONSERV RECY, V86, P38, DOI 10.1016/j.resconrec.2014.02.001
   YU MZ, 2019, EC RES J
   Zhao X, 2016, CHEM ENG DES COMMUN, V2, P189
   Zhou H, 2008, RECYCLING WASTE TREA
NR 25
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD JAN
PY 2020
VL 152
AR UNSP 104514
DI 10.1016/j.resconrec.2019.104514
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JN4KI
UT WOS:000496867700011
OA Bronze
DA 2020-05-12
ER

PT J
AU Uchida, D
   Nakatogawa, H
   Yamazoe, T
   Inenaga, C
   Tanaka, T
AF Uchida, Daiki
   Nakatogawa, Hirokazu
   Yamazoe, Tomohiro
   Inenaga, Chikanori
   Tanaka, Tokutaro
TI Neuroendoscopic Surgery with a Combination of Image Detectable Sheath,
   Intraoperative Computed Tomography Scan, and Navigation System Improves
   Accuracy and Safety in Minimally Invasive Evacuation of Intracerebral
   Hematoma: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracerebral hemorrhage; Intraoperative computed tomography scan;
   Minimum invasive surgery; Neuroendoscopic surgery; Stroke
ID ENDOSCOPIC SURGERY; HEMORRHAGE
AB BACKGROUND: Recent studies have confirmed the effectiveness of minimally invasive endoscopic surgery for intracerebral hematoma (ICH). However, improvements are needed because incomplete hematoma removal may offset the surgical benefits of the technique. We describe a technique of neuroendoscopic surgery using an image detectable sheath, intraoperative computed tomography (iCT) scan, and a navigation system.
   METHODS: This is a retrospective study of 15 consecutive patients with spontaneous ICH who received neuroendoscopic surgery. During the surgery, a transparent sheath was fastened tightly to the scalp with 3.0 nylon. The patient's head was covered with a sterilized vinyl sheet and subsequent iCT scan visualized the orientation of the endoscopic sheath and the extent of residual hematoma, allowing the surgeon to decide to continue to remove the hematoma or to finish the treatment.
   RESULTS: The median hematoma evacuation rate was 93% (interquartile range, 82.2%-95.9%). The Glasgow Coma Scale score of all patients significantly improved at 1 week after the operation (P < 0.05). No complications associated with the procedure were observed.
   CONCLUSIONS: The combination of our techniques improves accuracy and safety of minimally invasive surgical evacuation of hematoma. Performing surgery with iCT scan also improves the spatial recognition of surgeons and therefore may be of educational value.
C1 [Uchida, Daiki; Nakatogawa, Hirokazu; Yamazoe, Tomohiro; Inenaga, Chikanori; Tanaka, Tokutaro] Seirei Hamamatsu Gen Hosp, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
RP Uchida, D (reprint author), Seirei Hamamatsu Gen Hosp, Dept Neurosurg, Hamamatsu, Shizuoka, Japan.
EM d-uchida@sis.seirei.or.jp
CR AUER LM, 1989, J NEUROSURG, V70, P530, DOI 10.3171/jns.1989.70.4.0530
   Beynon C, 2015, NEUROSURG REV, V38, P421, DOI 10.1007/s10143-015-0606-6
   Chartrain AG, 2017, BMJ CASE REP, V2017
   Feng Y, 2016, TURK NEUROSURG, V26, P84, DOI 10.5137/1019-5149.JTN.12669-14.0
   Fiorella D, 2015, J NEUROINTERV SURG, V7, P752, DOI 10.1136/neurintsurg-2014-011358
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287
   Huttner HB, 2006, STROKE, V37, P404, DOI 10.1161/01.STR.0000198806.67472.5c
   Ishikawa T, 2019, INTERDISCIP NEUROSUR, V15, P53, DOI 10.1016/j.inat.2018.10.001
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7
   Mendelow AD, 2005, LANCET, V365, P387
   Miller CM, 2008, SURG NEUROL, V69, P441, DOI 10.1016/j.surneu.2007.12.016
   Nishihara T, 2000, J NEUROSURG, V92, P1053, DOI 10.3171/jns.2000.92.6.1053
   Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209
   Sadahiro H, 2015, J NEUROSURG, V123, P1151, DOI 10.3171/2014.11.JNS141508
   Scaggiante J, 2018, STROKE, V49, P2612, DOI 10.1161/STROKEAHA.118.020688
   Spiotta AM, 2015, OPER NEUROSURG, V11, P243, DOI 10.1227/NEU.0000000000000698
   Spiotta AM, 2015, NEUROSURGERY S2, V11, P251
   The Japan Stroke Society, 2015, JAP GUID MAN STROK
   Vespa P, 2016, STROKE, V47, P2749, DOI 10.1161/STROKEAHA.116.013837
   Xu XH, 2018, J NEUROSURG, V128, P553, DOI 10.3171/2016.10.JNS161589
   Xu XH, 2014, STROKE, V45, P3433, DOI 10.1161/STROKEAHA.114.007095
   Yamamoto Takuji, 2018, No Shinkei Geka, V46, P95, DOI 10.11477/mf.1436203684
   Yao Z, 2018, WORLD NEUROSURG, V113, P348, DOI 10.1016/j.wneu.2018.02.022
   Zazulia AR, 1999, STROKE, V30, P1167, DOI 10.1161/01.STR.30.6.1167
   Zhang HZ, 2014, BIOMED RES INT, DOI 10.1155/2014/898762
NR 27
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 1
EP 7
DI 10.1016/j.wneu.2019.09.058
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700158
PM 31541759
OA Bronze
DA 2020-05-12
ER

PT J
AU Oanh, DTH
   Jung, TY
   Kim, SK
   Yang, DH
   Kang, SR
   Lee, KH
AF Duong Thi Hoang Oanh
   Jung, Tae-Young
   Kim, Seul-Kee
   Yang, Deok-Hwan
   Kang, Sae-Ryung
   Lee, Kyung-Hwa
TI Multiple Brain Biopsies for Epstein-Barr Virus-Positive Diffuse Large
   B-Cell Lymphoma with Extensive Necrosis in a Posttransplant Patient
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central nervous system; Epstein-Barr virus; Immunocompromised host;
   Lymphoma; Multiple biopsy; Radiology
ID NERVOUS-SYSTEM LYMPHOMAS
AB BACKGROUND: Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) in an immunocompromised patient with organ transplantation demonstrated unusual brain magnetic resonance imaging (MRI) findings. Recognition of EBV-positive DLBCL by radiologists on MRI may prevent unnecessary neurosurgical resection, and it could be important to obtain viable cells for accurate diagnosis on stereotactic biopsy because of extensive necrosis.
   CASE DESCRIPTION: A 62-year-old woman presented to the emergency department with left hemiparesis grade Ill and dysarthria lasting for 3 weeks. She underwent kidney transplantation in 2007 and was taking immunosuppressants and had hypothyroidism. Brain MRI showed a 3.8-cm peripheral enhancing lesion with extensive central necrosis in association with marked perilesional edema. The irregular ringlike enhancing lesion showed diffusion restriction and mildly increased regional cerebral blood volume in the rim portion of the mass. 11C-Methionine positron emission tomography revealed slightly increased uptake in the peripheral lesion. The provisional diagnosis was a high-grade glioma. Stereotactic multiple biopsies were performed for the central necrotic area and peripheral enhancing lesion. The nonenhancing areas showed only necrotic material, without viable cells, and the enhancing portion showed viable cells for an accurate diagnosis in a frozen biopsy specimen. The pathologic diagnosis was EBV-positive DLBCL with extensive necrosis. Positron emission tomography of the chest, abdomen, pelvis, and neck soft tissues ruled out systemic diseases. She underwent whole-brain radiotherapy at a dose of 30.6 Gy. Eight months later, her neurologic symptoms had improved, with a stable brain lesion and improved perilesional edema.
   CONCLUSIONS: We report an immunocompromised patient with EBV-positive DLBCL, which showed atypical MRI findings, including extensive necrosis. Multiple biopsies were required for final diagnosis.
C1 [Duong Thi Hoang Oanh; Jung, Tae-Young] Chonnam Natl Univ Hosp, Dept Neurosurg, Gwangju, South Korea.
   [Kim, Seul-Kee] Chonnam Natl Univ Hosp, Dept Radiol, Gwangju, South Korea.
   [Yang, Deok-Hwan] Chonnam Natl Univ Hosp, Dept Internal Med, Gwangju, South Korea.
   [Kang, Sae-Ryung] Chonnam Natl Univ Hosp, Dept Nucl Med, Gwangju, South Korea.
   [Lee, Kyung-Hwa] Chonnam Natl Univ Hosp, Dept Pathol, Gwangju, South Korea.
   [Lee, Kyung-Hwa] Chonnam Natl Univ Hwasun & Med Sch, Gwangju, South Korea.
   [Duong Thi Hoang Oanh] Ho Chi Minh City Childrens Hosp, Dept Neurosurg, Ho Chi Minh City, Vietnam.
RP Jung, TY (reprint author), Chonnam Natl Univ Hosp, Dept Neurosurg, Gwangju, South Korea.
EM jung-ty@chonnam.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT, & Future Planning
   [2017R1A1A1A05001020]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF), funded by the Ministry
   of Science, ICT, & Future Planning (2017R1A1A1A05001020).
CR Batchelor TT, 2016, HEMATOL-AM SOC HEMAT, P379, DOI 10.1182/asheducation-2016.1.379
   Castillo JJ, 2011, ONCOLOGIST, V16, P87, DOI 10.1634/theoncologist.2010-0213
   Cheng G, 2019, NEUROL SCI, V40, P535, DOI 10.1007/s10072-018-3669-7
   Chiavazza C, 2018, BIOMED RES INT, DOI 10.1155/2018/3606970
   Chou Arthur P, 2011, Surg Neurol Int, V2, P130, DOI 10.4103/2152-7806.85471
   Crombie JL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00109
   El Jamal S, 2014, BRAIN TUMOR PATHOL, V31, P265, DOI 10.1007/s10014-013-0173-x
   Glesner MK, 2014, BMJ CASE REP, V1, P2014
   Haldorsen IS, 2011, AM J NEURORADIOL, V32, P984, DOI 10.3174/ajnr.A2171
   Hartmann M, 2003, NEUROSCI LETT, V338, P119, DOI 10.1016/S0304-3940(02)01367-8
   Kamble RB, 2015, J CLIN DIAGN RES, V9, pTC1, DOI 10.7860/JCDR/2015/11587.5880
   Lee HY, 2013, AM J NEURORADIOL, V34, P1562, DOI 10.3174/ajnr.A3429
   Low S, 2018, THER ADV NEUROL DISO, V11, DOI 10.1177/1756286418793562
   Phan TG, 2000, NEURO-ONCOLOGY, V2, P229, DOI 10.1093/neuonc/2.4.229
   Royer-Perron L, 2018, PRESSE MED, V47, pE215, DOI 10.1016/j.lpm.2018.04.016
   Sano H, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-582
   Su L, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011072
   Sugita Y, 2016, NEUROPATHOLOGY, V36, P313, DOI 10.1111/neup.12276
   Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015
   Utsuki S, 2011, BRAIN TUMOR PATHOL, V28, P145, DOI 10.1007/s10014-011-0020-x
   Wen JB, 2017, J COMPUT ASSIST TOMO, V41, P904, DOI 10.1097/RCT.0000000000000636
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 10
EP 13
DI 10.1016/j.wneu.2019.09.084
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700160
PM 31550543
OA Bronze
DA 2020-05-12
ER

PT J
AU Huang, M
   Qian, HR
   Wang, JS
   Zhao, QY
   Jiang, TA
AF Huang, Min
   Qian, Hongrong
   Wang, Junsen
   Zhao, Qiyu
   Jiang, Tian'an
TI Giant Presacral Schwannoma in Man: Report of a Case with Emphasis on
   Imaging Findings
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contrast-enhanced ultrasound; Presacral; Schwannoma; Ultrasound
ID ULTRASOUND FEATURES; RESECTION; BENIGN
AB BACKGROUND: Schwannoma is a tumor arising from peripheral nerve and commonly occurs in the head, neck, and upper and lower extremities. Schwannoma in the presacral space is relatively rare and is often misdiagnosed before pathologic diagnosis is made.
   CASE DESCRIPTION: Here we discuss a case of giant presacral schwannoma i 34-year-old man with an emphasis on imaging findings.
   CONCLUSIONS: Solid and encapsulated, round or oval, with rich blood supply may be the characteristic imaging findings of presacral schwannoma, which may narrow the differential diagnosis of hypervascular pelvic lesions.
C1 [Huang, Min; Zhao, Qiyu; Jiang, Tian'an] Zhejiang Univ, Affiliated Hosp 1, Dept Ultrasound, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Qian, Hongrong] Zhejiang Univ, Shengzhou Peoples Hosp, Affiliated Hosp 1, Shengzhou Branch,Dept Ultrasound, Shengzhou, Zhejiang, Peoples R China.
   [Wang, Junsen] Zhejiang Univ, Shengzhou Peoples Hosp, Affiliated Hosp 1, Shengzhou Branch,Dept Pathol, Shengzhou, Zhejiang, Peoples R China.
RP Jiang, TA (reprint author), Zhejiang Univ, Affiliated Hosp 1, Dept Ultrasound, Sch Med, Hangzhou, Zhejiang, Peoples R China.
EM tiananjiang@zju.edu.cn
CR Cantisani V, 2013, J ULTRASOUND, V16, P135, DOI 10.1007/s40477-013-0027-8
   Chan Peter T, 2007, BMC Urol, V7, P1, DOI 10.1186/1471-2490-7-1
   Crino SF, 2016, ENDOSC ULTRASOUND, V5, P396, DOI 10.4103/2303-9027.195873
   Emohare O, 2015, J NEUROSURG-SPINE, V23, P81, DOI 10.3171/2014.11.SPINE14396
   GETACHEW MM, 1994, AM J ROENTGENOL, V163, P1356, DOI 10.2214/ajr.163.6.7992727
   Hoarau N, 2013, Diagn Interv Imaging, V94, P1133, DOI 10.1016/j.diii.2013.06.002
   Imao Tetsuya, 2011, Hinyokika Kiyo, V57, P491
   Kim Eung Re, 2014, Korean J Thorac Cardiovasc Surg, V47, P487, DOI 10.5090/kjtcs.2014.47.5.487
   Klimo Paul Jr, 2003, Neurosurg Focus, V15, pE12
   Lee Byoung Hun, 2017, Korean J Spine, V14, P89, DOI 10.14245/kjs.2017.14.3.89
   Li CS, 2008, CLIN IMAG, V32, P121, DOI 10.1016/j.clinimag.2007.05.006
   Lin CL, 2016, EUR SPINE J, V25, P4103, DOI 10.1007/s00586-016-4782-z
   Mastoraki Aikaterini, 2013, J Gastrointest Cancer, V44, P371, DOI 10.1007/s12029-013-9510-x
   Santiago C, 2008, MIL MED, V173, P814, DOI 10.7205/MILMED.173.8.814
   Schindler Oliver S, 2002, J Orthop Surg (Hong Kong), V10, P77
   WHITE W, 1990, CANCER, V66, P1266, DOI 10.1002/1097-0142(19900915)66:6<1266::AID-CNCR2820660628>3.0.CO;2-E
NR 16
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 14
EP 16
DI 10.1016/j.wneu.2019.09.074
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700161
PM 31557553
OA Bronze
DA 2020-05-12
ER

PT J
AU Zafar, A
   Frygier, A
   Strickland, S
   Turney, R
   Spink, G
AF Zafar, Arif
   Frygier, Andrzej
   Strickland, Samantha
   Turney, Robert
   Spink, George
TI A Rare Case of Spinal Mastocytosis Presenting as an Extradural Mass
SO WORLD NEUROSURGERY
LA English
DT Article
DE Spinal Tumor; Spinal mastocytosis; Vertebral mastocytosis
ID SYSTEMIC MASTOCYTOSIS; BONE INVOLVEMENT
AB BACKGROUND: Systemic mastocytosis is a hematopoietic disorder of mast cell deposits in various systemic tissues that can include skin, spleen, liver, and bone marrow. When accumulation occurs within bone it has been reported to cause osteoporosis, osteosclerosis, or sometimes a mixed pattern. In exceptionally rare circumstances, it has been reported to present as an exophytic mass causing neural compression.
   CASE DESCRIPTION: A 72-year-old man was admitted with progressive worsening in his mobility and heavy and numb sensation in his bilateral lower limbs that worsened on walking. His weakness subsequently progressed such that he was no longer able to mobilize for 48 hours prior to admission. On examination he was found to be myelopathic with a sensory level noted at approximately the T10/11 area. Whole spine magnetic resonance imaging was conducted, which revealed a heterogeneous lesion involving the vertebral body and posterior elements of T10. The patient underwent T9-T11 laminecetomy with intralesional debulking of metastatic spinal column tumor. Postoperatively, the patient was noted to have improved anti-gravity power in the lower limbs. lntraoperative biopsy samples revealed focal paratrabecular infiltrates of abnormal mast cells with collagen fibrosis and focal bone destruction, along with cytogenetic features in keeping with systemic mastocytosis.
   CONCLUSIONS: We describe a rare case of systemic mastocytosis presenting as an extradural lesion causing compressive myelopathy and paraparesis. To our knowledge, this has only been described once before in literature. The patient underwent decompression surgery with improvement in neurology postoperatively. He was subsequently referred to the hematology team for further investigation and management.
C1 [Zafar, Arif; Spink, George] Hull Royal Infirm, Dept Neurosurg, Kingston Upon Hull, N Humberside, England.
   [Frygier, Andrzej] Hull Royal Infirm, Dept Haematol, Kingston Upon Hull, N Humberside, England.
   [Turney, Robert] Hull Royal Infirm, Dept Neuroradiol, Kingston Upon Hull, N Humberside, England.
   [Strickland, Samantha] Hull & York Med Sch, Sch Med, York, N Yorkshire, England.
RP Zafar, A (reprint author), Hull Royal Infirm, Dept Neurosurg, Kingston Upon Hull, N Humberside, England.
EM arifzafar86@gmail.com
CR Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822
   Barete S, 2010, ANN RHEUM DIS, V69, P1838, DOI 10.1136/ard.2009.124511
   Delsignore J L, 1996, Iowa Orthop J, V16, P126
   Haney K, 1996, SKELETAL RADIOL, V25, P171, DOI 10.1007/s002560050056
   Ho LM, 1996, AM J ROENTGENOL, V167, P716, DOI 10.2214/ajr.167.3.8751688
   Johansson C, 1996, AGE AGEING, V25, P1, DOI 10.1093/ageing/25.1.1
   Rossini M, 2014, IMMUNOL ALLERGY CLIN, V34, P383, DOI 10.1016/j.iac.2014.01.011
   TRAVIS WD, 1988, MEDICINE, V67, P345, DOI 10.1097/00005792-198811000-00001
   Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 17
EP 20
DI 10.1016/j.wneu.2019.08.185
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700162
PM 31491575
OA Bronze
DA 2020-05-12
ER

PT J
AU Tao, T
   Dai, W
   Li, W
   Hang, CH
AF Tao, Tao
   Dai, Wei
   Li, Wei
   Hang, Chun-hua
TI Giant Serpentine Distal Anterior Cerebral Artery Aneurysm Treated with
   In Situ Side-to-Side A3-A3 Anastomosis and Aneurysm Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anastomosis; Distal anterior cerebral aneurysm; Giant serpentine
   aneurysm; In situ bypass
ID SURGICAL-TREATMENT; BYPASS; EXPERIENCE
AB BACKGROUND: Giant serpentine aneurysms that occur in the distal anterior cerebral artery are extremely rare and challenging to manage because of their complex structure. In this case, we show an aneurysm resection performed after in situ side-to-side A3-A3 bypass to treat a giant serpentine distal anterior cerebral artery aneurysm.
   CASE DESCRIPTION: Here, we present the case of a 55-year-old man with a giant distal anterior cerebral artery serpentine aneurysm who presented with severe headache and progressive unconsciousness. Computed tomography and cerebral angiography revealed a giant serpentine aneurysm in the right A2 segment. Both the right pericallosal and callosal marginal arteries branched from the outflow tract. To relieve the mass effect and preserve distal blood flow, an in situ side-to-side A3-A3 anastomosis and a partial aneurysm resection were performed sequentially. Postoperative cerebral angiography revealed no aneurysm blood filling and good perfusion in both anterior cerebral artery territories.
   CONCLUSIONS: Anterior cerebral artery giant serpentine aneurysms are rare usually present with headache and mass effect. Aneurysm resection and distal flow protection are issues that we must consider. The sequential procedure of anastomosis and aneurysm resection is a feasible and safe option.
C1 [Tao, Tao; Dai, Wei; Li, Wei; Hang, Chun-hua] Nanjing Med Univ, Dept Neurosurg, Nanjing Drum Tower Hosp, Clin Coll, Nanjing, Jiangsu, Peoples R China.
RP Hang, CH (reprint author), Nanjing Med Univ, Dept Neurosurg, Nanjing Drum Tower Hosp, Clin Coll, Nanjing, Jiangsu, Peoples R China.
EM hang_neurosurgery@163.com
FU National Natural Science Foundation, ChinaNational Natural Science
   Foundation of China [81870922, 81771291]; Medical Science and Technology
   Development Foundation, Nanjing Department of Health [JQX18001];
   Fundamental Research Funds for the Central Universities,
   ChinaFundamental Research Funds for the Central Universities
   [021414380361]
FX This work was supported by National Natural Science Foundation, China
   (81870922, 81771291); Medical Science and Technology Development
   Foundation, Nanjing Department of Health (JQX18001); and the Fundamental
   Research Funds for the Central Universities, China (021414380361).
CR Abla AA, 2014, J NEUROSURG, V120, P1364, DOI 10.3171/2014.3.JNS132219
   Christiano LD, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0918
   Dunn GP, 2011, NEUROSURGERY, V68, pE587, DOI 10.1227/NEU.0b013e3182036012
   Fanning NF, 2003, BRIT J NEUROSURG, V17, P67, DOI 10.1080/026889031000093780
   ITO Z, 1981, Neurologia Medico-Chirurgica, V21, P931
   Kandemirli SG, 2018, AM J NEURORADIOL, V39, P1662, DOI 10.3174/ajnr.A5746
   Kim Sung Tae, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P141, DOI 10.7461/jcen.2016.18.2.141
   KUMABE T, 1990, NEUROSURGERY, V26, P1027, DOI 10.1227/00006123-199006000-00018
   Lee SH, 2018, WORLD NEUROSURG, V111, pE507, DOI [10.1016/J.WNEU.2017.12.115, 10.1016/j.wneu.2017.12.115]
   Moon HS, 2012, J KOREAN NEUROSURG S, V52, P501, DOI 10.3340/jkns.2012.52.5.501
   SEGAL HD, 1977, J NEUROSURG, V46, P115, DOI 10.3171/jns.1977.46.1.0115
   Sia SF, 2011, NEUROSURGERY, V69, P308, DOI 10.1227/NEU.0b013e318214b300
   SUZUKI S, 1992, ACTA NEUROCHIR, V117, P23, DOI 10.1007/BF01400630
   van Rooij WJ, 2008, AM J NEURORADIOL, V29, P1418, DOI 10.3174/ajnr.A1071
NR 14
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 21
EP 24
DI 10.1016/j.wneu.2019.09.052
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700163
PM 31526883
OA Bronze
DA 2020-05-12
ER

PT J
AU Mull, M
   Schubert, GA
   Obersheimer, J
   Jablawi, F
AF Mull, Michael
   Schubert, Gerrit Alexander
   Obersheimer, Jens
   Jablawi, Fidaa
TI Unique Angioarchitecture of Sacral Dural Arteriovenous Fistula
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterial supply; Sacral fistula; Spinal dural arteriovenous fistula;
   Spinal MRA
AB BACKGROUND: Spinal dural arteriovenous fistulas (DAVFs) in the sacral region are extremely rare. The location and complex angioarchitecture of these lesions make both identification and treatment challenging, even in experienced hands. We report on a sacral DAVF with a unique angioarchitecture and discuss its specific anatomy.
   CASE DESCRIPTION: A 76-year-old male presented with progressive distal paraparesis and spinal ataxia. Three lumbar decompression surgeries were performed between 2016 and 2018 elsewhere on the basis of suspected degenerative lumbar syndrome. On admission to our center, the patient was wheelchair dependent due to extensive spinal ataxia associated with bilateral foot paresis and hypoesthesia. Spinal contrast-enhanced time-resolved magnetic resonance angiography and digital subtraction angiography were performed after admission to our center.
   CONCLUSIONS: Sacral DAVFs present serious diagnostic difficulties and require a profound understanding of possible fistula-supplying arteries of the sacral region. Microsurgical interruption of the often ventrally located drainage vein presents an efficient treatment modality and could provide an immediate confirmation of fistula occlusion using indocyanine green videoangiography.
C1 [Mull, Michael] RWTH Aachen Univ Hosp, Dept Diagnost & Intervent Neuroradiol, Aachen, Germany.
   [Schubert, Gerrit Alexander] RWTH Aachen Univ Hosp, Dept Neurosurg, Aachen, Germany.
   [Jablawi, Fidaa] Justus Liebig Univ, Dept Neurosurg, Giessen, Germany.
   [Obersheimer, Jens] Klinikum Fulda, Dept Neuroradiol, Hesse, Germany.
RP Mull, M (reprint author), RWTH Aachen Univ Hosp, Dept Diagnost & Intervent Neuroradiol, Aachen, Germany.
EM mmull@ukaachen.de
OI Jablawi, Fidaa/0000-0001-5620-0384
CR Jablawi F, 2018, AM J NEURORADIOL, V39, P392, DOI 10.3174/ajnr.A5497
   Jablawi F, 2017, WORLD NEUROSURG, V103, P360, DOI 10.1016/j.wneu.2017.04.050
   Jellema K, 2003, J NEUROL NEUROSUR PS, V74, P1438, DOI 10.1136/jnnp.74.10.1438
   Mull M, 2007, AM J NEURORADIOL, V28, P1249, DOI 10.3174/ajnr.A0612
   Mull M, 2018, AM J NEURORADIOL, V39, P2095, DOI 10.3174/ajnr.A5854
   Schaat TJ, 2002, SPINE, V27, P893
   Thron A, 2015, CLIN NEURORADIOL, V25, P361, DOI 10.1007/s00062-015-0476-x
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 25
EP 28
DI 10.1016/j.wneu.2019.09.078
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700164
PM 31550539
OA Bronze
DA 2020-05-12
ER

PT J
AU Niu, XD
   Lin, J
   Liu, H
   Ren, YM
   Li, J
AF Niu, Xiaodong
   Lin, Jun
   Liu, Hao
   Ren, Yanming
   Li, Jin
TI Rare Spinal Dural Arteriovenous Fistula with Double Draining Veins: 1
   Draining Vein Mimicking Artery of Adamkiewicz: Case Report and Review of
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Artery of Adamkiewicz; Draining veins; Spinal dural arteriovenous
   fistula; Surgery
ID MALFORMATIONS; FEATURES; ORIGIN
AB BACKGROUND: Spinal dural arteriovenous fistula (DAVF) typically has a single intradural drainage vein, abnormally connecting with the radiculomeningeal artery at the dura root sleeve. Multiple intradural draining veins are extremely rare. To date, only 1 case of spinal DAVF with multiple draining veins has been reported.
   CASE DESCRIPTION: A 62-year-old woman presented with a 2-year history of progressive weakness and numbness in her lower extremities. Spinal magnetic resonance imaging showed extensive edema of the cord and prominent vascular flow voids. Spinal angiography demonstrated a right L3 DAVF with supply from the left L3 lumbar artery. The feeding artery was also thought to give rise to the artery of Adamkiewicz. The spinal DAVF was surgically treated, and the artery of Adamkiewicz was retained. Her postoperative symptoms gradually improved. Eight months after the surgery, her symptoms gradually worsened. Repeat spinal angiography revealed a right L3 DAVF at the same location of the first fistula. In retrospect, the draining vein identified on the second angiography was mistakenly considered as the artery of Adamkiewicz at the first angiography. Therefore the initial fistula was drained through double draining veins, 1 of them mimicking the artery of Adamkiewicz. The fistula was coagulated and divided. Postoperatively, the patient's symptoms gradually improved. Three months after the second surgery, she was able to walk independently.
   CONCLUSIONS: Spinal DAVF is a rare disease, but clinicians should be cautious of possible multiple drainage veins in diagnosis and treatment.
C1 [Niu, Xiaodong; Liu, Hao; Ren, Yanming; Li, Jin] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Lin, Jun] Sichuan Univ, Dept Anesthesia & Operat Room, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Li, J (reprint author), Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM lijinwestchina@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571131]
FX This study was supported by National Natural Science Foundation of China
   (81571131)
CR Adrianto Y, 2017, J NEUROINTERV SURG, V9, P405, DOI 10.1136/neurintsurg-2016-012267
   AMINOFF MJ, 1974, J NEUROL SCI, V23, P255, DOI 10.1016/0022-510X(74)90229-9
   AMINOFF MJ, 1974, BRAIN, V97, P211, DOI 10.1093/brain/97.1.211
   BENHAIEM N, 1983, ACTA NEUROPATHOL, V62, P103, DOI 10.1007/BF00684926
   DOPPMAN JL, 1985, RADIOLOGY, V154, P687, DOI 10.1148/radiology.154.3.3969471
   Endo T, 2018, WORLD NEUROSURG, V110, pE383, DOI 10.1016/j.wneu.2017.11.002
   Fugate JE, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11376
   Hadzipasic M, 2017, WORLD NEUROSURG, V97, DOI 10.1016/j.wneu.2016.10.102
   Jellema K, 2006, BRAIN, V129, P3150, DOI 10.1093/brain/awl220
   Jellema K, 2003, J NEUROL NEUROSUR PS, V74, P1438, DOI 10.1136/jnnp.74.10.1438
   Jeng Y, 2015, KOREAN J RADIOL, V16, P1119, DOI 10.3348/kjr.2015.16.5.1119
   McCutcheon IE, 1996, J NEUROSURG, V84, P215, DOI 10.3171/jns.1996.84.2.0215
   OLDFIELD EH, 1983, J NEUROSURG, V59, P1019, DOI 10.3171/jns.1983.59.6.1019
   Ren YM, 2019, WORLD NEUROSURG, V126, P164, DOI 10.1016/j.wneu.2019.02.129
   ROSENBLUM B, 1987, J NEUROSURG, V67, P795, DOI 10.3171/jns.1987.67.6.0795
   Safaee MM, 2018, J NEUROSURG-SPINE, V29, P85, DOI 10.3171/2017.11.SPINE17988
   Sanborn Matthew R, 2014, Neurosurgery, V61 Suppl 1, P6, DOI 10.1227/NEU.0000000000000386
   Symon L, 1984, J NEUROSURG, V60, P247
   van Dijk JMC, 2002, STROKE, V33, P1578, DOI 10.1161/01.STR.0000018009.83713.06
   Zhang SF, 2018, WORLD NEUROSURG, V118, P53, DOI 10.1016/j.wneu.2018.06.233
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 29
EP 33
DI 10.1016/j.wneu.2019.09.050
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700165
PM 31526887
OA Bronze
DA 2020-05-12
ER

PT J
AU Whiting, AC
   Catapano, JS
   Zavala, B
   Walker, CT
   Godzik, J
   Chen, T
   Smith, KA
AF Whiting, Alexander C.
   Catapano, Joshua S.
   Zavala, Baltazar
   Walker, Corey T.
   Godzik, Jakub
   Chen, Tsinsue
   Smith, Kris A.
TI Doing More with Less: A Minimally Invasive, Cost-Conscious Approach to
   Stereoelectroencephalography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epilepsy; Functional neurosurgery; SEEG; Stereoelectroencephalography
ID DEPTH ELECTRODES; SURGERY; SEEG; SAFE
AB BACKGROUND: Stereoelectroencephalography (SEEG) is a commonly used technique for mapping the epileptogenic zone before epilepsy surgery. Many SEEG depth electrode implantation techniques involve the use of extensive technological equipment and shaving of the patient's entire head before electrode implantation. Our goal was to evaluate an SEEG depth electrode implantation technique that used readily available cost-effective neurosurgical equipment, was minimally invasive in nature, and required negligible hair shaving.
   METHODS: Data on demographic characteristics, operative time, hemorrhagic complications, implantation complications, infection, morbidity, and mortality among patients who underwent this procedure were reviewed retrospectively.
   RESULTS: Between April 2016 and March 2018, 23 patients underwent implantation of 213 depth electrodes with use of this technique. Mean (SD) operative time was 123 (32) minutes (range, 66-181 minutes). A mean (SD) of 9.3 (1.4) electrodes were placed for each patient (range, 8-13 electrodes). Two of the 213 electrodes (0.9%) were associated with postimplantation asymptomatic hemorrhage. One of the 213 electrodes (0.5%) was placed extradurally or incorrectly. None of the 213 electrodes was associated with symptomatic complications. No patients experienced infectious complications at any point in the preoperative, perioperative, or postoperative stages.
   CONCLUSIONS: This minimally invasive, cost-effective technique for SEEG depth electrode implantation is a safe, efficient method that uses readily available basic neurosurgical equipment. This technique may be useful in neurosurgery centers with more limited resources. This study suggests that leaving the patient's hair largely intact throughout the procedure does not pose an additional infection risk.
C1 [Whiting, Alexander C.; Catapano, Joshua S.; Zavala, Baltazar; Walker, Corey T.; Godzik, Jakub; Chen, Tsinsue; Smith, Kris A.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Smith, KA (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
OI Whiting, Alexander/0000-0002-4585-5219
CR Abel TJ, 2018, J NEUROSURG-PEDIATR, V22, P37, DOI 10.3171/2018.1.PEDS17435
   Abou-Al-Shaar H, 2018, J CLIN NEUROSCI, V53, P132, DOI 10.1016/j.jocn.2018.04.064
   Balanescu B, 2014, STEREOT FUNCT NEUROS, V92, P117, DOI 10.1159/000360226
   BANCAUD J, 1970, ELECTROEN CLIN NEURO, V28, P85
   Broekman MLD, 2011, J NEUROSURG, V115, P670, DOI 10.3171/2011.5.JNS102003
   Dewan MC, 2018, J NEUROSURG, V129, P1173, DOI 10.3171/2017.6.JNS17881
   Dorfer C, 2014, NEUROSURGERY, V10, P590
   Dorfer C, 2017, J NEUROSURG, V126, P1622, DOI 10.3171/2016.5.JNS16388
   Dorfer C, 2014, OPER NEUROSURG, V10, P582, DOI 10.1227/NEU.0000000000000509
   Enatsu R, 2016, NEUROL MED-CHIR, V56, P221, DOI 10.2176/nmc.ra.2015-0319
   Engel J, 1993, SURG TREATMENT EPILE
   Garcia-Lorenzo B, 2019, NEUROSURGERY, V84, P326, DOI 10.1093/neuros/nyy261
   Gonzalez-Martinez J, 2016, NEUROSURGERY, V78, P169, DOI 10.1227/NEU.0000000000001034
   Gonzalez-Martinez J, 2014, J NEUROSURG, V120, P639, DOI 10.3171/2013.11.JNS13635
   Ho AL, 2018, J NEUROSURG-PEDIATR, V22, P489, DOI 10.3171/2018.5.PEDS17718
   Horgan MA, 1999, SKULL BASE SURG, V9, P253, DOI 10.1055/s-2008-1058134
   Isnard J, 2018, NEUROPHYSIOL CLIN, V48, P5, DOI 10.1016/j.neucli.2017.11.005
   Mullin JP, 2016, EPILEPSIA, V57, P386, DOI 10.1111/epi.13298
   Narvaez-Martinez Y, 2016, NEUROCIRUGIA, V27, P277, DOI 10.1016/j.neucir.2016.05.002
   Nowell M, 2014, NEUROSURGERY S4, V10, P533
   Nowell M, 2014, OPER NEUROSURG, V10, P525, DOI 10.1227/NEU.0000000000000544
   Podkorytova I, 2016, NEUROSURG CLIN N AM, V27, P97, DOI 10.1016/j.nec.2015.08.008
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   Yu H, 2018, WORLD NEUROSURG, V109, P82, DOI 10.1016/j.wneu.2017.09.089
NR 24
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 34
EP 40
DI 10.1016/j.wneu.2019.09.055
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700166
PM 31541761
OA Bronze
DA 2020-05-12
ER

PT J
AU Ferreira-Pinto, PHC
   Nigri, F
   Caparelli-Daquer, EM
   do Souto, AAD
   Christiani, MDC
AF Ferreira-Pinto, Pedro H. C.
   Nigri, Flavio
   Caparelli-Daquer, Egas M.
   Dutra do Souto, Antonio Aversa
   Chaves Christiani, Marcio de Miranda
TI Measurement of Active Motor Threshold Using a Dynamometer During
   Navigated Transcranial Magnetic Stimulation in a Patient with
   Postoperative Brain Tumor: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Active motor threshold; Brain tumor; Dynamometer; Navigated transcranial
   magnetic stimulation
ID EXCITABILITY; IMPROVES; MAGNETOENCEPHALOGRAPHY; SURGERY; TMS
AB BACKGROUND: Navigated transcranial magnetic stimulation (nTMS) is being used for different purposes in patients with brain tumors. However, the procedure requires a positive electrophysiological response. For patients with negative response in rest conditions, active motor threshold (AMT) may be used. However, sometimes it is difficult to obtain AMT measures owing to inability of the patient to sustain steady muscle contraction. Herein, we describe a simple method by using a hand dynamometer to obtain AMT measures during nTMS session.
   CASE DESCRIPTION: A woman aged 68 years underwent total removal of a right frontal lobe oligodendroglioma World Health Organization grade II 15 years ago. Cranial magnetic resonance imaging during follow-up revealed local recurrence. In the postoperative period, she developed left upper limb paresis. A postoperative nTMS session was performed for motor electrophysiological evaluation. However, using the standard technique for AMT measurement, the patient was unable to perform sustained muscle contraction as required. A hand dynamometer was used. It allowed sustained muscle contraction for AMT measurement. A counter force for the index finger flexion, the hand support to stabilize hand joints, and a numerical screen serving for both the examiner and the patient as a feedback parameter may explain the success obtained with this simple device.
   CONCLUSIONS: Although more studies are necessary to validate the method, the hand dynamometer should be considered for patients unable to sustain muscle contraction during AMT measurement.
C1 [Ferreira-Pinto, Pedro H. C.; Nigri, Flavio] Univ Estado Rio De Janeiro, Pedro Ernesto Univ Hosp, Dept Surg Specialties, Div Neurosurg, Rio De Janeiro, RJ, Brazil.
   [Caparelli-Daquer, Egas M.] Univ Estado Rio De Janeiro, Roberto Alcantara Gomes Biol Inst, Dept Physiol Sci, Rio De Janeiro, RJ, Brazil.
   [Ferreira-Pinto, Pedro H. C.; Nigri, Flavio; Caparelli-Daquer, Egas M.] Univ Estado Rio De Janeiro, Pedro Ernesto Univ Hosp, Dept Surg Specialties, LabEEL Lab Estimulacao Eletr Sistema Nervoso,Div, Rio De Janeiro, Brazil.
   [Dutra do Souto, Antonio Aversa; Chaves Christiani, Marcio de Miranda] Natl Canc Inst, Rio De Janeiro, RJ, Brazil.
RP Ferreira-Pinto, PHC (reprint author), Univ Estado Rio De Janeiro, Pedro Ernesto Univ Hosp, Dept Surg Specialties, Div Neurosurg, Rio De Janeiro, RJ, Brazil.; Ferreira-Pinto, PHC (reprint author), Univ Estado Rio De Janeiro, Pedro Ernesto Univ Hosp, Dept Surg Specialties, LabEEL Lab Estimulacao Eletr Sistema Nervoso,Div, Rio De Janeiro, Brazil.
EM pedrohcfp@gmail.com
OI Caparelli-Daquer, Egas/0000-0002-5026-7665
FU Rio de Janeiro State Research Support Foundation - Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
FX The authors received financial support from Rio de Janeiro State
   Research Support Foundation - Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro (FAPERJ) and Center of High Complexity Neurosurgery
   Intern Patients - Nucleo de Internacao de Pacientes Neurocirurgicos de
   Alta Complexidade (NIPNAC).
CR Baillet S, 2017, NAT NEUROSCI, V20, P327, DOI 10.1038/nn.4504
   Bartek J, 2019, OPER NEUROSURG, V17, pE124, DOI 10.1093/ons/opy321
   Butenschon VM, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.3.FOCUS1830
   Duffau H, 2013, ACTA NEUROCHIR, V155, P951, DOI 10.1007/s00701-013-1653-9
   Frey D, 2014, NEURO-ONCOLOGY, V16, P1365, DOI 10.1093/neuonc/nou110
   Hassanlouei H, 2017, J APPL PHYSIOL, V123, P364, DOI 10.1152/japplphysiol.01078.2016
   Hou BL, 2006, NEUROIMAGE, V32, P489, DOI 10.1016/j.neuroimage.2006.04.188
   Jung J, 2019, WORLD NEUROSURG, V122, pE1578, DOI 10.1016/j.wneu.2018.11.114
   Krieg SM, 2017, ACTA NEUROCHIR, V159, P1187, DOI 10.1007/s00701-017-3187-z
   Krieg SM, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00261
   Krieg SM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1258-1
   Krieg SM, 2014, NEURO-ONCOLOGY, V16, P1274, DOI 10.1093/neuonc/nou007
   Krieg SM, 2012, J NEUROSURG, V116, P994, DOI 10.3171/2011.12.JNS111524
   Krings T, 2001, MINIM INVAS NEUROSUR, V44, P234, DOI 10.1055/s-2001-19935
   Krings T, 2001, J NEUROL NEUROSUR PS, V70, P749, DOI 10.1136/jnnp.70.6.749
   Lauderdale K, 2015, ASN NEURO, V7, DOI 10.1177/1759091415605115
   Lebon F, 2012, EUR J NEUROSCI, V35, P323, DOI 10.1111/j.1460-9568.2011.07938.x
   Magill ST, 2018, J NEUROSURG, V129, P961, DOI 10.3171/2017.5.JNS163045
   Muller V, 2002, EUR J NEUROSCI, V15, P528, DOI 10.1046/j.0953-816x.2001.01886.x
   Ngomo S, 2012, J NEUROSCI METH, V205, P65, DOI 10.1016/j.jneumeth.2011.12.012
   Picht T, 2016, J NEURO-ONCOL, V126, P535, DOI 10.1007/s11060-015-1993-9
   Picht T, 2012, NEUROSURGERY, V70, P1248, DOI 10.1227/NEU.0b013e318243881e
   Picht T, 2009, NEUROSURGERY, V65, P93, DOI 10.1227/01.NEU.0000348009.22750.59
   Raffa G, 2019, CLIN NEUROL NEUROSUR, V180, P7, DOI 10.1016/j.clineuro.2019.03.003
   Raffa G, 2018, NEUROSURGERY, V83, P768, DOI 10.1093/neuros/nyx554
   Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001
   Rozand V, 2019, J NEUROPHYSIOL, V122, P241, DOI 10.1152/jn.00077.2019
   Sacko O, 2011, NEUROSURGERY, V68, P1192, DOI 10.1227/NEU.0b013e31820c02a3
   Seidel K, 2019, CLIN NEUROPHYSIOL, V130, P952, DOI 10.1016/j.clinph.2019.03.015
   Sollmann N, 2018, J NEUROSURG, V128, P800, DOI 10.3171/2016.11.JNS162322
   Sollmann N, 2017, BMC NEUROSCI, V18, DOI 10.1186/s12868-016-0321-4
   Sollmann N, 2017, BRAIN TOPOGR, V30, P98, DOI 10.1007/s10548-016-0536-9
   Takakura T, 2017, J NEUROSURG, V127, P877, DOI 10.3171/2016.8.JNS16442
   Tarapore PE, 2012, J NEUROSURG, V117, P354, DOI 10.3171/2012.5.JNS112124
   Temesi J, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-40
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 42
EP 48
DI 10.1016/j.wneu.2019.09.080
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700167
PM 31550542
OA Bronze
DA 2020-05-12
ER

PT J
AU Neeley, OJ
   Al-Hreish, KM
   Aoun, SG
   El Ahmadieh, TY
   Plitt, A
   Vance, AZ
   Jaso, JM
   Hatanpaa, KJ
   White, JA
AF Neeley, Om J.
   Al-Hreish, Khaled Mohammad
   Aoun, Salah G.
   El Ahmadieh, Tarek Y.
   Plitt, Aaron
   Vance, Awais Z.
   Jaso, Jesse Manuel
   Hatanpaa, Kimmo J.
   White, Jonathan A.
TI Tumoral Mimics of Subdural Hematomas: Case Report and Review of
   Diagnostic and Management Strategies in Primary B-Cell Lymphoma of the
   Subdural Space
SO WORLD NEUROSURGERY
LA English
DT Review
DE B-cell lymphoma; CNS lymphoma; Lymphoma; Marginal zone; Subdural
   hematoma mimic; Subdural space
ID DURAL LYMPHOMA; TISSUE
AB BACKGROUND: Subdural lymphomas are a rare subtype of primary central nervous system lymphomas that can radiographically mimic epidural blood and pose a diagnostic challenge. They can complicate treatment if not preemptively identified.
   METHODS: We present a case report of a subdural lymphoma that mimicked a compressive subdural hematoma, and we review the PubMed database for similar cases.
   RESULTS: A 77-year-old woman presented with a transient left facial droop and what appeared to be a subdural hematoma on computed tomography scan. The patient underwent surgery, during which grossly abnormal solid epicortical adherent tissue was noted instead of the expected appearance of a subdural hematoma. An intraoperative biopsy was suggestive of lymphoma, and the surgery was converted to a craniectomy. Pathology confirmed the diagnosis of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The patient underwent radiotherapy with no complications or recurrence. Magnetic resonance imaging demonstrated complete resolution of the mass at 3 months after treatment, at which time the patient underwent a synthetic cranioplasty. Seven case reports of primary dural lymphomas mimicking subdural blood were found, with variable pathologic subclassifications.
   CONCLUSIONS: Although rare, a primary dural lymphoma can be mistaken for a subdural hematoma on computed tomography scan. The most common subtype is low-grade extranodal marginal zone lymphomas. It is important to keep these diseases in the differential diagnosis, especially when there is incongruence between imaging and the clinical picture, as earlier detection correlates to a stronger therapeutic response.
C1 [Neeley, Om J.; Al-Hreish, Khaled Mohammad; Aoun, Salah G.; El Ahmadieh, Tarek Y.; Plitt, Aaron; Vance, Awais Z.; White, Jonathan A.] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA.
   [Jaso, Jesse Manuel; Hatanpaa, Kimmo J.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
RP Aoun, SG (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA.
EM salahaoun@hotmail.com
OI Plitt, Aaron/0000-0002-3933-7183; Vance, Awais/0000-0001-8815-3965
CR Ayanambakkam A, 2018, CL LYMPH MYELOM LEUK, V18, P34, DOI 10.1016/j.clml.2017.09.012
   Azevedo Roberta, 2015, Br J Haematol, V169, P156, DOI 10.1111/bjh.13290
   de la Fuente MI, 2017, LEUKEMIA LYMPHOMA, V58, P882, DOI 10.1080/10428194.2016.1218006
   Ferguson SD, 2010, J CLIN NEUROSCI, V17, P666, DOI 10.1016/j.jocn.2009.10.001
   Gocmen S, 2010, J CLIN NEUROSCI, V17, P380, DOI 10.1016/j.jocn.2009.02.014
   Goetz P, 2002, J NEUROSURG, V96, P611, DOI 10.3171/jns.2002.96.3.0611
   Hoskin PJ, 2014, LANCET ONCOL, V15, P457, DOI 10.1016/S1470-2045(14)70036-1
   Low YYS, 2014, SINGAP MED J, V55, pE187, DOI 10.11622/smedj.2014168
   Mathon B, 2013, NEUROLOGY, V81, pE128, DOI 10.1212/WNL.0b013e3182a956d0
   Ozikul-Wermester O, 2014, JAMA NEUROL, V71, P916, DOI 10.1001/jamaneurol.2013.6013
   Ramnarayan R, 2013, J Neurosci Rural Pract, V4, P216, DOI 10.4103/0976-3147.112774
NR 11
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 49
EP 54
DI 10.1016/j.wneu.2019.09.091
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700168
PM 31562973
OA Bronze
DA 2020-05-12
ER

PT J
AU Li, YC
   Chen, SH
   Sheinberg, D
   Buttrick, S
   Levine, CG
   Bhatia, RG
   Lam, BL
   Pasol, J
   Ayala, AR
   Starke, RM
AF Li, Yangchun
   Chen, Stephanie H.
   Sheinberg, Dallas
   Buttrick, Simon
   Levine, Corinna G.
   Bhatia, Rita G.
   Lam, Byron L.
   Pasol, Joshua
   Ayala, Alejandro R.
   Starke, Robert M.
TI Imaging Characteristics of a Hypervascular Pituitary Spindle Cell
   Oncocytoma on Magnetic Resonance Imaging and Digital Subtraction
   Angiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiography; Hypervascular; Imaging; MRI; Pituitary tumor; Spindle cell
   oncocytoma
ID ADENOHYPOPHYSIS
AB BACKGROUND: Spindle cell oncocytomas (SCOs) are rare neuroendocrine tumors of the posterior pituitary that are often misdiagnosed as nonfunctional pituitary tumors. Fewer than 50 cases of SCOs have been described in the literature, and many of these reports have documented the tumors to be hypervascular on imaging or histology.
   CASE DESCRIPTION: We present the first cerebral angiography imaging findings of an SCO before primary resection. The discovery of a prominent tumor blush, enlarged meningohypophyseal feeders bilaterally, and prominent tumor draining veins aided in preoperative planning and subsequent successful endoscopic transsphenoidal surgical resection.
   CONCLUSIONS: Despite being a rare entity, SCOs should be included in the differential diagnosis when working up a hypervascular sellar tumor. Flow voids may be present on initial magnetic resonance imaging evaluation. Subsequent digital subtraction angiography can be used to further investigate abnormal vasculature and aid in surgical planning.
C1 [Li, Yangchun; Chen, Stephanie H.; Sheinberg, Dallas; Buttrick, Simon; Starke, Robert M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Levine, Corinna G.] Univ Miami, Dept Otolaryngol, Miller Sch Med, Miami, FL 33136 USA.
   [Bhatia, Rita G.] Univ Miami, Dept Radiol, Miller Sch Med, Miami, FL 33136 USA.
   [Lam, Byron L.; Pasol, Joshua] Univ Miami, Dept Ophthalmol, Miller Sch Med, Miami, FL 33136 USA.
   [Ayala, Alejandro R.] Univ Miami, Dept Endocrinol, Miller Sch Med, Miami, FL 33136 USA.
RP Li, YC (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM yxl1845@miami.edu
OI Sheinberg, Dallas/0000-0002-1480-9500
CR Billeci D, 2017, J CLIN NEUROSCI, V39, P39, DOI 10.1016/j.jocn.2017.02.017
   Fujisawa H, 2012, NEUROL MED-CHIR, V52, P594, DOI 10.2176/nmc.52.594
   Hasiloglu ZI, 2016, CLIN RADIOL, V71, DOI 10.1016/j.crad.2016.04.022
   Kleinschmidt-DeMasters BK, 2013, BRAIN PATHOL, V23, P495, DOI 10.1111/bpa.12068
   Krokker L, 2019, NEUROCHEM RES, P1
   Larsen AMG, 2019, J NEUROSURG, V131, P517, DOI 10.3171/2018.4.JNS18211
   Lloyd RV, 2017, WHO CLASSIFICATION T
   Manoranjan B, 2017, J CLIN NEUROSCI, V43, P134, DOI 10.1016/j.jocn.2017.05.017
   Mete O, 2013, AM J SURG PATHOL, V37, P1694, DOI 10.1097/PAS.0b013e31829723e7
   Osman M, 2017, AM J CASE REP, V18, DOI 10.12659/AJCR.903702
   Roncaroli F, 2002, AM J SURG PATHOL, V26, P1048, DOI 10.1097/00000478-200208000-00010
   Shibuya M, 2018, BRAIN TUMOR PATHOL, V35, P62, DOI 10.1007/s10014-018-0311-6
   Vuong HG, 2016, PATHOL RES PRACT, V212, P222, DOI 10.1016/j.prp.2015.07.014
   Wolie SQ, 2008, NEUROSURGERY, V63, P173, DOI 10.1227/01.NEU.0000319520.30043.27
   Yoshida K, 2018, WORLD NEUROSURG, V119, P201, DOI 10.1016/j.wneu.2018.07.245
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 56
EP 59
DI 10.1016/j.wneu.2019.09.108
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700170
PM 31568904
OA Bronze
DA 2020-05-12
ER

PT J
AU Nonaka, Y
   Hayashi, N
   Matsumae, M
   Fukushima, T
AF Nonaka, Yoichi
   Hayashi, Naokazu
   Matsumae, Mitsunori
   Fukushima, Takanori
TI Micropatties Are Indispensable Instruments for Successful
   Microneurosurgery: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clean operative field; Micropatty; Microsurgical procedure;
   Neurovascular protective surgery
ID PRESERVING NORMAL ANATOMY; NEUROSURGICAL PATTIES
AB BACKGROUND: Neurosurgical micropatties (also as sponges or cottonoids) have been used in microsurgical procedures to protect the brain surface and aspirate cerebrospinal fluid and blood. We sought to describe unique applications of micropatties in neurosurgical interventions.
   METHODS: Various sizes of micropatties have been used neurosurgical interventions including tumor, vascular, and skull base surgeries to enhance safe surgical procedures and clear the operative field. Their roles are divided into 3 types: tissue protectors, instrument assistants, and instruments in the microsurgical procedures.
   RESULTS: Appropriate use of micropatties provides a well-visualized operative field, easy identification of bleeding spots, effective tumor elevation from the cleavage layer, and precise procedures around critical structures.
   CONCLUSIONS: To achieve safe and successful neurovescular protective surgery, micropatties play an important role in any type of microsurgical procedure in their various applications.
C1 [Nonaka, Yoichi; Hayashi, Naokazu; Matsumae, Mitsunori] Tokai Univ, Dept Neurosurg, Sch Med, Isehara, Kanagawa, Japan.
   [Fukushima, Takanori] Duke Univ, Med Ctr, Div Neurosurg, Durham, NC 27710 USA.
   [Fukushima, Takanori] Carolina Neurosci Inst, Raleigh, NC USA.
RP Nonaka, Y (reprint author), Tokai Univ, Dept Neurosurg, Sch Med, Isehara, Kanagawa, Japan.
EM ynonaka1971@yahoo.co.jp
OI NONAKA, YOICHI/0000-0001-5509-6175
CR Bellis CJ, 1942, ANN SURG, V116, P318
   Choque Velasquez J, 2016, J NEUROSURG SCI, V60, P44
   Fukushima T, 2010, FUKUSHIMA MANUAL SKU, P210
   Hernesniemi J, 2005, SURG NEUROL, V64, P195, DOI 10.1016/j.surneu.2005.04.031
   Kinoshita M, 2015, J NEUROSURG, V122, P1180, DOI 10.3171/2014.9.JNS14347
   Menovsky T, 2009, SURG NEUROL, V71, P326, DOI 10.1016/j.surneu.2007.12.018
   Stratton-Powell AA, 2015, J NEUROSURG, V123, P153, DOI 10.3171/2014.12.JNS14917
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 60
EP 65
DI 10.1016/j.wneu.2019.09.109
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700171
PM 31568903
OA Bronze
DA 2020-05-12
ER

PT J
AU Glauser, G
   Hurst, RW
   Pukenas, BA
   Sedora-Roman, NI
   Kung, D
   Choudhri, O
AF Glauser, Gregory
   Hurst, Robert W.
   Pukenas, Bryan A.
   Sedora-Roman, Neda, I
   Kung, David
   Choudhri, Omar
TI Subarachnoid Hemorrhage as Result of Retrocorporeal Artery Aneurysm
   Rupture: Rare Sequel of Subclavian Steal Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurovascular; Retrocorporeal artery aneurysm; Subarachnoid hemorrhage;
   Subclavian steal
AB BACKGROUND: Subclavian steal phenomenon can cause retrograde flow in the vertebral artery as a result of ipsilateral occlusion of the subclavian artery. This phenomenon has various clinical presentations, such as claudication of the affected extremity or intermittent vertebrobasilar ischemia. Aneurysm formation in the spinal cord circulation is exceptionally rare but may occur secondary to collateral formation in subclavian steal syndrome.
   CASE DESCRIPTION: The case presented herein is a 53-year-old male who presented with headache and severe neck pain. Imaging studies revealed that the patient had subarachnoid hemorrhage in the perimedullary and cervicomedullary cisterns and extending to C3-C7 ventrally. Computed tomography angiography reconstruction demonstrated an aneurysmally dilated vessel dorsal to the C6 vertebral body within the spinal canal. Catheter-based angiography of the right subclavian artery demonstrated retrograde flow within the left vertebral artery and confirmed proximal left subclavian artery occlusion, findings diagnostic of subclavian steal. Further, a branch of the right thyrocervical trunk supplied a retrocorporeal artery collateral to the left vertebral artery, which also contributed to the anterior spinal artery.
   CONCLUSIONS: After endovascular coiling of the aneurysm, the patient had no neurologic deficits or postoperative complications. Postoperative angiography revealed complete obliteration with no residual aneurysm. Imaging further demonstrated patency of the radiculomedullary (anterior spinal) artery.
C1 [Glauser, Gregory; Kung, David; Choudhri, Omar] Univ Penn, Dept Neurosurg, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Hurst, Robert W.; Pukenas, Bryan A.; Sedora-Roman, Neda, I] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Choudhri, O (reprint author), Univ Penn, Dept Neurosurg, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM omar.choudhri@uphs.upenn.edu
CR Domoto S, 2016, J VASC SURG, V63, P1631, DOI 10.1016/j.jvs.2015.07.070
   DOPPMAN J L, 1969, Clinical Radiology, V20, P192, DOI 10.1016/S0009-9260(69)80171-6
   Fondop J, 2014, NEUROCHIRURGIE, V60, P265, DOI 10.1016/j.neuchi.2014.03.005
   Guedon A, 2016, ACTA NEUROCHIR, V158, P1121, DOI 10.1007/s00701-016-2806-4
   Karakama J, 2010, NEUROL MED-CHIR, V50, P1015, DOI 10.2176/nmc.50.1015
   Kargiotis O, 2016, J NEUROIMAGING, V26, P473, DOI 10.1111/jon.12371
   Maiti TK, 2017, HAND CLINIC, V143, P215, DOI 10.1016/B978-0-444-63640-9.00020-5
   Mourya Chandan, 2016, Indian J Radiol Imaging, V26, P451, DOI 10.4103/0971-3026.195775
   Okuhara T, 2017, J STROKE CEREBROVASC, V26, pE160, DOI 10.1016/j.jstrokecerebrovasdis.2017.05.001
   Rafailidis V, 2018, CAN ASSOC RADIOL J, V69, P493, DOI 10.1016/j.carj.2018.08.003
   Sung THT, 2015, HONG KONG MED J, V21, P179, DOI 10.12809/hkmj144230
   Tonetti DA, 2019, WORLD NEUROSURG, V125, P101, DOI 10.1016/j.wneu.2019.01.186
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 66
EP 68
DI 10.1016/j.wneu.2019.09.129
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700172
PM 31574332
OA Bronze
DA 2020-05-12
ER

PT J
AU Baassiri, W
   Moussalem, CK
   Massaad, E
   Zeidan, YH
   Darwish, H
AF Baassiri, Wassim
   Moussalem, Charbel K.
   Massaad, Elie
   Zeidan, Youssef H.
   Darwish, Houssein
TI Craniocervical Rosai-Dorfman Disease Involving the Vertebral Artery:
   Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Craniocervical; Foramen magnum; Radiotherapy; Rosai-Dorfman disease;
   Surgical resection; Vertebral artery
ID MASSIVE LYMPHADENOPATHY; SINUS HISTIOCYTOSIS; MUTATIONS
AB BACKGROUND: Rosai-Dorfman disease (RDD), also known as sinus histiocytosis with massive lymphadenopathy, is a rare non-Langerhans cell reactive histiocytic disorder that rarely occurs in the central nervous system (CNS). Extranodal RDD most frequently involves the skin, upper respiratory tract, soft tissue, gastrointestinal tracts, bones, breast, and CNS.
   CASE DESCRIPTION: RDD of the CNS infiltrates most commonly the dura of sella, cavernous sinus, and the periclival regions. It is usually clinically and radiologically mistaken for meningioma because of its focal dural-based aspect. RDD is confirmed histologically by lymphoplasmacytic cells and histiocytes of varying size showing emperipolesis (lymphocytophagocytosis). To date, only 4 cases of RDD displaying spinal cord compression secondary to craniocervical junction involvement have been reported.
   CONCLUSION: We report the case of a patient diagnosed with RDD localized one foramen magnum extending to the base of the odontoid process and involving the V4 segment vertebral artery.
C1 [Baassiri, Wassim; Moussalem, Charbel K.; Darwish, Houssein] Amer Univ Beirut, Dept Surg, Div Neurosurg, Med Ctr, Beirut, Lebanon.
   [Massaad, Elie] Amer Univ Beirut, Fac Med, Med Ctr, Beirut, Lebanon.
   [Zeidan, Youssef H.] Amer Univ Beirut, Dept Radiat Oncol, Med Ctr, Beirut, Lebanon.
RP Darwish, H (reprint author), Amer Univ Beirut, Dept Surg, Div Neurosurg, Med Ctr, Beirut, Lebanon.
EM hd17@aub.edu.lb
CR Ambekar S, 2011, BRIT J NEUROSURG, V25, P297, DOI 10.3109/02688697.2010.508849
   Behling F, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0506-2
   Cai YA, 2017, ACTA HAEMATOL-BASEL, V138, P14, DOI 10.1159/000475588
   de Leona SCG, 2017, J CLIN NEUROL, V13, P312, DOI 10.3988/jcn.2017.13.3.312
   Das DK, 2001, DIAGN CYTOPATHOL, V24, P42, DOI 10.1002/1097-0339(200101)24:1<42::AID-DC1007>3.3.CO;2-E
   FOUCAR E, 1990, SEMIN DIAGN PATHOL, V7, P19
   Garces S, 2017, MODERN PATHOL, V30, P1367, DOI 10.1038/modpathol.2017.55
   Hadjipanayis CG, 2003, J NEUROSURG, V98, P165, DOI 10.3171/jns.2003.98.1.0165
   Karthigeyan M, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.08.073
   Kidd DP, 2006, NEUROLOGY, V67, P1551, DOI 10.1212/01.wnl.0000242893.55416.8e
   Maiti TK, 2011, NEUROL INDIA, V59, P438, DOI 10.4103/0028-3886.82769
   Mantilla JG, 2016, AM J CLIN PATHOL, V145, P211, DOI 10.1093/ajcp/aqv029
   Petzold A, 2001, J NEUROL NEUROSUR PS, V71, P538, DOI 10.1136/jnnp.71.4.538
   Richardson TE, 2018, ANN NEUROL, V84, P147, DOI 10.1002/ana.25281
   ROSAI J, 1969, ARCH PATHOL, V87, P63
   Sandoval-Sus JD, 2014, MEDICINE, V93, P165, DOI 10.1097/MD.0000000000000030
   Tubbs RS, 2005, CHILD NERV SYST, V21, P951, DOI 10.1007/s00381-004-1121-1
   Udono H, 1999, J NEUROSURG, V91, P335, DOI 10.3171/jns.1999.91.2.0335
   Wu M, 2001, Ann Diagn Pathol, V5, P96, DOI 10.1053/adpa.2001.23027
   Xia Yuanxuan, 2018, Surg Neurol Int, V9, P146, DOI 10.4103/sni.sni_140_18
   Xin Y, 2016, CHINESE NEUROSURG J, V2, P13
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 69
EP 73
DI 10.1016/j.wneu.2019.09.072
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700173
PM 31550540
OA Bronze
DA 2020-05-12
ER

PT J
AU Kim, M
   Lee, S
   Park, JC
   Jang, DM
   Ha, SI
   Kim, JU
   Ahn, JS
   Park, W
AF Kim, Moinay
   Lee, Seungjoo
   Park, Jung Cheol
   Jang, Dong-Min
   Ha, Seung Il
   Kim, Joung-Uk
   Ahn, Jae Sung
   Park, Wonhyoung
TI Anaphylactic Shock After Indocyanine Green Video Angiography During
   Cerebrovascular Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anaphylactic shock; Anaphylaxis; Cerebral aneurysm; Indocyanine green;
   Surgery
ID ADVERSE-REACTIONS
AB BACKGROUND: Indocyanine green (ICG) video angiography has been widely used in cerebrovascular surgery. ICG injection is generally safe, with a low incidence of complications. ICG-related anaphylactic reactions during neurosurgery have been rarely reported. We report the cases of 2 patients who had experienced anaphylactic shock in response to intravenous ICG injection (DID Indocyanine Green [Dongindang, Inc., Gyeonggi-do, Republic of Korea]) during intracranial aneurysm (IA) surgery.
   CASE DESCRIPTION: The first patient, a 69-year-old woman with an unruptured IA, had been undergoing clipping surgery under general anesthesia. Immediately after ICG injection, her blood pressure suddenly decreased from 140/80 mm Hg to 50/30 mm Hg and she developed a skin rash on her abdomen and all extremities. Chest compression was initiated, and her vital signs gradually recovered to their pre-ICG levels within 10 minutes. The second patient was a 58-year-old woman with an unruptured IA who had been undergoing clipping surgery. After ICG injection, her blood pressure had decreased from 130/80 rum Hg to 60/40 mm Hg, and a rash-like skin lesion was observed on her abdomen. After intravenous injection of norepinephrine and dexamethasone, her blood pressure recovered to its pre-ICG level within 30 minutes and remained stable thereafter. The postoperative ICG skin provocation test findings were positive for both patients; however, only 1 patient showed markedly increased serum tryp-tase levels.
   CONCLUSION: Despite the rarity of ICG-related anaphylaxis, clinicians should be aware of this unexpected, but potentially life-threatening, drug reaction in patients undergoing cerebrovascular surgery.
C1 [Kim, Moinay; Lee, Seungjoo; Park, Jung Cheol; Ahn, Jae Sung; Park, Wonhyoung] Univ Ulsan, Asan Med Ctr, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Jang, Dong-Min; Ha, Seung Il; Kim, Joung-Uk] Univ Ulsan, Asan Med Ctr, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea.
RP Park, W (reprint author), Univ Ulsan, Asan Med Ctr, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM elevenes@gmail.com
OI Park, Jung Cheol/0000-0001-6677-455X
CR Andersen JK, 2012, VITAL, V10, P22
   Balamurugan S, 2011, Asian J Neurosurg, V6, P88, DOI 10.4103/1793-5482.92168
   BATJER HH, 1988, J NEUROSURG, V68, P234, DOI 10.3171/jns.1988.68.2.0234
   BENYA R, 1989, CATHETER CARDIO DIAG, V17, P231, DOI 10.1002/ccd.1810170410
   Bjerregaard J, 2013, A A CASE REP, V1, P26, DOI 10.1097/ACC.0b013e3182933c12
   Bonte CA, 1998, RETINA-J RET VIT DIS, V18, P476, DOI 10.1097/00006982-199805000-00018
   Brown Simon G A, 2004, Emerg Med Australas, V16, P120, DOI 10.1111/j.1742-6723.2004.00562.x
   CARSKI TR, 1978, JAMA-J AM MED ASSOC, V240, P635
   Chu W, 2017, UROL CASE REP, V12, P37, DOI 10.1016/j.eucr.2017.02.006
   Cochran ST, 2001, AM J ROENTGENOL, V176, P1385, DOI 10.2214/ajr.176.6.1761385
   Dashti R, 2009, SURG NEUROL, V71, P543, DOI 10.1016/j.surneu.2009.01.027
   de Oliveira JG, 2008, NEUROSURGERY, V62, P1300, DOI [10.1227/01.NEU.0000279982.48426.A1, 10.1227/01.neu.0000333795.21468.d4]
   Fischer G, 2010, ACTA NEUROCHIR, V152, P1519, DOI 10.1007/s00701-010-0723-5
   FISHER MM, 1986, ANAESTH INTENS CARE, V14, P17, DOI 10.1177/0310057X8601400105
   FLOWER RW, 1972, AM J OPHTHALMOL, V73, P458, DOI 10.1016/0002-9394(72)90079-7
   Hardesty DA, 2014, J CLIN NEUROSCI, V21, P1377, DOI 10.1016/j.jocn.2014.02.006
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Kim Harold, 2011, Allergy Asthma Clin Immunol, V7 Suppl 1, pS6, DOI 10.1186/1710-1492-7-S1-S6
   LEEVY CM, 1967, J AMER MED ASSOC, V200, P236, DOI 10.1001/jama.200.3.236
   Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1
   LUNDJOHANSEN P, 1990, EUR HEART J, V11, P6, DOI 10.1093/eurheartj/11.suppl_I.6
   OBANA A, 1994, AM J OPHTHALMOL, V118, P749, DOI 10.1016/S0002-9394(14)72554-1
   Park W, 2015, ACTA NEUROCHIR, V157, P1015, DOI 10.1007/s00701-015-2408-6
   Payne V, 2004, ANAESTHESIA, V59, P695, DOI 10.1111/j.1365-2044.2004.03757.x
   Peavy RD, 2008, CURR OPIN ALLERGY CL, V8, P310, DOI 10.1097/ACI.0b013e3283036a90
   Raabe A, 2003, NEUROSURGERY, V52, P132, DOI 10.1097/00006123-200301000-00017
   Sala-Cunill A, 2015, CURR OPIN ALLERGY CL, V15, P329, DOI 10.1097/ACI.0000000000000184
   Singh H, 2016, J NEUROANAESTHESIOL, V3, P126
   SPEICH R, 1988, ANN INTERN MED, V109, P345, DOI 10.7326/0003-4819-109-4-345_2
   Trcka J, 2008, AM J ROENTGENOL, V190, P666, DOI 10.2214/AJR.07.2872
   Vitte J, 2019, ALLERGY, V74, P1157, DOI 10.1111/all.13752
   Waserman S, 2010, ALLERGY, V65, P1082, DOI 10.1111/j.1398-9995.2010.02418.x
   Zhai Q, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008766
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 74
EP 79
DI 10.1016/j.wneu.2019.09.135
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700174
PM 31574334
OA Bronze
DA 2020-05-12
ER

PT J
AU George, R
   Gaxa, L
   Lockhat, Z
   Hlahla, SK
   van der Meyden, CH
   Kisten, R
   Bida, M
AF George, Roshan
   Gaxa, Luvo
   Lockhat, Zarina
   Hlahla, Stevens Kgomotso
   van der Meyden, Cornelis Hendrikus
   Kisten, Ravendran
   Bida, Meshack
TI Suprasellar Cyst Presenting With Bobble-Head Doll Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cyst; Bobble-head doll syndrome; Head bobbing; Suprasellar
   cyst
AB BACKGROUND: Bobble-head doll syndrome is a rare neurological syndrome presenting with repetitive anteroposterior head movements. It is usually associated with expansile cystic lesions in the third ventricular region.
   CASE DESCRIPTION: An 8-year-old boy presented with involuntary bobbling head movements. Magnetic resonance imaging of the brain revealed an extensive suprasellar cyst resulting in obstructive hydrocephalus. Endoscopic ventriculo-cysto-cisternostomy resulted in improved clinical outcome.
   CONCLUSIONS: Endoscopic ventriculo-cysto-cisternostomy is an effective, less-invasive technique in the treatment of suprasellar cysts that results in resolution of the bobbling head movements.
C1 [George, Roshan; Gaxa, Luvo; Lockhat, Zarina] Univ Pretoria, Steve Biko Acad Hosp, Fac Hlth Sci, Dept Radiol, Pretoria, South Africa.
   [Hlahla, Stevens Kgomotso] Univ Pretoria, Steve Biko Acad Hosp, Fac Hlth Sci, Dept Neurosurg, Pretoria, South Africa.
   [van der Meyden, Cornelis Hendrikus; Kisten, Ravendran] Univ Pretoria, Steve Biko Acad Hosp, Fac Hlth Sci, Dept Neurol, Pretoria, South Africa.
   [Bida, Meshack] Univ Pretoria, Steve Biko Acad Hosp, Fac Hlth Sci, Dept Anat Pathol, Pretoria, South Africa.
RP George, R (reprint author), Univ Pretoria, Steve Biko Acad Hosp, Fac Hlth Sci, Dept Radiol, Pretoria, South Africa.
EM roshangeorge6@gmail.com
OI George, Roshan/0000-0002-8629-6986
CR BENTON JW, 1966, NEUROLOGY, V16, P725, DOI 10.1212/WNL.16.8.725
   Chowdhry SA, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.030
   Desai KI, 2003, NEUROL INDIA, V51, P407
   Ramesh S, 2015, J PEDIATR NEUROSCI, V10, P18, DOI 10.4103/1817-1745.154321
   Reddy OJ, 2014, J PEDIATR NEUROSCI, V9, P175, DOI 10.4103/1817-1745.139350
   Renne B, 2018, J NEUROSURG-PEDIATR, V21, P236, DOI 10.3171/2017.9.PEDS16704
   Shao ZH, 2016, IRAN J RADIOL, V13, DOI 10.5812/iranjradiol.16785
   Skjulsvik AJ, 2014, INT J CLIN EXP PATHO, V7, P8905
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 80
EP 83
DI 10.1016/j.wneu.2019.09.131
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700175
PM 31574329
OA Bronze
DA 2020-05-12
ER

PT J
AU Sattur, MG
   Spiotta, AM
AF Sattur, Mithun G.
   Spiotta, Alejandro M.
TI Anomalous "Middle" Meningeal Artery from Basilar Artery and Implications
   for Neuroendovascular Surgery: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anomalous origin; Embolization; Embryology of meningeal arteries;
   Endovascular; Middle meningeal artery; Subdural hematoma
AB BACKGROUND: The middle meningeal artery (MMA) is an important conduit for the endovascular treatment of skull base and intracranial pathologies including, recently, subdural hematomas. A key aspect of such procedures is to perform a thorough diagnostic angiogram to detect anomalous arterial origins and "dangerous" anastomoses with branches of the internal carotid arteries. Although the most common anomaly related to the MMA is an abnormal origin from the ophthalmic artery, anomalous origin from the posterior circulation is rare. Moreover, its recognition requires a concerted effort at performing a vertebral artery angiogram irrespective of the location of the pathology (e.g., in subdural hematoma).
   CASE DESCRIPTION: We describe a case of anomalous origin of MMA from the basilar artery as a lateral pontine artery branch that was detected in a patient with recurrent subdural hematoma who presented for endovascular MMA embolization.
   CONCLUSIONS: The embryologic origin of the entity is briefly discussed, along with suggestions for managing such an anomaly during endovascular embolization.
C1 [Sattur, Mithun G.; Spiotta, Alejandro M.] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
RP Sattur, MG (reprint author), Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
EM sattur@musc.edu
CR ALTMANN F, 1947, LARYNGOSCOPE, V57, P313
   Fiorella D, 2019, J NEUROINTERV SURG, V11, P912, DOI 10.1136/neurintsurg-2019-014730
   Hitier M, 2013, SURG RADIOL ANAT, V35, P883, DOI 10.1007/s00276-013-1127-z
   KATZ M, 1981, J NEUROSURG, V54, P677, DOI 10.3171/jns.1981.54.5.0677
   Kumar S, 2012, J NEUROINTERV SURG, V4, P43, DOI 10.1136/jnis.2010.004465
   Salem Mohamed M, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P364, DOI 10.7461/jcen.2014.16.4.364
   SEEGER JF, 1976, RADIOLOGY, V118, P367, DOI 10.1148/118.2.367
   Shah QA, 2007, J NEUROIMAGING, V17, P261, DOI 10.1111/j.1552-6569.2007.00108.x
   WAGA S, 1978, J NEUROSURG, V49, P450, DOI 10.3171/jns.1978.49.3.0450
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 84
EP 89
DI 10.1016/j.wneu.2019.09.130
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700003
PM 31574331
OA Bronze
DA 2020-05-12
ER

PT J
AU Li, YD
   Levi, A
AF Li, Yingda
   Levi, Allan
TI Proximal Adjacent Segment Disease Manifesting as Retroodontoid
   Pseudotumor After Fusion to C2
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent segment disease; Posterior cervical fusion
AB BACKGROUND: Although adjacent segment disease (ASD) following anterior cervical fusion has been well described in the literature, there is relative paucity of data on this pathology after posterior cervical fusion. To our knowledge, there have been no reported cases of proximal ASD following posterior fusion to C2.
   CASE DESCRIPTION: We present 2 cases of proximal ASD presenting as retroodontoid pseudotumors following posterior fusion to C2, both in middle-aged females without history of rheumatologic disease. The first occurred in a patient with Klippel-Feil deformity 13 years after C2-6 posterior cervical fusion, the second in a patient 3 and a half years following revisional circumferential C2-T2 fusion. Both were successfully treated with proximal extension of laminectomy and fusion to the occiput, supplemented in the first patient by transdural decompression of retroodontoid mass.
   CONCLUSIONS: Proximal ASD can manifest as retroodontoid pseudotumor at variable time intervals following posterior fusion to C2. Clinicians must account for this possibility in their decision making.
C1 [Li, Yingda; Levi, Allan] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
RP Li, YD (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM dryingdali@gmail.com
CR Chikuda H, 2009, SPINE, V34, pE110, DOI 10.1097/BRS.0b013e31818acd27
   Ghobrial GM, 2019, NEUROSURGERY, V84, P347, DOI 10.1093/neuros/nyy118
   Helgeson MD, 2013, SPINE J, V13, P342, DOI 10.1016/j.spinee.2012.12.009
   Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009
   Kong LD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004171
   Lavelle WF, 2019, SPINE, V44, P601, DOI 10.1097/BRS.0000000000002907
   Madhavan K, 2018, J NEUROSURG-SPINE, V28, P236, DOI 10.3171/2017.6.SPINE17429
   Nassr A, 2009, SPINE, V34, P189, DOI 10.1097/BRS.0b013e3181913872
   Park JB, 2005, J BONE JOINT SURG AM, V87A, P558, DOI 10.2106/JBJS.C.01555
   Uehara M, 2014, ASIAN SPINE J, V8, P759, DOI 10.4184/asj.2014.8.6.759
   Xia YX, 2019, NEUROSURGERY, V85, pE520, DOI 10.1093/neuros/nyz019
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 90
EP 96
DI 10.1016/j.wneu.2019.09.113
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700176
PM 31568901
OA Bronze
DA 2020-05-12
ER

PT J
AU Schmidt, BT
   Hanna, A
AF Schmidt, Bradley T.
   Hanna, Amgad
TI Deadly Proliferation and Transformation of Pilocytic Astrocytoma in
   Pregnancy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anaplasia; Neurofibromatosis type 1; Pilocytic astrocytoma; Pregnancy
ID NEUROFIBROMATOSIS TYPE-1; TUMOR; RESECTION; GLIOMAS; ADULTS
AB BACKGROUND: Intracranial tumor growth associated with pregnancy is not an uncommon phenomenon. Pilocytic astrocytoma is typically considered to be an indolent tumor with little to no risk of progression to higher-grade lesion. We present a rare case of cerebellar pilocytic astrocytoma transformation to hemorrhagic high-grade glioma during pregnancy.
   CASE DESCRIPTION: Patient EK was a 32-year-old female with neurofibromatosis type 1 and known cerebellar pilocytic astrocytoma. For nearly a decade before her pregnancy, her cerebellar tumor was stable on imaging. Routine magnetic resonance imaging (MRI) of the head obtained at 20 weeks' gestation continued to demonstrate tumor stability. At 24 weeks' gestation, the patient had sudden, severe headaches. MRI of the head showed evidence of significant tumor expansion. The following day, the patient was found unresponsive. Computed tomography of the head demonstrated hemorrhage within the tumor and tonsillar herniation. Her neurologic examination revealed no brainstem reflexes; however, given her age and pregnancy, she underwent emergent decompression and tumor debulking. Unfortunately, she never improved neuro-logically. Final pathology identified the lesion as high-grade glioma with anaplastic changes and hemorrhagic conversion.
   CONCLUSIONS: This is a unique case of indolent cerebellar pilocytic astrocytoma that transformed to high-grade glioma during pregnancy, proven by tumor growth on MRI and anaplasia on pathology. We hypothesize that increased levels of pregnancy hormones (progesterone, vascular endothelial growth factor, placental growth factor, among others) likely contributed to tumor growth. We recommend that all glial tumors be monitored extremely closely throughout pregnancy, and perhaps one should consider surgical treatment (if possible) before patients become pregnant.
C1 [Schmidt, Bradley T.; Hanna, Amgad] Univ Wisconsin Hosp & Clin, Dept Neurosurg, Madison, WI 53792 USA.
RP Schmidt, BT (reprint author), Univ Wisconsin Hosp & Clin, Dept Neurosurg, Madison, WI 53792 USA.
EM b.schmidt@neurosurgery.wisc.edu
CR Bell D, 2004, BRIT J NEUROSURG, V18, P613, DOI 10.1080/02688690400022896
   Bond KM, 2018, WORLD NEUROSURG, V110, P276, DOI 10.1016/j.wneu.2017.11.102
   Byrne S, 2017, J NEURO-ONCOL, V133, P609, DOI 10.1007/s11060-017-2475-z
   Daras M, 2014, J NEURO-ONCOL, V116, P113, DOI 10.1007/s11060-013-1261-9
   Helfferich J, 2016, CRIT REV ONCOL HEMAT, V104, P30, DOI 10.1016/j.critrevonc.2016.05.008
   Isla A, 1997, OBSTET GYNECOL, V89, P19, DOI 10.1016/S0029-7844(96)00381-X
   Johnson DR, 2012, J NEURO-ONCOL, V108, P187, DOI 10.1007/s11060-012-0829-0
   Nishio S, 1996, J CLIN NEUROSCI, V3, P334, DOI 10.1016/S0967-5868(96)90029-6
   Rodriguez FJ, 2008, J NEUROPATH EXP NEUR, V67, P240, DOI 10.1097/NEN.0b013e318165eb75
   Rodriguez FJ, 2010, AM J SURG PATHOL, V34, P147, DOI 10.1097/PAS.0b013e3181c75238
   Umehara T, 2016, MOL CLIN ONCOL, V4, P567, DOI 10.3892/mco.2016.773
   Yust-Katz S, 2014, NEURO-ONCOLOGY, V16, P1289, DOI 10.1093/neuonc/nou019
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 99
EP 103
DI 10.1016/j.wneu.2019.09.125
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700178
PM 31574330
OA Bronze
DA 2020-05-12
ER

PT J
AU Holmgren, AG
   Juth, N
   Lindblad, A
   Von Vogelsang, AC
AF Holmgren, Amina Guenna
   Juth, Niklas
   Lindblad, Anna
   Von Vogelsang, Ann-Christin
TI Restraint in a Neurosurgical Setting: A Mixed-Methods Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Autonomy; Nursing; Observational study; Physical restraint
ID NURSES DECISION-MAKING; INTENSIVE-CARE UNITS; PHYSICAL RESTRAINT;
   PERCEPTIONS; PREVALENCE; REDUCTION; AGITATION; INJURY
AB OBJECTIVE: To investigate the extent to which restraint is used in neurosurgical care, under what circumstances, and how it is documented.
   METHODS: A cross-sectional study with a mixed-methods approach was used to identify neurosurgical inpatients subjected to restraint. The data were collected in 2 phases: (1) a study-specific questionnaire was distributed to nurses in which they identified if restraints had occurred during their shifts, and if so, which restraint and to which patient; and (2) scrutinizing of electronic medical records of patients identified by the questionnaires. Numeric data were analyzed using descriptive and analytic statistical methods, and textual data were analyzed using qualitative content analysis. The findings from the different data sources were compared and merged.
   RESULTS: Of the 517 patients admitted to the studied department during the study period, 58 (11%) were reported to have been subjected to restraint and most of the restraining events occurred in the neurointensive care unit. Most restraint measures were not documented in the electronic medical records. The identified patients were predominantly diagnosed with traumatic brain injury or subarachnoid hemorrhage. The qualitative content analysis showed the circumstances when restraints were used: when patients were considered a danger to self or others (theme) and which symptoms and behaviors (categories) were observed in relation to the use of restraint.
   CONCLUSIONS: Restraint in neurosurgical care is mostly used to prevent patients from harming themselves or others. Because of the lack of documentation, restraint measures cannot be openly assessed, thus putting patients' safety at risk.
C1 [Holmgren, Amina Guenna; Juth, Niklas; Lindblad, Anna] Karolinska Inst, Stockholm Ctr Healthcare Eth CHE, Dept Learning Informat Management & Eth LIME, Stockholm, Sweden.
   [Von Vogelsang, Ann-Christin] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
   [Holmgren, Amina Guenna; Von Vogelsang, Ann-Christin] Karolinska Univ Hosp, Neuro Theme, Stockholm, Sweden.
RP Holmgren, AG (reprint author), Karolinska Inst, Stockholm Ctr Healthcare Eth CHE, Dept Learning Informat Management & Eth LIME, Stockholm, Sweden.; Holmgren, AG (reprint author), Karolinska Univ Hosp, Neuro Theme, Stockholm, Sweden.
EM amina.guenna.holmgren@ki.se
OI Von Vogelsang, Ann-Christin/0000-0002-3006-2443
CR Amato S, 2006, REHABIL NURS, V31, P235, DOI 10.1002/j.2048-7940.2006.tb00019.x
   Barr J, 2010, AUSTRALAS J NEUROSCI, V20, P21
   Benbenbishty Julie, 2010, Intensive Crit Care Nurs, V26, P241, DOI 10.1016/j.iccn.2010.08.003
   Caeiro L, 2011, EUR J NEUROL, V18, P857, DOI 10.1111/j.1468-1331.2010.03271.x
   Chang LY, 2008, AM J CRIT CARE, V17, P408
   Chapman R, 2016, J CLIN NURS, V25, P1273, DOI 10.1111/jocn.13159
   Cosper P, 2015, J NURS CARE QUAL, V30, P16, DOI 10.1097/NCQ.0000000000000074
   Creswell JW, 2014, RES DESIGN QUALITATI
   Creswell JW, 2011, DESIGNING CONDUCTING
   de Casterle BD, 2015, NURS ETHICS, V22, P642, DOI 10.1177/0969733014543215
   Evans D, 2003, J ADV NURS, V41, P274, DOI 10.1046/j.1365-2648.2003.02501.x
   Evans David, 2002, Contemp Nurse, V13, P126
   Gallinagh R, 2001, Br J Nurs, V10, P852
   Goethals S, 2012, J ADV NURS, V68, P1198, DOI 10.1111/j.1365-2648.2011.05909.x
   Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001
   Grover Sandeep, 2017, J Anaesthesiol Clin Pharmacol, V33, P480, DOI 10.4103/0970-9185.222505
   Hantikainen V, 2000, J ADV NURS, V32, P1196, DOI 10.1046/j.1365-2648.2000.01590.x
   Hughes R, 2010, RIGHTS RISK RESTRAIN
   Huizing AR, 2009, INT J NURS STUD, V46, P459, DOI 10.1016/j.ijnurstu.2008.03.005
   Jiang H, 2015, NURS ETHICS, V22, P652, DOI 10.1177/0969733014557118
   Kandeel NA, 2013, NURS HEALTH SCI, V15, P79, DOI 10.1111/nhs.12000
   Karlsson S, 2000, J CLIN NURS, V9, P842, DOI 10.1046/j.1365-2702.2000.00442.x
   Karlsson S, 2001, J AM GERIATR SOC, V49, P1722, DOI 10.1046/j.1532-5415.2001.49286.x
   Kruger C, 2013, INT J NURS STUD, V50, P1599, DOI 10.1016/j.ijnurstu.2013.05.005
   Lane C, 2011, INT J NURS PRACT, V17, P195, DOI 10.1111/j.1440-172X.2011.01925.x
   Ljunggren G, 1997, AGE AGEING, V26, P43, DOI 10.1093/ageing/26.suppl_2.43
   Matano F, 2017, WORLD NEUROSURG, V103, P424, DOI 10.1016/j.wneu.2017.03.139
   McNett M, 2012, BRAIN INJURY, V26, P1155, DOI 10.3109/02699052.2012.667587
   Minnick AF, 1998, J NURS ADMIN, V28, P19, DOI 10.1097/00005110-199811000-00007
   Minnick AF, 2007, J NURS SCHOLARSHIP, V39, P30, DOI 10.1111/j.1547-5069.2007.00140.x
   Mion LC, 2007, CRIT CARE MED, V35, P2714, DOI 10.1097/01.CCM.0000291651.12767.52
   Morrison EF, 2000, J NURS CARE QUAL, V14, P72, DOI 10.1097/00001786-200004000-00009
   Morshed RA, 2019, WORLD NEUROSURG, V126, pE930, DOI 10.1016/j.wneu.2019.03.012
   Patton M.Q., 2015, QUALITATIVE RES EVAL
   Polit D. F., 2012, NURSING RES GENERATI
   Reznik ME, 2017, NEUROCRIT CARE, V26, P428, DOI 10.1007/s12028-016-0331-1
   Salluh JIF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2538
   Singh R, 2014, BRAIN INJURY, V28, P336, DOI 10.3109/02699052.2013.873142
   Sjostrand M, 2015, BMC MED ETHICS, V16, DOI 10.1186/s12910-015-0029-5
   Svensk forfattningssamling, 1991, LAG PSYK TVANGSV
   Tannsjo T, 1999, COERCIVE CARE ETHICS
   Tashakkori A., 2003, HDB MIXED METHODS SO
   Turner O, 1940, Yale J Biol Med, V12, P459
   Via-Clavero G, 2019, NURS ETHICS, V26, P1458, DOI 10.1177/0969733017752547
   Woodward S, 2011, NEUROSCIENCE NURSING
   Yeh Shu-Hui, 2004, J Nurs Res, V12, P246
NR 46
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 104
EP 111
DI 10.1016/j.wneu.2019.09.105
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700179
PM 31568917
OA Bronze
DA 2020-05-12
ER

PT J
AU Sahlu, A
   Getachew, K
   Mekonnen, A
AF Sahlu, Abat
   Getachew, Kaleab
   Mekonnen, Abebe
TI Traumatic Retroclival Subdural Hematoma in a Child with Hemophilia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemophilia; Retroclival; Subdural
ID CLIVAL
AB BACKGROUND: Retroclival hematomas are a rare entity and may occur in 3 compartments, namely the epidural, subdural, and subarachnoid spaces. They are frequently secondary to trauma. Hemophilia is a clinical syndrome affecting usually men and characterized by the inherited tendency to bleed excessively after slight injury. Hemophilia is caused by a specific defect of coagulation factor VIII. The main concern associated with the disease is bleeding, especially after trauma and surgeries. The most serious site of bleeding is the central nervous system.
   CASE PRESENTATION: An 11-year-old boy diagnosed with hemophilia presented after sustaining a fall. On arrival to the emergency department, his vitals where within normal range and he was fully conscious. Neurologic examination was significant for bilateral abducens nerve palsy; the rest of the examination was unremarkable. Imaging studies with computed tomography (CT) scan and brain magnetic resonance imaging showed subacute retroclival subdural hemorrhage with left cerebellar and upper cervical spine extension. Follow-up imaging with CT scan showed progressive resolution of the hematoma, and the patient had a stable clinical course while receiving factor VII replacement.
   CONCLUSIONS: Retroclival subdural hematomas are rare and may present either spontaneously or after trauma. Conservative treatment is the usual course of treatment. Patients with hemophilia A are under a constant threat from bleeding, either spontaneous or after trivial injury. The most common cause of death in this patient population is intracranial hemorrhage. The most important aspect of intracranial hematoma management is the early replacement therapy of deficient coagulation factors in patients with hemophilia.
C1 [Sahlu, Abat; Getachew, Kaleab; Mekonnen, Abebe] Addis Ababa Univ, Coll Heath Sci, Addis Ababa, Ethiopia.
RP Getachew, K (reprint author), Addis Ababa Univ, Coll Heath Sci, Addis Ababa, Ethiopia.
EM kalget23@gmail.com
CR Ahn ES, 2005, J NEUROSURG, V103, P175, DOI 10.3171/ped.2005.103.2.0175
   Amalnath SD, 2018, NEUROLOGY, V91, pE999, DOI 10.1212/WNL.0000000000006125
   Azizyan A, 2015, J NEUROSURG, V123, P808, DOI 10.3171/2014.12.JNS14445
   Brock S, 2010, ACTA NEUROCHIR, V152, P1543, DOI 10.1007/s00701-010-0720-8
   Caramanti RL, 2019, BRAZ NEUROSURG, V38, P60, DOI 10.1055/s-0036-1593976
   Casey D, 2009, J NEUROSURG, V110, P1238, DOI 10.3171/2008.9.JNS17651
   Dayaratne S, 2015, CEYLON MED J, V60, P159, DOI 10.4038/cmj.v60i4.8225
   Dimichele DM, 2007, HAEMOPHILIA, V13, P1, DOI 10.1111/j.1365-2516.2007.01497.x
   Nguyen HS, 2016, CHILD NERV SYST, V32, P1749, DOI 10.1007/s00381-016-3098-y
   Kim Myoung Soo, 2012, Surg Neurol Int, V3, P39, DOI 10.4103/2152-7806.94287
   Koshy J, 2014, CHILD NERV SYST, V30, P835, DOI 10.1007/s00381-014-2369-8
   Krishnan P, 2013, NEUROL INDIA, V61, P550, DOI 10.4103/0028-3886.121951
   Lee IL, 2017, J NEUROL SURG REP, V78, pE46, DOI 10.1055/s-0037-1600914
   Mohamed AH, 2013, BRIT J NEUROSURG, V27, P845, DOI 10.3109/02688697.2013.798855
   MYERS DJ, 1995, ANN EMERG MED, V25, P249, DOI 10.1016/S0196-0644(95)70333-0
   Narvid J, 2016, J NEUROSURG, V124, P716, DOI 10.3171/2015.2.JNS142221
   Schievink WI, 2001, J NEUROSURG, V95, P522, DOI 10.3171/jns.2001.95.3.0522
   Sever A, 2017, APPL RADIOL, V46, P38
   Silvera VM, 2014, PEDIATR RADIOL, V44, P621, DOI 10.1007/s00247-014-3170-2
   Sridhar K, 2010, NEUROL INDIA, V58, P131, DOI 10.4103/0028-3886.73756
   van Rijn R R, 2003, JBR-BTR, V86, P174
   Yadav A, 2014, PUNJAB ACAD FORENSIC, V14, P115
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 112
EP 120
DI 10.1016/j.wneu.2019.09.059
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700180
PM 31562972
OA Bronze
DA 2020-05-12
ER

PT J
AU Xie, TH
   Xiu, P
   Song, YM
   Zeng, JC
   Huang, SS
AF Xie, Tianhang
   Xiu, Peng
   Song, Yueming
   Zeng, Jiancheng
   Huang, Shishu
TI Percutaneous Endoscopic Excision and Ablation of Osteoid Osteoma of the
   Lumbar Spine and Sacrum: A Technical Note and Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ablation; Bone tumor; Minimally invasive; Osteoid osteoma; Percutaneous
   endoscopic; Spine
ID OSTEOBLASTOMA; DISKECTOMY
AB OBJECTIVE: This study aimed to present a new endoscopic technique for osteoid osteoma (OO) of the lumbar spine and sacrum and to evaluate its safety and effectiveness.
   METHODS: Eleven consecutive patients with spinal OO underwent percutaneous endoscopic excision and ablation (PEEA) between March 2014 and May 2018. A cannula 0.7 cm in diameter was used for the procedure. According to the size of the nidus, whole-piece removal and piecemeal intralesional resection were used. Afterward, ablation was performed using an endoscopic radiofrequency electrode in the residual osteoma cavities. Clinical outcomes were assessed by Visual Analog Scale (VAS) scores. The efficacy of this technique was assessed using relevant clinical data and postoperative radiographs.
   RESULTS: The niduses of the 11 patients were all located in the posterior element of the lumbar spine and sacrum (10 in the lumbar spine and 1 in the sacrum). The preoperative VAS score was 7.18 (range, 6-9), the score on postoperative day 1 was 1 (range, 0-2), and the last follow-up VAS score was 0.27 (range, 0-1). All patients were discharged within 24 hours after surgery. The mean follow-up period was 21.8 months (range, 12-36 months). No serious complications were observed during the follow-up period.
   CONCLUSIONS: PEEA is a safe and effective technique for OO in the lumbar spine and sacrum in which the nidus is located in the posterior element. However, it has a steep learning curve. Further research with a larger and more comprehensive sample population is warranted.
C1 [Xie, Tianhang; Xiu, Peng; Song, Yueming; Zeng, Jiancheng; Huang, Shishu] Sichuan Univ, West China Hosp, Dept Orthoped, West China Sch Med, Chengdu, Sichuan, Peoples R China.
RP Zeng, JC (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped, West China Sch Med, Chengdu, Sichuan, Peoples R China.
EM tomzeng5@126.com
CR Ahmed M, 2014, J VASC INTERV RADIOL, V25, P1706, DOI 10.1016/j.jvir.2014.09.005
   ALANI WO, 1987, CLIN ORTHOP RELAT R, P308
   Albisinni U, 2017, SKELETAL RADIOL, V46, P1087, DOI 10.1007/s00256-017-2662-1
   Barlow E, 2013, J CLIN PATHOL, V66, P768, DOI 10.1136/jclinpath-2013-201492
   Boriani S, 1998, Chir Organi Mov, V83, P53
   Gangi A, 2007, RADIOLOGY, V242, P293, DOI 10.1148/radiol.2421041404
   Gasbarrini A, 2011, SPINE, V36, P2089, DOI 10.1097/BRS.0b013e3181ffeb5e
   JACKSON RP, 1977, CLIN ORTHOP RELAT R, P303
   Kadhim M, 2017, J PEDIATR ORTHOP B, V26, P362, DOI 10.1097/BPB.0000000000000406
   KEIM HA, 1975, J BONE JOINT SURG AM, VA 57, P159, DOI 10.2106/00004623-197557020-00005
   Klass D, 2009, EUR RADIOL, V19, P2238, DOI 10.1007/s00330-009-1404-8
   LEE DH, 1992, CLIN ORTHOP RELAT R, P229
   Martel J, 2009, EUR J RADIOL, V71, P564, DOI 10.1016/j.ejrad.2008.04.020
   Noordin S, 2018, ORTHOP REV, V10, P108, DOI 10.4081/or.2018.7496
   Orth P, 2017, ORTHOPADE, V46, P510, DOI 10.1007/s00132-017-3428-0
   Park JH, 2017, ORTHOPEDICS, V40, pE779, DOI 10.3928/01477447-20170531-02
   Quraishi NA, 2017, SPINE J, V17, P401, DOI 10.1016/j.spinee.2016.10.010
   RANSFORD AO, 1984, J BONE JOINT SURG BR, V66, P16
   Rybak LD, 2010, AM J ROENTGENOL, V195, pW293, DOI 10.2214/AJR.10.4192
   Saifuddin A, 1998, SPINE, V23, P47, DOI 10.1097/00007632-199801010-00010
   Sairyo K, 2018, J ORTHOP SCI, V23, P229, DOI 10.1016/j.jos.2017.10.015
   Tsoumakidou G, 2016, RADIOLOGY, V278, P936, DOI 10.1148/radiol.2015150491
   Wang B, 2017, EUR SPINE J, V26, P1884, DOI 10.1007/s00586-017-5080-0
   WOLD LE, 1988, MODERN PATHOL, V1, P129
   Xie TH, 2017, PAIN PHYSICIAN, V20, pE379
   YAMANE T, 1992, SPINE, V17, P1386, DOI 10.1097/00007632-199211000-00020
   Yu X, 2019, SPINE J, V19, P509, DOI 10.1016/j.spinee.2018.07.013
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 121
EP 126
DI 10.1016/j.wneu.2019.09.039
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700181
PM 31562970
OA Bronze
DA 2020-05-12
ER

PT J
AU Talamonti, G
   D'Aliberti, G
   Cenzato, M
AF Talamonti, Giuseppe
   D'Aliberti, Giuseppe
   Cenzato, Marco
TI Aulus Cornelius Celsus and the Head Injuries
SO WORLD NEUROSURGERY
LA English
DT Article
DE Celsus; Craniotomy; Extradural hematomas; Head injuries; History of
   neurosurgery; Neurotraumatology; Roman medicine
AB Aulus Cornelius Celsus lived in Rome during the reigns of Augustus and Tiberius. He developed the scientific Latin, and his work De Medicina was the first medical textbook to be written in Latin, and subsequently the first medical treatise to be printed. lie perhaps was a simple medical writer rather than a real physician, but his contributions to medical knowledge are outstanding. He described the tetrad of inflammation (dolor, rubor, calor, tumor), coined the term cancer, and reported several revolutionary surgical techniques. His eighth book, almost entirely dedicated to dislocations and fractures, provides an extensive description of head injuries such as extradural hematomas, lesions distant from the impact point, and intracranial damage in cases with no overlying fractures. He also provided the first description of brain swelling exceeding the level of the skull, described several surgical indications and craniotomy techniques, recommended treatment for depressed fractures (which had been previously considered untreatable), and detailed the surgical instruments employed. De Medicina was based on the previous Greek medical knowledge, but Celsus also provided original innovations, personal observations, and even comments and criticisms. Despite the fact that he was almost forgotten during the Middle Age, most of his concepts and surgical advices remained in the medical background of the following 2 millennia.
C1 [Talamonti, Giuseppe; D'Aliberti, Giuseppe; Cenzato, Marco] ASST Niguarda, Dept Neurosurg, Milan, Italy.
RP Talamonti, G (reprint author), ASST Niguarda, Dept Neurosurg, Milan, Italy.
EM tala_nch@yahoo.it
OI talamonti, giuseppe/0000-0002-9164-3292
CR Bianchi E., CA CORNELIO ENCICLOP
   Castiglioni A., 1941, HIST MED
   Chorney MA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13563
   Cybulska M., 2012, MILITARY PHARM MED, V2, P1
   D'Acquapendente GF, 1711, OPERE CHIRURG
   Donaldson IML, 2014, J ROY COLL PHYS EDIN, V44, P344, DOI 10.4997/JRCPE.2014.420
   Ganz JC, 2014, J HIST NEUROSCI, V23, P233, DOI 10.1080/0964704X.2013.823267
   Hyam JA, 2009, LANCET, V373, P1605, DOI 10.1016/S0140-6736(09)60907-7
   Kockerling F, 2013, LANGENBECK ARCH SURG, V398, P609, DOI 10.1007/s00423-013-1050-0
   Kshettry Varun R, 2007, Neurosurg Focus, V23, pE8
   Langslow David R., 2000, MED LATIN ROMAN EMPI
   Leopardi G, 1819, COMMUNICATION   0219
   Lindekleiv Haakon, 2005, Tidsskr Nor Laegeforen, V125, P3494
   Liu CY, 2003, NEUROSURGERY, V52, P3, DOI 10.1097/00006123-200301000-00001
   Majno G, 1975, HEALING HAND MAN WOU
   Mariani-Costantini R, 2000, LANCET, V355, P305, DOI 10.1016/S0140-6736(99)05064-3
   Martialis MV, 1871, EPIGRAMMATON LIBRI
   Martin G, 2000, J CLIN NEUROSCI, V7, P500, DOI 10.1054/jocn.1999.0677
   Marx F, 2019, CORPUS MEDICORUM LAT
   MEINECKE BRUNO, 1941, BULL HISTORY MED, V10, P288
   Noterman J, 2016, Rev Med Brux, V37, P504
   Pliny the Elder, 1469, NATURALIS HIST
   Prioreschi P. A, 1998, HIST MED ROMAN MED
   Quintilian MF, 1715, I ORTORIANUM LIBER 1
   ROSENTHAL T, 1961, ARCH DERMATOL, V84, P613, DOI 10.1001/archderm.1961.01580160077013
   Scarborough J., 1969, ROMAN MED
   Schanz M, 1935, GESCH ROMISCHEN LIT
   Scott WA, 1955, CANAD ANAES SOC J S, V2, P281
   Seneca LA., 1809, EPISTOLAE MORALES EP, V18, P131
   Spencer WG., 1938, CELSUS MED
   SPIVACK BS, 1991, J HIST MED ALL SCI, V46, P143, DOI 10.1093/jhmas/46.2.143
   Temkin O, 1935, BHM, V3, P249
   Thayer B., MED LACUSCURTIUS CEL
   Wellmann M. A, 1925, SUDHOFFS ARCH GESISC, V16, P209
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 127
EP 134
DI 10.1016/j.wneu.2019.09.119
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700182
PM 31568909
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, L
   Li, Q
   Ao, J
   Du, Q
   Xin, ZJ
   Liao, WB
AF Liu, Lei
   Li, Qing
   Ao, Jun
   Du, Qian
   Xin, Zhi-Jun
   Liao, Wen-Bo
TI Posterior Percutaneous Endoscopic Technique Through Bilateral
   Translaminar Osseous Channels for Thoracic Spinal Stenosis Caused by
   Ossification of the Ligamentum Flavum Combined with Disk Herniation at
   the T10-11 Level: A Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Minimally invasive surgery; Ossification of the ligamentum flavum;
   Percutaneous endoscopic technique; Thoracic disk herniation;
   Translaminar osseous channel approach
ID DECOMPRESSION; LAMINECTOMY; DISKECTOMY
AB BACKGROUND: The occurrence rate of thoracic spinal stenosis caused by ossification of the ligamentum flavum combined with disk herniation is lower than that of ossified ligamentum flavum in the thoracic spine, and the treatment method has rarely been reported. In this paper, we applied an endoscopic technique to a patient with thoracic spinal stenosis caused by ossification of the ligamentum flavum combined with disk herniation at the T10-11 level.
   METHODS: We performed surgical decompression of the thoracic spinal cord for a patient diagnosed with thoracic spinal stenosis at the T10-11 level caused by ossification of the ligamentum flavum combined with disk herniation using percutaneous endoscopic surgery via the bilateral translaminar osseous channel approach. Pre- and postoperative computed tomography (CT) scan and magnetic resonance imaging (MRI) examinations were performed, and pre- and postoperative neurologic status was evaluated using the Modified Japanese Orthopaedic Association and visual analog scale scores.
   RESULTS: The ossified ligamentum flavum and herniated material were removed through this osseous channel. Postoperative CT and MRI scanning revealed adequate decompression of the spinal cord at the T10-11 level. The patient was discharged home on postoperative day 3. At 6-month postoperative follow-up, the patient experienced complete resolution of T12 dermatomal numbness. The strength in her bilateral lower extremities improved slightly to grade 5.
   CONCLUSIONS: We have applied percutaneous endoscopic surgery via bilateral translaminar osseous channels for the treatment of thoracic spinal stenosis caused by ossification of the ligamentum flavum combined with disk herniation. This surgery could provide sufficient decompression for thoracic spinal cord with minimum trauma.
C1 [Liu, Lei; Ao, Jun; Du, Qian; Xin, Zhi-Jun] Zunyi Med Univ, Dept Orthopaed Surg, Affiliated Hosp, Zunyi, Guizhou, Peoples R China.
   [Liu, Lei; Ao, Jun; Du, Qian; Xin, Zhi-Jun; Liao, Wen-Bo] Zunyi Med Univ, Joint Orthopaed Res Ctr Zunyi Med Univ & Univ Roc, Zunyi, Guizhou, Peoples R China.
   [Li, Qing] Southwest Med Univ, Dept Radiol, Affiliated Hosp, Luzhou, Sichuan, Peoples R China.
RP Liao, WB (reprint author), Zunyi Med Univ, Joint Orthopaed Res Ctr Zunyi Med Univ & Univ Roc, Zunyi, Guizhou, Peoples R China.
EM wenbo900@sina.com
OI liu, lei/0000-0002-0387-0111
CR Aizawa T, 2006, J NEUROSURG-SPINE, V5, P514, DOI 10.3171/spi.2006.5.6.514
   Baba S, 2016, EUR SPINE J, V25, P1912, DOI 10.1007/s00586-015-4158-9
   Choi G, 2017, J KOREAN NEUROSURG S, V60, P485, DOI 10.3340/jkns.2017.0203.004
   Choi KY, 2010, MINIM INVAS NEUROSUR, V53, P25, DOI 10.1055/s-0029-1246159
   Court C, 2017, ORTHOP TRAUMATOL-SUR, V104, pS31
   Eun SS, 2017, J NEUROL SURG PART A, V78, P390, DOI 10.1055/s-0036-1592157
   Foreman PM, 2016, J NEUROSURG-SPINE, V24, P570, DOI 10.3171/2015.6.SPINE15169
   He SS, 2005, J NEUROSURG-SPINE, V3, P348, DOI 10.3171/spi.2005.3.5.0348
   Jho HD, 1997, J NEUROSURG, V87, P125, DOI 10.3171/jns.1997.87.1.0125
   Jia LS, 2010, NEUROSURGERY, V66, P1181, DOI 10.1227/01.NEU.0000369516.17394.B0
   Kim JS, 2009, MINIM INVAS NEUROSUR, V52, P74, DOI 10.1055/s-0029-1215580
   Komp M, 2011, J SPINAL DISORD TECH, V24, P281, DOI 10.1097/BSD.0b013e3181f9f55e
   Kuh SU, 2006, EUR SPINE J, V15, P485, DOI 10.1007/s00586-005-0903-9
   Lee CW, 2018, WORLD NEUROSURG, V113, pE129, DOI 10.1016/j.wneu.2018.01.195
   Li FC, 2006, J NEUROSURG-SPINE, V4, P191, DOI 10.3171/spi.2006.4.3.191
   LI KK, 2002, SPINE, V27, P308
   Miao XX, 2018, WORLD NEUROSURG, V114, P8, DOI [10.1016/J.WNEU.2018.02.152, 10.1016/j.wneu.2018.02.152]
   Miyakoshi N, 2003, J NEUROSURG, V99, P251, DOI 10.3171/spi.2003.99.3.0251
   Nie HF, 2013, MINIM INVASIVE SURG, V2013, DOI 10.1155/2013/264105
   Ruetten S, 2006, MINIM INVAS NEUROSUR, V49, P80, DOI 10.1055/s-2006-932172
   Wagner R, 2016, WORLD NEUROSURG, V90, P194, DOI 10.1016/j.wneu.2016.02.086
   Xin ZJ, 2017, BIOMED RES INT, DOI 10.1155/2017/3069575
   Zhong ZM, 2016, J CLIN NEUROSCI, V28, P77, DOI 10.1016/j.jocn.2015.09.023
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 135
EP 141
DI 10.1016/j.wneu.2019.08.215
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700183
PM 31505277
OA Bronze
DA 2020-05-12
ER

PT J
AU Meena, RK
   Doddamani, RS
   Gurjar, HK
   Kumar, A
   Chandra, PS
AF Meena, Rajesh Kumar
   Doddamani, Ramesh S.
   Gurjar, Hitesh K.
   Kumar, Amandeep
   Chandra, Poodipedi S.
TI Type 1.5 Split Cord Malformations: An Uncommon Entity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Composite SCM; Congenital; Intermediate SCM; Mixed SCM; Single dural
   sac; Split cord malformation; Ventral bony spur
ID COMPOSITE TYPE; BONY SPUR; DIASTEMATOMYELIA
AB BACKGROUND: Split cord malformations (SCMs) are among the rare congenital spinal anomalies. In 1992, Pang et al. proposed the unified theory of embryogenesis and explained the formation of SCM type 1 and 2. This theory has been widely accepted in the neurosurgical literature, backed by several studies. However, there have been reports in the literature that defy both the classification as well as the formation of SCMs, based on the unified theory of embryogenesis. We report a case of SCM that does not fit into this classification scheme and try to elucidate its embryologic basis, with review of the relevant literature. We also attempt to include this variety into the existing classification system of SCMs.
   CASE DESCRIPTION: An 11-year-old boy presented with low backache after trivial trauma. He was neurologically intact. Imaging showed low-lying tethered cord and a midline ventral bony spur (D12, L1) with a single dural sac encasing both the hemicords. Surgical exploration showed a ventral bony spur with 2 hemicords, enclosed in a single dural tube. Excision of the bony spur and detethering of the filum terminal were performed. The postoperative course was uneventful and the patient was discharged satisfactorily.
   CONCLUSIONS: SCMs possibly represent a continuum of changes beginning at the gestational age of days 20-30. Terminology such as mixed or intermediate type is used to denote SCMs that show features of both type 1 and type II. We prefer using type 1.5 SCMs for all such cases, thereby avoiding confusion and maintaining uniformity in the nomenclature. However, further experimental studies are required to substantiate our understanding of these complex embryologic anomalies on the basis of current hypotheses.
C1 [Meena, Rajesh Kumar; Doddamani, Ramesh S.; Gurjar, Hitesh K.; Kumar, Amandeep; Chandra, Poodipedi S.] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
RP Meena, RK (reprint author), All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
EM drrajeshmeena165@gmail.com
CR Agarwal A, 2018, J PEDIATR NEUROSCI, V13, P214, DOI 10.4103/jpn.JPN_99_17
   Akay KM, 2005, J NEUROSURG, V102, P436, DOI 10.3171/ped.2005.102.4.0436
   Akay KM, 2002, PEDIATR NEUROSURG, V36, P225, DOI 10.1159/000058424
   Basak M, 2002, ACTA RADIOL, V43, P626, DOI 10.1034/j.1600-0455.2002.430618.x
   Chandra PS, 1999, PEDIATR NEUROSURG, V31, P49, DOI 10.1159/000028831
   Emura T, 2002, PEDIATR NEUROSURG, V36, P229, DOI 10.1159/000058425
   Ersahin Y, 2000, PEDIATR NEUROSURG, V32, P109, DOI 10.1159/000028909
   Garg Kanwaljeet, 2015, Asian J Neurosurg, V10, P226, DOI 10.4103/1793-5482.161196
   Izci Y, 2011, PEDIATR NEUROSURG, V47, P461, DOI 10.1159/000339209
   Katoh M, 1998, CHILD NERV SYST, V14, P398, DOI 10.1007/s003810050253
   Khandelwal A, 2011, J PEDIATR NEUROSCI, V6, P58, DOI 10.4103/1817-1745.84411
   Klessinger S, 1996, NEUROSURGERY, V39, P1215, DOI 10.1097/00006123-199612000-00027
   Pang D, 2017, TXB PEDIAT NEUROSURG
   PANG DL, 1992, NEUROSURGERY, V31, P451, DOI 10.1227/00006123-199209000-00010
   Prasad G L, 2012, J Pediatr Neurosci, V7, P167, DOI 10.4103/1817-1745.106469
   Salunke P, 2011, CLIN NEUROL NEUROSUR, V113, P774, DOI 10.1016/j.clineuro.2011.07.023
   Singh PK, 2011, PEDIATR NEUROSURG, V47, P227, DOI 10.1159/000334278
   van Aalst J, 2005, CHILD NERV SYST, V21, P1020, DOI 10.1007/s00381-005-1159-8
   Zaleska-Dorobisz U, 2010, POL J RADIOL, V75, P82
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 142
EP 149
DI 10.1016/j.wneu.2019.09.076
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700184
PM 31557552
OA Bronze
DA 2020-05-12
ER

PT J
AU Imahori, T
   Okamura, Y
   Sakata, J
   Shose, H
   Yamanishi, S
   Kohmura, E
AF Imahori, Taichiro
   Okamura, Yusuke
   Sakata, Junichi
   Shose, Hiroyasu
   Yamanishi, Shunsuke
   Kohmura, Eiji
TI Delayed Rebleeding from Pseudoaneurysm After Mechanical Thrombectomy
   Using Stent Retriever Due to Small Artery Avulsion Confirmed by Open
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Mechanical thrombectomy; Pseudoaneurysm;
   Rebleeding; Stent retriever; Subarachnoid hemorrhage
ID TREVO PROVUE; STROKE; VESSEL
AB BACKGROUND: Pseudoaneurysm after mechanical thrombectomy (MT) is rare but is one of the potential complications associated with endovascular procedures. There is limited information regarding its mechanism of formation and the potential risk of delayed bleeding.
   CASE DESCRIPTION: An 84-year-old woman was admitted to our institution with right hemiplegia and global aphasia. Magnetic resonance imaging and angiography revealed occlusion of the M2 segment of the left middle cerebral artery with subtle acute ischemic change in this territory. After initiating intravenous thrombolysis, MT was performed for persistent occlusion of the M2. Successful revascularization was finally achieved with a single pass of a Trevo XP 3 mm x 20 mm stent retriever; significant deviation of the vessel occurred during withdrawal of the stent retriever. Anticoagulation was initiated after confirming resolution of a small amount of postprocedural subarachnoid hemorrhage 1 day after the procedure. However, 4 days after the procedure, computed tomography and angiography revealed a massive sylvian hematoma with de novo formation of a small pseudoaneurysm at the site where the stent retriever was deployed. Open surgery revealed a small artery avulsion at this site. The lesion was closed by microsurgical suturing.
   CONCLUSIONS: Angiographic and intraoperative findings showed that the mechanism of formation of the pseudoaneurysm was small artery avulsion resulting from deviation of the vessel during withdrawal of the stent retriever. When performing MT in a tortuous distal vessel, the possibility of small artery avulsion should be kept in mind to both prevent and manage critical hemorrhagic complications.
C1 [Imahori, Taichiro; Okamura, Yusuke; Sakata, Junichi; Shose, Hiroyasu; Yamanishi, Shunsuke] Toyooka Hosp, Dept Neurosurg, Toyooka, Hyogo, Japan.
   [Kohmura, Eiji] Kobe Univ, Dept Neurosurg, Grad Sch Med, Kobe, Hyogo, Japan.
   [Imahori, Taichiro] Hyogo Brain & Heart Ctr, Dept Neurosurg, Himeji, Hyogo, Japan.
RP Imahori, T (reprint author), Toyooka Hosp, Dept Neurosurg, Toyooka, Hyogo, Japan.; Imahori, T (reprint author), Hyogo Brain & Heart Ctr, Dept Neurosurg, Himeji, Hyogo, Japan.
EM taichiro.imahori@gmail.com
OI Imahori, Taichiro/0000-0002-8744-3044
CR Balami JS, 2018, INT J STROKE, V13, P348, DOI 10.1177/1747493017743051
   Goto S, 2018, WORLD NEUROSURG, V109, pE468, DOI 10.1016/j.wneu.2017.10.004
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Helou E, 2019, WORLD NEUROSURG, V128, P336, DOI 10.1016/j.wneu.2019.05.097
   Imahori T, 2017, NEUROL MED-CHIR, V57, P128, DOI 10.2176/nmc.oa.2016-0215
   Jeong Eun-Oh, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P296, DOI 10.7461/jcen.2016.18.3.296
   Misaki K, 2016, ACTA NEUROCHIR, V158, P2085, DOI 10.1007/s00701-016-2952-8
   Yoon W, 2013, STROKE, V44, P414, DOI 10.1161/STROKEAHA.112.675546
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 150
EP 154
DI 10.1016/j.wneu.2019.09.141
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700185
PM 31589986
OA Bronze
DA 2020-05-12
ER

PT J
AU Chidambaram, S
   Swong, K
   Ander, M
   Nockels, RP
AF Chidambaram, Swathi
   Swong, Kevin
   Ander, Michael
   Nockels, Russel P.
TI Pseudohypoxic Brain Swelling After Uncomplicated Lumbar Decompression
   and Fusion for Spondylolisthesis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbar decompression and fusion; Postoperative complications;
   Postoperative intracranial hypotension-associated venous; Pseudohypoxic
   brain swelling
ID SPONTANEOUS INTRACRANIAL HYPOTENSION; CEREBROSPINAL-FLUID LEAK; SURGERY
AB BACKGROUND: Pseudohypoxic brain swelling (RIBS), also known as post-operative intracranial hypotension-associated venous congestion, is a rare complication after neurosurgery characterized by rapid and often severe postoperative deterioration in consciousness and distinct imaging findings on brain magnetic resonance imaging. Imaging findings associated with PHBS include computed tomography and magnetic resonance imaging findings that resemble hypoxic changes and intracranial hypotensive changes in basal ganglia and thalamus, telencephalic, and infratentorial regions without notable changes in intracranial vasculature.
   CASE DESCRIPTION: This report describes the case of an L4-5 micro-diskectomy with posterior decompression and fusion complicated by clinical and radiographic findings resembling PHBS without a known intraoperative durotomy.
   CONCLUSIONS: Spine surgeons should be alerted to the possibility that PHBS occur in patients even after an operation without known durotomy or cerebrospinal fluid leakage and with spontaneous clinical resolution unrelated to suction drainage changes or epidural blood patches.
C1 [Chidambaram, Swathi; Swong, Kevin; Ander, Michael; Nockels, Russel P.] Loyola Univ Med Ctr, Dept Neurol Surg, Maywood, IL 60153 USA.
RP Nockels, RP (reprint author), Loyola Univ Med Ctr, Dept Neurol Surg, Maywood, IL 60153 USA.
EM rpnockels@mac.com
CR Albayram S, 2008, EUR SPINE J, V17, pS347, DOI 10.1007/s00586-008-0681-2
   Beck J, 2016, NEUROLOGY, V87, P1220, DOI 10.1212/WNL.0000000000003122
   Binder DK, 2005, J NEUROSURG-SPINE, V2, P614, DOI 10.3171/spi.2005.2.5.0614
   Bonow RH, 2016, J NEUROSURG-SPINE, V24, P389, DOI 10.3171/2015.6.SPINE1521
   Bothe AM, 2014, CLIN NEURORADIOL, V24, P65, DOI 10.1007/s00062-013-0202-5
   Chaves C, 2005, J NEUROSURG, V102, P152, DOI 10.3171/jns.2005.102.1.0152
   Evins AI, 2013, CLIN NEUROL NEUROSUR, V115, P2243, DOI 10.1016/j.clineuro.2013.07.007
   Fehnel CR, 2014, BMJ CASE REP, V10, P1
   Francia A, 2001, NEUROL SCI, V22, P385, DOI 10.1007/s100720100069
   Hadizadeh DR, 2010, AM J NEURORADIOL, V31, P100, DOI 10.3174/ajnr.A1749
   Inamasu Joji, 2006, Spine J, V6, P591, DOI 10.1016/j.spinee.2005.12.026
   Liao YJ, 2007, J NEUROSURG, V107, P173, DOI 10.3171/JNS-07/07/0173
   Messori A, 2001, NEUROL SCI, V22, P411, DOI 10.1007/s100720100076
   Parpaley Y, 2011, NEUROSURGERY, V68, pE277, DOI 10.1227/NEU.0b013e3181fead14
   Pham MH, 2016, EUR SPINE J, V25, P888, DOI 10.1007/s00586-015-4241-2
   Samadani U, 2003, NEUROSURGERY, V52, P148, DOI 10.1097/00006123-200301000-00019
   Savoiardo M, 2007, BRAIN, V130, P1884, DOI 10.1093/brain/awm101
   Sayer FT, 2006, NEUROSURGERY, V59, P204, DOI 10.1227/01.NEU.0000129843.34356.EE
   Schick U, 2016, NEUROLOGY, V12, P1220
   Schievink WI, 2012, J NEUROSURG, V116, P749, DOI 10.3171/2011.12.JNS111474
   Sporns PB, 2016, ROFO-FORTSCHR RONTG, V188, P451, DOI 10.1055/s-0035-1567034
   Van Roost D, 2003, NEUROSURGERY, V53, P1315, DOI 10.1227/01.NEU.0000093498.08913.9E
   Vogel TW, 2010, J NEUROSURG, V113, P955, DOI 10.3171/2010.5.JNS091405
   Yokota H, 2009, CLIN NEUROL NEUROSUR, V111, P900, DOI 10.1016/j.clineuro.2009.08.007
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 155
EP 158
DI 10.1016/j.wneu.2019.07.228
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700186
PM 31493605
OA Bronze
DA 2020-05-12
ER

PT J
AU Shah, KA
   Katz, JM
AF Shah, Kevin A.
   Katz, Jeffrey M.
TI Ruptured Persistent Trigeminal Artery-Basilar Artery Junction Aneurysm:
   Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Coil-embolization; Fetal carotid-basilar anastomosis; Persistent
   trigeminal artery aneurysm
ID INFERIOR CEREBELLAR ARTERY; VARIANT
AB BACKGROUND: The persistent trigeminal artery is the most common type of persistent fetal carotid-basilar anastomosis. Patients who are found to have a persistent trigeminal artery are more likely to harbor intracranial aneurysms, both along the persistent trigeminal artery and elsewhere in the cerebral vasculature.
   CASE DESCRIPTION: We report the case of a 48-year-old male who presented a ruptured persistent trigeminal artery aneurysm arising at the trigeminal artery-basilar junction. In this patient, the trigeminal artery was the primary blood supply to the internal carotid artery due to an absent common carotid artery. He was treated successfully with balloon-assisted coil embolization and occlusion of the persistent trigeminal artery.
   CONCLUSIONS: Although several variations of the persistent trigeminal ar-tery describe blood flow from the internal carotid to the posterior circulation, this is the first case to describe a persistent trigeminal artery that is the primary supply of the internal carotid artery due to an absent common carotid artery. Successful treatment of aneurysms of the persistent trigeminal artery may require occlusion of the artery.
C1 [Shah, Kevin A.] North Shore Univ Hosp, Dept Neurosurg, New York, NY 11030 USA.
   [Katz, Jeffrey M.] North Shore Univ Hosp, Dept Neurol, New York, NY USA.
RP Shah, KA (reprint author), North Shore Univ Hosp, Dept Neurosurg, New York, NY 11030 USA.
EM kshah8@northwell.edu
CR Aguiar GB, 2011, INTERV NEURORADIOL, V17, P343, DOI 10.1177/159101991101700310
   Ali S, 2008, NEUROSURGERY, V62, P746, DOI [10.1227/01.NEU.0000297127.23313.C6, 10.1227/01.neu.0000317327.17225.f8]
   Azab W, 2012, TURK NEUROSURG, V22, P399, DOI 10.5137/1019-5149.JTN.4427-11.1
   Baskaya MK, 2001, SURG RADIOL ANAT, V23, P169, DOI 10.1007/s00276-001-0169-9
   CHAMBERS AA, 1975, NEURORADIOLOGY, V9, P121, DOI 10.1007/BF00332958
   Chen WH, 2015, CLIN NEURORADIOL, V25, P207, DOI 10.1007/s00062-014-0314-6
   COBB SR, 1983, SURG NEUROL, V19, P263, DOI 10.1016/S0090-3019(83)80013-5
   Diana F, 2019, J NEUROINTERV SURG, V11, P1261, DOI 10.1136/neurintsurg-2019-015046
   Fan Y, 2019, J STROKE CEREBROVASC, V28, DOI 10.1016/j.jstrokecerebrovasdis.2019.104306
   HAUGHTON VM, 1978, AM J ROENTGENOL, V130, P1191, DOI 10.2214/ajr.130.6.1191
   Hou K, 2019, WORLD NEUROSURG, V124, P313, DOI 10.1016/j.wneu.2019.01.030
   Luh GY, 1999, AM J ROENTGENOL, V172, P1427, DOI 10.2214/ajr.172.5.10227532
   MERRY GS, 1977, J NEUROSURG, V47, P613, DOI 10.3171/jns.1977.47.4.0613
   MORITA A, 1989, J NEUROSURG, V70, P415, DOI 10.3171/jns.1989.70.3.0415
   Murai S, 2019, ACTA NEUROCHIR, V161, P407, DOI 10.1007/s00701-018-3767-6
   Nishio A, 2001, NEUROL MED-CHIR, V41, P446, DOI 10.2176/nmc.41.446
   Salas E, 1998, NEUROSURGERY, V43, P557, DOI 10.1097/00006123-199809000-00082
   SALTZMAN GF, 1959, ACTA RADIOL, V51, P329, DOI 10.3109/00016925909171103
   SCOTTI G, 1975, RADIOLOGY, V116, P93, DOI 10.1148/116.1.93
   Silver J, 1996, NEUROSURGERY, P1990
   TANAKA Y, 1983, J NEUROSURG, V59, P520, DOI 10.3171/jns.1983.59.3.0520
   TEAL JS, 1972, RADIOLOGY, V103, P335, DOI 10.1148/103.2.335
   Tubbs RS, 2011, J NEUROSURG, V114, P1127, DOI 10.3171/2010.11.JNS101527
   Weon YC, 2011, ACTA RADIOL, V52, P1043, DOI 10.1258/ar.2011.110191
   Zenteno Marco, 2018, Asian J Neurosurg, V13, P817, DOI 10.4103/ajns.AJNS_53_16
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 159
EP 162
DI 10.1016/j.wneu.2019.10.015
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700187
PM 31606505
OA Bronze
DA 2020-05-12
ER

PT J
AU Brusko, GD
   Luther, E
   Levi, AD
AF Brusko, G. Damian
   Luther, Evan
   Levi, Allan D.
TI Use of Cervical Disk Arthroplasty to Treat Noncontiguous Cervical Disk
   Herniations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arthroplasty; Bryan disk; Cervical; Disk herniation; Fusion; Multilevel
ID FUSION; DISKECTOMY
AB BACKGROUND: Cervical disk arthroplasty is now a widely accepted alter-to anterior cervical interbody fusion, which is known to reduce normal cervical motion and increase the incidence of adjacent segment disease. Although multiple studies report the use of cervical disk arthroplasty to treat multilevel cervical disease, this is the first report in the literature detailing the placement of multiple, noncontiguous artificial disks.
   CASE DESCRIPTION: We describe a 41-year-old male who presented with myelopathy and left upper extremity radiculopathy resulting from 2 cervical disk herniations separated by a normal intervening level. He underwent an anterior cervical diskectomy and placement of an artificial disk prosthesis at cervical (C) 4-5 and C6-7 while leaving C5-6 intact.
   CONCLUSIONS: This approach serves to preserve cervical motion, spinal stability, and lordosis across all 3 levels, thus demonstrating that it is a viable alternative to a multilevel anterior cervical interbody fusion.
C1 [Brusko, G. Damian; Luther, Evan; Levi, Allan D.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Lois Pope Life Ctr, Miami, FL 33136 USA.
RP Brusko, GD (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Lois Pope Life Ctr, Miami, FL 33136 USA.
EM g.brusko@med.miami.edu
OI Luther, Evan/0000-0001-9164-4984
CR Cardoso MJ, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS1031
   Chang SW, 2018, J CLIN NEUROSCI, V57, P185, DOI 10.1016/j.jocn.2018.08.050
   Finn MA, 2011, SPINE, V36, P448, DOI 10.1097/BRS.0b013e3181fd5d7c
   Ghobrial GM, 2019, NEUROSURGERY, V84, P347, DOI 10.1093/neuros/nyy118
   Goffin J, 2002, NEUROSURGERY, V51, P840, DOI 10.1227/01.NEU.0000026100.14273.B3
   Kim SW, 2009, EUR SPINE J, V18, P218, DOI 10.1007/s00586-008-0854-z
   Lavelle WF, 2019, SPINE, V44, P601, DOI 10.1097/BRS.0000000000002907
   Li Qin, 2007, Zhonghua Yi Xue Za Zhi, V87, P1173
   Luo JQ, 2018, WORLD NEUROSURG, V113, P225, DOI 10.1016/j.wneu.2018.02.113
   Sekhon LHS, 2005, J NEUROSURG-SPINE, V3, P335, DOI 10.3171/spi.2005.3.5.0335
   Sekhon LHS, 2004, J CLIN NEUROSCI, V11, P412, DOI 10.1016/j.jocn.2003.10.001
   Song Q P, 2018, Zhonghua Yi Xue Za Zhi, V98, P1686, DOI 10.3760/cma.j.issn.0376-2491.2018.21.013
   Sun QZ, 2016, INDIAN J ORTHOP, V50, P390, DOI 10.4103/0019-5413.185603
   Tu TH, 2011, J NEUROSURG-SPINE, V14, P457, DOI 10.3171/2010.11.SPINE10444
   Wang HR, 2013, J SPINAL DISORD TECH, V26, pE286, DOI 10.1097/BSD.0b013e31828679b3
   Wu JC, 2012, J NEUROSURG-SPINE, V16, P594, DOI 10.3171/2012.2.SPINE111066
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 163
EP 166
DI 10.1016/j.wneu.2019.10.019
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700188
PM 31606498
OA Bronze
DA 2020-05-12
ER

PT J
AU Zaed, I
   Attuati, L
   Tommasino, C
   Arosio, EM
   Navarria, P
   Stravato, A
   Colombo, G
   Picozzi, P
AF Zaed, Ismail
   Attuati, Luca
   Tommasino, Concezione
   Arosio, Enrico Massimo
   Navarria, Pierina
   Stravato, Antonella
   Colombo, Giovanni
   Picozzi, Piero
TI Gamma Knife Radiosurgery for Short Unilateral Neuralgiform Headache
   Attacks with Conjunctival injection and Tearing (SUNCT) Syndrome:
   Targeting the Trigeminal Nerve and the Sphenopalatine Ganglion. Case
   Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Gamma knife radiosurgery; Short-lasting unilateral neuralgiform headache
   attacks with conjunctival injection and tearing; Sphenopalatine
   ganglion; Trigeminal nerve
AB BACKGROUND: Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) is a primary headache syndrome with an unclear pathogenesis, and only in very few cases, SUNCT is secondary to known lesions (secondary SUNCT). Several pharmacological as well as interventional and invasive treatments have been used to treat SUNT cases, with no definitive results. We describe a patient with idiopathic SUNCT syndrome, successfully treated with gamma knife radiosurgery and we report a review of the cases of the literature treated with radiosurgery.
   CASE REPORT: A 63-year-old woman complained of episodes of intense and regular paroxysmal facial pain in the territory of the maxillary branch of the trigeminal nerve accompanied by inflammation of conjunctiva and involuntary lacrimation from 2006. During the following years, she received several treatments: combination of drugs, acupuncture, and endonasal infiltration of the sphenopalatine ganglion. The frequency of the painful attacks increased progressively and it was impossible for her to have a normal active life. Combined gamma knife radiosurgery treatment, targeting the trigeminal nerve (80 Gy maximum dose) and the sphenopalatine ganglion (80 Gy maximum dose) was performed in April 2016 (visual analog score before treatment = 6). Pain gradually reduced in the following months, as well as frequency and severity of the attacks. No sensory deficit developed. The follow-up length of our patient is 37 months: she is nearly pain free (visual analog score = 2) and has resumed a normal life.
   CONCLUSIONS: Patients with idiopathic SUNCT have few therapeutic options. Our case demonstrates that gamma knife radiosurgery is a feasible and effective noninvasive option to treat patients with medically refractory idiopathic SUNCT.
C1 [Zaed, Ismail; Attuati, Luca; Picozzi, Piero] Humanitas Clin & Res Ctr IRCCS, Neurosurg, Rozzano Milano, Italy.
   [Tommasino, Concezione] Univ Milan, ASST Santi Paolo & Carlo Univ Hosp, Dept Biomed Surg & Odontoiatr Sci, Milan, Italy.
   [Arosio, Enrico Massimo] Humanitas Clin & Res Ctr IRCCS, Anesthesia, Rozzano Milano, Italy.
   [Navarria, Pierina] Humanitas Clin & Res Ctr IRCCS, Radiat Oncol, Rozzano Milano, Italy.
   [Stravato, Antonella] Humanitas Clin & Res Ctr IRCCS, Med Phys, Rozzano Milano, Italy.
   [Colombo, Giovanni] Humanitas Clin & Res Ctr IRCCS, Otorhinolaryngol Unit, Rozzano Milano, Italy.
RP Zaed, I (reprint author), Humanitas Clin & Res Ctr IRCCS, Neurosurg, Rozzano Milano, Italy.
EM ismailzaed1@gmail.com
OI Attuati, Luca/0000-0002-4163-1779; zaed, ismail/0000-0003-3506-4111
CR Arca KN, 2018, CURR PAIN HEADACHE R, V22, DOI 10.1007/s11916-018-0707-3
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Black DF, 2002, CEPHALALGIA, V22, P201, DOI 10.1046/j.1468-2982.2002.00348.x
   Cao Y, 2018, J CLIN NEUROL, V14, P433, DOI 10.3988/jcn.2018.14.4.433
   Effendi K, 2011, CEPHALALGIA, V31, P870, DOI 10.1177/0333102411404716
   Goadsby PJ, 2001, ACTA NEUROL BELG, V101, P10
   Massager N, 2004, J NEUROSURG, V100, P597, DOI 10.3171/jns.2004.100.4.0597
   Mathew T, 2012, J HEADACHE PAIN, V13, P491, DOI 10.1007/s10194-012-0457-2
   PAREJA JA, 1994, HEADACHE, V34, P114, DOI 10.1111/j.1526-4610.1994.hed3402114.x
   Pareja JA, 2002, CNS DRUGS, V16, P373, DOI 10.2165/00023210-200216060-00002
   Pareja JA, 2013, CURR TREAT OPTION NE, V15, P28, DOI 10.1007/s11940-012-0211-8
   Schytz HW, 2013, CEPHALALGIA, V33, P831, DOI 10.1177/0333102413476370
   Tan DYH, 2013, CEPHALALGIA, V33, P1132, DOI 10.1177/0333102413484985
   Trucco M, 2004, CEPHALALGIA, V24, P173, DOI 10.1111/j.1468-2982.2003.00646.x
   Tuleasca C, 2019, J NEUROSURG, V130, P733, DOI 10.3171/2017.9.JNS17545
   Xu ZY, 2014, J NEUROSURG, V120, P716, DOI 10.3171/2013.10.JNS131596
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 167
EP 171
DI 10.1016/j.wneu.2019.10.016
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700189
PM 31606507
OA Bronze, Green Published
DA 2020-05-12
ER

PT J
AU Raper, DMS
   Rutledge, WC
   Winkler, EA
   Abla, AA
AF Raper, Daniel M. S.
   Rutledge, W. Caleb
   Winkler, Ethan A.
   Abla, Adib A.
TI Y-Stent Technique for Treatment of Wide-Necked Posterior Communicating
   Artery Aneurysm Associated with Fetal Posterior Cerebral Artery
   Technical Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Embolization; Endovascular; Stent; Technique
ID ENDOVASCULAR TREATMENT; CONFIGURATION; EMBOLIZATION
AB BACKGROUND: Despite a variety of technologies that are available for of complex intracranial aneurysms, certain anatomic configurations remain challenging to address endovascularly.
   CASE DESCRIPTION: A patient was found to have an incidental 12 mm x 11 x 10 mm, wide-necked right posterior communicating artery aneurysm with a fetal origin of the posterior cerebral artery arising directly from the aneurysm dome. After multidisciplinary discussion, a staged endovascular treatment approach was undertaken in 2 stages. First, a Y-stent construct using 2 overlapping Neuroform Atlas stents was placed into the M1 and fetal posterior cerebral artery segments. Two months later, after endothelialization of the stent construct, coil embolization of the aneurysm was performed. The patient tolerated both stages of the procedure well and was discharged the following day in each case. She remained neurologically intact, and at follow-up 5 months later had no evidence of residual or recurrent aneurysm.
   CONCLUSIONS: This case illustrates a number of important considerations in management approach for wide-necked intracranial aneurysms.
C1 [Raper, Daniel M. S.; Rutledge, W. Caleb; Winkler, Ethan A.; Abla, Adib A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
RP Abla, AA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM Adib.abla@ucsf.edu
CR Cagnazzo F, 2019, AM J NEURORADIOL, V40, P122, DOI 10.3174/ajnr.A5900
   Castano C, 2017, INTERV NEURORADIOL, V23, P362, DOI 10.1177/1591019917708568
   Chow MM, 2004, AM J NEURORADIOL, V25, P509
   Granja MF, 2019, J NEUROINTERV SURG, V11, P683, DOI 10.1136/neurintsurg-2018-014517
   Johnson AK, 2015, J NEUROSURG, V123, P453, DOI 10.3171/2014.10.JNS141361
   Melber K, 2017, J NEUROINTERV SURG, V9, P1233, DOI 10.1136/neurintsurg-2016-012858
   Samaniego EA, 2018, INTERV NEUROL, V7, P271, DOI 10.1159/000487545
   Tsang Anderson Chun On, 2015, Neurointervention, V10, P60, DOI 10.5469/neuroint.2015.10.2.60
   Ulfert C, 2018, J NEUROINTERV SURG, V10, P1192, DOI 10.1136/neurintsurg-2017-013516
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 173
EP 177
DI 10.1016/j.wneu.2019.09.153
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700191
PM 31605854
OA Bronze
DA 2020-05-12
ER

PT J
AU Huntoon, K
   Eltobgy, M
   Mohyeldin, A
   Elder, JB
AF Huntoon, Kristin
   Eltobgy, Mostafa
   Mohyeldin, Ahmed
   Elder, J. Bradley
TI Lower Extremity Paralysis After Radiofrequency Ablation of Vertebral
   Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Paralysis; Radiofrequency ablation; Spine
ID SPINAL METASTASES; THERMAL ABLATION; BONE METASTASES; PAIN RELIEF;
   THERAPY; VERTEBROPLASTY; OSTEOPLASTY; DEVICE; TUMORS; CEMENTOPLASTY
AB BACKGROUND: Radiofrequency ablation (RFA) focally destroys abnormal or dysfunctional tissue using thermal energy generated from alternating current. The utilization of RFA has gained popularity as a minimally invasive procedure for the treatment of skeletal metastases with a particular focus on palliative pain treatments to the spine, pelvis, long bones, sternum, and glenoid. More recently, single-session procedures that combine RFA with vertebral augmentation techniques have allowed treatment to areas of pain associated with pathologic fractures secondary to metastatic disease. Although many studies have been done to investigate the safety and efficacy of RFA, there have been no reported cases to date in which the use of RFA for the treatment of spinal metastases has led to any major permanent neurological injury.
   CASE DESCRIPTION: This report describes a case of a 61-year-old woman who underwent RFA and kyphoplasty for spinal metastases and noted the immediate onset of lower extremity paralysis after the procedure. To the best of our knowledge, this is the first documented case of permanent lower extremity paralysis in the medical literature after radiofrequency thermal ablation of spine metastases.
   CONCLUSIONS: Postoperative magnetic resonance imaging and physical examination suggest RFA-induced thermal injury as the most likely mechanism of paralysis. In this report, a review of previous in vivo models used in studying the efficacy and safety of spine RFA is conducted. Additionally, the literature has been reviewed for any neurological events reported with the use of RFA in the treatment of patients with vertebral pathology.
C1 [Huntoon, Kristin; Eltobgy, Mostafa; Elder, J. Bradley] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
   [Mohyeldin, Ahmed] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA USA.
RP Huntoon, K (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
EM Kristin.Huntoon@osumc.edu
FU Ohio State University Wexner Medical Center Neurological Surgery
   Department
FX This work was supported in part by The Ohio State University Wexner
   Medical Center Neurological Surgery Department.
CR Adachi A, 2008, RADIOLOGY, V247, P374, DOI 10.1148/radiol.2472070808
   Al-Qurainy R, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2539
   Anchala PR, 2014, PAIN PHYSICIAN, V17, P317
   Burgard CA, 2018, DIAGN INTERV RADIOL, V24, P158, DOI 10.5152/dir.2018.17265
   Buscarini L, 1992, INTERSTITIAL RADIOFR
   Cedeno DL, 2017, PAIN PHYSICIAN, V20, pE914
   Clarencon F, 2013, SKELETAL RADIOL, V42, P25, DOI 10.1007/s00256-011-1294-0
   David E, 2017, ANN PALLIAT MED, V6, P118, DOI 10.21037/apm.2016.12.02
   Delank KS, 2011, DTSCH ARZTEBL INT, V108, P71, DOI 10.3238/arztebl.2011.0071
   Di Staso M, 2011, EUR RADIOL, V21, P2004, DOI 10.1007/s00330-011-2133-3
   Dupuy DE, 2010, CANCER-AM CANCER SOC, V116, P989, DOI 10.1002/cncr.24837
   Elder JB, 2019, DIAGN PATHOL, V14, DOI 10.1186/s13000-019-0794-4
   Goetz MP, 2004, J CLIN ONCOL, V22, P300, DOI 10.1200/JCO.2004.03.097
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Greenwood TJ, 2015, PAIN PHYSICIAN, V18, P573
   Gronemeyer DHW, 2002, CANCER J, V8, P33
   Hillen TJ, 2014, RADIOLOGY, V273, P261, DOI 10.1148/radiol.14131664
   Hoffmann RT, 2008, J VASC INTERV RADIOL, V19, P419, DOI 10.1016/j.jvir.2007.09.016
   Iannaccone F, 2017, PAIN PHYSICIAN, V20, pE437
   Kim YS, 2011, RADIOGRAPHICS, V31, P377, DOI 10.1148/rg.312105056
   Klimo P, 2004, ONCOLOGIST, V9, P188, DOI 10.1634/theoncologist.9-2-188
   Lane MD, 2011, SKELETAL RADIOL, V40, P25, DOI 10.1007/s00256-010-1010-5
   Leggett LE, 2014, PAIN RES MANAG, V19, pE146, DOI 10.1155/2014/834369
   Li Shuling, 2012, Clin Epidemiol, V4, P87, DOI 10.2147/CLEP.S28339
   Masala S, 2011, SINGAP MED J, V52, P182
   Masala S, 2007, ANTICANCER RES, V27, P4259
   Munk PL, 2009, J VASC INTERV RADIOL, V20, P903, DOI 10.1016/j.jvir.2009.03.035
   Poulou LS, 2015, WORLD J HEPATOL, V7, P1054, DOI 10.4254/wjh.v7.i8.1054
   ROSENTHAL DI, 1995, RADIOLOGY, V197, P451, DOI 10.1148/radiology.197.2.7480692
   ROSSI S, 1993, J INTERVENT RADIOL, V8, P97
   Snyder NW, 2015, CHEM-BIOL INTERACT, V234, P144, DOI 10.1016/j.cbi.2014.10.029
   Stafford R. Jason, 2010, Critical Reviews in Biomedical Engineering, V38, P79
   Tomasian A, 2016, AM J NEURORADIOL, V37, P189, DOI 10.3174/ajnr.A4521
   Tomasian A, 2018, AM J ROENTGENOL, V210, P142, DOI 10.2214/AJR.17.18205
   Toyota N, 2005, CARDIOVASC INTER RAD, V28, P578, DOI 10.1007/s00270-004-0208-0
   Wallace AN, 2017, AM J NEURORADIOL, V38, P1653, DOI 10.3174/ajnr.A5228
   Wallace AN, 2016, AM J NEURORADIOL, V37, P759, DOI 10.3174/ajnr.A4595
   Wallace AN, 2015, J NEURO-ONCOL, V124, P111, DOI 10.1007/s11060-015-1813-2
   Wang Xudong, 2018, Spinal Cord Ser Cases, V4, P87, DOI 10.1038/s41394-018-0120-5
   West J, 2018, J NEUROINTERV SUR S2, V10, pA97
   YAMANE T, 1992, SPINE, V17, P1386, DOI 10.1097/00007632-199211000-00020
   You NK, 2013, SPINE, V38, pE1121, DOI 10.1097/BRS.0b013e31829c2e12
   Zhan Y, 2017, WORLD NEUROSURG, V101, P633, DOI 10.1016/j.wneu.2017.01.124
   Zhao ZZ, 2018, CANCER LETT, V421, P73, DOI 10.1016/j.canlet.2018.02.024
   Zheng LP, 2014, MED SCI MONITOR, V20, P556, DOI 10.12659/MSM.889742
   Zhu MM, 2017, QUANT IMAGING MED SU, V7, P356, DOI 10.21037/qims.2017.06.06
NR 46
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 178
EP 184
DI 10.1016/j.wneu.2019.09.163
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700192
PM 31606502
OA Bronze
DA 2020-05-12
ER

PT J
AU Kuroshima, K
   Waki, T
   Kanemura, A
   Ito, K
   Kuroda, R
AF Kuroshima, Kohei
   Waki, Takahiro
   Kanemura, Aritetsu
   Ito, Kenjiro
   Kuroda, Ryosuke
TI Spinal Subarachnoid Hematoma After Cerebrospinal Fluid Drainage in
   Thoracoabdominal Aortic Aneurysm Repair: Case Report and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebrospinal fluid drainage; Endovascular aortic repair; Spinal
   subarachnoid hematoma; Thoracoabdominal aortic aneurysm
ID PRACTICE GUIDELINES; COMPLICATIONS; OPERATIONS; SURGERY; PARAPLEGIA;
   EXPERIENCE; SOCIETY; RISK
AB BACKGROUND: Cerebrospinal fluid (CSF) drainage reduces the risk of paraplegia in thoracoabdominal aortic aneurysm (TAM) repair. Intracranial hemorrhage after TAAA repair has been reported as a rare complication of CSF drainage; however, spinal subarachnoid hematoma has never been reported. Here, we present a case of lumbosacral subarachnoid hematoma after CSF drainage in TAAA repair.
   CASE DESCRIPTION: The patient was a 76-year-old man who was hospitalized for TAAA repair. Just before the operation, a CSF drainage catheter was inserted into the L4/5 vertebral interspace. Continuous CSF drainage was performed during the operation. The CSF drain was clamped just after the operation, and the drainage catheters were removed at 24 hours after the operation. On postoperative day 1, the patient experienced pain and paralysis in both lower limbs that worsened over time. Magnetic resonance imaging of the brain and spinal cord was indicative of a spinal subarachnoid hematoma. Removal of hematoma with thoracolumbar and lumbosacral laminectomy was performed, and immediately after the surgery, the pain and paralysis in both lower limbs improved. Six months after the removal of the hematoma, the paralysis in both lower limbs completely resolved and the patient achieved the preinjury activity level.
   CONCLUSIONS: We present a rare case of lumbosacral subarachnoid hematoma after CSF drainage in TAAA repair. We should consider spinal subarachnoid hematoma when paralysis in the lower limbs occurs after CSF drainage.
C1 [Kuroshima, Kohei; Waki, Takahiro; Ito, Kenjiro] Akashi Med Ctr, Dept Orthoped Surg, Akashi, Hyogo, Japan.
   [Kanemura, Aritetsu] Kobe Rosai Hosp, Dept Orthoped Surg, Kobe, Hyogo, Japan.
   [Kuroda, Ryosuke] Kobe Univ, Grad Sch Med, Dept Orthoped Surg, Kobe, Hyogo, Japan.
RP Waki, T (reprint author), Akashi Med Ctr, Dept Orthoped Surg, Akashi, Hyogo, Japan.
EM waki1207@icloud.com
CR Breivik H, 2013, ACTA ANAESTH SCAND, V57, P541, DOI 10.1111/aas.12121
   Chaikof EL, 2018, J VASC SURG, V67, P2, DOI 10.1016/j.jvs.2017.10.044
   Cheung AT, 2003, ANN THORAC SURG, V76, P1190, DOI 10.1016/S0003-4975(03)00881-6
   Coselli JS, 2002, ANN THORAC SURG, V74, pS1881, DOI 10.1016/S0003-4975(02)04139-5
   CRAWFORD ES, 1986, J VASC SURG, V3, P389, DOI 10.1067/mva.1986.avs0030389
   Domenicucci M, 2005, ACTA NEUROCHIR, V147, P741, DOI 10.1007/s00701-004-0458-2
   Dua A, 2014, J VASC SURG, V59, P1512, DOI 10.1016/j.jvs.2014.01.007
   Eliason JL, 2008, CIRCULATION, V117, P1738, DOI 10.1161/CIRCULATIONAHA.107.747923
   Griepp RB, 1996, J THORAC CARDIOV SUR, V112, P1202, DOI 10.1016/S0022-5223(96)70133-2
   Hiratzka LF, 2010, CIRCULATION, V121, pE266, DOI 10.1161/CIR.0b013e3181d4739e
   Jacobs MJ, 2006, J VASC SURG, V43, P239, DOI 10.1016/j.jvs.2005.09.042
   Matsumura JS, 2014, J VASC SURG, V60, P1, DOI 10.1016/j.jvs.2014.01.043
   Miranda V, 2018, INT ANGIOL, V37, P112, DOI 10.23736/S0392-9590.18.03960-3
   Murakami H, 2004, J VASC SURG, V39, P243, DOI 10.1016/j.jvs.2003.07.013
   Safi HJ, 2003, ANN SURG, V238, P372, DOI 10.1097/01.sla.0000086664.90571.7a
   Sugiura J, 2017, INTERACT CARDIOV TH, V24, P609, DOI 10.1093/icvts/ivw436
   SVENSSON LG, 1993, J VASC SURG, V17, P357, DOI 10.1016/0741-5214(93)90421-H
   Wortmann M, 2017, Gefasschirurgie, V22, P35, DOI 10.1007/s00772-017-0261-z
   Wynn MM, 2015, J CARDIOTHOR VASC AN, V29, P342, DOI 10.1053/j.jvca.2014.06.024
   Wynn MM, 2009, J VASC SURG, V49, P29, DOI 10.1016/j.jvs.2008.07.076
NR 20
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 188
EP 191
DI 10.1016/j.wneu.2019.09.171
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700194
PM 31605857
OA Bronze
DA 2020-05-12
ER

PT J
AU Young, JS
   Morshed, RA
   Mansoori, Z
   Cha, S
   Berger, MS
AF Young, Jacob S.
   Morshed, Ramin A.
   Mansoori, Ziba
   Cha, Soonmee
   Berger, Mitchel S.
TI Disruption of Frontal Aslant Tract Is Not Associated with Long-Term
   Postoperative Language Deficits
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diffusion tensor imaging; Frontal aslant tract; Glioma; Language
   processing
ID SUPPLEMENTARY MOTOR AREA; BRAIN-STIMULATION; BROCAS AREA; CONNECTIVITY;
   RECOVERY; SURGERY; SPEECH
AB BACKGROUND: The frontal aslant tract (FAT) is a white matter fiber pathway connecting the superior frontal gyrus to the Broca area. This tract in the dominant hemisphere has been shown to play a role in speech initiation and production, and direct subcortical stimulation can induce stuttering and speech arrest in a patient. However, controversy remains as to whether disruption of this pathway will lead to a permanent language deficit and if it is even necessary to map this tract during tumor resections of the dominant frontal lobe.
   CASE DESCRIPTION: Here, we report a case of a patient with a lower-grade diffuse glioma invading the dominant FAT that was removed with an asleep craniotomy. In the immediate postoperative state, the patient had a transcortical motor dysphasia and was unable to initiate speech. These immediate language deficits quickly recovered, and the patient was neurologically intact at the time of discharge a few days after surgery.
   CONCLUSIONS: Given the high likelihood for a complete neurologic recovery including transient aphasia, we propose that awake mapping for the purpose of identifying the dominant FAT is unnecessary during tumor resection and that disruption of this tract is not associated with any long-term language deficits.
C1 [Young, Jacob S.; Morshed, Ramin A.; Cha, Soonmee; Berger, Mitchel S.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.
   [Mansoori, Ziba; Cha, Soonmee] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
RP Berger, MS (reprint author), Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.
EM Mitchel.berger@ucsf.edu
RI Young, Jacob/AAE-6194-2020
CR Acioly MA, 2015, J NEUROL SURG PART A, V76, P508, DOI 10.1055/s-0035-1558408
   Baker CM, 2018, BRAIN BEHAV, V8, DOI 10.1002/brb3.926
   Budisavljevic S, 2017, NEUROIMAGE, V146, P419, DOI 10.1016/j.neuroimage.2016.10.051
   Catani M, 2013, BRAIN, V136, P2619, DOI 10.1093/brain/awt163
   Catani M, 2012, CORTEX, V48, P273, DOI 10.1016/j.cortex.2011.12.001
   Chernoff BL, 2018, J COGNITIVE NEUROSCI, V30, P752, DOI 10.1162/jocn_a_01244
   Chivukula S, 2018, BRAIN LANG, V183, P41, DOI 10.1016/j.bandl.2018.05.006
   Duffau H, 2014, BRAIN LANG, V131, P1, DOI 10.1016/j.bandl.2013.05.011
   Duffau H, 2013, FRONT SYST NEUROSCI, V7, DOI 10.3389/fnsys.2013.00044
   Ford A, 2010, NEUROIMAGE, V52, P1230, DOI 10.1016/j.neuroimage.2010.05.018
   Fujii M, 2015, J NEUROSURG, V122, P1390, DOI 10.3171/2014.10.JNS14945
   Henry RG, 2004, NEUROIMAGE, V21, P616, DOI 10.1016/j.neuroimage.2003.09.047
   Kemerdere R, 2016, J NEUROL, V263, P157, DOI 10.1007/s00415-015-7949-3
   Kinoshita M, 2015, BRAIN STRUCT FUNCT, V220, P3399, DOI 10.1007/s00429-014-0863-0
   Kronfeld-Duenias V, 2016, BRAIN STRUCT FUNCT, V221, P365, DOI 10.1007/s00429-014-0912-8
   LAPLANE D, 1977, J NEUROL SCI, V34, P301, DOI 10.1016/0022-510X(77)90148-4
   Vassal F, 2014, BRIT J NEUROSURG, V28, P685, DOI 10.3109/02688697.2014.889810
   Vassal M, 2017, J NEUROSURG, V126, P1181, DOI 10.3171/2016.4.JNS152484
   Wilson SM, 2015, J NEUROSURG, V123, P581, DOI 10.3171/2015.4.JNS141962
NR 19
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 192
EP 195
DI 10.1016/j.wneu.2019.09.128
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700195
PM 31574328
OA Bronze
DA 2020-05-12
ER

PT J
AU Morassi, M
   Vivaldi, O
   Cobelli, M
   Liserre, B
   Zorzi, F
   Bna, C
AF Morassi, Mauro
   Vivaldi, Oscar
   Cobelli, Milena
   Liserre, Barbara
   Zorzi, Fausto
   Bna, Claudio
TI A Multifocal Glioneuronal Tumor with RGNT-Like Morphology Occupying the
   Supratentorial Ventricular System and Infiltrating the Brain Parenchyma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraventricular glioneuronal tumors; Perfusion-weighted imaging;
   Rosette forming glioneuronal tumor; Tumor contrast enhancement
   variability
ID CONTRAST ENHANCEMENT; IMAGING FEATURES; MRI
AB BACKGROUND: Rosette-forming glioneuronal tumors (RGNTs) with multifocal growth throughout the ventricular system are extremely rare, and only 1 case of RGNT with dissemination limited to supratentorial ventricles has previously been reported. Recent evidence based on molecular data suggest that low-grade glioneuronal tumors (GNT) involving the septum pellucid= and the lateral ventricles, with either dysembryoplastic neuroepithelial tumor-like or RGNT-like features, may belong to a neuropathologic entity distinct from cortical dysembryoplastic neuroepithelial tumor and "typical" fourth ventricle RGNT, respectively. Given their rarity, the classification of these neoplasms is still uncertain and their clinicopathological and radiological aspects are only partially known.
   CASE DESCRIPTION: A 24-year-old male presented a GNT with RGNT-like morphological features centered in the septum pellucidum with multifocal masses occupying the lateral ventricles and the third ventricle with extraventricular infiltration of the frontal lobe. The patient underwent subtotal resection and 4 years follow-up. The clinicopathological and radiological features of the neoplasm are discussed.
   CONCLUSIONS: Advanced magnetic resonance imaging (magnetic resonance spectroscopy and perfusion-weighted imaging) may provide valuable information in the differential diagnosis between rare GNTs and other more frequent intraventricular neoplasms. In the present case, the enhancing remnant portion of the tumor showed remarkable contrast enhancement variability during the follow-up with slow in situ progression. However, available data suggest that spontaneous contrast enhancement "fluctuations" over time in RGNT may not represent a reliable indicator of tumor behavior.
C1 [Morassi, Mauro; Cobelli, Milena; Bna, Claudio] Fdn Poliambulanza Hosp, Dept Radiol & Image Diagnost, Brescia, Italy.
   [Vivaldi, Oscar] Fdn Poliambulanza Hosp, Dept Neurosurg, Brescia, Italy.
   [Liserre, Barbara; Zorzi, Fausto] Fdn Poliambulanza Hosp, Dept Pathol, Brescia, Italy.
RP Morassi, M (reprint author), Fdn Poliambulanza Hosp, Dept Radiol & Image Diagnost, Brescia, Italy.
EM mauro.morassi@poliambulanza.it
CR Campos AR, 2009, NEURORADIOLOGY, V51, P433, DOI 10.1007/s00234-009-0511-1
   Christoforidis GA, 2011, IMAGING OF BRAIN TUMORS WITH HISTOLOGICAL CORRELATIONS, SECOND EDITION, P73, DOI 10.1007/978-3-540-87650-2_5
   Danchaivijitr N, 2008, RADIOLOGY, V247, P170, DOI 10.1148/radiol.2471062089
   Donoho D, 2015, NEUROSURG CLIN N AM, V26, P11, DOI 10.1016/j.nec.2014.09.012
   Fujiwara H, 2012, SHINDANBYORI, V29, P136
   Gao L, 2018, CLIN RADIOL, V73, P275, DOI 10.1016/j.crad.2017.10.011
   Gaudino S, 2012, NEURORADIOLOGY, V54, P989, DOI 10.1007/s00234-012-1010-3
   Haryu Shinya, 2015, NMC Case Rep J, V2, P65, DOI 10.2176/nmccrj.2014-0077
   Holveck A, 2010, J NEURORADIOLOGY, V37, P269, DOI 10.1016/j.neurad.2009.11.001
   Jayapalan Ronie Romelean, 2019, World Neurosurg X, V2, P100006, DOI 10.1016/j.wnsx.2018.100006
   Komori T, 2002, AM J SURG PATHOL, V26, P582, DOI 10.1097/00000478-200205000-00004
   KUCHELMEISTER K, 1995, ACTA NEUROPATHOL, V89, P385
   Kwon SM, 2019, WORLD NEUROSURG, V130, P271, DOI 10.1016/j.wneu.2019.06.042
   Li XD, 2018, EUR RADIOL, V28, P4306, DOI 10.1007/s00330-018-5442-y
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Medhi G, 2016, EUR RADIOL, V26, P262, DOI 10.1007/s00330-015-3808-y
   Pallud J, 2009, NEURO-ONCOLOGY, V11, P176, DOI 10.1215/15228517-2008-066
   Smits M, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20150857
   Solomon DA, 2018, ACTA NEUROPATHOL, V136, P339, DOI 10.1007/s00401-018-1883-2
   Tanaka Fumine, 2019, Radiol Case Rep, V14, P899, DOI 10.1016/j.radcr.2019.05.011
   Xiong J, 2012, NEUROPATHOLOGY, V32, P301, DOI 10.1111/j.1440-1789.2011.01261.x
   Yang C, 2017, ONCOTARGET, V8
   Yuh EL, 2009, CHILD NERV SYST, V25, P1203, DOI 10.1007/s00381-009-0878-7
   Zhou H, 2017, NEURO-ONCOLOGY, V19, P862, DOI 10.1093/neuonc/now256
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 196
EP 200
DI 10.1016/j.wneu.2019.10.017
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700196
PM 31606508
OA Bronze
DA 2020-05-12
ER

PT J
AU Aljuboori, Z
   Meyer, K
   Ding, D
   James, R
AF Aljuboori, Zaid
   Meyer, Kimberly
   Ding, Dale
   James, Robert
TI Endovascular Treatment of a Traumatic Middle Cerebral Artery
   Pseudoaneurysm with the Pipeline Flex Ernbolization Device
SO WORLD NEUROSURGERY
LA English
DT Article
DE Flow diversion; Pseudoaneurysm; Subarachnoid hemorrhage; Trauma
ID CAROTID-ARTERY; EMBOLIZATION DEVICE; CEREBELLAR ARTERY; ANEURYSM
AB OBJECTIVE: Traumatic pseudoaneurysms of the proximal middle cerebral artery (MCA) segments are challenging to treat. We describe the management of traumatic internal carotid artery and MCA pseudoaneurysms with flow diversion.
   CASE DESCRIPTION: A 19-year-old man had sustained a gunshot wound to the head. Delayed digital subtraction angiography showed de novo formation of the left internal carotid artery ophthalmic segment and left MCA M2 segment pseudoaneurysms. We had initially performed coil embolization of the left MCA pseudoaneurysm. However, it had recurred 2 weeks later. We treated both pseudoaneurysms with flow diversion using the Pipeline Flex embolization device. The patient has continued with dual antiplatelet therapy of aspirin and ticagrelor. Follow-up digital subtraction angiography at 6 months showed complete obliteration of both pseudoaneurysms with patent parent vessels. The patient remained neurologically intact.
   CONCLUSIONS: Flow diversion can be an efficacious treatment of traumatic MCA pseudoaneurysms in appropriately selected cases. The risks versus benefits of dual antiplatelet therapy must be weighed in trauma settings.
C1 [Aljuboori, Zaid; Meyer, Kimberly; Ding, Dale; James, Robert] Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA.
RP Aljuboori, Z (reprint author), Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA.
EM zaid.aljuboori@yahoo.com
RI Ding, Dale/AAN-3583-2020
OI Aljuboori, Zaid/0000-0002-3278-4749
CR Al-Mufti F, 2019, INTERV NEUROL, V8, P38, DOI 10.1159/000489016
   Ali MJ, 2002, NEUROSURGERY, V51, P258, DOI 10.1097/00006123-200207000-00043
   Appelboom G, 2010, NEUROSURGERY, V66, pE623, DOI 10.1227/01.NEU.0000365370.82554.08
   Asaithambi G, 2014, INT J EMERG MED, V7, DOI 10.1186/s12245-014-0044-1
   Awad AJ, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1748
   Becske T, 2017, J NEUROSURG, V127, P81, DOI 10.3171/2015.6.JNS15311
   Becske T, 2017, NEUROSURGERY, V80, P40, DOI 10.1093/neuros/nyw014
   Bhogal P, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00020
   Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004
   Cikla U, 2015, TURK NEUROSURG, V25, P305, DOI 10.5137/1019-5149.JTN.13039-14.1
   Colby GP, 2018, J NEUROSURG-PEDIATR, V22, P532, DOI 10.3171/2018.6.PEDS18165
   Colby GP, 2018, J NEUROSURG, V129, P1475, DOI 10.3171/2017.7.JNS171289
   Faria MD, 2011, AM J NEURORADIOL, V32, P2192, DOI 10.3174/ajnr.A2671
   Fukuma K, 2015, CEREBROVASC DIS, V40, P45, DOI 10.1159/000430945
   LEE RMKW, 1995, PHARMACOL THERAPEUT, V66, P149, DOI 10.1016/0163-7258(94)00071-A
   Lin CH, 2005, J NEUROL SCI, V235, P37, DOI 10.1016/j.jns.2005.03.047
   Manning NW, 2019, J NEUROINTERV SURG, V11, P694, DOI 10.1136/neurintsurg-2018-014363
   Nam Dong Hyuk, 2015, J Cerebrovasc Endovasc Neurosurg, V17, P108, DOI 10.7461/jcen.2015.17.2.108
   Nishizawa S, 2000, NEUROL MED-CHIR, V40, P408, DOI 10.2176/nmc.40.408
   O'Shaughnessy BA, 2005, J NEUROSURG, V102, P231, DOI 10.3171/jns.2005.102.2.0231
   Puri AS, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2014-011596.rep
NR 21
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 201
EP 204
DI 10.1016/j.wneu.2019.10.008
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700197
PM 31605851
OA Bronze
DA 2020-05-12
ER

PT J
AU Ripa, V
   Kwon, CS
   Burks, JD
   Morcos, JJ
AF Ripa, Valeria
   Kwon, Churl-Su
   Burks, Joshua D.
   Morcos, Jacques J.
TI Neuro-Behcet Disease Mimicking Lymphoma of the Brain and Coexisting with
   A Dural Arteriovenous Fistula: A Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterio-venous fistula; Brain lymphoma-like lesions; Neuro-Behcet
   disease
AB BACKGROUND: Diverse clinical manifestations have characterized reports of central nervous system involvement in Behcet disease. There is a limited number of published case reports of neuro-Behcet disease mimicking brain tumor.
   CASE DESCRIPTION: We present a rare case of neuro-Behcet disease exhibiting mixed systemic and neurological symptoms mimicking malignant lymphoma. Delayed presentation of oral aphthae and rapid improvement of symptoms with steroid treatment led to a diagnosis of neuro-Behcet disease without brain biopsy. The patient also underwent surgery for the resection of an arterio-venous fistula.
   CONCLUSIONS: We recommend management of neuro-Behcet disease based on perceived natural history risks, with the understanding that no data exist on this within patients population. A multidisciplinary team approach is always recommended because neuro-Behcet disease is an uncommon condition, especially in neurosurgical practice.
C1 [Ripa, Valeria; Burks, Joshua D.; Morcos, Jacques J.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Kwon, Churl-Su] Icahn Sch Med, Dept Neurol Surg, New York, NY USA.
RP Ripa, V (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM valeriaripa87@gmail.com
CR Akman-Demir G, 1999, BRAIN, V122, P2171, DOI 10.1093/brain/122.11.2171
   Al-Araji A, 2009, LANCET NEUROL, V8, P192, DOI 10.1016/S1474-4422(09)70015-8
   Behcet H, 1937, DERMATOL WOCHENSCHR, V105, P1152
   Davatchi F, 2014, J EUR ACAD DERMATOL, V28, P338, DOI 10.1111/jdv.12107
   de Menthon M, 2009, ARTHRIT CARE RES, V61, P1287, DOI 10.1002/art.24642
   Farah S, 1998, J NEUROL NEUROSUR PS, V64, P382, DOI 10.1136/jnnp.64.3.382
   GENY C, 1993, SURG NEUROL, V39, P374, DOI 10.1016/0090-3019(93)90203-D
   Gul A, 2015, SEMIN IMMUNOPATHOL, V37, P413, DOI 10.1007/s00281-015-0502-8
   KERMODE AG, 1989, NEUROLOGY, V39, P1251, DOI 10.1212/WNL.39.9.1251
   Kidd D, 1999, BRAIN, V122, P2183, DOI 10.1093/brain/122.11.2183
   Kural-Seyahi E, 2003, MEDICINE, V82, P60, DOI 10.1097/00005792-200301000-00006
   Lehner T, 1997, Int Rev Immunol, V14, P21, DOI 10.3109/08830189709116842
   LITVAN I, 1987, NEURORADIOLOGY, V29, P103, DOI 10.1007/BF00341056
   LUECK CJ, 1993, J NEUROL NEUROSUR PS, V56, P505, DOI 10.1136/jnnp.56.5.505
   Matsuo K, 2005, AM J NEURORADIOL, V26, P650
   Siva A, 2001, J NEUROL, V248, P95, DOI 10.1007/s004150170242
   Tramontini Pedro L, 2017, Surg Neurol Int, V8, P97, DOI 10.4103/sni.sni_3_17
   Tursen U, 2003, INT J DERMATOL, V42, P346, DOI 10.1046/j.1365-4362.2003.01741.x
   Yeo Minju, 2016, J Med Case Rep, V10, P360, DOI 10.1186/s13256-016-1151-9
   Yoshimura J, 2001, NEUROL SURG TOKYO, V29, P527
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 205
EP 211
DI 10.1016/j.wneu.2019.09.035
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700198
PM 31525480
OA Bronze
DA 2020-05-12
ER

PT J
AU Fricia, M
   Umana, GE
   Scalia, G
   Raudino, G
   Passanisi, M
   Spitaleri, A
   Cicero, S
AF Fricia, Marco
   Umana, Giuseppe Emmanuele
   Scalia, Gianluca
   Raudino, Giuseppe
   Passanisi, Maurizio
   Spitaleri, Angelo
   Cicero, Salvatore
TI Posttraumatic Triple Acute Epidural Hematomas: First Report of Bilateral
   Synchronous Epidural Hematoma and a Third Delayed
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed epidural hematoma; Epidural hematoma; Head injury; Skull
   fractures; Traumatic brain injury
AB BACKGROUND: Development of a delayed acute epidural hematoma (DEDH) represents a rare event, characterized by a high mortality rate. It is defined as an extradural bleeding not evident at the first brain computed tomography (CT) scan performed after traumatic brain injury but evidenced by further radiologic evaluations.
   CASE DESCRIPTION: A 22-year-old male was admitted to our unit after brain injury due to an assault. Immediate brain CT scan revealed a right frontal epidural hematoma (EDH) and a smaller left anterior temporal EDH with multiple, bilateral skull fractures in the frontal, parietal, and temporal bones. Both EDHs were surgically treated in the same session. Another immediate CT scan showed a third left parietal acute DEDH. The patient was retransferred to the operating room for a further left parietal craniotomy and EDH evacuation. The postoperative period was uneventful: the patient effectively improved. After 15 days, the patient left the hospital and was admitted to a rehabilitation center.
   CONCLUSIONS: To the best of our knowledge, this is the first report of a synchronous acute bilateral EDH with the development of a third DEDH located in a separate site. This finding is certainly related to the presence of multiple and bilateral skull fractures. In our experience, we suggest performing an intraoperative CT scan, if available, to early detect the possible development of DEDH.
C1 [Fricia, Marco; Umana, Giuseppe Emmanuele; Passanisi, Maurizio; Spitaleri, Angelo; Cicero, Salvatore] Cannizzaro Hosp, Trauma Ctr, Gamma Knife Ctr, Dept Neurosurg, Catania, Italy.
   [Scalia, Gianluca] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Div Neurosurg, Messina, Italy.
   [Raudino, Giuseppe] Monza Gen Hosp, Dept Neurosurg, Monza, Italy.
RP Umana, GE (reprint author), Cannizzaro Hosp, Trauma Ctr, Gamma Knife Ctr, Dept Neurosurg, Catania, Italy.
EM umana.nch@gmail.com
OI Scalia, Gianluca/0000-0002-9465-2506
CR Bir SC, 2015, CLIN NEUROL NEUROSUR, V138, P99, DOI 10.1016/j.clineuro.2015.07.021
   BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030
   DHARKER SR, 1991, ACTA NEUROCHIR, V110, P29, DOI 10.1007/BF01402044
   Eftekhar B, 2003, BMC EMERG MED, V3, P1, DOI [10.1186/1471-227X-3-1, DOI 10.1186/1471-227X-3-1]
   Ferrera PC, 1997, AM J EMERG MED, V15, P76, DOI 10.1016/S0735-6757(97)90055-3
   FEUERMAN T, 1988, NEUROSURGERY, V23, P480, DOI 10.1227/00006123-198810000-00013
   FUKAMACHI A, 1984, COMPUT RADIOL, V8, P197, DOI 10.1016/0730-4862(84)90123-9
   Gregori F, 2019, ACTA NEUROL BELG, V119, P15, DOI 10.1007/s13760-018-1049-y
   Rochat P, 2002, CLIN NEUROL NEUROSUR, V105, P39, DOI 10.1016/S0303-8467(02)00099-9
   Rosenthal AA, 2017, AM SURGEON, V83, pE438
   Roy GC, 1884, LANCET, V2, P319
   Solomiichuk Volodymyr O, 2013, Surg Neurol Int, V4, P134, DOI 10.4103/2152-7806.119234
   Yamakawa H, 2006, INJ EXTRA, V37, P38, DOI [10.1016/j.injury.2005.07.003, DOI 10.1016/J.INJURY.2005.07.003]
   Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 212
EP 215
DI 10.1016/j.wneu.2019.10.009
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700199
PM 31605850
OA Bronze
DA 2020-05-12
ER

PT J
AU Sadiya, N
   Halbe, S
   Ghosh, M
   Ghosh, S
AF Sadiya, Niamathullah
   Halbe, Swatee
   Ghosh, Mitra
   Ghosh, Siddhartha
TI Rare Intracranial Recurrent Meningioma with Unique Coexisting Atypical,
   Papillary and Lipomatous Component: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Atypical; Elderly male; Lipomatous; Meningioma; Papillary; Recurrence
ID PROGESTERONE; RECEPTORS
AB BACKGROUND: Meningiomas are common central nervous system tumors with a wide range of morphologic variants, the pathogenesis being their complex embryogenesis. Intracranial meningiomas with heterogenous histopathology in the same lesion are common in low-grade meningiomas but less frequent in recurrent and high-grade variants.
   CASE DESCRIPTION: A 75-year-old male presented elsewhere a year ago with complaints of slurred speech. Magnetic resonance imaging revealed a left frontotemporal, dural-based, extraaxial, solid cystic lesion with doubtful infiltration into the adjacent brain parenchyma. A subtotal excision was done. A diagnosis of meningioma with an aggressive biological behavior was rendered on histology, but the grade was deferred, in view of a single focus of small cell formation and no adjacent brain parenchyma to comment on invasion. The patient presented here with recurrence of his original symptoms. Magnetic resonance imaging of the brain with contrast revealed 2 dural-based, solid cystic enhancing lesions of sizes 29 mm x 25 mm x 24 mm and 25 mm x 16 mm seen at the left frontal region, indenting the adjacent brain parenchyma with diffuse meningeal thickening in the postoperative bed. Microscopy revealed a hypercellular meningeal neoplasm with increased mitosis and a pseudopapillary pattern with lipomatous changes.
   CONCLUSIONS: To date there are no case reports in current literature with such rare combinations in a recurrent meningioma. This highlights the multipotency of phenotypic transformation of primary meningothelial cells. The presence of papillary features, even if focal, should be quantified in the diagnosis. This is of importance because the most current literature suggests that meningioma harboring a papillary component has an increased risk of recurrence and progression to aggressive behavior.
C1 [Sadiya, Niamathullah; Ghosh, Mitra] Apollo Special Hosp, Dept Histopathol, Chennai, Tamil Nadu, India.
   [Halbe, Swatee] Apollo Special Hosp, Dept Radiol, Chennai, Tamil Nadu, India.
   [Ghosh, Siddhartha] Apollo Special Hosp, Dept Neurosci, Chennai, Tamil Nadu, India.
RP Sadiya, N (reprint author), Apollo Special Hosp, Dept Histopathol, Chennai, Tamil Nadu, India.
EM shajanabasraar@gmail.com
CR Basile P, 1986, CANCER, V58, P299
   Brignolio F, 1984, ZENTRALBL NEUROCHIR, V45, P75
   CHAN RC, 1984, J NEUROSURG, V60, P52, DOI 10.3171/jns.1984.60.1.0052
   Gasparinho MG, 2015, INT J SURG PATHOL, V23, P399, DOI 10.1177/1066896915583695
   Gursan N, 2002, INT J NEUROSCI, V112, P463, DOI 10.1080/00207450290025581
   LUDWIN SK, 1975, CANCER, V36, P1363, DOI 10.1002/1097-0142(197510)36:4<1363::AID-CNCR2820360427>3.0.CO;2-Z
   Marciscano AE, 2016, J NEUROSURG, V124, P106, DOI 10.3171/2015.1.JNS142228
   Perry A, 2016, WHO CLASSIFICATION T, P232
   Perry A, 2018, PRACTICAL SURG NEURO, P284
   Pravdenkova S, 2006, J NEUROSURG, V105, P163, DOI 10.3171/jns.2006.105.2.163
   Takayama Y, 2015, NEUROPATHOLOGY, V35, P158, DOI 10.1111/neup.12155
   Tang HL, 2013, CHINESE J CANCER RES, V25, P112, DOI 10.3978/j.issn.1000-9604.2013.01.10
   Walcott BP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00227
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 216
EP 220
DI 10.1016/j.wneu.2019.09.151
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700200
PM 31610245
OA Bronze
DA 2020-05-12
ER

PT J
AU Sotoudeh, H
   Chapman, PR
   Sotoudeh, E
   Singhal, A
   Choudhary, G
   Shafaat, O
AF Sotoudeh, Houman
   Chapman, Philip R.
   Sotoudeh, Ehsan
   Singhal, Aparna
   Choudhary, Gagandeep
   Shafaat, Omid
TI Pseudohypoxic Brain Swelling: Report of 2 Cases and Introduction of the
   Lentiform Rim Sign as Potential MRI Marker
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial hypotension; Magnetic resonance imaging; Neuroradiology;
   Postoperative intracranial hypotension; Pseudohypoxic brain swelling;
   Venous cerebral congestion; Venous congestion
ID SPONTANEOUS INTRACRANIAL HYPOTENSION; FORK SIGN; TEACHING NEUROIMAGES;
   VENOUS CONGESTION; PATTERN; INFARCTION; THROMBOSIS; SURGERY; CHILD
AB BACKGROUND: A rare but important complication related to otherwise uneventful brain and spine surgery is becoming more recognized and more frequently reported in the medical literature. This has been variably labeled as pseudohypoxic brain swelling or postoperative hypotension-associated venous congestion. This poorly understood condition occurs in the setting of surgical intervention and is thought to be related to cerebrospinal fluid leak or evacuation, decreased intracranial pressure, and subsequent development of deep venous congestion affecting the basal ganglia, thalami, and cerebellum. Clinically, patients may have global neurologic deficit and outcomes range from full recovery to vegetative state or death. The imaging correlate includes atypical edema, infarction, or hemorrhage and can overlap the appearance of diffuse hypoxic injury, for which this condition can be mistaken both clinically and radiologically. Although this deep brain tissue edema can be associated with other signs of cerebrospinal fluid hypotension such as dural thickening, brain sagging, and cerebellar herniation, it can be isolated, making the diagnosis challenging.
   CASE DESCRIPTION: We present 2 cases of unexpected clinical deterioration occurring in patients with otherwise uncomplicated neurosurgery, 1 with craniotomy and the other with lumbar spine intervention. Both patients exhibit similar appearing edema in the deep gray structures on postoperative magnetic resonance imaging scans. In addition to reviewing the prior literature and imaging findings, we evaluate the imaging findings to determine if there are unique features or signatures that might allow differentiation of PHBS from hypoxic-ischemic encephalopathy.
   CONCLUSIONS: The Ientiform rim sign can be helpful for differentiation of pseudohypoxic brain swelling versus hypoxic-ischemic encephalopathy.
C1 [Sotoudeh, Houman; Chapman, Philip R.; Singhal, Aparna; Choudhary, Gagandeep] Univ Alabama Birmingham, Dept Neuroradiol & Neurol, Birmingham, AL 35294 USA.
   [Sotoudeh, Ehsan] Iranian Hosp Dubai, Dept Surg, Dubai, U Arab Emirates.
   [Shafaat, Omid] Isfahan Univ Med Sci, Dept Radiol & Intervent Neuroradiol, Esfahan, Iran.
RP Sotoudeh, H (reprint author), Univ Alabama Birmingham, Dept Neuroradiol & Neurol, Birmingham, AL 35294 USA.
EM hsotoudeh@uabmc.edu
OI Shafaat, Omid/0000-0001-8793-7901
CR Binder DK, 2002, NEUROSURGERY, V51, P830, DOI 10.1227/01.NEU.0000024286.95876.2F
   Bowers CA, 2011, SPINE, V36, pE288, DOI 10.1097/BRS.0b013e3181f9b10f
   Chan AY, 2017, CUREUS, V9, DOI 10.7759/cureus.1292
   da Rocha AJ, 2013, CLIN NEUROL NEUROSUR, V115, P790, DOI 10.1016/j.clineuro.2012.07.013
   Dickinson J, 2018, CUREUS, V10, DOI 10.7759/cureus.2454
   Fernandes GC, 2015, NEUROLOGY, V84, pE15, DOI 10.1212/WNL.0000000000001154
   Fujimura M, 2004, CHILD NERV SYST, V20, P430, DOI 10.1007/s00381-003-0884-0
   Giannopoulos S, 2006, ARCH NEUROL-CHICAGO, V63, P1652, DOI 10.1001/archneur.63.11.1652
   Gladstone DJ, 2001, CAN J NEUROL SCI, V28, P159
   Grasso D, 2014, NEURORADIOL J, V27, P288, DOI 10.15274/NRJ-2014-10041
   Hadizadeh DR, 2010, AM J NEURORADIOL, V31, P100, DOI 10.3174/ajnr.A1749
   Herrmann KA, 2004, AM J NEURORADIOL, V25, P1351
   Hoitsma Elske, 2002, J Stroke Cerebrovasc Dis, V11, P47, DOI 10.1053/jscd.2002.123975
   Kaiwar C, 2015, NEUROLOGY, V85, P655, DOI 10.1212/WNL.0000000000001847
   Karaaslan P, 2008, ACTA ANAESTH SCAND, V52, P316, DOI 10.1111/j.1399-6576.2007.01526.x
   Kumar G, 2010, CLIN NEUROL NEUROSUR, V112, P805, DOI 10.1016/j.clineuro.2010.06.006
   Kumral E, 2001, ACTA NEUROL SCAND, V103, P35, DOI 10.1034/j.1600-0404.2001.00141.x
   Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746
   Moon HS, 2016, KOREAN J ANESTHESIOL, V69, P292, DOI 10.4097/kjae.2016.69.3.292
   Nomura Masashi, 2017, Asian J Neurosurg, V12, P794, DOI 10.4103/1793-5482.185070
   Park JW, 2015, J NEUROL SCI, V357, P343, DOI 10.1016/j.jns.2015.08.002
   Parpaley Y, 2011, NEUROSURGERY, V68, pE277, DOI 10.1227/NEU.0b013e3181fead14
   Rathi M, 2012, KIDNEY INT, V82, P365, DOI 10.1038/ki.2012.119
   Saini AG, 2017, BMJ CASE REP, V2017
   Savoiardo M, 2007, BRAIN, V130, P1884, DOI 10.1093/brain/awm101
   Snyder KA, 2016, NEUROCRIT CARE, V24, P448, DOI 10.1007/s12028-015-0207-9
   Sookaromdee P, 2019, ARQ NEURO-PSIQUIAT, V77, P216, DOI [10.1590/0004-282X20190016, 10.1590/0004-282x20190016]
   Van Roost D, 2003, NEUROSURGERY, V53, P1315, DOI 10.1227/01.NEU.0000093498.08913.9E
   Yokota H, 2009, CLIN NEUROL NEUROSUR, V111, P900, DOI 10.1016/j.clineuro.2009.08.007
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 221
EP 226
DI 10.1016/j.wneu.2019.10.018
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700201
PM 31606497
OA Bronze
DA 2020-05-12
ER

PT J
AU Lu, S
   Du, TJ
   Sun, ZM
   Xu, LX
   Tong, XG
   Yan, H
AF Lu, Shan
   Du, Tianjiao
   Sun, Zhiming
   Xu, Lixia
   Tong, Xiaoguang
   Yan, Hua
TI Timing of Extremity Fracture Fixation in Patients with Traumatic Brain
   Injury: A Meta-Analysis of Prognosis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Fracture fixation; Meta-analysis; Timing; Traumatic brain injury
ID LONG-BONE FRACTURE; GROWTH-HORMONE; EXTERNAL FIXATION; NONUNION; FEMUR;
   SHAFT; PRESSURE; OUTCOMES
AB BACKGROUND: Traumatic brain injury (TBI) is a common public health problem. The optimal timing of fracture fixation in patients with TBI has remained controversial. We conducted a meta-analysis to quantitatively discuss the effects of fixation timing on the prognosis of patients with extremity fracture and concomitant TBI.
   METHODS: A systematic search was performed in PubMed, EMBASE, the Cochrane Library and 4 Chinese databases from the inception date to May 19, 2019. Randomized controlled trials and cohort studies comparing early and late fracture fixation in adults with TBI concomitant with extremity fractures were selected. The risk ratio (RR) and standardized mean difference were calculated.
   RESULTS: A total of 14 cohort studies involving 1046 patients fulfilled our criteria. No statistically significant association was found between fixation timing and mortality rate (RR, 1.34; 95% confidence interval [Cl], 0.89-2.01). No significant association was found between fracture fixation timing and the incidence of death among the patients with severe TBI (RR, 1.82; 95% CI, 0.50-6.66), moderate or more serious TBI (RR, 3.78; 95% CI, 0.53-26.78), and unrestricted TBI type (RR, 0.80; 95% CI, 0.38-1.68). No significant association was found between fracture fixation timing and neurologic complications (RR, 0.71; 95% CI, 0.45-1.11). When the cutoff for fixation timing was set at 14 days, the incidence of nonunion or malunion in the earlier fixation group was lower than that in the later fixation group (RR, 0.39; 95% CI, 0.17-0.91).
   CONCLUSION: Late fracture fixation conducted >14 days after injury was associated with nonunion or malunion. Fixation performed within 24 hours did not influence mortality or adverse neurologic events.
C1 [Lu, Shan; Xu, Lixia; Tong, Xiaoguang; Yan, Hua] Tianjin Huanhu Hosp, Tianjin Neurosurg Inst, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, Tianjin, Peoples R China.
   [Sun, Zhiming; Tong, Xiaoguang; Yan, Hua] Tianjin Huanhu Hosp, Dept Neurosurg, Tianjin, Peoples R China.
   [Du, Tianjiao] Tianjin Med Univ, Dept Neurosurg, Tianjin, Peoples R China.
RP Yan, H (reprint author), Tianjin Huanhu Hosp, Tianjin Neurosurg Inst, Tianjin Key Lab Cerebral Vasc & Neurodegenerat Di, Tianjin, Peoples R China.; Yan, H (reprint author), Tianjin Huanhu Hosp, Dept Neurosurg, Tianjin, Peoples R China.
EM yanhua20042007@sina.com
FU Tianjin Municipal Health Commission [14KG115]
FX The present study was supported by the Tianjin Municipal Health
   Commission (grant 14KG115).
CR Ahmed Saeed, 2017, Indian J Psychol Med, V39, P114, DOI 10.4103/0253-7176.203129
   Andreassen TT, 2003, CALCIFIED TISSUE INT, V73, P258, DOI 10.1007/S00223-002-2074-6
   Anglen JO, 2003, J TRAUMA, V54, P1166, DOI 10.1097/01.TA.0000057232.66613.AC
   Brinker MR, 2007, J ORTHOP TRAUMA, V21, P634, DOI 10.1097/BOT.0b013e318156c2a2
   Egol KA, 2009, CLIN ORTHOP RELAT R, V467, P2979, DOI 10.1007/s11999-009-0883-x
   Flierl MA, 2010, J ORTHOP TRAUMA, V24, P107, DOI 10.1097/BOT.0b013e3181b6bdfc
   Harley BJ, 2002, J ORTHOP TRAUMA, V16, P484, DOI 10.1097/00005131-200208000-00006
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   HOFMAN PAM, 1991, J TRAUMA, V31, P261, DOI 10.1097/00005373-199131020-00020
   Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001
   Jamjoom BA, 2012, NEUROSCIENCES, V17, P111
   Jin YC, 2014, J PRACT HAND SURG, V28, P210
   Kalb DC, 1998, SURGERY, V124, P739, DOI 10.1067/msy.1998.91395
   KOTWICA Z, 1990, ACTA NEUROCHIR, V102, P19, DOI 10.1007/BF01402180
   Li L, 2019, NEURAL REGEN RES, V14, P1573, DOI 10.4103/1673-5374.255972
   Liao SF, 2003, CHINA J MOD MED, V13, P98
   Mills L, 2016, BONE JOINT RES, V5, P512, DOI 10.1302/2046-3758.510.BJR-2016-0138
   Morales-Vidal SG, 2019, CURR NEUROL NEUROSCI, V19, DOI 10.1007/s11910-019-0928-9
   Mousavi M, 2001, INJURY, V32, P679, DOI 10.1016/S0020-1383(01)00048-1
   Mrozek S, 2019, BIOMARK INSIGHTS, V14, DOI 10.1177/1177271919851515
   Nowotarski PJ, 2000, J BONE JOINT SURG AM, V82A, P781, DOI 10.2106/00004623-200006000-00004
   Oransky M, 2007, INJURY, V38, P489, DOI 10.1016/j.injury.2007.01.019
   Pape HC, 2009, J AM ACAD ORTHOP SUR, V17, P541, DOI 10.5435/00124635-200909000-00001
   POOLE GV, 1992, J TRAUMA, V32, P654, DOI 10.1097/00005373-199205000-00019
   Raschke M, 2007, EUR J ENDOCRINOL, V156, P341, DOI 10.1530/EJE-06-0598
   Seemann R, 2018, J MUSCULOSKEL NEURON, V18, P32
   SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003
   Shen GH, 2007, J PRACT MED TECHNOL, V14, P3211
   Starr AJ, 1998, J ORTHOP TRAUMA, V12, P17
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tae JY, 2019, EXP THER MED, V18, P326, DOI 10.3892/etm.2019.7543
   Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1
   Tian XY, 2009, MED INNOV CHINA, V6, P62
   Townsend RN, 1998, J TRAUMA, V44, P977, DOI 10.1097/00005373-199806000-00008
   Turner NE, 2019, PSYCHIAT RES, V272, P692, DOI 10.1016/j.psychres.2018.12.170
   Tuttle MS, 2009, J TRAUMA, V67, P602, DOI 10.1097/TA.0b013e3181aa21c0
   Velmahos GC, 1998, AM J SURG, V176, P324, DOI 10.1016/S0002-9610(98)00208-6
   Wang MC, 2007, J TRAUMA, V62, P1250, DOI 10.1097/01.ta.0000215581.50234.56
   Wang Yiping, 2002, MED THEORY PRACTICE, V15, P401
   Westgeest J, 2016, J ORTHOP TRAUMA, V30, P149, DOI 10.1097/BOT.0000000000000488
   WIEDERHOLT WC, 1989, NEUROLOGY, V39, P96, DOI 10.1212/WNL.39.1.96
   Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119
   Yan H, 2013, NEUROL RES, V35, P537, DOI 10.1179/1743132813Y.0000000201
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 227
EP 236
DI 10.1016/j.wneu.2019.09.136
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700202
PM 31574326
OA Bronze
DA 2020-05-12
ER

PT J
AU Maejima, R
   Aoyama, M
   Hara, M
   Miyachi, S
AF Maejima, Ryuya
   Aoyama, Masahiro
   Hara, Masahito
   Miyachi, Shigeru
TI Spinal Epidural Hematoma Associated with Epidural Metastasis After Minor
   Trauma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epidural metastasis; Small cell carcinoma; Spinal epidural hematoma;
   Spinal surgery
AB BACKGROUND: Spinal epidural hematoma associated with epidural metastasis is very rare. Epidural hematoma is unusual in itself, and metastatic epidural tumors do not commonly occur.
   CASE DESCRIPTION: A 76-year-old man with a medical history of untreated stage III rectal cancer and chronic obstructive pulmonary disease underwent emergency spine surgery for acute development of severe quadriplegia due to cervical epidural hematoma after minor indirect trauma. Hemorrhagic lesions, such as yellow ligaments, were accompanied by hematomas that adhered to the dura mater and were confirmed on pathology to be small cell carcinoma. Some nodules were detected in the right pulmonary hilar lesion and pleural lesion on computed tomography, and stage IV small cell carcinoma was diagnosed.
   CONCLUSIONS: To our knowledge, spinal epidural hematoma accompanied by epidural metastasis has not previously been reported. We hypothesized that tissue invasion of malignant neoplasms may cause hemorrhagic conditions. The presence of a tumor should therefore be considered in the differential diagnosis of cases of epidural hematoma.
C1 [Maejima, Ryuya; Aoyama, Masahiro; Miyachi, Shigeru] Aichi Med Univ, Dept Neurosurg, Nagakute, Aichi, Japan.
   [Aoyama, Masahiro; Hara, Masahito] Aichi Med Univ, Spine Ctr, Nagakute, Aichi, Japan.
RP Maejima, R (reprint author), Aichi Med Univ, Dept Neurosurg, Nagakute, Aichi, Japan.
EM sekuryu8@gmail.com
OI Maejima, Ryuya/0000-0002-1077-2499
CR Alexiadou-Rudolf C, 1998, SPINE, V23, P1810, DOI 10.1097/00007632-199808150-00018
   Batson OV, 1940, ANN SURG, V112, P138, DOI 10.1097/00000658-194007000-00016
   BYRNE TN, 1992, NEW ENGL J MED, V327, P614
   Cetinalp NE, 2017, NEUROL INDIA, V65, P1434, DOI 10.4103/0028-3886.217978
   Groen RJM, 1996, NEUROSURGERY, V39, P494, DOI 10.1097/00006123-199609000-00012
   GROEN RJM, 1990, J NEUROL SCI, V98, P121, DOI 10.1016/0022-510X(90)90253-J
   HARRIS DJ, 1978, J NEUROSURG, V49, P914, DOI 10.3171/jns.1978.49.6.0914
   Holtas S, 1996, RADIOLOGY, V199, P409, DOI 10.1148/radiology.199.2.8668786
   KAPLAN LI, 1949, AM J SURG, V78, P356, DOI 10.1016/0002-9610(49)90354-2
   Kim R Y, 1990, Ala Med, V60, P10
   Kreppel D, 2003, NEUROSURG REV, V26, P1, DOI 10.1007/s10143-002-0224-y
   Liao CC, 2004, J NEUROSURG, V100, P38, DOI 10.3171/spi.2004.100.1.0038
   Lin HS, 2009, SPINE, V34, pE266, DOI 10.1097/BRS.0b013e318197164f
NR 13
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 240
EP 244
DI 10.1016/j.wneu.2019.09.110
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700204
PM 31568906
OA Bronze
DA 2020-05-12
ER

PT J
AU Zeng, YJ
AF Zeng, Yuan-jie
TI Persistent Idiopathic Facial Pair Originating from Cervical
   Abnormalities
SO WORLD NEUROSURGERY
LA English
DT Article
DE Case report; Cervicogenic; Coblation; Continuous cervical epidural
   analgesia; Facial pain; Neuralgia
ID TRIGEMINAL NEURALGIA; STIMULATION; HEADACHE; AFFERENTS; DIAGNOSIS
AB BACKGROUND: Persistent idiopathic facial pain is characterized by persistent facial or oral pain in the absence of a neurologic deficit. This underexplored pain may be conducted by various nerves, including cranial nerves and upper cervical spinal roots, and its etiology is unclear.
   CASE DESCRIPTION: A patient presented with persistent idiopathic facial associated with occipital muscle stiffness after an improper neck massage. The patient achieved almost complete pain relief by coblation of right upper cervical nerves (C1 and C2 spinal roots) followed by continuous cervical epidural analgesia for a period of 3 weeks. The analgesic effect was stable during the 3-month follow-up period.
   CONCLUSIONS: Persistent idiopathic facial pain may be cervicogenic, and teratments focusing on cervical spinal roots may provide satisfactory pain control in patients with cervical abnormalities.
C1 [Zeng, Yuan-jie] Hunan Normal Univ, Hunan Prov Peoples Hosp, Joint Surg & Sport Med Dept, Affiliated Hosp 1, Changsha, Hunan, Peoples R China.
RP Zeng, YJ (reprint author), Hunan Normal Univ, Hunan Prov Peoples Hosp, Joint Surg & Sport Med Dept, Affiliated Hosp 1, Changsha, Hunan, Peoples R China.
EM yuanjie@me.com
CR Bayer Erin, 2005, Pain Pract, V5, P223, DOI 10.1111/j.1533-2500.2005.05314.x
   Benoliel R, 2017, CEPHALALGIA, V37, P680, DOI 10.1177/0333102417706349
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Corbacelli A, 2007, MINERVA ANESTESIOL, V73, P281
   Cuadrado ML, 2016, PAIN MED, V17, P1717, DOI 10.1093/pm/pnw040
   Deer TR, 2014, NEUROMODULATION, V17, P551, DOI 10.1111/ner.12215
   Goadsby PJ, 2008, HEADACHE, V48, P313, DOI 10.1111/j.1526-4610.2007.01022.x
   Goadsby PJ, 1997, J ANAT, V190, P367, DOI 10.1046/j.1469-7580.1997.19030367.x
   Graff-Radford Steven B, 2012, Continuum (Minneap Minn), V18, P869, DOI 10.1212/01.CON.0000418648.54902.42
   Hassanzadeh R, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-013-0392-1
   Klein J, 2016, CEPHALALGIA, V36, P445, DOI 10.1177/0333102415597526
   Kobayashi A, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-12
   Koopman JSHA, 2009, PAIN, V147, P122, DOI 10.1016/j.pain.2009.08.023
   La Touche R, 2011, CLIN J PAIN, V27, P48, DOI 10.1097/AJP.0b013e3181edc157
   Mueller D, 2011, CEPHALALGIA, V31, P1542, DOI 10.1177/0333102411424619
   Persson LCG, 2007, EUR SPINE J, V16, P953, DOI 10.1007/s00586-006-0268-8
   Peterson S, 2015, PHYSIOTHER THEOR PR, V31, P442, DOI 10.3109/09593985.2015.1010244
   Rahimpour S, 2016, NEUROSURG CLIN N AM, V27, P365, DOI 10.1016/j.nec.2016.02.010
   SESSLE BJ, 1986, PAIN, V27, P219, DOI 10.1016/0304-3959(86)90213-7
   Shinozaki T, 2006, TOHOKU J EXP MED, V210, P41, DOI 10.1620/tjem.210.41
   Tsuboi Y, 2004, PAIN, V111, P323, DOI 10.1016/j.pain.2004.07.014
   Weiss AL, 2017, CURR PAIN HEADACHE R, V21, DOI 10.1007/s11916-017-0609-9
   William A, 2016, ACTA NEUROCHIR, V158, P513, DOI 10.1007/s00701-015-2695-y
   Zhang ZJ, 2008, MICROSURG, V28, P347, DOI 10.1002/micr.20507
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 248
EP 252
DI 10.1016/j.wneu.2019.10.056
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700206
PM 31629148
OA Bronze
DA 2020-05-12
ER

PT J
AU Kosaka, T
   Ikeda, N
   Furuse, M
   Nonoguchi, N
   Hiramatsu, R
   Yagi, R
   Kawabata, S
   Miyachi, S
   Kuroiwa, T
   Wanibuchi, M
AF Kosaka, Takuya
   Ikeda, Naokado
   Furuse, Motomasa
   Nonoguchi, Naosuke
   Hiramatsu, Ryo
   Yagi, Ryokichi
   Kawabata, Shinji
   Miyachi, Shigeru
   Kuroiwa, Toshihiko
   Wanibuchi, Masahiko
TI Refractory Chronic Subdural Hematoma Associated with Dural Metastasis of
   Lung Adenocarcinoma Treated with Endovascular Embolization for the
   Middle Meningeal Artery: A Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chronic subdural hematoma; Dural metastasis; Embolization; Middle
   meningeal artery
ID SECONDARY; CANCER
AB BACKGROUND: Endovascular embolization of the middle meningeal artery (MMA) is effective for recurrent chronic subdural hematoma (CSDH). CSDH associated with dural metastasis is generally refractory to burr hole surgery and has poor prognosis even if any interventions are applied. To the best of our knowledge, this study is the first to report a case of refractory CSDH associated with dural metastasis that was successfully treated with embolization of the MMA.
   CASE DESCRIPTION: A 66-year-old man with a 1-year history of lung adenocarcinoma had also undergone whole-brain irradiation for multiple brain metastases 5 months before presentation, surgical removal of relapse of brain metastases 3 months prior, and stereotactic radiotherapy for the relapses 1 month prior. He was admitted to our institution with speech disturbance, severe headache, and right-sided motor weakness. Head computed tomography on admission revealed left-sided CSDH, and emergency burr hole irrigation surgery was performed. However, CSDH recurred twice in a short period after hospitalization. Histological examination revealed adenocarcinoma cells in the dura mater and in hematoma samples during the first surgery; therefore, the patient was diagnosed with refractory CSDH associated with dural metastasis of lung adenocarcinoma. We performed endovascular embolization of the MMA, followed by systemic chemotherapy at 1 month after embolization, and no recurrence of the CSDH was observed.
   CONCLUSIONS: Embolization of the MMA has few surgical risks and could be a treatment option for refractory CSDH associated with dural metastasis because it might prolong the therapeutic time window until radical therapies are administered.
C1 [Kosaka, Takuya; Ikeda, Naokado; Furuse, Motomasa; Nonoguchi, Naosuke; Hiramatsu, Ryo; Yagi, Ryokichi; Kawabata, Shinji; Kuroiwa, Toshihiko; Wanibuchi, Masahiko] Osaka Med Coll, Dept Neurosurg & Neuroendovasc Surg, Takatsuki, Osaka, Japan.
   [Miyachi, Shigeru] Aichi Med Univ, Dept Neurosurg & Neuroendovasc Ctr, Nagakute, Aichi, Japan.
   [Kuroiwa, Toshihiko] Tesseikai Neurosurg Hosp, Dept Neurosurg, Shijonawate, Osaka, Japan.
RP Ikeda, N (reprint author), Osaka Med Coll, Dept Neurosurg & Neuroendovasc Surg, Takatsuki, Osaka, Japan.
EM neu098@osaka-med.ac.jp
OI Kawabata, Shinji/0000-0001-5007-5279
CR Alvarez-Pinzon AM, 2016, CUREUS, V8, DOI 10.7759/cureus.613
   AMBIAVAGAR PC, 1978, CANCER, V42, P2015, DOI 10.1002/1097-0142(197810)42:4<2015::AID-CNCR2820420450>3.0.CO;2-Q
   Ashish K, 2014, TURK NEUROSURG, V24, P992, DOI [10.5137/1019-5149JTN.9708-13.0, 10.5137/1019-5149.JTN.9708-13.0]
   Chihara Hideo, 2014, NMC Case Rep J, V1, P1, DOI 10.2176/nmccrj.2013-0343
   Fukino K, 2004, NEUROL MED-CHIR, V44, P646, DOI 10.2176/nmc.44.646
   Ikeda H, 2018, WORLD NEUROSURG, V111, P201, DOI 10.1016/j.wneu.2017.12.116
   Kimura S, 2014, BRAIN TUMOR PATHOL, V31, P299, DOI 10.1007/s10014-013-0162-0
   LEECH RW, 1974, J NEUROSURG, V41, P610, DOI 10.3171/jns.1974.41.5.0610
   Mirsadeghi Seyed Mohammad Haji, 2008, Cases J, V1, P328, DOI 10.1186/1757-1626-1-328
   Sakaguchi M, 2018, ANTICANCER RES, V38, P6405, DOI 10.21873/anticanres.13001
   Srivatsan A, 2019, WORLD NEUROSURG, V122, P613, DOI 10.1016/j.wneu.2018.11.167
   Tempaku A, 2015, INTERV NEURORADIOL, V21, P366, DOI 10.1177/1591019915583224
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 256
EP 259
DI 10.1016/j.wneu.2019.10.035
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700208
PM 31629135
OA Bronze
DA 2020-05-12
ER

PT J
AU Menendez, RH
   Thompson, P
   Barea, H
   Lisdero, AP
   Lew, J
   Elvira, J
   Lehrner, PE
   Sole, HA
AF Menendez, Ricardo H.
   Thompson, Patricio
   Barea, Horacio
   Lisdero, Ana P.
   Lew, Javier
   Elvira, Jaqueline
   Lehrner, Pablo E.
   Sole, Horacio A.
TI Simultaneous Resection of Pituitary Macroadenoma and Sphenoid Sinus
   Inverted Papillorna: The Challenge of Operating Sinonasal and Skull Base
   Pathologies Through a Single-Stage Endoscopic Endonasal Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic endonasal approach; Inverted papilloma; Pituitary
   macroadenoma; Skull base surgery
ID RATHKES CLEFT CYST; COLLISION TUMOR; GONADOTROPH ADENOMA; MANAGEMENT;
   CRANIOPHARYNGIOMA; GANGLIOCYTOMA; COEXISTENCE; EXPERIENCE; LESIONS;
   SELLA
AB BACKGROUND: Coexistence of sinonasal and skull base tumors is uncommon but possible, and the endonasal route seems to be the best option to manage both lesions simultaneously. We report the first case in the English literature of concomitant sphenoid sinus inverted papilloma and pituitary macroadenoma treated through an endoscopic endonasal approach.
   CASE DESCRIPTION: A 68-year-old man presented with a history of progressive visual loss and nasal obstruction. Clinical examination disclosed bitemporal hemianopsia. Computed tomography scan and magnetic resonance imaging obtained on admission showed a large sellar/suprasellar enhancing lesion with a marked mass effect on the optic chiasm. Imaging also showed a second mass extending from the sphenoid sinus to the left nasal cavity with obstruction of the maxillary sinus ostium and development of maxillary sinus mucocele. Both tumors were entirely resected by an endoscopic endonasal approach. Additionally, middle meatal antrostomy and marsupialization with drainage of the maxillary mucocele was performed. Biopsy confirmed the coexistence of a pituitary macroadenoma and sphenoid sinus inverted papilloma.
   CONCLUSIONS: This case and the literature suggest that patients with concomitant nasal and skull base pathologies can be simultaneously managed. The otolaryngologist plays an essential role in removing the sinonasal lesion to ensure a safe surgical corridor before entering the intracranial cavity and for planning for the skull base reconstruction.
C1 [Menendez, Ricardo H.] Hosp Aleman, Dept Neurosci, Buenos Aires, DF, Argentina.
   [Menendez, Ricardo H.; Barea, Horacio; Elvira, Jaqueline; Lehrner, Pablo E.; Sole, Horacio A.] Sanatorio Julio Mendez, Div Neurosurg, Dept Surg, Buenos Aires, DF, Argentina.
   [Lisdero, Ana P.] Sanatorio Julio Mendez, Dept Internal Med, Div Endocrinol, Buenos Aires, DF, Argentina.
   [Lew, Javier] Sanatorio Julio Mendez, Dept Pathol, Buenos Aires, DF, Argentina.
   [Thompson, Patricio] Hosp Ignacio Pirovano, Dept Surg, Div Otolaryngol, Buenos Aires, DF, Argentina.
RP Menendez, RH (reprint author), Hosp Aleman, Dept Neurosci, Buenos Aires, DF, Argentina.; Menendez, RH (reprint author), Sanatorio Julio Mendez, Div Neurosurg, Dept Surg, Buenos Aires, DF, Argentina.
EM rhmenendez@hotmail.com
CR Adriaensen GFJPM, 2016, LARYNGOSCOPE, V126, P322, DOI 10.1002/lary.25522
   Chaudhry NS, 2016, J CLIN NEUROSCI, V33, P247, DOI 10.1016/j.jocn.2016.05.018
   Cossu G, 2016, CLIN NEUROL NEUROSUR, V149, P122, DOI 10.1016/j.clineuro.2016.08.002
   Doglietto Francesco, 2005, Neurosurg Focus, V19, pE3
   Finzi G, 2014, PITUITARY, V17, P53, DOI 10.1007/s11102-013-0465-5
   Gao MT, 2016, J CRANIOFAC SURG, V27, pE128, DOI 10.1097/SCS.0000000000002371
   Guillemaud JR, 2009, LARYNGOSCOPE, V119, P2466, DOI 10.1002/lary.20718
   Heng LJ, 2017, WORLD NEUROSURG, V106, DOI [10.1016/J.WNEU.2017.05.064, 10.1016/j.wneu.2017.05.064]
   Jin GS, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-178
   Jukes A, 2016, J CLIN NEUROSCI, V31, P202, DOI 10.1016/j.jocn.2016.02.024
   Karavitaki N, 2008, PITUITARY, V11, P317, DOI 10.1007/s11102-007-0070-6
   Koutourousiou M, 2010, PITUITARY, V13, P8, DOI 10.1007/s11102-009-0190-2
   Lee JY, 2008, LARYNGOSCOPE, V118, P1868, DOI 10.1097/MLG.0b013e31817f93d3
   Mahvash Mehran, 2014, Asian J Neurosurg, V9, P236, DOI 10.4103/1793-5482.146629
   Malli A, 2019, CUREUS, V11, DOI 10.7759/cureus.4911
   Nyquist GG, 2015, INT FORUM ALLERGY RH, V5, P339, DOI 10.1002/alr.21476
   Nyquist GG, 2014, WORLD NEUROSURG, V82, pS54, DOI 10.1016/j.wneu.2014.07.027
   Ogando-Rivas E, 2017, PITUITARY, V20, P702, DOI 10.1007/s11102-017-0826-6
   Pasquini E, 2004, AM J OTOLARYNG, V25, P178, DOI 10.1016/j.amjoto.2004.01.004
   Prevedello Daniel M, 2007, Neurosurgery, V60, pE401, DOI 10.1227/01.NEU.0000255359.94571.91
   Rivera J, 2010, PITUITARY, V13, P189, DOI 10.1007/s11102-008-0145-z
   Roberts S, 2016, PITUITARY, V19, P472, DOI 10.1007/s11102-016-0727-0
   Sahli R, 2011, PITUITARY, V14, P405, DOI 10.1007/s11102-009-0199-6
   Snyder R, 2019, WORLD NEUROSURG, V121, P211, DOI 10.1016/j.wneu.2018.10.048
   Syro LV, 2000, J ENDOCRINOL INVEST, V23, P37, DOI 10.1007/BF03343674
   Tanriover N, 2014, J CRANIOFAC SURG, V25, P1277, DOI 10.1097/SCS.0000000000000580
   Tomenzoli D, 2004, LARYNGOSCOPE, V114, P193, DOI 10.1097/00005537-200402000-00003
   Valdez R, 2002, HUM PATHOL, V33, P1044, DOI 10.1053/hupa.2002.128063
   Wu WH, 2018, CAN J NEUROL SCI, V45, P68, DOI 10.1017/cjn.2017.252
NR 29
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 260
EP 265
DI 10.1016/j.wneu.2019.09.159
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700209
PM 31605847
OA Bronze
DA 2020-05-12
ER

PT J
AU Lam, J
   Lee, DJ
   Oladunjoye, A
AF Lam, Jordan
   Lee, Darrin J.
   Oladunjoye, Azeem
TI Subdural Catheter Injection of Tissue Plasminogen Activator for Residual
   Hematoma Post Drainage of Acute-on-Chronic Subdural Hematoma: Novel Case
   Report of 2 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute subdural hematoma; Catheter injection; Chronic subdural hematoma;
   Recombinant tissue plasminogen activator; Thrombolytic therapy; tPA
ID HEMORRHAGE
AB BACKGROUND: Residual hematoma after operative management of acute subdural hematoma contributes to reoperation and is cited as a reason for deferment of less invasive drainage strategies. Although local antithrombolytic therapy has been studied in intracerebral hemorrhage and chronic subdural hematoma, to date there are no reports of recombinant tissue plasminogen activator for residual hematoma post drainage for acute subdural hematoma.
   CASE DESCRIPTION: Two patients presented with altered mental status secondary to acute-on-chronic subdural hematomas and underwent emergent craniotomies. The first, a 78-year-old man, had poor subdural drain output and deteriorated with seizures and evidence of new acute subdural hematoma formation. Recombinant tissue plasminogen activator was injected through the subdural catheter on postoperative day 3. The second patient, a 64-year-old male, received recombinant tissue plasminogen activator postoperatively. Subsequently, both experienced good subdural drainage, clinical and radiologic improvement, and successful discharge to a skilled nursing facility.
   CONCLUSIONS: Subdural thrombolytic therapy can improve hematoma evacuation. A potential implication of this is facilitation of minimally invasive options such as twist-drill craniotomy, previously deferred due to inadequate evacuation. However, there is a paucity of evidence and more research is needed to substantiate the safety and efficacy, refine this technique, and guide patient selection.
C1 [Lam, Jordan; Lee, Darrin J.] Univ Southern Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA 90007 USA.
   [Oladunjoye, Azeem] San Joaquin Gen Hosp, French Camp, CA USA.
RP Lam, J (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA 90007 USA.
EM lamjorda@usc.edu
OI Lam, Jordan/0000-0003-3955-9031
CR CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277
   Cho Seong-Woo, 2018, Korean J Neurotrauma, V14, P142, DOI 10.13004/kjnt.2018.14.2.142
   Chrastina J, 2020, EUR J TRAUMA EMERG S, V46, P347, DOI 10.1007/s00068-019-01077-6
   COLLEN D, 1984, CIRCULATION, V70, P1012, DOI 10.1161/01.CIR.70.6.1012
   Desai VR, 2016, CUREUS, V8, DOI 10.7759/cureus.616
   Doan Ninh B, 2018, Asian J Neurosurg, V13, P485, DOI 10.4103/ajns.AJNS_230_16
   Frenkel MB, 2017, CLIN NEUROPHARMACOL, V40, P279, DOI 10.1097/WNF.0000000000000247
   Graor RA, 1990, J VASC MED BIOL, V2, P310
   Hanley DF, 2019, LANCET, V393, P1021, DOI 10.1016/S0140-6736(19)30195-3
   Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13
   HUANG P, 2019, CHINESE NEUROSURG J, V5, P10
   Li YQ, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00371
   Marion DW, 2006, NEUROSURGERY, V58, P655
   Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359
   Morgan T, 2008, ACTA NEUROCHIR SUPPL, V105, P147
   Mould WA, 2013, STROKE, V44, P627, DOI 10.1161/STROKEAHA.111.000411
   Phan K, 2017, WORLD NEUROSURG, V101, P677, DOI 10.1016/j.wneu.2017.03.024
   SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503
   Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 266
EP 270
DI 10.1016/j.wneu.2019.10.007
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700210
PM 31605861
OA Bronze
DA 2020-05-12
ER

PT J
AU Rkhami, M
   Gader, G
   Loukil, B
   Badri, M
   Zammel, I
AF Rkhami, Mouna
   Gader, Ghassen
   Loukil, Bilel
   Badri, Mohamed
   Zammel, Ihsen
TI latrogenic Epidermoid Cyst of the Cauda Equina: A Late Complication of
   Lumbar Disc Herniation Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cauda equina; Disc herniation; Epidermoid cyst; latrogenic; Spinal tumor
ID TUMOR
AB BACKGROUND: Epidermoid cysts (ECs) account for 0.5% to 1% of all spinal tumors. They can be congenital or acquired. Acquired spinal ECs are extremely rare and are mostly caused by trauma, or secondary to iatrogenic procedure such as lumbar punctures or surgery for spina bifida. As far as we know, this is the first report of a spinal EC complicating surgery for a lumbar disc herniation.
   CASE DESCRIPTION: A 69-year-old woman, with a history of L3-L4 lumbar disc herniation surgery 30 years earlier, presented because of low back pain, weakness of her lower limbs, and bladder dysfunction evolving for 2 years. Magnetic resonance imaging identified an intradural cystic lesion extending from the medullary cone to the L4 level, evoking an EC. The diagnosis was confirmed peroperatively. Neurologic motor signs improved postoperatively but not the sphincter disorders.
   CONCLUSIONS: Despite the extreme rarity of this event, we should be aware of the potential de novo development of epidermoid tumors in patients who undergo surgery for lumbar disc herniation. Concerns must be given to persistent low back pain and delayed neurologic symptoms in these patients.
C1 [Rkhami, Mouna; Gader, Ghassen; Loukil, Bilel; Badri, Mohamed; Zammel, Ihsen] Univ Tunis, Burn & Trauma Ctr Ben Arous Tunisia, Dept Neurosurg, El Manar, Tunisia.
RP Gader, G (reprint author), Univ Tunis, Burn & Trauma Ctr Ben Arous Tunisia, Dept Neurosurg, El Manar, Tunisia.
EM gastghagad@yahoo.fr
OI Gader, Ghassen/0000-0002-3895-5270
CR Amato V G, 2002, J Neurosurg Sci, V46, P122
   Er U, 2006, J CLIN NEUROSCI, V13, P130, DOI 10.1016/j.jocn.2005.03.020
   Funao H, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1186-4
   Gonzalvo A, 2009, J CLIN NEUROSCI, V16, P142, DOI 10.1016/j.jocn.2008.04.017
   Kapoor JR, 2003, J SPINAL DISORD TECH, V16, P193, DOI 10.1097/00024720-200304000-00012
   Liu H, 2012, J CLIN NEUROSCI, V19, P712, DOI 10.1016/j.jocn.2011.07.046
   LUNARDI P, 1989, NEUROSURGERY, V25, P860, DOI 10.1227/00006123-198912000-00002
   MANNO NJ, 1962, J NEUROSURG, V19, P754, DOI 10.3171/jns.1962.19.9.0754
   Miyake S, 2005, NEUROL MED-CHIR, V45, P277, DOI 10.2176/nmc.45.277
   Mohapatra RN, 2007, J PEDIATR NEUROSCI, V2, P28, DOI 10.4103/1817-1745.32005
   Morita M, 2012, J SPINAL DISORD TECH, V25, P292, DOI 10.1097/BSD.0b013e31821e2464
   Munshi A, 2009, J CANCER RES THER, V5, P290, DOI 10.4103/0973-1482.59913
   Nica D A, 2011, J Med Life, V4, P305
   ROUX A, 1992, J NEUROSURG, V76, P528, DOI 10.3171/jns.1992.76.3.0528
   Russell DS, 1989, PATHOL TUMOURS NER, P693
   SARMA DP, 1984, J SURG ONCOL, V25, P64, DOI 10.1002/jso.2930250118
   Sheng HS, 2013, TURK NEUROSURG, V23, P800, DOI 10.5137/1019-5149.JTN.5216-11.1
   Singh Kulwant, 2016, Surg Neurol Int, V7, pS67, DOI 10.4103/2152-7806.174890
   Tang LL, 2006, J COMPUT ASSIST TOMO, V30, P507, DOI 10.1097/00004728-200605000-00026
   VANGILDER JC, 1967, J NEUROSURG, V26, P14, DOI 10.3171/jns.1967.26.1part1.0014
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 271
EP 274
DI 10.1016/j.wneu.2019.10.076
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700211
PM 31639501
OA Bronze
DA 2020-05-12
ER

PT J
AU Mansouri, A
   Boutet, A
   Elias, G
   Germann, J
   Yan, H
   Babu, H
   Lozano, AM
   Valiante, TA
AF Mansouri, Alireza
   Boutet, Alexandre
   Elias, Gavin
   Germann, Jurgen
   Yan, Han
   Babu, Harish
   Lozano, Andres M.
   Valiante, Taufik A.
TI Lesion Network Mapping Analysis Identifies Potential Cause of
   Postoperative Depression in a Case of Cingulate Low-Grade Glioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cingulate cortex; Connectomic analysis; Depression; Low-grade gliomas;
   Surgical innovation
ID DEEP BRAIN-STIMULATION; CONNECTIVITY
AB BACKGROUND: Depression following resection of diffuse low-grade glioma has rarely been described. Location of the tumor and surgical route are potential causes. Lesion network mapping (LNM), leveraging high-quality resting-state functional magnetic resonance imaging data from large samples of healthy adults, has been used to explore the broader network connectivity for given lesions. However, LNM has not been applied to large intra-axial masses or surgical lesions. We used LNM to examine a potential cause of postoperative depression in a patient with a cingulate diffuse low-grade glioma (zones I-III).
   CASE DESCRIPTION: A 34-year-old woman underwent surgery for medically refractory seizures attributable to diffuse low-grade glioma. Near-total resection was attained via a single-stage, transcortical route through the medial prefrontal cortex. Despite freedom from seizure and lack of tumor growth at 42 months of follow-up, she developed symptoms of major depressive disorder soon after surgery that persisted. To identify functional networks potentially engaged by the surgical corridor and tumor resection cavity, both were segmented separately and used as seeds for normative resting-state functional magnetic resonance imaging connectivity mapping. To study depression specifically, networks associated with the tumor and surgical approach were compared with networks associated with subgenual cingulate deep brain stimulation. LNM results suggested that the surgical corridor, rather than the tumor, had greater overlap with deep brain stimulation-based depression networks (32% vs. 8%).
   CONCLUSIONS: Early postoperative development of major depressive disorder following resection of a cingulate region tumor, although likely multifactorial, should be considered and patients appropriately counseled preoperatively. Further validation of LNM as a viable methodology for correlating symptoms to lesions could make it a valuable tool in selection of surgical approach and patient counseling.
C1 [Mansouri, Alireza; Yan, Han; Babu, Harish; Lozano, Andres M.; Valiante, Taufik A.] Toronto Western Hosp, Div Neurosurg, Toronto, ON, Canada.
   [Mansouri, Alireza] Penn State Hlth, Dept Neurosurg, Hershey, PA 17033 USA.
   [Boutet, Alexandre; Elias, Gavin; Germann, Jurgen] Univ Hlth Network, Toronto Western Hosp, Toronto, ON, Canada.
   [Boutet, Alexandre; Valiante, Taufik A.] Univ Toronto, Joint Dept Med Imaging, Toronto, ON, Canada.
   [Valiante, Taufik A.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.
   [Valiante, Taufik A.] Krembil Res Inst, Toronto, ON, Canada.
RP Mansouri, A (reprint author), Toronto Western Hosp, Div Neurosurg, Toronto, ON, Canada.; Mansouri, A (reprint author), Penn State Hlth, Dept Neurosurg, Hershey, PA 17033 USA.
EM amansouri@pennstatehealth.psu.edu
RI Valiante, Taufik A/C-3285-2015
OI Valiante, Taufik A/0000-0002-3443-3790; Lozano,
   Andres/0000-0001-8257-3694
CR Bubb EJ, 2018, NEUROSCI BIOBEHAV R, V92, P104, DOI 10.1016/j.neubiorev.2018.05.008
   Caruana F, 2018, BRAIN, V141, P3035, DOI 10.1093/brain/awy219
   Chang EF, 2011, J NEUROSURG, V114, P814, DOI 10.3171/2010.5.JNS091159
   Davies J, 2012, NEUROSURGERY, V71, P4, DOI 10.1227/NEU.0b013e318246a7f8
   Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0
   Horn A, 2019, NEUROIMAGE, V184, P293, DOI 10.1016/j.neuroimage.2018.08.068
   Horn A, 2017, ANN NEUROL, V82, P67, DOI 10.1002/ana.24974
   Horn A, 2017, NEUROIMAGE, V150, P395, DOI 10.1016/j.neuroimage.2017.02.004
   Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168
   Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132
   Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015
   Johansen-Berg H, 2008, CEREB CORTEX, V18, P1374, DOI 10.1093/cercor/bhm167
   Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471
   Oszvald A, 2012, J NEURO-ONCOL, V109, P341, DOI 10.1007/s11060-012-0898-0
   Tate MC, 2011, J NEUROSURG, V114, P640, DOI 10.3171/2010.9.JNS10709
   Torrey EF, 2000, SCHIZOPHR RES, V44, P151, DOI 10.1016/S0920-9964(99)00192-9
   von Lehe M, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.6.FOCUS09104
   Wu YP, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00084
NR 18
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 278
EP 282
DI 10.1016/j.wneu.2019.10.020
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700213
PM 31606510
OA Bronze
DA 2020-05-12
ER

PT J
AU Shapiro, SZ
   Sabacinski, KA
   Mansour, SA
   Echeverry, NB
   Shah, SS
   Stein, AA
   Snelling, BM
AF Shapiro, Stephen Z.
   Sabacinski, Kenneth A.
   Mansour, Samuel A.
   Echeverry, Nikolas B.
   Shah, Sumedh S.
   Stein, Alan A.
   Snelling, Brian M.
TI Use of Vycor Tubular Retractors in the Management of Deep Brain Lesions:
   A Review of Current Studies
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cyst; Foreign body; Hematoma evacuation; Intra-axial; Retractor; Tubular
   retractor; Tumor resection
ID RESECTION; SYSTEM; TUMORS
AB BACKGROUND: Traditional manual retraction to access deep-seated brain lesions has been associated with complications related to vascular compromise of cerebral tissue. Various techniques have been developed over time to minimize injury, such as self-sustaining retractors, neuronavigation, and endoscopic approaches. Recently, tubular retractors, such as the ViewSite Brain Access System (VBAS), have been developed to reduce mechanical damage from retraction by dispersing the force of the retractor radially over the parenchyma. Therefore, we sought to review the current literature to accurately assess the indications, benefits, and complications associated with use of VBAS retractors.
   METHODS: A literature search for English articles published between 2005 and 2019 was performed using the MEDLINE database archive with the search terminology "Vycor OR ViewSite OR Brain-Access-System NOT glass." The VBAS website was also examined. Only articles detailing neurosurgical procedures using the VBAS tubular retractor system alone, or in combination with other retractors, were included. Postoperative morbidity and mortality were analyzed to estimate complications linked to using the retractor.
   RESULTS: Twelve publications (106 patients) met the inclusion criteria. The VBAS retractor was used for tumor resections, hematoma evacuations, cyst removal, foreign body extractions, and lesion resection in toxoplasmosis and multiple sclerosis. These cases were subdivided into groups based on lesion location, size, and resection volume for further analysis. Gross total resection was achieved in 63% of tumor excisions, and subtotal resection was achieved in 37%. Hematoma evacuation was successful in all cases. There were 3 short-term postoperative complications linked to the retractor, with an overall complication rate of 2.8%.
   CONCLUSIONS: This report is the first formal assessment of the VBAS, highlighting technical considerations of the retractor from the surgeon's perspective, patient outcomes, and complications. The retractor is a safe and efficacious tubular retraction system that can be used for tumor biopsy and resection, colloid cyst removal, hematoma evacuation, and removal of foreign bodies. However, further randomized controlled trials are indicated to accurately assess complication rates and outcomes.
C1 [Shapiro, Stephen Z.; Sabacinski, Kenneth A.; Mansour, Samuel A.; Echeverry, Nikolas B.; Snelling, Brian M.] Florida Atlantic Univ, Dept Student Affairs, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
   [Shah, Sumedh S.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Stein, Alan A.] New York Med Coll, Dept Neurol Surg, Valhalla, NY 10595 USA.
   [Snelling, Brian M.] Boca Raton Reg Hosp, Marcus Neurosci Inst, Boca Raton, FL USA.
RP Snelling, BM (reprint author), Florida Atlantic Univ, Dept Student Affairs, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
EM brian.m.snelling@gmail.com
CR Akiyama Y, 2015, NEUROL RES, V37, P278, DOI 10.1179/1743132814Y.0000000439
   Bernardo A, 2015, WORLD NEUROSURG, V84, P132, DOI 10.1016/j.wneu.2015.02.042
   Cohen-Gadol AA, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2011.03.045
   Eichberg DG, 2019, OPER NEUROSURG, V16, P571, DOI 10.1093/ons/opy249
   Eichberg DG, 2018, WORLD NEUROSURG, V112, pE50, DOI 10.1016/j.wneu.2017.12.023
   GREENBERG IM, 1981, NEUROSURGERY, V8, P205, DOI 10.1227/00006123-198102000-00009
   Greenfield JP, 2008, NEUROSURGERY, V63, P334, DOI [10.1227/01.NEU.0000334741.61745.72, 10.1227/01.neu.0000334741.61745.72]
   Harris Anthony E, 2005, Neurosurgery, V56, P125
   Herrera Sebastian R, 2010, Surg Technol Int, V19, P47
   Jo KI, 2011, CHILD NERV SYST, V27, P1989, DOI 10.1007/s00381-011-1529-3
   KELLY PJ, 1988, J NEUROSURG, V69, P301, DOI 10.3171/jns.1988.69.2.0301
   Matsumoto Y, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3538-x
   Otani Yoshihiro, 2018, Surg Neurol Int, V9, P220, DOI 10.4103/sni.sni_62_18
   Ratre S, 2016, J NEUROL SURG PART A, V77, P312, DOI 10.1055/s-0036-1580595
   Raza SM, 2011, MINIM INVAS NEUROSUR, V54, P5, DOI 10.1055/s-0031-1273734
   Recinos PF, 2011, J NEUROSURG-PEDIATR, V7, P516, DOI 10.3171/2011.2.PEDS10515
   ROSENORN J, 1982, J NEUROSURG, V56, P826, DOI 10.3171/jns.1982.56.6.0826
   Rymarczuk GN, 2015, WORLD NEUROSURG, V84, P1055, DOI 10.1016/j.wneu.2015.05.067
   Vycor Medical, VIEWSITE BRAIN ACC S
   Wang WH, 2015, J CHIN MED ASSOC, V78, P101, DOI 10.1016/j.jcma.2014.08.013
   White T, 2017, CUREUS, V9, DOI 10.7759/cureus.1012
   Zhong J, 2003, NEUROL RES, V25, P831, DOI 10.1179/016164103771953925
NR 22
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 283
EP 290
DI 10.1016/j.wneu.2019.08.217
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700035
PM 31505282
OA Bronze
DA 2020-05-12
ER

PT J
AU Jang, K
   Rosenfeld, JV
   Di Ieva, A
AF Jang, Kevin
   Rosenfeld, Jeffrey, V
   Di Ieva, Antonio
TI Paulus of Aegina and the Historical Origins of Spine Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; History; Paulus of Aegina; Spinal injuries; Spine surgery;
   Spine trauma
ID NEUROSURGERY; SCIENCE; WORK
AB Paulus of Aegina (625-690 AD) was the last of the prolific Byzantine physicians. His works consolidated and extended the knowledge of his predecessors, with pioneering efforts to improve the surgical management of spinal injuries. In this article, we review the literature to present an overview of the remarkable evolution of spine surgery throughout classical antiquity. In particular, we discuss the contributions of Paulus to this corpus and explore his classic 7-book anthology, Epitomoe Medicae Libri Septem (Medical Compendium in Seven Books). In reviewing Paulus' legacy, we show the significant milestones in the early development of anatomic and functional knowledge of the spine.
C1 [Jang, Kevin] James Cook Univ, Coll Med & Dent, Townsville, Qld, Australia.
   [Rosenfeld, Jeffrey, V] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia.
   [Rosenfeld, Jeffrey, V] Monash Univ, Dept Surg, Clayton, Vic, Australia.
   [Rosenfeld, Jeffrey, V] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Surg, Bethesda, MD 20814 USA.
   [Di Ieva, Antonio] Macquarie Univ, Fac Med & Hlth Sci, Dept Clin Med, Neurosurg Unit, Sydney, NSW, Australia.
RP Di Ieva, A (reprint author), Macquarie Univ, Fac Med & Hlth Sci, Dept Clin Med, Neurosurg Unit, Sydney, NSW, Australia.
EM antonio.diieva@mq.edu.au
OI Jang, Kevin/0000-0001-7326-7214; Di Ieva, Antonio/0000-0002-5341-5416
CR Acar F, 2005, NEUROSURGERY, V56, P861, DOI 10.1227/01.NEU.0000156791.97198.58
   Aciduman A, 2006, NEUROSURGERY, V59, P397, DOI 10.1227/01.NEU.0000222659.46977.29
   Adams F, 1844, 7 BOOKS PAULUS AEGIN, V2, P455
   Adams F, 1844, 7 BOOKS PAULUS AEGIN
   Avicenna, 1556, LIBER CANONIS MED CO
   AWAD IA, 1995, J NEUROSURG, V83, P929, DOI 10.3171/jns.1995.83.5.0929
   Benini A, 1996, SPINE, V21, P1388, DOI 10.1097/00007632-199606010-00024
   Breasted JH, 1930, EDWIN SMITH PAPYRUS
   Celsus AC, 1528, MEDICINAE, VVIII
   Celsus AC, 1478, DE MEDICINA
   Chorney MA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13563
   Clarke E, 1996, HUMAN BRAIN SPINAL C, P292
   ConstantinusAfricanus, 1536, CONSTANTINI AFRICANI
   de Divitiis E, 2004, NEUROSURGERY, V55, P722, DOI 10.1227/01.NEU.0000139458.36781.31
   Di Ieva A, 2011, J NEUROSURG, V114, P1461, DOI 10.3171/2010.10.JNS101331
   Di Ieva Antonio, 2007, Neurosurg Focus, V23, pE15
   Feldman RP, 1999, CHILD NERV SYST, V15, P281, DOI 10.1007/s003810050395
   Galen, 1821, OPERA OMNIA
   Galen, 1964, CLAUDII GALENI OPERA, VIV, P42
   Galen C, 1917, ANN MED HIST, V1, P367
   Goodrich James Tait, 2004, Neurosurg Focus, V16, pE2
   Goodrich James Tait, 2007, Neurosurg Focus, V23, pE7
   Heiberg JL, 1921, PAULUS AEGINETA EPIT
   Herophilus, 1989, ART MED EARLY ALEXAN
   Hippocrates, 1527, APHORISMI CUM GALENI
   Hippocrates, 1927, 3 HIPPOCRATES LOEB C, P200
   Hippocrates, 1849, GENUINE WORKS HIPPOC, V2, P117
   Hippocrates, 1982, OEUVRES COMPLETES HI, V9, P162
   LeonardofBertapalia, 1519, GUY CHAULIAC CYRURGI
   LeonardofBertapalia, 1989, NERVE INJURIES SKULL
   Lifshutz Jason, 2004, Neurosurg Focus, V16, pE5
   Markatos K, 2018, WORLD NEUROSURG, V109, P338, DOI 10.1016/j.wneu.2017.10.047
   Marx KFH, 1838, HEROPHILUS BEITRAG G
   Milne J.S., 1907, SURG INSTRUMENTS GRE
   Missios S, 2014, J NEUROSURG, V120, P244, DOI 10.3171/2013.8.JNS13550
   Naderi S, 2003, NEUROSURGERY, V52, P1449, DOI 10.1227/01.NEU.0000064811.30933.7F
   Nanda A, 2016, WORLD NEUROSURG, V87, P647, DOI 10.1016/j.wneu.2015.11.016
   Panourias IG, 2011, J HIST NEUROSCI, V20, P177, DOI 10.1080/0964704X.2010.510180
   Papadakis M, 2018, ANZ J SURG, V88, P779, DOI 10.1111/ans.13027
   Pare A, 1564, 10 LIVRES CHIRURG, P107
   PaulusofAegineta, 1844, 7 BOOKS PAULUS AEGIN, V2, P493
   PaulusofAegineta, 1532, OPUS RE MED NUNC PRI
   Pifteau P, 2002, SURG W SALICETO
   Rengachary SS, 2009, NEUROSURGERY, V65, P787, DOI 10.1227/01.NEU.0000324991.45949.E4
   Riesman D, 1936, STORY MED MIDDLE AGE
   RogerofSalerno, 1519, GUY CHAULIAC CYRURGI
   Rosenman L, 2003, SURG MASTER H DEMOND
   Rosenman L, 2003, SURG LANFRANCHI MILA
   Rosenman L, 2002, SURG ROLAND PARMA
   Sahlas DJ, 2001, NEUROSURGERY, V48, P1352, DOI 10.1097/00006123-200106000-00037
   Salazar C F, 1998, Sudhoffs Arch, V82, P170
   Sanan A, 1996, NEUROSURGERY, V39, P657, DOI 10.1097/00006123-199610000-00001
   Siraisi N, 1990, MEDIEVAL EARLY RENAI
   Stroppiana L, 2002, CHIRURG R FRUGARD
   Sullivan R, 1996, J ROY SOC MED, V89, P467
   van Middendorp JJ, 2010, EUR SPINE J, V19, P1815, DOI 10.1007/s00586-010-1523-6
   Vasiliadis ES, 2009, SCOLIOSIS SPINAL DIS, V4, DOI 10.1186/1748-7161-4-6
   Viale GL, 2004, NEUROSURGERY, V54, P1490, DOI 10.1227/01.NEU.0000125545.46576.3F
   WilliamofSaliceto, 1474, CHIRURGIA
   ZIMMERMAN LM, 1993, GREAT IDEAS HIST SUR
NR 60
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 291
EP 301
DI 10.1016/j.wneu.2019.10.026
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700036
PM 31627004
OA Bronze
DA 2020-05-12
ER

PT J
AU Crea, A
   Bianco, A
   Cossandi, C
   Forgnone, S
   Fornaro, R
   Crobeddu, E
   Marino, D
   Piras, G
   Scalia, G
   Saglietti, C
   Boldorini, R
   Galzio, R
   Panzarasa, G
AF Crea, Antonio
   Bianco, Andrea
   Cossandi, Christian
   Forgnone, Sara
   Fornaro, Riccardo
   Crobeddu, Emanuela
   Marino, Daniele
   Piras, Giorgia
   Scalia, Gianluca
   Saglietti, Chiara
   Boldorini, Renato
   Galzio, Renato
   Panzarasa, Gabriele
TI Choroid Plexus Carcinoma in Adults: Literature Review and First Report
   of a Location into the Third Ventricle
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carcinoma; Choroid plexus; Gross total resection; Papilloma; Third
   ventricle
ID CHEMOTHERAPY; VENTRICLE
AB Choroid plexus carcinoma (CPC) is a rare intraventricular neoplasm originating from choroid plexus. CPC is the most aggressive choroid plexus tumor. Almost all the CPCs are detected in children, and the preferred location is the lateral ventricle. We reviewed the literature to evaluate the state of the art concerning the management of CPC in adults and report the first case described of the extremely rare localization into the third ventricle. A 38-year-old woman presented a medical history of Parinaud syndrome and occasional facial weakness. Brain magnetic resonance imaging revealed a mass lesion in the pineal region and posterior part of the third ventricle with obstructive hydrocephalus. She underwent subtotal resection through a supracerebellar infratentorial approach. After the histopathological diagnosis of CPC, the patient underwent a second surgery with gross total resection and adjuvant radiotherapy. CPC in adults, given its extreme rarity, does not have a standardized treatment. Gross total resection should be the first step of the treatment: however, according to the literature, gross total resection is achieved only in 40-75% of cases in CPC as opposed to 95% in choroid plexus papilloma, mainly due to the difficulty in managing a highly vascularized tumor in such a deep location. Chemotherapy has not an established role and adjuvant treatment is based on radiotherapy. In the case described hereby the gross total resection associated with surgical treatment of hydrocephalus and adjuvant radiotherapy has achieved a good clinical and radiological outcome.
C1 [Crea, Antonio; Bianco, Andrea; Cossandi, Christian; Forgnone, Sara; Fornaro, Riccardo; Crobeddu, Emanuela; Marino, Daniele; Piras, Giorgia; Panzarasa, Gabriele] Univ Hosp Maggiore della Carita, Dept Neurosurg, Novara, Italy.
   [Crea, Antonio; Piras, Giorgia; Galzio, Renato] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Neurosurg Unit, Pavia, Italy.
   [Scalia, Gianluca] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Div Neurosurg, Messina, Italy.
   [Saglietti, Chiara; Boldorini, Renato] Univ Piemonte Orientale, Dept Neuropathol, Novara, Italy.
RP Crea, A (reprint author), Univ Hosp Maggiore della Carita, Dept Neurosurg, Novara, Italy.; Crea, A (reprint author), Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Neurosurg Unit, Pavia, Italy.
EM antonio_crea89@virgilio.it
OI Scalia, Gianluca/0000-0002-9465-2506; Bianco, Andrea/0000-0002-8381-3861
CR Azhani C, 2017, SURG REHABIL, V1, P1
   BASKAYA MK, 1994, CLIN NEUROL NEUROSUR, V96, P47, DOI 10.1016/0303-8467(94)90029-9
   Bleggi-Torres LF, 2000, ARQ NEURO-PSIQUIAT, V58, P505, DOI 10.1590/S0004-282X2000000300017
   Bohara M, 2015, NEUROL MED-CHIR, V55, P891, DOI 10.2176/nmc.oa.2015-0126
   CARPENTER DB, 1982, J NEUROSURG, V56, P722, DOI 10.3171/jns.1982.56.5.0722
   DOHRMANN GJ, 1975, J NEUROSURG, V43, P225, DOI 10.3171/jns.1975.43.2.0225
   Guo P, 2015, J CRANIOFAC SURG, V26, pE664, DOI 10.1097/SCS.0000000000002103
   Han Seong Rok, 2006, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V40, P122
   Hashizume Akira, 1995, Neurologia Medico-Chirurgica, V35, P742, DOI 10.2176/nmc.35.742
   Izci Y, 2005, TURK NEUROSURG, V15, P105
   Kamaly-Asl Ian D, 2006, Neurosurg Focus, V20, pE10
   KIM T, 2019, [No title captured], V7, DOI DOI 10.3390/math7010047
   Kishore S, 2012, J NEUROSCI RURAL PRA, V3, P71, DOI 10.4103/0976-3147.91952
   Lozier AP, 2009, NEUROSURGERY, V65, P816, DOI 10.1227/01.NEU.0000348291.48810.C2
   MATSUDA M, 1991, SURG NEUROL, V36, P294, DOI 10.1016/0090-3019(91)90091-M
   Misaki K, 2011, BRAIN TUMOR PATHOL, V28, P259, DOI 10.1007/s10014-011-0033-5
   Osada H, 2006, NEUROL MED-CHIR, V46, P251, DOI 10.2176/nmc.46.251
   Ozdogan S, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.302.5854
   Pellerino A, 2015, NEUROL SCI, V36, P639, DOI 10.1007/s10072-014-1983-2
   Samuel TA, 2013, J NEUROL SURG PART A, V74, pE149, DOI 10.1055/s-0032-1333419
   Tabori U, 2010, J CLIN ONCOL, V28, P1995, DOI 10.1200/JCO.2009.26.8169
   Tena-Suck ML, 2007, ARQ NEURO-PSIQUIAT, V65, P705, DOI 10.1590/S0004-282X2007000400032
   Turkoglu E, 2014, ACTA NEUROCHIR, V156, P1461, DOI 10.1007/s00701-014-2138-1
   VAQUERO J, 1979, ACTA NEUROCHIR, V51, P105, DOI 10.1007/BF01401801
   Wyatt S S, 2001, Australas Radiol, V45, P369, DOI 10.1046/j.1440-1673.2001.00941.x
   Yip C.-M., 2014, SSO SCHWEIZ MON ZAHN, V05, P146
   Zhu VW, 2017, CLIN NEUROL NEUROSUR, V158, P46, DOI 10.1016/j.clineuro.2017.04.013
NR 27
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 302
EP 307
DI 10.1016/j.wneu.2019.10.051
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700037
PM 31629149
OA Bronze
DA 2020-05-12
ER

PT J
AU Retzlaff, AA
   Arispe, K
   Cochran, EJ
   Zwagerman, NT
AF Retzlaff, Amber A.
   Arispe, Karen
   Cochran, Elizabeth J.
   Zwagerman, Nathan T.
TI Intravascular Papillary Endothelial Hyperplasia of the Pineal Region: A
   Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intracranial; Intravascular papillary endothelial hyperplasia; IPEH;
   Masson's tumor; Pineal
ID MASSONS TUMOR; CORD COMPRESSION; HEMANGIOENDOTHELIOMA; RADIOSURGERY;
   MANAGEMENT; HISTORY; SURGERY; BASE
AB BACKGROUND: Intravascular papillary endothelial hyperplasia (IPEH) is a vascular lesion that is uncommon in the central nervous system. To our knowledge, there has been only one previous report of occurrence in the pineal region. We present a second case and a review of the literature.
   CASE DESCRIPTION: A 28-year-old woman presented with 1 month of Jaches and visual auras. Brain magnetic resonance imaging scan demonstrated a 2.6- x 1.8- x 1.3-cm nonenhancing T1-hypointense, T2-/fluid-attenuated inversion recovery-hyperintense pineal region mass with cerebral aqueduct obstruction and hydrocephalus. She underwent placement of a right extraventricular drain followed by complete surgical resection. Histologic analysis was consistent with IPEH.
   CONCLUSIONS: Although rare, IPEH is an entity that should be considered in differential diagnosis for intracranial masses with radiographic features characteristic of vascular lesions. Tissue sampling is imperative for distinction from more malignant entities. Complete resection is curative and is the standard of care when feasible. Given the risk of local progression and neurologic compromise with subtotal resection of central nervous system lesions, further study regarding adjuvant treatment options is warranted.
C1 [Retzlaff, Amber A.] Froedtert & Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA.
   [Arispe, Karen; Cochran, Elizabeth J.] Froedtert & Med Coll Wisconsin, Dept Pathol, Milwaukee, WI USA.
   [Zwagerman, Nathan T.] Froedtert & Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI USA.
RP Retzlaff, AA (reprint author), Froedtert & Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA.
EM aretzlaff@mcw.edu
CR Al-Qahtani KH, 2016, PAN ARAB J RHINOL, V6, P33
   ALI SZ, 1994, ANN CLIN LAB SCI, V24, P371
   Anez EM, 2016, J OTOLARYNGOL ENT RE, V4, P115
   Avellino AM, 1999, J NEUROSURG, V91, P308, DOI 10.3171/jns.1999.91.2.0308
   Balossier A, 2015, NEUROCHIRURGIE, V61, P216, DOI 10.1016/j.neuchi.2013.11.007
   Barritt Andrew W, 2017, Pract Neurol, V17, P214, DOI 10.1136/practneurol-2016-001573
   Baylor J E, 1998, Ear Nose Throat J, V77, P408
   Bologna-Molina R, 2010, CASE REP DERMATOL, V2, P22, DOI 10.1159/000279656
   Cagli S, 2004, NEUROL MED-CHIR, V44, P302, DOI 10.2176/nmc.44.302
   Charalambous LT, 2018, J NEUROSURG, V128, P1725, DOI 10.3171/2017.2.JNS162350
   Choudhry O, 2011, NEUROSURG CLIN N AM, V22, P321, DOI 10.1016/j.nec.2011.04.001
   Crocker A, 2007, CLIN NEUROL NEUROSUR, V109, P811, DOI 10.1016/j.clineuro.2007.07.005
   De Girolami U, 2008, REV NEUROL-FRANCE, V164, P882, DOI 10.1016/j.neurol.2008.01.008
   Deiana G, 2015, NEUROCHIRURGIE, V61, P113, DOI 10.1016/j.neuchi.2014.10.111
   Duong DH, 1997, ACTA NEUROCHIR, V139, P883, DOI 10.1007/BF01411407
   Faure-Conter C, 2015, NEUROCHIRURGIE, V61, P143, DOI 10.1016/j.neuchi.2013.12.006
   Frappaz D, 2015, NEUROCHIRURGIE, V61, P208, DOI 10.1016/j.neuchi.2014.03.003
   Hagiwara A, 1999, J COMPUT ASSIST TOMO, V23, P781, DOI 10.1097/00004728-199909000-00028
   IZUKAWA D, 1987, NEUROSURGERY, V21, P939, DOI 10.1227/00006123-198712000-00029
   Karamchandani J, 2012, NEUROSURGERY, V70, pE1043, DOI 10.1227/NEU.0b013e31822e81f9
   Kristof RA, 1997, J NEUROSURG, V86, P558, DOI 10.3171/jns.1997.86.3.0558
   Lee SK, 2012, J KOREAN NEUROSURG S, V52, P48, DOI 10.3340/jkns.2012.52.1.48
   Lesley WS, 2000, NEUROSURGERY, V47, P961, DOI 10.1097/00006123-200010000-00033
   LEVERE SM, 1994, J HAND SURG-AM, V19A, P559, DOI 10.1016/0363-5023(94)90256-9
   Mann P, 2016, AM J SURG PATHOL, V40, P81, DOI 10.1097/PAS.0000000000000539
   MBaye M, 2015, NEUROCHIRURGIE, V61, P184, DOI 10.1016/j.neuchi.2013.04.002
   Miller TR, 2013, CLIN NEUROL NEUROSUR, V115, P2264, DOI 10.1016/j.clineuro.2013.07.021
   Mottolese C, 2015, NEUROCHIRURGIE, V61, P65, DOI 10.1016/j.neuchi.2014.01.005
   Mottolese C, 2015, NEUROCHIRURGIE, V61, P176, DOI 10.1016/j.neuchi.2014.02.004
   Mottolese C, 2015, NEUROCHIRURGIE, V61, P155, DOI 10.1016/j.neuchi.2013.12.008
   Mottolese C, 2015, NEUROCHIRURGIE, V61, P168, DOI 10.1016/j.neuchi.2013.12.005
   Mottolese C, 2015, NEUROCHIRURGIE, V61, P61, DOI 10.1016/j.neuchi.2013.03.005
   Ohshima T, 2005, SURG NEUROL, V64, P266, DOI 10.1016/j.surneu.2004.11.035
   Ong SS, 2011, J NEURO-ONCOL, V102, P491, DOI 10.1007/s11060-010-0338-y
   Park KK, 2012, J KOREAN NEUROSURG S, V52, P52, DOI 10.3340/jkns.2012.52.1.52
   Prat GP, 2018, WORLD NEUROSURG, V114, P194, DOI 10.1016/j.wneu.2018.03.054
   PORTER DG, 1995, J NEUROSURG, V82, P125, DOI 10.3171/jns.1995.82.1.0125
   Rousselle C, 2015, NEUROCHIRURGIE, V61, P106, DOI 10.1016/j.neuchi.2013.08.009
   Safneck JR, 1995, OTOLARYNG HEAD NECK, V113, P766
   Shah HC, 2014, J PEDIATR NEUROSCI, V9, P260, DOI 10.4103/1817-1745.147584
   Shih CS, 2012, J NEURO-ONCOL, V108, P211, DOI 10.1007/s11060-012-0799-2
   Sim SY, 2015, J NEUROSURG-PEDIATR, V15, P384, DOI 10.3171/2014.9.PEDS13518
   Stoffman MR, 2003, J NEURO-ONCOL, V61, P17, DOI 10.1023/A:1021248504923
   Sun GH, 2012, LARYNGOSCOPE, V122, P212, DOI 10.1002/lary.22439
   WEN DY, 1991, J NEUROSURG, V75, P787, DOI 10.3171/jns.1991.75.5.0787
   Zhang R, 2005, SURG NEUROL, V64, P55, DOI 10.1016/j.surneu.2004.08.091
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 308
EP 313
DI 10.1016/j.wneu.2019.09.022
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700038
PM 31525486
OA Bronze
DA 2020-05-12
ER

PT J
AU Shah, LM
   Bisson, EF
AF Shah, Lubdha M.
   Bisson, Erica F.
TI Susceptibility of Cervical Spinal Stenosis to Hypoxic-lschemic Cord
   Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spinal stenosis; Hypoxia; Hypoxic-ischemic injury; Spinal cord
ID SPONDYLOTIC MYELOPATHY; ISCHEMIA; BRAIN; NEUROPATHOLOGY; PERFUSION;
   LESIONS; MODEL
AB BACKGROUND: The adult spinal cord is typically resistant to hypoxic-ischemic injury because of collateral blood supply; however, congenital or acquired stenosis may result in baseline maximal vasodilation, such as superimposed hemodynamic stresses, that cannot be accommodated, leaving the spinal cord vulnerable to ischemic injury. We present a rare case of spinal cord hypoxic-ischemic injury in an adult with underlying cervical spinal stenosis.
   CASE DESCRIPTION: A 37-year-old man with a history of morbid obesity, diabetes mellitus, hypertension, and obstructive sleep apnea presented after developing progressive weakness in the extremities. Preoperative computed tomography myelography demonstrated ossification of the posterior longitudinal ligament and severe spinal canal narrowing. Approximately 1 week after posterior decompression, the patient experienced spinal hypoxic-ischemic injury. Imaging revealed cord expansion and abnormal T2 signal intensity. Axial diffusion tensor images of the brain revealed delayed ischemic leukoencephalopathy with restricted diffusion in the cerebral cortex and deep white matter; this led to the decision to withdraw care, and the patient died.
   CONCLUSIONS: We hypothesize that vascular dysregulation due to cervical stenosis made the cord parenchyma vulnerable to hypoxic and/or hypoperfusion stresses.
C1 [Shah, Lubdha M.] Univ Utah, Dept Radiol & Imaging Sci, Salt Lake City, UT 84112 USA.
   [Bisson, Erica F.] Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT USA.
RP Shah, LM (reprint author), Univ Utah, Dept Radiol & Imaging Sci, Salt Lake City, UT 84112 USA.
EM lubdha.shah@hsc.utah.edu
CR AZZARELLI B, 1977, NEUROLOGY, V27, P1049, DOI 10.1212/WNL.27.11.1049
   BOHLMAN HH, 1988, SPINE, V13, P843, DOI 10.1097/00007632-198807000-00025
   Busl KM, 2010, NEUROREHABILITATION, V26, P5, DOI 10.3233/NRE-2010-0531
   DEGIROLAMI U, 1982, J NEUROPATH EXP NEUR, V41, P129, DOI 10.1097/00005072-198203000-00004
   FEUERSTEIN G, 1989, ANN NY ACAD SCI, V559, P313
   FOLLIS F, 1995, CAN J NEUROL SCI, V22, P202, DOI 10.1017/S0317167100039858
   GOODMAN ML, 1988, PEDIATR NEUROSCI, V14, P315, DOI 10.1159/000120411
   HALLENBECK JM, 1979, STROKE, V10, P629, DOI 10.1161/01.STR.10.6.629
   Ito T, 1996, SPINE, V21, P827, DOI 10.1097/00007632-199604010-00010
   JACOBS TP, 1987, STROKE, V18, P741, DOI 10.1161/01.STR.18.4.741
   JACOBS TP, 1992, STROKE, V23, P367, DOI 10.1161/01.STR.23.3.367
   Kalsi-Ryan S, 2013, NEUROSCIENTIST, V19, P409, DOI 10.1177/1073858412467377
   Lin CC, 2002, AM J PHYS MED REHAB, V81, P68, DOI 10.1097/00002060-200201000-00013
   MAYHEW JF, 1986, CAN J ANAESTH, V33, P216, DOI 10.1007/BF03010834
   MOORE WM, 1991, ANN SURG, V213, P427, DOI 10.1097/00000658-199105000-00007
   RORKE LB, 1992, AM J NEURORADIOL, V13, P517
   SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18
   SILVER JR, 1974, BRAIN, V97, P539, DOI 10.1093/brain/97.1.539
   SINGER R, 1991, J PEDIATR ORTHOPED, V11, P588
   SLADKY J T, 1986, Pediatric Pathology, V6, P87
   SVENSSON LG, 1993, J VASC SURG, V17, P357, DOI 10.1016/0741-5214(93)90421-H
   Uemura K, 2006, NEUROL MED-CHIR, V46, P581, DOI 10.2176/nmc.46.581
   VANNUETEN JM, 1980, BIOCHEM PHARMACOL, V29, P479, DOI 10.1016/0006-2952(80)90365-2
   Vintila I, 2010, ACTA MED TRANSILVANI, V2, P189
   WIETING JM, 1994, ARCH PHYS MED REHAB, V75, P106
   Yamaura I, 2002, SPINE, V27, P21, DOI 10.1097/00007632-200201010-00008
NR 26
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 314
EP 317
DI 10.1016/j.wneu.2019.10.070
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700039
PM 31648054
OA Bronze
DA 2020-05-12
ER

PT J
AU Grobelny, BT
   Smith, M
   Perin, NI
AF Grobelny, Bartosz T.
   Smith, Michael
   Perin, Noel, I
TI Failure of Surgery in Idiopathic Spinal Cord Herniation: Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Failure of surgery; Spinal cord herniation
ID DISC EXTRUSION
AB BACKGROUND: Idiopathic spinal cord herniation is a disorder in which the cord herniates through a dural defect. We present a case in which both the standard surgical method and a salvage method failed.
   CASE DESCRIPTION: A 36-year-old man presented with 2 years of progressive numbness and proximal hip flexion weakness of both lower extremities. Magnetic resonance imaging of the thoracic spine was suggestive for a ventral spinal cord herniation at the 16/7 level. He was initially treated with reduction of his cord herniation, placement of a ventral sling of collagen matrix over the dural defect to prevent re-herniation, with a laminoplasty. He developed a blood-pressure-dependent paraparesis that did not recover despite a return to the operating room (OR) for removal of the laminoplastic bone flap. He was again taken to the OR, the sling was removed and we enlarged the ventral dural defect rostrally and caudally to prevent strangulation of the hernia as described by Watanabe. Though in the short term he was able to recover and transfer to physical therapy, after going home he developed lower extremity weakness and low-pressure headaches. Magnetic resonance imaging showed a ventral epidural cerebrospinal fluid pocket retropulsing the spinal cord, as well as pockets of ventral cerebrospinal fluid collections remote from the surgery site. The patient returned to the OR and the initial surgery with the ventral sling was re-performed with resolution of the headaches; the patient was neurologically stable and transferred to rehabilitation. Long-term he developed left intercostal pain at the level of the surgery without radiological correlate.
   CONCLUSIONS: In this patient there was no single satisfactory surgical treatment of his ventrally herniated spinal cord-partly related to the herniated component of the cord acting as a mass within a narrow canal at the apex of the thoracic kyphosis. We encountered previously unreported complications of the ventral defect widening technique of surgical treatment.
C1 [Grobelny, Bartosz T.; Smith, Michael; Perin, Noel, I] NYU, Dept Neurosurg, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA.
RP Perin, NI (reprint author), NYU, Dept Neurosurg, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA.
EM Noel.perin@nyumc.org
OI Smith, Michael/0000-0003-3757-2726
CR Barrenechea IJ, 2006, J NEUROSURG-SPINE, V5, P294, DOI 10.3171/spi.2006.5.4.294
   BORGES LF, 1995, NEUROSURGERY, V36, P1028, DOI 10.1227/00006123-199505000-00023
   ISU T, 1991, NEUROSURGERY, V29, P137, DOI 10.1227/00006123-199107000-00027
   Miyaguchi M, 2001, SPINE, V26, P1090, DOI 10.1097/00007632-200105010-00022
   Najjar MW, 2004, SURG NEUROL, V62, P161, DOI 10.1016/j.surneu.2003.10.030
   Nakamura M, 2011, J ORTHOP SCI, V16, P347, DOI 10.1007/s00776-011-0065-z
   NAKAZAWA H, 1993, SPINE, V18, P2138, DOI 10.1097/00007632-199310001-00036
   Sagiuchi T, 2003, NEUROL MED-CHIR, V43, P364, DOI 10.2176/nmc.43.364
   Slavotinek JP, 1996, NEURORADIOLOGY, V38, P152
   Watanabe M, 2001, J NEUROSURG, V95, P169, DOI 10.3171/spi.2001.95.2.0169
   WORTZMAN G, 1974, J NEUROSURG, V41, P631, DOI 10.3171/jns.1974.41.5.0631
NR 11
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 318
EP 323
DI 10.1016/j.wneu.2019.08.099
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700040
PM 31449999
OA Bronze
DA 2020-05-12
ER

PT J
AU Narang, A
   Maheshwari, C
   Aggarwal, V
   Bansal, P
   Singh, P
AF Narang, Amit
   Maheshwari, Chandni
   Aggarwal, Varun
   Bansal, Puneet
   Singh, Paramdeep
TI Gorlin-Goltz Syndrome with Intracranial Meningioma: Case Report and
   Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Basal cell carcinoma; Gorlin-Goltz syndrome; Intracranial meningioma;
   Medulloblastoma; Radiation exposure
ID BASAL-CELL CARCINOMA; NEVUS SYNDROME; PATIENT; MEDULLOBLASTOMA;
   IRRADIATION; GENE; MANIFESTATIONS
AB BACKGROUND: Gorlin-Goltz syndrome is a rare hereditary disease affecting multiple organ systems. Medulloblastoma is the most common intracranial malignancy in these patients, radiotherapy makes them more susceptible to intracranial meningioma. Here we report an intracranial meningioma without radiation exposure.
   CASE DESCRIPTION: We present a case of intracranial meningioma in a woman wino was postoperatively diagnosed to have Gorlin-Goltz syndrome based on presence of calcification of bilateral tent and falx. Further clinical and radiological assessment helped us identify many other syndromic features and patient was promptly advised multispecialty consultations to screen for other malignancies and counselled regarding risk factors.
   CONCLUSIONS: Early identification of the syndrome is important for prevention of secondary radiation-induced malignancies, both intracranial and extracranial. Patients need multidisciplinary approach for management.
C1 [Narang, Amit; Aggarwal, Varun] Guru Gobind Singh Med Coll & Hosp, Dept Neurosurg, Faridkot, Punjab, India.
   [Maheshwari, Chandni] Guru Gobind Singh Med Coll & Hosp, Dept Anaesthesia, Faridkot, Punjab, India.
   [Bansal, Puneet] Guru Gobind Singh Med Coll & Hosp, Dept Surg, Faridkot, Punjab, India.
   [Singh, Paramdeep] Guru Gobind Singh Med Coll & Hosp, Dept Radiol, Faridkot, Punjab, India.
RP Aggarwal, V (reprint author), Guru Gobind Singh Med Coll & Hosp, Dept Neurosurg, Faridkot, Punjab, India.
EM drvarunaggarwal86@gmail.com
RI /D-8874-2011
OI /0000-0003-4226-201X
CR Acocella A, 2009, Minerva Stomatol, V58, P43
   ALBRECHT S, 1994, J NEUROSURG, V81, P466, DOI 10.3171/jns.1994.81.3.0466
   ALEGRE M, 1995, REV CLIN ESP, V195, P684
   AUMAITRE O, 1986, PRESSE MED, V15, P2105
   Campbell RM, 2005, J AM ACAD DERMATOL, V53, pS256, DOI 10.1016/j.jaad.2005.03.033
   Cohen MM, 1999, INT J ORAL MAX SURG, V28, P216, DOI 10.1034/j.1399-0020.1999.283280314.x
   Dawber RPR, 1980, BRIT J DERMATOL, V42, P103
   Deepa MS, 2003, J INDIAN ACAD ORAL M, V15, P203
   Endo M, 2012, AM J MED GENET A, V158A, P351, DOI 10.1002/ajmg.a.34421
   EVANS DGR, 1991, ARCH DIS CHILD-FETAL, V66, P1162, DOI 10.1136/adc.66.10_Spec_No.1162
   FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4
   Fukushima Y, 2004, NEUROL MED-CHIR, V44, P665, DOI 10.2176/nmc.44.665
   GORLIN RJ, 1960, NEW ENGL J MED, V262, P908, DOI 10.1056/NEJM196005052621803
   Jarisch W., 1894, ARCH DERMATOLOGIE SY, V28, P163
   JONES KL, 1986, AM HEART J, V111, P1013, DOI 10.1016/0002-8703(86)90664-2
   Kalogeropoulou Christina, 2009, Cases J, V2, P9087, DOI 10.1186/1757-1626-2-9087
   Kijima C, 2012, FAM CANCER, V11, P565, DOI 10.1007/s10689-012-9548-0
   Kimonis VE, 2004, GENET MED, V6, P495, DOI 10.1097/01.GIM.0000145045.17711.1C
   Kimonis VE, 1997, AM J MED GENET, V69, P299, DOI 10.1002/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.3.CO;2-#
   Lee CW, 2014, J CLIN NEUROSCI, V21, P349, DOI 10.1016/j.jocn.2013.02.033
   Lench NJ, 1997, HUM GENET, V100, P497, DOI 10.1007/s004390050541
   Lo Muzio L, 1999, J AM DENT ASSOC, V130, P669
   Manfredi M, 2004, INT J ORAL MAX SURG, V33, P117, DOI 10.1054/ijom.2003.0435
   Mishra P, 2019, NEUROL INDIA, V67, P595, DOI 10.4103/0028-3886.257991
   MORTIMER PS, 1984, J NEUROL NEUROSUR PS, V47, P210, DOI 10.1136/jnnp.47.2.210
   MUSA BS, 1995, BRIT J NEUROSURG, V9, P629, DOI 10.1080/02688699550040918
   Naydenov E, 2017, CASE REP ONCOL, V10, P1023, DOI 10.1159/000484404
   OMalley S, 1997, J NEUROSURG, V86, P286, DOI 10.3171/jns.1997.86.2.0286
   Patil K, 2005, J Indian Soc Pedod Prev Dent, V23, P198
   Pribila JT, 2008, J NEURO-OPHTHALMOL, V28, P41, DOI 10.1097/WNO.0b013e318167540e
   Ramaglia L, 2006, ORAL SURG ORAL MED O, V102, P217, DOI 10.1016/j.tripleo.2005.08.009
   SOUTHWICK GJ, 1979, CANCER, V44, P2294, DOI 10.1002/1097-0142(197912)44:6<2294::AID-CNCR2820440644>3.0.CO;2-G
   STOELINGA PJ, 1973, ORAL SURG ORAL MED O, V36, P686, DOI 10.1016/0030-4220(73)90141-2
   TAMONEY H J JR, 1969, American Surgeon, V35, P279
   Tate G, 2003, JPN J CLIN ONCOL, V33, P47, DOI 10.1093/jjco/hyg005
   White JC, 1894, J CUTAN GENITOURIN D, V12, P477
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 324
EP 330
DI 10.1016/j.wneu.2019.09.156
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700041
PM 31605858
OA Bronze
DA 2020-05-12
ER

PT J
AU Maehara, T
   Kamiya, K
   Fujimaki, T
   Matsumura, A
   Hongo, K
   Kuroda, S
   Matsumae, M
   Takeshima, H
   Sugo, N
   Nakao, N
   Saito, N
   Ikawa, F
   Tamura, N
   Sakurada, K
   Shimokawa, S
   Arai, H
   Tamura, K
   Sumita, K
   Hara, S
   Kato, Y
AF Maehara, Taketoshi
   Kamiya, Kazuko
   Fujimaki, Takamitsu
   Matsumura, Akira
   Hongo, Kazuhiro
   Kuroda, Satoshi
   Matsumae, Mitsunori
   Takeshima, Hideo
   Sugo, Nobuo
   Nakao, Naoyuki
   Saito, Nobuhito
   Ikawa, Fusao
   Tamura, Noriko
   Sakurada, Kaori
   Shimokawa, Shoko
   Arai, Hajime
   Tamura, Kaoru
   Sumita, Kazutaka
   Hara, Shoko
   Kato, Yoko
CA Japan Neurosurg Soc
TI A Questionnaire to Assess the Challenges Faced by Women Who Quit Working
   as Full-Time Neurosurgeons
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balancing career and family; Full-time neurosurgeon; Physical burden;
   Reinstatement; Woman neurosurgeon; Work-life balance
ID FEMALE; FUTURE
AB OBJECTIVE: To analyze why women quit full-time employment as neurosurgeons and to discuss the conditions required for their reinstatement.
   METHODS: We asked 94 core hospitals providing training programs in the board certification system adopted by the Japan Neurosurgical Society to indicate the total number and present status of women in their department and to send our anonymous questionnaire to women who had formerly worked as full-time neurosurgeons. The questionnaire consisted of closed and open questions on their reasons for quitting as full-time neurosurgeons.
   RESULTS: Among 427 women evaluated, 72 (17%) had quit full-time employment as neurosurgeons. Twenty-one women who had quit 3-21 years after starting their neurosurgery careers responded to the questionnaire, including 17 board-certified neurosurgeons, 11 individuals with master's degrees, and 16 mothers. Their main reasons for quitting full-time work were difficulty in balancing their neurosurgical career and motherhood (52%) and the physical burden (38%). At the time of quitting, only 2 units (5%) had a career counseling system for women. Two thirds of participants might resume full-time work as neurosurgeons in the future. Their support system during pregnancy and the child-raising period, and understanding of male bosses and colleagues were identified as the key themes.
   CONCLUSIONS: The Japan Neurosurgical Society could facilitate supportive environments for women in neurosurgery by enhancing adequate childcare services, changing the work style of full-time neurosurgeons to incorporate diverse working styles, shorter working hours, understanding of their bosses and colleagues, and a career counseling system.
C1 [Maehara, Taketoshi; Tamura, Kaoru; Sumita, Kazutaka; Hara, Shoko] Tokyo Med & Dent Univ, Dept Neurosurg, Bunkyo Ku, Tokyo, Japan.
   [Kamiya, Kazuko] Japan Med Assoc Res Inst, Tokyo, Japan.
   [Fujimaki, Takamitsu] Saitama Med Univ Hosp, Dept Neurosurg, Hidaka City, Saitama, Japan.
   [Matsumura, Akira] Univ Tsukuba, Dept Neurosurg, Fac Med, Tsukuba, Ibaraki, Japan.
   [Hongo, Kazuhiro] Shinshu Univ, Sch Med, Dept Neurosurg, Matsumoto, Nagano, Japan.
   [Kuroda, Satoshi] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Neurosurg, Toyama, Japan.
   [Matsumae, Mitsunori] Tokai Univ, Sch Med, Dept Neurosurg, Isehara, Kanagawa, Japan.
   [Takeshima, Hideo] Miyazaki Univ, Dept Neurosurg, Kiyotake, Miyazaki, Japan.
   [Sugo, Nobuo] Toho Univ, Sch Med, Dept Neurosurg Omori, Ota Ku, Tokyo, Japan.
   [Nakao, Naoyuki] Wakayama Med Univ, Dept Neurol Surg, Wakayama, Japan.
   [Saito, Nobuhito] Univ Tokyo, Dept Neurol Surg, Tokyo, Japan.
   [Ikawa, Fusao] Shimane Prefectural Cent Hosp, Dept Neurol Surg, Izumo, Shimane, Japan.
   [Tamura, Noriko] Tokyo Womens Med Univ, Dept Neurol Surg, Kawadacho, Tokyo, Japan.
   [Sakurada, Kaori] Yamagata Univ, Fac Med, Dept Neurosurg, Yamagata, Yamagata, Japan.
   [Shimokawa, Shoko] Saga Univ, Fac Med, Dept Neurosurg, Saga, Saga, Japan.
   [Arai, Hajime] Juntendo Univ, Dept Neurosurg, Bunkyo Ku, Tokyo, Japan.
   [Kato, Yoko] Fujita Hlth Univ, BANTANE Hosp, Dept Neurosurg, Nakagawa Ward, Nagoya, Aichi, Japan.
RP Maehara, T (reprint author), Tokyo Med & Dent Univ, Dept Neurosurg, Bunkyo Ku, Tokyo, Japan.
EM maehara.nsrg@tmd.ac.jp
OI Hara, Shoko/0000-0003-1097-2738
CR Abosch A, 2018, J NEUROSURG, V129, P277, DOI 10.3171/2018.4.JNS172878
   Adesoye T, 2017, JAMA INTERN MED, V177, P1033, DOI 10.1001/jamainternmed.2017.1394
   Alexy A, 2014, SOC SCI JPN J, V17, P259, DOI 10.1093/ssjj/jyu014
   Benard S, 2008, HASTINGS LAW J, V59, P1359
   Benzil DL, 2008, J NEUROSURG, V109, P378, DOI 10.3171/JNS/2008/109/9/0378
   Budig MJ, 2001, AM SOCIOL REV, V66, P204, DOI 10.2307/2657415
   Corley J, 2018, WORLD NEUROSURG, V111, P130, DOI 10.1016/j.wneu.2017.12.086
   Fujimaki T, 2016, NEUROL MED-CHIR, V56, P704, DOI 10.2176/nmc.oa.2016-0119
   Fukaura Hikoaki, 2013, Rinsho Shinkeigaku, V53, P1354
   Gender Equality Bureau Cabinet Office, ENH PAT LEAV JAP
   Halley MC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4926
   James KM, 2011, HEALTH SERV RES, V46, P232, DOI 10.1111/j.1475-6773.2010.01181.x
   Japan Institute of Labour Policy and Training, 2018, DAT INT LAB STAT 201, P53
   Japan Medical Association Woman Doctor Support Center, REP SURV REG WORK EN
   Japanese Cabinet Office, COOP HUSB COUNT FALL
   Kato Y, 2004, MINIM INVAS NEUROSUR, V47, P65, DOI 10.1055/s-2004-818470
   Komori M, 2014, SURG TODAY, V44, P982, DOI 10.1007/s00595-013-0670-x
   Koven S, 2017, NEW ENGL J MED, V376, P1907, DOI 10.1056/NEJMp1702010
   Lean Sandberg S., 2013, WOMEN WORK WILL LEAD
   Ministry of Health Labor and Welfare, 2019, SECT M SUPPL DEM PHY
   Organisation for Economic Co-operation and Development, 2016, TIM SPENT UNP PAID T
   Organisation for Economic Co-operation and Development, HLTH GLANC 2017 CHAR
   RAGINS BR, 1990, J VOCAT BEHAV, V37, P321, DOI 10.1016/0001-8791(90)90048-7
   Rangel EL, 2018, JAMA SURG, V153, P644, DOI 10.1001/jamasurg.2018.0153
   Renfrow JJ, 2018, NEUROSURGERY, V82, P576, DOI 10.1093/neuros/nyx251
   Riano NS, 2018, JAMA-J AM MED ASSOC, V319, P611, DOI 10.1001/jama.2017.19519
   Shinohara S., 2010, IS IT TRUE NUMBER BO
   SUZUKI M, 2017, JAPAN J NEUROSURG, V26, P817
   THORESON RW, 1990, RES HIGH EDUC, V31, P193, DOI 10.1007/BF00992262
   Tsugawa Y, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1343
   Tsugawa Y, 2017, JAMA INTERN MED, V177, P206, DOI 10.1001/jamainternmed.2016.7875
   World Economic Forum, 2018, GLOB GEND GAP REP 20
   Wronski L., 2019, 9 10 WORKERS WHO HAV
   Yeung J, JAPANESE MED SCH ALL
NR 34
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 331
EP 342
DI 10.1016/j.wneu.2019.08.045
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700042
PM 31437517
OA Bronze
DA 2020-05-12
ER

PT J
AU Sang, DC
   Cui, W
   Guo, Z
   Sang, HP
   Liu, BG
AF Sang, Dacheng
   Cui, Wei
   Guo, Ze
   Sang, Hongpeng
   Liu, Baoge
TI The Differences Among Kinematic Parameters for Evaluating the Quality of
   Intervertebral Motion of the Cervical Spine in Clinical and Experimental
   Studies: Concepts, Research and Measurement Techniques. A Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Center of rotation; Cervical spine; Instantaneous axis of rotation;
   Instantaneous center of rotation; Instantaneous helical axis; Kinematics
ID TOTAL DISC REPLACEMENT; IN-VIVO KINEMATICS; INSTANTANEOUS AXES;
   ARTIFICIAL-DISC; FLEXION-EXTENSION; AXIAL ROTATION; BIOMECHANICAL
   EVALUATION; SAGITTAL ALIGNMENT; FINITE CENTER; IMPLANTATION
AB BACKGROUND: The center of rotation (COR), instantaneous center of rotation (ICR), instantaneous axis of rotation, instantaneous helical axis, finite helical axis, and helical axis of motion are important kinematic parameters for evaluating the quality of intervertebral motion of the cervical spine (QIMC). These parameters embody different concepts and are calculated using various methods. In this review, the distinctions and connections between these kinematic parameters are analyzed according to the concepts, research, and measurement techniques to provide a theoretic basis for future research and new research directions.
   METHODS: The PubMed/MEDLINE databases were searched for studies published in English related to the concepts, research, and calculation of these parameters. The included studies were classified according to the different research or calculation methods, and the proportion of each study type was calculated and analyzed.
   RESULTS: Forty articles were selected. The methods for analyzing the QIMC include in vivo and in vitro studies and finite element analysis. The primary methods for calculating these parameters include the method of perpendicular bisectors and the finite helical axis method.
   CONCLUSIONS: COR was the simplest but not the most accurate parameter to evaluate the QIMC. Conversely, instantaneous helical axis/helical axis of motion were the most accurate, but relatively complex parameters to evaluate the QIMC. ICR showed dynamic changes during flexion-extension motion, but not the three-dimensional kinematic motion of the cervical spine. These parameters were equivalent only in certain situations but cannot be substituted for each other in the clinic. A dynamic radiographic in vivo study was the most convenient and frequently used research method to calculate COR, but failed to describe the dynamic movement. The method of perpendicular bisectors was widely used to calculate the COR or ICR. Therefore, a combination of new research and calculation methods to simply and effectively evaluate the QIMC requires further investigation.
C1 [Sang, Dacheng; Cui, Wei; Guo, Ze; Sang, Hongpeng; Liu, Baoge] Capital Med Univ, Beijing Tiantan Hosp, Dept Orthopaed Surg, Beijing, Peoples R China.
   [Sang, Dacheng; Cui, Wei; Guo, Ze; Sang, Hongpeng; Liu, Baoge] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
RP Liu, BG (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Orthopaed Surg, Beijing, Peoples R China.; Liu, BG (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
EM baogeliu@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81472137, 81772370]; Beijing Natural Science
   FoundationBeijing Natural Science Foundation [7162058]
FX work was supported by funding from the National Natural Science
   Foundation of China (grant numbers 81472137 and 81772370) and the
   Beijing Natural Science Foundation (grant number 7162058)
CR Ahn HS, 2008, SPINE, V33, P883, DOI 10.1097/BRS.0b013e31816b1f5c
   Ahn HS, 2007, SPINE, V32, pE330, DOI 10.1097/01.brs.0000263331.78903.61
   AMEVO B, 1991, CLIN BIOMECH, V6, P31, DOI 10.1016/0268-0033(91)90039-S
   AMEVO B, 1991, CLIN BIOMECH, V6, P111, DOI 10.1016/0268-0033(91)90008-E
   AMEVO B, 1992, SPINE, V17, P748, DOI 10.1097/00007632-199207000-00004
   AMEVO B, 1991, CLIN BIOMECH, V6, P38, DOI 10.1016/0268-0033(91)90040-W
   Anderst W, 2013, SPINE, V38, pE594, DOI 10.1097/BRS.0b013e31828ca5c7
   Anderst W, 2009, MED ENG PHYS, V31, P10, DOI 10.1016/j.medengphy.2008.03.003
   Anderst WJ, 2015, J BIOMECH, V48, P1286, DOI 10.1016/j.jbiomech.2015.02.049
   Anderst WJ, 2011, SPINE, V36, pE393, DOI 10.1097/BRS.0b013e31820b7e2f
   Baillargeon E, 2013, J BIOMECH, V46, P670, DOI 10.1016/j.jbiomech.2012.11.055
   Barrey C, 2012, EUR SPINE J, V21, P1648, DOI 10.1007/s00586-012-2180-8
   Beggs JS, 1983, KINEMATICS
   Bey MJ, 2006, J BIOMECH ENG-T ASME, V128, P604, DOI 10.1115/1.2206199
   Bogduk N, 2000, CLIN BIOMECH, V15, P633, DOI 10.1016/S0268-0033(00)00034-6
   BREKELMA.WA, 1972, ACTA ORTHOP SCAND, V43, P301, DOI 10.3109/17453677208998949
   CAPPOZZO A, 1995, CLIN BIOMECH, V10, P171, DOI 10.1016/0268-0033(95)91394-T
   Challis JH, 2001, MED ENG PHYS, V23, P227, DOI 10.1016/S1350-4533(01)00043-1
   Champain S, 2006, EUR SPINE J, V15, P982, DOI 10.1007/s00586-005-0927-1
   Colle KO, 2013, SPINE J, V13, P1640, DOI 10.1016/j.spinee.2013.06.026
   Crawford NR, 2012, INT J SPINE SURG, V6, P34, DOI 10.1016/j.ijsp.2011.10.003
   Dugailly PM, 2010, SURG RADIOL ANAT, V32, P141, DOI 10.1007/s00276-009-0556-1
   Duggal N, 2011, J SPINAL DISORD TECH, V24, P334, DOI 10.1097/BSD.0b013e3181fbf8aa
   DVORAK J, 1991, J ORTHOPAED RES, V9, P828, DOI 10.1002/jor.1100090608
   Eck JC, 2002, SPINE, V27, P2431, DOI 10.1097/00007632-200211150-00003
   FRANKEL VH, 1971, J BONE JOINT SURG AM, VA 53, P945, DOI 10.2106/00004623-197153050-00010
   Fuller DA, 1998, SPINE, V23, P1649, DOI 10.1097/00007632-199808010-00006
   Galbusera F, 2006, BIOMECH MODEL MECHAN, V5, P253, DOI 10.1007/s10237-006-0015-4
   Galbusera F, 2008, MED ENG PHYS, V30, P1127, DOI 10.1016/j.medengphy.2008.02.002
   Grassmann S, 1998, SPINE, V23, P1155, DOI 10.1097/00007632-199805150-00016
   Guo Z, 2019, ORTHOP SURG, V9999, P1
   HINDERAKER J, 1995, CEPHALALGIA, V15, P391, DOI 10.1046/j.1468-2982.1995.1505391.x
   Jonas R, 2018, SPINE J, V18, P515, DOI 10.1016/j.spinee.2017.10.065
   Kleinberger M., 1993, P 37 STAPP CAR CRASH, P261
   Koller H, 2013, EUR SPINE J, V22, P747, DOI 10.1007/s00586-012-2583-6
   Kowalczyk I, 2013, INT J SPINE SURG, V7, DOI 10.1016/j.ijsp.2013.10.003
   Kowalczyk I, 2011, J NEUROSURG-SPINE, V15, P630, DOI 10.3171/2011.8.SPINE11273
   Lazaro BCR, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1058
   Lee JH, 2016, SPINE, V41, pE893, DOI 10.1097/BRS.0000000000001468
   Liu BG, 2015, MED SCI MONITOR, V21, P1031, DOI 10.12659/MSM.892712
   Liu BG, 2014, EUR SPINE J, V23, P2307, DOI 10.1007/s00586-014-3431-7
   Lou JG, 2016, ACTA ORTHOP TRAUMATO, V50, P339, DOI 10.3944/AOTT.2016.15.0182
   Mansour M, 2004, J BIOMECH, V37, P583, DOI 10.1016/j.jbiomech.2003.09.001
   Martin DE, 2011, J ARTHROPLASTY, V26, P88, DOI 10.1016/j.arth.2009.12.004
   McCane B, 2005, MED ENG PHYS, V27, P75, DOI 10.1016/j.medengphy.2004.08.010
   Meisel HJ, 2016, J NEUROSURG-SPINE, V25, P556, DOI 10.3171/2016.3.SPINE15810
   Panjabi M, 2007, SPINE, V32, P959, DOI 10.1097/01.brs.0000260792.13893.88
   Panjabi MM, 2007, CLIN BIOMECH, V22, P257, DOI 10.1016/j.clinbiomech.2006.08.006
   PANJABI MM, 1988, SPINE, V13, P1129, DOI 10.1097/00007632-198810000-00013
   Park DK, 2011, SPINE, V36, P721, DOI 10.1097/BRS.0b013e3181df10fc
   PENNING L, 1978, AM J ROENTGENOL, V130, P317, DOI 10.2214/ajr.130.2.317
   PENNING L, 1987, SPINE, V12, P732, DOI 10.1097/00007632-198710000-00003
   PENNING L, 1988, CLIN BIOMECH, V3, P37, DOI 10.1016/0268-0033(88)90124-6
   PENNING L, 1964, AMER J ROENTGENOL RA, V91, P1036
   Penning L., 1960, FUNCTIONAL RADIOLOGI
   Piazza SJ, 2004, J BIOMECH, V37, P349, DOI 10.1016/S0021-9290(03)00288-4
   Pickett GE, 2005, SPINE, V30, P1949, DOI 10.1097/01.brs.0000176320.82079.ce
   Powell JW, 2010, J SPINAL DISORD TECH, V23, P89, DOI 10.1097/BSD.0b013e3181991413
   Pu T, 2014, ADV MATER RES-SWITZ, V850-851, P1202, DOI 10.4028/www.scientific.net/AMR.850-851.1202
   Rong X, 2014, SPINE, V39, pB12, DOI 10.1097/BRS.0000000000000634
   Rousseau MA, 2008, SPINE, V33, pE6, DOI 10.1097/BRS.0b013e31815e5dce
   Rousseau MA, 2008, SPINE, V33, pE10, DOI 10.1097/BRS.0b013e31815e62ea
   Ryu WHA, 2013, SPINE J, V13, P628, DOI 10.1016/j.spinee.2013.02.046
   SODERKVIST I, 1993, J BIOMECH, V26, P1473, DOI 10.1016/0021-9290(93)90098-Y
   SPOOR CW, 1980, J BIOMECH, V13, P391, DOI 10.1016/0021-9290(80)90020-2
   Wachowski M, 2007, ARCH MECH ENG, VLIV, P39
   Wachowski MM, 2009, J BIOMECH, V42, P2286, DOI 10.1016/j.jbiomech.2009.06.055
   Wachowski MM, 2017, EUR SPINE J, V26, P2425, DOI 10.1007/s00586-017-5073-z
   Wachowski MM, 2013, J BIOMECH, V46, P1739, DOI 10.1016/j.jbiomech.2013.03.027
   White A A 3rd, 1978, Spine (Phila Pa 1976), V3, P12
   WHITE AA, 1990, CLIN BIOMECHANICS SP
   Wilke H J, 1994, Eur Spine J, V3, P91, DOI 10.1007/BF02221446
   Yoshimoto H, 2004, SPINE, V29, P175, DOI 10.1097/01.BRS.0000107225.97653.CA
   Zhang QH, 2006, J BIOMECH, V39, P189, DOI 10.1016/j.jbiomech.2004.10.029
NR 74
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 343
EP +
DI 10.1016/j.wneu.2019.09.075
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700043
PM 31550538
OA Bronze
DA 2020-05-12
ER

PT J
AU Miller, LE
   Bhattacharyya, S
   Pracyk, J
AF Miller, Larry E.
   Bhattacharyya, Samir
   Pracyk, John
TI Minimally Invasive Versus Open Transforaminal Lumbar Interbody Fusion
   for Single-Level Degenerative Disease: A Systematic Review and
   Meta-Analysis of Randomized Controlled Trials
SO WORLD NEUROSURGERY
LA English
DT Review
DE Low back pain; Pseudarthrosis; TLIF
ID RADIATION-EXPOSURE; OPEN SURGERY; OUTCOMES; SPINE; MIS
AB OBJECTIVE: We compared the safety and effectiveness of minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) to open TLIF (0-TLIF) for lumbar degenerative disease.
   METHODS: We systematically searched Medline, Embase, and the Cochrane Central Register of Controlled Trials for randomized trials of MI-TLIF versus 0-TLIF. The perioperative outcomes included the procedure time, fluoroscopy time, blood loss, complications, and hospital stay. The midterm outcomes included pseudarthrosis, the Oswestry Disability Index, and pain severity-all reported at 1-year minimum follow-up.
   RESULTS: A total of 7 randomized trials including 496 patients (246 MI-TLIF; 250 0-TLIF) were included in our review. No statistically significant group differences in procedure time (mean difference [MD], -4 minutes; P = 0.70) were found. However, the fluoroscopy time was significantly longer with MI-TLIF (MD, 48 seconds; P < 0.001). MI-TLIF resulted in less perioperative blood loss (MD, -200 P < 0.001) and shorter hospitalization (MD, -2.2 days; P < 0.001) compared with 0-TLIF. The risk of perioperative complications was comparable between the 2 groups (risk ratio, 1.03; P = 0.94). No group differences were found in the incidence of pseudarthrosis at the 1-year minimum follow-up (risk ratio, 0.84; P = 0.67). Pain severity at midterm follow-up was comparable between the 2 groups (MD, -1; P = 0.59), and the ODI was slightly lower in the MI-TLIF group (MD, -3; P = 0.01).
   CONCLUSION: Relative to 0-TLIF, MI-TLIF was associated with less blood loss, a shorter hospital stay, and slightly less disability, at the expense of longer fluoroscopy times.
C1 [Miller, Larry E.] Miller Sci Consulting Inc, Asheville, NC 28803 USA.
   [Bhattacharyya, Samir; Pracyk, John] DePuy Synthes, Raynham, MA USA.
RP Miller, LE (reprint author), Miller Sci Consulting Inc, Asheville, NC 28803 USA.
EM larry@millerscientific.com
OI Miller, Larry/0000-0003-1594-1885
FU DePuy Synthes
FX The present study was supported by DePuy Synthes. Larry E. Miller
   discloses consultancy with DePuy Synthes, and Samir Bhattacharyya and
   John Pracyk are employees of DePuy Synthes.
CR American Nuclear Society, RAD DOS CALC
   Clark JC, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.5.FOCUS13144
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Foley Kevin T, 2002, Clin Neurosurg, V49, P499
   Goldstein CL, 2016, SPINE, V41, pS74, DOI 10.1097/BRS.0000000000001462
   HARMS J, 1982, Z ORTHOP GRENZGEB, V120, P343, DOI 10.1055/s-2008-1051624
   Hey HWD, 2017, SPINE J, V17, P1134, DOI 10.1016/j.spinee.2017.04.004
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hu W, 2016, INT ORTHOP, V40, P1883, DOI 10.1007/s00264-016-3153-z
   Imada AO, 2017, CUREUS, V9, DOI 10.7759/cureus.1488
   Karikari IO, 2010, SPINE, V35, pS294, DOI 10.1097/BRS.0b013e3182022ddc
   Khan NR, 2015, NEUROSURGERY, V77, P847, DOI 10.1227/NEU.0000000000000913
   Kim CH, 2016, CLIN SPINE SURG, V29, P52, DOI 10.1097/BSD.0000000000000351
   Kumar A, 2019, INT J SPINE SURG, V13, P39, DOI 10.14444/6006
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lee KH, 2014, J SPINAL DISORD TECH, V27, pE234, DOI 10.1097/BSD.0000000000000089
   Li AM, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0941-8
   Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Lin Y, 2016, J NEUROL SURG PART A, V77, P2, DOI 10.1055/s-0035-1554809
   Lv Y, 2017, MINIM INVASIV THER, V26, P168, DOI 10.1080/13645706.2016.1273837
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Phan K, 2015, EUR SPINE J, V24, P2503, DOI 10.1007/s00586-015-4126-4
   Phan K, 2015, EUR SPINE J, V24, P1017, DOI 10.1007/s00586-015-3903-4
   Qin RQ, 2019, WORLD NEUROSURG, V122, P180, DOI 10.1016/j.wneu.2018.10.202
   Qu JT, 2015, EUR SPINE J, V24, P1058, DOI 10.1007/s00586-015-3890-5
   Recnik G., 2015, Zdravniski Vestnik, V84, P358
   Resnick DK, 2005, J NEUROSURG-SPINE, V2, P692, DOI 10.3171/spi.2005.2.6.0692
   Rodriguez-Vela J, 2013, EUR SPINE J, V22, P2857, DOI 10.1007/s00586-013-2853-y
   Serban D, 2017, BIOMED RES INT, DOI 10.1155/2017/7236970
   Sun ZJ, 2013, CHINESE MED J-PEKING, V126, P3962, DOI 10.3760/cma.j.issn.0366-6999.20131539
   Tian NF, 2013, EUR SPINE J, V22, P1741, DOI 10.1007/s00586-013-2747-z
   Wang HL, 2011, CHINESE MED J-PEKING, V124, P3868, DOI 10.3760/cma.j.issn.0366-6999.2011.23.007
   Wang JA, 2010, EUR SPINE J, V19, P1780, DOI 10.1007/s00586-010-1404-z
   Xie L, 2016, CHINESE MED J-PEKING, V129, P1969, DOI 10.4103/0366-6999.187847
   Yang Y, 2017, J ORTHOP TRAUMATOL, V18, P395, DOI 10.1007/s10195-017-0464-9
   Yu E, 2014, CLIN ORTHOP RELAT R, V472, P1738, DOI 10.1007/s11999-014-3503-3
NR 37
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 358
EP +
DI 10.1016/j.wneu.2019.08.162
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700044
PM 31476471
OA Bronze
DA 2020-05-12
ER

PT J
AU Ghaffari-Rafi, A
   Samandouras, G
AF Ghaffari-Rafi, Arash
   Samandouras, George
TI Effect of Treatment Modalities on Progression-Free Survival and Overall
   Survival in Molecularly Subtyped World Health Organization Grade II
   Diffuse Gliomas: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Astrocytoma; Glioma; Low-grade glioma; Oligodendroglioma; Overall
   survival; Progression-free survival
ID PHASE-II; TEMOZOLOMIDE; CHEMOTHERAPY; MANAGEMENT; OUTCOMES; IMPACT
AB BACKGROUND: With the 2016 update of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System incorporating molecular subtyping to histology, WHO grade II diffuse astrocytic and oligodendroglial tumors are subcategorized by distinct molecular markers. There are no reported systematic reviews quantifying differences in progression-free survival (PFS) and overall survival (OS) on the basis of molecular subtypes of WHO grade II diffuse gliomas, against the background of administered treatments.
   METHODS: Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the Cochrane Handbook of Systemic Reviews of Interventions, we conducted a systematic review through MEDLINE, Embase, and CENTRAL (Cochrane Central Register of Controlled Trails).
   RESULTS: For OS, the first quartile (25%), median (50%), third quartile (75%), and 95% confidence interval, respectively, were identified (in months): astrocytoma-wild-type WHO II (A-wt II): 22.8, 32.2, 40.7, and 21.6-61.2; astrocytoma-mutant WHO II (A-mt II): 69.85, 115.2, 128.4, and 55.4-164.0; oligodendroglioma WHO H (OD-II): 106.3, 163.7, 213.3, and 67.3-235.4 (P value = 0.0002). For PFS, the 25th, 50th, and 75th percentiles, and 95% confidence interval, respectively, are as follows (in months): A-wt II: 6.90, 17.45, 19.57, and 3.00-23.69; A-mt II: 37.20, 43.20, 55.63, and 35.7-60.0; OD-II: 47.42, 59.2, 88.28, and 46.3-91.2 (P value = 0.015).
   CONCLUSIONS: This seems to be the first systematic review of OS and PFS in patients with WHO grade II low-grade gliomas (LGGs), against treatment modalities, in molecularly stratified subsets introduced by the WHO 2016 classification of central nervous system tumors. Overall, A-wt II was confirmed to have a significantly shorter OS than did A-mt II; no significant difference was found between OS of OD-II with A-wt II and A-mt II. In addition, all 3 molecular subtypes were found to have statistically significant differences between PFS, with OD-II having a statistically better PFS than A-mt II. These data can provide valuable prognostic insight to patients and clinicians. In addition, assessing survival differences enhances understanding of treatment recommendations against molecular markers and may facilitate future clinical trial design.
C1 [Ghaffari-Rafi, Arash] Univ Hawaii Manoa, John Burns Sch Med, Honolulu, HI 96822 USA.
   [Ghaffari-Rafi, Arash; Samandouras, George] UCL, Queen Sq Inst Neurol, London, England.
   [Samandouras, George] Univ Coll London Hosp NHS Trust, Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, London, England.
RP Ghaffari-Rafi, A (reprint author), Univ Hawaii Manoa, John Burns Sch Med, Honolulu, HI 96822 USA.; Ghaffari-Rafi, A (reprint author), UCL, Queen Sq Inst Neurol, London, England.
EM arashgr@hawaii.edu
CR Baumert BG, 2016, LANCET ONCOL, V17, P1521, DOI 10.1016/S1470-2045(16)30313-8
   Brandes AA, 2016, J CLIN ONCOLOGY S15, V34
   Buckner J, 2017, NAT REV NEUROL, V13, P340, DOI 10.1038/nrneurol.2017.54
   Etxaniz O, 2017, J NEURO-ONCOL, V135, P273, DOI 10.1007/s11060-017-2570-1
   Franceschi E, 2018, FUTURE ONCOL, V14, P1559, DOI 10.2217/fon-2017-0634
   Franceschi E, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2017
   Gao Y, 2018, EUR J CANCER, V94, P168, DOI 10.1016/j.ejca.2018.02.023
   Grier JT, 2006, ONCOLOGIST, V11, P681, DOI 10.1634/theoncologist.11-6-681
   Higgins J, 2011, COCHRANE COLLAB, V5, P1, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Houillier C, 2010, NEUROLOGY, V75, P1560, DOI 10.1212/WNL.0b013e3181f96282
   Jakola AS, 2017, ANN ONCOL, V28, P1942, DOI 10.1093/annonc/mdx230
   Jiang B, 2017, COCHRANE DB SYST REV, V4
   KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441
   Li MY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130872
   Louis D, 2011, WHO CLASSIFICATION T
   Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x
   Metellus P, 2010, ACTA NEUROPATHOL, V120, P719, DOI 10.1007/s00401-010-0777-8
   Moher D, 2015, SYST REV-LONDON, V4, DOI 10.1186/2046-4053-4-1
   Morshed RA, 2019, J NEURO-ONCOL, V141, P383, DOI 10.1007/s11060-018-03044-4
   Mura A, 2017, ANN ONCOL, V28, P76
   Opoku-Darko M, 2018, J NEUROSURG, V129, P19, DOI 10.3171/2017.3.JNS17159
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Pellerino A, 2017, NEURO-ONCOLOGY, V19, P21
   Poulen G, 2019, J NEUROSURG, V130, P1289, DOI 10.3171/2017.10.JNS171825
   Pouratian N, 2007, J NEURO-ONCOL, V82, P281, DOI 10.1007/s11060-006-9280-4
   Pouratian N, 2010, CURR NEUROL NEUROSCI, V10, P224, DOI 10.1007/s11910-010-0105-7
   R Core Team, 2018, R LANG ENV STAT COMP
   Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Straube C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4825-4
   van den Bent Martin J, 2015, CNS Oncol, V4, P281, DOI 10.2217/cns.15.35
   Villani V, 2017, TUMORI, V103, P255, DOI 10.5301/tj.5000565
   Wahl M, 2017, NEURO-ONCOLOGY, V19, P242, DOI 10.1093/neuonc/now176
   Whittle IR, 2004, J NEUROL NEUROSUR PS, V75, P31, DOI 10.1136/jnnp.2004.040501
   Wijnenga MMJ, 2018, NEURO-ONCOLOGY, V20, P103, DOI 10.1093/neuonc/nox176
   WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.2307/3001968
   Yeboa D, 2017, NEURO-ONCOLOGY, V19, P222
   Youland RS, 2017, J NEURO-ONCOL, V135, P535, DOI 10.1007/s11060-017-2599-1
NR 39
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 366
EP +
DI 10.1016/j.wneu.2019.08.111
PG 17
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700045
PM 31473344
OA Bronze
DA 2020-05-12
ER

PT J
AU Roethlisberger, M
   Jayapalan, RR
   Hostettler, IC
   Kadir, KAB
   Mun, KS
   Brand, Y
   Mariani, L
   Prepageran, N
   Waran, V
AF Roethlisberger, Michel
   Jayapalan, Ronie Romelean
   Hostettler, Isabel Charlotte
   Kadir, Khairul Azmi Bin Abd
   Mun, Kein Seong
   Brand, Yves
   Mariani, Luigi
   Prepageran, Narayanan
   Waran, Vicknes
TI Evolving Strategies for Resection of Sellar/Parasellar Synchronous
   Tumors via Endoscopic Endonasal Approach: A Technical Case Report and
   Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endoscopic endonasal transsphenoidal surgery; Intraoperative magnetic
   resonance imaging; Pituitary adenoma; Sella; Synchronous tumor;
   Tuberculum sellae meningioma
ID TUBERCULUM SELLAE MENINGIOMAS; SKULL BASE MENINGIOMAS; TRANSSPHENOIDAL
   SURGERY; PITUITARY-ADENOMAS; RECONSTRUCTION; EXPERIENCE; CLASSIFICATION;
   PREDICTORS; EVOLUTION; RECOVERY
AB BACKGROUND: Data on the endonasal endoscopic approach (EEA) to treat sellar/parasellar synchronous tumors remain sparse. This work aims to describe a minimally invasive approach with intraoperative magnetic resonance imaging (MRI) to remove a large sellar/parasellar synchronous tumor, and presents a systematic literature review.
   METHODS: The preoperative MRI of a 54-year-old woman revealed a sellar lesion (28 x 19 x 16 mm), presumably a pituitary macroadenoma, and a second extra-axial lesion (22 x 36 x 20 mm) expanding from the tuberculum sellae to the planum sphenoidale with encasement of the anterior communicating complex, presumably a meningioma. We used intraoperative MRI to assess the extent of the resection before reconstructing the large skull base defect. Furthermore, we systematically reviewed pertinent articles retrieved by a PubMed/Embase database search between 1961 and December 2018.
   RESULTS: Out of 63 patients with synchronous tumors reported in 43 publications, we found 3 patients in which the tumor was removed by EEA. In these 3 patients and the presented case, the resection of both lesions was successful, without major approach-related morbidity or mortality. More extensive removal of endonasal structures to gain an adequate tumor exposure was not necessary. We did not find any previous reports describing the benefits of intraoperative MRI in the presented setting.
   CONCLUSIONS: In the rare case of a synchronous meningioma and pituitary adenoma of the sellar region, intraoperative MRI might be beneficial in confirming residual disease before skull base reconstruction, and therefore radiologic follow-up.
C1 [Roethlisberger, Michel; Brand, Yves; Mariani, Luigi] Univ Basel, Univ Hosp Basel, Dept Neurosurg, Basel, Switzerland.
   [Roethlisberger, Michel; Jayapalan, Ronie Romelean; Waran, Vicknes] Univ Malaya, Univ Malaya Specialist Ctr, Dept Neurosurg, Kuala Lumpur, Malaysia.
   [Kadir, Khairul Azmi Bin Abd] Univ Malaya, Univ Malaya Specialist Ctr, Dept Biomed Imaging, Kuala Lumpur, Malaysia.
   [Mun, Kein Seong] Univ Malaya, Univ Malaya Specialist Ctr, Dept Pathol, Kuala Lumpur, Malaysia.
   [Roethlisberger, Michel; Prepageran, Narayanan] Univ Malaya, Univ Malaya Specialist Ctr, Dept Otorhinolaryngol, Kuala Lumpur, Malaysia.
   [Hostettler, Isabel Charlotte] UCL, Stroke Res Ctr, Inst Neurol, London, England.
   [Brand, Yves] Cantonal Hosp Graubuenden, Dept Otorhinolanryngol, Graubuenden, Switzerland.
RP Roethlisberger, M (reprint author), Univ Basel, Univ Hosp Basel, Dept Neurosurg, Basel, Switzerland.
EM Michel.Roethlisberger@usb.ch
FU Department of Surgery of the University Hospital of Basel (Basel,
   Switzerland); Gottfried and Julia Bangerter-Rhyner Foundation (Bern,
   Switzerland); Department of Neurosurgery of the University Hospital of
   Basel (Basel, Switzerland); University of Malaya Specialist Centre
   (Kuala Lumpur, Malaysia)
FX This study was supported by the Department of Surgery of the University
   Hospital of Basel (Basel, Switzerland), the Gottfried and Julia
   Bangerter-Rhyner Foundation (Bern, Switzerland), the Department of
   Neurosurgery of the University Hospital of Basel (Basel, Switzerland),
   and the University of Malaya Specialist Centre (Kuala Lumpur, Malaysia).
CR Abele TA, 2012, CLIN RADIOL, V67, P821, DOI 10.1016/j.crad.2012.01.001
   Amirjamshidi A, 2017, J SURG CASE REP, DOI 10.1093/jscr/rjx039
   Amirjamshidi A, 2011, J NEUROSURG-PEDIATR, V8, P342, DOI 10.3171/2011.7.PEDS11179
   Bayer S, 2017, INT J BIOMED IMAGING, DOI 10.1155/2017/6028645
   Bohman LE, 2012, ORL J OTO-RHINO-LARY, V74, P255, DOI 10.1159/000343794
   Bourdelot A, 2004, EUR J ENDOCRINOL, V150, P763, DOI 10.1530/eje.0.1500763
   CANNAVO S, 1993, J ENDOCRINOL INVEST, V16, P703, DOI 10.1007/BF03348915
   Chakraborty S, 2017, J EXP THER ONCOL, V12, P157
   Clark AJ, 2013, NEUROSURG REV, V36, P349, DOI 10.1007/s10143-013-0458-x
   Coburger J, 2014, J NEUROSURG, V120, P346, DOI 10.3171/2013.9.JNS122207
   Couldwell WT, 2004, NEUROSURGERY, V55, P539, DOI 10.1227/01.NEU.0000134287.19377.A2
   de Divitiis E, 2008, NEUROSURGERY, V62, P556, DOI 10.1227/01.neu.0000317303.93460.24
   Furtado SV, 2010, J CANCER RES THER, V6, P221, DOI 10.4103/0973-1482.65246
   Gnanalingham KK, 2005, J NEUROL NEUROSUR PS, V76, P415, DOI 10.1136/jnnp.2004.035576
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Jaskolski D J, 1990, Zentralbl Neurochir, V51, P229
   Kang MD, 2009, AM J NEURORADIOL, V30, P781, DOI 10.3174/ajnr.A1453
   Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5
   Kassam AB, 2008, NEUROSURGERY, V63, P57, DOI [10.1227/01.NEU.0000297013.35469.37, 10.1227/01.neu.0000317374.30443.23]
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P713, DOI 10.1016/j.wneu.2011.08.025
   Kong DS, 2019, J NEUROSURG, V130, P838, DOI 10.3171/2017.11.JNS171337
   Koutourousiou M, 2014, J NEUROSURG, V120, P1326, DOI 10.3171/2014.2.JNS13767
   Koutourousiou M, 2010, PITUITARY, V13, P8, DOI 10.1007/s11102-009-0190-2
   Learned KO, 2013, EUR J RADIOL, V82, P544, DOI 10.1016/j.ejrad.2012.09.029
   Learned KO, 2015, NEUROGRAPHICS, V5, P56
   Lee SC, 2008, CLIN EXP OTORHINOLAR, V1, P53, DOI 10.3342/ceo.2008.1.2.53
   Li J, 2015, ASIAN J SURG, V38, P168, DOI 10.1016/j.asjsur.2015.03.001
   Louis DN, 2016, WHO CLASSIFICATION T, V1
   Mahvash Mehran, 2014, Asian J Neurosurg, V9, P236, DOI 10.4103/1793-5482.146629
   Mascarella MA, 2016, WORLD NEUROSURG, V91, P582, DOI 10.1016/j.wneu.2016.04.093
   Mete O, 2017, ENDOCR PATHOL, V28, P228, DOI 10.1007/s12022-017-9498-z
   Mislow JMK, 2009, NEUROSURG CLIN N AM, V20, P137, DOI 10.1016/j.nec.2009.04.002
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Murad Mohammad Hassan, 2018, BMJ Evid Based Med, V23, P60, DOI 10.1136/bmjebm-2017-110853
   Muskens IS, 2018, ACTA NEUROCHIR, V160, P59, DOI 10.1007/s00701-017-3390-y
   Ottenhausen M, 2014, WORLD NEUROSURG, V82, P442, DOI 10.1016/j.wneu.2014.03.032
   Pal'a A, 2017, WORLD NEUROSURG, V102, P144, DOI 10.1016/j.wneu.2017.02.132
   Pamir MN, 2005, ACTA NEUROCHIR, V147, P1121, DOI 10.1007/s00701-005-0625-0
   POWELL M, 1995, BRIT J NEUROSURG, V9, P367, DOI 10.1080/02688699550041377
   Prevedello Daniel M, 2007, Neurosurgery, V60, pE401, DOI 10.1227/01.NEU.0000255359.94571.91
   Rennert J, 2007, CLIN NEUROL NEUROSUR, V109, P111, DOI 10.1016/j.clineuro.2006.11.001
   Riley CA, 2019, WORLD NEUROSURG, V124, P513, DOI 10.1016/j.wneu.2019.01.120
   Serra C, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.12.FOCUS15564
   Sigler AC, 2017, OTOLARYNG CLIN N AM, V50, P643, DOI 10.1016/j.otc.2017.01.015
   Song SW, 2018, WORLD NEUROSURG, V109, pE434, DOI 10.1016/j.wneu.2017.09.202
   Soni RS, 2014, J CLIN NEUROSCI, V21, P559, DOI 10.1016/j.jocn.2013.03.043
   Stienen MN, 2019, OPER NEUROSURG, V16, P756, DOI 10.1093/ons/opy205
   Syed S, 2018, WORLD NEUROSURG, V116, P454, DOI 10.1016/j.wneu.2018.04.109
   Tanriover N, 2014, J CRANIOFAC SURG, V25, P1277, DOI 10.1097/SCS.0000000000000580
   van Bunderen CC, 2013, PITUITARY, V16, P158, DOI 10.1007/s11102-012-0395-7
   Wu V, 2018, AM J RHINOL ALLERGY, V32, P52, DOI 10.2500/ajra.2018.32.4499
   Zaidi HA, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15515
   Zaidi HA, 2014, NEUROSURGERY, V74, pE335, DOI 10.1227/NEU.0000000000000191
   Zhao Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009139
NR 55
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 381
EP +
DI 10.1016/j.wneu.2019.08.102
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700046
PM 31476461
OA Bronze
DA 2020-05-12
ER

PT J
AU Ferrigno, AS
   Caro-Osorio, E
   Martinez, HR
   Martinez-Ordaz, L
   Figueroa-Sanchez, JA
AF Ferrigno, Ana S.
   Caro-Osorio, Enrique
   Martinez, Hector R.
   Martinez-Ordaz, Lourdes
   Figueroa-Sanchez, Jose A.
TI Coiling as a Rescue Strategy for Flow Diverter Prolapse into a Giant
   Intracranial Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coiling; Endovascular repair; Flow diverter; Intracranial aneurysm;
   Stent prolapse
ID PIPELINE EMBOLIZATION DEVICE; EXPERIENCE; MIDTERM; ARTERY; STENT
AB BACKGROUND: Up to 3.2% of the adult population has an unruptured intracranial aneurysm (IA). Flow diversion is a relatively new treatment technique that is especially useful for large and morphologically unfavorable IAs.
   METHODS: A previously healthy woman aged 32 years presented with a 6-month history of ptosis and ophthalmoplegia of the left eye. A magnetic resonance imaging scan revealed a giant left internal carotid artery aneurysm She was admitted for treatment using flow diversion. After delivery of the flow diverter (FD), prolapse of the proximal end of the stent into the aneurysmal sac was observed. FD stabilization was achieved by deploying multiple coils through a previously placed microcatheter to push the prolapsed end away from the aneurysmal lumen.
   RESULTS: The patient had a favorable outcome, with reduction of preoperative mass effect symptoms and complete obliteration of the aneurysm persisting at the 3-month follow-up.
   CONCLUSIONS: Giant IAs remain one of the most daunting clinical problems to treat. FD displacement is a rare (0.5%-0.75%) and possibly fatal complication. Currently, no clinical guidelines exist for its management. Adjunctive coiling is a possible rescue strategy for stabilizing an FD that foreshortened and prolapsed into the aneurysmal sac. Further studies are needed to identify the best approach to this complication.
C1 [Ferrigno, Ana S.; Caro-Osorio, Enrique; Martinez, Hector R.; Martinez-Ordaz, Lourdes; Figueroa-Sanchez, Jose A.] Tecnol Monterrey, Escuela Med & Ciencias Salud, Monterrey, Nuevo Leon, Mexico.
RP Figueroa-Sanchez, JA (reprint author), Tecnol Monterrey, Escuela Med & Ciencias Salud, Monterrey, Nuevo Leon, Mexico.
EM dr.figueroa@itesm.mx
OI Ferrigno, Ana/0000-0003-1855-1196; Figueroa-Sanchez, Jose
   Antonio/0000-0003-1427-9471
CR Alderazi YJ, 2014, STROKE RES TREAT, V2014, DOI 10.1155/2014/415653
   Becske T, 2017, J NEUROSURG, V127, P81, DOI 10.3171/2015.6.JNS15311
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Bender MT, 2018, J NEUROINTERV SURG, V10, P843, DOI 10.1136/neurintsurg-2017-013739
   Bowers CA, 2015, ACTA NEUROCHIR, V157, P2071, DOI 10.1007/s00701-015-2593-3
   Chalouhi N, 2013, AM J NEURORADIOL, V34, P2326, DOI 10.3174/ajnr.A3632
   Chalouhi N, 2013, STROKE, V44, P2150, DOI 10.1161/STROKEAHA.113.001785
   Chalouhi N, 2013, NEUROSURGERY, V72, P229
   Crowley RW, 2014, J NEUROINTERV SURG, V6, P439, DOI 10.1136/neurintsurg-2013-010806
   Gawlitza Matthias, 2020, J Neuroradiol, V47, P233, DOI 10.1016/j.neurad.2019.01.092
   Gregory TB, 2015, STROKE, V46, P2368
   Hauck EF, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f8530d
   Kan Peter, 2015, Surg Neurol Int, V6, pS284, DOI 10.4103/2152-7806.157797
   Lin N, 2015, NEUROSURGERY, V76, P142, DOI 10.1227/NEU.0000000000000579
   Lubicz B, 2010, STROKE, V41, P2247, DOI 10.1161/STROKEAHA.110.589911
   Martinez-Galdamez M, 2017, J NEUROINTERV SURG, V9, pE4, DOI 10.1136/neurintsurg-2016-012263.rep
   Navarro R, 2014, OPEN J MODERN NEUROS, V4, P163
   Nohra C, 2016, STROKE, V47, pA8
   Parkinson RJ, 2006, NEUROSURGERY, V59, P812, DOI 10.1227/01.NEU.0000232836.66310.46
   Piano M, 2013, J NEUROSURG, V118, P408, DOI 10.3171/2012.10.JNS112222
   Srinivasan VM, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1738
   Szikora I, 2010, AM J NEURORADIOL, V31, P1139, DOI 10.3174/ajnr.A2023
   Waleed B, 2013, STROKE, V44, P442
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Yu SCH, 2012, RADIOLOGY, V265, P893, DOI 10.1148/radiol.12120422
   Zhou G, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS16450
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 392
EP 397
DI 10.1016/j.wneu.2019.08.141
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700047
PM 31476475
OA Bronze
DA 2020-05-12
ER

PT J
AU Rubio, RR
   Vigo, V
   Gandhi, S
   Tabani, H
   Meybodi, AT
   Winkler, EA
   Abla, AA
   Lawton, MT
   Benet, A
AF Rubio, Roberto Rodriguez
   Vigo, Vera
   Gandhi, Sirin
   Tabani, Halima
   Meybodi, Ali Tayebi
   Winkler, Ethan A.
   Abla, Adib A.
   Lawton, Michael T.
   Benet, Arnau
TI An Anatomical Feasibility Study for Revascularization of the Ophthalmic
   Artery, Part II: Intraorbital Segment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extracranial-intracranial bypass; Intracanalicular; Intraorbital;
   Ophthalmic artery; Posterolateral orbitotomy; Superficial temporal
   artery; Superomedial orbitotomy
ID ANEURYSM; OCCLUSION; ORBITOTOMY; TUMORS
AB INTRODUCTION: Distal ophthalmic artery (OpA) aneurysms are a rare subset of vascular lesions with lack of optimal treatment. The management of these aneurysms may require complete occlusion of the parent vessel, carrying a risk of permanent visual impairment due to individual variations of extracranial collateral flow to the intraorbital ophthalmic artery (iOpA).
   OBJECTIVE: To test the feasibility of a superficial temporal artery (STA) to iOpA bypass to prevent acute ischemic retinal injury. Two different transorbital corridors (superomedial and posterolateral approaches) for this bypass were evaluated.
   METHODS: Each approach was carried out in 10 specimens (n = 20). The corridors were compared to achieve the optimal exposure of the iOpA until the central retinal artery origin was visualized. An end-to-end anastomosis was performed from STA-to-iOpA. The arterial caliber and length at the anastomotic sites, required donor artery length, and intraorbital surgical area were measured.
   RESULTS: STA-iOpA bypasses were performed in all specimens. For the posterolateral transorbital approach, the mean caliber of STA was 1.8 +/- 0.2 mm, and that of iOpA was 1.7 +/- 0.5 mm. The required STA graft length was 78.3 +/- 1 mm with lateral iOpA transposition of 8.2 +/- 1.1 mm. For the superomedial approach, the average STA length required for an intraorbital bypass was 130.8 +/- 14.0 mm. The mean calibers of iOpA and STA were 1.5 +/- 0.1 mm and 1.5 +/- 0.1 mm, respectively.
   CONCLUSIONS: This study demonstrates the feasibility of a novel revascularization technique of the iOpA using 2 different transorbital approaches. These techniques can be used in the management of intraorbital lesions such as OpA aneurysms, tumoral infiltrations, or intraoperative injuries.
C1 [Rubio, Roberto Rodriguez; Vigo, Vera; Tabani, Halima; Winkler, Ethan A.; Abla, Adib A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez; Vigo, Vera; Tabani, Halima; Winkler, Ethan A.; Abla, Adib A.] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
   [Gandhi, Sirin; Meybodi, Ali Tayebi; Lawton, Michael T.; Benet, Arnau] Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
RP Rubio, RR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
EM neurodriguez@gmail.com
CR Abuzayed B, 2012, NEUROSURG REV, V35, P573, DOI 10.1007/s10143-012-0393-2
   Al Balushi Ali, 2017, J Vasc Interv Neurol, V9, P14
   Benet A, 2014, J NEUROSURG, V120, P1229, DOI 10.3171/2014.1.JNS131857
   Bingham CM, 2014, OPHTHAL PLAST RECONS, V30, P215, DOI 10.1097/IOP.0000000000000052
   Chabot JD, 2017, NEUROSURGERY, V80, P309, DOI 10.1093/neuros/nyw045
   Choi BK, 2008, J KOREAN NEUROSURG S, V44, P43, DOI 10.3340/jkns.2008.44.1.43
   DAY AL, 1990, J NEUROSURG, V72, P677, DOI 10.3171/jns.1990.72.5.0677
   Dehdashti AR, 2002, NEURORADIOLOGY, V44, P600, DOI 10.1007/s00234-002-0786-y
   Della Pepa GM, 2014, BRIT J NEUROSURG, V28, P787, DOI 10.3109/02688697.2014.913776
   Erdogmus S, 2007, MINIM INVAS NEUROSUR, V50, P202, DOI 10.1055/s-2007-985862
   Erdogmus S, 2008, J NEURO-OPHTHALMOL, V28, P320, DOI 10.1097/WNO.0b013e318183c4bb
   Ernemann U, 2002, GRAEF ARCH CLIN EXP, V240, P575, DOI 10.1007/s00417-002-0503-x
   Finnerty KN, 2013, OPHTHAL PLAST RECONS, V29, pE108, DOI 10.1097/IOP.0b013e31827f5a9c
   FRIEDLANDER LD, 1995, SKULL BASE SURG, V5, P191, DOI 10.1055/s-2008-1058915
   Friedlander LD, 2015, J VASC MED SURG, V3, P190
   Hayreh SS, 2006, EYE, V20, P1130, DOI 10.1038/sj.eye.6702377
   HAYREH SS, 1980, OPHTHALMOLOGY, V87, P75, DOI 10.1016/s0161-6420(80)35283-4
   Hayreh SS, 2000, AM J OPHTHALMOL, V129, P786, DOI 10.1016/S0002-9394(00)00384-6
   Kawaguchi S, 1999, LANCET, V354, P2052, DOI 10.1016/S0140-6736(99)03671-5
   Kearns T P, 1978, Trans Am Ophthalmol Soc, V76, P247
   Kocabiyik N, 2009, NEUROANATOMY, V8, P36
   LANG J, 1990, SURG RADIOL ANAT, V12, P83, DOI 10.1007/BF01623328
   Liu Y, 2012, INT J OPHTHALMOL-CHI, V5, P212, DOI 10.3980/j.issn.2222-3959.2012.02.19
   Martins C, 2011, ANAT RES INT, V2011, DOI DOI 10.1155/2011/468727
   Naqvi J, 2013, ORBIT, V32, P124, DOI 10.3109/01676830.2013.764444
   NEUPERT JR, 1976, AM J OPHTHALMOL, V81, P600, DOI 10.1016/0002-9394(76)90123-9
   Pai SB, 2017, NEUROL INDIA, V65, P1094, DOI 10.4103/neuroindia.NI_726_17
   Perrini P, 2007, J NEUROSURG, V106, P142, DOI 10.3171/jns.2007.106.1.142
   Piche SL, 2005, AM J NEURORADIOL, V26, P1929
   Qiao LA, 2011, NEUROSURG REV, V34, P29, DOI 10.1007/s10143-010-0290-5
   Sabatino G, 2009, ACTA NEUROCHIR, V151, P831, DOI 10.1007/s00701-009-0352-z
   SHIBUYA M, 1990, ACTA NEUROCHIR, V103, P71, DOI 10.1007/BF01420195
   SUDAKEVITCH T, 1947, BRIT J OPHTHALMOL, V31, P738, DOI 10.1136/bjo.31.12.738
   Tsutsumi S, 2006, NEUROSURGERY, V59, P870, DOI 10.1227/01.NEU.0000232654.15306.4A
   van Overbeeke J, 2003, Orbit, V22, P81
   WYBAR K C, 1956, Br J Ophthalmol, V40, P65, DOI 10.1136/bjo.40.2.65
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 401
EP 408
DI 10.1016/j.wneu.2019.08.261
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700049
PM 31520756
OA Bronze
DA 2020-05-12
ER

PT J
AU Ghorbani, M
   Hejazian, SE
   Dastmalchi, A
   Chavoshinejad, M
   Asaadi, S
AF Ghorbani, Mohammad
   Hejazian, Seyed Ebrahim
   Dastmalchi, Alireza
   Chavoshinejad, Mehdi
   Asaadi, Sina
TI Orbital Compartment Syndrome Secondary to Direct Carotid Cavernous
   Fistula After Carotid Cavernous Aneurysm Rupture: Case Report and Review
   of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intracavernous aneurysm; Orbital compartment syndrome; Rupture
ID ENDOVASCULAR TREATMENT; NATURAL-HISTORY; COVERED STENTS; FLOW;
   MANAGEMENT; HEMORRHAGE; PRESSURE
AB BACKGROUND: Carotid cavernous aneurysm (CCA) rupture is rare. However, it can result in various complications such as carotid cavernous fistula (CCF), epistaxis, spontaneous thrombosis, and subarachnoid hemorrhage.
   CASE DESCRIPTION: We report a 65-year-old woman with a history of uncontrolled diabetes who was referred with complaints of acute headache, diplopia, proptosis, and chemosis. Ophthalmic examination revealed elevated intraocular pressure in the right eye, optic disk edema, and retinal venous congestion. Canthotomy was performed based on a diagnosis of orbital compartment syndrome (OCS). Further imaging revealed a dilated superior ophthalmic vein and cavernous sinus, as well as swelling of the extraocular muscles in the right eye. Digital subtraction angiography revealed the fistulous connection between the cavernous part of the internal carotid and cavernous sinus (direct CCF) due to the large ruptured CCA, resulting in retrograde flow through the superior and inferior ophthalmic veins. Successful endovascular coiling of the aneurysm resulted in complete occlusion of the fistula. Post-intervention ophthalmic examination demonstrated progressive improvement of ophthalmic signs and symptoms; however, the patient's right eye remained sightless.
   CONCLUSIONS: In patients with clinical manifestation of OCS with no history of any predisposing risk factors, diagnosis of ruptured cavernous sinus aneurysm and resulting direct CCF should be considered. In such cases, emergent imaging along with early endovascular intervention can resolve OCS and prevent permanent ocular injury and vision loss.
C1 [Ghorbani, Mohammad; Hejazian, Seyed Ebrahim; Dastmalchi, Alireza; Chavoshinejad, Mehdi; Asaadi, Sina] Firoozgar Hosp, Div Vasc & Endovasc Neurosurg, Tehran, Iran.
   [Asaadi, Sina] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran.
RP Asaadi, S (reprint author), Firoozgar Hosp, Div Vasc & Endovasc Neurosurg, Tehran, Iran.; Asaadi, S (reprint author), Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran.
EM s.asaadi90@gmail.com
RI Ghorbani, Mohammad/N-8636-2018
OI Ghorbani, Mohammad/0000-0002-7709-3095
CR Ambekar S, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.03.042
   Arai Nobuhiko, 2017, NMC Case Rep J, V4, P33, DOI 10.2176/nmccrj.cr.2016-0139
   ASHTON H, 1975, CLIN ORTHOP RELAT R, P15
   Cheung CA, 2014, AM J EMERG MED, V32, P221, DOI 10.1016/j.ajem.2013.11.015
   Cho KC, 2011, J KOREAN NEUROSURG S, V50, P126, DOI 10.3340/jkns.2011.50.2.126
   DAHN I, 1967, CLIN SCI, V32, P467
   DALLEY RW, 1989, AM J NEURORADIOL, V10, P181
   de Aguiar GB, 2016, REV ASSOC MED BRAS, V62, P78, DOI 10.1590/1806-9282.62.01.78
   Eddleman CS, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0920
   Ellis JA, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1223
   Gemmete JJ, 2009, J NEURO-OPHTHALMOL, V29, P62, DOI 10.1097/WNO.0b013e3181989fc0
   Ghorbani M, 2019, WORLD NEUROSURG, V127, P216, DOI 10.1016/j.wneu.2019.03.136
   Gomez F, 2007, AM J NEURORADIOL, V28, P1762, DOI 10.3174/ajnr.A0636
   Guan N, 2016, J STROKE CEREBROVASC, V25, P1929, DOI 10.1016/j.jstrokecerebrovasdis.2016.04.012
   HODES JE, 1988, J NEUROSURG, V69, P617, DOI 10.3171/jns.1988.69.4.0617
   Kalyanpur TM, 2011, NEUROL INDIA, V59, P895, DOI 10.4103/0028-3886.91373
   Korkmazer B, 2013, WORLD J RADIOL, V5, P143, DOI 10.4329/wjr.v5.i4.143
   Lee AG, 1996, NEUROSURGERY, V38, P596, DOI 10.1097/00006123-199603000-00038
   Lima V, 2009, SURV OPHTHALMOL, V54, P441, DOI 10.1016/j.survophthal.2009.04.005
   Malan J, 2012, INTERV NEURORADIOL, V18, P178, DOI 10.1177/159101991201800209
   Mercado Glenna B, 2011, Asian J Neurosurg, V6, P45, DOI 10.4103/1793-5482.85637
   Moron FE, 2005, AM J NEURORADIOL, V26, P1399
   Ogilvy CS, 2017, WORLD NEUROSURG, V105, P812, DOI 10.1016/j.wneu.2017.06.113
   Ringer AJ, 2005, NEUROSURG CLIN N AM, V16, P279, DOI 10.1016/j.nec.2004.08.004
   Stiebel-Kalish H, 2005, NEUROSURGERY, V57, P850, DOI 10.1227/01.NEU.0000179922.48165.42
   Taha MA, 2006, SURG NEUROL, V66, P277, DOI 10.1016/j.surneu.2005.12.031
   Tjoumakaris SI, 2009, NEUROSURG CLIN N AM, V20, P447, DOI 10.1016/j.nec.2009.07.013
   van Rooij WJ, 2006, AM J NEURORADIOL, V27, P185
   Wang YL, 2012, INTERV NEURORADIOL, V18, P172, DOI 10.1177/159101991201800208
   Wendl CM, 2017, CLIN NEURORADIOL, V27, P493, DOI 10.1007/s00062-016-0511-6
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Yin B, 2013, J CLIN NEUROSCI, V20, P367, DOI 10.1016/j.jocn.2012.02.030
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 409
EP 412
DI 10.1016/j.wneu.2019.08.037
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700050
PM 31421298
OA Bronze
DA 2020-05-12
ER

PT J
AU Heiland, T
   Karpel-Massler, G
   Scheuerle, A
   Wirtz, CR
   Halatsch, ME
AF Heiland, Tim
   Karpel-Massler, Georg
   Scheuerle, Angelika
   Wirtz, Christian-Rainer
   Halatsch, Marc-Eric
TI Rare Case of Sporadic Malignant Optic Pathway Glioma in 71-Year-Old
   Woman
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioma; Magnetic resonance tomography; Malignant; Neurosarcoidosis;
   Optic; Pathway
ID BACILLE-CALMETTE-GUERIN; MYCOBACTERIUM-BOVIS; TUBERCULOMA MIMICKING;
   INFECTION
AB A 71-year-old woman presented to our institution with a 2-week history of concentric bilateral left accentuated visual field loss. Examination of her eyes including funduscopy was normal. A gadolinium-enhanced magnetic resonance tomography showed contrast enhancement of the optic pathway in the T1-weighted sequence that included both optic nerves, the optic chiasm, and the left optic tract. Differential diagnoses of this kind of lesion extending along the optic nerves include neurosarcoidosis, lymphoma, and glioma. The patient was treated with high-dose corticosteroids under the suspicion of neurosarcoidosis. During that time her vision deteriorated, resulting in amaurosis on her left eye and marginal peripheral vision on the right. A biopsy of the left optic nerve revealed a pilocytic astrocytoma, which to some extent contrasted the observed clinical course. After discussing the treatment options including radiotherapy and chemotherapy, the patient opted for supportive care and died 3 months later.
C1 [Heiland, Tim; Karpel-Massler, Georg; Wirtz, Christian-Rainer; Halatsch, Marc-Eric] Ulm Univ Hosp, Dept Neurosurg, Ulm, Germany.
   [Scheuerle, Angelika] Ulm Univ Hosp, Dept Pathol, Div Neuropathol, Ulm, Germany.
RP Heiland, T (reprint author), Ulm Univ Hosp, Dept Neurosurg, Ulm, Germany.
EM tim.heiland@uni-ulm.de
CR BENMOUSSA H, 1992, NEUROSURG REV, V15, P71
   Bernaerts A, 2003, EUR RADIOL, V13, P1876, DOI 10.1007/s00330-002-1608-7
   COLEBUNDERS RL, 1988, JAMA-J AM MED ASSOC, V259, P352, DOI 10.1001/jama.1988.03720030020015
   COPPES MJ, 1992, CLIN INFECT DIS, V14, P662, DOI 10.1093/clinids/14.3.662
   DAMSKER B, 1974, AM REV RESPIR DIS, V110, P446
   Fitzgerald M J, 1991, Can Dis Wkly Rep, V17, P98
   Golub V, 2011, CAN J INFECT DIS MED, V22, P104, DOI 10.1155/2011/869286
   Gonzalez OY, 2003, CLIN INFECT DIS, V36, P140, DOI 10.1086/344908
   GUEST SS, 1987, COMPUT RADIOL, V11, P151, DOI 10.1016/0730-4862(87)90041-2
   HEATH PD, 1984, BRIT MED J, V288, P465, DOI 10.1136/bmj.288.6415.465
   Hesseling AC, 2007, VACCINE, V25, P14, DOI 10.1016/j.vaccine.2006.07.020
   KARLSON AG, 1970, ANN INTERN MED, V73, P979, DOI 10.7326/0003-4819-73-6-979
   LABHARD N, 1994, TUBERCLE LUNG DIS, V75, P454, DOI 10.1016/0962-8479(94)90120-1
   Parihar V, 2009, NEUROL INDIA, V57, P218, DOI 10.4103/0028-3886.51304
   Poonnoose SI, 2004, NEURORADIOLOGY, V46, P136, DOI 10.1007/s00234-003-1148-0
   Public Health Agency of Canada, CAN IMM GUID 4
   Robert J, 1999, INT J TUBERC LUNG D, V3, P711
   Sina F, 2017, NEUROL INT, V9, P69, DOI 10.4081/or.2017.7280
   STEELE JH, 1958, AM REV TUBERC PULM, V77, P908
   TALAMAS O, 1989, ARCH NEUROL-CHICAGO, V46, P529, DOI 10.1001/archneur.1989.00520410063025
   WHITTLE IR, 1983, J NEUROSURG, V59, P875, DOI 10.3171/jns.1983.59.5.0875
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 413
EP 418
DI 10.1016/j.wneu.2019.07.108
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700051
PM 31336173
OA Bronze
DA 2020-05-12
ER

PT J
AU Hartley, BR
   Hong, C
   Elowitz, E
AF Hartley, Benjamin R.
   Hong, Catherine
   Elowitz, Eric
TI Communication in Neurosurgery-The Tower of Babel
SO WORLD NEUROSURGERY
LA English
DT Article
DE Electronic medical record; Hospital consumer assessment of healthcare
   providers and systems; Medical communication; Medical error; Medical
   handoffs
ID PATIENT-REPORTED OUTCOMES; PRIMARY-CARE PHYSICIANS;
   INFORMATION-TRANSFER; MALPRACTICE CLAIMS; LESSONS; IMPACT;
   IMPLEMENTATION; STRATEGIES; CONTINUITY; EXPERIENCE
AB Clinical neurosurgery is a complex specialty with multiple participants, including a variety of providers, patients, family members, and administrators, who interact in complex fashions. Modern-day patient care requires near-constant team communication of vital, detailed clinical information; any breakdown in this process can result in patient harm. Medical communication practices with patients impact mutual rapport as well as the overall physician-patient relationship. Enhanced relationship-centered communication techniques have been shown to improve patient compliance and may positively influence malpractice litigation rates. Neurosurgeons frequently interact with other health care providers and members of the hospital administration on matters relating to billing, compliance, and quality. Communication among the stakeholders is complicated, however, by the fact that the participants may be speaking a variety of different, mutually unintelligible "languages." We discuss the details of the various types of information exchanges in neurosurgery, the key players involved, and the vulnerabilities to breakdowns in the system. In addition, we review the multifaceted, systems-level issues in neurosurgical communication and related weaknesses.
C1 [Hartley, Benjamin R.; Elowitz, Eric] Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
   [Hong, Catherine] Weill Cornell Med, Dept Emergency Med, New York, NY USA.
RP Elowitz, E (reprint author), Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
EM ere2006@med.cornell.edu
CR Accreditation Council for Graduate Medical Education, MILESTONES GUIDEBOOK
   Adams DL, 2002, J NATL MED ASSOC, V94, P430
   Ambady N, 2002, SURGERY, V132, P5, DOI 10.1067/msy.2002.124733
   Babu MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041810
   BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365
   Benke JR, 2013, INT J PEDIATR OTORHI, V77, P399, DOI 10.1016/j.ijporl.2012.11.039
   Boissy A, 2016, J GEN INTERN MED, V31, P755, DOI 10.1007/s11606-016-3597-2
   BOLAND RJ, 1978, MANAGE SCI, V24, P887, DOI 10.1287/mnsc.24.9.887
   Bonvicini KA, 2009, PATIENT EDUC COUNS, V75, P3, DOI 10.1016/j.pec.2008.09.007
   Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55
   CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254
   Drazen JM, 2002, NEW ENGL J MED, V347, P1271, DOI 10.1056/NEJMe020110
   Espino S, 2011, J SURG EDUC, V68, P447, DOI 10.1016/j.jsurg.2011.07.006
   Fargen Kyle M, 2012, J Grad Med Educ, V4, P415, DOI 10.4300/JGME-D-12-00113.1
   Fargen Kyle M, 2012, J Grad Med Educ, V4, P119, DOI 10.4300/JGME-D-11-00251.1
   Fischer JE, 2004, ACAD MED, V79, P381, DOI 10.1097/00001888-200405000-00004
   Foy R, 2010, ANN INTERN MED, V152, P247, DOI 10.7326/0003-4819-152-4-201002160-00010
   Gawande A, 2018, WHY DOCTORS HATE THE
   Giordano LA, 2010, MED CARE RES REV, V67, P27, DOI 10.1177/1077558709341065
   Gotay CC, 2008, J CLIN ONCOL, V26, P1355, DOI 10.1200/JCO.2007.13.3439
   Hartley BR, WORLD NEUROSURG, V133, P466
   HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359
   Jena AB, 2011, NEW ENGL J MED, V365, P629, DOI 10.1056/NEJMsa1012370
   Kaloostian PE, 2013, C Q, V14, P28
   Kehlet H, 1999, BRIT J SURG, V86, P227, DOI 10.1046/j.1365-2168.1999.01023.x
   Khoo CK, 2007, ANN SURG, V245, P867, DOI 10.1097/01.sla.0000259219.08209.36
   Krause SS, 2003, AIRCRAFT SAFETY ACCI, P205
   Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831
   KURTZ S, 2005, TEACHING LEARNING CO
   Lau M, 2014, CAN J DIABETES, V38, P17, DOI 10.1016/j.jcjd.2013.10.005
   Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553
   Ludwick DA, 2009, INT J MED INFORM, V78, P22, DOI 10.1016/j.ijmedinf.2008.06.005
   Manary MP, 2013, NEW ENGL J MED, V368, P201, DOI 10.1056/NEJMp1211775
   Mayer J.D., 1997, EMOTIONAL DEV EMOTIO, P3, DOI DOI 10.1177/1066480710387486
   McPheeters Matthew J, 2017, Surg Neurol Int, V8, P206, DOI 10.4103/sni.sni_83_17
   Mukherjee S, 2004, NEW ENGL J MED, V351, P1822, DOI 10.1056/NEJMp048085
   Murphy JG, 2010, CHEST, V138, P1292, DOI 10.1378/chest.10-2263
   National Transportation Safety Board, INV PROC
   National Transportation Safety Board, 2014, BOARD M CRASH AS FLI
   Newhouse J, 2000, HDB HLTH EC
   Parker J, 2015, ROOT CAUSE ANAL HLTH
   Patel SP, 2010, WORLD J SURG, V34, P2524, DOI 10.1007/s00268-010-0740-9
   Peerally MF, 2017, BMJ QUAL SAF, V26, P417, DOI 10.1136/bmjqs-2016-005511
   Rotman LE, 2018, WORLD NEUROSURG, V115, pE105, DOI 10.1016/j.wneu.2018.03.195
   Ruhstaller T, 2006, EUR J CANCER, V42, P2459, DOI 10.1016/j.ejca.2006.03.034
   Sarkar U, 2014, MED CARE, V52, P194, DOI 10.1097/MLR.0000000000000069
   Schaefer KG, 2009, CURR OPIN CRIT CARE, V15, P569, DOI 10.1097/MCC.0b013e328332f524
   Sexton JB, 2000, BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745
   Solet DJ, 2005, ACAD MED, V80, P1094, DOI 10.1097/00001888-200512000-00005
   STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127
   STEWART MA, 1995, CAN MED ASSOC J, V152, P1423
   Sutcliffe KM, 2004, ACAD MED, V79, P186, DOI 10.1097/00001888-200402000-00019
   Svarstad BL, 1976, GROWTH BUREAUCRATIC
   Takeuchi EE, 2011, J CLIN ONCOL, V29, P2910, DOI 10.1200/JCO.2010.32.2453
   Van Eaton EG, 2005, ARCH SURG-CHICAGO, V140, P230, DOI 10.1001/archsurg.140.3.230
   Vidyarthi AR, 2006, J HOSP MED, V1, P257, DOI 10.1002/jhm.103
   Warshaw AL, 2003, SURGERY, V134, P1, DOI 10.1067/msy.2003.200
   Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441
   Weiss HR, 2008, SCOLIOSIS SPINAL DIS, V3, DOI 10.1186/1748-7161-3-9
   Weng HC, 2011, MED EDUC, V45, P835, DOI 10.1111/j.1365-2923.2011.03985.x
   WESTERMAN RF, 1990, BRIT J GEN PRACT, V40, P445
   Whang EE, 2003, ANN SURG, V237, P449, DOI 10.1097/00000658-200304000-00001
   Williams RG, 2007, ANN SURG, V245, P159, DOI 10.1097/01.sla.0000242709.28760.56
   WILSON S, 1993, TLS-TIMES LIT SUPPL, P8
   Wu RC, 2013, J AM MED INFORM ASSN, V20, P766, DOI 10.1136/amiajnl-2012-001160
   Zolnierek KBH, 2009, MED CARE, V47, P826, DOI 10.1097/MLR.0b013e31819a5acc
   Zusman EE, 2012, NEUROSURGERY, V71, pN21, DOI 10.1227/01.neu.0000417536.07871.ed
NR 67
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 457
EP 465
DI 10.1016/j.wneu.2019.08.134
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700075
PM 31881580
OA Bronze
DA 2020-05-12
ER

PT J
AU Hartley, BR
   Elowitz, E
AF Hartley, Benjamin R.
   Elowitz, Eric
TI Barriers to the Enhancement of Effective Communication in Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cognitive bias; Electronic medical record; Medical communication;
   Medical handoffs
ID MEDICAL ERROR DISCLOSURE; PATIENT; PHYSICIANS; IMPACT; SKILLS;
   STRATEGIES; RESIDENTS; RESPONSES; EMPATHY; TIME
AB Communication issues play a major role within neurosurgery. There has been a growing awareness of the necessity of enhanced patient-centered communication between the physician and patient to improve patient satisfaction, compliance, and outcomes. In addition, the threat of malpractice litigation within neurosurgery is of particular concern, and improved communication may lead to some degree of risk mitigation. Within the neurosurgical and medical team, effective transmittal of vital clinical data is essential for patient safety. Despite the recent recognition of the critical role that communication plays in all aspects of medical care, multiple impediments hinder the improvement and use of effective techniques. We have identified 8 unique barriers to the advancement of communication practices: lack of recognition of the importance of communication skills; cognitive bias; sense that it "takes too much time"; cultural hierarchy within medicine; lack of formal communication skill training; fear that disclosure of medical errors will lead to malpractice litigation; the electronic medical record; and frequent shift changes and handoffs.
C1 [Hartley, Benjamin R.; Elowitz, Eric] Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
RP Elowitz, E (reprint author), Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
EM ere2006@med.cornell.edu
CR Alder Judith, 2007, Archives of Gynecology and Obstetrics, V276, P605, DOI 10.1007/s00404-007-0399-0
   Ambady N, 2002, SURGERY, V132, P5, DOI 10.1067/msy.2002.124733
   BARNES JH, 1984, STRATEGIC MANAGE J, V5, P129, DOI 10.1002/smj.4250050204
   Bates DW, 2000, ANN INTERN MED, V132, P763, DOI 10.7326/0003-4819-132-9-200005020-00025
   Belyansky I, 2011, J SURG RES, V171, P386, DOI 10.1016/j.jss.2011.04.011
   Berner ES, 2007, AM J MED, V121, pS2
   BLAU JN, 1989, BRIT MED J, V298, P39, DOI 10.1136/bmj.298.6665.39
   Chapman GB, 2000, DECISION MAKING HLTH, P183
   Chou C, 2014, PATIENT EXP J, V1, P36
   Clinton HR, 2006, NEW ENGL J MED, V354, P2205, DOI 10.1056/NEJMp068100
   Coxon JP, 2003, BJU INT, V91, P1, DOI 10.1046/j.1464-410X.2003.04003.x
   Croskerry P, 2003, ACAD MED, V78, P775, DOI 10.1097/00001888-200308000-00003
   Croskerry P, 2002, ACAD EMERG MED, V9, P1184, DOI 10.1111/j.1553-2712.2002.tb01574.x
   Croskerry P, 2013, BMJ QUAL SAF, V22, pii58, DOI 10.1136/bmjqs-2012-001712
   Croskerry P, 2013, NEW ENGL J MED, V368, P2445, DOI 10.1056/NEJMp1303712
   d'Agincourt-Canning LG, 2011, INDIAN J PEDIATR, V78, P703, DOI 10.1007/s12098-010-0311-y
   Devine EB, 2010, J AM MED INFORM ASSN, V17, P78, DOI 10.1197/jamia.M3285
   Dunn EJ, 2014, FED PRACT, V31, P18
   Dwamena F, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003267.pub2
   Elwy AR, 2016, JAMA SURG, V151, P1015, DOI 10.1001/jamasurg.2016.1787
   Engel KG, 2006, ACAD MED, V81, P86, DOI 10.1097/00001888-200601000-00021
   Ericsson KA, 2004, ACAD MED, V79, pS70, DOI 10.1097/00001888-200410001-00022
   Fallowfield L, 1998, J CLIN ONCOL, V16, P1961, DOI 10.1200/JCO.1998.16.5.1961
   Gawande A., 2018, NEW YORKER
   Graber M, 2002, ACAD MED, V77, P981, DOI 10.1097/00001888-200210000-00009
   Hartley BR, 2020, WORLD NEUROSURG, V133, P474, DOI 10.1016/j.wneu.2019.08.132
   Hartley BR, 2020, WORLD NEUROSURG, V133, P457, DOI 10.1016/j.wneu.2019.08.134
   Hojat M, 2011, ACAD MED, V86, P359, DOI 10.1097/ACM.0b013e3182086fe1
   Kachalia A, 2010, ANN INTERN MED, V153, P213, DOI 10.7326/0003-4819-153-4-201008170-00002
   Kim SS, 2004, EVAL HEALTH PROF, V27, P237, DOI 10.1177/0163278704267037
   Kitch BT, 2008, JT COMM J QUAL PATIE, V34, P563, DOI 10.1016/S1553-7250(08)34071-9
   Kuehster CR, 2010, J NURSES PROF DEV, V26, P123, DOI 10.1097/NND.0b013e3181993a95
   Langewitz W, 2002, BRIT MED J, V325, P682, DOI 10.1136/bmj.325.7366.682
   Leibowitz KA, 2018, J GEN INTERN MED, V33, P2051, DOI 10.1007/s11606-018-4627-z
   Levinson W, 2000, JAMA-J AM MED ASSOC, V284, P1021, DOI 10.1001/jama.284.8.1021
   Levinson W, 2010, HEALTH AFFAIR, V29, P1310, DOI 10.1377/hlthaff.2009.0450
   Liu CC, 2008, MED EDUC, V42, P74, DOI 10.1111/j.1365-2923.2007.02899.x
   Marvel MK, 1999, JAMA-J AM MED ASSOC, V281, P283, DOI 10.1001/jama.281.3.283
   Mazor KM, 2004, ARCH INTERN MED, V164, P1690, DOI 10.1001/archinte.164.15.1690
   McDonnell WM, 2008, ANN INTERN MED, V149, P811, DOI 10.7326/0003-4819-149-11-200812020-00007
   Nakagawa S, 2015, JAMA INTERN MED, V175, P1268, DOI 10.1001/jamainternmed.2015.2220
   *NAT QUAL FOR, SAF PRACT BETT HEALT
   Ngo-Metzger Q, 2003, J GEN INTERN MED, V18, P44, DOI 10.1046/j.1525-1497.2003.20205.x
   O'Daniel M., 2008, PATIENT SAFETY QUALI
   Ray S. J., 1999, STRATEGIC COMMUNICAT
   Riess H, 2012, J GEN INTERN MED, V27, P1280, DOI 10.1007/s11606-012-2063-z
   Schouten BC, 2006, PATIENT EDUC COUNS, V64, P21, DOI 10.1016/j.pec.2005.11.014
   SCHWENK CR, 1984, STRATEGIC MANAGE J, V5, P111, DOI 10.1002/smj.4250050203
   Stroud L, 2013, ACAD MED, V88, P884, DOI 10.1097/ACM.0b013e31828f898f
   Tabler N., 2007, HLTH LAWYER, V19, P23
   Wallack MK, 2001, ARCH SURG-CHICAGO, V136, P1426, DOI 10.1001/archsurg.136.12.1426
   Walton MM, 2006, QUAL SAF HEALTH CARE, V15, P229, DOI 10.1136/qshc.2006.019240
   Waterman AD, 2007, JT COMM J QUAL PATIE, V33, P467, DOI 10.1016/S1553-7250(07)33050-X
   Wu AW, 2013, J PUBLIC HEALTH RES, V2, P186, DOI 10.4081/jphr.2013.e32
NR 54
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 466
EP 473
DI 10.1016/j.wneu.2019.08.133
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700076
PM 31881581
OA Bronze
DA 2020-05-12
ER

PT J
AU Hartley, BR
   Elowitz, E
AF Hartley, Benjamin R.
   Elowitz, Eric
TI Future Directions in Communication in Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cognitive bias; Communication skills training; Delivery of bad news;
   Electronic medical record; Medical communication; Medical nomenclature
ID INFORMED-CONSENT; OPERATING-ROOM; PATIENT; MALPRACTICE; CARE;
   STRATEGIES; PHYSICIANS; EDUCATION; HANDOFF; SKILLS
AB Modern-day care of the neurosurgery patient has grown increasingly complex and typically involves a variety of medical team members. Proper communication and transmission of clinical data within the neurosurgery team is required for successful outcomes, especially within the operating room. Effective communication is also critical to the patient-physician relationship and can aid in improving rapport and possibly reducing malpractice lawsuit risk. In addition, interactions exist between practicing neurosurgeons and members of the administration, often focusing on reimbursement and quality issues. Although most physicians would agree that communication between all these stakeholders should improve, certain barriers are present, including the adoption of newer technologies and the lack of formal training. In this article, we review current and projected trends relating to the enhancement of neurosurgical communication at all levels.
C1 [Hartley, Benjamin R.; Elowitz, Eric] Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
RP Elowitz, E (reprint author), Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
EM ere2006@med.cornell.edu
CR Abushaiqa ME, 2007, AM J HEALTH-SYST PH, V64, P1170, DOI 10.2146/ajhp060173
   Accreditation Council for Graduate Medical Education, ACGME COMM PROGR REQ
   Ambady N, 2002, SURGERY, V132, P5, DOI 10.1067/msy.2002.124733
   Armstrong G, 2012, JT COMM J QUAL PATIE, V38, P5, DOI 10.1016/S1553-7250(12)38002-1
   Arriaga AF, 2014, ANN SURG, V259, P403, DOI 10.1097/SLA.0000000000000342
   BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365
   Bieber C, 2008, J PSYCHOSOM RES, V64, P13, DOI 10.1016/j.jpsychores.2007.05.009
   Bollschweiler E, 2008, ANN SURG, V248, P205, DOI 10.1097/SLA.0b013e318180a3a7
   Bonvicini KA, 2009, PATIENT EDUC COUNS, V75, P3, DOI 10.1016/j.pec.2008.09.007
   Bould MD, 2015, CAN J ANESTH, V62, P576, DOI 10.1007/s12630-015-0364-5
   Brenner LH, 2009, CLIN ORTHOP RELAT R, V467, P348, DOI 10.1007/s11999-008-0642-4
   Brown RF, 2007, PSYCHO-ONCOLOGY, V16, P507, DOI 10.1002/pon.1095
   Catchpole KR, 2007, PEDIATR ANESTH, V17, P470, DOI 10.1111/j.1460-9592.2006.02239.x
   Chou C, 2014, PATIENT EXP J, V1, P36
   Croskerry P, 2003, ACAD MED, V78, P775, DOI 10.1097/00001888-200308000-00003
   Croskerry P, 2003, ANN EMERG MED, V41, P110, DOI 10.1067/mem.2003.22
   Croskerry P, 2000, ACAD EMERG MED, V7, P1194, DOI 10.1111/j.1553-2712.2000.tb00464.x
   Espino S, 2011, J SURG EDUC, V68, P447, DOI 10.1016/j.jsurg.2011.07.006
   Gawande A, 2018, WHY DOCTORS HATE THE
   Giordano LA, 2010, MED CARE RES REV, V67, P27, DOI 10.1177/1077558709341065
   Greaves F, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2721
   Haig KM, 2006, JT COMM J QUAL PATIE, V32, P167, DOI 10.1016/S1553-7250(06)32022-3
   Hartley BR, WORLD NEUROSURG, V133, P466
   Hartley BR, WORLD NEUROSURG, V133, P457
   Holmboe E, MILESTONES GUIDEBOOK
   Jackson VA, 2011, J PALLIAT MED, V14, P775, DOI 10.1089/jpm.2010.0493
   Jena AB, 2011, NEW ENGL J MED, V365, P629, DOI 10.1056/NEJMsa1012370
   *JOINT COMM ACCR H, 2006 CRIT ACC HOSP H
   Kumar S, 2008, INT J HEALTH CARE Q, V21, P444, DOI 10.1108/09526860810890431
   Levinson W, 2000, JAMA-J AM MED ASSOC, V284, P1021, DOI 10.1001/jama.284.8.1021
   Levinson W, 2010, HEALTH AFFAIR, V29, P1310, DOI 10.1377/hlthaff.2009.0450
   Li M, 2007, IEEE T SYST MAN CY A, V37, P1088, DOI 10.1109/TSMCA.2007.904745
   Macready N, 1999, OR Manager, V15, P12
   Makary MA, 2006, J AM COLL SURGEONS, V202, P746, DOI 10.1016/j.jamcollsurg.2006.01.017
   Mardis M, 2017, AM J MED QUAL, V32, P34, DOI 10.1177/1062860615612923
   Moon S, 2014, J AM MED INFORM ASSN, V21, P299, DOI 10.1136/amiajnl-2012-001506
   Nahed BV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039237
   O'Daniel M, 2008, PATIENT SAFETY QUALI
   O'Malley Ann S, 2010, Issue Brief Cent Stud Health Syst Change, P1
   O'Malley AS, 2010, J GEN INTERN MED, V25, P177, DOI 10.1007/s11606-009-1195-2
   Patterson ES, 2010, JT COMM J QUAL PATIE, V36, P52, DOI 10.1016/S1553-7250(10)36011-9
   Peerally MF, 2017, BMJ QUAL SAF, V26, P417, DOI 10.1136/bmjqs-2016-005511
   Pian-Smith MCM, 2009, SIMUL HEALTHC, V4, P84, DOI 10.1097/SIH.0b013e31818cffd3
   Ptacek JT, 1996, JAMA-J AM MED ASSOC, V276, P496
   Rossi M, 2004, FOOT ANKLE INT, V25, P756, DOI 10.1177/107110070402501011
   Rotman LE, 2018, WORLD NEUROSURG, V115, pE105, DOI 10.1016/j.wneu.2018.03.195
   Samaranayake NR, 2014, CURR DRUG SAF, V9, P34, DOI 10.2174/1574886308666131223123721
   Saslaw M., 2017, PATIENT EXPERIENCE J, V4, P48
   Shanafelt TD, 2016, MAYO CLIN PROC, V91, P836, DOI 10.1016/j.mayocp.2016.05.007
   Shaw MJ, 2001, J CLIN GASTROENTEROL, V32, P142, DOI 10.1097/00004836-200102000-00010
   Spath PL, 2011, ERROR REDUCTION HLTH
   STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127
   Starmer AJ, 2014, NEW ENGL J MED, V371, P1803, DOI 10.1056/NEJMsa1405556
   STEWART MA, 1995, CAN MED ASSOC J, V152, P1423
   Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609
   Svarstad BL., 1976, GROWTH BUREAUCRATIC, P220
   Swayden KJ, 2012, PATIENT EDUC COUNS, V86, P166, DOI 10.1016/j.pec.2011.05.024
   Sydor DT, 2013, BRIT J ANAESTH, V110, P463, DOI 10.1093/bja/aes396
   Vidyarthi AR, 2006, J HOSP MED, V1, P257, DOI 10.1002/jhm.103
   Wegman B, 2012, CLIN ORTHOP RELAT R, V470, P1379, DOI 10.1007/s11999-012-2244-4
   Weis JM, 2014, CHEST, V145, P632, DOI 10.1378/chest.13-0886
   Windover Amy K, 2014, J Patient Exp, V1, P8, DOI 10.1177/237437431400100103
   Wohlauer MV, 2012, ACAD MED, V87, P411, DOI 10.1097/ACM.0b013e318248e766
   Wu AW, 2008, JAMA-J AM MED ASSOC, V299, P685, DOI 10.1001/jama.299.6.685
   Yap TY, 2009, ACAD MED, V84, P1036, DOI 10.1097/ACM.0b013e3181acfbcd
NR 65
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP 474
EP 482
DI 10.1016/j.wneu.2019.08.132
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700077
PM 31881582
OA Bronze
DA 2020-05-12
ER

PT J
AU Acarbas, A
AF Acarbas, Arsal
TI Value of N-Terminal Pro-Brain Natriuretic Peptide in Predicting
   Perioperative Complications Following Spine Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Medical adverse events; N-terminal pro-brain natriuretic peptide; Spine
   surgery
ID RISK
AB OBJECTIVE: The utility of preoperative biomarkers for assessing perioperative complications in patients undergoing spine surgery (SS) is unclear, and no study has assessed the ability of preoperative natriuretic peptides to predict adverse events following SS. This study aimed to evaluate the prognostic importance of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients undergoing SS.
   METHODS: We prospectively followed 154 consecutive adult patients >= 50 years old hospitalized for elective SS. The outcomes of interest were length of stay in hospital and perioperative medical complications during hospitalization, defined as pneumonia, deep or organ space surgical site infection, bacteremia, prolonged mechanical ventilation >48 hours, unplanned reintubation, acute renal failure, sepsis or septic shock, venous thromboembolism (deep vein thrombosis or pulmonary embolism), cardiac arrest, stroke, myocardial infarction, return to operating room, and in-hospital mortality.
   RESULTS: In 21 (13.6%) patients, 32 episodes of medical adverse events occurred. Older patients and patients with more comorbid conditions, such as heart failure, diabetes, cerebrovascular disease, coronary artery disease, and chronic obstructive pulmonary disease, tended to have a higher rate of adverse events. Patients with adverse events had higher NT-proBNP and troponin levels on admission compared with patients without adverse events. Multivariate analysis showed that NT-proBNP >242 pg/ml (odds ratio 2.374; 95% confidence interval, 1.000-2.958; P = 0.001) and presence of diabetes (odds ratio 2.16; 95% confidence interval, 1.86-7.89; P = 0.008) were significant and independent predictors of perioperative adverse events.
   CONCLUSIONS: This study demonstrates that preoperative NT-proBNP level in patients undergoing SS could be a valuable prognostic marker for several postoperative complications.
C1 [Acarbas, Arsal] Mugla Sitki Kocman Univ, Fac Med, Dept Neurosurg, Mugla, Turkey.
RP Acarbas, A (reprint author), Mugla Sitki Kocman Univ, Fac Med, Dept Neurosurg, Mugla, Turkey.
EM arsal5@hotmail.com
CR Brynildsen J, 2018, CLIN BIOCHEM, V53, P65, DOI 10.1016/j.clinbiochem.2018.01.012
   Carabini LM, 2014, J NEUROSURG ANESTH, V26, P205, DOI 10.1097/ANA.0000000000000014
   Edwards Angela F, 2018, Anesthesiol Clin, V36, P493, DOI 10.1016/j.anclin.2018.07.002
   Imajo Y, 2017, J ORTHOP SCI, V22, P10, DOI 10.1016/j.jos.2016.08.014
   Lakomkin N, 2018, SPINE J, V18, P993, DOI 10.1016/j.spinee.2017.10.010
   Ma JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121306
   McLynn RP, 2018, SPINE J, V18, P1149, DOI 10.1016/j.spinee.2017.11.008
   Mihailidis HG, 2017, ANZ J SURG, V87, P605, DOI 10.1111/ans.13885
   Nasser R, 2010, J NEUROSURG-SPINE, V13, P144, DOI 10.3171/2010.3.SPINE09369
   O'Lynnger TM, 2015, NEUROSURGERY, V77, pS136, DOI 10.1227/NEU.0000000000000945
   Passias PG, 2018, GLOB SPINE J, V8, P218, DOI 10.1177/2192568217718817
   Proietti L, 2013, INDIAN J ORTHOP, V47, P340, DOI 10.4103/0019-5413.114909
   Pu DR, 2010, HEART FAIL REV, V15, P293, DOI 10.1007/s10741-009-9142-1
   Richards AM, 2004, TRENDS ENDOCRIN MET, V15, P170
   Salvetti DJ, 2018, J NEUROSURG-SPINE, V29, P549, DOI 10.3171/2018.3.SPINE171183
   Smith JS, 2012, SPINE, V37, P1975, DOI 10.1097/BRS.0b013e318257fada
   Soroceanu A, 2016, SPINE, V41, P1718, DOI 10.1097/BRS.0000000000001636
   Swann MC, 2016, BEST PRACT RES-CLIN, V30, P103, DOI 10.1016/j.bpa.2016.01.002
   Thygesen K, 2019, EUR HEART J, V40, P237, DOI 10.1093/eurheartj/ehy462
NR 19
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E784
EP E788
DI 10.1016/j.wneu.2019.10.012
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700146
PM 31605859
OA Bronze
DA 2020-05-12
ER

PT J
AU Ahn, S
   Park, JS
   Song, JH
   Jeun, SS
   Hong, YK
AF Ahn, Stephen
   Park, Jae-Sung
   Song, Jin Ho
   Jeun, Sin-Soo
   Hong, Yong-Kil
TI Effect of a Time Delay for Concomitant Chemoradiation After Surgery for
   Newly Diagnosed Glioblastoma: A Single-Institution Study with Subgroup
   Analysis According to the Extent of Tumor Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Concomitant chemoradiotherapy; Delayed CCRT; Extent of resection;
   Glioblastoma; Survival
ID ADJUVANT TEMOZOLOMIDE; RADIOTHERAPY; SURVIVAL; INITIATION; IMPACT;
   CHEMORADIOTHERAPY; COMPLICATIONS; ASSOCIATION; THERAPY
AB BACKGROUND: Concomitant chemoradiation (CCRT) after surgical resection has been established as standard care for patients with newly diagnosed glioblastoma (GBM). However, the optimal time interval from surgery to starting CCRT (IST) remains controversial.
   METHODS: The electronic medical records of 160 patients with newly diagnosed GEM treated at our institution between 2009 and 2016 were examined retrospectively. The eligibility criteria were newly diagnosed GBM, pathology confirmed by craniotomy or stereotactic biopsy, and CCRT performed in our institution. Patients who received CCRT within 28 days after surgery were defined as the early group, and those who received CCRT at >28 days after surgery were defined as the delayed group.
   RESULTS: We included 138 patients who met our eligibility criteria. The median 1ST was 26 days (range, 10-55 days). In a Kaplan-Meier analysis, overall survival (OS) did not differ between groups (15.5 month for the early group vs. 14.5 months for the delayed group; P = 0.707). In the gross total resection (GTR) subgroup, OS did not differ significantly (20.0 months for the early vs. 21.0 months for the delayed group; P = 0.854). In the non-GTR subgroup, however, the early group had better OS than the delayed group (11.0 months vs. 5.0 months; P = 0.029).
   CONCLUSIONS: Performing CCRT within versus after 28 days after surgery did not result in a statistically significant difference in OS. However, a subgroup analysis showed that delayed CCRT may be associated with worse OS in the non-GTR group.
C1 [Ahn, Stephen; Park, Jae-Sung; Jeun, Sin-Soo; Hong, Yong-Kil] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
   [Song, Jin Ho] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Radiat Oncol, Seoul, South Korea.
RP Park, JS (reprint author), Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
EM jspark82@catholic.ac.kr
CR Adeberg S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1545-x
   Blumenthal DT, 2018, NEURO-ONCOLOGY, V20, P966, DOI 10.1093/neuonc/noy017
   Brown TJ, 2016, JAMA ONCOL, V2, P1460, DOI 10.1001/jamaoncol.2016.1373
   Byun J, 2019, WORLD NEUROSURG, V121, pE858, DOI 10.1016/j.wneu.2018.09.237
   De la Garza-Ramos R, 2016, CLIN NEUROL NEUROSUR, V140, P6, DOI 10.1016/j.clineuro.2015.11.005
   Gulati S, 2011, WORLD NEUROSURG, V76, P572, DOI 10.1016/j.wneu.2011.06.014
   Han SGJ, 2015, NEUROSURGERY, V77, P248, DOI 10.1227/NEU.0000000000000766
   Haubner F, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-162
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Louvel G, 2016, RADIOTHER ONCOL, V118, P9, DOI 10.1016/j.radonc.2016.01.001
   Loureiro LVM, 2016, RADIOTHER ONCOL, V118, P1, DOI 10.1016/j.radonc.2015.11.021
   Osborn VW, 2018, NEUROSURGERY, V83, P915, DOI 10.1093/neuros/nyx497
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Peker S, 2004, J NEURO-ONCOL, V70, P17, DOI 10.1023/B:NEON.0000040820.78643.0a
   Pirzkall A, 2009, NEURO-ONCOLOGY, V11, P842, DOI 10.1215/15228517-2009-005
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Santos VM, 2019, J NEURO-ONCOL, V143, P95, DOI 10.1007/s11060-019-03137-8
   Spratt DE, 2014, J NEURO-ONCOL, V116, P357, DOI 10.1007/s11060-013-1302-4
   Stensjoen AL, 2015, NEURO-ONCOLOGY, V17, P1402, DOI 10.1093/neuonc/nov029
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Sun MZ, 2015, J NEUROSURG, V122, P1144, DOI 10.3171/2014.9.JNS14193
   Valduvieco I, 2013, CLIN TRANSL ONCOL, V15, P278, DOI 10.1007/s12094-012-0916-x
   Wang CH, 2009, CANCER RES, V69, P9133, DOI 10.1158/0008-5472.CAN-08-3863
   Wang TJC, 2016, NEUROSURGERY, V78, P676, DOI 10.1227/NEU.0000000000001036
   Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E640
EP E645
DI 10.1016/j.wneu.2019.09.122
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700127
PM 31568907
OA Bronze
DA 2020-05-12
ER

PT J
AU Akyoldas, G
   Hergunsel, OB
   Yilmaz, M
   Sengoz, M
   Peker, S
AF Akyoldas, Goktug
   Hergunsel, Omer Batu
   Yilmaz, Meltem
   Sengoz, Meric
   Peker, Selcuk
TI Gamma Knife Radiosurgery for Anterior Clinoid Process Meningiomas: A
   Series of 61 Consecutive Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior clinoid process; Gamma Knife; Meningioma; Oncology;
   Stereotactic radiosurgery
ID TERM TUMOR-CONTROL; STEREOTACTIC RADIOSURGERY; FOLLOW-UP; SURGERY;
   OUTCOMES; COMPLICATIONS; EXPERIENCE; MANAGEMENT; RECURRENCE
AB OBJECTIVE: Gamma Knife radiosurgery (GKRS) outcomes for anterior clinoid process (ACP) meningiomas have not been specifically reported within any meningioma series. We present the initial and largest series in the literature that describes the presenting features, radiosurgery parameters, and radiologic and long-term clinical outcomes for 61 patients with ACP meningiomas treated with GKRS.
   METHODS: Medical records were reviewed for 61 consecutive patients at a single center who underwent GKRS for ACP meningioma between 2008 and 2016.
   RESULTS: Of 61 patients with ACP meningiomas, 49 (80%) were treated with GKRS as primary treatment, and 12 (20%) were treated with GKRS as an adjuvant therapy. Before GKRS, 29 patients presented with visual impairment and 50 patients presented with headache. Median patient age was 54.9 years. Median tumor volume was 3.2 cm(3), and median margin dose was 12.0 Gy. The median radiologic follow-up time after GKRS was 75 months. During follow-up, tumor volume regressed in 37 cases (61%) and remained unchanged in 24 cases (39%). None of the patients experienced tumor volume progression. Tumor volume <3 cm(3) was an independent predictor of tumor volume regression after GKRS (univariate analysis, P = 0.047; multivariate analysis, P = 0.049). Of 29 patients who presented with visual impairment, 16 (55%) improved after GKRS. None of the 61 patients developed new neurologic deficits after GKRS.
   CONCLUSIONS: GKRS provides a high rate of tumor volume control for ACP meningiomas as well as a low complication rate. Excellent tumor volume control was associated with smaller tumor size only.
C1 [Akyoldas, Goktug; Hergunsel, Omer Batu; Peker, Selcuk] Koc Univ, Dept Neurosurg, Sch Med, Istanbul, Turkey.
   [Yilmaz, Meltem] Acibadem Mehmet Ali Aydinlar Univ, Med Biotechnol, Sch Med, Istanbul, Turkey.
   [Sengoz, Meric] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Radiat Oncol, Istanbul, Turkey.
RP Akyoldas, G (reprint author), Koc Univ, Dept Neurosurg, Sch Med, Istanbul, Turkey.
EM goktug_akyoldas@hotmail.com
RI Peker, Selcuk/D-2516-2015
OI Peker, Selcuk/0000-0003-3057-3355
CR Al-Mefty O., 1991, MENINGIOMAS, P427
   ALMEFTY O, 1990, J NEUROSURG, V73, P840, DOI 10.3171/jns.1990.73.6.0840
   Bassiouni H, 2009, J NEUROSURG, V111, P1078, DOI 10.3171/2009.3.17685
   Bledsoe JM, 2010, J NEUROSURG, V112, P951, DOI 10.3171/2009.8.JNS09703
   BONNAL J, 1980, J NEUROSURG, V53, P587, DOI 10.3171/jns.1980.53.5.0587
   DiBiase SJ, 2004, INT J RADIAT ONCOL, V60, P1515, DOI 10.1016/j.ijrobp.2004.05.073
   Eustacchio S, 2002, ACT NEUR S, V84, P71
   Faramand A, 2018, J NEURO-ONCOL, V139, P341, DOI 10.1007/s11060-018-2866-9
   Feigl GC, 2007, NEUROSURGERY, V61, P281, DOI 10.1227/01.NEU.0000279999.95953.EA
   Flannery TJ, 2017, J NEUROSURG, V127, P67, DOI 10.3171/2009.8.JNS09695
   Ganz J, 2009, ACTA NEUROCHIR, V151, P1, DOI 10.1007/s00701-008-0166-4
   Goel A, 2000, NEUROL MED-CHIR, V40, P610, DOI 10.2176/nmc.40.610
   Harrison G, 2016, J NEUROSURG, V124, P146, DOI 10.3171/2014.12.JNS141341
   Hasegawa T, 2007, J NEUROSURG, V107, P745, DOI 10.3171/JNS-07/10/0745
   Haselsberger K, 2009, J NEUROL NEUROSUR PS, V80, P1172, DOI 10.1136/jnnp.2008.156745
   Hudgins WR, 1996, STEREOT FUNCT NEUROS, V66, P121, DOI 10.1159/000099777
   Hung YC, 2019, J NEURO-ONCOL, V143, P261, DOI 10.1007/s11060-019-03090-6
   Iwai Y, 2008, J NEUROSURG, V109, P804, DOI 10.3171/JNS/2008/109/11/0804
   Kollova A, 2007, J NEUROSURG, V107, P325, DOI 10.3171/JNS-07/08/0325
   Kondziolka D, 2016, AM J CLIN ONCOL-CANC, V39, P453, DOI 10.1097/COC.0000000000000080
   Kreil W, 2005, J NEUROL NEUROSUR PS, V76, P1425, DOI 10.1136/jnnp.2004.049213
   Lee JH, 2001, NEUROSURGERY, V48, P1012, DOI 10.1097/00006123-200105000-00009
   Lee JYK, 2002, J NEUROSURG, V97, P65, DOI 10.3171/jns.2002.97.1.0065
   Mathiesen T, 1996, NEUROSURGERY, V39, P2, DOI 10.1097/00006123-199607000-00002
   Milano Michael T, 2018, Int J Radiat Oncol Biol Phys, DOI 10.1016/j.ijrobp.2018.01.053
   MIRIMANOFF RO, 1985, J NEUROSURG, V62, P18, DOI 10.3171/jns.1985.62.1.0018
   Nicolato A, 2002, INT J RADIAT ONCOL, V53, P992, DOI 10.1016/S0360-3016(02)02802-X
   Oya S, 2011, J NEUROSURG, V114, P1250, DOI 10.3171/2010.12.JNS101623
   Pamir MN, 2008, ACTA NEUROCHIR, V150, P625, DOI 10.1007/s00701-008-1594-x
   Park KJ, 2019, J NEUROSURG, V130, P1799, DOI 10.3171/2018.2.JNS172361
   Pollock BE, 2005, INT J RADIAT ONCOL, V62, P1427, DOI 10.1016/j.ijrobp.2004.12.067
   Pollock BE, 2013, J NEUROSURG, V119, P675, DOI 10.3171/2013.5.JNS13206
   Pollock BE, 2012, NEUROSURGERY, V71, P604, DOI 10.1227/NEU.0b013e31825ea557
   Puzzilli F, 1999, Neuro Oncol, V1, P188, DOI 10.1093/neuonc/1.3.188
   RISI P, 1994, BRIT J NEUROSURG, V8, P295, DOI 10.3109/02688699409029617
   Samii M, 1993, SURG SKULL BASE MENI, P35
   Santacroce A, 2012, NEUROSURGERY, V70, P32, DOI 10.1227/NEU.0b013e31822d408a
   Seo Y, 2018, NEUROSURGERY, V83, P1040, DOI 10.1093/neuros/nyx585
   Sheehan JP, 2014, J NEUROSURG, V120, P1268, DOI 10.3171/2014.2.JNS13139
   Stafford SL, 2001, NEUROSURGERY, V49, P1029, DOI 10.1097/00006123-200111000-00001
   Starke RM, 2012, J NEUROSURG, V116, P588, DOI 10.3171/2011.11.JNS11530
   Sughrue M, 2015, CUREUS, V7, DOI 10.7759/cureus.321
   Sughrue ME, 2010, J NEUROSURG, V113, P1029, DOI 10.3171/2010.3.JNS091971
   Takanashi M, 2009, PROG NEUROL, V22, P96, DOI 10.1159/000163385
   Talacchi A, 2020, NEUROSURG REV, V43, P109, DOI 10.1007/s10143-018-1018-1
NR 45
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E529
EP E534
DI 10.1016/j.wneu.2019.09.089
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700113
PM 31562964
OA Bronze
DA 2020-05-12
ER

PT J
AU Alkhaibary, A
   Alharbi, A
   Abbas, M
   Algarni, A
   Abdullah, JM
   Almadani, WH
   Khairy, I
   Alkhani, A
   Aloraidi, A
   Khairy, S
AF Alkhaibary, Ali
   Alharbi, Ahoud
   Abbas, Munzir
   Algarni, Abdulaziz
   Abdullah, Jamal M.
   Almadani, Wedad H.
   Khairy, Ibtesam
   Alkhani, Ahmed
   Aloraidi, Ahmed
   Khairy, Sami
TI Predictors of Surgical Site Infection in Autologous Cranioplasty: A
   Retrospective Analysis of Subcutaneously Preserved Bone Flaps in
   Abdominal Pockets
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Craniectomy; Cranioplasty; Decompressive; Infection;
   Trauma
ID DECOMPRESSIVE CRANIECTOMY
AB BACKGROUND: Decompressive craniectomy (DC) is a surgical procedure performed to manage intracranial hypertension. Once performed, patients are obligated to undergo another surgical procedure known as cranioplasty to reconstruct the cranial defect. Cranioplasty still has one of the highest rates of infection. The factors contributing to the high rate of surgical site infection (SSI) after cranioplasty are not well established. This study aims to estimate the incidence of SSI and determine its possible risk factors for patients who underwent cranioplasty using bone flaps subcutaneously preserved in abdominal pockets.
   METHODS: A retrospective cohort study was conducted to investigate the predictors of infection among patients who underwent cranioplasty from subcutaneously preserved bone flaps in abdominal pockets between January 2005 and December 2018 at a level I trauma center.
   RESULTS: A total of 103 cases of cranioplasty from subcutaneously preserved bone flaps were included in the study. The mean age of the patients was 31.2 +/- 14.8 years (range, 5-67 years). The median interval between DC and cranioplasty was 115 days. The most frequent indication for DC was traumatic brain injury (76.4%). The incidence of SSI was noted in 15.7% of patients. The most significant predictors of infection in patients requiring cranioplasty were blood glucose levels and skull defect size (P = 0.03 and P = 0.02, respectively).
   CONCLUSIONS: Blood glucose levels and skull defect size were the only identifiable risk factors associated with SSI. Storing bone flaps in subcutaneous abdominal pockets is cost-efficient but carries considerable risk of infection.
C1 [Alkhaibary, Ali; Alharbi, Ahoud; Abbas, Munzir; Algarni, Abdulaziz; Abdullah, Jamal M.; Alkhani, Ahmed; Aloraidi, Ahmed; Khairy, Sami] King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, Riyadh, Saudi Arabia.
   [Alkhaibary, Ali; Alharbi, Ahoud; Abbas, Munzir; Algarni, Abdulaziz; Alkhani, Ahmed; Aloraidi, Ahmed; Khairy, Sami] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia.
   [Abbas, Munzir; Algarni, Abdulaziz; Alkhani, Ahmed; Aloraidi, Ahmed; Khairy, Sami] Minist Natl Guard Hlth Affairs, Dept Neurosurg, Riyadh, Saudi Arabia.
   [Abdullah, Jamal M.] Prince Sultan Mil Med City, Dept Neurosurg, Riyadh, Saudi Arabia.
   [Almadani, Wedad H.] Saudi Hlth Council, Natl Ctr Evidence Based Healthcare, Riyadh, Saudi Arabia.
   [Khairy, Ibtesam] Jazan Univ, Fac Appl Med Sci, Jazan, Saudi Arabia.
RP Alkhaibary, A (reprint author), King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, Riyadh, Saudi Arabia.; Alkhaibary, A (reprint author), King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia.
EM AlkhaibaryA@hotmail.com
OI Alharbi, Ahoud/0000-0002-8827-4588
CR Acciarri N, J NEUROSURG SCI, V6
   Aydin S, 2011, J NEUROSCI RURAL PRA, V2, P162, DOI 10.4103/0976-3147.83584
   Cheah PP, 2017, MALAYS J MED SCI, V24, P68, DOI 10.21315/mjms2017.24.6.8
   Cho Yong Jun, 2017, Korean J Neurotrauma, V13, P9, DOI 10.13004/kjnt.2017.13.1.9
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962
   Hng D, 2015, CRANIOMAX TRAUM REC, V8, P190, DOI 10.1055/s-0034-1395383
   Inamasu J, 2010, J TRAUMA, V68, P183, DOI 10.1097/TA.0b013e3181c45384
   Kim H, 2013, ACTA NEUROCHIR, V155, P2171, DOI 10.1007/s00701-013-1877-8
   Kreider GN, 1920, J AMER MED ASSOC, V74, P1024, DOI 10.1001/jama.1920.26210150001013
   Lee BS, 2012, KOREAN J NEUROTRAUMA, V8, P21
   Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17
   Riordan MA, 2016, WORLD NEUROSURG, V87, P207, DOI 10.1016/j.wneu.2015.11.070
   Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033
   Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86
   Tybor Krzysztof, 2005, Neurol Neurochir Pol, V39, P220
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E627
EP E632
DI 10.1016/j.wneu.2019.09.120
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700125
PM 31568916
OA Bronze
DA 2020-05-12
ER

PT J
AU Arai, S
   Mizutani, T
   Sugiyama, T
   Sumi, K
   Matsumoto, M
   Okumura, H
   Shimizu, K
AF Arai, Shintaro
   Mizutani, Tohru
   Sugiyama, Tatsuya
   Sumi, Kenji
   Matsumoto, Masaki
   Okumura, Hirotaka
   Shimizu, Katsuyoshi
TI An Experimental Clamping and Cutting Study of Carotid and Intracranial
   Stents: Preparation for Surgical Rescue in Stent Complications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clamp; Complications; Cut; Stent; Surgical rescue
ID EMBOLIC PROTECTION DEVICES; ENDOVASCULAR RESCUE; RETRIEVAL; ANGIOPLASTY;
   REMOVAL
AB OBJECTIVE: To carry out surgery safely in vessels with stents, it is essential to have knowledge of what would happen if the stents were clamped or cut. Using all stents that are permitted in Japan, we recorded with a surgical microscope the behavior of stents when they were clamped or cut and discussed the morphologic changes along with image findings.
   METHODS: We classified carotid artery and intracranial stents as group 1A and 18 or group 2A and 2B according to the structure of stent eye: laser cut or blade. Each stent was clamped using a Yasargil aneurysm clip, bulldog forceps, and vascular forceps. Degree of closure and presence or absence of stent deformation after declamping were recorded using a surgical microscope. Furthermore, we performed morphologic evaluations using high-resolution cone-beam computed tomography. Lastly, each stent was cut; the behavior of the cut stent was recorded, and differences between stents were examined.
   RESULTS: Complete clamping was confirmed both visually and based on image evaluations with bulldog forceps and vascular forceps in the groups of carotid artery stents, with the Yasargil aneurysm clip in the intracranial stents. In the blade-type stents, we found that the stents elongated during clamping, and the component wire scattered at the time of stent cutting. Furthermore, the stents could be easily separated by holding with forceps.
   CONCLUSIONS: Knowing the properties of each stent is essential to conduct safe surgery in response to complications. Special care must be taken when clamping and cutting blade-type stents.
C1 [Arai, Shintaro; Mizutani, Tohru; Sugiyama, Tatsuya; Sumi, Kenji; Matsumoto, Masaki; Okumura, Hirotaka; Shimizu, Katsuyoshi] Showa Univ, Dept Neurosurg, Sch Med, Shinagawa Ku, Tokyo, Japan.
RP Arai, S (reprint author), Showa Univ, Dept Neurosurg, Sch Med, Shinagawa Ku, Tokyo, Japan.
EM sarai@med.showa-u.ac.jp
CR Arai S, 2019, WORLD NEUROSURG, V122, P215, DOI 10.1016/j.wneu.2018.10.214
   Barburoglu M, 2016, WORLD NEUROSURG, V85, P349, DOI 10.1016/j.wneu.2015.08.066
   Bell RS, 2011, NEUROSURGERY, V68, P1056, DOI 10.1227/NEU.0b013e31820d5396
   Bowers CA, 2015, ACTA NEUROCHIR, V157, P2071, DOI 10.1007/s00701-015-2593-3
   Campbell JE, 2007, J ENDOVASC THER, V14, P600, DOI 10.1583/1545-1550(2007)14[600:EROAFM]2.0.CO;2
   Chen M, 2011, J NEUROINTERV SURG, V3, P25, DOI 10.1136/jnis.2010.002584
   Cremonesi A, 2003, STROKE, V34, P1936, DOI 10.1161/01.STR.0000081000.23561.61
   Daugherty WP, 2008, AM J NEURORADIOL, V29, P1594, DOI 10.3174/ajnr.A1118
   Ding Dale, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P26, DOI 10.7461/jcen.2014.16.1.26
   Ding Dale, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P241, DOI 10.7461/jcen.2013.15.3.241
   Lee JH, 2014, INTERV NEURORADIOL, V20, P100, DOI 10.15274/INR-2014-10015
   Li T, 2016, J SURG CASE REP, V6, P1
   Lian XG, 2012, CARDIOVASC INTER RAD, V35, P43, DOI 10.1007/s00270-011-0117-y
   Malik RK, 2009, J VASC SURG, V50, P216, DOI 10.1016/j.jvs.2009.01.040
   Mitchell Bartley, 2014, J Vasc Interv Neurol, V7, P1
   Nii K, 2015, J STROKE CEREBROVASC, V24, P210, DOI 10.1016/j.jstrokecerebrovasdis.2014.08.022
   Nishihori M, 2016, NKC, V1, P1
   Oh Yul, 2012, Neurointervention, V7, P50, DOI 10.5469/neuroint.2012.7.1.50
   Page Paul, 2018, Surg Neurol Int, V9, P123, DOI 10.4103/sni.sni_32_18
   Shilling Kimberly, 2006, Vasc Endovascular Surg, V40, P229, DOI 10.1177/153857440604000308
   Thomas J Alex, 2008, Neurosurgery, V63, pE817, DOI 10.1227/01.NEU.0000325489.65932.AB
   Turek G, 2015, J NEUROSURG, V123, P841, DOI 10.3171/2015.1.JNS132788
   Vijayvergiya R, 2010, TEX HEART I J, V37, P226
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E739
EP E744
DI 10.1016/j.wneu.2019.09.154
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700140
PM 31606499
OA Bronze
DA 2020-05-12
ER

PT J
AU Azab, WA
   Abdelnabi, EA
   Mostafa, KH
   Burhamah, TA
   Alhaj, AKH
   Khalil, AMB
   Yousef, W
   Nasim, K
AF Azab, Waleed A.
   Abdelnabi, Ehab A.
   Mostafa, Kamal H.
   Burhamah, Talal A.
   Alhaj, Ahmad K. H.
   Khalil, Ahmed M. B.
   Yousef, Waleed
   Nasim, Khurram
TI Effect of Sphenoid Sinus Pneumatization on the Surgical Windows for
   Extended Endoscopic Endonasal Transsphenoidal Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid; Endonasal; Endoscopic; Optic; Pneumatization; Sphenoid;
   Transsphenoidal
ID ANATOMIC VARIATIONS; CRANIOPHARYNGIOMAS; SUPRASELLAR; SEPTATION;
   FEATURES
AB BACKGROUND: Little is known on the impact of the pattern and extent of pneumatization of the sphenoid sinus (SS) on the dimensions of the surgical windows used in extended endoscopic endonasal transsphenoidal approaches. We therefore investigated whether the distances between the 2 optic canals and between the paired para-clival carotid arteries are influenced by the pattern and extent of pneumatization of the SS.
   METHODS: One hundred high-resolution computed tomography scans from 47 adult female and 53 adult male patients were analyzed. The pattern of SS pneumatization was classified into conchal, presellar, and sellar types. Sellar-type sinuses were then classified according to a newer detailed classification system. Maximal anteroposterior (AP), transverse (TR), and craniocaudal diameters of the SS, interoptic distance at the limbus sphenoidale (IODL) and at the entrance of the optic canal (IODE) and the intercarotid distance between the paraclival carotids (ICD) were measured. A 2-tailed Mann-Whitney U test and Pearson correlation coefficient (R) were used for statistical analysis. A P value <0.05 was considered statistically significant.
   RESULTS: Positive correlation was found between IODL and both AP and TR diameters of the SS; between IODE and both AP and TR diameters of the SS; and between ICD and all diameters of the SS. The highest correlation for each of the IODL, IODE, and ICD was noted with the TR diameter of the SS.
   CONCLUSIONS: During the development of the SS, pneumatization progress likely exerts quantitative and direction-specific forces, which gradually increase the interoptic and intercarotid distances.
C1 [Azab, Waleed A.; Mostafa, Kamal H.; Burhamah, Talal A.; Alhaj, Ahmad K. H.; Khalil, Ahmed M. B.; Yousef, Waleed; Nasim, Khurram] Ibn Sina Hosp, Dept Neurosurg, Kuwait, Kuwait.
   [Abdelnabi, Ehab A.] Ibn Sina Hosp, Dept Radiol, Kuwait, Kuwait.
RP Azab, WA (reprint author), Ibn Sina Hosp, Dept Neurosurg, Kuwait, Kuwait.
EM waleedazab@hotmail.com
CR Akgul MH, 2016, EUR ARCH OTO-RHINO-L, V273, P4321, DOI 10.1007/s00405-016-4138-7
   Alalade AF, 2018, J NEUROSURG-PEDIATR, V21, P72, DOI 10.3171/2017.7.PEDS17295
   Azab WA, 2019, WORLD NEUROSURG, V126, pE793, DOI 10.1016/j.wneu.2019.02.151
   BANNA M, 1983, J CAN ASSOC RADIOL, V34, P291
   Barbero JMR, 2019, OPER NEUROSURG, V16, P743, DOI 10.1093/ons/opy275
   Barbero JMR, 2018, WORLD NEUROSURG, V120, pE1234, DOI 10.1016/j.wneu.2018.09.052
   Cavallo LM, 2009, J NEUROSURG, V111, P578, DOI 10.3171/2009.2.JNS081026
   Cavallo LM, 2014, J NEUROSURG, V121, P100, DOI 10.3171/2014.3.JNS131521
   Clemente P., 2005, SINUS SURG ENDOSCOPI, P1
   de Notaris M, 2012, J NEUROSURG, V116, P622, DOI 10.3171/2011.11.JNS111162
   Di Somma A, 2019, J NEUROSURG, V130, P848, DOI 10.3171/2017.9.JNS171406
   Elshazly K, 2018, WORLD NEUROSURG, V114, pE447, DOI 10.1016/j.wneu.2018.03.006
   Gibelli D, 2018, SURG RADIOL ANAT, V40, P193, DOI 10.1007/s00276-017-1949-1
   Guldner C, 2012, ACTA RADIOL, V53, P214, DOI 10.1258/ar.2011.110381
   Hamid O, 2008, SKULL BASE-INTERD AP, V18, P9, DOI 10.1055/s-2007-992764
   HAMMER G, 1961, ACTA RADIOL, V56, P401, DOI 10.3109/00016926109172836
   Kayalioglu Gulgun, 2005, Neurosciences (Riyadh), V10, P79
   Lu YT, 2011, J ANAT, V219, P132, DOI 10.1111/j.1469-7580.2011.01380.x
   Nunes CF, 2016, ACTA NEUROCHIR, V158, P319, DOI 10.1007/s00701-015-2662-7
   Ozer CM, 2018, J CRANIOFAC SURG, V29, P2319, DOI 10.1097/SCS.0000000000004869
   Pirinc B, 2019, EUR ARCH OTO-RHINO-L, V276, P2887, DOI 10.1007/s00405-019-05549-8
   Prevedello DM, 2010, ACTA NEUROCHIR, V152, P1223, DOI 10.1007/s00701-009-0563-3
   SCUDERI AJ, 1993, AM J ROENTGENOL, V160, P1101, DOI 10.2214/ajr.160.5.8470585
   Sevinc O, 2014, INT J MORPHOL, V32, P1140, DOI 10.4067/S0717-95022014000400003
   Shkarubo AN, 2019, WORLD NEUROSURG, V121, pE246, DOI 10.1016/j.wneu.2018.09.090
   Stokovic N, 2016, ANN ANAT, V203, P69, DOI 10.1016/j.aanat.2015.02.013
   Tomovic S, 2013, J NEUROL SURG PART B, V74, P82, DOI 10.1055/s-0033-1333619
   Vaezi A, 2015, LARYNGOSCOPE, V125, P577, DOI 10.1002/lary.24989
   Vidya C.S, 2015, INT J ANAT RES, V3, P1611
   Wang J, 2010, NEUROSURGERY, V66, P797, DOI 10.1227/01.NEU.0000367619.24800.B1
   Zada G, 2011, J NEUROSURG, V114, P1319, DOI 10.3171/2010.11.JNS10768
NR 31
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E695
EP E701
DI 10.1016/j.wneu.2019.09.126
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700134
PM 31574333
OA Bronze
DA 2020-05-12
ER

PT J
AU Bligh, ER
   Sinha, P
   Smith, D
   Al-Tamimi, YZ
AF Bligh, Emily R.
   Sinha, Priyank
   Smith, Daisy
   Al-Tamimi, Yahia Z.
TI Thirty-Day Mortality and Survival in Elderly Patients Undergoing
   Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aging population; Elderly; Frailty score; Neurosurgery
ID FRAILTY INDEX; SURGERY; GLIOBLASTOMA; MANAGEMENT; PREDICTORS; OUTCOMES;
   INJURY; SCORE
AB OBJECTIVES: With an aging population and advances in neuroanesthesia and critical care, an increasing subgroup of elderly patients have been undergoing neurosurgery. Of particular relevance is the cohort aged >80 years. The aim of the present study was to investigate the 30-day mortality and survival in this cohort after emergency and elective neurosurgery.
   METHODS: We performed a retrospective cohort study of all patients aged >= 70 years who had undergone a neurosurgical procedure from 2015 to 2017. The patient demographic data were identified, and independent predictors were found using logistic regression analysis.
   RESULTS: A total of 796 patients were included, of whom 622 were aged <80 years (group A) and 174 were aged >80 years (group B). Overall survival was 86.3% in group A and 79.9% in group B. The 30-day mortality between the elective (0.8%) and emergency (10.1%) patients was significantly different statistically (P< 0.001). Of the patients in groups A and B, 84.7% and 68.9% were discharged back to their usual residence, respectively. Logistic regression found emergency surgery to he an independent predictor of mortality.
   CONCLUSIONS: The current model for accepting elderly patients has been associated with good overall outcomes. The elderly should not be refused neurosurgery on the basis of their age alone. However, we applied fairly strict criteria, especially for those with subarachnoid hemorrhage, which should be factored into our results.
C1 [Bligh, Emily R.] Univ Sheffield, Fac Med Dent & Hlth, Med Sch, Sheffield, S Yorkshire, England.
   [Sinha, Priyank; Smith, Daisy; Al-Tamimi, Yahia Z.] Natl Hlth Serv Fdn Trust, Sheffield Teaching Hosp, Dept Neurosurg, Sheffield, S Yorkshire, England.
RP Al-Tamimi, YZ (reprint author), Natl Hlth Serv Fdn Trust, Sheffield Teaching Hosp, Dept Neurosurg, Sheffield, S Yorkshire, England.
EM y.al-tamimi@sheffield.ac.uk
FU National Institute for Health Research (NIHR) Sheffield Biomedical
   Research Centre/NIHR Sheffield Clinical Research Facility
FX This research was supported by the National Institute for Health
   Research (NIHR) Sheffield Biomedical Research Centre/NIHR Sheffield
   Clinical Research Facility. The views expressed are those of the authors
   and not necessarily those of the National Health Service, NIHR, or
   Department of Health and Social Care.
CR Ahamat N., 2012, BULLETIN, V94, P300
   Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x
   Cloney Michael, 2016, World Neurosurg, V89, P362, DOI 10.1016/j.wneu.2015.12.096
   Fehnel CR, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006696
   Furlan JC, 2016, NEUROSURGERY, V79, P418, DOI 10.1227/NEU.0000000000001314
   Hightower CE, 2010, BRIT J ANAESTH, V104, P465, DOI 10.1093/bja/aeq034
   Ikawa F, 2017, NEUROL MED-CHIR, V57, P521, DOI 10.2176/nmc.ra.2017-0011
   Iosif C, 2014, J NEUROINTERV SURG, V6, P286, DOI 10.1136/neurintsurg-2013-010711
   Lansbury LN, 2017, BRIT J GEN PRACT, V67, pE751, DOI 10.3399/bjgp17X693089
   Lorimer CF, 2016, J GERIATR ONCOL, V7, P453, DOI 10.1016/j.jgo.2016.07.005
   Miller EK, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.10.FOCUS17472
   Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001
   Nashef SAM, 1999, EUR J CARDIO-THORAC, V16, P9, DOI 10.1016/S1010-7940(99)00134-7
   Pearce L, 2016, ANN ROY COLL SURG, V98, P367, DOI 10.1308/rcsann.2016.0180
   Pirracchio R, 2010, J NEUROSURG ANESTH, V22, P342, DOI 10.1097/ANA.0b013e3181e6daa2
   Prasad GL, 2018, WORLD NEUROSURG, V111, pE221, DOI 10.1016/j.wneu.2017.12.034
   Reponen E, 2015, J NEUROSURG, V123, P594, DOI 10.3171/2014.11.JNS141970
   Rolston JD, 2014, J NEUROSURG, V120, P736, DOI 10.3171/2013.10.JNS122419
   Sacko O, 2007, NEUROSURGERY, V61, P950, DOI 10.1227/01.neu.0000303190.80049.7d
   Searle Samuel D, 2008, BMC Geriatr, V8, P24, DOI 10.1186/1471-2318-8-24
   Shimoda K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.014
   Stein M, 2011, ACTA NEUROCHIR SUPPL, V112, P9, DOI 10.1007/978-3-7091-0661-7_2
   Tomlinson SB, 2017, WORLD NEUROSURG, V107, P959, DOI 10.1016/j.wneu.2017.07.081
   Whitehouse KJ, 2016, WORLD NEUROSURG, V94, P493, DOI 10.1016/j.wneu.2016.07.057
   Whitehouse KJ, 2016, WORLD NEUROSURG, V87, P446, DOI 10.1016/j.wneu.2015.10.099
   Wick A, 2018, NEURO-ONCOLOGY, V20, P174, DOI 10.1093/neuonc/nox133
   Youngerman BE, 2018, J NEURO-ONCOL, V136, P197, DOI 10.1007/s11060-017-2644-0
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E646
EP E652
DI 10.1016/j.wneu.2019.09.121
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700128
PM 31568913
OA Bronze
DA 2020-05-12
ER

PT J
AU Boschetti, G
   Santos, AJ
   Fermon, KP
   Honorio, GLD
   Batistella, G
   Kusma, SZ
   Stavale, JN
   Neto, MAD
   Malheiros, SMF
AF Boschetti, Gabriela
   Santos, Adrialdo Jose
   Fermon, Kellen Paiva
   de Freitas Honorio, Gustavo Lopes
   Batistella, Gabriel
   Kusma, Solena Ziemer
   Stavale, Joao Norberto
   de Paiva Neto, Manoel Antonio
   Fleury Malheiros, Suzana Maria
TI Adult Pilocytic Astrocytomas: A Brazilian Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult; Astrocytoma; Outcome; Pilocytic
ID CLINICAL-FEATURES
AB OBJECTIVE: Pilocytic astrocytoma (PA) is rare in adults comprising 5.1% of the primary central nervous system tumors. The aim is to describe the first Brazilian series of adult patients with PA and compare its features with the available literature.
   METHODS: We retrospectively review all patients 18 years or older with PA from our institution's database from 1991 to 2018. We analyzed information regarding clinical presentation, location, imaging features, extent of resection, adjuvant treatments, and follow-up.
   RESULTS: Twenty-three patients with PA were analyzed: 60.9% male; median age 26 years. The most frequent symptoms were headache (34.8%) and seizure (26.1%). Temporal and parietal lobes were the most common locations, 21.7% each. All patients underwent a surgical procedure, gross total resection in 40.9%, subtotal resection in 22.7%, and biopsy in 27.3%. Adjuvant treatment with radiotherapy was performed in 2 patients. Only 4 patients had disease progression, 2 after gross total resection and 2 after subtotal resection. They were all alive and without evidence of new progression at the last follow-up (October 2018). Median overall survival was not reached after a median follow-up time of 88.9 months.
   CONCLUSIONS: This is the first Brazilian series regarding adults with PA, and our patients had a favorable outcome as reported in recent literature reviews. The tumor's prevalence reduces within older patients and supratentorial lesions are more frequent, especially on the temporal lobe. There was no significant relationship between location and progression, although according to the literature the extent of resection remains the most important prognostic factor.
C1 [Boschetti, Gabriela; Santos, Adrialdo Jose; Fermon, Kellen Paiva; de Freitas Honorio, Gustavo Lopes; Batistella, Gabriel; de Paiva Neto, Manoel Antonio; Fleury Malheiros, Suzana Maria] Univ Fed Sao Paulo, Dept Neurosurg, Neurooncol Serv, Sao Paulo, SP, Brazil.
   [Stavale, Joao Norberto] Univ Fed Sao Paulo, Dept Pathol, Neuropathol Serv, Sao Paulo, SP, Brazil.
   [Fleury Malheiros, Suzana Maria] Hosp Israelita Albert Einstein, Dept Oncol, Sao Paulo, SP, Brazil.
   [Boschetti, Gabriela; Kusma, Solena Ziemer] Pontificia Univ Catolica Parana, Sch Med Deparment, Curitiba, Parana, Brazil.
   [Boschetti, Gabriela] Fac Pequeno Principe, Med Sch Dept, Curitiba, Parana, Brazil.
   [Kusma, Solena Ziemer] Univ Fed Parana, Dept Publ Hlth, Curitiba, Parana, Brazil.
   [Stavale, Joao Norberto] Hosp Israelita Albert Einstein, Dept Pathol, Sao Paulo, SP, Brazil.
RP Boschetti, G (reprint author), Univ Fed Sao Paulo, Dept Neurosurg, Neurooncol Serv, Sao Paulo, SP, Brazil.; Boschetti, G (reprint author), Pontificia Univ Catolica Parana, Sch Med Deparment, Curitiba, Parana, Brazil.; Boschetti, G (reprint author), Fac Pequeno Principe, Med Sch Dept, Curitiba, Parana, Brazil.
EM gabiboschetti@hotmail.com
OI Boschetti, Gilles/0000-0003-4039-7607
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior- Brasil
   (CAPES)CAPES [001]
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior- Brasil (CAPES)-Finance code 001.
CR Bell D, 2004, BRIT J NEUROSURG, V18, P613, DOI 10.1080/02688690400022896
   Bond KM, 2018, WORLD NEUROSURG, V110, P276, DOI 10.1016/j.wneu.2017.11.102
   Brown PD, 2015, NEURO-ONCOL PRACT, V2, P199, DOI 10.1093/nop/npv031
   Brown PD, 2004, INT J RADIAT ONCOL, V58, P1153, DOI 10.1016/j.ijrobp.2003.09.020
   Cyrine S, 2013, CLIN NEUROL NEUROSUR, V115, P1220, DOI 10.1016/j.clineuro.2012.11.009
   Ellis JA, 2009, J NEURO-ONCOL, V95, P377, DOI 10.1007/s11060-009-9935-z
   Ishkanian A, 2011, CANCER-AM CANCER SOC, V117, P4070, DOI 10.1002/cncr.25988
   Johnson DR, 2012, J NEURO-ONCOL, V108, P187, DOI 10.1007/s11060-012-0829-0
   Lee KJ, 2018, WORLD NEUROSURG, V112, pE881, DOI 10.1016/j.wneu.2018.01.208
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Pajtler KW, 2015, CANCER CELL, V27, P728, DOI 10.1016/j.ccell.2015.04.002
   Stuer C, 2007, CANCER-AM CANCER SOC, V110, P2799, DOI 10.1002/cncr.23148
   Theeler BJ, 2014, NEURO-ONCOLOGY, V16, P841, DOI 10.1093/neuonc/not246
   Wade A, 2013, ACTA NEUROCHIR, V155, P1431, DOI 10.1007/s00701-013-1790-1
   Ye JM, 2014, J CLIN NEUROSCI, V21, P2160, DOI 10.1016/j.jocn.2014.04.015
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E115
EP E120
DI 10.1016/j.wneu.2019.08.146
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700015
PM 31550545
OA Bronze
DA 2020-05-12
ER

PT J
AU Brzegowy, K
   Pekala, PA
   Zarzecki, MP
   Pekala, JR
   Roy, J
   Aziz, HM
   Tubbs, RS
   Walocha, JA
   Tomaszewski, KA
   Mikos, M
AF Brzegowy, Karolina
   Pekala, Przemyslaw A.
   Zarzecki, Michal P.
   Pekala, Jakub R.
   Roy, Joyeeta
   Aziz, Hasina M.
   Tubbs, R. Shane
   Walocha, Jerzy A.
   Tomaszewski, Krzysztof A.
   Mikos, Marcin
TI Prevalence and Clinical Implications of the Primitive Trigeminal Artery
   and its Variants: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid-basilar anastomosis; Fetal intracranial artery; Internal carotid
   artery; Primitive trigeminal artery; Vascular anatomy
ID MAGNETIC-RESONANCE ANGIOGRAPHY; INTERNAL CAROTID-ARTERY; MR-ANGIOGRAPHY;
   CONVENTIONAL ANGIOGRAPHY; CEREBELLAR ARTERY; ANATOMY; ANASTOMOSIS;
   MOYAMOYA; BRANCHES
AB BACKGROUND: The primitive trigeminal artery (PTA) is the most common and the largest persistent carotid-basilar anastomosis. Primitive trigeminal artery variants (PTAVs) are anastomoses between the internal carotid artery and cerebellar arteries. These vessels pose a risk of hemorrhagic or ischemic complications during neurosurgical procedures in the parasellar and intrasellar regions. The aim of this study was to determine the prevalence of both PTA and PTAVs and their clinically important anatomic features.
   METHODS: Major electronic databases were thoroughly searched for studies on PTA and PTAV. References in the included articles were also evaluated. Data regarding prevalence, laterality, origin, course patterns, and associated anomalies were extracted and pooled into a meta-analysis.
   RESULTS: A total of 39 studies (110,866 patients) were included in the meta-analysis. The total pooled prevalence estimate of PTA and PTAVs combined was 0.4% (95% confidence interval [CI], 0.3-0.5). Individually, PTA was present in 0.3% of patients and PTAV in 0.2%. Both arteries most often originated from the C4 internal carotid artery and took a course lateral to the dorsum sellae. The anterior inferior cerebellar artery type was the predominant PTAV (72.1%). Basilar artery hypoplasia was found in 42.5% of patients with a PTA.
   CONCLUSIONS: PTA and PTAVs are rare vessels, but they are clinically important because they can contribute to trigeminal neuralgia. Knowledge of the potential course of these arteries is essential in neuroradiology and neurosurgery, especially in minimally invasive procedures such as the endoscopic endonasal transsphenoidal approach to the pituitary gland and the percutaneous gasserian ganglion procedure.
C1 [Brzegowy, Karolina; Pekala, Przemyslaw A.; Zarzecki, Michal P.; Pekala, Jakub R.; Aziz, Hasina M.; Walocha, Jerzy A.; Tomaszewski, Krzysztof A.] Jagiellonian Univ, Dept Anat, Med Coll, Krakow, Poland.
   [Brzegowy, Karolina; Pekala, Przemyslaw A.; Zarzecki, Michal P.; Pekala, Jakub R.; Roy, Joyeeta; Aziz, Hasina M.; Walocha, Jerzy A.; Tomaszewski, Krzysztof A.; Mikos, Marcin] Int Evidence Based Anat Working Grp, Krakow, Poland.
   [Roy, Joyeeta] Univ Otago, Dept Anat, Dunedin, New Zealand.
   [Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA USA.
   [Tomaszewski, Krzysztof A.; Mikos, Marcin] Andrzej Frycz Modrzewski Krakow Univ, Fac Med & Hlth Sci, Krakow, Poland.
RP Tomaszewski, KA (reprint author), Jagiellonian Univ, Dept Anat, Med Coll, Krakow, Poland.; Tomaszewski, KA (reprint author), Int Evidence Based Anat Working Grp, Krakow, Poland.; Tomaszewski, KA (reprint author), Andrzej Frycz Modrzewski Krakow Univ, Fac Med & Hlth Sci, Krakow, Poland.
EM krtomaszewski@gmail.com
OI Brzegowy, Karolina/0000-0003-1944-2899; Tomaszewski,
   Krzysztof/0000-0001-5077-6948; Zarzecki, Michal P./0000-0002-0501-5645
CR Ali S, 2008, NEUROSURGERY, V62, P746, DOI [10.1227/01.NEU.0000297127.23313.C6, 10.1227/01.neu.0000317327.17225.f8]
   Allen JW, 2005, J NEUROSURG, V102, P45, DOI 10.3171/jns.2005.102.1.0045
   Arakawa T, 2007, ANN ANAT, V189, P489, DOI 10.1016/j.aanat.2006.11.012
   Arraez-Aybar LA, 2016, SURG RADIOL ANAT, V38, P445, DOI 10.1007/s00276-015-1578-5
   ATHALE SD, 1993, J COMPUT ASSIST TOMO, V17, P551
   Azab W, 2012, TURK NEUROSURG, V22, P399, DOI 10.5137/1019-5149.JTN.4427-11.1
   Bai M, 2013, CLIN RADIOL, V68, pE578, DOI 10.1016/j.crad.2013.05.099
   Bouthillier A, 1996, NEUROSURGERY, V38, P425, DOI 10.1097/00006123-199603000-00001
   BUFFARD P, 1965, Ann Radiol (Paris), V8, P25
   Busch W, 1966, Arch Psychiatr Nervenkr (1970), V208, P326, DOI 10.1007/BF00343049
   Carcavilla Longan L I, 1975, Rev Esp Otoneurooftalmol Neurocir, V33, P237
   Chen YC, 2011, J NEUROIMAGING, V21, P152, DOI 10.1111/j.1552-6569.2010.00472.x
   Cloft HJ, 1999, J NEUROSURG, V90, P865, DOI 10.3171/jns.1999.90.5.0865
   de Almeida G M, 1965, Rev Paul Med, V67, P195
   de Bondt BJ, 2007, NEURORADIOLOGY, V49, P23, DOI 10.1007/s00234-006-0150-8
   Dickmann GH, 1968, ACTA NEUROCHIR WIEN, V17, P205
   Dong KI, 1988, J KOREAN RADIOL SOC, P863
   FIELDS WS, 1968, RADIOLOGY, V91, P1096, DOI 10.1148/91.6.1096
   GESSINI L, 1954, Riv Neurol, V24, P338
   Gregg L, 2017, ANAT REC, V300, P2025, DOI 10.1002/ar.23633
   HARRISON CR, 1953, J NEUROSURG, V10, P205, DOI 10.3171/jns.1953.10.3.0205
   Henry BM, 2017, CLIN ANAT, V30, P6, DOI 10.1002/ca.22799
   Henry BM, 2016, ANN ANAT, V205, P16, DOI 10.1016/j.aanat.2015.12.002
   Higano S, 1987, JPN J CLIN RADIOL, V32, P263
   HIRAI T, 1995, J COMPUT ASSIST TOMO, V19, P495, DOI 10.1097/00004728-199505000-00027
   Ikushima I, 2002, CARDIOVASC INTER RAD, V25, P70, DOI 10.1007/s00270-001-0053-3
   Ishiguro T, 2019, WORLD NEUROSURG, V128, P122, DOI 10.1016/j.wneu.2019.05.003
   Kim MJ, 2015, SURG RADIOL ANAT, V37, P69, DOI 10.1007/s00276-014-1318-2
   KITAMI K, 1985, Neurological Surgery, V13, P1067
   KRAYENBUHL H, 1958, Acta Neurochir (Wien), V6, P30, DOI 10.1007/BF01577673
   KWAK R, 1983, J NEUROSURG, V59, P166, DOI 10.3171/jns.1983.59.1.0166
   LAMB J, 1961, Clin Radiol, V12, P179, DOI 10.1016/S0009-9260(61)80006-8
   Meckel S, 2013, NEURORADIOLOGY, V55, P5, DOI 10.1007/s00234-011-0995-3
   MORITA A, 1989, J NEUROSURG, V70, P415, DOI 10.3171/jns.1989.70.3.0415
   Nakajima K, 1976, No To Shinkei, V28, P197
   O'uchi E, 2010, NEURORADIOLOGY, V52, P1111, DOI 10.1007/s00234-010-0669-6
   Ohshima T, 2019, WORLD NEUROSURG, V128, P360, DOI 10.1016/j.wneu.2019.05.122
   OHSHIRO S, 1993, NEUROSURGERY, V32, P144, DOI 10.1227/00006123-199301000-00025
   OLIVEIRA H A, 1991, Arquivos de Neuro-Psiquiatria, V49, P315
   OURIEL K, 1988, J VASC SURG, V7, P774, DOI 10.1067/mva.1988.avs0070774
   PECKER J, 1967, NEUROCHIRURGIA, V10, P176
   POBLETE R, 1954, Med Contemp, V72, P637
   Rhee SJ, 2007, J KOREAN NEUROSURG S, V42, P446, DOI 10.3340/jkns.2007.42.6.446
   RUSSELL GLENN V., 1960, TEXAS REPTS BIOL AND MED, V18, P486
   Salas E, 1998, NEUROSURGERY, V43, P563, DOI 10.1097/00006123-199809000-00089
   Salas E, 1998, NEUROSURGERY, V43, P557, DOI 10.1097/00006123-199809000-00082
   SALTZMAN GF, 1959, ACTA RADIOL, V51, P329, DOI 10.3109/00016925909171103
   SAMRA K, 1969, J NEUROSURG, V30, P622, DOI 10.3171/jns.1969.30.5.0622
   Shen J, 2016, J NEUROL SURG PART B, V77, P449, DOI 10.1055/s-0036-1581066
   SIQUEIRA M, 1993, AM J NEURORADIOL, V14, P1229
   SUNDERLAND S, 1948, J NEUROL NEUROSUR PS, V11, P243, DOI 10.1136/jnnp.11.4.243
   Suto Y, 1998, ACTA NEUROL SCAND, V97, P336, DOI 10.1111/j.1600-0404.1998.tb05963.x
   Suttner N, 2000, NEUROSURGERY, V47, P428, DOI 10.1097/00006123-200008000-00030
   Suzuki S, 1996, SURG NEUROL, V45, P236, DOI 10.1016/0090-3019(95)00337-1
   TEAL JS, 1972, RADIOLOGY, V103, P335, DOI 10.1148/103.2.335
   Toda H, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.4.FOCUS18122
   Tomaszewski KA, 2018, CLIN ANAT, V31, P4, DOI 10.1002/ca.22994
   Tubbs RS, 2011, J NEUROSURG, V114, P1127, DOI 10.3171/2010.11.JNS101527
   Uchino A, 1996, CLIN IMAG, V20, P247, DOI 10.1016/0899-7071(95)00047-X
   Uchino A, 2000, EUR RADIOL, V10, P1801, DOI 10.1007/s003300000443
   Uchino A, 2012, SURG RADIOL ANAT, V34, P271, DOI 10.1007/s00276-011-0848-0
   Vasovic L, 2012, CHILD NERV SYST, V28, P33, DOI 10.1007/s00381-011-1622-7
   Walter W., 1959, ACTA NEUROCHIR, V7, P53
   Wenz H, 2015, SURG RADIOL ANAT, V37, P1079, DOI 10.1007/s00276-015-1457-0
   Weon YC, 2011, ACTA RADIOL, V52, P1043, DOI 10.1258/ar.2011.110191
   WIEDENMANN O, 1959, Fortschr Geb Rontgenstr Nuklearmed, V91, P350
   WISE BL, 1964, J NEUROSURG, V21, P199, DOI 10.3171/jns.1964.21.3.0199
   WISE BL, 1957, RADIOLOGY, V68, P731, DOI 10.1148/68.5.731
   WOLLSCHLAEGER G, 1964, AMER J ROENTGENOL RA, V92, P761
   Yan L, 2013, NEUROSURG QUART, V23, P175, DOI 10.1097/WNQ.0b013e31826b49e2
   Yilmaz E, 1995, Clin Anat, V8, P36, DOI 10.1002/ca.980080107
NR 71
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E401
EP E411
DI 10.1016/j.wneu.2019.09.042
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700096
PM 31536812
OA Bronze
DA 2020-05-12
ER

PT J
AU Bydon, M
   Schirmer, CM
   Oermann, EK
   Kitagawa, RS
   Pouratian, N
   Davies, J
   Sharan, A
   Chambless, LB
AF Bydon, Mohamad
   Schirmer, Clemens M.
   Oermann, Eric K.
   Kitagawa, Ryan S.
   Pouratian, Nader
   Davies, Jason
   Sharan, Ashwini
   Chambless, Lola B.
TI Big Data Defined: A Practical Review for Neurosurgeons
SO WORLD NEUROSURGERY
LA English
DT Review
DE Clinical practice; Data science; Machine learning; Registry
ID BRAIN-TUMORS; QUALITY; EPIDEMIOLOGY; CRANIOTOMY; MORTALITY; OUTCOMES;
   RECORDS; HEART; CARE
AB BACKGROUND: Modern science and healthcare aerate vast amounts of data, and, coupled with the increasingly inexpensive and accessible computing, a tremendous opportunity exists to use these data to improve care. A better understanding of data science and its relationship to neurosurgical practice will be increasingly important as we transition into this modern "big data" era.
   METHODS: A review of the literature was performed for referencing big data for neurosurgical care or related topics.
   RESULTS: In the present report, we first defined the nature and scope of data science from a technical perspective. We then discussed its relationship to the modern neurosurgical practice, highlighting key references, which might form a useful introductory reading list.
   CONCLUSIONS: Numerous challenges exist going for.rd; however, organized neurosurgery has an important role in fostering and facilitating these efforts to merge data science with neurosurgical practice.
C1 [Bydon, Mohamad] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Schirmer, Clemens M.] Geisinger Hlth Syst, Dept Neurosurg, Wilkes Barre, PA USA.
   [Oermann, Eric K.] Mt Sinai Hlth Syst, Dept Neurosurg, New York, NY USA.
   [Kitagawa, Ryan S.] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA.
   [Pouratian, Nader] Univ Calif Los Angeles, Med Ctr, Dept Neurosurg, Los Angeles, CA 90024 USA.
   [Davies, Jason] SUNY Buffalo, Dept Neurosurg, Buffalo, NY USA.
   [Sharan, Ashwini] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA.
   [Chambless, Lola B.] Vanderbilt Univ Sch Med, Dept Neurosurg, Nashville, TN 37212 USA.
RP Chambless, LB (reprint author), Vanderbilt Univ Sch Med, Dept Neurosurg, Nashville, TN 37212 USA.
EM lola.chambless@vanderbilt.edu
RI Oermann, Eric/AAD-9729-2020
OI Oermann, Eric/0000-0002-1876-5963; Pouratian, Nader/0000-0002-0426-3241
CR Asher AL, 2014, SPINE, V39, pS106, DOI 10.1097/BRS.0000000000000579
   Aziz A, 2016, J BIOMED INFORM, V60, P84, DOI 10.1016/j.jbi.2015.12.019
   Barker FG, 2004, CANCER-AM CANCER SOC, V100, P999, DOI 10.1002/cncr.20058
   Collins CJ, 1965, FINANCE ANAL J, V21, P45
   Cox M, 1997, VISUALIZATION '97 - PROCEEDINGS, P235, DOI 10.1109/VISUAL.1997.663888
   Dasenbrock HH, 2017, NEUROSURGERY, V81, P761, DOI 10.1093/neuros/nyx089
   Davis FG, 1998, J NEUROSURG, V88, P1, DOI 10.3171/jns.1998.88.1.0001
   Dunlay SM, 2008, ARCH INTERN MED, V168, P1692, DOI 10.1001/archinte.168.15.1692
   He K, 160305027V3CSCV ARXI
   Hirschi RS, 2017, J NEUROSURG, V126, pA1392
   Hosmer DW Jr, 2001, SOLUTIONS MANUAL ACC
   Hu KJ, 2016, WORLD NEUROSURG, V94, P409, DOI 10.1016/j.wneu.2016.07.023
   Jastrow KM, 2009, J AM COLL SURGEONS, V209, P320, DOI 10.1016/j.jamcollsurg.2009.05.002
   Karhade AV, 2018, NEUROSURGERY, V83, P333, DOI 10.1093/neuros/nyx408
   Kerezoudis P, 2016, CLIN NEUROL NEUROSUR, V149, P75, DOI 10.1016/j.clineuro.2016.07.027
   Lippmann RP, 1997, ANN THORAC SURG, V63, P1635, DOI 10.1016/S0003-4975(97)00225-7
   Lyu H, 2016, J HEALTHC QUAL, V38, P223, DOI 10.1097/JHQ.0000000000000001
   MACMAHON B, 1981, NEW ENGL J MED, V304, P630, DOI 10.1056/NEJM198103123041102
   Martens EP, 2006, EPIDEMIOLOGY, V17, P260, DOI 10.1097/01.ede.0000215160.88317.cb
   Mayer-Schonberger V, 2014, BIG DATA SPECIAL SAL
   McGirt MJ, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2012.10.FOCUS12297
   McGuire MF, 2012, J BIOMED INFORM, V45, P372, DOI 10.1016/j.jbi.2011.12.002
   McNeal GS., 2015, FORBES
   Mohammadi A, 2015, INT J COMPUT ASS RAD, V10, P1753, DOI 10.1007/s11548-015-1216-z
   Muhlestein WE, 2019, NEUROSURGERY, V85, P384, DOI 10.1093/neuros/nyy343
   Mummaneni PV, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17188
   Neuropoint Alliance, NEUR ALL QUAL OUTC
   Ohm P, 2009, BROKEN PROMISES PRIV
   Oravec CS, 2018, NEUROSURGERY, V82, P728, DOI 10.1093/neuros/nyx328
   Poplin R, 2018, NAT BIOTECHNOL, V36, P983, DOI 10.1038/nbt.4235
   Rodrigues JJPC, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2494
   Roger VL, 2015, AM J EPIDEMIOL, V181, P363, DOI 10.1093/aje/kwv011
   Rumsfeld JS, 2016, NAT REV CARDIOL, V13, P350, DOI 10.1038/nrcardio.2016.42
   Russakovsky O, 14090575VSCSCV ARXIV
   Schellinger KA, 2008, J NEURO-ONCOL, V87, P173, DOI 10.1007/s11060-007-9507-z
   Schonfeld E., 2008, GOOGLE PROCESSING 20
   Soubra D., 2012, 3VS DEFINE BIG DATA, P5
   Szegedy C, 2015, PROC CVPR IEEE, P1, DOI 10.1109/CVPR.2015.7298594
   Takabi H, 2010, IEEE SECUR PRIV, V8, P24, DOI 10.1109/MSP.2010.186
   Terhune C., 2015, LOS ANGELES TIMES
   Viceconti M, 2015, IEEE J BIOMED HEALTH, V19, P1209, DOI 10.1109/JBHI.2015.2406883
   Wei WQ, 2016, J AM MED INFORM ASSN, V23, pE20, DOI 10.1093/jamia/ocv130
   Xian Y, 2013, HEART FAIL CLIN, V9, P1, DOI 10.1016/j.hfc.2012.09.001
   Yadron D, 2014, WSJ ONLINE      0904
   Zech J, 2018, RADIOLOGY, V287, P570, DOI 10.1148/radiol.2018171093
   Zhou L, 2007, J BIOMED INFORM, V40, P183, DOI 10.1016/j.jbi.2006.12.009
NR 46
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E842
EP E849
DI 10.1016/j.wneu.2019.09.092
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700154
PM 31562965
OA Bronze
DA 2020-05-12
ER

PT J
AU Catapano, JS
   Israr, S
   Whiting, AC
   Hussain, OM
   Snyder, LA
   Albuquerque, FC
   Ducruet, AF
   Nakaji, P
   Lawton, MT
   Weinberg, JA
   Zabramski, JM
AF Catapano, Joshua S.
   Israr, Sharjeel
   Whiting, Alexander C.
   Hussain, Omar M.
   Snyder, Laura A.
   Albuquerque, Felipe C.
   Ducruet, Andrew F.
   Nakaji, Peter
   Lawton, Michael T.
   Weinberg, Jordan A.
   Zabramski, Joseph M.
TI Management of Extracranial Blunt Cerebrovascular Injuries: Experience
   with an Aspirin-Based Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE ASA; Extracranial blunt cerebral vascular injury; Stroke
ID CAROTID-ARTERY INJURIES; 10-YEAR RETROSPECTIVE ANALYSIS;
   TREATMENT-RELATED OUTCOMES; BCVI TAILORING TREATMENT; ENDOVASCULAR
   STENTS; SCREENING CRITERIA; TRAUMA CENTER.; ASSOCIATION; THERAPY; STROKE
AB BACKGROUND: Optimal management of patients with extracranial blunt cerebrovascular injury (BCVI) remains controversial, with both anticoagulation and antiplatelet therapy being recommended. The purpose of this study was to evaluate the efficacy and safety of using acetylsalicylic acid (ASA) in the management of BCVI.
   METHODS: Patients with BCVI were identified from the registry of a Level 1 trauma center between 2010 and 2017. Digital imaging and electronic medical records were reviewed for patient information including demographic characteristics, injury type, therapy, outcomes, and follow-up.
   RESULTS: Over the study period, 13,578 patients were admitted following blunt trauma, with 94 (03%) having confirmed BCVI (mean age, 42 years; 72% male). Mean Injury Severity Score and Glasgow Coma Score were 27 and 10, respectively. BCVI was identified in 130 vessels with Biffl grade I (38%) and grade II injury (29%) being most common. Twelve (13%) patients experienced an ischemic event, but only 3 events occurred after diagnosis. ASA was primary treatment for 56 (60%) patients. Thirty patients (32%) received no treatment; 21 patients died within 24 hours of primary injury. Only 4 patients had ASA contraindications. Four patients (7%) had ASA-related complications; there were 2 cases of intracranial hemorrhage progression and 2 cases of gastrointestinal bleeding. Follow-up vascular imaging at a mean of 36 days demonstrated stable or improved levels of BCVI in 94% of patients.
   CONCLUSIONS: An ASA-based management strategy for BCVI was efficacious and relatively safe in this study. This approach may be the preferred treatment for BCVI, but confirmation is needed.
C1 [Catapano, Joshua S.; Israr, Sharjeel; Whiting, Alexander C.; Hussain, Omar M.; Snyder, Laura A.; Albuquerque, Felipe C.; Ducruet, Andrew F.; Nakaji, Peter; Lawton, Michael T.; Weinberg, Jordan A.; Zabramski, Joseph M.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Zabramski, JM (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
OI Whiting, Alexander/0000-0002-4585-5219
CR Berne JD, 2008, J TRAUMA, V64, P398, DOI 10.1097/TA.0b013e31815eb788
   Biffl WL, 2009, J TRAUMA, V67, P1150, DOI 10.1097/TA.0b013e3181c1c1d6
   Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012
   Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003
   Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004
   Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da
   Brott TG, 2011, STROKE, V42, pE464, DOI 10.1161/STR.0b013e3182112cc2
   Burlew CC, 2014, J AM COLL SURGEONS, V218, P1012, DOI 10.1016/j.jamcollsurg.2014.01.042
   Cohen JE, 2012, J TRAUMA ACUTE CARE, V72, P216, DOI 10.1097/TA.0b013e31823f630a
   Colella JJ, 1996, AM SURGEON, V62, P212
   Cothren C. Clay, 2005, Clinics, V60, P489, DOI 10.1590/S1807-59322005000600011
   Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111
   Cothren CC, 2005, AM J SURG, V190, P845, DOI 10.1016/j.amsurg.2005.08.007
   Crawford JD, 2015, JAMA SURG, V150, P841, DOI 10.1001/jamasurg.2015.1692
   DAVIS JW, 1990, J TRAUMA, V30, P1514, DOI 10.1097/00005373-199012000-00013
   DiCocco JM, 2011, J AM COLL SURGEONS, V212, P549, DOI 10.1016/j.jamcollsurg.2010.12.035
   Duke BJ, 1997, J NEUROSURG, V87, P825, DOI 10.3171/jns.1997.87.6.0825
   Eachempati SR, 1998, J TRAUMA, V45, P997, DOI 10.1097/00005373-199812000-00004
   Edwards NM, 2007, J AM COLL SURGEONS, V204, P1007, DOI 10.1016/j.jamcollsurg.2006.12.041
   Fabian TC, 2002, ANN SURG, V235, P706
   Flint L, 2011, J AM COLL SURGEONS, V212, P557
   Foreman PM, 2017, CEREBROVASC DIS EXTR, V7, P72, DOI 10.1159/000455391
   Franz RW, 2012, J AM COLL SURGEONS, V214, P313, DOI 10.1016/j.jamcollsurg.2011.11.012
   Geddes AE, 2016, AM J SURG, V212, P1167, DOI 10.1016/j.amjsurg.2016.09.016
   Griessenauer CJ, 2013, J NEUROSURG, V118, P397, DOI 10.3171/2012.11.JNS121038
   Griffin RL, J NEUROSURG, DOI [10.3171/2017.12.JNS172284, DOI 10.3171/2017.12.JNS172284.]
   Jindal G, 2013, J TRAUMA ACUTE CARE, V75, P896, DOI 10.1097/TA.0b013e3182a686be
   Li W, 2010, J VASC SURG, V51, P593, DOI 10.1016/j.jvs.2009.10.108
   Malhotra A, 2018, WORLD J SURG, V42, P3451, DOI 10.1007/s00268-018-4518-9
   Moulakakis KG, 2010, EUR J VASC ENDOVASC, V40, P312, DOI 10.1016/j.ejvs.2010.05.003
   Nagpal P, 2018, AM J NEURORADIOL, V39, P406, DOI 10.3174/ajnr.A5412
   Nanda A, 2003, SURG NEUROL, V59, P184, DOI 10.1016/S0090-3019(03)00021-1
   Scott WW, 2015, J NEUROSURG, V122, P1196, DOI 10.3171/2015.1.JNS14642
   Scott WW, 2015, J NEUROSURG, V122, P610, DOI 10.3171/2014.10.JNS14875
   Sliker CW, 2008, RADIOGRAPHICS, V28, P1689, DOI 10.1148/rg.286085521
   Stager V, 2011, J VASC SURG, V53, P483, DOI 10.1016/j.jvs.2010.08.032
   Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146
   Wahl WL, 2002, J TRAUMA, V52, P896, DOI 10.1097/00005373-200205000-00012
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E385
EP E390
DI 10.1016/j.wneu.2019.09.013
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700093
PM 31521761
OA Bronze
DA 2020-05-12
ER

PT J
AU Chen, C
   Li, ZY
   Gao, Q
   Ling, C
   Li, H
   Wang, H
AF Chen, Chuan
   Li, Zhang-yu
   Gao, Qun
   Ling, Cong
   Li, Hao
   Wang, Hui
TI Complex Internal Carotid Aneurysms Treated by Superficial Temporal
   Artery Trunk-Radial Artery-Middle Cerebral Artery Bypass Combined with
   Balloon Occlusion of Internal Carotid Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balloon occlusion; Bypass; Complex internal carotid aneurysms; Middle
   cerebral artery; Superficial temporal artery trunk
ID GRAFT
AB OBJECTIVE: To evaluate the feasibility to treat complex internal carotid aneurysms by superficial temporal artery trunk-radial artery-middle cerebral artery (STAT-RAMCA) bypass combined with balloon occlusion of internal carotid artery.
   METHODS: Postoperative clinical symptoms, the patency of bridge vessels (radial artery graft [RAG]), STAT and RAG diameters, RAG flow, cerebral blood flow (CBF), and mean transit time (MU) were observed in 14 cases. Their correlations were analyzed.
   RESULTS: Except 1 case, RAG was patent in 13 cases. Glasgow Outcome Scale score was 4 in one case and 5 in 13 cases. In the 13 cases with postoperative RAG patency, the mean diameter of STAT increased from 2.1 mm before operation to 3.0 mm on the first day after operation; the mean diameter of RAG was 3.7 mm on the first day after operation. In 3 of the 13 cases, STAT and RAG diameters further increased to 4.0 mm and 4.7 mm, respectively, 3 months after operation. There was a positive correlation between STAT and RAG diameters (P = 0.0005). The STAT (P < 0.0001, P < 0.0001) and RAG (P < 0.0001, P = 0.0042) diameters were positively correlated with RAG flow and CBF, but the STAT (r(2) = 0.762, P< 0.0001) and RAG (r(2) = 0.54, P = 0.0042) diameters were negatively correlated with MIT.
   CONCLUSIONS: STAT-RA-MCA bypass combined with balloon occlusion of internal carotid artery is feasible for the treatment of complex internal carotid aneurysms.
C1 [Chen, Chuan; Li, Zhang-yu; Gao, Qun; Ling, Cong; Li, Hao; Wang, Hui] Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
RP Wang, H (reprint author), Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
EM doctorwanghui@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571202]; Guangdong Provincial Scientific and
   Technological Funds [2014B090901043]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 81571202) and Guangdong Provincial Scientific and
   Technological Funds (grant no. 2014B090901043).
CR Cantore G, 2008, NEUROSURGERY, V63, P279, DOI 10.1227/01.NEU.0000313122.58694.91
   CLOUGHESY TF, 1993, J CLIN NEUROPHYSIOL, V10, P363, DOI 10.1097/00004691-199307000-00010
   Fiorella D, 2005, NEUROSURGERY, V57, P210, DOI 10.1227/01.NEU.0000163685.23846.DD
   Inoue T, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000163682.31075.28
   IWATA Y, 1988, Microsurgery, V9, P14, DOI 10.1002/micr.1920090105
   Kumar NG, 2017, J NEUROL SCI, V372, P250, DOI 10.1016/j.jns.2016.11.057
   Matsukawa H, 2018, J NEUROSURG, V128, P1753, DOI 10.3171/2016.11.JNS161986
   Matsukawa H, 2017, NEUROSURGERY, V81, P672, DOI 10.1093/neuros/nyx075
   Matsukawa H, 2016, J NEUROSURG, V125, P239, DOI 10.3171/2015.5.JNS142524
   Nussbaum ES, 2019, J NEUROSURG, V130, P1498, DOI 10.3171/2018.1.JNS172466
   Schaller Bernhard, 2008, J Stroke Cerebrovasc Dis, V17, P287, DOI 10.1016/j.jstrokecerebrovasdis.2008.03.010
   van Rooij WJJ, 2000, NEUROSURGERY, V47, P116, DOI 10.1097/00006123-200007000-00025
   Vos PC, 2015, CLIN NEUROL NEUROSUR, V136, P139, DOI 10.1016/j.clineuro.2015.06.019
   Yang K, 2015, WORLD NEUROSURG, V83, P197, DOI 10.1016/j.wneu.2014.06.008
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E89
EP E96
DI 10.1016/j.wneu.2019.08.174
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700012
PM 31479795
OA Bronze
DA 2020-05-12
ER

PT J
AU Chen, H
   Yang, JS
   Zou, P
   Zhao, YT
   Liu, TJ
   Tian, Y
   Ding, KY
   Liu, P
   Zhang, JN
   Hao, DJ
AF Chen, Hao
   Yang, Jun-Song
   Zou, Peng
   Zhao, Yuan-Tin
   Liu, Tuan-Jiang
   Tian, Ye
   Ding, Ke-Yuan
   Liu, Peng
   Zhang, Jia-Nan
   Hao, Ding-Jun
TI Safety and Efficacy of Hydrogen Peroxide in Controlling Blood Loss and
   Surgical Site Infection After Multisegmental Lumbar Spine Surgery: A
   Retrospective, Case-Controlled Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood loss; Complications; Hydrogen peroxide; Lumbar surgery; Surgical
   site infection
ID RISK-FACTORS; IRRIGATION; EMBOLISM; PNEUMOCEPHALUS; OXYGENATION;
   PROPHYLAXIS; POWDER
AB OBJECTIVE: To explore the safety and efficacy of hydrogen peroxide H2O2 in controlling blood loss and surgical site infection (SSI) after multisegmental lumbar spine surgery.
   METHODS: A total of 2626 patients who had undergone multisegmental lumbar spinal surgery from January 2015 to January 2018 were included in the present study. Stratified by the use of H2O2 irrigation, they were divided into 2 groups: the control group (n = 1345) and the experimental group (n = 1281). The demographic parameters, laboratory examination results, and surgery-related information (e.g., operative time, number of operated levels, intraoperative blood loss, postoperative drainage, postoperative SSI, extubation time), and perioperative complications were recorded.
   RESULTS: No significant differences were seen regarding the demographic parameters, laboratory examination results, comorbidities, and surgery-related information. The extubation time and postoperative drainage collection were lower in the experimental group (3.6 +/- 0.5 vs. 4.1 +/- 0.6 days, P = 0.402; 251.8 +/- 67.5 vs. 291.8 +/- 71.3 ml, P = 0.013). In the control group, the rate of SSI was 2.4% (32 of 1345) and included 17 superficial wound infections and 15 deep wound infections. In the experimental group, the SSI rate was 1.4% (18 of 1281; 15 with a superficial wound infection and 3 with a deep wound infection). Staphylococcus aureus was the most common organism, especially in the experimental group (66.7% vs. 50%). No statistically significant difference was found between the 2 groups in the perioperative complications, including hematencephalon, deep vein thrombosis, pulmonary embolism, and myocardial infarction (P > 0.05). Pneumocephalus was not observed in either group.
   CONCLUSION: The application of H2O2 in posterior lumbar interbody fusion can reduce the blood loss and incidence of SSI after surgery and was quite beneficial for controlling the increasing number of vancomycin-resistant bacteria.
C1 [Chen, Hao; Yang, Jun-Song; Zou, Peng; Zhao, Yuan-Tin; Liu, Tuan-Jiang; Tian, Ye; Ding, Ke-Yuan; Liu, Peng; Zhang, Jia-Nan; Hao, Ding-Jun] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
   [Chen, Hao; Zou, Peng] Xian Med Univ, Grad Sch, Xian, Shaanxi, Peoples R China.
RP Hao, DJ (reprint author), Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
EM dingjun.hao@qq.com
OI chen, hao/0000-0002-7122-9027; liu, peng/0000-0003-3453-2278
FU Chinese National Natural Science FoundationNational Natural Science
   Foundation of China
FX We thank the Chinese National Natural Science Foundation for providing
   the grant in support of our study.
CR Altun H, 2018, TURK ARCH OTORHINOL, V56, P193, DOI 10.5152/tao.2018.2003
   AWAD JA, 1969, J SURG RES, V9, P487, DOI 10.1016/0022-4804(69)90123-1
   BAILLAT X, 1970, J PHYSIOL-PARIS, V62, P116
   BANNISTER GC, 1990, J BONE JOINT SURG BR, V72, P444
   Cheriyan T, 2015, SPINE J, V15, P752, DOI 10.1016/j.spinee.2015.01.013
   Chhabra R, 2000, BRIT J NEUROSURG, V14, P549
   Dagi TF, 2005, SURG CLIN N AM, V85, P1191, DOI 10.1016/j.suc.2005.10.013
   Despond O, 1997, CAN J ANAESTH, V44, P410, DOI 10.1007/BF03014463
   Eder C, 2016, EUR SPINE J, V25, P1021, DOI 10.1007/s00586-015-3943-9
   Fang A, 2005, SPINE, V30, P1460, DOI 10.1097/01.brs.0000166532.58227.4f
   Gande A, 2019, SPINE J, V19, P1076, DOI 10.1016/j.spinee.2019.01.002
   Ghobrial GM, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15258
   Hanssen AD, 2005, CLIN ORTHOP RELAT R, P111, DOI 10.1097/01.blo.0000175122.50804.ce
   Hey HWD, 2017, SPINE, V42, P267, DOI 10.1097/BRS.0000000000001710
   Ho C, 2007, SPINE, V32, P2272, DOI 10.1097/BRS.0b013e31814b1c0b
   Kanayama M, 2007, J NEUROSURG-SPINE, V6, P327, DOI 10.3171/spi.2007.6.4.7
   Kleffmann J, 2015, SPINE J, V15, pE5, DOI 10.1016/j.spinee.2014.12.006
   Klekamp J, 1999, J SPINAL DISORD, V12, P187
   Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763
   Lu Min, 2017, J Bone Jt Infect, V2, P3, DOI 10.7150/jbji.16690
   McLeod LM, 2013, SPINE, V38, P609, DOI 10.1097/BRS.0b013e318289b690
   Miller WR, 2016, INFECT DIS CLIN N AM, V30, P415, DOI 10.1016/j.idc.2016.02.006
   MORIKAWA H, 1995, CAN J ANAESTH, V42, P231, DOI 10.1007/BF03010684
   Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119
   Ohlin A, 2018, EUR SPINE J, V27, P2463, DOI 10.1007/s00586-018-5619-8
   Owens CD, 2008, J HOSP INFECT, V70, P3, DOI 10.1016/S0195-6701(08)60017-1
   Patankar PS, 2014, BRIT J NEUROSURG, V28, P556, DOI 10.3109/02688697.2013.865706
   Sweet FA, 2011, SPINE, V36, P2084, DOI 10.1097/BRS.0b013e3181ff2cb1
   TATNALL F M, 1990, Skin Pharmacology, V3, P157
   Tubaki VR, 2013, SPINE, V38, P2149, DOI 10.1097/BRS.0000000000000015
   Ulivieri S, 2011, ARCH ORTHOP TRAUM SU, V131, P1203, DOI 10.1007/s00402-011-1262-0
   Yao RN, 2018, J CLIN NEUROSCI, V52, P5, DOI 10.1016/j.jocn.2018.03.023
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E303
EP E307
DI 10.1016/j.wneu.2019.09.005
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700084
PM 31520754
OA Bronze
DA 2020-05-12
ER

PT J
AU Chung, KS
   Chang, WS
   Chang, JH
   Lee, SC
   Chang, JW
   Park, YG
   Jung, HH
AF Chung, Kyu Seon
   Chang, Won Seok
   Chang, Jong Hee
   Lee, Sung Chul
   Chang, Jin Woo
   Park, Yong Gou
   Jung, Hyun Ho
TI Gamma Knife Radiosurgery for Choroidal Hemangioma: A Single-Institute
   Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Choroidal hemangioma; Circumscribed type; Diffuse type with Sturge-Weber
   syndrome; Gamma knife radiosurgery
ID THERAPY
AB OBJECTIVE: Choroidal hemangioma (CH) is a benign vascular tumor that induces subretinal fluid collection or exudative retinal detachment and consequent visual symptoms. Current standard treatments for CH include cryotherapy, diathermy, photocoagulation, photodynamic therapy, transpupillary thermotherapy, and radiation therapy. Stereotactic radiosurgery has recently been applied to the treatment of CH because of its characteristic stiff dose-fall-off and accuracy. We have adopted gamma knife radiosurgery (GKRS) to treat CH and have retrospectively assessed tumor volume reductions and improvements to visual acuity achieved thereby.
   METHODS: Fourteen patients with CHs were treated with GKRS from November 2006 to December 2017. Eight patients had circumscribed CH, and 6 exhibited diffuse CHs and were diagnosed with Sturge-Weber syndrome. The mean age of patients was 27.1 years (range: 8-68 years) and the mean duration of clinical or radiological follow-up was 40.2 months (range: 5-105 months). The mean volume of the tumors at the time of GKRS was 533.5 mm(3) (range: 124-1150 mm(3)), and the mean prescribed marginal dose was 11.6 Gy (range: 10-16 Gy) with 50% isodose lines.
   RESULTS: The tumor volume decreased by the last follow-up in all patients. The visual acuity improved in 9 patients (64%) and decreased in 1 (7%). Six patients (43%) required trans-pars plana vitrectomy before or after GKRS. There were no symptomatic complications from radiation injury during the follow-up periods.
   CONCLUSIONS: GKRS could be an acceptable alternative treatment for symptomatic CH when standard therapy is not feasible.
C1 [Chung, Kyu Seon; Chang, Won Seok; Chang, Jong Hee; Chang, Jin Woo; Park, Yong Gou; Jung, Hyun Ho] Yonsei Univ, Severance Hosp, Coll Med, Dept Neurosurg,Brain Res Inst, Seoul, South Korea.
   [Lee, Sung Chul] Yonsei Univ, Severance Hosp, Coll Med, Dept Ophthalmol,Inst Vis Res, Seoul, South Korea.
RP Jung, HH (reprint author), Yonsei Univ, Severance Hosp, Coll Med, Dept Neurosurg,Brain Res Inst, Seoul, South Korea.
EM JUNGHH@yuhs.ac
OI Chang, Jong Hee/0000-0003-1509-9800; Chang, Won
   Seok/0000-0003-3145-4016; Jung, Hyun Ho/0000-0002-8289-564X; , Sung
   Chul/0000-0001-9438-2385; Chang, Jin Woo/0000-0002-2717-0101
CR Arnett ALH, 2017, STEREOT FUNCT NEUROS, V95, P363, DOI 10.1159/000478271
   Karimi Saeed, 2015, J Ophthalmic Vis Res, V10, P320, DOI 10.4103/2008-322X.170353
   Kim YT, 2011, INT J RADIAT ONCOL, V81, P1399, DOI 10.1016/j.ijrobp.2010.08.016
   Kong DS, 2007, AM J OPHTHALMOL, V144, P319, DOI 10.1016/j.ajo.2007.03.052
   Levy-Gabriel C, 2009, RETINA-J RET VIT DIS, V29, P170, DOI 10.1097/IAE.0b013e31818bccfb
   Mahdjoubi A, 2019, RETINA-J RET VIT DIS, V39, P692, DOI 10.1097/IAE.0000000000002002
   Medena CA, 2013, RETINAL PHYS, V10, P32
   Milano MT, 2018, INT J RADIAT ONCOL, P1
   Nam TK, 2005, ACTA NEUROCHIR, V147, P651, DOI 10.1007/s00701-005-0499-1
   Queiros L, 2016, RETIN TODAY, V11, P38
   Ramasubramanian A, 2010, RETIN TODAY, V1, P52
   Randon M, 2018, EYE, V32, P1067, DOI 10.1038/s41433-018-0024-4
   Ritland JS, 2001, ACTA OPHTHALMOL SCAN, V79, P184, DOI 10.1034/j.1600-0420.2001.079002184.x
   Song WK, 2009, BRIT J OPHTHALMOL, V93, P836, DOI 10.1136/bjo.2008.151316
   Zeisberg A, 2014, GRAEF ARCH CLIN EXP, V252, P1165, DOI 10.1007/s00417-014-2635-1
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E129
EP E134
DI 10.1016/j.wneu.2019.08.138
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700017
PM 31476453
OA Bronze
DA 2020-05-12
ER

PT J
AU Claus, CF
   Lytle, E
   Kaufmann, A
   Tong, D
   Bahoura, M
   Garmo, L
   Richards, B
   Soo, TM
   Houseman, C
AF Claus, Chad F.
   Lytle, Evan
   Kaufmann, Ascher
   Tong, Doris
   Bahoura, Matthew
   Garmo, Lucas
   Richards, Boyd
   Soo, Teck M.
   Houseman, Clifford
TI Minimally Invasive Sacroiliac Joint Fusion Using Triangular Titanium
   versus Cylindrical Threaded Implants: A Comparison of Patient-Reported
   Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arthrodesis; Cylindrical threaded implant; Minimally invasive surgery;
   Sacroiliac joint; SI joint fusion; Triangular titanium implant
ID RANDOMIZED CONTROLLED-TRIAL; LUMBOSACRAL FUSION; PAIN; ARTHRODESIS;
   MANAGEMENT; LUMBAR
AB BACKGROUND: Minimally invasive fusion of the sacroiliac (SI) joint has gained popularity for the treatment of refractory dysfunction. The purpose of this study was to compare the clinical outcomes of minimally invasive SI joint fusion between cylindrical threaded implants (CTIs) and triangular dowel implants (TDIs).
   METHODS: We retrospectively reviewed consecutive patients who underwent SI joint fusions with either CTIs or TDIs. Data collected included patient demographics, peri-operative data, and all patient-reported outcomes (PROs) including postoperative visual analog scale (VAS), Oswestry Disability Index, and Short Form-12 at 6 months and 1 year. The change from baseline PROs between the cohorts was analyzed as the primary outcome. Secondary outcomes included revision rates and time to revision between the two cohorts. A P value <0.05 was considered significant.
   RESULTS: One hundred fifty-six consecutive patients underwent SI joint fusion, 74 patients with CTIs and 82 with TDIs. There was a significant difference in procedure length with CTI averaging 60.0 minutes (confidence interval: 55.7-64.3) and TDI averaging 41.2 minutes (confidence interval: 38.4-43.9, P< 0.0005). In both cohorts, there was a significant improvement in all PROs at 6 months when compared with preoperative values. However, when compared, there was no significant difference between the cohorts at 6-month follow-up or 1-year follow-up for either VAS-back, VAS-leg, Oswestry Disability Index, or Short Form-12. A 6.1% revision rate in the CTI cohort was observed compared with a 2.4% revision rate in the TDI cohort (P = 0.11).
   CONCLUSIONS: SI joint fusions with TDI or CTI offer a significant improvement in pain, disability, and quality of life. However, no difference was observed between devices to suggest superior clinical outcomes. Increased revision rates in the Rialto group warrants further investigation.
C1 [Claus, Chad F.; Lytle, Evan; Kaufmann, Ascher; Tong, Doris; Bahoura, Matthew; Garmo, Lucas; Richards, Boyd; Soo, Teck M.; Houseman, Clifford] Michigan State Univ, Ascens Providence Hosp, Div Neurosurg, Coll Human Med, Southfield, MI 48075 USA.
RP Claus, CF (reprint author), Michigan State Univ, Ascens Providence Hosp, Div Neurosurg, Coll Human Med, Southfield, MI 48075 USA.
EM chadfclaus@gmail.com
OI Claus, Chad/0000-0002-2523-8811
CR Abbasi H, 2017, CUREUS, V9, DOI 10.7759/cureus.1787
   Beck CE, 2015, CUREUS, V7, DOI 10.7759/cureus.260
   Bruna-Rosso C, 2016, INT J SPINE SURG, V10, DOI 10.14444/3016
   Buchowski Jacob M, 2005, Spine J, V5, P520, DOI 10.1016/j.spinee.2005.02.022
   Cher D, 2014, MED DEVICES-EVID RES, V7, P73, DOI 10.2147/MDER.S59437
   Cher DJ, 2016, CLINICOECONOMIC OUTC, V8, P1, DOI 10.2147/CEOR.S94266
   Christen P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5855
   Cleveland Andrew W 3rd, 2019, J Spine Surg, V5, P31, DOI 10.21037/jss.2019.01.04
   Cross William W, 2018, Open Orthop J, V12, P7, DOI 10.2174/1874325001812010007
   Darr E, 2018, MED DEVICES-EVID RES, V11, P113, DOI 10.2147/MDER.S160989
   Dengler J, 2017, PAIN PHYSICIAN, V20, P537
   Duhon BS, 2016, INT J SPINE SURG, V10, DOI 10.14444/3013
   Ha KY, 2008, SPINE, V33, P1192, DOI 10.1097/BRS.0b013e318170fd35
   Heiney J, 2015, INT J SPINE SURG, V9, DOI 10.14444/2040
   Kancherla VK, 2017, ASIAN SPINE J, V11, P120, DOI 10.4184/asj.2017.11.1.120
   KRAEMER W, 1994, INJURY, V25, P5, DOI 10.1016/0020-1383(94)90176-7
   Kube Richard A, 2016, Open Orthop J, V10, P679, DOI 10.2174/1874325001610010679
   Lee DJ, 2016, J BIOMED RES, V30, P162, DOI 10.7555/JBR.30.20150090
   Li ZH, 2015, BONE, V81, P468, DOI 10.1016/j.bone.2015.08.017
   Liliang PC, 2011, PAIN MED, V12, P565, DOI 10.1111/j.1526-4637.2011.01087.x
   Lindsey DP, 2018, WORLD J ORTHOP, V9, P14, DOI 10.5312/wjo.v9.i3.14
   Mason LW, 2013, EUR SPINE J, V22, P2325, DOI 10.1007/s00586-013-2825-2
   Parker SL, 2012, J NEUROSURG-SPINE, V16, P61, DOI 10.3171/2011.8.SPINE1194
   Polly DW, 2015, NEUROSURGERY, V77, P674, DOI 10.1227/NEU.0000000000000988
   Rajpal S, 2019, WORLD NEUROSURG, V122, pE1588, DOI 10.1016/j.wneu.2018.11.116
   Rappoport LH, 2017, WORLD NEUROSURG, V101, P493, DOI 10.1016/j.wneu.2017.02.046
   Rudolf Leonard, 2014, Open Orthop J, V8, P375, DOI 10.2174/1874325001408010375
   Sachs D, 2016, MED DEVICES-EVID RES, V9, P213, DOI 10.2147/MDER.S109276
   Sachs D, 2014, MED DEVICES-EVID RES, V7, P299, DOI 10.2147/MDER.S56491
   Schoell K, 2016, SPINE J, V16, P1324, DOI 10.1016/j.spinee.2016.06.016
   Smith-Petersen MN, 1921, J BONE JT SURG, V3, P400
   Sturesson B, 2017, EUR SPINE J, V26, P708, DOI 10.1007/s00586-016-4599-9
   WAISBROD H, 1987, ARCH ORTHOP TRAUM SU, V106, P238, DOI 10.1007/BF00450461
   Whang P, 2015, INT J SPINE SURG, V9, DOI 10.14444/2006
   Wise CL, 2008, J SPINAL DISORD TECH, V21, P579, DOI 10.1097/BSD.0b013e31815ecc4b
   Tran ZV, 2019, PAIN PHYSICIAN, V22, P29
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E745
EP E750
DI 10.1016/j.wneu.2019.09.150
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700141
PM 31605853
OA Bronze
DA 2020-05-12
ER

PT J
AU Darrow, D
   Lee-Norris, A
   Larson, A
   Samadani, U
   Netoff, TI
AF Darrow, David
   Lee-Norris, Alex
   Larson, Anthony
   Samadani, Uzma
   Netoff, Theoden, I
TI Discrepancy Between Internal and External Intracranial Pressure
   Transducers: Quantification of an Old Source of Error in EVDs?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Accuracy; External ventricular drain; ICP; Intracranial pressure;
   Neurocritical care; Pressure transducer; Traumatic brain injury
ID CLINICAL-EVALUATION; IMPACT
AB BACKGROUND: Intracranial pressure monitoring remains the foundation for prevention of secondary injury after traumatic brain injury and is most commonly performed using an external ventricular drain or intraparenchymal pressure monitor. The Integra Flex ventricular catheter combines an external ventricular catheter with a pressure transducer embedded in the tip of the catheter to allow continuous pressure readings while simultaneously draining cerebrospinal fluid. Discrepancies between measurements from the continuously reported internal pressure transducer and intermittently assessed and externally transduced ventricular drain prompted an analysis and characterization of pressures transduced from the same ventricular source.
   METHODS: More than 500 hours of high-resolution (125 Hz) continuous recordings were manually reviewed to identify 73 hours of simultaneous measurements (clamped external ventricular drain) from internal and external transducers in patients with traumatic brain injury.
   RESULTS: A significant positive bias was found in pressure readings obtained from external relative to internal measurements. The 2 methods of measurement generally correlated poorly with each other and variably. Although proportional bias was found with Bland-Altman analysis, coherence revealed rare shifts in the external transducer as a major source of discrepancy. Infrequent changes in the 0-level of the external transducer were found to be the primary source of discrepancy. Relative to the observed differences, no significant trend was observed over time between the 2 modalities.
   CONCLUSIONS: This study suggests that the internal pressure transducer may be a more reliable estimate of intracranial pressure relative to bedside external transducers due to the inherent behavioral requirement of leveling.
C1 [Darrow, David] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
   [Lee-Norris, Alex] Midwestern Univ, Sch Med, Downers Grove, IL 60515 USA.
   [Larson, Anthony] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
   [Samadani, Uzma] Hennepin Cty Med Ctr, Dept Neurosurg, Minneapolis, MN 55415 USA.
   [Netoff, Theoden, I] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN USA.
RP Darrow, D (reprint author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
EM darro015@umn.edu
OI Netoff, Theoden/0000-0002-0115-1930
CR Aiolfi A, 2018, J NEUROSURG, V128, P828, DOI 10.3171/2016.11.JNS162198
   BARLOW P, 1985, J NEUROSURG, V63, P578, DOI 10.3171/jns.1985.63.4.0578
   Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363
   CZECH T, 1993, ACTA NEUROCHIR, V125, P169, DOI 10.1007/BF01401846
   Eide PK, 2006, MED ENG PHYS, V28, P542, DOI 10.1016/j.medengphy.2005.09.003
   GUILLAUME J, 1951, REV NEUROL, V84, P131
   Hawthorne C, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00121
   Kim N, 2016, J CLIN MONIT COMPUT, V30, P821, DOI 10.1007/s10877-015-9779-3
   Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292
   LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581
   MacLaughlin BW, 2015, AM J SURG, V210, P1082, DOI 10.1016/j.amjsurg.2015.08.007
   MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59
   MENDELOW AD, 1983, J NEUROSURG, V58, P45, DOI 10.3171/jns.1983.58.1.0045
   Morgalla MH, 1999, J MED ENG TECHNOL, V23, P10, DOI 10.1080/030919099294375
   Todd SR, 2015, AM J SURG, V210, P1086
   Zhong J, 2003, NEUROL RES, V25, P339, DOI 10.1179/016164103101201661
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E18
EP E25
DI 10.1016/j.wneu.2019.07.213
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700005
PM 31394360
OA Bronze
DA 2020-05-12
ER

PT J
AU Deng, XY
   Li, JH
   Ke, DB
   Liu, LH
   Ma, JP
   Cheng, J
   Hui, XH
AF Deng, Xueyun
   Li, Jiuhong
   Ke, Daibo
   Liu, Lihua
   Ma, Junpeng
   Cheng, Jian
   Hui, Xuhui
TI Mixed Signal Intensity on Preoperative T1 MRI Might be Associated with
   Delayed Postoperative Hemorrhage in Patients with Intracranial
   Epidermoid Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed postoperative hemorrhage; Intracranial epidermoid cyst; Mixed
   signal intensity; Surgery
ID TUMOR; FEATURES
AB OBJECTIVE: Delayed postoperative hemorrhage (DPOH) was a severe postoperative complication after intracranial epidermoid cyst (EC) surgery. This study was designed to investigate possible clinical data and image features related to DPOH in patients with EC.
   METHODS: We retrospectively investigated 186 cases of EC, and 8 cases presented an appearance of DPOH. Preoperative magnetic resonance imaging (MRI) and clinical data (age, sex, chief surgeon, tumor size, tumor location, and degree of resection) were reviewed and analyzed. The Student t test and the chi(2) test were used, and statistical significance was defined as P < 0.05.
   RESULTS: A total of 8 patients suffered from DPOH. Seven patients (87.5%) with DPOH showed atypical mixed signal intensity on preoperative T1 MRI compared with typical low intensity in another DPOH case. Only 1 case of mixed signal intensity on T1 MRI was found in 178 patients without DPOH. The mixed signal intensity on preoperative T1 MRI was highly related to DPOH and mortality (both P < 0.001). There was no significant difference in other relative clinical data between patients with or without DPOH.
   CONCLUSIONS: Mixed signal intensity on preoperative T1 MRI might be associated with DPOH in patients with EC. The surgeon should pay more attention to this rarely atypical imaging before surgery. Further observations are necessary to illustrate the relationship between mixed signal intensity and DPOH in EC and to guide reasonable therapy.
C1 [Deng, Xueyun; Li, Jiuhong; Ke, Daibo; Ma, Junpeng; Cheng, Jian; Hui, Xuhui] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Deng, Xueyun] North Sichuan Med Coll, Clin Med Coll 2, Nanchong Cent Hosp, Dept Neurosurg, Nanchong, Sichuan, Peoples R China.
   [Liu, Lihua] North Sichuan Med Coll, Clin Med Coll 2, Nanchong Cent Hosp, Dept Geriatr Med, Nanchong, Sichuan, Peoples R China.
RP Hui, XH (reprint author), Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM huixuhuiwch@126.com
OI Li, Jiuhong/0000-0001-9115-7246
CR AHMAD I, 1992, SURG NEUROL, V38, P341, DOI 10.1016/0090-3019(92)90019-J
   Aribandi M, 2008, Br J Radiol, V81, pe97, DOI 10.1259/bjr/42146967
   Chen CY, 2006, AM J NEURORADIOL, V27, P427
   DESOUZA CE, 1989, J NEUROL NEUROSUR PS, V52, P986, DOI 10.1136/jnnp.52.8.986
   Ecker RD, 2003, NEUROSURGERY, V52, P706, DOI 10.1227/01.NEU.0000048482.27700.3B
   GAO PY, 1992, AM J NEURORADIOL, V13, P863
   Gerlach R, 2004, NEUROL RES, V26, P61, DOI 10.1179/016164104773026543
   HASEGAWA H, 1981, SURG NEUROL, V15, P372, DOI 10.1016/0090-3019(81)90174-9
   Inoue Y, 2001, J NEUROSURG, V95, P902, DOI 10.3171/jns.2001.95.5.0902
   KALFAS IH, 1988, NEUROSURGERY, V23, P343, DOI 10.1227/00006123-198809000-00010
   Kallmes DF, 1997, AM J ROENTGENOL, V169, P883, DOI 10.2214/ajr.169.3.9275916
   Kumari R, 2009, NEUROL INDIA, V57, P359, DOI 10.4103/0028-3886.53266
   Link MJ, 2002, J NEUROSURG, V97, P1237, DOI 10.3171/jns.2002.97.5.1237
   Mohanty A, 1997, NEUROSURGERY, V40, P24, DOI 10.1097/00006123-199701000-00004
   Ren XH, 2017, WORLD NEUROSURG, V103, P484, DOI 10.1016/j.wneu.2017.04.027
   Ren XH, 2011, J NEUROSURG, V114, P1592, DOI 10.3171/2010.12.JNS10325
   Ren XH, 2012, J NEUROSURG, V116, P611, DOI 10.3171/2011.10.JNS111462
   Sirin S, 2005, CLIN NEUROL NEUROSUR, V107, P461, DOI 10.1016/j.clineuro.2004.11.007
   Talacchi A, 1998, NEUROSURGERY, V42, P242, DOI 10.1097/00006123-199802000-00020
   TAMPIERI D, 1989, AM J NEURORADIOL, V10, P351
NR 20
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E218
EP E224
DI 10.1016/j.wneu.2019.08.207
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700028
PM 31493609
OA Bronze
DA 2020-05-12
ER

PT J
AU Di Ieva, A
   Magnussen, JS
   McIntosh, J
   Mulcahy, MJ
   Pardey, M
   Choi, CH
AF Di Ieva, Antonio
   Magnussen, John S.
   McIntosh, Jeffery
   Mulcahy, Michael J.
   Pardey, Margery
   Choi, Changho
TI Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase
   Status in Gliomas: The New Frontiers of Spectrobiopsy in
   Neurodiagnostics
SO WORLD NEUROSURGERY
LA English
DT Article
DE 2HG; 2-Hydroxyglutarate; Glioma; Magnetic resonance spectroscopy; MRS;
   Neuroimaging
ID ONCOMETABOLITE 2-HYDROXYGLUTARATE; NONINVASIVE DETECTION; MR
   SPECTROSCOPY; IDH1 MUTATION; BRAIN; GLIOBLASTOMA; METABOLITES
AB BACKGROUND: In the era of integrated genomic-histologic analysis of brain tumors, new biomarkers have been introduced as diagnostic, prognostic, and therapeutic indicators. The analysis of the mutation in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 has provided important diagnostic and prognostic information for patients affected by diffuse glioma (i.e., the presence of the mutation has been related to an increased survival rate). The reference standard of IDH mutation detection has been its assessment in surgical specimens, immunohistochemistry, and/or genetic sequencing. Knowing the IDH status information preoperatively would be of great importance, because it has been related to tumor progression and the response to treatment. The oncometabolite 2-hydroxyglutarate (2HG), accumulated in gliomas with IDH mutation status, can be detected in vivo using magnetic resonance spectroscopy (MRS).
   METHODS: The 2HG-MRS technique remains technically challenging. We have summarized the results of the first pilot study in Australia, which included 10 patients affected by glioma. The data recorded from May 2017 to November 2018 were analyzed.
   RESULTS: In our exploratory study, we reached a sensitivity and specificity of 100%, confirming the strong predictive role of 2HG, as detected using MRS, in the diagnosis of glioma.
   CONCLUSION: In the present study, we have focused on methodological tips and future perspectives of the technique in the neuroimaging and neuro-oncological scenario. We would advocate the integration of 2HG-MRS into standard clinical practice.
C1 [Di Ieva, Antonio; Mulcahy, Michael J.] Macquarie Univ, Neurosurg Unit, Dept Clin Med, Fac Med & Hlth Sci, Sydney, NSW, Australia.
   [Di Ieva, Antonio; Magnussen, John S.] Macquarie Univ, Fac Med & Hlth Sci, Dept Clin Med, Computat NeuroSurg Lab, Sydney, NSW, Australia.
   [Magnussen, John S.; McIntosh, Jeffery; Pardey, Margery] Macquarie Univ Hosp, Macquarie Med Imaging, Sydney, NSW, Australia.
   [Choi, Changho] Univ Texas Southwestern Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA.
RP Di Ieva, A (reprint author), Macquarie Univ, Neurosurg Unit, Dept Clin Med, Fac Med & Hlth Sci, Sydney, NSW, Australia.; Di Ieva, A (reprint author), Macquarie Univ, Fac Med & Hlth Sci, Dept Clin Med, Computat NeuroSurg Lab, Sydney, NSW, Australia.
EM antonio.diieva@mq.edu.au
OI Di Ieva, Antonio/0000-0002-5341-5416; Pardey,
   Margery/0000-0002-5675-7606
CR An ZX, 2019, MAGN RESON MED, V81, P795, DOI 10.1002/mrm.27482
   An ZX, 2018, MAGN RESON MED, V79, P1851, DOI 10.1002/mrm.26884
   Andronesi OC, 2016, CLIN CANCER RES, V22, P1632, DOI 10.1158/1078-0432.CCR-15-0656
   Andronesi OC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002693
   Berrington A, 2018, NMR BIOMED, V31, DOI 10.1002/nbm.3886
   Bisdas S, 2016, J MAGN RESON IMAGING, V44, P823, DOI 10.1002/jmri.25221
   Branzoli F, 2018, NEURO-ONCOLOGY, V20, P907, DOI 10.1093/neuonc/nox214
   Chang K, 2018, CLIN CANCER RES, V24, P1073, DOI 10.1158/1078-0432.CCR-17-2236
   Choi CH, 2013, NMR BIOMED, V26, P1242, DOI 10.1002/nbm.2943
   Choi C, 2012, NAT MED, V18, P624, DOI 10.1038/nm.2682
   Crisi G, 2018, J COMPUT ASSIST TOMO, V42, P469, DOI 10.1097/RCT.0000000000000705
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   de la Fuente MI, 2016, NEURO-ONCOLOGY, V18, P283, DOI 10.1093/neuonc/nov307
   Di Ieva A, 2018, MACQUARIE U HOSP NEW
   Di Ieva A, 2018, NEURORADIOLOGY, V60, P129, DOI 10.1007/s00234-017-1957-1
   DiIeva A, 2016, SPR SER COMPUT NEURO, P1, DOI 10.1007/978-1-4939-3995-4
   Elkhaled A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002796
   Ganji SK, 2017, MAGN RESON MED, V77, P936, DOI 10.1002/mrm.26190
   Kalinina J, 2012, J MOL MED, V90, P1161, DOI 10.1007/s00109-012-0888-x
   Louis NL, 2016, WHO CLASSIFICATION T
   Maldonado MD, 2018, J NEURO-ONCOL, V140, P107, DOI 10.1007/s11060-018-2939-9
   McGirt MJ, 2005, J NEUROSURG, V102, P897, DOI 10.3171/jns.2005.102.5.0897
   Natsumeda M, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0158-y
   Paldor I, 2016, J CLIN NEUROSCI, V34, P128, DOI 10.1016/j.jocn.2016.05.017
   Paldor I, 2016, J CLIN NEUROSCI, V34, P117, DOI 10.1016/j.jocn.2016.05.016
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Pope WB, 2012, J NEURO-ONCOL, V107, P197, DOI 10.1007/s11060-011-0737-8
   PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604
   Pusch S, 2017, ACTA NEUROPATHOL, V133, P629, DOI 10.1007/s00401-017-1677-y
   Shen X, 2019, METABOLITES, V9, DOI 10.3390/metabo9020035
   Suh CH, 2018, NEURO-ONCOLOGY, V20, P1573, DOI 10.1093/neuonc/noy113
   Tietze A, 2018, J NEUROSURG, V128, P391, DOI 10.3171/2016.10.JNS161793
   Tong ZY, 2004, MAGN RESON IMAGING, V22, P1017, DOI 10.1016/j.mri.2004.02.007
   Tugnoli V, 2001, BIOPOLYMERS, V62, P297, DOI 10.1002/bip.10005
   Verma G, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1035-1
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Yu JH, 2017, EUR RADIOL, V27, P3509, DOI 10.1007/s00330-016-4653-3
   Zhou M, 2018, NEURO-ONCOLOGY, V20, P1262, DOI 10.1093/neuonc/noy022
NR 38
TC 4
Z9 4
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E421
EP E427
DI 10.1016/j.wneu.2019.09.040
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700098
PM 31526886
OA Bronze
DA 2020-05-12
ER

PT J
AU Du, YQ
   Qiao, GY
   Yin, YH
   Li, T
   Tong, HY
   Yu, XG
AF Du, Yue-Qi
   Qiao, Guang-Yu
   Yin, Yi-Heng
   Li, Teng
   Tong, Huai-Yu
   Yu, Xin-Guang
TI Usefulness of 3D Printed Models in the Management of Complex
   Craniovertebral Junction Anomalies: Choice of Treatment Strategy, Design
   of Screw Trajectory, and Protection of Vertebral Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printed model; Atlantoaxial dislocation; Basilar invagination;
   Craniovertebral junction anomaly; Posterior reduction
ID FIXED ATLANTOAXIAL DISLOCATION; FACET JOINT RELEASE; BASILAR
   INVAGINATION; POSTERIOR REDUCTION; 3-DIMENSIONAL MODELS;
   CLINICAL-APPLICATION; LATERAL MASS; FIXATION; DISTRACTION; COMPLICATIONS
AB OBJECTIVE: To evaluate the usefulness of 3-dimensional (3D) printed models as an aid for the treatment of complex CVJ anomalies.
   METHODS: 3D printed models were fabricated for 21 patients with complex CVJ anomalies, including vertebral artery anomaly, thin C2 pedicle, vertical atlantoaxial facet joint, or rotational dislocation combined with atlantoaxial dislocation and basilar invagination. Preoperative planning, surgical simulation, and intraoperative reference were achieved using the 3D model during the surgical treatment. The usefulness of 3D printed models, and postoperative clinical and radiological outcomes were assessed.
   RESULTS: Direct posterior reduction and atlantoaxial fixation were achieved in 19 patients. Transoral odontoidectomy followed by posterior fixation was implemented for 2 patients with vertical facet joint and rotational dislocation. All screws were safely inserted with no complication, and 90% patients achieved a >60% reduction of both horizontal and vertical dislocation. Clinical symptoms improved in all patients, with the averaged Japanese Orthopedic Association scores increasing from 11.14 to 14.43 (P < 0.01).
   CONCLUSIONS: The patient-specific 3D printed model would be an effective tool for evaluation of the reducibility of the atlantoaxial dislocation and basilar invagination, decision making in choosing the optimal surgical approach and way of fixation, and precise placement of the screw while protecting the vertebral artery and spinal cord. The risk of neurovascular injury was minimized, and encouraging outcomes were achieved with the aid of this technique.
C1 [Du, Yue-Qi; Qiao, Guang-Yu; Yin, Yi-Heng; Li, Teng; Tong, Huai-Yu; Yu, Xin-Guang] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Yin, YH (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM yihengyin@aliyun.com
CR Bransford RJ, 2012, SPINE J, V12, P231, DOI 10.1016/j.spinee.2012.02.011
   Chandra PS, 2017, NEUROSURGERY, V80, pE231, DOI 10.1093/neuros/nyw116
   Chandra PS, 2016, NEUROSURGERY, V78, P400
   Chandra PS, 2015, NEUROSURGERY, V77, P67, DOI 10.1227/NEU.0000000000000737
   Chandra PS, 2013, NEUROSURGERY, V72, P1040, DOI 10.1227/NEU.0b013e31828bf342
   Derman PB, 2016, SPINE, V41, P1586, DOI 10.1097/BRS.0000000000001603
   Duan SY, 2010, SURG RADIOL ANAT, V32, P39, DOI 10.1007/s00276-009-0552-5
   Gao FY, 2017, J NEUROSURG-SPINE, V27, P29, DOI 10.3171/2016.11.SPINE16713
   Goel A, 2004, J NEUROSURG-SPINE, V1, P281, DOI 10.3171/spi.2004.1.3.0281
   Goel A, 2016, J NEUROSURG-SPINE, V25, P740, DOI 10.3171/2016.4.SPINE151268
   GREENBERG AD, 1968, BRAIN, V91, P655, DOI 10.1093/brain/91.4.655
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Jian FZ, 2010, NEUROSURGERY, V66, P678, DOI 10.1227/01.NEU.0000367632.45384.5A
   Kaneyama S, 2014, J NEUROSURG-SPINE, V21, P231, DOI 10.3171/2014.3.SPINE13730
   Mao KY, 2010, EUR SPINE J, V19, P797, DOI 10.1007/s00586-010-1359-0
   Mizutani J, 2008, EUR SPINE J, V17, P644, DOI 10.1007/s00586-008-0611-3
   Mueller CA, 2010, EUR SPINE J, V19, P809, DOI 10.1007/s00586-010-1291-3
   Ohya J, 2015, WORLD NEUROSURG, V83, P603, DOI 10.1016/j.wneu.2014.12.019
   Ploch CC, 2016, WORLD NEUROSURG, V90, P668, DOI 10.1016/j.wneu.2016.02.081
   Salunke P, 2015, J NEUROSURG-SPINE, V23, P294, DOI 10.3171/2014.12.SPINE14310
   Sivaraju L, 2017, EUR SPINE J, V26, P1028, DOI 10.1007/s00586-016-4580-7
   Tjardes T, 2010, EUR SPINE J, V19, P25, DOI 10.1007/s00586-009-1091-9
   van Dijk M, 2001, SPINE, V26, P1920, DOI 10.1097/00007632-200109010-00020
   Wang SL, 2009, EUR SPINE J, V18, P1349, DOI 10.1007/s00586-009-1112-8
   Wang YT, 2016, CHIN J TRAUMATOL, V19, P31, DOI 10.1016/j.cjtee.2015.09.009
   Wright NM, 1998, J NEUROSURG, V88, P634, DOI 10.3171/jns.1998.88.4.0634
   Wu AM, 2018, EXPERT REV MED DEVIC, V15, P399, DOI 10.1080/17434440.2018.1483234
   Yeom JS, 2008, SPINE, V33, pE942, DOI 10.1097/BRS.0b013e3181870441
   Yin YH, 2016, NEUROSURGERY, V78, P391, DOI 10.1227/NEU.0000000000001026
   Yin YH, 2012, SPINE, V37, pE170, DOI 10.1097/BRS.0b013e318227efe7
   Zong R, 2019, WORLD NEUROSURG, V121, pE70, DOI 10.1016/j.wneu.2018.09.014
NR 31
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E722
EP E729
DI 10.1016/j.wneu.2019.09.139
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700138
PM 31589981
OA Bronze
DA 2020-05-12
ER

PT J
AU Ehresman, J
   Ahmed, AK
   Schilling, A
   Pennington, Z
   Lubelski, D
   Cottrill, E
   Goodwin, ML
   Liddy, A
   Abu-Bonsrah, N
   Goodwin, CR
   Sciubba, DM
AF Ehresman, Jeff
   Ahmed, A. Karim
   Schilling, Andrew
   Pennington, Zach
   Lubelski, Daniel
   Cottrill, Ethan
   Goodwin, Matthew L.
   Liddy, Alexandra
   Abu-Bonsrah, Nancy
   Goodwin, C. Rory
   Sciubba, Daniel M.
TI Preoperative Nutrition Consults Associated with Decreased Postoperative
   Complication Rate and Decreased Length of Hospital Stay After Spine
   Metastasis Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Malnutrition; Nutrition; Outcomes; Spinal metastasis
ID RISK INDEX; MALNUTRITION; PREDICTOR; SUPPORT; TOOLS
AB BACKGROUND: Preoperative malnutrition is associated with increased postoperative complication rate and hospital length of stay. However, the degree to which these risks can be mitigated by nutritional consultation has not been well described. To address this, we sought to determine if a preoperative nutrition consult was associated with decreased 30-day complication rate and hospital length of stay.
   METHODS: Adult patients who underwent neurosurgical intervention for spinal metastases at a tertiary care institution between 2008 and 2016 were retrospectively reviewed. Stepwise multivariable linear regression analyses were used to identify associations with 30-day complication rate and hospital length of stay.
   RESULTS: Among 95 patients who met inclusion criteria, the average length of stay was 8.9 days and 40 patients (42.1%) experienced one or more postoperative complications. On multivariable analysis, 30-day complication rates were higher in patients with the absence of a preoperative nutrition consult, a Modified Charlson Comorbidity Index score of greater than 2 points, greater operative blood loss, and malnutrition (Nutritional Risk Index score <97.5). Furthermore, hospitalization duration was increased with the absence of a nutrition consult, malnutrition, congestive heart failure, and prior systemic therapy in the multivariable analysis.
   CONCLUSIONS: On multivariable analysis, receipt of a preoperative nutrition consult was associated with both decreased 30-day complication rate and shorter hospitalization. We therefore posit that greater implementation of nutritional counseling may help to decrease complication rates and expedite discharge in patients undergoing surgical intervention for spinal metastases.
C1 [Ehresman, Jeff; Ahmed, A. Karim; Schilling, Andrew; Pennington, Zach; Lubelski, Daniel; Cottrill, Ethan; Goodwin, Matthew L.; Abu-Bonsrah, Nancy; Sciubba, Daniel M.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Liddy, Alexandra] Johns Hopkins Univ Hosp, Dept Clin Nutr, Baltimore, MD 21287 USA.
   [Goodwin, C. Rory] Duke Univ, Sch Med, Dept Neurosurg, Durham, NC USA.
RP Sciubba, DM (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM dsciubb1@jhmi.edu
OI Ehresman, Jeff/0000-0002-8900-8935; Goodwin, C.
   Rory/0000-0002-6540-2751; Cottrill, Ethan/0000-0001-5991-7962;
   Pennington, Zachary/0000-0001-8012-860X
CR Afaneh C, 2015, HEPATOBIL SURG NUTR, V4, P59, DOI 10.3978/j.issn.2304-3881.2014.08.07
   Ahmed AK, 2019, J NEUROSURG-SPINE, V30, P424, DOI 10.3171/2018.9.SPINE18607
   Antoun S, 2009, WORLD J SURG, V33, P1633, DOI 10.1007/s00268-009-0033-3
   Arrigo RT, 2011, SPINE, V36, pE1274, DOI 10.1097/BRS.0b013e318206cda3
   Barge-Caballero E, 2017, REV ESP CARDIOL, V70, P639, DOI [10.1016/j.recesp.2016.11.015, 10.1016/j.rec.2017.01.005]
   Calder PC, 2007, BRIT J NUTR, V98, pS133, DOI 10.1017/S0007114507832909
   Dreznik Y, 2018, DIGEST SURG, V35, P442, DOI 10.1159/000481408
   Hebuterne X, 2014, JPEN-PARENTER ENTER, V38, P196, DOI 10.1177/0148607113502674
   Koren-Hakim T, 2017, CLIN NUTR, V36, P912, DOI 10.1016/j.clnu.2017.01.018
   Kubota K, 2014, J NUTR HEALTH AGING, V18, P437, DOI 10.1007/s12603-014-0018-2
   Lin H, 2016, HEART FAIL REV, V21, P549, DOI 10.1007/s10741-016-9540-0
   Nussenbaum FD, 2018, J ARTHROPLASTY, V33, P10, DOI 10.1016/j.arth.2017.07.031
   Oh CA, 2012, WORLD J GASTROENTERO, V18, P673, DOI 10.3748/wjg.v18.i7.673
   Pereira NRP, 2019, SPINE J, V19, P144, DOI 10.1016/j.spinee.2018.05.037
   Pennington Z, 2019, CLIN SPINE SURG, V32, pE303, DOI 10.1097/BSD.0000000000000784
   Prasad N, 2016, Indian J Nephrol, V26, P27, DOI 10.4103/0971-4065.158449
   Sankar A, 2014, BRIT J ANAESTH, V113, P424, DOI 10.1093/bja/aeu100
   Takemoto E, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014741
   Vaid Sachin, 2012, Perm J, V16, P10
   Williams DGA, 2019, CURR OPIN ANESTHESIO, V32, P405, DOI 10.1097/ACO.0000000000000722
   Williams JD, 2017, AM J SURG, V213, P1010, DOI 10.1016/j.amjsurg.2016.10.008
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E173
EP E179
DI 10.1016/j.wneu.2019.08.197
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700022
PM 31493604
OA Bronze
DA 2020-05-12
ER

PT J
AU Fatima, N
   Razzaq, S
   El Beltagi, A
   Shuaib, A
   Saqqur, M
AF Fatima, Nida
   Razzaq, Sania
   El Beltagi, Ahmed
   Shuaib, Ashfaq
   Saqqur, Maher
TI Decompressive Craniectomy: A Preliminary Study of Comparative
   Radiographic Characteristics Predicting Outcome in Malignant Ischemic
   Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal cisterns; Cortical sulci; Decompressive hemicraniectomy; Malignant
   ischemic stroke
ID MIDDLE CEREBRAL-ARTERY; BRAIN EDEMA; TERRITORY INFARCTION;
   DETERIORATION; SURGERY; INJURY
AB OBJECTIVE: Decompressive craniectomy (DC) has been advocated as a lifesaving procedure in management of patients with raised intracranial pressure due to malignant ischemic stroke (MIS). The aim of this study was to identify comparative radiologic parameters after DC to predict functional outcome at 6 months in patients with MIS.
   METHODS: A retrospective analysis (2015-2018) of patients (median age 54 years; range, 29-80 years) with MIS who underwent postoperative computed tomography within 24 hours of DC was performed. Multivariate regression analysis was computed to predict clinical outcome at 6 months based on the Glasgow Coma Outcome Scale Extended.
   RESULTS: With median National Institutes of Health Stroke Scale score of 20 (range, 3-33), mean preoperative stroke volume was 250 +/- 75 cm(3). Median Glasgow Coma Outcome Scale Extended score at 6 months was 4. Multivariate regression analysis showed that the comparative radiographic characteristics of absence of effacement of cortical sulci (odds ratio 2.88; 95% confidence interval, 1.22-20.71; P = 0.02), absence of hemorrhagic transformation (odds ratio 1.09; 95% confidence interval, 1.99-12.89; P = 0.03), and absence of compression of lateral ventricles (odds ratio 3.75; 95% confidence interval, 1.28-22.4; P = 0.05) on postoperative computed tomography scan were significant independent predictors of good functional outcome (Glasgow Coma Outcome Scale Extended score 5-8).
   CONCLUSIONS: The comparative radiographic characteristics of absence of effacement of cortical sulci, hemorrhagic transformation, and compression of the lateral ventricles after DC in patients with MIS bore a significant relationship to predicting clinical outcome at 6 months.
C1 [Fatima, Nida] Hamad Gen Hosp, Dept Neurosurg, Doha, Qatar.
   [Razzaq, Sania; El Beltagi, Ahmed] Hamad Gen Hosp, Dept Neuro Radiol, Doha, Qatar.
   [Shuaib, Ashfaq; Saqqur, Maher] Univ Alberta, Dept Neurol, Edmonton, AB, Canada.
RP Fatima, N (reprint author), Hamad Gen Hosp, Dept Neurosurg, Doha, Qatar.
EM Nfatima@stanford.edu
CR Amorim RL, 2014, STROKE, V45, P1375, DOI 10.1161/STROKEAHA.113.003670
   Bardutzky J, 2007, STROKE, V38, P3084, DOI 10.1161/STROKEAHA.107.490193
   Fiorelli M, 1999, STROKE, V30, P2280, DOI 10.1161/01.STR.30.11.2280
   Frank JI, 2014, STROKE, V45, P781, DOI 10.1161/STROKEAHA.113.003200
   FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286
   Gean AD, 1994, IMAGING HEAD TRAUMA
   Hofmeijer J, 2008, CEREBROVASC DIS, V25, P176, DOI 10.1159/000113736
   Huttner HB, 2009, LANCET NEUROL, V8, P949, DOI 10.1016/S1474-4422(09)70224-8
   Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649
   Kamran S, 2018, NEUROSURG REV, V36, P1
   Kasner SE, 2001, STROKE, V32, P2117, DOI 10.1161/hs0901.095719
   Lu XC, 2014, SCI REP-UK, V4, DOI 10.1038/srep07070
   Ogata J, 1989, STROKE, V32, P1079
   Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E
   Pullicino PM, 1997, NEUROLOGY, V49, P1090, DOI 10.1212/WNL.49.4.1090
   ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017
   Sander A., 2002, EXTENDED GLASGOW OUT
   SCHUIER FJ, 1980, STROKE, V11, P593, DOI 10.1161/01.STR.11.6.593
   Serena J, 2005, STROKE, V36, P1921, DOI 10.1161/01.STR.0000177870.14967.94
   Sussman ES, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00069
   Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235
   Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4
   Wang KW, 2006, EUR J NEUROL, V13, P765, DOI 10.1111/j.1468-1331.2006.01365.x
   Wijdicks EFM, 2014, STROKE, V45, P1222, DOI 10.1161/01.str.0000441965.15164.d6
   Wijdicks EFM, 1998, MAYO CLIN PROC, V73, P829, DOI 10.4065/73.9.829
   Wilson JTL, 2002, STROKE, V33, P2243, DOI 10.1161/01.STR.0000027437.22450.BD
   Wirtz CR, 1997, NEUROSURG FOCUS, V2, P1
   Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9
   Zhang J, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.08
NR 29
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E267
EP E274
DI 10.1016/j.wneu.2019.08.223
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700034
PM 31505293
OA Bronze
DA 2020-05-12
ER

PT J
AU Flemming, KD
   Kumar, S
   Brown, RD
   Lanzino, G
AF Flemming, Kelly D.
   Kumar, Shivram
   Brown, Robert D., Jr.
   Lanzino, Giuseppe
TI Predictors of Initial Presentation with Hemorrhage in Patients with
   Cavernous Malformations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioma; Antithrombotic; Aspirin; Cavernoma; Cavernous; Cavernous
   malformations; Estrogen; Hemorrhage
ID NATURAL-HISTORY; BRAIN-STEM; RISK; METAANALYSIS
AB BACKGROUND: Cavernous malformations (CMs) are low-flow vascular malformations of the central nervous system which are incidental or present with hemorrhage, seizures, or focal neurologic deficit (FND). Little is known about the time course of symptoms and the predictors of initial hemorrhagic presentation.
   METHODS: Beginning in 2015, consecutive patients with radiologically confirmed CMs were recruited and completed a structured interview and written survey at baseline. Medical records and magnetic resonance imaging studies were reviewed. Data collected included the following: comorbid conditions, select medication use, and location of CMs. Logistic-regression models determined predictors of initial presentation with hemorrhage.
   RESULTS: Of 202 patients, 58.4% were women (average age at diagnosis, 43.7 +/- 16.5 years). Of the patients, 37.1%, 6.5%, and 14.8% presented with hemorrhage, FND, and seizures, respectively. CM was an incidental finding in 40.6%. Most patients presenting with hemorrhage (66.7%) deteriorated over 2-30 days after symptom onset. Brainstem location correlated with a higher likelihood of initial presentation with hemorrhage. Aspirin use and nonsteroidal anti-inflammatory drug use were more common in patients with CMs who did not present with hemorrhage. The effect of estrogen and aspirin was stronger in the sporadic compared with the familial form of CMs. In women, estrogen use increased the likelihood of presenting with hemorrhage.
   CONCLUSIONS: This prospective cohort study confirms brainstem location increases the likelihood of presenting with hemorrhage, but also supports a potential role of select medications on the initial clinical presentation of CMs. Further data from combined cohorts may aid in determining whether the influence of medications is different in familial versus sporadic form CMs.
C1 [Flemming, Kelly D.; Kumar, Shivram; Brown, Robert D., Jr.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
   [Lanzino, Giuseppe] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
RP Flemming, KD (reprint author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
EM Flemming.Kelly@mayo.edu
FU National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1 TR002377]
FX This publication (or project) was supported by the National Center for
   Advancing Translational Sciences (grant number UL1 TR002377). Its
   contents are solely the responsibility of the authors and do not
   necessarily represent the official views of the National Institutes of
   Health.
CR ABE M, 1989, J NEUROL NEUROSUR PS, V52, P167, DOI 10.1136/jnnp.52.2.167
   AIBA T, 1995, J NEUROSURG, V83, P56, DOI 10.3171/jns.1995.83.1.0056
   Al-Shahi SR, 2012, LANCET NEUROL, V11, P217, DOI DOI 10.1016/S1474-4422(12)70004-2
   [Anonymous], 2006, NIH Consens State Sci Statements, V23, P1
   Bervini D, 2019, J NEUROSURG, V130, P1922, DOI 10.3171/2018.1.JNS172547
   Chohan MO, 2019, JAMA NEUROL, V76, P492, DOI 10.1001/jamaneurol.2018.3634
   Dammann P, 2016, WORLD NEUROSURG, V91, P73, DOI 10.1016/j.wneu.2016.03.080
   Flemming KD, 2012, NEUROLOGY, V78, P632, DOI 10.1212/WNL.0b013e318248de9b
   Flemming KD, 2015, J CLIN NEUROSCI, V22, P969, DOI 10.1016/j.jocn.2015.01.007
   Flemming KD, 2013, J NEUROSURG, V118, P43, DOI 10.3171/2012.8.JNS112050
   Gazzaz M, 1999, NEUROCHIRURGIE, V45, P413
   Gibson CC, 2015, CIRCULATION, V131, P289, DOI 10.1161/CIRCULATIONAHA.114.010403
   Girard R, 2018, CIRC RES, V122, P1716, DOI 10.1161/CIRCRESAHA.118.312680
   Gross BA, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.3.FOCUS1165
   Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8
   Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024
   KONDZIOLKA D, 1995, J NEUROSURG, V83, P820, DOI 10.3171/jns.1995.83.5.0820
   Kumar S, 2019, J STROKE CEREBROVASC, V28, P1662, DOI 10.1016/j.jstrokecerebrovasdis.2019.02.025
   Kupersmith MJ, 2001, NEUROSURGERY, V48, P47, DOI 10.1097/00006123-200101000-00007
   Labauge P, 2000, NEURORADIOLOGY, V42, P327, DOI 10.1007/s002340050893
   Polster SP, 2019, NEUROSURGERY, V85, P843, DOI 10.1093/neuros/nyy539
   Polster SP, 2019, NEUROSURGERY, V84, P954, DOI 10.1093/neuros/nyy108
   Porter PJ, 1997, J NEUROSURG, V87, P190, DOI 10.3171/jns.1997.87.2.0190
   Retta SF, 2016, INT J BIOCHEM CELL B, V81, P254, DOI 10.1016/j.biocel.2016.09.011
   Revencu N, 2006, J MED GENET, V43, P716, DOI 10.1136/jmg.2006.041079
   RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605
   ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709
   Salman RAS, 2008, STROKE, V39, P3222, DOI 10.1161/STROKEAHA.108.515544
   Schneble HM, 2012, STROKE, V43, P3196, DOI 10.1161/STROKEAHA.112.668533
   Shenkar R, 2019, STROKE, V50, P738, DOI 10.1161/STROKEAHA.118.024058
   Starke RM, 2015, EXPERT REV NEUROTHER, V15, P1109, DOI 10.1586/14737175.2015.1071193
   Taslimi S, 2016, NEUROLOGY, V86, P1984, DOI 10.1212/WNL.0000000000002701
   Whitehead KJ, 2009, NAT MED, V15, P177, DOI 10.1038/nm.1911
   Zuurbier SM, 2019, LANCET NEUROL, V18, P935, DOI 10.1016/S1474-4422(19)30231-5
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E767
EP E773
DI 10.1016/j.wneu.2019.09.161
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700144
PM 31605843
OA Bronze
DA 2020-05-12
ER

PT J
AU Fu, PF
   Yuan, Q
   Lv, K
   Hu, J
AF Fu, Pengfei
   Yuan, Qiang
   Lv, Ke
   Hu, Jin
TI First Intracranial Pressure Monitoring or First Operation: Which One Is
   Better?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral contusion; Intracranial pressure monitoring; Propensity score
   matching; Traumatic brain injury
ID TRAUMATIC BRAIN-INJURY; MANAGEMENT; GUIDELINES; EPIDEMIOLOGY;
   PROGRESSION; MORTALITY; HEMATOMA
AB BACKGROUND: For patients with TBI, traditional methods such as clinical examination and imaging data are the primary references used for deciding whether to operate or not. Intracranial pressure (ICP) monitoring based on lateral ventricles or parenchymal pressure is a more direct reflection of ICP. However, the research on whether the outcome results of ICP monitoring are better than results based on clinical signs and imaging is sparse. Therefore, we compared treatment results for patients with TBI based on ICP monitoring and traditional methods.
   METHODS: This retrospective study included patients with TBI admitted to our collaborative hospitals between January 1, 2012, and December 31, 2013. All patients enrolled were divided into a traditional methods group and ICP monitoring group. Follow-up treatment was determined by ICP monitoring value or traditional methods in the 2 groups. Propensity matching scores were used to ensure that baseline characteristics of patients in the 2 groups were consistent.
   RESULTS: A significant association was found between the initial ICP value and neurologic deterioration (odds ratio 1.24; P < 0.001), and nonlinear correlation achieved the best fit (R-2 = 0.547). Both 6-month good recovery rate and favorable outcome rate were higher in the ICP monitoring group than the traditional methods group by propensity score analysis (P < 0.05).
   CONCLUSIONS: For patients with TBI with cerebral contusion volume >20 ml, both 6-month good recovery rate and favorable outcome rate were significantly higher in the ICP monitoring group than the traditional methods group.
C1 [Fu, Pengfei; Yuan, Qiang; Lv, Ke; Hu, Jin] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Hu, J (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM 17317821354@163.com
FU Shanghai Municipal Science and Technology Commission project
   [16411955300, 18441903300]; Shanghai Municipal Commission of Health and
   Family Planning project [201801075]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China [NSFC81601914]
FX This work was supported by the Shanghai Municipal Science and Technology
   Commission project (grant numbers 16411955300 and 18441903300), Shanghai
   Municipal Commission of Health and Family Planning project (grant number
   201801075), and National Natural Science Foundation of China (grant
   number NSFC81601914).
CR Aiolfi A, 2017, WORLD J SURG, V41, P1543, DOI 10.1007/s00268-017-3898-6
   Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369
   Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802
   Austin PC, 2008, STAT MED, V27, P2037, DOI 10.1002/sim.3150
   Brazinova A, 2016, J NEUROTRAUM, DOI 10.1089/neu.2015.4126
   Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Carney N, 2012, J NEUROTRAUM, V29, P2022, DOI 10.1089/neu.2011.2019
   Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976
   Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363
   Dawes AJ, 2015, J TRAUMA ACUTE CARE, V78, P492, DOI 10.1097/TA.0000000000000559
   Eaton J, 2017, WORLD NEUROSURG, V108, P650, DOI 10.1016/j.wneu.2017.09.084
   Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816
   Fink Matthew E, 2012, Continuum (Minneap Minn), V18, P640, DOI 10.1212/01.CON.0000415432.84147.1e
   Haviland A, 2007, PSYCHOL METHODS, V12, P247, DOI 10.1037/1082-989X.12.3.247
   Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122
   Maas A, 2016, NEUROSURGERY, V78, P368
   Marion DW, 2006, NEUROSURGERY, V58, P655
   Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188
   Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290
   Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7
   Picetti E, 2017, ACTA NEUROCHIR, V159, P615, DOI 10.1007/s00701-017-3118-z
   Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49
   SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003
   STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351
   Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313
   Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x
   Wu JJ, 1999, J TRAUMA, V47, P39, DOI 10.1097/00005373-199907000-00009
   Yuan Q, 2016, NEUROSURGERY, V78, P361, DOI 10.1227/NEU.0000000000001050
   Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965
   Yuan Q, 2015, J NEUROSURG, V122, P574, DOI 10.3171/2014.10.JNS1460
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E105
EP E114
DI 10.1016/j.wneu.2019.08.166
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700014
PM 31479786
OA Bronze
DA 2020-05-12
ER

PT J
AU Gai, SY
   Lv, N
   Zhang, Q
   Zuo, Q
   Liu, JM
   Huang, QH
AF Gai, Shiying
   Lv, Nan
   Zhang, Qi
   Zuo, Qiao
   Liu, Jianmin
   Huang, Qinghai
TI Multiple Intracranial Aneurysms Caused by Myxoma: Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Histological findings; Intracranial aneurysms; Myxoma; Treatment
ID LEFT ATRIAL-MYXOMA; LEFT CARDIAC MYXOMA; CEREBRAL ANEURYSMS; DELAYED
   COMPLICATION; FUSIFORM ANEURYSMS; RESECTION; PATIENT; MANIFESTATIONS;
   INTERLEUKIN-6; SERIES
AB OBJECTIVE: We present a case of multiple myxoma-related intracranial aneurysms and reviewed the recent relevant literature to investigate their natural course and develop a reasonable treatment algorithm.
   METHODS: We have reported a new case of multiple myxoma-related intracranial aneurysms and performed a search of current studies (2001 to the present) in PubMed. The keywords used were as follows (single words or combinations): neoplastic aneurysm, oncotic aneurysm, aneurysm, and myxoma. Only patients with multiple aneurysms resulting from cardiac myxoma and with adequate follow-up information pertinent to the analysis were included.
   RESULTS: A total of 41 patients, including our present patient, were studied. Of the 41 patients, 28 had received conservative treatment as the primary choice. Most lesions (n = 22) were stable during follow-up, except for 3 in which aneurysm evolution was observed. A total of 8 patients had undergone microsurgery, including aneurysm resection in 3, aneurysm clipping in 2, clipping followed by resection in 2, and aneurysm trapping in 1. Endovascular treatment was performed in 2 patients. Radiation therapy was used in 1 patient, and the parent artery proved to be occluded at the 1-year follow-up examination. A combination of chemotherapy and microsurgery was used in 1 patient. All the cases that had been managed aggressively were stable during further follow-up.
   CONCLUSION: The prognosis was good for most patients with multiple myxoma-related intracranial aneurysms, and most myxoma-related aneurysms were stable. Conservative treatment and routine follow-up are recommended for most patients. However, for patients with evolving or ruptured aneurysms, invasive treatment, including open surgery and endovascular treatment, should be considered.
C1 [Gai, Shiying] Zhejiang Univ, Affiliated Hosp 4, Dept Neurosurg, Sch Med, Yiwu, Peoples R China.
   [Lv, Nan; Zhang, Qi; Zuo, Qiao; Liu, Jianmin; Huang, Qinghai] Second Mil Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Huang, QH (reprint author), Second Mil Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM ocinhqh@163.com
OI Zuo, Qiao/0000-0003-4512-6363
FU National Research and Development Project of Key Chronic Diseases
   [2016YFC1300700]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [81571118, 81701775, 81771264]
FX The present study was supported by the National Research and Development
   Project of Key Chronic Diseases (grant 2016YFC1300700) and the National
   Natural Science Foundation of China (grants 81571118, 81701775, and
   81771264).
CR Al-Said Y, 2013, CASE REP NEUROL MED, DOI 10.1155/2013/839270
   Ashalatha R, 2005, Neurol India, V53, P216
   Baikoussis NG, 2011, HELL J CARDIOL, V52, P466
   Blanc JL, 2008, ARCH NEUROL-CHICAGO, V65, P1536, DOI 10.1001/archneur.65.11.1536
   Branscheidt M, 2014, J NEUROL, V261, P828, DOI 10.1007/s00415-014-7281-3
   Brinjikji W, 2015, CEREBROVASC DIS, V40, P35, DOI 10.1159/000381833
   Chen Z, 2005, INTERV NEURORADIOL, V11, P251, DOI 10.1177/159101990501100309
   Chiang KH, 2011, TZU CHI MED J, V23, P63, DOI 10.1016/j.tcmj.2011.01.002
   Eddleman CS, 2010, NEUROCRIT CARE, V13, P252, DOI 10.1007/s12028-010-9400-z
   Ezerioha N, 2015, CASE REP NEUROL, V7, P152, DOI 10.1159/000437256
   George KJ, 2012, BRIT J NEUROSURG, V26, P409, DOI 10.3109/02688697.2011.626877
   Gupta MM, 2015, POL J RADIOL, V80, P490, DOI 10.12659/PJR.894977
   Herbst M, 2005, AM J NEURORADIOL, V26, P666
   Hwang BJ, 2001, AM J ROENTGENOL, V177, P925, DOI 10.2214/ajr.177.4.1770925
   Iskandar ME, 2013, CASE REP SURG, DOI 10.1155/2013/642394
   Jean WC, 2001, NEUROSURGERY, V49, P200, DOI 10.1097/00006123-200107000-00031
   Josephson SA, 2005, NEUROLOGY, V64, P526, DOI 10.1212/01.WNL.0000145838.61057.E8
   Kim H, 2012, INT J CARDIOVAS IMAG, V28, P129, DOI 10.1007/s10554-012-0140-3
   Koo YH, 2009, J KOREAN NEUROSURG S, V45, P394, DOI 10.3340/jkns.2009.45.6.394
   Krishnan P, 2013, NEUROL INDIA, V61, P184, DOI 10.4103/0028-3886.111149
   Lee SJ, 2012, CEREBROVASC DIS, V33, P471, DOI 10.1159/000335830
   Lee Tsung-Han, 2011, Chang Gung Med J, V34, P315
   Morgan L, 2006, J NEUROL NEUROSUR PS, V77, P915, DOI 10.1136/jnnp.2005.081976
   Namura Osamu, 2007, Ann Thorac Cardiovasc Surg, V13, P423
   Oomen AWGJ, 2013, NETH HEART J, V21, P307, DOI 10.1007/s12471-013-0420-0
   Pinede L, 2001, MEDICINE, V80, P159, DOI 10.1097/00005792-200105000-00002
   Prasad H, 2008, EUR J NEUROL, V15, pE114, DOI [10.1111/j.1468-1331.2008.02325.x, 10.1111/j.1468-1331.2008.02295.x, 10.1111/j.1468-1331.2008.02323.x]
   Radoi MP, 2012, BRIT J NEUROSURG, V26, P893, DOI 10.3109/02688697.2012.692841
   Ryou KS, 2008, J NEUROSURG, V109, P318, DOI 10.3171/JNS/2008/109/8/0318
   Sabolek M, 2005, ACTA NEUROL SCAND, V111, P345, DOI 10.1111/j.1600-0404.2005.00413.x
   Saffie P, 2015, J STROKE CEREBROVASC, V24, pE69, DOI 10.1016/j.jstrokecerebrovasdis.2014.10.017
   Santillan A, 2012, ARCH NEUROL-CHICAGO, V69, P1204, DOI 10.1001/archneurol.2011.3503
   Sedat J, 2007, INTERV NEURORADIOL, V13, P179, DOI 10.1177/159101990701300209
   Sorenson TJ, 2019, WORLD NEUROSURG, V128, P200, DOI 10.1016/j.wneu.2019.05.051
   Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087
   Stock K, 2004, INTERV NEURORADIOL, V10, P335, DOI 10.1177/159101990401000408
   Sveinsson O, 2015, BMJ CASE REP, V2015
   Takenouchi T, 2014, ARCH DIS CHILD, V99, P849, DOI 10.1136/archdischild-2013-305807
   Tamuleviciute E, 2011, INTERV NEURORADIOL, V17, P188, DOI 10.1177/159101991101700208
   Vigano S, 2013, CLIN RADIOL, V68, pE624, DOI 10.1016/j.crad.2013.06.010
   Walker MT, 2003, J NEUROL NEUROSUR PS, V74, P281, DOI 10.1136/jnnp.74.2.281
   Xu QS, 2013, J THORAC DIS, V5, pE227, DOI 10.3978/j.issn.2072-1439.2013.11.27
   Yilmaz MB, 2003, INT J CARDIOL, V87, P303, DOI 10.1016/S0167-5273(02)00348-0
   Zeng T, 2015, ACTA NEUROL BELG, V115, P453, DOI 10.1007/s13760-014-0339-2
   Zhan RY, 2013, J CRANIOFAC SURG, V24, P651, DOI 10.1097/SCS.0b013e318264690f
   Zheng J, 2015, CLIN NEUROL NEUROSUR, V128, P107, DOI 10.1016/j.clineuro.2014.11.010
   Zheng J, 2015, J STROKE CEREBROVASC, V24, P232, DOI 10.1016/j.jstrokecerebrovasdis.2014.08.017
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E376
EP E384
DI 10.1016/j.wneu.2019.09.014
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700092
PM 31521750
OA Bronze
DA 2020-05-12
ER

PT J
AU Gamaleldin, OA
   Donia, MM
   Elsebaie, NA
   Abdelrazek, AA
   Rayan, T
   Khalifa, MH
AF Gamaleldin, Omneya A.
   Donia, Mohamed Mahmoud
   Elsebaie, Nermeen A.
   Abdelrazek, Ahmed Abdelkhalek
   Rayan, Tarek
   Khalifa, Mohamed Hossameldin
TI Role of Fused Three-Dimensional Time-of-Flight Magnetic Resonance
   Angiography and 3-Dimensional T2-Weighted Imaging Sequences in
   Neurovascular Compression
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemifacial spasm; MR imaging; Neurovascular compression; Trigeminal
   neuralgia
ID TRIGEMINAL NEURALGIA; MICROVASCULAR DECOMPRESSION; HEMIFACIAL SPASM;
   MR-ANGIOGRAPHY; NERVE; INTERFERENCE; CONTRAST; FIESTA; HEAD
AB BACKGROUND: To evaluate role of fused 3-dimensional time-of-flight magnetic resonance angiography (3D-TOF-MRA) and 3-dimensional constructive interference in steady state (3D-CISS) in neurovascular compression in trigeminal neuralgia (TN) and hemifacial spasm (HFS).
   MATERIAL AND METHODS: A prospective study was conducted on 30 patients (mean age 47.20 +/- 11.69 years), 17 (56.7%) male and 13 (43.3%) female, with TN and HFS. 3D-TOF-MRA and 3D-CISS sequences of the cerebellopontine angle were performed, as well as postprocessing with fusion of the images. Two independent readers assessed the degree of neurovascular conflict. The images were evaluated for site, signal, and degree of nerve compression and the offending vessel. The kappa test for interobserver agreement was done.
   RESULTS: The interobserver agreement of both readers was excellent for degree of compression (k = 0.70, 95% confidence interval [CI] 0.49-0.92, r = 0.856, P = 0.001), excellent for the side affected (k = 1.0, 95% CI = 1.0-1.0, r = 1.000, P = 0.001), excellent for the offending vessel (k = 0.85, 95% CI = 0.66-1.0, P = < 0.001), and excellent for the position of the offending vessel (k = 0.685, 95% CI = 0.489-0.882, r = 0.863, P 5 0.001). There was no significant correlation between the degree of compression and signal intensity.
   CONCLUSIONS: Fused 3D-TOF-MRA and 3D-CISS images are a reliable, noninvasive tool for the evaluation of offending vessel and degree of affection in patients with neurovascular compression. MRA-CISS can be used for evaluation and treatment planning of neurovascular compression in TN and HFS.
C1 [Gamaleldin, Omneya A.; Donia, Mohamed Mahmoud; Elsebaie, Nermeen A.; Khalifa, Mohamed Hossameldin] Alexandria Univ, Alexandria Fac Med, Diagnost & Intervent Radiol Dept, Alexandria, Egypt.
   [Rayan, Tarek] Alexandria Main Univ Hosp, Alexandria Fac Med, Neurosurg Dept, Alexandria, Egypt.
   [Abdelrazek, Ahmed Abdelkhalek] Mansoura Fac Med, Diagnost Radiol Dept, Mansoura, Egypt.
RP Gamaleldin, OA (reprint author), Alexandria Univ, Alexandria Fac Med, Diagnost & Intervent Radiol Dept, Alexandria, Egypt.
EM omneya.gamaleldin@alexmed.edu.eg
RI Abdel Razek, Ahmed/J-6737-2016
OI Abdel Razek, Ahmed/0000-0002-9613-5932
CR Anderson VC, 2006, NEUROSURGERY, V58, P666, DOI 10.1227/01.NEU.0000197117.34888.DE
   Antonini G, 2014, PAIN, V155, P1464, DOI 10.1016/j.pain.2014.04.020
   Blitz AM, 2014, NEUROIMAG CLIN N AM, V24, P17, DOI 10.1016/j.nic.2013.03.021
   Campos-Benitez M, 2008, J NEUROSURG, V109, P416, DOI 10.3171/JNS/2008/109/9/0416
   Cruccu G, 2016, NEUROLOGY, V87, P220, DOI 10.1212/WNL.0000000000002840
   Donahue JH, 2017, RADIOL CLIN N AM, V55, P123, DOI 10.1016/j.rcl.2016.08.001
   Duan YF, 2015, J NEUROSURG, V123, P1512, DOI 10.3171/2014.12.JNS142086
   Garcia M, 2012, AM J NEURORADIOL, V33, P1251, DOI 10.3174/ajnr.A2974
   Haller S, 2016, AM J NEURORADIOL, V37, P1384, DOI 10.3174/ajnr.A4683
   Hermier M, 2018, NEUROCHIRURGIE, V64, P117, DOI 10.1016/j.neuchi.2018.01.005
   Hughes MA, 2016, AM J ROENTGENOL, V206, P595, DOI 10.2214/AJR.14.14156
   Jia JM, 2016, CLIN NEURORADIOL, V26, P431, DOI 10.1007/s00062-015-0382-2
   Leal PRL, 2014, J NEUROSURG, V120, P1484, DOI 10.3171/2014.2.JNS131288
   Leal PRL, 2011, NEUROSURGERY, V69, P15, DOI 10.1227/NEU.0b013e318212bafa
   Lorenzoni J, 2012, EUR J RADIOL, V81, P1851, DOI 10.1016/j.ejrad.2009.09.017
   Lutz J, 2011, RADIOLOGY, V258, P524, DOI 10.1148/radiol.10100477
   Maarbjerg S, 2014, HEADACHE, V54, P1574, DOI 10.1111/head.12441
   Miller JP, 2009, J NEUROSURG, V110, P627, DOI 10.3171/2008.6.17620
   Razek AAKA, 2014, INT J ORAL MAX SURG, V43, P811, DOI 10.1016/j.ijom.2014.03.014
   Razek AAKA, 2017, CLIN RHEUMATOL, V36, P2319, DOI 10.1007/s10067-016-3463-y
   Razek AAKA, 2013, EUR J RADIOL, V82, P1885, DOI 10.1016/j.ejrad.2013.07.007
   Sarsam Z, 2010, BRIT J NEUROSURG, V24, P18, DOI 10.3109/02688690903370289
   Sekula RF, 2014, MOVEMENT DISORD, V29, P1299, DOI 10.1002/mds.25947
   Shang HB, 2010, J NEUROIMAGING, V20, P345, DOI 10.1111/j.1552-6569.2009.00378.x
   Sindou M, 2007, J NEUROSURG, V107, P1144, DOI 10.3171/JNS-07/12/1144
   Singh AK, 2015, CURR PROBL DIAGN RAD, V44, P60, DOI 10.1067/j.cpradiol.2014.05.011
   Tanrikulu L, 2015, CLIN NEUROL NEUROSUR, V129, P17, DOI 10.1016/j.clineuro.2014.11.005
   Yang DF, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20170557
   Zeng QS, 2013, J CLIN NEUROSCI, V20, P107, DOI 10.1016/j.jocn.2012.01.046
   Zhou Q, 2012, MAGN RESON IMAGING, V30, P666, DOI 10.1016/j.mri.2011.12.022
NR 30
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E180
EP E186
DI 10.1016/j.wneu.2019.08.190
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700023
PM 31493603
OA Bronze
DA 2020-05-12
ER

PT J
AU Gao, ZY
   Yu, LL
   Shi, BX
   Dong, ZL
   Sun, YJ
   Ma, HS
AF Gao, Zhi-Yong
   Yu, Liang-Liang
   Shi, Ben-Xia
   Dong, Zhen-Ling
   Sun, Yu-Jie
   Ma, Hou-Sheng
TI T140 Inhibits Apoptosis and Promotes Proliferation and Matrix Formation
   Through the SDF-1/CXC Receptor-4 Signaling Pathway in Endplate
   Chondrocytes of the Rat Intervertebral Discs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoptosis; Cartilage endplate cells; Matrix formation; Polyphemusin
   II-derived peptide; Proliferation; SDF-1/CXCR4 signaling pathway
ID CXCR4 ANTAGONISTS; CHEMOKINE; AXIS; CANCER; EXPRESSION; CXCL12;
   DEGENERATION; METASTASIS; MIGRATION; GROWTH
AB BACKGROUND: Cartilaginous endplate (CEP), a thin layer of hyaline cartilage located between the vertebral endplate and nucleus pulposus, transports the nutrient into the disc. The objective of this study was to evaluate the influence of T140 (polyphemusin II-derived peptide) on the CEP cell growth, apoptosis, and the matrix formation via the stromal cell-derived factor-1 (SDF-1)/cysteine X cysteine (CXC) receptor-4 (CXCR4) signaling pathway.
   METHODS: Sprague-Dawley rats were euthanized by cervical dislocation and dissected for the isolation and the appraisal of CEP cells that were extracted from the end-plate in rat intervertebral discs and were then added with different concentrations of reagents (SDF-1 and T140). The effect of T140 on CEP cell proliferation and apoptosis were analyzed. The messenger RNA (mRNA) and protein expressions of CXCR4, prominin-1, proteoglycans, type II collagen, B-cell lymphoma-2 (Bcl-2), and BcI-2 associated X protein were analyzed by reverse transcription quantitative polymerase chain reaction and Western blot analysis.
   RESULTS: T140 promoted the proliferation of CEP cells and inhibited the apoptosis of CEP cells. Additionally, T140 suppressed the mRNA and protein expression of CXCR4, prominin-1, and BcI-2 associated X protein, and increased the mRNA and protein expression of proteoglycans, type II collagen, and Bcl-2.
   CONCLUSIONS: T140 promotes the proliferation and matrix formation and inhibits the apoptosis of CEP cells by blocking the SDF-1/CXCR4 signaling pathway in vitro, which provides a certain therapeutic effect on the degeneration of intervertebral discs.
C1 [Gao, Zhi-Yong] Yantai Yuhuangding Hosp, Dept Rehabil, Yantai, Peoples R China.
   [Yu, Liang-Liang] Yantai Yuhuangding Hosp, Dept Cardiol, Yantai, Peoples R China.
   [Shi, Ben-Xia; Dong, Zhen-Ling] Yantai Yuhuangding Hosp, Hosp Preparat Ctr, Yantai, Peoples R China.
   [Sun, Yu-Jie] Yantai Yuhuangding Hosp, Dept Trauma Orthoped, Yantai, Peoples R China.
   [Ma, Hou-Sheng] Yantai Yuhuangding Hosp, Dept Imaging, Yantai, Peoples R China.
RP Ma, HS (reprint author), Yantai Yuhuangding Hosp, Dept Imaging, Yantai, Peoples R China.
EM gzy09059@163.com
CR [Anonymous], 2017, OXID MED CELL LONGEV
   Ariga K, 2001, SPINE, V26, P2414, DOI 10.1097/00007632-200111150-00004
   Burger JA, 2011, EXPERT REV ANTICANC, V11, P621, DOI [10.1586/era.11.11, 10.1586/ERA.11.11]
   Burger M, 2005, BLOOD, V106, P1824, DOI 10.1182/blood-2004-12-4918
   Dong YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060943
   Fahham D, 2012, J THORAC CARDIOV SUR, V144, P1167, DOI 10.1016/j.jtcvs.2012.07.031
   Gebura K, 2012, POSTEP HIG MED DOSW, V66, P252
   Grant MP, 2016, EUR CELLS MATER, V32, P137, DOI 10.22203/eCM.v032a09
   Grassi F, 2004, J CELL PHYSIOL, V199, P244, DOI 10.1002/jcp.10445
   Han YC, 2019, BIOCHEM BIOPH RES CO, V516, P1026, DOI 10.1016/j.bbrc.2017.03.111
   Hu QX, 2017, AM J TRANSL RES, V9, P2296
   Kim Ha-Yon, 2011, Korean J Hematol, V46, P244, DOI 10.5045/kjh.2011.46.4.244
   Kochetkova M, 2009, CELL DEATH DIFFER, V16, P664, DOI 10.1038/cdd.2008.190
   Koshiba T, 2000, CLIN CANCER RES, V6, P3530
   Kremer KN, 2013, J BIOL CHEM, V288, P22899, DOI 10.1074/jbc.M113.449926
   Lefrancois M, 2011, ACS MED CHEM LETT, V2, P597, DOI 10.1021/ml200084n
   Li PC, 2016, MOL MED REP, V14, P1475, DOI 10.3892/mmr.2016.5419
   Li T, 2015, INT J CLIN EXP PATHO, V8, P12525
   Lin ZT, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19183-7
   Liu LT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026285
   Liu XL, 2011, PROTEIN CELL, V2, P845, DOI 10.1007/s13238-011-1097-z
   Lu WW, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101522
   Masuda R, 2012, BIOCONJUGATE CHEM, V23, P1259, DOI 10.1021/bc300084h
   Matsuo Y, 2009, INT J CANCER, V124, P853, DOI 10.1002/ijc.24040
   Moon SM, 2013, EUR SPINE J, V22, P1820, DOI 10.1007/s00586-013-2798-1
   Narumi T, 2012, BIOORG MED CHEM LETT, V22, P4169, DOI 10.1016/j.bmcl.2012.04.032
   Neklyudova O, 2016, J CANCER RES CLIN, V142, P1739, DOI 10.1007/s00432-016-2185-5
   Rafeemanesh E, 2017, ASIAN SPINE J, V11, P44, DOI 10.4184/asj.2017.11.1.44
   Seeger FH, 2012, CIRC RES, V111, P854, DOI 10.1161/CIRCRESAHA.112.265678
   Shang J, 2015, BIOMED RES INT, DOI 10.1155/2015/604972
   Sun XJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-17
   Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109
   Tamamura H, 2001, BIOORG MED CHEM LETT, V11, P1897, DOI 10.1016/S0960-894X(01)00323-7
   Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X
   Tamamura H, 2008, PERSPECT MED CHEM, V2, P1
   Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329
   Wang JH, 2005, CELL SIGNAL, V17, P1578, DOI 10.1016/j.cellsig.2005.03.022
   Wei FY, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3930
   Wei L, 2006, J RHEUMATOL, V33, P1818
   Wu YR, 2013, MOL CELL BIOMECH, V10, P159
   Xu JG, 2007, AM J RESP CELL MOL, V37, P291, DOI 10.1165/rcmb.2006-0187OC
   Yu FX, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0465-1
   Zhang H, 2014, INT J MED SCI, V11, P240, DOI 10.7150/ijms.7489
   Zhao JJ, 2014, INT J CLIN EXP MED, V7, P2948
NR 44
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E165
EP E172
DI 10.1016/j.wneu.2019.08.140
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700021
PM 31476465
OA Bronze
DA 2020-05-12
ER

PT J
AU Gareev, I
   Yang, G
   Sun, JX
   Beylerli, O
   Chen, X
   Zhang, DM
   Zhao, BX
   Zhang, RT
   Sun, ZY
   Yang, Q
   Li, LL
   Pavlov, V
   Safin, S
   Zhao, SG
AF Gareev, Ilgiz
   Yang, Guang
   Sun, Jinxian
   Beylerli, Ozal
   Chen, Xin
   Zhang, Daming
   Zhao, Boxian
   Zhang, Ruotian
   Sun, Zhenying
   Yang, Quan
   Li, Lili
   Pavlov, Valentin
   Safin, Shamil
   Zhao, Shiguang
TI Circulating MicroRNAs as Potential Noninvasive Biomarkers of Spontaneous
   Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Circulating; Diagnosis; Intracerebral hemorrhage; MicroRNA; Plasma
ID SMOOTH-MUSCLE-CELLS; NLRP3 INFLAMMASOME; EXPRESSION; RECEPTOR; INJURY;
   BLOOD; RISK; GENE
AB BACKGROUND: Spontaneous intracerebral hemorrhage (ICH) is a common and severe neurological disorder that has been associated with high rates of mortality and morbidity. It is urgent to find new biomarkers for the early diagnosis and prevention of ICH. In recent years, microRNAs (miRNAs) have been proved to play an important role in vascular damage and inflammation in cerebrovascular diseases, including ICH. In the peripheral blood, circulating miRNAs will be present at a remarkably steady level. In the present study, we explored the circulating plasma microRNA (miR)-181b, miR-223, miR-155, and miR-145 as new potential biomarkers for the diagnosis of ICH.
   METHODS: The plasma samples from 106 patients with ICH and 50 patients without ICH (control group) were collected and subjected to quantitative real-time polymerase chain reaction analyses for the expression levels of circulating miR-181b, miR-223, miR-155, and miR-145.
   RESULTS: The expression levels of plasma circulating miR-145 (P < 0.001), miR-223, and miR-155 were increased in patients with ICH compared with those in the control group (P < 0.05). However, the expression of plasma circulating miR-181b was decreased in patients with ICH compared with that in the control group (P < 0.001). Receiver operating characteristic curve analyses were performed to determine the diagnostic sensitivity and specificity of niiR-145 and miR-181b to detect ICH. The area under the curve for miR-145 was 0.766 (95% confidence interval, 0.689-0.838) and for miR-181b was 0.78 (95% confidence interval, 0.70-0.86), suggesting that circulating miR-145 and miR-181b can he used to differentiate patients with ICH from those without ICH.
   CONCLUSION: Our results have shown that measurement of circulating miR-181b, miR-223, miR-155, and miR-145 in plasma samples could serve as a potential noninvasive tool for ICH detection.
C1 [Gareev, Ilgiz; Yang, Guang; Sun, Jinxian; Beylerli, Ozal; Chen, Xin; Zhang, Daming; Zhao, Boxian; Zhang, Ruotian; Sun, Zhenying; Yang, Quan; Li, Lili; Zhao, Shiguang] Harbin Med Univ, Dept Neurosurg, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China.
   [Gareev, Ilgiz; Yang, Guang; Sun, Jinxian; Beylerli, Ozal; Chen, Xin; Zhang, Daming; Zhao, Boxian; Zhang, Ruotian; Sun, Zhenying; Yang, Quan; Li, Lili; Zhao, Shiguang] Harbin Med Univ, Inst Brain Sci, Harbin, Heilongjiang, Peoples R China.
   [Gareev, Ilgiz; Beylerli, Ozal; Pavlov, Valentin; Safin, Shamil] Bashkir State Med Univ, Ufa, Russia.
RP Zhao, SG (reprint author), Harbin Med Univ, Dept Neurosurg, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China.; Zhao, SG (reprint author), Harbin Med Univ, Inst Brain Sci, Harbin, Heilongjiang, Peoples R China.
EM guangsz@hotmail.com
RI Gareev, Ilgiz/AAB-6746-2020; Beylerli, Ozal/AAH-2312-2020; Gareev,
   Ilgiz/AAE-5582-2019
OI Gareev, Ilgiz/0000-0002-4965-0835; Beylerli, Ozal/0000-0002-6149-5460;
   Zhang, Daming/0000-0003-0280-2093
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81572482, 81971135, 81972326]; China Postdoctoral
   Science FoundationChina Postdoctoral Science Foundation [2019T120284,
   2018M631964]; Financial Assistance under Heilongjiang Postdoctoral Fund
   [LBH-TZ19]; Grant of the Republic of Bashkortostan [CD-28]
FX The present study was funded by the National Natural Science Foundation
   of China (grant number 81572482, 81971135, 81972326), China Postdoctoral
   Science Foundation (grant number 2019T120284, 2018M631964), Financial
   Assistance under Heilongjiang Postdoctoral Fund (grant number LBH-TZ19),
   and Grant of the Republic of Bashkortostan to Young Scientists (February
   5, 2019; grant CD-28).
CR Acampa M, 2014, J STROKE, V16, P184, DOI 10.5853/jos.2014.16.3.184
   Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516
   Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304
   Pena-Philippides JC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0753-x
   Chen QY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042971, 10.1371/journal.pone.0037149]
   Chen YJ, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00057
   Dastur CK, 2017, STROKE VASC NEUROL, V2
   Elton TS, 2013, GENE, V532, P1, DOI 10.1016/j.gene.2012.12.009
   Feng SJ, 2018, FOLIA NEUROPATHOL, V56, P49, DOI 10.5114/fn.2018.74659
   Guo XC, 2016, INT CONF COMP INFO, P6, DOI 10.1038/srep35302
   Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109
   Hori D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174108
   Kohlstedt K, 2013, CIRC RES, V112, P1150, DOI 10.1161/CIRCRESAHA.113.301282
   Kumar A, 2014, NEUROL INDIA, V62, P183, DOI 10.4103/0028-3886.132383
   Lacolley P, 2017, PHYSIOL REV, V97, P1555, DOI 10.1152/physrev.00003.2017
   Liu BQ, 2012, NEUROL INDIA, V60, P3, DOI 10.4103/0028-3886.93581
   Mohl W, 2018, ESC HEART FAIL, V5, P1176, DOI 10.1002/ehf2.12354
   Moret I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082753
   Murthy SB, 2017, NEUROLOGY, V88, P1882, DOI 10.1212/WNL.0000000000003935
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Oh Young S, 2018, Clin Hypertens, V24, P17, DOI 10.1186/s40885-018-0102-8
   Roitbak T, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-25
   Sansing LH, 2016, SEMIN NEUROL, V36, P223, DOI 10.1055/s-0036-1583296
   Santovito D, 2013, EXPERT OPIN THER TAR, V17, P217, DOI 10.1517/14728222.2013.745512
   Shan Z, 2015, J AM COLL CARDIOL, V65, P2526, DOI 10.1016/j.jacc.2015.03.570
   Sheng L, 2018, BIOMED PHARMACOTHER, V103, P851, DOI 10.1016/j.biopha.2018.03.173
   Steiner T, 2017, STROKE, V48, P1432, DOI 10.1161/STROKEAHA.116.013343
   Sun P, 2019, EUR REV MED PHARMACO, V23, P3051, DOI 10.26355/eurrev_201904_17587
   Sun XH, 2014, CIRC RES, V114, P32, DOI 10.1161/CIRCRESAHA.113.302089
   Sun XH, 2012, J CLIN INVEST, V122, P1973, DOI 10.1172/JCI61495
   Van Matre ET, 2019, CRIT CARE NURS Q, V42, P148, DOI 10.1097/CNQ.0000000000000248
   Wang JL, 2016, J INT MED RES, V44, P419, DOI 10.1177/0300060516630852
   Wang Y, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-77
   Wang Y, 2018, EXP THER MED, V15, P548, DOI 10.3892/etm.2017.5371
   Wang ZY, 2019, IMMUNOL LETT, V206, P1, DOI 10.1016/j.imlet.2018.11.014
   Wei XX, 2017, DNA CELL BIOL, V36, P127, DOI 10.1089/dna.2016.3525
   Xie XM, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00383
   Xing GP, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.898980
   Xu JC, 2018, GENE, V679, P266, DOI 10.1016/j.gene.2018.09.010
   Yang Z, 2015, MOL IMMUNOL, V65, P267, DOI 10.1016/j.molimm.2014.12.018
   Yao Q, 2019, CURR OPIN CHEM BIOL, V51, P11, DOI 10.1016/j.cbpa.2019.01.024
   Zheng HW, 2012, CNS NEUROSCI THER, V18, P1003, DOI 10.1111/cns.12019
NR 42
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E369
EP E375
DI 10.1016/j.wneu.2019.09.016
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700091
PM 31525485
OA Bronze
DA 2020-05-12
ER

PT J
AU Graziano, F
   Gerardi, RM
   Lo Bue, E
   Basile, L
   Brunasso, L
   Somma, T
   Maugeri, R
   Nicoletti, G
   Giacopino, D
AF Graziano, Francesca
   Gerardi, Rosa Maria
   Lo Bue, Enrico
   Basile, Luigi
   Brunasso, Lara
   Somma, Teresa
   Maugeri, Rosario
   Nicoletti, Giovanni
   Giacopino, Domenico
TI Surgical Back Risk Syndrome and Spinal Cord Stimulation: Better Safe
   Than Sorry
SO WORLD NEUROSURGERY
LA English
DT Article
DE Failed back surgery syndrome; Spinal cord stimulation; Surgical back
   risk syndrome
ID DEVICE PEAK PLASMABLADE; SURGERY SYNDROME; NEUROSTIMULATION THERAPIES;
   APPROPRIATE USE; PAIN; COMPLICATIONS; MULTICENTER; NEUROPATHY; OUTCOMES;
   OBESITY
AB BACKGROUND: Recurrent and chronic low back pain, caused by degenerative lumbar spondylosis, commonly affects elderly patients, even those with no previous low back surgery. These patients, like those affected by failed back surgery syndrome (FBSS), may become unresponsive to medical conservative treatment and their quality of life could be easily compromised. Moreover, general comorbidities, obesity, and other typical conditions of the elderly may make surgery under general anesthesia riskier than the natural history of the disease. These patients could be considered affected by surgical back risk syndrome (SBRS).
   METHODS: In this article, we report our preliminary observational prospective study on the role of spinal cord stimulation (SCS) in 3 groups of patients: the FBSS group, the SBRS group, and the "other" group. Selection criteria, treatment modality, and outcomes for each patient group are described and discussed. Moreover, a potentially useful diagnostic and therapeutic flowchart on the management options for lumbar back diseases is discussed.
   RESULTS: The FBSS group included 25 patients, the SBRS group included 10 patients, and the other group included 3 patients. In 22/25 patients with FBSS (88% of the total), the implantation of a definitive neurostimulator was successful. In almost all patients in both the SBRS and the other groups, the implantation of a definitive neurostimulator was successful.
   CONCLUSIONS: In our opinion, SCS could be considered as a valid alternative treatment not only in selected patients affected by FBSS but also in selected patients affected by SBRS, in whom back surgery under general anesthesia may be challenging and overcome the potential benefit of the surgery itself. SBRS could be considered a new disease entity to be managed through SCS.
C1 [Graziano, Francesca; Lo Bue, Enrico; Basile, Luigi; Brunasso, Lara; Maugeri, Rosario; Giacopino, Domenico] AOUP Paolo Giaccone, Dept Expt Biomed & Clin Neurosci, Postgrad Residency Program Neurol Surg, Neurosurg Clin,Sch Med, Palermo, Italy.
   [Gerardi, Rosa Maria; Somma, Teresa] Univ Napoli Federico II, Dept Neurosci Reprod & Odontostomatol Sci, Div Neurosurg, Naples, Italy.
   [Nicoletti, Giovanni] ARNAS Garibaldi, Dept Neurosurg, PO Garibaldi Nesima, Catania, Italy.
RP Graziano, F (reprint author), AOUP Paolo Giaccone, Dept Expt Biomed & Clin Neurosci, Postgrad Residency Program Neurol Surg, Neurosurg Clin,Sch Med, Palermo, Italy.
EM francesca.graziano03@unipa.it
OI Nicoletti, Giovanni Federico/0000-0003-1182-9028; Gerardi, Rosa
   Maria/0000-0002-8944-530X
CR Adogwa O, 2018, WORLD NEUROSURG, V116, pE996, DOI 10.1016/j.wneu.2018.05.148
   Atkinson L, 2011, J CLIN NEUROSCI, V18, P1295, DOI 10.1016/j.jocn.2011.02.025
   Best NM, 2007, SPINE, V32, P1135, DOI 10.1097/01.brs.0000261486.51019.4a
   de Vos CC, 2014, PAIN, V155, P2426, DOI 10.1016/j.pain.2014.08.031
   Deer TR, 2014, NEUROMODULATION, V17, P599, DOI 10.1111/ner.12204
   Deer TR, 2014, NEUROMODULATION, V17, P571, DOI 10.1111/ner.12206
   Epstein Nancy E, 2017, Surg Neurol Int, V8, P66, DOI 10.4103/sni.sni_49_17
   Ganty P, 2012, BRIT J PAIN, V6, P153, DOI 10.1177/2049463712470222
   Giugno A, 2017, ACTA NEUROCHIR SUPPL, V124, P15, DOI 10.1007/978-3-319-39546-3_3
   Grasso G, 2012, NEUROSURGERY, V71, pE528, DOI 10.1227/NEU.0b013e31825d01f2
   Graziano F, 2019, Br J Neurosurg, P1, DOI 10.1080/02688697.2019.1584267
   Graziano F, 2018, WORLD NEUROSURG, V116, P472, DOI 10.1016/j.wneu.2018.03.039
   Grider J, 2016, PAIN PHYSICIAN, V19, pE33
   Haefeli M, 2008, EUR SPINE J, V17, P104, DOI 10.1007/s00586-007-0541-5
   Harned ME, 2010, PAIN PHYSICIAN, V13, P19
   Higgins DM, 2016, NEUROSURGERY, V78, P127, DOI 10.1227/NEU.0000000000001018
   Hou SY, 2016, NEUROMODULATION, V19, P398, DOI 10.1111/ner.12440
   Kumar K, 2006, NEUROSURGERY, V58, P481, DOI 10.1227/01.NEU.0000192162.99567.96
   Kumar K, 2005, NEUROMODULATION, V8, P213, DOI 10.1111/j.1525-1403.2005.00027.x
   Leveque JC, 2001, NEUROMODULATION, V4, P1, DOI 10.1046/j.1525-1403.2001.00001.x
   McClendon J, 2014, NEUROSURGERY, V74, P42, DOI 10.1227/NEU.0000000000000195
   North RB., 1997, NEUROSURGICAL MANAGE
   North RB, 2007, NEUROSURGERY, V61, P361, DOI 10.1227/01.NEU.0000255522.42579.EA
   Rihn JA, 2012, SPINE, V37, P1933, DOI 10.1097/BRS.0b013e31825e21b2
   Rock AK, 2019, NEUROSURG CLIN N AM, V30, P169, DOI 10.1016/j.nec.2018.12.003
   SHEALY CN, 1967, ANESTH ANAL CURR RES, V46, P489
   Ughratdar I, 2018, WORLD NEUROSURG, V112, P31, DOI 10.1016/j.wneu.2018.01.007
   van Beek M, 2015, DIABETES CARE, V38, pE132, DOI 10.2337/dc15-0740
   Waszak PM, 2016, ASIAN SPINE J, V10, P1195, DOI 10.4184/asj.2016.10.6.1195
   Willems P, 2013, ACTA ORTHOP, V84, P1, DOI 10.3109/17453674.2012.753565
NR 30
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E658
EP E665
DI 10.1016/j.wneu.2019.09.117
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700130
PM 31574335
OA Bronze
DA 2020-05-12
ER

PT J
AU Guan, Y
   Wang, CZ
   Zhu, HG
   Li, J
   Xu, WQ
   Sun, L
   Pan, L
   Dai, JZ
   Wang, Y
   Wang, EM
   Wang, X
AF Guan, Yun
   Wang, Chaozhuang
   Zhu, Huaguang
   Li, Jing
   Xu, Wenqian
   Sun, Lei
   Pan, Li
   Dai, Jiazhong
   Wang, Yang
   Wang, Enmin
   Wang, Xin
TI Hypofractionated Radiosurgery Plus Bevacizumab for Locally Recurrent
   Brain Metastasis with Previously High-Dose Irradiation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bevacizumab; Recurrent brain metastasis; SRS
ID SALVAGE STEREOTACTIC RADIOSURGERY; RADIATION NECROSIS;
   PROGNOSTIC-FACTORS; DIFFERENTIATION
AB BACKGROUND: Selection of appropriate treatment for patients with recurrent brain metastasis (BM) remains uncertain. Recent studies have demonstrated a significant response rate and acceptable toxicity using fractionated stereotactic radiosurgery (FSRS) in patients with locally recurrent large BM. The aim of this study was to evaluate efficacy and toxicity of FSRS with bevacizumab as a new salvage treatment for locally recurrent BM with previous high-dose irradiation.
   METHODS: Patients with recurrent BM previously irradiated were enrolled. Salvage FSRS dose was 9.5-29 Gy (2-5 fractions) with 62%-75% isodose line by CyberKnife according to the brain tumor volume, site, and previous dose. Bevacizumab was prescribed for 4 cycles (5 mg/kg, every 3 weeks). The primary objective was to identify the overall survival after salvage treatment. Secondary objectives included clinical response (Karnofsky performance scale), imaging response (magnetic resonance imaging) and treatment-related adverse events.
   RESULTS: From December 2009 to October 2016, 24 patients were enrolled. The 1-year overall survival after salvage stereotactic radiosurgery was 87.5%. Twenty-three (96%) patients had a positive imaging response with a T2 volume reduction range of 6-22 cm(3) (median 14 cm(3) , P = 0.032, paired t test). Significant clinical improvement was achieved (best Karnofsky performance scale score, P < 0.05, paired t test). Grade 1/2 fatigue was observed in 8 (33%) patients. Grade 3 fatigue and headache occurred in 1 patient.
   CONCLUSIONS: FSRS with adjuvant bevacizumab treatment showed favorable clinical and radiologic control as a salvage treatment regimen. The diagnoses of radiation necrosis and local recurrence after salvage FSRS warrant further study.
C1 [Wang, Xin] Fudan Univ, Huashan Hosp, Dept Neurosurg, Cyberknife Ctr, Shanghai, Peoples R China.
   Fudan Univ, Neurosurg Inst, Shanghai, Peoples R China.
RP Wang, X (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Cyberknife Ctr, Shanghai, Peoples R China.
EM wangxinck@fudan.edu.cn
FU Science and Technology Commission of Shanghai MunicipalityScience &
   Technology Commission of Shanghai Municipality (STCSM) [16411954000]
FX The study was supported by research grant from the Science and
   Technology Commission of Shanghai Municipality (No 16411954000).
CR ARBIT E, 1995, CANCER, V76, P765, DOI 10.1002/1097-0142(19950901)76:5<765::AID-CNCR2820760509>3.0.CO;2-E
   Caballero JA, 2012, INT J RADIAT ONCOL, V83, P303, DOI 10.1016/j.ijrobp.2011.06.1987
   Chao ST, 2008, CANCER, V113, P2198, DOI 10.1002/cncr.23821
   Chao ST, 2013, INT J RADIAT ONCOL, V87, P449, DOI 10.1016/j.ijrobp.2013.05.015
   Chernov M, 2005, MINIM INVAS NEUROSUR, V48, P228, DOI 10.1055/s-2005-870952
   Deibert CP, 2013, J NEURO-ONCOL, V115, P217, DOI 10.1007/s11060-013-1214-3
   Furuse M, 2011, J NEURO-ONCOL, V102, P471, DOI 10.1007/s11060-010-0333-3
   Gutin PH, 2009, INT J RADIAT ONCOL, V75, P156, DOI 10.1016/j.ijrobp.2008.10.043
   Koffer P, 2017, WORLD NEUROSURG, V104, P589, DOI 10.1016/j.wneu.2017.04.103
   Kurtz G, 2014, INT J RADIAT ONCOL, V88, P137, DOI 10.1016/j.ijrobp.2013.10.003
   Levin VA, 2011, INT J RADIAT ONCOL, V79, P1487, DOI 10.1016/j.ijrobp.2009.12.061
   Lubelski D, 2013, J NEURO-ONCOL, V115, P317, DOI 10.1007/s11060-013-1233-0
   Mckay WH, 2017, J NEUROSURG, V127, P148, DOI 10.3171/2016.5.JNS153051
   Minniti G, 2016, J NEURO-ONCOL, V126, P91, DOI 10.1007/s11060-015-1937-4
   Mitsuya K, 2010, J NEURO-ONCOL, V99, P81, DOI 10.1007/s11060-009-0106-z
   Muller-Riemenschneider F, 2009, RADIOTHER ONCOL, V91, P67, DOI 10.1016/j.radonc.2008.12.001
   Rana N, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00279
   Rush S, 2011, J NEUROSURG, V115, P37, DOI 10.3171/2011.2.JNS101724
   Terakawa Y, 2008, J NUCL MED, V49, P694, DOI 10.2967/jnumed.107.048082
   Wang X, 2012, INT J RADIAT ONCOL, V83, pE223, DOI 10.1016/j.ijrobp.2011.12.051
   Wang Y, 2014, J NEURO-ONCOL, V119, P369, DOI 10.1007/s11060-014-1488-0
   Yomo S, 2016, J NEURO-ONCOL, V127, P119, DOI 10.1007/s11060-015-2019-3
NR 22
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E252
EP E258
DI 10.1016/j.wneu.2019.08.233
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700032
PM 31505283
OA Bronze
DA 2020-05-12
ER

PT J
AU Guo, R
   Chen, RQ
   Yu, ZY
   Zhao, X
   You, C
   Li, H
   Ma, L
AF Guo, Rui
   Chen, Ruiqi
   Yu, Zhiyuan
   Zhao, Xin
   You, Chao
   Li, Hao
   Ma, Lu
TI Primary Intraventricular Hemorrhage in Pediatric Patients: Causes,
   Characteristics, and Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Pediatric; Primary intraventricular hemorrhage; Surgery; Vascular
   disorders
ID ARTERIOVENOUS-MALFORMATION; CLINICAL-FEATURES; RISK-FACTORS; ETIOLOGY;
   MULTICENTER; RESOLUTION; ADULTS; YIELD
AB BACKGROUND: Primary intraventricular hemorrhage (PIVH) is rare, and causes, characteristics, and outcomes remain unknown in children.
   METHODS: We retrospectively analyzed the clinical characteristics of patients 1 month to 21 years of age who were admitted to the hospital with PIVH over a 7-year period. PIVH was defined as bleeding confined to the ventricular system without parenchymal or subarachnoid hemorrhage involvement.
   RESULTS: Of 18 included patients, 55.6% were female, and mean age was 13.8 +/- 6.0 years. The most common presenting symptoms were headache (77.8%) and vomiting (33.3%). In 15 patients (83.3%), known etiologies were diagnosed, including arteriovenous malformations (66.7%), moyamoya disease (11.1%), and aneurysms (5.6%). Idiopathic PIVH was the diagnosis in 3 patients (16.7%). Surgery was performed in 15 patients (83.3%), and 3 patients (16.7%) received conservative treatment. Four patients (28.6%) had an unfavorable outcome at discharge, and 3 patients (16.7%) had an unfavorable outcome at the 3-month follow-up. Higher Graeb score was associated with an unfavorable outcome in both short-term and long-term follow-up.
   CONCLUSIONS: Arteriovenous malformations were diagnosed in most pediatric patients with PIVH. Specific surgical treatment of underlying etiologies should be required to increase clinical improvement. Children with a higher Graeb score at admission tended to have poor early and late outcomes.
C1 [Guo, Rui; Chen, Ruiqi; Yu, Zhiyuan; You, Chao; Li, Hao; Ma, Lu] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Zhao, Xin] Sichuan Univ, West China Sch Clin Med, Chengdu, Sichuan, Peoples R China.
RP Ma, L (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM huaxi_malu@163.com
CR Amlie-Lefond C, 2016, PEDIATR NEUROL, V56, P3, DOI 10.1016/j.pediatrneurol.2015.10.021
   Angelopoulos M, 1995, SURG NEUROL, V44, P433, DOI 10.1016/0090-3019(95)00261-8
   Arboix A, 2012, ISRN NEUROL, V2012
   Carhuapoma JR, 2002, J NEUROL SCI, V202, P1, DOI 10.1016/S0022-510X(02)00242-3
   DARBY DG, 1988, NEUROLOGY, V38, P68, DOI 10.1212/WNL.38.1.68
   Flint AC, 2008, NEUROCRIT CARE, V8, P330, DOI 10.1007/s12028-008-9070-2
   Giray S, 2009, TURK NEUROSURG, V19, P338
   GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795
   Hameed Bilal, 2005, JPMA Journal of the Pakistan Medical Association, V55, P315
   Hanley DF, 2017, LANCET, V389, P603, DOI 10.1016/S0140-6736(16)32410-2
   Hinson HE, 2010, CURR NEUROL NEUROSCI, V10, P73, DOI 10.1007/s11910-010-0086-6
   JAYAKUMAR PN, 1989, ACTA NEUROL SCAND, V80, P1, DOI 10.1111/j.1600-0404.1989.tb03833.x
   Kiymaz N, 2005, ADV THER, V22, P447, DOI 10.1007/BF02849864
   Kumar K, 2003, NEUROSURGERY, V52, P964, DOI 10.1227/01.NEU.0000053028.06474.C6
   Marti-Fabregas J, 1999, J NEUROL, V246, P287, DOI 10.1007/s004150050348
   MATSUSHIMA M, 1973, J NEUROSURG, V39, P666, DOI 10.3171/jns.1973.39.5.0666
   Naff NJ, 2001, NEUROSURGERY, V49, P614, DOI 10.1097/00006123-200109000-00015
   Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd
   Parmar Ramesh C, 2002, J Indian Med Assoc, V100, P254
   Passero S, 2002, ACTA NEUROL SCAND, V105, P115, DOI 10.1034/j.1600-0404.2002.1o118.x
   Rayen BS, 2005, EMERG MED J, V22, P672, DOI 10.1136/emj.2003.010116
   Srivastava T, 2014, NEUROL INDIA, V62, P144, DOI 10.4103/0028-3886.132333
   Staykov D, 2009, STROKE, V40, P3275, DOI 10.1161/STROKEAHA.109.551945
   Vaartjes I, 2009, CEREBROVASC DIS, V28, P564, DOI 10.1159/000247600
   Vazquez-Lopez M E, 2005, An Pediatr (Barc), V62, P583, DOI 10.1157/13075552
   Wagner I, 2012, EUR J NEUROL, V19, P1477, DOI 10.1111/j.1468-1331.2011.03628.x
   Webb AJS, 2012, STROKE, V43, P1666, DOI 10.1161/STROKEAHA.112.650523
   Ziai WC, 2014, INT J STROKE, V9, P536, DOI 10.1111/ijs.12097
NR 28
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E121
EP E128
DI 10.1016/j.wneu.2019.08.145
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700016
PM 31476469
OA Bronze
DA 2020-05-12
ER

PT J
AU Hall, S
   Stephens, JR
   Myers, MA
   Elmansouri, A
   Geoghegan, K
   Harrison, CH
   Nagy, E
   Anbu, D
   Parton, WJC
   Payne, DR
   Seaby, E
   Border, S
AF Hall, Samuel
   Stephens, Jonny R.
   Myers, Matthew A.
   Elmansouri, Ahmad
   Geoghegan, Kate
   Harrison, Charlotte H.
   Nagy, Eva
   Anbu, Deepika
   Parton, William J. C.
   Payne, December R.
   Seaby, Eleanor
   Border, Scott
TI The Career Impact of the National Undergraduate Neuroanatomy Competition
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neuroanatomy competition; Neurosurgery careers; Undergraduate events
ID MEDICAL-STUDENTS; NEUROSURGERY; EXPOSURE; MOTIVATION
AB BACKGROUND: Neurosurgery is a notoriously difficult to enter and requires medical students to engage in extracurricular activities to demonstrate their commitment to the specialty. The National Undergraduate Neuroanatomy Competition (NUNC) was established in 2013 as a means for students to display this commitment as well as academic ability.
   METHODS: A bespoke 22-item questionnaire was designed to determine career outcomes and the role of competition attendance in job applications. It was distributed using the SurveyMonkey website to the 87 attendees at the 2013 and 2014 competitions.
   RESULTS: Responses were received by 40 competitors (response rate, 46.0%). Twenty-four responders (60.0%) intended to pursue a career in either neurosurgery (n = 18) or neurology (n = 6). This included 10 responders (25.0%) who had successfully entered either neurosurgery (n = 9) or neurology (n = 1). The performance of these 10 was significantly better than the other responders (57.0 +/- 13.6% vs. 46.5 +/- 13.5% En = 30]; P = D.036). Seventeen responders (42.5%) either included their attendance at NUNC in a post-Foundation job application or intend to.
   CONCLUSIONS: The NUNC provides the opportunity for medical students to demonstrate their interest in neurosurgery. It has the potential to be used as a tool for recognizing medical students suitable for neurosurgery training.
C1 [Hall, Samuel; Stephens, Jonny R.; Myers, Matthew A.; Elmansouri, Ahmad; Geoghegan, Kate; Harrison, Charlotte H.; Nagy, Eva; Anbu, Deepika; Parton, William J. C.; Payne, December R.; Seaby, Eleanor; Border, Scott] Univ Southampton, Fac Med, Ctr Learning Anat Sci, Southampton, Hants, England.
   [Hall, Samuel] Univ Hosp NHS Fdn Trust, Wessex Neurol Ctr, Dept Neurosurg, Southampton, Hants, England.
   [Stephens, Jonny R.] London North West Univ Healthcare NHS Trust, Imperial Sch Anaesthet, London, England.
   [Seaby, Eleanor] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
RP Hall, S (reprint author), Univ Southampton, Fac Med, Ctr Learning Anat Sci, Southampton, Hants, England.; Hall, S (reprint author), Univ Hosp NHS Fdn Trust, Wessex Neurol Ctr, Dept Neurosurg, Southampton, Hants, England.
EM Samuel.hall@doctors.org.uk
RI Seaby, Eleanor G/AAM-7744-2020
OI Seaby, Eleanor G/0000-0002-6814-8648
CR Agarwal Nitin, 2013, World Neurosurg, V80, P745, DOI 10.1016/j.wneu.2013.08.027
   Clark DJ, 2016, BRIT J NEUROSURG, V30, P4, DOI 10.3109/02688697.2015.1114590
   Daniels M, 2017, WORLD NEUROSURG, V101, P350, DOI 10.1016/j.wneu.2017.02.028
   Dowie MJ, 2017, NEUROSCIENTIST, V23, P7, DOI 10.1177/1073858415600150
   El-Beheiry M, 2017, SURG ENDOSC, V31, P1643, DOI 10.1007/s00464-016-5152-y
   Enter DH, 2015, ANN THORAC SURG, V99, P870, DOI 10.1016/j.athoracsur.2014.09.051
   Haggerty KA, 2014, ANN THORAC SURG, V97, P2111, DOI 10.1016/j.athoracsur.2014.02.029
   Hall SR, 2014, EUR J ANAT, V18, P327
   Hanrahan J, 2019, BRIT J NEUROSURG, V33, P76, DOI 10.1080/02688697.2018.1527288
   Hanrahan J, 2018, ANN MED SURG, V34, P75, DOI 10.1016/j.amsu.2018.08.002
   Hashimoto DA, 2015, J SURG EDUC, V72, P1077, DOI 10.1016/j.jsurg.2015.06.005
   Health Education England, COMP RAT 2018
   Jiang GC, 2016, MED EDUC ONLINE, V21, DOI 10.3402/meo.v21.29889
   Joshi L, 2011, EYE, V25, P1027, DOI 10.1038/eye.2011.114
   Leraas HJ, 2018, J SURG EDUC, V75, P644, DOI 10.1016/j.jsurg.2017.09.007
   Leschke JM, 2018, WORLD NEUROSURG, V113, pE529, DOI 10.1016/j.wneu.2018.02.082
   Mathew RK, 2017, BRIT J HOSP MED, V78, pC45, DOI 10.12968/hmed.2017.78.3.C45
   McAbee JH, 2015, J NEUROSURG, V123, P161, DOI 10.3171/2014.12.JNS141348
   Mummareddy N, 2018, WORLD NEUROSURG, V110, P504, DOI 10.1016/j.wneu.2017.10.131
   Myers M, 12 TIPS MED STUDENTS
   National Resident Matching Program, CHART OUTC MATCH US
   Ottenhausen M, 2018, WORLD NEUROSURG, V120, pE100, DOI 10.1016/j.wneu.2018.07.195
   Saeed F, 2016, BMJ-BRIT MED J, V355
   The Russian Government Tyumen region, INT NEUR OL START TY
   Van Nuland SE, 2015, ANAT SCI EDUC, V8, P404, DOI 10.1002/ase.1498
   Zuccato JA, 2016, CAN J NEUROL SCI, V43, P410, DOI 10.1017/cjn.2015.332
   Zuckerman SL, 2016, WORLD NEUROSURG, V86, P120, DOI 10.1016/j.wneu.2015.08.081
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E535
EP E539
DI 10.1016/j.wneu.2019.09.086
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700114
PM 31562974
OA Bronze
DA 2020-05-12
ER

PT J
AU Harland, TA
   Wang, M
   Gunaydin, D
   Fringuello, A
   Freeman, J
   Hosokawa, PW
   Ormond, DR
AF Harland, Tessa A.
   Wang, Mary
   Gunaydin, Dicle
   Fringuello, Anthony
   Freeman, Jacob
   Hosokawa, Patrick W.
   Ormond, D. Ryan
TI Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor outcomes; Frailty; Hopkins Frailty score; Neurosurgery
ID OLDER-ADULTS; GLIOBLASTOMA-MULTIFORME; WOMENS HEALTH; RISK-FACTORS;
   RESECTION; EXTENT; DISABILITY; MORTALITY; SURVIVAL; PROGRAM
AB BACKGROUND: Preoperative risk assessment is important, but inexact because physiologic reserves are difficult to measure. When assessing quality of life for patients with brain tumors, having a better predictor of postsurgical outcome would be beneficial in counseling these patients. Frailty is thought to estimate physiologic reserves, and it has been found to predict postoperative complications, length of stay, and discharge to a skilled nursing facility or assisted living facility in patients undergoing various types of surgery. Frailty as an adjunct to preoperative assessment of neurosurgical patients has never been evaluated. This study aimed to determine whether frailty predicts neurosurgical complications in patients with brain tumors and enhances current perioperative risk models.
   METHODS: Frailty was preoperatively assessed in 260 patients undergoing surgery for brain tumor resection using a validated scale that assessed weakness, weight loss, exhaustion, low physical activity, and slowed walking speed. Patients were classified as nonfrail (score of 0-1), moderately frail (score of 2-3), or frail (score of 4-5). Moderately frail and frail patients were combined for analysis.
   RESULTS: Preoperative frailty was associated with an increased risk for discharge to a location other than home (10.36; 95% confidence interval, 3.6-30.1), postoperative complications (2.09; 95% confidence interval, 1.09-3.98), and a longer length of stay (1.66; 95% confidence interval, 1.24-2.21).
   CONCLUSIONS: Frailty independently predicts discharge disposition, postoperative complications, and length of stay in patients undergoing surgery for brain tumor resection. Preoperative assessment of frailty can help neurosurgeons and patients make more informed decisions about pursing surgical treatment.
C1 [Harland, Tessa A.; Wang, Mary; Gunaydin, Dicle; Fringuello, Anthony; Freeman, Jacob; Hosokawa, Patrick W.; Ormond, D. Ryan] Univ Colorado, Dept Neurosurg, Sch Med, Aurora, CO 80045 USA.
RP Ormond, DR (reprint author), Univ Colorado, Dept Neurosurg, Sch Med, Aurora, CO 80045 USA.
EM david.ormond@cuanschutz.edu
RI Ormond, David Ryan/R-4847-2017
OI Ormond, David Ryan/0000-0001-7027-2915
CR Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262
   Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716
   Buchner D M, 1992, Clin Geriatr Med, V8, P1
   Cameron ID, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-65
   Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315
   Dasgupta M, 2009, ARCH GERONTOL GERIAT, V48, P78, DOI 10.1016/j.archger.2007.10.007
   Davenport DL, 2006, ANN SURG, V243, P636, DOI 10.1097/01.sla.0000216508.95556.cc
   Eagle KA, 2002, J AM COLL CARDIOL, V39, P542, DOI 10.1016/S0735-1097(01)01788-0
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585
   Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115
   Gill TM, 2003, ARCH PHYS MED REHAB, V84, P394, DOI 10.1053/apmr.2003.50020
   Inouye SK, 2007, J AM GERIATR SOC, V55, P780, DOI 10.1111/j.1532-5415.2007.01156.x
   Keles GE, 1999, SURG NEUROL, V52, P371, DOI 10.1016/S0090-3019(99)00103-2
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Lee DH, 2010, CIRCULATION, V121, P973, DOI 10.1161/CIRCULATIONAHA.108.841437
   Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043
   Lin HS, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0329-8
   Makary MA, 2010, J AM COLL SURGEONS, V210, P901, DOI 10.1016/j.jamcollsurg.2010.01.028
   Partridge JSL, 2012, AGE AGEING, V41, P142, DOI 10.1093/ageing/afr182
   Purser JL, 2006, J AM GERIATR SOC, V54, P1674, DOI 10.1111/j.1532-5415.2006.00914.x
   Revenig LM, 2013, J AM COLL SURGEONS, V217, P665, DOI 10.1016/j.jamcollsurg.2013.06.012
   Robinson TN, 2009, ANN SURG, V250, P449, DOI 10.1097/SLA.0b013e3181b45598
   Saklad M, 1941, ANESTHESIOLOGY, V2, P281, DOI DOI 10.1097/00000542-194105000-00004
   Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf
   SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8
   Smith JS, 2008, J CLIN ONCOL, V26, P1338, DOI 10.1200/JCO.2007.13.9337
   Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742
   Wilson JRM, 2005, BJU INT, V95, P794, DOI 10.1111/j.1464-410X.2005.05403.x
   Woods NF, 2005, J AM GERIATR SOC, V53, P1321, DOI 10.1111/j.1532-5415.2005.53405.x
NR 30
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E813
EP E818
DI 10.1016/j.wneu.2019.10.010
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700150
PM 31605842
OA Bronze
DA 2020-05-12
ER

PT J
AU Hou, K
   Li, GC
   Luan, TF
   Xu, K
   Xu, BF
   Yu, JL
AF Hou, Kun
   Li, Guichen
   Luan, Tengfei
   Xu, Kan
   Xu, Baofeng
   Yu, Jinlu
TI Anatomical Study of Anterior Inferior Cerebellar Artery and Its
   Reciprocal Relationship with Posterior Inferior Cerebellar Artery Based
   on Angiographic Data
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior inferior cerebellar artery; Digital subtraction angiography;
   Posterior inferior cerebellar artery; Variation
AB BACKGROUND: Anterior inferior cerebellar artery (AICA) can present with a myriad of variations. However, the previous studies of AICA anatomy were based on small-scale cadaveric investigation. In this study, we performed an angiographic study of AICA in 500 Chinese with Han nationality based on digital subtraction angiography (DSA).
   METHODS: Patients admitted to our institution between 2015 and 2018 who had underwent DSA were potential candidates for this retrospective evaluation. The exclusion criteria were: a) patients with vascular diseases of the posterior circulation; b) ischemic diseases or moyamoya disease of the anterior circulation.
   RESULTS: Five hundred patients were identified. The patients ranged in age from 6 to 75 years. Two hundred thirty-seven (62.9%, 237 of 377) patients had bilateral AICAs at the same level, and 140 (37.1%, 140 of 377) had bilateral AICAs at different levels. The developing states of AICA were grade 0 in 31 (3.5%, 31 of 896), grade 1 in 373 (41.6%, 373 of 896), grade 2 in 313 (34.9%, 313 of 896), and grade 3 in 179 (20.0%, 179 of 896) hemispheres. Two hundred twenty-one (22.1%, 221 of 1000) presented with AICA-PICA common trunks. Thirty-one (3.1%, 31 of 1000) hemispheres showed no obvious AICA angiographically. AICA arose as a single trunk in 865 (86.5%, 865 of 1000) hemispheres, and as duplicate trunks in 104 (10.4%, 10 of 1000) hemispheres. Triplicate or more trunks were not seen. AICA originating from the basilar artery fenestration accounted for 4% (20 of 500) of the cases.
   CONCLUSIONS: This is the first attempt using DSA data to perform a large-scale investigation of AICA variations. The ever-growing need of endovascular intervention calls for more suitable anatomical explanation of the vascular structures.
C1 [Hou, Kun; Luan, Tengfei; Xu, Kan; Xu, Baofeng; Yu, Jinlu] First Hosp Jilin Univ, Dept Neurosurg, Changchun, Jilin, Peoples R China.
   [Li, Guichen] First Hosp Jilin Univ, Dept Neurol, Changchun, Jilin, Peoples R China.
RP Yu, JL (reprint author), First Hosp Jilin Univ, Dept Neurosurg, Changchun, Jilin, Peoples R China.
EM jlyu@jlu.edu.cn
RI ; Yu, Jinlu/G-7719-2019
OI Hou, Kun/0000-0001-7112-7883; Yu, Jinlu/0000-0003-2329-7946
CR Chen MM, 2018, J STROKE CEREBROVASC, V27, pE59, DOI 10.1016/j.jstrokecerebrovasdis.2017.10.007
   Delion M, 2017, CEREBELLUM, V16, P880, DOI 10.1007/s12311-016-0828-3
   Hou K, 2019, WORLD NEUROSURG, V126, P301, DOI 10.1016/j.wneu.2019.03.070
   Krings T, 2015, NEUROVASCULAR ANATOM, P94
   Lasjaunias PBA, 2001, SURG NEUROANGIOGRAPH, P243
   Lee H, 2002, STROKE, V33, P2807, DOI 10.1161/01.STR.0000038692.17290.24
   MARTIN RG, 1980, NEUROSURGERY, V6, P483, DOI 10.1227/00006123-198005000-00001
   Pekcevik Y, 2014, SURG RADIOL ANAT, V36, P455, DOI 10.1007/s00276-013-1208-z
   RHOTON AL, 2000, [No title captured], V47, pS2
   Rodriguez-Hernandez A, 2011, J NEUROSURG, V115, P387, DOI 10.3171/2011.3.JNS101413
   Shimano H, 2016, WORLD NEUROSURG, V92, P15, DOI 10.1016/j.wneu.2016.04.100
   Songur A, 2008, SURG RADIOL ANAT, V30, P257, DOI 10.1007/s00276-008-0309-6
   Stojanovic B, 2017, SURG RADIOL ANAT, V39, P689, DOI 10.1007/s00276-016-1764-0
NR 13
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E459
EP E472
DI 10.1016/j.wneu.2019.09.047
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700104
PM 31526888
OA Bronze
DA 2020-05-12
ER

PT J
AU Huang, H
   O'Neill, AH
   Chandra, RV
   Lai, LT
AF Huang, Helen
   O'Neill, Anthea H.
   Chandra, Ronil, V
   Lai, Leon T.
TI Asymptomatic Intracranial Aneurysms in the Elderly: Long-Term Clinical
   and Radiologic Follow-Up of 193 Consecutive Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aged; Conservative treatment; Intracranial aneurysm; Natural history;
   Observation; Population surveillance; Risk factors
ID UNRUPTURED CEREBRAL ANEURYSMS; RISK-FACTORS; NATURAL-HISTORY; GROWTH;
   RUPTURE; ANGIOGRAPHY; ENLARGEMENT; SINGLE
AB BACKGROUND: Evidence is lacking regarding the role of radiologic surveillance for asymptomatic intracranial aneurysms (AIAs) in the elderly (>= 65 years). We sought to establish if long-term clinical and radiologic observation is warranted for older patients with AIAs.
   METHODS: A retrospective cohort of 193 consecutive patients with 255 AIAs were clinically and radiologically observed between January 2011 and January 2019. The primary end points were documented aneurysm growth, subarachnoid hemorrhage, or definitive treatment with microsurgical clipping or endovascular coiling. Baseline patient and aneurysm characteristics were obtained. Univariate and multivariate comparisons were performed.
   RESULTS: Aneurysm growth was observed in 8 patients (4.2%) at a median follow-up of 58.2 months (interquartile range, 38.4-78.5 months). The median aneurysm size at initial diagnosis was 3.5 mm (interquartile range, 2.2-5 mm). Aneurysms larger than 7 mm selected for surveillance were noted in 37 patients (19.2%). The growth rate was estimated at 0.2 mm per person-year. At the end of the study period, 175 patients (90.7%) were alive, 6 (3.1%) were lost to follow-up, and 12 (6.2%) died of unrelated causes. During the 1025.2 person-years follow-up, no patient had experienced subarachnoid hemorrhage, and none required definitive treatment. The presence of aneurysmal bleb (odds ratio, 6.02; 95% confidence interval, 1.15-31.43; P = 0.033) and multiple intracranial aneurysms (odds ratio, 10.98; 95% confidence interval, 1.27-94.91; P = 0.029) were associated with growth.
   CONCLUSIONS: AIAs in older patients deemed suitable for conservative management do not require robust follow-up. The current study suggests a potential role for closer surveillance for patients with multiple intracranial aneurysms or aneurysms with bleb morphology.
C1 [Huang, Helen; O'Neill, Anthea H.; Lai, Leon T.] Monash Hlth, Dept Neurosurg, Clayton, Vic, Australia.
   [Chandra, Ronil, V] Monash Hlth, Dept Imaging, Neuro Intervent Radiol Unit, Clayton, Vic, Australia.
   [Chandra, Ronil, V; Lai, Leon T.] Monash Med Ctr, Dept Surg, Clayton, Vic, Australia.
RP Lai, LT (reprint author), Monash Hlth, Dept Neurosurg, Clayton, Vic, Australia.; Lai, LT (reprint author), Monash Med Ctr, Dept Surg, Clayton, Vic, Australia.
EM Leon.Lai@monashhealth.org
OI Chandra, Ronil/0000-0001-7555-2297
CR ASARI S, 1993, CLIN NEUROL NEUROSUR, V95, P205, DOI 10.1016/0303-8467(93)90125-Z
   Backes D, 2016, STROKE, V47, P951, DOI 10.1161/STROKEAHA.115.012162
   Backes D, 2015, STROKE, V46, P1221, DOI 10.1161/STROKEAHA.114.008198
   Bor ASE, 2015, STROKE, V46, P42, DOI 10.1161/STROKEAHA.114.005963
   Brinjikji W, 2016, AM J NEURORADIOL, V37, P615, DOI 10.3174/ajnr.A4575
   Burns JD, 2009, STROKE, V40, P406, DOI 10.1161/STROKEAHA.108.519165
   Chen XD, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010771
   Chien AC, 2013, J NEUROSURG, V119, P190, DOI 10.3171/2013.3.JNS121469
   Edward MT, 2016, WORLD NEUROSURG, V90, P20, DOI 10.1016/j.wneu.2016.02.008
   Etminan N, 2016, NAT REV NEUROL, V12, P699, DOI 10.1038/nrneurol.2016.150
   Frosen J, 2014, TRANSL STROKE RES, V5, P347, DOI 10.1007/s12975-014-0340-3
   Gondar R, 2016, J NEUROL NEUROSUR PS, V87, P1277, DOI 10.1136/jnnp-2016-313584
   Gualdi-Russo E, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16224336
   HisHikawa T, 2017, NEUROL MED-CHIR, V57, P247, DOI 10.2176/nmc.ra.2016-0286
   Hishikawa T, 2015, NEUROLOGY, V85, P1879, DOI 10.1212/WNL.0000000000002149
   Inoue T, 2012, J NEUROSURG, V117, P20, DOI 10.3171/2012.4.JNS112225
   Jeon JS, 2014, J NEUROL NEUROSUR PS, V85, P289, DOI 10.1136/jnnp-2013-305019
   Juvela S, 2019, J NEUROSURG, V131, P843, DOI 10.3171/2018.4.JNS18687
   Juvela S, 2017, NEUROSURGERY, V81, P432, DOI 10.1093/neuros/nyw049
   Koffijberg H, 2008, J NEUROSURG, V109, P176, DOI 10.3171/JNS/2008/109/8/0176
   Kubo Y, 2014, J NEUROSURG, V121, P599, DOI 10.3171/2014.5.JNS132048
   Matsubara S, 2004, J NEUROSURG, V101, P908, DOI 10.3171/jns.2004.101.6.0908
   Matsumoto K, 2013, ACTA NEUROCHIR, V155, P211, DOI 10.1007/s00701-012-1566-z
   Mehan WA, 2014, J NEUROINTERV SURG, V6, P761, DOI 10.1136/neurintsurg-2013-010944
   Miyazawa N, 2006, NEUROSURGERY, V58, P1047, DOI 10.1227/01.NEU.0000217366.02567.D2
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   O'Neill AH, 2019, J CLIN NEUROSCI, V62, P38, DOI 10.1016/j.jocn.2019.01.013
   Phan TG, 2002, J NEUROSURG, V97, P1023, DOI 10.3171/jns.2002.97.5.1023
   Ramachandran M, 2016, J NEUROSURG, V124, P288, DOI 10.3171/2015.2.JNS142265
   Rinaldo L, 2017, WORLD NEUROSURG, V108, P662, DOI 10.1016/j.wneu.2017.09.092
   Serrone JC, 2016, J NEUROSURG, V125, P1374, DOI 10.3171/2015.12.JNS151552
   So TY, 2010, J CLIN NEUROSCI, V17, P29, DOI 10.1016/j.jocn.2009.04.010
   Sonobe M, 2010, STROKE, V41, P1969, DOI 10.1161/STROKEAHA.110.585059
   Sturiale CL, 2013, STROKE, V44, P1897, DOI 10.1161/STROKEAHA.113.001524
   Villablanca JP, 2013, RADIOLOGY, V269, P258, DOI 10.1148/radiol.13121188
   Wermer MJH, 2006, STROKE, V37, P414, DOI 10.1161/01.STR.0000199077.06390.35
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Zylkowski J, 2015, VIDEOSURGERY MINIINV, V10, P178, DOI 10.5114/wiitm.2015.52707
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E600
EP E608
DI 10.1016/j.wneu.2019.09.103
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700122
PM 31568912
OA Bronze
DA 2020-05-12
ER

PT J
AU Hwang, SH
   Park, SW
   Kim, YB
AF Hwang, Sung Hwan
   Park, Seung-Won
   Kim, Young-Baeg
TI Risk Factors for Symptomatic Contralateral Foraminal Stenosis After
   Unilateral Transforaminal Lumbar Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cage location; Contralateral foraminal stenosis; Lumbar sagittal range
   of motion; Unilateral transforaminal lumbar interbody fusion
ID TITANIUM CAGES; SINGLE CAGE; POSTERIOR; MOTION; TLIF
AB OBJECTIVE: The most common cause of contralateral symptoms after unilateral transforaminal lumbar interbody fusion (TLIF) is contralateral foraminal stenosis (FS). This retrospective cohort study aimed to investigate the cause of and risk factors for contralateral FS after unilateral TLIF with a single cage.
   METHODS: Patients with degenerative lumbar spinal disorders who underwent unilateral TLIF at L4-5 were divided into 2 groups: those without contralateral radicular symptoms after surgery (group A; n = 340) and those with contralateral radicular symptoms after surgery (group B; n = 16). We investigated the influence of various radiological and cage-related factors on postoperative contralateral FS with radicular symptoms. The cage location indicates whether the cage's anterior tip crosses the disc midline-exceeding 50%-and in such a case, how far.
   RESULTS: Group B showed significantly increased postoperative corona! angle and sagittal angle and decreased contralateral foraminal height and foraminal area. Statistically significant (P < 0.01) factors according to the multivariate logistic regression analysis were the preoperative sagittal range of motion (odds ratio [OR]: 1.562, P = 0.004) and cage location (OR: 2.047, P = 0.015). The cutoff values for the sagittal range of motion and the cage location were 9.0 and 50.5%, respectively. The preoperative and postoperative 6-month visual analog scale scores and Oswestry disability index values were not significantly different between the groups.
   CONCLUSIONS: The 2 most meaningful risk factors were the preoperative sagittal range of motion and cage location. Inserting the cage beyond the disc midline, especially in patients with a high preoperative sagittal range of motion (>= 9.0 degrees), would help reduce postoperative complications.
C1 [Hwang, Sung Hwan] Armed Forces Capital Hosp Korea, Dept Neurosurg, Seongnam, South Korea.
   [Park, Seung-Won; Kim, Young-Baeg] Chung Ang Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
RP Park, SW (reprint author), Chung Ang Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM nspsw@cau.ac.kr
RI Won, Park Seung/F-2877-2014
OI Won, Park Seung/0000-0001-8305-7501
CR Blumenthal S, 2005, SPINE, V30, P1565, DOI 10.1097/01.brs.0000170587.32676.0e
   Brantigan JW, 2000, SPINE, V25, P1437, DOI 10.1097/00007632-200006010-00017
   DVORAK J, 1991, SPINE, V16, P562
   El Masry MA, 2008, ACTA ORTHOP BELG, V74, P667
   Fogel GR, 2007, J SPINAL DISORD TECH, V20, P60, DOI 10.1097/01.bsd.0000211251.59953.a4
   Hackenberg L, 2005, EUR SPINE J, V14, P551, DOI 10.1007/s00586-004-0830-1
   Harris BM, 2004, SPINE, V29, pE65, DOI 10.1097/01.BRS.0000113034.74567.86
   Humphreys SC, 2001, SPINE, V26, P567
   Hunt T, 2007, EUR SPINE J, V16, pS311, DOI 10.1007/s00586-007-0387-x
   Iwata T, 2015, J SPINAL DISORD TECH, V28, pE270, DOI 10.1097/BSD.0b013e318286bb14
   Jang KM, 2015, J KOREAN NEUROSURG S, V58, P350, DOI 10.3340/jkns.2015.58.4.350
   Kroppenstedt S, 2008, SPINE, V33, P2083, DOI 10.1097/BRS.0b013e31818448a9
   Leferink VJM, 2002, EUR SPINE J, V11, P2, DOI 10.1007/s005860100331
   Louis R., 1983, SURG SPINE SURG ANAT
   Ray CD, 1997, SPINE, V22, P667, DOI 10.1097/00007632-199703150-00019
   Schwender JD, 2005, J SPINAL DISORD TECH, V18, pS1, DOI 10.1097/01.bsd.0000132291.50455.d0
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Turner P., 1994, ANN M SPIN SOC AUSTR
   Wei F, 2010, CHINESE MED J-PEKING, V123, P1422, DOI 10.3760/cma.j.issn.0366-6999.2010.11.013
   Yang Y, 2018, EUR SPINE J, V27, P1925, DOI 10.1007/s00586-017-5417-8
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E452
EP E458
DI 10.1016/j.wneu.2019.09.048
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700103
PM 31526879
OA Bronze
DA 2020-05-12
ER

PT J
AU Ikeda, N
   Odate, S
   Shikata, J
AF Ikeda, Norimasa
   Odate, Seiichi
   Shikata, Jitsuhiko
TI Compensatory Mechanisms for Kyphotic Change in the Cervical Spine
   According to Alignment Analysis of the Cases after Anterior Cervical
   Corpectomy and Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alignment analysis; Anterior cervical corpectomy and fusion; Cervical
   spine; Compensatory mechanisms; Kyphosis; Kyphotic change
ID 3 RECONSTRUCTIVE TECHNIQUES; SURGICAL-MANAGEMENT; SAGITTAL ALIGNMENT;
   DEFORMITY; 4-LEVEL; SLOPE; ANGLE; LINE; COBB
AB BACKGROUND: Compensatory mechanisms for cervical kyphosis are unclear. Few alignment analyses have targeted ongoing cervical kyphosis and detailed the effects of compensatory alignment changes.
   METHODS: We analyzed the radiographic alignment parameters of 31 patients (21 men and 10 women) with postoperative kyphotic changes after anterior cervical corpectomy and fusion (ACCF) between 2006 and 2015. This analysis included lordotic angle of the fusion area, fusion area length, cervical lordosis angle (CL), 0-C7 angle (0-C7a), and cervical sagittal vertical axis (cSVA) as basic parameters and occipito-C2 angle (0-C2a), adjacent cranial angle, adjacent caudal angle, and T1 slope as compensatory parameters at 2 time points after surgery.
   RESULTS: Alignment analysis revealed that CL was significantly decreased by 5.0 +/- 7.7 (P < 0.01) and 0-C7a was changed by only -0.2 +/- 6.8 (P = 0.75). An inverse correlation was found between Delta CL and Delta 0-C2a (rho = -0.40), with a nearly 1:1 relationship in the scatter diagram. Delta T1 slope had no direct compensatory correlation with Delta CL (P = 0.28) but was strongly correlated with Delta cSVA (rho = 0.78). The scatter diagram of Delta cSVA and Delta T1 slope showed compensatory relevance and a shifted point to its collapse as the T1 slope lost control of Delta cSVA; thereafter, both parameters incessantly increased, and Delta T1 and Delta cSVA became positive.
   CONCLUSIONS: When CL decreased after ACCF, Delta 0-C2 immediately compensated for the CL loss that could lead to failure to obtain horizontal gaze. If cSVA increased, Delta caudal adjacent angle and Delta T1 slope (extension below the kyphosis) compensated for the horizontal offset translation. The noncompensatory status (Delta cSVA and Delta T1 positive) may necessitate further correction surgery in which the caudal fused level is beyond T1.
C1 [Ikeda, Norimasa; Odate, Seiichi; Shikata, Jitsuhiko] Gakkentoshi Hosp, Spine Ctr, Dept Orthoped Surg, Kyoto, Japan.
RP Ikeda, N (reprint author), Gakkentoshi Hosp, Spine Ctr, Dept Orthoped Surg, Kyoto, Japan.
EM i22525@yahoo.co.jp
CR Aghayev K, 2014, CLIN BIOMECH, V29, P21, DOI 10.1016/j.clinbiomech.2013.10.016
   Barrey Cedric, 2011, Eur Spine J, V20 Suppl 5, P626, DOI 10.1007/s00586-011-1930-3
   Briggs AM, 2007, SKELETAL RADIOL, V36, P761, DOI 10.1007/s00256-007-0284-8
   Diebo BG, 2016, SPINE, V41, P1795, DOI 10.1097/BRS.0000000000001698
   Harrison DE, 2000, SPINE, V25, P2072, DOI 10.1097/00007632-200008150-00011
   Hyun SJ, 2016, SPINE, V41, pE396, DOI 10.1097/BRS.0000000000001264
   Inada T, 2016, ASIAN SPINE J, V10, P744, DOI 10.4184/asj.2016.10.4.744
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kennamer BT, 2019, WORLD NEUROSURG, V122, pE408, DOI 10.1016/j.wneu.2018.10.062
   Koller H, 2007, EUR SPINE J, V16, P2055, DOI 10.1007/s00586-007-0398-7
   Lafage R, 2016, NEUROSURGERY, V79, P108, DOI 10.1227/NEU.0000000000001193
   Le Huec J C, 2011, Eur Spine J, V20 Suppl 5, P564, DOI 10.1007/s00586-011-1940-1
   Le Huec J C, 2011, Eur Spine J, V20 Suppl 5, P669, DOI 10.1007/s00586-011-1935-y
   Lee SH, 2012, J SPINAL DISORD TECH, V25, pE41, DOI 10.1097/BSD.0b013e3182396301
   Li Z, 2017, SPINE, V42, pE575, DOI 10.1097/BRS.0000000000001907
   Liu Y, 2012, SPINE, V37, pE1450, DOI 10.1097/BRS.0b013e31826c72b4
   Martin MD, 2010, NEUROSURGERY, V66, pA2, DOI 10.1227/01.NEU.0000365830.10052.87
   Matsubayashi Y, 2016, GLOB SPINE J, V6, P362, DOI 10.1055/s-0035-1563725
   Mizutani J, 2018, NEUROSURGERY, V82, P686, DOI 10.1093/neuros/nyx288
   Nori S, 2018, J CLIN NEUROSCI, V58, P64, DOI 10.1016/j.jocn.2018.10.049
   O'Connell CA, 2013, J HUM EVOL, V65, P156, DOI 10.1016/j.jhevol.2013.04.007
   Passias PG, 2018, CLIN SPINE SURG, V31, P428, DOI 10.1097/BSD.0000000000000742
   Passias PG, 2018, SPINE, V43, P1117, DOI 10.1097/BRS.0000000000002610
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Song KS, 2014, J BONE JOINT SURG AM, V96A, P557, DOI 10.2106/JBJS.M.00167
   Staub BN, 2019, J NEUROSURG-SPINE, V30, P31, DOI 10.3171/2018.5.SPINE171232
   Steinmetz MP, 2010, NEUROSURGERY, V66, pA7, DOI 10.1227/01.NEU.0000366109.85796.42
   Tang JA, 2012, NEUROSURGERY, V71, P662, DOI 10.1227/NEU.0b013e31826100c9
   van Royen BJ, 2007, EUR SPINE J, V16, P1445, DOI 10.1007/s00586-007-0371-5
   Yagi M, 2015, SPINE J, V15, P213, DOI 10.1016/j.spinee.2014.08.010
   Yilgor C, 2017, J BONE JOINT SURG AM, V99, DOI 10.2106/JBJS.16.01594
NR 31
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E233
EP E240
DI 10.1016/j.wneu.2019.08.241
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700030
PM 31518735
OA Bronze
DA 2020-05-12
ER

PT J
AU Ikemura, A
   Yuki, I
   Otani, K
   Ishibashi, T
   Dahmani, C
   Ebara, M
   Abe, Y
   Kajiwara, I
   Watanabe, M
   Murayama, Y
AF Ikemura, Ayako
   Yuki, Ichiro
   Otani, Katharina
   Ishibashi, Toshihiro
   Dahmani, Chihebeddine
   Ebara, Masaki
   Abe, Yukiko
   Kajiwara, Ikki
   Watanabe, Mitsuyoshi
   Murayama, Yuichi
TI Evaluation of Balloon Test Occlusion Before Therapeutic Carotid Artery
   Occlusion: Flat Detector Computed Tomography Cerebral Blood Volume
   Imaging versus Single-Photon Emission Computed Tomography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balloon test occlusion; Flat detector computed tomography cerebral blood
   volume; Internal carotid occlusion; Single-photon emission computed
   tomography
ID ACUTE ISCHEMIC-STROKE; SPECT; CT
AB OBJECTIVE: We aimed to compare flat detector computed tomography cerebral blood volume (FD-CBV) imaging to single-photon emission computed tomography (SPECT) as an adjunctive technique during balloon test occlusion (BTO) in patients with intracranial aneurysms or tumors.
   METHODS: Twelve patients who underwent SPECT (99mTc-ethyl cysteinate dimer) and FD-CBV imaging during BTO were enrolled. Color-coded cerebral blood flow (CBF) images and color-coded FD-CBV images were generated and visually inspected whether there were asymmetries between the ipsilateral and contralateral cerebral hemispheres. Region of interest measurements were performed on the color-coded images at the same locations for both modalities. The mean interhemispheric region of interest ratios were calculated, and the ratio between these were estimated using linear regression models.
   RESULTS: Ten patients had no symptoms during BTO. Two patients developed subtle but inconclusive neurologic changes approximately 10 minutes after balloon inflation; their images showed asymmetric color-coded images with decreased CBF and FD-CBV in the ipsilateral hemisphere. The mean interhemispheric ratio of CBF was significantly smaller in patients with subtle changes than in those without (0.84 vs. 0.98; P < 0.001). Similarly, the mean interhemispheric ratio of FD-CBV was significantly smaller in patients with subtle changes than in those without (0.88 vs. 1.06; P = 0.01). No patient showed increased CBF or FD-CBV in the ipsilateral hemisphere.
   CONCLUSIONS: The patients with decreased CBF on SPECT also showed decreased FD-CBV in the ipsilateral hemisphere. FD-CBV imaging may be useful as an adjunctive technique for BTO before potential therapeutic carotid artery occlusion.
C1 [Ikemura, Ayako; Yuki, Ichiro; Ishibashi, Toshihiro; Ebara, Masaki; Kajiwara, Ikki; Watanabe, Mitsuyoshi; Murayama, Yuichi] Jikei Univ, Dept Neurosurg, Sch Med, Tokyo, Japan.
   [Abe, Yukiko] Jikei Univ, Dept Radiol, Sch Med, Tokyo, Japan.
   [Otani, Katharina] Siemens Healthcare KK, Tokyo, Japan.
   [Dahmani, Chihebeddine] Siemens Healthcare Pte Ltd, Singapore, Singapore.
   [Yuki, Ichiro] Univ Calif Irvine, Dept Neurol Surg, Irvine, CA USA.
RP Ikemura, A (reprint author), Jikei Univ, Dept Neurosurg, Sch Med, Tokyo, Japan.
EM ayako.udgw613@gmail.com
OI Ishibashi, Toshihiro/0000-0003-1044-5604; Yuki,
   Ichiro/0000-0002-7673-9085
FU Siemens Healthcare K.K., Japan [C00210599]
FX This project was partially supported by a research grant from Siemens
   Healthcare K.K., Japan (grant number C00210599). Katharina Otani and
   Chihebeddine Dahmani are full-time employees of Siemens Healthcare.
   Siemens Healthcare provided support in the form of salaries for these
   coauthors but did not have any additional role in the study design, data
   collection, and decision to publish. All other authors declare that
   there are no actual or potential conflicts of interests in relation to
   this article.
CR Abud DG, 2005, AM J NEURORADIOL, V26, P2602
   American Society of Interventional and Therapeutic Neuroradiology, 2001, AJNR Am J Neuroradiol, V22, pS8
   ANON VV, 1992, NEURORADIOLOGY, V34, P245, DOI 10.1007/BF00596347
   Asai K, 2015, J STROKE CEREBROVASC, V24, P1506, DOI 10.1016/j.jstrokecerebrovasdis.2015.03.012
   Fujimoto M, 2018, CLIN NEURORADIOL, V28, P253, DOI 10.1007/s00062-016-0552-x
   Goyal M, 2013, RADIOLOGY, V266, P16, DOI 10.1148/radiol.12112134
   Kamran M, 2016, INTERV NEURORADIOL, V22, P165, DOI 10.1177/1591019915622168
   LINSKEY ME, 1994, AM J NEURORADIOL, V15, P829
   Lorberboym M, 1996, J NUCL MED, V37, P415
   Michel E, 2001, AM J NEURORADIOL, V22, P1590
   Murphy BD, 2006, STROKE, V37, P1771, DOI 10.1161/01.STR.0000227243.96808.53
   PETERMAN SB, 1991, AM J NEURORADIOL, V12, P1035
   Raymond SB, 2019, WORLD NEUROSURG, V124, pE182, DOI 10.1016/j.wneu.2018.12.064
   Ryu YH, 1996, J NUCL MED, V37, P551
   Snelling BM, 2017, WORLD NEUROSURG, V102, P229, DOI 10.1016/j.wneu.2017.03.023
   Struffert T, 2013, CLIN NEURORADIOL, V23, P285, DOI 10.1007/s00062-013-0208-z
   Struffert T, 2010, AM J NEURORADIOL, V31, P1462, DOI 10.3174/ajnr.A2083
   Struffert T, 2011, EUR RADIOL, V21, P882, DOI 10.1007/s00330-010-1957-6
   Takeuchi R, 2002, EUR J NUCL MED MOL I, V29, P331, DOI 10.1007/s00259-001-0715-z
   van Rooij WJ, 2005, AM J NEURORADIOL, V26, P175
   Yang M, 2015, CLIN NEURORADIOL, V25, P387, DOI 10.1007/s00062-014-0316-4
   Zellerhoff M, 2009, SPIE P, V7262
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E522
EP E528
DI 10.1016/j.wneu.2019.09.077
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700112
PM 31550537
OA Bronze
DA 2020-05-12
ER

PT J
AU Istemen, I
   Arslan, A
   Olguner, SK
   Gezercan, Y
   Okten, AI
   Afser, KA
AF Istemen, Ismail
   Arslan, Ali
   Olguner, Semih Kivanc
   Gezercan, Yurdal
   Okten, Ali Ihsan
   Afser, Kemal Alper
TI The Effect of Straight or Lordotic Rods on Cervical Subaxial Alignment
   While Fusing C1-C2
SO WORLD NEUROSURGERY
LA English
DT Article
DE C1-C2 fusion; C2 sagittal vertical axis; Cervical sagittal balance;
   Subaxial alignment
ID SAGITTAL ALIGNMENT; ATLANTOAXIAL DISLOCATION; CLINICAL-IMPLICATIONS;
   SCREW FIXATION; ARTHRODESIS; ADJACENT; SPINE; PLATE
AB BACKGROUND: The C1 lateral mass and C2 pedicle screw with rod fixation system has been used commonly in recent years. Despite the numerous reports on this technique in the literature, there are no studies regarding the effect of the angle of the rod used. We investigated the effect of rod angle on subaxial lordosis, cervical sagittal balance, and pain scores.
   METHODS: Clinical records and radiologic images of 58 patients who underwent procedures between 2011 and 2016 at our clinic were assessed retrospectively. We recorded clinical findings, visual analog scale (VAS) scores, angles of cervical and segmental lordosis, and the distance between the C2 sagittal vertical axis (SVA) and the C7 posterior-superior corner.
   RESULTS: A total of 36 male and 22 female patients were enrolled. A negative correlation was found between the C1C2 lordosis angle and the C2-C7 lordosis angle irrespective of surgical technique. In patients who were operated on using 30 degrees-angled rods, there was a postoperative increase in C1-C2 lordosis degree and an improvement in C2 cervical SVA values. Postoperative month 6 VAS scores were significantly better in the patients who were operated on with angled rods compared with those who received straight rods.
   CONCLUSIONS: We believe this is because of the positive effect of the angled rod on sagittal balance. Nevertheless, prospective case-control studies should be conducted with larger groups of subjects. Furthermore, every patient should be evaluated considering the whole spinal sagittal balance.
C1 [Istemen, Ismail; Arslan, Ali; Olguner, Semih Kivanc; Gezercan, Yurdal; Okten, Ali Ihsan; Afser, Kemal Alper] Univ Hlth Sci, Adana City Educ & Res Hosp, Neurosurg Dept, Adana, Turkey.
RP Istemen, I (reprint author), Univ Hlth Sci, Adana City Educ & Res Hosp, Neurosurg Dept, Adana, Turkey.
EM drismailistemen@gmail.com
CR ALDRICH EF, 1993, J NEUROSURG, V78, P702, DOI 10.3171/jns.1993.78.5.0702
   BROOKS AL, 1978, J BONE JOINT SURG AM, V60, P279, DOI 10.2106/00004623-197860030-00001
   CYBULSKI GR, 1988, NEUROSURGERY, V22, P429, DOI 10.1227/00006123-198802000-00030
   Garcia Rolando Jr, 2003, Spine J, V3, P166, DOI 10.1016/S1529-9430(02)00541-7
   Gluf WM, 2005, J NEUROSURG-SPINE, V2, P155, DOI 10.3171/spi.2005.2.2.0155
   Goal A, 2002, NEUROSURGERY, V51, P1356
   Goel A, 2005, J NEUROSURG-SPINE, V2, P505, DOI 10.3171/spi.2005.2.4.0505
   GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Goel A, 1998, J NEUROSURG, V88, P962, DOI 10.3171/jns.1998.88.6.0962
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   GROB D, 1992, SPINE, V17, P480, DOI 10.1097/00007632-199205000-00003
   Hardacker JW, 1997, SPINE, V22, P1472, DOI 10.1097/00007632-199707010-00009
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009
   Ishii K, 2010, SPINE, V35, P1551, DOI 10.1097/BRS.0b013e3181af0d85
   Lee SH, 2012, J SPINAL DISORD TECH, V25, pE41, DOI 10.1097/BSD.0b013e3182396301
   Magerl F, 1987, CERVICAL SPINE, P322, DOI DOI 10.1007/978-3-7091-8882-8_59
   Nojiri K, 2003, J NEUROSURG, V99, P80, DOI 10.3171/spi.2003.99.1.0080
   Oshima S, 2015, J SPINAL DISORD TECH, V28, pE49, DOI 10.1097/BSD.0000000000000144
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Sherekar SK, 2006, NEUROL INDIA, V54, P264
   Tang XS, 2018, PEDIATR NEUROSURG, V53, P143, DOI 10.1159/000481784
   TOYAMA Y, 1994, SPINE, V19, P2565, DOI 10.1097/00007632-199411001-00012
   Wang SL, 2013, EUR SPINE J, V22, P1603, DOI 10.1007/s00586-013-2742-4
   Yoshida G, 2010, J NEUROSURG-SPINE, V13, P443, DOI 10.3171/2010.4.SPINE09662
   Yoshimoto H, 2004, SPINE, V29, P175, DOI 10.1097/01.BRS.0000107225.97653.CA
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E653
EP E657
DI 10.1016/j.wneu.2019.09.118
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700129
PM 31568918
OA Bronze
DA 2020-05-12
ER

PT J
AU Jang, MK
   Park, CG
   Jang, S
   Kim, EH
AF Jang, Min Kyeong
   Park, Chang Gi
   Jang, Seonguk
   Kim, Eui Hyun
TI Prevalence and Impact of Postoperative Headaches in Nonfunctioning
   Pituitary Macroadenoma Patients: A Longitudinal Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Headache; Pituitary adenoma; Transsphenoidal surgery
ID INTRASELLAR PRESSURE; ADENOMA; SURGERY
AB BACKGROUND: Patients with nonfunctioning pituitary macroadenomas commonly experience headaches before and after surgery, and headaches have been reported to significantly detract from the quality of life. Despite this adverse impact, few studies have examined the prevalence and pattern of headaches on a long-term basis. Thus, this study employed a longitudinal cohort design to identify headache prevalence and severity during a 6-month postoperative period and its predictors.
   METHODS: Forty patients with nonfunctioning pituitary macroadenomas who underwent transsphenoidal surgery were enrolled as subjects, and Headache Impact Test-6 (HIT-6) was performed at 4 time points: before and 1, 3, and 6 months after surgery.
   RESULTS: This study revealed that patients with nonfunctioning pituitary macroadenoma suffered from headaches at each of the 4 time points and that 37.5%, 27.8%, 17.9%, and 12.8% of the patients experienced "substantial and severe impact headaches" before and 1, 3, and 6 months after surgery, respectively. In addition, total HIT-6 scores 1 month after surgery were a significant predictor (B = 0.41, P < 0.001) of headaches 3 and 6 months after surgery. Among the HIT-6 items, pain (B = 0.09, P < 0.001), cognitive function (B = 0.07, P < 0.001), and psychological distress (B = 0.07, P < 0.001) showed the greatest impact on long-term headaches.
   CONCLUSION: Headaches adversely affected patients even 6 months after surgery. In addition, headaches 1 month after surgery predicted the prevalence of long-term headaches at 3 and 6 months, demonstrating the importance of timely postsurgical measurement of headaches to anticipate patients' long-term headache patterns.
C1 [Jang, Min Kyeong] Univ Illinois, Canc Ctr, Chicago, IL USA.
   [Jang, Min Kyeong; Park, Chang Gi] Univ Illinois, Coll Nursing, Chicago, IL USA.
   [Jang, Seonguk] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA.
   [Kim, Eui Hyun] Yonsei Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
   [Kim, Eui Hyun] Severance Hosp, Pituitary Tumor Ctr, Seoul, South Korea.
   [Kim, Eui Hyun] Yonsei Univ, Coll Med, Yonsei Endocrine Res Inst, Seoul, South Korea.
RP Kim, EH (reprint author), Yonsei Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.; Kim, EH (reprint author), Severance Hosp, Pituitary Tumor Ctr, Seoul, South Korea.; Kim, EH (reprint author), Yonsei Univ, Coll Med, Yonsei Endocrine Res Inst, Seoul, South Korea.
EM euihyunkim@yuhs.ac
OI Jang, Min Kyeong/0000-0002-6073-161X
FU National Institute of Nursing Research of the National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Nursing
   Research (NINR) [K24NR015340]; Basic Science Research Program through
   the NRF of Korea [NRF-2018R1C1B5042687]; Korean Ministry of Science,
   ICT, and Future Planning
FX This work was supported by the National Institute of Nursing Research of
   the National Institutes of Health (K24NR015340); and the Basic Science
   Research Program through the NRF of Korea (NRF-2018R1C1B5042687) funded
   by the Korean Ministry of Science, ICT, and Future Planning. The content
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Chu M, 2008, J KOREAN NEUROL ASS, V27, P1
   Donovan LE, 2018, CURR PAIN HEADACHE R, V22, DOI 10.1007/s11916-018-0709-1
   Gondim JA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10167
   Gravdahl GB, 2016, WORLD NEUROSURG, V92, P284, DOI 10.1016/j.wneu.2016.04.071
   Hayashi Y, 2019, NEUROSURGERY, V84, P599, DOI 10.1093/neuros/nyy087
   Hayashi Y, 2016, PITUITARY, V19, P175, DOI 10.1007/s11102-015-0696-8
   Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193
   Kreitschmann-Andermahr I, 2013, CLIN ENDOCRINOL, V79, P760, DOI 10.1111/cen.12314
   Lee EJ, 2009, NEUROSURGERY, V64, pS62, DOI 10.1227/01.NEU.0000330406.73157.49
   Levy MJ, 2011, CURR NEUROL NEUROSCI, V11, P164, DOI 10.1007/s11910-010-0166-7
   Murad MH, 2010, CLIN ENDOCRINOL, V73, P777, DOI 10.1111/j.1365-2265.2010.03875.x
   Pereira-Neto A, 2010, ARQ NEURO-PSIQUIAT, V68, P350, DOI 10.1590/S0004-282X2010000300004
   Rizzoli P, 2016, NEUROSURGERY, V78, P316, DOI 10.1227/NEU.0000000000001067
   Schankin CJ, 2012, CEPHALALGIA, V32, P1198, DOI 10.1177/0333102412462639
   Siegel S, 2017, ENDOCRINE, V56, P325, DOI 10.1007/s12020-017-1266-9
   Suri H, 2018, CURR PAIN HEADACHE R, V22, DOI 10.1007/s11916-018-0710-8
   Wolf A, 2016, J NEUROSURG, V124, P1627, DOI 10.3171/2015.5.JNS1576
   Yu B, 2017, CEPHALALGIA, V37, P348, DOI 10.1177/0333102416648347
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E633
EP E639
DI 10.1016/j.wneu.2019.09.123
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700126
PM 31604133
OA Bronze
DA 2020-05-12
ER

PT J
AU Kanamori, F
   Araki, Y
   Yokoyama, K
   Uda, K
   Nishihori, M
   Izumi, T
   Okamoto, S
   Wakabayashi, T
AF Kanamori, Fumiaki
   Araki, Yoshio
   Yokoyama, Kinya
   Uda, Kenji
   Nishihori, Masahiro
   Izumi, Takashi
   Okamoto, Sho
   Wakabayashi, Toshihiko
TI Brain Compression by Encephalo-Myo-Synangiosis is a Risk Factor for
   Transient Neurological Deficits After Surgical Revascularization in
   Pediatric Patients with Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Pediatric moyamoya disease; Perioperative cerebral blood flow; Transient
   neurological deficits
ID HYPERPERFUSION; DETERIORATION
AB OBJECTIVE: In pediatric patients with moyamoya disease, the pathophysiology of transient neurological deficits and the clinical features of perioperative cerebral blood flow (CBF) changes are unclear. The purpose of this study was to investigate the risk factors of postoperative transient neurological deficits and identify predictors of perioperative CBF changes.
   METHODS: This retrospective study included 42 surgical procedures in 28 pediatric patients who underwent surgical revascularization for moyamoya disease, including encephalo-myo-synangiosis (EMS) with or without superficial temporal artery-middle cerebral artery (MCA) anastomosis. Magnetic resonance images and single photon emission computed tomography results were obtained. Brain compression by EMS was also checked in fluid attenuated inversion recovery images. Using single photon emission computed tomography, CBF was measured at each anterior and posterior part of the MCA region.
   RESULTS: Postoperative transient neurological deficits were observed in 12 (28.6%) out of 42 surgical procedures. Brain compression by EMS was a significant risk for transient neurological deficits (P = 0.009). The postoperative CBF in the anterior region increased in 9 cases (21.4%) and decreased in 10 cases (23.8%); in the posterior region, it increased in 12 cases (28.6%) and decreased in 10 cases (23.8%). Preoperative CBF of the anterior region was significantly related to both perioperative CBF changes in the MCA regions (anterior part, P = 0.004; posterior part, P = 0.025).
   CONCLUSIONS: Brain compression by EMS is a risk factor for postoperative transient neurological deficits in pediatric patients with moyamoya disease, and preoperative CBF of the anterior MCA region could predict perioperative CBF change in the MCA regions.
C1 [Kanamori, Fumiaki; Araki, Yoshio; Yokoyama, Kinya; Uda, Kenji; Nishihori, Masahiro; Izumi, Takashi; Okamoto, Sho; Wakabayashi, Toshihiko] Nagoya Univ, Dept Neurosurg, Grad Sch Med, Nagoya, Aichi, Japan.
   [Okamoto, Sho] Aichi Rehabil Hosp, Nishio City, Japan.
RP Kanamori, F (reprint author), Nagoya Univ, Dept Neurosurg, Grad Sch Med, Nagoya, Aichi, Japan.
EM shitetsu314@hotmail.co.jp
OI Yokoyama, Kinya/0000-0002-1039-4504
CR Fujimura M, 2011, NEUROSURGERY, V68, P957, DOI 10.1227/NEU.0b013e318208f1da
   Fujimura M, 2009, NEUROSURG REV, V32, P245, DOI 10.1007/s10143-009-0184-6
   Funaki T, 2016, J NEUROSURG, V124, P1766, DOI 10.3171/2015.6.JNS15845
   Golby AJ, 1999, NEUROSURGERY, V45, P50, DOI 10.1097/00006123-199907000-00013
   Hamano E, 2017, J NEUROSURG, V126, P1, DOI 10.3171/2015.10.JNS151022
   Hayashi T, 2010, J NEUROSURG-PEDIATR, V6, P73, DOI 10.3171/2010.4.PEDS09478
   Houkin K, 2005, CEREBROVASC DIS, V20, P347, DOI 10.1159/000087935
   Ishikawa T, 1997, STROKE, V28, P1170, DOI 10.1161/01.STR.28.6.1170
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kurokawa T, 1985, Pediatr Neurol, V1, P274, DOI 10.1016/0887-8994(85)90027-X
   Machida T, 2019, J NEUROSURG, V130, P1957, DOI 10.3171/2018.1.JNS172244
   Matsushima Y, 1997, CLIN NEUROL NEUROSUR, V99, pS147
   Takeuchi R, 2002, EUR J NUCL MED MOL I, V29, P331, DOI 10.1007/s00259-001-0715-z
NR 13
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E558
EP E566
DI 10.1016/j.wneu.2019.09.093
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700117
PM 31562963
OA Bronze
DA 2020-05-12
ER

PT J
AU Karsy, M
   Azab, MA
   Harper, J
   Abou-Al-Shaar, H
   Guan, J
   Eli, I
   Brock, AA
   Ormond, RD
   Hosokawa, PW
   Gouripeddi, R
   Butcher, R
   Cole, CD
   Menacho, ST
   Couldwell, WT
AF Karsy, Michael
   Azab, Mohammed A.
   Harper, Jonathan
   Abou-Al-Shaar, Hussam
   Guan, Jian
   Eli, Ilyas
   Brock, Andrea A.
   Ormond, Ryan D.
   Hosokawa, Patrick W.
   Gouripeddi, Ramkiran
   Butcher, Ryan
   Cole, Chad D.
   Menacho, Sarah T.
   Couldwell, William T.
TI Evaluation of a D-Dimer Protocol for Detection of Venous Thromboembolism
SO WORLD NEUROSURGERY
LA English
DT Article
DE D-dimer; Deep vein thrombosis; Pulmonary embolism; Venous
   thromboembolism; VTE
ID DEEP-VEIN THROMBOSIS; PLASMA D-DIMER; ANEURYSMAL SUBARACHNOID
   HEMORRHAGE; RISK-FACTORS; LEVEL; PREVALENCE; ADMISSIONS; DIAGNOSIS;
   OUTCOMES; MARKER
AB BACKGROUND: The use of venous duplex ultrasonography (VDU) for confirmation of deep venous thrombosis in neurosurgical patients is costly and requires experienced personnel. We evaluated a protocol using D-dimer levels to screen for venous thromboembolism (VTE), defined as deep venous thrombosis and asymptomatic pulmonary embolism.
   METHODS: We used a retrospective bioinformatics analysis to identify neurosurgical inpatients who had undergone a protocol assessing the serum D-dimer levels and had undergone a VDU study to evaluate for the presence of VTE from March 2008 through July 2017. The clinical risk factors and D-dimer levels were evaluated for the prediction of VTE.
   RESULTS: In the 1918 patient encounters identified, the overall VTE detection rate was 28.7%. Using a receiver operating characteristic curve, an area under the curve of 0.58 was identified for all D-dimer values (P = 0.0001). A D-dimer level of >= 2.5 mu g/mL on admission conferred a 30% greater relative risk of VTE (sensitivity, 0.43; specificity, 0.67; positive predictive value, 0.27; negative predictive value, 0.8). A D-dimer value of >= 3.5 mu g/mi during hospitalization yielded a 28% greater relative risk of VTE (sensitivity, 0.73; specificity, 0.32; positive predictive value, 0.24; negative predictive value, 0.81). Multivariable logistic regression showed that age, male sex, length of stay, tumor or other neurological disease diagnosis, and D-dimer level >= 3.5 mu g/mL during hospitalization were independent predictors of VTE.
   CONCLUSIONS: The D-dimer protocol was beneficial in identifying VTE in a heterogeneous group of neurosurgical patients by prompting VDU evaluation for patients with a D-dimer values of >= 3.5 mu g/mL during hospitalization. Refinement of this screening model is necessary to improve the identification of VTE in a practical and costeffective manner.
C1 [Karsy, Michael; Azab, Mohammed A.; Harper, Jonathan; Abou-Al-Shaar, Hussam; Guan, Jian; Eli, Ilyas; Brock, Andrea A.; Menacho, Sarah T.; Couldwell, William T.] Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84112 USA.
   [Gouripeddi, Ramkiran; Butcher, Ryan] Univ Utah, Dept Bioinformat, Salt Lake City, UT USA.
   [Abou-Al-Shaar, Hussam] Hofstra Northwell Sch Med, Dept Neurosurg, Manhasset, NY USA.
   [Ormond, Ryan D.; Hosokawa, Patrick W.] Univ Colorado, Dept Neurosurg, Aurora, CO USA.
   [Hosokawa, Patrick W.] Univ Colorado, Adult & Child Ctr Hlth Outcomes Res & Delivery Sc, Aurora, CO USA.
   [Cole, Chad D.] New York Med Coll, Dept Neurosurg, Valhalla, NY 10595 USA.
RP Couldwell, WT (reprint author), Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84112 USA.
EM neuropub@hsc.utah.edu
RI Karsy, Michael/AAH-8583-2020; Ormond, David Ryan/R-4847-2017
OI Karsy, Michael/0000-0002-0422-7937; Ormond, David
   Ryan/0000-0001-7027-2915
CR Achiha T, 2017, J STROKE CEREBROVASC, V26, P1521, DOI 10.1016/j.jstrokecerebrovasdis.2017.02.038
   Alons IME, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0389-y
   Bagot CN, 2008, BRIT J HAEMATOL, V143, P180, DOI 10.1111/j.1365-2141.2008.07323.x
   Boluijt J, 2015, J CEREBR BLOOD F MET, V35, P724, DOI 10.1038/jcbfm.2015.13
   Browd SR., 2004, NEUROSURG FOCUS, V17, pE1, DOI DOI 10.3171/F0C.2004.17.4.1
   Chen CW, 2016, J CLIN NEUROSCI, V29, P149, DOI 10.1016/j.jocn.2015.10.036
   Chen H, 2013, BIOMED RES INT, DOI 10.1155/2013/685174
   Cho Tack Geun, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P159, DOI 10.7461/jcen.2014.16.3.159
   Chua K, 2008, ARCH PHYS MED REHAB, V89, P2316, DOI 10.1016/j.apmr.2008.05.025
   Fukuda H, 2019, J NEUROSURG, V130, P509, DOI 10.3171/2017.7.JNS171129
   Fukuda H, 2017, J NEUROSURG, V127, P284, DOI 10.3171/2016.5.JNS16767
   Ganau M, 2017, J CLIN NEUROSCI, V45, P60, DOI 10.1016/j.jocn.2017.08.008
   Gerlach R, 2008, NEUROSURGERY, V63, P693, DOI 10.1227/01.NEU.0000325730.77263.7E
   Guo FY, 2015, J NEUROSCI RURAL PRA, V6, P471, DOI 10.4103/0976-3147.169801
   Guo XP, 2018, WORLD NEUROSURG, V114, pE982, DOI 10.1016/j.wneu.2018.03.128
   Gupta G, 2016, J CLIN DIAGN RES, V10, pPC4, DOI 10.7860/JCDR/2016/14638.7029
   Hamidi S, 2015, ASIAN SPINE J, V9, P232, DOI 10.4184/asj.2015.9.2.232
   Hu X, 2014, J CLIN NEUROSCI, V21, P1364, DOI 10.1016/j.jocn.2013.11.030
   Ikeda T, 2017, J ORTHOP SCI, V22, P197, DOI 10.1016/j.jos.2016.11.014
   Ilveskero S, 2005, NEUROSURGERY, V57, P16, DOI 10.1227/01.NEU.0000163085.48999.D6
   Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241
   Kawaguchi T, 2013, NEUROL MED-CHIR, V53, P467
   Kawaguchi T, 2011, J NEURO-ONCOL, V101, P495, DOI 10.1007/s11060-010-0276-8
   Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026
   Kuwashiro T, 2012, J STROKE CEREBROVASC, V21, P205, DOI 10.1016/j.jstrokecerebrovasdis.2010.06.009
   Liu JH, 2017, NEURAL REGEN RES, V12, P2014, DOI 10.4103/1673-5374.221158
   Liu L, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005269
   Mousa AY, 2015, ANN VASC SURG, V29, P311, DOI 10.1016/j.avsg.2014.07.032
   Nakano F, 2018, THROMB RES, V165, P95, DOI 10.1016/j.thromres.2018.03.016
   Natsumeda M, 2018, WORLD NEUROSURG, V112, pE103, DOI [10.1016/wneu.2017.12.139, 10.1016/j.wneu.2017.12.139]
   Patel AP, 2013, J NEUROSURG, V118, P505, DOI 10.3171/2012.11.JNS121243
   Prell J, 2013, J NEUROSURG, V119, P1340, DOI 10.3171/2013.5.JNS13151
   Streiff MB, 2015, J NEURO-ONCOL, V124, P299, DOI 10.1007/s11060-015-1840-z
   Sugimoto K, 2017, J NEUROTRAUM, V34, P3245, DOI 10.1089/neu.2017.5240
   Wada M, 2013, THROMB RES, V131, P487, DOI 10.1016/j.thromres.2013.04.022
   Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153
   Witek P, 2016, ENDOKRYNOL POL, V67, P283, DOI 10.5603/EP.a2016.0034
   Yablon SA, 2004, NEUROLOGY, V63, P485, DOI 10.1212/01.WNL.0000133009.24727.9F
   Yamada SM, 2016, YONSEI MED J, V57, P388, DOI 10.3349/ymj.2016.57.2.388
   Yoshiiwa T, 2011, J SPINAL DISORD TECH, V24, pE35, DOI 10.1097/BSD.0b013e3181f60603
   Yoshioka K, 2010, J NEUROSURG-SPINE, V13, P594, DOI 10.3171/2010.5.SPINE09883
   Yuan Q, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-017-0471-0
NR 42
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E774
EP E783
DI 10.1016/j.wneu.2019.09.160
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700145
PM 31605841
OA Bronze
DA 2020-05-12
ER

PT J
AU Kashiwazaki, D
   Saito, H
   Uchino, H
   Akioka, N
   Hori, E
   Shibata, T
   Tomita, T
   Akai, T
   Kuwayama, N
   Kuroda, S
AF Kashiwazaki, Daina
   Saito, Hisayasu
   Uchino, Haruto
   Akioka, Naoki
   Hori, Emiko
   Shibata, Takashi
   Tomita, Takahiro
   Akai, Takuya
   Kuwayama, Naoya
   Kuroda, Satoshi
TI Morbidity and Mortality Conference Can Reduce Avoidable Morbidity in
   Neurosurgery: Its Educational Effect on Residents and Surgical Safety
   Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Education; Mortality and morbidity conference; Neurosurgery; Residents
ID ADVERSE EVENTS; COMPARING MORBIDITY
AB BACKGROUND: Morbidity and mortality conferences (MMCs) are now widely implemented in clinical hospitals, but their impact on the education for neurosurgeons remains limited. This prospective study was aimed to assess the efficacy and benefit of MMCs on the education for neurosurgeon.
   METHODS: All morbidity and mortality events were prospectively recorded and were categorized on the basis of 2 viewpoints. First, they were classified into "avoidable" and "unavoidable" events, based on the quality of each event. Simultaneously, they were classified into 3 groups, including the residents, attendant members, or unclassifiable, based on the experience of the neurosurgeon who were most closely related to each event. The information was compared between early (2013-2014) and late (2015-2017) study periods to evaluate the education value of MMCs.
   RESULTS: During a 5-year study period, 44 mortality (2.1% per patient) and 201 morbidity events (9.7% per patient) were recorded. There were no significant differences in the incidence of mortality between 2 periods (P = 0.52). The incidence of morbidity significantly decreased from 11.5% (83/723) to 8.4% (118/1403; P < 0.04). Of these, "avoidable" events, but not "unavoidable" events significantly decreased from 7.5% (54/723) to 4.2% (59/1403; P = 0.001). The decrease in the incidence of "avoidable" morbidity was more pronounced in the residents than in the attendant members (P = 0.007 and P = 0.04, respectively).
   CONCLUSIONS: Knowledge acquisition from MMCs can significantly reduce "avoidable" morbidity events in both residents and experienced neurosurgeons. The educational effect was more distinct in the residents.
C1 [Kashiwazaki, Daina; Saito, Hisayasu; Uchino, Haruto; Akioka, Naoki; Hori, Emiko; Shibata, Takashi; Tomita, Takahiro; Akai, Takuya; Kuwayama, Naoya; Kuroda, Satoshi] Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Neurosurg, Toyama, Japan.
RP Kashiwazaki, D (reprint author), Univ Toyama, Grad Sch Med & Pharmaceut Sci, Dept Neurosurg, Toyama, Japan.
EM dkashiwa@med.u-toyama.ac.jp
RI Uchino, Haruto/L-6627-2019
OI Uchino, Haruto/0000-0001-6567-8136
CR Balakrishnan K, 2018, OTOLARYNG HEAD NECK, V158, P273, DOI 10.1177/0194599817737993
   Bernstein J, 2016, CLIN ORTHOP RELAT R, V474, P882, DOI 10.1007/s11999-016-4750-2
   Bonsanto MM, 2001, ACT NEUR S, V78, P139
   BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604
   CALABRO JJ, 1995, ANN EMERG MED, V26, P531
   Cromeens BP, 2017, J AM COLL SURGEONS, V224, P945, DOI 10.1016/j.jamcollsurg.2017.02.008
   de Vos MS, 2018, J SURG EDUC, V75, P33, DOI 10.1016/j.jsurg.2017.07.002
   Doll JA, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003538
   Giesbrecht V, 2016, JT COMM J QUAL PATIE, V42, P516, DOI 10.1016/S1553-7250(16)42094-5
   Goolsarran N, 2016, MED EDUC, V50, P1159, DOI 10.1111/medu.13199
   Harbison SP, 1999, AM J SURG, V177, P136, DOI 10.1016/S0002-9610(98)00319-5
   Hopkins ES., 1989, J QUAL ASSUR, V11, P36
   Houkin K, 2009, NEUROSURGERY, V65, P587, DOI 10.1227/01.NEU.0000350860.59902.68
   Risucci Donald A, 2003, Curr Surg, V60, P204, DOI 10.1016/S0149-7944(02)00735-3
   Rosenfeld Joel C, 2005, Curr Surg, V62, P664, DOI 10.1016/j.cursur.2005.06.009
   THOMPSON JS, 1992, J SURG RES, V52, P97, DOI 10.1016/0022-4804(92)90285-8
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E348
EP E355
DI 10.1016/j.wneu.2019.09.018
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700089
PM 31521755
OA Bronze
DA 2020-05-12
ER

PT J
AU Ke, WC
   Wang, BJ
   Hua, WB
   Lu, SD
   Li, XS
   Yang, C
AF Ke, Wencan
   Wang, Bingjin
   Hua, Wenbin
   Lu, Saideng
   Li, Xingsheng
   Yang, Cao
TI Biomechanical Evaluation of the Sacral Slope on the Adjacent Segment in
   Transforaminal Lumbar Interbody Fusion: A Finite Element Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent segment degeneration; Finite element analysis; Sacral slope
ID LUMBOSACRAL SPINAL-FUSION; SAGITTAL BALANCE; DEGENERATION; PARAMETERS;
   PREVALENCE; SURGERY; DISEASE
AB BACKGROUND: Spinopelvic sagittal parameters have a - zant influence on adjacent segment degeneration (ASD) after fusion surgery. The association between ASD and sagittal balance is not well understood. The purpose of this study was to investigate the biomechanical influence of various sacral slope (SS) degrees on adjacent segments after transforaminal lumbar interbody fusion (TLIF) at the L4-L5 level.
   METHODS: We conducted a finite element model of the L1-S1 based on computed tomography scan images. The L1-S1 model with L4-L5 TLIF was modified with various SS degrees (33 degrees, 38 degrees, 43 degrees, and 48 degrees) to investigate the biomechanical influence of SS on adjacent segments. The range of motion (ROM) and intradiscal pressure (IDP) of the adjacent segments (L3-L4 and L5-S1) were compared among models using various SS angles.
   RESULTS: When the SS angle increased, the ROM and IDP in L5-S1 decreased gradually after TLIF at the L4-L5 level in all motion patterns. Nevertheless, the ROM and IDP in L3-L4 were not significantly different among various SS angles.
   CONCLUSIONS: Decreased SS after lumbar fusion surmay pose a higher risk of ASD. Therefore, restoring appropriate SS should be considered during decision-making prior to fusion surgery to reduce the risk of degenerative changes.
C1 [Ke, Wencan; Wang, Bingjin; Hua, Wenbin; Lu, Saideng; Yang, Cao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan, Hubei, Peoples R China.
   [Li, Xingsheng] Valeo Foshan Tech Ctr, Foshan, Peoples R China.
RP Yang, C (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan, Hubei, Peoples R China.
EM caoyangunion@hust.edu.cn
OI Yang, Cao/0000-0002-0058-614X
CR Alentado VJ, 2016, SPINE, V41, P1167, DOI 10.1097/BRS.0000000000001493
   Berthonnaud E, 2005, J SPINAL DISORD TECH, V18, P40, DOI 10.1097/01.bsd.0000117542.88865.77
   Chen CS, 2001, MED ENG PHYS, V23, P483
   Chen L, 2016, 2016 FIRST IEEE INTERNATIONAL CONFERENCE ON COMPUTER COMMUNICATION AND THE INTERNET (ICCCI 2016), P41, DOI 10.1109/CCI.2016.7778874
   COLE TC, 1985, J ORTHOP RES, V3, P277, DOI 10.1002/jor.1100030304
   Di Martino A, 2014, EUR SPINE J, V23, pS693, DOI 10.1007/s00586-014-3551-0
   Drazin D, 2015, J NEUROSURG-SPINE, V23, P754, DOI 10.3171/2015.3.SPINE14557
   Etebar S, 1999, J NEUROSURG, V90, P163, DOI 10.3171/spi.1999.90.2.0163
   Gottfried ON, 2009, SPINE J, V9, P639, DOI 10.1016/j.spinee.2009.04.008
   Guo T, 2018, NANOSTRUCT SCI TECHN, P3, DOI 10.1007/978-3-319-78004-7_1
   Hackenberg L, 2005, EUR SPINE J, V14, P551, DOI 10.1007/s00586-004-0830-1
   Johnson RD, 2013, J CLIN NEUROSCI, V20, P576, DOI 10.1016/j.jocn.2012.05.032
   Kumar MN, 2001, EUR SPINE J, V10, P314, DOI 10.1007/s005860000239
   Lazennec JY, 2000, EUR SPINE J, V9, P47, DOI 10.1007/s005860050008
   Le Huec JC, 2015, INT ORTHOP, V39, P87, DOI 10.1007/s00264-014-2516-6
   LEE CK, 1984, SPINE, V9, P574, DOI 10.1097/00007632-198409000-00007
   LEE CK, 1988, SPINE, V13, P375, DOI 10.1097/00007632-198803000-00029
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
   Quirno M, 2009, SPINE, V34, P1470, DOI 10.1097/BRS.0b013e3181a8e418
   Salehi SA, 2004, NEUROSURGERY, V54, P368, DOI 10.1227/01.NEU.0000103493.25162.18
   Sears WR, 2011, SPINE J, V11, P11, DOI 10.1016/j.spinee.2010.09.026
   Wang BJ, 2019, WORLD NEUROSURG, V126, pE819, DOI 10.1016/j.wneu.2019.02.164
   Wang ZG, 2014, EUR SPINE J, V23, P560, DOI 10.1007/s00586-013-3064-2
   Xia XP, 2013, SPINE, V38, P597, DOI 10.1097/BRS.0b013e318273a2ea
   YAMAMOTO I, 1989, SPINE, V14, P1256, DOI 10.1097/00007632-198911000-00020
   YANG SW, 1986, SPINE, V11, P937
   Zhao X, 2018, WORLD NEUROSURG, V114, pE114, DOI 10.1016/j.wneu.2018.02.073
NR 27
TC 0
Z9 0
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E84
EP E88
DI 10.1016/j.wneu.2019.08.113
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700011
PM 31470152
OA Bronze
DA 2020-05-12
ER

PT J
AU Kessler, BA
   Catalino, MP
   Jordan, JD
AF Kessler, Brice A.
   Catalino, Michael P.
   Jordan, J. Dedrick
TI Reducing the Reported Mortality Index Within a Neurocritical Care Unit
   Through Documentation and Coding Accuracy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Medical coding; Medical documentation; Mortality index; Quality
   improvement
ID PROGRAM
AB BACKGROUND: The mortality index, or the ratio of observed to expected mortality, is a reported quality metric that has been assumed to directly reflect patient care. However, documentation and coding that does not use knowledge of how a reported mortality index is derived could reflect poorly on a hospital or service line. We present our effort at reducing the reported mortality index of neurosurgery and neurology patients within a neuro-critical care unit through documentation and coding accuracy with direct incorporation of mortality modeling.
   METHODS: Using a reported method from Vizient Inc., we generated a spreadsheet tool to enable direct manipulation of the data to identify documentation and coding issues that influenced the reported mortality index in a retrospective set of patients. Subsequently, we implemented the prospective changes to documentation and coding and compared our calculated mortality index to the reported Vizient mortality index.
   RESULTS: Prospective implementation of the documentation and coding issues identified through our spreadsheet tool resulted in a drastic reduction of both our calculated and the reported Vizient mortality index.
   CONCLUSIONS: Incorporating knowledge of mortality ex modeling into the documentation and coding resulted in impressive reductions in the reported mortality index for our patients, serving as a both an internal benchmark and a method of comparison with other institutions.
C1 [Kessler, Brice A.; Catalino, Michael P.; Jordan, J. Dedrick] Univ N Carolina, Dept Neurosurg, Sch Med, Chapel Hill, NC 27515 USA.
   [Jordan, J. Dedrick] Univ N Carolina, Dept Neurol, Sch Med, Chapel Hill, NC 27515 USA.
RP Jordan, JD (reprint author), Univ N Carolina, Dept Neurosurg, Sch Med, Chapel Hill, NC 27515 USA.; Jordan, JD (reprint author), Univ N Carolina, Dept Neurol, Sch Med, Chapel Hill, NC 27515 USA.
EM Dedrick@unc.edu
OI Kessler, Brice/0000-0002-2006-5026
CR Galloway Joseph D, 2016, Arthroplast Today, V2, P133, DOI 10.1016/j.artd.2016.03.003
   Hammers R, 2010, J NEUROSURG, V112, P257, DOI 10.3171/2009.6.JNS081235
   Horwood CR, 2018, SURGERY, V164, P687, DOI 10.1016/j.surg.2018.04.045
   Landon BE, 2017, NEW ENGL J MED, V377, P1211, DOI 10.1056/NEJMp1708084
   Momin SR, 2016, JAMA OTOLARYNGOL, V142, P533, DOI 10.1001/jamaoto.2016.0194
   Rosenbaum Benjamin P, 2014, Perspect Health Inf Manag, V11, p1c
   Spellberg B, 2013, AM J MED, V126, P739, DOI 10.1016/j.amjmed.2012.11.035
   Zalatimo O, 2014, J NEUROSURG, V120, P756, DOI 10.3171/2013.11.JNS13852
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E819
EP E827
DI 10.1016/j.wneu.2019.10.022
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700151
PM 31606500
OA Bronze
DA 2020-05-12
ER

PT J
AU Kubota, Y
   Nakamoto, H
   Miyao, S
   Kawamata, T
AF Kubota, Yuichi
   Nakamoto, Hidetoshi
   Miyao, Satoru
   Kawamata, Takakazu
TI Efficacy of Vagal Nerve Stimulation for Pharmacoresistant Poststroke
   Epilepsy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antiepileptic drugs; Poststroke epilepsy; Seizure; Vagal nerve
   stimulation
AB BACKGROUND: Vagal nerve stimulation (VNS) is an alternative palliative therapy for pharmacoresistant epilepsy. It has been reported to be effective for both focal and generalized epilepsy; however, most of the relevant studies have involved children or young patients. Some patients develop intractable epilepsy after stroke, despite taking antiepileptic drugs (AEDs). In this study, we investigated the efficacy of VNS for pharmacoresistant poststroke epilepsy (PPSE).
   METHODS: We retrospectively studied 10 patients who underwent vagal nerve stimulator implantation for poststroke epilepsy after the seizures had proved refractory to appropriate AEDs. The seizure outcome was evaluated using the McHugh classification 2 years after the implantation.
   RESULTS: In total, 4 patients (40%) remained seizure-free throughout the 2-year duration. In addition, seizures were reduced by >50% after 2 years in 6 patients (60%). McHugh classification was class I for 5 patients and class II for 5 patients. Neither intraoperative complications nor postoperative adverse effects were reported. The average intensity of VNS was 1.75 mA.
   CONCLUSIONS: In this small study, VNS proved to be a safe and effective therapy for PPSE. Patients with poststroke epilepsy experience physical or mental decline; therefore, it is important to control seizures in them to avoid deterioration in their quality of daily life.
C1 [Kubota, Yuichi; Nakamoto, Hidetoshi; Miyao, Satoru] TMG Asaka Med Ctr, Stroke & Epilepsy Ctr, Dept Neurosurg, Saitama, Japan.
   [Kubota, Yuichi; Nakamoto, Hidetoshi; Miyao, Satoru; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
RP Kubota, Y (reprint author), TMG Asaka Med Ctr, Stroke & Epilepsy Ctr, Dept Neurosurg, Saitama, Japan.; Kubota, Y (reprint author), Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
EM kubota.yuichi@twmu.ac.jp
CR Ben-Menachem E, 2002, LANCET NEUROL, V1, P477, DOI 10.1016/S1474-4422(02)00220-X
   Graham NSN, 2013, STROKE, V44, P605, DOI 10.1161/STROKEAHA.111.000220
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   McHugh JC, 2007, EPILEPSIA, V48, P375, DOI 10.1111/j.1528-1167.2006.00931.x
   Morris GL, 2003, EPILEPSY BEHAV, V4, P740, DOI 10.1016/j.yebeh.2003.08.025
   Pitkanen A, 2016, LANCET NEUROL, V15, P185, DOI 10.1016/S1474-4422(15)00248-3
   Roivainen R, 2013, EUR J NEUROL, V20, P1247, DOI 10.1111/ene.12157
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E448
EP E451
DI 10.1016/j.wneu.2019.09.049
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700102
PM 31526890
OA Bronze
DA 2020-05-12
ER

PT J
AU Kutlay, M
   Durmaz, O
   Kirik, A
   Yasar, S
   Ozer, I
   Ezgu, MC
   Kural, C
   Temiz, C
   Durmaz, A
   Daneyemez, MK
   Izci, Y
AF Kutlay, Murat
   Durmaz, Ozan
   Kirik, Alparslan
   Yasar, Soner
   Ozer, Ilker
   Ezgu, Mehmet Can
   Kural, Cahit
   Temiz, Caglar
   Durmaz, Abdullah
   Daneyemez, Mehmet Kadri
   Izci, Yusuf
TI Sellar Defect Reconstruction with Vascularized Superior Turbinate
   Mucosal Flaps in Endonasal Endoscopic Transsellar Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid; Endoscopic endonasal approach; Skull base
   reconstruction; Superior turbinate; Vascularized pedicled flap
ID SKULL BASE RECONSTRUCTION; CEREBROSPINAL-FLUID LEAKS; ANTERIOR CRANIAL
   BASE; TRANSSPHENOIDAL APPROACH; SURGERY; REPAIR; RESECTION; LESIONS
AB BACKGROUND: The pedicled nasoseptal flap (NSF) constitutes the primary reconstructive option for most skull base defects in endonasal endoscopic approaches. The superior nasal turbinate (ST) has received little attention. We report our preliminary experience with the use of the ST mucosal flap in selected cases.
   METHODS: We performed a retrospective review of patients who underwent endonasal endoscopic approaches and identified 9 patients who were reconstructed with vascularized ST mucosal flaps as part of a double-layer or triple-layer reconstruction. When there was no intraoperative cerebrospinal fluid (CSF) leak, we used a double-layer technique. If there was an intraoperative CSF leak, regardless of the quality of leakage, we preferred a triple-layer repair technique In patients with high-flow leaks, triple-layer repair was performed using only autologous tissue grafts and flaps.
   RESULTS: Intraoperative CSF leaks were noted in 7 of 9 patients. Among them, 4 patients had low-flow CSF leaks (grade 1 and 2) and 3 patients had high-flow CSF leaks (grade 3). All reconstructions had complete defect coverage with the ST flaps and NSFs were preserved. All the flaps were viable at 4 weeks without a CSF leak or complication at the reconstruction site. There was no contraction or partial loss of the flap. After a mean follow-up period of 9 months, none of the patients required a flap revision, developed a mucocele, infection, or other complication.
   CONCLUSIONS: An ST flap can be used for the vascularized reconstruction of sellar defects if it is bilaterally available. This option should not be overlooked and wasted.
C1 [Kutlay, Murat; Durmaz, Ozan; Kirik, Alparslan; Yasar, Soner; Ozer, Ilker; Ezgu, Mehmet Can; Kural, Cahit; Temiz, Caglar; Daneyemez, Mehmet Kadri; Izci, Yusuf] Univ Hlth Sci, Gulhane Sch Med, Dept Neurosurg, Ankara, Turkey.
   [Durmaz, Abdullah] Univ Hlth Sci, Gulhane Sch Med, Dept Otorhinolaryngol, Ankara, Turkey.
RP Izci, Y (reprint author), Univ Hlth Sci, Gulhane Sch Med, Dept Neurosurg, Ankara, Turkey.
EM yusufizci@yahoo.com
OI EZGU, MEHMET CAN/0000-0001-7537-0055
CR Bhatki AM, 2010, OP TECH OTOLARYNGOL, V21, P74, DOI DOI 10.1016/J.OTOT.2009.10.003
   Bhatki AM, 2010, ORAL MAXIL SURG CLIN, V22, P157, DOI 10.1016/j.coms.2009.10.005
   Cappabianca P, 1998, MINIM INVAS NEUROSUR, V41, P66, DOI 10.1055/s-2008-1052019
   Carrau RL, 2005, LARYNGOSCOPE, V115, P205, DOI 10.1097/01.mlg.0000154719.62668.70
   Cavallo LM, 2007, J NEUROSURG, V107, P713, DOI 10.3171/JNS-07/10/0713
   Chakravarthi S, 2017, SEMIN PLAST SURG, V31, P203, DOI 10.1055/s-0037-1607274
   Chin D, 2013, ADV OTO-RHINO-LARYNG, V74, P104, DOI 10.1159/000342285
   Clavenna MJ, 2015, CURR OPIN OTOLARYNGO, V23, P71, DOI 10.1097/MOO.0000000000000115
   Clerico DM, 1996, LARYNGOSCOPE, V106, P874, DOI 10.1097/00005537-199607000-00017
   Cobzeanu MD, 2014, ROM J MORPHOL EMBRYO, V55, P1099
   de Divitiis E, 2007, NEUROSURGERY, V60, P46, DOI 10.1227/01.NEU.0000249211.89096.25
   Dehdashti AR, 2009, NEUROSURGERY, V64, P677, DOI 10.1227/01.NEU.0000339121.20101.85
   Eloy JA, 2012, INT FORUM ALLERGY RH, V2, P397, DOI 10.1002/alr.21040
   Eloy JA, 2012, LARYNGOSCOPE, V122, P1219, DOI 10.1002/lary.23285
   Esposito F, 2007, NEUROSURGERY, V60, P295, DOI 10.1227/01.NEU.0000255354.64077.66
   Fortes FSG, 2007, LARYNGOSCOPE, V117, P1329, DOI 10.1097/mlg.0b013e318062111f
   Fortes FSG, 2007, LARYNGOSCOPE, V117, P970, DOI 10.1097/MLG.0b013e3180471482
   Frank G, 2006, NEUROSURGERY, V59, P75, DOI 10.1227/01.NEU.0000219897.98238.A3
   Gardner PA, 2008, NEUROSURGERY, V63, P36, DOI 10.1227/01.NEU.0000335069.30319.1E
   Griffiths CF, 2014, ACTA NEUROCHIR, V156, P1393, DOI 10.1007/s00701-014-2107-8
   Hachem RA, 2016, CURR OPIN OTOLARYNGO, V24, P91, DOI 10.1097/MOO.0000000000000233
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Harvey RJ, 2012, LARYNGOSCOPE, V122, P452, DOI 10.1002/lary.22475
   Harvey RJ, 2009, AM J RHINOL ALLERGY, V23, P522, DOI 10.2500/ajra.2009.23.3354
   Hegazy HM, 2000, LARYNGOSCOPE, V110, P1166, DOI 10.1097/00005537-200007000-00019
   Ila K, 2018, SURG RADIOL ANAT, V40, P841, DOI 10.1007/s00276-018-2010-8
   Jho HD, 1997, J NEUROSURG, V87, P44, DOI 10.3171/jns.1997.87.1.0044
   Jho HD, 2004, MINIM INVAS NEUROSUR, V47, P16, DOI 10.1088/s-2004-818347
   Kassam Amin, 2005, Neurosurg Focus, V19, pE8
   Kassam Amin, 2005, Neurosurg Focus, V19, pE3
   Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5
   Kaygusuz I, 2007, TURK ARCH OTORHINOL, V45, P80, DOI 10.2399/tao.05.049
   Kim GG, 2013, ADV OTO-RHINO-LARYNG, V74, P71, DOI 10.1159/000342282
   Klatt-Cromwell CN, 2016, OTOLARYNG CLIN N AM, V49, P107, DOI 10.1016/j.otc.2015.09.006
   Lavigne P, 2018, J NEUROL SURG PART B, V79, pS291, DOI 10.1055/s-0038-1668158
   Leng LZ, 2008, NEUROSURGERY, V62, P342, DOI [10.1227/01.NEU.0000312720.93685.17, 10.1227/01.neu.0000326017.84315.1f]
   Liu JK, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.5.FOCUS1255
   Locatelli D, 2006, NEUROSURGERY, V58, P246, DOI 10.1227/01.NEU.0000193924.65297.3F
   Netuka D, 2019, WORLD NEUROSURG, V129, pE907, DOI 10.1016/j.wneu.2019.05.061
   Nyquist GG, 2010, OTOLARYNG HEAD NECK, V142, P327, DOI 10.1016/j.otohns.2009.12.020
   Orlandi RR, 1999, AM J RHINOL, V13, P251, DOI 10.2500/105065899782102908
   Patel KS, 2013, J NEUROSURG, V119, P661, DOI 10.3171/2013.4.JNS13124
   Rivera-Serrano CM, 2011, LARYNGOSCOPE, V121, P990, DOI 10.1002/lary.21419
   San Turhan, 2014, Kulak Burun Bogaz Ihtis Derg, V24, P292, DOI 10.5606/kbbihtisas.2014.52385
   Schaberg MR, 2010, OTOLARYNG CLIN N AM, V43, P945, DOI 10.1016/j.otc.2010.04.022
   Zhang X, 2014, HEAD NECK-J SCI SPEC, V37, P1470
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E503
EP E512
DI 10.1016/j.wneu.2019.09.082
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700110
PM 31550544
OA Bronze
DA 2020-05-12
ER

PT J
AU Lador, R
   Regev, G
   Salame, K
   Khashan, M
   Lidar, Z
AF Lador, Ran
   Regev, Gilad
   Salame, Khalil
   Khashan, Morsi
   Lidar, Zvi
TI Use of 3-Dimensional Printing Technology in Complex Spine Surgeries
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printing; Custom-made implants; Custom-made tools; En bloc resection;
   Medical simulation; Preoperative models; Spine tumor
ID EN-BLOC RESECTIONS; COMPLICATIONS
AB BACKGROUND: Medical implications of 3-dimensional (3D) printing technology have evolved and are increasingly used. Surgical spine oncology involves at times complex resection using various surgical approaches and unique spinal reconstruction. As high general complication rates, including hardware failure, are reported, careful preoperative planning and optimized fixation techniques should be performed. 3D printing technology allows the improvement of preoperative planning, practice and exploration of various surgical approaches, and designing customized surgical tools and patient specific implants.
   OBJECTIVE: To investigate the use of 3D printing technology in complex spine surgeries.
   METHODS: Between 2015 and 2018, all complex spine oncological cases were evaluated and assessed for the possible benefit of use of 3D printing technology. Following high-quality imaging, a computerized integrated 3D model was created. Based on the planned procedure considering the various surgical steps, a customized 3D model was planned and printed, and in select cases a 3D custom-made implant was designed and printed in various sizes with matching trials.
   RESULTS: A total of 7 cases were selected for the use of a 3D printing technology. For all, a custom-made model was created. In 3 of these cases, a customized 3D-printed implant was used. Special customized intraoperative instruments were made for 2 cases, and a simulated surgical approach was performed in 5 cases. In 2 cases, pre-bent rods were made based on the model created and were used in surgery later on.
   CONCLUSIONS: For complex spine oncology cases, the use of 3D printing allowed better preoperative planning, simplified the operative procedure, and enabled improved reconstruction.
C1 [Lador, Ran; Regev, Gilad; Salame, Khalil; Khashan, Morsi; Lidar, Zvi] Tel Aviv Med Ctr & Sch Med, Neurosurg Dept, Spine Surg Unit, Tel Aviv, Israel.
   [Lador, Ran] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
RP Lador, R (reprint author), Tel Aviv Med Ctr & Sch Med, Neurosurg Dept, Spine Surg Unit, Tel Aviv, Israel.; Lador, R (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
EM Ladormd@gmail.com
OI Lador, Ran/0000-0002-2459-3520
CR Boriani S, 2017, WORLD NEUROSURG, V98, P217, DOI 10.1016/j.wneu.2016.10.086
   Boriani S, 2016, EUR SPINE J, V25, P3932, DOI 10.1007/s00586-016-4463-y
   Dea N, 2016, SPINE, V41, pS212, DOI 10.1097/BRS.0000000000001821
   Girolami M, 2018, EUR SPINE J, V27, P3073, DOI 10.1007/s00586-018-5708-8
   Luzzati AD, 2015, CLIN ORTHOP RELAT R, V473, P858, DOI 10.1007/s11999-014-3578-x
   Olivares-Navarrete R, 2012, SPINE J, V12, P265, DOI 10.1016/j.spinee.2012.02.002
   Verlaan JJ, 2015, EUR SPINE J, V24, P2209, DOI 10.1007/s00586-014-3729-5
   Wang JC, 1998, SPINE, V23, P1684, DOI 10.1097/00007632-199808010-00014
NR 8
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E327
EP E341
DI 10.1016/j.wneu.2019.09.002
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700087
PM 31520760
OA Bronze
DA 2020-05-12
ER

PT J
AU Lamba, N
   Hwang, WL
   Kim, DW
   Niemierko, A
   Marciscano, AE
   Mehan, WA
   Benayoun, MD
   Curry, WT
   Barker, FG
   Martuza, RL
   Dunn, IF
   Claus, E
   Bi, WL
   Aizer, AA
   Alexander, BM
   Oh, KS
   Loeffler, JS
   Shih, HA
AF Lamba, Nayan
   Hwang, William L.
   Kim, Daniel W.
   Niemierko, Andrzej
   Marciscano, Ariel E.
   Mehan, William A.
   Benayoun, Marc D.
   Curry, William T.
   Barker, Fred G., II
   Martuza, Robert L.
   Dunn, Ian F.
   Claus, Elizabeth
   Bi, Wenya Linda
   Aizer, Ayal A.
   Alexander, Brian M.
   Oh, Kevin S.
   Loeffler, Jay S.
   Shih, Helen A.
TI Atypical Histopathological Features and the Risk of Treatment Failure in
   Nonmalignant Meningiomas: A Multi-Institutional Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atypia; Atypical; Benign; Histopathological; Meningioma
ID GROSS TOTAL RESECTION; PROGNOSTIC-FACTORS; FREE SURVIVAL; GRADE I;
   RECURRENCE; INDEX; CLASSIFICATION; MUTATIONS; SYSTEM; MIB-1
AB BACKGROUND: Histopathological grading of meningiomas is insufficient for optimal risk stratification. The purpose of the present study was to determine the prognostic value of atypical histopathological features across all nonmalignant meningiomas (World Health Organization [WHO] grade I-II).
   METHODS: The data from 334 patients with WHO grade I (n = 275) and grade II (n = 59) meningiomas who had undergone surgical resection from 2001 to 2015 at 2 academic centers were pooled. Progression/recurrence (P/R) was determined radiographically and measured from the date of surgery.
   RESULTS: The median follow-up was 52 months. The patients were stratified by the number of atypical features: 0 (n = 151), 1 (n = 71), 2 (n = 66), 3 (n = 22), and 4 or 5 (n = 24). The risk of P/R increased with an increasing number of atypical features (log-rank test, P = 0.001). The 5-year actuarial rates of P/R stratified by the number of atypical features were as follows: 0, 16.3% (95% confidence interval [CI], 10.7-24.4); 1, 21.7% (95% CI, 12.8-35.2); 2, 28.2% (95% CI, 18.4-41.7); 3, 30.4% (95% CI, 13.8-58.7); and 4 or 5, 51.4% (95% CI, 31.7-74.5). On univariate analysis, the presence of high nuclear/cytoplasmic ratio (P = 0.007), prominent nucleoli (P = 0.007), and necrosis (P< 0.00005) were associated with an increased risk of P/R. On multivariate analysis, the number of atypical features (hazard ratio [HR], 1.30; 95% CI, 1.03-1.63; P = 0.03), >= 4 mitoses per high-power fields (HR, 2.45; 95% CI, 1.17-5.15; P = 0.02), subtotal resection (HR, 3.9; 95% CI, 2.5-6.3; P< 0.0005), and the lack of adjuvant radiotherapy (HR, 2.40; 95% CI, 1.19-4.80; P = 0.01) were associated with an increased risk of P/R.
   CONCLUSIONS: An increased number of atypical features, >= 4 mitoses per 10 high-power fields, subtotal resection, and the lack of adjuvant radiotherapy were independently associated with P/R of WHO grade I-II meningiomas. Patients with these features might benefit from intensified therapy.
C1 [Lamba, Nayan; Niemierko, Andrzej; Oh, Kevin S.; Loeffler, Jay S.; Shih, Helen A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
   [Mehan, William A.; Benayoun, Marc D.] Massachusetts Gen Hosp, Dept Radiol, 32 Fruit St, Boston, MA 02114 USA.
   [Curry, William T.; Barker, Fred G., II; Martuza, Robert L.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
   [Hwang, William L.; Kim, Daniel W.] Harvard Radiat Oncol Residency Program, Boston, MA USA.
   [Marciscano, Ariel E.] NCI, Radiat Oncol Branch, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Dunn, Ian F.] Univ Oklahoma, Dept Neurosurg, Oklahoma City, OK USA.
   [Claus, Elizabeth; Bi, Wenya Linda] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
   [Aizer, Ayal A.; Alexander, Brian M.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
RP Shih, HA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
EM hshih@mgh.harvard.edu
RI Niemierko, Andrzej/AAJ-2313-2020
OI Niemierko, Andrzej/0000-0002-8895-5500; Marciscano, Ariel
   E./0000-0001-8838-2127
CR Abbritti RV, 2016, CANCER GENOM PROTEOM, V13, P369
   Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Aizer AA, 2016, NEURO-ONCOLOGY, V18, P269, DOI 10.1093/neuonc/nov177
   Aizer AA, 2014, NEURO-ONCOLOGY, V16, P1547, DOI 10.1093/neuonc/nou098
   Apra C, 2018, EXPERT REV NEUROTHER, V18, P241, DOI 10.1080/14737175.2018.1429920
   Arikok AT, 2014, BRAIN TUMOR PATHOL, V31, P94, DOI 10.1007/s10014-013-0152-2
   Ayerbe J, 1999, ACTA NEUROCHIR, V141, P921, DOI 10.1007/s007010050398
   Backer-Grondahl T, 2014, APMIS, V122, P856, DOI 10.1111/apm.12248
   Bi WL, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00040
   Boetto J, 2017, NEURO-ONCOLOGY, V19, P345, DOI 10.1093/neuonc/now276
   Brokinkel B, 2017, NEURO-ONCOLOGY, V19, P1298, DOI 10.1093/neuonc/nox071
   Bruna J, 2007, NEUROPATHOLOGY, V27, P114, DOI 10.1111/j.1440-1789.2007.00750.x
   Champeaux C, 2016, J NEURO-ONCOL, V129, P337, DOI 10.1007/s11060-016-2181-2
   Gabeau-Lacet D, 2009, J NEUROPATH EXP NEUR, V68, P1155, DOI 10.1097/NEN.0b013e3181ba3952
   Goutagny S, 2014, BRAIN PATHOL, V24, P184, DOI 10.1111/bpa.12110
   Hasan S, 2015, WORLD NEUROSURG, V83, P808, DOI 10.1016/j.wneu.2014.12.037
   Ho DMT, 2002, CANCER, V94, P1538, DOI 10.1002/cncr.10351
   Hwang WL, 2016, NEURO-ONCOLOGY, V18, P863, DOI 10.1093/neuonc/nov285
   Ildan F, 2007, SKULL BASE-INTERD AP, V17, P157, DOI 10.1055/s-2007-970554
   Jenkinson MD, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1040-3
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Marciscano AE, 2016, J NEUROSURG, V124, P106, DOI 10.3171/2015.1.JNS142228
   Menger R, 2017, CUREUS, V9, DOI 10.7759/cureus.1820
   Olar A, 2015, BRAIN PATHOL, V25, P266, DOI 10.1111/bpa.12174
   Pasquier D, 2008, INT J RADIAT ONCOL, V71, P1388, DOI 10.1016/j.ijrobp.2007.12.020
   Perry A, 1997, AM J SURG PATHOL, V21, P1455, DOI 10.1097/00000478-199712000-00008
   Perry A, 1998, CANCER-AM CANCER SOC, V82, P2262, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2262::AID-CNCR23>3.3.CO;2-O
   Phonwijit L, 2017, WORLD NEUROSURG, V107, P698, DOI 10.1016/j.wneu.2017.08.057
   Rezvan PH, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0022-1
   Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1
   Ruiz J, 2010, HISTOL HISTOPATHOL, V25, P341, DOI 10.14670/HH-25.341
   Rydzewski NR, 2018, CANCER-AM CANCER SOC, V124, P734, DOI 10.1002/cncr.31088
   Sahm F, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv377
   Shakir SI, 2018, J NEUROSURG, V129, P1240, DOI 10.3171/2017.6.JNS17120
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Stafford SL, 1998, MAYO CLIN PROC, V73, P936, DOI 10.4065/73.10.936
   Tan LA, 2015, BRIT J NEUROSURG, V29, P77, DOI 10.3109/02688697.2014.957647
   Yesiloz U, 2017, NEURO-ONCOLOGY, V19, P1088, DOI 10.1093/neuonc/nox018
   Yoon H, 2015, J CANCER RES THER, V11, P59, DOI 10.4103/0973-1482.148708
NR 39
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E804
EP E812
DI 10.1016/j.wneu.2019.10.002
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700149
PM 31605839
OA Bronze
DA 2020-05-12
ER

PT J
AU Lan, M
   Dambrino, RJ
   Youssef, A
   Yengo-Kahn, A
   Dewan, MC
   Ehrenfeld, J
   Bonfield, CM
   Zuckerman, SL
AF Lan, Matthews
   Dambrino, Robert J.
   Youssef, Andrew
   Yengo-Kahn, Aaron
   Dewan, Michael C.
   Ehrenfeld, Jesse
   Bonfield, Christopher M.
   Zuckerman, Scott L.
TI Repeat Surgery After Decompressive Craniectomy for Traumatic
   Intracranial Hemorrhage: Outcomes and Predictors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Death; Decompressive craniectomy; Epidural hemorrhage;
   Morbidity; Subdural hemorrhage; Traumatic brain injury
ID ACUTE SUBDURAL-HEMATOMA; EVACUATION
AB INTRODUCTION: Repeat surgery (RS) after decompressive craniectomy/craniotomy (DC) for traumatic intracranial hemorrhage (TICH) is a devastating complication. In patients undergoing DC for TICH, we sought to 1) describe the population requiring RS, 2) compare outcomes of those requiring RS with those who did not, and 3) discern RS predictors.
   METHODS: A single-institution retrospective case-control study was conducted from 2000 to 2015. Inclusion criteria were DC for acute supratentorial TICH (subdural hemorrhage, epidural hemorrhage, and intraparenchymal hemorrhage) and day survival. Patients underwent RS within >= 7 days of DC; controls did not require RS. Outcomes and predictors of RS were evaluated with univariate and multivariate logistic regression (MLR).
   RESULTS: Of 201 patients requiring DC, 28 (14%) underwent RS. Common mechanisms were ground-level fall (45%) and motor vehicle collision (29%). Anticoagulation/antiplatelet medication was used by 44 patients (21%). Subdural hemorrhage was the most common hemorrhage (64%). Using MLR, those requiring RS were more likely to experience major complications (odds ratio [OR], 22.6; 95% confidence interval [CI], 5.06-101.35; P < 0.001) and in-hospital mortality (OR, 2.76; 95% CI, 1.02-7.43; P = 0.045) and he dead/dependent at 6 months (OR, 2.50; 95% CI, 1 08 - 5.82; P = 0.033) and 2 years (OR, 2.44; 95% CI, 0.99 6.00, P = 0.051). Predictors of undergoing RS identified by MLR were smaller hemorrhage (OR, 0.32; 95% CI, 0.13-0.78; P = 0.012), larger midline shift (OR, 4.40; 95% CI, 1.43-13.51; P = 0.010), and better preoperative Glasgow Coma Scale score (OR, 1.28; 95% CI, 1.13-1.46; P < 0.001).
   CONCLUSIONS: Patients requiring RS after DC represent a heterogenous population with worse outcomes. Although the identified risk factors for RS are not modifiable, surgeons should be aware of these factors during the initial surgery.
C1 [Lan, Matthews] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
   [Dambrino, Robert J.; Yengo-Kahn, Aaron; Dewan, Michael C.; Bonfield, Christopher M.; Zuckerman, Scott L.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA.
   [Ehrenfeld, Jesse] Vanderbilt Univ, Med Ctr, Dept Anesthesia, Nashville, TN USA.
   [Youssef, Andrew] Mehany Med Coll, Sch Med, Nashville, TN USA.
RP Zuckerman, SL (reprint author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA.
EM scott.zuckerman@vumc.org
RI Ehrenfeld, Jesse/AAI-2951-2020
CR Ban SP, 2010, J KOREAN NEUROSURG S, V48, P244, DOI 10.3340/jkns.2010.48.3.244
   Cepeda Santiago, 2019, J Neurosurg, P1, DOI 10.3171/2019.2.JNS182025
   Chrastina J, 2020, EUR J TRAUMA EMERG S, V46, P347, DOI 10.1007/s00068-019-01077-6
   Di GF, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1179
   Godlewski B, 2013, NEUROL MED-CHIR, V53, P26, DOI 10.2176/nmc.53.26
   Gopalakrishnan MS, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00977
   Gutowski P, 2018, WORLD NEUROSURG, V118, pE166, DOI 10.1016/j.wneu.2018.06.147
   Han Hokyun, 2016, Korean J Neurotrauma, V12, P61, DOI 10.13004/kjnt.2016.12.2.61
   Kumar A, 2019, J NEUROSURG, V130, P1784, DOI 10.3171/2018.11.JNS183191
   Lv JH, 2019, WORLD NEUROSURG, V122, P24, DOI 10.1016/j.wneu.2018.10.106
   Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359
   Matsuno A, 2003, SURG NEUROL, V60, P23, DOI 10.1016/S0090-3019(03)00023-5
   Mohindra S, 2005, BRIT J NEUROSURG, V19, P490, DOI 10.1080/02688690500495216
   PALMER JD, 1994, NEUROSURGERY, V35, P1061, DOI 10.1227/00006123-199412000-00007
   Shen J, 2013, NEUROL MED-CHIR, V53, P221, DOI 10.2176/nmc.53.221
   Shen J, 2013, ACTA NEUROCHIR, V155, P335, DOI 10.1007/s00701-012-1569-9
   Wang Y, 2018, PAN AFR MED J, V31, DOI 10.11604/pamj.2018.31.140.13982
   Wu RH, 2017, BMC SURG, V17, DOI 10.1186/s12893-017-0303-1
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E757
EP E766
DI 10.1016/j.wneu.2019.09.148
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700143
PM 31604134
OA Bronze
DA 2020-05-12
ER

PT J
AU Lee, BJ
   Park, JH
   Jeon, SR
   Roh, SW
   Rhim, SC
   Jung, SK
AF Lee, Byung-Jou
   Park, Jin Hoon
   Jeon, Sang-Ryong
   Roh, Sung Woo
   Rhim, Seung-Chul
   Jung, Sang Ku
TI Posterior Cervical Muscle-Preserving Interspinous Process Approach and
   Decompression: More Minimally Invasive and Modified Shiraishi's
   Selective Laminectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spondylotic myelopathy; Laminoplasty; Modified Shiraishi's
   method; Muscle preservation
ID OPEN-DOOR LAMINOPLASTY; PRESERVATION; OSSIFICATION; MYELOPATHY;
   LIGAMENT; SPINE
AB OBJECTIVE: The cervical extensor musculature is important in cases of neck pain and loss of cervical lordosis after laminoplasty. Therefore, various surgical methods have been developed to preserve the muscle during laminoplasty. We have developed a posterior cervical muscle-preserving interspinous process (MIS) approach and decompression method. We have described the operation details and clinical outcomes of selected patients who have undergone this procedure.
   METHODS: The MIS approach and decompression method were performed in 20 consecutive patients who had only required central decompression for cervical stenosis. This procedure includes an approach to the interspinous space that is similar to Shiraishi's method but includes decompression without fracturing the spina bifida.
   RESULTS: The patients had no complications and did not require conversion to conventional laminoplasty. The mean operative time and mean blood loss was 53.0 minutes and 63.0 mL per level, respectively, and the mean hospital stay was 4.0 days. The mean preoperative and 3-month postoperative modified Japanese Orthopedic Association scores were 12.6 and 16.2, and the mean preoperative and 3-month postoperative neck disability index scores were 15.4 and 2.5, respectively. The postoperative neck visual analog scale score was 0.8. The mean preoperative and postoperative sagittal vertical axis was 1.6 and 1.8 cm, respectively. The mean loss of lordosis was 1.0 degrees, and the mean cervical range of motion did not change from preoperatively to postoperatively.
   CONCLUSIONS: The MIS approach and decompression method was less invasive than both conventional laminoplasty and Shiraishi's selective laminectomy. It is a safe and effective minimally invasive technique for central stenosis caused by cervical spondylotic myelopathy.
C1 [Lee, Byung-Jou] Inje Univ, Ilsan Paik Hosp, Neurosci & Radiosurg Hybrid Res Ctr, Coll Med,Dept Neurosurg, Goyang Si, South Korea.
   [Park, Jin Hoon; Jeon, Sang-Ryong; Roh, Sung Woo; Rhim, Seung-Chul] Univ Ulsan, Asan Med Ctr, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Jung, Sang Ku] Univ Ulsan, Gangneung Asan Hosp, Dept Emergency Med, Coll Med, Gangneung Si, South Korea.
RP Park, JH (reprint author), Univ Ulsan, Asan Med Ctr, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM jhpark@amc.seoul.kr
CR HIRABAYASHI K, 1983, SPINE, V8, P693, DOI 10.1097/00007632-198310000-00003
   Hosono N, 2005, J NEUROSURG-SPINE, V3, P29, DOI 10.3171/spi.2005.3.1.0029
   HUKUDA S, 1988, J BONE JOINT SURG BR, V70, P325
   Iizuka H, 2006, SPINE, V31, P644, DOI 10.1097/01.brs.0000203707.79269.6a
   Iwasaki M, 2002, J NEUROSURG, V96, P180, DOI 10.3171/spi.2002.96.2.0180
   Kim P, 2007, J NEUROSURG-SPINE, V7, P293, DOI 10.3171/SPI-07/09/293
   Kotani Y, 2009, EUR SPINE J, V18, P663, DOI 10.1007/s00586-009-0892-1
   Kurokawa R, 2015, NEUROL MED-CHIR, V55, P529, DOI 10.2176/nmc.ra.2014-0387
   Lao LF, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749-799X-8-45
   Liu JY, 2007, SPINE J, V7, P159, DOI 10.1016/j.spinee.2006.07.007
   Machino M, 2012, SPINE, V37, pE1243, DOI 10.1097/BRS.0b013e3182659d3e
   NAKANO N, 1988, SPINE, V13, P792, DOI 10.1097/00007632-198807000-00014
   Nori S, 2018, SPINE, V43, P542, DOI 10.1097/BRS.0000000000002359
   Otani K, 2009, J HEALTHC MANAG, V54, P93
   Park JH, 2015, J CLIN NEUROSCI, V22, P308, DOI 10.1016/j.jocn.2014.07.018
   Riew K Daniel, 2013, Evid Based Spine Care J, V4, P42, DOI 10.1055/s-0033-1341606
   Secer HI, 2018, TURK NEUROSURG, V28, P257, DOI 10.5137/1019-5149.JTN.20007-17.1
   Seichi A, 2001, SPINE, V26, P479, DOI 10.1097/00007632-200103010-00010
   Shiraishi T, 2003, SPINE, V28, P2667, DOI 10.1097/01.BRS.0000103340.78418.B2
   Shiraishi Tateru, 2002, Spine J, V2, P108, DOI 10.1016/S1529-9430(01)00118-8
   Shiraishi T, 2012, SPINE, V37, pE286, DOI 10.1097/BRS.0b013e318239cc7e
   Tani S, 2002, NEUROSURGERY, V50, P97, DOI 10.1097/00006123-200201000-00017
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E412
EP E420
DI 10.1016/j.wneu.2019.09.041
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700097
PM 31536811
OA Bronze
DA 2020-05-12
ER

PT J
AU Lee, SH
   Kwun, BD
   Ryu, J
   Chung, Y
   Jeong, WJ
   Park, CK
   Lee, KM
   Kim, EJ
   Choi, SK
AF Lee, Sung Ho
   Kwun, Byung Duk
   Ryu, Jiwook
   Chung, Yeongu
   Jeong, Won Joo
   Park, Chang Kyu
   Lee, Kyung Mi
   Kim, Eui Jong
   Choi, Seok Keun
TI Incidental Microaneurysms During Microvascular Surgery: Incidence,
   Treatment, and Significance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Aneurysm neck clipping; Angiography; Brain
ID RUPTURED INTRACRANIAL ANEURYSMS; ROTATIONAL ANGIOGRAPHY;
   DIGITAL-SUBTRACTION; SIZE; RISK; LOCATION
AB BACKGROUND: Although new imaging tools have been developed for the detection of smaller aneurysms, angiographically negative microaneurysms are still encountered during cerebral microsurgery. Currently, only limited information regarding incidence and efficacy of treatment of these microaneurysms is available.
   METHODS: We investigated the incidence and treatment of incidental microaneurysms (IMAs) in the last 5 years. IMAs are unidentifiable and invisible on preoperative angiography, but are detected during microvascular surgery. The inclusion criteria were aneurysm cases treated with microsurgery via transsylvian approaches, and those undergoing preoperative digital subtraction angiography.
   RESULTS: This study enrolled 484 surgical cases (248 cases of subarachnoid hemorrhage and 236 cases of unruptured aneurysms) in 460 patients, and 33 tiny aneurysms were found in 31 operative cases (6.4% incidence per operation). The most typical type was located on another branching site of the middle cerebral artery found during neck clipping of the middle cerebral artery bifurcation aneurysm. A patient with multiple aneurysms presented a statistically significant risk (375/78 vs. 15/16; P < 0.001) of IMA identification. IMAs were treated by clipping and wrapping in 18 and 15 cases, respectively, without complications.
   CONCLUSIONS: This study revealed a 6.4% incidence of IMAs; however, this could be underestimated because of the limited range of inspection. Early detection of an IMA through careful inspection during microvascular surgery could be beneficial, especially in patients with multiple aneurysms.
C1 [Lee, Sung Ho] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Kwun, Byung Duk; Ryu, Jiwook; Park, Chang Kyu; Choi, Seok Keun] Kyung Hee Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
   [Lee, Kyung Mi; Kim, Eui Jong] Kyung Hee Univ, Coll Med, Dept Radiol, Seoul, South Korea.
   [Chung, Yeongu] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Neurosurg, Sch Med, Seoul, South Korea.
   [Jeong, Won Joo] Osan Hankook Hosp, Dept Neurosurg, Osan, South Korea.
RP Choi, SK (reprint author), Kyung Hee Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
EM nscsk@hanmail.net
RI Lee, Sung Ho/AAK-9066-2020
OI Lee, Sung Ho/0000-0002-0202-8969; Park, Chang Kyu/0000-0002-5935-8264
FU National Research Foundation of Korea - Korean governmentNational
   Research Foundation of KoreaKorean Government [2017R1C1B5017484]
FX This work was supported by the National Research Foundation of Korea
   grant funded by the Korean government (2017R1C1B5017484).
CR Bender MT, 2018, NEUROSURGERY, V83, P692, DOI 10.1093/neuros/nyx484
   Burkhardt JK, 2020, J NEUROSURG, V132, P797, DOI 10.3171/2018.10.JNS182540
   Dolati P, 2015, CUREUS, V7, DOI 10.7759/cureus.279
   Forget TR, 2001, NEUROSURGERY, V49, P1322, DOI 10.1097/00006123-200112000-00006
   Froelich JJ, 2016, WORLD NEUROSURG, V91, P260, DOI 10.1016/j.wneu.2016.04.044
   Hepokosi M, 2017, ANN INTERN MED, V166, pW20, DOI 10.7326/M17-0138
   Huh CW, 2018, J KOREAN NEUROSURG S, V61, P450, DOI 10.3340/jkns.2017.0606.004
   Ikawa F, 2020, J NEUROSURG, V132, P69, DOI 10.3171/2018.9.JNS181736
   Inamasu J, 2001, NEUROL RES, V23, P304, DOI 10.1179/016164101101198631
   Karasawa H, 1997, ACTA NEUROCHIR, V139, P416, DOI 10.1007/BF01808877
   Kucukay F, 2012, EUR J RADIOL, V81, P2794, DOI 10.1016/j.ejrad.2011.10.006
   Lee Gwang-Jin, 2015, J Cerebrovasc Endovasc Neurosurg, V17, P217, DOI 10.7461/jcen.2015.17.3.217
   McKinney AM, 2008, AM J NEURORADIOL, V29, P594, DOI 10.3174/ajnr.A0848
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Sato K, 2011, STROKE, V42, P3376, DOI 10.1161/STROKEAHA.111.625871
   Sonobe M, 2010, STROKE, V41, P1969, DOI 10.1161/STROKEAHA.110.585059
   van Rooij WJ, 2008, AM J NEURORADIOL, V29, P976, DOI 10.3174/ajnr.A0964
   Wermer MJH, 2005, BRAIN, V128, P2421, DOI 10.1093/brain/awh587
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Xu T, 2017, J NEUROINTERV SURG, V9, P278, DOI 10.1136/neurintsurg-2016-012294
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E149
EP E155
DI 10.1016/j.wneu.2019.08.159
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700019
PM 31476473
OA Bronze
DA 2020-05-12
ER

PT J
AU Li, CG
   Qi, YN
   Liu, GZ
   Yin, XC
   Jin, Y
   Jiang, ZH
   Li, PY
   Kang, XL
   Ye, C
AF Li, Chungen
   Qi, Yingna
   Liu, Genzhe
   Yin, Xincheng
   Jin, Yi
   Jiang, Zehui
   Li, Pengyang
   Kang, Xiaole
   Ye, Chao
TI Long-Term Clinical Outcomes of Percutaneous Cervical Nucleoplasty for
   Cervical Degenerative Diseases with Neck Pain and Cervical Vertigo
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical degenerative disc diseases; Cervical vertigo; Neck pain;
   Percutaneous cervical nucleoplasty
ID DISK; FUSION; SURGERY
AB BACKGROUND: Good short- and mid-term clinical efficacy of percutaneous cervical nucleoplasty (PCN) for cervical degenerative diseases (CDD) with neck pain has been reported. However, few studies have assessed its long-term influence in patients with both neck pain and cervical vertigo. This study aimed to evaluate the curative efficacy of PCN for CDD with neck pain and cervical vertigo with minimum of 6 years of follow-up.
   METHODS: Inpatients who underwent PCN for CDD with neck pain and cervical vertigo between April 2010 an d March 2013 were enrolled. Clinical outcomes were assessed using the Cervical Vertigo Evaluation Scale (CVES); greater CVES scores reflected less impairment. Additional open surgeries were recorded.
   RESULTS: Among 40 patients, 100% completed the 1-year short-term and 3-year mid-term follow-up (FU); 85% completed the 6-year long-term FU. Clinical effective rates were 67.5%, 67.5%, and 52.94% at short-, mid-, and long-term FU, respectively. CVES scores were greater than the preoperative CVES scores at all FU timepoints (P < 0.01). However, the CVES score was lower at the final FU than at the 3-year FU (P < 0.05). The neck pain score significantly decreased over time and was lower than the cervical vertigo score at the final FU (P> 0.05). Reoperation rates were 1/40 (2.50%) and 3/34 (8.82%) at mid- and long-term FU, respectively.
   CONCLUSIONS: PCN in patients with CDD neck pain and cervical vertigo showed satisfactory clinical efficacy at short- and mid-term FU, and it was fair at long-term FU. Thus, PCN could be a complementary operation for CDD.
C1 [Li, Chungen; Qi, Yingna; Liu, Genzhe; Yin, Xincheng; Jin, Yi] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Orthoped Dept, Beijing, Peoples R China.
   [Jiang, Zehui] Beijing First Hosp Integrated Chinese & Western M, Orthoped Dept, Beijing, Peoples R China.
   [Li, Pengyang; Kang, Xiaole; Ye, Chao] Beijing Univ Chinese Med, Orthoped Dept, Dongzhimen Hosp, Beijing, Peoples R China.
RP Qi, YN (reprint author), Capital Med Univ, Beijing Hosp Tradit Chinese Med, Orthoped Dept, Beijing, Peoples R China.
EM ayingqi119925@163.com
CR Castro W H, 1992, Acta Orthop Belg, V58, P400
   Cesaroni A, 2010, EUR SPINE J, V19, P477, DOI 10.1007/s00586-009-1189-0
   De la Garza-Ramos R, 2016, J NEUROSURG-SPINE, V25, P15, DOI 10.3171/2015.11.SPINE151021
   de Rooij JD, 2017, CLIN SPINE SURG, V30, P389, DOI 10.1097/BSD.0000000000000583
   Engquist M, 2017, J NEUROSURG-SPINE, V26, P19, DOI 10.3171/2016.6.SPINE151427
   Halim W, 2017, PAIN PRACT, V17, P729, DOI 10.1111/papr.12517
   Hey HWD, 2013, EUR SPINE J, V22, P116, DOI 10.1007/s00586-012-2486-6
   Kang LQ, 2013, ORTHOPEDICS, V36, pE88, DOI 10.3928/01477447-20121217-24
   Kim MK, 2018, WORLD NEUROSURG, V114, pE654, DOI 10.1016/j.wneu.2018.03.046
   Klessinger S, 2018, WORLD NEUROSURG, V117, pE552, DOI 10.1016/j.wneu.2018.06.075
   Li Jian, 2006, Zhonghua Wai Ke Za Zhi, V44, P822
   [李杰 Li Jie], 2016, [中国新药杂志, Chinese Journal New Drugs], V25, P1833
   Li YC, 2015, PAIN PHYSICIAN, V18, pE583
   Nardi PV, 2005, ACT NEUR S, V92, P73
   Sim SE, 2011, KOREAN J PAIN, V24, P36, DOI 10.3344/kjp.2011.24.1.36
   Swank M L, 1997, Eur Spine J, V6, P138, DOI 10.1007/BF01358747
   Tian P, 2015, SCI REP-UK, V5, DOI 10.1038/srep13454
   Wang CH, 1998, CHIN J REHABIL MED, V13, P245
   Wullems JA, 2014, PAIN PRACT, V14, P559, DOI 10.1111/papr.12122
   Yan DL, 2010, ARCH ORTHOP TRAUM SU, V130, P1371, DOI 10.1007/s00402-009-1041-3
   Yang L, 2017, SPINE, V42, P540, DOI 10.1097/BRS.0000000000001801
   Yang S-D, 2017, SCI REP, V7, P1
   Yin HD, 2015, BRIT J RADIOL, V90, P1
NR 23
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E205
EP E210
DI 10.1016/j.wneu.2019.08.210
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700026
PM 31493606
OA Bronze
DA 2020-05-12
ER

PT J
AU Li, DH
   Wen, R
   Gao, Y
   Xu, YY
   Xiong, BT
   Gong, FL
   Wang, W
AF Li, Denghui
   Wen, Rong
   Gao, Yuan
   Xu, Yangyang
   Xiong, Botao
   Gong, Feilong
   Wang, Wei
TI Pineal Region Gliomas: A Single-Center Experience with 25 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chemotherapy; Glioma; Pineal gland; Radiosurgery; Surgery
ID GRANULAR-CELL ASTROCYTOMA; STEREOTACTIC RADIOSURGERY; SURGICAL APPROACH;
   PAPILLARY TUMOR; MANAGEMENT; GLAND; OLIGODENDROGLIOMA; SURGERY;
   CHEMOTHERAPY; RESECTION
AB BACKGROUND: Pineal region glioma is a rare systematically reported tumor in the literatures, and little is known about its behavior, development, and best treatment strategies because of its complex anatomical relationship and rarity.
   OBJECTIVE: We reviewed the outcomes of patients with pineal region gliomas in West China hospital in the past 5 years and searched the literature to add more information. As a result, key factors related to prognosis are identified.
   METHODS: Twenty-five patients with pineal region gliomas were selected and information was collected about detailed medical history, imaging data, treatment methods, pathologic results, and latest neurosurgical radiologic progress during follow-up.
   RESULTS: Pilocytic astrocytomas (20%) and glioblastomas (24%) were the most common pathologic subtypes. Twenty-three patients underwent open surgery, 3 Gamma Knife radiosurgery, and 4 whole-brain radiation therapy. Chemotherapy was applied to 3 patients. Low-grade gliomas tended to have a better prognosis than did highgrade. Karnofsky Performance Status at admission (560) was intimately associated with prognosis for low-grade gliomas. As for high-grade gliomas, patients whose age at admission was <= 30 years had a better prognosis than did older patients ( > 30 years). However, whatever the grade, there was no overall survival difference as to gender, gross total resection versus not gross total resection, preoperative maximal tumor diameter (<= 4 vs. > 4 cm), and time since first symptoms (<= 30 vs. > 30 days), and radiation therapy versus no radiation therapy.
   CONCLUSIONS: Open surgery is the first-line strategy for pineal region gliomas with tolerable mortality and disability rate. Radiosurgery and chemotherapy can be applied as adjuvant or alternative methods when surgery is contraindicated.
C1 [Li, Denghui; Wen, Rong; Gao, Yuan; Xu, Yangyang; Xiong, Botao; Gong, Feilong; Wang, Wei] Sichuan Univ, Neurosurg Dept, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Wang, W (reprint author), Sichuan Univ, Neurosurg Dept, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM wcnsww@163.com
CR Blonski M, 2013, J NEURO-ONCOL, V113, P267, DOI 10.1007/s11060-013-1106-6
   BOGNAR L, 1994, ACTA NEUROCHIR, V127, P161, DOI 10.1007/BF01808760
   BRUCE JN, 1995, ACTA NEUROCHIR, V134, P130, DOI 10.1007/BF01417679
   Calaminus G, 2004, KLIN PADIATR, V216, P141, DOI 10.1055/s-2004-822626
   CHAO CKS, 1993, INT J RADIAT ONCOL, V27, P1185, DOI 10.1016/0360-3016(93)90542-4
   Das S, 2006, J NEUROSURG, V105, P461, DOI 10.3171/jns.2006.105.3.461
   DeGirolami U., 1982, CANCER, P1185
   EDWARDS MSB, 1988, J NEUROSURG, V68, P689, DOI 10.3171/jns.1988.68.5.0689
   Ellis DL, 2011, PEDIATR NEUROL, V45, P417, DOI 10.1016/j.pediatrneurol.2011.09.011
   Hasegawa T, 2002, NEUROSURGERY, V51, P880, DOI 10.1097/00006123-200210000-00006
   Hernesniemi J, 2008, SURG NEUROL, V70, P576, DOI 10.1016/j.surneu.2008.07.019
   HERRMANN HD, 1992, ACTA NEUROCHIR, V116, P137, DOI 10.1007/BF01540866
   HOFFMAN HJ, 1994, PEDIATR NEUROSURG, V21, P91, DOI 10.1159/000120821
   Jia WQ, 2011, J NEUROSURG-PEDIATR, V7, P98, DOI 10.3171/2010.10.PEDS0976
   Kano H, 2009, PROG NEUROL SURG, V23, P44, DOI 10.1159/000210052
   Konovalov AN, 2003, SURG NEUROL, V59, P250, DOI 10.1016/S0090-3019(03)00080-6
   Kreth FW, 1996, NEUROSURGERY, V39, P280, DOI 10.1097/00006123-199608000-00010
   Lamis FC, 2015, J NEUROL SURG REP, V76, P55, DOI 10.1055/s-0034-1396653
   LAPRAS C, 1987, PROG EXP TUMOR RES, V30, P268
   Lekovic Gregory P, 2007, Neurosurg Focus, V23, pE12
   LUO S, 1989, SURG NEUROL, V32, P36, DOI 10.1016/0090-3019(89)90032-3
   Magrini S, 2013, J NEURO-ONCOL, V115, P103, DOI 10.1007/s11060-013-1200-9
   MATSUMOTO K, 1995, ACTA NEUROCHIR, V136, P21, DOI 10.1007/BF01411431
   Matsuno A, 2009, BRIT J NEUROSURG, V20, P246
   Matsuyama J, 2011, NEUROSURG QUART, V21, P226, DOI 10.1097/WNQ.0b013e318218c21a
   Mori Y, 2009, PROG NEUROL SURG, V23, P106, DOI 10.1159/000210057
   Nagaishi M, 2011, NEUROPATHOLOGY, V31, P152, DOI 10.1111/j.1440-1789.2010.01143.x
   Nakamura H, 2009, BRAIN TUMOR PATHOL, V26, P73, DOI 10.1007/s10014-009-0250-3
   Nitta J, 2001, NEUROSURGERY, V49, P1458, DOI 10.1097/00006123-200112000-00030
   Ogura T, 2004, PEDIATR NEUROSURG, V40, P301, DOI 10.1159/000083744
   Ohta T, 2010, NEUROPATHOLOGY, V30, P615, DOI 10.1111/j.1440-1789.2009.01095.x
   Oi S, 2000, J NEUROSURG, V93, P245, DOI 10.3171/jns.2000.93.2.0245
   Ozgural O, 2013, TURK NEUROSURG, V23, P572, DOI 10.5137/1019-5149.JTN.5994-12.1
   PLUCHINO F, 1989, ACTA NEUROCHIR, V96, P26, DOI 10.1007/BF01403491
   Riis P, 2013, STEREOT FUNCT NEUROS, V91, P186, DOI 10.1159/000344023
   Sherman JH, 2005, SURG NEUROL, V63, P476, DOI 10.1016/j.surneu.2004.06.015
   Shin HJ, 1998, CHILD NERV SYST, V14, P174, DOI 10.1007/s003810050206
   SNIPES GJ, 1992, CANCER, V70, P2159, DOI 10.1002/1097-0142(19921015)70:8<2159::AID-CNCR2820700825>3.0.CO;2-C
   Sonabend AM, 2016, YOUMANS WINN NEUROLO, V7, P1048
   Stark AM, 2005, PEDIATR NEUROL, V33, P33, DOI 10.1016/j.pediatrneurol.2004.12.014
   Toyooka T, 2005, J CLIN NEUROSCI, V12, P834, DOI 10.1016/j.jocn.2004.09.027
   Tseng CK, 2011, J PEDIAT HEMATOL ONC, V33, pE138, DOI 10.1097/MPH.0b013e31820d0c69
   VAQUERO J, 1992, ACTA NEUROCHIR, V116, P23, DOI 10.1007/BF01541249
   Weiner HL, 2002, NEUROSURGERY, V50, P727, DOI 10.1097/00006123-200204000-00008
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E6
EP E17
DI 10.1016/j.wneu.2019.06.189
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700004
PM 31284062
OA Bronze
DA 2020-05-12
ER

PT J
AU Lin, M
   Bakhsheshian, J
   Strickland, B
   Rennert, RC
   Chen, JW
   Van Gompel, JJ
   Young, RL
   Kumar, PP
   Coppens, J
   Curry, WT
   Zacharia, BE
   Bailes, JE
   Zada, G
AF Lin, Michelle
   Bakhsheshian, Joshua
   Strickland, Ben
   Rennert, Robert C.
   Chen, Jefferson W.
   Van Gompel, Jamie J.
   Young, Ronald L., II
   Kumar, Promod P.
   Coppens, Jeroen
   Curry, William T.
   Zacharia, Brad E.
   Bailes, Julian E.
   Zada, Gabriel
TI Navigable Channel-Based Trans-Sulcal Resection of Third Ventricular
   Colloid Cysts: A Multicenter Retrospective Case Series and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Colloid cysts; Extracorporeal telescope; Intraoperative navigation;
   Minimally invasive surgery; Surgical Technique; Tubular retractor;
   Ventricular lesions
ID ENDOSCOPIC RESECTION; NATURAL-HISTORY; 3RD-VENTRICLE; MANAGEMENT;
   EXPERIENCE; REMOVAL; LESIONS; SYSTEM; SURGERY; TUMORS
AB BACKGROUND: Developments in frameless neuronavigation and tubular retractors hold the potential for minimizing iatrogenic injury to the overlying cortex and subcortical tracts, with improved access to the ventricular system. The objective of the present study was to evaluate the surgical outcomes after resection of third ventricular colloid cysts using an integrated neuronavigation and channel-based approach.
   METHODS: We performed a multicenter retrospective analysis of surgical Outcomes after surgical resection of third ventricular colloid cysts via a transtubular transsulcal approach.
   RESULTS: A total of 16 patients were included, with a mean age of 42 years (range, 23-62 years). The mean maximum diameter of cysts was 14 mm (range, 7-28 nun), and preoperative hydrocephalous was present in 12 patients (75%). Gross total resection was achieved in all 16 cases. Of the 12 patients, 4 (25%) had undergone septum pellucidotomy, in addition to cyst resection. No case had required conversion to open craniotomy. No perioperative mortalities occurred. Three patients (18.8%) had developed transient memory deficits, 1 of whom had also developed a pulmonary thromboembolism. The median length of hospital stay was 4 days (range, 2-18 days). All the patients reported resolution of preoperative symptoms at the 1-month follow-up examination. Only 1 patient (6.25%) had required insertion of a ventriculoperitoneal shunt. The median follow-up duration was 6.5 months (range, 3-24 months), and no recurrences were observed.
   CONCLUSION: Use of a channel-based navigable retractor provided a minimal trans-sulcal approach to third ventricular colloid cysts with the benefit of bimanual surgical control in an air medium for definitive resection of third ventricular colloid cysts.
C1 [Lin, Michelle; Bakhsheshian, Joshua; Strickland, Ben; Rennert, Robert C.; Zada, Gabriel] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
   [Chen, Jefferson W.] Univ Calif Irvine, Sch Med, Dept Neurol Surg, Irvine, CA 92717 USA.
   [Van Gompel, Jamie J.] Mayo Clin, Sch Med, Dept Neurol Surg, Rochester, MN USA.
   [Young, Ronald L., II] Brain & Spine Ctr, Delray Beach, FL USA.
   [Kumar, Promod P.] Loma Linda Univ, Med Ctr, Dept Neurol Surg, Loma Linda, CA 92350 USA.
   [Coppens, Jeroen] St Louis Univ Hosp, Dept Neurol Surg, St Louis, MO USA.
   [Curry, William T.] Massachusetts Gen Hosp, Dept Neurol Surg, Boston, MA 02114 USA.
   [Zacharia, Brad E.] Penn State Hershey Med Ctr, Dept Neurol Surg, Hershey, PA USA.
   [Bailes, Julian E.] Univ Chicago, Pritzker Sch Med, Dept Neurol Surg, Chicago, IL 60637 USA.
RP Bakhsheshian, J (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
EM Joshuabakh@gmail.com
OI Zacharia, Brad/0000-0002-2078-7635; Bakhsheshian,
   Joshua/0000-0003-2983-6082
CR Abdou MS, 1998, J NEUROSURG, V89, P1062, DOI 10.3171/jns.1998.89.6.1062
   ABERNATHEY CD, 1989, J NEUROSURG, V70, P525, DOI 10.3171/jns.1989.70.4.0525
   Agha RA, 2016, INT J SURG, V36, P319, DOI 10.1016/j.ijsu.2016.10.025
   Almenawer SA, 2013, NEUROSURG REV, V36, P321, DOI 10.1007/s10143-012-0442-x
   Alnaghmoosh N, 2006, CHILD NERV SYST, V22, P514, DOI 10.1007/s00381-005-0017-z
   AUER LM, 1988, ACTA NEUROCHIR, V90, P1, DOI 10.1007/BF01541260
   Bakhsheshian J, 2019, OPER NEUROSURG, V16, P159, DOI 10.1093/ons/opy079
   Bander ED, 2016, J NEUROSURG, V124, P1053, DOI 10.3171/2015.4.JNS142576
   Barlas O, 2004, ACTA NEUROCHIR, V146, P1199, DOI 10.1007/s00701-004-0367-4
   Bauer AM, 2017, OPER NEUROSURG, V13, P69, DOI 10.1227/NEU.0000000000001258
   Beaumont TL, 2016, J NEUROSURG, V125, P1420, DOI 10.3171/2015.11.JNS151396
   Boogaarts HD, 2011, NEUROSURGERY, V68, P179, DOI 10.1227/NEU.0b013e3181ffae71
   BOSCH DA, 1978, SURG NEUROL, V9, P15
   Cabbell KL, 1996, NEUROSURGERY, V38, P301, DOI 10.1097/00006123-199602000-00013
   CAMACHO A, 1989, NEUROSURGERY, V24, P693, DOI 10.1227/00006123-198905000-00006
   Cohen-Gadol AA, 2013, WORLD NEUROSURG, V79, pe7, DOI DOI 10.10.1016/J.WNEU.2011.03.045
   Day JD, 2017, NEUROSURGERY, V64, P151, DOI 10.1093/neuros/nyx324
   Decq P, 2013, WORLD NEUROSURG, V80, P498, DOI 10.1016/j.wneu.2012.10.034
   Desai KI, 2002, SURG NEUROL, V57, P295, DOI 10.1016/S0090-3019(02)00701-2
   Eliyas JK, 2016, WORLD NEUROSURG, V90, P556, DOI 10.1016/j.wneu.2015.12.100
   FRITSCH H, 1988, NEUROSURG REV, V11, P159, DOI 10.1007/BF01794682
   Gokalp HZ, 1996, ACTA NEUROCHIR, V138, P45, DOI 10.1007/BF01411723
   Greenlee JDW, 2008, NEUROSURGERY, V63, P51, DOI [10.1227/01.NEU.0000297004.20222.ED, 10.1227/01.neu.0000317373.00018.6f]
   Grondin RT, 2007, CAN J NEUROL SCI, V34, P197, DOI 10.1017/S0317167100006041
   Hamer PCD, 2002, J NEUROSURG, V96, P1041, DOI 10.3171/jns.2002.96.6.1041
   Hellwig D, 2003, NEUROSURGERY, V52, P525, DOI 10.1227/01.NEU.0000047671.27057.55
   Hernesniemi J, 1996, SURG NEUROL, V45, P2, DOI 10.1016/0090-3019(95)00379-7
   Hoffman CE, 2013, NEUROSURGERY, V73, P233, DOI 10.1227/01.neu.0000430300.10338.71
   Horn EM, 2007, NEUROSURGERY, V60, P613, DOI 10.1227/01.NEU.0000255409.61398.EA
   Kehler U, 2001, MINIM INVAS NEUROSUR, V44, P121, DOI 10.1055/s-2001-18122
   Kelly P J, 1989, J Neurosurg Sci, V33, P149
   KELLY PJ, 1988, NEUROSURGERY, V22, P7, DOI 10.1227/00006123-198801000-00002
   KONDZIOLKA D, 1991, J NEUROSURG, V75, P45, DOI 10.3171/jns.1991.75.1.0045
   KONDZIOLKA D, 1989, J NEUROSURG, V71, P91, DOI 10.3171/jns.1989.71.1.0091
   Lagman C, 2017, WORLD NEUROSURG, V107, P409, DOI 10.1016/j.wneu.2017.07.183
   Longatti P, 2006, CHILD NERV SYST, V22, P1263, DOI 10.1007/s00381-006-0105-8
   Mamelak AN, 2008, SURG INNOV, V15, P38, DOI 10.1177/1553350608315954
   Margetis K, 2014, J NEUROSURG, V120, P1259, DOI 10.3171/2014.3.JNS131289
   MATHIESEN T, 1993, J NEUROSURG, V78, P748, DOI 10.3171/jns.1993.78.5.0748
   Pollock BE, 1999, J NEUROSURG, V91, P364, DOI 10.3171/jns.1999.91.3.0364
   Pollock BE, 2000, NEUROSURGERY, V46, P1077, DOI 10.1097/00006123-200005000-00010
   Ratre S, 2016, J NEUROL SURG PART A, V77, P312, DOI 10.1055/s-0036-1580595
   Raza SM, 2011, MINIM INVAS NEUROSUR, V54, P5, DOI 10.1055/s-0031-1273734
   Recinos PF, 2011, J NEUROSURG-PEDIATR, V7, P516, DOI 10.3171/2011.2.PEDS10515
   Sabanci PA, 2017, TURK NEUROSURG, V27, P546, DOI 10.5137/1019-5149.JTN.17142-16.2
   Sheikh AB, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.06.024
   SHUCART WA, 1978, NEUROSURGERY, V3, P339, DOI 10.1227/00006123-197811000-00001
   Solaroglu I, 2004, NEUROSURG REV, V27, P89, DOI 10.1007/s10143-003-0309-2
   Sribnick EA, 2014, WORLD NEUROSURG, V81, P584, DOI 10.1016/j.wneu.2013.12.006
   Symss Nigel P, 2014, Asian J Neurosurg, V9, P51, DOI 10.4103/1793-5482.136708
   Turillazzi E, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-144
   Wilson DA, 2013, WORLD NEUROSURG, V80, P576, DOI 10.1016/j.wneu.2012.07.014
NR 52
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E702
EP E710
DI 10.1016/j.wneu.2019.09.134
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700135
PM 31574336
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, J
   Shen, YX
   Jiang, BW
   Yuan, Y
   Yu, YB
AF Liu, Jiang
   Shen, Yuxiao
   Jiang, Bowen
   Yuan, Yue
   Yu, Yanbing
TI Ameliorating Effect of Microvascular Decompression on Patients with
   Coexistence of Hemifacial Spasm and Glossopharyngeal Neuralgia: A
   Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glossopharyngeal neuralgia; Hemifacial spasm; Microvascular
   decompression
ID TRIGEMINAL NEURALGIA; SURGICAL-TREATMENT; MANAGEMENT
AB OBJECTIVE: Microvascular decompression (MVD) has been widely accepted for treating hemifacial spasm (HFS) and glossopharyngeal neuralgia (GN); an effective surgical treatment of coexistent HFS and GN still remains to be determined, however. In this paper we discuss the operative strategy of MVD for patients with coexistent HFS and GN.
   METHODS: This was a retrospective study. All cases of HFS with or without GN at China-Japan Friendship Hospital from January 2014 to June 2016 have been included. All patients underwent MVD and have been followed up for an average of 1.5 years.
   RESULTS: A total of 5375 cases of HFS were included, wherein 8 cases coexist with GN. Eight patients had same offending vessels) compressing the root entry zone of glossopharyngeal nerve and facial nerve. Posterior inferior cerebellar artery was identified as at least 1 of the offending arteries in all 8 patients. After MVD, spasm ceased in all 8 cases, with 7 cases ceasing immediately and 1 within 2 months. Pain disappeared also in all cases, with 7 cases immediately and 1 case after 4 days. No recurrence or complication was observed during the follow-ups.
   CONCLUSIONS: HFS combined with ipsilateral GN was rare. MVD could be performed to effectively relieve nerve root compression and associated symptoms for coexistent HFS and GN. Sufficient exposure of root entry zones of both nerves and fully decompression of offending blood vessels and exploratory sequences of different nerve roots are critical points for improving operative effect and reducing complications.
C1 [Liu, Jiang; Shen, Yuxiao; Yuan, Yue; Yu, Yanbing] China Japan Friendship Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Jiang, Bowen] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
RP Yu, YB (reprint author), China Japan Friendship Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM yuyanbing123@126.com
CR BALLANTYNE ES, 1994, J NEUROSURG, V80, P559, DOI 10.3171/jns.1994.80.3.0559
   Blumenfeld A, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0343-x
   Chang JW, 2001, CHILD NERV SYST, V17, P309, DOI 10.1007/s003810000432
   Chaudhry N, 2015, J NEUROL SCI, V356, P27, DOI 10.1016/j.jns.2015.06.032
   COOK BR, 1984, J NEUROSURG, V61, P949, DOI 10.3171/jns.1984.61.5.0949
   Dou NN, 2016, WORLD NEUROSURG, V87, P640, DOI 10.1016/j.wneu.2015.10.091
   Fujii Takashi, 2017, No Shinkei Geka, V45, P503, DOI 10.11477/mf.1436203540
   Ghali Michael G Z, 2018, Int Ophthalmol Clin, V58, P111, DOI 10.1097/IIO.0000000000000209
   Giglia G, 2011, J HEADACHE PAIN, V12, P653, DOI 10.1007/s10194-011-0370-0
   Hatem J, 2001, BRIT J NEUROSURG, V15, P496, DOI 10.1080/02688690120105101
   Kawashima M, 2010, NEUROSURGERY, V66, pONS275, DOI 10.1227/01.NEU.0000369662.36524.CF
   Khan M, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/7438326
   Kondo A, 2012, ACTA NEUROCHIR, V154, P773, DOI 10.1007/s00701-012-1277-5
   Lee MH, 2016, NEUROSURG REV, V39, P151, DOI 10.1007/s10143-015-0666-7
   Liu J, 2016, J NEUROSURG, V124, P397, DOI 10.3171/2015.3.JNS142501
   Lu Alex Y, 2014, ScientificWorldJournal, V2014, P349319, DOI 10.1155/2014/349319
   Ma Y, 2016, J NEUROSURG, V124, P1088, DOI 10.3171/2015.3.JNS141806
   Patel A, 2002, NEUROSURGERY, V50, P705, DOI 10.1097/00006123-200204000-00004
   Ray DK, 2010, STEREOT FUNCT NEUROS, V88, P383, DOI 10.1159/000319883
   Revuelta-Gutierrez Rogelio, 2016, Surg Neurol Int, V7, P51, DOI 10.4103/2152-7806.181824
   Rey-Dios R, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2012.12.FOCUS12391
   Rosenstengel C, 2012, DTSCH ARZTEBL INT, V109, P667, DOI 10.3238/arztebl.2012.0667
   RUSHTON JG, 1981, ARCH NEUROL-CHICAGO, V38, P201, DOI 10.1001/archneur.1981.00510040027002
   TAHA JM, 1995, NEUROSURGERY, V36, P926, DOI 10.1227/00006123-199505000-00006
   Wang YN, 2014, ACTA NEUROCHIR, V156, P1167, DOI 10.1007/s00701-014-2034-8
   Yue WL, 2014, INT J PEDIATR OTORHI, V78, P559, DOI 10.1016/j.ijporl.2013.12.020
   Zhao H, 2017, WORLD NEUROSURG, V102, P151, DOI 10.1016/j.wneu.2017.02.106
   Zhong J, 2011, NEUROSURGERY, V68, P916, DOI 10.1227/NEU.0b013e318208f5ac
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E62
EP E67
DI 10.1016/j.wneu.2019.08.069
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700008
PM 31442648
OA Bronze
DA 2020-05-12
ER

PT J
AU Ljubisavljevic, S
   Trajkovic, JZ
   Ignjatovic, A
   Stojanov, A
AF Ljubisavljevic, Srdjan
   Trajkovic, Jasna Zidverc
   Ignjatovic, Aleksandra
   Stojanov, Aleksandar
TI Parameters Related to Lumbar Puncture Do not Affect Occurrence of
   Postdural Puncture Headache heat Might Influence Its Clinical Phenotype
SO WORLD NEUROSURGERY
LA English
DT Article
DE Headache; Lumbar puncture; Post-dural puncture headache
ID TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; AMERICAN-ACADEMY; PREVENTION;
   MANAGEMENT; RISK; THERAPEUTICS; EPIDEMIOLOGY; DIAGNOSIS; CAFFEINE
AB BACKGROUND: Post-dural puncture headache (PDPH) has been the most common complication of diagnostic and therapeutic lumbar puncture (LP). The occurrence and clinical features of PDPH in relationship to different demographic, clinical, and paraclinical parameters and parameters related to LP were assessed.
   METHODS: We conducted a cohort, prospective, single-center study of 252 consecutive patients (105 men and 147 women; average age, 47.3 +/- 15.0 years), who had undergone LP for different medical reasons from February 2018 to June 2018 at the Clinic for Neurology Clinical Center of Serbia (Belgrade, Serbia).
   RESULTS: Of the 252 patients, PDPH was reported in 133 (52.8%). The incidence of PDPH was more frequent in women (64.7%; P = 0.043). Univariate analyses identified the following significant risk factors for PDPH: female gender (odds ratio [OR], 1.74; 95% confidence interval [CI], 1.05-2.89), age (OR, 0.95; 95% CI, 0.94-0.97), smoking duration (OR, 0.91; 95% CI, 0.88-0.95), preexisting headaches (OR, 2.40; 95% CI, 1.39-4.17), circulatory system disease (OR, 0.52; 95% CI, 0.29-0.92), and musculoskeletal system and connective tissue disease (OR, 0.31; 95% CI, 0.12-0.81). In the multivariable model, duration of smoking and preexisting headaches remained independent risk factors for PDPH (OR, 0.93; 95% CI, 0.88-0.97; P = 0.002; and OR, 4.23; 95% CI, 1.27-14.08; P = 0.019, respectively). For various PDPH characteristics, significant risk factors were identified, including age, female gender, body mass index, circular or endocrine system diseases, and the use of caffeinated drinks before LP. In addition, the caliber of the traumatic needle, direction and number of needle stitches during LP, occurrence, intensity, and radiation of pain during LP, volume of sampled cerebrospinal fluid, rest and hydration after LP, preexisting headache, and earlier PDPH were significant. All these models were well-calibrated (Hosmer-Lemeshow test, P> 0.05).
   CONCLUSION: The results of the present study are important for the prediction of the occurrence of PDPH and the differential diagnosis of headaches after LP.
C1 [Ljubisavljevic, Srdjan; Stojanov, Aleksandar] Clin Ctr Nis, Clin Neurol, Nish, Serbia.
   [Ljubisavljevic, Srdjan] Univ Nis, Fac Med, Dept Neurol, Nish, Serbia.
   [Trajkovic, Jasna Zidverc] Univ Belgrade, Fac Med, Clin Ctr Serbia, Clin Neurol, Belgrade, Serbia.
   [Ignjatovic, Aleksandra] Univ Nis, Fac Med, Dept Med Stat & Informat, Nish, Serbia.
RP Ljubisavljevic, S (reprint author), Clin Ctr Nis, Clin Neurol, Nish, Serbia.; Ljubisavljevic, S (reprint author), Univ Nis, Fac Med, Dept Neurol, Nish, Serbia.
EM srljub@gmail.com
RI Stojanov, Aleksandar/V-5300-2019
OI Stojanov, Aleksandar/0000-0002-6462-3528
CR Ahmed SV, 2006, POSTGRAD MED J, V82, P713, DOI 10.1136/pgmj.2006.044792
   Amorim JA, 2008, CEPHALALGIA, V28, P5, DOI 10.1111/j.1468-2982.2007.01454.x
   Amorim JA, 2012, CEPHALALGIA, V32, P916, DOI 10.1177/0333102412453951
   APRIL MD, 2018, ANN EMERG MED, V71, P55
   Arevalo-Rodriguez I, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009199.pub3
   Armon C, 2005, NEUROLOGY, V65, P510, DOI 10.1212/01.wnl.0000173034.96211.1b
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Bezov D, 2010, HEADACHE, V50, P1482, DOI 10.1111/j.1526-4610.2010.01758.x
   Bezov D, 2010, HEADACHE, V50, P1144, DOI 10.1111/j.1526-4610.2010.01699.x
   Boon JM, 2004, CLIN ANAT, V17, P544, DOI 10.1002/ca.10250
   Brandt T, 1996, NEUROLOGIC DISORDERS
   Carson D, 1996, NEUROLOGY, V47, P33, DOI 10.1212/WNL.47.1.33
   Collier CB, 2000, TXB OBSTET ANESTHESI, P504
   Diaz JH, 2001, REGION ANESTH PAIN M, V26, P582, DOI 10.1053/rapm.2001.28275
   Dieterich M, 1996, NEUROLOGIC DISORDERS, P59
   Dodge HS, 2013, PAIN PHYSICIAN, V16, pE25
   Doherty Carolynne M, 2014, Ulster Med J, V83, P93
   Duits FH, 2016, ALZHEIMERS DEMENT, V12, P154, DOI 10.1016/j.jalz.2015.08.003
   Esmaoglu A, 2005, J CLIN ANESTH, V17, P58, DOI 10.1016/j.jclinane.2004.04.003
   Evans RW, 2000, NEUROLOGY, V55, P909, DOI 10.1212/WNL.55.7.909
   Gaiser Robert R, 2017, Anesthesiol Clin, V35, P157, DOI 10.1016/j.anclin.2016.09.013
   Ghaleb A, 2010, ANESTHESIOL RES PRAC, V2010, DOI 10.1155/2010/102967
   Kokki H, 1999, PAEDIATR ANAESTH, V9, P429, DOI 10.1046/j.1460-9592.1999.00398.x
   Kuczkowski Krzysztof M., 2007, Archives of Gynecology and Obstetrics, V275, P125, DOI 10.1007/s00404-006-0146-y
   KUNTZ KM, 1992, NEUROLOGY, V42, P1884, DOI 10.1212/WNL.42.10.1884
   Kwak KH, 2017, KOREAN J ANESTHESIOL, V70, P136, DOI 10.4097/kjae.2017.70.2.136
   Lin W, 2002, WESTERN J MED, V176, P69, DOI 10.1136/ewjm.176.1.69
   Luostarinen Liisa, 2005, J Headache Pain, V6, P400, DOI 10.1007/s10194-005-0235-5
   LYBECKER H, 1990, ANESTH ANALG, V70, P389
   Monserrate AE, 2015, JAMA NEUROL, V72, P325, DOI 10.1001/jamaneurol.2014.3974
   Nowaczewska M, 2012, J NEUROL, V259, P665, DOI 10.1007/s00415-011-6236-1
   [R-Core-Team Computing R.F. f.S], 2014, R LANG ENV STAT COMP
   Richman JM, 2006, NEUROLOGIST, V12, P224, DOI 10.1097/01.nrl.0000219638.81115.c4
   Sachs A, 2014, SEMIN PERINATOL, V38, P386, DOI 10.1053/j.semperi.2014.07.007
   Seupaul RA, 2005, AM J EMERG MED, V23, P913, DOI 10.1016/j.ajem.2005.06.003
   Somri M, 2003, ANESTH ANALG, V96, P1809, DOI 10.1213/01.ANE.0000065907.85109.B0
   Sudlow C, 2002, COCHRANE DB SYST REV, V2
   Sudlow C, 2001, COCHRANE DB SYST REV, V2
   Turnbull DK, 2003, BRIT J ANAESTH, V91, P718, DOI 10.1093/bja/aeg231
   Van de Beek D, 2018, LANCET, V391, P1128, DOI 10.1016/S0140-6736(17)32480-7
   Wadud Roheena, 2006, J Coll Physicians Surg Pak, V16, P389
   Williams J, 2008, INTERN MED J, V38, P587, DOI 10.1111/j.1445-5994.2008.01631.x
   Wright BLC, 2012, J NEUROL, V259, P1530, DOI 10.1007/s00415-012-6413-x
   Wu CL, 2006, ANESTHESIOLOGY, V105, P613, DOI 10.1097/00000542-200609000-00027
   Wu CJ, 2018, NEUROLOGY, V90, pE1523, DOI 10.1212/WNL.0000000000005351
   Zetterberg H, 2010, EUR NEUROL, V63, P326, DOI 10.1159/000311703
   Zorrilla-Vaca A, 2017, PAIN PHYSICIAN, V20, pE521
NR 47
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E540
EP E550
DI 10.1016/j.wneu.2019.09.085
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700115
PM 31562971
OA Bronze
DA 2020-05-12
ER

PT J
AU Lu, GY
   Zhu, L
   Wang, XD
   Zhang, HZ
   Li, YP
AF Lu, Guangyu
   Zhu, Lei
   Wang, Xingdong
   Zhang, Hengzhu
   Li, Yuping
TI Decompressive Craniectomy for Patients with Traumatic Brain Injury: A
   Pooled Analysis of Randomized Controlled Trials
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decompressive craniectomy; Functional outcome; Meta-analysis; Traumatic
   brain injury
ID INTRACRANIAL-PRESSURE; CEREBRAL OXYGENATION; MANAGEMENT;
   HEMICRANIECTOMY; GUIDELINES; PERFUSION; CHILDREN
AB BACKGROUND: Decompressive hemicraniectomy (DHC) is widely applied for patients with traumatic brain injury (TBI). Although previous studies have indicated that DHC can lead to similar or worse outcomes compared with medical treatment (MT) in patients with TBI, recent trials have suggested the benefit of DHC for neurologic function recovery. Therefore, we performed this meta-analysis to assess the efficacy and functional outcomes of DHC in patients with TBI.
   METHODS: In accordance with PRISMA guidelines, we searched English and Chinese databases to identify relevant randomized controlled trials (RCTs) reporting DHC for TBI. The outcomes measures included mortality, favorable outcome, unfavorable outcome, postoperative intracranial pressure (ICP), adverse events with hematoma, and hospital stay.
   RESULTS: Seven RCTs with a total of 779 patients with TBI were included in this meta-analysis. Compared with the MT group, the DHC group demonstrated significantly lower rates of mortality (P < 0.00001), postoperative ICP (P < 0.00001), and postoperative hematoma (P = 0.01), and significantly shorter hospital length of stay (P = 0.02). However, the rate of unfavorable outcomes was higher in the DHC group compared with the MT group (P = 0.0001).
   CONCLUSIONS: Our results indicate that DHC could be effective in reducing the mortality rate, incidence of ICP, and hospital length of stay in patients with TBI. However, the proportion of patients surviving with unfavorable outcomes was significantly higher in the DHC group compared with the MT group. Despite the limitations of the metaanalysis, our findings target extremely important topic and provide important evidence to facilitate clinical decision making.
C1 [Lu, Guangyu] Yangzhou Univ, Dept Prevent Med, Med Coll, Yangzhou, Jiangsu, Peoples R China.
   [Zhu, Lei; Wang, Xingdong; Zhang, Hengzhu; Li, Yuping] Yangzhou Univ, Dept Neurosurg, Clin Med Coll, Yangzhou, Jiangsu, Peoples R China.
   [Li, Yuping] Xuzhou Med Univ, Dept Neurosurg, Yangzhou Clin Med Coll, Xuzhou, Jiangsu, Peoples R China.
RP Li, YP (reprint author), Yangzhou Univ, Dept Neurosurg, Clin Med Coll, Yangzhou, Jiangsu, Peoples R China.; Li, YP (reprint author), Xuzhou Med Univ, Dept Neurosurg, Yangzhou Clin Med Coll, Xuzhou, Jiangsu, Peoples R China.
EM dr.yuping.li@gmail.com
OI zhu, lei/0000-0001-5133-7840
FU Jiangsu Young Medical Talents Key Projects [QNRC2016326]; Jiangsu
   Commission of Health Projects [H2018064]
FX This study was funded by Jiangsu Young Medical Talents Key Projects
   (QNRC2016326) and the Jiangsu Commission of Health Projects (H2018064).
CR Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469
   [Anonymous], 2018, LANCET, V391, P813, DOI 10.1016/S0140-6736(18)30547-6
   Bor-Seng-Shu E, 2012, J NEUROSURG, V117, P589, DOI 10.3171/2012.6.JNS101400
   Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Cochrane Training, 2011, COCHRANE HDB SYSTEMA
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   FAIRBURN B, 1956, BMJ-BRIT MED J, V1, P1335, DOI 10.1136/bmj.1.4979.1335
   Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442
   Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5
   Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x
   Heppner P, 2006, J NEUROSURG, V104, P738, DOI 10.3171/jns.2006.104.5.738
   Higgins JPTGS, 2011, COCHRANE HDB SYSTEMA
   Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000
   Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513
   Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0
   Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337
   Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655
   Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106
   Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1
   Li PGLB, 2011, JIANGXI MED J, V46, P609
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231
   Moein H, 2012, NEUROSURG QUART, V22, P149, DOI 10.1097/WNQ.0b013e318240f1e0
   Munch E, 2000, NEUROSURGERY, V47, P315
   Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E
   Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178
   Shutter LA, 2016, NEW ENGL J MED, V375, P1183, DOI 10.1056/NEJMe1609722
   Soustiel JF, 2010, NEUROSURGERY, V67, P65, DOI 10.1227/01.NEU.0000370604.30037.F5
   Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241
   Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410
   Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066
   Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D
   Wang R, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001733
   Zhao G, 2015, ADV SOC SCI EDUC HUM, V17, P20
NR 37
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E135
EP E148
DI 10.1016/j.wneu.2019.08.184
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700018
PM 31491576
OA Bronze
DA 2020-05-12
ER

PT J
AU Lubelski, D
   Pennington, Z
   Sciubba, DM
   Theodore, N
   Bydon, A
AF Lubelski, Daniel
   Pennington, Zachary
   Sciubba, Daniel M.
   Theodore, Nicholas
   Bydon, Ali
TI Horner Syndrome After Anterior Cervical Discectomy and Fusion: Case
   Series and Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anterior cervical discectomy and fusion; Complications; Horner syndrome;
   Outcomes
ID SPINE SURGERY; SYMPATHETIC TRUNK; INTERBODY FUSION; UNITED-STATES;
   COMPLICATIONS; OUTCOMES; TRENDS; RATES
AB BACKGROUND: Horner syndrome is an infrequently seen complication of anterior cervical discectomy and fusion (ACDF). Multicenter studies have reported a very low incidence, less than 0.1%.
   OBJECTIVE: To identify the incidence in, characteristics of, and postoperative course in patients in whom postoperative Horner syndrome developed after ACDF.
   METHODS: We performed a retrospective review of all patients who experienced Horner syndrome after ACDF for cervical degenerative disease at a single tertiary care institution between 2017 and 2018. A systematic review was then performed to identify studies investigating prevalence, diagnosis, and treatment of postoperative Horner syndrome after ACDF.
   RESULTS: Of 1116 patients at our institution who underwent ACDF, the incidence of Horner syndrome was 0.45%. C4/5 and C5/6 were the 2 most common surgical levels. The complication was noted to occur immediately after surgery, and at least partial improvement was identified in all patients an average 3.5 months after surgery (range, 10 days to 6 months). These findings were consistent with our systematic review of 21 studies that showed an incidence of 0.6% (range, 0.02% to 4.0%), the most common surgical level C5/6 (64%), and 82% of patients experiencing at least partial resolution of symptoms within 1 year (6117% complete, 21.4% partial resolution).
   CONCLUSION: Homer syndrome occurs in 0.6% of patients undergoing ACDF. Careful postoperative examination should reveal this complication, which may be underdiagnosed or underreported in larger multicenter case series. The majority of of patients experience complete resolution of symptoms within 6 months to 1 year and can be treated conservatively and expectantly.
C1 [Lubelski, Daniel; Pennington, Zachary; Sciubba, Daniel M.; Theodore, Nicholas; Bydon, Ali] Johns Hopkins Univ Hosp, Dept Neurosurg, Baltimore, MD 21287 USA.
RP Bydon, A (reprint author), Johns Hopkins Univ Hosp, Dept Neurosurg, Baltimore, MD 21287 USA.
EM abydon1@jhmi.edu
OI Pennington, Zachary/0000-0001-8012-860X; Theodore,
   Nicholas/0000-0001-5355-2683
CR Andresen AK, 2018, GLOB SPINE J, V8, P703, DOI 10.1177/2192568218765398
   Arnold PM, 2016, SPINE, V41, P1075, DOI 10.1097/BRS.0000000000001466
   BERTALANFFY H, 1989, ACTA NEUROCHIR, V99, P41, DOI 10.1007/BF01407775
   Beutler WJ, 2001, SPINE, V26, P1337, DOI 10.1097/00007632-200106150-00014
   BUSCH G, 1978, J NEUROL, V219, P117, DOI 10.1007/BF00314394
   CUATICO W, 1981, ACTA NEUROCHIR, V57, P269, DOI 10.1007/BF01664843
   Derakhshan A, 2017, GLOB SPINE J, V7, P1155, DOI 10.1177/2192568216688194
   DOHN DF, 1966, J AMER MED ASSOC, V197, P897, DOI 10.1001/jama.197.11.897
   Ebraheim NA, 2000, SPINE, V25, P1603, DOI 10.1097/00007632-200007010-00002
   Fernandes Marques Manuel, 2018, JBJS Case Connect, V8, pe94, DOI 10.2106/JBJS.CC.18.00066
   FLYNN TB, 1982, SPINE, V7, P536, DOI 10.1097/00007632-198211000-00004
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Fringeli Y, 2017, J NEUROSURG-SPINE, V26, P684, DOI 10.3171/2016.11.SPINE16711
   Giombini S, 1980, SURG CERVICAL MYELOP, P302
   HANKINSON HL, 1975, J NEUROSURG, V43, P452, DOI 10.3171/jns.1975.43.4.0452
   Hasan G, 2018, J MUSCULOSKELET SURG, V2, P121
   JOHNSTON FG, 1995, J NEUROSURG, V82, P234, DOI 10.3171/jns.1995.82.2.0234
   Jung A, 2010, NEUROSURGERY, V67, P10, DOI 10.1227/01.NEU.0000370203.26164.24
   Kilburg C, 2006, J NEUROSURG-SPINE, V4, P273, DOI 10.3171/spi.2006.4.4.273
   Lied B, 2008, ACTA NEUROCHIR, V150, P111, DOI 10.1007/s00701-007-1472-y
   Mehra S, 2014, OTOLARYNG HEAD NECK, V150, P259, DOI 10.1177/0194599813515414
   Munigangaiah S, 2014, J ORTHOP SURG-HONG K, V22, P364, DOI 10.1177/230949901402200320
   Nanda A, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.09.022
   O'Neill KR, 2017, GLOB SPINE J, V7, P585, DOI 10.1177/2192568216688186
   O'Neill KR, 2016, CLIN SPINE SURG, V29, P234, DOI 10.1097/BSD.0b013e31828ffc54
   Park MS, 2016, YONSEI MED J, V57, P968, DOI 10.3349/ymj.2016.57.4.968
   Patil PG, 2005, NEUROSURGERY, V57, P753, DOI 10.1227/01.NEU.0000175729.79119.1d
   Saifi C, 2018, SPINE J, V18, P1022, DOI 10.1016/j.spinee.2017.10.072
   Saylam CY, 2009, CLIN ANAT, V22, P324, DOI 10.1002/ca.20764
   Shriver MF, 2017, GLOB SPINE J, V7, P95, DOI 10.1055/s-0036-1583944
   Shriver MF, 2015, SPINE J, V15, P2016, DOI 10.1016/j.spinee.2015.05.010
   Sonntag VKH, 2001, NEUROSURGERY, V49, P909, DOI 10.1097/00006123-200110000-00023
   Tew J M Jr, 1976, Clin Neurosurg, V23, P424
   Traynelis VC, 2017, GLOB SPINE J, V7, P1035, DOI 10.1177/2192568216688184
   Wang MC, 2009, SPINE, V34, P955, DOI 10.1097/BRS.0b013e31819e2fd5
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E68
EP E75
DI 10.1016/j.wneu.2019.08.101
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700009
PM 31465851
OA Bronze
DA 2020-05-12
ER

PT J
AU Macki, M
   Haider, SA
   Anand, SK
   Fakih, M
   Elmenini, J
   Suryadevara, R
   Chang, V
AF Macki, Mohamed
   Haider, Sameah A.
   Anand, Sharath Kumar
   Fakih, Mohamed
   Elmenini, Jaafar
   Suryadevara, Raviteja
   Chang, Victor
TI A Survey of Chemoprophylaxis Techniques in Spine Surgery Among American
   Neurosurgery Training Programs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chemoprophylaxis; Heparin; Low-molecular-weight heparin; LMWH; Spine;
   Unfractionated heparin; UFH
ID DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; THORACIC EPIDURAL
   CATHETER; UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; MEDICAL
   PATIENTS; HEMATOMA; ENOXAPARIN; PROPHYLAXIS; PATIENT
AB BACKGROUND: A paucity of randomized trials have compared prophylactic dose of unfractionated heparin (UFH) versus low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolic events in spinal surgery. Our objective was to determine the most prevalent chemoprophylactic techniques in spine surgery.
   METHODS: The Accreditation Council for Graduate Medical Education was queried for all neurosurgical residency programs, which were subsequently sent an electronic survey about prophylactic UFH versus LMWH in spine surgery for (1) degenerative/deformity, (2) traumatic, and (3) neoplastic pathologies.
   RESULTS: Of 69 unique responding residencies, the first dose of chemoprophylaxis for degenerative/deformity spinal disease started most commonly on postoperative day (POD) 1 in 75.3% of neurosurgery programs, followed by POD 2 in 10.1% of programs, POD 0 (same day of surgery) in 8.7% of programs, POD 3 in 1.4% of programs, and morning of surgery in 1.4% of programs. Choice of postoperative chemoprophylaxis did not differ statistically significantly between UFH versus LMWH: 56.5% versus 36.2% in degenerative/deformity pathologies (P = 0.080) and 50.7% versus 43.4% in traumatic pathologies (P = 0.535). Three programs (4.3%) in both the degenerative/deformity and trauma groups documented no chemoprophylaxis. Neoplastic pathologies saw a statistically significantly higher proportion of prophylactic UFH (60.8%) compared with prophylactic LMWH (36.2%) (P = 0.037). One program 1.4%) in the neoplastic group did not utilize chemoprophylaxis. Two institutions (2.8%) in the degenerative/ deformity cohort and 1 institution (1.4%) in the trauma and cancer cohorts reported "other".
   CONCLUSIONS: Prophylactic UFH was statistically more common than LMWH in neoplastic spinal surgery, but not in the degenerative/deformity and trauma groups (cohorts). Further trials are warranted.
C1 [Macki, Mohamed; Haider, Sameah A.; Anand, Sharath Kumar; Fakih, Mohamed; Elmenini, Jaafar; Suryadevara, Raviteja; Chang, Victor] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
RP Chang, V (reprint author), Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
EM vchang1@hfhs.org
CR Albaladejo P, 2005, CAN J ANAESTH, V52, P210, DOI 10.1007/BF03027735
   Bergqvist D, 1997, BRIT J SURG, V84, P1099
   Bindelglass DF, 2010, J ARTHROPLASTY, V25
   Bono CM, 2009, SPINE J, V9, P1046, DOI 10.1016/j.spinee.2009.09.005
   CAIN JE, 1995, SPINE, V20, P1600, DOI 10.1097/00007632-199507150-00008
   Chan L, 2004, J CLIN ANESTH, V16, P382, DOI 10.1016/j.jclinane.2004.05.001
   Deep K, 2001, SPINAL CORD, V39, P88, DOI 10.1038/sj.sc.3101122
   Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003
   Gerlach R, 2004, EUR SPINE J, V13, P9, DOI 10.1007/s00586-003-0642-8
   Gupta A, 2007, THROMB RES, V121, P281, DOI 10.1016/j.thromres.2007.03.016
   Han IS, 2010, KOREAN J ANESTHESIOL, V59, P119, DOI 10.4097/kjae.2010.59.2.119
   Herbstreit F, 2002, ANESTHESIOLOGY, V97, P733, DOI 10.1097/00000542-200209000-00029
   Hynson JM, 1996, ANESTH ANALG, V82, P1072, DOI 10.1097/00000539-199605000-00035
   Jooste EH, 2007, PEDIATR ANESTH, V17, P907, DOI 10.1111/j.1460-9592.2007.02290.x
   Kasodekar SV, 2009, J CLIN ANESTH, V21, P595, DOI 10.1016/j.jclinane.2008.12.022
   Khorana AA, 2007, ONCOLOGIST, V12, P1361, DOI 10.1634/theoncologist.12-11-1361
   Kleber FX, 2003, AM HEART J, V145, P614, DOI 10.1067/mhj.2003.189
   Litz RJ, 2004, ANESTHESIOLOGY, V101, P1467
   MENZIN J, 1994, ANN PHARMACOTHER, V28, P271, DOI 10.1177/106002809402800221
   Network NCC, 2012, NCCN CLIN PRACT GUID
   NURMOHAMED MT, 1995, AM J SURG, V169, P567, DOI 10.1016/S0002-9610(99)80222-0
   Ousmane ML, 2000, ANESTH ANALG, V90, P1250, DOI 10.1097/00000539-200005000-00065
   Pandazi A, 2010, ARCH MED SCI, V6, P281, DOI 10.5114/aoms.2010.13910
   Pariser JJ, 2017, J UROLOGY, V197, P302, DOI 10.1016/j.juro.2016.08.090
   Porterfield WR, 1997, J CLIN ANESTH, V9, P74, DOI 10.1016/S0952-8180(96)00205-X
   Rokito SE, 1996, SPINE, V21, P853, DOI 10.1097/00007632-199604010-00016
   Sharma S, 2004, J CARDIOTHOR VASC AN, V18, P759, DOI 10.1053/j.jvca.2004.08.015
   Silva Ranger Cavalcante da, 2006, Rev. Bras. Anestesiol., V56, P174, DOI 10.1590/S0034-70942006000200009
   STERNLO JE, 1995, ACTA ANAESTH SCAND, V39, P557, DOI 10.1111/j.1399-6576.1995.tb04119.x
   Strom RG, 2013, SPINE, V38, pE1498, DOI 10.1097/BRS.0b013e3182a4408d
   TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503
   Ulivieri S, 2009, G CHIR, V30, P51
   VOTH D, 1992, NEUROSURG REV, V15, P289
   Waclawski Eugene, 2012, Occup Med (Lond), V62, P477, DOI 10.1093/occmed/kqs075
   Wein L, 2007, ARCH INTERN MED, V167, P1476, DOI 10.1001/archinte.167.14.1476
   Xu RS, 2009, J NEUROSURG-SPINE, V11, P358, DOI 10.3171/2009.3.SPINE0916
   Yin B, 1999, BRIT J ANAESTH, V82, P288, DOI 10.1093/bja/82.2.288
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E428
EP E433
DI 10.1016/j.wneu.2019.09.033
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700099
PM 31525483
OA Bronze
DA 2020-05-12
ER

PT J
AU Majmundar, N
   Ward, M
   Liu, JK
AF Majmundar, Neil
   Ward, Max
   Liu, James K.
TI Feasibility and Challenges of Microsurgical Resection of Colloid Cysts
   in Patients with Preexisting Ventriculoperitoneal Shunts
SO WORLD NEUROSURGERY
LA English
DT Article
DE Colloid cyst; Endoscopy; Interforniceal; Microsurgery; Transcallosal;
   Ventriculoperitoneal shunt
ID LATERAL TRANSCALLOSAL APPROACH; 3RD VENTRICLE; 3RD-VENTRICLE;
   EXPERIENCE; MANAGEMENT; ASPIRATION; SURGERY; TUMORS
AB BACKGROUND: Colloid cysts are the most common third ventricular tumor and may present with symptoms related to obstructive hydrocephalus. Although definitive endoscopic or microsurgical resection is the standard of care, patients may receive temporizing ventriculoperitoneal shunts when definitive management is deferred. Subsequent definitive treatment can be challenging because of the ventricular collapse and narrowing of the operative corridor. There is currently no literature evaluating the feasibility of definitive colloid cyst resection in patients with preexisting ventriculoperitoneal shunts.
   METHODS: We retrospectively reviewed records for patients undergoing colloid cyst resection between 2009 and 2019 to identify patients with preexisting shunts prior to surgery.
   RESULTS: Three patients had preexisting ventriculoperitoneal shunts. Two patients had been shunted at outside institutions where microsurgical or endoscopic resection was not available. One patient received a shunt from an outside surgeon when she was deemed a poor surgical candidate because of cardiac instability. All 3 patients underwent successful gross total colloid cyst resection via the transcallosal approach without recurrences during a mean follow-up of 4.2 years. All patients had intact cognitive and memory function and returned to work.
   CONCLUSIONS: Surgical resection of colloid cysts is possible despite a preexisting ventriculoperitoneal shunt. Because the ventricular space may be collapsed postoperatively because of cerebrospinal fluid diversion, a transcortical route (either endoscopic or microscopic) can be complicated by a small operative corridor with reduced visibility. The transcallosal approach was safe and feasible in these cases for providing midline access with adequate visualization for complete resection despite ventricular collapse.
C1 [Majmundar, Neil; Ward, Max; Liu, James K.] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
RP Liu, JK (reprint author), Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
EM james.liu.md@rutgers.edu
OI Majmundar, Neil/0000-0001-5910-6094
CR Boogaarts HD, 2011, NEUROSURGERY, V68, P179, DOI 10.1227/NEU.0b013e3181ffae71
   BOSCH DA, 1978, SURG NEUROL, V9, P15
   Buttner A, 1997, INT J LEGAL MED, V110, P260, DOI 10.1007/s004140050082
   Charalampaki P, 2006, NEUROSURG REV, V29, P72, DOI 10.1007/s10143-005-0419-0
   Dandy WE, 1933, ANN SURG, V98, P841, DOI 10.1097/00000658-193311000-00005
   Gutierrez-Lara F, 1975, Surg Neurol, V3, P323
   HALL WA, 1987, J NEUROSURG, V66, P186, DOI 10.3171/jns.1987.66.2.0186
   Hernesniemi J, 2008, SURG NEUROL, V69, P447, DOI 10.1016/j.surneu.2007.11.005
   Hernesniemi J, 2008, SURG NEUROL, V69, P455, DOI 10.1016/j.surneu.2007.12.004
   Horn EM, 2007, NEUROSURGERY, V60, P613, DOI 10.1227/01.NEU.0000255409.61398.EA
   KONDZIOLKA D, 1994, ACT NEUR S, V61, P76
   KONDZIOLKA D, 1991, J NEUROSURG, V75, P45, DOI 10.3171/jns.1991.75.1.0045
   Kondziolka D, 1996, SURG NEUROL, V46, P485, DOI 10.1016/S0090-3019(96)00201-7
   Kumar V, 2010, ACTA NEUROCHIR, V152, P451, DOI 10.1007/s00701-009-0531-y
   LEWIS AI, 1994, J NEUROSURG, V81, P174, DOI 10.3171/jns.1994.81.2.0174
   LITTLE JR, 1974, J NEUROSURG, V40, P230, DOI 10.3171/jns.1974.40.2.0230
   Margetis K, 2013, NEUROSURG FOCUS S, V34
   MATHIESEN T, 1993, J NEUROSURG, V78, P748, DOI 10.3171/jns.1993.78.5.0748
   Mathiesen T, 1997, J NEUROSURG, V86, P5, DOI 10.3171/jns.1997.86.1.0005
   RYDER JW, 1986, J NEUROSURG, V64, P216, DOI 10.3171/jns.1986.64.2.0216
   Sampath R, 2010, NEUROSURGERY, V66, P368, DOI 10.1227/01.NEU.0000363858.17782.82
   Sheikh AB, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.06.024
   Timurkaynak E, 2006, SURG NEUROL, V66, P544, DOI 10.1016/j.surneu.2006.03.033
   Wang X, 2017, CLIN NEUROL NEUROSUR, V155, P58, DOI 10.1016/j.clineuro.2017.02.018
   Weaver KJ, 2016, J NEUROSURG, V125, P585, DOI 10.3171/2015.9.JNS151183
   Williams DJ, 1997, MED SCI LAW, V37, P254, DOI 10.1177/002580249703700311
   Winkler PA, 2000, NEUROSURGERY, V46, P879, DOI 10.1097/00006123-200004000-00020
   Yasargil MG, 2008, NEUROSURGERY, V62, P1029, DOI [10.1227/01.NEU.0000316427.57165.01, 10.1227/01.neu.0000333768.12951.9a]
   Yasargil MG, 2008, NEUROSURGERY S3, V62, P40
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E492
EP E497
DI 10.1016/j.wneu.2019.09.064
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700108
PM 31542439
OA Bronze
DA 2020-05-12
ER

PT J
AU Maragkos, GA
   Motiei-Langroudi, R
   Filippidis, AS
   Glazer, PA
   Papavassiliou, E
AF Maragkos, Georgios A.
   Motiei-Langroudi, Rouzbeh
   Filippidis, Aristotelis S.
   Glazer, Paul A.
   Papavassiliou, Efstathios
TI Factors Predictive of Adjacent Segment Disease After Lumbar Spinal
   Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent segment disease; Fusion; Lumbar; Prognostic factors
ID INTERBODY FUSION; RISK-FACTORS; INSTRUMENTED LUMBAR; DEGENERATION;
   ANTERIOR; SURGERY; LEVEL; OUTCOMES
AB OBJECTIVE: Adjacent segment disease (ASD) is a long-term complication of lumbar spinal fusion. This study aims to evaluate demographic and operative factors that influence development of ASD after fusion for lumbar degenerative pathologies.
   METHODS: A retrospective cohort study was performed on patients undergoing instrumented lumbar fusion for degenerative disorders (spondylolisthesis, stenosis, or intervertebral disk degeneration) with a minimum follow-up of 6 months.
   RESULTS: Our inclusion criteria were met by 568 patients; of patients had developed surgical ASD. Median follow-up was 2.8 years. Multivariate logistic regression analysis showed that decompression of segments outside the fusion construct had higher ASD (odds ratio = 2.6; P < 0.001), and those undergoing fusion for spondylolisthesis had lower ASD (odds ratio = 0.47; P = 0.003).
   CONCLUSIONS: Results of our study show that the most important surgical factor contributing to ASD is decompression beyond fused levels. Hence caution should be exercised when decompressing spinal segments outside the fusion construct. Conversely, spondylolisthesis patients had the lowest ASD rates in our cohort.
C1 [Maragkos, Georgios A.; Filippidis, Aristotelis S.; Papavassiliou, Efstathios] Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02215 USA.
   [Glazer, Paul A.] Beth Israel Deaconess Med Ctr, Dept Orthoped, Boston, MA 02215 USA.
   [Motiei-Langroudi, Rouzbeh] Univ Kentucky, Dept Neurosurg, Lexington, KY USA.
   [Motiei-Langroudi, Rouzbeh] Kentucky Neurosci Inst, Lexington, KY USA.
RP Papavassiliou, E (reprint author), Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02215 USA.
EM epapavas@bidmc.harvard.edu
CR Aiki H, 2005, J ORTHOP SCI, V10, P490, DOI 10.1007/s00776-005-0919-3
   Cheh G, 2007, SPINE, V32, P2253, DOI 10.1097/BRS.0b013e31814b2d8e
   Crandall DG, 2009, SPINE, V34, P2126, DOI 10.1097/BRS.0b013e3181b612db
   de la Garza-Ramos R, 2018, J NEUROSURG SCI, V62, P4, DOI 10.23736/S0390-5616.16.03492-5
   Deukmedjian AJ, 2015, J CRANIOVERTEBRAL JU, V6, P183, DOI 10.4103/0974-8237.167869
   Epstein Nancy E, 2016, Surg Neurol Int, V7, pS70, DOI 10.4103/2152-7806.174892
   Gard AP, 2013, J CLIN NEUROSCI, V20, P1554, DOI 10.1016/j.jocn.2013.02.012
   Ha KY, 2008, SPINE, V33, P1192, DOI 10.1097/BRS.0b013e318170fd35
   Heo Y, 2015, EUR SPINE J, V24, P2474, DOI 10.1007/s00586-015-4188-3
   Kobayashi K, 2018, EUR SPINE J, V27, P1972, DOI 10.1007/s00586-018-5508-1
   Lee CW, 2017, WORLD NEUROSURG, V105, P612, DOI 10.1016/j.wneu.2017.06.005
   Lee JC, 2014, SPINE, V39, pE339, DOI 10.1097/BRS.0000000000000164
   Li TF, 2018, WORLD NEUROSURG, V110, pE815, DOI 10.1016/j.wneu.2017.11.109
   Liu HC, 2013, J NEUROSURG-SPINE, V19, P201, DOI 10.3171/2013.5.SPINE12650
   Min JH, 2007, J NEUROSURG-SPINE, V7, P21, DOI 10.3171/SPI-07/07/021
   Miyagi M, 2013, EUR SPINE J, V22, P1877, DOI 10.1007/s00586-013-2694-8
   Radcliff KE, 2013, SPINE J, V13, P1339, DOI 10.1016/j.spinee.2013.03.020
   Rao PJ, 2015, NEUROSURGERY, V76, P7, DOI 10.1227/NEU.0000000000000561
   Rollinghoff M, 2010, ORTHOP REV, V2, P6, DOI 10.4081/or.2010.e3
   Sakaura H, 2013, J NEUROSURG-SPINE, V19, P90, DOI 10.3171/2013.4.SPINE12651
   Strube P, 2012, J SPINAL DISORD TECH, V25, P362, DOI 10.1097/BSD.0b013e3182263d91
   Tsuji T, 2016, J ORTHOP SCI, V21, P133, DOI 10.1016/j.jos.2015.12.007
   Virk SS, 2014, ORTHOPEDICS, V37, P547, DOI 10.3928/01477447-20140728-08
   Wang H, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006032
NR 24
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E690
EP E694
DI 10.1016/j.wneu.2019.09.112
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700133
PM 31568911
OA Bronze
DA 2020-05-12
ER

PT J
AU Matur, AV
   Nouri, A
   Huang, SW
   Elson, NC
   Jeong, W
   Bierbrauer, KS
   Mangano, FT
   Cheng, JS
AF Matur, Abhijith, V
   Nouri, Aria
   Huang, Shenwen
   Elson, Nora C.
   Jeong, William
   Bierbrauer, Karin S.
   Mangano, Francesco T.
   Cheng, Joseph S.
TI Complications in Children with Ehlers-Danlos Syndrome Following Spine
   Surgery: Analysis of the Pediatric National Surgery Quality Improvement
   Program Database
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Connective tissue disorder; Ehlers-Danlos; Outcomes;
   Pediatric; Spine
ID VASCULAR COMPLICATIONS; CERVICAL KYPHOSIS; DEFORMITY; PATIENT
AB BACKGROUND: Ehlers-Danlos syndrome (EDS) is a group of rare congenital disorders of connective tissue that result in tissue fragility and joint hyperextensibility. Owing to its rarity, outcomes of pediatric spine surgery in patients with EDS are poorly characterized. Although it has been suggested that complication rates are high, few studies have characterized these complications.
   METHODS: Pediatric National Surgery Quality Improvement Program data from 2012-2016 were analyzed. Patients with EDS undergoing spine surgery were identified along with patients without EDS undergoing the same surgeries using International Classification of Diseases, Ninth Revision and Current Procedural Terminology codes.
   RESULTS: Of 369,176 total patients, 279 were determined to have EDS. Of these, 56 patients underwent spine surgery; 46% were male and 54% were female (P = 0.108). Mean age at surgery was 11.59 years (P = 0.888) with a range of 1.77-17.33 years. The most common procedure was arthrodesis (n = 37). There were no differences in unplanned reoperations (n = 4, P = 0.119), wound infections or disruptions (n = 2, P = 0.670), or overall complications (n = 25, P = 0.751). Blood transfusions were required in 41% of patients with EDS, but this was not significant compared with patients without EDS undergoing the same procedures (n = 23, P = 0.580). The total amount of blood transfused (P = 0.508), length of hospital stay (P = 0.396), and total operative time (P = 0.357) were not different from control subjects.
   CONCLUSIONS: Pediatric patients with EDS do not appear to be at a higher risk of bleeding or other complications during spine surgery as reported in past case series. This is the largest retrospective review of its kind that has been performed in this patient population.
C1 [Matur, Abhijith, V; Nouri, Aria; Huang, Shenwen; Elson, Nora C.; Jeong, William; Bierbrauer, Karin S.; Mangano, Francesco T.; Cheng, Joseph S.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA.
   [Bierbrauer, Karin S.; Mangano, Francesco T.] Cincinnati Childrens Hosp, Div Pediat Neurosurg, Cincinnati, OH USA.
RP Cheng, JS (reprint author), Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA.
EM chengj6@ucmail.uc.edu
OI Elson, Nora/0000-0001-6038-4761; Nouri, Aria/0000-0002-4965-3059
CR Akpinar S, 2003, EUR SPINE J, V12, P135, DOI 10.1007/s00586-002-0507-6
   American College of Surgeons National Surgical Quality Improvement Program, 2016, US GUID 2016 ACS NSQ
   Artoni A, 2018, J THROMB HAEMOST, V16, P2425, DOI 10.1111/jth.14310
   Basques BA, 2017, J PEDIATR ORTHOPED, V37, P429, DOI 10.1097/BPO.0000000000000683
   De Paepe A, 2012, CLIN GENET, V82, P1, DOI 10.1111/j.1399-0004.2012.01858.x
   Fang H, 2019, WORLD J CLIN CASES, V7, P532, DOI 10.12998/wjcc.v7.i4.532
   Henderson FC, 2017, AM J MED GENET C, V175, P195, DOI 10.1002/ajmg.c.31549
   Henneton P, 2018, BMJ CASE REP, V2018
   Jasiewicz B, 2010, SCOLIOSIS SPINAL DIS, V5, DOI 10.1186/1748-7161-5-26
   Kobets AJ, 2018, CHILD NERV SYST, V34, P1411, DOI 10.1007/s00381-018-3750-9
   Liu Y, 2011, ORTHOPEDICS, V34, P483, DOI 10.3928/01477447-20110427-28
   Mast KJ, 2009, BRIT J HAEMATOL, V144, P230, DOI 10.1111/j.1365-2141.2008.07446.x
   Natarajan D, 2011, SPINE J, V11, pE1, DOI 10.1016/j.spinee.2011.02.029
   NUSS R, 1995, CLIN PEDIATR, V34, P552, DOI 10.1177/000992289503401008
   Stern CM, 2017, J PEDIATR-US, V181, P261, DOI 10.1016/j.jpeds.2016.10.078
   Stine KC, 1997, J PEDIAT HEMATOL ONC, V19, P156, DOI 10.1097/00043426-199703000-00012
   UDEN A, 1982, SCAND J HAEMATOL, V28, P425
   van Dijk FS, 2017, EUR J MED GENET, V60, P536, DOI 10.1016/j.ejmg.2017.07.011
   Vogel LC, 1996, SPINE, V21, P2508, DOI 10.1097/00007632-199611010-00021
   Wiesmann T, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0109-5
   Yang JS, 2009, SPINE, V34, pE153, DOI 10.1097/BRS.0b013e31818d58da
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E473
EP E478
DI 10.1016/j.wneu.2019.09.046
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700105
PM 31526884
OA Bronze
DA 2020-05-12
ER

PT J
AU Metwali, H
   Raemaekers, M
   Kniese, K
   Samii, A
AF Metwali, Hussam
   Raemaekers, Mathijs
   Kniese, Katja
   Samii, Amir
TI Intraoperative Resting-State Functional Connectivity and Resting-State
   Networks in Patients with Intracerehral Lesions: Detectability and
   Variations Between Sessions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Functional connectivity; Intraoperative brain mapping; Resting state
   fMRI
ID DEFAULT MODE; ALTERED STATES; BRAIN ACTIVITY; GLIOMAS; IMPACT
AB OBJECTIVE: To evaluate the functional connectivity (FC) and resting-state networks (RSNs) in patients under anesthesia operated for resection of intracerebral lesions.
   METHODS: We performed intraoperative resting-state functional magnetic resonance imaging (irs-fMRI) in 24 patients under anesthesia before and after lesion resection. Correlation matrices were established for each session (a total 48 of sessions). We analyzed the changes in overall FC and in FC of the healthy and operated hemispheres between the first and second sessions. We tested the correlation between changes in FC and clinical outcomes and the duration, rate, and total dosage of anesthesia. We also performed a group analysis to detect topographic changes in RSNs in patients under anesthesia. A single-subject analysis was performed to detect clinically relevant RSNs in each patient.
   RESULTS: FC decreased significantly in the second session, as did interhemispheric connectivity. The decrease in the pathological hemisphere was significant and significantly greater than the decrease in the intrahemispheric connectivity of the healthy hemisphere. The change in FC was not correlated with clinical outcome or with the duration, rate, or dosage of anesthesia. Group analysis showed topographic changes in RSNs, especially in high-level networks such as default mode and salience networks. Identification of clinically relevant networks was also possible.
   CONCLUSIONS: FC and RSNs could be identified under anesthesia and used for extended brain mapping. Further studies are needed to optimize the depth of hypnosis to stabilize FC between sessions.
C1 [Metwali, Hussam; Kniese, Katja; Samii, Amir] Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
   [Metwali, Hussam; Samii, Amir] Leibniz Inst Neurobiol, Magdeburg, Germany.
   [Raemaekers, Mathijs] Univ Med Ctr Utrecht, Rudolf Magnus Brain Ctr, Hannover, Germany.
RP Metwali, H (reprint author), Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
EM drhussamm@yahoo.com
CR Agarwal S, 2017, NEUROIMAG CLIN N AM, V27, P645, DOI 10.1016/j.nic.2017.06.004
   Agarwal S, 2016, BRAIN CONNECT, V6, P267, DOI 10.1089/brain.2015.0402
   Bisdas S, 2016, ACAD RADIOL, V23, P192, DOI 10.1016/j.acra.2015.10.013
   Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015
   Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5
   Buchfelder M, 2016, FRONT HORM RES, V45, P121, DOI 10.1159/000442328
   Buchfelder M, 2012, ENDOCRINE, V42, P483, DOI 10.1007/s12020-012-9752-6
   Esposito R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040231
   Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1
   Guldenmund P, 2012, ARCH ITAL BIOL, V150, P107, DOI 10.4449/aib.v150i2.1373
   Guldenmund P, 2016, BRAIN CONNECT, V6, P225, DOI 10.1089/brain.2015.0369
   Guldenmund P, 2013, BRAIN CONNECT, V3, P273, DOI 10.1089/brain.2012.0117
   Harris RJ, 2014, J NEURO-ONCOL, V116, P373, DOI 10.1007/s11060-013-1304-2
   Jakola AS, 2015, J NEUROL SURG PART A, V76, P149, DOI 10.1055/s-0034-1393925
   Kokkonen SM, 2009, MAGN RESON IMAGING, V27, P733, DOI 10.1016/j.mri.2008.11.002
   Liu HS, 2009, J NEUROSURG, V111, P746, DOI 10.3171/2008.10.JNS08846
   Maesawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118072
   Martino J, 2011, ANN NEUROL, V69, P521, DOI 10.1002/ana.22167
   Metwali H, 2019, WORLD NEUROSURG, V128, pE165, DOI 10.1016/j.wneu.2019.04.073
   Metwali H, 2019, WORLD NEUROSURG, V125, pE1160, DOI 10.1016/j.wneu.2019.01.266
   Metwali H, 2019, WORLD NEUROSURG, V125, P183, DOI 10.1016/j.wneu.2019.01.194
   Ottenhausen M, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS14611
   Park JE, 2016, NEURORADIOLOGY, V58, P311, DOI 10.1007/s00234-015-1621-6
   Quigley M, 2001, AM J NEURORADIOL, V22, P294
   Roder C, 2016, J NEUROSURG, V125, P401, DOI 10.3171/2015.7.JNS15617
   Shimony JS, 2009, ACAD RADIOL, V16, P578, DOI 10.1016/j.acra.2009.02.001
   Tsugu A, 2011, WORLD NEUROSURG, V76, P120, DOI 10.1016/j.wneu.2011.02.005
   Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073
   Zhang JS, 2015, NEUROSURG REV, V38, P319, DOI 10.1007/s10143-014-0585-z
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E197
EP E204
DI 10.1016/j.wneu.2019.08.188
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700025
PM 31491572
OA Bronze
DA 2020-05-12
ER

PT J
AU Miki, K
   Abe, H
   Nonaka, M
   Morishita, T
   Iwaasa, M
   Arima, H
   Inoue, T
AF Miki, Koichi
   Abe, Hiroshi
   Nonaka, Masani
   Morishita, Takashi
   Iwaasa, Mitsutoshi
   Arima, Hisatomi
   Inoue, Tooru
TI Impact of Spot Sign Etiology in Supratentorial Intracerebral Hemorrhage
   on Outcomes of Endoscopic Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic surgery; Intraventricular hemorrhage; Spontaneous
   intracerebral hemorrhage; Spot sign; Supratentorial
ID PREDICTS HEMATOMA EXPANSION; INTRAVENTRICULAR HEMORRHAGE; CONTRAST
   EXTRAVASATION; MORTALITY; SCORE; RISK
AB BACKGROUND: The spot sign (SS) in spontaneous intracerebral hemorrhage has been reported to be a predictive factor of poor outcome; however, how SS is related with the clinical outcome remains unclear. We aimed to investigate how etiology associated with SS affects the clinical outcome of endoscopic surgery.
   METHODS: We retrospectively analyzed data from 104 patients (43 women and 61 men, mean age: 64.2 +/- 11.0 years) who underwent endoscopic surgery for supratentorial intracerebral hemorrhage. The outcome variables analyzed were in-hospital mortality and modified Rankin scale score at 90 days from onset.
   RESULTS: The prevalence of intraventricular hemorrhage and the mean initial modified Graeb score were greater in SS-positive than in SS-negative patients (100% vs. 47.7%, P < 0.001, and 14.4 +/- 5.4 vs. 10.6 +/- 6.0, P = 0.03, respectively). Postoperative rebleeding occurred more frequently in SS-positive than -negative patients (25.0% vs. 6.8%, P = 0.045). The in-hospital mortality rate was 7.7% and was not significantly different between the groups (18.8% vs. 5.7%, P = 0.09). There was a significant unfavorable shift in modified Rankin scale scores at 90 days among SS-positive patients compared with SS-negative patients in an analysis with ordinal logistic regression (adjusted common odds ratio, 4.38; 95% confidence interval 0.06-0.79, P = 0.02).
   CONCLUSIONS: Intraventricular hemorrhage and postoperative rebleeding were considered to be associated with the poor outcome in patients with SS. The SS on computed tomography angiography may be valuable in predicting rebleeding and clinical outcome after surgery.
C1 [Miki, Koichi; Abe, Hiroshi; Nonaka, Masani; Morishita, Takashi; Inoue, Tooru] Fukuoka Univ Hosp, Dept Neurosurg, Fac Med, Fukuoka, Fukuoka, Japan.
   [Iwaasa, Mitsutoshi] Fukuoka Univ Hosp, Dept Emergency & Crit Care, Fac Med, Fukuoka, Fukuoka, Japan.
   [Arima, Hisatomi] Fukuoka Univ Hosp, Dept Prevent Med & Publ Hlth, Fac Med, Fukuoka, Fukuoka, Japan.
   [Arima, Hisatomi] Fukuoka Univ, Sch Med, Fukuoka, Fukuoka, Japan.
RP Abe, H (reprint author), Fukuoka Univ Hosp, Dept Neurosurg, Fac Med, Fukuoka, Fukuoka, Japan.
EM neuroabe1972@gmail.com
OI Morishita, Takashi/0000-0002-0789-7776
CR Al-Mufti F, 2018, INTERV NEUROL, V7, P118, DOI 10.1159/000484571
   Almandoz JED, 2010, STROKE, V41, P54, DOI 10.1161/STROKEAHA.109.565382
   Becker KJ, 1999, STROKE, V30, P2025, DOI 10.1161/01.STR.30.10.2025
   BRODERICK JP, 1992, NEW ENGL J MED, V326, P733, DOI 10.1056/NEJM199203123261103
   Brouwers HB, 2015, STROKE, V46, P2498, DOI 10.1161/STROKEAHA.115.009659
   Brouwers HB, 2014, NEUROLOGY, V83, P883, DOI 10.1212/WNL.0000000000000747
   Brouwers HB, 2012, STROKE, V43, P3427, DOI 10.1161/STROKEAHA.112.664003
   Davis SM, 2006, NEUROLOGY, V66, P1175, DOI 10.1212/01.wnl.0000208408.98482.99
   Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8
   Dowlatshahi D, 2014, STROKE, V45, P277, DOI 10.1161/STROKEAHA.113.003387
   Fujii Y, 2001, STROKE, V32, P883, DOI 10.1161/01.STR.32.4.883
   Goldstein JN, 2007, NEUROLOGY, V68, P889, DOI 10.1212/01.wnl.0000257087.22852.21
   Hanley DF, 2009, STROKE, V40, P1533, DOI 10.1161/STROKEAHA.108.535419
   Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891
   IKEDA Y, 1982, Neurologia Medico-Chirurgica, V22, P822, DOI 10.2176/nmc.22.822
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Li N, 2011, STROKE, V42, P3441, DOI 10.1161/STROKEAHA.111.623405
   LITTLE JR, 1977, SURG NEUROL, V8, P143
   Longatti PL, 2004, STROKE, V35, pE35, DOI 10.1161/01.STR.0000113736.73632.F6
   Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534
   Meretoja A, 2014, INT J STROKE, V9, P519, DOI 10.1111/ijs.12132
   Miki K, 2019, J NEUROSURG, V130, P1485, DOI 10.3171/2017.12.JNS172335
   Miki K, 2018, WORLD NEUROSURG, V116, pE513, DOI 10.1016/j.wneu.2018.05.022
   Morgan TC, 2013, STROKE, V44, P635, DOI 10.1161/STROKEAHA.112.670653
   Morotti A, 2017, JAMA NEUROL, V74, P950, DOI 10.1001/jamaneurol.2017.1014
   Steiner T, 2010, STROKE, V41, P402, DOI 10.1161/STROKEAHA.109.552919
   Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3
   Yaghi S, 2014, INT J NEUROSCI, V124, P890, DOI 10.3109/00207454.2014.887716
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E281
EP E287
DI 10.1016/j.wneu.2019.08.244
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700081
PM 31518739
OA Bronze
DA 2020-05-12
ER

PT J
AU Montaser, AS
   Prevedello, DM
   Gomez, M
   Lima, L
   Beer-Furlan, A
   Servian, D
   Otto, BA
   Carrau, RL
AF Montaser, Alaa S.
   Prevedello, Daniel M.
   Gomez, Matias
   Lima, Lucas
   Beer-Furlan, Andre
   Servian, Diego
   Otto, Bradley A.
   Carrau, Ricardo L.
TI Extended Endoscopic Endonasal Clipping of Intracranial Aneurysms: An
   Anatomic Feasibility Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping; Endoscopic endonasal; Extended endoscopic endonasal surgery;
   Intracranial aneurysm; Skull base surgery; Surgical technique
ID SKULL BASE SURGERY; COMMUNICATING ARTERY ANEURYSMS; TRANSCLIVAL
   APPROACH; MICRONEUROSURGICAL MANAGEMENT; CEREBRAL-ARTERY; POSTERIOR
   CIRCULATION; CEREBELLAR ARTERY; VERTEBRAL ARTERY; INJURY; PREVENTION
AB BACKGROUND: Intracranial aneurysms (IAs) located in the midline region represent formidable challenge owing to their deep location. The objective of this study was to assess feasibility and identify the limitations of endoscopic endonasal clipping of Ks. We further aimed to describe the locations and characteristics of aneurysms that may be amenable for endoscopic endonasal clipping; thus outlining the indications of these approaches.
   METHODS: Fifteen latex-injected cadaveric heads were used for endoscopic endonasal exposure of anterior and posterior cerebral circulations. An aneurysm simulator model with 2 different sizes was used at the common sites for !As to emulate a real surgery. Key measured parameters included "exposure of vessels and their respective perforators," "ability to gain proximal/distal control," and "possibility of clip placement" according to the size, direction, and location of the aneurysm model. Maneuverability of instruments and the need for pituitary gland transposition were assessed and recorded as well.
   RESULTS: Exposure of the anterior communicating artery complex and the common sites of posterior circulation aneurysms were feasible. The size, location, and direction of the aneurysm model had an impact on obtaining proximal and/or distal control, and the ability of clip placement.
   CONCLUSIONS: Clipping of midline aneurysms of the posterior circulation is feasible via endoscopic endonasal approach. Small-sized ventrally and medially directed aneurysm models carried a better probability of getting proximal and/or distal control, as well as better overall ability to place a clip. The endonasal route seems to provide a limited condition for proper management of anterior circulation aneurysms.
C1 [Montaser, Alaa S.; Prevedello, Daniel M.; Lima, Lucas; Beer-Furlan, Andre; Servian, Diego] Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Gomez, Matias; Otto, Bradley A.; Carrau, Ricardo L.] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Montaser, Alaa S.] Ain Shams Univ, Dept Neurol Surg, Cairo, Egypt.
RP Prevedello, DM (reprint author), Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
EM daniel.prevedello@osumc.edu
OI Prevedello, Daniel/0000-0003-0214-2339; Montaser,
   Alaa/0000-0001-7435-4723
CR Agrawal A, 2008, MINIM INVAS NEUROSUR, V51, P131, DOI 10.1055/s-2008-1073169
   AlQahtani A, 2016, OTOLARYNG CLIN N AM, V49, P237, DOI 10.1016/j.otc.2015.09.009
   Cheng WY, 2006, MINIM INVAS NEUROSUR, V49, P257, DOI 10.1055/s-2006-954575
   Ciporen JN, 2017, J NEUROL SURG PART B, V78, P235, DOI 10.1055/s-0036-1597278
   d'Avella E, 2015, ACTA NEUROCHIR, V157, P1495, DOI 10.1007/s00701-015-2497-2
   Dashti R, 2007, SURG NEUROL, V68, P366, DOI 10.1016/j.surneu.2007.07.084
   Di Somma A, 2014, BIOMED RES INT, DOI 10.1155/2014/703792
   Doan V, 2016, J NEUROL SURG PART B, V77, P207, DOI 10.1055/s-0035-1564055
   Drazin D, 2012, J CLIN NEUROSCI, V19, P144, DOI 10.1016/j.jocn.2011.07.013
   Ensenat J, 2011, NEUROSURGERY, V69, pE121, DOI 10.1227/NEU.0b013e318223b637
   Essayed WI, 2017, J NEUROSURG, V127, P1139, DOI 10.3171/2016.9.JNS161503
   Fernandez-Miranda JC, 2014, J NEUROSURG, V121, P91, DOI 10.3171/2014.3.JNS131865
   Froelich S, 2011, NEUROSURGERY, V68, P310, DOI 10.1227/NEU.0b013e3182117063
   Gardner PA, 2016, OTOLARYNG CLIN N AM, V49, P819, DOI 10.1016/j.otc.2016.03.003
   Gardner PA, 2015, WORLD NEUROSURG, V84, P1380, DOI 10.1016/j.wneu.2015.06.032
   Gardner PA, 2013, NEUROSURGERY, V73, P261, DOI 10.1227/01.neu.0000430821.71267.f2
   Germanwala AV, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e318207b684
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Hernesniemi J, 2008, SURG NEUROL, V70, P8, DOI 10.1016/j.surneu.2008.01.056
   Kassam A, 2005, NEUROSURG FOCUS, V19, P1, DOI DOI 10.3171/foc.2005.19.1.4
   Kassam AB, 2008, NEUROSURGERY, V63, P57, DOI [10.1227/01.NEU.0000297013.35469.37, 10.1227/01.neu.0000317374.30443.23]
   Kassam AB, 2007, J NEUROSURG, V107, P1047, DOI 10.3171/JNS-07/11/1047
   Kassam AB, 2007, CHILD NERV SYST, V23, P491, DOI 10.1007/s00381-006-0288-z
   Kassam AB, 2006, NEUROSURGERY, V59, P162
   Kassam AB, 2011, J NEUROSURG, V114, P1544, DOI 10.3171/2010.10.JNS09406
   Kotowski M, 2017, CLIN NUTR, V36, P912
   Lai LT, 2014, J CLIN NEUROSCI, V21, P827, DOI 10.1016/j.jocn.2013.07.034
   Lai LT, 2013, J NEUROL SURG PART B, V74, P386, DOI 10.1055/s-0033-1347370
   Lai LT, 2013, J CLIN NEUROSCI, V20, P587, DOI 10.1016/j.jocn.2012.03.042
   Lehecka M, 2008, SURG NEUROL, V70, P232, DOI 10.1016/j.surneu.2008.03.008
   Lemos-Rodriguez AM, 2016, J NEUROL SURG PART B, V77, P308, DOI 10.1055/s-0035-1566252
   Ma J, 2016, CHI NEUROSURG J, V2, P1086
   Morera VA, 2010, NEUROSURGERY, V66, pONS211, DOI 10.1227/01.NEU.0000369926.01891.5D
   Polifka AJ, 2015, WORLD NEUROSURG, V83, P730, DOI 10.1016/j.wneu.2015.01.026
   Profeta G, 2004, CHILD NERV SYST, V20, P811, DOI 10.1007/s00381-004-0935-1
   Sanmillan JL, 2016, WORLD NEUROSURG, V89, P368, DOI 10.1016/j.wneu.2016.01.081
   Sekhar LN, 2007, NEUROSURGERY, V61, P273, DOI 10.1227/01.neu.0000303980.96504.d9
   Sekhar LN, 2007, NEUROSURGERY, V61, P290
   Silva Danilo, 2012, Surg Neurol Int, V3, P64, DOI 10.4103/2152-7806.97008
   Snyderman Carl H., 2009, Keio Journal of Medicine, V58, P152
   Solares CA, 2010, OTOLARYNG CLIN N AM, V43, P817, DOI 10.1016/j.otc.2010.04.008
   Somanna S, 2015, ACTA NEUROCHIR, V157, P2077, DOI 10.1007/s00701-015-2610-6
   Spetzler RF, 2013, J NEUROSURG, V119, P146, DOI 10.3171/2013.3.JNS12683
   Szentirmai O, 2016, J NEUROSURG, V124, P463, DOI 10.3171/2015.1.JNS142650
   Unnithan AS, 2016, WORLD NEUROSURG, V89, P26, DOI 10.1016/j.wneu.2015.12.094
   Valentine R, 2016, CURR OPIN OTOLARYNGO, V24, P170, DOI 10.1097/MOO.0000000000000239
   Valentine R, 2011, LARYNGOSCOPE, V121, P562, DOI 10.1002/lary.21361
   Vaz-Guimaraes F, 2016, J NEUROSURG SCI, V60, P503
   Yildirim AE, 2015, J CRANIOFAC SURG, V26, P1378, DOI 10.1097/SCS.0000000000001760
   Zwagerman NT, 2016, J NEURO-ONCOL, V130, P319, DOI 10.1007/s11060-016-2274-y
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E356
EP E368
DI 10.1016/j.wneu.2019.09.017
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700090
PM 31521759
OA Bronze
DA 2020-05-12
ER

PT J
AU Muller, M
   Abusabha, Y
   Steiger, HJ
   Petridis, A
   Bostelmann, R
AF Mueller, Mareike
   Abusabha, Yousef
   Steiger, Hans-Jakob
   Petridis, Athanasios
   Bostelmann, Richard
TI The Role of Stabilization-Free Microsurgical Decompression in the
   Surgical Treatment of Spinal Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurologic improvement; Spinal metastases; Stabilization-free
   decompression
ID CORD COMPRESSION; MANAGEMENT; DIAGNOSIS; LIGAMENT
AB OBJECTIVE: Symptomatic spine metastases are found in about 10% of patients with cancer. As the long-term survival of patients with carcinoma rises, the number of patients with symptomatic spine metastases is also increasing. In our tertiary referral center, patients usually present rapidly progressive neurologic disorders, which require an urgent treatment decision. Treatment options include extensive 360 degrees stabilizations. These complex interventions are not always readily available. We examined the extent to which the patient population benefited from decompressive surgery without stabilization. We hypothesize that patients benefit from merely dorsal decompression, which preserves stability when they experience symptomatic spine metastases.
   METHODS: We performed a retrospective analysis of electronic patient data from 19 patients, who were treated for symptomatic spine metastases by hemilaminectomy between 2009 and 2017. We evaluated the preoperative and postoperative neurologic functions using the American Spinal Injury Association (ASIA) Impairment Scale. A comparative literature analysis was carried out to assess the Spinal Neoplastic Instability Score, Tokuhashi score, and Tomita score.
   RESULTS: Nine participants had prostate cancer, 4 had mammary carcinoma, 3 had bronchial carcinoma, and 3 had other cancers. The median preoperative ASIA score was C, postoperatively, the score significantly improved to D (sign test P = 0.002). None of the patients needed stabilization within the follow-up period of up to 56 months.
   CONCLUSIONS: In our patient population, minimal intervention could significantly improve neurologic disorders. This outcome was seen over the whole study period. Even though different scoring systems suggest stabilization, our results show that spinal decompression alone might be indicated as well.
C1 [Mueller, Mareike; Abusabha, Yousef; Steiger, Hans-Jakob; Petridis, Athanasios; Bostelmann, Richard] Univ Med Ctr Duesseldorf, Dept Neurosurg, Dusseldorf, Germany.
RP Bostelmann, R (reprint author), Univ Med Ctr Duesseldorf, Dept Neurosurg, Dusseldorf, Germany.
EM richard.bostelmann@med.uni-duesseldorf.de
RI Bostelmann, Richard/AAI-7162-2020
OI Bostelmann, Richard/0000-0002-0286-5724
CR [Anonymous], 1996, INT STAND NEUR CLASS
   ARGUELLO F, 1990, CANCER, V65, P98, DOI 10.1002/1097-0142(19900101)65:1<98::AID-CNCR2820650121>3.0.CO;2-K
   Bakar D, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.6.FOCUS16166
   CHAZAL J, 1985, J BIOMECH, V18, P167, DOI 10.1016/0021-9290(85)90202-7
   Ellingson AM, 2016, COMPUT METHOD BIOMEC, V19, P1009, DOI 10.1080/10255842.2015.1088524
   FOURNEY DR, 2003, [No title captured], V14, P1
   Furstenberg CH, 2009, J BONE JOINT SURG BR, V91B, P240, DOI 10.1302/0301-620X.91B2.20894
   HELWEGLARSEN S, 1994, EUR J CANCER, V30A, P396, DOI 10.1016/0959-8049(94)90263-1
   Ivancic PC, 2007, SPINE J, V7, P659, DOI 10.1016/j.spinee.2006.10.014
   Li Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007873
   Masuda K, 2018, ASIAN SPINE J, V12, P846, DOI 10.31616/asj.2018.12.5.846
   Nathan SS, 2005, J CLIN ONCOL, V23, P6072, DOI 10.1200/JCO.2005.08.104
   PANJABI MM, 1981, ACTA ORTHOP SCAND, V52, P315, DOI 10.3109/17453678109050109
   Quraishi NA, 2010, J BONE JOINT SURG BR, V92B, P1054, DOI 10.1302/0301-620X.92B8.22296
   Sciubba DM, 2006, SURG ONCOL, V15, P141, DOI 10.1016/j.suronc.2006.11.002
   SUNDARESAN N, 1991, NEUROSURGERY, V29, P645, DOI 10.1227/00006123-199111000-00001
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E498
EP E502
DI 10.1016/j.wneu.2019.09.083
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700109
PM 31562975
OA Bronze
DA 2020-05-12
ER

PT J
AU Mutlu, O
   Olcay, AB
   Bilgin, C
   Hakyemez, B
AF Mutlu, Onur
   Olcay, Ali Bahadir
   Bilgin, Cem
   Hakyemez, Bahattin
TI Evaluating the Effect of the Number of Wire of Flow Diverter Stents on
   the Nonstagnated Region Formation in an Aneurysm Sac Using Lagrangian
   Coherent Structure and Hyperbolic Time Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computational fluid dynamics; Lagrangian coherent structure; Stagnated
   and nonstagnated fluid flow zones; Wire number of a flow diverter stent
ID BLOOD-FLOW; INTRACRANIAL ANEURYSMS; EMBOLIZATION DEVICE; LEFT-VENTRICLE;
   STAGNATION; DIVERSION; TRANSPORT; VELOCITY; ARTERIES; VOLUME
AB BACKGROUND: Giant aneurysms at carotid arteries are typically treated with flow diverter (FD) stents in the clinic. Although the goal of an FD stent is to direct most of the blood flow into the main artery, not much is known regarding the effects of wire number an FD possesses on the hemodynamics inside the aneurysm.
   METHODS: In this study, 48-, 72-, and 96-wire FD stents were separately implanted into the site of aneurysm of a 45-year-old woman to evaluate the effects of the FD's number of wires on fluid flow behavior in the aneurysm sac. Time evolution of both finite-time Lyapunov exponent (FILE) and hyperbolic time fields in the aneurysm sac were calculated by using computational fluid dynamics along with Lagrangian coherent structure (LCS) methods.
   RESULTS: The computations reveal that a 48-wire FD stent allows a large amount of blood to enter inside the aneurysm sac revealing scattered nonstagnant flow zones formation. Besides, time-dependent results of LCS analysis show that most of the blood flow is diverted into the main artery when 72- and 96-wire number Surpass brand FD stents are separately implanted into the site of the aneurysm, yielding a small amount of blood flow to penetrate into the aneurysm sac.
   CONCLUSIONS: Furthermore, FILE and hyperbolic time field plots are in good agreement with the patient's digital subtraction angiography image captured 3.5 minutes after 72-wire Surpass brand FD stent implantation.
C1 [Mutlu, Onur; Olcay, Ali Bahadir] Yeditepe Univ, Fac Engn, Dept Mech Engn, Istanbul, Turkey.
   [Bilgin, Cem; Hakyemez, Bahattin] Uludag Univ, Sch Med, Dept Radiol, Bursa, Turkey.
RP Olcay, AB (reprint author), Yeditepe Univ, Fac Engn, Dept Mech Engn, Istanbul, Turkey.
EM bahadir.olcay@yeditepe.edu.tr
CR Albayrak R, 2007, J CLIN ULTRASOUND, V35, P27, DOI 10.1002/jcu.20301
   [Anonymous], 2013, SURP FLOW DIV SEL GU
   Arzani A, 2017, BIOMECH MODEL MECHAN, V16, P787, DOI 10.1007/s10237-016-0853-7
   Augsburger L, 2011, ANN BIOMED ENG, V39, P850, DOI 10.1007/s10439-010-0200-6
   Chalouhi N, 2013, STROKE, V44, P2150, DOI 10.1161/STROKEAHA.113.001785
   Doost SN, 2016, COMPUT METH PROG BIO, V127, P232, DOI 10.1016/j.cmpb.2015.12.020
   El-Chalouhi N, 2014, WORLD NEUROSURG, V82, P696, DOI 10.1016/j.wneu.2013.02.089
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   Ghorbani M, 2018, AM J NEURORADIOL, V39, P1107, DOI 10.3174/ajnr.A5607
   Hendabadi S, 2013, ANN BIOMED ENG, V41, P2603, DOI 10.1007/s10439-013-0853-z
   Joly F, 2018, COMPUT BIOL MED, V92, P98, DOI 10.1016/j.compbiomed.2017.10.033
   Li YJ, 2018, J BIOMECH, V80, P88, DOI 10.1016/j.jbiomech.2018.08.026
   Liu X, 2011, J BIOMECH, V44, P1123, DOI 10.1016/j.jbiomech.2011.01.024
   Mahajan A, 2018, WORLD NEUROSURG, V120, pE1061, DOI 10.1016/j.wneu.2018.09.011
   Meyers PM, 2019, STROKE, V50, P1473, DOI 10.1161/STROKEAHA.118.024135
   Mutlu O, 2019, WORLD NEUROSURG, V127, pE727, DOI 10.1016/j.wneu.2019.03.255
   Olcay AB, 2018, J APPL FLUID MECH, V11, P375, DOI 10.18869/acadpub.jafm.73.245.28185
   Olcay AB, 2008, EXP FLUIDS, V44, P235, DOI [10.1007/s00348-007-0397-9, 10.1007/S00348-007-0397-9]
   Olcay AB, 2016, PROG COMPUT FLUID DY, V16, P126, DOI 10.1504/PCFD.2016.075159
   PENINGTON DG, 1976, BRIT J HAEMATOL, V34, P365, DOI 10.1111/j.1365-2141.1976.tb03583.x
   Shadden SC, 2005, PHYSICA D, V212, P271, DOI 10.1016/j.physd.2005.10.007
   Shadden SC, 2008, ANN BIOMED ENG, V36, P1152, DOI 10.1007/s10439-008-9502-3
   Shadden SC, 2015, ANN BIOMED ENG, V43, P41, DOI 10.1007/s10439-014-1070-0
   Shadden SC, 2010, CHAOS, V20, DOI 10.1063/1.3272780
   Shapiro M, 2014, AM J NEURORADIOL, V35, P727, DOI 10.3174/ajnr.A3742
   Sindeev S, 2019, WORLD NEUROSURG, V122, pE577, DOI 10.1016/j.wneu.2018.10.107
   Toger J, 2012, ANN BIOMED ENG, V40, P2652, DOI 10.1007/s10439-012-0615-3
   van Beekvelt MCP, 2001, J APPL PHYSIOL, V90, P511
   Vetel J, 2009, EXP FLUIDS, V46, P1067, DOI 10.1007/s00348-009-0615-8
   Wakhloo AK, 2015, AM J NEURORADIOL, V36, P98, DOI 10.3174/ajnr.A4078
   WOMERSLEY JR, 1955, J PHYSIOL-LONDON, V127, P553, DOI 10.1113/jphysiol.1955.sp005276
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E666
EP E682
DI 10.1016/j.wneu.2019.09.116
PG 17
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700131
PM 31568908
DA 2020-05-12
ER

PT J
AU Newman, H
   Milne, N
   Lewis, SB
AF Newman, Hamish
   Milne, Nicholas
   Lewis, Stephen B.
TI Neurosurgical Anatomy of the Internal Carotid Artery: Magnetic Resonance
   Imaging Study of the Sellar Region
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus; Internal carotid artery; Transsphenoidal surgery
ID TRANSSPHENOIDAL SURGERY; SPHENOID SINUS; COMPLICATIONS; ANGIOGRAPHY;
   EXPERIENCE; DISTANCE
AB BACKGROUND: Transsphenoidal surgical approaches involve dissection of the posterior wall of the sphenoid sinus in close proximity to the internal carotid arteries. To reduce the risk of vascular injury, a detailed study of embalmed cadavers' sellae was conducted and found the internal carotid artery approached within 4 mm of the midline in 10% of cases, and the closest intercarotid distance (ICD) occurred in the cavernous sinus, sphenoid sinus, and supraclinoid segments in 82%, 14%, and 4% of cases, respectively. These measurements have not previously been compared with living patients with modern imaging techniques.
   METHODS: This study measured the closest ICD of 233 coronal magnetic resonance imaging head scans from 183 patients (male = 88, female = 95) at the cavernous sinus, sphenoid sinus, or supraclinoid segments of the internal carotid artery. ICD at the sphenoid sinus was taken for all scans.
   RESULTS: The internal carotid approached within 4 mm of the midline in 1.3% of cases. The closest ICD occurred in the cavernous sinus, sphenoid sinus, and supraclinoid segments in 24.5%, 35.8%, and 39.7%, respectively. Both results were significantly different from previous cadaveric studies (chisquared tests, P = 1.4 x 10(-4) and P = 6.1 x 10(-8), respectively).
   CONCLUSIONS: Surgically relevant measurements of the carotid arteries in the sellar are different in cadavers and living subjects. This is likely due to postmortem changes of surrounding structures. This study suggests clinically relevant anatomic studies using measurements taken from cadaveric specimens be updated with modern imaging techniques taken from living patients.
C1 [Newman, Hamish; Milne, Nicholas] Univ Western Australia, Sch Anat Physiol & Human Biol, Perth, WA, Australia.
   [Lewis, Stephen B.] Perth Neurosurg, Dept Neurosurg, Perth, WA, Australia.
RP Newman, H (reprint author), Univ Western Australia, Sch Anat Physiol & Human Biol, Perth, WA, Australia.
EM 21482057@student.uwa.edu.au
CR AHUJA A, 1992, NEUROSURGERY, V31, P774
   Cappabianca P, 2004, NEUROSURGERY, V55, P933, DOI 10.1227/01.NEU.0000137330.02549.0D
   Cebula N, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.09.021
   Chew FS, 2006, J COMPUT ASSIST TOMO, V30, P949, DOI 10.1097/01.rct.0000232473.30033.c8
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   Couldwell WT, 2004, NEUROSURGERY, V55, P539, DOI 10.1227/01.NEU.0000134287.19377.A2
   Pereira AD, 2007, ARQ NEURO-PSIQUIAT, V65, P355, DOI 10.1590/S0004-282X2007000200034
   Ebner FH, 2009, SURG NEUROL, V72, P456, DOI 10.1016/j.surneu.2009.07.006
   Fox J., 2017, RCMDR R COMMANDER CO
   Frank G, 2006, NEUROSURGERY, V59, P50, DOI 10.1227/01.NEU.0000219914.17221.55
   Gardner PA, 2008, J NEUROSURG, V109, P6, DOI 10.3171/JNS/2008/109/7/0006
   Hamid O, 2008, SKULL BASE-INTERD AP, V18, P9, DOI 10.1055/s-2007-992764
   Hatipoglu HG, 2009, J LARYNGOL OTOL, V123, P1331, DOI 10.1017/S0022215109991046
   Knappe UJ, 2009, CENT EUR NEUROSURG, V70, P130, DOI 10.1055/s-0029-1216363
   Levy AD, 2010, AM J FOREN MED PATH, V31, P12, DOI 10.1097/PAF.0b013e3181c65e1a
   Liu JK, 2001, J NEUROSURG, V95, P1083, DOI 10.3171/jns.2001.95.6.1083
   Nunes CF, 2016, ARQ NEURO-PSIQUIAT, V74, P396, DOI 10.1590/0004-282X20160046
   Raymond J, 1997, AM J NEURORADIOL, V18, P655
   RENN WH, 1975, J NEUROSURG, V43, P288, DOI 10.3171/jns.1975.43.3.0288
   SACHER M, 1986, J COMPUT ASSIST TOMO, V10, P1033, DOI 10.1097/00004728-198611000-00027
   Sasagawa Y, 2013, PITUITARY, V16, P465, DOI 10.1007/s11102-013-0492-2
   SCOTTI G, 1988, AM J ROENTGENOL, V151, P799, DOI 10.2214/ajr.151.4.799
   Silvestrini M, 2002, STROKE, V33, P1782, DOI 10.1161/01.STR.0000019123.47840.2D
   WOLLSCHL.G, 1967, AMER J ROENTGENOL RA, V101, P68, DOI 10.2214/ajr.101.1.68
   Zada G, 2011, J NEUROSURG, V114, P1319, DOI 10.3171/2010.11.JNS10768
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E711
EP E715
DI 10.1016/j.wneu.2019.09.145
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700136
PM 31589983
OA Bronze
DA 2020-05-12
ER

PT J
AU Nossek, E
   Lombardo, K
   Schneider, JR
   Kwan, K
   Chalif, DJ
   Setton, A
AF Nossek, Erez
   Lombardo, Kim
   Schneider, Julia R.
   Kwan, Kevin
   Chalif, David J.
   Setton, Avi
TI Unilateral Venous Approach to Contralateral or Bilateral Carotid
   Cavernous Shunts
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous; Cavernous carotid fistula; Contralateral; Shunt; Venous
   approach
ID TRANSVENOUS EMBOLIZATION; FISTULAS; SINUS; SERIES; FOCUS
AB BACKGROUND: Cavernous carotid fistulas (CCF) are anatomically complex vascular lesions. Treatment via the venous approach has been previously described and is highly dependent on the patency of the drainage pathways. The use of a unilateral approach to contralateral or bilateral shunts is technically challenging and not commonly described. We present our experience with the unilateral across-the-midline approach to both cavernous sinuses to treat shunts according to anatomic compartments to achieve anatomic cure.
   METHODS: Patients included in this study presented with either bilateral or unilateral shunts with unilateral venous drainage. We used a transarterial guiding catheter for road mapping and control angiography. A venous triaxial system was used to achieve support for distal navigation across the midline via the coronary sinus to the contralateral cavernous sinus. Coils were favored for embolization, with occasional complementary liquid embolic material.
   RESULTS: Five patients underwent complete occlusion in a single session. One patient required additional complementary transarterial embolization. Despite a successful unilateral approach to bilateral cavernous sinuses, 1 patient needed an additional ipsilateral transophthalmic venous approach to obliterate the anterior compartment of the cavernous sinus. No complications were encountered. Complete angiographic cure was observed in all patients by the end of the final procedures, with persistent occlusion in their follow-up imaging.
   CONCLUSIONS: Careful inspection of the venous anatomy and fistulization sites is critical when treating unilateral or bilateral carotid cavernous shunts. The contralateral venous route can serve as a safe approach when visualized. Crossing the midline via the anterior or posterior coronary sinuses is feasible and efficacious.
C1 [Nossek, Erez] NYU, Med Ctr, Dept Neurosurg, New York, NY 10016 USA.
   [Schneider, Julia R.] Hofstra Northwell Hlth, Zucker Sch Med, Dept Neurosurg, Lenox Hill Hosp, New York, NY USA.
   [Lombardo, Kim; Kwan, Kevin; Chalif, David J.; Setton, Avi] Hofstra Northwell Hlth, Zucker Sch Med, North Shore Hosp, Dept Neurosurg, Manhasset, NY USA.
   [Setton, Avi] Hofstra Northwell Hlth, Zucker Sch Med, North Shore Hosp, Dept Radiol, Manhasset, NY USA.
RP Nossek, E (reprint author), NYU, Med Ctr, Dept Neurosurg, New York, NY 10016 USA.
EM erez.nossek@nyulangone.org
CR Andreou A, 2007, NEURORADIOLOGY, V49, P259, DOI 10.1007/s00234-006-0180-2
   BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   Chalouhi N, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS123
   CHALOUPKA JC, 1993, J NEUROSURG, V79, P592, DOI 10.3171/jns.1993.79.4.0592
   Cheng KM, 2003, ACTA NEUROCHIR, V145, P17, DOI 10.1007/s00701-002-1013-7
   Dabus G, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.01.031
   Ducruet AF, 2013, WORLD NEUROSURG, V80, P538, DOI 10.1016/j.wneu.2013.02.033
   Ellis JA, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1223
   Geibprasert S, 2009, AM J NEURORADIOL, V30, P1459, DOI 10.3174/ajnr.A1500
   Guo H, 2018, INTERV NEURORADIOL, V24, P197, DOI 10.1177/1591019917751894
   Jahan R, 1998, NEURORADIOLOGY, V40, P189, DOI 10.1007/s002340050566
   Kim Myeong Jin, 2013, Neurointervention, V8, P15, DOI 10.5469/neuroint.2013.8.1.15
   Meyers PM, 2002, AM J OPHTHALMOL, V134, P85, DOI 10.1016/S0002-9394(02)01515-5
   Morton RP, 2015, J CLIN NEUROSCI, V22, P859, DOI 10.1016/j.jocn.2014.11.006
   Natarajan SK, 2010, WORLD NEUROSURG, V73, P365, DOI 10.1016/j.wneu.2010.01.009
   Ozanne A, 2008, NEUROIMAG CLIN N AM, V18, P431, DOI 10.1016/j.nic.2007.12.010
   Stiebel-Kalish H, 2002, OPHTHALMOLOGY, V109, P1685, DOI 10.1016/S0161-6420(02)01166-1
   VINUELA F, 1984, J NEUROSURG, V60, P976, DOI 10.3171/jns.1984.60.5.0976
   Yoshida K, 2010, AM J NEURORADIOL, V31, P651, DOI 10.3174/ajnr.A1882
   Zenteno Marco, 2015, Asian J Neurosurg, V10, P55, DOI 10.4103/1793-5482.151522
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E479
EP E486
DI 10.1016/j.wneu.2019.09.054
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700106
PM 31541756
OA Bronze
DA 2020-05-12
ER

PT J
AU Park, HJ
   Dho, YS
   Kim, JH
   Kim, JW
   Park, CK
   Kim, YH
AF Park, Hyun Joo
   Dho, Yun-Sik
   Kim, Jung Hee
   Kim, Jin Wook
   Park, Chul-Kee
   Kim, Yong Hwy
TI Recurrence Rate and Prognostic Factors for the Adult Craniopharyngiomas
   in Long-Term Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniopharyngioma; Long-term; Recurrence; Risk factor
ID SURGICAL-MANAGEMENT; PETROSAL APPROACH; RESECTION; CHILDREN; EXPERIENCE;
   OUTCOMES
AB BACKGROUND: Craniopharyngiomas show a high recurrence rate despite their pathologically benign nature. Thus, we analyzed the clinical features to elucidate the prognostic factors for the recurrence of craniopharyngiomas in adults with long-term follow-up.
   METHODS: This retrospective study reviewed and analyzed the preoperative features, surgical results, and tumor recurrence of patients who underwent an operation at a single institution from 2004 to 2013.
   RESULTS: This study analyzed the results of 64 consecutive adult patients, and the median follow-up period was 83.5 months (range 9-163 months). Ten patients had a history of surgery, whereas 4 had a history of adjuvant radiation. Retrochiasmatic tumors (n = 51, 79.7%) were more common than prechiasmatic tumors. Operations were performed via the transcranial approach in 31 (48.4%) patients and transsphenoidal approach in 33. Gross total removal was achieved in 44 (68.8%) patients, and the transsphenoidal approach showed a greater gross total removal rate than the transcranial approach did (97.0% vs. 38.7%, P< 0.001). Adjuvant radiotherapy was performed in 8 patients, and radiosurgery was performed in 2. Recurrence was identified in 25 (39.1%) patients in 45.0 months of the median time to recurrence. The overall actuarial 5- and 7-year progression-free survival rates were 71.8% and 63.6%, respectively. Multivariate analysis revealed that supra- and subdiaphragmatic tumor locations and subtotal removal were risk factors for long-term tumor recurrence.
   CONCLUSIONS: The long-term recurrence rate of craniopharyngiomas was high; therefore, long-term regular follow-up is mandatory. Adjuvant irradiation for remnant tumors showed a long-term tumor control rate comparable to that of completely removed tumors.
C1 [Park, Hyun Joo; Kim, Jin Wook; Park, Chul-Kee; Kim, Yong Hwy] Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
   [Kim, Jung Hee; Kim, Yong Hwy] Seoul Natl Univ Hosp, Pituitary Ctr, Seoul, South Korea.
   [Kim, Jung Hee] Seoul Natl Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea.
   [Dho, Yun-Sik] Chungbuk Natl Univ Hosp, Dept Neurosurg, Cheongju, South Korea.
RP Kim, YH (reprint author), Seoul Natl Univ Hosp, Dept Neurosurg, Seoul, South Korea.
EM kimyh96@snu.ac.kr
CR Akinduro OO, 2019, WORLD NEUROSURG, V127, pE656, DOI 10.1016/j.wneu.2019.03.239
   Al-Mefty O, 2008, NEUROSURGERY, V62, P331, DOI 10.1227/01.NEU.0000312352.13678.ef
   Ansari SF, 2016, J NEUROSURG-PEDIATR, V17, P439, DOI 10.3171/2015.8.PEDS15317
   Brix MK, 2017, EUR J RADIOL, V95, P28, DOI 10.1016/j.ejrad.2017.07.013
   Cheng J, 2016, J CRANIOFAC SURG, V27, pE763, DOI 10.1097/SCS.0000000000003176
   Dandurand C, 2018, NEUROSURGERY, V83, P631, DOI 10.1093/neuros/nyx570
   Duff JM, 2000, NEUROSURGERY, V46, P291, DOI 10.1097/00006123-200002000-00007
   Fahlbusch R, 1999, J NEUROSURG, V90, P237, DOI 10.3171/jns.1999.90.2.0237
   Goudihalli SR, 2018, J NEUROL SURG PART B, V79, pS208, DOI 10.1055/s-0037-1620248
   HETELEKIDIS S, 1993, INT J RADIAT ONCOL, V27, P189, DOI 10.1016/0360-3016(93)90227-M
   HOFFMAN HJ, 1994, PEDIATR NEUROSURG, V21, P44, DOI 10.1159/000120861
   HOFFMAN HJ, 1992, J NEUROSURG, V76, P47, DOI 10.3171/jns.1992.76.1.0047
   Jamshidi AO, 2018, J NEUROSURG, P1
   Jeswani S, 2016, J NEUROSURG, V124, P627, DOI 10.3171/2015.3.JNS142254
   Kassam AB, 2008, J NEUROSURG, V108, P715, DOI 10.3171/JNS/2008/108/4/0715
   Kim KH, 2018, WORLD NEUROSURG, V114, pE306, DOI 10.1016/j.wneu.2018.02.178
   Kim SK, 2001, CHILD NERV SYST, V17, P531, DOI 10.1007/s003810100458
   Koutourousiou M, 2013, J NEUROSURG, V119, P1194, DOI 10.3171/2013.6.JNS122259
   Lee EJ, 2015, J KOREAN NEUROSURG S, V58, P432, DOI 10.3340/jkns.2015.58.5.432
   Lin LL, 2008, J NEUROS-PEDIATR, V1, P126, DOI 10.3171/PED/2008/1/2/126
   Morisako H, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16211
   Mortini P, 2011, J NEUROSURG, V114, P1350, DOI 10.3171/2010.11.JNS10670
   Mou JM, 2019, WORLD NEUROSURG, V124, pE424, DOI 10.1016/j.wneu.2018.12.110
   Muller HL, 2008, HORM RES, V69, P193, DOI 10.1159/000113019
   Muller HL, 2017, PITUITARY, V20, P267, DOI 10.1007/s11102-016-0751-0
   Muller HL, 2014, HAND CLINIC, V124, P235, DOI 10.1016/B978-0-444-59602-4.00016-2
   Ohata Hiroki, 2019, J Neurosurg, P1, DOI 10.3171/2019.2.JNS183278
   Park CK, 2006, NEUROSURGERY, V59, P238, DOI 10.1227/01.NEU.0000223341.08402.C5
   RAJAN B, 1993, RADIOTHER ONCOL, V26, P1, DOI 10.1016/0167-8140(93)90019-5
   Rock AK, 2019, J NEURO-ONCOL, V144, P117, DOI 10.1007/s11060-019-03209-9
   Steno J, 2014, ACTA NEUROCHIR, V156, P113, DOI 10.1007/s00701-013-1938-z
   Sterkenburg AS, 2015, NEURO-ONCOLOGY, V17, P1029, DOI 10.1093/neuonc/nov044
   Tamasauskas A, 2014, TURK NEUROSURG, V24, P174, DOI 10.5137/1019-5149.JTN.6995-12.2
   Wang KC, 2005, CHILD NERV SYST, V21, P628, DOI 10.1007/s00381-005-1203-8
   Wannemuehler TJ, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16314
   WEINER HL, 1994, NEUROSURGERY, V35, P1001, DOI 10.1227/00006123-199412000-00001
   Xing HS, 2016, ONCOL LETT, V12, P147, DOI 10.3892/ol.2016.4555
   Yang I, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09307
   Zhang C, 2018, AM J CLIN ONCOL-CANC, V41, P807, DOI 10.1097/COC.0000000000000378
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E211
EP E217
DI 10.1016/j.wneu.2019.08.209
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700027
PM 31493596
OA Bronze
DA 2020-05-12
ER

PT J
AU Park, YJ
   Lee, SH
   Ryu, KH
   Kim, YK
   Shim, J
   Lee, HW
   Kim, YH
AF Park, Yoo Jung
   Lee, Sung Hyun
   Ryu, Kyoung-Ho
   Kim, Young-Kwon
   Shim, Jaegeum
   Lee, Hyo-Won
   Kim, Young Hwan
TI Novel Method for S1 Transforaminal Epidural Steroid Injection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fluoroscopy; Radiation; S1 transforaminal epidural steroid injection;
   Ultrasound
ID ULTRASOUND; LANDMARKS
AB BACKGROUND: S1 transforaminal epidural steroid injection (S1-TFESI) results in positive clinical outcomes for the treatment of pain associated with the S1 nerve root. S1-TFESI via the transforaminal approach is commonly performed under fluoroscopic guidance. Ultrasound guidance is an alternative to mitigate radiation exposure. However, performing spinal procedures under ultrasound guidance has some limitations in confirming the position of the needle tip and vascular uptake. New techniques are therefore needed to make ultrasound and fluoroscopy complementary. Our objective was to describe a novel technique for S1-TFESI and confirm its reproducibility.
   METHODS: Records of patients with S1 radiculopathy were reviewed retrospectively; those treated using the new S1-TFESI technique were selected. Initially, ultrasound was used to distinguish anatomy of the sacral foramen and guide initial placement of the needle entry point. Fluoroscopy was subsequently used to confirm needle tip position and vascular injection. The number of times the needle required reinsertion was recorded, and ultrasound and C-arm images were stored.
   RESULTS: Sixty-seven S1-TFESIs were performed in 56 patients. All injections exhibited epidural spread of contrast media, not only to the S1 nerve. The cephalad angle was 16.25 +/- 6.75 degrees (range, 5-27), the oblique angle was 2.48 +/- 2.62 degrees (range, 0-7 degrees), and the mean number of attempts was 1.24 +/- 1.25.
   CONCLUSIONS: The new technique, involving the use of ultrasound to guide initial placement of the needle entry point, followed by confirmatory imaging and any needed adjustment with the use of fluoroscopy, can be a technique to complement the shortcomings of using ultrasound or fluoroscopy alone.
C1 [Park, Yoo Jung] Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.
   [Lee, Sung Hyun; Ryu, Kyoung-Ho; Kim, Young-Kwon; Shim, Jaegeum; Lee, Hyo-Won] Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Sch Med, Seoul, South Korea.
   [Kim, Young Hwan] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Nucl Med, Sch Med, Seoul, South Korea.
RP Lee, SH (reprint author), Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Sch Med, Seoul, South Korea.
EM 4321hoho@naver.com
OI Lee, Sung Hyun/0000-0001-5616-6649
CR Bhatia A, 2016, ANESTH ANALG, V122, P857, DOI 10.1213/ANE.0000000000001155
   Cheng Joseph S, 2003, Neurosurg Focus, V15, pE3
   Chun EH, 2015, PAIN PHYSICIAN, V18, P519
   Eker HE, 2010, PAIN PHYSICIAN, V13, P451
   Furman MB, 2012, PAIN MED, V13, P1265, DOI 10.1111/j.1526-4637.2012.01474.x
   Hyung Kim Shin, 2010, PAIN, V23, P242
   Joo EY, 2017, PAIN PHYSICIAN, V20, pE107
   Kim DH, 2015, ANAESTHESIA, V70, P975, DOI 10.1111/anae.13079
   Manchikanti L, 2014, PAIN PHYSICIAN, V17, pE691
   Manchikanti L, 2012, PAIN PHYSICIAN, V15, pE199
   Park D, 2018, AM J PHYS MED REHAB, V97, pE66, DOI 10.1097/PHM.0000000000000856
   Park D, 2018, AM J PHYS MED REHAB, V97, pe14, DOI 10.1097/PHM.0000000000000754
   Park SJ, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/6426802
   Plastaras CT, 2016, PAIN MED, V17, P832, DOI 10.1093/pm/pnv013
   Povo A, 2016, TECH COLOPROCTOL, V20, P859, DOI 10.1007/s10151-016-1543-2
   Sato M, 2013, J ANESTH, V27, P775, DOI 10.1007/s00540-013-1591-y
   Shin J, 2013, ANESTH ANALG, V117, P1241, DOI 10.1213/ANE.0b013e3182a6d1bd
   Thompson BF, 2018, PM&R, V10, P382, DOI 10.1016/j.pmrj.2017.09.008
NR 18
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E443
EP E447
DI 10.1016/j.wneu.2019.09.051
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700101
PM 31526885
OA Bronze
DA 2020-05-12
ER

PT J
AU Patel, EA
   Aydin, A
   Cearns, M
   Dasgupta, P
   Ahmed, K
AF Patel, Ebrahim Adnan
   Aydin, Abdullatif
   Cearns, Michael
   Dasgupta, Prokar
   Ahmed, Kamran
TI A Systematic Review of Simulation-Based Training in Neurosurgery, Part
   1: Cranial Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Review
DE Education; Neurosurgery; Simulation; Training
ID ENDONASAL TRANSSPHENOIDAL SURGERY; VIRTUAL-REALITY SIMULATOR;
   CAROTID-ARTERY INJURY; BOOT CAMP; CONSTRUCT-VALIDITY; PRINTED MODELS;
   MANAGEMENT; VENTRICULOSTOMY; PERFORMANCE; SKILLS
AB OBJECTIVE: The recent emphasis on simulation-based training in neurosurgery has led to the development of many simulation models and training courses. We aim to identify the currently available simulators and training courses for neurosurgery, assess their validity, and determine their effectiveness.
   METHODS: Both MEDLINE and Embase were searched for English language articles which validate simulation models for neurosurgery. Each study was screened according to the Messick validity framework and rated in each domain. The McGaghie model of translational outcomes was then used to determine a level of effectiveness (LoE) for each simulator or training course.
   RESULTS: On screening of 6006 articles, 114 were identified to either validate or determine an LoE for 108 simulation-based training models or courses. Achieving the highest rating for each validity domain were 6 models and training courses for content validity, 12 for response processes, 4 for internal structure, 14 for relations to other variables, and none for consequences. For translational outcomes, 6 simulators or training achieved an LoE >2 and thus showed skills transfer beyond the simulation setting.
   CONCLUSIONS: With the advent of increasing neurosurgery simulators and training tools, there is a need for more validity studies. Further attempts to investigate translational outcomes to the operating theater when using these simulators is particularly warranted. More training tools incorporating full-immersion simulation and nontechnical skills training are recommended.
C1 [Patel, Ebrahim Adnan] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England.
   [Aydin, Abdullatif; Dasgupta, Prokar; Ahmed, Kamran] Kings Coll London, MRC, Ctr Transplantat, London, England.
   [Cearns, Michael] Inst Neurol Sci, Dept Neurosurg, Glasgow, Lanark, Scotland.
RP Aydin, A (reprint author), Kings Coll London, MRC, Ctr Transplantat, London, England.
EM abdullatif.aydin@kcl.ac.uk
OI Ahmed, Kamran/0000-0002-5135-9211; Cearns, Michael/0000-0002-1479-8979;
   Aydin, Abdullatif/0000-0002-5440-7741
CR Aboud E, 2015, J NEUROSURG, V123, P1339, DOI 10.3171/2014.12.JNS141551
   Akhigbe T, 2017, J CLIN NEUROSCI, V45, P40, DOI 10.1016/j.jocn.2017.07.025
   Alaraj A, 2015, NEUROSURGERY S2, V11, P1
   Almeida DB, 2006, ACTA NEUROCHIR, V148, P881, DOI 10.1007/s00701-006-0817-2
   Alotaibi FE, 2015, NEUROSURGERY S2, V11, P1
   AlZhrani G, 2015, J SURG EDUC, V72, P685, DOI 10.1016/j.jsurg.2014.12.014
   Ament JD, 2017, WORLD NEUROSURG, V104, P407, DOI 10.1016/j.wneu.2017.05.046
   American Educational Research Association American Psychological Association and National Council on Measurement in Education, 1999, STAND ED PSYCH TEST
   Aoun SG, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2012.05.024
   Ashour AM, 2016, WORLD NEUROSURG, V96, P261, DOI 10.1016/j.wneu.2016.04.048
   Banerjee PP, 2007, J NEUROSURG, V107, P515, DOI 10.3171/JNS-07/09/0515
   Beckman TJ, 2005, J GEN INTERN MED, V20, P1159, DOI 10.1111/j.1525-1497.2005.0258.x
   Belykh E, 2017, WORLD NEUROSURG, V105, P952, DOI 10.1016/j.wneu.2017.06.045
   Bernardo A, 2017, WORLD NEUROSURG, V106, P1015, DOI 10.1016/j.wneu.2017.06.140
   Borgersen NJ, 2018, ANN SURG, V267, P1063, DOI 10.1097/SLA.0000000000002652
   Bow H, 2019, OPER NEUROSURG, V16, P496, DOI 10.1093/ons/opy142
   Breimer GE, 2016, OPER NEUROSURG HAGER, V13, P1
   Breimer GE, 2015, OPER NEUROSURG HAGER, V15, P1
   Choudhury Nusrat, 2013, World Neurosurg, V80, pe9, DOI 10.1016/j.wneu.2012.08.022
   Christian EA, 2018, J NEUROSURG, V129, P792, DOI 10.3171/2017.5.JNS162982
   Ciporen JN, 2017, WORLD NEUROSURG, V98, P388, DOI 10.1016/j.wneu.2016.11.018
   Clarke DB, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0669-2
   Cleary DR, 2018, J NEUROSURG, V128, P1553, DOI 10.3171/2016.12.JNS162165
   Cobb MIPH, 2016, WORLD NEUROSURG, V89, P583, DOI 10.1016/j.wneu.2015.11.068
   Craven C, 2014, BRIT J NEUROSURG, V28, P707, DOI 10.3109/02688697.2014.913775
   Dasgupta D, 2019, J NEUROSURG, V131, P1620, DOI 10.3171/2018.5.JNS172881
   Dawe SR, 2014, ANN SURG, V259, P236, DOI 10.1097/SLA.0000000000000245
   Filho Francisco Vaz Guimaraes, 2011, Neurosurg Focus, V30, pE17, DOI 10.3171/2011.2.FOCUS10321
   Gagliardi F, 2017, J CRANIOFAC SURG, V29, P1
   Gasco Jaime, 2013, World Neurosurg, V80, P732, DOI 10.1016/j.wneu.2013.09.040
   Gasco J, 2013, NEUROSURGERY, V73, P39, DOI 10.1227/NEU.0000000000000102
   Gelinas-Phaneuf N, 2014, INT J COMPUT ASS RAD, V9, P1, DOI 10.1007/s11548-013-0905-8
   Gmeiner M, 2018, WORLD NEUROSURG, V112, pE313, DOI 10.1016/j.wneu.2018.01.042
   Gnanalingham KK, 2006, CLIN NEUROL NEUROSUR, V108, P117, DOI 10.1016/j.clineuro.2005.11.001
   Haji FA, 2013, J NEUROSURG, V118, P250, DOI 10.3171/2012.10.JNS12767
   Harrop J, 2013, NEUROSURGERY, V73, P25, DOI 10.1227/NEU.0000000000000101
   Holloway T, 2015, INT J COMPUT ASS RAD, V10, P1853, DOI 10.1007/s11548-015-1160-y
   Hooten KG, 2014, OPER NEUROSURG, V10, P576, DOI 10.1227/NEU.0000000000000503
   Jabbour P, 2013, NEUROSURGERY, V73, P81, DOI 10.1227/NEU.0000000000000090
   Kamel M, 2017, BRIT J NEUROSURG, V31, P724, DOI 10.1080/02688697.2017.1354123
   Kassab E, 2011, ANN SURG, V254, P1059, DOI 10.1097/SLA.0b013e318228944a
   Kerr B, 1999, AM SURGEON, V65, P1101
   Kirkman MA, 2013, J SURG EDUC, V70, P309, DOI 10.1016/j.jsurg.2012.11.011
   Leach P, 2010, NEUROSURGERY, V67, P1205, DOI 10.1227/NEU.0b013e3181ef25c5
   Lemole M, 2009, NEUROL RES, V31, P430, DOI 10.1179/174313208X353695
   Liu Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep44301
   Lobel DA, 2013, NEUROSURGERY, V73, P57, DOI 10.1227/NEU.0000000000000116
   Pham M, 2014, J NEUROL SURG PART B, V75, P309, DOI 10.1055/s-0034-1372470
   Mashiko T, 2018, WORLD NEUROSURG, V109, pE298, DOI 10.1016/j.wneu.2017.09.162
   Mashiko T, 2017, J SURG EDUC, V74, P681, DOI 10.1016/j.jsurg.2016.12.010
   Mashiko T, 2015, WORLD NEUROSURG, V83, P351, DOI 10.1016/j.wneu.2013.10.032
   Maza G, 2019, INT FORUM ALLERGY RH, V9, P53, DOI [10.1002/alr.22178, 10.1002/alr.22236]
   Mazur T, 2018, WORLD NEUROSURG, V110, P414, DOI 10.1016/j.wneu.2017.11.132
   McGaghie WC, 2014, MED EDUC, V48, P375, DOI 10.1111/medu.12391
   McGaghie WC, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000679
   MESSICK S, 1995, AM PSYCHOL, V50, P741, DOI 10.1037/0003-066X.50.9.741
   Muns A, 2014, ACTA NEUROCHIR, V156, P1237, DOI 10.1007/s00701-013-1918-3
   Muns Andrea, 2014, Surg Neurol Int, V5, P173, DOI 10.4103/2152-7806.146346
   Muto J, 2017, LARYNGOSCOPE, V127, P38, DOI 10.1002/lary.26181
   Narayanan V, 2015, EUR ARCH OTO-RHINO-L, V272, P753, DOI 10.1007/s00405-014-3300-3
   Noureldin YA, 2018, J ENDOUROL, V32, P84, DOI 10.1089/end.2017.0650
   Okonogi S, 2017, ACTA NEUROCHIR, V159, P1619, DOI 10.1007/s00701-017-3202-4
   Okuda T, 2014, ACTA NEUROCHIR, V156, P1403, DOI 10.1007/s00701-014-2035-7
   Oliveira MM, 2018, WORLD NEUROSURG, V119, pE694, DOI 10.1016/j.wneu.2018.07.246
   Oliveira MM, 2016, OPER NEUROSURG, V12, P61, DOI 10.1227/NEU.0000000000001030
   Panic N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083138
   Perin A, 2018, ACTA NEUROCHIR, V160, P2087, DOI 10.1007/s00701-018-3676-8
   Perin A, 2018, OPER NEUROSURG, V14, P572, DOI 10.1093/ons/opx144
   Ploch CC, 2016, WORLD NEUROSURG, V90, P668, DOI 10.1016/j.wneu.2016.02.081
   de Oliveira MMR, 2018, J NEUROSURG, V128, P846, DOI 10.3171/2016.10.JNS162083
   Rooney DM, 2016, SURGERY, V160, P571, DOI 10.1016/j.surg.2016.03.035
   Russin J, 2015, WORLD NEUROSURG, V83, P1057, DOI 10.1016/j.wneu.2014.12.038
   Schirmer CM, 2013, NEUROSURGERY, V73, P66, DOI 10.1227/NEU.0000000000000074
   Selden NR, 2013, J NEUROSURG, V119, P796, DOI 10.3171/2013.3.JNS122114
   Selden NR, 2012, NEUROSURGERY, V70, P971, DOI 10.1227/NEU.0b013e31823d7a45
   Shakur SF, 2015, OPER NEUROSURG, V11, P420, DOI 10.1227/NEU.0000000000000853
   Shen J, 2018, OPER NEUROSURG, V15, P231, DOI 10.1093/ons/opx262
   Singh R, 2016, WORLD NEUROSURG, V86, P259, DOI 10.1016/j.wneu.2015.09.045
   Tai BL, 2016, J NEUROSURG, V124, P811, DOI 10.3171/2015.3.JNS1552
   Tai BL, 2015, J NEUROSURG, V123, P1070, DOI 10.3171/2014.12.JNS141867
   Thawani JP, 2016, J CLIN NEUROSCI, V34, P112, DOI 10.1016/j.jocn.2016.05.036
   Vakharia VN, 2016, WORLD NEUROSURG, V88, P188, DOI 10.1016/j.wneu.2015.12.031
   Wang L, 2018, J CLIN NEUROSCI, V50, P77, DOI 10.1016/j.jocn.2018.01.074
   Wang L, 2017, WORLD NEUROSURG, V103, P671, DOI 10.1016/j.wneu.2017.04.098
   Waran V, 2015, SIMUL HEALTHC, V10, P43, DOI 10.1097/SIH.0000000000000060
   Waran V, 2014, J SURG EDUC, V71, P193, DOI 10.1016/j.jsurg.2013.08.010
   Weinstock P, 2017, J NEUROSURG-PEDIATR, V20, P1, DOI 10.3171/2017.1.PEDS16568
   Wen GD, 2016, CHILD NERV SYST, V32, P1109, DOI 10.1007/s00381-016-3051-0
   Winkler-Schwartz A, 2016, J SURG EDUC, V73, P942, DOI 10.1016/j.jsurg.2016.04.013
   Yudkowsky R, 2013, SIMUL HEALTHC, V8, P25, DOI 10.1097/SIH.0b013e3182662c69
   Zada G, 2018, OPER NEUROSURG, V14, P72, DOI 10.1093/ons/opx074
   Zheng JP, 2018, WORLD NEUROSURG, V111, pE773, DOI 10.1016/j.wneu.2017.12.169
   Zymberg S, 2010, MINIM INVAS NEUROSUR, V53, P44, DOI 10.1055/s-0029-1246169
NR 93
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E850
EP E873
DI 10.1016/j.wneu.2019.08.262
PG 24
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700155
PM 31541755
OA Bronze
DA 2020-05-12
ER

PT J
AU Patel, EA
   Aydin, A
   Cearns, M
   Dasgupta, P
   Ahmed, K
AF Patel, Ebrahim Adnan
   Aydin, Abdullatif
   Cearns, Michael
   Dasgupta, Prokar
   Ahmed, Kamran
TI A Systematic Review of Simulation-Based Training in Neurosurgery, Part
   2: Spinal and Pediatric Surgery, Neurointerventional Radiology, and
   Nontechnical Skills
SO WORLD NEUROSURGERY
LA English
DT Review
DE Education; Neurosurgery; Simulation; Training
ID VIRTUAL-REALITY; COMPUTER-SIMULATION; EDUCATIONAL-MODEL; CURRICULUM;
   VALIDITY; VALIDATION; RESIDENTS; KNOWLEDGE; SOCIETY
AB OBJECTIVE: The increasing challenges facing the training of future neurosurgeons have led to continued development of simulation-based training, particularly for neurosurgical subspecialties. The simulators must be scientifically validated to fully assess their benefit and determine their educational effects. In this second part, we aim to identify the available simulators for spine, pediatric neurosurgery, interventional neuroradiology, and nontechnical skills, assess their validity, and determine their effectiveness.
   METHODS: Both Medline and Embase were searched for English language articles that validate simulation models for neurosurgery. Each study was screened according to the Messick validity framework, and rated in each domain. The McGaghie model of translational outcomes was then used to determine a level of effectiveness for each simulator or training course.
   RESULTS: Overall, 114 articles for 108 simulation-based training models or courses were identified. These articles included 24 for spine simulators, 3 for nontechnical skills, 10 for 9 pediatric neurosurgery simulators, and 12 for 11 interventional neuroradiology simulators. Achieving the highest rating for each validity domain were 3 models for content validity; 16 for response processes; 1 for internal structure; 2 for relations to other variables; and only 1 for consequences. For translational outcomes, 2 training courses achieved a level of effectiveness of >2, showing skills transfer beyond the simulator environment.
   CONCLUSIONS: With increasing simulators, there is a need for more validity studies and attempts to investigate translational outcomes to the operating theater when using these simulators. Nontechnical skills training is notably lacking, despite demand within the field.
C1 [Patel, Ebrahim Adnan] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England.
   [Aydin, Abdullatif; Dasgupta, Prokar; Ahmed, Kamran] Kings Coll London, MRC Ctr Transplantat, London, England.
   [Cearns, Michael] Inst Neurol Sci, Dept Neurosurg, Glasgow, Lanark, Scotland.
RP Aydin, A (reprint author), Kings Coll London, MRC Ctr Transplantat, London, England.
EM abdullatif.aydin@kcl.ac.uk
OI Aydin, Abdullatif/0000-0002-5440-7741; Ahmed,
   Kamran/0000-0002-5135-9211; Cearns, Michael/0000-0002-1479-8979
CR Adermann J, 2014, EUR SPINE J, V23, P1978, DOI 10.1007/s00586-014-3257-3
   American Educational Research Association American Psychological Association and National Council on Measurement in Education, 1999, STAND ED PSYCH TEST
   Aoun SG, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2012.05.024
   Aydin A, 2016, J UROLOGY, V196, P312, DOI 10.1016/j.juro.2016.01.131
   Bailey J, 2013, J MED DEVICES, V7, DOI 10.1115/1.4024304
   Beckman TJ, 2005, J GEN INTERN MED, V20, P1159, DOI 10.1111/j.1525-1497.2005.0258.x
   Boody BS, 2018, GLOB SPINE J, V8, P557, DOI 10.1177/2192568217743505
   Boody BS, 2017, GLOB SPINE J, V7, P794, DOI 10.1177/2192568217703337
   Breimer GE, 2016, OPER NEUROSURG HAGER, V13, P1
   Breimer GE, 2015, OPER NEUROSURG HAGER, V15, P1
   Chitale R, 2013, NEUROSURGERY, V73, P107, DOI 10.1227/NEU.0000000000000091
   Ciporen J, 2016, J NEUROL SURG PART B, V77, P485, DOI 10.1055/s-0036-1584094
   Ciporen JN, 2017, WORLD NEUROSURG, V98, P388, DOI 10.1016/j.wneu.2016.11.018
   Cobb MIPH, 2016, WORLD NEUROSURG, V89, P583, DOI 10.1016/j.wneu.2015.11.068
   Coelho G, 2018, SPINE, V43, P1609, DOI 10.1097/BRS.0000000000002856
   Craven CL, 2018, J NEUROSURG-PEDIATR, V21, P329, DOI 10.3171/2017.8.PEDS17287
   Dawe SR, 2014, ANN SURG, V259, P236, DOI 10.1097/SLA.0000000000000245
   Dayal R, 2004, J VASC SURG, V40, P1112, DOI 10.1016/j.jvs.2004.09.028
   Dewan MC, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.7.FOCUS18249
   Eastwood KW, 2018, J NEUROSURG-PEDIATR, V22, P128, DOI 10.3171/2018.2.PEDS18121
   Fargen KM, 2013, NEUROSURGERY, V73, P46, DOI 10.1227/NEU.0000000000000059
   Fargen KM, 2012, J NEUROINTERV SURG, V4, P438, DOI 10.1136/neurintsurg-2011-010128
   Ferguson D, 2019, BRIT J NEUROSURG, V33, P337, DOI 10.1080/02688697.2018.1540765
   Fiorella D, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/neurintsurg-2012-010471
   Flodmark O, 2012, STROKE, V43, P2810, DOI 10.1161/STROKEAHA.112.657882
   Gasco J, 2014, NEUROL RES, V36, P968, DOI 10.1179/1743132814Y.0000000388
   Ghobrial GM, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.056
   Ghobrial GM, 2013, NEUROSURGERY, V73, P111, DOI 10.1227/NEU.0000000000000100
   Haji FA, 2013, J NEUROSURG, V118, P250, DOI 10.3171/2012.10.JNS12767
   Harrop J, 2013, NEUROSURGERY, V73, P94, DOI 10.1227/NEU.0000000000000103
   Hou Y, 2018, ARCH ORTHOP TRAUM SU, V138, P777, DOI 10.1007/s00402-018-2906-0
   Hsu JH, 2004, J VASC SURG, V40, P1118, DOI 10.1016/j.jvs.2004.08.026
   Kerr B, 1999, AM SURGEON, V65, P1101
   Khan A, 2018, WORLD NEUROSURG, V120, pE227, DOI 10.1016/j.wneu.2018.08.036
   Luciano CJ, 2013, NEUROSURGERY, V72, pA89, DOI 10.1227/NEU.0b013e3182750a8d
   Luciano CJ, 2011, NEUROSURGERY, V69, P14, DOI 10.1227/NEU.0b013e31821954ed
   Mattei TA, 2013, J NEUROSURG-PEDIATR, V12, P192, DOI 10.3171/2013.4.PEDS12540
   McGaghie WC, 2014, MED EDUC, V48, P375, DOI 10.1111/medu.12391
   McGaghie WC, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000679
   MESSICK S, 1995, AM PSYCHOL, V50, P741, DOI 10.1037/0003-066X.50.9.741
   Miranpuri AS, 2014, J NEUROINTERV SURG, V6, P561, DOI 10.1136/neurintsurg-2013-010826
   Mitha AP, 2013, NEUROSURGERY, V72, pA107, DOI 10.1227/NEU.0b013e31827981fd
   Morgan M, 2017, J SURG EDUC, V74, P698, DOI 10.1016/j.jsurg.2017.01.005
   Muir RT, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.7.FOCUS16273
   Musbahi O, 2017, J SURG EDUC, V74, P203, DOI 10.1016/j.jsurg.2016.09.007
   Nicholson William J, 2006, Simul Healthc, V1, P147, DOI 10.1097/01.SIH.0000244457.30080.fc
   Noureldin YA, 2018, J ENDOUROL, V32, P84, DOI 10.1089/end.2017.0650
   Panic N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083138
   Pannell JS, 2016, CUREUS, V8, DOI 10.7759/cureus.756
   Park HJ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0788-z
   Patel AD, 2006, J AM COLL CARDIOL, V47, P1796, DOI 10.1016/j.jacc.2005.12.053
   Patel EA, 2019, J PEDIATR SURG, V54, P1884, DOI 10.1016/j.jpedsurg.2018.11.019
   Pereira EAC, 2015, WORLD NEUROSURG, V84, P1511, DOI 10.1016/j.wneu.2015.06.066
   Podolsky DJ, 2010, J SPINAL DISORD TECH, V23, pE70, DOI 10.1097/BSD.0b013e3181d345cb
   Rambani R, 2014, J SURG EDUC, V71, P805, DOI 10.1016/j.jsurg.2014.04.012
   Ray WZ, 2013, NEUROSURGERY, V73, P100, DOI 10.1227/NEU.0000000000000088
   Regenbogen SE, 2007, ANN SURG, V246, P705, DOI 10.1097/SLA.0b013e31815865f8
   de Oliveira MMR, 2016, J NEUROSURG, V124, P1238, DOI 10.3171/2015.1.JNS141583
   Selden NR, 2013, J NEUROSURG, V119, P796, DOI 10.3171/2013.3.JNS122114
   Selden NR, 2012, NEUROSURGERY, V70, P971, DOI 10.1227/NEU.0b013e31823d7a45
   Spiotta AM, 2016, J NEUROINTERV SURG, V8, P429, DOI 10.1136/neurintsurg-2014-011546
   Spiotta AM, 2015, J NEUROINTERV SURG, V7, P777, DOI 10.1136/neurintsurg-2014-011353
   Spiotta AM, 2013, J NEUROINTERV SURG, V5, P376, DOI 10.1136/neurintsurg-2012-010319
   Sundar SJ, 2016, J NEUROSURG-SPINE, V24, P850, DOI 10.3171/2015.8.SPINE15119
   Tanner Gregory, 2017, BMC Res Notes, V10, P678, DOI 10.1186/s13104-017-3029-3
   Tomlinson JE, 2016, GLOB SPINE J, V6, P357, DOI 10.1055/s-0035-1563724
   Uramatsu M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013678
   Walker JB, 2009, NEUROSURGERY, V65, P188, DOI 10.1227/01.NEU.0000341534.82210.1B
   Weinstock P, 2017, J NEUROSURG-PEDIATR, V20, P1, DOI 10.3171/2017.1.PEDS16568
   Wucherer P, 2014, INT J COMPUT ASS RAD, V9, P785, DOI 10.1007/s11548-013-0970-z
   Xiang LB, 2015, J SPINAL DISORD TECH, V28, pE25, DOI 10.1097/BSD.0000000000000138
   Yule J, 2018, BRIT J SURG, V105, P876, DOI 10.1002/bjs.10800
   Zada G, 2018, OPER NEUROSURG, V14, P72, DOI 10.1093/ons/opx074
   Zammar SG, 2015, WORLD NEUROSURG, V84, P197, DOI 10.1016/j.wneu.2014.12.001
   Zammar Samer G, 2015, World Neurosurg, V83, P419, DOI 10.1016/j.wneu.2014.12.006
NR 75
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E874
EP E892
DI 10.1016/j.wneu.2019.08.263
PG 19
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700156
PM 31541754
OA Bronze
DA 2020-05-12
ER

PT J
AU Pedro, MT
   Eissler, A
   Scheuerle, A
   Schmidberger, J
   Kratzer, W
   Wirtz, CR
   Antoniadis, G
   Koenig, RW
AF Pedro, Maria Teresa
   Eissler, Alexandra
   Scheuerle, Angelika
   Schmidberger, Julian
   Kratzer, Wolfgang
   Wirtz, Christian R.
   Antoniadis, Gregor
   Koenig, Ralph Werner
TI Sodium Fluorescein as lntraoperative Visualization Tool During
   Peripheral Nerve Biopsies
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biopsy; Chronic inflammatory demyelinating polyneuropathy; Perineurioma;
   Sodium fluorescein
ID GUIDED RESECTION; TUMORS; PERINEURIOMA; ANGIOGRAPHY; MANAGEMENT;
   NEUROPATHY; SURGERY; GLIOMAS; BRAIN
AB OBJECTIVE: Owing to technical development of specific fluorophore filters, the neurosurgical application of sodium fluorescein (SF) has regained value in brain tumor surgery. The aim of this study was to determine the usefulness of SF during nerve biopsies.
   METHODS: This single-center study included 5 cases of nerve biopsies performed under microscope-based fluorescence with SF performed between March 2016 and February 2017. SF was applied intravenously (1 mg/kg body weight). After microsurgical dissection of the involved nerve segment, fluorescence-guided fascicular biopsy was performed. Selection of target fascicles was at the surgeon's discretion and took into account nerve stimulation for preservation of motor function and fluorescence intensity. Correlation to histopathologic examination was examined. Video analysis of intraoperative images comparing target fascicles with intense fluorescent response to adjacent fascicles of the same nerve segment was performed using ImageJ.
   RESULTS: All patients had motor or sensory deficits. Magnetic resonance imaging findings were similar, depicting long segments of gadolinium enhancement (minimum 11.7 cm). Each biopsy sample was positive resulting in diverse histopathologic results. Digital image analysis revealed a statistically significant difference of the complementary color green (P = 0.0473).
   CONCLUSIONS: Magnetic resonance imaging is the gold standard in diagnostic work-up of peripheral nerve disorders. Longitudinal nerve thickening with positive contrast enhancement is an unspecific magnetic resonance imaging finding. Various pathologies, such as tumors and inflammatory lesions, may cause this morphologic phenomenon. Nerve biopsies may be needed for diagnostic work-up. Intraoperative SF may help to depict the most affected fascicles and identify target fascicles for biopsy and increase diagnostic certainty of nerve biopsies.
C1 [Pedro, Maria Teresa; Wirtz, Christian R.; Antoniadis, Gregor; Koenig, Ralph Werner] Univ Ulm, Dept Neurosurg, Peripheral Nerve Surg Unit, Ulm, Germany.
   [Eissler, Alexandra; Schmidberger, Julian; Kratzer, Wolfgang] Univ Ulm, Dept Internal Med 1, Ulm, Germany.
   [Scheuerle, Angelika] Univ Ulm, Dept Neuropathol, Gunzburg, Germany.
RP Pedro, MT (reprint author), Univ Ulm, Dept Neurosurg, Peripheral Nerve Surg Unit, Ulm, Germany.
EM maria-teresa.pedro@uni-ulm.de
CR Acerbi Francesco, 2018, J Neurosurg Sci, DOI 10.23736/S0390-5616.18.04494-6
   Acerbi F, 2017, WORLD NEUROSURG, V108, P603, DOI 10.1016/j.wneu.2017.09.061
   Acerbi F, 2013, ACTA NEUROCHIR, V155, P1277, DOI 10.1007/s00701-013-1734-9
   Bennett Timothy J, 2016, Insight, V41, P5
   Boyanton BL, 2007, ARCH PATHOL LAB MED, V131, P1382
   Bradley LJ, 2006, NEUROMUSCULAR DISORD, V16, P126, DOI 10.1016/j.nmd.2005.11.006
   Chhabra A, 2013, AM J NEURORADIOL, V34, P802, DOI 10.3174/ajnr.A3316
   Chhabra A, 2018, EUR RADIOL, V28, P698, DOI 10.1007/s00330-017-4976-8
   de Laurentis C, 2019, J NEUROSURG SCI, V63, P679, DOI 10.23736/S0390-5616.19.04601-0
   Decard BF, 2018, CLIN NEUROPHYSIOL, V129, P155, DOI 10.1016/j.clinph.2017.10.028
   Diaz RJ, 2015, J NEUROSURG, V122, P1360, DOI 10.3171/2015.2.JNS132507
   DYCK PJ, 1975, MAYO CLIN PROC, V50, P641
   Francaviglia Natale, 2017, Surg Neurol Int, V8, P145, DOI 10.4103/sni.sni_89_17
   Gelinas D, 2019, J NEUROL SCI, V397, P84, DOI 10.1016/j.jns.2018.11.031
   Hara T, 1998, AM J OPHTHALMOL, V126, P560, DOI 10.1016/S0002-9394(98)00112-3
   Hohne J, 2019, WORLD NEUROSURG, V125, pE158, DOI 10.1016/j.wneu.2019.01.024
   IMAGINARIO JD, 1964, J NEUROL SCI, V1, P340
   Lee HY, 2009, J CLIN NEUROSCI, V16, P1633, DOI 10.1016/j.jocn.2009.02.013
   Macarenco RS, 2007, ARCH PATHOL LAB MED, V131, P625
   Mauermann ML, 2009, BRAIN, V132, P2265, DOI 10.1093/brain/awp169
   McMillan HJ, 2016, CHILD NERV SYST, V32, P1555, DOI 10.1007/s00381-016-3089-z
   MOORE GE, 1948, J NEUROSURG, V5, P392, DOI 10.3171/jns.1948.5.4.0392
   Pedro MT, 2019, WORLD NEUROSURG, V124, pE724, DOI 10.1016/j.wneu.2019.01.010
   Pedro MT, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.6.FOCUS15218
   RABB MF, 1978, SURV OPHTHALMOL, V22, P387, DOI 10.1016/0039-6257(78)90134-0
   Restrepo CE, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.6.FOCUS15225
   Rey-Dios R, 2013, ACTA NEUROCHIR, V155, P701, DOI 10.1007/s00701-013-1635-y
   Schebesch KM, 2018, CLIN NEUROL NEUROSUR, V172, P177, DOI 10.1016/j.clineuro.2018.07.011
   Schebesch KM, 2016, TURK NEUROSURG, V26, P185, DOI 10.5137/1019-5149.JTN.16952-16.0
   Schebesch KM, 2015, ACTA NEUROCHIR, V157, P899, DOI 10.1007/s00701-015-2395-7
   Scheller C, 2008, ZBL NEUROCHIR, V69, P134, DOI 10.1055/s-2008-1077081
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sommer C, 2018, CURR OPIN NEUROL, V31, P534, DOI 10.1097/WCO.0000000000000601
   Vallat JM, 2010, LANCET NEUROL, V9, P402, DOI 10.1016/S1474-4422(10)70041-7
   Van den Bergh PYK, 2010, EUR J NEUROL, V17, P356, DOI 10.1111/j.1468-1331.2009.02930.x
   Wilson TJ, 2019, NEUROSURGERY, V85, P786, DOI 10.1093/neuros/nyy476
   Wilson TJ, 2018, J NEUROSURG, V129, P1034, DOI 10.3171/2017.5.JNS17905
NR 37
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E513
EP E521
DI 10.1016/j.wneu.2019.09.081
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700111
PM 31550541
OA Bronze
DA 2020-05-12
ER

PT J
AU Pennington, Z
   Mehta, VA
   Lubelski, D
   Elliott, C
   Miller, JA
   Benzel, EC
   Mroz, TE
AF Pennington, Zach
   Mehta, Vikram A.
   Lubelski, Daniel
   Elliott, Charles
   Miller, Jacob A.
   Benzel, Edward C.
   Mroz, Thomas E.
TI Quality of Life and Cost Implications of Pseudarthrosis After Anterior
   Cervical Discectomy and Fusion and its Subsequent Revision Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical decompression and fusion; EQ-5D; Patient-reported
   outcomes; Postoperative complications; Pseudarthrosis; Revision surgery
ID OUTCOMES; DISABILITY; PAIN
AB BACKGROUND: More than 120,000 anterior cervical discectomy and fusions (ACDFs) are performed annually. Pseudarthrosis is a potential delayed adverse event that affects up to 33% of patients. The degree to which this adverse event affects both patient quality-of-life (QOL) outcomes and health care costs is poorly understood.
   METHODS: Patients who underwent revision surgery for pseudarthrosis between 2007 and 2012 were identified and matched to controls not experiencing pseudarthrosis in a 1:2 fashion (case/control). Cases and controls were compared regarding total health care costs incurred in the year after the index ACDF and QOL outcomes on the following metrics: EuroQol Five-Dimensions Questionnaire, Patient Health Questionnaire-9, and Pain Disability Questionnaire.
   RESULTS: Of 738 patients who underwent ACDF, 11 underwent surgery for pseudarthrosis. No differences were noted between cases and controls regarding any of the matched variables. Patients in the pseudarthrosis cohort had poorer postoperative scores on the EuroQol Five-Dimensions Questionnaire mobility, usual activities, pain/ discomfort, and quality-adjusted life-year dimensions. In addition, 64% of patients with pseudarthrosis had worsened quality-adjusted life-year scores compared with only 9% of controls (P < 0.01). Patients with pseudarthrosis also had poorer mental health (P < 0.01) and pain disability outcomes (P < 0.01) than did controls. Pseudarthrosis was associated with significant increases in direct costs, direct postoperative costs, and total costs (all P < 0.01).
   CONCLUSIONS: This is the first study to characterize the effect of surgical revision for pseudarthrosis on both QOL outcomes and care costs after ACDF. Patients requiring revision experienced significantly poorer QOL outcomes and higher care costs relative to controls.
C1 [Pennington, Zach; Lubelski, Daniel] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Mehta, Vikram A.] Duke Univ, Sch Med, Dept Neurosurg, Durham, NC USA.
   [Elliott, Charles] Univ Arizona, Dept Emergency Med, Tucson, AZ USA.
   [Miller, Jacob A.] Stanford Hosp, Dept Radiat Oncol, Palo Alto, CA USA.
   [Benzel, Edward C.; Mroz, Thomas E.] Cleveland Clin, Cleveland Clin Ctr Spine Hlth, Cleveland, OH 44106 USA.
   [Benzel, Edward C.; Mroz, Thomas E.] Cleveland Clin, Dept Neurol Surg, Cleveland, OH 44106 USA.
   [Benzel, Edward C.; Mroz, Thomas E.] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
RP Mroz, TE (reprint author), Cleveland Clin, Cleveland Clin Ctr Spine Hlth, Cleveland, OH 44106 USA.; Mroz, TE (reprint author), Cleveland Clin, Dept Neurol Surg, Cleveland, OH 44106 USA.; Mroz, TE (reprint author), Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
EM mrozt@ccf.org
OI Mehta, Vikram/0000-0002-4561-5020; Pennington,
   Zachary/0000-0001-8012-860X
CR Anagnostis C, 2004, SPINE, V29, P2290, DOI 10.1097/01.brs.0000142221.88111.0f
   Andresen AK, 2018, GLOB SPINE J, V8, P703, DOI 10.1177/2192568218765398
   [Anonymous], 2007, RED BOOK PHARM FUND
   Buttermann GR, 2018, SPINE, V43, P207, DOI 10.1097/BRS.0000000000002273
   Centers for Medicare & Medicaid Services, 2019, PHYS FEE SCHEDULE
   Chotai S, 2018, NEUROSURGERY, V83, P898, DOI 10.1093/neuros/nyy140
   Craig BM, 2018, MED CARE, V56, P529, DOI 10.1097/MLR.0000000000000912
   Etminan M, 2002, ORTHOP CLIN N AM, V33, P381, DOI 10.1016/S0030-5898(02)00005-6
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Kalakoti P, 2019, SPINE, V44, P334, DOI 10.1097/BRS.0000000000002825
   Kim JS, 2018, SPINE, V43, P1543, DOI 10.1097/BRS.0000000000002665
   Krawzik K, 2019, DRG EXPERTE, V1
   Krawzik K, 2019, DRG EXPERTE, V2
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lee DH, 2018, SPINE, V43, pE23, DOI 10.1097/BRS.0000000000002077
   Liow MHL, 2018, SPINE, V43, P477, DOI 10.1097/BRS.0000000000002395
   Martin Christopher T, 2018, Iowa Orthop J, V38, P167
   McAnany SJ, 2018, GLOB SPINE J, V8, P32, DOI 10.1177/2192568217726283
   Merrill RK, 2018, SPINE, V43, P610, DOI 10.1097/BRS.0000000000002380
   Nandyala SV, 2014, SPINE J, V14, P2841, DOI 10.1016/j.spinee.2014.03.037
   Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158
   Parker Scott L, 2015, Neurosurgery, V76 Suppl 1, pS64, DOI 10.1227/01.neu.0000462079.96571.dc
   Parker SL, 2011, J NEUROSURG-SPINE, V14, P598, DOI 10.3171/2010.12.SPINE10472
   Peters M, 2015, EUR J NUCL MED MOL I, V42, P1891, DOI 10.1007/s00259-015-3154-y
   Phillips FM, 1997, SPINE, V22, P1585, DOI 10.1097/00007632-199707150-00012
   Saifi C, 2018, SPINE J, V18, P1022, DOI 10.1016/j.spinee.2017.10.072
   Schroeder GD, 2018, SPINE, V43, pE752, DOI 10.1097/BRS.0000000000002511
   Shriver MF, 2015, SPINE J, V15, P2016, DOI 10.1016/j.spinee.2015.05.010
   Somani S, 2017, SPINE, V42, P565, DOI 10.1097/BRS.0000000000001850
   Veeravagu A, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.3.FOCUS1669
NR 30
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E592
EP E599
DI 10.1016/j.wneu.2019.09.104
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700121
PM 31568900
OA Bronze
DA 2020-05-12
ER

PT J
AU Pfister, G
   Ghabi, A
   de Carbonnieres, A
   Oberlin, C
   Belkheyar, Z
   Mathieu, L
AF Pfister, Georges
   Ghabi, Ammar
   de Carbonnieres, Anne
   Oberlin, Christophe
   Belkheyar, Zoubir
   Mathieu, Laurent
TI Direct Suturing of Sciatic Nerve Defects in High-degree Knee Flexion: An
   Experimental Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Knee flexion; Nerve defect; Nerve repair; Sciatic nerve
ID INJURIES; MANAGEMENT; REPAIR
AB OBJECTIVE: We sought to elucidate the conditions of direct suturing of sciatic nerve defects in high-degree knee flexion. We aimed to establish a correlation among the defect length, defect location, degree of knee flexion, and eventual need for hip immobilization in extension.
   METHODS: We performed an experimental study by completing bilateral dissection of the sciatic nerve in 6 cadavers. Three groups of lesions were identified: at the buttock (BG), in the thigh (TG), and in the popliteal fossa (PG). For each defect, a direct, tensionless suture was performed with minimal knee flexion. Next, the hip was progressively flexed until rupture. The nerve defect length correlated with the degree of knee flexion and hip extension required to perform and protect the installed sutures.
   RESULTS: A 30 degrees knee flexion allowed for direct suturing of defects >2 cm in the 3 groups. The largest suturable nerve defects measured 7 cm in the TG and PG and 6 cm in the BG. When considering the same-size defects, the required knee flexion tended to be significantly greater in the BG. A bowstringing effect was noted at the buttock and popliteal levels. Hip flexion placed tension on the nerve suture at all locations.
   CONCLUSIONS: The middle third of the thigh was the most compliant level, because the largest defects will be suturable without a visible bowstringing effect. Hip immobilization should be considered as soon as the defect has exceeded 2 cm, regardless of the location.
C1 [Pfister, Georges; Ghabi, Ammar; de Carbonnieres, Anne; Mathieu, Laurent] Percy Mil Hosp, Clin Orthoped Trauma & Reconstruct Surg, Clamart, France.
   [Oberlin, Christophe; Belkheyar, Zoubir] Mt Louis Private Hosp, Brachial Plexus & Peripheral Nerve Surg Unit, Paris, France.
   [Mathieu, Laurent] Ecole Val de Grace, French Mil Hlth Serv Acad, Paris, France.
RP Mathieu, L (reprint author), Percy Mil Hosp, Clin Orthoped Trauma & Reconstruct Surg, Clamart, France.; Mathieu, L (reprint author), Ecole Val de Grace, French Mil Hlth Serv Acad, Paris, France.
EM laurent_tom2@yahoo.fr
CR Abdou-Al-Shaar H, 2018, NEUROSURG FOCUS S1, V44, P3
   Birch R, 2012, J BONE JOINT SURG BR, V94B, P523, DOI 10.1302/0301-620X.94B4.28483
   Bourrel P, 1966, Ann Chir, V20, P1145
   BOURREL P, 1965, Mars Chir, V17, P203
   Burks SS, 2014, J NEUROSURG, V121, P210, DOI 10.3171/2014.2.JNS131667
   Choufani C, 2017, INT ORTHOP, V41, P1771, DOI 10.1007/s00264-017-3439-9
   Doring R, 2012, J SURG CASE REP, V11, P2012
   Gousheh J, 2008, PLAST RECONSTR SURG, V121, P878, DOI 10.1097/01.prs.0000299286.67932.88
   Jones PE, 2018, MIL MED, V183, pE434, DOI 10.1093/milmed/usy030
   Kim DH, 2004, J NEUROSURG, V101, P8, DOI 10.3171/jns.2004.101.1.0008
   Mathieu L, 2019, MIL MED, V184, pE939, DOI 10.1093/milmed/usz087
   Oberlin C, 2011, CHIR MAIN, V30, P176, DOI 10.1016/j.main.2011.04.010
   Roganovic Z, 2005, NEUROSURGERY, V57, P1201, DOI 10.1227/01.NEU.0000186035.58798.BF
   Samardzic MM, 1999, INJURY, V30, P15, DOI 10.1016/S0020-1383(98)00188-0
   Taha A, 1998, J TRAUMA, V45, P340, DOI 10.1097/00005373-199808000-00022
NR 15
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E288
EP E292
DI 10.1016/j.wneu.2019.08.258
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700082
PM 31518736
OA Bronze
DA 2020-05-12
ER

PT J
AU Qi, QH
   Huang, S
   Ling, ZM
   Chen, Y
   Hu, H
   Zhan, P
   Zhang, B
   Zou, XN
   Peng, XS
AF Qi, Qihua
   Huang, Sheng
   Ling, Zemin
   Chen, Yan
   Hu, Hao
   Zhan, Ping
   Zhang, Bin
   Zou, Xuenong
   Peng, Xinsheng
TI A New Diagnostic Medium for Cervical Spondylotic Myelopathy: Dynamic
   Somatosensory Evoked Potentials
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spondylotic myelopathy (CSM); Dynamic somatosensory evoked
   potential (DSSEP); Latency and amplitude; Neurophysiological assessment
ID AMYOTROPHIC-LATERAL-SCLEROSIS; SPINAL-CORD; NERVE-STIMULATION;
   COMPRESSION; ULNAR; PATHOPHYSIOLOGY; CLASSIFICATION; DYSFUNCTION
AB OBJECTIVE: To identify and reveal the sensitivity and efficiency of dynamic somatosensory evoked potentials (DSSEPs) in the diagnosis of cervical spondylotic myelopathy (CSM).
   METHODS: This retrospective study included 31 CSM and 15 control patients. All patients received SSEP examination with stimulation of median and ulnar nerves at neutral, flexed, and extended cervical positions; latency and amplitude were recorded at the C-2 and C-5 spinous processes and in the scalp over the primary sensory area (C-3'(/4')). The percentage changes in latency and amplitude with dynamic motion were examined for each lead and compared between groups; the diagnostic cutoff values were determined using receiver operating characteristic curve analysis.
   RESULTS: All the patients with CSM received surgeries and were followed up for 1 year. Amplitude parameters varied with a dynamic position in both groups; all recorded dynamic SSEP indices except right median stimulus recorded at C5 spinous process, right ulnar stimulus recorded at scalp point C3, and right ulnar stimulus recorded at C2 spinous process were significantly different between groups (P< 0.05), but latency was not (P> 0.05). At the neutral position, the amplitude of left media stimulus recorded at C2 spinous process (LMC2) was associated with CSM, but with low diagnostic accuracy (area tinder the curve = 0.199). At a dynamic position, the percentage change in amplitude of LMC2 and of left ulnar stimulus recorded at C2 spinous process (LUC2) were determined to be diagnostic of CSM (P < 0.05), with areas under the curve of 0.891 and 0.912, respectively. Both records had high sensitivity and specificity in the diagnosis of CSM; the diagnostic cutoff values of LMC2 and LUC2 were calculated as 10.2% and 19.25%, respectively.
   CONCLUSIONS: The percentage change in amplitude was obvious during cervical dynamic motion, with records from LMC2 and LUC2 being predictive of CSM diagnosis; dynamic SSEPs provided a simple, accurate, and noninvasive supplementary test for the diagnosis of complicated CSM.
C1 [Qi, Qihua; Huang, Sheng; Zhan, Ping; Zhang, Bin] Nanchang Univ, Dept Orthoped, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Ling, Zemin; Chen, Yan; Hu, Hao; Zou, Xuenong; Peng, Xinsheng] Sun Yat Sen Univ, Orthoped Res Inst, Dept Spine Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Ling, Zemin; Chen, Yan; Hu, Hao; Zou, Xuenong] Sun Yat Sen Univ, Guangdong Prov Key Lab Orthopaed & Traumatol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
RP Peng, XS (reprint author), Sun Yat Sen Univ, Orthoped Res Inst, Dept Spine Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
EM pengxs66@yahoo.com
RI peng, Xinsheng/Q-9115-2019
CR BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008
   Deftereos SN, 2009, FUNCT NEUROL, V24, P99
   Fang J, 2016, CHINESE MED J-PEKING, V129, P792, DOI 10.4103/0366-6999.178953
   Jutzeler CR, 2017, J NEUROTRAUM, V34, P2045, DOI 10.1089/neu.2016.4891
   Kaneko K, 2004, SPINE, V29, pE185, DOI 10.1097/00007632-200405010-00022
   Karadimas SK, 2013, SPINE, V38, pS21, DOI 10.1097/BRS.0b013e3182a7f2c3
   Kolcun JP, 2017, ASIAN SPINE J, V11, P1008, DOI 10.4184/asj.2017.11.6.1008
   Liu MS, 2013, MUSCLE NERVE, V48, P137, DOI 10.1002/mus.23767
   Lo YL, 2008, EUR J NEUROL, V15, P781, DOI 10.1111/j.1468-1331.2008.02199.x
   Michelini Giulia, 2018, Acta Biomed, V89, P89, DOI 10.23750/abm.v89i1-S.7012
   Morishita Y, 2013, J NEUROSURG-SPINE, V19, P288, DOI 10.3171/2013.5.SPINE12933
   Muhle C, 1998, INVEST RADIOL, V33, P444, DOI 10.1097/00004424-199808000-00004
   Muhle C, 1998, AM J NEURORADIOL, V19, P1763
   OGINO H, 1983, SPINE, V8, P1, DOI 10.1097/00007632-198301000-00001
   Park MK, 2018, EUR SPINE J, V27, pS330, DOI 10.1007/s00586-017-5236-y
   Qi QH, 2016, WORLD NEUROSURG, V93, P144, DOI 10.1016/j.wneu.2016.06.011
   RESTUCCIA D, 1992, Electromyography and Clinical Neurophysiology, V32, P389
   RESTUCCIA D, 1992, NEUROLOGY, V42, P1054, DOI 10.1212/WNL.42.5.1054
   RESTUCCIA D, 1994, J NEUROL NEUROSUR PS, V57, P301, DOI 10.1136/jnnp.57.3.301
   Stoffman MR, 2005, NEUROSURGERY, V57, P307, DOI 10.1227/01.NEU.0000166664.19662.43
   Tani T, 1999, J NEUROL NEUROSUR PS, V66, P456, DOI 10.1136/jnnp.66.4.456
   Ueta E, 1998, J SPINAL DISORD, V11, P514
   Ulrich A, 2013, NEUROLOGY, V80, P1393, DOI 10.1212/WNL.0b013e31828c2ed1
   VEILLEUX M, 1987, ELECTROEN CLIN NEURO, V68, P415, DOI 10.1016/0168-5597(87)90053-0
   Wang K, 2017, SPINE, V42, pE202, DOI 10.1097/BRS.0000000000001784
   Young WF, 2000, AM FAM PHYSICIAN, V62, P1064
   YU YL, 1985, BRAIN, V108, P273, DOI 10.1093/brain/108.2.273
   Yukawa Y, 2007, SPINE, V32, P1675, DOI 10.1097/BRS.0b013e318074d62e
   Zheng CJ, 2017, EUR SPINE J, V26, P1929, DOI 10.1007/s00586-017-5060-4
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E225
EP E232
DI 10.1016/j.wneu.2019.08.205
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700029
PM 31493599
OA Bronze
DA 2020-05-12
ER

PT J
AU Qiao, GX
   Feng, M
   Wang, XD
   Liu, J
   Ge, M
   Yang, B
   Yue, B
AF Qiao, Guangxi
   Feng, Min
   Wang, Xiaodong
   Liu, Jian
   Ge, Miao
   Yang, Bin
   Yue, Bin
TI Revision for Endoscopic Diskectomy: Is Lateral Lumbar Interbody Fusion
   an Option?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic diskectomy; Lateral lumbar interbody fusion (LLIF); ODI
   score; Revision surgery; TLIF; VAS score
ID RECURRENT HERNIATION; DISC HERNIATION; SURGERY
AB OBJECTIVE: This study aims to report the clinical outcome of stand-alone lateral lumbar interbody fusion (LLIF) on recurrent disk herniation and to compare the outcome of stand-alone LLIF to that of conventional transforaminal lumbar interbody fusion (TLIF).
   METHODS: A retrospective study of 47 patients with recurrent disk herniation was included from January 2008 to October 2016. The inclusion criteria were 1) with recurrent disk herniation that needs revision surgery, 2) with only 1 previous percutaneous endoscopic lumbar diskectomy surgery, 3) underwent 1-level stand-alone LLIF or 1-level TLIF surgery, and 4) with follow-up more than 1 year. Patients were asked to complete the following questionnaires for outcome evaluation: visual analog scales (VAS) for both low back pain and leg pain, the Oswestry Disability Index (ODI), and the 12-item Short-Form Health Survey.
   RESULTS: Eighteen patients underwent stand-alone LLIF, and 29 patients underwent TLIF surgery. Radiographic analysis revealed a similar baseline and postoperative lumbar lordosis in both the LLIF and TLIF groups. Two weeks after surgery, the ODI and VAS scores showed a significant decrease in both groups. The TLIF group showed significantly larger postoperative VAS back pain after surgery (P = 0.03). For both VAS leg pain and ODI score during follow-up, no significance difference was found between the LLIF and TLIF groups.
   CONCLUSIONS: Stand-alone LLIF is a safe and effective approach with low morbidity and acceptable complication rates for patients with recurrent disk herniation after a previous percutaneous endoscopic lumbar diskectomy surgery. Compared with the TLIF procedure, LLIF could achieve a similar improvement of patient-reported outcome with a better VAS back pain score.
C1 [Qiao, Guangxi] Qingdao Univ, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
   [Feng, Min] Binzhou Med Univ Hosp, Binzhou, Peoples R China.
   [Wang, Xiaodong] Peoples Hosp Qingdao, West Coast Dist, Peoples R China.
   [Liu, Jian] Eighth Peoples Hosp Qingdao, Qingdao, Shandong, Peoples R China.
   [Ge, Miao; Yang, Bin; Yue, Bin] Qingdao Univ, Dept Bone Tumor, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
RP Yue, B (reprint author), Qingdao Univ, Dept Bone Tumor, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
EM qdfyyb@sina.com
CR Campbell PG, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.10.FOCUS17566
   Castro C, 2014, CLIN ORTHOP RELAT R, V472, P1776, DOI 10.1007/s11999-013-3263-5
   Cheng JW, 2013, INT ORTHOP, V37, P1511, DOI 10.1007/s00264-013-1925-2
   Deutsch H, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1060
   Glassman Steven, 2006, Spine J, V6, P21, DOI 10.1016/j.spinee.2005.09.004
   Kim JM, 2007, MINIM INVAS NEUROSUR, V50, P82, DOI 10.1055/s-2007-982504
   Louie PK, 2018, SPINE J, V18, P2025, DOI 10.1016/j.spinee.2018.04.008
   Matsumoto M, 2013, J NEUROL SURG PART A, V74, P222, DOI 10.1055/s-0032-1320031
   McGirt MJ, 2009, NEUROSURGERY, V64, P338, DOI 10.1227/01.NEU.0000337574.58662.E2
   Osterman H, 2003, SPINE, V28, P621, DOI 10.1097/00007632-200303150-00019
   Park HY, 2018, SPINE, V43, pE813, DOI 10.1097/BRS.0000000000002507
   Phillips FM, 2013, SPINE, V38, P1853, DOI 10.1097/BRS.0b013e3182a43f0b
   Rodgers WB, 2011, SPINE, V36, P26, DOI 10.1097/BRS.0b013e3181e1040a
   Teli M, 2010, EUR SPINE J, V19, P443, DOI 10.1007/s00586-010-1290-4
   Yao Y, 2017, WORLD NEUROSURG, V100, P641, DOI 10.1016/j.wneu.2017.01.089
   Yao Y, 2017, WORLD NEUROSURG, V99, P89, DOI 10.1016/j.wneu.2016.11.120
   Youssef JA, 2010, SPINE, V35, pS302, DOI 10.1097/BRS.0b013e3182023438
NR 17
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E26
EP E30
DI 10.1016/j.wneu.2019.07.226
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700006
PM 31398523
OA Bronze
DA 2020-05-12
ER

PT J
AU Reed, SW
   Cools, MJ
   Quinsey, CS
   Elton, SW
AF Reed, Samuel W.
   Cools, Michael J.
   Quinsey, Carolyn S.
   Elton, Scott W.
TI Neonatal Hydrocephalus Treatment with Ultrasmall Valve Implantation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Ultra-small valve; Ventriculoperitoneal shunt
ID CEREBROSPINAL-FLUID SHUNT; COMPLICATIONS; INFECTION; PLACEMENT;
   OUTCOMES; DESIGN; UGANDA; RISK
AB OBJECTIVE: Neonatal hydrocephalus remains a difficult condition to manage, due to high failure rates among all management strategies. Neurosurgeons commonly manage hydrocephalus with ventriculoperitoneal shunt (VPS) implantation, and valves of variable sizes and profiles are available for implantation. This study examines primary ventricular shunt valve implantation complication rates based on valve profiles in pediatric patients with hydrocephalus.
   METHODS: This study retrospectively reviews pediatric patients younger than 1 year of age who underwent ventricular shunt placement at a single institution from January 2001 to January 2017. Patients were classified by valve profile and categorized as either ultrasmall valves or regular-sized valves. Time until complication and type of complication were studied.
   RESULTS: A total of 156 patients met the inclusion criteria. Forty-eight (31%) patients received an ultrasmall shunt valve, while 108 patients received a regular valve. On average, patients undergoing ultrasmall valve placement were younger (2.1 months) than patients undergoing placement of regular valves (3.1 months) (P = 0.03). The overall complication rate within 2 years of VPS placement was 37.5% in patients with the ultrasmall valve and 41.7% in the regular valve population. There was no difference in 1-year shunt survival rate between the 2 cohorts.
   CONCLUSION: Our review did not find a significant difference in complication rates between ultrasmall and regular valves in patients under 1 year of age. However, the etiology of shunt malfunction did differ between the groups. This work further supports evidence suggesting a surgeon's preference for shunt hardware alone does not significantly impact outcome.
C1 [Reed, Samuel W.; Cools, Michael J.; Quinsey, Carolyn S.; Elton, Scott W.] Univ N Carolina, Dept Neurosurg, Chapel Hill, NC 27515 USA.
RP Reed, SW (reprint author), Univ N Carolina, Dept Neurosurg, Chapel Hill, NC 27515 USA.
EM sam_reed@med.unc.edu
CR AMACHER AL, 1984, CHILD BRAIN, V11, P217
   AMMAR A, 1995, NEUROSURG REV, V18, P65, DOI 10.1007/BF00416481
   Baird LC, 2014, J NEUROSURG-PEDIATR, V14, P35, DOI 10.3171/2014.7.PEDS14325
   BORGBJERG BM, 1995, ACTA NEUROCHIR, V136, P1, DOI 10.1007/BF01411427
   Bot GM, 2014, CHILD NERV SYST, V30, P1431, DOI 10.1007/s00381-014-2433-4
   Cochrane DD, 2003, PEDIATR NEUROSURG, V38, P295, DOI 10.1159/000070413
   DIROCCO C, 1994, CHILD NERV SYST, V10, P321, DOI 10.1007/BF00335171
   Drake JM, 1998, NEUROSURGERY, V43, P294, DOI 10.1097/00006123-199808000-00068
   Hoshide Reid, 2017, Surg Neurol Int, V8, P49, DOI 10.4103/sni.sni_11_17
   Kahilogullari G, 2018, TURK NEUROSURG, V28, P303, DOI 10.5137/1019-5149.JTN.18547-16.1
   Kestle J, 2000, PEDIATR NEUROSURG, V33, P230, DOI 10.1159/000055960
   Maruyama H, 2015, ACTA MED OKAYAMA, V69, P87
   Pollack IF, 1999, NEUROSURGERY, V45, P1399, DOI 10.1097/00006123-199912000-00026
   Radmanesh F, 2009, J NEUROSURG-PEDIATR, V3, P516, DOI 10.3171/2009.2.PEDS08476
   Robinson S, 2002, PEDIATR NEUROSURG, V37, P287, DOI 10.1159/000066307
   Sinha Arvind, 2012, J Indian Assoc Pediatr Surg, V17, P54, DOI 10.4103/0971-9261.93962
   Vinchon M, 2006, CHILD NERV SYST, V22, P692, DOI 10.1007/s00381-005-0037-8
   Warf BC, 2005, J NEUROSURG, V102, P358, DOI 10.3171/ped.2005.102.4.0358
   Warf BC, 2010, J NEUROSURG-PEDIATR, V5, P143, DOI 10.3171/2009.9.PEDS09196
   Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E397
EP E400
DI 10.1016/j.wneu.2019.09.043
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700095
PM 31526889
OA Bronze
DA 2020-05-12
ER

PT J
AU Rinaldo, L
   Nesvick, CL
   Rabinstein, AA
   Lanzino, G
AF Rinaldo, Lorenzo
   Nesvick, Cody L.
   Rabinstein, Alejandro A.
   Lanzino, Giuseppe
TI Differences in Size Between Unruptured and Ruptured Saccular
   Intracranial Aneurysms by Location
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior communicating artery; Intracranial aneurysm; Risk factor; Size;
   Subarachnoid hemorrhage
ID CEREBRAL ANEURYSM; NATURAL-HISTORY; RISK
AB OBJECTIVE: It is generally accepted that larger saccular intracranial aneurysms are at greater risk to rupture. We investigated whether aneurysm location influences the effect of aneurysm size on the propensity of rupture.
   METHODS: We reviewed patient and aneurysm characteristics in a consecutive series of patients with unruptured and ruptured aneurysms presenting to our institution between 2006 and 2018. Differences between unruptured and ruptured aneurysms at different locations were subsequently investigated.
   RESULTS: A total of 766 aneurysms in 568 patients were included, with 355 and 411 unruptured and ruptured aneurysms, respectively. There were significant differences in the distribution of aneurysm location between unruptured and ruptured aneurysms (P < 0.001). The most common locations of unruptured aneurysms were the middle cerebral artery (MCA) (27.6%) and paraclinoid internal carotid artery (ICA) (25.4%), whereas the most common locations of ruptured aneurysms were the anterior communicating artery (ACOM) (34.8%) and posterior communicating artery (17.8%). Ruptured aneurysms were larger than unruptured aneurysms at all locations except at the ACOM, where there was no difference in size between unruptured and ruptured aneurysms (5.4 vs. 5.8 mm, respectively; P = 0.40). Ruptured ACOM aneurysms were also smaller than ruptured aneurysms of the paraclinoid ICA (5.8 vs. 10.3 mm; P < 0.001), MCA (5.8 vs. 8.0 mm; P = 0.021), and basilar apex (5.8 vs. 10.5 mm; P < 0.001), respectively.
   CONCLUSIONS: We observed no difference in size between unruptured and ruptured ACOM aneurysms, possibly suggesting a greater susceptibility for ACOM aneurysms to rupture at smaller sizes.
C1 [Rinaldo, Lorenzo; Nesvick, Cody L.; Lanzino, Giuseppe] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
   [Rabinstein, Alejandro A.] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Lanzino, Giuseppe] Mayo Clin, Dept Radiol, Rochester, MN USA.
RP Rinaldo, L (reprint author), Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
EM Rinaldo.Lorenzo@mayo.edu
CR Bijlenga P, 2013, STROKE, V44, P3018, DOI 10.1161/STROKEAHA.113.001667
   Froelich JJ, 2016, WORLD NEUROSURG, V91, P260, DOI 10.1016/j.wneu.2016.04.044
   Guresir E, 2013, STROKE, V44, P3027, DOI 10.1161/STROKEAHA.113.001107
   Ishibashi T, 2009, STROKE, V40, P313, DOI 10.1161/STROKEAHA.108.521674
   Juvela S, 2013, STROKE, V44, P2414, DOI 10.1161/STROKEAHA.113.001838
   Kang H, 2015, PLOS ONE, V10
   Mitchell P, 2000, J NEUROL NEUROSUR PS, V69, P760, DOI 10.1136/jnnp.69.6.760
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Murayama Y, 2016, STROKE, V47, P365, DOI 10.1161/STROKEAHA.115.010698
   Okamoto K, 2003, STROKE, V34, P422, DOI 10.1161/01.STR.0000053851.17964.C6
   Rahman M, 2011, NEUROSURGERY, V68, P155, DOI 10.1227/NEU.0b013e3181ff357c
   Rinaldo L, 2017, J NEUROSURG, V127, P89, DOI 10.3171/2016.7.JNS16736
   Sato K, 2011, STROKE, V42, P3376, DOI 10.1161/STROKEAHA.111.625871
   Schneiders JJ, 2014, AM J NEURORADIOL, V35, P1358, DOI 10.3174/ajnr.A3866
   Sonobe M, 2010, STROKE, V41, P1969, DOI 10.1161/STROKEAHA.110.585059
   Takao H, 2012, STROKE, V43, P1436, DOI 10.1161/STROKEAHA.111.640995
   Varble N, 2017, AM J NEURORADIOL, V38, P2105, DOI 10.3174/ajnr.A5341
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Yi J, 2016, J STROKE CEREBROVASC, V25, P1244, DOI 10.1016/j.jstrokecerebrovasdis.2016.01.031
NR 19
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E828
EP E834
DI 10.1016/j.wneu.2019.10.027
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700152
PM 31622680
OA Bronze
DA 2020-05-12
ER

PT J
AU Rubio, RR
   Gandhi, S
   Vigo, V
   Tabani, H
   Meybodi, AT
   Abla, AA
   Lawton, MT
   Benet, A
AF Rubio, Roberto Rodriguez
   Gandhi, Sirin
   Vigo, Vera
   Tabani, Halima
   Meybodi, Ali Tayebi
   Abla, Adib A.
   Lawton, Michael T.
   Benet, Arnau
TI An Anatomic Feasibility Study for Revascularization of the Ophthalmic
   Artery, Part I: Intracanalicular Segment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior clinoidectomy; Anterior temporal artery;
   Extracranial-intracranial bypass; Intracanalicular;
   Intracranial-intracranial bypass; Ophthalmic artery; Superficial
   temporal artery
ID ANTERIOR TEMPORAL ARTERY; ENDOVASCULAR TREATMENT; PARACLINOID ANEURYSMS;
   FLOW DIVERSION; MANAGEMENT; DONOR; OCCLUSION; OUTCOMES; BYPASS; GIANT
AB BACKGROUND: The anatomico-functional complexity of the ophthalmic segment aneurysms is attributable to the presence of critical neurovascular structures in the surgical field. Surgical clipping of the ophthalmic artery (OpA) aneurysms can result in postoperative visual deficit due to the complexity of the aneurysm, vasospasm, or optic nerve manipulation. In this study, we aimed to characterize the feasibility of an intracanalicular OpA (iOpA) revascularization with 2 donor vessels: an intracranial-intracranial (IC-IC) bypass using the anterior temporal artery (ATA) and an extracranial-intracranial (EC-IC) bypass using the superficial temporal artery (STA). We further discuss their potential role in "unclippable" OpA aneurysms.
   METHODS: Twenty cadaveric specimens were used to evaluate the operative exposure of the intradural and intracanalicular OpA segments using an extradural-intradural intracanalicular approach. The arterial caliber and length at the anastomotic sites and required donor artery lengths were measured. The feasibility of the bypass using both donors was assessed.
   RESULTS: The average length of the intradural and intracanalicular segment of the OpA was 9.5 +/- 1.6 mm. The mean caliber of the iOpA was 1.5 +/- 0.2 mm. The mean ATA length required for an ATA-OpA anastomosis was 26.7 +/- 8.9 mm, with a mean caliber of 1.0 +/- 0.1 nint The mean length of STA required for the bypass was 89.9 +/- 9.7 mm, with a mean caliber of 1.92 +/- 0.4 mm.
   CONCLUSIONS: This study confirms the feasibility of iOpA revascularization using IC-IC and EC-IC bypasses. These techniques could potentially be used for prophylactic or therapeutic neuroprotection from retinal ischemic injury while treating complex OpA aneurysms, infiltrative tumors, or intraoperative arterial injuries.
C1 [Rubio, Roberto Rodriguez; Abla, Adib A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez; Vigo, Vera; Abla, Adib A.] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Gandhi, Sirin; Tabani, Halima; Meybodi, Ali Tayebi; Lawton, Michael T.; Benet, Arnau] Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
RP Rubio, RR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
EM neurodriguez@gmail.com
OI Rodriguez-Rubio, Roberto/0000-0002-7206-309X
CR Arnautovic KI, 1998, SURG NEUROL, V50, P504, DOI 10.1016/S0090-3019(97)80415-6
   Arthur A, 2014, INDIAN J OPHTHALMOL, V62, P472, DOI 10.4103/0301-4738.121183
   Benet A, 2014, J NEUROSURG, V120, P1229, DOI 10.3171/2014.1.JNS131857
   Brown BL, 2016, J NEUROSURG, V124, P1107, DOI 10.3171/2015.4.JNS142790
   Burrows AM, 2016, AM J NEURORADIOL, V37, P1866, DOI 10.3174/ajnr.A4835
   CHOU PI, 1995, J NEURO-OPHTHALMOL, V15, P186
   Colli BO, 2013, NEUROSURG REV, V36, P99, DOI 10.1007/s10143-012-0415-0
   DAY AL, 1990, J NEUROSURG, V72, P677, DOI 10.3171/jns.1990.72.5.0677
   de Oliveira JG, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0924
   DOLENC VV, 1985, J NEUROSURG, V62, P667, DOI 10.3171/jns.1985.62.5.0667
   Dolenc VV, 1999, ACT NEUR S, V72, P89
   Durst CR, 2014, AM J NEURORADIOL, V35, P2140, DOI 10.3174/ajnr.A4032
   Erdogmus S, 2007, MINIM INVAS NEUROSUR, V50, P202, DOI 10.1055/s-2007-985862
   FRIEDLANDER LD, 1995, SKULL BASE SURG, V5, P191, DOI 10.1055/s-2008-1058915
   Friedlander LD, 2015, J VASC MED SURG, V3, P190
   Geibprasert S, 2009, AM J NEURORADIOL, V30, P1459, DOI 10.3174/ajnr.A1500
   Gross BA, 2014, CLIN NEUROL NEUROSUR, V123, P78, DOI 10.1016/j.clineuro.2014.05.014
   Hayreh S S, 1962, Br J Ophthalmol, V46, P65, DOI 10.1136/bjo.46.2.65
   Heran NS, 2007, J NEUROSURG, V106, P968, DOI 10.3171/jns.2007.106.6.968
   Hoh BL, 2001, NEUROSURGERY, V48, P78, DOI 10.1097/00006123-200101000-00014
   Iihara K, 2003, J NEUROSURG, V99, P241, DOI 10.3171/jns.2003.99.2.0241
   Javalkar V, 2011, J CLIN NEUROSCI, V18, P13, DOI 10.1016/j.jocn.2010.06.020
   Kanagalingam S, 2012, J NEURO-OPHTHALMOL, V32, P27, DOI 10.1097/WNO.0b013e31823b6c60
   Kawaguchi S, 1999, LANCET, V354, P2052, DOI 10.1016/S0140-6736(99)03671-5
   Kearns T P, 1978, Trans Am Ophthalmol Soc, V76, P247
   LANG J, 1990, SURG RADIOL ANAT, V12, P83, DOI 10.1007/BF01623328
   Louw L, 2015, CLIN ANAT, V28, P576, DOI 10.1002/ca.22470
   Meybodi AT, 2017, J NEUROSURG, V127, P740, DOI 10.3171/2016.8.JNS161225
   Meybodi AT, 2016, WORLD NEUROSURG, V93, P67, DOI 10.1016/j.wneu.2016.05.050
   Michalinos A, 2015, ANAT RES INT, V2015
   Mura J, 2014, J NEUROL SURG PART B, V75, P421, DOI 10.1055/s-0034-1383857
   Nacar OA, 2014, TURK NEUROSURG, V24, P937, DOI 10.5137/1019-5149.JTN.12586-14.1
   NEUPERT JR, 1976, AM J OPHTHALMOL, V81, P600, DOI 10.1016/0002-9394(76)90123-9
   Perrini P, 2007, J NEUROSURG, V106, P142, DOI 10.3171/jns.2007.106.1.142
   Quinones-Hinojosa Alfredo, 2008, Neurosurgery, V62, P1442, DOI 10.1227/01.neu.0000333808.64530.dd
   Rustemi O, 2016, NEUROSURGERY, V78, P332, DOI 10.1227/NEU.0000000000001074
   SCOTT JA, 1991, J NEUROSURG, V75, P146, DOI 10.3171/jns.1991.75.1.0146
   SHIBUYA M, 1990, ACTA NEUROCHIR, V103, P71, DOI 10.1007/BF01420195
   Silva MA, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1718
   Tobalem S, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0768-4
   Xu BN, 2010, WORLD NEUROSURG, V73, P137, DOI 10.1016/j.surneu.2009.07.042
   Yadla S, 2011, NEUROSURGERY, V68, P1434, DOI 10.1227/NEU.0b013e31820b4f85
   Yamamoto T, 2004, BRIT J OPHTHALMOL, V88, P505, DOI 10.1136/bjo.2003.025809
   Zhao JZ, 2006, J CLIN NEUROSCI, V13, P330, DOI 10.1016/j.jocn.2005.04.029
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E893
EP E901
DI 10.1016/j.wneu.2019.08.260
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700157
PM 31541753
OA Bronze
DA 2020-05-12
ER

PT J
AU Salunke, P
   Karthigeyan, M
   Rekhapalli, R
   Gupta, K
AF Salunke, Pravin
   Karthigeyan, Madhivanan
   Rekhapalli, Rajasekhar
   Gupta, Kirti
TI Tailored Posterior-Only Approach for C2 Vertebral Body Lesions: Our
   Surgical Experience in 10 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior approach; Axis; C2; Craniovertebral junction; Frozen; Posterior
   approach; Stabilization
ID CRANIOCERVICAL JUNCTION; SPONDYLECTOMY; RECONSTRUCTION; MANAGEMENT;
   CHORDOMA
AB BACKGROUND: C2 vertebral body (axis) lesions are often approached anteriorly and combined with posterior stabilization of the craniovertebral junction (CVJ). The anterior approach has its limitations. A posterolateral corridor is an alternative access to the C2 body lesions, and this alone may suffice in selected cases. We describe our experience with C2 body lesions, dealt primarily through a posterior approach, and propose an algorithm in the management of such cases.
   METHODS: Ten patients with axis lesions were operated through a midline posterior approach followed by posterior stabilization of the CVJ in the same sitting. Their preoperative and follow-up clinico-radiologic details were reviewed.
   RESULTS: The lesions included aneurysmal bone cysts (n = 2), fibrous dysplasia (n = 2), chordoma (n = 2), Ewing sarcoma (n = 1), metastases (n = 1), post-traumatic malunion (n = 1), and post-inflammatory deformity (n = 1). All patients presented with worsening neck pain. Five also had spastic quadriparesis. There were no perioperative complications. All showed clinical improvement at followup. Only 2 patients (chordoma: n = 1; aneurysmal bone cyst: n = 1) required an additional anterior procedure.
   CONCLUSIONS: Adequate debulking or total excision of lesion, neural decompression, and stabilization of the CVJ for axis body lesions can be achieved through a single midline posterior approach in most cases. If required, an anterior approach may be later added depending on the final histopathology.
C1 [Salunke, Pravin; Karthigeyan, Madhivanan; Rekhapalli, Rajasekhar] PGIMER, Dept Neurosurg, Chandigarh, India.
   [Gupta, Kirti] PGIMER, Dept Histopathol, Chandigarh, India.
RP Rekhapalli, R (reprint author), PGIMER, Dept Neurosurg, Chandigarh, India.
EM rajasekhar.rekhapalli@gmail.com
OI Rekapalli, Rajasekhar/0000-0003-0428-5042
CR Bilsky MH, 2002, SPINE, V27, P1062, DOI 10.1097/00007632-200205150-00011
   Fehlings MG, 2009, SPINE, V34, pS108, DOI 10.1097/BRS.0b013e3181bae1d2
   George B, 2006, ACTA NEUROCHIR, V148, P741, DOI 10.1007/s00701-006-0789-2
   McLoughlin GS, 2010, J SPINAL DISORD TECH, V23, P359, DOI 10.1097/BSD.0b013e3181aaca99
   Menezes AH, 2008, CHILD NERV SYST, V24, P1173, DOI 10.1007/s00381-008-0598-4
   Mirzaei L, 2015, NEUROSURGERY, V77, P718, DOI 10.1227/NEU.0000000000000903
   Moulding HD, 2010, NEUROSURGERY, V66, pA113, DOI 10.1227/01.NEU.0000365829.97078.B2
   O'Sullivan MD, 2018, GLOB SPINE J, V8, P866, DOI 10.1177/2192568218762379
   Rajasekhar R, 2019, EUR SPINE J, V28, P56, DOI 10.1007/s00586-019-05915-4
   Salunke P, 2018, WORLD NEUROSURG, V118, pE925, DOI 10.1016/j.wneu.2018.07.101
   Salunke P, 2015, J NEUROSURG-SPINE, V23, P294, DOI 10.3171/2014.12.SPINE14310
   Scheer JK, 2010, J NEUROSURG-SPINE, V12, P517, DOI 10.3171/2009.11.SPINE09480
   Sciubba DM, 2009, SPINE PHILA PA 197 S, V34, pS58
   Srivastava AK, 2017, NEUROL INDIA, V65, P1068, DOI 10.4103/neuroindia.NI_819_17
   Stulik J, 2010, J SPINAL DISORD TECH, V23, pE53, DOI 10.1097/BSD.0b013e3181d0c1e5
   Suchomel P, 2007, J NEUROSURG-SPINE, V6, P611, DOI 10.3171/spi.2007.6.6.611
   Yang X, 2011, NEUROSURGERY S, V69
   Yang XH, 2011, NEUROSURGERY, V69, P184, DOI 10.1227/NEU.0b013e31821bc7f9
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E730
EP E738
DI 10.1016/j.wneu.2019.09.155
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700139
PM 31605844
OA Bronze
DA 2020-05-12
ER

PT J
AU Schwartz, C
   Romagna, A
   Stefanits, H
   Zimmermann, G
   Ladisich, B
   Geiger, P
   Rechberger, J
   Winkler, S
   Weiss, L
   Fastner, G
   Trinka, E
   Weis, S
   Spiegl-Kreinecker, S
   Steinbacher, J
   McCoy, M
   Johannes, T
   Gruber, A
   Jahromi, BR
   Niemela, M
   Winkler, PA
   Thon, N
AF Schwartz, Christoph
   Romagna, Alexander
   Stefanits, Harald
   Zimmermann, Georg
   Ladisich, Barbara
   Geiger, Philipp
   Rechberger, Julian
   Winkler, Sophie
   Weiss, Lukas
   Fastner, Gerd
   Trinka, Eugen
   Weis, Serge
   Spiegl-Kreinecker, Sabine
   Steinbacher, Juergen
   McCoy, Mark
   Johannes, Trenkler
   Gruber, Andreas
   Jahromi, Behnam Rezai
   Niemelae, Mika
   Winkler, Peter A.
   Thon, Niklas
TI Risks and Benefits of Glioblastoma Resection in Older Adults: A
   Retrospective Austrian Multicenter Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjuvant treatment; Biomarker; Elderly; Glioblastoma multiforme;
   Outcome; Resection; Treatment-associated morbidity
ID NEWLY-DIAGNOSED GLIOBLASTOMA; ELDERLY-PATIENTS; SURVIVAL OUTCOMES;
   EUROPEAN ASSOCIATION; RESPONSE ASSESSMENT; RADIATION-THERAPY; MALIGNANT
   GLIOMA; TEMOZOLOMIDE; MULTIFORME; RADIOTHERAPY
AB OBJECTIVE: To assess the prognostic profile, clinical outcome, treatment-associated morbidity, and treatment burden of elderly patients with glioblastoma (GBM) undergoing microsurgical tumor resection as part of contemporary treatment algorithms.
   METHODS: We retrospectively identified patients with GBM >= 65 years of age who were treated by resection at 2 neuro-oncology centers. Survival was assessed by Kaplan-Meier analyses; log-rank tests identified prognostic factors.
   RESULTS: The study population included 160 patients (mean age, 73.1 +/- 5.1 years), and the median contrastenhancing tumor volume was 31.0 cm(3). Biomarker analyses revealed 0(6)-methylguanine-DNA methyltransferase-promoter methylation in 62.7% and wild-type isocitrate dehydrogenase in 97.5% of tumors. The median extent of resection (EOR) was 92.3%, surgical complications were noted in 10.0% of patients, and the median postoperative hospitalization period was 8 days. Most patients (60.0%) received adjuvant radio-/chemotherapy. The overall treatment-associated morbidity was 30.6%. The median progression-free and overall survival were 5A months (95% confidence interval [Cl], 4.6-6.4 months) and 10.0 months (95% CI, 7.9-11.7 months). The strongest predictors for favorable outcome were patient age <= 73.0 years (P = 0.0083), preoperative Karnofsky Performance Status Scale score >= 80% (P = 0.0179), postoperative modified Rankin Scale score <= 1 (P < 0.0001), adjuvant treatment (P < 0.0001), and no treatmentassociated morbidity (P = 0.0478). Increased EOR did not correlate with survival (P = 0.5046), but correlated significantly with treatment-associated morbidity (P = 0.0031).
   CONCLUSIONS: Clinical outcome for elderly patients with GBM remains limited. Nonetheless, the observed treatment-associated morbidity and treatment burden were moderate in the patients, and patient age and performance status remained the strongest predictors for survival. The risks and benefits of tumor resection in the age of biomarker-adjusted treatment concepts require further prospective evaluation.
C1 [Schwartz, Christoph; Romagna, Alexander; Ladisich, Barbara; Geiger, Philipp; Rechberger, Julian; Winkler, Peter A.] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Neurosurg, Salzburg, Austria.
   [Zimmermann, Georg; Trinka, Eugen] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Neurol, Salzburg, Austria.
   [Weiss, Lukas] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Internal Med 3 Haematol Med Oncol Haemostase, Salzburg, Austria.
   [Fastner, Gerd] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Radiotherapy & Radiooncol, Salzburg, Austria.
   [Steinbacher, Juergen; McCoy, Mark] Paracelsus Med Univ, Univ Hosp Salzburg, Div Neuroradiol, Salzburg, Austria.
   [Schwartz, Christoph; Jahromi, Behnam Rezai; Niemelae, Mika] Univ Helsinki, Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.
   [Stefanits, Harald; Winkler, Sophie; Spiegl-Kreinecker, Sabine; Gruber, Andreas] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Neurosurg, Neuromed Campus, Linz, Austria.
   [Weis, Serge] Johannes Kepler Univ Linz, Kepler Univ Hosp, Div Neuropathol, Neuromed Campus, Linz, Austria.
   [Johannes, Trenkler] Johannes Kepler Univ Linz, Kepler Univ Hosp, Inst Neuroradiol, Neuromed Campus, Linz, Austria.
   [Zimmermann, Georg] Paracelsus Med Univ, Ctr Cognit Neurosci, Salzburg, Austria.
   [Thon, Niklas] Ludwig Maximilians Univ Munchen, Univ Hosp Munich, Dept Neurosurg, Munich, Germany.
   [Romagna, Alexander] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada.
RP Schwartz, C (reprint author), Paracelsus Med Univ, Univ Hosp Salzburg, Dept Neurosurg, Salzburg, Austria.; Schwartz, C (reprint author), Univ Helsinki, Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.
EM c.schwartz@salk.at
OI Zimmermann, Georg/0000-0002-8282-1034; Rezai Jahromi,
   Behnam/0000-0003-3937-2816
CR Albert NL, 2016, NEURO-ONCOLOGY, V18, P1199, DOI 10.1093/neuonc/now058
   Arvold ND, 2014, CLIN INTERV AGING, V9, P357, DOI 10.2147/CIA.S44259
   Babu R, 2016, J NEUROSURG, V124, P998, DOI 10.3171/2015.4.JNS142200
   Chinot OL, 2011, ADV THER, V28, P334, DOI 10.1007/s12325-011-0007-3
   D'Amico RS, 2015, WORLD NEUROSURG, V84, P913, DOI 10.1016/j.wneu.2015.05.072
   de Castro DG, 2017, INT J RADIAT ONCOL, V98, P931, DOI 10.1016/j.ijrobp.2017.03.037
   Ewelt C, 2011, J NEURO-ONCOL, V103, P611, DOI 10.1007/s11060-010-0429-9
   Flanigan PM, 2018, NEUROSURGERY, V82, P64, DOI 10.1093/neuros/nyx148
   Glaser SM, 2017, J NEURO-ONCOL, V134, P107, DOI 10.1007/s11060-017-2493-x
   Harris G, 2017, INT J RADIAT ONCOL, V98, P802, DOI 10.1016/j.ijrobp.2017.02.028
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Heiland DH, 2018, J NEURO-ONCOL, V140, P385, DOI 10.1007/s11060-018-2964-8
   Hoffermann M, 2015, CLIN NEUROL NEUROSUR, V128, P60, DOI 10.1016/j.clineuro.2014.11.006
   Karsy M, 2018, J NEURO-ONCOL, V138, P123, DOI 10.1007/s11060-018-2777-9
   Korja M, 2019, NEURO-ONCOLOGY, V21, P370, DOI 10.1093/neuonc/noy164
   Liu YL, 2017, ONCOTARGETS THER, V10, P4029, DOI 10.2147/OTT.S123473
   Lombardi G, 2015, J NEURO-ONCOL, V125, P359, DOI 10.1007/s11060-015-1923-x
   Lorimer CF, 2017, CLIN ONCOL-UK, V29, P739, DOI 10.1016/j.clon.2017.05.010
   Lorimer CF, 2016, J GERIATR ONCOL, V7, P453, DOI 10.1016/j.jgo.2016.07.005
   Louis DN, 2016, WHO CLASSIFICATION T
   Malmstrom A, 2012, LANCET ONCOL, V13, P916, DOI 10.1016/S1470-2045(12)70265-6
   Morgan ER, 2017, CURR ONCOL, V24, pE92, DOI 10.3747/co.24.3424
   Park M, 2017, J NEURO-ONCOL, V134, P423, DOI 10.1007/s11060-017-2544-3
   Roa W, 2004, J CLIN ONCOL, V22, P1583, DOI 10.1200/JCO.2004.06.082
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Straube C, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0809-9
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Stummer W, 2011, J NEUROSURG, V114, P613, DOI 10.3171/2010.3.JNS097
   Tanaka S, 2013, J NEUROSURG, V118, P786, DOI 10.3171/2012.10.JNS112268
   Tsang DS, 2015, CLIN ONCOL-UK, V27, P176, DOI 10.1016/j.clon.2014.11.026
   da Cunha MLV, 2019, REV ASSOC MED BRAS, V65, P937, DOI 10.1590/1806-9282.65.7.937
   Vuorinen V, 2003, ACTA NEUROCHIR, V145, P5, DOI 10.1007/s00701-002-1030-6
   Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8
   Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Zanello M, 2017, J NEURO-ONCOL, V135, P285, DOI 10.1007/s11060-017-2573-y
   Zhang CC, 2016, WORLD NEUROSURG, V95, P77, DOI 10.1016/j.wneu.2016.07.079
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E583
EP E591
DI 10.1016/j.wneu.2019.09.097
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700120
PM 31561040
OA Green Published, Bronze
DA 2020-05-12
ER

PT J
AU Seaman, SC
   Dawson, JD
   Magnotta, V
   Menezes, AH
   Dlouhy, BJ
AF Seaman, Scott C.
   Dawson, Jeffrey D.
   Magnotta, Vincent
   Menezes, Arnold H.
   Dlouhy, Brian J.
TI Fourth Ventricle Enlargement in Chiari Malformation Type I
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid veil; Cerebellum; Chiari I malformation; Cognitive function;
   Dentate nucleus; Fourth ventricle; Tonsillar herniation
ID CEREBROSPINAL-FLUID FLOW; POSTERIOR-FOSSA; FORAMEN MAGNUM; EXECUTIVE
   DYSFUNCTION; DECOMPRESSION; MORPHOLOGY; VELOCITY; CHILDREN; POSITION;
   AUTISM
AB OBJECTIVE: How Chiari malformation type I (CM-I) affects posterior fossa brain structures and produces various symptoms remains unclear. The fourth ventricle is surrounded by critical structures required for normal function. The foramen of Magendie can be obstructed in CM-I; therefore, fourth ventricle changes may occur. To test this hypothesis, we assessed fourth ventricle volume in CM-I compared with healthy controls.
   METHODS: Using our database from 2007-2016, we studied 72 patients with CM-I and 30 age-matched healthy control subjects. Fourth and lateral ventricle volumes and posterior fossa volumes (PFV) were assessed and correlated with clinical signs and symptoms. Statistical analysis was performed.
   RESULTS: Patients with CM-I had larger fourth ventricle volumes compared with control subjects (1.31 vs. 0.95 ml; P = 0.012). There were no differences in lateral ventricle volume or PFV. CM-I fourth ventricle volume was associated with tonsillar descent (P = 0.030). CM-I fourth ventricle volume variance was larger than healthy controls (F-71,F- 29 = 8.33; P < 0.0001). Patients with CM-I with severe signs and symptoms had a significantly larger fourth ventricle than patients with CM-I with mild signs and symptoms (1.565 vs. 1.015 mL; P = 0. 0002).
   CONCLUSIONS: The fourth ventricle can be enlarged in CM-I independent of lateral ventricle size and is associated with greater tonsillar descent. Most importantly, fourth ventricle enlargement was associated with a worse clinical and radiographic presentation independent of PFV. Fourth ventricle enlargement can affect critical structures and may be a mechanism contributing to symptoms unexplained by tonsil descent. Fourth ventricle enlargement is a useful adjunct in assessing CM-I.
C1 [Seaman, Scott C.; Menezes, Arnold H.; Dlouhy, Brian J.] Univ Iowa Hosp & Clin, Univ Iowa Stead Family Childrens Hosp, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Dawson, Jeffrey D.] Univ Iowa Hosp & Clin, Coll Publ Hlth, Dept Biostat, Iowa City, IA 52242 USA.
   [Magnotta, Vincent] Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA.
   [Dlouhy, Brian J.] Univ Iowa, Carver Coll Med, Pappajohn Biomed Inst, Iowa City, IA 52242 USA.
   [Dlouhy, Brian J.] Univ Iowa, Iowa Neurosci Inst, Carver Coll Med, Iowa City, IA 52242 USA.
RP Dlouhy, BJ (reprint author), Univ Iowa Hosp & Clin, Univ Iowa Stead Family Childrens Hosp, Dept Neurosurg, Iowa City, IA 52242 USA.; Dlouhy, BJ (reprint author), Univ Iowa, Carver Coll Med, Pappajohn Biomed Inst, Iowa City, IA 52242 USA.; Dlouhy, BJ (reprint author), Univ Iowa, Iowa Neurosci Inst, Carver Coll Med, Iowa City, IA 52242 USA.
EM brian-dlouhy@uiowa.edu
OI Magnotta, Vincent/0000-0001-8639-5354
FU Moss family
FX Support provided by the Moss family.
CR ABOULEZZ AO, 1985, J COMPUT ASSIST TOMO, V9, P1033, DOI 10.1097/00004728-198511000-00005
   Allen G, 2004, BIOL PSYCHIAT, V56, P269, DOI 10.1016/j.biopsych.2004.06.005
   Allen PA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094844
   Alperin N, 2014, NEUROSURGERY, V75, P515, DOI 10.1227/NEU.0000000000000507
   ARMONDA RA, 1994, NEUROSURGERY, V35, P214, DOI 10.1227/00006123-199408000-00006
   Arnold J., 1894, BEITR PATHOL ANAT, V16, P1
   BADIE B, 1995, NEUROSURGERY, V37, P214, DOI 10.1227/00006123-199508000-00004
   Bagci AM, 2013, AM J NEURORADIOL, V34, P1758, DOI 10.3174/ajnr.A3435
   BARKOVICH AJ, 1986, AM J NEURORADIOL, V7, P795
   BHADELIA RA, 1995, RADIOLOGY, V196, P195, DOI 10.1148/radiology.196.1.7784567
   Chaskis C, 2001, J CLIN NEUROSCI, V8, P59, DOI 10.1054/jocn.2001.0879
   CHIARI H, 1947, Wien Klin Wochenschr, V59, P741
   D'Mello AM, 2017, J NEUROSCI, V37, P1604, DOI 10.1523/JNEUROSCI.2818-16.2017
   Dlouhy BJ, 2017, J NEUROSURG-PEDIATR, V20, P526, DOI 10.3171/2017.7.PEDS17224
   Dogan I, 2016, ANN CLIN TRANSL NEUR, V3, P572, DOI 10.1002/acn3.315
   Garcia M, 2018, CEREBELLUM, V17, P564, DOI 10.1007/s12311-018-0940-7
   Haughton VM, 2003, AM J NEURORADIOL, V24, P169
   Jacobsen LK, 1997, AM J PSYCHIAT, V154, P1663, DOI 10.1176/ajp.154.12.1663
   Kansal K, 2017, BRAIN, V140, P707, DOI 10.1093/brain/aww327
   Karagoz F, 2002, ACTA NEUROCHIR, V144, P165, DOI 10.1007/s007010200020
   Khalsa SSS, 2017, J NEUROSURG-PEDIATR, V19, P511, DOI 10.3171/2016.11.PEDS16263
   Klekamp J, 2012, NEUROSURGERY, V71, P365, DOI 10.1227/NEU.0b013e31825c3426
   Lacy M, 2018, PEDIATR NEUROSURG, V53, P371, DOI 10.1159/000488460
   Lacy M, 2016, PEDIATR NEUROSURG, V51, P236, DOI 10.1159/000445899
   Milhorat TH, 1999, NEUROSURGERY, V44, P1005, DOI 10.1097/00006123-199905000-00042
   Milhorat TH, 2010, ACTA NEUROCHIR, V152, P1117, DOI 10.1007/s00701-010-0636-3
   Morris EB, 2009, BRAIN, V132, P3087, DOI 10.1093/brain/awp241
   Nishikawa M, 1997, J NEUROSURG, V86, P40, DOI 10.3171/jns.1997.86.1.0040
   Noudel R, 2011, J NEUROSURG, V115, P647, DOI 10.3171/2010.11.JNS102148
   Olivito G, 2017, CEREBELLUM, V16, P283, DOI 10.1007/s12311-016-0795-8
   Onuki Y, 2015, CEREB CORTEX, V25, P313, DOI 10.1093/cercor/bht221
   Osborn AG, 2010, DIAGNOSTIC IMAGING B
   Quigley MF, 2004, RADIOLOGY, V232, P229, DOI 10.1148/radiol.2321030666
   Riva D, 2011, NEUROL SCI, V32, P307, DOI 10.1007/s10072-011-0779-x
   Rogers JM, 2018, NEUROPSYCHOL REV, V28, P176, DOI 10.1007/s11065-018-9368-6
   Roller LA, 2015, AM J ROENTGENOL, V204, P835, DOI 10.2214/AJR.14.13384
   Schmahmann JD, 1996, HUM BRAIN MAPP, V4, P174, DOI 10.1002/(SICI)1097-0193(1996)4:3<174::AID-HBM3>3.0.CO;2-0
   Stoodley CJ, 2016, NEUROIMAGE-CLIN, V12, P765, DOI 10.1016/j.nicl.2016.10.013
   Tubbs RS, 2004, J NEUROSURG, V100, P465, DOI 10.3171/ped.2004.100.5.0465
   Veretennikoff K, 2018, COGN BEHAV NEUROL, V31, P207, DOI 10.1097/WNN.0000000000000175
NR 40
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E259
EP E266
DI 10.1016/j.wneu.2019.08.230
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700033
PM 31513955
OA Bronze
DA 2020-05-12
ER

PT J
AU Seung, WB
   Jeong, JH
   Kim, YG
AF Seung, Won-Bae
   Jeong, Ju Ho
   Kim, Young Goo
TI Trajectories for Freehand-Guided Aspiration of Deep-Seated Spontaneous
   Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal ganglia; Catheter; Fibrinolysis; Intracerebral hemorrhage
ID VENTRICULOSTOMY; HEMATOMAS
AB OBJECTIVE: Although external landmarks and trajectories for external ventricular drainage have been described for the freehand-guided method, no standard trajectory has been reported for deep-seated intracerebral hemorrhage (ICH). This article presents a freehand-guided catheter insertion technique for deep-seated spontaneous ICH using external landmarks.
   METHOD: Freehand-guided hematoma aspiration using Kocher's point and the external auditory canal as landmarks was performed in 32 patients with a diagnosis of spontaneous ICH in basal ganglia treated between May 2015 and July 2018 at the author's institute.
   RESULTS: In computed tomographic images, the mean actual to planned catheter tip distance was 16.1 +/- 7.7 mm, the mean right-left deviation was 4.6 +/- 5.2 mm, the mean anterior-posterior deviation was 11.1 +/- 1- 9.5 mm, and the mean superior-inferior deviation was 8.7 +/- 4.4 mm. On largest hematoma slice, the mean distance from hematoma centers to inserted catheter was 9.8 +/- 4.9 mm, and the mean horizontal and vertical distances were 4.0 +/- 4.7 mm and 7.7 +/- 4.8 mm, respectively. In 29 of the 32 patients, all the catheter holes contacted hematomas, whereas in the other 3 patients, 1 or more holes were in contact with brain parenchymal tissue.
   CONCLUSION: For patients with basal ganglia hemorrhage, freehand-guided catheter insertion and hematoma aspiration with subsequent fibrinolysis is a feasible procedure that shortens procedural times. The described technique could be used as an alternative method because it can be performed when the patient is in a critical state without additional equipment.
C1 [Seung, Won-Bae; Jeong, Ju Ho] Dongguk Univ, Gyeongju Hosp, Coll Med, Dept Neurosurg, Gyeongju, South Korea.
   [Kim, Young Goo] Ewha Womans Univ, Mokdong Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
   [Kim, Young Goo] Kangwon Natl Univ, Coll Med, Dept Neurosurg, Chunchon, South Korea.
RP Kim, YG (reprint author), Ewha Womans Univ, Mokdong Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.; Kim, YG (reprint author), Kangwon Natl Univ, Coll Med, Dept Neurosurg, Chunchon, South Korea.
EM headkorea@naver.com
OI kim, young goo/0000-0003-1496-433X; Seung, Won-Bae/0000-0001-8436-9582
CR Chang Youn Hyuk, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P5, DOI 10.7461/jcen.2014.16.1.5
   FRIEDMAN WA, 1980, J NEUROSURG, V53, P662, DOI 10.3171/jns.1980.53.5.0662
   GHAJAR JBG, 1985, J NEUROSURG, V63, P985, DOI 10.3171/jns.1985.63.6.0985
   HONDO H, 1983, Tokushima Journal of Experimental Medicine, V30, P25
   Huyette DR, 2008, J NEUROSURG, V108, P88, DOI 10.3171/JNS/2008/108/01/0088
   Hwang Kihwan, 2015, J Cerebrovasc Endovasc Neurosurg, V17, P7, DOI 10.7461/jcen.2015.17.1.7
   KANNO T, 1984, J NEUROSURG, V61, P1091, DOI 10.3171/jns.1984.61.6.1091
   Kim JH, 2015, J KOREAN NEUROSURG S, V58, P373, DOI 10.3340/jkns.2015.58.4.373
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   MOHADJER M, 1990, J NEUROSURG, V73, P217, DOI 10.3171/jns.1990.73.2.0217
   MOSDAL C, 1986, ACTA NEUROCHIR, V83, P92, DOI 10.1007/BF01402384
   NATH FP, 1983, ACTA NEUROCHIR, V67, P29, DOI 10.1007/BF01401665
   OJEMANN RG, 1983, STROKE, V14, P468, DOI 10.1161/01.STR.14.4.468
   Pantazis G, 2006, SURG NEUROL, V66, P492, DOI 10.1016/j.surneu.2006.05.054
   Rehman T, 2012, CLIN NEUROL NEUROSUR, V114, P651, DOI 10.1016/j.clineuro.2011.12.040
   Vespa P, 2005, NEUROCRIT CARE, V2, P274, DOI 10.1385/NCC:2:3:274
   Yokosuka K, 2011, NEUROL MED-CHIR, V51, P543, DOI 10.2176/nmc.51.543
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E551
EP E557
DI 10.1016/j.wneu.2019.09.095
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700116
PM 31562966
OA Bronze
DA 2020-05-12
ER

PT J
AU Sheppard, JP
   Duong, C
   Romiyo, P
   Azzam, D
   Alkhalid, Y
   Nguyen, T
   Babayan, D
   Lagman, C
   Sun, MZ
   Prashant, GN
   Beckett, JS
   Yang, I
AF Sheppard, John P.
   Duong, Courtney
   Romiyo, Prasanth
   Azzam, Daniel
   Alkhalid, Yasmine
   Thien Nguyen
   Babayan, Diana
   Lagman, Carlito
   Sun, Matthew Z.
   Prashant, Giyarpuram N.
   Beckett, Joel S.
   Yang, Isaac
TI Patient Safety Analysis in Radiation Burden of Head Computed Tomography
   Imaging in 1185 Neurosurgical Inpatients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Head CT; Neurosurgery; Patient safety; Radiation
   burden; Radiometry; Risk assessment
ID ATOMIC-BOMB SURVIVORS; LOW-DOSE CT; CANCER-RISKS; SUBSEQUENT RISK;
   BRAIN-TUMORS; REDUCTION; EXPOSURE; CHILDREN; SCANS; CARE
AB OBJECTIVE: We performed a retrospective analysis in a cohort of 1185 patients at our institution who were identified as undergoing >= 1 head computed tomography (CT) examinations during their inpatient stay on the neurosurgery service, to quantify the number, type, and associated radiation burden of head CT procedures performed by the neurosurgery service.
   METHODS: CT procedure records and radiology reports were obtained via database search and directly validated against records retrieved from manual chart review. Next, dosimetry data from the head CT procedures were extracted via automated text mining of electronic radiology reports.
   RESULTS: Among 4510 identified adult head CT procedures, 88% were standard head CT examinations. A total of 3.65 +/- 3.60 head CT scans were performed during an average adult admission. The most common primary diagnoses were neoplasms, trauma, and other hemorrhage. The median cumulative effective dose per admission was 5.66 mSv (range, 1.06-84.5 mSv; mean, 8.56 +/- 8.95 mSv). The median cumulative effective dose per patient was 6.4 mSv (range, 1.1-127 mSv; mean, 9.26 +/- 10.0 mSv).
   CONCLUSIONS: The median cumulative radiation burden from head CT imaging in our cohort equates approximately to a single chest CT scan, well within accepted limits for safe CT imaging in adults. Refined methods are needed to characterize the safety profile of the few pediatric patients identified in our study.
C1 [Sheppard, John P.; Duong, Courtney; Romiyo, Prasanth; Azzam, Daniel; Alkhalid, Yasmine; Thien Nguyen; Babayan, Diana; Lagman, Carlito; Sun, Matthew Z.; Prashant, Giyarpuram N.; Beckett, Joel S.; Yang, Isaac] Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Los Angeles, CA 90032 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Dept Radiat Safety, David Geffen Sch Med, Los Angeles, CA 90032 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Phys & Biol Med Grad Program, David Geffen Sch Med, Los Angeles, CA 90032 USA.
   [Yang, Isaac] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90032 USA.
   [Yang, Isaac] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Sect Neuroradiol, Los Angeles, CA 90032 USA.
   [Yang, Isaac] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90032 USA.
   [Yang, Isaac] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90032 USA.
   [Yang, Isaac] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90032 USA.
   [Yang, Isaac] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles Biomed Res Inst, Los Angeles, CA 90032 USA.
   [Yang, Isaac] Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Los Angeles, CA 90032 USA.
RP Yang, I (reprint author), Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Los Angeles, CA 90032 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Dept Radiat Safety, David Geffen Sch Med, Los Angeles, CA 90032 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Phys & Biol Med Grad Program, David Geffen Sch Med, Los Angeles, CA 90032 USA.; Yang, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90032 USA.; Yang, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Sect Neuroradiol, Los Angeles, CA 90032 USA.; Yang, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90032 USA.; Yang, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90032 USA.; Yang, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90032 USA.; Yang, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles Biomed Res Inst, Los Angeles, CA 90032 USA.; Yang, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Los Angeles, CA 90032 USA.
EM iyang@mednet.ucla.edu
FU David Geffen Scholarship Program; Tina and Fred Segal Benign Brain Tumor
   and Skull Base Research Fellowship; AUA Carolyn Kuckein Student Research
   Fellowship; Neurosurgery Research & Education Foundation Medical Student
   Grant; Visionary Fund Grant; Eli and Edythe Broad Center of Regenerative
   Medicine and Stem Cell Research UCLA Scholars in Translational Medicine
   Program Award; Jason Dessel Memorial Seed Grant; UCLA Honberger
   Endowment Brain Tumor Research Seed Grant; STOPCANCER Research Career
   Development Award
FX P.S. and T.N. are partially supported by the David Geffen Scholarship
   Program. P.R. is supported by the Tina and Fred Segal Benign Brain Tumor
   and Skull Base Research Fellowship, the AUA Carolyn Kuckein Student
   Research Fellowship, and Neurosurgery Research & Education Foundation
   Medical Student Grant. I.Y. was partially supported by a Visionary Fund
   Grant, an Eli and Edythe Broad Center of Regenerative Medicine and Stem
   Cell Research UCLA Scholars in Translational Medicine Program Award, the
   Jason Dessel Memorial Seed Grant, the UCLA Honberger Endowment Brain
   Tumor Research Seed Grant, and the STOPCANCER Research Career
   Development Award. The remaining authors have no disclosures or
   conflicts of interest.
CR Albert GW, 2015, NEUROSURGERY, V77, P228, DOI 10.1227/NEU.0000000000000764
   Alessio AM, 2009, J NUCL MED, V50, P1570, DOI 10.2967/jnumed.109.065912
   Boone JM, 2012, RADIOLOGY, V265, P544, DOI 10.1148/radiol.12112201
   de Basea MB, 2015, J RADIOL PROT, V35, P611, DOI 10.1088/0952-4746/35/3/611
   Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149
   Brenner DJ, 2004, RADIOLOGY, V231, P440, DOI 10.1148/radiol.2312030880
   Brenner DJ, 2004, RADIOLOGY, V232, P735, DOI 10.1148/radiol.2323031095
   Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289
   Camera L, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160612
   Chen JX, 2014, OTOLARYNG HEAD NECK, V151, P554, DOI 10.1177/0194599814542588
   Chomentowski M, 2000, RADIAT RES, V153, P289, DOI 10.1667/0033-7587(2000)153[0289:RDDITA]2.0.CO;2
   Christner JA, 2010, AM J ROENTGENOL, V194, P881, DOI 10.2214/AJR.09.3462
   Corcuera-Solano I, 2014, AM J NEURORADIOL, V35, P1281, DOI 10.3174/ajnr.A3861
   de Gonzalez AB, 2016, BRIT J CANCER, V114, P388, DOI 10.1038/bjc.2015.415
   Doss M, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20140085
   Douple EB, 2011, DISASTER MED PUBLIC, V5, pS122, DOI 10.1001/dmp.2011.21
   Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454
   Huang WY, 2014, BRIT J CANCER, V110, P2354, DOI 10.1038/bjc.2014.103
   Huda W, 2011, MED PHYS, V38, P1261, DOI 10.1118/1.3544350
   *INT COMM RAD PROT, 2007 REC INT COMM RA
   Journy N, 2014, RADIAT ENVIRON BIOPH, V53, P39, DOI 10.1007/s00411-013-0491-8
   Karamat Muhammad Irfan, 2015, Critical Reviews in Biomedical Engineering, V43, P33, DOI 10.1615/CritRevBiomedEng.2015013977
   Khatonabadi M, 2013, MED PHYS, V40, DOI 10.1118/1.4798561
   Khatonabadi M, 2012, MED PHYS, V39, P5212, DOI 10.1118/1.4736807
   Krille L, 2015, RADIAT ENVIRON BIOPH, V54, P1, DOI 10.1007/s00411-014-0580-3
   Lautin EM, 2001, AM J ROENTGENOL, V177, P717, DOI 10.2214/ajr.177.3.1770717
   Lazoura O, 2016, INT J CARDIOVAS IMAG, V32, P347, DOI 10.1007/s10554-015-0776-x
   Linet MS, 2010, RADIAT RES, V174, P793, DOI 10.1667/RR2014.1
   Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360
   McNitt-Gray M, 2012, MED PHYS, V39, P3868, DOI 10.1118/1.4735793
   Morton RP, 2013, J NEUROSURG-PEDIATR, V12, P406, DOI 10.3171/2013.7.PEDS12631
   *NAT RES COUNC, 2005, HLTH RISKS EXP LOW L
   National Research Council (US) Committee on Health Effects of Exposure to Low Levels of Ionizing Radiations (BEIR V), 1990, HLTH EFF EXP LOW LEV
   Nichols AV, 2001, AM J ROENTGENOL, V177, P1218, DOI 10.2214/ajr.177.5.1771218a
   Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0
   Pierce DA, 2000, RADIAT RES, V154, P178, DOI 10.1667/0033-7587(2000)154[0178:RRCRAL]2.0.CO;2
   Potter-Lang S, 2012, RADIOLOGE, V52, P898, DOI 10.1007/s00117-012-2337-9
   Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1
   Preston RJ, 2008, HEALTH PHYS, V95, P541, DOI 10.1097/01.HP.0000326332.80829.63
   Rogers LF, 2002, AM J ROENTGENOL, V179, P299, DOI 10.2214/ajr.179.2.1790299
   Rogers LF, 2001, AM J ROENTGENOL, V176, P287, DOI 10.2214/ajr.176.2.1760287
   Rosen NS, 2001, AM J ROENTGENOL, V177, P715, DOI 10.2214/ajr.177.3.1770715b
   Selzer E, 2012, RADIOLOGE, V52, P892, DOI 10.1007/s00117-012-2336-x
   Sheppard John P, 2018, Brain Tumor Res Treat, V6, P1, DOI 10.14791/btrt.2018.6.e4
   Shuryak I, 2014, RADIAT RES, V181, P584, DOI 10.1667/RR13622.1
   Sodickson A, 2009, RADIOLOGY, V251, P175, DOI 10.1148/radiol.2511081296
   Stengel D, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-15
   Stojanovic S, 2009, Acta Chir Iugosl, V56, P57
   Strauss KJ, 2006, AM J ROENTGENOL, V187, P818, DOI 10.2214/AJR.06.0543
   Turner AC, 2011, MED PHYS, V38, P820, DOI 10.1118/1.3533897
   U.S. Environmental Protection Agency, MOD EPA RAD RISK MOD
   Ulsh BA., 2015, DOSE RESPONSE, V13
   Veronesi G, 2008, LUNG CANCER, V61, P340, DOI 10.1016/j.lungcan.2008.01.001
   Wattson DA, 2014, INT J RADIAT ONCOL, V90, P344, DOI 10.1016/j.ijrobp.2014.06.013
   Yi HJ, 2017, WORLD NEUROSURG, V100, P216, DOI 10.1016/j.wneu.2017.01.004
NR 55
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E308
EP E319
DI 10.1016/j.wneu.2019.09.004
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700085
PM 31520752
OA Bronze
DA 2020-05-12
ER

PT J
AU Shimamura, N
   Naraoka, M
   Matsuda, N
   Katayama, K
   Kakuta, K
   Katagai, T
   Fujiwara, N
   Hasegawa, S
   Ohkuma, H
AF Shimamura, Norihito
   Naraoka, Masato
   Matsuda, Naoya
   Katayama, Kosuke
   Kakuta, Kiyohide
   Katagai, Takeshi
   Fujiwara, Nozomi
   Hasegawa, Seiko
   Ohkuma, Hiroki
TI Use of Preprocedural, Multiple Antiplatelet Medications for Coil
   Embolization of Ruptured Cerebral Aneurysm in the Acute Stage Improved
   Clinical Outcome and Reduced Thromboembolic Complications without
   Hemorrhagic Complications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antiplatelet therapy; Cerebral aneurysm; Coiling; Subarachnoid
   hemorrhage
ID SUBARACHNOID HEMORRHAGE; INTRACRANIAL ANEURYSMS; DOUBLE-BLIND;
   VASOSPASM; CLOPIDOGREL; THERAPY; ASPIRIN; SAFETY; CELLS; RISK
AB BACKGROUND: The most uncontrollable complication during coil embolization of a ruptured cerebral aneurysm is thromboembolic ischemia. We analyzed whether thromboembolic complications could be reduced by using preoperative antiplatelet medications for acute subarachnoid hemorrhage in multicenter fashion.
   METHODS: We selected antiplatelet medicines according to an official protocol: a combination of 200 mg aspirin, 150 or 300 mg clopidogrel, and 200 mg cilostazol. Systemic heparinization was done after sheath insertion in all cases. One hundred and ten consecutive, ruptured cerebral saccular aneurysms that underwent coiling at our institute were analyzed. Procedure-related thrombus formation on digital subtraction angiography and clinical evidence of ischemia and procedure-related stroke on computed tomography scan were reviewed.
   RESULTS: Eighty cases (73%) were medicated with multiple antiplatelet medications, 22 cases (20%) were treated with a single medication, and 8 cases (7%) were treated without antiplatelet medication. Thromboembolic complications were reduced in an inverse relationship with the number of antiplatelet medications. Hemorrhagic complications because of antiplatelet medications did not occur. Postoperative symptomatic vasospasm tended to decrease, and outcome also tended to improve in the multiple medications groups. Reduction of thromboembolic complications significantly improved clinical outcome in logistic regression analysis.
   CONCLUSIONS: Preoperative multiple antiplatelet medication reduced thromboembolic events in coiling during acute stage subarachnoid hemorrhage and improved clinical outcomes.
C1 [Shimamura, Norihito; Naraoka, Masato; Katayama, Kosuke; Kakuta, Kiyohide; Katagai, Takeshi; Fujiwara, Nozomi; Ohkuma, Hiroki] Hirosaki Univ, Dept Neurosurg, Sch Med, Hirosaki, Aomori, Japan.
   [Matsuda, Naoya; Hasegawa, Seiko] Kuroishi Gen Hosp, Dept Neurosurg, Kuroishi, Aomori, Japan.
RP Shimamura, N (reprint author), Hirosaki Univ, Dept Neurosurg, Sch Med, Hirosaki, Aomori, Japan.
EM shimab@hirosaki-u.ac.jp
OI Shimamura, Norihito/0000-0003-3003-9160; Naraoka,
   Masato/0000-0001-6490-527X
CR Bertrand ME, 2000, CIRCULATION, V102, P624, DOI 10.1161/01.CIR.102.6.624
   Brinjikji W, 2015, AM J NEURORADIOL, V36, P1216, DOI 10.3174/ajnr.A4175
   Bruening R, 2006, AM J NEURORADIOL, V27, P1326
   Chung J, 2014, J NEUROSURG, V121, P4, DOI 10.3171/2014.4.JNS131662
   Coenen DM, 2017, BLOOD, V130, P2819, DOI 10.1182/blood-2017-04-780825
   ETTINGER M G, 1970, Stroke, V1, P139
   FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450
   Fujii Y, 1997, J NEUROSURG, V86, P594, DOI 10.3171/jns.1997.86.4.0594
   Golshani Kiarash, 2012, Surg Neurol Int, V3, P84, DOI 10.4103/2152-7806.99174
   JIMENEZ AH, 1992, AM J CARDIOL, V69, P258, DOI 10.1016/0002-9149(92)91316-V
   Li NL, 2000, ARTERIOSCL THROM VAS, V20, P2702, DOI 10.1161/01.ATV.20.12.2702
   Liu PX, 2016, J NEUROSURG, V124, P1265, DOI 10.3171/2015.3.JNS142841
   Matsuda N, 2016, CEREBROVASC DIS, V42, P97, DOI 10.1159/000445509
   Meckel S, 2011, AM J NEURORADIOL, V32, P764, DOI 10.3174/ajnr.A2392
   Nagahama Y, 2018, J NEUROSURG, V129, P702, DOI 10.3171/2017.5.JNS17831
   Nina P, 2001, SURG NEUROL, V55, P197, DOI 10.1016/S0090-3019(01)00402-5
   OHKUMA H, 1993, STROKE, V24, P1541, DOI 10.1161/01.STR.24.10.1541
   OHKUMA H, 1991, STROKE, V22, P854, DOI 10.1161/01.STR.22.7.854
   Peschillo S, 2016, AM J NEURORADIOL, V37, P856, DOI 10.3174/ajnr.A4606
   Roy D, 2001, STROKE, V32, P1998, DOI 10.1161/hs0901.095600
   Saber H, 2018, J STROKE CEREBROVASC, V27, P2979, DOI 10.1016/j.jstrokecerebrovasdis.2018.06.027
   Savcic M, 1999, SEMIN THROMB HEMOST, V25, P15
   Shimamura N, 2014, INTERV NEURORADIOL, V20, P413, DOI 10.15274/INR-2014-10035
   Soeda A, 2003, AM J NEURORADIOL, V24, P127
   Stiver SI, 1998, NEUROSURGERY, V43, P1203, DOI 10.1097/00006123-199811000-00106
   Ujiie H, 1999, NEUROSURGERY, V45, P119, DOI 10.1097/00006123-199907000-00028
   van den Bergh WM, 2009, STROKE, V40, P1969, DOI 10.1161/STROKEAHA.108.528802
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E751
EP E756
DI 10.1016/j.wneu.2019.09.149
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700142
PM 31604135
OA Bronze
DA 2020-05-12
ER

PT J
AU Shkarubo, AN
   Nikolenko, VN
   Chernov, IV
   Andreev, DN
   Shkarubo, MA
   Chmutin, KG
   Sinelnikov, MY
AF Shkarubo, Alexey Nikolaevich
   Nikolenko, Vladimir Nikolaevich
   Chernov, Ilia Valerievich
   Andreev, Dmitry Nikolaevich
   Shkarubo, Mikhail Alekseevich
   Chmutin, Kirill Gennadievich
   Sinelnikov, Mikhail Yegorovich
TI Anatomical Aspects of the Transnasal Endoscopic Access to the
   Craniovertebral Junction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniovertebral junction access; Endoscopic transnasal approach;
   Odontoid resection; Transnasal anatomy
ID CRANIO-VERTEBRAL JUNCTION; MALFORMATION TYPE-I; ENDONASAL APPROACH;
   TRANSORAL DECOMPRESSION; PATHOLOGICAL CONDITIONS; ODONTOIDECTOMY;
   STABILIZATION; FIXATION; RESECTION; SURGERY
AB OBJECTIVE: Interest in endoscopic transnasal access has increased with continued technological advances in endoscopic technology. The goals of this study were to review the normal anatomy in transnasal endoscopic neurosurgery and outline the anatomical basis for an expanded surgical approach. Defining anatomical aspects of surgical endoscopy helps guide the surgeon by defining normal anatomy of the access vector.
   METHODS: This anatomic study was conducted on 15 adult male cadaver specimens using various microsurgical tools and endoscopic instruments and 1 intraoperative case. The vasculature was injected with colored silicone to aid visualization. Different transnasal approach techniques were used, with angles of endoscope access at 0 degrees, 30 degrees, 45 degrees, and 70 degrees accordingly for extensive anatomical mapping.
   RESULTS: The proximity of critical structures is different in each approach degree. A full understanding of the possible structures to be met during transnasal access is described. As a result of the study, anatomical aspects and important structures were outlined, and a surgical protocol was defined for minimal risk access in respect to normal anatomy of the area.
   CONCLUSIONS: Thorough knowledge of topographic anatomy of the craniovertebral junction is required for performing minimal-risk surgical intervention in this region. It is important to know all anatomical aspects of the transnasal approach in order to reduce the risk of damage to vital structures. Transnasal endoscopic surgery of the craniovertebral junction is a relatively new direction in neurosurgery; therefore, anatomical studies such as the one described in this article are extremely important for the development of this access method.
C1 [Shkarubo, Alexey Nikolaevich; Chernov, Ilia Valerievich; Andreev, Dmitry Nikolaevich; Shkarubo, Mikhail Alekseevich] NN Burdenko Natl Med Res Ctr Neurosurg, Dept Neurosurg, Moscow, Russia.
   [Shkarubo, Alexey Nikolaevich; Chmutin, Kirill Gennadievich] RUDN Univ, Dept Neurosurg, Moscow, Russia.
   [Shkarubo, Alexey Nikolaevich] NN Priorov Cent Inst Traumatol & Orthoped, Dept Neurosurg, Moscow, Russia.
   [Nikolenko, Vladimir Nikolaevich; Sinelnikov, Mikhail Yegorovich] IM Sechenov First Moscow State Med vUniv, Minist Hlth Russian Federat, Sechenov Univ, Moscow, Russia.
   [Nikolenko, Vladimir Nikolaevich] Lomonosov Moscow State Univ, Dept Anat, Moscow, Russia.
RP Shkarubo, AN (reprint author), NN Burdenko Natl Med Res Ctr Neurosurg, Dept Neurosurg, Moscow, Russia.; Shkarubo, AN (reprint author), RUDN Univ, Dept Neurosurg, Moscow, Russia.; Shkarubo, AN (reprint author), NN Priorov Cent Inst Traumatol & Orthoped, Dept Neurosurg, Moscow, Russia.
EM ashkarubo@nsi.ru
OI Nikolenko, Vladimir/0000-0001-9532-9957
CR Abuzayed B, 2009, TURK NEUROSURG, V19, P249
   Ai FZ, 2011, SPINE, V36, pE556, DOI 10.1097/BRS.0b013e3181f57191
   Ponce-Gomez JA, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14301
   Baird CJ, 2009, NEUROSURGERY, V65, P158, DOI 10.1227/01.NEU.0000345641.97181.ED
   Cavallo LM, 2007, CHILD NERV SYST, V23, P665, DOI 10.1007/s00381-007-0332-7
   Chan AK, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15498
   Dasenbrock HH, 2012, NEUROSURGERY, V70, P351, DOI 10.1227/NEU.0b013e318230e59a
   de Almeida JR, 2009, LARYNGOSCOPE, V119, P239, DOI 10.1002/lary.20108
   DICKMAN CA, 1995, NEUROSURGERY, V36, P1146, DOI 10.1227/00006123-199506000-00013
   Fang CH, 2015, INT FORUM ALLERGY RH, V5, P754, DOI 10.1002/alr.21537
   Gonschorek O, 2018, GLOB SPINE J, V8, p12S, DOI 10.1177/2192568218768227
   Hankinson TC, 2010, J NEUROSURG-PEDIATR, V5, P549, DOI 10.3171/2010.2.PEDS09362
   Jhawar SS, 2016, J CRANIOVERTEBRAL JU, V7, P204, DOI 10.4103/0974-8237.193270
   Kassam AB, 2005, NEUROSURGERY, V57, P213, DOI 10.1227/01.NEU.0000163687.64774.E4
   Kassam Amin, 2005, Neurosurg Focus, V19, pE4
   Lee A, 2010, SKULL BASE-INTERD AP, V20, P199, DOI 10.1055/s-0029-1246220
   Leng LZ, 2008, NEUROSURGERY, V62, P342, DOI [10.1227/01.NEU.0000312720.93685.17, 10.1227/01.neu.0000326017.84315.1f]
   Locatelli Davide, 2019, Acta Neurochir Suppl, V125, P209, DOI 10.1007/978-3-319-62515-7_30
   Lopez AJ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14807
   Magrini S, 2008, NEUROSURGERY, V63, P373, DOI 10.1227/01.NEU.0000315285.84524.74
   Mangussi-Gomes J, 2016, OTOLARYNG CLIN N AM, V49, P167, DOI 10.1016/j.otc.2015.09.011
   Menezes AH, 2008, CHILD NERV SYST, V24, P1091, DOI 10.1007/s00381-008-0606-8
   Morales-Valero SF, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14831
   Naderi S, 1999, NEUROSURG FOCUS, V6, pe9
   Pacca Paolo, 2019, Acta Neurochir Suppl, V125, P25, DOI 10.1007/978-3-319-62515-7_5
   Patel AJ, 2012, CHILD NERV SYST, V28, P1971, DOI 10.1007/s00381-012-1818-5
   Pillai P, 2009, NEUROSURGERY, V64, P437, DOI 10.1227/01.NEU.0000334050.45750.C9
   Shkarubo AN, 2019, WORLD NEUROSURG, V124, pE387, DOI 10.1016/j.wneu.2018.12.103
   Shkarubo AN, 2018, WORLD NEUROSURG, V109, pE155, DOI 10.1016/j.wneu.2017.09.124
   Shkarubo AN, 2017, WORLD NEUROSURG, V102, P181, DOI 10.1016/j.wneu.2017.02.113
   Shkarubo MA, 2018, WORLD NEUROSURG, V112, P110, DOI 10.1016/j.wneu.2018.01.102
   Stulik J, 2007, ACTA CHIR ORTHOP TR, V74, P79
   Visocchi M, 2017, WORLD NEUROSURG, V101, P122, DOI 10.1016/j.wneu.2017.01.099
   Yin QS, 2005, SPINE, V30, pE375, DOI 10.1097/01.brs.0000168374.84757.d5
   Yu Y, 2013, EUR SPINE J, V22, P1127, DOI 10.1007/s00586-012-2605-4
   Zhang BC, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0662-7
   Zhong S, 2018, J CRANIOFAC SURG, V29, P1973, DOI 10.1097/SCS.0000000000004648
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E293
EP E302
DI 10.1016/j.wneu.2019.09.011
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700083
PM 31520764
OA Bronze
DA 2020-05-12
ER

PT J
AU Song, J
   Cui, ZY
   Chen, ZH
   Jiang, JY
AF Song, Jian
   Cui, Zhong-Yi
   Chen, Zhen-Hao
   Jiang, Jian-Yuan
TI Analysis of the Effect of Surgical Treatment for the Patients with
   Hirayama Disease from the Perspective of Cervical Spine Sagittal
   Alignment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical fusion; Cervical vertebrae; Hirayama disease;
   Rehabilitation; Sagittal parameters
AB OBJECTIVE: This study was carried out to analyze the surgical effect of cervical spine sagittal alignment for patients with Hirayama disease (HD).
   METHODS: Forty-four subjects were retrospectively analyzed for the parameters of cervical spine sagittal alignment. The case group consisted of 23 patients with HD, whereas the control group consisted of 21 healthy adolescent subjects. Pre- and postoperative cervical spine sagittal parameters of the patients with HD were collected; the cervical sagittal parameters of the healthy adolescent subjects were also collected. Sagittal alignment parameters were compared between the patients with HD and the healthy adolescent subjects, and between the pre- and postoperative parameters for the patients with HD.
   RESULTS: Forty-four subjects completed the follow-up, with the average follow-up period being 18.0 months. No significant differences were detected between the HD and control groups for clinical parameters (P> 0.05). The preoperative HD group had smaller values compared with the control group in the sagittal parameters of C2-7 cervical lordosis (CL) angle, T1 slope, thoracic inlet angle (TIA), and cervical tilt angle (P < 0.05). For the patients with HD, the preoperative values were smaller compared with the postoperative HD values for the parameters of C2-7 CL angle, T1 slope, and cervical tilt angle (P < 0.05). We found no significant differences between the postoperative patients with HD and the healthy subjects, including C2-7 CL angle, C2-7 sagittal vertical axis, T1 slope, slope, TIA, neck tilt angle, cervical tilt angle, and cranial tilt angle (P > 0.05).
   CONCLUSIONS: Patients with HD have sagittal imbalance of the cervical spine compared with age-matched healthy adolescent subjects, and surgical treatment could correct the sagittal imbalance.
C1 [Song, Jian; Cui, Zhong-Yi; Chen, Zhen-Hao; Jiang, Jian-Yuan] Fudan Univ, Huashan Hosp, Dept Orthoped, Shanghai, Peoples R China.
RP Jiang, JY (reprint author), Fudan Univ, Huashan Hosp, Dept Orthoped, Shanghai, Peoples R China.
EM jianyuanjiang@sina.com
CR Abelin-Genevois K, 2014, EUR SPINE J, V23, P1442, DOI 10.1007/s00586-013-3150-5
   Basques BA, 2019, SPINE J, V19, P1146, DOI 10.1016/j.spinee.2019.02.016
   Berger Ryan J, 2018, J Spine Surg, V4, P342, DOI 10.21037/jss.2018.05.17
   Canavese F, 2011, EUR SPINE J, V20, P1141, DOI 10.1007/s00586-011-1837-z
   Dejobert M, 2013, Diagn Interv Imaging, V94, P319, DOI 10.1016/j.diii.2012.10.008
   Ding Yan, 2015, Zhonghua Nei Ke Za Zhi, V54, P721
   Foster E, 2015, J CLIN NEUROSCI, V22, P951, DOI 10.1016/j.jocn.2014.11.025
   Hiyama A, 2016, EUR SPINE J, V25, P3226, DOI 10.1007/s00586-016-4701-3
   Hwang SW, 2011, J NEUROSURG-SPINE, V15, P491, DOI 10.3171/2011.6.SPINE1012
   Ito H, 2014, J NEUROSURG-SPINE, V21, P743, DOI 10.3171/2014.7.SPINE13955
   Jin X, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-349
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Song J, 2017, WORLD NEUROSURG, V105, P69, DOI 10.1016/j.wneu.2017.05.097
   Wang HL, 2018, WORLD NEUROSURG, V116, pE588, DOI 10.1016/j.wneu.2018.05.045
   Weng C, 2016, SPINE, V41, P185, DOI 10.1097/BRS.0000000000001353
   Xing R, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-1951-8
   Xu XJ, 2011, EUR J RADIOL, V78, P82, DOI 10.1016/j.ejrad.2010.08.012
   Yagi Mitsuru, 2014, Spine Deform, V2, P122, DOI 10.1016/j.jspd.2013.11.002
   Zheng CJ, 2018, CLIN NEUROPHYSIOL, V129, P2341, DOI 10.1016/j.clinph.2018.08.024
   Zhu C, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1590-5
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E342
EP E347
DI 10.1016/j.wneu.2019.09.025
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700088
PM 31562968
OA Bronze
DA 2020-05-12
ER

PT J
AU Sanchez, JAS
   Garcia, MES
   Solis, SS
   Garcia, MR
   Huerta, PT
   Escandon, OS
   Soria, ERF
   Romero-Rangel, JAI
AF Soriano Sanchez, Jose Antonio
   Soto Garcia, Manuel Eduardo
   Soriano Solis, Sergio
   Rodriguez Garcia, Manuel
   Trejo Huerta, Paul
   Sanchez Escandon, Oscar
   Flores Soria, Enrique Raul
   Israel Romero-Rangel, Jose Alberto
TI Microsurgical Resection of Intraspinal Benign Tumors Using Non-Expansile
   Tubular Access
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extramedullary tumors; Intradural tumors; Intramedullary tumors;
   Intraspinal tumors; Intratubular dural stitches; Minimally invasive;
   Non-expansile tubular approach
AB BACKGROUND: lntraspina tumors are 10 to 15 times less common than brain tumors. The midline approach with extensive laminectomies represents the current gold-standard for resection, causing instability, muscle damage, and kyphosis among other well-known complications. Minimally invasive series reported their results using retractor-based systems. We analyzed a patient series treated with a non-expansile tubular approach, describing the technique, grade of resection, and clinical outcomes.
   METHODS: A series of consecutive cases operated between 2016 and October 2018 were analyzed retrospectively. The database included age, sex, clinical presentation, intraspinal location (intra/extradural), number of laminotomies, grade of resection, surgical time, bleeding, and follow-up. The initial and follow-up clinical condition was analyzed using the Frankel scale.
   RESULTS: A total of 13 patients underwent surgery: 3 intraspinal/extradural (23%), 8 intradural/extramedullary (61.5%), and 2 intramedullary tumors (15.3%); these were classified as 5 meningiomas (38.4%), 4 neurofibromas (30.7%), 2 schwannomas (15.3%), 1 hemangioblastoma (7.6%), and 1 astrocytoma (7.6%). Eleven (84.61%) patients had complete motor improvement, 1 patient had partial improvement, and 1 patient had no improvement (7.6% each). An 18-mm working channel tube was used for extramedullary lesions and 20-mm tubes for intramedullary injuries. Total tumor resection was achieved in 11 patients (84.6%) and subtotal in 2 patients (15.38%) corresponding to intramedullary tumors.
   CONCLUSIONS: Although this study consisted of a small series, we have shown the possibility of resecting intraspinal tumors (some intradural-intramedullary) with nonexpansile tubes in a safe and effective way with no complications. Most of the patients had complete neurological improvement at the end of follow-up.
C1 [Soriano Sanchez, Jose Antonio] Amer British Cowdray Med Ctr IAP, Spine Clin, Campus Santa Fe, Mexico City, DF, Mexico.
   [Soto Garcia, Manuel Eduardo; Soriano Solis, Sergio; Rodriguez Garcia, Manuel; Trejo Huerta, Paul; Sanchez Escandon, Oscar; Flores Soria, Enrique Raul; Israel Romero-Rangel, Jose Alberto] Amer British Cowdray Med Ctr IAP Santa Fe, Mexico City, DF, Mexico.
   [Soto Garcia, Manuel Eduardo] High Specialty Reg Hosp Dr Juan Graham Casasus, Villahermosa, Tabasco, Mexico.
   [Soto Garcia, Manuel Eduardo] Angels Villahermosa Hosp, Villahermosa, Tabasco, Mexico.
   [Israel Romero-Rangel, Jose Alberto] Univ Nacl Autonoma Mexico, Mexico City, DF, Mexico.
   [Israel Romero-Rangel, Jose Alberto] Natl Inst Social Secur, Reg Gen Hosp 125, Mexico City, DF, Mexico.
   [Israel Romero-Rangel, Jose Alberto] Univ Sonora, Med Sch, Dept Neurol, Obregon City, Mexico.
RP Romero-Rangel, JAI (reprint author), Amer British Cowdray Med Ctr IAP Santa Fe, Mexico City, DF, Mexico.; Romero-Rangel, JAI (reprint author), Univ Nacl Autonoma Mexico, Mexico City, DF, Mexico.; Romero-Rangel, JAI (reprint author), Natl Inst Social Secur, Reg Gen Hosp 125, Mexico City, DF, Mexico.; Romero-Rangel, JAI (reprint author), Univ Sonora, Med Sch, Dept Neurol, Obregon City, Mexico.
EM gmaisrael@gmail.com
OI Romero-Rangel, Jose Alberto Israel/0000-0002-5405-4907
CR Cho JH, 2008, KNEE SURG SPORT TR A, V16, P683, DOI 10.1007/s00167-007-0483-9
   Harrop JS, 2009, SPINE, V34, pS69, DOI 10.1097/BRS.0b013e3181b95c6f
   Koc R, 2002, SPINAL CORD, V38, P92
   KURLAND LT, 1958, J NEUROSURG, V15, P627, DOI 10.3171/jns.1958.15.6.0627
   Luque LL, 2018, REV ARGENT NEUROCIR, V32, P173
   Minehan KJ, 2009, INT J RADIAT ONCOL, V73, P727, DOI 10.1016/j.ijrobp.2008.04.060
   Park P, 2010, J SPINAL DISORD TECH, V23, P486, DOI 10.1097/BSD.0b013e3181c7e901
   Thongtrangan I, 2004, NEUROSURG FOCUS, V16, P1
   Tobin MK, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15158
   Tredway TL, 2006, NEUROSURGERY, V58, P52, DOI 10.1227/01.NEU.0000192661.08192.1C
   Vertuani S, 2015, VALUE HEALTH, V18, P810, DOI 10.1016/j.jval.2015.05.002
   Wong AP, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15129
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E97
EP E104
DI 10.1016/j.wneu.2019.08.170
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700013
PM 31505279
OA Bronze
DA 2020-05-12
ER

PT J
AU Sridharan, M
   Malik, AT
   Kim, J
   Khan, SN
   Yu, E
AF Sridharan, Mathangi
   Malik, Azeem Tariq
   Kim, Jeffery
   Khan, Safdar N.
   Yu, Elizabeth
TI Does Increasing Body Mass Index Correlate with Adverse Outcomes
   Following Posterior Cervical Fusions?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Body mass index; NSQIP; Obesity; Outcomes; Posterior cervical fusions
ID SPINE SURGERY; RISK-FACTORS; OBESITY; TRENDS; IMPACT; PREVALENCE;
   INFECTION; ADULTS
AB BACKGROUND: Obesity has been shown to be associated with higher rates of complications after lumbar spine surgery. However, the evidence regarding the impact of body mass index (BMI) on outcomes following posterior cervical fusions (PCFs) remains limited.
   METHODS: The 2012-2017 American College of Surgeons National Surgical Quality Improvement Program database was queried using Current Procedural Terminology code 22600 to identify PCFs. Patients undergoing anterior cervical spine surgery and surgery for deformity, malignancy, or infection were excluded. Patients with missing data with regard to weight, height, and 30-day outcomes were excluded. BMI (kg/m(2)) was categorized into 4 groups: 1) <25.0, 2) 25.0-29.9, 3) 30.0-34.9, and 4) >= 35.0. Multivariate regression analyses were constructed to assess independent impact of BMI on 30-day outcomes while controlling for baseline clinical characteristics.
   RESULTS: Of 2786 patients with PCFs, 710 (25.5%) had BMI <25.0, 919 (33.0%) had BMI between 25.0 and 29.9, 655 (23.5%) had BMI between 30.0 and 34.9, and 502 (18.0%) had BMI >= 35.0. Following adjustment for baseline demographics and clinical characteristics, increased BMI was not associated with a higher risk of any adverse events, severe adverse events, minor adverse events, bleeding requiring transfusion, or readmissions within 30 days of surgery. BMI >= 35.0 versus BMI <25.0 was associated only with a higher risk of deep surgical site infections (odds ratio 4.61; P = 0.009).
   CONCLUSIONS: With the exception of a higher rate of deep surgical site infections seen in obese patients, increased BMI does not seem to have a major impact on 30-day outcomes following PCFs.
C1 [Sridharan, Mathangi; Malik, Azeem Tariq; Kim, Jeffery; Khan, Safdar N.; Yu, Elizabeth] Ohio State Univ, Wexner Med Ctr, Dept Orthopaed, Columbus, OH 43210 USA.
RP Yu, E (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Orthopaed, Columbus, OH 43210 USA.
EM Elizabeth.yu@osumc.edu
CR American College of Surgeons, 2017, US GUID ACS NSQIP 20
   Bono OJ, 2018, SPINE J, V18, P1204, DOI 10.1016/j.spinee.2017.11.015
   BOSTMAN OM, 1994, INT J OBESITY, V18, P709
   Buerba RA, 2014, SPINE J, V14, P1643, DOI 10.1016/j.spinee.2013.09.054
   Cao JM, 2016, J CLIN NEUROSCI, V28, P1, DOI 10.1016/j.jocn.2015.10.034
   Cheng CW, 2019, SPINE J, V19, P602, DOI 10.1016/j.spinee.2018.09.014
   Cunningham MRA, 2010, SPINE, V35, P537, DOI 10.1097/BRS.0b013e3181b204cc
   Djurasovic M, 2008, SPINE, V33, P1789, DOI 10.1097/BRS.0b013e31817b8f6f
   Fehlings MG, 2015, NEUROSURGERY, V77, pS1, DOI 10.1227/NEU.0000000000000953
   Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39
   Garrison LP, 2017, J PERS MED, V7, DOI 10.3390/jpm7030010
   Higgins DM, 2016, NEUROSURGERY, V78, P127, DOI 10.1227/NEU.0000000000001018
   Ho C, 2007, SPINE, V32, P2272, DOI 10.1097/BRS.0b013e31814b1c0b
   Kalanithi PA, 2012, SPINE, V37, P982, DOI 10.1097/BRS.0b013e31823bbeef
   Marquez-Lara A, 2014, SPINE, V39, P476, DOI 10.1097/BRS.0000000000000165
   Matsumoto M, 1998, J BONE JOINT SURG BR, V80B, P19, DOI 10.1302/0301-620X.80B1.7929
   Mehta AI, 2013, J BONE JOINT SURG AM, V95A, P323, DOI 10.2106/JBJS.L.00225
   Mummaneni PV, 2009, J NEUROSURG-SPINE, V11, P130, DOI 10.3171/2009.3.SPINE08728
   Oglesby M, 2013, SPINE, V38, P1226, DOI 10.1097/BRS.0b013e31828be75d
   Parratte S, 2014, ORTHOP TRAUMATOL-SUR, V100, pS91, DOI 10.1016/j.otsr.2013.11.003
   Patel N, 2007, J NEUROSURG-SPINE, V6, P291, DOI 10.3171/spi.2007.6.4.1
   Phan K, 2017, SPINE, V42, P261, DOI 10.1097/BRS.0000000000001711
   Pi-Sunyer FX, 1998, OBES RES, V6, p51S
   Sebastian A, 2016, SPINE J, V16, P504, DOI 10.1016/j.spinee.2015.12.009
   Telfeian AE, 2002, J NEUROSURG, V97, P20, DOI 10.3171/spi.2002.97.1.0020
   Vaidya R, 2009, SPINE, V34, P495, DOI 10.1097/BRS.0b013e318198c5f2
   Yalamanchili PK, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/783762
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E789
EP E795
DI 10.1016/j.wneu.2019.10.011
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700147
PM 31605849
OA Bronze
DA 2020-05-12
ER

PT J
AU Steinberg, JA
   Rennert, RC
   Ravina, K
   Strickland, B
   Russin, JJ
AF Steinberg, Jeffrey A.
   Rennert, Robert C.
   Ravina, Kristine
   Strickland, Ben A.
   Russin, Jonathan J.
TI Rescue Cerebral Revascularization in Patients with Progressive
   Steno-Occlusive Ischemia of the Anterior Intracranial Circulation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral bypass; Revascularization; Steno-occlusive ischemia; Stroke
ID STROKE; BYPASS; SURGERY
AB BACKGROUND: Despite the failure of 2 randomized controlled trials assessing the utility of bypass for steno-occlusive cerebrovascular disease, a specific subset of patients with progressive and/or refractory symptoms may benefit from cerebral revascularization. This study assessed the efficacy and outcomes of bypass surgery for progressive and/or refractory steno-occlusive cerebrovascular disease.
   METHODS: A retrospective database review was performed to identify patients who underwent bypass for progressive and/or refractory steno-occlusive disease of the internal carotid artery or middle cerebral artery over a 4-year period (July 2014-July 2018). Surgical and clinical outcomes were recorded.
   RESULTS: Seventeen patients (average age 62 +/- 11 years) underwent extracranial-intracranial bypass for refractory and/or progressive steno-occlusive disease of the internal carotid artery or middle cerebral artery. Thirteen patients presented with stroke, 3 presented with recurrent transient ischemic attacks, and 1 presented with progressive hemiparesis. All patients had preoperative perfusion imaging deficits. Average temporary clip time was 35 +/- 8 minutes. An interposition graft was used in 7 patients. There was 3 ischemic and 3 hemorrhagic perioperative strokes (35%); all were minor or related to anticoagulation. Over an average of 10 +/- 10 months of follow-up, there were no ischemic strokes in the bypass-dependent territories. Of 17 patients, 16 (78%) achieved a Glasgow Outcome Scale score >= 4, and 13 (85%) achieved a modified Rankin Scale score <= 2.
   CONCLUSIONS: Bypass for steno-occlusive disease of the anterior intracranial circulation is a potentially effective treatment for patients with progressive and/or refractory ischemic symptoms, although the complication rate is significant. Optimal patient selection criteria and timing of surgery remain open questions.
C1 [Steinberg, Jeffrey A.; Rennert, Robert C.] Univ Calif San Diego, Dept Neurol Surg, San Diego, CA 92103 USA.
   [Ravina, Kristine; Russin, Jonathan J.] Univ Southern Calif, Neurorestorat Ctr, Keck Sch Med, Los Angeles, CA 90007 USA.
   [Strickland, Ben A.] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
RP Russin, JJ (reprint author), Univ Southern Calif, Neurorestorat Ctr, Keck Sch Med, Los Angeles, CA 90007 USA.
EM jonathan.russin@med.usc.edu
OI Ravina, Kristine/0000-0002-0927-5719
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Amin-Hanjani S, 2012, NEUROSURGERY, V71, P557, DOI 10.1227/NEU.0b013e3182621488
   BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904
   Bauer AM, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.049
   Esposito G, 2016, STROKE, V47, P282, DOI 10.1161/STROKEAHA.115.008220
   Grubb RL, 1998, JAMA-J AM MED ASSOC, V280, P1055, DOI 10.1001/jama.280.12.1055
   Grubb RL, 2013, J NEUROSURG, V118, P25, DOI 10.3171/2012.9.JNS12551
   Kalani MYS, 2015, WORLD NEUROSURG, V83, P345, DOI 10.1016/j.wneu.2014.10.013
   Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Powers WJ, 2011, JAMA-J AM MED ASSOC, V306, P1983, DOI 10.1001/jama.2011.1610
   Rice CJ, 2019, NEUROSURGERY, V85, P656, DOI 10.1093/neuros/nyy411
   Wessels L, 2019, NEUROSURG REV, V42, P389, DOI 10.1007/s10143-018-0966-9
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E609
EP E618
DI 10.1016/j.wneu.2019.09.102
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700123
PM 31563694
OA Bronze
DA 2020-05-12
ER

PT J
AU Sur, S
   Menaker, SA
   Alvarez, C
   Chen, S
   Shah, SS
   Peterson, EC
   Elhammady, MS
   Starke, RM
AF Sur, Samir
   Menaker, Simon A.
   Alvarez, Carlos
   Chen, Stephanie
   Shah, Sumedh S.
   Peterson, Eric C.
   Elhammady, Mohamed Samy
   Starke, Robert M.
TI Multimodal Management of Carotid-Cavernous Fistulas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiography; Carotid artery; Carotid-cavernous fistula; Cavernous sinus;
   Embolization; Endovascular; Multimodal management
ID ONYX EMBOLIZATION; SINUS FISTULAS; COVERED STENT; PUNCTURE
AB BACKGROUND: Techniques for endovascular management of carotid-cavernous fistulas (CCFs) have evolved over the years. Current strategies include transarterial or transvenous approaches and direct puncture or exposure of the cavernous sinus. Rarely, complex CCFs may require multiple approaches or procedures. We describe our experience managing CCFs, reporting on outcomes and technical nuances.
   METHODS: A retrospective review of institutional records was conducted to identify consecutive cases of CCF treated between July 2005 and July 2016. Pertinent technical details and outcomes were recorded.
   RESULTS: In 44 patients, 51 procedures were performed. There were 13 direct CCFs and 31 indirect CCFs: 13 (30%) type A, 3 (7%) type B, 5 (11%) type C, and 23152%) type D. A transarterial approach was selected in 39% of cases (n = 20), resulting in a long-term successful embolization rate of 60% (n = 12). Transvenous methods via the inferior petrosal sinus or superior ophthalmic vein were used in 49% of cases (n = 25), resulting in a long-term obliteration rate of 88% (n = 22). Multimodal management was required in 5 patients, including 1 patient in whom a craniotomy was performed to facilitate coil embolization of the cavernous sinus under direct vision. A 7% complication rate (n = 3) was observed, with significant morbidity in 1 patient.
   CONCLUSIONS: CCFs are complex vascular lesions that require facility with various endovascular and surgical approaches. High-flow, direct-type fistulas may harbor a significant risk of recurrence after transarterial embolization. Partial or unsuccessful embolization may necessitate an open surgical approach to the superior ophthalmic vein or cavernous sinus.
C1 [Sur, Samir; Menaker, Simon A.; Alvarez, Carlos; Chen, Stephanie; Shah, Sumedh S.; Peterson, Eric C.; Elhammady, Mohamed Samy; Starke, Robert M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Starke, Robert M.] Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA.
RP Menaker, SA (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
EM simonmenaker@gmail.com
OI Alvarez, Carlos/0000-0002-2965-090X
CR Baranoski JF, 2019, J NEUROINTERV SURG, V11, P1129, DOI 10.1136/neurintsurg-2019-014731
   Barber SM, 2015, J NEUROINTERV SURG, V7, P762, DOI 10.1136/neurintsurg-2014-011266
   BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   Benndorf G, 2000, SURG NEUROL, V54, P42, DOI 10.1016/S0090-3019(00)00260-3
   Briganti F, 2009, INTERV NEURORADIOL, V15, P185, DOI 10.1177/159101990901500208
   Deniwar MA, 2015, NEUROL INDIA, V63, P606, DOI 10.4103/0028-3886.162080
   Elhammady MS, 2011, J NEUROSURG, V114, P129, DOI 10.3171/2010.1.JNS091433
   Elhammady MS, 2010, J NEUROSURG, V112, P589, DOI 10.3171/2009.6.JNS09132
   Gemmete JJ, 2009, NEUROIMAG CLIN N AM, V19, P241, DOI 10.1016/j.nic.2009.01.006
   Heiroth Hi-Jae, 2013, J Neurointerv Surg, V5, pe7, DOI 10.1136/neurintsurg-2011-010209
   Higashida R T, 1986, Acta Radiol Suppl, V369, P580
   KELTNER JL, 1987, OPHTHALMOLOGY, V94, P1585
   LEWIS AI, 1995, NEUROSURGERY, V36, P239, DOI 10.1227/00006123-199502000-00001
   Meijer FJA, 2009, INTERV NEURORADIOL, V15, P191, DOI 10.1177/159101990901500209
   Nadarajah M, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/neurintsurg-2011-010000
   Ogilvy CS, 2017, WORLD NEUROSURG, V105, P812, DOI 10.1016/j.wneu.2017.06.113
   Park SH, 2017, WORLD NEUROSURG, V106, P836, DOI 10.1016/j.wneu.2017.04.143
   Tang CL, 2017, J NEUROSURG, V127, P327, DOI 10.3171/2016.5.JNS16493
   Wenderoth J, 2017, J NEUROINTERV SURG, V9, P290, DOI 10.1136/neurintsurg-2016-012742
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E796
EP E803
DI 10.1016/j.wneu.2019.10.004
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700148
PM 31605852
OA Bronze
DA 2020-05-12
ER

PT J
AU Sweid, A
   Weinberg, JH
   Xu, V
   Shivashankar, K
   Alexander, TD
   Khalife, J
   Elmer, N
   Gooch, MR
   Herial, N
   Chalouhi, N
   Jabbour, P
   Rosenwasser, RH
   Tjoumakaris, S
AF Sweid, Ahmad
   Weinberg, Joushua H.
   Xu, Vivian
   Shivashankar, Kavya
   Alexander, Tyler D.
   Khalife, Jane
   Elmer, Nicholas
   Gooch, Michael R.
   Herial, Nabeel
   Chalouhi, Nohra
   Jabbour, Pascal
   Rosenwasser, Robert H.
   Tjoumakaris, Stavropoula
TI Mechanical Thrombectomy in Acute Ischemic Stroke Patients Greater than
   90 Years of Age: Experience in 26 Patients in a Large Tertiary Care
   Center and Outcome Comparison with Younger Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Extreme of age; Mechanical thrombectomy
AB BACKGROUND: Several independent randomized controlled trials have shown superior efficacy of mechanical thrombectomy (MT) for management of acute ischemic stroke (AIS). However, elderly patients have been underrepresented or excluded in these trials. The aim of this study was to investigate the feasibility and safety of MT in patients with AIS >= 90 years old.
   METHODS: A retrospective review was performed of patients >= 90 years old presenting with AIS who underwent MT between 2010 and 2018.
   RESULTS: Of 453 patients with MS, 5.74% (n = 26) were >= 90 years old, and 69.32% (n = 314) were 60-89 years old. Of baseline characteristics between both groups, there was a significant difference in age, sex, body mass index, smoking, hyperlipidemia, atrial fibrillation, and diabetes mellitus. Mean National Institutes of Health Stroke Scale score on admission was higher in the nonagenarians (17 vs. 15). Similar proportions of both groups received tissue plasminogen activator, 57.69% (n = 15) versus 42.68% (n = 134), P = 0.14). There was no difference in periprocedural and postprocedural complications, good Thrombolysis In Cerebral Infarction scores (88.46% [n = 23] vs. 87.58% [n = 275], P = 1.00), good modified Rankin Scale scores (34.62% [n = 4] vs. 49.36% [n = 155], P = 0.40), or mortality (11.54% [n = 3] vs. 13.06% [n = 41], P = 0.82).
   CONCLUSIONS: Age is a factor that affects functional outcome following MT. Advancements in catheter techniques, technical experience, and great outcomes with MT allow for pushing the boundaries to consider age as one factor, rather than an exclusion criterion. Our results show that MT is safe and feasible in nonagenarians.
C1 [Sweid, Ahmad; Weinberg, Joushua H.; Xu, Vivian; Shivashankar, Kavya; Alexander, Tyler D.; Elmer, Nicholas; Gooch, Michael R.; Herial, Nabeel; Chalouhi, Nohra; Jabbour, Pascal; Rosenwasser, Robert H.; Tjoumakaris, Stavropoula] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
   [Khalife, Jane] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.
   [Khalife, Jane] Jefferson Hosp Neurosci, Philadelphia, PA USA.
RP Tjoumakaris, S (reprint author), Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
EM Stavropoula.tjoumakaris@jefferson.edu
OI Weinberg, Joshua/0000-0002-3464-5697; Sweid, Ahmad/0000-0002-2652-2451;
   Herial, Nabeel/0000-0002-5790-783X
CR Alawieh A, 2018, J NEUROINTERV SURG, V10, P1209, DOI 10.1136/neurintsurg-2018-013787
   Calle IA, 2017, J STROKE CEREBROVASC, V26, P582, DOI 10.1016/j.jstrokecerebrovasdis.2016.11.117
   Denti L, 2010, J AM GERIATR SOC, V58, P12, DOI 10.1111/j.1532-5415.2009.02616.x
   Fiehler J, 2015, DTSCH ARZTEBL INT, V112, P830, DOI 10.3238/arztebl.2015.0830
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Imahori T, 2017, J STROKE CEREBROVASC, V26, P2793, DOI 10.1016/j.jstrokecerebrovasdis.2017.06.060
   Mueller-Kronast NH, 2017, STROKE, V48, P2760, DOI 10.1161/STROKEAHA.117.016456
   Murphy Sherry L, 2017, Natl Vital Stat Rep, V66, P1
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Slawski DE, 2018, INTERV NEUROL, V7, P246, DOI 10.1159/000487333
   Soderqvist AK, 2016, J STROKE CEREBROVASC, V25, P2276, DOI 10.1016/j.jstrokecerebrovasdis.2016.05.019
   Son S, 2017, ACTA NEUROCHIR, V159, P1663, DOI 10.1007/s00701-017-3269-y
   Sweid A, 2019, WORLD NEUROSURG, V127, P362, DOI 10.1016/j.wneu.2019.04.123
   Tonetti DA, 2018, WORLD NEUROSURG, V119, pE941, DOI 10.1016/j.wneu.2018.08.008
   Villwock MR, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004480
NR 15
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E835
EP E841
DI 10.1016/j.wneu.2019.10.024
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700153
PM 31614218
OA Bronze
DA 2020-05-12
ER

PT J
AU Tafreshi, AR
   Du, RB
   Rutkowski, MJ
   Donoho, DA
   Shiroishi, MS
   Liu, CSJ
   Kim, PE
   Carmichael, JD
   Zada, G
AF Tafreshi, Ali R.
   Du, Robin
   Rutkowski, Martin J.
   Donoho, Daniel A.
   Shiroishi, Mark S.
   Liu, Chia-Shang J.
   Kim, Paul E.
   Carmichael, John D.
   Zada, Gabriel
TI Differential Clinical Presentation, Intraoperative Management
   Strategies, and Surgical Outcomes After Endoscopic Endonasal Treatment
   of Cystic Sellar Masses
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adenoma; Arachnid cyst; Endoscopic; Pituitary; Rathke cleft cyst; Sella;
   Transsphenoidal
ID RATHKE CLEFT CYSTS; CEREBROSPINAL-FLUID LEAKS; TRANSSPHENOIDAL SURGERY;
   PITUITARY-ADENOMAS; LESIONS; DIAGNOSIS; EXPERIENCE; CRANIOPHARYNGIOMA;
   FEATURES; METAANALYSIS
AB BACKGROUND: Cystic sellar masses (CSMs) pose diagnostic and therapeutic challenges associated with subtotal cyst wall resection, cerebrospinal fluid (CSF) leak repair, and disease recurrence. Current magnetic resonance imaging (MRI) interpretation often cannot reliably differentiate CSMs, mandating adaptable intraoperative strategies. We reviewed our diagnostic and therapeutic experience after endoscopic endonasal approaches (EEAs) for CSMs.
   METHODS: A retrospective record review of patients with CSM managed via EEA at the University of Southern California from 2011 to 2018 was conducted. Patient demographics, preoperative characteristics, surgical details, pathologic findings, and postoperative outcomes were assessed.
   RESULTS: Analysis included 47 patients (mean age, 43.2 years); of these, 78.7% were women. Preoperative symptoms included headache (76.6%) and vision loss (42.6%). Histologically verified sellar pathology included 27 Rathke cleft cysts (RCCs) (57.4%), 17 cystic pituitary adenomas (CPAs) (36.2%), 2 arachnoid cysts (4.3%), and 1 xanthogranuloma (2.1%). Twelve patients (70.6%) with CPAs underwent complete resection and 5 (29.4%) underwent subtotal resection. All 27 patients with RCC and 2 patients with arachnoid cyst underwent complete fenestration and drainage. One xanthogranuloma was completely resected. There were 14 intraoperative (29.8%) and 4 postoperative CSF leaks (8.5%). Headaches, vision, and endocrinopathy improved in 69.2%, 80.0%, and 33.3% of patients with CPA and 73.9%, 71.4%, and 40.9% of patients with RCC, respectively. There were 2 RCC recurrences and 1 CPA recurrence over the follow-up period.
   CONCLUSIONS: Surgeons must prepare for versatile management strategies of CSMs based on pretest probability associated with MRI and intraoperative findings. Outcomes after EEA for CSMs show low complication profiles and excellent rates of headache and visual improvement, albeit lower rates of endocrine normalization.
C1 [Tafreshi, Ali R.; Du, Robin; Rutkowski, Martin J.; Donoho, Daniel A.; Carmichael, John D.; Zada, Gabriel] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
   [Shiroishi, Mark S.; Liu, Chia-Shang J.; Kim, Paul E.] Univ Southern Calif, Keck Sch Med, Dept Radiol, Div Neuroradiol, Los Angeles, CA 90007 USA.
   [Carmichael, John D.] Univ Southern Calif, Keck Sch Med, Dept Internal Med, Div Endocrinol, Los Angeles, CA 90007 USA.
RP Tafreshi, AR (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
EM tafreshi@usc.edu
OI Tafreshi, Ali/0000-0002-8956-3373
CR Agam MS, 2019, J NEUROSURG, V130, P1576, DOI 10.3171/2017.12.JNS172318
   Benveniste RJ, 2004, J NEUROSURG, V101, P577, DOI 10.3171/jns.2004.101.4.0577
   Cavallo LM, 2008, NEUROSURG REV, V31, P55, DOI 10.1007/s10143-007-0098-0
   Choi SH, 2007, CLIN RADIOL, V62, P453, DOI 10.1016/j.crad.2006.12.001
   Choudhry OJ, 2012, J NEUROL SURG PART A, V73, P324, DOI 10.1055/s-0032-1304814
   Clayton RN, 2004, FRONT HORM RES, V32, P186
   Connor SEJ, 2003, CLIN RADIOL, V58, P20, DOI 10.1053/crad.2002.1119
   D'Haens J, 2009, SURG NEUROL, V72, P336, DOI 10.1016/j.surneu.2009.04.012
   Dehdashti AR, 2008, NEUROSURGERY, V62, P1006, DOI 10.1227/01.neu.0000325862.83961.12
   DeKlotz TR, 2012, LARYNGOSCOPE, V122, P511, DOI 10.1002/lary.22479
   Do H, 2017, WORLD NEUROSURG, V102, P35, DOI 10.1016/j.wneu.2017.02.131
   Dubuisson AS, 2007, NEUROSURGERY, V61, P505, DOI 10.1227/01.NEU.0000290896.69825.40
   El-Mahdy W, 1998, NEUROSURGERY, V42, P7, DOI 10.1097/00006123-199801000-00003
   Fleseriu M, 2009, J NEUROSURG, V110, P354, DOI 10.3171/2008.8.JNS08805
   Fourman LT, 2015, J CLIN ENDOCR METAB, V100, P812, DOI 10.1210/jc.2014-3344
   Frank G, 2005, NEUROSURGERY, V56, P124, DOI 10.1227/01.NEU.0000144824.80046.1F
   Gaillard S, 2014, WORLD NEUROSURG, V82, pS116, DOI 10.1016/j.wneu.2014.07.033
   Gondim JA, 2010, PITUITARY, V13, P68, DOI 10.1007/s11102-009-0195-x
   Hama S, 2002, J NEUROSURG, V96, P209, DOI 10.3171/jns.2002.96.2.0209
   HARRISON MJ, 1994, J NEUROSURG, V80, P1018, DOI 10.3171/jns.1994.80.6.1018
   Hernandez-Estrada RA, 2017, J NEUROL SURG PART B, V78, pP131
   Higgins DM, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.5.FOCUS1175
   Iqbal J, 1999, ACTA NEUROCHIR, V141, P389, DOI 10.1007/s007010050315
   Jho HD, 1997, J NEUROSURG, V87, P44, DOI 10.3171/jns.1997.87.1.0044
   Jho HD, 2001, J NEURO-ONCOL, V54, P187, DOI 10.1023/A:1012969719503
   Kim JE, 2004, J NEUROSURG, V100, P33, DOI 10.3171/jns.2004.100.1.0033
   Laws ER, 2008, NAT CLIN PRACT ENDOC, V4, P662, DOI 10.1038/ncpendmet0975
   Levy A, 2004, J NEUROL NEUROSUR PS, V75, P47, DOI 10.1136/jnnp.2004.045740
   Lin M, 2019, J NEUROSURG, V130, P831, DOI 10.3171/2017.11.JNS171498
   Luo Chao-Bao, 2000, Kaohsiung Journal of Medical Sciences, V16, P26
   Madhok R, 2010, J NEUROSURG, V112, P1333, DOI 10.3171/2009.10.JNS09348
   Magro E, 2016, WORLD NEUROSURG, V89, P442, DOI 10.1016/j.wneu.2016.02.059
   MARAZUELA M, 1994, J ENDOCRINOL INVEST, V17, P703, DOI 10.1007/BF03347763
   Mehta GU, 2012, J NEUROSURG, V116, P1299, DOI 10.3171/2012.3.JNS112160
   Memel Z, 2019, OPER NEUROSURG, V16, P302, DOI 10.1093/ons/opy109
   Fernandez-Balsells MM, 2011, J CLIN ENDOCR METAB, V96, P905, DOI 10.1210/jc.2010-1054
   Molitch ME, 2017, JAMA-J AM MED ASSOC, V317, P516, DOI 10.1001/jama.2016.19699
   Ntali G, 2018, PITUITARY, V21, P111, DOI 10.1007/s11102-018-0869-3
   Park M, 2015, AM J NEURORADIOL, V36, P1866, DOI 10.3174/ajnr.A4387
   Rutkowski MJ, 2018, J NEUROSURG, V128, P1058, DOI 10.3171/2016.12.JNS162126
   Sanno N, 2003, EUR J ENDOCRINOL, V149, P123, DOI 10.1530/eje.0.1490123
   Shepard MJ, 2018, J NEUROSURG-PEDIATR, V21, P308, DOI 10.3171/2017.9.PEDS17400
   Shiley SG, 2003, LARYNGOSCOPE, V113, P1283, DOI 10.1097/00005537-200308000-00003
   Shin JL, 1999, J CLIN ENDOCR METAB, V84, P3972, DOI 10.1210/jc.84.11.3972
   Simard MF, 2003, NEUROSURG CLIN N AM, V14, P41, DOI 10.1016/S1042-3680(02)00036-0
   Snyder BJ, 2008, CONTEMP ENDOCRINOL S, P445, DOI 10.1007/978-1-59745-264-9_23
   Somma T, 2017, WORLD NEUROSURG, V100, P369, DOI 10.1016/j.wneu.2016.11.057
   Strickland BA, 2018, J NEUROSURG, V129, P425, DOI 10.3171/2017.4.JNS162451
   SUMIDA M, 1994, AM J NEURORADIOL, V15, P525
   Tabaee A, 2009, J NEUROSURG, V111, P545, DOI 10.3171/2007.12.17635
   VOELKER JL, 1991, J NEUROSURG, V74, P535, DOI 10.3171/jns.1991.74.4.0535
   Wedemeyer MA, 2018, J NEUROL SURG PART B, V79, pA072
   Zada G, 2011, J NEUROSURG, V114, P336, DOI 10.3171/2010.8.JNS10290
   Zada G, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10155
   Zada G, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS09318
   Zada G, 2009, NEUROSURGERY, V64, P1132, DOI 10.1227/01.NEU.0000341873.20737.56
NR 56
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E241
EP E251
DI 10.1016/j.wneu.2019.08.234
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700031
PM 31505289
OA Bronze
DA 2020-05-12
ER

PT J
AU Vakharia, K
   Waqas, M
   Munich, SA
   Lim, J
   Gong, A
   Chin, F
   Snyder, KV
   Siddiqui, AH
   Levy, EI
AF Vakharia, Kunal
   Waqas, Muhammad
   Munich, Stephan A.
   Lim, Jaims
   Gong, Andrew
   Chin, Felix
   Snyder, Kenneth, V
   Siddiqui, Adnan H.
   Levy, Elad, I
TI Is Contrast Stasis After Pipeline Embolization Device Deployment
   Associated with Higher Aneurysm Occlusion Rates?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm occlusion; Contrast stasis; Pipeline embolization device
ID INTRACRANIAL ANEURYSMS; FLOW DIVERSION; CEREBRAL ANEURYSMS; DIVERTOR;
   SCALE
AB OBJECTIVE: To assess the association of degree of contrast stasis in intracranial aneurysms (IAs) immediately after Pipeline embolization device (PED; Medtronic, Dublin, Ireland) deployment with 6- and 12-month angiographic occlusion rates.
   METHODS: This retrospective cohort study included consecutive patients undergoing PED deployment for saccular IA treatment at a large-volume cerebrovascular center over a 4-year 9-month period. Angiographic images obtained immediately after PED deployment were graded according to amount of intra-aneurysmal contrast flow during the late venous phase: 0 = no stasis; 1 = <50% contrast stasis; 2 = 50%-75% stasis; and 3 = >75%-99% stasis. Follow-up occlusion rates were determined by digital subtraction angiography, computed tomographic angiography, or magnetic resonance angiography.
   RESULTS: The study included 119 patients in whom 182 PEDs were deployed to treat 141 aneurysms. A single PED was deployed in 105 (74.5%) aneurysms. The internal carotid artery was the commonest aneurysm site (119 [85%]). Fifty-two (36.9%) aneurysms were grade 0; 33 (23.4%) were grade 1; 46 (32.6%) were grade 2; and 10 (7.1%) were grade 3 immediately post-treatment. A 6-month follow-up angiogram available for 101 aneurysms showed complete occlusion (no flow into the aneurysm) in 74 (73.3%) aneurysms. A 12-month follow-up study available for 132 aneurysms showed complete occlusion in 79.5%. At last follow-up, occlusion rates were not significantly different for different contrast stasis grades (P = 0.60). Mean angiographic follow up for all IAs was 23v +/- 17.7 months. IA size, sex, age, and smoking were not significant predictors of occlusion.
   CONCLUSIONS: The degree of aneurysm contrast stasis immediately after PED deployment is not statistically associated with 6- and 12-month angiographic occlusion rates.
C1 [Vakharia, Kunal; Waqas, Muhammad; Munich, Stephan A.; Lim, Jaims; Chin, Felix; Snyder, Kenneth, V; Siddiqui, Adnan H.; Levy, Elad, I] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, New York, NY 14260 USA.
   [Gong, Andrew] Univ Buffalo, Jacobs Sch Med & Biomed Sci, New York, NY USA.
   [Snyder, Kenneth, V] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurol, New York, NY USA.
   [Snyder, Kenneth, V; Siddiqui, Adnan H.; Levy, Elad, I] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Canon Stroke & Vasc Res Ctr, New York, NY 14260 USA.
   [Siddiqui, Adnan H.; Levy, Elad, I] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, New York, NY 14260 USA.
   [Vakharia, Kunal; Waqas, Muhammad; Munich, Stephan A.; Lim, Jaims; Gong, Andrew; Chin, Felix; Snyder, Kenneth, V; Siddiqui, Adnan H.; Levy, Elad, I] Kaleida Hlth, Gates Vasc Inst, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Snyder, Kenneth, V; Siddiqui, Adnan H.] Jacobs Inst, Buffalo, NY USA.
RP Levy, EI (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, New York, NY 14260 USA.; Levy, EI (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Canon Stroke & Vasc Res Ctr, New York, NY 14260 USA.; Levy, EI (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, New York, NY 14260 USA.; Levy, EI (reprint author), Kaleida Hlth, Gates Vasc Inst, Dept Neurosurg, Buffalo, NY 14260 USA.
EM elevy@ubns.com
OI Chin, Felix/0000-0001-6923-5033
CR Briganti F, 2015, NEURORADIOL J, V28, P365, DOI 10.1177/1971400915602803
   Cekirge HS, 2016, AM J NEURORADIOL, V37, P19, DOI 10.3174/ajnr.A4489
   Chua MMJ, 2019, ANN NEUROL, V85, P793, DOI 10.1002/ana.25484
   Eller JL, 2014, EXPERT REV MED DEVIC, V11, P137, DOI 10.1586/17434440.2014.877188
   Girdhar G, 2015, J THROMB THROMBOLYS, V40, P437, DOI 10.1007/s11239-015-1228-0
   Grunwald IQ, 2012, ACTA NEUROCHIR, V154, P21, DOI 10.1007/s00701-011-1177-0
   Jing LK, 2016, WORLD NEUROSURG, V89, P199, DOI 10.1016/j.wneu.2016.01.079
   Kamran M, 2011, NEURORADIOLOGY, V53, P501, DOI 10.1007/s00234-010-0767-5
   Labeyrie PE, 2016, INTERV NEURORADIOL, V22, P682, DOI 10.1177/1591019916662192
   Li CH, 2012, J NEUROSURG, V117, P276, DOI 10.3171/2012.5.JNS111558
   Mazur MD, 2016, J NEUROINTERV SURG, V8, P1294, DOI 10.1136/neurintsurg-2015-012193
   Mut F, 2015, J NEUROINTERV SURG, V7, P286, DOI 10.1136/neurintsurg-2013-011080
   O'Kelly CJ, 2010, INTERV NEURORADIOL, V16, P133, DOI 10.1177/159101991001600204
   Pereira VM, 2013, AM J NEURORADIOL, V34, P808, DOI 10.3174/ajnr.A3322
   Rangel-Castilla L, 2015, OPER NEUROSURG, V11, P426, DOI 10.1227/NEU.0000000000000864
   Sadasivan C, 2002, AM J NEURORADIOL, V23, P1214
   Texakalidis P, 2017, CLIN NEUROL NEUROSUR, V161, P78, DOI 10.1016/j.clineuro.2017.08.003
NR 17
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E434
EP E442
DI 10.1016/j.wneu.2019.09.032
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700100
PM 31525478
OA Bronze
DA 2020-05-12
ER

PT J
AU Vieira-Leite, C
   Mosqueira, AJ
   Arias-Rivas, S
   Rodriguez-Yanez, M
   Pumar, JM
AF Vieira-Leite, Cecilia
   Jesus Mosqueira, Antonio
   Arias-Rivas, Susana
   Rodriguez-Yanez, Manuel
   Manuel Pumar, Jose
TI Results of a Single Center's Stenting Procedure for the Treatment of
   Carotid Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid Doppler; Carotid stenosis; Carotid stent; Endarterectomy;
   Ischemic stroke
ID ENDARTERECTOMY; STROKE; EPIDEMIOLOGY; DIAGNOSIS
AB BACKGROUND: Stenting may be a safer alternative to endarterectomy for treating carotid artery stenosis (CAS), but its long-term efficacy is uncertain. There is a lack of long-term and noncontrolled clinical trial data that reflects "real-world" CAS. This study aimed to analyze the long-term efficacy and safety of our center's CAS procedure.
   METHODS: We retrospectively analyzed our database of patients who underwent CAS. Patient demographic data, previous risk factors, diagnostic and procedural information, and clinical and image follow-up data were collected from up to 1 year after treatment.
   RESULTS: Overall, 187 patients were analyzed. Our patients population largely comprised higher-risk patients compared with the patient populations of randomized controlled trials. We had more symptomatic (n = 145, 77.5%) than asymptomatic patients (n = 42, 22.5%), and 49% of patients had >90% stenosis. By the 30-day follow-up, there were 10 major adverse events (5.3%) observed in 8 patients (4.2%), including 7 strokes (3 ischemic and 4 hemorrhagic) and 3 deaths. By the 1-year follow-up, 6 strokes and 5 deaths occurred in 9 patients (4.8%), and color Doppler control showed that 87.6% of patients had stenosis-free stents.
   CONCLUSIONS: Despite our high-risk population group, there were high rates of successful stent placement, low complication rates, good clinical outcomes, and low rates of stenting restenosis.
C1 [Vieira-Leite, Cecilia; Jesus Mosqueira, Antonio; Manuel Pumar, Jose] Santiago de Compostela Univ Hosp, Dept Radiol, Santiago De Compostela, Spain.
   [Arias-Rivas, Susana; Rodriguez-Yanez, Manuel] Santiago de Compostela Univ Hosp, Dept Neurol, Santiago De Compostela, Spain.
RP Vieira-Leite, C (reprint author), Santiago de Compostela Univ Hosp, Dept Radiol, Santiago De Compostela, Spain.
EM maria.cecilia.vieira.leite.de.lima@sergas.es
CR Arias-Rivas S, 2012, REV NEUROLOGIA, V54, P385, DOI 10.33588/rn.5407.2011551
   Bonati LH, 2018, LANCET NEUROL, V17, P587, DOI 10.1016/S1474-4422(18)30195-9
   Bonati LH, 2015, LANCET, V385, P529, DOI 10.1016/S0140-6736(14)61184-3
   BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Brown MM, 2001, LANCET, V357, P1729
   Di Carlo A, 2009, AGE AGEING, V38, P4, DOI 10.1093/ageing/afn282
   Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5
   Ferguson GG, 1999, STROKE, V30, P1751, DOI 10.1161/01.STR.30.9.1751
   Fortuno JR, 2006, RADIOLOGIA-MADRID, V48, P119, DOI 10.1016/S0033-8338(06)73143-5
   Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80
   Grant EG, 2003, RADIOLOGY, V229, P340, DOI 10.1148/radiol.2292030516
   Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X
   JOHNSON BF, 1995, J VASC SURG, V21, P120, DOI 10.1016/S0741-5214(95)70250-4
   RANKIN J, 1957, Scott Med J, V2, P200
   Ti JP, 2013, NEUROL THER, P14
   Truelsen T, 2006, EUR J NEUROL, V13, P581, DOI 10.1111/j.1468-1331.2006.01138.x
   White CJ, 2014, J AM COLL CARDIOL, V64, P723, DOI 10.1016/j.jacc.2014.04.069
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E487
EP E491
DI 10.1016/j.wneu.2019.09.065
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700107
PM 31542440
OA Bronze
DA 2020-05-12
ER

PT J
AU Wang, DW
   Shu, HS
   Meng, Y
   Zhang, H
   Wang, H
   He, SW
AF Wang, Dawei
   Shu, Hansheng
   Meng, Ying
   Zhang, Hui
   Wang, Hao
   He, Shiwei
TI Factors Promoting Futile Recanalization After Stent Retriever
   Thrombectomy for Stroke Affecting the Anterior Circulation: A
   Retrospective Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute anterior circulation; Futile recanalization; Large vessel
   occlusion; Stent retriever thrombectomy
ID ACUTE ISCHEMIC-STROKE; MECHANICAL THROMBECTOMY; THERAPY; TIME
AB OBJECTIVE: To investigate the factors associated with recanalization after stent retriever thrombectomy in patients with acute ischemic stroke due to large vessel occlusion.
   METHODS: We retrospectively analyzed the medical records of 56 patients with an acute anterior circulation macrovascular occlusion who underwent successful stent retriever thrombectomy. Patients were classified as successful recanalization or futile recanalization at the follow-up. Univariate analysis and binary logic regression analysis were used to explore the association between patients' demographic and clinical characteristics and futile recanalization.
   RESULTS: The rate of futile recanalization was signifi-ntly higher after stent retrieval thrombectomy in patients with an Alberta Stroke Program Early CT (ASPECT) score <= 7 points versus >7 points (P < 0.001), >= 5 passes with the stent retriever versus <5 passes with the stent retriever (P = 0.036), or a longer recanalization time (P = 0.008). The influence of number of stent retriever pass is foremost, followed by ASPECT and occurrence to recanalization.
   CONCLUSIONS: Improving technical expertise with mechanical thrombectomy and shortening the therapeutic time window may improve the prognosis of patients with acute ischemic stroke due to large vessel occlusion.
C1 [Wang, Dawei; Shu, Hansheng; Zhang, Hui; Wang, Hao; He, Shiwei] Bengbu Med Coll, Dept Neurosurg, Affiliated Hosp 2, Bengbu, Peoples R China.
   [Meng, Ying] Bengbu Med Coll, Dept Neurol, Affiliated Hosp 2, Bengbu, Peoples R China.
RP Wang, DW (reprint author), Bengbu Med Coll, Dept Neurosurg, Affiliated Hosp 2, Bengbu, Peoples R China.
EM liangtiji@outlook.com
FU Natural Science Foundation for Colleges and Universities of Anhui
   Province [KJ2018A1016]; Excellent Young Talents Foundation for Colleges
   and Universities of Anhui Province [gxyq2019039]
FX Supported by the Natural Science Foundation for Colleges and
   Universities of Anhui Province (KJ2018A1016), and the Excellent Young
   Talents Foundation for Colleges and Universities of Anhui Province
   (gxyq2019039).
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Baek JH, 2018, STROKE, V49, P2088, DOI 10.1161/STROKEAHA.118.021320
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Dong Q, 2017, STROKE VASC NEUROL, V2, P147, DOI 10.1136/svn-2017-000074
   Flottmann F, 2018, STROKE, V49, P2523, DOI 10.1161/STROKEAHA.118.022737
   Higashida Randall, 2003, J Vasc Interv Radiol, V14, pS493
   Jia BX, 2018, J NEUROINTERV SURG, V10, P746, DOI 10.1136/neurintsurg-2017-013489
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Moore JM, 2016, CLIN NEUROL NEUROSUR, V148, P22, DOI 10.1016/j.clineuro.2016.06.007
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Xu AD, 2013, CNS NEUROSCI THER, V19, P543, DOI 10.1111/cns.12126
   Yoo AJ, 2017, J STROKE, V19, P121, DOI 10.5853/jos.2017.00752
   Yoo AJ, 2010, STROKE, V41, P1728, DOI 10.1161/STROKEAHA.110.582874
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E576
EP E582
DI 10.1016/j.wneu.2019.09.098
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700119
PM 31561042
OA Bronze
DA 2020-05-12
ER

PT J
AU Wettervik, TS
   Howells, T
   Hillered, L
   Nilsson, P
   Engquist, H
   Lewen, A
   Enblad, P
   Rostami, E
AF Wettervik, Teodor Svedung
   Howells, Timothy
   Hillered, Lars
   Nilsson, Pelle
   Engquist, Henrik
   Lewen, Anders
   Enblad, Per
   Rostami, Elham
TI Mild Hyperventilation in Traumatic Brain Injury-Relation to Cerebral
   Energy Metabolism, Pressure Autoregulation, and Clinical Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral energy metabolism; Clinical outcome; Hyperventilation;
   Neurointensive care; Pressure reactivity; Traumatic brain injury
ID SEVERE HEAD-INJURY; BLOOD-FLOW; PROLONGED HYPERVENTILATION; MODERATE
   HYPERVENTILATION; NEUROINTENSIVE CARE; REACTIVITY; MANAGEMENT; THERAPY
AB OBJECTIVE: Hyperventilation is a controversial treatment in traumatic brain injury (TBI). Prophylactic severe hyperventilation (below 3.3 kPa/25 mm Hg) is generally avoided, due to the risk of cerebral ischemia. Mild hyperventilation (arterial pCO(2) within 4.0-4.5 kPa/30-34 mm Hg) in cases of intracranial hypertension is commonly used, but its safety and benefits are not fully elucidated. The aim of this study was to evaluate the use of mild hyperventilation and its relation to cerebral energy metabolism, pressure autoregulation, and clinical outcome in TBI.
   METHODS: This retrospective study was based on 120 patients with severe TBI treated at the neurointensive care unit, Uppsala University Hospital, Sweden, between 2008 and 2018. Data from cerebral microdialysis (glucose, pyruvate, and lactate), arterial pCO(2), and pressure reactivity index were analyzed for the first 3 days post-injury.
   RESULTS: Mild hyperventilation, 4.0-4.5 kPa (30-34 mm Hg), was more frequently used early and the patients were gradually normoventilated. Low pCO(2) was associated with slightly higher intracranial pressure and slightly lower cerebral perfusion pressure (P < 0.01). There was no univariate correlation between low pCO(2) and worse cerebral energy metabolism. Multiple linear regression analysis showed that mild hyperventilation was associated with lower pressure reactivity index on day 2 (P = 0.03), suggesting better pressure autoregulation. Younger age and lower intracranial pressure were also associated with lower pressure reactivity index.
   CONCLUSIONS: These findings support the notion that mild hyperventilation is safe and may improve cerebravascular reactivity.
C1 [Wettervik, Teodor Svedung; Howells, Timothy; Hillered, Lars; Nilsson, Pelle; Lewen, Anders; Enblad, Per; Rostami, Elham] Uppsala Univ, Dept Neurosci, Sect Neurosurg, Uppsala, Sweden.
   [Engquist, Henrik] Uppsala Univ, Dept Surg Sci Anesthesia & Intens Care, Uppsala, Sweden.
RP Wettervik, TS (reprint author), Uppsala Univ, Dept Neurosci, Sect Neurosurg, Uppsala, Sweden.
EM teodor.svedung-wettervik@neuro.uu.se
OI Engquist, Henrik/0000-0002-9826-1422
CR Brandi G, 2019, CRIT CARE, V23, DOI 10.1186/s13054-018-2304-6
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Carrera E, 2010, J NEUROL NEUROSUR PS, V81, P793, DOI 10.1136/jnnp.2009.174425
   COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166
   Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88
   Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005
   Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007
   Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029
   Godoy DA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00250
   Haubrich Christina, 2012, Acta Neurochir Suppl, V114, P153, DOI 10.1007/978-3-7091-0956-4_28
   Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311
   Howells T, 2015, J CLIN MONIT COMPUT, V29, P97, DOI 10.1007/s10877-014-9573-7
   KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358
   MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011
   Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001
   Marklund N, 2014, J NEUROTRAUM, V31, P42, DOI 10.1089/neu.2013.2964
   Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009
   MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731
   MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923
   Neumann JO, 2008, INTENS CARE MED, V34, P1676, DOI 10.1007/s00134-008-1123-7
   NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424
   Nyholm L, 2013, UPSALA J MED SCI, V118, P169, DOI 10.3109/03009734.2013.806616
   Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023
   Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397
   Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17
   STRINGER WA, 1993, AM J NEURORADIOL, V14, P475
   Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587
   Wettervik TS, 2019, J NEUROTRAUM, V36, P1818, DOI 10.1089/neu.2018.6157
   Wilson JL, 1988, J NEUROTRAUM, V15, P573
   Zhang Y, 2016, ACTA NEUROCHIR SUPPL, V122, P205, DOI 10.1007/978-3-319-22533-3_41
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E567
EP E575
DI 10.1016/j.wneu.2019.09.099
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700118
PM 31561041
OA Bronze
DA 2020-05-12
ER

PT J
AU Wilde, H
   Gamblin, AS
   Reese, J
   Garry, JG
   Guan, J
   Mortenson, J
   Flis, A
   Rosenbluth, JP
   Karsy, M
   Bisson, EF
   Dailey, AT
AF Wilde, Herschel
   Gamblin, Austin S.
   Reese, Jared
   Garry, Jason G.
   Guan, Jian
   Mortenson, Janel
   Flis, Alexandra
   Rosenbluth, Jeffrey P.
   Karsy, Michael
   Bisson, Erica F.
   Dailey, Andrew T.
TI The Effect of Hospital Transfer on Patient Outcomes After Rehabilitation
   for Spinal Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE American Spinal Injury Association injury severity score; Functional
   independence measure; Hospital transfer; Outcomes; Rehabilitation;
   Spinal cord injury; Trauma
ID CORD-INJURY; INTERHOSPITAL TRANSFER; FUNCTIONAL OUTCOMES; UNITED-STATES;
   RECOVERY; THERAPY; SAMPLE; STAY; CARE
AB OBJECTIVE: Spine fractures, including associated spinal cord injury, account for 3%-6% of all skeletal fractures annually in the United States. Patients who undergo interhospital transfer after injury may have a greater likelihood of nonroutine disposition, longer hospital stay, and higher cost. We evaluated the effects of patient transfer on functional outcomes after spine trauma.
   METHODS: Patients were treated after acute traumatic spine injury at a rehabilitation hospital in 2011-2017. Compared patients were those directly admitted to the tertiary hospital or transferred from a community hospital.
   RESULTS: A total of 188 patients (mean age 46.1 +/- 18.6 years, 77.1% men) were evaluated, including 130 (69.1%) directly admitted and 58 (30.9%) transferred patients. The most common levels of injury were at C5 (19.1%) and C6 (12.2%), and most injuries were American Spinal Injury Association injury severity score grade D (33.2%) or grade A (32.1%). No statistical difference in age, injury pattern, timing from injury to surgery, or rehabilitation length of stay was seen between admitted and transferred patients. A significant improvement in ambulation distances was seen at discharge for directly admitted compared with transferred patients (447.7 +/- 724.9 vs. 159.9 +/- 359.5 feet; P = 0.005). However, no significant difference primary outcomes, namely American Spinal Injury Association injury severity score distribution (P = 0.2) or Functional Independence Measures (Delta 30.9 +/- 15.9 vs. 30.1 +/- 17.1; P = 0.7), were seen between admitted and transferred patients at time of rehabilitation discharge.
   CONCLUSIONS: Interhospital transfer status did not diminish time to rehabilitation after injury or reduce functional recovery, suggesting early surgical treatment in community settings may have merit prior to transfer.
C1 [Wilde, Herschel; Gamblin, Austin S.; Reese, Jared; Garry, Jason G.; Guan, Jian; Karsy, Michael; Bisson, Erica F.; Dailey, Andrew T.] Univ Utah, Dept Neurosurg, Salt Lake City, UT 84112 USA.
   [Mortenson, Janel; Flis, Alexandra; Rosenbluth, Jeffrey P.] Univ Utah, Dept Phys Med & Rehabil, Salt Lake City, UT USA.
RP Karsy, M (reprint author), Univ Utah, Dept Neurosurg, Salt Lake City, UT 84112 USA.
EM Michael.karsy@hsc.utah.edu
RI Karsy, Michael/AAH-8583-2020
OI Karsy, Michael/0000-0002-0422-7937; Reese, Jared/0000-0001-7942-0435
CR AlHuthaifi F, 2017, J SPINAL CORD MED, V40, P282, DOI 10.1080/10790268.2016.1238184
   Dvorak MF, 2015, J NEUROTRAUM, V32, P645, DOI 10.1089/neu.2014.3632
   Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037
   Greenwald BD, 2001, ARCH PHYS MED REHAB, V82, P1181, DOI 10.1053/apmr.2001.24891
   Guan Jian, 2017, Surg Neurol Int, V8, P210, DOI 10.4103/sni.sni_28_17
   Hawryluk GWJ, 2006, YOUMANS NEUROLOGICAL, P2730
   Holland CM, 2017, SPINE, V42, P1923, DOI 10.1097/BRS.0000000000002246
   Holland CM, 2017, NEUROSURGERY, V81, P450, DOI 10.1093/neuros/nyw124
   Horn SD, 2013, ARCH PHYS MED REHAB, V94, pS75, DOI 10.1016/j.apmr.2012.10.036
   Jain NB, 2015, JAMA-J AM MED ASSOC, V313, P2236, DOI 10.1001/jama.2015.6250
   Kirshblum S, 2004, ARCH PHYS MED REHAB, V85, P1811, DOI 10.1016/j.apmr.2004.03.015
   Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94
   Kuhn EN, 2016, NEUROSURGERY, V79, P541, DOI 10.1227/NEU.0000000000001378
   Lee BA, 2016, J SPINAL CORD MED, V39, P67, DOI 10.1179/2045772314Y.0000000280
   Looby S, 2011, RADIOL CLIN N AM, V49, P129, DOI 10.1016/j.rcl.2010.07.019
   Nas K, 2015, WORLD J ORTHOP, V6, P8, DOI 10.5312/wjo.v6.i1.8
   National SPinal Cord Injury Statistical Center, 2016, NATL SPINAL CORD INJ
   Schnurman Z, 2017, WORLD NEUROSURG, V104, P702, DOI 10.1016/j.wneu.2017.05.082
   Sherrod B, 2019, J NEUROSURG-SPINE, V31, P93, DOI 10.3171/2018.12.SPINE18964
   Tian WQ, 2013, ARCH PHYS MED REHAB, V94, pS125, DOI 10.1016/j.apmr.2012.10.039
   Truchon C, 2017, J NEUROTRAUM, V34, P2901, DOI 10.1089/neu.2016.4932
   Vedantam A, 2016, J NEUROSURG-PEDIATR, V18, P638, DOI 10.3171/2016.5.PEDS16155
   Weyhenmeyer J, 2018, J NEUROSURG, V128, P490, DOI 10.3171/2016.9.JNS16668
   Wilson JR, 2014, SPINE J, V14, P1192, DOI 10.1016/j.spinee.2013.08.005
   Wilson JR, 2012, J NEUROTRAUM, V29, P2263, DOI 10.1089/neu.2012.2417
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E76
EP E83
DI 10.1016/j.wneu.2019.08.091
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700010
PM 31521757
OA Bronze
DA 2020-05-12
ER

PT J
AU Wong, AK
   Shinners, M
   Wong, RH
AF Wong, Andrew K.
   Shinners, Michael
   Wong, Ricky H.
TI Minimally Invasive Repair of Tegmen Defects Through Keyhole Middle Fossa
   Approach to Reduce Hospitalization
SO WORLD NEUROSURGERY
LA English
DT Article
DE CSF leak; Keyhole craniotomy; Middle fossa approach; Minimally invasive;
   Tegmen defect
ID TEMPORAL BONE ENCEPHALOCELES; CEREBROSPINAL-FLUID OTORRHEA;
   CEREBRAL-BLOOD-FLOW; BRAIN RETRACTION; CRANIAL FOSSA; CSF OTORRHEA;
   MANAGEMENT; PRESSURE; TYMPANI; LEAKS
AB OBJECTIVE: The middle fossa craniotomy for tegmen defect repair provides wide access. This approach often requires temporal lobe manipulation, lumbar drain placement, and longer recovery. We describe a keyhole middle fossa approach with a simple titanium skull base repair that allows for wide access with no temporal lobe manipulation and does not require lumbar drain placement, which results in a dramatic reduction in hospital length of stay.
   METHODS: A retrospective review was performed on 14 consecutive patients with spontaneous cerebrospinal fluid (CSF) otorrhea. Each patient underwent a keyhole middle fossa approach followed by multilayer dural repair with titanium mesh "gull wing" skull base reconstruction. Postoperative measures included operative time, length of hospital stay, CSF leak recurrence, and surgical complications (seizures, hemorrhage, aphasia, infection).
   RESULTS: The average age of the patients was 60.7 +/- 12.7 years old, and average body mass index was 32.8 + 7.9 kg/m(2). Nine of the patients were female. The average operative time was 103 +/- 32.8 minutes. The average hospital length of stay was 1.4 days. There were no cases of postoperative CSF otorrhea, meningitis, aphasia, or seizures. There were no recurrences over a mean follow-up of 20.3 months (range: 5-48 months).
   CONCLUSIONS: A minimally invasive keyhole middle fossa approach with a multilayer dural reconstruction including titanium mesh "gull wing" skull base repair provides a quick, effective treatment for a broad spectrum of tegmen defects and meningoencephaloceles. This exposure and reconstruction technique do not require the use of a lumbar drain and result in minimal hospitalization.
C1 [Wong, Andrew K.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
   [Shinners, Michael] NorthShore Univ Hlth Syst, Sect Otolaryngol, Evanston, IL USA.
   [Wong, Ricky H.] NorthShore Univ Hlth Syst, Dept Neurosurg, Evanston, IL 60201 USA.
RP Wong, RH (reprint author), NorthShore Univ Hlth Syst, Dept Neurosurg, Evanston, IL 60201 USA.
EM Wong.ricky@gmail.com
CR ANDREWS R J, 1992, Neurological Research, V14, P12
   ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052
   Bakhsheshian J, 2015, JAMA OTOLARYNGOL, V141, P733, DOI 10.1001/jamaoto.2015.1128
   Buchanan IA, 2019, WORLD NEUROSURG, V122, pE1102, DOI 10.1016/j.wneu.2018.10.237
   Buchanan IA, 2018, WORLD NEUROSURG, V120, pE440, DOI 10.1016/j.wneu.2018.08.102
   Carlson ML, 2013, J NEUROSURG, V119, P1314, DOI 10.3171/2013.6.JNS13322
   De Carpentier J, 1999, CLIN OTOLARYNGOL, V24, P328, DOI 10.1046/j.1365-2273.1999.00273.x
   Francel P C, 1992, J Craniofac Surg, V3, P145, DOI 10.1097/00001665-199211000-00006
   GACEK RR, 1992, ARCH OTOLARYNGOL, V118, P327
   GACEK RR, 1990, ANN OTO RHINOL LARYN, V99, P854, DOI 10.1177/000348949009901102
   Goddard JC, 2010, OTOL NEUROTOL, V31, P940, DOI 10.1097/MAO.0b013e3181e8f36c
   Governale LS, 2008, NEUROSURGERY, V63, P379, DOI 10.1227/01.NEU.0000327023.18220.88
   KAPUR TR, 1986, J LARYNGOL OTOL, V100, P1129, DOI 10.1017/S0022215100100702
   Kari E, 2011, ACTA OTO-LARYNGOL, V131, P391, DOI 10.3109/00016489.2011.557836
   Kenning TJ, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.4.FOCUS1265
   Kutz JW, 2008, LARYNGOSCOPE, V118, P2195, DOI 10.1097/MLG.0b013e318182f833
   LANG DV, 1983, J LARYNGOL OTOL, V97, P685, DOI 10.1017/S0022215100094834
   Marchioni D, 2014, J NEUROL SURG PART B, V75, P279, DOI 10.1055/s-0034-1371524
   Markou K, 2011, AM J OTOLARYNG, V32, P135, DOI 10.1016/j.amjoto.2009.12.003
   Nelson RF, 2016, OTOL NEUROTOL, V37, P1625, DOI 10.1097/MAO.0000000000001208
   Oliaei S, 2012, AM J OTOLARYNG, V33, P556, DOI 10.1016/j.amjoto.2012.01.011
   Perez E, 2018, J NEUROL SURG PART B, V79, P451, DOI 10.1055/s-0037-1617439
   Prichard CN, 2006, OTOLARYNG HEAD NECK, V134, P767, DOI 10.1016/j.otohns.2006.01.002
   Rao AK, 2005, OTOL NEUROTOL, V26, P1171, DOI 10.1097/01.mao.0000179526.17285.cc
   Reese JC, 2019, WORLD NEUROSURG, V126, pE914, DOI 10.1016/j.wneu.2019.03.010
   Roehm PC, 2018, J NEUROSURG, V128, P1880, DOI 10.3171/2017.1.JNS161947
   ROSENORN J, 1982, J NEUROSURG, V56, P826, DOI 10.3171/jns.1982.56.6.0826
   Savva A, 2003, LARYNGOSCOPE, V113, P50, DOI 10.1097/00005537-200301000-00010
   Scurry WC, 2007, OTOLARYNG HEAD NECK, V136, P961, DOI 10.1016/j.otohns.2006.11.036
   Semaan MT, 2011, LARYNGOSCOPE, V121, P1765, DOI 10.1002/lary.21887
   Stucken EZ, 2012, OTOL NEUROTOL, V33, P1412, DOI 10.1097/MAO.0b013e318268d350
   Toth M, 2007, OTOL NEUROTOL, V28, P1120, DOI 10.1097/MAO.0b013e31815aee0c
   Welge-Luessen A, 2004, OTOLARYNG HEAD NECK, V130, P375, DOI 10.1016/j.otohns.2003.07.001
   Wind JJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.12.E11
   Wong RH, 2016, WORLD NEUROSURG, V89, P280, DOI 10.1016/j.wneu.2016.02.025
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E683
EP E689
DI 10.1016/j.wneu.2019.09.114
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700132
PM 31568915
OA Bronze
DA 2020-05-12
ER

PT J
AU Wu, GL
   Cai, HY
   Li, GM
   Meng, SH
   Huang, JY
   Xu, HY
   Chen, M
   Hu, MZ
   Yang, WN
   Wang, CY
   Wu, ZJ
   Cai, YF
AF Wu, Guangliang
   Cai, Haiyan
   Li, Guoming
   Meng, Shuhui
   Huang, Jingyan
   Xu, Haoyou
   Chen, Mei
   Hu, Mingzhe
   Yang, Weina
   Wang, Chuyang
   Wu, Zhijian
   Cai, Yefeng
TI Influence of the Matrix Metalloproteinase 9 Geners3918242 Polymorphism
   on Development of Ischemic Stroke: A Meta-analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE 1562C/T; Ischemic stroke; MMP-9; Polymorphism; rs3918242
ID METALLOPROTEINASE GENE POLYMORPHISMS; MATRIX METALLOPROTEINASES;
   CEREBRAL INFARCTION; GLOBAL BURDEN; ASSOCIATION; RISK; INHIBITION;
   SUSCEPTIBILITY; EPIDEMIOLOGY; INFLAMMATION
AB BACKGROUND: The association between matrix metalloproteinase 9 (MMP-9) gene -1562C/T (rs3918242) polymorphism and the susceptibility of ischemic stroke (IS) has been investigated. However, results were ambiguous and inconsistent. Therefore, we performed this study to better assess the potential relationship between rs3918242 polymorphism and susceptibility risk of IS.
   METHODS: We included case-control studies concerning the relationship between the rs3918242 polymorphism and IS, and odds ratios with corresponding 95% confidence intervals were used to describe the associations. Furthermore, meta-regression analyses, heterogeneity, cumulative analyses, sensitivity analyses, and publication bias were examined.
   RESULTS: A total of 19 studies were included for analysis. Significant associations with the risk of IS were detected for the rs3918242 polymorphism in overall population, Asians, and whites. When available data were stratified by gender, we found a significant correlation with the risk of IS in both males and females. Further subgroup analysis by the subtypes of IS showed that the rs3918242 polymorphism was significantly correlated with the risk of patients with large artery atherosclerosis. When stratified by age, we found that the rs3918242 polymorphism was significantly correlated with the risk of IS in patients both aged >= 65 years and >65 years. Both the diabetes and the nondiabetes subgroups reached significant results, and in an analysis stratified by smoking status, an increased risk of IS was associated with smoking.
   CONCLUSIONS: The rs3918242 polymorphism may be a susceptible predictor of susceptibility of IS. Further large-scale studies are needed to verify the results of our findings.
C1 [Wu, Guangliang; Li, Guoming; Xu, Haoyou; Yang, Weina; Wang, Chuyang; Cai, Yefeng] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China.
   [Cai, Haiyan; Wu, Zhijian] Guangzhou Pan Yu Dist Hosp Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Meng, Shuhui; Huang, Jingyan; Chen, Mei; Hu, Mingzhe] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China.
RP Wu, ZJ (reprint author), Guangzhou Pan Yu Dist Hosp Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China.
EM 2946969729@qq.com
CR Alcantara CC, 2018, NEUROREHAB NEURAL RE, V32, P1020, DOI 10.1177/1545968318809921
   Maasz A, 2010, GENOME MED, V2, DOI 10.1186/gm185
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Blankenberg S, 2003, CIRCULATION, V107, P1579, DOI 10.1161/01.CIR.0000058700.41738.12
   Buraczynska K, 2015, NEUROMOL MED, V17, P385, DOI 10.1007/s12017-015-8367-5
   Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396
   Demir R, 2012, ACTA NEUROL BELG, V112, P351, DOI 10.1007/s13760-012-0067-4
   Dichgans M, 2007, LANCET NEUROL, V6, P149, DOI 10.1016/S1474-4422(07)70028-5
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Epstein KA, 2017, NEUROLOGY, V89, P1723, DOI 10.1212/WNL.0000000000004524
   Fan ZZ, 2014, MOL BIOL REP, V41, P6787, DOI 10.1007/s11033-014-3564-0
   Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413
   Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4
   Flossmann E, 2004, STROKE, V35, P212, DOI 10.1161/01.STR.0000107187.84390.AA
   Foerch C, 2009, NEUROLOGY, V73, P393, DOI 10.1212/WNL.0b013e3181b05ef9
   Freije JMP, 2003, ADV EXP MED BIOL, V532, P91
   Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251
   Gao HH, 2014, DNA CELL BIOL, V33, P605, DOI 10.1089/dna.2013.2270
   Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238
   Gu L, 2013, AM J MED SCI, V345, P227, DOI 10.1097/MAJ.0b013e31825f92da
   Gu L, 2013, INT J NEUROSCI, V123, P1, DOI 10.3109/00207454.2012.725118
   Hao YH, 2015, INT J CLIN EXP PATHO, V8, P11647
   He T, 2017, J STROKE CEREBROVASC, V26, P1136, DOI 10.1016/j.jstrokecerebrovasdis.2016.12.036
   He W, 2017, CELL PHYSIOL BIOCHEM, V41, P701, DOI 10.1159/000458429
   Hou L, 2009, CHIN REM CLIN, V9, P575
   Ioannidis JPA, 2008, BMJ-BRIT MED J, V336, P1413, DOI 10.1136/bmj.a117
   Jeffs B, 1997, NAT GENET, V16, P364, DOI 10.1038/ng0897-364
   Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024
   Kong X, 2017, PROG MODERN BIOMED, V17, P5489
   Krause DN, 2006, J APPL PHYSIOL, V101, P1252, DOI 10.1152/japplphysiol.01095.2005
   Lapchak PA, 2000, STROKE, V31, P3034, DOI 10.1161/01.STR.31.12.3034
   Lee BC, 2004, NEUROSCI LETT, V357, P33, DOI 10.1016/j.neulet.2003.12.041
   Lee SR, 2004, J NEUROSCI, V24, P671, DOI 10.1523/JNEUROSCI.4243-03.2004
   Li AiFan, 2018, Chongqing Medicine, V47, P3410
   Li J, 2013, MED J QILU, V28, P321
   Li Y, 2018, CELL PHYSIOL BIOCHEM, V49, P2188, DOI 10.1159/000493823
   Lindgren A, 2014, J STROKE, V16, P114, DOI 10.5853/jos.2014.16.3.114
   Lindsberg PJ, 2003, STROKE, V34, P2518, DOI 10.1161/01.STR.0000089015.51603.CC
   Liu D, 2011, INT J CEREBROVASC DI, V19, P503
   Liu X, 2016, INT J CLIN EXP MED, V9, P18844
   Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270
   Lu SJ, 2018, NEUROPSYCH DIS TREAT, V14, P2225, DOI 10.2147/NDT.S171213
   Misra S, 2018, GENE, V672, P180, DOI 10.1016/j.gene.2018.06.027
   Montaner J, 2003, STROKE, V34, P2851, DOI 10.1161/01.STR.0000098648.54429.1C
   Na S, 2011, CHIN J CLIN NEUROSCI, V19, P476
   Nie SW, 2014, INT J CLIN EXP MED, V7, P400
   NINDS S, 2016, LANCET NEUROL, V0015
   Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5
   Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020
   Sakamoto Y, 2017, EUR J NEUROL, V24, P1399, DOI 10.1111/ene.13405
   Szczudlik P, 2010, NEUROL NEUROCHIR POL, V44, P350
   Vafadari B, 2016, J NEUROCHEM, V139, P91, DOI 10.1111/jnc.13415
   Wang BH, 2018, J CELL BIOCHEM, V119, P9801, DOI 10.1002/jcb.27299
   Wang J, 2017, NEURAL INJURY FUNCTI, V12
   Wells GA, NEWCASTLE OTTAWA SCA
   Wen D, 2014, MOL NEUROBIOL, V50, P979, DOI 10.1007/s12035-014-8687-8
   Whelton PK, 2018, HYPERTENSION, V71, pE13, DOI 10.1161/HYP.0000000000000065
   Yang Y, 2014, GASTROENTEROLOGY, V147, P1031, DOI 10.1053/j.gastro.2014.08.005
   Yi XY, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1294
   Yue Y, 2014, J CLIN NEUROL, V27, P97
   Zhang BP, 1999, HUM GENET, V105, P418, DOI 10.1007/s004390051124
   Zhang L, 2008, J CLIN NEUROL, V21, P425
   Zhao JH, 2015, GENET MOL RES, V14, P19418, DOI 10.4238/2015.December.30.3
   Zhong CK, 2017, NEUROLOGY, V89, P805, DOI 10.1212/WNL.0000000000004257
   [钟望涛 Zhong Wangtao], 2017, [中国神经精神疾病杂志, Chinese Journal of Nervous and Mental Diseases], V43, P410
   [周军 ZHOU Jun], 2009, [中国现代医学杂志, China Journal of Modern Medicine], V19, P1829
   [周元林 ZHOU Yuanlin], 2008, [中华神经科杂志, Chinese Journal of Neurology], V41, P97
NR 67
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E31
EP E61
DI 10.1016/j.wneu.2019.08.026
PG 31
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700007
PM 31415895
OA Bronze
DA 2020-05-12
ER

PT J
AU Xiao, L
   Zhao, QL
   Sun, XM
   Liu, C
   Zhang, Y
   Xu, HG
AF Xiao, Liang
   Zhao, Quanlai
   Sun, Xiumin
   Liu, Chen
   Zhang, Yu
   Xu, Hongguang
TI Relationship Between Alterations of Spinal/Pelvic Sagittal Parameters
   and Clinical Outcomes After Oblique Lumbar Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clinical outcome; Lumbar degenerative disease; Oblique lateral interbody
   fusion; Spinal/pelvic sagittal parameter
ID ADULT SPINAL DEFORMITY; FOLLOW-UP; BALANCE; DECOMPRESSION;
   COMPLICATIONS; ALIGNMENT; DISEASES
AB OBJECTIVE: To elucidate the correlation between changes in spinal/pelvic sagittal parameters and clinical treatment outcomes after oblique lumbar interbody fusion (OLIF).
   METHODS: Eighty-two patients with lumbar degenerative disease (LDD) treated by OLIF were retrospectively analyzed. The visual analog scale (VAS) score and Oswestry Disability Index (ODI) score were compared before and after surgery. Disk height (DH) and various spinal/pelvic sagittal parameters, including pelvic incidence (PI), pelvic tilt (PT), sacral slope (SS), lumbar lordosis (LL), and sagittal vertical axis (SVA), were measured preoperatively and at the last postoperative follow-up. The correlation between the changes in sagittal parameters before and after surgery and the clinical treatment outcomes were observed.
   RESULTS: ODI score, VAS score, and DH were significantly better at the last follow-up compared with before surgery. The change in PI was not statistically significant before and after surgery. PT significantly decreased and SS and LL significantly increased after surgery. Significant linear relationships were found for several independent variables (difference in DH before and after surgery, postoperative LL, difference in LL before and after surgery, PI- LL match status, and SVA status) and the dependent variable ODI. The difference in DH before and after surgery showed the strongest correlation. The percentages of PI- LL match were 37% before surgery and 66% after surgery. The percentage of the normal SVA was 9% before surgery and 62% after surgery.
   CONCLUSIONS: OLIF for treatment of LDD had significant clinical outcomes, effectively restored the spinal/ pelvic sagittal balance, and helped to improve the patients' clinical conditions.
C1 [Xiao, Liang; Zhao, Quanlai; Sun, Xiumin; Liu, Chen; Zhang, Yu; Xu, Hongguang] Wannan Med Coll, Dept Spine Surg, Yijishan Hosp, Spine Res Ctr, Wuhu, Anhui, Peoples R China.
RP Xu, HG (reprint author), Wannan Med Coll, Dept Spine Surg, Yijishan Hosp, Spine Res Ctr, Wuhu, Anhui, Peoples R China.
EM pumchxuhg@126.com
OI XIAO, Liang/0000-0002-5779-6092
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81972108, 81702158]; Natural Science Foundation of
   Anhui Province of ChinaNatural Science Foundation of Anhui Province
   [1708085MH185, 1708085QH205]; Foreign Cooperation and Technology
   Foundation of Anhui Province of China [1704e1002229]; "Panfeng"
   Innovation Team Project; "Peak" Training Program for Scientific Research
   of Yijishan Hospital,Wannan Medical College [PF2019007, GF2019T02,
   GF2019G07, GF2019G12]
FX This study was supported by grants from the National Natural Science
   Foundation of China (81972108 and 81702158), grants from the Natural
   Science Foundation of Anhui Province of China (1708085MH185 and
   1708085QH205), a grant from the Foreign Cooperation and Technology
   Foundation of Anhui Province of China (1704e1002229), and funding from
   the "Panfeng" Innovation Team Project and "Peak" Training Program for
   Scientific Research of Yijishan Hospital,Wannan Medical College
   (PF2019007, GF2019T02, GF2019G07, and GF2019G12).
CR Barrey C, 2007, NEUROSURGERY, V61, P981, DOI 10.1227/01.neu.0000303194.02921.30
   Barrey C, 2007, EUR SPINE J, V16, P1459, DOI 10.1007/s00586-006-0294-6
   Berthonnaud E, 2005, J SPINAL DISORD TECH, V18, P40, DOI 10.1097/01.bsd.0000117542.88865.77
   Booth KC, 1999, SPINE, V24, P1712, DOI 10.1097/00007632-199908150-00013
   Champagne PO, 2019, ASIAN SPINE J, V13, P450, DOI 10.31616/asj.2018.0128
   Di Martino A, 2014, EUR SPINE J, V23, pS693, DOI 10.1007/s00586-014-3551-0
   Dohzono S, 2015, J NEUROSURG-SPINE, V23, P49, DOI 10.3171/2014.11.SPINE14452
   Formica Carlo, 2019, Eur Spine J, DOI 10.1007/s00586-019-06100-3
   Fujibayashi S, 2015, SPINE, V40, pE175, DOI 10.1097/BRS.0000000000000703
   GILL K, 1993, ACTA ORTHOP SCAND, V64, P108, DOI 10.3109/17453679309160137
   Glassman SD, 2005, SPINE, V30, P682, DOI 10.1097/01.brs.0000155425.04536.f7
   Ishihara H, 2001, J SPINAL DISORD, V14, P91, DOI 10.1097/00002517-200104000-00001
   Jin CZ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0740-2
   Kaiser MG, 2014, J NEUROSURG-SPINE, V21, P2, DOI 10.3171/2014.4.SPINE14257
   Kumar MN, 2001, EUR SPINE J, V10, P314, DOI 10.1007/s005860000239
   Lamartina C, 2012, EUR SPINE J, V21, pS27, DOI 10.1007/s00586-012-2236-9
   Le Huec JC, 2015, INT ORTHOP, V39, P87, DOI 10.1007/s00264-014-2516-6
   Mac-Thiong Jean-Marc, 2009, Spine (Phila Pa 1976), V34, pE519, DOI 10.1097/BRS.0b013e3181a9c7ad
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Ohtori S, 2015, ASIAN SPINE J, V9, P565, DOI 10.4184/asj.2015.9.4.565
   Ohtori S, 2015, YONSEI MED J, V56, P1051, DOI 10.3349/ymj.2015.56.4.1051
   Sato J, 2017, EUR SPINE J, V26, P671, DOI 10.1007/s00586-015-4170-0
   Schwab F, 2006, SPINE, V31, P2109, DOI 10.1097/01.brs.0000231725.38943.ab
   Schwab F, 2010, SPINE, V35, P2224, DOI 10.1097/BRS.0b013e3181ee6bd4
   Schwab FJ, 2013, SPINE, V38, pE803, DOI 10.1097/BRS.0b013e318292b7b9
   Senteler M, 2014, EUR SPINE J, V23, P1384, DOI 10.1007/s00586-013-3132-7
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Sun C, 2018, WORLD NEUROSURG, V116, pE1204, DOI 10.1016/j.wneu.2018.05.234
   Tempel ZJ, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS13368
NR 29
TC 0
Z9 0
U1 4
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E156
EP E164
DI 10.1016/j.wneu.2019.08.158
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700020
PM 31476474
DA 2020-05-12
ER

PT J
AU Yamao, Y
   Takahashi, JC
   Funaki, T
   Mineharu, Y
   Kikuchi, T
   Okada, T
   Togashi, K
   Miyamoto, S
AF Yamao, Yukihiro
   Takahashi, Jun C.
   Funaki, Takeshi
   Mineharu, Yohei
   Kikuchi, Takyuki
   Okada, Tomohisa
   Togashi, Kaori
   Miyamoto, Susumu
TI Revascularization Surgery in Childhood Associated with a Low Incidence
   of Microbleeds in Adult Patients with Moyamoya
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bypass surgery; Hemorrhage; Microbleeds; Moyamoya disease
ID EXTRACRANIAL-INTRACRANIAL BYPASS; CEREBRAL MICROBLEEDS; LONGITUDINAL
   COURSE; DISEASE; CIRCULATION; HEMORRHAGE; LOCATIONS; VESSELS
AB BACKGROUND: The clinical significance of asymptomatic microbleeds in moyamoya disease remains unclear. The purpose of this study was to clarify the relationship between bypass surgery and the incidence of asymptomatic microbleeds.
   METHODS: This retrospective study included 142 adult patients (mean age, 37.7 +/- 13.5 years) with moyamoya disease, 36 of whom (25.3%) underwent bypass surgery in childhood. Hemorrhagic onset was diagnosed in 31 patients (21.8%). The incidence of microbleeds was evaluated on T2*-weighted or susceptibility-weighted imaging from 3-T magnetic resonance imaging. The patients were subsequently categorized into MBs (microbleeds) or non-MBs groups. Because previous microbleeds potentially lead to hemorrhage, the MBs group was defined as patients with radiographic evidence of bleeding, including asymptomatic microbleeds and/or hemorrhagic onset. The association of baseline characteristics was evaluated.
   RESULTS: Asymptomatic microbleeds were detected in 38 patients (26.8%). Of 31 patients with hemorrhagic onset, 18 had microbleeds, whereas 13 had no microbleeds. Therefore, 51 patients (35.9%) were classified into the MBs group. Bypass surgery in childhood (MBs, 7.8% vs. non-MBs, 35.2%; P < 0.01) and age (MBs, 42.9 +/- 1.8 years vs. non MBs, 34.7 +/- 1.4 years; P < 0.01) were statistically significant factors associated with microbleeds, but only bypass surgery in childhood remained statistically significant after multivariable adjustment (odds ratio, 0.25; 95% confidence interval, 0.07-0.87; P = 0.03).
   CONCLUSIONS: This study shows the clinical significance of revascularization surgery in childhood associated with a low incidence of asymptomatic microbleeds in adult patients with moyamoya disease. This finding indicates that a newly established bypass can reduce hemodynamic overstress.
C1 [Yamao, Yukihiro; Funaki, Takeshi; Mineharu, Yohei; Kikuchi, Takyuki; Miyamoto, Susumu] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan.
   [Togashi, Kaori] Kyoto Univ, Grad Sch Med, Dept Diagnost Imaging & Nucl Med, Kyoto, Japan.
   [Okada, Tomohisa] Kyoto Univ, Grad Sch Med, Human Brain Res Ctr, Kyoto, Japan.
   [Takahashi, Jun C.] Natl Cerebral & Cardiovasc Res Ctr Hosp, Dept Neurosurg, Suita, Osaka, Japan.
RP Yamao, Y (reprint author), Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan.
EM yyamao@kuhp.kyoto-u.ac.jp
RI Okada, Tomohisa/C-5939-2008
OI Mineharu, Yohei/0000-0002-6346-3999; Yamao, Yukihiro/0000-0002-9615-2353
CR Fazekas F, 1999, AM J NEURORADIOL, V20, P637
   Fujimura M, 2019, J KOREAN NEUROSURG S, V62, P136, DOI 10.3340/jkns.2018.0101
   Funaki T, 2017, J NEUROSURG, V14, P1
   Funaki T, 2018, NEUROL MED-CHIR, V58, P240, DOI 10.2176/nmc.ra.2018-0026
   Funaki T, 2014, ACTA NEUROCHIR, V156, P551, DOI 10.1007/s00701-013-1975-7
   Funaki T, 2013, J NEUROSURG-PEDIATR, V12, P626, DOI 10.3171/2013.9.PEDS13111
   KARASAWA J, 1992, J NEUROSURG, V77, P84, DOI 10.3171/jns.1992.77.1.0084
   Kato H, 2002, STROKE, V33, P1536, DOI 10.1161/01.STR.0000018012.65108.86
   Kazumata K, 2014, J STROKE CEREBROVASC, V23, P1421, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.007
   Kikuta K, 2005, J NEUROSURG, V102, P470, DOI 10.3171/jns.2005.102.3.0470
   Kikuta KI, 2008, NEUROSURGERY, V62, P104, DOI 10.1227/01.NEU.0000311067.41239.E6
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   Kuroda S, 2013, STROKE, V44, P516, DOI 10.1161/STROKEAHA.112.678805
   Miyamoto S, 1998, Neurosurg Focus, V5, pe5
   MIYAMOTO S, 1984, J NEUROSURG, V61, P1032, DOI 10.3171/jns.1984.61.6.1032
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Narducci A, 2019, ACTA NEUROCHIR, V161, P371, DOI 10.1007/s00701-019-03811-w
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, Neurol Med Chir (Tokyo), V52, P245
   Roob G, 2000, STROKE, V31, P2665, DOI 10.1161/01.STR.31.11.2665
   Ryan Robert W J, 2012, Surg Neurol Int, V3, P72, DOI 10.4103/2152-7806.97730
   Schrag M, 2014, J STROKE CEREBROVASC, V23, P2489, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.006
   Sun W, 2013, CEREBROVASC DIS, V35, P469, DOI 10.1159/000350203
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Takahashi JC, 2016, STROKE, V47, P37, DOI 10.1161/STROKEAHA.115.010819
   Wenz H, 2017, STROKE, V48, P307, DOI 10.1161/STROKEAHA.116.014335
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E716
EP E721
DI 10.1016/j.wneu.2019.09.144
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700137
PM 31589987
OA Bronze
DA 2020-05-12
ER

PT J
AU Yue, JK
   Hemmerle, DD
   Winkler, EA
   Thomas, LH
   Fernandez, XD
   Kyritsis, N
   Pan, JZ
   Pascual, LU
   Singh, V
   Weinstein, PR
   Talbott, JF
   Huie, JR
   Ferguson, AR
   Whetstone, WD
   Manley, GT
   Beattie, MS
   Bresnahan, JC
   Mummaneni, PV
   Dhall, SS
AF Yue, John K.
   Hemmerle, Debra D.
   Winkler, Ethan A.
   Thomas, Leigh H.
   Fernandez, Xuan Duong
   Kyritsis, Nikolaos
   Pan, Jonathan Z.
   Pascual, Lisa U.
   Singh, Vineeta
   Weinstein, Philip R.
   Talbott, Jason F.
   Huie, J. Russell
   Ferguson, Adam R.
   Whetstone, William D.
   Manley, Geoffrey T.
   Beattie, Michael S.
   Bresnahan, Jacqueline C.
   Mummaneni, Praveen, V
   Dhall, Sanjay S.
TI Clinical Implementation of Novel Spinal Cord Perfusion Pressure Protocol
   in Acute Traumatic Spinal Cord Injury at US Level I Trauma Center:
   TRACK-SCI Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Feasibility; Lumbar drain; Outcomes; Safety; Spinal cord injury; Spinal
   cord perfusion pressure; Spine surgery
ID MEAN ARTERIAL-PRESSURE; INTRASPINAL PRESSURE; NEUROLOGIC RECOVERY;
   VASOPRESSOR USAGE; BLOOD-FLOW; IMPROVEMENT
AB OBJECTIVE: We sought to report the safety of implementation of a novel standard of care protocol using spinal cord perfusion pressure (SCPP) maintenance for managing traumatic spinal cord injury (SCI) in lieu of mean arterial pressure goals at a U.S. Level I trauma center.
   METHODS: Starting in December 2017, blunt SCI patients presenting <24 hours after injury with admission American Spinal Injury Association Impairment Scale (AIS) A - C (or AIS D at neurosurgeon discretion) received lumbar subarachnoid drain (LSAD) placement for SCPP monitoring in the intensive care unit and were included in the TRACK-SCI (Transforming Research and Clinical Knowledge in Spinal Cord Injury) data registry. This SCPP protocol comprises standard care at our institution. SCPPs were monitored for 5 days (goal >= 65 mm Hg) achieved through intravenous fluids and vasopressor support. AISs were assessed at admission and day 7.
   RESULTS: Fifteen patients enrolled to date were aged 60.5 +/- 17 years. Injury levels were 93.3% (cervical) and 6.7% (thoracic). Admission AIS was 20.0%/20.0%/26.7%/ 33.3% for A/B/C/D. All patients maintained mean SCPP >= 65 mm Hg during monitoring. Fourteen of 15 cases required surgical decompression and stabilization with time to surgery 8.8 +/- 7.1 hours (71.4% <12 hours). At day 7, 33.3% overall and 50% of initial AIS A- C had an improved AIS. Length of stay was 14.7 +/- 8.3 days. None had LSAD-related complications. There were 7 respiratory complications.
   CONCLUSIONS: In our initial experience of 15 patients with acute SCI, standardized SCPP goal-directed care based on LSAD monitoring for 5 days was feasible. There were no SCPP-related complications. This is the first report of SCPP implementation as clinical standard of care in acute SCI.
C1 [Yue, John K.; Hemmerle, Debra D.; Winkler, Ethan A.; Thomas, Leigh H.; Fernandez, Xuan Duong; Kyritsis, Nikolaos; Weinstein, Philip R.; Huie, J. Russell; Ferguson, Adam R.; Manley, Geoffrey T.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Mummaneni, Praveen, V; Dhall, Sanjay S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA.
   [Pan, Jonathan Z.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA USA.
   [Pascual, Lisa U.] Univ Calif San Francisco, Dept Rehabilitat Med, San Francisco, CA USA.
   [Singh, Vineeta] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Talbott, Jason F.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA.
   [Whetstone, William D.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA USA.
   [Yue, John K.; Hemmerle, Debra D.; Winkler, Ethan A.; Thomas, Leigh H.; Fernandez, Xuan Duong; Kyritsis, Nikolaos; Pan, Jonathan Z.; Pascual, Lisa U.; Singh, Vineeta; Talbott, Jason F.; Huie, J. Russell; Ferguson, Adam R.; Whetstone, William D.; Manley, Geoffrey T.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Dhall, Sanjay S.] Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA.
RP Dhall, SS (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA.; Dhall, SS (reprint author), Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA.
EM sanjaydhall@gmail.com
RI Yue, John K/P-1348-2015
OI Yue, John K/0000-0001-9694-7722; Kyritsis, Nikos/0000-0001-7801-5796;
   Ferguson, Adam/0000-0001-7102-1608
FU Department of Defense CDMRP awardUnited States Department of Defense
   [SC120259]
FX Partial support was provided by Department of Defense CDMRP award
   SC120259 (M. S. B., J. C. B., A. R. F., G. T. M., W. D. W.).
CR [Anonymous], 1972, Acta Neurochir (Wien), V26, P327
   [Anonymous], 2016, J SPINAL CORD MED, V39, P123
   Catapano JS, 2016, WORLD NEUROSURG, V96, P72, DOI 10.1016/j.wneu.2016.08.053
   Chen SL, 2017, J NEUROTRAUM, V34, P2941, DOI 10.1089/neu.2017.4982
   Cozzens JW, 2013, NEUROSURGERY, V72, P2, DOI 10.1227/NEU.0b013e3182772981
   Dakson A, 2017, SPINAL CORD, V55, P1033, DOI 10.1038/sc.2017.52
   Dukes EM, 2018, NEUROSURGERY, V83, P445, DOI 10.1093/neuros/nyx425
   GUHA A, 1989, J TRAUMA, V29, P1440, DOI 10.1097/00005373-198910000-00025
   Hogg FRA, 2019, NEUROCRIT CARE, V30, P421, DOI 10.1007/s12028-018-0616-7
   Inoue T, 2014, J NEUROTRAUM, V31, P284, DOI 10.1089/neu.2013.3061
   Lau D, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2018.12.FOCUS18555
   Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158
   LEVI L, 1993, NEUROSURGERY, V33, P1007, DOI 10.1097/00006123-199312000-00008
   Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6
   Mirza SK, 1999, CLIN ORTHOP RELAT R, P104, DOI 10.1097/00003086-199902000-00011
   Phang I, 2016, J NEUROSURG-SPINE, V25, P398, DOI 10.3171/2016.1.SPINE151317
   Phillips AA, 2013, J NEUROTRAUM, V30, P1551, DOI 10.1089/neu.2013.2972
   Ploumis A, 2010, SPINAL CORD, V48, P356, DOI 10.1038/sc.2009.150
   Readdy WJ, 2015, J NEUROSURG-SPINE, V23, P574, DOI 10.3171/2015.2.SPINE14746
   Saadoun S, 2017, J NEUROL NEUROSUR PS, V88, P452, DOI 10.1136/jnnp-2016-314600
   SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198
   Spiess MR, 2009, J NEUROTRAUM, V26, P2027, DOI [10.1089/neu.2008.0760, 10.1089/neu.2008-0760]
   Squair JW, 2017, NEUROLOGY, V89, P1660, DOI 10.1212/WNL.0000000000004519
   Stahl G, 2019, SOC THEOR METH ED RE, P1
   Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239
   WATERS RL, 1991, PARAPLEGIA, V29, P573, DOI 10.1038/sc.1991.85
   Werndle MC, 2016, ACTA NEUROCHIR SUPPL, V122, P323, DOI 10.1007/978-3-319-22533-3_64
   Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038
   Yue JK, 2019, J NEUROSURG SCI, V63, P308, DOI 10.23736/S0390-5616.17.04003-6
NR 29
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E391
EP E396
DI 10.1016/j.wneu.2019.09.044
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700094
PM 31526882
OA Bronze
DA 2020-05-12
ER

PT J
AU Zakaria, HM
   Lipphardt, M
   Bazydlo, M
   Xiao, SJ
   Schultz, L
   Chedid, M
   Abdulhak, M
   Schwalb, JM
   Nerenz, D
   Easton, R
   Chang, V
AF Zakaria, Hesham Mostafa
   Lipphardt, Matthew
   Bazydlo, Michael
   Xiao Shujie
   Schultz, Lonni
   Chedid, Mokbel
   Abdulhak, Muwaffak
   Schwalb, Jason M.
   Nerenz, David
   Easton, Richard
   Chang, Victor
CA MSSIC Investigators
TI The Preoperative Risks and Two-Year Sequelae of Postoperative Urinary
   Retention: Analysis of the Michigan Spine Surgery Improvement
   Collaborative (MSSIC)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Patient-reported outcome measures; Patient satisfaction; Postoperative
   complications; Prospective studies; Quality improvement; Spine; Urinary
   retention
ID QUALITY IMPROVEMENT; GENERAL-ANESTHESIA; SURGICAL QUALITY; LUMBAR SPINE;
   REGISTRIES; HOSPITALIZATIONS; FAILURE; RESCUE; PAYERS
AB OBJECTIVE: Although postoperative urinary retention (POUR) is common after spine surgery, the association of this adverse event with other morbidities and patient-reported outcomes is not fully understood. We sought to examine the sequelae of POUR after lumbar spine surgery.
   METHODS: The Michigan Spine Surgery Improvement Collaborative (MSSIC) is a large prospective multicenter registry. MSSIC was queried with multivariate analysis for factors that are associated with POUR, the association of POUR with 90-day adverse events, and the effect of POUR on 2-year patient-reported outcomes and satisfaction.
   RESULTS: Multivariate analysis identified hardware revision (odds ratio [OR], 0.61), 1 operative level (OR, 0.74), and ambulation on postoperative day zero (OR, 0.65) to be protective for POUR. Factors associated with POUR included age (OR, 1.19), male gender (OR, 1.58), body mass index <25 (OR, 1.22), diabetes (OR, 1.28), coronary artery disease (OR, 1.20), fusion surgery (OR, 1.27), and longer surgery (OR, 1.11). Patients who had POUR were more likely to be readmitted, develop a urinary tract infection, and develop an infection (P < 0.001). POUR was associated with decreased likelihood of achieving Oswestry Disability Index minimal clinically important difference at 90 days (P < 0.001), but not at 1 year after surgery. POUR was associated with dissatisfaction with surgery at 90 days (P< 0.001), 1 year (P = 0.004), and 2 years after surgery (P = 0.011).
   CONCLUSIONS: POUR is common after lumbar spine surgery, and the demographic, diagnostic, and surgical factors that are associated with POUR are identified. POUR is associated with several adverse events, and patients who have POUR were less likely to be satisfied with surgery up to 2 years after surgery.
C1 [Zakaria, Hesham Mostafa; Chedid, Mokbel; Abdulhak, Muwaffak; Schwalb, Jason M.; Chang, Victor] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
   [Bazydlo, Michael; Xiao Shujie; Schultz, Lonni] Henry Ford Hosp, Dept Publ Hlth Res, Detroit, MI 48202 USA.
   [Nerenz, David] Henry Ford Hosp, Ctr Hlth Serv Res, Detroit, MI 48202 USA.
   [Lipphardt, Matthew; Easton, Richard] Oakland Univ, William Beaumont Sch Med, Dept Orthopaed Surg, Rochester, MI 48063 USA.
   [Lipphardt, Matthew; Easton, Richard] Beaumont Hlth Troy, Div Orthopaed Surg, Troy, MI USA.
RP Chang, V (reprint author), Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
EM vchang1@hfhs.org
CR Alsaidi Mohammed, 2013, Surg Neurol Int, V4, P61, DOI 10.4103/2152-7806.111088
   Altschul D, 2017, J NEUROSURG-SPINE, V26, P229, DOI 10.3171/2016.8.SPINE151371
   Asher AL, 2014, SPINE, V39, pS106, DOI 10.1097/BRS.0000000000000579
   Asher AL, 2014, SPINE, V39, pS136, DOI 10.1097/BRS.0000000000000543
   Asher AL, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2012.10.FOCUS12311
   Basheer Azam, 2017, Surg Neurol Int, V8, P75, DOI 10.4103/sni.sni_5_17
   Birkmeyer NJO, 2006, NEW ENGL J MED, V354, P864, DOI 10.1056/NEJMsb053364
   Birkmeyer NJO, 2005, SURGERY, V138, P815, DOI 10.1016/j.surg.2005.06.037
   Boulis NM, 2001, SURG NEUROL, V55, P23, DOI 10.1016/S0090-3019(01)00331-7
   Chang V, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.10.FOCUS15370
   De Rojas JO, 2014, CLIN NEUROL NEUROSUR, V119, P39, DOI 10.1016/j.clineuro.2014.01.016
   Englesbe MJ, 2007, ANN SURG, V246, P1100, DOI 10.1097/SLA.0b013e31815c3fe5
   Gandhi SD, 2014, SPINE, V39, P1905, DOI 10.1097/BRS.0000000000000572
   Ghaferi AA, 2016, BRIT J SURG, V103, pE47, DOI 10.1002/bjs.10031
   Ghaferi AA, 2009, ANN SURG, V250, P1029, DOI 10.1097/SLA.0b013e3181bef697
   Golubovsky JL, 2018, SPINE J, V18, P1533, DOI 10.1016/j.spinee.2018.01.022
   Hughes RE, 2015, ORTHOP RES REV, V7, P47, DOI 10.2147/ORR.S82732
   Jellish WS, 1996, ANESTH ANALG, V83, P559, DOI 10.1097/00000539-199609000-00021
   Lee Kwang Soo, 2011, Int Neurourol J, V15, P158, DOI 10.5213/inj.2011.15.3.158
   Lee KS, 2017, INT NEUROUROL J, V21, P320, DOI 10.5213/inj.1734994.497
   Lee S, 2017, SPINE J, V17, P469, DOI 10.1016/j.spinee.2016.03.017
   Mayo BC, 2016, SPINE, V41, P1441, DOI 10.1097/BRS.0000000000001554
   McGirt MJ, 2014, SPINE, V39, pS117, DOI 10.1097/BRS.0000000000000552
   McLain RF, 2005, J NEUROSURG-SPINE, V2, P17, DOI 10.3171/spi.2005.2.1.0017
   Share DA, 2011, HEALTH AFFAIR, V30, P636, DOI 10.1377/hlthaff.2010.0526
   TAMMELA T, 1986, SCAND J UROL NEPHROL, V20, P197, DOI 10.3109/00365598609024494
   Waljee JF, 2014, HAND CLIN, V30, P335, DOI 10.1016/j.hcl.2014.05.003
   Womble PR, 2015, J UROLOGY, V194, P403, DOI 10.1016/j.juro.2015.03.126
   Womble PR, 2014, J UROLOGY, V191, P1787, DOI 10.1016/j.juro.2013.12.026
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E619
EP E626
DI 10.1016/j.wneu.2019.09.107
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700124
PM 31568914
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhai, XD
   Yu, JX
   Li, CJ
   Ren, J
   Ji, Z
   He, C
   Ye, M
   Hu, P
   Zhang, HQ
AF Zhai, Xiao-Dong
   Yu, Jia-Xing
   Li, Chuan-Jie
   Ren, Jian
   Ji, Zhe
   He, Chuan
   Ye, Ming
   Hu, Peng
   Zhang, Hong-Qi
TI Morphological Characteristics of Pericallosal Artery Aneurysms and Their
   High Propensity for Rupture
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomical structure; Aspect ratio; High risk of rupture; Morphological
   parameters; Pericallosal artery aneurysms; Size ratio
ID INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; ASPECT RATIO; RISK;
   MANAGEMENT; SIZE; HEMODYNAMICS; HEMORRHAGE; EXPERIENCE; LOCATION
AB BACKGROUND: Compared with intracranial aneurysms (IAs) at other locations, pericallosal artery aneurysms (PAAs) have demonstrated an extremely high risk of rupture. However, owing to their rarity, our understanding of their morphological characteristics has been limited, and whether the morphological characteristics of PAAs contribute to this high rupture risk has remained unexplored. In the present study, we aimed to provide a detailed description of the morphological characteristics of PAAs and investigate the association between its morphology and rupture risk compared with anterior circulation IAs at other locations.
   METHODS: A total of 40 patients with 45 PAAs and 348 patients with 392 anterior circulation IAs at other locations were recruited. The clinical and radiological data for these patients were retrospectively reviewed. The differences in the morphological parameters, including the aneurysm diameter, neck width, height, width, parent artery diameter, inflow angle, aspect ratio (AR), size ratio (SR), and aneurysm diameter/width ratio, between PAAs and other IA groups were compared.
   RESULTS: Of the 45 PAAs, 22 (48.9%) had ruptured. The proportion of ruptured aneurysms was greater for PAAs than for anterior circulation IAs at other locations. For both ruptured and unruptured anterior circulation IAs, PAAs had the highest AR and SR among all IA groups and had the largest inflow angle.
   CONCLUSION: The morphological characteristics of PAAs are unique. Compared with other anterior circulation IAs, PAAs have significantly increased ARs, SRs, and inflow angles, which, ultimately, promote their high propensity toward rupture.
C1 [Zhai, Xiao-Dong; Yu, Jia-Xing; Ren, Jian; Ji, Zhe; He, Chuan; Ye, Ming; Hu, Peng; Zhang, Hong-Qi] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Zhai, Xiao-Dong; Yu, Jia-Xing; Ren, Jian; Ji, Zhe; He, Chuan; Ye, Ming; Hu, Peng; Zhang, Hong-Qi] China Int Neurosci Inst, Beijing, Peoples R China.
   [Li, Chuan-Jie] Shunyi Dist Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Zhang, HQ (reprint author), Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, HQ (reprint author), China Int Neurosci Inst, Beijing, Peoples R China.
EM xwzhanghq@163.com
FU National Key R&D program of China [2016YFC1300800]; Beijing Municipal
   Administration of Hospitals' Ascent Plan [DFL20180801]
FX This work was supported by the National Key R&D program of China (grant
   2016YFC1300800) and the Beijing Municipal Administration of Hospitals'
   Ascent Plan (grant DFL20180801).
CR Aboukais R, 2015, NEUROCHIRURGIE, V61, P244, DOI 10.1016/j.neuchi.2015.03.010
   Amenta PS, 2012, NEUROSURGERY, V70, P693, DOI 10.1227/NEU.0b013e3182354d68
   Baharoglu MI, 2010, STROKE, V41, P1423, DOI 10.1161/STROKEAHA.109.570770
   Cavalcanti DD, 2013, AM J NEURORADIOL, V34, P1593, DOI 10.3174/ajnr.A3408
   Chalouhi N, 2013, STROKE, V44, P3613, DOI 10.1161/STROKEAHA.113.002390
   Dinc N, 2017, WORLD NEUROSURG, V99, P566, DOI 10.1016/j.wneu.2016.12.079
   Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1
   Gross BA, 2014, CLIN NEUROL NEUROSUR, V123, P78, DOI 10.1016/j.clineuro.2014.05.014
   Hui FK, 2011, J NEUROINTERV SURG, V3, P319, DOI 10.1136/jnis.2011.004770
   Jiang H, 2016, ACTA NEUROCHIR, V158, P1367, DOI 10.1007/s00701-016-2826-0
   Kashiwazaki D, 2013, STROKE, V44, P2169, DOI 10.1161/STROKEAHA.113.001138
   Kataoka H, 2015, NEUROL MED-CHIR, V55, P214, DOI 10.2176/nmc.ra.2014-0337
   Korja M, 2017, J NEUROSURG, V127, P748, DOI 10.3171/2016.9.JNS161085
   Lehecka M, 2008, NEUROSURGERY, V63, P219, DOI 10.1227/01.NEU.0000310695.44670.32
   Lehecka M, 2008, NEUROSURGERY, V62, P590, DOI 10.1227/01.neu.0000317307.16332.03
   Marbacher S, 2014, STROKE, V45, P248, DOI 10.1161/STROKEAHA.113.002745
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Meng H, 2007, STROKE, V38, P1924, DOI 10.1161/STROKEAHA.106.481234
   Miura Y, 2013, STROKE, V44, P519, DOI 10.1161/STROKEAHA.112.675306
   Nader-Sepahi A, 2004, NEUROSURGERY, V54, P1343, DOI 10.1227/01.NEU.0000124482.03676.8B
   Nguyen TN, 2007, J NEUROSURG, V107, P973, DOI 10.3171/JNS-07/11/0973
   Petr O, 2017, WORLD NEUROSURG, V100, P557, DOI 10.1016/j.wneu.2016.11.134
   Shukla D, 2016, NEUROL INDIA, V64, P1204, DOI 10.4103/0028-3886.193827
   Sturiale CL, 2013, AM J NEURORADIOL, V34, P2317, DOI 10.3174/ajnr.A3629
   Tateshima S, 2010, NEURORADIOLOGY, V52, P1135, DOI 10.1007/s00234-010-0687-4
   Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070
   Tykocki T, 2014, NEUROL RES, V36, P733, DOI 10.1179/1743132813Y.0000000306
   Ujiie H, 1999, NEUROSURGERY, V45, P119, DOI 10.1097/00006123-199907000-00028
   Varble N, 2017, AM J NEURORADIOL, V38, P2105, DOI 10.3174/ajnr.A5341
   Vora N, 2010, J NEUROIMAGING, V20, P70, DOI 10.1111/j.1552-6569.2008.00324.x
   Zanaty M, 2014, NEUROL RES, V36, P308, DOI 10.1179/1743132814Y.0000000327
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E320
EP E326
DI 10.1016/j.wneu.2019.09.003
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700086
PM 31520758
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhang, WB
   Min, LZ
   Tao, BB
   Sun, QY
   Li, ST
   Wang, XQ
AF Zhang, Wen-Bo
   Min, Ling-Zhao
   Tao, Bang-Bao
   Sun, Qiu-Yang
   Li, Shi-Ting
   Wang, Xiao-Qiang
TI Prognosis Comparison of Different Branches of Trigeminal Neuralgia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Branch; Facial numbness; Microvascular decompression; Remission rate;
   Trigeminal neuralgia
ID MICROVASCULAR DECOMPRESSION; PAIN
AB OBJECTIVE: We explored the remission rate of different-inches of the trigeminal nerve after microvascular decompression.
   METHODS: A retrospective analysis of trigeminal neu-ralgia patients treated with microvascular decompression in our department from January 2014 to January 2015 was conducted to investigate the prognosis and factors affecting prognosis.
   RESULTS: One-hundred and fifty-five patients with tri-geminal neuralgia including 2 patients with V1 division had a remission rate of 100% at 1 day, 3 months, 1 year, and 3 years after surgery; 93.5%, 93.5%, 90.3%, and 67.7% of patients with V1-2 division. The patients with V1-3 division had rates of 91.7%, 87.5%, 75.0%, and 66.7%; V2 division rates were 88.4%, 81.4%, 76.7%, and 69.8%; V2-3 division rates were 90.2%, 90.2%, 87.8%, and 75.6%; and V3 division were 100%, 100%, 92.9%, and 92.9%.
   CONCLUSIONS: Postoperative remission rate of non-V2-related branches (V1, V3) are higher than V2-related branches (V2, V1-2, V1-3, V2-3).
C1 [Zhang, Wen-Bo; Min, Ling-Zhao; Tao, Bang-Bao; Sun, Qiu-Yang; Li, Shi-Ting; Wang, Xiao-Qiang] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neurosurg, Sch Med, Shanghai, Peoples R China.
   [Zhang, Wen-Bo; Min, Ling-Zhao; Tao, Bang-Bao; Sun, Qiu-Yang; Li, Shi-Ting; Wang, Xiao-Qiang] Shanghai Jiao Tong Univ, Ctr Diag & Treatment Cranial Nerve Dis, Shanghai, Peoples R China.
RP Wang, XQ (reprint author), Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neurosurg, Sch Med, Shanghai, Peoples R China.; Wang, XQ (reprint author), Shanghai Jiao Tong Univ, Ctr Diag & Treatment Cranial Nerve Dis, Shanghai, Peoples R China.
EM wangxiaoqiang@xinhuamed.com.cn
CR Barker FG, 1997, NEUROSURGERY, V40, P39, DOI 10.1097/00006123-199701000-00008
   BARKER FG, 1996, BRIT J NEUROSURG, V24, P18
   BEDERSON JB, 1989, J NEUROSURG, V71, P359, DOI 10.3171/jns.1989.71.3.0359
   Broggi G, 2000, J NEUROL NEUROSUR PS, V68, P59, DOI 10.1136/jnnp.68.1.59
   BURCHIEL KJ, 1988, J NEUROSURG, V69, P35, DOI 10.3171/jns.1988.69.1.0035
   CALVIN WH, 1977, PAIN, V3, P147, DOI 10.1016/0304-3959(77)90078-1
   CHO DY, 1994, NEUROSURGERY, V35, P665, DOI 10.1227/00006123-199410000-00012
   DANDY WE, 1934, AM J SURG, V24, P447, DOI DOI 10.1016/S0002-9610(34)90403-7
   Feng BH, 2015, J CRANIOFAC SURG, V26, P2381, DOI 10.1097/SCS.0000000000002147
   Hong WY, 2011, ACTA NEUROCHIR, V153, P1037, DOI 10.1007/s00701-011-0957-x
   Jannetta P J, 1985, Clin Neurosurg, V32, P334
   Kureshi SA, 1998, NEUROSURGERY, V43, P1111, DOI 10.1097/00006123-199811000-00061
   LAUDE M, 1976, Bulletin de l'Association des Anatomistes, V60, P151
   Li ST, 2004, SURG NEUROL, V62, P400, DOI 10.1016/j.surneu.2004.02.028
   Oesman C, 2011, SKULL BASE-INTERD AP, V21, P313, DOI 10.1055/s-0031-1284213
   Sandell T, 2008, NEUROSURGERY, V63, P93, DOI 10.1227/01.NEU.0000316856.32104.65
   Sekula RF, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09156
   Sindou M, 2002, ACTA NEUROCHIR, V144, P1, DOI 10.1007/s701-002-8269-4
   Theodosopoulos PV, 2002, ARCH NEUROL-CHICAGO, V59, P1297, DOI 10.1001/archneur.59.8.1297
   Tyler-Kabara EC, 2002, J NEUROSURG, V96, P527, DOI 10.3171/jns.2002.96.3.0527
   WALCHENBACH R, 1994, CLIN NEUROL NEUROSUR, V96, P290, DOI 10.1016/0303-8467(94)90116-3
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E1
EP E5
DI 10.1016/j.wneu.2019.06.115
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700002
PM 31252078
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhong, B
   Song, NY
   Deng, D
   Li, LK
   Du, JT
   Liu, F
   Liu, YF
   Liu, SX
AF Zhong, Bing
   Song, Ning-Ying
   Deng, Di
   Li, Lin-Ke
   Du, Jin-Tao
   Liu, Feng
   Liu, Ya-Feng
   Liu, Shi-Xi
TI Intraoperative Repair of Cerebrospinal Fluid Rhinorrhea in Skull Base
   Tumor Resection: A Retrospective Study of Acellular Dermal Matrix Versus
   Turbinate Flap
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acellular dermal matrix; Cerebrospinal fluid rhinorrhea; Endoscopic
   transnasal skull base resection; Reconstruction; Turbinate flap
ID ENDOSCOPIC RECONSTRUCTION; MUCOSAL GRAFT; ANTERIOR; DEFECTS; SURGERY;
   LEAK; LARYNGEAL
AB BACKGROUND: The acellular dermal matrix (ADM) and turbinate flap (TF) have been widely used in the reconstruction of skull base defects. However, owing to the lack of reported data, the therapeutic effects have been controversial. The purpose of the present study was to compare the effect of the ADM and TF on cerebrospinal fluid (CSF) rhinorrhea after nasal endoscopic resection of a skull base tumor.
   METHODS: The data from 46 patients who had undergone nasal endoscopic resection of a skull base tumor and repair of CSF rhinorrhea were retrospectively analyzed. The patients were divided into ADM and TF groups according to the difference in repair materials used. We compared and analyzed the intraoperative information and postoperative outcomes.
   RESULTS: The operation time, blood loss, defect area, and need for blood transfusion were not significantly different between the ALT and TF groups. The postoperative length of hospital stay (14.33 +/- 3.66 vs. 16.76 +/- 5.51 days; P = 0.669) and the incidence of complications, including wound infection (1 vs. 0; P = 0.270), intracranial infection (1 vs. 1; P = 0.900), hemorrhage (2 vs. 3; P = 0.788), 15-day CSF leak (1 vs. 2; P = 0.658), and respiratory infection (2 vs. 1; P = 0.450) were comparable between the 2 groups. The 6-month (0 vs. 0; P = 1.000) and 12-month (0 vs. 0; P = 1.000) incidence of recurrence also showed no significant differences.
   CONCLUSION: The use of the ADM for patients with CSF rhinorrhea showed comparable results in terms of postoperative outcomes compared with the use of TF. ADM could serve as a safe and feasible alternative for endoscopic repair of CSF rhinorrhea after nasal endoscopic resection of skull base tumors.
C1 [Zhong, Bing; Song, Ning-Ying; Deng, Di; Li, Lin-Ke; Du, Jin-Tao; Liu, Feng; Liu, Ya-Feng; Liu, Shi-Xi] Sichuan Univ, Dept Otolaryngol Head & Neck Surg, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP Liu, YF (reprint author), Sichuan Univ, Dept Otolaryngol Head & Neck Surg, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM lyfent@163.com
CR Amin SM, 2016, ANN OTO RHINOL LARYN, V125, P770, DOI 10.1177/0003489416654709
   Boetto J, 2019, OPER NEUROSURG, V16, P45, DOI 10.1093/ons/opy046
   Eloy JA, 2013, INT FORUM ALLERGY RH, V3, P204, DOI 10.1002/alr.21089
   Eloy JA, 2012, AM J OTOLARYNG, V33, P735, DOI 10.1016/j.amjoto.2012.07.005
   Fishpool SJC, 2017, EUR ARCH OTO-RHINO-L, V274, P837, DOI 10.1007/s00405-016-4287-8
   Germani RM, 2007, AM J RHINOL, V21, P615, DOI 10.2500/ajr.2007.21.3080
   He J, 2015, ONCOL RES TREAT, V38, P282, DOI 10.1159/000430898
   Hu F, 2015, WORLD NEUROSURG, V83, P181, DOI 10.1016/j.wneu.2014.06.004
   Ishii Y, 2014, NEUROL MED-CHIR, V54, P983, DOI 10.2176/nmc.st.2014-0081
   Ismail AS, 2007, SKULL BASE-INTERD AP, V17, P125, DOI 10.1055/s-2007-970556
   Jeon CM, 2017, J CLIN NEUROSCI, V45, P227, DOI 10.1016/j.jocn.2017.07.012
   Lorenz RR, 2003, LARYNGOSCOPE, V113, P496, DOI 10.1097/00005537-200303000-00019
   Lucke-Wold B, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.12.FOCUS17664
   Luk LJ, 2019, OTOLARYNG HEAD NECK, V161, P522, DOI 10.1177/0194599819847944
   Mericli AF, 2013, J CRANIOFAC SURG, V24, P1314, DOI 10.1097/SCS.0b013e3182953a39
   Oyama M, 2016, J CRANIOFAC SURG, V27, pE10, DOI 10.1097/SCS.0000000000002278
   Patel MR, 2010, SKULL BASE-INTERD AP, V20, P397, DOI 10.1055/s-0030-1253573
   Schreiber A, 2017, INT FORUM ALLERGY RH, V7, P199, DOI [10.1002/alr.21857, 10.1002/alr.22001]
   Shahangian A, 2017, INT FORUM ALLERGY RH, V7, P80, DOI 10.1002/alr.21845
   Suh JD, 2012, ANN OTO RHINOL LARYN, V121, P91, DOI 10.1177/000348941212100203
   Thakker JS, 2014, J ORAL MAXIL SURG, V72, P198, DOI 10.1016/j.joms.2013.05.017
   Wang L, 2015, J LARYNGOL OTOL, V129, P715, DOI 10.1017/S0022215115001413
   Wormald PJ, 2003, AM J RHINOL, V17, P299, DOI 10.1177/194589240301700508
NR 23
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E275
EP E280
DI 10.1016/j.wneu.2019.08.245
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700080
PM 31518747
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhou, Y
   Duan, GL
   Zhang, XX
   Yang, PF
   Fang, YB
   Li, Q
   Zhao, R
   Xu, Y
   Hong, B
   Huang, QH
   Liu, JM
AF Zhou, Yu
   Duan, Guoli
   Zhang, Xiaoxi
   Yang, Peng-fei
   Fang, Yi-Bin
   Li, Qiang
   Zhao, Rui
   Xu, Yi
   Hong, Bo
   Huang, Qing-Hai
   Liu, Jian-Min
TI Outcome and Prognostic Factors of Ruptured Middle Cerebral Artery
   Aneurysms Treated via Endovascular Approach: A Single-Center 11-Year
   Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Endovascular treatment; Middle cerebral artery; Outcome; Risk
   factor; Subarachnoid hemorrhage
ID INTRACRANIAL ANEURYSMS; COILING; SAFETY; EMBOLIZATION; TIROFIBAN; TRIAL
AB OBJECTIVE: To investigate outcomes and prognostic factors of ruptured middle cerebral artery (MCA) aneurysms, treated via endovascular approach, with improving treatment materials and techniques.
   PATIENTS AND METHODS: A total of 185 consecutive patients, admitted with acutely ruptured MCA aneurysms and treated by endovascular methods between 2006 and 2016, were retrospectively reviewed. Their baseline characteristics, procedure-related complications, and angiographic and clinical outcomes were collected. Univariate analysis and logistic regression analysis were completed to identify any association between procedure-related complications or clinical outcomes and potential risk factors.
   RESULTS: Procedure-related complications occurred in 28 patients (15.1%), including aneurysm rebleeding in 7 (3.8%), hematoma expansion in 10 (5.4%), and ischemia in 13 (7.0%) (concurrent hemorrhage and ischemia in 2 patients), which resulted in morbidity/mortality of 7% and 1.4%. Final evaluations indicated that 153 patients (82.7%, 153/185) had a good outcome (modified Rankin Scale score 0-2). Among 120 (69.4%) who underwent angiographic follow-up, 89 (74.2%) were completely occluded and 20/120 (16.7%) were recanalized. Multivariate analysis of clinical outcome indicated that a high preoperative Hunt and Hessgrade (IV-V), intrasylvian/intracerebral hematoma, and early period treatment (2006-2013) were associated with unfavorable outcomes.
   CONCLUSIONS: Endovascular treatment for patients with ruptured middle cerebral artery aneurysms may offer favorable clinical and angiographic outcomes. With the evolution of treatment materials and updated techniques, treatment complications have become less common than previously reported in literature, and clinical outcomes have been improved in recent years.
C1 [Zhou, Yu; Duan, Guoli; Zhang, Xiaoxi; Yang, Peng-fei; Fang, Yi-Bin; Li, Qiang; Zhao, Rui; Xu, Yi; Hong, Bo; Huang, Qing-Hai; Liu, Jian-Min] Second Mil Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Liu, JM (reprint author), Second Mil Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM liu118@vip.163.com
CR Alreshidi M, 2018, NEUROSURGERY, V83, P879, DOI 10.1093/neuros/nyx623
   Bracard S, 2010, J NEUROSURG, V112, P703, DOI 10.3171/2009.6.JNS09483
   Cho YD, 2012, EUR J RADIOL, V81, P2833, DOI 10.1016/j.ejrad.2011.11.023
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Egashira Y, 2013, J NEUROSURG, V118, P1003, DOI 10.3171/2012.11.JNS12610
   Fargen KM, 2018, J NEUROINTERV SURG, V10, P44, DOI 10.1136/neurintsurg-2016-012808
   Feng ZZ, 2015, J STROKE CEREBROVASC, V24, P1357, DOI 10.1016/j.jstrokecerebrovasdis.2015.02.016
   Gory B, 2014, AM J NEURORADIOL, V35, P715, DOI 10.3174/ajnr.A3781
   Iijima A, 2005, RADIOLOGY, V237, P611, DOI 10.1148/radiol.2372041015
   Kadkhodayan Y, 2015, NEUROSURGERY, V76, P54, DOI 10.1227/NEU.0000000000000562
   KASSELL NF, 1990, J NEUROSURG, V73, P37, DOI 10.3171/jns.1990.73.1.0037
   Kim S, 2016, AM J NEURORADIOL, V37, P508, DOI 10.3174/ajnr.A4551
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Mortimer AM, 2014, AM J NEURORADIOL, V35, P706, DOI 10.3174/ajnr.A3776
   Quintana EM, 2016, INTERV NEURORADIOL, V22, P649, DOI 10.1177/1591019916662383
   Naggara ON, 2012, RADIOLOGY, V263, P828, DOI 10.1148/radiol.12112114
   Quadros RS, 2007, AM J NEURORADIOL, V28, P1567, DOI 10.3174/ajnr.A0595
   Rinne J, 1996, NEUROSURGERY, V38, P2, DOI 10.1097/00006123-199601000-00002
   Rodriguez-Hernandez A, 2013, NEUROSURGERY, V72, P415, DOI 10.1227/NEU.0b013e3182804aa2
   Teleb MS, 2014, J NEUROINTERV SURG, V6, P490, DOI 10.1136/neurintsurg-2013-010836
   Wang CC, 2016, WORLD NEUROSURG, V94, P131, DOI 10.1016/j.wneu.2016.06.117
   White PM, 2011, LANCET, V377, P1655, DOI 10.1016/S0140-6736(11)60408-X
   Zhao B, 2017, J NEUROSURG SCI, V61, P403, DOI 10.23736/S0390-5616.16.03457-3
   Zhao XT, 2017, INT J NEUROSCI, V127, P433, DOI 10.1080/00207454.2016.1190923
   Zhou Y, 2014, J STROKE CEREBROVASC, V23, P1447, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.054
   Zijlstra IA, 2016, J NEUROINTERV SURG, V8, P24, DOI 10.1136/neurintsurg-2014-011478
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JAN
PY 2020
VL 133
BP E187
EP E196
DI 10.1016/j.wneu.2019.08.189
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA JX8QN
UT WOS:000503993700024
PM 31493611
OA Bronze
DA 2020-05-12
ER

PT J
AU Calvete, C
   Gonzalez, JM
   Ferrer, LM
   Ramos, JJ
   Lacasta, D
   Delgado, I
   Uriarte, J
AF Calvete, Carlos
   Gonzalez, Jose M.
   Ferrer, Luis M.
   Ramos, Juan J.
   Lacasta, Delia
   Delgado, Ignacio
   Uriarte, Joaquin
TI Assessment of targeted selective treatment criteria to control
   subclinical gastrointestinal nematode infections on sheep farms
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Productive efficiency; Small ruminants; Subclinical gastrointestinal
   nematodosis; Targeted selective treatments
ID STRATEGIC ANTHELMINTIC TREATMENT; BODY CONDITION SCORE; PARASITIC
   INFECTIONS; BREEDING PERFORMANCE; GROWTH; EWES; MANAGEMENT; RESISTANCE;
   EFFICACY; REGIMES
AB Control of sheep gastrointestinal nematode (GIN) infections mostly relies on the use of anthelmintics. Refugia-based control strategies as targeted selective treatments (TST) can delay anthelmintic resistance development, but the optimal decision criteria for selecting individuals to be treated in subclinical infection scenarios remain unclear. The present study aimed to evaluate the suitability of body condition score (BCS) and faecal egg counts (FEC) as treatment indicators and to determine their optimized threshold values for treatment in TST by determining the relationships of BCS, FEC and anthelmintic treatment with several productive parameters in premating and pre-partum periods at an individual level. Deworming in pre-mating period increased BCS gain, but its magnitude was directly associated with strongyle FEC before treatment. Deworming also increased fertility in ewes with BCS < 2.75 and the proportion of lambing ewes that got pregnant during the first ovulation cycle. Nevertheless, treatment did not yield productive benefits in ewes with higher BCS values. On the other hand, deworming in the pre-partum lowered lamb peri-partum mortality and increased lamb weight at birth and the growth of lambs during lactation, especially in lambs born from ewes with strongyle FEC > 400 epg before treatment. These results showed that FEC and especially BCS can be potential decision criteria for the implementation of TST in these types of scenarios. The TST scheme derived from the present results on the control of GIN infections should include anthelmintic treatment of ewes with BCS lower than approximate to 3 approximately five weeks before mating and lambing. In the pre-lambing period, treatment may be unnecessary if flock mean strongyle FEC is lower than approximate to 200 epg, as the proportion of ewes with individual FEC > 400 epg would be very low. The results suggest that implementation of this TST scheme would provide benefits, such as the improvement of productivity, a rational management of parasites in refugia, and preservation of future efficacy of anthelmintics, in comparison to traditional deworming schemes.
C1 [Calvete, Carlos; Delgado, Ignacio; Uriarte, Joaquin] Zaragoza Univ, CITA, Agrifood Inst Aragon IA2, Agrifood Res & Technol Ctr Aragon CITA,Anim Prod, Avda Montanana 930, Zaragoza 50059, Spain.
   [Gonzalez, Jose M.] Univ Zaragoza, Vet Fac, Anim Pathol Dept, E-50013 Zaragoza, Spain.
   [Ferrer, Luis M.; Ramos, Juan J.; Lacasta, Delia] Univ Zaragoza, Agrifood Inst AragonIA2, Vet Fac, Anim Pathol Dept,CITA, E-50013 Zaragoza, Spain.
RP Calvete, C (reprint author), Zaragoza Univ, CITA, Agrifood Inst Aragon IA2, Agrifood Res & Technol Ctr Aragon CITA,Anim Prod, Avda Montanana 930, Zaragoza 50059, Spain.
EM ccalvete@aragon.es
RI Calvete, Carlos/D-2038-2010; Lacasta Lozano, Delia Maria/K-8265-2014
OI Calvete, Carlos/0000-0001-5028-947X; Lacasta Lozano, Delia
   Maria/0000-0002-7822-6646
FU National Institute for Agricultural and Food Research and Technology
   (INIA)Instituto de Investigacion Agropecuaria (INIA)
   [RTA2013-00064-C02-01]
FX Funding for this project was provided by the RTA2013-00064-C02-01 grant
   from the National Institute for Agricultural and Food Research and
   Technology (INIA). Special thanks go to J.A. Tanco and A. Guillen for
   their assistance in field and laboratory work and to Carmen Margolles
   for her support. Thanks go also to the two anonymous reviewers for their
   valuable comments.
CR Abbot K.A., 2012, SUSTAINABLE WORM CON
   Adams NR, 2003, AUST J EXP AGR, V43, P1399, DOI 10.1071/EA03007
   Calvete C, 2012, VET PARASITOL, V184, P193, DOI 10.1016/j.vetpar.2011.08.020
   Charlier J, 2014, VET REC, V175, P250, DOI 10.1136/vr.102512
   Charlier J, 2014, TRENDS PARASITOL, V30, P361, DOI 10.1016/j.pt.2014.04.009
   Chaudhry M.A., 1987, PAK VET J, V1, P44
   Chylinski C, 2015, VET PARASITOL, V207, P85, DOI 10.1016/j.vetpar.2014.10.029
   Cornelius MP, 2014, VET PARASITOL, V206, P173, DOI 10.1016/j.vetpar.2014.10.031
   Dobson RJ, 2009, VET PARASITOL, V161, P162, DOI 10.1016/j.vetpar.2008.12.007
   Fthenakis GC, 2015, VET PARASITOL, V208, P56, DOI 10.1016/j.vetpar.2014.12.017
   Fthenakis GC, 2012, ANIM REPROD SCI, V130, P198, DOI 10.1016/j.anireprosci.2012.01.016
   Fthenakis GC, 2005, J VET MED A, V52, P78, DOI 10.1111/j.1439-0442.2004.00687.x
   Gallidis E, 2009, VET PARASITOL, V164, P53, DOI 10.1016/j.vetpar.2009.04.011
   Kenyon F, 2012, VET PARASITOL, V186, P10, DOI 10.1016/j.vetpar.2011.11.041
   Kenyon F, 2013, INT J PARASITOL-DRUG, V3, P77, DOI 10.1016/j.ijpddr.2013.02.001
   Kenyon PR, 2014, NEW ZEAL J AGR RES, V57, P38, DOI 10.1080/00288233.2013.857698
   Knox MR, 2006, VET PARASITOL, V139, P385, DOI 10.1016/j.vetpar.2006.04.026
   LEWIS K H C, 1975, New Zealand Journal of Experimental Agriculture, V3, P43
   MACKAY RR, 1980, VET PARASITOL, V7, P319, DOI 10.1016/0304-4017(80)90052-7
   MAFF, 1986, USDA TECHNICAL B, V18, P2
   Martinez-Royo A, 2008, ANIM GENET, V39, P294, DOI 10.1111/j.1365-2052.2008.01707.x
   Martinez-Valladares M, 2013, VET PARASITOL, V191, P177, DOI 10.1016/j.vetpar.2012.08.009
   Mavrot F, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1164-z
   MURRAY J, 1971, New Zealand Veterinary Journal, V19, P1, DOI 10.1080/00480169.1971.33919
   NILSSON O, 1986, NORD VET MED, V38, P74
   PANDEY VS, 1984, ANN RECH VET, V15, P491
   Rinaldi L, 2012, SMALL RUMINANT RES, V103, P18, DOI 10.1016/j.smallrumres.2011.10.014
   Rose H, 2015, VET REC, V176, DOI 10.1136/vr.102982
   RUSSEL AJF, 1969, J AGR SCI, V72, P451, DOI 10.1017/S0021859600024874
   Sargison ND, 2013, SMALL RUMINANT RES, V110, P78, DOI 10.1016/j.smallrumres.2012.11.008
   SCHIMEK MG, 2000, SMOOTHING REGRESSION
   Sweeny JPA, 2012, VET PARASITOL, V184, P298, DOI 10.1016/j.vetpar.2011.08.016
   Torres-Acosta JFJ, 2014, SMALL RUMINANT RES, V121, P27, DOI 10.1016/j.smallrumres.2014.01.009
   Valcarcel F, 2015, VET PARASITOL, V211, P71, DOI 10.1016/j.vetpar.2015.04.014
   Valvarcel F., 2013, REV IBERO LATINOAM P, V72, P151
   Van Wyk JA, 2001, ONDERSTEPOORT J VET, V68, P55
NR 36
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109018
DI 10.1016/j.vetpar.2019.109018
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800009
PM 31896020
OA Green Published, Bronze
DA 2020-05-12
ER

PT J
AU Chaudhari, AA
   Lee, Y
   Lillehoj, HS
AF Chaudhari, Atul A.
   Lee, Youngsub
   Lillehoj, Hyun S.
TI Beneficial effects of dietary supplementation of Bacillus strains on
   growth performance and gut health in chickens with mixed coccidiosis
   infection
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Direct-fed microbial; Bacillus; Cytokine; Gene; Gut health; Growth
   performance; Chicken; Coccidia
ID DIRECT-FED MICROBIALS; BARRIER GENE-EXPRESSION; IMMUNE-RESPONSES;
   SUBTILIS; PROBIOTICS; SALMONELLA; RESISTANCE; MICROFLORA; RADIATION;
   TENELLA
AB The present study investigated the effects of dietary supplementation with several Bacillus strains on growth performance, intestinal inflammatory and anti-inflammatory cytokines, anti-oxidants and tight junction (TJ) protein mRNA expression in broiler chickens challenged with mixed coccidia infection (oocysts of Eimeria tenella, Eimeria maxima and Eimeria acervulina). Ten different Bacillus strains were screened for their beneficial effects on coccidiosis challenge by measuring relative body weight gain (RBWG), lesion score, and total oocyst count. Three out of ten Bacillus strains were evaluated in depth by measuring RBWG, lesion score, total oocyst count, and the gene expression of proinflammatory (IL-6 and IL-8), anti-inflammatory (IL-10 and TGF-beta), anti-oxidant (SOD1 and HMOX1), and TJ (JAM2 and occludin) proteins. Our results showed that out of the ten different Bacillus strains, chickens fed with three strains, one Bacillus licheniformis and two Bacillus amyloliquefaciens, showed significantly higher RBWG, lower lesion scores (ceca, jejunum, and duodenum), and lower total fecal oocyst counts compared to non-Bacillus-fed control chickens. Post-coccidia challenge, the RBWG for the Bacillus-fed groups were 95-100 % as opposed to the control birds (70 %) at 6 days post infection (dpi) and 10 dpi. Similarly, the lesion scores for three organs were around 0.8-0.9 for the Bacillus-fed groups as opposed to control birds (lesion score range similar to 1.4-2). The total oocyst counts were much lower in the Bacillus-fed group (10-20 folds lesser) than the control group. Furthermore, the Bacillus-fed groups showed differential gene expression at 3 dpi in different tissues, such as caecum, jejunum, and duodenum. Bacillus-fed chickens showed significant proand anti-inflammatory responses and higher expression of anti-oxidants and TJ proteins in the ceca, duodenum, and jejunum. Overall, our results demonstrated that dietary supplementation with Bacillus strains as direct-fed microbials (DFM) significantly improved the body weight gain after mixed coccidia challenge compared to non Bacillus-fed and coccidia challenged control group. In conclusion, the results of this study are promising and indicate the many beneficial effects of DFM-supplementation in poultry diets to reduce the negative consequences of enteric diseases and to decrease economic losses imposed by coccidia infection in chickens.
C1 [Chaudhari, Atul A.; Lee, Youngsub; Lillehoj, Hyun S.] USDA, Anim Biosci & Biotechnol Lab, Beltsville Agr Res Ctr, Agr Res Ctr, Beltsville, MD 20705 USA.
RP Lillehoj, HS (reprint author), USDA, Anim Biosci & Biotechnol Lab, Beltsville Agr Res Ctr, Agr Res Ctr, Beltsville, MD 20705 USA.
EM Hyun.Lillehoj@ars.usda.gov
OI CHAUDHARI, ATUL/0000-0002-5809-1369
FU  [ARS CRIS8042-32000-107-00D]
FX Funding was partly supported by ARS CRIS8042-32000-107-00D.
CR Anderson J.M., 2017, PHYSIOLOGY, V16, P126
   Barbosa TM, 2005, APPL ENVIRON MICROB, V71, P968, DOI 10.1128/AEM.71.2.968-978.2005
   Chaiyawan N, 2010, THAI J VET MED, V40, P207
   da Silva PT, 2015, CIENC RURAL, V45, P1342, DOI 10.1590/0103-8478cr20140211
   Dalloul RA, 2006, EXPERT REV VACCINES, V5, P143, DOI 10.1586/14760584.5.1.143
   Dibner JJ, 2005, POULTRY SCI, V84, P634, DOI 10.1093/ps/84.4.634
   Gadde U, 2017, PROBIOTICS ANTIMICRO, V9, P397, DOI 10.1007/s12602-017-9275-9
   Gadde UD, 2017, RES VET SCI, V114, P236, DOI 10.1016/j.rvsc.2017.05.004
   Giannenas I, 2012, VET PARASITOL, V188, P31, DOI 10.1016/j.vetpar.2012.02.017
   Grant A, 2018, AVIAN PATHOL, V47, P339, DOI 10.1080/03079457.2018.1464117
   Groux H, 1999, IMMUNOL TODAY, V20, P442, DOI 10.1016/S0167-5699(99)01510-8
   Guo XH, 2006, ANTON LEEUW INT J G, V90, P139, DOI 10.1007/s10482-006-9067-9
   Haghighi HR, 2005, CLIN DIAGN LAB IMMUN, V12, P1387, DOI 10.1128/CDLI.12.12.1387-1392.2005
   Hong YH, 2006, VET IMMUNOL IMMUNOP, V114, P259, DOI 10.1016/j.vetimm.2006.08.006
   Hong YH, 2006, VET IMMUNOL IMMUNOP, V114, P209, DOI 10.1016/j.vetimm.2006.07.007
   Jakobsen M, 2010, INT J FOOD MICROBIOL, V141, pS1, DOI 10.1016/j.ijfoodmicro.2010.06.015
   Jia P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35081-4
   JOHNSON J, 1970, EXP PARASITOL, V28, P30, DOI 10.1016/0014-4894(70)90063-9
   Knap I, 2011, POULTRY SCI, V90, P1690, DOI 10.3382/ps.2010-01056
   La Ragione RM, 2003, VET MICROBIOL, V94, P245, DOI 10.1016/S0378-1135(03)00077-4
   Lan RX, 2019, J SCI FOOD AGR, V99, P1554, DOI 10.1002/jsfa.9333
   Lee KW, 2013, ASIAN AUSTRAL J ANIM, V26, P1592, DOI 10.5713/ajas.2013.13178
   Lee KW, 2010, POULTRY SCI, V89, P203, DOI 10.3382/ps.2009-00418
   Lee KW, 2014, RES VET SCI, V97, P304, DOI 10.1016/j.rvsc.2014.07.021
   Lee KW, 2011, RES VET SCI, V91, pE87, DOI 10.1016/j.rvsc.2011.01.018
   Lee KW, 2010, COMP IMMUNOL MICROB, V33, pE105, DOI 10.1016/j.cimid.2010.06.001
   Lee SH, 2016, BRIT POULTRY SCI, V57, P165, DOI 10.1080/00071668.2016.1141172
   Lee Y, 2017, RES VET SCI, V112, P149, DOI 10.1016/j.rvsc.2017.03.019
   Li Y, 2018, J ANIM SCI BIOTECHNO, V9, DOI 10.1186/s40104-018-0236-2
   Lillehoj HS, 2000, AVIAN DIS, V44, P408, DOI 10.2307/1592556
   Lin RQ, 2017, VET PARASITOL, V243, P79, DOI 10.1016/j.vetpar.2017.06.003
   Mackowiak P.A., 2013, FRONT PUBLIC HEALTH, V1, P52, DOI [10.3389/fpubh.2013.00052, DOI 10.3389/FPUBH.2013.00052]
   Mondola P, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00594
   MOORE PR, 1946, J BIOL CHEM, V165, P437
   Oh S, 2018, CURR DEV NUTR, V2, DOI 10.1093/cdn/nzy009
   Opalinski M, 2007, BRAZ J POULTRY SCI, V9, P99, DOI 10.1590/S1516-635X2007000200004
   Otte JM, 2004, AM J PHYSIOL-GASTR L, V286, pG613, DOI 10.1152/ajpgi.00341.2003
   Otterbein L.E., 2017, AM J PHYSIOL-LUNG C, V279, pL1029
   Park JH, 2014, POULTRY SCI, V93, P2054, DOI 10.3382/ps.2013-03818
   Schneider K, 2001, EUR J BIOCHEM, V268, P4200, DOI 10.1046/j.1432-1327.2001.02334.x
   Sen S, 2012, RES VET SCI, V93, P264, DOI 10.1016/j.rvsc.2011.05.021
   Setlow P, 2006, J APPL MICROBIOL, V101, P514, DOI 10.1111/j.1365-2672.2005.02736.x
   Shirley MW, 2012, AVIAN PATHOL, V41, P111, DOI 10.1080/03079457.2012.666338
   Shivaramaiah S, 2011, POULTRY SCI, V90, P1574, DOI 10.3382/ps.2010-00745
   Sumi CD, 2015, CAN J MICROBIOL, V61, P93, DOI 10.1139/cjm-2014-0613
   Thomas CM, 2010, GUT MICROBES, V1, P148, DOI 10.4161/gmic.1.3.11712
   Vila B, 2010, WORLD POULTRY SCI J, V66, P369, DOI 10.1017/S0043933910000474
   Wang Y, 2017, PROBIOTICS ANTIMICRO, V9, P292, DOI 10.1007/s12602-017-9252-3
   Wine E, 2009, FEMS MICROBIOL LETT, V300, P146, DOI 10.1111/j.1574-6968.2009.01781.x
   Yang JJ, 2020, PROBIOTICS ANTIMICRO, V12, P204, DOI 10.1007/s12602-019-09532-x
   Yang J, 2018, J CANCER RES THER, V14, P36, DOI 10.4103/jcrt.JCRT_387_17
   Yegani M, 2008, POULTRY SCI, V87, P2052, DOI 10.3382/ps.2008-00091
   Zhao PY, 2015, ANIM FEED SCI TECH, V200, P86, DOI 10.1016/j.anifeedsci.2014.12.010
   Zhou YF, 2020, PROBIOTICS ANTIMICRO, V12, P246, DOI 10.1007/s12602-019-9524-1
   Zhu JJ, 2000, POULTRY SCI, V79, P619, DOI 10.1093/ps/79.5.619
NR 55
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109009
DI 10.1016/j.vetpar.2019.109009
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800004
PM 31862509
OA Bronze
DA 2020-05-12
ER

PT J
AU Coelho, L
   de Paula, LGF
   Alves, SDA
   Sampaio, ALN
   Bezerra, GP
   Vilela, FMP
   Matos, RD
   Zeringota, V
   Borges, LMF
   Monteiro, C
AF Coelho, Leticia
   Ferreira de Paula, Luiza Gabriella
   Alecrim Alves, Susy das Gracas
   Nunes Sampaio, Aparecida Lorrany
   Bezerra, Giovana Pereira
   Pinto Vilela, Fernanda Maria
   Matos, Renata da Silva
   Zeringota, Viviane
   Ferreira Borges, Ligia Miranda
   Monteiro, Caio
TI Combination of thymol and eugenol for the control of Rhipicephalus
   sanguineus sensu lato: Evaluation of synergism on immature stages and
   formulation development
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Brown dog tick; Essential oil; Monoterpene; Phenylpropanoid; Botanical
   pesticide; Botanical acaricidal
ID BROWN DOG TICK; ESSENTIAL OIL; ACARICIDAL ACTIVITY;
   AMBLYOMMA-CAJENNENSE; INSECTICIDAL ACTIVITY; CATTLE TICK; IXODIDAE;
   MICROPLUS; LARVAE; LATREILLE
AB The aim of this study was to investigate whether the combination of thymol with eugenol has a synergistic effect on the immature life stages of Rhipicephalus sanguineus sensu lato (s.l.), to evaluate the cost-benefit ratio of using these compounds in combination, and to develop a formulation combining thymol with eugenol with activity on immature stages of R. sanguineus s.l. To evaluate synergism, thymol and eugenol, combined (ratio 1:1) or not, were tested at concentrations of 2.5, 5.0, 10.0, 15.0 and 20.0 mg/mL on unfed larvae and nymphs using a larval packet test, and 0.625, 1.25, 2.5, 5.0 and 10 mg/mL on engorged larvae and nymphs using an immersion test. A cost estimate was calculated to produce 1 L of a solution containing a concentration of thymol and eugenol, combined or not, that could cause a tick mortality rate greater than 95%. Finally, a formulation was developed, consisting of a micellar dispersion containing polymers (MDP), with thymol + eugenol (1:1), at concentrations of 2.5, 5.0, 10.0, 15.0 and 20.0 mg/mL, and the activity was evaluated on unfed and engorged larvae and nymphs. For unfed larvae and nymphs, concentrations of 2.5 and 5.0 mg/mL and 2.5, 5.0 and 10.0 mg/mL, respectively, presented synergistic effects. In tests with engorged larvae and nymphs, respective concentrations of 0.625, 1.25 and 2.5 mg/mL and 2.5 and 5.0 mg/mL had synergistic effects. The estimated costs for producing a solution of 1 L with efficacy greater than 95 % was $5.97 using only thymol (15 mg/mL), $ 5.93 using only eugenol (15 mg/mL), and $ 3.97 using thymol + eugenol (1:1 - 5,0 mg/mL). In tests with MDP, the combination of thymol + eugenol resulted in a mortality rate higher than 95 % at concentration of 10 mg/mL for unfed and engorged larvae and nymphs. Thus, the combination of thymol + eugenol, depending on the concentration, has synergistic effects and this combination lowers the cost for the active ingredients thymol and eugenol. The combination of thymol + eugenol in MDP had acaricidal activity against immature life stages of R. sanguineus s.l.
C1 [Coelho, Leticia; Ferreira de Paula, Luiza Gabriella; Zeringota, Viviane; Ferreira Borges, Ligia Miranda; Monteiro, Caio] Goias Fed Univ, Ave Esperanca S-N,Campus Samambaia, BR-74690900 Goiania, Go, Brazil.
   [Ferreira Borges, Ligia Miranda; Monteiro, Caio] Goias Fed Univ UFG, Inst Trop Pathol & Publ Hlth, Rua 235 S-N, BR-74605050 Goiania, Go, Brazil.
   [Alecrim Alves, Susy das Gracas; Nunes Sampaio, Aparecida Lorrany; Bezerra, Giovana Pereira] Ave Esperanca S-N,Campus Samambaia, BR-74690900 Goiania, Go, Brazil.
   [Pinto Vilela, Fernanda Maria] Rua Jose Lourenco Kelmer S-N, BR-36036330 Juiz De Fora, MG, Brazil.
   [Matos, Renata da Silva] Univ Fed Juiz de Fora, Dept Pharmaceut Sci, Rua Jose Lourenco Kelmer S-N, BR-36036900 Juiz De Fora, MG, Brazil.
RP Monteiro, C (reprint author), Goias Fed Univ, Ave Esperanca S-N,Campus Samambaia, BR-74690900 Goiania, Go, Brazil.
EM caiosat@gmail.com
RI Borges, Ligia Miranda Ferreira/AAJ-5772-2020; Monteiro, Caio/M-7688-2015
OI Monteiro, Caio/0000-0001-5253-5451
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq) [311889/2017-4]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brazil (CAPES)CAPES [001]
FX We thank the CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico) for the financial support (project financing and grants)
   and for the grants PQ to CMO. Monteiro (311889/2017-4). This study also
   was financed (scholarships) in part by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - Brazil (CAPES) Finance
   Code 001.
CR Ahmad A, 2011, EUR J CLIN MICROBIOL, V30, P41, DOI 10.1007/s10096-010-1050-8
   Araujo LX, 2016, MED VET ENTOMOL, V30, P377, DOI 10.1111/mve.12181
   Bakkali F, 2008, FOOD CHEM TOXICOL, V46, P446, DOI 10.1016/j.fct.2007.09.106
   Bassole IHN, 2012, MOLECULES, V17, P3989, DOI 10.3390/molecules17043989
   Becker S, 2019, TICKS TICK-BORNE DIS, V10, P1046, DOI 10.1016/j.ttbdis.2019.05.015
   Berdejo D, 2019, CURR OPIN FOOD SCI, V30, P14, DOI 10.1016/j.cofs.2018.08.004
   BITTENCOURT VREP, 1989, PESQUI AGROPECU BRAS, V24, P1193
   Borges L. M. F., 2007, Revista de Patologia Tropical, V36, P87
   Chou TC, 2005, COMPUSYN DRUG COMBIN
   Daemon E, 2012, PARASITOL RES, V111, P1901, DOI 10.1007/s00436-012-3033-4
   Daemon E, 2012, VET PARASITOL, V186, P542, DOI 10.1016/j.vetpar.2011.11.013
   Daemon E, 2009, PARASITOL RES, V105, P495, DOI 10.1007/s00436-009-1426-9
   Dantas-Torres F, 2008, VET PARASITOL, V152, P173, DOI 10.1016/j.vetpar.2007.12.030
   Dantas-Torres F, 2015, VET PARASITOL, V208, P9, DOI 10.1016/j.vetpar.2014.12.014
   de Monteiro CM, 2012, PARASITOL RES, V111, P1295, DOI 10.1007/s00436-012-2964-0
   Monteiro CMD, 2010, PARASITOL RES, V106, P615, DOI 10.1007/s00436-009-1709-1
   Delaquis PJ, 2002, INT J FOOD MICROBIOL, V74, P101, DOI 10.1016/S0168-1605(01)00734-6
   Delgado B, 2004, FOOD MICROBIOL, V21, P327, DOI 10.1016/S0740-0020(03)00075-3
   Delmonte C, 2017, PARASITOL RES, V116, P2957, DOI 10.1007/s00436-017-5604-x
   Devi KP, 2010, J ETHNOPHARMACOL, V130, P107, DOI 10.1016/j.jep.2010.04.025
   Didry N, 1994, Pharm Acta Helv, V69, P25, DOI 10.1016/0031-6865(94)90027-2
   DRUMMOND RO, 1973, J ECON ENTOMOL, V66, P130, DOI 10.1093/jee/66.1.130
   Eiden A.L, 2015, J MED ENTOMOL, V31, P1
   Ellse L, 2014, MED VET ENTOMOL, V28, P233, DOI 10.1111/mve.12033
   Enan E, 2001, COMP BIOCHEM PHYS C, V130, P325, DOI 10.1016/S1532-0456(01)00255-1
   Ferreira F.M., 2017, MED VET ENTOMOL, V32, P1
   Gallardo A, 2012, J MED ENTOMOL, V49, P332, DOI 10.1603/ME11142
   Gray J, 2013, TICKS TICK-BORNE DIS, V4, P171, DOI 10.1016/j.ttbdis.2012.12.003
   HSDB, THYM
   HSDB, EUG
   Lima RK, 2011, CIENC AGROTEC, V35, P664, DOI 10.1590/S1413-70542011000400004
   Novato TPL, 2015, VET PARASITOL, V212, P331, DOI 10.1016/j.vetpar.2015.08.021
   Marchesini P, 2018, VET PARASITOL, V254, P147, DOI 10.1016/j.vetpar.2018.03.009
   Matos RD, 2014, PARASITOL RES, V113, P4555, DOI 10.1007/s00436-014-4145-9
   Matos RS, 2020, TICKS TICK-BORNE DIS, V11, DOI 10.1016/j.ttbdis.2019.101308
   Matos RS, 2019, TICKS TICK-BORNE DIS, V10, P314, DOI 10.1016/j.ttbdis.2018.11.003
   Mendes AD, 2011, VET PARASITOL, V183, P136, DOI 10.1016/j.vetpar.2011.07.007
   Miller RJ, 2001, J MED ENTOMOL, V38, P298, DOI 10.1603/0022-2585-38.2.298
   Neves A.P., 2009, THESIS
   Ntalli NG, 2011, PEST MANAG SCI, V67, P341, DOI 10.1002/ps.2070
   Otranto D, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-2
   Pavela R., 2010, Journal of Biopesticides, V3, P573
   Pavela R, 2016, RES VET SCI, V109, P1, DOI 10.1016/j.rvsc.2016.09.001
   Pei RS, 2009, J FOOD SCI, V74, pM379, DOI 10.1111/j.1750-3841.2009.01287.x
   Priestley CM, 2003, BRIT J PHARMACOL, V140, P1363, DOI 10.1038/sj.bjp.0705542
   Reck J, 2018, TICKS TICK-BORNE DIS, V9, P1296, DOI 10.1016/j.ttbdis.2018.05.010
   Rodriguez-Vivas RI, 2017, MED VET ENTOMOL, V31, P72, DOI 10.1111/mve.12207
   Rodriguez-Vivas RI, 2017, VET PARASITOL, V233, P9, DOI 10.1016/j.vetpar.2016.11.015
   Rosado-Aguilar JA, 2017, VET PARASITOL, V238, P66, DOI 10.1016/j.vetpar.2017.03.023
   Scoralik MG, 2012, PARASITOL RES, V110, P645, DOI 10.1007/s00436-011-2539-5
   Senra TDS, 2013, PARASITOL RES, V112, P1461, DOI 10.1007/s00436-013-3289-3
   Senra TOS, 2013, PARASITOL RES, V112, P3471, DOI 10.1007/s00436-013-3527-8
   STONE B. F., 1962, BULL ENTOMOL RES, V53, P563
   Tisserand R, 2014, ESSENTIAL OIL SAFETY
   Tripathi A. K., 2009, J PHARMACOGNOSY PHYT, V1, P52
   Yuan WQ, 2019, FOOD CONTROL, V96, P112, DOI 10.1016/j.foodcont.2018.09.005
NR 56
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 108989
DI 10.1016/j.vetpar.2019.108989
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800002
PM 31794909
OA Bronze
DA 2020-05-12
ER

PT J
AU Diezma-Diaz, C
   Ferre, I
   Saldias, B
   Blanco-Murcia, J
   Ortega-Mora, LM
   Alvarez-Garcia, G
AF Diezma-Diaz, Carlos
   Ferre, Ignacio
   Saldias, Begonia
   Blanco-Murcia, Javier
   Miguel Ortega-Mora, Luis
   Alvarez-Garcia, Gema
TI Added value of IgM detection and low avidity index as markers of acute
   bovine besnoitiosis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Besnoitia besnoiti; Cattle; Acute Infection; Early diagnosis; IgM;
   Avidity-ELISA
ID TOXOPLASMA-GONDII INFECTION; NEOSPORA-CANINUM INFECTION; SEROLOGICAL
   DIAGNOSIS; PREGNANT SHEEP; ANTIBODIES; TESTS; TACHYZOITE; ELISA; CATTLE
AB Early in vivo diagnosis of bovine besnoitiosis is crucial for the success of control programmes. However, diagnosis in acutely infected animals is hindered by the low sensitivity of the available serological tools.
   In this study, a novel ELISA to detect specific anti-Besnoitia besnoiti IgM antibodies was developed. The usefulness of this tool together with an avidity ELISA were studied with a well-coded sera panel from experimentally and naturally infected cattle. First, the kinetics of specific IgM levels were determined in experimentally infected calves during the acute and chronic infection. Next, IgM levels were determined in naturally infected cattle with either acute or chronic infection. Finally, the IgG avidity index was monitored in both experimentally and naturally infected cattle.
   Specific IgM antibodies were detected prior to specific IgG antibodies (7-19 days vs. 17-26 days post-infection). A prompt IgM response was associated with the end of the febrile stage in experimentally infected calves. Naturally and experimentally infected animals with acute clinical signs tested IgM-positive but IgG-negative, followed by IgG seroconversion 2-3 weeks later. Chronically infected cattle developed both IgM and IgG specific antibodies. Moreover, a progressive increase in the avidity index (AI) was observed in all experimentally infected calves during the course of the experimental trials. However, a low AI coincided with visible tissue cysts. Low avidity values were also detected when naturally infected cattle with acute clinical signs seroconverted, in contrast to a high AI detected in chronically infected cattle.
   In summary, IgM and avidity ELISAs improved the early in vivo diagnosis of bovine besnoitiosis. IgM-positive but IgG-negative results were indicative of an acute infection, whereas IgG positive results accompanied by low avidity values confirmed a recent infection.
C1 [Diezma-Diaz, Carlos; Ferre, Ignacio; Saldias, Begonia; Blanco-Murcia, Javier; Miguel Ortega-Mora, Luis; Alvarez-Garcia, Gema] Univ Complutense Madrid, Fac Vet Sci, Anim Hlth Dept, SALUVET, Ciudad Univ S-n, Madrid 28040, Spain.
   [Blanco-Murcia, Javier] Univ Complutense Madrid, Fac Vet Sci, Anim Med & Surg Dept, Ciudad Univ S-N, Madrid 28040, Spain.
RP Alvarez-Garcia, G (reprint author), Univ Complutense Madrid, Fac Vet Sci, Anim Hlth Dept, SALUVET, Ciudad Univ S-n, Madrid 28040, Spain.
EM gemaga@vet.ucm.es
RI ALVAREZ-GARCIA, GEMA/E-3577-2016
OI ALVAREZ-GARCIA, GEMA/0000-0002-6627-7577
FU Spanish Ministry of Economy and Competitiveness [AGL2016-75202-R,
   BES-2014-069839]; Community of MadridComunidad de Madrid [PLATESA 2-CM,
   P2018/BAA-4370]
FX This study was financed by the Spanish Ministry of Economy and
   Competitiveness (AGL2016-75202-R) and by the Community of Madrid
   (PLATESA 2-CM;P2018/BAA-4370). Carlos Diezma-Diaz was financially
   supported through a grant from the Spanish Ministry of Economy and
   Competitiveness (BES-2014-069839).
CR Aguado-Martinez A, 2008, VET PARASITOL, V157, P182, DOI 10.1016/j.vetpar.2008.08.002
   Aguado-Martinez AA, 2005, J VET DIAGN INVEST, V17, P442, DOI 10.1177/104063870501700506
   Alvarez-Garcia G, 2013, TRENDS PARASITOL, V29, P407, DOI 10.1016/j.pt.2013.06.002
   Basso W, 2010, VET PARASITOL, V173, P24, DOI 10.1016/j.vetpar.2010.06.009
   Benavides J, 2014, PARASITOLOGY, V141, P1471, DOI 10.1017/S0031182014000638
   Bjorkman C, 2006, VET PARASITOL, V140, P273, DOI 10.1016/j.vetpar.2006.04.030
   Buxton D, 1997, J COMP PATHOL, V117, P1, DOI 10.1016/S0021-9975(97)80062-X
   BUXTON D, 1986, J COMP PATHOL, V96, P319, DOI 10.1016/0021-9975(86)90052-6
   Campero LM, 2018, TROP ANIM HEALTH PRO, V50, P75, DOI 10.1007/s11250-017-1401-x
   Dard C, 2016, TRENDS PARASITOL, V32, P492, DOI 10.1016/j.pt.2016.04.001
   Diezma-Diaz C, 2019, VET PARASITOL, V267, P21, DOI 10.1016/j.vetpar.2019.02.001
   Diezma-Diaz C, 2017, VET PARASITOL, V247, P10, DOI 10.1016/j.vetpar.2017.09.017
   Diezma-Diaz C, 2020, TRANSBOUND EMERG DIS, V67, P234, DOI 10.1111/tbed.13345
   Diezma-Diaz C, 2018, TRANSBOUND EMERG DIS, V65, P1979, DOI 10.1111/tbed.12980
   Dubey JP, 2006, VET PARASITOL, V140, P1, DOI 10.1016/j.vetpar.2006.03.035
   Dubey JP, 2013, J PARASITOL, V99, P459, DOI 10.1645/12-128.1
   Dubey J.P., 2010, TOXOPLASMOSIS ANIMAL
   Esteban-Gil A, 2017, VET PARASITOL, V236, P14, DOI 10.1016/j.vetpar.2016.12.018
   Fernandez-Garcia A, 2009, J PARASITOL, V95, P474, DOI 10.1645/GE-1772.1
   Fernandez-Garcia A, 2013, PARASITOLOGY, V140, P999, DOI 10.1017/S003118201300036X
   Fioretti DP, 2003, J VET MED B, V50, P399, DOI 10.1046/j.1439-0450.2003.00686.x
   Garcia-Lunar P, 2017, VET PARASITOL, V244, P176, DOI 10.1016/j.vetpar.2017.07.029
   Garcia-Lunar P, 2015, VET PARASITOL, V214, P49, DOI 10.1016/j.vetpar.2015.09.011
   Garcia-Lunar P, 2013, TRANSBOUND EMERG DIS, V60, P59, DOI 10.1111/j.1865-1682.2012.01318.x
   Garcia-Lunar P, 2013, VET PARASITOL, V195, P24, DOI 10.1016/j.vetpar.2012.12.040
   Gras L, 2004, EPIDEMIOL INFECT, V132, P541, DOI 10.1017/S0950268803001948
   Gutierrez-Exposito D, 2017, TRANSBOUND EMERG DIS, V64, P538, DOI 10.1111/tbed.12402
   Gutierrez-Exposito D, 2017, INT J PARASITOL, V47, P737, DOI 10.1016/j.ijpara.2017.08.003
   LUNDEN A, 1994, ACTA VET SCAND, V35, P273
   Murat JB, 2013, EXPERT REV ANTI-INFE, V11, P943, DOI 10.1586/14787210.2013.825441
   ODONOGHUE PJ, 1985, VET PARASITOL, V18, P1, DOI 10.1016/0304-4017(85)90002-0
   Ortega-Mora L.M., 2007, GUIDELINES DIAGNOSIS, P89
   PAYNE RA, 1988, EPIDEMIOL INFECT, V100, P205, DOI 10.1017/S0950268800067339
   Robert-Gangneux F, 2012, CLIN MICROBIOL REV, V25, P264, DOI 10.1128/CMR.05013-11
   Sager H, 2003, PARASITOL RES, V91, P171, DOI 10.1007/s00436-003-0964-9
   Schares G, 2016, VET PARASITOL, V216, P101, DOI 10.1016/j.vetpar.2015.12.016
   Schares G, 2013, INT J PARASITOL, V43, P143, DOI 10.1016/j.ijpara.2012.10.011
   Schares G, 2011, VET PARASITOL, V175, P52, DOI 10.1016/j.vetpar.2010.09.024
   Schares G, 2002, VET PARASITOL, V106, P293, DOI 10.1016/S0304-4017(02)00103-6
   Schares G, 2009, VET PARASITOL, V163, P315, DOI 10.1016/j.vetpar.2009.04.033
   Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046
   TREES AJ, 1989, RES VET SCI, V46, P67, DOI 10.1016/S0034-5288(18)31120-2
   Villard O, 2016, DIAGN MICR INFEC DIS, V84, P22, DOI 10.1016/j.diagmicrobio.2015.09.009
   Zulpo DL, 2018, VET PARASITOL, V249, P17, DOI 10.1016/j.vetpar.2017.10.021
NR 44
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109012
DI 10.1016/j.vetpar.2019.109012
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800008
PM 31884316
OA Bronze
DA 2020-05-12
ER

PT J
AU Duzlu, O
   Yildirim, A
   Yetismis, G
   Onder, Z
   Simsek, E
   Ciloglu, A
   Demirpolat, GS
   Inci, A
AF Duzlu, Onder
   Yildirim, Alparslan
   Yetismis, Gamze
   Onder, Zuhal
   Simsek, Emrah
   Ciloglu, Arif
   Demirpolat, Gozde Sahingoz
   Inci, Abdullah
TI Development and field evaluation of a species-specific mt-COI targeted
   SYBR-Green Real Time PCR for detection and quantification of Haemonchus
   contortus in cattle in Turkey
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cattle; COI; Haemonchus contortus; Phylogenetic characterization; SYBR
   Green qPCR; Turkey
ID DOMESTIC RUMINANTS; BENZIMIDAZOLE RESISTANCE; STRONGYLID INFECTIONS;
   PARASITIC NEMATODES; GENETIC DIVERSITY; PLACEI; SHEEP; IDENTIFICATION;
   POPULATION; LARVAE
AB Haemonchus contortus is one of the most important gastrointestinal nematodes (GINs) infecting sheep, goats, and cattle worldwide. We developed a SYBR Green real-time PCR (qPCR) assay for detection and quantification of H. contortus by using specific primers based on a conserved region of the mitochondrial cytochrome oxidase subunit I (mt-COI) gene, and evaluated this technique in the detection of H. contortus infections in cattle in Central Anatolia Region of Turkey. The newly developed qPCR assay successfully discriminated H. contortus from other GIN species infecting cattle in the specificity evaluations, with a specific melt peak of 77.5 degrees C. Our results revealed the efficient amplification of the proposed target COI region within the range of plasmid copies, from 2 x 10 (6) to 2 x 10 (1) per mu l, with 96.9 % efficiency, R-2 value of 0.999, and a slope of -3.398. Among the 920 cattle fecal samples from the field, 58 samples (6.3 %) were positive with qPCR assay, whereas 45 samples (4.9 %) were positive, as determined by larval culture, suggesting the utility of SYBR Green qPCR. Phylogenetic characterization of the partial COI gene of H. contortus isolates was also evaluated for 100 eggs and third stage larvae recovered from positive cattle faecal samples, which were verified with the qPCR assay prior to analyses. COI sequences were classified into three haplotypes (THC1 to THC3) with intraspecific nucleotide differences of 0.50 to 0.76 %. Phylogenetic analyses revealed that the haplotypes grouped with H. contortus isolates from several countries in a monophyletic cluster, with evidence of at least two main haplogroups. Overall, the SYBR Green qPCR assay was highly specific and sensitive, suggesting that it can be used for screening of H. contortus infections in livestock populations in epidemiological studies and the control of this important parasite.
C1 [Duzlu, Onder; Yildirim, Alparslan; Yetismis, Gamze; Onder, Zuhal; Ciloglu, Arif; Inci, Abdullah] Erciyes Univ, Fac Vet Med, Dept Parasitol, Kayseri, Turkey.
   [Simsek, Emrah] Erciyes Univ, Fac Vet Med, Preclin Sci, Kayseri, Turkey.
   [Demirpolat, Gozde Sahingoz] Bozok Univ, Vocat Sch Bogazliyan, Yozgat, Turkey.
RP Duzlu, O (reprint author), Erciyes Univ, Fac Vet Med, Dept Parasitol, Kayseri, Turkey.
EM onderduzlu@erciyes.edu.tr
FU Erciyes University Scientific Research Projects Coordination UnitErciyes
   University [TSA-2015-5777]
FX This study was supported by Erciyes University Scientific Research
   Projects Coordination Unit under grant number TSA-2015-5777.
CR Akkari H, 2013, VET PARASITOL, V193, P118, DOI 10.1016/j.vetpar.2012.12.014
   Amarante AFT, 1997, VET PARASITOL, V73, P89, DOI 10.1016/S0304-4017(97)00036-8
   Amarante MRV, 2017, J HELMINTHOL, V91, P757, DOI 10.1017/S0022149X16000882
   Archie EA, 2011, INT J PARASITOL, V41, P89, DOI 10.1016/j.ijpara.2010.07.014
   Bisset SA, 2014, VET PARASITOL, V200, P117, DOI 10.1016/j.vetpar.2013.12.002
   Blouin MS, 1998, MOL BIOL EVOL, V15, P1719, DOI 10.1093/oxfordjournals.molbev.a025898
   Bott NJ, 2009, INT J PARASITOL, V39, P1277, DOI 10.1016/j.ijpara.2009.03.002
   Brasil BSAF, 2012, INT J PARASITOL, V42, P469, DOI 10.1016/j.ijpara.2012.03.003
   Chaudhry U, 2015, INT J PARASITOL, V45, P149, DOI 10.1016/j.ijpara.2014.09.002
   Chaudhry U, 2014, VET PARASITOL, V204, P411, DOI 10.1016/j.vetpar.2014.05.025
   Dey AR, 2019, INFECT GENET EVOL, V68, P177, DOI 10.1016/j.meegid.2018.12.021
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Eljaki AA, 2016, VET PARASITOL, V227, P48, DOI 10.1016/j.vetpar.2016.07.022
   Favero FC, 2016, VET PARASITOL, V217, P25, DOI 10.1016/j.vetpar.2015.12.017
   Gasser RB, 2008, BIOTECHNOL ADV, V26, P325, DOI 10.1016/j.biotechadv.2008.03.003
   Getachew T, 2007, PARASITE, V14, P3, DOI 10.1051/parasite/2007141003
   GIBBONS L M, 1979, Systematic Parasitology, V1, P3, DOI 10.1007/BF00009771
   Grattapaglia D, 2011, BMC PLANT BIOL, V11, DOI 10.1186/1471-2229-11-65
   Grosz DD, 2013, VET PARASITOL, V196, P143, DOI 10.1016/j.vetpar.2013.01.026
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Hansen J., 1994, EPIDEMIOLOGY DIAGNOS
   Harmon A.F., 2009, Proceedings of the South Dakota Academy of Science, V88, P147
   Harmon AF, 2007, PARASITOL RES, V101, P71, DOI 10.1007/s00436-006-0428-0
   Hoglund J, 2013, VET PARASITOL, V197, P251, DOI 10.1016/j.vetpar.2013.04.044
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Hussain T, 2014, VET PARASITOL, V206, P188, DOI 10.1016/j.vetpar.2014.10.026
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Knight JS, 2015, VET PARASITOL, V214, P337, DOI 10.1016/j.vetpar.2015.10.019
   Kramme S, 2011, J MED MICROBIOL, V60, P454, DOI 10.1099/jmm.0.025338-0
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Learmount J, 2009, VET PARASITOL, V166, P268, DOI 10.1016/j.vetpar.2009.08.017
   Librado P, 2009, BIOINFORMATICS, V25, P1451, DOI 10.1093/bioinformatics/btp187
   Ljungstrom S, 2018, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00239
   Onder Z, 2016, KAFKAS UNIV VET FAK, V22, P93, DOI 10.9775/kvfd.2015.13960
   Pichler R, 2017, VET PARASITOL, V237, P94, DOI 10.1016/j.vetpar.2017.02.012
   Postollec F, 2011, FOOD MICROBIOL, V28, P848, DOI 10.1016/j.fm.2011.02.008
   ROBERTS FHS, 1954, AUST J ZOOL, V2, P275, DOI 10.1071/ZO9540275
   Roeber F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037327
   ROOS MH, 1993, INT J PARASITOL, V23, P419, DOI 10.1016/0020-7519(93)90021-P
   SANTIAGO M A M, 1975, Pesquisa Agropecuaria Brasileira Serie Veterinaria, V10, P51
   Santos MC, 2014, VET PARASITOL, V203, P127, DOI 10.1016/j.vetpar.2014.02.048
   Shen R, 2005, MUTAT RES-FUND MOL M, V573, P70, DOI 10.1016/j.mrfmmm.2004.07.022
   Stromberg BE, 2015, CAN J VET RES, V79, P290
   Sweeny JPA, 2012, VET PARASITOL, V187, P227, DOI 10.1016/j.vetpar.2012.01.007
   van Wyk JA, 2004, VET PARASITOL, V119, P277, DOI 10.1016/j.vetpar.2003.11.012
   van Wyk JA, 2013, ONDERSTEPOORT J VET, V80, DOI 10.4102/ojvr.v80i1.539
   von Samson-Himmestjerna G, 2002, INT J PARASITOL, V32, P1529, DOI 10.1016/S0020-7519(02)00163-7
   Wang N, 2013, PARASITOL INT, V62, P435, DOI 10.1016/j.parint.2013.05.004
   Wang YZ, 2014, EXP PARASITOL, V144, P96, DOI 10.1016/j.exppara.2014.06.019
   Zhan B, 2001, J PARASITOL, V87, P1227, DOI 10.1645/0022-3395(2001)087[1227:SSIOHH]2.0.CO;2
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109020
DI 10.1016/j.vetpar.2019.109020
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800010
PM 31896019
OA Bronze
DA 2020-05-12
ER

PT J
AU Avila, HG
   Mozzoni, C
   Trangoni, MD
   Cravero, SLP
   Perez, VM
   Valenzuela, F
   Gertiser, ML
   Butti, MJ
   Kamenetzky, L
   Jensen, O
   Rosenzvit, MC
AF Gabriel Avila, Hector
   Mozzoni, Cecilia
   David Trangoni, Marcos
   Pedro Cravero, Silvio Lorenzo
   Mirtha Perez, Veronica
   Valenzuela, Federico
   Laura Gertiser, Maria
   Javier Butti, Marcos
   Kamenetzky, Laura
   Jensen, Oscar
   Cecilia Rosenzvit, Mara
TI Development of a copro-LAMP assay for detection of several species of
   Echinococcus granulosus sensu lato complex
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Echinococcus granulosus sensu lato; Loop mediated isothermal
   amplification; LAMP; Copro-diagnosis; Molecular epidemiology; Cystic
   echinococcosis
ID ISOTHERMAL AMPLIFICATION LAMP; GENOTYPES; IDENTIFICATION; EPIDEMIOLOGY;
   DIAGNOSIS; PATENT; G1
AB Cystic echinococcosis represents a significant problem in human and animal health and constitutes one of the most severe Neglected Tropical Diseases prioritized by the World Health Organization. The etiological agent is the complex Echinococcus granulosus sensu lato (s. l.), composed of several species/genotypes. Diagnosis in the definitive host and molecular epidemiology studies are important points for cystic echinococcosis control. Here we developed a new copro-LAMP assay, LAMP EGSL, for diagnosis in the definitive host for simultaneous detection of Echinococcus granulosus sensu stricto (s. s.), Echinococcus ortleppi, and Echinococcus canadensis species. Also, the analytical sensitivity, specificity and plausibility of performance in a rural context of a previously reported species-specific LAMP reaction, was evaluated. Both reactions showed high analytical sensitivity values (10 fg-100 fg DNA) and did not show cross reaction with DNA from host or other helminthic parasites. LAMP EGSL was performed with samples from an endemic area. In addition, the alkaline hydrolysis of one E. granulosus s. s. adult parasite followed by specific LAMP to E. granulosus s. s. was performed in a laboratory with low resources from another cystic echinococcosis endemic area. The results obtained suggest that LAMP EGSL represents a potential tool for canine diagnosis that could be useful for cystic echinococcosis control programs. In addition, we showed that LAMP reaction for E. granulous s. s., E. ortleppi and E. canadensis specific detection, could be useful for molecular epidemiology studies applicable to the definitive host. Both reactions were performed in endemic, rural areas without sophisticated equipment.
C1 [Gabriel Avila, Hector; Kamenetzky, Laura; Cecilia Rosenzvit, Mara] UBA, Fac Med, CONICET, IMPAM,Inst Invest Microbiol & Parasitol Med, Paraguay 2155,Piso 13, RA-1121 Buenos Aires, DF, Argentina.
   [Gabriel Avila, Hector; Laura Gertiser, Maria; Jensen, Oscar] Ctr Invest Zoonosis, Sarmiento, Chubut, Argentina.
   [Mozzoni, Cecilia] Minist Salud & Ambiente, Hosp Zonal Caleta Olivia, Santa Cruz, Argentina.
   [David Trangoni, Marcos; Pedro Cravero, Silvio Lorenzo] INTA, Lab Brucella Campylobacter & Microbiota, Buenos Aires, DF, Argentina.
   [Mirtha Perez, Veronica; Valenzuela, Federico] Div Zoonosis, San Juan, Argentina.
   [Javier Butti, Marcos] Univ Nacl La Plata, Fac Ciencias Vet, Catedra Parasitol Comparada, Lab Parasitosis Humanas & Zoonosis Parasitarias, Buenos Aires, DF, Argentina.
RP Rosenzvit, MC (reprint author), UBA, Fac Med, CONICET, IMPAM,Inst Invest Microbiol & Parasitol Med, Paraguay 2155,Piso 13, RA-1121 Buenos Aires, DF, Argentina.
EM mrosenzvit@fmed.uba.ar
OI Butti, Marcos Javier/0000-0002-8537-7389
FU Fundacion Mundo Sano; Agencia Nacional de Promocion Cientifica y
   Tecnologica (ANPCyT), ArgentinaANPCyT [2966]; Consejo Nacional de
   Investigaciones Cientificas y Tecnologicas (CONICET)Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET); Ministerio de Salud de
   la Provincia de San Juan; Ministerio de Salud de la Provincia del Chubut
FX This work was supported by Fundacion Mundo Sano; Agencia Nacional de
   Promocion Cientifica y Tecnologica (ANPCyT), Argentina, project PICT
   2017 No 2966; Consejo Nacional de Investigaciones Cientificas y
   Tecnologicas (CONICET); Ministerio de Salud de la Provincia de San Juan
   and Ministerio de Salud de la Provincia del Chubut.
CR Abdullah J, 2014, BRAZ J MICROBIOL, V45, P1385, DOI 10.1590/S1517-83822014000400032
   Abrasi I, 2003, AM J TROP MED HYG, V69, P324, DOI 10.4269/ajtmh.2003.69.324
   Ahmed ME, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0809-2
   Cucher MA, 2016, TROP MED INT HEALTH, V21, P166, DOI 10.1111/tmi.12647
   Avila HG, 2017, PARASITOL INT, V66, P250, DOI 10.1016/j.parint.2017.02.001
   Azizi M., 2019, ACS SENSORS, DOI [10.1021/acssensors.8601206, DOI 10.1021/ACSSENSORS.8601206]
   Bakhtiari S, 2016, JUNDISHAPUR J MICROB, V9, DOI 10.5812/jjm.28831
   Bell AS, 2002, TRENDS PARASITOL, V18, P337, DOI 10.1016/S1471-4922(02)02331-0
   Besuschio SA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005779
   BOWLES J, 1992, MOL BIOCHEM PARASIT, V54, P165, DOI 10.1016/0166-6851(92)90109-W
   Bretagne S, 2003, CLIN MICROBIOL INFEC, V9, P505, DOI 10.1046/j.1469-0691.2003.00677.x
   Cabrera M, 2002, DIAGN MICR INFEC DIS, V44, P29, DOI 10.1016/S0732-8893(02)00414-5
   Casulli A., 2017, PARASSITOLOGIA, V39, P349, DOI [10.13140/RG.2.2.19444.35204, DOI 10.13140/RG.2.2.19444.35204]
   Craig P.S., 1996, COMPENDIUM CYSTIC EC
   Craig P, 2015, VET PARASITOL, V213, P132, DOI 10.1016/j.vetpar.2015.07.028
   Cucher M, 2011, INT J PARASITOL, V41, P439, DOI 10.1016/j.ijpara.2010.11.010
   de Ruiter CM, 2014, J CLIN MICROBIOL, V52, P3147, DOI 10.1128/JCM.00372-14
   Deng MH, 2019, INFECT DIS POVERTY, V8, DOI 10.1186/s40249-019-0530-z
   Eckert J, 2004, CLIN MICROBIOL REV, V17, P107, DOI 10.1128/CMR.17.1.107-135.2004
   ECKERT J, 1981, GUIDELINES SURVEILLA
   Eiken sf, 2018, PRIMEREXPLORERV5
   Debiaggi MF, 2017, PARASITOL RES, V116, P2599, DOI 10.1007/s00436-017-5555-2
   Gallas-Lindemann C, 2016, ACTA TROP, V158, P43, DOI 10.1016/j.actatropica.2016.02.005
   Han ET, 2007, J CLIN MICROBIOL, V45, P2521, DOI 10.1128/JCM.02117-06
   Ito A, 2017, ACTA TROP, V165, P3, DOI 10.1016/j.actatropica.2016.05.013
   Karani M, 2014, EPIDEMIOL INFECT, V142, P1671, DOI 10.1017/S0950268813002677
   Karanis P, 2007, APPL ENVIRON MICROB, V73, P5660, DOI 10.1128/AEM.01152-07
   Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841
   Morel N, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001967
   Naidich A, 2006, MOL CELL PROBE, V20, P5, DOI 10.1016/j.mcp.2005.08.001
   Nakao M, 2003, INFECT GENET EVOL, V3, P159, DOI 10.1016/S1567-1348(03)00070-4
   Pham NTK, 2015, JPN J INFECT DIS, V68, P432, DOI 10.7883/yoken.JJID.2014.450
   Ni Xing-Wei, 2014, PLoS One, V9, pe100877, DOI 10.1371/journal.pone.0100877
   Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63
   Nzelu CO, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007698
   PANAFTOSA, 2015, EQ INF EP REG AM SUR
   Pawlowski Z.S., 2001, WHO OIE MANUAL ECHIN
   Piepenburg O, 2006, PLOS BIOL, V4, P1115, DOI 10.1371/journal.pbio.0040204
   Plutzer J, 2009, PARASITOL RES, V104, P1527, DOI 10.1007/s00436-009-1391-3
   Repetto SA, 2013, ACTA TROP, V126, P110, DOI 10.1016/j.actatropica.2013.02.003
   Rojas CAA, 2013, PARASITE IMMUNOL, V35, P99, DOI 10.1111/pim.12009
   Salant H, 2012, AM J TROP MED HYG, V87, P883, DOI 10.4269/ajtmh.2012.12-0184
   Sambrook J., 2001, HUM MUTAT, DOI [10.1002/humu.1186.abs, DOI 10.1002/HUMU.1186.ABS]
   Sheather A.L., 1923, J PATHOL THER, V36
   Singh P, 2013, WORLD J MICROB BIOT, V29, P27, DOI 10.1007/s11274-012-1154-7
   Stefanic S, 2004, PARASITOL RES, V92, P347, DOI 10.1007/s00436-003-1043-y
   Telemann W, 1908, DEUT MED WOCHENSCHR, V34, P1510, DOI 10.1055/s-0028-1135692
   Thompson RCA, 2017, ADV PARASIT, V95, P65, DOI 10.1016/bs.apar.2016.07.001
   Soriano SV, 2016, VET PARASITOL, V228, P6, DOI 10.1016/j.vetpar.2016.08.008
   Wang SY, 2019, BIOSENS BIOELECTRON, V140, P69, DOI 10.1016/j.bios.2019.111333
   Wang Y, 2015, MOLECULES, V20, P21515, DOI 10.3390/molecules201219787
   Wassermann M, 2014, VET PARASITOL, V200, P97, DOI 10.1016/j.vetpar.2013.12.012
   WHO, 2010, 1 WHO REP NEGL TROP, DOI [10.1177/1757913912449575, DOI 10.1177/1757913912449575]
   Wong YP, 2018, J APPL MICROBIOL, V124, P626, DOI 10.1111/jam.13647
   Xu GL, 2012, SCI REP-UK, V2, DOI 10.1038/srep00246
NR 55
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109017
DI 10.1016/j.vetpar.2019.109017
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800011
PM 31901535
OA Bronze
DA 2020-05-12
ER

PT J
AU Giapitzoglou, S
   Saridomichelakis, MN
   Leontides, LS
   Kasabalis, D
   Chatzis, M
   Apostolidis, K
   Theodorou, K
   Roumpeas, E
   Mylonakis, ME
AF Giapitzoglou, Smaro
   Saridomichelakis, Manolis N.
   Leontides, Leonidas S.
   Kasabalis, Dimitris
   Chatzis, Manolis
   Apostolidis, Kosmas
   Theodorou, Konstantina
   Roumpeas, Efstathios
   Mylonakis, Mathios E.
TI Evaluation of serum symmetric dimethylarginine as a biomarker of kidney
   disease in canine leishmaniosis due to Leishmania infantum
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Chronic kidney disease; Dog; Leishmania infantum; Proteinuria; Symmetric
   dimethylarginine
ID DOGS; CREATININE; PROTEINURIA; DIAGNOSIS; MARKER; CATS
AB Canine leishmaniosis (CanL)-associated chronic kidney disease is a leading cause of morbidity and mortality in Mediterranean countries. Novel renal biomarkers, such as serum symmetric dimethylarginine (sSDMA), may be useful surrogates for the detection of renal functional impairment. The objectives of this study were to investigate sSDMA concentrations in dogs with CanL, with and without azotemia, and to establish any potential association with the prevalence and severity of proteinuria, with the prevalence of decreased urine specific gravity and with the LeishVet clinical stages of CanL. Serum samples from 68 dogs with CanL (50 nonazotemic and 18 azotemic) and 17 healthy dogs were retrospectively examined. Increased sSDMA was documented in 26 % of dogs with CanL without azotemia and in 83.3 % of dogs with azotemia. Serum SDMA was significantly higher in azotemic compared to nonazotemic dogs and was associated with the presence and severity of proteinuria, the decreased urine specific gravity and the advanced clinical stages of CanL. The results of the present study indicate that sSDMA may be a useful adjunct to serum creatinine and urine protein/creatinine ratio for the detection of CanL-associated nephropathy, but it is of limited value for distinguishing among the LeishVet clinical stages of CanL.
C1 [Giapitzoglou, Smaro; Theodorou, Konstantina; Roumpeas, Efstathios; Mylonakis, Mathios E.] Aristotle Univ Thessaloniki CAC AUTh, Sch Vet Med, Compan Anim Clin, 11 Stavrou Voutyra Str, Thessaloniki 54627, Greece.
   [Saridomichelakis, Manolis N.; Kasabalis, Dimitris; Chatzis, Manolis; Apostolidis, Kosmas] Univ Thessaly CM UTh, Sch Vet Sci, Clin Med, 224 Trikalon Str, Kardhitsa 43132, Greece.
   [Leontides, Leonidas S.] Univ Thessaly, Sch Vet Sci, Lab Epidemiol Biostat & Anim Hlth Econ, 224 Trikalon Str, Kardhitsa 43132, Greece.
RP Mylonakis, ME (reprint author), Aristotle Univ Thessaloniki CAC AUTh, Sch Vet Med, Compan Anim Clin, 11 Stavrou Voutyra Str, Thessaloniki 54627, Greece.
EM mmylonak@vet.auth.gr
OI Saridomichelakis, Manolis/0000-0001-8308-3371
FU Companion Animal Clinic, School of Veterinary Medicine, AUTh, Greece;
   Clinic of Medicine, School of Veterinary Science, UTh, Greece;
   Gerolymatos International (Boehringer Ingelheim)Boehringer Ingelheim
FX The study was funded by the Companion Animal Clinic, School of
   Veterinary Medicine, AUTh, Greece, the Clinic of Medicine, School of
   Veterinary Science, UTh, Greece, and the Gerolymatos International
   (Boehringer Ingelheim). No funding sources had any involvement in study
   design, in collection, analysis and interpretation of data, in writing
   report(s), and in the decision to submit the article for publication.
CR Braun JP, 2003, VET CLIN PATH, V32, P162, DOI 10.1111/j.1939-165X.2003.tb00332.x
   Choi BS, 2017, CAN J VET RES, V81, P228
   Dahlem DP, 2017, J VET INTERN MED, V31, P799, DOI 10.1111/jvim.14694
   Elliot J., 2009, KIRKS CURRENT VET TH, P883
   Hall JA, 2016, J VET INTERN MED, V30, P794, DOI 10.1111/jvim.13942
   Hall JA, 2014, J VET INTERN MED, V28, P1676, DOI 10.1111/jvim.12445
   Hall JA, 2015, J VET INTERN MED, V29, P808, DOI 10.1111/jvim.12607
   Kielstein JT, 2006, NEPHROL DIAL TRANSPL, V21, P2446, DOI 10.1093/ndt/gfl292
   Koutinas AF, 2014, VET PATHOL, V51, P527, DOI 10.1177/0300985814521248
   Koutinas AF, 1999, J AM ANIM HOSP ASSOC, V35, P376, DOI 10.5326/15473317-35-5-376
   Liffman R, 2018, VET CLIN PATH, V47, P458, DOI 10.1111/vcp.12638
   Martinez J, 2017, J VET INTERN MED, V31, P988, DOI 10.1111/jvim.14720
   Melendez-Lazo A, 2018, RES VET SCI, V117, P18, DOI 10.1016/j.rvsc.2017.10.011
   Nabity MB, 2015, J VET INTERN MED, V29, P1036, DOI 10.1111/jvim.12835
   Noli C, 2014, VET J, V202, P425, DOI 10.1016/j.tvjl.2014.09.002
   Pardo-Marin L, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-0956-0
   Pelander L, 2019, J VET INTERN MED, V33, P630, DOI 10.1111/jvim.15445
   Petanides TA, 2008, J VET INTERN MED, V22, P866, DOI 10.1111/j.1939-1676.2008.0129.x
   Plevraki K, 2006, J VET INTERN MED, V20, P228, DOI 10.1892/0891-6640(2006)20[228:EOATOT]2.0.CO;2
   Qurollo BA, 2019, J VET INTERN MED, V33, P618, DOI 10.1111/jvim.15354
   Relford R, 2016, VET CLIN N AM-SMALL, V46, P941, DOI 10.1016/j.cvsm.2016.06.010
   Rentko V, 2013, J VET INTERN MED, V27, P750
   Saridomichelakis MN, 2009, VET DERMATOL, V20, P471, DOI 10.1111/j.1365-3164.2009.00823.x
   Solano-Gallego L, 2017, TRENDS PARASITOL, V33, P706, DOI 10.1016/j.pt.2017.06.004
   Solano-Gallego L, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-86
   Torrent Esther, 2018, Vet Med Int, V2018, P7517359, DOI 10.1155/2018/7517359
   Vaden SL, 2016, VET CLIN N AM-SMALL, V46, P1115, DOI 10.1016/j.cvsm.2016.06.009
   Wehner A, 2008, VET REC, V162, P141, DOI 10.1136/vr.162.5.141
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109015
DI 10.1016/j.vetpar.2019.109015
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800007
PM 31874403
OA Bronze
DA 2020-05-12
ER

PT J
AU Kelley, JM
   Rathinasamy, V
   Elliott, TP
   Rawlin, G
   Beddoe, T
   Stevenson, MA
   Spithill, TW
AF Kelley, Jane M.
   Rathinasamy, Vignesh
   Elliott, Timothy P.
   Rawlin, Grant
   Beddoe, Travis
   Stevenson, Mark A.
   Spithill, Terry W.
TI Determination of the prevalence and intensity of Fasciola hepatica
   infection in dairy cattle from six irrigation regions of Victoria,
   South-eastern Australia, further identifying significant triclabendazole
   resistance on three properties
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Fasciola hepatica; Liver fluke; Dairy cattle; cELISA; Prevalence;
   Triclabendazole resistance
ID ANTIBODY-LEVELS; ASSOCIATIONS; HERDS; ELISA; SEROPREVALENCE; ENGLAND;
   SAMPLES; LOSSES; SHEEP; MILK
AB Fasciola hepatica (liver fluke) is a widespread parasite infection of livestock in Victoria, South-eastern Australia, where high rainfall and a mild climate is suitable for the main intermediate host Austropeplea tomentosa. The aims of this study were to quantify the prevalence and intensity of F. hepatica in dairy cattle in the irrigated dairy regions of Victoria and determine if triclabendazole resistance was present in infected herds. Cattle in 83 herds from the following six irrigation regions were tested for F. hepatica: Macalister Irrigation District (MID), Upper Murray (UM), Murray Valley (MV), Central Goulburn (CG), Torrumbarry (TIA) and Loddon Valley (LV). Twenty cattle from each herd were tested using the F. hepatica faecal egg count (FEC) as well as the coproantigen ELISA (cELISA). The mean individual animal true prevalence of F. hepatica across all regions was 39 % (95 % credible interval [CrI] 27%-51%) by FEC and 39 % (95 % CrI 27%-50%) by cELISA with the highest true prevalence (75-80 %) found in the MID. Our results show that 46 % of the herds that took part in this study were likely to experience fluke-associated production losses, based on observations that herd productivity is impaired when the true within-herd prevalence is > 25 %. Using the FEC and cELISA reduction tests, triclabendazole resistance was assessed on 3 herds in total (2 from the 83 in the study; and 1 separate herd that did not take part in the prevalence study) and resistance was confirmed in all 3 herds. This study has confirmed that F. hepatica is endemic in several dairy regions in Victoria: triclabendazole resistance may be contributing to the high prevalence in some herds. From our analysis, we estimate that the state-wide economic loss associated with fasciolosis is in the order of AUD 129 million (range AUD 38-193 million) per year or about AUD 50,000 (range AUD 15,000-75,000) per herd per year.
C1 [Kelley, Jane M.; Rathinasamy, Vignesh; Beddoe, Travis; Spithill, Terry W.] La Trobe Univ, Ctr AgriBiosci, Dept Anim Plant & Soil Sci, Bundoora, Vic 3083, Australia.
   [Elliott, Timothy P.] Invetus, Armidale, NSW 2350, Australia.
   [Rawlin, Grant] La Trobe Univ, Ctr AgriBiosci, Dept Jobs Precincts & Reg, Bundoora, Vic 3083, Australia.
   [Stevenson, Mark A.] Univ Melbourne, Fac Vet & Agr Sci, Parkville, Vic 3010, Australia.
RP Spithill, TW (reprint author), La Trobe Univ, Ctr AgriBiosci, Dept Anim Plant & Soil Sci, Bundoora, Vic 3083, Australia.
EM t.spithill@latrobe.edu.au
FU Science and Innovation Awards for Young People in Agriculture, Fisheries
   and ForestryAustralian GovernmentDepartment of Agriculture and Water
   Resources; Gardiner Dairy Foundation; Dairy AustraliaDairy Australia; La
   Trobe University
FX We would like to thank the Gippsland Veterinary Hospital, Tatura
   Veterinary Clinic, Rochester Veterinary Clinic, Kyabram Veterinary
   Clinic, Clavin and Rogers and Agriculture Victoria for their involvement
   in this study. We would like to thank Jakob Malmo, Lauren Clyne, Jeff
   Cave, Sarah Hall, Hannah Delahunty, Luke Ramsden, Alex Perry, Szymon
   Ziety, Alex Crosbie, Anna Niblett, Alastair Murray, and Paul Clavin for
   collecting the faecal samples on our behalf. We thank Chris Hosking,
   Laura Griomo, Mary Fletcher, Jesse Kruse, Rebecca Black, Clare Condos,
   Lincoln Ferrie and Lakisha Jong for their assistance in processing the
   samples. This work was supported by funds from the Science and
   Innovation Awards for Young People in Agriculture, Fisheries and
   Forestry (to JK), the Gardiner Dairy Foundation, Dairy Australia and La
   Trobe University.
CR Agriculture Victoria, 2014, DAIR IND PROF DEP EC
   APVMA, 2015, EFF STAND RUM ANTH A
   Bennema SC, 2011, INT J PARASITOL, V41, P225, DOI 10.1016/j.ijpara.2010.09.003
   Boray J. C., 1969, Adv Parasitology, V7, P95, DOI 10.1016/S0065-308X(08)60435-2
   Boray J.C., 2007, LIVER FLUKE DIS SHEE
   BORAY JC, 1983, VET REC, V113, P315, DOI 10.1136/vr.113.14.315
   Brockwell YM, 2013, VET PARASITOL, V196, P417, DOI 10.1016/j.vetpar.2013.04.012
   Brockwell YM, 2014, INT J PARASITOL-DRUG, V4, P48, DOI 10.1016/j.ijpddr.2013.11.005
   Charlier J, 2014, PARASITOLOGY, V141, P326, DOI 10.1017/S0031182013001662
   Charlier J, 2008, VET PARASITOL, V153, P44, DOI 10.1016/j.vetpar.2008.01.035
   Charlier J, 2007, PREV VET MED, V78, P57, DOI 10.1016/j.prevetmed.2006.09.010
   Charlier J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043216
   COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U
   Dhand NK, 2010, J AGR BIOL ENVIR ST, V15, P452, DOI 10.1007/s13253-010-0032-8
   Durr PA, 2005, PREV VET MED, V71, P157, DOI 10.1016/j.prevetmed.2005.07.013
   Elliott TP, 2015, VET PARASITOL, V209, P117, DOI 10.1016/j.vetpar.2015.02.014
   Flanagan AM, 2011, VET PARASITOL, V176, P34, DOI 10.1016/j.vetpar.2010.10.037
   GMW, 2015, GOULB MURR IRR DISTR
   Hope Cawdery M.J., 1984, IRISH VET NEWS  0914
   Howell A, 2015, PREV VET MED, V121, P41, DOI 10.1016/j.prevetmed.2015.05.013
   Kelley JM, 2016, TRENDS PARASITOL, V32, P458, DOI 10.1016/j.pt.2016.03.002
   Kuerpick B, 2013, PARASITOLOGY, V140, P1051, DOI 10.1017/S0031182013000395
   Lane J., MLA FINAL REPORT PRI
   MALONE JB, 1990, COMP CONT EDUC PRACT, V12, P747
   Martinez-Sernandez V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004872
   Mazeri S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161621
   McCann CM, 2010, VET REC, V166, P612, DOI 10.1136/vr.b4836
   MCCAUSLAND I, 1980, AUST VET J, V56, P324, DOI 10.1111/j.1751-0813.1980.tb05739.x
   Messam Locksley L. McV., 2008, Animal Health Research Reviews, V9, P1, DOI 10.1017/S1466252307001314
   Mezo M, 2004, J PARASITOL, V90, P845, DOI 10.1645/GE-192R
   Mezo M, 2011, VET PARASITOL, V180, P237, DOI 10.1016/j.vetpar.2011.03.009
   Nash D, 2008, ENVIRONMENTAL IMPACTS OF PASTURE-BASED FARMING, P232, DOI 10.1079/9781845934118.0232
   Novobilsky A, 2015, GEOSPATIAL HEALTH, V9, P293, DOI 10.4081/gh.2015.351
   Nzalawahe J, 2015, PARASITOLOGY, V142, P1430, DOI 10.1017/S0031182015000827
   OVEREND DJ, 1995, AUST VET J, V72, P275, DOI 10.1111/j.1751-0813.1995.tb03546.x
   Plummer M., 2003, P 3 INT WORKSH DISTR, V3, P20
   Rapsch C, 2006, INT J PARASITOL, V36, P1153, DOI 10.1016/j.ijpara.2006.06.001
   ROGAN WJ, 1978, AM J EPIDEMIOL, V107, P71, DOI 10.1093/oxfordjournals.aje.a112510
   Salimi-Bejestani MR, 2005, VET REC, V156, P729, DOI 10.1136/vr.156.23.729
   Schweizer G, 2005, VET REC, V157, P188, DOI 10.1136/vr.157.7.188
   SPRATT DM, 1981, AUST J EXP BIOL MED, V59, P713, DOI 10.1038/icb.1981.62
   SRW, 2019, FACTAND FIG
   Takeuchi-Storm N, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3248-z
   Vercruysse J, 2001, VET PARASITOL, V98, P195, DOI 10.1016/S0304-4017(01)00431-9
   Wakefield JC, 2000, SPATIAL EPIDEMIOLOGY, P104
   Watt G., 1977, ABATTOIR SURVEY PREV
   Watt G., 1979, P 2 INT S VET EP EC, P152
NR 47
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109019
DI 10.1016/j.vetpar.2019.109019
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800013
PM 31918044
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, Y
   Reichel, MP
   Lo, WC
AF Liu, Yue
   Reichel, Michael P.
   Lo, Wing-Cheong
TI Combined control evaluation for Neospora caninum infection in dairy:
   Economic point of view coupled with population dynamics
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Neospora caninum; Dairy cattle; Infectious disease; Economic
   considerations; Combined control
ID VERTICAL TRANSMISSION; HORIZONTAL TRANSMISSION; BOVINE NEOSPOROSIS;
   MILK-PRODUCTION; CONTROL OPTIONS; CATTLE; ABORTION; SEROPREVALENCE;
   IMPACT; RISK
AB Neospora caninum infection is regarded as one of the most important infectious causes of abortion in dairy cattle. To intervene in its spread, four potential controls including test-and-cull, medication, vaccination, and selective breeding are considered and assessed in this study. The cost of each control, together with the inevitable annual loss due to population dynamics, is adopted as an assessment criterion from an economic point of view. By performing simulation and sensitivity analysis, our results demonstrate that compared with each single control, combined controls are worthwhile with better financial outcomes. For farm affected with significant prevalence (equal to or greater than 30%), vaccine treatment is the most effective and economical option among all control strategies. On the other hand, for farm where prevalence is relatively low (around 10%), combined control, by applying vaccination followed with test-and-cull, medication or selective breeding, could be alternative treatment to provide better financial outcome against single control in an observed period.
C1 [Liu, Yue; Lo, Wing-Cheong] City Univ Hong Kong, Dept Math, Kowloon, Tat Chee Ave, Hong Kong, Peoples R China.
   [Reichel, Michael P.] City Univ Hong Kong, Coll Vet Med & Life Sci, Kowloon, Tat Chee Ave, Hong Kong, Peoples R China.
RP Liu, Y (reprint author), City Univ Hong Kong, Dept Math, Kowloon, Tat Chee Ave, Hong Kong, Peoples R China.
EM yue.liu@my.cityu.edu.hk
RI Reichel, Michael/AAJ-5329-2020
OI Reichel, Michael/0000-0002-9792-8336; LIU, Yue/0000-0002-3921-6509
FU CityU Strategic Research Grant [CityU 11303719]; University Grants
   Committee (UGC) in Hong Kong
FX The authors are supported by CityU Strategic Research Grant (Project No.
   CityU 11303719). Y. Liu thanks the University Grants Committee (UGC) in
   Hong Kong for the financial support.
CR Almeria S, 2013, RES VET SCI, V95, P303, DOI [10.1016/j.rvsc.2013.04.008, 10.]
   Atkinson RA, 2000, AUST VET J, V78, P262, DOI 10.1111/j.1751-0813.2000.tb11752.x
   Bartels CJM, 2007, VET PARASITOL, V148, P83, DOI 10.1016/j.vetpar.2007.06.004
   Crawshaw WM, 2003, VET REC, V152, P201, DOI 10.1136/vr.152.7.201
   Davison HC, 1999, INT J PARASITOL, V29, P1683, DOI 10.1016/S0020-7519(99)00129-0
   Diniz LVD, 2019, TROP ANIM HEALTH PRO, V51, P1751, DOI 10.1007/s11250-019-01828-y
   Santos RRD, 2012, REV BRAS PARASITOL V, V21, P294, DOI 10.1590/S1984-29612012000300021
   DOHOO IR, 1993, COMP CONT EDUC PRACT, V15, P515
   Dubey JP, 2011, VET PARASITOL, V180, P90, DOI 10.1016/j.vetpar.2011.05.031
   Dubey J.P., 2003, J PARASITOL S, V89, pS42
   Dubey JP, 1996, VET PARASITOL, V67, P1, DOI 10.1016/S0304-4017(96)01035-7
   Dubey JP, 2017, NEOSPOROSIS ANIMALS
   Dyer RM, 2000, VET PARASITOL, V90, P171, DOI 10.1016/S0304-4017(00)00253-3
   French NP, 1999, INT J PARASITOL, V29, P1691, DOI 10.1016/S0020-7519(99)00131-9
   Fuehrer HP, 2010, PARASITOL RES, V107, P469, DOI 10.1007/s00436-010-1905-z
   Hasler B, 2006, PREV VET MED, V77, P230, DOI 10.1016/j.prevetmed.2006.07.006
   Hasler B, 2006, PREV VET MED, V77, P254, DOI 10.1016/j.prevetmed.2006.07.007
   Hall CA, 2005, VET PARASITOL, V128, P231, DOI 10.1016/j.vetpar.2004.12.012
   He Q, 2004, AUST VET J, V82, P99, DOI 10.1111/j.1751-0813.2004.tb14656.x
   Hernandez J, 2002, J AM VET MED ASSOC, V221, P1742, DOI 10.2460/javma.2002.221.1741
   Hernandez J, 2001, J AM VET MED ASSOC, V219, P632, DOI 10.2460/javma.2001.219.632
   Kritzner Sandra, 2002, Ann Clin Microbiol Antimicrob, V1, P4, DOI 10.1186/1476-0711-1-4
   Larson RL, 2004, JAVMA-J AM VET MED A, V224, P1597, DOI 10.2460/javma.2004.224.1597
   Liddell S, 1999, J PARASITOL, V85, P1072, DOI 10.2307/3285670
   Lindsay DS, 1996, J PARASITOL, V82, P657, DOI 10.2307/3283798
   McAllister MM, 1998, INT J PARASITOL, V28, P1473, DOI 10.1016/S0020-7519(98)00138-6
   McDougall S, 2005, NEW ZEAL VET J, V53, P279, DOI 10.1080/00480169.2005.36561
   Miller C, 2005, INT J PARASITOL, V35, P821, DOI 10.1016/j.ijpara.2005.03.006
   Moen AR, 1998, THERIOGENOLOGY, V49, P1301, DOI 10.1016/S0093-691X(98)00077-6
   Morales E, 2001, J COMP PATHOL, V125, P58, DOI 10.1053/jcpa.2001.0477
   Morales E, 2001, J VET DIAGN INVEST, V13, P413
   Otranto D, 2003, VET PARASITOL, V118, P7, DOI 10.1016/j.vetpar.2003.10.008
   Pare J, 1998, J AM VET MED ASSOC, V213, P1595
   Pare J, 1996, CAN J VET RES, V60, P133
   Pfeiffer DU, 2002, PREV VET MED, V54, P11, DOI 10.1016/S0167-5877(02)00011-9
   Reichel MP, 2006, VET PARASITOL, V142, P23, DOI 10.1016/j.vetpar.2006.06.027
   Reichel MP, 2013, INT J PARASITOL, V43, P133, DOI 10.1016/j.ijpara.2012.10.022
   Reichel MP, 1998, NEW ZEAL VET J, V46, P38, DOI 10.1080/00480169.1998.36049
   Reichel MP, 2002, NEW ZEAL VET J, V50, P86, DOI 10.1080/00480169.2002.36288
   Sala G, 2018, PREV VET MED, V161, P127, DOI 10.1016/j.prevetmed.2018.10.024
   Schaefer ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104953
   Schares G, 2003, INT J PARASITOL, V33, P1631, DOI 10.1016/S0020-7519(03)00266-2
   Schares G, 1998, VET PARASITOL, V80, P87, DOI 10.1016/S0304-4017(98)00195-2
   THORNTON RN, 1991, NEW ZEAL VET J, V39, P129, DOI 10.1080/00480169.1991.35679
   Thurmond MC, 1997, J AM VET MED ASSOC, V210, P672
   Trees AJ, 1999, INT J PARASITOL, V29, P1195, DOI 10.1016/S0020-7519(99)00093-4
   Uggla A, 1998, INT J PARASITOL, V28, P1467, DOI 10.1016/S0020-7519(98)00110-6
   Weston JF, 2012, PREV VET MED, V103, P136, DOI 10.1016/j.prevetmed.2011.08.010
   Wilson DJ, 2016, VET PARASITOL, V218, P46, DOI 10.1016/j.vetpar.2016.01.006
   Wouda W, 1997, J PARASITOL, V83, P545, DOI 10.2307/3284431
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 108967
DI 10.1016/j.vetpar.2019.108967
PG 13
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800003
PM 31812121
OA Bronze
DA 2020-05-12
ER

PT J
AU May, K
   Bohlsen, E
   Konig, S
   Strube, C
AF May, Katharina
   Bohlsen, Ernst
   Koenig, Sven
   Strube, Christina
TI Fasciola hepatica seroprevalence in Northern German dairy herds and
   associations with milk production parameters and milk ketone bodies
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Fasciolosis; Liver fluke; Milk production; Somatic cell count; Linear
   mixed models; Dairy cows; Germany
ID BETA-HYDROXYBUTYRATE CONCENTRATIONS; PRODUCTION TRAITS; CLINICAL
   KETOSIS; ANTIBODY-LEVELS; CATTLE; INFECTIONS; PREVALENCE; SHEEP; RISK;
   SAMPLES
AB Infections with the liver fluke Fasciola hepatica remain a serious problem in dairy herds causing significant production losses. In sheep, a strong relationship between F. hepatica infections and an increase in serum ketone bodies due to reduced feed intake and liver damage was demonstrated. We hypothesized that F. hepatica infections might contribute to an increase in milk ketone bodies in dairy herds. Thus, the objective of the study was to estimate the association between F. hepatica bulk tank milk (BTM) antibodies and milk production parameters (milk yield, milk protein, fat yield), somatic cell count (SCC) and the milk ketone bodies beta-hydroxybutyrate (BHB) and acetone, inferred from Fourier transform infrared (FTIR) spectrometry, via linear mixed model analysis. A further aim was to follow up the F. hepatica seroprevalence in dairy herds in the northern German region East Frisia. We collected BTM samples between October and December from 1022 herds in 2017 and 1318 herds in 2018. Overall, 33.1 % of the herds tested positive in 2017 and 37.0 % in 2018, showing decreased F. hepatica seroprevalences compared to prior seroprevalence studies in the same region in 2010, 2008 and 2006 ( > 45 % positive herds). We estimated a significant negative association (P < 0.001) between herd F. hepatica infection category and average milk yield with a loss of -1.62 kg per cow per day in strongly infected herds compared to BTM ELISA negative herds. Moreover, F. hepatica infection category had a significant effect on herd average milk protein and fat yield (P < 0.001), showing a decrease of 0.06 kg for both parameters from BTM ELISA negative herds to strongly infected herds. No significant association with milk SCC was found (P = 0.664). Regarding ketone bodies, we estimated significant higher average BHB values in strongly infected herds compared to the other three infection categories in the model analysis (P = 0.002). The association between F. hepatica infection category and acetone values was not significant (P = 0.079). Besides primary ketosis, fasciolosis should be considered as differential diagnosis in dairy herds with increased BHB values.
C1 [May, Katharina; Koenig, Sven] Justus Liebig Univ Giessen, Inst Anim Breeding & Genet, D-35390 Giessen, Germany.
   [Bohlsen, Ernst] Landeskontrollverband LKV Weser Ems eV, State Control Assoc Milk Recording, D-26789 Leer, Germany.
   [Strube, Christina] Univ Vet Med Hannover, Ctr Infect Med, Inst Parasitol, Buenteweg 17, D-30559 Hannover, Germany.
RP May, K (reprint author), Justus Liebig Univ Giessen, Inst Anim Breeding & Genet, D-35390 Giessen, Germany.
EM katharina.may@agrar.uni-giessen.de
CR AITKEN MM, 1978, J COMP PATHOL, V88, P75, DOI 10.1016/0021-9975(78)90063-4
   Arias M, 2011, VET REC, V168, P408, DOI 10.1136/vr.d85
   BAIRD GD, 1982, J DAIRY SCI, V65, P1, DOI 10.3168/jds.S0022-0302(82)82146-2
   Baldissera MD, 2015, PATHOL RES PRACT, V211, P871, DOI 10.1016/j.prp.2015.09.006
   Belay TK, 2017, J DAIRY SCI, V100, P6298, DOI 10.3168/jds.2016-12458
   Bennema S, 2009, VET PARASITOL, V165, P51, DOI 10.1016/j.vetpar.2009.07.006
   BERRY CI, 1976, VET PARASITOL, V2, P317, DOI 10.1016/0304-4017(76)90061-3
   Brady MT, 1999, INFECT IMMUN, V67, P5372, DOI 10.1128/IAI.67.10.5372-5378.1999
   Byrne AW, 2018, PARASITOL RES, V117, P2725, DOI 10.1007/s00436-018-5961-0
   Chandler TL, 2018, J DAIRY SCI, V101, P2476, DOI 10.3168/jds.2017-13209
   Charlier J, 2007, PREV VET MED, V78, P57, DOI 10.1016/j.prevetmed.2006.09.010
   Charlier J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043216
   Charlier J, 2009, VET PARASITOL, V166, P235, DOI 10.1016/j.vetpar.2009.09.040
   Claridge J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1840
   de Roos APW, 2007, J DAIRY SCI, V90, P1761, DOI 10.3168/jds.2006-203
   FERRE I, 1994, VET PARASITOL, V55, P71, DOI 10.1016/0304-4017(94)90056-6
   Gaddis KLP, 2018, J DAIRY SCI, V101, P413, DOI 10.3168/jds.2017-13383
   Heuer C, 2001, J DAIRY SCI, V84, P575, DOI 10.3168/jds.S0022-0302(01)74510-9
   Hillyer GV, 1996, VET PARASITOL, V61, P211, DOI 10.1016/0304-4017(95)00831-4
   Hoglund J, 2010, VET PARASITOL, V171, P293, DOI 10.1016/j.vetpar.2010.04.002
   Howell A, 2015, PREV VET MED, V121, P41, DOI 10.1016/j.prevetmed.2015.05.013
   Ikonen T, 2004, J DAIRY SCI, V87, P458, DOI 10.3168/jds.S0022-0302(04)73185-9
   Kaplan R M, 2001, Vet Ther, V2, P40
   Koeck A, 2014, J DAIRY SCI, V97, P7286, DOI 10.3168/jds.2014-8405
   Kostenberger K, 2017, PARASITOL RES, V116, P1981, DOI 10.1007/s00436-017-5481-3
   Kowalczyk SJ, 2018, VET PARASITOL, V254, P15, DOI 10.1016/j.vetpar.2018.02.038
   Kozat S, 2010, J PARASITOL, V96, P657, DOI 10.1645/GE-2104.1
   Kuerpick B, 2013, PARASITOLOGY, V140, P1051, DOI 10.1017/S0031182013000395
   Kuerpick B, 2012, PARASITOL RES, V111, P1085, DOI 10.1007/s00436-012-2935-5
   Kuerpick B, 2012, BERL MUNCH TIERARZTL, V125, P345, DOI 10.2376/0005-9366-125-345
   Lucena AN, 2017, VET J, V222, P9, DOI 10.1016/j.tvjl.2017.02.007
   May K, 2019, VET PARASITOL, V267, P32, DOI 10.1016/j.vetpar.2019.01.012
   Mehmood K, 2017, MICROB PATHOGENESIS, V109, P253, DOI 10.1016/j.micpath.2017.06.006
   Mezo M, 2011, VET PARASITOL, V180, P237, DOI 10.1016/j.vetpar.2011.03.009
   Molina-Hernandez V, 2015, VET PARASITOL, V208, P101, DOI 10.1016/j.vetpar.2015.01.004
   Olsen A, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0773-x
   Ortiz PL, 2000, VET PARASITOL, V93, P121, DOI 10.1016/S0304-4017(00)00360-5
   Oviedo-Boyso J, 2007, J INFECTION, V54, P399, DOI 10.1016/j.jinf.2006.06.010
   Phiri IK, 2007, VET PARASITOL, V143, P287, DOI 10.1016/j.vetpar.2006.09.001
   Pineda A, 2015, J DAIRY SCI, V98, P8818, DOI 10.3168/jds.2015-9667
   Reist M, 2002, J DAIRY SCI, V85, P3314, DOI 10.3168/jds.S0022-0302(02)74420-2
   Renaud DL, 2019, J DAIRY SCI, V102, P1589, DOI 10.3168/jds.2018-14778
   Santschi DE, 2016, J DAIRY SCI, V99, P9263, DOI 10.3168/jds.2016-11128
   SAS, 2013, VERS 9 4
   Schwarz D., 2015, ICAR Technical Series, P5
   Schweizer G, 2005, VET REC, V157, P188, DOI 10.1136/vr.157.7.188
   Tatone EH, 2017, J DAIRY SCI, V100, P1308, DOI 10.3168/jds.2016-11453
   Tremblay M, 2018, J DAIRY SCI, V101, P7311, DOI 10.3168/jds.2017-13582
   Yiiksek N., 2013, REV MED VET, V164, P163
   Zwald NR, 2004, J DAIRY SCI, V87, P4287, DOI 10.3168/jds.S0022-0302(04)73573-0
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109016
DI 10.1016/j.vetpar.2019.109016
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800012
PM 31901738
OA Bronze
DA 2020-05-12
ER

PT J
AU Nagamori, Y
   Payton, ME
   Looper, E
   Apple, H
   Johnson, EM
AF Nagamori, Yoko
   Payton, Mark E.
   Looper, Emily
   Apple, Hadley
   Johnson, Eileen M.
TI Retrospective survey of parasitism identified in feces of client-owned
   cats in North America from 2007 through 2018
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Feline; Prevalence; Intestinal parasites; United States
ID PREVALENCE; DOGS; INFECTION; GIARDIA
AB Ownership of domestic cats in North America has been on the increase; however, there are only a few surveys conducted on the prevalence of parasitism in client-owned cats over years. Our study objective was to evaluate parasite prevalence through statistical analysis of fecal examination results for client-owned cats on samples submitted to the veterinary parasitology diagnostic laboratory of Oklahoma State University over a 12-year period. All results of centrifugal flotation, saline direct smear, sedimentation, and Baermann examinations on fecal samples submitted to the Boren Veterinary Medical Hospital and Oklahoma Animal Disease Diagnostic Laboratory of Oklahoma State University from 2007 through 2018 were included. The impacts of sex, age, and seasonality on the prevalence of infection were also analyzed. A total of 2586 client-owned cat cases were included for this study. Parasites, eggs, oocysts, larvae, or cysts were not detected in the majority of cases (75.5%; 1,953/2586). Approximately 18.8% (485/2586) of client-owned cats were infected by one parasite, and 5.7% (148/2586) of cats were infected by multiple parasites. The most common parasite stage observed was Cystoisospora oocysts (9.4%; 243/2586), followed by Toxocara cati eggs (7.8%; 202/2586), Giardia cysts (4.0%; 104/2586), Alaria eggs (3.5%; 91/2586), Ancylostoma eggs (1.2%; 32/2586), taeniid proglottids/eggs (1.2%; 30/2586), Dipylidium caninum proglottids/egg packets (1.1 %; 29/2586), and Eucoleus aerophilus eggs (0.7%; 18/2586). Less commonly, Physalopetra eggs (0.19%; 5/2586), Toxascaris leonina eggs (0.19%; 5/2586), Tritrichomonas blagburni trophozoites (0.15%; 4/2586), Ollulanus tricuspis larvae/adults (0.12%; 3/2586), Platynosomum fastosum eggs (0.12%; 3/2586), Aelurostrongylus abstrusus larvae (0.08%; 2/2323), Sarcocystis sporocysts (0.08%; 2/2586), Spirometra eggs (0.08%; 2/2586), Mesocestoides proglottids/eggs (0.08%; 2/2586), Trichuris fells eggs (0.08%; 2/2586), Cryptosporidium oocysts (0.04%; 1/2586), and Toxoplasma-like small coccidian oocysts (0.04%; 1/2586) were detected. Additionally, fecal examinations revealed some ectoparasites: Demodex mites (0.9%; 24/2586), Cheyletiella mites (0.15%; 4/2586), and Otodectes cynotis mites (0.04%; 1/2586). There was no statistical significance between different sex groups (p = 0.3316). Age affected the prevalence of Cystoisospora, T. cati, Giardia, and Alaria infections with prevalence decreasing as age increased (p < 0.0001). Statistical analyses also revealed significant differences by months; the higher prevalence of infection occurred from summer through fall (p = 0.0004). Overall, as the number of submittals increased, the prevalence of infection increased over the last 12 years (p < 0.0001). This study supports continuing the current practice of routine broad-spectrum anthelmintic and ectoparasitic treatments for client-owned cats as well as annual/biannual fecal examination.
C1 [Nagamori, Yoko; Looper, Emily; Apple, Hadley; Johnson, Eileen M.] Oklahoma State Univ, Coll Vet Med, Dept Vet Pathobiol, Stillwater, OK 74078 USA.
   [Payton, Mark E.] Oklahoma State Univ, Dept Stat, Stillwater, OK 74078 USA.
RP Nagamori, Y (reprint author), Oklahoma State Univ, Coll Vet Med, Dept Vet Pathobiol, DACVM Parasitol, 250 McElroy Hall, Stillwater, OK 74078 USA.
EM yokon@okstate.edu; mark.payton@okstate.edu; emilysk@okstate.edu;
   hadleya@okstate.edu; eileen.johnson@okstate.edu
CR American Society for the Prevention of Cruelty to Animals (ASPCA), 2019, PET STAT
   Animal Sheltering/the Humane Society of the United States, 2019, PETS NUMB
   Bouzid M, 2015, VET PARASITOL, V207, P181, DOI 10.1016/j.vetpar.2014.12.011
   Bowman ail, 2014, GEORGIS PARASITOLOGY
   Bowman D.D., 2002, FELINE CLIN PARASITO, P5
   Bush AO, 1997, J PARASITOL, V83, P575, DOI 10.2307/3284227
   Companion Animal Parasite Council, 2019, PAR PREV MAPS INT PA
   De Santis-Kerr AC, 2006, J FELINE MED SURG, V8, P292, DOI 10.1016/j.jfms.2006.02.005
   DUBEY JP, 1993, VET CLIN N AM-SMALL, V23, P37, DOI 10.1016/S0195-5616(93)50003-7
   Gates MC, 2009, VET PARASITOL, V166, P153, DOI 10.1016/j.vetpar.2009.07.041
   Griffin B., 2001, SMALL ANIM EXOTICS, V1051, P12
   Hill SL, 2000, J AM VET MED ASSOC, V216, P687, DOI 10.2460/javma.2000.216.687
   Johnson EM, 2017, JAVMA-J AM VET MED A, V250, P881, DOI 10.2460/javma.250.8.881
   KIRKPATRICK CE, 1988, VET PARASITOL, V30, P113, DOI 10.1016/0304-4017(88)90158-6
   KIRKPATRICK CE, 1986, J SMALL ANIM PRACT, V27, P69, DOI 10.1111/j.1748-5827.1986.tb02124.x
   Krecek RC, 2010, VET PARASITOL, V172, P147, DOI 10.1016/j.vetpar.2010.04.033
   Little S, 2015, J AM ANIM HOSP ASSOC, V51, P359, DOI 10.5326/JAAHA-MS-6221
   Lucio-Forster A, 2011, J FELINE MED SURG, V13, P300, DOI 10.1016/j.jfms.2010.12.013
   MALLOY WF, 1978, CAN J COMP MED, V42, P29
   Nagamori Yoko, 2018, Vet Parasitol Reg Stud Reports, V14, P50, DOI 10.1016/j.vprsr.2018.08.008
   Pouya C, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2019.0113
   Rozsa L, 2000, J PARASITOL, V86, P228, DOI 10.1645/0022-3395(2000)086[0228:QPISOH]2.0.CO;2
   Shukla R, 2006, CAN VET J, V47, P1179
   Society for the Prevention of Cruelty to Animals, 2014, DEV STAG KITT BEH
   SOKAL RR, 1997, BIOMETRY
   Spain CV, 2001, J VET INTERN MED, V15, P33, DOI 10.1892/0891-6640(2001)015&lt;0033:POEZAI&gt;2.3.CO;2
   Taylor M.A., 2016, VET PARASITOLOGY
   Villeneuve A, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0870-x
   VISCO RJ, 1978, J AM VET MED ASSOC, V172, P797
   Wyrosdick Heidi M, 2017, Vet Parasitol Reg Stud Reports, V10, P20, DOI 10.1016/j.vprsr.2017.07.002
   Zajac A.M., 2012, VETEIRNARY CLIN PARA
NR 31
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109008
DI 10.1016/j.vetpar.2019.109008
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800006
PM 31841945
OA Bronze
DA 2020-05-12
ER

PT J
AU Rostang, A
   Devos, J
   Chartier, C
AF Rostang, Antoine
   Devos, Jacques
   Chartier, Christophe
TI Review of the Eprinomectin effective doses required for dairy goats:
   Where do we go from here?
SO VETERINARY PARASITOLOGY
LA English
DT Review
DE Eprinomectin; Goat; Gastrointestinal nematodes; Dose regimen;
   Resistance; Anthelmintic
ID ANTHELMINTIC RESISTANCE; HAEMONCHUS-CONTORTUS; POUR-ON; GASTROINTESTINAL
   NEMATODES; TELADORSAGIA-CIRCUMCINCTA; TOPICAL EPRINOMECTIN;
   BENZIMIDAZOLE RESISTANCE; TRICHOSTRONGYLUS-COLUBRIFORMIS; EXPERIMENTAL
   INFECTIONS; IVERMECTIN RESISTANCE
AB Eprinomectin (EPM) has been recently granted a marketing authorisation in the European Union for use in goats, with a zero-day milk withdrawal period. Considering the high prevalence of benzimidazole resistance worldwide and the economic implications of managing milk residues, EPM may today be considered the main (or even the only) affordable treatment option, at least in dairy goats in the EU. However, the chosen dose (1 mg/kg) seems to be suboptimal, especially for lactating goats, and the chosen route of administration (Pour-on) highly subject to inter-individual variability. Considering the scarcity of anthelmintic resources, such a dosage regimen might threat the sustainability of this crucial drug in goat milk production and needs to be urgently discussed and reassessed.
C1 [Rostang, Antoine] Univ Lyon, VetAgro Sup, UPSP ICE Interact Cellules Environm, F-69280 Marcy Letoile, France.
   [Devos, Jacques] Natl Soc Vet Tech Grp, French SNGTV Parasitol Comm, F-42360 Panissieres, France.
   [Chartier, Christophe] INRAE, ONIRIS, BIOEPAR, F-44307 Nantes, France.
RP Rostang, A (reprint author), Univ Lyon, VetAgro Sup, UPSP ICE Interact Cellules Environm, F-69280 Marcy Letoile, France.
EM antoine.rostang@vetagro-sup.fr
OI Chartier, Christophe/0000-0002-2926-3563; ROSTANG,
   Antoine/0000-0002-6930-6652
CR Aksit D, 2016, NEW ZEAL VET J, V64, P207, DOI 10.1080/00480169.2016.1146172
   Alka, 2004, VET PARASITOL, V121, P277, DOI 10.1016/j.vetpar.2004.03.007
   Alvinerie M, 1999, VET RES COMMUN, V23, P449, DOI 10.1023/A:1006373609314
   Anastasio A, 2005, J FOOD PROTECT, V68, P1097, DOI 10.4315/0362-028X-68.5.1097
   [Anonymous], 1999, GL14 VICH
   [Anonymous], 2000, GL7 VICH
   Ansell C, 2019, ADMIN SOC, V51, P1079, DOI 10.1177/0095399717747655
   Authority I.H.P.R.A, 2016, 7018435 CRN AUTH IHP
   AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305
   Badie C, 2015, VET PARASITOL, V209, P56, DOI 10.1016/j.vetpar.2015.02.013
   Baoliang P, 2006, VET RES COMMUN, V30, P263, DOI 10.1007/s11259-006-3230-7
   Barnes EH, 2001, INT J PARASITOL, V31, P720, DOI 10.1016/S0020-7519(01)00174-6
   Bartley DJ, 2015, INT J PARASITOL-DRUG, V5, P69, DOI 10.1016/j.ijpddr.2015.05.001
   Bassissi MF, 2004, COMP BIOCHEM PHYS C, V138, P437, DOI 10.1016/j.cca.2004.07.011
   Bengone-Ndong T, 2006, PARASITOL RES, V98, P501, DOI 10.1007/s00436-005-0103-x
   Bichuette MA, 2015, SMALL RUMINANT RES, V133, P93, DOI 10.1016/j.smallrumres.2015.09.009
   BOGAN J, 1987, J VET PHARMACOL THER, V10, P305, DOI 10.1111/j.1365-2885.1987.tb00106.x
   Bordes L., 2019, 27 C WORLD ASS ADV V, P272
   BORGSTEEDE FHM, 1993, VET PARASITOL, V50, P117, DOI 10.1016/0304-4017(93)90012-C
   Bousquet-Melou A, 2011, INT J PARASITOL, V41, P563, DOI 10.1016/j.ijpara.2010.12.007
   Brique-Pellet C, 2017, VET PARASITOL, V241, P43, DOI 10.1016/j.vetpar.2017.05.021
   Cabaret J., 2000, P 7 INT C GOATS TOUR, P793
   Chandra S, 2015, VET PARASITOL, V208, P263, DOI 10.1016/j.vetpar.2015.01.005
   Chandrawathani P, 1999, VET PARASITOL, V82, P305, DOI 10.1016/S0304-4017(99)00028-X
   Chartier A., 2015, PRESENTED AT THE 25T, P540
   Chartier C, 2004, VET PARASITOL, V125, P415, DOI 10.1016/j.vetpar.2004.07.022
   Chartier C, 2001, J HELMINTHOL, V75, P325, DOI 10.1017/S0022149X01000506
   Chartier C, 1999, VET REC, V144, P99, DOI 10.1136/vr.144.4.99
   Chartier C, 1998, SMALL RUMINANT RES, V29, P33, DOI 10.1016/S0921-4488(97)00116-8
   Chartier C., 2013, JNGTV NANTES 2013 PR, P89
   Chartier C., 2008, PRESENTED AT THE 9TH, P486
   Committee for Medicinal Products for Veterinary Use, 2018, EMEAVC0042910000 COM
   Cringoli G, 2004, SMALL RUMINANT RES, V55, P209, DOI 10.1016/j.smallrumres.2004.02.008
   DAVIS L E, 1988, Veterinary and Human Toxicology, V30, P9
   Chagas ACD, 2007, PARASITOL RES, V100, P391, DOI 10.1007/s00436-006-0316-7
   Dupuy J, 2001, PARASITOL RES, V87, P294, DOI 10.1007/PL00008581
   Elard L, 1998, PARASITOLOGY, V117, P571, DOI 10.1017/S0031182098003436
   Falzon LC, 2014, PREV VET MED, V117, P388, DOI 10.1016/j.prevetmed.2014.07.003
   GEARY TG, 1993, EXP PARASITOL, V77, P88, DOI 10.1006/expr.1993.1064
   GILL JH, 1995, INT J PARASITOL, V25, P463, DOI 10.1016/0020-7519(94)00087-5
   Gokbulut C, 2009, RES VET SCI, V87, P445, DOI 10.1016/j.rvsc.2009.04.003
   Gokbulut C, 2009, VET PARASITOL, V162, P342, DOI 10.1016/j.vetpar.2009.03.004
   Canga AG, 2009, VET J, V179, P25, DOI 10.1016/j.tvjl.2007.07.011
   Gonzalez-Canga A, 2012, CURR PHARM BIOTECHNO, V13, P924, DOI 10.2174/138920112800399112
   Gopal RM, 2001, NEW ZEAL VET J, V49, P133, DOI 10.1080/00480169.2001.36220
   Hamel D, 2015, SMALL RUMINANT RES, V127, P74, DOI 10.1016/j.smallrumres.2015.04.003
   Hellriegel ET, 1996, CLIN PHARMACOL THER, V60, P601, DOI 10.1016/S0009-9236(96)90208-8
   HENNESSY DR, 1993, INT J PARASITOL, V23, P321, DOI 10.1016/0020-7519(93)90006-K
   Hodoscek L, 2008, VET PARASITOL, V154, P129, DOI 10.1016/j.vetpar.2008.02.032
   Hoste H, 2004, VET REC, V154, P782, DOI 10.1136/vr.154.25.782
   Hoste H, 2000, VET RES COMMUN, V24, P459, DOI 10.1023/A:1006499522154
   Hoste H, 2010, TRENDS PARASITOL, V26, P376, DOI 10.1016/j.pt.2010.04.007
   Howell SB, 2008, JAVMA-J AM VET MED A, V233, P1913, DOI 10.2460/javma.233.12.1913
   Imperiale F, 2006, J FOOD PROTECT, V69, P2424, DOI 10.4315/0362-028X-69.10.2424
   Jackson F, 2012, SMALL RUMINANT RES, V103, P3, DOI 10.1016/j.smallrumres.2011.10.012
   James CE, 2009, INT J PARASITOL, V39, P213, DOI 10.1016/j.ijpara.2008.06.009
   Kaplan RM, 2004, TRENDS PARASITOL, V20, P477, DOI 10.1016/j.pt.2004.08.001
   KETTLE PR, 1983, NEW ZEAL VET J, V31, P139, DOI 10.1080/00480169.1983.34999
   Knapp-Lawitzke F, 2015, VET PARASITOL, V209, P84, DOI 10.1016/j.vetpar.2015.02.005
   Kotze AC, 2014, VET PARASITOL, V203, P294, DOI 10.1016/j.vetpar.2014.04.005
   Laffont CM, 2003, VET RES, V34, P445, DOI 10.1051/vetres:2003014
   Laing R, 2016, INT J PARASITOL, V46, P621, DOI 10.1016/j.ijpara.2016.03.010
   Lanusse C, 2018, TRENDS PARASITOL, V34, P664, DOI 10.1016/j.pt.2018.05.005
   Leathwick DM, 2013, VET PARASITOL, V191, P293, DOI 10.1016/j.vetpar.2012.09.020
   Leathwick DM, 2017, VET PARASITOL, V243, P29, DOI 10.1016/j.vetpar.2017.05.032
   Leathwick DM, 2001, NEW ZEAL VET J, V49, P227, DOI 10.1080/00480169.2001.36237
   Lespine A, 2005, VET PARASITOL, V128, P251, DOI 10.1016/j.vetpar.2004.11.028
   Lespine A, 2004, PARASITOL RES, V93, P121, DOI 10.1007/s00436-004-1084-x
   Lespine A, 2003, PARASITOL RES, V89, P120, DOI 10.1007/s00436-002-0727-z
   Lespine A, 2012, SMALL RUMINANT RES, V103, P10, DOI 10.1016/j.smallrumres.2011.10.013
   Lifschitz A, 2008, VET PARASITOL, V156, P284, DOI 10.1016/j.vetpar.2008.05.014
   Lifschitz A, 2017, NEW ZEAL VET J, V65, P176, DOI 10.1080/00480169.2017.1317222
   Lifschitz A, 2016, VET PARASITOL, V215, P11, DOI 10.1016/j.vetpar.2015.11.005
   Lifschitz A, 1999, VET PARASITOL, V86, P203, DOI 10.1016/S0304-4017(99)00142-9
   Lifschitz A, 2000, VET PARASITOL, V87, P327, DOI 10.1016/S0304-4017(99)00175-2
   Lloberas M, 2012, EXP PARASITOL, V131, P304, DOI 10.1016/j.exppara.2012.04.014
   Lloberas M, 2013, INT J PARASITOL-DRUG, V3, P20, DOI 10.1016/j.ijpddr.2012.11.001
   Martinez MN, 2014, J VET PHARMACOL THER, V37, P2, DOI 10.1111/jvp.12063
   McKellar QA, 2012, CURR PHARM BIOTECHNO, V13, P888
   Menez C, 2016, ANTIMICROB AGENTS CH, V60, P4809, DOI 10.1128/AAC.00713-16
   Mortensen LL, 2003, J AM VET MED ASSOC, V223, P495, DOI 10.2460/javma.2003.223.495
   Murri S, 2014, VET PARASITOL, V203, P114, DOI 10.1016/j.vetpar.2014.02.052
   Nunes RL, 2013, REV BRAS PARASITOL V, V22, P548, DOI 10.1590/S1984-29612013000400015
   Paraud C, 2017, SUSTAINABLE GOAT PRO, VI, P267
   Pomroy W., 2004, P 34 SEM, P63
   Rehbein S, 2014, PARASITOL RES, V113, P4039, DOI 10.1007/s00436-014-4072-9
   Rehbein S, 2012, PARASITOL RES, V111, P1343, DOI 10.1007/s00436-012-2970-2
   Riviere JE, 2011, COMPARATIVE PHARMACOKINETICS: PRINCIPLES, TECHNIQUES, AND APPLICATIONS, 2ND EDITION, P1, DOI 10.1002/9780470959916
   Rose H, 2015, VET REC, V176, DOI 10.1136/vr.102982
   SANGSTER NC, 1991, RES VET SCI, V51, P258, DOI 10.1016/0034-5288(91)90074-X
   Scheuerle MC, 2009, WIEN KLIN WOCHENSCHR, V121, P46, DOI 10.1007/s00508-009-1235-2
   Schnyder M, 2005, VET PARASITOL, V128, P285, DOI 10.1016/j.vetpar.2004.12.010
   Scott I, 2013, VET PARASITOL, V198, P166, DOI 10.1016/j.vetpar.2013.07.037
   Silvestre A, 2002, VET RES, V33, P465, DOI 10.1051/vetres:2002033
   Silvestre A., 2007, Rencontres Autour des Recherches sur les Ruminants, V14, P207
   Smith G, 1999, INT J PARASITOL, V29, P77, DOI 10.1016/S0020-7519(98)00186-6
   Toutain PL, 2010, HANDB EXP PHARMACOL, V199, P19, DOI 10.1007/978-3-642-10324-7_2
   Toutain PL, 2004, J VET PHARMACOL THER, V27, P415, DOI 10.1111/j.1365-2885.2004.00605.x
   Toutain PL, 2004, J VET PHARMACOL THER, V27, P455, DOI 10.1111/j.1365-2885.2004.00604.x
   Toutain PL, 2002, RES VET SCI, V73, P105, DOI 10.1016/S0034-5288(02)00039-5
   Van Wyk JA, 1999, ONDERSTEPOORT J VET, V66, P273
   Van Wyk JA, 2001, ONDERSTEPOORT J VET, V68, P55
   Van Zeveren AM, 2007, VET PARASITOL, V150, P104, DOI 10.1016/j.vetpar.2007.09.004
   Wen HQ, 2010, VET PARASITOL, V174, P72, DOI 10.1016/j.vetpar.2010.08.017
   Zanzani SA, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-114
NR 105
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 108992
DI 10.1016/j.vetpar.2019.108992
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800001
PM 31835054
OA Bronze
DA 2020-05-12
ER

PT J
AU Upadhaya, D
   Kumar, B
   Kumar, S
   Sharma, AK
   Fular, A
   Bisht, N
   Srivastava, S
   Boruah, RR
   Nagar, G
   Shakya, M
   Nath, T
   Nandi, SP
   Karivaradharaja, S
   Ghosh, S
AF Upadhaya, Deepak
   Kumar, Bhanu
   Kumar, Sachin
   Sharma, Anil Kumar
   Fular, Ashutosh
   Bisht, Nisha
   Srivastava, Sharad
   Boruah, Rashmi Rekha
   Nagar, Gaurav
   Shakya, Mukesh
   Nath, Tankeswar
   Nandi, Shoma Paul
   Karivaradharaja, S.
   Ghosh, Srikant
TI Characterization of acaricide resistance in Rhipicephalus microplus
   populations infesting cattle in northeastern India and assessment of
   local plant extracts for tick management
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Acaricides; Antitick plants; Detoxifying enzymes; Mutation;
   Rhipicephalus microplus resistance; Sodium channel
ID SODIUM-CHANNEL GENE; PYRETHROID RESISTANCE; DISCRIMINATING
   CONCENTRATIONS; HYALOMMA-ANATOLICUM; IDENTIFICATION; MUTATIONS;
   FIPRONIL; ESTERASE; TESTS; LC50
AB In the present study, the tick isolates were collected from Assam state, of northeastern region (NER) and characterized using in vitro bioassay, biochemical and molecular assays. Comparing LC50 value of susceptible IVRI-I and larvae of field isolates, revealed that RF against deltamethrin was highest for Morigaon (MGN = 21.8) and lowest for Sonitpur (SNP = 3.3) isolate. The RF against cypermethrin was highest for Nagaon (NGO = 5.0) and lowest for Barpeta (BPT = 1.2) isolate. Against coumaphos, the highest RF of 4.5 was calculated for BPT (4.5) and lowest for NGO (1.3) isolate. While using adults based assay, highest RF of 24.68 against deltamethrin and lowest RF of 4.96 was determined for MGN and SNP isolate, respectively. In contrast to the results obtained using larvae, against cypermethrin, highest RF was recorded for Kamrup Metropolitan (KMP) while it was NGO isolate using larvae. In case of coumaphos, both larvae and adults of BPT isolate were also highly resistant and lowest RF was detected in SNP (2.30) isolate. All the isolates were susceptible to ivermectin. A significant correlation (p < 0.01) between deltamethrin resistance and higher expression of glutathioneS-transferase was observed while no correlation with esterase and monooxygenase enzymes activity was noted. For the development of possible ecofriendly control measure, different accessions of Argemone mexicana and Datura metel plant species were collected, extracted and screened against adult ticks. Two accessions, NEA-03 and NED-06 collected from Amlighat and Diphu (East Karbi Anglong) were more than 90 % effective. Further dose response study of these accessions determined the LC50 values of 4.86 and 3.96 %, respectively.The resistance status of the collected tick isolates was compared with the data generated from other regions having higher livestock population and possibility of exploitation of identified plant species for the development of natural antitick product is discussed.
C1 [Upadhaya, Deepak; Kumar, Sachin; Sharma, Anil Kumar; Fular, Ashutosh; Bisht, Nisha; Nagar, Gaurav; Shakya, Mukesh; Ghosh, Srikant] Indian Vet Res Inst, Div Parasitol, Entomol Lab, ICAR, Bareilly 243122, Uttar Pradesh, India.
   [Kumar, Bhanu; Srivastava, Sharad] Natl Bot Res Inst, Pharmacognosy & Ethnopharmacol Div, CSIR, Lucknow 226001, Uttar Pradesh, India.
   [Boruah, Rashmi Rekha; Nath, Tankeswar] Assam Agr Univ, DBT AAU Ctr, Jorhat 785013, Assam, India.
   [Nandi, Shoma Paul] Amity Univ, Amity Inst Biotechnol, Sect 125, Noida 201303, UP, India.
   [Karivaradharaja, S.] Indian Agr Res Inst, Div Microbiol, ICAR, New Delhi 110012, India.
RP Ghosh, S (reprint author), Indian Vet Res Inst, Div Parasitol, Entomol Lab, ICAR, Bareilly 243122, Uttar Pradesh, India.
EM sghoshtick@gmail.com
FU Indian Council of Agricultural Research, New DelhiIndian Council of
   Agricultural Research (ICAR); National Agricultural Science Fund;
   Department of Biotechnology Ministry of Science
   [NASF/ABA-6015/2016-17/357, BT/PR16667/NER/95/237/2015]
FX The authors are grateful to the Indian Council of Agricultural Research,
   New Delhi for funding through the National Agricultural Science Fund and
   Department of Biotechnology Ministry of Science, Project No.
   NASF/ABA-6015/2016-17/357 and BT/PR16667/NER/95/237/2015.
CR Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a
   Baffi MA, 2005, GENET MOL BIOL, V28, P749, DOI 10.1590/S1415-47572005000500016
   Barman U., 2018, J ENTOMOL ZOOL STUD, V6, P1613
   Castro-Janer E, 2009, VET PARASITOL, V162, P120, DOI 10.1016/j.vetpar.2009.02.013
   Chakravarty Sumit, 2012, Indian Forester, V138, P702
   Chigure GM, 2018, INT J ACAROL, V44, P28, DOI 10.1080/01647954.2017.1400588
   Das M., 2017, ARCH PARASITOL, V1, P2
   Drummond R.O., 1983, WORLD ANIMAL REV FAO, V36, P28
   [FAO Animal Production and Health Division], 2004, RES MAN INT PAR CONT, P25
   Finney DJ, 1962, PROBIT ANAL STAT TRE, P1
   Fular A, 2018, TICKS TICK-BORNE DIS, V9, P1184, DOI 10.1016/j.ttbdis.2018.04.014
   Ghosh S, 2007, EXP APPL ACAROL, V43, P137, DOI 10.1007/s10493-007-9100-3
   Ghosh S, 2015, EXP APPL ACAROL, V66, P159, DOI 10.1007/s10493-015-9890-7
   Godara R., 2014, SCI WORLD J
   Gurusubramanian G, 2008, J ENVIRON BIOL, V29, P813
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   He HQ, 1999, BIOCHEM BIOPH RES CO, V261, P558, DOI 10.1006/bbrc.1999.1076
   Hemingway J., 1998, WHOCTDCPCMAL986
   Hernandez EP, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3044-9
   Jamroz RC, 2000, J INSECT PHYSIOL, V46, P685, DOI 10.1016/S0022-1910(99)00157-2
   Jonsson NN, 2010, INT J PARASITOL, V40, P1659, DOI 10.1016/j.ijpara.2010.07.006
   Kumar S, 2016, INDIAN J ANIM SCI, V86, P14
   Kumar S, 2015, TICKS TICK-BORNE DIS, V6, P383, DOI 10.1016/j.ttbdis.2015.03.003
   Laha R, 2013, VET WORLD, V6, P109, DOI 10.5455/vetworld.2013.109-112
   Lovis L, 2012, INT J PARASITOL-DRUG, V2, P216, DOI 10.1016/j.ijpddr.2012.08.001
   Minjauw B., 2003, TICK BORNE DIS POVER
   Morgan JAT, 2009, INT J PARASITOL, V39, P775, DOI 10.1016/j.ijpara.2008.12.006
   Nandi A, 2018, VET PARASITOL, V250, P30, DOI 10.1016/j.vetpar.2017.12.009
   Nandi A, 2015, EXP APPL ACAROL, V66, P141, DOI 10.1007/s10493-015-9884-5
   Patle P. N., 2018, INT J CHEM STUD, V6, P270
   Sabatini GA, 2001, VET PARASITOL, V95, P53, DOI 10.1016/S0304-4017(00)00406-4
   Sagar S.V., 2019, TROP ANIM HLTH PROD, P1
   SHANAHAN GJ, 1966, NATURE, V212, P1466, DOI 10.1038/2121466b0
   Sharma AK, 2012, VET PARASITOL, V188, P337, DOI 10.1016/j.vetpar.2012.03.050
   Stone NE, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0456-z
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JAN
PY 2020
VL 277
AR UNSP 109011
DI 10.1016/j.vetpar.2019.109011
PG 10
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KG2MK
UT WOS:000509776800005
PM 31841946
OA Bronze
DA 2020-05-12
ER

PT J
AU Chiu, ML
   Luo, ST
   Chen, YY
   Chung, WY
   Duong, V
   Dussart, P
   Chan, YF
   Perera, D
   Ooi, MH
   Thao, NTT
   Truong, HK
   Lee, MS
AF Chiu, Mu-Lin
   Luo, Shu-Ting
   Chen, Ya-Yen
   Chung, Wan Yu
   Duong, Veasna
   Dussart, Philippe
   Chan, Yoke-Fun
   Perera, David
   Ooi, Mong How
   Nguyen Thi Thanh Thao
   Huu Khanh Truong
   Lee, Min-Shi
TI Establishment of Asia-Pacific Network for Enterovirus Surveillance
SO VACCINE
LA English
DT Article
DE Enterovirus; Vaccine; Asia-Pacific region
ID MOUTH-DISEASE; MOLECULAR EPIDEMIOLOGY; 71-ASSOCIATED HAND; GENETIC
   DIVERSITY; 71 INFECTION; FOOT; VP1; EVOLUTION; OUTBREAKS; FEATURES
AB Enteroviruses (EV), the major pathogens of hand, foot, and mouth disease (HFMD) and herpangina, affect millions of children each year. Most human enteroviruses cause self-limited infections except polio-viruses, enterovirus A71 (EV-A71), enterovirus D68 (EV-D68), and several echoviruses (Echo) and cox-sackieviruses (CV). Especially, EV-A71 has repeatedly caused large-scale outbreaks in the Asia-Pacific region since 1997. Some Asian countries have experienced cyclical outbreaks of severe EV-A71 infections and initiated development of EV-A71 vaccines. Five EV-A71 vaccine candidates have been clinically evaluated and three of them were approved for marketing in China. However, none of the China-approved products seek marketing approval in other countries.
   This situation supports a role for collaboration among Asian countries to facilitate clinical trials and licensure of EV-A71 vaccines. Additionally, enterovirus D68 outbreaks have been reported in the US and Taiwan currently and caused severe complications and deaths. Hence, an Asia-Pacific Network for Enterovirus Surveillance (APNES) has been established to estimate disease burden, understand virus evolution, and facilitate vaccine development through harmonizing laboratory diagnosis and data collection. Founded in 2017, the APNES is comprised of internationally recognized experts in the field of enterovirus in Asian countries working to raise awareness of this potentially fatal and debilitating disease. This article demonstrated the summaries of the first expert meeting, 2017 International Workshop on Enterovirus Surveillance and Vaccine Development, held by APNES in Taipei, Taiwan, March 2017.
C1 [Chiu, Mu-Lin; Luo, Shu-Ting; Chen, Ya-Yen; Chung, Wan Yu; Lee, Min-Shi] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Zhunan, Taiwan.
   [Duong, Veasna; Dussart, Philippe] Inst Pasteur Cambodge, Virol Unit, Phnom Penh, Cambodia.
   [Chan, Yoke-Fun] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia.
   [Perera, David; Ooi, Mong How] Univ Malaysia Sarawak, Inst Hlth & Community Med, Kota Samarahan, Malaysia.
   [Ooi, Mong How] Sarawak Gen Hosp, Sarawak, Malaysia.
   [Nguyen Thi Thanh Thao] Pasteur Inst Ho Chi Minh City, Enterovirus Unit, Ho Chi Minh City, Vietnam.
   [Huu Khanh Truong] Children Hosp 1, Dept Infect Dis, Ho Chi Minh City, Vietnam.
RP Lee, MS (reprint author), Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Zhunan, Taiwan.
EM minshi@nhri.edu.tw
RI Chan, Yoke Fun/B-5351-2010; Dussart, Philippe/P-4152-2014; Duong,
   Veasna/I-9684-2014
OI Chan, Yoke Fun/0000-0001-7089-0510; Dussart,
   Philippe/0000-0002-1931-3037; Duong, Veasna/0000-0003-0353-1678
FU National Flagship Project, Taiwan [MOST 106-3114-Y404-002]
FX This project is partialy funded by National Flagship Project, Taiwan
   (MOST 106-3114-Y404-002). We thank Dr. Paul Mendelman for critical
   review.
CR Akhmadishina LV, 2015, EMERG INFECT DIS, V21, P1440, DOI 10.3201/eid2108.141084
   Badran SA, 2011, SCAND J INFECT DIS, V43, P642, DOI 10.3109/00365548.2011.577094
   Barnadas C, 2017, J CLIN VIROL, V93, P40, DOI 10.1016/j.jcv.2017.05.017
   Bessaud M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090624
   Brown BA, 1999, J VIROL, V73, P9969, DOI 10.1128/JVI.73.12.9969-9975.1999
   Cardosa MJ, 2003, EMERG INFECT DIS, V9, P461
   Chan JHY, 2017, HONG KONG MED J, V23, P177, DOI 10.12809/hkmj166098
   Chan KP, 2003, EMERG INFECT DIS, V9, P78
   Chan TC, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-11
   Chang Luan-Yin, 2008, Pediatrics and Neonatology, V49, P103, DOI 10.1016/S1875-9572(08)60023-6
   Chang LY, 2004, JAMA-J AM MED ASSOC, V291, P222, DOI 10.1001/jama.291.2.222
   Chang LY, 1999, PEDIATR INFECT DIS J, V18, P1092, DOI 10.1097/00006454-199912000-00013
   Chang LY, 2004, PEDIATR INFECT DIS J, V23, P327, DOI 10.1097/00006454-200404000-00010
   Chang PC, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13090890
   Chatproedprai S, 2010, JPN J INFECT DIS, V63, P229
   Cheng A, 2013, VACCINE, V31, P2471, DOI 10.1016/j.vaccine.2013.03.015
   Chia MY, 2014, PEDIATR NEONATOL, V55, P243, DOI 10.1016/j.pedneo.2013.07.007
   Chien YS, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0541-x
   Chien YS, 2019, J FORMOS MED ASSOC, V118, P641, DOI 10.1016/j.jfma.2018.09.021
   Chong P, 2015, CLIN INFECT DIS, V60, P797, DOI 10.1093/cid/ciu852
   Chou AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079783
   Cordey S, 2017, J CLIN VIROL, V89, P22, DOI 10.1016/j.jcv.2017.01.008
   Diedrich S, 2009, ARCH VIROL, V154, P1139, DOI 10.1007/s00705-009-0413-x
   Duong V, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.101
   European Centre for Disease Prevention and Control, 2016, OUTBR ENT A71 SEV NE
   Geoghegan JL, 2015, J VIROL, V89, P8871, DOI 10.1128/JVI.00706-15
   Harvala H, 2018, J CLIN VIROL, V101, P11, DOI 10.1016/j.jcv.2018.01.008
   Harvala H, 2017, EUROSURVEILLANCE, V22, P12, DOI 10.2807/1560-7917.ES.2017.22.45.16-00807
   Hosoya M, 2006, PEDIATR INFECT DIS J, V25, P691, DOI 10.1097/01.inf.0000227959.89339.c3
   Kapusinszky B, 2010, VIRUS GENES, V40, P163, DOI 10.1007/s11262-009-0440-4
   Khetsuriani N, 2006, PEDIATR INFECT DIS J, V25, P889, DOI 10.1097/01.inf.0000237798.07462.32
   Kim HJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1755-0
   Kung YA, 2014, EXPERT OPIN BIOL TH, V14, P1455, DOI 10.1517/14712598.2014.935330
   Thoa LPK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069895
   Lee MS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001737
   Lin TY, 2003, EMERG INFECT DIS, V9, P291, DOI 10.3201/eid0903.020285
   Linsuwanon P, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-16
   Lu QB, 2014, J MED MICROBIOL, V63, P408, DOI 10.1099/jmm.0.068247-0
   Majumdar M, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy250
   Majumdar M, 2018, J INFECT DIS, V217, P1222, DOI 10.1093/infdis/jix667
   McMinn PC, 2002, FEMS MICROBIOL REV, V26, P91, DOI 10.1111/j.1574-6976.2002.tb00601.x
   Mirand A, 2015, EMERG INFECT DIS, V21, P707, DOI 10.3201/eid2104.141093
   National Institute of Infectious Diseases Japan, 2018, INFECT AGENTS SURVEI
   Nguyen NTB, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-341
   Nix WA, 2006, J CLIN MICROBIOL, V44, P2698, DOI 10.1128/JCM.00542-06
   Oberste MS, 1999, J CLIN MICROBIOL, V37, P1288, DOI 10.1128/JCM.37.5.1288-1293.1999
   Oberste MS, 1999, J VIROL, V73, P1941, DOI 10.1128/JVI.73.3.1941-1948.1999
   Ooi MH, 2007, J CLIN MICROBIOL, V45, P1858, DOI 10.1128/JCM.01394-06
   Ortner B, 2009, J MED VIROL, V81, P317, DOI 10.1002/jmv.21374
   Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557
   Perera D, 2010, J MED VIROL, V82, P649, DOI 10.1002/jmv.21652
   Pichichero ME, 1998, PEDIATRICS, V102, P1126, DOI 10.1542/peds.102.5.1126
   Pogka V, 2017, APPL ENVIRON MICROB, V83, DOI [10.1128/AEM.02872-16, 10.1128/aem.02872-16]
   Pourianfar HR, 2015, J MICROBIOL IMMUNOL, V48, P1, DOI 10.1016/j.jmii.2013.11.011
   Qiu J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02658-4
   Rao CD, 2012, EMERG INFECT DIS, V18, P1833, DOI 10.3201/eid1811.111457
   Reed Z, 2016, VACCINE, V34, P2967, DOI 10.1016/j.vaccine.2016.02.077
   Roth B, 2007, J MED VIROL, V79, P956, DOI 10.1002/jmv.20917
   Sanders SA, 2006, ARCH VIROL, V151, P1003, DOI 10.1007/s00705-005-0684-9
   Saxena VK, 2015, EMERG INFECT DIS, V21, P123, DOI 10.3201/eid2101.140743
   SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304
   Schuffenecker I, 2011, J CLIN VIROL, V50, P50, DOI 10.1016/j.jcv.2010.09.019
   Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8
   Taiwan Centers for Disease Control, 2018, TAIW NAT INF DIS STA
   Tan EL, 2006, MOL CELL PROBE, V20, P135, DOI 10.1016/j.mcp.2005.11.003
   Tan EL, 2008, J CLIN VIROL, V42, P203, DOI 10.1016/j.jcv.2008.01.001
   Khanh TH, 2012, EMERG INFECT DIS, V18, P2002, DOI 10.3201/eid1812.120929
   van der Sanden S, 2009, J CLIN MICROBIOL, V47, P2826, DOI 10.1128/JCM.00507-09
   Wang SM, 2009, EXPERT REV ANTI-INFE, V7, P735, DOI [10.1586/eri.09.45, 10.1586/ERI.09.45]
   Weng YW, 2017, MED SCI MONITOR, V23, P2508, DOI 10.12659/MSM.901364
   WHO Regional Office for Europe, 2015, ENT SURV GUID GUID E
   WHO WPRO, 2017, HAND FOOT MOUTH DIS
   World Health Organization ( WHO), 2011, GUID CLIN MAN PUBL H
   Xiao XL, 2009, ARCH VIROL, V154, P121, DOI 10.1007/s00705-008-0266-8
   Xing WJ, 2014, LANCET INFECT DIS, V14, P308, DOI 10.1016/S1473-3099(13)70342-6
   Yi EJ, 2017, CLIN EXP VACCINE RES, V6, P4, DOI [10.7774/cevr.2017.6.1.4., 10.7774/cevr.2017.6.1.4]
   Zander A, 2014, MED J AUSTRALIA, V201, P663, DOI 10.5694/mja14.00014
   Zhang Y, 2009, J CLIN VIROL, V44, P262, DOI 10.1016/j.jcv.2009.02.002
   Zhou Y, 2016, EXPERT REV VACCINES, V15, P803, DOI 10.1080/14760584.2016.1191357
NR 79
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 1
EP 9
DI 10.1016/j.vaccine.2019.09.111
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400001
PM 31679864
OA Bronze
DA 2020-05-12
ER

PT J
AU Shen, AK
   Warnock, R
   Selna, W
   MaCurdy, TE
   Chu, S
   Kelman, JA
AF Shen, Angela K.
   Warnock, Rob
   Selna, Weston
   MaCurdy, Thomas E.
   Chu, Steve
   Kelman, Jeffrey A.
TI Characteristics of vaccinating providers reported through Medicare
   claims in office-based settings: Volume of influenza and pneumococcal
   vaccinations
SO VACCINE
LA English
DT Article
DE Medicare; Vaccine; Immunization; Providers; Advisory committee on
   immunization practices (ACIP)
ID IMMUNIZATION
AB Vaccination coverage among older adults is low in the United States. A recommendation from a provider is a strong predictor of vaccine receipt.
   Using Medicare Fee-For-Service data (2015-2017) this study characterized providers by the number of influenza and pneumococcal vaccines administered in physician offices, age, gender, and professional specialty to determine the volume of vaccines provided by individual providers and characteristics of these providers.
   Half of all vaccinations were provided by 10% of providers. The mean age of 224,483 and 165,710 unique influenza and pneumococcal providers respectively was 49 years (SD: 12 years) with males and females equally distributed. The highest vaccinating quartile of providers tended to be older, more likely male and more likely general physicians. Those who administered a high volume of one vaccine were likely to administer a high volume of the other.
   Providers administering vaccines in office-based settings can do more to increase vaccination coverage rates. Published by Elsevier Ltd.
C1 [Shen, Angela K.] US Dept HHS, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Washington, DC 20201 USA.
   [Warnock, Rob; Selna, Weston; MaCurdy, Thomas E.] Acumen LLC, Burlingame, CA USA.
   [Chu, Steve; Kelman, Jeffrey A.] Ctr Medicare & Medicaid Serv, Ctr Medicare, Baltimore, MD USA.
   [Shen, Angela K.] US PHS, Washington, DC 20201 USA.
   [Shen, Angela K.] US Dept HHS, Natl Vaccine Program Off, Washington, DC 20201 USA.
RP Shen, AK (reprint author), 200 Independence Ave SW,Room 715H, Washington, DC 20201 USA.
EM angela.k.shen@gmail.com
OI Shen, Angela/0000-0003-3761-0016
CR [Anonymous], MED B
   Bhatt A, 2014, PUBLIC HEALTH REP, V129, P115
   Centers for disease control and prevention, IMM SCHED IMM SCHED
   Centers for Disease Control and Prevention, VACC REC GUID ACIP I
   Gellin Bruce G, 2016, AM J PREV MED, V51, P1079, DOI [10.1016/j.amepre.2016.04.014, DOI 10.1016/J.AMEPRE.2016.04.014]
   Hurley LP, 2014, ANN INTERN MED, V160, P161, DOI 10.7326/M13-2332
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Lochner KA, 2011, MED MED RES REV, V1, pE1
   Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016
   OHara B., 2013, HLTH STATUS HLTH INS
   Shen AK, 2018, HUM VACC IMMUNOTHER, P1
   Shen AK, 2017, VACCINE, V35, P7302, DOI 10.1016/j.vaccine.2017.10.105
   Shen AK, 2017, VACCINE, V35, P6938, DOI 10.1016/j.vaccine.2017.10.055
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   2012, PUBLIC HEALTH REP S1, V127, P1
NR 15
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 15
EP 19
DI 10.1016/j.vaccine.2019.10.029
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400003
PM 31679862
OA Bronze
DA 2020-05-12
ER

PT J
AU Orije, MRP
   Maertens, K
   Corbiere, V
   Wanlapakorn, N
   Van Damme, P
   Leuridan, E
   Mascart, F
AF Orije, Marjolein R. P.
   Maertens, Kirsten
   Corbiere, Veronique
   Wanlapakorn, Nasamon
   Van Damme, Pierre
   Leuridan, Elke
   Mascart, Francoise
TI The effect of maternal antibodies on the cellular immune response after
   infant vaccination: A review
SO VACCINE
LA English
DT Review
DE Maternal antibodies; Maternal immunization; Blunting; Cellular immune
   response; Humoral immune response
ID MEASLES VACCINATION; PERTUSSIS IMMUNIZATION; ADVISORY-COMMITTEE;
   PREGNANT-WOMEN; VACCINES; VIRUS; RECOMMENDATIONS; PROLIFERATION;
   PSEUDORABIES; NEWBORN
AB During the last few decades, maternal immunization as a strategy to protect young infants from infectious diseases has been increasingly recommended, yet some issues have emerged. Studies have shown that for several vaccines, such as live attenuated, toxoid and conjugated vaccines, high maternal antibody titers inhibit the infant's humoral immune response after infant vaccination. However, it is not clear whether this decreased antibody titer has any clinical impact on the infant's protection, as the cellular immune responses are often equally important in providing disease protection and may therefore compensate for diminished antibody levels. Reports describing the effect of maternal antibodies on the cellular immune response after infant vaccination are scarce, probably because such studies are expensive, labor intensive and utilize poorly standardized laboratory techniques. Therefore, this review aims to shed light on what is currently known about the cellular immune responses after infant vaccination in the presence of high (maternal) antibody titers both in animal and human studies. Overall, the findings suggest that maternally derived antibodies do not interfere with the cellular immune responses after infant vaccination. However, more research in humans is clearly needed, as most data originate from animal studies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Orije, Marjolein R. P.; Maertens, Kirsten; Van Damme, Pierre; Leuridan, Elke] Univ Antwerp, Vaccine & Infect Dis Inst, Ctr Evaluat Vaccinat, Antwerp, Belgium.
   [Corbiere, Veronique; Mascart, Francoise] ULB, Fac Med, Lab Vaccinol & Mucosal Immun, Brussels, Belgium.
   [Wanlapakorn, Nasamon] Chulalongkorn Univ, Fac Med, Dept Pediat, Ctr Excellence Clin Virol, Bangkok, Thailand.
RP Orije, MRP (reprint author), Univ Pl 1, B-2610 Antwerp, Belgium.
EM Marjolein.orije@uantwerp.be
FU FWO (Fund for Scientific Research-Flanders)FWO [FWO 12R5719N]
FX Kirsten Maertens is the beneficiary of a postdoctoral mandate fellowship
   from the FWO (Fund for Scientific Research-Flanders; FWO 12R5719N).
CR Aaby P, 2014, CLIN INFECT DIS, V59, P484, DOI 10.1093/cid/ciu354
   ALBRECHT P, 1977, J PEDIATR-US, V91, P715, DOI 10.1016/S0022-3476(77)81021-4
   Amirthalingam G, 2016, CLIN INFECT DIS, V63, pS236, DOI 10.1093/cid/ciw559
   Arck PC, 2013, NAT MED, V19, P548, DOI 10.1038/nm.3160
   Baldwin WM, 2019, AM J TRANSPLANT, DOI [10.1111/ait.15366, DOI 10.1111/AIT.15366]
   Bertley FMN, 2004, VACCINE, V23, P444, DOI 10.1016/j.vaccine.2004.06.021
   Blomqvist GAM, 2003, VACCINE, V21, P2022, DOI 10.1016/S0264-410X(02)00776-4
   Bouma A, 1998, RES VET SCI, V64, P167, DOI 10.1016/S0034-5288(98)90014-5
   Campbell H, 2018, J MED MICROBIOL, V67, P1426, DOI 10.1099/jmm.0.000829
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   Crowe JE, 2001, CLIN INFECT DIS, V33, P1720, DOI 10.1086/322971
   Eberhardt CS, 2017, CLIN INFECT DIS, V64, P1129, DOI 10.1093/cid/cix046
   Endsley JJ, 2003, BIOLOGICALS, V31, P123, DOI 10.1016/S1045-1056(03)00027-7
   Esposito S, 2009, EARLY HUM DEV, V85, pS43, DOI 10.1016/j.earlhumdev.2009.08.011
   Faucette AN, 2015, HUM VACC IMMUNOTHER, V11, P2549, DOI 10.1080/21645515.2015.1070984
   Fink K, 2008, EUR J IMMUNOL, V38, P90, DOI 10.1002/eji.200737872
   Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Gans H, 2003, VACCINE, V21, P3398, DOI 10.1016/S0264-410X(03)00341-4
   Gans HA, 1999, J IMMUNOL, V162, P5569
   Gans HA, 2013, J INFECT DIS, V207, P574, DOI 10.1093/infdis/jis719
   Hardy-Fairbanks AJ, 2013, PEDIATR INFECT DIS J, V32, P1257, DOI 10.1097/INF.0b013e3182a09b6a
   Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x
   KARRON RA, 1995, PEDIATR INFECT DIS J, V14, P10, DOI 10.1097/00006454-199501000-00002
   Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009
   Kollmann TR, 2016, TRENDS IMMUNOL, V37, P523, DOI 10.1016/j.it.2016.05.005
   Lam JH, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94500
   Lambert PH, 2005, NAT MED, V11, pS54, DOI 10.1038/nm1216
   Lindsey B, 2013, CURR OPIN INFECT DIS, V26, P248, DOI 10.1097/QCO.0b013e3283607a58
   Maertens K, 2016, CLIN INFECT DIS, V63, pS197, DOI 10.1093/cid/ciw551
   Maertens K, 2016, VACCINE, V34, P142, DOI 10.1016/j.vaccine.2015.10.100
   Marleau AM, 2003, LAB INVEST, V83, P673, DOI 10.1097/01.LAB.0000067500.85003.32
   Mascart F, 2007, VACCINE, V25, P391, DOI 10.1016/j.vaccine.2006.06.046
   McGovern ME, 2015, AM J EPIDEMIOL, V182, P791, DOI 10.1093/aje/kwv125
   Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
   Pabst HF, 1999, VACCINE, V17, P1910, DOI 10.1016/S0264-410X(98)00472-1
   Palmeira P, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/985646
   Plotkin SA, 2012, VACCINES
   Poehling KA, 2011, AM J OBSTET GYNECOL, V204, pS141, DOI 10.1016/j.ajog.2011.02.042
   Pomorska-Mol M, 2010, VET MICROBIOL, V144, P450, DOI 10.1016/j.vetmic.2010.01.015
   Premenko-Lanier M, 2006, VIROLOGY, V350, P429, DOI 10.1016/j.virol.2006.02.029
   Rowe J, 2004, VACCINE, V22, P3986, DOI 10.1016/j.vaccine.2004.03.052
   SARVAS H, 1992, J INFECT DIS, V165, P977, DOI 10.1093/infdis/165.5.977
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Siegrist CA, 1998, EUR J IMMUNOL, V28, P4138, DOI 10.1002/(SICI)1521-4141(199812)28:12<4138::AID-IMMU4138>3.0.CO;2-L
   Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6
   Siegrist CA, 1998, VACCINE, V16, P1409, DOI 10.1016/S0264-410X(98)00100-5
   Smith SG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007972
   Thome JJC, 2016, NAT MED, V22, P72, DOI 10.1038/nm.4008
   Thome JJC, 2014, CELL, V159, P814, DOI 10.1016/j.cell.2014.10.026
   van den Berg JP, 2011, EARLY HUM DEV, V87, P67, DOI 10.1016/j.earlhumdev.2010.11.003
   Van Rie Annelies, 2005, Pediatr Infect Dis J, V24, pS62, DOI 10.1097/01.inf.0000160915.93979.8f
   vanBinnendijk RS, 1997, J INFECT DIS, V175, P524, DOI 10.1093/infdis/175.3.524
   Weeratna RD, 2001, FEMS IMMUNOL MED MIC, V30, P241, DOI 10.1111/j.1574-695X.2001.tb01577.x
   Wilcox CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01548
NR 54
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 20
EP 28
DI 10.1016/j.vaccine.2019.10.025
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400004
PM 31672332
OA Bronze
DA 2020-05-12
ER

PT J
AU Shahbari, NAE
   Gesser-Edelsburg, A
   Mesch, GS
AF Shahbari, Nour Abed Elhadi
   Gesser-Edelsburg, Anat
   Mesch, Gustavo S.
TI Perceived trust in the health system among mothers and nurses and its
   relationship to the issue of vaccinations among the Arab population of
   Israel: A qualitative research study
SO VACCINE
LA English
DT Article
DE Perceived trust; Vaccinations; Arab minority; Decision making;
   Qualitative research
ID HUMAN-PAPILLOMAVIRUS VACCINATION; PUBLIC-HEALTH; INFLUENZA VACCINATION;
   DECISION-MAKING; HPV VACCINATION; INFORMATION; DISPARITIES; ATTITUDES;
   REFUSAL; WHITE
AB The literature indicates that trust plays an important role in people's decision-making with respect to vaccinations. This research seeks to examine the impact of trust on the high response rate to vaccinations among the minority Arab population living in Israel.
   The research employs the qualitative phenomenological research method, using personal interviews to identify and analyze perceived trust among mothers of young children and teenagers (n = 70) and among nurses (n = 20) in the Arab population in the context of vaccinations and the high response rate to vaccinations among this population.
   The research findings point to differing levels of trust in the medical system. The participants placed the highest trust in the nurses working in the Tipat Halav Family Health Centers run by the Ministry of Health. These nurses are the main communicators of information about childhood vaccinations in Israel. Moreover, the interviewees saw vaccinations as an example of the state offering equal and optimal services to the Arab minority population. In addition, the interviewees consider the explanatory materials to be limited, superficial and not culturally appropriate.
   These positive attitudes toward vaccinations alongside reports that no importance is attributed to the explanatory materials due to their low quality may cause the population to accept vaccination recommendations as they are and to delegate responsibility and authority to the state. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shahbari, Nour Abed Elhadi; Gesser-Edelsburg, Anat] Univ Haifa, Sch Publ Hlth, 199 Aba Khoushy Ave Mt Carmel, IL-3498838 Haifa, Israel.
   [Gesser-Edelsburg, Anat] Univ Haifa, Hlth & Risk Commun Res Ctr, 199 Aba Khoushy Ave Mt Carmel, IL-3498838 Haifa, Israel.
   [Mesch, Gustavo S.] Univ Haifa, Dept Sociol, 199 Aba Khoushy Ave Mt Carmel, IL-3498838 Haifa, Israel.
   [Gesser-Edelsburg, Anat] Univ Haifa, Sch Publ Hlth, Hlth Promot Program, 199 Aba Khoushy Ave Mt Carmel, IL-3498838 Haifa, Israel.
RP Shahbari, NAE (reprint author), Univ Haifa, Sch Publ Hlth, 199 Aba Khoushy Ave Mt Carmel, IL-3498838 Haifa, Israel.
EM nabede01@campus.haifa.ac.il; ageser@univ.haifa.ac.il;
   gustavo@soc.haifa.ac.il
OI Gesser-Edelsburg, PhD, Prof. Anat/0000-0003-4467-8799
CR Adalah, 2010, EC CULT SOC RIGHTS
   Aharon AA, 2017, PATIENT EDUC COUNS, V100, P768, DOI 10.1016/j.pec.2016.11.016
   Attena F, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-211
   Bennett P, 2010, RISK COMMUNICATION P
   Bensman J, 1988, AESTHETICS POLITICS
   Blume S, 2006, SOC SCI MED, V63, P1825, DOI 10.1016/j.socscimed.2006.04.014
   Boas H, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0119-y
   Bodemer N, 2012, VACCINE, V30, P3747, DOI 10.1016/j.vaccine.2012.03.005
   Bonevski B, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-42
   Bos Nathan, 2002, EFFECTS 4 COMPUTER M, P135
   Boulware LE, 2003, PUBLIC HEALTH REP, V118, P358, DOI 10.1016/S0033-3549(04)50262-5
   Brookdale, 2016, SURV HLTH SYST
   Casiday RE, 2007, SOC SCI MED, V65, P1059, DOI 10.1016/j.socscimed.2007.04.023
   Chatterjee A, 2010, EXPERT REV VACCINES, V9, P497, DOI [10.1586/erv.10.36, 10.1586/ERV.10.36]
   Cooper DL, 2017, VACCINE, V35, P2661, DOI 10.1016/j.vaccine.2017.03.083
   Creswell J. W., 2009, RES DESIGNS QUALITAT
   Cummings TG, 2014, CENGAGE LEARNING
   Dahm MR, 2012, HEALTH COMMUN, V27, P682, DOI 10.1080/10410236.2011.629411
   Dallo FJ, 2015, AM J MENS HEALTH, V9, P124, DOI 10.1177/1557988314532285
   Dan YM, 2014, ISR J HEALTH POLICY, V3, DOI 10.1186/2045-4015-3-13
   Daoud N, 2008, WOMEN HEALTH, V48, P145, DOI 10.1080/03630240802313530
   DeLong G, 2012, ACCOUNT RES, V19, P65, DOI 10.1080/08989621.2012.660073
   Devos T, 2002, BRIT J SOC PSYCHOL, V41, P481, DOI 10.1348/014466602321149849
   Donovan Helen, 2013, Nurs Child Young People, V25, P16, DOI 10.7748/ncyp2013.11.25.9.16.e466
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Ein-Gal Y, 2014, PUBLIC HEALTH NURS, V31, P454, DOI 10.1111/phn.12122
   Frew PM, 2011, PEDIATRICS, V127, pS113, DOI 10.1542/peds.2010-1722Q
   Fu LDY, 2017, VACCINE, V35, P802, DOI 10.1016/j.vaccine.2016.12.045
   Gautret P, 2010, EUR J PUBLIC HEALTH, V20, P438, DOI 10.1093/eurpub/ckp196
   Gesser-Edelsburg A, 2016, RISK COMMUNICATION I
   Gesser-Edelsburg A, 2017, AM J INFECT CONTROL, V45, P267, DOI 10.1016/j.ajic.2016.10.009
   Gesser-Edelsburg A, 2015, J HEALTH COMMUN, V20, P1287, DOI 10.1080/10810730.2015.1018642
   Gesser-Edelsburg A, 2016, J RISK RES, V19, P405, DOI 10.1080/13669877.2014.983947
   Gilkey MB, 2016, VACCINE, V34, P1187, DOI 10.1016/j.vaccine.2016.01.023
   Grandahl M, 2014, ACTA PAEDIATR, V103, P436, DOI 10.1111/apa.12545
   Gross L, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000114
   Guttmann A, 2008, AMBUL PEDIATR, V8, P205, DOI 10.1016/j.ambp.2008.01.010
   Haron Y, 2019, PUBLIC HEALTH NURS, V36, P79, DOI 10.1111/phn.12578
   Herman T., 2016, ISRAELI DEMOCRACY IN, P132
   Hernandez Jf, 2015, TRUST PHARM SECT ANA
   Holman DM, 2014, JAMA PEDIATR, V168, P76, DOI 10.1001/jamapediatrics.2013.2752
   Holmes JG, 1989, TRUST CLOSE RELATION
   Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687
   Huber M, 2008, QUALITY EQUALITY ACC
   Huberman M., 2002, QUALITATIVE RES COMP
   Kanner E, 2015, LANCET INFECT DIS, V15, P1236, DOI 10.1016/S1473-3099(15)00064-X
   KAPLAN B, 2005, EVALUATING ORG IMPAC, P30, DOI DOI 10.1007/0-387-30329-4_2
   Keefe RH, 2010, SOC WORK PUBLIC HLTH, V25, P237, DOI 10.1080/19371910903240589
   Keshet Y, 2015, ISR J HEALTH POLICY, V4, DOI 10.1186/s13584-015-0004-0
   Knishkowy B, 2003, STUDENT HLTH USEFUL
   Laird LD, 2007, ARCH DIS CHILD, V92, P922, DOI 10.1136/adc.2006.104364
   Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8
   Larson HJ, 2015, PLOS CURR OUTBREAKS, V7
   Lee C, 2016, VACCINE, V34, P3972, DOI 10.1016/j.vaccine.2016.06.048
   Lyren A, 2006, CLIN PEDIATR, V45, P399, DOI 10.1177/0009922806289581
   Manika D, 2014, J HEALTH COMMUN, V19, P1232, DOI 10.1080/10810730.2013.872727
   Marlow LAV, 2009, J EPIDEMIOL COMMUN H, V63, P1010, DOI 10.1136/jech.2008.085886
   Martin KD, 2013, MED CARE, V51, P151, DOI 10.1097/MLR.0b013e31827632a2
   Mesch GS, 2015, HEALTH PROMOT INT, V30, P213, DOI 10.1093/heapro/dau094
   Mesch GS, 2012, COMPUT HUM BEHAV, V28, P1471, DOI 10.1016/j.chb.2012.03.010
   Meyer S, 2008, HEALTH SOCIOL REV, V17, P177, DOI 10.5172/hesr.451.17.2.177
   Ministry of Health, 2017, INF HLTH ISS SOC SUR
   Ministry of Health Israel, 2016, FLU VACC SCH QUEST A
   Ministry of Health Israel, 2013, VACC PAP
   Ministry of Health Israel, 2015, 122015 MIN HLTH ISR
   Mishalia M, 2016, J INT FOOD AGRIBUS M, V28, P225, DOI 10.1080/08974438.2015.1061466
   Muhsen K, 2012, VACCINE, V30, P2109, DOI 10.1016/j.vaccine.2012.01.044
   Neumeyer-Gromen A, 2011, BUNDESGESUNDHEITSBLA, V54, P1197, DOI 10.1007/s00103-011-1347-5
   O'Flanagan D, 2010, ANAL DETERMINANTS LO
   Ozawa S, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1867-7
   Popper-Giveon A, 2017, ED EMPLOYMENT UNIQUE, P101
   Quach S, 2012, CAN MED ASSOC J
   Quach S, 2012, CAN MED ASSOC J, V184, P1673, DOI 10.1503/cmaj.111628
   Quinn SC, 2017, VACCINE, V35, P1167, DOI 10.1016/j.vaccine.2016.12.046
   Raude J, 2016, EXPERT REV VACCINES, V15, P937, DOI 10.1080/14760584.2016.1184092
   Reiss DR, 2019, SSRN ELECT J
   Shahbari NAE, 2019, J MED INTERNET RES, V21, DOI 10.2196/13373
   Society for Patients Rights in Israel, 2014, STRENGTH FORT PUBL H
   Straits-Troster KA, 2006, AM J PREV MED, V31, P375, DOI 10.1016/j.amepre.2006.07.018
   Tackett S, 2018, WOMEN STUD INT FORUM, V69, P190, DOI 10.1016/j.wsif.2018.02.009
   Tang LY, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-472
   Tol G, 2014, POLIT RELIG IDEOL, V15, P161, DOI 10.1080/21567689.2014.888347
   Tolley EE, 2016, QUALITATIVE METHODS
   Uslaner EM, 2011, COMP SOCIOL, V10, P221, DOI 10.1163/156913311X566571
   van der Schee E, 2007, HEALTH POLICY, V81, P56, DOI 10.1016/j.healthpol.2006.04.004
   van der Wal MF, 2005, ARCH DIS CHILD, V90, P36, DOI 10.1136/adc.2003.047126
   Velan B, 2012, HUM VACC IMMUNOTHER, V8, P1272, DOI 10.4161/hv.21183
   Velan B, 2011, VACCINE, V29, P1173, DOI 10.1016/j.vaccine.2010.12.006
   Vigoda-Gadot E, 2016, PUBLIC TRUST CIVIL P
   Wang YD, 2005, COMPUT HUM BEHAV, V21, P105, DOI 10.1016/j.chb.2003.11.008
   World Health Organization, 2016, HPV VACC COMM SPEC C
   Wynia MK, 2007, AM J BIOETHICS, V7, P4, DOI 10.1080/15265160701429599
   Yosef ARO, 2008, J TRANSCULT NURS, V19, P284, DOI 10.1177/1043659608317450
   Zeraiq L, 2015, SCAND J PUBLIC HEALT, V43, P408, DOI 10.1177/1403494815569105
NR 94
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 29
EP 38
DI 10.1016/j.vaccine.2019.10.002
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400005
PM 31611101
OA Bronze
DA 2020-05-12
ER

PT J
AU Saadeh, K
   Park, I
   Gargano, JW
   Whitney, E
   Querec, TD
   Hurley, L
   Silverberg, M
AF Saadeh, Kayla
   Park, Ina
   Gargano, Julia W.
   Whitney, Erin
   Querec, Troy D.
   Hurley, Leo
   Silverberg, Michael
TI Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity
   and sociodemographic factors in women with high-grade cervical
   intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California,
   United States
SO VACCINE
LA English
DT Article
DE Human papillomavirus (HPV); HPV type prevalence; HPV vaccine impact;
   Cervical intraepithelial neoplasia (CIN); Racial disparities
ID VACCINATION COVERAGE; LESIONS; ERA
AB We evaluated racial/ethnic differences in prevalence of oncogenic HPV types targeted by the quadrivalent HPV vaccine (16/18) and nonavalent HPV vaccine (31/33/45/52/58) in women diagnosed with CIN2/3/AIS after quadrivalent HPV vaccine introduction (2008-2015). Typing data from 1810 cervical tissue specimen from HPV-IMPACT (Alameda County, California, US), a population-based CIN2/3/AIS surveillance effort, were analyzed. Using log-binomial regression, we calculated adjusted prevalence ratios (aPR) and 95% confidence intervals (CI) comparing type prevalence by race/ethnicity, adjusted for health insurance, age, CIN2/3/AIS grade, and time period, overall and in the "early vaccine era" (2008-2011) and "later vaccine era" (2012-2015). Overall, oncogenic HPV16/18 prevalence was significantly lower among black (43%) and Hispanic (43%) women compared with white (52%) women (aPR (95% CI): 0.80 (0.70, 0.93) and 0.80 (0.70, 0.91), respectively). In 2008-2011, proportion of HPV16/18 detected was significantly lower in black (47%), Hispanic (46%), and Asian (42%) women compared to white (58%) women (aPR (95% CI): 0.80 (0.67, 0.96), 0.75 (0.63, 0.90), and 0.73 (0.58, 0.90), respectively). There were no significant differences in 2012-2015. Between the two eras, HPV16/18 prevalence declined in white (-11%), black (-9%), and Hispanic (-6%) women, and increased in Asian women (12%). Decreasing HPV 16/18 prevalence in CIN2/3/AIS lesions in white, black, and Hispanic women may suggest benefit from quadrivalent vaccination. In our unadjusted analysis of HPV31/33/45/52/58, prevalence did not differ significantly by race/ethnicity, but was significantly higher among Hispanic women (32%) compared to white women (27%) after adjustment (aPR (95%Cl): 1.22 (1.02, 1.47). Prevalence was also non-significantly higher among black (32%) and Asian (33%) women. This analysis suggests that the nonavalent vaccine's potential for impact against cervical precancers will not be lower in women of color compared to white women. These data underscore the importance of equitable vaccination in facilitating continued declines of vaccine-preventable HPV types among all women. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Saadeh, Kayla; Whitney, Erin] CDPH, STDCB, DCDC, CID, Richmond, CA 94804 USA.
   [Saadeh, Kayla; Whitney, Erin] CEIP, Oakland, CA USA.
   [Park, Ina] Univ Calif San Francisco, Sch Med, Dept Family & Community Med, San Francisco, CA USA.
   [Gargano, Julia W.] Ctr Dis Control & Prevent CDC, Viral Vaccine Preventable Dis Branch, DVD, NCIRD, Atlanta, GA USA.
   [Querec, Troy D.] CDC, Chron Viral Dis Branch, DHCPP, Atlanta, GA 30333 USA.
   [Hurley, Leo; Silverberg, Michael] KPNC, Div Res, Oakland, CA USA.
RP Saadeh, K (reprint author), CDPH, STDCB, DCDC, CID, Richmond, CA 94804 USA.
EM Kayla.saadeh@cdph.ca.gov
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
FX This work was supported entirely by the Centers for Disease Control and
   Prevention.
CR Alameda County Public Health Department, 2019, HLTH AL COUNT 2019 D
   Barr E, 2007, CLIN INFECT DIS, V45, P609, DOI 10.1086/520654
   Benard VB, 2017, JAMA ONCOL, V3, P833, DOI 10.1001/jamaoncol.2016.3609
   Cofie LE, 2018, AM J PREV MED, V54, P20, DOI 10.1016/j.amepre.2017.08.017
   Endeshaw M, 2018, J LOW GENIT TRACT DI, V22, P280, DOI 10.1097/LGT.0000000000000422
   Gargano JW, 2019, CLIN INFECT DIS, V68, P1282, DOI 10.1093/cid/ciy707
   Gong J, 2014, ARCH GYNECOL OBSTET, V289, P85, DOI 10.1007/s00404-013-2955-0
   Hariri S, 2015, CANCER-AM CANCER SOC, V121, P2775, DOI 10.1002/cncr.29266
   Hariri S, 2015, CANCER EPIDEM BIOMAR, V24, P393, DOI 10.1158/1055-9965.EPI-14-0649
   Hariri S, 2012, J INFECT DIS, V206, P1878, DOI 10.1093/infdis/jis627
   Jaisamrarn U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079260
   Jang S., 2018, AM PUBL HLTH ASS 201
   Kruzikas D, 2012, CANCER EPIDEM BIOMAR, V21, P1469, DOI 10.1158/1055-9965.EPI-11-1019
   Liu G, 2016, SEX TRANSM DIS, V43, P633, DOI 10.1097/OLQ.0000000000000492
   McBride E, 2019, INT J CANCER, DOI [10.1002/jic.32540, DOI 10.1002/JIC.32540]
   McClung NM, 2019, MMWR-MORBID MORTAL W, V68, P337, DOI 10.15585/mmwr.mm6815a1
   McClung NM, 2019, CANCER EPIDEM BIOMAR, V28, P602, DOI 10.1158/1055-9965.EPI-18-0885
   Niccolai LM, 2013, CANCER-AM CANCER SOC, V119, P3052, DOI 10.1002/cncr.28038
   Oakley F, 2018, AM J PREV MED, V55, P19, DOI 10.1016/j.amepre.2018.03.015
   Saraiya M, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv086
   Serrano B, 2012, INFECT AGENTS CANCER, V7, DOI 10.1186/1750-9378-7-38
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188
   U.S. Cancer Statistics Working Group, 2019, US CANC STAT DAT VIS
   Walker TY, 2018, MMWR-MORBID MORTAL W, V67, P909, DOI 10.15585/mmwr.mm6733a1
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
NR 26
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 39
EP 45
DI 10.1016/j.vaccine.2019.09.103
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400006
PM 31611099
OA Bronze
DA 2020-05-12
ER

PT J
AU Fernandes, EG
   Sartori, AMC
   de Soarez, PC
   Amaku, M
   Neto, RSD
   Novaes, HMD
AF Fernandes, Eder Gatti
   Christovam Sartori, Ana Marli
   de Soarez, Patricia Coelho
   Amaku, Marcos
   de Azevedo Neto, Raymundo Soares
   Dutilh Novaes, Hillegonda Maria
TI Cost-effectiveness analysis of universal adult immunization with
   tetanus-diphtheria-acellular pertussis vaccine (Tdap) versus current
   practice in Brazil
SO VACCINE
LA English
DT Article
DE Cost-benefit analysis; Cost-effectiveness analysis;
   Diphtheria-tetanus-acellular pertussis vaccines; Pertussis vaccine;
   Whooping cough; Adult
ID BORDETELLA-PERTUSSIS; BOOSTER VACCINATION; INFANT PERTUSSIS;
   YOUNG-ADULTS; ADOLESCENTS; SAFETY; INFECTION; PREGNANCY; SURVEILLANCE;
   TRANSMISSION
AB Background: A pertussis outbreak occurred in Brazil from 2011 to 2014, despite high coverage of whole-cell pertussis containing vaccines in early childhood. Infants were the most affected. This study aimed to evaluate the cost-effectiveness of introducing universal adult vaccination with Tdap into the National Immunization Program in Brazil.
   Methods: Economic evaluation using a dynamic model to compare two strategies: (1) universal vaccination with single dose of Tdap at 20 years of age and (2) current practice (only pregnant women pertussis vaccination). The health system perspective was adopted. Temporal horizon was 10 years. Discount rate of 5% was applied to costs and benefits. Vaccine effectiveness (VE) was obtained from a population-based observational study. Epidemiological, resource utilization and cost estimates were obtained from the Brazilian Health Information Systems. The primary outcome was cost per life year saved (LYS), based on life expectancy at birth in Brazil in 2015. Univariate and multivariate sensitivity analysis were performed.
   Results: Adult vaccination with VE of 82.6% and coverage of 40%, at price of US$7.01 per dose, and assuming herd protection would avoid 167 infant deaths by pertussis, saving 12,325 years of life and costing a total of US$105495891.61, from the health system perspective. The universal immunization would result in ICER of US$8459.13. The results were highly sensitive to disease incidence.
   Conclusions: The results suggest that universal adult vaccination with Tdap would not be a cost-effective intervention for preventing pertussis cases and deaths in infants in Brazil. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fernandes, Eder Gatti; de Soarez, Patricia Coelho; Dutilh Novaes, Hillegonda Maria] Univ Sao Paulo, Fac Med, Dept Med Prevent, Av Dr Arnaldo 455,2 Andar,Sala 2228, BR-01246903 Sao Paulo, SP, Brazil.
   [Fernandes, Eder Gatti] Coordenadoria Controle Doencas Secretaria Estado, Ctr Vigilancia Epidemiol Prof Alexandre Vranjac, Div Imunizacao, Av Dr Arnaldo 351,6 Andar, BR-01246000 Sao Paulo, SP, Brazil.
   [Christovam Sartori, Ana Marli] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, ICHC, Av Dr Eneas de Carvalho Aguiar 255,4 Andar, BR-05403000 Sao Paulo, SP, Brazil.
   [Christovam Sartori, Ana Marli; de Soarez, Patricia Coelho; Dutilh Novaes, Hillegonda Maria] Hlth Technol Assessment Inst IATS, Porto Alegre, RS, Brazil.
   [Amaku, Marcos; de Azevedo Neto, Raymundo Soares] Univ Sao Paulo, Fac Med, Dept Patol, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
RP Fernandes, EG (reprint author), Univ Sao Paulo, Fac Med, Dept Med Prevent, Av Dr Arnaldo 455,2 Andar,Sala 2228, BR-01246903 Sao Paulo, SP, Brazil.
EM edergatti@hotmail.com; ana.sartori@hc.fm.usp.br;
   patricia.soareze@usp.br; amaku@vps.fmvz.usp.br; razevedo@usp.br;
   hidutilh@usp.br
RI Amaku, Marcos/D-5252-2012
OI Amaku, Marcos/0000-0003-4752-6774
FU  [1.073.607]
FX The study was approved by the Research Ethics Committee of Medical
   Scholl of Sao Paulo University, license number 1.073.607.
CR [Anonymous], 2015, Wkly Epidemiol Rec, V90, P433
   Atkins KE, 2016, AM J EPIDEMIOL, V183, P1159, DOI 10.1093/aje/kwv347
   Baptista PN, 2010, INT J INFECT DIS, V14, pE111, DOI 10.1016/j.ijid.2009.03.026
   Baptista PN, 2005, PEDIATR INFECT DIS J, V24, P1027, DOI 10.1097/01.inf.0000186293.85867.e8
   Berezin EN, 2014, PEDIATR INFECT DIS J, V33, P1289, DOI 10.1097/INF.0000000000000424
   Beytout J, 2009, HUM VACCINES, V5, P315, DOI 10.4161/hv.5.5.6911
   Bisgard KM, 2004, PEDIATR INFECT DIS J, V23, P985, DOI 10.1097/01.inf.0000145263.37198.2b
   Brasil. Ministerio da Sadde. Secretaria de Ciencia Tecnologia e Insumos Estrategicos. Departamento de Ciencia e Tecnologia., 2014, DIR MET DIR AV EC
   Calugar A, 2006, CLIN INFECT DIS, V42, P981, DOI 10.1086/500321
   Caro J Jaime, 2005, Pediatr Infect Dis J, V24, pS75, DOI 10.1097/01.inf.0000160918.72953.51
   Castagnini LA, 2010, J PEDIATR-US, V156, P498, DOI 10.1016/j.jpeds.2009.10.013
   Cherry JD, 2014, EXPERT REV VACCINES, V13, P1073, DOI 10.1586/14760584.2014.935765
   Sartori AMC, 2016, VACCINE, V34, P1531, DOI 10.1016/j.vaccine.2016.02.026
   Coudeville L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006284
   Crowcroft NS, 2006, LANCET, V367, P1926, DOI 10.1016/S0140-6736(06)68848-X
   de Melker HE, 2006, J INFECTION, V53, P106, DOI 10.1016/j.jinf.2005.10.020
   de Vries R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013392
   Edmunds WJ, 2002, VACCINE, V20, P1316, DOI 10.1016/S0264-410X(01)00473-X
   Arlant LHF, 2014, EXPERT REV ANTI-INFE, V12, P1265, DOI 10.1586/14787210.2014.948846
   Fernandes EG, 2019, VACCINE, V37, P5481, DOI 10.1016/j.vaccine.2019.03.049
   Fernandes EG, 2019, HUM VACC IMMUNOTHER, V15, P14, DOI 10.1080/21645515.2018.1509646
   Fernandes EG, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3004-1
   Greer AL, 2011, PEDIATRICS, V128, pE591, DOI 10.1542/peds.2010-0796
   Guimaraes LM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1222-3
   Guiso N, 2009, CLIN INFECT DIS, V49, P1565, DOI 10.1086/644733
   Halperin SA, 2000, VACCINE, V18, P1312, DOI 10.1016/S0264-410X(99)00415-6
   Hardy-Fairbanks AJ, 2013, PEDIATR INFECT DIS J, V32, P1257, DOI 10.1097/INF.0b013e3182a09b6a
   Fernandez-Cano MI, 2015, VACCINE, V33, P2213, DOI 10.1016/j.vaccine.2015.03.045
   Iskedjian M, 2004, VACCINE, V22, P4215, DOI 10.1016/j.vaccine.2004.04.025
   Iskedjian Michael, 2005, Paediatr Drugs, V7, P123, DOI 10.2165/00148581-200507020-00005
   Itatani T, 2013, VACCINE, V31, P2891, DOI 10.1016/j.vaccine.2013.03.032
   Kilgore PE, 2016, CLIN MICROBIOL REV, V29, P449, DOI 10.1128/CMR.00083-15
   Klein NP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3326
   Lapidot Rotem, 2016, Trop Dis Travel Med Vaccines, V2, P26, DOI 10.1186/s40794-016-0043-8
   Lee GM, 2005, PEDIATRICS, V115, P1675, DOI 10.1542/peds.2004-2509
   Lee GM, 2008, VACCINE, V26, P3673, DOI 10.1016/j.vaccine.2008.04.068
   Lee GM, 2007, AM J PREV MED, V32, P186, DOI 10.1016/j.amepre.2006.10.016
   Lee HJ, 2017, CLIN EXP VACCINE RES, V6, P22, DOI [10.7774/cevr.2017.6.1.22., 10.7774/cevr.2017.6.1.22]
   Leuridan E, 2011, PEDIATR INFECT DIS J, V30, P608, DOI 10.1097/INF.0b013e3182093814
   McGarry LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0072723
   McGarry LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067260
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Pichichero ME, 2005, PEDIATR INFECT DIS J, V24, pS117, DOI 10.1097/01.inf.0000166157.21561.78
   Rozenbaum MH, 2012, VACCINE, V30, P7327, DOI 10.1016/j.vaccine.2012.06.026
   Talbird SE, 2015, J MANAG CARE SPEC PH, V21, P88, DOI 10.18553/jmcp.2015.21.1.88
   Talbot EA, 2010, VACCINE, V28, P8001, DOI 10.1016/j.vaccine.2010.09.034
   Tan Tina, 2005, Pediatr Infect Dis J, V24, pS10, DOI 10.1097/01.inf.0000160708.43944.99
   Terranella A, 2013, PEDIATRICS, V131, pE1748, DOI 10.1542/peds.2012-3144
   Ward JI, 2005, NEW ENGL J MED, V353, P1555, DOI 10.1056/NEJMoa050824
   Wearing HJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000647
   Wei SC, 2010, CLIN INFECT DIS, V51, P315, DOI 10.1086/653938
   Wendelboe AM, 2007, PEDIATR INFECT DIS J, V26, P293, DOI 10.1097/01.inf.0000258699.64164.6d
   Wendelboe AM, 2005, PEDIATR INFECT DIS J, V24, P558
   Wiley KE, 2013, VACCINE, V31, P618, DOI 10.1016/j.vaccine.2012.11.052
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Winter K, 2014, MMWR-MORBID MORTAL W, V63, P1129
   Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017
   Yih WK, 2009, VACCINE, V27, P4257, DOI 10.1016/j.vaccine.2009.05.036
   Zoldi V, 2017, VACCINE, V35, P5249, DOI 10.1016/j.vaccine.2017.08.008
NR 59
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 46
EP 53
DI 10.1016/j.vaccine.2019.09.100
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400007
PM 31648911
OA Bronze
DA 2020-05-12
ER

PT J
AU Reyes, MSGL
   Lee, KMG
   Pedron, AML
   Pimentel, JMT
   Pinlac, PAV
AF Reyes, Ma. Sophia Graciela L.
   Lee, Karen Mae G.
   Pedron, Adrianna Michelle L.
   Pimentel, Jennel Mae T.
   Pinlac, Paul Adrian V.
TI Factors associated with the willingness of primary caregivers to avail
   of a dengue vaccine for their 9 to 14-year-olds in an urban community in
   the Philippines
SO VACCINE
LA English
DT Article
DE Dengue fever; Dengue vaccine; Vaccine acceptance; Health belief model
AB To help address the need for preventive measures against dengue fever, a leading cause of child mortality in the Philippines, vaccine trials are ongoing and a tetravalent vaccine (Dengvaxia (TM), Sanofi Pasteur) has been developed. It is hypothesized that while acceptability would be high among primary caregivers (i.e., parents/guardians), the willingness to have one's child immunized against dengue would be associated with socio-demographic variables, attitudes and knowledge regarding dengue and vaccination, and past experience with dengue. This study aimed to assess the aforementioned factors' association with primary caregivers' willingness to avail of a dengue vaccine for their 9 to 14-year-old children in an urban community in the Philippines.
   A cross-sectional study utilizing interviews was conducted to determine which factors were associated with willingness-to-avail assuming a free vaccine, and a case study utilizing a focus group discussion was employed to capture some underlying reasons for their willingness. Data were analyzed using multiple logistic regression and thematic analysis.
   Among the 202 study participants, 193 (95.54%) were willing to avail of the vaccine. There was a high probability of vaccine acceptance by primary caregivers (95.54%), with good attitude towards vaccination (>= 12/15 points) (aOR 10.62, 90% CI (1.73-26.28)] and large household size (>5) [aOR 9.63, 90% CI (2.04-45.58)] being positively associated with willingness-to-avail, and good knowledge regarding dengue fever [aOR 0.10, 90% CI (0.03-0.74)] and older age (>44 years) [aOR 0.14, 90% CI (0.03-0.61)] being negatively associated.
   Crude analysis showed that household size, knowledge regarding dengue, and attitude towards vaccination were significantly associated with willingness. Multivariate analysis revealed that these factors and the primary caregiver's age were associated with willingness. Thematic analysis showed various perceptions regarding dengue and vaccination. Knowing these factors are associated with willingness-to-avail of the vaccine may help in understanding the audience of health promotion projects aimed at increasing immunization coverage. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Reyes, Ma. Sophia Graciela L.; Lee, Karen Mae G.; Pedron, Adrianna Michelle L.; Pimentel, Jennel Mae T.] Univ Philippines Manila, Coll Publ Hlth, 625 Pedro Gil St, Manila 1000, Philippines.
   [Pinlac, Paul Adrian V.] Univ Philippines Manila, Coll Publ Hlth, Dept Epidemiol & Biostat, Manila 1000, Philippines.
RP Reyes, MSGL (reprint author), Univ Philippines Manila, Coll Publ Hlth, 625 Pedro Gil St, Manila 1000, Philippines.
EM mIreyes8@up.edu.ph; alpe-dron@up.edu.ph; pvpinlac@up.edu.ph
CR Bonalos P., 2016, CNN
   Crinson I, 2009, HLTH POLICY CRITICAL
   Dahlstrom LA, 2010, INT J CANCER, V126, P500, DOI 10.1002/ijc.24712
   Department of Health, 2014, LEAD CAUS CHILD MORT
   Edillo FE, 2015, AM J TROP MED HYG, V92, P360, DOI 10.4269/ajtmh.14-0139
   Geronimo JY, RAPPLER
   Hadisoemarto PF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002427
   Harapan H, 2016, VACCINE, V34, P3670, DOI 10.1016/j.vaccine.2016.05.026
   Kaliyaperumal K., 2004, AECS ILLUMINATION, V4, P7
   LaClair BJ, 2014, ATTITUDES CONCERNS K
   Larson HJ, 2019, HUM VACC IMMUNOTHER, V15, P625, DOI 10.1080/21645515.2018.1522468
   Rimer BK, 2005, NIH PUBLICATION
   World Health Organization, DET VACC HES SAMPL S
   World Health Organization, 2017, DENG VACC RES
   World Health Organization. WHO, 2017, DENG CONTR STRAT
   World Health Organization (WHO), QUEST ANSW DENG VACC
   Yboa BC, 2013, AM J PUBLIC HLTH RES, V1, P47, DOI DOI 10.12691/AJPHR-1-2-2
NR 17
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 54
EP 62
DI 10.1016/j.vaccine.2019.10.001
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400008
PM 31668819
OA Bronze
DA 2020-05-12
ER

PT J
AU Sato, R
AF Sato, Ryoko
TI Differential determinants and reasons for the non- and partial
   vaccination of children among Nigerian caregivers
SO VACCINE
LA English
DT Article
DE Reasons; Non-vaccination; Partial-vaccination; Determinants
AB Background: Vaccination has saved millions of lives. However, the vaccination rate in Nigeria remains low. We differentiate reasons for incomplete vaccination by status: not- and partially-vaccinated, and examine the association between sociodemographic characteristics of caregivers and reasons for incomplete vaccination.
   Methods: Data from the Multiple Indicator Cluster Survey (MICS) conducted in Nigeria in 2016 and 2017 was analyzed. The logistic regression was used to evaluate associations between sociodemographic characteristics of caregivers and incomplete vaccination according to different reasons.
   Results: The most common reason for non-vaccination is that caregivers have no faith in immunization (27.0%), followed by lack of awareness of the need for immunization (26.0%) and the perception that the place where immunization is given is too far/inconvenient (24.3%). The most common reason for partial vaccination is that caregivers thought the children had already been fully immunized (44.8%), followed by the inconvenient location for immunization (15.3%) and supply-side issues such as shortage of vaccine stock and absence of vaccinators (14.4%). Among caregivers whose children are never vaccinated, a lower level of education is correlated with more likelihood of having no faith in immunization and poorer households are more likely to state a lack of awareness of the need for immunization need and an inconvenient place as the reasons for non-vaccination. Among caregivers whose children are only partially vaccinated, educated and wealthier caregivers are more likely to state that they thought their children were fully vaccinated, while poorer caregivers tend to give an inconvenient immunization place as the reason for incomplete vaccination. Supply-side barriers are not systematically correlated with educational attainment or wealth level of caregivers.
   Conclusion: Barriers to vaccination are different according to vaccination status: not- and partially-vaccinated, as is the association between sociodemographic characteristics of caregivers and reasons for incomplete vaccination. The policy to increase vaccination take-up should take these differentials into consideration. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sato, Ryoko] Harvard TH Chan Sch Publ Hlth, Global Hlth & Populat, 90 Smith St,332-1, Boston, MA 02120 USA.
RP Sato, R (reprint author), Harvard TH Chan Sch Publ Hlth, Global Hlth & Populat, 90 Smith St,332-1, Boston, MA 02120 USA.
EM rsato@hsph.harvard.edu
CR Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   Belongia Edward A, 2003, Clin Med Res, V1, P87
   Bolu O, 2018, MMWR-MORBID MORTAL W, V67, P253, DOI 10.15585/mmwr.mm6708a5
   Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0
   Feldstein LR, 2017, MMWR-MORBID MORTAL W, V66, P1252, DOI 10.15585/mmwr.mm6645a3
   Francis MR, 2018, VACCINE, V36, P6559, DOI 10.1016/j.vaccine.2017.08.026
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Jegede AS, 2007, PLOS MED, V4, P417, DOI 10.1371/journal.pmed.0040073
   Kaufmann JR, 2009, HEALTH AFFAIR, V28, P1091, DOI 10.1377/hlthaff.28.4.1091
   National Bureau of Statistics (NBS) United Nations Children's Fund (UNICEF), 2017, MULT IND CLUST SURV
   National Bureau of Statistics of Nigeria United Nations Children's Fund., 2018, NIG MULT IND CLUST S
   Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Riaz A, 2018, VACCINE, V36, P5288, DOI 10.1016/j.vaccine.2018.07.024
   WHO, 2015, IMM PRACT PRACT GUID
   World Health Organization, 2018, WHO VACC PREV DIS MO
NR 16
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 63
EP 69
DI 10.1016/j.vaccine.2019.09.097
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400009
PM 31615717
OA Bronze
DA 2020-05-12
ER

PT J
AU Aun, MV
   de Almeida, FM
   Saraiva-Romanholo, BM
   Martins, MD
   Kalil, J
   Arantes-Costa, FM
   Giavina-Bianchi, P
AF Aun, Marcelo Vivolo
   de Almeida, Francine Maria
   Saraiva-Romanholo, Beatriz Mangueira
   Martins, Milton de Arruda
   Kalil, Jorge
   Arantes-Costa, Fernanda Magalhaes
   Giavina-Bianchi, Pedro
TI Diphteria-tetanus-pertussis vaccine reduces specific IgE, inflammation
   and remodelling in an animal model of mite-induced respiratory allergy
SO VACCINE
LA English
DT Article
DE Asthma; Animal model; IgE; Remodelling; Vaccine; Bordetella pertussis
ID HOUSE-DUST MITE; GROWTH-FACTOR-BETA; BORDETELLA-PERTUSSIS; AIRWAY
   INFLAMMATION; INFECTION; ASTHMA; IMMUNOTHERAPY; SENSITIZATION;
   EXACERBATION; IMMUNIZATION
AB Background: Adjuvants, such as bacterial lipopolysaccharides, have been studied to improve the efficacy of allergen-specific immunotherapy. The Bordetella pertussis (Pw) vaccine has been shown to have a protective role in ovalbumin-induced asthma models. However, its role in allergy to mites is unknown. We evaluated the effects of the diphtheria-tetanus-pertussis (DTPw) vaccine on a murine model of respiratory allergy induced by Dermatophagoides pteronyssinus (Derp).
   Methods: In a 30-day protocol, BALB/c mice were immunized subcutaneously with saline or Derp, alone or in combination with diphtheria-tetanus (DT) or DTPw vaccines (days 0, 7 and 14). Subsequently, they underwent a daily intranasal challenge with saline or Derp (days 22-28) and were then sacrificed (day 29). We evaluated serum-specific immunoglobulins, bronchoalveolar lavage (BAL) cellularity, remodelling of the lower airways, density of polymorphonuclear leukocytes (PMNs) and acidic nasal mucus content.
   Results: The animals sensitized with Derp produced high levels of specific immunoglobulins, increased density of PMNs and nasal mucus content, and elevated BAL cellularity and remodelling. Vaccines led to a reduction in IgE levels, with the Derp-DTPw group being similar to the saline groups. The vaccinated groups had reductions of BAL cellularity and remodelling, with more expressive results in the Derp-DTPw group compared to the Derp-DT group. The DT and DTPw vaccines inhibited the nasal PMN infiltrate, and DTPw modulated the production of acidic nasal mucus.
   Conclusions: The DTPw vaccine reduced serum specific IgE, nasal and pulmonary inflammation and remodelling of the lower airways. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Aun, Marcelo Vivolo; Kalil, Jorge; Giavina-Bianchi, Pedro] Univ Sao Paulo, Clin Immunol & Allergy Div, Sao Paulo, SP, Brazil.
   [Aun, Marcelo Vivolo; de Almeida, Francine Maria; Saraiva-Romanholo, Beatriz Mangueira; Martins, Milton de Arruda; Arantes-Costa, Fernanda Magalhaes] Univ Sao Paulo, Dept Internal Med, Lab Expt Therapeut LIM20, Sao Paulo, SP, Brazil.
RP Aun, MV (reprint author), Ave Brigadeiro Luis Antonio 4267, BR-01401002 Sao Paulo, SP, Brazil.
EM marcelovivoloaun@gmail.com
RI KALIL, JORGE/C-8029-2012
OI KALIL, JORGE/0000-0001-8415-4274
FU National Institute of Science and Technology (INCT); Sao Paulo Research
   Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)
FX This work was supported by National Institute of Science and Technology
   (INCT) and Sa similar to o Paulo Research Foundation (FAPESP).
CR Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022
   Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088
   Aun MV, 2015, EINSTEIN-SAO PAULO, V13, P560, DOI 10.1590/S1679-45082015AO3389
   Barnard A, 1996, IMMUNOLOGY, V87, P372, DOI 10.1046/j.1365-2567.1996.497560.x
   Blanco-Quiros A, 2005, PEDIAT ALLERG IMM-UK, V16, P637, DOI 10.1111/j.1399-3038.2005.00331.x
   Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x
   Capili CR, 2012, J ALLERGY CLIN IMMUN, V129, P957, DOI 10.1016/j.jaci.2011.11.020
   Casale TB, 2014, J ALLERGY CLIN IMMUN, V133, P612, DOI 10.1016/j.jaci.2014.01.007
   Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034
   Cui YB, 2013, MOL BIOL REP, V40, P681, DOI 10.1007/s11033-012-2108-8
   Dong W, 2003, TOXICOL SCI, V72, P113, DOI 10.1093/toxsci/kfg015
   Drachenberg K J, 2003, Allergol Immunopathol (Madr), V31, P270
   Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x
   Ennis DP, 2005, CLIN DIAGN LAB IMMUN, V12, P409, DOI 10.1128/CDLI.12.3.409-417.2005
   Ennis DP, 2005, IMMUNOL LETT, V97, P91, DOI 10.1016/j.imlet.2004.10.011
   Ennis DP, 2004, CLIN EXP ALLERGY, V34, P1488, DOI 10.1111/j.1365-2222.2004.02042.x
   Evans Jay T, 2003, Expert Rev Vaccines, V2, P219, DOI 10.1586/14760584.2.2.219
   Fattouh R, 2011, AM J RESP CRIT CARE, V183, P179, DOI 10.1164/rccm.200905-0736OC
   Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064
   Gandhi VD, 2013, CURR ALLERGY ASTHM R, V13, P262, DOI 10.1007/s11882-013-0349-9
   Giavina-Bianchi P, 2016, J ASTHMA ALLERGY, V9, P93, DOI 10.2147/JAA.S81541
   Gruber C, 2006, ALLERGY, V61, P820, DOI 10.1111/j.1398-9995.2006.01093.x
   Hagner S, 2016, INT ARCH ALLERGY IMM, V170, P22, DOI 10.1159/000446155
   Halwani R, 2011, AM J RESP CELL MOL, V44, P127, DOI 10.1165/rcmb.2010-0027TR
   Hizume DC, 2012, RESP PHYSIOL NEUROBI, V181, P167, DOI 10.1016/j.resp.2012.03.005
   Jacobsen EA, 2014, CLIN EXP ALLERGY, V44, P1119, DOI 10.1111/cea.12358
   Johnson JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016175
   Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC
   Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047
   Kendirli SG, 2009, ALLERGOL IMMUNOPATH, V37, P21, DOI 10.1016/S0301-0546(09)70247-2
   Kim YS, 2004, IMMUNOLOGY, V112, P624, DOI 10.1111/j.1365-2567.2004.01880.x
   Lambert AL, 1998, AM J RESP CRIT CARE, V157, P1991, DOI 10.1164/ajrccm.157.6.9704057
   Lee YG, 2015, AM J RESP CELL MOL, V52, P772, DOI 10.1165/rcmb.2014-0255OC
   Liu YC, 2014, INT J BIOL SCI, V10, P520, DOI 10.7150/ijbs.8879
   Nagatal Makoto, 2010, Allergology International, V59, P15, DOI 10.2332/allergolint.09-RAI-0150
   PAUWELS R, 1983, ALLERGY, V38, P239, DOI 10.1111/j.1398-9995.1983.tb01617.x
   Prado CM, 2019, PULM MED, V2019, DOI 10.1155/2019/4781528
   Quintilio W, 2009, VACCINE, V27, P4219, DOI 10.1016/j.vaccine.2009.04.047
   REDHEAD K, 1993, INFECT IMMUN, V61, P3190, DOI 10.1128/IAI.61.8.3190-3198.1993
   Ryan M, 1997, DEV BIOLOGICALS, V89, P297
   Siddiqui S, 2008, CLIN EXP ALLERGY, V38, P1381, DOI 10.1111/j.1365-2222.2008.03009.x
   Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001
   Wheeler AW, 2001, INT ARCH ALLERGY IMM, V126, P135, DOI 10.1159/000049504
   WJST M, 1994, ANN ALLERGY, V73, P450
   Yang Y, 2014, ALLERGY, V69, P699, DOI 10.1111/all.12403
   Yoshizaki K, 2014, EFFECTS PARTICIPATIO
NR 46
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 70
EP 78
DI 10.1016/j.vaccine.2019.09.095
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400010
PM 31630941
OA Bronze
DA 2020-05-12
ER

PT J
AU Bernstein, DI
   Morello, CS
   Cardin, RD
   Bravo, FJ
   Kraynyak, KA
   Spector, DH
AF Bernstein, David I.
   Morello, Christopher S.
   Cardin, Rhonda D.
   Bravo, Fernando J.
   Kraynyak, Kimberly A.
   Spector, Deborah H.
TI A vaccine containing highly purified virus particles in adjuvant
   provides high level protection against genital infection and disease in
   guinea pigs challenged intravaginally with homologous and heterologous
   strains of herpes simplex virus type 2
SO VACCINE
LA English
DT Article
DE Genital herpes; Herpes simplex virus; Vaccine; Guinea pigs; Inactivated
   virus adjuvanted vaccine
ID GLYCOPROTEIN VACCINE; ANTIBODY-RESPONSE; HSV-2 INFECTION; STATES; TRIAL
AB Infection with Herpes Simplex Viruses (HSVs) represents a significant health burden worldwide with HSV-1 and HSV-2 causing genital disease and HSV-2 contributing to human immunodeficiency virus acquisition. Despite great need, there is currently no licensed vaccine against HSV. In this report, we evaluated the protective efficacy of a vaccine containing highly purified, inactivated HSV-2 particles (with and without additional recombinant glycoprotein D) formulated with a monophosphoryl lipid A/Alhydrogel adjuvant in a guinea pig HSV genital model. The key results from 3 independent studies were: (1) vaccination consistently provided significant 3-3.5 Log10 reductions in vaginal HSV-2 titers on day 2 postchallenge; (2) following homologous or heterologous challenge with two U.S. isolates, all vaccine groups showed complete protection against lesion formation, significant 3 Log10 reductions in day 2 virus shedding, enhanced virus clearance, significant reductions in HSV-2 DNA within ganglia, and no detectable shedding (<2 PFU) or latent viral DNA in some immunized animals; (3) following challenge with a third heterologous strain, vaccination provided complete protection against primary and recurrent lesions, significant reductions in primary virus shedding, a 50% reduction in recurrent shedding days, and undetectable latent virus in the ganglia and spinal cords of most animals; and (4) adding glycoprotein D provided no enhanced protection relative to that elicited by the inactivated HSV-2 particles alone. Together, these data provide strong support for further development of this exceedingly protective and highly feasible vaccine candidate for human trials. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bernstein, David I.; Cardin, Rhonda D.; Bravo, Fernando J.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH USA.
   [Morello, Christopher S.; Kraynyak, Kimberly A.; Spector, Deborah H.] Univ Calif San Diego, Dept Cellular & Mol Med, San Diego, CA 92103 USA.
   [Spector, Deborah H.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA.
   [Cardin, Rhonda D.] Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA.
   [Kraynyak, Kimberly A.] Inovio, Plymouth Meeting, PA USA.
RP Spector, DH (reprint author), Univ Calif San Diego, Dept Cellular & Mol Med, San Diego, CA 92103 USA.; Spector, DH (reprint author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA.; Morello, CS (reprint author), Emergent BioSolut, San Diego, CA 92121 USA.
EM csmorello@att.net; dspector@ucsd.edu
FU NIH NIAID, United States [1R21 AI073585]; King Abdulaziz City for
   Science and Technology (KACST) in Saudi Arabia; NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201700017I]
FX This work was supported by NIH NIAID, United States grant 1R21 AI073585
   (D.H.S.) and King Abdulaziz City for Science and Technology (KACST) in
   Saudi Arabia. Study #3 was supported by NIAID contract
   #HHSN272201700017I (D.I.B., R.D.C).
CR Awasthi S, 2017, HUM VACC IMMUNOTHER, V13, P2785, DOI 10.1080/21645515.2017.1323604
   Awasthi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006141
   Awasthi S, 2014, J INFECT DIS, V210, P571, DOI 10.1093/infdis/jiu177
   Baldridge JR, 1999, METHODS, V19, P103, DOI 10.1006/meth.1999.0834
   Belshe RB, 2014, J INFECT DIS, V209, P828, DOI 10.1093/infdis/jit651
   Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151
   Bernard MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121518
   Bernstein DI, 2019, VACCINE, V37, P6470, DOI 10.1016/j.vaccine.2019.08.077
   Bernstein DI, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0129-1
   Bernstein DI, 2019, VACCINE, V37, P61, DOI 10.1016/j.vaccine.2018.11.042
   Bernstein DI, 2013, CLIN INFECT DIS, V56, P344, DOI 10.1093/cid/cis891
   Bernstein DI, 2011, VACCINE, V29, P2071, DOI 10.1016/j.vaccine.2011.01.005
   BERNSTEIN DI, 1986, J GEN VIROL, V67, P1601, DOI 10.1099/0022-1317-67-8-1601
   Bourne N, 2005, J INFECT DIS, V192, P2117, DOI 10.1086/498247
   Bradley H, 2014, J INFECT DIS, V209, P325, DOI 10.1093/infdis/jit458
   BURKE RL, 1992, CURR TOP MICROBIOL, V179, P137
   Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331
   Delagrave S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046714
   Dropulic LK, 2019, J INFECT DIS, V220, P990, DOI 10.1093/infdis/jiz225
   Dudek TE, 2011, J INFECT DIS, V203, P1434, DOI 10.1093/infdis/jir047
   EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357
   GUDNADOTTIR M, 1964, EXP NEUROL, V9, P85, DOI 10.1016/0014-4886(64)90008-1
   Hensel MT, 2017, J VIROL, V91, DOI 10.1128/JVI.02257-16
   Hook LM, 2019, VACCINE, V37, P664, DOI 10.1016/j.vaccine.2018.11.076
   MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653
   Morello CS, 2012, VACCINE, V30, P6541, DOI 10.1016/j.vaccine.2012.08.049
   Morello CS, 2011, J VIROL, V85, P3461, DOI 10.1128/JVI.02521-10
   MYERS MG, 1988, ANTIVIR RES, V10, P83, DOI 10.1016/0166-3542(88)90016-2
   O'Keeffe R, 1998, BIOTECHNOL BIOENG, V57, P262, DOI 10.1002/(SICI)1097-0290(19980205)57:3<262::AID-BIT2>3.0.CO;2-F
   O'Keeffe RS, 1999, BIOTECHNOL BIOENG, V62, P537, DOI 10.1002/(SICI)1097-0290(19990305)62:5<537::AID-BIT5>3.0.CO;2-1
   Skoberne M, 2013, J VIROL, V87, P3930, DOI 10.1128/JVI.02745-12
   Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915
   STANBERRY LR, 1987, J INFECT DIS, V155, P914, DOI 10.1093/infdis/155.5.914
   Thurman AR, 2012, INT J STD AIDS, V23, P613, DOI 10.1258/ijsa.2012.011356
   Todd J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059037
   Torrone EA, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002511
   Willis SH, 1998, J VIROL, V72, P5937, DOI 10.1128/JVI.72.7.5937-5947.1998
   Xu F., 2010, Morbidity and Mortality Weekly Report, V59, P456
   Zhang PW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101373
NR 39
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 79
EP 89
DI 10.1016/j.vaccine.2019.09.090
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400011
PM 31611098
OA Bronze
DA 2020-05-12
ER

PT J
AU Lee, B
   Dickson, DM
   Alam, M
   Afreen, S
   Kader, A
   Afrin, F
   Ferdousi, T
   Damon, CF
   Gullickson, SK
   McNeal, MM
   Bak, DM
   Tolba, M
   Carmolli, MP
   Taniuchi, M
   Haque, R
   Kirkpatrick, BD
AF Lee, Benjamin
   Dickson, Dorothy M.
   Alam, Masud
   Afreen, Sajia
   Kader, Abdul
   Afrin, Faria
   Ferdousi, Tania
   Damon, Christina F.
   Gullickson, Soyeon K.
   McNeal, Monica M.
   Bak, Daniel M.
   Tolba, Mona
   Carmolli, Marya P.
   Taniuchi, Mami
   Haque, Rashidul
   Kirkpatrick, Beth D.
TI The effect of increased inoculum on oral rotavirus vaccine take among
   infants in Dhaka, Bangladesh: A double-blind, parallel group,
   randomized, controlled trial
SO VACCINE
LA English
DT Article
DE Rotavirus; Oral vaccine; Vaccine underperformance; Immunogenicity;
   Vaccine shedding; Vaccine take
ID LIVE ATTENUATED TETRAVALENT; PLACEBO-CONTROLLED TRIAL;
   BOVINE-HUMAN-REASSORTANT; POLIOVIRUS VACCINES; IMMUNOGENICITY; SAFETY;
   EFFICACY; RIX4414; CHILDREN; GASTROENTERITIS
AB Background: Oral, live-attenuated rotavirus vaccines suffer from impaired immunogenicity and efficacy in low-income countries. Increasing the inoculum of vaccine might improve vaccine response, but this approach has been inadequately explored in low-income countries.
   Methods: We performed a double-blind, parallel group, randomized controlled trial from June 2017 through June 2018 in the urban Mirpur slum of Dhaka, Bangladesh to compare vaccine take (primary outcome) among healthy infants randomized to receive either the standard dose or double the standard dose of oral Rotarix (GlaxoSmithKline) vaccine at 6 and 10 weeks of life. Infants with congenital malformations, birth or enrollment weight <2000 gm, known immunocompromising condition, enrollment in another vaccine trial, or other household member enrolled in the study were excluded. Infants were randomized using random permuted blocks. Vaccine take was defined as detection of post-vaccination fecal vaccine shedding by real-time reverse transcription polymerase chain reaction with sequence confirmation or plasma rotavirus-specific immunoglobulin A (RV-IgA) seroconversion 4 weeks following the second dose.
   Results: 220 infants were enrolled and randomized (110 per group). 97 standard-dose and 92 high-dose infants completed the study per-protocol. For the primary outcome, no significant difference was observed between groups: vaccine take occurred in 62 (67%) high-dose infants versus 69 (71%) standard-dose infants (RR 0.92, 95% CI 0.67-1.24). However, in post-hoc analysis, children with confirmed vaccine replication had significantly increased RV-IgA responses, independent of the intervention. No significant adverse events related to study participation were detected.
   Conclusions: Administration of double the standard dose of an oral, live-attenuated rotavirus vaccine (Rotarix) did not improve vaccine take among infants in urban Dhaka, Bangladesh. However, improved immunogenicity in children with vaccine replication irrespective of initial inoculum provides further evidence for the need to promote in-host replication and improved gut health to improve oral vaccine response in low-income settings. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lee, Benjamin; Dickson, Dorothy M.; Damon, Christina F.; Gullickson, Soyeon K.; Bak, Daniel M.; Tolba, Mona; Carmolli, Marya P.; Kirkpatrick, Beth D.] Univ Vermont, Larner Coll Med, UVM Vaccine Testing Ctr, Burlington, VT 05405 USA.
   [Lee, Benjamin] Univ Vermont, Larner Coll Med, Dept Pediat, Burlington, VT 05405 USA.
   [Dickson, Dorothy M.; Damon, Christina F.; Gullickson, Soyeon K.; Bak, Daniel M.; Tolba, Mona; Carmolli, Marya P.; Kirkpatrick, Beth D.] Univ Vermont, Lamer Coll Med, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA.
   [Alam, Masud; Afreen, Sajia; Kader, Abdul; Afrin, Faria; Ferdousi, Tania; Haque, Rashidul] Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci & Parasitol Lab, Dhaka 1212, Bangladesh.
   [McNeal, Monica M.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA.
   [McNeal, Monica M.] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA.
   [Taniuchi, Mami] Univ Virginia, Dept Med, Div Infect Dis & Int Hlth, Charlottesville, VA 22908 USA.
RP Lee, B (reprint author), Univ Vermont, Larner Coll Med, UVM Vaccine Testing Ctr, Burlington, VT 05405 USA.; Lee, B (reprint author), Univ Vermont, Larner Coll Med, Dept Pediat, Burlington, VT 05405 USA.
EM blee7@uvm.edu
OI Lee, Benjamin/0000-0001-7213-5631
FU Charles H. Hood Foundation Child Health Research Awards Program;
   Thrasher Research Fund Early Career Award Program; University of Vermont
   Internal Grants Program
FX This work was supported by the Charles H. Hood Foundation Child Health
   Research Awards Program, the Thrasher Research Fund Early Career Award
   Program, and the University of Vermont Internal Grants Program, to BL.
CR Ali SA, 2014, J INFECT DIS, V210, P1772, DOI 10.1093/infdis/jiu335
   Anderson EJ, 2008, LANCET INFECT DIS, V8, P642, DOI 10.1016/S1473-3099(08)70231-7
   Angel J, 2014, HUM VACC IMMUNOTHER, V10, P3659, DOI 10.4161/hv.34361
   Armah GE, 2018, J INFECT DIS
   Bautista-Marquez A, 2016, VACCINE, V34, P5284, DOI 10.1016/j.vaccine.2016.09.006
   Bernstein DI, 1999, LANCET, V354, P287, DOI 10.1016/S0140-6736(98)12106-2
   Bernstein DI, 1998, VACCINE, V16, P381, DOI 10.1016/S0264-410X(97)00210-7
   Bhandari N, 2009, J INFECT DIS, V200, P421, DOI 10.1086/600104
   Bines JE, 2018, NEW ENGL J MED, V378, P719, DOI 10.1056/NEJMoa1706804
   Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186
   Church JA, 2019, LANCET INFECT DIS, V19, P203, DOI 10.1016/S1473-3099(18)30602-9
   Church JA, 2018, FUTURE MICROBIOL, V13, P1055, DOI 10.2217/fmb-2018-0016
   Colgate ER, 2016, CLIN INFECT DIS, V63, P634, DOI 10.1093/cid/ciw346
   De Vos Beatrice, 2004, Pediatr Infect Dis J, V23, pS179
   Dennehy PH, 2005, PEDIATR INFECT DIS J, V24, P481, DOI 10.1097/01.inf.0000164763.55558.71
   Dhingra MS, 2014, VACCINE, V32, pA117, DOI 10.1016/j.vaccine.2014.03.069
   Emperador DM, 2016, CLIN INFECT DIS, V62, P150, DOI 10.1093/cid/civ807
   Glass RI, 2014, J INFECTION, V68, pS9, DOI 10.1016/j.jinf.2013.09.010
   Groome MJ, 2017, LANCET INFECT DIS
   Jiang BM, 2008, VACCINE, V26, P6754, DOI 10.1016/j.vaccine.2008.10.008
   Jonesteller CL, 2017, CLIN INFECT DIS OFFI
   Kompithra RZ, 2014, VACCINE, V32, pA129, DOI 10.1016/j.vaccine.2014.03.002
   Lee B, 2018, CLIN INFECT DIS, V67, P186, DOI 10.1093/cid/ciy076
   Lee B, 2018, J INFECT DIS, V217, P1399, DOI 10.1093/infdis/jiy054
   Levine MM, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-129
   Lewnard JA, 2017, J INFECT DIS, V216, P317, DOI 10.1093/infdis/jix310
   Liu J, 2016, LANCET, V388, P1291, DOI 10.1016/S0140-6736(16)31529-X
   Liu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158199
   Liu J, 2011, J CLIN VIROL, V50, P308, DOI 10.1016/j.jcv.2010.12.009
   Madhi SA, 2012, VACCINE, V30, pA44, DOI 10.1016/j.vaccine.2011.08.080
   Parker EPK, 2018, FUTURE MICROBIOL, V13, P97, DOI 10.2217/fmb-2017-0128
   Patel M, 2013, J INFECT DIS, V208, P284, DOI 10.1093/infdis/jit166
   Patel M, 2012, VACCINE, V30, pA30, DOI 10.1016/j.vaccine.2011.11.093
   Paul A, 2014, VACCINE, V32, P3094, DOI 10.1016/j.vaccine.2014.03.013
   Phua KB, 2005, J INFECT DIS, V192, pS6, DOI 10.1086/431511
   Pollock L, 2018, CLIN INFECT DIS OFFI
   Salinas M, 2005, PEDIATR INFECT DIS J, V24, P807, DOI 10.1097/01.inf.0000178294.13954.a1
   SIMANJUNTAK CH, 1993, J INFECT DIS, V168, P1169, DOI 10.1093/infdis/168.5.1169
   Steele AD, 2010, J INFECT DIS, V202, pS93, DOI 10.1086/653550
   SUHARYONO, 1992, LANCET, V340, P689, DOI 10.1016/0140-6736(92)92231-4
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Vesikari T, 2004, VACCINE, V22, P2836, DOI 10.1016/j.vaccine.2004.01.044
   Vesikari T, 2006, VACCINE, V24, P4821, DOI 10.1016/j.vaccine.2006.03.025
   VIEW-hub.org, 2019, RV VACC INTR VACC PR
   WARD RL, 1986, J INFECT DIS, V154, P871, DOI 10.1093/infdis/154.5.871
   Zade JK, 2014, VACCINE, V32, pA124, DOI 10.1016/j.vaccine.2014.03.003
   Zaman K, 2016, J INFECT DIS, V213, P1686, DOI 10.1093/infdis/jiw024
   Zaman K, 2009, VACCINE, V27, P1333, DOI 10.1016/j.vaccine.2008.12.059
NR 48
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 3
PY 2020
VL 38
IS 1
BP 90
EP 99
DI 10.1016/j.vaccine.2019.09.088
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA JW2MS
UT WOS:000502892400012
PM 31607603
OA Bronze
DA 2020-05-12
ER

PT J
AU Browne, SK
   Beeler, JA
   Roberts, JN
AF Browne, Sarah K.
   Beeler, Judy A.
   Roberts, Jeffrey N.
TI Summary of the Vaccines and Related Biological Products Advisory
   Committee meeting held to consider evaluation of vaccine candidates for
   the prevention of respiratory syncytial virus disease in RSV-naive
   infants
SO VACCINE
LA English
DT Article
DE Respiratory syncytial virus; RSV; Enhanced respiratory disease; ERD;
   Infants; RSV-naive; RSV vaccine
ID ENHANCED PULMONARY PATHOLOGY; COTTON RATS; CYTOKINE RESPONSES; BOVINE
   MODEL; IMMUNIZATION; CHILDREN; GLYCOPROTEIN; OPPORTUNITIES; CHALLENGES;
   ANTIBODIES
AB Respiratory syncytial virus (RSV), is a common cause of serious acute lower respiratory tract illness in infants and young children, causing substantial morbidity and mortality globally. Treatment is mainly supportive and currently there is no licensed preventive vaccine. Clinical trials conducted in the 1960s evaluating a formalin-inactivated RSV vaccine (FI-RSV) in RSV-nave infants resulted in observations of enhanced respiratory disease (ERD) following subsequent natural RSV infection in vaccinees. In these studies, infants immunized with FI-RSV had higher rates of severe RSV disease compared with controls. This outcome redirected focus on identifying the immunologic mechanisms that precipitated ERD as a prerequisite to further vaccine development. Improved understanding of the immunopathogenesis of ERD derived from animal models has stimulated development of new candidate vaccines and engendered discussions among RSV experts about the safety data needed to advance these products into the clinic, and ultimately, into the target population of RSV-naIve infants. The recognition that multiple products would soon be ready for testing in infants and children prompted the FDA to hold a Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to seek perspectives and advice of experts regarding the types and extent of preclinical and clinical data that might be needed to support testing in RSV-naIve infants for specific types of candidate RSV vaccines. Committee members agreed that, if certain conditions are met in preclinical and early clinical studies, it would be reasonable to move forward from studies in adults and older children and into clinical trials evaluating vaccine safety and efficacy in RSV-naive infants. Herein, we review and summarize perspectives on the discussion regarding recommendations for RSV vaccine development in this population.
C1 [Browne, Sarah K.; Beeler, Judy A.; Roberts, Jeffrey N.] US FDA, Off Vaccines Res & Review, Ctr Biol Res & Review, Silver Spring, MD 20993 USA.
RP Browne, SK (reprint author), US FDA, Off Vaccines Res & Review, Ctr Biol Res & Review, Silver Spring, MD 20993 USA.
EM sarah.browne@fda.hhs.gov
CR Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15
   Bates JT, 2016, VACCINE, V34, P950, DOI 10.1016/j.vaccine.2015.12.045
   CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957
   Christiaansen AF, 2016, PEDIATR RES, V80, P702, DOI 10.1038/pr.2016.130
   CONNORS M, 1992, VACCINE, V10, P475, DOI 10.1016/0264-410X(92)90397-3
   de Waal L, 2004, VACCINE, V22, P915, DOI 10.1016/j.vaccine.2003.10.008
   FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956
   Gershwin LJ, 1998, VACCINE, V16, P1225, DOI 10.1016/S0264-410X(98)80123-0
   Graham BS, 2011, IMMUNOL REV, V239, P149, DOI 10.1111/j.1600-065X.2010.00972.x
   GRAHAM BS, 1993, J IMMUNOL, V151, P2032
   KAKUK TJ, 1993, J INFECT DIS, V167, P553, DOI 10.1093/infdis/167.3.553
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954
   Killikelly AM, 2016, SCI REP-UK, V6, DOI 10.1038/srep34108
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Knudson CJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004757
   Modjarrad K, 2016, VACCINE, V34, P190, DOI 10.1016/j.vaccine.2015.05.093
   MURPHY BR, 1988, J CLIN MICROBIOL, V26, P1595, DOI 10.1128/JCM.26.8.1595-1597.1988
   MURPHY BR, 1986, J CLIN MICROBIOL, V24, P197, DOI 10.1128/JCM.24.2.197-202.1986
   NADER PR, 1968, J PEDIATR-US, V72, P22, DOI 10.1016/S0022-3476(68)80396-8
   NICHOLAS JA, 1990, J VIROL, V64, P4232, DOI 10.1128/JVI.64.9.4232-4241.1990
   Peebles R Stokes Jr, 2005, Proc Am Thorac Soc, V2, P110, DOI 10.1513/pats.200501-002AW
   Pickles RJ, 2015, J PATHOL, V235, P266, DOI 10.1002/path.4462
   Polack FP, 2003, NAT MED, V9, P1209, DOI 10.1038/nm918
   Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781
   PRINCE GA, 1986, J VIROL, V57, P721, DOI 10.1128/JVI.57.3.721-728.1986
   Prince GA, 2001, J GEN VIROL, V82, P2881, DOI 10.1099/0022-1317-82-12-2881
   Roberts JN, 2016, VACCINE, V34, P4843, DOI 10.1016/j.vaccine.2016.07.057
   Schneider-Ohrum K, 2019, J VIROL, V93, DOI 10.1128/JVI.00695-19
   Schneider-Ohrum K, 2017, J VIROL, V91, DOI 10.1128/JVI.02180-16
   Shaw CA, 2013, VACCINE, V31, P306, DOI 10.1016/j.vaccine.2012.11.006
   Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]
   Srikiatkhachorn A, 1997, J VIROL, V71, P678, DOI 10.1128/JVI.71.1.678-685.1997
   Srikiatkhachorn A, 1997, J EXP MED, V186, P421, DOI 10.1084/jem.186.3.421
   Taylor G, 2017, VACCINE, V35, P469, DOI 10.1016/j.vaccine.2016.11.054
   Taylor G, 2013, CURR TOP MICROBIOL, V372, P327, DOI 10.1007/978-3-642-38919-1_16
   Wright PF, 2007, VACCINE, V25, P7372, DOI 10.1016/j.vaccine.2007.08.014
NR 36
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 101
EP 106
DI 10.1016/j.vaccine.2019.10.048
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700001
PM 31706809
DA 2020-05-12
ER

PT J
AU Chun, JY
   Park, WB
   Kim, NJ
   Choi, EH
   Funk, S
   Oh, MD
AF Chun, June Young
   Park, Wan Beom
   Kim, Nam Joong
   Choi, Eun Hwa
   Funk, Sebastian
   Oh, Myoung-don
TI Estimating contact-adjusted immunity levels against measles in South
   Korea and prospects for maintaining elimination status
SO VACCINE
LA English
DT Article
DE Measles; Seroprevalence; Republic of Korea; Herd immunity
ID VACCINATION
AB Measles has been reemerging in South Korea since December 2018 resulting in 185 cases by September 2019.
   We calculated contact-adjusted immunity levels against measles in South Korea using national sero-prevalence data in 2014, vaccination uptake rates, and an age-specific contact matrix. We further explored options to achieve a contact-adjusted immunity level of 93% for herd immunity.
   The assessed contact-adjusted immunity level has increased from 86% in 2014 to 92% in 2018. Herd immunity could be achieved with immunizing 50% of susceptibles among birth cohorts 1999-2003 in 2018.
   Contact-adjusted immunity levels against measles have increased recently in South Korea, although they might not yet be high enough to guarantee herd immunity. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Chun, June Young; Park, Wan Beom; Kim, Nam Joong; Oh, Myoung-don] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea.
   [Choi, Eun Hwa] Seoul Natl Univ, Dept Pediat, Coll Med, Seoul, South Korea.
   [Funk, Sebastian] London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, London, England.
   [Funk, Sebastian] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Chun, June Young] Natl Canc Ctr, Dept Internal Med, Goyang, South Korea.
RP Oh, MD (reprint author), Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea.; Funk, S (reprint author), London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM sebastian.funk@lshtm.ac.uk; mdohmd@snu.ac.kr
OI Funk, Sebastian/0000-0002-2842-3406
FU Wellcome TrustWellcome Trust [210758/Z/18/Z]
FX Dr. Sebastian Funk was supported by a Wellcome Trust Senior Research
   Fellowship (210758/Z/18/Z).
CR Choe YJ, 2015, J KOREAN MED SCI, V30, pS115, DOI 10.3346/jkms.2015.30.S2.S115
   Fu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045113
   Funk S, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1413-7
   Guerra FM, 2017, LANCET INFECT DIS, V17, pE420, DOI 10.1016/S1473-3099(17)30307-9
   Ibuka Y, 2016, J EPIDEMIOL COMMUN H, V70, P162, DOI 10.1136/jech-2015-205777
   Kang HJ, 2017, VACCINE, V35, P4126, DOI 10.1016/j.vaccine.2017.06.058
   Kim ES, 2012, VACCINE, V30, P3355, DOI 10.1016/j.vaccine.2012.03.073
   Korea Ministry of Health and Welfare, 1997 STAT ANN REP
   Korea National Institute of Health, COMM DIS MONTHL REP
   Korea National Institute of Health, 2001, FIN REP NAT SER SURV
   Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   Ramsay M, 1997, 010205 EURICPCMDS
   Read JM, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0268
   World Health O, 2017, VACCINE, V37, P219, DOI [10.1016/ivaccine.2017.07.066, DOI 10.1016/IVACCINE.2017.07.066]
   World Health Organisation, WHO UNICEF COV EST 1
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 107
EP 111
DI 10.1016/j.vaccine.2019.10.040
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700002
PM 31679860
OA Green Accepted, Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Koc, OM
   Damoiseaux, J
   van Loo, IHM
   Masquillier, HIL
   Lashof, AMLO
AF Koc, Ozgur M.
   Damoiseaux, Jan
   van Loo, Inge H. M.
   Masquillier, Heloise I. L.
   Lashof, Astrid M. L. Oude
TI Case report of delayed seroprotection rather than non-response after
   primary three-dose hepatitis B vaccination
SO VACCINE
LA English
DT Article
DE Hepatitis B; Vaccine; Non-responder; Humoral Immunity; Delayed
   seroprotection
ID IMMUNOGENICITY; EFFICACY
AB We describe a delayed hepatitis B seroprotection 12 weeks after the primary vaccination schedule in a 57-year-old male with smoldering multiple myeloma. Based on undetectable anti-HBs antibodies 6 weeks after the third vaccination, the index person was previously considered to be a hepatitis B vaccine non-responder. Because hepatitis B vaccination started in the 1980s, many hepatitis B vaccine non-responders have received a revaccination regimen. If more cases of genuine delayed hepatitis B seroprotection surface in patients with hematologic malignancies, delayed seroprotection should be considered before the commencement of hepatitis B revaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Koc, Ozgur M.; Lashof, Astrid M. L. Oude] Maastricht Univ, Sch NUTRIM, Dept Med Microbiol, Med Ctr, POB 5800, NL-6202 AZ Maastricht, Netherlands.
   [Koc, Ozgur M.] Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Schiepse Bos 6, B-3600 Genk, Belgium.
   [Koc, Ozgur M.] Hasselt Univ, Fac Med & Life Sci, Martelarenlaan 42, B-3500 Hasselt, Belgium.
   [Damoiseaux, Jan] Maastricht Univ, Cent Diagnost Lab, Med Ctr, POB 5800, NL-6202 AZ Maastricht, Netherlands.
   [van Loo, Inge H. M.] Maastricht Univ, Sch CAPHRI, Dept Med Microbiol, Med Ctr, POB 5800, NL-6202 AZ Maastricht, Netherlands.
   [Masquillier, Heloise I. L.] Maastricht Univ, Dept Hematol, Med Ctr, POB 5800, NL-6202 AZ Maastricht, Netherlands.
RP Koc, OM (reprint author), Maastricht Univ, Med Ctr, Sch NUTRIM & Translat Res Metab, Dept Med Microbiol, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM o.koc@mumc.nl; jan.damoiseaux@mumc.nl; ihm.van.loo@mumc.nl;
   heloise.masquillier@mumc.nl; a.oudelashof@mumc.nl
RI Damoiseaux, Jan/B-8993-2009
CR Ackermann M, 2015, EMBO MOL MED, V7, P1388, DOI 10.15252/emmm.201505301
   Guillerey C, 2016, CELL MOL LIFE SCI, V73, P1569, DOI 10.1007/s00018-016-2135-z
   HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401
   Hahne SJM, 2012, EPIDEMIOL INFECT, V140, P1469, DOI 10.1017/S095026881100224X
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   Leonardi S, 2010, AM J GASTROENTEROL, V105, P2117, DOI 10.1038/ajg.2010.195
   Lippi G, 2010, BIOCHEM MEDICA, V20, P126
   Mendelsohn JB, 2015, EMERG THEMES EPIDEMI, V12, DOI 10.1186/s12982-015-0033-8
   Paiva B, 2011, LEUKEMIA, V25, P697, DOI 10.1038/leu.2010.320
   WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362
   Walayat S, 2015, WORLD J HEPATOL, V7, P2503, DOI 10.4254/wjh.v7.i24.2503
   Yu AS, 2006, INFECT DIS CLIN N AM, V20, P27, DOI 10.1016/j.idc.2006.01.004
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 112
EP 114
DI 10.1016/j.vaccine.2019.10.022
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700003
PM 31648909
OA Other Gold
DA 2020-05-12
ER

PT J
AU Cavalli, A
   Desario, C
   Marinaro, M
   Losurdo, M
   Camero, M
   Decaro, N
   Catella, C
   Lanave, G
   Buonavoglia, C
AF Cavalli, A.
   Desario, C.
   Marinaro, M.
   Losurdo, M.
   Camero, M.
   Decaro, N.
   Catella, C.
   Lanave, G.
   Buonavoglia, C.
TI Oral administration of modified live canine parvovirus type 2b induces
   systemic immune response
SO VACCINE
LA English
DT Article
DE Pups; Canine parvovirus; Maternally derived antibodies; Oral vaccination
ID TIME PCR ASSAY; FIELD STRAINS; VACCINE; PUPS
AB Different strategies have been proposed to overcome maternally derived antibody (MDA) interference with canine parvovirus type 2 (CPV-2) immunisation, including intranasal vaccination, which presents some practical limitations. In the present study, the results of the oral administration of a commercial CPV-2b modified live virus (MLV) vaccine in pups with MDA are reported. The CPV-2b vaccine was orally administered to 14 6-week-old pups with a bait. Blood samples and rectal swabs were collected at different days post-vaccination (dpv) to determine CPV-2 antibody titres and DNA loads. Thirteen pups were positive to serological and virological tests after the first vaccination and one pup became positive after the second vaccine administration. The findings of this study suggest that systemic immunity against CPV-2 may be achieved by the use of an MLV CPV-2b vaccine administered orally even in the presence of MDA titres that usually interfere with vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cavalli, A.; Desario, C.; Losurdo, M.; Camero, M.; Decaro, N.; Catella, C.; Lanave, G.; Buonavoglia, C.] Univ Bari Aldo Moro, Dept Vet Med, Str Prov Per Casamassima Km 3, I-70010 Valenzano, BA, Italy.
   [Marinaro, M.] Ist Super Sanita, Dept Infect Dis, Viale Regina Elena, I-00161 Rome, Italy.
RP Decaro, N (reprint author), Univ Bari, Dept Vet Med, Bari, Italy.
EM nicola.decaro@uniba.it
RI Decaro, Nicola/K-2560-2018
OI Decaro, Nicola/0000-0001-6348-7969
CR Bouvet J, 2018, VET IMMUNOL IMMUNOP, V205, P93, DOI 10.1016/j.vetimm.2018.11.001
   BURTONBOY S, 1991, VET REC, V128, P377, DOI 10.1136/vr.128.16.377
   Cavalli A, 2008, CLIN VACCINE IMMUNOL, V15, P534, DOI 10.1128/CVI.00444-07
   Cotmore SF, 2019, J GEN VIROL, V100, P367, DOI 10.1099/jgv.0.001212
   Decaro N, 2005, VET MICROBIOL, V105, P19, DOI 10.1016/j.vetmic.2004.09.018
   Decaro N, 2006, J VIROL METHODS, V138, P10, DOI 10.1016/j.jviromet.2006.07.011
   Decaro N, 2006, J VIROL METHODS, V133, P92, DOI 10.1016/j.jviromet.2005.10.026
   Decaro N, 2006, J VIROL METHODS, V136, P65, DOI 10.1016/j.jviromet.2006.03.030
   Decaro N, 2017, VET J, V221, P23, DOI 10.1016/j.tvjl.2017.01.020
   Decaro N, 2014, VACCINE, V32, P3850, DOI 10.1016/j.vaccine.2014.04.050
   Decaro N, 2012, VET MICROBIOL, V155, P1, DOI 10.1016/j.vetmic.2011.09.007
   Freisl M, 2017, VET J, V219, P15, DOI 10.1016/j.tvjl.2016.11.011
   Greene CE, 2012, INFECT DIS DOG CAT, P67
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Martella V, 2005, CLIN DIAGN LAB IMMUN, V12, P1243, DOI 10.1128/CDLI.12.10.1243-1245.2005
NR 15
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 115
EP 118
DI 10.1016/j.vaccine.2019.10.016
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700004
PM 31628031
DA 2020-05-12
ER

PT J
AU Li, YW
   Zhu, PF
   Wu, MF
   Zhang, YQ
   Li, L
AF Li, Yaowei
   Zhu, Pengfei
   Wu, Meifen
   Zhang, Yiqing
   Li, Li
TI Immunogenicity and safety of human papillomavirus vaccine coadministered
   with other vaccines in individuals aged 9-25 years: A systematic review
   and meta-analysis
SO VACCINE
LA English
DT Review
DE Human papillomavirus; Vaccines; Immunogenicity; Adverse effects;
   Concomitant; Meta-analysis
ID COMBINED HEPATITIS-A; B-VACCINE; AS04-ADJUVANTED VACCINE;
   CERVICAL-CANCER; GENOTYPE ATTRIBUTION; ADVISORY-COMMITTEE;
   UNITED-STATES; ADOLESCENTS; DIPHTHERIA; PERTUSSIS
AB Introduction: Adolescents and young adults are at a high risk of developing human papillomavirus (HPV) infections, which can be prevented with the use of vaccines. Moreover, a combined immunization strategy for administration of HPV vaccines with other routine vaccines may lead to better compliance. We aim to comprehensively evaluate immunogenicity and safety in the case of concomitantly administered HPV vaccine in individuals aged 9-25 years.
   Methods: Relevant studies, published up to December 27, 2018, were identified through searches of Medline/PubMed, EMBASE, Web of Knowledge. The pooled relative risk (RR) of immunogenicity and safety information pertaining to the concomitant administration of HPV vaccines with other routine vaccines in healthy participants aged 9-25 years were evaluated.
   Results: A total of 13 papers (11,657 participants) were included in this meta-analysis. The analyses showed that, between the concomitant and nonconcomitant administration groups, the seroconversion rate for the specific antibodies against all HPV types (type 16-, 18-, 6-, 11-, 31-, 33-, 45-, 52-, and 58) were the same (the pooled RR = 1.00, 95% confidence interval (CI) of 1.00-1.00); for the bivalent HPV (2vHPV) vaccine, the risks of local adverse events showed no significant difference (the pooled RR = 1.00, 95%CI: 0.97-1.04), and the risks of systemic adverse events were almost similar (the pooled RR =1.10, 95% CI: 1.03-1.18); for the non-bivalent HPV (4vHPV and 9vHPV) vaccines, the risks of local adverse events were slightly higher in the concomitant administration groups (the pooled RR =1.31, 95%CI: 1.17-1.47), and the risks of systemic adverse events were higher in the concomitant administration groups (the pooled RR = 2.09, 95% CI: 1.69-2.59).
   Conclusions: We believe that the concomitant administration of other vaccines along with HPV vaccine is acceptable and there is no interference with the immune response to HPV vaccine. Concomitant vaccine administration has the potential to minimize the number of vaccination visits, leading to increased compliance, hence more effective disease prevention. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Yaowei; Li, Li] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Gynecol Oncol,Minist Educ, Key Lab Early Prevent & Treatment Reg High Freque, Nanning, Guangxi, Peoples R China.
   [Li, Yaowei; Zhu, Pengfei; Wu, Meifen; Zhang, Yiqing] Shangyu Peoples Hosp, Dept Gynecol & Obstet, Shangyu, Zhejiang, Peoples R China.
RP Li, L (reprint author), Guangxi Med Univ, Affiliated Tumor Hosp, Dept Gynecol Oncol, Nanning 530021, Peoples R China.
EM lili@gxmu.edu.cn
FU Natural Science Foundation of GuangxiNational Natural Science Foundation
   of Guangxi Province [2014jjAA40673]; Science and Technology Development
   Project of Guangxi [GuiKeGong14124004]
FX This study was funded by the Natural Science Foundation of Guangxi (NO.
   2014jjAA40673) and the Science and Technology Development Project of
   Guangxi (NO. GuiKeGong14124004).
CR Alemany L, 2015, INT J CANCER, V136, P98, DOI 10.1002/ijc.28963
   Arguedas A, 2010, VACCINE, V28, P3171, DOI 10.1016/j.vaccine.2010.02.045
   Bilukha Oleg O., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Bonanni Paolo, 2015, Ther Adv Vaccines, V3, P3, DOI 10.1177/2051013614557476
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Broder Karen R., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003
   Collins S, 2002, BJOG-INT J OBSTET GY, V109, P96, DOI 10.1111/j.1471-0528.2002.01053.x
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Garcia-Sicilia J, 2010, J ADOLESCENT HEALTH, V46, P142, DOI 10.1016/j.jadohealth.2009.11.205
   Garland SM, 2009, J INFECT DIS, V199, P805, DOI 10.1086/597071
   Gilca V, 2014, HUM VACC IMMUNOTHER, V10, P2438, DOI 10.4161/hv.29617
   HAUSEN HZ, 1989, CANCER RES, V49, P4677
   Herweijer E, 2018, VACCINE, V36, P1917, DOI 10.1016/j.vaccine.2018.02.097
   Joura EA, 2014, CANCER EPIDEM BIOMAR, V23, P1997, DOI 10.1158/1055-9965.EPI-14-0410
   Kavanagh K, 2017, LANCET INFECT DIS, V17, P1293, DOI 10.1016/S1473-3099(17)30468-1
   Kjaer SK, 2018, CLIN INFECT DIS, V66, P339, DOI 10.1093/cid/cix797
   Konno R, 2018, VACCINE, V36, P7913, DOI 10.1016/j.vaccine.2018.05.048
   Kosalaraksa P, 2015, PEDIATR INFECT DIS J, V34, P627, DOI 10.1097/INF.0000000000000694
   Lehtinen M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-015867
   Luostarinen T, 2018, INT J CANCER, V142, P2186, DOI 10.1002/ijc.31231
   Machalek DA, 2018, J INFECT DIS, V217, P1590, DOI 10.1093/infdis/jiy075
   Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Mesher D, 2018, J INFECT DIS, V218, P911, DOI 10.1093/infdis/jiy249
   Middleman AB, 2006, J ADOLESCENT HEALTH, V38, P321, DOI 10.1016/j.jadohealth.2006.01.002
   Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873
   Moscicki AB, 1996, OBSTET GYN CLIN N AM, V23, P675
   Noronha AS, 2014, VACCINE, V32, P2670, DOI 10.1016/j.vaccine.2013.12.037
   Oliver SE, 2017, J INFECT DIS, V216, P594, DOI 10.1093/infdis/jix244
   Pedersen C, 2012, J ADOLESCENT HEALTH, V50, P38, DOI 10.1016/j.jadohealth.2011.10.009
   Pitisuttithum P, 2015, EXPERT REV VACCINES, V14, P1405, DOI 10.1586/14760584.2015.1089174
   Rambout L, 2014, PREV MED, V58, P22, DOI 10.1016/j.ypmed.2013.10.009
   Reisinger KS, 2010, PEDIATRICS, V125, P1142, DOI 10.1542/peds.2009-2336
   Rivera L, 2018, VACCINE, V36, P3967, DOI 10.1016/j.vaccine.2018.05.051
   Schilling A, 2015, PEDIATRICS, V136, pE563, DOI 10.1542/peds.2014-4199
   Schmeink CE, 2011, VACCINE, V29, P9276, DOI 10.1016/j.vaccine.2011.08.037
   Senders S, 2016, PEDIATR INFECT DIS J, V35, P548, DOI 10.1097/INF.0000000000001072
   Serrano B, 2015, EUR J CANCER, V51, P1732, DOI 10.1016/j.ejca.2015.06.001
   Serrano B, 2012, INFECT AGENTS CANCER, V7, DOI 10.1186/1750-9378-7-38
   Small W, 2017, CANCER-AM CANCER SOC, V123, P2404, DOI 10.1002/cncr.30667
   Steben M, 2018, J MED VIROL, V90, P592, DOI 10.1002/jmv.24968
   Sterbenc A, 2018, ACTA DERMATOVEN ALP, V27, P193, DOI 10.15570/actaapa.2018.40
   Vesikari T, 2010, PEDIATR INFECT DIS J, V29, P314, DOI 10.1097/INF.0b013e3181c177fb
   Wellings K, 2006, LANCET, V368, P1706, DOI 10.1016/S0140-6736(06)69479-8
   Wheeler CM, 2008, VACCINE, V26, P686, DOI 10.1016/j.vaccine.2007.11.043
   Wheeler CM, 2011, PEDIATR INFECT DIS J, V30, pE225, DOI 10.1097/INF.0b013e31822d28df
   Winer RL, 2003, AM J EPIDEMIOL, V157, P218, DOI 10.1093/aje/kwf180
   World Health Organization, 2018, VACC NAT IMM PROGR U
NR 49
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 119
EP 134
DI 10.1016/j.vaccine.2019.10.092
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700005
PM 31831220
DA 2020-05-12
ER

PT J
AU Vekemans, J
   Brennan, MJ
   Hatherill, M
   Schrager, L
   Fritzell, B
   Rutkowski, K
   De Vos, B
   Zignol, M
   Thiry, G
   Ginsberg, AM
   Walker, B
AF Vekemans, Johan
   Brennan, Michael James
   Hatherill, Mark
   Schrager, Lewis
   Fritzell, Bernard
   Rutkowski, Kathryn
   De Vos, Beatrice
   Zignol, Matteo
   Thiry, Georges
   Ginsberg, Ann M.
   Walker, Barry
TI Preferred product characteristics for therapeutic vaccines to improve
   tuberculosis treatment outcomes: Key considerations from World Health
   Organization consultations
SO VACCINE
LA English
DT Review
DE Tuberculosis; Mycobacterium tuberculosis; Vaccines; Immunotherapeutic;
   Prevention; Relapse
ID MYCOBACTERIUM-TUBERCULOSIS; BEDAQUILINE; RESISTANCE; RELAPSE; HISTORY
AB Treating tuberculosis (TB) requires a multidrug course of treatment lasting 6 months, or longer for drug-resistant TB, which is difficult to complete and often not well tolerated. Treatment failure and recurrence after end-of-treatment can have devastating consequences, including progressive debilitation, death, the transmission of Mycobacterium tuberculosis - the infectious agent responsible for causing TB - to others, and may be associated with the development of drug-resistant TB. The burden on health systems is important, with severe economic consequences. Vaccines have the potential to serve as immunotherapeutic adjuncts to antibiotic treatment regimens for TB. A therapeutic vaccine for TB patients, administered towards completion of a prescribed course of drug therapy or at certain time(s) during treatment, could improve outcomes through immune-mediated control and even clearance of bacteria, potentially prevent re-infection, and provide an opportunity to shorten and simplify drug treatment regimens. The preferred product characteristics (PPC) for therapeutic TB vaccines described in this document are intended to provide guidance to scientists, funding agencies, public and private sector organizations developing such vaccine candidates. This document presents potential clinical end-points for evidence generation and discusses key considerations about potential clinical development strategies. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Vekemans, Johan; Schrager, Lewis; Zignol, Matteo] WHO, Geneva, Switzerland.
   [Hatherill, Mark] Univ Cape Town, South African TB Vaccine Initiat, Cape Town, South Africa.
   [Fritzell, Bernard; De Vos, Beatrice; Thiry, Georges; Walker, Barry] TB Vaccine Initiat, Lelystad, Netherlands.
   [Rutkowski, Kathryn; Ginsberg, Ann M.] Int Aids Vaccine Initiat, New York, NY USA.
RP Vekemans, J (reprint author), WHO, Geneva, Switzerland.
EM vekemansj@who.int
FU Tuberculosis Vaccine Initiative, Lelystad, The NetherlandsNetherlands
   Government
FX Tuberculosis Vaccine Initiative, Lelystad, The Netherlands
CR Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285
   [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
   [Anonymous], 2018, GLOB TUB REP 2018
   Cardona PJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01536
   Chahar Mamta, 2018, Indian J Tuberc, V65, P335, DOI 10.1016/j.ijtb.2018.08.004
   Coler RN, 2013, J INFECT DIS, V207, P1242, DOI 10.1093/infdis/jis425
   Daniel TM, 2011, INT J TUBERC LUNG D, V15, P161
   Daniel TM, 2006, RESP MED, V100, P1862, DOI 10.1016/j.rmed.2006.08.006
   Diacon AH, 2014, NEW ENGL J MED, V371, P723, DOI 10.1056/NEJMoa1313865
   Diel R, 2014, RESP MED, V108, P1677, DOI 10.1016/j.rmed.2014.09.021
   Gillard P, 2016, TUBERCULOSIS, V100, P118, DOI 10.1016/j.tube.2016.07.005
   Grose MJ, 2011, HEALTH PLACE, V17, P94, DOI 10.1016/j.healthplace.2010.08.018
   Huang CY, 2017, HUM VACC IMMUNOTHER, V13, P1960, DOI 10.1080/21645515.2017.1335374
   Imperial MZ, 2018, NAT MED, V24, P1708, DOI 10.1038/s41591-018-0224-2
   Kim MS, 2014, CURR APPL PHYS, V14, P1, DOI 10.1016/j.cap.2013.10.008
   Luabeya AKK, 2015, VACCINE, V33, P4130, DOI 10.1016/j.vaccine.2015.06.051
   Mantell BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019831
   Moodley R, 2016, EUR RESPIR REV, V25, DOI 10.1183/16000617.0080-2015
   Munro SA, 2007, PLOS MED, V4, P1230, DOI 10.1371/journal.pmed.0040238
   Murray JF, 2015, ANN AM THORAC SOC, V12, P1749, DOI 10.1513/AnnalsATS.201509-632PS
   Nell AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089612
   Nunn AJ, 2010, INT J TUBERC LUNG D, V14, P241
   Orme IM, 2015, NAT IMMUNOL, V16, P57, DOI 10.1038/ni.3048
   Perciaccante Antonio, 2018, Infez Med, V26, P280
   Pym AS, 2016, EUR RESPIR J, V47, P564, DOI 10.1183/13993003.00724-2015
   Ravimohan S, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0077-2017
   ROOK GAW, 1991, TUBERCLE, V72, P13, DOI 10.1016/0041-3879(91)90019-O
   Schrager LK, 2018, LANCET INFECT DIS, V18, P828, DOI 10.1016/S1473-3099(18)30421-3
   Schrager LK, 2019, F1000RES, V7, P1732, DOI DOI 10.12688/F1000RESEARCH.16521.2
   Scriba TJ, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TBTB2-0016-2016
   Nguyen TVA, 2018, CLIN INFECT DIS, V66, P1625, DOI 10.1093/cid/cix992
   Thomas A, 2005, INT J TUBERC LUNG D, V9, P556
   Tiemersma EW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017601
   Van der Meeren O, 2018, NEW ENGL J MED, V379, P1621, DOI 10.1056/NEJMoa1803484
   Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC
   Wallstedt H, 2015, INT J INFECT DIS, V32, P179, DOI 10.1016/j.ijid.2015.01.018
   WHO, 2017, SYST PREQ VACC UN SU
   WHO, 2017, VACC PRES PACK ADV G
   World Health Organization, 2016, WHO TREATM GUID DRUG
   World Health Organization, 2017, GUID TREATM DRUG SUS
   World Health Organization, 2017, GLOB TUB REP 2017
   World Health Organization (WHO), 2013, DEF REP FRAM TUB
   Zumla A, 2013, NEW ENGL J MED, V368, P745, DOI 10.1056/NEJMra1200894
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 135
EP 142
DI 10.1016/j.vaccine.2019.10.072
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700006
PM 31733944
OA Other Gold
DA 2020-05-12
ER

PT J
AU Grafl, B
   Berger, E
   Wernsdorf, P
   Hess, M
AF Grafl, Beatrice
   Berger, Evelyn
   Wernsdorf, Patricia
   Hess, Michael
TI Successful reproduction of adenoviral gizzard erosion in 20-week-old SPF
   layer-type chickens and efficacious prophylaxis due to live vaccination
   with an apathogenic fowl adenovirus serotype 1 strain (CELO)
SO VACCINE
LA English
DT Article
DE Fowl adenovirus; FAdV-1; Gizzard erosion; Egg drop; SPF layers;
   Vaccination
ID PATHOGEN-FREE CHICKENS; VERTICAL TRANSMISSION; BROILER BREEDERS; EGG
   TRANSMISSION; INFECTION; VIRUS; FLOCKS
AB Recently, outbreaks of adenoviral gizzard erosion (AGE) have been documented in pullets and layers housed free range and in enriched cage systems characterized by increased mortality and a negative impact on egg production. In the present study the pathogenicity of a fowl adenovirus serotype 1 (FAdV-1) field strain as well as the aetiological role of a FAdV-8a strain, both isolated from AGE affected pullets, were investigated in vivo in 20-week-old specific-pathogen-free (SPF) layer-type chickens. Furthermore, the efficacy of a single (week 17) and double (week 14 and 17) application of a live vaccine consisting of an apathogenic FAdV-1 (CELO strain) against challenge with virulent FAdV-1 was investigated.
   For the first time, AGE was successfully reproduced in adult birds after oral infection of 20-week-old SPF birds with a virulent FAdV-1 field isolate, characterized by pathological changes of the gizzard from 7 days post challenge onwards. In addition, a negative impact of the FAdV-1 infection on the development of the reproductive tract was observed. Thus, confirming the pathogenicity and aetiological role of FAdV-1 in the development of AGE and economic losses due to AGE in layers. In contrast, no pathological changes were observed in birds infected with FAdV-8a.
   Independent of a single or double application of the live FAdV-1 vaccine strain CELO, no gross pathological changes were observed in gizzards post challenge with the virulent FAdV-1, indicating that complete protection of layers against horizontal induction of AGE was achieved. Nonetheless, virulent FAdV-1 was detected in cloacal swabs and gizzards in both vaccinated groups post challenge determined by the application of an amplification refractory mutation system quantitative PCR used to differentiate between vaccine and challenge strains. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Grafl, Beatrice; Berger, Evelyn; Wernsdorf, Patricia; Hess, Michael] Univ Vet Med Vienna, Dept Farm Anim & Vet Publ Hlth, Clin Poultry & Fish Med, Vet Pl 1, A-1210 Vienna, Austria.
RP Grafl, B (reprint author), Univ Vet Med Vienna, Dept Farm Anim & Vet Publ Hlth, Clin Poultry & Fish Med, Vet Pl 1, A-1210 Vienna, Austria.
EM beatrice.grafl@vetmeduni.ac.at; evelyn.berger@vetmeduni.ac.at;
   patricia.wernsdorf@vetmeduni.ac.at; michael.hess@vetmeduni.ac.at
CR Abe T, 1998, AVIAN DIS, V42, P606, DOI 10.2307/1592690
   CHRISTENSEN NH, 1989, AVIAN DIS, V33, P622, DOI 10.2307/1591135
   COOK JKA, 1968, VET REC, V82, P294
   COWEN B, 1978, AVIAN DIS, V22, P115, DOI 10.2307/1589514
   DAWSON GJ, 1981, AM J VET RES, V42, P1833
   DAWSON GJ, 1979, AM J VET RES, V40, P1624
   Domanska-Blicharz K, 2015, P 19 WORLD VET POULT, P464
   Grafl B, 2018, AVIAN PATHOL, V47, P63, DOI 10.1080/03079457.2017.1367364
   Grafl B, 2014, VET MICROBIOL, V172, P177, DOI 10.1016/j.vetmic.2014.05.020
   Grafl B, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-38
   Grafl B, 2012, AVIAN PATHOL, V41, P599, DOI 10.1080/03079457.2012.740614
   Gunes A, 2012, J VIROL METHODS, V183, P147, DOI 10.1016/j.jviromet.2012.04.005
   Hess M., 2013, DIS POULTRY, P290
   Lim TH, 2012, POULTRY SCI, V91, P1113, DOI 10.3382/ps.2011-02050
   Mase M, 2014, J VET MED SCI, V76, P1535, DOI 10.1292/jvms.14-0312
   Matczuk AK, 2017, INFECT GENET EVOL, V48, P47, DOI 10.1016/j.meegid.2016.12.008
   Mazaheri A, 2003, ARCH GEFLUGELKD, V67, P6
   MCFERRAN JB, 1977, AVIAN PATHOL, V6, P405, DOI 10.1080/03079457708418249
   MONREAL G, 1984, ARCH GEFLUGELKD, V48, P245
   Nakamura K, 1999, AVIAN DIS, V43, P414, DOI 10.2307/1592638
   Okuda Y, 2004, J VET MED SCI, V66, P1561, DOI 10.1292/jvms.66.1561
   Okuda Y, 2001, AVIAN DIS, V45, P819, DOI 10.2307/1592862
   Okuda Y, 2001, AVIAN DIS, V45, P19, DOI 10.2307/1593007
   Ono M, 2004, VET PATHOL, V41, P483, DOI 10.1354/vp.41-5-483
   Ono M, 2003, VET REC, V153, P775
   Ono M, 2003, VET PATHOL, V40, P294, DOI 10.1354/vp.40-3-294
   Ono M, 2007, J VET MED SCI, V69, P1005, DOI 10.1292/jvms.69.1005
   REECE RL, 1985, AUST VET J, V62, P136, DOI 10.1111/j.1751-0813.1985.tb07266.x
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Schachner A, 2018, AVIAN PATHOL, V47, P111, DOI 10.1080/03079457.2017.1385724
   Schat KA, 2008, LAB MANUAL IDENTIFIC, P195
   Schonewille E, 2010, AVIAN DIS, V54, P905, DOI 10.1637/8999-072309-Reg.1
   Svihus B, 2011, WORLD POULTRY SCI J, V67, P207, DOI 10.1017/S0043933911000249
   Toro H, 2001, AVIAN DIS, V45, P215, DOI 10.2307/1593031
   Totsuka M., 2015, J JAPANESE SOC POULT, V51, P11
NR 35
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 143
EP 149
DI 10.1016/j.vaccine.2019.10.039
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700007
PM 31672334
DA 2020-05-12
ER

PT J
AU Harbecke, R
   Jensen, NJ
   Depledge, DP
   Johnson, GR
   Ashbaugh, ME
   Schmid, DS
   Breuer, J
   Levin, MJ
   Oxman, MN
AF Harbecke, Ruth
   Jensen, Nancy J.
   Depledge, Daniel P.
   Johnson, Gary R.
   Ashbaugh, Mark E.
   Schmid, D. Scott
   Breuer, Judith
   Levin, Myron J.
   Oxman, Michael N.
TI Recurrent herpes zoster in the Shingles Prevention Study: Are second
   episodes caused by the same varicella-zoster virus strain?
SO VACCINE
LA English
DT Article
DE Varicella-zoster virus; Herpes zoster; Shingles Prevention Study; Herpes
   zoster recurrence; Whole-genome sequencing; Reiteration regions
ID POSTHERPETIC NEURALGIA; IMMUNE-RESPONSES; TERM PERSISTENCE; VACCINE
   STRAINS; SIMPLEX-VIRUS; LONG-TERM; R2 REGION; WILD-TYPE; EVOLUTION;
   GENOTYPES
AB Herpes zoster (HZ) is caused by reactivation of varicella zoster virus (VZV) that established latency in sensory and autonomic neurons during primary infection. In the Shingles Prevention Study (SPS), a large efficacy trial of live attenuated Oka/Merck zoster vaccine (ZVL), PCR-confirmed second episodes of HZ occurred in two of 660 placebo and one of 321 ZVL recipients with documented HZ during a mean follow-up of 3.13 years. An additional two ZVL recipients experienced a second episode of HZ in the Long-Term Persistence Substudy. All episodes of HZ were caused by wild-type VZV. The first and second episodes of HZ occurred in different dermatomes in each of these five participants, with contralateral recurrences in two. Time between first and second episodes ranged from 12 to 28 months.
   One of the five participants, who was immunocompetent on study enrollment, was immunocompromised at the onset of his first and second episodes of HZ.
   VZV DNA isolated from rash lesions from the first and second episodes of HZ was used to sequence the full-length VZV genomes. For the unique-sequence regions of the VZV genome, we employed target enrichment of VZV DNA, followed by deep sequencing. For the reiteration regions, we used PCR amplification and Sanger sequencing. Our analysis and comparison of the VZV genomes from the first and second episodes of HZ in each of the five participants indicate that both episodes were caused by the same VZV strain. This is consistent with the extraordinary stability of VZV during the replication phase of varicella and the subsequent establishment of latency in sensory ganglia throughout the body. Our observations also indicate that VZV is stable during the persistence of latency and the subsequent reactivation and replication that results in HZ. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Harbecke, Ruth; Ashbaugh, Mark E.; Oxman, Michael N.] VA San Diego Healthcare Syst, Dept Vet Affairs, San Diego, CA 92161 USA.
   [Harbecke, Ruth; Oxman, Michael N.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA.
   [Jensen, Nancy J.; Schmid, D. Scott] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA.
   [Depledge, Daniel P.; Breuer, Judith] UCL, Div Infect & Immun, London, England.
   [Depledge, Daniel P.] NYU, Sch Med, Dept Med, New York, NY USA.
   [Johnson, Gary R.] Vet Affairs Connecticut Healthcare Syst, Cooperat Studies Program Coordinating Ctr, West Haven, CT USA.
   [Levin, Myron J.] Univ Colorado, Dept Med & Dept Pediat, Anschutz Med Campus, Aurora, CO USA.
RP Harbecke, R (reprint author), VA San Diego Healthcare Syst, 3350 Jolla Village Dr,111F-1, San Diego, CA 92161 USA.
EM rharbecke@ucsd.edu
FU Department of Veterans Affairs (VA) Cooperative Studies ProgramUS
   Department of Veteran Affairs; San Diego Veterans Medical Research
   Foundation; VA's John Blair Barnwell Award; Centers for Disease Control
   and PreventionUnited States Department of Health & Human ServicesCenters
   for Disease Control & Prevention - USA; James R. and Jesse V. Scott Fund
   for Shingles Research; Medical Research Foundation, UKMedical Research
   Council UK (MRC); UCL/UCLH NIHR Biomedical Research Centre
FX This work was supported by the Department of Veterans Affairs (VA)
   Cooperative Studies Program, the San Diego Veterans Medical Research
   Foundation, the VA's John Blair Barnwell Award, the Centers for Disease
   Control and Prevention, the James R. and Jesse V. Scott Fund for
   Shingles Research, and private charitable donations. D.P.D. was
   supported by a New Investigator Award from the Medical Research
   Foundation, UK. J.B. received funding from the UCL/UCLH NIHR Biomedical
   Research Centre. The VA Cooperative Studies Program had ultimate
   responsibility for the conduct of the SPS and its Substudies, the source
   of the data and specimens for this research. None of the funding sources
   were directly involved in the design and conduct of the research or in
   the preparation of this manuscript.
CR Arvin A., 2013, FIELDS VIROLOGY, P2015
   ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200
   Breuer J, 2010, CURR TOP MICROBIOL, V342, P15, DOI 10.1007/82_2010_9
   Coplan PM, 2004, J PAIN, V5, P344, DOI 10.1016/j.jpain.2004.06.001
   DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759
   Depledge DP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03569-2
   Depledge DP, 2014, J VIROL, V88, P13936, DOI 10.1128/JVI.02337-14
   Depledge DP, 2014, MOL BIOL EVOL, V31, P397, DOI 10.1093/molbev/mst210
   Depledge DP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027805
   DONAHUE JG, 1995, ARCH INTERN MED, V155, P1605, DOI 10.1001/archinte.155.15.1605
   Ha JW, 2017, ANN DERMATOL, V29, P602, DOI 10.5021/ad.2017.29.5.602
   Han ES, 1994, KOREAN J DERMATOL, V32, P286
   Harbecke R, 2009, J MED VIROL, V81, P1310, DOI 10.1002/jmv.21506
   HAYAKAWA Y, 1986, J GEN VIROL, V67, P1817, DOI 10.1099/0022-1317-67-9-1817
   HESKEL NS, 1984, J AM ACAD DERMATOL, V10, P486, DOI 10.1016/S0190-9622(84)80099-7
   HONDO R, 1988, J VIROL, V62, P2916, DOI 10.1128/JVI.62.8.2916-2921.1988
   HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106
   Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68
   Ida M, 2000, J DERMATOL SCI, V23, P63, DOI 10.1016/S0923-1811(99)00092-4
   Izurieta HS, 2017, CLIN INFECT DIS, V64, P785, DOI 10.1093/cid/ciw854
   KALMAN CM, 1986, AM J MED, V81, P775, DOI 10.1016/0002-9343(86)90343-8
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833
   Kim YJ, 2019, J KOREAN MED SCI, V34, DOI 10.3346/jkms.2019.34.e1
   KINOSHITA H, 1988, J VIROL, V62, P1097, DOI 10.1128/JVI.62.3.1097-1100.1988
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lee Chan Hee, 2014, Journal of Bacteriology and Virology, V44, P326, DOI 10.4167/jbv.2014.44.4.326
   Levin MJ, 2008, J INFECT DIS, V197, P825, DOI 10.1086/528696
   McGeoch DJ, 2009, J GEN VIROL, V90, P963, DOI 10.1099/vir.0.007658-0
   MOLIN L, 1969, ACTA DERM-VENEREOL, V49, P569
   Morrison VA, 2015, CLIN INFECT DIS, V60, P900, DOI 10.1093/cid/ciu918
   Nakamura Y, 2016, J AM ACAD DERMATOL, V75, P950, DOI 10.1016/j.jaad.2016.05.037
   Norberg P, 2006, J VIROL, V80, P9569, DOI 10.1128/JVI.00835-06
   Norberg P, 2015, J VIROL, V89, P7133, DOI 10.1128/JVI.00437-15
   Oxman MN, 1995, NEUROLOGY, V45, pS41, DOI 10.1212/WNL.45.12_Suppl_8.S41
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   Quinlivan M, 2009, J CLIN VIROL, V44, P66, DOI 10.1016/j.jcv.2008.09.004
   RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003
   Sauerbrei A, 2007, INTERVIROLOGY, V50, P40, DOI 10.1159/000096311
   Schmader KE, 2012, CLIN INFECT DIS, V55, P1320, DOI 10.1093/cid/cis638
   Schmader KE, 2007, CLIN J PAIN, V23, P490, DOI 10.1097/AJP.0b013e318065b6c9
   Scott Fiona T., 2003, Journal of Medical Virology, V70, pS24, DOI 10.1002/jmv.10316
   Shiraki K, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx007
   SLAVIN HB, 1950, AM J MED, V8, P456, DOI 10.1016/0002-9343(50)90227-0
   STRAUS SE, 1984, NEW ENGL J MED, V311, P1362, DOI 10.1056/NEJM198411223112107
   Suo LD, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2416-7
   Taha Y, 2006, CLIN INFECT DIS, V43, P1301, DOI 10.1086/508539
   TAKADA M, 1995, J CLIN MICROBIOL, V33, P658, DOI 10.1128/JCM.33.3.658-660.1995
   Tseng HF, 2016, J INFECT DIS, V213, P1872, DOI 10.1093/infdis/jiw047
   Tseng HF, 2014, CLIN INFECT DIS, V58, P1125, DOI 10.1093/cid/ciu058
   Tseng HF, 2012, J INFECT DIS, V206, P190, DOI 10.1093/infdis/jis334
   Tyler SD, 2007, VIROLOGY, V359, P447, DOI 10.1016/j.virol.2006.09.037
   Weinberg A, 2009, J INFECT DIS, V200, P1068, DOI 10.1086/605611
   Weinert LA, 2015, MOL BIOL EVOL, V32, P1020, DOI 10.1093/molbev/msu406
   Yawn BP, 2011, MAYO CLIN PROC, V86, P88, DOI 10.4065/mcp.2010.0618
   Yoshida M, 2003, J DERMATOL SCI, V31, P129, DOI 10.1016/S0923-1811(02)00147-0
   Yoshida M, 1999, J VIROL METHODS, V80, P213, DOI 10.1016/S0166-0934(99)00035-X
   Zell R, 2012, J VIROL, V86, P1608, DOI 10.1128/JVI.06233-11
   정성규, 2012, [Korean Journal of Dermatology, 대한피부과학회지], V50, P287
NR 59
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 150
EP 157
DI 10.1016/j.vaccine.2019.10.038
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700008
PM 31679866
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pebody, RG
   Zhao, H
   Whitaker, HJ
   Ellis, J
   Donati, M
   Zambon, M
   Andrews, N
AF Pebody, R. G.
   Zhao, H.
   Whitaker, H. J.
   Ellis, J.
   Donati, M.
   Zambon, M.
   Andrews, N.
TI Effectiveness of influenza vaccine in children in preventing influenza
   associated hospitalisation, 2018/19, England
SO VACCINE
LA English
DT Article
DE Influenza vaccine effectiveness; Children; LAIV; Hospitalisation
AB 2013/14 saw the start of the introduction of a new live attenuated influenza vaccine (LAIV) programme for children in England. 2018/19 saw co-circulation of both A(H1N1)pdm09 and A(H3N2), when LAIV was offered to all healthy children 2-9 years of age. LAIV effectiveness against influenza hospitalisation is not well described. This paper presents the 2018/19 end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza related hospitalisation in children aged 2-17. The test negative case control approach was used to estimate aVE by influenza A subtype and vaccine type. Cases and controls were selected from a sentinel laboratory surveillance system which collates details of individuals tested for influenza with reverse-transcription polymerase chain reaction (RT-PCR) on respiratory samples. Vaccine and clinical history was obtained from general practitioners of study participants. There were 307 hospitalised cases and 679 hospitalised controls. End-of-season influenza aVE was 53.0% (95% CI: 33.3, 66.8) against influenza confirmed hospitalisation; 63.5% (95% CI: 34.4, 79.7) against influenza A(H1N1)pdm09 hospitalisation and 31.1% (95% CI: -53.9, 69.2) against influenza A(H3N2). LAIV aVE was 49.1% (95% CI: 25.9, 65.0) for any influenza and 70.7% (95% CI: 41.8, 85.3) for A(H1N1)pdm09, whereas for those receiving quadrivalent inactivated influenza vaccine (QIV), aVE was 64.4% (95% CI: 29.4, 82.0) and 44.4% (95% CI: -51.9, 79.6) respectively. We provide evidence of overall significant VE for both LAIV and QIV against influenza associated hospitalisation in children 2-17 years of age, most notably against influenza A(H1N1)pdm09, with non-significant protection against A(H3N2). Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Pebody, R. G.; Zhao, H.; Whitaker, H. J.; Ellis, J.; Zambon, M.; Andrews, N.] Publ Hlth England, Natl Infect Serv, London, England.
   [Donati, M.] Publ Hlth England, Natl Infect Serv, Bristol, Avon, England.
RP Pebody, RG (reprint author), Publ Hlth England, Natl Infect Serv, London, England.
EM Richard.Pebody@phe.gov.uk
RI Whitaker, Heather/O-4995-2017
OI Whitaker, Heather/0000-0001-5833-1863
FU Sanofi Pasteur MSD
FX The authors declare the following financial interests/personal
   relationships which may be considered as potential competing interests:
   MD received lecturing fee from Sanofi Pasteur MSD; SpeeDx provided
   partial financial support for an educational meeting and UK Clinical
   Virology Network (UK CVN) which he chairs is a registered charity which
   includes a number of commercial partners. No other co-authors had
   conflicts to declare.
CR Belongia EA, 2019, CLIN INFECT DIS, DOI [10.1093/CID/CI7411, DOI 10.1093/CID/CI7411]
   Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554
   Buchan SA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187834
   Chiu SS, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.5.1900056
   Chung JR, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3279
   El Omeiri N, 2018, VACCINE, V36, P3555, DOI 10.1016/j.vaccine.2017.06.036
   Ilyushina NA, 2015, J INFECT DIS, V211, P352, DOI 10.1093/infdis/jiu458
   Jorgensen L, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0675-z
   Pebody R, 2017, EUROSURVEILLANCE, V22, P18, DOI 10.2807/1560-7917.ES.2017.22.4.30450
   Pebody R, 2018, ARCH DIS CHILD, V103, P101, DOI 10.1136/archdischild-2016-312165
   Penttinen PM, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.38.30350
   Shang M, 2018, VACCINE, V36, P8047, DOI 10.1016/j.vaccine.2018.10.093
   Zhao H, 2014, EUROSURVEILLANCE, V19, P5, DOI 10.2807/1560-7917.ES2014.19.3.20680
NR 13
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 158
EP 164
DI 10.1016/j.vaccine.2019.10.035
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700009
PM 31648914
DA 2020-05-12
ER

PT J
AU Mahumud, RA
   Gow, J
   Alam, K
   Keramat, SA
   Hossain, MG
   Sultana, M
   Sarker, AR
   Islam, SMS
AF Mahumud, Rashidul Alam
   Gow, Jeff
   Alam, Khorshed
   Keramat, Syed Afroz
   Hossain, Md Golam
   Sultana, Marufa
   Sarker, Abdur Razzaque
   Islam, Sheikh M. Shariful
TI Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix)
   and quadrivalent (Gardasil) HPV vaccination for adolescent girls in
   Bangladesh
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Bi-valent and quadrivalent vaccines;
   Cost-effectiveness analysis; Incremental cost-effectiveness ratios;
   Disability-adjusted life years; Bangladesh
ID HUMAN-PAPILLOMAVIRUS VACCINES; CERVICAL-CANCER
AB Background: Cervical cancer is one of the most prevalent cancers in women caused by the human papillomavirus (HPV) that leads to a substantial disease burden for health systems. Prevention through vaccination can significantly reduce the prevalence of cervical cancer. The objective of this study is to evaluate the potential health and economic impacts of introducing two-dose bivalent (Cervarix) and quadrivalent (Gardasil) HPV vaccines in Bangladesh.
   Methods: The study uses the Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model to assess the cost-effectiveness of introducing HPV vaccination. The incremental cost-effectiveness ratios (ICERs) were estimated per disability-adjusted life years (DALYs) averted using the cost-effectiveness threshold (CET). The analyses were done from a health system perspective in terms of vaccine delivery routes.
   Results: Introduction of bi-valent HPV vaccination was found highly cost-effective (ICER = US$488/DALY) at Gavi (The Vaccine Alliance for Vaccines and Immunizations) negotiated prices. The value of ICERs were US$710, US$356 and US$397 per DALY averted for school-based, health facility-based, and outreachbased programs, respectively, which is consistent with the CET range (US$67 to US$854). However, bivalent and quadrivalent vaccines at listed prices were not found cost-effective, with ICERs of US$1405 and US$3250 per DALY averted, respectively, that exceeds the CETs values.
   Conclusions: Introducing a two-dose bi-valent HPV vaccination program is cost-effective in Bangladesh at Gavi negotiated prices. Vaccine price is the dominating parameter for the cost-effectiveness of bivalent and quadrivalent vaccines. Both vaccines are not cost-effective at listed prices in Bangladesh. The evaluation highlights that introducing the two-dose bivalent HPV vaccine at Gavi negotiated prices into a national immunization program in Bangladesh is economically viable to reduce the burden of cervical cancer. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mahumud, Rashidul Alam; Gow, Jeff; Alam, Khorshed; Keramat, Syed Afroz] Univ Southern Queensland, Ctr Hlth Informat & Econ Res, Hlth Econ & Policy Res, Toowoomba, Qld 4350, Australia.
   [Mahumud, Rashidul Alam; Gow, Jeff; Alam, Khorshed; Keramat, Syed Afroz] Univ Southern Queensland, Sch Commerce, Toowoomba, Qld 4350, Australia.
   [Mahumud, Rashidul Alam] Icddr B, Hlth Syst & Populat Studies Div, Hlth Econ Res, Dhaka 1212, Bangladesh.
   [Mahumud, Rashidul Alam; Hossain, Md Golam] Univ Rajshahi, Dept Stat, Hlth & Epidemiol Res, Rajshahi 6205, Bangladesh.
   [Gow, Jeff] Univ KwaZulu Natal, Sch Accounting Econ & Finance, ZA-4000 Durban, South Africa.
   [Keramat, Syed Afroz] Khulna Univ, Social Sci Sch, Econ Discipline, Khulna 9208, Bangladesh.
   [Sultana, Marufa] Deakin Univ, Sch Hlth & Social Dev, Melbourne, Vic, Australia.
   [Sarker, Abdur Razzaque] BIDS, Dhaka 1212, Bangladesh.
   [Islam, Sheikh M. Shariful] Deakin Univ, IPAN, Geelong, Vic, Australia.
RP Mahumud, RA (reprint author), Univ Southern Queensland, Fac Business Educ Law & Arts, Ctr Hlth Informat & Econ Res, Hlth Econ & Policy Res, Toowoomba, Qld 4350, Australia.
EM rashidul.icddrb@gmail.com
RI Keramat, Syed Afroz/AAN-2755-2020; Mahumud, Rashidul/O-2477-2018
OI Keramat, Syed Afroz/0000-0001-8747-9891; Mahumud,
   Rashidul/0000-0001-9788-1868
CR Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3
   Ally M, 2012, BMC MED, V10, P1, DOI [10.1186/1741-701-10-136, DOI 10.1186/1741-701-10-136]
   Apollo Hospital Dhaka, 2019, VACC OFF HUM PAP VAC
   Bangladesh Bureau of Statistics, 2019, BANGL EC FIN IND
   Botwright S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182663
   Brunet J, 2011, J SPORT EXERCISE PSY, V33, P759, DOI 10.1123/jsep.33.6.759
   Bruni L. A. G., 2019, ICO IARC INFORM CTR
   Chowdhury M., 2018, DAILY STAR
   De La Fuente J, 2019, HUM VACC IMMUNOTHER, V15, P1949, DOI 10.1080/21645515.2018.1560770
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   Drolet M, 2014, INT J CANCER, V134, P2264, DOI 10.1002/ijc.28541
   Gavi Full Country Evaluations Team, 2015, OV GAV FULL COUNTR E
   Goldie SJ, 2008, VACCINE, V26, pM17, DOI 10.1016/j.vaccine.2008.06.018
   Haseen F, 2017, PROCESS DOCUMENTATIO
   Herlihy N, 2016, HEALTH AFFAIR, V35, P227, DOI 10.1377/hlthaff.2015.1411
   Minh HV, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2297-x
   Jit M, 2014, LANCET GLOB HEALTH, V2, pE406, DOI 10.1016/S2214-109X(14)70237-2
   Kiatpongsan S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106836
   Levin A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101114
   Lew JB, 2012, BMC HEALTH SERV RES, V12, P1, DOI [10.1186/1472-6963-12-44e, DOI 10.1186/1472-6963-12-44E]
   Malagon T, 2012, LANCET INFECT DIS, V12, P781, DOI 10.1016/S1473-3099(12)70187-1
   Mennini FS, 2017, COST EFFECT RESOUR A, V15, DOI 10.1186/s12962-017-0073-8
   Ministry of Health and Family Welfare, 2017, NAT STRAT CERV CANC
   Aguilar IBM, 2015, VACCINE, V33, pA167, DOI 10.1016/j.vaccine.2014.12.067
   Mukerji C., 2015, ET BUREAU FIND OUT B
   Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737
   Tan-Torres Edejer T., 2003, MAKING CHOICES HLTH
   Walwyn L, 2015, VACCINE, V33, pA174, DOI 10.1016/j.vaccine.2014.12.042
   Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017
   World Health Organization, 2014, COMPR CERV CANC CONT
   World Health Organization, IMM VACC BIOL IVB CA
   World Health Organization, HUM PAP HPV CERV CAN
   World Health Organization (WHO), 2018, WHO CERV CANC PREV C
   Yaghoubi Mohsen, 2018, Value Health Reg Issues, V15, P112, DOI 10.1016/j.vhri.2018.03.001
NR 34
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 165
EP 172
DI 10.1016/j.vaccine.2019.10.037
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700010
PM 31668820
DA 2020-05-12
ER

PT J
AU Pebody, R
   Whitaker, H
   Zhao, HX
   Andrews, N
   Ellis, J
   Donati, M
   Zambon, M
AF Pebody, Richard
   Whitaker, Heather
   Zhao, Hongxin
   Andrews, Nick
   Ellis, Joanna
   Donati, Matthew
   Zambon, Maria
TI Protection provided by influenza vaccine against influenza-related
   hospitalisation in >= 65 year olds: Early experience of introduction of
   a newly licensed adjuvanted vaccine in England in 2018/19
SO VACCINE
LA English
DT Article
DE Elderly; Influenza; Adjuvanted vaccine; Effectiveness
ID METAANALYSIS
AB 2018/19 was the first season of introduction in England of a newly licensed adjuvanted influenza vaccine (aTIV) for adults 65 years or older, who were previously offered standard-dose, non-adjuvanted vaccine, achieving uptake levels >70%, often with poor effectiveness. This paper presents the end-of-season adjusted vaccine effectiveness (aVE) against laboratory confirmed influenza hospitalisation in this population. A frequency-matched test negative case control approach was used to estimate aVE by influenza A subtype and vaccine type. Cases were influenza confirmed hospitalisations and controls influenza negative hospitalisations who were 65 years or more. Cases and controls were selected from a sentinel laboratory surveillance system which collates details of inpatients and outpatients routinely tested on clinical advice for influenza infection with reverse-transcription polymerase chain reaction (RT-PCR) on respiratory samples. Vaccine and clinical history was obtained from the general practitioners of study participants. A total of 428 cases and 1013 controls were included in the analysis. End-of-season any-influenza aVE against hospitalisation was 53.4% (95% CI: 39.9, 63.9). By influenza A subtype, aVE was 64.8% (95% CI: 49.6, 75.3) against influenza A(H1N1)pdm09 and 39.3% (95% CI: 6.5, 60.6) against influenza A(H3N2). There was insufficient data to estimate influenza B VE. aVE estimates for all influenza, influenza A(H1N1)pdm09 and influenza A(H3N2) for aTIV were 53.8% (39.8, 64.5); 65.9% (50.6, 76.4) and 39.5% (4.8, 61.5) respectively. We provide evidence of significant influenza VE in the elderly, most notably against influenza A(H1N1)pdm09, but also against A(H3N2) for aTIV. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Pebody, Richard; Whitaker, Heather; Zhao, Hongxin; Andrews, Nick; Ellis, Joanna; Zambon, Maria] Publ Hlth England, London, England.
   [Donati, Matthew] Publ Hlth England, Bristol, Avon, England.
RP Pebody, R (reprint author), Publ Hlth England, Natl Infect Serv, Immunisat & Countermeasures Div, London, England.
EM richard.pebody@phe.gov.uk
RI Whitaker, Heather/O-4995-2017
OI Whitaker, Heather/0000-0001-5833-1863
CR [Anonymous], INFL IMM INF DIS, P185
   Belongia EA, 2017, EXPERT REV VACCINES, V16, P865, DOI 10.1080/14760584.2017.1355177
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Black S, 2015, VACCINE, V33, pB3, DOI 10.1016/j.vaccine.2014.11.062
   Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011
   Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2
   Gilca R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132195
   Greenland S, 2015, ANNU REV PUBL HEALTH, V36, P89, DOI 10.1146/annurev-publhealth-031914-122559
   Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716
   Kissling E, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.1900121
   Nunzi E, 2017, HUM VACC IMMUNOTHER, V13, P2659, DOI 10.1080/21645515.2017.1373226
   Pebody RG, 2018, EUROSURVEILLANCE, V23, DOI [10.2807/1560-7917.E.5.201823.391800097, DOI 10.2807/1560-7917.E.5.201823.391800097]
   Rondy M, 2017, EUROSURVEILLANCE, V22, DOI [10.2807/1560-7917.ES.2017.22.41.1700645, DOI 10.2807/1560-7917.ES.2017.22.41.1700645]
   Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010
   Skowronski DM, 2019, EUROSURVEILLANCE, V24, P6, DOI 10.2807/1560-7917.ES.2019.24.4.1900055
   Spadea A, 2014, VACCINE, V32, P5290, DOI 10.1016/j.vaccine.2014.07.077
   Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059
   Zhao H, 2014, EUROSURVEILLANCE, V19, P5, DOI 10.2807/1560-7917.ES2014.19.3.20680
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 173
EP 179
DI 10.1016/j.vaccine.2019.10.032
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700011
PM 31653528
DA 2020-05-12
ER

PT J
AU Frawley, JE
   McManus, K
   McIntyre, E
   Seale, H
   Sullivan, E
AF Frawley, Jane E.
   McManus, Korie
   McIntyre, Erica
   Seale, Holly
   Sullivan, Elizabeth
TI Uptake of funded influenza vaccines in young Australian children in
   2018; parental characteristics, information seeking and attitudes
SO VACCINE
LA English
DT Article
DE Influenza; Immunisation; Vaccination; Vaccine; Children; Infants
ID VACCINATION; COVERAGE; VALIDITY
AB Objective: Infants and children under 5-years are at an increased risk of complications from influenza. We aimed to evaluate characteristics associated with uptake of Australian state and territory funded influenza vaccine programs in 2018 for children aged 6-months to 5-years.
   Materials and methods: A national online survey of 1002 Australian parents with at least one child aged between 6-months and 5-years (response rate 29.9%). A 23-item online questionnaire asked parents about health service use, 2017 and 2018 influenza vaccine uptake, and routine childhood vaccine status for their youngest child. Parents were also asked a range of questions about their demographics, sources of vaccine information, and beliefs and attitudes towards immunisation.
   Results: A total of 1002 parents completed the questionnaire and 52.9% of children aged 6-months to 5-years in our sample were immunised against influenza in 2018; representing a significant increase from 2017. Knowing the vaccine was free for their child, and being influenced by a pharmacist increased the likelihood that their child received the influenza vaccine. Not receiving an influenza vaccine recommendation from a health care provider significantly reduced the likelihood of immunisation. Some parents were worried about the safety of the influenza vaccine for their child (36.4%), while 26.5% of parents agreed that you can catch influenza from the vaccine.
   Conclusions: Uptake of influenza vaccine for Australian children aged 6-months to 5-years increased significantly in 2018. Continuing efforts to build parents' trust in childhood influenza vaccination are still required. Increasing opportunities for health care providers to recommend vaccination will lead to further improvements in uptake for young children. (C) 2019 Published by Elsevier Ltd.
C1 [Frawley, Jane E.; McManus, Korie; McIntyre, Erica; Sullivan, Elizabeth] Univ Technol Sydney, Fac Hlth, 235 Jones St, Ultimo, NSW, Australia.
   [Seale, Holly] Univ New South Wales, Sch Publ Hlth & Community Med, Randwick, NSW, Australia.
   [Sullivan, Elizabeth] Univ Newcastle, Fac Hlth & Med, Univ Dr, Callaghan, NSW, Australia.
   [McManus, Korie] NYU, Coll Global Publ Hlth, New York, NY USA.
RP Frawley, JE (reprint author), Univ Technol Sydney, Fac Hlth, ACPPHR, 235 Jones St, Ultimo, NSW 2007, Australia.
EM jane.frawley@uts.edu.au; km4259@nyu.edu; erica.mcintyre@uts.edu.au;
   h.seale@unsw.edu.au; elizabeth.sullivan@uts.edu.au
RI ; Frawley, Jane/G-4476-2016
OI Seale, Holly/0000-0002-1877-5395; Frawley, Jane/0000-0001-6037-0140
FU National Health and Medical Research Council (NHMRC), AustraliaNational
   Health and Medical Research Council of Australia [GNT1124075]; Sanofi
   Pasteur, France
FX We are grateful to the National Health and Medical Research Council
   (NHMRC), Australia for an Early Career Fellowship (GNT1124075) that
   supported Jane Frawley during this research.; Jane Frawley, Korrie
   McManus, Erica McIntyre and Elizabeth Sullivan have no Conflicts of
   Interest to disclose. Holly Seale has previously received funding from
   Sanofi Pasteur, France for travel costs/honoraria to attend an
CR Australian Government Department of Health, 2017, INFL SEAS AUSTR SUMM
   Australian Technical Advisory Group on Immunisation, AUSTR IMM HDB
   Beard FH, 2019, MED J AUSTRALIA, V210, P484, DOI 10.5694/mja2.50141
   Biezen R, 2018, VACCINE, V36, P859, DOI 10.1016/j.vaccine.2017.12.066
   Blyth CC, 2019, CLIN INFECT DIS, V68, P940, DOI 10.1093/cid/ciy597
   Blyth CC, 2014, VACCINE, V32, P4075, DOI 10.1016/j.vaccine.2014.05.055
   Blyth CC, 2011, MED J AUSTRALIA, V195, P52, DOI 10.5694/j.1326-5377.2011.tb03194.x
   Brown C, 2011, VACCINE, V29, P9488, DOI 10.1016/j.vaccine.2011.10.023
   Carlson SJ, 2019, VACCINE, V37, P5994, DOI 10.1016/j.vaccine.2019.08.021
   Esposito S, 2006, VACCINE, V24, P5251, DOI 10.1016/j.vaccine.2006.03.059
   Frawley JE, 2018, VACCINE, V36, P866, DOI 10.1016/j.vaccine.2017.12.036
   Hull B, 2017, ANN IMMUNISATION COV
   Lin CJ, 2006, J URBAN HEALTH, V83, P874, DOI 10.1007/s11524-006-9084-z
   Mak DB, 2012, AUST NZ J PUBL HEAL, V36, P494, DOI 10.1111/j.1753-6405.2012.00925.x
   National Centre for Immunisation Research and Surveilance, INFL VACC FACT SHEET
   Newcombe J, 2014, VACCINE, V32, P6364, DOI 10.1016/j.vaccine.2014.06.044
   Pandolfi E, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-984
   Shinall MC, 2007, PEDIATRICS, V120, pe783, DOI 10.1542/peds.2007-0052
   Tuckerman J, 2018, VACCINE, V36, P8138, DOI 10.1016/j.vaccine.2018.09.039
   Willis GA, 2019, INFLUENZA OTHER RESP, V13, P18, DOI 10.1111/irv.12604
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 180
EP 186
DI 10.1016/j.vaccine.2019.10.033
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700012
PM 31668365
DA 2020-05-12
ER

PT J
AU D'Souza, MP
   Rele, S
   Haynes, BF
   Hu, DJ
   Kaplan, DL
   Mamaghani, S
   Rampulla, D
AF D'Souza, M. Patricia
   Rele, Shyam
   Haynes, Barton F.
   Hu, Dale J.
   Kaplan, David L.
   Mamaghani, Shadi
   Rampulla, David
TI Engineering immunity for next generation HIV vaccines: The intersection
   of bioengineering and immunology
SO VACCINE
LA English
DT Article
DE HIV vaccine; Immunology; Bioengineering; Adjuvants; Neutralizing
   antibodies
ID RESPONSES; INFECTION; ANTIGEN; DESIGN; PATHS; CELLS
AB Bioengineering approaches grounded in immunology have the potential for the discovery and development of a successful HIV vaccine. The overarching goal is to engineer immunity through a fusion of immunology with bioengineering to create novel strategies for the design, development and delivery of vaccines based on the controlled modulation of the immune system. To foster these collaborations, the National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) brought together a group of experts (see Table 1) from these diverse fields for a workshop in September 2018 to: (1) engage the engineering, immunology, and HIV vaccinology communities to dialogue on the topic of an HIV vaccine and; (2) generate a framework of new and innovative research avenues to explore in HIV vaccinology between knowledge stakeholders and problem solvers. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [D'Souza, M. Patricia; Hu, Dale J.] NIAID, Div Aids, Bethesda, MD 20892 USA.
   [Rele, Shyam] NIAID, Div AIDS Contractor, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Haynes, Barton F.] Duke Univ, Duke Human Vaccine Inst, Durham, NC USA.
   [Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.
   [Mamaghani, Shadi] NIBIB, Div Discovery Sci & Technol Contractor, Bethesda, MD USA.
   [Rampulla, David] NIBIB, Div Discovery Sci & Technol, Bethesda, MD USA.
   [Rele, Shyam] Kelly Govt Solut, Rockville, MD USA.
   [Mamaghani, Shadi] AAAS, Sci & Technol Policy Fellowship Program, Washington, DC USA.
RP D'Souza, MP (reprint author), NIAID, Div Aids, Bethesda, MD 20892 USA.
CR Abbott RK, 2018, IMMUNITY, V48, P133, DOI 10.1016/j.immuni.2017.11.023
   Ackerman ME, 2018, NAT MED, V24, P1590, DOI 10.1038/s41591-018-0161-0
   Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/S0140-6736(18)31364-3, 10.1016/s0140-6736(18)31364-3]
   Benedict KF, 2013, CURR TOP MICROBIOL, V363, P201, DOI 10.1007/82_2012_249
   Bianchi M, 2018, IMMUNITY, V49, P288, DOI 10.1016/j.immuni.2018.07.009
   Bonsignori M, 2017, IMMUNOL REV, V275, P145, DOI [10., 10.1111/imr.12509]
   Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027
   Corey L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7732
   D'Souza MP, 2018, VACCINE, V36, P5671, DOI 10.1016/j.vaccine.2018.07.071
   Dingens AS, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007159
   Escolano A, 2016, CELL, V166, P1445, DOI 10.1016/j.cell.2016.07.030
   Fauci AS, 2017, JAMA-J AM MED ASSOC, V318, P1535, DOI 10.1001/jama.2017.13505
   Francica JR, 2017, BLOOD ADV, V1, P2329, DOI 10.1182/bloodadvances.2017011411
   Gosselin EA, 2018, NAT MATER, V17, P484, DOI 10.1038/s41563-018-0077-6
   Haynes BF, 2017, SCIENCE, V355, P1129, DOI 10.1126/science.aan0662
   Haynes BF, 2017, IMMUNOL REV, V275, P5, DOI 10.1111/imr.12517
   Haynes BF, 2012, NAT BIOTECHNOL, V30, P423, DOI 10.1038/nbt.2197
   He YP, 2018, ACS NANO, V12, P10272, DOI 10.1021/acsnano.8b05373
   Hernandez HL, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201800275
   Janes HE, 2017, J INFECT DIS, V215, P1376, DOI 10.1093/infdis/jix086
   Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195
   Kimmerling RJ, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1576-0
   Kong R, 2016, SCIENCE, V352, P828, DOI 10.1126/science.aae0474
   Kwong PD, 2018, IMMUNITY, V48, P855, DOI 10.1016/j.immuni.2018.04.029
   Lin L, 2015, NAT BIOTECHNOL, V33, P610, DOI 10.1038/nbt.3187
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109
   Moysi E, 2018, CURR OPIN HIV AIDS, V13, P112, DOI [10.1097/COH.0000000000000437, 10.1097/coh.0000000000000437]
   Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Rowe SP, 2019, ANNU REV MED, V70, P461, DOI 10.1146/annurev-med-062117-073027
   Sadtler K, 2019, BIOMATERIALS, V192, P405, DOI 10.1016/j.biomaterials.2018.11.002
   Sanders RW, 2017, IMMUNOL REV, V275, P161, DOI 10.1111/imr.12481
   Stamatatos L, 2017, IMMUNOL REV, V275, P203, DOI 10.1111/imr.12483
   Statistics. U.G.H., 2017, 2017 GLOB HIV STAT
   Steichen JM, 2016, IMMUNITY, V45, P483, DOI 10.1016/j.immuni.2016.08.016
   Swartz MA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003763
   Wang H, 2018, NAT MATER, V17, P761, DOI 10.1038/s41563-018-0147-9
   Wiehe K, 2018, CELL HOST MICROBE, V23, P759, DOI 10.1016/j.chom.2018.04.018
   Wilson DS, 2019, NAT MATER, V18, P175, DOI 10.1038/s41563-018-0256-5
   Wu TYH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009980
   Xing PY, 2018, ADV MATER, V30, DOI 10.1002/adma.201805175
   Yavuz B, 2018, ADV THER-GERMANY, V1, DOI 10.1002/adtp.201800054
   Zhou TQ, 2013, IMMUNITY, V39, P245, DOI 10.1016/j.immuni.2013.04.012
NR 44
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 187
EP 193
DI 10.1016/j.vaccine.2019.10.036
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700013
PM 31759734
DA 2020-05-12
ER

PT J
AU Gajewska, M
   Gorynski, P
   Paradowska-Stankiewicz, I
   Lewtak, K
   Piotrowicz, M
   Urban, E
   Cianciara, D
   Wysocki, MJ
   Ksiazek, A
   Izurieta, P
AF Gajewska, Malgorzata
   Gorynski, Pawel
   Paradowska-Stankiewicz, Iwona
   Lewtak, Katarzyna
   Piotrowicz, Maria
   Urban, Ewa
   Cianciara, Dorota
   Wysocki, Miroslaw J.
   Ksiazek, Alicja
   Izurieta, Patricia
TI Monitoring of community-acquired pneumonia hospitalisations before the
   introduction of pneumococcal conjugate vaccine into Polish National
   Immunisation Programme (2009-2016): A nationwide retrospective database
   analysis
SO VACCINE
LA English
DT Article
DE Community-acquired pneumonia; Hospitalisation rates; Poland;
   Pneumococcal vaccination; National Immunisation Programme; National
   public statistic
ID CHILDREN; ADULTS; TRENDS; EPIDEMIOLOGY; BURDEN; ADMISSIONS; SCHEDULE;
   DISEASE; EUROPE; KIELCE
AB Purpose: Community-acquired pneumonia (CAP) is a common infection with significant morbidity and mortality. In January 2017, Poland introduced pneumococcal conjugate vaccine (PCV) into their national immunisation programme to protect children against invasive pneumococcal disease. This study was designed to investigate pneumonia-related hospitalisation rates and trends from 2009 to 2016 prior to the introduction of nationally funded PCV vaccination.
   Methods: Using national public statistic data available from the National Institute of Public Health National Institute of Hygiene, annual hospitalisation rates for pneumonia were analysed, categorised by aetiology and age (<2, 2-3, 4-5, 6-19, 20-59, 60+ years). Trends over time were assessed, as well as in-hospital mortality.
   Results: The overall hospitalisation rate due to pneumonia varied between 325.9 and 372.2/100,000 population. Higher rates of hospitalisation were seen in older adults and children <= 5 years. Trends were observed when analysing hospitalisations by pneumonia aetiology within age groups: between 2009 and 2016, Streptococcus pneumoniae hospitalisations significantly increased for children aged <2, 2-3, and 4-5 years, from 53 to 12.4, 5.2 to 8.2, and 1.9 to 4.6/100,000 population respectively. Whereas hospitalisations due to Haemophilus influenzae pneumonia decreased significantly from 7.8 to 1.8 and 4.8 to 1.9/100,000 children aged <2 and 2-3 years respectively. The numbers of in-hospital deaths increased from 5578 in 2009 to 8149 in 2016, with >85% of deaths in the 60+ age group.
   Conclusions: This is the first national study of pneumonia hospitalisations in Poland, providing the baseline data from which to investigate the impact of the change in vaccination policy on pneumonia hospitalisations in Poland. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Gajewska, Malgorzata; Lewtak, Katarzyna; Piotrowicz, Maria; Urban, Ewa; Cianciara, Dorota; Wysocki, Miroslaw J.] Natl Inst Hyg, Dept Hlth Promot & Chron Dis Prevent, Natl Inst Publ Hlth, Chocimska 24, PL-00791 Warsaw, Poland.
   [Gorynski, Pawel] Natl Inst Hyg, Ctr Monitoring & Anal Populat Hlth Status & Hlth, Natl Inst Publ Hlth, Chocimska 24, PL-00791 Warsaw, Poland.
   [Paradowska-Stankiewicz, Iwona] Natl Inst Hyg, Dept Epidemiol Infect Dis & Surveillance, Natl Inst Publ Hlth, Chocimska 24, PL-00791 Warsaw, Poland.
   [Cianciara, Dorota] Ctr Postgrad Med Educ, Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Chocimska 24, PL-00791 Warsaw, Poland.
   [Ksiazek, Alicja] GSK, Med Dept, Rzymowskiego 53, PL-02697 Warsaw, Poland.
   [Izurieta, Patricia] GSK, Med Affairs, Ave Fleming 20, B-1300 Wavre, Belgium.
RP Ksiazek, A (reprint author), GSK, Med Dept, Rzymowskiego 53, PL-02697 Warsaw, Poland.
EM mgajewska@pzh.gov.pl; pawel@pzh.gov.pl; istankiewicz@pzh.gov.pl;
   klewtak@pzh.gov.pl; mpiotrowicz@pzh.gov.pl; eurban@pzh.gov.pl;
   dcianciara@pzh.gov.pl; mjwysocki@pzh.gov.pl; ksiazek@gsk.com;
   patricia.s.izurieta@gsk.com
OI Lewtak, Katarzyna/0000-0002-2996-583X; Ksiazek,
   Alicja/0000-0002-2188-7259
CR Abramson Joseph H, 2011, Epidemiol Perspect Innov, V8, P1, DOI 10.1186/1742-5573-8-1
   Alicino C, 2017, VACCINE, V35, P5776, DOI 10.1016/j.vaccine.2017.09.005
   Baldo V, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-485
   de Miguel-Diez J, 2017, EUR J INTERN MED, V40, P64, DOI 10.1016/j.ejim.2016.12.010
   European Respiratory Society, 2019, EUR LUNG WHIT BOOK
   Ewig S, 2009, THORAX, V64, P1062, DOI 10.1136/thx.2008.109785
   Froes F, 2013, EUR RESPIR J, V41, P1141, DOI 10.1183/09031936.00216711
   Gajewska M, 2016, CENT EUR J PUBL HEAL, V24, P188, DOI 10.21101/cejph.a4164
   Gil-Prieto R, 2011, VACCINE, V29, P412, DOI 10.1016/j.vaccine.2010.11.025
   Glowny Urzad Statystyczny [Central Office for Statistics], 2018, BAZ DEM
   Golebiewska A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002671
   Grzesiowski P, 2008, EUR J CLIN MICROBIOL, V27, P883, DOI 10.1007/s10096-008-0512-8
   Lim WS, 2001, THORAX, V56, P296, DOI 10.1136/thorax.56.4.296
   Marshall DC, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0781-4
   Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701
   Munson S, 2015, SCAND J PUBLIC HEALT, V43, P657, DOI 10.1177/1403494815581695
   National Institute of Public Health-National Institute of Hygiene, 2018, SZCZEP INF 2017 POL
   National Institute of Public Health-National Institute of Hygiene, 2017, SZCZEP INF SZCZEP PR
   National Institute of Public Health-National Institute of Hygiene, 2018, SZCZEP INF IMM SCHED
   Patrzalek M, 2016, CURR MED RES OPIN, V32, P397, DOI 10.1185/03007995.2015.1119676
   Patrzalek M, 2012, EUR J CLIN MICROBIOL, V31, P3023, DOI 10.1007/s10096-012-1656-0
   Patrzalek M, 2010, EUR J CLIN MICROBIOL, V29, P787, DOI 10.1007/s10096-010-0928-9
   Polkowska A, 2019, VACCINE, V37, P1365, DOI 10.1016/j.vaccine.2018.12.028
   Polkowska Aleksandra, 2011, Przegl Epidemiol, V65, P213
   Rozenbaum MH, 2015, VACCINE, V33, P3193, DOI 10.1016/j.vaccine.2015.05.001
   Skoczynska A, 2015, EUR J CLIN MICROBIOL, V34, P779, DOI 10.1007/s10096-014-2283-8
   Skoczynska A, 2011, VACCINE, V29, P2199, DOI 10.1016/j.vaccine.2010.09.100
   Sogaard M, 2014, RESP MED, V108, P1214, DOI 10.1016/j.rmed.2014.05.004
   Tichopad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071375
   Tikhomirova A, 2013, PATHOG DIS, V69, P114, DOI 10.1111/2049-632X.12073
   Torres A, 2018, RESP MED, V137, P6, DOI 10.1016/j.rmed.2018.02.007
   Trotter CL, 2008, EMERG INFECT DIS, V14, P727, DOI 10.3201/eid1405.071011
   Vila-Corcoles A, 2009, RESP MED, V103, P309, DOI 10.1016/j.rmed.2008.08.006
   Welte T, 2012, THORAX, V67, P71, DOI 10.1136/thx.2009.129502
   World Health Organization, 2019, WKLY EPIDEMIOL REC, V94, P85
   World Health Organization, 2016, FACT SHEETS PNEUM
   Wysocki J, 2016, ARCH MED SCI, V12, P629, DOI 10.5114/aoms.2016.59936
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 194
EP 201
DI 10.1016/j.vaccine.2019.10.031
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700014
PM 31653527
OA Other Gold
DA 2020-05-12
ER

PT J
AU Neal, EFG
   Flasche, S
   Nguyen, CD
   Ratu, FT
   Dunne, EM
   Koyamaibole, L
   Reyburn, R
   Rafai, E
   Kama, M
   Ortika, BD
   Boelsen, LK
   Kado, J
   Tikoduadua, L
   Devi, R
   Tuivaga, E
   Satzke, C
   Mulholland, EK
   Edmunds, WJ
   Russell, FM
AF Neal, Eleanor F. G.
   Flasche, Stefan
   Nguyen, Cattram D.
   Ratu, F. Tupou
   Dunne, Eileen M.
   Koyamaibole, Lanieta
   Reyburn, Rita
   Rafai, Eric
   Kama, Mike
   Ortika, Belinda D.
   Boelsen, Laura K.
   Kado, Joseph
   Tikoduadua, Lisi
   Devi, Rachel
   Tuivaga, Evelyn
   Satzke, Catherine
   Mulholland, E. Kim
   Edmunds, W. John
   Russell, Fiona M.
TI Associations between ethnicity, social contact, and pneumococcal
   carriage three years post-PCV10 in Fiji
SO VACCINE
LA English
DT Article
DE Social contact; Pneumococcal; Carriage; PCV10; Indigenous; Density
ID STREPTOCOCCUS-PNEUMONIAE COLONIZATION; CONJUGATE VACCINE; SEROTYPE
   DISTRIBUTION; VIRAL COINFECTION; YOUNG-CHILDREN; DISEASE; DENSITY;
   RESISTANCE; AUSTRALIA; PATTERNS
AB Background: Pneumococcal carriage is a prerequisite for pneumococcal disease. Little is known about whether social contact frequency and intensity are associated with pneumococcal carriage. In Fiji, indigenous iTaukei have higher prevalence of pneumococcal carriage compared with Fijians of Indian Descent (FID). We hypothesised that contact differences may contribute to ethnic differences in pneumococcal carriage prevalence and density.
   Methods: In 2015, young infants (5-8 weeks), toddlers (12-23 months), children (2-6 years), and caregivers from Suva and surrounding areas, participated in a cross-sectional survey (n = 2014), three years post pneumococcal conjugate vaccine introduction. Demographic and contact data, and nasopharyngeal swabs were collected. Pneumococci were detected, and quantified using quantitative real-time PCR, with molecular serotyping by microarray. Associations between ethnicity, contact, and pneumococcal carriage and density were estimated using multivariable generalised estimating equation regression models.
   Results: iTaukei participants had larger household sizes, higher pneumococcal carriage rates, more contacts, and more frequent contacts of longer duration, compared with FID. The odds of vaccine-type carriage increased by 28% (95% CI 8-53%) P < 0.01 in association with physical contact with 7-14 year old children. iTaukei ethnicity was associated with vaccine-type carriage (aOR) 1.73; 95% CI 1.06-2.82, P = 0.03) and non-vaccine type carriage (aOR 5.98; 95% CI 4.47-8.00, P < 0.01). Ethnicity and contact were not associated with pneumococcal density.
   Conclusions: iTaukei had greater frequency and intensity of contact compared with FID. Physical contact was associated with pneumococcal carriage. Observed differences in pneumococcal nasopharyngeal carriage prevalence between iTaukei and FID were not explained by differences in social contact patterns by ethnicity. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Neal, Eleanor F. G.; Nguyen, Cattram D.; Dunne, Eileen M.; Reyburn, Rita; Ortika, Belinda D.; Boelsen, Laura K.; Satzke, Catherine; Mulholland, E. Kim; Russell, Fiona M.] Murdoch Childrens Res Inst, Infect & Immun, Parkville, Vic, Australia.
   [Neal, Eleanor F. G.; Russell, Fiona M.] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Parkville, Vic, Australia.
   [Flasche, Stefan; Mulholland, E. Kim; Edmunds, W. John] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Nguyen, Cattram D.; Dunne, Eileen M.; Satzke, Catherine] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia.
   [Ratu, F. Tupou; Koyamaibole, Lanieta; Rafai, Eric; Kama, Mike; Tikoduadua, Lisi; Devi, Rachel; Tuivaga, Evelyn] Minist Hlth & Med Serv, Suva, Fiji.
   [Kado, Joseph] Fiji Natl Univ, Coll Med Nursing & Hlth Sci, Suva, Fiji.
   [Kado, Joseph] Univ Western Australia, Telethon Kids Inst, Nedlands, WA, Australia.
   [Satzke, Catherine] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Parkville, Vic, Australia.
RP Neal, EFG (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Infect & Immun, Flemington Rd, Parkville, Vic 3052, Australia.
EM eleanor.neal@rch.org.au
RI ; Satzke, Catherine/D-6501-2013
OI Neal, Eleanor/0000-0001-7998-0942; Kado, Joseph/0000-0003-3121-4397;
   Satzke, Catherine/0000-0003-3164-8849; Dunne,
   Eileen/0000-0001-5542-0780; Flasche, Stefan/0000-0002-5808-2606;
   Boelsen, Laura/0000-0002-2480-0753
FU Bill & Melinda Gates FoundationGates Foundation [OPP1126272,
   OPP1084341]; Victorian Government's Operational Infrastructure Support
   Project; Department of Foreign Affairs and Trade of the Australian
   GovernmentAustralian Government; Fiji Health Sector Support Program;
   NHMRCNational Health and Medical Research Council of Australia; Wellcome
   TrustWellcome Trust; Royal SocietyRoyal Society of London
   [208812/Z/17/Z]
FX This work was supported by the Bill & Melinda Gates Foundation [grant
   numbers OPP1126272 and OPP1084341], the Victorian Government's
   Operational Infrastructure Support Project, and the Department of
   Foreign Affairs and Trade of the Australian Government, the Fiji Health
   Sector Support Program. FHSSP was implemented by Abt JTA on behalf of
   the Australian Government. Fiona Russell held a National Health and
   Research Medical Council (NHMRC) Early Career Fellowship and NHMRC TRIP
   Fellowship; Catherine Satzke holds a NHMRC Career Development Fellowship
   and a Veski Inspiring Women Fellowship; Eleanor Neal holds an Australian
   Government Research Training Program Scholarship; Stefan Flasche is
   supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome
   Trust and the Royal Society (grant number 208812/Z/17/Z).
CR Abdullahi O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030787
   Adetifa IMO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030548
   Althouse BM, 2017, EPIDEMIOL INFECT, V145, P2750, DOI 10.1017/S095026881700125X
   Baggett HC, 2017, CLIN INFECT DIS, V64, pS317, DOI 10.1093/cid/cix100
   Ballinger GA, 2004, ORGAN RES METHODS, V7, P127, DOI 10.1177/1094428104263672
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Bolton KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030893
   Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06
   Chen C, 2019, LANCET GLOB HEALTH, V7, pE58, DOI 10.1016/S2214-109X(18)30422-4
   de Waroux OL, 2018, EPIDEMICS-NETH, V25, P72, DOI 10.1016/j.epidem.2018.05.008
   Dunne EM, 2018, LANCET GLOB HEALTH, V6, pE1375, DOI 10.1016/S2214-109X(18)30383-8
   Edmunds WJ, 2006, EMERG THEMES EPIDEMI, V3, DOI 10.1186/1742-7622-3-10
   Fadlyana E, 2018, PNEUMONIA, V10, DOI 10.1186/s41479-018-0058-1
   Fan RR, 2016, EMERG INFECT DIS, V22, P1996, DOI 10.3201/eid2211.160902
   Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517
   Fiji Bureau of Statistics, 2017, CENS POP HOUS POP CE
   Flasche S, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001839
   Hanke CR, 2016, PEDIATR INFECT DIS J, V35, P432, DOI 10.1097/INF.0000000000001030
   Horby P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016965
   Huong TTV, 2011, PEDIATR INFECT DIS J, V30, P11, DOI 10.1097/INF.0b013e3181f111a2
   Ibuka Y, 2016, J EPIDEMIOL COMMUN H, V70, P162, DOI 10.1136/jech-2015-205777
   Kiti MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104786
   Koroivueta DJ, 2016, 76 MIN HLTH MED SERV, P95
   Kumar S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209039
   Lai JYR, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-409
   Melegaro A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170459
   MORRIS M, 1991, MATH BIOSCI, V107, P349, DOI 10.1016/0025-5564(91)90014-A
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Rinta-Kokko H, 2018, VACCINE, V36, P1934, DOI 10.1016/j.vaccine.2018.03.001
   Russell FM, 2006, ANN TROP PAEDIATR, V26, P187, DOI 10.1179/146532806X120273
   Russell FM, 2010, PEDIATR INFECT DIS J, V29, P870, DOI 10.1097/INF.0b013e3181ec7ae2
   Satzke C, 2019, VACCINE, V37, P296, DOI 10.1016/j.vaccine.2018.10.077
   Satzke C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001903
   Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062
   Schaumburg F, 2013, T ROY SOC TROP MED H, V107, P105, DOI 10.1093/trstmh/trs018
   Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0
   Sigauque B, 2018, PEDIATR INFECT DIS J, V37, P1054, DOI 10.1097/INF.0000000000002134
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Toms C, 2016, COMMUN DIS INTELL, V40, pE267
   Valles X, 2006, TROP MED INT HEALTH, V11, P358, DOI 10.1111/j.1365-3156.2006.01565.x
   Vino T, 2017, PEERJ, V5, DOI 10.7717/peerj.3958
   Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X
   Wallinga J, 2006, AM J EPIDEMIOL, V164, P936, DOI 10.1093/aje/kwj317
   Watson CH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186911
   Weinberger DM, 2019, AM J EPIDEMIOL, V188, P160, DOI 10.1093/aje/kwy219
   Weinberger DM, 2013, AM J EPIDEMIOL, V178, P1488, DOI 10.1093/aje/kwt156
   Wolter N, 2014, J INFECT DIS, V210, P1649, DOI 10.1093/infdis/jiu326
   World Health Organization, 2019, PNEUM CONJ VACC INF
NR 49
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 202
EP 211
DI 10.1016/j.vaccine.2019.10.030
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700015
PM 31668367
OA Green Published, Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Mantel, C
   Chu, SY
   Hyde, TB
   Lambach, P
   Hlinskaya, I
   Khadasevich, S
   Maaroufi, A
   Youbi, M
   Hind, E
   Cherkaoui, I
   Thantithaveewat, T
   Yoocharoen, P
   Lindblade, K
   Praphasiri, P
   Mott, J
   McCarron, M
   Akanmori, BD
   Brown, R
   Fitzner, J
   Friede, M
   Grankov, V
   Grubo, M
   Hombach, J
   Hutubessy, R
   Jorgensen, P
   Langar, H
   Liyanage, JBL
   Malik, SMM
   Moen, A
   Alvarez, AMR
   Souteyrand, Y
AF Mantel, Carsten
   Chu, Susan Y.
   Hyde, Terri B.
   Lambach, Philipp
   Hlinskaya, Iryna
   Khadasevich, Sviatlana
   Maaroufi, Abderrahmane
   Youbi, Mohammed
   Hind, Ezzine
   Cherkaoui, Imad
   Thantithaveewat, Thanawadee
   Yoocharoen, Pornsak
   Lindblade, Kim
   Praphasiri, Prabda
   Mott, Josh
   McCarron, Margaret
   Akanmori, Bartholomew Dicky
   Brown, Richard
   Fitzner, Julia
   Friede, Martin
   Grankov, Viatcheslav
   Grubo, Myriam
   Hombach, Joachim
   Hutubessy, Raymond
   Jorgensen, Pernille
   Langar, Houda
   Liyanage, Jayantha Bandula L.
   Malik, Sk Md Mamunur
   Moen, Ann
   Alvarez, Alba Maria Ropero
   Souteyrand, Yves
CA IPIE Pilot Implementation Grp
TI Seasonal influenza vaccination in middle-income countries: Assessment of
   immunization practices in Belarus, Morocco, and Thailand
SO VACCINE
LA English
DT Article
DE Seasonal influenza vaccination; Post-introduction evaluation;
   Middle-income countries; National Immunization Program; Program
   implementation; IPIE; Health worker vaccination
ID HEALTH-CARE WORKERS; KNOWLEDGE; ATTITUDES; OUTBREAK; UNIT
AB Background: Vaccines for the control of seasonal influenza are recommended by the World Health Organization (WHO) for use in specific risk groups, but their use requires operational considerations that may challenge immunization programs. Several middle-income countries have recently implemented seasonal influenza vaccination. Early program evaluation following vaccine introduction can help ascertain positive lessons learned and areas for improvement.
   Methods: An influenza vaccine post-introduction evaluation (IPIE) tool was developed jointly by WHO and the U.S. Centers for Disease Control and Prevention to provide a systematic approach to assess influenza vaccine implementation processes. The tool was used in 2017 in three middle-income countries: Belarus, Morocco and Thailand.
   Results: Data from the three countries highlighted a number of critical factors: Health workers (HWs) are a key target group, given their roles as key influences of acceptance by other groups, and for ensuring vaccine delivery and improved coverage. Despite WHO recommendations, pregnant women were not always prioritized and may present unique challenges for acceptance. Target group denominators need to be better defined, and vaccine coverage should be validated with vaccine distribution data, including from the private sector. There is a need for strengthening adverse events reporting and for addressing potential vaccine hesitancy through the establishment of risk communication plans. The assessments led to improvements in the countries' influenza vaccination programs, including a revision of policies, changes in vaccine management and coverage estimation, enhanced strategies for educating HWs and intensified collaboration between departments involved in implementing seasonal influenza vaccination.
   Conclusion: The IPIE tool was found useful for delineating operational strengths and weaknesses of seasonal influenza vaccination programs. HWs emerged as a critical target group to be addressed in followup action. Findings from this study can help direct influenza vaccination programs in other countries, as well as contribute to pandemic preparedness efforts. The updated IPIE tool is available on the WHO website http://www.who.int/immunization/research/development/influenza/en/indexl.html . (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Mantel, Carsten] MMGH Consulting, Kuerbergstr 1, CH-8049 Zurich, Switzerland.
   [Chu, Susan Y.; Hyde, Terri B.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
   [Lambach, Philipp; Friede, Martin; Hombach, Joachim; Hutubessy, Raymond] WHO, Initiat Vaccine Res, Geneva, Switzerland.
   [Hlinskaya, Iryna] Republ Ctr Hyg Epidemiol & Publ Hlth, Minsk, BELARUS.
   [Khadasevich, Sviatlana] Minist Hlth Republ Belarus, Minsk, BELARUS.
   [Maaroufi, Abderrahmane; Youbi, Mohammed; Hind, Ezzine; Cherkaoui, Imad] Minist Hlth, Rabat, Morocco.
   [Thantithaveewat, Thanawadee; Yoocharoen, Pornsak] Minist Publ Hlth, Nonthaburi, Thailand.
   [Lindblade, Kim; Praphasiri, Prabda; Mott, Josh] US CDC, Nonthaburi, Thailand.
   [McCarron, Margaret] US CDC, Atlanta, GA USA.
   [Akanmori, Bartholomew Dicky] WHO Reg Off Africa, Immunizat & Vaccine Dev, Brazzaville, Rep Congo.
   [Brown, Richard] WHO Country Off Thailand, Nonthaburi, Thailand.
   [Fitzner, Julia] WHO, High Threat Pathogens, Geneva, Switzerland.
   [Grankov, Viatcheslav] WHO Country Off, Minsk, BELARUS.
   [Grubo, Myriam] WHO, Hlth Syst & Innovat, Geneva, Switzerland.
   [Jorgensen, Pernille] WHO Reg Off Europe, Influenza & Other Resp Pathogens, Copenhagen, Denmark.
   [Langar, Houda] WHO Eastern Mediterranean Reg Off, Vaccines Regulat & Prod, Cairo, Egypt.
   [Liyanage, Jayantha Bandula L.] WHO Reg Off South East Asia, Vaccine Preventable Dis, Immunizat Syst Strengthening, New Delhi, India.
   [Malik, Sk Md Mamunur] WHO Eastern Mediterranean Reg Off, Infect Hazard Management, Cairo, Egypt.
   [Moen, Ann] WHO, Influenza Preparedness & Response, Geneva, Switzerland.
   [Alvarez, Alba Maria Ropero] WHO Reg Off Amer, Immunizat, Washington, DC USA.
   [Souteyrand, Yves] WHO Representatives Off, Tunis, Tunisia.
RP Mantel, C (reprint author), MMGH Consulting, Kuerbergstr 1, CH-8049 Zurich, Switzerland.
EM mantelc@mmglobalhealth.org
FU WHO Initiative for Vaccine Research (IVR)World Health Organization; US
   CDCUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA [U50CK000431]
FX The development and piloting of the IPIE tool was funded by a grant from
   the WHO Initiative for Vaccine Research (IVR). The authors would like to
   acknowledge the contributions of the US CDC, which provides financial
   support to the WHO IVR (U50CK000431) and, through its collaborative
   agreement with the Thailand MOPH, for the Thailand evaluation.
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   [Anonymous], 2014, EV SEAS INFL VACC PO
   Apisarnthanarak A, 2010, INFECT CONT HOSP EP, V31, P996, DOI 10.1086/656565
   Assi TM, 2012, VACCINE, V30, P4517, DOI 10.1016/j.vaccine.2012.04.041
   Barlow G, 2000, LANCET, V355, P1187, DOI 10.1016/S0140-6736(05)72268-6
   Beguin C, 1998, Am J Med Qual, V13, P223, DOI 10.1177/106286069801300408
   Caini S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152310
   Cherian T, 2019, VACCINE, V37, P6255, DOI 10.1016/j.vaccine.2019.07.079
   Cunney RJ, 2000, INFECT CONT HOSP EP, V21, P449, DOI 10.1086/501786
   Ditsungnoen D, 2016, VACCINE, V34, P2141, DOI 10.1016/j.vaccine.2016.01.056
   Halder S, 2000, LANCET, V355, P1187, DOI 10.1016/S0140-6736(05)72269-8
   Heinrich-Morrison K, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0765-7
   Hofmann F, 2006, INFECTION, V34, P142, DOI 10.1007/s15010-006-5109-5
   Hollmeyer H, 2013, INFLUENZA OTHER RESP, V7, P604, DOI 10.1111/irv.12002
   Horcajada JP, 2003, EUR RESPIR J, V21, P303, DOI 10.1183/09031936.03.00040503
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Jenkin Dawn C, 2019, Vaccine X, V2, P100036, DOI 10.1016/j.jvacx.2019.100036
   Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052
   Lohiniva AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096244
   Maltezou HC, 2009, CURR DRUG TARGETS, V10, P1041, DOI 10.2174/138945009789577972
   Maltezou HC, 2011, INFLUENZA OTHER RESP, V5, P382, DOI 10.1111/j.1750-2659.2011.00240.x
   Meerhoff TJ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-014-0722-x
   Meeyai A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001829
   Murray SB, 2002, AUST NZ J PUBL HEAL, V26, P65, DOI 10.1111/j.1467-842X.2002.tb00273.x
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   Ott JJ, 2013, HUM VACC IMMUNOTHER, V9, P1500, DOI 10.4161/hv.24704
   Palache A, 2011, VACCINE, V29, P9459, DOI 10.1016/j.vaccine.2011.10.030
   Sagrera X, 2002, PEDIATR INFECT DIS J, V21, P196, DOI 10.1097/00006454-200203000-00007
   Salgado CD, 2002, LANCET INFECT DIS, V2, P145, DOI 10.1016/S1473-3099(02)00221-9
   Sartor C, 2002, INFECT CONT HOSP EP, V23, P615, DOI 10.1086/501981
   Smedley J, 2002, OCCUP MED-OXFORD, V52, P271, DOI 10.1093/occmed/52.5.271
   Sullivan S., 2017, LANCET
   Tagajdid Mohamed Rida, 2011, Int J Risk Saf Med, V23, P249, DOI 10.3233/JRS-2011-0544
   WHO/EURO, 2015, TAIL IMM PROGR SEAS
   WHO/IVB/EPI, 2010, NEW VACC POST EV PIE
   WHO/IVB/EPI, 2017, GUID COND EXP PROGR
   [WHO/IVB/IVR V.a.B. Dept Immunization], 2017, INTR MAN NAT IMM PRO
   Wodi AP, 2005, INFECT CONT HOSP EP, V26, P867, DOI 10.1086/502510
   Worasathit R, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0137-6
   World Health Organization, 2019, IMPL SEAS INFL VACC
   [World Health Organization Global Advisory Committee on Vaccine Safety], 2014, REV EV
   World Health Organization, 2018, INFL VACC PROGR EV B
   World Health Organization, 2012, OBS RAT VACC REACT I
NR 43
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 212
EP 219
DI 10.1016/j.vaccine.2019.07.028
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700016
PM 31699507
DA 2020-05-12
ER

PT J
AU Pallas, SW
   Ahmeti, A
   Morgan, W
   Preza, I
   Nelaj, E
   Ebama, M
   Levin, A
   Lafond, KE
   Bino, S
AF Pallas, Sarah Wood
   Ahmeti, Albana
   Morgan, Winthrop
   Preza, Iria
   Nelaj, Erida
   Ebama, Malembe
   Levin, Ann
   Lafond, Kathryn E.
   Bino, Silvia
TI Program cost analysis of influenza vaccination of health care workers in
   Albania
SO VACCINE
LA English
DT Article
DE Influenza; Economic evaluation; Cost analysis; Health care workers; Low-
   and middle-income countries
ID MIDDLE-INCOME COUNTRIES; BURDEN
AB Background: Since 2012, WHO has recommended influenza vaccination for health care workers (HCWs), which has different costs than routine infant immunization; however, few cost estimates exist from low-and middle-income countries. Albania, a middle-income country, has self-procured influenza vaccine for some HCWs since 2014, supplemented by vaccine donations since 2016 through the Partnership for Influenza Vaccine Introduction (PIVI). We conducted a cost analysis of HCW influenza vaccination in Albania to inform scale-up and sustainability decisions.
   Methods: We used the WHO's Seasonal Influenza Immunization Costing Tool (SIICT) micro-costing approach to estimate incremental costs from the government perspective of facility-based vaccination of HCWs in Albania with trivalent inactivated influenza vaccine for the 2018-19 season based on 2016-17 season data from administrative records, key informant consultations, and a convenience sample of site visits. Scenario analyses varied coverage, vaccine presentation, and vaccine prices.
   Results: In the baseline scenario, 13,377 HCWs (70% of eligible HCWs) would be vaccinated at an incremental financial cost of US$61,296 and economic cost of US$161,639. Vaccine and vaccination supplies represented the largest share of financial (89%) and economic costs (44%). Per vaccinated HCW financial cost was US$4.58 and economic cost was US$12.08 including vaccine and vaccination supplies (US$0.49 and US$6.76 respectively without vaccine and vaccination supplies). Scenarios with higher coverage, prefilled syringes, and higher vaccine prices increased total economic and financial costs, although the economic cost per HCW vaccinated decreased with higher coverage as some costs were spread over more HCWs. Across all scenarios, economic costs were <0.07% of Albania's estimated government health expenditure, and <5.07% of Albania's estimated immunization program economic costs.
   Conclusions: Cost estimates can help inform decisions about scaling up influenza vaccination for HCWs and other risk groups. Published by Elsevier Ltd.
C1 [Pallas, Sarah Wood; Lafond, Kathryn E.] US Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Ahmeti, Albana; Preza, Iria; Nelaj, Erida; Bino, Silvia] Inst Publ Hlth, Tirana, Albania.
   [Morgan, Winthrop; Levin, Ann] Levin & Morgan, Bethesda, MD USA.
   [Ebama, Malembe] Task Force Global Hlth, Atlanta, GA USA.
RP Pallas, SW (reprint author), Ctr Dis Control & Prevent, MS H24-2,1600 Clifton Rd NE, Atlanta, GA 30329 USA.
EM spallas@cdc.gov
FU U.S. Centers for Disease Control and PreventionUnited States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
FX This work was supported by funding from the U.S. Centers for Disease
   Control and Prevention.
CR Albania Institute of Statistics, 2018, CONS PRIC IND
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P201
   [Anonymous], 2017, PIVIS WORK ALB
   Bank of Albania, 2017, EXCH RAT ARCH
   Bino S, 2017, ANN INFLUENZA EPIDEM
   Chicaíza-Becerra Liliana A, 2008, Rev. salud pública, V10, P756
   Coulibaly Y, 2008, TROP MED INT HEALTH, V13, P1430, DOI 10.1111/j.1365-3156.2008.02174.x
   de Boer PT, 2018, VACCINE, V36, P997, DOI 10.1016/j.vaccine.2017.12.073
   de Francisco N, 2015, VACCINE, V33, P6537, DOI 10.1016/j.vaccine.2015.10.066
   Hanvoravongchai P, 2011, J INFECT DIS, V204, pS82, DOI 10.1093/infdis/jir091
   Imai C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198685
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Kittikraisak W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183391
   Ministria E Shendetesise dhe Mbrojtjes Sociale, 2016, TAB RAP INT KOH 3 MU
   Mounier-Jack S, 2016, HEALTH POLICY PLANN, V31, P1225, DOI 10.1093/heapol/czw054
   Neuzil KM, 2017, VACCINE, V35, P5734, DOI 10.1016/j.vaccine.2017.08.088
   Newall AT, 2018, INFLUENZA OTHER RESP, V12, P211, DOI 10.1111/irv.12510
   Orenstein EW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171499
   Ott JJ, 2013, HUM VACC IMMUNOTHER, V9, P1500, DOI 10.4161/hv.24704
   Peasah SK, 2013, VACCINE, V31, P5339, DOI 10.1016/j.vaccine.2013.09.013
   Pecenka C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190006
   World Health Organization, 2018, MAT INFL IMM GUID IN
   World Health Organization, 2016, WHO MAT SEAS INFL VA
   World Health Organization, 2018, MI4A MARK INF ACC VA
   Zoidze A., 2015, FINAL EVALUATION GAV
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 220
EP 227
DI 10.1016/j.vaccine.2019.10.027
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700017
PM 31669063
DA 2020-05-12
ER

PT J
AU Becerra-Culqui, TA
   Sy, LS
   Ackerson, BK
   Slezak, JM
   Luo, Y
   Fischetti, CA
   Ohadike, YU
   Curina, C
   Pellegrini, M
   Solano, Z
   Tartof, SY
   Tseng, HF
AF Becerra-Culqui, Tracy A.
   Sy, Lina S.
   Ackerson, Bradley K.
   Slezak, Jeff M.
   Luo, Yi
   Fischetti, Christine A.
   Ohadike, Yvonne U.
   Curina, Carlo
   Pellegrini, Michele
   Solano, Zendi
   Tartof, Sara Y.
   Tseng, Hung Fu
TI Safety of quadrivalent meningococcal conjugate vaccine in infants and
   toddlers 2 to 23-months old
SO VACCINE
LA English
DT Article
DE Safety; Meningococcal conjugate vaccine; Infants; Observational study
ID DISEASE RECOMMENDATIONS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE;
   CHILDREN; IMMUNOGENICITY; PREVENTION
AB Introduction: The quadrivalent meningococcal conjugate vaccine MenACWY-CRM is recommended for 2-23 month-old infants/toddlers at increased risk for meningococcal disease. This study adds to the current knowledge of MenACWY-CRM safety among this age group in a clinical care setting.
   Methods: Kaiser Permanente Southern California members aged 2-23 months who received MenACWY-CRM between July 2014 and June 2017 were included. Electronic health records were searched for emergency department (ED) and hospitalization encounters, and diagnoses associated with these visits up to 6 months after each dose.
   Results: There were 138 infants/toddlers who received MenACWY-CRM, with 59.4% being African American and 66.7% receiving only one dose. Most infants either had a high-risk condition (i.e., anatomic/functional asplenia or DiGeorge syndrome) (42.0%), or a travel indication (54.3%). The incidence rate of ED visits was 0.6/person-year (95% confidence interval [CI]: 0.5-0.8), 0.4/person-year (CI: 0.3-0.5) for hospitalizations, and 0.1/person-year (CI: 0.1-0.3) for ED to hospital transfers. Overall, 29.0% of recipients had an incident diagnosis in the ED or hospital setting. Fever and acute upper respiratory infections were the most common diagnoses, with 46 out of 47 diagnoses occurring among infants with high-risk conditions.
   Conclusions: Data from this descriptive observational study do not suggest safety concerns associated with MenACWY-CRM when used as part of clinical care of 2-23 month-old infants/toddlers indicated for vaccination. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Becerra-Culqui, Tracy A.; Sy, Lina S.; Slezak, Jeff M.; Luo, Yi; Fischetti, Christine A.; Solano, Zendi; Tartof, Sara Y.; Tseng, Hung Fu] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles,Calif Suite 201, Pasadena, CA 91101 USA.
   [Ackerson, Bradley K.] Southern Calif Permanente Med Grp, Pediat & Pediat Infect Dis, 25965 S Normandie Ave, Harbor City, CA USA.
   [Ohadike, Yvonne U.; Curina, Carlo; Pellegrini, Michele] GSK, Clin Res & Dev Ctr, Via Fiorentina 1, I-53100 Siena Si, Italy.
RP Tseng, HF (reprint author), Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles,Calif Suite 201, Pasadena, CA 91101 USA.
EM Hung-Fu.X.Tseng@kp.org
OI Curina, Carlo/0000-0002-3536-124X; PELLEGRINI,
   MICHELE/0000-0001-8505-9260; Slezak, Jeff/0000-0002-6108-9198; Becerra,
   Tracy/0000-0002-8957-5155
FU Novartis Vaccines and Diagnostics Inc.; GSKGlaxoSmithKline
FX This study was sponsored by Novartis Vaccines and Diagnostics Inc., now
   part of the GSK group of companies.
CR Centers for Disease Control and Prevention, 2015, EPIDEMIOLOGY PREVENT
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   [GlaxoSmithKline Biologicals S.A Food and Drug Administration], 2017, MENVEO PACK INS HIGH
   Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032
   Keshavan P, 2018, EXPERT REV VACCINES, V17, P865, DOI 10.1080/14760584.2018.1521280
   Klein NP, 2012, PEDIATR INFECT DIS J, V31, P64, DOI 10.1097/INF.0b013e31823dce5c
   Koebnick Corinna, 2012, Perm J, V16, P37
   MacNeil JR, 2018, CLIN INFECT DIS, V66, P1276, DOI 10.1093/cid/cix993
   MacNeil JR, 2014, MMWR-MORBID MORTAL W, V63, P527
   Nolan TM, 2014, HUM VACC IMMUNOTHER, V10, P280, DOI 10.4161/hv.27051
   Price VE, 2007, INFECT DIS CLIN N AM, V21, P697, DOI 10.1016/j.idc.2007.07.002
   Raphael JL, 2013, J NATL MED ASSOC, V105, P157, DOI 10.1016/S0027-9684(15)30109-7
   Reeves SL, 2019, BLOOD ADV, V3, P1574, DOI 10.1182/bloodadvances.2018028043
   Tregnaghi M, 2014, INT J INFECT DIS, V26, P22, DOI 10.1016/j.ijid.2014.03.1390
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 228
EP 234
DI 10.1016/j.vaccine.2019.10.024
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700018
PM 31648912
OA Other Gold
DA 2020-05-12
ER

PT J
AU Zahraei, SM
   Mokhtari-Azad, T
   Izadi, S
   Mohammadi, M
   Sabouri, A
AF Zahraei, Seyed Mohsen
   Mokhtari-Azad, Talat
   Izadi, Shahrokh
   Mohammadi, Mahdi
   Sabouri, Azam
TI Seroprevalence of anti-rubella and anti-measles antibodies in women at
   the verge of marriage in Iran
SO VACCINE
LA English
DT Article
DE Rubella; Measles; Seroprevalence; Antibody; Iran; Women
ID VACCINE FAILURES; PREGNANT-WOMEN; MMR-VACCINE; IMMUNITY; AVIDITY;
   ELIMINATION
AB Background: Measles and rubella as two highly contagious eruptive diseases are on the agenda to be eliminated in Iran by 2020. To evaluate the seroimmunity of the future mothers against rubella and measles, a nationwide serosurvey was implemented in 10 provinces, selected at random from 31 provinces in the country.
   Methods: using a multistage sampling method, 1600 participants were interviewed and blood sampled in 40 'Pre-marriage Consultation Centers' across 40 districts. Using ELISA method, the sera were tested for anti-rubella and anti-measles IgG antibodies in the National Reference Laboratory for Measles and Rubella, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
   Results: Of the 1600 initial participants, the sera of 1573 participants were tested for rubella and 1569 for measles. The total seroprevalence of anti-rubella and anti-measles antibodies were 90.6% (95%CI: 89.1 to 92.0%) and 80.7% (95%CI: 78.7 to 82.6%) respectively. After 14 years, the effect of the immunization campaign of 2003 against rubella and measles on the age group of 5 to 25 years, was still apparent, i.e., there was a sharp difference between the seroprevalence of antibody (against both measles and rubella) of those who at the time of the present study were above 18 years with the younger age cohorts. For both diseases, higher seroprevalence of antibodies was detected in women above 18 years old.
   Conclusion: Implementation of a Supplemental Immunization activity or revision of the national immunization schedule to add a third dose of measles and rubella containing vaccine during adolescence are/might be considered as possible options for bridging the gap in the seroimmunity of the younger age groups. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zahraei, Seyed Mohsen] Minist Hlth & Med Educ, Ctr Communicable Dis Control, Tehran, Iran.
   [Mokhtari-Azad, Talat] Univ Tehran Med Sci, Sch Publ Hlth, Natl Reference Lab Measles & Rubella, Tehran, Iran.
   [Izadi, Shahrokh; Mohammadi, Mahdi] Zahedan Univ Med Sci, Hlth Promot Res Ctr, Sch Publ Hlth, Zahedan, Iran.
   [Sabouri, Azam] Minist Hlth & Med Educ, Ctr Communicable Dis Control, Focal Point Measles & Rubella Surveillance, Tehran, Iran.
RP Izadi, S (reprint author), POB 98155-759, Zahedan, Iran.
EM izadish@yahoo.com
RI Izadi, Shahrokh/J-2409-2017
OI Izadi, Shahrokh/0000-0002-0496-7847
FU World Health Organization, Tehran Office [201700169, 2017/700717-0]
FX This work was supported by the World Health Organization, Tehran Office,
   [WHO CONTRACT NO: 201700169; WHO REFERENCE NO: 2017/700717-0; WHO
   OFFICE: EM_IRA WHO Representative's Office, Iran]. Our deepest
   appreciation goes to the hard-working health workers, at all levels,
   from the managerial levels to the most front-line workers of health
   services of the involved universities for helping make this study
   possible. In addition, the authors would like to thank and appreciate
   the hard work of all the staff of the Reference National Measles/Rubella
   Laboratory in the School of Public Health, Tehran University of Medical
   Sciences, Tehran, Iran.
CR Adam O, 2013, E MEDITERR HEALTH J, V19, P812
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205
   [Anonymous], 2011, Wkly Epidemiol Rec, V86, P301
   [Anonymous], 2017, IMMUNIZATION VACCINA
   Barah FA, 2010, SAUDI MED J, V31, P78
   Cardemil CV, 2016, INT J INFECT DIS, V49, P189, DOI 10.1016/j.ijid.2016.05.020
   Cheng WY, 2011, EMERG INFECT DIS, V17, P1523, DOI [10.3201/edi1708.100800, 10.3201/eid1708.100800]
   Cohen BJ, 2006, J VIROL METHODS, V131, P209, DOI 10.1016/j.jviromet.2005.08.001
   Doroudohi M., 2001, Eastern Mediterranean Health Journal, V7, P128
   DOWDLE WR, 1970, B WORLD HEALTH ORGAN, V42, P419
   Gans HA, 2013, J INFECT DIS, V207, P574, DOI 10.1093/infdis/jis719
   Goncalves G, 2015, VACCINE, V33, P5057, DOI 10.1016/j.vaccine.2015.08.057
   GRILLNER L, 1983, SCAND J INFECT DIS, V15, P321, DOI 10.3109/inf.1983.15.issue-4.01
   Halloran ME, 2010, DESIGN ANAL VACCINE
   He HQ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2046-5
   He HQ, 2013, VACCINE, V31, P533, DOI 10.1016/j.vaccine.2012.11.014
   Honarvar B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055043
   Izadi S, 2015, E MEDITERR HEALTH J, V21, P396, DOI 10.26719/2015.21.6.396
   Izadi S, 2018, HUM VACC IMMUNOTHER, V14, P2957, DOI 10.1080/21645515.2018.1504537
   Izadi S, 2018, HUM VACC IMMUNOTHER, V14, P1412, DOI 10.1080/21645515.2018.1436920
   Kontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568
   Low N, 2015, NEW ENGL J MED, V372, P1519, DOI 10.1056/NEJMoa1407417
   Pannuti CS, 2004, CLIN DIAGN LAB IMMUN, V11, P119, DOI 10.1128/CDLI.11.1.119-122.2004
   Park S, 2012, ACM T INTERACT INTEL, V2, DOI 10.1145/2209310.2209311
   Paunio M, 2000, EPIDEMIOL INFECT, V124, P263, DOI 10.1017/S0950268899003222
   Perez SC, 2017, CLIN INFECT DIS, V65, P1094, DOI 10.1093/cid/cix510
   Sawadkohi RB, 2014, IRAN RED CRESCENT ME, V16, DOI 10.5812/ircmj.10431
   Sharma HJ, 2011, J INFECT DEV COUNTR, V5, P874, DOI 10.3855/jidc.1847
   Siemens Enzygnost Anti-Measles Virus/IgG, 2011, ENZ IMM QUAL DET QUA
   Thompson KM, 2016, RISK ANAL, V36, P1383, DOI 10.1111/risa.12637
   Tischer A, 2007, EPIDEMIOL INFECT, V135, P787, DOI 10.1017/S0950268807008266
   Tischer A, 2007, J CLIN VIROL, V38, P204, DOI 10.1016/j.jcv.2006.12.017
   WHO, 2018, RUB FACT SHEET
   Word Health Organization, 2015, VACC COV CLUST SURV
   World Health Organization, 2018, WEEKLY EPIDEMIOL REC, V93, P321
   World Health Organization. Regional Office for the Eastern Mediterranean, 2019, WHOEMEPI353E
   Zahraei SM, 2019, HUM VACC IMMUNOTHER, V15, P2117, DOI 10.1080/21645515.2018.1504527
   Zahraei SM, 2011, J INFECT DIS, V204, pS305, DOI 10.1093/infdis/jir076
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 235
EP 241
DI 10.1016/j.vaccine.2019.10.026
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700019
PM 31668816
DA 2020-05-12
ER

PT J
AU Essink, B
   Fierro, C
   Rosen, J
   Figueroa, AL
   Zhang, B
   Verhoeven, C
   Edelman, J
   Smolenov, I
AF Essink, Brandon
   Fierro, Carlos
   Rosen, Jeffrey
   Figueroa, Amparo L.
   Zhang, Bin
   Verhoeven, Carole
   Edelman, Jonathan
   Smolenov, Igor
TI Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza
   vaccine versus standard and alternate B strain MF59-adjuvanted trivalent
   influenza vaccines in older adults
SO VACCINE
LA English
DT Article
DE MF59; Influenza vaccine; Fluad; Adjuvanted quadrivalent influenza
   vaccine; Adjuvanted trivalent influenza vaccine; Elderly
ID MF59
AB Objective: Evaluate whether adjuvanted quadrivalent influenza vaccine (aQIV) elicits a noninferior immune response compared with a licensed adjuvanted trivalent influenza vaccine (aTIV-1; Fluad (TM)) and aTIV-2 containing an alternate B strain, examine whether aQIV had immunological superiority for the B strain absent from aTIV comparators, and evaluate reactogenicity and safety among adults >= 65 years.
   Methods: In a multicenter, double-blind, randomized controlled trial, adults >= 65 years were randomized 2:1:1 to vaccination with aQIV (n = 889), aTIV-1 (n = 445), or aTIV-2 (n = 444) during the 2017-2018 influenza season. Immunogenicity was assessed by hemagglutination inhibition (HI) assay conducted on serum samples collected before vaccination and 21 days after vaccination for homologous influenza strains.
   Results: aQIV met non-inferiority criteria for geometric mean titer ratios (GMT ratios) and seroconversion rate (SCR) differences against aTIV. The upper bounds of the 2-sided 95% confidence interval (CI) for GMT ratios were <1.5 for all 4 strains (A/H1N1 = 1.27, A/H3N2 = 1.09, B-Yamagata = 1.08, B-Victoria = 1.08). The upper bounds of the 95% CI of the SCR differences were <10% for all 4 strains (A/H1N1 = 7.76%, A/H3N2 = 4.96%, B-Yamagata = 3.27%, B-Victoria = 2.55%). aQIV also met superiority criteria (upper bound of 95% CI for GMT ratios <1 and SCR differences <0) for B strain absent from aTIV comparators (B-Yamagata GMT ratio = 0.70, SCR difference = -8.81%; B-Victoria GMT ratio = 0.78, SCR difference = -8.11%). aQIV and aTIV vaccines were immunogenic and well-tolerated. The immunological benefit of aQIV was also demonstrated in age subgroups 65-74 years, 75-84 years, and >= 85 years and in those with high comorbidity risk scores. Reactogenicity profiles were generally comparable.
   Conclusion: aQIV induces a similar immune response as the licensed aTIV vaccine against homologous influenza strains and has a comparable reactogenicity and safety profile. Superior immunogenicity against the additional B strain was observed, indicating that aQIV could provide a broader protection than aTIV against influenza in older adults. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Essink, Brandon] Meridian Clin Res, Creighton, NE USA.
   [Fierro, Carlos] Johnson Cty Clin Trials, Lenexa, KS USA.
   [Rosen, Jeffrey] Alliance MultiSpecial Res, Coral Gables, FL USA.
   [Figueroa, Amparo L.; Zhang, Bin; Edelman, Jonathan; Smolenov, Igor] Seqirus Inc, Clin Vaccines, Cambridge, MA 02139 USA.
   [Verhoeven, Carole] Seqirus Netherlands BV, Amsterdam, Netherlands.
RP Smolenov, I (reprint author), Seqirus Inc, 50 Hampshire St, Cambridge, MA 02139 USA.
EM bessink@mcrmed.com; cfierro@jcct.com; Jeffrey.Rosen@amrllc.com;
   amparo.figueroa@seqirus.com; bin.zhang@seqirus.com;
   Carole.Verhoeven@Seqirus.com; Jonathan.edelman@seqirus.com;
   Igor.Smolenov@Seqirus.com
FU Seqirus Inc.
FX The clinical trial was funded by Seqirus Inc. The sponsor had primary
   responsibility for clinical trial design and study vaccines, protocol
   development, study monitoring, data management, and statistical analyses
   and writing the clinical study report and drafting of this manuscript.
CR Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623
   Caini S, 2015, INFLUENZA OTHER RESP, V9, P3, DOI 10.1111/irv.12319
   Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Camilloni B, 2015, HUM VACC IMMUNOTHER, V11, P553, DOI 10.1080/21645515.2015.1011562
   Center for Biologics Evaluation and Research, 2007, GUID IND CLIN DAT EN
   Centers for Disease Control and Prevention, 2018, TRANSCR CDC UPD FLU
   Centers for Disease Control and Prevention, 2018, EST INFL VACC COV AD
   Da Silva FT, 2013, VACCINE, V31, P1870, DOI 10.1016/j.vaccine.2013.01.042
   Frey SE, 2014, VACCINE, V32, P5027, DOI 10.1016/j.vaccine.2014.07.013
   Galli G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI 10.1073/pnas.0903181106
   Greenberg DP, 2017, HUM VACC IMMUNOTHER, V13, P2058, DOI 10.1080/21645515.2017.1344375
   Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1
   Hak E, 2004, J INFECT DIS, V189, P450, DOI 10.1086/381165
   Khurana S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002336
   Kobayashi Osamu, 2014, Trop Med Health, V42, P87, DOI 10.2149/tmh.2014-S12
   Mannino S, 2012, AM J EPIDEMIOL, V176, P527, DOI 10.1093/aje/kws313
   Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105
   Mullooly JP, 2007, VACCINE, V25, P846, DOI 10.1016/j.vaccine.2006.09.041
   O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/erv.12.140, 10.1586/ERV.12.140]
   Pellegrini M, 2009, VACCINE, V27, P6959, DOI 10.1016/j.vaccine.2009.08.101
   Ray R, 2017, HUM VACC IMMUNOTHER, V13, P1640, DOI 10.1080/21645515.2017.1313375
   Reber AJ, 2012, AGING DIS, V3, P68
   Rothberg MB, 2008, AM J MED, V121, P258, DOI 10.1016/j.amjmed.2007.10.040
   Sasaki S, 2011, J CLIN INVEST, V121, P3109, DOI 10.1172/JCI57834
   Seidman JC, 2012, INFLUENZA OTHER RESP, V6, P52, DOI 10.1111/j.1750-2659.2011.00268.x
   Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402
   Seubert A, 2011, P NATL ACAD SCI USA, V108, P11169, DOI 10.1073/pnas.1107941108
   Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059
   Viboud C, 2008, PLOS MED, V5, P1423, DOI 10.1371/journal.pmed.0050216
   Wood J M, 2011, Pharmeur Bio Sci Notes, V2011, P36
   World Health Organization, 2017, REC COMP INFL VIR VA
   World Health Organization (WHO), 2019, WHO REC COMP INFL VI
   Zamparo E, 2011, J Prev Med Hyg, V52, P116
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 242
EP 250
DI 10.1016/j.vaccine.2019.10.021
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700020
PM 31635976
OA Other Gold
DA 2020-05-12
ER

PT J
AU Rainisch, G
   Adhikari, B
   Meltzer, MI
   Langley, G
AF Rainisch, Gabriel
   Adhikari, Bishwa
   Meltzer, Martin, I
   Langley, Gayle
TI Estimating the impact of multiple immunization products on
   medically-attended respiratory syncytial virus (RSV) infections in
   infants
SO VACCINE
LA English
DT Article
DE RSV; Maternal vaccination; Passive immunization; Model; Infants; United
   States
ID UNITED-STATES; REDUCES HOSPITALIZATION; VACCINATION STRATEGIES;
   YOUNG-CHILDREN; DISEASE; PALIVIZUMAB; BURDEN; RISK
AB Background: Palivizumab, a monoclonal antibody and the only licensed immunization product for preventing respiratory syncytial virus (RSV) infection, is recommended for children with certain high-risk conditions. Other antibody products and maternal vaccines targeting young infants are in clinical development. Few studies have compared products closest to potential licensure and have primarily focused on the effects on hospitalizations only. Estimates of the impact of these products on medically-attended (MA) infections in a variety of healthcare settings are needed to assist with developing RSV immunization recommendations.
   Methods: We developed a tool for practicing public health officials to estimate the impact of immunization strategies on RSV-associated MA lower respiratory tract infections (LRTIs) in various healthcare settings among infants <12 months. Users input RSV burden and seasonality and examine the influence of altering product efficacy and uptake assumptions. We used the tool to evaluate candidate products' impacts among a US birth cohort.
   Results: We estimated without immunization, 407,360 (range: 339,650-475,980) LRTIs are attended annually in outpatient clinics, 147,240 (126,070-168,510) in emergency departments (EDs), and 33,180 (24,760-42,900) in hospitals. A passive antibody candidate targeting all infants prevented the most LRTIs: 196,470 (48% of visits without immunization) outpatient clinic visits (range: 163,810-229,650), 75,250 (51%) EDs visits (64,430-86,090), and 18,140 (55%) hospitalizations (13,770-23,160). A strategy combining maternal vaccine candidate and palivizumab prevented 58,210 (14% of visits without immunization) LRTIs in outpatient clinics (range: 48,520-67,970), 19,580 (13%) in EDs (16,760-22,400), and 8,190 (25%) hospitalizations (6,390-10,150).
   Conclusions: Results underscore the potential for anticipated products to reduce serious RSV illness. Our tool (provided to readers) can be used by different jurisdictions and accept updated data. Results can aid economic evaluations and public health decision-making regarding RSV immunization products. Published by Elsevier Ltd.
C1 [Rainisch, Gabriel; Adhikari, Bishwa; Meltzer, Martin, I; Langley, Gayle] US Ctr Dis Control & Prevent, CDC, Atlanta, GA USA.
   [Rainisch, Gabriel; Adhikari, Bishwa; Meltzer, Martin, I] NCEZID, Atlanta, GA USA.
   [Langley, Gayle] NCIRD, Atlanta, GA USA.
RP Rainisch, G (reprint author), Ctr Dis Control & Prevent CDC, 1600 Clifton Rd NE,Mailstop MS H24-11, Atlanta, GA 30333 USA.
EM GRainisch@cdc.gov
FU Intramural CDC HHS [CC999999]
CR Acedo L, 2010, EPIDEMIOL INFECT, V138, P853, DOI 10.1017/S0950268809991373
   Andabaka T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006602.pub4
   [Anonymous], 2018, FLUVAXVIEW
   Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303
   Byington CL, 2015, PEDIATRICS, V135, pE24, DOI 10.1542/peds.2014-2151
   Cromer D, 2017, LANCET PUBLIC HEALTH, V2, pE367, DOI 10.1016/S2468-2667(17)30103-2
   Feltes TF, 2003, J PEDIATR-US, V143, P532, DOI 10.1067/S0022-3476(03)00454-2
   GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026
   Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877
   Haynes AK, 2013, J INFECT DIS, V208, pS246, DOI 10.1093/infdis/jit515
   Healy CM, 2015, VACCINE, V33, P4983, DOI 10.1016/j.vaccine.2015.07.018
   Hill HA, 2017, MMWR-MORBID MORTAL W, V66, P1171, DOI 10.15585/mmwr.mm6643a3
   Hogan AB, 2017, VACCINE, V35, P6172, DOI 10.1016/j.vaccine.2017.09.043
   Kimberlin D. W., 2018, REPORT COMMITTEE INF
   Lively JY, 2019, J PEDIAT INFECT DIS
   Medlmmune, 2016, MEDI8897PH2B MEDL
   Novavax, 2015, STUD DET SAF EFF RSV
   Novavax, 2019, WORLD VACC C WASH DC
   Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531
   O'Brien KL, 2015, LANCET INFECT DIS, V15, P1398, DOI 10.1016/S1473-3099(15)00247-9
   Pan-Ngum W, 2017, VACCINE, V35, P403, DOI 10.1016/j.vaccine.2016.10.073
   PATH, 2018, RSV VACC MAB SNAPSH
   Pavilack M, 2017, INFECT DIS THER
   Poletti P, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0283-x
   Regnier SA, 2013, VACCINE, V31, P4347, DOI 10.1016/j.vaccine.2013.07.024
   RINCON B, 2016, NATL VITAL STAT REPO, V67, DOI DOI 10.3989/GYA.0562161
   Rose EB, 2018, MMWR-MORBID MORTAL W, V67, P71, DOI 10.15585/mmwr.mm6702a4
   Scheltema NM, 2018, VACCINE, V36, P4693, DOI 10.1016/j.vaccine.2018.06.021
   Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]
   Stewart DL, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-334
   Wong SK, 2018, EXPERT REV RESP MED, V12, P27, DOI 10.1080/17476348.2018.1401926
   Yamin D, 2016, P NATL ACAD SCI USA, V113, P13239, DOI 10.1073/pnas.1522597113
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 251
EP 257
DI 10.1016/j.vaccine.2019.10.023
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700021
PM 31740097
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Salerno-Goncalves, R
   Tettelin, H
   Luo, D
   Guo, Q
   Ardito, MT
   Martin, WD
   De Groot, AS
   Sztein, MB
AF Salerno-Goncalves, Rosangela
   Tettelin, Herve
   Luo, David
   Guo, Qin
   Ardito, Matthew T.
   Martin, William D.
   De Groot, Anne S.
   Sztein, Marcelo B.
TI Differential functional patterns of memory CD4(+) and CD8(+) T-cells
   from volunteers immunized with Ty21 a typhoid vaccine observed using a
   recombinant Escherichia coli system expressing S. Typhi proteins
SO VACCINE
LA English
DT Article
DE Salmonella; T-cells; Recombinant E. coli; Vaccine; Human
ID SALMONELLA-TYPHI; MEDIATED-IMMUNITY; ORAL IMMUNIZATION; RESPONSES;
   ANTIGEN; EFFECTOR; STRAINS; LINEAGE; OMPR; IDENTIFICATION
AB It is widely accepted that CD4(+) and CD8(+) T-cells play a significant role in protection against Salmonella enterica serovar Typhi (S. Typhi), the causative agent of the typhoid fever. However, the antigen specificity of these T-cells remains largely unknown. Previously, we demonstrated the feasibility of using a recombinant Escherichia coli (E. coli) expression system to uncover the antigen specificity of CD4(+) and CD8(+) T cells. Here, we expanded these studies to include the evaluation of 12 additional S. Typhi proteins: 4 outer membrane proteins (OmpH, OmpL, OmpR, OmpX), 3 Vi-polysaccharide biosynthesis proteins (TviA, TviB, TviE), 3 cold shock proteins (CspA, CspB, CspC), and 2 conserved hypothetical proteins (Chp 1 and Chp 2), all selected based on the bioinformatic analyses of the content of putative T-cell epitopes. CD4(+) and CD8(+). T cells from 15 adult volunteers, obtained before and 42 days after immunization with oral live attenuated Ty21a vaccine, were assessed for their functionality (i.e., production of cytokines and cytotoxic expression markers in response to stimulation with selected antigens) as measured by flow cytometry. Although volunteers differed on their T-cell antigen specificity, we observed T-cell immune responses against all S. Typhi proteins evaluated. These responses included 9 proteins, OmpH, OmpR, TviA, TviE, CspA, CspB, CspC, Chp 1 and Chp 2, which have not been previously reported to elicit T-cell responses. Interestingly, we also observed that, regardless of the protein, the functional patterns of the memory T-cells were different between CD4(+) and CD8(+) T cells. In sum, these studies demonstrated the feasibility of using bioinformatic analysis and the E. coli expressing system described here to uncover novel immunogenic T-cell proteins that could serve as potential targets for the production of protein-based vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Salerno-Goncalves, Rosangela; Luo, David; Sztein, Marcelo B.] Univ Maryland, Sch Med, Dept Pediat, Ctr Vaccine Dev & Global Hlth CVD, 685 West Baltimore St,HSF1, Baltimore, MD 21201 USA.
   [Tettelin, Herve; Guo, Qin] Univ Maryland, Sch Med, Dept Microbiol & Immunol, 670 West Baltimore St,HSF3, Baltimore, MD 21201 USA.
   [Tettelin, Herve; Guo, Qin] Univ Maryland, Sch Med, Inst Genome Sci, 670 West Baltimore St,HSF3, Baltimore, MD 21201 USA.
   [Ardito, Matthew T.; Martin, William D.; De Groot, Anne S.] Univ Rhode Isl, Dept Cell & Mol Biol, Inst Immunol & Informat iCubed, 80 Washington St, Providence, RI 02908 USA.
   [Ardito, Matthew T.; Martin, William D.; De Groot, Anne S.] EpiVax Inc, 188 Valley St Suite 424, Providence, RI USA.
RP Salerno-Goncalves, R (reprint author), Univ Maryland, Sch Med, Dept Pediat, Ctr Vaccine Dev & Global Hlth CVD, 685 West Baltimore St,HSF1, Baltimore, MD 21201 USA.
EM rmezghan@som.umaryland.edu
OI Salerno-Goncalves, Rosangela/0000-0003-2999-4275
FU National Institute of Allergy and Infectious Diseases (NIAID), National
   Institutes of Health (NIH), Department of Health and Human Services
   (DHHS) [R01 A1036525, U19 AI082655, U19 A1082642]
FX This work was supported, in part, by National Institute of Allergy and
   Infectious Diseases (NIAID), National Institutes of Health (NIH),
   Department of Health and Human Services (DHHS) federal research grants
   (https://www.niaid.nih.gov) R01 A1036525, and U19 AI082655 (Cooperative
   Center for Human Immunology [CCHI]) to M.B. Sztein; and U19 A1082642
   (CCHI) to De Groot. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institute of Allergy and Infectious Diseases, the National
   Institutes of Health. The funders had no role in study design, data
   collection, and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 1997, Int Dig Health Legis, V48, P231
   Baker S, 2007, CLIN INFECT DIS, V45, pS29, DOI 10.1086/518143
   Barat S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002966
   Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5
   Booth JS, 2019, HUM VACC IMMUNOTHER, V15, P1409, DOI 10.1080/21645515.2018.1564570
   Booth JS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00294
   Bouwer HGA, 2006, P NATL ACAD SCI USA, V103, P5102, DOI 10.1073/pnas.0509381103
   Bumann D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00381
   Coren LV, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-64
   Deng W, 2003, J BACTERIOL, V185, P2330, DOI 10.1128/JB.185.7.2330-2337.2003
   Eloe-Fadrosh EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062026
   Fernandez-Mora M, 2004, J BACTERIOL, V186, P2909, DOI 10.1128/JB.186.10.2909-2920.2004
   Fresnay S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00208
   Fresnay S, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0819-7
   Galdiero S, 2012, CURR PROTEIN PEPT SC, V13, P843, DOI 10.2174/138920312804871120
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Hu PQ, 2004, J IMMUNOL, V172, P1595, DOI 10.4049/jimmunol.172.3.1595
   Ishihama Y, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-102
   Kirkpatrick BD, 2005, J INFECT DIS, V192, P360, DOI 10.1086/431605
   Lamoreaux L, 2006, NAT PROTOC, V1, P1507, DOI 10.1038/nprot.2006.268
   LEVINE MM, 1987, LANCET, V1, P1049
   Levine MM, 1999, VACCINE, V17, pS22, DOI 10.1016/S0264-410X(99)00231-5
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Lundin BS, 2002, INFECT IMMUN, V70, P5622, DOI 10.1128/IAI.70.10.5622-5627.2002
   MASTROENI P, 1992, MICROB PATHOGENESIS, V13, P477, DOI 10.1016/0882-4010(92)90014-F
   McArthur MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038408
   McConnell SC, 2016, P NATL ACAD SCI USA, V113, pE5014, DOI 10.1073/pnas.1607602113
   Michaux C, 2017, P NATL ACAD SCI USA, V114, P6824, DOI 10.1073/pnas.1620772114
   Moise L, 2015, HUM VACC IMMUNOTHER, V11, P2312, DOI 10.1080/21645515.2015.1061159
   Moreno-Eutimio MA, 2013, IMMUNOLOGY, V139, P459, DOI 10.1111/imm.12093
   Muranski P, 2013, BLOOD, V121, P2402, DOI 10.1182/blood-2012-09-378653
   Muranski P, 2011, IMMUNITY, V35, P972, DOI 10.1016/j.immuni.2011.09.019
   Napolitani G, 2018, NAT IMMUNOL, V19, P742, DOI 10.1038/s41590-018-0133-z
   Nickerson KP, 2018, EBIOMEDICINE, V31, P92, DOI 10.1016/j.ebiom.2018.04.005
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   Perez-Toledo Marisol, 2017, Front Immunol, V8, P230, DOI 10.3389/fimmu.2017.00230
   PICKARD D, 1994, INFECT IMMUN, V62, P3984, DOI 10.1128/IAI.62.9.3984-3993.1994
   Salerno-Goncalves R, 2002, J IMMUNOL, V169, P2196, DOI 10.4049/jimmunol.169.4.2196
   Salerno-Goncalves R, 2005, INFECT IMMUN, V73, P3521, DOI 10.1128/IAI.73.6.3521-3530.2005
   Salerno-Goncalves R, 2004, J IMMUNOL, V173, P5852, DOI 10.4049/jimmunol.173.9.5852
   Salerno-Goncalves R, 2003, J IMMUNOL, V170, P2734, DOI 10.4049/jimmunol.170.5.2734
   Salerno-Goncalves R, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007650
   Salerno-Goncalves R, 2006, TRENDS MICROBIOL, V14, P536, DOI 10.1016/j.tim.2006.10.004
   Salerno-Goncalves R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02543
   Salerno-Goncalves R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005912
   Salerno-Goncalves R, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00511
   Salerno-Goncalves R, 2011, GASTROENTEROLOGY, V141, pE18, DOI 10.1053/j.gastro.2011.04.062
   Salerno-Goncalves R, 2010, CLIN VACCINE IMMUNOL, V17, P1305, DOI 10.1128/CVI.00234-10
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Sheikh A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001193
   Sheikh A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000908
   Singh R, 2007, CLIN EXP IMMUNOL, V148, P486, DOI 10.1111/j.1365-2249.2007.03362.x
   Song JM, 2013, NATURE, V499, P350, DOI 10.1038/nature12377
   Sztein MB, 2007, CLIN INFECT DIS, V45, pS15, DOI 10.1086/518140
   Sztein MB, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029546
   SZTEIN MB, 1995, J IMMUNOL, V155, P3987
   Takahashi S, 2003, CANCER RES, V63, P5213
   Terry FE, 2015, EXPERT REV VACCINES, V14, P21, DOI 10.1586/14760584.2015.955478
   Tipton AG, 2016, ECOSPHERE, V7, DOI 10.1002/ecs2.1570
   Viret JF, 1999, INFECT IMMUN, V67, P3680, DOI 10.1128/IAI.67.7.3680-3685.1999
   Wahid R, 2008, MUCOSAL IMMUNOL, V1, P389, DOI 10.1038/mi.2008.30
   Wahid R, 2007, VACCINE, V25, P1416, DOI 10.1016/j.vaccine.2006.10.040
   Winter SE, 2008, CELL MICROBIOL, V10, P247, DOI 10.1111/j.1462-5822.2007.01037.x
   Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x
   Zhang Y, 2018, CURR MICROBIOL, V75, P773, DOI 10.1007/s00284-018-1447-7
   Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001
NR 66
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 258
EP 270
DI 10.1016/j.vaccine.2019.10.020
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700022
PM 31629569
DA 2020-05-12
ER

PT J
AU Chen, WW
   Stoecker, C
AF Chen, Weiwei
   Stoecker, Charles
TI Mass media coverage and influenza vaccine uptake
SO VACCINE
LA English
DT Article
DE Influenza vaccines; Media coverage; The elderly
ID SEASONAL INFLUENZA; VACCINATIONS; RECEIPT
AB Background: Despite the high risk and economic burden of influenza-related diseases, about one-third of adults aged 65 and older still forego annual influenza vaccination. Mass media, as a leading source of health information for the public, can influence and promote health behaviors, such as vaccination. However, empirical evidence on the effect of media coverage on influenza vaccination uptake remains limited.
   Objective: We examine the impact of media coverage by month on influenza vaccination among the elderly.
   Methods: This study exploits variation in the number of influenza-related news reports by month and across seasons and examines its impact on vaccine uptake in a linear probability model with state fixed effects and seasonable random effects. We combine individual-level influenza vaccination data from the Behavioral Risk Factor Surveillance System (BRFSS), 2010-2017, and media coverage data from the NewsBank database along with several other data sources including weather data from the Global Historical Climatology Network and data on the influenza season from FluView from the Centers for Disease Control and Prevention.
   Results: Our main results indicate every 100 additional media reports about influenza published in October were associated with an increase in the vaccination uptake rate among those aged 65+ of 0.3 percentage points. This association holds in January, but not in November or December. It was more pronounced in late-peak seasons and in seasons where the vaccine was highly effective.
   Conclusion: This study provides suggestive evidence that variation in the number of media reports is associated with variation in influenza vaccination uptake. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Weiwei] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Hlth Policy & Management, 11200 SW 8th St, Miami, FL 33199 USA.
   [Stoecker, Charles] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Hlth Policy & Management, 1440 Canal St,Suite 1900, New Orleans, LA 70112 USA.
RP Chen, WW (reprint author), 11200 SW 8th St, Miami, FL 33199 USA.
EM wechen@fiu.edu
CR [Anonymous], 2019, FLU SEAS
   [Anonymous], 2018, RES GUID NEWS ENG 36
   Beyer WEP, 2013, VACCINE, V31, P6030, DOI 10.1016/j.vaccine.2013.09.063
   Burger AE, 2014, VACCINE, V32, P3950, DOI 10.1016/j.vaccine.2014.05.032
   CDC, 2018, KEY FACTS SEAS FLU V
   CDC, 2018, SEAS INFL VACC EFF 2
   CDC, 2019, 2010 11 2017 18 INFL
   CDC. National, 2018, FLUVIEW
   Engle M., LIBGUIDES NEWS DATAB
   Fishman JM, 2006, MAYO CLIN PROC, V81, P291, DOI 10.4065/81.3.291
   Ma KK, 2006, PEDIATRICS, V117, pE157, DOI 10.1542/peds.2005-1079
   Meyer SB, 2016, J HEALTH COMMUN, V21, P1088, DOI 10.1080/10810730.2016.1222038
   Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046
   Shropshire AM, 2013, J AM COLL HEALTH, V61, P435, DOI 10.1080/07448481.2013.830619
   Signorelli C, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h116
   Smith MJ, 2008, PEDIATRICS, V121, pE836, DOI 10.1542/peds.2007-1760
   Trombetta CM, 2018, HUM VACC IMMUNOTHER, V14, P657, DOI 10.1080/21645515.2017.1423153
   Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0
   Wakefield MA, 2010, LANCET, V376, P1261, DOI 10.1016/S0140-6736(10)60809-4
   Yoo BK, 2010, HEALTH SERV RES, V45, P1287, DOI 10.1111/j.1475-6773.2010.01127.x
   Zimmerman RK, 2003, VACCINE, V21, P1486, DOI 10.1016/S0264-410X(02)00698-9
NR 21
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 271
EP 277
DI 10.1016/j.vaccine.2019.10.019
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700023
PM 31699506
DA 2020-05-12
ER

PT J
AU Mandon, ED
   Pizzorno, A
   Traversier, A
   Champagne, A
   Hamelin, ME
   Lina, B
   Boivin, G
   Dejean, E
   Rosa-Calatrava, M
   Jawhari, A
AF Mandon, Elodie Desuzinges
   Pizzorno, Andres
   Traversier, Aurelien
   Champagne, Anne
   Hamelin, Marie Eve
   Lina, Bruno
   Boivin, Guy
   Dejean, Emmanuel
   Rosa-Calatrava, Manuel
   Jawhari, Anass
TI Novel calixarene-based surfactant enables low dose split inactivated
   vaccine protection against influenza infection
SO VACCINE
LA English
DT Article
DE Split inactivated influenza antigen; Hemagglutinin;
   Detergent/surfactant; Triton; Calixarene; Immunization; H1N1
ID QUANTITATIVE-DETERMINATION; VIRUS; ANTIBODIES; PROTEINS; EFFICACY;
   ANTIGEN
AB Influenza A viruses cause major morbidity and represent a severe global health problem. Current influenza vaccines are mainly egg-based products requiring the split of whole viruses using classical detergents such as Triton X-100, which implies certain limitations. Here, we report the use of the novel calixarene-based surfactant CALX133ACE as an alternative to classical detergents for influenza inactivated split vaccine preparation. We confirmed that CALX133ACE-based split HA antigens are fully functional and quantifiable by the "gold standard" method SRID. Additionally, as in the case of the Triton X-100-based split, the CALX133ACE-based split antigens are stable for at least 6 months at 4 degrees C. Moreover, immunization of mice with CALXI33ACE-based split NYMC X-179A (H1N1) antigens harboring 10 to 30-fold less antigen than the commercialized trivalent inactivated vaccines Vaxigrip (R) or Fluviral (R) induced comparable efficient protection and neutralizing antibody responses against A (H1N1)pdm09 infection. Taken together, our results demonstrate for the first time the use of a calixarene-based detergent as an efficient splitting agent for the production of optimized influenza split antigens, paving the way for significant improvement in the vaccine manufacturing process, notably with regard to the current regulation on the prohibition of endocrine disruptors, such as Triton X-100. (C) 2019 Published by Elsevier Ltd.
C1 [Mandon, Elodie Desuzinges; Champagne, Anne; Dejean, Emmanuel; Jawhari, Anass] CALIXAR, 60 Ave Rockefeller 69008, Lyon, France.
   [Pizzorno, Andres; Traversier, Aurelien; Lina, Bruno; Rosa-Calatrava, Manuel] Univ Lyon, Virol & Pathol Humaine VirPath Team, CIRI, INSERM U1111,CNRS,UMR5308 ENS Lyon,Univ Claude Be, Lyon, France.
   [Traversier, Aurelien; Rosa-Calatrava, Manuel] Univ Lyon, Fac Med RTH Laennec, VirNext, Univ Claude Bernard Lyon 1, F-69008 Lyon, France.
   [Hamelin, Marie Eve; Boivin, Guy] CHU Quebec, Res Ctr Infect Dis, Quebec City, PQ G1V 4G2, Canada.
   [Hamelin, Marie Eve; Boivin, Guy] Laval Univ, Quebec City, PQ G1V 4G2, Canada.
   [Lina, Bruno] Hosp Civils Lyon, Grp Hosp Nord, Inst Agents Infect, Lab Virol,Ctr Natl Reference Virus Influenza Sud, F-69317 Lyon, France.
RP Jawhari, A (reprint author), CALIXAR, 60 Ave Rockefeller 69008, Lyon, France.; Rosa-Calatrava, M (reprint author), Univ Lyon, Virol & Pathol Humaine VirPath Team, CIRI, INSERM U1111,CNRS,UMR5308 ENS Lyon,Univ Claude Be, Lyon, France.
EM manuel.rosa-calatrava@univ-lyon1.fr; ajawhari@calixar.com
RI Pizzorno, Mario Andres/L-7810-2017
OI Pizzorno, Mario Andres/0000-0002-0918-6804; Rosa-calatrava,
   Manuel/0000-0002-7559-9527; JAWHARI, Anass/0000-0001-8170-0524
FU INSERMInstitut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Claude Bernard Lyon 1; Region Auvergne
   Rhone-alpesRegion Auvergne-Rhone-Alpes
FX GB is the holder of the Canada. Research Chair on Influenza Viruses and
   Other Respiratory Viruses (2006-13, renewed for 2013-20). Parts of this
   work were supported by INSERM, Universite Claude Bernard Lyon 1 and
   Region Auvergne Rhone-alpes.
CR Agez M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15739-1
   Akpinar F, 2015, J VIROL METHODS, V218, P71, DOI 10.1016/j.jviromet.2015.02.006
   Belanger JM, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-72
   Chaptal V, 2017, SCI REP-UK, V7, DOI 10.1038/srep41751
   Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595
   de Graaf H, 2015, EXPERT REV VACCINES, V14, P1055, DOI 10.1586/14760584.2015.1057573
   Fortin T, 2009, MOL CELL PROTEOMICS, V8, P1006, DOI 10.1074/mcp.M800238-MCP200
   Gerdil C, 2003, VACCINE, V21, P1776, DOI 10.1016/S0264-410X(03)00071-9
   GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7
   Grohskopf LA, 2017, AM J TRANSPLANT, V17, P2970, DOI 10.1111/ajt.14511
   Gupta K, 2017, NATURE, V541, P421, DOI 10.1038/nature20820
   Hardy D, 2018, METHODS
   Hendriks J, 2011, VACCINE, V29, pA8, DOI 10.1016/j.vaccine.2011.04.124
   Hirst GK, 1942, J EXP MED, V75, P49, DOI 10.1084/jem.75.1.49
   Kon TC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150700
   Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529
   Lee KKH, 2016, HUM VACC IMMUNOTHER, V12, P1757, DOI 10.1080/21645515.2016.1141846
   Mandon ED, 2017, PROTEIN EXPRES PURIF, V131, P42, DOI 10.1016/j.pep.2016.11.001
   Mandon ED, 2017, ANAL BIOCHEM, V517, P40, DOI 10.1016/j.ab.2016.11.008
   Manini I, 2015, EXPERT REV VACCINES, V14, P789, DOI 10.1586/14760584.2015.1039520
   Matar-Merheb R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018036
   McDonald J, 2011, PAED CHILD HEALT-CAN, V16, P31, DOI 10.1093/pch/16.1.31
   Pica N, 2013, ANNU REV MED, V64, P189, DOI [10.1146/annure, 10.1146/annurev-med-120611-145115]
   Rosati A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9695
   Scheiblhofer S, 2017, EXPERT REV VACCINES, V16, P479, DOI 10.1080/14760584.2017.1306441
   Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023
   Wei CJ, 2008, J VIROL, V82, P6200, DOI 10.1128/JVI.00187-08
   WHO. Global Influenza Surveillance Network, 2011, GLOB INFL SURV NETW
   Wibowo N, 2014, VACCINE, V32, P3651, DOI 10.1016/j.vaccine.2014.04.062
   WOOD JM, 1977, J BIOL STAND, V5, P237, DOI 10.1016/S0092-1157(77)80008-5
NR 30
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 278
EP 287
DI 10.1016/j.vaccine.2019.10.018
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700024
PM 31630939
DA 2020-05-12
ER

PT J
AU Sun, WL
   Li, Q
   Ning, XZ
   Yang, Y
   Guo, JJ
   Zhu, Q
   Guo, Y
   Li, H
   Wang, YP
   Zhou, YS
   Kou, ZH
AF Sun, Weilai
   Li, Qiao
   Ning, Xiuzhe
   Yang, Yi
   Guo, Jingjing
   Zhu, Qing
   Guo, Yan
   Li, Hao
   Wang, Yuepeng
   Zhou, Yusen
   Kou, Zhihua
TI TFPR1 acts as an immune regulator and an efficient adjuvant for proteins
   and peptides by activating immune cells, primarily through TLR2
SO VACCINE
LA English
DT Article
DE Adjuvant; Triflin; Pathogenesis-related-1 family; TLRs
ID RICH SECRETORY PROTEINS; ONCHOCERCA-VOLVULUS; T-CELLS; VENOM; VACCINE;
   EXPRESSION; OV-ASP-1; ANTIGEN; IDENTIFICATION; RECOGNITION
AB Triflin, a non-toxic protein found in the venom of the Habu snake, belongs to the CRISP (cysteine-rich secretory protein) family, which comprises two domains: a C-terminal cysteine-rich domain (CRD) and an N-terminal pathogenesis-related-1 (PR-1) domain. The function of the highly structurally conserved PR-1 domain is unknown. Here, we successfully expressed the PR-1 domain of triflin (hereafter called TFPR1) in E. cot/. Animal experiments showed that TFPR1 augmented Th1-biased antibody- and cell-mediated immune responses in mice immunized with two protein antigens (OVA and HBsAg) or a peptide antigen (HIV-1 pep). A flow cytometry-based binding assay and in vitro stimulation with TFPR1 showed that it triggered Th1-biased proinflammatory and immunoregulatory cytokine secretion primarily by binding to B cells and macrophages within the mouse splenocyte population. Quantitative RT-PCR, antibody blocking assays using a specific anti-mTLR2 antibody, and stimulatory experiments in vitro using splenocytes from TLR2-KO mice demonstrated that TFPR1 activated murine immune cells, primarily by stimulating toll-like receptor 2 (TLR2). These results suggest that TFPR1 acts as a novel immune modulator and potent adjuvant primarily by activating TLR2. Thus, the PR-1-based core domain might play a role in immune regulation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sun, Weilai; Li, Qiao; Ning, Xiuzhe; Yang, Yi; Guo, Jingjing; Zhu, Qing; Guo, Yan; Li, Hao; Wang, Yuepeng; Zhou, Yusen; Kou, Zhihua] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
   [Li, Qiao; Wang, Yuepeng; Zhou, Yusen; Kou, Zhihua] Anhui Med Univ, Grad Sch, Hefei 230032, Peoples R China.
RP Kou, ZH (reprint author), Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
EM zh_69kou@163.com
FU Mega-Projects of Science and Technology Research [SKLPBS1416]; 
   [2017ZX10304402-003]
FX This work was supported by grants from SKLPBS1416, and partially by
   Mega-Projects of Science and Technology Research #2017ZX10304402-003.
CR Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732
   Ali F, 2001, PARASITE IMMUNOL, V23, P237, DOI 10.1046/j.1365-3024.2001.00383.x
   Aoki N, 2008, BBA-PROTEINS PROTEOM, V1784, P621, DOI 10.1016/j.bbapap.2007.12.010
   Asojo OA, 2005, J MOL BIOL, V346, P801, DOI 10.1016/j.jmb.2004.12.023
   Basto AP, 2014, J IMMUNOL RES, DOI 10.1155/2014/619410
   Bhat SK, 2016, TOXICON, V124, P63, DOI 10.1016/j.toxicon.2016.11.001
   Brahmakshatriya V, 2017, J IMMUNOL, V198, P2819, DOI 10.4049/jimmunol.1601119
   Cardoso DF, 1997, TOXICON, V35, P607, DOI 10.1016/S0041-0101(96)00134-1
   Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Davies JM, 2010, IMMUNOLOGY, V131, P438, DOI 10.1111/j.1365-2567.2010.03317.x
   de Oliveira NG, 2013, CELL MOL LIFE SCI, V70, P4645, DOI 10.1007/s00018-013-1345-x
   Dolasia K, 2018, INT REV IMMUNOL, V37, P3, DOI 10.1080/08830185.2017.1397656
   Dudek AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00438
   Fink A, 2013, J IMMUNOL, V190, P6410, DOI 10.4049/jimmunol.1202033
   Gasanov SE, 2014, J CLIN TOXICOL, V4, DOI DOI 10.4172/2161-0495.1000181
   Gibbs GM, 2008, ENDOCR REV, V29, P865, DOI 10.1210/er.2008-0032
   Gingras MC, 2000, EXP HEMATOL, V28, P65, DOI 10.1016/S0301-472X(99)00126-5
   Guo JJ, 2015, VACCINE, V33, P1974, DOI 10.1016/j.vaccine.2015.02.053
   He P, 2015, HUM VACC IMMUNOTHER, V11, P477, DOI 10.1080/21645515.2014.1004026
   He YX, 2009, J IMMUNOL, V182, P4005, DOI 10.4049/jimmunol.0800531
   Hu JH, 2018, MOL HUM REPROD, V24, P111, DOI 10.1093/molehr/gay001
   Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038
   Jayaraman G, 2000, PROTEIN SCI, V9, P637
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391
   Laine M, 2007, ARTHRITIS RHEUM, V56, P2575, DOI 10.1002/art.22828
   Lee HL, 2016, ARCH TOXICOL, V90, P463, DOI 10.1007/s00204-014-1393-5
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Liao Q, 2003, HISTOL HISTOPATHOL, V18, P425, DOI 10.14670/HH-18.425
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MacDonald AJ, 2004, PARASITE IMMUNOL, V26, P53, DOI 10.1111/j.0141-9838.2004.00685.x
   MacLeod MKL, 2011, P NATL ACAD SCI USA, V108, P7914, DOI 10.1073/pnas.1104588108
   Matsunaga Y, 2009, J BIOCHEM, V145, P365, DOI 10.1093/jb/mvn174
   McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005
   Moga MA, 2018, MOLECULES, V23, DOI 10.3390/molecules23030692
   MURPHY EV, 1995, GENE, V159, P131, DOI 10.1016/0378-1119(95)00061-A
   Oth T, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0247-y
   Qian F, 2015, VACCINE, V33, P2038, DOI 10.1016/j.vaccine.2015.03.006
   Sales TA, 2017, TOXINS, V9, DOI 10.3390/toxins9110341
   Sampaio NG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202408
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Sulca MA, 2017, TOXICON, V134, P30, DOI 10.1016/j.toxicon.2017.05.019
   Sunagar K, 2012, MOL BIOL EVOL, V29, P1807, DOI 10.1093/molbev/mss058
   Suzuki N, 2008, ACTA CRYSTALLOGR D, V64, P1034, DOI 10.1107/S0907444908023512
   Thompson EA, 2017, CURR OPIN IMMUNOL, V47, P1, DOI 10.1016/j.coi.2017.06.006
   Thompson TC, 2010, YONSEI MED J, V51, P479, DOI 10.3349/ymj.2010.51.4.479
   Udby L, 2002, J LEUKOCYTE BIOL, V72, P462
   Van Eynde A, 2011, ASIAN J ANDROL, V13, P205, DOI 10.1038/aja.2010.120
   van Loon LC, 2006, ANNU REV PHYTOPATHOL, V44, P135, DOI 10.1146/annurev.phyto.44.070505.143425
   Wang YL, 2010, J BIOL CHEM, V285, P37872, DOI 10.1074/jbc.M110.146290
   Yamazaki Y, 2002, EUR J BIOCHEM, V269, P2708, DOI 10.1046/j.1432-1033.2002.02940.x
   Yang Y, 2017, HUM VACC IMMUNOTHER, V13, P1466, DOI 10.1080/21645515.2017.1281488
   Yang Y, 2015, HUM VACC IMMUNOTHER, V11, P795, DOI 10.1080/21645515.2015.1012017
   Yee KT, 2018, TOXICON, V146, P31, DOI 10.1016/j.toxicon.2018.03.005
   Zhu JL, 2014, EVID-BASED COMPL ALT, DOI 10.1155/2014/969482
NR 56
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 288
EP 297
DI 10.1016/j.vaccine.2019.10.017
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700025
PM 31629567
DA 2020-05-12
ER

PT J
AU Kolb, EA
   Buterbaugh, RE
   Rinehart, CL
   Ensley, D
   Perry, GA
   Abdelsalam, KW
   Chase, CCL
AF Kolb, Elizabeth A.
   Buterbaugh, Robin E.
   Rinehart, Carol L.
   Ensley, Douglas
   Perry, George A.
   Abdelsalam, Karim W.
   Chase, Christopher C. L.
TI Protection against bovine respiratory syncytial virus in calves
   vaccinated with adjuvanted modified live vaccine administered in the
   face of maternal antibody
SO VACCINE
LA English
DT Article
DE Bovine respiratory syncytial virus; Maternal antibody; Vaccine; IgA;
   Adjuvant
ID IMMUNE-RESPONSES; EFFICACY; INFECTION; TYPE-2
AB Bovine respiratory syncytial virus (BRSV) is major viral contributor to bovine respiratory disease (BRD). BRD is a major cause of morbidity and mortality in all classes of cattle but particularly young beef and dairy calves. Passive antibodies not only help protect the calf against infection, but may interfere with the immune responses following vaccination. The purpose of this study was to evaluate the efficacy of an adjuvanted modified live virus (MLV) vaccine in the presence of well-defined maternal passive immunity. Calves were vaccinated at approximately 1 month of age and challenged similar to 90 days later when BRSV systemic antibodies were <= 1:4. Body temperature was lower at 6 and 7 days post challenge and other clinical signs were also lower in the vaccinates. Nasal viral shed was 3-4 times lower in the vaccinated animals as measured by virus isolation and polymerase chain reaction (PCR) and peaked 5 days post challenge compared to the controls (who peaked at days 6 and 7). On day 8 following challenge, animals were necropsied, and lung lobes were scored and tested for virus by PCR and indirect fluorescent assay (IFA). There was a 25-fold reduction in PCR virus detection in vaccinates and two of the vaccinated calves' lungs were PCR negative. Only 29.4% of vaccinated calves were BRSV positive on IFA testing at necropsy, while 87.5% of control calves were BRSV positive. Vaccinated calves developed a mucosal BRSV IgA response with over 50% of the vaccinated calves having IgA prior to challenge and all vaccinated calves were positive following challenge. Additionally, vaccination stimulated the production of Interferon gamma (IFN-gamma) in mononuclear cells to prime the immune system. This study established that an adjuvanted MLV vaccine could provide protection against BRSV as measured by clinical, virological, and pathological parameters while also activating both mucosal and systemic immunity. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Kolb, Elizabeth A.; Buterbaugh, Robin E.; Rinehart, Carol L.; Abdelsalam, Karim W.; Chase, Christopher C. L.] RTI LLC, 801 32nd Ave, Brookings, SD 57006 USA.
   [Ensley, Douglas] Boehringer Ingelhe Anim Hlth USA Inc, 2621 North Belt Hwy, St Joseph, MO 64506 USA.
   [Perry, George A.] South Dakota State Univ, Coll Agr Food & Environm Sci, Dept Anim Sci, Brookings, SD 57007 USA.
   [Chase, Christopher C. L.] South Dakota State Univ, Coll Agr Food & Environm Sci, Dept Vet & Biomed Sci, Brookings, SD 57007 USA.
   [Kolb, Elizabeth A.] Trans Ova Genet, 2938 380th St, Sioux Ctr, IA 51250 USA.
RP Chase, CCL (reprint author), South Dakota State Univ, Dept Vet & Biomed Sci, POB 2175,ADR Rm 125,N Campus Dr, Brookings, SD 57007 USA.
EM Christopher.Chase@sdstate.edu
RI ; Chase, Christopher/U-2796-2017
OI Perry, George/0000-0002-0102-9046; Chase,
   Christopher/0000-0001-6000-4095
FU Boehringer Ingelheim Animal Health USABoehringer Ingelheim
FX The authors declare that they have no known competing financial
   interests or personal relationships that could have appeared to
   influence the work reported in this paper. The project was funded by
   Boehringer Ingelheim Animal Health USA.
CR Achenbach JE, 2004, J VIROL METHODS, V121, P1, DOI 10.1016/j.jviromet.2004.05.004
   [Anonymous], 2008, MAN STAND DIAGN TEST
   BAKER JC, 1986, AM J VET RES, V47, P240
   Beam AL, 2009, J DAIRY SCI, V92, P3973, DOI 10.3168/jds.2009-2225
   BELKNAP EB, 1991, J INFECT DIS, V163, P470, DOI 10.1093/infdis/163.3.470
   Bissey L L, 1991, J Vet Diagn Invest, V3, P16
   Chamorro MF, 2014, CAN J VET RES, V78, P81
   Cochran W. G., 1989, STAT METHODS
   Ellis J, 2014, CAN VET J, V55, P1180
   Ellis JA, 2017, VET MICROBIOL, V206, P59, DOI 10.1016/j.vetmic.2016.11.030
   Ellis JA, 2010, JAVMA-J AM VET MED A, V236, P991, DOI 10.2460/javma.236.9.991
   Federation of Animal Science Societies, 2010, GUID CAR US AGR AN R
   Gershwin LJ, 2005, VET IMMUNOL IMMUNOP, V107, P119, DOI 10.1016/j.vetimm.2005.04.004
   Harmeyer SS, 2006, VET REC, V159, P456, DOI 10.1136/vr.159.14.456
   Horohov DW, 2015, VET IMMUNOL IMMUNOP, V164, P24, DOI 10.1016/j.vetimm.2014.12.015
   Johnson KK, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00189
   Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914
   KIMMAN TG, 1989, VET IMMUNOL IMMUNOP, V22, P145, DOI 10.1016/0165-2427(89)90057-3
   Kirkpatrick J., 2001, Bovine Practitioner, V35, P47
   Littell RC, 1998, J ANIM SCI, V76, P1216
   Marchioro SB, 2013, VACCINE, V31, P1305, DOI 10.1016/j.vaccine.2012.12.068
   Martelli P, 2014, VET MICROBIOL, V168, P357, DOI 10.1016/j.vetmic.2013.11.025
   McGill JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21292-2
   Stevens E T, 2009, Vet Ther, V10, pE1
   Su F, 2016, HUM VACC IMMUNOTHER, V12, P1070, DOI 10.1080/21645515.2015.1114195
   Timsit E, 2010, J VET DIAGN INVEST, V22, P238, DOI 10.1177/104063871002200211
   Tizard I., 2013, VET IMMUNOLOGY, P225
   USDA-APHIS-VS-CEAH, 2010, MORT CALV CATTL US B, P1
   USDA-APHIS-VS-CEAH, 2018, HLTH MAN PRACT US 3, P1
   VANDERPOEL WHM, 1993, ARCH VIROL, V133, P309, DOI 10.1007/BF01313771
   Vangeel I, 2007, VET J, V174, P627, DOI 10.1016/j.tvjl.2006.10.013
   West K, 1999, VACCINE, V18, P907, DOI 10.1016/S0264-410X(99)00324-2
   Woolums AR, 2004, AM J VET RES, V65, P363, DOI 10.2460/ajvr.2004.65.363
   Zimmerman AD, 2006, JAVMA-J AM VET MED A, V228, P1757, DOI 10.2460/javma.228.11.1757
   Zimmerman Alicia D., 2009, Bovine Practitioner, V43, P35
NR 35
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 298
EP 308
DI 10.1016/j.vaccine.2019.10.015
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700026
PM 31668818
OA Other Gold
DA 2020-05-12
ER

PT J
AU Singh, S
   Wilson, JC
   Cripps, AW
   Massa, H
   Ozberk, V
   Grice, ID
   Peak, IR
AF Singh, Sanjesh
   Wilson, Jennifer C.
   Cripps, Allan W.
   Massa, Helen
   Ozberk, Victoria
   Grice, I. Darren
   Peak, Ian R.
TI Immunological characterisation of truncated lipooligosaccharide-outer
   membrane protein based conjugate vaccine against Moraxella catarrhalis
   and nontypeable Haemophilus influenzae
SO VACCINE
LA English
DT Article
DE Moraxella catarrhalis; Nontypeable Haemophilus influenzae;
   Lipooligosaccharide mutant; Outer membrane protein; Conjugate vaccine;
   Conserved antigens
ID ACUTE OTITIS-MEDIA; BRANHAMELLA-CATARRHALIS; BACTERICIDAL ACTIVITY;
   MONOCLONAL-ANTIBODY; PULMONARY CLEARANCE; MUCOSAL VACCINE; OMP26;
   LIPOPOLYSACCHARIDE; CD; BIOSYNTHESIS
AB Moraxella catarrhalis and nontypeable Haemophilus influenzae are important bacterial causes of otitis media in children and respiratory diseases in adults. Lipooligosaccharide (LOS) from M. catarrhalis and outer membrane protein 26 (OMP26) from NTHi are major surface antigens identified as potential vaccine components against these organisms. We previously constructed M. catarrhalis in which LOS is truncated, but contains a structure common to the three known serotypes of M. catarrhalis. OMP26 is known to enhance clearance of NTHi following vaccination in animal models, so was chosen as the carrier protein. In this study, we conjugated wild-type and truncated M. catarrhalis detoxified-LOS to a recombinant modified OMP26, rOMP26VTAL. Vaccination of mice with these conjugates resulted in a significant increase in anti-LOS and anti-rOMP26VTAL lgG levels. Importantly, mouse antisera showed complement-mediated bactericidal activity against all M. catarrhalis serotype A and B strains and a NTHi strain tested. Serotypes A & B make up more than 90% of isolates. These data suggest that the LOS and OMP based conjugate can be used as vaccine components and require further investigation in animal models. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Singh, Sanjesh; Wilson, Jennifer C.; Cripps, Allan W.; Massa, Helen] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Australia.
   [Singh, Sanjesh; Ozberk, Victoria; Grice, I. Darren; Peak, Ian R.] Griffith Univ, Inst Glyc, Gold Coast, Australia.
   [Singh, Sanjesh; Wilson, Jennifer C.; Massa, Helen; Grice, I. Darren; Peak, Ian R.] Griffith Univ, Sch Med Sci, Gold Coast, Australia.
   [Cripps, Allan W.] Griffith Univ, Sch Med, Gold Coast, Australia.
RP Grice, ID; Peak, IR (reprint author), Griffith Univ, Inst Glyc, Gold Coast, Australia.; Grice, ID; Peak, IR (reprint author), Griffith Univ, Sch Med Sci, Gold Coast, Australia.
EM d.grice@griffith.edu.au; i.peak@griffith.edu.au
FU John Villier's Trust; Institute for Glycomics; School of Medical
   Science; Griffith Health Postgraduate Research Scholarship
FX This research was funded by The John Villier's Trust. The John Villier's
   Trust did not contribute to the study design, collection, analysis,
   interpretation of data, writing of the report, nor the decision to
   submit the article for publication. The Institute for Glycomics and the
   School of Medical Science are thanked for financial support. S. Singh
   was supported by a Griffith Health Postgraduate Research Scholarship. We
   thank Professor Jennelle Kyd for the provision of the recombinant E coli
   strain containing the expression plasmid of the His-tagged omp26VTAL. We
   thank Courtney McCalman and Keith K. Cheung for technical assistance.
CR Aebi C, 1998, INFECT IMMUN, V66, P540, DOI 10.1128/IAI.66.2.540-548.1998
   Behrouzi Ava, 2017, Iranian Biomedical Journal, V21, P69, DOI 10.18869/acadpub.ibj.21.2.69
   Blakeway LV, 2017, MICROBIOL-SGM, V163, P1371, DOI 10.1099/mic.0.000523
   Brito LA, 2011, J PHARM SCI-US, V100, P34, DOI 10.1002/jps.22267
   CARSON RT, 1994, IMMUNOLOGY, V83, P107
   Cerquetti M, 2016, HUM VACC IMMUNOTHER, V12, P2357, DOI 10.1080/21645515.2016.1174354
   Chen DX, 1996, INFECT IMMUN, V64, P1900, DOI 10.1128/IAI.64.6.1900-1905.1996
   Cox AD, 2011, GLYCOCONJUGATE J, V28, P165, DOI 10.1007/s10719-011-9332-7
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   El-Adhami W, 1999, INFECT IMMUN, V67, P1935
   Ercoli G, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0420-x
   Erwin AL, 2007, TRENDS MICROBIOL, V15, P355, DOI 10.1016/j.tim.2007.06.004
   FOMSGAARD JS, 1991, INFECT IMMUN, V59, P3346, DOI 10.1128/IAI.59.9.3346-3349.1991
   GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x
   Gergova RT, 2007, CURR MICROBIOL, V54, P85, DOI 10.1007/s00284-005-0463-6
   GU XX, 1993, INFECT IMMUN, V61, P1873, DOI 10.1128/IAI.61.5.1873-1880.1993
   Gu XX, 1998, INFECT IMMUN, V66, P1891, DOI 10.1128/IAI.66.5.1891-1897.1998
   Holme T, 1999, EUR J BIOCHEM, V265, P524, DOI 10.1046/j.1432-1327.1999.00731.x
   Hu EG, 2000, INFECT IMMUN, V68, P4980, DOI 10.1128/IAI.68.9.4980-4985.2000
   Hu WG, 2004, FEMS IMMUNOL MED MIC, V41, P109, DOI 10.1016/j.femsim.2004.02.001
   Hu WG, 2001, INFECT IMMUN, V69, P1358, DOI 10.1128/IAI.69.3.1358-1363.2001
   Jurcisek JA, 2007, MOL MICROBIOL, V65, P1288, DOI 10.1111/j.1365-2958.2007.05864.x
   Khan MN, 2012, FEMS IMMUNOL MED MIC, V65, P439, DOI 10.1111/j.1574-695X.2012.00967.x
   Kunthalert D, 2013, HUM VACC IMMUNOTHER, V9, P625, DOI 10.4161/hv.23255
   Kyd JM, 2003, INFECT IMMUN, V71, P4691, DOI 10.1128/IAI.71.8.4691-4699.2003
   Kyd JM, 1998, INFECT IMMUN, V66, P2272, DOI 10.1128/IAI.66.5.2272-2278.1998
   McGrath J, 2007, THESIS
   Meier PS, 2002, VACCINE, V20, P1754, DOI 10.1016/S0264-410X(02)00030-0
   Murphy TF, 1998, J INFECT DIS, V178, P1667, DOI 10.1086/314501
   Murphy TF, 2005, EXPERT REV VACCINES, V4, P843, DOI 10.1586/14760584.4.6.843
   Murphy TF, 2015, CLIN VACCINE IMMUNOL, V22, P459, DOI 10.1128/CVI.00089-15
   Pandey M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006122
   Peak IR, 2007, FEBS J, V274, P2024, DOI 10.1111/j.1742-4658.2007.05746.x
   Peng D, 2007, FEBS J, V274, P5350, DOI 10.1111/j.1742-4658.2007.06060.x
   Peng DX, 2005, INFECT IMMUN, V73, P4222, DOI 10.1128/IAI.73.7.4222-4230.2005
   Perdomo R., 2006, BIOTECNOL APL, V23, P124
   Perez AC, 2017, HUM VACC IMMUNOTHER, V13, P2322, DOI [10.1080/21645515.2017.1374522, 10.1080/21645515.2017.1356951]
   Pichichero ME, 2010, VACCINE, V28, P7184, DOI 10.1016/j.vaccine.2010.08.063
   Ren DB, 2016, EXPERT OPIN THER TAR, V20, P19, DOI 10.1517/14728222.2015.1081686
   Ren DB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029553
   Ren DB, 2011, VACCINE, V29, P4210, DOI 10.1016/j.vaccine.2011.03.102
   Riedmann EM, 2011, HUM VACCINES, V7, P99, DOI 10.4161/hv.7.0.14569
   Schaechter M., 2009, ENCY MICROBIOLOGY
   Schwingel JM, 2009, INFECT IMMUN
   Singh B, 2013, INFECT IMMUN
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   VANEECHOUTTE M, 1990, J CLIN MICROBIOL, V28, P182, DOI 10.1128/JCM.28.2.182-187.1990
   Yang M, 2011, INFECT IMMUN, V79, P846, DOI 10.1128/IAI.00314-10
   Yang YP, 1997, FEMS IMMUNOL MED MIC, V17, P187, DOI 10.1111/j.1574-695X.1997.tb01012.x
   Yu SQ, 2007, INFECT IMMUN, V75, P2974, DOI 10.1128/IAI.01915-06
   Yu SQ, 2005, INFECT IMMUN, V73, P2790, DOI 10.1128/IAI.73.5.2790-2796.2005
   Zaleski A, 2000, INFECT IMMUN, V68, P5261, DOI 10.1128/IAI.68.9.5261-5268.2000
   Zaman M, 2016, SCI REP, V6
NR 53
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 309
EP 317
DI 10.1016/j.vaccine.2019.10.014
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700027
PM 31668366
DA 2020-05-12
ER

PT J
AU Song, JY
   Noh, JY
   Lee, JS
   Wie, SH
   Kim, YK
   Lee, J
   Jeong, HW
   Kim, SW
   Lee, SH
   Park, KH
   Choi, WS
   Cheong, HJ
   Kim, WJ
AF Song, Joon Young
   Noh, Ji Yun
   Lee, Jin Soo
   Wie, Seong-Heon
   Kim, Young Keun
   Lee, Jacob
   Jeong, Hye Won
   Kim, Shin Woo
   Lee, Sun Hee
   Park, Kyung-Hwa
   Choi, Won Suk
   Cheong, Hee Jin
   Kim, Woo Joo
TI Effectiveness of repeated influenza vaccination among the elderly
   population with high annual vaccine uptake rates during the three
   consecutive A/H3N2 epidemics
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Effectiveness; Antigenic determinants;
   Pneumonia; Hospitalization
ID IMMUNIZATION; IMPACT; VIRUS; PROTECTION; PNEUMONIA; A(H3N2)
AB Background: Annually, about 80% of the Korean elderly aged >= 65 years receive influenza vaccination. Repeated annual vaccination has been suggested as an important factor of poor influenza vaccine effectiveness (VE), though reported conflicting results.
   Methods: During the consecutive A/H3N2-dominant influenza seasons between 2012 and 2015, we comparatively evaluated the VE (repeated vs. current season only) against laboratory-confirmed influenza, pneumonia and hospitalization in the elderly aged >= 65 years with influenza-like illness (ILI). Clinical and demographic data were collected prospectively, and vaccination status of prior and current seasons was verified using the immunization registry data of Korean Centers for Disease Control and Prevention.
   Results: During the first A/H3N2-dominant season in 2012-2013, influenza vaccine showed statistically significant effectiveness against influenza A infection only and when vaccinated in the current season only (VE 53%, 95% CI 15-77). In the latter two seasons (2013-2015 years), the adjusted VE for influenza A was indistinguishable between repeated vaccination and vaccination in the current season only.
   Conclusion: During consecutive influenza A/H3N2 epidemics, poor influenza vaccine effectiveness may be more pronounced among the elderly population with a high annual vaccine uptake rate. (C) 2019 Published by Elsevier Ltd.
C1 [Song, Joon Young; Noh, Ji Yun; Choi, Won Suk; Cheong, Hee Jin; Kim, Woo Joo] Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul, South Korea.
   [Song, Joon Young; Noh, Ji Yun; Cheong, Hee Jin; Kim, Woo Joo] APII, Seoul, South Korea.
   [Lee, Jin Soo] Inha Univ, Dept Internal Med, Div Infect Dis, Sch Med, Incheon, South Korea.
   [Wie, Seong-Heon] Catholic Univ, St Vincents Hosp, Dept Internal Med, Div Infect Dis,Med Coll, Suwon, South Korea.
   [Kim, Young Keun] Yonsei Univ, Wonju Coll Med, Dept Internal Med, Div Infect Dis, Wonju, South Korea.
   [Lee, Jacob] Hallym Univ, Dept Internal Med, Div Infect Dis, Coll Med, Chunchon, South Korea.
   [Jeong, Hye Won] Chungbuk Natl Univ, Div Infect Dis, Coll Med, Cheongju, South Korea.
   [Kim, Shin Woo] Kyungpook Natl Univ, Dept Internal Med, Div Infect Dis, Sch Med, Daegu, South Korea.
   [Lee, Sun Hee] Pusan Natl Univ, Dept Internal Med, Div Infect Dis, Sch Med, Pusan, South Korea.
   [Park, Kyung-Hwa] Chonnam Natl Univ, Dept Internal Med, Div Infect Dis, Med Sch, Gwangju, South Korea.
RP Kim, WJ (reprint author), Korea Univ, Dept Internal Med, Div Infect Dis, Guro Hosp,Coll Med, Gurodong Ro 148, Seoul 08308, South Korea.
EM wjkim@korea.ac.kr
FU Korea Healthcare Technology R&D Project of the Ministry of Health &
   Welfare of the Republic of Korea [A103001]; National Research Foundation
   of Korea (NRF) - Korean Government [NRF-2016R1A5A1010148]
FX This study was supported by a grant from the Korea Healthcare Technology
   R&D Project of the Ministry of Health & Welfare of the Republic of Korea
   (No. A103001) and National Research Foundation of Korea (NRF) Grant
   funded by the Korean Government (NRF-2016R1A5A1010148).
CR Allen JD, 2018, HUM VACC IMMUNOTHER, V14, P1840, DOI 10.1080/21645515.2018.1462639
   Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554
   Beyer WEP, 1999, ARCH INTERN MED, V159, P182, DOI 10.1001/archinte.159.2.182
   Bodi M, 2005, CLIN INFECT DIS, V41, P1709, DOI 10.1086/498119
   Cheng AC, 2017, CLIN INFECT DIS, V64, P1564, DOI 10.1093/cid/cix209
   Dunn J, 2014, DIAGN MICR INFEC DIS, V79, P10, DOI 10.1016/j.diagmicrobio.2014.01.018
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Heo JY, 2018, HUM VACC IMMUNOTHER, V14, P744, DOI 10.1080/21645515.2017.1405200
   HOSKINS TW, 1979, LANCET, V1, P33
   Kim JI, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172059
   Korean Center for Infectious Disease Control and Prevention, 2016, PUBLIC HLTH WKLY REP, V8, P1096
   Korean Society of Infectious Diseases, 2019, AD VACC
   McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647
   McLean HQ, 2014, CLIN INFECT DIS, V59, P1375, DOI 10.1093/cid/ciu680
   Mese S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1811-9
   Nicholson KG., 1998, TXB INFLUENZA, P219
   Noh JY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178010
   O'Gorman WE, 2014, VACCINE, V32, P5989, DOI 10.1016/j.vaccine.2014.07.115
   Ortqvist A, 2018, VACCINE, V36, P5556, DOI 10.1016/j.vaccine.2018.07.052
   Petrie JG, 2016, CLIN INFECT DIS, V63, P1017, DOI 10.1093/cid/ciw432
   Ramsay LC, 2019, BMC MED, V17, DOI 10.1186/s12916-018-1239-8
   Rizzo C, 2018, HUM VACC IMMUNOTHER, V14, P693, DOI 10.1080/21645515.2017.1367463
   Saito N, 2018, CLIN INFECT DIS, V67, P897, DOI 10.1093/cid/ciy202
   Skowronski DM, 2017, J INFECT DIS, V215, P1059, DOI 10.1093/infdis/jix074
   Smith DJ, 1999, P NATL ACAD SCI USA, V96, P14001, DOI 10.1073/pnas.96.24.14001
   Song JY, 2013, J MED VIROL, V85, P910, DOI 10.1002/jmv.23548
   Song JY, 2010, VACCINE, V28, P3929, DOI 10.1016/j.vaccine.2010.03.067
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Valenciano M, 2015, VACCINE, V33, P2813, DOI 10.1016/j.vaccine.2015.04.012
   Yang JH, 2010, PROCEEDINGS OF THE ASME INTERNATIONAL HEAT TRANSFER CONFERENCE - 2010, VOL 1, P101
   Yun JW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209643
   Yun JW, 2017, INFECT CHEMOTHER, V49, P247, DOI 10.3947/ic.2017.49.4.247
NR 32
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 318
EP 322
DI 10.1016/j.vaccine.2019.10.012
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700028
PM 31690467
DA 2020-05-12
ER

PT J
AU Shioda, K
   de Oliveira, LH
   Sanwogou, J
   Rey-Benito, G
   Azzad, DN
   Castillo, RE
   Ramirez, MLG
   Von Horoch, MR
   Weinberger, DM
   Pitzer, VE
AF Shioda, Kayoko
   de Oliveira, Lucia Helena
   Sanwogou, Jennifer
   Rey-Benito, Gloria
   Nunez Azzad, Diana
   Elizabeth Castillo, Roxana
   Gamarra Ramirez, Maria Liz
   Raquel Von Horoch, Marta
   Weinberger, Daniel M.
   Pitzer, Virginia E.
TI Identifying signatures of the impact of rotavirus vaccines on
   hospitalizations using sentinel surveillance data from Latin American
   countries
SO VACCINE
LA English
DT Article
DE Rotavirus; Latin America; Sentinel surveillance; Vaccine evaluation;
   Imperfect surveillance data; Harmonic regression
ID SEASONALITY; VACCINATION; EFFICACY
AB Background: Passive surveillance data are often the only available source of data that can be used to evaluate the population-level impact of vaccination, but such data often suffer from important limitations such as changes in surveillance efforts. This study provides an example of how to identify important signatures of rotavirus vaccine impact, including evaluating the overall effectiveness and changes in rotavirus seasonal dynamics.
   Methods: We used data from a standardized sentinel rotavirus surveillance network in six Latin American countries (Bolivia, El Salvador, Guatemala, Honduras, Paraguay, and Venezuela) from 2004 to 2017. A random-effects model was used to evaluate changes in the proportion of rotavirus-associated hospitalizations following vaccine introduction. Harmonic regression models were used to estimate vaccine impact on the number of rotavirus hospitalizations, controlling for trends in rotavirus-negative cases. Changes to rotavirus seasonality were evaluated using center of gravity analysis, wavelet analysis, and harmonic regression.
   Results: All countries observed declines in the proportion of rotavirus-positive acute diarrhea samples with a mean reduction of 16% (95% confidence interval: 10-22%). We estimate that each 10% increase in vaccine coverage was associated with declines in the number of rotavirus-positive cases, ranging from 4.3% (1.3-7.2%) in Honduras to 21.4% (16.8-25.9%) in Venezuela. The strength of the seasonal peak in rotavirus incidence became smaller after vaccine introduction in Guatemala, Honduras, and Venezuela. Seasonal peaks also shifted later in the surveillance year, especially in higher-mortality countries.
   Conclusions: The combination of methods we applied have different strengths that allow us to identify common signatures of rotavirus vaccine impact. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shioda, Kayoko; Weinberger, Daniel M.; Pitzer, Virginia E.] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, 60 Coll St, New Haven, CT 06520 USA.
   [de Oliveira, Lucia Helena; Sanwogou, Jennifer; Rey-Benito, Gloria] Pan Amer Hlth Org, Immunizat Unit, Washington, DC 20037 USA.
   [Nunez Azzad, Diana] Jefa Unidad Vigilancia Salud, Secretaria Salud Honduras, Ave Miguel Cervantes, Tegucigalpa, Honduras.
   [Elizabeth Castillo, Roxana] Lab Nacl, Tegucigalpa, Honduras.
   [Gamarra Ramirez, Maria Liz] Lab Cent Salud Publ Paraguay, Asuncion, Paraguay.
   [Raquel Von Horoch, Marta] Minist Salud Publ & Bienestar Social, Direcc Gen Vigilancia Salud, Asuncion, Paraguay.
RP Shioda, K (reprint author), Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, 60 Coll St, New Haven, CT 06520 USA.
EM kayoko.shioda@yale.edu
OI Weinberger, Daniel/0000-0003-1178-8086
FU National Institute of Health, National Institute of Allergy and
   Infectious Diseases, United States [R01 AI112970]; Funai Foundation for
   Information Technology, Japan [Funai Overseas Scholarship]
FX The study was supported by from the National Institute of Health,
   National Institute of Allergy and Infectious Diseases, United States
   [R01 AI112970 to V.E.P.] and by the Funai Foundation for Information
   Technology, Japan [Funai Overseas Scholarship to K.S.].
CR Agostinelli C., 2017, R PACKAGE CIRCULAR C
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Bruhn CAW, 2017, P NATL ACAD SCI USA, V114, P1524, DOI 10.1073/pnas.1612833114
   Bruhn CAW, 2017, EPIDEMIOLOGY, V28, P233, DOI 10.1097/EDE.0000000000000598
   Cazelles B, 2007, J R SOC INTERFACE, V4, P625, DOI 10.1098/rsif.2007.0212
   de Oliveira LH, 2015, VACCINE, V33, pA248, DOI 10.1016/j.vaccine.2014.11.060
   de Oliveira Lucia Helena, 2009, J Infect Dis, V200 Suppl 1, pS131, DOI 10.1086/605060
   de Palma O, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2825
   Gastanaduy PA, 2016, CLIN INFECT DIS, V62, pS121, DOI 10.1093/cid/civ1208
   Halloran ME, 1997, AM J EPIDEMIOL, V146, P789
   Johansson MA, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000168
   Levy K, 2009, INT J EPIDEMIOL, V38, P1487, DOI 10.1093/ije/dyn260
   Linhares AC, 2008, LANCET, V371, P1181, DOI 10.1016/S0140-6736(08)60524-3
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   Naumova EN, 2007, ADV STAT METHODS HLT
   Pan American Health Organization, 2017, YEAR INTR ROT PNEUM
   Pan American Health Organization, 2007, VIG EP DIARR CAUS RO
   Parashar UD, 2016, CLIN INFECT DIS, V62, pS91, DOI 10.1093/cid/civ1015
   Patel MM, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3726
   Patel MM, 2013, PEDIATR INFECT DIS J, V32, pE134, DOI 10.1097/INF.0b013e31827d3b68
   PATH, ROT VACC COUNTR INTR
   Pitzer VE, 2009, SCIENCE, V325, P290, DOI 10.1126/science.1172330
   Rosettie KL, 2018, AM J TROP MED HYG, V98, P1197, DOI 10.4269/ajtmh.17-0705
   Santos VS, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0173-2
   Staat A. M., 2008, Morbidity and Mortality Weekly Report, V57, P697
   Tate JE, 2009, PEDIATRICS, V124, P465, DOI 10.1542/peds.2008-3528
   Velazquez RF, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-016-0771-y
   Vesikari T, 2007, INT J INFECT DIS, V11, pS29, DOI 10.1016/S1201-9712(07)60019-8
   WHO, LIST MEMB STAT WHO R
   WHO-UNICEF, WHO UNICEF EST ROTAC
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 323
EP 329
DI 10.1016/j.vaccine.2019.10.010
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700029
PM 31672333
DA 2020-05-12
ER

PT J
AU Barrenechea, GG
   Bastos, LS
AF Barrenechea, Guillermo G.
   Bastos, Leonardo S.
TI Evaluation of impact of one dose varicella vaccine on the incidence of
   chickenpox in Argentina
SO VACCINE
LA English
DT Article
DE Varicella; Time series studies; Chickenpox vaccine; Health impact
   assessment; Public policies
ID HERPES-ZOSTER; CHILDHOOD VARICELLA; LATIN-AMERICA; EPIDEMIOLOGY;
   IMMUNIZATION; CHILDREN; HOSPITALIZATIONS; COVERAGE; PROGRAM; AGE
AB Introduction: Varicella, also known as chickenpox is one of the most common immunizable diseases. In 1998, the World Health Organization (WHO) recommended to incorporate this vaccine in the national immunization programs, which Argentina did in 2015.
   Objectives: To describe the behavior of the varicella time series for the 2005-2017 period, and to evaluate the impact of the vaccine in Argentina.
   Methodology: An ecological observational study was performed, using the varicella cases reported in the National Health Monitoring System, and the data of the National census as secondary data sources. A model based time series analysis of the notified varicella cases in Argentina was performed, using a Negative Binomial Mixed Model. For the verification of the vaccine impact, the 2005-2014 period was selected, and a prognosis for the following years was performed. Impact was evaluated by comparing the rates and confidence intervals between the predicted and observed values.
   Results: Argentina reported 1,775,587 varicella cases for the 2005-2017 period. The series exhibited seasonality, and, a decreasing trend in the number of cases was observed in 2016 and 2017. A reduction of the incidence rate after the implementation of the vaccine was observed. The transmission risk decreased in the country after vaccine implementation.
   Conclusions: This study is the first concrete evidence of the varicella incidence decline after the implementation of a single dose application program in Argentina. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Barrenechea, Guillermo G.] Dept Bioquim, Lab Salud Publ, Mendoza 128 4 Piso, RA-4107 San Miguel De Tucuman, Tucuman, Argentina.
   [Barrenechea, Guillermo G.] Direcc Invest Salud, Virgen Merced 189 1 Piso, RA-4107 San Miguel De Tucuman, Tucuman, Argentina.
   [Bastos, Leonardo S.] Fundacao Oswaldo Cruz, Sci Comp Program, Av Brasil 4365, BR-21040900 Manguinho, RJ, Brazil.
   [Bastos, Leonardo S.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
RP Barrenechea, GG (reprint author), Dept Bioquim, Lab Salud Publ, Mendoza 128 4 Piso, RA-4107 San Miguel De Tucuman, Tucuman, Argentina.
EM barrenecheagg@gmail.com
OI Bastos, Leonardo/0000-0002-1406-0122
FU National Health Ministry, through the Health Research Direction,
   Argentina
FX The present scientific research was carried out with the support of the
   SALUD INVESTIGA "Dr. Abraam Sonis" grants, individual category, awarded
   by the National Health Ministry, through the Health Research Direction,
   Argentina.
CR Al-Tawfiq JA, 2013, TRAVEL MED INFECT DI, V11, P310, DOI 10.1016/j.tmaid.2013.06.002
   Andrade AL, 2018, VACCINE, V36, P479, DOI 10.1016/j.vaccine.2017.12.011
   [Anonymous], 2014, WKLY EPIDEMIOL REC, V89, P265
   [Anonymous], 2015, FEBR CHIK MAN CLIN, P1
   Argentino C, 2000, PREVENTION OF ISCHEMIC STROKE, P1
   Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361, DOI 10.1128/CMR.9.3.361
   Avila-Aguero ML, 2018, EXPERT REV VACCINES, V17, P175, DOI 10.1080/14760584.2018.1418327
   Avila-Aguero ML, 2017, EXPERT REV VACCINES, V16, P229, DOI 10.1080/14760584.2017.1247700
   Banz Kurt, 2004, Eur J Health Econ, V5, P46, DOI 10.1007/s10198-003-0200-7
   Bardach A, 2012, PEDIATR INFECT DIS J, V31, P1263, DOI 10.1097/INF.0b013e31826ff3a5
   Barrenechea GG, 2017, INVESTIGACION SALUD, V1, P32
   Baxter R, 2014, PEDIATRICS, V134, P24, DOI 10.1542/peds.2013-4251
   Bechini A, 2015, HUM VACC IMMUNOTHER, V11, P63, DOI 10.4161/hv.34311
   Brisson M, 2002, VACCINE, V20, P2500, DOI 10.1016/S0264-410X(02)00180-9
   Brisson M, 2010, VACCINE, V28, P3385, DOI 10.1016/j.vaccine.2010.02.079
   Cenoz MG, 2008, INCIDENCIA VARICELA, V30, P2005
   Chao DY, 2012, EPIDEMIOL INFECT, V140, P1131, DOI 10.1017/S0950268811001786
   Garcia RC, 2018, ATEN PRIM, V50, P29
   Dennehy PH, 2007, ACTIVE IMMUNIZATION, V14, P872
   Depledge DP, 2018, VIRUSES, V10, P1
   Dinleyici EC, 2015, VACCINE, V33, P3983, DOI 10.1016/j.vaccine.2015.06.029
   Fu J, 2010, INT J INFECT DIS, V2015, pe14
   Gater A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1514-y
   Giglio N, 2018, J MED ECON, V21, P416, DOI 10.1080/13696998.2018.1431919
   Gil-Prieto R, 2014, VACCINE, V32, P7043, DOI 10.1016/j.vaccine.2014.10.076
   Gould Dinah, 2014, Nurs Stand, V28, P52, DOI 10.7748/ns2014.04.28.33.52.e8249
   Hattori F, 2017, VACCINE, V35, P4936, DOI 10.1016/j.vaccine.2017.07.090
   Havard R, 2007, J R STAT SOC B, P1
   Latasa P, 2018, HUM VACC IMMUNOTHER, V14, P2274, DOI 10.1080/21645515.2018.1475813
   Lian IB, 2011, VACCINE, V29, P1448, DOI 10.1016/j.vaccine.2010.12.032
   Marinelli I, 2017, EPIDEMICS-NETH, V19, P1, DOI 10.1016/j.epidem.2016.11.001
   Perella D, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2802
   Quian J, 2008, ARCH DIS CHILD, V93, P845, DOI 10.1136/adc.2007.126243
   R Core Team, 2017, R LANG ENV STAT COMP
   Rieck T, 2017, EUROSURVEILLANCE, V22, P21, DOI 10.2807/1560-7917.ES.2017.22.17.30521
   Rue H, 2016, BAYESIAN COMPUTING I, P1
   Salleras L, 2015, ENFERM INFEC MICR CL, V33, P411, DOI 10.1016/j.eimc.2015.05.005
   Sciences RB, 2013, DIS MANAGEMENT ARIMA, V11, P128
   Scotta MC, 2018, VACCINE, V36, P280, DOI 10.1016/j.vaccine.2017.11.057
   Seward JF, 2004, JAMA-J AM MED ASSOC, V292, P704, DOI 10.1001/jama.292.6.704
   Seward JF, 2002, JAMA-J AM MED ASSOC, V287, P606, DOI 10.1001/jama.287.5.606
   Sheridan SL, 2017, VACCINE, V35, P3490, DOI 10.1016/j.vaccine.2017.05.013
   Tafuri S, 2015, HUM VACC IMMUNOTHER, V11, P214, DOI 10.4161/hv.36153
   Takahashi M, 1996, INFECT DIS CLIN N AM, V10, P469, DOI 10.1016/S0891-5520(05)70309-3
   Tanuseputro P, 2011, VACCINE, V29, P8580, DOI 10.1016/j.vaccine.2011.09.024
   Valentim J, 2008, VACCINE, V26, P6281, DOI 10.1016/j.vaccine.2008.07.021
   Varela FH, 2019, HUMAN VACCINES IMMUN, P645, DOI [10.1080/21645.51520181546575, DOI 10.1080/21645.51520181546575]
   Waye A, 2013, VACCINE, V31, P4744, DOI 10.1016/j.vaccine.2013.08.022
   World Health Organization, 2018, WHO VACC PREV DIS MO
   Wutzler P, 2017, EXPERT REV VACCINES, V16, P833, DOI 10.1080/14760584.2017.1343669
   Yin MJ, 2018, EXPERT REV VACCINES, V17, P351, DOI 10.1080/14760584.2018.1433999
   Yoshikawa T, 2016, VACCINE, V34, P1965, DOI 10.1016/j.vaccine.2016.02.058
   Zhu S, 2018, AM J INFECT CONTROL, V46, pE1, DOI 10.1016/j.ajic.2017.07.029
NR 53
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 330
EP 335
DI 10.1016/j.vaccine.2019.10.003
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700030
PM 31630938
DA 2020-05-12
ER

PT J
AU McClenahan, SJ
   Kormos, CM
   Gunnell, M
   Hambuchen, MD
   Lamb, P
   Carroll, FI
   Lewin, AH
   Peterson, EC
   Owens, SM
AF McClenahan, Samantha J.
   Kormos, Chad M.
   Gunnell, Melinda
   Hambuchen, Michael D.
   Lamb, Pamela
   Carroll, Frank Ivy
   Lewin, Anita H.
   Peterson, Eric C.
   Owens, Samuel Michael
TI Design, synthesis and biological evaluation of a bi-specific vaccine
   against alpha-pyrrolidinovalerophenone (alpha-PVP) and
   3,4-methylenedioxypyrovalerone (MDPV) in rats
SO VACCINE
LA English
DT Article
DE 3,4-methylenedioxypyrovalerone; alpha-pyrrolidinovalerophenone; Hapten;
   Vaccine; Affinity; Pharmacokinetics
ID CONSTITUENT 3,4-METHYLENEDIOXYPYROVALERONE; SALTS; ANTIBODIES; COCAINE;
   DRUGS; MICE
AB alpha-PVP (alpha-pyrrolidinovalerophenone) and MDPV (3,4-methylenedioxypyrovalerone) are potent abused stimulants that are members of the synthetic cathinone class of drugs. Although these drugs are taken with recreational intent, high doses can lead to unintended adverse effects including agitation, cardiovascular effects, sympathomimetic syndromes, hallucinations, and psychoses. One possible treatment is the use of a vaccine to block or attenuate adverse medical effects. These studies report the preparation of a vaccine that generates high affinity antibodies specific for both drugs and the pharmacological testing of this vaccine in male rats. Alkylation of a hydroxy-alpha-PVP analog with an appropriate thiol-bearing linker afforded the hapten. When hapten-conjugated carrier protein was mixed with adjuvant, the resulting vaccine stimulated production of antibodies in male Sprague Dawley rats that were found to significantly reduce alpha-PVP- and MDPV-induced hyperlocomotion as well as to significantly reduce the concentrations of MDPV drugs in critical organs. The novel vaccine produced high affinity antibodies against MDPV, (R)-MDPV, (S)-MDPV, and alpha-PVP. Cross-reactivity testing against nine structurally similar cathinones showed very limited binding, and no binding to off-target endogenous and exogenous compounds. Antibodies generated by this bi-specific vaccine also significantly shortened the duration of locomotor activity induced by both drugs up to a dose of 5.6 mg/kg in male rats. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [McClenahan, Samantha J.; Gunnell, Melinda; Hambuchen, Michael D.; Peterson, Eric C.; Owens, Samuel Michael] Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA.
   [Kormos, Chad M.; Lamb, Pamela; Carroll, Frank Ivy; Lewin, Anita H.] Res Triangle Inst, POB 12194, Res Triangle Pk, NC 27709 USA.
   [Hambuchen, Michael D.] Marshall Univ, Sch Pharm, Pharmaceut Sci & Res, 1 John Marshall Dr, Huntington, WV 25755 USA.
RP Owens, SM (reprint author), Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA.
EM mowens@uams.edu
FU National Institute on Drug Abuse, USAUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [R01DA039195, F31DA046121]; National
   Institute of General Medical Sciences, USAUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [T32GM106999]
FX This research was supported by the National Institute on Drug Abuse, USA
   R01DA039195 and F31DA046121, and the National Institute of General
   Medical Sciences, USA T32GM106999. We thank Greg Gorman, PhD of the
   McWhorter School of Pharmacy, Samford University, Birmingham, AL for the
   analysis of serum and tissue concentrations of oc-PVP. We thank Michael
   Berquist, PhD of the College of Medicine, Department of Pharmacology and
   Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR
   for help with statistical analysis.
CR Baumann MH, 2014, J NEUROSCI, V34, P15150, DOI 10.1523/JNEUROSCI.3223-14.2014
   Bremer P. T, 2016, ANGEW CHEM, V128, P3836
   Bremer PT, 2017, J AM CHEM SOC, V139, P8601, DOI 10.1021/jacs.7b03334
   Carroll FI, 2011, J MED CHEM, V54, P5221, DOI 10.1021/jm2004943
   Fox BS, 1996, NAT MED, V2, P1129, DOI 10.1038/nm1096-1129
   Gannon BM, 2017, BEHAV PHARMACOL, V28, P578, DOI 10.1097/FBP.0000000000000315
   Gannon BM, 2016, J PHARMACOL EXP THER, V356, P615, DOI 10.1124/jpet.115.229500
   Hambuchen MD, 2017, DRUG ALCOHOL DEPEN, V179, P347, DOI 10.1016/j.drugalcdep.2017.07.011
   Hambuchen MD, 2017, ANAL METHODS-UK, V9, P609, DOI [10.1039/c6ay03176e, 10.1039/C6AY03176E]
   Hambuchen MD, 2015, J MED CHEM, V58, P4665, DOI 10.1021/acs.jmedchem.5b00220
   Horsley RR, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00144
   Kolanos R, 2015, ACS CHEM NEUROSCI, V6, P771, DOI 10.1021/acschemneuro.5b00006
   Leffler AM, 2014, FORENSIC SCI INT, V234, P50, DOI 10.1016/j.forsciint.2013.08.021
   Majchrzak M, 2018, FORENSIC TOXICOL, V36, P33, DOI 10.1007/s11419-017-0385-6
   Martin Hastedt, 2015, FORENSIC SCI MED PAT, V11, P147, DOI [10.1007/s12024-014-9602-3C, DOI 10.1007/S12024-014-9602-3C]
   Marusich JA, 2014, NEUROPHARMACOLOGY, V87, P206, DOI 10.1016/j.neuropharm.2014.02.016
   McCluskie MJ, 2015, INT IMMUNOPHARMACOL, V25, P518, DOI 10.1016/j.intimp.2015.02.030
   Nelson KH, 2019, PSYCHOPHARMACOLOGY, V236, P1067, DOI 10.1007/s00213-018-5070-x
   Nguyen JD, 2017, NEUROPHARMACOLOGY, V116, P1, DOI 10.1016/j.neuropharm.2016.12.005
   Novellas J, 2015, J PSYCHOPHARMACOL, V29, P1209, DOI 10.1177/0269881115598415
   Peterson EC, 2007, J PHARMACOL EXP THER, V322, P30, DOI 10.1124/jpet.106.117150
   Peterson EC, 2014, BIOCONJUGATE CHEM, V25, P2112, DOI 10.1021/bc500456z
   Pravetoni M, 2012, VACCINE, V30, P4617, DOI 10.1016/j.vaccine.2012.04.101
   Ruedi-Bettschen D, 2013, VACCINE, V31, P4596, DOI 10.1016/j.vaccine.2013.07.038
   Simmler LD, 2013, BRIT J PHARMACOL, V168, P458, DOI 10.1111/j.1476-5381.2012.02145.x
   Stevens MW, 2016, INT IMMUNOPHARMACOL, V35, P137, DOI 10.1016/j.intimp.2016.03.028
   UNODC, 2014, GLOB SYNTH DRUG ASS, P76
   Wojcieszak J, 2018, NEUROTOX RES, V34, P613, DOI 10.1007/s12640-018-9923-1
   Woloshchuk CJ, 2016, DRUG ALCOHOL DEPEN, V167, P121, DOI 10.1016/j.drugalcdep.2016.08.008
   Zawilska JB, 2017, FORENSIC TOXICOL, V35, P201, DOI 10.1007/s11419-016-0353-6
NR 30
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 336
EP 344
DI 10.1016/j.vaccine.2019.10.008
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700031
PM 31629568
DA 2020-05-12
ER

PT J
AU Dowall, SD
   Kempster, S
   Findlay-Wilson, S
   Mattiuzzo, G
   Graham, VA
   Page, M
   Hewson, R
   Almond, N
AF Dowall, Stuart D.
   Kempster, Sarah
   Findlay-Wilson, Stephen
   Mattiuzzo, Giada
   Graham, Victoria A.
   Page, Mark
   Hewson, Roger
   Almond, Neil
TI Towards quantification of protective antibody responses by passive
   transfer of the 1st WHO International Standard for Ebola virus antibody
   in a guinea pig model
SO VACCINE
LA English
DT Article
DE Ebola; Standards; Efficacy
ID VACCINE; DISEASE; TRIAL
AB Ebola virus (EBOV) represents a major concern to global health due to the unpredictable nature of outbreaks. Infection with EBOV can cause a severe viral haemorrhagic fever with no licensed vaccine or treatment, restricting work with live EBOV to Containment/Biosafety Level 4 facilities. Whilst the magnitude of recent outbreaks has provided an impetus for vaccine and antiviral development, establishing the efficacy of candidate vaccine materials relies on EBOV challenge models and advanced human trials should outbreaks occur and where logistics and funding allow. To address these hurdles in vaccine development, we investigated whether a recently established serological reference standard, the 1st WHO International Standard for Ebola virus antibody, could be used to provide a quantifiable correlate of immune protection in vivo. Dilutions of the International Standard were inoculated into naive guinea pigs 24 h before challenge with a lethal dose of Ebola virus. Only subjects receiving the highest dose of the International Standard exhibited evidence of delayed progression. Due to it being a WHO established reagent and available globally upon request, this standard allows for effective comparisons of data between laboratories and may prove valuable to select the candidate vaccines that are most likely to confer humoral immune protection ensuring the most promising candidates progress into efficacy studies. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Dowall, Stuart D.; Findlay-Wilson, Stephen; Graham, Victoria A.; Hewson, Roger] Publ Hlth England, Natl Infect Serv, Salisbury SP4 0JG, Wilts, England.
   [Kempster, Sarah; Mattiuzzo, Giada; Page, Mark; Almond, Neil] Natl Inst Biol Stand & Controls, Blanche Lane, Potters Bar EN6 3QG, Herts, England.
RP Dowall, SD (reprint author), Publ Hlth England, Natl Infect Serv, Salisbury SP4 0JG, Wilts, England.; Almond, N (reprint author), Natl Inst Biol Stand & Controls, Blanche Lane, Potters Bar EN6 3QG, Herts, England.
EM stuart.dowall@phe.gov.uk
OI Dowall, Stuart/0000-0001-7378-8167; kempster, sarah/0000-0002-4309-1489
FU Official Development Assistance (ODA) [971527]; NIHR Policy Research
   Programme (NIBSC Regulatory Science Research Unit)
FX This report is work commissioned by Innovate UK and the Department of
   Health and Social Care (Project title "Serological Vaccine Standards for
   Ebola, Zika and MERS-CoV"; File Ref. 971527) and is funded through
   Official Development Assistance (ODA), alongside research commissioned
   and funded, in part, by the NIHR Policy Research Programme (NIBSC
   Regulatory Science Research Unit). The views expressed in this
   publication are those of the author(s) and not necessarily those of
   Innovate UK, the Department of Health and Social Care, NHS, the NIHR,
   'arms' length bodies or other government departments.
CR Blaney JE, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003389
   Bukreyev AA, 2014, ARCH VIROL, V159, P821, DOI 10.1007/s00705-013-1846-9
   Claude KM, 2018, LANCET, V392, P1399, DOI 10.1016/S0140-6736(18)32419-X
   Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330
   De Santis O, 2016, LANCET INFECT DIS, V16, P311, DOI 10.1016/S1473-3099(15)00486-7
   Dey CJ, 2017, NAT ECOL EVOL, V1, DOI 10.1038/s41559-017-0137
   Dowall SD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03910-7
   Dowall SD, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0540-x
   Dowall SD, 2016, J INFECT DIS, V213, P1124, DOI 10.1093/infdis/jiv565
   Edwards T, 2016, CLIN TRIALS, V13, P13, DOI 10.1177/1740774515621056
   Ewer K, 2016, NEW ENGL J MED, V374, P1635, DOI 10.1056/NEJMoa1411627
   Fuse S, 2008, CRIT REV IMMUNOL, V28, P159, DOI 10.1615/CritRevImmunol.v28.i2.40
   Garske T, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0308
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Huttner A, 2018, LANCET INFECT DIS, V18, P738, DOI 10.1016/S1473-3099(18)30165-8
   Jones SM, 2007, J INFECT DIS, V196, pS404, DOI 10.1086/520591
   Kasereka MC, 2019, VACCINE
   Krause PR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8202
   Ledgerwood JE, 2017, NEW ENGL J MED, V376, P928, DOI [10.1056/NEJMoa1410863, 10.1056/nejmoa1410863]
   Marzi A, 2013, P NATL ACAD SCI USA, V110, P1893, DOI 10.1073/pnas.1209591110
   Meyer M, 2019, TRENDS MICROBIOL, V27, P8, DOI 10.1016/j.tim.2018.08.008
   NIBSC, 1 INT STAND EB VIR E
   Pavot V, 2016, CLIN IMMUNOL, V173, P44, DOI 10.1016/j.clim.2016.10.016
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Sullivan NJ, 2009, NAT REV MICROBIOL, V7, P393, DOI 10.1038/nrmicro2129
   Wilkinson DE, 2017, VACCINE, V35, P1347, DOI 10.1016/j.vaccine.2016.11.083
   Wong G, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004582
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 345
EP 349
DI 10.1016/j.vaccine.2019.10.009
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700032
PM 31668821
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wolff, GG
AF Wolff, Greg G.
TI Influenza vaccination and respiratory virus interference among
   Department of Defense personnel during the 2017-2018 influenza season
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Virus interference; Department of Defense;
   Respiratory illness
ID TEST-NEGATIVE DESIGN; UNITED-STATES; PROTECTION
AB Purpose: Receiving influenza vaccination may increase the risk of other respiratory viruses, a phenomenon known as virus interference. Test-negative study designs are often utilized to calculate influenza vaccine effectiveness. The virus interference phenomenon goes against the basic assumption of the test-negative vaccine effectiveness study that vaccination does not change the risk of infection with other respiratory illness, thus potentially biasing vaccine effectiveness results in the positive direction. This study aimed to investigate virus interference by comparing respiratory virus status among Department of Defense personnel based on their influenza vaccination status. Furthermore, individual respiratory viruses and their association with influenza vaccination were examined.
   Results: We compared vaccination status of 2880 people with non-influenza respiratory viruses to 3240 people with pan-negative results. Comparing vaccinated to non-vaccinated patients, the adjusted odds ratio for non-flu viruses was 0.97 (95% confidence interval (CI): 0.86, 1.09; p = 0.60). Additionally, the vaccination status of 3349 cases of influenza were compared to three different control groups: all controls (N = 6120), non-influenza positive controls (N = 2880), and pan-negative controls (N = 3240). The adjusted ORs for the comparisons among the three control groups did not vary much (range: 0.46-0.51).
   Conclusions: Receipt of influenza vaccination was not associated with virus interference among our population. Examining virus interference by specific respiratory viruses showed mixed results. Vaccine derived virus interference was significantly associated with coronavirus and human metapneumovirus; however, significant protection with vaccination was associated not only with most influenza viruses, but also parainfluenza, RSV, and non-influenza virus coinfections. Published by Elsevier Ltd.
C1 [Wolff, Greg G.] Armed Forces Hlth Surveillance Branch Air Force S, 2510 5th St,Bldg 840, Wright Patterson AFB, OH 45433 USA.
RP Wolff, GG (reprint author), Armed Forces Hlth Surveillance Branch Air Force S, 2510 5th St,Bldg 840, Wright Patterson AFB, OH 45433 USA.
EM gregory.wolff.3@us.af.mil
CR [Anonymous], 2016, CDC INFL A SUBT KIT
   [Anonymous], 2017, BIOF FILMARRAY RESP
   [Anonymous], 2016, NXTAG RESP PATH PAN
   [Anonymous], 2016, CDC INFL A B SUBT KI
   Centers for Disease Control and Prevention, 2019, SEAS INFL VACC EFF 2
   Coleman Robert, 2018, MSMR, V25, P16
   Cooper M., 2014, VACC REL BIOL PROD A
   Cowling BJ, 2012, EPIDEMIOLOGY, V23, P930, DOI 10.1097/EDE.0b013e31826b300e
   Cowling BJ, 2012, CLIN INFECT DIS, V54, P1778, DOI 10.1093/cid/cis307
   Defense Health Agency, 2018, SEAS INFL VACC PROGR, P1
   Feng S, 2017, EPIDEMIOLOGY, V28, P514, DOI 10.1097/EDE.0000000000000670
   Foppa IM, 2016, INT J EPIDEMIOL, V45, P2052, DOI 10.1093/ije/dyw022
   Foppa IM, 2013, VACCINE, V31, P3104, DOI 10.1016/j.vaccine.2013.04.026
   Jackson ML, 2017, NEW ENGL J MED, V377, P534, DOI [10.1056/NEJMoa1700153, 10.1056/nejmoa1700153]
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647
   National Vaccine Information Center, 2019, WHAT IS HIST INFL VA
   Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736
   Rikin S, 2018, VACCINE, V36, P1958, DOI 10.1016/j.vaccine.2018.02.105
   Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064
   Sundaram ME, 2013, CLIN INFECT DIS, V57, P789, DOI 10.1093/cid/cit379
   Suzuki M, 2014, EPIDEMIOL INFECT, V142, P2642, DOI 10.1017/S0950268814000107
   Treanor JJ, 2012, CLIN INFECT DIS, V55, P951, DOI 10.1093/cid/cis574
NR 23
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 350
EP 354
DI 10.1016/j.vaccine.2019.10.005
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700033
PM 31607599
OA Bronze, Green Published
DA 2020-05-12
ER

PT J
AU Yadav, PK
   Chandrakar, P
   Sharma, P
   Vishwakarma, P
   Parmar, N
   Srivastava, M
   Kar, S
AF Yadav, Pawan Kumar
   Chandrakar, Pragya
   Sharma, Pankaj
   Vishwakarma, Preeti
   Parmar, Naveen
   Srivastava, Mrigank
   Kar, Susanta
TI Reciprocal changes in CD11c(+)CD11b(+) and CD11c(+)CD8 alpha(+)
   dendritic cell subsets determine protective or permissive immune
   response in murine experimental VL
SO VACCINE
LA English
DT Article
DE L. donovani; CD11c(+)CD8 alpha(+) dendritic cells; CD11c(+)CD11b(+)
   dendritic cells; Sema4A; OX40L; Th1/Th2 response
ID REGULATORY T-CELLS; OX40 LIGAND; LEISHMANIA-MAJOR; VACCINATION;
   EXPRESSION; DIFFERENTIATION; IMMUNOTHERAPY; COSTIMULATION; CD8-ALPHA(+);
   SEMAPHORINS
AB CD11c(+)CD8 alpha and CD11c(+)CD11b(+) dendritic cells are two major subsets of murine splenic CD11c(+) DCs which play a crucial role in T cell priming and shaping Th1/Th2 responses, but their role in the context of experimental visceral leishmaniasis (VL) is poorly understood. Herein, we showed that L donovani infection in Balb/c mice preferentially decreased the population abundance of CD11c(+)CD11b(+) DCs and increased relative abundance of splenic CD11c(+)CD8 alpha +DCs. During infection, splenic CD11c(+)CD11b(+) DCs induced TM differentiation whereas CD11c(+)CD8 alpha(+) DCs promoted Th2 differentiation. Additionally, treatment of infected mice with miltefosine as experimental control exhibited host defense allowing the restoration of CD11c(+)CD11b(+) population and decrease in CD11c(+)CD8 alpha(+) subset. Furthermore, reciprocal regulation of immune accessory surface molecules, Sema4A and OX4OL critically determined Th1/Th2 response induced by these DC subsets during VL. L. donovani infection significantly induced OX4OL expression and slightly downregulated SEMA 4A expression in CD11c(+)CD8 alpha(+) DCs whereas miltefosine treatment significantly downregulated OX4OL expression along with pronounced upregulation of SEMA 4A expression in CD11c(+)CD11b(+) DCs. SiRNA mediated knockdown of SEMA 4A markedly reduced CD11c(+)CD11b(+) driven IFN-gamma, TNF-alpha and IL-12 synthesis in miltefosine treated mice whereas functional blocking of OX4OL decreased CD11c(+)CD8 alpha(+) induced IL-10, IL-4 and TGF-beta synthesis in L. donovani infected group. Vaccination of Balb/c mice with antigen-pulsed + CpG-ODN-activated DC subsets revealed that only antigen-pulsed CD11c(+)CD11b(+) DCs eliminated parasite load in visceral organ and restored protective Th1 cytokine response. Collectively, our results suggest that differential regulation of splenic CD11c(+) subsets by L. donovani is essential for disease progression and specific subtypes may be exploited as prophylactic measures against visceral leishmaniasis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yadav, Pawan Kumar; Chandrakar, Pragya; Sharma, Pankaj; Vishwakarma, Preeti; Parmar, Naveen; Srivastava, Mrigank; Kar, Susanta] Cent Drug Res Inst, Div Parasitol, CSIR, Lucknow, Uttar Pradesh, India.
   [Yadav, Pawan Kumar; Chandrakar, Pragya; Vishwakarma, Preeti; Parmar, Naveen; Srivastava, Mrigank; Kar, Susanta] Acad Sci & Innovat Res AcSIR, New Delhi, India.
RP Kar, S (reprint author), Cent Drug Res Inst, CSIR, Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
EM susantakar@cdri.res.in
OI Srivastava, Mrigank/0000-0001-9324-7843
FU Department of Science and Technology, Government of IndiaDepartment of
   Science & Technology (India) [SB/FT/LS-310/2012]; Council of Scientific
   and Industrial Research Government of IndiaCouncil of Scientific &
   Industrial Research (CSIR) - India [CSIR NWP BSC0114]
FX This work was supported by the Department of Science and Technology
   (Grant no. SB/FT/LS-310/2012), Government of India and Council of
   Scientific and Industrial Research (CSIR NWP BSC0114) Government of
   India. The funding agency did not have any role in study design; in the
   data collection and interpretation; in the preparation of the manuscript
   or in the decision to publish.
CR Agallou M, 2012, VACCINE, V30, P5086, DOI 10.1016/j.vaccine.2012.05.075
   Agallou M, 2011, VACCINE, V29, P5053, DOI 10.1016/j.vaccine.2011.04.089
   Akiba H, 2000, J EXP MED, V191, P375, DOI 10.1084/jem.191.2.375
   Chen AI, 1999, IMMUNITY, V11, P689, DOI 10.1016/S1074-7613(00)80143-0
   Das S, 2014, BRIT J PHARMACOL, V171, P1260, DOI 10.1111/bph.12530
   Delgoffe GM, 2013, NATURE, V501, P252, DOI 10.1038/nature12428
   Desch AN, 2011, J EXP MED, V208, P1789, DOI 10.1084/jem.20110538
   Fajardo-Moser M, 2008, INT J MED MICROBIOL, V298, P11, DOI 10.1016/j.ijmm.2007.07.003
   Freitas-Silva Rafael, 2014, Front Immunol, V5, P604, DOI 10.3389/fimmu.2014.00604
   Fujimi S, 2009, J LEUKOCYTE BIOL, V85, P862, DOI 10.1189/jlb.0408257
   Garcia F, 2013, HUM VACC IMMUNOTHER, V9, P2445, DOI 10.4161/hv.25876
   GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365
   Ghosh M, 2003, J IMMUNOL, V170, P5625, DOI 10.4049/jimmunol.170.11.5625
   Ito T, 2004, J IMMUNOL, V172, P4253, DOI 10.4049/jimmunol.172.7.4253
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kastenmuller K, 2011, J CLIN INVEST, V121, P1782, DOI 10.1172/JCI45416
   Kim Tae Hoon, 2014, Immune Netw, V14, P128, DOI 10.4110/in.2014.14.3.128
   Kumanogoh A, 2005, IMMUNITY, V22, P305, DOI 10.1016/j.immuni.2005.01.014
   Lemos MP, 2003, J IMMUNOL, V171, P5077, DOI 10.4049/jimmunol.171.10.5077
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maldonado-Lopez R, 2001, SEMIN IMMUNOL, V13, P275, DOI 10.1006/smim.2001.0323
   Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587
   Manzotti CN, 2006, EUR J IMMUNOL, V36, P1413, DOI 10.1002/eji.200535170
   Maroof A, 2008, INFECT IMMUN, V76, P239, DOI 10.1128/IAI.00643-07
   McLachlan JB, 2009, IMMUNITY, V30, P277, DOI 10.1016/j.immuni.2008.11.013
   Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016
   Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734
   Mukherjee AK, 2012, INT IMMUNOPHARMACOL, V12, P565, DOI 10.1016/j.intimp.2012.02.002
   Murata K, 2000, J EXP MED, V191, P365, DOI 10.1084/jem.191.2.365
   Nakatsuji Y, 2012, J IMMUNOL, V188, P4858, DOI 10.4049/jimmunol.1102023
   Nkyimbeng-Takwi E, 2011, IMMUNOL RES, V50, P10, DOI 10.1007/s12026-010-8201-y
   O'Connor BP, 2008, IMMUNOL RES, V41, P217, DOI 10.1007/s12026-008-8026-0
   Ohshima Y, 1998, BLOOD, V92, P3338, DOI 10.1182/blood.V92.9.3338.421k19_3338_3345
   Ohshima Y, 1997, J IMMUNOL, V159, P3838
   Okwor I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00128
   Pillarisetty VG, 2004, J IMMUNOL, V172, P1009, DOI 10.4049/jimmunol.172.2.1009
   Qi H, 2001, J IMMUNOL, V167, P4534, DOI 10.4049/jimmunol.167.8.4534
   Remer KA, 2007, EUR J IMMUNOL, V37, P2463, DOI 10.1002/eji.200636780
   Ritter U, 2004, EUR J IMMUNOL, V34, P1542, DOI 10.1002/eji.200324586
   Schleicher U, 2007, J EXP MED, V204, P893, DOI 10.1084/jem.20061293
   Schmid M, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00074
   Schnitzer JK, 2010, VACCINE, V28, P5785, DOI 10.1016/j.vaccine.2010.06.077
   Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746
   Shortman K, 2010, IMMUNOL REV, V234, P18, DOI 10.1111/j.0105-2896.2009.00870.x
   Soong L, 2008, J IMMUNOL, V180, P4355, DOI 10.4049/jimmunol.180.7.4355
   Takamatsu H, 2010, NAT IMMUNOL, V11, P594, DOI 10.1038/ni.1885
   Tanaka H, 2000, J EXP MED, V192, P405, DOI 10.1084/jem.192.3.405
   Ukyo N, 2003, IMMUNOLOGY, V109, P226, DOI 10.1046/j.1365-2567.2003.01648.x
   von Stebut E, 2000, EUR J IMMUNOL, V30, P3498, DOI 10.1002/1521-4141(2000012)30:12&lt;3498::AID-IMMU3498&gt;3.0.CO;2-6
NR 49
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 355
EP 365
DI 10.1016/j.vaccine.2019.10.004
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700034
PM 31648908
DA 2020-05-12
ER

PT J
AU Frawley, JE
   McKenzie, K
   Sinclair, L
   Cummins, A
   Wardle, J
   Hall, H
AF Frawley, Jane E.
   McKenzie, Kirsty
   Sinclair, Lynn
   Cummins, Allison
   Wardle, Jon
   Hall, Helen
TI Midwives' knowledge, attitudes and confidence in discussing maternal and
   childhood immunisation with parents: A national study
SO VACCINE
LA English
DT Article
DE Midwives; Vaccination; Immunisation; Maternal; Pertussis; Influenza
ID INFLUENZA VACCINE UPTAKE; PERTUSSIS; PREGNANCY
AB Introduction: Despite the enormous benefits of childhood and maternal immunisation to individual and population health, the uptake of maternal vaccines during pregnancy remains suboptimal. Midwives are a trusted information source for parents and play an important role in the provision of immunisation information. Understanding midwives' attitudes and vaccine knowledge, along with their confidence to discuss maternal and childhood immunisation with parents, is key to reducing parental decisional conflict and achieving immunisation goals.
   Methods: An online study was conducted to investigate midwives' knowledge and attitudes towards maternal and childhood vaccination along with their confidence to answer parents' vaccine-related questions. Midwives were recruited by email via the midwifery peek body, the Australian College of Midwives.
   Results: A total of 359 midwives completed the online survey. The majority of midwives supported maternal (influenza 83%, pertussis 90.5%) and childhood immunisation (85.8%); however, 69.4% of respondents wanted further training about immunisation. Midwives who felt their midwifery education adequately covered immunisation were more confident advising parents about maternal (p = 0.007) and childhood immunisation (p < 0.001). Similarly, Midwives were significantly more likely to confidently advise parents about maternal (p < 0.001) and childhood immunisations (p < 0.001) if they had completed a specific immunisation training course outside of their midwifery course.
   Conclusion: Most midwives working in Australia support vaccination. However, access to contemporary, culturally appropriate education that enables midwives to engage confidently with parents about immunisation is lacking. Education based on a women-centred approach within the pre-registration curriculum along with continuing professional development programs could enable midwives to reduce the evidence to practice gap by increasing vaccine uptake. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Frawley, Jane E.; McKenzie, Kirsty] Univ Technol Sydney, Australian Ctr Publ & Populat Hlth Res, L8,Bldg 10,235 Jones St, Ultimo, NSW 2007, Australia.
   [Sinclair, Lynn; Cummins, Allison] Univ Technol Sydney, Ctr Midwifery Child & Family Hlth, 235 Jones St, Ultimo, NSW, Australia.
   [Wardle, Jon] Univ Technol Sydney, Australian Res Ctr Complementary & Integrat Med, 235 Jones St, Ultimo, NSW, Australia.
   [Hall, Helen] Monash Univ, Monash Nursing & Midwifery, McMahons Rd, Frankston, Vic, Australia.
RP Frawley, JE (reprint author), Univ Technol Sydney, Australian Ctr Publ & Populat Hlth Res, L8,Bldg 10,235 Jones St, Ultimo, NSW 2007, Australia.
EM jane.frawley@uts.edu.au
RI ; Cummins, Allison/G-8614-2015; Frawley, Jane/G-4476-2016
OI Wardle, Jonathan/0000-0001-8813-3542; Cummins,
   Allison/0000-0003-0626-3365; Frawley, Jane/0000-0001-6037-0140
FU National Health and Medical Research Council (NHMRC)National Health and
   Medical Research Council of Australia [GNT1124075]
FX We are grateful to the National Health and Medical Research Council
   (NHMRC) for an Early Career Fellowship (GNT1124075) that supported Dr
   Jane Frawley during this research. We would also like to acknowledge
   Professor Cathrine Fowler for her help in designing this study.
CR Attwell K, 2018, VACCINE, V36, P6531, DOI 10.1016/j.vaccine.2018.02.028
   Attwell K, 2018, HUM VACC IMMUNOTHER, P1
   Australian Government Department of Health, 2009, REPORT MATERNITY SER
   Australian Institute of Health and Welfare, 2015, NURS MIDW WORKF 2015
   Australian Nursing and Midwifery Accreditation Council, 2014, MIDW STAND CRIT ACCR
   Australian Technical Advisory Group on Immunisation, 2018, AUSTR IMM HDB
   Bisset KA, 2018, VACCINE, V36, P2751, DOI 10.1016/j.vaccine.2018.04.013
   Danchin MH, 2018, VACCINE, V36, P6473, DOI 10.1016/j.vaccine.2017.08.003
   Donnolley N, 2016, HEALTH INF MANAG J, V45, P64, DOI 10.1177/1833358316639454
   Higgins D, 2016, VACCINE, V34, P2870, DOI 10.1016/j.vaccine.2016.03.109
   Ishola DA, 2013, J PUBLIC HEALTH-UK, V35, P570, DOI 10.1093/pubmed/fds109
   Krishnaswamy S, 2018, AUST NZ J OBSTET GYN
   Leask J, 2008, AUST NZ J PUBL HEAL, V32, P224, DOI 10.1111/j.1753-6405.2008.00220.x
   Maisa A, 2018, PUBLIC HEALTH, V162, P111, DOI 10.1016/j.puhe.2018.05.025
   McCarthy EA, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0486-3
   Nursing and Midwifery Board of Australia, REP PRER 1 APR 2018
   Ogburn T, 2007, J REPROD MED, V52, P753
   Regan AK, 2018, MIDWIFERY, V62, P199, DOI 10.1016/j.midw.2018.04.004
   Regan AK, 2016, WOMEN BIRTH, V29, P423, DOI 10.1016/j.wombi.2016.01.009
   Taylor LE, 2014, VACCINE, V32, P3623, DOI 10.1016/j.vaccine.2014.04.085
   Vekemans J, 2018, VACCINE
   Wiley KE, 2013, VACCINE, V31, P3972, DOI 10.1016/j.vaccine.2013.06.015
   Wiley KE, 2013, MED J AUSTRALIA, V198, P373, DOI 10.5694/mja12.11849
NR 23
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 366
EP 371
DI 10.1016/j.vaccine.2019.10.006
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700035
PM 31628030
DA 2020-05-12
ER

PT J
AU van Aalst, R
   Gravenstein, S
   Mor, V
   Mahmud, SM
   Wilschut, J
   Postma, M
   Chit, A
AF van Aalst, Robertus
   Gravenstein, Stefan
   Mor, Vincent
   Mahmud, Salaheddin M.
   Wilschut, Jan
   Postma, Maarten
   Chit, Ayman
TI Comparative effectiveness of high dose versus adjuvanted influenza
   vaccine: A retrospective cohort study
SO VACCINE
LA English
DT Article
DE HD-IIV3; aIIV3; High-dose; Adjuvanted; Influenza vaccine; Comparative
   effectiveness; Relative vaccine effectiveness; rVE; Previous event rate
   ratio; PERR; Unmeasured confounding factors; Residual confounding
ID EVENT RATE RATIO; RESPIRATORY SYNCYTIAL VIRUS; OLDER-ADULTS;
   UNITED-STATES; ADJUSTMENT; HOSPITALIZATIONS; MORTALITY; EFFICACY; DEATHS
AB Background: Adults 65 years and older (seniors) experience more complications following influenza infection than younger adults. We estimated the relative vaccine effectiveness (rVE) of a trivalent high dose (HD-IIV3) versus an adjuvanted trivalent influenza vaccine (aIIV3) in seniors for respiratory-related hospitalizations.
   Methods: We conducted a retrospective cohort study using claims data from Optum's Clinformatics (R) Data Mart to compare outcome rates between seniors who received HD-IIV3 versus aIIV3 during the 2016/17 and 2017/18, predominantly A/H3N2 respiratory seasons. Rates were adjusted for demographic characteristics, comorbid conditions, previous influenza vaccination, and geography. We used the previous event rate ratio (PERR) approach to address bias by time-fixed unmeasured confounders.
   Results: We identified 842,282 HD-IIV3 and 34,157 aIIV3 recipients for the 2016/17 season and 1,058,638 HD-IIV3 and 189,636 aIIV3 recipients for the 2017/18 season. The pooled rVE of HD-IIV3 versus aIIV3 for respiratory-related hospitalizations over both seasons was 12% (95% confidence interval: 3.3%-20%); 13% (-6.4% to 32%) for the 2016/17 season and 12% (2.1%-21%) for the 2017/18 season.
   Conclusions: Pooled over two predominantly A/H3N2 respiratory seasons, HD-IIV3 was associated with fewer respiratory hospital admissions than aIIV3 in senior members of large national managed health care company in the U.S. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [van Aalst, Robertus; Postma, Maarten] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands.
   [van Aalst, Robertus; Chit, Ayman] Sanofi Pasteur, Vaccine Epidemiol & Modelling, Swiftwater, PA USA.
   [Gravenstein, Stefan; Mor, Vincent] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA.
   [Gravenstein, Stefan; Mor, Vincent] Providence VA Med Ctr, Ctr Long Term Serv & Support, Providence, RI USA.
   [Gravenstein, Stefan] Ctr Gerontol & Healthcare Res, Providence, RI USA.
   [Gravenstein, Stefan] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Mahmud, Salaheddin M.] Univ Manitoba, Coll Med, Dept Community Hlth Sci, Winnipeg, MB, Canada.
   [Mahmud, Salaheddin M.] Univ Manitoba, George & Fay Yee Ctr Healthcare Innovat, Winnipeg Reg Hlth Author, Winnipeg, MB, Canada.
   [Wilschut, Jan] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.
   [Postma, Maarten] Univ Groningen, Dept Pharm, Unit PharmacoTherapy Epidemiol & Econ PTE2, Groningen, Netherlands.
   [Postma, Maarten] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, Groningen, Netherlands.
   [Chit, Ayman] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.
RP van Aalst, R (reprint author), 1 Discovery Dr, Swiftwater, PA 18370 USA.
EM rob.vanaalst@sanofi.com
RI van Aalst, Robertus/F-8207-2016
OI van Aalst, Robertus/0000-0003-3025-7811
FU Sanofi Pasteur, Inc., Swiftwater, PA, USA
FX This study was funded by a research grant from Sanofi Pasteur, Inc.,
   Swiftwater, PA, USA.
CR Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Blanton L, 2017, MMWR-MORBID MORTAL W, V66, P668, DOI 10.15585/mmwr.mm6625a3
   Campitelli MA, 2010, VACCINE, V29, P240, DOI 10.1016/j.vaccine.2010.10.049
   Desai RJ, 2017, EPIDEMIOLOGY, V28, P249, DOI 10.1097/EDE.0000000000000595
   DiazGranados CA, 2015, VACCINE, V33, P4988, DOI 10.1016/j.vaccine.2015.07.006
   DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727
   Garten R, 2018, MMWR-MORBID MORTAL W, V67, P634, DOI 10.15585/mmwr.mm6722a4
   Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7
   Izurieta HS, 2015, LANCET INFECT DIS, V15, P293, DOI 10.1016/S1473-3099(14)71087-4
   Izurieta HS, 2018, J INFECT DIS, pjiy716
   Jackson ML, 2007, ARCH INTERN MED, V167, P1553, DOI 10.1001/archinte.167.14.1553-b
   Lambert ND, 2012, EXPERT REV VACCINES, V11, P985, DOI [10.1586/erv.12.61, 10.1586/ERV.12.61]
   Lee JKH, 2018, EXPERT REV VACCINES, V17, P435, DOI 10.1080/14760584.2018.1471989
   Levine MZ, 2019, J INFECT DIS, V219, P1904, DOI 10.1093/infdis/jiz049
   Lin NX, 2016, STAT MED, V35, P5149, DOI 10.1002/sim.7051
   Mannino S, 2012, AM J EPIDEMIOL, V176, P527, DOI 10.1093/aje/kws313
   Ng TWY, 2019, J INFECT DIS, V219, P1525, DOI 10.1093/infdis/jiy720
   Prevention CfDCa, EST INFL ILLN MED VI
   Prevention CfDCa, 2018 19 ACIP BACKGR
   Prevention CIDCa, 2019, CDC SAYS TAK 3 ACT F
   Richardson DM, 2015, CLIN INFECT DIS, V61, P171, DOI 10.1093/cid/civ261
   Robison SG, 2018, VACCINE
   Rosenbaum P, 2002, OBSERVATIONAL STUDIE
   Services CfMaM, 2019, ICD 10 GM OFF GUID C
   Services USDoHaH, 2012, GUID REG METH DEID P
   Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641
   Tannen RL, 2008, PHARMACOEPIDEM DR S, V17, P671, DOI 10.1002/pds.1584
   Tannen RL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b81
   Thompson WW, 2009, INFLUENZA OTHER RESP, V3, P37, DOI 10.1111/j.1750-2659.2009.00073.x
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   Uddin MJ, 2015, PHARMACOEPIDEM DR S, V24, P468, DOI 10.1002/pds.3724
   Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059
   Yinong YX, 2019, VACCINE, V37, P1484, DOI 10.1016/j.vaccine.2019.01.063
   Young-Xu YN, 2018, J INFECT DIS, V217, P1718, DOI 10.1093/infdis/jiy088
   Young-Xu Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169344
   Yu M, 2012, PHARMACOEPIDEMIOL S2, P60
   Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211
NR 40
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 372
EP 379
DI 10.1016/j.vaccine.2019.09.105
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700036
PM 31606249
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Havers, FP
   Cho, BH
   Walker, JW
   Hariri, S
AF Havers, Fiona P.
   Cho, Bo-Hyun
   Walker, Joseph W.
   Hariri, Susan
TI Economic impact of implementing decennial tetanus toxoid, reduced
   diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults
   in the United States
SO VACCINE
LA English
DT Article
DE Pertussis; Whooping cough; Tdap; Adult; Vaccination; Cost-effectiveness
ID ANTIGEN CONTENT DIPHTHERIA; COST-EFFECTIVENESS; ADOLESCENTS; VACCINES;
   AGE; IMMUNIZATION; PREVENTION; IMMUNITY; VISITS; COUGH
AB Background: In the United States, persons >= 11 years are recommended to receive one dose of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine, followed by decennial tetanus- and diphtheria-toxoid (Td) boosters. Many providers use Tdap instead of Td. We evaluated epidemiologic and economic impacts of replacing Td boosters with Tdap.
   Methods: We used a static cohort model to examine replacing Td with Tdap over the lifetime of 4,386,854 adults >= 21 years. Because pertussis is underdiagnosed and true incidence is unknown, we varied incidence from 2.5 cases/100,000 person-years to 500 cases/100,000 person-years. We calculated vaccine and medical costs from claims data. We estimated cost per case prevented and per quality-adjusted life year (QALY) saved; sensitivity analyses were conducted on vaccine effectiveness (VE), protection duration, vaccine cost, disease duration, hospitalization rates, productivity loss and missed work. We did not include programmatic advantages resulting from use of a single tetanus-toxoid containing vaccine.
   Results: At lowest incidence estimates, administering Tdap resulted in high costs per averted case ($111,540) and QALY saved ($8,972,848). As incidence increased, cases averted increased and cost per QALY saved decreased rapidly. With incidence estimates of 250 cases/100,000 person-years, cost per averted case and QALY saved were $984 and $81,678 respectively; at 500 cases/100,000 person-years, these values were $427 and $35,474. In multivariate sensitivity analyses, assuming 250 cases/100,000 personyears, estimated cost per QALY saved ranged from $971 (most favorable) to $217,370 (least favorable).
   Conclusions: Our findings suggest that replacing Td with Tdap for the decennial booster would result in high cost per QALY saved based on reported cases. However, programmatic considerations were not accounted for, and if pertussis incidence, which is incompletely measured, is assumed to be higher than reported through national surveillance, substituting Tdap for Td may lead to moderate decreases in pertussis cases and cost per QALY. (C) 2019 Published by Elsevier Ltd.
C1 [Havers, Fiona P.; Hariri, Susan] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA.
   [Cho, Bo-Hyun] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA.
   [Walker, Joseph W.] Univ Georgia, Coll Publ Hlth, Dept Epidemiol, Athens, GA 30602 USA.
RP Havers, FP (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop H24-5, Atlanta, GA 30333 USA.
EM fhavers@cdc.gov
OI Havers, Fiona/0000-0001-9873-6195
FU National Center for Immunization and Respiratory Diseases, Centers for
   Disease Control and Prevention, Atlanta, GA, United States
FX National Center for Immunization and Respiratory Diseases, Centers for
   Disease Control and Prevention, Atlanta, GA, United States. This
   research did not receive any specific grant from funding agencies in the
   public, commercial, or not-for-profit sectors.
CR Acosta AM, 2015, PEDIATRICS, V135, P981, DOI [10.1542/peds.2014-3358, 10.1542/peds.2014-4118]
   Analytics TH, TRUVEN HLTH MARKETSC
   Anonymous, 2012, Morbidity and Mortality Weekly Report, V61, P468
   [Anonymous], PERT WHOOP COUGH BOR
   [Anonymous], 2006, MED CLAIMS DAT DAT
   [Anonymous], 2017, NCHS BRIDG RAC POP E
   [Anonymous], 2018, CDC VACC PRIC LIST
   Arias L, 2014, US LIFE TABLES 2014
   AVENDANO P, 1993, PEDIATR INFECT DIS J, V12, P897, DOI 10.1097/00006454-199311000-00001
   Baughman AL, 2004, CLIN DIAGN LAB IMMUN, V11, P1045, DOI 10.1128/CDLI.11.6.1045-1053.2004
   Birkebaek NH, 1999, CLIN INFECT DIS, V29, P1239, DOI 10.1086/313448
   Booy R, 2010, VACCINE, V29, P45, DOI 10.1016/j.vaccine.2010.10.025
   Breakwell L, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3973
   Bureau of Economic Analysis, PERS CONS EXP PRIC I
   Chen CC, 2016, HUM VACC IMMUNOTHER, V12, P2536, DOI 10.1080/21645515.2016.1186313
   Corso P.S.H., 2003, PREVENTION EFFECTIVE
   Cortese MM, 2007, AM J PREV MED, V32, P177, DOI 10.1016/j.amepre.2006.10.015
   Dunn A, 2018, HEALTH SERV RES, V53, P175, DOI 10.1111/1475-6773.12612
   Fernandes EG, 2018, HUM VACC LMMUNOTHERA, P1
   Grosse SD, 2019, J MED ECON, V22, P501, DOI 10.1080/13696998.2018.1542520
   Halperin SA, 2018, PEDIAT INFECT DIS SO
   Halperin SA, 2012, VACCINE, V30, P974, DOI 10.1016/j.vaccine.2011.11.035
   Halperin SA, 2011, VACCINE, V29, P8459, DOI 10.1016/j.vaccine.2011.07.068
   Jackson ML, 2018, PHARMACOEPIDEM DR S, V27, P921, DOI 10.1002/pds.4569
   Kamiya H, 2016, VACCINE, V34, P1832, DOI 10.1016/j.vaccine.2016.02.027
   Klein NP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3326
   Koepke R, 2014, J INFECT DIS, V210, P942, DOI 10.1093/infdis/jiu322
   Kovac M, 2018, HUM VACC IMMUNOTHERA, P1
   Lee GM, 2005, PEDIATRICS, V115, P1675, DOI 10.1542/peds.2004-2509
   Lee GM, 2004, CLIN INFECT DIS, V39, P1572, DOI 10.1086/425006
   Lee GM, 2007, AM J PREV MED, V32, P186, DOI 10.1016/j.amepre.2006.10.016
   Lee Grace M, 2005, Health Qual Life Outcomes, V3, P17, DOI 10.1186/1477-7525-3-17
   Liang JL, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6702a1
   Masseria C, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1269-1
   McGarry LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0072723
   McGuiness CB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-32
   McNamara LA, 2017, CLIN INFECT DIS, V65, P811, DOI 10.1093/cid/cix421
   Melegaro A, 2004, VACCINE, V22, P4203, DOI 10.1016/j.vaccine.2004.05.003
   Mertsola J, 2010, CLIN INFECT DIS, V51, P656, DOI 10.1086/655825
   Moro PL, 2011, VACCINE, V29, P9404, DOI 10.1016/j.vaccine.2011.05.100
   Nennig ME, 1996, JAMA-J AM MED ASSOC, V275, P1672, DOI 10.1001/jama.275.21.1672
   Russell LB, 2008, PATIENT, V1, P211, DOI 10.2165/1312067-200801030-00008
   Senzilet LD, 2001, CLIN INFECT DIS, V32, P1691, DOI 10.1086/320754
   Smallridge WE, 2014, J INFECT DIS, V209, P1981, DOI 10.1093/infdis/jiu030
   Strebel P, 2001, J INFECT DIS, V183, P1353, DOI 10.1086/319853
   Tomovici A, 2012, VACCINE, V30, P2647, DOI 10.1016/j.vaccine.2012.02.013
   Tseng HF, 2013, CLIN INFECT DIS, V56, P315, DOI 10.1093/cid/cis871
   Ward JI, 2005, NEW ENGL J MED, V353, P1555, DOI 10.1056/NEJMoa050824
   Warfel JM, 2014, P NATL ACAD SCI USA, V111, P787, DOI 10.1073/pnas.1314688110
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 380
EP 387
DI 10.1016/j.vaccine.2019.09.104
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700037
PM 31676198
DA 2020-05-12
ER

PT J
AU Kydd, JH
   Hannant, D
   Robinson, RS
   Bryant, N
   Osterrieder, N
AF Kydd, Julia H.
   Hannant, Duncan
   Robinson, Robert S.
   Bryant, Neil
   Osterrieder, Nikolaus
TI Vaccination of foals with a modified live, equid herpesvirus-1 gM
   deletion mutant (RacH Delta gM) confers partial protection against
   infection
SO VACCINE
LA English
DT Article
DE Equine; Equid herpesvirus-1; Vaccine; Deletion mutant; Immune response
ID WHOLE VIRUS-VACCINE; IMMUNE-RESPONSES; TYPE-1 EHV-1; PERIPHERAL-BLOOD;
   DOWN-REGULATION; GLYCOPROTEIN-M; STRAIN RACH; CHALLENGE; INFLUENZA;
   EFFICACY
AB Equid herpesvirus-1 (EHV-1) causes respiratory and neurological disease and late gestation abortion in pregnant mares. Current vaccines contain either inactivated or live EHV-1, but fail to provide complete clinical or virological protection, namely prevention of nasopharyngeal shedding and cell-associated viraemia. Thus, the development of novel products, such as modified live virus (MLV) vaccines which stimulate virus-specific, humoral and cell mediated immune responses more effectively remains a priority. Two groups of weaned foals (n = 6 each group) were used in a longitudinal, prospective, experimental study to evaluate immune responses elicited by two vaccinations with a glycoprotein M (gM) deletion mutant of EHV-1 (RacHdeltagM). Following two concurrent intranasal and intramuscular inoculations six weeks apart, vaccinated (8.4 +/- 0.2 months old) and control foals (6.2 +/- 0.4 months) were challenge infected intranasally with EHV-1 Ab4/8 four weeks after the second vaccination and clinical signs and virological replication measured.
   Vaccination caused no adverse events, but did stimulate significantly higher complement fixing and virus neutralizing antibodies in serum compared with control foals at either equivalent or pre-vaccination time points. Virus-specific nasopharyngeal antibody levels and cytotoxic T lymphocyte responses were not significantly different between the groups. Following challenge infection, these immune responses were associated with a reduction in clinical signs and virological replication in the vaccinated foals, including a reduction in duration and magnitude of pyrexia, nasopharyngeal shedding and cell-associated viraemia. We conclude that the RacH Delta gM MLV primed EHV-1-specific humoral immune responses in weaned foals. However, complete virological protection by vaccination against EHV-1 requires further research. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kydd, Julia H.; Hannant, Duncan; Bryant, Neil] Anim Hlth Trust, Ctr Prevent Med, Lanwades Pk, Newmarket CB8 7UU, Suffolk, England.
   [Kydd, Julia H.; Hannant, Duncan; Robinson, Robert S.] Univ Nottingham, Sch Vet Med & Sci, Loughborough LE12 5RD, Leics, England.
   [Osterrieder, Nikolaus] Zentrum Infekt Med, Inst Virol Robert von Ostertag Haus, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany.
RP Kydd, JH (reprint author), Anim Hlth Trust, Ctr Prevent Med, Lanwades Pk, Newmarket CB8 7UU, Suffolk, England.; Kydd, JH (reprint author), Univ Nottingham, Sch Vet Med & Sci, Loughborough LE12 5RD, Leics, England.
FU Animal Health Trust; University of Nottingham; Deutsche
   ForschungsgemeinschaftGerman Research Foundation (DFG) [Os 143/2-2]
FX JHK, NB and DH were supported by the Animal Health Trust, RSR by
   University of Nottingham and NO by grant Os 143/2-2 from the Deutsche
   Forschungsgemeinschaft. The authors thank the Animal Health Trust's'
   technicians within the Diagnostic Virology Service for their efficient
   serological testing and estate staff for their excellent animal handling
   expertise.
CR ALLEN G, 1995, J VIROL, V69, P606, DOI 10.1128/JVI.69.1.606-612.1995
   Allen G. P., 1999, Equine infectious diseases VIII: Proceedings of the Eighth International Conference, Dubai, 23rd-26th March 1998., P129
   Gonzalez DA, 2010, IMMUNOL LETT, V133, P6, DOI 10.1016/j.imlet.2010.07.001
   American Association of Equine Practitioners A, 2019, RISK BAS VACC GUID E
   [Anonymous], 2019, COD PRACT EQ HERP
   Bannai H, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2036-0
   Bannai H, 2018, VET MICROBIOL, V222, P18, DOI 10.1016/j.vetmic.2018.06.015
   Blondeau C, 2013, J VIROL, V87, P13124, DOI 10.1128/JVI.02250-13
   Breathnach CC, 2006, VET IMMUNOL IMMUNOP, V112, P199, DOI 10.1016/j.vetimm.2006.02.010
   Breathnach CC, 2006, VET IMMUNOL IMMUNOP, V111, P117, DOI 10.1016/j.vetimm.2006.01.014
   Breathnach CC, 2001, EQUINE VET J, V33, P651, DOI 10.2746/042516401776249318
   Bryant NA, 2018, TRANSBOUND EMERG DIS, V65, P817, DOI 10.1111/tbed.12809
   CLAY CM, 1992, VET CLIN N AM-EQUINE, V8, P31, DOI 10.1016/S0749-0739(17)30465-0
   CORNICK J, 1990, CAN J VET RES, V54, P260
   Crouch CF, 2005, VET IMMUNOL IMMUNOP, V108, P345, DOI 10.1016/j.vetimm.2005.06.009
   Damiani AM, 2014, VET MICROBIOL, V172, P555, DOI 10.1016/j.vetmic.2014.06.023
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   Demmers S, 2001, EQUINE VET J, V33, P676, DOI 10.2746/042516401776249327
   DOLBY CA, 1995, BRIT VET J, V151, P27, DOI 10.1016/S0007-1935(05)80061-2
   EDINGTON N, 1986, ARCH VIROL, V90, P111, DOI 10.1007/BF01314149
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   Flaminio MJBF, 2000, VET IMMUNOL IMMUNOP, V73, P267, DOI 10.1016/S0165-2427(00)00149-5
   Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601
   Fleury H, 2017, AIDS RES HUM RETROVI
   GIBSON JS, 1992, ARCH VIROL, V123, P351, DOI 10.1007/BF01317269
   Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Giron-Gonzalez JA, 2000, EUR J ENDOCRINOL, V143, P31, DOI 10.1530/eje.0.1430031
   Goehring LS, 2010, VACCINE, V28, P5203, DOI 10.1016/j.vaccine.2010.05.065
   Goodman LB, 2012, CLIN VACCINE IMMUNOL, V19, P235, DOI 10.1128/CVI.05522-11
   Goodman LB, 2006, VACCINE, V24, P3636, DOI 10.1016/j.vaccine.2006.01.062
   Hamza E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120661
   Hannan MA, 2019, THERIOGENOLOGY, V132, P212, DOI 10.1016/j.theriogenology.2019.04.014
   Heldens JGM, 2001, VACCINE, V19, P4307, DOI 10.1016/S0264-410X(01)00131-1
   Hellfritzsch M, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080375
   HOFFMAN AM, 1993, AM J VET RES, V54, P1608
   Holmes MA, 2006, VET IMMUNOL IMMUNOP, V111, P67, DOI 10.1016/j.vetimm.2006.01.010
   Holznagel DL, 2003, EQUINE VET J, V35, P620, DOI 10.2746/042516403775467153
   Huang T, 2015, J VIROL, V89, P6251, DOI 10.1128/JVI.00032-15
   Hubert PH, 1996, J VET MED B, V43, P1, DOI 10.1111/j.1439-0450.1996.tb00282.x
   Hussey GS, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-23
   Jessett D. M., 1999, Equine infectious diseases VIII: Proceedings of the Eighth International Conference, Dubai, 23rd-26th March 1998., P414
   KAASHOEK MJ, 1994, VACCINE, V12, P439, DOI 10.1016/0264-410X(94)90122-8
   Kim IJ, 2013, J VIROL, V87, P8029, DOI 10.1128/JVI.01181-13
   Kydd JH, 2006, VET IMMUNOL IMMUNOP, V111, P15, DOI 10.1016/j.vetimm.2006.01.005
   Kydd JH, 2006, J GEN VIROL, V87, P2507, DOI 10.1099/vir.0.82070-0
   LEHMAN JR, 1994, J AM VET MED ASSOC, V205, P1581
   Lewis MJ, 2008, MOL IMMUNOL, V45, P818, DOI 10.1016/j.molimm.2007.06.158
   LUNN DP, 1991, EQUINE VET J S, V12, P35
   Ma GG, 2013, VET MICROBIOL, V167, P123, DOI 10.1016/j.vetmic.2013.06.018
   Ma GG, 2012, J VIROL, V86, P3554, DOI 10.1128/JVI.06994-11
   Matsumura T, 1998, VIROLOGY, V242, P68, DOI 10.1006/viro.1997.8984
   Minke JM, 2006, VET IMMUNOL IMMUNOP, V111, P47, DOI 10.1016/j.vetimm.2006.01.008
   Minke JM, 2004, VET RES, V35, P425, DOI 10.1051/vetres:2004019
   Mlodawska W, 2018, THERIOGENOLOGY, V121, P13, DOI [10.1016/j.theriogenology2018.07.026, 10.1016/j.theriogenology.2018.07.026]
   Moraru M, 2012, J IMMUNOL, V188, P4412, DOI 10.4049/jimmunol.1103434
   Neubauer A, 1997, VIROLOGY, V239, P36, DOI 10.1006/viro.1997.8857
   Newton JR, 2007, EQUINE VET J, V39, P164, DOI 10.2746/042516407X166954
   OIE World Organisation for Animal Health, 2019, MANUAL DIAGNOSTIC TE
   Osterrieder N, 1996, VIROLOGY, V226, P243, DOI 10.1006/viro.1996.0652
   Osterrieder N, 2001, VET MICROBIOL, V81, P219, DOI 10.1016/S0378-1135(01)00357-1
   Osterrieder N, 1996, J VIROL, V70, P4110, DOI 10.1128/JVI.70.6.4110-4115.1996
   Ostlund EN, EQUINE INFECT DIS, V2992, P277
   Patel JR, 2003, VET MICROBIOL, V92, P1, DOI 10.1016/S0378-1135(02)00358-9
   Perkins GA, 2015, EQUINE VET J, V47, P267, DOI 10.1111/evj.12387
   Perkins G, 2019, VIROLOGY, V531, P219, DOI 10.1016/j.virol.2019.03.014
   RECZKO EVA, 1963, ARCH GES VIRUSFORSCH, V13, P591, DOI 10.1007/BF01267802
   Rosas CT, 2006, EXPERT REV VACCINES, V5, P119, DOI 10.1586/14760584.5.1.119
   Roth J A, 2000, Vet Ther, V1, P220
   Rousseau K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019678
   Ryan C, 2010, CLIN VACCINE IMMUNOL, V17, P1896, DOI 10.1128/CVI.00328-10
   Ryan C, 2010, VET IMMUNOL IMMUNOP, V133, P66, DOI 10.1016/j.vetimm.2009.06.010
   SANADA Y, 1992, J VET MED A, V39, P69, DOI 10.1111/j.1439-0442.1992.tb00157.x
   Schnabel CL, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1563-4
   Shakya AK, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00211
   Sheoran AS, 2000, AM J VET RES, V61, P1099, DOI 10.2460/ajvr.2000.61.1099
   SLATER JD, 1993, J GEN VIROL, V74, P819, DOI 10.1099/0022-1317-74-5-819
   SMITH KC, 1993, EQUINE VET J, V25, P36, DOI 10.1111/j.2042-3306.1993.tb02898.x
   Soboll G, 2003, J GEN VIROL, V84, P2625, DOI 10.1099/vir.0.19268-0
   Spiekermann GM, 2002, J EXP MED, V196, P303, DOI 10.1084/jem.20020400
   STUDDERT MJ, 1992, AUST VET J, V69, P104, DOI 10.1111/j.1751-0813.1992.tb07462.x
   Tallmadge RL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177831
   TEWARI D, 1993, ARCH VIROL, V132, P101, DOI 10.1007/BF01309846
   Thomas SL, 2004, LANCET INFECT DIS, V4, P26, DOI 10.1016/S1473-3099(03)00857-0
   THOMSON G R, 1976, Equine Veterinary Journal, V8, P58, DOI 10.1111/j.2042-3306.1976.tb03291.x
   Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702
   Tsujimura K, 2009, J VET MED SCI, V71, P1439, DOI 10.1292/jvms.001439
   Van Cleemput J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16804-5
   Van de Walle GR, 2010, VACCINE, V28, P1048, DOI 10.1016/j.vaccine.2009.10.123
   Wagner B, 2011, VET IMMUNOL IMMUNOP, V143, P116, DOI 10.1016/j.vetimm.2011.06.032
   Wagner BD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170120
   Warden C, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/124595
   Wilson WD, 2001, EQUINE VET J, V33, P644, DOI 10.2746/042516401776249435
   Woof JM, 2006, J PATHOL, V208, P270, DOI 10.1002/path.1877
   Yang XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051054
   Zhang L, 2015, EXPERT REV VACCINES, V14, P1509, DOI 10.1586/14760584.2015.1081067
NR 95
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 388
EP 398
DI 10.1016/j.vaccine.2019.09.106
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700038
PM 31629571
DA 2020-05-12
ER

PT J
AU Clarke, E
   Bashorun, AO
   Okoye, M
   Umesi, A
   Hydara, MB
   Adigweme, I
   Dhere, R
   Sethna, V
   Kampmann, B
   Goldblatt, D
   Tate, A
   Weiner, DH
   Flores, J
   Alderson, MR
   Lamola, S
AF Clarke, Ed
   Bashorun, Adedapo O.
   Okoye, Michael
   Umesi, Ama
   Hydara, Mariama Badjie
   Adigweme, Ikechukwu
   Dhere, Rajeev
   Sethna, Vistasp
   Kampmann, Beate
   Goldblatt, David
   Tate, Andi
   Weiner, Debra H.
   Flores, Jorge
   Alderson, Mark R.
   Lamola, Steve
TI Safety and immunogenicity of a novel 10-valent pneumococcal conjugate
   vaccine candidate in adults, toddlers, and infants in The Gambia-Results
   of a phase 1/2 randomized, double-blinded, controlled trial
SO VACCINE
LA English
DT Article
DE Phase 1/2; Reactogenicity; Tolerability; Safety; immunogenicity; Adult;
   Toddler; Infant; Pneumococcal conjugate vaccine
ID SEROTYPE-SPECIFIC HYPORESPONSIVENESS; STREPTOCOCCUS-PNEUMONIAE;
   NASOPHARYNGEAL CARRIAGE; IMMUNOCOMPETENT ADULTS; COST-EFFECTIVENESS;
   DISEASE; POLYSACCHARIDE; CHILDREN; EFFICACY; BOOSTER
AB Background: A more affordable pneumococcal conjugate vaccine (PCV) that provides comparable protection to current PCVs is needed to ensure sustainable access in resource-limited settings. Serum Institute of India Pvt. Ltd.'s PCV candidate (SIIPL-PCV) has the potential to meet this need as manufacturing efficiency has been optimized and the vaccine targets the most prevalent disease-causing serotypes in Africa and Asia. We report SIIPL-PCV's safety, tolerability, and immunogenicity in adults, toddlers, and infants in The Gambia.
   Methods: This phase 1/2, randomized, double-blind trial sequentially enrolled 34 PCV-naive adults (18-40 years old), 112 PCV (Prevenar 13 (R) [PCV13])-primed toddlers (12-15 months old), and 200 PCV-naive infants (6-8 weeks old), who were randomized (1:1) to receive SIIPL-PCV or a licensed comparator vaccine. Infants received three-doses of SIIPL-PCV or PCV13 at 6, 10, and 14 weeks of age co-administered with routine Expanded Program on Immunization (EPI) vaccines. Reactogenicity was solicited through seven-days post-vaccination; unsolicited adverse events (AEs) were assessed throughout the study. The safety and immunogenicity of a matching booster at 10-14 months of age were evaluated in a subset of 96 infants. Immune responses were evaluated post-primary and pre- and post-booster vaccinations.
   Results: Reactogenicity was primarily mild-to-moderate in severity. In infants, the most common solicited reactions were injection-site tenderness and fever, with no meaningful treatment-group differences. There were no serious or severe vaccine-related AEs and no meaningful trends in SAES, vaccine-related AEs, or overall AEs. Infant post-primary seroresponse rates (IgG level >= 0.35 mu g/mL) were >= 89% for all serotypes except 6A (79%) in the SIIPL-PCV group. IgG GMCs were >1 mu g/mL for all serotypes in both SIIPL-PCV and PCV13 groups. Post-booster GMCs were comparable between groups.
   Conclusion: SIIPL-PCV was well-tolerated, had an acceptable safety profile, and was immunogenic for all vaccine serotypes. Results support the evaluation of SIIPL-PCV in a phase 3 non-inferiority trial. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Clarke, Ed; Bashorun, Adedapo O.; Okoye, Michael; Umesi, Ama; Hydara, Mariama Badjie; Adigweme, Ikechukwu; Kampmann, Beate] London Sch Hyg & Trop Med, Med Res Council MRC Unit Gambia, Atlantic Rd,POB 273, Banjul, Gambia.
   [Dhere, Rajeev; Sethna, Vistasp] Serum Inst India Pvt Ltd, 212-2 Off Soli Poonawalla Rd Hadapsar, Pune 411028, Maharashtra, India.
   [Kampmann, Beate] London Sch Hyg & Trop Med, Vaccine Ctr, Fac Infect & Trop Dis, Keppel St, London, England.
   [Goldblatt, David] UCL, Inst Child Hlth, Biomed Res Ctr, Great Ormond St,30 Guilford St, London, England.
   [Tate, Andi; Flores, Jorge; Alderson, Mark R.; Lamola, Steve] PATH, 2201 Westlake Ave,Suite 200, Seattle, WA USA.
   [Weiner, Debra H.] FHI 360,359 Blackwell St,Suite 200, Durham, NC USA.
RP Clarke, E (reprint author), London Sch Hyg & Trop Med, Med Res Council MRC Unit Gambia, Atlantic Rd,POB 273, Banjul, Gambia.
EM Ed.Clarke@lshtm.ac.uk
RI Goldblatt, David/C-5972-2008
OI Goldblatt, David/0000-0002-0769-5242
FU PATH by the Bill & Melinda Gates Foundation
FX This manuscript is based on research funded through PATH by the Bill &
   Melinda Gates Foundation. The findings and conclusions contained within
   are those of the authors and do not necessarily reflect positions or
   policies of the foundation.
CR [Anonymous], PNEUMOVAX23 PNEUM VA
   [Anonymous], PREVENARL3 PNEUM 13
   Barker N, 2005, PHUSE C 2005
   Chen C, 2019, LANCET GLOB HEALTH, V7, pE58, DOI 10.1016/S2214-109X(18)30422-4
   Chevallier B, 2009, PEDIATR INFECT DIS J, V28, pS109, DOI 10.1097/INF.0b013e318199f62d
   Clutterbuck EA, 2012, J INFECT DIS, V205, P1408, DOI 10.1093/infdis/jis212
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2010, J INFECT DIS, V201, P1570, DOI 10.1086/652006
   Diao WQ, 2016, VACCINE, V34, P1496, DOI 10.1016/j.vaccine.2016.02.023
   Efron B., 1993, INTRO BOOTSTRAP
   Farooqui H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129191
   Goldblatt D, 2011, CLIN VACCINE IMMUNOL, V18, P1728, DOI 10.1128/CVI.05252-11
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Idoko OT, 2017, VACCINE, V35, P3256, DOI 10.1016/j.vaccine.2017.04.049
   Jodar L, 2003, VACCINE, V21, P3265, DOI 10.1016/S0264-410X(03)00230-5
   Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348
   Kieninger DM, 2010, VACCINE, V28, P4192, DOI 10.1016/j.vaccine.2010.04.008
   Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8
   Mackenzie GA, 2016, LANCET INFECT DIS, V16, P703, DOI 10.1016/S1473-3099(16)00054-2
   Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Odutola A, 2017, VACCINE, V35, P2531, DOI 10.1016/j.vaccine.2017.03.071
   Palmu AA, 2013, LANCET, V381, P214, DOI 10.1016/S0140-6736(12)61854-6
   Paradiso PR, 2011, CLIN INFECT DIS, V52, P1241, DOI 10.1093/cid/cir142
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494
   Roca A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001107
   Romero-Steiner S, 2003, CLIN DIAGN LAB IMMUN, V10, P1019, DOI 10.1128/CDLI.10.6.1019-1024.2003
   Rose CE, 2011, CLIN VACCINE IMMUNOL, V18, P135, DOI 10.1128/CVI.00370-10
   Saokaew S, 2016, PHARMACOECONOMICS, V34, P1211, DOI 10.1007/s40273-016-0439-3
   Schuerman L, 2011, CLIN VACCINE IMMUNOL, V18, P2161, DOI 10.1128/CVI.05313-11
   Target WHO, 2008, PROD PROF TPP ADV MA
   Truck J, 2016, PEDIATR INFECT DIS J, V35, P787, DOI 10.1097/INF.0000000000001180
   Urbancikova I, 2017, VACCINE, V35, P5186, DOI 10.1016/j.vaccine.2017.07.103
   Usuf E, 2018, CLIN INFECT DIS
   Vadlamudi NK, 2019, VACCINE, V37, P1021, DOI 10.1016/j.vaccine.2019.01.014
   Vakevainen M, 2010, J PEDIATR-US, V157, P778, DOI 10.1016/j.jpeds.2010.04.071
   Vesikari T, 2009, PEDIATR INFECT DIS J, V28, pS66, DOI 10.1097/INF.0b013e318199f8ef
   Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   Wijmenga-Monsuur AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144739
   World Health Organization, REC ASS QUAL SAF EFF
   Yeh SH, 2010, PEDIATRICS, V126, pE493, DOI 10.1542/peds.2009-3027
   Zunt JR, 2018, LANCET NEUROL, V17, P1061, DOI 10.1016/S1474-4422(18)30387-9
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2020
VL 38
IS 2
BP 399
EP 410
DI 10.1016/j.vaccine.2019.08.072
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG0DU
UT WOS:000509612700039
PM 31843266
OA Other Gold
DA 2020-05-12
ER

PT J
AU Resiere, D
   Villalta, M
   Arias, AS
   Kallel, H
   Neviere, R
   Vidal, N
   Mehdaoui, H
   Gutierrez, JM
AF Resiere, Dabor
   Villalta, Mauren
   Arias, Ana Silvia
   Kallel, Hatem
   Neviere, Remi
   Vidal, Nicolas
   Mehdaoui, Hossein
   Maria Gutierrez, Jose
TI Snakebite envenoming in French Guiana: Assessment of the preclinical
   efficacy against the venom of Bothrops atrox of two polyspecific
   antivenoms
SO TOXICON
LA English
DT Article
DE Snake venoms; French Guiana; Antivenom; Neutralization; Preclinical
   efficacy; Polival-ICP (R); Antivipmyn Tri (R)
ID NEUTRALIZATION; ENVENOMATION
AB Snakebite envenoming is a relevant public health problem in French Guiana, and Bothrops atrox is responsible for the vast majority of envenomings in this overseas French territory. The preclinical efficacy of freeze-dried antivenoms manufactured in Costa Rica (Polival-ICP (R)) and Mexico (Antivipmyn Tri (R)) was assessed against the lethal, hemorrhagic, in vitro coagulant, and myotoxic effects of Bothrops atrox venom from French Guiana. Antivenoms differ in protein concentration and in the type of active principle (IgG and F (ab')(2), respectively). Polival-ICP (R) showed significantly higher neutralizing activity against lethal, hemorrhagic and in vitro coagulant activities of the venom. Antivenoms neutralized myotoxic effect to a similar extent. In the case of lethal activity, Antivipmyn Trig did not neutralize the effect at the highest antivenom level tested (1 mg venom/mL antivenom).
C1 [Resiere, Dabor; Neviere, Remi; Mehdaoui, Hossein] Ctr Hosp Univ Ft de France, Serv Urgences & Reanimat Polyvalente, Fort De France, Martinique, France.
   [Villalta, Mauren; Arias, Ana Silvia; Maria Gutierrez, Jose] Univ Costa Rica, Inst Clodomiro Picado, Fac Microbiol, San Jose 11501, Costa Rica.
   [Kallel, Hatem] Cayenne Gen Hosp, Intens Care Unit, Cayenne, French Guiana, France.
   [Vidal, Nicolas] Univ Antilles, Sorbonne Univ, Inst Systemat Evolut & Biodiversite, UMR 7205,MNHN,CNRS,EPHE, CP 30,57 Rue Cuvier, F-75005 Paris, France.
RP Gutierrez, JM (reprint author), Univ Costa Rica, Inst Clodomiro Picado, Fac Microbiol, San Jose 11501, Costa Rica.
EM jose.gutierrez@ucr.ac.cr
OI resiere, dabor/0000-0001-9144-7323
FU Vicerrectoria de Investigacion, Universidad de Costa Rica
FX The authors thank Daniela Solano (Institute Clodomiro Picado) for her
   cooperation in the laboratory work. This study was supported by
   Vicerrectoria de Investigacion, Universidad de Costa Rica and by the
   project ANR MitoBothrops 2018(support to DR and RN).
CR Bogarin G, 2000, TOXICON, V38, P1429, DOI 10.1016/S0041-0101(99)00236-6
   Chippaux J P, 2002, Med Trop (Mars), V62, P177
   Chippaux JP, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005662
   CHIPPAUX JP, 1987, ANN TROP MED PARASIT, V81, P301, DOI 10.1080/00034983.1987.11812123
   Del-Rei THM, 2019, TOXICON, V164, P61, DOI 10.1016/j.toxicon.2019.04.001
   Estevez J., 2008, Bulletin de la Societe de Pathologie Exotique, V101, P353, DOI 10.3185/pathexo3174
   Finney D.J., 1971, PROBIT ANAL
   GENE JA, 1989, TOXICON, V27, P841, DOI 10.1016/0041-0101(89)90096-2
   Gutierrez J.M., 2018, TOXIONS BASEL, V11, pE5
   GUTIERREZ JM, 1980, TOXICON, V18, P603, DOI 10.1016/0041-0101(80)90087-2
   GUTIERREZ JM, 1985, TOXICON, V23, P887, DOI 10.1016/0041-0101(85)90380-0
   Kallel H, 2018, TOXICON, V146, P87, DOI 10.1016/j.toxicon.2018.04.004
   Kallel H, 2018, TOXICON, V146, P91, DOI 10.1016/j.toxicon.2018.04.003
   Laines J, 2014, TOXICON, V88, P34, DOI 10.1016/j.toxicon.2014.06.008
   Gutierrez JM, 2017, TOXINS, V9, DOI 10.3390/toxins9050163
   Mutricy R, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006482
   Mutricy R, 2018, INTENS CARE MED, V44, P115, DOI 10.1007/s00134-017-4929-3
   Nadaud A, 2019, ANAESTH CRIT CARE PA, V38, P193, DOI 10.1016/j.accpm.2018.06.004
   OTERO R, 1995, TOXICON, V33, P809, DOI 10.1016/0041-0101(95)00009-B
   Resiere D, 2018, TOXICON, V148, P50, DOI 10.1016/j.toxicon.2018.04.010
   Rojas E, 2005, ACTA TROP, V93, P85, DOI 10.1016/j.actatropica.2004.09.008
   ROJAS G, 1994, TOXICON, V32, P351, DOI 10.1016/0041-0101(94)90087-6
   Segura A, 2010, TOXICON, V56, P980, DOI 10.1016/j.toxicon.2010.07.001
   Warrell D.A., 2004, VENOMOUS REPTILES W, P709
   World Health Organization, 2018, WHO GUID PROD CONTR
NR 25
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 1
EP 4
DI 10.1016/j.toxicon.2019.11.001
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100001
PM 31726079
OA Bronze
DA 2020-05-12
ER

PT J
AU de Oliveira-Mendes, BBR
   Chatzaki, M
   Sales-Medina, DF
   Leal, HG
   van der Veer, R
   Biscoto, GL
   Goncalves, PM
   da Silva, TS
   Guerra-Duarte, C
   Kalapothakis, E
   Horta, CCR
AF Ribeiro de Oliveira-Mendes, Birbara Bruna
   Chatzaki, Maria
   Sales-Medina, Douglas Ferreira
   Leal, Hortensia Gomes
   van der Veer, Ray
   Biscoto, Gabriela Lago
   Goncalves, Priscila Mendes
   da Silva, Thais Soares
   Guerra-Duarte, Clara
   Kalapothakis, Evanguedes
   Rebello Horta, Carolina Campolina
TI From taxonomy to molecular characterization of brown spider venom: An
   overview focused on Loxosceles similis
SO TOXICON
LA English
DT Review
DE Loxosceles; Brown spider; Venom; Loxoscelism; Brazil
ID SPHINGOMYELINASE-D ACTIVITY; INTERMEDIA MELLO-LEITAO; PHOSPHOLIPASE-D
   TOXINS; LOXTOX PROTEIN FAMILY; B-CELL EPITOPES; DERMONECROTIC TOXIN;
   FUNCTIONAL-CHARACTERIZATION; RECLUSE SPIDER; CUTANEOUS LOXOSCELISM;
   ARANEAE SICARIIDAE
AB Loxosceles spp. (Araneae, Sicariidae), known as brown spiders, are distributed in temperate and tropical regions worldwide. Accidents caused by these spiders are known as loxoscelism and constitute a public health problem, especially in Brazil. The present review describes the taxonomy, distribution, and ecological profile of brown spiders, as well as the molecular and biochemical aspects of Loxosceles venom. Additionally, it presents an overview on L. similis, a species found in the Southeastern region of Brazil. In this region, the number of Loxosceles accidents has been increasing in the past few years, thus calling attention to its raising importance as a medically relevant spider species in Brazil.
C1 [Ribeiro de Oliveira-Mendes, Birbara Bruna; Sales-Medina, Douglas Ferreira; Leal, Hortensia Gomes; van der Veer, Ray; Biscoto, Gabriela Lago; da Silva, Thais Soares; Kalapothakis, Evanguedes] Univ Fed Minas Gerais, Dept Biol Geral, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Chatzaki, Maria] Democritus Univ Thrace, Dept Mol Biol & Genet, Dragana 68100, Alexandroupoli, Greece.
   [van der Veer, Ray] Living Lab Biobased Brazil, POB 90-116, NL-4800 RA Breda, Netherlands.
   [van der Veer, Ray; Goncalves, Priscila Mendes; Rebello Horta, Carolina Campolina] Ctr Univ Sete Lagoas, Mestrado Profiss Biotecnol & Gestao Inovacao, BR-35701242 Sete Lagoas, MG, Brazil.
   [Guerra-Duarte, Clara] Fundacao Ezequiel Dias, BR-30510010 Belo Horizonte, MG, Brazil.
RP Horta, CCR (reprint author), Univ Sao Paulo, Inst Ciencias Biomed 2, Ave Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, SP, Brazil.
EM carolina.horta@usp.br
RI Duarte, Clara Guerra/H-1409-2012
OI Duarte, Clara Guerra/0000-0002-7698-3811; Gomes Leal,
   Hortensia/0000-0003-0767-8781
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES Edital Toxinologia) [63/2010]; Fundacao de Amparo a Pesquisa do
   Estado de Minas Gerais (FAPEMIG)Minas Gerais State Research Foundation
   (FAPEMIG) [APQ-02826-15, MPR-00172-16]
FX This research was funded by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES Edital Toxinologia 63/2010;
   CAPES/PNPD), and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG; APQ-02826-15, MPR-00172-16).
CR Appel MH, 2008, BBA-GEN SUBJECTS, V1780, P167, DOI 10.1016/j.bbagen.2007.11.007
   Araujo SC, 2003, TOXICON, V41, P261, DOI 10.1016/S0041-0101(02)00282-9
   Atilla R, 2004, VET HUM TOXICOL, V46, P306
   Bajin MS, 2011, CUTAN OCUL TOXICOL, V30, P302, DOI 10.3109/15569527.2011.577494
   Barbaro KC, 2010, TOXICON, V56, P972, DOI 10.1016/j.toxicon.2010.06.022
   Barbaro KC, 1996, J PROTEIN CHEM, V15, P337, DOI 10.1007/BF01886859
   Barbaro KC, 2005, TOXICON, V45, P489, DOI 10.1016/j.toxicon.2004.12.009
   Barbaro KC, 1996, BRAZ J MED BIOL RES, V29, P1491
   Bertani R, 2018, ZOOKEYS, P47, DOI 10.3897/zookeys.806.27404
   Binford GJ, 2005, TOXICON, V45, P547, DOI 10.1016/j.toxicon.2004.11.011
   Binford GJ, 2003, COMP BIOCHEM PHYS B, V135, P25, DOI 10.1016/S1096-4959(03)00045-9
   Binford GJ, 2009, MOL BIOL EVOL, V26, P547, DOI 10.1093/molbev/msn274
   Brugiolo S.S.S., 2011, REV APS, V14, P120
   Catalan A, 2011, J BIOCHEM MOL TOXIC, V25, P393, DOI 10.1002/jbt.20399
   Catalan A, 2014, TOXICON, V81, P43, DOI 10.1016/j.toxicon.2014.01.011
   Chaim OM, 2011, BBA-MOL CELL BIOL L, V1811, P84, DOI 10.1016/j.bbalip.2010.11.005
   Chaim OM, 2011, TOXINS, V3, P309, DOI 10.3390/toxins3030309
   Chaim OM, 2006, TOXICOL APPL PHARM, V211, P64, DOI 10.1016/j.taap.2005.05.015
   Chatzaki M, 2012, TOXICON, V60, P21, DOI 10.1016/j.toxicon.2012.03.007
   Chaves-Moreira D, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0097-8
   Chaves-Moreira D, 2017, J CELL BIOCHEM, V118, P726, DOI 10.1002/jcb.25678
   Chaves-Moreira D, 2011, J CELL BIOCHEM, V112, P2529, DOI 10.1002/jcb.23177
   Chaves-Moreira D, 2009, J CELL BIOCHEM, V107, P655, DOI 10.1002/jcb.22148
   Chen X, 2012, GENE, V495, P170, DOI [10.1016/j.gene.2011.12.051, 10.1016/j.biocel.2011.10.013]
   Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753
   Christoff ADO, 2008, TOXICON, V52, P695, DOI 10.1016/j.toxicon.2008.08.001
   Coronado MA, 2015, CURR PROTEIN PEPT SC, V16, P768, DOI 10.2174/1389203716666150505231625
   Cunha RB, 2003, J PROTEIN CHEM, V22, P135, DOI 10.1023/A:1023470829671
   da Silva PH, 2004, TOXICON, V44, P693, DOI 10.1016/j.toxicon.2004.07.012
   Da Silveira RB, 2007, BIOCHEM J, V406, P355, DOI 10.1042/BJ20070363
   da Silveira RB, 2007, TOXICON, V49, P758, DOI 10.1016/j.toxicon.2006.11.024
   da Silveira RB, 2007, BIOCHIMIE, V89, P289, DOI 10.1016/j.biochi.2006.12.002
   da Silveira RB, 2006, BIOCHIMIE, V88, P1241, DOI 10.1016/j.biochi.2006.02.008
   Dantas AE, 2016, TOXICON, V120, P97, DOI 10.1016/j.toxicon.2016.08.002
   Dantas AE, 2014, TOXICON, V84, P56, DOI 10.1016/j.toxicon.2014.04.002
   de Andrade SA, 2006, TOXICON, V47, P380, DOI 10.1016/j.toxicon.2005.12.005
   de Castro CS, 2004, TOXICON, V44, P273, DOI 10.1016/j.toxicon.2004.05.028
   de Giuseppe PO, 2011, BIOCHEM BIOPH RES CO, V409, P622, DOI 10.1016/j.bbrc.2011.05.053
   de Oliveira KC, 2005, TOXICON, V45, P421, DOI 10.1016/j.toxicon.2004.08.022
   de Oliveira KC, 1999, TOXICON, V37, P217, DOI 10.1016/S0041-0101(98)00130-5
   Ferrara GID, 2009, TOXICON, V53, P743, DOI 10.1016/j.toxicon.2009.02.013
   Desai A, 2000, INFLAMMATION, V24, P1, DOI 10.1023/A:1006995023982
   Dias BC, 2013, ZOOLOGY, V116, P168, DOI 10.1016/j.zool.2012.12.001
   Dias-Lopes C, 2018, TOXINS, V10, DOI 10.3390/toxins10090365
   Dias-Lopes C, 2010, TOXICON, V56, P1426, DOI 10.1016/j.toxicon.2010.08.008
   Dragulev B, 2007, J INVEST DERMATOL, V127, P1264, DOI 10.1038/sj.jid.5700644
   Dufour L, 1820, ANN GEN SCI PHYS, V5, P198
   Duncan RP, 2010, MOL PHYLOGENET EVOL, V55, P234, DOI 10.1016/j.ympev.2009.11.026
   Farace F, 2006, J PLAST RECONSTR AES, V59, P197, DOI 10.1016/j.bjps.2005.05.018
   Feitosa L, 1998, TOXICON, V36, P1039, DOI 10.1016/S0041-0101(97)00083-4
   Felicori L, 2006, TOXICON, V48, P509, DOI 10.1016/j.toxicon.2006.06.019
   Felicori L, 2009, VACCINE, V27, P4201, DOI 10.1016/j.vaccine.2009.04.038
   Fernandes-Pedrosa MD, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-279
   Ferreira EL, 2005, REV BRAS ZOOCIENCIAS, V7
   Ferreira Rodrigo Lopes, 2001, Ecotropica, V6, P105
   Ferrer VP, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002206
   Figueiredo LFM, 2014, TOXICON, V86, P59, DOI 10.1016/j.toxicon.2014.05.007
   Fischer ML, 2006, J ARACHNOL, V34, P485, DOI 10.1636/M03-51.1
   Fischer Marta Luciane, 2009, Biotemas, V22, P155
   Fischer ML, 2005, J ARACHNOL, V33, P670, DOI 10.1636/S03-40.1
   Fischer ML, 2005, J ARACHNOL, V33, P758, DOI 10.1636/S03-39.1
   Fischer ML, 2005, J MED ENTOMOL, V42, P756, DOI 10.1603/0022-2585(2005)042[0756:MOBLIA]2.0.CO;2
   FORRESTER LJ, 1978, ARCH BIOCHEM BIOPHYS, V187, P355, DOI 10.1016/0003-9861(78)90046-2
   FUTRELL JM, 1992, AM J MED SCI, V304, P261, DOI 10.1097/00000441-199210000-00008
   Gertsch W.J., 1967, B AMNH, V136
   Gertsch W.J., 1958, SPIDER GENUS LOXOSCE
   GERTSCH WJ, 1983, B AM MUS NAT HIST, V175, P265
   Golay V, 2013, RENAL FAILURE, V35, P538, DOI 10.3109/0886022X.2013.768936
   Gomes MTR, 2011, TOXICON, V57, P574, DOI 10.1016/j.toxicon.2011.01.001
   Goncalves de Andrade Rute Maria, 2001, Revista da Sociedade Brasileira de Medicina Tropical, V34, P275
   Gremski LH, 2014, TOXICON, V83, P91, DOI 10.1016/j.toxicon.2014.02.023
   Gremski LH, 2010, MOL BIOSYST, V6, P2403, DOI 10.1039/c004118a
   Harvey Mark S., 1996, Records of the Western Australian Museum, V18, P223
   Hogan CJ, 2004, ANN EMERG MED, V44, P608, DOI 10.1016/j.annemergmed.2004.08.028
   Horta CCR, 2013, J INVEST DERMATOL, V133, P1682, DOI 10.1038/jid.2013.40
   Isbister GK, 2011, LANCET, V378, P2039, DOI 10.1016/S0140-6736(10)62230-1
   Jerusalem K, 2018, TOXICON, V156, P7, DOI 10.1016/j.toxicon.2018.10.304
   Kalapothakis E, 2007, TOXICON, V50, P938, DOI 10.1016/j.toxicon.2007.07.001
   Kalapothakis E, 2002, TOXICON, V40, P1691, DOI 10.1016/S0041-0101(02)00201-5
   KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8
   Lajoie DM, 2015, J BIOL CHEM, V290, P10994, DOI 10.1074/jbc.M115.636951
   Lajoie DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072372
   Lee S, 2005, BIOCHEM J, V391, P317, DOI 10.1042/BJ20050043
   Lima SD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00653
   Machado Ewerton O., 2005, Lundiana, V6, P113
   Machado LF, 2005, PROTEOMICS, V5, P2167, DOI 10.1002/pmic.200401096
   Magalhaes GS, 2013, BIOCHIMIE, V95, P1773, DOI 10.1016/j.biochi.2013.06.002
   Malaque CMS, 2011, TOXICON, V58, P664, DOI 10.1016/j.toxicon.2011.09.011
   Marques-da-Silva E, 2005, REV SOC BRAS MED TRO, V38, P331, DOI 10.1590/S0037-86822005000400010
   Matsubara FH, 2017, INSECT MOL BIOL, V26, P25, DOI 10.1111/imb.12268
   Md Saude, 2001, MAN DIAGN TRAT AC AN
   Mendes TM, 2013, VACCINE, V31, P2749, DOI 10.1016/j.vaccine.2013.03.048
   Merchant ML, 1998, TOXICON, V36, P537, DOI 10.1016/S0041-0101(97)00078-0
   Ministerio da SaUde, 2019, SIST INF AGR NOT SIN
   Moenkhaus W.J., 1898, CONTRIBUICAO CONHECI
   Monteiro CLB, 2002, TOXICON, V40, P409, DOI 10.1016/S0041-0101(01)00209-4
   Morales-Moreno HJ, 2016, J EUR ACAD DERMATOL, V30, P1431, DOI 10.1111/jdv.13274
   MOTA I, 1995, J TOXICOL-TOXIN REV, V14, P401, DOI 10.3109/15569549509019471
   Murakami M.T., 2005, MOL BASIS ACTIVITY S
   Murakami MT, 2006, BIOCHEM BIOPH RES CO, V342, P323, DOI 10.1016/j.bbrc.2006.01.123
   Murakami MT, 2005, J BIOL CHEM, V280, P13658, DOI 10.1074/jbc.M412437200
   Nentwig W, 2017, TOXICON, V132, P19, DOI 10.1016/j.toxicon.2017.04.007
   NEWLANDS G, 1982, T ROY SOC TROP MED H, V76, P610, DOI 10.1016/0035-9203(82)90222-X
   NEWLANDS G, 1988, S AFR MED J, V73, P235
   Nicolet H, 1849, ZOOLOGIA, V3, P319, DOI DOI 10.5962/BHL.TITLE.16172
   Nowatzki J, 2012, TOXICON, V60, P396, DOI 10.1016/j.toxicon.2012.04.333
   Nowatzki J, 2010, TOXICON, V56, P535, DOI 10.1016/j.toxicon.2010.03.027
   Okamoto CK, 2017, TOXINS, V9, DOI 10.3390/toxins9030090
   Olvera A, 2006, TOXICON, V48, P64, DOI 10.1016/j.toxicon.2006.04.010
   Paixao-Cavalcante D, 2007, J INVEST DERMATOL, V127, P1410, DOI 10.1038/sj.jid.5700688
   Paludo KS, 2006, TOXICON, V47, P844, DOI 10.1016/j.toxicon.2006.02.006
   Paludo KS, 2009, COMP BIOCHEM PHYS C, V149, P323, DOI 10.1016/j.cbpc.2008.08.009
   PATEL KD, 1994, J CLIN INVEST, V94, P631, DOI 10.1172/JCI117379
   Pedrosa MD, 2002, BIOCHEM BIOPH RES CO, V298, P638
   Pedroso A, 2015, BMC EVOL BIOL, V15, DOI 10.1186/s12862-015-0561-4
   Pereira NB, 2014, TOXICON, V84, P7, DOI 10.1016/j.toxicon.2014.03.003
   Pereira W, 2004, J ARACHNOL, V32, P22, DOI 10.1636/S02-35
   Plamick N.I., 2019, WORLD SPIDER CATALOG
   Plamick N.I., 1991, SPINNERET MORPHOLOGY
   Planas E, 2015, ZOOL J LINN SOC-LOND, V174, P47, DOI 10.1111/zoj.12226
   Planas E, 2015, TOXICON, V93, P11, DOI 10.1016/j.toxicon.2014.10.005
   Planas E, 2014, J BIOGEOGR, V41, P1255, DOI 10.1111/jbi.12321
   Pretel F, 2005, TOXICON, V45, P449, DOI 10.1016/j.toxicon.2004.12.002
   Ramos-Cerrillo B, 2004, TOXICON, V44, P507, DOI 10.1016/j.toxicon.2004.06.013
   REES RS, 1988, TOXICON, V26, P1035, DOI 10.1016/0041-0101(88)90202-4
   REES RS, 1984, J INVEST DERMATOL, V83, P270, DOI 10.1111/1523-1747.ep12340340
   Ribeiro ROS, 2007, TOXICON, V50, P1162, DOI 10.1016/j.toxicon.2007.08.001
   Ribuffo D, 2012, EUR REV MED PHARMACO, V16, P414
   Rinaldi Isabela M.P., 1998, Bulletin of the British Arachnological Society, V11, P57
   Rivera IG, 2015, TOXINS, V7, P1457, DOI 10.3390/toxins7051457
   Robinson JR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174941
   de la Vega RCR, 2010, TOXICON, V56, P1155, DOI 10.1016/j.toxicon.2009.11.010
   Rubenstein E, 2016, INFECTION, V44, P383, DOI 10.1007/s15010-015-0869-4
   Sams HH, 2001, J AM ACAD DERMATOL, V44, P561, DOI 10.1067/mjd.2001.112385
   Sandidge Jamel S., 2005, Transactions of the Kansas Academy of Science, V108, P99, DOI 10.1660/0022-8443(2005)108[0099:BRSARO]2.0.CO;2
   Sandidge JS, 2003, NATURE, V426, P30, DOI 10.1038/426030a
   Sapag A, 2014, BIOL RES, V47, DOI 10.1186/0717-6287-47-2
   Saupe EE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017731
   SCHENONE FH, 2001, CHILE REV CHIL PEDIA, V72, DOI DOI 10.4067/S0370-41062001000200004
   Shimokawa-Falcao LHAL, 2017, TOXINS, V9, DOI 10.3390/toxins9030082
   Silveira A. L., 2015, REV MED MINAS GERAIS, V25, P37, DOI DOI 10.5935/2238-3182.20150008
   Silveira A.L, 2017, REV MED MINAS GERAIS, V27, P31, DOI [10.5935/2238-3182.20170053, DOI 10.5935/2238-3182.20170053]
   Silveira AL, 2009, REV SOC BRAS MED TRO, V42, P723, DOI 10.1590/S0037-86822009000600021
   Silvestre FG, 2005, TOXICON, V46, P927, DOI 10.1016/j.toxicon.2005.09.002
   Simon E., 1897, LISTE ARACHNIDES REC
   SMITH CW, 1970, LAB INVEST, V22, P90
   Souza ED, 2011, ANIM BEHAV, V81, P127, DOI 10.1016/j.anbehav.2010.09.023
   Souza MFVR, 2018, ZOOTAXA, V4438, P575, DOI 10.11646/zootaxa.4438.3.9
   Souza-Silva Marconi, 2014, Speleobiology Notes, V6, P27
   Sunderkotter C, 2001, EXP DERMATOL, V10, P391, DOI 10.1034/j.1600-0625.2001.100602.x
   Tambourgi DV, 2007, MOL IMMUNOL, V44, P576, DOI 10.1016/j.molimm.2006.02.002
   Tambourgi D.V., 2011, MOL CLONING SELECTED, DOI [10.5772/24357, DOI 10.5772/24357]
   Tambourgi DV, 2010, TOXICON, V56, P1113, DOI 10.1016/j.toxicon.2010.01.021
   Tambourgi DV, 1998, BIOCHEM BIOPH RES CO, V251, P366, DOI 10.1006/bbrc.1998.9474
   Tambourgi DV, 2005, J INVEST DERMATOL, V124, P725, DOI 10.1111/j.0022-202X.2005.23654.x
   Tambourgi DV, 2004, MOL IMMUNOL, V41, P831, DOI 10.1016/j.molimm.2004.03.027
   Trajano Eleonora, 1992, Revista Brasileira de Zoologia, V7, P383, DOI 10.1590/S0101-81751990000300017
   Trevisan-Silva D, 2010, BIOCHIMIE, V92, P21, DOI 10.1016/j.biochi.2009.10.003
   Ul-Hasan S., 2019, TOXICON 10, V4, DOI [10.1016/j.toxcx.2019.100016, DOI 10.1016/J.TOXCX.2019.100016]
   Ullah A, 2014, ACTA CRYSTALLOGR F, V70, P1418, DOI 10.1107/S2053230X14019207
   Ullah A, 2011, ACTA CRYSTALLOGR F, V67, P234, DOI 10.1107/S1744309110050931
   van Meeteren LA, 2004, J BIOL CHEM, V279, P10833, DOI 10.1074/jbc.C300563200
   Veiga SS, 2001, THROMB RES, V102, P229, DOI 10.1016/S0049-3848(01)00254-7
   Veiga SS, 2001, BRAZ J MED BIOL RES, V34, P843, DOI 10.1590/S0100-879X2001000700002
   Veiga SS, 2000, HISTOCHEM J, V32, P397, DOI 10.1023/A:1004031019827
   Vetter RS, 2008, ANNU REV ENTOMOL, V53, P409, DOI 10.1146/annurev.ento.53.103106.093503
   Vetter RS, 2015, TOXICON, V93, P171, DOI 10.1016/j.toxicon.2014.11.229
   Vuitika L, 2016, BBA-MOL CELL BIOL L, V1861, P970, DOI 10.1016/j.bbalip.2016.05.009
   Vuitika L, 2013, J CELL BIOCHEM, V114, P2479, DOI 10.1002/jcb.24594
   Young AR, 2001, TOXICON, V39, P391, DOI 10.1016/S0041-0101(00)00145-8
   Zanetti VC, 2002, BLOOD COAGUL FIBRIN, V13, P135, DOI 10.1097/00001721-200203000-00009
   Zela SP, 2004, ACTA CRYSTALLOGR D, V60, P1112, DOI 10.1107/S090744490400678X
   Zobel-Thropp PA, 2012, TOXICON, V60, P265, DOI 10.1016/j.toxicon.2012.04.350
   Zobel-Thropp PA, 2010, TOXICON, V55, P1274, DOI 10.1016/j.toxicon.2010.01.019
NR 174
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 5
EP 19
DI 10.1016/j.toxicon.2019.11.002
PG 15
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100002
PM 31726080
OA Bronze
DA 2020-05-12
ER

PT J
AU Krishnan, A
   Koski, G
   Mou, XZ
AF Krishnan, Anjali
   Koski, Gary
   Mou, Xiaozhen
TI Characterization of microcystin-induced apoptosis in HepG2 hepatoma
   cells
SO TOXICON
LA English
DT Article
DE Microcystin; HepG2; Apoptosis; Caspases
ID PRIMARY HUMAN HEPATOCYTES; INDUCED CYTOTOXICITY; INTRINSIC APOPTOSIS;
   OXIDATIVE STRESS; LIVER-INJURY; LR; INVOLVEMENT; MECHANISMS; PATHWAYS;
   DEATH
AB Microcystins (MCs) are a class of hepatotoxins that are commonly produced by freshwater cyanobacteria. MCs harm liver cells through inhibiting protein phosphatases 1 and 2A (PP1 and PP2A) and can produce dualistic effects, i.e., cell death and uncontrolled cellular proliferation. The induction of programmed cell death, i.e., apoptosis, in MC treated hepatic cells has been described previously; however, its exact pathway remains unclear. To address this, HepG2 human hepatoma cells were exposed to MC-LR, the most prevalent isomer of MCs, and morphological and physiological responses were examined. Microscopy and Alamar Blue assay showed that HepG2 cells responded to MC-LR treatment with apoptosis characteristics, such as clumping and shrinking of cells and detachment from the monolayer culture surface. A fluorescent caspase activation assay further revealed activation of all tested apoptosis-dependent caspases (i.e., caspase-3/7, 8 and 9) after 24 h of MC-LR treatment. Furthermore, caspase-8 was found being activated 4 h after MC-LR treatment, earlier than observed activation of caspase-9 (8 h after MC-LR treatment). These data demonstrated that MC-LR can induce apoptosis of HepG2 cells through both extrinsic and intrinsic pathways and that the extrinsic pathway may be activated before the intrinsic pathway. This indicates that extrinsic pathway is more sensitive than intrinsic pathway in MC induced apoptosis. This knowledge contributes to a better understanding of MC hepatotoxicity and can be further used for developing treatments for MC exposed hepatic cells.
C1 [Krishnan, Anjali; Koski, Gary; Mou, Xiaozhen] Kent State Univ, Biol Sci Dept, Kent, OH 44242 USA.
RP Mou, XZ (reprint author), Kent State Univ, Biol Sci Dept, Kent, OH 44242 USA.
EM xmou@kent.edu
RI Mou, Xiaozhen/AAG-2806-2020
FU National Science FoundationNational Science Foundation (NSF) [1605161];
   Kent State University
FX We would like to thank Drs. P Pathak and J Chiang from North East Ohio
   Medical University for providing us with the HepG2 cells. This work is
   supported by the National Science Foundation under Grant No. 1605161 and
   the Kent State University.
CR Abderrahim LA, 2019, TOXICON, V169, P38, DOI 10.1016/j.toxicon.2019.08.005
   Azevedo SMFO, 2002, TOXICOLOGY, V181, P441, DOI 10.1016/S0300-483X(02)00491-2
   Basu A, 2018, ENVIRON SCI TECHNOL, V52, P10078, DOI 10.1021/acs.est.8b02291
   Blaha Ludek, 2009, Interdiscip Toxicol, V2, P36, DOI 10.2478/v10102-009-0006-2
   Botha N, 2004, TOXICON, V43, P85, DOI 10.1016/j.toxicon.2003.10.025
   Campos A, 2010, INT J MOL SCI, V11, P268, DOI 10.3390/ijms11010268
   Chen L., 2014, ENVIRON TOXICOL, V31, P552
   Chen L, 2016, MINI-REV MED CHEM, V16, P1018, DOI 10.2174/1389557516666160219130407
   Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1
   Cummings B., 2013, CURT PROTOC PHARAM, V1, P1
   da Silva DD, 2013, ARCH TOXICOL, V87, P2165, DOI 10.1007/s00204-013-1082-9
   de Magalhaes VF, 2001, TOXICON, V39, P1077
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Feng G, 2011, MOL CELL BIOCHEM, V352, P209, DOI 10.1007/s11010-011-0756-y
   Fischer WJ, 2005, TOXICOL APPL PHARM, V203, P257, DOI 10.1016/j.taap.2004.08.012
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Gerets HHJ, 2012, CELL BIOL TOXICOL, V28, P69, DOI 10.1007/s10565-011-9208-4
   Ghobrial MG, 2015, EGYPT J AQUATIC RES, V41, P69, DOI DOI 10.1016/j.ejar.2015.01.001
   Hisbergues M, 2003, ARCH MICROBIOL, V180, P402, DOI 10.1007/s00203-003-0605-9
   Huang H, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00397
   Huang X, 2015, AQUAT TOXICOL, V165, P41, DOI 10.1016/j.aquatox.2015.05.009
   Ji Y, 2011, INT J MOL SCI, V12, P4722, DOI 10.3390/ijms12074722
   Klumpp DJ, 2006, INFECT IMMUN, V74, P5106, DOI 10.1128/IAI.00376-06
   Krishnan A, 2018, B ENVIRON CONTAM TOX, V101, P617, DOI 10.1007/s00128-018-2468-4
   Lamkanfi M, 2010, CELL HOST MICROBE, V8, P44, DOI 10.1016/j.chom.2010.06.007
   Lankoff A, 2006, TOXICON, V48, P957, DOI 10.1016/j.toxicon.2006.08.003
   Li Y, 2012, ENVIRON TOXICOL PHAR, V33, P318, DOI 10.1016/j.etap.2011.12.015
   Li Y, 2016, EXP THER MED, V12, P633, DOI 10.3892/etm.2016.3423
   Liu JH, 2016, TOXICOL LETT, V240, P214, DOI 10.1016/j.toxlet.2015.10.015
   Magalhaes VF, 2003, TOXICON, V42, P289, DOI 10.1016/S0041-0101(03)00144-2
   McLellan NL, 2017, TOXICOL RES-UK, V6, P391, DOI [10.1039/c7tx00043j, 10.1039/C7TX00043J]
   Menezes C, 2013, TOXICOL IN VITRO, V27, P138, DOI 10.1016/j.tiv.2012.09.009
   Moreira DA, 2019, TOXICON, V166, P76, DOI 10.1016/j.toxicon.2019.05.002
   Mou XZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061890
   Niedermeyer T., 2013, FIGSHARE DATASET, DOI [10.6084/m9.figshare.880756, DOI 10.6084/M9.FIGSHARE.880756]
   Paerl HW, 2013, MICROB ECOL, V65, P995, DOI 10.1007/s00248-012-0159-y
   Pichardo S, 2005, TOXICOL IN VITRO, V19, P865, DOI 10.1016/j.tiv.2005.06.016
   Piyathilaka MAPC, 2015, MICROBIOL-SGM, V161, P819, DOI 10.1099/mic.0.000046
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Rampersad SN, 2012, SENSORS-BASEL, V12, P12347, DOI 10.3390/s120912347
   Scoltock AB, 2004, EXP CELL RES, V297, P212, DOI 10.1016/j.yexcr.2004.03.025
   Sun Y, 2014, ENVIRON TOXICOL, V29, P1236, DOI 10.1002/tox.21854
   Takser L, 2016, TOXICOL REP, V3, P180, DOI 10.1016/j.toxrep.2015.12.008
   Ueno Y, 1996, CARCINOGENESIS, V17, P1317, DOI 10.1093/carcin/17.6.1317
   Valerio E, 2016, MINI-REV MED CHEM, V16, P1032, DOI 10.2174/1389557516666160219130553
   Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6
   WATANABE MF, 1988, TOXICON, V26, P1017, DOI 10.1016/0041-0101(88)90200-0
   Weng D, 2007, TOXICOLOGY, V232, P15, DOI 10.1016/j.tox.2006.12.010
   Woolbright BL, 2017, TOXICON, V125, P99, DOI 10.1016/j.toxicon.2016.11.254
   Yin X, 2013, CANCER GENE THER, V20, P77, DOI 10.1038/cgt.2012.86
   Zhang X, 2013, J APPL TOXICOL, V33, P1180, DOI 10.1002/jat.2749
   Zhao Y, 2010, CANCER LETT, V288, P42, DOI 10.1016/j.canlet.2009.06.021
   Ziegler U, 2004, NEWS PHYSIOL SCI, V19, P124, DOI 10.1152/nips.01519.2004
NR 53
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 20
EP 26
DI 10.1016/j.toxicon.2019.11.003
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100003
PM 31734250
OA Bronze
DA 2020-05-12
ER

PT J
AU Garcia-Guerrero, IA
   Carcamo-Noriega, E
   Gomez-Lagunas, F
   Gonzalez-Santillan, E
   Zamudio, FZ
   Gurrola, GB
   Possani, LD
AF Garcia-Guerrero, I. A.
   Carcamo-Noriega, E.
   Gomez-Lagunas, F.
   Gonzalez-Santillan, E.
   Zamudio, F. Z.
   Gurrola, G. B.
   Possani, L. D.
TI Biochemical characterization of the venom from the Mexican scorpion
   Centruroides ornatus, a dangerous species to humans
SO TOXICON
LA English
DT Article
DE Centruroides ornatus; Mass-spectrometry analysis; Primary structure;
   Scorpion toxin; Sodium-channel
ID MASS-SPECTROMETRY ANALYSIS; TOXIN RECEPTOR-SITES; BETA-TOXINS;
   SODIUM-CHANNELS; FUNCTIONAL SURFACE; ACTIVATION; PEPTIDES; SPECIFICITY;
   COMPONENTS; CURRENTS
AB Every year in Mexico, around 300,000 people suffer from accidents related to scorpion stings. Among the scorpion species dangerous to human is Centruroides ornatus, whose venom characterization is described here. From this venom, a total of 114 components were found using chromatographic separation and mass spectrometry analysis. The most abundant ones have molecular masses between 3000-4000 Da and 6000-8000 Da respectively, similar to other known K+ and Na+-channel specific scorpion peptides. Using intraperitoneal injections into CD1 mice, we were able to identify and fully sequenced three new lethal toxins. We propose to name them Co1, Co2 and Co3 toxins, which correspond to toxins 1 to 3 of the abbreviated species name (Co). Electrophysiology analysis of these peptides using heterologously expressed human Na+-channels revealed a typical beta-toxin effect. Peptide Co52 (the most abundant peptide in the venom) showed no activity in our in vivo and in vitro model assays. A phylogenetic analysis groups the Co1, Co2 and Co3 among other beta-toxins from Centruroides scorpions. Peptide Co52 segregates among peptides of unknown defined functions.
C1 [Garcia-Guerrero, I. A.; Carcamo-Noriega, E.; Gonzalez-Santillan, E.; Zamudio, F. Z.; Gurrola, G. B.; Possani, L. D.] Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Med Mol & Bioproc, Ave Univ 2001, Cuernavaca 62210, Morelos, Mexico.
   [Gomez-Lagunas, F.] Univ Nacl Autonoma Mexico, Fac Med, Dept Fisiol, Ciudad De Mexico 04510, Mexico.
RP Possani, LD (reprint author), Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Med Mol & Bioproc, Ave Univ 2001, Cuernavaca 62210, Morelos, Mexico.
EM possani@ibt.unam.mx
RI Santillan, Edmundo Gonzalez/B-7648-2014
OI Santillan, Edmundo Gonzalez/0000-0003-1340-068X
FU Direction General de Asuntos del Personal Academico of UNAM [IN202619];
   CONACyTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [740685]
FX Partially supported by grant IN202619 from Direction General de Asuntos
   del Personal Academico of UNAM given to LDP. The authors greatly
   acknowledged the support received by Dr. Rita Restano Cassulini from our
   Department for helping with the analyses of the newly obtained
   electrophysiological experiments. IAGG received a scholarship (number
   740685) from CONACyT.
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Batista CVF, 2004, J CHROMATOGR B, V803, P55, DOI 10.1016/j.jchromb.2003.09.002
   Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6
   Cohen L, 2005, J BIOL CHEM, V280, P5045, DOI 10.1074/jbc.M408427200
   Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200
   Cook WJ, 2002, PROTEIN SCI, V11, P479, DOI 10.1110/ps.39202
   Corona M, 2001, TOXICON, V39, P1893, DOI 10.1016/S0041-0101(01)00174-X
   COURAUD F, 1982, TOXICON, V20, P9, DOI 10.1016/0041-0101(82)90138-6
   de Armas Luis F., 2008, Boletin de la SEA, V43, P7
   de la Vega RCR, 2005, TOXICON, V46, P831, DOI 10.1016/j.toxicon.2005.09.006
   Hoang DT, 2018, MOL BIOL EVOL, V35, P518, DOI 10.1093/molbev/msx281
   Gomez-Lagunas F, 2017, J CELL PHYSIOL, V232, P2019, DOI 10.1002/jcp.25448
   Gonzalez-Santillan E, 2018, ACTA TROP, V187, P264, DOI 10.1016/j.actatropica.2018.08.002
   Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010
   Gurevitz M, 2012, TOXICON, V60, P502, DOI 10.1016/j.toxicon.2012.03.022
   Jimenez-Vargas JM, 2017, TOXICON, V128, P5, DOI 10.1016/j.toxicon.2017.01.015
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Olamendi-Portugal T, 2017, PEPTIDES, V87, P34, DOI 10.1016/j.peptides.2016.11.008
   Olamendi-Portugal T, 2016, TOXICON, V115, P1, DOI 10.1016/j.toxicon.2016.02.017
   Oliveira JS, 2004, J BIOL CHEM, V279, P33323, DOI 10.1074/jbc.M404344200
   Ortiz E, 2015, TOXICON, V93, P125, DOI 10.1016/j.toxicon.2014.11.233
   Escalona MP, 2013, FRONT BIOSCI-LANDMRK, V18, P572, DOI 10.2741/4121
   Ponce-Saavedra J, 2016, FOLIC ENTOMOL MEX, V2
   Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x
   Quintero-Hernandez V, 2013, TOXICON, V76, P328, DOI 10.1016/j.toxicon.2013.07.012
   Ramirez-Dominguez ME, 2002, J EXP BIOL, V205, P869
   Riano-Umbarila L, 2017, TOXICON, V138, P130, DOI 10.1016/j.toxicon.2017.08.022
   Santibanez-Lopez C.E, 2015, TOXINS, V8
   Schiavon E, 2012, TOXICON, V59, P283, DOI 10.1016/j.toxicon.2011.12.003
   Schwartz EF, 2008, TOXICON, V51, P1499, DOI 10.1016/j.toxicon.2008.03.029
   Towler W.L, 2001, BIOGEOGRAPHICA, P157
   Trifinopoulos J, 2016, NUCLEIC ACIDS RES, V44, pW232, DOI 10.1093/nar/gkw256
   Valdez-Velazquez LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066486
   Vandendriessche T, 2010, TOXICON, V56, P613, DOI 10.1016/j.toxicon.2010.06.008
   VAZQUEZ A, 1995, TOXICON, V33, P1161, DOI 10.1016/0041-0101(95)00058-T
   Yacioob R, 2016, PAK J ZOOL, V48, P265
NR 36
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 27
EP 38
DI 10.1016/j.toxicon.2019.11.004
PG 12
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100004
PM 31734253
OA Bronze
DA 2020-05-12
ER

PT J
AU Wang, SQ
   Qiu, JB
   Zhao, MY
   Li, FX
   Yu, RC
   Li, AF
AF Wang, Shuqin
   Qiu, Jiangbing
   Zhao, Mingyue
   Li, Fangxiao
   Yu, Rencheng
   Li, Aifeng
TI Accumulation and distribution of neurotoxin BMAA in aquatic animals and
   effect on the behavior of zebrafish in a T-maze test
SO TOXICON
LA English
DT Article
DE beta-N-mothylamino-L-alanine (BMAA); Toxin accumulation; Opossum shrimp;
   Zebrafish; T-maze test
ID METHYLAMINO-L-ALANINE; DAB 2,4-DIAMINOBUTYRIC ACID; CYANOBACTERIAL TOXIN
   BMAA; FRESH-WATER; NEURODEGENERATIVE DISEASE; MASS-SPECTROMETRY;
   SHELLFISH; ISOMERS; OPTIMIZATION; SUGGESTS
AB Neurotoxin beta-N-methylamino-L-alanine (BMAA) has been widely detected in diverse aquatic organisms within diffefent ecosystem trophic levels in recent years. It was the goal of this study to investigate the accumulation and tissue distribution of BMAA in marine opossum shrimp (Neomysis awatschensis) and freshwater zebrafish (Danio rerio) in exposure experiments. A T-maze test was tentatively adopted to assess the effects of BMAA on the learning and memory ability of zebrafish. Interestingly, N. awatschensis was testified to be capable of accumulating free soluble BMAA from bathing seawater through a biological filtration pathway (max. 110.6 mu g g(-1) wet weight). BMAA was transferred quickly from viscus to muscle and head tissues of zebrafish after intraperitoneal administration of 16.3 mu g BMAA per individual twice in two weeks. BMAA accumulated mainly as the total soluble form in both experimental organisms. Results do not support the hypothesis that free BMAA molecules can be largely incorporated into protein in aquatic animals. Behavior of zebrafish in the T-maze test demonstrated that the short-term learning and memory ability was negatively impacted to some degree after three-days exposure to BMAA. Moreover, on Day 3, certain individual zebrafish exhibited freezing and loitering behavior. However, further investigation will be required to discern the long-term effects of BMAA on animals in order to evaluate the risk of BMAA exposure to human health.
C1 [Wang, Shuqin; Qiu, Jiangbing; Zhao, Mingyue; Li, Fangxiao; Li, Aifeng] Ocean Univ China, Coll Environm Sci & Engn, Qingdao 266100, Peoples R China.
   [Wang, Shuqin; Qiu, Jiangbing; Zhao, Mingyue; Li, Fangxiao; Li, Aifeng] Ocean Univ China, Key Lab Marine Environm & Ecol, Minist Educ, Qingdao 266100, Peoples R China.
   [Yu, Rencheng] Chinese Acad Sci, Inst Oceanol, Key Lab Marine Ecol & Environm Sci, Qingdao 266071, Peoples R China.
RP Li, AF (reprint author), Ocean Univ China, Coll Environm Sci & Engn, Qingdao 266100, Peoples R China.
EM lafouc@ouc.edu.cn
RI Yu, Rencheng/J-4450-2017; Qiu, Jiangbing/J-4852-2018
OI Yu, Rencheng/0000-0001-6430-9224; Qiu, Jiangbing/0000-0002-0973-1809
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41676093]; Fundamental Research Funds for the
   Central Universities, ChinaFundamental Research Funds for the Central
   Universities [201841003]
FX This work was funded by the National Natural Science Foundation of China
   (41676093) and the Fundamental Research Funds for the Central
   Universities, China (201841003). The authors would like to thank Dr.
   Gregory Doucette, at the National Centers for Coastal Ocean Science
   NOAA, USA, for English edition before submission.
CR Anderson DM, 2012, ANNU REV MAR SCI, V4, P143, DOI 10.1146/annurev-marine-120308-081121
   Beach DG, 2015, ANAL BIOANAL CHEM, V407, P8397, DOI 10.1007/s00216-015-9012-8
   Blanco J, 2019, TOXINS, V11, DOI 10.3390/toxins11070395
   Bradley WG, 2009, AMYOTROPH LATERAL SC, V10, P7, DOI 10.3109/17482960903286009
   Brand LE, 2010, HARMFUL ALGAE, V9, P620, DOI 10.1016/j.hal.2010.05.002
   Brooke-Jones M, 2018, TOXINS, V10, DOI 10.3390/toxins10120527
   Buenz EJ, 2007, NEUROTOXICOLOGY, V28, P702, DOI 10.1016/j.neuro.2007.02.010
   Cox PA, 2003, P NATL ACAD SCI USA, V100, P13380, DOI 10.1073/pnas.2235808100
   Cox PA, 2002, NEUROLOGY, V58, P956, DOI 10.1212/WNL.58.6.956
   Dell'Aversano C, 2005, J CHROMATOGR A, V1081, P190, DOI 10.1016/j.chroma.2005.05.056
   Diener M, 2007, J SEP SCI, V30, P1821, DOI 10.1002/jssc.200700025
   Dunlop RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075376
   Esterhuizen M, 2011, ECOTOX ENVIRON SAFE, V74, P74, DOI 10.1016/j.ecoenv.2010.04.005
   Esterhuizen-Londt M, 2015, TOXICON, V100, P20, DOI 10.1016/j.toxicon.2015.03.021
   Faassen EJ, 2016, MAR DRUGS, V14, DOI 10.3390/md14030045
   Fan H, 2015, ENVIRON SCI POLLUT R, V22, P5943, DOI 10.1007/s11356-014-3766-y
   Hsieh YS, 2008, J SEP SCI, V31, P1481, DOI 10.1002/jssc.200700451
   Jiang L., 2014, PUBRAW SCI, V1, P1
   Jiao YY, 2014, SCI TOTAL ENVIRON, V468, P457, DOI 10.1016/j.scitotenv.2013.08.064
   Johnson HE, 2008, J ETHNOPHARMACOL, V118, P159, DOI 10.1016/j.jep.2008.04.008
   Jonasson S, 2010, P NATL ACAD SCI USA, V107, P9252, DOI 10.1073/pnas.0914417107
   Karamyan VT, 2008, LIFE SCI, V82, P233, DOI 10.1016/j.lfs.2007.11.020
   Karlsson O, 2015, SCI REP-UK, V5, DOI 10.1038/srep15570
   Karlsson O, 2009, TOXICOL SCI, V109, P286, DOI 10.1093/toxsci/kfp062
   Kerrin ES, 2017, ANAL BIOANAL CHEM, V409, P1481, DOI 10.1007/s00216-016-0091-y
   Kruger T, 2010, TOXICON, V55, P547, DOI 10.1016/j.toxicon.2009.10.009
   Lage S, 2015, MAR DRUGS, V13, P1185, DOI 10.3390/md13031185
   Lage S, 2014, AQUAT TOXICOL, V152, P131, DOI 10.1016/j.aquatox.2014.03.029
   Lepoutre A, 2018, TOXINS, V10, DOI 10.3390/toxins10030106
   Li AF, 2018, TOXICON, V151, P129, DOI 10.1016/j.toxicon.2018.07.004
   Li AF, 2018, TOXINS, V10, DOI 10.3390/toxins10070273
   Li AF, 2016, MAR DRUGS, V14, DOI 10.3390/md14110202
   [李爱峰 LI Aifeng], 2007, [海洋环境科学, Marine Environmental Science], V26, P112
   Li X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141134
   Lurling M, 2011, J PLANKTON RES, V33, P333, DOI 10.1093/plankt/fbq130
   Mess JN, 2009, BIOANALYSIS, V1, P57, DOI 10.4155/bio.09.9
   Mondo K, 2014, FOOD CHEM TOXICOL, V70, P26, DOI 10.1016/j.fct.2014.04.015
   Mondo K, 2012, MAR DRUGS, V10, P509, DOI 10.3390/md10020509
   Murch SJ, 2004, P NATL ACAD SCI USA, V101, P12228, DOI 10.1073/pnas.0404926101
   Ninkovic J, 2006, METHODS, V39, P262, DOI 10.1016/j.ymeth.2005.12.007
   Okle O, 2013, TOXICOL APPL PHARM, V270, P9, DOI 10.1016/j.taap.2013.04.003
   Purdie EL, 2009, AQUAT TOXICOL, V95, P279, DOI 10.1016/j.aquatox.2009.02.009
   Purdie EL, 2009, AMYOTROPH LATERAL SC, V10, P67, DOI 10.3109/17482960903273551
   Reveillon D, 2016, HARMFUL ALGAE, V58, P45, DOI 10.1016/j.hal.2016.07.008
   Reveillon D, 2016, TOXICON, V110, P35, DOI 10.1016/j.toxicon.2015.11.011
   Reveillon D, 2015, MAR ENVIRON RES, V110, P8, DOI 10.1016/j.marenvres.2015.07.015
   Rosen J, 2008, ANALYST, V133, P1785, DOI 10.1039/b809231a
   Scott L, 2019, NEUROTOX RES, V35, P711, DOI 10.1007/s12640-019-9996-5
   SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037
   Swain HA, 2004, NEUROTOXICOL TERATOL, V26, P725, DOI 10.1016/j.ntt.2004.06.009
   Turrell E, 2008, J AOAC INT, V91, P1372
   VEGA A, 1968, PHYTOCHEMISTRY, V7, P1885, DOI 10.1016/S0031-9422(00)86667-4
   Violi JP, 2019, ECOTOX ENVIRON SAFE, V172, P72, DOI 10.1016/j.ecoenv.2019.01.046
   Waidyanatha S, 2018, TOXICOL APPL PHARM, V339, P151, DOI 10.1016/j.taap.2017.12.008
   Yan BY, 2017, ANAL CHEM, V89, P10991, DOI 10.1021/acs.analchem.7b02867
NR 55
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 39
EP 47
DI 10.1016/j.toxicon.2019.11.005
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100005
PM 31734252
OA Bronze
DA 2020-05-12
ER

PT J
AU Abdul, NS
   Nagiah, S
   Anand, K
   Chuturgoon, AA
AF Abdul, Naeem Sheik
   Nagiah, Savania
   Anand, Krisnan
   Chuturgoon, Anil A.
TI Molecular docking and mechanisms of fusaric acid induced mitochondrial
   sirtuin aberrations in glycolytically and oxidatively poised human
   hepatocellular carcinoma (HepG2) cells
SO TOXICON
LA English
DT Article
DE Fusaric acid; Micro RNA; Molecular docking; PGC-1 alpha; Post
   translational modifications; Sirtuins
ID ANTIOXIDANT DEFENSE; NAD METABOLISM; FUMONISIN B-1; DYSFUNCTION;
   APOPTOSIS; STRESS; PROLIFERATION; DEACETYLATION; PGC-1-ALPHA; MYCOTOXINS
AB Fusaric acid (FA) is a ubiquitous yet neglected mycotoxin. The toxicity of FA is associated with mitochondrial dysfunction and oxidative stress. Sirtuins (SIRTs) are key mediators of cell stress responses through deacetylation of antioxidant, mitochondrial maintenance and energy metabolism proteins. Dietary bioactive compounds have profound effects on SIRT activity, however little is known regarding common foodborne toxins and SIRTs. In this study the interaction of FA with mitochondrial SIRTs - SIRT3 and SIRT5, were firstly studied by molecular docking. Thereafter we substantiated the in silica findings by investigating the effect of FA on expression profiles of SIRT3 and SIRT5, and transcriptional and post-transcriptional regulators, PGC-1 alpha and miRNA-30c using western blots and qPCR in vitro. FA was predicted to bind to the active site of SIRT3 and SIRT5 having implications for biological activity. Furthermore, protein expression of SIRT3 and SIRT5 was down-regulated despite elevated mRNA levels. Further experimentation revealed post-transcriptional regulation of both SIRTs as evidenced by elevated miRNA-30c despite induction of PGC-1 alpha. This study highlights the potential of a diet contaminated with FA to dysregulate mitochondrial specific proteins that can lead to initiation and progression of sirtuin related diseases including cancer and insulin resistance.
C1 [Abdul, Naeem Sheik; Nagiah, Savania; Anand, Krisnan; Chuturgoon, Anil A.] Univ KwaZulu Natal, Coll Hlth Sci, Sch Lab Med & Med Sci, Discipline Med Biochem, Durban, South Africa.
RP Chuturgoon, AA (reprint author), Univ KwaZulu Natal, Fac Hlth Sci, Discipline Med Biochem, Howard Coll, George Campbell Bldg, ZA-4041 Durban, South Africa.
EM chutur@ukzn.ac.za
RI Abdul, Naeem Sheik/AAL-7013-2020
OI Abdul, Naeem Sheik/0000-0001-6026-3759
FU DAAD-NRF joint in-country scholarship programme [UID: 101837]; College
   of Health Sciences (UKZN)
FX This work was supported by the DAAD-NRF joint in-country scholarship
   programme (UID: 101837) and the College of Health Sciences (UKZN).
CR Abdul NS, 2020, TOXICOL LETT, V318, P74, DOI 10.1016/j.toxlet.2019.10.013
   Abdul NS, 2016, TOXICON, V119, P336, DOI 10.1016/j.toxicon.2016.07.002
   Alhazzazi TY, 2016, ANTICANCER RES, V36, P49
   Bacon CW, 1996, APPL ENVIRON MICROB, V62, P4039, DOI 10.1128/AEM.62.11.4039-4043.1996
   BACON CW, 1995, MYCOPATHOLOGIA, V129, P29, DOI 10.1007/BF01139334
   Bao JJ, 2010, CELL MOL LIFE SCI, V67, P3073, DOI 10.1007/s00018-010-0402-y
   Biovia D.S., 2015, DISCOVERY STUDIO MOD
   Bouitbir J, 2012, EUR HEART J, V33, P1397, DOI 10.1093/eurheartj/ehr224
   Buler M, 2014, FASEB J, V28, P3225, DOI 10.1096/fj.13-245241
   CARDWELL KF, 2001, MYCOTOXINS COST ACHI
   Chandel NS, 2015, CELL METAB, V22, P204, DOI 10.1016/j.cmet.2015.05.013
   Chen YH, 2011, EMBO REP, V12, P534, DOI 10.1038/embor.2011.65
   Cheng Z, 2013, MITOCHONDRIA METABOL
   Chuturgoon A, 2014, TOXICOLOGY, V315, P65, DOI 10.1016/j.tox.2013.11.004
   Cimen H, 2010, BIOCHEMISTRY-US, V49, P304, DOI 10.1021/bi901627u
   Cosconati S, 2010, EXPERT OPIN DRUG DIS, V5, P597, DOI 10.1517/17460441.2010.484460
   Cunha ES, 2017, STRUCTURE, V25, P53, DOI 10.1016/j.str.2016.11.003
   Devnarain N, 2017, TOXICON, V126, P4, DOI 10.1016/j.toxicon.2016.12.006
   Dhani S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03183-0
   Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861
   Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x
   Feldman JL, 2015, BIOCHEMISTRY-US, V54, P3037, DOI 10.1021/acs.biochem.5b00150
   Feldman JL, 2012, J BIOL CHEM, V287, P42419, DOI 10.1074/jbc.R112.378877
   Fenton J.J, 2001, TOXICOLOGY CASE ORIE
   Finley LWS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023295
   Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014
   Fischer F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045098
   Ghazi T, 2017, J CELL BIOCHEM, V118, P3866, DOI 10.1002/jcb.26037
   Gounden S, 2015, METAB SYNDR RELAT D, V13, P255, DOI 10.1089/met.2014.0140
   Gromiha MM, 2010, PROTEIN BIOINFORMATICS: FROM SEQUENCE TO FUNCTION, P1
   Guan XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107729
   Guarente L, 2011, COLD SPRING HARB SYM, P81
   Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Hirschey M.D, 2015, MOL CELL PROTEOM
   Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778
   Hsu CC, 2016, EXP BIOL MED, V241, P1281, DOI 10.1177/1535370216641787
   Jennings MD, 2017, ELIFE, V6, DOI 10.7554/eLife.24542
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   Khan FI, 2017, J BIOMOL STRUCT DYN, V35, P2123, DOI 10.1080/07391102.2016.1206837
   Khan FI, 2016, INT J BIOL MACROMOL, V85, P48, DOI 10.1016/j.ijbiomac.2015.12.072
   Khan S, 2018, INT J BIOL MACROMOL, V111, P548, DOI 10.1016/j.ijbiomac.2017.12.160
   Kim JA, 2008, CIRC RES, V102, P401, DOI 10.1161/CIRCRESAHA.107.165472
   Kincaid B, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00048
   Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707
   KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0
   Laskowski R.A., 2011, LIGPLOT MULTIPLE LIG
   Laurent JM, 2010, PROTEOMICS, V10, P4209, DOI 10.1002/pmic.201000327
   Liu JX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.564
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07
   lwahashi H, 1999, CHEM-BIOL INTERACT, V118, P201
   Madsen A.S, 2016, J BIOL CHEM
   Malovrh T, 2010, FOOD CHEM TOXICOL, V48, P2907, DOI 10.1016/j.fct.2010.07.026
   Mamur S., 2018, DRUG CHEM TOXICOL, P1, DOI 10.1080/01480545.2018.1499772.
   Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052
   Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026
   Naz F, 2018, INT J BIOL MACROMOL, V107, P2580, DOI 10.1016/j.ijbiomac.2017.10.143
   Osborne B, 2016, FREE RADICAL BIO MED, V100, P164, DOI 10.1016/j.freeradbiomed.2016.04.197
   Papa L, 2013, MOL CELL BIOL
   Park J, 2013, MOL CELL, V50, P919, DOI 10.1016/j.molcel.2013.06.001
   Qi X, 2017, J CELL BIOL, V216, P555, DOI 10.1083/jcb.201701062
   Ramachandran A, 2018, J CLIN T RES, V4
   Rardin MJ, 2013, CELL METAB, V18, P920, DOI 10.1016/j.cmet.2013.11.013
   Rardin MJ, 2013, P NATL ACAD SCI USA, V110, P6601, DOI 10.1073/pnas.1302961110
   Rigsby RE, 2016, BIOCHEM MOL BIOL EDU, V44, P433, DOI 10.1002/bmb.20966
   Rolo AP, 2006, TOXICOL APPL PHARM, V212, P167, DOI 10.1016/j.taap.2006.01.003
   Sauve AA, 2012, CURR OPIN CHEM BIOL, V16, P535, DOI 10.1016/j.cbpa.2012.10.003
   Singh VK, 2014, BOT STUD, V55, DOI 10.1186/s40529-014-0066-2
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Stein LR, 2012, TRENDS ENDOCRIN MET, V23, P420, DOI 10.1016/j.tem.2012.06.005
   Streit E, 2013, TOXINS, V5, P504, DOI 10.3390/toxins5030504
   Swamy HVLN, 2002, POULTRY SCI, V81, P966, DOI 10.1093/ps/81.7.966
   Tao RD, 2014, ANTIOXID REDOX SIGN, V20, P1646, DOI 10.1089/ars.2013.5482
   Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013
   Telles-Pupulin AR, 1998, COMP BIOCHEM PHYS C, V120, P43, DOI 10.1016/S0742-8413(98)00004-8
   Tomankova T, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-159
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Valle I, 2005, CARDIOVASC RES, V66, P562, DOI 10.1016/j.cardiores.2005.01.026
   van de Ven RAH, 2017, TRENDS MOL MED, V23, P320, DOI 10.1016/j.molmed.2017.02.005
   Yang LL, 2017, SCI CHINA LIFE SCI, V60, P249, DOI 10.1007/s11427-016-0060-7
   Yang TL, 2006, AAPS J, V8, pE632, DOI 10.1208/aapsj080472
   Yin ES, 2015, BIOMETALS, V28, P783, DOI 10.1007/s10534-015-9855-7
   Zain ME, 2011, J SAUDI CHEM SOC, V15, P129, DOI 10.1016/j.jscs.2010.06.006
   Zhang XK, 2018, CIRCULATION, V137, P2052, DOI 10.1161/CIRCULATIONAHA.117.030486
   Zhou YY, 2012, J BIOL CHEM, V287, P28307, DOI 10.1074/jbc.M112.384511
NR 87
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 48
EP 56
DI 10.1016/j.toxicon.2019.11.009
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100006
PM 31778683
OA Bronze
DA 2020-05-12
ER

PT J
AU Itoi, S
   Tabuchi, S
   Abe, M
   Ueda, H
   Oyama, H
   Ogata, R
   Okabe, T
   Kishiki, A
   Sugita, H
AF Itoi, Shiro
   Tabuchi, Sora
   Abe, Misato
   Ueda, Hiroyuki
   Oyama, Hikaru
   Ogata, Ryuya
   Okabe, Taiki
   Kishiki, Ayano
   Sugita, Haruo
TI Difference in tetrodotoxin content between two sympatric planocerid
   flatworms, Planocera multitentaculata and Planocera reticulata
SO TOXICON
LA English
DT Article
DE Flatworm; Planocera; Planocerid; Polycladida; Tetrodotoxin (TTX)
ID PLEUROBRANCHAEA-MACULATA; TTX ACCUMULATION; NEUROTOXIN
AB Planocerid flatworms and the related species (Platyhelminthes: polycladida) are known as tetrodotoxin (TTX)-bearing organisms, and they contribute to toxification of marine organisms at higher trophic levels, such as pufferfish and sea slugs. However, little is known of their biology or ecology. In this study, we therefore investigated the occurrence and toxicity of two sympatric planocerids, Planocera multitentaculata and Planocera reticulata, in intertidal zones of the central region of mainland Honshu, Japanese Islands. Planocera multitentaculata was much more abundant than P. reticulata. Body weight was greater in P. multitentaculata than in P. reticulata. Although a significant difference in TTX concentration was not observed between the two species, total TTX content per individual was greater in P. multitentaculata.
C1 [Itoi, Shiro; Tabuchi, Sora; Abe, Misato; Ueda, Hiroyuki; Oyama, Hikaru; Ogata, Ryuya; Okabe, Taiki; Kishiki, Ayano; Sugita, Haruo] Nihon Univ, Dept Marine Sci & Resources, Fujisawa, Kanagawa 2520880, Japan.
RP Itoi, S (reprint author), Nihon Univ, Dept Marine Sci & Resources, Fujisawa, Kanagawa 2520880, Japan.
EM sitoi@nihon-u.ac.jp
FU Towa Foundation for Food Science Research; Japan Society for the
   Promotion of Science (JSPS)Ministry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT)Japan Society for the Promotion of
   Science [26660177]; JSPSMinistry of Education, Culture, Sports, Science
   and Technology, Japan (MEXT)Japan Society for the Promotion of Science
   [18K19238, 15H04552]
FX This study was supported in part by the Towa Foundation for Food Science
   & Research (S.I.), Grant-in-Aid for Challenging Exploratory Research
   from Japan Society for the Promotion of Science (JSPS) (26660177, S.I.),
   Grant-in-Aid for Scientific Research (B) from JSPS (15H04552, S.I.) and
   Grant-in-Aid for Challenging Research (Exploratory) from JSPS (18K19238,
   S.I.).
CR COLQUHOUN D, 1972, J PHYSIOL-LONDON, V227, P95, DOI 10.1113/jphysiol.1972.sp010022
   GOTO T, 1965, TETRAHEDRON, V21, P2059, DOI 10.1016/S0040-4020(01)98344-9
   Hwang DF, 1996, FISHERIES SCI, V62, P500, DOI 10.2331/fishsci.62.500
   HWANG DF, 1991, MAR BIOL, V111, P65, DOI 10.1007/BF01986347
   Ishida S, 1998, MORPHO DIFFERENTIATI, P241
   Itoi S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30696-z
   Itoi S, 2018, TOXICON, V148, P95, DOI 10.1016/j.toxicon.2018.04.014
   Itoi S, 2016, TOXICON, V114, P53, DOI 10.1016/j.toxicon.2016.02.020
   Itoi S, 2015, TOXICON, V108, P141, DOI 10.1016/j.toxicon.2015.10.009
   Itoi S, 2014, TOXICON, V78, P35, DOI 10.1016/j.toxicon.2013.11.003
   Kato K., 1940, Japanese Journal of Zoology, V8, P537
   Kawabata T., 1978, FOOD HYGIENE EXAMINA, V2, P232
   Knutsen HK, 2017, EFSA J, V15, DOI 10.2903/j.efsa.2017.4752
   McNabb P, 2010, TOXICON, V56, P466, DOI 10.1016/j.toxicon.2010.04.017
   MIYAZAWA K, 1986, TOXICON, V24, P645, DOI 10.1016/0041-0101(86)90027-9
   MIYAZAWA K, 1988, TOXICON, V26, P867, DOI 10.1016/0041-0101(88)90327-3
   Miyazawa K, 2001, J TOXICOL-TOXIN REV, V20, P11, DOI 10.1081/TXR-100103081
   MOSHER HS, 1964, SCIENCE, V144, P1100, DOI 10.1126/science.144.3622.1100
   Narahashi T, 2001, J TOXICOL-TOXIN REV, V20, P67, DOI 10.1081/TXR-100102537
   Noguchi T, 2006, COMP BIOCHEM PHYS D, V1, P145, DOI 10.1016/j.cbd.2005.10.006
   NOGUCHI T, 1987, MAR BIOL, V94, P625, DOI 10.1007/BF00431409
   NOGUCHI T, 1973, TOXICON, V11, P305, DOI 10.1016/0041-0101(73)90060-3
   Noguchi T, 2008, MAR DRUGS, V6, P220, DOI 10.3390/md20080011
   Ritson-Williams R, 2006, P NATL ACAD SCI USA, V103, P3176, DOI 10.1073/pnas.0506093103
   Salvitti LR, 2015, MAR DRUGS, V13, P756, DOI 10.3390/md13020756
   SHEUMACK DD, 1978, SCIENCE, V199, P188, DOI 10.1126/science.619451
   SIMIDU U, 1987, APPL ENVIRON MICROB, V53, P1714, DOI 10.1128/AEM.53.7.1714-1715.1987
   Tahara Y., 1909, J PHARM SOC JPN, V29, P587
   Tanu MB, 2004, TOXICON, V44, P515, DOI 10.1016/j.toxicon.2004.06.014
   TSUDA K, 1964, CHEM PHARM BULL, V12, P1357
   Ueda H, 2018, MAR DRUGS, V16, DOI 10.3390/md16010037
   Wood SA, 2012, MAR DRUGS, V10, P163, DOI 10.3390/md10010163
   Woodward R.B., 1964, PURE APPL CHEM, V9, P49, DOI 10.1021/ja01076a076.
   Yamada R, 2017, MAR DRUGS, V15, DOI 10.3390/md15030056
   YOTSUYAMASHITA M, 1992, TOXICON, V30, P1489, DOI 10.1016/0041-0101(92)90526-B
NR 35
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 57
EP 61
DI 10.1016/j.toxicon.2019.11.008
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100007
PM 31778684
OA Bronze
DA 2020-05-12
ER

PT J
AU Wang, H
   Wang, Y
   Shi, FF
   Zhang, S
   Fang, WT
   Qi, LM
   Wang, N
   Huang, C
   Fang, HQ
   Li, HJ
AF Wang, Hong
   Wang, Yan
   Shi, Fei-Fan
   Zhang, Shuo
   Fang, Wei-Ting
   Qi, La-Mei
   Wang, Nan
   Huang, Can
   Fang, Hai-Qin
   Li, Hai-Jiao
TI A case report of acute renal failure caused by Amanita neoovoidea
   poisoning in Anhui Province, eastern China
SO TOXICON
LA English
DT Review
DE Poisonous mushroom; Amanita neoovoidea; Acute renal failure; Treatment
AB Amanita neoovoidea (genus Amanita Pers.) poisoning leads to acute renal failure. Here, we present seven case reports of acute renal failure with acute hepatic failure due to ingestion of A. neoovoidea. Clinical manifestations included gastrointestinal symptoms 1-72 h after ingestion; elevation of renal parameters and blood uric acid, blood urea nitrogen, and creatinine levels; a few abnormal hepatic parameters, primarily albumin decrease and alanine aminotransferase increase; and elevation of zymogram parameters such as cholinesterase and lactate dehydrogenase. To determine whether the hepatic/renal lesions were caused by amanitins, we analyzed the blood and urine samples of patients and specimens of poisonous mushrooms. Morphological and molecular biological analyses indicated that the mushroom was A. neoovoidea. However, no amatoxins and phallotoxins were detected in its basidiomata.
C1 [Wang, Hong; Wang, Yan; Qi, La-Mei; Wang, Nan; Huang, Can] Anhui Med Univ, Anqing Affiliated Hosp, Anqing 246004, Peoples R China.
   [Shi, Fei-Fan] Southwest Minzu Univ, Coll Life Sci & Technol, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Shuo; Fang, Hai-Qin] China Natl Ctr Food Safety Risk Assessment, Beijing 100021, Peoples R China.
   [Fang, Wei-Ting] Anhui Med Univ, Affiliated Prov Hosp, Anqing, Peoples R China.
   [Fang, Wei-Ting] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei 230001, Anhui, Peoples R China.
   [Li, Hai-Jiao] Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poison Control, 29th Bldg,Nan Wei Rd, Beijing 100050, Peoples R China.
RP Li, HJ (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Occupat Hlth & Poison Control, 29th Bldg,Nan Wei Rd, Beijing 100050, Peoples R China.; Fang, HQ (reprint author), China Natl Ctr Food Safety Risk Assessment CFSA, Bldg 2,37 Guangqu Rd, Beijing 100022, Peoples R China.
EM fanghaiqin@cfsa.net.cn; lihaijiao715@126.com
FU China Food Safety Talent Competency Development Initiative [CFSA 523];
   Natural Science Foundation of Beijing CityBeijing Natural Science
   Foundation [7142128]
FX The authors would like to express their deep gratitude to Dr Jing Si
   (Beijing Forestry University, China) for improving the manuscript and
   special thanks to Prof. Bing Shao and Dr. Yu-Min Niu (Beijing Center for
   Disease Control and Prevention, China) for amatoxin detection. This work
   was supported by China Food Safety Talent Competency Development
   Initiative: CFSA 523 Program and the Natural Science Foundation of
   Beijing City (No. 7142128).
CR Apperley S, 2013, CLIN TOXICOL, V51, P249, DOI 10.3109/15563650.2013.778995
   Besancon A, 2012, ANN FR ANESTH, V31, P466, DOI 10.1016/j.annfar.2012.01.021
   Chen ZuoHong, 2014, Mycosystema, V33, P493
   Chen ZH, 2014, FUNGAL DIVERS, V64, P123, DOI 10.1007/s13225-013-0260-7
   CHILTON WS, 1976, LLOYDIA, V39, P150
   CHILTON WS, 1973, LLOYDIA, V36, P169
   Cui YY, 2018, FUNGAL DIVERS, V91, P5, DOI 10.1007/s13225-018-0405-9
   Fu XY, 2017, MYCOSCIENCE, V58, P121, DOI 10.1016/j.myc.2016.12.004
   Gioacchino LC, 2019, INDIAN J NEPHROL, V29, P73, DOI 10.4103/ijn.IJN_33_18
   Kang E, 2015, KIDNEY RES CLIN PRAC, V34, P233, DOI 10.1016/j.krcp.2015.05.007
   Kirchmair M, 2012, NEPHROL DIAL TRANSPL, V27, P1380, DOI 10.1093/ndt/gfr511
   Lee JH, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e230
   Li HJ, 2015, MYCOL PROG, V14, DOI 10.1007/s11557-015-1055-x
   Liu J.Q., 2001, LIFE SCI RES, V5, P281
   PELIZZARI V, 1994, MYCOLOGIA, V86, P555, DOI 10.2307/3760749
   Sun J., 2018, THESIS, P1
   Sun J, 2018, TOXICON, V143, P59, DOI 10.1016/j.toxicon.2018.01.008
   [王锐 Wang Rui], 2014, [中国公共卫生, China Journal of Public Health], V30, P158
   West PL, 2009, J MED TOXICOL, V5, P32, DOI 10.1007/BF03160979
   White J, 2019, TOXICON, V157, P53, DOI 10.1016/j.toxicon.2018.11.007
   Yang XiangFu, 2005, Journal of Wuhan Botanical Research, V23, P393
   Yang Z.L, 2005, CHINESE MYCOFLORA, P1
   Yang Z.L, 2015, ATLAS CHINESE SPECIE, P1
   Zhang S, 2016, TOXINS, V8, DOI 10.3390/toxins8050128
NR 24
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 62
EP 67
DI 10.1016/j.toxicon.2019.11.007
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100008
PM 31759921
OA Bronze
DA 2020-05-12
ER

PT J
AU Garcia, JA
   Rosas, JE
   Santos, CGY
   Streitenberger, N
   Feijoo, M
   Dutra, F
AF Garcia, Juan A.
   Rosas, Juan E.
   Garcia y Santos, Carmen
   Streitenberger, Nicolas
   Feijoo, Matias
   Dutra, Fernando
TI Senecio spp. transboundary introduction and expansion affecting cattle
   in Uruguay: Clinico-pathological, epidemiological and genetic survey,
   and experimental intoxication with Senecio oxyphyllus
SO TOXICON
LA English
DT Article
DE Plant invasion; Hepatotoxicity; Ruminants; Ecological disturbance;
   Genomic divergence
ID GRANDE-DO-SUL; PYRROLIZIDINE ALKALOIDS; MADAGASCARIENSIS POIR.; PLANT
   INVASION; ASTERACEAE; DEFENSE; DIVERSITY; EVOLUTION; BRAZIL;
   DIFFERENTIATION
AB The genus Senecio is distributed worldwide, being responsible of poisoning in livestock and humans. Many species of Senecio have high invasion and expansion capacity, highly competitive with agricultural and native plant species, causing ecological damage. Particularly in Uruguay, poisoning by Senecio have grown exponentially to reach epidemic proportions. Herein we describe Seneciosis as a re-emerging and expanding epidemic disease affecting cattle, by describing clinico-pathological, epidemiological and genetic variation of species involved, as well as an experimental intoxication with Senecio oxyphyllus. For this, a study was carried out on 28 cattle farms in Eastern Uruguay, with history of seneciosis from 2010 to 2016. Plants of fifty populations of Senecio were sampled, in 2015 and 2016, for identification, analysis of alkaloids and study of genetic variation. In turn, post-mortem examination was performed in cattle of natural and an experimental case to confirm the intoxication, showing microscopic characteristic lesions (hepatomegalocytosis, diffuse fibrosis and ductal reaction). Four species of Senecio were identified: S. oxyphyllus, S. madagascariensis, S. selloi and S. brasiliensis. In the genetic study, 489 molecular markers of amplified sequence-related polymorphisms (SRAP), associated with species and pasture, were used for genetic variation analysis. There was no statistically significant association between genetic variation determined by molecular markers and population (specimens of same species collected from the same farm), botanically determined species, or geographical origin. The increase of seneciosis in cattle in the last years, the presence of species not identified to the moment with implication in the poisoning outbreaks and expansion of these plants shows that the disease is in an epidemic growing active stage. In turn, the experimental poisoning with S. oxyphyllus confirms its chronic hepatotoxic effect, being an emergent species for the region, of high distribution and toxic risk. This latter turned out the main Senecio species involved. This case of expansion of harmful plant for animal production and desirable plant species, can be useful as a model of ecopathological characterization, which is likely to occur with other toxic plants in different geographical ranges globally.
C1 [Garcia, Juan A.; Feijoo, Matias] Univ Republ, Ctr Univ Reg Este, Treinta Tres, Uruguay.
   [Rosas, Juan E.] Inst Nacl Invest Agr, Treinta Tres, Uruguay.
   [Garcia y Santos, Carmen] Univ Republica, Fac Vet, Montevideo, Uruguay.
   [Streitenberger, Nicolas] Univ Nacl La Plata, Catedra Patol Especial, Fac Ciencias Vet, La Plata, Argentina.
   [Dutra, Fernando] DILAVE Miguel C Rubino Reg Este, Avelino Miranda 2045,CP33000, Treinta Tres, Uruguay.
RP Dutra, F (reprint author), DILAVE Miguel C Rubino Reg Este, Avelino Miranda 2045,CP33000, Treinta Tres, Uruguay.
EM fdutra@mgap.gub.uy
OI Garcia, Juan/0000-0002-8047-6724; Dutra Quintela,
   Fernando/0000-0003-4886-9429
CR Garcia JA, 2018, CIENC RURAL, V48, DOI 10.1590/0103-8478cr20170621
   ARAI M, 2010, APPL IMMUNOHISTO M M, V8, DOI DOI 10.1186/1479-5876-8-51
   Boppre M, 2011, FOOD ADDIT CONTAM A, V28, P260, DOI 10.1080/19440049.2011.555085
   Bossdorf O, 2005, OECOLOGIA, V144, P1, DOI 10.1007/s00442-005-0070-z
   Boszormenyi A, 2009, J AGR FOOD CHEM, V57, P4663, DOI 10.1021/jf9005092
   Bradley B.A., 2009, GLOBAL CHANGE BIOL, V15, P1365
   Bradley BA, 2010, TRENDS ECOL EVOL, V25, P310, DOI 10.1016/j.tree.2009.12.003
   Brazeiro A., 2012, CLASSIFICATION ECORE, P41
   Burrows G.E, 2013, TOXIC PLANTS N AM, P203
   Cano L, 2008, J ECOL, V96, P468, DOI 10.1111/j.1365-2745.2008.01363.x
   Carvalho S, 2013, ISPRS J PHOTOGRAMM, V80, P51, DOI 10.1016/j.isprsjprs.2013.03.004
   Castells E, 2014, PHYTOCHEMISTRY, V108, P137, DOI 10.1016/j.phytochem.2014.09.006
   Celesti-Grapow L, 2016, PLANT BIOSYST, V150, P1119, DOI 10.1080/11263504.2016.1218974
   Comes HP, 2001, EVOLUTION, V55, P1943, DOI 10.1111/j.0014-3820.2001.tb01312.x
   COOMBS EM, 2004, BIOL CONTROL INVASIV
   Cullen J.M., 2016, JUBB KENNEDY PALMERS, P336
   De Masi L, 2006, EUR FOOD RES TECHNOL, V223, P273, DOI 10.1007/s00217-005-0201-0
   Dietz H, 2006, ECOLOGY, V87, P1359, DOI 10.1890/0012-9658(2006)87[1359:RTCPCD]2.0.CO;2
   Doorduin LJ, 2011, PHYTOCHEM REV, V10, P99, DOI 10.1007/s11101-010-9195-8
   DRIEMEIER D, 1992, PESQUISA VET BRASIL, V12, P33
   Dutra F, 2016, PUBLICACION DILAVE R, V19
   Dutra F, 2010, PUBLICACION DILAVE R, V2
   Dutra F, 2015, PUBLICACION DILAVE R, V18
   EXCOFFIER L, 1992, GENETICS, V131, P479
   Garcia J.A., 2016, XLIV JORNADAS URUGUA
   Gardner DR, 2006, BIOCHEM SYST ECOL, V34, P736, DOI 10.1016/j.bse.2006.05.010
   GOUDET J, 2001, FSTAT PROGRAM ESTIMA
   Hagenblad J, 2015, BMC GENET, V16, DOI 10.1186/s12863-015-0242-8
   Haldimann P, 2003, MOL ECOL, V12, P2541, DOI 10.1046/j.1365-294X.2003.01915.x
   Hol WHG, 2011, PHYTOCHEM REV, V10, P119, DOI 10.1007/s11101-010-9188-7
   Kalusova V., 2017, P NATL ACAD SCI, V114
   Karam FC, 2011, PESQUI VET BRASIL, V31, P603, DOI 10.1590/S0100-736X2011000700010
   Karam FSC, 2004, PESQUI VET BRASIL, V24, P191, DOI 10.1590/S0100-736X2004000400004
   Kirk H, 2010, J CHEM ECOL, V36, P378, DOI 10.1007/s10886-010-9772-8
   Krabbe AA, 2017, PESQUI VET BRASIL, V37, P1423, DOI [10.1590/S0100-736X2017001200011, 10.1590/s0100-736x2017001200011]
   Lambrinos JG, 2004, ECOLOGY, V85, P2061, DOI 10.1890/03-8013
   Larson DL, 2001, ECOL APPL, V11, P128, DOI 10.1890/1051-0761(2001)011[0128:APIIMG]2.0.CO;2
   Le Roux JJ, 2006, DIVERS DISTRIB, V12, P694, DOI 10.1111/j.1472-4642.2006.00271.x
   Roux JJ, 2010, BIOL INVASIONS, V12, P2251, DOI 10.1007/s10530-009-9635-9
   Li G, 2001, THEOR APPL GENET, V103, P455, DOI 10.1007/s001220100570
   Liebhold A, 2017, BIOL INVASIONS, V19, P3437, DOI 10.1007/s10530-017-1458-5
   Lucena RB, 2010, PESQUISA VET BRASIL, V30, P447, DOI 10.1590/S0100-736X2010000500013
   Macel M, 2004, PHYTOCHEMISTRY, V65, P865, DOI 10.1016/j.phytochem.2004.02.009
   Mader G, 2016, GENET MOL BIOL, V39, P135, DOI 10.1590/1678-4685-GMB-2015-0167
   Mattocks A.R, 1986, CHEM TOXICOLOGY PYRR, P393
   Muller-Scharer H, 2008, BIOL INVASIONS, V10, P859, DOI 10.1007/s10530-008-9238-x
   Muller-Scharer H, 2004, TRENDS ECOL EVOL, V19, P417, DOI 10.1016/j.tree.2004.05.010
   Nan P, 2003, Z NATURFORSCH C, V58, P57
   Oduor AMO, 2016, J ECOL, V104, P957, DOI 10.1111/1365-2745.12578
   Panziera W, 2018, PESQUI VET BRASIL, V38, P1459, DOI [10.1590/1678-5150-PVB-5795, 10.1590/1678-5150-pvb-5795]
   Panziera W, 2017, PESQUI VET BRASIL, V37, P8, DOI 10.1590/s0100-736x2017000100002
   Pelser PB, 2007, TAXON, V56, P1077, DOI 10.2307/25065905
   Peterson EE, 2010, ECOLOGY, V91, P644, DOI 10.1890/08-1668.1
   Prakash AS, 1999, MUTAT RES-GEN TOX EN, V443, P53, DOI 10.1016/S1383-5742(99)00010-1
   Preliasco M, 2011, POISONING BY PLANTS, MYCOTOXINS, AND RELATED TOXINS, P198, DOI 10.1079/9781845938338.0198
   Preliasco M, 2017, TOXICON, V133, P68, DOI 10.1016/j.toxicon.2017.05.004
   Riet-Correa F, 2001, PESQUISA VET BRASIL, V21, P38, DOI 10.1590/S0100-736X2001000100008
   Rivero R, 2017, 1 C REG TOX VET 7 8
   Scherber C, 2003, DIVERS DISTRIB, V9, P415, DOI 10.1046/j.1472-4642.2003.00049.x
   Stegelmeier B.L, 1999, J NAT TOXINS, V8
   Stegelmeier BL, 2011, VET CLIN N AM-FOOD A, V27, P419, DOI 10.1016/j.cvfa.2011.02.013
   Stigger AL, 2014, PESQUI VET BRASIL, V34, P851, DOI 10.1590/S0100-736X2014000900008
   Tewes LJ, 2018, J ECOL, V106, P714, DOI 10.1111/1365-2745.12869
   Trindade H, 2009, BIOCHEM SYST ECOL, V37, P670, DOI 10.1016/j.bse.2009.10.006
   Venables W. N., 2002, MODERN APPL STAT S, P271, DOI DOI 10.1007/978-0-387-21706-2_10
   Verschave SH, 2015, VET PARASITOL, V210, P159, DOI 10.1016/j.vetpar.2015.03.031
   Villalba J, 2005, TAMBO, V129, P46
   VRIELING K, 1993, PHYTOCHEMISTRY, V32, P1141, DOI 10.1016/S0031-9422(00)95079-9
   Wardle DA, 1995, AGR ECOSYST ENVIRON, V56, P19, DOI 10.1016/0167-8809(95)00636-2
   Wiedenfeld H, 2011, PHYTOCHEM REV, V10, P137, DOI 10.1007/s11101-010-9174-0
   Wolf VC, 2012, BIOL CONTROL, V61, P240, DOI 10.1016/j.biocontrol.2012.01.009
   Wolf VC, 2011, BIOL INVASIONS, V13, P2091, DOI 10.1007/s10530-011-0028-5
   WRIGHT S, 1965, EVOLUTION, V19, P395, DOI 10.2307/2406450
   Grass MAY, 2012, J PLANT INTERACT, V7, P175, DOI 10.1080/17429145.2011.591504
   Yang Y, 2011, CHEM BIODIVERS, V8, P13, DOI 10.1002/cbdv.201000027
   Yu XQ, 2014, BIOL INVASIONS, V16, P2351, DOI 10.1007/s10530-014-0669-2
NR 76
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 68
EP 74
DI 10.1016/j.toxicon.2019.11.013
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100009
PM 31785285
OA Bronze
DA 2020-05-12
ER

PT J
AU Gajecka, M
   Dabrowski, M
   Otrocka-Domagala, I
   Brzuzan, P
   Rykaczewska, A
   Cieplinska, K
   Barasinska, M
   Gajecki, MT
   Zielonka, L
AF Gajecka, Magdalena
   Dabrowski, Michal
   Otrocka-Domagala, Iwona
   Brzuzan, Pawel
   Rykaczewska, Anna
   Cieplinska, Katarzyna
   Barasinska, Marzena
   Gajecki, Maciej T.
   Zielonka, Lukasz
TI Correlations between exposure to deoxynivalenol and zearalenone and the
   immunohistochemical expression of estrogen receptors in the intestinal
   epithelium and the mRNA expression of selected colonic enzymes in
   pre-pubertal gilts
SO TOXICON
LA English
DT Article
DE Deoxynivalenol; Zearalenone; Immunohistochemistry; Estrogen receptors;
   CYP1A1 mRNA; GSTP1 mRNA; Intestines; Pre-pubertal gilts
ID GENE-EXPRESSION; FUSARIUM TOXINS; ER-ALPHA; BETA; MYCOTOXINS; ENDOCRINE;
   CELL; PROLIFERATION; GENOTOXICITY; MICROBIOTA
AB Plant-based materials used in the production of pig feed are very often contaminated with deoxynivalenol and zearalenone. Daily intake of small amounts of these mycotoxins with feed induces various subclinical states in gilts and influences different biological processes. The aim of this preclinical study was to determine the correlation between monotonic doses of zearalenone and deoxynivalenol (40 mu g/kg body weight and 12 mu g/kg body weight, respectively, administered over a period of 42 days) and the immunohistochemical expression of estrogen receptors in the intestinal tract and the mRNA expression of selected colonic enzymes. The immunohistochemical expression of estrogen receptor alpha was observed in the colon, but its intensity varied in different weeks of exposure. A minor increase in estrogen receptor beta expression was noted only in the colon, whereas the expression of cytochrome P450 1A1 enzyme mRNA and mRNA isoform of the glutathione S-transferase pi gene decreased. The observed correlations suggest that the risk of loss of control over the biotransformation and biological activity of the parent compounds in distal intestinal mucosa is delayed.
C1 [Gajecka, Magdalena; Dabrowski, Michal; Rykaczewska, Anna; Barasinska, Marzena; Gajecki, Maciej T.; Zielonka, Lukasz] Univ Warmia & Mazury, Fac Vet Med, Dept Vet Prevent & Feed Hyg, Oczapowskiego 13, PL-10718 Olsztyn, Poland.
   [Otrocka-Domagala, Iwona] Univ Warmia & Mazury, Fac Vet Med, Dept Pathol Anat, Oczapowskiego 13D, PL-10718 Olsztyn, Poland.
   [Brzuzan, Pawel] Univ Warmia & Mazury, Fac Environm Sci & Fisheries, Dept Environm Biotechnol, Sloneczna 45G, PL-10719 Olsztyn, Poland.
   [Cieplinska, Katarzyna] Nonpubl Hlth Care Ctr, Microbiol Lab, Ul Limanowskiego 31A, PL-10342 Olsztyn, Poland.
RP Gajecka, M (reprint author), Univ Warmia & Mazury, Fac Vet Med, Dept Vet Prevent & Feed Hyg, Oczapowskiego 13, PL-10718 Olsztyn, Poland.
EM mgaja@uwm.edu.pl; michal.dabrowski@uwm.edu.pl;
   i.otrocka-domagala@uwm.edu.pl; brzuzan@uwm.edu.pl;
   anna.rykaczewska@uwm.edu.pl; kasiacieplinska@gmail.com;
   marzenap@uwm.edu.pl; gajecki@uwm.edu.pl; lukasz.zielonka@uwm.ed.pl
OI Brzuzan, Pawel/0000-0001-9701-5716
FU Polish Ministry of Science and Higher EducationMinistry of Science and
   Higher Education, Poland [12-0080-10/2010]; "Healthy Animal - Safe Food"
   Scientific Consortium of the Leading National Research Centre (KNOW)
   pursuant to a decision of the Ministry of Science and Higher Education
   [05-1/KNOW2/2015]
FX The study was supported by the Polish Ministry of Science and Higher
   Education as part of Project No. 12-0080-10/2010. The publication was
   supported by the "Healthy Animal - Safe Food" Scientific Consortium of
   the Leading National Research Centre (KNOW) pursuant to a decision of
   the Ministry of Science and Higher Education No. 05-1/KNOW2/2015.
CR Adibnia E, 2016, TOXICON, V120, P133, DOI 10.1016/j.toxicon.2016.08.009
   Akbari P, 2017, ARCH TOXICOL, V91, P1007, DOI 10.1007/s00204-016-1794-8
   [Anonymous], 2006, OFF J EUR UNION, V229, P7
   Arukwe A, 2006, ENVIRON SCI TECHNOL, V40, P7944, DOI 10.1021/es0615223
   Balaguer P., 2019, CURR OPIN ENDO METAB, V7, P1, DOI DOI 10.1016/J.C0EMR.2019.04.008
   Barton M, 2016, STEROIDS, V111, P37, DOI 10.1016/j.steroids.2016.02.016
   Barton M, 2012, STEROIDS, V77, P935, DOI 10.1016/j.steroids.2012.04.001
   Basharat Z, 2017, GENE, V609, P19, DOI 10.1016/j.gene.2017.01.034
   Bilat PA, 2017, DRUG DISCOV TODAY, V22, P761, DOI 10.1016/j.drudis.2017.01.007
   Broekaert N, 2016, FOOD CHEM TOXICOL, V95, P103, DOI 10.1016/j.fct.2016.06.012
   Chang SY, 2018, TOXICON, V151, P111, DOI 10.1016/j.toxicon.2018.06.081
   Chen KL, 2018, STEROIDS, V133, P38, DOI 10.1016/j.steroids.2017.10.015
   Cieplinska K, 2019, TOXINS, V11, DOI 10.3390/toxins11050296
   Dabrowski M, 2017, POL J VET SCI, V20, P213, DOI 10.1515/pjvs-2017-0026
   Dabrowski M, 2017, MOLECULES, V22, DOI 10.3390/molecules22050691
   Dabrowski M, 2016, MOLECULES, V21, DOI 10.3390/molecules21050557
   Demaegdt H, 2016, FOOD CHEM TOXICOL, V96, P107, DOI 10.1016/j.fct.2016.07.033
   Freedland J, 2017, MUTAT RES-GEN TOX EN, V815, P35, DOI 10.1016/j.mrgentox.2017.02.002
   Freire L, 2018, FOOD CHEM TOXICOL, V111, P189, DOI 10.1016/j.fct.2017.11.021
   Frizzell C, 2011, TOXICOL LETT, V206, P210, DOI 10.1016/j.toxlet.2011.07.015
   Gajecka M, 2013, POL J VET SCI, V16, P55, DOI 10.2478/pjvs-2013-0008
   Gajecka M, 2011, THERIOGENOLOGY, V75, P1085, DOI 10.1016/j.theriogenology.2010.11.017
   Gajecka M, 2018, TOXICON, V153, P1, DOI 10.1016/j.toxicon.2018.08.002
   Gajecka M, 2017, MOLECULES, V22, DOI 10.3390/molecules22010018
   Gajecka M, 2017, TOXICON, V125, P32, DOI 10.1016/j.toxicon.2016.11.007
   Gajecka M, 2015, MOLECULES, V20, P20669, DOI 10.3390/molecules201119726
   Gerez JR, 2015, EXP TOXICOL PATHOL, V67, P89, DOI 10.1016/j.etp.2014.10.001
   Gregoraszczuk EL, 2016, TOXICOLOGY, V366, P53, DOI 10.1016/j.tox.2016.08.004
   He J, 2018, MOL CELL ENDOCRINOL, V461, P43, DOI 10.1016/j.mce.2017.08.010
   Heberer T, 2007, TOXICOL LETT, V175, P118, DOI 10.1016/j.toxlet.2007.10.002
   Hickey GL, 2012, ENVIRON TOXICOL CHEM, V31, P1903, DOI 10.1002/etc.1891
   Hokaiwado N, 2008, CARCINOGENESIS, V29, P1134, DOI 10.1093/carcin/bgn097
   Jo H, 2016, ANIM FEED SCI TECH, V219, P77, DOI 10.1016/j.anifeedsci.2016.06.006
   Kostecki M, 1991, Mycotoxin Res, V7 Suppl 2, P160, DOI 10.1007/BF03192203
   Kostecki M, 1991, Mycotoxin Res, V7 Suppl 2, P156, DOI 10.1007/BF03192202
   Kovacevic Z, 2017, BBA-GEN SUBJECTS, V1861, P995, DOI 10.1016/j.bbagen.2017.02.021
   Kowalska K, 2016, ENVIRON TOXICOL PHAR, V48, P141, DOI 10.1016/j.etap.2016.10.015
   Lathe R, 2015, J STEROID BIOCHEM, V151, P1, DOI 10.1016/j.jsbmb.2015.01.008
   Lewczuk B, 2016, EXP TOXICOL PATHOL, V68, P157, DOI 10.1016/j.etp.2015.11.008
   Li HX, 2019, STEROIDS, V141, P36, DOI 10.1016/j.steroids.2018.09.013
   Liew WPP, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00060
   Liu JYH, 2019, GEN COMP ENDOCR, V272, P63, DOI 10.1016/j.ygcen.2018.11.016
   Lopez-Calderero I, 2014, HUM PATHOL, V45, P2437, DOI 10.1016/j.humpath.2014.08.008
   Mackowiak B, 2016, BBA-GENE REGUL MECH, V1859, P1130, DOI 10.1016/j.bbagrm.2016.02.006
   Martins C, 2018, FOOD CHEM, V239, P132, DOI 10.1016/j.foodchem.2017.06.088
   Meiers I, 2010, ATLAS GENET CYTOGENE, V14, P1181
   Nandekar PP, 2016, EUR J MED CHEM, V115, P82, DOI 10.1016/j.ejmech.2016.02.061
   Neal GE, 1998, TOXICOL APPL PHARM, V151, P152, DOI 10.1006/taap.1998.8440
   Norrby M, 2013, ANIM REPROD SCI, V138, P90, DOI 10.1016/j.anireprosci.2013.01.011
   Nowak A, 2015, VET MED-CZECH, V60, P133, DOI 10.17221/8058-VETMED
   Park H, 2019, BIOORGAN MED CHEM, V27, P2075, DOI 10.1016/j.bmc.2019.04.003
   Paterni I, 2014, STEROIDS, V90, P13, DOI 10.1016/j.steroids.2014.06.012
   Payros D, 2016, ARCH TOXICOL, V90, P2931, DOI 10.1007/s00204-016-1826-4
   Pinton P, 2015, MOL NUTR FOOD RES, V59, P1076, DOI 10.1002/mnfr.201500005
   Pinton P, 2014, TOXINS, V6, P1615, DOI 10.3390/toxins6051615
   Piotrowska M, 2014, TOXINS, V6, P2064, DOI 10.3390/toxins6072064
   Pizzo F, 2016, TOXICON, V109, P70, DOI 10.1016/j.toxicon.2015.11.018
   Przybylska-Gornowicz B, 2018, TOXINS, V10, DOI 10.3390/toxins10040148
   Przybylska-Gornowicz B, 2015, TOXINS, V7, P4684, DOI 10.3390/toxins7114684
   Reddy KE, 2018, ASIAN AUSTRAL J ANIM, V31, P595, DOI 10.5713/ajas.17.0466
   Robert H., 2017, J TOXICOL ENV HEAL B, P1, DOI [10.1080/254255, DOI 10.1080/254255]
   Rykaczewska A, 2018, TOXICON, V152, P84, DOI 10.1016/j.toxicon.2018.07.013
   Singhai R, 2011, N AM J MED SCI, V3, P227, DOI 10.4297/najms.2011.3227
   Slomczynska M, 2001, EXP CLIN ENDOCR DIAB, V109, P238, DOI 10.1055/s-2001-15112
   Soler L, 2018, J PROTEOMICS, V178, P114, DOI 10.1016/j.jprot.2017.12.017
   Spachmo B, 2012, AQUAT TOXICOL, V108, P112, DOI 10.1016/j.aquatox.2011.07.018
   Taylor SE, 2010, CANCER LETT, V288, P133, DOI 10.1016/j.canlet.2009.06.017
   Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093
   Vandenbroucke V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023871
   Viegas S, 2019, TOXINS, V11, DOI 10.3390/toxins11020078
   Wan LYM, 2013, FOOD CHEM TOXICOL, V57, P276, DOI 10.1016/j.fct.2013.03.034
   Wan LYM, 2014, TOXICOL SCI, V139, P83, DOI 10.1093/toxsci/kfu019
   Wang ZK, 2014, ALIMENT PHARM THER, V39, P751, DOI 10.1111/apt.12665
   Warner M, 2015, J STEROID BIOCHEM, V145, P245, DOI 10.1016/j.jsbmb.2014.08.003
   Waskiewicz A, 2014, TOXINS, V6, P973, DOI 10.3390/toxins6030973
   Wesolowska M, 2016, BIOMED PHARMACOTHER, V83, P314, DOI 10.1016/j.biopha.2016.06.048
   Williams C, 2016, CANCER LETT, V372, P48, DOI 10.1016/j.canlet.2015.12.009
   Xia SA, 2017, BIOSENS BIOELECTRON, V97, P345, DOI 10.1016/j.bios.2017.06.002
   Yan XJ, 2014, J PAIN, V15, P204, DOI 10.1016/j.jpain.2013.10.012
   Yang R, 2016, MOL CELL ENDOCRINOL, V437, P62, DOI 10.1016/j.mce.2016.08.012
   Zielonka L, 2015, POL J VET SCI, V18, P391, DOI 10.1515/pjvs-2015-0050
   Zielonka L, 2015, TOXINS, V7, P3210, DOI 10.3390/toxins7083210
   Zielonka L, 2014, TOXICON, V89, P26, DOI 10.1016/j.toxicon.2014.06.021
   Zwierzchowski W., 2004, Polish Journal of Veterinary Sciences, V7, P289
NR 84
TC 1
Z9 1
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 15
PY 2020
VL 173
BP 75
EP 93
DI 10.1016/j.toxicon.2019.11.006
PG 19
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KE7NT
UT WOS:000508739100010
PM 31734251
OA Bronze
DA 2020-05-12
ER

PT J
AU Arabi, A
   Salhi, Y
   Zenati, Y
   Si-Ahmed, EK
   Legrand, J
AF Arabi, A.
   Salhi, Y.
   Zenati, Y.
   Si-Ahmed, E. K.
   Legrand, J.
TI On gas-liquid intermittent flow in a horizontal pipe: Influence of
   sub-regime on slug frequency
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas-liquid two-phase flow; Intermittent flow; Slug frequency;
   Differential pressure fluctuations
ID 2-PHASE FLOW; DIAMETER; PRESSURE; PREDICTION; PATTERNS; TRANSITION;
   SUBREGIMES; PARAMETERS; CORROSION; VELOCITY
AB Among the intrinsic parameters identified in intermittent gas-liquid flows; slug frequency is known as the most complicated one to model. The present work concerns the investigation of slug frequency for various sub-regimes which might be found in intermittent flow. Experiments, near atmospheric pressure conditions, were carried out in a 13-meter long horizontal pipe with a 30 mm inside diameter. The study involved plug regime, less aerated slug and highly aerated slug flows. Comparison between different methods of slug frequency quantification, from pressure drop signal, was performed with counting, Wilkens & Thomas as well as the Power Spectral Density (PSD) methods. PSD was found to be the best method for slug frequency measurements. A new flow map, using dimensionless numbers as coordinates for the sub-regimes distinction, was established. After performing substantial comparisons between the present results and models available in the literature a new correlation is proposed including the sub-regime types. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Arabi, A.] SONATRACH, Direct Cent Rech & Dev, Ave 1er Novembre, Boumerdes 35000, Algeria.
   [Arabi, A.; Salhi, Y.; Zenati, Y.] Univ Sci & Technol Houari Boumedienne, Phys Fac Lab Theoret & Appl Fluid Mech, LMFTA, BP 32 El Alia, Algiers 16111, Algeria.
   [Si-Ahmed, E. K.; Legrand, J.] Nantes Univ, ONIRIS, UMR6144, CNRS,GEPEA, 37 Bd Univ BP406, F-44602 St Nazaire, France.
RP Si-Ahmed, EK (reprint author), Nantes Univ, CNRS, UMR 6144, GEPEA, CRTT 37 Bd Univ BP406, F-44602 St Nazaire, France.
EM el-khider.si-ahmed@univ-nantes.fr
RI ARABI, Abderraouf/AAG-1255-2020; SALHI, Yacine/AAK-7497-2020
OI ARABI, Abderraouf/0000-0002-3581-5416; SALHI,
   Yacine/0000-0003-3218-8135; SI-AHMED, EL-KHIDER/0000-0002-5556-6314
FU  [SH-U.S.T.H.B. RD No1]
FX This work was partially funded by the project SONATRACH-U.S. T.H.B.
   (project number: SH-U.S.T.H.B. RD No1).
CR Abdelsalam A, 2016, INT J MULTIPHAS FLOW, V81, P15, DOI 10.1016/j.ijmultiphaseflow.2015.12.008
   Abdulkadir M, 2016, CHEM ENG SCI, V156, P147, DOI 10.1016/j.ces.2016.09.015
   Ahmed W.H., 2012, NUCL POWER PRACTICAL
   Al-Safran E., 2012, 8 N AM C MULT TECHN
   Al-Safran E, 2009, J PETROL SCI ENG, V69, P143, DOI 10.1016/j.petrol.2009.08.009
   Al-Safran EM, 2016, J PETROL SCI ENG, V138, P88, DOI 10.1016/j.petrol.2015.12.008
   Arabi A, 2018, MECCANICA, V53, P3321, DOI 10.1007/s11012-018-0892-5
   Archibong A., 2015, THESIS
   Archibong-Eso A, 2018, J PETROL SCI ENG, V163, P600, DOI 10.1016/j.petrol.2017.12.071
   Azzi A, 2010, CHEM ENG SCI, V65, P3986, DOI 10.1016/j.ces.2010.03.037
   Baba YD, 2017, FLOW MEAS INSTRUM, V54, P109, DOI 10.1016/j.flowmeasinst.2017.01.002
   Bagci S, 2004, ENERG SOURCE, V26, P627, DOI 10.1080/00908310490438614
   Bai D, 1997, AICHE J, V43, P1357, DOI 10.1002/aic.690430525
   BARNEA D, 1980, INT J MULTIPHAS FLOW, V6, P217, DOI 10.1016/0301-9322(80)90012-9
   BENDIKSEN KH, 1984, INT J MULTIPHAS FLOW, V10, P467, DOI 10.1016/0301-9322(84)90057-0
   Bertola V, 2003, EXP FLUIDS, V34, P122, DOI 10.1007/s00348-002-0543-3
   Bertola V, 2002, EXP FLUIDS, V32, P722, DOI 10.1007/s00348-002-0442-7
   Bertola V, 2002, AIAA J, V40, P1010, DOI 10.2514/2.1742
   Bertola V., 2001, 15 AIAA COMP FLUID D, P3035
   Cai JY, 1999, MULTIPHASE FLOW AND HEAT TRANSFER, P195
   de Gaspari C.A., 2007, 19 INT C MECH ENG NO
   de Oliveira WR, 2015, INT J MULTIPHAS FLOW, V69, P18, DOI 10.1016/j.ijmultiphaseflow.2014.10.014
   Deendarlianto, 2019, INT J HEAT MASS TRAN, V130, P187, DOI 10.1016/j.ijheatmasstransfer.2018.10.085
   Deendarlianto, 2016, J PETROL SCI ENG, V147, P779, DOI 10.1016/j.petrol.2016.09.019
   Dinaryanto O., 2018, AIP C P
   Dinaryanto O, 2017, EXP THERM FLUID SCI, V81, P93, DOI 10.1016/j.expthermflusci.2016.10.013
   Elperin T, 2002, EXP FLUIDS, V32, P674, DOI 10.1007/s00348-002-0415-x
   FABRE J, 1992, ANNU REV FLUID MECH, V24, P21, DOI 10.1146/annurev.fl.24.010192.000321
   Fetter C.P., 1988, THESIS
   Fossa M, 2003, FLOW MEAS INSTRUM, V14, P161, DOI 10.1016/S0955-5986(03)00021-9
   Gokcal B., 2010, SPE PROJ FACIL CONST, V5, P136, DOI DOI 10.2118/124057-PA
   Govan A.H., 1988, ATOMIC ENERGY RES ES
   GREGORY GA, 1969, AICHE J, V15, P933, DOI 10.1002/aic.690150623
   GRESKOVICH EJ, 1972, IND ENG CHEM PROC DD, V11, P317, DOI 10.1021/i260042a030
   Hanratty TJ, 2013, PHYSICS OF GAS-LIQUID FLOWS, P1, DOI 10.1017/CBO9781139649421
   HEYWOOD NI, 1979, CHEM ENG SCI, V34, P17, DOI 10.1016/0009-2509(79)85174-X
   Hill T., 1994, U TULS CENT PETR ENG
   Hill T.J., 1996, SPE ANN TECHN C EXH
   Hubbard M.G., 1965, THESIS
   Hudaya AZ, 2019, EXP THERM FLUID SCI, V103, P304, DOI 10.1016/j.expthermflusci.2019.01.021
   JEPSON WP, 1993, INT J MULTIPHAS FLOW, V19, P411, DOI 10.1016/0301-9322(93)90057-2
   Kadri U, 2014, OIL GAS SCI TECHNOL, V69, P331, DOI 10.2516/ogst/2012070
   Kadri U, 2009, INT J MULTIPHAS FLOW, V35, P439, DOI 10.1016/j.ijmultiphaseflow.2009.02.003
   Kesana NR, 2017, J NAT GAS SCI ENG, V46, P477, DOI 10.1016/j.jngse.2017.08.010
   Kong R, 2017, INT J MULTIPHAS FLOW, V94, P137, DOI 10.1016/j.ijmultiphaseflow.2017.04.020
   Kong R, 2017, NUCL ENG DES, V312, P266, DOI 10.1016/j.nucengdes.2016.06.016
   Lin MS, 2013, AIP CONF PROC, V1547, P253, DOI 10.1063/1.4816874
   LIN PY, 1987, INT J MULTIPHAS FLOW, V13, P549, DOI 10.1016/0301-9322(87)90021-8
   LIN PY, 1987, INT J MULTIPHAS FLOW, V13, P13, DOI 10.1016/0301-9322(87)90003-6
   Losi G, 2016, CHEM ENG SCI, V148, P190, DOI 10.1016/j.ces.2016.04.005
   Mandhane J. M., 1974, International Journal of Multiphase Flow, V1, P537, DOI 10.1016/0301-9322(74)90006-8
   Manolis IG, 1995, MULTIPHASE FLOW 1995, P347
   Miwa S, 2015, PROG NUCL ENERG, V78, P270, DOI 10.1016/j.pnucene.2014.10.003
   MOFFAT RJ, 1988, EXP THERM FLUID SCI, V1, P3, DOI 10.1016/0894-1777(88)90043-X
   Nydal O.J., 1991, THESIS
   NYDAL OJ, 1992, INT J MULTIPHAS FLOW, V18, P439, DOI 10.1016/0301-9322(92)90027-E
   Okezue C., 2013, WIT T ENG SCI, V79, P447
   Paglianti A, 1996, INT J MULTIPHAS FLOW, V22, P783, DOI 10.1016/0301-9322(96)00019-5
   Parsi M, 2017, INT J MULTIPHAS FLOW, V96, P1, DOI 10.1016/j.ijmultiphaseflow.2017.06.007
   Rahmandhika A, 2018, AIP CONF PROC, V2001, DOI 10.1063/1.5049975
   Schulkes R., 2011, 15 INT C MULT PROD T
   Shea R.H., 2004, P 4 N AM C MULT TECH, P227
   Silva F.S., 1997, EXP HEAT TRANSFER FL, P893
   TAITEL Y, 1977, INT J MULTIPHAS FLOW, V3, P585, DOI 10.1016/0301-9322(77)90031-3
   Thaker J, 2016, NUCL ENG DES, V310, P363, DOI 10.1016/j.nucengdes.2016.10.020
   Thaker J, 2016, J PETROL SCI ENG, V145, P298, DOI 10.1016/j.petrol.2016.05.006
   Thaker J, 2015, J PETROL SCI ENG, V135, P561, DOI 10.1016/j.petrol.2015.10.018
   TRONCONI E, 1990, AICHE J, V36, P701, DOI 10.1002/aic.690360507
   van Ommen JR, 2011, INT J MULTIPHAS FLOW, V37, P403, DOI 10.1016/j.ijmultiphaseflow.2010.12.007
   Vaze MJ, 2011, P I MECH ENG C-J MEC, V225, P382, DOI 10.1243/09544062JMES2033
   Vaze MJ, 2012, CAN J CHEM ENG, V90, P1295, DOI 10.1002/cjce.20626
   Vicencio F.E., 2015, ASME 2015 INT MECH E
   Villarreal J, 2006, CORROS SCI, V48, P2363, DOI 10.1016/j.corsci.2005.09.003
   Wang SF, 2003, INT J HEAT MASS TRAN, V46, P1519, DOI 10.1016/S0017-9310(02)00455-6
   Wang WW, 2019, CHEM ENG SCI, V193, P15, DOI 10.1016/j.ces.2018.08.058
   Wang X, 2007, INT J HEAT MASS TRAN, V50, P2439, DOI 10.1016/j.ijheatmasstransfer.2006.12.011
   WEISMAN J, 1979, INT J MULTIPHAS FLOW, V5, P437, DOI 10.1016/0301-9322(79)90031-4
   Wilkens RJ, 2008, J ENERG RESOUR-ASME, V130, DOI 10.1115/1.2824297
   Wood D.G., 1990, SPE ANN TECHN C EXH
   Wood M.H., 2013, 26331 EUR EUR COMM J
   Woods BD, 1999, INT J MULTIPHAS FLOW, V25, P1195, DOI 10.1016/S0301-9322(99)00058-0
   Woods BD, 2006, INT J MULTIPHAS FLOW, V32, P902, DOI 10.1016/j.ijmultiphaseflow.2006.02.020
   Wren E, 2005, EXP THERM FLUID SCI, V29, P893, DOI 10.1016/j.expthermflusci.2005.01.004
   Zabaras GJ, 2000, SPE J, V5, P252, DOI 10.2118/65093-PA
   Zhao Y., 2013, 16 INT C MULT PROT T
   Zhong XF, 2007, AIP CONF PROC, V914, P537, DOI 10.1063/1.2747477
NR 86
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115251
DI 10.1016/j.ces.2019.115251
PG 18
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300048
OA Bronze
DA 2020-05-12
ER

PT J
AU Atkinson, H
   Bara, JE
   Turner, CH
AF Atkinson, Henry
   Bara, Jason E.
   Turner, C. Heath
TI Molecular-level analysis of the wetting behavior of imidazolium-based
   ionic liquids on bismuth telluride surfaces
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Interface; Surface tension; Contact angle; Thermoelectric; Molecular
   dynamics; Solvation
ID BINARY-MIXTURES; DYNAMICS SIMULATIONS; WATER DROPLETS; FORCE-FIELD;
   TENSION; EXFOLIATION; BI2TE3; NANODROPLETS; WETTABILITY; DENSITY
AB Bismuth telluride is among the most studied thermoelectric materials. Its performance, which is among the highest around room temperature, is dependent on exfoliation to thin nanosheets. While previous research has examined the exfoliation mechanism by ionic liquids (ILs), this study provides more detailed information about the solid-liquid interface, including predicted values for IL contact angles (theta) on Bi2Te3. Molecular dynamics simulations are employed to compute theta and other properties of interest, including mass and charge ordering, adsorption energy, and electrostatic potential. All properties save the latter are strongly dependent on anion size and slightly dependent on cation size. The IL contact angles display a wide range of values, from 97.7 degrees for the smallest ions to 53.2 degrees for the largest ions. An analysis of the molecular-level interactions in these systems serves to explain this behavior, and they indicate that reduced cohesive interactions in bulkier liquids are primarily responsible. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Atkinson, Henry; Bara, Jason E.; Turner, C. Heath] Univ Alabama, Dept Chem & Biol Engn, Box 870203, Tuscaloosa, AL 35487 USA.
RP Turner, CH (reprint author), Univ Alabama, Dept Chem & Biol Engn, Box 870203, Tuscaloosa, AL 35487 USA.
EM hturner@eng.ua.edu
FU National Science FoundationNational Science Foundation (NSF)
   [CBET-1605411]
FX Financial support for this work was provided by the National Science
   Foundation (CBET-1605411).
CR Abedini A, 2016, LANGMUIR, V32, P9982, DOI 10.1021/acs.langmuir.6b02663
   Andrews JE, 2016, PHYS CHEM CHEM PHYS, V18, P23482, DOI 10.1039/c6cp01936f
   Angell CA, 2012, FARADAY DISCUSS, V154, P9, DOI 10.1039/c1fd00112d
   Bhushan B, 2011, PROG MATER SCI, V56, P1, DOI 10.1016/j.pmatsci.2010.04.003
   Bordes E, 2018, J CHEM PHYS, V148, DOI 10.1063/1.5010604
   Brutin D, 2018, CHEM SOC REV, V47, P558, DOI 10.1039/c6cs00902f
   Burt R, 2016, J PHYS CHEM C, V120, P15244, DOI 10.1021/acs.jpcc.6b04696
   Chen S, 2018, J PHYS CHEM C, V122, P4622, DOI 10.1021/acs.jpcc.7b10788
   Cione AM, 2009, J PHYS CHEM C, V113, P2384, DOI 10.1021/jp808098w
   De Coninck J, 2008, ANNU REV MATER RES, V38, P1, DOI 10.1146/annurev.matsci.38.060407.130339
   Delcheva I, 2015, ADV COLLOID INTERFAC, V222, P162, DOI 10.1016/j.cis.2014.07.003
   Ding ZF, 2009, J MATER CHEM, V19, P2588, DOI 10.1039/b820226e
   Dong DP, 2018, J CHEM PHYS, V148, DOI 10.1063/1.5016309
   FEUTELAIS Y, 1993, MATER RES BULL, V28, P591, DOI 10.1016/0025-5408(93)90055-I
   Gao LC, 2007, J AM CHEM SOC, V129, P3804, DOI 10.1021/ja070169d
   Ghalami F, 2019, J PHYS CHEM C, V123, P13551, DOI 10.1021/acs.jpcc.8b11987
   Goldsmid HJ, 2014, MATERIALS, V7, P2577, DOI 10.3390/ma7042577
   Guan YJ, 2017, J PHYS CHEM C, V121, P23716, DOI 10.1021/acs.jpcc.7b07474
   Han C, 2016, ADV ENERGY MATER, V6, DOI 10.1002/aenm.201600498
   Hung SW, 2018, J PHYS CHEM C, V122, P8423, DOI 10.1021/acs.jpcc.8b01344
   Jian SR, 2017, J APPL PHYS, V121, DOI 10.1063/1.4982911
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Klomfar J, 2018, J CHEM THERMODYN, V118, P225, DOI 10.1016/j.jct.2017.11.012
   Kowsari E, 2014, APPL SURF SCI, V289, P478, DOI 10.1016/j.apsusc.2013.11.017
   KULLMANN W, 1990, PHYS STATUS SOLIDI B, V162, P125, DOI 10.1002/pssb.2221620109
   Leroy F, 2016, J CHEM PHYS, V145, DOI 10.1063/1.4966215
   Li JF, 2010, NPG ASIA MATER, V2, P152, DOI 10.1038/asiamat.2010.138
   Li JF, 2017, SCI CHINA TECHNOL SC, V60, P1347, DOI 10.1007/s11431-017-9058-8
   Li Z, 2019, J CHEM THERMODYN, V132, P214, DOI 10.1016/j.jct.2018.12.036
   Liang YF, 2017, ACCOUNTS CHEM RES, V50, P1530, DOI 10.1021/acs.accounts.7b00049
   Liu FY, 2016, MACROMOLECULES, V49, P6106, DOI 10.1021/acs.macromol.6b01171
   Lopes JNC, 2004, J PHYS CHEM B, V108, P2038, DOI 10.1021/jp0362133
   Ludwig T, 2015, LANGMUIR, V31, P3644, DOI 10.1021/acs.langmuir.5b00239
   Lundgren M, 2002, LANGMUIR, V18, P10462, DOI 10.1021/la026191w
   Luzinov I, 2004, PROG POLYM SCI, V29, P635, DOI 10.1016/j.progpolymsci.2004.03.001
   Malali S, 2017, J PHYS CHEM C, V121, P11226, DOI 10.1021/acs.jpcc.6b12065
   Mamur H, 2018, RENEW SUST ENERG REV, V82, P4159, DOI 10.1016/j.rser.2017.10.112
   Martinez L, 2009, J COMPUT CHEM, V30, P2157, DOI 10.1002/jcc.21224
   Paneru M, 2010, J AM CHEM SOC, V132, P8301, DOI 10.1021/ja9106397
   Parobek D, 2015, 2D MATER, V2, DOI 10.1088/2053-1583/2/3/032001
   Plechkova NV, 2008, CHEM SOC REV, V37, P123, DOI 10.1039/b006677j
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Ren L, 2012, J MATER CHEM, V22, P4921, DOI 10.1039/c2jm15973b
   Shojaeian A, 2019, THERMOCHIM ACTA, V673, P119, DOI 10.1016/j.tca.2019.01.018
   Souckova M, 2017, FLUID PHASE EQUILIBR, V454, P43, DOI 10.1016/j.fluid.2017.08.022
   Tariq M, 2012, CHEM SOC REV, V41, P829, DOI 10.1039/c1cs15146k
   Teweldebrhan D, 2010, NANO LETT, V10, P1209, DOI 10.1021/nl903590b
   Thorat JB, 2018, MAT SCI SEMICON PROC, V79, P119, DOI 10.1016/j.mssp.2018.02.002
   VARGAFTIK NB, 1983, J PHYS CHEM REF DATA, V12, P817, DOI 10.1063/1.555688
   Vega C, 2011, PHYS CHEM CHEM PHYS, V13, P19663, DOI 10.1039/c1cp22168j
   Wandschneider A, 2008, J CHEM ENG DATA, V53, P596, DOI 10.1021/je700621d
   Werder T, 2003, J PHYS CHEM B, V107, P1345, DOI 10.1021/jp0268112
   Wilkes JS, 2002, GREEN CHEM, V4, P73, DOI 10.1039/b110838g
   Yang L, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201701797
   Zhang J, 2015, RSC ADV, V5, P52322, DOI 10.1039/c5ra09296e
   ZISMAN WA, 1964, ADV CHEM SER, V43, P1, DOI DOI 10.1021/BA-1964-0043.CH001
NR 58
TC 0
Z9 0
U1 13
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115270
DI 10.1016/j.ces.2019.115270
PG 9
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300041
OA Bronze
DA 2020-05-12
ER

PT J
AU Attalla, M
   Maghrabie, HM
AF Attalla, M.
   Maghrabie, Hussein M.
TI Investigation of effectiveness and pumping power of plate heat exchanger
   with rough surface
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Plate heat exchanger; Relative roughness; Effectiveness; Number of
   transfer units; Pumping power; Specific heat rate
ID PRESSURE-DROP; OPTIMAL-DESIGN; MINI-CHANNEL; FLUID-FLOW; PERFORMANCE;
   NANOFLUIDS; FRICTION
AB In the present paper, an experimental study of the effectiveness and pumping power of plate heat exchanger (PHE) with rough surface was performed. The experiments were developed for different values of relative roughness, Rr, of 2.6 * 10(-4) (smooth surface), 3.4 * 10(-4) , 7.5 * 10(-4) and 9.8 * 10(-4) for Reynolds number, Re, varied from 500 to 5000. The average heat transfer rate, Q(avg), hence the effectiveness of PHE, epsilon, and number of transfer units, NTU, as well as pressure drop, Delta p, consequently pumping power, P, and specfic heat rate, SHR, were estimated. The results show that Q(avg) and NTU are enhanced with increasing Rr; while, they are decreased with increasing Re. At Re = 5000, the effectiveness of PHE with relative roughness of 3.4 * 10(-4), 7.5 * 10(-)(4) and 9.8 * 10(-4) is greater than that of the smooth surface by 11.5%, 16.6% and 18.6%, respectively. Furthermore, Delta p and P are increased by increasing Rr and Re. Moreover, at Re = 500, SHR is enhanced with increasing Rr and its improvements compared with the smooth surface are 39.5%, 23.4% and 6.9% for Rr of 3.4 * 10(-4), 7.5 * 10(-)(4) and 9.8 * 10(-)(4), respectively. In addition, empirical correlations are proposed to estimate SHR as a function of Rr and Re with a standard deviation of 5.1%. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Attalla, M.; Maghrabie, Hussein M.] South Valley Univ, Fac Engn, Dept Mech Engn, Qena, Egypt.
RP Attalla, M (reprint author), South Valley Univ, Fac Engn, Dept Mech Engn, Qena, Egypt.
EM moha_attalla@yahoo.com
OI Maghrabie, Hussein/0000-0002-1016-1049
CR Abou Elmaaty TM, 2017, RENEW SUST ENERG REV, V70, P852, DOI 10.1016/j.rser.2016.11.266
   Abu-Khader MM, 2012, RENEW SUST ENERG REV, V16, P1883, DOI 10.1016/j.rser.2012.01.009
   Attalla M, 2016, EXP THERM FLUID SCI, V75, P199, DOI 10.1016/j.expthermflusci.2016.01.019
   Barzegarian R, 2016, EXP THERM FLUID SCI, V74, P11, DOI 10.1016/j.expthermflusci.2015.11.018
   BERGLES AE, 1988, J HEAT TRANS-T ASME, V110, P1082, DOI 10.1115/1.3250612
   Bergles AE, 2002, EXP THERM FLUID SCI, V26, P335, DOI 10.1016/S0894-1777(02)00145-0
   Bergles AE, 2001, CHEM ENG RES DES, V79, P437, DOI 10.1205/026387601750282562
   Bergles AE, 2011, HEAT MASS TRANSFER, V47, P1001, DOI 10.1007/s00231-011-0872-y
   Bhutta MMA, 2012, APPL THERM ENG, V32, P1, DOI 10.1016/j.applthermaleng.2011.09.001
   Brackbill TP, 2007, ICNMM2007: PROCEEDINGS OF THE 5TH INTERNATIONAL CONFERENCE ON NANOCHANNELS, MICROCHANNELS, AND MINICHANNELS, P509
   Cengel YA, 2015, HEAT MASS TRANSFER F
   Champagne PR, 2001, J ENHANC HEAT TRANSF, V8, P341, DOI 10.1615/JEnhHeatTransf.v8.i5.50
   Dai BM, 2014, APPL THERM ENG, V67, P283, DOI 10.1016/j.applthermaleng.2014.03.028
   Dixit T, 2015, RENEW SUST ENERG REV, V41, P1298, DOI 10.1016/j.rser.2014.09.024
   Faizal M, 2012, EXP THERM FLUID SCI, V36, P242, DOI 10.1016/j.expthermflusci.2011.09.019
   Fernandez-Seara J, 2007, APPL THERM ENG, V27, P2745, DOI 10.1016/j.applthermaleng.2007.04.004
   Ghajar A.J., 2008, P 6 INT ASME C NAN M, P1
   Ghajar AJ, 2010, HEAT TRANSFER ENG, V31, P646, DOI 10.1080/01457630903466613
   Guo L, 2015, APPL THERM ENG, V84, P399, DOI 10.1016/j.applthermaleng.2015.04.001
   Ham J, 2016, APPL THERM ENG, V108, P1020, DOI 10.1016/j.applthermaleng.2016.07.196
   Hesselgreaves J.E., 2001, COMPACT HEAT EXCHANG
   Huang D, 2016, EXP THERM FLUID SCI, V72, P190, DOI 10.1016/j.expthermflusci.2015.11.009
   Huang D, 2015, INT J HEAT MASS TRAN, V89, P620, DOI 10.1016/j.ijheatmasstransfer.2015.05.082
   Kakac S., 1988, 2 PHASE FLOW HEAT EX
   Kanaris AG, 2009, INT J THERM SCI, V48, P1184, DOI 10.1016/j.ijthermalsci.2008.11.001
   Kandlikar S. G., 2005, Bulletin of the Polish Academy of Sciences, Technical Sciences, V53, P343
   Kandlikar SG, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1896985
   Kline SJ, 1953, MECH ENG, V75, P3, DOI DOI 10.1016/J.CHAOS.2005.11.046
   Kumar V, 2016, ENERGY, V114, P1107, DOI 10.1016/j.energy.2016.08.091
   Kwon OK, 2009, TRANS KOREAN SOC MEC, V33, P520, DOI 10.3795/KSME-B.2009.33.7.520
   Liu YP, 2015, INT J HEAT MASS TRAN, V83, P11, DOI 10.1016/j.ijheatmasstransfer.2014.11.060
   Luan HB, 2017, NUMER HEAT TR A-APPL, V71, P250, DOI 10.1080/10407782.2016.1264761
   Muley A, 1999, J HEAT TRANS-T ASME, V121, P110, DOI 10.1115/1.2825923
   Najafi H, 2010, HEAT MASS TRANSFER, V46, P639, DOI 10.1007/s00231-010-0612-8
   Naphon P, 2009, INT COMMUN HEAT MASS, V36, P39, DOI 10.1016/j.icheatmasstransfer.2008.09.001
   Nilpueng K, 2015, EXP THERM FLUID SCI, V68, P268, DOI 10.1016/j.expthermflusci.2015.04.009
   Pelevic N, 2016, INT J THERM SCI, V99, P125, DOI 10.1016/j.ijthermalsci.2015.08.012
   Salman W.T., 2016, INT J RES ENG TECHNO, V5, P56
   Shah RK, 2003, FUNDAMENTALS HEAT EX
   Stasiek J, 1996, INT J HEAT MASS TRAN, V39, P149, DOI 10.1016/S0017-9310(96)85013-7
   Steinke M. E., 2004, HEAT TECHNOL, V22, P3
   Tamakuwala H., 2016, P ASME 2016 HEAT TRA, P1
   Dang T, 2011, HEAT MASS TRANSFER, V47, P1311, DOI 10.1007/s00231-011-0793-9
   Wang LK, 2003, APPL THERM ENG, V23, P295, DOI 10.1016/S1359-4311(02)00195-3
   Webb RL, 2006, PRINCIPLES ENHANCED
NR 45
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115277
DI 10.1016/j.ces.2019.115277
PG 11
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300032
OA Bronze
DA 2020-05-12
ER

PT J
AU Bahramian, A
   Elyasi, S
AF Bahramian, Azadeh
   Elyasi, Siamak
TI One-dimensional drift-flux model and a new approach to calculate drift
   velocity and gas holdup in bubble columns
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multiphase flow; Bubbly flow; Gas holdup; Distribution parameter; Drift
   velocity
ID FLOW REGIME TRANSITION; WATER 2-PHASE FLOW; RISE VELOCITY; LIQUID FLOW;
   DISTRIBUTION PARAMETER; INTERFACIAL AREA; WASTE-WATER; PREDICTION;
   DYNAMICS; REACTOR
AB In view of the practical importance of the drift-flux model and the variety of industrial applications of large-diameter columns, the model coefficients, including the distribution parameter (C-0) and drift velocity (C-1), have been investigated for the upward two-phase flow in large- and small-diameter columns. The distribution parameter and drift velocity reflect the non-uniformity in the flow and the local relative motion between two phases, respectively. As the formation of cap bubbles and occurrence of liquid recirculation are two of the most important characteristics in a large-diameter column, the distribution parameter and drift velocity in such a column are rather different from those in a small-diameter column. In this study, the local flow parameters measured by other researchers were collected, and C-0 and C-1 were calculated based on their definitions. The experimental values in small- and large-diameter columns were compared, and the performances of various existing constitutive equations for the drift-flux model were re-evaluated. Two semi-empirical correlations for the drift velocity and gas holdup were developed, and their performances were verified against experimental data for various two-phase flow conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bahramian, Azadeh; Elyasi, Siamak] Lakehead Univ, Dept Chem Engn, Thunder Bay, ON, Canada.
RP Bahramian, A (reprint author), Lakehead Univ, Dept Chem Engn, Thunder Bay, ON, Canada.
EM abahrami@lakeheadu.ca
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada
FX We gratefully acknowledge the financial support of the Natural Sciences
   and Engineering Research Council of Canada (NSERC).
CR Abdulkadir M., 2010, WORLD ACAD SCI ENG T, V4, P18
   ACHARYA A, 1978, AICHE J, V24, P348, DOI 10.1002/aic.690240227
   AKITA K, 1974, IND ENG CHEM PROC DD, V13, P84, DOI 10.1021/i260049a016
   Besagni G, 2017, CHEM ENG SCI, V170, P270, DOI 10.1016/j.ces.2017.03.043
   Bhagwat SM, 2014, INT J MULTIPHAS FLOW, V59, P186, DOI 10.1016/j.ijmultiphaseflow.2013.11.001
   Brooks CS, 2014, PROG NUCL ENERG, V70, P209, DOI 10.1016/j.pnucene.2013.10.006
   Cheng H, 1998, INT J MULTIPHAS FLOW, V24, P431, DOI 10.1016/S0301-9322(97)00067-0
   CLARK N, 1986, INT J MULTIPHAS FLOW, V12, P299, DOI 10.1016/0301-9322(86)90032-7
   CLARK NN, 1985, AICHE J, V31, P500, DOI 10.1002/aic.690310323
   Clift R., 1978, BUBBLES DROPS PARTIC
   DAS SK, 1992, CAN J CHEM ENG, V70, P431, DOI 10.1002/cjce.5450700304
   Davidson J., 1960, T I CHEM ENG-LOND, V38, P144, DOI DOI 10.1016/S0263-8762(97)80008-1
   DAVIDSON JF, 1966, CHEM ENG SCI, V21, P731, DOI 10.1016/0009-2509(66)87001-X
   DAVIES RM, 1950, PROC R SOC LON SER-A, V200, P375, DOI 10.1098/rspa.1950.0023
   De Sousa LG, 2018, J SOLID STATE ELECTR, V22, P1349, DOI 10.1007/s10008-017-3812-z
   Debellefontaine H, 1999, CHEM ENG SCI, V54, P4953, DOI 10.1016/S0009-2509(99)00217-1
   Doig SD, 2005, BIOTECHNOL PROGR, V21, P1175, DOI 10.1021/bp050064j
   Dumitrescu DT, 1943, Z ANGEW MATH MECH, V23, P139, DOI 10.1002/zamm.19430230303
   Esmaeili A, 2015, CHEM ENG SCI, V129, P193, DOI 10.1016/j.ces.2015.01.071
   Eversole WG, 1941, IND ENG CHEM, V33, P1459, DOI 10.1021/ie50383a032
   Haberman W.L., 1956, T AM SOC CIVIL ENG, V121, P227
   Hibiki T, 2003, INT J HEAT MASS TRAN, V46, P1773, DOI 10.1016/S0017-9310(02)00473-8
   Hibiki T, 2000, NUCL ENG DES, V195, P69, DOI 10.1016/S0029-5493(99)00176-4
   Hibiki T, 2002, INT J HEAT MASS TRAN, V45, P707, DOI 10.1016/S0017-9310(01)00195-8
   Hibiki T, 1999, INT J HEAT MASS TRAN, V42, P3019, DOI 10.1016/S0017-9310(99)00014-9
   Hills J. H., 1976, CHEM ENG J, V12, P89
   HUGHES RR, 1955, CHEM ENG PROG, V51, P557
   Ishii M., 1977, ONE DIMENSIONAL DRIF
   JAMIALAHMADI M, 1994, CHEM ENG RES DES, V72, P119
   Jamialahmadi M, 2000, CHEM ENG TECHNOL, V23, P919, DOI 10.1002/1521-4125(200010)23:10<919::AID-CEAT919>3.0.CO;2-R
   Joshi J.B., 1998, P INDIAN NATL SCI A, V64, P441
   JOSHI JB, 1990, CAN J CHEM ENG, V68, P705, DOI 10.1002/cjce.5450680501
   Kantarci N, 2005, PROCESS BIOCHEM, V40, P2263, DOI 10.1016/j.procbio.2004.10.004
   KATAOKA I, 1987, INT J HEAT MASS TRAN, V30, P1927
   KAWANISHI K, 1990, NUCL ENG DES, V120, P447, DOI 10.1016/0029-5493(90)90394-D
   KAWASE Y, 1987, IND ENG CHEM RES, V26, P933, DOI 10.1021/ie00065a014
   Kim JY, 2017, J IND ENG CHEM, V56, P450, DOI 10.1016/j.jiec.2017.07.043
   Krishna R, 1999, CHEM ENG SCI, V54, P171, DOI 10.1016/S0009-2509(98)00245-0
   Krishna R, 1996, AICHE J, V42, P2627, DOI 10.1002/aic.690420923
   KUMAR R, 1970, ADV CHEM ENG, V8
   LAPIDUS L, 1957, AICHE J, V3, P63, DOI 10.1002/aic.690030112
   LEHRER HG, 1976, J CHEM ENG JPN, V9, P237
   Liu T.J, 1989, THESIS
   Lubbert A, 1996, BIOTECHNOL BIOENG, V52, P248, DOI 10.1002/(SICI)1097-0290(19961020)52:2<248::AID-BIT6>3.0.CO;2-Q
   Maretto C, 2001, CATAL TODAY, V66, P241, DOI 10.1016/S0920-5861(00)00626-X
   MARRUCCI G, 1965, IND ENG CHEM FUND, V4, P224, DOI 10.1021/i160014a022
   MENDELSON HD, 1967, AICHE J, V13, P250, DOI 10.1002/aic.690130213
   Mishima K, 1996, INT J MULTIPHAS FLOW, V22, P703, DOI 10.1016/0301-9322(96)00010-9
   Nedeltchev S, 2008, J CHEM ENG JPN, V41, P744, DOI 10.1252/jcej.08we005
   NICKENS HV, 1987, INT J MULTIPHAS FLOW, V13, P57, DOI 10.1016/0301-9322(87)90007-3
   Ohnuki A, 2000, INT J MULTIPHAS FLOW, V26, P367, DOI 10.1016/S0301-9322(99)00024-5
   PEEBLES FN, 1953, CHEM ENG PROG, V49, P88
   REILLY IG, 1994, CAN J CHEM ENG, V72, P3, DOI 10.1002/cjce.5450720102
   RICHARDSON JF, 1954, T I CHEM ENG-LOND, V32, P35, DOI DOI 10.1016/S0263-8762(97)80006-8
   Rodrigue D, 2001, AICHE J, V47, P39, DOI 10.1002/aic.690470106
   Rollbusch P, 2015, INT J MULTIPHAS FLOW, V75, P88, DOI 10.1016/j.ijmultiphaseflow.2015.05.009
   Schlegel JP, 2013, NUCL ENG DES, V263, P138, DOI 10.1016/j.nucengdes.2013.04.008
   Schlegel JP, 2012, EXP THERM FLUID SCI, V41, P12, DOI 10.1016/j.expthermflusci.2012.01.034
   Schlegel JP, 2009, NUCL ENG DES, V239, P2864, DOI 10.1016/j.nucengdes.2009.08.004
   Schlegel J, 2010, PROG NUCL ENERG, V52, P666, DOI 10.1016/j.pnucene.2010.03.007
   Serizawa A, 1991, MULTIPHASE SCI TECHN, V6, P275
   Shaikh A, 2007, INT J CHEM REACT ENG, V5, DOI 10.2202/1542-6580.1368
   Shawkat ME, 2008, INT J MULTIPHAS FLOW, V34, P767, DOI 10.1016/j.ijmultiphaseflow.2008.01.007
   Shen X., 2014, FRONTIERS PROGR MULT, VI, P55
   Shen XZ, 2010, NUCL ENG DES, V240, P3991, DOI 10.1016/j.nucengdes.2010.01.004
   SHIPLEY DG, 1984, CHEM ENG SCI, V39, P163, DOI 10.1016/0009-2509(84)80143-8
   Singh BK, 2017, CHEM ENG SCI, V158, P124, DOI 10.1016/j.ces.2016.10.006
   Smith JS, 1996, IND ENG CHEM RES, V35, P1688, DOI 10.1021/ie9503656
   Stokes G. G., 1851, T CAMBRIDGE PHILOS S, V9, P8, DOI DOI 10.1017/CBO9780511702266.002
   TSUGE H, 1986, J CHEM ENG JPN, V19, P326, DOI 10.1252/jcej.19.326
   WALLIS GB, 1969, ONE DIMENSIONAL 2 PH
   WILKINSON PM, 1994, CHEM ENG SCI, V49, P1417, DOI 10.1016/0009-2509(93)E0022-5
   WILKINSON PM, 1992, AICHE J, V38, P544, DOI 10.1002/aic.690380408
   Woldesemayat MA, 2007, INT J MULTIPHAS FLOW, V33, P347, DOI 10.1016/j.ijmultiphaseflow.2006.09.004
   Woo KJ, 2010, FUEL PROCESS TECHNOL, V91, P434, DOI 10.1016/j.fuproc.2009.04.021
   Xing CT, 2013, CHEM ENG SCI, V95, P313, DOI 10.1016/j.ces.2013.03.022
   Yang GQ, 2003, AICHE J, V49, P1995, DOI 10.1002/aic.690490810
   Zhang JP, 1997, CHEM ENG SCI, V52, P3979, DOI 10.1016/S0009-2509(97)00241-8
   ZUBER N, 1965, J HEAT TRANSF, V87, P453, DOI 10.1115/1.3689137
NR 79
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115302
DI 10.1016/j.ces.2019.115302
PG 15
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300047
OA Bronze
DA 2020-05-12
ER

PT J
AU Bornhorst, M
   Kuntz, C
   Tischer, S
   Deutschmann, O
AF Boernhorst, M.
   Kuntz, C.
   Tischer, S.
   Deutschmann, O.
TI Urea derived deposits in diesel exhaust gas after-treatment: Integration
   of urea decomposition kinetics into a CFD simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Urea decomposition; Deposit formation; CFD; Kinetics
ID SELECTIVE CATALYTIC-REDUCTION; WATER-SOLUTION; MODEL; IMPINGEMENT;
   EVAPORATION; HYDROLYSIS; PYROLYSIS; INJECTION; DROPLET; IMPACT
AB Formation of solid urea by-products in mixing sections of SCR systems is a well-known problem in development and design of exhaust gas after treatment systems. Spray impingement induces liquid film formation on mixer blades and tailpipe walls, from which urea by-products can be derived in dependence on temperature and residence time. This work presents a comprehensive modeling approach for prediction of by-product formation. An existing kinetic model for urea decomposition is integrated into CFD simulations by user coding. Implementation is evaluated by 3D simulations of thermogravimetric decomposition of urea and its by-products. Results are compared to experimental data and simulation results from a OD model. Furthermore, the procedure is applied to simulations of a flow setup including urea injection for demonstration of the model capabilities. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Boernhorst, M.; Kuntz, C.; Tischer, S.; Deutschmann, O.] KIT, Kaiserstr 12, D-76128 Karlsruhe, Germany.
   [Boernhorst, M.; Kuntz, C.; Tischer, S.] KIT, Inst Chem Technol & Polymer Chem, Karlsruhe, Germany.
   [Boernhorst, M.; Kuntz, C.; Tischer, S.] KIT, Inst Catalysis Res & Technol, Karlsruhe, Germany.
RP Deutschmann, O (reprint author), KIT, Inst Chem Technol & Polymer Chem, Karlsruhe, Germany.; Deutschmann, O (reprint author), KIT, Inst Catalysis Res & Technol, Karlsruhe, Germany.
RI Tischer, Steffen/P-7417-2018
OI Tischer, Steffen/0000-0002-9272-5556
FU Ministry of Science, Research and Art and the universities of the state
   of Baden-Wurttemberg; Ministry of Science, Research and Art
   Baden-Wurttemberg; German Research Foundation (Deutsche
   Forschungsgemeinschaft, DFG)German Research Foundation (DFG); Research
   Association for Combustion Engines eV (Forschungsvereinigung
   Verbrennungskraftmaschinen e.V., FVV); German Federation of Industrial
   Research Associations (Arbeitsgemeinschaft industrieller
   Forschungsvereinigungen, AiF); FVV [6012623]
FX All presented computations were performed on the bwUniCluster supported
   by the Ministry of Science, Research and Art and the universities of the
   state of Baden-Wurttemberg and on the high performance computer ForHLR1
   supported by the Ministry of Science, Research and Art Baden-Wurttemberg
   and the German Research Foundation (Deutsche Forschungsgemeinschaft,
   DFG).; The authors kindly acknowledge financial support by the Research
   Association for Combustion Engines eV (Forschungsvereinigung
   Verbrennungskraftmaschinen e.V., FVV) and the German Federation of
   Industrial Research Associations (Arbeitsgemeinschaft industrieller
   Forschungsvereinigungen, AiF). We would like to sincerely thank Thomas
   Lauer (TU Vienna) for fruitful discussions and cooperation in our joint
   project (FVV 6012623) and for inviting M. B. to a valuable research stay
   in his group.
CR Abu-Ramadan E., 2012, 2012011301 SAE, DOI [10.4271/2012-01-1301, DOI 10.4271/2012-01-1301]
   Bai C., 1996, 960626 SAE, DOI [10.4271/960626, DOI 10.4271/960626]
   Bernhard AM, 2012, APPL CATAL B-ENVIRON, V115, P129, DOI 10.1016/j.apcatb.2011.12.013
   Birkhold F., 2006, 2006010643 SAE, DOI [10.4271/2006-01-0643, DOI 10.4271/2006-01-0643]
   Birkhold F, 2007, APPL CATAL B-ENVIRON, V70, P119, DOI 10.1016/j.apcatb.2005.12.035
   Bornhorst M, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.09.016
   Bornhorst M, 2018, INT J HEAT FLUID FL, V69, P55, DOI 10.1016/j.ijheatfluidflow.2017.10.007
   Brack W., 2016, EMIRS CONTROL SCI TE, V2, P115, DOI DOI 10.1007/s40825-016-0042-2
   Brack W, 2014, CHEM ENG SCI, V106, P1, DOI 10.1016/j.ces.2013.11.013
   Budziankou U., 2017, SAE INT J FUELS LUBR, DOI [10.4271/2017-01-0971, DOI 10.4271/2017-01-0971]
   DEUFLHARD P, 1987, NUMER MATH, V51, P501, DOI 10.1007/BF01400352
   Deutschmann O, 2018, DETCHEM SOFTWARE PAC
   DUKOWICZ JK, 1980, J COMPUT PHYS, V35, P229, DOI 10.1016/0021-9991(80)90087-X
   Eakle S., 2016, 2016010989 SAE, DOI [10.4271/2016-01-0989, DOI 10.4271/2016-01-0989]
   Ebrahimian V, 2012, AICHE J, V58, P1998, DOI 10.1002/aic.12736
   Eichelbaum M, 2010, APPL CATAL B-ENVIRON, V97, P90, DOI 10.1016/j.apcatb.2010.03.027
   Fischer S, 2012, THESIS
   Fischer S, 2012, SAE INT J ENGINES, V5, P1443, DOI 10.4271/2012-01-1291
   Grout S, 2013, FUEL, V106, P166, DOI 10.1016/j.fuel.2012.09.022
   Habchi C, 2010, OIL GAS SCI TECHNOL, V65, P331, DOI 10.2516/ogst/2009062
   Habchi C., 2018, J MAT SCI NANOTECHNO, V6, DOI [10.15744/2348-9812.6.104, DOI 10.15744/2348-9812.6.104]
   Habchi C., 2019, 2019010992 SAE, DOI [10.4271/2019-01-0992, DOI 10.4271/2019-01-0992]
   Huthwelker T, 1996, J CHEM PHYS, V105, P1661, DOI 10.1063/1.472025
   Incropera F.P., 2013, FUNDAMENTALS HEAT MA
   Kim J.Y., 2004, P ICEF04 2004 FALL T
   Kontin S., 2010, 23 ANN C LIQ AT SPAR
   Kuhnke D., 2004, THESIS
   Liao YJ, 2017, APPL ENERG, V205, P964, DOI 10.1016/j.apenergy.2017.08.088
   Lin W, 2016, AICHE J, V62, P880, DOI 10.1002/aic.15078
   Lucefin Group, 2001, TECHN CARD X5CRNI18
   Lundstrom A, 2009, CHEM ENG J, V150, P544, DOI 10.1016/j.cej.2009.03.044
   Michelin J, 2015, 2015011020 SAE, DOI [10.4271/2015-01-1020, DOI 10.4271/2015-01-1020]
   Munnannur A., 2010, 2010010889 SAE, DOI [10.4271/2010-01-0889, DOI 10.4271/2010-01-0889]
   Musa S.N.A., 2006, 10 INT C LIQ AT SPAR
   Nayak N.S., 2013, 2013240162 SAE, DOI [10.4271/2013-24-0162, DOI 10.4271/2013-24-0162]
   Nishad K, 2018, ENERGIES, V11, DOI 10.3390/en11010222
   Postrioti L, 2015, FUEL, V150, P548, DOI 10.1016/j.fuel.2015.02.067
   Prabhu SS, 2017, APPL THERM ENG, V111, P1211, DOI 10.1016/j.applthermaleng.2016.09.134
   Rohsenow W.M., 1952, T ASME, V74, P969
   Schaber PA, 2004, THERMOCHIM ACTA, V424, P131, DOI 10.1016/j.tca.2004.05.018
   Shu-zhan Bai, 2014, Advanced Materials Research, V937, P74, DOI 10.4028/www.scientific.net/AMR.937.74
   Siemens 2018. Siemens Product Lifecycle Management Software Inc, 2018, STEV PORT SEL CAT RE
   Smith H., 2015, 2015011054 SAE, DOI [10.4271/2015-01-1054, DOI 10.4271/2015-01-1054]
   Smith Harriet M. J., 2016, THESIS
   Smith H, 2014, SAE INT J FUELS LUBR, V7, P525, DOI 10.4271/2014-01-1563
   Stein M., 2017, J EMISS CONTROL SCI, V3, P263, DOI [10.1007/s40825-017-0075-1, DOI 10.1007/S40825-017-0075-1]
   Strots V, 2009, SAE INT J FUELS LUBR, V2, P283, DOI 10.4271/2009-01-2780
   Sun Y, 2018, INTL CONF POWER SYST, P185, DOI 10.1109/POWERCON.2018.8601799
   Tischer S, 2019, PHYS CHEM CHEM PHYS, V21, P16785, DOI 10.1039/c9cp01529a
   Varna A, 2015, APPL ENERG, V157, P824, DOI 10.1016/j.apenergy.2015.03.015
   Wang TJ, 2009, AICHE J, V55, P3267, DOI 10.1002/aic.11939
   Weeks CL, 2015, SAE INT J ENGINES, V8, P1219, DOI 10.4271/2015-01-1037
   Wruck N, 1998, THESIS
   Wurzenberger J.C., 2005, 2005010948 SAE, DOI [10.4271/2005-01-0948, DOI 10.4271/2005-01-0948]
NR 54
TC 0
Z9 0
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115319
DI 10.1016/j.ces.2019.115319
PG 15
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300059
OA Bronze
DA 2020-05-12
ER

PT J
AU Branco, D
   Yablonsky, GS
   Marin, GB
   Constales, D
AF Branco, D.
   Yablonsky, G. S.
   Marin, G. B.
   Constales, D.
TI Invariant expressions for linear complex mechanisms: Generalization for
   polar two-step sub-mechanisms
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Conservatively Perturbed Equilibrium; Invariant expression; Two-step
   mechanism; Polar two-step sub-mechanism; Linear complex mechanism;
   Single-step substance
ID CHEMICAL-KINETICS INTERSECTIONS; THERMODYNAMIC TIME-INVARIANCES;
   COINCIDENCES; EVENTS
AB We generalize the results on invariances found for linear two-step mechanism within our approach to joint kinetics. It is demonstrated that similar invariances can be formulated for complex linear mechanisms if within these mechanisms there is a specific sub-mechanism, i.e. a so-called polar two step sub mechanism involving A reversible arrow B reversible arrow C where B can be part of a linear sub-mechanism not otherwise involving the poles A and C. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Branco, D.] VITO Flemish Inst Technol Res, Dept Separat & Convers Technol, Boeretang 200, B-2400 Mol, Belgium.
   [Yablonsky, G. S.] Washington Univ, McKelvey Sch Engn, Dept Energy Environm & Chem Engn, 1 Brookings Dr, St Louis, MO 63130 USA.
   [Marin, G. B.] Univ Ghent, Lab Chem Technol, Technol Pk 125, B-9052 Ghent, Belgium.
   [Constales, D.] Univ Ghent, Dept Elect & Informat Syst ELIS, Bldg S-8,Krijgslaan 281, B-9000 Ghent, Belgium.
RP Branco, D (reprint author), VITO Flemish Inst Technol Res, Dept Separat & Convers Technol, Boeretang 200, B-2400 Mol, Belgium.
EM Daniel.BrancoPinto@vito.be
CR Branco D, 2016, COMPUT CHEM ENG, V125, P606
   Branco PD, 2017, CHEM ENG SCI, V158, P370, DOI 10.1016/j.ces.2016.10.032
   Branco PD, 2018, CHEM ENG SCI, V184, P25, DOI 10.1016/j.ces.2018.02.020
   Branco PD, 2018, CHEM ENG SCI, V178, P183, DOI 10.1016/j.ces.2017.12.018
   Constales D, 2012, CHEM ENG SCI, V73, P20, DOI 10.1016/j.ces.2012.01.017
   Constales D, 2011, CHEM ENG SCI, V66, P4683, DOI 10.1016/j.ces.2011.06.033
   Constales D, 2019, ADV DATA ANAL MODELL
   Constales D, 2015, CHEM ENG SCI, V123, P328, DOI 10.1016/j.ces.2014.11.030
   DOERING FJ, 1987, J MOL CATAL, V41, P313, DOI 10.1016/0304-5102(87)80109-8
   Eliel E. L., 1994, STEREOCHEMISTRY ORGA
   GUTHRIE JP, 1984, CAN J CHEM, V62, P1441, DOI 10.1139/v84-243
   Hankins MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173786
   KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010
   Marin G.B., 2019, KINETICS CHEM REACTI
   Peng BX, 2018, CHEM ENG SCI, V191, P262, DOI 10.1016/j.ces.2018.06.065
   Pinto DB, 2015, ENTROPY-SWITZ, V17, P6783, DOI 10.3390/e17106783
   Song-Lin Zhang, 2016, ORG BIOMOL CHEM, V14, P7282
   Wade L. G., 2013, ORGANIC CHEM
   WEI J, 1962, ADV CATAL, V13, P203, DOI 10.1016/S0360-0564(08)60289-8
   Yablonskii G, 1991, COMPREHENSIVE CHEM K, V32
   Yablonsky GS, 2015, ADV CHEM PHYS, V157, P69
   Yablonsky GS, 2011, EPL-EUROPHYS LETT, V93, DOI 10.1209/0295-5075/93/20004
   Yablonsky GS, 2011, CHEM ENG SCI, V66, P111, DOI 10.1016/j.ces.2010.10.014
   Yablonsky GS, 2010, CHEM ENG SCI, V65, P6065, DOI 10.1016/j.ces.2010.04.007
   Yablonsky GS, 2019, CHEM ENG SCI, V205, P165, DOI 10.1016/j.ces.2019.04.048
   Yablonsky GS, 2019, CHEM ENG SCI, V196, P384, DOI 10.1016/j.ces.2018.11.010
NR 26
TC 1
Z9 1
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115291
DI 10.1016/j.ces.2019.115291
PG 8
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300031
OA Bronze
DA 2020-05-12
ER

PT J
AU Brito, MSCA
   Dias, MM
   Santos, RJ
   Lopes, JCB
   Fonte, CP
AF Brito, M. S. C. A.
   Dias, M. M.
   Santos, R. J.
   Lopes, J. C. B.
   Fonte, C. P.
TI Fully resolved modelling and simulation of micromixing in confined
   impinging jets
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mixing; Chemical reactor; Micromixing test reactions; Confined impinging
   jets; Lamellar model; Computational fluid dynamics
ID FLOW-FIELD; SCALE-UP; DEFLECTING OSCILLATION; NUMERICAL EXAMINATION;
   STRIATION THICKNESS; LAMELLAR MODEL; T-MIXER; RIM; PRECIPITATION;
   LAMINAR
AB Confined Impinging Jets (CIJs) are fast mixing meso sized devices for fast reaction applications, where two opposed jets contact the reactants that are mixed by chaotic flow patterns in very short times. Fully resolved CFD chemical reaction in CIJs is out of reach for engineering practice since on the order of 10(11) computational cells would be required. This paper presents a theoretical methodology to describe micromixing in CIJs using a lamellar model that considers the dynamics of striation thinning and diffusion at the interface of the mixing fluids. A lamellar micromixing (LM) model based on mixing evolution functions was applied to simulate chemical reactions. The evolution of mixing scales in CIJs was also studied from fully-resolved CFD simulations that validate the mixing scales predicted from theoretical models. This LM model completely describes the experimental results, and it is thus directly applicable to the design of CIJs technology for chemical processes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Brito, M. S. C. A.; Dias, M. M.; Santos, R. J.; Lopes, J. C. B.] Univ Porto, Fac Engn, LSRE, LCM, Rua Dr Roberto Frias, P-4200465 Porto, Portugal.
   [Fonte, C. P.] Univ Manchester, Dept Chem Engn & Analyt Sci, Oxford Rd, Manchester M13 9PL, Lancs, England.
RP Fonte, CP (reprint author), Univ Manchester, Dept Chem Engn & Analyt Sci, Oxford Rd, Manchester M13 9PL, Lancs, England.
EM claudio.fonte@manchester.ac.uk
RI Lopes, Jose Carlos B/B-6880-2013; Santos, Ricardo J/B-3450-2013
OI Lopes, Jose Carlos B/0000-0001-6127-6340; Santos, Ricardo
   J/0000-0002-9133-2187; Abrunhosa de Brito,
   Margarida/0000-0003-1134-1743; Fonte, Claudio/0000-0001-9714-0779
FU Associate Laboratory LSRE-LCM - FCT/MCTES (PIDDAC) [UID/EQU/50020/2019];
   European Regional Development Fund (ERDF) -Programa Operacional
   Competitividade e Internacionalizacao (POCI)European Union (EU)
   [POCI-01-0145-FEDER-016851, POCI-01-0145-FEDER-030445]; FCT - Fundacao
   para a Ciencia e a Tecnologia I.P.; FCTPortuguese Foundation for Science
   and Technology [PD/BD/135060/2017]
FX This work was financially supported by: Associate Laboratory LSRE-LCM
   UID/EQU/50020/2019 - funded by national funds through FCT/MCTES (PIDDAC)
   and by POCI-01-0145-FEDER-016851 and POCI-01-0145-FEDER-030445 - funded
   by European Regional Development Fund (ERDF) -Programa Operacional
   Competitividade e Internacionalizacao (POCI) -and by national funds
   through FCT - Fundacao para a Ciencia e a Tecnologia I.P.; M.S.C. A.
   Brito acknowledges her FCT scholarship PD/BD/135060/2017.
CR Andreussi T, 2015, COMPUT CHEM ENG, V76, P150, DOI 10.1016/j.compchemeng.2015.02.017
   Sultan MA, 2012, CHEM ENG SCI, V73, P388, DOI 10.1016/j.ces.2012.02.010
   BALDYGA J, 1983, POLYM ENG SCI, V23, P556, DOI 10.1002/pen.760231005
   BALDYGA J, 1999, TURBULENT MIXING CHE
   Bothe D, 2006, CHEM ENG SCI, V61, P2950, DOI 10.1016/j.ces.2005.10.060
   Bothe D, 2008, COMPUT CHEM ENG, V32, P108, DOI 10.1016/j.compchemeng.2007.08.001
   Bothe D, 2011, CHEM ENG SCI, V66, P6424, DOI 10.1016/j.ces.2011.08.045
   Bothe D, 2010, AICHE J, V56, P1406, DOI 10.1002/aic.12067
   BOURNE JR, 1990, IND ENG CHEM RES, V29, P1761, DOI 10.1021/ie00105a004
   BOURNE JR, 1985, CHEM ENG COMMUN, V37, P293, DOI 10.1080/00986448508911287
   Delgado JMPQ, 2001, TRANSPORT POROUS MED, V44, P165, DOI 10.1023/A:1010769402206
   Dreher S, 2009, HEAT TRANSFER ENG, V30, P91, DOI 10.1080/01457630802293480
   Engler M, 2004, CHEM ENG J, V101, P315, DOI 10.1016/j.cej.2003.10.017
   Erkoc E, 2007, CHEM ENG SCI, V62, P5276, DOI 10.1016/j.ces.2007.03.036
   Fani A, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4809591
   Feng H, 2005, AICHE J, V51, P2649, DOI 10.1002/aic.10527
   Fiorentini C, 2012, DEV PROCESSING EQUIP
   Fonte CP, 2016, AICHE J, V62, P2200, DOI 10.1002/aic.15169
   Fonte CP, 2015, CHEM ENG J, V260, P316, DOI 10.1016/j.cej.2014.08.090
   Galletti C, 2012, CHEM ENG J, V185, P300, DOI 10.1016/j.cej.2012.01.046
   Gavi E, 2007, CHEM ENG RES DES, V85, P735, DOI 10.1205/cherd06176
   Gavi E, 2007, CHEM ENG SCI, V62, P2228, DOI 10.1016/j.ces.2006.12.077
   GHOLAP RV, 1994, CHEM ENG TECHNOL, V17, P102, DOI 10.1002/ceat.270170206
   Gobby D, 2001, J MICROMECH MICROENG, V11, P126, DOI 10.1088/0960-1317/11/2/307
   Gomes NMO, 2016, CHEM ENG RES DES, V105, P31, DOI 10.1016/j.cherd.2015.10.042
   Goncalves ND, 2017, AICHE J, V63, P2335, DOI 10.1002/aic.15566
   Gradl J, 2006, CHEM ENG PROCESS, V45, P908, DOI 10.1016/j.cep.2005.11.012
   Gradl J, 2009, CHEM ENG SCI, V64, P709, DOI 10.1016/j.ces.2008.08.023
   Hoffmann M, 2006, CHEM ENG SCI, V61, P2968, DOI 10.1016/j.ces.2005.11.029
   Icardi M, 2011, APPL MATH MODEL, V35, P1591, DOI 10.1016/j.apm.2010.09.035
   Icardi M, 2011, CHEM ENG J, V166, P294, DOI 10.1016/j.cej.2010.09.046
   Johnson DA, 1996, CAN J CHEM ENG, V74, P40, DOI 10.1002/cjce.5450740106
   Johnson DA, 2000, INT COMMUN HEAT MASS, V27, P443, DOI 10.1016/S0735-1933(00)00127-5
   Johnson DA, 2000, INT COMMUN HEAT MASS, V27, P455, DOI 10.1016/S0735-1933(00)00128-7
   KOLODZIEJ P, 1986, J POLYM SCI POL PHYS, V24, P2359, DOI 10.1002/polb.1986.090241017
   KOLODZIEJ P, 1982, POLYM ENG SCI, V22, P388, DOI 10.1002/pen.760220611
   Krupa K, 2014, CHEM ENG SCI, V111, P48, DOI 10.1016/j.ces.2014.02.018
   Krupa K, 2012, CHEM ENG J, V207, P931, DOI 10.1016/j.cej.2012.07.062
   KUSCH HA, 1989, IND ENG CHEM RES, V28, P302, DOI 10.1021/ie00087a009
   LEE LJ, 1980, POLYM ENG SCI, V20, P868, DOI 10.1002/pen.760201306
   Li WF, 2016, CHEM ENG SCI, V144, P116, DOI 10.1016/j.ces.2016.01.024
   Li WF, 2015, AICHE J, V61, P333, DOI 10.1002/aic.14617
   Lince F, 2009, CHEM ENG RES DES, V87, P543, DOI 10.1016/j.cherd.2008.11.009
   Liu Y, 2006, AICHE J, V52, P731, DOI 10.1002/aic.10633
   Liu Y, 2009, LAB CHIP, V9, P1110, DOI 10.1039/b818617k
   MALGUARNERA SC, 1977, POLYM ENG SCI, V17, P111, DOI 10.1002/pen.760170209
   Mariotti A, 2019, IND ENG CHEM RES, V58, P13340, DOI 10.1021/acs.iecr.9b01259
   Mariotti A, 2018, CHEM ENG J, V341, P414, DOI 10.1016/j.cej.2018.01.108
   Nakamura S, 2000, ASME FLUIDS ENG SUMM
   Nunes MI, 2012, CHEM ENG SCI, V74, P276, DOI 10.1016/j.ces.2012.02.054
   Orsi G, 2013, CHEM ENGINEER TRANS, V32, P1471, DOI 10.3303/CET1332246
   Orsi G, 2013, CHEM ENG SCI, V95, P174, DOI 10.1016/j.ces.2013.03.015
   Ottino J.M, 1990, KINEMATICS MIXING ST
   OTTINO JM, 1982, J FLUID MECH, V114, P83, DOI 10.1017/S0022112082000056
   OTTINO JM, 1980, CHEM ENG SCI, V35, P1377, DOI 10.1016/0009-2509(80)85131-1
   OTTINO JM, 1979, CHEM ENG SCI, V34, P877, DOI 10.1016/0009-2509(79)85145-3
   RANZ WE, 1986, IND ENG CHEM FUND, V25, P561, DOI 10.1021/i100024a016
   RANZ WE, 1979, AICHE J, V25, P41, DOI 10.1002/aic.690250105
   Ritcher E.B., 1978, POLYM ENG SCI, V18
   Santos R.J, 2003, THESIS
   Santos RJ, 2008, AICHE J, V54, P1153, DOI 10.1002/aic.11472
   Santos RJ, 2013, CHEM ENG TECHNOL, V36, P937, DOI 10.1002/ceat.201200678
   Santos RJ, 2010, INT J CHEM REACT ENG, V8, DOI 10.2202/1542-6580.1791
   Santos RJ, 2009, AICHE J, V55, P1338, DOI 10.1002/aic.11771
   Santos RJ, 2002, INT POLYM PROC, V17, P387, DOI 10.3139/217.1707
   Schwarzer HC, 2004, AICHE J, V50, P3234, DOI 10.1002/aic.10277
   Shi ZH, 2015, CHEM ENG SCI, V138, P216, DOI 10.1016/j.ces.2015.08.014
   Siddiqui SW, 2009, IND ENG CHEM RES, V48, P7945, DOI 10.1021/ie801562y
   Soleymani A, 2008, CHEM ENG J, V135, pS219, DOI 10.1016/j.cej.2007.07.048
   Sultan MA, 2013, CHEM ENG TECHNOL, V36, P323, DOI 10.1002/ceat.201200141
   Teixeira A.M., 2000, THESIS
   Telib H, 2004, PHYS FLUIDS, V16, P2717, DOI 10.1063/1.1751204
   Thomas S, 2010, EXP FLUIDS, V49, P1231, DOI 10.1007/s00348-010-0863-7
   Tu GY, 2014, CHEM ENG SCI, V116, P734, DOI 10.1016/j.ces.2014.06.003
   Tu GY, 2014, CHEM ENG J, V247, P125, DOI 10.1016/j.cej.2014.02.097
   TUCKER CL, 1980, POLYM ENG SCI, V20, P887, DOI 10.1002/pen.760201308
   Unger DR, 1998, CAN J CHEM ENG, V76, P546, DOI 10.1002/cjce.5450760327
   Wong SH, 2004, SENSOR ACTUAT B-CHEM, V100, P359, DOI 10.1016/j.snb.2004.02.008
   WOOD P, 1991, PHYS FLUIDS A-FLUID, V3, P1362, DOI 10.1063/1.858205
   Zhao Y, 1998, CAN J CHEM ENG, V76, P536, DOI 10.1002/cjce.5450760326
NR 80
TC 0
Z9 0
U1 12
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115299
DI 10.1016/j.ces.2019.115299
PG 16
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300025
OA Bronze
DA 2020-05-12
ER

PT J
AU Cappello, V
   Plais, C
   Vial, C
   Augier, F
AF Cappello, Vincenzo
   Plais, Cecile
   Vial, Christophe
   Augier, Frederic
TI Bubble size and liquid-side mass transfer coefficient measurements in
   aerated stirred tank reactors with non-Newtonian liquids
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multiphase reactor; Bioreactor; Mass transfer; Bubble size;
   Non-Newtonian fluid
ID TRICHODERMA-REESEI; VISCOUS-LIQUID; SCALE; COLUMNS; PHASE; BIOREACTOR;
   TURBULENCE; SURFACE
AB Oxygen transfer is a key element in aerobic fermentations, especially if the culture broth's rheology is non-Newtonian, as in the case of cultures of filamentous fungi. Viscosity negatively affects the volumetric mass transfer coefficient (k(L)a), but mechanisms involved in terms of change of interfacial area (a) and liquid-side mass transfer coefficient (k(L)) have still not been clearly identified. This lack of knowledge is in part due to the difficulty in measuring bubble size in viscous fluids. In this study, an innovative technique was used to measure bubble Sauter diameter (d(32)) in water and in xanthan gum solutions. Additional experiments were carried out to obtain the volumetric mass transfer coefficient and the global gas holdup (alpha(G)). It was then possible to obtain the liquid-side mass transfer coefficient and to compare it with existing models. Finally, empirical correlations were proposed to estimate d(32), alpha(G), k(L)a and k(L) in a mechanically stirred tank. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cappello, Vincenzo; Plais, Cecile; Augier, Frederic] Rond Point Echangeur Solaize, IFP Energies Nouvelles, BP 3, F-69360 Solaize, France.
   [Cappello, Vincenzo; Vial, Christophe] Univ Clermont Auvergne, Inst Pascal, Sigma Clermont, CNRS, F-63000 Clermont Ferrand, France.
RP Augier, F (reprint author), Rond Point Echangeur Solaize, IFP Energies Nouvelles, BP 3, F-69360 Solaize, France.
EM frederic.augier@ifpen.fr
OI VIAL, Christophe/0000-0002-9503-1605
CR AlRubeai M, 2015, CELL ENG, V9, P1, DOI 10.1007/978-3-319-10320-4
   Alves SS, 2002, CHEM ENG J, V89, P109, DOI 10.1016/S1385-8947(02)00008-6
   Amirnia S, 2013, CHEM ENG SCI, V94, P60, DOI 10.1016/j.ces.2013.02.032
   Bach C, 2017, CHEM ENG SCI, V171, P19, DOI 10.1016/j.ces.2017.05.001
   BARIGOU M, 1992, CHEM ENG SCI, V47, P2009, DOI 10.1016/0009-2509(92)80318-7
   BHAVARAJU SM, 1978, AICHE J, V24, P454, DOI 10.1002/aic.690240310
   Bombac A, 1997, AICHE J, V43, P2921, DOI 10.1002/aic.690431105
   Bouaifi MI, 1998, CAN J CHEM ENG, V76, P390, DOI 10.1002/cjce.5450760307
   BUJALSKI W, 1987, CHEM ENG SCI, V42, P317, DOI 10.1016/0009-2509(87)85061-3
   CALDERBANK PH, 1961, CHEM ENG SCI, V16, P39, DOI 10.1016/0009-2509(61)87005-X
   Clift R., 2005, BUBBLES DROPS PARTIC
   Cox AR, 2009, FOOD HYDROCOLLOID, V23, P366, DOI 10.1016/j.foodhyd.2008.03.001
   DANCKWERTS PV, 1951, IND ENG CHEM, V43, P1460, DOI 10.1021/ie50498a055
   Delvigne F, 2017, MICROB BIOTECHNOL, V10, P1267, DOI 10.1111/1751-7915.12803
   Gabelle JC, 2012, CHEM ENG SCI, V75, P408, DOI 10.1016/j.ces.2012.03.053
   Gabelle JC, 2011, CAN J CHEM ENG, V89, P1139, DOI 10.1002/cjce.20571
   Gabelle J.C., 2012, THESIS
   Garcia-Ochoa F, 2009, BIOTECHNOL ADV, V27, P153, DOI 10.1016/j.biotechadv.2008.10.006
   Gemello L, 2018, CHEM ENG SCI, V184, P93, DOI 10.1016/j.ces.2018.03.043
   Hardy N, 2017, CHEM ENG SCI, V172, P158, DOI 10.1016/j.ces.2017.06.034
   Haringa C, 2017, CHEM ENG SCI, V170, P653, DOI 10.1016/j.ces.2017.01.014
   HO CS, 1988, BIOTECHNOL BIOENG, V32, P8, DOI 10.1002/bit.260320104
   KAWASE Y, 1987, CHEM ENG SCI, V42, P1609, DOI 10.1016/0009-2509(87)80165-3
   KAWASE Y, 1992, BIOTECHNOL BIOENG, V39, P1133, DOI 10.1002/bit.260391109
   LAMONT JC, 1970, AICHE J, V16, P513, DOI 10.1002/aic.690160403
   Lapin A, 2006, CHEM ENG SCI, V61, P4783, DOI 10.1016/j.ces.2006.03.003
   Linek V, 2004, CHEM ENG PROCESS, V43, P1511, DOI 10.1016/j.cep.2004.02.009
   Linek V, 2005, CHEM ENG PROCESS, V44, P121, DOI 10.1016/j.cep.2004.05.009
   Machon V, 1997, CHEM ENG RES DES, V75, P339, DOI 10.1205/026387697523651
   Momiroski V, 2018, ASIA-PAC J CHEM ENG, V13, DOI 10.1002/apj.2267
   Montante G, 2008, CHEM ENG SCI, V63, P2107, DOI 10.1016/j.ces.2008.01.005
   Paul E.L., 2004, HDB IND MIXING SCI P
   Petricek R, 2018, INT J HEAT MASS TRAN, V124, P1117, DOI 10.1016/j.ijheatmasstransfer.2018.04.045
   Pinelli D, 2010, INT J CHEM REACT ENG, V8
   PRASHER BD, 1973, IND ENG CHEM PROC DD, V12, P351, DOI 10.1021/i260047a023
   Raimundo PM, 2016, CHEM ENG SCI, V155, P504, DOI 10.1016/j.ces.2016.08.041
   Perez JAS, 2006, CHEM ENG J, V124, P1, DOI 10.1016/j.cej.2006.07.002
   Tchuenbou-Magaia FL, 2009, FOOD HYDROCOLLOID, V23, P1877, DOI 10.1016/j.foodhyd.2009.03.005
   VANTRIET K, 1979, IND ENG CHEM PROC DD, V18, P357, DOI 10.1021/i260071a001
   VAZQUEZ G, 1995, J CHEM ENG DATA, V40, P611, DOI 10.1021/je00019a016
   WELLEK RM, 1966, AICHE J, V12, P854, DOI 10.1002/aic.690120506
   Zhang ZB, 1996, CHEM ENG COMMUN, V140, P207, DOI 10.1080/00986449608936464
NR 42
TC 0
Z9 0
U1 16
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115280
DI 10.1016/j.ces.2019.115280
PG 13
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300013
OA Bronze
DA 2020-05-12
ER

PT J
AU Cervo, H
   Ferrasse, JH
   Descales, B
   Van Eetvelde, G
AF Cervo, Helene
   Ferrasse, Jean-Henry
   Descales, Bernard
   Van Eetvelde, Greet
TI Blueprint: A methodology facilitating data exchanges to enhance the
   detection of industrial symbiosis opportunities - application to a
   refinery
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Circular economy; Industrial symbiosis; Data confidentiality; Resource
   efficiency; Pinch analysis; Refining
ID ALLOCATION; EMISSIONS; HYDROGEN
AB The European Union has put the concept of circularity at the heart of its strategy for transitioning towards a low-carbon economy. Measures have been taken in order to promote Industrial Symbiosis (IS). However, one of the main barriers to the dissemination of IS remains the exchange of (confidential) data between industries. This paper presents the concept of industrial sector blueprints as a solution in order to overcome the challenge of sharing information. A blueprint is constituted of a series of profiles providing insights into the key inputs and outputs of a given industry in terms of thermal and electrical energy, materials and services. A methodology, detailing a step-by-step approach for building the profiles and the type of data required, is presented. To demonstrate the feasibility of the methods, it is applied to a typical refinery followed by an example, showing how it can be used in an IS context. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cervo, Helene; Ferrasse, Jean-Henry] Aix Marseille Univ, M2P2 Marseille, Cent Marseille, CNRS, Marseille, France.
   [Cervo, Helene; Van Eetvelde, Greet] Univ Ghent, Fac Engn & Architecture, Energy & Cluster Management, Ghent, Belgium.
   [Cervo, Helene; Descales, Bernard; Van Eetvelde, Greet] INEOS Technol France, Lavera, France.
RP Cervo, H (reprint author), Aix Marseille Univ, M2P2 Marseille, Cent Marseille, CNRS, Marseille, France.; Cervo, H; Van Eetvelde, G (reprint author), Univ Ghent, Fac Engn & Architecture, Energy & Cluster Management, Ghent, Belgium.; Cervo, H; Van Eetvelde, G (reprint author), INEOS Technol France, Lavera, France.
EM helene.cervo@etu.univ-amu.fr; Greet.VanEetvelde@UGent.be
RI Cervo, Helene/AAD-6069-2020; Cervo, Helene/T-7237-2019
OI Cervo, Helene/0000-0001-7157-4608
FU European UnionEuropean Union (EU) [679386]; Swiss State Secretariat for
   Education, Research and Innovation (SERI) [15.0217]
FX The EPOS project has received funding from the European Union's Horizon
   2020 research and innovation programme under grant agreement No. 679386.
   This work was supported by the Swiss State Secretariat for Education,
   Research and Innovation (SERI) under contract number 15.0217. The
   opinions expressed and arguments employed herein do not necessarily
   reflect the official views of the Swiss Government.
CR Baetens J., 2017, ENERGHENTIC LAUNCH E
   Barthe P., 2015, JRC SCI POLICY REPOR
   Becker H, 2012, COMPUT CHEM ENG, V37, P104, DOI 10.1016/j.compchemeng.2011.09.014
   Benedict M., 2018, PACIS 2018 P
   Brueske S., 2012, TECHNICAL REPORT
   Bungener S, 2016, THESIS
   Butun H., 2018, COMPUTER AIDED CHEM, V44, P1195
   Cecelja F, 2015, J CLEAN PROD, V98, P336, DOI 10.1016/j.jclepro.2014.08.051
   Cervo H, 2017, SMART INNOV SYST TEC, V68, P569, DOI 10.1007/978-3-319-57078-5_54
   Chambre de Commerce et d'Industrie Occitanie, 2017, TECHNICAL REPORT
   Chertow M, 2012, J IND ECOL, V16, P13, DOI 10.1111/j.1530-9290.2011.00450.x
   Chertow MR, 2007, J IND ECOL, V11, P11, DOI 10.1162/jiec.2007.1110
   Chertow MR, 2000, ANNU REV ENERG ENV, V25, P313, DOI 10.1146/annurev.energy.25.1.313
   Chew IML, 2009, J CLEAN PROD, V17, P1611, DOI 10.1016/j.jclepro.2009.08.005
   DHOLE VR, 1993, COMPUT CHEM ENG, V17, pS101, DOI 10.1016/0098-1354(93)85015-E
   Du Plessis F, 2008, IMPROVING COMPETITIV
   EPOS, 2017, D2 3 SECT BLUEPR VIR
   EPOS, 2017, D2 1 SECT CROSS SECT
   EPOS, 2018, ENH EN RES EFF PERF
   European Commission, 2015, TECHNICAL REPORT
   Eurostat, 2008, OCLC455049151 EUR
   Geldermann J, 2004, J CLEAN PROD, V12, P389, DOI 10.1016/S0959-6526(03)00032-5
   Golev A, 2015, J IND ECOL, V19, P141, DOI 10.1111/jiec.12159
   Hackl R, 2011, ENERGY, V36, P4609, DOI 10.1016/j.energy.2011.03.023
   Hiete M, 2012, J IND ECOL, V16, P689, DOI 10.1111/j.1530-9290.2012.00462.x
   IPIECA, 2014, TECHNICAL REPORT
   Johnston D, 1996, OIL GAS J, V94, P74
   Kantor I, 2012, INT J HYDROGEN ENERG, V37, P5347, DOI 10.1016/j.ijhydene.2011.08.084
   Kastner CA, 2015, APPL ENERG, V155, P599, DOI 10.1016/j.apenergy.2015.05.037
   Kennedy A.B.W., 1898, MINUTES P I CIVIL EN, V134, P278
   Li SX, 2011, 2011 INTERNATIONAL CONFERENCE ON COMPUTATIONAL SCIENCE AND APPLICATIONS, P1, DOI 10.1109/GSIS.2011.6044018
   LINNHOFF B, 1983, CHEM ENG SCI, V38, P745, DOI 10.1016/0009-2509(83)80185-7
   Liu SF, 2016, GREY SYST, V6, P2, DOI 10.1108/GS-09-2015-0054
   Lombardi DR, 2012, J IND ECOL, V16, P28, DOI 10.1111/j.1530-9290.2011.00444.x
   Lowe EA, 1995, J CLEAN PROD, V3, P47, DOI DOI 10.1016/0959-6526(95)00045-G
   Maqbool AS, 2017, SMART INNOV SYST TEC, V68, P579, DOI 10.1007/978-3-319-57078-5_55
   Mechaussie E.M., 2016, 29 INT C EFF COST OP
   Mechaussie E.M., 2018, THESIS
   Mirata M, 2004, J CLEAN PROD, V12, P967, DOI 10.1016/j.jclepro.2004.002.031
   Nobatek, 2016, BEAR EUR CLIM ZON BI
   PlasticsEurope, 2011, TECHNICAL REPORT
   Rahm E., 2000, IEEE DATA ENG B, V23, P3, DOI DOI 10.1145/1317331.1317341
   Shreve RN, 1956, CHEM PROCESS IND
   Su N, 2000, CEMENT CONCRETE RES, V30, P1773, DOI 10.1016/S0008-8846(00)00401-4
   Suciu R, 2019, FRONT ENERGY RES, V7, DOI 10.3389/fenrg.2019.00069
   Towler GP, 1996, IND ENG CHEM RES, V35, P2378, DOI 10.1021/ie950359+
   Van Eetvelde G., 2018, RESOURCE EFFICIENCY, P441
   Van Eetvelde G., 2005, GROEIBOEK DUURZAME B
   Wang M, 2004, INT J LIFE CYCLE ASS, V9, P34, DOI 10.1007/BF02978534
   Wood J.C., 2005, CRITICAL EVALUATIONS
   Zhao Y, 2008, ENVIRON MONIT ASSESS, V139, P339, DOI 10.1007/s10661-007-9840-x
NR 51
TC 2
Z9 2
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115254
DI 10.1016/j.ces.2019.115254
PG 18
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300012
OA Bronze
DA 2020-05-12
ER

PT J
AU Chen, C
   Yao, AR
   Yao, CD
   Wang, H
   Liu, MK
   Li, ZZ
AF Chen, Chao
   Yao, Anren
   Yao, Chunde
   Wang, Hui
   Liu, Mingkuan
   Li, Zhuangzhuang
TI Selective catalytic reduction of nitrogen oxides with methanol over the
   (cobalt-molybdenum)/alumina dual catalysts under the diesel methanol
   dual fuel exhaust conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Diesel methanol dual fuel engine; Methanol-SCR; Nitrogen oxides;
   (cobalt-molybdenum)/alumina
ID LEAN NOX REDUCTION; ENGINE PERFORMANCE; IGNITION ENGINE; SCR;
   COMPRESSION; COMBUSTION; HYDROGEN; HYDROCARBONS; PROMOTION; EMISSIONS
AB The (cobalt-molybdenum)/alumina ((Co-Mo)/Al2O3) dual catalysts have an excellent performance on the selective catalytic reduction (SCR) of nitric oxide with methanol (methanol-SCR) on the synthetic gas test bench. The catalytic performance of (Co-Mo)/Al2O3 needs to be studied on the engine test bench due to the complicated emissions of engines. Tests were carried out on the diesel methanol dual fuel (DMDF) engine. The effect of methanol supply methods, methanol dosing, injection timings of diesel fuel and exhaust gas recirculation (EGR) ratios on the performance of methanol-SCR was investigated. Results show that the performance of methanol-SCR on the engine test bench slightly deteriorates compared with that on the synthetic gas test bench. The performance of methanol-SCR on the active methanol supply mode is superior to that on the passive methanol supply mode. The low nitrogen oxides (NOx) conversion with passive methanol supply mode suggests that the ratio of carbon monoxide to hydrocarbons (more than 1) and the ratio of nitrogen dioxide to NOx are the critical factors on NOx conversion during the catalyst selection. However, the passive methanol supply mode has less effect on the fuel consumption. The catalytic efficiency of methanol-SCR is improved by the increased methanol dosing and EGR ratios and the retarded injection timings. The methanol dosing increases the particulate emissions and the fuel consumption. Increasing EGR ratios is less bad for the fuel consumption than retarding injection timings. A combination of the DMDF engine and the methanol-SCR realizes the ultra-low NOx emissions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Chao; Yao, Anren; Yao, Chunde; Wang, Hui; Liu, Mingkuan; Li, Zhuangzhuang] Tianjin Univ, State Key Lab Engines, Tianjin 300072, Peoples R China.
RP Yao, CD (reprint author), Tianjin Univ, 92 Weijin Rd, Tianjin 300072, Peoples R China.
EM arcdyao@tju.edu.cn
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51676134]
FX The authors wish to thank the Natural Science Foundation of China (No.
   51676134) for the financial support.
CR Agarwal AK, 2017, PROG ENERG COMBUST, V61, P1, DOI 10.1016/j.pecs.2017.02.001
   Al-Harbi M, 2012, CAN J CHEM ENG, V90, P1527, DOI 10.1002/cjce.20659
   Arve K, 2004, CHEM ENG SCI, V59, P5277, DOI 10.1016/j.ces.2004.08.036
   Bae C, 2017, P COMBUST INST, V36, P3389, DOI 10.1016/j.proci.2016.09.009
   Boningari T, 2016, CURR OPIN CHEM ENG, V13, P133, DOI 10.1016/j.coche.2016.09.004
   Burch R, 1998, APPL CATAL B-ENVIRON, V17, P115, DOI 10.1016/S0926-3373(98)00005-8
   Chen C, 2019, APPL THERM ENG, V148, P391, DOI 10.1016/j.applthermaleng.2018.11.062
   Cheng S.W.S., 2009, 2009012779 SAE
   Cheng XX, 2014, PARTICUOLOGY, V16, P1, DOI 10.1016/j.partic.2014.01.006
   Eyidogan M, 2010, FUEL, V89, P2713, DOI 10.1016/j.fuel.2010.01.032
   Frobert A, 2012, SAE INT J FUELS LUBR, V5, P389, DOI 10.4271/2011-01-2092
   Furfori S, 2010, CHEM ENG SCI, V65, P120, DOI 10.1016/j.ces.2009.01.065
   Gough B., 2012, 2012011957 SAE
   Hamada H, 2012, APPL CATAL A-GEN, V421, P1, DOI 10.1016/j.apcata.2012.02.005
   Huang ZH, 2004, BIORESOURCE TECHNOL, V95, P331, DOI 10.1016/j.biortech.2004.02.018
   Korakianitis T, 2011, PROG ENERG COMBUST, V37, P89, DOI 10.1016/j.pecs.2010.04.002
   Mannikko M, 2016, APPL CATAL B-ENVIRON, V180, P291, DOI 10.1016/j.apcatb.2015.06.002
   Mannikko M, 2013, TOP CATAL, V56, P145, DOI 10.1007/s11244-013-9944-1
   Mannikko M, 2012, APPL CATAL B-ENVIRON, V119, P256, DOI 10.1016/j.apcatb.2012.03.006
   Masters SG, 1998, CATAL TODAY, V42, P137, DOI 10.1016/S0920-5861(98)00084-4
   Maunula T, 2007, NOX REDUCTION HYDROC
   Metkar PS, 2013, CHEM ENG SCI, V87, P51, DOI 10.1016/j.ces.2012.09.008
   Mrad R, 2015, APPL CATAL A-GEN, V504, P542, DOI 10.1016/j.apcata.2014.10.021
   Nova I., 2014, UREA SCR TECHNOLOGY
   Park JW, 2007, TOP CATAL, V42-43, P259, DOI 10.1007/s11244-007-0187-x
   Piumetti M, 2015, CATAL STRUCT REACT, V1, P155, DOI 10.1080/2055074X.2015.1105615
   Prikhodko V.Y., 2015, 2015011008 SAE
   Satokawa S, 2007, CHEM ENG SCI, V62, P5335, DOI 10.1016/j.ces.2006.12.034
   Sayin C, 2010, FUEL, V89, P1407, DOI 10.1016/j.fuel.2009.10.035
   Schar CM, 2006, IEEE T CONTR SYST T, V14, P641, DOI 10.1109/TCST.2006.876634
   Schmieg SJ, 2009, SAE INT J FUELS LUBR, V1, P1540, DOI 10.4271/2008-01-2486
   TABATA M, 1995, APPL CATAL B-ENVIRON, V6, P169, DOI 10.1016/0926-3373(95)00013-5
   Theinnoi K, 2008, ENERG FUEL, V22, P4109, DOI 10.1021/ef8004515
   Viola M.B, 2009, 2009012775 SAE
   Wang B, 2018, FUEL, V218, P295, DOI 10.1016/j.fuel.2018.01.028
   Wei HY, 2017, FUEL, V207, P33, DOI 10.1016/j.fuel.2017.06.070
   Wei LJ, 2015, FUEL, V140, P156, DOI 10.1016/j.fuel.2014.09.070
   Wu Y, 2017, SCI TOTAL ENVIRON, V574, P332, DOI 10.1016/j.scitotenv.2016.09.040
   [姚春德 Yao Chunde], 2018, [工程热物理学报, Journal of Engineering Thermophysics], V39, P1139
   Yao CD, 2017, FUEL, V209, P713, DOI 10.1016/j.fuel.2017.08.038
   Yusri IM, 2017, RENEW SUST ENERG REV, V77, P169, DOI 10.1016/j.rser.2017.03.080
   Zhao Y, 2017, CHEM ENG SCI, V164, P258, DOI 10.1016/j.ces.2017.02.009
   Zhen XD, 2015, RENEW SUST ENERG REV, V52, P477, DOI 10.1016/j.rser.2015.07.083
   Zou S, 2015, CAN J CHEM ENG, V93, P2117, DOI 10.1002/cjce.22328
NR 44
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115320
DI 10.1016/j.ces.2019.115320
PG 15
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300052
OA Bronze
DA 2020-05-12
ER

PT J
AU Ding, BX
   Dong, MZ
   Yu, L
AF Ding, Boxin
   Dong, Mingzhe
   Yu, Long
TI A model of emulsion plugging ability in sandpacks: Yield pressure drop
   and consistency parameter
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oil-in-water emulsion; Sandpack; Yield pressure; Emulsion flow in porous
   media; Mathematical model
ID IN-WATER EMULSIONS; HEAVY OIL-RECOVERY; PREFORMED PARTICLE GELS;
   POROUS-MEDIA; CONFORMANCE CONTROL; STABLE EMULSIONS; CRUDE-OIL; PIPELINE
   TRANSPORTATION; FILTRATION MODEL; FLOW
AB In this study, a total of 20 sandpack flood tests, each with 11 different flow rates, were conducted to evaluate oil-in-water (O/W) emulsion plugging ability in sandpacks. Four conditions of emulsion flow in porous media were observed, identified, and discussed, in terms of the capillary number. A general model for the pressure drop versus flow rate based on the bi-viscosity model was developed from a comprehensive analysis of the experimental data. This model expresses that the flow of emulsion in porous media has two distinct mobility in porous media demarcated by a critical pressure drop. The inverse of the mobility is determined as consistency parameter and the critical pressure drop as the yield pressure drop. Effects of interfacial tension (IFT), emulsion quality, droplet size, emulsion slug size, and sandpack permeability on the yield pressure drop and consistency parameter were experimentally and numerically investigated. The newly proposed model has a good agreement between the predicted and experimental plugging pressure drop of emulsion. Besides giving guides on preparation of O/W emulsions and injection strategies in a specific oil reservoir, use of the proposed model can also help model reservoir scale O/W emulsion flow to reduce or shut-in the mobility in thief zones. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ding, Boxin; Dong, Mingzhe; Yu, Long] Univ Calgary, Dept Chem & Petr Engn, Calgary, AB T2N 1N4, Canada.
RP Dong, MZ (reprint author), Univ Calgary, Dept Chem & Petr Engn, Calgary, AB T2N 1N4, Canada.
EM mingzhe.dong@ucalgary.ca
OI Ding, Boxin/0000-0001-8344-8465
FU BitCan; PetroChina Canada; Natural Sciences and Engineering Council
   (NSERC) of CanadaNatural Sciences and Engineering Research Council of
   Canada [CRDPJ498953-16]
FX The authors acknowledge with thanks support from BitCan, PetroChina
   Canada, and Natural Sciences and Engineering Council (NSERC) of Canada
   through an NSERC CRD grant (CRDPJ498953-16).
CR Abdulbaki M, 2014, J PETROL SCI ENG, V122, P741, DOI 10.1016/j.petrol.2014.06.034
   Abdurahman NH, 2012, J PETROL SCI ENG, V90-91, P139, DOI 10.1016/j.petrol.2012.04.025
   Ahmed NS, 1999, FUEL, V78, P593, DOI 10.1016/S0016-2361(98)00157-4
   Alboudwarej H, 2016, OILF REV, V18, P34
   ALVARADO DA, 1979, SOC PETROL ENG J, V19, P369, DOI 10.2118/5859-PA
   Arhuoma M, 2009, IND ENG CHEM RES, V48, P7092, DOI 10.1021/ie801818n
   Ashrafizadeh SN, 2010, J PETROL SCI ENG, V71, P205, DOI 10.1016/j.petrol.2010.02.005
   Bryan J, 2009, J CAN PETROL TECHNOL, V48, P37, DOI 10.2118/09-02-37
   Chien S.-F., 1990, SPE LAT AM PETR ENG, V9
   Cobos S, 2009, INT J MULTIPHAS FLOW, V35, P507, DOI 10.1016/j.ijmultiphaseflow.2009.02.018
   Coussot P, 2014, J NON-NEWTON FLUID, V211, P31, DOI 10.1016/j.jnnfm.2014.05.006
   Devereux O. F., 1974, Chemical Engineering Journal, V7, P121, DOI 10.1016/0300-9467(74)85005-7
   Devereux O.F., 1974, CHEM ENG J, V7, P129, DOI DOI 10.1016/0300-9467(74)85006-9
   Ding BX, 2019, FUEL, V257, DOI 10.1016/j.fuel.2019.116024
   Ding BX, 2019, FUEL, V244, P335, DOI 10.1016/j.fuel.2019.02.021
   Dong MZ, 2012, PARTICUOLOGY, V10, P298, DOI 10.1016/j.partic.2011.09.008
   Dong MZ, 2009, FUEL, V88, P1049, DOI 10.1016/j.fuel.2008.11.014
   Fuseni AB, 2018, J PET EXPLOR PROD TE, V8, P1341, DOI 10.1007/s13202-018-0431-x
   Fustic M., 2006, P CSPG CSEG CWLS JOI, P15
   Gao ZY, 2013, J GEOPHYS ENG, V10, DOI 10.1088/1742-2132/10/2/025014
   Gates ID, 2008, J CAN PETROL TECHNOL, V47, P40, DOI 10.2118/08-09-40
   Gong HJ, 2016, COLLOID SURFACE A, V488, P28, DOI 10.1016/j.colsurfa.2015.09.042
   Goodarzi F., 2019, IND ENG CHEM RES
   Goodarzi F, 2019, CAN J CHEM ENG, V97, P281, DOI 10.1002/cjce.23336
   Goudarzi A, 2015, FUEL, V140, P502, DOI 10.1016/j.fuel.2014.09.081
   Guillen VR, 2012, TRANSPORT POROUS MED, V94, P197, DOI 10.1007/s11242-012-9997-9
   Hein F. J., 2006, NATURAL RESOUR RES, V15, P85, DOI DOI 10.1007/S11053-006-9015-4
   Herschel WH, 1926, KOLLOID Z, V39, P291, DOI 10.1007/BF01432034
   HOFMAN JAMH, 1991, COLLOID SURFACE, V61, P317, DOI 10.1016/0166-6622(91)80318-I
   Hu LL, 2016, J DISPER SCI TECHNOL, V37, P345, DOI 10.1080/01932691.2015.1018424
   Ikebuchi M, 1998, RADIAT RES, V150, P416, DOI 10.2307/3579660
   Imqam A, 2015, FUEL, V148, P178, DOI 10.1016/j.fuel.2015.01.022
   JENNINGS HY, 1974, J PETROL TECHNOL, V26, P1344, DOI 10.2118/4741-PA
   Kolodzie P.A., 1974, J PETROL TECHNOL
   Larter S., 2006, CAN INT PETR C
   Li YJ, 2017, ENERG FUEL, V31, P3960, DOI 10.1021/acs.energyfuels.6b02923
   Liu Q, 2006, COLLOID SURFACE A, V273, P219, DOI 10.1016/j.colsurfa.2005.10.016
   Liu Q, 2007, COLLOID SURFACE A, V293, P63, DOI 10.1016/j.colsurfa.2006.07.013
   Lu C, 2018, J ENERG RESOUR-ASME, V140, DOI 10.1115/1.4040200
   Mandal A, 2015, PETROL SCI, V12, P273, DOI 10.1007/s12182-015-0025-x
   Mandal A, 2010, IND ENG CHEM RES, V49, P12756, DOI 10.1021/ie101589x
   MCAULIFFE CD, 1973, J PETROL TECHNOL, V25, P727, DOI 10.2118/4369-PA
   Ni Y., 2019, INT PETR TECHN C INT, P21
   ODONOVAN EJ, 1984, J NON-NEWTON FLUID, V15, P75, DOI 10.1016/0377-0257(84)80029-4
   Romero MI, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.046305
   Salager JL, 2012, ENERG FUEL, V26, P4027, DOI 10.1021/ef3001604
   Sang Q, 2014, FUEL, V136, P295, DOI 10.1016/j.fuel.2014.07.065
   Schramm L.L., 1992, EMUL FUNDAMENT APPL
   SOO H, 1986, CHEM ENG SCI, V41, P273, DOI 10.1016/0009-2509(86)87008-7
   SOO H, 1986, CHEM ENG SCI, V41, P263, DOI 10.1016/0009-2509(86)87007-5
   SOO H, 1984, J COLLOID INTERF SCI, V102, P462, DOI 10.1016/0021-9797(84)90249-2
   SOO H, 1984, IND ENG CHEM FUND, V23, P342, DOI 10.1021/i100015a014
   TIEN C, 1979, AICHE J, V25, P737, DOI 10.1002/aic.690250502
   Verzaro F., 2002, SPE INT THERM OPERAT
   [王凤琴 Wang Fengqin], 2003, [西北大学学报. 自然科学版, Journal of Northwest University.Natural Science Edition], V33, P603
   Wang J., 2016, SPE EOR C OIL GAS W
   Wright R., 1933, AAPG BULL, V17, P1521, DOI DOI 10.1306/3D932BDC-16B1-11D7-8645000102C1865D
   Yao CJ, 2015, IND ENG CHEM RES, V54, P10925, DOI 10.1021/acs.iecr.5b02717
   Yu L, 2019, FUEL, V241, P53, DOI 10.1016/j.fuel.2018.12.014
   Yu L, 2018, IND ENG CHEM RES, V57, P14795, DOI 10.1021/acs.iecr.8b03805
   Yu L, 2018, CHEM ENG SCI, V178, P335, DOI 10.1016/j.ces.2017.12.043
   Yu L, 2017, IND ENG CHEM RES, V56, P9237, DOI 10.1021/acs.iecr.7b01770
   Zaki NN, 1997, COLLOID SURFACE A, V125, P19, DOI 10.1016/S0927-7757(96)03768-5
   Zhang T., 2009, SPE INT S OILF CHEM
NR 64
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115248
DI 10.1016/j.ces.2019.115248
PG 17
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300005
OA Bronze
DA 2020-05-12
ER

PT J
AU Fakroun, A
   Benkreira, H
AF Fakroun, A.
   Benkreira, H.
TI Rheology of waxy crude oils in relation to restart of gelled pipelines
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Waxy crude oil; Rheology; Re-start pressure yield stress;
   Crystallisation
ID YIELD-STRESS; START-UP; BEHAVIOR; MODEL; FLOW; STRENGTH; GELATION; SHEAR
AB Waxy crude oils are pumped hot but upon power cut, pumping stops, the oil cools below the wax appearance temperature to precipitation of the wax and the formation of a gel throughout the pipe. In such a situation, what is the minimum pressure required to restart flow, not to merely deform the gel or break it? This paper provides a solution to this problem using microscopic observations under controlled cooling conditions and rheological data conducted in constant stress mode under controlled temperature and cooling conditions and restart experiments in laboratory pipelines replicating the rheometric conditions and deviations from them to inform large diameter operation in the field. Three important findings derive from the experimental data collected: (i) A fragmentation stress tau(f), rather than the static stress tau(s) that precedes it, is found to be the more accurate predictor of flow re-start pressures; (ii) Waxy crude oils gels exhibit true yield stress and yielding process but also show flow on application of the slightest stress below yielding; (iii) This flow, in the elastic region, is jagged rather than continuous suggesting a consolidation process of the crystals and their agglomerates forming the gel. In the broader context of the existence of a yield stress, the data presented here show that there is such a thing as a yield stress and the concepts of a yield stress and that everything flows are not mutually exclusive. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fakroun, A.; Benkreira, H.] Univ Bradford, Dept Chem Engn, Bradford, W Yorkshire, England.
RP Benkreira, H (reprint author), Univ Bradford, Dept Chem Engn, Bradford, W Yorkshire, England.
EM H.Benkreira@bradford.ac.uk
FU Libyan Petroleum Institute (Libya)
FX This work forms part of a continuing programme of work on the rheology
   of waxy crude oils which has been sponsored over the years by the Libyan
   Petroleum Institute (Libya), the support of whom we gratefully
   acknowledge. We also acknowledge BP and the National Oil Corporation
   (NOC) of Libya for providing the oil samples.
CR Andrade DEV, 2018, RHEOL ACTA, V57, P673, DOI 10.1007/s00397-018-1108-6
   Andrade DEV, 2015, RHEOL ACTA, V54, P149, DOI 10.1007/s00397-014-0812-0
   Barnes HA, 1999, J NON-NEWTON FLUID, V81, P133, DOI 10.1016/S0377-0257(98)00094-9
   Barnes HA, 2007, APPL RHEOL, V17
   Betancourt S, 2007, OILFIELD REV, V19, P56
   Cawkwell M. G., 1989, J PIPELINE, V7, P251
   Chala GT, 2018, J NON-NEWTON FLUID, V251, P69, DOI 10.1016/j.jnnfm.2017.11.008
   Chang C, 1998, IND ENG CHEM RES, V37, P1551, DOI 10.1021/ie970588r
   Chang C, 1999, J NON-NEWTON FLUID, V87, P127, DOI 10.1016/S0377-0257(99)00059-2
   Chang C, 2000, SPE J, V5, P148
   Chen J, 2004, THERMOCHIM ACTA, V410, P23, DOI 10.1016/S0040-6031(03)00367-8
   Chen S, 2006, ANN T NORD RHEOL SOC, V14, P6
   Cheng D.C.-H., 1985, 540 LR MH WARR SPRIN
   da Silva JAL, 2004, RHEOL ACTA, V43, P433, DOI 10.1007/s00397-004-0367-6
   Davidson MR, 2004, J NON-NEWTON FLUID, V123, P269, DOI 10.1016/j.jnnfm.2004.09.007
   de Oliveira GM, 2015, J NON-NEWTON FLUID, V220, P137, DOI 10.1016/j.jnnfm.2014.12.010
   Dimitriou CJ, 2011, ENERG FUEL, V25, P3040, DOI 10.1021/ef2002348
   EIA, 2018, INT EN OUTL 2018
   Fakroun A., 2018, THESIS
   Gibaud T, 2009, SOFT MATTER, V5, P3026, DOI 10.1039/b906274b
   Guo XH, 2006, ENERG FUEL, V20, P250, DOI 10.1021/ef050163e
   Hou L, 2010, PETROL SCI TECHNOL, V28, P690, DOI 10.1080/10916460902804648
   Huang ZY, 2011, AICHE J, V57, P2955, DOI 10.1002/aic.12517
   Kane M, 2004, FUEL, V83, P1591, DOI 10.1016/j.fuel.2004.01.017
   Kok MV, 2018, J PETROL SCI ENG, V168, P542, DOI 10.1016/j.petrol.2018.05.045
   Kok MV, 1996, FUEL, V75, P787, DOI 10.1016/0016-2361(96)00046-4
   Lee HS, 2008, ENERG FUEL, V22, P480, DOI 10.1021/ef700212v
   Lin MZ, 2011, J PETROL SCI ENG, V77, P351, DOI 10.1016/j.petrol.2011.04.010
   Magda JJ, 2009, ENERG FUEL, V23, P1311, DOI 10.1021/ef800628g
   Marchesini FH, 2012, ENERG FUEL, V26, P2566, DOI 10.1021/ef201335c
   Moller PCF, 2006, SOFT MATTER, V2, P274, DOI 10.1039/b517840a
   Morozov EV, 2016, ENERG FUEL, V30, P9003, DOI 10.1021/acs.energyfuels.6b01535
   Mullin J., 2001, CRYSTALLIZATION
   PERKINS TK, 1971, J PETROL TECHNOL, V23, P301, DOI 10.2118/2997-PA
   PETRELLIS NC, 1973, CAN J CHEM ENG, V51, P291, DOI 10.1002/cjce.5450510305
   Ronningsen HP, 1992, J PETROL SCI ENG, V7, P177
   Ronningsen HP, 2012, ENERG FUEL, V26, P4124, DOI 10.1021/ef300288g
   Roy S, 2016, SOFT MATTER, V12, P9402, DOI 10.1039/c6sm02175a
   RUSSELL RJ, 1971, J I PETROL, V57, P117
   Singh P, 2001, AICHE J, V47, P6, DOI 10.1002/aic.690470103
   Southgate J., 2004, THESIS
   Speight H.J.G., 2015, HDB PETROLEUM PRODUC
   Tarcha BA, 2015, RHEOL ACTA, V54, P479, DOI 10.1007/s00397-015-0835-1
   Van Der Geest C, 2017, J NON-NEWTON FLUID, V247, P188, DOI 10.1016/j.jnnfm.2017.07.004
   Van Der Geest C, 2015, RHEOL ACTA, V54, P545, DOI 10.1007/s00397-015-0849-8
   Venkatesan R, 2005, CHEM ENG SCI, V60, P3587, DOI 10.1016/j.ces.2005.02.045
   Vinay G, 2006, J NON-NEWTON FLUID, V136, P93, DOI 10.1016/j.jnnfm.2006.03.003
   Visintin RFG, 2005, LANGMUIR, V21, P6240, DOI 10.1021/la050705k
   Visintin RFG, 2008, J NON-NEWTON FLUID, V149, P34, DOI 10.1016/j.jnnfm.2007.07.008
   Vlassopoulos D., 2007, RHEOL REV, P179
   WARDHAUGH LT, 1991, J RHEOL, V35, P1121, DOI 10.1122/1.550168
   WARDHAUGH LT, 1991, AICHE J, V37, P871, DOI 10.1002/aic.690370610
   Webber RM, 2001, IND ENG CHEM RES, V40, P195, DOI 10.1021/ie000417d
   World Energy Council, 2016, WORLD ENERGY RESOURC
   Yi SZ, 2011, ENERG FUEL, V25, P1686, DOI 10.1021/ef200059p
NR 55
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115212
DI 10.1016/j.ces.2019.115212
PG 13
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300051
OA Bronze
DA 2020-05-12
ER

PT J
AU Fontana, E
   Capeletto, CA
   Santos, VGS
   Garbin, E
   Cunha, MM
   Luz, LFL
AF Fontana, Eliton
   Capeletto, Claudia A.
   Santos, Victor G. S.
   Garbin, Evandro
   Cunha, Mariana M.
   Luz Jr, Luiz F. L.
TI Numerical analysis of heat recuperation in micro-combustors using
   internal recirculation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Micro-combustor; Heat recuperation; Energetic efficiency; Computational
   fluid dynamics; Metal foams
ID THERMAL PERFORMANCE; FLAME STABILITY; ENERGY-CONVERSION; POROUS-MEDIA;
   CONDUCTIVITY; ENHANCEMENT; EFFICIENCY; IGNITION; CHANNEL; PROPANE
AB Heat recuperation in micro-combustors used as a radiation source for micro-thermophotovoltaic devices is an important mechanism to increase system efficiency and improve flame stability. A novel combustor structure is proposed to improve the heat transfer from the combustion gases to the combustor outer wall using an internal recirculation region filled with porous media. Numerical results indicate that the temperature difference in the recirculation region can be reduced up to 10 times using metal foams as porous media, which significantly increase the outer wall temperature. Different porous media and recirculation positions were investigated and it was found that the average radiation emission efficiency, for different inlet velocities, can be increased up to 24% in comparison with combustors without recirculation and up to 18% in comparison with combustors with open-channel recirculation (no porous media). The performance improvement is more significant for higher inlet velocities, with increases up to 40%. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fontana, Eliton; Santos, Victor G. S.; Garbin, Evandro; Cunha, Mariana M.; Luz Jr, Luiz F. L.] Fed Univ Parana UFPR, Dept Chem Engn, BR-81531980 Curitiba, Parana, Brazil.
   [Capeletto, Claudia A.] State Univ Maringa UEM, Dept Chem Engn, BR-87020900 Maringa, PR, Brazil.
RP Fontana, E (reprint author), Fed Univ Parana UFPR, Dept Chem Engn, BR-81531980 Curitiba, Parana, Brazil.
EM eliton.fontana@ufpr.br
RI de Lima Luz Junior, Luiz Fernando/AAB-9115-2020
OI de Lima Luz Junior, Luiz Fernando/0000-0002-7379-9840
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   Brazil)National Council for Scientific and Technological Development
   (CNPq) [407625/2016-0]
FX The authors would like to thank CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico Brazil) through the process
   407625/2016-0 for the financial support.
CR Akhtar S, 2017, APPL ENERG, V192, P134, DOI 10.1016/j.apenergy.2017.01.097
   Ansari M, 2018, CHEM ENG SCI, V175, P243, DOI 10.1016/j.ces.2017.10.001
   ANSYS, 2018, FLUENT US GUID
   Aravind B, 2019, APPL THERM ENG, V148, P22, DOI 10.1016/j.applthermaleng.2018.11.016
   Aravind B, 2018, ENERG CONVERS MANAGE, V156, P224, DOI 10.1016/j.enconman.2017.11.021
   Bahlouli K, 2014, ENERG CONVERS MANAGE, V79, P85, DOI 10.1016/j.enconman.2013.12.005
   Bani S, 2018, APPL THERM ENG, V129, P596, DOI 10.1016/j.applthermaleng.2017.10.024
   Chen XJ, 2019, FUEL, V251, P249, DOI 10.1016/j.fuel.2019.04.011
   Chou SK, 2010, APPL ENERG, V87, P2862, DOI 10.1016/j.apenergy.2009.06.039
   E JQ, 2018, APPL THERM ENG, V141, P114, DOI 10.1016/j.applthermaleng.2018.05.101
   Ho C.Y., 1977, TECHNICAL REPORT
   Innocentini M. D. M., 1999, MAT RES, V2, P283, DOI DOI 10.1590/S1516-14391999000400008
   Jejurkar SY, 2017, CHEM ENG J, V313, P1426, DOI 10.1016/j.cej.2016.11.050
   Jejurkar SY, 2011, INT J HYDROGEN ENERG, V36, P7326, DOI 10.1016/j.ijhydene.2011.02.098
   Lei YF, 2016, APPL THERM ENG, V100, P348, DOI 10.1016/j.applthermaleng.2016.01.162
   Li J, 2009, CHEM ENG SCI, V64, P3282, DOI 10.1016/j.ces.2009.04.005
   Li J, 2016, FUEL, V167, P98, DOI 10.1016/j.fuel.2015.11.033
   Li JW, 2017, COMBUST SCI TECHNOL, V189, P1198, DOI 10.1080/00102202.2017.1279154
   Li QQ, 2019, P COMBUST INST, V37, P5645, DOI 10.1016/j.proci.2018.06.023
   Liu Y, 2016, APPL THERM ENG, V101, P239, DOI 10.1016/j.applthermaleng.2016.02.099
   Park JH, 2011, INT J HEAT MASS TRAN, V54, P1046, DOI 10.1016/j.ijheatmasstransfer.2010.11.028
   Peng QG, 2019, APPL ENERG, V242, P424, DOI 10.1016/j.apenergy.2019.03.137
   Peng QG, 2018, ENERG CONVERS MANAGE, V155, P276, DOI 10.1016/j.enconman.2017.10.095
   Shan XC, 2005, J MICROMECH MICROENG, V15, pS215, DOI 10.1088/0960-1317/15/9/S07
   Shukla H, 2017, INT J ENERG MATER CH, V16, P115, DOI 10.1615/IntJEnergeticMaterialsChemProp.2018024455
   Tang AK, 2018, FUEL PROCESS TECHNOL, V180, P23, DOI 10.1016/j.fuproc.2018.07.034
   Tang AK, 2015, INT J HYDROGEN ENERG, V40, P16587, DOI 10.1016/j.ijhydene.2015.09.101
   Taywade UW, 2013, FUEL PROCESS TECHNOL, V109, P179, DOI 10.1016/j.fuproc.2012.11.002
   Turkeli-Ramadan Z, 2015, CHEM ENG SCI, V138, P414, DOI 10.1016/j.ces.2015.08.026
   Wierzbicki TA, 2014, APPL ENERG, V130, P350, DOI 10.1016/j.apenergy.2014.05.069
   Woolf DN, 2018, OPTICA, V5, P213, DOI 10.1364/OPTICA.5.000213
   Xiao X, 2014, INT J THERM SCI, V81, P94, DOI 10.1016/j.ijthermalsci.2014.03.006
   Xu HJ, 2019, CHEM ENG SCI, V195, P462, DOI 10.1016/j.ces.2018.09.045
   Yan YF, 2015, FUEL, V159, P45, DOI 10.1016/j.fuel.2015.06.069
   Yang WM, 2014, ENERG CONVERS MANAGE, V78, P81, DOI 10.1016/j.enconman.2013.10.040
   Yang WM, 2012, APPL ENERG, V97, P749, DOI 10.1016/j.apenergy.2011.12.024
   Yang X, 2019, INT J HYDROGEN ENERG, V44, P1213, DOI 10.1016/j.ijhydene.2018.10.239
   Yilmaz I, 2018, FUEL, V217, P536, DOI 10.1016/j.fuel.2018.01.015
NR 38
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115301
DI 10.1016/j.ces.2019.115301
PG 12
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300044
OA Bronze
DA 2020-05-12
ER

PT J
AU Geng, SJ
   Li, Z
   Liu, HY
   Yang, C
   Gao, F
   He, TB
   Huang, QS
AF Geng, Shujun
   Li, Zhuo
   Liu, Hongyan
   Yang, Chao
   Gao, Fei
   He, Taobo
   Huang, Qingshan
TI Hydrodynamics and mass transfer in a slurry external airlift loop
   reactor integrating mixing and separation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE External airlift loop reactor; Mixing; Separation; Hydrocyclone;
   Hydrodynamics; Mass transfer
ID CIRCULATION LIQUID VELOCITY; FLOW REGIME TRANSITION; GAS HOLD-UP;
   BUBBLE-COLUMN; TRANSFER COEFFICIENT; HEAT-TRANSFER; BEHAVIOR; SOLIDS;
   WATER; DISTRIBUTIONS
AB A pilot external airlift loop reactor (EALR) integrating mixing and separation was first proposed by combining directional flow in the EALR and liquid-solid separation in two parallel hydrocyclones. In this developed reactor, mixing, mass transfer, and liquid-solid separation can be simultaneously realized without extra energy input. Technical feasibility was firstly verified, and then hydrodynamics and mass transfer were measured. It was found that the minimum diameter of solid particles retained for circulation was 6.82 mu m, and the treatment capacity of clean liquid was up to 3.0 m(3)/h. Additionally, global gas holdup, liquid circulating velocity, and volumetric mass transfer coefficient increased monotonously with increasing the superficial gas velocity while declined with the increase of solid concentration. Axial inhomogeneity of solid particles was decayed with increasing the superficial gas velocity and solid concentration. This new type of slurry EALR is promising to be applied in the gas-liquid-solid catalytic industries. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Geng, Shujun; Li, Zhuo; Yang, Chao; Huang, Qingshan] Chinese Acad Sci, Qingdao Inst Bioenergy & Bioproc Technol QIBEBT, Key Lab Biofuels, Qingdao 266101, Shandong, Peoples R China.
   [Li, Zhuo; Liu, Hongyan] Hebei Univ Technol, Sch Chem Engn & Technol, Tianjin 300130, Peoples R China.
   [Geng, Shujun; Huang, Qingshan] Dalian Natl Lab Clean Energy DNL, Dalian 116023, Liaoning, Peoples R China.
   [Yang, Chao; Huang, Qingshan] Chinese Acad Sci, Inst Proc Engn, Key Lab Green Proc & Engn, Beijing 100190, Peoples R China.
   [Gao, Fei; He, Taobo] CNPC, Petrochem Res Inst, Beijing 100083, Peoples R China.
   [Geng, Shujun; Huang, Qingshan] Univ Chinese Acad Sci, Beijing 100080, Peoples R China.
RP Huang, QS (reprint author), Chinese Acad Sci, Qingdao Inst Bioenergy & Bioproc Technol QIBEBT, Key Lab Biofuels, Qingdao 266101, Shandong, Peoples R China.
EM qshuang@ipe.ac.cn
RI Yang, Chao/B-4039-2008
OI Yang, Chao/0000-0001-6067-7505
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21808234, 21878318, 91434114]; Instrument
   Developing Project of the CAS [YZ201641]; "Transformational Technologies
   for Clean Energy and Demonstration", Strategic Priority Research Program
   of the CAS [XDA21060400]; QIBEBT of the CAS [QIBEBT ZZBS201803]; Dalian
   National Laboratory for Clean Energy of the CAS [QIBEBT ZZBS201803]; CAS
   Key Technology Talent Program; Project of CNPC-DICP Joint Research
   Center
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 21808234; 21878318; 91434114), the Instrument Developing
   Project of the CAS (YZ201641), "Transformational Technologies for Clean
   Energy and Demonstration", Strategic Priority Research Program of the
   CAS (XDA21060400), QIBEBT and Dalian National Laboratory for Clean
   Energy of the CAS (QIBEBT ZZBS201803), CAS Key Technology Talent
   Program, and Project of CNPC-DICP Joint Research Center.
CR Abdel-Aziz MH, 2013, INT J HEAT MASS TRAN, V58, P735, DOI 10.1016/j.ijheatmasstransfer.2012.11.054
   Ahmed MA, 2016, IND ENG CHEM RES, V3, P85
   Al-Qodah Z, 2001, BIOCHEM ENG J, V7, P7, DOI 10.1016/S1369-703X(00)00095-4
   ANDERSON JH, 2003, Patent No. 6652760
   Bakopoulos A, 2001, CHEM ENG SCI, V56, P5131, DOI 10.1016/S0009-2509(01)00184-1
   BENHAM CB, 2000, Patent No. 6068760
   Besagni G, 2016, CHEM ENG SCI, V146, P259, DOI 10.1016/j.ces.2016.02.043
   Cao CQ, 2008, IND ENG CHEM RES, V47, P4008, DOI 10.1021/ie0715254
   Cao CQ, 2007, IND ENG CHEM RES, V46, P7317, DOI 10.1021/ie070690g
   Cao CQ, 2009, CHEM ENG SCI, V64, P4992, DOI 10.1016/j.ces.2009.08.006
   Choi KH, 1996, KOREAN J CHEM ENG, V13, P379, DOI 10.1007/BF02705965
   CHOI KH, 1993, J CHEM TECHNOL BIOT, V56, P51
   CLERICI GCE, 2005, Patent No. 2403433
   Dhaouadi H, 2006, CHEM ENG SCI, V61, P1300, DOI 10.1016/j.ces.2005.08.024
   Fan LS, 1999, CHEM ENG SCI, V54, P4681, DOI 10.1016/S0009-2509(99)00348-6
   FRANKEL NA, 1967, CHEM ENG SCI, V22, P847, DOI 10.1016/0009-2509(67)80149-0
   Freitas C, 1998, BIOPROCESS ENG, V18, P267, DOI 10.1007/s004490050441
   Freitas C, 2001, CHEM ENG J, V84, P57, DOI 10.1016/S1385-8947(00)00274-6
   Gourich B, 2006, CHEM ENG PROCESS, V45, P214, DOI 10.1016/j.cep.2005.09.002
   Gourich B, 2005, CHEM ENG PROCESS, V44, P1047, DOI 10.1016/j.cep.2004.12.002
   Guettel R, 2008, CHEM ENG TECHNOL, V31, P746, DOI 10.1002/ceat.200800023
   Guo X, 2015, BIORESOURCE TECHNOL, V190, P189, DOI 10.1016/j.biortech.2015.04.077
   Han TL, 2019, CHEM ENG RES DES, V145, P12, DOI 10.1016/j.cherd.2019.02.040
   Hong T, 1999, INT J MULTIPHAS FLOW, V25, P477, DOI 10.1016/S0301-9322(98)00056-1
   Hu L., 2013, A slurry airlift loop reactor and continuous separation equipment, Patent No. [CN203018065, 203018065]
   Huang Q., 2014, J CHEM IND ENG, V65, P2465
   Huang QS, 2017, ENGINEERING-PRC, V3, P318, DOI 10.1016/J.ENG.2017.03.020
   Huang QS, 2015, CHEM ENG SCI, V135, P441, DOI 10.1016/j.ces.2015.01.003
   Huang QS, 2011, CHEM ENG SCI, V66, P3930, DOI 10.1016/j.ces.2011.05.032
   Huang QS, 2010, CHEM ENG SCI, V65, P5527, DOI 10.1016/j.ces.2010.07.021
   JAMIALAHMADI M, 1991, CAN J CHEM ENG, V69, P390, DOI 10.1002/cjce.5450690149
   JOSHI JB, 1990, CAN J CHEM ENG, V68, P705, DOI 10.1002/cjce.5450680501
   Jurascik M, 2006, CHEM ENG J, V125, P81, DOI 10.1016/j.cej.2006.08.013
   KIM SD, 1977, CHEM ENG SCI, V32, P1299, DOI 10.1016/0009-2509(77)85024-0
   Krishna R, 1997, AICHE J, V43, P311, DOI 10.1002/aic.690430204
   Li D, 2018, CHINESE J CHEM ENG, V26, P1359, DOI 10.1016/j.cjche.2018.03.020
   Mena PC, 2005, CHEM ENG SCI, V60, P6013, DOI 10.1016/j.ces.2005.04.020
   Milivojevic M, 2012, J CHEM TECHNOL BIOT, V87, P1529, DOI 10.1002/jctb.3783
   Olivieri G, 2003, CHEM ENG J, V96, P45, DOI 10.1016/j.cej.2003.08.003
   Pashkova A, 2008, CHEM ENG J, V139, P165, DOI 10.1016/j.cej.2007.09.003
   Rabha S, 2013, AICHE J, V59, P1709, DOI 10.1002/aic.13920
   SADA E, 1986, AICHE J, V32, P853, DOI 10.1002/aic.690320516
   Sasaki S, 2017, EXP THERM FLUID SCI, V82, P359, DOI 10.1016/j.expthermflusci.2016.11.032
   Savchenko VI, 2016, CAN J CHEM ENG, V94, P518, DOI 10.1002/cjce.22413
   Su XF, 2003, CAN J CHEM ENG, V81, P412
   van der Zon A, 2002, CHEM ENG SCI, V57, P4845
   Verlaan P., 1987, P INT C BIOR BIOTR, P363
   Wang TF, 2003, POWDER TECHNOL, V137, P83, DOI 10.1016/j.powtec.2003.08.032
   Wen JP, 2003, BIOCHEM ENG J, V15, P153
   WHITE CM, 1998, Patent No. 5827903
   WILKINSON PM, 1992, AICHE J, V38, P544, DOI 10.1002/aic.690380408
   Xiao H, 2019, CHEM ENG SCI, V200, P214, DOI 10.1016/j.ces.2019.02.009
   Yang T, 2018, CHEM ENG SCI, V184, P126, DOI 10.1016/j.ces.2018.03.040
   Yang XF, 2014, PROCEEDINGS OF THE ASME INTERNAL COMBUSTION ENGINE DIVISION FALL TECHNICAL CONFERENCE, 2013, VOL 2
   ZAHRADNIK J, 1992, CHEM ENG PROCESS, V31, P263, DOI 10.1016/0255-2701(92)87019-D
   Zhang K, 2010, FUEL, V89, P1361, DOI 10.1016/j.fuel.2009.09.009
   Zhang QH, 2012, CHEM ENG TECHNOL, V35, P1842, DOI 10.1002/ceat.201200172
   Zhang WP, 2014, CHINESE J CHEM ENG, V22, P611, DOI 10.1016/S1004-9541(14)60089-6
   ZUBER N, 1965, J HEAT TRANSF, V87, P453, DOI 10.1115/1.3689137
NR 59
TC 0
Z9 0
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115294
DI 10.1016/j.ces.2019.115294
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300028
OA Bronze
DA 2020-05-12
ER

PT J
AU Gruber, S
   Vorhauer, N
   Schulz, M
   Hilmer, M
   Peters, J
   Tsotsas, E
   Foerst, P
AF Gruber, S.
   Vorhauer, N.
   Schulz, M.
   Hilmer, M.
   Peters, J.
   Tsotsas, E.
   Foerst, P.
TI Estimation of the local sublimation front velocities from neutron
   radiography and tomography of particulate matter
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Freeze-drying; Neutron radiography; Neutron tomography; Maltodextrin;
   Bulk; Sublimation front
ID PRIMARY DRYING TIMES; THERMAL-CONDUCTIVITY; MATHEMATICAL-MODEL; FROZEN;
   TRANSPORT; SIZE; FACILITY; DESIGN
AB With this study it was possible for the first time to visualize local sublimation front velocities of particle beds with neutron radiography and tomography. Few theoretical studies exist on the freeze-drying behavior of particle beds, but no experimental validation of the models exists basically due to the limits of traditional measurement techniques. The study was conducted at the neutron imaging facility ANTARES at the Heinz Maier Leibnitz Centre. Maltodextrin particles (x = 3550 mu m) with different solid concentrations (c = 0.05 w/w; c = 0.2 w/w) were investigated. For the radiography measurements, it is shown that a main sublimation front evolves from the bottom to the top of the bed. Tomography measurements (for particles with c= 0.05 w/w) confirmed the formation of radial drying fronts throughout the bed in addition to the main sublimation front. In general, both methods show overall good agreement and will be a valuable tool for further investigations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gruber, S.; Hilmer, M.; Foerst, P.] Tech Univ Munich, Chair Proc Syst Engn, Gregor Mendel Str 4, D-85354 Freising Weihenstephan, Germany.
   [Vorhauer, N.; Tsotsas, E.] Otto von Guericke Univ, Inst Proc Engn, Univ Pl 2, D-39106 Magdeburg, Germany.
   [Schulz, M.; Peters, J.] Tech Univ Munich, Heinz Maier Leibnitz Zentrum, Lichtenbergstr 1, D-85748 Garching, Germany.
RP Gruber, S (reprint author), Tech Univ Munich, Chair Proc Syst Engn, Gregor Mendel Str 4, D-85354 Freising Weihenstephan, Germany.
EM sebi.gruber@tum.de
RI Foerst, Petra/AAE-5957-2020; Tsotsas, Evangelos/E-6610-2013
OI Foerst, Petra/0000-0002-6381-1543; Tsotsas,
   Evangelos/0000-0001-9575-1138
FU FRM IIFondation pour la Recherche Medicale
FX We also gratefully acknowledge the financial support provided by FRM II
   to perform the neutron imaging measurements at the Heinz Maier-Leibnitz
   Zentrum (MLZ), Garching, Germany.
CR Aregawi W, 2013, INT J HEAT MASS TRAN, V67, P173, DOI 10.1016/j.ijheatmasstransfer.2013.08.017
   Arsiccio A, 2017, CRYST GROWTH DES, V17, P4573, DOI 10.1021/acs.cgd.7b00319
   Calzada E, 2009, NUCL INSTRUM METH A, V605, P50, DOI 10.1016/j.nima.2009.01.192
   Chen M., 2012, INT DRYING S
   Chitu T, 2015, DRY TECHNOL, V33, P1892, DOI 10.1080/07373937.2015.1066386
   Defraeye T, 2016, J FOOD ENG, V178, P198, DOI 10.1016/j.jfoodeng.2016.01.023
   Defraeye T, 2014, PLANTA, V240, P423, DOI 10.1007/s00425-014-2093-3
   Defraeye T, 2013, FOOD BIOPROCESS TECH, V6, P3353, DOI 10.1007/s11947-012-0999-y
   Foerst P., 2017, VISUALIZATION QUANTI
   Foerst P, 2019, J FOOD ENG, V260, P50, DOI 10.1016/j.jfoodeng.2019.05.002
   Hilmer M., 2019, SCI INSTRUMENT UNPUB
   Hottot A, 2004, DRY TECHNOL, V22, P2009, DOI 10.1081/DRT-200032717
   Koerner S, 2001, NUCL INSTRUM METH A, V471, P69, DOI 10.1016/S0168-9002(01)00917-2
   Krokida MK, 2001, INT J FOOD PROP, V4, P111, DOI 10.1081/JFP-100002191
   Li HY, 2006, NUCL INSTRUM METH A, V564, P405, DOI 10.1016/j.nima.2006.04.063
   Li XH, 2006, J PHARM SCI-US, V95, P2516, DOI 10.1002/jps.20731
   Liapis AI, 2009, INT J HEAT MASS TRAN, V52, P100, DOI 10.1016/j.ijheatmasstransfer.2008.06.026
   Maa YF, 1999, PHARMACEUT RES, V16, P249, DOI 10.1023/A:1018828425184
   Meister E., 2009, THESIS, P2009
   Meister E, 2009, J PHARM SCI-US, V98, P3072, DOI 10.1002/jps.21586
   Nakagawa K, 2018, EUR J PHARM BIOPHARM, V127, P279, DOI 10.1016/j.ejpb.2018.02.027
   Nakagawa K, 2015, J FOOD ENG, V161, P55, DOI 10.1016/j.jfoodeng.2015.03.033
   Oetjen G.-W., 1997, GEFRIERTROCKNEN
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pikal M.J., 1990, BIOPHARM, V3, P18
   Rutledge D. N., 1994, Journal of Food Process Engineering, V17, P325, DOI 10.1111/j.1745-4530.1994.tb00342.x
   Schulz M., 2015, J LARGE SCALE RES FA, V1, pA17, DOI [10.17815/jlsrf-1-42, DOI 10.17815/JLSRF-1-42]
   Schulz M., 2017, RESTAURIERUNG ARCHAO, V8, P9, DOI DOI 10.11588/RA.2015.0.37016
   Scussat S, 2016, FOOD BIOPHYS, V11, P207, DOI 10.1007/s11483-016-9431-x
   Sebastiao IB, 2019, J PHARM SCI-US, V108, P2063, DOI 10.1016/j.xphs.2019.01.009
   Sedighi-Gilani M, 2012, INT J HEAT MASS TRAN, V55, P6211, DOI 10.1016/j.ijheatmasstransfer.2012.06.045
   SLACK GA, 1980, PHYS REV B, V22, P3065, DOI 10.1103/PhysRevB.22.3065
   Tang XL, 2004, PHARM RES-DORDR, V21, P191, DOI 10.1023/B:PHAM.0000016234.73023.75
   Trelea IC, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3142975
   Wang W, 2018, INT J HEAT MASS TRAN, V122, P1353, DOI 10.1016/j.ijheatmasstransfer.2018.02.054
   Wang W, 2015, AICHE J, V61, P2048, DOI 10.1002/aic.14769
   Warning AD, 2015, FOOD BIOPROD PROCESS, V94, P637, DOI 10.1016/j.fbp.2014.08.011
NR 37
TC 2
Z9 2
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115268
DI 10.1016/j.ces.2019.115268
PG 11
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300019
OA Bronze
DA 2020-05-12
ER

PT J
AU Gu, JR
   Shao, YJ
   Zhong, WQ
AF Gu, Jinrao
   Shao, Yingjuan
   Zhong, Wenqi
TI Study on oxy-fuel combustion behaviors in a S-CO2 CFB by 3D CFD
   simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Oxy-fuel combustion; S-CO2 power cycle; Circulating fluidized bed;
   Computational fluid dynamics; Eulerian-Lagrangian approach
ID CIRCULATING FLUIDIZED-BED; CO2 POWER CYCLE; COAL COMBUSTION; DYNAMICS
   SIMULATION; TECHNOLOGY; PLANT; FLOW; AIR; CONVERSION; EMISSION
AB The supercritical CO2(S-CO2) power cycle CFB with oxy-fuel combustion is considered as a perspective carbon capture technology with high net efficiency. A three-dimensional (3D) CFD simulation using MP-PIC method was developed to predict oxy-fuel combustion in a 12 MWth S-CO2 CFB. This model couples the gas-solid flow, the heat transfers with combustion reactions, and takes into account of the particle size distribution. The effects of the different thermal wall boundary conditions and various O-2 concentration on the particle motion, combustion characteristics and gaseous pollutant emissions were systemically studied in this work. Results show that the combustion efficiency and the emission of CO, NO and SO2 in the S-CO2 boiler were higher than those in the conventional steam boiler. The increase in the inlet O-2 concentration increased the temperature of gas phase, the combustion efficiency and the desulfurization efficiency in the S-CO2 boiler. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gu, Jinrao; Shao, Yingjuan; Zhong, Wenqi] Southeast Univ, Sch Energy & Env Onment, Minist Educ, Key Lab Energy Thermal Convers & Control, Nanjing 210096, Jiangsu, Peoples R China.
RP Zhong, WQ (reprint author), Sipailou 2, Nanjing 210096, Jiangsu, Peoples R China.
EM wqzhong@seu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51876037]; Key Research and Development Program of
   Jiangsu Province [BE2017159]
FX This work was supported by the National Natural Science Foundation of
   China (51876037) and Key Research and Development Program of Jiangsu
   Province (BE2017159).
CR AMAND LE, 1991, ENERG FUEL, V5, P815
   Amarasinghe Widuramina S., 2017, International Journal of Modeling and Optimization, V7, P152, DOI 10.7763/IJMO.2017.V7.575
   Amoo LM, 2015, FUEL, V140, P178, DOI 10.1016/j.fuel.2014.09.076
   Basu P, 1999, CHEM ENG SCI, V54, P5547, DOI 10.1016/S0009-2509(99)00285-7
   Binotti M, 2017, ENRGY PROCED, V105, P1116, DOI 10.1016/j.egypro.2017.03.475
   Buhre BJP, 2005, PROG ENERG COMBUST, V31, P283, DOI 10.1016/j.pecs.2005.07.001
   Cui Y., 2018, 13 INT C CFD MIN PRO, P214
   Czakiert T, 2006, FUEL PROCESS TECHNOL, V87, P531, DOI 10.1016/j.fuproc.2005.12.003
   Czakiert T, 2012, ENERG FUEL, V26, P5437, DOI 10.1021/ef3011838
   Duan LB, 2019, COMBUST FLAME, V206, P227, DOI 10.1016/j.combustflame.2019.05.008
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Fei Y, 2015, FUEL PROCESS TECHNOL, V131, P45, DOI 10.1016/j.fuproc.2014.10.042
   Fitzsimmons M, 2019, DOEGTI0025160, DOI [10.2172/1503904, DOI 10.2172/1503904]
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Gu JR, 2019, POWDER TECHNOL, V351, P16, DOI 10.1016/j.powtec.2019.04.008
   Gu JR, 2018, CHEM ENG SCI, V192, P619, DOI 10.1016/j.ces.2018.08.008
   Guedea I, 2013, CHEM ENG J, V228, P179, DOI 10.1016/j.cej.2013.04.085
   Gungor A, 2008, INT J THERM SCI, V47, P157, DOI 10.1016/j.ijthermalsci.2007.01.017
   Gyftopoulos EP, 2005, THERMODYNAMICS FDN A
   Holcomb GR, 2016, CORROS SCI, V109, P22, DOI 10.1016/j.corsci.2016.03.018
   Krzywanski J, 2010, FUEL PROCESS TECHNOL, V91, P290, DOI 10.1016/j.fuproc.2009.10.011
   Le Moullec Y, 2013, ENERGY, V49, P32, DOI 10.1016/j.energy.2012.10.022
   Lee WW, 2017, DESALINATION, V409, P136, DOI 10.1016/j.desal.2017.01.013
   Li MJ, 2017, APPL THERM ENG, V126, P255, DOI 10.1016/j.applthermaleng.2017.07.173
   Li SY, 2017, APPL ENERG, V197, P203, DOI 10.1016/j.apenergy.2017.03.028
   Li SY, 2016, APPL ENERG, V173, P197, DOI 10.1016/j.apenergy.2016.02.054
   Li W, 2014, ENERG FUEL, V28, P1249, DOI 10.1021/ef4020422
   Liu QW, 2019, POWDER TECHNOL, V349, P40, DOI 10.1016/j.powtec.2019.03.035
   Liu XJ, 2019, ENERGY, V176, P468, DOI 10.1016/j.energy.2019.03.170
   Loison R., 1964, PYROLYSE RAPIDE CHAR
   Mecheri M, 2016, ENERGY, V103, P758, DOI 10.1016/j.energy.2016.02.111
   Moldestad B.M.E., 2017, P 58 C SIM MOD 2017, P60, DOI [10.3384/ecp1713860, DOI 10.3384/ECP1713860]
   Rao AB, 2002, ENVIRON SCI TECHNOL, V36, P4467, DOI 10.1021/es0158861
   Shi Y, 2019, J THERM SCI, V28, P505, DOI 10.1007/s11630-019-1094-8
   Snider DM, 2011, CHEM ENG SCI, V66, P1285, DOI 10.1016/j.ces.2010.12.042
   Stewart MC, 2012, FUEL, V92, P107, DOI 10.1016/j.fuel.2011.06.054
   Tan Y, 2012, APPL ENERG, V92, P343, DOI 10.1016/j.apenergy.2011.11.037
   Toftegaard MB, 2010, PROG ENERG COMBUST, V36, P581, DOI 10.1016/j.pecs.2010.02.001
   Upadhyay M, 2017, POWDER TECHNOL, V318, P350, DOI 10.1016/j.powtec.2017.06.021
   Wang FJ, 2018, APPL THERM ENG, V143, P711, DOI 10.1016/j.applthermaleng.2018.07.145
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Wright S.A., 2010, SANDIA REP, DOI [10.2172/984129, DOI 10.2172/984129]
   Wu Y, 2018, FUEL, V216, P596, DOI 10.1016/j.fuel.2017.12.042
   Xie J, 2017, ENERG FUEL, V31, P14248, DOI 10.1021/acs.energyfuels.7b02693
   Xu JL, 2018, ENERGY, V157, P227, DOI 10.1016/j.energy.2018.05.162
   Yin CG, 2011, FUEL, V90, P2519, DOI 10.1016/j.fuel.2011.03.023
   YOON H, 1978, AICHE J, V24, P885, DOI 10.1002/aic.690240515
   Yue GX, 2017, POWDER TECHNOL, V316, P18, DOI 10.1016/j.powtec.2016.10.062
   Zhou W, 2011, INT J GREENH GAS CON, V5, P1489, DOI 10.1016/j.ijggc.2011.08.006
NR 49
TC 1
Z9 1
U1 22
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115262
DI 10.1016/j.ces.2019.115262
PG 12
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300055
OA Bronze
DA 2020-05-12
ER

PT J
AU Izida, T
   Silva, JR
   Andrade, LHC
   Simionatto, E
   Simionatto, EL
   Scharf, DR
   Lima, SM
AF Izida, T.
   Silva, J. R.
   Andrade, L. H. C.
   Simionatto, E.
   Simionatto, E. L.
   Scharf, D. R.
   Lima, S. M.
TI Modeling transesterification reaction kinetics using fluorescence
   spectroscopy to interpret biodiesel production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluorescence; Biodiesel; Transesterification kinetics; Glycerol
   fluorescence; Ester production
ID SUNFLOWER OIL; ETHANOL; ESTERS
AB In this work, the time dependence of the crude glycerol production was obtained experimentally in different reactions by fluorescence spectroscopy, and the curves were fitted by a new mathematical model, derived from rate equations, in order to elucidate the behavior of the compounds involved in transesterification reactions, including the speed and ester yield. The values were validated by comparison with the results of analyses performed using gas chromatography with flame ionization detection. The fitting of the glycerol fluorescence signal as a function of time by the proposed theoretical model was shown to be highly suitable for indicating the time at which the reaction should be stopped, hence minimizing costs and the time required for biodiesel production. Keywords: Fluorescence Biodiesel Transesterification kinetics Glycerol fluorescence Ester production. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Izida, T.; Silva, J. R.; Andrade, L. H. C.; Simionatto, E.; Lima, S. M.] Univ Estadual Mato Grosso do Sul, Grp Espectroscopia Opt & Fototerm, Programa Posgrad Recursos Nat, CP 351, BR-79804970 Dourados, MS, Brazil.
   [Simionatto, E. L.; Scharf, D. R.] Fundacao Univ Reg Blumenau, Lab Cromatog, Rua Sao Paulo 3259, BR-89030000 Blumenau, SC, Brazil.
RP Lima, SM (reprint author), Univ Estadual Mato Grosso do Sul UEMS, GEOF, PGRN, CP 351, BR-79804970 Dourados, MS, Brazil.
EM smlima@uems.br
RI Silva, R/H-3919-2012; Lima, Sandro Marcio/O-5825-2018
OI Silva, R/0000-0002-7268-6465; Lima, Sandro Marcio/0000-0002-3270-6628
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e
   Tecnologia do Estado de Mato Grosso do Sul (FUNDECT)Fundect; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [304029/2015-7, 305412/2014-0]
FX The authors thank Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) for an undergraduate fellowship awarded to the first
   author, Fundacao de Apoio ao Desenvolvimento do Ensino, Ciencia e
   Tecnologia do Estado de Mato Grosso do Sul (FUNDECT) and Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), (SML, grant
   number 304029/2015-7), (LHCA, grant number 305412/2014-0).
CR Chowdhury Jahangir, 2017, International Journal of Mathematical Models and Methods in Applied Sciences, V11, P130
   Conceicao JN, 2019, FUEL PROCESS TECHNOL, V183, P1, DOI 10.1016/j.fuproc.2018.10.022
   de Lima SM, 2014, FUEL, V115, P46, DOI 10.1016/j.fuel.2013.06.057
   European Standards, 14103 EN
   Froehner S, 2017, ENVIRON SCI POLLUT R, V24, P20747, DOI 10.1007/s11356-017-9593-1
   Fukuda H, 2001, J BIOSCI BIOENG, V92, P405, DOI 10.1016/S1389-1723(01)80288-7
   Fukuda T, 2014, SENSOR ACTUAT B-CHEM, V203, P536, DOI 10.1016/j.snb.2014.06.045
   Hoque ME, 2011, BIOMASS BIOENERG, V35, P1582, DOI 10.1016/j.biombioe.2010.12.024
   Izida T, 2015, FUEL, V145, P109, DOI 10.1016/j.fuel.2014.12.077
   Janajreh I, 2015, ENRGY PROCED, V75, P547, DOI 10.1016/j.egypro.2015.07.451
   Kamil RNM, 2010, BIORESOURCE TECHNOL, V101, P5877, DOI 10.1016/j.biortech.2010.02.084
   Killner MHM, 2011, FUEL, V90, P3268, DOI 10.1016/j.fuel.2011.06.025
   Knothe G, 2006, J AM OIL CHEM SOC, V83, P823, DOI 10.1007/s11746-006-5033-y
   Komers K, 2002, EUR J LIPID SCI TECH, V104, P728, DOI 10.1002/1438-9312(200211)104:11<728::AID-EJLT728>3.0.CO;2-J
   Leung DYC, 2010, APPL ENERG, V87, P1083, DOI 10.1016/j.apenergy.2009.10.006
   Likozar B, 2014, FUEL PROCESS TECHNOL, V122, P30, DOI 10.1016/j.fuproc.2014.01.017
   Marjanovic AV, 2010, FUEL, V89, P665, DOI 10.1016/j.fuel.2009.09.025
   Michels FS, 2017, FUEL, V193, P395, DOI 10.1016/j.fuel.2016.12.085
   Noureddini H, 1997, J AM OIL CHEM SOC, V74, P1457, DOI 10.1007/s11746-997-0254-2
   Pinzi S, 2011, BIORESOURCE TECHNOL, V102, P1044, DOI 10.1016/j.biortech.2010.08.029
   Pinzi S, 2012, FUEL, V92, P354, DOI 10.1016/j.fuel.2011.07.006
   Qin TY, 2018, SENSOR ACTUAT B-CHEM, V277, P484, DOI 10.1016/j.snb.2018.09.056
   Reyero I, 2015, FUEL PROCESS TECHNOL, V129, P147, DOI 10.1016/j.fuproc.2014.09.008
   Richard R, 2013, CHEM ENG SCI, V87, P258, DOI 10.1016/j.ces.2012.10.014
   Richard R, 2011, BIORESOURCE TECHNOL, V102, P6702, DOI 10.1016/j.biortech.2011.03.111
   Yunus R, 2004, J AM OIL CHEM SOC, V81, P497, DOI 10.1007/s11746-004-0930-7
NR 26
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115292
DI 10.1016/j.ces.2019.115292
PG 9
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300039
OA Bronze
DA 2020-05-12
ER

PT J
AU Jantzen, T
   Petersen, S
   Hack, K
AF Jantzen, Tatjana
   Petersen, Stephan
   Hack, Klaus
TI Thermodynamic assessment of the Fe-Sr-O system with special attention to
   the Perovskite phase
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Strontium oxide; Perovskite; Strontium ferrites; Phase diagrams;
   Thermodynamic modelling
ID REGULAR SOLUTION MODEL
AB In the present work a thermodynamic assessment for the Fe-Sr-O system is presented using all available experimental data on phase equilibria and thermodynamic properties. All sub-systems including elemental combinations were considered in order to generate a self-consistent Gibbs energy dataset for further calculation and prediction of thermodynamic properties of the system. The modified associate species model was used for the description of the liquid phase. Particular attention was given to the phase Perovskite SrFeO3-(delta) based on Brownmillerite SrFeO2.5 and extending significantly to higher amounts of oxygen, i.e. the SrFeO3 composition, according to the formula SrFeO3-delta. In addition to the component oxides five quasi-binary compounds located in the Fe2O3-SrO binary subsystem have also been included in the database as stoichiometric phases. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jantzen, Tatjana; Petersen, Stephan; Hack, Klaus] GTT Technol, Kaiserstr 103, D-52134 Herzogenrath, Germany.
RP Jantzen, T (reprint author), GTT Technol, Kaiserstr 103, D-52134 Herzogenrath, Germany.
EM tj@gtt-technologies.de
FU state of Northrhine-Westfalia, Germany [EFRE-0800605]; European EFRE
   fundEuropean Union (EU)
FX This work has received funding in the framework of the project DUSOL
   (EFRE-0800605) which is co-funded in the Klimaschutzwettbewerb
   "ErneuerbareEnergien.NRW" by the state of Northrhine-Westfalia, Germany,
   and the European EFRE fund.
CR AGEEV YA, 1985, ZH FIZ KHIM+, V59, P838
   Bale CW, 2016, CALPHAD, V54, P35, DOI 10.1016/j.calphad.2016.05.002
   Batti P, 1962, ANN CHIM-ROME, V52, P941
   Besmann TM, 2002, J AM CERAM SOC, V85, P2887
   Bulfin B, 2019, CHEM ENG SCI, V203, P68, DOI 10.1016/j.ces.2019.03.057
   Fossdal A, 2004, J SOLID STATE CHEM, V177, P2933, DOI 10.1016/j.jssc.2004.05.007
   Goto Y, 1971, J JAPAN SOC POWDER P, V17, P193
   HILLERT M, 1970, ACTA CHEM SCAND, V24, P3618, DOI 10.3891/acta.chem.scand.24-3618
   Lukas H.L.H.L., 2007, COMPUTATIONAL THERMO
   Massalski TB, 1990, BINARY ALLOY PHASE D
   MIZUSAKI J, 1992, J SOLID STATE CHEM, V99, P166, DOI 10.1016/0022-4596(92)90301-B
   Pearson W.B., 1967, HDB LATTICE SPACINGS, V2
   Peng YBA, 2011, J PHASE EQUILIB DIFF, V32, P42, DOI 10.1007/s11669-010-9818-1
   Rakshit SK, 2007, J SOLID STATE CHEM, V180, P523, DOI 10.1016/j.jssc.2006.11.012
   Revzin B., 1995, S C THERMODYNAMICS K, V398, P649
   Risold D, 1996, CALPHAD, V20, P353, DOI 10.1016/S0364-5916(96)00037-5
   Sharma P, 2005, J MATER PROCESS TECH, V168, P147, DOI 10.1016/j.jmatprotec.2004.12.003
   Stull D.R., 1985, THERMOCHEMICAL TABLE
   SUNDMAN B, 1985, CALPHAD, V9, P153, DOI 10.1016/0364-5916(85)90021-5
   SUNDMAN B, 1981, J PHYS CHEM SOLIDS, V42, P297, DOI 10.1016/0022-3697(81)90144-X
   Sundman B., 1991, J PHASE EQUILIB, V12, P127, DOI DOI 10.1007/BF02645709
   Swanson H.E, 1956, NBS CIRC, V539
   TAKEDA Y, 1986, J SOLID STATE CHEM, V63, P237, DOI 10.1016/0022-4596(86)90174-X
   Vieten J, 2016, J MATER CHEM A, V4, P13652, DOI 10.1039/c6ta04867f
NR 24
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115271
DI 10.1016/j.ces.2019.115271
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300057
OA Bronze
DA 2020-05-12
ER

PT J
AU Jiang, ZC
   Rieck, C
   Buck, A
   Tsotsas, E
AF Jiang, Zhaochen
   Rieck, Christian
   Bueck, Andreas
   Tsotsas, Evangelos
TI Modeling of inter- and intra-particle coating uniformity in a Wurster
   fluidized bed by a coupled CFD-DEM-Monte Carlo approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Coating; Surface coverage; Monte Carlo; CFD-DEM; Wurster fluidized bed
ID RESIDENCE TIME DISTRIBUTIONS; DROP IMPACT; WET GRANULATION;
   SOLID-SURFACES; SPRAY ZONE; SIMULATION; ATOMIZATION; THICKNESS;
   DYNAMICS; EVAPORATION
AB A coupled CFD-DEM and Monte Carlo approach was developed to investigate coating properties in a Wurster fluidized bed by considering gas flow, particle motion, droplet deposition, and the drying and solidifying of droplets on particle surfaces. Based on the spherical centroidal Voronoi tessellation (CVT), the Monte Carlo approach can model the deposition and splashing of spray droplets on the surface of individual particles. The capillary force induced by liquid bridges between particles was accounted in the DEM to investigate its influence on the coating and agglomeration behavior. The new model can provide information about the cycle time distribution, residence time distribution, coating coverage, uniformity of porosity (influenced by splashing) and layer thickness distributions on each individual particle (intra particle) and in the particle population (inter particle). The simulation results are compared with experimental data on residence time and intra-particle layer thickness distributions. Good agreement is observed between the simulation and the measurements. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jiang, Zhaochen; Bueck, Andreas] FAU Erlangen Nuremberg, Inst Particle Technol LFG, Cauerstr 4, D-91058 Erlangen, Germany.
   [Jiang, Zhaochen; Rieck, Christian; Tsotsas, Evangelos] Otto von Guericke Univ, Thermal Proc Engn, Univ Pl 2, D-39106 Magdeburg, Germany.
RP Jiang, ZC (reprint author), FAU Erlangen Nuremberg, Inst Particle Technol LFG, Cauerstr 4, D-91058 Erlangen, Germany.
EM zhaochen.jiang@fau.de
RI Tsotsas, Evangelos/E-6610-2013
OI Tsotsas, Evangelos/0000-0001-9575-1138
FU German Federal Ministry of Science and Education (BMBF)Federal Ministry
   of Education & Research (BMBF) [03IPT701X]; German Research Foundation
   (DFG)German Research Foundation (DFG) [DFG-SPP 1679]
FX The authors gratefully acknowledge the funding of this work by the
   German Federal Ministry of Science and Education (BMBF) as part of the
   InnoProfile-Transfer project NaWiTec (03IPT701X) and by the German
   Research Foundation (DFG) as part of the priority program "Dyn-Sim-FP"
   (DFG-SPP 1679).
CR Ai J, 2011, POWDER TECHNOL, V206, P269, DOI 10.1016/j.powtec.2010.09.030
   Antypov D, 2011, EPL-EUROPHYS LETT, V94, DOI 10.1209/0295-5075/94/50004
   Askarishahi M, 2017, AICHE J, V63, P2569, DOI 10.1002/aic.15616
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Beetstra R, 2007, CHEM ENG SCI, V62, P246, DOI 10.1016/j.ces.2006.08.054
   Borner M, 2017, CHEM ENG SCI, V161, P187, DOI 10.1016/j.ces.2016.12.020
   Borner M, 2014, CHEM ENG SCI, V116, P317, DOI 10.1016/j.ces.2014.05.007
   Buck A, 2016, POWDER TECHNOL, V300, P37, DOI 10.1016/j.powtec.2016.03.019
   Cheng XX, 2000, PHARM DEV TECHNOL, V5, P311, DOI 10.1081/PDT-100100546
   Crowe C.T., 2011, MULTIPHASE FLOWS DRO
   Du Q, 1999, SIAM REV, V41, P637, DOI 10.1137/S0036144599352836
   Freireich B, 2015, CHEM ENG SCI, V131, P197, DOI 10.1016/j.ces.2015.03.013
   Freireich B, 2010, CHEM ENG SCI, V65, P1117, DOI 10.1016/j.ces.2009.09.066
   Fries L, 2011, CHEM ENG SCI, V66, P2340, DOI 10.1016/j.ces.2011.02.038
   Gnielinski V., 2010, VDI HEAT ATLAS, P743
   Goniva C, 2012, PARTICUOLOGY, V10, P582, DOI 10.1016/j.partic.2012.05.002
   Hampel N, 2013, CHEM ENG SCI, V86, P87, DOI 10.1016/j.ces.2012.05.034
   Hede PD, 2008, CHEM ENG SCI, V63, P3821, DOI 10.1016/j.ces.2008.04.014
   Heinrich S., 2015, MESOSCALE MODELING C, V46, P83, DOI DOI 10.1016/BS.ACHE.2015.10.012
   Hilton JE, 2013, CHEM ENG SCI, V99, P141, DOI 10.1016/j.ces.2013.05.051
   Jiang X, 2010, PROG ENERG COMBUST, V36, P131, DOI 10.1016/j.pecs.2009.09.002
   Jiang ZC, 2020, POWDER TECHNOL, V360, P352, DOI 10.1016/j.powtec.2019.10.072
   Jiang ZC, 2018, DRY TECHNOL, V36, P638, DOI 10.1080/07373937.2017.1319852
   Jiang ZC, 2018, CHEM ENG SCI, V179, P115, DOI 10.1016/j.ces.2018.01.013
   Jiang ZC, 2017, CHEM ENG SCI, V167, P297, DOI 10.1016/j.ces.2017.04.024
   Josserand C, 2016, ANNU REV FLUID MECH, V48, P365, DOI 10.1146/annurev-fluid-122414-034401
   Kieckhefen P, 2019, PARTICUOLOGY, V42, P92, DOI 10.1016/j.partic.2018.01.008
   Knop K, 2013, INT J PHARMACEUT, V457, P527, DOI 10.1016/j.ijpharm.2013.01.062
   Koay CG, 2011, J COMPUT SCI-NETH, V2, P88, DOI 10.1016/j.jocs.2010.12.003
   Kulju T, 2016, CHEM ENG SCI, V142, P190, DOI 10.1016/j.ces.2015.11.032
   Laksmana FL, 2009, PHARM RES-DORDR, V26, P965, DOI 10.1007/s11095-008-9805-y
   Li L, 2015, POWDER TECHNOL, V280, P124, DOI 10.1016/j.powtec.2015.04.031
   Li L, 2015, AICHE J, V61, P756, DOI 10.1002/aic.14692
   LIAN GP, 1993, J COLLOID INTERF SCI, V161, P138, DOI 10.1006/jcis.1993.1452
   Lin HY, 2017, J PHARM SCI-US, V106, P1075, DOI 10.1016/j.xphs.2016.12.012
   Liu DY, 2016, AICHE J, V62, P2259, DOI 10.1002/aic.15219
   LLOYD SP, 1982, IEEE T INFORM THEORY, V28, P129, DOI 10.1109/TIT.1982.1056489
   Luo K, 2019, PROG ENERG COMBUST, V73, P65, DOI 10.1016/j.pecs.2019.03.001
   Meric RA, 1998, LANGMUIR, V14, P1915, DOI 10.1021/la970147c
   Muller D, 2019, POWDER TECHNOL, V342, P572, DOI 10.1016/j.powtec.2018.10.024
   MUNDO C, 1995, INT J MULTIPHAS FLOW, V21, P151, DOI 10.1016/0301-9322(94)00069-V
   Peglow M, 2011, MODERN DRYING TECHNOLOGY, VOL 3: PRODUCT QUALITY AND FORMULATION, P295
   Pei CL, 2017, CHEM ENG SCI, V172, P286, DOI 10.1016/j.ces.2017.06.029
   Poozesh S, 2018, CHEM ENG SCI, V180, P42, DOI 10.1016/j.ces.2018.01.033
   Rajniak P, 2009, POWDER TECHNOL, V189, P190, DOI 10.1016/j.powtec.2008.04.027
   Rieck C, 2015, POWDER TECHNOL, V272, P120, DOI 10.1016/j.powtec.2014.11.019
   Rieck C, 2016, AICHE J, V62, P2670, DOI 10.1002/aic.15237
   Rioboo R, 2002, EXP FLUIDS, V33, P112, DOI [10.1007/s00348-002-0431-X, 10.1007/s00348-002-0431-x]
   ROBERTS RJ, 1994, INT J PHARM, V105, P177, DOI 10.1016/0378-5173(94)90463-4
   Schmidt M, 2017, ADV POWDER TECHNOL, V28, P2921, DOI 10.1016/j.apt.2017.08.020
   Sondej F, 2016, POWDER TECHNOL, V287, P330, DOI 10.1016/j.powtec.2015.09.039
   Sondej F, 2015, POWDER TECHNOL, V273, P165, DOI 10.1016/j.powtec.2014.12.050
   Soulie F, 2006, INT J NUMER ANAL MET, V30, P213, DOI 10.1002/nag.476
   Suzzi D, 2010, CHEM ENG SCI, V65, P5699, DOI 10.1016/j.ces.2010.07.007
   Terrazas-Velarde K, 2011, CHEM ENG SCI, V66, P1866, DOI 10.1016/j.ces.2011.01.037
   Turton R, 2008, POWDER TECHNOL, V181, P186, DOI 10.1016/j.powtec.2006.12.006
   Wang JW, 2011, CHEM ENG SCI, V66, P4229, DOI 10.1016/j.ces.2011.06.004
   Werner SRL, 2007, POWDER TECHNOL, V171, P25, DOI 10.1016/j.powtec.2006.08.014
   Yarin AL, 2006, ANNU REV FLUID MECH, V38, P159, DOI 10.1146/annurev.fluid.38.050304.092144
   YARIN AL, 1995, J FLUID MECH, V283, P141, DOI 10.1017/S0022112095002266
   Zhang W, 2015, POWDER TECHNOL, V283, P128, DOI 10.1016/j.powtec.2015.05.025
   Zhao H, 2007, POWDER TECHNOL, V173, P38, DOI 10.1016/j.powtec.2006.12.010
   Zhong WQ, 2016, POWDER TECHNOL, V302, P108, DOI 10.1016/j.powtec.2016.07.010
   Zhong WQ, 2016, CHEM ENG SCI, V140, P16, DOI 10.1016/j.ces.2015.09.035
   Zhou ZY, 2010, J FLUID MECH, V661, P482, DOI 10.1017/S002211201000306X
   Zhu RR, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.022206
NR 66
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115289
DI 10.1016/j.ces.2019.115289
PG 18
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300038
OA Bronze
DA 2020-05-12
ER

PT J
AU Kalman, H
   Rawat, A
AF Kalman, Haim
   Rawat, Anubhav
TI Flow regime chart for pneumatic conveying
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pneumatic conveying; Flow regime chart; Plug flow; Dune flow; Dilute
   phase flow
ID PRESSURE-DROP; PARTICULATE PLUGS; SLUG; VELOCITY; TRANSPORT
AB Dense phase pneumatic conveying is preferred by industry over dilute phase flow due to its advantages. Models enabling to calculate pressure drop are worthless for a designer if he is unable to predict in advance the mode of conveying. Therefore, this research is focused on developing a new flow regime chart. Based on hundreds of experiments all required threshold velocities are defined by Reynolds number as a simple power function of Archimedes number. This work, revealed two new kind of plugs unknown before. Using the threshold functions a new flow regime chart was plotted By comparing the results to previously published models characterizing only the material properties revealed that the feeder is probably have a major role controlling the final mode of flow. Taking into account the findings in this paper, one might have ideas of how to improve the feeders in order to fully fulfill the flow potential. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kalman, Haim; Rawat, Anubhav] Ben Gurion Univ Negev, Dept Mech Engn, Lab Conveying & Handling Particulate Solids, POB 653, IL-84105 Beer Sheva, Israel.
   [Kalman, Haim] Aron Fish Chair Mech Engn Fracture Mech, Beer Sheva, Israel.
RP Kalman, H (reprint author), Ben Gurion Univ Negev, Dept Mech Engn, Lab Conveying & Handling Particulate Solids, POB 653, IL-84105 Beer Sheva, Israel.; Kalman, H (reprint author), Aron Fish Chair Mech Engn Fracture Mech, Beer Sheva, Israel.
EM hkalman@bgu.ac.il
FU Israeli Ministry of Science, Technology, and Space [2015-6-145]
FX This research is supported by the Israeli Ministry of Science,
   Technology, and Space (2015-6-145).
CR AZIZ ZB, 1990, POWDER TECHNOL, V62, P41, DOI 10.1016/0032-5910(90)80021-P
   BORZONE LA, 1987, POWDER TECHNOL, V53, P273, DOI 10.1016/0032-5910(87)80100-6
   Borzone LA, 2010, CHEM ENG COMMUN, V197, P1215, DOI 10.1080/00986440903574891
   Dixon G., 1979, P INT C PNEUM CONV 1
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   Hong G., 1989, POWDER TECHNOL, V57, P59
   Janssen H.A., 1895, Z VEREINS DTSCH ING, V39, P1045
   JONES M.G., 1990, POWDER HANDLING PROC, V2, P117
   Jones M.G., 1988, THESIS
   Kalman H, 2005, POWDER TECHNOL, V160, P103, DOI 10.1016/j.powtec.2005.08.009
   KONRAD K, 1984, POWDER TECHNOL, V39, P191, DOI 10.1016/0032-5910(84)85036-6
   Konrad K., 1980, P PNEUM 5, V5
   Lecreps I, 2014, POWDER TECHNOL, V262, P82, DOI 10.1016/j.powtec.2014.04.058
   Lecreps I, 2014, POWDER TECHNOL, V254, P508, DOI 10.1016/j.powtec.2014.01.056
   Lecreps I, 2009, PARTICUL SCI TECHNOL, V27, P297, DOI 10.1080/02726350902990991
   Lecreps  I., 2007, BULK SOLIDS POWDER S, V2, P95
   Li J, 2002, PARTICUL SCI TECHNOL, V20, P283, DOI 10.1080/02726350216189
   Mainwaring N. J., 1987, BULK SOLIDS HANDLING, V7, P415
   MI B, 1995, POWDER TECHNOL, V84, P91, DOI 10.1016/0032-5910(95)02974-7
   MUSCHELKNAUTZ E, 1969, CHEM-ING-TECH, V41, P1164, DOI 10.1002/cite.330412104
   Nied C, 2017, POWDER TECHNOL, V321, P310, DOI 10.1016/j.powtec.2017.07.072
   Pahk JB, 2010, PARTICUL SCI TECHNOL, V28, P511, DOI 10.1080/02726350903579322
   Pan R, 1999, POWDER TECHNOL, V104, P157, DOI 10.1016/S0032-5910(99)00044-3
   Pan R, 1997, POWDER TECHNOL, V94, P123, DOI 10.1016/S0032-5910(97)03290-7
   Rabinovich E, 2008, POWDER TECHNOL, V183, P304, DOI 10.1016/j.powtec.2007.07.030
   Rabinovich E, 2008, POWDER TECHNOL, V185, P67, DOI 10.1016/j.powtec.2007.10.001
   Rabinovich E, 2011, POWDER TECHNOL, V207, P119, DOI 10.1016/j.powtec.2010.10.017
   Rabinovich E, 2010, CHEM ENG SCI, V65, P739, DOI 10.1016/j.ces.2009.09.027
   Rawat A., 2019, PARTICLE VELOC UNPUB
   Rawat A, 2019, POWDER TECHNOL, V347, P243, DOI 10.1016/j.powtec.2019.03.005
   Rawat A, 2017, POWDER TECHNOL, V321, P293, DOI 10.1016/j.powtec.2017.08.043
   Sanchez L, 2005, POWDER TECHNOL, V153, P142, DOI 10.1016/j.powtec.2005.03.005
   Sanchez L, 2003, POWDER TECHNOL, V138, P93, DOI 10.1016/j.powtec.2003.08.061
   Shaul S, 2015, POWDER TECHNOL, V283, P579, DOI 10.1016/j.powtec.2015.05.047
   Shaul S, 2015, POWDER TECHNOL, V272, P322, DOI 10.1016/j.powtec.2014.12.004
   Shaul S, 2014, POWDER TECHNOL, V256, P310, DOI 10.1016/j.powtec.2014.02.036
   Tomita Y, 2009, POWDER TECHNOL, V196, P14, DOI 10.1016/j.powtec.2009.06.012
   Vasquez N, 2003, POWDER TECHNOL, V137, P167, DOI 10.1016/j.powtec.2003.08.060
NR 38
TC 2
Z9 2
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115256
DI 10.1016/j.ces.2019.115256
PG 12
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300024
OA Bronze
DA 2020-05-12
ER

PT J
AU Li, F
   Leung, DYC
AF Li, Fang
   Leung, Dennis Y. C.
TI Highly enhanced performance of heterojunction Bi2S3/BiVO4 photoanode for
   photoelectrocatalytic hydrogen production under solar light irradiation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE BiVO4; Bi2S3; Heterojunction; Photoelectrocatalysis; Hydrogen production
ID CHARGE-CARRIER SEPARATION; DOPED BIVO4; PHOTOCATALYTIC PERFORMANCES;
   BI2S3 NANOWIRES; QUANTUM DOTS; WATER; TIO2; DEGRADATION; FABRICATION;
   INSIGHT
AB A heterojunction structure of BiVO4 coupled with a narrow bandgap photocatalyst Bi2S3 was fabricated forming a composite material with strong capacity in visible light absorption and enhancement in the separation rate of photogenerated charge carriers owing to their suitable band structures. As a result, efficiency of hydrogen production through photoelectrocatalysis is highly enhanced. The morphology and composition of as-prepared sample electrodes are measured through X-Ray Diffraction (XRD), scanning electron microscopy (SEM), high resolution transmission electron microscopy (HR-TEM) and X-ray photoelectron spectroscopy (XPS). The performance of the hybrid nanostructure Bi2S3/BiVO4 photoelectrode was found to be related to the growing process of Bi2S3 nanowire during the hydrothermal preparation process. The composited Bi2S3/BiVO4 photoanode achieved a photoconversion efficiency of 2.9% which is nearly 3-fold that of the bare BiVO4 electrode under visible light irradiation, while the hydrogen production was greatly enhanced by nearly 5-fold in the photoelectrocatalytic hydrogen production reaction. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Fang; Leung, Dennis Y. C.] Univ Hong Kong, Dept Mech Engn, Hong Kong, Peoples R China.
RP Leung, DYC (reprint author), Univ Hong Kong, Dept Mech Engn, Hong Kong, Peoples R China.
EM ycleung@hku.hk
OI Leung, Dennis Y.C./0000-0002-8917-0916
FU Research Grants Council (RGC) of Hong KongHong Kong Research Grants
   Council [HKU718/15]
FX The project is supported by the Research Grants Council (RGC) of Hong
   Kong (HKU718/15).
CR Behara DK, 2016, CHEM ENG SCI, V154, P150, DOI 10.1016/j.ces.2016.06.063
   Cui WQ, 2014, CATAL COMMUN, V48, P55, DOI 10.1016/j.catcom.2014.01.026
   Elbakkay MH, 2018, APPL SURF SCI, V439, P1088, DOI 10.1016/j.apsusc.2018.01.070
   FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0
   Gan JY, 2014, NANOSCALE, V6, P7142, DOI 10.1039/c4nr01181c
   Ge ZH, 2012, J MATER CHEM, V22, P17589, DOI 10.1039/c2jm33603k
   Hernandez-Gordillo A, 2014, APPL CATAL B-ENVIRON, V144, P507, DOI 10.1016/j.apcatb.2013.07.030
   Iwase A, 2018, J PHOTOCH PHOTOBIO A, V353, P284, DOI 10.1016/j.jphotochem.2017.11.025
   Jiang WJ, 2018, APPL CATAL B-ENVIRON, V236, P428, DOI 10.1016/j.apcatb.2018.05.050
   Jo WJ, 2012, ANGEW CHEM INT EDIT, V51, P3147, DOI 10.1002/anie.201108276
   Kumar SG, 2017, APPL SURF SCI, V391, P124, DOI 10.1016/j.apsusc.2016.07.081
   Lee JM, 2019, J MATER CHEM A, V7, P9019, DOI 10.1039/c9ta00205g
   Li F, 2019, J NANOPART RES, V21, DOI 10.1007/s11051-018-4443-8
   Li GS, 2013, NANOSCALE, V5, P2118, DOI 10.1039/c3nr34253k
   Li HJ, 2015, ADV FUNCT MATER, V25, P998, DOI 10.1002/adfm.201401636
   Li H, 2019, CHEM COMMUN, V55, P2741, DOI 10.1039/c9cc00050j
   Li HQ, 2014, MATER SCI ENG B-ADV, V181, P1, DOI 10.1016/j.mseb.2013.11.001
   Li LF, 2018, ACS APPL ENERG MATER, V1, P6871, DOI 10.1021/acsaem.8b01215
   Liu CJ, 2016, CHEM ENG J, V302, P717, DOI 10.1016/j.cej.2016.05.126
   Liu CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23451
   Liu CJ, 2015, RSC ADV, V5, P71692, DOI 10.1039/c5ra13171e
   Ma YM, 2014, CHEM SCI, V5, P2964, DOI 10.1039/c4sc00469h
   Mahadik MA, 2018, ACS SUSTAIN CHEM ENG, V6, P12489, DOI 10.1021/acssuschemeng.8b03140
   Malekshoar G, 2016, CHEM ENG SCI, V152, P35, DOI 10.1016/j.ces.2016.05.029
   Malik O, 2015, J MATER RES, V30, P1894, DOI 10.1557/jmr.2015.159
   Mane RS, 1999, MATER CHEM PHYS, V60, P196, DOI 10.1016/S0254-0584(99)00085-1
   Massonnet N, 2014, J MATER CHEM C, V2, P1278, DOI 10.1039/c3tc31674b
   Medles M, 2006, THIN SOLID FILMS, V497, P58, DOI 10.1016/j.tsf.2005.09.186
   Nasir SNFM, 2017, J PHYS CHEM C, V121, P6218, DOI 10.1021/acs.jpcc.7b01149
   Park HS, 2013, CHEMPHYSCHEM, V14, P2277, DOI 10.1002/cphc.201201044
   Park H, 2016, ENERG ENVIRON SCI, V9, P411, DOI 10.1039/c5ee02575c
   Pattengale B, 2016, J PHYS CHEM C, V120, P1421, DOI 10.1021/acs.jpcc.5b11451
   Poldme N, 2019, CHEM SCI, V10, P99, DOI 10.1039/c8sc02575d
   Rath AK, 2011, ADV MATER, V23, P3712, DOI 10.1002/adma.201101399
   Regmi C, 2019, APPL SURF SCI, V466, P787, DOI 10.1016/j.apsusc.2018.10.069
   Regmi C, 2017, APPL SURF SCI, V413, P253, DOI 10.1016/j.apsusc.2017.04.056
   Rettie AJE, 2013, J AM CHEM SOC, V135, P11389, DOI 10.1021/ja405550k
   Tian MK, 2015, ACS NANO, V9, P10482, DOI 10.1021/acsnano.5b04712
   Tong R, 2017, INT J HYDROGEN ENERG, V42, P5496, DOI 10.1016/j.ijhydene.2016.08.168
   Turolla A, 2018, CHEM ENG SCI, V182, P171, DOI 10.1016/j.ces.2018.02.041
   Wang DS, 2017, DATA, V2, DOI 10.3390/data2030029
   Wang DS, 2009, NANO RES, V2, P130, DOI 10.1007/s12274-009-9010-2
   Wang M, 2019, J COLLOID INTERF SCI, V534, P338, DOI 10.1016/j.jcis.2018.09.056
   Wang WC, 2016, APPL SURF SCI, V362, P490, DOI 10.1016/j.apsusc.2015.11.228
   Xiao K, 2019, CHEMOSPHERE, V222, P141, DOI 10.1016/j.chemosphere.2019.01.109
   Xie SL, 2014, INT J HYDROGEN ENERG, V39, P4820, DOI 10.1016/j.ijhydene.2014.01.072
   Yan L, 2016, DALTON T, V45, P11346, DOI 10.1039/c6dt02027e
   Yang QQ, 2017, CHEM ENG SCI, V162, P33, DOI 10.1016/j.ces.2016.12.071
   Yuan HM, 2015, J COLLOID INTERF SCI, V444, P58, DOI 10.1016/j.jcis.2014.12.034
   Zhang H, 2003, NANOTECHNOLOGY, V14, P974, DOI 10.1088/0957-4484/14/9/307
   Zhang QL, 2006, MATER LETT, V60, P1188, DOI 10.1016/j.matlet.2005.10.105
   Zhang XF, 2015, J MATER CHEM A, V3, P21630, DOI 10.1039/c5ta05838d
   Zhao W, 2019, APPL CATAL B-ENVIRON, V245, P448, DOI 10.1016/j.apcatb.2019.01.001
   Zhao W, 2019, CHEM ENG J, V369, P716, DOI 10.1016/j.cej.2019.03.115
   Zhao W, 2018, APPL CATAL B-ENVIRON, V229, P171, DOI 10.1016/j.apcatb.2018.02.008
   Zhou Z, 2018, MAT SCI SEMICON PROC, V75, P334, DOI 10.1016/j.mssp.2017.11.011
   Zhu XD, 2016, APPL CATAL A-GEN, V521, P42, DOI 10.1016/j.apcata.2015.10.017
NR 57
TC 1
Z9 2
U1 36
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115266
DI 10.1016/j.ces.2019.115266
PG 9
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300027
OA Bronze
DA 2020-05-12
ER

PT J
AU Li, K
   Zhang, JW
   Liu, CG
   Mehmood, MA
   Bai, FW
AF Li, Kai
   Zhang, Jia-Wei
   Liu, Chen-Guang
   Mehmood, Muhammad Aamer
   Bai, Feng-Wu
TI Elucidating the molecular mechanism of TEMPOL-mediated improvement on
   tolerance under oxidative stress in Saccharomyces cerevisiae
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE TEMPOL; Oxidative stress; ROS; Tolerance; Redox pairs; Saccharomyces
   cerevisiae
ID BIOETHANOL PRODUCTION; ACETIC-ACID; INCREASE; NAD(+)
AB Reactive oxygen species (ROS) appear in universal stress pathways and damage cell components. In this study, 4-hydroxy-2,2,6,6-tetramethylpiperidin-l-oxyl (TEMPOL), a redox-cycling nitroxide and membrane-permeable antioxidant, was investigated for its ability to clear out intracellular ROS induced by hydrogen peroxide (H2O2) shock in Saccharomyces cerevisiae. Cell growth was improved by TEMPOL addition. The mechanism of ROS removal was elucidated by investigating activities of related genes, enzyme, and cofactors. TEMPOL increased the expression of genes involved in oxidative stress response, and enhanced the activities of the superoxide dismutase (SOD) and catalase (CAT) antioxidative proteins. TEMPOL also increased intracellular glutathione (GSH) to remove ROS by supplying more NADPH in cells. Finally, TEMPOL might catalyze the reaction of NADH and ROS due to its dual redox states. Interestingly, the early addition of TEMPOL resulted in a better H2O2 tolerance, because TEMPOL required time to expand its benefits in different metabolic levels for constructing an enzymatic antioxidant defense system and accumulating non-enzymatic reducing power in advance, akin to a "preventive stimulator". (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Kai; Zhang, Jia-Wei; Liu, Chen-Guang; Mehmood, Muhammad Aamer; Bai, Feng-Wu] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Joint Int Res Lab Metab & Dev Sci,Minist Educ, Shanghai 200240, Peoples R China.
   [Mehmood, Muhammad Aamer] Govt Coll Univ Faisalabad, Dept Bioinformat & Biotechnol, Faisalabad 38000, Pakistan.
RP Liu, CG; Mehmood, MA (reprint author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, State Key Lab Microbial Metab, Joint Int Res Lab Metab & Dev Sci,Minist Educ, Shanghai 200240, Peoples R China.
EM cg.liu@sjtu.edu.cn; draamer@gcuf.edu.pk
FU National Key R&D Program of China from Ministry of Science and
   Technology of the People's Republic of China [2018YFB1501401]; Natural
   Science Foundation of Shanghai, ChinaNatural Science Foundation of
   Shanghai [18ZR1420700]; Shanghai Minhang Science and Technology
   Commission, China [2017MH294]
FX This work was financially supported by National Key R&D Program of China
   from Ministry of Science and Technology of the People's Republic of
   China [grant number 2018YFB1501401], the Natural Science Foundation of
   Shanghai, China [grant number 18ZR1420700], and the Shanghai Minhang
   Science and Technology Commission, China [grant number 2017MH294].
CR Aditiya HB, 2016, RENEW SUST ENERG REV, V66, P631, DOI 10.1016/j.rser.2016.07.015
   Allen SA, 2010, BIOTECHNOL BIOFUELS, V3, DOI 10.1186/1754-6834-3-2
   Auchere F, 2008, HUM MOL GENET, V17, P2790, DOI 10.1093/hmg/ddn178
   Batinic-Haberle I, 2010, ANTIOXID REDOX SIGN, V13, P877, DOI 10.1089/ars.2009.2876
   Baumber J, 2000, J ANDROL, V21, P895
   Benjaphokee S, 2012, NEW BIOTECHNOL, V29, P379, DOI 10.1016/j.nbt.2011.07.002
   CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633
   Fedoseeva IV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02736-7
   Holm AK, 2010, J BIOL CHEM, V285, P17498, DOI 10.1074/jbc.M109.095570
   KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537
   Kudo W, 2008, FREE RADICAL RES, V42, P505, DOI 10.1080/10715760802112809
   Kuhad RC, 2016, RENEW SUST ENERG REV, V55, P249, DOI 10.1016/j.rser.2015.10.132
   La Piana G, 2005, ARCH BIOCHEM BIOPHYS, V436, P91, DOI 10.1016/j.abb.2004.12.029
   Li K, 2019, CHEM ENG SCI, V196, P54, DOI 10.1016/j.ces.2018.11.059
   Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829
   Liu LM, 2006, J BIOTECHNOL, V126, P173, DOI 10.1016/j.jbiotec.2006.04.014
   Ma C, 2015, APPL MICROBIOL BIOT, V99, P2441, DOI [10.1007/s00253-014-6343-x, 10.1007/s00253-014-6254-x]
   Medina VG, 2010, APPL ENVIRON MICROB, V76, P190, DOI 10.1128/AEM.01772-09
   Olofsson K, 2008, BIOTECHNOL BIOFUELS, V1, DOI 10.1186/1754-6834-1-7
   Qiu ZL, 2017, BIOTECHNOL BIOFUELS, V10, DOI 10.1186/s13068-017-0806-0
   Reczek CR, 2015, CURR OPIN CELL BIOL, V33, P8, DOI 10.1016/j.ceb.2014.09.010
   Rouhier N, 2010, TRENDS BIOCHEM SCI, V35, P43, DOI 10.1016/j.tibs.2009.08.005
   Vazquez J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01066
   Wallace-Salinas V, 2013, BIOTECHNOL BIOFUELS, V6, DOI 10.1186/1754-6834-6-151
   Wang M, 2017, BIOTECHNOL ADV, V35, P1032, DOI 10.1016/j.biotechadv.2017.09.008
   Wilcox CS, 2010, PHARMACOL THERAPEUT, V126, P119, DOI 10.1016/j.pharmthera.2010.01.003
   Wilcox CS, 2008, PHARMACOL REV, V60, P418, DOI 10.1124/pr.108.000240
   Xu K, 2018, CHEM ENG SCI, V175, P335, DOI 10.1016/j.ces.2017.10.016
   Yamato M, 2016, REDOX BIOL, V8, P316, DOI 10.1016/j.redox.2016.02.007
   Zhang MM, 2015, BIOTECHNOL J, V10, P1903, DOI 10.1002/biot.201500508
NR 30
TC 1
Z9 1
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115306
DI 10.1016/j.ces.2019.115306
PG 8
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300018
OA Bronze
DA 2020-05-12
ER

PT J
AU Li, SK
   Chu, FQ
   Zhang, J
   Brutin, D
   Wen, DS
AF Li, Shaokang
   Chu, Fuqiang
   Zhang, Jun
   Brutin, David
   Wen, Dongsheng
TI Droplet jumping induced by coalescence of a moving droplet and a static
   one: Effect of initial velocity
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet jumping; Initial velocity; Morphology; Departure velocity;
   Energy conversion rate
ID LATTICE BOLTZMANN SIMULATIONS; SUPERHYDROPHOBIC SURFACES; NUMERICAL
   SIMULATIONS; SELF-PROPULSION; CONDENSATION; FABRICATION; MECHANISM
AB To explore the effect of initial velocity on the droplet jumping induced by coalescence of a moving droplet and a static one, we performed simulations using the volume of fluid method with a dynamic contact angle model, and validated the simulation results against our experiments. The results show that the initial velocity of the moving droplet accelerates the droplet deformation during jumping, resulting in a unique departure feature. Droplet departs at different stages under different initial velocities, and the droplet departure velocity in the vertical direction is approximately constant at the first stage and then increases after Reynolds number reaches a critical value. The horizontal departure velocity is proportional to the initial velocity with a ratio of 0.4. The initial velocity also affects the energy conversion during the droplet jumping greatly. This work shall bring new insights into the droplet jumping behavior and promote its application in related fields. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Shaokang; Chu, Fuqiang; Zhang, Jun; Wen, Dongsheng] Beihang Univ, Sch Aeronaut Sci & Engn, Beijing 100191, Peoples R China.
   [Brutin, David] Aix Marseille Univ, IUSTI UMR CNRS 7343, Marseille, France.
   [Wen, Dongsheng] Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
RP Chu, FQ; Wen, DS (reprint author), Beihang Univ, Sch Aeronaut Sci & Engn, Beijing 100191, Peoples R China.
EM chufq18@buaa.edu.cn; d.wen@buaa.edu.cn
RI Wen, Dongsheng/A-5307-2010; Zhang, Jun/B-5278-2015; Brutin,
   David/AAL-7305-2020
OI Wen, Dongsheng/0000-0003-3492-7982; Zhang, Jun/0000-0002-3731-4594;
   Brutin, David/0000-0002-0006-6822; Chu, Fuqiang/0000-0002-4054-143X
FU National Postdoctoral Program for Innovative Talents [BX20180024]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2019M650444]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [11772034]
FX This work is supported by the National Postdoctoral Program for
   Innovative Talents (No. BX20180024), the China Postdoctoral Science
   Foundation (No. 2019M650444), and the National Natural Science
   Foundation of China (No. 11772034).
CR Afkhami S, 2009, J COMPUT PHYS, V228, P5370, DOI 10.1016/j.jcp.2009.04.027
   Attarzadeh R, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4973823
   Berg JC, 1993, WETTABILITY, V49, P311
   Boreyko JB, 2013, ACS NANO, V7, P1618, DOI 10.1021/nn3055048
   Boreyko JB, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3666818
   Boreyko JB, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.184501
   Cha Hyeongyun, 2016, PHYS REV FLUIDS, V1, P6
   Chen Y, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5046056
   Cheng YQ, 2019, APPL PHYS LETT, V114, DOI 10.1063/1.5082727
   Cheng YP, 2016, INT J HEAT MASS TRAN, V95, P506, DOI 10.1016/j.ijheatmasstransfer.2015.11.074
   Chu FQ, 2018, LANGMUIR, V34, P14562, DOI 10.1021/acs.langmuir.8b03347
   Chu FQ, 2018, INT J HEAT MASS TRAN, V121, P315, DOI 10.1016/j.ijheatmasstransfer.2018.01.027
   Chu FQ, 2018, ACS APPL MATER INTER, V10, P1415, DOI 10.1021/acsami.7b16087
   Chu FQ, 2016, APPL PHYS LETT, V108, DOI 10.1063/1.4949010
   Chu FQ, 2016, APPL SURF SCI, V371, P322, DOI 10.1016/j.apsusc.2016.02.208
   Dietz C, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3460275
   Enright R, 2014, ACS NANO, V8, P10352, DOI 10.1021/nn503643m
   Lecointre P, 2019, PHYS REV FLUIDS, V4, DOI 10.1103/PhysRevFluids.4.013601
   Li BB, 2019, CHEM ENG SCI, V201, P298, DOI 10.1016/j.ces.2019.02.041
   Li DW, 2019, CHEM ENG J, V367, P169, DOI 10.1016/j.cej.2019.02.093
   Liu FJ, 2014, J FLUID MECH, V752, P39, DOI 10.1017/jfm.2014.320
   Liu FJ, 2014, J FLUID MECH, V752, P22, DOI 10.1017/jfm.2014.319
   Liu XL, 2015, INT COMMUN HEAT MASS, V64, P7, DOI 10.1016/j.icheatmasstransfer.2015.03.002
   Liu XL, 2014, INT J HEAT MASS TRAN, V73, P195, DOI 10.1016/j.ijheatmasstransfer.2014.01.060
   Lv CJ, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4812976
   Malgarinos I, 2014, ADV COLLOID INTERFAC, V212, P1, DOI 10.1016/j.cis.2014.07.004
   Miljkovic N, 2013, NANO LETT, V13, P179, DOI 10.1021/nl303835d
   Mouterde T, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.112001
   Mulroe MD, 2017, ACS NANO, V11, P8499, DOI 10.1021/acsnano.7b04481
   Nam Y, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4825273
   Nikolopoulos N, 2007, INT J HEAT MASS TRAN, V50, P303, DOI 10.1016/j.ijheatmasstransfer.2006.06.012
   Renardy M, 2001, J COMPUT PHYS, V171, P243, DOI 10.1006/jcph.2001.6785
   Roisman IV, 2008, COLLOID SURFACE A, V322, P183, DOI 10.1016/j.colsurfa.2008.03.005
   Shen YZ, 2019, APPL THERM ENG, V156, P111, DOI 10.1016/j.applthermaleng.2019.04.052
   Shirtcliffe NJ, 2010, ADV COLLOID INTERFAC, V161, P124, DOI 10.1016/j.cis.2009.11.001
   Vahabi H, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau3488
   Vahabi H, 2017, ACS APPL MATER INTER, V9, P29328, DOI 10.1021/acsami.7b09344
   Wang FC, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3553782
   Wang K, 2017, APPL PHYS LETT, V111, DOI 10.1063/1.4998443
   Wang K, 2017, LANGMUIR, V33, P6258, DOI 10.1021/acs.langmuir.7b00901
   Wang K, 2016, RSC ADV, V6, P99314, DOI 10.1039/c6ra22421k
   Wasserfall J, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.123601
   Watson GS, 2014, BIOFOULING, V30, P427, DOI 10.1080/08927014.2014.880885
   Weller HG, 1998, COMPUT PHYS, V12, P620, DOI 10.1063/1.168744
   Wiedenheft KF, 2017, APPL PHYS LETT, V110, DOI 10.1063/1.4979477
   Xu CL, 2017, CHEM ENG J, V313, P1328, DOI 10.1016/j.cej.2016.11.024
   Yan X, 2019, ACS NANO, V13, P1309, DOI 10.1021/acsnano.8b06677
   Yuan ZP, 2019, INT J HEAT MASS TRAN, V135, P345, DOI 10.1016/j.ijheatmasstransfer.2019.01.147
   Zhang J, 2017, INT J HEAT MASS TRAN, V115, P886, DOI 10.1016/j.ijheatmasstransfer.2017.07.034
   Zhang QL, 2013, CHEM COMMUN, V49, P4516, DOI 10.1039/c3cc40592c
NR 50
TC 1
Z9 1
U1 13
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115252
DI 10.1016/j.ces.2019.115252
PG 9
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300017
OA Bronze
DA 2020-05-12
ER

PT J
AU Li, XL
   Zhang, GQ
   Zhao, XR
   Zhou, JW
   Du, GC
   Chen, J
AF Li, Xueliang
   Zhang, Guoqiang
   Zhao, Xinrui
   Zhou, Jingwen
   Du, Guocheng
   Chen, Jian
TI A conceptual air-lift reactor design for large scale animal cell
   cultivation in the context of in vitro meat production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Cultured meat; Scaling up; Animal cell culture; Air-lift reactor; CFD
ID CULTURED MEAT; OXYGEN-TRANSFER; BUBBLE-COLUMN; MASS-TRANSFER; CFD
   SIMULATION; STEM-CELLS; LIQUID; GAS; BIOREACTORS; FLOW
AB Cell-based meat, or cultured meat is at the early commercialization stage, but thorough considerations of the scaling-up challenges are scarce and the physiological data of animal muscle cells required by reliable process design are severely lacking. To make cultured meat an economically viable source of animal proteins, we propose a rational approach towards the design of a large scale air-lift reactor for cultured meat manufacturing. Computational fluid dynamics (CFD) modeling is used as a primary tool to provide an a priori estimation of the mass transfer and mixing performance of the reactor and the effects of reactor internals are investigated. The mass transfer coefficient of 36 1/h, energy dissipation rate of 46 W/m(3) and a mixing time of 103 s are all within acceptable ranges typical to animal cells. It is estimated that a single reactor of 300 m(3) can supply the meat demand of a population of 75,000. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Xueliang; Zhao, Xinrui; Chen, Jian] Jiangnan Univ, Sch Biotechnol, Key Lab Ind Biotechnol, Minist Educ, Wuxi 214122, Jiangsu, Peoples R China.
   [Zhang, Guoqiang; Zhou, Jingwen] Jiangnan Univ, Natl Engn Lab Cereal Fermentat Technol, Wuxi 214122, Jiangsu, Peoples R China.
   [Du, Guocheng] Jiangnan Univ, Key Lab Carbohydrate Chem & Biotechnol, Minist Educ, Wuxi 214122, Jiangsu, Peoples R China.
RP Li, XL; Chen, J (reprint author), Jiangnan Univ, Sch Biotechnol, 1800 Lihu Ave, Wuxi 214122, Jiangsu, Peoples R China.
EM bruce.li@jiangnan.edu.cn; jchen@jiangnan.edu.cn
RI Zhao, Xinrui/AAK-7972-2020
OI Li, Xueliang/0000-0001-7111-8485
CR Bach C, 2017, CHEM ENG SCI, V171, P19, DOI 10.1016/j.ces.2017.05.001
   Bauer P, 2000, BIOTECHNOL PROGR, V16, P125, DOI 10.1021/bp9901318
   Bhat Z.F., 2011, J STORED PRODUCTS PO, V2, P1
   Borchers O, 1999, CHEM ENG SCI, V54, P5927, DOI 10.1016/S0009-2509(99)00181-5
   Chalmers JJ, 2015, CELL ENG, V9, P169, DOI 10.1007/978-3-319-10320-4_6
   Chen LM, 2017, CHEM ENG RES DES, V119, P33, DOI 10.1016/j.cherd.2017.01.008
   CHISTI MY, 1987, CHEM ENG COMMUN, V60, P195, DOI 10.1080/00986448708912017
   CLARK NN, 1987, AICHE J, V33, P515, DOI 10.1002/aic.690330321
   Clarkson JR, 1999, J COLLOID INTERF SCI, V215, P323, DOI 10.1006/jcis.1999.6255
   Cooper CM, 1944, IND ENG CHEM, V36, P504, DOI 10.1021/ie50414a005
   Datar I, 2010, INNOV FOOD SCI EMERG, V11, P13, DOI 10.1016/j.ifset.2009.10.007
   Edelman PD, 2005, TISSUE ENG, V11, P659, DOI 10.1089/ten.2005.11.659
   Fujiwara M, 2007, J BIOSCI BIOENG, V104, P510, DOI 10.1263/jbb.104.510
   GANZEVELD KJ, 1995, BIOPROCESS ENG, V12, P239
   Goodwin JN, 2013, MEAT SCI, V95, P445, DOI 10.1016/j.meatsci.2013.05.027
   Hidalgo-Bastida LA, 2012, BIOTECHNOL BIOENG, V109, P1095, DOI 10.1002/bit.24368
   Higbie R, 1935, T AM INST CHEM ENG, V31, P365
   Hocquette A, 2015, J INTEGR AGR, V14, P273, DOI 10.1016/S2095-3119(14)60886-8
   Ismadi MZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106493
   Kadim IT, 2015, J INTEGR AGR, V14, P222, DOI 10.1016/S2095-3119(14)60881-9
   Kolmogorov A.N, 1941, DOKLADY AKAD NAUK SS, V32
   Krichnavaruk S, 2002, CHEM ENG J, V89, P203, DOI 10.1016/S1385-8947(02)00010-4
   Laborde-Boutet C, 2009, CHEM ENG SCI, V64, P4399, DOI 10.1016/j.ces.2009.07.009
   Laestadius LI, 2015, PUBLIC HEALTH NUTR, V18, P2457, DOI 10.1017/S1368980015000622
   Langheinrich C, 2002, FOOD BIOPROD PROCESS, V80, P39, DOI 10.1205/096030802753479098
   Li X., 2017, Patent, Patent No. [US9617509B2, 9617509]
   Li XL, 2012, INT J MULTIPHAS FLOW, V42, P24, DOI 10.1016/j.ijmultiphaseflow.2011.12.009
   Li XL, 2010, INT J MINER PROCESS, V94, P14, DOI 10.1016/j.minpro.2009.10.002
   Maes F, 2009, BIOTECHNOL BIOENG, V103, P621, DOI 10.1002/bit.22277
   Malavasi S, 2012, FLOW MEAS INSTRUM, V28, P57, DOI 10.1016/j.flowmeasinst.2012.07.006
   Martens DE, 1996, CYTOTECHNOLOGY, V21, P45, DOI 10.1007/BF00364836
   MERCHUK JC, 1988, J CHEM TECHNOL BIOT, V41, P105
   MERCHUK JC, 1990, TRENDS BIOTECHNOL, V8, P66, DOI 10.1016/0167-7799(90)90138-N
   Merchuk JC, 1998, CHEM ENG SCI, V53, P709, DOI 10.1016/S0009-2509(97)00340-0
   Miron AS, 2004, CHEM ENG RES DES, V82, P1367, DOI 10.1205/cerd.82.10.1367.46742
   Mollet M, 2004, BIOTECHNOL PROGR, V20, P1437, DOI 10.1021/bp0498488
   Mudde RF, 1999, CHEM ENG SCI, V54, P5061, DOI 10.1016/S0009-2509(99)00234-1
   Naganuma T, 1996, PROGR BIOTECHNOL, V13, P73
   Nam JH, 2007, BIOTECHNOL PROGR, V23, P652, DOI 10.1021/bp070007l
   Neethling SJ, 2001, CHEM ENG SCI, V56, P6303, DOI 10.1016/S0009-2509(01)00248-2
   Neunstoecklin B, 2015, J BIOTECHNOL, V194, P100, DOI 10.1016/j.jbiotec.2014.12.003
   Nienow AW, 2006, CYTOTECHNOLOGY, V50, P9, DOI 10.1007/s10616-006-9005-8
   Nienow AW, 2015, CELL ENG, V9, P137, DOI 10.1007/978-3-319-10320-4_5
   Oosterhuis N, 2018, 4 INT C CULT MEATMAA
   ORAZEM ME, 1979, BIOTECHNOL BIOENG, V21, P69, DOI 10.1002/bit.260210107
   PERSSON B, 1992, BIOPROCESS ENG, V8, P157, DOI 10.1007/BF01254232
   Portner R, 2015, CELL ENG, V9, P89, DOI 10.1007/978-3-319-10320-4_4
   Shi WB, 2019, CHEM ENG J, V371, P470, DOI 10.1016/j.cej.2019.04.047
   SMITH SRL, 1980, [No title captured], V290, P341
   Sokolichin A, 1997, CHEM ENG SCI, V52, P611, DOI 10.1016/S0009-2509(96)00425-3
   Specht EA, 2018, BIOCHEM ENG J, V132, P161, DOI 10.1016/j.bej.2018.01.015
   Stephens N, 2018, TRENDS FOOD SCI TECH, V78, P155, DOI 10.1016/j.tifs.2018.04.010
   Stevenson P., 2014, FOAM FRACTIONATION P
   Super A, 2016, BIOTECHNOL J, V11, P1179, DOI 10.1002/biot.201500479
   Takagi M, 1995, J FERMENT BIOENG, V80, P619, DOI 10.1016/0922-338X(96)87744-0
   Toye D, 2010, CAN J CHEM ENG, V88, P671, DOI 10.1002/cjce.20302
   van Baten JM, 2003, CHEM ENG PROCESS, V42, P733, DOI 10.1016/S0255-2701(02)00076-4
   van der Weele C, 2014, TRENDS BIOTECHNOL, V32, P294, DOI 10.1016/j.tibtech.2014.04.009
   van Eelen W.F, 1999, Patent No. [EP1037966, 1037966]
   Varley J, 1999, CYTOTECHNOLOGY, V29, P177, DOI 10.1023/A:1008008021481
   Vein J, 2001, Patent No. [US6,835,390, 6835390]
   Verbruggen S, 2018, CYTOTECHNOLOGY, V70, P503, DOI 10.1007/s10616-017-0101-8
   Villiger TK, 2018, BIOCHEM ENG J, V131, P84, DOI 10.1016/j.bej.2017.12.004
   Wadaugsorn K, 2016, CHEM ENG RES DES, V113, P125, DOI 10.1016/j.cherd.2016.07.017
   WESTLAKE R, 1986, CHEM-ING-TECH, V58, P934, DOI 10.1002/cite.330581203
   Xu YY, 2011, CAN J CHEM ENG, V89, P360, DOI 10.1002/cjce.20405
   Youssef Ahmed A, 2013, INT J CHEM REACTOR E, V169
NR 67
TC 1
Z9 1
U1 18
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115269
DI 10.1016/j.ces.2019.115269
PG 12
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300002
OA Bronze
DA 2020-05-12
ER

PT J
AU Li, Y
   Xu, J
   Yu, WF
   Ray, AK
AF Li, Yan
   Xu, Jin
   Yu, Weifang
   Ray, Ajay K.
TI Multi-objective optimization of sequential simulated moving bed for the
   purification of xylo-oligosaccharides
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Xylo-oligosaccharides; Sequential simulated moving bed; Multi-objective
   optimization; Purification; Adsorptive separation
ID POLYETHYLENE TUBULAR REACTOR; KETOPROFEN ENANTIOMERS; CHROMATOGRAPHIC
   PROCESSES; VARICOL PROCESSES; UNIFIED DESIGN; SEPARATION; SMB; FRUCTOSE;
   EQUILIBRIUM; OPERATION
AB This paper investigates feasibility of xylo-oligosaccharides (XOS) purification by sequential simulated moving bed (SSMB) that has three sub-steps. Multi-objective optimizations were carried out for three cases with various objective functions, decision variables and constraints. It was found that, for a given SSMB unit, there exist a Pareto curve when product purity and unit throughput are simultaneously maximized with practical constraint on recovery. The corresponding values of flowrate ratio, however, exhibit some trends different from those of conventional Simulated Moving Bed (SMB). Analyses on component mass flow and dimensional operating parameters reveal that these differences can be attributed to the fact that the three sub-steps with different durations and flow patterns have their individual functional roles. Pareto solutions to several other optimization problems with solvent consumption as one of the objectives were acquired. The corresponding flow rate ratios are not enough to give qualitative guidance for tuning the dimensional operating parameters. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Yan; Xu, Jin; Yu, Weifang] Wenzhou Univ, Chem Engn Dept, Wenzhou 325035, Zhejiang, Peoples R China.
   [Li, Yan; Ray, Ajay K.] Western Univ, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
RP Xu, J; Yu, WF (reprint author), Wenzhou Univ, Chem Engn Dept, Wenzhou 325035, Zhejiang, Peoples R China.; Ray, AK (reprint author), Western Univ, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
EM xujin@wzu.edu.cn; ywf@wzu.edu.cn; aray@eng.uwo.ca
FU Zhejiang Provincial Natural Science Foundations [Y18B060008,
   Y19B060034]; COFCO Ltd.
FX The project is supported by Zhejiang Provincial Natural Science
   Foundations (Y18B060008, Y19B060034). Yan Li's PhD experiment in China
   was partially supported by COFCO Ltd.
CR Agrawal N, 2006, IND ENG CHEM RES, V45, P3182, DOI 10.1021/ie050977i
   Agrawal N, 2007, CHEM ENG SCI, V62, P2346, DOI 10.1016/j.ces.2007.01.030
   Azevedo DCS, 2001, AICHE J, V47, P2042, DOI 10.1002/aic.690470915
   Beste YA, 2000, J CHROMATOGR A, V868, P169, DOI 10.1016/S0021-9673(99)01136-X
   Bhaskar V, 2001, COMPUT CHEM ENG, V25, P391, DOI 10.1016/S0098-1354(00)00665-7
   Bhutani N, 2006, IND ENG CHEM RES, V45, P1354, DOI 10.1021/ie050423f
   David L, 2017, ADSORPTION, V23, P577, DOI 10.1007/s10450-017-9878-1
   Faria RPV, 2015, J CHROMATOGR A, V1421, P82, DOI 10.1016/j.chroma.2015.08.045
   Gomes PS, 2006, ADSORPTION, V12, P375, DOI 10.1007/s10450-006-0566-9
   Hyoky G., 1999, 30 GEN M AM SOC SUG
   Jermann S, 2014, J CHROMATOGR A, V1361, P125, DOI 10.1016/j.chroma.2014.07.101
   Jermann S, 2012, ORG PROCESS RES DEV, V16, P311, DOI 10.1021/op200239e
   Jiang CW, 2014, J CHROMATOGR A, V1334, P87, DOI 10.1016/j.chroma.2014.02.010
   Jiang XX, 2018, J CHROMATOGR A, V1531, P131, DOI 10.1016/j.chroma.2017.11.045
   Kasat RB, 2002, IND ENG CHEM RES, V41, P4765, DOI 10.1021/ie020087s
   Kaspereit M, 2007, J CHROMATOGR A, V1162, P2, DOI 10.1016/j.chroma.2007.02.063
   Katsuo S, 2010, J CHROMATOGR A, V1217, P3067, DOI 10.1016/j.chroma.2010.02.083
   Katsuo S, 2010, J CHROMATOGR A, V1217, P1354, DOI 10.1016/j.chroma.2009.12.065
   Klatt KU, 2002, J PROCESS CONTR, V12, P203, DOI 10.1016/S0959-1524(01)00005-1
   Lee  E.-B., 1967, FDN OPTIMAL CONTROL
   Lee FC, 2007, BIOTECHNOL BIOENG, V98, P586, DOI 10.1002/bit.21443
   Li Y., 2019, CHEM ENG SCI
   Li Y, 2019, SEP PURIF TECHNOL, V215, P360, DOI 10.1016/j.seppur.2019.01.019
   Ludemann-Hombourger O, 2000, SEPAR SCI TECHNOL, V35, P1829, DOI 10.1081/SS-100100622
   Lutin F, 2002, DESALINATION, V148, P121, DOI 10.1016/S0011-9164(02)00664-1
   Ma Z, 1997, AICHE J, V43, P2488, DOI 10.1002/aic.690431012
   Mao SM, 2012, J SEP SCI, V35, P2273, DOI 10.1002/jssc.201200322
   Mazzotti M, 1997, J CHROMATOGR A, V769, P3, DOI 10.1016/S0021-9673(97)00048-4
   Minceva M, 2005, COMPUT CHEM ENG, V29, P2215, DOI 10.1016/j.compchemeng.2005.08.001
   Minceva M, 2002, IND ENG CHEM RES, V41, P3454, DOI 10.1021/ie010095t
   NANDASANA AD, 2003, INT J CHEM REACT ENG, V1, P1
   Nicoud R-M, 2015, CHROMATOGRAPHIC PROC
   Nicoud RM, 2014, IND ENG CHEM RES, V53, P3755, DOI 10.1021/ie5005866
   Pais LS, 2003, J CHROMATOGR A, V1006, P33, DOI 10.1016/S0021-9673(03)00557-0
   Pynnonen B, 1998, J CHROMATOGR A, V827, P143, DOI 10.1016/S0021-9673(98)00732-8
   Rajendran A, 2009, J CHROMATOGR A, V1216, P709, DOI 10.1016/j.chroma.2008.10.075
   Rajesh JK, 2001, CHEM ENG SCI, V56, P999, DOI 10.1016/S0009-2509(00)00316-X
   Ribeiro AE, 2008, SEP PURIF TECHNOL, V61, P375, DOI 10.1016/j.seppur.2007.11.010
   Ribeiro AE, 2011, SEP SCI TECHNOL, V46, P1726, DOI 10.1080/01496395.2011.582070
   Rodrigues A., 2015, SIMULATED MOVING BED
   Sainio T, 2016, CHEM ENG SCI, V152, P547, DOI 10.1016/j.ces.2016.06.038
   Schmidt-Traub H, 2006, PREPARATIVE CHROMATOGRAPHY OF FINE CHEMICALS AND PHARMACEUTICAL AGENTS, pXIII
   Siitonen J, 2015, CHEM ENG SCI, V122, P436, DOI 10.1016/j.ces.2014.10.004
   STORTI G, 1993, AICHE J, V39, P471, DOI 10.1002/aic.690390310
   Tangpromphan P, 2018, CHEM ENG PROCESS, V126, P23, DOI 10.1016/j.cep.2018.02.001
   Tarafder A, 2007, COMPUT CHEM ENG, V31, P1257, DOI 10.1016/j.compchemeng.2006.10.010
   Tarafder A, 2005, IND ENG CHEM RES, V44, P124, DOI 10.1021/ie049953m
   Tarafder A, 2005, CHEM ENG SCI, V60, P347, DOI 10.1016/j.ces.2004.07.120
   Wei F., 2012, SEP SCI ENG, V4, P673
   Xu J, 2015, J CHROMATOGR A, V1422, P163, DOI 10.1016/j.chroma.2015.10.018
   Xu J, 2013, J CHROMATOGR A, V1273, P49, DOI 10.1016/j.chroma.2012.11.052
   Yu W.F., 2004, J CHIN INST CHEM ENG, V1, P1
   Yu WF, 2005, CHEM ENG J, V112, P57, DOI 10.1016/j.cej.2005.06.008
   Yu WF, 2003, IND ENG CHEM RES, V42, P6743, DOI 10.1021/ie0302241
   Zhang Y, 2009, SEP PURIF TECHNOL, V65, P311, DOI 10.1016/j.seppur.2008.10.050
   Zhang ZY, 2002, AICHE J, V48, P2800, DOI 10.1002/aic.690481209
   Zhang ZY, 2002, IND ENG CHEM RES, V41, P3213, DOI 10.1021/ie0106940
NR 57
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115279
DI 10.1016/j.ces.2019.115279
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300042
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, HT
   Shi, J
   Pu, Y
   Wang, JX
   Wang, D
   Chen, JF
AF Liu, Haotian
   Shi, Jie
   Pu, Yuan
   Wang, Jie-Xin
   Wang, Dan
   Chen, Jian-Feng
TI In situ visualization and real-time tracking of emulsion and
   miniemulsion polymerization at the microscale via fluorescence imaging
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE In situ visualization; Emulsion and miniemulsion polymerization;
   Polystyrene nanoparticles; Fluorescent imaging; Aggregation induced
   emission
ID AGGREGATION-INDUCED EMISSION; CAMPHORQUINONE; INITIATOR; KINETICS
AB We report a simply designed liquid sample cell to visualize the processes of emulsion and miniemulsion polymerization by real-time fluorescence imaging of aggregation-induced emission fluorogens (AlEgens) in the emulsions. A unique phase separation phenomenon was observed in the styrene droplets during miniemulsion polymerization, which is beneficial for surface engineering of the polymer nanoparticles. Accordingly, a process intensified synthesis approach to polystyrene (PS) nanodispersion via emulsifier-free miniemulsion polymerization was developed in rotating packed bed reactors. Superhydrophobic fluorescent PS nanoparticles are fabricated via a cost-effective approach and exhibited a water/air contact angle of over 155 degrees, which are promising for fluorescent liquid marbles. These findings not only provide the basis for real-time tracking and characterization of polymerization processes at the microscale via fluorescence imaging of AlEgens, but also offer a new route for the cost-effective production of superhydrophobic polymer nanoparticles for advanced applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Haotian; Shi, Jie; Wang, Jie-Xin; Wang, Dan; Chen, Jian-Feng] Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
   [Liu, Haotian; Shi, Jie; Pu, Yuan; Wang, Jie-Xin; Wang, Dan; Chen, Jian-Feng] Beijing Univ Chem Technol, Res Ctr, Minist Educ High Grav Engn & Technol, Beijing 100029, Peoples R China.
   [Wang, Dan] Harvard Univ, Harvard John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
RP Wang, D (reprint author), Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
EM wangdan@mail.buct.edu.cn
RI Wang, Dan/B-9997-2013
OI Wang, Dan/0000-0002-3515-4590
FU National Key R&D Program of China [2017YFB0404405/2017YFB0404400];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21622601]
FX This work was supported by the National Key R&D Program of China
   (2017YFB0404405/2017YFB0404400) and National Natural Science Foundation
   of China (21622601). We are grateful to the "CHEMCLOUDCOMPUTING" of BUCT
   for computational support.
CR Alvim HH, 2007, DENT MATER, V23, P1245, DOI 10.1016/j.dental.2006.11.002
   Asua JM, 2014, PROG POLYM SCI, V39, P1797, DOI 10.1016/j.progpolymsci.2014.02.009
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   Castor CA, 2015, CHEM ENG SCI, V131, P340, DOI 10.1016/j.ces.2015.02.037
   COOK WD, 1992, POLYMER, V33, P600, DOI 10.1016/0032-3861(92)90738-I
   Delley B, 2006, J PHYS CHEM A, V110, P13632, DOI 10.1021/jp0653611
   Drache M, 2018, PHYS CHEM CHEM PHYS, V20, P10796, DOI 10.1039/c7cp07768h
   Fan JB, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1603203
   Fukui T, 2018, ANGEW CHEM INT EDIT, V57, P15465, DOI 10.1002/anie.201809165
   Gharieh A, 2019, ADV COLLOID INTERFAC, V269, P152, DOI 10.1016/j.cis.2019.04.010
   Guan WJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11811
   Hans M, 2009, MACROMOLECULES, V42, P1031, DOI 10.1021/ma802391s
   He XL, 2019, NANO ENERGY, V62, P1, DOI 10.1016/j.nanoen.2019.05.024
   Hejmady P, 2019, SOFT MATTER, V15, P1373, DOI 10.1039/c8sm02081g
   Hong YN, 2009, CHEM COMMUN, P4332, DOI 10.1039/b904665h
   Huang CJ, 2017, POLYM CHEM-UK, V8, P6972, DOI 10.1039/c7py01608e
   Huang J, 2016, CHEM SCI, V7, P3829, DOI 10.1039/c6sc00377j
   Jakubiak J, 2003, POLYMER, V44, P5219, DOI 10.1016/S0032-3861(03)00568-8
   Jiang QM, 2014, POLYM CHEM-UK, V5, P1863, DOI 10.1039/c3py01437a
   Landfester K, 2009, ANGEW CHEM INT EDIT, V48, P4488, DOI 10.1002/anie.200900723
   Leung CWT, 2016, ADV HEALTHC MATER, V5, P427, DOI 10.1002/adhm.201500674
   Liu HT, 2019, CHEM ENG PROCESS, V136, P36, DOI 10.1016/j.cep.2018.12.012
   Liu SJ, 2018, ANGEW CHEM INT EDIT, V57, P6274, DOI 10.1002/anie.201803268
   Mei J, 2015, CHEM REV, V115, P11718, DOI 10.1021/acs.chemrev.5b00263
   Neuville A, 2017, LAB CHIP, V17, P293, DOI 10.1039/c6lc01253a
   Pyun J, 2005, MACROMOLECULES, V38, P2674, DOI 10.1021/ma047375f
   Qin W, 2012, ADV FUNCT MATER, V22, P771, DOI 10.1002/adfm.201102191
   Rao JP, 2011, PROG POLYM SCI, V36, P887, DOI 10.1016/j.progpolymsci.2011.01.001
   Sacci RL, 2014, CHEM COMMUN, V50, P2104, DOI 10.1039/c3cc49029g
   Sajjadi S, 2006, CHEM ENG SCI, V61, P3001, DOI 10.1016/j.ces.2005.11.043
   STEPHENS PJ, 1994, J PHYS CHEM-US, V98, P11623, DOI 10.1021/j100096a001
   Thickett S.C, 2019, POLYM CHEM
   Tian R, 2019, LAB CHIP, V19, P934, DOI 10.1039/c8lc01336e
   Truong NP, 2017, POLYM CHEM-UK, V8, P1353, DOI 10.1039/c6py02158a
   Wang ZY, 2019, REACT CHEM ENG, V4, P507, DOI 10.1039/c8re00265g
   Yuan YY, 2014, CHEM COMMUN, V50, P11465, DOI 10.1039/c4cc05255b
   Zhang YL, 2015, LAB CHIP, V15, P575, DOI 10.1039/c4lc01046a
   Zhang YJ, 2016, J MATER CHEM A, V4, P15597, DOI 10.1039/c6ta06612g
   Zhao YY, 2016, NANOSCALE, V8, P12520, DOI 10.1039/c5nr08782a
NR 39
TC 0
Z9 0
U1 13
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115288
DI 10.1016/j.ces.2019.115288
PG 8
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300030
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, P
   Cao, JX
   Xu, Z
   Yang, CL
   Wang, XD
   Liu, F
AF Liu, Piao
   Cao, Jianxin
   Xu, Zheng
   Yang, Chunliang
   Wang, Xiaodan
   Liu, Fei
TI Thiolation of methanol with H2S using core-shell structured ZSM-5@t-ZrO2
   catalyst
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE ZSM-5@t-ZrO2; Core-shell structure; Deactivation behavior; Thiolation;
   Methanethiol
ID HYDROGEN-SULFIDE; DIMETHYL SULFIDE; ACIDIC PROPERTIES; BRONSTED ACIDITY;
   METAL-OXIDES; ADSORPTION; METHANETHIOL; PROPYLENE; ZEOLITES; ALCOHOLS
AB Core-shell structured ZSM-5@t-ZrO2 catalysts were prepared by a hydrothermal coating method, and their physicochemical properties, catalytic performance, and deactivation behavior in thiolation reactions were studied using a ZSM-5/t-ZrO2 physically-blended catalyst as a comparison. Reactions using the core-shell ZSM-5@t-ZrO2 catalyst were carried out at a pressure of 0.7 MPa, 370 degrees C, a H2S:CH3OH molar ratio of 2:1, and a N-2 flow rate of 90 ml.min(-)(1). The conversion of CH3OH, and the selectivity and yield of CH3SH under these conditions were 92.07%, 90.89%, and 83.68%, respectively, and the catalytic lifetime was longer than 30 h. Compared with the ZSM-54-ZrO2 physically-blended catalyst, the CH3SH yield and the catalytic lifetime of the core-shell structured ZSM-5@t-ZrO2 catalyst were higher by 5.37% and 150%, respectively. The unique reaction pathway of the shell (t-ZrO2 , Lewis (L) base active site)-core (ZSM-5, Bronsted (B) acid active site) and the Lewis-Bronsted acid active center based on a composite solid-solution interface were mainly responsible for the high activity of the thiolation reaction. Meanwhile, the formation of a micro-mesoporous system increased the diffusion of molecules and reduced the deactivation rate of carbon- and sulfur-containing deposits. Generally, carbon- and sulfur-containing substances deposited on catalysts were mainly composed of polymethylbenzene, polymethyl naphthalene, cyclic elemental sulfur, and other compounds containing C-S and S-S bonds. Finally, the core-shell structured catalysts showed excellent resistance to deactivation by carbon- and sulfur-containing deposits. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Piao; Cao, Jianxin; Xu, Zheng; Yang, Chunliang; Liu, Fei] Guizhou Univ, Sch Chem & Chem Engn, Guiyang 550025, Guizhou, Peoples R China.
   [Liu, Piao; Cao, Jianxin; Yang, Chunliang; Wang, Xiaodan; Liu, Fei] Guizhou Univ, Key Lab Green Chem & Clean Energy Technol, Guiyang 550025, Guizhou, Peoples R China.
   [Cao, Jianxin; Xu, Zheng; Yang, Chunliang; Wang, Xiaodan; Liu, Fei] Guizhou Univ, Engn Res Ctr Efficient Utilizat Ind Waste, Guiyang 550025, Guizhou, Peoples R China.
RP Liu, F (reprint author), Guizhou Univ, Sch Chem & Chem Engn, Guiyang 550025, Guizhou, Peoples R China.
EM ce.feiliu@gzu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21666007]; Scientific and Technological Innovation
   Talents Team Project of Guizhou [20185607]; One Hundred Person Project
   of Guizhou [20165655]; Science and Technology Project of Guizhou
   [20175788, 20185781]; Natural Science Foundation of Guizhou [20177260]
FX This work was supported by National Natural Science Foundation of China
   (21666007), Scientific and Technological Innovation Talents Team Project
   of Guizhou (20185607), One Hundred Person Project of Guizhou (20165655),
   Science and Technology Project of Guizhou (20175788 and 20185781) and
   Natural Science Foundation of Guizhou (20177260).
CR Bermejo-Deval R., 2017, CATALYSIS SCI TECHNO, V7
   Calvino-Casilda V, 2006, APPL CATAL A-GEN, V303, P121, DOI 10.1016/j.apcata.2006.02.013
   Chen SP, 2012, J MOL CATAL A-CHEM, V365, P60, DOI 10.1016/j.molcata.2012.08.009
   Duan C, 2013, FUEL PROCESS TECHNOL, V108, P31, DOI 10.1016/j.fuproc.2012.03.015
   Khan EA, 2009, MICROPOR MESOPOR MAT, V118, P210, DOI 10.1016/j.micromeso.2008.08.031
   Komanoya T, 2015, J PHYS CHEM C, V119, P26540, DOI 10.1021/acs.jpcc.5b08355
   Lamonier C, 2011, CATAL TODAY, V164, P124, DOI 10.1016/j.cattod.2010.10.035
   Mashkina AV, 2006, PETROL CHEM+, V46, P28, DOI 10.1134/S0965544106010063
   Mauge F, 2002, J CATAL, V207, P353, DOI 10.1006/jcat.2002.3533
   Nie RF, 2012, FUEL, V96, P419, DOI 10.1016/j.fuel.2011.12.048
   Nowak I., 2010, CHEM REV, V31, P3603
   Oliviero L, 2009, IND ENG CHEM RES, V48, P1237, DOI 10.1021/ie800768a
   Panpa W, 2008, APPL CATAL B-ENVIRON, V80, P271, DOI 10.1016/j.apcatb.2007.11.029
   Pashigreva AV, 2017, J CATAL, V345, P308, DOI 10.1016/j.jcat.2016.11.036
   Paskach TJ, 2002, J CATAL, V211, P285, DOI 10.1006/jcat.2002.3684
   Plaisance CP, 2009, CATAL LETT, V128, P449, DOI 10.1007/s10562-008-9772-2
   Razavian M, 2015, MICROPOR MESOPOR MAT, V201, P176, DOI 10.1016/j.micromeso.2014.09.022
   Rep M, 2000, J PHYS CHEM B, V104, P8624, DOI 10.1021/jp0001945
   Taifan W, 2017, CATAL SCI TECHNOL, V7, P3546, DOI 10.1039/c7cy00857k
   Taifan W, 2016, APPL CATAL B-ENVIRON, V198, P525, DOI 10.1016/j.apcatb.2016.05.081
   Travert A, 2002, J PHYS CHEM B, V106, P1350, DOI 10.1021/jp0126762
   Trejda M, 2008, MICROPOR MESOPOR MAT, V110, P271, DOI 10.1016/j.micromeso.2007.06.015
   Trejda M, 2006, CATAL LETT, V108, P141, DOI 10.1007/s10562-006-0035-9
   Wan E, 2017, CHEMCATCHEM, V9, P2358, DOI 10.1002/cctc.201700171
   Yang GH, 2010, J AM CHEM SOC, V132, P8129, DOI 10.1021/ja101882a
   Zhang YH, 2012, CATAL COMMUN, V22, P48, DOI 10.1016/j.catcom.2012.02.017
   Ziolek M, 1996, ZEOLITES, V16, P42, DOI 10.1016/0144-2449(95)00105-0
   Ziolek M, 1996, CATAL LETT, V37, P223, DOI 10.1007/BF00807758
   ZIOLEK M, 1993, J PHYS CHEM-US, V97, P9761, DOI 10.1021/j100140a037
   Ziolek M, 1998, APPL CATAL A-GEN, V171, P109, DOI 10.1016/S0926-860X(98)00070-2
   Ziolek M, 1998, MICROPOR MESOPOR MAT, V23, P45, DOI 10.1016/S1387-1811(98)00044-4
   ZIOLEK M, 1995, J MOL CATAL A-CHEM, V97, P49, DOI 10.1016/1381-1169(94)00068-9
   ZIOLEK M, 1994, J CHEM SOC FARADAY T, V90, P1029, DOI 10.1039/ft9949001029
NR 33
TC 1
Z9 1
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115273
DI 10.1016/j.ces.2019.115273
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300058
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, Q
   Tadrent, S
   Proust, C
   Gomez, F
   Khelfa, A
   Luart, D
   Len, C
AF Liu, Qi
   Tadrent, Sarra
   Proust, Christophe
   Gomez, Francois
   Khelfa, Anissa
   Luart, Denis
   Len, Christophe
TI Theoretical analysis of the "green" synthesis of aniline by reduction of
   nitrobenzene
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reaction mechanism; Thermodynamics; Reduction of nitrobenzene; Reaction
   scheme
ID HYDROGENATION; EQUILIBRIUM; PREDICTABILITY; NITROARENES; MECHANISM;
   CATALYST; UNIFAC
AB Recently a new chemical production means was proposed for producing aniline by reducing nitrobenzene in a much more environmentally friendly way (Tadrent et al., 2018). In particular, activated carbon and water are used instead of hydrogen on a metal catalyst without a precise detail of the process. In the present paper, a theoretical analysis is proposed based on a step by step thermodynamic examination of elementary reactions. It is found that the Haber mechanism is theoretically possible but that due to the size of the pores of the carbon, inside which the reduction occurs, only the smallest molecules can move so that the "direct" path is favored. This can explain why the yield is rather good. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Qi; Tadrent, Sarra; Proust, Christophe; Gomez, Francois; Len, Christophe] Univ Technol Compiegne, Sorbonne Univ, Ctr Rech Royallieu, CS60319, F-60203 Compiegne, France.
   [Proust, Christophe] INERIS, Dept DRA, Parc Technol Alata,POB 2, F-60550 Verneuil En Halatte, France.
   [Khelfa, Anissa; Luart, Denis] Ecole Super Chim Organ & Minerale, 1 Rue Reseau Jean Marie Buckmaster, F-60200 Compiegne, France.
   [Len, Christophe] PSL Res Univ, Inst Chem Life & Hlth Sci, CNRS, Chim ParisTech, 11 Rue Pierre & Marie Curie, F-75005 Paris, France.
RP Proust, C (reprint author), INERIS, Dept DRA, Parc Technol Alata,POB 2, F-60550 Verneuil En Halatte, France.
EM christophe.proust@ineris.fr
RI ; PROUST, Christophe/X-6078-2018
OI LIU, Qi/0000-0002-5031-2964; PROUST, Christophe/0000-0002-9097-4292;
   LEN, Christophe/0000-0001-8013-0881
FU Ministere de l'Enseignement Superieur et de la RechercheEstonian
   Research Council
FX The authors thank the Ministere de l'Enseignement Superieur et de la
   Recherche for its constant supports.
CR [Anonymous], 2009, PLUS ASP
   Blaser HU, 2009, CHEMCATCHEM, V1, P210, DOI 10.1002/cctc.200900129
   BOUKOUVALAS C, 1994, FLUID PHASE EQUILIBR, V92, P75, DOI 10.1016/0378-3812(94)80043-X
   CONDIT PC, 1949, IND ENG CHEM, V41, P1700, DOI 10.1021/ie50476a042
   Couto CS, 2015, CHEM ENG TECHNOL, V38, P1625, DOI 10.1002/ceat.201400468
   FREDENSLUND A, 1977, IND ENG CHEM PROC DD, V16, P450, DOI 10.1021/i260064a004
   Gheewala SH, 1997, WATER SCI TECHNOL, V36, P53, DOI 10.1016/S0273-1223(97)00642-2
   Gibbs J.W., 1948, COLLECTED WORKS JW G
   GORDON SR, 1994, PROG HISTOCHEM CYTOC, V28, P1
   Haber F, 1898, ELEKTROCHEM ANGEW PH, V22, P506, DOI DOI 10.1002/BBPC
   Liu Q., 2019, CHEM ENG SCI UNPUB
   Liu Q, 2019, IND ENG CHEM RES, V58, P2654, DOI 10.1021/acs.iecr.8b03604
   Liu Q, 2019, IND ENG CHEM RES, V58, P411, DOI 10.1021/acs.iecr.8b03571
   MATVEEV VG, 1975, B ACAD SCI USSR CH+, V24, P697, DOI 10.1007/BF00920676
   Pardey AJ, 2002, INORG CHIM ACTA, V329, P22, DOI 10.1016/S0020-1693(01)00782-4
   Pardey AJ, 2000, J MOL CATAL A-CHEM, V164, P225, DOI 10.1016/S1381-1169(00)00264-8
   Sivcev VP, 2014, J SUPERCRIT FLUID, V86, P137, DOI 10.1016/j.supflu.2013.12.012
   Tadrent S, 2018, J ORG CHEM, V83, P7431, DOI 10.1021/acs.joc.8b00406
   Tong W.R., 1978, LOSS PREVENTION, V11, P71
   Travis A. S., 2007, CHEM ANILINES, P715
   Varkolu M, 2016, APPL PETROCHEM RES, V6, P15, DOI 10.1007/s13203-015-0115-0
   WISNIAK J, 1984, IND ENG CHEM PROD RD, V23, P44, DOI 10.1021/i300013a009
   Zanetti J. E., 1917, J IND ENG CHEM, V9, P350, DOI DOI 10.1021/IE50088A009
NR 23
TC 0
Z9 0
U1 13
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115275
DI 10.1016/j.ces.2019.115275
PG 8
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300056
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, XL
   Zhang, QF
   Ye, GH
   Li, JJ
   Li, P
   Zhou, XG
   Keil, FJ
AF Liu, Xinlei
   Zhang, Qunfeng
   Ye, Guanghua
   Li, Jinjin
   Li, Ping
   Zhou, Xinggui
   Keil, Frerich J.
TI Deactivation and regeneration of Claus catalyst particles unraveled by
   pore network model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Deactivation; Regeneration; Claus catalyst; Pore network model; Multiple
   steady states; Sulfur condensation
ID SULFUR CONDENSATION; COMPUTER-SIMULATIONS; HYSTERESIS; DIFFUSION;
   DIOXIDE; H2S; FORMULATION; SOLUBILITY; PARAMETERS; CONVERSION
AB A pore network model is proposed to study the deactivation of Claus catalysts caused by sulfur condensation, as well as the corresponding regeneration. This model allows to describe the coupled reaction, diffusion, and sulfur condensation from a single pore to a catalyst particle. The results show that the deactivation branch of apparent activities is well above the regeneration branch in the temperature and pressure ranges where capillary condensation of sulfur occurs. This phenomenon of multiple steady states can be attributed to the inconsistent contents of liquid sulfur in the catalyst particle when changing temperature and pressure in different directions. The catalyst particle shape and pore network structure directly influence diffusion resistance, internal surface area for reaction, and sulfur condensation, and subsequently pass these influences on to the apparent activity. This work should provide a proper model and some useful guidelines for the design of catalyst particles for the Claus reaction. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Xinlei; Zhang, Qunfeng; Ye, Guanghua; Li, Ping; Zhou, Xinggui] East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
   [Li, Jinjin] PetroChina Southwest Oil & Gas Field Co, Res Inst Nat Gas Technol, Chengdu 610213, Sichuan, Peoples R China.
   [Keil, Frerich J.] Hamburg Univ Technol, Inst Chem React Engn, D-21073 Hamburg, Germany.
RP Ye, GH (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
EM guanghuaye@ecust.edu.cn
OI Li, Ping/0000-0002-6790-0754
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21706067]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2018T110358]; Shanghai
   Education Development Foundation [17CG29]; Shanghai Municipal Education
   CommissionShanghai Municipal Education Commission (SHMEC) [17CG29];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [222201714004, 222201718003]
FX This work was supported by the National Natural Science Foundation of
   China (21706067), the China Postdoctoral Science Foundation
   (2018T110358), the "Chenguang Program" supported by Shanghai Education
   Development Foundation and Shanghai Municipal Education Commission
   (17CG29), and the Fundamental Research Funds for the Central
   Universities (222201714004 and 222201718003).
CR Al-Futaisi A, 2003, PHYSICA A, V321, P665, DOI 10.1016/S0378-4371(02)01586-8
   ALVAREZ E, 1993, APPL CATAL A-GEN, V93, P231, DOI 10.1016/0926-860X(93)85196-V
   Androutsopoulos GP, 2000, IND ENG CHEM RES, V39, P3764, DOI 10.1021/ie000163w
   ARBABI S, 1991, CHEM ENG SCI, V46, P1739, DOI 10.1016/0009-2509(91)87020-D
   ARBABI S, 1991, CHEM ENG SCI, V46, P1749, DOI 10.1016/0009-2509(91)87021-4
   Chun SW, 1998, APPL CATAL B-ENVIRON, V16, P235
   Clark PD, 2002, APPL CATAL A-GEN, V235, P61, DOI 10.1016/S0926-860X(02)00235-1
   Cohan LH, 1938, J AM CHEM SOC, V60, P433, DOI 10.1021/ja01269a058
   Elsner MP, 2003, CATAL TODAY, V79, P487, DOI 10.1016/S0920-5861(03)00071-3
   Eow JS, 2002, ENVIRON PROG, V21, P143, DOI 10.1002/ep.670210312
   FAIRBANKS DF, 1950, IND ENG CHEM, V42, P471, DOI 10.1021/ie50483a022
   FANELLI R, 1949, IND ENG CHEM, V41, P2031, DOI 10.1021/ie50477a047
   GEORGE ZM, 1978, CAN J CHEM ENG, V56, P711, DOI 10.1002/cjce.5450560610
   Ibrahim S, 2015, FUEL, V150, P1, DOI 10.1016/j.fuel.2015.02.001
   Ishihara D, 2016, CHEM ENG J, V306, P784, DOI 10.1016/j.cej.2016.08.014
   Johannessen E, 2007, IND ENG CHEM RES, V46, P4245, DOI 10.1021/ie061444s
   KEIL FJ, 1994, CHEM ENG SCI, V49, P4811
   Keil FJ, 1999, CATAL TODAY, V53, P245, DOI 10.1016/S0920-5861(99)00119-4
   Kohl A.L, 1997, GAS PURIFICATION
   KRISHNA R, 1993, CHEM ENG SCI, V48, P845, DOI 10.1016/0009-2509(93)80324-J
   Larraz R, 2002, CHEM ENG J, V86, P309, DOI 10.1016/S1385-8947(01)00189-9
   Lepsoe R, 1938, IND ENG CHEM, V30, P92
   Liu C., 1976, P 6 EUR 4 INT S CHEM, P196
   Marriott RA, 2008, FLUID PHASE EQUILIBR, V269, P69, DOI 10.1016/j.fluid.2008.05.001
   Mora RL, 2000, J HAZARD MATER, V79, P103, DOI 10.1016/S0304-3894(00)00193-X
   PEARSON MJ, 1977, IND ENG CHEM PROD RD, V16, P154, DOI 10.1021/i360062a009
   Poling B. E., 2001, PROPERTIES GASES LIQ
   RAZZAGHI M, 1984, CAN J CHEM ENG, V62, P413, DOI 10.1002/cjce.5450620320
   SCHOOFS GR, 1985, HYDROCARB PROCESS, V64, P71
   Sui RH, 2019, APPL CATAL B-ENVIRON, V241, P217, DOI 10.1016/j.apcatb.2018.09.027
   Tao K, 2011, CHEM ENG J, V170, P258, DOI 10.1016/j.cej.2011.03.038
   Tong SM, 1997, IND ENG CHEM RES, V36, P4087, DOI 10.1021/ie970277g
   TOURO FJ, 1966, J PHYS CHEM-US, V70, P3531, DOI 10.1021/j100883a028
   Wang G, 2007, CHEM ENG SCI, V62, P5110, DOI 10.1016/j.ces.2007.01.046
   WIECKOWSKA J, 1995, CATAL TODAY, V24, P405, DOI 10.1016/0920-5861(95)00021-7
   Wongkoblap A, 2011, J COLLOID INTERF SCI, V356, P672, DOI 10.1016/j.jcis.2011.01.074
   Wood J, 2002, CHEM ENG SCI, V57, P3033, DOI 10.1016/S0009-2509(02)00183-5
   Wood J, 2002, CHEM ENG SCI, V57, P3047, DOI 10.1016/S0009-2509(02)00184-7
   Wu SC, 2013, CHEM ENG SCI, V93, P350, DOI 10.1016/j.ces.2013.01.061
   Ye GH, 2019, AICHE J, V65, DOI 10.1002/aic.16687
   Ye GH, 2019, AICHE J, V65, P140, DOI 10.1002/aic.16410
   Ye GH, 2017, CHEM ENG J, V329, P56, DOI 10.1016/j.cej.2017.02.036
   Ye GH, 2017, AICHE J, V63, P78, DOI 10.1002/aic.15415
   Ye GH, 2016, AICHE J, V62, P451, DOI 10.1002/aic.15095
   Yu YM, 2012, IND ENG CHEM RES, V51, P8735, DOI 10.1021/ie201901z
   Zagoruiko AN, 2002, CHEM ENG J, V87, P73, DOI 10.1016/S1385-8947(01)00203-0
   ZareNezhad B, 2009, J IND ENG CHEM, V15, P143, DOI 10.1016/j.jiec.2008.08.020
   Zhang X, 2015, ACS CATAL, V5, P1053, DOI 10.1021/cs501476p
   Zhang Y., 2011, CHIN J CHEM PHYS, V19, P102
NR 49
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115305
DI 10.1016/j.ces.2019.115305
PG 12
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300016
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, YX
   Ohhashi, S
   Kameoka, S
   Tsai, AP
AF Liu, Yi-Xin
   Ohhashi, Satoshi
   Kameoka, Satoshi
   Tsai, An Pang
TI Highly dispersive Au nanoparticles on TiO2 nanofibers as a supported
   catalyst synthesized from Al-Ti-Au intermetallic compound
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Intermetallic compound; L1(2) phase; Leaching; Catalysis; Au/TiO2
ID LOW-TEMPERATURE OXIDATION; ONE-STEP SYNTHESIS; CO OXIDATION; AU/TIO2;
   ACTIVATION; STABILITY; REMOVAL
AB In the present study, we highly dispersed the Gold nanoparticles onto TiO2 nanofibers from leached Al-Ti-Au intermetallic compounds (IMCs) as a catalyst. The IMCs have an ordered structure, which could let the substitutional Au atoms neighboring to Ti atoms in IMC structure. The Al-based IMC single phase was proposed to obtain a high specific area and highly dispersive Au nanoparticles instead of the solid solution after leaching.
   Therefore, single phase L1(2)-Al67Ti25Au8 was prepared and homogenized by arc-melting and conducted annealing. The ingot of L1(2)-Al67Ti25Au8 was crushed and gathered under 25 mu m as precursors. The leaching processes were using the aq. NaOH and aq. HCl. The removal Al of the precursors achieved 95%, and exhibits the special urchin-like particles with TiOx nanofibers. The urchin-like morphology provided a high surface area. After heat treatment, the TiOx transformed to the anatase TiO2 at 500 degrees C for 2 h under the air or CO/O-2/He. The TEM images showed lots of Gold nanoparticles dispersing homogeneously onto the TiOx nanofibers. The CO conversion efficiency of Au/TiO2 was 50% at 50 degrees C without heat-treatment. Although the contribution mainly attributed to Au nanoparticles, Au/TiO2 exhibited significantly higher catalytic activity than Au/TiOx composite. The CO oxidation activity Au/TiO2 could reach up to 98% when as lower as 50 degrees C. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Yi-Xin; Ohhashi, Satoshi; Kameoka, Satoshi; Tsai, An Pang] Tohoku Univ, IMRAM, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.
RP Kameoka, S (reprint author), Tohoku Univ, IMRAM, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.
EM satoshi.kameoka.b4@tohoku.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT) of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [15H02299, 18H01783]; NIMS microstructural characterization
   platform as a program of "Nanotechnology Platform" [12024046]; Dynamic
   Alliance for Open Innovation Bridging Human, Environment and Materials
FX The authors are grateful to Dr. Masahiko Shimoda (NIMS, Japan), Dr.
   Shigenori Ueda (NIMS, Japan), Professor Kazuya Kobiro (Kochi University
   of Technology, Japan), Mr. Jhong-Ren Huang (IMRAM Tohoku University,
   Japan) for fruitful discussions, Mr. Shun Ito and Mr. Eiji Aoyagi (IMR
   Tohoku University, Japan) for TEM observations. The HAXPES measurements
   at BL15XU of SPring-8 were performed with the approval of the NIMS
   Synchrotron X-ray Station (Proposal Nos. 2018A4910, 2018B4912,
   2019A4906). This work was supported financially by Grants-in-Aid for
   Scientific Research [(A) 15H02299, (B) 18H01783] from the Ministry of
   Education, Culture, Sports, Science and Technology (MEXT) of Japan, NIMS
   microstructural characterization platform as a program of
   "Nanotechnology Platform" (Project No. 12024046), and "Dynamic Alliance
   for Open Innovation Bridging Human, Environment and Materials."
CR Ayati A, 2014, CHEMOSPHERE, V107, P163, DOI 10.1016/j.chemosphere.2014.01.040
   Bagheri Samira, 2014, ScientificWorldJournal, V2014, P727496, DOI 10.1155/2014/727496
   Banfield JF, 2000, SCIENCE, V289, P751, DOI 10.1126/science.289.5480.751
   Chen YL, 2010, CATAL COMMUN, V11, P1003, DOI 10.1016/j.catcom.2010.03.018
   Costello CK, 2004, J PHYS CHEM B, V108, P12529, DOI 10.1021/jp048643e
   Dasgupta A, 2019, CATAL TODAY, V330, P2, DOI 10.1016/j.cattod.2018.05.048
   Fan GJ, 1997, MAT SCI ENG A-STRUCT, V231, P111, DOI 10.1016/S0921-5093(97)00035-X
   Haruta M, 2001, APPL CATAL A-GEN, V222, P427, DOI 10.1016/S0926-860X(01)00847-X
   HARUTA M, 1993, J CATAL, V144, P175, DOI 10.1006/jcat.1993.1322
   Haruta M, 1997, CATAL TODAY, V36, P153, DOI 10.1016/S0920-5861(96)00208-8
   HARUTA M, 1989, J CATAL, V115, P301, DOI 10.1016/0021-9517(89)90034-1
   Howard A, 2002, SURF SCI, V518, P210, DOI 10.1016/S0039-6028(02)02124-6
   Kameoka S, 2016, CATAL LETT, V146, P1309, DOI 10.1007/s10562-016-1757-y
   Leal GB, 2018, CATAL COMMUN, V116, P38, DOI 10.1016/j.catcom.2018.07.021
   Lu ZC, 2018, MAT SCI ENG A-STRUCT, V721, P274, DOI 10.1016/j.msea.2018.02.085
   Lu ZC, 2016, MATER DESIGN, V110, P466, DOI 10.1016/j.matdes.2016.08.025
   Maeda Y, 2013, J AM CHEM SOC, V135, P906, DOI 10.1021/ja310999c
   NAKAYAMA Y, 1993, INTERMETALLICS, V1, P41, DOI 10.1016/0966-9795(93)90020-V
   Nayak SS, 2004, MAT SCI ENG A-STRUCT, V367, P218, DOI 10.1016/j.msea.2003.09.097
   Okumura M, 2015, ACS CATAL, V5, P4699, DOI 10.1021/acscatal.5b01122
   Parida KM, 2010, J MOL CATAL A-CHEM, V319, P92, DOI 10.1016/j.molcata.2009.12.005
   Peters S, 2013, SURF SCI, V608, P129, DOI 10.1016/j.susc.2012.09.024
   PRAKASH U, 1992, J MATER SCI, V27, P2001, DOI 10.1007/BF01117910
   Sekino T, 2010, TOP APPL PHYS, V117, P17, DOI 10.1007/978-3-642-03622-4_2
   Shimizu K, 2007, J PHYS CHEM C, V111, P6481, DOI 10.1021/jp070322q
   Teoh WY, 2005, CHEM ENG SCI, V60, P5852, DOI 10.1016/j.ces.2005.05.037
   Widmann D, 2016, CHINESE J CATAL, V37, P1684, DOI 10.1016/S1872-2067(16)62452-X
   Xu G, 2016, CRYSTENGCOMM, V18, P2268, DOI 10.1039/c6ce00067c
   Yang JH, 2005, J PHYS CHEM B, V109, P10319, DOI 10.1021/jp050818c
   Yang YF, 2009, INT J HYDROGEN ENERG, V34, P8912, DOI 10.1016/j.ijhydene.2009.08.087
   Yao Q, 2016, J PHYS CHEM C, V120, P9174, DOI 10.1021/acs.jpcc.5b12712
   Zhao ZF, 2016, CRYSTENGCOMM, V18, P1636, DOI 10.1039/c6ce00071a
   Zhao ZF, 2015, CORROS SCI, V98, P651, DOI 10.1016/j.corsci.2015.06.007
NR 33
TC 0
Z9 0
U1 22
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115249
DI 10.1016/j.ces.2019.115249
PG 9
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300026
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, YH
   Zhu, N
   Hu, X
   Huang, WJ
   Wu, JQ
   Bin, XN
   Qiu, JK
   Duan, JD
   Fang, Z
   Guo, K
AF Liu, Yihuan
   Zhu, Ning
   Hu, Xin
   Huang, Weijun
   Wu, Jiaqi
   Bin, Xinni
   Qiu, Jiangkai
   Duan, Jindian
   Fang, Zheng
   Guo, Kai
TI Continuous flow rare earth phenolates catalyzed chemoselective
   ring-opening polymerization
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Continuous flow; Rare earth phenolates; Chemoselective ring-opening
   polymerization; Microscale effect; Thiol-functionalized polymer; Kinetic
   comparison
ID MOLECULAR-WEIGHT DISTRIBUTIONS; RADICAL POLYMERIZATION;
   EPSILON-CAPROLACTONE; RAFT POLYMERIZATION; SYNTHETIC APPROACH;
   POLY(EPSILON-CAPROLACTONE); KINETICS; COPOLYMERS; MECHANISM; MICRO
AB A novel chemoselective polymerization methodology was established by employing rare earth catalysis and microflow technology. The microscale effect (inner size and flow rate) on chemoselectivity and polymerization kinetic were investigated for the model system of mercapto-alcohol initiating ring-opening polymerizations (ROP) of caprolactone (epsilon-CL) in the presence of lanthanum tris(2,6-di-tert-butyl-4-methylphenolate)s. By reducing the inner diameter (ID) of the microreactor tube from 4 mm to 0.5 mm, the chemoselectivity (thiol fidelity) was firstly increased from 63% into 74% and then decreased to 69%. Faster flow rates enabled better chemoselective (82% at 667 mu L min(-1) vs 63% at 167 mu L min(-1)). The chemoselective polymerization kinetics were compared between batch reactor and microreactor with varied ID. In contrast to the batchwise reaction, flow chemistry brought great benefits in the chemoselective polymerization, including faster polymerization, higher thiol fidelity, more controlled molecular weight and distributions. Microreactor with 2 mm ID showed better performance than that with 1 mm ID, which was consistent with the results of microscale effect study. Six varied rare earth phenolates were utilized to demonstrate the versatility of microflow system and resultant polymer exhibited thiol fidelity over 87%. By applying this continuous flow chemoselective ROP strategy, series of welldefined thiol-terminated poly poly(epsilon-caprolactone)s were efficiently synthesized under optimized flow conditions with high thiol fidelity (>91%) and varied molecular weights (3440-15,090 g mol(-1)). This work would provide deep insight into microflow technology and chemoselective polymerization. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Yihuan; Zhu, Ning; Huang, Weijun; Wu, Jiaqi; Bin, Xinni; Qiu, Jiangkai; Duan, Jindian; Fang, Zheng; Guo, Kai] Nanjing Tech Univ, Coll Biotechnol & Pharmaceut Engn, Nanjing 211800, Jiangsu, Peoples R China.
   [Hu, Xin] Nanjing Tech Univ, Coll Mat Sci & Engn, Nanjing 211800, Jiangsu, Peoples R China.
   [Guo, Kai] Nanjing Tech Univ, State Key Lab Mat Oriented Chem Engn, Nanjing 211800, Jiangsu, Peoples R China.
RP Guo, K (reprint author), Nanjing Tech Univ, State Key Lab Mat Oriented Chem Engn, Coll Biotechnol & Pharmaceut Engn, Nanjing 211800, Jiangsu, Peoples R China.
EM guok@njtech.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21504039, 21878145, 21604037]; Jiangsu Synergetic
   Innovation Center for Advanced Bio-Manufacture, China [XTD1823, XTD1821,
   XTB1802]; Postgraduate Research & Practice Innovation Program of Jiangsu
   Province; Jiangsu Student's Platform for innovation and entrepreneurship
   training program [201810291069Z]
FX This work was supported by The National Natural Science Foundation of
   China (21504039, 21878145, 21604037), The Jiangsu Synergetic Innovation
   Center for Advanced Bio-Manufacture, China (XTD1823, XTD1821, XTB1802),
   the Postgraduate Research & Practice Innovation Program of Jiangsu
   Province and the Jiangsu Student's Platform for innovation and
   entrepreneurship training program (201810291069Z).
CR Asano S, 2017, CHEM ENG PROCESS, V119, P73, DOI 10.1016/j.cep.2017.05.016
   Ashraf MA, 2019, REACT CHEM ENG, V4, P27, DOI 10.1039/c8re00176f
   Chen LF, 2017, MACROMOLECULES, V50, P9598, DOI 10.1021/acs.macromol.7b02238
   Corrigan N, 2018, MACROMOLECULES, V51, P4553, DOI 10.1021/acs.macromol.8b00673
   Corrigan N, 2017, MACROMOLECULES, V50, P8438, DOI 10.1021/acs.macromol.7b01890
   Corrigan N, 2016, MACROMOLECULES, V49, P6779, DOI 10.1021/acs.macromol.6b01306
   Derboven P, 2015, MACROMOL RAPID COMM, V36, P2149, DOI 10.1002/marc.201500357
   Eckardt O, 2017, REACT CHEM ENG, V2, P479, DOI 10.1039/c7re00013h
   Gowda RR, 2017, PHILOS T R SOC A, V375, DOI 10.1098/rsta.2017.0003
   Gowda RR, 2016, ACS MACRO LETT, V5, P772, DOI 10.1021/acsmacrolett.6b00370
   Hedfors C, 2005, MACROMOLECULES, V38, P647, DOI 10.1021/ma048056r
   Hong M, 2014, MACROMOLECULES, V47, P3614, DOI 10.1021/ma5007717
   Hoyle CE, 2010, CHEM SOC REV, V39, P1355, DOI 10.1039/b901979k
   Hu X, 2017, REACT CHEM ENG, V2, P20, DOI 10.1039/c6re00206d
   Hu X, 2016, EUR POLYM J, V80, P177, DOI 10.1016/j.eurpolymj.2016.04.006
   Junkers T, 2016, REACT CHEM ENG, V1, P60, DOI 10.1039/c5re00042d
   Kundu S, 2011, J AM CHEM SOC, V133, P6006, DOI 10.1021/ja111346c
   Li X, 2012, MACROMOL RAPID COMM, V33, P1008, DOI 10.1002/marc.201100848
   Lin JO, 2013, MACROMOLECULES, V46, P7769, DOI 10.1021/ma401218p
   Ling J, 2005, J POLYM SCI POL CHEM, V43, P1787, DOI 10.1002/pola.20648
   Ling J, 2001, MACROMOLECULES, V34, P7613, DOI 10.1021/ma0107657
   Liu JZ, 2009, J MOL CATAL A-CHEM, V300, P59, DOI 10.1016/j.molcata.2008.10.038
   Liu YH, 2018, PROG CHEM, V30, P1133, DOI 10.7536/PC180115
   Liu YH, 2017, RSC ADV, V7, P37412, DOI 10.1039/c7ra06781j
   Lu YC, 2016, IND ENG CHEM RES, V55, P1215, DOI 10.1021/acs.iecr.5b04265
   Mizuno M, 2017, REACT CHEM ENG, V2, P642, DOI 10.1039/c7re00089h
   Nagaki A, 2004, J AM CHEM SOC, V126, P14702, DOI 10.1021/ja044879k
   Nagaki A, 2010, MACROMOLECULES, V43, P8424, DOI 10.1021/ma101663x
   Pelegri-O'Day EM, 2017, J AM CHEM SOC, V139, P1145, DOI 10.1021/jacs.6b10776
   Qiu L, 2016, CHEM ENG J, V284, P233, DOI 10.1016/j.cej.2015.08.055
   Ramakers G, 2017, MACROMOL RAPID COMM, V38, DOI 10.1002/marc.201700423
   Ramsey BL, 2017, MACROMOLECULES, V50, P2668, DOI 10.1021/acs.macromol.6b02791
   Romain C, 2016, J AM CHEM SOC, V138, P4120, DOI 10.1021/jacs.5b13070
   Rubens M., 2018, ANGEW CHEM INT ED EN
   Ryan MD, 2017, MACROMOLECULES, V50, P4616, DOI 10.1021/acs.macromol.7b00502
   Tang J, 2017, EUR POLYM J, V95, P678, DOI 10.1016/j.eurpolymj.2017.05.043
   Tang XY, 2016, J AM CHEM SOC, V138, P14326, DOI 10.1021/jacs.6b07974
   Tonhauser C, 2012, MACROMOLECULES, V45, P9551, DOI 10.1021/ma301671x
   van den Berg SA, 2016, MACROMOLECULES, V49, P2054, DOI 10.1021/acs.macromol.5b02533
   Veneral JG, 2018, CHEM ENG SCI, V175, P139, DOI 10.1016/j.ces.2017.09.037
   Vidal F, 2015, J AM CHEM SOC, V137, P9469, DOI 10.1021/jacs.5b05811
   Wang H, 2017, ANGEW CHEM INT EDIT, V56, P6339, DOI 10.1002/anie.201702193
   Wang K, 2011, CHEM ENG J, V169, P290, DOI 10.1016/j.cej.2011.02.072
   Wang PJ, 2015, RSC ADV, V5, P64055, DOI 10.1039/c5ra10275h
   Xu N, 2007, CHEM J CHINESE U, V28, P1791
   Xue YR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5348
   Yu DP, 2015, CHEM COMMUN, V51, P14778, DOI 10.1039/c5cc05249a
   Zaquen N, 2018, MACROMOLECULES, V51, P5165, DOI 10.1021/acs.macromol.8b00887
   Zhang XY, 2016, NAT CHEM, V8, P1047, DOI [10.1038/NCHEM.2574, 10.1038/nchem.2574]
   Zhu N, 2018, CHEMPHOTOCHEM, V2, P831, DOI 10.1002/cptc.201800032
   Zhu N, 2018, MACROMOL RAPID COMM, V39, DOI 10.1002/marc.201700807
   Zhu N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22171-6
   Zhu N, 2018, CHEM ENG J, V333, P43, DOI 10.1016/j.cej.2017.09.143
   Zhu N, 2016, EUR POLYM J, V80, P234, DOI 10.1016/j.eurpolymj.2016.04.010
   Zhu N, 2016, POLYMER, V84, P391, DOI 10.1016/j.polymer.2016.01.019
   Zhu N, 2015, POLYMER, V80, P88, DOI 10.1016/j.polymer.2015.10.053
   Zhu N, 2015, CHINESE CHEM LETT, V26, P361, DOI 10.1016/j.cclet.2014.11.016
   Zhu N, 2015, RSC ADV, V5, P31554, DOI 10.1039/c5ra02583d
   Zhu N, 2010, J POLYM SCI POL CHEM, V48, P4366, DOI 10.1002/pola.24233
   Zhu S, 2016, EUR POLYM J, V80, P219, DOI 10.1016/j.eurpolymj.2016.01.034
NR 60
TC 0
Z9 0
U1 22
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115290
DI 10.1016/j.ces.2019.115290
PG 7
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300015
OA Bronze
DA 2020-05-12
ER

PT J
AU Ma, XR
   Dang, R
   Liu, ZP
   Yang, F
   Li, HG
   Guo, T
   Luo, J
AF Ma, Xiangrong
   Dang, Rui
   Liu, Zhipan
   Yang, Fang
   Li, Huigui
   Guo, Tian
   Luo, Jiao
TI Facile synthesis of heterogeneous recyclable Pd/CeO2/TiO2 nanostructured
   catalyst for the one pot hydroxylation of benzene to phenol
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ternary nanocomposites; Dispersed; Benzene; Selective oxidation; Phenol
ID SELECTIVE OXIDATION; MOLECULAR-OXYGEN; DEACTIVATION; DEGRADATION;
   STABILITY; ALKANES; TOLUENE
AB In this work we adopted, a facile method to synthesis Pd/CeO2/TiO2 nanocomposite in large scale and evaluated its catalytic property towards the benzene hydroxylation into phenol. The as-synthesized Pd/CeO2/TiO2 composite was vigilantly investigated using XRD, SEM, TEM, elemental mapping, XPS, TGA and BET studies. The uniformly dispersed Pd/CeO2 /TiO2 with size 5-20 nm shows the high benzene conversion of 73% with 95% selectivity of phenol at 80 degrees C. The influence of various reaction conditions such as role of solvents, temperature, benzene to peroxide molar ratio, reaction time, etc were specifically investigated. The catalyst also showed pronounced photocatalytic activity for hydroxylation of benzene under the visible light conditions. The heterogeneity of the catalyst was additionally confirmed by Sheldon's hot filtration test where no leaching up to 5 cycle, confirming the heterogeneity of the catalyst. (C) 2019 Published by Elsevier Ltd.
C1 [Ma, Xiangrong; Dang, Rui; Liu, Zhipan; Yang, Fang; Li, Huigui; Guo, Tian; Luo, Jiao] Yu Lin Univ, Sch Chem & Chem Engn, Yu Lin 719000, Shaanxi, Peoples R China.
RP Ma, XR; Dang, R (reprint author), Yu Lin Univ, Sch Chem & Chem Engn, Yu Lin 719000, Shaanxi, Peoples R China.
EM maxiangrong615@sina.com; dangrui8381@163.com
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [51762042]; Shaanxi Province Science and Technology
   Resources Open Sharing Platform Project [2019PT-18]; Science and
   Technology Program of Shaanxi Province [2018GY-086, 2016GY-245,
   2017GY-131, 2017JM2039, 2016CXY-03]; Special Research Program of Yulin
   University [14YK22]
FX We thank National Nature Science Foundation of China (51762042), Shaanxi
   Province Science and Technology Resources Open Sharing Platform Project
   (2019PT-18), Science and Technology Program of Shaanxi Province
   (2018GY-086, 2016GY-245, 2017GY-131, 2017JM2039), Technology Program of
   Yulin (2016CXY-03), and Special Research Program of Yulin University
   (14YK22) for financial support.
CR Acharyya SS, 2014, CATAL SCI TECHNOL, V4, P4232, DOI 10.1039/c4cy00615a
   Acharyya SS, 2014, ACS APPL MATER INTER, V6, P14451, DOI 10.1021/am503722t
   Ameen S, 2014, CHEM ENG J, V247, P193, DOI 10.1016/j.cej.2014.02.104
   Bal R, 2006, ANGEW CHEM INT EDIT, V45, P448, DOI 10.1002/anie.200502940
   Balducci L., 2003, ANGEW CHEM, V115, P5087, DOI DOI 10.1002/ANGE.200352184
   Bekkum H, 2001, FINE CHEM HETEROGENE, P1
   Bianchi D, 2000, ANGEW CHEM INT EDIT, V39, P4321, DOI 10.1002/1521-3773(20001201)39:23<4321::AID-ANIE4321>3.0.CO;2-5
   Bitter JH, 1999, J CATAL, V183, P336, DOI 10.1006/jcat.1999.2402
   Borah P, 2012, ANGEW CHEM INT EDIT, V51, P7756, DOI 10.1002/anie.201203275
   Cargnello M, 2012, SCIENCE, V337, P713, DOI [10.1126/science.1222887, 10.1126/science.1223488]
   Cargnello M, 2010, CHEM MATER, V22, P4335, DOI 10.1021/cm101499x
   Centi G, 2009, CATAL TODAY, V143, P145, DOI 10.1016/j.cattod.2008.09.032
   Chen Y, 2018, MATER LETT, V232, P138, DOI 10.1016/j.matlet.2018.08.065
   Deng WL, 2006, ANGEW CHEM INT EDIT, V45, P2285, DOI 10.1002/anie.200503220
   Ding ZX, 2011, CHEMSUSCHEM, V4, P274, DOI 10.1002/cssc.201000149
   Iqbal M, 2019, SMALL, V15, DOI 10.1002/smll.201804378
   Ji XB, 2019, J ALLOY COMPD, V783, P583, DOI 10.1016/j.jallcom.2018.12.307
   Kamata K, 2010, NAT CHEM, V2, P478, DOI [10.1038/NCHEM.648, 10.1038/nchem.648]
   Lempers HEB, 1998, J CATAL, V175, P62, DOI 10.1006/jcat.1998.1979
   Li GS, 2009, PHYS CHEM CHEM PHYS, V11, P3775, DOI 10.1039/b819167k
   Li XL, 2019, J MATER CHEM A, V7, P23878, DOI 10.1039/c9ta03410b
   Liu J, 2009, J MATER CHEM, V19, P6073, DOI 10.1039/b900116f
   Mao YB, 2006, J AM CHEM SOC, V128, P8217, DOI 10.1021/ja0607483
   Meekins BH, 2009, ACS NANO, V3, P3437, DOI 10.1021/nn900897r
   Meku E, 2016, J ELECTROCHEM SOC, V163, pF132, DOI 10.1149/2.0031603jes
   Mo M, 2005, ADV MATER, V17, P756, DOI 10.1002/adma.200401477
   OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0
   Park S, 2004, SCIENCE, V303, P348, DOI 10.1126/science.1093276
   Piera J, 2008, ANGEW CHEM INT EDIT, V47, P3506, DOI 10.1002/anie.200700604
   Pourmortazavi SM, 2012, APPL SURF SCI, V263, P745, DOI 10.1016/j.apsusc.2012.09.153
   Service RF, 2005, SCIENCE, V309, P95, DOI 10.1126/science.309.5731.95
   Sharma D, 2018, J ALLOY COMPD, V749, P329, DOI 10.1016/j.jallcom.2018.03.228
   SMITH JRL, 1963, J CHEM SOC, P2897, DOI 10.1039/jr9630002897
   Sun HL, 2005, CHEM COMMUN, P4339, DOI 10.1039/b507240a
   Tada M, 2007, J PHYS CHEM C, V111, P10095, DOI 10.1021/jp072928k
   Tani M, 2005, ANGEW CHEM INT EDIT, V44, P2586, DOI 10.1002/anie.200462769
   Thomas JM, 1999, NATURE, V398, P227, DOI 10.1038/18417
   Wang HF, 2018, CHEM ENG SCI, V177, P399, DOI 10.1016/j.ces.2017.11.023
   Wang JL, 2008, J PHYS CHEM A, V112, P8226, DOI 10.1021/jp803204z
   Wu MY, 2019, CHEM ENG SCI, V195, P985, DOI 10.1016/j.ces.2018.10.044
   Xin HC, 2009, CHEM COMMUN, P7590, DOI 10.1039/b917038c
   Yang JH, 2013, ENERG ENVIRON SCI, V6, P793, DOI 10.1039/c3ee23623d
   Zhang Y, 2018, APPL SURF SCI, V427, P1009, DOI 10.1016/j.apsusc.2017.09.008
NR 43
TC 0
Z9 0
U1 19
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115274
DI 10.1016/j.ces.2019.115274
PG 9
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300023
OA Bronze
DA 2020-05-12
ER

PT J
AU Mach, J
   Parisien, V
   Wiens, J
   McKnight, CA
   Macchi, A
AF Mach, Jacob
   Parisien, Valois
   Wiens, Jason
   McKnight, Craig A.
   Macchi, Arturo
TI Impact of plenum conditions and gas-liquid distributor on bubble column
   hydrodynamics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas-liquid distributor; Plenum conditions; Energy dissipation rate;
   Turbulent bubble breakup
ID OPTICAL PROBES; MASS-TRANSFER; FLOWS; DISPERSION; 2-PHASE
AB In an LC-Fining (TM) hydroprocessor, the orientation of the free surface in the plenum chamber and the efficiency of the internal gas-liquid separator impact the amounts of the gas and the liquid passing through individual bubble cap risers in the grid. Various gas and liquid flowrates were thus passed through a single bubble cap riser to determine resulting bubble properties. Bubble sizes correlated well with energy dissipation rate and gas-to-liquid velocity ratio to the power of -0.4 and 0.6, respectively, in agreement with theory on the turbulent breakup of dense dispersions. Bubbles were also influenced by the gas-liquid distributor geometry, where the bubble cap produced larger bubbles than a perforated plate. Finally, the size of bubbles sparged in the plenum marginally affected overall gas holdup, suggesting that a bubble cap distributor redesign should be prioritized over upstream gas introduction equipment to optimize the performance of the hydroprocessor. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mach, Jacob; Parisien, Valois; Macchi, Arturo] Univ Ottawa, Ctr Catalysis Res & Innovat, Dept Chem & Biol Engn, Ottawa, ON K1N 6N5, Canada.
   [Wiens, Jason; McKnight, Craig A.] Syncrude Canada Ltd, 9421-17 Ave, Edmonton, AB T6N 1H4, Canada.
RP Macchi, A (reprint author), Univ Ottawa, Ctr Catalysis Res & Innovat, Dept Chem & Biol Engn, Ottawa, ON K1N 6N5, Canada.
EM arturo.macchi@uottawa.ca
OI Mach, Jacob/0000-0001-6018-1753
FU Natural Sciences and Engineering Research Council of CanadaNatural
   Sciences and Engineering Research Council of Canada; Ontario's Ministry
   of Training, Colleges and Universities; Syncrude Canada Ltd.
FX The authors are grateful to Stephane Gluck and Nicolas Zuanon of A2
   Photonic Sensors for their valuable insights and technical support. The
   authors would also like to thank the Natural Sciences and Engineering
   Research Council of Canada, Ontario's Ministry of Training, Colleges and
   Universities, and Syncrude Canada Ltd. for financial assistance.
CR Barrau E, 1999, INT J MULTIPHAS FLOW, V25, P229, DOI 10.1016/S0301-9322(98)00042-1
   Brauner N, 2001, INT J MULTIPHAS FLOW, V27, P885, DOI 10.1016/S0301-9322(00)00056-2
   Camarasa E, 1999, CHEM ENG PROCESS, V38, P329, DOI 10.1016/S0255-2701(99)00024-0
   Cartellier A, 2001, CHEM ENG TECHNOL, V24, P535, DOI 10.1002/1521-4125(200105)24:5<535::AID-CEAT535>3.0.CO;2-X
   Chaumat H, 2005, CHEM ENG SCI, V60, P5930, DOI 10.1016/j.ces.2005.04.026
   Colvert J.H, 1989, US Patent, Patent No. 4874583
   Deen N., 2010, ULLMANNS ENCY IND CH
   Gandhi B, 1999, CAN J CHEM ENG, V77, P383, DOI 10.1002/cjce.5450770226
   GELDART D, 1985, POWDER TECHNOL, V42, P67, DOI 10.1016/0032-5910(85)80039-5
   Guan XP, 2017, CHEM ENG RES DES, V127, P103, DOI 10.1016/j.cherd.2017.09.017
   Han L, 2007, CHEM ENG SCI, V62, P131, DOI 10.1016/j.ces.2006.08.010
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   Julia JE, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.1862192
   Kulkarni AV, 2011, CHEM ENG RES DES, V89, P1986, DOI 10.1016/j.cherd.2011.01.014
   Kulkarni AV, 2011, CHEM ENG RES DES, V89, P1972, DOI 10.1016/j.cherd.2011.01.004
   Kumar S, 2012, PROCEDIA ENGINEER, V42, P782, DOI 10.1016/j.proeng.2012.07.470
   Lau R, 2009, CAN J CHEM ENG, V87, P847, DOI 10.1002/cjce.20224
   McKnight CA, 2003, CAN J CHEM ENG, V81, P338
   Mena PC, 2008, CHEM ENG SCI, V63, P4100, DOI 10.1016/j.ces.2008.05.010
   MIDDLEMAN S, 1974, IND ENG CHEM PROC DD, V13, P78, DOI 10.1021/i260049a015
   Nigam K.D, 1996, 3 PHASE SPARGED REAC
   OUYANG CJP, 1987, CHEM ENG COMMUN, V49, P197, DOI 10.1080/00986448708911803
   Parisien V, 2017, CHEM ENG SCI, V157, P88, DOI 10.1016/j.ces.2016.04.051
   Rahimpour F, 2017, CAN J CHEM ENG, V95, P2221, DOI 10.1002/cjce.22895
   Sharaf S, 2016, CHEM ENG J, V288, P489, DOI 10.1016/j.cej.2015.11.106
   Song S.X., 2016, US Patent, Patent No. [9314759 B2, 9314759]
   Vreman AW, 2007, J FLUID MECH, V584, P235, DOI 10.1017/S0022112007006556
NR 27
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115296
DI 10.1016/j.ces.2019.115296
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300029
OA Bronze
DA 2020-05-12
ER

PT J
AU Michelon, M
   Leopercio, BC
   Carvalho, MS
AF Michelon, Mariano
   Leopercio, Bruna C.
   Carvalho, Marcio S.
TI Microfluidic production of aqueous suspensions of gellan-based
   microcapsules containing hydrophobic compounds
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microfluidics; Gellan gum; Biopolymer; Microcapsules
ID DOUBLE EMULSIONS; MECHANICAL-PROPERTIES; GELATION; GENERATION; CAPSULES;
   PH; COLLOIDOSOMES; ENCAPSULATION; FABRICATION; DEVICE
AB We discuss the production of microcapsules with hydrogel-based shells by ionotropic gelation of gellan gum from monodispersed oil-in-water-in-oil (O/W/O) double emulsion templates obtained using glass-capillary microfluidic devices. An oil extraction step was added after the shell gelation process to enable the dispersion of the microcapsules in an aqueous medium. The proposed approach for producing biopolymer-based microcapsules for hydrophobic agents dispersed in a water phase has a broad range of applications in delivery of hydrophobic compounds dispersed in an aqueous medium. We report the operability window for the production of monodispersed microcapsules as a function of the flow rate of each fluid phase and the dimensions of the device. Microcapsules with mean diameters ranging from 95 to 260 mu m and a maximum coefficient of variation of 5% were formed. The results show how to independently control the capsule diameter and shell thickness by varying the outer and middle phase flow rates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Michelon, Mariano; Leopercio, Bruna C.; Carvalho, Marcio S.] Pontificia Univ Catolica Rio de Janeiro, Dept Mech Engn, Lab Microhydrodynam & Flow Porous Media, BR-22451900 Rio De Janeiro, RJ, Brazil.
RP Carvalho, MS (reprint author), Pontificia Univ Catolica Rio de Janeiro, Dept Mech Engn, Lab Microhydrodynam & Flow Porous Media, BR-22451900 Rio De Janeiro, RJ, Brazil.
EM michelonmariano@gmail.com; bruna@lmmp.mec.puc-rio.br; msc@puc-rio.br
RI Michelon, Mariano/Z-4275-2019
OI Michelon, Mariano/0000-0003-3335-5249
FU Shell Brasil under the ANP RD levy
FX This work was performed in association with the ongoing project entitled
   "Complex dispersion flow through porous media" funded by Shell Brasil
   under the ANP R&D levy. The authors also would like to thank CP Kelco
   and DuPont Nutrition & Health for the donation of materials.
CR Abate AR, 2011, LAB CHIP, V11, P253, DOI [10.1039/c0lc00236d, 10.1039/c01c00236d]
   Abbaspourrad A, 2013, LANGMUIR, V29, P12697, DOI 10.1021/la403064f
   Abbaspourrad A, 2013, J AM CHEM SOC, V135, P7744, DOI 10.1021/ja401960f
   Agnello S, 2017, INT J BIOL MACROMOL, V98, P646, DOI 10.1016/j.ijbiomac.2017.02.029
   Akamatsu K, 2015, LANGMUIR, V31, P7166, DOI 10.1021/acs.langmuir.5b01514
   Amstad E, 2017, ACS MACRO LETT, V6, P841, DOI 10.1021/acsmacrolett.7b00472
   Anna SL, 2016, ANNU REV FLUID MECH, V48, P285, DOI 10.1146/annurev-fluid-122414-034425
   Bacelar AH, 2016, J MATER CHEM B, V4, P6164, DOI 10.1039/c6tb01488g
   Balcaen M, 2016, FOOD HYDROCOLLOID, V58, P356, DOI 10.1016/j.foodhyd.2016.03.011
   Chen PW, 2012, LANGMUIR, V28, P144, DOI 10.1021/la203088u
   Datta SS, 2014, ADV MATER, V26, P2205, DOI 10.1002/adma.201305119
   do Nascimento DF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11950-2
   Picone CSF, 2010, FOOD HYDROCOLLOID, V24, P502, DOI 10.1016/j.foodhyd.2009.12.007
   Franco Z, 2011, FUEL, V90, P838, DOI 10.1016/j.fuel.2010.09.044
   Graham S, 2019, CARBOHYD POLYM, V207, P143, DOI 10.1016/j.carbpol.2018.11.053
   Silva KCG, 2018, LWT-FOOD SCI TECHNOL, V89, P503, DOI [10.1016/j.lwt.2017.11.026, 10.1016/j.1wt.2017.11.026]
   Hennequin Y, 2009, LANGMUIR, V25, P7857, DOI 10.1021/la9004449
   Kim SH, 2013, MICROFLUID NANOFLUID, V14, P509, DOI 10.1007/s10404-012-1069-5
   Kong F, 2014, LANGMUIR, V30, P3905, DOI 10.1021/la404201m
   Lapidot N, 2003, J SOL-GEL SCI TECHN, V26, P67, DOI 10.1023/A:1020785217895
   Lee D, 2008, ADV MATER, V20, P3498, DOI 10.1002/adma.200800918
   Lee D, 2009, SMALL, V5, P1932, DOI 10.1002/smll.200900357
   Liu L, 2013, J COLLOID INTERF SCI, V404, P85, DOI 10.1016/j.jcis.2013.04.044
   Michelon M, 2019, CHEM ENG J, V366, P27, DOI 10.1016/j.cej.2019.02.021
   Nabavi SA, 2017, J COLLOID INTERF SCI, V505, P315, DOI 10.1016/j.jcis.2017.05.115
   Nabavi SA, 2017, CHEM ENG J, V322, P140, DOI 10.1016/j.cej.2017.04.008
   Nabavi SA, 2015, CHEM ENG SCI, V130, P183, DOI 10.1016/j.ces.2015.03.004
   Vilela JAP, 2011, FOOD HYDROCOLLOID, V25, P1710, DOI 10.1016/j.foodhyd.2011.03.012
   Costa ALR, 2017, J FOOD ENG, V209, P18, DOI 10.1016/j.jfoodeng.2017.04.007
   Santos TP, 2018, CARBOHYD POLYM, V192, P111, DOI 10.1016/j.carbpol.2018.03.062
   Steegmans MLJ, 2009, LANGMUIR, V25, P9751, DOI 10.1021/la901103r
   Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164
   Vilanova N, 2013, ACS APPL MATER INTER, V5, P5247, DOI 10.1021/am4010896
   Vladisavljevic GT, 2012, PROG COLL POL SCI S, V139, P115, DOI 10.1007/978-3-642-28974-3_20
   Werner JG, 2018, MACROMOLECULES, V51, P5798, DOI 10.1021/acs.macromol.8b00843
   Xu S, 2018, CONSTR BUILD MATER, V169, P379, DOI 10.1016/j.conbuildmat.2018.01.046
   Yamamoto F, 2007, CARBOHYD POLYM, V68, P517, DOI 10.1016/j.carbpol.2006.11.009
   Zhao YJ, 2011, LANGMUIR, V27, P13988, DOI 10.1021/la2034774
NR 38
TC 0
Z9 0
U1 18
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115314
DI 10.1016/j.ces.2019.115314
PG 11
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300037
OA Bronze
DA 2020-05-12
ER

PT J
AU Nino, L
   Gelves, R
   Ali, H
   Solsvik, J
   Jakobsen, H
AF Nino, Lilibeth
   Gelves, Ricardo
   Ali, Haider
   Solsvik, Jannike
   Jakobsen, Hugo
TI Applicability of a modified breakage and coalescence model based on the
   complete turbulence spectrum concept for CFD simulation of gas-liquid
   mass transfer in a stirred tank reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bioreactor; k(L)a Gas-liquid mass transfer; Energy spectrum; Population
   balance
ID DISCRETIZED POPULATION BALANCE; TRANSFER COEFFICIENT; SIZE
   DISTRIBUTIONS; RUSHTON TURBINE; PITCHED BLADE; GROWTH; FLOW; PREDICTION;
   AERATION; SYSTEM
AB A generalized model for bubble breakage and coalescence is proposed using Computational Fluid Dynamics - CFD for considering the complete energy spectrum. An eulerian model and balance equations are simultaneously used to simulate the multiphase flow and bubble size distribution, respectively. The turbulent kinetic energy and its dissipation are calculated using the standard turbulence model k - epsilon. A semiempirical model that solves the second-order longitudinal structure function based on an interpolation function is coupled to CFD via UDF (User Defined Functions) code. CFD results are compared with experimental data obtained from Sauter mean diameter measurements at different bioreactor positions and stirred by a Rushton turbine. A reasonable prediction is obtained in comparison with the original Coulaloglou and Tavlarides (Break up) and Prince and Blanch (Coalescence) model. Further, the generalized model was extended to other stirring and aeration geometries using the same 10 litter tank bioreactor. The latter for evaluating strategies for overcoming gas-liquid mass transfer problems commonly found in bioreactors and a significant effect of the energy spectrum is reached in the geometries studied. The above, explained by the k(L)a oxygen transfer rate and bubble size determinations. It is numerically demonstrated that flow patterns and bubble size significantly influence the average k(L)a mass transfer in a bioreactor. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nino, Lilibeth] Univ Antioquia, Fac Exact & Nat & Sci, Calle 67 53-108, Medellin, Colombia.
   [Gelves, Ricardo] Univ Francisco de Paula Santander, Dept Environm, Av Gran Colombia 12E-96, Cucuta, Colombia.
   [Ali, Haider; Solsvik, Jannike; Jakobsen, Hugo] Norwegian Univ Sci & Technol, Dept Chem Engn, N-7491 Trondheim, Norway.
RP Gelves, R (reprint author), Univ Francisco de Paula Santander, Dept Environm, Av Gran Colombia 12E-96, Cucuta, Colombia.
EM germanricardogz@ufps.edu.co
RI Ali, Haider/H-4059-2017
OI Ali, Haider/0000-0001-5610-4499
CR Alopaeus V, 2003, COMP AID CH, V14, P545
   Alopaeus V, 1999, CHEM ENG SCI, V54, P5887, DOI 10.1016/S0009-2509(99)00170-0
   BAKKER A, 1994, CHEM ENG RES DES, V72, P594
   Batchelor G.K, 1956, THE THEORY OF HOMOGE
   Betancur G.A, 2013, METODOLOGIA SELECCIO
   CHATZI EG, 1989, IND ENG CHEM RES, V28, P1704, DOI 10.1021/ie00095a022
   Chen P, 2005, CHEM ENG SCI, V60, P1085, DOI 10.1016/j.ces.2004.09.070
   Chorin AJ, 1994, VORTICITY TURBULENCE
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   Czermak P., 2005, PUBL SER IBPT U APPL, V1, P1
   Druzinec D, 2015, CHEM ENG SCI, V126, P160, DOI 10.1016/j.ces.2014.12.020
   Eibl R, 2009, CELL TISSUE REACTION
   Gabelle JC, 2012, CHEM ENG SCI, V75, P408, DOI 10.1016/j.ces.2012.03.053
   Gelves R, 2014, BIOPROC BIOSYST ENG, V37, P365, DOI 10.1007/s00449-013-1001-8
   Hagesaether L, 2000, COMPUTER AIDED CHEM, V8, P367
   HOUNSLOW MJ, 1988, AICHE J, V34, P1821, DOI 10.1002/aic.690341108
   Jakobsen HA, 2005, IND ENG CHEM RES, V44, P5107, DOI 10.1021/ie049447x
   Jenne M, 1999, CHEM ENG SCI
   Kerdouss F, 2008, COMPUT CHEM ENG, V32, P1943, DOI 10.1016/j.compchemeng.2007.10.010
   Kerdouss F, 2005, INT J CHEM REACT ENG, V3, DOI 10.2202/1542-6580.1217
   Laakkonen M, 2006, DEV VALIDATION MASS
   Lane GL, 2002, APPL MATH MODEL, V26, P223, DOI 10.1016/S0307-904X(01)00057-9
   Lehr F, 2002, AICHE J, V48, P2426, DOI 10.1002/aic.690481103
   Lehr F, 2001, CHEM ENG SCI, V56, P1159, DOI 10.1016/S0009-2509(00)00335-3
   Liao YX, 2010, CHEM ENG SCI, V65, P2851, DOI 10.1016/j.ces.2010.02.020
   LITSTER JD, 1995, AICHE J, V41, P591
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Luo J.Y, 1994, I CHEM ENG S SER
   LUO JY, 1994, INST CHEM E, P549
   Micale G, 1999, AICHE J
   Moucha T, 2003, CHEM ENG SCI, V58, P1839, DOI 10.1016/S0009-2509(02)00682-6
   Moutafchieva D, 2018, J CHEM TECHNOL METAL, V53, P511
   Nehring D, 2004, BIOTECHNOL PROGR, V20, P1710, DOI 10.1021/bp049762e
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   RAMKRISHNA D, 2000, POPULATION BALANCES
   Rau U, 1992, J IND MICROBIOL
   Rutherford K, 1996, AICHE J
   Sanyal J, 2005, IND ENG CHEM RES, V44, P5063, DOI 10.1021/ie049555j
   Schmalzriedt S, 2003, ADV BIOCHEM ENG BIOT, V80, P19
   Soler Andrea, 2010, Rev. colomb. biotecnol, V12, P124
   Solsvik J, 2016, AICHE J
   Solsvik J, 2017, J DISPER SCI TECHNOL, V38, P973, DOI 10.1080/01932691.2016.1216440
   Solsvik J, 2016, IND ENG CHEM RES, V55, P1449, DOI 10.1021/acs.iecr.5b04077
   Tabor A, 1996, ICHEME
   Valverde MR, 2016, THEOR FOUND CHEM EN+, V50, P945, DOI 10.1134/S0040579516060178
   Venneker BCH, 2002, AICHE J, V48, P673, DOI 10.1002/aic.690480404
   Willmott, 1981, PHYSICAL GEOGR, V2, P184, DOI DOI 10.1080/02723646.1981.10642213
   WILLMOTT CJ, 1985, J GEOPHYS RES-OCEANS, V90, P8995, DOI 10.1029/JC090iC05p08995
NR 48
TC 0
Z9 0
U1 14
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115272
DI 10.1016/j.ces.2019.115272
PG 11
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300011
OA Bronze
DA 2020-05-12
ER

PT J
AU Paolinelli, LD
AF Paolinelli, Luciano D.
TI A comprehensive model for stability of dispersed oil-water flow in
   horizontal and inclined pipes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dispersed flow; Liquid-liquid; Pipes; Stability bounds; Droplet
   accumulation; Modeling
ID DROP SIZE DISTRIBUTIONS; LIQUID-LIQUID; PHASE INVERSION; IMMISCIBLE
   LIQUIDS; UNIFIED MODEL; 2-PHASE FLOW; VISCOSITY; PATTERN; SUSPENSIONS;
   TRANSITION
AB Prediction of dispersed flow regimes in liquid-liquid pipe flow is of great importance for many industrial processes. This work proposes a mechanistic model to determine the stability bounds of dispersed liquid-liquid flow patterns that presents significant improvements compared to other classical criteria. The model accounts for turbulent break-up of dispersed phase droplets, sedimentation, dispersion, and accumulation of droplets. In addition, droplet coalescence and segregation are considered by means of attaining critical concentrations that can be associated with the phase inversion point of the liquid-liquid mixture. Modeled bounds are compared with available experimental data, showing good agreement in flows of mineral oil and water, as well as flows of crude oil and water. Moreover, the model is more accurate and descriptive than other predictions from commonly used criteria. The effect of fluid properties, flow rates, and pipe geometry are discussed. Limitations and possible refinements of the suggested model are also treated. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Paolinelli, Luciano D.] Ohio Univ, Inst Corros & Multiphase Technol, Dept Chem & Biomol Engn, 342 W State St, Athens, OH 45701 USA.
RP Paolinelli, LD (reprint author), Ohio Univ, Inst Corros & Multiphase Technol, Dept Chem & Biomol Engn, 342 W State St, Athens, OH 45701 USA.
EM paolinel@ohio.edu
FU BP; ConocoPhillips; Enbridge; ExxonMobil; Petronas; Total; ShellRoyal
   Dutch Shell
FX The author wants to thank BP, ConocoPhillips, Enbridge, ExxonMobil,
   Petronas, Total and Shell for their financial support to the Water
   Wetting JIP held at the Institute for Corrosion and Multiphase
   Technology. Helpful comments of Dr. Bert Pots and Dr. Marc Singer are
   also greatly appreciated.
CR Al-Sarkhi A, 2017, J PETROL SCI ENG, V151, P284, DOI 10.1016/j.petrol.2017.01.016
   Al-Wahaibi T, 2007, CHEM ENG SCI, V62, P2915, DOI 10.1016/j.ces.2007.01.024
   Amundsen L, 2011, THESIS
   Angeli P, 1998, INT J MULTIPHAS FLOW, V24, P1183
   Angeli P, 2000, CHEM ENG SCI, V55, P3133, DOI 10.1016/S0009-2509(99)00585-0
   Angeli P, 2000, INT J MULTIPHAS FLOW, V26, P1117, DOI 10.1016/S0301-9322(99)00081-6
   ARASHMID M, 1980, AICHE J, V26, P51, DOI 10.1002/aic.690260109
   Arirachakaran S., 1989, SPE PROD OP S
   BARNEA D, 1987, INT J MULTIPHAS FLOW, V13, P1, DOI 10.1016/0301-9322(87)90002-4
   BRAUNER N, 1992, INT J MULTIPHAS FLOW, V18, P103, DOI 10.1016/0301-9322(92)90009-6
   Brauner N, 2002, INT J MULTIPHAS FLOW, V28, P1177, DOI 10.1016/S0301-9322(02)00017-4
   Brauner N, 2001, INT J MULTIPHAS FLOW, V27, P885, DOI 10.1016/S0301-9322(00)00056-2
   BRINKMAN HC, 1952, J CHEM PHYS, V20, P571, DOI 10.1063/1.1700493
   Brodkey R. S, 1967, PHENOMENA FLUID MOTI
   Crowe CT, 2000, INT J MULTIPHAS FLOW, V26, P719, DOI 10.1016/S0301-9322(99)00050-6
   Elseth G., 2001, THESIS
   Feng ZG, 2001, J FLUID ENG-T ASME, V123, P841, DOI 10.1115/1.1412458
   Flores J.G., 1997, THESIS
   HAALAND SE, 1983, J FLUID ENG-T ASME, V105, P89, DOI 10.1115/1.3240948
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   Ioannou K, 2005, EXP THERM FLUID SCI, V29, P331, DOI 10.1016/j.expthermflusci.2004.05.003
   Jayawardena SS, 2000, BHR GR CONF SER PUBL, P77
   KARABELAS AJ, 1977, AICHE J, V23, P426, DOI 10.1002/aic.690230404
   KARABELAS AJ, 1978, AICHE J, V24, P170, DOI 10.1002/aic.690240203
   Kaushal DR, 2002, POWDER TECHNOL, V125, P89, DOI 10.1016/S0032-5910(02)00031-1
   Kostoglou M, 2005, CHEM ENG SCI, V60, P6584, DOI 10.1016/j.ces.2005.05.051
   Kroes R., 2013, THESIS
   KUBIE J, 1977, CHEM ENG SCI, V32, P195, DOI 10.1016/0009-2509(77)80105-X
   Kumara WAS, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/11/114004
   Liao YX, 2010, CHEM ENG SCI, V65, P2851, DOI 10.1016/j.ces.2010.02.020
   Lovick J, 2005, J CHEM TECHNOL BIOT, V80, P545, DOI 10.1002/jctb.1205
   Lovick J, 2004, INT J MULTIPHAS FLOW, V30, P139, DOI 10.1016/j.ijmultiphaseflow.2003.11.011
   Lum JYL, 2006, INT J MULTIPHAS FLOW, V32, P413, DOI 10.1016/j.ijmultiphaseflow.2006.01.001
   MLYNEK Y, 1972, AICHE J, V18, P122, DOI 10.1002/aic.690180122
   MUKHERJEE H, 1981, J ENERG RESOUR-ASME, V103, P56, DOI 10.1115/1.3230815
   NACE, 2008, SP02082008 NACE
   Nadler M, 1997, INT J MULTIPHAS FLOW, V23, P55, DOI 10.1016/S0301-9322(96)00055-9
   Pal R, 1996, AICHE J, V42, P3181, DOI 10.1002/aic.690421119
   Paolinelli LD, 2018, CHEM ENG SCI, V183, P200, DOI 10.1016/j.ces.2018.03.023
   Piela K, 2008, INT J MULTIPHAS FLOW, V34, P665, DOI 10.1016/j.ijmultiphaseflow.2007.12.004
   Plasencia J, 2013, J PETROL SCI ENG, V101, P35, DOI 10.1016/j.petrol.2012.11.009
   Pots B.F.M., 2006, NACE CORROSION 2006
   Richardson JF, 1997, CHEM ENG RES DES, V75, pS82, DOI 10.1016/S0263-8762(97)80006-8
   Rivkind V. Y., 1976, FLUID DYNAM, V11, P5
   Rodriguez OMH, 2006, INT J MULTIPHAS FLOW, V32, P323, DOI 10.1016/j.ijmultiphaseflow.2005.11.001
   SAFFMAN PG, 1965, J FLUID MECH, V22, P385, DOI 10.1017/S0022112065000824
   Sarica C., 2008, DEV NEXT GENERATION
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   Segev A., 1984, ANN AICHE M AICHE SA, p124a
   SELKER AH, 1965, CAN J CHEM ENG, V43, P298, DOI 10.1002/cjce.5450430606
   Sharma A, 2011, INT J MULTIPHAS FLOW, V37, P326, DOI 10.1016/j.ijmultiphaseflow.2010.11.002
   Simmons MJH, 2001, INT J MULTIPHAS FLOW, V27, P843, DOI 10.1016/S0301-9322(00)00055-0
   Torres C.F., 2015, J ENERGY RESOURCES T, V138
   Trallero J., 1995, THESIS
   Valle A., 2000, THESIS
   Velima M., 2008, SPE PROJ FACIL CONST, P1, DOI 10.2118/115485-MS
   VIGNEAUX P, 1988, AICHE J, V34, P781, DOI 10.1002/aic.690340508
   WANG CY, 1986, AICHE J, V32, P667, DOI 10.1002/aic.690320417
   Wang ZM, 2017, SPE J, V22, P353, DOI 10.2118/183641-PA
   Zavareh F., 1988, SPE ANN TECHN C EXH
   Zhai LS, 2015, INT J MULTIPHAS FLOW, V76, P168, DOI 10.1016/j.ijmultiphaseflow.2015.07.007
   ZHANG H. Q., 2006, SPE PROJECT FACILITI, V1, P1, DOI DOI 10.2118/95749-PA
   Zhang HQ, 2003, INT J MULTIPHAS FLOW, V29, P97, DOI 10.1016/S0301-9322(02)00111-8
NR 63
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115325
DI 10.1016/j.ces.2019.115325
PG 19
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300001
OA Bronze
DA 2020-05-12
ER

PT J
AU Qiao, CZ
   Zhang, J
   Jiang, P
   Zhao, SL
   Song, XF
   Yu, JG
AF Qiao, Chongzhi
   Zhang, Jie
   Jiang, Peng
   Zhao, Shuangliang
   Song, Xingfu
   Yu, Jianguo
TI A molecular approach for predicting phase diagrams of ternary aqueous
   saline solutions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Aqueous saline solution; Phase diagrams; Solubility; Classical density
   functional theory; Ternary system
ID DENSITY-FUNCTIONAL THEORY; LITHIUM-ION BATTERIES;
   RESTRICTED-PRIMITIVE-MODEL; METAL-ORGANIC FRAMEWORKS; SOLID-LIQUID
   EQUILIBRIA; ELECTRIC DOUBLE-LAYERS; MEAN SPHERICAL MODEL; ASYMMETRIC
   ELECTROLYTES; THERMODYNAMIC MODEL; SYSTEM KCL-KBR-H2O
AB Phase diagrams of aqueous saline systems constitute the cornerstone for chemical industry of inorganic salts. Although quite a few of theoretical models have been proposed, most of them rely on the empirical parameters that are determined in prior by fitting experimental data. Herein, we propose a new molecular thermodynamic approach for predicting the phase diagrams of aqueous saline solutions. This approach is developed relying on the molecular interaction and the assumption that the ion dissolution in solvent is analogous to gas adsorption. By means of this approach, the phase diagrams of several typical types of ternary aqueous saline solutions are predicted, by combining classical density functional theory with the solubility data of one single salt. The predictions have overall good agreements with the corresponding experimental measurement. The developed approach is simple yet generic, and it can be extended to investigate phase diagrams for multi-salt aqueous solutions and other related systems. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Qiao, Chongzhi; Jiang, Peng; Zhao, Shuangliang] East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
   [Qiao, Chongzhi; Jiang, Peng; Zhao, Shuangliang] East China Univ Sci & Technol, Sch Chem Engn, Shanghai 200237, Peoples R China.
   [Zhang, Jie; Song, Xingfu; Yu, Jianguo] East China Univ Sci & Technol, Natl Engn Res Ctr Integrated Utilizat Salt Lake R, Shanghai, Peoples R China.
   [Zhang, Jie] Sinopec Shanghai Res Inst Petrochem Technol, State Key Lab Green Chem Engn & Ind Catalysis, Shanghai 201208, Peoples R China.
RP Zhao, SL (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.; Zhao, SL (reprint author), East China Univ Sci & Technol, Sch Chem Engn, Shanghai 200237, Peoples R China.; Song, XF (reprint author), East China Univ Sci & Technol, Natl Engn Res Ctr Integrated Utilizat Salt Lake R, Shanghai, Peoples R China.
EM szhao@ecust.edu.cn; xfsong@ecust.edu.cn
RI Zhao, Shuangliang/B-6139-2017
OI Zhao, Shuangliang/0000-0002-9547-4860
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1707602, 21878078]; 111 Project of ChinaMinistry
   of Education, China - 111 Project [B08021]; Fok Ying Tong Education
   FoundationFok Ying Tung Education Foundation [151069]
FX This work is supported by the National Natural Science Foundation of
   China (No. U1707602 and 21878078), the 111 Project of China (No.
   B08021). S.Z. acknowledges the support of Fok Ying Tong Education
   Foundation (151069).
CR Aragones JL, 2012, J CHEM PHYS, V136, DOI 10.1063/1.4728163
   BLUM L, 1975, MOL PHYS, V30, P1529, DOI 10.1080/00268977500103051
   BLUM L, 1977, J PHYS CHEM-US, V81, P1311, DOI 10.1021/j100528a019
   Chung TH, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3099335
   COTTERMAN RL, 1986, AICHE J, V32, P1787, DOI 10.1002/aic.690321104
   CUI ST, 1995, J PHYS CHEM-US, V99, P2900, DOI 10.1021/j100009a054
   [丁秀萍 DING Xiu-ping], 2009, [盐湖研究, Journal of Salt Lake Research], V17, P40
   Diouf B, 2015, RENEW ENERG, V76, P375, DOI 10.1016/j.renene.2014.11.058
   Ferrario M, 2002, J CHEM PHYS, V117, P4947, DOI 10.1063/1.1498820
   Fu C, 2016, J CHEM ENG DATA, V61, P1071, DOI 10.1021/acs.jced.5b00570
   Gendre L, 2009, CHEM PHYS LETT, V474, P366, DOI 10.1016/j.cplett.2009.04.077
   Gillespie D, 2002, J PHYS-CONDENS MAT, V14, P12129, DOI 10.1088/0953-8984/14/46/317
   Guo LJ, 2012, J CHEM ENG DATA, V57, P817, DOI 10.1021/je201044n
   Hannan MA, 2017, RENEW SUST ENERG REV, V78, P834, DOI 10.1016/j.rser.2017.05.001
   Hu B, 2007, CALPHAD, V31, P541, DOI 10.1016/j.calphad.2007.03.002
   Hu YX, 2014, J CHEM ENG DATA, V59, P802, DOI 10.1021/je400931p
   Iddir H, 2010, J PHYS CHEM C, V114, P20903, DOI 10.1021/jp1086569
   Jaguemont J, 2016, APPL ENERG, V164, P99, DOI 10.1016/j.apenergy.2015.11.034
   Jiang DE, 2011, CHEM PHYS LETT, V504, P153, DOI 10.1016/j.cplett.2011.01.072
   Jiang J, 2014, J PHYS-CONDENS MAT, V26, DOI 10.1088/0953-8984/26/28/284102
   JOHNSON JK, 1993, MOL PHYS, V78, P591, DOI 10.1080/00268979300100411
   Joung IS, 2009, J PHYS CHEM B, V113, P13279, DOI 10.1021/jp902584c
   Kobayashi K, 2014, J CHEM PHYS, V140, DOI 10.1063/1.4870417
   Li D, 2014, BRAZ J CHEM ENG, V31, P561, DOI 10.1590/0104-6632.20140312s00002760
   Li DD, 2018, CALPHAD, V60, P163, DOI 10.1016/j.calphad.2018.01.002
   Li DD, 2016, CALPHAD, V53, P78, DOI 10.1016/j.calphad.2016.03.007
   Li DD, 2015, CALPHAD, V51, P1, DOI 10.1016/j.calphad.2015.05.001
   Li YH, 2000, CALPHAD, V24, P295
   Lian C, 2016, ACS ENERGY LETT, V1, P21, DOI 10.1021/acsenergylett.6b00010
   Lin YZ, 2002, J CHEM PHYS, V117, P407, DOI 10.1063/1.1481380
   Lisal M, 2005, J PHYS CHEM B, V109, P12956, DOI 10.1021/jp0507492
   Liu Y, 2010, J PHYS CHEM B, V114, P9905, DOI 10.1021/jp104121q
   Liu Y, 2015, CHEM ENG SCI, V137, P170, DOI 10.1016/j.ces.2015.06.036
   Liu Y, 2015, AICHE J, V61, P2951, DOI 10.1002/aic.14842
   Liu Y, 2013, J CHEM THEORY COMPUT, V9, P1896, DOI 10.1021/ct3010936
   Liu Y, 2010, J PHYS CHEM B, V114, P2820, DOI 10.1021/jp9104932
   Liu YH, 2015, FLUID PHASE EQUILIBR, V391, P85, DOI 10.1016/j.fluid.2015.02.009
   Lovera JA, 2009, CALPHAD, V33, P388, DOI 10.1016/j.calphad.2008.11.002
   Manzetti S, 2015, RENEW SUST ENERG REV, V51, P1004, DOI 10.1016/j.rser.2015.07.010
   Martin-Molina A, 2006, J PHYS CHEM B, V110, P1326, DOI 10.1021/jp053970n
   Meng LZ, 2014, RUSS J PHYS CHEM A+, V88, P2283, DOI 10.1134/S0036024414130135
   Meng LZ, 2014, J CHEM ENG DATA, V59, P4193, DOI 10.1021/je500881x
   Moucka F, 2013, J CHEM PHYS, V138, DOI 10.1063/1.4801322
   Moucka F, 2011, J PHYS CHEM B, V115, P7849, DOI 10.1021/jp202054d
   Nakayama Y, 2015, J CHEM PHYS, V142, DOI 10.1063/1.4906319
   Paluch AS, 2010, J CHEM PHYS, V133, DOI 10.1063/1.3478539
   Patsahan OV, 2019, J MOL LIQ, V275, P443, DOI 10.1016/j.molliq.2018.11.078
   Peng LL, 2016, ADV ENERGY MATER, V6, DOI 10.1002/aenm.201600025
   Qiao CZ, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4984773
   Sang SH, 2014, J SOLUTION CHEM, V43, P2133, DOI 10.1007/s10953-014-0264-2
   Sanz E, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2397683
   Saw LH, 2016, J CLEAN PROD, V113, P1032, DOI 10.1016/j.jclepro.2015.11.011
   Schmidt CL, 2001, J POWER SOURCES, V97-8, P742, DOI 10.1016/S0378-7753(01)00648-6
   Suzette M.K., 2017, MINERAL COMMODITY SU
   Tagliazucchi M, 2011, J AM CHEM SOC, V133, P17753, DOI 10.1021/ja2063605
   Wagner F.S, 2000, KIRK OTHMER ENCY CHE, P1
   Wang SQ, 2016, J CHEM ENG DATA, V61, P1155, DOI 10.1021/acs.jced.5b00805
   Wu JZ, 2011, SOFT MATTER, V7, P11222, DOI 10.1039/c1sm06089a
   Wu JZ, 2006, AICHE J, V52, P1169, DOI 10.1002/aic.10713
   Yang JM, 2013, RUSS J PHYS CHEM A+, V87, P2195, DOI 10.1134/S003602441313013X
   Yin LC, 2016, NANO ENERGY, V25, P203, DOI 10.1016/j.nanoen.2016.04.053
   [余疆江 Yu Jiangjiang], 2013, [化工进展, Chemical Industry and Engineering Progress], V32, P13
   Yu XC, 2018, CHEM ENG SCI, V188, P170, DOI 10.1016/j.ces.2018.05.035
   Yu YX, 2004, J CHEM PHYS, V120, P7223, DOI 10.1063/1.1676121
   Zeng DW, 2008, J CHEM THERMODYN, V40, P1157, DOI 10.1016/j.jct.2008.02.010
   Zhao S., 2015, ADV CHEM ENG, V47, P1
NR 66
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115278
DI 10.1016/j.ces.2019.115278
PG 9
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300007
OA Bronze
DA 2020-05-12
ER

PT J
AU Rice, HP
   Peakall, J
   Fairweather, M
   Hunter, TN
AF Rice, Hugh P.
   Peakall, Jeffrey
   Fairweather, Michael
   Hunter, Timothy N.
TI Extending estimation of the critical deposition velocity in solid-liquid
   pipe flow to ideal and non-ideal particles at low and intermediate solid
   volume fractions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Particle-laden flow; Acoustic measurements; Ultrasonics; Sediment
   transport; Radioactive waste
ID MINIMUM TRANSPORT VELOCITY; RANDOM CLOSE PACKING; SEDIMENT EROSION;
   HORIZONTAL PIPES; SUSPENSIONS; SIZE; THRESHOLD; VISCOSITY; BEHAVIOR;
   MODEL
AB The critical deposition velocity in horizontal pipe flow of liquid-solid slurries separates bed-forming and fully suspended flows. A compilation of critical deposition velocity data is presented using new experimental data (for particles ranging from 9 to 690 mu m in diameter) along with data from the literature, and a close correlation between the particle Reynolds number and the Archimedes number (which describe the properties of the flow and the liquid and solid phases) is found. The role of solid particle packing is discussed and suggestions are made for the incorporation of solid-phase material properties - specifically particle shape and angularity, and surface forces - into an empirical parameter, the volume factor, alpha, to account for the deviation of particle behaviour from ideal, non-interacting, hard-sphere behaviour. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rice, Hugh P.; Fairweather, Michael; Hunter, Timothy N.] Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
   [Peakall, Jeffrey] Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England.
   [Rice, Hugh P.] Univ Leeds, Sch Mech Engn, Leeds LS2 9JT, W Yorkshire, England.
RP Rice, HP (reprint author), Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.; Rice, HP (reprint author), Univ Leeds, Sch Mech Engn, Leeds LS2 9JT, W Yorkshire, England.
EM h.p.rice@leeds.ac.uk
RI Rice, Hugh P/E-3272-2010
OI Hunter, Timothy/0000-0003-3922-491X
FU U.K. Engineering and Physical Sciences Research Council
   (EPSRC)Engineering & Physical Sciences Research Council (EPSRC)
   [EP/L014041/1]
FX The authors thank Peter Dawson, Bob Harris, Tony Windross, Gareth Keevil
   and Robert Thomas for their technical assistance, and Olivier Mariette
   at Met-Flow, Switzerland, for his support and advice. The authors also
   thank the U.K. Engineering and Physical Sciences Research Council
   (EPSRC) for financial support of this study through grant EP/L014041/1:
   Decommissioning, Immobilisation and Storage Solutions for Nuclear Waste
   Inventories (DISTINCTIVE). We also warmly thank the editor and three
   anonymous reviewers for their comments, which improved the paper.
CR Al-lababidi S, 2012, J ENERG RESOUR-ASME, V134, DOI 10.1115/1.4006433
   Babcock H, HYDROTRANSPORT 1
   Bain A. G., 1970, HYDRAULIC TRANSPORT
   Balastre M, 2002, COLLOID SURFACE A, V211, P145, DOI 10.1016/S0927-7757(02)00240-6
   Balastre M, 1999, J COLLOID INTERF SCI, V219, P155, DOI 10.1006/jcis.1999.6469
   BERGSTROM L, 1992, J AM CERAM SOC, V75, P3305, DOI 10.1111/j.1151-2916.1992.tb04426.x
   BERGSTROM L, 1992, J CHEM SOC FARADAY T, V88, P3201, DOI 10.1039/ft9928803201
   Brouwers HJH, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.052211
   Bux J, 2017, AICHE J, V63, P2618, DOI 10.1002/aic.15683
   CABREJOS FJ, 1994, POWDER TECHNOL, V79, P173, DOI 10.1016/0032-5910(94)02815-X
   Cairns R, 1960, BRIT CHEM ENG, V5, P849
   Clark AH, 2015, PHYS REV E, V92, DOI 10.1103/PhysRevE.92.042202
   Corey AT, 1949, THESIS
   Crowe C.T., 2006, MULTIPHASE FLOW HDB
   Desmond KW, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.022204
   DIETRICH WE, 1982, WATER RESOUR RES, V18, P1615, DOI 10.1029/WR018i006p01615
   Doron P, 1996, INT J MULTIPHAS FLOW, V22, P273, DOI 10.1016/0301-9322(95)00071-2
   DORON P, 1995, CHEM ENG SCI, V50, P1595, DOI 10.1016/0009-2509(95)00024-Y
   Durand R, 1952, C HYDR TRANSP COAL 1
   Farr RS, 2013, POWDER TECHNOL, V245, P28, DOI 10.1016/j.powtec.2013.04.009
   GILLIES RG, 1991, CAN J CHEM ENG, V69, P173, DOI 10.1002/cjce.5450690120
   GILLIES RG, 1991, CAN J CHEM ENG, V69, P1225, DOI 10.1002/cjce.5450690525
   Goedde E, 1978, HYDROTRANSPORT 5
   Gondret P, 1997, J RHEOL, V41, P1261, DOI 10.1122/1.550850
   Graf W.H, 1970, FRITZ LAB REPORTS
   Hayden J.W, 1971, ADV SOLID LIQUID FLO
   Heersink J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.253601
   HUGHMARK GA, 1961, IND ENG CHEM, V53, P389, DOI 10.1021/ie50617a029
   Hunter TN, 2013, CHEM ENG RES DES, V91, P722, DOI 10.1016/j.cherd.2013.02.002
   Johnson M, 2016, IND ENG CHEM RES, V55, P9983, DOI 10.1021/acs.iecr.6b02383
   Liddell K.C, 2000, CRITICAL TRANSPORT V
   Liu SJ, 2002, POWDER TECHNOL, V126, P283, DOI 10.1016/S0032-5910(02)00075-X
   MCGEARY RK, 1961, J AM CERAM SOC, V44, P513, DOI 10.1111/j.1151-2916.1961.tb13716.x
   MICHAELS AS, 1962, IND ENG CHEM FUND, V1, P24, DOI 10.1021/i160001a004
   Miedema SA, 2016, OCEAN ENG, V123, P422, DOI 10.1016/j.oceaneng.2016.07.031
   MIZUNO M, 1991, KONA POWDER PART J, V9, P19, DOI DOI 10.14356/KONA.1991007
   Murphy G, 1954, PROGR REPORT FRICTIO
   Newitt D. M., 1955, T I CHEM ENGRS, V33, P93
   OROSKAR AR, 1980, AICHE J, V26, P550, DOI 10.1002/aic.690260405
   PARZONKA W, 1981, CAN J CHEM ENG, V59, P291, DOI 10.1002/cjce.5450590305
   Paul N, 2017, POWDER TECHNOL, V322, P75, DOI 10.1016/j.powtec.2017.09.002
   Paul N, 2013, CHEM ENG RES DES, V91, P742, DOI 10.1016/j.cherd.2013.02.017
   Peker S.M, 2007, SOLID LIQUID 2 PHASE
   Peysson Y, 2009, INT J MULTIPHAS FLOW, V35, P597, DOI 10.1016/j.ijmultiphaseflow.2009.02.007
   Poloski AP, 2010, CAN J CHEM ENG, V88, P182, DOI 10.1002/cjce.20260
   Powers M.C., 1953, J SEDIMENT PETROL, V23, P117, DOI DOI 10.1306/D4269567-2B26-11D7-8648000102C1865D
   Rabinovich E, 2011, REV CHEM ENG, V27, P215, DOI 10.1515/REVCE.2011.011
   Rice H.P, 2013, THESIS
   Rice HP, 2017, INT J MULTIPHAS FLOW, V93, P1, DOI 10.1016/j.ijmultiphaseflow.2017.03.007
   Rice HP, 2015, CHEM ENG SCI, V126, P759, DOI 10.1016/j.ces.2014.12.039
   Rice HP, 2014, J ACOUST SOC AM, V136, P156, DOI 10.1121/1.4883376
   RICHARDSON JF, 1954, CHEM ENG SCI, V3, P65, DOI 10.1016/0009-2509(54)85015-9
   Sinclair C.G, 1962, S INT FLUIDS PART 3
   Smith R, 1955, T I CHEM ENG-LOND, V33, P85
   Soepyan FB, 2014, AICHE J, V60, P76, DOI 10.1002/aic.14255
   Spells K.E, 1955, T I CHEM ENG-LOND, P79
   SUDDUTH RD, 1993, J APPL POLYM SCI, V48, P37, DOI 10.1002/app.1993.070480105
   Syvitski J.P.M., 2007, PRINCIPLES METHODS A
   THOMAS AD, 1979, INT J MULTIPHAS FLOW, V5, P113, DOI 10.1016/0301-9322(79)90040-5
   THOMAS DG, 1962, AICHE J, V8, P373, DOI 10.1002/aic.690080323
   THOMAS DG, 1961, AICHE J, V7, P423, DOI 10.1002/aic.690070316
   Torquato S, 2000, PHYS REV LETT, V84, P2064, DOI 10.1103/PhysRevLett.84.2064
   TURIAN RM, 1987, POWDER TECHNOL, V51, P35, DOI 10.1016/0032-5910(87)80038-4
   Vesilind P A, 1968, WATER SEWAGE WORKS, V115, P302
   Wasp E.J., 1977, SOLID LIQUID FLOW SL
   Welch T.D, 2001, TANK WASTE TRANSPORT
   Wilson K.C, 1965, 51 QUEENS U CIV ENG
   Worster R.C., 1955, P I MECH ENG, V169, P563
NR 68
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115308
DI 10.1016/j.ces.2019.115308
PG 9
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300022
OA Bronze
DA 2020-05-12
ER

PT J
AU Ruan, X
   Chen, S
   Li, SQ
AF Ruan, Xuan
   Chen, Sheng
   Li, Shuiqing
TI Structural evolution and breakage of dense agglomerates in shear flow
   and Taylor-Green vortex
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Discrete element method; Adhesion; Microparticle; Agglomerate; Breakage;
   Fluid stress
ID DISCRETE-ELEMENT METHOD; COMPUTER-SIMULATION; SURFACE-ENERGY; AGGREGATE
   SIZE; DISPERSION; PARTICLES; COLLISION; BEHAVIOR; DEFORMATION;
   DEPENDENCE
AB We perform adhesive discrete-element method (DEM) calculations to investigate the structural evolution and the breakage of dense agglomerates in a shear flow and a Taylor-Green vortex. By means of adhesive DEM, all possible modes of particle contacting interactions are resolved and the free-draining approximation is employed to calculate the hydrodynamic drag. We demonstrate that, for shear flows, dense agglomerates undergo significant restructuring before breakage. The normal force between contacting particles scales in a linear way as the shear rate increases. Based on extensive simulation results, a criterion for breakage is then proposed, which is valid across a wide range of shear stress and interparticle adhesion values. The average size of fragments at the quasi-steady state after the breakage follows a power function of a particle adhesion parameter. By defining an effective shear rate, we are able to extend the findings in simple shear flows to the breakage process in the vortex. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ruan, Xuan; Chen, Sheng; Li, Shuiqing] Tsinghua Univ, Dept Energy & Power Engn, Key Lab Thermal Sci & Power Engn, Minist Educ, Beijing 100084, Peoples R China.
   [Chen, Sheng] Huazhong Univ Sci & Technol, Sch Energy & Power Engn, State Key Lab Coal Combust, Wuhan 430074, Hubei, Peoples R China.
RP Li, SQ (reprint author), Tsinghua Univ, Dept Energy & Power Engn, Key Lab Thermal Sci & Power Engn, Minist Educ, Beijing 100084, Peoples R China.
EM lishuiqing@tsinghua.edu.cn
FU National Key Research and Development Program of China [2016YFB0600602];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51725601]
FX SQL acknowledges support from the National Key Research and Development
   Program of China (Grant No. 2016YFB0600602) and the National Natural
   Science Foundation of China (51725601). We are grateful to Prof. Eric
   Climent at Universite de Toulouse and Prof. Qiang Yao at Tsinghua
   University for helpful suggestions.
CR Babler MU, 2015, J FLUID MECH, V766, DOI 10.1017/jfm.2015.13
   Becker V, 2009, J COLLOID INTERF SCI, V339, P362, DOI 10.1016/j.jcis.2009.07.022
   Becker V, 2008, PHYS REV E, V78, DOI 10.1103/PhysRevE.78.061404
   Bubakova P, 2013, POWDER TECHNOL, V235, P540, DOI 10.1016/j.powtec.2012.11.014
   Chen S, 2019, PHYS REV FLUIDS, V4, DOI 10.1103/PhysRevFluids.4.024304
   Chen S, 2019, CHEM ENG SCI, V193, P336, DOI 10.1016/j.ces.2018.09.026
   Chen S, 2015, POWDER TECHNOL, V274, P431, DOI 10.1016/j.powtec.2015.01.051
   De Bona J, 2014, J FLUID MECH, V755, DOI 10.1017/jfm.2014.421
   Dizaji FF, 2019, J FLUID MECH, V862, P592, DOI 10.1017/jfm.2018.959
   Eggersdorfer ML, 2010, J COLLOID INTERF SCI, V342, P261, DOI 10.1016/j.jcis.2009.10.062
   Fang Z, 2019, J AEROSOL SCI, V134, P80, DOI 10.1016/j.jaerosci.2019.04.018
   FRIEDLANDER SK, 2000, SMOKE DUST HAZE FUND
   Harada S, 2007, COLLOID SURFACE A, V302, P396, DOI 10.1016/j.colsurfa.2007.03.003
   Harada S, 2006, J COLLOID INTERF SCI, V301, P123, DOI 10.1016/j.jcis.2006.04.051
   Hassanpour A, 2007, CHEM ENG SCI, V62, P935, DOI 10.1016/j.ces.2006.10.026
   Higashitani K, 2001, CHEM ENG SCI, V56, P2927, DOI 10.1016/S0009-2509(00)00477-2
   HORWATT SW, 1992, CHEM ENG SCI, V47, P1849, DOI 10.1016/0009-2509(92)80303-T
   Hunt T C. R., 1988, P SUMM PROGR
   Iimura K, 2009, ADV POWDER TECHNOL, V20, P210, DOI 10.1016/j.apt.2008.09.003
   Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1
   Jaworek A, 2018, PROG ENERG COMBUST, V67, P206, DOI 10.1016/j.pecs.2018.03.003
   JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141
   Jones T B, 1995, ELECTROMECHANICS PAR, DOI [10.1017/CBO9780511574498, DOI 10.1017/CBO9780511574498]
   Lapuerta M, 2006, J COLLOID INTERF SCI, V303, P149, DOI 10.1016/j.jcis.2006.07.066
   Li SQ, 2007, J AEROSOL SCI, V38, P1031, DOI 10.1016/j.jaerosci.2007.08.004
   Li SQ, 2011, PROG ENERG COMBUST, V37, P633, DOI 10.1016/j.pecs.2011.02.001
   Liu DY, 2018, POWDER TECHNOL, V336, P102, DOI 10.1016/j.powtec.2018.05.051
   Liu LF, 1999, PHYSICA A, V268, P433, DOI 10.1016/S0378-4371(99)00106-5
   Liu WW, 2019, PHYS FLUIDS, V31, DOI 10.1063/1.5095758
   Liu WW, 2016, POWDER TECHNOL, V302, P414, DOI 10.1016/j.powtec.2016.08.068
   Manounou AK, 2014, PHYSICA A, V412, P66, DOI 10.1016/j.physa.2014.06.023
   Marchioli C, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.053003
   Marshall J, 2014, ADHESIVE PARTICLE FL, DOI [10.1017/CBO9781139424547, DOI 10.1017/CBO9781139424547, 10.1017/cbo9781139424547]
   Marshall JS, 2009, J COMPUT PHYS, V228, P1541, DOI 10.1016/j.jcp.2008.10.035
   POTANIN AA, 1993, J COLLOID INTERF SCI, V157, P399, DOI 10.1006/jcis.1993.1202
   Renault F, 2009, CHEM ENG J, V155, P775, DOI 10.1016/j.cej.2009.09.023
   Royer JR, 2009, NATURE, V459, P1110, DOI 10.1038/nature08115
   SAFFMAN PG, 1956, J FLUID MECH, V1, P16, DOI 10.1017/S0022112056000020
   Fellay LS, 2012, J COLLOID INTERF SCI, V388, P47, DOI 10.1016/j.jcis.2012.08.050
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   Schutte KCJ, 2018, J FLUID MECH, V857, P539, DOI 10.1017/jfm.2018.716
   Selomulya C, 2003, CHEM ENG SCI, V58, P327, DOI 10.1016/S0009-2509(02)00523-7
   Selomulya C, 2001, J COLLOID INTERF SCI, V236, P67, DOI 10.1006/jcis.2000.7372
   Seto R, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.041405
   SONNTAG RC, 1986, J COLLOID INTERF SCI, V113, P399, DOI 10.1016/0021-9797(86)90175-X
   Soos M, 2006, CHEM ENG SCI, V61, P2349, DOI 10.1016/j.ces.2005.11.001
   Soos M, 2008, J COLLOID INTERF SCI, V319, P577, DOI 10.1016/j.jcis.2007.12.005
   Sorensen CM, 2011, AEROSOL SCI TECH, V45, P765, DOI 10.1080/02786826.2011.560909
   TSUJI Y, 1992, POWDER TECHNOL, V71, P239, DOI 10.1016/0032-5910(92)88030-L
   Vanni M, 2014, P ASME 2014 4 JOINT, DOI 10.1115/FEDSM2014-21558
   Villiger TK, 2015, AICHE J, V61, P1735, DOI 10.1002/aic.14753
   Voss A, 2002, INT J PHARM, V248, P39, DOI 10.1016/S0378-5173(02)00319-8
   Wang GC, 2019, CHEM ENG SCI, V201, P201, DOI 10.1016/j.ces.2019.03.004
   Wang L, 2005, J COLLOID INTERF SCI, V282, P380, DOI 10.1016/j.jcis.2004.08.127
   Wang LP, 2000, J FLUID MECH, V415, P117, DOI 10.1017/S0022112000008661
   WANG LP, 1992, PHYS FLUIDS A-FLUID, V4, P1789, DOI 10.1063/1.858401
   Washino K, 2018, POWDER TECHNOL, V325, P202, DOI 10.1016/j.powtec.2017.11.024
   Yao Y, 2018, PHYS REV FLUIDS, V3, DOI 10.1103/PhysRevFluids.3.034301
NR 58
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115261
DI 10.1016/j.ces.2019.115261
PG 13
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300054
OA Bronze
DA 2020-05-12
ER

PT J
AU Shi, PY
   Rzehak, R
AF Shi, Pengyu
   Rzehak, Roland
TI Lift forces on solid spherical particles in wall-bounded flows
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Lift force; Particles; Wall-bounded flow; Particle rotation; Inner/outer
   region; Correlation
ID LINEAR SHEAR-FLOW; MACROSCOPIC RIGID SPHERES; SLOW VISCOUS MOTION;
   INERTIAL MIGRATION; LATERAL MIGRATION; POISEUILLE FLOW; VERTICAL WALL;
   PLANE WALL; RADIAL MIGRATION; REYNOLDS-NUMBER
AB The present work is concerned with the lift forces acting on particles immersed in a wall-bounded fluid. Conditions where the particle translates in a fluid at rest and in a linear shear flow are considered. Likewise, non-rotating particles and particles in free rotation driven solely by the flow are considered. Furthermore, situations where the wall lies in the inner region and in the outer region of the flow disturbance produced by the particle are distinguished. The focus is on solid spherical particles at Reynolds numbers up to O(10(2)) which are relevant for particulate flows in chemical and minerals engineering. A comprehensive review of existing results from analytical, experimental, and direct numerical simulation studies is given. The available correlations are critically assessed by comparison to data from these studies. Based on the comparison recommendations are given which correlations to use, including some new proposals, and gaps in the data are identified. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shi, Pengyu; Rzehak, Roland] Helmholtz Zentrum Dresden Rossendorf, Inst Fluid Dynam, Bautzner Landstr 400, D-01328 Dresden, Germany.
   [Shi, Pengyu] Tech Univ Dresden, Fac Mech Engn, Inst Power Engn, D-01062 Dresden, Germany.
RP Shi, PY (reprint author), Helmholtz Zentrum Dresden Rossendorf, Inst Fluid Dynam, Bautzner Landstr 400, D-01328 Dresden, Germany.
EM p.shi@hzdr.de
RI SHI, Pengyu/F-1207-2019
OI SHI, Pengyu/0000-0001-6402-4720
FU Chinese Scholarship Council (CSC)China Scholarship Council
FX This work was supported by the Chinese Scholarship Council (CSC). We
   wish to thank Professor Jacques Magnaudet, Professor John B. McLaughlin,
   and Professor Francois Feuillebois for valuable discussions on their
   individual publications on inertial lift forces. Some of the numerical
   data used for comparison are provided by Professor M. Grae Worster on
   behalf of the JFM Editorial Office.
CR Abbas M, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4902952
   Asmolov E. S., 1990, Fluid Dynamics, V25, P886
   Asmolov E. S., 1989, Fluid Dynamics, V24, P710
   Asmolov ES, 1999, J FLUID MECH, V381, P63, DOI 10.1017/S0022112098003474
   Asmolov ES, 2018, J FLUID MECH, V840, P613, DOI 10.1017/jfm.2018.95
   Bagchi P, 2002, PHYS FLUIDS, V14, P2719, DOI 10.1063/1.1487378
   Baskurt OK, 2003, SEMIN THROMB HEMOST, V29, P435
   Bhagat AAS, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2998844
   Bluemink JJ, 2008, J FLUID MECH, V600, P201, DOI 10.1017/S0022112008000438
   BRETHERTON FP, 1962, J FLUID MECH, V14, P284, DOI 10.1017/S002211206200124X
   Charru F, 2013, ANNU REV FLUID MECH, V45, P469, DOI 10.1146/annurev-fluid-011212-140806
   CHERUKAT P, 1995, J FLUID MECH, V285, P407, DOI 10.1017/S0022112095000590
   Cherukat P, 1999, INT J MULTIPHAS FLOW, V25, P15, DOI 10.1016/S0301-9322(98)00034-2
   CHERUKAT P, 1990, INT J MULTIPHAS FLOW, V16, P899, DOI 10.1016/0301-9322(90)90011-7
   CHERUKAT P, 1994, INT J MULTIPHAS FLOW, V20, P339, DOI 10.1016/0301-9322(94)90086-8
   Chiu YY, 2016, BIOMICROFLUIDICS, V10, DOI 10.1063/1.4939944
   Choi YS, 2011, LAB CHIP, V11, P460, DOI [10.1039/c0lc00212g, 10.1039/c01c00212g]
   Chun B, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2176587
   Cox R. G., 1977, International Journal of Multiphase Flow, V3, P201, DOI 10.1016/0301-9322(77)90001-5
   COX RG, 1968, CHEM ENG SCI, V23, P147, DOI 10.1016/0009-2509(68)87059-9
   Dherbecourt D, 2016, CHEM ENG RES DES, V108, P109, DOI 10.1016/j.cherd.2016.02.025
   Di Carlo D, 2007, P NATL ACAD SCI USA, V104, P18892, DOI 10.1073/pnas.0704958104
   Di Carlo D, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.094503
   DREW DA, 1988, CHEM ENG SCI, V43, P769, DOI 10.1016/0009-2509(88)80071-X
   DREW DA, 1983, ANNU REV FLUID MECH, V15, P261, DOI 10.1146/annurev.fl.15.010183.001401
   FISCHER TM, 1987, Z ANGEW MATH PHYS, V38, P339, DOI 10.1007/BF00944955
   GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P637, DOI 10.1016/0009-2509(67)80047-2
   GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4
   HALOW JS, 1970, AICHE J, V16, P281, DOI 10.1002/aic.690160222
   HALOW JS, 1970, IND ENG CHEM FUND, V9, P603, DOI 10.1021/i160036a013
   Han M, 1999, J RHEOL, V43, P1157, DOI 10.1122/1.551019
   HO BP, 1974, J FLUID MECH, V65, P365, DOI 10.1017/S0022112074001431
   HOGG AJ, 1994, J FLUID MECH, V272, P285, DOI 10.1017/S0022112094004477
   Hood K, 2015, J FLUID MECH, V765, P452, DOI 10.1017/jfm.2014.739
   JEFFREY RC, 1965, J FLUID MECH, V22, P721, DOI 10.1017/S0022112065001106
   KAPLUN S, 1957, J MATH MECH, V6, P585
   KARNIS A, 1966, CAN J CHEM ENG, V44, P181, DOI 10.1002/cjce.5450440401
   Kazerooni HT, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.084301
   Kim YW, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/6/065015
   KRISHNAN GP, 1995, PHYS FLUIDS, V7, P2538, DOI 10.1063/1.868755
   Lee H, 2010, J FLUID MECH, V657, P89, DOI 10.1017/S0022112010001382
   Legendre D, 1997, PHYS FLUIDS, V9, P3572, DOI 10.1063/1.869466
   Legendre D, 1998, J FLUID MECH, V368, P81, DOI 10.1017/S0022112098001621
   LEIGHTON D, 1985, Z ANGEW MATH PHYS, V36, P174, DOI 10.1007/BF00949042
   Lovalenti P.M, 1994, J FLUID MECH, V263, P1
   Magnaudet J, 2003, J FLUID MECH, V476, P115, DOI 10.1017/S0022112002002902
   Majji MV, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5020220
   Majji MV, 2018, J FLUID MECH, V835, P936, DOI 10.1017/jfm.2017.754
   Matas JP, 2009, J FLUID MECH, V621, P59, DOI 10.1017/S0022112008004977
   Matas JP, 2004, J FLUID MECH, V515, P171, DOI 10.1017/S0022112004000254
   MCLAUGHLIN JB, 1993, J FLUID MECH, V246, P249, DOI 10.1017/S0022112093000114
   MCLAUGHLIN JB, 1991, J FLUID MECH, V224, P261, DOI 10.1017/S0022112091001751
   MEI RW, 1994, PHYS FLUIDS, V6, P418, DOI 10.1063/1.868039
   Miura K, 2014, J FLUID MECH, V749, P320, DOI 10.1017/jfm.2014.232
   Morita Y, 2017, J FLUID MECH, V813, P750, DOI 10.1017/jfm.2016.881
   Nakagawa N, 2015, J FLUID MECH, V779, P776, DOI 10.1017/jfm.2015.456
   Nakayama S, 2019, J FLUID MECH, V871, P952, DOI 10.1017/jfm.2019.325
   Ogbonnaya SK, 2017, FRONT HEAT MASS TRAN, V9, DOI 10.5098/hmt.9.31
   OLIVER DR, 1962, NATURE, V194, P1269, DOI 10.1038/1941269b0
   ONEILL ME, 1967, J FLUID MECH, V27, P705, DOI 10.1017/S0022112067002551
   Paie P, 2017, MICROSYST NANOENG, V3, DOI 10.1038/micronano.2017.27
   PROUDMAN I, 1957, J FLUID MECH, V2, P237, DOI 10.1017/S0022112057000105
   Rida Z, 2019, EXP FLUIDS, V60, DOI 10.1007/s00348-019-2710-9
   SAFFMAN PG, 1965, J FLUID MECH, V22, P385, DOI 10.1017/S0022112065000824
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   SCHONBERG JA, 1989, J FLUID MECH, V203, P517, DOI 10.1017/S0022112089001564
   SEGRE G, 1962, J FLUID MECH, V14, P136, DOI 10.1017/S0022112062001111
   SEGRE G, 1962, J FLUID MECH, V14, P115, DOI 10.1017/S002211206200110X
   Shampine LF, 2008, J COMPUT APPL MATH, V211, P131, DOI 10.1016/j.cam.2006.11.021
   Shao XM, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.3005427
   Shi PY, 2019, CHEM ENG SCI, V208, DOI 10.1016/j.ces.2019.08.003
   Shichi H, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.044201
   Sinha SL, 2017, PARTICUL SCI TECHNOL, V35, P103, DOI 10.1080/02726351.2015.1131792
   Stone HA, 2000, J FLUID MECH, V409, P165, DOI 10.1017/S0022112099007697
   Subramaniam S, 2013, PROG ENERG COMBUST, V39, P215, DOI 10.1016/j.pecs.2012.10.003
   Sugioka K, 2015, INT J MULTIPHAS FLOW, V71, P32, DOI 10.1016/j.ijmultiphaseflow.2014.12.001
   Tachibana M., 1973, Rheologica Acta, V12, P58, DOI 10.1007/BF01526901
   Takagi S, 2011, ANNU REV FLUID MECH, V43, P615, DOI 10.1146/annurev-fluid-122109-160756
   Takemura F, 2003, J FLUID MECH, V495, P235, DOI 10.1017/S0022112003006232
   Takemura F, 2004, PHYS FLUIDS, V16, P204, DOI 10.1063/1.1629129
   Takemura F, 2002, J FLUID MECH, V461, P277, DOI 10.1017/S0022112002008388
   Takemura F, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3206729
   Takemura F, 2009, J FLUID MECH, V634, P463, DOI 10.1017/S0022112009007605
   VASSEUR P, 1976, J FLUID MECH, V78, P385, DOI 10.1017/S0022112076002498
   VASSEUR P, 1977, J FLUID MECH, V80, P561, DOI 10.1017/S0022112077001840
   Wang Y., 2019, ARXIV190307975
   Yahiaoui S, 2010, J FLUID MECH, V662, P447, DOI 10.1017/S0022112010003307
   Yang BH, 2005, J FLUID MECH, V540, P109, DOI 10.1017/S0022112005005677
   Yu ZS, 2004, J FLUID MECH, V518, P61, DOI 10.1017/S0022112004000771
   Zeng LY, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3082232
   Zeng LY, 2005, J FLUID MECH, V536, P1, DOI 10.1017/S0022112005004738
   Zhou ZD, 2017, INT J MULTIPHAS FLOW, V92, P1, DOI 10.1016/j.ijmultiphaseflow.2017.01.018
NR 92
TC 1
Z9 1
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115264
DI 10.1016/j.ces.2019.115264
PG 22
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300036
OA Bronze
DA 2020-05-12
ER

PT J
AU Song, SL
   Yue, XY
   Zhao, QB
   Chong, DT
   Chen, WX
   Yan, JJ
AF Song, Shilin
   Yue, Xiaoyu
   Zhao, Quanbin
   Chong, Daotong
   Chen, Weixiong
   Yan, Junjie
TI Numerical study on mechanism of condensation oscillation of unstable
   steam jet
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Numerical simulation; Steam bubble condensation; Pressure oscillation;
   Oscillation mechanism
ID DIRECT-CONTACT CONDENSATION; PRESSURE OSCILLATION; HEAT-TRANSFER; BUBBLE
   CONDENSATION; SUBMERGED JET; FLOW; WATER; SIMULATION; POOL; MASS
AB Submerged steam jet condensation is widely used in many industries. However, this process may cause damage to equipment due to pressure oscillation, especially at low steam mass flux. The dynamic process of steam bubble and different pressure oscillation types were investigated in this numerical study. Five typical stages were observed, which were bubble growth stage, bubble slow necking stage, bubble rapid necking stage, bubble detachment stage and secondary bubble oscillation stage. Two pressure oscillation types were found by the synchronization analysis of bubble pattern and pressure field. The mechanisms of condensation oscillation of unstable steam jet were revealed. As for the first type, two pressure peaks existed in the fluctuation process of secondary bubble volume. The higher pressure peak was generated when secondary bubble was oscillated to its minimum volume, and the other was generated when secondary bubble was collapsed. As for the second type, only one pressure peak existed and secondary bubble was quickly contracted without volume fluctuation. Pressure peak was generated when secondary bubble was quickly contracted to its minimum volume. Moreover, analyses of flow field pressure at different locations were carried out. Results indicated that the pressure fluctuation was mainly induced by the condensation oscillation of secondary bubble for both types. The trends of pressure at different locations were the same as that of secondary bubble internal pressure. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Song, Shilin; Yue, Xiaoyu; Zhao, Quanbin; Chong, Daotong; Chen, Weixiong; Yan, Junjie] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
RP Chong, DT (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM ssl123@stu.xjtu.edu.cn; yuexiaoyu@stu.xjtu.edu.cn;
   zhaoquanbin122@mail.xjtu.edu.cn; dtchong@mail.xjtu.edu.cn;
   chenweixiong@mail.xjtu.edu.cn; yanjj@mail.xjtu.edu.cn
RI Chong, Daotong/O-6550-2014
OI Chong, Daotong/0000-0003-2135-154X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51876166]; Natural Science Foundation of Shaanxi
   Province of ChinaNatural Science Foundation of Shaanxi Province
   [2018JC-005]
FX This work was supported by National Natural Science Foundation of China
   (No. 51876166) and Natural Science Foundation of Shaanxi Province of
   China (2018JC-005).
CR Al Issa S, 2017, INT J MULTIPHAS FLOW, V94, P173, DOI 10.1016/j.ijmultiphaseflow.2017.04.019
   Al Issa S, 2014, INT J HEAT MASS TRAN, V70, P918, DOI 10.1016/j.ijheatmasstransfer.2013.11.049
   Anglart H, 1996, NUCL ENG DES, V163, P81, DOI 10.1016/0029-5493(95)01160-9
   Ansys, 2017, ANSYS FLUENT V18 2 A
   AYA I, 1991, NUCL ENG DES, V131, P17, DOI 10.1016/0029-5493(91)90314-8
   CHAN CK, 1982, INT J MULTIPHAS FLOW, V8, P11, DOI 10.1016/0301-9322(82)90003-9
   Chen WX, 2016, EXP THERM FLUID SCI, V76, P24, DOI 10.1016/j.expthermflusci.2016.03.003
   Chong DT, 2019, INT J HEAT MASS TRAN, V139, P648, DOI 10.1016/j.ijheatmasstransfer.2019.05.043
   Chong DT, 2015, EXP THERM FLUID SCI, V68, P744, DOI 10.1016/j.expthermflusci.2015.07.011
   Dahikar SK, 2010, CHEM ENG SCI, V65, P4606, DOI 10.1016/j.ces.2010.05.004
   Damasio C., 1985, EXPT STUDY UNSTABLE
   Gulawani SS, 2006, CHEM ENG SCI, V61, P5204, DOI 10.1016/j.ces.2006.03.032
   Gulawani SS, 2009, CHEM ENG SCI, V64, P1719, DOI 10.1016/j.ces.2008.12.020
   Hong SJ, 2012, INT J MULTIPHAS FLOW, V39, P66, DOI 10.1016/j.ijmultiphaseflow.2011.10.007
   HUGHMARK GA, 1967, AICHE J, V13, P1219, DOI 10.1002/aic.690130638
   JEJE A, 1990, CHEM ENG SCI, V45, P639, DOI 10.1016/0009-2509(90)87007-F
   Kurul N, 1990, THESIS
   Li SQ, 2015, PROG NUCL ENERG, V78, P201, DOI 10.1016/j.pnucene.2014.10.002
   LIANG KS, 1994, NUCL ENG DES, V147, P425, DOI 10.1016/0029-5493(94)90225-9
   Moreno-Prosper M, 2013, 15 INT TOP M NUCL RE
   NARIAI H, 1986, NUCL ENG DES, V95, P35, DOI 10.1016/0029-5493(86)90034-8
   Patel G, 2017, NUCL ENG DES, V321, P328, DOI 10.1016/j.nucengdes.2016.08.026
   Qiu BB, 2014, EXP THERM FLUID SCI, V52, P270, DOI 10.1016/j.expthermflusci.2013.09.020
   Qu XH, 2016, CHEM ENG SCI, V144, P216, DOI 10.1016/j.ces.2015.09.009
   Qu XH, 2017, NUCL ENG DES, V320, P123, DOI 10.1016/j.nucengdes.2017.04.009
   Tang JG, 2015, CHEM ENG SCI, V137, P384, DOI 10.1016/j.ces.2015.06.058
   Tanskanen V, 2014, ANN NUCL ENERGY, V66, P133, DOI 10.1016/j.anucene.2013.12.007
   UNAL HC, 1976, INT J HEAT MASS TRAN, V19, P643, DOI 10.1016/0017-9310(76)90047-8
   Wang LT, 2018, EXP THERM FLUID SCI, V91, P451, DOI 10.1016/j.expthermflusci.2017.10.036
   Wu XZ, 2009, CHEM ENG SCI, V64, P5002, DOI 10.1016/j.ces.2009.08.007
   Xu Q, 2013, INT J HEAT MASS TRAN, V66, P808, DOI 10.1016/j.ijheatmasstransfer.2013.07.083
   Youn DH, 2003, J NUCL SCI TECHNOL, V40, P881, DOI 10.3327/jnst.40.881
   Yuan F, 2016, INT J HEAT MASS TRAN, V98, P193, DOI 10.1016/j.ijheatmasstransfer.2016.03.035
   Zhao QB, 2018, PROG NUCL ENERG, V107, P31, DOI 10.1016/j.pnucene.2017.12.014
   Zhao QB, 2015, ANN NUCL ENERGY, V85, P512, DOI 10.1016/j.anucene.2015.05.032
   Zhou L, 2017, INT COMMUN HEAT MASS, V83, P48, DOI 10.1016/j.icheatmasstransfer.2016.11.004
   Zhou L, 2017, INT J HEAT MASS TRAN, V108, P351, DOI 10.1016/j.ijheatmasstransfer.2016.12.013
NR 37
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115303
DI 10.1016/j.ces.2019.115303
PG 13
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300046
OA Bronze
DA 2020-05-12
ER

PT J
AU Stavrou, AG
   Hare, C
   Hassanpour, A
   Wu, CY
AF Stavrou, Alexandros Georgios
   Hare, Colin
   Hassanpour, Ali
   Wu, Chuan-Yu
TI Investigation of powder flowability at low stresses by DEM modelling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Powder flowability; Low consolidation stresses; Ball indentation; Shear
   cell; DEM modelling
ID BALL INDENTATION; COHESIVE POWDERS; CONTACT; FLOW; CALIBRATION;
   PARAMETERS; SIMULATION; ADHESIVE; STRAIN; BEDS
AB Ball indentation is a technique capable of assessing powder flowability down to very low consolidation stresses (<= 1 kPa). With this method, powder flowability is determined by measuring the hardness of a powder bed, which allows the unconfined yield strength to be inferred via the constraint factor. The latter is well established for continuum materials, whereas for particulate systems its dependency on stress level and powder properties is not well defined. This work investigates these factors by simulating the ball indentation method using DEM. The constraint factor is shown to be independent of pre-consolidation stress. Constraint factor generally increases with interface energy for relatively cohesion-less powders, though not for cohesive powders. An increase in plastic yield stress leads to a decrease in the constraint factor. Increasing the coefficient of interparticle static friction reduces the constraint factor, while increasing the coefficient of inter-particle rolling friction significantly increases the constraint factor. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Stavrou, Alexandros Georgios; Hare, Colin; Wu, Chuan-Yu] Univ Surrey, Fac Engn & Phys Sci, Dept Chem & Proc Engn, Guildford GU2 7XH, Surrey, England.
   [Hassanpour, Ali] Univ Leeds, Fac Engn, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
RP Hare, C (reprint author), Univ Surrey, Fac Engn & Phys Sci, Dept Chem & Proc Engn, Guildford GU2 7XH, Surrey, England.
EM c.hare@surrey.ac.uk
OI Hare, Colin/0000-0002-5348-5748; Wu, Charley/0000-0003-2721-5231;
   Hassanpour, Ali/0000-0002-7756-1506
FU International Fine Particle Research Institute (IFPRI)
FX The financial support of the International Fine Particle Research
   Institute (IFPRI) is gratefully acknowledged. Furthermore, the authors
   greatly appreciate the MATLAB code provided by Dr. Massih Pasha (The
   Chemours Company) for the calculation of the input parameters for the
   DEM contact model used in this work.
CR Alizadeh M, 2018, POWDER TECHNOL, V339, P789, DOI 10.1016/j.powtec.2018.08.028
   Bagi K, 1996, MECH MATER, V22, P165, DOI 10.1016/0167-6636(95)00044-5
   Cundall P.A, 1971, P INT S ROCK MECH 19
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Freeman R, 2005, POWDER HANDL PROCESS, V17, P294
   Groger T, 2006, COMPUT-AIDED CHEM EN, V21, P533
   Hare C, 2013, AIP CONF PROC, V1542, P887, DOI 10.1063/1.4812074
   HARNBY N, 1987, CHEM ENG SCI, V42, P879, DOI 10.1016/0009-2509(87)80046-5
   Hassanpour A, 2007, PART PART SYST CHAR, V24, P117, DOI 10.1002/ppsc.200601111
   Hill R., 1950, MATH THEORY PLASTICI
   Hohner D, 2014, POWDER TECHNOL, V253, P256, DOI 10.1016/j.powtec.2013.11.023
   Jenike A., 1964, BULLETIN, V123
   Jenike A.W., 1961, BULLETIN, V108
   Johnson K. L., 1985, CONTACT MECH
   JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141
   KOZLOV GV, 1994, MECH COMPOS MATER, V30, P506
   Luding S, 2008, GRANUL MATTER, V10, P235, DOI 10.1007/s10035-008-0099-x
   Pasha M, 2015, CHEM ENG SCI, V123, P92, DOI 10.1016/j.ces.2014.10.026
   Pasha M, 2013, POWDER TECHNOL, V233, P80, DOI 10.1016/j.powtec.2012.08.017
   Pasha M., 2013, THESIS
   Pasha M, 2014, GRANUL MATTER, V16, P151, DOI 10.1007/s10035-013-0476-y
   Rios M., 2006, PHARM TECHNOL, V30
   Schulze D., 2008, POWDERS BULK SOLIDS
   Sogaard SV, 2014, INT J PHARMACEUT, V475, P315, DOI 10.1016/j.ijpharm.2014.08.060
   Stavrou A.G., 2019, THESIS
   Tabor D, 1996, PHILOS MAG A, V74, P1207, DOI 10.1080/01418619608239720
   Tabor D, 1951, HARDNESS METALS
   Tardos GI, 2003, POWDER TECHNOL, V131, P23, DOI 10.1016/S0032-5910(02)00315-7
   Thakur SC, 2016, POWDER TECHNOL, V293, P130, DOI 10.1016/j.powtec.2015.05.051
   Thornton C, 1998, POWDER TECHNOL, V99, P154, DOI 10.1016/S0032-5910(98)00099-0
   Tomas J, 2007, CHEM ENG SCI, V62, P1997, DOI 10.1016/j.ces.2006.12.055
   Walton OR, 2009, AIP CONF PROC, V1145, P897, DOI 10.1063/1.3180075
   Wang C, 2008, PARTICUOLOGY, V6, P282, DOI 10.1016/j.partic.2008.05.004
   Zafar U., 2013, THESIS
   Zafar U, 2017, POWDER TECHNOL, V310, P300, DOI 10.1016/j.powtec.2017.01.047
NR 35
TC 1
Z9 1
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115307
DI 10.1016/j.ces.2019.115307
PG 11
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300034
OA Bronze
DA 2020-05-12
ER

PT J
AU Sun, LJ
   Song, Y
   Li, BH
   Guan, GQ
   Jiang, YB
AF Sun, Liangjie
   Song, Yang
   Li, Binghui
   Guan, Guoqiang
   Jiang, Yanbin
TI A modified method for modelling, optimization and control of an
   anti-solvent crystallization process
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Anti-solvent crystallization; Modeling; Method of characteristic;
   Crystal size distribution; Non-linear model predicted control;
   beta-Artemether
ID POPULATION BALANCE-EQUATIONS; BATCH INDUSTRIAL CRYSTALLIZATION;
   PREDICTIVE CONTROL; SIMULTANEOUS STRATEGIES; EFFICIENT SOLUTION;
   NUMERICAL-SOLUTION; QUADRATURE METHOD; STATE ESTIMATION;
   BETA-ARTEMETHER; NUCLEATION
AB Crystallization is a complex process of heat and mass transfer, its product quality is affected by many factors, thus it is a challenge to control this process. Modelling and optimization of the manipulated variables is a feasible way to improve the product quality of crystallization. In this paper, a modified numerical scheme is developed to solve the process model of anti-solvent batch crystallization. The proposed numerical scheme can handle growth, nucleation, agglomeration and breakage kinetics by means of the Method of Characteristics (MOC), which provides an accurate and efficient result of the crystal size distribution (CSD). Then Non-linear Model Predictive Control (NMPC) and non-linear Moving Horizon Estimation (MHE) are presented to provide a temperature profile for optimizing the CSD. The result of case studies indicates that the calculated results of the MOC modified process model were in agreement with the experimental results, which indicated that the MOC method could deal with the specific crystallization process efficiently and accurately. The NMPC-MHE optimized temperature control strategy was tested using the verification experiment of anti-solvent crystallization of p-Artemether, the validated result indicated that the method developed had high feasibility and accuracy. The computational time for the MHE and NMPC formulations with 90 control and sampling steps is well within the sampling interval, which allows for real time process control. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sun, Liangjie; Song, Yang; Li, Binghui; Guan, Guoqiang; Jiang, Yanbin] South China Univ Technol, Sch Chem & Chem Engn, Guangdong Prov Key Lab Green Chem Prod Technol, Guangzhou 510640, Guangdong, Peoples R China.
RP Jiang, YB (reprint author), South China Univ Technol, Sch Chem & Chem Engn, Guangdong Prov Key Lab Green Chem Prod Technol, Guangzhou 510640, Guangdong, Peoples R China.
EM cebjiang@scut.edu.cn
OI Jiang, Yanbin/0000-0001-8984-0302
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21776102, 21676097]; Natural Science Foundation of
   Guangdong ProvinceNational Natural Science Foundation of Guangdong
   Province [2014A030312007]
FX Financial support from the National Natural Science Foundation of China
   (Nos. 21776102, 21676097) and Natural Science Foundation of Guangdong
   Province (No. 2014A030312007) is greatly appreciated.
CR Aamir E, 2009, IND ENG CHEM RES, V48, P8575, DOI 10.1021/ie900430t
   Abbas A, 2007, SEP PURIF TECHNOL, V53, P153, DOI 10.1016/j.seppur.2006.06.027
   Acevedo D, 2015, IND ENG CHEM RES, V54, P2156, DOI 10.1021/acs.iecr.5b00173
   Biegler LT, 2007, CHEM ENG PROCESS, V46, P1043, DOI 10.1016/j.cep.2006.06.021
   Biegler LT, 2002, CHEM ENG SCI, V57, P575, DOI 10.1016/S0009-2509(01)00376-1
   Cao YK, 2017, CONTROL ENG PRACT, V69, P1, DOI 10.1016/j.conengprac.2017.08.008
   Cogoni G, 2014, COMPUT CHEM ENG, V63, P82, DOI 10.1016/j.compchemeng.2014.01.001
   Derdour L, 2015, AICHE J, V61, P4456, DOI 10.1002/aic.15007
   Durr R, 2018, IFAC PAPERSONLINE, V51, P290, DOI 10.1016/j.ifacol.2018.03.050
   Falola A, 2013, COMPUT CHEM ENG, V56, P1, DOI 10.1016/j.compchemeng.2013.04.017
   Feng LH, 2017, AICHE J, V63, P3832, DOI 10.1002/aic.15749
   Fevotte F, 2010, CHEM ENG SCI, V65, P3191, DOI 10.1016/j.ces.2010.02.009
   HULBURT HM, 1964, CHEM ENG SCI, V19, P555, DOI 10.1016/0009-2509(64)85047-8
   Kumar S, 1997, CHEM ENG SCI, V52, P4659, DOI 10.1016/S0009-2509(97)00307-2
   Lim YI, 2002, CHEM ENG SCI, V57, P3715, DOI 10.1016/S0009-2509(02)00236-1
   Ma DL, 2002, COMPUT CHEM ENG, V26, P1103, DOI 10.1016/S0098-1354(02)00033-9
   Mahoney AW, 2002, CHEM ENG SCI, V57, P1107, DOI 10.1016/S0009-2509(01)00427-4
   Marchisio DL, 2003, AICHE J, V49, P1266, DOI 10.1002/aic.690490517
   Mayne DQ, 2000, AUTOMATICA, V36, P789, DOI 10.1016/S0005-1098(99)00214-9
   Mesbah A, 2011, AICHE J, V57, P1557, DOI 10.1002/aic.12366
   Mesbah A, 2011, J PROCESS CONTR, V21, P652, DOI 10.1016/j.jprocont.2010.11.013
   Mesbah A, 2009, CHEM ENG SCI, V64, P4262, DOI 10.1016/j.ces.2009.06.060
   Motz S, 2008, J PROCESS CONTR, V18, P361, DOI 10.1016/j.jprocont.2007.10.010
   Perez-Calvo JF, 2016, AICHE J, V62, P3992, DOI 10.1002/aic.15295
   Pilon L, 2003, INT J NUMER METH FL, V42, P1211, DOI 10.1002/fld.586
   Porru M, 2017, IND ENG CHEM RES, V56, P9578, DOI 10.1021/acs.iecr.7b00243
   Porru M, 2017, IND ENG CHEM RES, V56, P5980, DOI 10.1021/acs.iecr.7b00240
   Prasad V, 2002, J PROCESS CONTR, V12, P353, DOI 10.1016/S0959-1524(01)00044-0
   Qin SJ, 2003, CONTROL ENG PRACT, V11, P733, DOI 10.1016/S0967-0661(02)00186-7
   QIU YF, 1994, AICHE J, V40, P799, DOI 10.1002/aic.690400507
   Ramkrishna D., 1985, REV CHEM ENG, V3, P49
   Rawlings J.B, 2002, IEEE CONTR SYST MAG, V20, P38
   Simone E, 2017, CHEM ENG SCI, V174, P374, DOI 10.1016/j.ces.2017.09.034
   Szilagyi B, 2018, IND ENG CHEM RES, V57, P3320, DOI 10.1021/acs.iecr.7b03964
   Wachter A, 2006, MATH PROGRAM, V106, P25, DOI 10.1007/s10107-004-0559-y
   Zhang Y, 2015, CHEM ENG RES DES, V95, P187, DOI 10.1016/j.cherd.2014.10.018
   Zhang Y, 2011, J CRYST GROWTH, V314, P185, DOI 10.1016/j.jcrysgro.2010.10.165
   Zhang Y, 2009, J CHEM ENG DATA, V54, P1340, DOI 10.1021/je800946x
   Zhao Y, 2015, CHEM ENG SCI, V133, P106, DOI 10.1016/j.ces.2015.02.019
NR 39
TC 0
Z9 0
U1 12
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115253
DI 10.1016/j.ces.2019.115253
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300006
OA Bronze
DA 2020-05-12
ER

PT J
AU Tellabide, M
   Estiati, I
   Pablos, A
   Altzibar, H
   Aguado, R
   Olazar, M
AF Tellabide, Mikel
   Estiati, Idoia
   Pablos, Aitor
   Altzibar, Haritz
   Aguado, Roberto
   Olazar, Martin
TI New operation regimes in fountain confined conical spouted beds
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fine particles; Conical spouted bed; Fountain confiner; Hydrodynamic
   curves; Scaling up; Draft tube
ID DRAFT-TUBE; THERMAL PERFORMANCE; PARTICLE-VELOCITY; CIRCULATION RATES;
   FINE; HYDRODYNAMICS; BIOMASS; PYROLYSIS; GAS; DEPOSITION
AB The spouted bed regime is an alternative to fixed and fluidized beds due to the excellent gas-solid contact and the high reduction in operating pressure drop. Nevertheless, the most important limitation of this technology lies in its scaling up, since the inlet diameter/particle diameter ratio must be below 20-30 to avoid bed instability. In order to overcome this limitation, a new internal device called fountain confiner has been developed, which stabilises the system and allows operating with fine particles even without any type of draft tube. Runs have been carried out using the fountain confiner in order to analyse the stability of beds composed of very fine particles and the characteristic hydrodynamic curves (pressure drop vs. air velocity) have been obtained. The use of this new device allows attaining highly stable operation regimes, widening the operational range to 4 times that of plain spouted beds, and increasing the inlet diameter/particle diameter ratio from 20-30 to 1000. Moreover, the optimum distance between the bed surface and the lower end of the confiner has been delimited for the range of operating conditions studied, 0.06 - 0.08 m (between 1/2 and 1/3 the confiner diameter), since it is a key parameter for system stability. Finally, the effect of several geometric factors and the scaling up of this technology has been analysed for fine particles of different size and density. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tellabide, Mikel; Estiati, Idoia; Pablos, Aitor; Altzibar, Haritz; Aguado, Roberto; Olazar, Martin] Univ Basque Country, Dept Chem Engn, UPV EHU, POB 644, E-48080 Bilbao, Spain.
RP Tellabide, M (reprint author), Univ Basque Country, Dept Chem Engn, UPV EHU, POB 644, E-48080 Bilbao, Spain.
EM mikel.tellabide@ehu.eus
RI Aguado, Roberto/G-4849-2011
OI Aguado, Roberto/0000-0001-8743-5696; TELLABIDE VECINA,
   MIKEL/0000-0002-7211-2672
FU Spain's Ministry of Economy and Competitiveness (AEI/FEDER, UE)
   [CTQ2016-75535-R]; European Commission (HORIZON H2020-MSCA RISE-2018)
   [823745]; Spain's Ministry of Education, Culture and Sport
   [FPU14/05814]; University of the Basque CountryUniversity of Basque
   Country [ESPDOC18/14]
FX This work has received funding from Spain's Ministry of Economy and
   Competitiveness (CTQ2016-75535-R (AEI/FEDER, UE)) and the European
   Commission (HORIZON H2020-MSCA RISE-2018. Contract No.: 823745). M.
   Tellabide thanks Spain's Ministry of Education, Culture and Sport for
   his Ph.D. grant (FPU14/05814). I. Estiati thanks the University of the
   Basque Country for her postgraduate grant (ESPDOC18/14).
CR Altzibar H, 2008, DRY TECHNOL, V26, P308, DOI 10.1080/07373930801898018
   Altzibar H, 2013, IND ENG CHEM RES, V52, P15959, DOI 10.1021/ie401412j
   Altzibar H, 2009, CHEM ENG TECHNOL, V32, P463, DOI 10.1002/ceat.200800605
   Altzibar H, 2017, POWDER TECHNOL, V312, P334, DOI 10.1016/j.powtec.2017.01.071
   Altzibar H, 2013, CAN J CHEM ENG, V91, P1865, DOI 10.1002/cjce.21913
   Altzibar H, 2013, IND ENG CHEM RES, V52, P2995, DOI 10.1021/ie302407f
   Altzibar H, 2011, CHEM ENG TECHNOL, V34, P1130, DOI 10.1002/ceat.201100032
   Alvarez J, 2018, FUEL, V224, P111, DOI 10.1016/j.fuel.2018.03.028
   Amutio M, 2012, ENERG FUEL, V26, P1353, DOI 10.1021/ef201662x
   Berghel J, 2014, DRY TECHNOL, V32, P519, DOI 10.1080/07373937.2013.840648
   Buchanan R.H., 1965, MECH CHEM ENG T, V1, P117
   Caussat B, 2006, POWDER TECHNOL, V165, P65, DOI 10.1016/j.powtec.2006.03.020
   Cortazar M, 2018, ENERGY, V153, P455, DOI 10.1016/j.energy.2018.04.067
   Du W, 2015, POWDER TECHNOL, V281, P138, DOI 10.1016/j.powtec.2015.04.077
   Du W, 2015, POWDER TECHNOL, V276, P134, DOI 10.1016/j.powtec.2015.02.016
   Elordi G, 2007, J ANAL APPL PYROL, V79, P450, DOI 10.1016/j.jaap.2006.11.010
   Epstein J.R., 2011, SPOUTED SPOUT FLUID
   Estiati I, 2019, POWDER TECHNOL, V344, P278, DOI 10.1016/j.powtec.2018.12.035
   Estiati I, 2017, POWDER TECHNOL, V316, P87, DOI 10.1016/j.powtec.2017.01.040
   Freire JT, 2012, DRY TECHNOL, V30, P330, DOI 10.1080/07373937.2011.638149
   Freitas L.A.P., 2000, SLOT RECTAN SPOUTED, V2014, P37, DOI [10.1080/00986440008912823, DOI 10.1080/00986440008912823]
   Gao HY, 2017, POWDER TECHNOL, V317, P216, DOI 10.1016/j.powtec.2017.05.007
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   Golshan S, 2017, CHEM ENG RES DES, V121, P315, DOI 10.1016/j.cherd.2017.03.022
   ISHIKURA T, 1983, CAN J CHEM ENG, V61, P317, DOI 10.1002/cjce.5450610310
   Ishikura T, 2003, POWDER TECHNOL, V131, P56, DOI 10.1016/S0032-5910(02)00321-2
   Jiao Y, 2014, IEEE POSITION LOCAT, P37, DOI 10.1109/PLANS.2014.6851355
   John R., 2004, HYDRODYNAMIC STUDIES, V2014, P37, DOI [10.1080/00986440490277992, DOI 10.1080/00986440490277992]
   Kmiec A, 2009, CHEM ENG TECHNOL, V32, P450, DOI 10.1002/ceat.200800558
   Lopez G, 2017, FUEL, V203, P825, DOI 10.1016/j.fuel.2017.05.014
   Lopez G, 2016, ENERGY, V107, P493, DOI 10.1016/j.energy.2016.04.040
   MATHUR KB, 1955, AICHE J, V1, P157, DOI 10.1002/aic.690010205
   Mathur N., 1974, SPOUTED BEDS
   Mostou N., 2015, FLOW STRUCTURE CHARA, V269, P392, DOI [10.1016/j.powtec.2014.09.028, DOI 10.1016/J.POWTEC.2014.09.028]
   Nagashima H, 2013, CAN J CHEM ENG, V91, P1755, DOI 10.1002/cjce.21847
   Nagashima H, 2009, CAN J CHEM ENG, V87, P228, DOI 10.1002/cjce.20150
   OLAZAR M, 1993, IND ENG CHEM RES, V32, P2826, DOI 10.1021/ie00023a053
   OLAZAR M, 1992, IND ENG CHEM RES, V31, P1784, DOI 10.1021/ie00007a025
   Olazar M, 2012, DRY TECHNOL, V30, P207, DOI 10.1080/07373937.2011.633194
   Pablos A, 2018, POWDER TECHNOL, V328, P38, DOI 10.1016/j.powtec.2017.12.090
   Perazzini M.T.B., 2017, STABILITY PERFORMANC, DOI [10.1080/07373937.2017.1331240, DOI 10.1080/07373937.2017.1331240]
   PICCININI N, 1983, CAN J CHEM ENG, V61, P448, DOI 10.1002/cjce.5450610328
   Rudolph V, 2006, PREDICTION MINIMUM S, P338, DOI [10.1080/009864491007660, DOI 10.1080/009864491007660]
   Saadevandi BA, 2004, CHEM ENG COMMUN, V191, P1379, DOI 10.1080/00986440490472661
   Saldarriaga JF, 2018, FUEL, V227, P256, DOI 10.1016/j.fuel.2018.04.060
   Saldarriaga JF, 2015, CHEM ENG RES DES, V102, P80, DOI 10.1016/j.cherd.2015.05.042
   Sarafraz MM, 2018, EXP THERM FLUID SCI, V91, P509, DOI 10.1016/j.expthermflusci.2017.11.007
   Sarafraz MM, 2017, APPL THERM ENG, V121, P388, DOI 10.1016/j.applthermaleng.2017.04.083
   Shao YJ, 2014, CAN J CHEM ENG, V92, P742, DOI 10.1002/cjce.21888
   Shirvanian PA, 2004, CHEM ENG J, V103, P29, DOI 10.1016/j.cej.2004.07.004
   Shojaeizadeh A, 2018, MEASUREMENT, V122, P325, DOI 10.1016/j.measurement.2018.02.033
   Swasdisevi T, 2004, CHEM ENG TECHNOL, V27, P971, DOI 10.1002/ceat.200401918
   Wang SY, 2010, CHEM ENG SCI, V65, P1322, DOI 10.1016/j.ces.2009.09.060
   Wu M, 2015, CAN J CHEM ENG, V93, P1819, DOI 10.1002/cjce.22264
   Xavier TP, 2016, POWDER TECHNOL, V299, P210, DOI 10.1016/j.powtec.2016.05.034
   Zhang H, 2017, POWDER TECHNOL, V307, P175, DOI 10.1016/j.powtec.2016.11.024
   Zhao XL, 2006, CHEM ENG TECHNOL, V29, P875, DOI 10.1002/ceat.200600087
   Zhu QY, 2005, CAN J CHEM ENG, V83, P644
NR 58
TC 3
Z9 3
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115255
DI 10.1016/j.ces.2019.115255
PG 14
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300043
OA Bronze
DA 2020-05-12
ER

PT J
AU Vazquez-Pufleau, M
   Yamane, M
AF Vazquez-Pufleau, Miguel
   Yamane, Martin
TI Relative kinetics of nucleation and condensation of silane pyrolysis in
   a helium atmosphere provide mechanistic insight in the initial stages of
   particle formation and growth
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Silicon; Nucleation; Polysilicon; Magnetic nucleation; Condensation and
   nucleation rates; Silane pyrolysis kinetics; Silicon nanoparticles
   synthesis
ID CHEMICAL-VAPOR-DEPOSITION; SILICON NANOPARTICLE FORMATION;
   FLUIDIZED-BED; THERMAL-DECOMPOSITION; DYNAMICS; MODEL; SPECTROSCOPY;
   COAGULATION; CHEMISTRY; EVOLUTION
AB Chemical nucleation for the synthesis of solid nanoparticles from gas phase precursor is a fundamental process of technological relevance, yet, not well understood. In this work, a silane pyrolysis system was built to obtain insights in particle formation and growth. Primary particle analysis was used to determine the relative condensation and nucleation rates in the aerosol process of silane pyrolysis. TEM, XRD and SMPS allow the comparison between primary particle and agglomerate dynamics. The analysis reveals that nucleation is correlated to silane concentration to the power of 2/3. This relationship and other observations are used to assess the impact of magnetic interactions in classical Brownian agglomeration in the initial stages of primary particle dynamics in silane pyrolysis. Furthermore, this mechanism is consistent with key observations reported in the literature regarding nanoparticles of various materials, suggesting the proposed mechanism could be valid for more materials and deserves further attention. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Vazquez-Pufleau, Miguel; Yamane, Martin] Washington Univ, Dept Energy Environm & Chem Engn, Aerosol & Air Qual Res Lab, St Louis, MO 63130 USA.
   [Vazquez-Pufleau, Miguel] Washington Univ, Dept Energy Environm & Chem Engn, Interface Res Grp, St Louis, MO 63130 USA.
RP Vazquez-Pufleau, M (reprint author), Washington Univ, Dept Energy Environm & Chem Engn, Aerosol & Air Qual Res Lab, St Louis, MO 63130 USA.
EM miguel@wustl.edu
OI Vazquez-Pufleau, Miguel/0000-0001-6836-5098
FU National Science FoundationNational Science Foundation (NSF); Government
   of India, through the Department of Science and Technology
   [IUSSTF/JCERDC-SERIIUS/2012]; Solar Energy Research Institute for India
   and the United States (SERIIUS) - U.S. Department of Energy (Office of
   Science) [DE-AC36-08GO28308]; Solar Energy Research Institute for India
   and the United States (SERIIUS) - U.S. Department of Energy (Office of
   Basic Energy Sciences)United States Department of Energy (DOE)
   [DE-AC36-08GO28308]; Solar Energy Research Institute for India and the
   United States (SERIIUS) - U.S. Department of Energy (Energy Efficiency
   and Renewable Energy, Solar Energy Technology Program)United States
   Department of Energy (DOE) [DE-AC36-08GO28308]
FX We would like to acknowledge Prof. Pratim Biswas for very interesting
   discussions and for providing managerial resources for the realization
   of this work, also Prof. Elijah Thimsen for his guidance in the
   construction of the silane reactor, as well as very content rich
   discussions, Alexis Grabbe for his help on safety and reactor design,
   Shalinee Kavadiya for reviewing setup drawings and Girish Sharma for
   providing the python program for coagulation based on the method of
   moments. This work was partially supported by the National Science
   Foundation and the Solar Energy Research Institute for India and the
   United States (SERIIUS), funded jointly by the U.S. Department of Energy
   (Office of Science, Office of Basic Energy Sciences, and Energy
   Efficiency and Renewable Energy, Solar Energy Technology Program, under
   Subcontract DE-AC36-08GO28308 to the National Renewable Energy
   Laboratory, Golden, Colorado). It was also supported by the Government
   of India, through the Department of Science and Technology under
   Subcontract IUSSTF/JCERDC-SERIIUS/2012. The Nano Research Facility (NRF)
   at Washington University in St. Louis, a member of the National
   Nanotechnology Infrastructure Network (NNIN) was used for SEM and TEM.
CR ALAM MK, 1986, AEROSOL SCI TECH, V5, P237, DOI 10.1080/02786828608959090
   BELL TN, 1984, J PHYS CHEM-US, V88, P116, DOI 10.1021/j150645a029
   BERNHEIM RA, 1970, J CHEM PHYS, V53, P1280, DOI 10.1063/1.1674129
   BORSELLA E, 1988, APPL PHYS B-PHOTO, V46, P347, DOI 10.1007/BF00686458
   Campargue A, 1998, J PHYS D APPL PHYS, V31, P1168, DOI 10.1088/0022-3727/31/10/007
   CAUSSAT B, 1995, CHEM ENG SCI, V50, P3625, DOI 10.1016/0009-2509(95)00173-3
   CAUSSAT B, 1995, CHEM ENG SCI, V50, P3615, DOI 10.1016/0009-2509(95)00172-2
   Clarke FW, 1924, COMPOSITION EARTHS C
   DOYLE JR, 1990, J APPL PHYS, V68, P4375, DOI 10.1063/1.346186
   DUXBURY G, 1993, J CHEM PHYS, V98, P811, DOI 10.1063/1.464245
   Filtvedt WO, 2012, SOL ENERG MAT SOL C, V107, P188, DOI 10.1016/j.solmat.2012.08.014
   Filtvedt WO, 2010, SOL ENERG MAT SOL C, V94, P1980, DOI 10.1016/j.solmat.2010.07.027
   Filtvedt W.O., 2012, SILANE BASED CVD GRO
   Fischer P, 2011, MAT SCI ENG R, V72, P81, DOI 10.1016/j.mser.2011.03.002
   Francis P, 2013, SILICON-NETH, V5, P255, DOI 10.1007/s12633-013-9150-6
   FRENKLACH M, 1987, J COLLOID INTERF SCI, V118, P252, DOI 10.1016/0021-9797(87)90454-1
   FRIEDLANDER SK, 2000, SMOKE DUST HAZE
   Girshick SL, 2000, J ELECTROCHEM SOC, V147, P2303, DOI 10.1149/1.1393525
   Groschel M, 2012, CHEM ENG SCI, V73, P181, DOI 10.1016/j.ces.2012.01.035
   HASHIMOTO K, 1990, J ELECTROCHEM SOC, V137, P1000, DOI 10.1149/1.2086544
   Hinds W., 2012, AEROSOL TECHNOLOGY P
   Hogness TR, 1936, J AM CHEM SOC, V58, P108, DOI 10.1021/ja01292a036
   HSU G, 1984, J ELECTROCHEM SOC, V131, P660, DOI 10.1149/1.2115668
   HSU G, 1987, AICHE J, V33, P784, DOI 10.1002/aic.690330511
   JASINSKI JM, 1991, ACCOUNTS CHEM RES, V24, P9, DOI 10.1021/ar00001a002
   KLEIJN CR, 1991, J ELECTROCHEM SOC, V138, P2190, DOI 10.1149/1.2085948
   Kokkin DL, 2016, J CHEM PHYS, V144, DOI 10.1063/1.4954702
   Kopnov G, 2007, ADV MATER, V19, P925, DOI 10.1002/adma.200601762
   KRUIS FE, 1993, AEROSOL SCI TECH, V19, P514, DOI 10.1080/02786829308959656
   LANDGREBE JD, 1990, J COLLOID INTERF SCI, V139, P63, DOI 10.1016/0021-9797(90)90445-T
   Lee SR, 2005, AEROSOL SCI TECH, V39, P358, DOI 10.1080/027868290931753
   Lunden M.M, 1995, SINTERING AEROSOL AG
   MacKay DDS, 1999, MON NOT R ASTRON SOC, V302, P793, DOI 10.1046/j.1365-8711.1999.02175.x
   Makowe J, 2004, ISOTOPICALLY SELECTI
   Manchanda P., 2014, IEEE T MAGN, V50, P1
   Mi JL, 2015, CRYSTENGCOMM, V17, P6868, DOI 10.1039/c5ce00544b
   Montero MI, 2002, J PHYS D APPL PHYS, V35, P2398, DOI 10.1088/0022-3727/35/19/311
   Nakajima M, 2002, CHEM PHYS LETT, V364, P99, DOI 10.1016/S0009-2614(02)01308-8
   NEWMAN CG, 1979, INT J CHEM KINET, V11, P1167, DOI 10.1002/kin.550111104
   NGUYEN HV, 1991, LANGMUIR, V7, P1807, DOI 10.1021/la00056a038
   Onischuk AA, 2000, J AEROSOL SCI, V31, P1263, DOI 10.1016/S0021-8502(00)00031-8
   PURNELL JH, 1966, PROC R SOC LON SER-A, V293, P543, DOI 10.1098/rspa.1966.0189
   Ranjan S, 2011, COMPUT CHEM ENG, V35, P1439, DOI 10.1016/j.compchemeng.2011.04.017
   RING MA, 1992, J PHYS CHEM-US, V96, P10848, DOI 10.1021/j100205a046
   Rumpf K, 2014, HDB POROUS SILICON, P281
   Slipchenko LV, 2002, J CHEM PHYS, V117, P4694, DOI 10.1063/1.1498819
   Sundaresan A, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.161306
   Sundaresan A, 2009, SOLID STATE COMMUN, V149, P1197, DOI 10.1016/j.ssc.2009.04.028
   Swihart MT, 1999, CHEM PHYS LETT, V307, P527, DOI 10.1016/S0009-2614(99)00545-X
   Swihart MT, 1999, J PHYS CHEM B, V103, P64, DOI 10.1021/jp983358e
   Talukdar SS, 2004, J AEROSOL SCI, V35, P889, DOI 10.1016/j.jaerosci.2004.02.004
   THOMAN JW, 1987, J CHEM PHYS, V86, P5909, DOI 10.1063/1.452475
   Tomono K, 2013, SEP PURIF TECHNOL, V120, P304, DOI 10.1016/j.seppur.2013.10.014
   Turkevich J, 1942, J AM CHEM SOC, V64, P1179, DOI 10.1021/ja01257a050
   Vazquez-Pufleau M, 2016, APPL AEROSOL TECHNOL
   Vazquez-Pufleau M, 2017, SCI REP-UK, V7, DOI 10.1038/srep40535
   Vazquez-Pufleau M, 2015, IND ENG CHEM RES, V54, P5914, DOI 10.1021/acs.iecr.5b00577
   Vokoun D, 2009, J MAGN MAGN MATER, V321, P3758, DOI 10.1016/j.jmmm.2009.07.030
   WALSH AD, 1953, J CHEM SOC, P2260, DOI 10.1039/jr9530002260
   Wang Y, 2015, J NANOPART RES, V17, DOI 10.1007/s11051-015-2964-y
   WHITE RT, 1985, INT J CHEM KINET, V17, P1029, DOI 10.1002/kin.550171003
   Williams ED, 2002, ENVIRON SCI TECHNOL, V36, P5504, DOI 10.1021/es025643o
   Wong HW, 2004, J PHYS CHEM A, V108, P10122, DOI 10.1021/jp049591w
   WU JJ, 1988, J COLLOID INTERF SCI, V123, P339
   Zaari RR, 2015, J PHYS CHEM A, V119, P1332, DOI 10.1021/jp509515e
NR 65
TC 3
Z9 3
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115230
DI 10.1016/j.ces.2019.115230
PG 15
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300050
OA Bronze
DA 2020-05-12
ER

PT J
AU Wang, HT
   Verdugo, AS
   Sun, JY
   Wang, JD
   Yang, YR
   Jimenez, FH
AF Wang, Haotong
   Soria Verdugo, Antonio
   Sun, Jingyuan
   Wang, Jingdai
   Yang, Yongrong
   Hernandez Jimenez, Fernando
TI Experimental study of bubble dynamics and flow transition recognition in
   a fluidized bed with wet particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Incoherent analysis; Wet particle; Flow transition; Bubble dynamics;
   Turbulence
ID NONINTRUSIVE DETERMINATION; PRESSURE-FLUCTUATIONS; INTERPARTICLE FORCES;
   LIQUID PROPERTIES; CFD SIMULATION; BEHAVIOR; SIZE; HYDRODYNAMICS;
   STABILITY; MODEL
AB This paper studies the bubble dynamics and flow transition behavior in wet particle systems. Non-coherent algorithm was used to quantitatively calculate the bubble diameters in a three-dimensional fluidized bed system loaded with wet particles, obtaining the bubble dynamics under the action of liquid. The results indicate that the incoherent analysis can detect the formation of even tiny bubbles in the fluidized bed. The kurtosis and skewness of the pressure fluctuation signal was used to obtain the critical transition conditions of the flow pattern from turbulent to laminar. Through the decay index of the incoherent spectrum, the operating conditions of the Levy-Kolmogorov flow pattern to the Kolmogorov flow region were determined. From the comparison of the liquid bridge and the drag forces, the competitive mechanism of different forces acting on the particles that conformed the bed was analyzed, reflecting the change of the apparent minimum fluidization velocity of wet particles. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Haotong; Sun, Jingyuan; Wang, Jingdai; Yang, Yongrong] Zhejiang Univ, Coll Chem & Biol Engn, Zhejiang Prov Key Lab Adv Chem Engn Manufacture T, Hangzhou 310027, Zhejiang, Peoples R China.
   [Soria Verdugo, Antonio; Hernandez Jimenez, Fernando] Univ Carlos III Madrid, Dept Ingn Term & Fluidos, ISE Res Grp, Avda Univ 30, Madrid 28911, Spain.
RP Sun, JY (reprint author), Zhejiang Univ, Coll Chem & Biol Engn, Zhejiang Prov Key Lab Adv Chem Engn Manufacture T, Hangzhou 310027, Zhejiang, Peoples R China.
EM sunjy@zju.edu.cn
RI Lungu, Musango/D-6067-2012
OI Lungu, Musango/0000-0002-3062-6376
FU Science Fund for Creative Research Groups of National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [61621002]; National Natural Science Foundation of China for
   YoungNational Natural Science Foundation of China [21808198]; Major
   Research Project of National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [91834303]; Natural Science
   Foundation of Zhejiang Province for YoungNatural Science Foundation of
   Zhejiang Province [LQ18B060001]; National Science Fund for Distinguished
   YoungNational Natural Science Foundation of ChinaNational Science Fund
   for Distinguished Young Scholars [21525627]
FX This work is supported by the Science Fund for Creative Research Groups
   of National Natural Science Foundation of China (No. 61621002), the
   National Natural Science Foundation of China for Young (No. 21808198),
   the Major Research Project of National Natural Science Foundation of
   China (No. 91834303), the Natural Science Foundation of Zhejiang
   Province for Young (No. LQ18B060001), the National Science Fund for
   Distinguished Young (No. 21525627).
CR Abbasi A, 2010, AICHE J, V56, P597, DOI 10.1002/aic.12046
   Ariyapadi S, 2003, INT J CHEM REACT ENG, V1, DOI 10.2202/1542-6580.1114
   Bacelos MS, 2007, POWDER TECHNOL, V174, P114, DOI 10.1016/j.powtec.2007.01.023
   Berruti F, 2009, POWDER TECHNOL, V192, P250, DOI 10.1016/j.powtec.2009.01.005
   Bouffard J, 2012, AICHE J, V58, P3685, DOI 10.1002/aic.13765
   Briens C, 2009, CHEM ENG PROCESS, V48, P871, DOI 10.1016/j.cep.2008.11.006
   Briongos JV, 2006, CHEM ENG SCI, V61, P6963, DOI 10.1016/j.ces.2006.07.023
   Chen S, 2016, CHEM ENG SCI, V153, P58, DOI 10.1016/j.ces.2016.07.003
   Chen W., 2005, MATHEMATICS
   DARTON RC, 1977, T I CHEM ENG-LOND, V55, P274
   Dong KZ, 2015, AICHE J, V61, P1160, DOI 10.1002/aic.14725
   Eliaers P, 2013, DRY TECHNOL, V31, P236, DOI 10.1080/07373937.2012.726304
   ENNIS BJ, 1990, CHEM ENG SCI, V45, P3071, DOI 10.1016/0009-2509(90)80054-I
   Gao JS, 2001, AICHE J, V47, P677, DOI 10.1002/aic.690470315
   Gomez-Hernandez J, 2012, CHEM ENG J, V195, P198, DOI 10.1016/j.cej.2012.04.096
   KATO K, 1969, CHEM ENG SCI, V24, P1351, DOI 10.1016/0009-2509(69)85055-4
   LEE GS, 1988, J CHEM ENG JPN, V21, P515, DOI 10.1252/jcej.21.515
   Liu MX, 2010, CHEM ENG SCI, V65, P3485, DOI 10.1016/j.ces.2010.02.049
   Mallat S., 1999, WAVELET TOUR SIGNAL
   McDougall S, 2005, CHEM ENG PROCESS, V44, P701, DOI 10.1016/j.cep.2004.07.003
   McDougall S, 2005, POWDER TECHNOL, V149, P61, DOI 10.1016/j.powtec.2004.09.043
   McLaughlin LJ, 2001, POWDER TECHNOL, V114, P213, DOI 10.1016/S0032-5910(00)00325-9
   Mohagheghi M, 2014, POWDER TECHNOL, V256, P5, DOI 10.1016/j.powtec.2014.01.083
   Parveen F, 2013, POWDER TECHNOL, V237, P376, DOI 10.1016/j.powtec.2012.12.021
   Parveen F, 2013, POWDER TECHNOL, V237, P46, DOI 10.1016/j.powtec.2012.12.057
   Perchard V., 1985, I CHEM ENG S SER, V91, P147
   Popov VL, 2010, CONTACT MECHANIC AND FRICTION: PHYSICAL PRINCIPLES AND APPLICATIONS, P1, DOI 10.1007/978-3-642-10803-7
   Poutiainen S, 2012, POWDER TECHNOL, V228, P149, DOI 10.1016/j.powtec.2012.05.010
   Razzak SA, 2007, CHEM ENG SCI, V62, P7253, DOI 10.1016/j.ces.2007.08.057
   Razzak SA, 2019, INT J MULTIPHAS FLOW, V113, P279, DOI 10.1016/j.ijmultiphaseflow.2018.10.016
   Sasic S, 2006, CHEM ENG J, V121, P27, DOI 10.1016/j.cej.2006.05.005
   Seville JPK, 2000, POWDER TECHNOL, V113, P261, DOI 10.1016/S0032-5910(00)00309-0
   SEVILLE JPK, 1984, POWDER TECHNOL, V37, P117, DOI 10.1016/0032-5910(84)80011-X
   Sun JY, 2012, CHEM ENG SCI, V71, P507, DOI 10.1016/j.ces.2011.11.019
   Sun JY, 2011, CHEM ENG SCI, V66, P4972, DOI 10.1016/j.ces.2011.06.035
   Sutkar VS, 2016, CHEM ENG J, V288, P185, DOI 10.1016/j.cej.2015.11.044
   Sutkar VS, 2013, CHEM ENG SCI, V104, P790, DOI 10.1016/j.ces.2013.10.005
   van der Schaaf J, 2002, INT J MULTIPHAS FLOW, V28, P865, DOI 10.1016/S0301-9322(01)00090-8
   van Ommen JR, 2011, INT J MULTIPHAS FLOW, V37, P403, DOI 10.1016/j.ijmultiphaseflow.2010.12.007
   van Ommen JR, 2000, AICHE J, V46, P2183, DOI 10.1002/aic.690461111
   van Ommen JR, 2004, POWDER TECHNOL, V139, P264, DOI 10.1016/j.powtec.2003.12.009
   van Wachem BGM, 1998, COMPUT CHEM ENG, V22, pS299, DOI 10.1016/S0098-1354(98)00068-4
   van Wachem BGM, 1999, CHEM ENG SCI, V54, P2141, DOI 10.1016/S0009-2509(98)00303-0
   van Willigen FK, 2003, INT J CHEM REACT ENG, V1
   Wang HG, 2007, CHEM ENG SCI, V62, P1524, DOI 10.1016/j.ces.2006.11.047
   Wang TY, 2016, AICHE J, V62, P1970, DOI 10.1002/aic.15195
   Weber S, 2006, POWDER TECHNOL, V165, P115, DOI 10.1016/j.powtec.2006.03.006
   Weigert T, 1999, PART PART SYST CHAR, V16, P238, DOI 10.1002/(SICI)1521-4117(199910)16:5<238::AID-PPSC238>3.0.CO;2-E
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Wormsbecker M, 2008, CHEM ENG SCI, V63, P4063, DOI 10.1016/j.ces.2008.05.023
   Xu HB, 2017, POWDER TECHNOL, V314, P377, DOI 10.1016/j.powtec.2016.09.006
   YASUI G, 1958, AICHE J, V4, P445, DOI 10.1002/aic.690040413
   Zhang YM, 2010, AICHE J, V56, P869, DOI 10.1002/aic.12052
   Zhou YF, 2013, IND ENG CHEM RES, V52, P4455, DOI 10.1021/ie302730a
   Zhou YF, 2017, CHEM ENG J, V330, P840, DOI 10.1016/j.cej.2017.07.117
   Zhou YF, 2016, AICHE J, V62, P1454, DOI 10.1002/aic.15157
   Zhou YF, 2016, CHEM ENG J, V285, P121, DOI 10.1016/j.cej.2015.09.058
   Zhou YF, 2013, AICHE J, V59, P1056, DOI 10.1002/aic.13883
   Zhu JX, 2000, CAN J CHEM ENG, V78, P82, DOI 10.1002/cjce.5450780113
NR 59
TC 0
Z9 0
U1 12
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115257
DI 10.1016/j.ces.2019.115257
PG 14
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300021
OA Bronze
DA 2020-05-12
ER

PT J
AU Wu, B
   Li, J
   Li, CH
   He, JX
   Luo, PC
AF Wu, Bin
   Li, Jing
   Li, Chunhui
   He, Jinxuan
   Luo, Peicheng
TI Antisolvent crystallization intensified by a jet crystallizer and a
   method for investigating crystallization kinetics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Antisolvent crystallization; Jet crystallizer; Kinetics; Population
   balance equation (PBE); Plug flow model (PFM); CFD
ID SOLVENT-SOLVENT INTERACTIONS; SIZE DISTRIBUTION; GROWTH-KINETICS;
   SOLUTE-SOLVENT; IMPINGING-JETS; PARTICLE-SIZE; NUCLEATION;
   PRECIPITATION; SIMULATION; DESIGN
AB In this study, the antisolvent crystallization of NaCl in water-ethanol binary solvent mixtures in a multiorifice-impinging transverse (MOLT) jet crystallizer is studied both experimentally and numerically. Plug flow model coupled with population balance equation (PFM-PBE) is employed for the estimation of nucleation and crystal growth rate parameters at different supersaturation levels. Computational fluid dynamics coupled with population balance equation (CFD-PBE) is used to evaluate the macromixing and micromixing effect on the crystallization process. It is found that several microns NaCl crystals with narrow crystal size distribution (CSD) are prepared. The mixing process of the antisolvent and the solution is intensified by the MOLT jet crystallizer so that the mixing effect becomes insignificant due to a small Da number. The crystallization kinetics have also been obtained and confirmed by combining PFM-PBE and CFD-PBE approaches with the experiments. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wu, Bin; Li, Chunhui; Luo, Peicheng] Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Jiangsu, Peoples R China.
   [Li, Jing] China Acad Ordnance Sci, Beijing 100089, Peoples R China.
   [Wu, Bin; He, Jinxuan] Sci & Technol Aerosp Chem Power Lab, Xiangyang 441003, Peoples R China.
RP Luo, PC (reprint author), Southeast Univ, Sch Chem & Chem Engn, Nanjing 211189, Jiangsu, Peoples R China.
EM luopeicheng@seu.edu.cn
OI Luo, peicheng/0000-0003-1798-0693
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21476048]; Open Research Fund Program of Science
   and Technology on Aerospace Chemical Power Laboratory
   [STACPL120181B02-1]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [2242019k1G024]; Postgraduate Research & Practice Innovation Program of
   Jiangsu Province [KYCX18_0131]
FX We acknowledge the financial support from the National Natural Science
   Foundation of China (Grant No. 21476048), the Funds by Open Research
   Fund Program of Science and Technology on Aerospace Chemical Power
   Laboratory (Grant No. STACPL120181B02-1), the Fundamental Research Funds
   for the Central Universities (Grant No. 2242019k1G024) and the
   Postgraduate Research & Practice Innovation Program of Jiangsu Province
   (Grant No. KYCX18_0131).
CR Abbas A, 2007, SEP PURIF TECHNOL, V53, P153, DOI 10.1016/j.seppur.2006.06.027
   Cheng JC, 2017, CHEM ENG SCI, V171, P500, DOI 10.1016/j.ces.2017.06.011
   Cogoni G, 2015, CHEM ENG SCI, V138, P592, DOI 10.1016/j.ces.2015.08.041
   Cogoni G, 2012, AICHE J, V58, P3731, DOI 10.1002/aic.13760
   DiPasquale N, 2012, CHEM ENG SCI, V84, P671, DOI 10.1016/j.ces.2012.08.043
   Ebert S, 2017, FOOD RES INT, V92, P48, DOI 10.1016/j.foodres.2016.12.020
   Ferri A, 2017, CAN J CHEM ENG, V95, P1690, DOI 10.1002/cjce.22867
   Galleguillos HR, 2003, J CHEM ENG DATA, V48, P405, DOI 10.1021/je020173z
   Ghadipasha N, 2015, AICHE J, V61, P2188, DOI 10.1002/aic.14815
   Granberg RA, 2001, CHEM ENG SCI, V56, P2305, DOI 10.1016/S0009-2509(00)00439-5
   Hansen N, 2003, EVOL COMPUT, V11, P1, DOI 10.1162/106365603321828970
   Hansen N, 2001, EVOL COMPUT, V9, P159, DOI 10.1162/106365601750190398
   Jacqueline RD, 2017, J CRYST GROWTH, V472, P29, DOI 10.1016/j.jcrysgro.2016.12.057
   Jiang M, 2015, CHEM ENG PROCESS, V97, P242, DOI 10.1016/j.cep.2015.09.005
   KAMLET MJ, 1986, J PHARM SCI, V75, P338, DOI 10.1002/jps.2600750405
   Kim KJ, 2006, CHEM ENG TECHNOL, V29, P951, DOI 10.1002/ceat.200600081
   Li HY, 2017, IND ENG CHEM RES, V56, P4060, DOI 10.1021/acs.iecr.6b04914
   Lindenberg C, 2011, AICHE J, V57, P942, DOI 10.1002/aic.12326
   Liu Y, 2006, AICHE J, V52, P731, DOI 10.1002/aic.10633
   Luo PC, 2016, IND ENG CHEM RES, V55, P8858, DOI 10.1021/acs.iecr.6b01778
   Luo PC, 2013, CHEM ENG J, V228, P554, DOI 10.1016/j.cej.2013.05.051
   Maitra A, 2008, J MOL LIQ, V137, P131, DOI 10.1016/j.molliq.2007.06.002
   Marchisio DL, 2006, AICHE J, V52, P1877, DOI 10.1002/aic.10786
   Nagy ZK, 2008, J PROCESS CONTR, V18, P856, DOI 10.1016/j.jprocont.2008.06.002
   Nagy ZK, 2012, CHEM ENG SCI, V84, P656, DOI 10.1016/j.ces.2012.08.048
   Nowee SM, 2008, CHEM ENG SCI, V63, P5457, DOI 10.1016/j.ces.2008.08.003
   O'Ciardha CT, 2012, CRYST GROWTH DES, V12, P5247, DOI 10.1021/cg3006822
   Oh DH, 2018, CHEM ENG TECHNOL, V41, P1226, DOI 10.1002/ceat.201700626
   Pirkle C, 2015, CHEM ENG PROCESS, V97, P213, DOI 10.1016/j.cep.2015.07.006
   Randolph A.D., 1988, THEORY PARTICULATE P
   Schall JM, 2018, CRYST GROWTH DES, V18, P1560, DOI 10.1021/acs.cgd.7b01528
   Takiyama H, 1998, CHEM ENG RES DES, V76, P809, DOI 10.1205/026387698525559
   Tari T, 2015, INT J PHARMACEUT, V478, P96, DOI 10.1016/j.ijpharm.2014.11.021
   Wu B, 2017, POWDER TECHNOL, V321, P180, DOI 10.1016/j.powtec.2017.08.042
   Zhao Y, 2015, CHEM ENG SCI, V133, P106, DOI 10.1016/j.ces.2015.02.019
   Zheng M, 2018, J MOL LIQ, V264, P285, DOI 10.1016/j.molliq.2018.05.057
   Zhou GX, 2006, CRYST GROWTH DES, V6, P892, DOI 10.1021/cg0504049
   Zimmermann NER, 2015, J AM CHEM SOC, V137, P13352, DOI 10.1021/jacs.5b08098
NR 38
TC 0
Z9 0
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115259
DI 10.1016/j.ces.2019.115259
PG 13
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300010
OA Bronze
DA 2020-05-12
ER

PT J
AU Wu, H
   Gui, N
   Yang, XT
   Tu, JY
   Jiang, SY
AF Wu, Hao
   Gui, Nan
   Yang, Xingtuan
   Tu, Jiyuan
   Jiang, Shengyao
TI Analysis and evaluations of four models of thermal radiation for densely
   packed granular systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Particle emissivity; Thermal radiation; Granular particle; Packed bed;
   Discrete element method
ID DISCRETE PARTICLE SIMULATION; RADIANT-HEAT TRANSFER; CFD-DEM SIMULATION;
   PEBBLE BEDS; CONDUCTIVITY; PERFORMANCE; EMISSIVITY; VALIDATION; SPHERES;
   SCALE
AB Thermal radiation is an important part of heat transfer in granular systems, such as the packed pebble bed of high-temperature gas-cooled reactor (HTGR), bubbling fluidized bed, and other packed granular beds. In this paper, four models of multiple-body radiation within the packed granular bed were proposed and discussed in full integral scales, i.e. black radiation model, uniform radiation model, local radiation model and particle scale radiation model. For particle radiation with black surfaces, the black radiation model was proven to be valid strictly and it agreed with existing correlations and models. The radiative flux in the packed bed increased significantly with the particle emissivity. However, the existed Asakuma radiation model, two-flux model and the newly proposed local radiation model were almost independent of the particle emissivity since the uniform assumption was inappropriate for the gray radiation in the packed bed. The effect of emissivity was handled correctly in the local radiation model without the uniform assumption. Since the computation cost of local radiation model in large-scale granular systems was huge and not applicable in the CFD-DEM simulation, the particle scale radiation model was developed in this study to predict the radiation flux in discrete element method (DEM). It was shown that the effect of particle emissivity was a separable term in the radiative heat transfer equation. The particle scale radiation model provided a good approximation of the local radiation model and enabled efficient prediction of radiative heat transfer in a densely packed bed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wu, Hao; Gui, Nan; Yang, Xingtuan; Tu, Jiyuan; Jiang, Shengyao] Tsinghua Univ, Collaborat Innovat Ctr Adv Nucl Energy Technol, Inst Nucl & New Energy Technol, Key Lab Adv Reactor Engn & Safety,Minist Educ, Beijing 100084, Peoples R China.
   [Tu, Jiyuan] RMIT Univ, Sch Engn, Melbourne, Vic 3083, Australia.
RP Gui, N; Jiang, SY (reprint author), Tsinghua Univ, Collaborat Innovat Ctr Adv Nucl Energy Technol, Inst Nucl & New Energy Technol, Key Lab Adv Reactor Engn & Safety,Minist Educ, Beijing 100084, Peoples R China.
EM guinan@mail.tsinghua.edu.cn; shengyaojiang@sina.com
RI Gui, Nan/G-2394-2014
OI Gui, Nan/0000-0003-4731-3082
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2018 M640141]; National Natural Science Foundations of
   ChinaNational Natural Science Foundation of China [51576211]; Science
   Fund for Creative Research Groups of National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China [51621062];
   National High Technology Research and Development Program of China
   (863)National High Technology Research and Development Program of China
   [2014AA052701]
FX The authors are grateful for the support of this research by the China
   Postdoctoral Science Foundation (Grant No. 2018 M640141) and the
   National Natural Science Foundations of China (Grant No. 51576211), the
   Science Fund for Creative Research Groups of National Natural Science
   Foundation of China (Grant No. 51621062), the National High Technology
   Research and Development Program of China (863) (2014AA052701).
CR ARGO WB, 1953, CHEM ENG PROG, V49, P443
   Asakuma Y, 2014, INT J HEAT MASS TRAN, V73, P97, DOI 10.1016/j.ijheatmasstransfer.2014.01.065
   BREITBACH G, 1980, NUCL TECHNOL, V49, P392, DOI 10.13182/NT80-A17687
   CHEN JC, 1963, AICHE J, V9, P35, DOI 10.1002/aic.690090108
   Cheng GJ, 2013, IND ENG CHEM RES, V52, P12202, DOI 10.1021/ie3033137
   CHIEW YC, 1983, IND ENG CHEM FUND, V22, P276, DOI 10.1021/i100011a002
   Earnshaw JW, 1998, FUSION TECHNOL, V33, P31, DOI 10.13182/FST98-A13
   Gao ZY, 2002, NUCL ENG DES, V218, P51, DOI 10.1016/S0029-5493(02)00198-X
   GODBEE HW, 1966, J APPL PHYS, V37, P40, DOI 10.1063/1.1707849
   Gui N, 2019, J HYDRODYN, V31, P864, DOI 10.1007/s42241-019-0044-y
   Gusarov AV, 2018, J HEAT TRANS-T ASME, V140, DOI 10.1115/1.4040482
   Gusarov AV, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.064202
   Hou QF, 2012, AICHE J, V58, P1422, DOI 10.1002/aic.12700
   Howell J.R., 2010, THERMAL RAD HEAT TRA
   Jiang S., 2019, EXP COMPUT MULTIPHAS, V1, P159
   Jung E, 2014, J PHYS D APPL PHYS, V47, DOI 10.1088/0022-3727/47/26/265306
   KASPAREK G, 1976, WARME STOFFUBERTRAG, V9, P117, DOI 10.1007/BF01589465
   Kaviany M., 1991, PRINCIPLES HEAT TRAN
   Kloss C, 2012, PROG COMPUT FLUID DY, V12, P140, DOI 10.1504/PCFD.2012.047457
   Krause B, 2017, INT J THERM SCI, V117, P121, DOI 10.1016/j.ijthermalsci.2017.03.017
   LAUBITZ MJ, 1959, CAN J PHYS, V37, P798, DOI 10.1139/p59-086
   Lu G, 2015, CHEM ENG SCI, V127, P425, DOI 10.1016/j.ces.2014.11.050
   Ma F, 2017, ENERG CONVERS MANAGE, V150, P500, DOI 10.1016/j.enconman.2017.08.040
   MALTBY JD, 1991, NUMER HEAT TR B-FUND, V19, P191, DOI 10.1080/10407799108944963
   MATSUMOTO T, 1995, INT J THERMOPHYS, V16, P267, DOI 10.1007/BF01438977
   Mehrabian R, 2014, FUEL, V122, P164, DOI 10.1016/j.fuel.2014.01.027
   Modest MF, 2013, RADIATIVE HEAT TRANSFER, 3RD EDITION, P1
   NASR K, 1994, J HEAT TRANS-T ASME, V116, P829, DOI 10.1115/1.2911455
   Oppenheim A., 1956, T ASME, V78, P725
   Rousseau PG, 2014, NUCL ENG DES, V271, P444, DOI 10.1016/j.nucengdes.2013.12.015
   Sakatani N, 2017, AIP ADV, V7, DOI 10.1063/1.4975153
   SCHOTTE W, 1960, AICHE J, V6, P63, DOI 10.1002/aic.690060113
   Sih SS, 2004, PARTICUL SCI TECHNOL, V22, P427, DOI 10.1080/02726350490501682
   SINGH BP, 1991, INT J HEAT MASS TRAN, V34, P2869, DOI 10.1016/0017-9310(91)90247-C
   SINGH BP, 1994, INT J HEAT MASS TRAN, V37, P2579, DOI 10.1016/0017-9310(94)90295-X
   Vargas WL, 2001, AICHE J, V47, P1052, DOI 10.1002/aic.690470511
   VORTMEYER D, 1979, CHEM-ING-TECH, V51, P839, DOI 10.1002/cite.330510904
   Wakao N., 1969, J CHEM ENGNG JAPAN, V2, P24, DOI DOI 10.1252/JCEJ.2.24
   Walker T., 2013, USE PRIMITIVES CALCU
   Wang S, 2019, CHEM ENG SCI, V197, P280, DOI 10.1016/j.ces.2018.12.031
   Wu H, 2020, ANN NUCL ENERGY, V135, DOI 10.1016/j.anucene.2019.107000
   Wu H, 2018, J HEAT TRANS-T ASME, V140, DOI 10.1115/1.4039913
   Wu H, 2018, J HEAT TRANS-T ASME, V140, DOI 10.1115/1.4038231
   Wu H, 2018, INT J HEAT MASS TRAN, V118, P275, DOI 10.1016/j.ijheatmasstransfer.2017.10.123
   Wu H, 2017, INT J HEAT MASS TRAN, V110, P393, DOI 10.1016/j.ijheatmasstransfer.2017.03.035
   Wu H, 2016, INT J HEAT MASS TRAN, V101, P562, DOI 10.1016/j.ijheatmasstransfer.2016.05.090
   YAGI S, 1957, AICHE J, V3, P373, DOI 10.1002/aic.690030317
   Zbogar A, 2005, PROG ENERG COMBUST, V31, P371, DOI 10.1016/j.pecs.2005.08.002
   Zhang ZY, 2009, NUCL ENG DES, V239, P1212, DOI 10.1016/j.nucengdes.2009.02.023
   Zhong WQ, 2016, CHEM ENG SCI, V140, P16, DOI 10.1016/j.ces.2015.09.035
   Zhou JH, 2007, J HEAT TRANS-T ASME, V129, P363, DOI 10.1115/1.2430721
   Zhou ZY, 2010, J FLUID MECH, V661, P482, DOI 10.1017/S002211201000306X
   Zhou ZY, 2009, AICHE J, V55, P868, DOI 10.1002/aic.11823
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
NR 54
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115309
DI 10.1016/j.ces.2019.115309
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300008
OA Bronze
DA 2020-05-12
ER

PT J
AU Yang, WJ
   Wang, YF
   Zhou, JH
   Yao, YY
   Zhu, XY
   Cen, KF
AF Yang, Weijuan
   Wang, Yefeng
   Zhou, Junhu
   Yao, Yanyi
   Zhu, Xiaoyu
   Cen, Kefa
TI Simulation of hetero/homogeneous combustion characteristics of CH4/air
   in a half packed-bed catalytic combustor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Heterogeneous combustion; Homogeneous combustion; Catalytic combustion;
   Packed-bed combustor
ID METHANE-AIR; GAS-PHASE; HOMOGENEOUS IGNITION; HYDROGEN ADDITION;
   HYDROCARBON FUELS; MICRO-COMBUSTION; PLATINUM; MIXTURES; PROPANE;
   OXIDATION
AB The catalytic combustion of CH4/air mixtures in a half packed-bed combustor was investigated numerically to acquire the hetero/homogeneous combustion characteristics. Three combustion modes: completed heterogeneous combustion, hetero-homogeneous combustion, and incomplete heterogeneous combustion are discovered and investigated, respectively under low (0.05-1.53 m/s), middle (1.53-8.7 m/s), and high (8.7-12.4 m/s) inlet velocity. Under middle inlet velocity, heterogeneous reaction triggers homogeneous reaction downstream. The interface between catalyst and gas-phase zones was analyzed to reveal the effects of the upstream heterogeneous combustion on the trigging of downstream homogeneous combustion. Three zones in the interface: burned zone, transition zone and unburned zone, were defined and analyzed. A parameter of transition zone in the interface, Gamma was defined to evaluate the level of temperature gradient versus inlet velocity. When Gamma < 0.011, homogeneous combustion is not trigged due to the relative weak heterogeneous combustion which brings downstream gases unfavorable conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Weijuan; Wang, Yefeng; Zhou, Junhu; Yao, Yanyi; Zhu, Xiaoyu; Cen, Kefa] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
RP Yang, WJ (reprint author), Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
EM yangwj@zju.edu.cn
OI Yang, Weijuan/0000-0003-4820-7302
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51876189, 51336010]
FX This research is supported by National Natural Science Foundation of
   China [No. 51876189 and 51336010].
CR Ahn JM, 2005, P COMBUST INST, V30, P2463, DOI 10.1016/j.proci.2004.08.265
   Badra JA, 2012, COMBUST FLAME, V159, P817, DOI 10.1016/j.combustflame.2011.08.026
   Barbato PS, 2015, CHEM ENG J, V259, P381, DOI 10.1016/j.cej.2014.07.123
   Chao YC, 2004, COMBUST SCI TECHNOL, V176, P1755, DOI 10.1080/00102200490487599
   Chen J, 2017, INT J HYDROGEN ENERG
   Chen JJ, 2016, CHEM ENG J, V284, P1028, DOI 10.1016/j.cej.2015.09.076
   Demoulin O, 2008, APPL CATAL A-GEN, V344, P1, DOI 10.1016/j.apcata.2008.03.026
   Deng C, 2015, FUEL, V150, P339, DOI 10.1016/j.fuel.2015.02.018
   Deutschmann O, 2000, CATAL TODAY, V59, P141, DOI 10.1016/S0920-5861(00)00279-0
   Deutschmann O, 1996, TWENTY-SIXTH SYMPOSIUM (INTERNATIONAL) ON COMBUSTION, VOLS 1 AND 2, P1747
   Dogwiler U, 1998, TWENTY-SEVENTH SYMPOSIUM (INTERNATIONAL) ON COMBUSTION, VOLS 1 AND 2, P2275
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Fu X, 1998, EXP THERM FLUID SCI, V17, P285
   Garrido GI, 2008, CHEM ENG SCI, V63, P5202, DOI 10.1016/j.ces.2008.06.015
   Giovannoni V, 2016, CHEM ENG SCI, V152, P591, DOI 10.1016/j.ces.2016.06.039
   HARUTA M, 1982, INT J HYDROGEN ENERG, V7, P729, DOI 10.1016/0360-3199(82)90022-2
   Howell JR, 1996, PROG ENERG COMBUST, V22, P121, DOI 10.1016/0360-1285(96)00001-9
   Ju YG, 2011, PROG ENERG COMBUST, V37, P669, DOI 10.1016/j.pecs.2011.03.001
   Kaisare NS, 2009, P COMBUST INST, V32, P3027, DOI 10.1016/j.proci.2008.06.132
   Kaviany M, 1995, PRINCIPLES HEAT TRAN, pB100
   Kee R.J, 1986, MULTICOMPON TRANSP P
   Lee DH, 2003, MICROSCALE THERM ENG, V7, P235, DOI 10.1080/10893950390219074
   Li J, 2016, COMBUST FLAME, V171, P152, DOI 10.1016/j.combustflame.2016.06.007
   Liu Y, 2015, INT J HEAT MASS TRAN, V91, P18, DOI 10.1016/j.ijheatmasstransfer.2015.07.100
   Qu ZG, 2015, FUEL, V159, P128, DOI 10.1016/j.fuel.2015.06.066
   Ran JY, 2015, ENERG CONVERS MANAGE, V97, P188, DOI 10.1016/j.enconman.2015.03.058
   Reinke M, 2004, COMBUST FLAME, V136, P217, DOI 10.1016/j.combustflame.2003.10.003
   Reinke M, 2002, P COMBUST INST, V29, P1021, DOI 10.1016/S1540-7489(02)80129-8
   Reinke M, 2005, COMBUST FLAME, V141, P448, DOI 10.1016/j.combustflame.2005.01.016
   Reinke M, 2005, P COMBUST INST, V30, P2519, DOI 10.1016/j.proci.2004.08.054
   Reinke M, 2007, COMBUST SCI TECHNOL, V179, P553, DOI 10.1080/00102200600671930
   Rieger J, 2015, J CLEAN PROD, V88, P254, DOI 10.1016/j.jclepro.2014.07.028
   Sabia P, 2015, COMBUST FLAME, V162, P533, DOI 10.1016/j.combustflame.2014.08.009
   Sankaran R, 2007, P COMBUST INST, V31, P1291, DOI 10.1016/j.proci.2006.08.025
   Shahamiri SA, 2009, CHEM ENG J, V149, P102, DOI 10.1016/j.cej.2008.09.046
   Shahamiri SA, 2014, INT J GREEN ENERGY, V11, P12, DOI 10.1080/15435075.2012.727927
   Shahamiri SA, 2011, APPL MATH MODEL, V35, P1915, DOI 10.1016/j.apm.2010.10.020
   Smith G., 1999, GRI 3 0 MECH
   Smyth SA, 2012, COMBUST FLAME, V159, P802, DOI 10.1016/j.combustflame.2011.08.022
   TAKENO T, 1979, COMBUST SCI TECHNOL, V20, P73, DOI 10.1080/00102207908946898
   Takeno T., 1981, P COMBUST INST, V18, P465, DOI DOI 10.1016/50082-0784(81)80052-5
   Turkeli-Ramadan Z, 2015, CHEM ENG SCI, V138, P414, DOI 10.1016/j.ces.2015.08.026
   Wang G, 2018, ENERGY
   Wang W, 2019, ENERGY, V167, P902, DOI 10.1016/j.energy.2018.11.006
   Wang YF, 2018, FUEL, V234, P20, DOI 10.1016/j.fuel.2018.07.004
   Warnatz J, 1993, VERBRENNUNG
   Wierzba I, 2003, CHEM ENG J, V91, P287, DOI 10.1016/S1385-8947(02)00165-1
   Wierzbicki TA, 2014, APPL ENERG, V130, P350, DOI 10.1016/j.apenergy.2014.05.069
   Yan YF, 2014, INT J HYDROGEN ENERG, V39, P19204, DOI 10.1016/j.ijhydene.2014.09.064
   Yang B, 1998, COMBUST FLAME, V112, P16, DOI 10.1016/S0010-2180(97)81754-3
   Yang WJ, 2017, CHEM ENG SCI, V158, P30, DOI 10.1016/j.ces.2016.09.027
   Yang WJ, 2016, ENERG FUEL, V30, P6110, DOI 10.1021/acs.energyfuels.6b00724
   Yang WJ, 2016, APPL THERM ENG, V100, P325, DOI 10.1016/j.applthermaleng.2016.02.010
   Yao R, 2014, ENRGY PROCED, V61, P2528, DOI 10.1016/j.egypro.2014.12.038
   Younis LB, 2004, J POROUS MEDIA, V7, P93, DOI 10.1615/JPorMedia.v7.i2.20
   YOUNIS LB, 1993, INT J HEAT MASS TRAN, V36, P1425, DOI 10.1016/S0017-9310(05)80053-5
   Zabetacis M.G, 1964, SYNTHETIC FUELS
   Zhang Y, 2018, J ENERGY I
   [周俊虎 Zhou Junhu], 2010, [农业机械学报, Transactions of the Chinese Society of Agricultural Machinery], V41, P90
NR 59
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115247
DI 10.1016/j.ces.2019.115247
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300053
OA Bronze
DA 2020-05-12
ER

PT J
AU Yang, X
   Liang, YJ
   Chen, W
AF Yang, Xu
   Liang, Yingjie
   Chen, Wen
TI Anomalous imbibition of non-Newtonian fluids in porous media
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Anomalous imbibition; Non-Newtonian fluid; Fractional calculus; Modeling
ID CAPILLARY RISE; LAW; PENETRATION; DYNAMICS; WATER; FLOW; MODELS; OIL
AB The imbibition of a complex fluid in porous media often exhibits anomalous behavior, which is dominated by multiple time-spatial scales. In this work, a spatiotemporal fractional imbibition model (SFIM) is proposed to capture anomalous imbibition. The anomalous exponent and the non-Newtonian index of SFIM are introduced to characterize the heterogeneity of porous media and the nonlocality of the non-Newtonian fluid. It is found that the anomalous exponent is inversely proportional to the fractal dimension of tortuosity. The non-Newtonian index unveils the radius variation due to the interaction between the non-Newtonian fluid and the interface of porous media. In addition, the proposed model is superior to the Lucas-Washburn model (LWM) with respect to the experimental data of oil and epoxy resin. This work is provided as a preliminary probe into a study on anomalous imbibition via fractional calculus. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Xu; Liang, Yingjie; Chen, Wen] Hohai Univ, Coll Mech & Mat, Inst Soft Matter Mech, Nanjing 211100, Jiangsu, Peoples R China.
RP Liang, YJ (reprint author), Hohai Univ, Coll Mech & Mat, Inst Soft Matter Mech, Nanjing 211100, Jiangsu, Peoples R China.
EM liangyj@hhu.edu.cn
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2019B81014, 2018B687X14,
   2019B16114]; Postgraduate Research & Practice Innovation Program of
   Jiangsu Province [KYCX18_0532]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [11772121, 11702085];
   China Scholarship Council (CSC)China Scholarship Council [201806710065]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities (Grant No. 2019B81014, 2018B687X14, 2019B16114),
   the Postgraduate Research & Practice Innovation Program of Jiangsu
   Province (Grant No. KYCX18_0532), the National Natural Science
   Foundation of China (11772121, 11702085), and the China Scholarship
   Council (CSC) (Grant No. 201806710065).
CR Alava M, 2004, ADV PHYS, V53, P83, DOI 10.1080/00018730410001687363
   Alderete NM, 2019, CEMENT CONCRETE RES, V120, P256, DOI 10.1016/j.cemconres.2019.04.001
   Amico SC, 2002, POLYM COMPOSITE, V23, P249, DOI 10.1002/pc.10429
   Benavente D, 2002, TRANSPORT POROUS MED, V49, P59, DOI 10.1023/A:1016047122877
   Berli CLA, 2014, MICROFLUID NANOFLUID, V17, P1079, DOI 10.1007/s10404-014-1388-9
   Cai JC, 2014, LANGMUIR, V30, P5142, DOI 10.1021/la5007204
   Cai JC, 2011, TRANSPORT POROUS MED, V89, P251, DOI 10.1007/s11242-011-9767-0
   Chen DTN, 2010, ANNU REV CONDEN MA P, V1, P301, DOI 10.1146/annurev-conmatphys-070909-104120
   Chen YJ, 2015, J PHYS CHEM C, V119, P12508, DOI 10.1021/acs.jpcc.5b03157
   Daniel RC, 2006, ADV COLLOID INTERFAC, V123, P439, DOI 10.1016/j.cis.2006.05.012
   de Meijer M, 2001, J COATING TECHNOL, V73, P39
   Delannoy J, 2019, SOFT MATTER, V15, P2757, DOI 10.1039/c8sm02485e
   Dumitru B, 2012, FRACTIONAL CALCULUS
   Feng D, 2018, LANGMUIR, V34, P7714, DOI 10.1021/acs.langmuir.8b01397
   Frey JM, 1999, TRANSPORT POROUS MED, V37, P25, DOI 10.1023/A:1006546717409
   Fries N, 2008, J COLLOID INTERF SCI, V320, P259, DOI 10.1016/j.jcis.2008.01.009
   Gorce JB, 2016, LANGMUIR, V32, P1560, DOI 10.1021/acs.langmuir.5b04495
   Gravelle S, 2016, PHYS REV E, V93, DOI 10.1103/PhysRevE.93.033123
   HANDY LL, 1960, T AM I MIN MET ENG, V219, P75
   Holm S., 2019, WAVES POWER LAW ATTE
   HORVATH VK, 1995, PHYS REV E, V52, P5166, DOI 10.1103/PhysRevE.52.5166
   Kelly S, 2016, NANOSCALE, V8, P2751, DOI 10.1039/c5nr04462f
   Leverett MC, 1939, T AM I MIN MET ENG, V132, P149, DOI 10.2118/939149-G
   Li CP, 2007, APPL MATH COMPUT, V187, P777, DOI 10.1016/j.amc.2006.08.163
   Lucas R, 1918, KOLLOID Z, V23, P15, DOI 10.1007/BF01461107
   Magin RL, 2006, FRACTIONAL CALCULUS
   Mainardi F, 2010, FRACTIONAL CALCULUS
   Metzler R, 2000, PHYS REP, V339, P1, DOI 10.1016/S0370-1573(00)00070-3
   Monje CA, 2010, ADV IND CONTROL, P3, DOI 10.1007/978-1-84996-335-0
   Morrow NR, 2001, CURR OPIN COLLOID IN, V6, P321, DOI 10.1016/S1359-0294(01)00100-5
   Munson B. R., 2014, FUNDAMENTALS FLUID M
   Parada M, 2017, TRANSPORT POROUS MED, V119, P611, DOI 10.1007/s11242-017-0901-5
   Pearson JRA, 2002, J NON-NEWTON FLUID, V102, P447, DOI 10.1016/S0377-0257(01)00191-4
   Podlubny I, 1999, FRACTIONAL DIFFERENT
   Ponomarenko A, 2011, J FLUID MECH, V666, P146, DOI 10.1017/S0022112010005276
   Ridgway CJ, 2002, J COLLOID INTERF SCI, V252, P373, DOI 10.1006/jcis.2002.8468
   Sharifi-Viand A, 2012, J ELECTROANAL CHEM, V671, P51, DOI 10.1016/j.jelechem.2012.02.014
   Shou DH, 2015, CHEM ENG SCI, V137, P583, DOI 10.1016/j.ces.2015.07.009
   Sun HG, 2019, FRACT CALC APPL ANAL, V22, P27, DOI 10.1515/fca-2019-0003
   Sun HG, 2018, COMMUN NONLINEAR SCI, V64, P213, DOI 10.1016/j.cnsns.2018.04.019
   Sun HG, 2018, COMMUN NONLINEAR SCI, V62, P409, DOI 10.1016/j.cnsns.2018.02.007
   Vinogradova IS, 2016, J STRUCT CHEM+, V57, P812, DOI 10.1134/S0022476616040272
   Washburn EW, 1921, PHYS REV, V17, P273, DOI 10.1103/PhysRev.17.273
   Wiklund HS, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.023006
   Wu PK, 2017, LANGMUIR, V33, P7862, DOI 10.1021/acs.langmuir.7b01762
   Yu BM, 2008, APPL MECH REV, V61, DOI 10.1115/1.2955849
   Zarandi MAF, 2018, AICHE J, V64, P294, DOI 10.1002/aic.15965
NR 47
TC 0
Z9 0
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115265
DI 10.1016/j.ces.2019.115265
PG 5
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300009
OA Bronze
DA 2020-05-12
ER

PT J
AU Yang, Y
   Zhang, P
   He, LL
   Sun, JY
   Huang, ZL
   Wang, JD
   Yang, YR
AF Yang, Yao
   Zhang, Peng
   He, Lelu
   Sun, Jingyuan
   Huang, Zhengliang
   Wang, Jingdai
   Yang, Yongrong
TI Acoustic analysis of particle-wall interactions of plug flow in vertical
   pneumatic conveying
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Plug flow; Unsteady flow; Particle-wall interactions; Acoustic emission;
   Pressure drop
ID PULVERIZED COAL; EMISSION AE; SIGNALS
AB The plug flow was investigated in both the single plug and the continuous plug experiments. In the single plug flow, the pressure drop might rise for two times with a longer plug, and the second increase was proved to be caused by the collision between the falling particles and the plug by acoustic emission detection. In continuous plug flow, the interaction between the bulk of the plug and the pipe wall was dominated by the friction. And the sources of acoustic signals in continuous plug flow can be mainly divided into two parts: the collision between the falling particles and the plug and the friction between the bulk of plug and the wall. Based on this, the acoustic model was derived and the energy fraction can be predicted accurately. And the model further provides a possibility for the non-intrusive, real-time and online detection of Janssen coefficient. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Yao; Zhang, Peng; He, Lelu; Sun, Jingyuan; Huang, Zhengliang] Zhejiang Univ, Coll Chem & Biol Engn, Zhejiang Prov Key Lab Adv Chem Engn Manufacture T, Hangzhou 310027, Zhejiang, Peoples R China.
   [Wang, Jingdai; Yang, Yongrong] Zhejiang Univ, Coll Chem & Biol Engn, State Key Lab Chem Engn, Hangzhou 310027, Zhejiang, Peoples R China.
RP Sun, JY (reprint author), Zhejiang Univ, Coll Chem & Biol Engn, Zhejiang Prov Key Lab Adv Chem Engn Manufacture T, Hangzhou 310027, Zhejiang, Peoples R China.
EM sunjy@zju.edu.cn
RI Yao, Yang/AAB-7210-2019; Lungu, Musango/D-6067-2012
OI Lungu, Musango/0000-0002-3062-6376
FU National Natural Science Foundation of China, ChinaNational Natural
   Science Foundation of China [21808197]; National Science Fund for
   Distinguished Young, China [21525627]; Science Fund for Creative
   Research Groups of National Natural Science Foundation of China, China
   [61621002]
FX The authors acknowledge the support and encouragement of the National
   Natural Science Foundation of China, China (21808197), The National
   Science Fund for Distinguished Young, China (21525627) and the Science
   Fund for Creative Research Groups of National Natural Science Foundation
   of China, China (61621002).
CR Cong XL, 2013, CHEM ENG SCI, V101, P303, DOI 10.1016/j.ces.2013.05.058
   Daoud K., 1993, KONA, V11, P119, DOI DOI 10.14356/K0NA.1993014
   Dong KZ, 2015, AICHE J, V61, P3628, DOI 10.1002/aic.14933
   He LL, 2016, AICHE J, V62, P2635, DOI 10.1002/aic.15240
   He LL, 2014, IND ENG CHEM RES, V53, P9938, DOI 10.1021/ie404088k
   He YJ, 2009, AICHE J, V55, P2563, DOI 10.1002/aic.11878
   Jiang XJ, 2007, IND ENG CHEM RES, V46, P6904, DOI 10.1021/ie070457i
   Klinzing GE, 2010, PART TECHNOL SER, V8, P1, DOI 10.1007/978-90-481-3609-4
   KONRAD K, 1987, J PIPELINE, V6, P99
   KONRAD K, 1989, CAN J CHEM ENG, V67, P245, DOI 10.1002/cjce.5450670211
   Konrad K., 1980, PNEUMOTRANSPORT, P225
   Kuang SB, 2008, IND ENG CHEM RES, V47, P470, DOI 10.1021/ie070991q
   Levy A, 2000, POWDER TECHNOL, V112, P263, DOI 10.1016/S0032-5910(00)00301-6
   Li K, 2013, AIP CONF PROC, V1542, P1154, DOI 10.1063/1.4812141
   Mason D. John, 1991, STUDY MODES GAS SOLI
   Pahk JB, 2013, IND ENG CHEM RES, V52, P199, DOI 10.1021/ie3005385
   Pahk JB, 2012, POWDER TECHNOL, V222, P58, DOI 10.1016/j.powtec.2012.01.040
   Pan R, 1999, POWDER TECHNOL, V104, P157, DOI 10.1016/S0032-5910(99)00044-3
   Pu WH, 2010, CHEM ENG SCI, V65, P2500, DOI 10.1016/j.ces.2009.12.025
   Qiu JB, 2019, IEEE T FUZZY SYST, V27, P2152, DOI 10.1109/TFUZZ.2019.2895560
   Rabinovich E, 2012, POWDER TECHNOL, V219, P143, DOI 10.1016/j.powtec.2011.12.030
   RICHARDSON JF, 1954, T I CHEM ENG-LOND, V32, P35, DOI DOI 10.1016/S0263-8762(97)80006-8
   Roberts A., 1966, 2 ANN C
   Roberts AW, 2003, PARTICUL SCI TECHNOL, V21, P25, DOI 10.1080/02726350307497
   SUN KK, 2019, IEEE T FUZZY SYST, V27, P1587, DOI DOI 10.1109/TFUZZ.2018.2883374
   Vasquez N, 2003, POWDER TECHNOL, V137, P167, DOI 10.1016/j.powtec.2003.08.060
   Wang H, 2010, PROCESS EQ PIP, V47, P21
   Wang JD, 2010, AICHE J, V56, P1173, DOI 10.1002/aic.12071
   Wang JD, 2009, IND ENG CHEM RES, V48, P8508, DOI 10.1021/ie8018774
   Wypych PW, 2003, POWDER TECHNOL, V129, P111, DOI 10.1016/S0032-5910(02)00224-3
   Yang Y., 2004, Patant, Patent No. [CN1544140, 1544140]
NR 31
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115260
DI 10.1016/j.ces.2019.115260
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300003
OA Bronze
DA 2020-05-12
ER

PT J
AU Yin, PB
   Cao, XW
   Zhang, P
   Yang, W
   Bian, J
   Guo, D
AF Yin, Pengbo
   Cao, Xuewen
   Zhang, Pan
   Yang, Wen
   Bian, Jiang
   Guo, Dan
TI Investigation of slug flow characteristics in hilly terrain pipeline
   using ultrasonic Doppler method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ultrasonic Doppler; Slug flow; Slug unit division; Gas-liquid interface;
   Velocity profile
ID VELOCITY-MEASUREMENT; LIQUID FLOWS; GAS; BEHAVIOR; SENSOR
AB An ultrasonic Doppler method is proposed for investigating the two-phase slug flow in a hilly terrain pipeline. To obtain the distribution of the velocity and gas-liquid interface, the velocity profile and echo profile of the slug flow were measured via ultrasonic Doppler velocimetry (UDV) with and without the addition of tracer particles in the liquid phase, respectively. An individual 8 MHz transducer with a diameter of 3 mm and an individual 2 MHz transducer with a diameter of 5 mm were employed for the liquid film and liquid slug measurement respectively. Using MATLAB programs based on the measured data, the investigation of the flow characteristics of the slug flow was divided into three parts: the liquid film, the front of the liquid slug, and the center of the liquid slug. The statistical analysis of the average length of every part indirectly reflected the formation and development behavior of the slug flow. The characteristic parameters of the gas-liquid interface, such as the thickness of the liquid film and the bubble distribution in the liquid slug, were extracted from the echo signals. The boundary layer of the liquid film was extracted from the velocity profiles. The average value and variation coefficient of the velocity profile were calculated for the liquid film and the center of the liquid slug. The effects of the superficial velocities and measured positions on the aforementioned flow parameters were examined. The UDV measurement and relevant data processing offer an effective method for the non-intrusive investigation of the slug flow in a hilly terrain pipeline. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yin, Pengbo; Cao, Xuewen; Zhang, Pan; Bian, Jiang; Guo, Dan] China Univ Petr, Coll Pipeline & Civil Engn, Qingdao 266580, Shandong, Peoples R China.
   [Yang, Wen] Sinopec Sales Co Ltd, Guangzhou 510620, Guangdong, Peoples R China.
RP Cao, XW (reprint author), China Univ Petr, Coll Pipeline & Civil Engn, Qingdao 266580, Shandong, Peoples R China.
EM caoxw@upc.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51874340]
FX The financial support of the National Natural Science Foundation of
   China (No. 51874340) is appreciated.
CR Abbagoni BM, 2016, MEAS SCI TECHNOL, V27, DOI 10.1088/0957-0233/27/8/084002
   Ahmed WH, 2011, INT J MULTIPHAS FLOW, V37, P876, DOI 10.1016/j.ijmultiphaseflow.2011.05.007
   Al-Safran E, 2005, INT J MULTIPHAS FLOW, V31, P337, DOI 10.1016/j.ijmultiphaseflow.2004.11.002
   BARNEA D, 1987, INT J MULTIPHAS FLOW, V13, P1, DOI 10.1016/0301-9322(87)90002-4
   Belt R.J., 2015, BHR GROUP C SER PUBL, P233
   Coutinho FR, 2014, SENSORS-BASEL, V14, P9093, DOI 10.3390/s140509093
   DEHENAU V, 1995, INT J MULTIPHAS FLOW, V21, P365, DOI 10.1016/0301-9322(94)00081-T
   Dong XX, 2017, IEEE T INSTRUM MEAS, V66, P3064, DOI 10.1109/TIM.2017.2717218
   Dong XX, 2015, CHEM ENG SCI, V135, P155, DOI 10.1016/j.ces.2015.05.011
   EGGELS JGM, 1994, J FLUID MECH, V268, P175, DOI 10.1017/S002211209400131X
   Liang FC, 2017, AICHE J, V63, P2348, DOI 10.1002/aic.15570
   LIN PY, 1987, INT J MULTIPHAS FLOW, V13, P13, DOI 10.1016/0301-9322(87)90003-6
   Murai Y, 2010, FLOW MEAS INSTRUM, V21, P356, DOI 10.1016/j.flowmeasinst.2010.03.007
   Murai Y, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/11/114003
   Murakawa H, 2005, EXP THERM FLUID SCI, V29, P843, DOI 10.1016/j.expthermflusci.2005.03.002
   Murakawa H, 2008, FLOW MEAS INSTRUM, V19, P205, DOI 10.1016/j.flowmeasinst.2007.06.010
   Parsi M, 2015, CHEM ENG SCI, V130, P221, DOI 10.1016/j.ces.2015.03.033
   SHEMER L, 1987, PHYSICOCHEM HYDRODYN, V8, P243
   Shi XW, 2019, INT J MULTIPHAS FLOW, V111, P219, DOI 10.1016/j.ijmultiphaseflow.2018.11.006
   Shukla A, 2006, CHEM ENG SCI, V61, P2468, DOI 10.1016/j.ces.2005.11.027
   Siddiqui M.I, 2016, J VISUAL-JAPAN, V19, P1
   Soleimani A, 2003, INT J MULTIPHAS FLOW, V29, P51, DOI 10.1016/S0301-9322(02)00124-6
   Sousa RG, 2005, CHEM ENG SCI, V60, P1859, DOI 10.1016/j.ces.2004.11.035
   Stolojanu V, 1997, CHEM ENG SCI, V52, P4225, DOI 10.1016/S0009-2509(97)00265-0
   Taitel Y, 1998, CHEM ENG SCI, V53, P2089, DOI 10.1016/S0009-2509(98)00007-4
   Taitel Y, 2016, INT J MULTIPHAS FLOW, V86, P21, DOI 10.1016/j.ijmultiphaseflow.2016.07.001
   TAKEDA Y, 1995, EXP THERM FLUID SCI, V10, P444, DOI 10.1016/0894-1777(94)00124-Q
   TAKEDA Y, 1991, NUCL ENG DES, V126, P277, DOI 10.1016/0029-5493(91)90117-Z
   Talley JD, 2015, INT J MULTIPHAS FLOW, V76, P212, DOI 10.1016/j.ijmultiphaseflow.2015.06.011
   Tan C, 2015, CHEM ENG SCI, V134, P153, DOI 10.1016/j.ces.2015.04.046
   Thaker J, 2015, J PETROL SCI ENG, V135, P561, DOI 10.1016/j.petrol.2015.10.018
   Vieira RE, 2015, CHEM ENG SCI, V134, P324, DOI 10.1016/j.ces.2015.05.013
   Wang G, 2001, EXP FLUIDS, V31, P428, DOI 10.1007/s003480100326
   Westerweel J, 1996, EXP FLUIDS, V20, P165, DOI 10.1007/BF00190272
   Yin PB, 2018, INT J MULTIPHAS FLOW, V101, P85, DOI 10.1016/j.ijmultiphaseflow.2018.01.004
   Zhai LS, 2016, CHEM ENG SCI, V144, P346, DOI 10.1016/j.ces.2016.01.058
   Zhai LS, 2013, CHEM ENG SCI, V94, P271, DOI 10.1016/j.ces.2013.02.049
   ZHENG G, 1994, INT J MULTIPHAS FLOW, V20, P63, DOI 10.1016/0301-9322(94)90006-X
   Zheng Y, 2004, CHEM ENG SCI, V59, P3505, DOI 10.1016/j.ces.2004.05.016
NR 39
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115300
DI 10.1016/j.ces.2019.115300
PG 18
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300035
OA Bronze
DA 2020-05-12
ER

PT J
AU Yin, WJ
   Wang, S
   Zhang, K
   He, YR
AF Yin, Weijie
   Wang, Shuai
   Zhang, Kai
   He, Yurong
TI Investigation of oxygen-enriched biomass gasification with TFM-DEM
   hybrid model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidized bed; TFM-DEM hybrid model; Particle size distribution; Biomass
   gasification
ID BENEFICIATION FLUIDIZED-BED; PARTICLE SEGREGATION; CFD; SIMULATION;
   GELDART
AB A clear discrepancy of particle size makes it difficult for the simulation of multiphase systems with binary mixture. In this work, a Two-Fluid Model (TFM)-Discrete Element Method (DEM) hybrid model incorporating chemical reactions is developed to investigate the oxygen-enriched biomass gasification process in a fluidized bed reactor. The bed material granular flow is described with the TFM, whereas biomass fuel particles are tracked with the DEM. The species transport and chemical reactions are further taken into consideration under the framework of the TFM-DEM hybrid model. By comparing with experimental data, the model can give a good prediction. Meanwhile, the particle size distribution (PSD) during the gasification process and the effect of operating velocity are also analyzed. The results demonstrate that there exists the discrepancy of PSD for different layers of bed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yin, Weijie; Wang, Shuai; Zhang, Kai; He, Yurong] Harbin Inst Technol, Sch Energy Sci & Engn, Harbin 150001, Heilongjiang, Peoples R China.
RP Wang, S (reprint author), Harbin Inst Technol, Sch Energy Sci & Engn, Harbin 150001, Heilongjiang, Peoples R China.
EM shuaiwang@hit.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51606053]
FX This research is conducted with financial support from the National
   Natural Science Foundation of China (51606053).
CR Antolini D, 2019, FUEL, V253, P1473, DOI 10.1016/j.fuel.2019.05.116
   Chen GY, 2019, FUEL, V247, P324, DOI 10.1016/j.fuel.2019.03.002
   Gomez-Barea A, 2010, PROG ENERG COMBUST, V36, P444, DOI 10.1016/j.pecs.2009.12.002
   Grace JR, 2010, PARTICUOLOGY, V8, P498, DOI 10.1016/j.partic.2010.09.003
   Gu HD, 2019, J ENERGY INST, V92, P1329, DOI 10.1016/j.joei.2018.10.002
   Hernandez-Jimenez F, 2015, CHEM ENG SCI, V134, P57, DOI 10.1016/j.ces.2015.04.028
   Hong K, 2016, POWDER TECHNOL, V296, P2, DOI 10.1016/j.powtec.2015.07.003
   Ku XK, 2017, CHEM ENG SCI, V168, P235, DOI 10.1016/j.ces.2017.04.050
   Ku XK, 2015, CHEM ENG SCI, V122, P270, DOI 10.1016/j.ces.2014.08.045
   Kumar U, 2019, CHEM ENG SCI, V195, P413, DOI 10.1016/j.ces.2018.09.038
   Lan WJ, 2019, J ENERGY INST, V92, P613, DOI 10.1016/j.joei.2018.03.011
   LEBOWITZ JL, 1964, PHYS REV, V133, pA895, DOI 10.1103/PhysRev.133.A895
   Liu CQ, 2018, INT J HYDROGEN ENERG, V43, P14214, DOI 10.1016/j.ijhydene.2018.05.154
   Liu H, 2016, INT J HYDROGEN ENERG, V41, P11974, DOI 10.1016/j.ijhydene.2016.04.205
   Liu H, 2015, APPL ENERG, V160, P489, DOI 10.1016/j.apenergy.2015.09.065
   Loha C, 2014, RENEW SUST ENERG REV, V40, P688, DOI 10.1016/j.rser.2014.07.199
   McDonough JR, 2019, CHEM ENG SCI, V200, P294, DOI 10.1016/j.ces.2019.01.048
   Motta IL, 2018, RENEW SUST ENERG REV, V94, P998, DOI 10.1016/j.rser.2018.06.042
   Owoyemi O, 2007, AICHE J, V53, P1924, DOI 10.1002/aic.11227
   Shi ZS, 2011, CHEM ENG SCI, V66, P5541, DOI 10.1016/j.ces.2011.07.020
   Syamlal M., 1987, PARTICLE PARTICLE DR
   Syamlal M., 1993, MFIX DOCUMENTATION T, DOI [10.2172/10145548, DOI 10.2172/10145548]
   Wang JW, 2009, CHEM ENG SCI, V64, P622, DOI 10.1016/j.ces.2008.09.028
   Wang QG, 2015, POWDER TECHNOL, V283, P570, DOI 10.1016/j.powtec.2015.06.007
   Wang QG, 2015, CHEM ENG SCI, V131, P256, DOI 10.1016/j.ces.2015.03.063
   Wang QG, 2015, CHEM ENG J, V260, P240, DOI 10.1016/j.cej.2014.08.052
   Wang S, 2018, ENERG CONVERS MANAGE, V173, P296, DOI 10.1016/j.enconman.2018.07.043
   Yan LB, 2018, BIORESOURCE TECHNOL, V269, P384, DOI 10.1016/j.biortech.2018.08.099
   Yang HT, 2019, FUEL PROCESS TECHNOL, V192, P140, DOI 10.1016/j.fuproc.2019.04.025
   Yang SL, 2019, ENERG CONVERS MANAGE, V196, P1, DOI 10.1016/j.enconman.2019.05.105
   Zhao LX, 2018, J SUPERCRIT FLUID, V131, P26, DOI 10.1016/j.supflu.2017.07.022
NR 31
TC 1
Z9 1
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115293
DI 10.1016/j.ces.2019.115293
PG 9
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300033
OA Bronze
DA 2020-05-12
ER

PT J
AU Yu, X
   Li, SJ
   Zhou, H
   Jing, S
   Lan, WJ
   Li, SW
AF Yu, Xiong
   Li, Shaojie
   Zhou, Han
   Jing, Shan
   Lan, Wenjie
   Li, Shaowei
TI Numerically simulating droplet breakup in droplet swarm using modified
   level set method with multi-levels
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet breakup; Interface capturing; Level set method; Pulsed disc and
   doughnut column
ID LIQUID-LIQUID-EXTRACTION; PULSED DISC; THEORETICAL-MODEL; DOUGHNUT
   COLUMN; CFD SIMULATION; PIPE-FLOW; INSTABILITY
AB A modified level set method with multi-levels was developed to simulate the breakup behavior of multi-droplets in the turbulent flow of a pulsed disc and doughnut column. This free interface capturing method uncovered the mechanisms of three droplet breakup patterns that were observed in experiments: (1) breakup owing to shearing effect, (2) breakup because of collision with plate surfaces, and (3) breakup due to interface instability. The simulation results also indicated that the breakup frequency of 2-mm droplets increased from 0.1 to 0.6 s(-1) and the breakup duration decreased from 0.025 to 0.015 s when the pulsation intensity increased from 8 to 14 mm/s. Multiple breakage occurred when the droplet size increased to 3 mm. The simulation results agreed well with our previous experimental results. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yu, Xiong; Zhou, Han; Jing, Shan; Li, Shaowei] Tsinghua Univ, Collaborat Innovat Ctr Adv Nucl Energy Technol, Inst Nucl & New Energy Technol, Beijing 100084, Peoples R China.
   [Li, Shaojie] China Text Acad, Beijing 100025, Peoples R China.
   [Lan, Wenjie] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
   [Li, Shaowei] Tsinghua Univ, State Key Lab Chem Engn, Beijing 100084, Peoples R China.
RP Jing, S; Li, SW (reprint author), Tsinghua Univ, Collaborat Innovat Ctr Adv Nucl Energy Technol, Inst Nucl & New Energy Technol, Beijing 100084, Peoples R China.
EM s-jing@tsinghua.edu.cn; lsw@tsinghua.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21776151, 21576147, 21376132]
FX We gratefully acknowledge the support of the National Natural Science
   Foundation of China (21776151, 21576147, and 21376132) for this
   research.
CR ACRIVOS A, 1978, J FLUID MECH, V86, P641, DOI 10.1017/S0022112078001329
   Adamo A, 2016, SCIENCE, V352, P61, DOI 10.1126/science.aaf1337
   Azizi F, 2011, CHEM ENG J, V166, P715, DOI 10.1016/j.cej.2010.11.050
   Bogdan AR, 2009, ANGEW CHEM INT EDIT, V48, P8547, DOI 10.1002/anie.200903055
   Choi M, 2017, COMPUT FLUIDS, V145, P153, DOI 10.1016/j.compfluid.2016.12.014
   Coquerelle M, 2016, J COMPUT PHYS, V305, P838, DOI 10.1016/j.jcp.2015.11.014
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   Fang Q, 2017, CHEM ENG SCI, V161, P274, DOI 10.1016/j.ces.2016.12.051
   Galinat S, 2007, AICHE J, V53, P56, DOI 10.1002/aic.11055
   Galinat S, 2005, CHEM ENG SCI, V60, P6511, DOI 10.1016/j.ces.2005.05.012
   Gutmann B, 2015, ANGEW CHEM INT EDIT, V54, P6688, DOI 10.1002/anie.201409318
   Haghshenas M, 2017, INT J MULTIPHAS FLOW, V90, P13, DOI 10.1016/j.ijmultiphaseflow.2016.12.002
   Han LC, 2013, CHEM ENG SCI, V102, P186, DOI 10.1016/j.ces.2013.06.046
   Hua JS, 2007, AICHE J, V53, P2534, DOI 10.1002/aic.11287
   Korb C, 2017, HYDROMETALLURGY, V173, P71, DOI 10.1016/j.hydromet.2017.08.009
   Lan WJ, 2015, CHEM ENG SCI, V134, P76, DOI 10.1016/j.ces.2015.05.004
   Lan WJ, 2014, IND ENG CHEM RES, V53, P4913, DOI 10.1021/ie403060w
   Lehr F, 2001, CHEM ENG SCI, V56, P1159, DOI 10.1016/S0009-2509(00)00335-3
   Li CM, 2005, PROC CVPR IEEE, P430
   Liu HQ, 2016, IND ENG CHEM RES, V55, P2242, DOI 10.1021/acs.iecr.5b04661
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Mansur MB, 2008, J HAZARD MATER, V150, P669, DOI 10.1016/j.jhazmat.2007.05.019
   Mead-Hunter R, 2012, LANGMUIR, V28, P6731, DOI 10.1021/la300622h
   Min C, 2010, J COMPUT PHYS, V229, P2764, DOI 10.1016/j.jcp.2009.12.032
   NARSIMHAN G, 1984, AICHE J, V30, P457, DOI 10.1002/aic.690300315
   Neves CMSS, 2011, GREEN CHEM, V13, P1517, DOI 10.1039/c1gc15079k
   PERCY JS, 1983, AICHE J, V29, P161, DOI 10.1002/aic.690290125
   Salgado AL, 2003, J POWER SOURCES, V115, P367, DOI 10.1016/S0378-7753(03)00025-9
   Solsvik J, 2016, IND ENG CHEM RES, V55, P2872, DOI 10.1021/acs.iecr.6b00591
   Solsvik J, 2015, CHEM ENG SCI, V131, P219, DOI 10.1016/j.ces.2015.03.059
   Sussman M, 1999, J COMPUT PHYS, V148, P81, DOI 10.1006/jcph.1998.6106
   SWARTZ JE, 1970, AICHE J, V16, P254, DOI 10.1002/aic.690160218
   van der Graaf S, 2006, LANGMUIR, V22, P4144, DOI 10.1021/la052682f
   Wang TF, 2003, CHEM ENG SCI, V58, P4629, DOI 10.1016/j.ces.2003.07.009
   Watanabe S, 2017, ADV POWDER TECHNOL, V28, P3104, DOI 10.1016/j.apt.2017.09.005
   Watanabe S, 2017, CHEM ENG J, V313, P724, DOI 10.1016/j.cej.2016.12.118
   Weber MW, 2007, MICROFLUID NANOFLUID, V3, P195, DOI 10.1007/s10404-006-0120-9
   Wen JW, 2018, HYDROMETALLURGY, V177, P57, DOI 10.1016/j.hydromet.2018.02.013
   Wonga VL, 2017, CHEM ENG SCI, V174, P157, DOI 10.1016/j.ces.2017.08.027
   Xiong QQ, 2018, CHEM ENG SCI, V185, P157, DOI 10.1016/j.ces.2018.04.022
   Xu SX, 2016, COMMUN COMPUT PHYS, V20, P1163, DOI 10.4208/cicp.210815.180316a
   YARIN AL, 1993, PHYS FLUIDS A-FLUID, V5, P91, DOI 10.1063/1.858792
   Yu X, 2018, SOLVENT EXTR ION EXC, V36, P480, DOI 10.1080/07366299.2018.1494528
   Zhou H, 2019, CHEM ENG SCI, V195, P23, DOI 10.1016/j.ces.2018.11.035
   Zhou H, 2019, CHEM ENG SCI, V197, P172, DOI 10.1016/j.ces.2018.12.017
   Zhou H, 2017, AICHE J, V63, P4188, DOI 10.1002/aic.15742
NR 46
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115263
DI 10.1016/j.ces.2019.115263
PG 12
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300045
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhang, C
   Grossier, R
   Lacaria, L
   Rico, F
   Candoni, N
   Veesler, S
AF Zhang, Cheng
   Grossier, Romain
   Lacaria, Leda
   Rico, Felix
   Candoni, Nadine
   Veesler, Stephane
TI A microfluidic method generating monodispersed microparticles with
   controllable sizes and mechanical properties
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microfluidic; Microparticle; Hydrogel; Alginate; Microdroplet
ID PATHOLOGICAL ERYTHROCYTES; ALGINATE; MICROGELS; CELL
AB Seeking to produce microparticles that mimic red blood cells (RBCs), we present a microfluidic method of generating monodispersed hydrogel microparticles of Na-/Ca-alginate with controllable sizes (micrometer range) and mechanical properties. No surfactant is used. Transformation from Na-alginate to Caalginate microparticles is realized via ex situ gelation, which proves essential to obtaining desired microparticle properties, such as insolubility in water and RBC-like mechanical properties. For both Na-alginate and Ca-alginate microparticles, a smooth surface and a porous inner structure are observed under a scanning electron microscope. A platform of microgrippers is successfully developed to manipulate the microparticles. The Young's modulus measured using an atomic force microscope on the surface of Ca-alginate microparticles is of the same order as that of RBCs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Cheng; Grossier, Romain; Candoni, Nadine; Veesler, Stephane] Aix Marseille Univ, CNRS, CINaM Ctr Interdisciplinaire Nanosci Marseille, Campus Luminy,Case 913, F-13288 Marseille 09, France.
   [Lacaria, Leda; Rico, Felix] INSERM U1067, Adhes & Inflammat Lab LAI, CNRS UMR 7333, 163 Ave Luminy,Case 937, F-13288 Marseille 09, France.
RP Veesler, S (reprint author), Aix Marseille Univ, CNRS, CINaM Ctr Interdisciplinaire Nanosci Marseille, Campus Luminy,Case 913, F-13288 Marseille 09, France.
EM veesler@cinam.univ-mrs.fr
OI Lacaria, Leda/0000-0002-1273-1551
FU ANR CUMBAFrench National Research Agency (ANR) [ANR-15-CE19-0017-03];
   LABEX Mecanique et Complexite (Aix-Marseille Universite)
FX First, we are grateful to ANR CUMBA (ANR-15-CE19-0017-03) for its
   financial support of this work and LABEX Mecanique et Complexite
   (Aix-Marseille Universite) for financial support of the microgripppers.
   Second, we would like to thank Michel Maton (Alliance Gums and
   Industries) for his kind provision of sodium alginate. Third, we are
   also grateful to Mehdi Lagaize for providing technical support for these
   experiments and Cecilia Colomes for experimental assistance during her
   graduate training period. Last but not least, we thank Marjorie Sweetko
   for English revision.
CR de Monchy R, 2018, J ACOUST SOC AM, V143, P2207, DOI 10.1121/1.5031121
   Dulinska Molak I, 2006, J BIOCHEM BIOPH METH, V66, P1, DOI 10.1016/j.jbbm.2005.11.003
   Freitas S, 2005, J CONTROL RELEASE, V102, P313, DOI 10.1016/j.jconrel.2004.10.015
   Girasole M, 2012, MICRON, V43, P1273, DOI 10.1016/j.micron.2012.03.019
   Hati AG, 2016, LAB CHIP, V16, P3718, DOI 10.1039/c6lc00769d
   Ildefonso M, 2012, ORG PROCESS RES DEV, V16, P556, DOI 10.1021/op200291z
   Lee KY, 2007, PROG POLYM SCI, V32, P669, DOI 10.1016/j.progpolymsci.2007.04.001
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Ouwerx C, 1998, POLYM GELS NETW, V6, P393, DOI 10.1016/S0966-7822(98)00035-5
   Pittermannova A, 2016, RSC ADV, V6, P103532, DOI 10.1039/c6ra23003b
   Rondeau E, 2008, LANGMUIR, V24, P6937, DOI 10.1021/la703339u
   STEPHENSON R, 1986, J CHEM ENG DATA, V31, P56, DOI 10.1021/je00043a019
   Sugaya S, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4826936
   Utech S, 2015, ADV HEALTHC MATER, V4, P1628, DOI 10.1002/adhm.201500021
   Yamada M, 2012, SOFT MATTER, V8, P3122, DOI 10.1039/c2sm07263g
   Yang JM, 2015, RSC ADV, V5, P7297, DOI 10.1039/c4ra13275k
   Zhang H, 2007, MACROMOL RAPID COMM, V28, P527, DOI 10.1002/marc.200600776
   Zhang SH, 2015, CHEM ENG SCI, V138, P128, DOI 10.1016/j.ces.2015.07.046
NR 18
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115322
DI 10.1016/j.ces.2019.115322
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300004
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhang, W
   Machida, H
   Takano, H
   Izumiya, K
   Norinaga, K
AF Zhang, Wei
   Machida, Hiroshi
   Takano, Hiroyuki
   Izumiya, Koichi
   Norinaga, Koyo
TI Computational fluid dynamics simulation of CO2 methanation in a
   shell-and-tube reactor with multi-region conjugate heat transfer
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE OpenFOAM; Heat transfer; Methanation; Simulation
ID CARBON-DIOXIDE; KINETICS; HYDROGENATION; FLOW
AB Methanation is one of the promising candidates in developing CO2 utilization technology. Because of its exothermic behavior, the methanation reactor must be carefully designed to avoid the hotspots formation and the deterioration of catalysts. This study presents a numerical study simulates heat transfer between the reacting gas in a porous catalyst layer, reactor tube, and coolant in a shell-and-tube reactor. The aim is to develop a tool can predict the hotspots appearing in the reactor used in CO2 methanation. The open-source toolbox OpenFOAM is adopted and modified. The catalyst bed is assumed to be a continuous porous medium. The results revealed that the solver captures the trends of temperature profiles along both axial and radial directions. The maximum catalyst temperature predicted by this solver is in good agreement with the experimental result, indicating that the solver is a promising tool for future applications in reactor optimization and heat management. (C) 2019 Published by Elsevier Ltd.
C1 [Zhang, Wei; Machida, Hiroshi; Norinaga, Koyo] Nagoya Univ, Grad Sch Engn, Dept Chem Syst Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.
   [Takano, Hiroyuki; Izumiya, Koichi] Hitachi Zosen Corp, Suminoe Ku, 7-89,Nankokita 1 Chome, Osaka 5598559, Japan.
RP Norinaga, K (reprint author), Nagoya Univ, Grad Sch Engn, Dept Chem Syst Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.
EM norinaga@nagoya-u.jp
OI zhang, wei/0000-0003-2685-0102
FU New Energy and Industrial Technology Development Organization of
   JapanNew Energy and Industrial Technology Development Organization
   (NEDO)
FX This work is supported by New Energy and Industrial Technology
   Development Organization of Japan.
CR Abe T, 2009, ENERG ENVIRON SCI, V2, P315, DOI 10.1039/b817740f
   Alarcon A, 2018, CHEM ENG RES DES, V140, P155, DOI 10.1016/j.cherd.2018.10.017
   Aziz MAA, 2015, CHEM ENG J, V260, P757, DOI 10.1016/j.cej.2014.09.031
   Chein RY, 2016, J NAT GAS SCI ENG, V29, P243, DOI 10.1016/j.jngse.2016.01.019
   CHIANG JH, 1983, IND ENG CHEM PROD RD, V22, P225, DOI 10.1021/i300010a011
   Cuellar-Franca RM, 2015, J CO2 UTIL, V9, P82, DOI 10.1016/j.jcou.2014.12.001
   DEW JN, 1955, IND ENG CHEM, V47, P140, DOI 10.1021/ie50541a044
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Fujita SI, 1997, CHEM ENG J, V68, P63, DOI 10.1016/S1385-8947(97)00074-0
   Gao X, 2011, CHEM ENG SCI, V66, P6028, DOI 10.1016/j.ces.2011.08.031
   Hafsteinsson H.E., 2009, POROUS MEDIA OPENFOA
   HERWIJNEN TV, 1973, J CATAL, V28, P391
   Hsu CT, 1999, J HEAT TRANS-T ASME, V121, P733, DOI 10.1115/1.2826043
   International Energy Agency, 2018, KEY WORLD EN STAT 20
   KAI T, 1988, CAN J CHEM ENG, V66, P343, DOI 10.1002/cjce.5450660226
   Kiewidt L, 2015, CHEM ENG SCI, V132, P59, DOI 10.1016/j.ces.2015.03.068
   Koschany F, 2016, APPL CATAL B-ENVIRON, V181, P504, DOI 10.1016/j.apcatb.2015.07.026
   Kreitz B, 2019, CHEM ENG SCI, V195, P541, DOI 10.1016/j.ces.2018.09.053
   Kumagai N. H, 2015, HYDROGEN ENERGY SYST, V40, P230
   Massachusetts Institute of Technology, 2007, FUT COAL
   Rahmani S., 2016, IRANIAN J HYDROGEN F, V3, P59
   Sabatier P., 1902, COMPTES RENDUS HEBDO, V134
   SALETORE DA, 1977, IND ENG CHEM PROC DD, V16, P70, DOI 10.1021/i260061a011
   Schlereth D, 2014, CHEM ENG RES DES, V92, P702, DOI 10.1016/j.cherd.2013.11.014
   Takano H., 2016, THESIS
   Yu KP, 2008, APPL CATAL B-ENVIRON, V84, P112, DOI 10.1016/j.apcatb.2008.03.009
NR 26
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115276
DI 10.1016/j.ces.2019.115276
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300014
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhang, YN
   Fang, TM
   Li, RC
   Yan, YG
   Guo, WY
   Zhang, J
AF Zhang, Yingnan
   Fang, Timing
   Li, Ruchuan
   Yan, Youguo
   Guo, Wenyue
   Zhang, Jun
TI Molecular insight into the oil charging mechanism in tight reservoirs
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Tight reservoirs; Oil charging; Molecular dynamics simulation; Size
   effect; Capillary pressure; Accumulation threshold
ID QUANTITATIVE FLUORESCENCE TECHNIQUES; SUPERCRITICAL CARBON-DIOXIDE;
   DYNAMICS SIMULATIONS; INTERFACIAL-TENSION; INORGANIC NANOPORES; YANCHANG
   FORMATION; ADSORPTION; TRANSPORT; BASIN; PORES
AB Tight oil reservoirs are dominated by nano-pore throats that significantly impede the migration of crude oil. Understanding the oil charging behavior in these nanoscale channels is critical to assess the oil accumulation. In this work, molecular dynamics (MD) simulations were adopted to uncover molecular insights into the oil charging and migration through differently-sized hydrophilic nano-pore throats. On the one hand, the dynamic pathway and the energetic driving force of the oil charging process were clarified. On the other hand, with analyzing the force that the oil undergoes when going across nano-pore throats, the capillary pressure for different throat sizes was calculated; based on which, we propose an MD simulation method to assess the oil accumulation threshold of tight reservoirs. Taken together, this work expends our knowledge of the fluid migration through nano-pores, and it could facilitate future studies on the evaluation of tight oil reservoirs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Yingnan; Fang, Timing; Li, Ruchuan; Yan, Youguo; Guo, Wenyue; Zhang, Jun] China Univ Petr, Sch Mat Sci & Engn, Qingdao 266580, Shandong, Peoples R China.
   [Fang, Timing] Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117576, Singapore.
RP Guo, WY; Zhang, J (reprint author), China Univ Petr, Sch Mat Sci & Engn, Qingdao 266580, Shandong, Peoples R China.
EM wyguo@upc.edu.cn; zhangjun.upc@gmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51874332]; Shandong Provincial Natural Science
   FoundationNatural Science Foundation of Shandong Province [ZR2019MB023];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [19CX05001A]
FX This work is financially supported by the National Natural Science
   Foundation of China (51874332), the Shandong Provincial Natural Science
   Foundation (ZR2019MB023), and the Fundamental Research Funds for the
   Central Universities (19CX05001A).
CR BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Bourg IC, 2012, J PHYS CHEM C, V116, P11556, DOI 10.1021/jp301299a
   Cai BY, 1996, J CHEM ENG DATA, V41, P493, DOI 10.1021/je950259a
   [操应长 Cao Yingchang], 2018, [石油学报, Acta Petrolei Sinica], V39, P247
   Chen W, 2015, PHYS REV LETT, V114, DOI 10.1103/PhysRevLett.114.095502
   Clarkson CR, 2013, FUEL, V103, P606, DOI 10.1016/j.fuel.2012.06.119
   Collin M, 2018, J PHYS CHEM C, V122, P17764, DOI 10.1021/acs.jpcc.8b03902
   Cygan RT, 2004, J PHYS CHEM B, V108, P1255, DOI 10.1021/jp0363287
   de Almeida JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep28128
   Dimitrov DI, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.054501
   Falk K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7949
   Fang TM, 2019, CHEM ENG SCI, V197, P204, DOI 10.1016/j.ces.2018.12.016
   Fang TM, 2017, CHEM ENG SCI, V164, P17, DOI 10.1016/j.ces.2017.01.067
   Gong YJ, 2018, ENERG FUEL, V32, P4885, DOI 10.1021/acs.energyfuels.8b00174
   Guo XW, 2011, ORG GEOCHEM, V42, P1343, DOI 10.1016/j.orggeochem.2011.08.017
   Guo XW, 2010, AAPG BULL, V94, P1859, DOI 10.1306/05191009179
   Helmy AK, 2007, APPL SURF SCI, V253, P6878, DOI 10.1016/j.apsusc.2007.01.127
   Hou DS, 2019, COMPOS PART B-ENG, V162, P433, DOI 10.1016/j.compositesb.2018.12.142
   Hou DS, 2018, ACS SUSTAIN CHEM ENG, V6, P9498, DOI 10.1021/acssuschemeng.8b02126
   Huang L, 2018, APPL ENERG, V210, P28, DOI 10.1016/j.apenergy.2017.10.122
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Izrailev S., 1999, COMPUTATIONAL MOL DY, P39, DOI DOI 10.1007/978-3-642-58360-5_2
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Koretsky CM, 1998, AM J SCI, V298, P349, DOI 10.2475/ajs.298.5.349
   Lai FP, 2018, ENERG FUEL, V32, P3368, DOI 10.1021/acs.energyfuels.8b00193
   Le T, 2015, J PHYS CHEM C, V119, P15274, DOI 10.1021/acs.jpcc.5b03160
   Le T, 2015, CHEM ENG SCI, V121, P292, DOI 10.1016/j.ces.2014.08.022
   [李潮流 Li Chaoliu], 2018, [石油学报, Acta Petrolei Sinica], V39, P1019
   Liang MC, 2015, MICROFLUID NANOFLUID, V19, P1, DOI 10.1007/s10404-014-1541-5
   Liu B, 2017, ENERG FUEL, V31, P738, DOI 10.1021/acs.energyfuels.6b02377
   Liu K, 2007, J PETROL SCI ENG, V57, P139, DOI 10.1016/j.petrol.2005.11.019
   Liu KY, 2005, ORG GEOCHEM, V36, P1023, DOI 10.1016/j.orggeochem.2005.02.008
   [刘震 Liu Zhen], 2012, [石油学报, Acta Petrolei Sinica], V33, P996
   [刘震 Liu Zhen], 2012, [石油学报, Acta Petrolei Sinica], V33, P1
   Loucks RG, 2009, J SEDIMENT RES, V79, P848, DOI 10.2110/jsr.2009.092
   Luo P, 2017, FUEL, V208, P626, DOI 10.1016/j.fuel.2017.07.044
   Ma Y, 2016, J PHYS CHEM C, V120, P19389, DOI 10.1021/acs.jpcc.6b04832
   Nelson PH, 2009, AAPG BULL, V93, P329, DOI 10.1306/10240808059
   NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201
   Obliger A, 2016, J PHYS CHEM LETT, V7, P3712, DOI 10.1021/acs.jpclett.6b01684
   Piri M, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.061603
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Sedghi M, 2016, LANGMUIR, V32, P3375, DOI 10.1021/acs.langmuir.5b04713
   Sedghi M, 2014, J CHEM PHYS, V141, DOI 10.1063/1.4901752
   Skelton AA, 2011, LANGMUIR, V27, P8700, DOI 10.1021/la2005826
   Skelton AA, 2011, J PHYS CHEM C, V115, P2076, DOI 10.1021/jp109446d
   Smith WO, 1930, J AM CHEM SOC, V52, P1345, DOI 10.1021/ja01367a007
   TOUKAN K, 1985, PHYS REV B, V31, P2643, DOI 10.1103/PhysRevB.31.2643
   Velusamy S, 2017, IND ENG CHEM RES, V56, P13521, DOI 10.1021/acs.iecr.7b02528
   Wang GW, 2017, MAR PETROL GEOL, V83, P84, DOI 10.1016/j.marpetgeo.2017.03.008
   Wang JL, 2015, ENERGY, V82, P31, DOI 10.1016/j.energy.2014.12.042
   Wang Q, 2018, PETROL SCI TECHNOL, V36, P1298, DOI 10.1080/10916466.2018.1471495
   Wang S, 2016, FUEL, V171, P74, DOI 10.1016/j.fuel.2015.12.071
   Wang S, 2015, INT J COAL GEOL, V147, P9, DOI 10.1016/j.coal.2015.06.002
   Wu TT, 2016, J SUPERCRIT FLUID, V107, P499, DOI 10.1016/j.supflu.2015.07.005
   Xi KL, 2016, MAR PETROL GEOL, V76, P1, DOI 10.1016/j.marpetgeo.2016.05.001
   Xi KL, 2015, SEDIMENT GEOL, V330, P90, DOI 10.1016/j.sedgeo.2015.10.007
   Yan H, 2016, J PHYS CHEM C, V120, P2667, DOI 10.1021/acs.jpcc.5b09841
   Yan YG, 2017, PHYS CHEM CHEM PHYS, V19, P30439, DOI 10.1039/c7cp05759h
   Yan YG, 2017, FUEL, V190, P253, DOI 10.1016/j.fuel.2016.11.019
   [杨华 Yang Hua], 2013, [石油学报, Acta Petrolei Sinica], V34, P1
   Yang S, 2017, FUEL, V190, P409, DOI 10.1016/j.fuel.2016.10.105
   Yao JL, 2013, PETROL EXPLOR DEV+, V40, P161, DOI 10.1016/S1876-3804(13)60019-1
   [曾溅辉 Zeng Jianhui], 2014, [地球科学进展, Advance in Earth Sciences], V29, P651
   Zhang H, 2014, PETROL EXPLOR DEV+, V41, P408, DOI 10.1016/S1876-3804(14)60047-1
   Zhang J, 2017, ENERG FUEL, V31, P7026, DOI 10.1021/acs.energyfuels.7b01001
   Zhang JF, 2013, ENERG FUEL, V27, P2741, DOI 10.1021/ef400283n
   Zhang LH, 2016, ENERG FUEL, V30, P149, DOI 10.1021/acs.energyfuels.5b02142
   Zhao J, 2017, PETROLEUM RES, V2, P131, DOI [10.1016/j.ptlrs.2017.02.001, DOI 10.1016/J.PTLRS.2017.02.001]
   Zheng M, 2016, PETROL EXPLOR DEV+, V43, P241, DOI 10.1016/S1876-3804(16)30027-1
   Zou CN, 2013, EARTH-SCI REV, V126, P358, DOI 10.1016/j.earscirev.2013.08.006
   [邹才能 Zou Caineng], 2013, [石油勘探与开发, Petroleum Exploration and Development], V40, P385
   窦宏恩, 2014, [中国科学. 地球科学, Scientia Sinica Terrae], V44, P1751
NR 73
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115297
DI 10.1016/j.ces.2019.115297
PG 10
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300040
OA Bronze
DA 2020-05-12
ER

PT J
AU Zhou, YF
   Kang, PX
   Huang, ZL
   Yan, P
   Sun, JY
   Wang, JD
   Yang, YR
AF Zhou, Yefeng
   Kang, Panxing
   Huang, Zhengliang
   Yan, Pan
   Sun, Jingyuan
   Wang, Jingdai
   Yang, Yongrong
TI Experimental measurement and theoretical analysis on bubble dynamic
   behaviors in a gas-liquid bubble column
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE PTV and HSI; Bubble column reactors (BCRs); Bubble dynamic behaviors;
   Gas-liquid interactions; Bubble terminal velocity; Bubbly flow radial
   distribution patterns
ID SIZE DISTRIBUTION; SINGLE BUBBLES; RISE VELOCITY; TERMINAL VELOCITY;
   PARTICLE TRACKING; AIR BUBBLES; MODELS; FLOW; COALESCENCE; SIMULATION
AB Bubble dynamic behaviors have significant effects on the interfacial area between gas and liquid phases, the gas-phase residence time and the efficiency of heat and mass transfer. This study mainly investigated the single bubble dynamic behaviors and the radial distribution patterns of bubbly flow in a bubble column through Particle Tracking Velocimetry (PTV) and High Speed Imaging (HSI). As the results indicate, with the bubble size increasing, bubble deformation and bubble rising velocity are intensified and bubble trajectories change accordingly. Meanwhile, theoretically calculated values of single bubble terminal velocities are in accord with experimental values. According to the study, gas-liquid interaction has a noticeable impact on multiple radial distribution patterns of bubbly flow, including bubble size, velocity, the number of small bubbles and the width of gas-liquid interaction region. Finally, a correlation is proposed in this work to predict the width of gas-liquid interaction region based on a dimensionless analysis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhou, Yefeng; Kang, Panxing] Xiangtan Univ, Chem Proc Simulat & Optimizat Engn Res Ctr, Natl & Local United Engn Res Ctr Chem Proc Simula, Minist Educ, Xiangtan 411105, Peoples R China.
   [Zhou, Yefeng; Huang, Zhengliang; Yan, Pan; Sun, Jingyuan; Wang, Jingdai; Yang, Yongrong] Zhejiang Univ, State Key Lab Chem Engn, Hangzhou 310027, Zhejiang, Peoples R China.
   [Zhou, Yefeng; Huang, Zhengliang; Yan, Pan; Sun, Jingyuan; Wang, Jingdai; Yang, Yongrong] Zhejiang Univ, Coll Chem & Biol Engn, Hangzhou 310027, Zhejiang, Peoples R China.
RP Sun, JY (reprint author), Zhejiang Univ, State Key Lab Chem Engn, Hangzhou 310027, Zhejiang, Peoples R China.; Sun, JY (reprint author), Zhejiang Univ, Coll Chem & Biol Engn, Hangzhou 310027, Zhejiang, Peoples R China.
EM sunjy@zju.edu.cn
RI Kang, Panxing/AAD-3397-2020; Lungu, Musango/D-6067-2012; Zhou,
   Yefeng/B-5698-2016
OI Kang, Panxing/0000-0001-8809-6534; Lungu, Musango/0000-0002-3062-6376;
   Zhou, Yefeng/0000-0002-4568-4552
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21506181, 91834303]; Science Fund for Creative
   Research Groups of National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [61621002]; National Science Fund
   for Distinguished YoungNational Natural Science Foundation of
   ChinaNational Science Fund for Distinguished Young Scholars [21525627];
   Natural Science Foundation of Hunan ProvinceNatural Science Foundation
   of Hunan Province [2019JJ40281]; China Scholarship CouncilChina
   Scholarship Council [201707230001]; Research Foundation of Education
   Bureau of Hunan Province [18B088]; Hunan Key Laboratory of Environment
   Friendly Chemical Process Integration; Hunan 2011 Collaborative
   Innovation Center of Chemical Engineering & Technology with
   Environmental Benignity and Effective Resource Utilization
FX The work was supported by National Natural Science Foundation of China
   (21506181, 91834303), the Science Fund for Creative Research Groups of
   National Natural Science Foundation of China (61621002), the National
   Science Fund for Distinguished Young (21525627), Natural Science
   Foundation of Hunan Province (2019JJ40281), China Scholarship Council
   (201707230001) Research Foundation of Education Bureau of Hunan Province
   (18B088). Hunan Key Laboratory of Environment Friendly Chemical Process
   Integration and Hunan 2011 Collaborative Innovation Center of Chemical
   Engineering & Technology with Environmental Benignity and Effective
   Resource Utilization.
CR Basarova P, 2018, CHEM ENG SCI, V192, P74, DOI 10.1016/j.ces.2018.07.008
   Besagni G, 2019, FLOW MEAS INSTRUM, V67, P55, DOI 10.1016/j.flowmeasinst.2019.04.008
   Cheng JC, 2018, CHINESE J CHEM ENG, V26, P1773, DOI 10.1016/j.cjche.2017.11.012
   Clift R., 1978, BUBBLES DROPS PARTIC
   DEKEE D, 1986, CHEM ENG SCI, V41, P2273, DOI 10.1016/0009-2509(86)85078-3
   DUINEVELD PC, 1995, J FLUID MECH, V292, P325, DOI 10.1017/S0022112095001546
   Ellingsen K, 2001, J FLUID MECH, V440, P235, DOI 10.1017/S0022112001004761
   Esmaeili A, 2016, AICHE J, V62, P1382, DOI 10.1002/aic.15130
   Esmaeili A, 2015, CHEM ENG SCI, V129, P193, DOI 10.1016/j.ces.2015.01.071
   FAN LS, 1990, BUBBLE WAKE DYNAMICS
   Gordiychuk A, 2016, EXP THERM FLUID SCI, V70, P51, DOI 10.1016/j.expthermflusci.2015.08.014
   HARMATHY TZ, 1960, AICHE J, V6, P281, DOI 10.1002/aic.690060222
   Hassan N M S, 2008, WSEAS Transactions on Fluid Mechanics, V3, P261
   ISHII M, 1979, AICHE J, V25, P843, DOI 10.1002/aic.690250513
   JAMIALAHMADI M, 1994, CHEM ENG RES DES, V72, P119
   Jo D, 2010, CHEM ENG SCI, V65, P4231, DOI 10.1016/j.ces.2010.04.019
   Khuntia S, 2012, REV CHEM ENG, V28, P191, DOI 10.1515/revce-2012-0007
   Korevaar MW, 2015, AICHE J, V61, P3616, DOI 10.1002/aic.14928
   Kulkarni AA, 2005, IND ENG CHEM RES, V44, P5873, DOI 10.1021/ie049131p
   Lau YM, 2013, CHEM ENG SCI, V98, P203, DOI 10.1016/j.ces.2013.05.024
   Lau YM, 2013, CHEM ENG SCI, V94, P20, DOI 10.1016/j.ces.2013.02.043
   Legendre D, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4705527
   Li XN, 2017, CHEM ENG J, V328, P1122, DOI 10.1016/j.cej.2017.07.107
   Liang XF, 2016, CHEM ENG RES DES, V112, P88, DOI 10.1016/j.cherd.2016.06.014
   Liao YX, 2010, CHEM ENG SCI, V65, P2851, DOI 10.1016/j.ces.2010.02.020
   Liao YX, 2009, CHEM ENG SCI, V64, P3389, DOI 10.1016/j.ces.2009.04.026
   Ma D, 2012, CHEM ENG SCI, V72, P61, DOI 10.1016/j.ces.2012.01.013
   Magnaudet J, 2000, ANNU REV FLUID MECH, V32, P659, DOI 10.1146/annurev.fluid.32.1.659
   Manjrekar ON, 2017, CHEM ENG SCI, V168, P55, DOI 10.1016/j.ces.2017.04.016
   Manjrekar ON, 2015, CHEM ENG SCI, V131, P313, DOI 10.1016/j.ces.2015.03.027
   Maxworthy T, 1996, J FLUID MECH, V321, P421, DOI 10.1017/S0022112096007781
   MENDELSON HD, 1967, AICHE J, V13, P250, DOI 10.1002/aic.690130213
   MOORE DW, 1965, J FLUID MECH, V23, P749, DOI 10.1017/S0022112065001660
   Mosdorf R, 2011, ARCH THERMODYN, V32, P3, DOI 10.2478/v10173-011-0001-9
   Nezu I, 2011, J HYDRO-ENVIRON RES, V5, P215, DOI 10.1016/j.jher.2011.05.004
   PEEBLES FN, 1953, CHEM ENG PROG, V49, P88
   Pourtousi M, 2014, CHEM ENG PROCESS, V75, P38, DOI 10.1016/j.cep.2013.11.001
   Rasouli M, 2015, AICHE J, V61, P384, DOI 10.1002/aic.14644
   Rodrigue D, 2001, AICHE J, V47, P39, DOI 10.1002/aic.690470106
   Schiller L., 1935, Z VER DTSCH ING, V77, P318
   Shew WL, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.144508
   Shu SL, 2019, RENEW ENERG, V141, P613, DOI 10.1016/j.renene.2019.04.020
   Shuai Y, 2019, AICHE J, V65, DOI 10.1002/aic.16565
   Simmons MJH, 2009, AICHE J, V55, P2765, DOI 10.1002/aic.11889
   Sujatha KT, 2015, CHEM ENG SCI, V130, P18, DOI 10.1016/j.ces.2015.02.029
   Talaia MAR, 2007, PROC WRLD ACAD SCI E, V22, P264
   Taqieddin A, 2017, J ELECTROCHEM SOC, V164, pE448, DOI 10.1149/2.1161713jes
   Tollkotter A, 2014, PROCESSES, V2, P200, DOI 10.3390/pr2010200
   Tomiyama A, 2002, INT J MULTIPHAS FLOW, V28, P1497, DOI 10.1016/S0301-9322(02)00032-0
   Tomiyama A, 1998, JSME INT J B-FLUID T, V41, P472, DOI 10.1299/jsmeb.41.472
   Veldhuis C, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2911042
   Wallis G. B., 1974, International Journal of Multiphase Flow, V1, P491, DOI 10.1016/0301-9322(74)90003-2
   Wang QG, 2016, INT J HEAT MASS TRAN, V98, P799, DOI 10.1016/j.ijheatmasstransfer.2016.03.064
   Wu MM, 2002, PHYS FLUIDS, V14, pL49, DOI 10.1063/1.1485767
   Xue J, 2017, CHINESE J CHEM ENG, V25, P249, DOI 10.1016/j.cjche.2016.08.006
   Yang N, 2017, CHEM ENG SCI, V170, P241, DOI 10.1016/j.ces.2017.01.026
   Yang Z, 2007, AICHE J, V53, P1941, DOI 10.1002/aic.11224
   Yin JL, 2015, INT J HEAT MASS TRAN, V91, P218, DOI 10.1016/j.ijheatmasstransfer.2015.05.076
   Zhao L, 2019, INT J MULTIPHAS FLOW, V114, P192, DOI 10.1016/j.ijmultiphaseflow.2019.02.003
   Zhao L, 2017, PROG NUCL ENERG, V97, P74, DOI 10.1016/j.pnucene.2017.01.004
   Zhao LHB, 2018, CHEM ENG J, V354, P304, DOI 10.1016/j.cej.2018.06.019
   Zheng L, 2000, J HYDRAUL ENG-ASCE, V126, P852, DOI 10.1061/(ASCE)0733-9429(2000)126:11(852)
   Ziegenhein T, 2017, EXP THERM FLUID SCI, V85, P248, DOI 10.1016/j.expthermflusci.2017.03.009
   Ziegenhein T, 2016, CHEM ENG SCI, V150, P54, DOI 10.1016/j.ces.2016.04.039
NR 64
TC 2
Z9 2
U1 25
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115295
DI 10.1016/j.ces.2019.115295
PG 12
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300020
OA Bronze
DA 2020-05-12
ER

PT J
AU Zivkovic, LA
   Pohar, A
   Likozar, B
   Nikacevic, NM
AF Zivkovic, Luka A.
   Pohar, Andrej
   Likozar, Blaz
   Nikacevic, Nikola M.
TI Reactor conceptual design by optimization for hydrogen production
   through intensified sorption- and membrane-enhanced water-gas shift
   reaction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Water-gas shift reaction; Multi-objective optimization;
   Sorption-enhanced reaction; Membrane reactor; Process intensification;
   Trickle solids reactor
ID MULTIOBJECTIVE OPTIMIZATION; HEAT-TRANSFER; FLOW; TECHNOLOGY;
   ADSORPTION; BEDS; CO2
AB In this feasibility study, a novel industrial-scale reactor structure for continuous hydrogen production via intensified water-gas shift (WGS) reaction is proposed. It considers both trickling calcium-oxide sorbent for carbon dioxide removal (SOR) and Pd-based membrane for hydrogen separation (MEM). It is shown that WGS, SOR, MEM, and cooling can be decoupled with a special reactor superstructure mathematically represented with the pseudo-homogenous one-dimensional model. The final reactor structure and operating conditions are determined by using rigorous multi-objective optimization. Two objective functions take all main costs into account (total reactor volume and respective volumetric fractions for the catalyst, sorbent, and membrane) and the main benefit (hydrogen yield). The results show that the best cost-benefit relation can be achieved with the two-module reactor and combined WGS and SOR processes, with 95% carbon monoxide conversion (64% higher than the equilibrium conversion at the same conditions) and the outlet-stream containing only 0.7% of carbon dioxide. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zivkovic, Luka A.; Nikacevic, Nikola M.] Univ Belgrade, Fac Technol & Met, Dept Chem Engn, Belgrade 11060, Serbia.
   [Pohar, Andrej; Likozar, Blaz] Natl Inst Chem, Dept Catalysis & Chem React Engn, Ljubljana 1000, Slovenia.
RP Zivkovic, LA (reprint author), Univ Belgrade, Fac Technol & Met, Dept Chem Engn, Belgrade 11060, Serbia.
EM lzivkovic@tmf.bg.ac.rs
FU Ministry of Education, Science and Technological Development of the
   Republic of Serbia [172022]; European Commission (Basileus V. Erasmus
   Mundus project); Slovenian Research AgencySlovenian Research Agency -
   Slovenia [P2-0152]
FX This research was supported by the Ministry of Education, Science and
   Technological Development of the Republic of Serbia (Project 172022),
   the European Commission (Basileus V. Erasmus Mundus project) and the
   Slovenian Research Agency (Project P2-0152).
CR Al-Ghrami M.S., 2018, ENHANCED LIGHT OLEFI
   Arora A, 2018, CHEM ENG SCI, V192, P335, DOI 10.1016/j.ces.2018.07.031
   Arora A, 2018, COMPUT CHEM ENG, V115, P89, DOI 10.1016/j.compchemeng.2018.04.004
   Baier T, 2007, CHEM ENG SCI, V62, P4602, DOI 10.1016/j.ces.2007.04.047
   Balat M, 2008, INT J HYDROGEN ENERG, V33, P4013, DOI 10.1016/j.ijhydene.2008.05.047
   Barelli L, 2008, ENERGY, V33, P554, DOI 10.1016/j.energy.2007.10.018
   Bayat M, 2014, J TAIWAN INST CHEM E, V45, P481, DOI 10.1016/j.jtice.2013.06.013
   Bollas GM, 2002, IND ENG CHEM RES, V41, P5410, DOI 10.1021/ie0202423
   Farshi A, 2011, PETROL SCI TECHNOL, V29, P875, DOI 10.1080/10916460903451985
   Froment G.F., 2010, CHEM REACTOR ANAL DE
   Gallucci F, 2013, CHEM ENG SCI, V92, P40, DOI 10.1016/j.ces.2013.01.008
   Garcia-Garcia FR, 2014, CATAL TODAY, V236, P57, DOI 10.1016/j.cattod.2014.02.050
   Geilen F., 2014, CLEANING LIQUID HYDR
   Gil AG, 2015, CHEM ENG SCI, V137, P364, DOI 10.1016/j.ces.2015.06.051
   Groppi G, 2005, CATAL TODAY, V105, P297, DOI 10.1016/j.cattod.2005.06.041
   Holladay JD, 2009, CATAL TODAY, V139, P244, DOI 10.1016/j.cattod.2008.08.039
   JACOBS GK, 1981, PHYS CHEM MINER, V7, P55, DOI 10.1007/BF00309451
   Jang HM, 2012, CHEM ENG SCI, V73, P431, DOI 10.1016/j.ces.2012.02.015
   Karafyllis I, 2002, COMPUT CHEM ENG, V26, P1087, DOI 10.1016/S0098-1354(02)00027-3
   Koros WJ, 2001, J MEMBRANE SCI, V181, P141, DOI 10.1016/S0376-7388(00)00676-1
   LeValley TL, 2014, INT J HYDROGEN ENERG, V39, P16983, DOI 10.1016/j.ijhydene.2014.08.041
   Li J, 2013, IND ENG CHEM RES, V52, P11084, DOI 10.1021/ie400250c
   Mahecha-Botero A, 2008, CHEM ENG SCI, V63, P2752, DOI 10.1016/j.ces.2008.02.032
   Mamaghani AH, 2015, APPL THERM ENG, V77, P1, DOI 10.1016/j.applthermaleng.2014.12.016
   Martinez I, 2013, INT J HYDROGEN ENERG, V38, P15180, DOI 10.1016/j.ijhydene.2013.09.062
   Mendes D, 2010, ASIA-PAC J CHEM ENG, V5, P111, DOI 10.1002/apj.364
   Mendes D, 2010, INT J HYDROGEN ENERG, V35, P12596, DOI 10.1016/j.ijhydene.2010.07.159
   Moad G, 1999, PROG POLYM SCI, V24, P81, DOI 10.1016/S0079-6700(98)00017-3
   Muldowney G.P, 1993, FCC PROCESS UPFLOW D
   Myrstad T., 2000, REDUCTION SULPHUR CO
   Nikacevic N.M., 2008, INVESTIGATION MULTIP
   Nikacevic NM, 2009, CHEM ENG SCI, V64, P2501, DOI 10.1016/j.ces.2009.02.029
   Perejon A, 2016, APPL ENERG, V162, P787, DOI 10.1016/j.apenergy.2015.10.121
   Phuakpunk K, 2018, CHEM ENG SCI, V192, P1041, DOI 10.1016/j.ces.2018.08.042
   Rahmanifard H, 2018, COMPUT CHEM ENG, V119, P258, DOI 10.1016/j.compchemeng.2018.09.006
   Rajan KS, 2008, INT J HEAT MASS TRAN, V51, P2801, DOI 10.1016/j.ijheatmasstransfer.2007.09.042
   Rajesh JK, 2000, IND ENG CHEM RES, V39, P706, DOI 10.1021/ie9905409
   Rajesh JK, 2001, CHEM ENG SCI, V56, P999, DOI 10.1016/S0009-2509(00)00316-X
   Ramage M.P, 1981, FCC REACTOR DOWNFLOW
   Rostrup-Nielsen JR, 2002, CATTECH, V6, P150, DOI 10.1023/A:1020163012266
   Smith S, 2010, IEEE INT C MICROELEC, P8, DOI 10.1109/ICMTS.2010.5466870
   Soria MA, 2019, CHEM ENG J, V356, P727, DOI 10.1016/j.cej.2018.09.044
   Soria MA, 2015, FUEL, V159, P854, DOI 10.1016/j.fuel.2015.07.035
   Stevens RW, 2010, FUEL, V89, P1280, DOI 10.1016/j.fuel.2009.11.035
   Sutherland W., 1893, LONDON EDINBURGH DUB, V36, P507, DOI DOI 10.1080/14786449308620508
   Valverde JM, 2014, APPL ENERG, V126, P161, DOI 10.1016/j.apenergy.2014.03.081
   Voncken RJW, 2018, CHEM ENG SCI, V191, P369, DOI 10.1016/j.ces.2018.07.005
   Wess R, 2015, CHEM ENG SCI, V134, P86, DOI 10.1016/j.ces.2015.04.002
   WHITAKER S, 1972, AICHE J, V18, P361, DOI 10.1002/aic.690180219
   ZHU JX, 1995, CAN J CHEM ENG, V73, P662, DOI 10.1002/cjce.5450730510
   Zivkovic LA, 2016, CHEM ENG RES DES, V113, P189, DOI 10.1016/j.cherd.2016.07.008
   Zivkovic LA, 2016, APPL ENERG, V178, P844, DOI 10.1016/j.apenergy.2016.06.071
NR 52
TC 2
Z9 2
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JAN 16
PY 2020
VL 211
AR 115174
DI 10.1016/j.ces.2019.115174
PG 17
WC Engineering, Chemical
SC Engineering
GA JP8PH
UT WOS:000498520300049
OA Bronze
DA 2020-05-12
ER

PT J
AU Fouda, GG
   De Paris, K
   Levy, O
   Marchant, A
   Gray, G
   Permar, S
   Marovich, M
   Singh, A
AF Fouda, Genevieve G.
   De Paris, Kristina
   Levy, Ofer
   Marchant, Arnaud
   Gray, Glenda
   Permar, Sallie
   Marovich, Mary
   Singh, Anjali
TI Immunological mechanisms of inducing HIV immunity in infants
SO VACCINE
LA English
DT Article
DE Early life; Immune system; HIV; Vaccine; Broadly neutralizing antibodies
ID BROADLY NEUTRALIZING ANTIBODIES; NEWBORN; IMMUNIZATION; RESPONSES;
   CELLS; IMPACT
AB The potential advantages and unique challenges of the early life immune system for the development of HIV-specific broadly neutralizing antibodies were discussed during a workshop entitled "Immunological Mechanisms of Inducing HIV Immunity in Infants" sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) in conjunction with the 2018 HIVR4P Conference held in Madrid, Spain. A safe and effective HIV vaccine remains a critical need in the fight against the HIV pandemic, especially to prevent emerging infections in infants, adolescents, and young adults. To successfully target these populations, a vaccine should ideally induce protective immune responses during childhood. Interestingly, several recent studies highlighting differences in immune responses between adults and children have suggested that the early life immune system could present advantages for the elicitation of broadly neutralizing antibodies (bnAbs), a response highly desired for an HIV vaccine. Notably, HIV-infected children develop bnAbs responses earlier and more frequently than infected adults; with emerging evidence that the pathways of elicitation of bnAb lineages may differ between adults and children. Moreover, there is precedent for the prevention of lifelong infections with pediatric immunization, and early life provides a unique window of opportunity for the administration of a multi-dose HIV vaccine that will likely be needed to achieve protective immunity. Further understanding of how the distinct early life immune system can be harnessed to trigger bnAb lineages for induction of durable and polyfunctional HIV-specific immunity is warranted. This strategy will include testing promising HIV vaccine candidates in pediatric populations in preclinical and clinical studies. Novel approaches to identify molecular markers of protection are also key to guide and accelerate pediatric HIV vaccine development.
C1 [Fouda, Genevieve G.; Permar, Sallie] Duke Univ, Dept Pediat, Med Sch, Durham, NC 27706 USA.
   [Fouda, Genevieve G.; Permar, Sallie] Duke Univ, Sch Med, Human Vaccine Inst, Durham, NC USA.
   [De Paris, Kristina] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA.
   [Levy, Ofer] Boston Childrens Hosp, Div Infect Dis, Precis Vaccines Program, Boston, MA USA.
   [Levy, Ofer] Harvard Med Sch, Boston, MA 02115 USA.
   [Levy, Ofer] Broad Inst Mit & Harvard Univ, Cambridge, MA USA.
   [Marchant, Arnaud] Univ Libre Bruxelles, Inst Med Immunol, B-6041 Charleroi, Belgium.
   [Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Marovich, Mary; Singh, Anjali] NIAID, Vaccine Res Program, Div AIDS, NIH, Rockville, MD USA.
RP Fouda, GG (reprint author), Duke Human Vaccine Inst, DUMC Box 103020, Durham, NC 27710 USA.
EM Genevieve.fouda@duke.edu
OI Permar, Sallie/0000-0003-1438-4554
FU NIH, NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19A1118608, HHSN272201800047C]; Boston
   Children's Hospital Department of Pediatrics; Chief Scientific Office
FX We thank the workshop panelists for their contributions: Drs. Rama Rao
   Amara, Barton F. Haynes, Thomas J. Hope, Andrea Hulse, Richard A. Koup,
   M. Anthony Moody, Penny L. Moore, Maximilian Muenchhof, Nina Russell,
   Rogier W. Sanders, Stuart Z. Shapiro, Leonidas A. Stamatatos, Georgia D.
   Tomaras, Richard T. Wyatt, and Wilton B. Williams. We are also extremely
   grateful to Dr. Ashley Nelson for her help with manuscript preparation.
   Dr. Ofer Levy's research is in part funded by the NIH, NIAID Human
   Immunology Project U19A1118608 as well as Adjuvant Development Program
   contract HHSN272201800047C and internal awards from the Boston
   Children's Hospital Department of Pediatrics and Chief Scientific
   Office.
CR Andrabi R, 2018, CURR OPIN IMMUNOL, V53, P143, DOI 10.1016/j.coi.2018.04.025
   Bonsignori M, 2017, IMMUNOL REV, V275, P145, DOI [10., 10.1111/imr.12509]
   Borrow P, 2017, IMMUNOL REV, V275, P62, DOI 10.1111/imr.12504
   Ditse Z, 2018, J VIROL, V92, DOI [10.1128/JVI.00878-18, 10.1128/jvi.00878-18]
   Dowling DJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91020
   Escolano A, 2016, CELL, V166, P1445, DOI 10.1016/j.cell.2016.07.030
   Fouda GG, 2015, J INFECT DIS, V211, P508, DOI 10.1093/infdis/jiu444
   Giuliano AR, 2007, J INFECT DIS, V196, P1153, DOI 10.1086/521679
   Goetghebuer T, 2019, CLIN INFECT DIS, V68, P1193, DOI 10.1093/cid/ciy673
   Goo L, 2014, NAT MED, V20, P655, DOI 10.1038/nm.3565
   Goo L, 2012, J VIROL, V86, P9566, DOI 10.1128/JVI.00953-12
   Hioe CE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02441
   Jardine JG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005815
   Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195
   Jennewein MF, 2017, SEMIN IMMUNOPATHOL, V39, P605, DOI 10.1007/s00281-017-0653-x
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2017, UNAIDS DAT 2017
   Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009
   Kumar A, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006944
   Kumar S, 2019, J VIROL, V93, DOI 10.1128/JVI.01495-18
   Lee AH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08794-x
   Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031
   McGuire EP, 2018, J VIROL, V92, DOI 10.1128/JVI.01070-17
   Muenchhoff M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1048
   Nelson AN, 2019, J VIROL, V93, DOI 10.1128/JVI.00168-19
   Ng CT, 2010, NAT MED, V16, P1117, DOI 10.1038/nm.2233
   Nielsen SCA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat2004
   Olin A, 2018, CELL, V174, P1277, DOI 10.1016/j.cell.2018.06.045
   Ota MOC, 2004, VACCINE, V22, P511, DOI 10.1016/j.vaccine.2003.07.020
   Phillips B, 2018, J VIROL, V92, DOI 10.1128/JVI.01051-18
   Roider J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01975
   Sadanand S, 2016, ANNU REV MED, V67, P185, DOI 10.1146/annurev-med-091014-090749
   Saunders KO, 2017, CELL REP, V21, P3681, DOI 10.1016/j.celrep.2017.12.028
   Schroeder KMS, 2017, J EXP MED, V214, P2283, DOI 10.1084/jem.20161190
   Simonich CA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09481-7
   Simonich CA, 2016, CELL, V166, P77, DOI 10.1016/j.cell.2016.05.055
   Slike BM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169247
   Sok D, 2017, NATURE, V548, P108, DOI 10.1038/nature23301
   Stamatatos L, 2017, IMMUNOL REV, V275, P203, DOI 10.1111/imr.12483
   Tanaka M, 2017, ALLERGOL INT, V66, P515, DOI 10.1016/j.alit.2017.07.010
   UNAIDS, 2019, WOM HIV SPOTL AD GIR
   van Haren SD, 2016, J IMMUNOL, V197, P4413, DOI 10.4049/jimmunol.1600282
   Walker LM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001028
   Wiehe K, 2018, CELL HOST MICROBE, V23, P759, DOI 10.1016/j.chom.2018.04.018
   Williams WB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01336-3
   Yacoob C, 2016, CELL REP, V17, P1560, DOI 10.1016/j.celrep.2016.10.017
NR 45
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 411
EP 415
DI 10.1016/j.vaccine.2019.11.011
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900001
PM 31761501
DA 2020-05-12
ER

PT J
AU Sistere-Oro, M
   Martinez-Pulgarin, S
   Solanes, D
   Veljkovic, V
   Lopez-Serrano, S
   Cordoba, L
   Cordon, I
   Escribano, JM
   Darji, A
AF Sistere-Oro, Marta
   Martinez-Pulgarin, Susana
   Solanes, David
   Veljkovic, Veljko
   Lopez-Serrano, Sergi
   Cordoba, Lorena
   Cordon, Ivan
   Escribano, Jose M.
   Darji, Ayub
TI Conserved HA-peptides expressed along with flagellin in Trichoplusia ni
   larvae protects chicken against intranasal H7N1 HPAIV challenge
SO VACCINE
LA English
DT Article
DE Avian influenza; H7 subtype; Baculovirus; Pandemic flu; Influenza
   vaccine; Conserved peptides; Flagellin; Cross-protection
ID INFLUENZA; VACCINE; HEMAGGLUTININ; RESPONSES; LIGANDS; SITE
AB The immunization of poultry where H5 and H7 influenza viruses (IVs) are endemic is one of the strategies to prevent unexpected zoonoses. Our group has been focused on conserved HA-epitopes as potential vaccine candidates to obtain multivalent immune responses against distinct IV subtypes. In this study, two conserved epitopes (NG-34 and CS-17) fused to flagellin were produced in a Baculovirus platform based on Trichoplusia ni larvae as living biofactories. Soluble extracts obtained from larvae expressing "flagellin-NG34/CS17 antigen" were used to immunize chickens and the efficacy of the vaccine was evaluated against a heterologous H7N1 HPAIV challenge in chickens. The flagellin-NG34/CSI7 vaccine protected the vaccinated chickens and blocked viral shedding orally and cloacally. Furthermore, no apparent clinical signs were monitored in 10/12 vaccinated individuals. The mechanism of protection conferred is under investigation. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Sistere-Oro, Marta; Solanes, David; Lopez-Serrano, Sergi; Cordoba, Lorena; Cordon, Ivan; Darji, Ayub] UAB, Ctr Recerca Sanitat Anim, IRTA, Campus Univ Autonoma Barcelona, Barcelona 08193, Spain.
   [Martinez-Pulgarin, Susana; Escribano, Jose M.] Univ Politecn Madrid, Ctr Empresarial, Alternat Gene Express SL ALGENEX, Parque Cient & Tecnol,Campus Montegancedo, Pozuelo De Alarcon 28223, Spain.
   [Veljkovic, Veljko] Biomed Protect, Galveston, TX 77550 USA.
RP Darji, A (reprint author), UAB, Ctr Recerca Sanitat Anim, IRTA, Campus Univ Autonoma Barcelona, Barcelona 08193, Spain.
EM david.solanes@irta.cat; sergi.lopez@irta.cat; lorena.cordoba@irta.cat;
   ivan.cordon@irta.cat; ayub.darji@irta.cat
FU company Alternative Gene Expression SL (ALGENEX)
   [191008-SER-IRTA-0001-AGR]; Spanish Government, Ministerio de Economia y
   Competitividad de Espana (MINECO) [AGL2013-48923-C2-2-R]; Ministry of
   Education, Science and Technological Development of the Republic of
   Serbia [173001]; European Comission (EC) under Horizon 2020
   [Transvac2-730964-INFRAIA-2016-1]; CERCA Programme/Generalitat de
   Catalunya
FX The present work was supported by funds from the company Alternative
   Gene Expression SL (ALGENEX), contract: 191008-SER-IRTA-0001-AGR.
   Furthermore, it was funded in part by the Spanish Government, Ministerio
   de Economia y Competitividad de Espana (MINECO), project:
   AGL2013-48923-C2-2-R. Other funds were also received from the Ministry
   of Education, Science and Technological Development of the Republic of
   Serbia (Grant No. 173001) and by the collaborative infrastructure
   project funded by the European Comission (EC) under Horizon 2020,
   project Transvac2-730964-INFRAIA-2016-1. IRTA is supported by CERCA
   Programme/Generalitat de Catalunya.
CR Abe Y, 2004, J VIROL, V78, P9605, DOI 10.1128/JVI.78.18.9605-9611.2004
   Astill J, 2018, VIRAL IMMUNOL, V31, P605, DOI 10.1089/vim.2018.0072
   Bianchi E, 2005, J VIROL, V79, P7380, DOI 10.1128/JVI.79.12.7380-7388.2005
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Busquets N, 2010, VET RES, V41, DOI 10.1051/vetres/2010046
   Co MDT, 2012, HUM VACC IMMUNOTHER, V8, P1218, DOI 10.4161/hv.21025
   Cox MMJ, 2005, CURR OPIN MOL THER, V7, P24
   Cox RJ, 2009, INFLUENZA OTHER RESP, V3, P107, DOI 10.1111/j.1750-2659.2009.00082.x
   Dunand CJH, 2016, CELL HOST MICROBE, V19, P800, DOI 10.1016/j.chom.2016.05.014
   Gerdil C, 2003, VACCINE, V21, P1776, DOI 10.1016/S0264-410X(03)00071-9
   Gomez-Sebastian S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096562
   Horvath A, 1998, IMMUNOL LETT, V60, P127, DOI 10.1016/S0165-2478(97)00137-5
   Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062
   Huleatt JW, 2007, VACCINE, V25, P763, DOI 10.1016/j.vaccine.2006.08.013
   Jadhao SJ, 2010, AVIAN DIS, V54, P302, DOI 10.1637/8926-051509-ResNote.1
   Kamal RP, 2017, J VIROL, V91, DOI 10.1128/JVI.01202-17
   Krammer F, 2014, J VIROL, V88, P3976, DOI 10.1128/JVI.03095-13
   Liu FX, 2013, COMP IMMUNOL MICROB, V36, P343, DOI 10.1016/j.cimid.2013.02.002
   Liu Yi, 2007, V388, P267
   Malik P. J. S., 2009, REV SCI TECH, V28, P161, DOI DOI 10.20506/RST.28.1.1871
   Manicassamy B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000745
   Matrosovich M, 2000, J VIROL, V74, P8502, DOI 10.1128/JVI.74.18.8502-8512.2000
   OIE, 2012, MANUAL DIAGNOSTIC TE
   Reber A, 2013, EXPERT REV VACCINES, V12, P519, DOI [10.1586/erv.13.35, 10.1586/ERV.13.35]
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Sistere-Oro M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212431
   Skountzou I, 2014, CLIN VACCINE IMMUNOL, V21, P1481, DOI 10.1128/CVI.00374-14
   Song L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01846
   Ushirogawa H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1738-1
   Vergara-Alert J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040524
   Waffarn EE, 2011, J IMMUNOL, V186, P3823, DOI 10.4049/jimmunol.1002090
   Wilson JR, 2015, VIROLOGY, V485, P252, DOI 10.1016/j.virol.2015.08.004
NR 32
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 416
EP 422
DI 10.1016/j.vaccine.2019.11.006
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900002
PM 31735501
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Berenson, AB
   Hirth, JM
   Southerland, JH
AF Berenson, Abbey B.
   Hirth, Jacqueline M.
   Southerland, Janet H.
TI Knowledge of human papillomavirus among dental providers: A mixed
   methods study
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Dentists; Dental hygienists; Oropharyngeal cancer;
   HPV vaccine
ID VACCINATION; DENTISTS; CANCER; STAGE
AB Dental professionals are encouraged by the American Dental Association (ADA) to recommend the HPV vaccine to eligible patients. To better understand their comfort level in following this recommendation, we conducted a mixed methods study of dentists and dental hygienists. A total of 173 providers were surveyed and 8 interviewed. The majority felt they had an important role in preventing HPV-related OPC and that they should educate their patients and encourage HPV vaccination. However, most providers had low knowledge about HPV and expressed a need to obtain more information on the topic. In particular, they desired information about the HPV vaccine, its connection to cancer and where to refer patients for vaccination. They also wanted access to visual aids to help them bring up the topic. This study demonstrates the need to develop and disseminate educational programs for dental providers so they can assist with efforts to raise HPV vaccination rates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Berenson, Abbey B.; Hirth, Jacqueline M.] Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Dept Obstet & Gynecol, Galveston, TX 77555 USA.
   [Southerland, Janet H.] Univ Texas Med Branch, Inst Effectiveness & Hlth Educ Ctr, Interprofess Educ, Galveston, TX 77555 USA.
RP Berenson, AB (reprint author), Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Dept Obstet & Gynecol, Interprofess Educ Inst Effectiveness & Hlth Educ, 301 Univ Blvd, Galveston, TX 77555 USA.
EM abberens@utmb.edu
CR Arora Shelly, 2018, J Oral Biol Craniofac Res, V8, P35, DOI 10.1016/j.jobcr.2017.12.002
   Blackman E, 2013, INFECT DIS OBSTET GY, V2013
   Bratic JS, 2016, CURR OPIN PEDIATR, V28, P407, DOI 10.1097/MOP.0000000000000353
   Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403
   Daley E, 2014, PUBLIC HEALTH, V128, P231, DOI 10.1016/j.puhe.2013.12.002
   Daley E, 2011, J PUBLIC HEALTH DENT, V71, P136, DOI 10.1111/j.1752-7325.2011.00212.x
   Daley EM, 2018, J CANCER EDUC, V33, P901, DOI 10.1007/s13187-016-1156-5
   Dorell CG, 2011, PEDIATRICS, V128, P830, DOI 10.1542/peds.2011-0950
   Gilkey MB, 2015, CANCER EPIDEM BIOMAR, V24, P1673, DOI 10.1158/1055-9965.EPI-15-0326
   Holmes JD, 2003, J ORAL MAXIL SURG, V61, P285, DOI 10.1053/joms.2003.50056
   Hosking YP, 2017, PEDIATR DENT, V39, P383
   Kahn JA, 2007, AMBUL PEDIATR, V7, P367, DOI 10.1016/j.ambp.2007.05.010
   Kepka Deanna, 2019, Prev Med Rep, V15, P100957, DOI 10.1016/j.pmedr.2019.100957
   Kline N, 2018, PAPILLOMAVIRUS RES, V5, P104, DOI 10.1016/j.pvr.2018.03.002
   Langevin SM, 2012, CANCER CAUSE CONTROL, V23, P1821, DOI 10.1007/s10552-012-0061-4
   Manchir MADA, 2018, AM DENT ASS
   Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI 10.15585/mmwr.mm6832a3
   Shepperd JA, 2013, AM J HEALTH BEHAV, V37, P755, DOI 10.5993/AJHB.37.6.4
   Stull Cynthia L, 2019, J Dent Hyg, V93, P33
   Thompson Erika L, 2017, J Dent Hyg, V91, P37
   Vazquez-Otero C, 2018, J AM DENT ASSOC, V149, P9, DOI 10.1016/j.adaj.2017.08.021
   Viens LJ, 2016, MMWR-MORBID MORTAL W, V65, P661, DOI 10.15585/mmwr.mm6526a1
   Walker KK, 2019, HUMAN VACC IMMUNO, P1
   Warner EL, 2017, JMIR CANCER, V3, DOI 10.2196/cancer.7345
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 423
EP 426
DI 10.1016/j.vaccine.2019.10.068
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900003
PM 31690468
DA 2020-05-12
ER

PT J
AU Brousseau, N
   Skowronski, DM
   Bellemare, D
   Amini, R
   Joffres, Y
   Clarke, Q
   Quach, C
   Rallu, F
   Hoang, LD
   De Serres, G
AF Brousseau, Nicholas
   Skowronski, Danuta M.
   Bellemare, David
   Amini, Rachid
   Joffres, Yayuk
   Clarke, Quinten
   Quach, Caroline
   Rallu, Fabien
   Hoang, Linda
   De Serres, Gaston
TI Impact of the adolescent pertussis booster dose on the incidence of
   pertussis in British Columbia and Quebec, Canada
SO VACCINE
LA English
DT Article
DE Immunization; Vaccination; Pertussis; Whooping cough; Acellular
   pertussis vaccine; Adolescent booster dose
ID VACCINE; AGE
AB Impact of an adolescent tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine program was assessed in the provinces of British Columbia and Quebec, Canada. In both provinces, the Tdap booster has been in place since 2004, targeting Grade 9 students (14-15-years-of-age). Incidence rate ratios (IRRs) standardizing notification rates among teens 15-19-years-old to infants <1-year-old decreased following introduction of the Tdap program and were significantly halved during the 2009-2012 post-Tdap versus 2000-2003 pre-Tdap period. This program impact, however, is tempered by the observation that pertussis incidence among 15-19-year-olds was already lower than any other pediatric age group, following gradual decline from pre-teen rates even before the Tdap program. The risk of hospitalization among adolescents 15-19-years-old was also low throughout at <1/100,000. Furthermore, IRRs increased in 2013-2017 when an increasing proportion of 15-19-year-olds were primed with acellular pertussis vaccine only, suggesting short-lived Tdap booster-dose effectiveness that warrants further monitoring. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Brousseau, Nicholas; Amini, Rachid; De Serres, Gaston] Inst Natl Sante Publ Quebec, Risques Biol & Sante Travail, Quebec City, PQ G1V 5B3, Canada.
   [Brousseau, Nicholas; Bellemare, David; De Serres, Gaston] Univ Laval, Dept Med Sociale & Prevent, Laval, PQ G1V 0A6, Canada.
   [Skowronski, Danuta M.; Joffres, Yayuk; Clarke, Quinten] BC Ctr Dis Control, Communicable Dis & Immunizat Serv, Vancouver, BC V5Z 4R4, Canada.
   [Skowronski, Danuta M.] Univ British Columbia, Sch Populat & Publ Hlth, Dept Med, Vancouver, BC V6T 1Z3, Canada.
   [Quach, Caroline; Rallu, Fabien] Univ Montreal, Dept Microbiol Infect Dis & Immunol, Montreal, PQ H3T 1J4, Canada.
   [Quach, Caroline; Rallu, Fabien] CHU St Justine, Div Paediat Infect Dis, Montreal, PQ H3T 1C5, Canada.
   [Quach, Caroline; Rallu, Fabien] CHU St Justine, Dept Med Microbiol, Montreal, PQ H3T 1C5, Canada.
   [Hoang, Linda] BC Ctr Dis Control, Publ Hlth Lab, Vancouver, BC V5Z 4R4, Canada.
   [Hoang, Linda] Univ British Columbia, Dept Med, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada.
RP Brousseau, N (reprint author), Inst Natl Sante Publ Quebec, 2400 Estimauville, Quebec City, PQ G1E 7G9, Canada.
EM nicholas.brousseau.ciussscn@ssss.gouv.qc.ca
OI Quach, Caroline/0000-0002-1170-9475
CR Amirthalingam G, 2013, ARCH DIS CHILD, V98, P552, DOI 10.1136/archdischild-2012-302968
   BentsiEnchill AD, 1997, VACCINE, V15, P301, DOI 10.1016/S0264-410X(96)00176-4
   Canadian Institute for Health Information, 2019, DISCH ABSTR DAT HOSP
   Chambers C, 2014, Can Commun Dis Rep, V40, P31
   Cherry JD, 2006, PEDIATR INFECT DIS J, V25, P361, DOI 10.1097/01.inf.0000210478.60841.69
   Chit A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197970
   Choi YH, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0665-8
   Committee to Advise on Tropical Medicine and Travel (CATMAT), 2009, Can Commun Dis Rep, V35 Suppl 1, P1
   Diavatopoulos DA, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029553
   Direction de la gestion des donnees et des outils de diffusion de ('information statistique, 2018, MAINT EXPL DONN ET C, P2018
   Gambhir M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004138
   Halperin SA, 2005, PEDIATR INFECT DIS J, V24, pS141, DOI 10.1097/01.inf.0000166163.02135.8b
   Ntezayabo B, 2003, PEDIATR INFECT DIS J, V22, P22, DOI 10.1097/00006454-200301000-00009
   Public Health Agency of Canada, 2005, CAN COMMUN DIS REP, V3452, P1
   Schwartz KL, 2016, CAN MED ASSOC J, V188, pE399, DOI 10.1503/cmaj.160193
   Skoff TH, 2016, JAMA PEDIATR, V170, P453, DOI 10.1001/jamapediatrics.2015.4875
   Skowronski DM, 2012, CLIN INFECT DIS, V54, P318, DOI 10.1093/cid/cir836
   Skowronski DM, 2002, J INFECT DIS, V185, P1448, DOI 10.1086/340280
   van Hoek AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076180
   Warfel JM, 2014, P NATL ACAD SCI USA, V111, P787, DOI 10.1073/pnas.1314688110
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 427
EP 432
DI 10.1016/j.vaccine.2019.10.063
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900004
PM 31685295
OA Other Gold
DA 2020-05-12
ER

PT J
AU Frascella, B
   Oradini-Alacreu, A
   Balzarini, F
   Signorelli, C
   Lopalco, PL
   Odone, A
AF Frascella, Beatrice
   Oradini-Alacreu, Aurea
   Balzarini, Federica
   Signorelli, Carlo
   Lopalco, Pier Luigi
   Odone, Anna
TI Effectiveness of email-based reminders to increase vaccine uptake: a
   systematic review
SO VACCINE
LA English
DT Review
DE Systematic review; Immunisation; Vaccination uptake; Vaccination
   reminders; Email; Digital health
ID INFLUENZA VACCINATION; COMMUNICATION TECHNOLOGIES; INFORMATION;
   INTERVENTIONS; ADOLESCENTS; COMPLETION; COVERAGE; PREFERENCES; DEFAULT;
   RATES
AB Background: In times of vaccine hesitancy and decreasing immunization coverage, it is crucial to exploit the potential of digital solutions to support immunization programmes and ultimately increase vaccine uptake. Scant evidence exists on the impact of email-based immunization reminders. In particular, while email communication is exponentially increasing at the global level, its use for health communication is still sporadic and limited data exists on its application to immunization programmes. The objective of this study is to systematically retrieve and critically appraise the available literature on the effectiveness of email-based reminders to increase vaccine uptake, with the ultimate aim to inform and encourage its integration in the implementation of immunization programmes.
   Methods: We conducted a systematic review of literature following the PRISMA. We included studies providing quantitative comparative data on any measure of vaccine uptake. We extracted data on study design, study population, vaccine type and details of email-based interventions; data were pooled by type of comparison (no reminders, traditional reminders, other digital reminders).
   Results: Eleven studies were included, 90% with experimental study designs. While email communication succeeds in increasing vaccine uptake when compared with no intervention, weak and heterogeneous data exist supporting the superiority of email reminders, as compared to traditional methods or other digital reminders. Encouraging evidence report the effectiveness of reminder methods combining different strategies and tailored to target populations' preferences.
   Conclusions: Theoretically, email communication offers many advantages: it is cheaper and faster, it can be automated and linked to electronic immunization registries, and reach people on the move. As we urge the need for further research to prove email communication impact on vaccine uptake in different settings, we underline the importance of identifying how to best integrate email communication in vaccine delivery equipping immunization programmes with technical infrastructures and normative frameworks suitable to embrace innovation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Frascella, Beatrice; Oradini-Alacreu, Aurea; Balzarini, Federica; Signorelli, Carlo; Odone, Anna] Univ Vita Salute San Raffaele, Fac Med, Sch Publ Hlth, Via Olgettina 58, I-20132 Milan, Italy.
   [Lopalco, Pier Luigi] Univ Pisa, Dept Translat Res, New Technol Med & Surg, Pisa, Italy.
RP Odone, A (reprint author), Univ Vita Salute San Raffaele, Fac Med, Sch Publ Hlth, Via Olgettina 58, I-20132 Milan, Italy.
EM odone.anna@hsr.it
OI Balzarini, Federica/0000-0002-2104-8471; Oradini-Alacreu,
   Aurea/0000-0003-2975-6859
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX Part of the funding for this study was provided by GlaxoSmithKline
   Biologicals SA.
CR Addona V, 2012, INT J BIOSTAT, V8, DOI 10.1515/1557-4679.1419
   Amicizia D, 2013, HUM VACC IMMUNOTHER, V9, P2634, DOI 10.4161/hv.26010
   [Anonymous], 13 GEN PROGR WORK 20
   Atkinson KM, 2019, VACCINE, V37, P3050, DOI 10.1016/j.vaccine.2019.03.063
   Baskin E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192594
   Cadena J, 2011, INFECT CONT HOSP EP, V32, P616, DOI 10.1086/660198
   Chapman GB, 2010, JAMA-J AM MED ASSOC, V304, P43, DOI 10.1001/jama.2010.892
   Clark SJ, 2011, PEDIATRICS, V128, pE1100, DOI 10.1542/peds.2011-0270
   CPSTF Community Preventive Services Task Force, 2015, VACC PROGR CLIENT RE
   CPSTF Community Preventive Services Task Force, 2015, VACC PROGR PRIV REM
   Dombkowski KJ, 2017, VACCINE, V35, P3089, DOI 10.1016/j.vaccine.2017.04.033
   Francis DB, 2017, PATIENT EDUC COUNS, V100, P1280, DOI 10.1016/j.pec.2017.02.004
   Ghadieh AS, 2015, VACCINE, V33, P5868, DOI 10.1016/j.vaccine.2015.07.050
   Goyder C, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007979.pub3
   Groom H, 2015, J PUBLIC HEALTH MAN, V21, P227, DOI 10.1097/PHH.0000000000000069
   Halpern SD, 2007, NEW ENGL J MED, V357, P1340, DOI 10.1056/NEJMsb071595
   Harvey H, 2015, VACCINE, V33, P2862, DOI 10.1016/j.vaccine.2015.04.085
   HIGGINS JPT, 2011, BMJ BRIT MED J, V343
   Jacob V, 2016, AM J PREV MED, V50, P797, DOI 10.1016/j.amepre.2015.11.003
   Kang GJ, 2017, VACCINE, V35, P1987, DOI 10.1016/j.vaccine.2017.03.014
   Kempe A, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2857
   Lehmann BA, 2016, VACCINE, V34, P1389, DOI 10.1016/j.vaccine.2016.01.046
   Llupia A, 2010, AM J INFECT CONTROL, V38, P476, DOI 10.1016/j.ajic.2010.01.013
   LoMurray K, 2011, PUBLIC HEALTH REP, V126, P78, DOI 10.1177/00333549111260S210
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Morris J, 2015, J ADOLESCENT HEALTH, V56, pS27, DOI 10.1016/j.jadohealth.2015.01.010
   Nehme EK, 2019, AM J HEALTH PROMOT, V33, P916, DOI 10.1177/0890117118823157
   NHLBI National Heart Lung and Blood Institute, 2014, QUAL ASS TOOL PREP S
   Niccolai LM, 2015, JAMA PEDIATR, V169, P686, DOI 10.1001/jamapediatrics.2015.0310
   Odone A, 2017, VACCINE, V35, P1209, DOI 10.1016/j.vaccine.2015.11.051
   Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313
   Ozawa S, 2018, VACCINE, V36, P3641, DOI 10.1016/j.vaccine.2018.05.030
   Patel A, 2014, VACCINE, V32, P2428, DOI 10.1016/j.vaccine.2014.02.095
   Quan KA, 2014, INFECT CONT HOSP EP, V35, P1421, DOI 10.1086/678415
   Ramaswami R, 2018, ANNU REV PUBL HEALTH, V39, P153, DOI 10.1146/annurev-publhealth-040617-014158
   Rand CM, 2015, J ADOLESCENT HEALTH, V57, P299, DOI 10.1016/j.jadohealth.2015.06.006
   Richman AR, 2016, J AM COLL HEALTH, V64, P269, DOI 10.1080/07448481.2015.1117466
   Sackey DM, 2018, INT J INTEGR CARE, V18, DOI 10.5334/ijic.s1079
   Shojania KG, 2009, COCHRANE DATABASE SY, V3
   Signorelli C, 2018, LANCET INFECT DIS, V18, P26, DOI 10.1016/S1473-3099(17)30696-5
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Stockwell MS, 2013, HUM VACC IMMUNOTHER, V9, P1802, DOI 10.4161/hv.25031
   Szilagyi PG, 2018, J ADOLESCENT HEALTH, V62, P157, DOI 10.1016/j.jadohealth.2017.09.021
   Szilagyi PG, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1746
   Thomas RE, 2014, COCHRANE DB SYST REV, V7
   Watterson JL, 2015, BIOMED RES INT, DOI 10.1155/2015/153402
NR 47
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 433
EP 443
DI 10.1016/j.vaccine.2019.10.089
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900005
PM 31806532
DA 2020-05-12
ER

PT J
AU Tadount, F
   Doyon-Plourde, P
   Rafferty, E
   MacDonald, S
   Sadarangani, M
   Quach, C
AF Tadount, Fazia
   Doyon-Plourde, Pamela
   Rafferty, Ellen
   MacDonald, Shannon
   Sadarangani, Manish
   Quach, Caroline
TI Is there a difference in the immune response, efficacy, effectiveness
   and safety of seasonal influenza vaccine in males and females? - A
   systematic review
SO VACCINE
LA English
DT Review
DE Influenza; Vaccines; Sex differences; Immunity; Safety
ID GUILLAIN-BARRE-SYNDROME; ADULTS 65 YEARS; SEX-DIFFERENCES; ADVERSE
   EVENTS; CONTROLLED-TRIAL; ELDERLY-PEOPLE; IMMUNOGENICITY; AGE;
   HOSPITALIZATIONS; OLDER
AB Introduction: Seasonal influenza is an important cause of morbidity and mortality, despite being vaccine-preventable. Sex factors (genes and hormones) seem to impact individuals' susceptibility to infectious diseases and their response to vaccination. However, most vaccine studies do not explicitly assess sex differences in vaccine response, but rather adjust for sex.
   Methods: We conducted a systematic review to analyze immunogenicity, efficacy, effectiveness and/or safety of seasonal influenza vaccine data stratified by sex. We searched PubMed, EMBASE, CINAHL, Web of Science and clinicaltrials.gov for observational studies and phase III/IV trials from January 1990 to June 2018, published in English or French. Two reviewers independently screened all references, then proceeded to data extraction and quality assessment using the Cochrane tools (RoB and ROBINS-I) on included studies.
   Results: Of the 5,745 citations retrieved, 46 studies were included in the SR Overall, 18 studies assessed immunogenicity, 1 estimated efficacy, 6 measured effectiveness and 25 evaluated safety of seasonal influenza vaccine in females and males (four studies reported on two sex-stratified outcomes concomitantly).
   Conclusion: No clear conclusion could be drawn regarding the effect of sex on the immunogenicity and effectiveness of seasonal influenza vaccine, but higher rates of adverse events following immunization (AEFIs) were reported in females. The heterogeneity of data and studies' low quality prevented us from conducting a meta-analysis. There is a need to emphasize on the appropriate use of the terms sex and gender in biomedical research. Evidence of higher quality is needed to better understand sex differences in response to influenza vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tadount, Fazia; Doyon-Plourde, Pamela; Quach, Caroline] Univ Montreal, Fac Med, Dept Microbiol Infect Dis & Immunol, Montreal, PQ, Canada.
   [Tadount, Fazia; Doyon-Plourde, Pamela; Quach, Caroline] CHU St Justine, Res Inst, Montreal, PQ, Canada.
   [Rafferty, Ellen; MacDonald, Shannon] Univ Alberta, Fac Nursing, Edmonton, AB, Canada.
   [Sadarangani, Manish] BC Childrens Hosp Res Inst, Vaccine Evaluat Ctr, Vancouver, BC, Canada.
   [Sadarangani, Manish] Univ British Columbia, Dept Pediat, Div Infect Dis, Vancouver, BC, Canada.
   [Quach, Caroline] CHU St Justine, Dept Pediat Lab Med, Montreal, PQ, Canada.
   [Quach, Caroline] CHU St Justine, Infect Prevent & Control, Montreal, PQ, Canada.
RP Quach, C (reprint author), Univ Montreal, Dept Microbiol Infect Dis & Immunol, CHU St Justine, 3175 Ch Cote St Catherine, Montreal, PQ H3T 1C5, Canada.
EM c.quach@umontreal.ca
OI Quach, Caroline/0000-0002-1170-9475
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR)
FX This work was funded by a grant from the Canadian Institutes of Health
   Research (CIHR).
CR Ambrose CS, 2013, VACCINE, V31, P857, DOI 10.1016/j.vaccine.2012.12.028
   Barrett PN, 2011, LANCET, V377, P751, DOI 10.1016/S0140-6736(10)62228-3
   Bernin H, 2014, J INFECT DIS, V209, pS107, DOI 10.1093/infdis/jit610
   Boulianne N, 2001, Can Commun Dis Rep, V27, P85
   Bragstad K, 2013, EUROSURVEILLANCE, V18, P11
   Bupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01269
   Burwen DR, 2010, AM J PREV MED, V39, P296, DOI 10.1016/j.amepre.2010.05.022
   Carmen Giefing-Kro PB Gunter, 2015, SEX AGE AFFECT IMMUN
   Centers for Disease Control and Prevention, 2018, EST INFL ILLN MED VI
   Coleman BL, 2015, VACCINE, V33, P6635, DOI 10.1016/j.vaccine.2015.10.095
   Coleman BL, 2012, VACCINE, V30, P6287, DOI 10.1016/j.vaccine.2012.08.006
   Cook IF, 2009, HUM VACCINES, V5, P441, DOI 10.4161/hv.8476
   Cook IF, 2006, VACCINE, V24, P2395, DOI 10.1016/j.vaccine.2005.11.057
   Crighton EJ, 2007, EPIDEMIOL INFECT, V135, P253, DOI 10.1017/S095026880600690X
   D'Alessandro D, 2004, INDIAN J MED RES, V119, P108
   De Serres G, 2003, VACCINE, V21, P2346, DOI 10.1016/S0264-410X(03)00095-1
   Dunkle LM, 2017, J INFECT DIS, V216, P1219, DOI 10.1093/infdis/jix478
   Emborg HD, 2016, EUROSURVEILLANCE B E, V21
   Engler RJM, 2008, ARCH INTERN MED, V168, P2405, DOI 10.1001/archinternmed.2008.513
   Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790
   Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718
   Fraund S, 1999, J HEART LUNG TRANSPL, V18, P220, DOI 10.1016/S1053-2498(98)00013-8
   Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111
   Galdas PM, 2005, J ADV NURS, V49, P616, DOI 10.1111/j.1365-2648.2004.03331.x
   Gauthey L, 1996, ANN MED INTERNE, V147, P10
   Ghosh S, 2017, J IMMUNOL, V198, P1782, DOI 10.4049/jimmunol.1601166
   Gilca R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132195
   Gorse GJ, 2015, VACCINE, V33, P1151, DOI 10.1016/j.vaccine.2015.01.025
   GOVAERT TME, 1994, VACCINE, V12, P1185, DOI 10.1016/0264-410X(94)90241-0
   GOVAERT TME, 1993, BMJ-BRIT MED J, V307, P988, DOI 10.1136/bmj.307.6910.988
   Guerra-Silveira F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062390
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Hagihara Y, 2014, J CROHNS COLITIS, V8, P223, DOI 10.1016/j.crohns.2013.08.008
   Hajiabdolbaghi M, 2009, IRAN J PUBLIC HEALTH, V38, P51
   Hajiabdolbaghi Mahboube, 2010, Acta Med Iran, V48, P95
   Hara M, 2016, J EPIDEMIOL, V26, P300, DOI 10.2188/jea.JE20150036
   Higgins JPT, 2016, COCHRANE METHODS COC, P2016
   Hopping AM, 2016, VACCINE, V34, P540, DOI 10.1016/j.vaccine.2015.11.058
   Honkanen PO, 1996, ARCH INTERN MED, V156, P205, DOI 10.1001/archinte.156.2.205
   Jackson LA, 2001, VACCINE, V19, P4703, DOI 10.1016/S0264-410X(01)00225-0
   Jackson LA, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-71
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   Jager KJ, 2008, KIDNEY INT, V73, P256, DOI 10.1038/sj.ki.5002650
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2014, J INFECT DIS, V209, pS114, DOI 10.1093/infdis/jiu066
   Klein SL, 2010, SEX GENDER INFLUENZA
   Kwong JC, 2013, CLIN INFECT DIS, V57, P820, DOI 10.1093/cid/cit404
   Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501
   Last J. M., 2001, DICT EPIDEMIOLOGY
   Looker C, 2014, TOXICOL SCI, V138, P76, DOI 10.1093/toxsci/kft269
   Markle JG, 2014, TRENDS IMMUNOL, V35, P97, DOI 10.1016/j.it.2013.10.006
   Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310
   McEvoy SP, 2012, VACCINE, V30, P2801, DOI 10.1016/j.vaccine.2011.09.001
   Mori M, 2008, VACCINE, V26, P6459, DOI 10.1016/j.vaccine.2008.06.040
   Moynihan JA, 2004, PSYCHOSOM MED, V66, P950, DOI 10.1097/01.psy.0000140001.49208.2d
   Nakaya HI, 2015, IMMUNITY, V43, P1186, DOI 10.1016/j.immuni.2015.11.012
   Naz H, 2009, J INFECT DEV COUNTR, V3, P50, DOI 10.3855/jidc.105
   Olafsdottir TA, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01872
   Phengxay M, 2015, INFLUENZA OTHER RESP, V9, P94, DOI 10.1111/irv.12299
   Potluri T, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0124-6
   Quach C, 2003, PEDIATRICS, V112, pE197, DOI 10.1542/peds.112.3.e197
   Rapezzi D, 2003, EUR J HAEMATOL, V70, P225, DOI 10.1034/j.1600-0609.2003.00028.x
   Rivera L, 2012, VACCINE, V30, P5285, DOI 10.1016/j.vaccine.2012.05.021
   Robb H, 1996, MIL MED, V161, P29
   Sanyal M, 2019, J INFECT DIS, V219, P1586, DOI 10.1093/infdis/jiy685
   Scheifele DW, 2003, CLIN INFECT DIS, V36, P850, DOI 10.1086/368189
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Sex Oakley A., 1991, SEX OAKL
   Spila-Alegiani S, 1999, VACCINE, V17, P1898, DOI 10.1016/S0264-410X(98)00467-8
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Strindhall J, 2016, INFECT DIS-NOR, V48, P436, DOI 10.3109/23744235.2015.1135252
   Talbot HK, 2011, J INFECT DIS, V203, P500, DOI 10.1093/infdis/jiq076
   Trebbien R, 2017, J CLIN VIROL, V94, P1, DOI 10.1016/j.jcv.2017.06.007
   van Balveren-Slingerland L, 2015, VACCINE, V33, P2283, DOI 10.1016/j.vaccine.2015.03.014
   Voigt EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00180
   vom Steeg LG, 2019, SEMIN IMMUNOPATHOL, V41, P189, DOI 10.1007/s00281-018-0718-5
   Welch V, 2017, Res Integr Peer Rev, V2, P15, DOI 10.1186/s41073-017-0039-6
   World Health Organization, 2018, INFL SEAS
   Zheng Y, 2018, HUM VACC IMMUNOTHER, V14, P671, DOI 10.1080/21645515.2017.1390638
NR 79
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 444
EP 459
DI 10.1016/j.vaccine.2019.10.091
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900006
PM 31711676
DA 2020-05-12
ER

PT J
AU Hughes, SL
   Bolotin, S
   Khan, S
   Li, Y
   Johnson, C
   Friedman, L
   Tricco, AC
   Hahne, SJM
   Heffernan, JM
   Dabbagh, A
   Durrheim, DN
   Orenstein, WA
   Moss, WJ
   Jit, M
   Crowcroft, NS
AF Hughes, Stephanie L.
   Bolotin, Shelly
   Khan, Sumaiya
   Li, Ye
   Johnson, Caitlin
   Friedman, Lindsay
   Tricco, Andrea C.
   Hahne, Susan J. M.
   Heffernan, Jane M.
   Dabbagh, Alya
   Durrheim, David N.
   Orenstein, Walter A.
   Moss, William J.
   Jit, Mark
   Crowcroft, Natasha S.
TI The effect of time since measles vaccination and age at first dose on
   measles vaccine effectiveness - A systematic review
SO VACCINE
LA English
DT Review
DE Measles; Vaccine effectiveness; Waning immunity; Eliminated; Endemic;
   Immunisation
ID IMMUNIZATION STRATEGIES; ANTIBODY-LEVELS; EPIDEMIC; EFFICACY; OUTBREAK;
   CHILDREN; ELIMINATION; IMMUNITY; POPULATION; STANDARD
AB Background: In settings where measles has been eliminated, vaccine-derived immunity may in theory wane more rapidly due to a lack of immune boosting by circulating measles virus. We aimed to assess whether measles vaccine effectiveness (VE) waned over time, and if so, whether differentially in measles-eliminated and measles-endemic settings.
   Methods: We performed a systematic literature review of studies that reported VE and time since vaccination with measles-containing vaccine (MCV). We extracted information on case definition (clinical symptoms and/or laboratory diagnosis), method of vaccination status ascertainment (medical record or vaccine registry), as well as any biases which may have arisen from cold chain issues and a lack of an age at first dose of MCV. We then used linear regression to evaluate VE as a function of age at first dose of MCV and time since MCV.
   Results: After screening 14,782 citations, we identified three full-text articles from measles-eliminated settings and 33 articles from measles-endemic settings. In elimination settings, two-dose VE estimates increased as age at first dose of MCV increased and decreased as time since MCV increased; however, the small number of studies available limited interpretation. In measles-endemic settings, one-dose VE increased by 1.5% (95% CI 0.5, 2.5) for every month increase in age at first dose of MCV. We found no evidence of waning VE in endemic settings.
   Conclusions: The paucity of data from measles-eliminated settings indicates that additional studies and approaches (such as studies using proxies including laboratory correlates of protection) are needed to answer the question of whether VE in measles-eliminated settings wanes. Age at first dose of MCV was the most important factor in determining VE. More VE studies need to be conducted in elimination settings, and standards should be developed for information collected and reported in such studies. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Hughes, Stephanie L.; Bolotin, Shelly; Khan, Sumaiya; Li, Ye; Johnson, Caitlin; Friedman, Lindsay; Crowcroft, Natasha S.] Publ Hlth Ontario, Toronto, ON, Canada.
   [Bolotin, Shelly; Li, Ye; Tricco, Andrea C.; Crowcroft, Natasha S.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Bolotin, Shelly; Crowcroft, Natasha S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Tricco, Andrea C.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Hahne, Susan J. M.] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Bilthoven, Netherlands.
   [Heffernan, Jane M.] York Univ, Ctr Dis Modelling, Dept Math & Stat, Toronto, ON, Canada.
   [Dabbagh, Alya] WHO, Dept Immunisat Vaccines & Biol, Geneva, Switzerland.
   [Durrheim, David N.] Hunter New England Hlth, New Lambton Hts, NSW, Australia.
   [Durrheim, David N.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia.
   [Durrheim, David N.] James Cook Univ, Publ Hlth & Trop Med, Townsville, Qld, Australia.
   [Orenstein, Walter A.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Orenstein, Walter A.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.
   [Moss, William J.] Johns Hopkins Univ, Int Vaccine Access Ctr, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Jit, Mark] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London, England.
   [Jit, Mark] Publ Hlth England, Modelling & Econ Unit, London, England.
   [Crowcroft, Natasha S.] ICES, Toronto, ON, Canada.
RP Crowcroft, NS (reprint author), Dalla Lana Sch Publ Hlth, 155 Coll St Room 500, Toronto, ON M5T 3M7, Canada.
EM natasha.crowcroft@utoronto.ca
RI Tricco, Andrea/B-9920-2011
OI Tricco, Andrea/0000-0002-4114-8971
FU World Health OrganizationWorld Health Organization
FX This study was supported by the World Health Organization.
CR [Anonymous], 1984, WKLY EPIDEMIOL REC, P127
   [Anonymous], 1986, WKLY EPIDEMIOL REC, P356, DOI [https://doi.org/10.5380/rf.v39il.13735., 10.5380/rf.v39il.13735, DOI 10.5380/RF.V39IL.13735]
   Barrabeig I, 2011, VACCINE, V29, P8024, DOI 10.1016/j.vaccine.2011.08.056
   Bhuniya Satinath, 2013, Indian J Public Health, V57, P272, DOI 10.4103/0019-557X.123273
   Bitzegeio J, 2019, EUROSURVEILLANCE, V24, P25, DOI 10.2807/1560-7917.ES.2019.24.17.1800529
   Breakwell L, 2015, MMWR-MORBID MORTAL W, V64, P1088, DOI 10.15585/mmwr.mm6438a7
   Centers for Disease Control and Prevention, 2019, MEAS CAS OUTBR MEAS
   CHEAH D, 1993, J PAEDIATR CHILD H, V29, P455
   Choe YJ, 2017, J KOREAN MED SCI, V32, P1876, DOI 10.3346/jkms.2017.32.11.1876
   Chung HJ, 2016, BMC INT HEALTH HUM R, V16, DOI 10.1186/s12914-016-0085-z
   Cochrane Methods, 2019, COCHRANE METHODS ROB
   Dabbagh A, 2017, MMWR-MORBID MORTAL W, V66, P1148, DOI 10.15585/mmwr.mm6642a6
   De Serres G, 2012, CLIN INFECT DIS, V55, P394, DOI 10.1093/cid/cis439
   Durrhelm DN, 2019, J INFECT DIS, DOI [10.1093/infdis/iiz01110.1080/02626667. 2015.1006226, DOI 10.1093/INFDIS/IIZ01110.1080/02626667.2015.1006226]
   Dyer O, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l739
   FERNANDES V, 1985, BRIT MED J, V291, P1685, DOI 10.1136/bmj.291.6510.1685
   Guerra FM, 2018, VACCINE, V36, P1248, DOI 10.1016/j.vaccine.2018.01.002
   Guris D, 1996, PEDIATR INFECT DIS J, V15, P1082, DOI 10.1097/00006454-199612000-00005
   Hahne SJM, 2016, J INFECT DIS, V214, P1980, DOI 10.1093/infdis/jiw480
   HARRISON GP, 1992, NEW ZEAL MED J, V105, P280
   Hennessey KA, 1999, AM J EPIDEMIOL, V150, P1250, DOI 10.1093/oxfordjournals.aje.a009952
   HULL HF, 1983, LANCET, V1, P972
   Hutchins SS, 2001, AM J EPIDEMIOL, V154, P1064, DOI 10.1093/aje/154.11.1064
   Janaszek W, 2003, VACCINE, V21, P473, DOI 10.1016/S0264-410X(02)00482-6
   John S, 2009, J TROP PEDIATRICS, V55, P253, DOI 10.1093/tropej/fmn079
   Kang HJ, 2017, VACCINE, V35, P4126, DOI 10.1016/j.vaccine.2017.06.058
   Kaninda AV, 1998, PEDIATR INFECT DIS J, V17, P1034, DOI 10.1097/00006454-199811000-00014
   KIM SK, 1995, PEDIATR INFECT DIS J, V14, P346, DOI 10.1097/00006454-199505000-00002
   Kontio M, 2016, J INFECT DIS, V213, P2005, DOI 10.1093/infdis/jiw058
   Kontio M, 2012, J INFECT DIS, V206, P1542, DOI 10.1093/infdis/jis568
   LAMB WH, 1988, REV INFECT DIS, V10, P457
   Lee J-K, 2007, Morbidity and Mortality Weekly Report, V56, P304
   Leuridan E, 2010, BRIT MED J, V340, P1123
   Lochlainn L.N., 2015, MEASLES VACCINATION
   LYONS RA, 1994, EPIDEMIOL INFECT, V113, P367, DOI 10.1017/S0950268800051797
   Mahomva A. I., 1997, Central African Journal of Medicine, V43, P254
   MALFAIT P, 1994, PEDIATR INFECT DIS J, V13, P38, DOI 10.1097/00006454-199401000-00009
   MARKOWITZ LE, 1992, J INFECT DIS, V166, P205, DOI 10.1093/infdis/166.1.205
   Martins C, 2014, J INFECT DIS, V210, P693, DOI 10.1093/infdis/jiu117
   Marufu T., 1995, Central African Journal of Medicine, V41, P241
   MCDONNELL LF, 1995, MED J AUSTRALIA, V162, P471, DOI 10.5694/j.1326-5377.1995.tb140008.x
   MCINTYRE RC, 1982, B WORLD HEALTH ORGAN, V60, P767
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Mossong J, 2003, VACCINE, V21, P4597, DOI 10.1016/S0264-410X(03)00449-3
   Mudzamiri W. S., 1996, Central African Journal of Medicine, V42, P195
   Muller CP, 2001, VACCINE, V19, P2258, DOI 10.1016/S0264-410X(00)00455-2
   Mupere E, 2006, VACCINE, V24, P4111, DOI 10.1016/j.vaccine.2006.02.038
   Nsubuga F, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-017-2941-4
   Ong Gary, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P96
   Pillsbury A, 2015, WEST PAC SURVEILL RE, V6, P43, DOI [10.5365/WPSAR.2015.6.2.007, 10.5365/wpsar.2015.6.2.007]
   Plotkin SA, 2018, PLOTKINS VACCINES
   Puri A, 2002, Indian Pediatr, V39, P556
   RAMSAY MEB, 1994, EPIDEMIOL INFECT, V112, P409, DOI 10.1017/S0950268800057824
   Redd SC, 2004, J INFECT DIS, V189, pS116, DOI 10.1086/378691
   Regional Office for Europe (EURO) World Health Organization (WHO), 2014, EL MEAS RUB FRAM VER
   ReliefWeb, 2019, MEASLES OUTBREAK DG
   Schmid D, 2010, EPIDEMIOL INFECT, V138, P415, DOI 10.1017/S0950268809990604
   SHARMA R S, 1988, Journal of Communicable Diseases, V20, P38
   Sheppeard V, 2009, COMMUN DIS INTELL, V33, P21
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Uzicanin A, 2011, J INFECT DIS, V204, pS133, DOI 10.1093/infdis/jir102
   Velicko I, 2008, VACCINE, V26, P6980, DOI 10.1016/j.vaccine.2008.09.012
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   World Health Organization, 2009, Vaccine, V27, P7219, DOI 10.1016/j.vaccine.2009.09.116
   World Health Organization, 2018, 4 HOC M TECHN ADV GR
   World Health Organization, 2009, INF YOUNG CHILD FEED, V155, DOI [10.1111/j.1740-8709.2009.00234.x, DOI 10.1111/J.1740-8709.2009.00234.X]
NR 66
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 460
EP 469
DI 10.1016/j.vaccine.2019.10.090
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900007
PM 31732326
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Guzman-Holst, A
   DeAntonio, R
   Prado-Cohrs, D
   Juliao, P
AF Guzman-Holst, Adriana
   DeAntonio, Rodrigo
   Prado-Cohrs, David
   Juliao, Patricia
TI Barriers to vaccination in Latin America: A systematic literature review
SO VACCINE
LA English
DT Review
DE Vaccine hesitancy; Latin America and Caribbean; Vaccination barriers;
   Vaccination coverage; Contextual influences; Individual/group
   influences; Vaccine/vaccination specific issues
ID HUMAN-PAPILLOMAVIRUS HPV; UNITED-STATES RECOMMENDATIONS; INFLUENZA-A
   H1N1; CHILDHOOD IMMUNIZATION; PREGNANT-WOMEN; SAO-PAULO; MISSED
   OPPORTUNITIES; HIGH PREVALENCE; URBAN AREA; COVERAGE
AB Current vaccination coverage rates in Latin America and the Caribbean (LAC) are lower than the region wide rates set by the Pan American Health Organization. To improve vaccination uptake, it is crucial to identify barriers to vaccination. We conducted a systematic literature review to identify the key barriers to vaccination in the LAC region, and to classify and quantify factors affecting vaccination coverage using the barrier categories outlined by the Strategic Advisory Group of Experts (SAGE) working group. We mapped knowledge gaps in the understanding of region-specific and population-specific vaccine hesitancy. Nine databases (Medline via PubMed, Web of Science, LILACS, MedCarib, SciELO, Scopus, PATH, SAGE Online and Google Scholar) were searched for articles published in English, Spanish and Portuguese up to 15 July 2017. A total of 6867 articles were identified of which 75 were included in the review. Majority of the articles were quantitative in nature and nearly half from Brazil. Many other countries in LAC have limited published evidence on barriers to vaccination. The most commonly investigated target population was parents (of children <8 years of age [yoa] and adolescents 9-10 yoa) but there was a balance in the number of publications that reported on influenza, childhood and human papillomavirus vaccination. There was limited direct evidence which reported insights on the new generation of childhood vaccines (pneumococcal or meningococcal vaccines) or studies targeting adolescents and pregnant women. Among the SAGE barrier categories, 'individual/group influences' were the most frequently reported barrier category (68%) followed by 'contextual influences' (47%). Adverse socioeconomic factors, a low level of education, lack of awareness of diseases and their vaccines, religious and cultural beliefs are commonly cited as obstacles to vaccination acceptance. Additional evidence is needed to fully understand the barriers to vaccination for different target populations, countries in the region and specific vaccine types. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Guzman-Holst, Adriana] Imperial Coll London, St Marys Hosp, Sch Publ Hlth, Norfolk Pl, London W2 1PG, England.
   [DeAntonio, Rodrigo; Juliao, Patricia] GSK Panama, Edificio 230, Panama City, Panama.
   [Prado-Cohrs, David] GSK Guatemala, Piso 8,3a Ave 13-78 Zona 10, Guatemala City, Guatemala.
RP Juliao, P (reprint author), GSK Panama, Edificio 230, Panama City, Panama.
EM patricia.d.juliao@gsk.com
FU GlaxoSmithKline Biologicals S.A.GlaxoSmithKline [HO-17-19012]
FX GlaxoSmithKline Biologicals S.A. funded this study (HO-17-19012) and all
   costs related to the development of related publications.
CR Acevedo G, 2015, REV SALUD PUBLICA, V3, P31
   Acosta-Ramirez N, 2005, REV SAUDE PUBL, V39, P421, DOI 10.1590/S0034-89102005000300013
   Acosta-Ramírez Naydu, 2010, Rev. Gerenc. Polit. Salud, V9, P116
   Alder S, 2015, ONCOL REP, V33, P2521, DOI 10.3892/or.2015.3817
   Alder S, 2013, INT J ONCOL, V43, P1310, DOI 10.3892/ijo.2013.2023
   Barbieri CLA, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311x00173315, 10.1590/0102-311X00173315, 10.15900102-311X001733/15]
   Barbieri CLA, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049005149
   Alves Figueiredo G, 2011, REV LATINO AM ENFERM, V19
   Arrossi S, 2012, VACCINE, V30, P2467, DOI 10.1016/j.vaccine.2012.01.032
   Barata RB, 2012, J EPIDEMIOL COMMUN H, V66, P934, DOI 10.1136/jech-2011-200341
   Barrera L, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-231
   BARRETO TV, 1992, J EPIDEMIOL COMMUN H, V46, P357, DOI 10.1136/jech.46.4.357
   Bartolini RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048017
   Bettinger JA, 2016, J OBSTET GYNAECOL CA, V38, P1045, DOI 10.1016/j.jogc.2016.08.004
   Bingham A, 2009, ARCH PEDIAT ADOL MED, V163, P455, DOI 10.1001/archpediatrics.2009.50
   Bracho-Churio YT, 2017, ANN CLIN MICROB ANTI, V16, DOI 10.1186/s12941-017-0213-1
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Brown B, 2015, SEX TRANSM DIS, V42, P198, DOI 10.1097/OLQ.0000000000000258
   Brown B, 2010, VACCINE, V28, P7743, DOI 10.1016/j.vaccine.2010.09.063
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   Burghouts J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170227
   Campos EC, 2012, CAD SAUDE PUBLICA, V28, P878, DOI 10.1590/S0102-311X2012000500007
   Gutierrez CC, 2016, COLOMB MEDICA, V47, P25
   Carolan K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190984
   Yokokura AVCP, 2013, CAD SAUDE PUBLICA, V29, P522, DOI 10.1590/S0102-311X2013000300010
   Celi AP, 2015, REV PANAM INFECTOL, V17, P98
   Chaparro RM, 2016, ARCH ARGENT PEDIATR, V114, P36, DOI [10.5546/aap.2016.eng.36, 10.5546/aap.2016.36]
   Chiang EDO, 2015, J HUM GROWTH DEV, V25, P341
   Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2
   Clavijo GC, 2016, PHYS REV SAUDE COLET, V26
   Cockman P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5703
   COREIL J, 1989, INT J EPIDEMIOL, V18, pS33, DOI 10.1093/ije/18.Supplement_2.S33
   Couto MT, 2015, CIENC SAUDE COLETIVA, V20, P105, DOI 10.1590/1413-81232014201.21952013
   Branco FLCC, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0118-y
   D'Ardenne KK, 2016, VACCINE, V34, P1719, DOI 10.1016/j.vaccine.2016.01.060
   da Silva AAM, 1999, REV SAUDE PUBL, V33, P147, DOI 10.1590/S0034-89101999000200006
   da Silva LMV, 1997, REV PANAM SALUD PUBL, V16, P449
   de la Hoz F, 2005, TROP MED INT HEALTH, V10, P322, DOI 10.1111/j.1365-3156.2005.01399.x
   Restrepo FD, 2017, REV PANAM SALUD PUBL, V41, DOI 10.26633/RPSP.2017.124
   Succi RCD, 2018, J PEDIAT-BRAZIL, V94, P574, DOI 10.1016/j.jped.2018.01.008
   de Oliveira LH, 2013, VACCINE, V31, pC114, DOI 10.1016/j.vaccine.2013.05.032
   de Souza EP, 2012, REV INST MED TROP SP, V54, P77, DOI 10.1590/S0036-46652012000200004
   Dip RM, 2010, CAD SAUDE PUBLICA, V26, P1035, DOI 10.1590/S0102-311X2010000500025
   Donalisio MR, 2006, REV SAUDE PUBL, V40, P115, DOI 10.1590/S0034-89102006000100018
   Osis MJD, 2014, REV SAUDE PUBL, V48, P123, DOI 10.1590/S0034-8910.2014048005026
   Esposito S, 2016, CLIN MICROBIOL INFEC, V22, pS89, DOI 10.1016/j.cmi.2016.01.003
   Esteves-Jaramillo A, 2009, ARCH MED RES, V40, P705, DOI 10.1016/j.arcmed.2010.01.004
   Jimenez-Corona ME, 2012, SALUD PUBLICA MEXICO, V54, P607, DOI 10.1590/s0036-36342012000600009
   de Araujo TME, 2007, REV BRAS ENFERM, V60, P439, DOI 10.1590/S0034-71672007000400015
   Farias CC, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1677-y
   Fernandes Ana Catharina Nunes, 2015, Rev. bras. epidemiol., V18, P870, DOI 10.1590/1980-5497201500040015
   Ferreira Raquel Conceição, 2012, Rev. bras. epidemiol., V15, P315, DOI 10.1590/S1415-790X2012000200009
   FOWKES FGR, 1991, BRIT MED J, V302, P1136, DOI 10.1136/bmj.302.6785.1136
   Francisco PM, 2006, REV BRAS EPIDEMIOL, V9
   Garcia DA, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-669
   Garib Z, 2016, BIOMED RES INT, DOI 10.1155/2016/4721836
   Gatti MAN, 2005, SALUSVITA, V24, P427
   Gentile A, 2015, VACCINE, V33, P3913, DOI 10.1016/j.vaccine.2015.06.065
   Gentile A, 2011, ARCH ARGENT PEDIATR, V109, P219, DOI 10.1590/S0325-00752011000300006
   Gentile AS, 2012, REV ARGENT SALUD PUB, V3, P30
   Gichane MW, 2017, J PEDIATR ADOL GYNEC, V30, P96, DOI 10.1016/j.jpag.2016.07.003
   Gram L, 2014, TROP MED INT HEALTH, V19, P802, DOI 10.1111/tmi.12324
   Gualano MR, 2018, VACCINE, V36, P3368, DOI 10.1016/j.vaccine.2018.04.029
   Hussain A, 2018, CUREUS, V10, DOI 10.7759/cureus.2919
   Ibarra Alfredo, 2014, Arch Med Int, V36, P49
   JPTGS Higging, 2011, COCHRANE HDB SYSTEMA
   Kfouri RD, 2013, EINSTEIN-SAO PAULO, V11, P53, DOI 10.1590/S1679-45082013000100010
   Koivogui A, 2017, TRAVEL MED INFECT DI, V15, P37, DOI 10.1016/j.tmaid.2016.08.012
   KOTSOPOULOS N, 2015, J MARK ACCESS HLTH P, V5, DOI DOI 10.1186/S13561-015-0054-6
   LaMontagne DS, 2011, B WORLD HEALTH ORGAN, V89, P821, DOI [10.2471/BLT.11.08986, 10.2471/BLT.11.089862]
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lazcano-Ponce E, 2001, ARCH MED RES, V32, P243, DOI 10.1016/S0188-4409(01)00277-6
   Lima-Costa MF, 2008, REV SAUDE PUBL, V42, P100, DOI 10.1590/S0034-89102008000100013
   Luciani S, 2018, SALUD PUBLICA MEXICO, V60, P683, DOI 10.21149/9090
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Maisa A, 2018, PUBLIC HEALTH, V162, P111, DOI 10.1016/j.puhe.2018.05.025
   Mazzadi A, 2012, SALUD PUBLICA MEXICO, V54, P515, DOI 10.1590/s0036-36342012000500008
   Mendoza-Sassi RA, 2015, CAD SAUDE PUBLICA, V31, P1247, DOI 10.1590/0102-311X00084514
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Moisi JC, 2010, VACCINE, V28, P5725, DOI 10.1016/j.vaccine.2010.06.011
   Barros MGM, 2015, EPIDEMIOL SERV SAUDE, V24, P701, DOI 10.5123/S1679-49742015000400012
   Moura RF, 2015, CAD SAUDE PUBLICA, V31, P2157, DOI 10.1590/0102-311X00065414
   Munoz FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00436
   Neves RG, 2016, EPIDEMIOL SERV SAUDE, V25, P755, DOI 10.5123/S1679-49742016000400009
   Nigenda-Lopez G, 1990, Salud Publica Mex, V32, P325
   NITAG Resource Center, 2017, NITAG STAT DEC 2017
   Orenstein WA, 2015, PUBLIC HEALTH REP, V130, P573
   Pan American Health Organization, 2017, HLTH AM SUMM REG OUT
   Pan American Health Organization, 2017, HLTH SIT AM COR IND
   Pan American Health Organization, 2014, STAT PLAN 2014 2019
   Parez N, 2014, LANCET INFECT DIS, V14, P416, DOI 10.1016/S1473-3099(14)70035-0
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Perkins RB, 2012, INT J PUBLIC HEALTH, V57, P143, DOI 10.1007/s00038-011-0271-7
   PERNAMBUCO AP, 2015, CIENC SAUDE COLETIVA, V23, P172, DOI DOI 10.1080/24708593.2017.1357664
   PLISA-Health Information Platform for the Americas, 2018, VACC COV VACC COUNTR
   Plotkin SA, 2012, VACCINES
   Qazi U, 2019, VACCINE, V37, P4618, DOI 10.1016/j.vaccine.2018.01.044
   Ozaki LMTR, 2007, REV LAT-AM ENFERM, V15, P529, DOI 10.1590/S0104-11692007000400002
   Sanderson S, 2007, INT J EPIDEMIOL, V36, P666, DOI 10.1093/ije/dym018
   Santos ZMG, 2010, EPIDEMIOL SERV SAUDE, V19, P205
   Sato APS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052001199, 10.11606/s1518-8787.2018052001199]
   Sato APS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123840
   Shuaib FMB, 2010, W INDIAN MED J, V59, P549
   Simone B, 2012, EURO SURVEILLANCE B, V17
   Francisco PMSB, 2006, REV PANAM SALUD PUBL, V19, P259, DOI 10.1590/S1020-49892006000400006
   Francisco PMSB, 2011, CAD SAUDE PUBLICA, V27, P417, DOI 10.1590/S0102-311X2011000300003
   Strategic Advisory Group of Experts (SAGE) on Immunization, ASS REP GLOB VACC AC
   Suarez-Castaneda E, 2014, VACCINE, V32, P437, DOI 10.1016/j.vaccine.2013.11.072
   Tapia-Conyer R, 2013, VACCINE, V31, P3826, DOI 10.1016/j.vaccine.2012.12.062
   Fregnani JHTG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062647
   Tirado F, 2007, MED UPB, V26, P33
   Tohme RA, 2014, TROP MED INT HEALTH, V19, P1105, DOI 10.1111/tmi.12335
   Veliz L, 2016, REV CHIL INFECTOL, V33, P30, DOI 10.4067/S0716-10182016000100005
   Ventola C Lee, 2016, P T, V41, P492
   Victor JF, 2014, REV ESC ENFERM USP, V48, P57, DOI 10.1590/S0080-623420140000100007
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Wiesner Carolina, 2010, Rev. salud pública, V12, P961
   Wohlin C., 2014, GUIDELINES SNOWBALLI
   World Health Organization, 2014, REP SAGE WORK GROUP
   World Health Organization, 2019, 3 DOS DIPHTH TOX TET
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World Health Organization, DRAFT 13 GEN PROGR W
NR 122
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 470
EP 481
DI 10.1016/j.vaccine.2019.10.088
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900008
PM 31767469
OA Other Gold
DA 2020-05-12
ER

PT J
AU Silveira, MF
   Buffarini, R
   Bertoldi, AD
   Santos, IS
   Barros, AJD
   Matijasevich, A
   Menezes, AMB
   Goncalves, H
   Horta, BL
   Barros, FC
   Barata, RB
   Victora, CG
AF Silveira, Mariangela F.
   Buffarini, Romina
   Bertoldi, Andrea D.
   Santos, Ina S.
   Barros, Aluisio J. D.
   Matijasevich, Alicia
   Menezes, Ana Maria B.
   Goncalves, Helen
   Horta, Bernardo L.
   Barros, Fernando C.
   Barata, Rita B.
   Victora, Cesar G.
TI The emergence of vaccine hesitancy among upper-class Brazilians: Results
   from four birth cohorts, 1982-2015
SO VACCINE
LA English
DT Article
DE Immunization coverage; Vaccination hesitancy; Economic status;
   Educational status; Socioeconomic factors; Public health; Cohort studies
ID ELECTRONIC IMMUNIZATION REGISTRY; CHILD HEALTH; PELOTAS; INEQUALITIES;
   COVERAGE; TRENDS; PROFILE; METHODOLOGY; CONTEXT; STATE
AB Vaccine hesitancy has been increasingly reported in Brazil. We describe secular trends and socioeconomic disparities from 1982 to 2015, using data from four population-based birth cohorts carried out in the city of Pelotas. Full immunization coverage (FIC) was defined as having received four basic vaccines (one dose of BCG and measles, and three doses of polio and DTP) scheduled for the first year of life. Information on income was collected through standardized questionnaires, and the slope index of inequality (SII) was calculated to express the difference in percent points between the rich and poor extremes of the income distribution. Full immunization coverage was 80.9% (95% CI 79.8%; 82.0%) in 1982, 97.2% (96.1%; 98.0%) in 1993, 87.8% (86.7%; 88.8%) in 2004 and 77.2% (75.8%; 78.4%) in 2015. In 1982 there was a strong social gradient with higher coverage among children from wealthy families (SII = 25.0, P < 0.001); by 2015, the pattern was inverted with higher coverage among poor children (SII = -6.0; P = 0.01). Vertical immunization programs in the 1980s and creation of the National Health Services in 1980 eliminated the social gradient that had been present up to the 1980s, to reach near universal coverage. The recent decline in coverage is likely associated with the growing complexity of the vaccination schedule and underfunding of the health sector. In addition, the faster decline observed among children from wealthy families is probably due to vaccine hesitancy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Silveira, Mariangela F.; Buffarini, Romina; Bertoldi, Andrea D.; Santos, Ina S.; Barros, Aluisio J. D.; Menezes, Ana Maria B.; Goncalves, Helen; Horta, Bernardo L.; Victora, Cesar G.] Univ Fed Pelotas, Postgrad Program Epidemiol, Pelotas, RS, Brazil.
   [Matijasevich, Alicia] Univ Sao Paulo, Fac Med FMUSP, Dept Med Prevent, Sao Paulo, SP, Brazil.
   [Barros, Fernando C.] Univ Catolica Pelotas, Postgrad Program Hlth & Behav, Pelotas, RS, Brazil.
   [Barata, Rita B.] Santa Casa Sao Paulo FCMSCSP, Dept Collect Hlth, Sch Med Sci, Sao Paulo, SP, Brazil.
RP Silveira, MF (reprint author), Univ Fed Pelotas, Marechal Deodoro 1160,3rd Floor, BR-96020220 Pelotas, RS, Brazil.
EM mariangelafreitassilveira@gmail.com
RI ; Matijasevich, Alicia/C-5576-2009
OI da Silveira, Mariangela Freitas/0000-0002-2861-7139; Matijasevich,
   Alicia/0000-0003-0060-1589
FU Wellcome TrustWellcome Trust; International Development Research Center;
   World Health OrganizationWorld Health Organization; Overseas Development
   Administration of the United Kingdom; European UnionEuropean Union (EU);
   Brazilian National Support Program for Centers of Excellence (PRONEX);
   Brazilian National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Science and Technology Department (DECIT) of the Brazilian
   Ministry of Health; Research Support Foundation of the State of Rio
   Grande do Sul (FAPERGS)Foundation for Research Support of the State of
   Rio Grande do Sul (FAPERGS); Brazilian Pastorate of the Child; Brazilian
   Association for Collective Health (ABRASCO); CNPqNational Council for
   Scientific and Technological Development (CNPq); Departamento de Ciencia
   e Tecnologia (DECIT), Brasil
FX The four cohorts received funding from the following agencies: Wellcome
   Trust, International Development Research Center, World Health
   Organization, Overseas Development Administration of the United Kingdom,
   European Union, Brazilian National Support Program for Centers of
   Excellence (PRONEX), Brazilian National Council for Scientific and
   Technological Development (CNPq), Science and Technology Department
   (DECIT) of the Brazilian Ministry of Health, Research Support Foundation
   of the State of Rio Grande do Sul (FAPERGS), Brazilian Pastorate of the
   Child, and Brazilian Association for Collective Health (ABRASCO). MFS,
   ADB, ISS, AJDB, AM, AMBM, HG, BH, FCB, RBB and CGV are supported by the
   CNPq.RB issupportedbyDepartamento de Ciencia e Tecnologia (DECIT),
   Brasil.
CR Ballalai Isabella, 2018, MEASLES BRAZIL UNWEL
   Barata RB, 2012, J EPIDEMIOL COMMUN H, V66, P934, DOI 10.1136/jech-2011-200341
   Barreto ML, 2011, LANCET, V377, P1877, DOI 10.1016/S0140-6736(11)60202-X
   Barros AJD, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001390
   Bedford H, 2000, BRIT MED J, V320, P240, DOI 10.1136/bmj.320.7229.240
   Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728
   Bertoldi AD, 2019, INT J EPIDEMIOL, V48, pi4, DOI 10.1093/ije/dyy170
   Binyaruka P, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3270-z
   Yokokura AVCP, 2013, CAD SAUDE PUBLICA, V29, P522, DOI 10.1590/S0102-311X2013000300010
   Castro MC, 2019, LANCET, V394, P345, DOI 10.1016/S0140-6736(19)31243-7
   Centro de Vigirancia Epidemiologica. Govern do Estado de Sao Paulo, 2019, B EPIDEMIOLOGICO, V1
   Centro Estadual De VigilSncia em Saticle (CEVS), 2018, VIG DOEN IM 2017
   Couto MT, 2015, CIENC SAUDE COLETIVA, V20, P105, DOI 10.1590/1413-81232014201.21952013
   Branco FLCC, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0118-y
   Succi RCD, 2018, J PEDIAT-BRAZIL, V94, P574, DOI 10.1016/j.jped.2018.01.008
   Ferreira VLD, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311X00184317, 10.1590/0102-311x00184317]
   Goncalves H, 2019, INT J EPIDEMIOL, V48, pi80, DOI 10.1093/ije/dyy233
   Hallal PC, 2018, INT J EPIDEMIOL, V47, P1048, DOI 10.1093/ije/dyx219
   Hortal M, 2019, REV PANAM SALUD PUBL, V43, DOI 10.26633/RPSP.2019.54
   Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Luhm KR, 2011, REV SAUDE PUBL, V45, P90, DOI 10.1590/s0034-89102010005000054
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003
   Menezes AMB, 2019, INT J EPIDEMIOL, V48, pi54, DOI 10.1093/ije/dyy129
   Middleton E, 2003, BMJ-BRIT MED J, V326, P854, DOI 10.1136/bmj.326.7394.854
   Miko D, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55060282
   Ministerio da mulher dfeddh, 2019, EST CRINC AD
   Ministerio da Sande, 2018, COORD GER DOENC TRAN
   Ministerio da Saude. Secretaria de Vigilancia em Satide, 2015, COB VAC BRAS PER 201
   Moraes JC, 2000, REV PANAM SALUD PUBL, V8, P332, DOI DOI 10.1590/S1020-49892000001000003
   Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Plotkin SA, 2008, VACCINES
   Santos IS, 2011, INT J EPIDEMIOL, V40, P1461, DOI 10.1093/ije/dyq130
   Sato APS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052001199, 10.11606/s1518-8787.2018052001199]
   Silva FD, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311x00041717, 10.1590/0102-311X00041717]
   Suarez L, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e3
   Tauil MD, 2017, EPIDEMIOL SERV SAUDE, V26, P835, DOI [10.5123/S1679-49742017000400014, 10.5123/s1679-49742017000400014]
   VALADEZ JJ, 1992, AM J PUBLIC HEALTH, V82, P120, DOI 10.2105/AJPH.82.1.120
   Victora CG, 2008, INT J EPIDEMIOL, V37, P704, DOI 10.1093/ije/dym177
   VICTORA CG, 1991, REV SAUDE PUBL, V25, P218, DOI 10.1590/S0034-89101991000300009
   Victora CG, 2006, INT J EPIDEMIOL, V35, P237, DOI 10.1093/ije/dyi290
   Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0
   WHO, 2018, IMM COV
   Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430
   World Health Organization, 2018, 2018 ASS REP GLOB VA
NR 47
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 482
EP 488
DI 10.1016/j.vaccine.2019.10.070
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900009
PM 31718899
DA 2020-05-12
ER

PT J
AU Pebody, RG
   Whitaker, H
   Ellis, J
   Andrews, N
   Marques, DFP
   Cottrell, S
   Reynolds, AJ
   Gunson, R
   Thompson, C
   Galiano, M
   Lackenby, A
   Robertson, C
   O'Doherty, MG
   Owens, K
   Yonova, I
   Shepherd, SJ
   Moore, C
   Johnston, J
   Donati, M
   McMenamin, J
   de Lusignan, S
   Zambon, M
AF Pebody, Richard G.
   Whitaker, Heather
   Ellis, Joanna
   Andrews, Nick
   Marques, Diogo F. P.
   Cottrell, Simon
   Reynolds, Arlene J.
   Gunson, Rory
   Thompson, Catherine
   Galiano, Monica
   Lackenby, Angie
   Robertson, Chris
   O'Doherty, Mark G.
   Owens, Katie
   Yonova, Ivelina
   Shepherd, Samantha J.
   Moore, Catherine
   Johnston, Jillian
   Donati, Matthew
   McMenamin, Jim
   de Lusignan, Simon
   Zambon, Maria
TI End of season influenza vaccine effectiveness in primary care in adults
   and children in the United Kingdom in 2018/19
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine; Effectiveness; Primary care
ID VIRUSES; STATES; BIAS
AB 2018/19 was the first season of introduction of a newly licensed adjuvanted influenza vaccine (aTIV) for adults aged 65 years and over and the sixth season in the roll-out of a childhood influenza vaccination programme with a quadrivalent live attenuated influenza vaccine (LAIV). The season saw mainly A(H1N1)pdm09 and latterly A(H3N2) circulation.
   End-of-season adjusted vaccine effectiveness (aVE) estimates against laboratory confirmed influenza infection in primary care were calculated using the test negative case control method adjusting for key confounders. End-of-season aVE was 44.3% (95% CI: 26.8, 57.7) against all laboratory-confirmed influenza; 45.7% (95% CI: 26.0, 60.1) against influenza A(H1N1)pdm09 and 35.1% (95% CI: -3.7,59.3) against A(H3N2). Overall aVE was 49.9% (95%CI: -13.7, 77.9) for all those >= 65 years of age and 62.0% (95% CI: 3.4, 85.0) for those who received aTIV. Overall aVE for 2-17 year olds receiving LAIV was 48.6% (95% CI: -4.4, 74.7). The paper provides evidence of overall significant influenza VE in 2018/19, most notably against influenza A(H1N1)pdm09, however, as seen in 2017/18, there was reduced, non-significant VE against A(H3N2). aTIV provided significant protection for those 65 years of age and over. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Pebody, Richard G.; Whitaker, Heather; Ellis, Joanna; Andrews, Nick; Thompson, Catherine; Galiano, Monica; Lackenby, Angie; Owens, Katie; Zambon, Maria] Publ Hlth England, 61 Colindale Ave, London NW9 5EQ, England.
   [Marques, Diogo F. P.; Reynolds, Arlene J.; McMenamin, Jim] Hlth Protect Scotland, Glasgow, Lanark, Scotland.
   [Cottrell, Simon; Moore, Catherine] Publ Hlth Wales, Cardiff, Wales.
   [Gunson, Rory; Shepherd, Samantha J.] West Scotland Specialist Virol Ctr, Glasgow, Lanark, Scotland.
   [Robertson, Chris] Univ Strathclyde, Glasgow, Lanark, Scotland.
   [O'Doherty, Mark G.; Johnston, Jillian] Publ Hlth Agcy Northern Ireland, Belfast, Antrim, North Ireland.
   [Yonova, Ivelina] Univ Surrey Guildford, Guildford, Surrey, England.
   [Yonova, Ivelina; de Lusignan, Simon] Royal Coll Gen Practitioners Res & Surveillance C, London, England.
   [Donati, Matthew] Publ Hlth England, Bristol, Avon, England.
   [de Lusignan, Simon] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England.
RP Pebody, RG (reprint author), Publ Hlth England, 61 Colindale Ave, London NW9 5EQ, England.
EM Richard.Pebody@phe.gov.uk
RI Whitaker, Heather/O-4995-2017
OI Whitaker, Heather/0000-0001-5833-1863
CR Cullen KA, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6502a1
   Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011
   Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2
   FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755
   Fleming DM, 2010, J EPIDEMIOL COMMUN H, V64, P1062, DOI 10.1136/jech.2009.093450
   Gunson R, 2010, J VIROL METHODS, V163, P258, DOI 10.1016/j.jviromet.2009.10.006
   Hakin B, 2013, FLU IMMUNISATION PRO
   Kissling E, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.1900121
   Matrosovich M, 2003, J VIROL, V77, P8418, DOI 10.1128/JVI.77.15.8418-8425.2003
   Pathirannehelage Sameera, 2018, Stud Health Technol Inform, V247, P161
   Pebody R, 2016, EUROSURVEILLANCE, V21, P41, DOI 10.2807/1560-7917.ES.2016.21.38.30348
   Penttinen PM, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.38.30350
   Poehling KA, 2018, CLIN INFECT DIS, V66, P665, DOI 10.1093/cid/cix869
   Skowronski DM, 2019, EUROSURVEILLANCE, V24, P39, DOI 10.2807/1560-7917.ES.2019.24.46.1900585
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   ZAMBON M, 1998, TXB INFLUENZA, P291
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
NR 17
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 489
EP 497
DI 10.1016/j.vaccine.2019.10.071
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900010
PM 31685296
DA 2020-05-12
ER

PT J
AU Mitilian, E
   Malli, F
   Verger, P
AF Mitilian, Eva
   Malli, Fady
   Verger, Pierre
TI Image of the new vaccination obligation through the media
SO VACCINE
LA English
DT Article
DE Vaccines; Media; Qualitative analysis; Immunization; Obligations; Public
   health
ID HEPATITIS-B VACCINATION; VACCINES; HESITANCY
AB Introduction: Vaccination campaigns always go hand by hand with controversies about their safety and usefulness. The widespread perception of vaccines as dangerous induces a decrease in the population immunization coverage, which led The French Ministry of Health to add 8 new mandatory vaccines to the 3 existing ones. The objective of this study is to analyze the information conveyed by the media and received by the French population about this new legislation.
   Method: The newspaper articles and television and radio programs were selected from the media with the highest audience rate from January 2016 to May 2018. They were analyzed according to the grounded theory, up to data saturation, with double coding.
   Results: The qualitative analysis included 38 written press articles, 18 radio programs and 18 television programs.
   After coding, several themes emerged. Discussions about the usefulness of vaccination, trust in vaccines, vaccination coverage, and the cost of measure were controversial in the media. Questions about ethics were also mentioned. The description of anti-vaccines by journalists and some doctors conveyed a negative image while reminding their strong mobilization through social media. The law and its implementation details were frequently reminded across the different media.
   Discussion-Conclusion: Traditional media give opposing views on immunization obligations. Vaccination is supported by a majority of doctors. Parents share their fears and concerns about vaccination and its adverse effects. An effort regarding public communication seems necessary in order to reassure the population. The study of other media, such as the Internet, could help to deepen this study. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mitilian, Eva; Malli, Fady] Aix Marseille Univ, Dept Univ Med Gen, Marseille, France.
   [Mitilian, Eva; Verger, Pierre] IHU Mediterranee Infect, Marseille, France.
   [Verger, Pierre] Aix Marseille Univ, IRD, AP HM, SSA,VITROME, Marseille, France.
   [Verger, Pierre] ORS PACA, Marseille, France.
   [Mitilian, Eva; Malli, Fady; Verger, Pierre] Aix Marseille Univ, Fac Med, Marseille, France.
RP Mitilian, E (reprint author), 40 Rue St Bruno, F-13004 Marseille, France.
EM eva.MITILIAN@univ-amu.fr
CR Andre FE, 2003, VACCINE, V21, P593, DOI 10.1016/S0264-410X(02)00702-8
   [Anonymous], AM J PREV MED
   [Anonymous], 2016, B EPIDEMIOLOGIQUE HE
   [Anonymous], 2017, B EPIDEMIOL HEBD PAR
   [Anonymous], 2018, ETUDE MEDIAMETRIE JE
   [Anonymous], 2019, B SANTE PUBLIQUE VAC
   [Anonymous], 2019, B SANTE DE SANTE PUB
   [Anonymous], 2016, RAPPORT IPSOS USAGES
   [Anonymous], 2017, B WORLD HEALTH ORGAN, DOI DOI 10.2471/BLT.16.178475
   [Anonymous], 2018, DIGITAL NEWS REPORT
   [Anonymous], 2013, EURO SURVEILL
   [Anonymous], 2016, EUROSURVEILLANCE
   [Anonymous], 2015, BMC PEDIATR, DOI DOI 10.1186/S12887-015-0318-7
   [Anonymous], ALUMINIUM ADJUVANTED
   [Anonymous], 2012, VACCINE, DOI DOI 10.1016/J.VACCINE.2011.11.117
   Aquino F, 2017, VACCINE, V35, P4494, DOI 10.1016/j.vaccine.2017.07.029
   Frederiksen JL, 2017, ACTA NEUROL SCAND, V136, P49, DOI 10.1111/ane.12837
   Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061
   Karan A, 2018, BMC INT HEALTH HUM R, V18, DOI 10.1186/s12914-018-0148-4
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Levy-Bruhl D, 2019, EUROSURVEILLANCE, V24, P6, DOI 10.2807/1560-7917.ES.2019.24.25.1900301
   Lorton F, 2018, PAEDIATR PERINAT EP, V32, P442, DOI 10.1111/ppe.12500
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Mouchet J, 2018, VACCINE, V36, P1548, DOI 10.1016/j.vaccine.2018.02.036
   Moyroud L, 2017, HUM VACC IMMUNOTHER, V13, P998, DOI 10.1080/21645515.2016.1264549
   Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018
   Wang E, 2014, AM J PUBLIC HEALTH, V104, pE62, DOI 10.2105/AJPH.2014.302190
   Ward JK, 2018, VACCINE, V36, P1801, DOI 10.1016/j.vaccine.2018.02.095
   Ward JK, 2015, VACCINE, V33, P1063, DOI 10.1016/j.vaccine.2014.12.064
   Yang YT, 2018, VACCINE, V36, P595, DOI 10.1016/j.vaccine.2017.12.065
NR 31
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 498
EP 511
DI 10.1016/j.vaccine.2019.10.069
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900011
PM 31711675
DA 2020-05-12
ER

PT J
AU Jamison, AM
   Broniatowski, DA
   Dredze, M
   Wood-Doughty, Z
   Khan, D
   Quinn, SC
AF Jamison, Amelia M.
   Broniatowski, David A.
   Dredze, Mark
   Wood-Doughty, Zach
   Khan, DureAden
   Quinn, Sandra Crouse
TI Vaccine-related advertising in the Facebook Ad Archive
SO VACCINE
LA English
DT Article
DE Social Media; Advertising; Facebook; Vaccine Hesitancy; Transparency;
   Misinformation
ID TOBACCO
AB Background: In 2018, Facebook introduced Ad Archive as a platform to improve transparency in advertisements related to politics and "issues of national importance." Vaccine-related Facebook advertising is publicly available for the first time. After measles outbreaks in the US brought renewed attention to the possible role of Facebook advertising in the spread of vaccine-related misinformation, Facebook announced steps to limit vaccine-related misinformation. This study serves as a baseline of advertising before new policies went into effect.
   Methods: Using the keyword 'vaccine', we searched Ad Archive on December 13, 2018 and again on February 22, 2019. We exported data for 505 advertisements. A team of annotators sorted advertisements by content: pro-vaccine, anti-vaccine, not relevant. We also conducted a thematic analysis of major advertising themes. We ran Mann-Whitney U tests to compare ad performance metrics.
   Results: 309 advertisements were included in analysis with 163 (53%) pro-vaccine advertisements and 145 (47%) anti-vaccine advertisements. Despite a similar number of advertisements, the median number of ads per buyer was significantly higher for anti-vaccine ads. First time buyers are less likely to complete disclosure information and risk ad removal. Thematically, anti-vaccine advertising messages are relatively uniform and emphasize vaccine harms (55%). In contrast, pro-vaccine advertisements come from a diverse set of buyers (83 unique) with varied goals including promoting vaccination (49%), vaccine related philanthropy (15%), and vaccine related policy (14%).
   Conclusions: A small set of anti-vaccine advertisement buyers have leveraged Facebook advertisements to reach targeted audiences. By deeming all vaccine-related content an issue of "national importance," Facebook has further the politicized vaccines. The implementation of a blanket disclosure policy also limits which ads can successfully run on Facebook. Improving transparency and limiting misinformation should not be separate goals. Public health communication efforts should consider the potential impact on Facebook users' vaccine attitudes and behaviors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jamison, Amelia M.; Khan, DureAden; Quinn, Sandra Crouse] Univ Maryland, Ctr Hlth Equ, 3302 Sch Publ Hlth Bldg,4200 Valley Dr, College Pk, MD 20742 USA.
   [Broniatowski, David A.] George Washington Univ, Sch Engn & Appl Sci, Dept Engn Management & Syst Engn, Washington, DC 20052 USA.
   [Dredze, Mark; Wood-Doughty, Zach] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA.
   [Quinn, Sandra Crouse] Univ Maryland, Sch Publ Hlth, Dept Family Sci, College Pk, MD 20742 USA.
RP Jamison, AM (reprint author), Maryland Ctr Hlth Equ, 3302D Sch Publ Hlth Bldg,4200 Valley Dr, College Pk, MD 20742 USA.
EM ajam1@umd.edu
FU National Institute of General Medical Sciences, National Institutes of
   Health (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [5R01GM114771]
FX This research was supported by the National Institute of General Medical
   Sciences, National Institutes of Health (NIH; award 5R01GM114771). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of NIH.
CR Andreou A, 2019, MEASURING FACEBOOK A
   Arciga J., 2015, ANTIVAXXER L COOK HA
   Barry AE, 2015, ALCOHOL ALCOHOLISM, V50, P89, DOI 10.1093/alcalc/agu078
   Bickert M, 2019, FACEBOOK NEWSROOM
   Bono L., 2018, CHILDRENS HLTH DEFEN
   Caron C., 2019, NY TIMES, pA23
   Chu K-H, 2015, JMIR PUBLIC HLTH SUR, V1
   Dredze M, 2016, VACCINE, V34, P3441, DOI 10.1016/j.vaccine.2016.05.008
   Dredze M, 2016, AM J PREV MED, V50, P550, DOI 10.1016/j.amepre.2015.10.002
   Dutt R, 2018, ARXIV180910158CS
   Grier SA, 2010, ANNU REV PUBL HEALTH, V31, P349, DOI 10.1146/annurev.publhealth.012809.103607
   Hitlin P, 2019, FACEBOOK ALGORITHMS
   Hoffman BL, 2019, VACCINE, V37, P2216, DOI 10.1016/j.vaccine.2019.03.003
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Kahan DM, 2010, LAW HUMAN BEHAV, V34, P501, DOI 10.1007/s10979-009-9201-0
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Lapowsky J., 2018, 21 COUNTING BIGGEST
   Madrigal AC, ATLANTIC
   Matsa K. E., 2018, NEWS USE SOCIAL MEDI
   Metz C., 2017, NY TIMES, P3
   Mnookin S., 2011, PANIC VIRUS TRUE STO
   Pew Research Center, 2017, VAST MAJ AM SAY BEN
   Pilkington E, GUARDIAN
   Richardson A, 2015, TOB CONTROL, V24, P341, DOI 10.1136/tobaccocontrol-2013-051246
   Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040
   Shearer E., 2018, SOCIAL MEDIA OUTPACE
   Silber T., 2018, FACEBOOK AD SPEND GR
   Speicher Till, 2018, C FAIRN ACC TRANSP, V81, P1
   Telford T., 2019, WASHINGTON POST
   Vanderslott S, 2019, SOC SCI MED, V222, P59, DOI 10.1016/j.socscimed.2018.12.033
   WARNER KE, 1985, HEALTH EDUC QUART, V12, P115, DOI 10.1177/109019818501200111
   World Health Organization, 10 THREATS GLOB HLTH
NR 32
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 512
EP 520
DI 10.1016/j.vaccine.2019.10.066
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900012
PM 31732327
DA 2020-05-12
ER

PT J
AU Rafferty, ERS
   McDonald, W
   Osgood, ND
   Qian, WC
   Doroshenko, A
AF Rafferty, Ellen R. S.
   McDonald, Wade
   Osgood, Nathaniel D.
   Qian, Weicheng
   Doroshenko, Alexander
TI Seeking the optimal schedule for chickenpox vaccination in Canada: Using
   an agent-based model to explore the impact of dose timing, coverage and
   waning of immunity on disease outcomes
SO VACCINE
LA English
DT Article
DE Chickenpox; Agent-based model; Vaccine schedule; Vaccination;
   Immunization; Dose timing
ID VARICELLA-ZOSTER-VIRUS; EPIDEMIOLOGY; IMMUNIZATION; MEASLES; HEALTH;
   RUBELLA; MUMPS; HOSPITALIZATIONS; PROGRAMS
AB Many countries continue to consider implementing a universal chickenpox vaccine program; however, there is no consensus on the most appropriate and effective timing between vaccine doses. The chickenpox vaccine schedule debate is highlighted in Canada, where there are currently eight different vaccine schedules across the country. The objective of this study was to test the overall effectiveness of chickenpox vaccination, as well as the specific impact of two different vaccine schedules, on chickenpox disease outcomes in Alberta over 75 years. Using an agent-based model of chickenpox disease, we tested the impact of three vaccination scenarios including: baseline (no vaccination), a long dosing interval Schedule LDI (1st dose - 12 months; 2nd dose - 4-6 years) and a short dosing interval-Schedule SDI (1st dose - 12 months; 2nd dose - 18 months) on chickenpox and shingles disease outcomes. Chickenpox vaccination led to a substantial decrease in chickenpox incidence over 75 years post-vaccine implementation. Compared to Schedule LDI, Schedule SDI resulted in a significantly lower chickenpox incidence, a higher age of chickenpox infection, a lower chickenpox breakthrough rate and a higher shingles incidence rate. Our model findings suggest that the chickenpox vaccine is effective over a long period of time and the dose timing of the vaccine may impact disease outcomes and vaccine effectiveness. However, the effectiveness of the vaccine dose timing is only one consideration for policy-makers who are implementing a chickenpox vaccine program, with others including risk of adverse events, the impact of the schedule on other antigens in a combination vaccine, parental acceptance and the cost associated with different schedules. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rafferty, Ellen R. S.] Univ Saskatchewan, Sch Publ Hlth, 104 Clin Pl, Saskatoon, SK S7N 2Z4, Canada.
   [McDonald, Wade; Osgood, Nathaniel D.; Qian, Weicheng] Univ Saskatchewan, Dept Comp Sci, 176 Thorvaldson Bldg,110 Sci Pl, Saskatoon, SK S7N 5C9, Canada.
   [Doroshenko, Alexander] Univ Alberta, Fac Med & Dent, Dept Med, Div Prevent Med, 5-30 Univ Terrace,8303-112 St, Edmonton, AB T6G 2T4, Canada.
RP Rafferty, ERS (reprint author), Univ Alberta, Fac Nursing, Edmonton Clin Hlth Acad, Level 3,11405-87 Ave, Edmonton, AB T6G 1C9, Canada.
EM ellen.rafferty@ualberta.ca
FU Alberta Health, University of Alberta [RES0025110]
FX This study was funded by the grant from Alberta Health, University of
   Alberta project number RES0025110. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alberta Health, 2019, INTERACTIVE HEALTH D
   Bauchau V, 2015, DRUG SAFETY, V38, P1095, DOI 10.1007/s40264-015-0326-4
   Betta M, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.0054
   Bilcke J, 2012, EPIDEMIOL INFECT, V140, P2096, DOI 10.1017/S0950268811002640
   Bollaerts K, 2017, EPIDEMIOL INFECT, V145, P2666, DOI 10.1017/S0950268817001546
   Bonanni P, 2013, PEDIATR INFECT DIS J, V32, pE305, DOI 10.1097/INF.0b013e31828b7def
   Brisson M, 2000, EPIDEMIOL INFECT, V125, P651, DOI 10.1017/S0950268800004714
   Brisson M, 2001, EPIDEMIOL INFECT, V127, P305, DOI 10.1017/S0950268801005921
   Brisson M, 2010, VACCINE, V28, P3385, DOI 10.1016/j.vaccine.2010.02.079
   Buttenheim AM, 2013, HUM VACC IMMUNOTHER, V9, P1819, DOI 10.4161/hv.25635
   Carrel M, 2015, PEDIATRICS, V136, P80, DOI 10.1542/peds.2015-0831
   Chaves SS, 2007, NEW ENGL J MED, V356, P1121, DOI 10.1056/NEJMoa064040
   Doroshenko A, 2016, PEERJ, V4, P1, DOI [10 7717/peerj 2337, DOI 10.7717/PEERJ2337]
   Duncan JR, 2017, VACCINE, V35, P2351, DOI 10.1016/j.vaccine.2017.03.054
   European Centre for Disease Prevention and Control, 2015, ECDC GUID VAR VACC E
   Gao Z, 2010, EPIDEMIOL INFECT, V138, P457, DOI 10.1017/S0950268809990860
   Gershon AA, 2012, VACCINES, P837
   Gil-Prieto R, 2014, VACCINE, V32, P7043, DOI 10.1016/j.vaccine.2014.10.076
   Hanquet G, 2013, VACCINE, V31, P5634, DOI 10.1016/j.vaccine.2013.07.006
   Holl K, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3738-x
   Klein NP, 2014, HUM VACC IMMUNOTHER, V10, P2684, DOI 10.4161/hv.29576
   Kuter B, 2004, PEDIATR INFECT DIS J, V23, P132, DOI 10.1097/01.inf.0000109287.97518.67
   Kwong JC, 2008, VACCINE, V26, P6006, DOI 10.1016/j.vaccine.2008.08.016
   Law B, 1999, PEDIATRICS, V104, P1, DOI 10.1542/peds.104.1.1
   Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154
   Macartney K, 2017, JAMA PEDIATR, V171, P992, DOI 10.1001/jamapediatrics.2017.1965
   MacDonald SE, 2014, CMAJ, V186, P812, DOI [10 1503/ rmaj 14077R, DOI 10.1503/RMAJ14077R]
   Marin M, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3741
   Marshall DA, 2015, VALUE HEALTH, V18, P5, DOI 10.1016/j.jval.2014.12.001
   Michalik DE, 2008, J INFECT DIS, V197, P944, DOI 10.1086/529043
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   National Advisory Committee on Immunization, 2010, COL CANC, P36
   Nowgesic E, 1999, 19992511 CAN COM DIS, V25-11, P1
   Osgood ND, 2004, 22 INT C SYST DYN SO, P46
   Osgood ND, 2009, P 27 INT C SYST DYN, P20
   Perez SC, 2017, CLIN INFECT DIS, V65, P1094, DOI 10.1093/cid/cix510
   Public Health Agency of Canada, 2018, CAN PROV TERR ROUT C
   Public Health Agency of Canada, 2012, VAR CHICK 2012
   Rafferty E, 2018, PEERJ, V6, DOI 10.7717/peerj.5012
   Riche B, 2016, EXPERT REV VACCINES, V15, P927, DOI 10.1080/14760584.2016.1183483
   Russell ML, 2014, VACCINE, V32, P6319, DOI 10.1016/j.vaccine.2013.09.018
   Salathe M, 2008, J R SOC INTERFACE, V5, P1505, DOI 10.1098/rsif.2008.0271
   Salvadori Ml, 2011, PAEDIAT CHILD HLTH O, V16, P1
   Shinefield H, 2005, PEDIATR INFECT DIS J, V24, P665, DOI 10.1097/01.inf.0000172902.25009.a1
   Statistics Canada, 2016, POP EST JUL 1 AG SEX
   Statistics Canada, 2008, PREGN OUTC AG GROUP
   Statistics Canada, 2016, LIF TABL CAN PROV TE
   Tan B, 2012, PEDIATR INFECT DIS J, V31, P956, DOI 10.1097/INF.0b013e318260cc4d
   van Hoek AJ, 2011, VACCINE, V29, P2411, DOI 10.1016/j.vaccine.2011.01.037
   Waye A, 2013, VACCINE, V31, P4744, DOI 10.1016/j.vaccine.2013.08.022
   Whitney CG, 2014, PEDIATR INFECT DIS J, V33, pS172, DOI 10.1097/INF.0000000000000076
   Wormsbecker AE, 2015, PLOS ONE, V10, P5, DOI [10 13711joitrnal pone 0129483, DOI 10.1371/JOURNALPONE0129483]
NR 52
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 521
EP 529
DI 10.1016/j.vaccine.2019.10.065
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900013
PM 31735499
DA 2020-05-12
ER

PT J
AU Bravo, LC
   Carlos, JC
   Gatchalian, SR
   Montellano, MEB
   Tabora, CFCB
   Thierry-Carstensen, B
   Tingskov, PN
   Sorensen, C
   Wachmann, H
   Bandyopadhyay, AS
   Nielsen, PI
   Kusk, MV
AF Bravo, Lulu C.
   Carlos, Josefina C.
   Gatchalian, Salvacion R.
   Montellano, May Emmeline B.
   Tabora, Charissa Fay Corazon B.
   Thierry-Carstensen, Birgit
   Tingskov, Pernille Nyholm
   Sorensen, Charlotte
   Wachmann, Henrik
   Bandyopadhyay, Ananda S.
   Nielsen, Pernille Ingemann
   Kusk, Mie Vestergaard
TI Immunogenicity and safety of an adjuvanted inactivated polio vaccine,
   IPV-Al, compared to standard IPV: A phase 3 observer-blinded,
   randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks
   and 9 months of age
SO VACCINE
LA English
DT Article
DE Affordable IPV; Aluminium hydroxide adjuvant; Booster vaccination;
   Immunogenicity; Polio; Primary vaccination
ID RESPONSES; NEEDLE
AB Background: A dose-sparing inactivated polio vaccine (IPV-Al), obtained by adsorption of inactivated virus to an aluminium hydroxide adjuvant, can help mitigate global supply and the cost constraints of IPV. The objective of this trial was to demonstrate the non-inferiority of IPV-Al to standard IPV.
   Methods: This phase 3, observer-blinded, randomised, controlled trial was conducted at 5 investigational sites in the Philippines. Infants not previously vaccinated with any polio vaccines were randomised to receive three IPV-AI (n = 502) or IPV vaccinations (n = 500) at 6, 10 and 14 weeks of age plus a booster vaccination at 9 months. The primary endpoint was type-specific seroconversion, defined as an antibody titre >= 4-fold higher than the estimated maternal antibody titre and a titre >= 8, one month after the primary vaccination series.
   Results: Seroconversion rates following primary vaccination with IPV-Al (483 infants in the per-protocol analysis set) or IPV (478 infants) were: polio type 1, 97.1% versus 99.0%; type 2, 94.2% versus 99.0%; and type 3, 98.3% versus 99.6%. IPV-Al was non-inferior to IPV, as the lower 95% confidence limits of the treatment differences were above the predefined 10%-point limit: type 1, -1.85% (-3.85; -0.05); type 2, -4.75% (-7.28; -2.52); type 3, -1.24 (-2.84; 0.13). The booster effect (geometric mean titre (GMT) post-booster / GMT pre-booster) was: type 1, 63 versus 43; type 2, 54 versus 47; type 3, 112 versus 80. IPV-Al was well tolerated with a safety profile comparable to that of IPV. Serious adverse events were recorded for 29 infants (5.8%, 37 events) in the IPV-Al group compared to 28 (5.6%, 48 events) in the IPV group.
   Conclusion: Non-inferiority of IPV-Al to IPV with respect to seroconversion was confirmed and a robust booster response was demonstrated. Both vaccines had a similar safety profile. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Bravo, Lulu C.] Univ Philippines Manila, Manila, Philippines.
   [Carlos, Josefina C.] Univ East Ramon Magsaysay Mem Med Ctr Inc, Manila, Philippines.
   [Gatchalian, Salvacion R.] UP CM Univ Philippines, Dept Pediat, Philippine Gen Hosp, Manila, Philippines.
   [Montellano, May Emmeline B.] Mary Chiles Gen Hosp, Manila, Philippines.
   [Tabora, Charissa Fay Corazon B.] Res Inst Trop Med, Muntinlupa, Metro Manila, Philippines.
   [Thierry-Carstensen, Birgit; Tingskov, Pernille Nyholm] Statens Serum Inst, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.
   [Sorensen, Charlotte; Nielsen, Pernille Ingemann; Kusk, Mie Vestergaard] AJ Vaccines, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.
   [Wachmann, Henrik] Larix AS, Lyskaer 8b, DK-2730 Herlev, Denmark.
   [Bandyopadhyay, Ananda S.] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Kusk, MV (reprint author), AJ Vaccines, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.
EM BTC@ssi.dk; PNT@ssi.dk; CHS@ajvaccines.com; HEW@larixcro.com;
   Ananda.bandyopadhyay@gatesfoundation.org; PXN@ajvac-cines.com;
   MHK@ajvaccines.com
RI Murphy, Georgina/AAG-4805-2020
OI Murphy, Georgina/0000-0001-5978-483X; Bandyopadhyay,
   Ananda/0000-0002-8395-2001
FU Bill & Melinda Gates Foundation, Seattle, WA, USAGates Foundation
   [OPP1095741]
FX This work was supported by the Bill & Melinda Gates Foundation, Seattle,
   WA, USA (grant number OPP1095741).
CR Andreasen LV, 2015, VACCINE, V33, P1873, DOI 10.1016/j.vaccine.2015.02.011
   [Anonymous], 2000, JAMA, V284, P3043
   Bandyopadhyay AS, 2015, FUTURE MICROBIOL, V10, P791, DOI [10.2217/FMB.15.19, 10.2217/fmb.15.19]
   Brown GC, 2 SEROLOGICAL STUDIE, P71
   Cadorna-Carlos J, 2012, INT J INFECT DIS, V16, pE110, DOI 10.1016/j.ijid.2011.10.002
   Donken R, 2015, VACCINE, V33, P1426, DOI 10.1016/j.vaccine.2015.01.072
   Edwards KM, 2015, VACCINE, V33, P6469, DOI 10.1016/j.vaccine.2015.07.085
   El-Sayed N, 2008, NEW ENGL J MED, V359, P1655, DOI 10.1056/NEJMoa0800390
   Estivariz CF, 2013, CURR OPIN VIROL, V3, P309, DOI 10.1016/j.coviro.2013.05.007
   Haastrup E, 2004, VACCINE, V22, P958, DOI 10.1016/j.vaccine.2003.09.011
   Hawken J, 2012, VACCINE, V30, P6971, DOI 10.1016/j.vaccine.2012.09.059
   Hickling J, IMPROVING AFFORDABIL
   International Conference on Harmonisation, 2016, ICH HARM GUID INT AD
   Lindgren LM, 2017, VACCINE, V35, P596, DOI 10.1016/j.vaccine.2016.12.027
   Melnick JL, 1984, VIRAL INFECTIONS HUM, P187
   Minor P, 2009, VACCINE, V27, P2649, DOI 10.1016/j.vaccine.2009.02.071
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Okayasu H, 2017, J INFECT DIS, V216, pS161, DOI 10.1093/infdis/jix038
   Pietrzyk JJ, 2008, VACCINE, V26, P5296, DOI 10.1016/j.vaccine.2008.07.033
   Plotkin SA, 2011, EXPERT REV VACCINES, V10, P981, DOI [10.1586/erv.11.72, 10.1586/ERV.11.72]
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Resik S, 2010, J INFECT DIS, V201, P1344, DOI 10.1086/651611
   Rivera L, 2017, LANCET INFECT DIS, V17, P745, DOI 10.1016/S1473-3099(17)30177-9
   Robertson S, 1993, IMMUNOLOGICAL BASIS
   Thierry-Carstensen B, 2013, VACCINE, V31, P5178, DOI 10.1016/j.vaccine.2013.08.034
   Thierry-Carstensen B, 2012, VACCINE, V30, P5464, DOI 10.1016/j.vaccine.2012.06.073
   Vidor E, 2018, PLOTKINS VACCINES, P841
   Voysey M, 2017, JAMA PEDIATR, V171, P637, DOI 10.1001/jamapediatrics.2017.0638
   Wang HD, 2016, LANCET, V388, P1725, DOI 10.1016/S0140-6736(16)31575-6
   World Health Organization, 2019, POL
   World Health Organization (WHO), 2013, POL ER ENDG STRAT PL
NR 31
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 530
EP 538
DI 10.1016/j.vaccine.2019.10.064
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900014
PM 31703934
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Luu, LDW
   Octavia, S
   Aitken, C
   Zhong, L
   Raftery, MJ
   Sintchenko, V
   Lan, RT
AF Luu, Laurence Don Wai
   Octavia, Sophie
   Aitken, Chelsea
   Zhong, Ling
   Raftery, Mark J.
   Sintchenko, Vitali
   Lan, Ruiting
TI Surfaceome analysis of Australian epidemic Bordetella pertussis reveals
   potential vaccine antigens
SO VACCINE
LA English
DT Article
DE Bordetella pertussis; Comparative proteomics; Surfaceome; Vaccine
   candidates; Acellular vaccine; Whole cell vaccine; Surface shaving;
   Housekeeping proteins; Moonlighting proteins; Pathogen evolution
ID III SECRETION SYSTEM; IDENTIFICATION; PERTACTIN; PROTEIN; TOXIN;
   PREDICTION; PROTEOMICS; VIRULENCE; BINDING
AB Since acellular vaccines (ACV) were introduced in Australia, epidemic Bordetella pertussis strains changed from single nucleotide polymorphism (SNP) cluster II to SNP cluster I. Our previous proteomic analysis identified potential proteomic adaptations in the whole cell and secretome of SNP cluster I. Additionally, current ACVs were shown to be less efficacious against cluster I in mice models and there is a pressing need to discover new antigens to improve the ACV. One important source of novel antigens is the surfaceome. Therefore, in this study we established surface shaving in B. pertussis to compare the surfaceome of SNP cluster I (L1423) and II (L1191), and identify novel surface antigens for vaccine development. Surface shaving using 1 mu g of trypsin for 5 min identified 126 proteins with the most abundant being virulence-associated and known outer membrane proteins. Cell viability counts showed minimal lysis from shaving. The proportion of immunogenic proteins was higher in the surfaceome than in the whole cell and secretome. Key differences in the surfaceome were identified between SNP cluster I and II, consistent with those identified in the whole cell proteome and secretome. These differences include unique transport proteins and decreased immunogenic proteins in L1423, and provides further evidence of proteomic adaptation in SNP cluster I. Finally, a comparison of proteins in each sub-proteome identified 22 common proteins. These included 11 virulence proteins (Pm, PtxA, FhaB, CyaA, TcfA, SphB1, Vag8, BrkA, BopD, Bsp22 and BipA) and 11 housekeeping proteins (TuF, CtpA, TsF, OmpH, GltA, SucC, SucD, FusA, GroEL, BP3330 and BP3561) which were immunogenic, essential and consistently expressed thus demonstrating their potential as future targets. This study established surface shaving in B. pertussis, confirmed key expression differences and identified unknown surface proteins which may be potential vaccine antigens. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Luu, Laurence Don Wai; Octavia, Sophie; Aitken, Chelsea; Lan, Ruiting] Univ New South Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.
   [Zhong, Ling; Raftery, Mark J.] Univ New South Wales, Bioanalyt Mass Spectrometry Facil, Sydney, NSW, Australia.
   [Sintchenko, Vitali] Westmead Hosp, Ctr Infect Dis & Microbiol Publ Hlth, Inst Clin Pathol & Med Res Pathol West, Westmead, NSW, Australia.
   [Sintchenko, Vitali] Univ Sydney, Sydney Med Sch, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia.
RP Lan, RT (reprint author), Univ New South Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.
EM r.lan@unsw.edu.au
OI Luu, Laurence/0000-0003-2516-2121
FU National Health and Medical Research Council of Australia
   (NHMRC)National Health and Medical Research Council of Australia;
   Australian Government Research Training Program (RTP)
   ScholarshipAustralian GovernmentDepartment of Industry, Innovation and
   Science
FX The funding for this project was provided by the National Health and
   Medical Research Council of Australia (NHMRC). LL was supported by an
   Australian Government Research Training Program (RTP) Scholarship.
CR Altindis E, 2009, VACCINE, V27, P542, DOI 10.1016/j.vaccine.2008.11.020
   Bart MJ, 2014, MBIO, V5, DOI 10.1128/mBio.01074-14
   Bart MJ, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-627
   Bottero D, 2007, CLIN VACCINE IMMUNOL, V14, P1490, DOI 10.1128/CVI.00177-07
   CHARLES I, 1994, MICROBIOL-UK, V140, P3301, DOI 10.1099/13500872-140-12-3301
   de Gouw D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105011
   de Gouw D, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.58
   de Gouw D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084523
   Dick LW, 2009, J CHROMATOGR B, V877, P230, DOI 10.1016/j.jchromb.2008.12.009
   Dunne A, 2015, MUCOSAL IMMUNOL, V8, P607, DOI 10.1038/mi.2014.93
   Fennelly NK, 2008, INFECT IMMUN, V76, P1257, DOI 10.1128/IAI.00836-07
   Gasperini G, 2017, MOL CELL PROTEOMICS
   Gonyar LA, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00694-18
   Gray MC, 2004, MOL MICROBIOL, V53, P1709, DOI 10.1111/j.1365-2958.2004.04227.x
   Henderson B, 2011, INFECT IMMUN, V79, P3476, DOI 10.1128/IAI.00179-11
   Hovingh ES, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30558-8
   Huvent I, 2006, J MOL BIOL, V356, P1014, DOI 10.1016/j.jmb.2005.11.096
   Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703
   Kamiya S, 1998, J CLIN GASTROENTEROL, V27, pS35, DOI 10.1097/00004836-199800001-00007
   King AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062613
   Kunert A, 2007, J IMMUNOL, V179, P2979, DOI 10.4049/jimmunol.179.5.2979
   Lam C, 2014, EMERG INFECT DIS, V20, P626, DOI 10.3201/eid2004.131478
   Luu LDW, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02851
   Luu LDW, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700237
   Luu LDW, 2017, J PROTEOMICS, V158, P43, DOI 10.1016/j.jprot.2017.02.010
   Medhekar B, 2009, MOL MICROBIOL, V71, P492, DOI 10.1111/j.1365-2958.2008.06543.x
   Moller Jens, 2019, BMC Res Notes, V12, P329, DOI 10.1186/s13104-019-4373-2
   Mooi FR, 2009, EMERG INFECT DIS, V15, P1206, DOI 10.3201/eid1508.081511
   Nilsson SK, 2018, MOL CELL PROTEOMICS, V17, P57, DOI 10.1074/mcp.RA117.000076
   Octavia S, 2012, J INFECT DIS, V205, P1220, DOI 10.1093/infdis/jis178
   Octavia S, 2011, MOL BIOL EVOL, V28, P707, DOI 10.1093/molbev/msq245
   Olaya-Abril A, 2014, J PROTEOMICS, V97, P164, DOI 10.1016/j.jprot.2013.03.035
   Olaya-Abril A, 2012, J PROTEOMICS, V75, P3733, DOI 10.1016/j.jprot.2012.04.037
   Omasits U, 2014, BIOINFORMATICS, V30, P884, DOI 10.1093/bioinformatics/btt607
   Paoletti AC, 2006, P NATL ACAD SCI USA, V103, P18928, DOI 10.1073/pnas.0606379103
   Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227
   Petousis-Harris H, 2017, LANCET, V390, P1603, DOI 10.1016/S0140-6736(17)31449-6
   Raeven RHM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01364
   Raeven RHM, 2015, J PROTEOME RES, V14, P2929, DOI 10.1021/acs.jproteome.5b00258
   Roberts R, 2008, VACCINE, V26, P4639, DOI 10.1016/j.vaccine.2008.07.004
   Safarchi A, 2016, VACCINE, V34, P3967, DOI 10.1016/j.vaccine.2016.06.052
   Safarchi A, 2016, J INFECTION, V72, P468, DOI 10.1016/j.jinf.2016.01.005
   Semchenko EA, 2018, CLIN INFECT DIS
   Solis N, 2010, PROTEOMICS, V10, P2037, DOI 10.1002/pmic.200900564
   Stenson TH, 2003, INFECT IMMUN, V71, P1316, DOI 10.1128/IAI.71.3.1316-1320.2003
   Stockbauer KE, 2001, MOL MICROBIOL, V39, P65, DOI 10.1046/j.1365-2958.2001.02191.x
   Tefon BE, 2011, VACCINE, V29, P3583, DOI 10.1016/j.vaccine.2011.02.086
   Walters MS, 2009, J MICROBIOL METH, V78, P131, DOI 10.1016/j.mimet.2009.04.013
   West R, 2012, J PROTEOMICS, V75, P1966, DOI 10.1016/j.jprot.2011.12.034
   Williamson YM, 2012, J MICROBIOL METH, V90, P119, DOI 10.1016/j.mimet.2012.04.007
   Wong TY, 2019, MSPHERE, V4, DOI 10.1128/mSphereDirect.00154-19
   Xu Z, 2019, EMERG INFECT DIS, V25, P1196, DOI 10.3201/eid2506.180240
   Yu NY, 2010, BIOINFORMATICS, V26, P1608, DOI 10.1093/bioinformatics/btq249
   Zhu YZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013915
NR 54
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 539
EP 548
DI 10.1016/j.vaccine.2019.10.062
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900015
PM 31703933
DA 2020-05-12
ER

PT J
AU Wang, YF
   Zhou, YP
   Zhang, JH
   Wang, XH
   Lv, TX
   Shi, XN
   Huang, HB
   Bai, F
   Wu, Q
   Hao, YQ
AF Wang, Yanfang
   Zhou, Yaping
   Zhang, Jianhua
   Wang, Xiaohui
   Lv, Tianxing
   Shi, Xiaona
   Huang, Haibi
   Bai, Fan
   Wu, Qian
   Hao, Yongqing
TI iTRAQ-based proteomic analysis of Mycoplasma bovis NM-28 strain from two
   generations for vaccine screening
SO VACCINE
LA English
DT Article
DE Mycoplasma bovis; Isobaric tags for relative and absolute quantitation
   technology; Generation; Colony-forming units; Reverse transcriptase
   polymerase chain reaction; Vaccine
ID ELONGATION-FACTOR TU; ANTIGENIC CHARACTERIZATION; IMMUNOGENIC PROTEINS;
   SURFACE LIPOPROTEIN; IDENTIFICATION; CAPRICOLUM; METABOLISM; EXPRESSION;
   PNEUMONIA
AB Mycoplasma bovis is an important pathogenic bacterium affecting cows and cattle. Clinically, an inactivated vaccine of M. bovis is mainly used to prevent infection by this bacterium. The changes that occur in the antigen when M. bovis is continuously passaged in vitro remain unknown. Therefore, we performed an in vitro serial passage of the M. bovis NM-28 strain, which was isolated and identified in our laboratory. An isobaric tags for relative and absolute quantitation (iTRAQ)-based quantitative proteomics method was used to analyse the differences between generations 3 and 60. Many major membrane proteins or protective antigens reported in the literature did not exhibit changes between these generations. We found an imbalance between growth rate and nutrition in the 60th generation. The proteomics results were verified by western blotting and real-time PCR. Growth curves were also prepared based on colony-forming units (CFUs) between the 3rd and 60th generations. The number of colonies in the 60th generation in the stationary phase was 5 x 10(9) CFU mL(-1), which was 10-fold higher than that in the 3rd generation. The 60th generation of the NM-28 strain can be used as an inactivated vaccine strain of M. bovis to lower production costs compared to use of the 3rd generation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Yanfang; Zhou, Yaping; Zhang, Jianhua; Wang, Xiaohui; Lv, Tianxing; Shi, Xiaona; Huang, Haibi; Bai, Fan; Wu, Qian; Hao, Yongqing] Inner Mongolia Agr Univ, Coll Vet Med, Key Lab Microbiol & Immunol, Hohhot 010018, Peoples R China.
   [Wang, Yanfang; Wang, Xiaohui; Lv, Tianxing] Baotou Med Sch, Fdn Med Coll, Baotou 014040, Peoples R China.
RP Hao, YQ (reprint author), 306 Zhaowuda Rd, Hohhot 010018, Peoples R China.
EM haoyq1960@163.com
FU Special Project of Animal and Plant Breeding in Inner Mongolia
   Agricultural University, China [YZGC2017027]
FX The study was supported by the Special Project of Animal and Plant
   Breeding in Inner Mongolia Agricultural University, China (YZGC2017027).
   The funders had no roles in design of the study, analysis, and
   interpretation of the data, or preparation of the manuscript.
CR Alonso JMM, 2002, VET MICROBIOL, V89, P277, DOI 10.1016/S0378-1135(02)00258-4
   Arcangioli MA, 2008, VET J, V177, P89, DOI 10.1016/j.tvjl.2007.03.008
   Bai ZD, 2011, AFR J BIOTECHNOL, V10, P12333
   Caswell JL, 2010, VET CLIN N AM-FOOD A, V26, P365, DOI 10.1016/j.cvfa.2010.03.003
   Caswell Jeff L., 2007, Animal Health Research Reviews, V8, P161, DOI 10.1017/S1466252307001351
   Chen SL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00379
   Chen W, 2012, J NE AGR U
   Corona L, 2013, VET MICROBIOL, V167, P434, DOI 10.1016/j.vetmic.2013.08.024
   Dai XF, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.231
   Dallo SF, 2002, MOL MICROBIOL, V46, P1041, DOI 10.1046/j.1365-2958.2002.03207.x
   De Angelis M, 2015, PROTEOMICS, V15, P2244, DOI 10.1002/pmic.201400363
   Fu P, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-42
   Gagea MI, 2006, J VET DIAGN INVEST, V18, P29, DOI 10.1177/104063870601800105
   HALE HH, 1962, CORNELL VET, V52, P582
   Herbrich SM, 2013, J PROTEOME RES, V12, P594, DOI 10.1021/pr300624g
   Hui S, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145697
   Khan Farhan Anwar, 2018, Oncotarget, V9, P28322, DOI 10.18632/oncotarget.22265
   Klumpp S, 2013, P NATL ACAD SCI USA, V110, P16754, DOI 10.1073/pnas.1310377110
   Onisko B, 2007, J AM SOC MASS SPECTR, V18, P1070, DOI 10.1016/j.jasms.2007.03.009
   Perez-Casal J, 2017, VACCINE, V35, P2902, DOI 10.1016/j.vaccine.2017.03.095
   Prysliak T, 2016, CAN J MICROBIOL, V62, P492, DOI 10.1139/cjm-2015-0762
   Rasheed MA, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00177
   Robino P, 2007, VET RES COMMUN, V31, P257, DOI 10.1007/s11259-007-0019-2
   Robino P, 2005, VET MICROBIOL, V109, P201, DOI 10.1016/j.vetmic.2005.05.007
   Sachse K, 2000, INFECT IMMUN, V68, P680, DOI 10.1128/IAI.68.2.680-687.2000
   Scott M, 2010, SCIENCE, V330, P1099, DOI 10.1126/science.1192588
   Soehnlen MK, 2011, VACCINE, V29, P5347, DOI 10.1016/j.vaccine.2011.05.092
   SU Wei-De, 2016, J AGR BIOTECHNOL
   Sun ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088328
   Vihinen M, 2001, BIOMOL ENG, V18, P241, DOI 10.1016/S1389-0344(01)00099-5
   Wang XH, 2018, J INTEGR AGR, V17, P428, DOI [10.1016/S2095-3119(17)61747-7, 10.1016/s2095-3119(17)61747-7]
   Wiggins MC, 2011, COMP IMMUNOL MICROB, V34, P49, DOI 10.1016/j.cimid.2010.02.001
   Yi L, 2016, VET RES, V47, DOI 10.1186/s13567-016-0334-0
   You CH, 2013, NATURE, V500, P301, DOI 10.1038/nature12446
   Zhang P, 2016, J PROTEOMICS, V133, P93, DOI 10.1016/j.jprot.2015.12.014
   Zhang R, 2014, VACCINE, V32, P3107, DOI 10.1016/j.vaccine.2013.12.004
   Zhao P, 2012, J VET MED SCI, V74, P1109, DOI 10.1292/jvms.12-0095
   Zhu ML, 2019, NUCLEIC ACIDS RES, V47, P4684, DOI 10.1093/nar/gkz211
NR 38
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 549
EP 561
DI 10.1016/j.vaccine.2019.10.061
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900016
PM 31740094
DA 2020-05-12
ER

PT J
AU Gilbert, SS
   Bulula, N
   Yohana, E
   Thompson, J
   Beylerian, E
   Werner, L
   Shearer, JC
AF Gilbert, Sarah Skye
   Bulula, Ngwegwe
   Yohana, Emmanuel
   Thompson, Jenny
   Beylerian, Emily
   Werner, Laurie
   Shearer, Jessica C.
TI The impact of an integrated electronic immunization registry and
   logistics management information system (EIR-eLMIS) on vaccine
   availability in three regions in Tanzania: A pre-post and time-series
   analysis
SO VACCINE
LA English
DT Article
DE Digital health; Supply chain; Information system; Immunization;
   Tanzania; Stock notification
AB Background: Since 2016, the Government of Tanzania has been implementing TImR, an integrated Electronic Immunization registry-logistics management information system (EIR-LMIS) that includes stock notifications. The objective of this study is to estimate the impact of this intervention on vaccine availability.
   Methods: Monthly stock-out data were collected from paper registers at facilities, an Excel-based system at districts, and the new system (TImR) across all 924 health facilities in Arusha, Tanga and Kilimanjaro Regions. Six months of stockout rates pre- and post-introduction, by antigen, were compared via a two-way analysis of variance (ANOVA). A mixed-effects logistic regression model with the TImR data identified predictors of vaccine availability across antigens.
   Findings: Post-introduction, ANOVA models estimated that overall stock-out rates declined from a monthly average of 7.1% to 2.1% (p < 0.01). Three specific vaccines had fewer stock-outs; OPV's monthly average dropped from 12.5% to 2.1% (p < 0.01), MR from 9.4% to 1.0% (p < 0.01) and DTP-HepB-HiB from 8.1% to 1.7% (p < 0.01). In the mixed-effects logistic regression model, controlling for antigen, odds of stock-out were 4.1% (95% CI: 33 - 4.9) lower for each week of tenure. Compared to DTP-HepB-HiB vaccine, odds of BCG vaccine being stocked out were 4.31 as high (95% CI: 3.1 - 5.0). The odds of being stocked-out were 29.7% lower for PCV (95% CI: 8.8 - 45.8) and 26.6% (95% CI: 3.4 - 44.1) lower for rota virus vaccines compared to DTP-HepB-HiB. The odds of stock out were 37.7% lower for MR vaccine than DTP-HepB-HiB (95% Cl: 18.1 - 52.6).
   Conclusions: Tanzania's integrated EIR-eLMIS may increase vaccine availability compared to its paper and Excel based system. Post-introduction of an eLMIS, the odds of a vaccine stock-out reduced over time. Further research could determine the impact of this intervention on vaccine wastage and replenishment response times. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Gilbert, Sarah Skye; Thompson, Jenny; Beylerian, Emily; Werner, Laurie; Shearer, Jessica C.] PATH, POB 900922, Seattle, WA 98109 USA.
   [Bulula, Ngwegwe; Yohana, Emmanuel] Univ Dodoma, Govt Tanzania, Minist Hlth Community Dev Gender Elderly & Childr, Fac Social Sci Community Dev, Bldg 11,POB 743, Dodoma 40478, Tanzania.
RP Gilbert, SS (reprint author), PATH, POB 900922, Seattle, WA 98109 USA.
EM sskyegilbert@gmail.com
FU Government of Tanzania; Bill & Melinda Gates FoundationGates Foundation
FX The authors would like to thank the Government of Tanzania for its deep
   thought partnership in developing these interventions and evaluating
   their efficacy. In addition, the authors would like to acknowledge the
   contributions of additional members of the analytics team, including Mr.
   Hassan Mtenga, Dr. Alain Labrique, Ms. Emma Korpi, Dr. Hil Hyons, Dr.
   Tove Ryman, Mr. John Richard and Ms. Emily Carnahan. Finally, the
   authors would like to thank the Bill & Melinda Gates Foundation for
   funding and supporting this research.
CR Abdekhoda M, 2015, J BIOMED INFORM, V53, P174, DOI 10.1016/j.jbi.2014.10.008
   Agarwal S, 2018, COCHRANE DB SYST REV, V2018, DOI /101002/ 14651858.CD012907
   Agarwal S, 2015, TROP MED INT HEALTH, V20, P1003, DOI 10.1111/tmi.12525
   Bogan M, 2009, PRESENT W3C WORK ROL
   Central Bureau of Statistics G of T, COUNTRYSTAT UNITED R
   Chaiyachati KH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064662
   Gilbert SS, 2017, VACCINE, V35, P2203, DOI 10.1016/j.vaccine.2016.11.101
   Jo Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102224
   John Kotter, 2007, HARY BUS REV, P96, DOI [10.1109/EMR.2009.5235501, DOI 10.1109/EMR.2009.5235501]
   Nguyen L, 2017, CAMB INT LAW J, V6, P1, DOI 10.4337/cilj.2017.01.00
   Lydon P, 2017, VACCINE, V35, P2121, DOI 10.1016/j.vaccine.2016.12.071
   Manda TD, 2010, IMPLEMENTING MOBILE, P95
   Medhi I, 2012, COMBATING RURAL CHIL, P635, DOI [10.1145/2399016.2399113, DOI 10.1145/2399016.2399113]
   Mwanyika H., BID INITIAT BLOG
   Petter S, 2008, EUR J INFORM SYST, V17, P236, DOI 10.1057/ejis.2008.15
   Prosser W, 2017, VACCINE, V35, P2162, DOI 10.1016/j.vaccine.2016.09.073
   Public Health Informatics Institute, 2019, COLL REQ DEV METH
   Ramanujapuram A, P 5 ACM S COMP DEV N, P11, DOI [10.1145/2.674377.26743R?, DOI 10.1145/2674377.2674382]
   Sarley D, 2017, VACCINE, V35, P2167, DOI 10.1016/j.vaccine.2016.11.068
   Shieshia M, 2014, J GLOB HEALTH, V4, P117, DOI 10.7189/jogh.04.020406
   Sirkin HL, 2005, HARVARD BUS REV, V83, P108
   Wagenaar BH, 2016, HEALTH POLICY PLANN, V31, P129, DOI 10.1093/heapol/czv029
   WHO, 2016, IMM SUPPL CHAIN LOG
   WHO & UNICEF, 2015, EFF VACC MAN EVM GLO
   World Health Organization, 2019, REC DIG INT HLTH SYS, P175
   World Health Organization, 2018, UPD CONS GUID PROGR, P1
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 562
EP 569
DI 10.1016/j.vaccine.2019.10.059
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900017
PM 31706808
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Goettler, D
   Streng, A
   Kemmling, D
   Schoen, C
   von Kries, R
   Rose, MA
   van der Linden, M
   Liese, JG
AF Goettler, D.
   Streng, A.
   Kemmling, D.
   Schoen, C.
   von Kries, R.
   Rose, M. A.
   van der Linden, M.
   Liese, J. G.
TI Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic
   pleural effusion/empyema after the introduction of PCV13 in Germany
SO VACCINE
LA English
DT Article
DE Pleural empyema; Parapneumonic pleural effusion; Streptococcus
   pneumoniae; Serotype 3; Vaccine breakthrough; Children
ID PNEUMOCOCCAL CONJUGATE VACCINE; COMMUNITY-ACQUIRED PNEUMONIA;
   DETERMINING CAPSULAR SEROTYPES; SEQUENTIAL MULTIPLEX PCR; US CHILDREN;
   TEMPORAL TRENDS; 13-VALENT; EMPYEMA; DISEASE; HOSPITALIZATIONS
AB Introduction: Pediatric pneumococcal pneumonia complicated by parapneumonic pleural effusion/empyema (PPE/PE) remains a major concern despite general immunization with pneumococcal conjugate vaccines (PCVs).
   Methods: In a nationwide pediatric hospital surveillance study in Germany we identified 584 children <18 years of age with bacteriologically confirmed PPE/PE from October 2010 to June 2018. Streptococcus pneumoniae was identified by culture and/or PCR of blood samples and/or pleural fluid and serotyped.
   Results: S. pneumoniae was identified in 256 of 584 (43.8%) children by culture (n = 122) and/or PCR (n = 207). The following pneumococcal serotypes were detected in 114 children: serotype 3 (42.1%), 1 (25.4%), 7F (12.3%), 19A (7.9%), other PCV13 serotypes (4.4%) and non-PCV13 serotypes (7.9%). Between October 2010 and June 2014 serotype 1 (38.1%) and serotype 3 (25.4%) were most prevalent, whereas between July 2014 and June 2018 serotype 3 (62.7%) and non-PCV13 serotypes (15.7%) were dominant. Compared to children with other pneumococcal serotypes, children with serotype 3 associated PPE/PE were younger (median 3.2 years [IQR 2.1-4.3 years] vs. median 5.6 years [IQR 3.8-8.2 years]; p < 0.001) and more frequently admitted to intensive care (43 [89.6%] vs. 48 [73.8%]; p = 0.04). Seventy-six of 114 (66.7%) children with pneumococcal PPE/PE had been vaccinated with pneumococcal vaccines. Thirty-nine of 76 (51.3%) had received a vaccine covering the serotype detected. Thirty of these 39 breakthrough cases were age-appropriately vaccinated with PCV13 and considered vaccine failures, including 26 children with serotype 3, three children with serotype 19A and one child with serotype 1.
   Conclusion: Following the introduction of PCV13 in general childhood vaccination we observed a strong emergence of serotype 3 associated PPE/PE in the German pediatric population, including a considerable number of younger children with serotype 3 vaccine breakthrough cases and failures. Future PCVs should not only cover newly emerging serotypes, but also include a more effective component against serotype 3. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Goettler, D.; Streng, A.; Kemmling, D.; Liese, J. G.] Univ Hosp Wurzburg, Dept Pediat, Josef Schneider Str 2, D-97080 Wurzburg, Germany.
   [Schoen, C.] Univ Wurzburg, Inst Hyg & Microbiol, Wurzburg, Germany.
   [von Kries, R.] Ludwig Maximilians Univ Munchen, Inst Social Pediat & Adolescent Med, Div Epidemiol, Munich, Germany.
   [Rose, M. A.] Olgahosp Stuttgart, Stuttgart, Germany.
   [Rose, M. A.] Goethe Univ Frankfurt, Pediat Pulmonol Allergy & CF, Frankfurt, Germany.
   [van der Linden, M.] Univ Hosp RWTH Aachen, Natl Reference Ctr Streptococci, Dept Med Microbiol, Aachen, Germany.
RP Liese, JG (reprint author), Univ Hosp Wurzburg, Dept Pediat, Josef Schneider Str 2, D-97080 Wurzburg, Germany.
EM davidgoettler@posteo.de; Streng_A@ukw.de; Kemmling_D@ukw.de;
   E_Schoen_C@ukw.de; ruediger.kries@med.uni-muenchen.de;
   m.rose@klinikum-stuttgart.de; mlinden@ukaachen.de; Liese_J@ukw.de
OI Streng, Andrea/0000-0003-2377-7106
FU Pfizer Pharma GmbH, Berlin, Germany [WS 1792995]
FX This investigator-initiated study was supported by an unrestricted
   financial grant by Pfizer Pharma GmbH, Berlin, Germany; grant ID WS
   1792995. The funding source had no role in the design or conduct of the
   study, the collection, management, analysis or interpretation of data or
   in the preparation or approval of the manuscript.
CR Abu Seir R, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0206927e0206927, DOI 10.1371/JOURNAL.PONE.0206927E0206927.]
   Almeida AF, 2016, EUR J PUBLIC HEALTH, V26, P887, DOI 10.1093/eurpub/ckw089
   Angoulvant F, 2014, CLIN INFECT DIS, V58, P918, DOI 10.1093/cid/ciu006
   Antachopoulos C, 2014, PEDIATR INFECT DIS J, V33, P81, DOI 10.1097/INF.0000000000000041
   Asner SA, 2019, CLIN INFECT DIS, DOI [10.1093./idiriy1139, DOI 10.1093/IDIRIY1139]
   Azzari C, 2019, VACCINE, V37, P2704, DOI 10.1016/j.vaccine.2019.04.012
   Bender JM, 2008, CLIN INFECT DIS, V46, P1346, DOI 10.1086/586747
   Bernaola E, 2018, PEDIATR INFECT DIS J, V37, pE87, DOI 10.1097/INF.0000000000001798
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Burgos J, 2013, CURR OPIN PULM MED, V19, P350, DOI 10.1097/MCP.0b013e3283606ab5
   Byington CL, 2005, CLIN INFECT DIS, V41, P21, DOI 10.1086/430604
   Choi EH, 2016, CLIN VACCINE IMMUNOL, V23, P162, DOI 10.1128/CVI.00591-15
   Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428
   De Wals P, 2018, VACCINE, V36, P421, DOI 10.1016/j.vaccine.2017.11.054
   Dias CA, 2007, J MED MICROBIOL, V56, P1185, DOI 10.1099/jmm.0.47347-0
   Diaz-Conradi A, 2019, PEDIATR PULM, V54, P517, DOI 10.1002/ppul.24279
   Ebrahimi-Fakhari D, 2018, KLIN PADIATR, V230, P215, DOI 10.1055/a-0586-4365
   Fenoll A, 2009, J CLIN MICROBIOL, V47, P1012, DOI 10.1128/JCM.01454-08
   Fletcher MA, 2014, EUR J CLIN MICROBIOL, V33, P879, DOI 10.1007/s10096-014-2062-6
   Godot C, 2015, PEDIATR INFECT DIS J, V34, pE260, DOI 10.1097/INF.0000000000000818
   Goldbart AD, 2009, SCAND J INFECT DIS, V41, P182, DOI 10.1080/00365540802688378
   Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165
   Grijalva CG, 2011, THORAX, V66, P663, DOI 10.1136/thx.2010.156406
   Grijalva CG, 2010, CLIN INFECT DIS, V50, P805, DOI 10.1086/650573
   Heininger U, 2012, VACCINE, V30, P1265, DOI 10.1016/j.vaccine.2011.12.048
   Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348
   Kaplan SL, 2013, PEDIATR INFECT DIS J, V32, P203, DOI 10.1097/INF.0b013e318275614b
   Levy C, 2017, VACCINE, V35, P5058, DOI 10.1016/j.vaccine.2017.06.057
   Li STT, 2010, PEDIATRICS, V125, P26, DOI 10.1542/peds.2009-0184
   Liese JG, 2018, CLIN MICROBIOL INFEC, DOI [10.1016/j.cmi.2018.10.020, DOI 10.1016/J.RMI701R10070]
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Madhi F, 2014, PEDIATR INFECT DIS J, V33, P545, DOI 10.1097/INF.0000000000000252
   Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3
   Moraga-Llop F, 2016, PEDIATR INFECT DIS J, V35, P460, DOI 10.1097/INF.0000000000001041
   Nath S, 2015, ARCH DIS CHILD, V100, P255, DOI 10.1136/archdischild-2014-306525
   Novak D, 2013, SCAND J INFECT DIS, V45, P411, DOI 10.3109/00365548.2012.737019
   Nunes MC, 2011, EXPERT REV VACCINES, V10, P951, DOI [10.1586/erv.11.76, 10.1586/ERV.11.76]
   Nyambat B, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-90
   Olarte L, 2017, CLIN INFECT DIS, V64, P1699, DOI 10.1093/cid/cix115
   Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006
   Picazo JJ, 2019, VACCINE, V37, P2200, DOI 10.1016/j.vaccine.2019.03.015
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Roth GA, 2017, J AM COLL CARDIOL, V70, P1, DOI 10.1016/j.jacc.2017.04.052
   Rudan I, 2013, J GLOB HEALTH, V3, DOI [10.7189Ljogh.03010401010401, DOI 10.7189/JOGH.03010401010401]
   Sahn SA, 2007, CLIN INFECT DIS, V45, P1480, DOI 10.1086/522996
   Shen CF, 2013, J FORMOS MED ASSOC, V112, P561, DOI 10.1016/j.jfma.2013.05.015
   Silva-Costa C, 2018, EMERG INFECT DIS, V24, P1307, DOI 10.3201/eid2407.180029
   Sings HL, 2019, CLIN INFECT DIS, V68, P2135, DOI 10.1093/cid/ciy920
   Slotved HC, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00198
   Snape MD, 2010, PEDIATR INFECT DIS J, V29, pE71, DOI 10.1097/INF.0b013e3181f59f6d
   Steens A, 2013, VACCINE, V31, P6232, DOI 10.1016/j.vaccine.2013.10.032
   STIKO, 2006, EPIDEMIOL B, V32, P271
   STIKO, 2001, EPIDEMIOL B, V28, P201
   STIKO, 2015, EPIDEMIOL B, V36, P377, DOI [https://doi.org/10.17886/EpiBull-2015-005., 10.17886/EpiBull-2015-005]
   Theidel U, 2013, GESUNDHEITSWESEN, V75, P309, DOI 10.1055/s-0032-1321747
   van der Linden M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161257
   Vanderkooi OG, 2012, PEDIATR INFECT DIS J, V31, P72, DOI 10.1097/INF.0b013e318233049d
   Weigl JAI, 2005, KLIN PADIATR, V217, P211, DOI 10.1055/s-2004-822699
   Weinberger DM, 2010, CLIN INFECT DIS, V51, P692, DOI 10.1086/655828
   Weinberger R, 2018, VACCINE, V36, P572, DOI 10.1016/j.vaccine.2017.11.085
   Weiss S, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.10.21057
   Wiese AD, 2019, EXPERT REV VACCINES, V18, P327, DOI 10.1080/14760584.2019.1582337
   Wiese AD, 2016, VACCINE, V34, P6243, DOI 10.1016/j.vaccine.2016.10.062
   Yu JG, 2011, J CLIN MICROBIOL, V49, P534, DOI 10.1128/JCM.01827-10
NR 64
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 570
EP 577
DI 10.1016/j.vaccine.2019.10.056
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900018
PM 31735502
OA Other Gold
DA 2020-05-12
ER

PT J
AU Otten, G
   Matassa, V
   Ciarlet, M
   Leav, B
AF Otten, Gillis
   Matassa, Vincent
   Ciarlet, Max
   Leav, Brett
TI A phase 1, randomized, observer blind, antigen and adjuvant dosage
   finding clinical trial to evaluate the safety and immunogenicity of an
   adjuvanted, trivalent subunit influenza vaccine in adults >= 65 years of
   age
SO VACCINE
LA English
DT Article
DE MF59; Influenza vaccine; Elderly; Immunogenicity; Safety
ID ELDERLY SUBJECTS; EMULSION; MF59
AB Objective: To assess the safety and immunogenicity of the MF59 (R)-adjuvanted trivalent influenza vaccine (aTIV; Fluad (R)) compared with modified aTIV formulations.
   Methods: A total of 196 subjects >= 65 years were randomized to receive 7 different formulations of vaccine containing a range of adjuvant and antigen doses by single injection, or divided into two injections at a single time point. The primary study objective was to compare the serologic response of different formulations of aTIV containing increased amounts of adjuvant and antigen 21 days after vaccination. Subjects were followed for immunogenicity and safety for one year.
   Results: The highest immune response, as measured by hemagglutination inhibition (HI) assay, 3 weeks after vaccination was observed in subjects in Group 6 with GMT 382.2 (95% confidence interval [CI] 237.5 to 615.0), 552.3 (364.8 to 836.1), and 54.1 (36.9 to 79.4) against A/H1N1, A/H3N2, and B respectively. Rates of seroconversion were also generally highest in this treatment group: 75% (95% CI 55.1 to 89.3), 75% (55.1 to 89.3), and 42.9% (24.5 to 62.8), respectively, against A/H1N1, A/H3N2, and B strains. The highest incidence of solicited adverse events (AEs) was reported by subjects who received both the highest dosage of antigen in combination with the highest dosage of adjuvant at the same site: 67.9% and 57.1% in Groups 4 and 6, respectively. The majority of solicited AEs were mild to moderate in severity. The number of unsolicited AEs was similar across the different dosages.
   Conclusion: In this phase I trial of adults >= 65 years of age who received increased adjuvant and antigen dosages relative to the licensed aTIV, increased dosage of MF59 resulted in increased immunogenicity against all 3 components of seasonal influenza vaccine. The increase in immunogenicity was accompanied by an increase in the incidence of local reactogenicity. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Otten, Gillis; Leav, Brett] Seqirus Inc, 50 Hampshire St, Cambridge, MA 02139 USA.
   [Matassa, Vincent] Seqirus Australia, 63 Poplar Rd, Parkville, Vic 3052, Australia.
   [Ciarlet, Max] Novartis Vaccines & Diagnost, 45 Sidney St, Cambridge, MA 02139 USA.
RP Leav, B (reprint author), Seqirus Inc, 50 Hampshire St, Cambridge, MA 02139 USA.
EM Gillis.Otten@Seqirus.com; Vince.Matassa@Seqirus.com;
   Brett.Leav@Seqirus.com
FU Seqirus Inc.
FX The authors thank all the participants and the investigator and site
   personnel who participated in the conduct of this trial. Thomas Kornicke
   advised on operational aspects of the study design (particularly
   observer blinding) and study administration. The authors also
   acknowledge Andrea Feller, Christian W. Mandl, Lesley Nguyen, and
   Allison August (Novartis Vaccines) for crucial clinical input in the
   clinical trial design and protocol development. The manuscript was
   drafted with editorial assistance from medical writing consultants C.
   Gordon Beck and Amanda Justice, which was funded by Seqirus Inc.
CR [Anonymous], 2007, GUID IND TOX GRAD SC
   Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Centers for Disease Control and Prevention, 2018, TRANSCR CDC UPD FLU
   Frey SE, 2014, VACCINE, V32, P5027, DOI 10.1016/j.vaccine.2014.07.013
   Izurieta HS, 2018, J INFECT DIS
   Khurana S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002336
   Kobayashi Osamu, 2014, Trop Med Health, V42, P87, DOI 10.2149/tmh.2014-S12
   Mannino S, 2012, AM J EPIDEMIOL, V176, P527, DOI 10.1093/aje/kws313
   MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211
   Minutello M, 1999, VACCINE, V17, P99, DOI 10.1016/S0264-410X(98)00185-6
   Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105
   Mullooly JP, 2007, VACCINE, V25, P846, DOI 10.1016/j.vaccine.2006.09.041
   Nolan T, 2014, VACCINE, V32, P6146, DOI 10.1016/j.vaccine.2014.08.068
   O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/erv.12.140, 10.1586/ERV.12.140]
   Reber AJ, 2012, AGING DIS, V3, P68
   Sasaki S, 2011, J CLIN INVEST, V121, P3109, DOI 10.1172/JCI57834
   Seubert A, 1950, J IMMUNOL, V2008, P5402
   Seubert A, 2011, P NATL ACAD SCI USA, V108, P11169, DOI 10.1073/pnas.1107941108
   Spensieri F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157066
   Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059
   Vesikari T, 2018, LANCET RESP MED, V6, P345, DOI [10.1016/s2213-2600(18)30108-5, 10.1016/S2213-2600(18)30108-5]
   Viboud C, 2008, PLOS MED, V5, P1423, DOI 10.1371/journal.pmed.0050216
   Villa M, 2013, AM J EPIDEMIOL, V178, P1139, DOI 10.1093/aje/kwt078
   Zamparo E, 2011, J Prev Med Hyg, V52, P116
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 578
EP 587
DI 10.1016/j.vaccine.2019.10.058
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900019
PM 31679865
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ikilezi, G
   Augusto, OJ
   Dieleman, JL
   Sherr, K
   Lim, SS
AF Ikilezi, Gloria
   Augusto, Orvalho J.
   Dieleman, Joseph L.
   Sherr, Kenneth
   Lim, Stephen S.
TI Effect of donor funding for immunization from Gavi and other development
   assistance channels on vaccine coverage: Evidence from 120 low and
   middle income recipient countries
SO VACCINE
LA English
DT Article
DE Vaccine; Gavi; Recipient countries; Development assistance for health;
   GVAP; Universal immunization coverage
ID HEALTH; VALIDITY; IMPACT
AB Donor assistance for immunization has remained resilient with increased resource mobilization efforts in recent years to achieve current global coverage targets. As a result, more countries continue to introduce new vaccines while optimizing coverage for traditional vaccines. Gavi the Vaccine Alliance has been at the forefront of immunization support specifically among low and middle income countries, alongside other channels of development assistance which continue to play a vital role in immunization.
   Using available recipient country level data from 1996 to 2016, we estimate the impact of Gavi support for vaccines and health systems strengthening on vaccine coverage for 3 dose DPT, 3 dose pneumococcal conjugate vaccine, 3 dose pentavalent, 2 dose measles and 2 dose rotavirus vaccines. We investigate the same effects of total aid for immunization from other channels of development assistance. Standard time series cross sectional analysis methods are applied to investigate the effects of vaccine support controlling for country income, governance and population, with robustness tests implemented using different model specifications. Double counting was eliminated and results are presented in real 2017 US dollars.
   We found significant positive effects of aid particularly among the newer vaccines. Using 2016 country specific disbursements and coverage levels as baseline, we estimated that among recipient countries below the universal target, additional DAH per capita required to reach 90%, ranged from 0.01USD to 4.33USD for PCV, 0.03USD to 9.06USD for pentavalent vaccine and 0.01USD to 2.57USD for rotavirus vaccine. The estimated number of children vaccinated through 2016, attributable to Gavi support totaled 46.6million, 75.2million and 12.3million for PCV, pentavalent and rotavirus vaccines respectively.
   Our analysis suggests substantial success both from a historical and prospective perspective in the implementation of global immunization initiatives thus far. As more vaccines are rolled out and countries transition from donor aid, strategies for fiscal sustainability and efficiency need to be strengthened in order to achieve universal immunization coverage. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Ikilezi, Gloria; Dieleman, Joseph L.; Lim, Stephen S.] Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA.
   [Augusto, Orvalho J.; Sherr, Kenneth] Univ Washington, Dept Global Hlth, Harris Hydraul Lab, Box 357965, Seattle, WA 98195 USA.
RP Ikilezi, G (reprint author), Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA.
EM gri@uw.edu
RI Augusto, Orvalho/J-8767-2019
OI Augusto, Orvalho/0000-0002-0005-3968
CR [Anonymous], 2017, WHO UNICEF JOINT REP
   [Anonymous], 2018, FIN GLOB HLTH 2017 F
   Anya BPM, 2016, VACCINE, V34, P5187, DOI 10.1016/j.vaccine.2016.05.062
   Arsenault C, 2017, VACCINE, V35, P2479, DOI 10.1016/j.vaccine.2017.03.029
   Biscaye PE, 2017, REV DEV ECON, V21, P1425, DOI 10.1111/rode.12303
   Bojang KA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000409
   Fullman N, 2017, LANCET, V390, P1423, DOI 10.1016/S0140-6736(17)32336-X
   Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3
   Gavi The Vaccine Alliance, 2018, FACTAND FIG
   Gavi The Vaccine Alliance, 2016 2020 STRAT IND
   Gavi The Vaccine Alliance, 2018, VACC SUPP
   Gavi The Vaccine Alliance, DISB COMM
   Gavi The Vaccine Alliance, GAV STRAT PHAS 4 201
   Gulrajani N., 2016, BILATERAL VERSUS MUL, P24
   Haddad S, 2010, HEALTH POLICY PLANN, V25, P393, DOI 10.1093/heapol/czq007
   Hellevik O, 2009, QUAL QUANT, V43, P59, DOI 10.1007/s11135-007-9077-3
   Ikilezi G, 2018, VACCINE, V36, P7487, DOI 10.1016/j.vaccine.2018.10.062
   Institute for Health Metrics and Evaluation, 2017, GLOB HLTH DAT EXCH 1
   Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1
   Kaufmann D, 2011, HAGUE J RULE LAW, V3, P220, DOI 10.1017/S1876404511200046
   KEJA K, 1988, World Health Statistics Quarterly, V41, P59
   Koehlmoos TP, 2011, J INFECT DIS, V204, pS90, DOI 10.1093/infdis/jir086
   Leach-Kemon K, 2012, HEALTH AFFAIR, V31, P228, DOI 10.1377/hlthaff.2011.1154
   Leiderer S, 2015, J INT DEV, V27, P1422, DOI 10.1002/jid.3184
   Lim SS, 2008, LANCET, V372, P2031, DOI 10.1016/S0140-6736(08)61869-3
   Lu CL, 2006, LANCET, V368, P1088, DOI 10.1016/S0140-6736(06)69337-9
   Murray CJL, 2003, LANCET, V362, P1022, DOI 10.1016/S0140-6736(03)14411-X
   Njoroge AW, 2014, THESIS
   Plowman B, 2009, HLTH SYSTEMS STRENGT
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Roodman D., 2006, 982943 SOC SCI RES N
   UNICEF Supply, 2018, UNICEF PRIC DAT OV
   Universal Health Coverage Partnership, 2018, HIST STEP HLTH ALL B
   Wallace AS, 2017, J INFECT DIS, V216, pS280, DOI 10.1093/infdis/jix164
   Wang SA, 2013, VACCINE, V31, pB122, DOI 10.1016/j.vaccine.2012.10.116
   Wangmo S, 2017, QUAL PRIM CARE, V25
   World Health Organization, 2018, SUMM WHO POS PAP REC
   World Health Organization, 2018, SOM LAYS FDN STRONG
   World Health Organization, 2013, GLOB VACC ACT PLAN
NR 39
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 588
EP 596
DI 10.1016/j.vaccine.2019.10.057
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900020
PM 31679863
OA Other Gold
DA 2020-05-12
ER

PT J
AU Zeng, WG
   Horrocks, KJ
   Tan, ACL
   Wong, CY
   Chua, BY
   Jackson, DC
AF Zeng, Weiguang
   Horrocks, Kylie J.
   Tan, Amabel C. L.
   Wong, Chinn Yi
   Chua, Brendon Y.
   Jackson, David C.
TI Modular platforms for the assembly of self-adjuvanting lipopeptide-based
   vaccines for use in an out-bred population
SO VACCINE
LA English
DT Article
DE Vaccines; Lipopeptide; Adjuvant; T helper cell epitope; Antibody
   responses
ID T-CELL RESPONSES; CHEMOSELECTIVE LIGATION; CONJUGATE VACCINE; PEPTIDE
   VACCINES; DENDRITIC CELLS; B-CELL; INFLUENZA; EPITOPES; PROTECTION;
   MAGNITUDE
AB To facilitate the preparation of synthetic epitope-based self-adjuvanting vaccines capable of eliciting antibody responses in an out-bred population, we have developed two modular approaches. In the first, the Toll-like receptor 2 agonist Pam(2)Cys and the target antibody epitope are assembled as a module which is then coupled to a carrier protein as a source of antigens to stimulate T cell help. A vaccine candidate made in this way was shown to induce a specific immune response in four different strains of mice without the need for extraneous adjuvant. In the second approach, three vaccine components in the form of a target antibody epitope, a T helper cell epitope and Pam(2)Cys, were prepared separately each carrying different chemical functional groups. By using pH-mediated chemo-selective ligations, the vaccine was assembled in a one-pot procedure. Using this approach, a number of vaccine constructs including a lipopeptide-protein conjugate were made and also shown to elicit immune responses in different strains of mice. These two modular approaches thus constitute a powerful platform for the assembly of self-adjuvanting lipopeptide-based vaccines that can potentially be used to induce robust antibody responses in an outbred population. Finally, our study of the impact of chemical linkages on immunogenicity of a lipopeptide vaccine shows that a stable covalent bond between Pam(2)Cys and a B cell epitope, rather than between Pam(2)Cys and T helper cell epitope is critical for the induction of antibody responses and biological efficacy, indicating that Pam(2)Cys functions not only as an adjuvant but also participates in processing and presentation of the immunogen. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zeng, Weiguang; Horrocks, Kylie J.; Tan, Amabel C. L.; Wong, Chinn Yi; Chua, Brendon Y.; Jackson, David C.] Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Parkville, Vic 3010, Australia.
RP Zeng, WG (reprint author), Univ Melbourne, Dept Microbiol & Immunol, Peter Doherty Inst Infect & Immun, Parkville, Vic 3010, Australia.
EM weiguang@unimelb.edu.au
FU National Health and Medical Research Council of AustraliaNational Health
   and Medical Research Council of Australia [567122]
FX This work was supported by Program Grant 567122 from the National Health
   and Medical Research Council of Australia.
CR AICHELE P, 1990, J EXP MED, V171, P1815, DOI 10.1084/jem.171.5.1815
   Alexander J, 2002, J IMMUNOL, V168, P6189, DOI 10.4049/jimmunol.168.12.6189
   ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0
   Alphs HH, 2008, P NATL ACAD SCI USA, V105, P5850, DOI 10.1073/pnas.0800868105
   Arcuri M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189100
   BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004
   Bottger R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178943
   Brown Lorena E., 2005, Current Drug Delivery, V2, P383, DOI 10.2174/156720105774370258
   Chen JH, 2003, BIOCONJUGATE CHEM, V14, P614, DOI 10.1021/bc025651u
   Chen Z, 2006, TISSUE ANTIGENS, V68, P210, DOI 10.1111/j.1399-0039.2006.00656.x
   Chen ZJ, 2002, J IMMUNOL, V168, P3050, DOI 10.4049/jimmunol.168.6.3050
   Cobbin JCA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115356
   DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0
   DRIJFHOUT JW, 1991, INT J PEPT PROT RES, V37, P27
   Dunshea FR, 2001, J ANIM SCI, V79, P2524
   Fu TM, 2009, VACCINE, V27, P1440, DOI 10.1016/j.vaccine.2008.12.034
   GJERTSEN MK, 1995, LANCET, V346, P1399, DOI 10.1016/S0140-6736(95)92408-6
   Go YM, 2008, BBA-GEN SUBJECTS, V1780, P1271, DOI 10.1016/j.bbagen.2008.01.011
   Gowans EJ, 2010, J HEPATOL, V53, P599, DOI 10.1016/j.jhep.2010.05.007
   He R, 2019, MOLECULES, V24
   JACKSON D C, 1991, Peptide Research, V4, P114
   Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101
   Jones KL, 2008, J VIRAL HEPATITIS, V15, P761, DOI 10.1111/j.1365-2893.2008.01003.x
   Kimura T, 2017, NAT REV UROL, V14, P501, DOI 10.1038/nrurol.2017.77
   KJELDSEN K, 1985, LANCET, V1, P900
   Lau YF, 2006, INT IMMUNOL, V18, P1801, DOI 10.1093/intimm/dxl114
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Mathur D, 2016, SCI REP-UK, V6, DOI 10.1038/srep36617
   Mifsud EJ, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00079
   Nardin EH, 1998, VACCINE, V16, P590, DOI 10.1016/S0264-410X(97)00238-7
   Nardin EH, 2001, J IMMUNOL, V166, P481, DOI 10.4049/jimmunol.166.1.481
   Oh JZ, 2011, BLOOD, V118, P3028, DOI 10.1182/blood-2011-04-348839
   Oh JZ, 2010, J IMMUNOL, V185, P4602, DOI 10.4049/jimmunol.1001892
   Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224
   Richmond P, 1999, J INFECT DIS, V179, P1569, DOI 10.1086/314753
   Robertson JM, 2000, J IMMUNOL, V164, P4706, DOI 10.4049/jimmunol.164.9.4706
   Rose K, 1996, BIOCONJUGATE CHEM, V7, P552, DOI 10.1021/bc960039m
   Rose K, 1995, MOL IMMUNOL, V32, P1031, DOI 10.1016/0161-5890(95)00090-9
   Rose K, 1999, BIOCONJUGATE CHEM, V10, P1038, DOI 10.1021/bc9900587
   Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h
   Tan ACL, 2013, IMMUNOL CELL BIOL, V91, P96, DOI 10.1038/icb.2012.54
   Tan ACL, 2012, MOL PHARMACEUT, V9, P2710, DOI 10.1021/mp300257x
   Tan ACL, 2011, J IMMUNOL, V187, P1895, DOI 10.4049/jimmunol.1100664
   Thaysen-Andersen M, 2007, VACCINE, V25, P2213, DOI 10.1016/j.vaccine.2006.12.033
   Tontini M, 2013, VACCINE, V31, P4827, DOI 10.1016/j.vaccine.2013.07.078
   Wijayadikusumah AR, 2017, AMINO ACIDS, V49, P1691, DOI 10.1007/s00726-017-2466-6
   Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102
   Wille-Reece U, 2006, J EXP MED, V203, P1249, DOI 10.1084/jem.20052433
   Zeng WG, 2012, VACCINE, V30, P4800, DOI 10.1016/j.vaccine.2012.05.017
   Zeng WG, 2011, J BIOL CHEM, V286, P12944, DOI 10.1074/jbc.M111.227744
   Zeng WG, 2011, MOL IMMUNOL, V48, P490, DOI 10.1016/j.molimm.2010.10.003
   Zeng WG, 2002, J IMMUNOL, V169, P4905, DOI 10.4049/jimmunol.169.9.4905
   Zeng WG, 2001, VACCINE, V19, P3843, DOI 10.1016/S0264-410X(01)00152-9
NR 53
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 597
EP 607
DI 10.1016/j.vaccine.2019.10.055
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900021
PM 31740096
DA 2020-05-12
ER

PT J
AU Patel, MM
   Davis, W
   Beacham, L
   Spencer, S
   Campbell, AP
   Lafond, K
   Rolfes, M
   Levine, MZ
   Azziz-Baumgartner, E
   Thompson, MG
   Fry, AM
AF Patel, Manish M.
   Davis, William
   Beacham, Lauren
   Spencer, Sarah
   Campbell, Angela P.
   Lafond, Kathryn
   Rolfes, Melissa
   Levine, Min Z.
   Azziz-Baumgartner, Eduardo
   Thompson, Mark G.
   Fry, Alicia M.
TI Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza
   vaccines in children - A systematic review and a meta-analysis
SO VACCINE
LA English
DT Review
DE Influenza; Inactivated influenza vaccine; Adjuvants; Children;
   Immunogenicity
ID YOUNG-CHILDREN; IMMUNE-RESPONSES; PHASE-III; IMMUNOGENICITY; TRIVALENT;
   LIVE; SAFETY; INFANTS; BURDEN; VIRUS
AB Background: Identifying optimal priming strategies for children <2 years could substantially improve the public health benefits of influenza vaccines. Adjuvanted seasonal influenza vaccines were designed to promote a better immune response among young vaccine-naive children.
   Methods: We systematically reviewed randomized trials to assess hemagglutination inhibition (HAI) antibody response to MF59-adjuvanted inactivated influenza vaccine (aIIV) versus nonadjuvanted IIV among children. We estimated pooled ratios of post-vaccination HAI geometric mean titer (GMT) for aIIV versus IIV and confidence intervals (CIs) using the pooled variances derived from reported CIs.
   Results: Mean age was 28 months (range, 6-72 months). Children received vaccines with either 7.5 mu g (6-35 months) or 15 mu g (>36 months) hemagglutinin of each strain depending on age. Seven of eight trials administered trivalent vaccines and one used quadrivalent vaccine. Pooled post-vaccination GMT ratios against the three influenza vaccine strains were 2.5-3.5 fold higher after 2-dose-aIIV versus 2-dose-IIV among children 6-72 months, and point estimates were higher among children 6-35 months compared with older children. When comparing 1-dose-aIIV to 2-dose-IIV doses, pooled GMT ratios were not significantly different against A/H1N1 (1.0; 95% CI: 0.5-1.8; p = 0.90) and A/H3N2 viruses (1.0; 95% CI: 0.7-1.5; p = 0.81) and were significantly lower against B viruses (0.6; 95% CI: 0.4-0.8; p < 0.001) for both age groups. Notably, GMT ratios for vaccine-mismatched heterologous viruses after 2-dose-aIIV compared with 2-dose-IIV were higher against A/H1N1 (2.0; 95% CI: 1.1-3.4), A/H3N2 (2.9; 95% CI: 1.9-4.2), and B-lineage viruses (2.1; 95% CI: 1.8-2.6).
   Conclusions: Two doses of adjuvanted IIV consistently induced better humoral immune responses against Type A and B influenza viruses compared with nonadjuvanted IIVs in young children, particularly among those 6-35 months. One adjuvanted IIV dose had a similar response to two nonadjuvanted IIV doses against Type A influenza viruses. Longer-term benefits from imprinting and cell-mediated immunity, including trials of clinical efficacy, are gaps that warrant investigation. Published by Elsevier Ltd.
C1 [Patel, Manish M.; Davis, William; Beacham, Lauren; Spencer, Sarah; Campbell, Angela P.; Lafond, Kathryn; Rolfes, Melissa; Levine, Min Z.; Azziz-Baumgartner, Eduardo; Thompson, Mark G.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA.
RP Patel, MM (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd,MS H24-7, Atlanta, GA 30329 USA.
EM aul3@cdc.gov
CR Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002
   BERNSTEIN DI, 1982, PEDIATRICS, V69, P404
   Black S, 2011, PEDIATR INFECT DIS J, V30, P1081, DOI 10.1097/INF.0b013e3182367662
   Bodewes R, 2011, CLIN VACCINE IMMUNOL, V18, P469, DOI 10.1128/CVI.00396-10
   Neto HB, 2009, PEDIATR INFECT DIS J, V28, P365, DOI 10.1097/INF.0b013e31819219b8
   BURRI PH, 1984, ANNU REV PHYSIOL, V46, P617, DOI 10.1146/annurev.ph.46.030184.003153
   Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Casella G., 2001, STAT INFERENCE
   Chaves SS, 2014, PEDIATR INFECT DIS J, V33, P912, DOI 10.1097/INF.0000000000000321
   CLERICI M, 1993, J CLIN INVEST, V91, P2829, DOI 10.1172/JCI116526
   Cruz-Valdez A, 2018, HUM VACC IMMUNOTHER, V14, P386, DOI 10.1080/21645515.2017.1373227
   Della Cioppa G, 2011, VACCINE, V29, P8696, DOI 10.1016/j.vaccine.2011.08.111
   Diallo A, 2018, VACCINE, V36, P6424, DOI 10.1016/j.vaccine.2018.08.032
   Durand CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071079
   Edwards KM, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-4313
   El Omeiri N, 2018, VACCINE, V36, P3555, DOI 10.1016/j.vaccine.2017.06.036
   Englund JA, 2006, PEDIATRICS, V118, pE579, DOI 10.1542/peds.2006-0201
   Flannery B, 2018, J INFECT DIS, V218, P189, DOI 10.1093/infdis/jix634
   Galli G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI 10.1073/pnas.0903181106
   Garcia-Sastre A, 2016, P NATL ACAD SCI USA, V113, P1689, DOI 10.1073/pnas.1525361113
   Gilca V, 2011, VACCINE, V30, P35, DOI 10.1016/j.vaccine.2011.10.062
   GLEZEN WP, 1980, JAMA-J AM MED ASSOC, V243, P1345
   Glezen WP, 1997, PEDIATR INFECT DIS J, V16, P1065, DOI 10.1097/00006454-199711000-00012
   Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1
   GROSS PA, 1977, J INFECT DIS, V136, pS616, DOI 10.1093/infdis/136.Supplement_3.S616
   Gruber WC, 1996, J INFECT DIS, V173, P1313, DOI 10.1093/infdis/173.6.1313
   Heikkinen T, 2012, NEW ENGL J MED, V366, P383, DOI 10.1056/NEJMc1113381
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hoft DF, 2011, J INFECT DIS, V204, P845, DOI 10.1093/infdis/jir436
   Jain VK, 2017, J PEDIATR INFECT DIS, V6, P9, DOI 10.1093/jpids/piw068
   Katz JM, 2011, EXPERT REV ANTI-INFE, V9, P669, DOI [10.1586/eri.11.51, 10.1586/ERI.11.51]
   Khurana S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095496
   Khurana S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002336
   Ko EJ, 2018, HUM VACC IMMUNOTHER, V14, P3041, DOI 10.1080/21645515.2018.1495301
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   Lanthier PA, 2011, VACCINE, V29, P7849, DOI 10.1016/j.vaccine.2011.07.093
   Marshall Stephen W, 2007, Epidemiol Perspect Innov, V4, P4, DOI 10.1186/1742-5573-4-4
   Moore DL, 2018, PAED CHILD HEALT-CAN, V23, pE10, DOI 10.1093/pch/pxx189
   Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Nakaya HI, 2016, P NATL ACAD SCI USA, V113, P1853, DOI 10.1073/pnas.1519690113
   Neuzil KM, 2006, J INFECT DIS, V194, P1032, DOI 10.1086/507309
   Neuzil KM, 2018, LANCET RESP MED, V6, P317, DOI 10.1016/S2213-2600(18)30138-3
   Neuzil KM, 2006, J PEDIATR-US, V149, P737, DOI 10.1016/j.jpeds.2006.09.002
   Neuzil KM, 2002, J INFECT DIS, V185, P147, DOI 10.1086/338363
   Ng TWY, 2019, J INFECT DIS, V219, P1525, DOI 10.1093/infdis/jiy720
   Nolan T, 2014, VACCINE, V32, P6146, DOI 10.1016/j.vaccine.2014.08.068
   O'Hagan DT, 2011, EXPERT REV VACCINES, V10, P447, DOI [10.1586/erv.11.23, 10.1586/ERV.11.23]
   Ploin D, 2007, PEDIATR INFECT DIS J, V26, P142, DOI 10.1097/01.inf.0000253062.41648.60
   Solares AR, 2014, J INFECT DEV COUNTR, V8, P1160, DOI 10.3855/jidc.4594
   Ross TM, 2014, HUM VACC IMMUNOTHER, V10, P1195, DOI 10.4161/hv.28313
   Sancho A, 2012, NEW ENGL J MED, V366, P2528, DOI 10.1056/NEJMc1205643
   Sauerbrei A, 2008, EUROSURVEILLANCE, V2014, P19
   Segaloff HE, 2019, CLIN INFECT DIS
   Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402
   Shi T, 2015, J GLOB HEALTH, V5, P122, DOI 10.7189/jogh.05.010408
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Stassijns J, 2016, VACCINE, V34, P714, DOI 10.1016/j.vaccine.2015.12.024
   Steinhoff MC, 2010, NEW ENGL J MED, V362, P1644, DOI 10.1056/NEJMc0912599
   STOCKS J, 1977, EARLY HUM DEV, V1, P285, DOI 10.1016/0378-3782(77)90041-X
   SWIERKOSZ EM, 1994, J INFECT DIS, V169, P1121, DOI 10.1093/infdis/169.5.1121
   Thompson MG, 2016, PEDIATR INFECT DIS J, V35, P299, DOI 10.1097/INF.0000000000001006
   Vesikari T, 2009, VACCINE, V27, P6291, DOI [10.1016/j.vaccine.2009.02.004, 10.1016/j.vaccine.2009.09.115]
   Vesikari T, 2018, LANCET RESP MED, V6, P345, DOI [10.1016/s2213-2600(18)30108-5, 10.1016/S2213-2600(18)30108-5]
   Vesikari T, 2015, HUM VACC IMMUNOTHER, V11, P2102, DOI 10.1080/21645515.2015.1044167
   Vesikari T, 2011, NEW ENGL J MED, V365, P1406, DOI 10.1056/NEJMoa1010331
   Vesikari T, 2009, PEDIATR INFECT DIS J, V28, P563, DOI 10.1097/INF.0b013e31819d6394
   Viboud C, 2004, BRIT J GEN PRACT, V54, P684
   Walter EB, 2006, PEDIATRICS, V118, pE570, DOI 10.1542/peds.2006-0198
   Ward BJ, 2018, HUM VACC IMMUNOTHER, V14, P647, DOI 10.1080/21645515.2017.1413518
   Webby R, 2016, NAT MED, V22, P1387, DOI 10.1038/nm.4248
   WEBSTER RG, 1982, NATURE, V296, P115, DOI 10.1038/296115a0
   World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU
   WRIGHT PF, 1976, J INFECT DIS, V134, P633, DOI 10.1093/infdis/134.6.633
   Zedda L, 2015, PEDIATR INFECT DIS J, V34, P73, DOI 10.1097/INF.0000000000000465
   Zhu XY, 2012, J VIROL, V86, P13371, DOI 10.1128/JVI.01426-12
NR 78
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 608
EP 619
DI 10.1016/j.vaccine.2019.10.053
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900022
PM 31735505
DA 2020-05-12
ER

PT J
AU Hester, MM
   Lee, CK
   Abraham, A
   Khoshkenar, P
   Ostroff, GR
   Levitz, SM
   Specht, CA
AF Hester, Maureen M.
   Lee, Chrono K.
   Abraham, Ambily
   Khoshkenar, Payam
   Ostroff, Gary R.
   Levitz, Stuart M.
   Specht, Charles A.
TI Protection of mice against experimental cryptococcosis using glucan
   particle-based vaccines containing novel recombinant antigens
SO VACCINE
LA English
DT Article
DE Cryptococcus; Fungal vaccine; T cell vaccine; C57BL/6 mouse; BALB/c
   mouse; Acquired immune deficiency syndrome
ID T-CELL RESPONSES; NEOFORMANS; MANNOPROTEIN; IDENTIFICATION;
   GLYCOSYLATION
AB Meningitis due to Cryptococcus neoformans is responsible for upwards of 180,000 deaths worldwide annually, mostly in immunocompromised individuals. Currently there are no licensed fungal vaccines, and even with anti-fungal drug treatment, cryptococcal meningitis is often fatal. Our lab previously demonstrated vaccination with recombinant cryptococcal proteins delivered in glucan particles (GPs) protects mice against an otherwise lethal infection. The aim of the present study was to discover additional cryptococcal antigens affording vaccine-mediated protection. Sixteen proteins, each with evidence of extracellularity, were selected for in vivo testing based on their abundance in protective alkaline extracts of an acapsular C. neoformans strain, their known immunogenicity, and/or their high transcript level during human infection. Candidate antigens were recombinantly expressed in E. coli, purified and loaded into GPs. BALB/c and C57BL/6 mice received three subcutaneous injections of GP-based vaccine, and survival was assessed for 84 days following a lethal orotracheal challenge with strain KN99. As with our six published GP-vaccines, we saw differences in overall protection between mouse strains such that BALB/c mice typically demonstrated better survival than C57BL/6 mice. From these studies, we identified seven new proteins which, when administered as GP-vaccines, protect BALB/c and/or C5713146 mice against cryptococcal infection. With these results, we expand the pool of novel protective antigens to eleven proteins and demonstrate the potential for selection of highly transcribed extracellular proteins as vaccine targets. These screens highlight the efficacy of GP-subunit vaccines and identify promising antigens for further testing in anti-cryptococcal, multi-epitope vaccine formulations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hester, Maureen M.; Lee, Chrono K.; Levitz, Stuart M.; Specht, Charles A.] Univ Massachusetts, Med Sch, Dept Med, Worcester, MA 01605 USA.
   [Abraham, Ambily; Khoshkenar, Payam; Ostroff, Gary R.] Univ Massachusetts, Program Mol Med, Med Sch, Worcester, MA 01605 USA.
RP Levitz, SM; Specht, CA (reprint author), Lazare Res Bldg,370D 364 Plantat St, Worcester, MA 01605 USA.
EM stuart.levitz@umassmed.edu; charles.specht@umassmed.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 A1025780, R01 AI102618,
   R01A1125045, R01 HL112671, R01 A1072195, T32 A1095213]
FX We acknowledge NIH grants R01 A1025780, R01 AI102618, R01A1125045, R01
   HL112671, and R01 A1072195. MMH was par-tially supported by NIH Training
   Grant T32 A1095213. The funders had no role in study design, data
   collection and interpretation, or the decision to submit the work for
   publication.
CR Agarwal S, 2011, MBIO, V2
   Basenko EY, 2018, J FUNGI, V4, DOI 10.3390/jof4010039
   Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028
   Campbell LT, 2015, EUKARYOT CELL, V14, P554, DOI 10.1128/EC.00052-15
   Chaturvedi AK, 2013, PROTEOMICS, V13, P3429, DOI 10.1002/pmic.201300213
   Chen GH, 2008, INFECT IMMUN, V76, P2379, DOI 10.1128/IAI.01143-07
   Chen Y, 2014, MBIO, V5
   Clarke SC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006051
   Delic M, 2013, FEMS MICROBIOL REV, V37, P872, DOI 10.1111/1574-6976.12020
   Eigenheer RA, 2007, FEMS YEAST RES, V7, P499, DOI 10.1111/j.1567-1364.2006.00198.x
   Firacative C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21039-z
   Geddes JMH, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0532-3
   Ferrareze PAG, 2017, MICROORGANISMS, V5, DOI 10.3390/microorganisms5030049
   Huang C, 2002, INFECT IMMUN, V70, P5485, DOI 10.1128/IAI.70.10.5485-5493.2002
   Huang HB, 2013, CLIN VACCINE IMMUNOL, V20, P1585, DOI 10.1128/CVI.00463-13
   Huang HB, 2012, J IMMUNOL, V189, P312, DOI 10.4049/jimmunol.1200603
   Huang HB, 2010, MBIO, V1, DOI 10.1128/mBio.00164-10
   Huffnagle GB, 1998, J IMMUNOL, V160, P2393
   Janbon G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004261
   Levitz SM, 2001, P NATL ACAD SCI USA, V98, P10422, DOI 10.1073/pnas.181331398
   Mandel MA, 2000, INFECT IMMUN, V68, P6196, DOI 10.1128/IAI.68.11.6196-6201.2000
   Mansour MK, 2002, J IMMUNOL, V168, P2872, DOI 10.4049/jimmunol.168.6.2872
   Nascimento IP, 2012, BRAZ J MED BIOL RES, V45, P1102, DOI 10.1590/S0100-879X2012007500142
   Park YD, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004037
   Patel SS, 1996, DRUGS, V52, P254, DOI 10.2165/00003495-199652020-00010
   Rajasingham R, 2017, LANCET INFECT DIS, V17, P873, DOI [10.1016/S1473-3099(17)30243-8, 10.1016/s1473-3099(17)30243-8]
   Rodrigues ML, 2008, EUKARYOT CELL, V7, P58, DOI 10.1128/EC.00370-07
   Specht CA, 2007, J INFECT DIS, V196, P796, DOI 10.1086/520536
   Specht CA, 2017, MBIO, V8, DOI 10.1128/mBio.01872-17
   Specht CA, 2015, MBIO, V6, DOI 10.1128/mBio.01905-15
   Upadhya R, 2018, MBIO, V9, DOI [10.1128/mBio.02087-18, 10.1128/mbio.02087-18]
   Reuwsaat JCV, 2018, MSPHERE, V3, DOI [10.1128/mSphere.00023-18, 10.1128/msphere.00023-18]
   Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/nchembio.1403, 10.1038/NCHEMBIO.1403]
   Young M, 2009, PROTEOMICS, V9, P2578, DOI 10.1002/pmic.200800713
   Zhou JY, 2018, TRENDS IMMUNOL, V39, P523, DOI 10.1016/j.it.2018.04.004
NR 35
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 620
EP 626
DI 10.1016/j.vaccine.2019.10.051
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900023
PM 31699504
DA 2020-05-12
ER

PT J
AU Zaidi, S
   Riaz, A
   Hussain, SS
   Omer, SB
   Ali, A
AF Zaidi, Shehla
   Riaz, Atif
   Hussain, Syed Shahzad
   Omer, Saad B.
   Ali, Asad
TI Applying a governance barometer to vaccine delivery systems: Lessons
   from a rural district of Pakistan
SO VACCINE
LA English
DT Article
DE Routine immunization; Balanced scorecard; Pakistan
ID BALANCED SCORECARD; IMMUNIZATION; SERVICES; QUALITY; TRENDS
AB Introduction: Weak vaccine delivery systems in countries off-track for routine immunization targets, need in-depth evidence on system level barriers to be critically resourced and monitored. We applied a Balanced Score Card (BSC) approach in a rural underserved district of Pakistan to (i) identify critical areas needing support in the government vaccine delivery system; and (ii) for benchmarking improvements in the vaccine delivery system.
   Methodology: BSC was developed drawing on desk review, government consultations and field testing. 45 immunization indicators were finalized across 8 domains: human resource; vaccine supply; safe vaccination practice; cold chain maintenance; outreach preparedness; records & supervision; verifiable vaccination volume; and client communication. Data were collected through health facility assessments, client exit interviews and household vaccination assessment. A composite score was calculated for each domain and banded into unsatisfactory, borderline and satisfactory categories. 5 lowest ranking domains were targeted for 2 years of health systems strengthening (HSS) interventions. Post-intervention assessment tracked progress.
   Results: The district obtained a cumulative score of 51% (unsatisfactory) at pre-intervention and improved to 82% (satisfactory) at post-intervention. At pre-intervention, 4 domains scored satisfactory and 4 scored unsatisfactory. Unsatisfactory scores were received for: outreach preparedness; records & supervision; verifiable vaccination volume; and client communication. Post intervention 6 of 8 domains scored satisfactory and 2 moved from unsatisfactory to borderline. Highest percentage point (pp) improvements were seen in outreach preparedness (53 pp, p = 0.01), EPI supervision (52 pp, p = 0.01) and verified vaccination volume (46 pp, p = 0.02). 3 domains that were not intervened through HSS interventions had minimal change in scoring - cold chain maintenance (6 pp), safe vaccination practice (12 pp) and vaccine supply (11 pp).
   Conclusion: BSC served to prioritize interventions towards critical unmet needs for vaccine delivery in the district health system and particularly helped to improve outreach preparedness, EPI supervision and verified vaccination volume. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zaidi, Shehla; Riaz, Atif; Hussain, Syed Shahzad; Ali, Asad] Aga Khan Univ, Women & Child Hlth Div, Karachi, Pakistan.
   [Zaidi, Shehla; Riaz, Atif] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan.
   [Omer, Saad B.] Emory Univ, Dept Global Hlth, Atlanta, GA 30322 USA.
   [Omer, Saad B.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Omer, Saad B.] Emory Univ, Dept Paediat, Atlanta, GA 30322 USA.
   [Omer, Saad B.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.
RP Zaidi, S (reprint author), Aga Khan Univ, Dept Community Hlth Sci, Women & Child Hlth Div, Stadium Rd, Karachi, Pakistan.
EM shehla.zaidi@aku.edu
OI Ali, Syed Asad/0000-0001-5274-7665; Zaidi, Shehla/0000-0001-7620-9247
FU Gavi-the vaccine alliance [PP33961213A1]
FX The study was funded by Gavi-the vaccine alliance (grant #PP33961213A1).
CR Ajay Parmar, 2014, National Journal of Community Medicine, V5, P378
   Andersson N, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S8
   Anjum Qudsia, 2004, JPMA Journal of the Pakistan Medical Association, V54, P610
   Ateudjieu Jerome, 2013, BMC Res Notes, V6, P101, DOI 10.1186/1756-0500-6-101
   Central Statistics Organization (CSO) MoPHM and ICF, 2017, AFGH DEM HLTH SURV 2
   DeSavigny D, 2009, SYSTEMS THINKING FOR HEALTH SYSTEMS STRENGTHENING, P1
   Edward A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001066
   Gao T, 2006, LIVES BALANCE MANAGI
   Haddad S, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S15
   Inamdar N, 2002, J HEALTHC MANAG, V47, P179
   KAPLAN R. S., 1996, BALANCED SCORECARD T
   Kazi A, 2013, B WORLD HEALTH ORGAN, V92, P220
   Khan MM, 2013, INT J HEALTH PLAN M, V28, P202, DOI 10.1002/hpm.2136
   Mansuri F, 2003, J AYUB MED COLL ABBO, V15
   Murhekar MV, 2013, B WORLD HEALTH ORGAN, V91, P906, DOI 10.2471/BLT.13.119974
   Mutale W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093977
   Mutale W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058650
   NDHS, 2019, NIG DEM HLTH SURV 20
   Ophori Endurance A, 2014, Trop Med Health, V42, P67, DOI 10.2149/tmh.2013-13
   Owais A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-239
   Pdhs, 2018, PAK DEM HLTH SURV 20
   Perry H, 1998, TROP MED INT HEALTH, V3, P981, DOI 10.1046/j.1365-3156.1998.00333.x
   Peters DH, 2007, B WORLD HEALTH ORGAN, V85, P146, DOI 10.2471/BLT.06.033746
   Rabbani F, 2015, INT J HEALTH CARE Q, V28, P520, DOI 10.1108/IJHCQA-05-2014-0066
   Restrepo-Mendez MC, 2016, B WORLD HEALTH ORGAN, V94, P794, DOI 10.2471/BLT.15.162172
   Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001
   Szilagyi PG, 2000, JAMA-J AM MED ASSOC, V284, P1820, DOI 10.1001/jama.284.14.1820
   Tushar Patel, 2011, Healthline, Journal of Indian Association of Preventive and Social Medicine, V2, P17
   Usman HR, 2011, TROP MED INT HEALTH, V16, P334, DOI 10.1111/j.1365-3156.2010.02698.x
   Usman HR, 2009, VACCINE, V27, P467, DOI 10.1016/j.vaccine.2008.10.048
   WHO, 2017, PROGR CHALL ACH UN I
   WHO UNICEF World Bank, 2009, STATE WORLD VACCINES
   Zaidi S, 2015, HEALTH RES POLICY SY, V13, DOI 10.1186/s12961-015-0041-8
   Zelman William N, 2003, J Health Care Finance, V29, P1
NR 34
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 627
EP 634
DI 10.1016/j.vaccine.2019.10.052
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900024
PM 31699503
DA 2020-05-12
ER

PT J
AU McEntee, CP
   Moran, HBT
   Munoz-Wolf, N
   Liddicoat, AM
   Carroll, EC
   Erbo-Wern, J
   Coulter, IS
   Andersen, P
   Follmann, F
   Lavelle, EC
AF McEntee, Craig P.
   Moran, Hannah B. T.
   Munoz-Wolf, Natalia
   Liddicoat, Alex M.
   Carroll, Elizabeth C.
   Erbo-Wern, Jeanette
   Coulter, Ivan S.
   Andersen, Peter
   Follmann, Frank
   Lavelle, Ed C.
TI Type I IFN signalling is required for cationic adjuvant formulation
   (CAF) 01-induced cellular immunity and mucosal priming
SO VACCINE
LA English
DT Article
DE Vaccine; Adjuvant; Chlamydia; Type 1 interferon; Mucosal; Oral vaccine;
   Cellular immunity; Cationic adjuvant formulation
ID CHLAMYDIA-TRACHOMATIS INFECTION; T-CELLS; PROTECTIVE IMMUNITY; VACCINE;
   MACROPHAGES; GAMMA; POPULATION; TRYPTOPHAN; ANTIBODIES; INDUCTION
AB Despite being in the midst of a global pandemic of infections caused by the pathogen Chlamydia trachomatis, a vaccine capable of inducing protective immunity remains elusive. Given the C. trachomatis mucosal port of entry, a formulation compatible with mucosal administration and capable of eliciting potent genital tract immunity is highly desirable. While subunit vaccines are considered safer and better tolerated, these are typically poorly immunogenic and require co-formulation with immune-potentiating adjuvants. However, of the adjuvants licensed for use in humans, very few drive robust cellular responses, a pre-requisite for protection against C. trachomatis infection. Recently, the cationic adjuvant formulations (CAF) have been shown to induce robust humoral and cellular immunity in pre-clinical models of chlamydia, malaria and tuberculosis (TB). Here, we demonstrate that CAF01 induces potent immune responses when combined with the major outer membrane protein (MOMP) of C. trachomatis following parenteral immunisation and also as part of a heterologous prime/boost regime. We show that a subcutaneous prime with CAF01-adjuvanted recombinant MOMP licenses antigen-specific immunity at distant mucosal sites which can be activated following oral antigen re-encounter in the absence of concomitant adjuvant stimulation. Finally, we shed light on the mechanism(s) through which CAF01 elicits robust antigen-specific immunity to co-formulated MOMP via type I interferon (IFN) signalling. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [McEntee, Craig P.; Moran, Hannah B. T.; Munoz-Wolf, Natalia; Liddicoat, Alex M.; Carroll, Elizabeth C.; Lavelle, Ed C.] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Adjuvant Res Grp, Dublin, Ireland.
   [Erbo-Wern, Jeanette; Andersen, Peter; Follmann, Frank] Staten Serum Inst, Dept Infect Dis Immunol, Adjuvant Res, Copenhagen, Denmark.
   [Coulter, Ivan S.] Dublin City Univ, Invent Ctr, Sigmoid Pharma, Dublin, Ireland.
   [Lavelle, Ed C.] Trinity Coll Dublin, CRANN, Adv Mat & BioEngn Res Ctr AMBER, Dublin, Ireland.
   [McEntee, Craig P.] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester Collaborat Ctr Inflammat Res, Manchester, Lancs, England.
RP Lavelle, EC (reprint author), Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Adjuvant Res Grp, Dublin, Ireland.
EM lavellee@tcd.ie
RI ; Lavelle, Ed/A-1716-2008
OI Andersen, Peter/0000-0002-5869-2551; Lavelle, Ed/0000-0002-3167-1080;
   McEntee, Craig/0000-0002-4762-7607
FU European Commission through the ADITEC consortium
   [FP7-HEALTH-2011.1.4-4-280873]; Science Foundation Ireland investigator
   awardScience Foundation Ireland [12/IA/1421]; SFI Research Centre,
   Advanced Materials and BioEngineering Research (AMBER)Science Foundation
   Ireland [SF1/12/12C/2278]
FX This study was supported by the European Commission through the ADITEC
   consortium contract [FP7-HEALTH-2011.1.4-4-280873], a Science Foundation
   Ireland investigator award (12/IA/1421) to E.C.L. and the SFI Research
   Centre, Advanced Materials and BioEngineering Research (AMBER) under
   Grant number SF1/12/12C/2278.
CR Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285
   Agger EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003116
   Al-Zeer MA, 2013, AUTOPHAGY, V9, P50, DOI 10.4161/auto.22482
   Bai H, 2009, J IMMUNOL, V183, P5886, DOI 10.4049/jimmunol.0901584
   BEATTY WL, 1994, INFECT IMMUN, V62, P3705, DOI 10.1128/IAI.62.9.3705-3711.1994
   Beje S, 2015, IMMUNOL CELL BIOL, P1, DOI [10.1038/kb201579, DOI 10.1038/KB201579]
   Budhwar S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02776
   Burton MJ, 2009, PLOS NEGLTROP DIS, V3
   CAO H, 1989, J IMMUNOL, V143, P3524
   Carroll EC, 2016, IMMUNITY, V44, P597, DOI 10.1016/j.immuni.2016.02.004
   Chawla R, 2004, Indian J Med Microbiol, V22, P185
   Christensen DL, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6503a1
   Christensen D, 2009, J LIPOSOME RES, V19, P2, DOI 10.1080/08982100902726820
   Ciabattini A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00380
   Ciabattini A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00430
   Crotzer VL, 2009, J IMMUNOL, V182, P3335, DOI 10.4049/jimmunol.0803458
   Fernandez-Boyanapalli R, 2010, J IMMUNOL, V185, P4030, DOI 10.4049/jimmunol.1001778
   Gondek DC, 2012, J IMMUNOL, V189, P2441, DOI 10.4049/jimmunol.1103032
   Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552
   Johansson M, 1997, INFECT IMMUN, V65, P1032, DOI 10.1128/IAI.65.3.1032-1044.1997
   Karlsson I, 2013, CLIN IMMUNOL, V146, P120, DOI 10.1016/j.clim.2012.12.005
   Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570
   Koff WC, 2014, NAT IMMUNOL, V15, P589, DOI 10.1038/ni.2871
   Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821
   Lorenzen E, 2015, VET RES, V46
   Lorenzen E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00628
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Miguel RDV, 2012, AM J REPROD IMMUNOL, V68, P499, DOI 10.1111/aji.12008
   Mori A, 2012, EUR J IMMUNOL, V42, P2709, DOI 10.1002/eji.201242372
   Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595
   Newman L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143304
   O'Meara CP, 2014, IMMUNOL CELL BIOL, V92, P287, DOI 10.1038/icb.2013.92
   Olsen AW, 2015, J INFECT DIS, V212, P978, DOI 10.1093/infdis/jiv137
   Olsen AW, 2014, VACCINE, V32, P685, DOI 10.1016/j.vaccine.2013.11.100
   Olsen AW, 2017, FRONT IMMUNOL, V8
   Owusu-Edusei K, 2015, EMERG INFECT DIS, V21, P960, DOI 10.3201/eid2106.141270
   Owusu-Edusei K, 2010, SEX TRANSM DIS, V37, P519, DOI 10.1097/OLQ.0b013e3181d73e4c
   Ryu SY, 2000, ANTICANCER RES, V20, P3331
   SCHUBERT R, 1983, DIGESTION, V28, P181, DOI 10.1159/000198984
   Scurlock AM, 2011, INFECT IMMUN, V79, P1349, DOI 10.1128/IAI.00984-10
   SHEMERAVNI Y, 1989, INFECT IMMUN, V57, P3484, DOI 10.1128/IAI.57.11.3484-3490.1989
   Su H, 1999, J INFECT DIS, V180, P1252, DOI 10.1086/315046
   Sun HS, 2012, J LEUKOCYTE BIOL, V92, P815, DOI 10.1189/jlb.0711336
   van Dissel JT, 2014, VACCINE, V32, P7098, DOI 10.1016/j.vaccine.2014.10.036
   Wern JE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00569
   Woodworth JS, 2017, MUCOSAL IMMUNOL, V10, P555, DOI 10.1038/mi.2016.70
NR 46
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 635
EP 643
DI 10.1016/j.vaccine.2019.10.047
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900025
PM 31727505
DA 2020-05-12
ER

PT J
AU Russo, AT
   Berhanu, A
   Bigger, CB
   Prigge, J
   Silvera, PM
   Grosenbach, DW
   Hruby, D
AF Russo, Andrew T.
   Berhanu, Aklile
   Bigger, Catherine B.
   Prigge, Jon
   Silvera, Peter M.
   Grosenbach, Douglas W.
   Hruby, Dennis
TI Co-administration of tecovirimat and ACAM2000 (TM) in non-human
   primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and
   efficacy versus lethal monkeypox virus challenge
SO VACCINE
LA English
DT Article
DE Smallpox; TPDXX (R); ACAM2000; Biodefense; Tecovirimat; ST-246 (R);
   Monkeypox virus; Vaccinia; Variola; Antiviral; Animal Rule
ID SMALLPOX VACCINE; ST-246; MODEL; REEMERGENCE; COMBINATION; THERAPY; DRUG
AB Naturally occurring smallpox has been eradicated but research stocks of variola virus (VARV), the causative agent of smallpox, still exist in secure laboratories. Clandestine stores of the virus or resurrection of VARV via synthetic biology are possible and have led to concerns that VARV could be used as a biological weapon. The US government has prepared for such an event by stockpiling smallpox vaccines and TPDXX (R), SIGA Technologies' smallpox antiviral drug. While vaccination is effective as a pre-exposure prophylaxis, protection is limited when administered following exposure. Safety concerns preclude general use of the vaccine unless there is a smallpox outbreak. TPDXX is approved by the FDA for use after confirmed diagnosis of smallpox disease. Tecovirimat, the active pharmaceutical ingredient in TPDXX, targets a highly conserved orthopoxviral protein, inhibiting long-range dissemination of virus. Although indications for use of the vaccine and TPDXX do not overlap, concomitant use is possible, especially if the TPDXX indication is expanded to include post-exposure prophylaxis. It is therefore important to understand how vaccine and TPDXX may interact. In studies presented here, monkeys were vaccinated with the ACAM2000 (TM) live attenuated smallpox vaccine and concomitantly treated with tecovirimat or placebo. Immune responses to the vaccine and protective efficacy versus a lethal monkeypox virus (MPXV) challenge were evaluated. In two studies, primary and anamnestic humoral immune responses were similar regardless of tecovirimat treatment while the third study showed reduction in vaccine elicited humoral immunity. Following lethal MPXV challenge, all (12 of 12) vaccinated/placebo treated animals survived, and 12 of 13 vaccinated/tecovirimat treated animals survived. Clinical signs of disease were elevated in tecovirimat treated animals compared to placebo treated animals. This suggests that TPDXX may affect the immunogenicity of ACAM2000 if administered concomitantly. These studies may inform on how vaccine and TPDXX are used during a smallpox outbreak. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Russo, Andrew T.; Grosenbach, Douglas W.] SIGA Technol Inc, Poxvirus Res Grp, Corvallis, OR USA.
   [Berhanu, Aklile] SIGA Technol, Corvallis, OR USA.
   [Bigger, Catherine B.] Battelle Biomed Res Ctr, Columbus, OH USA.
   [Prigge, Jon; Silvera, Peter M.] Southern Res Inst, Frederick, MD USA.
   [Hruby, Dennis] SIGA Technol Inc, Corvallis, OR 97333 USA.
   [Berhanu, Aklile] Genentech Inc, San Francisco, CA 94080 USA.
   [Bigger, Catherine B.] Tauri Grp, Med Countermeasures Syst Joint Program Execut Off, 110 Thomas Johnson Dr,Suite 240,Cubicle 250, Frederick, MD 21702 USA.
   [Prigge, Jon] BIOQUAL Inc, Rockville, MD USA.
   [Grosenbach, Douglas W.] Adv Biosci Labs Inc, Rockville, MD USA.
RP Russo, AT; Grosenbach, DW (reprint author), 4575 SW Res Way,Suite 110, Corvallis, OR 97333 USA.
EM arusso@siga.com; catherine.a.bigger.ctr@mail.mil; dgrosenbach@siga.com
FU National Institute of Allergy and Infectious Diseases at the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [N01-AI-30063]; SBIR/STTR Phase
   2 Grant [5R44AI075747]
FX These studies were supported by the National Institute of Allergy and
   Infectious Diseases at the National Institutes of Health [Contract No.
   N01-AI-30063]; and SBIR/STTR Phase 2 Grant [Grant Number: 5R44AI075747].
   MPXV stock supply of Monkeypox Virus, Zaire 79 (V79 -I-005), NR-2324 by
   BEI Resources. The content is solely the responsibility of the authors
   and does not necessarily represent the official views of the funding
   agencies.
CR Artenstein AW, 2008, EXPERT REV VACCINES, V7, P1225, DOI 10.1586/14760584.7.8.1225
   AZEVEDO CJ, 2015, OPEN FORUM INFECT DI, V2, DOI DOI 10.1212/NXI.0000000000000102
   BARCLAY WR, 1978, JAMA-J AM MED ASSOC, V240, P1991, DOI 10.1001/jama.1978.03290180065033
   BARDA, 2009, SMALLP ANT STRAT NAT
   Berhanu A, 2015, ANTIMICROB AGENTS CH, V59, P4296, DOI 10.1128/AAC.00208-15
   Berhanu A, 2010, VACCINE, V29, P289, DOI 10.1016/j.vaccine.2010.10.039
   Bray M, 2003, ANTIVIR RES, V58, P101, DOI 10.1016/S0166-3542(03)00008-1
   BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204
   Cann JA, 2013, J COMP PATHOL, V148, P6, DOI 10.1016/j.jcpa.2012.06.007
   Council N.R, 2011, GUIDE CARE USE LAB A
   DERIA A, 1980, B WORLD HEALTH ORGAN, V58, P279
   Duraffour S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055808
   Fenner F, CLIN FEATURES SMALLP, P1
   Fenner F, SMALLPOX ITS ERADICA, P302
   Fenner FD, SMALLPOX ITS ERADICA, P539
   Finin P, 2013, BIOSECUR BIOTERROR, V11, P59, DOI 10.1089/bsp.2012.0037
   Geddes AM, 2006, CLIN DERMATOL, V24, P152, DOI 10.1016/j.clindermatol.2005.11.009
   GREENBERG M, 1948, AM J DIS CHILD, V76, P492
   Grosenbach DW, 2008, VACCINE, V26, P933, DOI 10.1016/j.vaccine.2007.11.095
   Grosenbach DW, 2011, FUTURE VIROL, V6, P653, DOI 10.2217/fvl.11.27
   Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127
   Henderson DA, P ROYAL SOC LONDON B, P199
   Huggins J, 2009, ANTIMICROB AGENTS CH, V53, P2620, DOI 10.1128/AAC.00021-09
   Jordan R, 2010, VIRUSES-BASEL, V2, P2409, DOI 10.3390/v2112409
   Jordan R, 2009, ANTIMICROB AGENTS CH, V53, P1817, DOI 10.1128/AAC.01596-08
   Keckler MS, 2013, VACCINE, V31, P5192, DOI 10.1016/j.vaccine.2013.08.039
   Kretzschmar M, 2006, PLOS MED, V3, P1341, DOI 10.1371/journal.pmed.0030272
   Kulesh DA, 2004, J CLIN MICROBIOL, V42, P601, DOI 10.1128/JCM.42.2.601-609.2004
   MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214
   Massoudi MS, 2003, J INFECT DIS, V188, P973, DOI 10.1086/378357
   Melamed S, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010008
   Metzger W, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004913.pub2
   Mucker EM, 2013, ANTIMICROB AGENTS CH, V57, P6246, DOI 10.1128/AAC.00977-13
   Nalca A, 2005, CLIN INFECT DIS, V41, P1765, DOI 10.1086/498155
   Nalca A, 2008, ANTIVIR RES, V79, P121, DOI 10.1016/j.antiviral.2008.03.005
   Nalca A, 2010, DRUG DES DEV THER, V4, P71
   Organization WH, 2017, 19 M 1 2 NOV 2017 GE
   PAYNE LG, 1980, J GEN VIROL, V50, P89, DOI 10.1099/0022-1317-50-1-89
   Petersen BW, 2015, MMWR RECOMM REP, V64, P1
   Quenelle DC, 2007, ANTIMICROB AGENTS CH, V51, P689, DOI 10.1128/AAC.00879-06
   Ratto-Kim S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01397
   Russo AT, 2018, J INFECT DIS, V218, P1490, DOI 10.1093/infdis/jiy326
   SARKAR JK, 1975, B WORLD HEALTH ORGAN, V52, P307
   Sklenovska N, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00241
   Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915
   USFDA, 2015, PROD DEV AN RUL GUID
   Yang G, 2005, J VIROL, V79, P13139, DOI 10.1128/JVI.79.20.13139-13149.2005
   Yinka-Ogunleye A, 2018, EMERG INFECT DIS, V24, P1149, DOI 10.3201/eid2406.180017
NR 48
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 644
EP 654
DI 10.1016/j.vaccine.2019.10.049
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900026
PM 31677948
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mottram, L
   Lundgren, A
   Svennerholm, AM
   Leach, S
AF Mottram, Lynda
   Lundgren, Anna
   Svennerholm, Ann-Mari
   Leach, Susannah
TI Booster vaccination with a fractional dose of an oral cholera vaccine
   induces comparable vaccine-specific antibody avidity as a full dose: A
   randomised clinical trial
SO VACCINE
LA English
DT Article
DE Oral vaccination; Booster; Fractional dose; Antibody avidity; ALS
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; HUMORAL IMMUNE-RESPONSES; ETEC
   VACCINE; IMMUNOLOGICAL MEMORY; COLONIZATION FACTORS; CELL RESPONSES;
   DOUBLE-BLIND; IMMUNOGENICITY; SAFETY; DMLT
AB Antibody avidity is an important measure of the quality of vaccine-induced immune responses. Murine and human studies suggest that antibody avidity may be augmented by limiting access to antigen. The primary objective of this study was to evaluate in primed Swedish adults if booster vaccination with fractional doses (I/5th and 1/25th) of a model oral vaccine, the cholera vaccine Dukoral (R), results in higher avidity antibody responses compared to boosting with a full vaccine dose. We also evaluated if fractional booster vaccination elicited similar magnitudes of antibody response compared to a full dose, and if the previously observed increase in antibody avidity after booster vaccination 1-2 years later occurred when boosting after a shorter interval.
   To this end, a randomised, open-label, exploratory Phase-II trial was performed. Swedish adults (n = 44), primed with two full doses of Dukoral (R), were randomised into three groups and given a booster dose at either full (n = 14), 1/5th (n = 17) or 1/25th (n = 13) dose four months later. Antibody responses to cholera toxin B-subunit (CTB) were measured in serum and mucosal antibody in lymphocyte secretions (ALS).
   We found that the 1/5th and 1/25th booster doses had similar abilities as the full dose to induce significantly higher avidity anti-CTB antibody responses in both ALS and serum samples, as compared to after priming vaccination. There was a non-significant trend to lower magnitudes of ALS and serum IgA responses after the 1/5th compared to the full booster dose, and responses after the 1/25th dose were significantly lower.
   Our findings suggest fractional booster doses of Dukoral four months after priming result in antitoxoid mucosal antibody responses with increased antibody avidity compared to after priming vaccinations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mottram, Lynda; Lundgren, Anna; Svennerholm, Ann-Mari; Leach, Susannah] Univ Gothenburg, Vaccine Res Inst GUVAX, Dept Microbiol & Immunol, Gothenburg Univ, Gothenburg, Sweden.
   [Leach, Susannah] Sahlgrens Univ Hosp, Dept Clin Pharmacol, Gothenburg, Sweden.
RP Leach, S (reprint author), Univ Gothenburg, Dept Microbiol & Immunol, Box 435, S-40530 Gothenburg, Sweden.
EM lynda.mottram@gu.se; anna.lundgren@microbio.gu.se;
   ann-mari.svennerholm@microbio.gu.se; susannah.leach@microbio.gu.se
OI Mottram, Lynda/0000-0003-0007-3229
FU Swedish Foundation for Strategic Research (SSF)Swedish Foundation for
   Strategic Research [SB12-0072]; Swedish government [ALFGBG-679621];
   Swedish county councils, the ALF-agreement [ALFGBG-679621]
FX We thank Joanna Kaim and Jenni Adamsson for their excellent technical
   assistance. This work was supported by grants from the Swedish
   Foundation for Strategic Research (SSF) grant no. SB12-0072, and the
   Swedish state under the agreement between the Swedish government and the
   county councils, the ALF-agreement (ALFGBG-679621).
CR Akhtar M, 2019, VACCINE, V37, P5645, DOI 10.1016/j.vaccine.2018.11.040
   Alam MM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002822
   Alam MM, 2013, CLIN VACCINE IMMUNOL, V20, P1541, DOI 10.1128/CVI.00341-13
   Alam MM, 2013, CLIN VACCINE IMMUNOL, V20, P17, DOI 10.1128/CVI.00521-12
   Bourgeois AL, 2016, VACCINE, V34, P2880, DOI 10.1016/j.vaccine.2016.02.076
   Carpenter CM, 2006, VACCINE, V24, P3709, DOI 10.1016/j.vaccine.2005.07.022
   European Medicines Agency, 2015, DUK
   Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894
   GOLDBLATT D, 1993, J IMMUNOL METHODS, V166, P281, DOI 10.1016/0022-1759(93)90369-I
   Gonzales-Fernandez A, 2001, IMMUNOLOGY, V93, P149
   Guerin PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000342
   Harro C, 2011, CLIN VACCINE IMMUNOL, V18, P2118, DOI 10.1128/CVI.05342-11
   HOLM S, 1979, SCAND J STAT, V6, P65
   Holmgren J, 2013, VACCINE, V31, P2457, DOI 10.1016/j.vaccine.2013.03.027
   Jertborn M, 1998, VACCINE, V16, P255, DOI 10.1016/S0264-410X(97)00169-2
   Larena M, 2015, J IMMUNOL, V194, P3829, DOI 10.4049/jimmunol.1401633
   Leach S., 2015, APPROACHES ENHANCE E
   Leach S, 2017, VACCINE, V35, P3966, DOI 10.1016/j.vaccine.2017.06.006
   Leach S, 2013, VACCINE, V31, P3035, DOI 10.1016/j.vaccine.2013.04.066
   Leach S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051718
   Lundgren A, 2013, VACCINE, V31, P1163, DOI 10.1016/j.vaccine.2012.12.063
   Lundgren A, 2016, VACCINE, V34, P3132, DOI 10.1016/j.vaccine.2016.04.055
   Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069
   Lundgren A, 2009, VACCINE, V27, P4529, DOI 10.1016/j.vaccine.2009.05.005
   Obaro SK, 2006, VACCINE, V24, P6460, DOI 10.1016/j.vaccine.2006.06.051
   Qadri F, 2019, LANCET INFECT DIS
   Regules JA, 2016, J INFECT DIS, V214, P762, DOI 10.1093/infdis/jiw237
   Resik S, 2013, NEW ENGL J MED, V368, P416, DOI 10.1056/NEJMoa1202541
   Romero-Steiner S, 1999, CLIN INFECT DIS, V29, P281, DOI 10.1086/520200
   Saha D, 2004, J INFECT DIS, V189, P2318, DOI 10.1086/421275
   Saletti G, 2013, NAT PROTOC, V8, P1073, DOI 10.1038/nprot.2013.058
   Shlomchik MJ, 2012, IMMUNOL REV, V247, P52, DOI 10.1111/j.1600-065X.2012.01124.x
   Svennerholm AM, 2012, EXPERT REV VACCINES, V11, P495, DOI [10.1586/erv.12.12, 10.1586/ERV.12.12]
   Walker RI, 2015, VACCINE, V33, P954, DOI 10.1016/j.vaccine.2014.11.049
NR 34
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 655
EP 662
DI 10.1016/j.vaccine.2019.10.050
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900027
PM 31703936
DA 2020-05-12
ER

PT J
AU Kang, YM
   Cho, HK
   Kim, HM
   Lee, MH
   To, TL
   Kang, HM
AF Kang, Yong-Myung
   Cho, Hyun-Kyu
   Kim, Hyun-Mi
   Lee, Myoung-Heon
   Thanh Long To
   Kang, Hyun-Mi
TI Protective efficacy of vaccines of the Korea national antigen bank
   against the homologous H5Nx Glade 2.3.2.1 and Glade 2.3.4.4 highly
   pathogenic avian influenza viruses
SO VACCINE
LA English
DT Article
DE Highly pathogenic avian influenza; Inactivation; Antigen bank; Chicken;
   Vaccine
ID SOUTH-KOREA; REVERSE GENETICS; DOMESTIC POULTRY; MIGRATORY BIRDS; A
   VIRUSES; DUCKS; VACCINATION; CHICKENS; CHALLENGE; MULTIPLE
AB The occurrence of severe outbreaks of highly pathogenic avian influenza in Korea led to establishment of a national antigen bank for emergency preparedness. Here, we developed five vaccines for this bank (Glade 2.3.2.1C, Glade 2.3.4.4A, B, C, and D) by reverse genetics, inactivated them with formalin, and evaluated the protective efficacy and potency of serial dilutions against lethal homologous challenge in specific-pathogen-free chickens. After vaccination with one dose, each vaccine resulted in 100% survival, with no clinical symptoms, or lack of detectable virus shedding, and high levels of pre-challenge protective immunity (8.4-10.2 log(2)). After vaccination with one-tenth of the full dose, protection was similar to that with the full dose. After vaccination with one-hundredth of the initial dose, survival was 20-80%, and all vaccines showed virus shedding. Four vaccines (excluding Glade 2.3.2.1C) had satisfactory potency. In antibody-persistence tests, all vaccines maintained long-lasting protective immunity. Our results suggest that inactivated reverse-genetics vaccines genetically matched to outbreak viruses provide adequate protection after a single vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kang, Yong-Myung; Cho, Hyun-Kyu; Kim, Hyun-Mi; Lee, Myoung-Heon; Kang, Hyun-Mi] Anim & Plant Quarantine Agcy, 177 Hyeoksin 8 Ro, Gimcheon Si 39660, Gyeongsangbuk D, South Korea.
   [Thanh Long To] Natl Ctr Vet Diagnost, 11,78th Lane,GiaiPhong Rd, Hanoi, Vietnam.
RP Kang, HM (reprint author), Anim & Plant Quarantine Agcy, Avian Influenza Res & Diagnost Div, 177 Hyeoksin 8 Ro, Gimcheon Si 39660, Gyeongsangbuk D, South Korea.
EM greenkang@korea.kr
FU Animal and Plant Quarantine Agency of the Republic of Korea
   [P-153418-2018-20-03]
FX This research was supported by a grant from the Animal and Plant
   Quarantine Agency (P-153418-2018-20-03) of the Republic of Korea. We
   thank the Korea Centers for Disease Control & Preven-tion and Professor
   Young-Ki Choi of Chungbuk National University for providing us with
   v2pHW vector at no charge.
CR [Anonymous], 2018, OFFLU AVIAN INFLUENZ
   Beato MS, 2007, VACCINE, V25, P4064, DOI 10.1016/j.vaccine.2007.02.042
   Bertran K, 2017, VACCINE, V35, P6336, DOI 10.1016/j.vaccine.2017.05.051
   Bertran K, 2013, VACCINE, V31, P3572, DOI 10.1016/j.vaccine.2013.05.039
   Bhat S, 2015, MICROB PATHOGENESIS, V88, P87, DOI 10.1016/j.micpath.2015.08.010
   Boltz DA, 2009, ARCH VIROL, V154, P939, DOI 10.1007/s00705-009-0385-x
   Cai ZP, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000949
   Cuong NV, 2016, TRANSBOUND EMERG DIS, V63, P127, DOI 10.1111/tbed.12470
   Nguyen DT, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0100-7
   Ebrahimi SM, 2010, MOL BIOL REP, V37, P2877, DOI 10.1007/s11033-009-9846-2
   Eggert D, 2010, AVIAN DIS, V54, P1224, DOI 10.1637/9410-052810-Reg.1
   Gamon K, 2016, J VETMEDSCI, V78, P139, DOI DOI 10.1292/IVMS.15-0324
   Thanh HD, 2018, COMP IMMUNOL MICROB, V56, P45, DOI 10.1016/j.cimid.2018.01.001
   Hoffmann E, 2002, VACCINE, V20, P3165, DOI 10.1016/S0264-410X(02)00268-2
   Jeong J, 2014, VET MICROBIOL, V173, P249, DOI 10.1016/j.vetmic.2014.08.002
   Kang HM, 2015, EMERG INFECT DIS, V21, P298, DOI 10.3201/eid2102.141268
   Kapczynski DR, 2017, VACCINE, V35, P6345, DOI 10.1016/j.vaccine.2017.04.042
   Kilany WH, 2011, VET MICROBIOL, V150, P28, DOI 10.1016/j.vetmic.2010.12.016
   Kim HR, 2010, VET MICROBIOL, V141, P362, DOI 10.1016/j.vetmic.2009.09.011
   Lee CW, 2005, J VIROL, V79, P3692, DOI 10.1128/JVI.79.6.3692-3702.2005
   Lee EK, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0104-3
   Lee EK, 2017, INFECT GENET EVOL, V51, P21, DOI 10.1016/j.meegid.2017.03.005
   Lee YJ, 2008, EMERG INFECT DIS, V14, P487, DOI 10.3201/eid1403.070767
   Liu CG, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-321
   Magor KE, 2011, DEV COMP IMMUNOL, V35, P1008, DOI 10.1016/j.dci.2011.02.011
   OIE, 2016, MANUAL DIAGNOSTIC TE
   Ramakrishnan Muthannan Andavar, 2016, World J Virol, V5, P85, DOI 10.5501/wjv.v5.i2.85
   Si Y, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.1.30434
   Song MS, 2013, J GEN VIROL, V94, P1230, DOI 10.1099/vir.0.051284-0
   Steensels M, 2009, VACCINE, V27, P646, DOI 10.1016/j.vaccine.2008.11.044
   Swayne D. E., 2016, Animal influenza, P378
   Swayne DE, 2013, DEV BIOLOGICALS, V135, P79, DOI 10.1159/000325276
   Swayne DE, 2011, REV SCI TECH OIE, V30, P839
   Swayne DE, 2015, J VIROL, V89, P3746, DOI 10.1128/JVI.00025-15
   Swayne DE, 2014, ECOHEALTH, V11, P94, DOI 10.1007/s10393-013-0861-3
   Swayne DE, 2012, EXPERT REV VACCINES, V11, P877, DOI 10.1586/ERV.12.60
   Nguyen TH, 2015, COMP IMMUNOL MICROB, V42, P21, DOI 10.1016/j.cimid.2015.08.001
   Torchetti MK, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.00195-15
   Webster RG, 2006, VIROLOGY, V351, P303, DOI 10.1016/j.virol.2006.01.044
   WHO, 2002, WHO MAN AN INFL DIAG
   Yoon H, 2005, J VET MED B, V52, P428, DOI 10.1111/j.1439-0450.2005.00891.x
   Yoon SW, 2014, CURR TOP MICROBIOL, V385, P359, DOI 10.1007/82_2014_396
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 663
EP 672
DI 10.1016/j.vaccine.2019.10.044
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900028
PM 31669062
DA 2020-05-12
ER

PT J
AU Cui, TT
   Zhang, XF
   Wang, Q
   Yue, N
   Zheng, MY
   Wang, DL
   Duan, CX
   Yu, XG
   Bao, CJ
   Jiang, RJ
   Xu, SL
   Yuan, ZH
   Qian, YK
   Chen, LL
   Hang, H
   Zhang, Z
   Sun, HM
   Jin, H
AF Cui, Tingting
   Zhang, Xuefeng
   Wang, Qiang
   Yue, Na
   Zheng, Mengyun
   Wang, Donglei
   Duan, Chunxiao
   Yu, Xiaoge
   Bao, Changjun
   Jiang, Renjie
   Xu, Shilin
   Yuan, Zhaohu
   Qian, Yunke
   Chen, Liling
   Hang, Hui
   Zhang, Zhong
   Sun, Hongmin
   Jin, Hui
TI Disease burden concerning hepatitis E-infected inpatients in Jiangsu
   province, China
SO VACCINE
LA English
DT Article
DE Hepatitis E; Disease burden; Inpatients; Jiangsu province of China
ID ECONOMIC-EVALUATION; PREGNANT-WOMEN; EPIDEMIOLOGY; RISK
AB Objective: This study aimed to determine the disease burden of hepatitis E virus (HEV)-infected inpatients in Jiangsu province, China.
   Methods: Between July 1, 2016 and October 31, 2018, 1152 HEV-infected inpatients were identified from four cities in Jiangsu province, namely, Nanjing, Suzhou, Yancheng, and Zhenjiang. The disease burden comprised the economic burden and loss of health due to HEV infection. Factors influencing the disease burden were analyzed using univariate and multivariate analyses.
   Results: The average direct, indirect, and total economic burden for 1152 HEV-infected inpatients was US $ 4,986.40, US$ 1,507.28, and US$ 6,493.68, respectively, accounting for 46.66%, 14.11%, and 60.77% of per capita disposable income (PCDI) in Jiangsu province, respectively. The disease burden for HEV-infected inpatients with hepatitis B was significantly higher than that for other inpatients. The average EQ-5D utility value of 1152 HEV-infected inpatients was 0.72 +/- 0.18 quality-adjusted life years (QALYs) and the average EQ-visual analogue score (EQ-VAS) was 0.66 +/- 0.17 points. Multivariate analysis showed that the direct economic burden and the total economic burden were influenced by variables such as hospitalization days, outcomes, past history of other diseases, and regions (P < 0.05). It was estimated the direct economic burden, the indirect economic burden, and the total economic burden for all HEVinfected inpatients in Jiangsu province in 2018 was approximately US$ 9.2 million, US$ 2.8 million and US$ 12.0 million, respectively.
   Conclusion: The disease burden of HEV infection in Jiangsu province is severe, and more attention should be paid to the prevention of hepatitis E and the treatment of comorbidities. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cui, Tingting; Wang, Qiang; Yue, Na; Zheng, Mengyun; Wang, Donglei; Duan, Chunxiao; Yu, Xiaoge; Jin, Hui] Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Nanjing 210009, Peoples R China.
   [Zhang, Xuefeng; Bao, Changjun] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing 210009, Peoples R China.
   [Wang, Qiang; Yue, Na; Zheng, Mengyun; Wang, Donglei; Duan, Chunxiao; Yu, Xiaoge; Jin, Hui] Southeast Univ, Sch Publ Hlth, Key Lab Environm Med Engn, Minist Educ, Nanjing 210009, Peoples R China.
   [Jiang, Renjie; Xu, Shilin] Yancheng Ctr Dis Control & Prevent, Yancheng 224001, Peoples R China.
   [Yuan, Zhaohu; Qian, Yunke] Zhenjiang Ctr Dis Control & Prevent, Zhenjiang 212004, Jiangsu, Peoples R China.
   [Chen, Liling; Hang, Hui] Suzhou Ctr Dis Control & Prevent, Suzhou 215004, Peoples R China.
   [Zhang, Zhong; Sun, Hongmin] Nanjing Ctr Dis Control & Prevent, Nanjing 210003, Peoples R China.
RP Jin, H (reprint author), Southeast Univ, Sch Publ Hlth, Key Lab Environm Med Engn, Minist Educ, Nanjing 210009, Peoples R China.; Jin, H (reprint author), Southeast Univ, Dept Epidemiol & Hlth Stat, Nanjing 210009, Peoples R China.
EM jinhuihld@seu.edu.cn
CR Buchholz I, 2018, PHARMACOECONOMICS, V36, P645, DOI 10.1007/s40273-018-0642-5
   Cattoir L, 2018, J CLIN VIROL, V103, P8, DOI 10.1016/j.jcv.2018.03.004
   Cheng XQ, 2017, HUM VACC IMMUNOTHER, V13, P1873, DOI 10.1080/21645515.2017.1316913
   Forni D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-017-0009-6
   Hakim MS, 2017, LIVER INT, V37, P19, DOI 10.1111/liv.13237
   Jacques P, 2017, ANN RHEUM DIS, V76, P763, DOI 10.1136/annrheumdis-2017-eular.5115
   Janssen MF, 2018, PHARMACOECONOMICS, V36, P675, DOI 10.1007/s40273-018-0623-8
   Janssen MF, 2018, EUR J HEALTH ECON, P1
   Jiang H, 2017, EPIDEMIOL INFECT, V145, P908, DOI 10.1017/S0950268816003071
   Jin H, 2016, EPIDEMIOL INFECT, V144, P2098, DOI 10.1017/S0950268816000418
   Kamar N, 2014, CLIN MICROBIOL REV, V27, P116, DOI 10.1128/CMR.00057-13
   Kim JH, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-308
   Kmush B, 2013, SEMIN LIVER DIS, V33, P15, DOI 10.1055/s-0033-1338111
   [李茜瑶 Li Xiyao], 2018, [中国公共卫生, China Journal of Public Health], V34, P777
   Lloyd A, 2018, VALUE HEALTH, V21, P57, DOI 10.1016/j.jval.2017.11.007
   Muller A, 2017, INT J FOOD MICROBIOL, V242, P107, DOI 10.1016/j.ijfoodmicro.2016.11.018
   Rein DB, 2007, PEDIATRICS, V119, pE12, DOI 10.1542/peds.2006-1573
   REIN DB, 2011, HEPATOLOGY, V54, pA117
   Ren X, 2017, EMERG INFECT DIS, V23, P276, DOI [10.3201/2302.161095, 10.3201/eid2302.161095]
   Teshale EH, 2011, WORLD J HEPATOL, V3, P285, DOI 10.4254/wjh.v3.i12.285
   Xiu S., 2011, DIS BURDEN HEPATITIS
   Xu Z, 2013, CHINA CANC, V22, P638
   Yu X, 2015, CHINESE J VIRAL DIS, V5, P471
   Zhao Y., 2016, DIS BURDEN HEPATITIS
   Zhao YY, 2016, HUM VACC IMMUNOTHER, V12, P2003, DOI 10.1080/21645515.2016.1141844
   Zhou FJ, 2014, PEDIATRICS, V133, P577, DOI 10.1542/peds.2013-0698
   Zhou T, 2016, CHINESE HLTH EC, V35, P17
NR 27
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 673
EP 679
DI 10.1016/j.vaccine.2019.10.045
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900029
PM 31668822
DA 2020-05-12
ER

PT J
AU Feldstein, LR
   Fox, G
   Shefer, A
   Conklin, LM
   Ward, K
AF Feldstein, Leora R.
   Fox, Garrett
   Shefer, Abigail
   Conklin, Laura M.
   Ward, Kirsten
TI School-based delivery of routinely recommended vaccines and
   opportunities to check vaccination status at school, a global summary,
   2008-2017
SO VACCINE
LA English
DT Article
DE School-based delivery; Routine immunization schedule; School-aged
   children; Adolescents; Vaccination coverage; Vaccines
ID MEASLES ELIMINATION; COVERAGE; SERVICES; PROGRESS; LEVEL
AB School-based vaccination (SBV) and checking students' vaccination records at school have the potential to optimize vaccination coverage among school-aged children. The primary aim of this paper is to describe adoption of SBV by countries from 2008 to 2017, including target age groups and vaccines delivered in 2017, as reported annually through the World Health Organization (WHO)-United Nations Children's fund (UNICEF) Joint Reporting Form (JRF). Expanding upon previous analyses, country-specific rates of primary school enrollment and home-based record (HBR) ownership were linked to the WHO-UNICEF JRF data, to identify countries with high potential to implement vaccination record checks at school. The proportion of countries reporting delivery of at least one routinely recommended vaccine dose in school settings increased from 95 (of 163 reporting; 58%) in 2008 to 108 (of 181 reporting; 60%) in 2017. The 13 additional countries that reported using SBV in 2017 were among 31 countries for which SBV data from the JRF were unavailable in 2017. The most common antigens delivered through SBV in 2017 were tetanus (94 countries), diphtheria (89 countries), and human papillomavirus (52 countries). Among 93 countries with data available for net primary school enrollment and HBR ownership, 52 (56%) countries had both >= 80% net primary school enrollment and >= 80% of children aged 12-23 months ever owning an HBR; 33 (63%) of these used SBV. If not already doing so, these 33 countries represent an opportunity to introduce routine checking of vaccination status at entry to, or during primary school. With the growing number of new vaccines and booster doses of childhood vaccines targeting school age children, implementation of SBV and checking of student vaccination records at school may help improve vaccination coverage; however, additional data are needed to assess global prevalence of checking vaccination status at school and to identify factors facilitating optimal implementation of this strategy. Published by Elsevier Ltd.
C1 [Feldstein, Leora R.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30329 USA.
   [Feldstein, Leora R.; Fox, Garrett; Shefer, Abigail; Conklin, Laura M.; Ward, Kirsten] US Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Immunizat Syst Branch, Atlanta, GA 30329 USA.
RP Feldstein, LR (reprint author), 1600 Clifton Rd NE, Atlanta, GA 30329 USA.
EM nqw5@cdc.gov
FU U.S Centers for Disease Control and PreventionUnited States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
FX The findings and conclusions in this paper are those of the authors and
   do not necessarily represent the official position of the U.S Centers
   for Disease Control and Prevention. The authors appreciate the
   contributions from the following colleagues, Mar-garet Watkins, Laure
   Dumolard, Stephanie Shendale, Aaron Wal-lace, and Susan Chu.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205
   Arsenault C, 2017, VACCINE, V35, P2479, DOI 10.1016/j.vaccine.2017.03.029
   Baltag V, 2015, HEALTH BEHAV POLICY, V2, P268, DOI 10.14485/HBPR.2.4.4
   Binagwaho A, 2012, B WORLD HEALTH ORGAN, V90, P623, DOI 10.2471/BLT.11.097253
   Brown DW, 2015, VACCINE, V33, P2584, DOI 10.1016/j.vaccine.2015.03.101
   Brown DW, 2014, VACCINE, V32, P1775, DOI 10.1016/j.vaccine.2014.01.098
   Brown DW, HOME BASED RECORD OW
   Brown DW, 2015, LEVERAGING DELIVERY
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   Choe YJ, 2018, VACCINE, V36, P5497, DOI 10.1016/j.vaccine.2018.07.013
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   D'Addario M, 2017, VACCINE, V35, P2892, DOI 10.1016/j.vaccine.2017.03.096
   Duan MJ, 2018, VACCINE, V36, P6231, DOI 10.1016/j.vaccine.2018.07.070
   Gallagher KE, 2017, PAPILLOMAVIRUS RES, V4, P72, DOI 10.1016/j.pvr.2017.09.001
   Gallagher KE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177773
   Gavi the vaccine alliance, 2016, ANN PROGR REP 2016
   Goodson JL, 2017, EXPERT REV VACCINES, V16, P1203, DOI 10.1080/14760584.2017.1393337
   La Vincente SF, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2579-3
   LaMontagne DS, 2017, INT J GYNECOL OBSTET, V138, P7, DOI 10.1002/ijgo.12186
   LaMontagne DS, 2017, DIS CONTROL PRIORITI, P199
   Loharikar A, 2016, MMWR-MORBID MORTAL W, V65, P1136, DOI 10.15585/mmwr.mm6541a3
   MacDonald NE, 2018, VACCINE, V36, P5811, DOI 10.1016/j.vaccine.2018.08.042
   Mackroth MS, 2010, VACCINE, V28, P1138, DOI 10.1016/j.vaccine.2009.11.008
   Orenstein WA, 1999, VACCINE, V17, pS19, DOI 10.1016/S0264-410X(99)00290-X
   PATH, COUNTR DEL STRAT CHA
   Paul P, 2014, VACCINE, V32, P320, DOI 10.1016/j.vaccine.2013.11.070
   Pebody RG, 2014, EUROSURVEILLANCE, V19, P5, DOI 10.2807/1560-7917.ES2014.19.22.20823
   Perman S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4168-0
   Robbins SCC, 2011, VACCINE, V29, P9588, DOI 10.1016/j.vaccine.2011.10.033
   SAGE working group on maternal and neonatal tetanus elimination and broader tetanus prevention, REP SAGE WORK GROUP
   Takashima Y, 2015, MMWR-MORBID MORTAL W, V64, P357
   Torres-Rueda S, 2016, SEX REPROD HEALTHC, V7, P46, DOI 10.1016/j.srhc.2015.11.006
   UNICEF, STAT WORLDS CHILDR
   United nations educational scientific and cultural organization, INT STAND CLASS ED I
   United States agency for international development (USAID), DHS PROGR WE WORK
   Vandelaer J, 2015, VACCINE, V33, P719, DOI 10.1016/j.vaccine.2014.11.037
   VanderEnde K, 2018, MMWR-MORBID MORTAL W, V67, P1261, DOI 10.15585/mmwr.mm6745a2
   Ward K, 2013, COMMUN DIS INTELL, V37, pE156
   Wei X, 2011, CHIN J SCH HLTH, V32, P711
   WHO, WHO REC ROUT IMM SUM
   WHO, 2018, EXPL IN CHILDH IMM
   *WHO, IMM SCHED ANT
   WHO, 2015, IMM PRACT PRACT GUID
   World Bank, HIST CLASS INC XLS F
   World health organization, 2018, WHO UNICEF EST NAT I
   World health organization, SCH VACC READ ASS TO
   World health organization, SCH IMM PROGR MAL
   World health organization, WHO UNICEF JOINT REP
   World health organization, SCH IMM PROGR SRI LA
   World Health Organization, 2016, MEAS RUB GLOB STRAT
   World health organization, SCH BAS IMM
   World health organization, 2018, WHO REC ROUT IMM SUM
   World Health Organization, IMM VACC BIOL DAT ST
   World health organization, SCH IMM PROGR TUN
   World health organization, SCH IMM PROGR IND
   World health organization, S E ASIA REG IMM TEC
   World Health Organization, 2019, PROT ALL TET GUID SU
   World health organization, DAT STAT GFAPH 6 4 I
   World health organization and UNICEF, CAM WHO UNICEF EST I
   World health organization western Pacific region, 2018, 27 M TECHN ADV GROUP
   World Health Organization (WHO), 2012, GLOB MEASL RUB STRAT
   Yin X-W, 2016, CHINESE J VACCINE IM, V22, P546
   Young SL, 2015, INT HEALTH, V7, P247, DOI 10.1093/inthealth/ihv014
   Zhang D, 2013, MODERN PREVENTIVE ME, V40, P855
   Zhang M, 2016, CHINESE VACCINE IMMU, V22, P606
   Zuo SY, 2015, VACCINE, V33, P2050, DOI 10.1016/j.vaccine.2015.02.078
NR 66
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 680
EP 689
DI 10.1016/j.vaccine.2019.10.054
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900030
PM 31679861
DA 2020-05-12
ER

PT J
AU Ng, TWY
   Cowling, BJ
   So, HC
   Ip, DKM
   Liao, QY
AF Ng, Tiffany W. Y.
   Cowling, Benjamin J.
   So, Hau Chi
   Ip, Dennis K. M.
   Liao, Qiuyan
TI Testing an integrative theory of health behavioural change for
   predicting seasonal influenza vaccination uptake among healthcare
   workers
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination uptake; Healthcare personnel; Behaviour
ID PANDEMIC INFLUENZA; HONG-KONG; NURSES; DECISION; COVERAGE; MODELS
AB Background: Although annual seasonal influenza vaccination is recommended for healthcare personnel (HCPs), their vaccination uptake has been suboptimal. This study aimed to examine the psychosocial determinants of influenza vaccination among HCPs in Hong Kong using a longitudinal study design based on behavioral change theories.
   Methods: Participants were invited to complete a baseline survey before the 2017/18 influenza vaccination campaign to measure their baseline perceptions and vaccination intention, and followed up for 9 months to measure actual vaccination uptake. The survey used a theoretical framework combining the Health Belief Model and Theory of Planned Behaviour with extended psychosocial factors for predicting HCPs' vaccination uptake. Structural equation modelling was used to test the theoretical model and estimate path coefficients (p) to infer associations of psychosocial factors with HCPs' influenza vaccination uptake.
   Results: Of the 845 participants who completed follow-up, 43.0% indicated intending to take vaccination and 30.8% reported actual receipt of the vaccination. The structural equation modeling analysis showed that positive attitude towards influenza vaccination (beta= 0.69), greater perceived susceptibility to influenza virus infection (beta = 0.34), greater anticipated regret for not vaccinating (beta = 0.31), and more cues to action (beta= 0.29) were significantly associated with higher vaccination intention which directly predicted greater vaccination uptake (beta = 0.82). Norms were found to have an indirect association with vaccination intention through the mediation of attitude towards influenza vaccination (beta = 0.63). Self-efficacy was significantly associated with actual receipt of influenza vaccination (beta = 0.13) but not vaccination intention. The structural equation model explained 84.7% and 69.6% of the variance, respectively, in HCPs' intention to receive and actual receipt of influenza vaccination.
   Conclusions: Attitude towards influenza vaccination was the strongest predictor of HCPs' intention and actual receipt of influenza vaccination. Social norm approach may be an intervention strategy to shape HCPs' attitude towards influenza vaccination and their subsequent decision-making for influenza vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ng, Tiffany W. Y.; Cowling, Benjamin J.; So, Hau Chi; Ip, Dennis K. M.; Liao, Qiuyan] Univ Hong Kong, Li Ka Shing Fac Med, WHO Collaborating Ctr Infect Dis Epidemiol & Cont, Sch Publ Hlth, Hong Kong, Peoples R China.
   [Liao, Qiuyan] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Div Behav Sci, Hong Kong, Peoples R China.
RP Cowling, BJ (reprint author), Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, Pokfulam, 7 Sassoon Rd, Hong Kong, Peoples R China.
EM bcowling@hku.hk
OI Ng, Tiffany/0000-0003-0480-0948
FU Health and Medical Research Fund of the Food and Health Bureau of the
   Hong Kong SAR Government [16150852]
FX This work was supported by the Health and Medical Research Fund of the
   Food and Health Bureau of the Hong Kong SAR Government (grant no.:
   16150852).
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Allen JD, 2009, PREV MED, V48, P420, DOI 10.1016/j.ypmed.2008.12.005
   Bellia C, 2013, INFLUENZA OTHER RESP, V7, P97, DOI 10.1111/irv.12088
   Beran Tanya N, 2010, BMC Res Notes, V3, P267, DOI 10.1186/1756-0500-3-267
   Black CL, 2018, MMWR-MORBID MORTAL W, V67, P1050, DOI 10.15585/mmwr.mm6738a2
   Centers for Disease Control and Prevention, 2018, INFL VACC INF HLTH C
   Centre for Health Protection, 2017, SEAS INFL VACC PROGR
   Chan DPC, 2015, J HOSP INFECT, V90, P354, DOI 10.1016/j.jhin.2015.04.017
   Corace KM, 2016, VACCINE, V34, P3235, DOI 10.1016/j.vaccine.2016.04.071
   Cornally Nicola, 2013, Br J Nurs, V22, P1207
   Dempsey RC, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02180
   Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442
   European Centre for Disease Prevention and Control, 2017, SEAS INFL VACC EUR V
   Glanz K, 1997, NIH PUBLICATION, P97
   Godin G, 1996, AM J HEALTH PROMOT, V11, P87, DOI 10.4278/0890-1171-11.2.87
   Godin G, 2010, INFECT CONT HOSP EP, V31, P689, DOI 10.1086/653614
   Grewal R, 2004, MARKET SCI, V23, P519, DOI 10.1287/mksc.1040.0070
   Hopfer S, 2011, QUAL HEALTH RES, V21, P262, DOI 10.1177/1049732310383868
   Hopman CE, 2011, J HOSP INFECT, V77, P327, DOI 10.1016/j.jhin.2010.10.009
   Imai C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198685
   Jeon J., 2015, INT J INNOV RES SCI, V49
   Lee SS, 2013, EMERG INFECT DIS, V19, P1660, DOI 10.3201/eid1910.130195
   Liao Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023786
   Liao QY, 2016, INT J BEHAV MED, V23, P621, DOI 10.1007/s12529-016-9551-1
   Looijmans-van den Akker I, 2009, VACCINE, V27, P4724, DOI 10.1016/j.vaccine.2009.05.013
   Meijboom MJ, 2018, INFLUENZA OTHER RESP, V12, P457, DOI 10.1111/irv.12558
   NOTANI A, 1998, J CONSUM PSYCHOL, V7, P247, DOI DOI 10.1207/S15327663JCP0703_02
   Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018
   Quinn SC, 2017, HEALTH EDUC RES, V32, P473, DOI 10.1093/her/cyx070
   Rebmann T, 2012, INFECT CONT HOSP EP, V33, P243, DOI 10.1086/664057
   Shahrabani S, 2009, EUR J HEALTH ECON, V10, P227, DOI 10.1007/s10198-008-0124-3
   Shiu WH, 2018, CAN WE IMPROVE INFLU
   Smith J, 2009, GROUP NORMS ATTITUDE
   Smith S, 2016, J CLIN NURS, V25, P2730, DOI 10.1111/jocn.13243
   Streiner DL, 2003, J PERS ASSESS, V80, P217, DOI 10.1207/S15327752JPA8003_01
   Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd
   Ting EEK, 2017, VACCINE, V35, P1828, DOI 10.1016/j.vaccine.2017.02.044
   To KW, 2015, HUM VACC IMMUNOTHER, V11, P1345, DOI 10.1080/21645515.2015.1034916
   Vet R, 2011, HEALTH EDUC RES, V26, P192, DOI 10.1093/her/cyq074
   Werner C., 2010, DECIDING COMPETING M
   Wong SYS, 2012, INT J INFECT DIS, V16, pE687, DOI 10.1016/j.ijid.2012.03.015
NR 41
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 690
EP 698
DI 10.1016/j.vaccine.2019.10.041
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900031
PM 31668824
DA 2020-05-12
ER

PT J
AU Ohori, J
   Iuchi, H
   Maseda, Y
   Kurono, Y
AF Ohori, Junichiro
   Iuchi, Hiroyuki
   Maseda, Yoshiko
   Kurono, Yuichi
TI Phosphorylcholine intranasal immunization with a 13-valent pneumococcal
   conjugate vaccine can boost immune response against Streptococcus
   pneumoniae
SO VACCINE
LA English
DT Article
DE 13-valent pneumococcal conjugate vaccine; Phosphorylcholine; Nasal
   vaccine
ID SURFACE PROTEIN-A; SEROTYPE REPLACEMENT; INFECTION
AB Objective: This study aimed to investigate whether systemic immunization with a 13-valent pneumococcal conjugate vaccine (PCV13) followed by intranasal (IN) immunization with phosphorylcholine (PC) can boost immune response against Streptococcus pneumoniae.
   Materials and methods: Two weeks after the intraperitoneal (IP) injection of PCV13, mice were divided into two groups (mice requiring another IP injection of PCV13 and mice requiring PC-keyhole limpet hemocyanin IN immunization in combination with cholera toxin as a mucosal adjuvant) to compare the magnitude of systemic and mucosal immune responses against S. pneumoniae and PC.
   Results: Serum immunoglobulin (Ig) G antibody titer against the vaccine strains of S. pneumoniae was similar between the PCV13 systemic immunization group and PC IN immunization group, while the serum IgG antibody titer against PC was significantly higher in the PC IN immunization group. PC-specific IgA antibody titer in the nasal lavage and PC-specific IgA-producing cell number in the nasal mucosa were also significantly higher in the PC IN immunization group. Induction of PC-specific IgA in the PC IN immunization group enhanced the clearance of bacteria from the middle ear.
   Conclusion: Additional IN immunization with PC after PCV13 immunization, which is currently conducted under a periodic vaccination program, can produce a booster effect comparable to that achieved by additional systemic immunization as well as PC-specific mucosal immune response, thereby providing protection against S. pneumoniae serotypes not contained in PCV13. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ohori, Junichiro; Iuchi, Hiroyuki; Maseda, Yoshiko; Kurono, Yuichi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Otolaryngol Head & Neck Surg, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
RP Ohori, J (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Otolaryngol Head & Neck Surg, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM juno@m3.kufm.kagoshima-u.ac.jp
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17K11335]
FX This work was supported by the JSPS KAKENHI (grant number 17K11335).
CR [Anonymous], ASS REP PREV
   Briles DE, 2003, J INFECT DIS, V188, P339, DOI 10.1086/376571
   Goodridge HS, 2007, PARASITE IMMUNOL, V29, P127, DOI 10.1111/j.1365-3024.2006.00926.x
   HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159
   Kodama S, 2000, INFECT IMMUN, V68, P2294, DOI 10.1128/IAI.68.4.2294-2300.2000
   Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016
   Maseda Y, 2018, AURIS NASUS LARYNX, V45, P273, DOI 10.1016/j.anl.2017.04.009
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Nagano H, 2018, LARYNGOSCOPE, V128, pE91, DOI 10.1002/lary.26971
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sugino H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137546
   Tanaka N, 2007, VACCINE, V25, P2680, DOI 10.1016/j.vaccine.2006.10.014
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
   Young NM, 2013, MOL IMMUNOL, V56, P563, DOI 10.1016/j.molimm.2013.05.237
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 16
PY 2020
VL 38
IS 3
BP 699
EP 704
DI 10.1016/j.vaccine.2019.10.043
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KG3BG
UT WOS:000509816900032
PM 31668823
DA 2020-05-12
ER

PT J
AU Choe, YJ
   Son, H
AF Choe, Young June
   Son, Hyunjin
TI The changing gender differences in hepatitis a incidence in South Korea
SO VACCINE
LA English
DT Article
DE Hepatitis A; Incidence; Vaccine; Gender
ID NEURAMINIDASE; ANTIBODY
AB We examined the trend in gender difference for hepatitis A incidence in South Korea after introducing universal vaccination in toddlers and in military recruits. We found that the male-female incidence rate ratio has decreased significantly especially among persons aged 20-29 years, suggesting additional impact from vaccinating military recruits. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Choe, Young June] Hallym Univ, Dept Social & Prevent Med, Coll Med, 1 Hallymdaehak Gil, Chuncheon Si 24252, Gangwon Do, South Korea.
   [Choe, Young June] Brown Univ, Warren Alpert Med Sch, Div Pediat Infect Dis, Providence, RI 02912 USA.
   [Son, Hyunjin] Busan Natl Univ Hosp, Busan Ctr Infect Dis Control & Prevent, Busan, South Korea.
RP Choe, YJ (reprint author), Hallym Univ, Dept Social & Prevent Med, Coll Med, 1 Hallymdaehak Gil, Chuncheon Si 24252, Gangwon Do, South Korea.
EM ychoe@hallym.ac.kr
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [FDN-148458]
FX This work was supported by funding from the Canadian Institutes of
   Health Research with a grant number of FDN-148458.
CR BENDER ML, 1966, J AM CHEM SOC, V88, P5890, DOI 10.1021/ja00976a034
   Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039
   Eichelberger MC, 2019, J INFECT DIS, V219, pS75, DOI 10.1093/infdis/jiz017
   Eichelberger MC, 2018, CURR OPIN IMMUNOL, V53, P38, DOI 10.1016/j.coi.2018.03.025
   Fersht A., 1999, STRUCTURE MECH PROTE
   Gao ZZ, 2017, ANGEW CHEM INT EDIT, V56, P6112, DOI 10.1002/anie.201610544
   Krammer F, 2018, MBIO, V9, DOI 10.1128/mBio.02332-17
   Memoli M., 2016, MBIO, V7, P1, DOI DOI 10.1128/MBI0.00417-16
   Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195
   Wilson JR, 2017, VIROLOGY, V511, P214, DOI 10.1016/j.virol.2017.08.016
   Wohlbold TJ, 2017, NAT MICROBIOL, V2, P1415, DOI 10.1038/s41564-017-0011-8
   Wohlbold TJ, 2015, MBIO, V6, DOI 10.1128/mBio.02556-14
   Wohlbold TJ, 2014, VIRUSES-BASEL, V6, P2465, DOI 10.3390/v6062465
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 712
EP 718
DI 10.1016/j.vaccine.2019.11.048
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200002
PM 31787416
DA 2020-05-12
ER

PT J
AU Pulido, MR
   Garcia-Quintanilla, M
   Pachon, J
   McConnell, MJ
AF Pulido, Marina R.
   Garcia-Quintanilla, Meritxell
   Pachon, Jeronimo
   McConnell, Michael J.
TI A lipopolysaccharide-free outer membrane vesicle vaccine protects
   against Acinetobacter baumannii infection
SO VACCINE
LA English
DT Article
DE Acinetobacter baumannii; Outer membrane vesicles; Vaccine;
   Lipopolysaccharide
AB Outer membrane vesicles (OMVs) were isolated from an Acinetobacter strain deficient in lipopolysaccharide (LPS) due to a mutation in lpxD (IB010). Two immunizations with 10 mu g of IB010 OMVs elicited total IgG, IgM, IgG1 and IgG2c titers similar to those observed after immunization with OMVs derived from the parental strain (ATCC 19606), and IB010 OMVs plus purified LPS. Immunization with IB010 OMVs resulted in significantly reduced post-infection spleen bacterial loads and serum IL-1 beta and IL-6 levels compared to control mice in a disseminated sepsis model. Mice immunized with 10 mu g IB010 OMVs demonstrated significant, but partial, protection (75%) against infection, whereas mice immunized with ATCC 19606 OMVs or IB010 OMVs plus purified LPS were completely protected. Immunization of mice with 100 mu g of IB010 OMVs completely protected mice from infection. This study demonstrates that LPS deficient A. baumannii produces OMVs, and that immunization with these OMVs elicits protective immunity against infection. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pulido, Marina R.; Garcia-Quintanilla, Meritxell; Pachon, Jeronimo] Univ Seville, CSIC, Univ Hosp Virgen del Rocio, Inst Biomed Seville IBiS, Seville, Spain.
   [Pachon, Jeronimo] Univ Seville, Dept Med, Seville, Spain.
   [McConnell, Michael J.] Inst Salud Carlos III, Natl Ctr Microbiol, Madrid, Spain.
RP McConnell, MJ (reprint author), Inst Salud Carlos III, Natl Ctr Microbiol, Carretera Majadahonda Pozuelo,Km 2, Majadahonda 28821, Spain.
EM michael.mcconnell@isciii.es
OI McConnell, Michael/0000-0003-1028-381X; Pulido, Marina
   Rosa/0000-0003-1633-4294
FU Plan Nacional de I+D+i; Institute de Salud Carlos III, Subdireccion
   General de Redes y Centros de Investigacion Cooperativa, Ministerio de
   Economia, Industria y Competitividad, Spanish Network for Research in
   Infectious Diseases [REIPI RD16/0016/0009]; European Development
   Regional Fund "A way to achieve Europe", Operative program Intelligent
   Growth; la Consejeria de Economia, Innovacion, Ciencia y Empleo
   [PIE-CTS-2027]; Fundacion Progreso y Salud/Consejeria de Igualdad, Salud
   y Politicas Sociales of Junta de Andalucia [PI-0098-2014]; Ministerio de
   Economia y Competitividad of Spain [CD14/00014]
FX This work was supported by Plan Nacional de I+D+i 2013-2016 and
   Institute de Salud Carlos III, Subdireccion General de Redes y Centros
   de Investigacion Cooperativa, Ministerio de Economia, Industria y
   Competitividad, Spanish Network for Research in Infectious Diseases
   (REIPI RD16/0016/0009) - cofinanced by European Development Regional
   Fund "A way to achieve Europe", Operative program Intelligent Growth
   2014-2020, a grant from the la Consejeria de Economia, Innovacion,
   Ciencia y Empleo (PIE-CTS-2027), and a grant from the Fundacion Progreso
   y Salud/Consejeria de Igualdad, Salud y Politicas Sociales of Junta de
   Andalucia (PI-0098-2014). M.R.P. was supported by the Subprograma Sara
   Borrell from the Ministerio de Economia y Competitividad of Spain
   (CD14/00014).
CR Badmasti F, 2015, MOL IMMUNOL, V67, P552, DOI 10.1016/j.molimm.2015.07.031
   Cabral MP, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15480
   Cai W, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0768-y
   Cecil JD, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.PSIB-0001-2018
   Erridge C, 2007, J MED MICROBIOL, V56, P165, DOI 10.1099/jmm.0.46823-0
   Zurita ME, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00125
   Fingermann M, 2018, HUM VACC IMMUNOTHER, V14, P2208, DOI 10.1080/21645515.2018.1490381
   Garcia-Quintanilla M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114410
   Garcia-Quintanilla M, 2014, ANTIMICROB AGENTS CH, V58, P2972, DOI 10.1128/AAC.02642-13
   Huang WQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100727
   Masignani V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00751
   McConnell MJ, 2011, VACCINE, V29, P5705, DOI 10.1016/j.vaccine.2011.06.001
   McConnell MJ, 2011, INFECT IMMUN, V79, P518, DOI 10.1128/IAI.00741-10
   McConnell MJ, 2010, VACCINE, V29, P1, DOI 10.1016/j.vaccine.2010.10.052
   McConnell MJ, 2006, INFECT IMMUN, V74, P1009, DOI 10.1128/IAI.74.2.1009-1015.2006
   Pulido MR, 2018, VACCINE, V36, P4153, DOI 10.1016/j.vaccine.2018.05.113
   Sheweita SA, 2019, J INFECT PUBLIC HLTH
   van der Ley P, 2011, HUM VACCINES, V7, P886, DOI 10.4161/hv.7.8.16086
NR 18
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 719
EP 724
DI 10.1016/j.vaccine.2019.11.043
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200003
PM 31843268
DA 2020-05-12
ER

PT J
AU Gerend, MA
   Murdock, C
   Grove, K
AF Gerend, Mary A.
   Murdock, Caitlyn
   Grove, Kelly
TI An intervention for increasing HPV vaccination on a university campus
SO VACCINE
LA English
DT Article
DE Young adult; College students; Papillomavirus vaccines; Student health
   services
ID HUMAN-PAPILLOMAVIRUS VACCINATION; PREDICTORS; WOMEN; RISK
AB Purpose: To evaluate the effects of a human papillomavirus (HPV) vaccination intervention implemented on a large university campus in the United States.
   Methods: The intervention consisted of student-directed campaign materials promoting HPV vaccination (e.g., posters, yard signs, social media posts) and provider recommendation for HPV vaccine to students attending university health services (UHS) from January through March of 2019.
   Results: We observed a 75% increase in HPV vaccine doses administered at UHS in the spring semester of 2019 vs. 2018. In both semesters a higher percentage of doses was given to females than males. Further, the increase from 2018 to 2019 was larger for females than males. Age at vaccine receipt did not differ by year.
   Conclusions: Partnering with college and university health centers to implement HPV vaccine interventions could be a promising strategy for increasing HPV vaccination coverage among young adult college students across the country. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gerend, Mary A.] FSU, Coll Med, Dept Behav Sci & Social Med, 1115 West Call St, Tallahassee, FL 32304 USA.
   [Murdock, Caitlyn] FSU, Coll Med, Tallahassee, FL 32304 USA.
   [Grove, Kelly] FSU, Ctr Hlth Advocacy & Wellness, UHS, Tallahassee, FL 32304 USA.
   [Grove, Kelly] Florida Dept Hlth, Div Publ Hlth Stat & Performance Management, Tallahassee, FL USA.
RP Gerend, MA (reprint author), FSU, Coll Med, Dept Behav Sci & Social Med, 1115 West Call St, Tallahassee, FL 32304 USA.
EM mary.gerend@med.fsu.edu; clm17f@med.fsu.edu; kgrove@fsu.edu
OI Gerend, Mary/0000-0001-5413-1426
FU Florida State University College of Medicine
FX This research was supported by the Florida State University College of
   Medicine through departmental research funds and a summer research
   fellowship.
CR Barnard M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182266
   Fernandez ME, 2010, ANNU REV PUBL HEALTH, V31, P235, DOI 10.1146/annurev.publhealth.012809.103609
   Fontenot HB, 2014, J AM COLL HEALTH, V62, P186, DOI 10.1080/07448481.2013.872649
   Gerend MA, 2016, SEX TRANSM INFECT, V92, P104, DOI 10.1136/sextrans-2015-052088
   Gerend MA, 2013, HEALTH PSYCHOL, V32, P361, DOI 10.1037/a0026248
   Katz ML, 2011, J MENS HEALTH, V8, P175, DOI 10.1016/j.jomh.2011.04.002
   Lewis RM, 2018, VACCINE, V36, P2567, DOI 10.1016/j.vaccine.2018.03.083
   Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI 10.15585/mmwr.mm6832a3
   National HPV Vaccination Roundtable, 2018, CANCER PREVENTION TH
   Ragan KR, 2018, VACCINE, V36, P331, DOI 10.1016/j.vaccine.2017.07.041
   Thompson EL, 2016, PREV MED, V86, P92, DOI 10.1016/j.ypmed.2016.02.003
   Thompson VLS, 2017, HEALTH SOC WORK, V42, pE1, DOI 10.1093/hsw/hlw050
   US Food and Drug Administration, 2018, FDA APPR EXP US GARD
   Vaidya V, 2012, J WOMENS HEALTH, V21, P140, DOI 10.1089/jwh.2011.2876
   Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2
NR 15
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 725
EP 729
DI 10.1016/j.vaccine.2019.11.028
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200004
PM 31767468
DA 2020-05-12
ER

PT J
AU Im, JH
   Woo, H
   Ha, BM
   Lee, JS
   Chung, MH
   Jung, J
AF Im, Jae Hyoung
   Woo, Hyeongtaek
   Ha, Beom Man
   Lee, Jin-Soo
   Chung, Moon-Hyun
   Jung, Jaehun
TI Effectiveness of a single dose of the quadrivalent meningococcal
   conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis; Vaccines; Conjugate; Meningococcal vaccines
ID NEISSERIA-MENINGITIDIS; IMMUNOGENICITY; DISEASE; ADOLESCENTS;
   PREVENTION; SAFETY; SEROGROUPS; ADULTS
AB Conjugate vaccines are widely used to overcome the disadvantages of polysaccharide vaccines in the prevention of meningococcal disease. However, limited studies have examined the clinical effectiveness of single-dose meningococcal quadrivalent conjugate vaccines in adults. We assessed the effectiveness of the meningococcal vaccination program in the Republic of Korea Armed Forces, since 2013. Following vaccination program implementation, meningococcal disease cases decreased from 0.52/100,000 to 0.06/100,000 and the number of deaths declined from four to zero. Two meningococcal cases that developed post-implementation were identified as serotype B and X. The effectiveness of single-dose conjugate vaccination in recruits, expressed as the incidence rate ratio, was 0.88 during a 19-23-month observation period. These results indicate that meningococcal infections can be prevented by single-dose administration of the quadrivalent conjugate vaccine in at-risk groups, such as soldiers, travelers, and students in dormitories. Continuous investigation is needed to determine serogroup change, including B serogroups. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Im, Jae Hyoung; Lee, Jin-Soo] Inha Univ, Dept Internal Med, Div Infect Dis, Coll Med, Incheon, South Korea.
   [Woo, Hyeongtaek; Ha, Beom Man] Armed Force Med Command, Dept Prevent Med, Seongnam, South Korea.
   [Chung, Moon-Hyun] Seogwipo Med Ctr, Dept Internal Med, Jeju, South Korea.
   [Jung, Jaehun] Gachon Univ, Dept Prevent Med, Coll Med, Incheon, South Korea.
RP Jung, J (reprint author), 38-13 Dokjeom Ro,3Beon Gil, Incheon, South Korea.
EM dylife83@naver.com; since2002sz@gmail.com; hbm1130@naver.com;
   ljinsoo@inha.ac.kr; MHchungID@daum.net; eastside1st@gmail.com
OI Jung, Jaehun/0000-0002-4856-3668
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health and Welfare, Korea
   [HI14C1135]; Gachon University Gil Medical Center [2018-17]
FX This study was supported by grants from the Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute (KHIDI),
   funded by the Ministry of Health and Welfare, Korea (Grant number:
   HI14C1135); and the Gachon University Gil Medical Center (Grant number:
   2018-17). The sponsor of the study was not involved in the study design;
   data collection, analysis, interpretation of data; writing of the
   report; or the decision to submit the study results for publication.
CR Bae SM, 2008, JPN J INFECT DIS, V61, P434
   Balmer P, 2002, J MED MICROBIOL, V51, P717, DOI 10.1099/0022-1317-51-9-717
   Cohn AC, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2193
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   Heo JY, 2015, J KOREAN MED SCI, V30, P353, DOI 10.3346/jkms.2015.30.4.353
   Hwang IU, 2010, J KOREAN MIL MED ASS, V41, P188
   Jackson LA, 2009, CLIN INFECT DIS, V49, pE1, DOI 10.1086/599117
   Kang JH, 2016, INFECT CHEMOTHER, V48, P12, DOI 10.3947/ic.2016.48.1.12
   Kim DS, 2016, INT J INFECT DIS, V45, P59, DOI 10.1016/j.ijid.2016.02.010
   Kim HW, 2017, J KOREAN MED SCI, V32, P1111, DOI 10.3346/jkms.2017.32.7.1111
   Kim HW, 2016, YONSEI MED J, V57, P1511, DOI 10.3349/ymj.2016.57.6.1511
   Lee HJ, 2014, INT J INFECT DIS, V28, P204, DOI 10.1016/j.ijid.2014.06.008
   Lee SO, 2003, J KOREAN MED SCI, V18, P163, DOI 10.3346/jkms.2003.18.2.163
   MacNeil JR, 2011, PEDIATR INFECT DIS J, V30, P451, DOI 10.1097/INF.0b013e31820a8b3c
   Mandell Mandell G., 2011, MANDELL DOUGLAS BENN, P12
   Mehlhorn AJ, 2006, ANN PHARMACOTHER, V40, P666, DOI 10.1345/aph.1G486
   Poland GA, 2010, CLIN INFECT DIS, V50, pS45, DOI 10.1086/648964
   Reisinger KS, 2009, CLIN VACCINE IMMUNOL, V16, P1810, DOI 10.1128/CVI.00207-09
   Stamboulian D, 2010, INT J INFECT DIS, V14, pE868, DOI 10.1016/j.ijid.2010.03.017
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 730
EP 732
DI 10.1016/j.vaccine.2019.11.015
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200005
PM 31787413
DA 2020-05-12
ER

PT J
AU Degiuseppe, JI
   Stupka, JA
AF Ignacio Degiuseppe, Juan
   Andres Stupka, Juan
TI Genotype distribution of Group A rotavirus in children before and after
   massive vaccination in Latin America and the Caribbean: Systematic
   review
SO VACCINE
LA English
DT Review
DE Rotavirus; Massive vaccination; Genetic diversity; Latin America
ID RIO-DE-JANEIRO; MOLECULAR CHARACTERIZATION; HOSPITALIZED CHILDREN;
   MONOVALENT VACCINATION; ACUTE GASTROENTERITIS; EMERGING ROTAVIRUS;
   BUENOS-AIRES; STRAINS; BRAZIL; VACCINES
AB Background: During the last decade, most of Latin American and the Caribbean (LAC) countries have implemented oral live rotavirus vaccines in their national vaccination programs with remarkable results. However, it has been suggested that massive vaccination could lead to the replacement of circulating genotypes or the emergence of new variants or neutralizing antibodies escape mutants, which may reduce the effectiveness of the vaccine. The objective was to analyze the genetic diversity of Group A rotavirus before and after the introduction of universal vaccination in LAC.
   Methods: We conducted a systematic review of studies published in PubMed, Scielo and LILACS. There were considered only LAC countries with rotavirus massive vaccination strategy which had described circulating genotypes data in children under 5 years of age, either for surveillance or vaccine effectiveness purposes, from 2001 to 2017. Systematic review stages were carried out following the recommendations of PRISMA.
   Results: Of the 18 countries that included any of the two licensed rotavirus vaccines in their national schedules since 2006, only 7 (similar to 39%) presented studies of RVA genetic diversity before and after implementation, and met the inclusion criteria. Four of them (Argentina, Brazil, Colombia and Nicaragua) experienced a rapid switch from Wa-like to DS-1-like strains. Also, G1P[8] association, considered the most predominant worldwide in the pre-vaccination era, decreased significantly and was only frequently detected in Venezuela and Nicaragua. No defined pattern of emergence at high frequencies of unusual associations was observed in the post vaccination period, except for some evidence of G9P[4] in Colombia, G3P[6] and G1P[4] in Nicaragua.
   Conclusions: Even though the evidence shows a DS-1-like change trend, data from studies conducted in Latin America and the Caribbean are diverse and still not sufficient to assess the impact of vaccines on viral ecology or if genetic diversity is influenced by natural mechanisms of fluctuation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ignacio Degiuseppe, Juan; Andres Stupka, Juan] INEI ANLIS Dr Carlos G Malbran, Lab Viral Gastroenteritis, Ave Velez Sarsfield 563, Buenos Aires, DF, Argentina.
RP Degiuseppe, JI (reprint author), INEI ANLIS Dr Carlos G Malbran, Lab Viral Gastroenteritis, Ave Velez Sarsfield 563, Buenos Aires, DF, Argentina.
EM jdegiuseppe@anlis.gov.ar
CR [Anonymous], 2009, Wkly Epidemiol Rec, V84, P533
   Banyai K, 2012, VACCINE, V30, pA122, DOI 10.1016/j.vaccine.2011.09.111
   Banyai Krisztian, 2007, Orv Hetil, V148, P2043, DOI 10.1556/OH.2007.28159
   Becker-Dreps S, 2011, AM J TROP MED HYG, V85, P957, DOI 10.4269/ajtmh.2011.11-0401
   Bourdett-Stanziola L, 2011, INTERVIROLOGY, V54, P49, DOI 10.1159/000318863
   Bucardo F, 2007, J CLIN MICROBIOL, V45, P990, DOI 10.1128/JCM.01992-06
   Bucardo F, 2015, INFECT GENET EVOL, V34, P106, DOI 10.1016/j.meegid.2015.06.013
   Bucardo F, 2012, INFECT GENET EVOL, V12, P1282, DOI 10.1016/j.meegid.2012.03.007
   Caceres DC, 2006, REV PANAM SALUD PUBL, V20, P9, DOI 10.1590/S1020-49892006000700002
   Carvalho-Costa FA, 2006, MEM I OSWALDO CRUZ, V101, P291, DOI 10.1590/S0074-02762006000300012
   Carvalho-Costa FA, 2011, PEDIATR INFECT DIS J, V30, pS35, DOI 10.1097/INF.0b013e3181fefd5f
   Carvalho-Costa FA, 2009, EMERG INFECT DIS, V15, P95, DOI 10.3201/eid1501.071136
   Chavers T, 2018, EXPERT REV VACCINES, V17, P1037, DOI 10.1080/14760584.2018.1541409
   CHIBA S, 1986, LANCET, V2, P417
   Cilli A, 2011, J PEDIAT-BRAZIL, V87, P445, DOI [10.2223/JPED.2122, 10.1590/S0021-75572011000500013]
   Cortes J, 2012, TROP MED INT HEALTH, V17, P254, DOI 10.1111/j.1365-3156.2011.02911.x
   Costa Paulo S. S., 2004, J. Pediatr. (Rio J.), V80, P119, DOI 10.1590/S0021-75572004000200008
   Cotes-Cantillo K, 2014, VACCINE, V32, P3035, DOI 10.1016/j.vaccine.2014.03.064
   de Oliveira LH, 2015, VACCINE, V33, pA248, DOI 10.1016/j.vaccine.2014.11.060
   Degiuseppe JI, 2018, EPIDEMIOL INFECT, V146, P1948, DOI 10.1017/S0950268818001954
   Dulgheroff ACB, 2014, BRAZ J MED BIOL RES, V47, P1091, DOI 10.1590/1414-431X20144156
   Espinoza F, 2006, PEDIATR INFECT DIS J, V25, P1078, DOI 10.1097/01.inf.0000242739.44424.0e
   Esteban LE, 2010, J MED VIROL, V82, P1083, DOI 10.1002/jmv.21745
   Franco MA, 2006, VACCINE, V24, P2718, DOI 10.1016/j.vaccine.2005.12.048
   Gastanaduy PA, 2016, CLIN INFECT DIS, V62, pS121, DOI 10.1093/cid/civ1208
   Gouvea Vera S, 2007, Open Virol J, V1, P47, DOI 10.2174/1874357900701010047
   Gurgel RQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110217
   Degiuseppe JI, 2017, J MED VIROL, V89, P423, DOI 10.1002/jmv.24650
   Degiuseppe JI, 2013, ARCH ARGENT PEDIATR, V111, P148, DOI [10.5546/aap.2013.148, 10.1590/S0325-00752013000200010]
   Jere KC, 2018, J VIROL, V92, DOI 10.1128/JVI.01246-17
   Justino MCA, 2011, PEDIATR INFECT DIS J, V30, P396, DOI 10.1097/INF.0b013e3182055cc2
   Kandasamy S, 2014, GUT MICROBES, V5, P639, DOI 10.4161/19490976.2014.969972
   Khawaja S, 2014, PEDIATR INFECT DIS J, V33, pE25, DOI 10.1097/INF.0000000000000074
   Leite M, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759045, 10.1590/s1678-9946201759045]
   Lo SW, 2019, LANCET INFECT DIS, V19, P759, DOI 10.1016/S1473-3099(19)30297-X
   Luchs A, 2010, BRAZIL REV SOC BRAS, V2013, P227, DOI [10.1590/10037- 8682-1162-2013., DOI 10.1590/0037-8682-1162-2013.]
   Luchs A, 2019, J GEN VIROL, V100, P7, DOI 10.1099/jgv.0.001171
   Luchs A, 2016, ACTA TROP, V156, P87, DOI 10.1016/j.actatropica.2015.12.008
   Luchs A, 2015, J MED VIROL, V87, P1881, DOI 10.1002/jmv.24241
   Mandile MG, 2014, J CLIN VIROL, V60, P282, DOI 10.1016/j.jcv.2014.04.022
   Martinez M, 2010, ARCH VIROL, V155, P525, DOI 10.1007/s00705-010-0617-0
   Matthijnssens J, 2008, ARCH VIROL, V153, P1621, DOI 10.1007/s00705-008-0155-1
   Matthijnssens J, 2008, J VIROL, V82, P3204, DOI 10.1128/JVI.02257-07
   Matthijnssens J, 2012, EXPERT REV VACCINES, V11, P1347, DOI [10.1586/erv.12.105, 10.1586/ERV.12.105]
   Matthijnssens J, 2011, ARCH VIROL, V156, P1397, DOI 10.1007/s00705-011-1006-z
   McAtee CL, 2016, AM J TROP MED HYG, V94, P212, DOI 10.4269/ajtmh.15-0203
   Miyazaki A, 2018, VACCINE, V36, P6270, DOI 10.1016/j.vaccine.2018.09.008
   Montenegro FMU, 2007, J MED VIROL, V79, P335, DOI 10.1002/jmv.20803
   Morillo SG, 2010, J PEDIAT-BRAZIL, V86, P155, DOI [10.2223/JPED.1981, 10.1590/S0021-75572010000200013]
   Costa MSM, 2012, REV SOC BRAS MED TRO, V45, P520, DOI 10.1590/S0037-86822012000400021
   Naranjo A, 2008, J MED VIROL, V80, P1106, DOI 10.1002/jmv.21181
   Neves MAO, 2016, J MED VIROL, V88, P782, DOI 10.1002/jmv.24404
   Safadi MAP, 2010, PEDIATR INFECT DIS J, V29, P1019, DOI 10.1097/INF.0b013e3181e7886a
   Parra GI, 2007, J CLIN VIROL, V40, P135, DOI 10.1016/j.jcv.2007.07.006
   Patel M, 2016, CLIN INFECT DIS, V62, pS127, DOI 10.1093/cid/civ1017
   Patel MM, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3726
   Pelaez-Carvajal D, 2014, J MED VIROL, V86, P1083, DOI 10.1002/jmv.23899
   Pringle KD, 2016, CLIN INFECT DIS, V62, pS115, DOI 10.1093/cid/civ1026
   Rivera R, 2013, INT J INFECT DIS, V17, pE762, DOI 10.1016/j.ijid.2013.03.016
   Ferreira MSR, 2012, MEM I OSWALDO CRUZ, V107, P1064, DOI 10.1590/S0074-02762012000800017
   Roczo-Farkas S, 2018, J INFECT DIS, V218, P546, DOI 10.1093/infdis/jiy197
   Sa ACC, 2015, J MED VIROL, V87, P1480, DOI 10.1002/jmv.24144
   Sandra CA, 2014, ARCH VIROL, V159, P1139, DOI 10.1007/s00705-013-1847-8
   Santos N, 2005, J CLIN MICROBIOL, V43, P4064, DOI 10.1128/JCM.43.8.4064-4069.2005
   Santos N, 2005, REV MED VIROL, V15, P29, DOI 10.1002/rmv.448
   Santos VS, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0173-2
   Shamseer L, 2015, BMJ-BRIT MED J, V350, DOI [10.1136Ibrrh.g7647g7647, DOI 10.1136/BMJ.G7647G7647]
   Sindhu KNC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016577
   Sindhu KNC, 2017, CURR OPIN INFECT DIS, V30, P473, DOI 10.1097/QCO.0000000000000397
   Siqueira AA, 2010, INT J INFECT DIS, V14, pE898, DOI 10.1016/j.ijid.2010.03.024
   Soares LD, 2014, J MED VIROL, V86, P1065, DOI 10.1002/jmv.23797
   Soares LD, 2012, ARCH VIROL, V157, P135, DOI 10.1007/s00705-011-1111-z
   Stupka JA, 2012, J CLIN VIROL, V54, P162, DOI 10.1016/j.jcv.2012.02.011
   Stupka JA, 2009, INFECT GENET EVOL, V9, P1225, DOI 10.1016/j.meegid.2009.07.002
   Borges AMT, 2011, MEM I OSWALDO CRUZ, V106, P499, DOI 10.1590/S0074-02762011000400018
   Montenegro FMU, 2015, J TROP PEDIATRICS, V61, P206, DOI 10.1093/tropej/fmv006
   Velazquez RF, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-016-0771-y
   Almeida TNV, 2015, REV SOC BRAS MED TRO, V48, P599, DOI 10.1590/0037-8682-0023-2015
   Vizzi E, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0721-9
   Vizzi E, 2011, J MED VIROL, V83, P2225, DOI 10.1002/jmv.22211
   Volotao EM, 2006, J MED VIROL, V78, P263, DOI 10.1002/jmv.20535
   Ward R, 2009, PEDIATR INFECT DIS J, V28, pS57, DOI 10.1097/INF.0b013e3181967c16
NR 82
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 733
EP 740
DI 10.1016/j.vaccine.2019.11.017
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200006
PM 31771863
DA 2020-05-12
ER

PT J
AU McLaughlin, JM
   Khan, FL
   Thoburn, EA
   Isturiz, RE
   Swerdlow, DL
AF McLaughlin, John M.
   Khan, Farid L.
   Thoburn, Elizabeth A.
   Isturiz, Raul E.
   Swerdlow, David L.
TI Rates of hospitalization for community-acquired pneumonia among US
   adults: A systematic review
SO VACCINE
LA English
DT Review
DE Pneumonia; Community-acquired pneumonia (CAP); Adult; Incidence; Burden;
   Epidemiology; Review
ID PNEUMOCOCCAL CONJUGATE VACCINE; CARE-ASSOCIATED PNEUMONIA;
   UNITED-STATES; REQUIRING HOSPITALIZATION; ECONOMIC BURDEN; HEALTH;
   OLDER; RISK; AGE; EPIDEMIOLOGY
AB Background: Community-acquired pneumonia (CAP) is associated with significant disease burden in adults but has not been measured uniformly. Reconciling differences across studies is critical for understanding the true burden of CAP.
   Methods: We performed a systematic literature review of the incidence of hospitalized CAP among US adults and described the impact of key study characteristics on these estimates.
   Results: After review of 8361 articles as of January 31, 2019, we identified 28 studies with 41 unique estimates of hospitalized CAP incidence. Among adults >= 65 years of age, annual rates of hospitalized CAP ranged from 847 to 3500 per 100,000 persons with median = 1830. Rates were lower in studies that excluded patients with healthcare-associated (but community-onset) pneumonia (HCAP; median = 2003 vs 1286; P = 0.02) or immunocompromising conditions (median = 1895 vs 1409; P = 0.27) compared to those that did not. Rates of CAP were also lower in studies that used more restrictive criteria for diagnosing pneumonia (eg, pneumonia coded in any diagnosis position [median = 22701 vs pneumonia coded in the first position only [median = 1375] in studies of administrative claims; P = 0.02). For adults <65 years of age, rates of CAP were lower (range: 89 to 1138 per 100,000; median = 199).
   Conclusions: CAP causes a significant disease burden among adults, particularly among those >= 65 years of age. Commonly-applied exclusion criteria (eg, persons with HCAP or immunocompromising conditions) or restrictive case definitions (eg, only including pneumonias coded in the primary diagnosis position) have led to systematic underestimation of CAP incidence in many previous studies. In studies that did not apply these restrictive criteria, the rate of hospitalization was approximately 2000 per 100,000 annually. Understanding the true burden of adult CAP is critical for highlighting the ongoing need for expanded prevention programs, including vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [McLaughlin, John M.; Khan, Farid L.; Thoburn, Elizabeth A.; Isturiz, Raul E.; Swerdlow, David L.] Pfizer Vaccines, Collegeville, PA USA.
RP McLaughlin, JM (reprint author), Pfizer Vaccines, Pneumococcal Vaccines, 500 Arcola Rd, Collegeville, PA 19426 USA.
EM john.mclaughlin@pfizer.com
FU Pfizer Inc.Pfizer
FX This study was sponsored by Pfizer Inc.
CR [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST
   Broulette J, 2013, AM HEALTH DRUG BENEF, V6, P494
   Brown JD, 2018, BMC GERIATR, V18, DOI [10.1186/s12877-018-0787-2, 10.1186/s12876-018-0860-5]
   CDC/NCHS, 2010, AV LENGTH STAY DISCH
   Chalmers JD, 2014, CLIN INFECT DIS, V58, P330, DOI 10.1093/cid/cit734
   Corrado RE, 2017, CHEST, V152, P930, DOI 10.1016/j.chest.2017.04.162
   Cortellaro F, 2012, EMERG MED J, V29, P19, DOI 10.1136/emj.2010.101584
   Esayag Y, 2010, AM J MED, V123, pE13, DOI 10.1016/j.amjmed.2010.02.025
   File TM, 2004, AM J MED, V117, P39, DOI 10.1016/j.amjmed.2004.07.007
   Fry AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/jama.294.21.2712
   Gessner BD, 2019, VACCINE, V37, P5777, DOI 10.1016/j.vaccine.2018.05.097
   Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165
   Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9
   Gross AE, 2014, ANTIMICROB AGENTS CH, V58, P5262, DOI 10.1128/AAC.02582-14
   Hayden GE, 2009, J EMERG MED, V36, P266, DOI 10.1016/j.jemermed.2007.11.042
   Hayes BH, 2018, CHEST, V153, P427, DOI 10.1016/j.chest.2017.09.041
   Healthcare Infection Control Practices Advisory Committee, 2003, GUID PREV HLTH CAR A
   Houston M S, 1995, J Am Board Fam Pract, V8, P347
   Indian Health Service, 2018, IND HLTH DISP
   Isturiz RE, 2018, EXPERT REV VACCINES, V17, P45, DOI 10.1080/14760584.2018.1411196
   Jackson ML, 2004, CLIN INFECT DIS, V39, P1642, DOI 10.1086/425615
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Juthani-Mehta M, 2013, J AM GERIATR SOC, V61, P1111, DOI 10.1111/jgs.12325
   Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353
   Kaplan V, 2002, AM J RESP CRIT CARE, V165, P766, DOI 10.1164/ajrccm.165.6.2103038
   Kea B, 2013, AM J EMERG MED, V31, P1268, DOI 10.1016/j.ajem.2013.04.021
   Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709
   McLaughlin JM, 2018, HUM VACCIN IMMUNOTHE
   Metersky ML, 2000, ARCH INTERN MED, V160, P3385, DOI 10.1001/archinte.160.22.3385
   Michael Lessa FS, 2019, IDWEEK
   National Center for Health Statistics, 2012, NAT HOSP DISCH SURV
   National Center for Health Statistics, 2014, CLASS DIS INJ
   National Center for Health Statistics, 1998, CLASS DIS INJ
   Nelson JC, 2008, VACCINE, V26, P4947, DOI 10.1016/j.vaccine.2008.07.016
   Park H, 2015, CLIN THER, V37, P1466, DOI 10.1016/j.clinthera.2015.04.013
   Pelton SI, 2019, CLIN INFECT DIS, V68, P1831, DOI 10.1093/cid/ciy800
   Prevention CFDCA, 2018, NATL VITAL STAT REPO
   Ramirez JA, 2017, CLIN INFECT DIS, V65, P1806, DOI 10.1093/cid/cix647
   Ruhnke GW, 2011, AM J MED, V124, P171, DOI 10.1016/j.amjmed.2010.08.019
   Rui PKK, 2015, EMERGENCY DEP SUMMAR
   Ryan M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075887
   Sato R, 2013, APPL HEALTH ECON HEA, V11, P251, DOI 10.1007/s40258-013-0026-0
   Self WH, 2014, J INFECTION, V68, P156, DOI 10.1016/j.jinf.2013.10.005
   Self WH, 2013, AM J EMERG MED, V31, P401, DOI 10.1016/j.ajem.2012.08.041
   Shea KM, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu024
   Simonsen L, 2014, LANCET RESP MED, V2, P387, DOI 10.1016/S2213-2600(14)70032-3
   Simonsen L, 2011, MBIO, V2, DOI 10.1128/mBio.00309-10
   Storms AD, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0552-x
   Thomas CP, 2012, CHEST, V142, P973, DOI 10.1378/chest.11-1160
   Watt JP, 2010, EPIDEMIOL INFECT, V138, P1146, DOI 10.1017/S0950268809991464
   Yap V, 2013, INFECT DIS CLIN N AM, V27, P1, DOI 10.1016/j.idc.2012.11.002
   Yu H, 2012, J AM GERIATR SOC, V60, P2137, DOI 10.1111/j.1532-5415.2012.04208.x
NR 52
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 741
EP 751
DI 10.1016/j.vaccine.2019.10.101
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200007
PM 31843272
DA 2020-05-12
ER

PT J
AU Tsuzuki, S
   Baguelin, M
   Pebody, R
   van Leeuwen, E
AF Tsuzuki, Shinya
   Baguelin, Marc
   Pebody, Richard
   van Leeuwen, Edwin
TI Modelling the optimal target age group for seasonal influenza
   vaccination in Japan
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination policy; Mathematical model; Cost-effectiveness
   analysis; Japan
ID COST-EFFECTIVENESS ANALYSIS; SOCIAL CONTACTS; IMMUNIZATION PROGRAM;
   SCHOOLCHILDREN; INFECTION; STRATEGIES; CHILDREN; DISEASE; PEOPLE; SPREAD
AB Background: In Japan, the current influenza vaccination programme is targeting older individuals. On the other hand, epidemics of influenza are likely to be mainly driven by children. In this study, we consider the most cost-effective target age group for a seasonal influenza vaccination programme in Japan.
   Methods: We constructed a deterministic compartmental Susceptible-Exposed-Infectious-Recovered (SEIR) model with data from the 2012/13 to 2014/15 influenza seasons in Japan. Bayesian inference with Markov Chain Monte Carlo method was used for parameter estimation. Cost-effectiveness analyses were conducted from public health care payer's perspective.
   Results: A scenario targeting children under 15 was expected to reduce the number of cases 6,382,345 compared to the current strategy. A scenario targeting elderly population (age over 49 years) was expected to reduce the number of cases 693,206. The children targeted scenario demonstrated negative ICER (incremental cost-effectiveness ratio) value. On the other hand, elderly targeted scenario demonstrated higher ICER value than the willingness to pay (50,000 USD/QALY).
   Conclusions: A vaccination programme which targets children under 15 is predicted to have much larger epidemiological impact than those targeting elderly. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tsuzuki, Shinya] Natl Ctr Global Hlth & Med, Dis Control & Prevent Ctr, Tokyo, Japan.
   [Tsuzuki, Shinya] Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium.
   [Tsuzuki, Shinya; Baguelin, Marc; Pebody, Richard; van Leeuwen, Edwin] Publ Hlth England, Resp Dis Dept, London, England.
   [Baguelin, Marc] Imperial Coll London, MRC Ctr Global Infect Dis Anal, Sch Publ Hlth, London W2 1PG, England.
   [Baguelin, Marc] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
RP Tsuzuki, S (reprint author), 21-1 Toyama,Shinjuku Ku, Tokyo 1628655, Japan.
EM stsuzuki@hosp.ncgm.go.jp
FU MRC Centre for Global Infectious Disease Analysis [MR/R015600/1]; UK
   National Institute for Health Research Health Protection Research Unit
   (NIHR HPRU) in Modelling Methodology (Imperial College London) and
   Immunization (London School of Hygiene and Tropical Medicine); Public
   Health England (PHE) [HPRU-2012-10080]
FX MB thanks the MRC Centre for Global Infectious Disease Analysis (grant
   MR/R015600/1) and the UK National Institute for Health Research Health
   Protection Research Unit (NIHR HPRU) in Modelling Methodology (Imperial
   College London) and Immunization (London School of Hygiene and Tropical
   Medicine) in partnership with Public Health England (PHE) (grant
   HPRU-2012-10080) for funding. The views expressed are those of the
   authors and not necessarily those of the MRC, the UK National Health
   Service, the UK National Institute for Health Research, the UK Medical
   Research Council, the UK Department of Health, or Public Health England.
CR Akaishi Y, 2016, INT J INFECT DIS, V52, P55, DOI 10.1016/j.ijid.2016.10.002
   Akazawa M, 2014, HEALTH POLICY, V118, P127, DOI 10.1016/j.healthpol.2014.07.016
   Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527
   Baguelin M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0452-y
   Basta NE, 2009, AM J EPIDEMIOL, V170, P679, DOI 10.1093/aje/kwp237
   Bilcke J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102634
   Briggs AH, 2012, VALUE HEALTH, V15, P835, DOI 10.1016/j.jval.2012.04.014
   Cai Li, 2006, Kobe Journal of Medical Sciences, V52, P97
   Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375
   Centers for Disease Control and Prevention, 2017, INFL FLU
   Charu V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026282
   Cromer D, 2014, J INFECTION, V68, P363, DOI 10.1016/j.jinf.2013.11.013
   Eichner M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2399-4
   Eichner M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-365
   European Center for Disease Prevention and Control, 2017, VACC SCHED
   Fleming DM, 2010, J EPIDEMIOL COMMUN H, V64, P1062, DOI 10.1136/jech.2009.093450
   Giese C, 2016, VACCINE, V34, P3657, DOI 10.1016/j.vaccine.2016.05.028
   Hens N, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-187
   Hoshi SL, 2007, VACCINE, V25, P6511, DOI 10.1016/j.vaccine.2007.05.067
   Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002
   Ibuka Y, 2016, J EPIDEMIOL COMMUN H, V70, P162, DOI 10.1136/jech-2015-205777
   Jefferson T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004876.pub3
   Jit M, 2013, HUM VACC IMMUNOTHER, V9, P834, DOI 10.4161/hv.23637
   Kanaan MN, 2005, EPIDEMIOL INFECT, V133, P1009, DOI 10.1017/S0950268805004528
   Kawai S, 2011, CLIN INFECT DIS, V53, P130, DOI 10.1093/cid/cir336
   Leval A, 2016, EUROSURVEILLANCE, V21, P43, DOI DOI 10.2807/1560-7917.ES
   Ministry of Health Labour and Welfare, 2017, INFL Q A
   Ministry of Health Labour and Welfare Japan, 2017, INFL EXCL AV INFL NO
   Mizumoto K, 2013, COMPUT MATH METHOD M, DOI 10.1155/2013/637064
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   National Institute of Infectious Diseases Japan, CURR SIT VACC INFL E
   National Institute of Infectious Diseases Japan, 2009, WEEKL REP INFL VIR I
   Newall AT, 2013, PHARMACOECONOMICS, V31, P693, DOI 10.1007/s40273-013-0060-7
   Reed C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048187
   Reichert TA, 2001, NEW ENGL J MED, V344, P889, DOI 10.1056/NEJM200103223441204
   Rizzo C, 2018, HUM VACC IMMUNOTHER, V14, P693, DOI 10.1080/21645515.2017.1367463
   Saito MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072866
   Saitoh A, 2014, VACCINE, V32, P4253, DOI 10.1016/j.vaccine.2014.06.022
   Saitoh A, 2012, VACCINE, V30, P4752, DOI 10.1016/j.vaccine.2012.04.026
   Santermans E, 2017, MATH BIOSCI, V285, P43, DOI 10.1016/j.mbs.2016.12.004
   Shimada T, 2015, JPN J INFECT DIS, V68, P151, DOI 10.7883/yoken.JJID.2014.125
   Shimazawa R, 2012, HEALTH POLICY, V107, P312, DOI 10.1016/j.healthpol.2012.05.012
   Shiroiwa T, 2017, VALUE HEALTH, V20, P372, DOI 10.1016/j.jval.2016.08.726
   Thomas RE, 2014, VACCINE, V32, P2143, DOI 10.1016/j.vaccine.2014.02.059
   Thorrington D, 2015, VACCINE, V33, P5415, DOI 10.1016/j.vaccine.2015.08.031
   Tsuzuki S, 2018, VACCINE, V36, P624, DOI 10.1016/j.vaccine.2017.12.058
   van Leeuwen E, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005838
   vanLeeuwen Edwin, 2017, USING FLUEVIDENCESYN
   Wallinga J, 2006, AM J EPIDEMIOL, V164, P936, DOI 10.1093/aje/kwj317
   Worby CJ, 2015, EPIDEMICS-NETH, V13, P10, DOI 10.1016/j.epidem.2015.04.003
   Worlds Health Organization, 2016, INFL SEAS FACT SHEET
NR 51
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 752
EP 762
DI 10.1016/j.vaccine.2019.11.001
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200008
PM 31735503
DA 2020-05-12
ER

PT J
AU Van Mulder, TJS
   Van Nuffel, D
   Demolder, M
   De Meyer, G
   Moens, S
   Beyers, KCL
   Vankerckhoven, VVJ
   Van Damme, P
   Theeten, H
AF Van Mulder, T. J. S.
   Van Nuffel, D.
   Demolder, M.
   De Meyer, G.
   Moens, S.
   Beyers, K. C. L.
   Vankerckhoven, V. V. J.
   Van Damme, P.
   Theeten, H.
TI Skin thickness measurements for optimal intradermal injections in
   children
SO VACCINE
LA English
DT Article
DE Skin thickness; Children; Intradermal; Injection device; Vaccine
   delivery
ID HIGH-FREQUENCY ULTRASOUND; ECHOGRAPHIC MEASUREMENT; MICRONEEDLE DEVICE;
   VACCINATION; RECOMMENDATIONS; DELIVERY; INFANTS; SITES
AB Background: In the context of precision medicine and in response to the highly needed capacity of rapid interventions towards new infectious diseases and pandemic outbreaks, intradermal immunization is gaining increased attention. However, the currently used Mantoux technique for ID injection is difficult to standardize and requires training, especially when used in children.
   To allow determining the maximum penetration depth and needle characteristics for the development of a platform of medical devices suited for intradermal injection, VAX-ID (R) and to ensure an accurate ID injection in children, the epidermal and dermal thickness at the proximal ventral and dorsal forearm (PVF & PDF) and at the deltoid region in children aged 8 weeks to 18 years were assessed. The lateral part of the upper leg was assessed as well in children aged 8 weeks to 2 years since it is a commonly used injection site in this population.
   Materials & Methods: Mean thickness of the PVF, PDF, lateral part of the upper leg and deltoid were measured using high-frequency ultrasound. Association with gender, age and BMI was assessed using Mann-Whitney U Test, Spearman correlation and Wilcoxon Signed Ranks Test, respectively.
   Results: Results showed an overall mean skin thickness of 0.99 mm (SD: 0.14 mm) at the PVF, 1.20 mm (SD: 0.17) at the PDF, 1.28 mm (SD: 0.16) at the lateral part of the upper leg and increasing to 1.32 mm (0.25) at the deltoid region. Age and BMI correlated significantly (p < 0.001) with skin thickness at all investigated body sites. Gender did not affect skin thickness in the investigated population.
   Conclusion: Significant differences in skin thickness at the PVF, PDF and deltoid region were seen according to age and BMI. An optimal needle length of 0.7 mm is advised to guarantee intradermal injection in children at all investigated injection sites. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Van Mulder, T. J. S.; Beyers, K. C. L.; Vankerckhoven, V. V. J.] Novosanis, Bijkhoevelaan 32c, BE-2110 Wijnegem, Belgium.
   [Van Mulder, T. J. S.; Vankerckhoven, V. V. J.; Van Damme, P.; Theeten, H.] Univ Antwerp, Ctr Evaluat Vaccinat, Vaccine & Infect Dis Inst, Campus Drie Eiken,Univ Pl 1, BE-2610 Antwerp, Belgium.
   [Van Nuffel, D.] Univ Antwerp, Dept Biomed Sci, Campus Drie Eiken,Univ Pl 1, BE-2610 Antwerp, Belgium.
   [Demolder, M.; De Meyer, G.] Univ Antwerp, Dept Pharmaceut Sci, Campus Drie Eiken,Univ Pl 1, BE-2610 Antwerp, Belgium.
   [Moens, S.; Beyers, K. C. L.] Voxdale, Bijkhoevelaan 32c, BE-2110 Wijnegem, Belgium.
RP Van Mulder, TJS (reprint author), Univ Antwerp, Campus Orie Eiken,Univ Pl 1, BE-2610 Antwerp, Belgium.
EM timothi.vanmulder@uantwerpen.be
RI De Meyer, Guido/R-8129-2016
OI De Meyer, Guido/0000-0003-3848-8702
FU Flemish Government (VLAIO VAX-ID(R) project); VLAIO Baekeland
FX This study was supported by the Flemish Government (VLAIO VAX-ID (R)
   project). Van Mulder TJS is supported via VLAIO Baekeland.
CR [Anonymous], 2018, LANCET INFECT DIS, V18, P697, DOI 10.1016/S1473-3099(18)30364-5
   Combadiere B, 2011, HUM VACCINES, V7, P811, DOI 10.4161/hv.7.8.16274
   Derraik JGB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086637
   Escoffier C, J INVEST DERMATOL, P353
   FLYNN PM, 1994, CHEST, V106, P1463, DOI 10.1378/chest.106.5.1463
   Gibney MA, 2010, CURR MED RES OPIN, V26, P1519, DOI 10.1185/03007995.2010.481203
   Konig IR, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00391-2017
   Laurent A, 2007, VACCINE, V25, P6423, DOI 10.1016/j.vaccine.2007.05.046
   Levin Y, 2015, HUM VACC IMMUNOTHER, V11, P991, DOI 10.1080/21645515.2015.1010871
   Lim STJ, 2018, J CLIN TRANSL ENDOCR, V12, P26, DOI 10.1016/j.jcte.2018.04.004
   Lo Presti D, 2012, PEDIATR DIABETES, V13, P525, DOI 10.1111/j.1399-5448.2012.00865.x
   Morens DM, 2018, NEW ENGL J MED, V379, P2285, DOI 10.1056/NEJMp1814447
   Ploin D, 2011, VACCINE, V29, P8438, DOI 10.1016/j.vaccine.2011.07.111
   Saitoh A, 2015, VACCINE, V33, P3384, DOI 10.1016/j.vaccine.2015.04.081
   Schou AJ, 2004, SKIN RES TECHNOL, V10, P200, DOI 10.1111/j.1600-0846.2004.00070.x
   Seidenari S, 2000, DERMATOLOGY, V201, P218, DOI 10.1159/000018491
   Sharrer G Terry, 2017, Methods Mol Biol, V1606, P37, DOI 10.1007/978-1-4939-6990-6_3
   TAN CY, 1982, BRIT J DERMATOL, V106, P657, DOI 10.1111/j.1365-2133.1982.tb11680.x
   Tuan-Mahmood TM, 2013, EUR J PHARM SCI, V50, P623, DOI 10.1016/j.ejps.2013.05.005
   Van Damme P, 2009, VACCINE, V27, P454, DOI 10.1016/j.vaccine.2008.10.077
   Van Mulder TJS, 2019, VACCINE, V37, P581, DOI 10.1016/j.vaccine.2018.12.016
   Van Mulder TJS, 2017, VACCINE, V35, P1810, DOI 10.1016/j.vaccine.2016.07.039
   Van Mulder TJS, 2014, HUM VACC IMMUNOTHER, V10, P3746, DOI 10.4161/21645515.2014.979655
   Waller JM, 2005, SKIN RES TECHNOL, V11, P221, DOI 10.1111/j.0909-725X.2005.00151.x
   Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301
   Young F, 2011, VACCINE, V29, P8788, DOI 10.1016/j.vaccine.2011.09.077
   Zehrung D, 2011, VACCINE SKIN VACCINA, V2013, P3392
NR 27
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 763
EP 768
DI 10.1016/j.vaccine.2019.11.002
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200009
PM 31767463
DA 2020-05-12
ER

PT J
AU Steigerwald, R
   Brake, DA
   Barrera, J
   Schutta, CJ
   Kalla, M
   Wennier, ST
   Volkmann, A
   Hurtle, W
   Clark, BA
   Zurita, M
   Pisano, M
   Kamicker, BJ
   Puckette, MC
   Rasmussen, MV
   Neilan, JG
AF Steigerwald, Robin
   Brake, David A.
   Barrera, Jose
   Schutta, Christopher J.
   Kalla, Markus
   Wennier, Sonia T.
   Volkmann, Ariane
   Hurtle, William
   Clark, Benjamin A.
   Zurita, Mariceny
   Pisano, Melia
   Kamicker, Barbara J.
   Puckette, Michael C.
   Rasmussen, Max, V
   Neilan, John G.
TI Evaluation of modified Vaccinia Ankara-based vaccines against
   foot-and-mouth disease serotype A24 in cattle
SO VACCINE
LA English
DT Article
DE Efficacy; Foot-and-mouth disease virus; MVA vectored vaccine; FMDV; DIVA
ID VIRUS EMPTY CAPSIDS; IMMUNOGENICITY; VACCINATION; CLEAVAGE; CELLS; HOST;
   EXPRESSION; ANTIBODIES; PROTEINS; ADJUVANT
AB To prepare foot-and-mouth disease (FMD) recombinant vaccines in response to newly emerging FMD virus (FMDV) field strains, we evaluated Modified Vaccinia virus Ankara-Bavarian Nordic (MVA-BN (R)) as an FMD vaccine vector platform. The MVA-BN vector has the capacity to carry and express numerous foreign genes and thereby has the potential to encode antigens from multiple FMDV strains. Moreover, this vector has an extensive safety record in humans. All MVA-BN-FMD constructs expressed the FMDV A24 Cruzeiro P1 capsid polyprotein as antigen and the FMDV 3C protease required for processing of the polyprotein. Because the FMDV wild-type 3C protease is detrimental to mammalian cells, one of four FMDV 3C protease variants were utilized: wild-type, or one of three previously reported mutants intended to dampen protease activity (C142T, C142L) or to increase specificity and thereby reduce adverse effects (L127P). These 3C coding sequences were expressed under the control of different promoters selected to reduce 3C protease expression. Four MVA-BN-FMD constructs were evaluated in vitro for acceptable vector stability, FMDV P1 polyprotein expression, processing, and the potential for vaccine scale-up production. Two MVA-BN FMD constructs met the in vitro selection criteria to qualify for clinical studies: MVA-mBN3606 (carrying a C142T mutant 3C protease and an HIV frameshift for reduced expression) and MVA-mBN386B (carrying a L127P mutant 3C protease). Both vaccines were safe in cattle and elicited low to moderate serum neutralization titers to FMDV following multiple dose administrations. Following FMDV homologous challenge, both vaccines conferred 100% protection against clinical FMD and viremia using single dose or prime-boost immunization regimens. The MVA-BN FMD vaccine platform was capable of differentiating infected from vaccinated animals (DIVA). The demonstration of the successful application of MVA-BN as an FMD vaccine vector provides a platform for further FMD vaccine development against more epidemiologically relevant FMDV strains. Published by Elsevier Ltd.
C1 [Steigerwald, Robin; Kalla, Markus; Wennier, Sonia T.; Volkmann, Ariane] Bavarian Nordic GmbH, Fraunhoferstr 13, D-82152 Martinsried, Germany.
   [Brake, David A.] BioQuest Associates LLC, Plum Isl Anim Dis Ctr, POB 848, Greenport, NY 11944 USA.
   [Barrera, Jose; Clark, Benjamin A.; Zurita, Mariceny; Pisano, Melia; Kamicker, Barbara J.] Leidos, Plum Isl Anim Dis Ctr, POB 848, Greenport, NY 11944 USA.
   [Schutta, Christopher J.; Hurtle, William; Puckette, Michael C.; Rasmussen, Max, V; Neilan, John G.] US Dept Homeland Secur Sci & Technol Directorate, Plum Isl Anim Dis Ctr, POB 848, Greenport, NY 11944 USA.
RP Neilan, JG (reprint author), US Dept Homeland Secur Sci & Technol Directorate, Plum Isl Anim Dis Ctr, POB 848, Greenport, NY 11944 USA.
EM robin.steigerwald@bavarian-nordic.com; david.brake@st.dhs.gov;
   jose.barrera@st.dhs.gov; christopher.schutta@st.dhs.gov;
   markus.kalla@bavarian-nordic.com; sonia.wennier@bavarian-nordic.com;
   ariane.volkmann@bavarian-nordic.com; william.hurtle@st.dhs.gov;
   benjamin.a.clark@usda.gov; mariceny.zurita@st.dhs.gov;
   melia.pisano@st.dhs.gov; barbara.kamicker@st.dhs.gov;
   michael.puckette@st.dhs.gov; max.rasmussen@st.dhs.gov;
   john.neilan@st.dhs.gov
OI Clark, Benjamin/0000-0002-0306-3184
FU DHS S&T, United States funded Bavarian Nordic, Germany
   [HSHQDC-12-C-00051]; Leidos Inc., United States [HSHQDC-14-F-00035]
FX We appreciate and thank Bavarian Nordic scientists Charlotte
   Steinhausser, Ursula Wielert and Nicole Maylander for generation and in
   vitro characterization of the recombinant MVA-BN-FMD vaccines. We also
   thank the Plum Island Animal Disease Center Animal Resource Branch for
   providing excellent assistance with the cattle studies. We also thank
   our U.S. Department of Homeland Security Science and Technology
   Directorate (DHS S&T) Program Managers, Drs. Michelle Colby and Roxann
   Motroni. DHS S&T, United States funded Bavarian Nordic, Germany under
   contract number HSHQDC-12-C-00051 and Leidos Inc., United States under
   contract HSHQDC-14-F-00035. The authors alone were responsible for the
   study design, collection, analysis, and interpretation of data; writing
   of the report; and the decision to submit the article for publication.
   The opinions expressed do not necessarily reflect the policies or views
   of DHS S&T or Bavarian Nordic GmbH.
CR 01E, 2018, FOOT MOUTH DIS INF F
   ABRAMS CC, 1995, J GEN VIROL, V76, P3089, DOI 10.1099/0022-1317-76-12-3089
   ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0
   Antonis AFG, 2007, VACCINE, V25, P4818, DOI 10.1016/j.vaccine.2007.04.002
   Barrera J, 2018, VACCINE, V36, P7345, DOI 10.1016/j.vaccine.2018.10.031
   Barrera J, 2018, VACCINE, V36, P1078, DOI 10.1016/j.vaccine.2018.01.026
   Boshra H, 2013, ANTIVIR RES, V98, P217, DOI 10.1016/j.antiviral.2013.02.016
   Brocchi E, 2006, VACCINE, V24, P6966, DOI 10.1016/j.vaccine.2006.04.050
   Callahan JD, 2002, J AM VET MED ASSOC, V220, P1636, DOI 10.2460/javma.2002.220.1636
   Callendret B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192312
   Calvo-Pinilla E, 2018, ANTIVIR RES, V154, P132, DOI 10.1016/j.antiviral.2018.04.015
   Curry S, 1997, J VIROL, V71, P9743, DOI 10.1128/JVI.71.12.9743-9752.1997
   de los Santos T, 2018, CURR OPIN VIROL, V29, P16, DOI 10.1016/j.coviro.2018.02.005
   de Vries RD, 2018, J INFECT DIS, V218, P614, DOI 10.1093/infdis/jiy214
   Dinman JD, 2012, ADV PROTEIN CHEM STR, V86, P129, DOI 10.1016/B978-0-12-386497-0.00004-9
   Drexler I, 1998, J GEN VIROL, V79, P347, DOI 10.1099/0022-1317-79-2-347
   FALK MM, 1990, J VIROL, V64, P748, DOI 10.1128/JVI.64.2.748-756.1990
   FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990
   FRENKEL HS, 1951, AM J VET RES, V12, P187
   Frenz T, 2010, EUR J IMMUNOL, V40, P2769, DOI 10.1002/eji.201040453
   Garcia-Briones MM, 2004, VIROLOGY, V322, P264, DOI 10.1016/j.virol.2004.01.027
   Gilbert SC, 2013, VACCINE, V31, P4241, DOI 10.1016/j.vaccine.2013.03.020
   Green CA, 2019, J INFECTION, V78, P382, DOI 10.1016/j.jinf.2019.02.003
   HRUBY DE, 1980, J GEN VIROL, V47, P485, DOI 10.1099/0022-1317-47-2-485
   Hu WG, 2018, VACCINE, V36, P5194, DOI 10.1016/j.vaccine.2018.06.064
   Kyriakis CS, 2009, VACCINE, V27, P2258, DOI 10.1016/j.vaccine.2009.02.006
   Lopera-Madrid J, 2017, VET IMMUNOL IMMUNOP, V185, P20, DOI 10.1016/j.vetimm.2017.01.004
   Lorenzo G, 2018, VET RES, V49, DOI 10.1186/s13567-018-0516-z
   Magnusson SE, 2018, IMMUNOL RES, V66, P224, DOI 10.1007/s12026-018-8991-x
   MAYR A, 1964, ZENTBL BAKTERIOLOG P, V195, P24
   MAYR A, 1978, ZBL BAKT MIK HYG B, V167, P375
   Meisinger-Henschel C, 2007, J GEN VIROL, V88, P3249, DOI 10.1099/vir.0.83156-0
   Meisinger-Henschel C, 2010, J VIROL, V84, P9907, DOI 10.1128/JVI.00756-10
   Milligan ID, 2016, JAMA-J AM MED ASSOC, V315, P1610, DOI 10.1001/jama.2016.4218
   OIE, 2013, FOOT MOUTH DIS
   Porta C, 2013, J VIROL METHODS, V187, P406, DOI 10.1016/j.jviromet.2012.11.011
   Puckette M, 2017, J VIROL, V91, DOI [10.1128/jvi.00924-17, 10.1128/JVI.00924-17]
   Sanz-Parra A, 1999, VIROLOGY, V259, P129, DOI 10.1006/viro.1999.9717
   Schutta C, 2016, VACCINE, V34, P3214, DOI 10.1016/j.vaccine.2015.12.018
   Suter M, 2009, VACCINE, V27, P7442, DOI 10.1016/j.vaccine.2009.05.095
   Sweeney TR, 2007, J VIROL, V81, P115, DOI 10.1128/JVI.01587-06
   Tan WG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181578
   Tiono AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208328
   VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829
   Volz A, 2017, ADV VIRUS RES, V97, P187, DOI 10.1016/bs.aivir.2016.07.001
   Wennier ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073511
   Wernike K, 2018, VACCINE, V36, P5116, DOI 10.1016/j.vaccine.2018.07.047
   Yang M, 2007, VET IMMUNOL IMMUNOP, V115, P126, DOI 10.1016/j.vetimm.2006.10.002
   Zhou ZG, 2013, J VIROL, V87, P11721, DOI 10.1128/JVI.01355-13
NR 49
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 769
EP 778
DI 10.1016/j.vaccine.2019.10.103
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200010
PM 31718901
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wilkie, M
   Satti, I
   Minhinnick, A
   Harris, S
   Riste, M
   Ramon, RL
   Sheehan, S
   Thomas, ZRM
   Wright, D
   Stockdale, L
   Hamidi, A
   O'Shea, MK
   Dwivedi, K
   Behrens, HM
   Davenne, T
   Morton, J
   Vermaak, S
   Lawrie, A
   Moss, P
   McShane, H
AF Wilkie, Morven
   Satti, Iman
   Minhinnick, Alice
   Harris, Stephanie
   Riste, Michael
   Ramon, Raquel Lopez
   Sheehan, Sharon
   Thomas, Zita-Rose Manjaly
   Wright, Daniel
   Stockdale, Lisa
   Hamidi, Ali
   O'Shea, Matthew K.
   Dwivedi, Kritica
   Behrens, Hannah Michaela
   Davenne, Tamara
   Morton, Joshua
   Vermaak, Samantha
   Lawrie, Alison
   Moss, Paul
   McShane, Helen
TI A phase I trial evaluating the safety and immunogenicity of a candidate
   tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost in
   healthy UK adults
SO VACCINE
LA English
DT Article
DE Tuberculosis; Vaccine; ChAdOx1 85A; MVA85A; Safety; Immunogenicity
ID T-CELL RESPONSES; INTERFERON-GAMMA; CHIMPANZEE ADENOVIRUS; PROTECTIVE
   EFFICACY; BCG; MVA85A; IMMUNIZATION; METAANALYSIS; MENINGITIS; CORRELATE
AB Background: This phase I trial evaluated the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost, previously demonstrated to be protective in animal studies, in healthy UK adults.
   Methods: We enrolled 42 healthy, BCG-vaccinated adults into 4 groups: low dose Starter Group (n = 6; ChAdOx1 85A alone), high dose groups; Group A (n = 12; ChAdOx1 85A), Group B (n = 12; ChAdOx1 85A prime - MVA85A boost) or Group C (n = 12; ChAdOx1 85A - ChAdOx1 85A prime - MVA85A boost). Safety was determined by collection of solicited and unsolicited vaccine-related adverse events (AEs). Immunogenicity was measured by antigen-specific ex-vivo IFN-gamma ELISpot, IgG serum ELISA, and antigen-specific intracellular IFN-gamma, TNF-alpha, IL-2 and IL-17.
   Results: AEs were mostly mild/moderate, with no Serious Adverse Events. ChAdOx1 85A induced Ag85A-specific ELISpot and intracellular cytokine CD4+ and CD8+ T cell responses, which were not boosted by a second dose, but were boosted with MVA85A. Polyfunctional CD4+ T cells (IFN-gamma, TNF-alpha and IL-2) and IFN-gamma+, TNF-alpha+ CD8+ T cells were induced by ChAdOx1 85A and boosted by MVA85A. ChAdOx1 85A induced serum Ag85A IgG responses which were boosted by MVA85A.
   Conclusion: A ChAdOx1 85A prime - MVA85A boost is well tolerated and immunogenic in healthy UK adults. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Wilkie, Morven; Satti, Iman; Minhinnick, Alice; Harris, Stephanie; Riste, Michael; Ramon, Raquel Lopez; Sheehan, Sharon; Thomas, Zita-Rose Manjaly; Wright, Daniel; Stockdale, Lisa; Hamidi, Ali; O'Shea, Matthew K.; Dwivedi, Kritica; Behrens, Hannah Michaela; Davenne, Tamara; Morton, Joshua; Vermaak, Samantha; Lawrie, Alison; McShane, Helen] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England.
   [Moss, Paul] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, W Midlands, England.
   [Stockdale, Lisa] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England.
RP McShane, H (reprint author), Jenner Inst, Old Rd Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.
EM helen.mcshane@ndm.ox.ac.uk
OI Davenne, Tamara/0000-0002-6582-2668; Behrens, Hannah
   Michaela/0000-0002-7406-7086
FU Wellcome TrustWellcome Trust [095780/Z/11/Z]; National Institute for
   Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford
   University Hospitals NHS Trust; University of Oxford; European
   UnionEuropean Union (EU) [643381 (TBVAC2020), MCA002]; National
   Institute for Health Research Clinical Research Network Thames Valley
   and South Midlands (TVCLRN); National Institute for Health Research
   (NIHR)/Wellcome Trust Birmingham Clinical Research Facility
FX This research was supported by the Wellcome Trust (grant 095780/Z/11/Z
   awarded to HMcS), the National Institute for Health Research (NIHR)
   Oxford Biomedical Research Centre based at Oxford University Hospitals
   NHS Trust and University of Oxford, the European Union's Horizon 2020
   research and innovation programme under grant agreement No 643381
   (TBVAC2020), Aeras (MCA002), and the National Institute for Health
   Research Clinical Research Network Thames Valley and South Midlands
   (TVCLRN), and carried out at the University of Oxford and the National
   Institute for Health Research (NIHR)/Wellcome Trust Birmingham Clinical
   Research Facility. The views expressed are those of the authors and not
   necessarily those of the NHS, the NIHR or the Department of Health. HMcS
   is a Jenner Institute Investigator.
CR [Anonymous], 2016, GLOBAL PLAN END TB P
   Antrobus RD, 2014, MOL THER, V22, P668, DOI 10.1038/mt.2013.284
   Babu S, 2010, J INFECT DIS, V201, P20, DOI 10.1086/648735
   Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.200737504
   Chen CY, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000392
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385
   Ewer K, 2016, NEW ENGL J MED, V374, P1635, DOI 10.1056/NEJMoa1411627
   Ewer KJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3836
   Fletcher HA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11290
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Hanekom WA, 2004, J IMMUNOL METHODS, V291, P185, DOI 10.1016/j.jim.2004.06.010
   Harris J, 2010, CLIN EXP IMMUNOL, V161, P1, DOI 10.1111/j.1365-2249.2010.04146.x
   Jacobs AJ, 2016, TUBERCULOSIS, V101, P102, DOI 10.1016/j.tube.2016.08.001
   Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604
   Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449
   Lewinsohn DA, 2003, AM J RESP CRIT CARE, V168, P1346, DOI 10.1164/rccm.200306-837OC
   Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592
   McShane H, 2005, TUBERCULOSIS, V85, P47, DOI 10.1016/j.tube.2004.09.015
   McShane H, 2001, INFECT IMMUN, V69, P681, DOI 10.1128/IAI.69.2.681-686.2001
   Meyer J, 2013, VACCINE, V31, P1026, DOI 10.1016/j.vaccine.2012.12.042
   Milligan ID, 2016, JAMA-J AM MED ASSOC, V315, P1610, DOI 10.1001/jama.2016.4218
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Ogwang C, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2373
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Saxena M, 2013, MICROBIOL-SGM, V159, P1, DOI 10.1099/mic.0.049601-0
   Sheehan S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141687
   Sheehy SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031208
   SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876
   Sousa AO, 2000, P NATL ACAD SCI USA, V97, P4204, DOI 10.1073/pnas.97.8.4204
   Stylianou E, 2015, VACCINE, V33, P6800, DOI 10.1016/j.vaccine.2015.10.017
   Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
   Van der Meeren O, 2018, NEW ENGL J MED, V379, P1621, DOI 10.1056/NEJMoa1803484
   Vordermeier HM, 2004, IMMUNOLOGY, V112, P461, DOI 10.1111/j.1365-2567.2004.01903.x
   Vordermeier HM, 2006, INFECT IMMUN, V74, P1416, DOI 10.1128/IAI.74.2.1416-1418.2006
   World Health Organization [WHO], 2017, GLOB TUB REP 2016
   Xing Z, 2007, EXPERT REV VACCINES, V6, P539, DOI 10.1586/14760584.6.4.539
NR 39
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 779
EP 789
DI 10.1016/j.vaccine.2019.10.102
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200011
PM 31735500
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Insulander, M
   Lindh, G
   Stenkvist, J
   Samuelson, A
   Fischler, B
AF Insulander, Mona
   Lindh, Gudrun
   Stenkvist, Jenny
   Samuelson, Agneta
   Fischler, Bjorn
TI Long-term follow-up of a vaccination program for infants born to
   HBsAg-positive mothers in Stockholm County, Sweden
SO VACCINE
LA English
DT Article
DE Hepatitis B virus; Mother-to-child transmission; Vaccination; Serology;
   Long term follow-up
ID HEPATITIS-B-VACCINE; TRANSMISSION; IMMUNITY
AB We investigated the long-term antibody response to hepatitis B virus (HBV) vaccination in babies born to chronically infected mothers. They received one dose of monovalent HBV vaccination at birth and one month of age, followed by 3 doses of hexavalent vaccine including an HBV component at ages 3, 5, and 12 months, respectively, with a very high percentage of protective anti-HBs levels at 13 months. At the age of 8-12 years, 56 out of 68 children (82%) had protective levels of anti-HBs, two had signs of anti-HBc seroconversion without any history of clinical disease and none had ongoing infection. A small subgroup was retested after one booster dose, in all resulting in increase in anti-HBs from below 10 IU/L. to levels corresponding to protective immunity. We conclude that this vaccination strategy is effective throughout the first decade of life in avoiding chronic infection and in maintaining a good serological response. (C) 2019 Published by Elsevier Ltd.
C1 [Insulander, Mona; Stenkvist, Jenny] Stockholm Cty Council, Dept Communicable Dis Control & Prevent, Stockholm, Sweden.
   [Lindh, Gudrun] Karolinska Inst, Dept Med Huddinge, Div Infect Dis, Stockholm, Sweden.
   [Stenkvist, Jenny] Karolinska Inst, Dept Med Solna, Div Infect Dis, Stockholm, Sweden.
   [Samuelson, Agneta] Karolinska Inst, Dept Lab Med, Div Clin Microbiol, Stockholm, Sweden.
   [Samuelson, Agneta] Karolinska Univ Hosp, Dept Clin Microbiol, Stockholm, Sweden.
   [Fischler, Bjorn] Karolinska Inst, Karolinska Univ Hosp, CLINTEC, Dept Pediat, Barngatan B57, SE-14186 Stockholm, Sweden.
RP Fischler, B (reprint author), Karolinska Inst, Karolinska Univ Hosp, CLINTEC, Dept Pediat, Barngatan B57, SE-14186 Stockholm, Sweden.
EM bjorn.fischler@sll.se
FU Stockholm County CouncilStockholm County Council
FX This research was supported by a grant from Stockholm County Council.
CR Al Ghamdi SS, 2013, J MED VIROL, V85, P1518, DOI 10.1002/jmv.23658
   Bruce MG, 2016, J INFECT DIS, V214, P16, DOI 10.1093/infdis/jiv748
   Carollo M, 2013, VACCINE, V31, P506, DOI 10.1016/j.vaccine.2012.11.029
   Chan PKS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107163
   Hammitt LL, 2007, VACCINE, V25, P6958, DOI 10.1016/j.vaccine.2007.06.059
   Insulander M, 2013, VACCINE, V31, P4284, DOI 10.1016/j.vaccine.2013.06.065
   Klinger G, 2018, VACCINE, V36, P2288, DOI 10.1016/j.vaccine.2018.03.028
   Lee LY, 2019, J PAEDIATR CHILD H, V55, P327, DOI 10.1111/jpc.14194
   Leuridan E, 2011, CLIN INFECT DIS, V53, P68, DOI 10.1093/cid/cir270
   Li XF, 2018, VACCINE, V36, P2442, DOI 10.1016/j.vaccine.2018.03.044
   Lu Y, 2017, VACCINE, V35, P40, DOI 10.1016/j.vaccine.2016.11.061
   Peto TJ, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-7
   Schillie SF, 2013, VACCINE, V31, P2506, DOI 10.1016/j.vaccine.2012.12.012
   Tong CYW, 2013, VACCINE, V31, P3174, DOI 10.1016/j.vaccine.2013.04.083
   Whitford K, 2018, B WORLD HEALTH ORGAN, V96, P484, DOI 10.2471/BLT.17.205153
NR 15
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 790
EP 793
DI 10.1016/j.vaccine.2019.10.100
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200012
PM 31740095
DA 2020-05-12
ER

PT J
AU Daudel, L
   Mary, J
   Epaulard, O
AF Daudel, Lola
   Mary, Jessica
   Epaulard, Olivier
TI Perception of mandatory infant vaccines and trust in vaccination among
   first-year healthcare students: An opportunity window for the training
   of future healthcare workers
SO VACCINE
LA English
DT Article
DE Mandatory vaccines; Students; Healthcare workers; Perceptions;
   Legitimacy
ID CONTROVERSIES
AB Introduction: A high level of vaccine hesitancy is observed in France; to maintain a high level of vaccine coverage, a policy of mandatory vaccines has been applied since January 2019. As vaccine hesitancy has been described among healthcare workers, we aimed to assess the adhesion to vaccination in students enrolled in the first common year of healthcare studies (PACES), and their perceptions regarding the mandatory vaccine policy.
   Methods: We elaborated an anonymous online questionnaire and asked the 35 French universities offering PACES studies to diffuse it to their students; 26 accepted.
   Results: Overall, 4326 participants completed the questionnaire (age 18.7 +/- 1.5 years, female 76.1%). They evaluated vaccine usefulness and harmfulness at a median of 90 [IQT:80-100] and 25 [IQT:10-50], respectively; on the same scale, their median trust in vaccines was 82 [IQT:70-94]. Among the five main age classes (17 to 21 years), the positive perceptions of vaccination declined with age. A majority declared that making vaccines mandatory was morally and scientifically justified (65.7% and 84.7%, respectively); in response to the questionnaire showing a blatant anti-mandatory vaccine billboard, 52.3% and 28.6%, respectively, strongly disagreed or rather disagreed with it. Again, these proportions declined between 17 and 21 years. Participants were asked whether the mandatory vaccine policy would improve their perceptions of vaccination; those with poorer perceptions were less likely to answer this question positively.
   Conclusion: The perceptions of vaccination and the recent mandatory vaccine policy are positive in first-year students but better in younger ones, thus suggesting that vaccination should be taught early, during this study year. The mandatory vaccine policy may not improve the perceptions of those with a high level of vaccine hesitancy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Epaulard, Olivier] Grenoble Alpes Univ Hosp, Infect & Trop Dis Unit, Grenoble, France.
   Univ Grenoble Alpes, Federat Infectiol Multidisciplinaire Arc Alpin, Grenoble, France.
RP Epaulard, O (reprint author), CHU Grenoble Alpes, Serv Malad Infect, CS10217, F-38043 Grenoble 09, France.
EM OEpaulard@chu-grenoble.fr
CR Baldovin T, 2019, HUM VACC IMMUNOTHER, V15, P1641, DOI 10.1080/21645515.2018.1564432
   DArgenio P, 1996, VACCINE, V14, P1289, DOI 10.1016/S0264-410X(96)00069-2
   Francois G, 2005, PEDIATR INFECT DIS J, V24, P953, DOI 10.1097/01.inf.0000183853.16113.a6
   Freed GL, 2011, PEDIATRICS, V127, pS107, DOI 10.1542/peds.2010-1722P
   Gautier A, 2017, B EPIDEMIOL HEBD, V2016, P21
   Ghandora H, 2019, HUM VACC IMMUNOTHER, V15, P700, DOI 10.1080/21645515.2018.1543523
   Griffin DS, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e01006
   Guilbeault D, 2018, P NATL ACAD SCI USA, V115, P9714, DOI 10.1073/pnas.1722664115
   Jaures FJ, 2019, COMPLOTISM FRANCE CO
   Kundi M, 2015, CURR DRUG SAF, V10, P16, DOI 10.2174/157488631001150407104320
   Larson HJ, 2019, HUM VACC IMMUNOTHER, V15, P625, DOI 10.1080/21645515.2018.1522468
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Le Marechal M, 2018, CLIN MICROBIOL INFEC, V24, P858, DOI 10.1016/j.cmi.2017.10.021
   Malo TL, 2016, CANCER EPIDEM BIOMAR, V25, P1383, DOI 10.1158/1055-9965.EPI-16-0224
   Massot E, 2018, VACCINE, V36, P5204, DOI 10.1016/j.vaccine.2018.06.050
   Merrill RM, 2010, MED SCI MONITOR, V16, pPH29
   Moyroud L, 2017, HUM VACC IMMUNOTHER, V13, P998, DOI 10.1080/21645515.2016.1264549
   Ramsay ME, 2002, BRIT J GEN PRACT, V52, P912
   Rogers CJ, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6041-1
   Simas C, 2019, HUM VACC IMMUNOTHER, V15, P163, DOI 10.1080/21645515.2018.1511667
   Vasilevska M, 2014, INFECT CONT HOSP EP, V35, P699, DOI 10.1086/676427
   WHO, 2019, 10 THREATS GLOB HLTH
NR 22
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 794
EP 799
DI 10.1016/j.vaccine.2019.10.099
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200013
PM 31708179
DA 2020-05-12
ER

PT J
AU McDonald, JU
   Rigsby, P
   Atkinson, E
   Engelhardt, OG
   Boukhvalova, M
   Piedra, PA
   Khurana, S
   van Baalen, C
   Layman, H
   Cooper, D
   Schmittwolf, C
   Thornbug, N
   Nyiro, J
   Nokes, J
   Do, LAH
   Anderson, J
   Licciardi, P
   Mulholland, K
   Zheng, ZZ
   Sun, YP
AF McDonald, Jacqueline U.
   Rigsby, Peter
   Atkinson, Eleanor
   Engelhardt, Othmar G.
   Boukhvalova, Marina
   Piedra, Pedro A.
   Khurana, Surender
   van Baalen, Carel
   Layman, Hans
   Cooper, David
   Schmittwolf, Carolin
   Thornbug, Natalie
   Nyiro, Joyce
   Nokes, James
   Lien Anh Ha Do
   Anderson, Jeremy
   Licciardi, Paul
   Mulholland, Kim
   Zheng, Zi-Zheng
   Sun, Yong-Peng
CA Study Participants
TI Expansion of the 1st WHO international standard for antiserum to
   respiratory syncytial virus to include neutralisation titres against RSV
   subtype B: An international collaborative study
SO VACCINE
LA English
DT Article
DE Respiratory syncytial virus; RSV/B; Neutralisation assay; International
   standard; Standardisation; Collaborative study; Complement
ID COMPLEMENT; ANTIBODY; ASSAYS
AB An International Standard to harmonise results from RSV subtype A neutralisation assays was generated and established by the World Health Organization in 2018. Here we report on a study to expand the use of that standard to include neutralisation assays using human sera against RSV subtype B and to test its ability to harmonise neutralisation titres from neutralisation assays including complement.
   The study included 11 laboratories from 6 countries. All participants used their own in-house virus neutralisation assay and their own virus stocks. The study samples comprised the current International Standard (16/284) and its potential replacement (16/322), individual sera from naturally infected humans, a monoclonal antibody to RSV (palivizumab) and samples from the BEI Resources panel of human antiserum and immune globulin to RSV. Of the 11 laboratories that took part in the study, 5 returned data from neutralisation assays with and without the inclusion of serum complement.
   The study showed that inter-laboratory variability in neutralisation titres was significantly reduced when values were expressed relative to 16/284 or 16/322. Complement did not affect the ability of the International Standard to decrease inter-laboratory variability as the standard was able to reduce the differences between titres from assays with and without complement. Based on these results, we will recommend to the WHO Expert Committee on Biological Standardisation (ECBS) that 16/284 and 16/322 be expanded in their use to include neutralisation assays against RSV/B. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [McDonald, Jacqueline U.; Engelhardt, Othmar G.] NIBSC, Div Virol, Potters Bar EN6 3QG, Herts, England.
   [Rigsby, Peter; Atkinson, Eleanor] NIBSC, Mostat, Potters Bar EN6 3QG, Herts, England.
   [Boukhvalova, Marina] Sigmovir Biosyst, Rockville, MD USA.
   [Piedra, Pedro A.] Baylor Coll Med, Houston, TX 77030 USA.
   [Khurana, Surender] FDA, Silver Spring, MD USA.
   [van Baalen, Carel] Viroclin, Rotterdam, Netherlands.
   [Layman, Hans] AstraZeneca, San Francisco, CA USA.
   [Cooper, David] Pfizer, Pearl River, NY USA.
   [Schmittwolf, Carolin] Bavarian Nordic, Munich, Germany.
   [Thornbug, Natalie] Ctr Dis Control & Prevent CDC, Atlanta, GA USA.
   [Nyiro, Joyce; Nokes, James] Kemri Wellcome Trust, Kilifi, Kenya.
   [Lien Anh Ha Do; Anderson, Jeremy; Licciardi, Paul; Mulholland, Kim] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
   [Zheng, Zi-Zheng] Xiamen Univ, Xiamen, Peoples R China.
RP McDonald, JU; Engelhardt, OG (reprint author), NIBSC, Div Virol, Potters Bar EN6 3QG, Herts, England.
EM Jacqueline.mcdonald@nibsc.org; Othmar.Engelhardt@nibsc.org
OI McDonald, Jacqueline/0000-0003-4156-2176
FU PATH, Seattle, WA
FX This work was funded by PATH, Seattle, WA.
CR Andri Signorell et mult a, 2017, DESCTOOLS TOOLS DESC
   Borchers A.T., 2013, RESP SYNCYTIAL VIRUS, P331
   Colosia AD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182321
   EDQM, COMBISTATS V5 0
   Falsey AR, 2000, CLIN MICROBIOL REV, V13, P371, DOI 10.1128/CMR.13.3.371-384.2000
   Hosken N, 2017, VACCINE, V35, P3082, DOI 10.1016/j.vaccine.2017.04.053
   Jacqueline U, 2017, 10112017 TRS WHO EXP
   Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115
   KAUL TN, 1981, J CLIN MICROBIOL, V13, P957, DOI 10.1128/JCM.13.5.957-962.1981
   McDonald JU, 2018, VACCINE, V36, P7641, DOI 10.1016/j.vaccine.2018.10.087
   Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468
   Modjarrad K, 2016, VACCINE, V34, P190, DOI 10.1016/j.vaccine.2015.05.093
   PATH, 2019, RSV VACC MAB SNAPSH
   Peret TCT, 2000, J INFECT DIS, V181, P1891, DOI 10.1086/315508
   Ruzin A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200319
   Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]
   Yoder SM, 2004, J MED VIROL, V72, P688, DOI 10.1002/jmv.20046
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 800
EP 807
DI 10.1016/j.vaccine.2019.10.095
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200014
PM 31708177
OA Other Gold
DA 2020-05-12
ER

PT J
AU Onello, E
   Friedrichsen, S
   Krafts, K
   Simmons, G
   Diebel, K
AF Onello, Emily
   Friedrichsen, Samantha
   Krafts, Kristine
   Simmons, Glenn, Jr.
   Diebel, Kevin
TI First year allopathic medical student attitudes about vaccination and
   vaccine hesitancy
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Vaccine attitudes; Medical student education
ID MEASLES
AB First year medical students at an allopathic medical school regional campus were asked to complete a 10-question survey at both the beginning and the conclusion of a required course on immunology, hematology and oncology. The survey was designed to solicit student attitudes about vaccination and the students' level of comfort with and exposure to vaccine hesitant patients. Surveys were administered to five consecutive classes from 2013 to 2017. Total response rate for completion of both surveys was 58.0% (178/307). Pre- and post-course surveys were administered to assess whether curricular experiences altered the students' perceptions about vaccinations and their ability to counsel vaccine hesitant patients. Curricular elements were presented in several different formats aimed at increasing student knowledge about vaccinations and student capacity to work with vaccine hesitant patients and families (problem-based learning, didactic lecture and interactive panel discussion). In the pre-survey, the majority of students reported having already encountered people who decline vaccinations (78.8%). Additionally, in the pre-survey the majority of medical students expressed strong support for vaccination (99.6% agreed with the statement that Vaccinations are a great public health accomplishment) and strong disagreement with both of the assertions that childhood vaccines cause autism and vaccine preservatives cause adverse health effects. In response to questions about comfort level while talking with patients about vaccine choices, baseline responses demonstrated a moderately high level of comfort. Post-course surveys revealed a statistically significant increase in student-rated comfort level in talking with patients about vaccine choices (pre-survey 79.2% report comfort versus post 97.8%; p < 0.001). Though this study is limited to student self-reporting, survey responses suggest that targeted curricular elements can improve medical student confidence in counseling patients about vaccinations. Future curricular elements designed to directly observe student performance could provide verification of counseling skill acquisition. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Onello, Emily; Krafts, Kristine; Simmons, Glenn, Jr.; Diebel, Kevin] Univ Minnesota, Med Sch, Duluth Campus,1035 Univ Dr, Duluth, MN 55812 USA.
   [Friedrichsen, Samantha] Profess Data Analysts, 219 Main St SE,Suite 302, Minneapolis, MN 55414 USA.
   [Krafts, Kristine] Univ Minnesota, Dent Sch, 515 Delaware St SE, Minneapolis, MN 55455 USA.
RP Onello, E (reprint author), Univ Minnesota, Med Sch, Duluth Campus,1035 Univ Dr, Duluth, MN 55812 USA.
EM econello@d.umn.edu; sfriedrichsen@pdastats.com; kkrafts@umn.edu;
   gsimmons@d.umn.edu; kwdiebel@d.umn.edu
RI Simmons Jr, Glenn/A-1777-2015
OI Simmons Jr, Glenn/0000-0003-2081-5672
CR Caruso Brown Amy E, 2017, Narrat Inq Bioeth, V7, P59, DOI 10.1353/nib.2017.0018
   de Winter JC, 2010, PRACT ASSESS RES EVA, V15, P1
   Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025
   Henrikson NB, 2015, PEDIATRICS, V136, P70, DOI 10.1542/peds.2014-3199
   Kerneis S, 2017, AM J PREV MED, V53, pE97, DOI 10.1016/j.amepre.2017.01.014
   Lo NC, 2017, JAMA PEDIATR, V171, P887, DOI 10.1001/jamapediatrics.2017.1695
   Marotta C, 2017, J Prev Med Hyg, V58, pE93
   Messonnier N, 2018, HARRISONS PRINC INT
   Morhardt T, 2016, MEDEDPORTAL PUBL, V12, DOI [10.15766/mep_2374-8765.10400, DOI 10.15766/MEP_2374-8765.10400]
   Patel M, 2019, MMWR-MORBID MORTAL W, V68, P402, DOI 10.15585/mmwr.mm6817e1
   Pelly LP, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-86
   Philpott SE, 2017, PATIENT EDUC COUNS, V100, P1701, DOI 10.1016/j.pec.2017.05.002
   Schnaith AM, 2018, VACCINE, V36, P3830, DOI 10.1016/j.vaccine.2018.05.014
   Sullivan Gail M, 2013, J Grad Med Educ, V5, P541, DOI 10.4300/JGME-5-4-18
NR 14
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 808
EP 814
DI 10.1016/j.vaccine.2019.10.094
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200015
PM 31791810
DA 2020-05-12
ER

PT J
AU Smatti, MK
   Nasrallah, GK
   Al Thani, AA
   Yassine, HM
AF Smatti, Maria K.
   Nasrallah, Gheyath K.
   Al Thani, Asmaa A.
   Yassine, Hadi M.
TI Measuring influenza hemagglutinin (HA) stem-specific antibody-dependent
   cellular cytotoxicity (ADCC) in human sera using novel stabilized stem
   nanoparticle probes
SO VACCINE
LA English
DT Article
DE Influenza; ADCC; Hemagglutinin; Stabilized stem; Vaccine
ID VIRUS; INFECTION
AB Background: Generating vaccine that confers a complete protection is a major goal in designing a universal influenza vaccine. Currently, there is a considerable interest in the broadly neutralizing antibodies (bnAb) targeting the conserved HA stem region. These antibodies have been shown to activate cellular immune responses, such as ADCC, in addition to their neutralization activity. We had previously demonstrated that immunization with H1-based stabilized stem (SS) nanoparticles (np) protects against heterosubtypic lethal H5N1 challenge, despite the absence of detectable neutralizing activity. Utilizing these novel SS probes to develop an ADCC assay would help in understanding the mechanism of action of stem-specific antibodies, as well as evaluating future influenza vaccines.
   Objectives: To develop a new protocol to assess the ADCC activity mediated by stem-directed antibodies in human sera using novel SS np probes.
   Study design: Human sera samples were screened for binding and ADCC activities to different influenza group 1 SS probes (H1, H2, and H5) using trimeric SS or multivalent SS-np (n = 8 trimers) formats.
   Results: Initial screening revealed 63% (57/90) seroprevalence of anti-HA (H1) stem-epitope antibodies, as determined by the differential binding to HA SS and its corresponding epitope-mutant (Ile45Arg/Thr49Arg) probe. Using equimolar amounts, the multivalent presentation of HA SS on np induced significantly higher ADCC activity compared to the monovalent (trimer) SS probes (2-6 fold increase). Further, ADCC activity was similarly reported against different group 1 influenza subtypes: H1, H2, and H5. Importantly, ADCC was mediated mainly by antibodies targeting the bnAb-epitope on the HA stem.
   Conclusion: We report on an assay to measure stem-specific ADCC activity using SS np probes. Our results indicate high prevalence of HA-stem antibodies with cross-reactive ADCC activity. Such assay could be utilized in the assessment of next generation influenza vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Smatti, Maria K.; Nasrallah, Gheyath K.; Al Thani, Asmaa A.; Yassine, Hadi M.] Qatar Univ, Biomed Res Ctr, Doha, Qatar.
   [Nasrallah, Gheyath K.; Al Thani, Asmaa A.; Yassine, Hadi M.] Qatar Univ, Coll Hlth Sci, QU Hlth, Biomed Sci Program, Doha, Qatar.
RP Yassine, HM (reprint author), Qatar Univ, Biomed Res Ctr, QU NRC, Bldg H10,Zone 5,Room D101,POB 2713, Doha, Qatar.
EM Hyassine@qu.edu.qa
FU Qatar University [QUUG-BRC-15\16-1]
FX We thank the Viral Pathogenesis Laboratory, Vaccine Research Center,
   National Institute of Health, for providing the plasmids (encoding HA
   antibodies, HA SS, and HA SS np) needed for this work. This study was
   supported by Qatar University Internal Grant No. QUUG-BRC-15\16-1. The
   findings achieved herein are solely the responsibility of the authors.
CR [Anonymous], 2019, NIH BEG 1 IN HUM TRI
   [Anonymous], 2018, INFL SEAS
   Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039
   Deng L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02725-4
   DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428
   Grohskopf LA, 2017, AM J TRANSPLANT, V17, P2970, DOI 10.1111/ajt.14511
   Han T, 2011, ANN NY ACAD SCI, V1217, P178, DOI 10.1111/j.1749-6632.2010.05829.x
   HASHIMOTO G, 1983, J INFECT DIS, V148, P785, DOI 10.1093/infdis/148.5.785
   Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263
   Jegaskanda S, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020027
   Jegaskanda S, 2016, J INFECT DIS, V214, P945, DOI 10.1093/infdis/jiw262
   Jegaskanda S, 2014, J IMMUNOL, V193, P469, DOI 10.4049/jimmunol.1400432
   Jegaskanda S, 2013, J VIROL, V87, P5512, DOI 10.1128/JVI.03030-12
   Jegaskanda S, 2013, J IMMUNOL, V190, P1837, DOI 10.4049/jimmunol.1201574
   Laursen NS, 2013, ANTIVIR RES, V98, P476, DOI 10.1016/j.antiviral.2013.03.021
   Lingwood D, 2012, NATURE, V489, P566, DOI 10.1038/nature11371
   Nachbagauer R, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.15
   Nasrallah GK, 2017, TRANSFUSION, V57, P1801, DOI 10.1111/trf.14116
   OKUNO Y, 1993, J VIROL, V67, P2552, DOI 10.1128/JVI.67.5.2552-2558.1993
   Rondy M, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.9.18-00086
   Sautto GA, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0918-y
   Smatti MK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189033
   Tada M, 2018, MABS-AUSTIN, V10, P370, DOI 10.1080/19420862.2018.1424610
   Tang J, 1999, IN VITRO CELL DEV-AN, V35, P1
   Trombetta CM, 2014, VACCINES-BASEL, V2, P707, DOI 10.3390/vaccines2040707
   van der Lubbe JEM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02350
   VELLA S, 1980, J MED VIROL, V6, P203, DOI 10.1002/jmv.1890060303
   Wu Y, 2014, TRENDS MICROBIOL, V22, P183, DOI 10.1016/j.tim.2014.01.010
   Yassine HM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26538-7
   Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927
   Zhang D, 2016, J BIOL CHEM, V291, P27134, DOI 10.1074/jbc.M116.757773
NR 31
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 815
EP 821
DI 10.1016/j.vaccine.2019.10.093
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200016
PM 31735504
DA 2020-05-12
ER

PT J
AU Tsunekuni, R
   Tanikawa, T
   Nakaya, T
   Saito, T
AF Tsunekuni, Ryota
   Tanikawa, Taichiro
   Nakaya, Takaaki
   Saito, Takehiko
TI Improvement of a recombinant avian avulavirus serotype 10 vectored
   vaccine by the addition of untranslated regions
SO VACCINE
LA English
DT Article
DE Avian avulavirus (AAvV); Highly pathogenic avian influenza (HPAI);
   Vaccine vector; Emergency vaccination; Untranslated region (UTR)
ID NEWCASTLE-DISEASE VIRUS; HEMAGGLUTININ GENE; INFLUENZA-VIRUS; PROTECTS
   CHICKENS; H5N1; PATHOGENICITY; OUTBREAKS; POULTRY; DELTA
AB Background: We have previously developed a recombinant avian avulavirus serotype 10 (rAAvV-10/HA) expressing the hemagglutinin (HA) gene of a highly pathogenic avian influenza virus (HPAIV) as an emergency vaccine for poultry. rAAvV-10/HA can overcome the activity of the anti-AAvV-1 (Newcastle disease virus) antibody acquired by commercial chickens upon routine vaccination. Most chickens do not have the anti-AAvV-10 antibody, which could interfere with the vaccine efficacy. However, the vaccine efficacy of rAAvV-10/HA is not satisfactory in chickens even though it affords protection against an HPAIV challenge. In the present study, we improved the rAAvV-10/HA vaccine by enhancing the expression of the exogenous HA protein.
   Methods: The 5' and 3' untranslated regions (UTR) of each AAvV-10 gene were flanked with the exogenous HA gene cassette to modify rAAvV-10/HA, yielding different rAAv10-UTRs. As a control, rAAv10-nonUTR that did not contain any UTRs was generated. The effects of UTRs on mRNA transcription, HA protein expression, and vaccine efficacy were then examined using embryonated chicken eggs and white leghorn chickens.
   Results: The proportion of the HA gene mRNA among the vector-derived mRNAs (1.55-1.84-fold increase vs. the control) and HA protein levels (148-1151-fold increase vs. the control) in cells infected with rAAv10-UTRs were higher than in those infected with rAAv10-nonUTFL In vivo, vaccination of chickens with rAAv10-UTRs resulted in 100% protection against an HPAIV challenge. No chickens vaccinated with rAAv10-NP-UTR, rAAv10-F-UTR, or rAAv10-HN-UTR shed the virus in the throat and cloaca swabs. By contrast, rAAv10-nonUTR vaccination offered 70% protection, with 50% of chickens shedding the virus in the cloaca or throat swabs after the challenge. We conclude that the AAvV-10 UTRs can enhance the expression of the exogenous HA gene, resulting in improved efficacy of the rAAvV-10/HA vector vaccine. This improvement aids in the protection of flocks worldwide from the highly pathogenic avian influenza. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Tsunekuni, Ryota; Tanikawa, Taichiro; Saito, Takehiko] Natl Agr & Food Res Org, Div Transboundary Anim Dis, Natl Inst Anim Hlth, 3-1-5 Kannondai, Tsukuba, Ibaraki 3050854, Japan.
   [Nakaya, Takaaki] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Infect Dis, Kamigyo Ku, Kajii Cho,Kawaramachi Hirokoji, Kyoto 6028566, Japan.
   [Saito, Takehiko] Gifu Univ, United Grad Sch Vet Sci, 1-1 Yanagido, Gifu, Gifu 5011193, Japan.
RP Saito, T (reprint author), Natl Agr & Food Res Org, Div Transboundary Anim Dis, Natl Inst Anim Hlth, 3-1-5 Kannondai, Tsukuba, Ibaraki 3050854, Japan.
EM tune@affrc.go.jp; ttanikawa@affrc.go.jp; tnakaya@koto.kpu-m.ac.jp;
   taksaito@affrc.go.jp
FU Ministry of Agriculture, Forestry and Fisheries of JapanMinistry of
   Agriculture Forestry & Fisheries - Japan [FY2018-2022]
FX This study was conducted under the research project on "Development of
   the Management Technologies for the Risk of Introduction of Livestock
   Infectious Diseases and Their Wildlife -borne Spreads in Japan" funded
   by the Ministry of Agriculture, Forestry and Fisheries of Japan [grant
   number FY2018-2022]. The sponsor did not play any role in study design;
   in the collection, analysis, and interpretation of data; in the writing
   of the report; and in the decision to submit the article for
   publication.
CR ABENES G, 1986, ARCH VIROL, V90, P97, DOI 10.1007/BF01314148
   Aljabr W, 2016, J VIROL, V90, P4876, DOI 10.1128/JVI.02349-15
   Been MD, 1997, EUR J BIOCHEM, V247, P741, DOI 10.1111/j.1432-1033.1997.00741.x
   Bouma A, 2008, REV SCI TECH OIE, V27, P633, DOI 10.20506/rst.27.3.1823
   Capua I, 2003, AVIAN PATHOL, V32, P335, DOI 10.1080/0307945031000121077
   Carnero E, 2009, J VIROL, V83, P584, DOI 10.1128/JVI.01443-08
   Chen H, 2009, REV SCI TECH OIE, V28, P267, DOI 10.20506/rst.28.1.1860
   Chulakasian S, 2013, FEBS J, V280, P1237, DOI 10.1111/febs.12115
   Cui HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053340
   Desvaux S, 2013, EPIDEMIOL INFECT, V141, P776, DOI 10.1017/S0950268812001628
   Fan ST, 2014, INFLUENZA OTHER RESP, V8, P646, DOI 10.1111/irv.12289
   Gao WT, 2006, J VIROL, V80, P1959, DOI 10.1128/JVI.80.4.1959-1964.2006
   Harris VM, 2015, METHODS MOL BIOL, V1312, P465, DOI 10.1007/978-1-4939-2694-7_47
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kim SH, 2010, J VIROL, V84, P2629, DOI 10.1128/JVI.02049-09
   Lamb R, 2006, FIELDS VIROLOGY, P1449
   Lee DH, 2017, J VET SCI, V18, P269, DOI [10.4142/jvs.2017.18.s1.269, 10.4142/jvs.2017.18.S1.269]
   Li YQ, 2011, VACCINE, V29, P8257, DOI 10.1016/j.vaccine.2011.08.115
   Liu JJ, 2018, ARCH VIROL, V163, P3365, DOI 10.1007/s00705-018-4016-2
   Mase M, 2005, VIROLOGY, V332, P167, DOI 10.1016/j.virol.2004.11.016
   Mayers J, 2017, VACCINE, V35, P5974, DOI 10.1016/j.vaccine.2017.09.008
   Nakaya T, 2001, J VIROL, V75, P11868, DOI 10.1128/JVI.75.23.11868-11873.2001
   Nayak B, 2012, VACCINE, V30, P2220, DOI 10.1016/j.vaccine.2011.12.090
   Office International des Epizooties, 2013, NEWC DIS MAN DIAGN V
   Pasick J, 2015, SCI REP-UK, V5, DOI 10.1038/srep09484
   Pavlova SP, 2009, VACCINE, V27, P5085, DOI 10.1016/j.vaccine.2009.06.048
   Peyre Marisa, 2009, J Mol Genet Med, V3, P198
   Presnyak V, 2015, CELL, V160, P1111, DOI 10.1016/j.cell.2015.02.029
   Qi X, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00706-14
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Steensels M, 2009, VACCINE, V27, P646, DOI 10.1016/j.vaccine.2008.11.044
   Steglich C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072530
   Suarez DL, 2012, AVIAN DIS, V56, P836, DOI 10.1637/10207-041512-Review.1
   Suarez DL, 2005, BIOLOGICALS, V33, P221, DOI 10.1016/j.biologicals.2005.08.003
   Takeda M, 2005, J VIROL, V79, P14346, DOI 10.1128/JVI.79.22.14346-14354.2005
   Tanikawa T, 2016, MICROBIOL IMMUNOL, V60, P243, DOI 10.1111/1348-0421.12369
   Tenbusch M, 2010, VACCINE, V28, P3273, DOI 10.1016/j.vaccine.2010.02.090
   Tsunekuni R, 2017, AVIAN DIS, V61, P296, DOI 10.1637/11512-100616-RegR1
   Tsunekuni R, 2014, VET IMMUNOL IMMUNOP, V160, P184, DOI 10.1016/j.vetimm.2014.05.001
   Veits J, 2006, P NATL ACAD SCI USA, V103, P8197, DOI 10.1073/pnas.0602461103
   Wei JB, 2019, BIOCHEM BIOPH RES CO, V508, P1221, DOI 10.1016/j.bbrc.2018.12.044
   World_Organisation_for_Animal_Health, OIE SIT REP AV INF
   Xu XY, 1999, VIROLOGY, V261, P15, DOI 10.1006/viro.1999.9820
   YUSOFF K, 1988, VIRUS RES, V11, P319, DOI 10.1016/0168-1702(88)90005-6
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 822
EP 829
DI 10.1016/j.vaccine.2019.10.098
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200017
PM 31718900
OA Other Gold
DA 2020-05-12
ER

PT J
AU Nunez, IA
   Ross, TM
AF Nunez, Ivette A.
   Ross, Ted M.
TI Human COBRA 2 vaccine contains two major epitopes that are responsible
   for eliciting neutralizing antibody responses against heterologous
   clades of viruses
SO VACCINE
LA English
DT Article
DE COBRA; Influenza; H5N1; Highly pathogenic avian influenza; HPAI; H5N1
   vaccine; H5 glycosylation
ID COMPUTATIONALLY OPTIMIZED HEMAGGLUTININ; INFLUENZA-A VIRUS; H5N1
   VIRUSES; ANTIGENIC ARCHITECTURE; GLOBULAR HEAD; FERRETS; ESCAPE; SITES
AB Highly pathogenic H5N1 influenza viruses continue to spread around the globe and reassort with low pathogenic avian influenza viruses often resulting in morbidity and mortality to not only waterfowl, but also poultry. Our group previously developed two hemagglutinin (HA) based vaccines using a methodology termed computationally optimized broadly reactive antigen (COBRA). Each of these HA antigens, Human COBRA 2 (Hu-CO) and Human-Avian COBRA 2 (Hu-Av CO) elicit antibodies with hemagglutination-inhibition (HAI) activity against viruses from various clades, but not always the same viruses. Here, we have sought to identify residues in these two HA molecules that are critical for differential HAI activity against various H5Nx influenza viruses. The two HA antigens are remarkedly similar in the globular head region, except for 4 residues at amino acids 140, 141, 155, and 156. By mutating these amino acids in each HA antigen, chimeric HA proteins were used to elicit immune responses in mice. When the Asn-Thr pair at position 155-156 in the Hu-CO HA was converted to the Ser-Ala residues found in the Hu-Av CO HA, the elicited antibodies lost HAI activity against Glade 2.3.2.1 H5Nx viruses, such as A/Hubei/01/2010. When this Asn-Thr motif was added at these positions in the Hu-Av CO HA molecule, HAI activity in the elicited sera against A/Hubei/01/2010 was significantly increased. We speculate that a putative N-linked glycosylation at this location in the Hu-CO HA antigen is a key driver in the elicitation of antibodies with HAI activity to different locations on wild-type H5 HA molecules resulting in differential neutralization of viral infection and protection in vivo against H5 influenza virus induced disease. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nunez, Ivette A.; Ross, Ted M.] Univ Georgia, Ctr Vaccines & Immunol, 501 DW Brooks Dr,CVI Room 1504, Athens, GA 30602 USA.
   [Ross, Ted M.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA.
RP Ross, TM (reprint author), Univ Georgia, Ctr Vaccines & Immunol, 501 DW Brooks Dr,CVI Room 1504, Athens, GA 30602 USA.
EM tedross@uga.edu
OI Ross, Ted/0000-0003-1947-7469
FU University of Georgia; Georgia Research Alliance as an Eminent Scholar
FX We thank James D Allen, Connor Grady, Hyesun Jang, Simon O. Owino, and
   Ying Huang for assistance with the animal work and technical assistance.
   H5Nx influenza viruses were obtained from the international reagent
   resource (IRR). Sequences for A/chicken/Egypt/CAL3-RLQP/2017 and
   A/duck/Egypt/S78-RLQP/2017 were provided by Dr. Mohamed Elhussieny at
   the Animal Health Research Institute, Giza, Egypt. We thank the
   University of Georgia Animal Resource staff, technicians, and
   veterinarians for the excellent animal care. This study was supported
   through an award from the University of Georgia to Ted M Ross. Ted M
   Ross is also supported, in part, by the Georgia Research Alliance as an
   Eminent Scholar.
CR Agriculture USDo, FIN RE 2014 2015 OUT
   Allen JD, 2017, VACCINE, V35, P5209, DOI 10.1016/j.vaccine.2017.07.107
   Anderson CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160510
   BarPeled V, 2019, VACCINE
   Cai ZP, 2012, J MOL BIOL, V422, P145, DOI 10.1016/j.jmb.2012.05.011
   Carter DM, 2016, J VIROL, V90, P4720, DOI 10.1128/JVI.03152-15
   Carter DM, 2013, J VIROL, V87, P1400, DOI 10.1128/JVI.02257-12
   CATON AJ, 1982, CELL, V31, P417, DOI 10.1016/0092-8674(82)90135-0
   Chen WHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039039
   Crevar CJ, 2015, HUM VACC IMMUNOTHER, V11, P572, DOI 10.1080/21645515.2015.1012013
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Eggink D, 2014, J VIROL, V88, P699, DOI 10.1128/JVI.02608-13
   Forrest HL, 2009, VACCINE, V27, P4187, DOI 10.1016/j.vaccine.2009.04.050
   Giles BM, 2012, J INFECT DIS, V205, P1562, DOI 10.1093/infdis/jis232
   Giles BM, 2012, CLIN VACCINE IMMUNOL, V19, P128, DOI 10.1128/CVI.05533-11
   Giles BM, 2011, VACCINE, V29, P3043, DOI 10.1016/j.vaccine.2011.01.100
   Govorkova EA, 2006, J INFECT DIS, V194, P159, DOI 10.1086/505225
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hatter J, 2012, J IMMUNOL
   Herve PL, 2015, VIROLOGY, V486, P134, DOI 10.1016/j.virol.2015.08.033
   Kaverin NV, 2004, J VIROL, V78, P240, DOI 10.1128/JVI.78.1.240-249.2004
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Layton RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020641
   Lin SZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042146
   Lin SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092822
   Matrosovich M, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-63
   Organization WH, COM NUMB CONF HUM CA
   Organization WH Network WGIS, 2011, NETW WGIS MAN LAB DI
   PHILPOTT M, 1990, J VIROL, V64, P2941, DOI 10.1128/JVI.64.6.2941-2947.1990
   Rockman S, 2013, J VIROL, VJVI
   Ross TM, 2019, VACCINE, V37, P2369, DOI 10.1016/j.vaccine.2019.03.018
   Schrodinger L., 2015, PYMOL MOL GRAPHICS S
   Sullivan K, 2012, J VIROL METHODS, V179, P81, DOI 10.1016/j.jviromet.2011.10.003
   Velkov T, 2013, MOL IMMUNOL, V56, P705, DOI 10.1016/j.molimm.2013.07.010
   WALLS HH, 1986, J CLIN MICROBIOL, V23, P240, DOI 10.1128/JCM.23.2.240-245.1986
   Wang SF, 2009, BIOCHEM BIOPH RES CO, V382, P691, DOI 10.1016/j.bbrc.2009.03.119
   Waterhouse A, 2018, NUCLEIC ACIDS RES
   Wong SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44727
   Wong TM, 2017, J VIROL, V91, DOI 10.1128/JVI.01581-17
   Wu WL, 2008, J VIROL, V82, P1798, DOI 10.1128/JVI.02256-07
NR 41
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 830
EP 839
DI 10.1016/j.vaccine.2019.10.097
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200018
PM 31733946
DA 2020-05-12
ER

PT J
AU Harmon, SHE
   Faour, D
   MacDonald, NE
   Graham, J
   Steffen, C
   Henaff, L
   Shendale, S
AF Harmon, Shawn H. E.
   Faour, David
   MacDonald, Noni E.
   Graham, Janice
   Steffen, Christoph
   Henaff, Louise
   Shendale, Stephanie
TI Strengthening vaccination frameworks: Findings of a study on the legal
   foundations of National Immunization Technical Advisory Groups (NITAGs)
SO VACCINE
LA English
DT Article
DE National Immunization Technical Advisory; Groups; NITAGs; Foundation;
   Authority; Legal framework; Vaccination laws
ID ESTABLISHMENT; OWNERSHIP
AB In 2017, the Strategic Advisory Group of Experts on Immunization's Assessment Report of the Global Vaccine Action Plan noted the need to "better document the ways in which legislation and regulations have been used to promote or undermine immunization at the national level". Despite National Immunization Technical Advisory Groups (NITAGs) now existing in over 134 countries worldwide, there has been very little academic consideration of their legal underpinnings. In this paper, we compare the legal foundations and authority of 28 NITAGs from the six WHO Regions. All are members of the Global NITAG Network. We categorize the NITAGs based on their legal foundation and on the authority granted to them by their government, organizing them into a taxonomy of models. We then propose legal considerations for governments contemplating establishing or reforming a NITAG. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Harmon, Shawn H. E.] Dalhousie Univ, Fac Law, Halifax, NS, Canada.
   [Harmon, Shawn H. E.] Dalhousie Univ, Fac Med, Dept Pediat, Halifax, NS, Canada.
   [Faour, David] Dalhousie Univ, Fac Med, Halifax, NS, Canada.
   [MacDonald, Noni E.; Graham, Janice] Dalhousie Univ, IWK Hlth Ctr, Dept Paediat, Halifax, NS, Canada.
   [Steffen, Christoph; Henaff, Louise; Shendale, Stephanie] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland.
RP Harmon, SHE (reprint author), Dalhousie Univ, Weldon Law Bldg,Rm 331,6061 Univ Ave, Halifax, NS B3H 4R2, Canada.
EM shawn.harmon@dal.ca
FU World Health Organization, Department of Immunization, Vaccines and
   Biologicals
FX This work was supported by the World Health Organization, Department of
   Immunization, Vaccines and Biologicals.
CR 54th Directing Council of the Pan American Health Organization, 2015, 2015 2020 REG IMM AC
   Bennion F, 2006, WEB J CURRENT LEGAL, V3, P1
   Centers for Disease Control and Prevention, 2018, CHART ADV COMM IMM P
   Duclos P, 2013, VACCINE, V31, P5314, DOI 10.1016/j.vaccine.2013.08.084
   Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027
   MacDonald NE, 2017, VACCINE, V35, P6925, DOI 10.1016/j.vaccine.2017.10.048
   McQuestion M, 2017, J PUBLIC HEALTH POL, V38, P3, DOI 10.1057/s41271-016-0052-x
   McQuestion M, 2016, HEALTH AFFAIR, V35, P266, DOI 10.1377/hlthaff.2015.1067
   Nelson E. A. S., 2010, Vaccine, V28, pA1
   NITAG Resource Center, NAT IMM TECHN ADV GR
   Sabin Vaccine Institute, 2018, LEG LANDSC REV LEG A
   Shen AK, 2016, HEALTH AFFAIR, V35, P272, DOI 10.1377/hlthaff.2015.1418
   Trumbo S, 2018, VACCINE, V37, P4840, DOI [10.1016/jvaccine201810.069, DOI 10.1016/JVACCINE201810.069]
   Wilson SE, 2012, CAN J PUBLIC HEALTH, V103, P34, DOI 10.1007/BF03404066
   World Health Organization, 2019, GLOB VACC ACT PLAN M
   World Health Organization Strategic Advisory Group of Experts on Immunization, 2017, 2017 ASS REP GLOB VA
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 840
EP 846
DI 10.1016/j.vaccine.2019.10.085
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200019
PM 31706811
DA 2020-05-12
ER

PT J
AU Furer, V
   Zisman, D
   Kaufman, I
   Arad, U
   Berman, M
   Sarbagil-Maman, H
   Elias, M
   Hadad, A
   Paran, D
   Drori, Y
   Friedman, N
   Mandelboim, M
   Elkayam, O
AF Furer, Victoria
   Zisman, Devy
   Kaufman, Ilana
   Arad, Uri
   Berman, Mark
   Sarbagil-Maman, Hagit
   Elias, Muna
   Hadad, Amir
   Paran, Daphna
   Drori, Yaron
   Friedman, Nehemya
   Mandelboim, Michal
   Elkayam, Ori
TI Immunogenicity and safety of vaccination against seasonal influenza
   vaccine in patients with psoriatic arthritis treated with secukinumab
SO VACCINE
LA English
DT Article
DE Psoriatic arthritis; Secukinumab; Influenza vaccine
ID RHEUMATOID-ARTHRITIS; IMMUNE-RESPONSE; DISEASE-ACTIVITY; RITUXIMAB;
   RECOMMENDATIONS; USTEKINUMAB; EFFICACY; VIRUS; ALPHA; RISK
AB Objective: To assess the immunogenicity and safety of vaccination against seasonal influenza in psoriatic arthritis (PsA) patients treated with secukinumab versus healthy controls (HC).
   Methods: PsA patients administered secukinumab for >= 3 months and HC received the Sanofi Pasteur vaccine composed of 3 antigens (H3N3, H1N1, and B) and underwent clinical and laboratory assessments on the day of vaccination and 4-6 weeks later. Immunogenicity of the vaccine was evaluated by hemagglutination inhibition assay against those 3 antigens. Responders to each antigen were defined by a 4-fold increase in the antigen titer or by seroconversion in patients whose baseline level was <1/40.
   Results: Thirty-two consecutive PsA patients treated with secukinumab for >= 3 months comprised the study group, 10 of whom received concomitant conventional synthetic disease-modifying drugs, mostly methotrexate. There were 17 age- and gender-matched HC (median age 48.5 years, 6 females). The geometric mean titers of each antigen increased significantly in both groups. The number of responders in each group was similar for H3N2 and H1N1, and significantly higher for B/Brisbane in the PsA group. The proportion of patients with a seroprotective level (a titer >1/40) was high and similar in both groups. There was no correlation between the response rate and age, gender, or selected parameters of disease activity (tender/swollen joint counts, Leeds enthesitis index, physician and patient global assessment, psoriasis area severity index, and C-reactive protein). No disease exacerbation was observed following the vaccination. No serious adverse effects were observed in both groups during the study period.
   Conclusion: Secukinumab treatment does not affect the humoral response to influenza vaccine of patients with PsA. (C) 2019 Published by Elsevier Ltd.
C1 [Furer, Victoria; Kaufman, Ilana; Arad, Uri; Berman, Mark; Sarbagil-Maman, Hagit; Paran, Daphna; Elkayam, Ori] Tel Aviv Med Ctr & Sch Med, Dept Rheumatol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
   [Zisman, Devy; Elias, Muna; Hadad, Amir; Mandelboim, Michal] Carmel Hosp, Unit Rheumatol, Haifa, Israel.
   [Drori, Yaron; Friedman, Nehemya; Mandelboim, Michal] Sheba Med Ctr, Cent Virol Lab, Tel Hashomer, Israel.
   [Furer, Victoria; Arad, Uri; Paran, Daphna; Drori, Yaron; Friedman, Nehemya; Elkayam, Ori] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
RP Elkayam, O (reprint author), Tel Aviv Med Ctr & Sch Med, Dept Rheumatol, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM Oribe14@gmail.com
CR Adler S, 2012, RHEUMATOLOGY, V51, P695, DOI 10.1093/rheumatology/ker389
   Alten R, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1082-z
   Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034
   Brodmerkel C, 2013, J DRUGS DERMATOL, V12, P1122
   Caso F, 2016, CLIN EXP RHEUMATOL, V34, P507
   Chioato A, 2012, CLIN VACCINE IMMUNOL, V19, P1597, DOI 10.1128/CVI.00386-12
   Coates LC, 2016, ARTHRITIS RHEUMATOL, V68, P1060, DOI 10.1002/art.39573
   Committee for proprietary medicinal products (CPMP), 1997, NOT GUID HARM REQ IN
   Committee for proprietary medicinal products (CPMP), 2001, CPMPEPW104501
   Danza A, 2013, LUPUS, V22, P1286, DOI 10.1177/0961203313493032
   Elkayam O, 2011, ARTHRIT CARE RES, V63, P1062, DOI 10.1002/acr.20465
   Germano V, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-77
   Gossec L, 2016, ANN RHEUM DIS, V75, P499, DOI 10.1136/annrheumdis-2015-208337
   Gunes AT, 2015, J IMMUNOL RES, DOI 10.1155/2015/258430
   Hua C, 2014, ARTHRIT CARE RES, V66, P1016, DOI 10.1002/acr.22246
   Huang YF, 2017, CURR MED RES OPIN, V33, P1901, DOI 10.1080/03007995.2017.1329140
   Kogure T, 2014, CLIN RHEUMATOL, V33, P323, DOI 10.1007/s10067-013-2483-0
   Maroof A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003875
   McInnes IB, 2017, RHEUMATOLOGY, V56, P1993, DOI 10.1093/rheumatology/kex301
   McKinstry KK, 2009, J IMMUNOL, V182, P7353, DOI 10.4049/jimmunol.0900657
   Mease PJ, 2018, RMD OPEN, V4
   Oren S, 2008, ANN RHEUM DIS, V67, P937, DOI 10.1136/ard.2007.077461
   PALMER DF, 1975, ADV LAB TECHNIQUES I
   Polachek A, 2015, CLIN EXP RHEUMATOL, V33, P181
   Ramiro S, 2017, ANN RHEUM DIS, V76, P1093, DOI 10.1136/annrheumdis-2016-210708
   Roberts J, 2018, IMMUNOTHERAPY-UK, V10, P361, DOI 10.2217/imt-2017-0149
   Shi CR, 2017, VACCINE, V35, P4785, DOI 10.1016/j.vaccine.2017.06.067
   Subesinghe S, 2018, J RHEUMATOL, V45, P733, DOI 10.3899/jrheum.170710
   Taylor W, 2006, ARTHRITIS RHEUM, V54, P2665, DOI 10.1002/art.21972
   Tsuru T, 2014, MOD RHEUMATOL, V24, P511, DOI 10.3109/14397595.2013.843743
   van Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216
   van Assen S, 2010, ARTHRITIS RHEUM-US, V62, P75, DOI 10.1002/art.25033
   Weaver A, 2013, J RHEUMATOL, V40, P1275, DOI 10.3899/jrheum.121288
NR 33
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 847
EP 851
DI 10.1016/j.vaccine.2019.10.081
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200020
PM 31767465
DA 2020-05-12
ER

PT J
AU Kongchanagul, A
   Samnuan, K
   Wirachwong, P
   Surichan, S
   Puthavathana, P
   Pitisuttithum, P
   Boonnak, K
AF Kongchanagul, Alita
   Samnuan, Karnyart
   Wirachwong, Ponthip
   Surichan, Somchaiya
   Puthavathana, Pilaipan
   Pitisuttithum, Punnee
   Boonnak, Kobporn
TI A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces
   influenza virus hemagglutinin stalk specific antibody responses
SO VACCINE
LA English
DT Article
DE Stalk antibody; Influenza vaccine; Prime-boost vaccination
ID IMMUNOGENICITY; INFECTION; VACCINES; SAFETY; HUMANS; HEAD
AB Background: The emergence and spread of highly pathogenic avian influenza (H5N1) viruses have raised global concerns of a possible human pandemic, spurring efforts towards H5N1 influenza vaccine development and improvements in vaccine administration methods. We previously showed that a prime-boost vaccination strategy induces robust and broadly cross-reactive antibody responses against the hemagglutinin globular head domain. Here, we specifically measure antibodies against the conserved hemagglutinin stem region in serum samples obtained from the prior study to determine whether stalk-reactive antibodies can also be induced by the prime-boost regimen.
   Method: Serum samples collected from 60 participants before vaccination and on days 7, 28 and 90 following boosting vaccination were used in this study. 40 participants received two doses of live attenuated H5N2 vaccine (LAIV H5N2) followed by one dose of inactivated H5N1 vaccine a year later, while 20 participants received only the inactivated H5N1 vaccine. We tested these serum samples for stalk-reactive antibodies via enzyme-linked immunosorbent (ELISA) and microneutralization assays.
   Results: Stalk-specific antibody levels measured by both assays were found to be significantly higher in primed individuals than the unprimed group. ELISA results showed that 22.5, 70.5 and 57.5% of primed participants had a four-fold or more increase in stalk antibody titers on days 7, 28 and 90 following boosting vaccination, respectively; whereas the unprimed group had no increase. Peak geometric mean titers (GMT) for stalk antibodies in the LAIV H5N2 experienced group (24,675 [95% CI; 19,531-31,174]) were significantly higher than those who received only the inactivated H5N1 vaccine (8877 [7140-11,035]; p < 0.0001). Moreover, stalk antibodies displaying neutralizing activity also increased in primed participants, but not in the unprimed group.
   Conclusion: Our finding emphasizes the importance of prime-boost vaccination for effectively inducing stalk antibodies, which is an attractive target for developing vaccines that induce stalk reactive antibodies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kongchanagul, Alita] Mahidol Univ, Inst Mol Biosci, Bangkok, Thailand.
   [Samnuan, Karnyart; Boonnak, Kobporn] Mahidol Univ, Fac Trop Med, Dept Microbiol & Immunol, Bangkok, Thailand.
   [Wirachwong, Ponthip; Surichan, Somchaiya] Govt Pharmaceut Org, Bangkok, Thailand.
   [Puthavathana, Pilaipan] Mahidol Univ, Fac Med Technol, Bangkok, Thailand.
   [Pitisuttithum, Punnee] Mahidol Univ, Fac Trop Med, Dept Clin Trop Med, Bangkok, Thailand.
   [Pitisuttithum, Punnee] Mahidol Univ, Fac Trop Med, Vaccine Trial Ctr, Bangkok, Thailand.
RP Boonnak, K (reprint author), Mahidol Univ, Fac Trop Med, Dept Microbiol & Immunol, Bangkok, Thailand.
EM Kobporn.boo@mahidol.ac.th
FU Thailand Research FundThailand Research Fund (TRF) [MRG5680078];
   National Vaccine Institute (NVI), Thailand
FX A.K. was supported by a research grant (MRG5680078) from the Thailand
   Research Fund. This work was financially supported by the National
   Vaccine Institute (NVI), Thailand.
CR Baz M, 2013, VIRUS RES, V178, P78, DOI 10.1016/j.virusres.2013.05.006
   Chen GL, 2011, J INFECT DIS, V203, P930, DOI 10.1093/infdis/jiq144
   DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443
   Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839
   Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491
   Hai R, 2012, J VIROL, V86, P5774, DOI 10.1128/JVI.00137-12
   Halliley JL, 2015, J INFECT DIS, V212, P1270, DOI 10.1093/infdis/jiv210
   Islam S, 2017, VACCINE, V35, P5666, DOI 10.1016/j.vaccine.2017.08.044
   Krammer F, 2016, CURR OPIN VIROL, V17, P95, DOI 10.1016/j.coviro.2016.02.002
   Krammer F, 2015, CELL HOST MICROBE, V18, P395, DOI 10.1016/j.chom.2015.10.003
   Krammer F, 2014, J VIROL, V88, P3432, DOI 10.1128/JVI.03004-13
   Krammer F, 2013, CURR OPIN VIROL, V3, P521, DOI 10.1016/j.coviro.2013.07.007
   Krammer F, 2012, J VIROL, V86, P10302, DOI 10.1128/JVI.01336-12
   Lee ML, 2016, J MICROBIOL IMMUNOL, V49, P554, DOI 10.1016/j.jmii.2014.08.014
   Li GM, 2012, P NATL ACAD SCI USA, V109, P9047, DOI 10.1073/pnas.1118979109
   Margine I, 2014, PATHOGENS, V3, P845, DOI 10.3390/pathogens3040845
   Margine I, 2013, J VIROL, V87, P4728, DOI 10.1128/JVI.03509-12
   Miller MS, 2013, J INFECT DIS, V207, P98, DOI 10.1093/infdis/jis652
   Moody MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025797
   Nachbagauer R, 2014, J VIROL, V88, P13260, DOI 10.1128/JVI.02133-14
   Pica N, 2012, P NATL ACAD SCI USA, V109, P2573, DOI 10.1073/pnas.1200039109
   Pitisuttithum P, 2017, LANCET INFECT DIS, V17, P833, DOI [10.1016/S1473-3099(17)30240-2, 10.1016/s1473-3099(17)30240-2]
   Rudenko L, 2015, HUM VACC IMMUNOTHER, V11, P2839, DOI 10.1080/21645515.2015.1069931
   Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566
   Tan GS, 2012, J VIROL, V86, P6179, DOI 10.1128/JVI.00469-12
   Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778
   Wohlbold TJ, 2015, MBIO, V6, DOI 10.1128/mBio.02556-14
   Wrammert J, 2008, NATURE, V453, P667, DOI 10.1038/nature06890
   Wrammert J, 2011, J EXP MED, V208, P181, DOI 10.1084/jem.20101352
   Zangwill KM, 2008, J INFECT DIS, V197, P580, DOI 10.1086/526537
NR 30
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 852
EP 858
DI 10.1016/j.vaccine.2019.10.084
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200021
PM 31708176
DA 2020-05-12
ER

PT J
AU Klausberger, M
   Leneva, IA
   Egorov, A
   Strobl, F
   Ghorbanpour, SM
   Falynskova, IN
   Poddubikov, AV
   Makhmudova, NR
   Krokhin, A
   Svitich, OA
   Grabherr, R
AF Klausberger, Miriam
   Leneva, Irina A.
   Egorov, Andrey
   Strobl, Florian
   Ghorbanpour, Sahar M.
   Falynskova, Irina N.
   Poddubikov, Alexander, V
   Makhmudova, Nailya R.
   Krokhin, Artem
   Svitich, Oxana A.
   Grabherr, Reingard
TI Off-target effects of an insect cell-expressed influenza HA-pseudotyped
   Gag-VLP preparation in limiting postinfluenza Staphylococcus aureus
   infections
SO VACCINE
LA English
DT Article
DE Influenza; Staphylococcus aureus; Secondary bacterial infection; Vaccine
   off-target effects; VLP vaccine
ID VIRUS-LIKE PARTICLES; BACTERIAL PNEUMONIA; PANDEMIC INFLUENZA;
   IMMUNE-RESPONSES; VACCINE; PROTEIN; MICE; INACTIVATION; PROTECTION;
   MORTALITY
AB Clinical and historical data underscore the ability of influenza viruses to ally with Staphylococcus aureus and predispose the host for secondary bacterial pneumonia, which is a leading cause of influenza-associated mortality. This is fundamental because no vaccine for S. aureus is available and the number of antibiotic-resistant strains is alarmingly rising. Hence, this leaves influenza vaccination the only strategy to prevent postinfluenza staphylococcal infections. In the present work, we assessed the off-target effects of a Tnms42 insect cell-expressed BEI-treated Gag-VLP preparation expressing the HA of A/Puerto Rico/8/1934 (H1N1) in preventing S. aureus superinfection in mice pre-infected with a homologous or heterologous H1N1 viral challenge strain. Our results demonstrate that matched anti-hemagglutinin immunity elicited by a VLP preparation may suffice to prevent morbidity and mortality caused by lethal secondary bacterial infection. This effect was observed even when employing a single low antigen dose of 50 ng HA per animal. However, induction of anti-hemagglutinin immunity alone was not helpful in inhibiting heterologous viral replication and subsequent bacterial infection. Our results indicate the potential of the VLP vaccine approach in terms of immunogenicity but suggest that anti-HA immunity should not be considered as the sole preventive method for combatting influenza and postinfluenza bacterial infections. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Klausberger, Miriam; Krokhin, Artem; Grabherr, Reingard] Univ Nat Resources & Life Sci BOKU, Dept Biotechnol, Muthgasse 18, A-1190 Vienna, Austria.
   [Leneva, Irina A.; Egorov, Andrey; Falynskova, Irina N.; Makhmudova, Nailya R.; Svitich, Oxana A.] I Mechnikov Res Inst Vaccines & Sera, Dept Virol, Moscow, Russia.
   [Egorov, Andrey] Smorodintsev Res Inst Influenza, St Petersburg, Russia.
   [Strobl, Florian; Ghorbanpour, Sahar M.] ACIB, Vienna, Austria.
   [Poddubikov, Alexander, V] I Mechnikov Res Inst Vaccines & Sera, Dept Microbiol, Moscow, Russia.
RP Klausberger, M (reprint author), Univ Nat Resources & Life Sci BOKU, Dept Biotechnol, Muthgasse 18, A-1190 Vienna, Austria.
EM Miriam.klausberger@boku.ac.at
RI ; Klausberger, Miriam/C-7885-2017
OI Poddubikov, Alexander/0000-0001-8962-4765; Klausberger,
   Miriam/0000-0001-8409-454X
FU Austrian Science Fund (FWF)Austrian Science Fund (FWF) [I 3490-B30];
   Russian Science Foundation (RSF)Russian Science Foundation (RSF)
   [18-45-05002]; Competence Centre ACIB in the framework of the Austrian
   FFG-COMET-Funding Program - Federal Ministry for Transport, Innovation
   and Technology (bmvit); Federal Ministry for Digital and Economic
   Affairs (bmwd); Styrian Business Promotion Agency SFG, Standortagentur
   Tirol; Government of Lower Austria; ZIT-the Technology Agency of the
   City of Vienna
FX This bilateral joint-project is funded by the Austrian Science Fund (FWF
   grant I 3490-B30) and the Russian Science Foundation (RSF grant
   18-45-05002). FS and SG were funded by the Competence Centre ACIB in the
   framework of the Austrian FFG-COMET-Funding Program supported by the
   Federal Ministry for Transport, Innovation and Technology (bmvit), the
   Federal Ministry for Digital and Economic Affairs (bmwd) the Styrian
   Business Promotion Agency SFG, Standortagentur Tirol, the Government of
   Lower Austria and ZIT-the Technology Agency of the City of Vienna. The
   funding agencies had no influence on the conduct of this research.
CR Bradley KC, 2011, J VIROL, V85, P12387, DOI 10.1128/JVI.05570-11
   Bright RA, 2007, VACCINE, V25, P3871, DOI 10.1016/j.vaccine.2007.01.106
   Chaussee MS, 2011, VACCINE, V29, P3773, DOI 10.1016/j.vaccine.2011.03.031
   Finelli L, 2008, PEDIATRICS, V122, P805, DOI 10.1542/peds.2008-1336
   Fowler VG, 2014, CLIN MICROBIOL INFEC, V20, P66, DOI 10.1111/1469-0691.12570
   Hodgins B, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00273-17
   Huber VC, 2010, J VIROL, V84, P4105, DOI 10.1128/JVI.02621-09
   Iverson AR, 2011, J INFECT DIS, V203, P880, DOI 10.1093/infdis/jiq113
   Kasermann F, 2001, ANTIVIR RES, V52, P33, DOI 10.1016/S0166-3542(01)00157-7
   Klausberger M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153579
   Klausberger M, 2014, VACCINE, V32, P355, DOI 10.1016/j.vaccine.2013.11.036
   Koczka K, 2018, J BIOTECHNOL, V270, P61, DOI 10.1016/j.jbiotec.2018.02.001
   Krammer F, 2010, MOL BIOTECHNOL, V45, P226, DOI 10.1007/s12033-010-9268-3
   Krammer F, 2010, BIOTECHNOL J, V5, P17, DOI 10.1002/biot.200900267
   Lee GJ, 2016, VACCINE, V34, P3764, DOI 10.1016/j.vaccine.2016.06.011
   Margine I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051559
   McCullers JA, 2004, J INFECT DIS, V190, P519, DOI 10.1086/421525
   McNeely TB, 2014, HUM VACC IMMUNOTHER, V10, P3513, DOI 10.4161/hv.34407
   Metersky ML, 2012, INT J INFECT DIS, V16, pE321, DOI 10.1016/j.ijid.2012.01.003
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Nika L, 2017, PROTEIN EXPRES PURIF, V136, P27, DOI 10.1016/j.pep.2017.06.005
   Nita-Lazar M, 2015, MOL IMMUNOL, V65, P1, DOI 10.1016/j.molimm.2014.12.010
   PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989
   Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008
   Quan FS, 2009, J VIROL, V83, P4489, DOI 10.1128/JVI.02035-08
   Quan FS, 2007, J VIROL, V81, P3514, DOI 10.1128/JVI.02052-06
   Rajendran M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194830
   Redi D, 2018, NEW MICROBIOL, V41, P208
   Reiter K, 2019, J CHROMATOGR A, V1588, P77, DOI 10.1016/j.chroma.2018.12.035
   ROBERTSON L, 1958, LANCET, V2, P233
   ROELVINK PW, 1992, J GEN VIROL, V73, P1481, DOI 10.1099/0022-1317-73-6-1481
   Rohrmann GF, 2013, BACULOVIRUS REPLICAT
   Rynda-Apple A, 2014, EUR J IMMUNOL, V44, P3263, DOI 10.1002/eji.201444582
   She YM, 2013, PROTEOMICS, V13, P3537, DOI 10.1002/pmic.201300096
   Shepardson KM, 2016, MBIO, V7, DOI 10.1128/mBio.00506-16
   Shrestha A, 2018, J VIROL, V92, DOI [10.1128/JVI.01277-18, 10.1128/jvi.01277-18]
   Nguyen T, 2012, CRIT CARE MED, V40, P3246, DOI 10.1097/CCM.0b013e318260c7f8
   Warnking K, 2015, CELL MICROBIOL, V17, P303, DOI 10.1111/cmi.12375
   Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4
   Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12
   Zurli V, 2016, J INFECT DIS, V213, P1876, DOI 10.1093/infdis/jiw048
NR 41
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 859
EP 867
DI 10.1016/j.vaccine.2019.10.083
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200022
PM 31718898
OA Other Gold
DA 2020-05-12
ER

PT J
AU Hawksworth, A
   Jayachander, M
   Hester, S
   Mohammed, S
   Hutchinson, E
AF Hawksworth, Amy
   Jayachander, Mahesh
   Hester, Svenja
   Mohammed, Shabaz
   Hutchinson, Edward
TI Proteomics as a tool for live attenuated influenza vaccine
   characterisation
SO VACCINE
LA English
DT Article
DE Vaccine manufacturing; Mass spectrometry; Live-attenuated influenza
   vaccine; LAIV; Influenza virus
ID SEASONAL INFLUENZA; SCALE-UP; QUANTIFICATION; PURIFICATION; CHILDREN;
   VIRUS; HEMAGGLUTININ; NEURAMINIDASE; METAANALYSIS; MORTALITY
AB Many viral vaccines, including the majority of influenza vaccines, are grown in embryonated chicken eggs and purified by sucrose gradient ultracentrifugation. For influenza vaccines this process is well established, but the viral strains recommended for use in vaccines are updated frequently. As viral strains can have different growth properties and responses to purification, these updates risk changes in the composition of the vaccine product. Changes of this sort are hard to assess, as influenza virions are complex structures containing variable ratios of both viral and host proteins. To address this, we used liquid chromatography and tandem mass spectrometry (LC-MS/MS), a flexible and sensitive method ideally suited to identifying and quantifying the proteins present in complex mixtures. By applying LC-MS/MS to the pilot scale manufacturing process of the live attenuated influenza vaccine (LAIV) FluMist (R) Quadrivalent vaccine (AstraZeneca), we were able to obtain a detailed description of how viral and host proteins are removed or retained at each stage of LAIV purification. LC-MS/MS allowed us to quantify the removal of individual host proteins at each stage of the purification process, confirming that LAIV purification efficiently depletes the majority of host proteins and identifying the small subset of host proteins which are associated with intact virions. LC-MS/MS also identified substantial differences in the retention of the immunosuppressive viral protein NS1 in purified virions. Finally, LC-MS/MS allowed us to detect subtle variations in the LAIV production process, both upstream of purification and during downstream purification stages. This demonstrates the potential utility of LC-MS/MS for optimising the purification of complex biological mixtures and shows that it is a promising approach for process optimisation in a wide variety of vaccine manufacturing platforms. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Hawksworth, Amy; Jayachander, Mahesh] AstraZeneca Liverpool, Flu BPD, Plot 7 Renaissance Way, Liverpool L24 9JW, Merseyside, England.
   [Hawksworth, Amy] Allergan Biol, 12 Estuary Banks, Liverpool L24 8RB, Merseyside, England.
   [Hester, Svenja; Mohammed, Shabaz] Univ Oxford, Dept Biochem, Adv Prote Facil, South Parks Rd, Oxford OX1 3QU, England.
   [Hutchinson, Edward] Univ Glasgow, Ctr Virus Res, MRC, Sir Michael Stoker Bldg,Garscube Campus, Glasgow G61 1QH, Lanark, Scotland.
RP Hutchinson, E (reprint author), Univ Glasgow, Ctr Virus Res, MRC, Sir Michael Stoker Bldg,Garscube Campus, Glasgow G61 1QH, Lanark, Scotland.
EM Edward.Hutchinson@glasgow.ac.uk
RI Mohammed, Shabaz/D-1042-2010; Hutchinson, Edward/M-7136-2016
OI Mohammed, Shabaz/0000-0003-2640-9560; Hutchinson,
   Edward/0000-0003-3673-9096
FU MRCMedical Research Council UK (MRC) [MR/N008618/1, MR/K000241/1]
FX Edward Hutchinson was funded by an MRC Career Development Award
   [MR/N008618/1] and by an MRC programme grant [MR/K000241/1] awarded to
   Ervin Fodor (University of Oxford).
CR Aldington S, 2007, J CHROMATOGR B, V848, P64, DOI 10.1016/j.jchromb.2006.11.032
   Ambrose CS, 2012, VACCINE, V30, P886, DOI 10.1016/j.vaccine.2011.11.104
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Boyce TG, 1999, VACCINE, V18, P82, DOI 10.1016/S0264-410X(99)00183-8
   Buckland BC, 2005, NAT MED, V11, pS16, DOI 10.1038/nm1218
   Caspard H, 2016, VACCINE, V34, P77, DOI 10.1016/j.vaccine.2015.11.010
   Creskey MC, 2012, VACCINE, V30, P4762, DOI 10.1016/j.vaccine.2012.05.036
   Des Roches A, 2015, J ALLER CL IMM-PRACT, V3, P138, DOI 10.1016/j.jaip.2014.08.008
   Galassie AC, 2015, PROTEOM CLIN APPL, V9, P972, DOI 10.1002/prca.201500054
   Gaspard N, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx111
   Getie-Kebtie M, 2013, INFLUENZA OTHER RESP, V7, P521, DOI 10.1111/irv.12001
   Hoft DF, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00414-16, 10.1128/cvi.00414-16]
   Hutchinson EC, 2018, METHODS MOL BIOL, V1836, P1, DOI 10.1007/978-1-4939-8678-1_1
   Hutchinson EC, 2018, METHODS MOL BIOL, V1836, P89, DOI 10.1007/978-1-4939-8678-1_5
   Hutchinson EC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5816
   Hutchinson EC, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002993
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   James KT, 2016, SCI REP-UK, V6, DOI 10.1038/srep36826
   Kursteiner O, 2006, VACCINE, V24, P6632, DOI 10.1016/j.vaccine.2006.05.084
   Kunisaki KM, 2009, LANCET INFECT DIS, V9, P493, DOI 10.1016/S1473-3099(09)70175-6
   Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009
   MAASSAB HF, 1967, NATURE, V213, P612, DOI 10.1038/213612a0
   Mangtani P, 2004, J INFECT DIS, V190, P1, DOI 10.1086/421274
   Manini I, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5030018
   Marc D, 2014, J GEN VIROL, V95, P2594, DOI 10.1099/vir.0.069542-0
   MCCOMBS RM, 1968, J VIROL, V2, P409, DOI 10.1128/JVI.2.5.409-414.1968
   McCraw DM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28700-7
   Milne JJ, 2017, METHODS MOL BIOL, V1485, P71, DOI 10.1007/978-1-4939-6412-3_5
   Nakatsu S, 2016, MBIO, V7, DOI 10.1128/mBio.01248-16
   Neuzil Kathleen M, 2002, Semin Pediatr Infect Dis, V13, P174, DOI 10.1053/spid.2002.125860
   Public Health England, 2017, SEAS INFL VACC UPT C
   REIMER C. B., 1967, J VIROL, V1, P1207
   Rhorer J, 2009, VACCINE, V27, P1101, DOI 10.1016/j.vaccine.2008.11.093
   Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Shaw ML, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000085
   Thompson CM, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-141
   Tsuge Y, 1996, BIOSCI BIOTECH BIOCH, V60, P1503, DOI 10.1271/bbb.60.1503
   Turner PJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6291
   Turner PJ, 2015, J ALLERGY CLIN IMMUN, V136, P376, DOI 10.1016/j.jaci.2014.12.1925
   Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136
   Williams TL, 2008, VACCINE, V26, P2510, DOI 10.1016/j.vaccine.2008.03.014
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Wu XR, 2009, KIDNEY INT, V75, P1153, DOI 10.1038/ki.2009.73
   Yudin MH, 2014, IN J WOMENS HEALTH, V6, P681, DOI 10.2147/IJWH.S47235
NR 44
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 868
EP 877
DI 10.1016/j.vaccine.2019.10.082
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200023
PM 31708181
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Xu, WB
   Li, Y
   Li, D
   Fang, Y
   An, ZJ
   Teng, X
   Wang, HQ
   Shang, QL
AF Xu Wen-bo
   Li Yan
   Li Di
   Fang Yong
   An Zhi-jie
   Teng Xu
   Wang Hua-qing
   Shang Qing-long
TI Investigation and analysis of antibody levels of hepatitis A among
   children before and after implementing the Expanded National
   Immunization Program in China
SO VACCINE
LA English
DT Article
DE Hepatitis A vaccine; Immunization coverage; Antibody; Positive rate
ID FOLLOW-UP; VACCINE; OUTBREAK
AB Objective: To analyze changes of hepatitis A antibody levels and immunization coverage of HAV vaccine among children before and after implementing the Expanded National Immunization Program in five counties of China, and to provide evidence for developing hepatitis A vaccine immunization strategies.
   Methods: 449 children born in 2001, 2005 and 2009 were selected from five counties for an immunization coverage and a sero-prevalence survey of hepatitis A. The chemiluminescence microparticle immunoassays (CMIA) were used to detect hepatitis A IgG antibody and analyzed the factors which influenced the immunization coverage and positive rates.
   Results: Among 449 subjects of children born in 2001, 2005 and 2009, the immunization coverage were 53.02%, 78.52% and 99.34% (chi(2) = 91.285, P < 0.001). The positivity rates of hepatitis A IgG antibody were 61.07%, 81.21%, 95.36% (chi(2) = 54.198, P < 0.001), respectively. The immunization coverage and positivity rate significantly increased with the delay of birth year. Children accepting different doses of HA vaccines are significantly different in positive rates of HA antibody, while there are no significant differences of different genders, years of birth, residence types, or types of registered permanent residence in different regions. The positivity rate increased significantly with administration of hepatitis A vaccine and shorter intervals between sample collection and HAV immunization.
   Conclusions: After the Expanded National Immunization Program was implemented, hepatitis A antibody levels were significantly increased in five counties, which indicates a successful result of EN. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xu Wen-bo; Li Di; Fang Yong; Teng Xu; Shang Qing-long] Harbin Med Univ, Dept Microbiol, Harbin, Peoples R China.
   [Li Yan; An Zhi-jie; Wang Hua-qing] China Ctr Dis Control & Prevent, Dept Natl Immunizat Program, Beijing 100050, Peoples R China.
RP Shang, QL (reprint author), Harbin Med Univ, Dept Microbiol, Harbin, Peoples R China.; Wang, HQ (reprint author), China Ctr Dis Control & Prevent, Dept Natl Immunizat Program, Beijing 100050, Peoples R China.
EM wanghq@chinacdc.cn; 13029712295@163.com
FU National Major Scientific and Technological Special Project for
   'Clinical trial evaluation system for infectious disease vaccine'
   [2012ZX10004-703]
FX This study was supported by the National Major Scientific and
   Technological Special Project for 'Clinical trial evaluation system for
   infectious disease vaccine' (grant no. 2012ZX10004-703).
CR Chen Y, 2018, VACCINE, V36, P114, DOI 10.1016/j.vaccine.2017.11.036
   Craig AS, 2007, AM J MED SCI, V334, P180, DOI 10.1097/MAJ.0b013e3181425411
   CUI J, 2016, CHIN J VAC IMMUN, V22, P34
   Dagan R, 2016, PEDIATR INFECT DIS J, V35, pE220, DOI 10.1097/INF.0000000000001176
   Dogru AO, 2017, ENVIRON RES, V156, P349, DOI 10.1016/j.envres.2017.04.001
   Freeman E, 2014, VACCINE, V32, P5509, DOI 10.1016/j.vaccine.2014.07.048
   Jiang DY, 2007, PREVENT MED TRIBUNE, V13, P492
   LIU Y M, 2010, CHINESE J VACCINES I, V16, P453
   Luo J, 2018, CLIN MICROBIOL INFEC, P30731
   Ma F, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.06.004
   Ministry of Health, 2008, CHINESE J VACC IMMU, V14, P183
   Parron I, 2017, HUM VACC IMMUNOTHER, V13, P423, DOI 10.1080/21645515.2017.1264798
   Scavia G, 2017, J MED MICROBIOL, V66, P342, DOI 10.1099/jmm.0.000433
   Song I.X., 2015, ANAL CURRENT EPIDEMI
   SUN Ying-chun, 2016, CHINA MODERN MED, V23, P156
   Tan C, 2016, J APPL PREVENT MED, V22, P232
   Theeten H, 2015, VACCINE, V33, P5723, DOI 10.1016/j.vaccine.2015.07.008
   Wheeler C, 2005, NEW ENGL J MED, V353, P890, DOI 10.1056/NEJMoa050855
   WHO, 2017, HEP FACT SHEET HEP A
   WHO (World Health Organization), 2016, TECHNICAL REPORT
   Zheng H, 2011, VACCINE, V29, P9098, DOI 10.1016/j.vaccine.2011.08.078
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 878
EP 881
DI 10.1016/j.vaccine.2019.10.086
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200024
PM 31733948
DA 2020-05-12
ER

PT J
AU Marin-Lopez, A
   Barreiro-Pineiro, N
   Utrilla-Trigo, S
   Barriales, D
   Benavente, J
   Nogales, A
   Martinez-Costas, J
   Ortego, J
   Calvo-Pinilla, E
AF Marin-Lopez, Alejandro
   Barreiro-Pineiro, Natalia
   Utrilla-Trigo, Sergio
   Barriales, Diego
   Benavente, Javier
   Nogales, Aitor
   Martinez-Costas, Jose
   Ortego, Javier
   Calvo-Pinilla, Eva
TI Cross-protective immune responses against African horse sickness virus
   after vaccination with protein NS1 delivered by avian reovirus muNS
   microspheres and modified vaccinia virus Ankara
SO VACCINE
LA English
DT Article
DE African horse sickness; Microspheres; MVA; Multiserotype; Vaccine
ID RECOMBINANT CANARYPOX VIRUS; VP2; INFECTION; EPITOPES; AHSV
AB African horse sickness virus (AHSV) is an insect-borne pathogen that causes acute disease in horses and other equids. In an effort to improve the safety of currently available vaccines and to acquire new knowledge about the determinants of AHSV immunogenicity, new generation vaccines are being developed. In this work we have generated and tested a novel immunization approach comprised of nonstructural protein 1 (NS1) of AHSV serotype 4 (AHSV-4) incorporated into avian reovirus muNS protein microspheres (MS-NS1) and/or expressed using recombinant modified vaccinia virus Ankara vector (MVA-NS1). The protection conferred against AHSV by a homologous MS-NS1 or heterologous MS-NS1 and MVA-NS1 prime/boost was evaluated in IFNAR (-/-) mice. Our results indicate that immunization based on MS-NS1 and MVA-NS1 afforded complete protection against the infection with homologous AHSV-4. Moreover, priming with MS-NS1 and boost vaccination with MVA-NS1 (MS-MVA-NS1) triggered NS1 specific cytotoxic CD8 + T cells and prevented AHSV disease in IFNAR (-/-) mice after challenge with heterologous serotype AHSV-9. Cross-protective immune responses are highly important since AHS can be caused by nine different serotypes, which means that a universal polyvalent vaccination would need to induce protective immunity against all serotypes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Marin-Lopez, Alejandro; Utrilla-Trigo, Sergio; Barriales, Diego; Nogales, Aitor; Ortego, Javier; Calvo-Pinilla, Eva] Inst Nacl Invest & Tecnol Agr & Alimentaria, Ctr Invest Sanidad Anim INIA CISA, Madrid, Spain.
   [Barreiro-Pineiro, Natalia; Benavente, Javier; Martinez-Costas, Jose] Univ Santiago de Compostela, Ctr Singular Invest Quim Biol & Mat Mol CIQUS, Santiago De Compostela, Spain.
   [Barreiro-Pineiro, Natalia; Benavente, Javier; Martinez-Costas, Jose] Univ Santiago de Compostela, Dept Bioquim & Biol Mol, Santiago De Compostela, Spain.
   [Marin-Lopez, Alejandro] Yale Univ, Dept Internal Med, Sect Infect Dis, Sch Med, New Haven, CT 06510 USA.
   [Barriales, Diego] CIC BioGUNE, Lab Inflammat, Parque Tecnol Bizkaia, Derio, Bizkaia, Spain.
   [Barriales, Diego] CIC BioGUNE, Macrophage Plast Lab, Parque Tecnol Bizkaia, Derio, Bizkaia, Spain.
RP Ortego, J (reprint author), Inst Nacl Invest & Tecnol Agr & Alimentaria, Ctr Invest Sanidad Anim INIA CISA, Madrid, Spain.
EM ortego@inia.es
RI Martinez-Costas, Jose/E-9005-2011; Ortego, Javier/K-6020-2014
OI Martinez-Costas, Jose/0000-0002-8877-7775; Ortego,
   Javier/0000-0002-4275-7277; NOGALES, AITOR/0000-0002-2424-7900;
   Barriales, Diego/0000-0002-6433-3379
FU Ministerio de Ciencia, Innovacion y Universidades, Spain
   [AGL-2014-57430-R, AGL2017-82570-R, BFU2013-43513-R]; Xunta de
   GaliciaXunta de Galicia [ED431G/09, ED431B 2018/04]; European Regional
   Development Fund (ERDF)European Union (EU)
FX This work was supported by grants from the Ministerio de Ciencia,
   Innovacion y Universidades, Spain (AGL-2014-57430-R, AGL2017-82570-R and
   BFU2013-43513-R). The Xunta de Galicia [Centro singular de investigacion
   de Galicia accreditation 2016-2019 (ED431G/09) and ED431B 2018/04], and
   the European Regional Development Fund (ERDF) are gratefully
   acknowledged. We thank Rebeca Menaya for excellent technical assistance.
CR Alberca B, 2014, VACCINE, V32, P3670, DOI 10.1016/j.vaccine.2014.04.036
   ANDERSON EC, 1989, VET REC, V125, P489, DOI 10.1136/vr.125.19.489-a
   Barreiro-Pineiro Natalia, 2016, Methods Mol Biol, V1349, P25, DOI 10.1007/978-1-4939-3008-1_2
   Baum F, 2014, HEALTH PROMOT INT, V29, P130, DOI 10.1093/heapro/dau032
   Berthoud TK, 2011, CLIN INFECT DIS, V52, P1, DOI 10.1093/cid/ciq015
   Boyce M, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-178
   Brandariz-Nunez A, 2011, J BIOTECHNOL, V155, P284, DOI 10.1016/j.jbiotec.2011.07.010
   Brandariz-Nunez A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013961
   Brandariz-Nunez A, 2010, J VIROL, V84, P4289, DOI 10.1128/JVI.02534-09
   BURRAGE TG, 1993, VIROLOGY, V196, P799, DOI 10.1006/viro.1993.1537
   Castillo-Olivares J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016503
   COETZER JAW, 2004, AFRICAN HORSE SICKNE, P1231
   de la Poza F, 2015, VIRUS RES, V210, P149, DOI 10.1016/j.virusres.2015.08.005
   de la Poza F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070197
   Delany I, 2014, EMBO MOL MED, V6, P708, DOI 10.1002/emmm.201403876
   Du Toit R. M., 1944, ONDERSTEPOORT JOUR VET SCI AND ANIMAL INDUST, V19, P7
   El Garch H, 2012, VET IMMUNOL IMMUNOP, V149, P76, DOI 10.1016/j.vetimm.2012.06.009
   Gomez CE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035485
   Gilbert SC, 2013, VACCINE, V31, P4241, DOI 10.1016/j.vaccine.2013.03.020
   Guthrie AJ, 2009, VACCINE, V27, P4434, DOI 10.1016/j.vaccine.2009.05.044
   JEGGO MH, 1984, IMMUNOLOGY, V52, P403
   Kerviel A, 2019, NAT MICROBIOL, V4, P837, DOI 10.1038/s41564-019-0369-x
   LAEGREID WW, 1992, VET PATHOL, V29, P554, DOI 10.1177/030098589202900615
   Manning NM, 2017, VACCINE, V35, P6024, DOI 10.1016/j.vaccine.2017.04.005
   Manning NM, 2017, VACCINE
   Maree FF, 1997, J GEN VIROL, V78, P1077, DOI 10.1099/0022-1317-78-5-1077
   Marin-Lopez A, 2018, J VIROL, V92, DOI 10.1128/JVI.00938-18
   Marin-Lopez A, 2014, ANTIVIR RES, V110, P42, DOI 10.1016/j.antiviral.2014.07.008
   MartinezTorrecuadrada JL, 1996, J GEN VIROL, V77, P1211, DOI 10.1099/0022-1317-77-6-1211
   Mellor PS, 2004, VET RES, V35, P445, DOI 10.1051/vetres:2004021
   NEWSHOLME SJ, 1983, ONDERSTEPOORT J VET, V50, P7
   Roy P, 1998, ARCH VIROL, P177
   Roy P, 1996, J GEN VIROL, V77, P2053, DOI 10.1099/0022-1317-77-9-2053
   ROY P, 1994, COMP IMMUNOL MICROB, V17, P243, DOI 10.1016/0147-9571(94)90046-9
   Scanlen M, 2002, VACCINE, V20, P1079, DOI 10.1016/S0264-410X(01)00445-5
   Sung PY, 2019, J VIROL, V93, DOI 10.1128/JVI.02023-18
   SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847
   van de Water SGP, 2015, J VIROL, V89, P8764, DOI 10.1128/JVI.01052-15
   von Teichman BF, 2010, VACCINE, V28, P6505, DOI 10.1016/j.vaccine.2010.06.105
   Weyer CT, 2013, EQUINE VET J, V45, P117, DOI 10.1111/j.2042-3306.2012.00590.x
   Weyer CT, 2016, EMERG INFECT DIS, V22, P2087, DOI 10.3201/eid2212.160718
   Wittman EJ, 2001, REV SCI TECH OIE, V20, P731, DOI 10.20506/rst.20.3.1306
   Woodland DL, 2004, TRENDS IMMUNOL, V25, P98, DOI 10.1016/j.it.2003.11.009
NR 43
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 882
EP 889
DI 10.1016/j.vaccine.2019.10.087
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200025
PM 31708178
DA 2020-05-12
ER

PT J
AU Cacheiro-Llaguno, C
   Parody, N
   Renshaw-Calderon, A
   Osuna, C
   Alonso, C
   Carnes, J
AF Cacheiro-Llaguno, Cristina
   Parody, Nuria
   Renshaw-Calderon, Ana
   Osuna, Cristina
   Alonso, Carlos
   Carnes, Jeronimo
TI Vaccination with LetiFend (R) reduces circulating immune complexes in
   dogs experimentally infected with L. infantum
SO VACCINE
LA English
DT Article
DE Canine leishmaniosis; Circulating immune complexes; Complement system;
   Leishmania infantum; LetiFend (R); Vaccine
ID LEISHMANIA-INFANTUM; VISCERAL LEISHMANIASIS; COMPLEMENT ACTIVATION;
   CANINE LEISHMANIASIS; CONFERS PROTECTION; INNATE IMMUNITY;
   PROMASTIGOTES; MECHANISM; ANTIGENS; DEFENSE
AB Domestic dogs constitute the main reservoir of Leishmania infantum and play a key role in transmission to humans. The main tool for controlling infection spread is a safe and effective vaccine, as successful immunization of dogs could significantly reduce the incidence of human visceral leishmaniosis (VL) and is the most cost-effective control strategy.
   The factors that determine disease progression in canine leishmaniosis (CanL) remain poorly understood, though a previous study in naturally infected dogs has demonstrated a clear relationship between the presence of circulating immune complexes (CIC) in the blood and disease progression. Thus, the aim of this study was to compare CIC levels in serum samples from dogs vaccinated or unvaccinated with LetiFend (R), a new vaccine containing recombinant Protein Q, and experimentally infected with L. infantum.
   CIC were isolated from vaccinated or unvaccinated dogs after experimental infection with L. infantum and their levels measured by ELISA. Furthermore, reverse phase-liquid chromatography-mass spectrometry (RP-LC-MS/MS) analysis was used to investigate the protein composition of precipitated CIC.
   At all the time points analyzed after infection, the amount of CIC was lower in the vaccinated group compared to the placebo group. Furthermore, there were differences in the protein composition of precipitated CIC between the vaccinated and unvaccinated groups.
   In conclusion, administration of LetiFend (R) was able to reduce CIC elicited after experimental infection with L infantum in a dog model in a process that may be related to complement system activation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cacheiro-Llaguno, Cristina; Parody, Nuria; Osuna, Cristina; Carnes, Jeronimo] LETI SL, Allergy & Immunol Labs, R&D Unit, Madrid, Spain.
   [Renshaw-Calderon, Ana; Alonso, Carlos] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Madrid, Spain.
RP Carnes, J (reprint author), LETI SL, Allergy & Immunol Labs, R&D Unit, Madrid, Spain.
EM jcarnes@leti.com
OI Carnes, Jeronimo/0000-0003-4050-2577
FU PE I+D+i - ISCIII [PT17/0019]; ERDFEuropean Union (EU)
FX Proteomic analysis was performed in the 'CBMSO PROTEIN CHEMISTRY
   FACILITY', that belongs to ProteoRed, PRB3-ISCIII, financed by PE I+D+i
   2013-2016 grant PT17/0019, funded by ISCIII and ERDF. We would like to
   acknowledge the outstanding technical assistance of Anabel Marina and
   Esperanza Morato.
CR Aboud L, 2014, AM J REPROD IMMUNOL, V71, P12, DOI 10.1111/aji.12166
   Ambrosio AR, 2005, PARASITE IMMUNOL, V27, P333, DOI 10.1111/j.1365-3024.2005.00782.x
   [Anonymous], 2003, VET PATHOL, V40, P677, DOI [10.1354/vp.40-6-677, DOI 10.1354/VP.40-6-677]
   Baneth G, 2008, TRENDS PARASITOL, V24, P324, DOI 10.1016/j.pt.2008.04.001
   Bao JL, 2018, PEERJ, V6, DOI 10.7717/peerj.4557
   Bonifati C, 2006, INT J ARTIF ORGANS, V29, P41
   Campino L, 2000, VET PARASITOL, V92, P269, DOI 10.1016/S0304-4017(00)00313-7
   Carrillo E, 2009, VET IMMUNOL IMMUNOP, V128, P67, DOI 10.1016/j.vetimm.2008.10.310
   Costa DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060535
   Vilas VJD, 2014, VET REC, V175, P42, DOI 10.1136/vr.g4378
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Farley K, 2012, J IMMUNOL, V189, P4574, DOI 10.4049/jimmunol.1201167
   Cotrina JF, 2018, VACCINE, V36, P1972, DOI 10.1016/j.vaccine.2018.02.111
   Gurung P, 2015, CELL MICROBIOL, V17, P1286, DOI 10.1111/cmi.12484
   Iborra S, 2004, VACCINE, V22, P3865, DOI 10.1016/j.vaccine.2004.04.015
   Jiang D, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-122
   Kasahara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2879
   Laurenti MD, 2004, BRAZ J MED BIOL RES, V37, P427, DOI 10.1590/S0100-879X2004000300021
   Lemesre JL, 2005, VACCINE, V23, P2825, DOI 10.1016/j.vaccine.2004.11.061
   Lucena R, 1994, Zentralbl Veterinarmed A, V41, P48
   Makni S, 1998, ANN CHIR, V52, P668
   MANCIANTI F, 1988, AM J VET RES, V49, P1409
   MANCIANTI F, 1989, Parassitologia (Rome), V31, P213
   Martinez F, 2002, CONTRACEPTION, V66, P315, DOI 10.1016/S0010-7824(02)00392-X
   Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470
   Molano I, 2003, VET IMMUNOL IMMUNOP, V92, P1, DOI 10.1016/S0165-2427(02)00315-X
   MOSSER DM, 1984, J IMMUNOL, V132, P1501
   MOSSER DM, 1986, EXP PARASITOL, V62, P394, DOI 10.1016/0014-4894(86)90048-2
   Muller Karl Erik, 2018, Tidsskr Nor Laegeforen, V137, DOI 10.4045/tidsskr.17.0620
   NIETO CG, 1992, VET PARASITOL, V45, P33, DOI 10.1016/0304-4017(92)90025-5
   Ordeix L, 2005, VET DERMATOL, V16, P187, DOI 10.1111/j.1365-3164.2005.00454.x
   Palatnik-de-Sousa CB, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-197
   Parody N, 2004, PARASITE IMMUNOL, V26, P283, DOI 10.1111/j.0141-9838.2004.00711.x
   Parody N, 2019, VET PARASITOL, V274, DOI 10.1016/j.vetpar.2019.108921
   PEARSON RD, 1980, J IMMUNOL, V125, P2195
   RAJA A, 1995, J LAB CLIN MED, V125, P581
   Riera C, 1999, VET PARASITOL, V84, P33, DOI 10.1016/S0304-4017(99)00084-9
   Rossi M, 2018, INT IMMUNOL, V30, P103, DOI 10.1093/intimm/dxx075
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Solano-Gallego L, 2009, VET PARASITOL, V165, P1, DOI 10.1016/j.vetpar.2009.05.022
   Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 890
EP 896
DI 10.1016/j.vaccine.2019.10.078
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200026
PM 31706810
DA 2020-05-12
ER

PT J
AU Otieno, L
   Mendoza, YG
   Adjei, S
   Agbenyega, T
   Agnandji, ST
   Aide, P
   Akoo, P
   Ansong, D
   Asante, KP
   Berkley, JA
   Gesase, S
   Hamel, MJ
   Hoffman, I
   Kaali, S
   Kamthunzi, P
   Kariuki, S
   Kremsner, P
   Lanaspa, M
   Lell, B
   Lievens, M
   Lusingu, J
   Malabeja, A
   Masoud, NS
   Mtoro, AT
   Njuguna, P
   Ofori-Anyinam, O
   Otieno, GA
   Otieno, W
   Owusu-Agyei, S
   Schuerman, L
   Sorgho, H
   Tanner, M
   Tinto, H
   Valea, I
   Vandoolaeghe, P
   Sacarlal, J
   Oneko, M
AF Otieno, Lucas
   Mendoza, Yolanda Guerra
   Adjei, Samuel
   Agbenyega, Tsiri
   Agnandji, Selidji Todagbe
   Aide, Pedro
   Akoo, Pauline
   Ansong, Daniel
   Asante, Kwaku Poku
   Berkley, James A.
   Gesase, Samwel
   Hamel, Mary J.
   Hoffman, Irving
   Kaali, Seyram
   Kamthunzi, Portia
   Kariuki, Simon
   Kremsner, Peter
   Lanaspa, Miguel
   Lell, Bertrand
   Lievens, Marc
   Lusingu, John
   Malabeja, Anangisye
   Masoud, Nahya Salim
   Mtoro, Ali Takadir
   Njuguna, Patricia
   Ofori-Anyinam, Opokua
   Otieno, Godfrey Allan
   Otieno, Walter
   Owusu-Agyei, Seth
   Schuerman, Lode
   Sorgho, Hermann
   Tanner, Marcel
   Tinto, Halidou
   Valea, Innocent
   Vandoolaeghe, Pascale
   Sacarlal, Jahit
   Oneko, Martina
TI Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants
   and children identified as HIV-infected during a randomized trial in
   sub-Saharan Africa
SO VACCINE
LA English
DT Article
DE HIV; Malaria; RTS; S/AS01 vaccine; Safety; Immunogenicity; Children
ID PHASE-3 TRIAL; IMMUNIZATION; EFFICACY
AB Background: We assessed the safety and immunogenicity of the RTS,S/AS01 malaria vaccine in a subset of children identified as HIV-infected during a large phase III randomized controlled trial conducted in seven sub-Saharan African countries.
   Methods: Infants 6-12 weeks and children 5-17 months old were randomized to receive 4 RTS,S/AS01 doses (R3R group), 3 RTS,S/AS01 doses plus 1 comparator vaccine dose (R3C group), or 4 comparator vaccine doses (C3C group) at study months 0, 1, 2 and 20. Infants and children with WHO stage III/IV HIV disease were excluded but HIV testing was not routinely performed on all participants; our analyses included children identified as HIV-infected based on medical history or clinical suspicion and confirmed by polymerase chain reaction or antibody testing. Serious adverse events (SAEs) and anti-circumsporozoite (CS) antibodies were assessed.
   Results: Of 15459 children enrolled in the trial, at least 1953 were tested for HIV and 153 were confirmed as HIV-infected (R3R: 51; R3C: 54; C3C: 48). Among these children, SAEs were reported for 92.2% (95% CI: 81.1-97.8) in the R3R, 85.2% (72.9-93.4) in the R3C and 87.5% (74.8-95.3) in the C3C group over a median follow-up of 39.3, 39.4 and 38.3 months, respectively. Fifteen HIV-infected participants in each group (R3R: 29.4%, R3C: 27.8%, C3C: 31.3%) died during the study. No deaths were considered vaccinationrelated. In a matched case-control analysis, 1 month post dose 3 anti-CS geometric mean antibody concentrations were 193.3 EU/mL in RTS,S/AS01-vaccinated HIV-infected children and 491.5 EU/mL in RTS,S/AS01-vaccinated immunogenicity controls with unknown or negative HIV status (p = 0.0001).
   Conclusions: The safety profile of RTS,S/AS01 in HIV-infected children was comparable to that of the comparator (meningococcal or rabies) vaccines. RTS,S/AS01 was immunogenic in HIV-infected children but antibody concentrations were lower than in children with an unknown or negative HIV status. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Otieno, Lucas; Otieno, Godfrey Allan; Otieno, Walter] KEMRI Walter Reed Project, Kombewa, Kenya.
   [Mendoza, Yolanda Guerra; Lievens, Marc; Ofori-Anyinam, Opokua; Schuerman, Lode; Vandoolaeghe, Pascale] GSK, Wavre, Belgium.
   [Adjei, Samuel; Agbenyega, Tsiri; Ansong, Daniel] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana.
   [Agnandji, Selidji Todagbe; Kremsner, Peter; Lell, Bertrand] Ctr Rech Med Lambarene, Lambarene, Gabon.
   [Agnandji, Selidji Todagbe; Kremsner, Peter; Lell, Bertrand] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Aide, Pedro; Lanaspa, Miguel; Sacarlal, Jahit] Ctr Invest Saude Manhica, Manhica, Mozambique.
   [Aide, Pedro] Minist Hlth, Natl Inst Hlth, Maputo, Mozambique.
   [Akoo, Pauline; Berkley, James A.; Njuguna, Patricia] Kenya Med Res Inst Wellcome Trust Res Programme, Ctr Geog Med Res, Kilifi, Kenya.
   [Asante, Kwaku Poku; Kaali, Seyram; Owusu-Agyei, Seth] Kintampo Hlth Res Ctr, Kintampo, Ghana.
   [Berkley, James A.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England.
   [Gesase, Samwel; Lusingu, John; Malabeja, Anangisye] Natl Inst Med Res, Korogwe, Tanzania.
   [Hamel, Mary J.] Ctr Dis Control & Prevent, Ctr Global Hlth, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA.
   [Hoffman, Irving; Kamthunzi, Portia] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA.
   [Kariuki, Simon; Oneko, Martina] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.
   [Lanaspa, Miguel] Hosp Clin Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain.
   [Masoud, Nahya Salim; Tanner, Marcel] MUHAS, Dar Es Salaam, Tanzania.
   [Masoud, Nahya Salim; Mtoro, Ali Takadir; Tanner, Marcel] Ifakara Hlth Inst, Bagamoyo, Tanzania.
   [Njuguna, Patricia] Pwani Univ, Kilifi, Kenya.
   [Owusu-Agyei, Seth] London Sch Hyg & Trop Med, Dis Control Dept, London, England.
   [Sorgho, Hermann; Tinto, Halidou; Valea, Innocent] Inst Rech Sci Sante, Nanoro, Burkina Faso.
   [Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
   [Tanner, Marcel] Univ Basel, Basel, Switzerland.
   [Sacarlal, Jahit] UEM, Fac Med, Maputo, Mozambique.
RP Mendoza, YG (reprint author), Ave Fleming 20, B-1300 Wavre, Belgium.
EM Lucas.Tina@usamru-k.org; Yolanda.x.guerra@gsk.com; kwakusam@yahoo.com;
   tsiri@ghana.com; agnandjis@lambarene.org; pedro.aide@manhica.net;
   byancamy@gmail.com; ansongd@yahoo.com;
   kwakupoku.asante@kintampo-hrc.org; JBerkley@kemri-wellcome.org;
   sgesase@yahoo.com; hamelm@who.int; hoffmani@med.unc.edu;
   kaali.seyram@kintampo-hrc.org; pkamthunzi@unclilongwe.org;
   SKariuki@kemricdc.org; peter.kremsner@uni-tuebingen.de;
   mlanaspa@sjdhospitalbarcelona.org; bertrand.lell@lambarene.org;
   marc.lievens@gsk.com; jpalusingu@yahoo.co.uk; malabeja1@yahoo.com;
   nsalim@ihi.or.tz; amtoro@ihi.or.tz; njugunap@who.int;
   opokua.ofori-anyinam@gsk.com; Allan.Otieno@usamru-k.org;
   Walter.otieno@usamru-k.org; seth.owusu-agyei@kintampo-hrc.org;
   lode.schuerman@gsk.com; hsorgho@hotmail.com; marcel.tanner@unibas.ch;
   halidoutinto@gmail.com; innocentvalea@yahoo.fr;
   pascale.vandoolaeghe@gsk.com; jahityash2002@gmail.com;
   tinaoneko@gmail.com
FU PATH Malaria Vaccine Initiative (MVI)United States Agency for
   International Development (USAID); MVI; Bill & Melinda Gates
   FoundationGates Foundation; GlaxoSmithKline Biologicals
   SAGlaxoSmithKline
FX The trial was sponsored by GlaxoSmithKline Biologicals SA and was funded
   by GlaxoSmithKline Biologicals SA and the PATH Malaria Vaccine
   Initiative (MVI). All centers received a grant from the MVI for running
   the trial. GlaxoSmithKline Biologicals SA received a grant from the MVI
   to run the trial. The MVI received a grant from the Bill & Melinda Gates
   Foundation to run this trial and to compensate MVI authors for
   trial-related travel. GlaxoSmithKline Biologicals SA developed and
   manufactured the RTS,S/AS01 vaccine. GlaxoSmithKline Biologicals SA took
   in charge all costs related to the development and publication of this
   article.
CR Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P33
   Asante KP, 2011, LANCET INFECT DIS, V11, P741, DOI 10.1016/S1473-3099(11)70100-1
   Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381
   Bonhoeffer J, 2004, VACCINE, V22, P557, DOI 10.1016/j.vaccine.2003.09.008
   CIOMS, 2005, MAN SAF INF CLIN TRI
   Clement F, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-384
   Drakeley C, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2078-3
   European Medicines Agency, 2015, COMM MED PROD HUM US
   Falconer O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00328
   Gonzalez R, 2012, EXPERT REV ANTI-INFE, V10, P153, DOI [10.1586/eri.11.167, 10.1586/ERI.11.167]
   Groome MJ, 2012, VACCINE, V30, pA173, DOI 10.1016/j.vaccine.2011.08.004
   Jallow S, 2017, EXPERT REV VACCINES, V16, P453, DOI 10.1080/14760584.2017.1307740
   Klein SL, 2016, MBIO, V7, DOI 10.1128/mBio.00514-16
   Kwenti TE, 2018, RES REP TROP MED, V9, P123, DOI 10.2147/RRTM.S154501
   Leach A, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-224
   Lievens M, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-222
   Madhi SA, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005881
   Mendoza YG, 2019, HUM VACC IMMUNOTHER, V15, P2386, DOI 10.1080/21645515.2019.1586040
   Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394
   Moss WJ, 2003, B WORLD HEALTH ORGAN, V81, P61
   Muema DM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175570
   Naing C, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003205
   Otieno L, 2016, LANCET INFECT DIS, V16, P1134, DOI 10.1016/S1473-3099(16)30161-X
   PAVIA AT, 1992, PEDIATR INFECT DIS J, V11, P996, DOI 10.1097/00006454-199211120-00002
   RTSS Clinical Trials Partnership, 2014, PLOS MED, V11, DOI DOI 10.1371/JOURNAL.PMED.1001685E1001685
   Schoub BD, 2012, VACCINE, V30, pC1, DOI 10.1016/j.vaccine.2012.06.094
   Swysen C, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-223
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   Titanji K, 2006, BLOOD, V108, P1580, DOI 10.1182/blood-2005-11-013383
   UNAIDS, 2018, UNAIDS DAT 2018
   Vandoolaeghe P, 2016, EXPERT REV VACCINES, V15, P1481, DOI 10.1080/14760584.2016.1236689
   Vekemans J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-221
   WHO, 2018, WORLD MAL REP 2018
   WHO, 2005, POCK BOOK HOSP CAR C
   WHO, 2013, POCK BOOK HOSP CAR C
   World Health Organization, VERB AUT STAND ASC A
   World Health Organization Europe, PROT 12 IMM PEOPL LI
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 897
EP 906
DI 10.1016/j.vaccine.2019.10.077
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200027
PM 31708182
OA Green Published, Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Hassan, IA
   Wang, YN
   Zhou, YZ
   Cao, J
   Zhang, HS
   Zhou, JL
AF Hassan, Ibrahim A.
   Wang, Yanan
   Zhou, Yongzhi
   Cao, Jie
   Zhang, Houshuang
   Zhou, Jinlin
TI Cross protection induced by combined Subolesin-based DNA and protein
   immunizations against adult Haemaphysalis longicornis
SO VACCINE
LA English
DT Article
DE Anti-tick vaccine; Subolesin; Ribosomal P0; DNA vaccine; Chimeric
   polypeptide
ID TICK-BORNE ENCEPHALITIS; BOOPHILUS-MICROPLUS; VECTOR INFESTATIONS; RNA
   INTERFERENCE; VACCINE EFFICACY; IMMUNE-RESPONSE; BM86 ANTIGEN; CATTLE
   TICK; IDENTIFICATION; EXPRESSION
AB Vaccination against ticks is an environmentally friendly alternative control method compared to chemical acaricide applications. Subolesin is a conserved protein in ticks, which can provide protection against some tick species. In this study, we evaluated the capacity of cocktail vaccination with Subolesin and ribosomal acidic protein 0 (P0) peptide against adults of Haemaphysalis longicornis. Priming with DNA vaccine expressing subolesin, followed by boosters of a single antigen (rRhSub) or a chimeric polypeptide (rRhSub/P0), provided cross protection. This treatment resulted in significant mortality, reduced blood ingestion and reduced reproduction in H. longicornis adults. Vaccination efficacies of 79.3% and 86.6% are reported in groups supplemented with rRhSub and rRhSub/P0, respectively. Conserved antigens, such as subolesin, formulated as DNA vaccine and enhanced with chimeric polypeptides, could be used as an anti-tick vaccine application, especially for control of infestation involving several tick species. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Hassan, Ibrahim A.; Wang, Yanan; Zhou, Yongzhi; Cao, Jie; Zhang, Houshuang; Zhou, Jinlin] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Key Lab Anim Parasitol, Minist Agr, Shanghai 200241, Peoples R China.
RP Zhou, JL (reprint author), Chinese Acad Agr Sci, Shanghai Vet Res Inst, Key Lab Anim Parasitol, Minist Agr, Shanghai 200241, Peoples R China.
EM jinlinzhou@shvri.ac.cn
FU National Key Research and Development Program of China [2017YFD0501200]
FX This work was supported by a grant (No. 2017YFD0501200) from the
   National Key Research and Development Program of China.
CR Almazan C, 2005, VACCINE, V23, P5294, DOI 10.1016/j.vaccine.2005.08.004
   Almazan C, 2005, VACCINE, V23, P4403, DOI 10.1016/j.vaccine.2005.04.012
   Almazan C, 2010, PARASITOL RES, V106, P471, DOI 10.1007/s00436-009-1689-1
   Artigas-Jeronimo S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00462
   Artigas-Jeronimo S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01612
   Bensaci M, 2012, VACCINE, V30, P6040, DOI 10.1016/j.vaccine.2012.07.053
   Blouin EE, 2008, ANN NY ACAD SCI, V1149, P41, DOI 10.1196/annals.1428.058
   Canales M, 2009, VACCINE, V27, P7244, DOI 10.1016/j.vaccine.2009.09.123
   Carreon D, 2012, VACCINE, V30, P273, DOI 10.1016/j.vaccine.2011.10.099
   Contreras M, 2016, VACCINE, V34, P3010, DOI 10.1016/j.vaccine.2016.04.092
   de la Fuente J, 2000, VET PARASITOL, V92, P209, DOI 10.1016/S0304-4017(00)00308-3
   de la Fuente J, 1999, GENET ANAL-BIOMOL E, V15, P143, DOI 10.1016/S1050-3862(99)00018-2
   de la Fuente J, 2013, TRANSBOUND EMERG DIS, V60, P172, DOI 10.1111/tbed.12146
   De La Fuente J, 2000, ANN NY ACAD SCI, V916, P617
   de la Fuente Jose, 2007, Animal Health Research Reviews, V8, P23
   de la Fuente J, 2006, VACCINE, V24, P4082, DOI 10.1016/j.vaccine.2006.02.046
   de la Fuente J, 2011, VET PARASITOL, V181, P17, DOI 10.1016/j.vetpar.2011.04.018
   de la Fuente J, 2010, VACCINE, V28, P1786, DOI 10.1016/j.vaccine.2009.12.007
   de la Fuente J, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-372
   De Rose R, 1999, VET IMMUNOL IMMUNOP, V71, P151, DOI 10.1016/S0165-2427(99)00038-0
   De Vos S, 2001, EXP APPL ACAROL, V25, P245, DOI 10.1023/A:1010609007009
   Fragoso H, 1998, VACCINE, V16, P1990, DOI 10.1016/S0264-410X(98)00116-9
   Fragoso H, 1995, MICROPLUS CAN
   FUJISAKI K, 1994, PARASITOL TODAY, V10, P31, DOI 10.1016/0169-4758(94)90355-7
   Galindo RC, 2009, DEV COMP IMMUNOL, V33, P612, DOI 10.1016/j.dci.2008.11.002
   George JE, 2004, PARASITOLOGY, V129, pS353, DOI 10.1017/S0031182003004682
   Gong HY, 2008, VET PARASITOL, V151, P268, DOI 10.1016/j.vetpar.2007.11.015
   Goto A, 2008, NAT IMMUNOL, V9, P97, DOI 10.1038/ni1543
   Green MR, 2018, COLD SPRING HARBOR P, V2018
   Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967
   Justice MC, 1999, J BIOL CHEM, V274, P4869, DOI 10.1074/jbc.274.8.4869
   Kusakisako K, 2018, EXP APPL ACAROL, V74, P73, DOI 10.1007/s10493-018-0209-3
   Lew-Tabor AE, 2014, TICKS TICK-BORNE DIS, V5, P500, DOI 10.1016/j.ttbdis.2014.03.005
   Lu PY, 2016, EXP APPL ACAROL, V68, P113, DOI 10.1007/s10493-015-9987-z
   Macqueen DJ, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-34
   Merino O, 2011, VACCINE, V29, P2248, DOI 10.1016/j.vaccine.2011.01.050
   Moreno-Cid JA, 2013, VACCINE, V31, P1187, DOI 10.1016/j.vaccine.2012.12.073
   Mugabi KN, 2010, TROP ANIM HEALTH PRO, V42, P131, DOI 10.1007/s11250-009-9396-6
   Peter RJ, 2005, VET PARASITOL, V132, P205, DOI 10.1016/j.vetpar.2005.07.004
   Popara M, 2013, VACCINE, V31, P4728, DOI 10.1016/j.vaccine.2013.08.031
   RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065
   Rodriguez-Mallon A, 2015, TICKS TICK-BORNE DIS, V6, P530, DOI 10.1016/j.ttbdis.2015.04.007
   Rodriguez-Mallon A, 2012, VACCINE, V30, P1782, DOI 10.1016/j.vaccine.2012.01.011
   Rodriguez-Valle M, 2012, VACCINE, V30, P3453, DOI 10.1016/j.vaccine.2012.03.020
   Ruiz LM, 2007, VET PARASITOL, V144, P138, DOI 10.1016/j.vetpar.2006.09.033
   Shakya M, 2014, VACCINE, V32, P3488, DOI 10.1016/j.vaccine.2014.04.053
   Singh S, 2002, MOL BIOCHEM PARASIT, V119, P121, DOI 10.1016/S0166-6851(01)00394-2
   Sun RX, 2017, TICKS TICK-BORNE DIS, V8, P631, DOI 10.1016/j.ttbdis.2017.04.009
   Torina A, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-10
   Wu XB, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-119
   Yacoub A, 1996, NUCLEIC ACIDS RES, V24, P4298, DOI 10.1093/nar/24.21.4298
   Yi X, 2017, VACCINE, V35, P1227, DOI 10.1016/j.vaccine.2017.01.015
   Yin H, 1997, TROP ANIM HEALTH PRO, V29, p11S, DOI 10.1007/BF02632908
   Zhou JL, 2006, GENE, V372, P191, DOI 10.1016/j.gene.2005.12.020
NR 54
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 907
EP 915
DI 10.1016/j.vaccine.2019.10.076
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200028
PM 31699505
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kim, E
   Won, G
   Lee, JH
AF Kim, Eunha
   Won, Gayeon
   Lee, John Hwa
TI Construction of a novel tetravalent dengue vaccine with a Salmonella
   Typhimurium bacterial ghost and evaluation of its immunogenicity and
   protective efficacy using a murine model
SO VACCINE
LA English
DT Article
DE DENV; Inactivated vaccine; Salmonella delivery vector; EDIII protein
ID HETEROLOGOUS DNA-PRIME; VIRUS-INFECTION; DOMAIN-III; ANTIBODY-RESPONSES;
   SEQUENTIAL IMMUNIZATION; COMMERCIAL VACCINE; ESCHERICHIA-COLI; ENVELOPE
   PROTEIN; DENDRITIC CELLS; T-CELL
AB Efforts to develop a safe, effective, and affordable dengue vaccine have focused on providing simultaneous immunity against all four serotypes of the dengue virus (DENV). In the current study, Salmonella Typhimurium (ST) lysed by gene E activation was genetically constructed to deliver the envelope protein domain III (EDIII) of all four serotypes of DENV using a foreign antigen delivery and expression vector, pJHL184. Each DENV-EDIII protein expressed in the constructed strain was validated by immunoblot analysis. To assess the immunogenicity and protective efficacy of the constructs against dengue infection, BALB/c mice were injected once orally with either the individual ST-EDIII constructs or a mix of all four ST-EDIII constructs followed by intramuscular administration of the purified EDIII protein. Significantly elevated titers of EDIII-specific IgG, IgG1, and IgG2a were observed in the immunized mice (P < 0.01). Furthermore, lymphocyte proliferative activity and CD3(+)CD4(+) T-cell subpopulations increased significantly in vitro in re-pulsed splenic T cells compared with those from non-immunized mice. In addition, a lower viral load was detected in the BG-EDIII vaccinated group after challenge with DENV-infected K562 cells. Collectively, the results demonstrate that DENV-EDIII expressed in the inactivated ST strain could induce robust humoral and cell-mediated immunity specific to the target antigen and could provide significant protective potential. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kim, Eunha; Won, Gayeon; Lee, John Hwa] Jeonbuk Natl Univ, Coll Vet Med, Iksan Campus,Gobong Ro 79, Iksan 54596, South Korea.
RP Lee, JH (reprint author), Jeonbuk Natl Univ, Coll Vet Med, Iksan Campus,Gobong Ro 79, Iksan 54596, South Korea.
EM johnhlee@jbnu.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [2019R1A6A1A03033084]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (2019R1A6A1A03033084).
CR Aguiar M, 2018, LANCET INFECT DIS, V18, P245, DOI 10.1016/S1473-3099(17)30752-1
   Andraud M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049085
   [Anonymous], 2001, IMMUNOBIOLOGY IMMUNE
   Bal J, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-018-0876-0
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Block OKT, 2010, VACCINE, V28, P8085, DOI 10.1016/j.vaccine.2010.10.004
   Chen L, 2007, J VIROL, V81, P11634, DOI 10.1128/JVI.00996-07
   Chiang CY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30648
   Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001
   Epstein JE, 2004, VACCINE, V22, P1592, DOI 10.1016/j.vaccine.2004.01.031
   Ferguson NM, 2016, SCIENCE, V353, P1033, DOI 10.1126/science.aaf9590
   Flipse J, 2016, SCI REP-UK, V6, DOI 10.1038/srep29201
   Gasper DJ, 2014, CRIT REV IMMUNOL, V34, P121, DOI 10.1615/CritRevImmunol.2014010373
   Gibbons RV, 2007, AM J TROP MED HYG, V77, P910, DOI 10.4269/ajtmh.2007.77.910
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Hajam IA, 2017, VET RES, V48, DOI 10.1186/s13567-017-0442-5
   Hajam IA, 2018, VET RES, V49, DOI 10.1186/s13567-018-0593-z
   Hajam IA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144397
   Hajam IA, 2013, VET ITAL, V49, P181, DOI 10.12834/VetIt.2013.492.187.192
   Halstead SB, 2018, HUM VACC IMMUNOTHER, V20181, P5
   Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014
   Haslberger AG, 2000, J BIOTECHNOL, V83, P57, DOI 10.1016/S0168-1656(00)00298-4
   HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990
   HENRICH B, 1982, MOL GEN GENET, V185, P493, DOI 10.1007/BF00334146
   Hung JJ, 2004, J VIROL, V78, P378, DOI 10.1128/JVI.78.1.378-388.2004
   Hur J, 2015, VET IMMUNOL IMMUNOP, V164, P101, DOI 10.1016/j.vetimm.2015.01.010
   Hur J, 2011, CLIN VACCINE IMMUNOL, V18, P203, DOI 10.1128/CVI.00407-10
   Jawale CV, 2014, VACCINE, V32, P5925, DOI 10.1016/j.vaccine.2014.08.072
   Kennedy JS, 2008, VACCINE, V26, P4420, DOI 10.1016/j.vaccine.2008.05.090
   Khetarpal N, 2016, J IMMUNOL RES, DOI 10.1155/2016/6803098
   Kim SH, 2013, INT IMMUNOL, V25, P623, DOI 10.1093/intimm/dxt029
   Kudela P, 2010, VACCINE, V28, P5760, DOI 10.1016/j.vaccine.2010.06.087
   KURANE I, 1990, ARCH VIROL, V110, P91, DOI 10.1007/BF01310705
   Li J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022553
   Liu Y, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.74
   Manoff SB, 2015, VACCINE, V33, P7126, DOI 10.1016/j.vaccine.2015.09.101
   Matsuda K, 2011, AVIAN DIS, V55, P407, DOI 10.1637/9680-020611-Reg.1
   Modis Y, 2005, J VIROL, V79, P1223, DOI 10.1128/JVI.79.2.1223-1231.2005
   Osorio JE, 2015, VACCINE, V33, P7112, DOI 10.1016/j.vaccine.2015.11.022
   Peng SW, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0080-z
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Porter KR, 2015, VACCINE, V33, P7135, DOI 10.1016/j.vaccine.2015.09.102
   Rather IA, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00336
   Rivino L, 2016, EXPERT REV VACCINES, V15, P443, DOI 10.1586/14760584.2016.1116948
   Roehrig JT, 1998, VIROLOGY, V246, P317, DOI 10.1006/viro.1998.9200
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Scharpe J, 2009, AM J KIDNEY DIS, V54, P77, DOI 10.1053/j.ajkd.2008.11.032
   Simmons M, 1998, AM J TROP MED HYG, V58, P655, DOI 10.4269/ajtmh.1998.58.655
   Simmons M, 1998, AM J TROP MED HYG, V58, P144, DOI 10.4269/ajtmh.1998.58.144
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Thullier P, 2001, J GEN VIROL, V82, P1885, DOI 10.1099/0022-1317-82-8-1885
   Tripathi NK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01919
   Wang RB, 2004, J IMMUNOL, V172, P5561, DOI 10.4049/jimmunol.172.9.5561
   Wen J, 2012, VACCINE, V30, P5733, DOI 10.1016/j.vaccine.2012.07.008
   WITTE A, 1990, J BACTERIOL, V172, P4109, DOI 10.1128/jb.172.7.4109-4114.1990
   Won G, 2018, J VET SCI, V19, P536, DOI 10.4142/jvs.2018.19.4.536
   Won G, 2017, SCI REP-UK, V7, DOI 10.1038/srep45139
   Wu KP, 2003, J BIOL CHEM, V278, P46007, DOI 10.1074/jbc.M307776200
   Yamanaka A, 2009, VACCINE, V27, P3735, DOI 10.1016/j.vaccine.2009.03.083
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Zellweger RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003723
   Zhou JY, 2014, BURNS TRAUMA, V2, DOI 10.4103/2321-3868.126088
   Zompi S, 2012, J IMMUNOL, V188, P404, DOI 10.4049/jimmunol.1102124
   Zuest R, 2015, VACCINE, V33, P1474, DOI 10.1016/j.vaccine.2015.01.074
NR 67
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 916
EP 924
DI 10.1016/j.vaccine.2019.10.075
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200029
PM 31706812
DA 2020-05-12
ER

PT J
AU Yu, QZ
   Li, YF
   Dimitrov, K
   Afonso, CL
   Spatz, S
   Zsak, L
AF Yu, Qingzhong
   Li, Yufeng
   Dimitrov, Kiril
   Afonso, Claudio L.
   Spatz, Stephen
   Zsak, Laszlo
TI Genetic stability of a Newcastle disease virus vectored infectious
   laryngotracheitis virus vaccine after serial passages in chicken embryos
SO VACCINE
LA English
DT Article
DE NDV vector; ILTV-gD; Recombinant vaccine; Genetic stability;
   Next-generation sequencing
ID VIRULENCE; STRAIN; REPLICATION; PROTEINS; SEQUENCE; MUTATION; RATES;
   CDNA; RULE; GD
AB Previously, we have demonstrated that the recombinant Newcastle disease virus (NDV) expressing the infectious laryngotracheitis virus (ILTV) glycoprotein D (gD) conferred protection against both virulent NDV and ILTV challenges in chickens. In this study, we evaluated the genetic stability of the recombinant vaccine after eight serial passages in embryonated chicken eggs (ECE). The vaccine master seed virus at the original egg-passage level 3 (EP3) was diluted and passaged in three separate repetitions (A, B and C) in ECE eight times (EP4 to EP11). RT-PCR analysis of the vaccine seed and egg-passaged virus stocks showed that there was no detectable insertion/deletion in the ILTV gD insert region. Next-generation sequencing analysis of the EP3 and EP11 virus stocks confirmed their genome integrity and revealed a total of thirteen single-nucleotide polymorphisms (SNPs). However, none of these SNPs were located in the ILTV gD insert or any of the known critical biological determinant positions. Virological and immunofluorescent assays provided additional evidence that the EP11 virus stocks retained their growth kinetics, low pathogenicity, and robust level of gD expression comparable to that of the vaccine master seed virus. This indicated that the SNPs were non-detrimental sporadic mutations. These results demonstrated that the insertion of ILTV gD gene into the NDV LaSota backbone did not significantly affect the genetic stability of the recombinant virus and that the rLS/ILTV-gD virus is a safe and genetically stable vaccine candidate after at least eight serial passages in ECE. Published by Elsevier Ltd.
C1 [Yu, Qingzhong; Li, Yufeng; Dimitrov, Kiril; Afonso, Claudio L.; Spatz, Stephen; Zsak, Laszlo] ARS, Southeast Poultry Res Lab, US Natl Poultry Res Ctr, USDA, 934 Coll Stn Rd, Athens, GA 30605 USA.
   [Li, Yufeng] Shandong Poultry Res Inst, Jinan 250023, Shandong, Peoples R China.
   [Dimitrov, Kiril] Texas A&M Vet Med Diagnost Lab, Amarillo, TX USA.
RP Yu, QZ (reprint author), ARS, Southeast Poultry Res Lab, US Natl Poultry Res Ctr, USDA, 934 Coll Stn Rd, Athens, GA 30605 USA.
EM qingzhong.yu@ars.usda.gov
OI Afonso, Claudio/0000-0001-5699-4743; Yu, Qingzhong/0000-0003-0386-793X
FU USDA, ARS projects [6040-32000-073-00D, 6040-32000-074-00D]
FX The authors wish to thank Xiuqin Xia, Fenglan Li and Dawn
   Williams-Coplin for excellent technical assistance, Jesse Gallagher for
   MiSeq next-generation sequencing, and Ron lorio for a gift of anti-NDV
   HN monoclonal antibody. This research was supported by USDA, ARS
   projects 6040-32000-073-00D and 6040-32000-074-00D. Mention of trade
   names or commercial products in this publication is solely to provide
   specific information and does not imply recommendation or endorsement by
   the U.S. Department of Agriculture.
CR Afonso CL, 2008, J VIROL, V82, P9303, DOI 10.1128/JVI.01231-08
   Alexander DJ, 1998, LAB MANUAL ISOLATION, P156
   Ayala AJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162484
   Barr J, 2010, J GEN VIROL, V91, P1373, DOI 10.1099/vir.0.020818-0
   Bello MB, 2018, BIOMED RES INT, DOI 10.1155/2018/7278459
   CALAIN P, 1993, J VIROL, V67, P4822, DOI 10.1128/JVI.67.8.4822-4830.1993
   Collins PL, 2013, CURR TOP MICROBIOL, V372, P3, DOI 10.1007/978-3-642-38919-1_1
   Coppo MJC, 2013, AVIAN PATHOL, V42, P195, DOI 10.1080/03079457.2013.800634
   Crotty S, 2002, MICROBES INFECT, V4, P1301, DOI 10.1016/S1286-4579(02)00008-4
   de Leeuw O, 1999, J GEN VIROL, V80, P131, DOI 10.1099/0022-1317-80-1-131
   Dimitrov KM, 2017, VET MICROBIOL, V206, P126, DOI 10.1016/j.vetmic.2016.12.019
   Dimitrov KM, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0741-5
   DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171
   Fuchs W, 2007, VET RES, V38, P261, DOI 10.1051/vetres:200657
   GARCIA OG, 2013, DIS POULTRY, P161
   GELENCZEI EF, 1965, AVIAN DIS, V9, P44, DOI 10.2307/1587792
   Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86
   GOLDHAFT TM, 1980, AVIAN DIS, V24, P297, DOI 10.2307/1589696
   GUY JS, 1990, AVIAN DIS, V34, P106, DOI 10.2307/1591340
   GUY JS, 1991, AVIAN DIS, V35, P348, DOI 10.2307/1591188
   Hu HX, 2011, VACCINE, V29, P8624, DOI 10.1016/j.vaccine.2011.09.007
   HUGHES CS, 1991, ARCH VIROL, V121, P213, DOI 10.1007/BF01316755
   HUGHES CS, 1989, RES VET SCI, V46, P274, DOI 10.1016/S0034-5288(18)31158-5
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kolakofsky D, 2005, J GEN VIROL, V86, P1869, DOI 10.1099/vir.0.80986-0
   KOTIW M, 1995, VET MICROBIOL, V45, P71, DOI 10.1016/0378-1135(94)00115-D
   Lamb RA, 2013, FIELDS VIROLOGY, V1, P957
   Lee SW, 2012, SCIENCE, V337, P188, DOI 10.1126/science.1217134
   Menendez KR, 2014, AVIAN PATHOL
   Meng CC, 2016, J VIROL, V90, P2052, DOI 10.1128/JVI.01801-15
   Meulemans G., 1988, Newcastle disease., P318
   Miller PJ, 2013, DIS POULTRY, P98
   Ortin J, 2015, VIROLOGY, V479, P532, DOI 10.1016/j.virol.2015.03.018
   Pavlova S, 2013, AVIAN DIS, V57, P416, DOI 10.1637/10332-082612-Reg.1
   Peeters BPH, 1999, J VIROL, V73, P5001, DOI 10.1128/JVI.73.6.5001-5009.1999
   Phan SI, 2017, J VIROL, V91, DOI 10.1128/JVI.00559-17
   Samal SK, 2011, BIOLOGY OF PARAMYXOVIRUSES, P69
   SAMBERG Y, 1969, Refuah Veterinarith, V26, P54
   Yu QZ, 2017, VACCINE, V35, P789, DOI 10.1016/j.vaccine.2016.12.038
   YU QZ, 1995, J VIROL, V69, P2412, DOI 10.1128/JVI.69.4.2412-2419.1995
   Zhao W, 2014, J VIROL, V88, P8397, DOI 10.1128/JVI.01321-14
NR 41
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 925
EP 932
DI 10.1016/j.vaccine.2019.10.074
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200030
PM 31703935
DA 2020-05-12
ER

PT J
AU Zhang, LJ
   Sun, MX
   Zhang, QS
   Wang, J
   Cao, YX
   Cui, SJ
   Su, JL
AF Zhang, Lijiao
   Sun, Mengxu
   Zhang, Qingshui
   Wang, Jun
   Cao, Yanxin
   Cui, Shangjin
   Su, Jingliang
TI Long-term passage of duck Tembusu virus in BHK-21 cells generates a
   completely attenuated and immunogenic population with increased genetic
   diversity
SO VACCINE
LA English
DT Article
DE Tembusu virus; Duck; Live-attenuated vaccine; Serial passage; Virus
   diversity (quasi-species); Flavivirus
ID WEST-NILE-VIRUS; VACCINE CANDIDATE; ENTERITIS VIRUS; SERIAL PASSAGE;
   ADAPTATION; FLAVIVIRUSES; ENCEPHALITIS; EFFICACY; STRAIN; DETERMINANTS
AB Duck Tembusu virus (TMUV) is an emerging pathogenic flavivirus that causes severe egg-drop and fatal encephalitis in domestic ducks and geese. Although a live-attenuated virus vaccine is effective for disease control, the stability of the attenuation has not been clearly evaluated due to a poor understanding of the attenuation mechanism. Here, a virulent duck TMUV isolate was successively passaged in BHK-21 cells, leading to an approximately 100-fold increase of virus production in cell culture and a complete attenuation of virulence for ducks. The passaged virus induced high titers of TMUV-specific antibody and provided efficient protection against a virulent TMUV challenge after a single-dose vaccination. One hundred and two, and eighteen single-nucleotide polymorphisms (SNPs) at a frequency of >1% were respectively identified in the attenuated virus population and the original isolate by deep sequencing. The increased SNPs numbers suggested that the accumulated variants of virus population may have conferred the phenotypic changes. We cloned and characterized a dominant variant exhibiting similar fitness to the mixed population, and 23 amino acid substitutions were identified across the viral open reading frame. Using reverse genetics, two chimeric viruses were generated by introducing the mutated E or NS5 gene into the backbone of virulent TMUV. We found that mutations in the E gene conferred a fitness advantage in BHK-21 cells and decreased the virus pathogenicity, whereas NS5 mutations reduced the virus infectivity in ducklings without altering the in vitro fitness. In conclusion, increased mutations in a virulent TMUV strain did substantially reduce the virus virulence, and mutations in multiple genes co-contribute to TMUV attenuation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Lijiao; Sun, Mengxu; Zhang, Qingshui; Wang, Jun; Cao, Yanxin; Su, Jingliang] China Agr Univ, Coll Vet Med, Key Lab Anim Epidemiol & Zoonosis, Minist Agr, Beijing 100193, Peoples R China.
   [Zhang, Lijiao] Jiangsu Acad Agr Sci, Inst Vet Med, Nanjing 210014, Peoples R China.
   [Cui, Shangjin] Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China.
   [Cui, Shangjin] Minist Agr, Beijing Observat Stn Vet Biol Tech, Beijing 100193, Peoples R China.
RP Cui, SJ (reprint author), Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China.; Su, JL (reprint author), China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.
EM cuishangjin@126.com; suzhang@cau.edu.cn
OI Sun, MengXu/0000-0003-4181-9058
FU China Ministry of Science and Technology National Key RD Program
   [2016YFD0500106]; Natural Science Foundation of China (NSFC)National
   Natural Science Foundation of China [31672567, 31802200]
FX This study was supported by grants from the China Ministry of Science
   and Technology National Key R&D Program (Grant No. 2016YFD0500106) and
   the Natural Science Foundation of China (NSFC Grant No. 31672567 and
   31802200). We thank Katie Oakley, PhD, from Liwen Bianji, Edanz Editing
   China (www.liwenbianji.cn/ac), for editing the English text of a draft
   of this manuscript.
CR Beck A, 2014, J INFECT DIS, V209, P334, DOI 10.1093/infdis/jit546
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Borderia AV, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004838
   Chen PC, 2014, VACCINE, V32, P5271, DOI 10.1016/j.vaccine.2014.07.082
   Ciota AT, 2007, J GEN VIROL, V88, P2398, DOI 10.1099/vir.0.83061-0
   Ciota AT, 2007, J GEN VIROL, V88, P865, DOI 10.1099/vir.0.82606-0
   Ciota AT, 2007, VIROLOGY, V357, P165, DOI 10.1016/j.virol.2006.08.005
   Domingo E, 2012, MICROBIOL MOL BIOL R, V76, P159, DOI 10.1128/MMBR.05023-11
   Gromowski GD, 2015, J VIROL, V89, P6328, DOI 10.1128/JVI.00219-15
   Hanley Kathryn A, 2011, Evolution (N Y), V4, P635
   Ivancic-Jelecki J, 2016, VACCINE, V34, P2383, DOI 10.1016/j.vaccine.2016.03.033
   Jerzak G, 2005, J GEN VIROL, V86, P2175, DOI 10.1099/vir.0.81015-0
   Kautz TF, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110600
   Kautz TF, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey004
   Khou C, 2017, INTERVIROLOGY, V60, P8, DOI 10.1159/000479966
   Kono Y, 2000, AM J TROP MED HYG, V63, P94, DOI 10.4269/ajtmh.2000.63.94
   Lauring AS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001005
   Lei WW, 2017, VET MICROBIOL, V201, P32, DOI 10.1016/j.vetmic.2017.01.003
   Li GX, 2014, VIROLOGY, V450, P233, DOI 10.1016/j.virol.2013.12.028
   Li XS, 2015, J CLIN MICROBIOL, V53, P2734, DOI 10.1128/JCM.00770-15
   Lin J, 2015, AVIAN DIS, V59, P244, DOI 10.1637/10960-101514-Reg
   Lindenbach BD, 2013, FLAVIVIRIDAE FIELDS
   Liu FX, 2016, COMP IMMUNOL MICROB, V47, P7, DOI 10.1016/j.cimid.2016.05.007
   Liu PP, 2012, J GEN VIROL, V93, P2158, DOI 10.1099/vir.0.043554-0
   Mackenzie JS, 2009, ZOONOSES PUBLIC HLTH, V56, P338, DOI 10.1111/j.1863-2378.2008.01208.x
   Maeda J, 2008, J VIROL METHODS, V148, P244, DOI 10.1016/j.jviromet.2007.12.005
   Monath TP, 2005, EXPERT REV VACCINES, V4, P553, DOI 10.1586/14760584.4.4.553
   Moratorio G, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.88
   Ninvilai P, 2018, TRANSBOUND EMERG DIS, V65, P1208, DOI 10.1111/tbed.12859
   O'Guinn ML, 2013, AM J TROP MED HYG, V89, P1023, DOI 10.4269/ajtmh.13-0160
   Pugachev KV, 2002, VACCINE, V20, P996, DOI 10.1016/S0264-410X(01)00439-X
   Sanz-Ramos M, 2008, J VIROL, V82, P10465, DOI 10.1128/JVI.00825-08
   Sanz-Ramos M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039941
   Sauder CJ, 2006, VIROLOGY, V350, P48, DOI 10.1016/j.virol.2006.01.035
   Seligman SJ, 2008, J INFECT DIS, V198, P794, DOI 10.1086/590915
   Su JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018106
   Sun L, 2014, CLIN VACCINE IMMUNOL, V21, P1046, DOI 10.1128/CVI.00154-14
   Sun MH, 2018, VET MICROBIOL, V218, P60, DOI 10.1016/j.vetmic.2018.03.027
   Thontiravong A, 2015, EMERG INFECT DIS, V21, P2164, DOI 10.3201/eid2112.150600
   Vignuzzi M, 2006, NATURE, V439, P344, DOI 10.1038/nature04388
   Yan DW, 2018, J VIROL, V92, DOI [10.1128/JVI.00427-18, 10.1128/jvi.00427-18]
   Yu YX, 2010, VACCINE, V28, P3635, DOI 10.1016/j.vaccine.2010.02.105
   Yuste E, 1999, J VIROL, V73, P2745, DOI 10.1128/JVI.73.4.2745-2751.1999
   Zhang LJ, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1537-6
   Zhang LJ, 2017, RES VET SCI, V110, P72, DOI 10.1016/j.rvsc.2016.11.002
   Zhang QS, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0074-5
   Zhao YQ, 2015, P NATL ACAD SCI USA, V112, P14834, DOI 10.1073/pnas.1514978112
   Zou Z, 2014, VIRUSES-BASEL, V6, P2428, DOI 10.3390/v6062428
NR 48
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 933
EP 941
DI 10.1016/j.vaccine.2019.10.080
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200031
PM 31708180
DA 2020-05-12
ER

PT J
AU Federizon, J
   Frye, A
   Huang, WC
   Hart, TM
   He, XD
   Beltran, C
   Marcinkiewicz, AL
   Mainprize, IL
   Wills, MKB
   Lin, YP
   Lovell, JF
AF Federizon, Jasmin
   Frye, Amber
   Huang, Wei-Chiao
   Hart, Thomas M.
   He, Xuedan
   Beltran, Christopher
   Marcinkiewicz, Ashley L.
   Mainprize, Iain L.
   Wills, Melanie K. B.
   Lin, Yi-Pin
   Lovell, Jonathan F.
TI Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt
   porphyrin-phospholipid liposomes
SO VACCINE
LA English
DT Article
DE Liposomes; Adjuvant; Particle vaccine; Lyme disease; OspA
ID OUTER SURFACE PROTEIN; BORRELIA-BURGDORFERI; VACCINE; IDENTIFICATION;
   ANTIBODY; PROTECTION; EFFICACY; BINDING; EPITOPE
AB Outer surface protein A (OspA) is a Borrelia lipoprotein and an established Lyme disease vaccine target. Admixing non-lipidated, recombinant B. burgdorferi OspA with liposomes containing cobalt porphyrin-phospholipid (CoPoP) resulted in rapid, particulate surface display of the conformationally intact antigen. Particleization was serum-stable and led to enhanced antigen uptake in murine macrophages in vitro. Mouse immunization using CoPoP liposomes that also contained a synthetic monophosphoryl lipid A (PHAD) elicited a Th1-biased OspA antibody response with higher IgG production compared to other vaccine adjuvants. Antibodies were reactive with intact B. burgdorferi spirochetes and Borrelia lysates, and induced complement-mediated borreliacidal activity in vitro. One year after initial immunization, mice maintained high levels of circulating borreliacidal antibodies capable of blocking B. burgdorferi transmission from infected ticks to human blood in a feeding chamber. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Federizon, Jasmin; Huang, Wei-Chiao; He, Xuedan; Lovell, Jonathan F.] SUNY Buffalo, Dept Biomed Engn, Buffalo, NY 14260 USA.
   [Frye, Amber; Hart, Thomas M.; Beltran, Christopher; Marcinkiewicz, Ashley L.; Lin, Yi-Pin] New York State Dept Hlth, Wadsworth Ctr, Div Infect Dis, Albany, NY 12208 USA.
   [Frye, Amber; Lin, Yi-Pin] SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA.
   [Hart, Thomas M.] SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA.
   [Mainprize, Iain L.; Wills, Melanie K. B.] Univ Guelph, Dept Mol & Cellular Biol, G Magnotta Lyme Dis Res Lab, Guelph, ON N1G 2W1, Canada.
RP Lovell, JF (reprint author), SUNY Buffalo, Dept Biomed Engn, Buffalo, NY 14260 USA.
EM jflovell@buffalo.edu
OI Wills, Melanie/0000-0002-7448-8657; Mainprize, Iain/0000-0002-8872-5350
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R21AI122964,
   DP50D017898]; National Science FoundationNational Science Foundation
   (NSF) [1555220, IOS1755286, DBI1757170]; Department of DefenseUnited
   States Department of Defense [TB170111]; New York State Department of
   Health - Wadsworth Center Start-Up Grant
FX We thank Vladimir V. Bamm for lysate of E. coli expressing recombinant
   OspA protein. This work was supported by the National Institutes of
   Health (R21AI122964 and DP50D017898; JFL), the National Science
   Foundation (1555220; JFL, IOS1755286; YL and DBI1757170; CB), the
   Department of Defense (TB170111; YL) and the New York State Department
   of Health - Wadsworth Center Start-Up Grant (YL).
CR ALVING CR, 1991, J IMMUNOL METHODS, V140, P1, DOI 10.1016/0022-1759(91)90120-5
   Andrade JJ, 2014, J MED ENTOMOL, V51, P878, DOI 10.1603/ME13180
   Ball EC, 2015, VANGUARD CRLYME CHIM
   Beermann C, 2000, CELL IMMUNOL, V201, P124, DOI 10.1006/cimm.2000.1640
   CHU HJ, 1992, J AM VET MED ASSOC, V201, P403
   Comstedt P, 2015, VACCINE, V33, P5982, DOI 10.1016/j.vaccine.2015.07.095
   Comstedt P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184357
   Comstedt P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113294
   Conlon J A, 2000, Vet Ther, V1, P96
   de Silva AM, 1999, INFECT IMMUN, V67, P30, DOI 10.1128/IAI.67.1.30-35.1999
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   deSilva AM, 1996, J EXP MED, V183, P271, DOI 10.1084/jem.183.1.271
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Ding W, 2000, J MOL BIOL, V302, P1153, DOI 10.1006/jmbi.2000.4119
   Dumic I, 2018, CAN J INFECT DIS MED, V2018, P10
   Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M
   Elias AF, 2002, INFECT IMMUN, V70, P2139, DOI 10.1128/IAI.70.4.2139-2150.2002
   ERDILE LF, 1993, INFECT IMMUN, V61, P81, DOI 10.1128/IAI.61.1.81-90.1993
   Federizon J, 2019, BIOCONJUGATE CHEM, V30, P1259, DOI 10.1021/acs.bioconjchem.9b00167
   FIKRIG E, 1992, P NATL ACAD SCI USA, V89, P5418, DOI 10.1073/pnas.89.12.5418
   FRANCE LL, 1992, BIOCHIM BIOPHYS ACTA, V1120, P59, DOI 10.1016/0167-4838(92)90424-C
   Hart T, 2018, TICKS TICK-BORNE DIS, V9, P1057, DOI 10.1016/j.ttbdis.2018.03.033
   Huang WC, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201800011
   Huang WC, 2018, NAT NANOTECHNOL, V13, P1174, DOI 10.1038/s41565-018-0271-3
   Huang XL, 1998, J MOL BIOL, V281, P61, DOI 10.1006/jmbi.1998.1930
   Izac JR, 2017, VACCINE, V35, P3178, DOI 10.1016/j.vaccine.2017.04.079
   JIANG W, 1994, CLIN DIAGN LAB IMMUN, V1, P406, DOI 10.1128/CDLI.1.4.406-412.1994
   JOHNSON RC, 1984, INT J SYST BACTERIOL, V34, P496, DOI 10.1099/00207713-34-4-496
   Koide S, 2005, J MOL BIOL, V350, P290, DOI 10.1016/j.jmb.2005.04.066
   Krober T, 2007, PEST MANAG SCI, V63, P17, DOI 10.1002/ps.1293
   Krupka M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148497
   Krupka M, 2012, J CONTROL RELEASE, V160, P374, DOI 10.1016/j.jconrel.2012.02.017
   LaFleur RL, 2009, CLIN VACCINE IMMUNOL, V16, P253, DOI 10.1128/CVI.00373-08
   Levy SA, 2010, INT J APPL RES VET M, V8, P123
   Levy Steven A, 2002, Vet Ther, V3, P420
   Lindgren E, 2006, STUD WRIT, V18, P157
   MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4
   Marcinkiewicz AL, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.12998
   Nigrovic LE, 2007, EPIDEMIOL INFECT, V135, P1, DOI 10.1017/S0950268806007096
   Pal U, 2004, CELL, V119, P457, DOI 10.1016/j.cell.2004.10.027
   Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036
   Ramirez-Sierra MJ, 2016, J MED ENTOMOL, V53, P20, DOI 10.1093/jme/tjv157
   SCHAIBLE UE, 1990, P NATL ACAD SCI USA, V87, P3768, DOI 10.1073/pnas.87.10.3768
   Shao S, 2015, NAT CHEM, V7, P438, DOI [10.1038/nchem.2236, 10.1038/NCHEM.2236]
   Steere AC, 2006, J EXP MED, V203, P961, DOI 10.1084/jem.20052471
   STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301
   Steere AC, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.90
   TURANEK J, 2014, MOL VACCINES PROPHYL, V2, P561
   Walker A, 2011, SCI REP-UK, V1, DOI 10.1038/srep00005
   WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994
   Willett TA, 2004, P NATL ACAD SCI USA, V101, P1303, DOI 10.1073/pnas.0305680101
NR 51
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 22
PY 2020
VL 38
IS 4
BP 942
EP 950
DI 10.1016/j.vaccine.2019.10.073
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM2YH
UT WOS:000513988200032
PM 31727504
DA 2020-05-12
ER

PT J
AU Constable, C
   Caplan, A
AF Constable, Catherine
   Caplan, Arthur
TI Comparison of the implementation of human papillomavirus and hepatitis B
   vaccination programs in the United States: Implications for future
   vaccines
SO VACCINE
LA English
DT Review
DE Human papillomavirus vaccine; HPV vaccine; Hepatitis B vaccine; HBV
   vaccine; Vaccine hesitancy; Vaccine uptake; Immunization
ID SCHOOL-LOCATED VACCINATION; AGED 13-17 YEARS; HPV VACCINE; IMMUNIZATION
   COVERAGE; MANDATORY IMMUNIZATION; CERVICAL-CANCER; VIRUS VACCINE; NEWS
   COVERAGE; ADOLESCENTS; RISK
AB Vaccines for two viruses which cause cancer, human papillomavirus (HPV) and hepatitis B virus (HBV), are recommended for all children in the United States. Numerous parallels exist between the two vaccines in addition to their roles in cancer prevention, including transmission through sexual contact, multiple doses needed for series completion, and vaccine administration in adolescence for HPV and in the initial phase of the HBV vaccination program. All of these factors were viewed as potential barriers to achieving high rates of coverage, yet the ultimate success of the HBV vaccination program led to predictions that similarly high rates of coverage could be achieved for the HPV vaccine. However, currently, only the recommendation for HBV vaccination is supported by mandates for school entry in most states. Uptake of the HPV vaccine has lagged far behind U.S. goals for public health promotion. The aim of this paper is to examine factors which may account for the divergent pathways of the two vaccines. Four main factors are identified: logistical challenges of vaccine administration, attitudes of parents and healthcare providers, safety concerns, and cost. For each factor examined, recommendations are offered to confront similar barriers likely to arise for future vaccines. The authors conclude that gender-neutral state mandates coupled with school-located vaccination programs, stronger gender-neutral messaging from pharmaceutical companies and healthcare providers, and younger age of vaccine administration, if approved, present the most promising approaches to improving uptake of the HPV vaccine, and similar vaccines down the road. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Constable, Catherine] NYU, Dept Med, Sch Med, New York, NY 10016 USA.
   [Constable, Catherine; Caplan, Arthur] NYU, Dept Populat Hlth, Sch Med, Div Eth, New York, NY 10016 USA.
RP Constable, C (reprint author), NYU, Langone Med Ctr, Internal Med, Room 1803,550 First Ave, New York, NY 10016 USA.
EM catherine.constable@nyumc.org
OI Caplan, Art/0000-0002-4061-8011
CR Adolescent Health Services, ADOLESCENT HLTH SERV
   ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218
   Ananian Arbi, 2006, N Y State Dent J, V72, P14
   [Anonymous], 1996, MMWR Recomm Rep, V45, P1
   [Anonymous], IMM INF DIS
   [Anonymous], 2019, HUM PAP HPV 5 WAYS B
   [Anonymous], 2007, MED NEWS TODAY
   [Anonymous], PRES CANC PAN ANN RE
   [Anonymous], VACC CHILDR PROGR CD
   [Anonymous], PHYS SCRIPT HPV VACC
   Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3
   Arnheim-Dahlstom L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5906
   Averhoff F, 2004, AM J PUBLIC HEALTH, V94, P978, DOI 10.2105/AJPH.94.6.978
   Bach PB, 2010, LANCET, V375, P963, DOI 10.1016/S0140-6736(09)62029-8
   Barnighausen T, 2012, CLIN MICROBIOL INFEC, V18, P70, DOI 10.1111/j.1469-0691.2012.03977.x
   Balinska MA, 2009, J CLIN VIROL, V46, P202, DOI 10.1016/j.jcv.2009.07.024
   Barraza L, 2016, PUBLIC HEALTH REP, V131, P728, DOI 10.1177/0033354916663184
   Baumgaertner B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191728
   Beavis A, 2018, J ADOLESCENT HEALTH, V63, P652, DOI 10.1016/j.jadohealth.2018.06.024
   Bednarczyk RA, 2012, PEDIATRICS, V130, P798, DOI 10.1542/peds.2012-1516
   Bingham A, 2009, ARCH PEDIAT ADOL MED, V163, P455, DOI 10.1001/archpediatrics.2009.50
   Brewer NT, 2007, PREV MED, V45, P107, DOI 10.1016/j.ypmed.2007.05.013
   Briss PA, 2005, GUIDE COMMUNITY PREV, P223
   Buller DB, 2019, HUM VACC IMMUNOTHER, V15, P1479, DOI 10.1080/21645515.2019.1581555
   Cameron JC, 2007, J EPIDEMIOL COMMUN H, V61, P1018, DOI 10.1136/jech.2007.059832
   Canfell K, 2012, VACCINE, V30, pF157, DOI 10.1016/j.vaccine.2012.06.091
   Casciotti DM, 2014, J SCHOOL HEALTH, V84, P71, DOI 10.1111/josh.12126
   Casper MJ, 2008, SOCIOL HEALTH ILL, V30, P886, DOI 10.1111/j.1467-9566.2008.01100.x
   Centers for Disease C. Prevention, 2013, MMWR-MORBID MORTAL W, V62, P685
   Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870
   Colafrancesco S, 2013, AM J REPROD IMMUNOL, V70, P309, DOI 10.1111/aji.12151
   Colgrove J, 2010, NEW ENGL J MED, V363, P785, DOI 10.1056/NEJMsr1003547
   Constantine NA, 2007, J ADOLESCENT HEALTH, V40, P108, DOI 10.1016/j.jadohealth.2006.10.007
   Cooper GS, 2003, AUTOIMMUN REV, V2, P119, DOI 10.1016/S1568-9972(03)00006-5
   Crawford M, 2003, J SEX RES, V40, P13, DOI 10.1080/00224490309552163
   Daley EM, 2017, PAPILLOMAVIRUS RES, V3, P142, DOI 10.1016/j.pvr.2017.04.004
   Dekker Rebecca L, 2008, Policy Polit Nurs Pract, V9, P40, DOI 10.1177/1527154408317851
   Dempsey AF, 2018, ACAD PEDIATR, V18, pS23, DOI 10.1016/j.acap.2017.09.001
   Dempsey AF, 2010, PEDIATRICS, V125, P43, DOI 10.1542/peds.2009-1044
   Denis F, 2013, MED MALADIES INFECT, V43, P272, DOI 10.1016/j.medmal.2013.06.016
   DeStefano F, 2019, CLIN INFECT DIS
   Dickerson JB, 2011, HUM VACCINES, V7, P211, DOI 10.4161/hv.7.2.13633
   Doan AE, 2013, POLICY STUD J, V41, P295, DOI 10.1111/psj.12018
   Dominiak-Felden G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132404
   Donken R, 2018, CAN FAM PHYSICIAN, V64, P509
   Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3
   Dunn AG, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4343
   Faber MT, 2019, VACCINE, V37, P265, DOI 10.1016/j.vaccine.2018.11.030
   Fairley CK, 2009, SEX TRANSM INFECT, V85, P499, DOI 10.1136/sti.2009.037788
   Fleming WS, 2018, J COMMUN HEALTH, V43, P448, DOI 10.1007/s10900-017-0457-x
   Fogarty KJ, 2004, PUBLIC HEALTH REP, V119, P163, DOI 10.1177/003335490411900209
   Food and Drug Administration, 2014, GARD 9 HUM PAP 9 VAL
   Forster A, 2010, J HEALTH COMMUN, V15, P205, DOI 10.1080/10810730903528066
   Global Observatory on Health R&D, HLTH PROD PIP INF DI
   Gollust SE, 2016, HUM VACC IMMUNOTHER, V12, P1430, DOI 10.1080/21645515.2015.1109169
   Grimaldi-Bensouda L, 2014, J INTERN MED, V275, P398, DOI 10.1111/joim.12155
   Grimaldi-Bensouda L, 2017, J AUTOIMMUN, V79, P84, DOI 10.1016/j.jaut.2017.01.005
   Harris PA, 1997, J SCHOOL HEALTH, V67, P273, DOI 10.1111/j.1746-1561.1997.tb03448.x
   Heffernan ME, 2010, SEX HEALTH, V7, P383, DOI 10.1071/SH09134
   Hirth J, 2018, VACCINE, V36, P7682, DOI 10.1016/j.vaccine.2018.10.075
   Horlick G, 2008, PEDIATRICS, V121, pS79, DOI 10.1542/peds.2007-1115I
   Hurley LP, 2016, PUBLIC HEALTH REP, V131, P320, DOI 10.1177/003335491613100216
   Kahan DM, 2010, LAW HUMAN BEHAV, V34, P501, DOI 10.1007/s10979-009-9201-0
   Keith Wailoo, 2010, 3 SHOTS PREVENTION H
   Kempe A, 2018, ACAD PEDIATR, V18, pS101, DOI 10.1016/j.acap.2017.08.010
   Kim WR, 2009, HEPATOLOGY, V49, pS28, DOI 10.1002/hep.22975
   Kolaczinski JH, 2004, FOOD CHEM TOXICOL, V42, P697, DOI 10.1016/j.fct.2003.12.008
   Kostaras D, 2019, EXPERT REV PHARM OUT, V19, P147, DOI 10.1080/14737167.2019.1555039
   Krakow M, 2016, HEALTH COMMUN, V31, P1081, DOI 10.1080/10410236.2015.1038773
   Kulczycki A, 2016, MATERN CHILD HLTH J, V20, P2539, DOI 10.1007/s10995-016-2079-9
   Landy R, 2018, INT J CANCER, V142, P709, DOI 10.1002/ijc.31094
   Lantos JD, 2010, CURR PROB PEDIATR AD, V40, P38, DOI 10.1016/j.cppeds.2010.01.003
   Larson HJ, 2014, HUM VACC IMMUNOTHER, V10, P2543, DOI 10.4161/21645515.2014.969618
   Leidner AJ, 2019, VACCINE, V37, P226, DOI 10.1016/j.vaccine.2018.11.056
   Limper HM, 2014, PEDIATRICS, V134, P803, DOI 10.1542/peds.2014-1339
   Lindley MC, 2008, PEDIATRICS, V121, pS46, DOI 10.1542/peds.2007-1115F
   Little DT, 2012, BMJ CASE REP, V2012
   Luna J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083431
   McKee M, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2144
   McKie R., 2017, GUARDIAN
   MEHEUS A, 1995, VACCINE, V13, pS31
   Mello MM, 2012, AM J PUBLIC HEALTH, V102, P893, DOI 10.2105/AJPH.2011.300576
   Middleman AB, 2006, J ADOLESCENT HEALTH, V38, P321, DOI 10.1016/j.jadohealth.2006.01.002
   Morita JY, 2008, PEDIATRICS, V121, pE547, DOI 10.1542/peds.2007-0799
   Naleway AL, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0943
   Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477
   Ortega-Sanchez IR, 2008, PEDIATRICS, V121, pS63, DOI 10.1542/peds.2007-1115H
   Pedersen K, 2018, EUR J CANCER, V91, P68, DOI 10.1016/j.ejca.2017.12.018
   Perman S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4168-0
   Robbins SCC, 2011, VACCINE, V29, P9588, DOI 10.1016/j.vaccine.2011.10.033
   Rossi C, 2018, Rev Med Brux, V39, P352
   Salathe M, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002199
   Scheller NM, 2015, JAMA-J AM MED ASSOC, V313, P54, DOI 10.1001/jama.2014.16946
   Schwartz JL, 2007, CLIN PHARMACOL THER, V82, P760, DOI 10.1038/sj.clpt.6100397
   Schwartz JL, 2015, JAMA-J AM MED ASSOC, V314, P185, DOI 10.1001/jama.2015.6041
   Senkomago V, 2019, MMWR-MORBID MORTAL W, V68, P724, DOI 10.15585/mmwr.mm6833a3
   Shah PD, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1872
   Shelton RC, 2013, J RELIG HEALTH, V52, P1120, DOI 10.1007/s10943-011-9553-x
   Siegrist CA, 2007, PEDIATR INFECT DIS J, V26, P979, DOI 10.1097/INF.0b013e318149dfea
   Spencer JC, 2019, PREV MED, V123, P197, DOI 10.1016/j.ypmed.2019.03.037
   Stokley S, 2014, MMWR-MORBID MORTAL W, V63, P620
   Stratton K, 2002, IMMUNIZATION SAFETY
   Sturm L, 2017, J ADOLESCENT HEALTH, V61, P246, DOI 10.1016/j.jadohealth.2017.02.006
   Taylor JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115154
   Tung CS, 2005, J ADOLESCENT HEALTH, V37, P61, DOI 10.1016/j.jadohealth.2004.07.019
   Vadaparampil ST, 2011, VACCINE, V29, P8634, DOI 10.1016/j.vaccine.2011.09.006
   Van Dyne EA, 2018, MMWR-MORBID MORTAL W, V67, P918, DOI 10.15585/mmwr.mm6733a2
   Verhoeven V, 2010, PATIENT EDUC COUNS, V81, P101, DOI 10.1016/j.pec.2009.12.006
   Viens LJ, 2016, MMWR-MORBID MORTAL W, V65, P661, DOI 10.15585/mmwr.mm6526a1
   Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2
   Walker TY, 2018, MMWR-MORBID MORTAL W, V67, P909, DOI 10.15585/mmwr.mm6733a1
   Whitney CG, 2014, MMWR-MORBID MORTAL W, V63, P352
   Yoo W, 2017, PLOS ONE, V12
NR 113
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 954
EP 962
DI 10.1016/j.vaccine.2019.11.073
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100002
PM 31843271
DA 2020-05-12
ER

PT J
AU Mangtani, P
   Evans, SJW
   Lange, B
   Oberle, D
   Smith, J
   Drechsel-Baeuerle, U
   Keller-Stanislawski, B
AF Mangtani, Punam
   Evans, Stephen J. W.
   Lange, Berit
   Oberle, Doris
   Smith, Julianna
   Drechsel-Baeuerle, Ursula
   Keller-Stanislawski, Brigitte
TI Safety profile of rubella vaccine administered to pregnant women: A
   systematic review of pregnancy related adverse events following
   immunisation, including congenital rubella syndrome and congenital
   rubella infection in the foetus or infant
SO VACCINE
LA English
DT Review
DE Rubella containing vaccine; Adverse events following immunisation;
   Vaccine safety; Pregnancy; Congenital rubella syndrome; Congenital
   rubella infection
ID POSSIBLE TRANSPLACENTAL INFECTION; MATERNAL RUBELLA; MASS CAMPAIGN;
   CONSEQUENCES; BRAZIL
AB Background: Data on the safety of inadvertent rubella vaccination in pregnancy is important for rubella vaccination programs aimed at preventing congenital rubella syndrome.
   Methods: The association between monovalent rubella or combination vaccinations in or shortly before pregnancy and potential harm to the foetus was examined by conducting a systematic review and meta-analysis using fixed effect methods and simulation.
   Results: Four cohort studies of inadvertently vaccinated and unvaccinated women were found, 15 cohorts of pregnant women who were rubella susceptible at time of inadvertent vaccination and 9 cohort studies with no information on susceptibility and case series. No case of vaccine associated congenital rubella syndrome (CRS) was identified. Cohort studies with an unvaccinated comparison group were limited in number and size, and based on these only a theoretical additional risk of 6 or more cases of CRS per 1000 vaccinated women (0% observed, upper 95% CI 0.6%) could be excluded. Based on cohorts of vaccinated rubella susceptible pregnant women a maximum theoretical risk of 1 CRS case in 1008 vaccinated women (0% observed, upper 95% CI 0.099%) was estimated. Asymptomatic rubella vaccine virus infection of the neonate was also noted (fixed effects estimate of risk overall 1.74%, 95% CI 1.21, 2.28).
   Conclusion: There is no evidence that CRS is caused by rubella-containing vaccines but transplacental vaccine virus infection can occur. CRS is effectively prevented by vaccination, thus the risk/benefit balance is unequivocally in favour of vaccination. The data confirm previous recommendations that inadvertent vaccination during pregnancy is not an indication for termination of pregnancy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mangtani, Punam; Evans, Stephen J. W.; Lange, Berit; Smith, Julianna] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
   [Oberle, Doris; Drechsel-Baeuerle, Ursula; Keller-Stanislawski, Brigitte] Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.
   [Lange, Berit] Univ Freiburg, Med Ctr, Fac Med, Infect Dis,Dept Med 2, Freiburg, Germany.
   [Lange, Berit] Helmholtz Ctr Infect Res HZI, Dept Epidemiol, Braunschweig, Germany.
RP Mangtani, P (reprint author), London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM Punam.Mangtani@lshtm.ac.uk
OI Mangtani, Punam/0000-0001-7074-2999
FU World Health Organisation's Global Advisory Committee on Vaccine Safety,
   Geneva
FX This work was part funded by a small grant from The World Health
   Organisation's Global Advisory Committee on Vaccine Safety, Geneva. The
   research did not receive any other specific grants from funding
   agencies, the public, commercial or not -for-profit sectors.
CR Andrade JQ, 2006, J CLIN VIROL, V35, P285, DOI 10.1016/j.jcv.2005.09.007
   [Anonymous], 2011, Wkly Epidemiol Rec, V86, P301
   [Anonymous], 1983, JAMA, V250, P1383
   [Anonymous], 2000, WKLY EPIDEMIOL REC, V75, P161
   [Anonymous], 2013, STATA STAT SOFTW REL
   [Anonymous], 2018, CONGENITAL RUBELLA S
   [Anonymous], 1986, DRUG INTELLIGENCE CL, V20, P637
   Badilla X, 2007, PEDIATR INFECT DIS J, V26, P830, DOI 10.1097/INF.0b013e318124a9f4
   Bar-Oz B, 2004, AM J MED GENET A, V130A, P52, DOI 10.1002/ajmg.a.30225
   BART SW, 1985, REV INFECT DIS, V7, pS95
   BOLOGNESE RJ, 1973, AM J OBSTET GYNECOL, V117, P939, DOI 10.1016/0002-9378(73)90065-3
   Brown LD, 2002, ANN STAT, V30, P160
   Castillo-Solorzano C, 2011, J INFECT DIS, V204, pS713, DOI 10.1093/infdis/jir489
   Centers for Disease C. & Prevention, 2010, MMWR-MORBID MORTAL W, V59, P1307
   Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P1117
   Centers for Disease Control (CDC), 1989, MMWR Morb Mortal Wkly Rep, V38, P289
   COLOMBO ML, 1976, MINERVA PEDIATR, V28, P2429
   Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55
   da Silva GR, 2006, REV PANAM SALUD PUBL, V19, P371, DOI 10.1590/S1020-49892006000600002
   da Silva Sa GR, 2011, J INFECT DIS S2, V204, pS722
   Dabbagh A, 2018, MMWR-MORBID MORTAL W, V67, P1323, DOI 10.15585/mmwr.mm6747a6
   de Oliveira SA, 2011, J INFECT DIS, V204, pS664, DOI 10.1093/infdis/jir356
   EBBIN AJ, 1973, AM J OBSTET GYNECOL, V117, P505, DOI 10.1016/0002-9378(73)90112-9
   Emadi H, 2007, INT J ANTIMICROB AG, V29, pS288, DOI 10.1016/S0924-8579(07)70913-5
   ENDERS G, 1984, DEUT MED WOCHENSCHR, V109, P1806, DOI 10.1055/s-2008-1069458
   ENDERS G, 1985, REV INFECT DIS, V7, pS103
   Enders G, 2005, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V48, P685, DOI 10.1007/s00103-005-1066-x
   ENDERS G, 1988, LANCET, V1, P1445
   FLEET WF, 1974, JAMA-J AM MED ASSOC, V227, P621, DOI 10.1001/jama.227.6.621
   Hamkar R, 2006, VACCINE, V24, P3558, DOI 10.1016/j.vaccine.2006.02.001
   Hofmann J, 2000, J MED VIROL, V61, P155, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;155::AID-JMV25&gt;3.0.CO;2-O
   Katow S, 1998, INTERVIROLOGY, V41, P163, DOI 10.1159/000024931
   Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052
   Lambert N, 2015, LANCET
   LARSON HE, 1971, NEW ENGL J MED, V284, P870, DOI 10.1056/NEJM197104222841602
   Leads from the MMWR, 1989, JAMA-J AM MED ASSOC, V261, P3374
   Levichek Z, 2001, CLIN PHARMACOL THER, V69, pP83
   Lina MD, 2008, INVESTIG ANDINA, V10, P77
   Mangtani P. S.J., 2013, SAFETY PROFILE RUBEL
   McLean H, 2012, MANUAL SURVEILLANCE
   MILLER E, 1982, LANCET, V2, P781
   Minussi L, 2008, REPROD TOXICOL, V25, P120, DOI 10.1016/j.reprotox.2007.09.002
   Mistchenko AS, 2008, DRUG SAFETY, V31, P934
   Namaei MH, 2008, INDIAN J MED RES, V127, P551
   Pardon F, 2011, J INFECT DIS, V204, pS745, DOI 10.1093/infdis/jir442
   PHILLIPS CA, 1970, J AMER MED ASSOC, V213, P624, DOI 10.1001/jama.213.4.624
   PREBLUD SR, 1981, JAMA-J AM MED ASSOC, V246, P1413
   Reyna J, 2011, WORLD J VACC, V1, P1
   Rubella vaccination during pregnancy-United States, 1971, MORBIDITY MORTALITY, V33, P365
   Rubella Vaccination during Pregnancy-United States, 1971, MMWR 1987 MORBIDITY, V36, P457
   Rubella vaccination during pregnancy-United States 1971-1985, 1986, MMWR-MORBID MORTAL W, V35, P281
   Rubella vaccination during pregnancy-United States 1971-1985, 1971, MORBIDITY MORTALITY, V35, P275
   Sato HK, 2011, J INFECT DIS, V204, pS737, DOI 10.1093/infdis/jir419
   Shahhosseini Z, 2009, INT J GYNECOL OBSTET, V107, pS634
   SHEPPARD S, 1986, BRIT MED J, V292, P727, DOI 10.1136/bmj.292.6522.727
   Soares RC, 2011, J INFECT DIS, V204, pS729, DOI 10.1093/infdis/jir429
   Sterne JAC, 2014, COCHRANE RISK BIAS A
   The American College Of O, 1993, INT J GYNECOL OBSTET, V42, P60
   THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z
   Tookey P, 2001, BRIT MED J, V322, P1489, DOI 10.1136/bmj.322.7300.1489
   Tookey P A, 1991, CDR (Lond Engl Rev), V1, pR86
   VAHERI A, 1972, Scandinavian Journal of Infectious Diseases Supplementum, V6, P24
NR 62
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 963
EP 978
DI 10.1016/j.vaccine.2019.11.070
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100003
PM 31839467
DA 2020-05-12
ER

PT J
AU Cutts, FT
   Dansereau, E
   Ferrari, MJ
   Hanson, M
   McCarthy, KA
   Metcalf, CJE
   Takahashi, S
   Tatem, AJ
   Thakkar, N
   Truelove, S
   Utazi, E
   Wesolowski, A
   Winter, AK
AF Cutts, F. T.
   Dansereau, E.
   Ferrari, M. J.
   Hanson, M.
   McCarthy, K. A.
   Metcalf, C. J. E.
   Takahashi, S.
   Tatem, A. J.
   Thakkar, N.
   Truelove, S.
   Utazi, E.
   Wesolowski, A.
   Winter, A. K.
TI Using models to shape measles control and elimination strategies in low-
   and middle-income countries: A review of recent applications
SO VACCINE
LA English
DT Review
DE Measles; Measles vaccination; Rubella; Epidemiology; Elimination;
   Mathematical models
ID CONGENITAL-RUBELLA SYNDROME; VACCINATION COVERAGE; IMMUNIZATION
   ACTIVITIES; DYNAMICS; CAMPAIGN; IMMUNITY; PROGRESS; CHALLENGES;
   INFECTION; IMPACT
AB After many decades of vaccination, measles epidemiology varies greatly between and within countries. National immunization programs are therefore encouraged to conduct regular situation analyses and to leverage models to adapt interventions to local needs. Here, we review applications of models to develop locally tailored interventions to support control and elimination efforts. In general, statistical and semi-mechanistic transmission models can be used to synthesize information from vaccination coverage, measles incidence, demographic, and/or serological data, offering a means to estimate the spatial and age-specific distribution of measles susceptibility. These estimates complete the picture provided by vaccination coverage alone, by accounting for natural immunity. Dynamic transmission models can then be used to evaluate the relative impact of candidate interventions for measles control and elimination and the expected future epidemiology. In most countries, models predict substantial numbers of susceptible individuals outside the age range of routine vaccination, which affects outbreak risk and necessitates additional intervention to achieve elimination. More effective use of models to inform both vaccination program planning and evaluation requires the development of training to enhance broader understanding of models and where feasible, building capacity for modelling in-country, pipelines for rapid evaluation of model predictions using surveillance data, and clear protocols for incorporating model results into decision-making. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Cutts, F. T.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Dansereau, E.; Hanson, M.] Bill & Melinda Gates Fdn, Global Dev, Vaccine Delivery, Seattle, WA USA.
   [Ferrari, M. J.] Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA.
   [McCarthy, K. A.; Thakkar, N.] Inst Dis Modeling, 3150 139th Ave SE, Bellevue, WA 98005 USA.
   [Metcalf, C. J. E.; Takahashi, S.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.
   [Takahashi, S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Tatem, A. J.; Utazi, E.] Univ Southampton, Dept Geog & Environm Sci, WorldPop, Southampton SO17 1BJ, Hants, England.
   [Truelove, S.; Wesolowski, A.; Winter, A. K.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
RP Cutts, FT (reprint author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
EM felicity.cutts@lshtm.ac.uk
OI McCarthy, Kevin/0000-0002-9148-8448
FU Bill and Melinda Gates Foundation (BMGF)Gates Foundation [OPP1094816];
   Bill & Melinda Gates through the Global Good Fund, Bellevue, WA, USA;
   National Library Of Medicine of the National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Library of Medicine (NLM) [DP2LM013102];
   Career Award at the Scientific Interface by the Burroughs Wellcome Fund;
   NIH/NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19A1089674]; Bill & Melinda Gates
   FoundationGates Foundation [OPP1106427, 1032350, OPP1134076]; Clinton
   Health Access Initiative; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; Wellcome Trust Sustaining Health Grant [106866/Z/15/Z]
FX This work was funded in part by the Bill and Melinda Gates Foundation
   (BMGF). FC received consultancy fees from BMGF. AKW, CJM, MJF are
   supported by BMGF (OPP1094816). KM and NT are supported by Bill &
   Melinda Gates through the Global Good Fund, Bellevue, WA, USA. AW is
   supported by the National Library Of Medicine of the National Institutes
   of Health under Award Number DP2LM013102. AW is also support by a Career
   Award at the Scientific Interface by the Burroughs Wellcome Fund. A.J.T.
   is supported by funding from NIH/NIAID (U19A1089674), the Bill & Melinda
   Gates Foundation (OPP1106427, 1032350, OPP1134076), the Clinton Health
   Access Initiative, National Institutes of Health and a Wellcome Trust
   Sustaining Health Grant (106866/Z/15/Z). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health or other funding
   agencies. The funders did not play any role in the collection, analysis,
   interpretation, writing of final reports, or decision to submit this
   research.
CR Alegana VA, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0073
   [Anonymous], 2011, Wkly Epidemiol Rec, V86, P301
   [Anonymous], 2018, VACC COV CLUST SURV
   Beraud G, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.25.1700796
   Bharti N, 2011, SCIENCE, V334, P1424, DOI 10.1126/science.1210554
   Bharti N, 2010, EPIDEMIOL INFECT, V138, P1308, DOI 10.1017/S0950268809991385
   Bharti N, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.256
   Bharti N, 2016, SCI REP-UK, V6, DOI 10.1038/srep34541
   Bishai D, 2011, J INFECT DIS, V204, pS107, DOI 10.1093/infdis/jir131
   Brownwright TK, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4961-9
   Buckee CO, 2017, TRENDS PARASITOL, V33, P10, DOI 10.1016/j.pt.2016.10.006
   Danovaro-Holliday MC, 2014, REV PANAM SALUD PUBL, V35, P453
   Choisy M, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz030
   Chong KC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205339
   Columbia University, 2019, PHIA PROJ ZAMB
   Cutts FT, 2016, TROP MED INT HEALTH, V21, P1086, DOI 10.1111/tmi.12737
   Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053
   Cutts FT, 2013, EXPERT REV VACCINES, V12, P917, DOI 10.1586/14760584.2013.814847
   Cutts FT, 2013, PLOS MED, V10, DOI [10.1371/journal.pmed1001404, DOI 10.1371/JOURNAL.PMED1001404]
   Dabbagh A, 2017, MMWR-MORBID MORTAL W, V66, P1148, DOI 10.15585/mmwr.mm6642a6
   Dansereau Emily, 2019, Gates Open Res, V3, P923, DOI 10.12688/gatesopenres.12916.1
   Delamater PL, 2019, EMERG INFECT DIS, V25, P1, DOI 10.3201/eid2501.171901
   Dietz V, 2004, REV PANAM SALUD PUBL, V16, P432, DOI 10.1590/S1020-49892004001200013
   Ferrari MJ, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0141
   Ferrari MJ, 2010, EPIDEMIOL INFECT, V138, P108, DOI 10.1017/S0950268809990173
   Ferrari MJ, 2008, NATURE, V451, P679, DOI 10.1038/nature06509
   FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121
   Fonnesbeck CJ, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2017.0575
   Fumanelli L, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002673
   Funk S, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1413-7
   Gavi the Vaccine Alliance, 2019, APPL VACC SUPP
   Gay NJ, 2004, J INFECT DIS, V189, pS36, DOI 10.1086/377695
   Gay NJ, 2004, J INFECT DIS, V189, pS27, DOI 10.1086/381592
   Glasser JW, 2016, LANCET INFECT DIS, V16, P599, DOI 10.1016/S1473-3099(16)00004-9
   Graham M, 2019, SCIENCE, V364, P584, DOI 10.1126/science.aau6299
   Graham M, 2018, AM J TROP MED HYG, V98, P1489, DOI 10.4269/ajtmh.17-0218
   Grassly NC, 2006, P ROY SOC B-BIOL SCI, V273, P2541, DOI 10.1098/rspb.2006.3604
   Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9
   GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859
   GRIFFITHS DA, 1974, ROY STAT SOC C-APP, V23, P330
   Grout L, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-193
   Guerra FM, 2017, LANCET INFECT DIS, V17, pE420, DOI 10.1016/S1473-3099(17)30307-9
   Hachiya M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194931
   Hagedorn BL, 2019, VACCINE, V37, P6093, DOI 10.1016/j.vaccine.2019.08.049
   Hao L, 2019, INT J EPIDEMIOL, DOI [10.1093/ije/dyz058, DOI 10.1093/W4705R]
   Isere E E, 2014, Ann Ib Postgrad Med, V12, P15
   Jimenez G, 2007, PEDIATR INFECT DIS J, V26, P382, DOI 10.1097/01.inf.0000260000.84792.9e
   Kundrick A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5628-x
   Kuroiwa C, 2003, VACCINE, V21, P479, DOI 10.1016/S0264-410X(02)00480-2
   Lee AD, 2019, J INFECT DIS, V219, P1616, DOI 10.1093/infdis/jiy701
   Lee BY, 2019, VACCINE, V37, P2377, DOI 10.1016/j.vaccine.2019.03.007
   Lessler J, 2011, EPIDEMIOL INFECT, V139, P1039, DOI 10.1017/S0950268810002232
   Lessler J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067639
   Lessler J, 2012, EXPERT REV VACCINES, V11, P747, DOI [10.1586/erv.12.47, 10.1586/ERV.12.47]
   Li S, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002255
   Lochlainn LN, 2016, EUROSURVEILLANCE, V21, P39, DOI 10.2807/1560-7917.ES.2016.21.13.30177
   Masresha Balcha, 2018, J Immunol Sci, VSuppl, P130
   Mckee A, 2018, EPIDEMIOL INFECT, V146, P468, DOI 10.1017/S0950268817003077
   Mckee A, 2015, THEOR ECOL-NETH, V8, P261, DOI 10.1007/s12080-014-0250-8
   MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P111, DOI 10.1017/S0950268800065614
   Metcalf CJE, 2015, EPIDEMICS-NETH, V10, P93, DOI 10.1016/j.epidem.2014.08.008
   Metcalf CJE, 2015, EPIDEMICS-NETH, V10, P11, DOI 10.1016/j.epidem.2014.08.004
   Metcalf CJE, 2015, EPIDEMIOL INFECT, V143, P1457, DOI 10.1017/S0950268814001988
   Metcalf CJE, 2012, EPIDEMIOL INFECT, V140, P2290, DOI 10.1017/S0950268812000131
   Metcalf CJE, 2011, EPIDEMIOL INFECT, V139, P1029, DOI 10.1017/S0950268810002165
   Metcalf CJE, 2011, J R SOC INTERFACE, V8, P369, DOI 10.1098/rsif.2010.0320
   Metcalf CJE, 2011, EPIDEMIOL INFECT, V139, P265, DOI 10.1017/S0950268810001329
   Minetti A, 2014, AM J EPIDEMIOL, V179, P245, DOI 10.1093/aje/kwt236
   Minetti A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001544
   Morice A, 2003, J INFECT DIS, V187, pS158, DOI 10.1086/368053
   Mosser JF, 2019, LANCET, V393, P1843, DOI 10.1016/S0140-6736(19)30226-0
   Murakami H, 2008, B WORLD HEALTH ORGAN, V86, P948, DOI 10.2471/BLT.07.048579
   Nigatu W, 2008, VACCINE, V26, P4769, DOI 10.1016/j.vaccine.2008.07.005
   Nimpa MM, 2019, PAN AFR MED J
   NOKES DJ, 1990, INT J EPIDEMIOL, V19, P703, DOI 10.1093/ije/19.3.703
   Ntirampeba D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201700
   Ohuma EO, 2009, EPIDEMIOL INFECT, V137, P227, DOI 10.1017/S0950268808000848
   Pacheco FC, 2019, VACCINE, V37, P2651, DOI 10.1016/j.vaccine.2019.04.019
   Panagiotopoulos T, 1999, BRIT MED J, V319, P1462, DOI 10.1136/bmj.319.7223.1462
   Portnoy A, 2018, VACCINE, V36, P170, DOI 10.1016/j.vaccine.2017.10.080
   Prada JM, 2017, VACCINE, V35, P1488, DOI 10.1016/j.vaccine.2017.02.008
   Restrepo-Mendez MC, 2016, B WORLD HEALTH ORGAN, V94, P794, DOI 10.2471/BLT.15.162172
   Rios-Doria D, 2009, MATH STAT ESTIMATION, P325
   Rivadeneira MF, 2018, VACCINE, V36, P5251, DOI 10.1016/j.vaccine.2018.07.051
   Simons E, 2012, LANCET, V379, P2173, DOI 10.1016/S0140-6736(12)60522-4
   Subaiya S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199786
   Szusz Emily K, 2010, BMC Res Notes, V3, P75, DOI 10.1186/1756-0500-3-75
   Takahashi S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15585
   Takahashi S, 2015, SCIENCE, V347, P1240, DOI 10.1126/science.aaa3438
   Tatem AJ, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.4
   Tatem AJ, 2014, INT HEALTH, V6, P153, DOI 10.1093/inthealth/ihu057
   Thakkar N, 2019, P NATL ACAD SCI USA, V116, P11069, DOI 10.1073/pnas.1818433116
   Trentini F, 2017, LANCET INFECT DIS, V17, P1089, DOI 10.1016/S1473-3099(17)30421-8
   Truelove SA, 2019, VACCINE, V37, P732, DOI 10.1016/j.vaccine.2018.12.012
   Utazi CE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09611-1
   Utazi CE, 2018, VACCINE, V36, P1583, DOI 10.1016/j.vaccine.2018.02.020
   Utazi CE, 2018, STAT METHODS MED RES, V1177, DOI [10.1177/0962260218797367, DOI 10.1177/0962260218797367962280218797362]
   Uzicanin A, 2011, J INFECT DIS, V204, pS133, DOI 10.1093/infdis/jir102
   Verguet S, 2015, VACCINE, V33, P1291, DOI 10.1016/j.vaccine.2014.11.050
   Wardrop NA, 2018, P NATL ACAD SCI USA, V115, P3529, DOI 10.1073/pnas.1715305115
   Wedlock PT, 2019, VACCINE, V37, P637, DOI 10.1016/j.vaccine.2018.12.010
   Wesolowski A, 2018, EPIDEMIOL INFECT, V146, P1575, DOI 10.1017/S0950268818001449
   Wesolowski A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02064-4
   Wesolowski A, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2015.1101
   Wesolowski A, 2015, P NATL ACAD SCI USA, V112, P11114, DOI 10.1073/pnas.1423542112
   Winter AK, 2018, EPIDEMIOL INFECT, V146, P65, DOI 10.1017/S0950268817002527
   Winter AK, 2018, AM J EPIDEMIOL, V187, P2219, DOI 10.1093/aje/kwy114
   Winter AK, 2018, J INFECT DIS, V218, P355, DOI 10.1093/infdis/jiy137
   World Health Organization, 2017, WKLY EPIDEMIOL REC, V92, P205
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World Health Organization, 2018, MEASL PROGR RISK ASS
   Yang W, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006806
   Zimmermann M, 2019, VACCINE, V37, P6039, DOI 10.1016/j.vaccine.2019.08.050
   zu Erbach-Schoenberg E, 2016, POPUL HEALTH METR, V14, DOI 10.1186/s12963-016-0106-0
NR 114
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 979
EP 992
DI 10.1016/j.vaccine.2019.11.020
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100004
PM 31787412
OA Green Accepted, Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Dhamayanti, M
   Tarigan, R
   Fadlyana, E
   Prasetyo, D
   Amalia, N
   Rusmil, VK
   Sari, RM
   Bachtiar, NS
   Rusmil, K
   Kartasasmita, CB
AF Dhamayanti, Meita
   Tarigan, Rodman
   Fadlyana, Eddy
   Prasetyo, Dwi
   Amalia, Nelly
   Rusmil, Viramitha K.
   Sari, Rini Mulia
   Bachtiar, Novilia Sjafri
   Rusmil, Kusnandi
   Kartasasmita, Cissy B.
TI Immunogenicity and safety of Quadrivalent Influenza HA vaccine in
   Indonesian children: An open-labeled, bridging, clinical study
SO VACCINE
LA English
DT Article
DE Children; Indonesia; Immunogenicity; Safety; Quadrivalent Influenza
   Vaccine
ID EFFICACY; BURDEN
AB Background: Influenza B (Yamagata/Victoria lineage) can cause severe forms of respiratory infection among the pediatric population as welt as influenza A strains (H3N2/H1N1). Vaccination against all four strains is required to prevent infection and severe outcome. This study is the first study to assess the immunogenicity of Quadrivalent Influenza HA vaccine (QIV) and ascertain safety among children in Indonesia.
   Methods: This is an open labeled, single arm, bridging clinical study involving unprimed healthy children 6-35 months of age (Group I) and 3-8 years of age (Group II). Subjects on both groups receiving two doses of QIV with a 28 days interval. Serology tests were performed on baseline and 28 days post-vaccination. Hemagglutination inhibition antibody titers were analyzed for Geometric Mean Titer (GMT), seroprotection, and seroconversion rates. Solicited reactions, unsolicited adverse events, and serious adverse events were observed up to 28 days post-vaccination.
   Results: Out of 270 subjects enrolled, 269 subjects completed the study. Immunogenicity analysis were evaluated on 254 subjects. Seroprotection rates were >= 85% for all vaccine strains in both groups. Seroconversion of more than 4 folds for all strains occurred in both groups post-vaccination. In Group I, the increase of GMT for A/H1N1, A/H3N2, B/Texas, and B/Phuket was 12.5, 14.5, 8.2, and 6.4 folds, respectively. In Group II the increase of GMT for A/HIN1, A/H3N2, B/Texas, and B/Phuket was 14, 17, 10, and 8 folds, respectively. The majority of local adverse events (AEs) after the first and second immunizations were immediate injection-site pain (10.4% and 12.6%). The majority of systemic AEs after the first and second immunizations were delayed unsolicited AEs (14.8% and 14.9%). No vaccine-related serious adverse events or deaths were reported.
   Conclusion: The investigational QIV was immunogenic with an acceptable safety profile in children 6 months to 8 years of age. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Dhamayanti, Meita; Tarigan, Rodman; Fadlyana, Eddy; Prasetyo, Dwi; Amalia, Nelly; Rusmil, Viramitha K.; Rusmil, Kusnandi; Kartasasmita, Cissy B.] Univ Padjadjaran, Dept Child Hlth, Fac Med, Hasan Sadikin Hosp, Jl Pasteur 38, Bandung, West Java, Indonesia.
   [Sari, Rini Mulia; Bachtiar, Novilia Sjafri] PT Bio Farma, Surveillance & Clin Trial Div, Bandung, Indonesia.
RP Dhamayanti, M (reprint author), Univ Padjadjaran, Dept Child Hlth, Fac Med, Hasan Sadikin Hosp, Jl Pasteur 38, Bandung, West Java, Indonesia.
EM meita.dhamayanti@unpad.ac.id; rini.mu-lia@biofarma.co.id;
   novilia@biofarma.co.id
OI Dhamayanti, Meita/0000-0001-9661-0708
FU PT Bio Farma [04310/DIR/XI/2017, PO-00017403]
FX This study was fully funded by PT Bio Farma, no 04310/DIR/XI/2017,
   PO-00017403.
CR Adam K, 2017, BIOMED RES INT, DOI 10.1155/2017/9541619
   Cadorna-Carlos JB, 2015, VACCINE, V33, P2485, DOI 10.1016/j.vaccine.2015.03.065
   El Guerche-Seblain C, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3920-8
   Fiore AEBC, 2013, VACCINE
   Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137
   Jefferson T, 2018, COCHRANE DATABASE SY, V2
   Jennings L, 2018, INFLUENZA OTHER RESP, V12, P383, DOI 10.1111/irv.12522
   Kondrich J, 2017, CURR OPIN PEDIATR, V29, P297, DOI 10.1097/MOP.0000000000000495
   Kosasih H, 2013, INFLUENZA OTHER RESP, V7, P312, DOI 10.1111/j.1750-2659.2012.00403.x
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0
   Pepin S, 2019, VACCINE, V37, P1876, DOI 10.1016/j.vaccine.2018.11.074
   Rhorer J, 2009, VACCINE, V27, P1101, DOI 10.1016/j.vaccine.2008.11.093
   Setiawaty V, 2018, MEDIA PENELITIAN DAN, V28, P257
   Smith S, 2006, EVID BASED CHILD HLT, V1, P367
   Soedjatmiko S, 2018, VACCINE, V36, P2126, DOI 10.1016/j.vaccine.2018.02.114
   Statler VA, 2019, VACCINE, V37, P343, DOI 10.1016/j.vaccine.2018.07.036
   Wang L, 2016, J PEDIAT INF DIS SOC, V5, P170, DOI 10.1093/jpids/piv041
   WHO, 2012, VACC INFL
   Wijnans L, 2016, INFLUENZA OTHER RESP, V10, P2, DOI 10.1111/irv.12351
   World Health Organization, 2014, INFL VIR INF HUM
   World Health Organization, 2015, MAN EST DIS BURD ASS
   Yan SK, 2017, HUM VACC IMMUNOTHER, V13, P2041, DOI 10.1080/21645515.2017.1345400
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 993
EP 1000
DI 10.1016/j.vaccine.2019.12.008
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100005
PM 31862195
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mallory, RM
   Nyborg, A
   Kalyani, RN
   Yuan, Y
   Block, SL
   Dubovsky, F
AF Mallory, Raburn M.
   Nyborg, Andrew
   Kalyani, Rubana N.
   Yuan, Yuan
   Block, Stan L.
   Dubovsky, Filip
TI A study to evaluate the immunogenicity and shedding of live attenuated
   influenza vaccine strains in children 24-< 48 months of age
SO VACCINE
LA English
DT Article
DE Live attenuated influenza vaccine; Pediatric; Seasonal influenza
ID CULTURE-CONFIRMED INFLUENZA; ANN-ARBOR STRAIN; UNITED-STATES; SEASONAL
   INFLUENZA; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; YOUNG-CHILDREN;
   EFFICACY; RECOMMENDATIONS; PREVENTION
AB Background: Quadrivalent live attenuated influenza vaccine (LAIV4) showed reduced effectiveness against the A/H1N1 component in the 2013-2014 and 2015-2016 influenza seasons. The most likely cause of reduced LAIV effectiveness against A(H1N1)pdm09 strains was poor intranasal replication.
   Objectives: To compare the immunogenicity and shedding of a new A/H1N1 strain (A/Slovenia), to a A/H1N1 strain known to have reduced effectiveness (A/Bolivia).
   Patients/methods: This was a randomized, double-blind, multicenter study. Children aged 24-<48 months of age were randomized 1:1:1 to receive two doses of LAIV4 2017-2018 (LAIV4(A/slovenia)), or LAIV4 2015-2016 or trivalent LAIV (LAIV3) 2015-2016 formulations (LAIV4(A/Bolivia) or LAIV3(A/)(Bolivia), respectively) on days 1 and 28. The primary endpoint was strain-specific hemagglutination inhibition (HAI) antibody seroresponse at 28 days post each dose, and secondary endpoints included immunogenicity, shedding, and safety. Solicited symptoms, adverse events (AEs), and serious AEs (SAEs) were recorded. Prespecified statistical testing was limited to the primary endpoint of HAI antibody responses.
   Results: A total of 200 children were randomized (median age 35.3 months; 53% male; 57% had previously received influenza vaccine). Significantly higher HAI antibody responses for the A/Slovenia strain were observed after Dose 1 and Dose 2. Neutralizing antibodies and nasal immunoglobulin A antibody responses were higher for A/Slovenia versus A/Bolivia. More children shed the A/Slovenia vaccine strain than the A/Bolivia strain on Days 4-7 after Dose 1. No deaths, SAEs, or discontinuations from vaccine occurred.
   Conclusions: The new A(H1N1)pdm09 A/Slovenia LAIV strain demonstrated improved immunogenicity compared with a previous strain with reduced effectiveness and induced immune responses comparable to a highly efficacious pre-pandemic H1N1 LAIV strain. These results support the use of LAIV4 containing A/Slovenia as a vaccine option in clinical practice. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mallory, Raburn M.; Nyborg, Andrew; Kalyani, Rubana N.; Yuan, Yuan; Dubovsky, Filip] MedImmune, 1 MedImmune Way, Gaithersburg, MD 20878 USA.
   [Block, Stan L.] Kentucky Pediat & Adult Res Inc, Bardstown, KY USA.
   [Nyborg, Andrew] Horizon Pharma, Lake Forest, IL USA.
RP Mallory, RM (reprint author), MedImmune, 1 MedImmune Way, Gaithersburg, MD 20878 USA.
EM malloryr@MedImmune.com
RI Yuan, Yuan/H-4007-2013
OI Yuan, Yuan/0000-0003-4706-7897
FU Medlmmune UK Ltd.
FX All work was funded by Medlmmune UK Ltd.
CR Appiah GD, 2015, MMWR-MORBID MORTAL W, V64, P583
   Bandell A, 2011, EXPERT REV VACCINES, V10, P1131, DOI [10.1586/ERV.11.73, 10.1586/erv.11.73]
   Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002
   Block SL, 2008, VACCINE, V26, P4940, DOI 10.1016/j.vaccine.2008.07.013
   Neto HB, 2009, PEDIATR INFECT DIS J, V28, P365, DOI 10.1097/INF.0b013e31819219b8
   Coelingh KL, 2014, EXPERT REV VACCINES, V13, P855, DOI 10.1586/14760584.2014.922417
   Flannery B, 2018, MMWR-MORBID MORTAL W, V67, P180, DOI 10.15585/mmwr.mm6706a2
   Flannery B, 2017, MMWR-MORBID MORTAL W, V66, P167, DOI 10.15585/mmwr.mm6606a3
   Gaspard N, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx111
   Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1
   Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1
   Grohskopf LA, 2015, MMWR-MORBID MORTAL W, V64, P818, DOI [10.15585/mmwr.mm6430a3, 10.1111/ajt.13505]
   Grohskopf LA, 2014, MMWR-MORBID MORTAL W, V63, P691
   Kissling E, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.1900121
   Mallory RM, 2018, INFLUENZA OTHER RESP, V12, P438, DOI 10.1111/irv.12555
   Mallory RM, 2011, VACCINE, V29, P4322, DOI 10.1016/j.vaccine.2011.04.022
   Mallory RM, 2018, ADV COMM IMM PRACT A
   Mallory RM, 2017, ADV COMM IMM PRACT A
   McLean HQ, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3742
   Penttinen PM, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.38.30350
   Public Health England, 2018, INFL VACC EFF VE AD
   Tam JS, 2007, PEDIATR INFECT DIS J, V26, P619, DOI 10.1097/INF.0b013e31806166f8
   Vesikari T, 2006, PEDIATRICS, V118, P2298, DOI 10.1542/peds.2006-0725
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1001
EP 1008
DI 10.1016/j.vaccine.2019.11.055
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100006
PM 31796225
DA 2020-05-12
ER

PT J
AU Gidudu, JF
   Shaum, A
   Dodoo, A
   Bosomprah, S
   Bonsu, G
   Amponsa-Achiano, K
   Darko, DM
   Sabblah, G
   Opare, J
   Nyaku, M
   Owusu-Boakye, B
   Oduro, A
   Aborigo, R
   Conklin, L
   Welaga, P
   Ampadu, HH
AF Gidudu, Jane F.
   Shaum, Anna
   Dodoo, Alex
   Bosomprah, Samuel
   Bonsu, George
   Amponsa-Achiano, Kwame
   Darko, Delese M.
   Sabblah, George
   Opare, Joseph
   Nyaku, Mawuli
   Owusu-Boakye, Bernice
   Oduro, Abraham
   Aborigo, Raymond
   Conklin, Laura
   Welaga, Paul
   Ampadu, Hilda H.
TI Barriers to healthcare workers reporting adverse events following
   immunization in four regions of Ghana
SO VACCINE
LA English
DT Article
DE Adverse events following immunization; Barriers to reporting; Healthcare
   workers; Four regions in Ghana
AB Despite didactic training on adverse events following immunization (AEFI) in Ghana, the reporting ratio of AEFI was 1.56 per 100,000 surviving infants in 2015, below the minimum reporting ratio of 10. We aimed to estimate the proportion of health care workers (HCWs) reporting AEFI and to identify barriers to reporting.
   We conducted a cross-sectional survey of HCWs in four regions in Ghana. A simple random sample of 176 health facilities was selected and up to two HCWs were randomly selected per facility. We used the Rao-Scott Chi-squared test to compare factors associated with reporting of AEFI in the last year. We used an open-ended question to identify reasons for low reporting. One supervisor from each facility, responsible for overall reporting and management of AEFI, was also interviewed.
   A total of 306 HCWs from 169 facilities were interviewed. Of these, 176 (57.5%) reported they had ever encountered an AEFI. Of the 120 who had encountered an AEFI in the last year, 66 (55.0%) indicated they had reported the AEFI, and 38 (31.7%) completed a reporting form. HCWs (n = 120) reported multiple barriers to reporting of AEFI; the most common barriers were fear of personal consequences (44.1%), lack of knowledge or training (25.2%), and not believing an AEFI was serious enough to report (22.2%). Discussion of AEFI during the last supervisory visit was significantly associated with reporting in the past year (OR 7.39; p < .001). Of 172 supervisors interviewed, 65 (37.8%) mentioned their facilties had ever encountered an AEFI; over 90% of facilities had reporting forms.
   We identified low reporting of AEFI and multiple barriers to reporting among HCWs in the four selected regions of Ghana. Discussing AEFI during supervisory visits with HCWs might improve reporting. Additionally, strategies to address fear of personal consequences as a barrier to reporting of AEFI are needed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gidudu, Jane F.; Shaum, Anna; Nyaku, Mawuli; Conklin, Laura] Ctr Dis Control & Prevent, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA USA.
   [Dodoo, Alex; Owusu-Boakye, Bernice; Ampadu, Hilda H.] African Collaborating Ctr Pharmacovigilance, Accra, Ghana.
   [Bosomprah, Samuel] Univ Ghana, Sch Publ Hlth, Dept Biostat, Accra, Ghana.
   [Bonsu, George; Amponsa-Achiano, Kwame] Ghana Hlth Serv, Dept Dis Control & Prevent, Publ Hlth Div, Accra, Ghana.
   [Darko, Delese M.; Sabblah, George] Ghana Food & Drugs Author, Accra, Ghana.
   [Opare, Joseph] Univ Ghana, Sch Publ Hlth, African Field Epidemiol Network, Accra, Ghana.
   [Oduro, Abraham; Aborigo, Raymond; Welaga, Paul] Ghana Hlth Serv, Navrongo Hlth Res Ctr, Hlth Res Div, Navrongo, Ghana.
RP Gidudu, JF (reprint author), 1600 Clifton Rd, Atlanta, GA 30033 USA.
EM bwv5@cdc.gov
RI Sabblah, George/AAM-1168-2020
FU US Centers for Disease Control and Prevention (CDC)United States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA
FX The US Centers for Disease Control and Prevention (CDC) provided funding
   for this study.
CR Addison J, 2007, DRUG SAFETY, V30, P982
   Ankrah DNA, 2018, HUM VACC IMMUNOTHER, V14, P172, DOI 10.1080/21645515.2017.1384105
   [Anonymous], 2015, DAT STAT GRAPH IMM S
   Chen RT, 2015, VACCINE, V33, pD46, DOI 10.1016/j.vaccine.2015.06.073
   GAVI Alliance, COUNTR FACT SHEET GH
   Harvard Humanitarian Initiative, KOB TOOLB 2 0
   Henry Linda L, 2005, Policy Polit Nurs Pract, V6, P127, DOI 10.1177/1527154404272611
   Kochhar S, 2013, EXPERT REV VACCINES, V12, P1465, DOI 10.1586/14760584.2013.855612
   Lei JY, 2018, VACCINE, V36, P1577, DOI 10.1016/j.vaccine.2018.02.012
   Masika C, 2016, BIOMED RES INT, DOI 10.1155/2016/3745298
   Mekonnen Alemayehu B, 2018, Drugs Real World Outcomes, V5, P1, DOI 10.1007/s40801-017-0125-6
   Muchekeza M, 2014, J VACC VACCINOL, V5
   Nyaku Mawuli, 2017, Pan Afr Med J, V27, P4, DOI 10.11604/pamj.supp.2017.27.3.12182
   Ogunyemi Riyike Alaba, 2016, Niger Postgrad Med J, V23, P79, DOI 10.4103/1117-1936.186300
   Parrella A, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-313
   SAS Institute Inc, 2013, SAS ACCESS 9 4 INT A
   World Health Organization, Q A MAL VACC IMPL PR
   World Health Organization, 2012, GLOB VACC SAF BLUEPR
   World Health Organization, 1980, WHO UNICEF IMM COV E
   World Health Organization, PROF GHAN EXP PROGR
   Zvanaka S, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.308.12730
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1009
EP 1014
DI 10.1016/j.vaccine.2019.11.050
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100007
PM 31787409
DA 2020-05-12
ER

PT J
AU Joubert, IA
   Kovacs, D
   Scheiblhofer, S
   Winter, P
   Korotchenko, E
   Strandt, H
   Weiss, R
AF Joubert, Isabella A.
   Kovacs, Daniel
   Scheiblhofer, Sandra
   Winter, Petra
   Korotchenko, Evgeniia
   Strandt, Helen
   Weiss, Richard
TI Mast cells and gamma delta T cells are largely dispensable for adaptive
   immune responses after laser-mediated epicutaneous immunization
SO VACCINE
LA English
DT Article
DE Epicutaneous vaccination; Skin immunology; Innate immunity; Phl p 5;
   Glycoconjugates; Mannan; Barrier disruption
ID LYMPHOID STRESS-SURVEILLANCE; TRANSCUTANEOUS VACCINATION; LECTIN
   RECEPTORS; SKIN VACCINATION; DELIVERY; IMMUNOTHERAPY; EPIDERMIS;
   CYTOKINE; EFFICACY
AB Background: The skin resembles an attractive target for vaccination due to its accessibility and abundance of resident immune cells. Cells like gamma delta T cells and mast cells (MCs) are part of the first line of defence against exogenous threats. Despite being important mediators for eliciting TH2 immune responses after epithelial stress, gamma delta T cell and MC functions still remain to be completely understood. Here, we aimed to characterize their roles in shaping adaptive immune responses after laser-mediated epicutaneous immunization (EPI).
   Methods: gamma delta T cell knock out, MC-depleted, and wildtype control mice were immunized with mannan-conjugated grass pollen allergen Phl p 5 (P5-MN) by laser-mediated EPI. After 2-3 immunizations, cytokine expression, T helper polarization, and antigen-specific IgG1/IgE levels were analysed. Furthermore, the local cytokine/chemokine milieu after laser microporation was determined.
   Results: The majority of inflammatory chemokines and cytokines induced by laser treatment were not affected by the presence of gamma delta T cells or MCs. However, RANTES was elevated in gamma delta T cell knock out mice and GROce, TSLP, and IL-33 were significantly decreased after MC depletion. The absence of gamma delta T cells or depletion of MCs had no substantial effect on adaptive immune responses after laser-mediated EPI, except for slightly reduced IgG1 and effector T cell levels in MC-depleted mice.
   Conclusions: gamma delta T cells did not play a pivotal role in shaping the humoral and cellular adaptive immune response after laser-mediated EPI. MC depletion decreased the numbers of effector T cells, indicating a potential role of MCs in the activation and maturation of T cells after EPI. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Joubert, Isabella A.; Kovacs, Daniel; Scheiblhofer, Sandra; Winter, Petra; Korotchenko, Evgeniia; Strandt, Helen; Weiss, Richard] Univ Salzburg, Dept Biosci, Hellbrunnerstr 34, A-5020 Salzburg, Austria.
   [Kovacs, Daniel] Tech Univ Munich, Dept Hematol & Med Oncol, Klinikum Rechts Isar, Munich, Germany.
   [Kovacs, Daniel] Tech Univ Munich, TranslaTUM Canc Ctr, Munich, Germany.
RP Weiss, R (reprint author), Univ Salzburg, Dept Biosci, Hellbrunnerstr 34, A-5020 Salzburg, Austria.
EM Richard.Weiss@sbg.ac.at
RI Weiss, Richard/N-7279-2013
OI Weiss, Richard/0000-0003-3185-7253
CR Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782
   Bach D, 2012, ALLERGY, V67, P1365, DOI 10.1111/all.12005
   Balkow S, 2010, BLOOD, V116, P1885, DOI 10.1182/blood-2009-05-224428
   Benito-Villalvilla C, 2018, ALLERGO J, V27, P34, DOI 10.1007/s40629-018-0069-8
   BERGSTRESSER PR, 1993, J INVEST DERMATOL, V100, pS80, DOI 10.1038/jid.1993.28
   Boismenu R, 1996, Semin Immunol, V8, P323, DOI 10.1006/smim.1996.0043
   Boismenu R, 1996, J IMMUNOL, V157, P985
   Bulfone-Paus S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00394
   Chen XY, 2013, EXPERT REV VACCINES, V12, P1313, DOI 10.1586/14760584.2013.844070
   Chen XY, 2012, CLIN CANCER RES, V18, P2240, DOI 10.1158/1078-0432.CCR-11-2654
   Chen XY, 2012, J CONTROL RELEASE, V159, P43, DOI 10.1016/j.jconrel.2012.01.002
   Dudeck A, 2011, EUR J IMMUNOL, V41, P1883, DOI 10.1002/eji.201040994
   Gutowska-Owsiak D, 2012, J INVEST DERMATOL, V132, P940, DOI 10.1038/jid.2011.398
   Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007
   Hayday AC, 2009, IMMUNITY, V31, P184, DOI 10.1016/j.immuni.2009.08.006
   Hessenberger M, 2013, VACCINE, V31, P3427, DOI 10.1016/j.vaccine.2012.09.086
   Hoving JC, 2014, CELL MICROBIOL, V16, P185, DOI 10.1111/cmi.12249
   Hsu CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011944
   Jameson J, 2007, IMMUNOL REV, V215, P114, DOI 10.1111/j.1600-065X.2006.00483.x
   Johannssen T, 2017, TRENDS BIOTECHNOL, V35, P334, DOI 10.1016/j.tibtech.2016.10.002
   Kenney RT, 2004, NEW ENGL J MED, V351, P2295, DOI 10.1056/NEJMoa043540
   Kim YC, 2011, DRUG DELIV TRANSL RE, V1, P7, DOI 10.1007/s13346-010-0005-z
   Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x
   Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310
   Lepenies B, 2013, ADV DRUG DELIVER REV, V65, P1271, DOI 10.1016/j.addr.2013.05.007
   Liang F, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.19
   Machado Y, 2017, J CONTROL RELEASE, V266, P87, DOI 10.1016/j.jconrel.2017.09.020
   Marichal T, 2013, CANCER IMMUNOL RES, V1, P269, DOI 10.1158/2326-6066.CIR-13-0119
   Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020
   Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013
   Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201
   Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538
   Park JH, 2008, INT J PHARMACEUT, V359, P94, DOI 10.1016/j.ijpharm.2008.03.032
   Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746
   Scheiblhofer S, 2017, VACCINE, V35, P1802, DOI 10.1016/j.vaccine.2016.11.105
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Strid J, 2011, SCIENCE, V334, P1293, DOI 10.1126/science.1211250
   Taddio A, 2012, VACCINE, V30, P4807, DOI 10.1016/j.vaccine.2012.05.011
   Terhorst D, 2015, J IMMUNOL, V194, P5895, DOI 10.4049/jimmunol.1500564
   Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014
   Van Damme P, 2009, VACCINE, V27, P454, DOI 10.1016/j.vaccine.2008.10.077
   Walker ME, 2012, BBA-MOL BASIS DIS, V1822, P57, DOI 10.1016/j.bbadis.2011.02.009
   Wang J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5447
   Weinberger EE, 2013, VACCINE, V31, P6113, DOI 10.1016/j.vaccine.2013.08.005
   Weiss R, 2012, J CONTROL RELEASE, V162, P391, DOI 10.1016/j.jconrel.2012.06.031
   WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884
   Yang D, 2017, IMMUNOL REV, V280, P41, DOI 10.1111/imr.12577
NR 47
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1015
EP 1024
DI 10.1016/j.vaccine.2019.11.051
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100008
PM 31812465
DA 2020-05-12
ER

PT J
AU Chua, GT
   Ho, FK
   Tung, KT
   Wong, RS
   Cheong, KN
   Yip, PS
   Fan, SY
   Wong, WH
   Qiao, YL
   Chui, CS
   Li, SX
   Ip, P
AF Chua, Gilbert T.
   Ho, Frederick K.
   Tung, Keith T.
   Wong, Rosa S.
   Cheong, Kai Ning
   Yip, Paul S.
   Fan, Susan Y.
   Wong, Wilfred H.
   Qiao, Youlin
   Chui, Celine S.
   Li, Shirley X.
   Ip, Patrick
TI Sexual behaviors and intention for cervical screening among
   HPV-vaccinated young Chinese females
SO VACCINE
LA English
DT Article
DE HPV vaccination; Chinese; Cervical screening; Sexual behaviour
ID HUMAN-PAPILLOMAVIRUS VACCINATION; HONG-KONG; QUADRIVALENT VACCINE;
   CANCER PREVENTION; ADOLESCENT GIRLS; DAUGHTERS; EDUCATION; COVERAGE;
   CAMPAIGN; MOTHERS
AB Background and objectives: Human papillomavirus (HPV) vaccination and cervical screening prevent cervical cancer effectively. However, there are concerns whether vaccination leads to high-risk sexual behaviors and less intention for cervical screening. We aimed to evaluate the influence of HPV vaccination on high-risk sexual behaviors, and intention for cervical screening among young Chinese females. We also reported the latest HPV vaccination uptake in Hong Kong.
   Methods: A population-based survey was conducted between September 2016 and January 2017. Subjects were school-age girls from twenty-five secondary schools (in-school) and community females between 18 and 27 years (out-school). Demographics, vaccine-related attitudes, intention for cervical screening and participants' sexual behaviors were examined.
   Results: We surveyed 2260 females from in-school (n = 1664) and out-school (n = 596) settings. 11.5% in-school and 23.5% out-school participants received at least one dose of HPV vaccine. Vaccination was not associated with age (in-school Odds Ratio [OR] 0.99, p = 0.87; out-school OR 1, p = 0.94), ethnicity (in-school OR 0.82, p = 0.72; out-school OR 0, p = 0.98), maternal education (in-school OR for secondary school 1.19, p = 0.43; for post-secondary school 1.28, p = 0.48), underage sex (in-school OR 1.22, p = 0.80; out-school OR 0.63, p = 0.67), earlier sexual exposure (in-school beta 0.01, p = 0.99; out-school 0.13, p = 0.68), multiple sex partners (in-school OR 3.27, p = 0.22; out-school OR 1.16, p = 0.43), and unprotected sex (in-school OR 1.14, p = 0.78; out-school OR 0.60, p = 0.10). Out-school females with higher personal education level was associated with higher vaccine uptake (post-secondary OR 3.4, p < 0.001; bachelor's degree or above OR 3.71, p < 0.001). More vaccinated females intended for cervical screening (in-school 23.6% vs. 21.1%; out-school 53.6% vs. 43.6%). Costs and knowledge were important factors for non-vaccination and non-intention for cervical screening.
   Conclusions: HPV vaccination was not associated with earlier and high risk sexual behavior among Chinese young females. Vaccinated Chinese young females had a higher intention for cervical screening. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chua, Gilbert T.; Ho, Frederick K.; Tung, Keith T.; Wong, Rosa S.; Cheong, Kai Ning; Wong, Wilfred H.; Chui, Celine S.; Li, Shirley X.; Ip, Patrick] Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Dept Paedaitr & Adolescent Med, Room 115,1-F,New Clin Bldg,102 Pokfulam Rd, Hong Kong, Peoples R China.
   [Yip, Paul S.; Chui, Celine S.; Li, Shirley X.] Univ Hong Kong, Fac Social Sci, Dept Social Work & Social Adm, Hong Kong, Peoples R China.
   [Fan, Susan Y.] Family Planning Assoc Hong Kong, Hong Kong, Peoples R China.
   [Qiao, Youlin] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China.
   [Chui, Celine S.; Li, Shirley X.] Univ Hong Kong, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm, Hong Kong, Peoples R China.
RP Ip, P (reprint author), Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Dept Paedaitr & Adolescent Med, Room 115,1-F,New Clin Bldg,102 Pokfulam Rd, Hong Kong, Peoples R China.
EM patricip@hku.hk
RI Qiao, You-Lin/B-4139-2012
OI Qiao, You-Lin/0000-0001-6380-0871; Chua, Gilbert/0000-0003-0333-0059;
   Li, Xue/0000-0003-4836-7808
CR Anderson JO, 2009, HEALTH EDUC RES, V24, P867, DOI 10.1093/her/cyp023
   Brewer NT, 2007, ANN BEHAV MED, V34, P95, DOI 10.1007/BF02879925
   Brouwer AF, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7134-1
   Centre for Health Protection, 2018, CERV CANC
   Choi HCW, 2013, VACCINE, V32, P78, DOI 10.1016/j.vaccine.2013.10.068
   Colombara DV, 2013, VACCINE, V31, P4057, DOI 10.1016/j.vaccine.2013.06.031
   de Gonzalez AB, 2007, INT J CANCER, V120, P885, DOI 10.1002/ijc.22357
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   Department of Health TGotHKSAR, 2018, CERV SCREEN PROGR
   Forster A, 2010, J HEALTH COMMUN, V15, P205, DOI 10.1080/10810730903528066
   Franco EL, 2006, VACCINE S3, V24
   Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760
   Gollust SE, 2016, HUM VACC IMMUNOTHER, V12, P1430, DOI 10.1080/21645515.2015.1109169
   Hansen BT, 2014, VACCINE, V32, P4945, DOI 10.1016/j.vaccine.2014.07.025
   Hong Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep04704
   Kessels SJM, 2012, VACCINE, V30, P3546, DOI 10.1016/j.vaccine.2012.03.063
   KISH L, 1949, J AM STAT ASSOC, V44, P380, DOI 10.2307/2280236
   Kwan TTC, 2011, PATIENT EDUC COUNS, V84, P118, DOI 10.1016/j.pec.2010.06.018
   Lam TH, 2004, ARCH SEX BEHAV, V33, P487, DOI 10.1023/B:ASEB.0000037429.79394.c6
   Lee A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-925
   Leung Shuk On Annie, 2019, Vaccine X, V3, P100037, DOI 10.1016/j.jvacx.2019.100037
   Levin CE, 2015, VACCINE, V33, P2830, DOI 10.1016/j.vaccine.2015.02.052
   Li SL, 2013, VACCINE, V31, P5785, DOI 10.1016/j.vaccine.2013.10.027
   LI W, UPDATE HPV VACCINE
   Lim WT, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1029
   Liu A, 2018, J PAEDIATR CHILD H, V54, P302, DOI 10.1111/jpc.13693
   Liu CR, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6823-0
   Lua CY, 2012, VACCINE, V30, P2250, DOI 10.1016/j.vaccine.2011.10.070
   McGregor S, 2018, VACCINE, V36, P4311, DOI 10.1016/j.vaccine.2018.05.104
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X
   Ogilvie GS, 2007, CAN MED ASSOC J, V177, P1506, DOI 10.1503/cmaj.071022
   Ogilvie GS, 2018, CAN MED ASSOC J, V190, pE1221, DOI 10.1503/cmaj.180628
   Ortiz RR, 2019, HUM VACC IMMUNOTHER, V15, P1465, DOI 10.1080/21645515.2019.1581543
   Piedimonte S, 2018, J OBSTET GYNAECOL CA, V40, P440, DOI 10.1016/j.jogc.2017.07.028
   Siu JYM, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-73
   Smith LM, 2015, CAN MED ASSOC J, V187, pE74, DOI 10.1503/cmaj.140900
   St Laurent J, 2018, CURR PROB CANCER, V42, P493, DOI 10.1016/j.currproblcancer.2018.06.004
   Suppli CH, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6268-x
   Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
   Vorsters A, 2019, PAPILLOMAVIRUS RES, V8, DOI 10.1016/j.pvr.2019.100183
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Wang LDL, 2015, GYNECOL ONCOL, V138, P311, DOI 10.1016/j.ygyno.2015.05.018
   Wong CKH, 2018, VALUE HEALTH, V21, P622, DOI 10.1016/j.jval.2017.10.012
   Wong MCS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071827
   Xue L, 2018, HUM VACC IMMUNOTHER, V14, P404, DOI 10.1080/21645515.2017.1393132
   Yuen WWY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194159
   Zhang YR, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2873-8
   Zhao FH, 2012, CANCER EPIDEMIOL, V36, P384, DOI 10.1016/j.canep.2012.01.009
   Zhao FH, 2019, LANCET, V393, P969, DOI 10.1016/S0140-6736(18)32849-6
   2016, OBSTET GYNECOL, V128, pE11
NR 51
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1025
EP 1031
DI 10.1016/j.vaccine.2019.11.044
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100009
PM 31786002
DA 2020-05-12
ER

PT J
AU Lama, Y
   Hancock, GR
   Freimuth, VS
   Jamison, AM
   Quinn, SC
AF Lama, Yuki
   Hancock, Gregory R.
   Freimuth, Vicki S.
   Jamison, Amelia M.
   Quinn, Sandra Crouse
TI Using classification and regression tree analysis to explore parental
   influenza vaccine decisions
SO VACCINE
LA English
DT Article
DE Influenza vaccination; Influenza; Child health; Vaccine decision-making
ID AFRICAN-AMERICAN; FLU VACCINE; CHILDREN; HEALTH; ATTITUDES; HESITANCY;
   DETERMINANTS; IMMUNIZATION; ASSOCIATION; DISCUSSIONS
AB Background and objectives: Influenza poses a public health threat for children and adults. The CDC recommends annual influenza vaccination for children <18 years, yet vaccine uptake remains low for children (57.9%) and adults (37.1%). Given that parental decision-making is key in childhood vaccine uptake, there is a critical need to understand vaccine hesitancy among parents who decide not to vaccinate their children. This study aims to explore predictors of children's influenza vaccine status given parental vaccination status and examine the factors that contribute to concordance or discordance between parental and children's vaccine uptake.
   Methods: Classification and regression tree (CART) analyses were used to identify drivers of parental decisions to vaccinate their children against influenza. Hierarchy and interactions of these variables in predicting children's vaccination status were explored.
   Results: From a nationally representative sample of non-Hispanic Black and White parents who completed an online survey (n = 328), the main factors influencing parents' decisions to vaccinate their children were vaccine behavior following physician recommendation, knowledge of influenza recommendations for children, influenza vaccine confidence and disease risk. Among unvaccinated parents, the greatest concordance was observed among parents who usually do not get vaccinated following physician recommendation and had lower knowledge of recommendations for influenza vaccination for children. The greatest discordance was observed among unvaccinated parents who had lower hesitancy about recommended vaccines.
   Conclusions: Understanding drivers of parental decisions to vaccinate themselves and their children can provide insights on health communication and provider approaches to increase influenza vaccine coverage and prevent influenza related mortality. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lama, Yuki; Quinn, Sandra Crouse] Univ Maryland, Dept Family Sci, College Pk, MD 20742 USA.
   [Hancock, Gregory R.] Univ Maryland, Dept Human Dev & Quantitat Methods, College Pk, MD 20742 USA.
   [Freimuth, Vicki S.] Univ Georgia, Ctr Hlth & Risk Commun Emeritus, Athens, GA 30602 USA.
   [Jamison, Amelia M.; Quinn, Sandra Crouse] Univ Maryland, Ctr Hlth Equ, College Pk, MD 20742 USA.
RP Lama, Y (reprint author), Univ Maryland, Sch Publ Hlth, Dept Family Sci, 4200 Valley Dr,Bldg 225, College Pk, MD 20742 USA.
EM lamay@terpmail.umd.edu
FU Center of Excellence in Race, Ethnicity and Health Disparities Research
   [NIH-NIMHD: P20MD006737]
FX This study was funded by the Center of Excellence in Race, Ethnicity and
   Health Disparities Research (NIH-NIMHD: P20MD006737; PIs, Quinn and
   Thomas).
CR Allison MA, 2010, PEDIATR INFECT DIS J, V29, P751, DOI 10.1097/INF.0b013e3181d8562c
   Bhat-Schelbert K, 2012, VACCINE, V30, P2448, DOI 10.1016/j.vaccine.2012.01.049
   Bleser WK, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4664
   Breiman L, 1984, CLASSIFICATION REGRE
   Broniatowski DA, 2016, VACCINE, V34, P3225, DOI 10.1016/j.vaccine.2016.04.044
   Brown KF, 2010, VACCINE, V28, P4181, DOI 10.1016/j.vaccine.2010.04.012
   Brunson EK, 2013, VACCINE, V31, P5466, DOI 10.1016/j.vaccine.2013.08.104
   Byington CL, 2014, PEDIATRICS, V134, P377, DOI 10.1542/peds.2014-1494
   Chen MF, 2011, J COMMUN HEALTH NURS, V28, P29, DOI 10.1080/07370016.2011.539087
   Crawley MJ, 2012, R BOOK
   Dore RA, 2014, J PSYCHOL, V148, P477, DOI 10.1080/00223980.2013.808603
   Dube E, 2016, QUAL HEALTH RES, V26, P411, DOI 10.1177/1049732315573207
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Flood EM, 2010, CLIN THER, V32, P1448, DOI 10.1016/j.clinthera.2010.06.020
   Freed GL, 2011, PEDIATRICS, V127, pS107, DOI 10.1542/peds.2010-1722P
   Freimuth VS, 2017, SOC SCI MED, V193, P70, DOI 10.1016/j.socscimed.2017.10.001
   Frisman L, 2008, J PSYCHOACTIVE DRUGS, V40, P447, DOI 10.1080/02791072.2008.10400651
   Garten R, 2018, MMWR-MORBID MORTAL W, V67, P634, DOI 10.15585/mmwr.mm6722a4
   Gust D, 2005, AM J HEALTH BEHAV, V29, P81, DOI 10.5993/AJHB.29.1.7
   Gust DA, 2008, PEDIATRICS, V122, P718, DOI 10.1542/peds.2007-0538
   Hilyard KM, 2014, HEALTH EDUC BEHAV, V41, P307, DOI 10.1177/1090198113515244
   Hofstetter AM, 2017, VACCINE, V35, P2709, DOI 10.1016/j.vaccine.2017.03.077
   Imburgia TM, 2017, VACCINE, V35, P2338, DOI 10.1016/j.vaccine.2017.03.060
   Jamison AM, 2019, SOC SCI MED, V221, P87, DOI 10.1016/j.socscimed.2018.12.020
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Kennedy A, 2011, PEDIATRICS, V127, pS92, DOI 10.1542/peds.2010-1722N
   Kuhn L, 2014, J ADV NURS, V70, P1276, DOI 10.1111/jan.12288
   Lau JTF, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1026
   Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154
   Lemon SC, 2003, ANN BEHAV MED, V26, P172, DOI 10.1207/S15324796ABM2603_02
   Liu SJ, 2011, HUM VACCINES, V7, P1072, DOI 10.4161/hv.7.10.16781
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Malosh R, 2014, VACCINE, V32, P1841, DOI 10.1016/j.vaccine.2014.01.075
   Marentette T, 2011, CLIN NURS RES, V20, P422, DOI 10.1177/1054773811409032
   Mergler MJ, 2013, VACCINE, V31, P4591, DOI 10.1016/j.vaccine.2013.07.039
   Offutt-Powell TN, 2014, EPIDEMIOL INFECT, V142, P134, DOI 10.1017/S0950268813000782
   Opel DJ, 2013, PEDIATRICS, V132, P1037, DOI 10.1542/peds.2013-2037
   Paterson P, 2018, VACCINE, V36, P5397, DOI 10.1016/j.vaccine.2017.08.016
   Poland GA, 2012, HUM IMMUNOL, V73, P859, DOI 10.1016/j.humimm.2012.03.014
   Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033
   Quinn SC, 2017, VACCINE, V35, P1167, DOI 10.1016/j.vaccine.2016.12.046
   Robison SG, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2883
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Shang M, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-2918
   Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046
   Smith LE, 2017, VACCINE, V35, P1936, DOI 10.1016/j.vaccine.2017.02.031
   Tafuri S, 2014, VACCINE, V32, P4860, DOI 10.1016/j.vaccine.2013.11.006
   Tang MY, 2016, J HEALTH PSYCHOL, V21, P781, DOI 10.1177/1359105314539527
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1032
EP 1039
DI 10.1016/j.vaccine.2019.11.039
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100010
PM 31806534
DA 2020-05-12
ER

PT J
AU Waller, J
   Forster, A
   Ryan, M
   Richards, R
   Bedford, H
   Marlow, L
AF Waller, Jo
   Forster, Alice
   Ryan, Mairead
   Richards, Rebecca
   Bedford, Helen
   Marlow, Laura
TI Decision-making about HPV vaccination in parents of boys and girls: A
   population-based survey in England and Wales
SO VACCINE
LA English
DT Article
DE HPV vaccine; Attitudes; Precaution adoption process model; Adolescent;
   Boys
ID ATTITUDES; IMMUNIZATION; CRISIS
AB Background: School-based HPV vaccination in the UK will soon be extended to boys. Based on other countries' experience, uptake may initially be lower in boys than girls. We assessed HPV vaccine attitudes and decision-making in parents of boys and girls, to explore sex differences and inform public health messages.
   Methods: We carried out a cross-sectional population-based survey using home-based interviews in spring 2019. Participants were adults in England and Wales, with a child in school years 5-7 (aged 9-12 and eligible for HPV vaccination within 3 years). Measures included awareness of HPV and the vaccine, demographic factors, previous vaccine refusal and (after exposure to brief information) whether participants would allow their child to have the HPV vaccine (decided to vaccinate; decided not to vaccinate; undecided). We also assessed vaccine attitudes. Data were weighted to adjust for non-response. Multinomial logistic regression was used to explore predictors of deciding to (or not to) vaccinate compared with being undecided.
   Results: Among 1049 parents (weighted n = 1156), 55% were aware of HPV and the girls' vaccination programme, but only 23% had heard of plans to vaccinate boys. After information exposure, 62% said they would vaccinate their child, 10% would not, and 28% were undecided. Parents of girls were more willing to vaccinate than parents of boys (adjusted odds ratio: 1.80 (1.32-2.45)). Positive attitudes and HPV/vaccine awareness were significantly independently associated with deciding to vaccinate. Previous vaccine refusal for a child was the strongest predictor of not wanting the HPV vaccine.
   Conclusions: Our findings suggest a need for public health campaigns to raise awareness of plans to extend HPV vaccination to boys. Reassuringly only 10% of all parents were unwilling to vaccinate and our data suggest further information, including about safety and efficacy, may be important in supporting undecided parents to make the decision to vaccinate. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Waller, Jo; Marlow, Laura] Guys Hosp, Kings Coll London, Sch Canc & Pharmaceut Sci, Canc Prevent Grp, Great Maze Pond, London SE1 9RT, England.
   [Waller, Jo; Forster, Alice; Ryan, Mairead; Richards, Rebecca; Marlow, Laura] UCL, Dept Behav Sci & Hlth, Canc Commun & Screening Grp, Gower St, London WC1E 6BT, England.
   [Bedford, Helen] UCL Great Ormond St Inst Child Hlth, Populat Policy & Practice Res & Teaching Dept, 30 Guilford St, London WC1N 1EH, England.
RP Waller, J (reprint author), Guys Hosp, Kings Coll London, Sch Canc & Pharmaceut Sci, Canc Prevent Grp, Great Maze Pond, London SE1 9RT, England.
EM jo.waller@kcl.ac.uk; alice.forster@ucl.ac.uk;
   mairead.ryan.16@alumni.ucl.ac.uk; Rebecca.Richards@mrc-epid.cam.ac.uk;
   h.bedford@ucl.ac.uk; l.marlow@kcl.ac.uk
OI Marlow, Laura/0000-0003-1709-2397; Waller, Jo/0000-0003-4025-9132
FU Cancer Research UK Career Development FellowshipCancer Research UK
   [C7492/A17219]; Cancer Research UK fellowshipCancer Research UK
   [C49896/A17429]
FX This work was funded by a Cancer Research UK Career Development
   Fellowship (C7492/A17219). AF is partly funded by a Cancer Research UK
   fellowship (C49896/A17429).
CR [Anonymous], 2018, BBC NEWS
   [Anonymous], 2019, BBC NEWS
   Brotherton JML, 2011, LANCET, V377, P2085, DOI 10.1016/S0140-6736(11)60551-5
   Campbell H, 2017, VACCINE, V35, P2979, DOI 10.1016/j.vaccine.2017.03.089
   Chaturvedi AK, 2018, J CLIN ONCOL, V36, P262, DOI 10.1200/JCO.2017.75.0141
   Corcoran B, 2018, LANCET, V391, P2103, DOI 10.1016/S0140-6736(18)30854-7
   Department of Health and Social Care, 2018, HPV VACC BE GIV BOYS
   Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3
   Francis MR, 2018, VACCINE, V36, P6559, DOI 10.1016/j.vaccine.2017.08.026
   Gorjana R, 2017, PREV MED, V95, P26, DOI 10.1016/j.ypmed.2016.11.019
   Hanley SJB, 2015, LANCET, V385, P2571, DOI 10.1016/S0140-6736(15)61152-7
   Joint Committee on Vaccination and Immunisation, 2018, STAT HPV VACC
   Lacombe-Duncan A, 2018, VACCINE, V36, P2545, DOI 10.1016/j.vaccine.2018.02.079
   Marlow LAV, 2007, VACCINE, V25, P1945, DOI 10.1016/j.vaccine.2007.01.059
   McRee AL, 2010, SEX TRANSM DIS, V37, P234, DOI 10.1097/OLQ.0b013e3181c37e15
   Newman PA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019206
   NHS England, 2019, NHS LONG TERM PLAN
   Palmer T., 2019, BMJ-BRIT MED J, V365, P11161, DOI [10.1136/bmj.11161, DOI 10.1136/BMJ.I1161]
   Perez S, 2016, SEX TRANSM DIS, V43, P626, DOI 10.1097/OLQ.0000000000000506
   Prue G, 2018, LANCET, V392, P913, DOI 10.1016/S0140-6736(18)31821-X
   Samad L, 2006, BMJ-BRIT MED J, V332, P1312, DOI 10.1136/bmj.332.7553.1312
   Serrano B, 2018, BEST PRACT RES CL OB, V47, P14, DOI 10.1016/j.bpobgyn.2017.08.006
   Shapiro GK, 2018, PREV MED, V116, P203, DOI 10.1016/j.ypmed.2018.09.017
   Sherman SM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195801
   Stanley M, 2014, HUM VACC IMMUNOTHER, V10, P2106, DOI 10.4161/hv.29137
   Tatar O, 2019, HUM VACC IMMUNOTHER, V15, P1803, DOI 10.1080/21645515.2019.1575711
   WEINSTEIN ND, 1988, HEALTH PSYCHOL, V7, P355, DOI 10.1037/0278-6133.7.4.355
   WHO, 2019, 10 THREATS GLOB HLTH
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1040
EP 1047
DI 10.1016/j.vaccine.2019.11.046
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100011
PM 31787415
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Pan, SC
   Hsu, WT
   Lee, WS
   Wang, NC
   Chen, TJ
   Liu, MC
   Pai, HC
   Hsu, YS
   Chang, MG
   Hsieh, SM
AF Pan, Sung-Ching
   Hsu, Wei-Ting
   Lee, Wen-Sen
   Wang, Ning-Chi
   Chen, Tzeng-Ji
   Liu, Ming-Che
   Pai, Hui-Chen
   Hsu, Yu-Shen
   Chang, Mingi
   Hsieh, Szu-Min
TI A double-blind, randomized controlled trial to evaluate the safety and
   immunogenicity of an intranasally administered trivalent inactivated
   influenza vaccine with the adjuvant LTh(alpha K): A phase II study
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Administration; Intranasal; Adjuvant; LTh(alpha K)
ID HEAT-LABILE ENTEROTOXIN; SEASONAL INFLUENZA; ANTIBODY-RESPONSES; MUCOSAL
   ADJUVANTS; VIRUS-INFECTION; IGA ANTIBODIES; UNITED-STATES; SECRETORY
   IGA; PREVENTION; EFFICACY
AB Background: Intranasal influenza vaccines may provide protective efficacy by inducing both systemic antibodies and local secretory IgA. Live attenuated intranasal vaccines are not feasible for high-risk groups. A previously constructed inactivated vaccine with adjuvant revealed an association with neurological events in some studies. In this phase II trial, we aimed to evaluate the safety and immunogenicity of an intranasal influenza vaccine with a novel adjuvant, heat-labile enterotoxin (LT)-derived from E. coli (LTh(alpha K)).
   Methods: This study is a multicenter, randomized controlled, double-blind, phase II trial of an intranasal influenza vaccine containing 22.5 mu g of the hemagglutinin (HA) antigen of three influenza strains in combination with 2 different LTh(alpha K) adjuvant doses (group 1: 30 mu g; group 2: 45 mu g) in subjects 20-70 years old. The control vaccine was 22.5 mu g of influenza HA antigen alone (group 3). The vaccine was intranasally administered on days 1 and 8. Serum anti-HA antibody and nasal secretory IgA were measured, and adverse events (AEs) were recorded prevaccination and 29 (+/- 2) days postvaccination.
   Results: Of 354 participants randomized in the study, 340 received two vaccine doses. AEs were mostly mild, and there was no discontinuation related to the vaccine. Only a higher frequency of diarrhea after the first dose was noted among group 2 (11.5%) than among group 3 (2.8%), and there was no significant difference after the second dose. The three groups had comparable serum anti-HA antibody immunogenicity. However, the adjuvanted vaccines induced greater mucosal IgA antibody production than the control vaccine. In a subgroup analysis, group 1 participants achieved adequate immunogenicity among both 20- to 60- and 61- to 70-year-old participants.
   Conclusion: The intranasal influenza vaccine adjuvanted with LTh(alpha K) is generally safe and could provide systemic and local antibody responses. Adjuvanted vaccines were significantly more immunogenic than the nonadjuvanted control vaccine in mucosal immunity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pan, Sung-Ching; Hsu, Wei-Ting; Hsieh, Szu-Min] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Dept Internal Med, Taipei, Taiwan.
   [Lee, Wen-Sen] Taipei Med Univ, Coll Med, Wan Fang Med Ctr, Dept Internal Med, Taipei, Taiwan.
   [Wang, Ning-Chi] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Taipei, Taiwan.
   [Chen, Tzeng-Ji] Taipei Vet Gen Hosp, Dept Family Med, Taipei, Taiwan.
   [Liu, Ming-Che] Taipei Med Univ Hosp, Dept Urol, Taipei, Taiwan.
   [Pai, Hui-Chen; Hsu, Yu-Shen; Chang, Mingi] Advagene Biopharma Co Ltd, Taipei, Taiwan.
   [Pai, Hui-Chen; Hsu, Yu-Shen; Chang, Mingi] Dev Ctr Biotechnol, New Taipei, Taiwan.
RP Hsieh, SM (reprint author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan South Rd, Taipei 100, Taiwan.
EM hsmaids@hotmail.com
FU Ministry of Economic Affairs, ROC (Ministry of Economic Technology
   development programs A + Industrial Innovation R&D program fast-track
   plan) [106-EC-17 -A22 -I5-0-0010]; Advagene Biopharma
FX The present study was financially supported by the Ministry of Economic
   Affairs, ROC (the Ministry of Economic Technology development programs A
   + Industrial Innovation R&D program fast-track plan (106-EC-17 -A22
   -I5-0-0010)) and Advagene Biopharma.
CR Ainai A, 2017, VIRAL IMMUNOL, V30, P451, DOI 10.1089/vim.2017.0022
   Arden NH, 1986, OPTIONS CONTROL INFL, P155
   Auewarakul P, 2007, VACCINE, V25, P659, DOI 10.1016/j.vaccine.2006.08.026
   Carter NJ, 2011, DRUGS, V71, P1591, DOI 10.2165/11206860-000000000-00000
   Centers for Disease Control and Prevention, 2016, VACC COV AD US NAT H
   CLEMENTS JD, 1988, VACCINE, V6, P269, DOI 10.1016/0264-410X(88)90223-X
   CLEMENTS ML, 1986, J CLIN MICROBIOL, V24, P157, DOI 10.1128/JCM.24.1.157-160.1986
   di Valserra MDB, 2002, CLIN THER, V24, P100, DOI 10.1016/S0149-2918(02)85008-1
   Durrer P, 2003, VACCINE, V21, P4328, DOI 10.1016/S0264-410X(03)00457-2
   Gauger PC, 2014, METHODS MOL BIOL, V1161, P303, DOI 10.1007/978-1-4939-0758-8_25
   Gluck R, 2000, J INFECT DIS, V181, P1129, DOI 10.1086/315337
   Gluck U, 1999, J VIROL, V73, P7780
   Glueck R, 2001, VACCINE, V20, pS42, DOI 10.1016/S0264-410X(01)00292-4
   Glueck R, 2001, ADV DRUG DELIVER REV, V51, P203, DOI 10.1016/S0169-409X(01)00174-0
   Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1
   Gustin KM, 2011, J INFECT DIS, V204, P1491, DOI 10.1093/infdis/jir596
   Hashigucci K, 1996, VACCINE, V14, P113, DOI 10.1016/0264-410X(95)00174-Y
   Kende M, 2007, VACCINE, V25, P3219, DOI 10.1016/j.vaccine.2007.01.036
   Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999
   Lin IP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090293
   Lu PJ, 2013, AM J EPIDEMIOL, V178, P1478, DOI 10.1093/aje/kwt158
   Marien AG, 2019, ARCH PEDIATRIE, V26, P71, DOI 10.1016/j.arcped.2018.11.002
   Ministry of Healthwarefare, 2018, NAT VACC POL
   MURPHY BR, 1989, CURR TOP MICROBIOL, V146, P107
   Murphy BR, 1994, HDB MUCOSAL IMMUNOLO
   Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595
   Pan SC, 2019, VACCINE, V37, P1994, DOI 10.1016/j.vaccine.2019.02.006
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Stephenson I, 2006, J VIROL, V80, P4962, DOI 10.1128/JVI.80.10.4962-4970.2006
   Suzuki T, 2017, VACCINE, V35, P5297, DOI 10.1016/j.vaccine.2017.07.093
   Suzuki T, 2015, P NATL ACAD SCI USA, V112, P7809, DOI 10.1073/pnas.1503885112
   TAMURA S, 1991, EUR J IMMUNOL, V21, P1337, DOI 10.1002/eji.1830210602
   Tamura S, 2016, JPN J INFECT DIS, V69, P165, DOI 10.7883/yoken.JJID.2015.560
   Tamura SI, 2004, JPN J INFECT DIS, V57, P236
   Wacheck V, 2010, J INFECT DIS, V201, P354, DOI 10.1086/649428
   WALKER RI, 1994, VACCINE, V12, P387, DOI 10.1016/0264-410X(94)90112-0
   WHO, 2018, NEWSR INFL SEAS
   World Health Organization, 2015, MAN EST DIS BURD ASS
   World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1048
EP 1056
DI 10.1016/j.vaccine.2019.11.047
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100012
PM 31812463
DA 2020-05-12
ER

PT J
AU Jiang, MH
   Li, PC
   Wang, WH
   Zhao, MY
   Atif, N
   Zhu, S
   Fang, Y
AF Jiang, Minghuan
   Li, Pengchao
   Wang, Weihua
   Zhao, Mingyue
   Atif, Naveel
   Zhu, Shan
   Fang, Yu
TI Cost-effectiveness of quadrivalent versus trivalent influenza vaccine
   for elderly population in China
SO VACCINE
LA English
DT Article
DE Quadrivalent influenza vaccine; Trivalent influenza vaccine;
   Cost-effectiveness; Elderly; China
ID SEASONAL INFLUENZA; MORTALITY; BURDEN
AB Background: Influenza associated excess death occurred most in the elderly. We aimed to assess the cost-effectiveness of quadrivalent influenza vaccine (QIV) versus trivalent influenza vaccine (TIV) for prevention of influenza infection among elderly population in China.
   Methods: A decision-analytic model was developed to compare 1-year clinical and economic outcomes of three influenza vaccination options (no vaccination, TIV, and QIV) in a hypothetical cohort of Chinese elderly aged 69 years. Outcome measures included cost, influenza infection rate, influenza-related mortality rate, quality-adjusted life-years (QALY) loss, and incremental cost-effectiveness ratio (ICER) from societal perspective. Sensitivity analyses were performed to examine the uncertainty of model inputs.
   Results: Base-case results showed no vaccination was dominated (more costly at higher QALY loss) by TIV and QIV. QIV was more costly (USD56.29 versus USD54.28) with lower influenza infection rate (0.608 versus 0.623), mortality rate (0.00199 versus 0.00204), and QALY loss (0.01213 versus 0.01243) than TIV. QIV was cost-effective compared to TIV with 10ER of 6,700 USD/QALY below the willingness-to-pay threshold (29,580 USD/QALY). One-way sensitivity analysis found the cost-effectiveness of Q1V was subject to the relative risk of vaccine effectiveness of QIV versus TIV, and TIV would be cost-effective if the relative risk was below 1.05. In 10,000 Monte Carlo simulations, the probabilities of QIV, TIV, and no vaccination to be cost-effective were 86.3%, 13.7%, and 0%, respectively.
   Conclusion: QIV appears to be a cost-effective option compared to TIV and no influenza vaccination for elderly population in China. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jiang, Minghuan; Li, Pengchao; Zhao, Mingyue; Atif, Naveel; Zhu, Shan; Fang, Yu] Xi An Jiao Tong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian 710061, Peoples R China.
   [Jiang, Minghuan; Li, Pengchao; Zhao, Mingyue; Atif, Naveel; Zhu, Shan; Fang, Yu] Xi An Jiao Tong Univ, Ctr Drug Safety & Policy Res, Xian 710061, Peoples R China.
   [Jiang, Minghuan; Li, Pengchao; Zhao, Mingyue; Atif, Naveel; Zhu, Shan; Fang, Yu] Shaanxi Ctr Hlth Reform & Dev Res, Xian 710061, Peoples R China.
   [Wang, Weihua] Shaanxi Prov Ctr Dis Control & Prevent, Dept Noncommunicable Chron Dis Control & Prevent, Xian 710054, Peoples R China.
RP Fang, Y (reprint author), Xi An Jiao Tong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian 710061, Peoples R China.
EM jiangmh2017@xjtu.edu.cn; lipengchao1996@stu.xjtu.edu.cn;
   495928425@qq.com; mingyue0204@163.com; naveel_atif87@hotmail.com;
   zoey0323@163.com; yufang@mail.xjtu.edu.cn
FU China Postdoctoral Science Foundation, ChinaChina Postdoctoral Science
   Foundation [2018M631179]
FX This work was supported by the China Postdoctoral Science Foundation,
   China [2018M631179]. The funding had no role in the study design,
   collection, analysis, and interpretation of the data, writing the
   manuscript, and decision to submit the manuscript for publication.
CR Bauch CT, 2016, PLOS ONE, V11, DOI [10.1371/journalpone.0154970, DOI 10.1371/JOURNALPONE.0154970]
   Beyer WEP, 2013, VACCINE, V31, P6030, DOI 10.1016/j.vaccine.2013.09.063
   Chen J, 2015, ASIA-PAC J PUBLIC HE, V27, pNP936, DOI 10.1177/1010539512460269
   Chinese Center for Disease Control and Prevention, 2018, TECHN GUID SEAS INFL
   eng Z, 2015, BMC INFECT DIS, V143, DOI [10.1186/512879- 015-0884-1, DOI 10.1186/512879-015-0884-1]
   Feng LZ, 2012, B WORLD HEALTH ORGAN, V90, P279, DOI 10.2471/BLT.11.096958
   International Monetary Fund, PEOPL REP CHIN COUNT, DOI 10.1016a vaccine 2018,03.052
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Leung MK, 2016, VACCINE, V34, P2469, DOI 10.1016/j.vaccine.2016.04.008
   Mennini FS, 2018, HUM VACC IMMUNOTHER, V14, P1867, DOI 10.1080/21645515.2018.1469368
   Moa AM, 2016, VACCINE, V34, P4092, DOI 10.1016/j.vaccine.2016.06.064
   National Bureau of Statistics of China, ANN DAT
   National Health Commission of the People's Republic of China, 2018, 2018 CHIN HLTH STAT
   Petrie JG, 2011, J INFECT DIS, V203, P1309, DOI 10.1093/infdis/jir015
   Reber AJ, 2012, AGING DIS, V3, P68
   Shaanxi Provincial Public Resource Trading Center, ANN COMP CONS RES 2
   Somes MP, 2018, VACCINE, V36, P3199, DOI 10.1016/j.vaccine.2018.04.063
   Thommes EW, 2017, HUM VACC IMMUNOTHER, V13, P867, DOI 10.1080/21645515.2016.1251537
   Thorrington D, 2017, BMC MED, V166, P15, DOI [10.1186/c12916-017-0917-1, DOI 10.1186/C12916-017-0917-1,]
   Tsuzuki S, 2018, VACCINE, V36, P624, DOI 10.1016/j.vaccine.2017.12.058
   Van Bellinghen LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098437
   Wang Q, 2018, VACCINE, V36, P7262, DOI 10.1016/j.vaccine.2018.10.045
   Wendlandt R, 2018, VACCINE, V36, P2673, DOI 10.1016/j.vaccine.2018.03.052
   WHO, 2019, 10 THREATS GLOB HLTH
   World Health Organization, 2002, WORLD HLTH REP 2002
   Wu SS, 2018, INFLUENZA OTHER RESP, V12, P88, DOI 10.1111/irv.12515
   Yang J, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2801-2
   Yang J, 2016, VACCINE, V34, P5724, DOI 10.1016/j.vaccine.2016.10.013
   Yang J, 2015, J HIST-NCCU, V44, P43
   Yang MC, 2017, HUM VACC IMMUNOTHER, V13, P81, DOI 10.1080/21645515.2016.1225636
   You H, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6086-1
   You JHS, 2015, HUM VACC IMMUNOTHER, V11, P564, DOI 10.1080/21645515.2015.1011016
   You JHS, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0618-9
   Yu HJ, 2017, COMPEND PL GENOME, P53
   Zhou L, 2013, PLOS ONE, V8, DOI [10.1371/jourbalpone.0063788, DOI 10.1371/JOURBALPONE.0063788]
NR 35
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1057
EP 1064
DI 10.1016/j.vaccine.2019.11.045
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100013
PM 31787414
DA 2020-05-12
ER

PT J
AU Enticott, G
   Maye, D
   Naylor, R
   Brunton, L
   Downs, SH
   Donnelly, CA
AF Enticott, Gareth
   Maye, Damian
   Naylor, Rhiannon
   Brunton, Lucy
   Downs, Sara H.
   Donnelly, Christl A.
TI An assessment of risk compensation and spillover behavioural adaptions
   associated with the use of vaccines in animal disease management
SO VACCINE
LA English
DT Article
DE Risk compensation; Spillover behaviour; Veterinary vaccination; Bovine
   tuberculosis; Biosecurity; Agriculture; Farmer behaviour
ID HPV VACCINATION; TUBERCULOSIS; BADGERS; FARMERS; EFFICACY; TRUST
AB This paper analyses farmers' behavioural responses to Government attempts to reduce the risk of disease transmission from badgers to cattle through badger vaccination. Evidence for two opposing behavioural adaptions is examined in response to the vaccination of badgers to reduce the risk of transmission to farmed cattle. Risk compensation theory suggests that interventions that reduce risk, such as vaccination, are counterbalanced by negative behavioural adaptions. By contrast, the spillover effect suggests that interventions can prompt further positive behaviours. The paper uses data from a longitudinal mixed methods study of farmers' attitudes to badger vaccination to prevent the spread of bovine tuberculosis, their reports of biosecurity practices, and cattle movement data in 5 areas of England, one of which experienced badger vaccination. Analysis finds limited evidence of spillover behaviours following vaccination. Lack of spillover is attributed to farmers' beliefs in the effectiveness of biosecurity and the lack of similarity between badger vaccination and vaccination for other animal diseases. Risk compensation behaviours are associated with farmers' beliefs as to who should manage animal disease. Rather than farmers' belief in vaccine effectiveness, it is more likely that farmers' low sense of being able to do anything to prevent disease influences their apparent risk compensation behaviours. These findings address the gap in the literature relating to farmers' behavioural adaptions to vaccine use in the management of animal disease. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Enticott, Gareth] Cardiff Univ, Sch Geog & Planning, Cardiff CF10 3WA, Wales.
   [Maye, Damian] Univ Gloucestershire, Countryside & Community Res Inst, Cheltenham GL50 4AZ, Glos, England.
   [Naylor, Rhiannon] Royal Agr Univ, Cirencester GL7 6JS, Glos, England.
   [Brunton, Lucy] Royal Vet Coll, Hawkshead Lane, Hatfield AL9 7TA, Herts, England.
   [Downs, Sara H.] Anim & Plant Hlth Agcy, Woodham Lane, Addlestone KT15 3NB, Surrey, England.
   [Donnelly, Christl A.] Univ Oxford, Dept Stat, Oxford, England.
   [Donnelly, Christl A.] Imperial Coll London, MRC Ctr Global Infect Dis Anal, Dept Infect Dis Epidemiol, London, England.
RP Enticott, G (reprint author), Cardiff Univ, Sch Geog & Planning, Cardiff CF10 3WA, Wales.
EM enticottg@cardiff.ac.uk
OI Enticott, Gareth/0000-0001-5510-9597; Donnelly,
   Christl/0000-0002-0195-2463; Maye, Damian/0000-0002-4459-6630
FU Department for Environment, Food and Rural AffairsDepartment for
   Environment, Food & Rural Affairs (DEFRA) [SE3121, SE3135]; UK Medical
   Research CouncilMedical Research Council UK (MRC); Department for
   International Development
FX Research was funded by the Department for Environment, Food and Rural
   Affairs (projects SE3121 and SE3135). We are grateful to the farmers and
   vets that took part in the study, and the assistance of staff in the
   Animal Health and Plant Agency (Woodchester Park and Weybridge) for
   extracting data and providing information on the Badger Vaccination
   Deployment Project. Interpretation of the results rests with the
   authors. Christi A. Donnelly acknowledges joint Centre funding from the
   UK Medical Research Council and Department for International
   Development.
CR Adams J., 1995, RISK
   Animal and plant health agency, 2015, BADG VACC DEPL PROJ
   Animal and Plant Health Agency, 2018, BOV TUB ENGL 2017 EP
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191
   Brewer NT, 2007, ANN BEHAV MED, V34, P95, DOI 10.1007/BF02879925
   Broughan JM, 2016, PREV VET MED, V129, P88, DOI 10.1016/j.prevetmed.2016.05.007
   Burton RJF, 2004, SOCIOL RURALIS, V44, P195, DOI 10.1111/j.1467-9523.2004.00270.x
   Carrique-Mas JJ, 2008, PREV VET MED, V84, P85, DOI 10.1016/j.prevetmed.2007.11.001
   Carter S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035110
   Cassidy A, 2012, SOCIOL RURALIS, V52, P192, DOI 10.1111/j.1467-9523.2012.00562.x
   Chambers MA, 2011, P ROY SOC B-BIOL SCI, V278, P1913, DOI 10.1098/rspb.2010.1953
   Choi JY, 2006, SOC SCI MED, V63, P107, DOI 10.1016/j.socscimed.2005.11.063
   DAERA, 2018, TUB DIS STAT NO IR N
   Defra, 2018, MONTHL PUBL OFF STAT
   Defra, 2009, BOV TB BADG VACC DEP
   Dietz T, 2009, P NATL ACAD SCI USA, V106, P18452, DOI 10.1073/pnas.0908738106
   Enticott G, 2012, VET REC, V170, P204, DOI 10.1136/vr.100079
   Enticott G, 2008, T I BRIT GEOGR, V33, P433, DOI 10.1111/j.1475-5661.2008.00321.x
   Enticott G, 2016, J RURAL STUD, V45, P312, DOI 10.1016/j.jrurstud.2016.04.008
   Enticott G, 2015, EUR J WILDLIFE RES, V61, P387, DOI 10.1007/s10344-015-0905-9
   Fisher R, 2013, J RURAL STUD, V31, P13, DOI 10.1016/j.jrurstud.2013.02.006
   Godfray C, 2018, BOVINE TB STRATEGY R
   Godfray HCJ, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.1634
   Hansen BT, 2016, HUM VACC IMMUNOTHER, V12, P1451, DOI 10.1080/21645515.2016.1158367
   Hansen BT, 2014, VACCINE, V32, P4945, DOI 10.1016/j.vaccine.2014.07.025
   Hedlund J, 2000, Inj Prev, V6, P82, DOI 10.1136/ip.6.2.82
   Heffernan C, 2008, VACCINE, V26, P2433, DOI 10.1016/j.vaccine.2008.02.045
   Hidano A, 2016, PREV VET MED, V133, P31, DOI 10.1016/j.prevetmed.2016.09.015
   Holland RW, 2002, EUR J SOC PSYCHOL, V32, P869, DOI 10.1002/ejsp.135
   Independent Scientific Group (ISG), 2007, BOV TUB SCI EV
   Johnston WT, 2005, BIOL LETT-UK, V1, P53, DOI 10.1098/rsbl.2004.0249
   Lanzini P, 2014, J ENVIRON PSYCHOL, V40, P381, DOI 10.1016/j.jenvp.2014.09.006
   Lehane R, 1996, BEATING ODDS BIG COU
   Livingstone PG, 2015, NEW ZEAL VET J, V63, P98, DOI 10.1080/00480169.2015.1013581
   Metlay D, 1999, SOCIAL TRUST MANAGEM, P100
   Naylor R, 2018, SOCIOL RURALIS, V58, P3, DOI 10.1111/soru.12127
   Painter JE, 2017, VACCINE, V35, P3558, DOI 10.1016/j.vaccine.2017.05.024
   Perez S, 2018, DRUGS, V78, P1385, DOI 10.1007/s40265-018-0975-6
   PODSAKOFF PM, 1986, J MANAGE, V12, P531, DOI 10.1177/014920638601200408
   Poortinga W, 2005, RISK ANAL, V25, P199, DOI 10.1111/j.0272-4332.2005.00579.x
   Poortinga W, 2013, J ENVIRON PSYCHOL, V36, P240, DOI 10.1016/j.jenvp.2013.09.001
   Radcliffe R, 2010, RESPONSIBILITY COST
   Shortall O, 2018, SOCIOL RURALIS, V58, P583, DOI 10.1111/soru.12205
   Sutherland LA, 2012, J ENVIRON MANAGE, V104, P142, DOI 10.1016/j.jenvman.2012.03.013
   Thogersen J, 2004, J ENVIRON PSYCHOL, V24, P93, DOI 10.1016/S0272-4944(03)00039-2
   Thogersen J, 2003, J ENVIRON PSYCHOL, V23, P225, DOI 10.1016/S0272-4944(03)00018-5
   Thogersen J, 1999, J ECON PSYCHOL, V20, P53, DOI 10.1016/S0167-4870(98)00043-9
   Tiefenbeck V, 2013, ENERG POLICY, V57, P160, DOI 10.1016/j.enpol.2013.01.021
   Wiethoelter AK, 2017, PREV VET MED, V140, P67, DOI 10.1016/j.prevetmed.2017.03.003
   Woodroffe R, 2006, J APPL ECOL, V43, P1, DOI 10.1111/j.1365-2664.2005.01144.x
   Woodroffe R, 2017, J APPL ECOL, V54, P718, DOI 10.1111/1365-2664.12837
   Young AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101047
NR 52
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1065
EP 1075
DI 10.1016/j.vaccine.2019.11.037
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100014
PM 31813650
OA Green Published, Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Hesse, EM
   Atanasoff, S
   Hibbs, BF
   Adegoke, OJ
   Ng, C
   Marquez, P
   Osborn, M
   Su, JR
   Moro, PL
   Shimabukuro, T
   Nair, N
AF Hesse, Elisabeth M.
   Atanasoff, Sarah
   Hibbs, Beth F.
   Adegoke, Oluwasegun J.
   Ng, Carmen
   Marquez, Paige
   Osborn, Mark
   Su, John R.
   Moro, Pedro L.
   Shimabukuro, Tom
   Nair, Narayan
TI Shoulder Injury Related to Vaccine Administration (SIRVA): Petitioner
   claims to the National Vaccine Injury Compensation Program, 2010-2016
SO VACCINE
LA English
DT Article
DE Shoulder injury related to vaccine administration (SIRVA); National
   Vaccine Injury Compensation Program (VICP); Petitioner claims;
   Concession; Vaccination; Shoulder injury
ID BURSITIS; INJECTION
AB Background: Since 2010, petitioner claims of shoulder injury related to vaccine administration (SIRVA) to the National Vaccine Injury Compensation Program (VICP) have been increasing.
   Objective: To conduct a scientific review of clinical characteristics of SIRVA petitions to the VICP.
   Methods: We queried the VICP's Injury Compensation System database for medical reports of alleged SIRVA and SIRVA-like injuries. Medical reports are summaries of petitioner claims and supporting documentation along with a VICP clinician reviewer diagnosis and assessment of criteria for concession. We conducted a descriptive analysis of SIRVA petitioner claims recommended by the VICP for concession as SIRVA injuries.
   Results: We identified 476 petitioner claims recommended for concession. Claims per year increased from two in 2011, the first full year in the analytic period, to 227 in 2016. Median age was 51 years, 82.8% were women, and median body mass index was 25.1 (range 17.0-48.9). Four hundred cases (84.0%) involved influenza vaccine. Pharmacy or store (n = 168; 35.3%) was the most common place of vaccination followed by doctor's office (n = 147; 30.9%). Fewer than half of cases reported a suspected administration error; 172 (36.1%) reported 'injection too high' on the arm. Shoulder pain, rotator cuff problems, and bursitis were common initial diagnoses. Most (80.0%) cases received physical or occupational therapy, 60.1% had at least one steroid injection, and 32.6% had surgery. Most (71.9%) healthcare providers who gave opinions on causality considered the injury was caused by vaccination. A minority (24.3%) of cases indicated that symptoms had resolved by the last visit available in medical records.
   Conclusions: Most conceded claims for SIRVA were in women and involved influenza vaccines. Injection too high on the arm could be a factor due to the risk of injecting into underlying non-muscular tissues. Healthcare providers should be aware of proper injection technique and anatomical landmarks when administering vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hesse, Elisabeth M.] US Dept HHS, Epidem Intelligence Serv, Ctr Dis Control & Prevent, 1600 Clifton Rd,MS V24-5, Atlanta, GA 30329 USA.
   [Hesse, Elisabeth M.; Hibbs, Beth F.; Ng, Carmen; Marquez, Paige; Su, John R.; Moro, Pedro L.; Shimabukuro, Tom] US Dept HHS, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis,Ctr Dis Con, 1600 Clifton Rd,MSV18-4, Atlanta, GA 30329 USA.
   [Atanasoff, Sarah; Osborn, Mark; Nair, Narayan] US Dept HHS, Natl Vaccine Injury Compensat Program, Hlth Resources & Serv Adm, 5600 Fishers Lane, Rockville, MD 20857 USA.
   [Adegoke, Oluwasegun J.] US Dept HHS, Publ Hlth Informat Fellowship Program, Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Adegoke, Oluwasegun J.] US Dept HHS, Global Immunizat Div, Ctr Global Hlth, Ctr Dis Control & Prevent, 1600 Clifton Rd,MS H24-2, Atlanta, GA 30329 USA.
RP Hesse, EM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS H24-11, Atlanta, GA 30333 USA.
EM nrn3@cdc.gov
CR [Anonymous], 2018, NATL VACCINE INJURY
   [Anonymous], 2017, VACC INJ TABL
   Atanasoff S, 2010, VACCINE, V28, P8049, DOI 10.1016/j.vaccine.2010.10.005
   Barnes MG, 2012, J AM BOARD FAM MED, V25, P919, DOI 10.3122/jabfm.2012.06.110334
   Bodor M, 2007, VACCINE, V25, P585, DOI 10.1016/j.vaccine.2006.08.034
   Borick JM, 2008, ARTHROSCOPY, V24, P846, DOI 10.1016/j.arthro.2007.01.024
   Cook IF, 2014, HUM VACC IMMUNOTHER, V10, P605, DOI 10.4161/hv.27232
   Cook IF, 2006, VACCINE, V24, P937, DOI 10.1016/j.vaccine.2005.08.098
   Cook KM, 2011, PEDIATRICS, V127, pS74, DOI 10.1542/peds.2010-1722K
   Division of Nutrition Physical Activity and Obesity, 2017, AD BMI
   Health and Human Services, 2015, FED REGISTER, P45132
   Kraus R, 2010, KNEE SURG SPORT TR A, V18, P1738, DOI 10.1007/s00167-010-1092-6
   Kuether G, 2011, VACCINE, V29, P6830, DOI 10.1016/j.vaccine.2011.07.052
   Kvalvaag E, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1827-3
   Lippert WC, 2008, PEDIATRICS, V122, pE556, DOI 10.1542/peds.2008-0374
   Arias LHM, 2017, VACCINE, V35, P4870, DOI 10.1016/j.vaccine.2017.07.055
   National Center for Immunizations and Respiratory Diseases, 2018, HIST REF SEAS INFL V
   Okur G, 2014, SKELETAL RADIOL, V43, P1325, DOI 10.1007/s00256-014-1875-9
   Salmon JH, 2015, VACCINE, V33, P6152, DOI 10.1016/j.vaccine.2015.09.090
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Shimabukuro TT, 2017, REPORTS SHOULDER DYS
   Stratton KR, 2012, ADVERSE EFFECTS VACC
   Uchida S, 2012, VACCINE, V31, P27, DOI 10.1016/j.vaccine.2012.10.075
   Wofford JL, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-4
NR 24
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1076
EP 1083
DI 10.1016/j.vaccine.2019.11.032
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100015
PM 31771864
DA 2020-05-12
ER

PT J
AU Einarsdottir, S
   Ljungman, P
   Kaijser, B
   Nicklasson, M
   Horal, P
   Norder, H
   Bergstrom, T
   Brune, M
AF Einarsdottir, Sigrun
   Ljungman, Per
   Kaijser, Bertil
   Nicklasson, Malin
   Horal, Peter
   Norder, Helen
   Bergstrom, Tomas
   Brune, Mats
TI Humoral immunity to tetanus, diphtheria and polio in adults after
   treatment for hematological malignancies
SO VACCINE
LA English
DT Article
DE Hematological malignancy; Immunosuppression; Rituximab; Clinical
   immunology; Diphtheria; Polio; Tetanus
ID ACUTE-LYMPHOBLASTIC-LEUKEMIA; HYPOGAMMAGLOBULINEMIA; CHILDREN
AB Introduction: After chemotherapy, children with acute lymphocytic leukemia lose immunity and need revaccination against tetanus and diphtheria. However, little is known about immunity in adult patients after treatment for hematological malignancies. In this study, we assessed serology levels against polio, diphtheria and tetanus in adult patients after conventional treatment for leukemia and lymphoma.
   Patients: One hundred and four patients, age 61 (19-86) years, were included at a median of 18 (4-77) months after chemotherapy for acute leukemia (n = 24) or lymphoma (n = 80). Pre-treatment sera were available in 73 cases for a pre-versus post treatment comparison. Healthy, age- and sex matched controls were available for 47 pts.
   Methods: Tetanus antibodies were quantified using ELISA, and antibody levels >= 0.01 IU/mL were considered protective. Diphtheria antibodies were analyzed using neutralization test (n = 60) or by ELISA (n = 44). In both tests values >= 0.01 IU/mL were considered protective. Antibodies against poliovirus serotype 1 and 3 were assessed by a neutralizing test. A microneutralization titer of >= 2 was considered protective.
   Results: Tetanus: There were significantly more non-immune patients after treatment (24%), compared to before (12%), p = 0.02. Post-treatment antibody levels were significantly lower than pre-treatment levels (p = 0.02). Diphtheria: There was a trend, p = 0.06, towards more non-immune patients after treatment (21%) compared to before (27%). Antibody levels post treatment were lower than pre treatment levels (p = 0.03) and lower than controls (p = 0.01). Polio: There was no significant difference in the number of non-immune patients before vs after chemotherapy for either PV1 or PV3. Protective immunity against serotype 1 and 3 was preserved in 90 and 97%, respectively.
   Conclusions: After standard chemotherapy for leukemia and lymphoma a significant proportion of patients had impaired humoral immunity to diphtheria and tetanus. However, polio immunity was well preserved. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Einarsdottir, Sigrun; Nicklasson, Malin; Brune, Mats] Univ Gothenburg, Sahlgrenska Acad, Inst Med & Clin Nutr, Dept Hematol & Coagulat, Gothenburg, Sweden.
   [Ljungman, Per] Karolinska Inst, Dept Med, Div Hematol, Karolinska Univ Hosp,Dept Cellular Therapy & Allo, Stockholm, Sweden.
   [Kaijser, Bertil; Horal, Peter; Norder, Helen; Bergstrom, Tomas] Sahlgrens Univ Hosp, Dept Clin Microbiol, Gothenburg, Sweden.
RP Einarsdottir, S (reprint author), Sahlgrens Univ Hosp, Dept Hematol, Bruna Straket 5, SE-41345 Gothenburg, Sweden.
EM sigrun.einarsdottir@vgregion.se; Per.ljung-man@ki.se;
   malin.nicklasson@telia.se; Peter.horal@-microbio.gu.se;
   norder@microbio.gu.se; tomas.bergstrom@microbio.gu.se; brune@gu.se
FU Vastra Gotalandsregionen (FOU) [12203, 5257]; Gothenburg Medical Society
   [784051]
FX This work was supported by local research and development funds: Vastra
   Gotalandsregionen (FOU) number: 12203 and 5257, and the Gothenburg
   Medical Society number 784051.
CR [Anonymous], 2016, Wkly Epidemiol Rec, V91, P145
   Bottiger M, 1998, INT J EPIDEMIOL, V27, P916, DOI 10.1093/ije/27.5.916
   Calaminus G, 2007, KLIN PADIATR, V219, P355, DOI 10.1055/s-2007-990290
   Christou EAA, 2017, INT REV IMMUNOL, V36, P352, DOI 10.1080/08830185.2017.1346092
   Ek T, 2004, J PEDIAT HEMATOL ONC, V26, P727, DOI 10.1097/00043426-200411000-00008
   Folkhalsomyndigheten [Public Health Agency of Sweden], 2007, VACC SER TVARSN
   Hamarstrom V, 1998, SUPPORT CARE CANCER, V6, P469, DOI 10.1007/s005200050196
   Khaled Y, 2013, BIOL BLOOD MARROW TR, V19, pS235, DOI 10.1016/j.bbmt.2012.11.297
   Socialstyrelsen [The National Board of Health and Welfare], 2009, REK PROF VUXN MOT ST
   Wagner KS, 2012, EMERG INFECT DIS, V18, P217, DOI 10.3201/eid1802.110987
   Walker AR, 2008, CANCER INVEST, V26, P431, DOI 10.1080/07357900701809068
   World Hlth Org, 2018, VACCINE, V36, P199, DOI 10.1016/j.vaccine.2017.08.024
   World Hlth Org, 2018, VACCINE, V36, P3573, DOI 10.1016/j.vaccine.2017.02.034
   Yri OE, 2011, BLOOD, V118, P6769, DOI 10.1182/blood-2011-08-372649
   Zengin E, 2009, PEDIATR BLOOD CANCER, V53, P967, DOI 10.1002/pbc.22135
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1084
EP 1088
DI 10.1016/j.vaccine.2019.11.034
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100016
PM 31787417
DA 2020-05-12
ER

PT J
AU Top, KA
   Esteghamati, A
   Kervin, M
   Henaff, L
   Graham, JE
   MacDonald, NE
AF Top, Karina A.
   Esteghamati, Abdoulreza
   Kervin, Melissa
   Henaff, Louise
   Graham, Janice E.
   MacDonald, Noni E.
TI Governing off-label vaccine use: An environmental scan of the Global
   National Immunization Technical Advisory Group Network
SO VACCINE
LA English
DT Article
DE Immunisation; Regulation; Vaccination; Vaccine policy
ID RECOMMENDATIONS; DIPHTHERIA; TETANUS; WOMEN; TDAP
AB Background: National Regulatory Authorities approve the indications for vaccine use in the product information. Occasionally, National Immunization Technical Advisory Groups (NITAGs) make off-label recommendations for use in different age groups, populations, and dosing schedules from the product information. We sought to determine the rationale, policies and procedures for NITAG off-label recommendations.
   Methods: We conducted an environmental scan of Global NITAG Network members, immunization program managers and regulators in 38 high-, middle- and low-income countries. Participants completed an online survey regarding policies, procedures, and legislation governing development of off-label recommendations. A sub-sample of respondents met for a focus group and interviews which were analyzed qualitatively.
   Results: Thirty-four people responded from 26/38 (68%) countries surveyed; 76% of respondents were NITAG members or immunization program managers. Recommendations for off-label vaccine use were made in 14/26 (54%) countries; the NITAG made those recommendations in 8/14 (57%) countries. Reasons for off-label vaccine recommendations included response to disease outbreaks or vaccine shortages. Only one country had standard operating procedures for developing off-label recommendations while 6/14 (43%) countries had policies for implementing off-label recommendations. Nine respondents from 8 countries agreed to participate in a focus group (n = 6) or individual interviews (n = 3). Barriers to off-label recommendations included legal concerns, lack of standard definition for off-label use, and manufacturer reluctance to update product information. Facilitators included confidence in the decision-making process, and transparency of open communication among stakeholders.
   Conclusions: Best practice guidelines are needed that define off-label use and outline a transparent, evidence-based approach to develop off-label recommendations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Top, Karina A.; Graham, Janice E.; MacDonald, Noni E.] Dalhousie Univ, Dept Pediat, 5850-5980 Univ Ave, Halifax, NS B3K 6R8, Canada.
   [Top, Karina A.; Esteghamati, Abdoulreza; Kervin, Melissa; Graham, Janice E.; MacDonald, Noni E.] Dalhousie Univ, Canadian Ctr Vaccinol, IWK Hlth Ctr, Nova Scotia Hlth Author, 5850-5980 Univ Ave, Halifax, NS, Canada.
   [Esteghamati, Abdoulreza; Henaff, Louise] WHO, Ave Appia 20, Geneva, Switzerland.
RP Top, KA (reprint author), IWK Hlth Ctr, 4th Floor Goldbloom RCC Pavil,5850-5980 Univ Ave, Halifax, NS B3K 6R8, Canada.
EM karina.top@dal.ca; melissa.kervin@iwk.nshealth.ca; henaffl@who.int;
   janice.graham@dal.ca; noni.macdonald@dal.ca
OI Top, Karina/0000-0002-9981-368X
FU Public Health Agency of Canada [4500371527]
FX This study was funded by the Public Health Agency of Canada (contract
   #4500371527).
CR [Anonymous], 2016, Wkly Epidemiol Rec, V91, P145
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P433
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Dobson SRM, 2013, JAMA-J AM MED ASSOC, V309, P1793, DOI 10.1001/jama.2013.1625
   Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027
   Healy CM, 2013, CLIN INFECT DIS, V56, P539, DOI 10.1093/cid/cis923
   Kharbanda EO, 2014, JAMA-J AM MED ASSOC, V312, P1897, DOI 10.1001/jama.2014.14825
   MacDonald NE, 2017, VACCINE, V35, P6925, DOI 10.1016/j.vaccine.2017.10.048
   National Advisory Committee on Immunization, 2019, 2019 20 NAT ADV COMM
   National Advisory Committee on Immunization, 2015, UPD REC HUM PAP HPV
   National Energy Board, 2016, CISC VIS NETW IND GL, P1
   Neels P, 2017, VACCINE, V35, P2329, DOI 10.1016/j.vaccine.2017.02.056
   Nowell LS, 2017, INT J QUAL METH, V16, DOI 10.1177/1609406917733847
   Ramsay M, 2014, IMMUNISATION INFECT
   Salido-Monzu D., 2013, P INT C IND POS IND, P1, DOI [10.1109/IPIN.2013.6817870, DOI 10.1109/IPIN.2013.6817870]
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   WHO Secretariat, 2016, FRACT DOS YELL FEV V
   World Health Organization, 2018, IND SPOR
   World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1089
EP 1095
DI 10.1016/j.vaccine.2019.11.033
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100017
PM 31786003
DA 2020-05-12
ER

PT J
AU Yan, XY
   Zhou, M
   Yu, S
   Jin, Z
   Zhao, K
AF Yan, Xingye
   Zhou, Mo
   Yu, Shuang
   Jin, Zheng
   Zhao, Kai
TI An overview of biodegradable nanomaterials and applications in vaccines
SO VACCINE
LA English
DT Article
DE Biodegradable materials; Nanoparticles; Vaccine adjuvant; Delivery
   system; Nano vaccine
ID POLY-L-LYSINE; DRUG-DELIVERY SYSTEMS; PEPTIDE AMPHIPHILE MICELLES;
   PROTECTIVE IMMUNE-RESPONSE; DNA VACCINE; CHITOSAN NANOPARTICLES; LIPID
   NANOPARTICLE; POLY(L-LYSINE) DENDRIGRAFTS; EPSILON-POLYLYSINE;
   NEWCASTLE-DISEASE
AB Vaccination is the most cost-effective and sustainable way to prevent and eliminate infectious diseases. Compared with traditional vaccines, novel vaccines have better stability, longer duration and require less antigen usage. In addition, novel vaccines have better immune effects and significantly less toxic side effects. However, both novel vaccines and traditional vaccines require carrier molecules or adjuvants to produce an optimal immune response. There is an increasing demand for vaccine adjuvants and delivery systems that can induce stronger immune response whilst reducing production cost and the dose of vaccine. In recent years, nanotechnology has played an important role in the development of novel vaccine adjuvants and nano-delivery systems. Biodegradable materials have also received a lot of attention in medical science because they have excellent biocompatibility, biodegradability and low toxicity, which can protect antigens from degradation, increase antigen stability and provide slow release; resulting in enhanced immunogenicity. Therefore, biodegradable nanoparticles have attracted much attention in the formulation of vaccines. In this review, we outline some key features of biodegradable nanomaterials in the developing safer and more effective vaccines. The properties, structural characteristics, advantages and disadvantage of the biodegradable nanomaterials will be systematically reviewed. Additionally, applications, research progress and future prospects of biodegradable nanomaterials are discussed. This review will be help in future research work directed at developing biodegradable vaccine adjuvants or delivery carriers. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yan, Xingye; Zhou, Mo; Yu, Shuang; Zhao, Kai] Heilongjiang Univ, Engn Res Ctr Agr Microbiol Technol, Minist Educ, Harbin 150080, Peoples R China.
   [Yan, Xingye; Zhou, Mo; Yu, Shuang; Zhao, Kai] Heilongjiang Univ, Coll Heilongjiang Prov, Sch Life Sci, Key Lab Microbiol, Harbin 150080, Peoples R China.
   [Jin, Zheng] Heilongjiang Univ, Coll Chem & Mat Sci, Key Lab Chem Engn Proc & Technol High Efficiency, Harbin 150080, Peoples R China.
RP Zhao, K (reprint author), Heilongjiang Univ, Coll Heilongjiang Prov, Sch Life Sci, Key Lab Microbiol, Harbin 150080, Peoples R China.
EM zybin395@126.com
FU National Key Research and Development Program of China [2017YFD0500706];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31771000]; Excellent Youth Natural Science
   Foundation of Heilongjiang Province of China [JC2018008]; Cultivation
   Project of Scientific and Technological Achievements for Provincial
   Universities in Heilongjiang [TSTAUC2018017]; Special Project of
   Innovation Ability Enhancement of Science and Technology Institutions in
   Heilongjiang Province [YC2016D004]; Technological innovation talent of
   special funds for outstanding subject leaders in Harbin [2017RAXXJ001]
FX We gratefully acknowledge the Heilongjiang Provincial Key Laboratory of
   Plant Genetic Engineering and Biological Fermentation Engineering for
   Cold Region to carry out this work. This work was supported in part by
   the National Key Research and Development Program of China
   (2017YFD0500706), National Natural Science Foundation of China
   (31771000), Excellent Youth Natural Science Foundation of Heilongjiang
   Province of China (JC2018008), Cultivation Project of Scientific and
   Technological Achievements for Provincial Universities in Heilongjiang
   (TSTAUC2018017), Special Project of Innovation Ability Enhancement of
   Science and Technology Institutions in Heilongjiang Province
   (YC2016D004) and Technological innovation talent of special funds for
   outstanding subject leaders in Harbin (2017RAXXJ001).
CR Ahmed TA, 2016, DRUG DES DEV THER, V10, P483, DOI 10.2147/DDDT.S99651
   Aiedeh K, 1999, ARCH PHARM, V332, P103, DOI 10.1002/(SICI)1521-4184(19993)332:3<103::AID-ARDP103>3.0.CO;2-U
   Allison DD, 2006, TISSUE ENG, V12, P2131, DOI 10.1089/ten.2006.12.2131
   An S, 2013, BIOMATERIALS, V34, P8949, DOI 10.1016/j.biomaterials.2013.07.060
   Ashhurst AS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194620
   Babo PS, 2016, J BIOMATER APPL, V31, P693, DOI 10.1177/0885328216669475
   Bastola R, 2017, ARCH PHARM RES, V40, P1238, DOI 10.1007/s12272-017-0969-z
   Basu A, 2018, ADV MATER, V30, DOI 10.1002/adma.201706815
   Binjawadagi B, 2014, INT J NANOMED, V9, P679, DOI 10.2147/IJN.S56127
   Black M, 2012, ADV MATER, V24, P3845, DOI 10.1002/adma.201200209
   Black M, 2010, EXPERT REV VACCINES, V9, P157, DOI [10.1586/erv.09.160, 10.1586/ERV.09.160]
   Bozzuto G, 2015, INT J NANOMED, V10, P975, DOI 10.2147/IJN.S68861
   Camacho AI, 2013, VACCINE, V31, P3288, DOI 10.1016/j.vaccine.2013.05.020
   Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113
   Chen HC, 2017, J MATER CHEM B, V5, P972, DOI 10.1039/c6tb02714h
   Chong CSW, 2005, J CONTROL RELEASE, V102, P85, DOI 10.1016/j.jconrel.2004.09.014
   Collet H, 2010, CHEM-EUR J, V16, P2309, DOI 10.1002/chem.200901734
   Cordeiro AS, 2016, PHARM PAT ANAL, V5, P49, DOI 10.4155/ppa.15.38
   Coumes F, 2015, BIOMACROMOLECULES, V16, P3666, DOI 10.1021/acs.biomac.5b01150
   Ngo DH, 2015, FOOD HYDROCOLLOID, V51, P200, DOI 10.1016/j.foodhyd.2015.05.023
   Demento SL, 2012, BIOMATERIALS, V33, P4957, DOI 10.1016/j.biomaterials.2012.03.041
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Dobakhti F, 2009, MICROBES INFECT, V11, P296, DOI 10.1016/j.micinf.2008.12.003
   Doroud D, 2011, PARASITE IMMUNOL, V33, P335, DOI 10.1111/j.1365-3024.2011.01289.x
   Doroud D, 2011, J CONTROL RELEASE, V153, P154, DOI 10.1016/j.jconrel.2011.04.011
   Doroud D, 2010, J PHARM PHARM SCI, V13, P320, DOI 10.18433/J3R30T
   DOWNS EC, 1992, J CELL PHYSIOL, V152, P422, DOI 10.1002/jcp.1041520225
   Draget KI, 2011, FOOD HYDROCOLLOID, V25, P251, DOI 10.1016/j.foodhyd.2009.10.007
   Ekici S, 2011, CARBOHYD POLYM, V84, P1306, DOI 10.1016/j.carbpol.2011.01.028
   Fan YC, 2015, J CONTROL RELEASE, V208, P121, DOI 10.1016/j.jconrel.2015.04.010
   FLOREA BI, 2000, P INT S CONTR REL BI, V27, P846
   Francoia JP, 2018, CHEM-EUR J, V24, P2806, DOI 10.1002/chem.201704147
   Francoia JP, 2017, J CHEM INF MODEL, V57, P2173, DOI 10.1021/acs.jcim.7b00258
   Fundueanu G, 1999, BIOMATERIALS, V20, P1427, DOI 10.1016/S0142-9612(99)00050-2
   Gagliardi M, 2016, THER DELIV, V7, P809, DOI 10.4155/tde-2016-0051
   Gomathi T, 2017, INT J BIOL MACROMOL, V104, P1794, DOI 10.1016/j.ijbiomac.2017.08.057
   Gupta NK, 2011, VACCINE, V29, P9026, DOI 10.1016/j.vaccine.2011.09.033
   Gupta RK, 1998, DEV BIOLOGICALS, V92, P63
   Hakimi S, 2017, INT J BIOL MACROMOL, V95, P574, DOI 10.1016/j.ijbiomac.2016.10.094
   Hanson MC, 2015, J CLIN INVEST, V125, P2532, DOI 10.1172/JCI79915
   Harde H, 2014, NANOMEDICINE-UK, V9, P2511, DOI [10.2217/NNM.13.225, 10.2217/nnm.13.225]
   Haughney SL, 2013, ACTA BIOMATER, V9, P8262, DOI 10.1016/j.actbio.2013.06.006
   Hofman J, 2013, MACROMOL BIOSCI, V13, P167, DOI 10.1002/mabi.201200303
   Huang GL, 2017, DRUG DELIV, V24, P108, DOI 10.1080/10717544.2017.1399305
   Hussain A, 2017, INT J NANOMED, V12, P5087, DOI 10.2147/IJN.S138267
   Ibrahim A, 2013, MACROMOLECULES, V46, P533, DOI 10.1021/ma302125f
   Ilkhanizadeh S, 2019, INT J BIOL MACROMOL, V140, P605, DOI 10.1016/j.ijbiomac.2019.08.154
   Ilyinskii PO, 2014, VACCINE, V32, P2882, DOI 10.1016/j.vaccine.2014.02.027
   Irache Juan M, 2010, Front Biosci (Schol Ed), V2, P876
   Jaganathan KS, 2006, VACCINE, V24, P4201, DOI 10.1016/j.vaccine.2006.01.011
   Jahantigh D, 2014, J DRUG DELIV SCI TEC, V24, P33, DOI 10.1016/S1773-2247(14)50005-6
   Jain D, 2014, DRUG DEV IND PHARM, V40, P1576, DOI 10.3109/03639045.2014.917657
   JANI P, 1989, J PHARM PHARMACOL, V41, P809, DOI 10.1111/j.2042-7158.1989.tb06377.x
   Jimenez-Sanchez G, 2015, PHARM RES-DORDR, V32, P311, DOI 10.1007/s11095-014-1465-5
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Kodama Y, 2014, EUR J PHARM BIOPHARM, V87, P472, DOI 10.1016/j.ejpb.2014.04.013
   Kraft JC, 2014, J PHARM SCI-US, V103, P29, DOI 10.1002/jps.23773
   Lee J, 2018, VET IMMUNOL IMMUNOP, V200, P40, DOI 10.1016/j.vetimm.2018.04.006
   Li JF, 2013, BIOMATERIALS, V34, P9142, DOI 10.1016/j.biomaterials.2013.08.030
   Li L, 2013, J FISH DIS, V36, P987, DOI 10.1111/jfd.12032
   Li L, 2016, EXPERT REV VACCINES, V15, P313, DOI 10.1586/14760584.2016.1124762
   Liu HP, 2014, NATURE, V507, P519, DOI 10.1038/nature12978
   Liu Y, 2014, MOL PHARMACEUT, V11, P3330, DOI 10.1021/mp500084s
   Lopes M, 2017, EXPERT OPIN DRUG DEL, V14, P769, DOI 10.1080/17425247.2016.1214564
   Lu ZZ, 2018, NANOSCALE, V10, P9957, DOI 10.1039/c8nr01184b
   Ma TT, 2014, ASIAN J PHARM SCI, V9, P129, DOI 10.1016/j.ajps.2014.03.002
   Machado AHE, 2012, LANGMUIR, V28, P4131, DOI 10.1021/la204944j
   Maiti S., 2015, NANOPARTICLES PROMIS
   Manish M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061885
   Mauro N, 2016, RSC ADV, V6, P77256, DOI 10.1039/c6ra14935a
   Mckee AS, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-37
   Mohammed MA, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9040053
   Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109
   Nazeri S, 2018, MED MICROBIOL IMMUN, V207, P271, DOI 10.1007/s00430-018-0545-2
   Oliveira CR, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001894
   Pandey Rajesh, 2004, Current Drug Delivery, V1, P195, DOI 10.2174/1567201043334669
   Petersen LK, 2012, MOL PHARMACEUT, V9, P874, DOI 10.1021/mp2004059
   Petersen LK, 2011, BIOMATERIALS, V32, P6815, DOI 10.1016/j.biomaterials.2011.05.063
   Phanse Y, 2017, J BIOMED MATER RES A, V105, P2762, DOI 10.1002/jbm.a.36128
   Phanse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep03775
   Reitinger S, 2013, GERONTOLOGY, V59, P71, DOI 10.1159/000342200
   Rosenblatt KM, 2017, EUR J PHARM BIOPHARM, V117, P49, DOI 10.1016/j.ejpb.2017.03.010
   Sahariah P, 2017, BIOMACROMOLECULES, V18, P3846, DOI 10.1021/acs.biomac.7b01058
   Sahdev P, 2014, PHARM RES-DORDR, V31, P2563, DOI 10.1007/s11095-014-1419-y
   Salman HH, 2009, VACCINE, V27, P4784, DOI 10.1016/j.vaccine.2009.05.091
   Sharma S, 2013, J MICROENCAPSUL, V30, P283, DOI 10.3109/02652048.2012.726279
   Shi C, 2015, J BIOMAT SCI-POLYM E, V26, P1343, DOI 10.1080/09205063.2015.1095023
   Sideratou Z, 2010, J COLLOID INTERF SCI, V351, P433, DOI 10.1016/j.jcis.2010.07.072
   Silva AL, 2016, HUM VACC IMMUNOTHER, V12, P1056, DOI 10.1080/21645515.2015.1117714
   Singh M, 2001, J CONTROL RELEASE, V70, P267, DOI 10.1016/S0168-3659(00)00330-8
   Sisavath N, 2013, J CHROMATOGR A, V1289, P127, DOI 10.1016/j.chroma.2013.03.016
   Stary G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa8205
   Tanbour R, 2016, CURR PHARM DESIGN, V22, P2796, DOI 10.2174/1381612822666160217125215
   Tang M, 2016, J MATER CHEM B, V4, P1284, DOI 10.1039/c5tb02224j
   Torchilin VP, 2007, PHARM RES-DORDR, V24, P1, DOI 10.1007/s11095-006-9132-0
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Torres MP, 2011, ACTA BIOMATER, V7, P2857, DOI 10.1016/j.actbio.2011.03.023
   Trent A, 2015, AAPS J, V17, P380, DOI 10.1208/s12248-014-9707-3
   Trivedi R, 2010, NANOMEDICINE-UK, V5, P485, DOI 10.2217/NNM.10.10
   Tsogas I, 2007, BIOMACROMOLECULES, V8, P3263, DOI 10.1021/bm700668w
   Verheul RJ, 2011, J CONTROL RELEASE, V156, P46, DOI 10.1016/j.jconrel.2011.07.014
   Vicente S, 2013, J CONTROL RELEASE, V172, P773, DOI 10.1016/j.jconrel.2013.09.012
   Wang N, 2014, EUR J PHARM BIOPHARM, V88, P194, DOI 10.1016/j.ejpb.2014.04.007
   Xing L, 2018, MOLECULES, V23, DOI 10.3390/molecules23020229
   Yao WJ, 2013, MOL PHARMACEUT, V10, P2904, DOI 10.1021/mp4000053
   Yevlampieva N, 2012, POLYMERS-BASEL, V4, P20, DOI 10.3390/polym4010020
   Younes I, 2015, MAR DRUGS, V13, P1133, DOI 10.3390/md13031133
   Yu R, 2018, J DRUG TARGET, V27, P1
   Yuan J, 2018, COLLOID SURFACE B, V171, P406, DOI 10.1016/j.colsurfb.2018.07.058
   Zepp F, 2010, VACCINE, V28, pC14, DOI 10.1016/j.vaccine.2010.07.020
   Zhang WB, 2017, I0P C SERIES MAT SCI, V275
   Zhao DY, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10040462
   Zhao K, 2018, MOL PHARMACEUT, V15, P226, DOI 10.1021/acs.molpharmaceut.7b00826
   Zhao K, 2017, DRUG DELIV, V24, P1574, DOI 10.1080/10717544.2017.1388450
   Zhao K, 2014, INT J NANOMED, V9, P389, DOI 10.2147/IJN.S54226
   Zhao K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082648
   Zhao K, 2010, J MICROENCAPSUL, V27, P178, DOI 10.3109/02652040903059239
   Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069
NR 119
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1096
EP 1104
DI 10.1016/j.vaccine.2019.11.031
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100018
PM 31813649
DA 2020-05-12
ER

PT J
AU Ward, K
   Mugenyi, K
   MacNeil, A
   Luzze, H
   Kyozira, C
   Kisakye, A
   Matseketse, D
   Newall, AT
   Heywood, AE
   Bloland, P
   Pallas, SW
AF Ward, Kirsten
   Mugenyi, Kevin
   MacNeil, Adam
   Luzze, Henry
   Kyozira, Carol
   Kisakye, Annet
   Matseketse, David
   Newall, Anthony T.
   Heywood, Anita E.
   Bloland, Peter
   Pallas, Sarah W.
TI Financial cost analysis of a strategy to improve the quality of
   administrative vaccination data in Uganda
SO VACCINE
LA English
DT Article
DE Health expenditures; Cost study; Immunization; Vaccination; Data
   accuracy; Workforce development
ID PRIMARY-HEALTH-CARE; MIDDLE-INCOME COUNTRIES; IMMUNIZATION SERVICES;
   SYSTEMATIC ANALYSIS; SUPERVISION; COVERAGE; INCREASE; IMPACT
AB Background: High-quality vaccination data are critical to planning, implementation and evaluation of immunization programs. However, sub-optimal administrative vaccination data quality in low- and middle-income countries persist for heterogeneous reasons, though most relate to organizational factors and human behavior. The nationwide Data Improvement Team (DIT) strategy in Uganda aimed to strengthen human resource capacity to generate quality administrative vaccination data at the health facility.
   Methods: A financial cost analysis of the Uganda DIT strategy (2014-2016) was conducted from the program funder perspective. Activity-based micro-costing from funder financial and program monitoring records was used to estimate total and unit costs by program area (in 2016 US dollars). Hypothetical scenarios were developed to illustrate potential approaches to reducing costs.
   Results: Over 25 months the DIT strategy was implemented in all 116 operational districts and 3443 (89%) health facilities in Uganda at a total financial cost of US $575 275. Training and deployment of DITs accounted for the highest proportion of expenditure across program areas (69%). Transport, per diems, lodging, and honoraria for DIT members and national supervisors were the main cost drivers of the strategy. Deployment of 557 DIT members cost US $839 per DIT member, US $4 030 per district, and US $136 per health facility. The estimated opportunity cost of government staff time wasn't a major cost driver (2.5%) of total cost.
   Conclusion: The results provide the first estimates of the magnitude and drivers of cost to implement a national workforce capacity building strategy to improve administrative vaccination data quality in a low- or middle-income country. Financial costs are a critical input to combine with future outcome data to describe the cost of strategies relative to performance outcomes. The operational costs of the strategy were modest (0.5-1.6%) relative to the estimated operational costs of Uganda's national immunization program. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ward, Kirsten; MacNeil, Adam; Bloland, Peter; Pallas, Sarah W.] US Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,Mailstop H24-2, Atlanta, GA 30317 USA.
   [Mugenyi, Kevin] African Field Epidemiol Network AFENET Secretaria, Lugogo House,Plot 42, Kampala, Uganda.
   [Luzze, Henry] Republ Uganda Minist Hlth, Uganda Natl Expanded Program Immunizat, Plot 6,Lourdel Rd, Kampala, Uganda.
   [Kyozira, Carol] Republ Uganda Minist Hlth, Div Hlth Informat Management, Plot 6,Lourdel Rd, Kampala, Uganda.
   [Kisakye, Annet] WHO, Plot 60 Prince Charles Ave, Kampala, Uganda.
   [Matseketse, David] United Nat Childrens Fund UNICEF, Plot 9,George St, Kampala, Uganda.
   [Ward, Kirsten; Newall, Anthony T.; Heywood, Anita E.] Univ New South Wales, Sch Publ Hlth & Community Med, Samuels Bldg,F25,Samuel Terry Ave, Kensington, NSW 2033, Australia.
RP Ward, K (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop H24-4, Atlanta, GA 30317 USA.
EM wvk8@cdc.gov; kmugenyi@afenet.net; aho3@cdc.gov; luzzehenry@hotmail.com;
   ckyozira@gmail.com; kisakyean@who.int; dmatseketse@unicef.org;
   a.newall@unsw.edu.au; a.heywood@unsw.edu.au; pbloland@gmail.com;
   xgx4@cdc.gov
OI Heywood, Anita/0000-0003-4400-7960
FU United States Centers for Disease Control and PreventionUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA
FX Financial support for this work was provided by the United States
   Centers for Disease Control and Prevention. The findings and conclusions
   in this paper are those of the authors and do not necessarily represent
   the official position of the United States Centers for Disease Control
   and Prevention. Thanks to those who supported the development,
   implementation and monitoring of the first phase of the DIT strategy: Dr
   Bernard Opar, Ampeire Immaculate, Frehd Nghania, Carol Balwanaki,
   Johnathon Tewodros, Amalia Benke, Dr Patricia Tanifum, Olivia Bbombokka,
   Sarah Kasozi, Lillian Akello, and all the Data Improvement Team members
   and national support staff.
CR Asante A, U NEW S WALES SCH PU
   Bailey C, 2016, INT J GYNECOL OBSTET, V132, P117, DOI 10.1016/j.ijgo.2015.10.004
   Bank of Uganda, 2017, MON FIN SECT STAT EX
   Batt K, 2004, B WORLD HEALTH ORGAN, V82, P689
   Better Immunization Data (BID) Initiative, BID INT BRIEFS REC L
   Bino S, 2013, OPTIMIZE ALBANIA REP
   Bloland P, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6709-1
   Bosch-Capblanch X, 2008, TROP MED INT HEALTH, V13, P369, DOI 10.1111/j.1365-3156.2008.02012.x
   Bradley S, 2013, HUM RESOUR HEALTH, V11, DOI 10.1186/1478-4491-11-43
   Byford S, 1998, BRIT MED J, V316, P1529, DOI 10.1136/bmj.316.7143.1529
   Chen H, 2014, STUD HEALTH TECHNOL, V204, P13, DOI 10.3233/978-1-61499-427-5-13
   Dougherty L, 2014, LIT REV IMPROVING DA
   Drummond Michael F., 2015, METHODS EC EVALUATIO
   Dunn A, 2016, HEALTH SERV RES, V53, P175
   Egger D, 2007, 8 DEP HLTH POL
   Feldstein LR, 2017, MMWR-MORBID MORTAL W, V66, P1252, DOI 10.15585/mmwr.mm6645a3
   Gandhi G, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-67
   Geng F, 2017, HEALTH POLICY PLANN, V32, P1174, DOI 10.1093/heapol/czx067
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Haddix AC, 2003, PREVENTION EFFECTIVE
   Hagopian A, 2009, HEALTH AFFAIR, V28, pW863, DOI 10.1377/hlthaff.28.5.w863
   Holmes CB, 2012, HEALTH AFFAIR, V31, P1553, DOI 10.1377/hlthaff.2012.0562
   Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1
   KEJA K, 1988, World Health Statistics Quarterly, V41, P59
   Kimaro HC, 2006, ELECTR J INF SYS DEV, V26
   Levin A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101114
   Lim SS, 2008, LANCET, V372, P2031, DOI 10.1016/S0140-6736(08)61869-3
   LOEVINSOHN BP, 1995, HEALTH POLICY PLANN, V10, P144, DOI 10.1093/heapol/10.2.144
   LOEVINSOHN BP, 1994, INT J EPIDEMIOL, V23, P194, DOI 10.1093/ije/23.1.194
   Maokola W, 2011, TROP MED INT HEALTH, V16, P721, DOI 10.1111/j.1365-3156.2011.02751.x
   Marquez L, 2002, 4 MAQ USAID
   Murray CJL, 2003, LANCET, V362, P1022, DOI 10.1016/S0140-6736(03)14411-X
   Nicol E, 2013, STUD HEALTH TECHNOL, V192, P788, DOI 10.3233/978-1-61499-289-9-788
   Panda B, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.25772
   Pegurri E, 2005, VACCINE, V23, P1624, DOI 10.1016/j.vaccine.2004.02.029
   Quentin W, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-137
   Rabarison KM, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/fpubh.2015.00164
   Republic of Uganda Ministry of Health, 2016, FIN SUST PLAN UG IMM
   Ronveaux O, 2005, B WORLD HEALTH ORGAN, V83, P503
   Rowe AK, 2018, LANCET GLOB HEALTH, V6, pE1163, DOI 10.1016/S2214-109X(18)30398-X
   Ryman T, 2010, J PUBLIC HEALTH-UK, V32, P18, DOI 10.1093/pubmed/fdp048
   SAGE Working Group on Quality and Use of Immunization and Surveillance Data, 2019, SAGE WORK GROUP QUAL
   Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001
   Strategic Advisory Group of Experts (SAGE), 2016, 2016 MIDT REV GLOB V
   Suraratdecha C, 2008, B WORLD HEALTH ORGAN, V86, P221, DOI 10.2471/BLT.06.039495
   The Republic of Uganda Ministry of Health, 2016, UG NAT EXP PROGR IMM
   Thompson G, 2009, STAT LIT GUIDE ADJUS
   Tweheyo R, 2017, BMJ GLOB HEALTH, V2, DOI 10.1136/bmjgh-2017-000455
   Vandelaer J, 2008, B WORLD HEALTH ORGAN, V86
   Vasan A, 2016, HLTH POLICY PLAN, P1
   VERNON R, 1994, STUD FAMILY PLANN, V25, P232, DOI 10.2307/2137906
   Vian T, 2013, HEALTH POLICY PLANN, V28, P237, DOI 10.1093/heapol/czs056
   Ward K, 2019, VACCINE, V37, P2821, DOI 10.1016/j.vaccine.2019.04.015
   Ward K, 2017, EMERG INFECT DIS, V23, pS85, DOI 10.3201/eid2313.170627
   WASSWA H, 2017, BMJ-BRIT MED J, V359, DOI DOI 10.1136/BMJ.J5221
   Wetherill O, 2017, ANN INFECT DIS EPIDE, V2, P1012
   World Health Organization, 2017, DAT QUAL REV TOOK FA
   World Health Organization, IMM COV
   World Health Organization, 2012, GLOB VACC ACT PLAN A
   World Health Organization, IMM VACC BIOL
   World Health. Organization, 2008, TRAIN MIDL MAN MLM M
   World Health Organization, 2017, COST IMM SERV DEL UG
NR 62
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1105
EP 1113
DI 10.1016/j.vaccine.2019.11.030
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100019
PM 31767466
DA 2020-05-12
ER

PT J
AU Dochez, C
   Al Awaidy, S
   Mohsni, E
   Fahmy, K
   Bouskraoui, M
AF Dochez, Carine
   Al Awaidy, Salah
   Mohsni, Ezzeddine
   Fahmy, Kamal
   Bouskraoui, Mohammed
TI Strengthening national teams of experts to support HPV vaccine
   introduction in Eastern Mediterranean countries: Lessons learnt and
   recommendations from an international workshop
SO VACCINE
LA English
DT Article
DE Cervical cancer; HPV vaccines; Eastern Mediterranean Region; NITAGs
ID HUMAN-PAPILLOMAVIRUS
AB Several countries have started to introduce the HPV vaccine into their national immunisation programme, with the majority of these countries being high or upper-middle income countries. Currently, 91 countries have introduced the HPV vaccine globally. One of the regions lagging behind in the introduction of the HPV vaccine is the Eastern Mediterranean Region, with currently only Libya and the United Arab Emirates having introduced the HPV vaccine.
   In order to support countries in the Eastern Mediterranean Region with their decision-making process for HPV vaccine introduction, a regional workshop was organised to explore the current status of HPV vaccine introduction plans in the Eastern Mediterranean countries, gaps in information about HPV disease burden in the region and the need for quality HPV data to make an informed decision to introduce the HPV vaccine, socio-cultural and religious challenges with HPV vaccine introduction, and the role of NITAGs in formulating recommendations for HPV vaccine introduction.
   Participating countries reflected on their respective status of decision making process about HPV vaccine introduction; they discussed any needs for operational research to support the decision-making process; and highlighed technical and financial support that might be required from partners to assist with HPV vaccine introduction. Recommendations were made on how to advance the decision-making process for HPV vaccine introduction.
   The workshop increased the awareness of the need of data on burden of disease and the associated benefits of HPV vaccination in Eastern Mediterranean countries. The importance of collaboration between different programmes including: immunisation, adolescent health, school health, sexual and reproductive health and cancer control programmes was clearly emphasized. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dochez, Carine] Univ Antwerp, Dept Epidemiol & Social Med, NESI, Univ Pl 1, B-2610 Antwerp, Belgium.
   [Al Awaidy, Salah] Minist Hlth, Muscat, Oman.
   [Mohsni, Ezzeddine] Global Hlth Dev Eastern Mediterranean Publ Hlth N, Amman, Jordan.
   [Fahmy, Kamal] WHO, Reg Off Eastern Mediterranean WHO EMRO, Cairo, Egypt.
   [Bouskraoui, Mohammed] Univ Cadi Ayyad, Marrakech, Morocco.
   [Bouskraoui, Mohammed] Soc Marocaine Infectiol Pediat & Vaccinol SOMIPEV, Marrakech, Morocco.
RP Dochez, C (reprint author), Univ Antwerp, Dept Epidemiol & Social Med, NESI, Univ Pl 1, B-2610 Antwerp, Belgium.
EM carine.dochez@uantwerpen.be
OI Dochez, Carine/0000-0002-8003-7959
FU World Health OrganizationWorld Health Organization [001]
CR Adjagba A, 2017, VACCINE, V35, P3007, DOI 10.1016/j.vaccine.2017.04.039
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P241
   Broutet N, 2013, J ADOLESCENT HEALTH, V53, P6, DOI 10.1016/j.jadohealth.2013.02.022
   Bruni L, 2019, HUMAN PAPILLOMAVIRUS
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   Dochez C, 2017, PAPILLOMAVIRUS RES, V4, P66, DOI 10.1016/j.pvr.2017.08.003
   Gessner BD, 2010, VACCINE, V28, pA1, DOI 10.1016/j.vaccine.2010.02.025
   International Agency for Research on Cancer, GLOB 2018
   Seoud M, 2013, VACCINE, V31, pVII, DOI 10.1016/j.vaccine.2012.05.038
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   World Health Organization, 2013, GLOB VACC ACT PLAN
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1114
EP 1119
DI 10.1016/j.vaccine.2019.11.027
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100020
PM 31771862
DA 2020-05-12
ER

PT J
AU Ko, MK
   Jo, HE
   Choi, JH
   You, SH
   Shin, SH
   Jo, H
   Lee, MJ
   Kim, SM
   Kim, B
   Park, JH
AF Ko, Mi-Kyeong
   Jo, Hye-Eun
   Choi, Joo-Hyung
   You, Su-Hwa
   Shin, Sung Ho
   Jo, Hyundong
   Lee, Min Ja
   Kim, Su-Mi
   Kim, Byounghan
   Park, Jong-Hyeon
TI Improved foot-and-mouth disease vaccine with O PanAsia-2 strain protect
   pigs against O/Jincheon/SKR/2014 originated from South Korea
SO VACCINE
LA English
DT Article
DE Foot-and-mouth disease; O PanAsia-2; Pig; Cattle; Vaccine
ID MANISA MONOVALENT VACCINE; HETEROLOGOUS CHALLENGE; CLINICAL VARIATION;
   SEROTYPE O; EAST-ASIA; VIRUS; EPIDEMIC; EFFICACY
AB Efforts are required to develop foot-and-mouth disease (FMD) vaccines in Asia that can respond to the type O outbreaks that have continued with the devastating damage since 2010. It is necessary to develop vaccine strains that can provide protection against the ME-SA topotype, which has tended to spread into neighboring areas, and the frequent SEA topotype outbreaks. To this end, this study aimed to develop a FMD vaccine utilizing O PanAsia-2 that is able to provide broad protection against ME-SA as the vaccine strain, with a focus on the Ogincheon/SKR/2014 virus (SEA topotype), the outbreaks of which have persisted in spite of the enforcement of FMD vaccination. The virus neutralizing antibody (VN) titer to the ME-SA topotype (especially, Ind2001 lineage) virus in pigs was the highest, followed by SEA, while the VN titers to the Cathay and EURO-SA topotypes were similar. In the O/Jincheon/SKR/2014 virus challenge test, all pigs were protected against the virus, and almost no virus shedding was detected after the virus challenge. In the immunization test performed on cattle and pigs, antibodies with sufficient protective activity were produced in cattle two weeks after the first immunization, and pigs exhibited lower immunity compared to cattle. However, immunity was improved enough in pigs to provide protection against the virus challenge after the second immunization, with a significant increase in antibody production. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ko, Mi-Kyeong; Jo, Hye-Eun; Choi, Joo-Hyung; You, Su-Hwa; Shin, Sung Ho; Jo, Hyundong; Lee, Min Ja; Kim, Su-Mi; Kim, Byounghan; Park, Jong-Hyeon] Anim & Plant Quarantine Agcy, Ctr Foot & Mouth Dis Vaccine Res, 177 Hyeoksin 8 Ro, Gimcheon City 39660, Gyeongsangbuk D, South Korea.
RP Park, JH (reprint author), Anim & Plant Quarantine Agcy, 177 Hyeoksin 8 Ro, Gimcheon City 39660, Gyeongsangbuk D, South Korea.
EM parkjhvet@korea.kr
OI Park, Jong-Hyeon/0000-0003-0825-8121
FU Animal and Plant Quarantine Agency, Gimcheon, Gyeongsangbuk-do, Republic
   of Korea
FX Supported by Animal and Plant Quarantine Agency, Gimcheon,
   Gyeongsangbuk-do, Republic of Korea.
CR Bo LL, 2018, TRANSBOUND EMERG DIS, DOI [10.1111/ thed.13112, DOI 10.1111/THED.13112]
   Brito BP, 2017, TRANSBOUND EMERG DIS, V64, P316, DOI 10.1111/tbed.12373
   Novo SG, 2018, VACCINE, V36, P1570, DOI 10.1016/j.vaccine.2018.02.015
   Horsington J, 2017, VACCINE, V35, P5179, DOI 10.1016/j.vaccine.2017.07.102
   Kardjadj M, 2018, VET ITAL, V54, P5, DOI 10.12834/VetIt.928.4711.2
   Kim RH, 2015, CLIN EXP VACCINE RES, V4, P114, DOI 10.7774/cevr.2015.4.1.114
   Kitching RP, 2002, REV SCI TECH OIE, V21, P513, DOI 10.20506/rst.21.3.1367
   Kitching RP, 2002, REV SCI TECH OIE, V21, P499, DOI 10.20506/rst.21.3.1343
   Knowles NJ, 2012, EMERG INFECT DIS, V18, P499, DOI 10.3201/eid1803.110908
   Ko MK, 2019, VET MICROBIOL, V229, P124, DOI 10.1016/j.vetmic.2018.12.023
   Lee SY, 2017, J VIROL, V91, DOI [10.1128/JVI.00155-17, 10.1128/jvi.00155-17]
   Liao PC, 2003, VACCINE, V21, P1807, DOI 10.1016/S0264-410X(03)00030-6
   Mahapatra M, 2019, J GEN VIROL, V100, P804, DOI 10.1099/jgv.0.001259
   Mahapatra M, 2018, EXPERT REV VACCINES, V17, P577, DOI 10.1080/14760584.2018.1492378
   Mahapatra M, 2017, VACCINE, V35, P7147, DOI 10.1016/j.vaccine.2017.10.099
   Park JN, 2014, VACCINE, V32, P1882, DOI 10.1016/j.vaccine.2014.01.067
   Park JH, 2018, J VET SCI, V19, P271, DOI 10.4142/jvs.2018.19.2.271
   Park JH, 2016, CLIN EXP VACCINE RES, V5, P83, DOI 10.7774/cevr.2016.5.1.83
   Park JH, 2013, EMERG INFECT DIS, V19, P655, DOI 10.3201/eid1904.121320
   Park JH, 2013, CLIN EXP VACCINE RES, V2, P8, DOI 10.7774/cevr.2013.2.1.8
   Wilna V, 2015, VACCINE, V33, P2778, DOI 10.1016/j.vaccine.2015.04.045
   Zheng HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055228
   Zhu Z, 2018, TRANSBOUND EMERG DIS, V65, P2027, DOI 10.1111/tbed.12895
NR 23
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1120
EP 1128
DI 10.1016/j.vaccine.2019.11.029
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100021
PM 31810782
DA 2020-05-12
ER

PT J
AU Forstner, C
   Kolditz, M
   Kesselmeier, M
   Ewig, S
   Rohde, G
   Barten-Neiner, G
   Rupp, J
   Witzenrath, M
   Welte, T
   Pletz, MW
   Dreher, M
   Cornelissen, C
   Knuppel, W
   Stolz, D
   Suttorp, N
   Witzenrath, M
   Creutz, P
   Mikolajewska, A
   Bauer, T
   Krieger, D
   Pankow, W
   Thiemig, D
   Hauptmeier, B
   Ewig, S
   Wehde, D
   Prediger, M
   Schmager, S
   Kolditz, M
   Schulte-Hubbert, B
   Langner, S
   Albrich, W
   Welte, T
   Freise, J
   Barten, G
   Toro, OA
   Nawrocki, M
   Nairn, J
   Witte, M
   Kroner, W
   Illig, T
   Klopp, N
   Kreuter, M
   Herth, F
   Hummler, S
   Ravn, P
   Vestergaard-Jensen, A
   Baunbaek-Knudsen, G
   Pletz, M
   Kroegel, C
   Forstner, C
   Winning, J
   Schleenvoigt, B
   Dalhoff, K
   Rupp, J
   Horster, R
   Dromann, D
   Rohde, G
   Drijkoningen, J
   Braeken, D
   Buschmann, H
   Schaberg, T
   Hering, I
   Panning, M
   Wallner, M
AF Forstner, Christina
   Kolditz, Martin
   Kesselmeier, Miriam
   Ewig, Santiago
   Rohde, Gernot
   Barten-Neiner, Grit
   Rupp, Jan
   Witzenrath, Martin
   Welte, Tobias
   Pletz, Mathias W.
   Dreher, M.
   Cornelissen, C.
   Knueppel, W.
   Stolz, D.
   Suttorp, N.
   Witzenrath, M.
   Creutz, P.
   Mikolajewska, A.
   Bauer, T.
   Krieger, D.
   Pankow, W.
   Thiemig, D.
   Hauptmeier, B.
   Ewig, S.
   Wehde, D.
   Prediger, M.
   Schmager, S.
   Kolditz, M.
   Schulte-Hubbert, B.
   Langner, S.
   Albrich, W.
   Welte, T.
   Freise, J.
   Barten, G.
   Toro, O. Arenas
   Nawrocki, M.
   Nairn, J.
   Witte, M.
   Kroener, W.
   Illig, T.
   Klopp, N.
   Kreuter, M.
   Herth, F.
   Hummler, S.
   Ravn, P.
   Vestergaard-Jensen, A.
   Baunbaek-Knudsen, G.
   Pletz, M.
   Kroegel, C.
   Forstner, C.
   Winning, J.
   Schleenvoigt, B.
   Dalhoff, K.
   Rupp, J.
   Hoerster, R.
   Droemann, D.
   Rohde, G.
   Drijkoningen, J.
   Braeken, D.
   Buschmann, H.
   Schaberg, T.
   Hering, I
   Panning, M.
   Wallner, M.
CA CAPNETZ Study Grp
TI Pneumococcal conjugate serotype distribution and predominating role of
   serotype 3 in German adults with community-acquired pneumonia
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Conjugate vaccine; Herd immunity;
   Serotype-specific urinary antigen detection assay; Serotype 3
ID NASOPHARYNGEAL COLONIZATION; COMPETENCE NETWORK; 13-VALENT; VACCINE;
   DISEASE; PCV13; ASSOCIATION; EFFICACY; ENGLAND; BURDEN
AB Introduction: Implementation of the 7-valent pneumococcal conjugate vaccine (PCV7) in infant vaccination programs has substantially reduced the burden of PCV7 serotypes also in adult community-acquired pneumonia (CAP). Currently, it is unclear, if this extensive herd protection effect can be extrapolated to the additional 6 serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13), which replaced PCV7 in Germany in 2010.
   Objectives: We investigated changing trends for PCV13 serotypes in adult CAP patients between three to seven years after implementation of PCV13 infant immunization in Germany.
   Methods: Between December 2012 and January 2017, urine samples from German adult patients with radiologically confirmed CAP were prospectively collected by the multi-center cohort study CAPNETZ and analyzed by the serotype-specific multiplex urinary antigen detection assay (SSUAD) allowing for the detection of PCV13 serotypes.
   Results: PCV13 serotypes were found in 59 of 796 (7.4%) patients with all-cause CAP, most prevalent was serotype 3 (30 of 59 patients, 50.8%). All patients with serotype 3-CAP were admitted to hospital and the majority required oxygen at admission (83.3% of patients with serotype 3-CAP versus 50.9% of patients with pneumococcal CAP by other serotypes, p = 0.005). Compared to SSUAD testing, conventional microbiological workup missed 27 of 30 (90.0%) serotype 3-CAP cases. We could not observe a time trend in the proportions of PCV13 serotypes and serotype 3 in all-cause CAP between 2013 and 2016 (OR trend per year 0.84, 95% CI 0.64-1.11 for PCV13 serotypes and OR trend per year 0.95, 95% CI 0.70-1.28 for serotype 3). Conclusions: Conventional methods underestimate serotype 3-CAP that can cause severe disease. Changes in overall PCV13 coverage were not detected during the years 2013 to 2016, mostly driven by a high proportion of serotype. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Forstner, Christina; Pletz, Mathias W.] Jena Univ Hosp, Inst Infect Dis & Infect Control, Klinikum 1, D-07747 Jena, Germany.
   [Forstner, Christina] Med Univ Vienna, Dept Med 1, Div Infect Dis & Trop Med, Vienna, Austria.
   [Kolditz, Martin] Univ Hosp Carl Gustav Carus, Med Dept 1, Div Pulmonol, Dresden, Germany.
   [Kolditz, Martin; Ewig, Santiago; Rohde, Gernot; Barten-Neiner, Grit; Rupp, Jan; Witzenrath, Martin; Welte, Tobias; Pletz, Mathias W.] CAPNETZ STIFTUNG, Hannover, Germany.
   [Kesselmeier, Miriam] Jena Univ Hosp, CSCC, Res Grp Clin Epidemiol, Jena, Germany.
   [Ewig, Santiago] Evangelikal Protestant Hosp Herne, Thorax Ctr Ruhr Area, Dept Resp Med & Infect Dis, Bochum, Germany.
   [Ewig, Santiago] Augusta Hosp Bochum, Bochum, Germany.
   [Rohde, Gernot] Goethe Univ Hosp, Med Dept 1, Dept Resp Med, Frankfurt, Germany.
   [Rohde, Gernot; Barten-Neiner, Grit; Welte, Tobias] Biomed Res Endstage & Obstruct Lung Dis Hannover, Hannover, Germany.
   [Rohde, Gernot; Barten-Neiner, Grit; Welte, Tobias] German Ctr Lung Res DZL, Marburg, Germany.
   [Rupp, Jan] Univ Hosp Schleswig Holstein, Dept Infect Dis & Microbiol, Lubeck, Germany.
   [Rupp, Jan] German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, Hamburg, Germany.
   [Witzenrath, Martin] Charite Univ Med Berlin, Dept Infect Dis & Pulm Med, Berlin, Germany.
   [Witzenrath, Martin] Charite Univ Med Berlin, Div Pulm Inflammat, Berlin, Germany.
   [Welte, Tobias] Hannover Med Sch, Dept Pneumol, Hannover, Germany.
RP Forstner, C (reprint author), Jena Univ Hosp, Inst Infect Dis & Infect Control, Klinikum 1, D-07747 Jena, Germany.
EM christina.forstner@med.uni-jena.de
RI Kesselmeier, Miriam/G-5546-2016
OI Kesselmeier, Miriam/0000-0001-6462-2579; Pletz,
   Mathias/0000-0001-8157-2753
FU German Federal Ministry of Education and Research grant [01KI07145];
   German Federal Ministry of Education and Research KliFo 2.0 [01KI1501];
   Pfizer GermanyPfizer; Integrated Research and Treatment Center Center
   for Sepsis Control and Care (CSCC) at the Jena University Hospital -
   German Federal Ministry of Education and Research (BMBF)Federal Ministry
   of Education & Research (BMBF) [01E01502]
FX CAPNETZ was founded by a German Federal Ministry of Education and
   Research grant (01KI07145) 2001-2011. CF and MWP: are partly supported
   by a grant of the German Federal Ministry of Education and Research
   KliFo 2.0 (grant number 01KI1501). This study was supported by an
   unrestricted grant from Pfizer Germany. MKe was supported by the
   Integrated Research and Treatment Center Center for Sepsis Control and
   Care (CSCC) at the Jena University Hospital funded by the German Federal
   Ministry of Education and Research (BMBF No. 01E01502).
CR Ahl J, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-492
   Andrews N, 2019, VACCINE, V37, P4491, DOI 10.1016/j.vaccine.2019.06.071
   Athlin S, 2014, CLIN VACCINE IMMUNOL, V21, P1541, DOI 10.1128/CVI.00259-14
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Burgos J, 2014, EUR RESPIR J, V43, P545, DOI 10.1183/09031936.00050413
   Choi EH, 2016, CLIN VACCINE IMMUNOL, V23, P162, DOI 10.1128/CVI.00591-15
   Dagan R, 2015, J INFECT DIS, V211, P1144, DOI 10.1093/infdis/jiu576
   Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428
   Djennad Abdelmajid, 2018, EClinicalMedicine, V6, P42, DOI 10.1016/j.eclinm.2018.12.007
   Ewig S, 2009, THORAX, V64, P1062, DOI 10.1136/thx.2008.109785
   Feldman C, 2018, EXPERT REV RESP MED
   Forstner C, 2016, J INFECTION, V72, P554, DOI 10.1016/j.jinf.2016.02.010
   Galanis I, 2016, EUR RESPIR J, V47, P1208, DOI 10.1183/13993003.01451-2015
   Gessner BD, 2019, VACCINE
   Grabenstein JD, 2014, VACCINE, V32, P2399, DOI 10.1016/j.vaccine.2014.02.096
   Horacio AN, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01616
   Isturiz RE, 2019, VACCINE, V37, P3352, DOI 10.1016/j.vaccine.2019.04.087
   Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5
   LeBlanc JJ, 2019, VACCINE, V37, P5466, DOI 10.1016/j.vaccine.2019.05.003
   Menendez R, 2017, VACCINE, V35, P5264, DOI 10.1016/j.vaccine.2017.08.007
   Mizgerd JP, 2015, NEW ENGL J MED, V373, P2380, DOI 10.1056/NEJMc1511751
   Pick H, 2019, THORAX, P1
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Pletz M W, 2012, Pneumologie, V66, P470
   Pletz MW, 2016, VACCINE, V34, P2342, DOI 10.1016/j.vaccine.2016.03.052
   Pride MW, 2012, CLIN VACCINE IMMUNOL, V19, P1131, DOI 10.1128/CVI.00064-12
   Rodrigo C, 2015, EUR RESPIR J, V45, P1632, DOI 10.1183/09031936.00183614
   Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0
   Shoji H, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00787-17
   Silva-Costa C, 2018, EMERG INFECT DIS, V24, P1307, DOI 10.3201/eid2407.180029
   Southern J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195799
   Sugimoto Naomi, 2017, BMC Res Notes, V10, P21, DOI 10.1186/s13104-016-2353-3
   Suttorp N, 2016, BUNDESGESUNDHEITSBLA, V59, P475, DOI 10.1007/s00103-016-2318-7
   van der Linden M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220453
   van der Linden M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131494
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
   Weinberger DM, 2010, CLIN INFECT DIS, V51, P692, DOI 10.1086/655828
   Welte T, 2004, INFECTION, V32, P234, DOI 10.1007/s15010-004-3107-z
   Wunderink RG, 2018, CLIN INFECT DIS, V66, P1504, DOI 10.1093/cid/cix1066
NR 40
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1129
EP 1136
DI 10.1016/j.vaccine.2019.11.026
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100022
PM 31761500
DA 2020-05-12
ER

PT J
AU Hibbs, BF
   Ng, CS
   Museru, O
   Moro, PL
   Marquez, P
   Woo, EJ
   Cano, MV
   Shimabukuro, TT
AF Hibbs, Beth F.
   Ng, Carmen S.
   Museru, Oidda
   Moro, Pedro L.
   Marquez, Paige
   Woo, Emily Jane
   Cano, Maria, V
   Shimabukuro, Tom T.
TI Reports of atypical shoulder pain and dysfunction following inactivated
   influenza vaccine, Vaccine Adverse Event Reporting System (VAERS),
   2010-2017
SO VACCINE
LA English
DT Article
DE Shoulder pain; Shoulder injury related to vaccine administration
   (SIRVA); Vaccination; Vaccine safety; Vaccine administration; Vaccine
   Adverse Event Reporting System (VAERS)
ID NEEDLE LENGTH; IMMUNIZATION; BURSITIS; VACCINATIONS; DEFINITION;
   PREVENTION; INJECTION
AB Background: Vaccines administered into or too close to underlying joint structures have the potential to cause shoulder injuries. Limited data exist on the epidemiology of such events.
   Objective: To describe case reports of atypical shoulder pain and dysfunction following injection of inactivated influenza vaccine (IIV).
   Methods: We searched the Vaccine Adverse Event Reporting System (VAERS) database from July 2010 to June 2017 for reports of atypical shoulder pain and dysfunction following IIV. When identifying reports, we made no assumptions about true incident injury or causality with respect to vaccination. Pain had to begin <48 h after vaccination and signs and symptoms had to continue for >7 days to differentiate from self-limited local reactions. We conducted descriptive analysis.
   Results: We identified 1220 reports that met our case definition (2.0% of all IIV reports, range 1.5%-2.5% across influenza seasons). Median age was 52 years (range 16-94) and most patients (82.6%) were female. Shoulder pain (44.1%), injected limb mobility decreased (40.8%), joint range of motion decreased (21.2%), rotator cuff syndrome (9.2%), and bursitis (9.0%) were frequently reported. In 86.6% of reports, signs and symptoms had not resolved by the time of report submission. In reports that included descriptions suggesting contributing factors (n = 266), vaccination given "too high" on the arm was cited in 81.2%. Nearly half (n = 605, 49.6%) of reports described a healthcare provider evaluation. Treatments included non-narcotic analgesics, physical therapy, and corticosteroid injection. Vaccinations were most commonly administered in a pharmacy or retail store (41.0%) or doctor's office or hospital (31.6%).
   Conclusions: Reports of atypical shoulder pain and dysfunction following IIV were uncommon, considering the amount of IIV use, and stable across influenza seasons. While specific etiology of cases is unknown, improperly administered vaccine, which is preventable, might be a factor. Prevention strategies include education, training, and adherence to best practices for vaccine administration. Published by Elsevier Ltd.
C1 [Hibbs, Beth F.; Ng, Carmen S.; Museru, Oidda; Moro, Pedro L.; Marquez, Paige; Cano, Maria, V; Shimabukuro, Tom T.] Ctr Dis Control & Prevent CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Immunizat Safety Off, Atlanta, GA USA.
   [Woo, Emily Jane] US Food & Drug Adm FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
   [Ng, Carmen S.] Univ Hong Kong, Sch Publ Hlth, Div Hlth Econ Policy & Management, Sandy Bay, 7 Sassoon Rd, Hong Kong, Peoples R China.
RP Hibbs, BF (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, 1600 Clifton Rd,MS V18-4, Atlanta, GA 30329 USA.
EM bhibbs@cdc.gov
CR [Anonymous], 2019, COMMUNICATION
   Atanasoff S, 2010, VACCINE, V28, P8049, DOI 10.1016/j.vaccine.2010.10.005
   Barnes MG, 2012, J AM BOARD FAM MED, V25, P919, DOI 10.3122/jabfm.2012.06.110334
   Bliddal H, 2017, UGESKR LAEGER, V179
   Bodor M, 2007, VACCINE, V25, P585, DOI 10.1016/j.vaccine.2006.08.034
   Cook IF, 2014, HUM VACC IMMUNOTHER, V10, P605, DOI 10.4161/hv.27232
   Cook IF, 2011, HUM VACCINES, V7, P845, DOI 10.4161/hv.7.8.16271
   Cook IF, 2006, VACCINE, V24, P937, DOI 10.1016/j.vaccine.2005.08.098
   Cook KM, 2011, PEDIATRICS, V127, pS74, DOI 10.1542/peds.2010-1722K
   Cross GB, 2016, AUST FAM PHYSICIAN, V45, P303
   Davidson KM, 2013, J NURS ED PRACTICE, V3, P120
   Degreef I, 2012, ACTA CHIR BELG, V112, P447, DOI 10.1080/00015458.2012.11680872
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Food and Drug Administration, 1997, FED REGISTER, V62, P52252
   Foster S, 2013, J AM PHARM ASSOC, V53, P102, DOI 10.1331/JAPhA.2013.13503
   Gidudu J, 2008, VACCINE, V26, P6800, DOI 10.1016/j.vaccine.2008.10.006
   Health Resources and Services Administration (HRSA), 2017, FED REGISTER, V82, P6294
   Kasper D, 2015, PERIARTICULAR DISORD
   Koster MP, 2009, PEDIATRICS, V124, P667, DOI 10.1542/peds.2008-1127
   Kroger AT, BEST PRACTICES GUIDA
   Kvalvaag E, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1827-3
   Lippert WC, 2008, PEDIATRICS, V122, pE556, DOI 10.1542/peds.2008-0374
   Arias LHM, 2017, VACCINE, V35, P4870, DOI 10.1016/j.vaccine.2017.07.055
   McConeghy KW, 2016, VACCINE, V34, P3463, DOI 10.1016/j.vaccine.2016.04.076
   McGarvey M A, 2005, Ir Med J, V98, P105
   Messerschmitt PJ, 2012, ORTHOPEDICS, V35, pE283, DOI 10.3928/01477447-20120123-26
   Poland GA, 1997, JAMA-J AM MED ASSOC, V277, P1709, DOI 10.1001/jama.277.21.1709
   Raynor MB, 2016, J SHOULDER ELB SURG, V25, P688, DOI 10.1016/j.jse.2015.09.023
   Salmon JH, 2015, VACCINE, V33, P6152, DOI 10.1016/j.vaccine.2015.09.090
   Shankar Nachiket, 2014, Med J Armed Forces India, V70, P338, DOI 10.1016/j.mjafi.2014.08.005
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Stratton K, 2011, ADVERSE EFFECTS VACC
   Uchida S, 2012, VACCINE, V31, P27, DOI 10.1016/j.vaccine.2012.10.075
   Vicenti G, 2016, J BIOL REG HOMEOS AG, V30, P867
   Whelton C, 2018, Eur J Orthop Surg Traumatol, V28, P363, DOI 10.1007/s00590-017-2068-8
   Williams RM, 1998, PHYS THER, V78, P613, DOI 10.1093/ptj/78.6.613
   Winslow EH, 1996, AM J NURS, V96, P53
   Zreik NH, 2016, MLTJ-MUSCLE LIGAMENT, V6, P26, DOI 10.11138/mltj/2016.6.1.026
   Zuckerman JN, 2000, BRIT MED J, V321, P1237, DOI 10.1136/bmj.321.7271.1237
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1137
EP 1143
DI 10.1016/j.vaccine.2019.11.023
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100023
PM 31784231
DA 2020-05-12
ER

PT J
AU Wilson, R
   Zaytseva, A
   Bocquier, A
   Nokri, A
   Fressard, L
   Chamboredon, P
   Carbonaro, C
   Bernardi, S
   Dube, E
   Verger, P
AF Wilson, Rose
   Zaytseva, Anna
   Bocquier, Aurelie
   Nokri, Amale
   Fressard, Lisa
   Chamboredon, Patrick
   Carbonaro, Christian
   Bernardi, Stephane
   Dube, Eve
   Verger, Pierre
TI Vaccine hesitancy and self-vaccination behaviors among nurses in
   southeastern France
SO VACCINE
LA English
DT Article
DE Health care workers; Vaccination perceived risks; Trust;
   Self-vaccination behavior; Vaccine hesitancy
ID INFLUENZA VACCINATION; ATTITUDES; QUEBEC; RISK
AB Background: Health care worker vaccine uptake rates are below official targets, and studies demonstrate some are vaccine hesitant. We assessed self-vaccination behavior, vaccine hesitancy (VH), and associated factors in a representative sample of nurses.
   Methods: Cross-sectional questionnaire survey in 2017-18 in southeastern France (5 million inhabitants): community nurses were randomly selected from a list provided by the Inter-Regional Nurses' Council (stratified by gender and district of practice) and interviewed by telephone. Because no such list exists for hospital nurses (74% of all nurses in southeastern France), we randomly selected hospitals, taking their size into account and stratifying by district. Hospital nurses practicing in medicine, surgery, obstetrics, and gynecology departments and present at the time of the survey were included and interviewed face-to face. We measured VH according to the WHO definition (refusal, delay, or acceptance with doubts about at least one vaccine). Interviewers administered the questionnaires. We used multivariable logistic regression to analyze potential associations between VH, vaccine risk perceptions and trust in health authorities.
   Results: Interviews were completed with 1539 nurses (response rate: 85%). Self-reported vaccine coverage ranged from 27% (seasonal influenza vaccine, recommended, 2016/17 season) to 96% (Bacillus Calmette-Guerin vaccine, mandatory). The VH prevalence rate was 44% (95% confidence interval: 38.7-48.4) and most often concerned seasonal influenza or A(H1N1) vaccines (54%) and the hepatitis B vaccine (18%). VH was significantly more frequent among nurses with low trust in health authorities or high vaccine risk perceptions.
   Conclusion: Nurses in southeastern France have low levels of self-vaccination acceptance for most recommended vaccines. In addition, they have a high VH prevalence focused on the same vaccines as among the general population. These are important findings given that nurses are in regular contact with patients vulnerable to vaccine-preventable diseases and their VH could negatively influence patients' vaccination acceptance. (C) 2019 Published by Elsevier Ltd.
C1 [Wilson, Rose; Zaytseva, Anna; Bocquier, Aurelie; Nokri, Amale; Fressard, Lisa; Verger, Pierre] ORS PACA, Southeastern Hlth Reg Observ, Marseille, France.
   [Wilson, Rose; Bocquier, Aurelie; Verger, Pierre] Aix Marseille Univ, AP HM, IRD, SSA,VITROME,IHU Mediterranee, Marseille, France.
   [Chamboredon, Patrick; Carbonaro, Christian; Bernardi, Stephane] CIROI PACA, Corse, Conseil Interreg Ordre Infirmiers, Marseille, France.
   [Dube, Eve] Laval Univ, CHU Quebec, Quebec City, PQ, Canada.
RP Verger, P (reprint author), Observ Reg Sante, Fac Med, 27 Bd Jean Moulin, F-13005 Marseille, France.
EM pierre.verger@inserm.fr
FU French National Research Agency (ANR)French National Research Agency
   (ANR) [ANR-15-CE36-0008-01]; Agence Regionale de Sante PACA; Institut
   Hospitalo-Universitaire (IHU) Mediterranee Infection: the ANR under the
   program "Investissements d'avenir"French National Research Agency (ANR)
   [ANR-10-IAHU-03]; Region Sud Provence-AlpesCote d'Azur
FX This study was supported by the French National Research Agency (ANR -
   grant nb ANR-15-CE36-0008-01); Agence Regionale de Sante PACA; the
   Institut Hospitalo-Universitaire (IHU) Mediterranee Infection: the ANR
   under the program "Investissements d'avenir", nb ANR-10-IAHU-03; the
   Region Sud Provence-AlpesCote d'Azur.
CR [Anonymous], 2019, RECOMMANDATIONS VACC
   Brandt C, 2011, EURO SURVEILL, V16
   Brien S, 2012, VACCINE, V30, P1255, DOI 10.1016/j.vaccine.2011.12.089
   Collange F, 2016, VACCINE, V34, P762, DOI 10.1016/j.vaccine.2015.12.054
   Cour des comptes, 2018, RAPPORT PUBLIC ANNUE, P205
   Dube E, 2011, CONNAISSANCES ATTITU
   Dube E, 2017, ENQUETE QUEBECOISE V
   Dube E, 2015, HUM VACC IMMUNOTHER, V11, P956, DOI 10.1080/21645515.2015.1009816
   Dube E, 2014, AM J INFECT CONTROL, V42, pE55, DOI 10.1016/j.ajic.2014.01.006
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Friedl A, 2012, INFECTION, V40, P57, DOI 10.1007/s15010-011-0193-6
   Fuscaldo W, 2018, PHYS REV APPL, V9, DOI 10.1103/PhysRevApplied.9.054005
   Gautier A, 2016, B EPIDEMIOL HEBD 201, P28, DOI DOI 10.1016/S0992-5945(17130241-6
   Gheorghiu MD, 2013, HOPITAL MOUVEMENT CH
   Giannattasio A, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1090-x
   Guthmann JP, 2012, VACCINE, V30, P995, DOI 10.1016/j.vaccine.2011.12.011
   Haute Autorite de Sante, 2018, REC VACC EXT COMP PR
   Hollmeyer HG, 2009, VACCINE, V27, P3935, DOI 10.1016/j.vaccine.2009.03.056
   Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029
   Kiely Marilou, 2012, Perspect Infirm, V9, P61
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Leask J, 2011, NATURE, V473, P443, DOI 10.1038/473443a
   Llupia A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039496
   Lorenc T, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2703-4
   Ministere des Affaires Sociales et de la Sante, CAL VACC REC VACC 20
   Ministere des Affaires Sociales et de la Sante, 2016, CAL VACC REC VACC 20
   Mouchet J, 2018, VACCINE, V36, P1548, DOI 10.1016/j.vaccine.2018.02.036
   Pless A, 2017, INFLUENZA OTHER RESP, V11, P247, DOI 10.1111/irv.12441
   Rey D, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.23.17.17-00816
   Verger P, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.47.30406
   Verger P, 2013, EBIOMEDICINE 2013, V2015
   Verger P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041837
   Ward JK, 2019, NAT IMMUNOL, V20, P1257, DOI 10.1038/s41590-019-0488-9
   Ward JK, 2018, VACCINE, V36, P1801, DOI 10.1016/j.vaccine.2018.02.095
   Wilson R, 2019, HUM VACC IMMUNOTHER, V4, P1
   Wilson RJ, 2017, RES SOCIOL HEALTH CA, V35, P59, DOI 10.1108/S0275-495920170000035004
   Zhang J, 2010, VACCINE, V28, P7207, DOI 10.1016/j.vaccine.2010.08.065
NR 37
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1144
EP 1151
DI 10.1016/j.vaccine.2019.11.018
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100024
PM 31810781
DA 2020-05-12
ER

PT J
AU Porter, RM
   Goldin, S
   Lafond, KE
   Hedman, L
   Ungkuldee, M
   Kurzum, J
   Azziz-Baumgartner, E
   Nannei, C
   Bresee, JS
   Moen, A
AF Porter, Rachael M.
   Goldin, Shoshanna
   Lafond, Kathryn E.
   Hedman, Lisa
   Ungkuldee, Mellissa
   Kurzum, Jordan
   Azziz-Baumgartner, Eduardo
   Nannei, Claudia
   Bresee, Joseph S.
   Moen, Ann
TI Does having a seasonal influenza program facilitate pandemic
   preparedness? An analysis of vaccine deployment during the 2009 pandemic
SO VACCINE
LA English
DT Article
DE Influenza; Pandemic; Vaccination; Preparedness; Program; Deployment plan
AB Background: National seasonal influenza programs have been recommended as a foundation for pandemic preparedness. During the 2009 pandemic, WHO aimed to increase Member States' equitable access to influenza vaccines through pandemic vaccine donation.
   Methods: This analysis explores whether the presence of a seasonal influenza program contributed to more rapid national submission of requirements to receive vaccine during the 2009 influenza pandemic. Data from 2009 influenza vaccine donation, deployment, and surveillance initiatives were collected during May-September 2018 from WHO archival material. Data about the presence of seasonal influenza vaccine programs prior to 2009 were gathered from the WHO-UNICEF Joint Reporting Form. Cox proportional hazards models were used to assess the relationship between presence of a seasonal influenza program and time to submission of a national deployment and vaccination plan and to vaccine delivery.
   Finding: Of 97 countries eligible to receive WHO-donated vaccine, 83 (86%) submitted national deployment and vaccination plans and 77 (79%) received vaccine. Countries with a seasonal influenza vaccine program were more likely to submit a national deployment and vaccination plan (hazards ratio [HR] 2.1; 95% confidence interval [CI]. Countries with regulatory delays were less likely to receive vaccine than those without these delays (HR 0.4, 95% CI: 0.2-0.6).
   Interpretation: During the 2009 pandemic, eligible countries with a seasonal influenza vaccine program were more ready to receive and use donated vaccines than those without a program. Our findings suggest that robust seasonal influenza vaccine programs increase national familiarity with the management of influenza vaccines and therefore enhance pandemic preparedness. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Porter, Rachael M.; Lafond, Kathryn E.; Azziz-Baumgartner, Eduardo; Bresee, Joseph S.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA.
   [Goldin, Shoshanna; Hedman, Lisa; Nannei, Claudia; Moen, Ann] WHO, Geneva, Switzerland.
   [Ungkuldee, Mellissa] Yale Sch Publ Hlth, New Haven, CT USA.
   [Kurzum, Jordan] Sidney Kimmel Med Coll, Philadelphia, PA USA.
RP Porter, RM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM ocd8@cdc.gov
FU World Health OrganizationWorld Health Organization [001]; Intramural CDC
   HHS [CC999999]
CR [Anonymous], 2009, ANN 2 REQ BE ACC REC
   [Anonymous], 2014, EV SEAS INFL VACC PO
   [Anonymous], 2009, WHO UNICEF JOINT REP
   [Anonymous], 2018, FLUNET INFL LAB SURV
   [Anonymous], 2009, WHO PAND VACC DEPL
   [Anonymous], 2012, REP WHO PAND INFL A
   [Anonymous], 2011, MAIN OP LESS LEARNT
   [Anonymous], 2013, EV PAND A H1N1 2009
   [Anonymous], 2018, DATA STAT GRAPHICS
   [Anonymous], 2010, PAND VACC DEPL
   Bank TW, 2017, WORLD INC REG
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Bresee J, 2018, EMERG INFECT DIS, V24, P1173, DOI 10.3201/eid2407.171270
   Gertisser R., 2010, GEOL TODAY, V26, P94, DOI DOI 10.1111/J.1365-2451.2010.00757.X
   Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Kieny MP, 2006, VACCINE, V24, P6367, DOI 10.1016/j.vaccine.2006.07.021
   Maurer J, 2010, PREV MED, V51, P185, DOI 10.1016/j.ypmed.2010.05.008
   Mihigo R, 2012, J INFECT DIS, V206, pS22, DOI 10.1093/infdis/jis535
   Poland GA, 2010, VACCINE, V28, pD3, DOI 10.1016/j.vaccine.2010.08.024
   Ropero-Alvarez AM, 2012, VACCINE, V30, P916, DOI 10.1016/j.vaccine.2011.11.092
   WHO, 2012, M STRAT ADV GROUP EX
   WHO, 2019, GLOB INFL STRAT 2019
   Zhang WQ, 2017, VACCINE, V35, P851, DOI 10.1016/j.vaccine.2016.12.056
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1152
EP 1159
DI 10.1016/j.vaccine.2019.11.025
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100025
PM 31839465
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Costa, JC
   Weber, AM
   Darmstadt, GL
   Abdalla, S
   Victora, CG
AF Costa, Janaina Calu
   Weber, Ann M.
   Darmstadt, Gary L.
   Abdalla, Safa
   Victora, Cesar G.
TI Religious affiliation and immunization coverage in 15 countries in
   Sub-Saharan Africa
SO VACCINE
LA English
DT Article
DE Demographic surveys; Religion; Immunization; Gender bias
ID INDEX
AB Background: Although religious affiliation has been identified as a potential barrier to immunization in some African countries, there are no systematic multi-country analyses, including within-country variability, on this issue. We investigated whether immunization varied according to religious affiliation and sex of the child in sub-Saharan African (SSA) countries.
   Methods: We used data from 15 nationally representative surveys from 2010 to 2016. The major religious groups were described by country in terms of wealth, residence, and education. Proportions of fully immunized and unvaccinated children were stratified by country, maternal religion, and sex of the child. Poisson regression with robust variance was used to assess whether the outcomes varied according to religion, with and without adjustment for the above cited sociodemographic confounders. Interactions between child sex and religion were investigated.
   Results: Fifteen countries had >10% of families affiliated with Christianity and >10% affiliated with Islam, and four also had >10% practicing folk religions. In general, Christians were wealthier, more educated and more urban. Nine countries had significantly lower full immunization coverage among Muslims than Christians (pooled prevalence ratio = 0.81; 95%CI: 0.79-0.83), of which seven remained significant after adjustment for confounders (pooled ratio = 0.90; 0.87-0.92). Four countries had higher coverage among Muslims, of which two remained significant after adjustment. Regarding unvaccinated children, six countries showed higher proportions among Muslims, all of which remained significant after adjustment [crude pooled ratio = 1.83 (1.59-2.07); adjusted = 1.31 (1.14-1.48)]. Children from families practicing folk religions did not show any consistent patterns in immunization. Child sex was not consistently associated with vaccination.
   Conclusion: Muslim religion was associated with lower vaccine coverage in several SSA countries, both for boys and girls. The involvement of religious leaders is essential for increasing immunization coverage and supporting the leave no one behind agenda of the Sustainable Development Goals. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Costa, Janaina Calu; Victora, Cesar G.] Univ Fed Pelotas, Int Ctr Equ Hlth, Rua Marechal Deodoro 1160,3rd Floor, BR-96020220 Pelotas, RS, Brazil.
   [Weber, Ann M.] Univ Nevada, Sch Community Hlth Sci, Reno, NV 89557 USA.
   [Darmstadt, Gary L.; Abdalla, Safa] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA.
RP Costa, JC (reprint author), Univ Fed Pelotas, Int Ctr Equ Hlth, Rua Marechal Deodoro 1160,3rd Floor, BR-96020220 Pelotas, RS, Brazil.
EM jcosta@equidade.org; annweber@unr.edu; gdarmsta@stanford.edu;
   sabdalla@stanford.edu; cvictora@equidade.org
FU Bill and Melinda Gates FoundationGates Foundation [OPP1148933]; Wellcome
   TrustWellcome Trust; Associacao Brasileira de Saude Coletiva
FX Bill and Melinda Gates Foundation (Grant Number: OPP1148933), Wellcome
   Trust, and Associacao Brasileira de Saude Coletiva. The funders had no
   role in the data analysis, data interpretation, or writing of the paper.
   The corresponding author had full access to all the data and had final
   responsibility for the decision to submit for publication.
CR Abakar MF, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0873-2
   Ahmed A, 2018, J INFECT PUBLIC HEAL, V11, P153, DOI 10.1016/j.jiph.2017.09.007
   Akseer N, 2018, LANCET, V391, P1493, DOI 10.1016/S0140-6736(18)30183-1
   [Anonymous], 2018, SUST DEV GOALS REP 2
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Beverley P, 2013, VACCINE, V31, P1086, DOI 10.1016/j.vaccine.2012.12.024
   Boerma T, 2018, LANCET, V391, P1538, DOI 10.1016/S0140-6736(18)30104-1
   Brinda EM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1449-3
   Chido-Amajuoyi OG, 2018, VACCINE, V36, P6953, DOI 10.1016/j.vaccine.2018.10.006
   Corsi DJ, 2012, INT J EPIDEMIOL, V41, P1602, DOI 10.1093/ije/dys184
   Ewerling F, 2017, LANCET GLOB HEALTH, V5, pE916, DOI 10.1016/S2214-109X(17)30292-9
   Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.1353/dem.2001.0003
   Glatman-Freedman Aharona, 2012, Hum Vaccin Immunother, V8, P293, DOI 10.4161/hv.19003
   Gyimah SO, 2006, SOC SCI MED, V62, P2930, DOI 10.1016/j.socscimed.2005.11.034
   Gyimah SO, 2007, J BIOSOC SCI, V39, P923, DOI 10.1017/S0021932007001927
   Ha W, 2014, SOC SCI MED, V118, P80, DOI 10.1016/j.socscimed.2014.07.066
   Hancioglu A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001391
   Koenig HG, 2015, INT ENCY SOCIAL BEHA, P263
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Mohamud AN, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-865
   National Bureau of Statistics (NBS) United Nations Children's Fund (UNICEF), 2017, MULT IND CLUST SURV
   Oleribe Obinna, 2017, Pan Afr Med J, V26, P220, DOI 10.11604/pamj.2017.26.220.11453
   Ophori Endurance A, 2014, Trop Med Health, V42, P67, DOI 10.2149/tmh.2013-13
   Pew Research Center, 2015, FUT WORLD REL POP GR
   Pew Research Center, 2012, GLOBAL RELIG LANDSCA
   Pew Research Center, 2010, TOL TENS ISL CHRIST
   Razzak J. A., 2011, Eastern Mediterranean Health Journal, V17, P948
   Restrepo-Mendez MC, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30963
   Rutstein S. O., 2004, DHS COMP REPORTS
   StataCorp LP, 2013, STAT SURV DAT REF MA
   United Nations Children's Fund (UNICEF), 2004, BUILD TRUST IMM PART
   United Nations General Assembly, 2015, TRANSF OUR WORLD 203
   United Nations Inter-agency Group for Child Mortality Estimation, 2018, LEV TRENDS CHILD MOR
   Utazi CE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09611-1
   Weber AM, 2019, LANCET, V393, P2455, DOI 10.1016/S0140-6736(19)30765-2
   WHO UNICEF World Bank, 2009, STATE WORLD VACCINES
   World Bank, 2018, GDP CAP PPP CURR INT
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1160
EP 1169
DI 10.1016/j.vaccine.2019.11.024
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100026
PM 31791811
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Vila-Corcoles, A
   Hospital, I
   Ochoa-Gondar, O
   Satue, E
   de Diego, C
   Vila-Rovira, A
   Gomez-Bertomeu, F
   Raga, X
   Aragon, M
AF Vila-Corcoles, Angel
   Hospital, Immaculada
   Ochoa-Gondar, Olga
   Satue, Eva
   de Diego, Cinta
   Vila-Rovira, Angel
   Gomez-Bertomeu, Frederic
   Raga, Xavier
   Aragon, Maria
TI Clinical effectiveness of 13-valent and 23-valent pneumococcal
   vaccination in middle-aged and older adults: The EPIVAC cohort study,
   2015-2016
SO VACCINE
LA English
DT Article
DE Adults; Effectiveness; Pneumococcal conjugate vaccine; Pneumococcal
   polysaccharide vaccine; Pneumonia
ID POLYSACCHARIDE VACCINE; CONJUGATE VACCINE; PNEUMONIA; DISEASE; RISK;
   RECOMMENDATIONS; IMMUNOGENICITY; INTERMEDIATE; EFFICACY; SAFETY
AB Background: Clinical benefits using the 23-valent pneumococcal polysaccharide vaccine (PPsV23) or the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness for both PPsV23 and PCV13 in preventing pneumonia among middle-aged and older adults.
   Methods: Population-based cohort study involving 2,025,730 persons >= 50 years in Catalonia, Spain, who were prospectively followed between 01/01/2015 and 31/12/2016. Primary outcomes were hospitalisation from pneumococcal or all-cause pneumonia and main explanatory variable was PCV13/PPsV23 vaccination status. Multivariable Cox regression models were used to estimate vaccination effectiveness adjusted for age and baseline-risk conditions.
   Results: Cohort members were followed for 3,897,151 person-years (17,496 PCV13 vaccinated and 1,551,502 PPsV23 vaccinated), observing 3259 pneumococcal pneumonias (63 in PCV13 vaccinated, 2243 in PPsV23 vaccinated) and 24,079 all-cause pneumonias (566 in PCV13 vaccinated, 17,508 in PPsV23 vaccinated). Global incidence rates (per 100,000 person-years) were 83.6 for pneumococcal pneumonia (360.1 in PCV13 vaccinated, 144.6 in PPsV23 vaccinated) and 617.9 for all-cause pneumonia (3235.0 in PCV13 vaccinated, 1128.5 in PPsV23 vaccinated). In the multivariable analyses, the PCV13 appeared significantly associated with an increased risk of pneumococcal pneumonia (hazard ratio [HR]: 1.52; 95% confidence interval [CI]: 1.17-1.97; p = 0.002) and all-cause pneumonia (HR: 1.76; 95% CI: 1.61-1.92; p < 0.001) whereas the PPsV23 did not alter the risk of pneumococcal pneumonia (HR: 1.08; 95% CI: 0.98-1.19: p = 0.132) and slightly increased the risk of all-cause pneumonia (HR: 1.17; 95% CI: 1.13-1.21; p < 0.001). In stratified analyses focused on specific target population subgroups (i.e., elderly people, at-risk and high-risk individuals), protective effects of vaccination did not emerge either.
   Conclusion: Data does not support clinical benefits from pneumococcal vaccination (nor PCV13 neither PPsV23) against pneumonia among Catalonian adults in the current era of universal PCV's childhood immunisation. (C) 2019 Published by Elsevier Ltd.
C1 [Vila-Corcoles, Angel; Hospital, Immaculada; Ochoa-Gondar, Olga; Satue, Eva; de Diego, Cinta] Inst Catala Salut, Primary Hlth Care Serv Camp Tarragona, Tarragona, Spain.
   [Vila-Rovira, Angel] Inst Univ Invest Atencio Primaria Jordi Gol IDIA, Unitat Suport Recerca Tarragona, Tarragona, Spain.
   [Gomez-Bertomeu, Frederic] Hosp Joan 23, Dept Lab & Microbiol, Tarragona, Spain.
   [Raga, Xavier] Hosp Santa Tecla, Dept Lab & Microbiol, Tarragona, Spain.
   [Aragon, Maria] Univ Autonoma Barcelona, Primary Care Res Inst Jordi Gol, Informat Syst Improvement Res Primary Care SIDIAP, Barcelona, Spain.
RP Ochoa-Gondar, O (reprint author), Rambla Nova 124,D,1 A, Tarragona 43007, Spain.
EM oochoa.tgn.ics@gencat.cat
OI GOMEZ, FREDERIC/0000-0002-8039-2889
FU "Fondo de Investigacion Sanitaria" (FIS) of the "Instituto de Salud
   Carlos III"Instituto de Salud Carlos III [PI15/01230]; Pla Estrategic de
   Recerca i Innovacio en Salut (PERIS) of the Departament de Salut de la
   Generalitat de Catalunya [SLT002/16/00063]; European Union through the
   "Fondo Europeo de Desarrollo Regional" (FEDER)European Union (EU)
FX This work is supported by a grant from the "Fondo de Investigacion
   Sanitaria" (FIS) of the "Instituto de Salud Carlos III" (call 2015) for
   the "Accion Estrategica en Salud 2013-2016 del Programa Estatal de
   Investigacion Orientado a los Retos de la Sociedad", framing in the
   "Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion
   2013-2016"; code file PI15/01230, cofinanced by the European Union
   through the "Fondo Europeo de Desarrollo Regional" (FEDER) and a grant
   from the Pla Estrategic de Recerca i Innovacio en Salut (PERIS) of the
   Departament de Salut de la Generalitat de Catalunya; code file
   SLT002/16/00063. The funders had no role in the study design, data
   collection, data analysis, data interpretation or write up of the
   manuscript.
CR [Anonymous], 1997, MMWR Recomm Rep, V46, P1
   [Anonymous], 1999, APPL SURVIVAL ANAL R
   Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816
   Bonnave C, 2019, EUR J CLIN MICROBIOL, V38, P785, DOI 10.1007/s10096-019-03485-3
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Brunkard Joan M., 2012, Morbidity and Mortality Weekly Report, V61, P309
   Camara J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175224
   Ciruela P, 2012, EPIDEMIOLOGIA MALALT
   Ciruela P, 2018, VACCINE, V36, P7744, DOI 10.1016/j.vaccine.2018.05.026
   Corcoran M, 2019, Ir Med J, V112, P894
   Diao WQ, 2016, VACCINE, V34, P1496, DOI 10.1016/j.vaccine.2016.02.023
   Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368
   Fedson DS, 2014, HUM VACC IMMUNOTHER, V10, P1322, DOI 10.4161/hv.28797
   GABLE CB, 1990, JAMA-J AM MED ASSOC, V264, P2910, DOI 10.1001/jama.264.22.2910
   Garcia-Gil M Del Mar, 2011, Inform Prim Care, V19, P135
   Georgalis L, 2017, EUR J CLIN MICROBIOL, V36, P575, DOI 10.1007/s10096-016-2834-2
   Gil-Prieto R, 2016, HUM VACC IMMUNOTHER, V12, P1900, DOI 10.1080/21645515.2016.1143577
   Gonzalez R, 2015, ENFERM INFEC MICR CL, V33, P597, DOI 10.1016/j.eimc.2015.01.003
   Grabenstein JD, 2014, CLIN INFECT DIS, V58, P854, DOI 10.1093/cid/cit800
   Hanquet G, 2019, THORAX, V74, P473, DOI 10.1136/thoraxjnl-2018-211767
   Honkanen PO, 1999, VACCINE, V17, P2493, DOI 10.1016/S0264-410X(99)00069-9
   Isturiz RE, 2019, VACCINE, V37, P3352, DOI 10.1016/j.vaccine.2019.04.087
   Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678
   Jackson LA, 2013, VACCINE, V31, P3577, DOI 10.1016/j.vaccine.2013.04.085
   Jackson LA, 2013, VACCINE, V31, P3585, DOI 10.1016/j.vaccine.2013.05.010
   McLaughlin JM, 2018, CLIN INFECT DIS, V67, P1498, DOI 10.1093/cid/ciy312
   Moberley S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000422.pub3
   Musher DM, 2017, CLIN INFECT DIS, V65, P1736, DOI 10.1093/cid/cix549
   Musher DM, 2016, HUM VACC IMMUNOTHER, V12, P331, DOI 10.1080/21645515.2015.1098794
   Musher DM, 2014, HUM VACC IMMUNOTHER, V10, P1331, DOI 10.4161/hv.29031
   Ortqvist A, 1998, LANCET, V351, P399, DOI 10.1016/S0140-6736(97)07358-3
   Papadatou I, 2016, CLIN VACCINE IMMUNOL, V23, P388, DOI 10.1128/CVI.00721-15
   Prato R, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019034
   Schiffner-Rohe J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146338
   The World Medical Association, WMA DECL HELS ETH PR
   Tin Tin Htar M, 2017, PLOS ONE, V12
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   Treskova M, 2019, PHARMACOECONOMICS, V37, P1093, DOI 10.1007/s40273-019-00805-5
   Vila-Corcoles A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3096-7
   Vila-Corcoles A, 2016, HUM VACC IMMUNOTHER, V12, P2953, DOI 10.1080/21645515.2016.1210744
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1170
EP 1180
DI 10.1016/j.vaccine.2019.11.012
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100027
PM 31759735
DA 2020-05-12
ER

PT J
AU Maltezou, HC
   Karantoni, H
   Petrikkos, P
   Georgota, P
   Katerelos, P
   Liona, A
   Tsagarakis, S
   Theodoridou, M
   Hatzigeorgiou, D
AF Maltezou, Helena C.
   Karantoni, Heleni
   Petrikkos, Panagiotis
   Georgota, Persephoni
   Katerelos, Panos
   Liona, Aikaterini
   Tsagarakis, Stephanos
   Theodoridou, Maria
   Hatzigeorgiou, Dimitrios
TI Vaccination coverage and immunity levels against vaccine-preventable
   diseases in male Air Force recruits in Greece
SO VACCINE
LA English
DT Article
DE Vaccine-preventable diseases; Susceptibility; Vaccination coverage;
   Immunity; Measles; Greece
ID SELF-REPORTED HISTORY; HEALTH-CARE WORKERS; VARICELLA; MEASLES;
   SEROPREVALENCE; STUDENTS
AB Aim: Data about susceptibility rates in young adults are scarce. We estimated the complete vaccination rates, timeliness of vaccinations and susceptibility rates among male military recruits in Greece.
   Methods: A standardized form was used to collect data. Immunity against measles, rubella, varicella, hepatitis A and hepatitis B was serologically estimated.
   Results: We studied 385 recruits with a mean age of 23.5 years (range: 18.3-29.9 years). Complete vaccination rates were 94.3% for measles, 100% for rubella, 15% for varicella, 73.9% for hepatitis A and 96.5% for hepatitis B. Only 10.8% of participants were fully vaccinated against all five diseases. Timely vaccination was 47.2% for measles, 89.3% for rubella and 48.1% for hepatitis B. Recruits >23 years had a 1.5-fold increased probability for incomplete vaccinations compared to younger recruits. Laboratory-confirmed immunity rates were 80% against measles, 85.7% against rubella, 85.2% against varicella, 69.4% against hepatitis A and 77.1% against hepatitis B. It is estimated that approximately 388,696 persons aged 18-30 years are susceptible to measles, 277,640 persons to rubella, 287,736 persons to varicella, 595,664 persons to hepatitis A and 444,224 persons to hepatitis B in Greece.
   Conclusion: Our study showed that young adults have significant immunity gaps against measles, rubella, varicella, hepatitis A and hepatitis B. Complete vaccination rates were suboptimal against hepatitis A and varicella. Strategies to access young adults and increase immunity rates through catch-up vaccination services should be investigated. A third dose of MMR vaccine should be considered for young adolescents in Greece. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Maltezou, Helena C.; Katerelos, Panos; Liona, Aikaterini] Hellen Ctr Dis Control & Prevent, Dept Intervent Hlth Care Facil, 3-5 Agrafon St, Athens, Greece.
   [Karantoni, Heleni; Petrikkos, Panagiotis] 251 Hellen Air Force Gen Hosp, Athens, Greece.
   [Georgota, Persephoni; Tsagarakis, Stephanos] 251 Airforce Gen Hosp, Immunol Lab, Athens, Greece.
   [Theodoridou, Maria] Univ Athens, Aghia Sophia Childrens Hosp, Dept Pediat 1, Athens, Greece.
   [Hatzigeorgiou, Dimitrios] Med Directorate, Athens, Greece.
RP Maltezou, HC (reprint author), Hellen Ctr Dis Control & Prevent, Dept Intervent Hlth Care Facil, 3-5 Agrafon St, Athens, Greece.
EM helen-maltezou@ath.forthnet.gr
FU Hellenic Airforce (Athens, Greece)
FX We would like to thank the recruits for completing the questionnaires.
   We also thank Natasa Tedoma for technical assistance. The study was
   funded by the Hellenic Airforce General Staff, Hellenic Airforce
   (Athens, Greece). The opinions presented in this article are those of
   the authors, and do not necessarily represent those of their
   institutions.
CR Allerberger F, 2017, CLIN MICROBIOL INFEC, V23, P502, DOI 10.1016/j.cmi.2017.04.008
   Antona D, 2019, EPIDEMIOL INFECT, V147
   Bollaerts K, 2017, EPIDEMIOL INFECT, V145, P2666, DOI 10.1017/S0950268817001546
   Ponde RAD, 2019, ARCH VIROL, V164, P2645, DOI 10.1007/s00705-019-04369-9
   De Juanes JR, 2005, VACCINE, V23, P1434, DOI 10.1016/j.vaccine.2004.10.003
   dos Santos AMN, 2008, AM J INFECT CONTROL, V36, P142, DOI 10.1016/j.ajic.2007.04.283
   Durrheim DN, 2018, VACCINE, V36, P4001, DOI 10.1016/j.vaccine.2018.04.036
   European Centre for Disease Prevention and Control, MONTHL MEASL RUB MON
   Fefferman NH, 2015, LANCET INFECT DIS, V15, P922, DOI 10.1016/S1473-3099(15)00053-5
   Funk S., 2017, LONDON SCH HYGIENE T
   Georgakopoulou T, 2018, EPIDEMIOL INFECT, V146, P1692, DOI [10.1017/s0950268818002170, 10.1017/S0950268818002170]
   German V, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-163
   Griffin DE, 2018, VIRAL IMMUNOL, V31, P86, DOI 10.1089/vim.2017.0143
   Hellenic Statistical Authority, POP CENS
   Holt E, 2018, LANCET, V392, P724, DOI 10.1016/S0140-6736(18)32031-2
   Karageorgou K, 2014, VACCINE, V32, P5083, DOI 10.1016/j.vaccine.2014.06.031
   Maltezou HC, 2018, J HOSP INFECT, V100, pE261, DOI 10.1016/j.jhin.2018.06.007
   Maltezou HC, 2019, VACCINE, V37, P4419, DOI [10.10164/j.vaccine.2019.05.095, 10.1016/j.vaccine.2019.05.095]
   Mellou K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116939
   National School of Public Health, 2012, NAT STUD VACC COV CH
   Ndumbi P, 2018, EURO SURVEILL, V23
   R Core Team, 2019, R LANG ENV STAT COMP
   Ristic M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216219
   Su TH, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.28
   Trevisan A, 2007, INFECT CONT HOSP EP, V28, P564, DOI 10.1086/516657
   van Panhuis WG, 2013, NEW ENGL J MED, V369, P2152, DOI 10.1056/NEJMms1215400
   Vantarakis A, 2010, EPIDEMIOL INFECT, V138, P1025, DOI 10.1017/S0950268809991257
   Wicker S, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-121
NR 28
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1181
EP 1185
DI 10.1016/j.vaccine.2019.11.021
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100028
PM 31761499
DA 2020-05-12
ER

PT J
AU Shilling, H
   Murray, G
   Brotherton, JML
   Hawkes, D
   Saville, M
   Sivertsen, T
   Chambers, I
   Roberts, J
   Farnsworth, A
   Garland, SM
   Hocking, JS
   Kaldor, J
   Guy, R
   Atchison, S
   Costa, AM
   Molano, M
   Machalek, DA
AF Shilling, Hannah
   Murray, Gerald
   Brotherton, Julia M. L.
   Hawkes, David
   Saville, Marion
   Sivertsen, Terri
   Chambers, Ian
   Roberts, Jennifer
   Farnsworth, Annabelle
   Garland, Suzanne M.
   Hocking, Jane S.
   Kaldor, John
   Guy, Rebecca
   Atchison, Steph
   Costa, Anna-Maria
   Molano, Monica
   Machalek, Dorothy A.
TI Monitoring human papillomavirus prevalence among young Australian women
   undergoing routine chlamydia screening
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Vaccine impact; Surveillance; Nonavalent HPV
   vaccine
ID ANYPLEX II HPV28; VACCINE; INFECTION; ATTRIBUTION; LESIONS; ASSAY; MEN;
   SEX
AB Introduction: Australia has recently implemented major changes in cervical cancer prevention policies including introduction of primary human papillomavirus (HPV) screening starting at age 25, and replacement of the quadrivalent HPV vaccine with the nonavalent vaccine in the national school-based program. We assessed the feasibility and utility of conducting HPV testing in residual clinical specimens submitted for routine Chlamydia trachomatis screening, as a means of tracking HPV vaccine program impact among young sexually active women.
   Methods: De-identified residual specimens from women aged 16-24 years submitted for chlamydia testing were collected from three pathology laboratories in Victoria and New South Wales. Limited demographic information, and chlamydia test results were also collected. Patient identifiers were sent directly from the laboratories to the National HPV Vaccination Program Register, to obtain HPV vaccination histories. Samples underwent HPV genotyping using Seegene Anyplex II HPV 28 assay.
   Results: Between April and July 2018, 362 residual samples were collected, the majority (60.2%) of which were cervical swabs. Demographic data and vaccination histories were received for 357 (98.6%) women (mean age 21.8, SD 2.0). Overall, 65.6% of women were fully vaccinated, 9.8% partially, and 24.7% unvaccinated. The majority (86.0%) resided in a major city, 35.9% were classified in the upper quintile of socioeconomic advantage and chlamydia positivity was 7.8%. The prevalence of quadrivalent vaccine-targeted types (HPV6/11/16/18) was 2.8% (1.5-5.1%) overall with no differences by vaccination status (p = 0.729). The prevalence of additional nonavalent vaccine-targeted types (HPV31/33/45/52/58) was 19.3% (15.6-23.8%). One or more oncogenic HPV types were detected in 46.8% (95% CI 41.6-52.0%) of women.
   Conclusions: HPV testing of residual chlamydia specimens provides a simple, feasible method for monitoring circulating genotypes. Applied on a larger scale this method can be utilised to obtain a timely assessment of nonavalent vaccine impact among young women not yet eligible for cervical screening. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shilling, Hannah; Murray, Gerald; Garland, Suzanne M.; Atchison, Steph; Molano, Monica; Machalek, Dorothy A.] Royal Womens Hosp, Ctr Womens Infect Dis, Melbourne, Vic, Australia.
   [Shilling, Hannah; Murray, Gerald; Garland, Suzanne M.; Atchison, Steph; Machalek, Dorothy A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Murray, Gerald; Saville, Marion; Garland, Suzanne M.] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia.
   [Brotherton, Julia M. L.; Hocking, Jane S.; Machalek, Dorothy A.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Brotherton, Julia M. L.; Hawkes, David; Saville, Marion] VCS Fdn, VCS Pathol, Melbourne, Vic, Australia.
   [Hawkes, David] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia.
   [Hawkes, David] Univ Malaya, Dept Pathol, Kuala Lumpur, Malaysia.
   [Sivertsen, Terri; Chambers, Ian; Roberts, Jennifer; Farnsworth, Annabelle] Douglass Hanly Moir Pathol, Sydney, NSW, Australia.
   [Farnsworth, Annabelle] Univ Notre Dame, Sydney, NSW, Australia.
   [Kaldor, John; Guy, Rebecca] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Costa, Anna-Maria] Royal Childrens Hosp, Melbourne, Vic, Australia.
RP Machalek, DA (reprint author), Royal Womens Hosp, Ctr Womens Infect Dis, 20 Flemington Rd, Parkville, Vic 3052, Australia.
EM Dorothy.machalek@thewomens.org.au
OI Murray, Gerald/0000-0003-3330-4433
FU Commonwealth Department of Health HPV Surveillance Fund [4-8FG4IWD]
FX This work is supported by the Commonwealth Department of Health HPV
   Surveillance Fund (Activity number 4-8FG4IWD). The funders had no role
   in study design, data collection, analyses, and interpretation of data,
   writing of the report, or in the decision to submit the article for
   publication.
CR ASHA, 2016, AUSTR STI MAN GUID U
   Australian Bureau of Statistics, 2013, SOC IND AR SEIFA
   Australian Government Department of Health and Aged Care, 2011, MEAS REM ACC REM IND
   Brotherton JML, 2019, VACCINE, V37, P412, DOI 10.1016/j.vaccine.2018.11.075
   Cancer council Australia cervical cancer screening guidelines working party, 2017, CANC COUNC AUSTR CER
   Chow EPF, 2015, LANCET INFECT DIS, V15, P1314, DOI 10.1016/S1473-3099(15)00055-9
   Cornall AM, 2017, PAPILLOMAVIRUS RES, V4, P79, DOI 10.1016/j.pvr.2017.10.002
   D'Addario M, 2017, VACCINE, V35, P2892, DOI 10.1016/j.vaccine.2017.03.096
   DiClemente RJ, 2011, PEDIATRICS, V127, P208, DOI 10.1542/peds.2009-0892
   Dimech W, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-325
   Dobson SRM, 2013, JAMA-J AM MED ASSOC, V309, P1793, DOI 10.1001/jama.2013.1625
   Eklund C, 2018, J CLIN VIROL, V101, P74, DOI 10.1016/j.jcv.2018.01.016
   Estrade C, 2014, J CLIN MICROBIOL, V52, P607, DOI 10.1128/JCM.02749-13
   Garland SM, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-104
   Hall MT, 2019, LANCET PUBLIC HEALTH, V4, pE19, DOI 10.1016/S2468-2667(18)30183-X
   Hariri S, 2015, CANCER EPIDEM BIOMAR, V24, P393, DOI 10.1158/1055-9965.EPI-14-0649
   Huh WK, 2017, LANCET
   Joura EA, 2014, CANCER EPIDEM BIOMAR, V23, P1997, DOI 10.1158/1055-9965.EPI-14-0410
   Kreimer AR, 2015, LANCET ONCOL, V16, P775, DOI 10.1016/S1470-2045(15)00047-9
   Kwon MJ, 2014, J CLIN VIROL, V59, P246, DOI 10.1016/j.jcv.2014.01.015
   Machalek DA, 2018, J INFECT DIS, V217, P1590, DOI 10.1093/infdis/jiy075
   Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
   Mesher D, 2018, J INFECT DIS, V218, P911, DOI 10.1093/infdis/jiy249
   Mesher D, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009915
   Naldini G, 2019, INT J PUBLIC HEALTH, V64, P943, DOI 10.1007/s00038-019-01261-w
   Patel C, 2018, EURO SURVEILL, V23
   Redmond SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115753
   Simms KT, 2016, LANCET PUBLIC HEALTH, V1, pE66, DOI 10.1016/S2468-2667(16)30019-6
   Soederlund-Strand A, 2014, CANCER EPIDEM BIOMAR, V23, P2757, DOI 10.1158/1055-9965.EPI-14-0687
   Tabrizi SN, 2014, LANCET INFECT DIS, V14, P958, DOI 10.1016/S1473-3099(14)70841-2
   Tabrizi SN, 2012, J INFECT DIS, V206, P1645, DOI 10.1093/infdis/jis590
   The Kirby Institute, 2018, VIR HEP SEX TRANSM I
   The Kirby Institute, 2015, VIR HEP SEX TRANSM I
   VCS foundation, 2019, NAT HPV VACC PROGR R
   Vorsters A, 2014, EUR J CLIN MICROBIOL, V33, P2005, DOI 10.1007/s10096-014-2147-2
   World Health Organization Department of immunization vaccines and biologicals, M HPV VACC COV IMP M
   World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069
   Zou HC, 2015, LANCET INFECT DIS, V15, P65, DOI 10.1016/S1473-3099(14)70994-6
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1186
EP 1193
DI 10.1016/j.vaccine.2019.11.019
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100029
PM 31767467
DA 2020-05-12
ER

PT J
AU Reinders, S
   Romero, C
   Carcamo, C
   Tinoco, Y
   Valderrama, M
   La Rosa, S
   Mallma, P
   Neyra, J
   Soto, G
   Azziz-Baumgartner, E
   Garcia, PJ
AF Reinders, Stefan
   Romero, Candice
   Carcamo, Cesar
   Tinoco, Yeny
   Valderrama, Maria
   La Rosa, Sayda
   Mallma, Patricia
   Neyra, Joan
   Soto, Giselle
   Azziz-Baumgartner, Eduardo
   Garcia, Patricia J.
TI A community-based survey on influenza and vaccination knowledge,
   perceptions and practices in Peru
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine coverage; Barriers; Peru; Knowledge; Perceptions;
   Practices
ID HEALTH BELIEF MODEL; PREGNANT-WOMEN; BURDEN; MORTALITY; PROGRESS;
   AMERICA
AB Background: Although Peru provides safe and effective influenza vaccines free-of-charge, coverage among vaccine target groups like pregnant women and older adults remains low. To improve risk communication messages and vaccine uptake, we explored knowledge, perceptions and practices about influenza illness and vaccination.
   Methods: A cross-sectional, community-based survey with a three-stage cluster sampling design was conducted in three cities in Peru. We included mothers of young children, pregnant women and persons >= 65 years. Participants completed a questionnaire about knowledge, perceptions and practices about influenza illness and vaccination against influenza during the past year. Generalized linear models were used to explore factors associated with vaccination in the past year.
   Results: 624/645 (97%) mothers, 54/55 (98%) pregnant women and 622/673 (92%) older adults approached provided informed consent and were surveyed. While most mothers, pregnant women and older adults (94%, 96% and 91%, respectively) perceived influenza as a potentially serious illness, few pregnant women (13%) and older adults (34%) self-identified themselves as a target group for influenza vaccination. Only 28% of mothers, 19% pregnant women, and 27% older adults were vaccinated against influenza during the previous year. Among the participants that did not get vaccinated against influenza in the previous year, "being afraid of vaccination and its effects" was the most commonly cited barrier. Knowledge of the recommendation for annual vaccination was significantly associated with vaccination status among pregnant women (p = 0.048) and older adults (p = 0.004).
   Conclusion: Despite a government subsidized vaccine program, vaccine utilization remained low among pregnant women and older adults, who seemed typically unaware of their status as high-risk groups targeted for vaccination. Those aware of the recommendations for annual vaccination were more likely to be vaccinated. Information campaigns addressing fears and highlighting populations at risk for severe influenza illness that are targeted for vaccination might increase vaccine coverage in Peru. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Reinders, Stefan; Carcamo, Cesar; Valderrama, Maria; La Rosa, Sayda; Mallma, Patricia; Garcia, Patricia J.] Univ Peruana Cayetano Heredia, Sch Publ Hlth & Adm, STD & HIV Unit, Epidemiol, Lima, Peru.
   [Romero, Candice; Tinoco, Yeny; Neyra, Joan; Soto, Giselle] US Naval Med Res Unit 6, Lima, Peru.
   [Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, NCIRD, Influenza Div, Atlanta, GA USA.
RP Garcia, PJ (reprint author), Univ Peruana Cayetano Heredia, Sch Publ Hlth & Adm, STD & HIV Unit, Epidemiol, Lima, Peru.
EM patricia.garcia@upch.pe
FU Inter-Agency Agreement [NMR-9619]; CDC influenza divisionUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA
FX This work was supported by the Inter-Agency Agreement Number NMR-9619.
   Funds were provided by CDC influenza division. The study protocol was
   approved by the Naval Medical Research Unit 6 Institutional Review Board
   (Protocol NAMRU6.2016.0005) in compliance with all applicable Federal
   regulations governing the protection of human subjects.
CR Alvarez AMR, 2017, REV PANAM SALUD PUBL, V41, DOI 10.26633/RPSP.2017.150
   Bhat-Schelbert K, 2012, VACCINE, V30, P2448, DOI 10.1016/j.vaccine.2012.01.049
   Blank PR, 2009, J INFECTION, V58, P446, DOI 10.1016/j.jinf.2009.04.001
   Bodeker B, 2014, VACCINE, V32, P4131, DOI 10.1016/j.vaccine.2014.06.007
   Bohmer MM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-938
   Chen MF, 2011, J COMMUN HEALTH NURS, V28, P29, DOI 10.1080/07370016.2011.539087
   Cheng PY, 2015, INFLUENZA OTHER RESP, V9, P13, DOI 10.1111/irv.12317
   Ditsungnoen D, 2016, VACCINE, V34, P2141, DOI 10.1016/j.vaccine.2016.01.056
   Durand LO, 2016, INFLUENZA OTHER RESP, V10, P170, DOI 10.1111/irv.12371
   Fischer JCM, 2015, SISTEMAS VIGILANCIA
   Frew PM, 2014, VACCINE, V32, P1736, DOI 10.1016/j.vaccine.2014.01.030
   Hartung C., 2010, P 4 ACM IEEE INT C I
   Henninger M, 2013, OBSTET GYNECOL, V121, P741, DOI 10.1097/AOG.0b013e3182878a5a
   Henninger ML, 2015, J WOMENS HEALTH, V24, P394, DOI 10.1089/jwh.2014.5105
   Institute Nacional de estadistica e Informatica (INEI), SIST INF GEOGR SIGE
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Lau L, 2009, INT J NURS STUD, V46, P768, DOI 10.1016/j.ijnurstu.2008.12.006
   luliano AD, 2018, LANCET, V31, P391
   Matsui D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-149
   Meharry PM, 2013, MATERN CHILD HLTH J, V17, P156, DOI 10.1007/s10995-012-0957-3
   Ministry of Health of Peru, 2013, NORM TECN SAL QUE ES
   Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4
   Palache A, 2015, VACCINE, V33, P5598, DOI 10.1016/j.vaccine.2015.08.082
   Ropero-Alvarez AM, 2016, HUM VACC IMMUNOTHER, V12, P2206, DOI 10.1080/21645515.2016.1157240
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Tinoco YO, 2017, CLIN INFECT DIS, V65, P1532, DOI 10.1093/cid/cix565
   Tinoco YO, 2016, INFLUENZA OTHER RESP, V10, P301, DOI 10.1111/irv.12357
   Wiley KE, 2013, MED J AUSTRALIA, V198, P373, DOI 10.5694/mja12.11849
   Yuen CYS, 2014, J PERINAT NEONAT NUR, V28, P261, DOI 10.1097/JPN.0000000000000068
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1194
EP 1201
DI 10.1016/j.vaccine.2019.11.016
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100030
PM 31787411
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kiely, M
   Boulianne, N
   Talbot, D
   Ouakki, M
   Guay, M
   Landry, M
   Sauvageau, C
   De Serres, G
AF Kiely, Marilou
   Boulianne, Nicole
   Talbot, Denis
   Ouakki, Manale
   Guay, Maryse
   Landry, Monique
   Sauvageau, Chantal
   De Serres, Gaston
TI Children vaccination coverage surveys: Impact of multiple sources of
   information and multiple contact attempts
SO VACCINE
LA English
DT Article
DE Vaccination coverage surveys; Vaccination booklets; Vaccine providers;
   Bias
ID NONRESPONSE BIAS; VALIDITY; RATES; CARDS
AB Background: Monitoring vaccination coverage is an essential component of vaccination program evaluation. In Quebec (Canada), children vaccination coverage surveys are conducted every two years since 2006. The objectives of this study were to evaluate the impact of supplementing data based on vaccination booklets with data from vaccine providers, on the final estimated vaccination coverage and to compare vaccination coverage between respondents to each survey contact attempt.
   Methods: Data from six cross-sectional surveys were used, which included 3508 children aged 2 years. Parents were invited to transcribe the information available in their child's vaccination booklet on the questionnaire received by mail. The survey included a maximum of 4 contact attempts to obtain a response. Data were completed among vaccine providers identified by parents. The main outcome was a complete vaccination status by 24 months of age.
   Results: The addition of data from vaccine providers to those present in vaccination booklets increased the proportion of children fully vaccinated from 5.5% to 23.7% depending on the survey year. The proportion of children fully vaccinated by 24 months of age estimated among respondents to contact 1 was only 2.1% higher than the estimates among all respondents.
   Conclusions: Without validation among vaccine providers for children with missing doses according to vaccination booklets, results underestimated vaccination coverage in the target population. Conducting multiple contact attempts increased the response rate but had limited impact on the validity of estimates. It would be useful in future surveys to present the coverage obtain from respondents to each contact attempt. Published by Elsevier Ltd.
C1 [Kiely, Marilou; Ouakki, Manale; Guay, Maryse; Sauvageau, Chantal; De Serres, Gaston] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada.
   [Kiely, Marilou; Talbot, Denis; Sauvageau, Chantal; De Serres, Gaston] Laval Univ, Dept Social & Prevent Med, Quebec City, PQ, Canada.
   [Boulianne, Nicole; Talbot, Denis; Sauvageau, Chantal; De Serres, Gaston] Univ Laval, CHU Quebec, Quebec City, PQ, Canada.
   [Guay, Maryse] Sherbrooke Univ, Dept Community Hlth Sci, Sherbrooke, PQ, Canada.
   [Guay, Maryse] Ctr Rech CSIS, Ctr Integre Sante & Serv Sociaux, Monteregie Ctr, Greenfield Pk, PQ, Canada.
   [Landry, Monique] Minist Sante & Serv Sociaux, Quebec City, PQ, Canada.
RP Kiely, M (reprint author), 2400 Estimauville Ave, Quebec City, PQ G1E 7G9, Canada.
EM marilou.kiely@inspq.qc.ca
FU Fonds de recherche du Quebec-Sante (FRQS); Ministere de la Sante et des
   Services sociaux du Quebec
FX MK has received a scholarship from the Fonds de recherche du
   Quebec-Sante (FRQS).; Vaccination coverage surveys from 2006 were
   supported by the Ministere de la Sante et des Services sociaux du
   Quebec. Funding sources had no involvement on the conduct of this
   research and on the redaction of this manuscript.
CR Braeckman T, 2014, VACCINE, V32, P345, DOI [10., 10.1016/j.vaccine.2013.11.041]
   Centers for disease control and prevention, NAT CTR IMM RESP DIS
   Curtin R, 2000, PUBLIC OPIN QUART, V64, P413, DOI 10.1086/318638
   Cutts FT, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001404
   Dillman D, 2000, MAIL INTERNET SURVEY
   Dillman D. A., 2014, INTERNET PHONE MAIL
   GOLDSTEIN KP, 1993, JAMA-J AM MED ASSOC, V270, P2190, DOI 10.1001/jama.270.18.2190
   Groves RM, 2008, PUBLIC OPIN QUART, V72, P167, DOI 10.1093/poq/nfn011
   Groves RM, 2006, PUBLIC OPIN QUART, V70, P646, DOI 10.1093/poq/nfl033
   Hanley JA, 2011, J BIOMET BIOSTAT, V2, P5
   Hill Holly A, 2016, MMWR Morb Mortal Wkly Rep, V65, P1065, DOI 10.15585/mmwr.mm6539a4
   Hill Holly A, 2016, MMWR-MORBID MORTAL W, V2017, P1171
   Hull BP, 2009, VACCINE, V27, P5054, DOI 10.1016/j.vaccine.2009.06.056
   Kiely M, 2017, ENQUETE COUVERTURE V
   Law C, 2019, AUST NZ J PUBL HEAL, V43, P214, DOI 10.1111/1753-6405.12891
   Luman ET, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-99
   Luman ET, 2009, VACCINE, V27, P2534, DOI 10.1016/j.vaccine.2008.10.002
   Miles M, 2013, VACCINE, V31, P1560, DOI 10.1016/j.vaccine.2012.10.089
   Olson K, 2006, PUBLIC OPIN QUART, V70, P737, DOI 10.1093/poq/nfl038
   PAGANINIHILL A, 1993, EPIDEMIOLOGY, V4, P375, DOI 10.1097/00001648-199307000-00014
   Public Health Agency of Canada, 2016, VACC COV CAN CHILDR
   Statistics Canada, 2017, VACC COV 2 YEAR OLD
   World health organization, 2015, WHO VACC COV CLUST S
   Zell ER, 1999, PUBLIC HEALTH REP, V114, P3
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1202
EP 1210
DI 10.1016/j.vaccine.2019.11.014
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100031
PM 31759736
DA 2020-05-12
ER

PT J
AU Frade, J
   Nunes, C
   Mesquita, JR
   Nascimento, MS
   Prasad, L
   Goncalves, G
AF Frade, Joao
   Nunes, Carla
   Mesquita, Joao Rodrigo
   Sao Jose Nascimento, Maria
   Prasad, Leonie
   Goncalves, Guilherme
TI Mumps antibodies in the cord blood: Association with maternal recall of
   mumps. Possible consequences for vaccination strategies
SO VACCINE
LA English
DT Article
DE Mumps; Vaccination; MMR; Antibody
ID MMR-VACCINE; RUBELLA; MEASLES; PERSISTENCE; PREVALENCE; AGE
AB The present study aims to contribute to the evaluation of the serological impact of vaccination against mumps in Portugal, measuring anti-mumps IgG (MuIgG) levels in cord sera and the corresponding proportions of seropositive newborns, and their association with potential predictive variables. The data from this study came from 198 umbilical cord sera. Detailed vaccination records were available for all mothers. MulgG were measured in the sera, using a commercial immunoassay. The geometric mean concentration (GMC) of MuIgG was 31.7 RU/ml. Seropositive/immune sera (concentration >= 16 RU/ml) were 75.3%. While 49 mothers were "unsure" about ever having had mumps, 46 said they had had the disease and 103 said they had not had it. Eighty eight women did not receive a single dose of MMR while the other received 1 or 2 doses, with different combinations of vaccine strains. This study found that recalling mumps was predictive of higher MuIgG GMC and seropositivity. Maternal age and vaccination status were not associated with GMC or seropositivity. Nevertheless, in the small subset of newborns from vaccinated mothers not recalling mumps, receiving two doses was predictive of higher GMC than just receiving one. Maternal recall of mumps is highly predictive of seropositivity while not recalling the disease results in numerous false-negatives. This is consistent with other studies and with the fact that infection with mumps virus can result in a wide range of clinical manifestations. We agree on the need for further research to support a recommendation of a three (or more)-dose MMR strategy but we also believe that evidence is fast accumulating in favour of a higher dose strategy. The issue of waning immunity due to vaccines when vaccination succeeds in controlling (and nationally eliminating) target diseases like measles and mumps must be urgently taken into account. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Frade, Joao; Prasad, Leonie; Goncalves, Guilherme] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Multidisciplinary Unit Biomed Res UMIB, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
   [Nunes, Carla] Univ Nova Lisboa, Publ Hlth Res Ctr, Natl Sch Publ Hlth, Ave Padre Cruz, P-1600560 Lisbon, Portugal.
   [Mesquita, Joao Rodrigo] Univ Porto, Inst Saude Publ ISPUP, Inst Biomed Sci Abel Salazar ICBAS, Epidemiol Res Unit, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
   [Sao Jose Nascimento, Maria] Univ Porto, Dept Biol Sci, Lab Microbiol, Fac Pharm, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
   [Frade, Joao] Polytech Inst Leiria, Sch Hlth Sci, Hlth Res Unit, Campus 2 Morro do Lena Alto Vieiro,Apartado 4137, P-2411901 Leiria, Portugal.
RP Goncalves, G (reprint author), Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Multidisciplinary Unit Biomed Res UMIB, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
EM joao.frade@ipleiria.pt; CNunes@ensp.unl.pt; saojose@ff.up.pt;
   aggoncalves@icbas.up.pt
RI ; Mesquita, Joao/B-6960-2016
OI Goncalves, Guilherme/0000-0003-0030-3346; Garcia Alexandre, Maria Sao
   Jose/0000-0002-6157-4978; Mesquita, Joao/0000-0001-8769-8103; Graca
   Frade, Joao Manuel/0000-0002-4947-1052
CR BROWN EG, 1991, VACCINE, V9, P840, DOI 10.1016/0264-410X(91)90223-S
   Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309
   CongaIves G, 1998, ACTA MEDICA PORT, V11, P1079
   Frade J, 2018, EPIDEMIOL INFECT, V146, P600, DOI [10.1017/S0950268818000237, 10.1017/s0950268818000237]
   Fraizzoli G, 1989, Ann Ig, V1, P1163
   Goncalves G, 1998, Euro Surveill, V3, P119
   Goncalves G, 2016, VACCINE, V34, P2750, DOI 10.1016/j.vaccine.2016.04.007
   Goncalves G, 2015, VACCINE, V33, P5057, DOI 10.1016/j.vaccine.2015.08.057
   Institute Nacional de Saude Doutor Ricardo Jorge, 2017, INQ SER NAC 2015 201
   Kumakura S, 2014, J INFECT CHEMOTHER, V20, P194, DOI 10.1016/j.jiac.2013.10.006
   LeBaron CW, 2009, J INFECT DIS, V199, P552, DOI 10.1086/596207
   Marin M, 2018, MMWR-MORBID MORTAL W, V67, P33, DOI 10.15585/mmwr.mm6701a7
   Mclean HQ, 2010, WHO IMMUNOLOGICAL BA
   Nardone A, 2003, EPIDEMIOL INFECT, V131, P691, DOI 10.1017/S0950268803008768
   Plans P, 2015, EUR J CLIN MICROBIOL, V34, P1161, DOI 10.1007/s10096-015-2339-4
   Portugal. DireccAo-Geral da Saude, 2001, DIR GER SAUD PROGR N
   Portugal. Ministerio da Saude, 1990, 10DTF MIN SAUD
   Portugal. Ministerio da Saude. Direccao Geral dos Cuidados de Saude Primarios, 1987, 5DTP MIN SAUD
   Takemoto K, 2016, JPN J INFECT DIS, V69, P314, DOI 10.7883/yoken.JJID.2015.366
   Vandermeulen C, 2007, VACCINE, V25, P6672, DOI 10.1016/j.vaccine.2007.07.008
NR 20
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1211
EP 1215
DI 10.1016/j.vaccine.2019.11.013
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100032
PM 31767464
DA 2020-05-12
ER

PT J
AU Madlon-Kay, DJ
   Smith, ER
AF Madlon-Kay, Diane J.
   Smith, Emily R.
TI Interpreters' knowledge and perceptions of childhood vaccines: Effect of
   an educational session
SO VACCINE
LA English
DT Article
DE Vaccines; Vaccination; Measles; Communication barriers; Translating;
   Emigrants and immigrants
ID MEASLES OUTBREAK; HEALTH-CARE; MINNESOTA
AB Background: Interpreters improve the care of patients with limited English proficiency. They can potentially act as unofficial health educators to help dispel misunderstandings about medical risks in a culturally appropriate manner. Somali parents in Minnesota are less likely to immunize their children for MMR than other parents because they believe the MMR vaccine causes autism. The low MMR vaccination rate contributed to measles outbreaks in the state in 2011 and 2017.
   Objective: To investigate the effects of an educational session on interpreter beliefs and knowledge about childhood vaccines.
   Methods: A large interpreter service in Minneapolis holds quarterly educational sessions for their interpreters. The investigators presented a one-hour interactive session on childhood vaccinations at one of the meetings. The interpreters were surveyed pre- and post-training to assess their (1) beliefs regarding childhood vaccines, (2) knowledge of childhood vaccination indications and safety, and surveyed pre-training about their perceived impact on patient decision-making.
   Results: Fifty-five of the 78 interpreters attending the training session completed both the pre- and post-training surveys. Participants made significant improvements in their knowledge of vaccines after the training. Interpreters were less likely to believe that vaccines causes autism after the presentation (p = 0.02), and were more likely to indicate that the current evidence does not support a vaccine - autism connection (p < 0.001).
   Nineteen percent of the interpreters were from Somalia. Somali interpreters were significantly more likely to expand on what is said by the physician than their non-Somali colleagues (OR = 16.2, 95% CI = 2.8-92.9). They were also significantly more likely to encounter parental worry over vaccine safety (OR = 16.2, 95% CI = 1.9-140.5), and to believe that children get too many vaccines (OR = 30.1, 95% CI = 3.4-271.5).
   Conclusions: The training was an effective method to improve interpreters' knowledge and perceptions of vaccine safety. By training Somali interpreters, they can become a part of a team working toward better MMR vaccination rates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Madlon-Kay, Diane J.; Smith, Emily R.] Univ Minnesota, Dept Family Med & Community Hlth, Med Sch, 2020 E 28th St, Minneapolis, MN 55407 USA.
   [Smith, Emily R.] Allina West St Paul Clin, 150 Emerson Ave E, West St Paul, MN 55118 USA.
RP Madlon-Kay, DJ (reprint author), Univ Minnesota, Dept Family Med & Community Hlth, Med Sch, 2020 E 28th St, Minneapolis, MN 55407 USA.
EM madlo001@tc.umn.edu
FU Minnesota Academy of Family Physicians Foundation
FX This work was supported by the Minnesota Academy of Family Physicians
   Foundation.
CR Avery M-PB, 2001, ROLE HLTH CARE INTER
   Flores G, 2005, MED CARE RES REV, V62, P255, DOI 10.1177/1077558705275416
   Hall V, 2017, MMWR-MORBID MORTAL W, V66, P713, DOI 10.15585/mmwr.mm6627a1
   Hsieh E, 2012, PATIENT EDUC COUNS, V89, P158, DOI 10.1016/j.pec.2012.07.001
   Karliner LS, 2007, HEALTH SERV RES, V42, P727, DOI 10.1111/j.1475-6773.2006.00629.x
   Leeds M, 2017, MMWR-MORBID MORTAL W, V66, P1125, DOI 10.15585/mmwr.mm6642a1
   Leslie TF, 2018, VACCINE, V36, P1808, DOI 10.1016/j.vaccine.2018.02.086
   National Council on Interpreting in Health Care, 2005, NAT STAND PRACT INT
   Sleptsova M, 2014, J COMMUN HEALTH NURS, V31, P167, DOI 10.1080/07370016.2014.926682
   Wolff ER, 2014, J AM BOARD FAM MED, V27, P458, DOI 10.3122/jabfm.2014.04.130275
NR 10
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1216
EP 1219
DI 10.1016/j.vaccine.2019.11.010
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100033
PM 31757578
DA 2020-05-12
ER

PT J
AU Hsu, CH
   Harvey, B
   Mohamed, A
   Elfakki, E
   Ehrhardt, D
   Farag, NH
AF Hsu, Christopher H.
   Harvey, Bonnie
   Mohamed, Abdinoor
   Elfakki, Eltayeb
   Ehrhardt, Derek
   Farag, Noha H.
TI Assessment of in-country capacity to maintain communicable disease
   surveillance and response services after polio eradication-Somalia
SO VACCINE
LA English
DT Article
DE Polio; Eradication; Transition; Somalia; Capacity
AB One objective of the 2013-2018 Global Polio Eradication Initiative (GPEI) Strategic Plan was the transition of GPEI polio essential functions to other public health programs [1]. For many developing countries, in addition to polio essential functions, GPEI funding has been supporting integrated communicable disease surveillance and routine immunization programs. As GPEI progresses toward polio eradication, GPEI funding for some polio-free countries is being scaled back. The Somalia Polio Eradication Program, led by international organizations in collaboration with local authorities, is a critical source of immunizations for >2.5 million children. In addition, the polio program has been supporting a range of communicable disease surveillance, basic health services (e.g. routine immunizations) as well as emergency response activities (e.g. outbreak response). To assess current capacities in Somalia, interviews were conducted with representatives of relief organizations and ministries of health (MoHs) from Somaliland, Puntland, and South-Central political zones to elicit their opinions on their agency's capacity to assume public health activities currently supported by GPEI funds. Seventy percent of international and 62% of representatives of domestic relief agencies reported low capacity to conduct communicable disease surveillance without GPEI funds. Responses from MoH representatives for the three zones in Somalia ranged from "very weak" to "strong" regarding capacity to conduct both polio and non-polio related communicable disease surveillance and outbreak response activities. Zones programs are unprepared to provide communicable diseases services if GPEI funding were substantially reduced abruptly. Polio transition planning must strategically plan for shifting of GPEI staffing, operational assets and funding to support identified gaps in Somalia's public health infrastructure. Published by Elsevier Ltd.
C1 [Hsu, Christopher H.; Mohamed, Abdinoor; Ehrhardt, Derek; Farag, Noha H.] Ctr Dis Control & Prevent, Polio Eradicat Branch, Atlanta, GA 30333 USA.
   [Harvey, Bonnie] Ctr Dis Control & Prevent, Strateg Informat & Workforce Dev Branch, Atlanta, GA USA.
   [Elfakki, Eltayeb] WHO, Somalia Country Off, Nairobi, Kenya.
RP Hsu, CH (reprint author), Ctr Dis Control & Prevent, Polio Eradicat Branch, Atlanta, GA 30333 USA.
EM chsu@cdc.gov
FU Centers for Disease Control and Prevention through the African Field
   Epidemiology Network Polio Outbreak Response Cooperative Agreement
   [NU2GGH001876]
FX We would like to thank Steven Cochi and Steve Wassilak (CDC) for
   contributing their expertise and insights. We would also like to thank
   GRASP (CDC) for help with mapping. This project was funded by the
   Centers for Disease Control and Prevention through the African Field
   Epidemiology Network Polio Outbreak Response Cooperative Agreement
   NU2GGH001876.
CR [Anonymous], 2018, WORKSH POL TRANS PLA
   Cochi SL, 2014, J INFECT DIS, V210, pS540, DOI 10.1093/infdis/jiu345
   Craig AS, 2017, J INFECT DIS, V216, pS343, DOI 10.1093/infdis/jix034
   Jeene H, 2014, LANCET, V383, P2209, DOI 10.1016/S0140-6736(14)61079-5
   Mbaeyi C, 2014, J INFECT DIS, V210, pS173, DOI 10.1093/infdis/jit808
   Pervaiz A, 2017, MMWR-MORBID MORTAL W, V66, P1295, DOI 10.15585/mmwr.mm6647a4
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1220
EP 1224
DI 10.1016/j.vaccine.2019.11.008
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100034
PM 31753675
DA 2020-05-12
ER

PT J
AU Nowak, GJ
   Evans, NJ
   Wojdynski, BW
   Ahn, SJ
   Len-Rios, ME
   Carera, K
   Hale, S
   McFalls, D
AF Nowak, Glen J.
   Evans, Nathaniel J.
   Wojdynski, Bartosz W.
   Ahn, Sun Joo (Grace)
   Len-Rios, Maria E.
   Carera, Karen
   Hale, Scott
   McFalls, Deborah
TI Using immersive virtual reality to improve the beliefs and intentions of
   influenza vaccine avoidant 18-to-49-year-olds: Considerations, effects,
   and lessons learned
SO VACCINE
LA English
DT Article
DE Influenza vaccine acceptance; Virtual reality; Vaccination communication
   and education; Vaccine hesitancy
ID HEALTH-PROMOTION CAMPAIGNS; PSYCHOLOGICAL SCIENCE; ENVIRONMENTS;
   METAANALYSIS; INVOLVEMENT; CONSUMPTION; TECHNOLOGY; PREVENTION; SELF; US
AB Objective: Only one-third of adults 18-49 years old in the United States receive a recommended annual influenza vaccination. This study examined whether supplementing vaccine information statements (VIS) with an immersive virtual reality (VR), short video or electronic pamphlet story designed to convey the community immunity benefits of influenza vaccination would improve influenza vaccine avoidant participants' influenza-related perceptions as well as their influenza vaccination-related beliefs, confidence and intentions.
   Method: A one-way between-subjects experimental design compared the effects of adding a supplemental education experience prior to VIS exposure with flu vaccine avoidant 18-to-49-year-olds. The 171 participants recruited from the community were randomly assigned to one of three modality treatment conditions [VR, video, or e-pamphlet (i.e., story board presented via electronic tablet)] or a VIS-only control condition.
   Results: Compared to the modalities, the VR intervention created a stronger perception of presence (i.e., feeling of "being there" in the story), which, in turn, increased participants' concern about transmitting influenza to others and raised vaccination intention. Increased concern about transmitting influenza to others was associated with positive effects on influenza vaccination-related beliefs, including confidence that one's flu vaccination would protect others. Neither the e-pamphlet nor the video intervention were able to elicit a sense of presence nor were they able to improve the impact of the VIS on the outcome measures.
   Conclusions: Immersive VR has much potential to increase understanding of key immunization concepts, such as community immunity, through creative executions that increase a sense of presence. Given the need to increase influenza vaccination uptake among 18-to-49-year-olds, and the projected growth in VR accessibility and use, additional applications and assessments related to vaccination communication and education are needed and warranted. By increasing the ability to convey key vaccine and immunization concepts, immersive VR could help address vaccination hesitancy and acceptance challenges. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nowak, Glen J.; Evans, Nathaniel J.; Wojdynski, Bartosz W.; Ahn, Sun Joo (Grace); Len-Rios, Maria E.] Univ Georgia, Grady Coll Journalism & Mass Commun, Ctr Hlth & Risk Commun, Athens, GA 30602 USA.
   [Nowak, Glen J.; Evans, Nathaniel J.; Ahn, Sun Joo (Grace); Len-Rios, Maria E.] Univ Georgia, Grady Coll Journalism & Mass Commun, Dept Advertising & Publ Relat, Athens, GA 30602 USA.
   [Wojdynski, Bartosz W.] Univ Georgia, Grady Coll Journalism & Mass Commun, Dept Journalism, Athens, GA 30602 USA.
   [Carera, Karen; Hale, Scott; McFalls, Deborah] Oak Ridge Associated Univ, 100 Orau Way, Oak Ridge, TN 37830 USA.
RP Nowak, GJ (reprint author), Univ Georgia, Grady Coll Journalism & Mass Commun, Ctr Hlth & Risk Commun, Athens, GA 30602 USA.; Nowak, GJ (reprint author), Univ Georgia, Grady Coll Journalism & Mass Commun, Dept Advertising & Publ Relat, Athens, GA 30602 USA.
EM gnowak@uga.edu
OI Nowak, Glen/0000-0002-9153-2189
FU Oak Ridge Associated Universities (ORAU); National Center for Advancing
   Translational Sciences of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002378]
FX This research was supported with a grant from Oak Ridge Associated
   Universities (ORAU). In addition, the University of Georgia Clinical
   Translational Research Unit (CTRU) involvement was supported by the
   National Center for Advancing Translational Sciences of the National
   Institutes of Health under Award Number UL1TR002378. We also acknowledge
   the contributions of the University of Georgia doctoral students who
   carried out the research data collection. This article's content and
   conclusions are solely the responsibility of the authors and do not
   necessarily represent the official views of ORAU, the academic
   researchers' affiliated university or the National Institutes of Health.
CR Ahn SJ, 2019, MEDIA PSYCHOL, V22, P626, DOI 10.1080/15213269.2018.1492939
   Ahn SJ, 2018, J MEDIA PSYCHOL-GER, V30, P91, DOI 10.1027/1864-1105/a000184
   Ahn SJG, 2016, J COMPUT-MEDIAT COMM, V21, P399, DOI 10.1111/jcc4.12173
   Ahn SJ, 2016, CYBERPSYCH BEH SOC N, V19, P86, DOI 10.1089/cyber.2015.0224
   Ahn SJ, 2015, HEALTH COMMUN, V30, P545, DOI 10.1080/10410236.2013.869650
   Ahn SJ, 2013, MEDIA PSYCHOL, V16, P7, DOI 10.1080/15213269.2012.755877
   [Anonymous], HLTH PEOPL 2020 GOAL
   Betsch C, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0056
   Biocca F., 1997, J COMPUT-MEDIAT COMM, V3, P1, DOI [DOI 10.1111/J.1083-6101.1997.TB00070.X, 10.1111/j.1083-6101.1997.tb00070.x]
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Bridges CB, 2015, AM J PREV MED, V49, pS455, DOI 10.1016/j.amepre.2015.08.014
   Bronchetti ET, 2015, J ECON BEHAV ORGAN, V116, P270, DOI 10.1016/j.jebo.2015.04.003
   Centers for Disease Control and Prevention, KEY FACTS INFL FLU
   Centers for Disease Control and Prevention, VACC INF STAT FACTS
   Centers for Disease Control and Prevention (CDC), 2018, EST INFL VACC COV AD
   Cohen J, STAT POWER ANAL BEHA
   Cummings JJ, 2016, MEDIA PSYCHOL, V19, P272, DOI 10.1080/15213269.2015.1015740
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Hakim H, 2019, VACCINE, V37, P235, DOI 10.1016/j.vaccine.2018.11.016
   Hayes A. F., 2018, INTRO MEDIATION MODE
   Herrera F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204494
   Kim S, 2019, HEALTH COMMUN, V34, P21, DOI 10.1080/10410236.2017.1384353
   Kim T., 1997, J COMPUT-MEDIAT COMM, V3, P2, DOI DOI 10.1111/J.1083-6101.1997.TB00073.X
   Kitta A, 2017, CRIT PUBLIC HEALTH, V27, P506, DOI 10.1080/09581596.2016.1235259
   Lee YI, 2018, SOC MARK Q, V24, P89, DOI 10.1177/1524500418771283
   Logan J, 2018, VACCINE, V36, P4118, DOI 10.1016/j.vaccine.2018.05.037
   Lombard M, 2000, HUM COMMUN RES, V26, P75, DOI 10.1111/j.1468-2958.2000.tb00750.x
   Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046
   Neimand A., 2018, STANFORD SOC INNOV R
   Nowak GJ, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040711
   Nowak GJ, 2017, VACCINE, V35, P5543, DOI 10.1016/j.vaccine.2017.08.064
   Nowak GJ, 2015, VACCINE, V33, P4204, DOI 10.1016/j.vaccine.2015.04.039
   Nowak GJ, 2015, VACCINE, V33, P2741, DOI 10.1016/j.vaccine.2015.04.064
   Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017
   Oh SY, 2016, COMPUT HUM BEHAV, V60, P398, DOI 10.1016/j.chb.2016.02.007
   Plans-Rubio P, 2012, PREV MED, V55, P72, DOI 10.1016/j.ypmed.2012.02.015
   Poland CM, 2011, VACCINE, V29, P6145, DOI 10.1016/j.vaccine.2011.07.131
   Real FJ, 2017, ACAD PEDIATR, V17, P431, DOI 10.1016/j.acap.2017.01.010
   Regenbrecht H, 2002, PRESENCE-TELEOP VIRT, V11, P425, DOI 10.1162/105474602760204318
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Sheridan T. B., 1992, PRESENCE-TELEOP VIRT, V1, P120, DOI DOI 10.1162/PRES.1992.1.1.120
   Simis MJ, 2016, PUBLIC UNDERST SCI, V25, P400, DOI 10.1177/0963662516629749
   STEUER J, 1992, J COMMUN, V42, P73, DOI 10.1111/j.1460-2466.1992.tb00812.x
   Sun Joo Ahn, 2014, Intelligent Virtual Agents. 14th International Conference (IVA 2014). Proceedings: LNCS 8637, P1, DOI 10.1007/978-3-319-09767-1_1
   Van Vugt M, 2009, CURR DIR PSYCHOL SCI, V18, P169, DOI 10.1111/j.1467-8721.2009.01630.x
   Wheelock A, 2013, EXPERT REV VACCINES, P1
NR 46
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1225
EP 1233
DI 10.1016/j.vaccine.2019.11.009
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100035
PM 31806533
DA 2020-05-12
ER

PT J
AU Ounnavong, P
   Chanthavilay, P
   Khampanisong, P
   Reinharz, D
   Muller, CP
   Black, AP
AF Ounnavong, Phoumsavath
   Chanthavilay, Phetsavanh
   Khampanisong, Phonepaseuth
   Reinharz, Daniel
   Muller, Claude P.
   Black, Antony P.
TI Seroprevalence of anti-tetanus antibodies in mothers and cord blood and
   associated factors in health-care settings in Lao People's Democratic
   Republic
SO VACCINE
LA English
DT Article
DE Seroprevalence; Anti-tetanus antibodies; Maternal and neonatal tetanus;
   Vaccine; Laos
ID TETANUS; WOMEN
AB Background: Maternal neonatal tetanus (MNT) was eliminated from Lao People's Democratic Republic (PDR) in 2014. WHO recommends 80% coverage of 2 or more tetanus vaccinations (TT2+) in pregnancy to maintain MNT control. Vaccination coverage in Lao PDR varies among regions although the reasons are not clear.
   Methods: 185 pregnant women giving birth in three district hospitals in Savannakhet province, Lao PDR were recruited. A questionnaire was administered to determine factors associated with seroprotection and blood was taken from mother and cord blood to be tested for anti-tetanus antibodies by ELISA.
   Results: 77% of mothers and 79% of newborns had sufficiently protective antibody titres (>0.5 IU/ml) against tetanus. Only 70% of the mothers received one dose of TT vaccination during antenatal care (ANC) consultation and 45% received the recommended two injections. Although most of the vaccination took place during ANC 1 and 2, many were missed at these time-points. Anti-tetanus seroprotection in the mothers was associated with maternal age, number of ANC visits, number of TT vaccinations during and before pregnancy and gestational age.
   Conclusion: Seroprevalence of anti-tetanus antibodies in mothers and newborns was intermediate but TT2+ coverage was low in healthcare settings in Lao PDRAT2+ coverage during ANC is likely to be significantly lower in settings with less robust ANC practices. Missed opportunities to vaccinate in ANC 1 and 2 suggest a need to promote vaccine awareness and vaccination at first ANC visit. A booster dose of TT containing vaccine should be considered for children aged between 4 and 7 years old. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ounnavong, Phoumsavath; Chanthavilay, Phetsavanh; Reinharz, Daniel] Inst Francophonie Med Tropicale, Viangchan, Laos.
   [Khampanisong, Phonepaseuth; Muller, Claude P.; Black, Antony P.] Inst Pasteur Laos, Lao Lux Lab, Viangchan, Laos.
   [Reinharz, Daniel] Laval Univ, Dept Social & Prevent Med, Quebec City, PQ, Canada.
   [Muller, Claude P.] Luxembourg Inst Hlth, Dept Infect & Immun, Esch Sur Alzette, Luxembourg.
   [Muller, Claude P.] Lab Natl Sante, Dudelange, Luxembourg.
RP Black, AP (reprint author), Inst Pasteur Laos, Rue Samsenthai, Viangchan, Laos.
EM a.black@pasteur.la
FU Luxembourg Ministry of Cooperation; Luxembourg Institute of Health
FX This work was supported by the Luxembourg Ministry of Cooperation and
   the Luxembourg Institute of Health.
CR American College of Obstetricians and Gynecologists, 2017, OBSTET GYNECOL, V130, P153
   [Anonymous], 2014, Wkly Epidemiol Rec, V89, P465
   [Anonymous], 2002, Wkly Epidemiol Rec, V77, P277
   Black AP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123647
   Boudreaux C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089784
   Thuy DB, 2017, AM J TROP MED HYG, V96, P93, DOI 10.4269/ajtmh.16-0470
   Evdokimov K, 2017, CLIN MICROBIOL INFEC, V23, P197, DOI 10.1016/j.cmi.2016.10.007
   Global Advisory Committee on Vaccine Safety, 2014, GLOB ADV COMM VACC S
   Khan R, 2015, IN J WOMENS HEALTH, V7, P171, DOI 10.2147/IJWH.S50539
   Kongsap A, 2014, HLTH SYST TRANSIT, V4, P160
   Masuno K, 2009, VACCINE, V27, P4284, DOI 10.1016/j.vaccine.2009.05.024
   Perry AL, 2009, CLIN VACCINE IMMUNOL, V16, P1837, DOI 10.1128/CVI.00294-09
   Phoxay C, 2001, ASIA PACIFIC J PUBLI, V13, DOI [10.1177/101053950101300104, DOI 10.1177/101053950101300104]
   Roper MH, 2007, LANCET, V370, P1947, DOI 10.1016/S0140-6736(07)61261-6
   Scobie HM, 2016, CLIN VACCINE IMMUNOL, V23, P546, DOI 10.1128/CVI.00052-16
   Sirivong Amone, 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P919
   WHO, 2018, WHO IMM BAS IMM SER, V3
   World Health Organization, 2003, AD HOC COMM MAT NEON
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1234
EP 1240
DI 10.1016/j.vaccine.2019.11.007
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100036
PM 31735506
DA 2020-05-12
ER

PT J
AU Biffar, L
   Blunt, L
   Atkins, W
   Anderson, P
   Holder, T
   Xing, Z
   Vordermeier, M
   McShane, H
   Villarreal-Ramos, B
AF Biffar, Lucia
   Blunt, Laura
   Atkins, William
   Anderson, Paul
   Holder, Tom
   Xing, Zhou
   Vordermeier, Martin
   McShane, Helen
   Villarreal-Ramos, Bernardo
TI Evaluating the sensitivity of the bovine BCG challenge model using a
   prime boost Ad85A vaccine regimen
SO VACCINE
LA English
DT Article
DE Bovine BCG challenge model; Bovine tuberculosis; Ad85A; BCG Tokyo;
   Intranodal challenge; Predictors of protection
ID MYCOBACTERIUM-TUBERCULOSIS; IMMUNITY; PROTECTION; ADENOVIRUS; CATTLE
AB In the absence of biomarkers of protective immunity, newly developed vaccines against bovine tuberculosis need to be evaluated in virulent Mycobacterium bovis challenge experiments, which require the use of expensive and highly in demand Biological Safety Level 3 (BSL3) animal facilities. The recently developed bovine BCG challenge model offers a cheaper and faster way to test new vaccine candidates and additionally reduces the severity of the challenge compared to virulent M. bovis challenge in line with the remits of the NC3Rs. In this work we sought to establish the sensitivity of the BCG challenge model by testing a prime boost vaccine regimen that previously increased protection over BCG alone against M. bovis challenge. All animals, except the control group, were vaccinated subcutaneously with BCG Danish, and half of those were then boosted with a recombinant adenoviral vector expressing Antigen 85A, Ad85A. All animals were challenged with BCG Tokyo into the prescapular lymph node and the bacterial load within the lymph nodes was established. All vaccinated animals, independent of the vaccination regimen, cleared BCG significantly faster from the lymph node than control animals, suggesting a protective effect. There was however, no difference between the BCG and the BCG-Ad85A regimens. Additionally, we analysed humoral and cellular immune responses taken prior to challenge for possible predictors of protection. Cultured ELISpot identified significantly higher IFN-gamma responses in protected vaccinated animals, relative to controls, but not in unprotected vaccinated animals. Furthermore, a trend for protected animals to produce more IFN-gamma by quantitative PCR and intracellular staining was observed. Thus, this model can also be an attractive alternative to M. bovis challenge models for the discovery of protective biomarkers. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Biffar, Lucia; McShane, Helen] Jenner Inst Oxford, Old Rd Campus Res Build,Roosevelt Dr, Oxford OX3 7DQ, England.
   [Biffar, Lucia; Blunt, Laura; Atkins, William; Anderson, Paul; Holder, Tom; Vordermeier, Martin; Villarreal-Ramos, Bernardo] Anim & Plant Hlth Agcy, Dept Bacteriol, TB Immunol & Vaccinol Team, Weybridge KT15 3NB, Surrey, England.
   [Xing, Zhou] McMaster Univ, McMaster Immunol Res Ctr, Hamilton, ON L8S 4K1, Canada.
   [Vordermeier, Martin; Villarreal-Ramos, Bernardo] Aberystwyth Univ, IBERS, Aberystwyth SY23 3DA, Ceredigion, Wales.
RP Villarreal-Ramos, B (reprint author), Anim & Plant Hlth Agcy, Dept Bacteriol, TB Immunol & Vaccinol Team, Weybridge KT15 3NB, Surrey, England.
EM Bernardo.Villarreal-Ramos@apha.gov.uk
OI McShane, Helen/0000-0002-2126-5142
FU National Centre of the 3 Rs (NC3Rs strategic award) [NC/M001997/1]
FX This work was supported by the National Centre of the 3 Rs (NC3Rs
   strategic award number NC/M001997/1).
CR Bosio CM, 2000, J IMMUNOL, V164, P6417, DOI 10.4049/jimmunol.164.12.6417
   Chan J, 2014, SEMIN IMMUNOL, V26, P588, DOI 10.1016/j.smim.2014.10.005
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Dean AS, 2018, LANCET INFECT DIS, V18, P137, DOI 10.1016/S1473-3099(18)30013-6
   Dean G, 2014, VACCINE, V32, P1304, DOI 10.1016/j.vaccine.2013.11.045
   DEFRA, 2014, STRAT ACG OFF BOV TU
   GRIFFIN JFT, 1995, TRENDS MICROBIOL, V3, P418, DOI 10.1016/S0966-842X(00)88994-5
   Harris SA, 2014, J INFECT DIS, V209, P1259, DOI 10.1093/infdis/jit647
   Krebs J. R., 1997, BOVINE TUBERCULOSIS
   Minassian AM, 2012, J INFECT DIS, V205, P1035, DOI 10.1093/infdis/jis012
   Minhinnick A, 2016, J INFECT DIS, V213, P824, DOI 10.1093/infdis/jiv482
   Muller B, 2013, EMERG INFECT DIS, V19, P899, DOI 10.3201/eid1906.120543
   Russel WMS, 1959, PRINCIPLES HUMANE
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Smaill F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006843
   Torres-Gonzalez P, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2001-5
   Villarreal-Ramos B, 2014, VACCINE, V32, P5645, DOI 10.1016/j.vaccine.2014.08.009
   Vordermeier HM, 2016, ANNU REV ANIM BIOSCI, V4, P87, DOI 10.1146/annurev-animal-021815-111311
   Vordermeier HM, 2009, INFECT IMMUN, V77, P3364, DOI 10.1128/IAI.00287-09
   Vordermeier HM, 2006, INFECT IMMUN, V74, P1416, DOI 10.1128/IAI.74.2.1416-1418.2006
   Waters WR, 2012, VACCINE, V30, P2611, DOI 10.1016/j.vaccine.2012.02.018
   Whelan AO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029194
   WHO DFID, 2006, CONTR NEGL ZOON DIS
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1241
EP 1248
DI 10.1016/j.vaccine.2019.11.005
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100037
PM 31759733
OA Other Gold
DA 2020-05-12
ER

PT J
AU Haralambieva, IH
   Ovsyannikova, IG
   Kennedy, RB
   Goergen, KM
   Grill, DE
   Chen, MH
   Hao, LJ
   Icenogle, J
   Poland, GA
AF Haralambieva, Iana H.
   Ovsyannikova, Inna G.
   Kennedy, Richard B.
   Goergen, Krista M.
   Grill, Diane E.
   Chen, Min-hsin
   Hao, Lijuan
   Icenogle, Joseph
   Poland, Gregory A.
TI Rubella virus-specific humoral immune responses and their
   interrelationships before and after a third dose of
   measles-mumps-rubella vaccine in women of childbearing age
SO VACCINE
LA English
DT Article
DE Rubella; Rubella Vaccine; Measles-Mumps-Rubella Vaccine; Immunity;
   Humoral; Antibody; Viral
ID CONGENITAL-RUBELLA; B-CELLS; ANTIBODIES; PERSISTENCE; OUTBREAK; ASSAY;
   POLYMORPHISMS; IMMUNIZATION; ASSOCIATIONS; CHILDREN
AB In the U.S., measles, mumps, and rubella vaccination is recommended as two vaccine doses. A third dose of measles-mumps-rubella (MMR) vaccine is being administered in certain situations (e.g., identified seronegativity and during outbreaks).
   We studied rubella-specific humoral immunity (neutralizing antibody, enzyme-linked immunosorbent assay/ELISA IgG titer and antibody avidity) and the frequencies of antigen-specific memory B cells before and after a third dose of MMR-II in 109 female participants of childbearing age (median age, 34.5 years old) from Olmsted County, MN, with two documented prior MMR vaccine doses. The participants were selected from a cohort of 1117 individuals if they represented the high and the low ends of the rubella-specific antibody response spectrum. Of the 109 participants, we identified four individuals (3.67% of all study participants; 7.14% of the low-responder group) that were seronegative at Baseline (rubella-specific ELISA IgG titers <10 IU/mL), suggesting a lack of protection against rubella before receipt of a third MMR vaccine dose. The peak geometric mean neutralizing antibody titer one month following the third dose of MMR vaccine for the cohort was 243 NT50 (CI; 241, 245), which is expected for a cohort with two doses of MMR, and the peak geometric mean lgG titer was 150 IU/mL (CI; 148, 152) with no seronegative individuals at Day 28. One-third of all subjects (31.8% for the neutralizing antibody; 30.8% for the IgG titer) experienced a significant boost (>= 4-fold) of antibody titers one month following vaccination. Antibody titers and other tested immune-response variables were significantly higher in the high-responder group compared to the low-responder group. The frequencies of rubella-specific memory B cells were modestly associated with the antibody titers. Our study suggests the importance of yet unknown inherent biologic and immune factors for the generation and maintenance of rubella-vaccine-induced humoral immune responses. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Haralambieva, Iana H.; Ovsyannikova, Inna G.; Kennedy, Richard B.; Poland, Gregory A.] Mayo Clin, Vaccine Res Grp, Rochester, MN 55905 USA.
   [Goergen, Krista M.; Grill, Diane E.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA.
   [Chen, Min-hsin; Hao, Lijuan; Icenogle, Joseph] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
RP Poland, GA (reprint author), Mayo Clin, Mayo Vaccine Res Grp, Guggenheim 611C,200 First St SW, Rochester, MN 55905 USA.
EM poland.gregory@mayo.edu
FU National Institute of Allergy And Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R37AI048793, R01Al033144]
FX Research reported in this review was supported by the National Institute
   of Allergy And Infectious Diseases of the National Institutes of Health
   under Award Number R37AI048793 and R01Al033144. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. The findings and
   conclusions in this report are those of the authors and do not
   necessarily represent the official position of the United States Centers
   for Disease Control and Prevention.
CR Aboudy Y, 1997, J INFECTION, V34, P273, DOI 10.1016/S0163-4453(97)94507-2
   Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092
   Amanna IJ, 2010, IMMUNOL REV, V236, P125, DOI 10.1111/j.1600-065X.2010.00912.x
   Buisman AM, 2009, VACCINE, V28, P179, DOI 10.1016/j.vaccine.2009.09.102
   Bullens D, 2000, CLIN PEDIATR, V39, P113, DOI 10.1177/000992280003900207
   Chen MH, 2007, J VIROL METHODS, V146, P414, DOI 10.1016/j.jviromet.2007.08.021
   Crooke SN, 2019, VACCINE, V37, P3876, DOI 10.1016/j.vaccine.2019.05.049
   Crotty S, 2015, NAT REV IMMUNOL, V15, P185, DOI 10.1038/nri3803
   Danovaro-Holliday MC, 2000, JAMA-J AM MED ASSOC, V284, P2733, DOI 10.1001/jama.284.21.2733
   Davidkin I, 1998, VACCINE, V16, P2052, DOI 10.1016/S0264-410X(98)00081-4
   Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993
   Ellebedy AH, 2016, NAT IMMUNOL, V17, P1226, DOI 10.1038/ni.3533
   Fiebelkorn AP, 2016, J INFECT DIS, V213, P1115, DOI 10.1093/infdis/jiv555
   Frolich D, 2010, J IMMUNOL, V185, P3103, DOI 10.4049/jimmunol.1000911
   Grant GB, 2015, MMWR-MORBID MORTAL W, V64, P1052, DOI 10.15585/mmwr.mm6437a5
   Hammarlund E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01901-w
   Haralambieva IH, 2019, EXPERT REV VACCINES, V18, P75, DOI 10.1080/14760584.2019.1559063
   Haralambieva IH, 2018, METHODS MOL BIOL, V1808, P221, DOI 10.1007/978-1-4939-8567-8_19
   Haralambieva IH, 2016, VACCINE, V34, P3993, DOI 10.1016/j.vaccine.2016.06.034
   Haralambieva IH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099997
   Haralambieva LH, 2014, VACCINE, V32, P1946, DOI 10.1016/j.vaccine.2014.01.090
   HETHCOTE HW, 1983, AM J EPIDEMIOL, V117, P2, DOI 10.1093/oxfordjournals.aje.a113511
   Isaac BM, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00102-17, 10.1128/cvi.00102-17]
   Janta D, 2012, EUROSURVEILLANCE, V17
   Kakoulidou M, 2013, VACCINE, V31, P711, DOI 10.1016/j.vaccine.2012.11.031
   Kennedy RB, 2014, HUM GENET, V133, P1407, DOI 10.1007/s00439-014-1471-z
   Kennedy RB, 2014, IMMUNOGENETICS, V66, P493, DOI 10.1007/s00251-014-0776-3
   Ki M, 2002, EPIDEMIOL INFECT, V129, P557, DOI 10.1017/S0950268802007811
   Lambert N, 2015, LANCET, V385, P2297, DOI 10.1016/S0140-6736(14)60539-0
   Lambert ND, 2015, J INFECT DIS, V211, P898, DOI 10.1093/infdis/jiu553
   Lambert ND, 2014, CLIN VACCINE IMMUNOL, V21, P340, DOI 10.1128/CVI.00681-13
   Lambert ND, 2014, IMMUNOL RES, V58, P1, DOI 10.1007/s12026-013-8475-y
   Lanzieri TM, 2004, PEDIATR INFECT DIS J, V23, P1116, DOI 10.1097/01.inf.0000145479.04559.97
   Latner DR, 2011, CLIN VACCINE IMMUNOL, V18, P35, DOI 10.1128/CVI.00284-10
   Lavinder JJ, 2014, P NATL ACAD SCI USA, V111, P2259, DOI 10.1073/pnas.1317793111
   LeBaron CW, 2007, ARCH PEDIAT ADOL MED, V161, P294, DOI 10.1001/archpedi.161.3.294
   LeBaron CW, 2009, J INFECT DIS, V200, P888, DOI 10.1086/605410
   McLean HQ, 2018, VACCINE, V36, P5732, DOI 10.1016/j.vaccine.2018.08.010
   Minakami H, 2014, J INFECTION, V68, P99, DOI 10.1016/j.jinf.2013.09.002
   Orenstein WA, 2018, VACCINE, V36, pA35, DOI 10.1016/j.vaccine.2017.10.065
   Painter SD, 2015, VACCINE, V33, P4422, DOI 10.1016/j.vaccine.2015.06.101
   Papania MJ, 2014, JAMA PEDIATR, V168, P148, DOI 10.1001/jamapediatrics.2013.4342
   Paradowska-Stankiewicz I, 2013, EURO SURVEILL, V18
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Poland GA, 1997, JAMA-J AM MED ASSOC, V277, P1156, DOI 10.1001/jama.277.14.1156
   Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886
   REEF SE, 2006, CLIN INFECT DIS S3, V43, pS12
   Reef SE, 2012, VACCINES, P688
   ROBINSON J, 1994, PEDIATR INFECT DIS J, V13, P812, DOI 10.1097/00006454-199409000-00013
   Seagle EE, 2018, VACCINE, V36, P818, DOI 10.1016/j.vaccine.2017.12.075
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Siegrist CA, 2012, VACCINES, P14
   Skendzel LP, 1996, AM J CLIN PATHOL, V106, P170
   Vesikari L, 2012, VACCINE, V30, P3082, DOI 10.1016/j.vaccine.2012.02.062
NR 54
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1249
EP 1257
DI 10.1016/j.vaccine.2019.11.004
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100038
PM 31732325
DA 2020-05-12
ER

PT J
AU Welliver, RC
   Papin, JF
   Preno, A
   Ivanov, V
   Tian, JH
   Lu, H
   Guebre-Xabier, M
   Flyer, D
   Massare, MJ
   Glenn, G
   Ellingsworth, L
   Smith, G
AF Welliver, Robert C.
   Papin, James F.
   Preno, Alisha
   Ivanov, Vadim
   Tian, Jing-Hui
   Lu, Hanxin
   Guebre-Xabier, Mimi
   Flyer, David
   Massare, Michael J.
   Glenn, Greg
   Ellingsworth, Larry
   Smith, Gale
TI Maternal immunization with RSV fusion glycoprotein vaccine and
   substantial protection of neonatal baboons against respiratory syncytial
   virus pulmonary challenge
SO VACCINE
LA English
DT Article
DE RSV F nanoparticle; Vaccine; Respiratory syncytial virus; Maternal
   immunization; Baboon
ID F NANOPARTICLE VACCINE; MONOCLONAL-ANTIBODY; PREGNANT-WOMEN; HEALTHY
   WOMEN; INFECTION; INFANTS; RISK
AB Globally, human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infection in infants and young children. There are no licensed vaccines despite the high worldwide disease burden. RSV fusion (F) glycoprotein vaccine is the most advanced candidate for maternal immunization. In this report, a baboon maternal immunization model was used to assess the immunogenicity and protection of infants against pulmonary challenge with human RSV/A. Vaccination in the third trimester produced high anti-RSV F IgG titers and virus-neutralizing antibodies. Infants born to immunized females had high levels of serum RSV antibodies that were comparable to maternal levels at birth and persisted for over 50 days with a half-life of 14-24 days. Furthermore, infants from immunized females and challenged with RSV/A were healthy, developed less severe disease, and had only mild pulmonary inflammatory changes whereas infants born to non-vaccinated females developed more severe disease with marked to moderate interstitial pneumonia, pulmonary edema, and bronchiolar obstruction. These results support the further development of the RSV F vaccine for maternal immunization. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Welliver, Robert C.; Ivanov, Vadim] Univ Oklahoma, Coll Med, Dept Pediat, Hlth Sci Ctr, 1100 North Lindsay Ave, Oklahoma City, OK 73104 USA.
   [Papin, James F.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 1100 North Lindsay Ave, Oklahoma City, OK 73104 USA.
   [Papin, James F.; Preno, Alisha] Univ Oklahoma, Hlth Sci Ctr, Div Comparat Med, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.
   [Tian, Jing-Hui; Lu, Hanxin; Guebre-Xabier, Mimi; Flyer, David; Massare, Michael J.; Glenn, Greg; Ellingsworth, Larry; Smith, Gale] Novavax Inc, 21 Firstfield Rd, Gaithersburg, MD 20878 USA.
RP Smith, G (reprint author), Novavax Inc, 21 Firstfield Rd, Gaithersburg, MD 20878 USA.
EM Robert-welliver@ouhsc.edu; james-papin@ouhsc.edu;
   alisha-preno@ouhsc.edu; vadim-ivanov@ouhsc.edu; jhtian@novavax.com;
   hlu@novavax.com; mguebre-xabier@novavax.com; MMassare@novavax.com;
   gglenn@novavax.com; gsmith@novavax.com
FU Novavax, Inc.; Novavax, Inc., USA
FX This work was supported by Novavax, Inc. This research did not receive
   any grants from funding agencies in the public or not-forprofit sectors.
   Funding for editorial support by Phase Five Communications Inc. was
   provided by Novavax, Inc., USA.
CR ACOG Committee on Obstetric Practice, 2004, Obstet Gynecol, V104, P1125
   August A, 2017, VACCINE, V35, P3749, DOI 10.1016/j.vaccine.2017.05.045
   Awasthi S, 2009, IMMUNOL CELL BIOL, V87, P419, DOI 10.1038/icb.2009.2
   BEELER JA, 1989, J VIROL, V63, P2941, DOI 10.1128/JVI.63.7.2941-2950.1989
   Beran J, 2018, J INFECT DIS, V217, P1616, DOI 10.1093/infdis/jiy065
   Cicconi P, 2019, CLIN INFECT DIS
   Del Vecchio A, 2018, MINERVA PEDIATR, V70, P579, DOI 10.23736/S0026-4946.18.05300-8
   DESIERRA TM, 1993, J PEDIATR-US, V122, P787, DOI 10.1016/S0022-3476(06)80027-2
   Falloon J, 2017, J INFECT DIS, V216, P1362, DOI 10.1093/infdis/jix503
   Falloon J, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/cvi.00157-17, 10.1128/CVI.00157-17]
   Falloon J, 2016, VACCINE, V34, P2847, DOI 10.1016/j.vaccine.2016.04.002
   Fries L, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0090-7
   Gilbert BE, 2018, VACCINE, V36, P8069, DOI 10.1016/j.vaccine.2018.10.073
   Glenn GM, 2016, J INFECT DIS, V213, P411, DOI 10.1093/infdis/jiv406
   GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3
   Green CA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008748
   Green CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5745
   Harper Scott A., 2004, Morbidity and Mortality Weekly Report, V53, P1
   Hjalmarson O, 2002, AM J RESP CRIT CARE, V165, P83, DOI 10.1164/ajrccm.165.1.2107093
   Johnson S, 1997, J INFECT DIS, V176, P1215, DOI 10.1086/514115
   LAMPRECHT CL, 1976, J INFECT DIS, V134, P211, DOI 10.1093/infdis/134.3.211
   Langley JM, 2017, J INFECT DIS, V215, P24, DOI 10.1093/infdis/jiw453
   Marshall H, 2016, HUM VACC IMMUNOTHER, V12, P848, DOI 10.1080/21645515.2015.1127485
   Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531
   OGILVIE MM, 1981, J MED VIROL, V7, P263, DOI 10.1002/jmv.1890070403
   Papin JF, 2013, AM J PHYSIOL-LUNG C, V304, pL530, DOI 10.1152/ajplung.00173.2012
   Patel N, 2019, VACCINE, V37, P6112, DOI 10.1016/j.vaccine.2019.07.089
   Raghunandan R, 2014, VACCINE, V32, P6485, DOI 10.1016/j.vaccine.2014.09.030
   Roca A, 2002, J MED VIROL, V67, P616, DOI 10.1002/jmv.10148
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Scheltema NM, 2018, VACCINE, V36, P4693, DOI 10.1016/j.vaccine.2018.06.021
   Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]
   Smith G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050852
   Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P398, DOI 10.1016/j.jaci.2008.10.043
   Stensballe LG, 2009, J PEDIATR-US, V154, P296, DOI 10.1016/j.jpeds.2008.07.053
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1258
EP 1270
DI 10.1016/j.vaccine.2019.11.003
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100039
PM 31761502
DA 2020-05-12
ER

PT J
AU Guiso, N
   Meade, BD
   von Konig, CHW
AF Guiso, Nicole
   Meade, Bruce D.
   von Koenig, Carl Heinz Wirsing
TI Pertussis vaccines: The first hundred years
SO VACCINE
LA English
DT Article
DE Pertussis vaccine whole-cell acellular history
ID WHOOPING-COUGH; VACCINATION; ADOLESCENTS; DIAGNOSIS
AB Vaccines against pertussis have been used for more than a hundred years. This review describes the development of whole-cell (wP) and acellular pertussis (aP) vaccines, which, as DTP combination vaccines, have significantly reduced morbidity and mortality from pertussis, and which currently serve as the building blocks for a variety of vaccines used to immunize all infants worldwide. Two series of efficacy trials done in the 1950s for wP vaccines and in the 1990s for aP-vaccines have established standards for studying vaccine effectiveness. However, irrespective of their longtime use, critical aspects of pertussis vaccines remain unknown, including the exact mechanisms of protective immunity and a correlate of protection. Research to improve on the effectiveness and the duration of protection is ongoing, but although the vaccines are not perfect, only their continued use with a high coverage will ensure that infants and children are being protected from pertussis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Guiso, Nicole] Inst Pasteur, Paris, France.
   [Meade, Bruce D.] Meade Biol LLC, Hillsborough, NC USA.
   [von Koenig, Carl Heinz Wirsing] Helios Klinikum Krefeld, Krefeld, Germany.
RP von Konig, CHW (reprint author), Helios Klinikum Krefeld, Krefeld, Germany.
EM chwvk@gmx.de
CR Alderslade R, 1981, WHOOPING COUGH REPOR
   American Academy of Pediatrics, 1944, REP COMM INT DIS PER
   Amirthalingam G, 2013, EUROSURVEILLANCE, V18, P19, DOI 10.2807/1560-7917.ES2013.18.38.20587
   Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   [Anonymous], 1951, BMJ-BRIT MED J, V1, P1463
   [Anonymous], 1956, Br Med J, V2, P454
   [Anonymous], 1988, LANCET, Vi, P955
   [Anonymous], 1991, WHO ORG M CAS DEF PE, P4
   Baron S, 1998, PEDIATR INFECT DIS J, V17, P412, DOI 10.1097/00006454-199805000-00013
   BASS JW, 1994, PEDIATR INFECT DIS J, V13, P343, DOI 10.1097/00006454-199405000-00002
   Bell JA, 1941, PUBLIC HEALTH REP, V56, P1535, DOI 10.2307/4583816
   Bordet J, 1910, ANN I PASTEUR, V6, P476
   BRODY M, 1947, NEW YORK STATE J MED, V47, P1016
   Brown F, 1997, DEV BIOL STAND, V89
   Burns DL, 2014, J INFECT DIS, V209, pS32, DOI 10.1093/infdis/jit491
   CODY CL, 1981, PEDIATRICS, V68, P650
   Coulter HL, 1991, SHOT DARK
   Council on Pharmacy and Chemistry of the American Medical Association, 2010, NEW UN REM, P247
   Dellepiane N, 2018, VACCINE, V36, P3389, DOI 10.1016/j.vaccine.2018.03.049
   EDWARDS KM, 1995, PEDIATRICS, V96, P548
   Edwards KM, 2017, PLOTKINS VACCINES
   EHRENGUT W, 1974, DEUT MED WOCHENSCHR, V99, P2273, DOI 10.1055/s-0028-1108124
   Ehrlich P, 1897, JENA, V6, P299
   Glenney AT, 1926, J PATHOL BACTERIOL, V29, P38
   GORDON JE, 1951, AM J MED SCI, V222, P333, DOI 10.1097/00000441-195109000-00011
   Granstrom M, 2011, HISTORY OF VACCINE DEVELOPMENT, P73, DOI 10.1007/978-1-4419-1339-5_10
   HARRISON W. T., 1938, Public Health Reports, V53, P793, DOI 10.2307/4582538
   Hellenbrand W, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-22
   Hewlett EL, 2014, J INFECT DIS, V209, P982, DOI 10.1093/infdis/jit639
   Hill JC, 1979, INT S PERT P C SPONS
   Howson CP, 1991, ADVERSE EFFECTS PERT
   Jefferson T, 2007, J ROY SOC MED, V100, P343, DOI 10.1258/jrsm.100.7.343
   KEJA K, 1988, World Health Statistics Quarterly, V41, P59
   Kendrick P, 1935, AM J PUBLIC HEALTH N, V25, P147, DOI 10.2105/AJPH.25.2.147
   Kendrick P, 1936, AM J PUBLIC HEALTH N, V26, P8, DOI 10.2105/AJPH.26.1.8
   Kendrick PL, 1943, AM J HYG, V38, P193, DOI 10.1093/oxfordjournals.aje.a118881
   KENDRICK PL, 1949, AM J PUBLIC HEALTH, V39, P179
   KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46
   Le Bordet J, 1906, ANN I PASTEUR, V2, P731
   Leslie PH, 1931, J HYG-CAMBRIDGE, V31, P423, DOI 10.1017/S0022172400010950
   Madsen T, 1933, J AMER MED ASSOC, V101, P187, DOI 10.1001/jama.1933.02740280007003
   Madsen T, 1925, BOSTON MED SURG J, V192, P50, DOI 10.1056/NEJM192501081920202
   McFarlan A M, 1945, Br Med J, V2, P205
   Meade BD, 2014, J INFECT DIS, V209, pS24, DOI 10.1093/infdis/jit531
   Medical Research Council, 1959, BMJ-BRIT MED J, V1, P994
   Nicolle C, 1913, CR HEBD ACAD SCI, V16, P1849
   NOBLE GR, 1987, JAMA-J AM MED ASSOC, V257, P1351, DOI 10.1001/jama.257.10.1351
   PITTMAN M, 1979, REV INFECT DIS, V1, P401
   Plotkin SA, 2013, CLIN INFECT DIS, V56, P1458, DOI 10.1093/cid/cit048
   ROMANUS V, 1987, PEDIATR INFECT DIS J, V6, P364, DOI 10.1097/00006454-198704000-00005
   SATO Y, 1984, LANCET, V1, P122
   Snyder A, 2012, LANCET, V379, P2336, DOI 10.1016/S0140-6736(12)61008-3
   Sricharoenchai S, 2018, LANCET INFECT DIS, V18, P58, DOI [10.1016/S1473-3099(17)30612-6, 10.1016/s1473-3099(17)30612-6]
   STROM J, 1960, BRIT MED J, V2, P1184, DOI 10.1136/bmj.2.5207.1184
   von Konig CHW, 2002, LANCET INFECT DIS, V2, P744, DOI 10.1016/S1473-3099(02)00452-8
   Ward JI, 2005, NEW ENGL J MED, V353, P1555, DOI 10.1056/NEJMoa050824
   Wendelboe Aaron M, 2005, Pediatr Infect Dis J, V24, pS58, DOI 10.1097/01.inf.0000160914.59160.41
   World Health Organization, 2015, PERT VACC WHO POS PA
NR 58
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JAN 29
PY 2020
VL 38
IS 5
BP 1271
EP 1276
DI 10.1016/j.vaccine.2019.11.022
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KM6ML
UT WOS:000514252100040
PM 31780181
DA 2020-05-12
ER

PT J
AU Huang, HN
   Lu, JL
   Lin, SE
   Zheng, RJ
   Lin, J
AF Huang, Hong-Nan
   Lu, Jia-Li
   Lin, Shou-Er
   Zheng, Ren-Jin
   Lin, Jie
TI Simultaneous determination of twelve paralytic shellfish poisoning
   toxins in bivalve molluscs by UPLC-MS/MS and its applications to a food
   poisoning incident
SO TOXICON
LA English
DT Article
DE Bivalve molluscs; Paralytic shellfish poisoning toxins; Food poisoning;
   UPLC-MS/MS
ID CHROMATOGRAPHY-MASS SPECTROMETRY; LIQUID-CHROMATOGRAPHY;
   QUANTITATIVE-DETERMINATION; PSP TOXINS; QUANTIFICATION; OPTIMIZATION;
   SAXITOXIN
AB In this study, an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was originally developed for simultaneously quantitative analysis of twelve paralytic shellfish poisoning toxins, referring to STX, NEO, dcSTX, GTX1, GTX2, GTX3, GTX4, GTX5, C1, C2, dcGTX2, and dcGTX3 in bivalve molluscs. Chromatographic separations were performed on a TSK-Gel Amide-80 column (5 mu m, 2.0 x 150 mu m, Tosoh Corporation) by gradient elution with 2 mmol L-1 ammonium formate solution-acetonitrile (containing 0.1% formic acid) as mobile phases. The samples were pretreated by extraction with acetonitrile-water (80:20, v/v; containing 0.1% formic acid), followed by cleaning up using an Oasis HLB extraction cartridge (500 mg/6 mL). The present method showed good linearity (r(2) > 0.99) with the limits of detection (LODs) and limits of quantification (LOQs) ranged from 1.03 to 10.65 mu g/kg and 3.43-35.46 mu g/kg, respectively for these toxins. Owing to its sensitivity and rapid properties, the presented method was applied to the determination of PSP toxins in bivalve molluscs involved in a food poisoning incident occurred in Zhangzhou, China, in June 2017.
C1 [Huang, Hong-Nan; Lu, Jia-Li; Lin, Shou-Er; Zheng, Ren-Jin; Lin, Jie] Fujian Ctr Dis Prevent & Control, Fujian Prov Key Lab Zoonosis Res, Fuzhou 350001, Peoples R China.
   [Huang, Hong-Nan; Lu, Jia-Li; Lin, Jie] Fujian Med Univ, Sch Pharm, Fuzhou 350122, Peoples R China.
RP Lin, J (reprint author), Fujian Ctr Dis Prevent & Control, Fujian Prov Key Lab Zoonosis Res, Fuzhou 350001, Peoples R China.
EM 804183531@qq.com
OI Zheng, Renjin/0000-0001-7242-9621
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21275028]
FX The authors acknowledge the financial support by the National Natural
   Science Foundation of China (Grant No. 21275028).
CR Ben-Gigirey B, 2012, TOXICON, V60, P864, DOI 10.1016/j.toxicon.2012.05.022
   Blay P, 2011, ANAL BIOANAL CHEM, V400, P577, DOI 10.1007/s00216-011-4772-2
   Boundy MJ, 2015, J CHROMATOGR A, V1387, P1, DOI 10.1016/j.chroma.2015.01.086
   Dell'Aversano C, 2005, J CHROMATOGR A, V1081, P190, DOI 10.1016/j.chroma.2005.05.056
   Dell'Aversano C, 2004, J CHROMATOGR A, V1028, P155, DOI 10.1016/j.chroma.2003.11.083
   Diener M, 2007, J SEP SCI, V30, P1821, DOI 10.1002/jssc.200700025
   EFSA, 2009, EFSA J, V7, DOI 10.2903/j.efsa.2009.228r
   Halme M, 2012, J CHROMATOGR B, V880, P50, DOI 10.1016/j.jchromb.2011.11.015
   Jansson D, 2015, J CHROMATOGR A, V1417, P41, DOI 10.1016/j.chroma.2015.09.029
   Krock B, 2008, ANAL BIOANAL CHEM, V392, P797, DOI 10.1007/s00216-008-2221-7
   Lawrence JF, 2005, J AOAC INT, V88, P1714
   Li F., 2015, FOOD RES DEV, V36, P184
   Mattarozzi M, 2016, FOOD CONTROL, V60, P138, DOI 10.1016/j.foodcont.2015.07.027
   Nogueira ICG, 2004, TOXICON, V44, P773, DOI 10.1016/j.toxicon.2004.08.006
   OSHIMA Y, 1995, J AOAC INT, V78, P528
   Pereira P, 2000, TOXICON, V38, P1689, DOI 10.1016/S0041-0101(00)00100-8
   Pomati F, 2004, BBA-GEN SUBJECTS, V1674, P60, DOI 10.1016/j.bbagen.2004.05.006
   Turner AD, 2015, J AOAC INT, V98, P609, DOI 10.5740/jaoacint.14-275
   Turrell E, 2008, J AOAC INT, V91, P1372
   Usleber E, 2001, J AOAC INT, V84, P1649
   Watanabe R, 2013, FOOD ADDIT CONTAM A, V30, P1351, DOI 10.1080/19440049.2013.793456
   Wekell JC, 2004, J SHELLFISH RES, V23, P927
   Yang XL, 2017, TOXINS, V9, DOI 10.3390/toxins9070206
   Zhuo LY, 2013, FOOD CHEM, V137, P115, DOI 10.1016/j.foodchem.2012.10.010
NR 24
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 30
PY 2020
VL 174
BP 1
EP 7
DI 10.1016/j.toxicon.2019.11.012
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KJ7EP
UT WOS:000512221400001
PM 31786272
DA 2020-05-12
ER

PT J
AU Gao, W
   Yamada, M
   Ohki, R
   Nagashima, Y
   Tatsuno, R
   Ikeda, K
   Kawatsu, K
   Takatani, T
   Arakawa, O
AF Gao, Wei
   Yamada, Misako
   Ohki, Rieko
   Nagashima, Yuji
   Tatsuno, Ryohei
   Ikeda, Koichi
   Kawatsu, Kentaro
   Takatani, Tomohiro
   Arakawa, Osamu
TI Evaluation of the tetrodotoxin uptake ability of pufferfish Takifugu
   rubripes tissues according to age using an in vitro tissue slice
   incubation method
SO TOXICON
LA English
DT Article
DE Tetrodotoxin; Pufferfish; Takifugu rubripes; Tissue slice;
   Immunohistochemistry
ID INTRAMUSCULARLY ADMINISTERED TETRODOTOXIN; BINDING-PROTEIN; TRANSFER
   PROFILE; LIVER; FISH; LOCALIZATION; SAXITOXIN; SKIN; ACCUMULATION;
   TOXIFICATION
AB The tetrodotoxin (TTX) uptake ability of pufferfish Takifugu rubripes tissues and its growth-associated changes were investigated using an in vitro tissue slice incubation method. Tissue slices prepared from the liver, skin, and intestine of a non-toxic cultured adult T. rubripes (20 months old) and incubated with incubation buffer containing 25 mu g/mL TTX for 1-48 h showed a time-dependent increase in the TTX content in all tissues. The TTX contents of the skin and intestine slices were comparable to or slightly higher than that of the liver slices, with a similar transition pattern, suggesting similar TTX uptake ability among the skin, intestine, and liver. The TTX uptake ability of the liver and intestine did not differ significantly between young (8 months old) and adult (20 months old) fish, but the skin slices of young fish took up approximately twice as much TTX as that of adult fish, suggesting that the TTX uptake ability of the skin is involved in the growth-dependent changes in the toxin distribution inside the body in T. rubripes. To estimate the TTX uptake pathway in each tissue, an immunohistochemical technique was used to observe temporal changes in the intra-tissue microdistribution of TTX during incubation. The findings suggested that TTX is transferred and accumulates from pancreatic exocrine cells to hepatic parenchymal cells in the liver, from connective tissues to basal cells in the skin, and from villi epithelial cells via the lamina propria to the muscle layer in the intestine.
C1 [Gao, Wei; Yamada, Misako; Takatani, Tomohiro; Arakawa, Osamu] Nagasaki Univ, Grad Sch Fisheries & Environm Sci, Nagasaki, Nagasaki 8528521, Japan.
   [Ohki, Rieko] Tokyo Univ Marine Sci & Technol, Dept Food Sci & Technol, Minato Ku, Tokyo 1088477, Japan.
   [Nagashima, Yuji] Niigata Agrofood Univ, Tainai, Niigata 9592702, Japan.
   [Tatsuno, Ryohei] Natl Fisheries Univ, Dept Food Sci & Technol, Japan Fisheries Res & Educ Agcy, Shimonoseki, Yamaguchi 7596595, Japan.
   [Ikeda, Koichi] Kwassui Womens Univ, Nagasaki, Nagasaki 8508515, Japan.
   [Kawatsu, Kentaro] Osaka Inst Publ Hlth, Osaka, Osaka 5370025, Japan.
RP Arakawa, O (reprint author), Nagasaki Univ, Grad Sch Fisheries & Environm Sci, Nagasaki, Nagasaki 8528521, Japan.
EM arakawa@nagasaki-u.ac.jp
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [15H04551, 19H03051]
FX This study was supported in part by Grant-in-Aids for Scientific
   Research (15H04551 and 19H03051 to 0.A.) from the Japan Society for the
   Promotion of Science.
CR ARAKAWA O, 1994, FISHERIES SCI, V60, P769, DOI 10.2331/fishsci.60.769
   Gao W, 2019, TOXINS, V11, DOI 10.3390/toxins11080470
   Gao W, 2018, FISHERIES SCI, V84, P723, DOI 10.1007/s12562-018-1209-2
   Geffeney SL, 2006, MAR DRUGS, V4, P143, DOI 10.3390/md403143
   Hashiguchi Y, 2015, J EVOLUTION BIOL, V28, P1103, DOI 10.1111/jeb.12634
   Honda S, 2005, NIPPON SUISAN GAKK, V71, P815, DOI 10.2331/suisan.71.815
   Ikeda K, 2009, THESIS
   Ikeda K, 2010, TOXICON, V55, P289, DOI 10.1016/j.toxicon.2009.08.001
   Ikeda K, 2009, TOXICON, V53, P99, DOI 10.1016/j.toxicon.2008.10.018
   Itoi S, 2016, TOXICON, V114, P53, DOI 10.1016/j.toxicon.2016.02.020
   Itoi S, 2012, TOXICON, V60, P1000, DOI 10.1016/j.toxicon.2012.07.006
   Kawatsu K, 1997, JPN J MED SCI BIOL, V50, P133, DOI 10.7883/yoken1952.50.133
   Kiriake A, 2016, TOXICON, V111, P6, DOI 10.1016/j.toxicon.2015.12.007
   KODAMA M, 1985, MAR BIOL, V87, P199, DOI 10.1007/BF00539429
   KODAMA M, 1986, TOXICON, V24, P819, DOI 10.1016/0041-0101(86)90107-8
   Magarlamov TY, 2017, TOXINS, V9, DOI 10.3390/toxins9050166
   Mahmud Y, 2003, TOXICON, V41, P605, DOI 10.1016/S0041-0101(03)00003-5
   MATSUI T, 1982, B JPN SOC SCI FISH, V48, P253
   Matsumoto T, 2005, FISH PHYSIOL BIOCHEM, V31, P95, DOI 10.1007/s10695-006-0001-x
   Matsumoto T, 2007, TOXICON, V50, P173, DOI 10.1016/j.toxicon.2007.03.004
   Miyazawa K, 2001, J TOXICOL-TOXIN REV, V20, P11, DOI 10.1081/TXR-100103081
   Nagashima Y, 2003, TOXICON, V41, P569, DOI 10.1016/S0041-0101(02)00385-9
   Narahashi T, 2001, J TOXICOL-TOXIN REV, V20, P67, DOI 10.1081/TXR-100102537
   Noguchi T, 2008, MAR DRUGS, V6, P220, DOI 10.3390/md20080011
   Noguchi T, 2006, COMP BIOCHEM PHYS D, V1, P153, DOI 10.1016/j.cbd.2005.11.003
   Okita K, 2013, TOXICON, V71, P128, DOI 10.1016/j.toxicon.2013.05.018
   SAITO T, 1985, B JPN SOC SCI FISH, V51, P1175
   Tanu MB, 2002, TOXICON, V40, P103, DOI 10.1016/S0041-0101(01)00179-9
   Tatsuno R., 2012, THESIS
   Tatsuno R, 2017, TOXICON, V130, P73, DOI 10.1016/j.toxicon.2017.03.001
   Tatsuno R, 2013, TOXICON, V65, P76, DOI 10.1016/j.toxicon.2013.01.011
   Tatsuno R, 2013, BIOSCI BIOTECH BIOCH, V77, P208, DOI 10.1271/bbb.120701
   Wang J, 2011, TOXICON, V58, P565, DOI 10.1016/j.toxicon.2011.08.019
   Yamamori K, 2004, J FOOD HYG SOC JPN, V45, P73, DOI 10.3358/shokueishi.45.73
   Yotsu-Yamashita M, 2001, EUR J BIOCHEM, V268, P5937, DOI 10.1046/j.0014-2956.2001.02547.x
   Yotsu-Yamashita M, 2013, TOXICON, V72, P23, DOI 10.1016/j.toxicon.2013.06.002
NR 36
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 30
PY 2020
VL 174
BP 8
EP 12
DI 10.1016/j.toxicon.2019.11.014
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KJ7EP
UT WOS:000512221400002
PM 31785287
DA 2020-05-12
ER

PT J
AU Ren, DL
   Diao, EJ
   Hou, HX
   Dong, HZ
AF Ren, Dongliang
   Diao, Enjie
   Hou, Hanxue
   Dong, Haizhou
TI Degradation and ozonolysis pathway elucidation of deoxynivalenol
SO TOXICON
LA English
DT Article
DE Deoxynivalenol; Criegee mechanism; Ozone; Ozonolysis products;
   Degradation pathway
ID AFLATOXIN B-1; OZONE TREATMENT; IN-VIVO; WHEAT; DON; DETOXIFICATION;
   TRICHOTHECENES; MYCOTOXINS
AB To explore the degradation products and ozonolysis pathway of deoxynivalenol (DON), DON (similar to 50 mg/L) in acetonitrile solution was treated by ozone at a concentration of 10.84 g/m(3) and a flow rate of 80 mL/min for the times ranging from 0 to 9 min. The results showed that DON concentration rapidly reduced from 51.11 mg/L to 14.97 mg/L within 9 min of ozone exposure with 98.30% of degradation rate, and the ozonolysis of DON followed the first-order kinetic model. Four ozonolysis products of DON were identified based on the analysis of Liquid chromatography quadrupole time-of-flight mass spectra (LC-QTOF/MS). Their structures were similar to that of DON, while the double bond at C9-C10, 12,13-epoxide ring, and the hydroxyl group at C3 or C7 of DON were all destroyed by ozone. It is deduced that the toxicity of ozonolysis products significantly reduced based on the relationship between structure and toxicity of DON. The ozonolysis pathway of DON followed the Criegee reaction mechanism of ozone according to the chemical structures, accurate mass and molecular formulas of these products.
C1 [Ren, Dongliang; Hou, Hanxue; Dong, Haizhou] Shandong Agr Univ, Coll Food Sci & Engn, Tai An 271018, Shandong, Peoples R China.
   [Ren, Dongliang; Diao, Enjie] Huaiyin Normal Univ, Jiangsu Collaborat Innovat Ctr Reg Modern Agr & E, Huaian 223300, Peoples R China.
   [Diao, Enjie] Huaiyin Normal Univ, Jiangsu Key Lab Food Safety & Nutr Funct Evaluat, Huaian 223300, Peoples R China.
RP Hou, HX (reprint author), Shandong Agr Univ, Coll Food Sci & Engn, Tai An 271018, Shandong, Peoples R China.; Diao, EJ (reprint author), Huaiyin Normal Univ, Jiangsu Collaborat Innovat Ctr Reg Modern Agr & E, Huaian 223300, Peoples R China.
EM dej110@163.com
FU National Key Research & Development Program of China [2017YFC1600904];
   Major Projects of Natural Science Research in Colleges and Universities,
   Jiangsu Province, China [19KJA430012]; Young Talents Project for Jiangsu
   Collaborative Innovation Center of Regional Modern Agriculture &
   Environmental Protection [HSXT2-312]; Huai'an Municipal Science &
   Technology Project [HABZ201703]
FX This work was financially supported by National Key Research &
   Development Program of China (2017YFC1600904), Major Projects of Natural
   Science Research in Colleges and Universities, Jiangsu Province, China
   (19KJA430012), Young Talents Project for Jiangsu Collaborative
   Innovation Center of Regional Modern Agriculture & Environmental
   Protection (HSXT2-312), and Huai'an Municipal Science & Technology
   Project (HABZ201703).
CR Aiko V, 2015, J BIOSCIENCES, V40, P943, DOI 10.1007/s12038-015-9569-6
   Alexandre APS, 2017, J ENVIRON SCI HEAL B, V52, P516, DOI 10.1080/03601234.2017.1303325
   Bateman KP, 2007, RAPID COMMUN MASS SP, V21, P1485, DOI 10.1002/rcm.2996
   Bretz M, 2006, J AGR FOOD CHEM, V54, P6445, DOI 10.1021/jf061008g
   Diao EJ, 2018, TRENDS FOOD SCI TECH, V81, P139, DOI 10.1016/j.tifs.2018.09.016
   Diao EJ, 2013, TRENDS FOOD SCI TECH, V33, P21, DOI 10.1016/j.tifs.2013.06.002
   Diao EJ, 2012, J AGR FOOD CHEM, V60, P9364, DOI 10.1021/jf302528e
   dos Santos JS, 2013, FOOD CHEM, V138, P90, DOI 10.1016/j.foodchem.2012.09.100
   Ennouari A, 2013, FOOD CONTROL, V32, P115, DOI 10.1016/j.foodcont.2012.10.036
   Feng PS, 2012, CHINESE J ANAL CHEM, V40, P119, DOI 10.3724/SP.J.1096.2012.10208
   Fuchs E, 2002, FOOD ADDIT CONTAM, V19, P379, DOI 10.1080/02652030110091154
   Graziani F, 2015, TOXICOL SCI, V145, P372, DOI 10.1093/toxsci/kfv058
   Ikunaga Y, 2011, APPL MICROBIOL BIOT, V89, P419, DOI 10.1007/s00253-010-2857-z
   Li MM, 2015, FOOD ADDIT CONTAM A, V32, P544, DOI 10.1080/19440049.2014.976596
   McKenzie KS, 1997, FOOD CHEM TOXICOL, V35, P807, DOI 10.1016/S0278-6915(97)00052-5
   Miller FA, 2013, FOOD ENG REV, V5, P77, DOI 10.1007/s12393-013-9064-5
   Mishra S, 2014, FOOD ADDIT CONTAM A, V31, P121, DOI 10.1080/19440049.2013.861613
   Mortishire-Smith RJ, 2005, RAPID COMMUN MASS SP, V19, P2659, DOI 10.1002/rcm.2111
   Nagy CM, 2005, J MOL STRUC-THEOCHEM, V726, P55, DOI 10.1016/j.theochem.2005.02.079
   Pestka JJ, 2010, ARCH TOXICOL, V84, P663, DOI 10.1007/s00204-010-0579-8
   Pestka JJ, 2010, TOXINS, V2, P1300, DOI 10.3390/toxins2061300
   Savard C, 2015, VET MICROBIOL, V176, P257, DOI 10.1016/j.vetmic.2015.02.004
   Sobrova Pavlina, 2010, Interdiscip Toxicol, V3, P94, DOI 10.2478/v10102-010-0019-x
   Sun C, 2016, FOOD CONTROL, V69, P185, DOI 10.1016/j.foodcont.2016.04.041
   Vereecken L, 2014, PHYS CHEM CHEM PHYS, V16, P4039, DOI 10.1039/c3cp54514h
   Wang L, 2017, FOOD ADDIT CONTAM A, V34, P103, DOI 10.1080/19440049.2016.1253112
   Wang L, 2016, FOOD CONTROL, V66, P137, DOI 10.1016/j.foodcont.2016.01.038
   Wang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157137
   Wu QH, 2013, CURR DRUG METAB, V14, P641, DOI 10.2174/1389200211314060002
   Young JC, 2006, FOOD CHEM TOXICOL, V44, P417, DOI 10.1016/j.fct.2005.08.015
   Zhou JY, 2017, TOXINS, V9, DOI 10.3390/toxins9030100
   Zorlugenc B, 2008, FOOD CHEM TOXICOL, V46, P3593, DOI 10.1016/j.fct.2008.09.003
NR 32
TC 0
Z9 0
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 30
PY 2020
VL 174
BP 13
EP 18
DI 10.1016/j.toxicon.2019.11.015
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KJ7EP
UT WOS:000512221400003
PM 31790702
DA 2020-05-12
ER

PT J
AU Zhong, SZ
   Liu, Y
   Wang, F
   Wu, ZW
   Zhao, SJ
AF Zhong, Shengzheng
   Liu, Ying
   Wang, Fang
   Wu, Zaiwei
   Zhao, Sujuan
TI Microcystin-LR induced oxidative stress, inflammation, and apoptosis in
   alveolar type II epithelial cells of ICR mice in vitro
SO TOXICON
LA English
DT Article
DE Microcystin-LR; Alveolar type II epithelial cells; Inflammation;
   Apoptosis; Oxidative stress
ID RISK-ASSESSMENT; LASSBIO 596; LIVER; LUNG; ROS; INVOLVEMENT; ACTIVATION;
   MECHANISMS; TOXICOLOGY; PULMONARY
AB Previous studies have shown that microcystin-LR (MC-LR) produced by toxic cyanobacterial blooms could inflict damage to the lung. However, the mechanisms underlying MC-induced pulmonary toxicity are not fully described. In this study, the primary' fetal alveolar type II epithelial cells (AEC II) from ICR mice, which are involved in formation of bioactive component of pulmonary epithelium and secretion of pulmonary surfactants, were exposed to MC-LR at different concentrations (0, 0.625, 1.25, 2.5, 5, 10, 20 mu g/mL) for different time (12, 24, 36 h). Results showed that the viabilities of AEC II exposed to 10 and 20 mu g MC-LR/mL were significantly decreased compared with the control group. Furthermore, MC-LR exposure resulted in overproduction of reactive oxygen species (ROS) and induced a significant reduction in superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Expressions of apoptosis-related proteins including bax, cyt-c, and caspase-9 were significantly up-regulated by exposure to 2.5, 5, 10, or 20 mu g MC-LR/mL. When exposed to 5, 10, or 20 mu g MC-LR/mL, expressions of proteins involved in inflammatory, p-65 and iNOS were significantly greater than those of the controls. In conclusion, inflammation and apoptosis might be responsible for MC-LR-induced pulmonary injury.
C1 [Zhong, Shengzheng; Wang, Fang; Wu, Zaiwei; Zhao, Sujuan] Anhui Med Univ, Sch Publ Hlth, Hefei 230032, Peoples R China.
   [Liu, Ying] Chinese Acad Sci, Hefei Inst Phys Sci, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Peoples R China.
RP Zhao, SJ (reprint author), Anhui Med Univ, Sch Publ Hlth, Hefei 230032, Peoples R China.
EM zsj_700@hotmail.com
RI Zhao, Sujuan/AAM-3285-2020
OI Zhao, Sujuan/0000-0002-7057-2413
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31971521]; Project Foundation for the Young Talents
   in Colleges of Anhui Province [gxyq2019011]
FX This work was funded by National Natural Science Foundation of China
   (31971521) and the Project Foundation for the Young Talents in Colleges
   of Anhui Province (Grand Number: gxyq2019011). We also want to thanks
   the platform of pathogenesis and precision therapy for major autoimmune
   diseases, the platform of environmental exposure and life health
   research, and the translational medicine project of environmental
   exposure and life health research in Anhui Medical University.
CR Abdel-Latif AM, 2009, CLIN EXP DERMATOL, V34, P390, DOI 10.1111/j.1365-2230.2008.03029.x
   Benson JM, 2005, TOXICON, V45, P691, DOI 10.1016/j.toxicon.2005.01.004
   Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313
   Bhattacharya R, 1996, HUM EXP TOXICOL, V15, P105, DOI 10.1177/096032719601500202
   BOE R, 1991, EXP CELL RES, V195, P237, DOI 10.1016/0014-4827(91)90523-W
   Boudoulas KD, 2017, HELL J CARDIOL, V58, P110, DOI 10.1016/j.hjc.2016.10.002
   BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3
   Cao JY, 2013, ENVIRON TOXICOL PHAR, V36, P320, DOI 10.1016/j.etap.2013.04.011
   CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2
   Carvalho GMC, 2010, TOXICON, V56, P604, DOI 10.1016/j.toxicon.2010.06.005
   Casquilho NV, 2011, TOXICON, V58, P195, DOI 10.1016/j.toxicon.2011.05.018
   CHANCE B, 1979, PHYSIOL REV, V59, P527
   D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   Duy TN, 2000, REV ENVIRON CONTAM T, V163, P113
   Efferth T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000693
   Ferguson A. J. D., 1999, J APPL PHYCOL, V11, P595
   Forstermann U, 2012, EUR HEART J, V33, P829, DOI 10.1093/eurheartj/ehr304
   Gerry AB, 2014, ATHEROSCLEROSIS, V233, P537, DOI 10.1016/j.atherosclerosis.2014.01.014
   Harding WR, 1995, J S AFR VET ASSOC, V66, P256
   Hermansky S.J., 2010, J APPL TOXICOL JAT, V11, P65
   HONKANEN RE, 1990, J BIOL CHEM, V265, P19401
   HOOSER SB, 1989, VET PATHOL, V26, P246, DOI 10.1177/030098588902600309
   Ito E, 2001, TOXICON, V39, P265, DOI 10.1016/S0041-0101(00)00124-0
   Jayaraj R, 2006, TOXICON, V48, P272, DOI 10.1016/j.toxicon.2006.05.012
   Jiang JQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055729
   Jochimsen EM, 1998, NEW ENGL J MED, V338, P873, DOI 10.1056/NEJM199803263381304
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   McDermott CM, 1998, TOXICON, V36, P1981, DOI 10.1016/S0041-0101(98)00128-7
   Meng GM, 2015, ENVIRON TOXICOL, V30, P366, DOI 10.1002/tox.21914
   Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1
   Mittler R, 2011, TRENDS PLANT SCI, V16, P300, DOI 10.1016/j.tplants.2011.03.007
   Myhre O, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20327-y
   Nakamura T, 2001, BIOCHEM BIOPH RES CO, V284, P203, DOI 10.1006/bbrc.2001.4927
   Niu ZG, 2018, CHEMOSPHERE, V193, P403, DOI 10.1016/j.chemosphere.2017.11.037
   Pan G, 1999, AM J PATHOL, V155, P193, DOI 10.1016/S0002-9440(10)65113-9
   Pang JJ, 2004, AM J PHYSIOL-HEART C, V286, pH1063, DOI 10.1152/ajpheart.00648.2003
   Picanco MR, 2004, BRAZ J MED BIOL RES, V37, P1225, DOI 10.1590/S0100-879X2004000800013
   RATAN RR, 1994, J NEUROCHEM, V62, P376
   ROONEY SA, 1994, FASEB J, V8, P957
   Salakou S, 2007, IN VIVO, V21, P123
   Sharma V, 2012, APOPTOSIS, V17, P852, DOI 10.1007/s10495-012-0705-6
   Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952
   Soares RM, 2007, TOXICON, V50, P330, DOI 10.1016/j.toxicon.2007.04.003
   Svircev Z, 2017, ARCH TOXICOL, V91, P621, DOI 10.1007/s00204-016-1921-6
   Toygar M, 2015, HUM EXP TOXICOL, V34, P198, DOI 10.1177/0960327114533808
   TURNER PC, 1990, BRIT MED J, V300, P1440, DOI 10.1136/bmj.300.6737.1440
   Wang C, 2016, TOXICON, V115, P81, DOI 10.1016/j.toxicon.2016.03.007
   Wang Q, 2010, THESCIENTIFICWORLDJO, V10, P1795, DOI 10.1100/tsw.2010.172
   Wang Q, 2008, TOXICON, V52, P721, DOI 10.1016/j.toxicon.2008.08.004
   Xu XY, 2009, INT J DERMATOL, V48, P186, DOI 10.1111/j.1365-4632.2009.03946.x
   Yang F, 2018, TOXINS, V10, DOI 10.3390/toxins10090363
   Zhao SJ, 2018, TOXICON, V150, P304, DOI 10.1016/j.toxicon.2018.06.072
   Zhao SJ, 2016, ENVIRON POLLUT, V212, P197, DOI 10.1016/j.envpol.2015.12.055
   Zhi-Quan H.U., 2008, ASIAN J ECOTOXICOL, V3, P377
NR 54
TC 0
Z9 0
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 30
PY 2020
VL 174
BP 19
EP 25
DI 10.1016/j.toxicon.2019.12.152
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KJ7EP
UT WOS:000512221400004
PM 31874178
DA 2020-05-12
ER

PT J
AU Muniandy, KV
   Chung, ELT
   Jaapar, MS
   Hamdan, MHM
   Salleh, A
   Jesse, FFA
AF Muniandy, Kalai Vaani
   Chung, Eric Lim Teik
   Jaapar, Mimi Syazwani
   Hamdan, Muhammad Hazziq Mohd
   Salleh, Annas
   Jesse, Faez Firdaus Abdullah
TI Filling the gap of Brachiaria decumbens (signal grass) research on
   clinico-pathology and haemato-biochemistry in small ruminants: A review
SO TOXICON
LA English
DT Review
DE Brachiaria decumbens; Steroidal saponins; Clinical sign; Blood profile;
   Pathology; Acute phase proteins
ID ACUTE-PHASE PROTEINS; CRYSTAL-ASSOCIATED CHOLANGIOHEPATOPATHY;
   HEPATOGENOUS PHOTOSENSITIZATION; NARTHECIUM-OSSIFRAGUM; STEROIDAL
   SAPONIN; SHEEP; IDENTIFICATION; BRIZANTHA; EPISMILAGENIN; HAPTOGLOBIN
AB Brachiaria decumbens (signal grass) is a highly productive tropical grass that is widespread in some tropical countries due to its adaptation to a wide range of environments and soil types. However, a limiting factor for the use of this grass is its toxicity from steroidal saponins. Sporadic outbreaks of hepatogenous photosensitization in ruminants grazing on this grass have been reported. Sheep are more susceptible than other animal species and the young are more susceptible than adults. This review article will critically shed light on the B. decumbens profile, its toxic compounds, mechanisms, clinical responses, blood profile alterations, pathological changes, and acute phase responses related to signal grass intoxication. Further research is needed to integrate new findings on B. decumbens intoxication with previous preventive and therapeutic trials to minimize or remove its deleterious toxic effect.
C1 [Muniandy, Kalai Vaani; Chung, Eric Lim Teik; Jesse, Faez Firdaus Abdullah] Univ Putra Malaysia, Inst Trop Agr & Food Secur, Upm Serdang 43400, Selangor, Malaysia.
   [Chung, Eric Lim Teik; Jaapar, Mimi Syazwani; Hamdan, Muhammad Hazziq Mohd] Univ Putra Malaysia, Fac Agr, Dept Anim Sci, Upm Serdang 43400, Selangor, Malaysia.
   [Salleh, Annas] Univ Putra Malaysia, Fac Vet Med, Dept Vet Pathol & Microbiol, Upm Serdang 43400, Selangor, Malaysia.
   [Jesse, Faez Firdaus Abdullah] Univ Putra Malaysia, Fac Vet Med, Dept Vet Clin Studies, Upm Serdang 43400, Selangor, Malaysia.
RP Chung, ELT (reprint author), Univ Putra Malaysia, Inst Trop Agr & Food Secur, Upm Serdang 43400, Selangor, Malaysia.
EM ericlim@upm.edu.my
OI Chung, Eric Lim Teik/0000-0003-1038-1057
FU Putra Grant -Putra Young Initiative (GP-IPM), Universiti Putra Malaysia
   [9638400]
FX The project was funded by the Putra Grant -Putra Young Initiative
   (GP-IPM), Universiti Putra Malaysia (Grant no: 9638400).
CR Abdullah AS, 1997, ANIM FEED SCI TECH, V69, P79, DOI 10.1016/S0377-8401(97)81624-0
   Aregheore EM, 2001, ASIAN AUSTRAL J ANIM, V14, P1389, DOI 10.5713/ajas.2001.1389
   Assumaidaee A. A., 2010, Pertanika Journal of Tropical Agricultural Science, V33, P151
   Assumaidee A.J.M., 2012, J ADV MED RES, V2, P18
   BABER R, 1989, TROP ANIM HEALTH PRO, V21, P277, DOI 10.1007/BF02261108
   Badenes-Perez FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095766
   Badiei K, 2009, SMALL RUMINANT RES, V82, P99, DOI 10.1016/j.smallrumres.2009.02.002
   Bastos BL, 2011, VET CLIN PATH, V40, P496, DOI 10.1111/j.1939-165X.2011.00355.x
   Beesley NJ, 2018, TRANSBOUND EMERG DIS, V65, P199, DOI 10.1111/tbed.12682
   Brum KB, 2007, PESQUI VET BRASIL, V27, P39, DOI 10.1590/S0100-736X2007000100007
   Brum KB, 2009, CIENC RURAL, V39, P279, DOI 10.1590/S0103-84782008005000034
   BUTTON C, 1987, AUST VET J, V64, P176, DOI 10.1111/j.1751-0813.1987.tb09677.x
   Caicedo J. A, 2012, Rev. Med. Vet. Zoot., V59, P102
   Cardona-Alvarez J, 2016, REV MVZ CORDOBA, V21, P5366, DOI 10.21897/rmvz.603
   Castro MB, 2018, SMALL RUMINANT RES, V158, P42, DOI 10.1016/j.smallrumres.2017.12.001
   Ceciliani F, 2012, J PROTEOMICS, V75, P4207, DOI 10.1016/j.jprot.2012.04.004
   CHEEKE PR, 1995, J ANIM SCI, V73, P909
   Cheeke PR, 1996, ADV EXP MED BIOL, V405, P377
   Chung ELT, 2018, TROP ANIM HEALTH PRO, V50, P1727, DOI 10.1007/s11250-018-1641-4
   Cray C, 2009, COMPARATIVE MED, V59, P517
   Cruz C, 2001, J VET DIAGN INVEST, V13, P170, DOI 10.1177/104063870101300215
   de Lima FG, 2015, CIENC RURAL, V45, P858, DOI 10.1590/0103-8478cr20141305
   De Oliveira CHS, 2013, TOXICON, V73, P121, DOI 10.1016/j.toxicon.2013.07.001
   Driemeier D, 2002, TOXICON, V40, P1027, DOI 10.1016/S0041-0101(01)00276-8
   Eckersall PD, 2010, VET J, V185, P23, DOI 10.1016/j.tvjl.2010.04.009
   Eckersall Peter D, 2007, BMC Vet Res, V3, P35, DOI 10.1186/1746-6148-3-35
   El-Deeb W. M., 2015, Comparative Clinical Pathology, V24, P581, DOI 10.1007/s00580-014-1949-z
   Faccin TC, 2014, TOXICON, V82, P1, DOI 10.1016/j.toxicon.2014.02.008
   Ferreira M., 2009, POISONING PLANTS MYC, P2
   FLAOYEN A, 1993, NEW ZEAL VET J, V41, P171, DOI 10.1080/00480169.1993.35764
   Flaoyen A, 1997, VET RES COMMUN, V21, P335, DOI 10.1023/A:1005860220462
   Flaoyen A, 1996, ADV EXP MED BIOL, V405, P395
   Francis G, 2002, BRIT J NUTR, V88, P587, DOI 10.1079/BJN2002725
   Garcia MT, 2011, BLOWOUT: SAL CASTRO AND THE CHICANO STRUGGLE FOR EDUCATIONAL JUSTICE, P110
   Gomar MS, 2005, J VET MED A, V52, P18, DOI 10.1111/j.1439-0442.2004.00683.x
   Gracindo CV, 2014, TROP ANIM HEALTH PRO, V46, P733, DOI 10.1007/s11250-014-0556-y
   GRAYDON RJ, 1991, AUST VET J, V68, P234, DOI 10.1111/j.1751-0813.1991.tb03214.x
   Haligur M, 2011, REV MED VET-TOULOUSE, V162, P475
   Iliev P. T., 2019, Bulgarian Journal of Veterinary Medicine, V22, P1
   Jesse FFA, 2019, TROP ANIM HEALTH PRO, V51, P289, DOI 10.1007/s11250-018-1683-7
   Knight A.P., 2003, PLANTS AFFECTING SKI
   LAJIS NH, 1993, STEROIDS, V58, P387, DOI 10.1016/0039-128X(93)90043-M
   Lelis DL, 2018, SMALL RUMINANT RES, V169, P24, DOI 10.1016/j.smallrumres.2018.08.018
   Lima F. G., 2012, International Journal of Poisonous Plant Research, V2, P45
   Low SG, 2015, AGRICULTURE-BASEL, V5, P971, DOI 10.3390/agriculture5040971
   Mazni OA, 1985, MARDI RES B, V13, P203
   Meagher LP, 2001, ANIM FEED SCI TECH, V91, P157, DOI 10.1016/S0377-8401(01)00223-1
   Meling S, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-113
   MILES CO, 1993, J AGR FOOD CHEM, V41, P914, DOI 10.1021/jf00030a015
   MILES CO, 1992, J AGR FOOD CHEM, V40, P1606, DOI 10.1021/jf00021a026
   MILES CO, 1994, ONDERSTEPOORT J VET, V61, P215
   MUNDAY SC, 1993, J AGR FOOD CHEM, V41, P267, DOI 10.1021/jf00026a025
   Murata H, 2004, VET J, V168, P28, DOI 10.1016/S1090-0233(03)00119-9
   Ng KF, 1997, J AGR SCI, V128, P347, DOI 10.1017/S0021859696004248
   NOORDIN MM, 1989, VET RES COMMUN, V13, P491, DOI 10.1007/BF00402573
   OPASINA BA, 1985, TROP GRASSLANDS, V19, P120
   Ortolani E. L., 2001, Ciencia Rural, V31, P257, DOI 10.1590/S0103-84782001000200011
   OTHMAN A M, 1988, Pertanika, V11, P57
   PFEFFER A, 1993, RES VET SCI, V55, P360, DOI 10.1016/0034-5288(93)90108-R
   PFEFFER A, 1989, RES VET SCI, V46, P118, DOI 10.1016/S0034-5288(18)31130-5
   Pupin RC, 2016, PESQUI VET BRASIL, V36, P383, DOI 10.1590/S0100-736X2016000500005
   Riet-Correa B, 2011, PESQUI VET BRASIL, V31, P183, DOI 10.1590/S0100-736X2011000300001
   Rosa FB, 2016, PESQUI VET BRASIL, V36, P389, DOI 10.1590/S0100-736X2016000500006
   Sparg SG, 2004, J ETHNOPHARMACOL, V94, P219, DOI 10.1016/j.jep.2004.05.016
   Tothova C, 2014, VET MED-CZECH, V59, P163, DOI 10.17221/7478-VETMED
   Ulutas PA, 2006, VET RES COMMUN, V30, P485, DOI 10.1007/s11259-006-3246-z
   Wells B, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-103
   Wina E, 2005, J AGR FOOD CHEM, V53, P8093, DOI 10.1021/jf048053d
NR 68
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 30
PY 2020
VL 174
BP 26
EP 31
DI 10.1016/j.toxicon.2019.12.158
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KJ7EP
UT WOS:000512221400005
PM 31989927
DA 2020-05-12
ER

PT J
AU Huang, C
   Feng, L
   Liu, XA
   Jiang, WD
   Wu, P
   Liu, Y
   Jiang, J
   Kuang, SY
   Tang, L
   Zhou, XQ
AF Huang, Chen
   Feng, Lin
   Liu, Xiang-An
   Jiang, Wei-Dan
   Wu, Pei
   Liu, Yang
   Jiang, Jun
   Kuang, Sheng-Yao
   Tang, Ling
   Zhou, Xiao-Qiu
TI The toxic effects and potential mechanisms of deoxynivalenol on the
   structural integrity of fish gill: Oxidative damage, apoptosis and tight
   junctions disruption
SO TOXICON
LA English
DT Article
DE Deoxynivalenol; Gill; Structural integrity; Oxidative injury; Apoptosis;
   Tight junctions
ID NF-KAPPA-B; CARP CTENOPHARYNGODON-IDELLA; IMMUNE FUNCTION; DEATH
   RECEPTOR; UP-REGULATION; HEAD KIDNEY; NRF2; GROWTH; DEFICIENCY; MLCK
AB Deoxynivalenol (DON) is a common mycotoxin existed in animal feed, and lead to significant economic loss due to its negative impacts on animal growth performance and animal health. The gill is a primary mucosal immune organ in teleosts, and the structural integrity of the gill is closely relevant with fish healthy growth. Hence, this study assessed the influences of DON on the gill structural integrity of juvenile grass carp, Ctenopharyngodan idella (initial average weight 12.17 +/- 0.01 g), when offered with six different diets which contained various content of DON (27, 318, 636, 922, 1243 and 1515 mu g/kg diet) for 60 days. Our research firstly systematically elaborated that DON caused histopathological lesions, oxidative injury, reduction of antioxidant ability, apoptosis as well as damages of tight junctions in fish gills. Comparing these data to the control, we found that DON at dose of more than 318 mu g/kg diet led to oxidative injury, apoptosis and disruption of tight junctions in fish gill, which were likely to be relevant with Nrf2, JNK and MLCK signalling pathways, respectively. It was worth noting that DON was not found to affect the gene expressions of Keap1b (rather than Keap1a), claudin-b, claudin-3c and claudin-15b (not claudin-15a) in fish gills. Furthermore, based on MDA and T-AOC activities in the gill, the maximum permissible levels of DON were evaluated to be 375.60 as well as 412.91 mu g/kg diet in grass carp, respectively.
C1 [Huang, Chen; Feng, Lin; Jiang, Wei-Dan; Wu, Pei; Liu, Yang; Jiang, Jun; Zhou, Xiao-Qiu] Sichuan Agr Univ, Anim Nutr Inst, Chengdu 611130, Peoples R China.
   [Feng, Lin; Jiang, Wei-Dan; Wu, Pei; Liu, Yang; Jiang, Jun; Zhou, Xiao-Qiu] Sichuan Agr Univ, Fish Nutr & Safety Prod Univ Key Lab Sichuan Prov, Chengdu 611130, Peoples R China.
   [Feng, Lin; Zhou, Xiao-Qiu] Key Lab Anim Dis Resistance Nutr, Chengdu, Sichuan, Peoples R China.
   [Jiang, Wei-Dan; Wu, Pei; Jiang, Jun] Minist Educ, Key Lab Anim Dis Resistance Nutr, Beijing, Peoples R China.
   [Liu, Yang] Minist Agr & Rural Affairs, Key Lab Anim Dis Resistant Nutr & Feed, Beijing, Peoples R China.
   [Liu, Xiang-An; Kuang, Sheng-Yao; Tang, Ling] Sichuan Acad Anim Sci, Anim Nutr Inst, Chengdu 610066, Peoples R China.
RP Zhou, XQ (reprint author), Sichuan Agr Univ, Anim Nutr Inst, Chengdu 611130, Peoples R China.
EM xqzhouqq@tom.com
FU National Key R&D Program of China [2018YFD0900400]; Earmarked Fund for
   China Agriculture Research System [CARS-45]; Outstanding Talents and
   Innovative Team of Agricultural Scientific Research (Ministry of
   Agriculture); Foundation of Sichuan Youth Science and Technology
   Innovation Research Team [2017TD0002]; Sichuan Science and Technology
   Program [2019YFN0036]; 111 projectMinistry of Education, China - 111
   Project [D17015]
FX This research was financially supported by National Key R&D Program of
   China (2018YFD0900400), the Earmarked Fund for China Agriculture
   Research System (CARS-45), Outstanding Talents and Innovative Team of
   Agricultural Scientific Research (Ministry of Agriculture), Foundation
   of Sichuan Youth Science and Technology Innovation Research Team
   (2017TD0002), Supported by Sichuan Science and Technology Program
   (2019YFN0036) and the 111 project (D17015). The authors would like to
   thank the personnel of these teams for their kind assistance.
CR Al-Bairuty GA, 2013, AQUAT TOXICOL, V126, P104, DOI 10.1016/j.aquatox.2012.10.005
   Awad WA, 2005, POULTRY SCI, V84, P921, DOI 10.1093/ps/84.6.921
   Binder EM, 2007, ANIM FEED SCI TECH, V137, P265, DOI 10.1016/j.anifeedsci.2007.06.005
   Bossus MC, 2015, COMP BIOCHEM PHYS A, V187, P74, DOI 10.1016/j.cbpa.2015.04.017
   Buckley BJ, 2003, BIOCHEM BIOPH RES CO, V307, P973, DOI 10.1016/S0006-291X(03)01308-1
   Chen BH, 2017, PAK J ZOOL, V49, P1437, DOI 10.17582/journal.pjz/2017.49.4.1437.1448
   Chen K, 2017, FISH SHELLFISH IMMUN, V63, P103, DOI 10.1016/j.fsi.2017.02.007
   Choi BK, 2013, MYCOTOXIN RES, V29, P185, DOI 10.1007/s12550-013-0161-3
   Chung YJ, 2003, TOXICOL APPL PHARM, V193, P188, DOI 10.1016/S0041-008X(03)00299-0
   Danicke S, 2005, J ANIM PHYSIOL AN N, V89, P303, DOI 10.1111/j.1439-0396.2005.00513.x
   Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8
   Dong YW, 2018, FISH SHELLFISH IMMUN, V72, P161, DOI 10.1016/j.fsi.2017.10.048
   Evans DH, 2005, PHYSIOL REV, V85, P97, DOI 10.1152/physrev.00050.2003
   Feng L, 2017, FISH SHELLFISH IMMUN, V60, P185, DOI 10.1016/j.fsi.2016.11.048
   Gomez D, 2013, FISH SHELLFISH IMMUN, V35, P1729, DOI 10.1016/j.fsi.2013.09.032
   Goncalves RA, 2018, REV AQUACULT, V10, P263, DOI 10.1111/raq.12159
   Huang C, 2019, FISH SHELLFISH IMMUN, V84, P470, DOI 10.1016/j.fsi.2018.10.039
   Huang C, 2018, FISH SHELLFISH IMMUN, V80, P376, DOI 10.1016/j.fsi.2018.06.013
   Islam MR, 2013, TOXICOL LETT, V221, P152, DOI 10.1016/j.toxlet.2013.05.656
   Ji J, 2016, TOXICON, V120, P175, DOI 10.1016/j.toxicon.2016.08.003
   Jiang WD, 2015, AQUAT TOXICOL, V159, P245, DOI 10.1016/j.aquatox.2014.12.020
   Jiang WD, 2010, FOOD CHEM, V120, P692, DOI 10.1016/j.foodchem.2009.10.062
   Katika MR, 2012, TOXICOL APPL PHARM, V264, P51, DOI 10.1016/j.taap.2012.07.017
   Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751
   Li SA, 2017, FISH SHELLFISH IMMUN, V67, P475, DOI 10.1016/j.fsi.2017.06.032
   Li XY, 2014, FISH PHYSIOL BIOCHEM, V40, P659, DOI 10.1007/s10695-013-9874-7
   Liang JJ, 2012, AQUACULT NUTR, V18, P181, DOI 10.1111/j.1365-2095.2011.00887.x
   MA TY, 2000, MICROSC RES TECHNIQ, V118, pA1268
   Madson DM, 2014, J SWINE HEALTH PROD, V22, P78
   Matejova I., 2014, BIOMED RES INT, V2014, P1, DOI DOI 10.1155/2014/310680
   Matejova I, 2017, FISH SHELLFISH IMMUN, V60, P458, DOI 10.1016/j.fsi.2016.11.032
   Miron DD, 2008, AQUACULTURE, V277, P192, DOI 10.1016/j.aquaculture.2008.02.023
   Ohtsuka T, 2003, ONCOGENE, V22, P2034, DOI 10.1038/sj.onc.1206290
   Oldenburg E, 2007, Mycotoxin Res, V23, P7, DOI 10.1007/BF02946018
   Pan FY, 2016, FISH SHELLFISH IMMUN, V56, P208, DOI 10.1016/j.fsi.2016.07.020
   Pan JH, 2018, AQUACULTURE, V484, P13, DOI 10.1016/j.aquaculture.2017.10.028
   Pestka JJ, 2008, TOXICOL LETT, V178, P83, DOI 10.1016/j.toxlet.2008.02.005
   Prasad S, 2005, LAB INVEST, V85, P1139, DOI 10.1038/labinvest.3700316
   Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6
   Rahimnejad S, 2017, J WORLD AQUACULT SOC, V48, P103, DOI 10.1111/jwas.12320
   Ren ZH, 2016, EXP TOXICOL PATHOL, V68, P241, DOI 10.1016/j.etp.2016.01.001
   Sanden M, 2012, FOOD CHEM TOXICOL, V50, P4441, DOI 10.1016/j.fct.2012.08.042
   Shi L, 2015, FISH SHELLFISH IMMUN, V47, P289, DOI 10.1016/j.fsi.2015.09.023
   Sisperova E, 2015, J APPL ICHTHYOL, V31, P855, DOI 10.1111/jai.12809
   Su YN, 2018, FISH SHELLFISH IMMUN, V74, P101, DOI 10.1016/j.fsi.2017.12.051
   Tang QQ, 2013, BIOL TRACE ELEM RES, V155, P370, DOI 10.1007/s12011-013-9785-6
   Tashjian DH, 2006, AQUAT TOXICOL, V79, P401, DOI 10.1016/j.aquatox.2006.07.008
   Wu P, 2014, FISH SHELLFISH IMMUN, V38, P374, DOI 10.1016/j.fsi.2014.03.032
   Yang Y, 2014, FISH SHELLFISH IMMUN, V40, P245, DOI 10.1016/j.fsi.2014.07.015
   Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045
   Yu D, 2010, P NATL ACAD SCI USA, V107, P8237, DOI 10.1073/pnas.0908869107
   Zeng YY, 2016, AQUACULT NUTR, V22, P1251, DOI 10.1111/anu.12337
   Zeng ZZ, 2019, AQUACULTURE, V500, P1, DOI 10.1016/j.aquaculture.2018.09.064
   Zheng L, 2018, FISH SHELLFISH IMMUN, V82, P408, DOI 10.1016/j.fsi.2018.08.038
   Zhou L, 2018, ENVIRON POLLUT, V235, P245, DOI 10.1016/j.envpol.2017.12.073
   Zhu H, 2005, FEBS LETT, V579, P3029, DOI 10.1016/j.febslet.2005.04.058
NR 56
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 30
PY 2020
VL 174
BP 32
EP 42
DI 10.1016/j.toxicon.2019.12.151
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KJ7EP
UT WOS:000512221400006
PM 31881237
DA 2020-05-12
ER

PT J
AU Wang, Q
   Sun, MF
   Lv, HL
   Lu, P
   Ma, CJ
   Liu, Y
   Liu, SQ
   Tong, HQ
   Hu, Z
   Gao, YX
AF Wang, Qiang
   Sun, Meifeng
   Lv, Hailin
   Lu, Peng
   Ma, Chengjun
   Liu, Yun
   Liu, Shuqin
   Tong, Haiqing
   Hu, Zhao
   Gao, Yanxia
TI Amanita fuliginea poisoning with thrombocytopenia: A case series
SO TOXICON
LA English
DT Review
DE Amanita fuliginea; Thrombocytopenia; Acute liver failure
ID PHALLOIDES; AMATOXINS; LETHAL; TOXINS
AB Amanita fuliginea (A. fuliginea) poisoning is an uncommon and potentially fatal amatoxin exposure. We present 3 cases of severe A. fuliginea poisoning associated with thrombocytopenia in China. Three patients consumed foraged A. fuliginea and developed nausea, vomiting, abdominal pain, and diarrhea. They were transferred from primary clinics to our hospital 19-39 h after mushroom ingestion. They all presented with acute hepatic injury, coagulopathy, thrombocytopenia (6-41 x 10(9)/L), and positive fecal occult blood. Intravenous fluids and antioxidants were administered immediately after admission. Fibrinogen and platelets were given to patients A, B and C. Patient A developed fulminant liver failure and died on day 5 after mushroom exposure. Patients B and C recovered and were discharged on days 11 and 9, respectively. The main targets of A. fuliginea poisoning are the liver and digestive tract. To our knowledge this is the first report of thrombocytopenia associated with A. fuliginea ingestion.
C1 [Wang, Qiang; Lv, Hailin; Lu, Peng; Ma, Chengjun; Liu, Yun; Tong, Haiqing; Gao, Yanxia] Shandong Univ Qingdao, Dept Nephrol, Qilu Hosp, 758 Hefei Rd, Qingdao, Peoples R China.
   [Sun, Meifeng] Qingdao Univ, Dept Tradit Chinese Med, Affiliated Hosp, Qingdao, Peoples R China.
   [Hu, Zhao] Shandong Univ, Dept Nephrol, Qilu Hosp, Jinan, Peoples R China.
   [Liu, Shuqin] Qingdao Univ, Dept Rehabil, Affiliated Hosp, Qingdao, Peoples R China.
RP Gao, YX (reprint author), Shandong Univ Qingdao, Dept Nephrol, Qilu Hosp, 758 Hefei Rd, Qingdao, Peoples R China.
EM gaoyanxia31@163.com
FU Youth foundation of Qilu Hospital of Shandong University (Qingdao)
   [QDKY2017QN01]
FX This work was supported by the Youth foundation of Qilu Hospital of
   Shandong University (Qingdao) (QDKY2017QN01).
CR Cai Q, 2014, BMC EVOL BIOL, V14, DOI 10.1186/1471-2148-14-143
   Chen ZH, 2014, FUNGAL DIVERS, V64, P123, DOI 10.1007/s13225-013-0260-7
   Garcia J, 2015, FOOD CHEM TOXICOL, V86, P41, DOI 10.1016/j.fct.2015.09.008
   Karlson-Stiber C, 2003, TOXICON, V42, P339, DOI 10.1016/S0041-0101(03)00238-1
   Luo LL, 2019, THROMB RES, V173, P131, DOI 10.1016/j.thromres.2018.11.022
   Mengs U, 2012, CURR PHARM BIOTECHNO, V13, P1964, DOI 10.2174/138920112802273353
   Parnmen S, 2016, J TOXICOL SCI, V41, P65, DOI 10.2131/jts.41.65
   Tang SS, 2016, TOXICON, V120, P78, DOI 10.1016/j.toxicon.2016.07.018
   Vo KT, 2017, MMWR-MORBID MORTAL W, V66, P549, DOI 10.15585/mmwr.mm6621a1
   WIELAND T, 1978, CRC CR REV BIOCH MOL, V5, P185, DOI 10.3109/10409237809149870
   Yilmaz I, 2015, WILD ENVIRON MED, V26, P491, DOI 10.1016/j.wem.2015.08.002
   Zhou Jing, 2016, Chinese Journal of Emergency Medicine, V25, P724
NR 12
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 30
PY 2020
VL 174
BP 43
EP 47
DI 10.1016/j.toxicon.2019.12.156
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KJ7EP
UT WOS:000512221400007
PM 31989928
DA 2020-05-12
ER

PT J
AU Bazzoni, AM
   Cangini, M
   Mudadu, AG
   Lorenzoni, G
   Arras, I
   Sanna, G
   Pino, F
   Milandri, A
   Virgilio, S
AF Bazzoni, Anna Maria
   Cangini, Monica
   Mudadu, Alessandro G.
   Lorenzoni, Giuseppa
   Arras, Igor
   Sanna, Giovanna
   Pino, Fiorella
   Milandri, Anna
   Virgilio, Sebastiano
TI Recent findings of paralytic shellfish toxins linked to the genus
   Alexandrium Halim in Mediterranean mollusc production areas
SO TOXICON
LA English
DT Article
DE Alexandrium minutum; Alexandrium pacificum; PSP toxin profile; Sardinia;
   Shellfish
ID DINOPHYCEAE; SEA
AB Paralytic shellfish poisoning is a human intoxication syndrome associated with the consumption of seafood that has been contaminated with paralytic shellfish toxins (PSTs), a group of natural neurotoxic alkaloids produced by marine dinoflagellates, including some Alexandrium species. This study presents findings of PSTs in mussels (Mytilus galloprovincialis) during 2018-2019 in several mollusc production areas of Sardinia (Italy, western Mediterranean). Investigations of the presence and abundance of PST-producing microalgal species in marine water and of the toxins associated with shellfish were carried out concomitantly. Overall, the results suggested a spatio-temporal expansion of Alexandrium pacificum and Alexandrium minutwn in recent years, with an increasing number of PSTs present in molluscs and increased occurrences of toxicity cases. Liquid chromatography with fluorescence detection determined the toxin profile to be composed primarily of the carbamate gonyautoxin-5 and N-sulphocarbamoyltoxins 1 and 2. The study highlights the potential high risk to consumers of poisoning by bivalve molluscs bred in Sardinia, where shellfish production is a very important industrial sector. For this reason, routine monitoring is strongly recommended in order to mitigate any harm to human health as well as negative socio-economic consequences.
C1 [Bazzoni, Anna Maria; Mudadu, Alessandro G.; Lorenzoni, Giuseppa; Arras, Igor; Sanna, Giovanna; Virgilio, Sebastiano] Vet Publ Hlth Inst Sardinia, Lab Control Anim Origin Food, Via Ducda degli Abruzzi 8, I-07100 Sassari, Italy.
   [Cangini, Monica; Pino, Fiorella; Milandri, Anna] Fdn Ctr Ric Marine, Natl Reference Lab Marine Biotoxins, Vle A Vespucci 2, I-47042 Cesenatico, FC, Italy.
RP Bazzoni, AM (reprint author), Vet Publ Hlth Inst Sardinia, Via Duca Abruzzi 8, I-07100 Sassari, Italy.
EM ambazzoni@gmail.com
RI mudadu, alessandro/C-8482-2017
OI Mudadu, Alessandro/0000-0002-7078-4838
FU Autonomous Region of SardiniaRegione Sardegna
FX This study was supported by the Autonomous Region of Sardinia.
CR Anderson DM, 2012, HARMFUL ALGAE, V14, P10, DOI 10.1016/j.hal.2011.10.012
   AOAC, 2005, OFF METH AN
   BALECH E, 1995, GENUS ALEXANDRIUM HA
   Bazzoni AM, 2018, J VET RES, V62, P137, DOI 10.2478/jvetres-2018-0022
   Bazzoni AM, 2016, ITAL J FOOD SAF, V5, P194, DOI 10.4081/ijfs.2016.6095
   Bazzoni AM, 2015, ENVIRON MONIT ASSESS, V187, DOI 10.1007/s10661-014-4250-3
   Bhunia A.K., 2018, FOOD SCI TEXT SERIES
   Campbell K, 2011, FOOD ADDIT CONTAM A, V28, P711, DOI 10.1080/19440049.2010.531198
   Cembella A.D., 2018, HARMFUL ALGAL BLOOMS
   Corriero G, 2016, AQUAT CONSERV, V26, P392, DOI 10.1002/aqc.2550
   Edwards L.J., 2018, COMM DIS INTELL, V42, P1
   Etheridge SM, 2010, TOXICON, V56, P108, DOI 10.1016/j.toxicon.2009.12.013
   Farabegoli F, 2018, MAR DRUGS, V16, DOI 10.3390/md16060188
   Fertouna-Bellakhal M, 2015, HARMFUL ALGAE, V48, P69, DOI 10.1016/j.hal.2015.07.007
   FRITZ L, 1985, J PHYCOL, V21, P662, DOI 10.1111/j.0022-3646.1985.00662.x
   John U, 2014, PROTIST, V165, P779, DOI 10.1016/j.protis.2014.10.001
   Kodama Masaaki, 2010, Aqua-Bioscience Monographs, V3, P1
   Laanaia N, 2013, HARMFUL ALGAE, V28, P31, DOI 10.1016/j.hal.2013.05.016
   LAORE, 2013, AQ SARD TRAD INN FLA
   Lewis AM, 2018, J PHYCOL, V54, P581, DOI 10.1111/jpy.12768
   Liu Y, 2017, MAR POLLUT BULL, V115, P324, DOI 10.1016/j.marpolbul.2016.12.023
   Llewellyn L, 2006, TOXIN REV, V25, P159, DOI 10.1080/15569540600599217
   Lorenzoni G, 2011, ITAL J FOOD SAFETY, V2, P95
   Lorenzoni G, 2013, ITAL J FOOD SAF, V2, P104, DOI 10.4081/ijfs.2013.e30
   Luglie A., 2011, BIOL MARINA MEDITERR, V18, P2
   Luglie A., 2003, BOCCONEA, V16, P1045
   Luglie A., 2002, HARMFUL ALGAE 2002, P329
   Luglie A, 2017, MICROORGANISMS, V5, DOI 10.3390/microorganisms5040072
   Milandri A., 2008, BIOL MAR MEDIT, V15, P38
   Moestrup O., 2009, IOC UNESCO TAXONOMIC
   Murk A.J., 2019, CHEM HAZARDS FOODS A, P207, DOI [10.3920/978-90-8686-877-3_09, DOI 10.3920/978-90-8686-877-3_09]
   Navone A., 2004, NEW STRATEGY MONITOR, P23
   O'Mahony M, 2018, TOXINS, V10, DOI 10.3390/toxins10030118
   Penna A, 2005, MAR BIOL, V148, P13, DOI 10.1007/s00227-005-0067-5
   Penna A, 2008, EUR J PHYCOL, V43, P163, DOI 10.1080/09670260701783730
   Researches Sardinia, 2018, RES TECHNOLOGICAL DE
   Sardinia Region, 2016, REG PLAN SURV SAN CO
   Satta CT, 2010, DEEP-SEA RES PT II, V57, P256, DOI 10.1016/j.dsr2.2009.09.013
   Turki S, 2014, ECOL ENG, V67, P39, DOI 10.1016/j.ecoleng.2014.03.028
   Utermohl H., 1958, MITT INT VER LIMNOL, V9, P1, DOI DOI 10.1080/05384680.1958.11904091
   Valbi E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40664-w
   Virgilio S., 2010, ITALIAN J FOOD SAFET, V8, P71
   Visciano P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01051
   Wiese M, 2010, MAR DRUGS, V8, P2185, DOI 10.3390/md8072185
NR 44
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 30
PY 2020
VL 174
BP 48
EP 56
DI 10.1016/j.toxicon.2019.12.157
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KJ7EP
UT WOS:000512221400008
PM 31989929
DA 2020-05-12
ER

PT J
AU Dizaji, R
   Sharafi, A
   Pourahmad, J
   Vatanpour, S
   Hosseini, MJ
   Vatanpour, H
AF Dizaji, Rana
   Sharafi, Ali
   Pourahmad, Jalal
   Vatanpour, Saba
   Hosseini, Mir-Jamal
   Vatanpour, Hossein
TI The effects of Hemiscorpius lepturus induced-acute kidney injury on
   PGC-1 alpha gene expression: From induction to suppression in mice
SO TOXICON
LA English
DT Article
DE Hemiscorpius lepturus; Heme oxygenase-1; PGC-1 alpha; Nrf-2; PPAR-alpha;
   Bax/ Bcl-2
ID MITOCHONDRIAL-FUNCTION; OXIDATIVE STRESS; IN-VIVO; APOPTOSIS;
   BIOGENESIS; METABOLISM; PROTECTS; VENOM
AB Hemiscorpius lepturus envenomation induces acute kidney injury (AKI) through hemoglubinoria and mitochondrial dysfunction. Mitochondria supports ATP production to promote the regulation of fluid and electrolyte balance. Mitochondrial homeostasis in different metabolic environments can be adjusted by overexpression of PGC-1 alpha. High reactive oxygen species (ROS) production after H. lepturus envenomation and heme oxygenase-1 (HO-1) overexpression causes ATP depletion as well as mitochondrial homeostasis disruption, which lead to progression in renal diseases. The present study aims to evaluate the role of venom induced-AM in modulating mitochondrial function in cell death and metabolic signaling associated with PPAR-alpha, PGC-1 alpha, and Nrf-2 as the main transcription factors involved in metabolism. Based on the data, two significant events occurred after envenomation: reduction of gl glutathione level and overexpression of the cytoprotective enzyme HO-1. Apaoptosis induction is associated with a significant decrease in the transcription of PPAR-alpha, PGC-1 alpha and Nrf2 after administrating lethal dose of venom (10 mg/kg). Furthermore, at the lower doses of venom (1 and 5 mg/kg), with a significant recovery accompanied with PGC-1 alpha upregulation occurs after AKI. As the findings indicate, PGC-1 alpha has a key role in restoring the mitochondrial function at the recovery phase of mouse model of AM, which highlights the PGC-1 alpha as a therapeutic target for venom induced-AKI prevention and treatment.
C1 [Dizaji, Rana; Hosseini, Mir-Jamal] Zanjan Univ Med Sci, Zanjan Appl Pharmacol Res Ctr, Zanjan, Iran.
   [Dizaji, Rana; Pourahmad, Jalal; Vatanpour, Hossein] Shahid Beheshti Univ Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, POB 14155-6153, Tehran, Iran.
   [Sharafi, Ali] Zanjan Univ Med Sci, Zanjan Pharmaceut Biotechnol Res Ctr, Zanjan, Iran.
   [Vatanpour, Saba] Univ British Columbia, Dept Biol, Vancouver, BC, Canada.
   [Hosseini, Mir-Jamal] Zanjan Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, Zanjan, Iran.
RP Vatanpour, H (reprint author), Shahid Beheshti Univ Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, POB 14155-6153, Tehran, Iran.; Hosseini, MJ (reprint author), Zanjan Univ Med Sci, Zanjan Appl Pharmacol Res Ctr, Dept Pharmacol & Toxicol, Sch Pharm, POB 45139-56184, Zanjan, Iran.
EM jamal_hossini@yahoo.com; vatanpour.hossein@gmail.com
RI Sharafi, Ali/J-9647-2016
OI Sharafi, Ali/0000-0002-6012-1424; Hosseini,
   Mir-Jamal/0000-0002-4469-9488
FU Zanjan University of Medical Sciences [A-12-769-30]
FX This work was supported by the deputy of research of Zanjan University
   of Medical Sciences (Grant NO: A-12-769-30).
CR Amini-Khoei H, 2017, PROG NEURO-PSYCHOPH, V76, P169, DOI 10.1016/j.pnpbp.2017.02.022
   Bhargava P, 2017, NAT REV NEPHROL, V13, P629, DOI 10.1038/nrneph.2017.107
   Bolisetty S, 2016, AM J PHYSIOL-RENAL, V310, pF385, DOI 10.1152/ajprenal.00335.2015
   Dam AD, 2013, BBA-MOL CELL RES, V1833, P3426, DOI 10.1016/j.bbamcr.2013.04.014
   Daraie B, 2012, IRAN J PHARM RES, V11, P495
   Deuel JW, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.392
   Dizaji R, 2019, TOXICON, V163, P23, DOI 10.1016/j.toxicon.2019.03.011
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Emma F, 2016, NAT REV NEPHROL, V12, P267, DOI 10.1038/nrneph.2015.214
   Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794
   Gao L, 2018, BBA-MOL BASIS DIS, V1864, P3322, DOI 10.1016/j.bbadis.2018.07.019
   Goven D, 2009, FEBS LETT, V583, P3508, DOI 10.1016/j.febslet.2009.10.010
   Havasi A, 2011, KIDNEY INT, V80, P29, DOI 10.1038/ki.2011.120
   Jiang XY, 2013, DIABETES RES CLIN PR, V100, P368, DOI 10.1016/j.diabres.2013.03.036
   LaGory EL, 2015, CELL REP, V12, P116, DOI 10.1016/j.celrep.2015.06.006
   Li QW, 2014, CELL BIOCHEM BIOPHYS, V69, P495, DOI 10.1007/s12013-014-9823-9
   Li S.-Y., 2018, SEMINARS NEPHROLOGY, P121
   Li SY, 2009, KIDNEY INT, V76, P1049, DOI 10.1038/ki.2009.330
   Lynch MR, 2018, AM J PHYSIOL-RENAL, V314, pF1, DOI 10.1152/ajprenal.00263.2017
   Mei SQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep44892
   Naserzadeh P, 2017, BIOMED ENVIRON SCI, V30, P581, DOI 10.3967/bes2017.077
   Nath KA, 2014, CURR OPIN NEPHROL HY, V23, P17, DOI 10.1097/01.mnh.0000437613.88158.d3
   Palikaras K, 2014, EXP GERONTOL, V56, P182, DOI 10.1016/j.exger.2014.01.021
   Piantadosi C.A., 2011, J BIOL CHEM, P16374
   Pipelzadeh MH, 2007, TOXICON, V50, P984, DOI 10.1016/j.toxicon.2007.07.018
   Pipelzadeh MH, 2006, TOXICON, V48, P93, DOI 10.1016/j.toxicon.2006.04.017
   Pipelzadeh MH, 2015, TOXICON, V100, P13, DOI 10.1016/j.toxicon.2015.03.023
   Qaisiya M, 2014, CELL SIGNAL, V26, P512, DOI 10.1016/j.cellsig.2013.11.029
   Rubio-Navarro A, 2018, J PATHOL, V244, P296, DOI 10.1002/path.5011
   Ruiz-Andres O, 2016, KIDNEY INT, V89, P399, DOI 10.1038/ki.2015.332
   Smith JA, 2015, J PHARMACOL EXP THER, V352, P346, DOI 10.1124/jpet.114.221085
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Suttner DM, 1999, FASEB J, V13, P1800
   Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957
   Tran M., 2011, J CLIN INVESTIG, V121
   Wang H, 2015, SHOCK, V44, P173, DOI 10.1097/SHK.0000000000000390
   Wang ZH, 2018, BIOCHEM PHARMACOL, V150, P54, DOI 10.1016/j.bcp.2018.01.034
   Xu L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.22
   Zhao M, 2016, ONCOTARGET, V7, P12150, DOI 10.18632/oncotarget.7859
NR 39
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JAN 30
PY 2020
VL 174
BP 57
EP 63
DI 10.1016/j.toxicon.2019.12.154
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KJ7EP
UT WOS:000512221400009
PM 31887316
DA 2020-05-12
ER

PT J
AU Abhyankar, N
   Lin, J
   Liu, X
   Sifuentes, F
AF Abhyankar, Nikit
   Lin, Jiang
   Liu, Xu
   Sifuentes, Froylan
TI Economic and environmental benefits of market-based power-system reform
   in China: A case study of the Southern grid system
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE China; Southern grid; Power Market reforms; Dispatch modeling; CO2
   emissions
ID RESOURCE ASSESSMENT; WIND; IMPACT
AB China, whose power system accounts for about 13% of global energy-related CO2 emissions, has begun implementing market-based power-sector reforms. This paper simulates power system dispatch in China's Southern Grid region and examines the economic and environmental impacts of market-based operations. We find that market-based operation can increase efficiency and reduce costs in all Southern Grid provinces-reducing wholesale electricity costs by up to 35% for the entire region relative to the 2016 baseline. About 60% of the potential cost reduction can be realized by creating independent provincial markets within the region, and the rest by creating a regional market without transmission expansion. The wholesale market revenue is adequate to recover generator fixed costs; however, financial restructuring of current payment mechanisms may be necessary. Electricity markets could also reduce the Southern Grid's CO2 emissions by up to 10% owing to more efficient thermal dispatch and avoided hydro/renewable curtailment. The benefits of regional electricity markets with expanded transmission likely will increase as China's renewable generation increases.
C1 [Abhyankar, Nikit; Lin, Jiang; Liu, Xu; Sifuentes, Froylan] Lawrence Berkeley Natl Lab, Int Energy Anal Dept, 1 Cyclotron Rd, Berkeley, CA 94720 USA.
   [Lin, Jiang; Sifuentes, Froylan] Univ Calif Berkeley, Berkeley, CA 94720 USA.
RP Lin, J (reprint author), Lawrence Berkeley Natl Lab, Int Energy Anal Dept, 1 Cyclotron Rd, Berkeley, CA 94720 USA.
EM J_lin@lbl.gov
RI Liu, Xu/AAA-1964-2020
OI Liu, Xu/0000-0002-5784-1244; Abhyankar, Nikit/0000-0003-3383-8558
FU William and Flora Hewlett Foundation; MJS Foundation through the U.S.
   Department of EnergyUnited States Department of Energy (DOE)
   [DE-ACO2-05CH11231]
FX This work was supported by the William and Flora Hewlett Foundation and
   the MJS Foundation through the U.S. Department of Energy under Contract
   No. DE-ACO2-05CH11231.
CR Abhyankar Nikit, 2017, TECHNO EC ASSESSMENT, V60
   Abrams Alicia, 2013, ENERGY STORAGE COST
   Ackermann T, 2009, IEEE POWER ENERGY M, V7, P65, DOI 10.1109/MPE.2009.934658
   [Anonymous], 2016, PEOPLE CHINA NE 0725
   [Anonymous], 2019, XINHUA NET      0905
   [Anonymous], 2015 2016 TRANSM PLA
   Cai Q., 2014, LOAD CHARACTERISTICS
   China Electric Council, 2019, CHIN EL POW STAT REP
   China Electric Council, 2017, CHIN POW STAT YB 201
   China Electric Council, 2019, SO GRID START GUANGD
   China Electricity Council, 2017, EL POW IND STAT COMP
   Cicala S, 2015, AM ECON REV, V105, P411, DOI 10.1257/aer.20131377
   Cicala Steve, 2017, W23053 NAT BUR EC RE, DOI [10.3386/w23053, DOI 10.3386/W23053]
   Corcoran BA, 2012, ENERG POLICY, V46, P399, DOI 10.1016/j.enpol.2012.03.079
   DeCesaro J., 2009, ELECT J, V22, P15
   Eichman Josh, 2015, RENEW ENERGY, V94
   Ener Nex Corporation, 2006, 2006 MINN WIND INT S
   European Climate Foundation, 2010, ROADM 2050 PRACT GUI, VI
   Fabrizio Kira R., 2007, AM ECON REV, V97, P31
   GE Energy NREL, 2010, NRELSR55047434, DOI [10.2172/981991, DOI 10.2172/981991]
   Goggin Michael, 2018, CUSTOMER FOCUSED CLE
   Gramlich Robert, 2008, ABILITY CURRENT US E, V6
   GREEN RJ, 1992, J POLIT ECON, V100, P929, DOI 10.1086/261846
   Guangdong Statistics, 2016, KEY STAT GUANGD
   Guizhou Statistical Bureau, 2017, GUIZH MONTHL STAT RE
   He G, 2016, RENEW ENERG, V85, P74, DOI 10.1016/j.renene.2015.06.027
   He G, 2014, ENERG POLICY, V74, P116, DOI 10.1016/j.enpol.2014.07.003
   Holttinen H., 2007, DESIGN OPERATION POW
   International Energy Agency, 2018, GLOB EN CO2 STAT REP
   Jorgenson J., 2014, NRELTP6A2061685, DOI [10.2172/1134134, DOI 10.2172/1134134]
   Joskow Paul L., 2008, CAPACITY MECH IMPERF, V16, P159, DOI [10.1016/flup.2007.10.003.3, DOI 10.1016/FLUP.2007.10.003.3]
   King J., 2011, NRELTP550052330, DOI [10.2172/1028530, DOI 10.2172/1028530]
   Kirby B., 2008, NRELTP50043251
   Li Xiaolu, 2014, ANAL LOAD FORECASTIN, V17
   Lin J, 2019, APPL ENERG, V238, P1093, DOI 10.1016/j.apenergy.2019.01.128
   Lin J, 2018, NATURE, V562, P39, DOI 10.1038/d41586-018-06894-0
   Liu Shucheng, 2015, CAISO 2015 2016 TRAN
   Lv Yi, 2013, LOAD CURVE TREND HAI
   Miller N., 2006, IMPACT CONTROL AREAS
   Milligan M, 2008, WIND ENG, V32, P379, DOI 10.1260/0309-524X.32.4.379
   National Development and Reform Commission, 2019, CHIN EL COAL PRIC IN
   National Development and Reform Commission, 2017, EM FACT REG GRIDS CH
   National Development and Reform Commission (NDRC), 2019, 1 TIME          0531
   National Energy Administration, 2017, NOT PIL EL WHOL MARK
   Palchak D., 2017, GREENING GRID PATHWA, DOI [10.2172/1369138, DOI 10.2172/1369138]
   People's Government of Hainan Province, 2017, HAIN MONTHL STAT REP
   Smith JC, 2007, IEEE T POWER SYST, V22, P900, DOI 10.1109/TPWRS.2007.901598
   Wei YM, 2018, ENERG ECON, V74, P330, DOI 10.1016/j.eneco.2018.06.017
   Yang Zhuo, 2014, LOAD CHARACTERISTICS
   Yunnan Statistical Bureau, 2017, YUNN EC OP INF
   Zhang Xiuzhao, 2014, STUDIES LOAD CHARACT
NR 51
TC 0
Z9 0
U1 30
U2 30
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104558
DI 10.1016/j.resconrec.2019.104558
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200013
OA Other Gold
DA 2020-05-12
ER

PT J
AU Bag, S
   Wood, LC
   Xu, L
   Dhamija, P
   Kayikci, Y
AF Bag, Surajit
   Wood, Lincoln C.
   Xu, Lei
   Dhamija, Pavitra
   Kayikci, Yasanur
TI Big data analytics as an operational excellence approach to enhance
   sustainable supply chain performance
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Big data analytics; Operational excellence; Dynamic capability view;
   Supply chain sustainability; Learning performance
ID LEAN 6 SIGMA; HUMAN-RESOURCE MANAGEMENT; FIRM PERFORMANCE; INDUSTRY 4.0;
   PREDICTIVE ANALYTICS; DYNAMIC CAPABILITIES; BUSINESS STRATEGY; GREEN;
   IMPLEMENTATION; INNOVATION
AB Operations management is a core organizational function involved in the management of activities to produce and deliver products and services. Appropriate operations decisions rely on assessing and using information; a task made more challenging in the Big Data era. Effective management of data (big data analytics; BDA), along with staff capabilities (the talent capability in the use of big data) support firms to leverage big data analytics and organizational learning in support of sustainable supply chain management outcomes. The current study uses dynamic capability theory as a foundation for evaluating the role of BDA capability as an operational excellence approach in improving sustainable supply chain performance. We surveyed mining executives in the emerging economy of South Africa and received 520 valid responses (47% response rate). We used Partial Least Squares Structural Equation Modelling (PLS-SEM) to analyze the data. The findings show that big data analytics management capabilities have a strong and significant effect on innovative green product development and sustainable supply chain outcomes. Big data analytics talent capabilities have a weaker but still significant effect on employee development and sustainable supply chain outcomes. Innovation and learning performance affect sustainable supply chain performance, and supply chain innovativeness has an important moderating role. A contribution of the study is identifying two pathways that managers can use to improve sustainable supply chain outcomes in the mining industry, based on big data analytics capabilities.
C1 [Bag, Surajit] Univ Johannesburg, Post Grad Sch Engn Management, Fac Engn & Built Environm, Johannesburg, South Africa.
   [Wood, Lincoln C.] Univ Otago, Dept Management, Dunedin, New Zealand.
   [Wood, Lincoln C.] Curtin Univ, Sch Management, Perth, WA, Australia.
   [Xu, Lei] Civil Aviat Univ China, Econ & Management Coll, Tianjin 300300, Peoples R China.
   [Xu, Lei] Civil Aviat Univ China, Res Ctr Environm & Sustainable Dev China Civil Av, Tianjin 300300, Peoples R China.
   [Dhamija, Pavitra] Univ Johannesburg, Dept Ind Psychol & People Management, Coll Business & Econ, Johannesburg, South Africa.
   [Kayikci, Yasanur] Turkish German Univ, Engn Fac, Sahinkaya Cad 86, TR-34820 Beykoz, Turkey.
RP Wood, LC (reprint author), Univ Otago, Dept Management, Dunedin, New Zealand.; Wood, LC (reprint author), Curtin Univ, Sch Management, Perth, WA, Australia.
EM surajit.bag@gmail.com; lincoln.wood@otago.ac.nz; chully.xu@gmail.com;
   pavitradhamija@gmail.com; yasanur.kayikci@gmail.com
RI Kayikci, Yasanur/D-3681-2014; Bag, Surajit/AAF-4874-2020
OI Kayikci, Yasanur/0000-0003-2406-3164; BAG, SURAJIT/0000-0002-2344-9551
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71672125, 91646117]
FX The work of Lei XU was supported in part by National Natural Science
   Foundation of China (Grant No. 71672125), major research project of
   National Natural Science Foundation of China (Grant No. 91646117).
CR Ahmadi HB, 2017, RESOUR CONSERV RECY, V126, P99, DOI 10.1016/j.resconrec.2017.07.020
   Akgun AE, 2014, INT J PROD RES, V52, P888, DOI 10.1080/00207543.2013.843796
   Akter S, 2016, INT J PROD ECON, V182, P113, DOI 10.1016/j.ijpe.2016.08.018
   Augier M, 2009, ORGAN SCI, V20, P410, DOI 10.1287/orsc.1090.0424
   Azadegan A, 2010, J OPER MANAG, V28, P488, DOI 10.1016/j.jom.2010.02.001
   Bag S., 2017, GLOBAL J FLEXIBLE SY, V18, P231, DOI DOI 10.1007/s40171-017-0158-4
   Bag S, 2019, MANAGE DECIS, V57, P863, DOI 10.1108/MD-07-2018-0724
   Bag S, 2018, BENCHMARKING, V25, P3951, DOI 10.1108/BIJ-06-2017-0132
   Bag S, 2017, INT J INF SYST SUPPL, V10, P66, DOI 10.4018/IJISSCM.2017040104
   Beske P, 2012, INT J PHYS DISTR LOG, V42, P372, DOI 10.1108/09600031211231344
   Bititci U, 2016, INT J PROD RES, V54, P1571, DOI 10.1080/00207543.2015.1005770
   Braganza A, 2017, J BUS RES, V70, P328, DOI 10.1016/j.jbusres.2016.08.006
   Breidbach CF, 2015, SERV IND J, V35, P5, DOI 10.1080/02642069.2014.979404
   Chams N, 2019, RESOUR CONSERV RECY, V141, P109, DOI 10.1016/j.resconrec.2018.10.006
   Chiou TY, 2011, TRANSPORT RES E-LOG, V47, P822, DOI 10.1016/j.tre.2011.05.016
   Davenport ML, 2019, RESOUR CONSERV RECY, V150, DOI 10.1016/j.resconrec.2019.104440
   Daxini A, 2019, RESOUR CONSERV RECY, V146, P280, DOI 10.1016/j.resconrec.2019.03.027
   Dedahanov AT, 2017, CAREER DEV INT, V22, P334, DOI 10.1108/CDI-12-2016-0234
   Dries N, 2012, J VOCAT BEHAV, V81, P271, DOI 10.1016/j.jvb.2011.10.006
   Dubey Rameshwar, 2013, International Journal of Procurement Management, V6, P187
   Frank AG, 2019, INT J PROD ECON, V210, P15, DOI 10.1016/j.ijpe.2019.01.004
   Ghadimi P, 2019, RESOUR CONSERV RECY, V140, P72, DOI 10.1016/j.resconrec.2018.09.005
   Gong MF, 2018, RESOUR CONSERV RECY, V128, P155, DOI 10.1016/j.resconrec.2016.11.001
   Gunasekaran A, 2017, J BUS RES, V70, P308, DOI 10.1016/j.jbusres.2016.08.004
   Hazen BT, 2014, INT J PROD ECON, V154, P72, DOI 10.1016/j.ijpe.2014.04.018
   Hu JY, 2019, RESOUR CONSERV RECY, V149, P177, DOI 10.1016/j.resconrec.2019.05.042
   Hult GTM, 2004, IND MARKET MANAG, V33, P429, DOI 10.1016/j.indmarman.2003.08.015
   Imran MK, 2018, J ORGAN CHANGE MANAG, V31, P512, DOI 10.1108/JOCM-10-2016-0202
   Janssen M, 2017, J BUS RES, V70, P338, DOI 10.1016/j.jbusres.2016.08.007
   Kock N., 2017, WARP PLS 6 0
   Lechuga Sancho MP, 2018, PERS REV, V47, P1215, DOI 10.1108/PR-05-2017-0165
   Lin KP, 2018, RESOUR CONSERV RECY, V128, P134, DOI 10.1016/j.resconrec.2016.11.017
   Lun YHV, 2011, RESOUR CONSERV RECY, V55, P559, DOI 10.1016/j.resconrec.2010.12.001
   Lundkvist AH, 2018, VOCAT LEARN, V11, P45, DOI 10.1007/s12186-017-9179-6
   Luthra S, 2018, RESOUR CONSERV RECY, V138, P194, DOI 10.1016/j.resconrec.2018.07.005
   Malik AR, 2014, HUM RESOUR MANAGE R, V24, P330, DOI 10.1016/j.hrmr.2014.06.001
   Mangla S. K, 2019, RESOUR CONSERV RECY, V142, P277, DOI DOI 10.1016/J.RESCONREC.2018.11.014
   Marshall Anthony, 2015, Strategy & Leadership, V43, P32, DOI 10.1108/SL-06-2015-0054
   Mathivathanan D, 2018, RESOUR CONSERV RECY, V128, P284, DOI 10.1016/j.resconrec.2017.01.003
   Olugu EU, 2011, RESOUR CONSERV RECY, V55, P567, DOI 10.1016/j.resconrec.2010.06.003
   Powers R.F., 1989, J BUSINESS LOGISTICS, V10, P106
   Pujari D, 2003, J BUS RES, V56, P657, DOI 10.1016/S0148-2963(01)00310-1
   PWC South Africa, 2018, PWC S AFR IND 4 0 S
   Richey R. G., 2005, International Journal of Physical Distribution & Logistics Management, V35, P233, DOI 10.1108/09600030510599913
   Samaranayake P, 2009, BUS PROCESS MANAG J, V15, P504, DOI 10.1108/14637150910975516
   Shah N, 2017, J BUS RES, V70, P366, DOI 10.1016/j.jbusres.2016.08.010
   Silvestre BS, 2015, INT J PROD ECON, V167, P156, DOI 10.1016/j.ijpe.2015.05.025
   Singh RK, 2019, RESOUR CONSERV RECY, V147, P10, DOI 10.1016/j.resconrec.2019.04.014
   Sivarajah U, 2017, J BUS RES, V70, P263, DOI 10.1016/j.jbusres.2016.08.001
   Taelman S., 2019, RESOUR CONSERV RECY, VX
   Tan KH, 2015, INT J PROD ECON, V165, P223, DOI 10.1016/j.ijpe.2014.12.034
   Tao F, 2018, INT J ADV MANUF TECH, V94, P3563, DOI 10.1007/s00170-017-0233-1
   Teece DJ, 2014, ACAD MANAGE PERSPECT, V28, P328, DOI 10.5465/amp.2013.0116
   Telukdarie A, 2018, PROCESS SAF ENVIRON, V118, P316, DOI 10.1016/j.psep.2018.06.030
   Tiwari S, 2018, COMPUT IND ENG, V115, P319, DOI 10.1016/j.cie.2017.11.017
   Tseng ML, 2018, RESOUR CONSERV RECY, V131, P146, DOI 10.1016/j.resconrec.2017.12.028
   Wamba SF, 2017, J BUS RES, V70, P356, DOI 10.1016/j.jbusres.2016.08.009
   Wang G, 2016, INT J PROD ECON, V176, P98, DOI 10.1016/j.ijpe.2016.03.014
   Wang ZQ, 2015, INT J PROD RES, V53, P6294, DOI 10.1080/00207543.2015.1053578
   Wood LC, 2018, J MACROMARKETING, V38, P364, DOI 10.1177/0276146718781915
   Wood LC, 2017, INT J LOGIST-RES APP, V20, P426, DOI 10.1080/13675567.2016.1267126
   Wood LC, 2016, J CLEAN PROD, V112, P903, DOI 10.1016/j.jclepro.2015.08.101
   Wu H.J., 1995, INT J PHYS DISTRIB, V25, P20, DOI DOI 10.1108/09600039510083925
   Yadav Gunjan, 2017, TQM Journal, V29, P488, DOI 10.1108/TQM-04-2016-0041
   Yadav G, 2018, INT J PROD RES, V56, P6259, DOI 10.1080/00207543.2018.1472406
   Yadav G, 2018, PROD PLAN CONTROL, V29, P185, DOI 10.1080/09537287.2017.1402134
   Yadav G, 2017, J MANUF TECHNOL MANA, V28, P794, DOI 10.1108/JMTM-03-2017-0043
   Yadav G, 2016, INT J LEAN SIX SIG, V7, P2, DOI 10.1108/IJLSS-05-2015-0015
   Zhan YZ, 2018, ANN OPER RES, V270, P577, DOI 10.1007/s10479-016-2379-x
   Zhong RY, 2016, COMPUT IND ENG, V101, P572, DOI 10.1016/j.cie.2016.07.013
   Zhou XG, 2015, RESOUR CONSERV RECY, V100, P58, DOI 10.1016/j.resconrec.2015.04.009
NR 71
TC 2
Z9 2
U1 119
U2 119
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104559
DI 10.1016/j.resconrec.2019.104559
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200012
DA 2020-05-12
ER

PT J
AU Becci, A
   Amato, A
   Fonti, V
   Karaj, D
   Beolchini, F
AF Becci, Alessandro
   Amato, Alessia
   Fonti, Viviana
   Karaj, Dafina
   Beolchini, Francesca
TI An innovative biotechnology for metal recovery from printed circuit
   boards
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Printed circuit boards; Biotechnology; At. ferrooxidans; Copper; Zinc;
   Carbon footprint
ID ENVIRONMENTAL-IMPACT ASSESSMENT; FERROUS SULFATE OXIDATION; MOBILE PHONE
   PCBS; E-WASTE; ACIDITHIOBACILLUS-FERROOXIDANS; ELECTRONIC WASTE;
   HEAVY-METALS; THIOBACILLUS-FERROOXIDANS; CYANOGENIC BACTERIA;
   COPPER-EXTRACTION
AB The increase of waste from electric and electronic equipment has pushed the research towards the development of high sustainability treatments for their exploitation. The end-of-life printed circuit boards (PCBs) represent one of the most significant waste in this class. The interest for these scraps is due to the high Cu and Zn content, with concentrations around 25% and 2% respectively, combined with further precious metals (e.g. Au, Ag, Pd). Currently, the most common approaches developed for PCBs recycling include pyrometallurgical and hydrometallurgical treatments. On the other hand, biohydrometallurgical strategies are gaining increasing prominence, for the possibility to decrease both the environmental and the economic costs. Nevertheless, these techniques show the main limit due to the possibility to treat low quantities of waste, which makes unsustainable the further scale-up. To overcome this criticality, the present paper introduces an innovative bioleaching process carried out by Acidithiobacillus ferrooxidans (At. ferrooxidans) and Leptospirillum ferrooxidans (L. ferrooxidans). The developed technology allows to reach high PCB concentration, up to 5% (w/v), thanks to a high efficiency two-step design, able to reduce the metal toxicity on the bacteria metabolism. The treatment uses the ferric iron generated by bacterial oxidation, as oxidant, to leach Cu and Zn from PCBs. The possibility to overcome the solid concentration criticality is combined with high yield of 94% and 70% for Cu and Zn, respectively. The best selected conditions involve the At. ferrooxidans bacteria use at: 30 degrees C, solid concentration of 5% (w/v), 10 g/L of Fe2+, time of treatment 9 days. The experimental results are further enhanced by the carbon footprint assessment which proved the environmental advantage, compared to both the reference chemical treatment through ferric iron and literature processes (hydrometallurgical and bioleaching approaches). The analysis explained as the PCBs concentration in the solution allows to decrease the bioreactor size with the consequent reduction of energy and raw material demand. This benefit can be translated into a 4 times reduction of the CO2-eq./kg treated PCB emissions, compared to the best bioleaching processes, reported in the literature.
C1 [Becci, Alessandro; Amato, Alessia; Beolchini, Francesca] Univ Politecn Marche, Dept Life & Environm Sci, Via Brecce Bianche, I-60131 Ancona, Italy.
   [Fonti, Viviana] Univ Exeter, Coll Engn Math & Phys Sci, Camborne Sch Mines, Stocker Rd, Exeter EX4 4PY, Devon, England.
   [Karaj, Dafina] Univ Politekn Tiranes, Dept Chem, Sheshi Nene Tereza, Tirana, Albania.
RP Beolchini, F (reprint author), Univ Politecn Marche, Dept Life & Environm Sci, Via Brecce Bianche, I-60131 Ancona, Italy.
EM a.becci@pm.univpm.it; a.amato@univpm.it; v.fonti@exeter.ac.uk;
   dfn_karaj@yahoo.com; f.beolchini@univpm.it
OI Amato, Alessia/0000-0002-0840-1584; Fonti, Viviana/0000-0003-1827-7297
FU FENIX Project [H2020-760792]
FX This work has been carried out within a subcontract of the H2020-760792
   FENIX Project. Part of the work has been realized thanks to Doctorate
   exchange and Post-Doc within S.U.N.B.E.A.M. Project Erasmus Mundus
   Action 2 -Strand 1. The authors are highly grateful to Marcello
   Centofanti for his support for the chemical analyses.
CR Amato A, 2019, PROG PHOTOVOLTAICS, V27, P229, DOI 10.1002/pip.3082
   Amato A, 2016, PHYS STATUS SOLIDI C, V13, P979, DOI 10.1002/pssc.201600114
   Amato A, 2017, WASTE MANAGE, V59, P432, DOI 10.1016/j.wasman.2016.09.024
   Arshadi M, 2015, SEP PURIF TECHNOL, V147, P210, DOI 10.1016/j.seppur.2015.04.020
   Arshadi M, 2015, BIORESOURCE TECHNOL, V175, P315, DOI 10.1016/j.biortech.2014.10.083
   Balde C.P., 2017, GLOBAL E WASTE MONIT
   Bas AD, 2013, HYDROMETALLURGY, V138, P65, DOI 10.1016/j.hydromet.2013.06.015
   Bas AD, 2014, SEP PURIF TECHNOL, V130, P151, DOI 10.1016/j.seppur.2014.04.008
   Behnamfard A, 2013, WASTE MANAGE, V33, P2354, DOI 10.1016/j.wasman.2013.07.017
   Beolchini F, 2012, WASTE MANAGE, V32, P949, DOI 10.1016/j.wasman.2011.10.014
   Birloaga I, 2016, J ENVIRON CHEM ENG, V4, P20, DOI 10.1016/j.jece.2015.11.021
   Boon M, 1999, APPL MICROBIOL BIOT, V51, P820, DOI 10.1007/s002530051468
   Brandl H, 2001, HYDROMETALLURGY, V59, P319, DOI 10.1016/S0304-386X(00)00188-2
   Cabrera G, 2005, PROCESS BIOCHEM, V40, P2683, DOI 10.1016/j.procbio.2004.12.005
   Cabrera G, 2005, ENZYME MICROB TECH, V36, P301, DOI 10.1016/j.enzmictec.2004.09.008
   Chi TD, 2011, MINER ENG, V24, P1219, DOI 10.1016/j.mineng.2011.05.009
   Chisholm IA, 1998, ANTON LEEUW INT J G, V73, P245, DOI 10.1023/A:1001009931616
   Choi NS, 2004, J ENVIRON SCI HEAL A, V39, P2973, DOI 10.1081/LESA-200034763
   Creamer NJ, 2006, BIOTECHNOL LETT, V28, P1475, DOI 10.1007/s10529-006-9120-9
   Crundwell FK, 1997, BIOELECTROCH BIOENER, V43, P115, DOI 10.1016/S0302-4598(96)05175-6
   Daoud J, 2006, MINER ENG, V19, P960, DOI 10.1016/j.mineng.2005.10.024
   Dopson M, 2003, MICROBIOL-SGM, V149, P1959, DOI 10.1099/mic.0.26296-0
   Faraji F, 2018, J ENVIRON MANAGE, V217, P775, DOI 10.1016/j.jenvman.2018.04.043
   Goto M, 1996, J SUPERCRIT FLUID, V9, P128, DOI 10.1016/S0896-8446(96)90009-1
   Hong Y, 2014, J CLEAN PROD, V65, P465, DOI 10.1016/j.jclepro.2013.08.043
   Hubau A, 2019, WASTE MANAGE, V91, P62, DOI 10.1016/j.wasman.2019.04.041
   Ilyas S, 2014, CHEMBIOENG REV, V1, P148, DOI 10.1002/cben.201400001
   Ilyas S, 2013, HYDROMETALLURGY, V131, P138, DOI 10.1016/j.hydromet.2012.11.010
   Ippolito NM, 2017, J CLEAN PROD, V153, P287, DOI 10.1016/j.jclepro.2017.03.195
   Jadhav U, 2016, RSC ADV, V6, P43442, DOI 10.1039/c6ra04169h
   Joshi V, 2017, ENVIRON SCI POLLUT R, V24, P28277, DOI 10.1007/s11356-017-0780-x
   Latunussa CEL, 2016, SOL ENERG MAT SOL C, V156, P101, DOI 10.1016/j.solmat.2016.03.020
   Lee JC, 2012, WASTE MANAGE, V32, P3, DOI 10.1016/j.wasman.2011.08.010
   Leung AOW, 2008, ENVIRON SCI TECHNOL, V42, P2674, DOI 10.1021/es071873x
   Li J, 2007, ENVIRON SCI TECHNOL, V41, P1995, DOI 10.1021/es0618245
   Liang GB, 2016, J MATER CYCLES WASTE, V18, P742, DOI 10.1007/s10163-015-0375-x
   Liang GB, 2013, J HAZARD MATER, V250, P238, DOI 10.1016/j.jhazmat.2013.01.077
   Liang GB, 2010, ENZYME MICROB TECH, V47, P322, DOI 10.1016/j.enzmictec.2010.08.002
   Liu Yong, 2011, Patent No. [CN102218437, 102218437]
   Musson SE, 2006, ENVIRON SCI TECHNOL, V40, P2721, DOI 10.1021/es051557n
   Natarajan G, 2015, CHEMOSPHERE, V136, P232, DOI 10.1016/j.chemosphere.2015.05.046
   Natarajan G, 2014, BIORESOURCE TECHNOL, V152, P80, DOI 10.1016/j.biortech.2013.10.108
   Nie HY, 2015, APPL BIOCHEM BIOTECH, V177, P675, DOI 10.1007/s12010-015-1772-2
   Nie HY, 2015, J CHEM TECHNOL BIOT, V90, P714, DOI 10.1002/jctb.4363
   Ojumu TV, 2006, HYDROMETALLURGY, V83, P21, DOI 10.1016/j.hydromet.2006.03.033
   Pant D, 2012, WASTE MANAGE, V32, P979, DOI 10.1016/j.wasman.2011.12.002
   Pham VA, 2009, ADV MATER RES-SWITZ, V71-73, P661, DOI 10.4028/www.scientific.net/AMR.71-73.661
   Pradhan JK, 2012, WASTE MANAGE RES, V30, P1151, DOI 10.1177/0734242X12437565
   Priya A, 2018, HYDROMETALLURGY, V177, P132, DOI 10.1016/j.hydromet.2018.03.005
   Priya A, 2017, ENVIRON SCI POLLUT R, V24, P6989, DOI 10.1007/s11356-016-8313-6
   Rawlings D.E., 2017, REV REASONS WHY LEPT, P5
   Rocchetti L, 2018, J CLEAN PROD, V178, P814, DOI 10.1016/j.jclepro.2018.01.076
   Rocchetti L, 2013, ENVIRON SCI TECHNOL, V47, P1581, DOI 10.1021/es302192t
   Rodrigues MLM, 2015, WASTE MANAGE, V41, P148, DOI 10.1016/j.wasman.2015.04.001
   Ruan JJ, 2018, ENVIRON INT, V118, P92, DOI 10.1016/j.envint.2018.05.038
   Shen CF, 2008, ENVIRON SCI TECHNOL, V42, P49, DOI 10.1021/es071162z
   The European Commission, 2018, 20181147 EU, P20
   Tkaczyk AH, 2018, J PHYS D APPL PHYS, V51, DOI 10.1088/1361-6463/aaba99
   TUOVINEN OH, 1971, ANTON VAN LEE J M S, V37, P489, DOI 10.1007/BF02218519
   Veit HM, 2005, WASTE MANAGE, V25, P67, DOI 10.1016/j.wasman.2004.09.009
   Vestola EA, 2010, HYDROMETALLURGY, V103, P74, DOI 10.1016/j.hydromet.2010.02.017
   Wang JW, 2009, J HAZARD MATER, V172, P1100, DOI 10.1016/j.jhazmat.2009.07.102
   Wang LL, 2018, WASTE MANAGE, V71, P411, DOI 10.1016/j.wasman.2017.10.002
   Wu WJ, 2018, BIORESOUR BIOPROCESS, V5, DOI 10.1186/s40643-018-0196-6
   Xiang Y, 2010, J HAZARD MATER, V184, P812, DOI 10.1016/j.jhazmat.2010.08.113
   Yamane LH, 2011, WASTE MANAGE, V31, P2553, DOI 10.1016/j.wasman.2011.07.006
   Yang T, 2009, HYDROMETALLURGY, V97, P29, DOI 10.1016/j.hydromet.2008.12.011
   Yang YK, 2014, J BIOTECHNOL, V173, P24, DOI 10.1016/j.jbiotec.2014.01.008
   Yuan ZH, 2019, J HAZARD MATER, V377, P284, DOI 10.1016/j.jhazmat.2019.05.051
   Yuan ZH, 2018, J HAZARD MATER, V353, P135, DOI 10.1016/j.jhazmat.2018.04.007
   Zhang LG, 2016, J CLEAN PROD, V127, P19, DOI 10.1016/j.jclepro.2016.04.004
   Zhu NW, 2011, J HAZARD MATER, V192, P614, DOI 10.1016/j.jhazmat.2011.05.062
NR 72
TC 2
Z9 2
U1 54
U2 54
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104549
DI 10.1016/j.resconrec.2019.104549
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200006
DA 2020-05-12
ER

PT J
AU Bravi, L
   Francioni, B
   Murmura, F
   Savelli, E
AF Bravi, Laura
   Francioni, Barbara
   Murmura, Federica
   Savelli, Elisabetta
TI Factors affecting household food waste among young consumers and actions
   to prevent it. A comparison among UK, Spain and Italy
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Household leftovers; Young consumers; Food consumption
ID SUPPLY CHAIN; BEHAVIOR; ATTITUDES; MANAGEMENT; CONVENIENCE; CONSUMPTION;
   GENERATION; BARRIERS; DRIVERS; LOSSES
AB Food waste is a critical issue with multiple ethical, environmental and economic consequences. The aim of this study is to investigate which factors most affect food waste and determine what actions are undertaken to prevent it at the household level. The study, while privileging a behavioural perspective, focuses on the overall consumption process, from purchasing through final food consumption, thus assuming a broad perspective. The data for this study were collected among Italian, Spanish and English populations using three public online questionnaires administered from January to September 2017. This resulted in a total of 3323 usable questionnaires referring to a sample population aged between 18 and 35 years. As for the main motivation to waste food, the research findings provide strong evidence of the importance of in-store behaviour and food management at home in reducing the frequency of food waste in all the three countries examined. As for the actions preventing food waste, the consumption of leftovers appears as a relevant determinant in minimising food waste. The findings confirm that food waste is a complex issue that requires a broad approach of analysis considering several factors simultaneously. The study also provides further insights regarding the relationship between eating outside the home and food waste, which is a topic of debate in the extant literature. Finally, the study improves the overall knowledge about actions that prevent food waste, which have previously been poorly investigated.
C1 [Bravi, Laura; Murmura, Federica; Savelli, Elisabetta] Univ Urbino Carlo Bo, Dept Econ, Soc, Polit, Via Saffi 42, I-61029 Urbino, Italy.
   [Francioni, Barbara] Dept Commun Sci Humanities & Int Studies, Cultures, Languages, Literatures,Arts,Media, Via Saffi 15, I-61029 Urbino, Italy.
RP Bravi, L (reprint author), Univ Urbino Carlo Bo, Dept Econ, Soc, Polit, Via Saffi 42, I-61029 Urbino, Italy.
EM laura.bravi@uniurb.it; barbara.francioni@uniurb.it;
   federica.murmura@uniurb.it; elisabetta.savelli@uniurb.it
RI Francioni, Barbara/I-6522-2015; Murmura, Federica/P-4102-2015
OI Francioni, Barbara/0000-0001-8782-6814; Murmura,
   Federica/0000-0001-8443-8680
CR Abdulla M, 2012, J AGRIC FOOD SYST CO, V3, P137
   Abeliotis K, 2014, WASTE MANAGE RES, V32, P237, DOI 10.1177/0734242X14521681
   Ai N., 2019, J AGR FOOD SYSTEMS C, V9, P1
   Amirudin N, 2019, RESOUR CONSERV RECY, V151, DOI 10.1016/j.resconrec.2019.05.011
   Aschemann-Witzel J, 2018, GLOBAL ENVIRON CHANG, V49, P85, DOI 10.1016/j.gloenvcha.2018.02.002
   Baker R, 2010, PUBLIC OPIN QUART, V74, P711, DOI 10.1093/poq/nfq048
   Barone AM, 2019, RESOUR CONSERV RECY, V149, P97, DOI 10.1016/j.resconrec.2019.05.037
   Bell DR, 2011, J MARKETING, V75, P31, DOI 10.1509/jmkg.75.1.31
   Beretta C, 2013, WASTE MANAGE, V33, P764, DOI 10.1016/j.wasman.2012.11.007
   Bolton LE, 2012, J CONSUM PSYCHOL, V22, P369, DOI 10.1016/j.jcps.2011.09.002
   Brook L., 2007, FOOD BEHAV CONSUMER
   Buzby JC, 2012, FOOD POLICY, V37, P561, DOI 10.1016/j.foodpol.2012.06.002
   Cappellini B., 2009, Journal of Consumer Behaviour, V8, P365, DOI 10.1002/cb.299
   Chandon P, 2006, J MARKETING, V70, P118, DOI 10.1509/jmkg.70.4.118
   Clark J, 2018, RESOUR CONSERV RECY, V130, P20, DOI 10.1016/j.resconrec.2017.11.005
   Comber R, 2013, PERS UBIQUIT COMPUT, V17, P1197, DOI 10.1007/s00779-012-0587-1
   Cristobal J, 2018, WASTE MANAGE, V72, P3, DOI 10.1016/j.wasman.2017.11.007
   Davenport ML, 2019, RESOUR CONSERV RECY, V150, DOI 10.1016/j.resconrec.2019.104440
   De Laurentiis V, 2018, WASTE MANAGE, V77, P238, DOI 10.1016/j.wasman.2018.04.001
   Di Talia E, 2019, J CLEAN PROD, V214, P166, DOI 10.1016/j.jclepro.2018.12.216
   Diaz-Mendez C, 2017, APPETITE, V119, P14, DOI 10.1016/j.appet.2017.03.047
   Diaz-Ruiz R, 2019, RESOUR CONSERV RECY, V149, P249, DOI 10.1016/j.resconrec.2019.05.031
   Djekic I, 2019, J CLEAN PROD, V229, P44, DOI 10.1016/j.jclepro.2019.04.400
   Dreyer HC, 2019, J CLEAN PROD, V210, P505, DOI 10.1016/j.jclepro.2018.11.012
   Elimelech E, 2018, WASTE MANAGE, V76, P68, DOI 10.1016/j.wasman.2018.03.031
   Ellison B, 2019, RESOUR CONSERV RECY, V144, P276, DOI 10.1016/j.resconrec.2019.01.046
   European Commission, 2015, EU ACT FOOD WAST
   Evans D, 2011, CRIT PUBLIC HEALTH, V21, P429, DOI 10.1080/09581596.2011.608797
   FAO, 2013, FOOD WAST FOOTPR IMP
   Farr-Wharton G, 2014, J CONSUM BEHAV, V13, P393, DOI 10.1002/cb.1488
   Field A., 2005, DISCOVERING STAT USI
   Food and Agriculture Organization (FAO), 2012, STAT FOOD AGR 2010 2
   Galvan AM, 2018, J COMMUN HEALTH, V43, P944, DOI 10.1007/s10900-018-0509-x
   Garrone P, 2014, FOOD POLICY, V46, P129, DOI 10.1016/j.foodpol.2014.03.014
   Girotto F, 2015, WASTE MANAGE, V45, P32, DOI 10.1016/j.wasman.2015.06.008
   Graham-Rowe E, 2014, RESOUR CONSERV RECY, V84, P15, DOI 10.1016/j.resconrec.2013.12.005
   Grainger MJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192075
   Grandhi B, 2016, J FOOD PROD MARK, V22, P471, DOI 10.1080/10454446.2014.885863
   Griffin M, 2009, AGR HUM VALUES, V26, P67, DOI 10.1007/s10460-008-9178-1
   Gustaysson J., 2011, GLOBAL FOOD LOSSES F
   Harman D., 1967, J PSYCHOL, V35, P359
   Hartikainen H, 2014, J CLEAN PROD, V73, P285, DOI 10.1016/j.jclepro.2013.09.018
   Heald G., 1987, NUTR CATERING
   Hebrok M, 2019, J CLEAN PROD, V210, P1435, DOI 10.1016/j.jclepro.2018.11.141
   Hebrok M, 2017, J CLEAN PROD, V151, P380, DOI 10.1016/j.jclepro.2017.03.069
   Hilton A., 2006, MICROBIOLOGIST, V6, P34
   HLPE, 2014, FOOD LOSS WAST CONT
   Hodge KL, 2016, ENVIRON SCI TECHNOL, V50, P8444, DOI 10.1021/acs.est.6b00893
   Hyde K. F., 2000, QUALITATIVE MARKET R, V3, P82, DOI DOI 10.1108/13522750010322089
   Jorissen J, 2015, SUSTAINABILITY-BASEL, V7, P2695, DOI 10.3390/su7032695
   Katajajuuri JM, 2014, J CLEAN PROD, V73, P322, DOI 10.1016/j.jclepro.2013.12.057
   Koivupuro HK, 2012, INT J CONSUM STUD, V36, P183, DOI 10.1111/j.1470-6431.2011.01080.x
   Kummu M, 2012, SCI TOTAL ENVIRON, V438, P477, DOI 10.1016/j.scitotenv.2012.08.092
   Lemaire A, 2019, J CLEAN PROD, V234, P1221, DOI 10.1016/j.jclepro.2019.06.226
   Leverenz D, 2019, RESOUR CONSERV RECY, V150, DOI 10.1016/j.resconrec.2019.104417
   Link MW, 2005, EPIDEMIOLOGY, V16, P701, DOI 10.1097/01.ede.0000172138.67080.7f
   Link MW, 2005, J STUD ALCOHOL, V66, P239, DOI 10.15288/jsa.2005.66.239
   Liu C, 2016, J CLEAN PROD, V133, P557, DOI 10.1016/j.jclepro.2016.06.026
   Liu JG, 2013, ENVIRON SCI TECHNOL, V47, P10137, DOI 10.1021/es401426b
   Malhotra MK, 1998, J OPER MANAG, V16, P407, DOI 10.1016/S0272-6963(98)00021-7
   Mallinson LJ, 2016, APPETITE, V103, P17, DOI 10.1016/j.appet.2016.03.017
   MARKOWSKI CA, 1990, AM STAT, V44, P322, DOI 10.2307/2684360
   Mattar L, 2018, J CLEAN PROD, V198, P1219, DOI 10.1016/j.jclepro.2018.07.085
   McCarthy B, 2017, AUSTRALAS MARK J, V25, P126, DOI 10.1016/j.ausmj.2017.04.007
   Milbrandt A, 2018, RESOUR CONSERV RECY, V137, P32, DOI 10.1016/j.resconrec.2018.05.023
   Miller CC, 2008, J BEHAV DECIS MAKING, V21, P598, DOI 10.1002/bdm.607
   Mirabella N, 2014, J CLEAN PROD, V65, P28, DOI 10.1016/j.jclepro.2013.10.051
   Mirghotbi M., 2013, J PARAMED SCI, V4, P75, DOI [10.22037/jps.v4i3.4661, DOI 10.22037/JPS.V4I3.4661]
   Mondejar-Jimenez JA, 2016, J CLEAN PROD, V138, P8, DOI 10.1016/j.jclepro.2016.06.018
   Monier V., 2011, PREPARATORY STUDY FO
   Muriana C, 2017, WASTE MANAGE, V68, P557, DOI 10.1016/j.wasman.2017.06.047
   Nunnally JC, 2004, PSYCHOMETRIC THEORY
   Ozcicek-Dolekoglu C, 2019, FRESEN ENVIRON BULL, V28, P156
   Papargyropoulou E, 2014, J CLEAN PROD, V76, P106, DOI 10.1016/j.jclepro.2014.04.020
   Parfitt J, 2010, PHILOS T R SOC B, V365, P3065, DOI 10.1098/rstb.2010.0126
   Parizeau K, 2015, WASTE MANAGE, V35, P207, DOI 10.1016/j.wasman.2014.09.019
   Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9010.88.5.879
   Ponis ST, 2017, J CLEAN PROD, V149, P1268, DOI 10.1016/j.jclepro.2017.02.165
   Porpino G, 2015, INT J CONSUM STUD, V39, P619, DOI 10.1111/ijcs.12207
   Principato L, 2015, BRIT FOOD J, V117, P731, DOI 10.1108/BFJ-10-2013-0314
   Quested T., 2009, HOUSEHOLD FOOD DRINK
   Quested TE, 2013, RESOUR CONSERV RECY, V79, P43, DOI 10.1016/j.resconrec.2013.04.011
   Quested TE, 2011, NUTR BULL, V36, P460, DOI 10.1111/j.1467-3010.2011.01924.x
   Quinn EL, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.170377
   Rajan J, 2018, J HUNGER ENVIRON NUT, V13, P573, DOI 10.1080/19320248.2017.1374900
   Reynolds CJ, 2014, WASTE MANAGE RES, V32, DOI 10.1177/0734242X14549797
   Richter B, 2017, RESOUR CONSERV RECY, V125, P181, DOI 10.1016/j.resconrec.2017.06.006
   Romani S, 2018, APPETITE, V121, P215, DOI 10.1016/j.appet.2017.11.093
   Roodhuyzen DMA, 2017, TRENDS FOOD SCI TECH, V68, P37, DOI 10.1016/j.tifs.2017.07.009
   Santos J.R.A., 1999, J EXTENSION, V37, P1, DOI DOI 10.1080/09500690802187025
   Schanes K, 2018, J CLEAN PROD, V182, P978, DOI 10.1016/j.jclepro.2018.02.030
   Scholliers P, 2015, APPETITE, V94, P2, DOI 10.1016/j.appet.2015.02.017
   Schott ABS, 2015, J ENVIRON MANAGE, V147, P219, DOI 10.1016/j.jenvman.2014.07.048
   Shaw Peter J., 2018, Recycling, V3, DOI 10.3390/recycling3020024
   Silvennoinen K, 2014, BRIT FOOD J, V116, P1058, DOI 10.1108/BFJ-12-2012-0311
   Stancu V, 2016, APPETITE, V96, P7, DOI 10.1016/j.appet.2015.08.025
   Stangherlin ID, 2018, BRIT FOOD J, V120, P2364, DOI 10.1108/BFJ-12-2017-0726
   Stapleton S.R., 2018, ED DIMENSIONS SCH LU
   Stefan V, 2013, FOOD QUAL PREFER, V28, P375, DOI 10.1016/j.foodqual.2012.11.001
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   Vanham D, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/8/084008
   Venkat K., 2011, International Journal on Food System Dynamics, V2, P431
   Vermeir I, 2006, J AGR ENVIRON ETHIC, V19, P169, DOI 10.1007/s10806-005-5485-3
   Visschers VHM, 2016, J ENVIRON PSYCHOL, V45, P66, DOI 10.1016/j.jenvp.2015.11.007
   Wansink B, 2018, J FOOD PROD MARK, V24, P500, DOI 10.1080/10454446.2018.1472694
   Warde A., 2000, EATING OUT SOCIAL DI
   Watson M, 2012, SOCIOL REV, V60, P102, DOI 10.1111/1467-954X.12040
   Whitton C, 2011, BRIT J NUTR, V106, P1899, DOI 10.1017/S0007114511002340
   Wikstrom F, 2019, SUSTAINABILITY-BASEL, V11, DOI 10.3390/su11092641
   Williams H, 2012, J CLEAN PROD, V24, P141, DOI 10.1016/j.jclepro.2011.11.044
   WRAP, 2008, THE FOOD WE WAST
   WRAP, 2007, UND FOOD WAST
   Wrap-Waste and Resources Action Programme, 2013, OV WAST UK HOSP FOOD
   Zepeda L, 2017, INT J CONSUM STUD, V41, P627, DOI 10.1111/ijcs.12376
   Zmud J, 2013, TRANSPORT SURVEY METHODS: BEST PRACTICE FOR DECISION MAKING, P1
NR 115
TC 2
Z9 2
U1 30
U2 30
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104586
DI 10.1016/j.resconrec.2019.104586
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200023
DA 2020-05-12
ER

PT J
AU Cui, JY
   Zhu, NW
   Li, Y
   Luo, DL
   Wu, PX
   Dang, Z
AF Cui, Jiaying
   Zhu, Nengwu
   Li, Yao
   Luo, Deliang
   Wu, Pingxiao
   Dang, Zhi
TI Rapid and green process for valuable materials recovery from waste
   liquid crystal displays
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Waste LCDs; Materials recovery; Indium; Aspergillus niger; Leaching;
   Optimization
ID INDIUM-TIN OXIDE; ASPERGILLUS-NIGER; LCD PANELS; RECYCLING INDIUM;
   VACUUM PYROLYSIS; METALS; ACID; ENHANCEMENT; EFFICIENCY; RESOURCES
AB The current researches on the recycling of waste liquid crystal displays (LCDs) are hard to widely industrialize that require low-cost, rapid and green technologies. In this study, we shortened the acetone soaking time from at least 20 h to 30 min to separate polarizer. In addition, indium bioleaching using Aspergillus niger (A. niger) was firstly explored. The efficiency of indium bioleaching from fermentation broth could reach 100% within 90 min at 70 degrees C, and the glass residues could be reused. Oxalic acid showed excellent abilities on indium bioleaching process according to the analysis of Fourier transform infrared spectroscopy and kinetics. Furthermore, the leaching parameters of low-concentration oxalic acid solution were optimized using response surface method to improve the powder dosage from 10 to 150 g/L. Therefore, this research promoted bioleaching technology development using A. niger and formed a sustainable process in industry for the recovery of valuable materials from waste LCDs.
C1 [Cui, Jiaying; Zhu, Nengwu; Li, Yao; Luo, Deliang; Wu, Pingxiao; Dang, Zhi] South China Univ Technol, Guangzhou Higher Educ Mega Ctr, Sch Environm & Energy, Guangzhou 510006, Guangdong, Peoples R China.
   [Cui, Jiaying] Duke Univ, Dept Mech Engn & Mat Sci, 101 Sci Dr, Durham, NC 27708 USA.
   [Zhu, Nengwu; Wu, Pingxiao; Dang, Zhi] Minist Educ, Guangzhou Higher Educ Mega Ctr, Key Lab Pollut Control & Ecosyst Restorat Ind Clu, Guangzhou 510006, Guangdong, Peoples R China.
   [Zhu, Nengwu] Guangzhou Higher Educ Mega Ctr, Guangdong Environm Protect Key Lab Solid Waste Tr, Guangzhou 510006, Guangdong, Peoples R China.
RP Zhu, NW (reprint author), South China Univ Technol, Guangzhou Higher Educ Mega Ctr, Sch Environm & Energy, Guangzhou 510006, Guangdong, Peoples R China.
EM nwzhu@scut.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51178191]; Program for New Century Excellent
   Talents in UniversityProgram for New Century Excellent Talents in
   University (NCET) [NCET-11-0166]; Guangdong Science and Technology
   Project [2017A020216013]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [2017PY012]; Guangzhou Science and Technology Project [201604020055];
   China Scholarship CouncilChina Scholarship Council; Duke University
FX The authors would like to thank South China University of Technology for
   providing equipment to perform this research. The work was supported by
   National Natural Science Foundation of China (51178191), Program for New
   Century Excellent Talents in University (NCET-11-0166) and Guangdong
   Science and Technology Project (2017A020216013), the Fundamental
   Research Funds for the Central Universities (2017PY012) and Guangzhou
   Science and Technology Project (201604020055). Besides, the financial
   support to Jiaying Cui from China Scholarship Council and Duke
   University is also appreciated. The authors thank Dr. Xuan Hu for
   editorial help.
CR Abdel-Rahman MA, 2013, BIOTECHNOL ADV, V31, P877, DOI 10.1016/j.biotechadv.2013.04.002
   Amato A, 2018, J ENVIRON MANAGE, V225, P1, DOI 10.1016/j.jenvman.2018.07.035
   Assefi M, 2018, J CLEAN PROD, V180, P814, DOI 10.1016/j.jclepro.2018.01.165
   Bahaloo-Horeh N, 2018, J CLEAN PROD, V197, P1546, DOI 10.1016/j.jclepro.2018.06.299
   Boundy T, 2018, MINERAL MET MAT SER, P297, DOI 10.1007/978-3-319-72362-4_26
   Candelise C, 2011, RENEW SUST ENERG REV, V15, P4972, DOI 10.1016/j.rser.2011.06.012
   Chen Y, 2017, J HAZARD MATER, V327, P55, DOI 10.1016/j.jhazmat.2016.12.026
   Choi D, 2014, RSC ADV, V4, P50975, DOI 10.1039/c4ra11085d
   Cui JY, 2019, ACS SUSTAIN CHEM ENG, V7, P3849, DOI 10.1021/acssuschemeng.8b04756
   Dacera DD, 2009, J HAZARD MATER, V167, P866, DOI 10.1016/j.jhazmat.2009.01.064
   Dodbiba G, 2012, WASTE MANAGE, V32, P1937, DOI 10.1016/j.wasman.2012.05.016
   Frohlich P, 2017, ANGEW CHEM INT EDIT, V56, P2544, DOI 10.1002/anie.201605417
   Frost RL, 2011, J RAMAN SPECTROSC, V42, P1690, DOI 10.1002/jrs.2917
   He YX, 2014, J HAZARD MATER, V268, P185, DOI 10.1016/j.jhazmat.2014.01.011
   Heydarian A, 2018, J POWER SOURCES, V378, P19, DOI 10.1016/j.jpowsour.2017.12.009
   Hong HS, 2018, J MATER CYCLES WASTE, V20, P2054, DOI 10.1007/s10163-018-0758-x
   Jowkar MJ, 2018, J CLEAN PROD, V180, P417, DOI 10.1016/j.jclepro.2018.01.136
   Lee CH, 2013, WASTE MANAGE, V33, P730, DOI 10.1016/j.wasman.2012.10.002
   Li CX, 2018, DESALIN WATER TREAT, V130, P44, DOI 10.5004/dwt.2018.22974
   Li F, 2015, J HAZARD MATER, V299, P103, DOI 10.1016/j.jhazmat.2015.06.015
   Li JH, 2009, WASTE MANAGE, V29, P2033, DOI 10.1016/j.wasman.2008.12.013
   Lu F, 2016, BIORESOURCE TECHNOL, V220, P433, DOI 10.1016/j.biortech.2016.08.062
   Lu RX, 2012, J HAZARD MATER, V243, P311, DOI 10.1016/j.jhazmat.2012.10.035
   Lyoo WS, 2001, POLYM TEST, V20, P503, DOI 10.1016/S0142-9418(00)00065-9
   Ma E, 2012, GREEN CHEM, V14, P3395, DOI 10.1039/c2gc36241d
   Park KS, 2009, THERMOCHIM ACTA, V493, P105, DOI 10.1016/j.tca.2009.03.003
   Rasoulnia P, 2016, BIORESOURCE TECHNOL, V216, P729, DOI 10.1016/j.biortech.2016.05.114
   Reck BK, 2012, SCIENCE, V337, P690, DOI 10.1126/science.1217501
   Savvilotidou V, 2015, WASTE MANAGE, V45, P314, DOI 10.1016/j.wasman.2015.05.025
   Silveira AVM, 2015, WASTE MANAGE, V45, P334, DOI 10.1016/j.wasman.2015.04.007
   Souada M, 2018, ULTRASON SONOCHEM, V40, P929, DOI 10.1016/j.ultsonch.2017.08.043
   Teng Q, 2018, COLLOID SURFACE A, V544, P60, DOI 10.1016/j.colsurfa.2018.02.022
   Thiebaud E, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10082658
   Vakilchap F, 2016, BIORESOURCE TECHNOL, V218, P991, DOI 10.1016/j.biortech.2016.07.059
   Wang HY, 2014, CONSTR BUILD MATER, V50, P664, DOI 10.1016/j.conbuildmat.2013.09.015
   Wang S, 2018, J CLEAN PROD, V189, P464, DOI 10.1016/j.jclepro.2018.04.096
   Wang XY, 2013, J HAZARD MATER, V244, P342, DOI 10.1016/j.jhazmat.2012.11.059
   Werner TT, 2015, T I MIN METALL B, V124, P213, DOI 10.1179/1743275815Y.0000000007
   Willner J, 2018, PHYSICOCHEM PROBL MI, V54, P639, DOI 10.5277/ppmp1878
   Yoshida H, 2015, J SUPERCRIT FLUID, V104, P40, DOI 10.1016/j.supflu.2015.05.016
   You H, 2012, J MEMBRANE SCI, V394, P241, DOI 10.1016/j.memsci.2011.12.047
   Zeng XL, 2015, ACS SUSTAIN CHEM ENG, V3, P1306, DOI 10.1021/acssuschemeng.5b00020
   Zhang KH, 2017, WASTE MANAGE, V64, P236, DOI 10.1016/j.wasman.2017.03.031
   Zhang KH, 2015, RESOUR CONSERV RECY, V104, P276, DOI 10.1016/j.resconrec.2015.07.015
   Zhang LG, 2018, ACS SUSTAIN CHEM ENG, V6, P541, DOI 10.1021/acssuschemeng.7b02828
   Zhang LG, 2017, ACS SUSTAIN CHEM ENG, V5, P8918, DOI 10.1021/acssuschemeng.7b01737
   Zhang LG, 2017, J CLEAN PROD, V162, P1472, DOI 10.1016/j.jclepro.2017.06.159
   Zhao K, 2013, INT J PRECIS ENG MAN, V14, P1043, DOI 10.1007/s12541-013-0140-9
NR 48
TC 0
Z9 0
U1 22
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104544
DI 10.1016/j.resconrec.2019.104544
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200008
DA 2020-05-12
ER

PT J
AU Dev, NK
   Shankar, R
   Qaiser, FH
AF Dev, Navin K.
   Shankar, Ravi
   Qaiser, Fahham Hasan
TI Industry 4.0 and circular economy: Operational excellence for
   sustainable reverse supply chain performance
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Operations excellence; Sustainable reverse supply chain; Industry 4.0;
   Circular economy; ReSOLVE model; Family-based scheduling
ID FUTURE; MANAGEMENT; LOGISTICS; DESIGN; CHALLENGES; STRATEGIES;
   INVENTORY; CONSUMER; SYSTEMS; IMPACT
AB The present research proposes a roadmap to the excellence of operations for sustainable reverse supply chain/logistics by the joint implementation of principles of Industry 4.0 (I4.0) and ReSOLVE model of circular economy (CE) approaches. The connection between I4.0 and CE is unveiled by addressing the case-based model affecting the economic and environmental performances imparting two important dimensions: (i) the information sharing with the reverse logistics system is in real-time mode, and (ii) diffusion of green product in the market. The effectiveness of the virtual world in I4.0 environment is explored using simulation of reverse logistics model involving operations such as inventory and production planning policy, family-based dispatching rules of remanufacturing, and additive manufacturing. The remanufacturing model examines the trade-off between set-up delays and the availability of green transportation. For managerial insights, Taguchi experimental design framework has been used for the analysis. Based on the trade-off analysis between environmental and economic performances, the findings of the paper suggest appropriate combinations of information-sharing and family-based dispatching rules. Further, the findings suggest that, given the I4.0 and circular capabilities, it is necessary to focus on the cost of the socially influenced operations involving factors such as collection investment and size of the end-user market that governs the product returns. Therefore, in the present paper, the integration of I4.0 and CE represents a real-time decision model for the sustainable reverse logistics system.
C1 [Dev, Navin K.] Dayalbagh Educ Inst, Dept Mech Engn, Agra, Uttar Pradesh, India.
   [Shankar, Ravi] Indian Inst Technol Delhi, Dept Management Studies, New Delhi, India.
   [Qaiser, Fahham Hasan] Nottingham Trent Univ, Nottingham Business Sch, Nottingham, England.
RP Dev, NK (reprint author), Dayalbagh Educ Inst, Dept Mech Engn, Agra, Uttar Pradesh, India.
EM navinkumardev@yahoo.com; ravi1@dms.iitd.ac.in; fahham.qaiser@ntu.ac.uk
FU University Grant Commission, New Delhi, India under UGC-UKIERI Joint
   Research Programme (UKIERI-III) [F.184-11/2017(IC)]
FX One of the co-authors of this paper would like to acknowledge the
   funding support received through University Grant Commission, New Delhi,
   India. Grant No.: F.184-11/2017(IC) under UGC-UKIERI Joint Research
   Programme (UKIERI-III) on a research project on "Advance Analytics for
   Green and Resilient Supply Chain Decision Making".
CR Abdul-Rashid SH, 2017, INT J OPER PROD MAN, V37, P182, DOI 10.1108/IJOPM-04-2015-0223
   Ahmadov Y, 2018, ANN OPER RES, V270, P5, DOI 10.1007/s10479-016-2304-3
   Akcali E, 2011, INT J PROD RES, V49, P2373, DOI 10.1080/00207541003692021
   Alayon C, 2017, J CLEAN PROD, V141, P693, DOI 10.1016/j.jclepro.2016.09.079
   AMEYA Logistics, 2019, CONT FREIGHT STAT TA
   Amini M, 2015, INT J PROD RES, V53, P5669, DOI 10.1080/00207543.2015.1058537
   APM Terminals, 2019, APM TERM PIP
   Atasu A, 2008, PROD OPER MANAG, V17, P483, DOI 10.3401/poms.1080.0051
   BASS FM, 1969, MANAGE SCI, V15, P215, DOI 10.1287/mnsc.15.5.215
   Bektat T., 2007, BRIEF OVERVIEW INTER
   Chukwuekwe D. O, 2016, P EFNMS EUR MAINT C
   Chunyang Yu, 2015, Manufacturing Letters, V6, P5, DOI 10.1016/j.mfglet.2015.11.005
   CONCOR, 2017, CONT CORP IND
   Department of Transport, 2017, TECH REP
   Despeisse M, 2017, TECHNOL FORECAST SOC, V115, P75, DOI 10.1016/j.techfore.2016.09.021
   Dev N.K., 2019, INT J PROD ECON, DOI [10.1016/j.ijpe.2019.107519, DOI 10.1016/J.IJPE.2019.107519]
   Dev NK, 2017, INT J PROD ECON, V183, P345, DOI 10.1016/j.ijpe.2016.06.017
   Dev NK, 2014, COMPUT IND ENG, V78, P1, DOI 10.1016/j.cie.2014.09.017
   Dubey R, 2017, J CLEAN PROD, V142, P1119, DOI 10.1016/j.jclepro.2016.03.117
   ELKINGTON J, 1994, CALIF MANAGE REV, V36, P90, DOI 10.2307/41165746
   Fettermann DC, 2018, J IND PROD ENG, V35, P255, DOI 10.1080/21681015.2018.1462863
   Flapper SDP, 2002, PROD PLAN CONTROL, V13, P26, DOI 10.1080/09537280110061548
   Ford S, 2016, J CLEAN PROD, V137, P1573, DOI 10.1016/j.jclepro.2016.04.150
   Ganzha M, 2017, J NETW COMPUT APPL, V81, P111, DOI 10.1016/j.jnca.2016.08.007
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Gonzalez-Benito J, 2006, BUSINESS STRATEGY EN, V15, P87, DOI DOI 10.1002/BSE.450
   Guarnieri P, 2016, J CLEAN PROD, V133, P1105, DOI 10.1016/j.jclepro.2016.06.025
   Guide VDR, 2000, J OPER MANAG, V18, P467, DOI 10.1016/S0272-6963(00)00034-6
   Gunasekaran A, 2014, J OPER RES SOC, V65, P801, DOI 10.1057/jors.2014.26
   Gunasekaran A, 2014, J OPER RES SOC, V65, P806, DOI 10.1057/jors.2013.171
   Hermann M, 2016, P ANN HICSS, P3928, DOI 10.1109/HICSS.2016.488
   Hofmann E, 2017, COMPUT IND, V89, P23, DOI 10.1016/j.compind.2017.04.002
   Holmstrom J, 2012, OPER MANAGE RES, V5, P37, DOI 10.1007/s12063-011-0060-8
   Huang SH, 2013, INT J ADV MANUF TECH, V67, P1191, DOI 10.1007/s00170-012-4558-5
   Jabbour CJC, 2019, TECHNOL FORECAST SOC, V144, P546, DOI 10.1016/j.techfore.2017.09.010
   Jakhar SK, 2018, RESOUR CONSERV RECY, V139, P262, DOI 10.1016/j.resconrec.2018.08.019
   Kagennann H., 2011, IND 4 0 INTERNET THI
   Karmeshu Baliga P., 2011, TECHNOL OPER MANAGE, V2, P90
   Kenandy, 2019, CLOUD ERP EV GUID MA
   Kim HJ, 2007, INT J PROD RES, V45, P4465, DOI 10.1080/00207540701440097
   Kirchherr J, 2018, ECOL ECON, V150, P264, DOI 10.1016/j.ecolecon.2018.04.028
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Kleindorfer PR, 2005, PROD OPER MANAG, V14, P482
   Jabbour ABLD, 2018, ANN OPER RES, V270, P273, DOI 10.1007/s10479-018-2772-8
   Luthra S, 2018, PROCESS SAF ENVIRON, V117, P168, DOI 10.1016/j.psep.2018.04.018
   Luthra S, 2018, RESOUR CONSERV RECY, V138, P194, DOI 10.1016/j.resconrec.2018.07.005
   MacArthur D.E., 2015, GROWTH CIRCULAR EC V
   Mangla S. K, 2019, RESOUR CONSERV RECY, V142, P277, DOI DOI 10.1016/J.RESCONREC.2018.11.014
   Matsumoto M, 2016, INT J PR ENG MAN-GT, V3, P129, DOI 10.1007/s40684-016-0016-4
   McDowall W, 2017, J IND ECOL, V21, P651, DOI 10.1111/jiec.12597
   Nomden G, 2008, INT J PROD RES, V46, P73, DOI 10.1080/00207540500517749
   Olson EL, 2013, J PROD INNOVAT MANAG, V30, P782, DOI 10.1111/jpim.12022
   Park D, 2012, INT J URBAN SCI, V16, P85, DOI 10.1080/12265934.2012.668322
   Paul D, 2014, OMICS IN CLINICAL PRACTICE: GENOMICS, PHARMACOGENOMICS, PROTEOMICS, AND TRANSCRIPTOMICS IN CLINICAL RESEARCH, P381, DOI 10.1155/2013/783131
   Pingyu Jiang, 2016, Manufacturing Letters, V7, P15, DOI 10.1016/j.mfglet.2015.12.002
   Pour M.A., 2017, INT J SYST SC OPER L, V6, P1
   Qu Y, 2016, NETW SPAT ECON, V16, P303, DOI 10.1007/s11067-014-9227-9
   Reike D, 2018, RESOUR CONSERV RECY, V135, P246, DOI 10.1016/j.resconrec.2017.08.027
   Rogers EM, 2003, DIFFUSION INNOVATION
   Rymaszewska A, 2017, INT J PROD ECON, V192, P92, DOI 10.1016/j.ijpe.2017.02.016
   Savaskan RC, 2006, MANAGE SCI, V52, P1, DOI 10.1287/mnsc.1050.0454
   Schramm ME, 2010, DECIS SUPPORT SYST, V50, P234, DOI 10.1016/j.dss.2010.08.004
   Sehnem S, 2019, RESOUR CONSERV RECY, V149, P236, DOI 10.1016/j.resconrec.2019.05.021
   Singh A, 2015, INT J PROD ECON, V164, P462, DOI 10.1016/j.ijpe.2014.09.019
   Souza GC, 2013, DECISION SCI, V44, P7, DOI 10.1111/j.1540-5915.2012.00394.x
   Stock T, 2016, PROC CIRP, V40, P536, DOI 10.1016/j.procir.2016.01.129
   Stock T, 2018, PROCESS SAF ENVIRON, V118, P254, DOI 10.1016/j.psep.2018.06.026
   Sun Y., 2012, COMMUNICATIONS MOBIL, V1, P1, DOI DOI 10.1186/2192-1121-1-4
   Tibben-Lembke R.S., 2002, SUPPLY CHAIN MANAG, V7, P271, DOI DOI 10.1108/13598540210447719
   Tortorella GL, 2018, INT J PROD RES, V56, P2975, DOI 10.1080/00207543.2017.1391420
   Urbinati A, 2017, J CLEAN PROD, V168, P487, DOI 10.1016/j.jclepro.2017.09.047
   Vanderroost M, 2017, COMPUT IND, V87, P15, DOI 10.1016/j.compind.2017.01.004
   Wagner M., 2003, Greener Management International, P5
   Wagner M., 2001, GREENER MANAGEMENT I, V34, P94, DOI DOI 10.9774/GLEAF.3062.2001.su.00009
   Wang WY, 2017, INT J PROD ECON, V183, P551, DOI 10.1016/j.ijpe.2016.06.010
   Wei S., 2015, J REMANUFACTURING, V5, P1
   Zhao SL, 2017, ANN OPER RES, V257, P661, DOI 10.1007/s10479-015-2021-3
   Zhong RY, 2017, ENGINEERING, V3, P616, DOI 10.1016/J.ENG.2017.05.015
NR 78
TC 1
Z9 1
U1 84
U2 84
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104583
DI 10.1016/j.resconrec.2019.104583
PG 15
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200024
DA 2020-05-12
ER

PT J
AU Ertz, M
   Patrick, K
AF Ertz, Myriam
   Patrick, Kubiat
TI The future of sustainable healthcare: Extending product lifecycles
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Sustainable healthcare; Product lifetime; Product lifetime extension;
   Business model; Third-Party contractors; Medical waste
ID CIRCULAR ECONOMY; BUSINESS MODELS; DESIGN STRATEGIES; CONSUMPTION;
   EXPERIENCES; EXTENSION; TAXONOMY; IMPACT
AB The business model theory has been applied across a variety of contexts and especially in order to develop more sustainable organizations. Given the rise in municipal solid waste emanating from healthcare institutions' disposition of durable or semidurable products, and the ensuing challenges arising both in the environmental and in the social realms, product lifetime extension constitutes a valuable approach to curb product disposition and contribute to sustainability. This paper explores product lifetime extension opportunities among healthcare institutions' third-party contractors who are in charge of supplying and maintaining products in the medical sector. Product lifetime extension business models involve either nature strategies that improve product durability through improved design or nurture strategies that prolong product lifetime while in use and as long as the product remains functional. The paper uses a case study approach to investigate organizations articulating product lifetimes extension in their business model blueprint. The business models are analyzed and compared to gain useful insights that will contribute to develop professional practice, future research as well as policy making and decision making that is focused on achieving through product lifetime extension.
C1 [Ertz, Myriam; Patrick, Kubiat] Univ Quebec Chicoutimi, LaboNFC, 555 Blvd Univ, Chicoutimi, PQ G7H 2B1, Canada.
RP Ertz, M (reprint author), Univ Quebec Chicoutimi, LaboNFC, 555 Blvd Univ, Chicoutimi, PQ G7H 2B1, Canada.
EM Myriam_Ertz@uqac.ca
OI Ertz, Myriam/0000-0001-9959-2779
FU Fonds de recherche du Quebec -Societe et culture (FRQSC)
   [2020-NP-267004]
FX Fonds de recherche du Quebec -Societe et culture (FRQSC) Grant ID:
   2020-NP-267004.
CR Abouelmehdia K., 2017, J BIG DATA, V5, P1
   Bakker C., 2014, PRODUCTS LAST PRODUC
   Bakker C, 2014, J CLEAN PROD, V69, P10, DOI 10.1016/j.jclepro.2014.01.028
   Bhamra T., 2004, DESIGN MANUFACTURE S
   Bocken NMP, 2016, ENVIRON INNOV SOC TR, V18, P41, DOI 10.1016/j.eist.2015.07.010
   Bocken NMP, 2015, J IND PROD ENG, V32, P67, DOI 10.1080/21681015.2014.1000399
   BOX JMF, 1983, EUR J MARKETING, V17, P34, DOI 10.1108/EUM0000000004830
   Campion N, 2015, J CLEAN PROD, V94, P46, DOI 10.1016/j.jclepro.2015.01.076
   Cooper T., 2004, J CONSUMER POLICY, V27, P421, DOI DOI 10.1007/S10603-004-2284-6
   Cooper Tim, 2010, LONGER LASTING PRODU
   Cox J, 2013, RESOUR CONSERV RECY, V79, P21, DOI 10.1016/j.resconrec.2013.05.003
   Cramer J., 2005, BUS STRATEG ENVIRON, V14, P286, DOI DOI 10.1002/BSE.491
   den Hollander MC, 2017, J IND ECOL, V21, P517, DOI 10.1111/jiec.12610
   Despeisse M, 2017, TECHNOL FORECAST SOC, V115, P75, DOI 10.1016/j.techfore.2016.09.021
   Dyllick T, 2002, BUSINESS STRATEGY EN, V11.2, P130, DOI DOI 10.1002/BSE.323
   Eckelman M, 2012, ANESTH ANALG, V114, P1067, DOI 10.1213/ANE.0b013e31824f6959
   Eckelman MJ, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002623
   Eckelman MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157014
   Ellen MacArthur Foundation SUN McKinsey Center for Business and Environment, 2015, GROWTH CIRC EC VIS C
   Ertz M, 2019, RESOUR CONSERV RECY, V150, DOI 10.1016/j.resconrec.2019.104437
   Ertz M, 2019, J CLEAN PROD, V234, P867, DOI 10.1016/j.jclepro.2019.06.264
   Gaiardelli P, 2014, J CLEAN PROD, V66, P507, DOI 10.1016/j.jclepro.2013.11.032
   HANSON JW, 1980, J CONSUM AFF, V14, P49, DOI 10.1111/j.1745-6606.1980.tb00652.x
   HARRELL GD, 1992, J CONSUM AFF, V26, P397, DOI 10.1111/j.1745-6606.1992.tb00034.x
   Hartmann PM, 2016, INT J OPER PROD MAN, V36, P1382, DOI 10.1108/IJOPM-02-2014-0098
   Kagawa S, 2006, ECOL ECON, V58, P108, DOI 10.1016/j.ecolecon.2005.06.003
   Kaiser B., 2001, SOLUTIONS HLTH CARE, DOI [10.1289/ehp.01109205, DOI 10.1289/EHP.01109205]
   Kane GM, 2018, RESOUR CONSERV RECY, V135, P38, DOI 10.1016/j.resconrec.2017.07.030
   Karlsson M, 2005, J CLEAN PROD, V13, P1071, DOI 10.1016/j.jclepro.2004.12.012
   Lewandowski M, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8010043
   Maldini I, 2019, J CLEAN PROD, V210, P1414, DOI 10.1016/j.jclepro.2018.11.056
   Malik A, 2018, LANCET PLANET HEALTH, V2, pE27, DOI 10.1016/S2542-5196(17)30180-8
   Martin D., 2012, SUSTAINABLE MARKETIN
   Mont OK, 2002, J CLEAN PROD, V10, P237, DOI 10.1016/S0959-6526(01)00039-7
   Nishijima D, 2017, ENERG POLICY, V104, P340, DOI 10.1016/j.enpol.2017.01.045
   Nosratabadi S, 2019, SUSTAINABILITY-BASEL, V11, DOI 10.3390/su11061663
   Nussholz JLK, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9101810
   Osterwalder A., 2010, BUSINESS MODEL GENER
   Patton M.Q., 2002, QUALITATIVE RES EVAL
   Prahalad CK, 2004, J INTERACT MARK, V18, P5, DOI 10.1002/dir.20015
   Saghbini J., 2016, SUPPLY CHAIN STRATEG
   Smith J, 2013, AM J TRANSPLANT, V13, P37
   Tran L., 2016, PROJECT MANAGEMENT L
   Tukker A., 2004, BUSINESS STRATEGY EN, V13, P246, DOI DOI 10.1002/BSE.414
   Tunn VSC, 2019, J CLEAN PROD, V212, P324, DOI 10.1016/j.jclepro.2018.11.290
   United Nations, 2017, WORLD POP AG
   Van Nes N., 2003, J SUSTAIN PROD DES, V3, P101, DOI DOI 10.1007/S10970-005-2144-8
   van Nes N, 2006, J CLEAN PROD, V14, P1307, DOI 10.1016/j.jclepro.2005.04.006
   Wilhelm W.B., 2012, INT J BUS SOC SCI, V3, P17
   Young W., 2006, BUSINESS STRATEGY EN, V15, P402, DOI DOI 10.1002/BSE.510
   Zhang KS, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00221
   Zhong S, 2018, RESOUR CONSERV RECY, V128, P48, DOI 10.1016/j.resconrec.2017.09.023
NR 52
TC 0
Z9 0
U1 26
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104589
DI 10.1016/j.resconrec.2019.104589
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200021
DA 2020-05-12
ER

PT J
AU Gorman, M
   Dzombak, D
AF Gorman, Miranda
   Dzombak, David
TI Stocks and flows of copper in the US: Analysis of circularity 1970-2015
   and potential for increased recovery
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Material flow analysis; Circular economy; Copper; Non-fuel minerals;
   Stocks and flow analysis; Sustainable resource management
ID UNITED-STATES; CHINA; FUTURE
AB An analysis of the copper life cycle in the U.S. was performed to investigate the circularity of copper from 1970 to 2015. A stocks and flows model for copper was developed for the major life cycle phases by collecting extensive primary data from government and private sector sources, via available data and surveys and interviews with individuals within companies, government, and other organizations. The data were integrated into a stocks and flows model. Collection and inclusion of primary end-of-life data into the model represents a contribution of the material flow analysis presented and provides insight into specific limitations and opportunities for improving the circularity of copper. The analysis incorporates 45 years of data, providing historical context and insight into changing trends. A number of key findings emerged from of the stocks and flows analysis. First, end-of-life collection is a complicated ecosystem. The largest stock accumulation of copper is in the use phase-on the order of 72 million tons since 1970. Over half of this is in buildings and construction, an order of magnitude more than the total accumulation in any other part of the copper life cycle. The analysis also revealed that while there are losses of copper via process losses, degradation, and tailings generation, exports (much of which are unaccounted for as embedded flows) and hibernating stock are much more significant losses from the U.S. circular economy. Finally, building and construction and electric/electronic products are the two use phases where improved collection and recycling would yield the most impact to improving circularity of copper since they together comprise more than 80% of total accumulation.
C1 [Gorman, Miranda; Dzombak, David] Carnegie Mellon Univ, Civil & Environm Engn, 119 Porter Hall,5000 Forbes Ave, Pittsburgh, PA 15213 USA.
RP Gorman, M (reprint author), Carnegie Mellon Univ, Civil & Environm Engn, 119 Porter Hall,5000 Forbes Ave, Pittsburgh, PA 15213 USA.
EM mgorman@andrew.cmu.edu
FU Steinbrenner Institute U.S. Environmental Sustainability Ph.D.
   Fellowship; Colcom Foundation; Steinbrenner Institute for Environmental
   Education and Research at Carnegie Mellon University; College of
   Engineering Dean's Fellowship; Hamerschlag University
FX This work was supported by a Steinbrenner Institute U.S. Environmental
   Sustainability Ph.D. Fellowship to Miranda Gorman. The fellowship
   program is supported by a grant from the Colcom Foundation and by the
   Steinbrenner Institute for Environmental Education and Research at
   Carnegie Mellon University. Additional support for the study was
   provided by a College of Engineering Dean's Fellowship to Miranda
   Gorman, and by the Hamerschlag University Professorship of David
   Dzombak.; The authors would like to thank Randy Castriota at ,Castriota
   Metals, Ned Eldridge at E-Loop, Phil Elbaz at Hussey Copper, Morgan
   Scott and Charles Visonhaler at EPRI, Kent Kiser previously with Scrap
   Magazine and ISRI, among others who provided useful insight and data for
   this work.
CR ALLAN R, 1995, J GEOCHEM EXPLOR, V52, P1, DOI 10.1016/0375-6742(94)00051-C
   [Anonymous], 2008, RECYCLING TODAY
   Cascadia Consulting Group, 2015, 2014 DISP FAC BAS CH
   Cascadia Consulting Group, 2016, SEATTL PUBL UT 2015
   Cencic O, 2008, J ENV ENG MANAGEMENT, V18, P5
   Chen WQ, 2012, ENVIRON SCI TECHNOL, V46, P8574, DOI 10.1021/es3010333
   Chen W, 2016, RESOUR CONSERV RECY, V111, P67, DOI 10.1016/j.resconrec.2016.04.014
   Copper Development Association, 2018, TOD COPP PLAYS CRIT
   DSM Environmental, 2017, 2016 CONSTR DEM DEBR
   Earley K., 2013, GUARDIAN
   Ellen Macarthur Foundation Grants Design, 2015, CIRC IND APPR MEAS C
   Elshkaki A, 2016, GLOBAL ENVIRON CHANG, V39, P305, DOI 10.1016/j.gloenvcha.2016.06.006
   Fisher Henry, 2008, METRO AREA CONSTRUCT
   Florida DEP: Department of Environmental Protection, 2000, C D DEBR REC STUD FI, P47
   Fu XK, 2017, RESOUR CONSERV RECY, V122, P219, DOI 10.1016/j.resconrec.2017.02.012
   Gorman MR, 2018, RESOUR CONSERV RECY, V137, P281, DOI 10.1016/j.resconrec.2018.06.001
   Graedel TE, 2004, ENVIRON SCI TECHNOL, V38, P1242, DOI 10.1021/es030433c
   Green solutions, 2000, THURST COUNT WAST CO
   Gunson AJ, 2012, J CLEAN PROD, V21, P71, DOI 10.1016/j.jclepro.2011.08.020
   Tran PH, 2016, ENVIRON SCI TECHNOL, V50, P2424, DOI 10.1021/acs.est.5b01388
   Henckens MLCM, 2014, RESOUR CONSERV RECY, V93, P1, DOI 10.1016/j.resconrec.2014.09.012
   ICA: International Copper Alliance, 2017, ICA ANN REP
   ICAO: International Civil Aviation Organization, 2016, ICAO ENV REP 2016 AV, P250, DOI [10.1016/j.jval.2012.11.010, DOI 10.1016/J.JVAL.2012.11.010]
   Johnson J, 2008, J IND ECOL, V12, P739, DOI 10.1111/j.1530-9290.2008.00092.x
   Kelly T.D., 2005, HIST STAT MINERAL MA, V140
   Krausmann F, 2009, ECOL ECON, V68, P2696, DOI 10.1016/j.ecolecon.2009.05.007
   Kuster T., 1995, NEW SOURCE SCRAP OLD
   Laurence D, 2011, J CLEAN PROD, V19, P278, DOI 10.1016/j.jclepro.2010.08.019
   Lifset RJ, 2012, SCI TOTAL ENVIRON, V417, P138, DOI 10.1016/j.scitotenv.2011.09.075
   Matos G, 1998, ANNU REV ENERG ENV, V23, P107, DOI 10.1146/annurev.energy.23.1.107
   Midwest Assistance Program, 2000, APP C MISS SOL WAST
   Miranda M., 2005, FRAMEWORK RESPONSIBL, V19
   Mosbergen D., 2018, HUFFINGTON POST, P1
   MSW Consultants, 2010, 2009 WISC STAT WID W, P112
   Nakamura S, 2014, ENVIRON SCI TECHNOL, V48, P7207, DOI 10.1021/es500820h
   Nassar NT, 2012, ENVIRON SCI TECHNOL, V46, P1071, DOI 10.1021/es203535w
   Norgate T, 2010, J CLEAN PROD, V18, P266, DOI 10.1016/j.jclepro.2009.09.020
   Northey S, 2013, J CLEAN PROD, V40, P118, DOI 10.1016/j.jclepro.2012.09.027
   Oregon Department of Environmental Quality, 2007, OR SOL WAST COMP M S
   Parchomenko A, 2019, J CLEAN PROD, V210, P200, DOI 10.1016/j.jclepro.2018.10.357
   Pennsylvania DEP, 2015, 2015 REC MAT
   Powell J.T., 2016, ENVIRON SCI TECHNOL, DOI [10.1021/acs.est6b02848, DOI 10.1021/ACS.EST6B02848]
   Reuter M.U.N.E.P., 2013, METAL RECYCLING OPPO
   Solid Waste Management Coordinating Board, 2007, MINN CONSTR DEM IND
   Spatari S, 2005, ECOL ECON, V54, P37, DOI 10.1016/j.ecolecon.2004.11.018
   Steinberger JK, 2010, ECOL ECON, V69, P1148, DOI 10.1016/j.ecolecon.2009.12.009
   U. S. Environmental Protection Agency, 2018, ADV SUST MAT MAN 201
   U.S. Geological Survey, 2019, COPP STAT INF MIN YB
   UNCTAD: United Nations Conference on Trade and Development Statistics, 2017, SHIP SCRAPP COUNTR D
   US Census Bureau, 2018, POP HOUS UN EST DAT
   US EPA, 2019, NONF MET MAT SPEC DA
   Van Passel S, 2013, J CLEAN PROD, V55, P92, DOI 10.1016/j.jclepro.2012.03.024
   Wang MX, 2017, RESOUR POLICY, V52, P235, DOI 10.1016/j.resourpol.2016.12.009
   Wang MX, 2015, RESOUR CONSERV RECY, V105, P36, DOI 10.1016/j.resconrec.2015.10.012
   Zhang L, 2015, SCI TOTAL ENVIRON, V536, P142, DOI 10.1016/j.scitotenv.2015.07.021
   Zhang L, 2014, SCI TOTAL ENVIRON, V478, P80, DOI 10.1016/j.scitotenv.2014.01.070
NR 56
TC 0
Z9 0
U1 12
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104542
DI 10.1016/j.resconrec.2019.104542
PG 15
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200004
DA 2020-05-12
ER

PT J
AU Guarnieri, P
   Cerqueira-Streit, JA
   Batista, LC
AF Guarnieri, Patricia
   Cerqueira-Streit, Jorge A.
   Batista, Luciano C.
TI Reverse logistics and the sectoral agreement of packaging industry in
   Brazil towards a transition to circular economy
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Brazilian Policy of Solid Waste; Circular economy; Recycling of
   packaging waste; Reverse logistics; Sectoral agreement of reverse
   logistics of packaging; Shared responsibility
ID SUPPLY CHAIN; WASTE MANAGEMENT
AB The objective of this article is to describe the first phase of the implementation of the Sectoral Agreement of Reverse Logistics of Packaging in Brazil, from the perspective of the transition to the circular economy. For this purpose, a case study was carried out, considering as analysis unit the Brazilian sectoral agreement of reverse logistics of packaging. The data collection was conducted through documental analysis and interviews with waste pickers associations, managers in the business sector and government representatives, who are the key signatories of the agreement in focus. The results were triangulated in order to show different perspectives unveiled by the research sources and methods. The analysis of results was carried out based on content analysis proposed by Bardin (1977), in which categories were defined a priori and adjusted a posteriori. The main results show that the concept of circular economy, although not formally expressed in the Brazilian law and sectoral agreement, guides the actions developed by the signatories of the agreement. This article can serve as an input for researchers and practitioners interested in sectoral agreements in Brazil and in developing countries, as well as input for managers in the public and private sectors and other key stakeholders concerned with the implementation of reverse logistics under relevant legislations on solid waste management that reinforce transitions to the circular economy.
C1 [Guarnieri, Patricia; Cerqueira-Streit, Jorge A.] Univ Brasilia, FACE, ICC Norte, Gleba A,Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
   [Batista, Luciano C.] Aston Business Sch, Birmingham, W Midlands, England.
RP Guarnieri, P (reprint author), Univ Brasilia, FACE, ICC Norte, Gleba A,Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
EM pguarnieri@unb.br
RI Guarnieri, Patricia/F-1644-2013; Batista, Luciano/I-5497-2012
OI Guarnieri, Patricia/0000-0001-5298-5348; Cerqueira Streit, Jorge
   Alfredo/0000-0003-4963-4306; Batista, Luciano/0000-0002-0367-2975
CR Alaerts L, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10051487
   Andersen MS, 2007, SUSTAIN SCI, V2, P133, DOI 10.1007/s11625-006-0013-6
   Bardin L., 1977, CONTENT ANAL, V70
   Batista L, 2019, INT J PROD RES, V57, P7248, DOI 10.1080/00207543.2018.1558295
   Batista L, 2018, PROD PLAN CONTROL, V29, P438, DOI 10.1080/09537287.2017.1343502
   Batista L, 2018, PROD PLAN CONTROL, V29, P419, DOI 10.1080/09537287.2018.1449267
   Bouzon M, 2015, RESOUR POLICY, V46, P27, DOI 10.1016/j.resourpol.2015.02.001
   Braungart M., 2002, CORPORATE ENV STRATE, V9, P251, DOI DOI 10.1016/S1066-7938(02)00069-6
   Braungart M, 2007, J CLEAN PROD, V15, P1337, DOI 10.1016/j.jclepro.2006.08.003
   Brazilian Organization of Waste Pickers, 2013, POL NAC RES SOL PAP
   Caiado N, 2017, RESOUR CONSERV RECY, V118, P47, DOI 10.1016/j.resconrec.2016.11.021
   Cempre-Business Commitment for Recycling, 2018, TECHN REP SECT AGR R
   De Angelis R, 2018, PROD PLAN CONTROL, V29, P425, DOI 10.1080/09537287.2018.1449244
   Denzin N.K., 1994, HDB QUALITATIVE RES
   Dervojeda K., 2014, CLEAN TECHNOLOGIES C
   Domenech T, 2019, RESOUR CONSERV RECY, V141, P76, DOI 10.1016/j.resconrec.2018.09.016
   Ellen MacArthur Foundation, 2017, EC CIRC BRAS AB EXPL
   Ellen MacArthur Foundation, 2015, CIRCULAR EC BUSINESS
   Ferri GL, 2015, WASTE MANAGE, V40, P173, DOI 10.1016/j.wasman.2015.02.036
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Gibbert M, 2010, ORGAN RES METHODS, V13, P710, DOI 10.1177/1094428109351319
   Gibbert M, 2008, STRATEGIC MANAGE J, V29, P1465, DOI 10.1002/smj.722
   Guamieri P., 2016, J CLEAN PROD, V133, P1105, DOI DOI 10.1016/JJCLEPR0.2016.06.025
   Guarnieri P., 2015, LAT AM J MANAG SUSTA, V2, P19, DOI DOI 10.1504/LAJMSD.2015.067468
   Hayes AF, 2007, COMMUN METHODS MEAS, V1, P77, DOI 10.1080/19312450709336664
   Howard M, 2019, INT J PROD RES, V57, P7300, DOI 10.1080/00207543.2018.1524166
   IPEA-Institute of Applied Economics Research, 2012, PLAN NAC RES SOL DIA, P145
   Kalmykova Y, 2018, RESOUR CONSERV RECY, V135, P190, DOI 10.1016/j.resconrec.2017.10.034
   Krippendorff K., 2009, CONTENT ANAL READER, P350
   Jabbour ABLDS, 2014, CLEAN TECHNOL ENVIR, V16, P7, DOI 10.1007/s10098-013-0600-z
   Mrkajic V, 2018, RESOUR CONSERV RECY, V136, P130, DOI 10.1016/j.resconrec.2018.04.008
   Murray A, 2017, J BUS ETHICS, V140, P369, DOI 10.1007/s10551-015-2693-2
   Reike D, 2018, RESOUR CONSERV RECY, V135, P246, DOI 10.1016/j.resconrec.2017.08.027
   Ritzen S, 2017, PROC CIRP, V64, P7, DOI 10.1016/j.procir.2017.03.005
   Ryberg MW, 2019, RESOUR CONSERV RECY, V151, DOI 10.1016/j.resconrec.2019.104459
   Santos R.C.S.C., 2016, REV GESTAO INOVACAO, V2
   Silverman D., 2005, FORUM QUAL SOC RES, V6
   Singh S, 2019, RESOUR CONSERV RECY, V141, P499, DOI 10.1016/j.resconrec.2018.05.013
   SINIR-Sistema Nacional de Informacoes sobre a Gestic dos Resfduos Salidos, 2018, BRAZ SYST SOL WAST M
   Wilson MG, 2014, SYST REV, V3, DOI 10.1186/2046-4053-3-143
   Yin R. K., 2017, CASE STUDY RES APPL
   Yuan Z., 2008, J IND ECOL
   Zhang K, 2012, ENVIRON SCI TECHNOL, V46, P10861, DOI 10.1021/es303166s
NR 43
TC 1
Z9 1
U1 29
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104541
DI 10.1016/j.resconrec.2019.104541
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200015
DA 2020-05-12
ER

PT J
AU Guo, R
   Lv, S
   Liao, T
   Xi, FR
   Zhang, J
   Zuo, XT
   Cao, XJ
   Feng, Z
   Zhang, YL
AF Guo, Ru
   Lv, Shuang
   Liao, Ting
   Xi, Furong
   Zhang, Jing
   Zuo, Xiuting
   Cao, Xiaojing
   Feng, Zhi
   Zhang, Yalei
TI Classifying green technologies for sustainable innovation and investment
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Green technology; Classification; Sustainable innovation; Green
   investment; Technology transfer
ID BARRIERS; ADOPTION; IMPLEMENTATION; FRAMEWORK; SUBSIDY; GROWTH; ROLES
AB Green technology plays a fundamental role in achieving the global sustainable development goals. However, the lack of a widely accepted classification system for green technology often hinders the development and adoption of green technology. To promote and support sustainable innovation and investment, China initiated the Green Technology Bank (GTB) in 2016, establishing an online database of green technologies. To provide the standardized criterion for classifying these technologies, this study designed a three-level classification system of green technology (CSGT) through a hybrid method that integrates top-down and bottom-up approaches. The proposed CSGT divides green technologies into five major categories, including environmental quality, resource utilization, energy utilization, life health and ecological safety, with 30 secondary categories and 87 tertiary categories. The CSGT enabled the analysis of 2453 selected examples of green technologies. The results provide valuable information for decision makers and green investors to understand the development of green technologies from the perspective of different sources, sectors, application stages, and spatial distribution. The CSGT developed in this study concerns both immediate green challenges and the ultimate goals of sustainable development by integrating long-term visions and market practices, which can reflect national green strategy and local demands at the same time. The CSGT can be applied to other countries and regions to boost their green technology development and can also be used as a communication tool for multiple stakeholders such as technology investors, users, owners, governments, and the general public.
C1 [Guo, Ru; Lv, Shuang; Liao, Ting; Zhang, Jing; Cao, Xiaojing; Feng, Zhi; Zhang, Yalei] Tongji Univ, Inst Environm Planning & Management, Coll Environm Sci & Engn, Shanghai, Peoples R China.
   [Guo, Ru; Feng, Zhi; Zhang, Yalei] State Key Lab Pollut Control & Resource Reuse, Shanghai, Peoples R China.
   [Guo, Ru; Zhang, Yalei] Shanghai Inst Pollut Control & Ecol Secur, Shanghai, Peoples R China.
   [Xi, Furong; Zuo, Xiuting] Adm Ctr Green Technol Bank, Shanghai, Peoples R China.
   [Xi, Furong; Zuo, Xiuting] Shanghai Sci & Technol Exchange Ctr, Shanghai, Peoples R China.
RP Zhang, YL (reprint author), Tongji Univ, Coll Environm Sci & Engn, Shanghai, Peoples R China.
EM zhangyalei@tongji.edu.cn
FU Shanghai Pujiang ProgramShanghai Pujiang Program [17PJC098]; National
   Key R&D Program entitled Research on Green Technology Evaluation and Its
   Industrial Policy System of the Ministry of Science and Technology
   [2017YFCO212901]; Scientific Research Project entitled Research on Green
   Technology Standards and Its Evaluation System of Shanghai Science and
   Technology [16dz1206604]; Ministry of Science and Technology Reform
   Special Project entitled Key Issues of Building Market-oriented Green
   Technology Innovation System; Green Technology Bank; Shanghai Science
   and Technology Exchange Center; Key Laboratory of Cities Mitigation and
   Adaptation to Climate Change in Shanghai
FX This study was supported by the Shanghai Pujiang Program (Grant
   17PJC098), the National Key R&D Program entitled Research on Green
   Technology Evaluation and Its Industrial Policy System of the Ministry
   of Science and Technology (Grant 2017YFCO212901); the Scientific
   Research Project entitled Research on Green Technology Standards and Its
   Evaluation System of Shanghai Science and Technology (Grant
   16dz1206604); The Ministry of Science and Technology Reform Special
   Project entitled Key Issues of Building Market-oriented Green Technology
   Innovation System. Many thanks to the invaluable comments and
   suggestions from the reviewers. Moreover, many appreciations for the
   support from the Green Technology Bank, the Shanghai Science and
   Technology Exchange Center and Key Laboratory of Cities Mitigation and
   Adaptation to Climate Change in Shanghai.
CR Agyemang M, 2018, RESOUR CONSERV RECY, V136, P209, DOI 10.1016/j.resconrec.2018.04.011
   Bhandari D, 2019, RESOUR CONSERV RECY, V146, P156, DOI 10.1016/j.resconrec.2019.02.038
   BRAUN E, 1994, TECHNOL ANAL STRATEG, V6, P259, DOI 10.1080/09537329408524171
   Campiglio E, 2016, ECOL ECON, V121, P220, DOI 10.1016/j.ecolecon.2015.03.020
   Chen Q.D., 2012, J MOD INFORM, V32, P27
   Chen YN, 2018, ENERG POLICY, V116, P1, DOI 10.1016/j.enpol.2017.12.051
   Dangelico RM, 2010, J CLEAN PROD, V18, P1608, DOI 10.1016/j.jclepro.2010.07.007
   Darko A, 2018, J CLEAN PROD, V200, P687, DOI 10.1016/j.jclepro.2018.07.318
   Darko A, 2017, ENERG BUILDINGS, V144, P320, DOI 10.1016/j.enbuild.2017.03.060
   European Commission, 2014, GEN VER PROT VERS 1
   Federal Ministry for the Environment Nature Conservation Building and Nuclear Safety, 2018, GREENTECH MAD GERM 2
   Federal Ministry for the Environment Nature Conservation Building and Nuclear Safety, 2014, GREENTECH MAD GERM 4
   Fernando Y, 2019, RESOUR CONSERV RECY, V141, P8, DOI 10.1016/j.resconrec.2018.09.031
   Geddes A, 2018, ENERG POLICY, V115, P158, DOI 10.1016/j.enpol.2018.01.009
   Hansen MH, 2018, GLOBAL ENVIRON CHANG, V53, P195, DOI 10.1016/j.gloenvcha.2018.09.014
   He LY, 2019, J CLEAN PROD, V208, P363, DOI 10.1016/j.jclepro.2018.10.119
   Ishak I, 2017, ADV SCI LETT, V23, P8558, DOI 10.1166/asl.2017.9928
   Jardins Des, 2002, ENV ETHICS
   Ji Q, 2019, ENERG POLICY, V128, P114, DOI 10.1016/j.enpol.2018.12.047
   Kirchherr J, 2018, ENERG POLICY, V119, P600, DOI 10.1016/j.enpol.2018.05.001
   Lee SH, 2015, RENEW SUST ENERG REV, V50, P186, DOI 10.1016/j.rser.2015.04.158
   Li ZH, 2018, J CLEAN PROD, V187, P421, DOI 10.1016/j.jclepro.2018.03.066
   Liao XC, 2018, ENERG POLICY, V119, P554, DOI 10.1016/j.enpol.2018.05.020
   Luthra S, 2015, RENEW SUST ENERG REV, V41, P762, DOI 10.1016/j.rser.2014.08.077
   Mazzucato M, 2016, J ECON POLICY REFORM, V19, P305, DOI 10.1080/17487870.2016.1216416
   Murillo-Luna JL, 2011, J CLEAN PROD, V19, P1417, DOI 10.1016/j.jclepro.2011.05.005
   OECD, 2017, MOB BOND MARK LOW CA
   OECD, 2016, GREEN INV BANKS SCAL
   OECD, 2017, GREEN INV BANKS INN
   UNEP, 2018, TRAD ENV SOUND TECHN
   UNEP, 2012, APPL SUST ASS TECHN
   UNEP EPO, 2015, CLIM CHANG MIT TECHN
   United Nations Conference on Trade and Development (UNCTAD), 2018, TECHN INN REP 2018 H
   US Bureau of Labor Statistics, 2010, GREEN GOODS SERV IND
   USPTO, 2018, EST CONC
   van Stel A, 2005, SMALL BUS ECON, V24, P311, DOI 10.1007/s11187-005-1996-6
   Vieira LC, 2016, J CLEAN PROD, V113, P5, DOI 10.1016/j.jclepro.2015.11.034
   Wakeford JJ, 2017, J CLEAN PROD, V166, P503, DOI 10.1016/j.jclepro.2017.08.067
   Wang C, 2017, J CLEAN PROD, V148, P111, DOI 10.1016/j.jclepro.2017.01.145
   WIPO, 2019, WIPO GREEN STRAT PLA
   WIPO, 2010, WIPO GREEN INV
   Xia D, 2019, RESOUR CONSERV RECY, V143, P99, DOI 10.1016/j.resconrec.2018.12.022
   Yoshino N, 2019, ECON MODEL, V77, P34, DOI 10.1016/j.econmod.2018.11.018
   Yu HJ, 2019, J CLEAN PROD, V219, P833, DOI 10.1016/j.jclepro.2019.02.014
NR 44
TC 0
Z9 0
U1 43
U2 43
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104580
DI 10.1016/j.resconrec.2019.104580
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200016
DA 2020-05-12
ER

PT J
AU Guo, Y
   Tian, JP
   Chen, LJ
AF Guo, Yang
   Tian, Jinping
   Chen, Lyujun
TI Water-energy nexus in China's industrial parks
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Water-energy nexus; Industrial park; Life-cycle thinking; Water
   management; China
ID LIFE-CYCLE ASSESSMENT; POWER-GENERATION; WIND POWER; OPTIMIZATION;
   SYSTEM; SYNERGY; IMPACTS; REUSE; CITY
AB Industrial parks are main sites for industrial sectors and are critical clients for water and energy management. However, the water-energy nexus at the industrial park-level is still poorly understood. This study established high-resolution profiles of water use and energy consumption and their linkages in Chinese industrial parks for the first time. Based on this inventory, the water use and energy consumption of 209 Chinese national industrial parks were uncovered from a life-cycle perspective. The total water use of these parks accounted for 6% of national industrial water use, while the total energy consumption accounted for 10% of national energy consumption. Surface water and coal played an undeniably dominant role in direct water and energy structures, with a share of 95% and 74%, respectively. The water-energy nexus was then analyzed, and we observed that the indirect water use embodied in the energy sector (29% of the total water use) was much more significant than the indirect energy consumption induced by the water sector (nearly 0% of the total energy consumption). Moreover, water and energy were closely linked and positively correlated in industrial parks; energy-intensive parks generally tended to be water-intensive. Finally, water use and energy consumption in the parks toward 2020 and 2030 were targeted, according to cap and intensity controls highlighted in national strategies. The results indicated that to achieve the governing goals, water and energy should be managed jointly, particularly considering the indirect water use embodied in the energy sector.
C1 [Guo, Yang; Tian, Jinping; Chen, Lyujun] Tsinghua Univ, Sch Environm, Beijing 100084, Peoples R China.
   [Tian, Jinping; Chen, Lyujun] Tsinghua Univ, Ctr Ecol Civilizat, Beijing 100084, Peoples R China.
   [Chen, Lyujun] Tsinghua Univ, Yangtze Delta Reg Inst, Zhejiang Prov Key Lab Water Sci & Technol, Dept Environm, Jiaxing 314006, Zhejiang, Peoples R China.
RP Tian, JP (reprint author), Tsinghua Univ, Sch Environm, Beijing 100084, Peoples R China.
EM tianjp@tsinghua.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41671530]
FX The authors acknowledge the National Natural Science Foundation of China
   for its financial support through project 41671530. The authors are
   grateful to local governments of the industrial parks for their
   assistance with interviews and data collection.
CR BP, 2018, BP STAT REV WORLD EN
   Cai BM, 2014, ENVIRON SCI TECHNOL, V48, P11760, DOI 10.1021/es502655m
   Chen SQ, 2016, APPL ENERG, V184, P905, DOI 10.1016/j.apenergy.2016.03.042
   Feng K, 2014, RENEW SUST ENERG REV, V39, P342, DOI 10.1016/j.rser.2014.07.080
   Giljum S, 2015, J IND ECOL, V19, P792, DOI 10.1111/jiec.12214
   GLEICK PH, 1994, ANNU REV ENERG ENV, V19, P267, DOI 10.1146/annurev.eg.19.110194.001411
   Gu A, 2014, ENERG CONVERS MANAGE, V85, P630, DOI 10.1016/j.enconman.2014.04.054
   Gu C, 2013, ENRGY PROCED, V36, P243, DOI 10.1016/j.egypro.2013.07.028
   Guo Y, 2018, ENVIRON SCI TECHNOL, V52, P7754, DOI 10.1021/acs.est.8b00537
   Hardy L, 2012, INT J WATER RESOUR D, V28, P151, DOI 10.1080/07900627.2012.642240
   Holland RA, 2015, P NATL ACAD SCI USA, V112, pE6707, DOI 10.1073/pnas.1507701112
   Jin Y, 2017, RESOUR CONSERV RECY, V127, P206, DOI 10.1016/j.resconrec.2017.09.004
   Lee SJ, 2015, J IND ECOL, V19, P416, DOI 10.1111/jiec.12188
   Li X, 2019, APPL ENERG, V235, P827, DOI 10.1016/j.apenergy.2018.10.097
   Li X, 2012, ENERG POLICY, V45, P440, DOI 10.1016/j.enpol.2012.02.054
   Liao XW, 2016, GLOBAL ENVIRON CHANG, V41, P142, DOI 10.1016/j.gloenvcha.2016.09.007
   Lim SR, 2010, IND ENG CHEM RES, V49, P1351, DOI 10.1021/ie9014233
   MET (Ministry of Industry and Information Technology of China), 2016, STRAT IND GREEN DEV
   MILT (Ministry of Industry and Information Technology of China), 2012, UND PLAN IND TRANSF
   MWR (Ministry of Water Resources of China), 2015, WAT RES B
   National Bureau of Statistics (NBS), 2016, CHINA ENERGY STAT YB
   National Development and Reform Commission (NDRC) National Energy Administration (NEA), 2016, 13 5 YEAR PLAN EN DE
   NBS (National Bureau of Statistics of China), 2016, CHIN STAT YB
   NDRC (National Development and Reform Commission of China), 2016, REV STRAT EN PROD CO
   NDRC (National Development and Reform Commission of China), 2018, CAT CHIN IND PARKS
   Pacetti T, 2015, J CLEAN PROD, V101, P278, DOI 10.1016/j.jclepro.2015.03.084
   SC (State Council of China), 2015, MADE IN CHINA 2025
   SC (State Council of China), 2012, PROP STRICT WAT RES
   SC (State Council of China), 2017, 13 5 YEAR PLAN EN SA
   SC (State Council of China), 2018, STRENGTH ENV PROT FI
   Siddiqi A, 2011, ENERG POLICY, V39, P4529, DOI 10.1016/j.enpol.2011.04.023
   Stillwell Ashlynn S, 2010, Sustainability, V2, P945, DOI 10.3390/su2040945
   Stokes J, 2006, INT J LIFE CYCLE ASS, V11, P335, DOI 10.1065/lca2005.06.214
   Taskhiri MS, 2011, RESOUR CONSERV RECY, V55, P730, DOI 10.1016/j.resconrec.2011.03.001
   Tian JP, 2012, ENERGY, V46, P459, DOI 10.1016/j.energy.2012.08.003
   Tian XK, 2015, J COASTAL RES, P298, DOI 10.2112/SI73-052.1
   Tong L, 2013, J ENVIRON MANAGE, V129, P471, DOI 10.1016/j.jenvman.2013.08.018
   Valek AM, 2017, SCI TOTAL ENVIRON, V590, P258, DOI 10.1016/j.scitotenv.2017.02.234
   Venkatesh G, 2014, ENERGY, V75, P153, DOI 10.1016/j.energy.2014.06.111
   Walker ME, 2013, ENVIRON SCI TECHNOL, V47, P13060, DOI 10.1021/es403715z
   WB (World Bank), 2018, ANN FRESHW WITHDR CO
   Yan J, 2016, APPL ENERG, V169, P1, DOI 10.1016/j.apenergy.2016.02.010
   Zhang C, 2018, NAT ENERGY, V3, P792, DOI 10.1038/s41560-018-0236-7
   Zhang C, 2014, ENVIRON SCI TECHNOL, V48, P11082, DOI 10.1021/es5026454
   Zhang C, 2013, ENVIRON SCI TECHNOL, V47, P14459, DOI 10.1021/es402556x
   Zhu XJ, 2015, APPL ENERG, V151, P345, DOI 10.1016/j.apenergy.2015.04.082
NR 46
TC 0
Z9 0
U1 22
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104551
DI 10.1016/j.resconrec.2019.104551
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200019
DA 2020-05-12
ER

PT J
AU Helbig, C
   Thorenz, A
   Tuma, A
AF Helbig, Christoph
   Thorenz, Andrea
   Tuma, Axel
TI Quantitative assessment of dissipative losses of 18 metals
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Dissipation; Dissipative losses; Material flow analysis; Recycling;
   Criticality; Metals
ID MULTILEVEL CYCLE; FLOW-ANALYSIS; STEEL; LOST; RESOURCE; TRACKING;
   COPPER; STOCKS; FATE
AB Dissipative losses of metals are unrecoverable material flows representing the real consumption of metals. They occur during any process in the global metal cycle from primary production to waste management and have different receiving mediums. Avoiding dissipative losses can reduce both primary material requirements and potential negative environmental impacts of metals. However, there are currently no quantitative indicators available for the assessment of global dissipative losses of metals covering all processes before and after the use-phase. Here we present three indicators, the Dissipation-to-Extraction Ratio, the Dissipation-to-Final-Production Ratio, and the Expected Lifetime in the Anthroposphere. These indicators are further applied to 18 metals. The results show that the severity of dissipative losses throughout the periodic table differs a lot. Dissipation ratios are lowest for mass metals like iron, aluminum, and nickel, and highest for technology metals like gallium, germanium, and tellurium. Expected lifetimes vary between just months for metals with high dissipation ratios and up to a century for aluminum and iron. The assessment shows that there are important measures in material efficiency and recycling efforts to be taken to decrease dissipative losses for a wide range of metals. For each metal, the most effective options for action can be identified based on our results.
C1 [Helbig, Christoph; Thorenz, Andrea; Tuma, Axel] Univ Augsburg, Resource Lab, Univ Str 16, D-86159 Augsburg, Germany.
RP Helbig, C (reprint author), Univ Augsburg, Resource Lab, Univ Str 16, D-86159 Augsburg, Germany.
EM christoph.helbig@wiwi.uni-augsburg.de
OI Helbig, Christoph/0000-0001-6709-373X
CR Ayres RU, 2013, PHILOS T R SOC A, V371, DOI 10.1098/rsta.2011.0563
   Bertram M, 2017, RESOUR CONSERV RECY, V125, P48, DOI 10.1016/j.resconrec.2017.05.014
   Brunner PH, 2004, PRACTICAL HDB MAT FL
   Cencic O, 2008, ENVIROINFO 2008 ENV, V2008, P440
   Chen WQ, 2012, ENVIRON SCI TECHNOL, V46, P8574, DOI 10.1021/es3010333
   Ciacci L, 2016, ENVIRON SCI TECHNOL, V50, P11394, DOI 10.1021/acs.est.6b02714
   Ciacci L, 2015, ENVIRON SCI TECHNOL, V49, P9443, DOI 10.1021/es505515z
   Cullen JM, 2013, ENVIRON SCI TECHNOL, V47, P3057, DOI 10.1021/es304256s
   De Meester S, 2019, RESOUR CONSERV RECY, V142, P1, DOI 10.1016/j.resconrec.2018.10.015
   Du XY, 2011, SCI REP-UK, V1, DOI 10.1038/srep00145
   Gaustad G, 2012, RESOUR CONSERV RECY, V58, P79, DOI 10.1016/j.resconrec.2011.10.010
   Gloser-Chahoud S., 2017, QUANTITATIVE ANAL KR, DOI [10.21268/20170724-133145, DOI 10.21268/20170724-133145]
   Graedel TE, 2015, P NATL ACAD SCI USA, V112, P6295, DOI 10.1073/pnas.1312752110
   Harper EM, 2012, ENVIRON SCI TECHNOL, V46, P1079, DOI 10.1021/es201874e
   Helbig C., 2019, IND ECOLOGY
   Izard CF, 2010, RESOUR CONSERV RECY, V54, P1436, DOI 10.1016/j.resconrec.2010.06.008
   Johnson J, 2005, ENVIRON SCI TECHNOL, V39, P4655, DOI 10.1021/es048319x
   Johnson J, 2006, ENVIRON SCI TECHNOL, V40, P7060, DOI 10.1021/es060061i
   Kavlak G, 2013, RESOUR CONSERV RECY, V76, P21, DOI 10.1016/j.resconrec.2013.04.007
   Kavlak G, 2013, RESOUR CONSERV RECY, V73, P17, DOI 10.1016/j.resconrec.2013.01.013
   Kolotzek C, 2018, J CLEAN PROD, V176, P566, DOI 10.1016/j.jclepro.2017.12.162
   Kral U, 2013, SCI TOTAL ENVIRON, V461, P819, DOI 10.1016/j.scitotenv.2012.08.094
   Leal-Ayala DR, 2015, RESOUR CONSERV RECY, V103, P19, DOI 10.1016/j.resconrec.2015.07.003
   Licht C, 2015, J IND ECOL, V19, P890, DOI 10.1111/jiec.12287
   Lifset RJ, 2012, SCI TOTAL ENVIRON, V417, P138, DOI 10.1016/j.scitotenv.2011.09.075
   Mao JS, 2008, RESOUR CONSERV RECY, V52, P1050, DOI 10.1016/j.resconrec.2008.04.005
   Mao JS, 2009, ENVIRON POLLUT, V157, P2670, DOI 10.1016/j.envpol.2009.05.003
   Meylan G., 2015, G14AP00059 USGS
   Meylan G, 2017, RESOUR CONSERV RECY, V123, P1, DOI 10.1016/j.resconrec.2016.01.006
   Muller E, 2014, ENVIRON SCI TECHNOL, V48, P2102, DOI 10.1021/es403506a
   Myers RJ, 2019, J IND ECOL, V23, P222, DOI 10.1111/jiec.12730
   Nakamura S, 2017, ENVIRON SCI TECHNOL, V51, P9469, DOI 10.1021/acs.est.7b01683
   Nakamura S, 2014, ENVIRON SCI TECHNOL, V48, P7207, DOI 10.1021/es500820h
   Nassar NT, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1400180
   Nassar NT, 2017, RESOUR CONSERV RECY, V125, P233, DOI 10.1016/j.resconrec.2017.06.002
   Pauliuk S, 2018, RESOUR CONSERV RECY, V129, P81, DOI 10.1016/j.resconrec.2017.10.019
   Pauliuk S, 2017, RESOUR CONSERV RECY, V116, P84, DOI 10.1016/j.resconrec.2016.09.029
   Rechberger H, 2002, ECOL ECON, V42, P59, DOI 10.1016/S0921-8009(02)00102-7
   Reck BK, 2012, J IND ECOL, V16, P518, DOI 10.1111/j.1530-9290.2012.00499.x
   Reller A, 2016, CURR OPIN GREEN SUST, V1, P25, DOI 10.1016/j.cogsc.2016.08.001
   Rudnick, 2003, TREATISE GEOCHEMISTR, V3, P1, DOI DOI 10.1016/B0-08-043751-6/03016-4
   Wang T, 2007, ENVIRON SCI TECHNOL, V41, P5120, DOI 10.1021/es062761t
   Werner TT, 2018, ENVIRON SCI TECHNOL, V52, P2055, DOI 10.1021/acs.est.7b05022
   Winterstetter A, 2015, RESOUR CONSERV RECY, V96, P19, DOI 10.1016/j.resconrec.2015.01.004
   Zampori L., 2017, FEASIBILITY STUDY IM, DOI [10.2760/869503, DOI 10.2760/869503]
   Zimmermann T., 2015, CYCLES CRITICAL META
   Zimmermann T, 2017, J IND ECOL, V21, P1198, DOI 10.1111/jiec.12492
   Zimmermann T, 2013, SCI TOTAL ENVIRON, V461, P774, DOI 10.1016/j.scitotenv.2013.05.040
NR 48
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104537
DI 10.1016/j.resconrec.2019.104537
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200010
DA 2020-05-12
ER

PT J
AU Jie, T
   Wei, WD
   Jiang, L
AF Jie, Tao
   Wei, Wendong
   Jiang, Lu
TI A sustainability-oriented optimal allocation strategy of sharing
   bicycles: Evidence from ofo usage in Shanghai
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Sustainability; Allocation strategy; Data-driven approach; Sharing
   bicycle; Ofo
ID BIKE; ECONOMY; PERFORMANCE; EFFICIENCY; MANAGEMENT; RESOURCE; COST; DEA
AB Sharing bicycles is a widely recognized way to reduce resource consumption, promote green travel and improve traffic efficiency, yet the discrepancy between bicycle distribution and demand limits its impact on sustainable economic development. By employing a data-driven approach and using 10 ofo shared bicycle parking lots as the case, this paper aims to explore an optimal resource allocation strategy of sharing bicycles, including the layout of parking lots and the quantity of distributed bicycles, in order to maximize the positive effect of sharing bicycles with the goal of sustainability. The findings show that there is a large amount of redundancy in the allocation of ofo bicycles, which is mainly due to the "locust-like" mode of development in earlier times. These findings indicate that shared bicycle companies should adjust their strategies to more sustainable long-term objectives, and it is also practical to move the excess bicycles in urban areas to remote areas. Furthermore, with respect to sharing bicycles at universities, the findings suggest an inverted "U"-shaped relationship between the allocation efficiency and the distance to subway stations. This characteristic is consistent with the fact that sharing bicycles serves as an effective solution to the "last mile" problem. In addition, a simple but effective rule for bicycle allocation is proposed; that is, more bicycle resources should be invested in bustling residential areas, while fewer resources should be placed in famous business districts and areas with low residential density.
C1 [Jie, Tao; Wei, Wendong] Univ Shanghai Sci & Technol, Business Sch, 516 Jungong Rd, Shanghai 200093, Peoples R China.
   [Jiang, Lu] Shanghai Univ, Sch Management, 99 Shangda Rd, Shanghai, Peoples R China.
RP Wei, WD (reprint author), Univ Shanghai Sci & Technol, Business Sch, 516 Jungong Rd, Shanghai 200093, Peoples R China.
EM taojie@usst.edu.cn; weiwendong@usst.edu.cn; eliza_lujiang@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71601117, 71704101, 71904125]; Science and
   Technology Innovation Action Program of Shanghai [19692104600]; Shanghai
   Sailing Program [18YF1417500]; Philosophy and Social Science Project of
   Shanghai [2018EGL003]; Ministry of Education in China Project of
   Humanities and Social Sciences [17YJC630094]
FX This study is supported by National Natural Science Foundation of China
   (Grant Nos. 71601117, 71704101 and 71904125), Science and Technology
   Innovation Action Program of Shanghai (Grant No. 19692104600), Shanghai
   Sailing Program (Grant No. 18YF1417500), Philosophy and Social Science
   Project of Shanghai (Grant No. 2018EGL003), Ministry of Education in
   China Project of Humanities and Social Sciences (Grant No. 17YJC630094).
CR Albinski S, 2018, TRANSPORT RES E-LOG, V116, P59, DOI 10.1016/j.tre.2018.05.011
   Apte UM, 2019, CALIF MANAGE REV, V61, P104, DOI 10.1177/0008125619826025
   Benjaafar S, 2019, MANAGE SCI, V65, P477, DOI 10.1287/mnsc.2017.2970
   Caggiani L, 2018, TRANSPORT RES C-EMER, V87, P159, DOI 10.1016/j.trc.2018.01.001
   Cook WD, 2009, EUR J OPER RES, V192, P1, DOI 10.1016/j.ejor.2008.01.032
   Cooper W.W., 2006, INTRO DATA ENVELOPME
   Du J, 2014, EUR J OPER RES, V235, P206, DOI 10.1016/j.ejor.2013.10.002
   Dula JH, 2011, INFORMS J COMPUT, V23, P284, DOI 10.1287/ijoc.1100.0400
   Eckhardt GM, 2019, J MARKETING, V83, P5, DOI 10.1177/0022242919861929
   Ertz M, 2018, J CLEAN PROD, V196, P1073, DOI 10.1016/j.jclepro.2018.06.095
   Faghih-Imani A, 2017, TRANSPORT RES A-POL, V101, P11, DOI 10.1016/j.tra.2017.05.006
   Faghih-Imani A, 2017, TRANSPORT RES A-POL, V97, P177, DOI 10.1016/j.tra.2016.12.007
   Fidelis R, 2018, RESOUR CONSERV RECY, V130, P152, DOI 10.1016/j.resconrec.2017.12.002
   Fishman E, 2014, TRANSPORT RES D-TR E, V31, P13, DOI 10.1016/j.trd.2014.05.013
   Forma IA, 2015, TRANSPORT RES B-METH, V71, P230, DOI 10.1016/j.trb.2014.10.003
   Liu W, 2018, RESOUR CONSERV RECY, V139, P50, DOI 10.1016/j.resconrec.2018.07.017
   Luo H, 2019, RESOUR CONSERV RECY, V146, P180, DOI 10.1016/j.resconrec.2019.03.003
   Ma Y, 2018, J CLEAN PROD, V197, P356, DOI 10.1016/j.jclepro.2018.06.213
   Martin CJ, 2016, ECOL ECON, V121, P149, DOI 10.1016/j.ecolecon.2015.11.027
   Mi ZF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09260-4
   Pal A, 2017, TRANSPORT RES C-EMER, V80, P92, DOI 10.1016/j.trc.2017.03.016
   Parente RC, 2018, J INT MANAG, V24, P52, DOI 10.1016/j.intman.2017.10.001
   Song ML, 2018, RESOUR CONSERV RECY, V128, P197, DOI 10.1016/j.resconrec.2016.08.015
   Tao J, 2015, COMPUT IND ENG, V87, P308, DOI 10.1016/j.cie.2015.05.026
   ter Huurne M, 2017, J CONSUM BEHAV, V16, P485, DOI 10.1002/cb.1667
   Wu G, 2018, RESOUR CONSERV RECY, V128, P373, DOI 10.1016/j.resconrec.2016.08.020
   Xu T, 2017, RESOUR CONSERV RECY, V125, P17, DOI 10.1016/j.resconrec.2017.05.008
   You YQ, 2016, OMEGA-INT J MANAGE S, V60, P85, DOI 10.1016/j.omega.2014.11.011
   Zervas G, 2017, J MARKETING RES, V54, P687, DOI 10.1509/jmr.15.0204
   Zhang LL, 2018, RESOUR CONSERV RECY, V136, P248, DOI 10.1016/j.resconrec.2018.04.032
   Zhang YP, 2018, APPL ENERG, V220, P296, DOI 10.1016/j.apenergy.2018.03.101
NR 31
TC 0
Z9 0
U1 34
U2 34
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104510
DI 10.1016/j.resconrec.2019.104510
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200005
DA 2020-05-12
ER

PT J
AU Karimi, H
   Yu, QL
   Brouwers, HJH
AF Karimi, H.
   Yu, Q. L.
   Brouwers, H. J. H.
TI Valorization of waste baby diapers in concrete
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Waste diaper; Cement grout; Concrete; Rheology; Viscosity modifying
   admixture; Sustainability
ID SUPPLEMENTARY CEMENTITIOUS MATERIAL; MUNICIPAL SOLID-WASTE; DISPOSABLE
   DIAPERS; SUPERABSORBENT POLYMERS; BIODEGRADATION; TEMPERATURE;
   PERFORMANCE; ADMIXTURES; RESISTANCE; LANDFILL
AB Waste baby diapers constitute a significant part of hygiene waste and currently are primarily landfilled or incinerated. The present study explores the applicability of shredded waste diapers (SWDs) as an innovative viscosity modifying admixture for cement grouts and concrete. A model was proposed which formulates the chemicals that SWDs add to concrete. The model was combined with the building and environmental standards to present the legal framework about using SWDs in different types of concrete. Cement grouts and self-consolidating concrete were designed to validate the viscosity modifying properties of SWDs. A Bingham viscosity model and flow tests were used to evaluate the viscosity modifying performance of SWDs. The present results show that the SWDs are a sustainable route to manufacture highly-effective viscosity-modifying admixtures for concrete.
C1 [Karimi, H.; Yu, Q. L.; Brouwers, H. J. H.] Eindhoven Univ Technol, Dept Built Environm, Bldg Mat, POB 513, NL-5600 MB Eindhoven, Netherlands.
   [Yu, Q. L.] Wuhan Univ, Sch Civil Engn, Wuhan 430072, Hubei, Peoples R China.
RP Yu, QL (reprint author), Eindhoven Univ Technol, Dept Built Environm, Bldg Mat Grp, Eindhoven, Netherlands.
EM q.yu.1@tue.nl
OI Yu, Qingliang/0000-0001-8578-3945
CR ACI Committee, 2016, 212 ACI
   ACI Committee, 2007, 238 ACI
   ACI Committee 201, 2017, 201 ACI
   Aguilar-Virgen Q, 2014, J CLEAN PROD, V79, P53, DOI 10.1016/j.jclepro.2014.05.025
   Aitcin PC, 2016, WOOD PUBL SER CIVIL, V59, P75, DOI 10.1016/B978-0-08-100693-1.00005-9
   Aitcin P. C., 1998, HIGH PERFORMANCE CON
   [Anonymous], 2012, C09402012 ASTM, DOI [10.1520/C1602C1602M-12, DOI 10.1520/C1602C1602M-12]
   [Anonymous], 2007, 237 ACI
   [Anonymous], 173SC3 ISOTC
   Aprianti SE, 2017, J CLEAN PROD, V142, P4178, DOI 10.1016/j.jclepro.2015.12.115
   Arena U, 2016, J CLEAN PROD, V127, P289, DOI 10.1016/j.jclepro.2016.03.164
   Asako Y, 2004, NUMER HEAT TR A-APPL, V45, P49, DOI 10.1080/1040778049026738
   Assmann A, 2013, THESIS
   BANFILL PFG, 1990, MAG CONCRETE RES, V42, P213, DOI 10.1680/macr.1990.42.153.213
   Banfill PFG, 2006, RHEOL REV, V2006, P61, DOI [10.4324/9780203473290, DOI 10.4324/9780203473290]
   Behnood A, 2016, CONSTR BUILD MATER, V105, P176, DOI 10.1016/j.conbuildmat.2015.12.032
   Braun D.B., 2000, RHEOLOGY MODIFIERS H, DOI [10.1017/S0017383509990313, DOI 10.1017/S0017383509990313]
   Brouwers HJH, 2005, CEMENT CONCRETE RES, V35, P2116, DOI 10.1016/j.cemconres.2005.06.002
   BSI Committee, B51612 BSI
   BSI Committee, B5171 BSI
   BSI Committee B/517/1, 2009, B5171 BSI
   BSI Committee B/517/1, 2002, B5171 BSI
   Chen MX, 2018, CONSTR BUILD MATER, V189, P601, DOI 10.1016/j.conbuildmat.2018.09.037
   Chopin D, 2004, CEMENT CONCRETE RES, V34, P2237, DOI 10.1016/j.cemconres.2004.02.012
   Colon J, 2013, WASTE MANAGE, V33, P1097, DOI 10.1016/j.wasman.2013.01.018
   Colon J, 2011, WASTE MANAGE RES, V29, P249, DOI 10.1177/0734242X10364684
   Conway M.E., 1996, USOO, DOI 10.1016/S0959-6526(97)82420-1, Patent No. [5558745A, 05558745A]
   Cook JD, 2007, J ANAL TOXICOL, V31, P486, DOI 10.1093/jat/31.8.486
   Cordella M, 2015, J CLEAN PROD, V95, P322, DOI 10.1016/j.jclepro.2015.02.040
   Cox JA, 2015, PROC INST CIV ENG-WA, V168, P115, DOI 10.1680/warm.14.00012
   EDANA, 2015, 2400R215 EDANA NWSP
   EDANA, 2008, SUST REP 2007 2008
   EDANA, 2015, 2410R215 EDANA NWSP
   EDANA, 2015, 2420R215 EDANA NWSP
   EDANA, 2015, SUST REP
   EFNARC, 2005, EUR GUID SELF COMP C
   ENCI, 2017, PORTL CEM CEM I 52 5
   ENCI, 2006, PORTL CEM CEM I 52 5
   Eriksen L, 1996, WATER RES, V30, P1026, DOI 10.1016/0043-1354(95)00258-8
   Espinosa RM, 2003, INT J CHEM REACT ENG, V1
   Espinosa-Valdemar RM, 2014, RESOUR CONSERV RECY, V87, P153, DOI 10.1016/j.resconrec.2014.03.015
   FARRELL JB, 1974, J WATER POLLUT CON F, V46, P113
   Federico LM, 2009, CEMENT CONCRETE COMP, V31, P606, DOI 10.1016/j.cemconcomp.2009.02.001
   GERBA CP, 1995, WASTE MANAGE RES, V13, P315, DOI 10.1177/0734242X9501300403
   Girotto F, 2017, J MATER CYCLES WASTE, V19, P570, DOI 10.1007/s10163-015-0420-9
   Correa RCG, 2016, TRENDS FOOD SCI TECH, V50, P103, DOI 10.1016/j.tifs.2016.01.012
   Gomes SD, 2019, RESOUR CONSERV RECY, V145, P148, DOI 10.1016/j.resconrec.2019.02.032
   Grubesa I. Netinger, 2016, CHARACTERISTICS USES, P1, DOI [10.1016/C2014-0-03994-9, DOI 10.1016/C2014-0-03994-9, 10.1016/c2014-0-03994-9.]
   Husken G, 2008, CEMENT CONCRETE RES, V38, P1246, DOI 10.1016/j.cemconres.2008.04.002
   Jensen OM, 2008, RILEM PROC, V61, P757
   Khayat KH, 2012, WOODHEAD PUBL MATER, P209
   Khayat KH, 1996, ACI MATER J, V93, P134
   Khoo SC, 2019, PROCESS SAF ENVIRON, V123, P116, DOI 10.1016/j.psep.2018.12.016
   Kim HY, 2017, CONSTR BUILD MATER, V156, P790, DOI 10.1016/j.conbuildmat.2017.09.042
   Kim KS, 2017, WASTE MANAGE, V67, P11, DOI 10.1016/j.wasman.2017.04.027
   Larrard F.D., 1999, CONCRETE MIXTURE PRO
   Laustsen S, 2015, MATER STRUCT, V48, P357, DOI 10.1617/s11527-013-0188-0
   Leemann A, 2007, CEMENT CONCRETE COMP, V29, P341, DOI 10.1016/j.cemconcomp.2007.01.004
   Li C, 2018, CONSTR BUILD MATER, V175, P342, DOI 10.1016/j.conbuildmat.2018.04.176
   Lucas N, 2008, CHEMOSPHERE, V73, P429, DOI 10.1016/j.chemosphere.2008.06.064
   Maamari O, 2016, WASTE MANAGE, V49, P462, DOI 10.1016/j.wasman.2016.01.014
   Neville A.M., 2010, CONCRETE TECHNOLOGY
   Ouyang J, 2016, CONSTR BUILD MATER, V125, P643, DOI 10.1016/j.conbuildmat.2016.08.085
   Palacios J, 2015, GLOBAL SURGERY AND ANESTHESIA MANUAL: PROVIDING CARE IN RESOURCE-LIMITED SETTINGS, P415
   PANCORBO OC, 1988, APPL ENVIRON MICROB, V54, P118, DOI 10.1128/AEM.54.1.118-123.1988
   Pathak VM, 2017, BIORESOUR BIOPROCESS, V4, DOI 10.1186/s40643-017-0145-9
   Poulsen E., 2006, DIFFUSION CHLORIDE C
   Putnam D. F., 1971, CR1802 NASA
   R&R Market Research, 2015, GLOB CHIN SUP POL SA
   Rana A, 2016, J CLEAN PROD, V135, P312, DOI 10.1016/j.jclepro.2016.06.126
   Randall DG, 2016, WATER RES, V95, P361, DOI 10.1016/j.watres.2016.03.007
   Riyazi S, 2017, CONSTR BUILD MATER, V147, P669, DOI 10.1016/j.conbuildmat.2017.05.001
   Maria EVR, 2011, WASTE MANAGE, V31, P1683, DOI 10.1016/j.wasman.2011.03.007
   Saikia N, 2012, CONSTR BUILD MATER, V34, P385, DOI 10.1016/j.conbuildmat.2012.02.066
   Sanchez C, 2009, BIOTECHNOL ADV, V27, P185, DOI 10.1016/j.biotechadv.2008.11.001
   Shah AA, 2008, BIOTECHNOL ADV, V26, P246, DOI 10.1016/j.biotechadv.2007.12.005
   Skalny J., 2002, SULFATE ATTACK CONCR
   Smith A., 2001, WASTE MANAGEMENT OPT, DOI [10.1016/S1352-2310(01)00532-5, DOI 10.1016/S1352-2310(01)00532-5]
   STEGMANN R, 1993, WASTE MANAGE RES, V11, P155, DOI 10.1177/0734242X9301100207
   Sun XF, 2016, PROCEDIA ENVIRON SCI, V31, P535, DOI 10.1016/j.proenv.2016.02.079
   Sun XX, 2017, MATER DESIGN, V114, P92, DOI 10.1016/j.matdes.2016.10.050
   Taylor H.F.W., 1997, CEMENT CHEM
   Torrijos M, 2014, WASTE MANAGE, V34, P669, DOI 10.1016/j.wasman.2013.11.009
   tura P., 2006, INT RILEM C VOL CHAN
   van Kuijk SJA, 2015, BIOTECHNOL ADV, V33, P191, DOI 10.1016/j.biotechadv.2014.10.014
   WBCSD, 2009, CEMENT SUSTAINABILIT
   Weisbrod AV, 2012, INT J LIFE CYCLE ASS, V17, P145, DOI 10.1007/s11367-011-0343-1
NR 87
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104548
DI 10.1016/j.resconrec.2019.104548
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200017
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kelly, C
   Sen, B
   Tatari, O
AF Kelly, Carolina
   Sen, Burak
   Tatari, Omer
TI A system dynamics analysis of the alternative roofing market and its
   potential impacts on urban environmental problems: A case study in
   Orlando, Florida
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Green roofs; Solar PV roofs; System dynamics modeling; Urban
   sustainability; Sustainable buildings
ID PHOTOVOLTAIC-GREEN ROOFS; LIFE-CYCLE ASSESSMENT; HEAT-ISLAND;
   RESIDENTIAL BUILDINGS; ENERGY; MODEL; BENEFITS; COOL; REDUCTION;
   RETENTION
AB Recent advances in sustainable construction and development methods have allowed urban developers to significantly reduce urban environmental problems caused by buildings such as increased energy consumption and greenhouse gas emissions, urban runoff, and the urban heat island effect. Newer forms of green infrastructure, including alternative roofing (green roofs, solar BIPV systems, etc.), have emerged as potential solutions to these urban environmental problems. However, a number of practical and socioeconomic factors are currently limiting their market penetration to a marginal share. This study employs a System Dynamics modeling approach to analyze these hindrances in Orlando's alternative roofing market, as well as the potential of societal, economic, and developmental investments in different alternative roofing markets to address these issues. Conventional roofs have been found to remain predominant in Orlando's roofing market under all policy scenarios, with solar roof system being the most mature out of the three alternative roofing markets considered, and consequently has the most potential for future market penetration. It has been found that the studied alternative roof systems (ARSs) reach only a marginal market share in the year 2040, and for this reason, could not result in significant improvements in the studied impact categories at the city level. However, the studied ARSs yield important reductions in all of the impact categories when analyzed at the building level. The results of this study indicate that the alternative roofing market has significant growth potential, but further research, development, and improvement will be essential to achieve more effective, long-term benefits in Orlando.
C1 [Kelly, Carolina; Sen, Burak; Tatari, Omer] Univ Cent Florida, Dept Civil Environm & Construct Engn, Orlando, FL 32816 USA.
RP Tatari, O (reprint author), Univ Cent Florida, Dept Civil Environm & Construct Engn, Orlando, FL 32816 USA.
EM tatari@ucf.edu
OI Tatari, Omer/0000-0002-8150-992X
CR Alirezaei M, 2017, SYSTEMS, V5, DOI 10.3390/systems5010006
   Alirezaei M, 2016, ENERG BUILDINGS, V130, P465, DOI 10.1016/j.enbuild.2016.08.044
   Alshayeb MJ, 2018, ENERGIES, V11, DOI 10.3390/en11051110
   Andersson C., 2001, SYSTEM DYNAMICS SIMU
   [Anonymous], 1971, WORLD DYNAMICS
   Bai XM, 2017, ANNU REV ENV RESOUR, V42, P215, DOI 10.1146/annurev-environ-102016-061128
   BASS FM, 1969, MANAGE SCI, V15, P215, DOI 10.1287/mnsc.15.5.215
   BASS FM, 1994, MARKET SCI, V13, P203, DOI 10.1287/mksc.13.3.203
   Berardi U, 2014, APPL ENERG, V115, P411, DOI 10.1016/j.apenergy.2013.10.047
   Berto R, 2018, BUILD ENVIRON, V127, P58, DOI 10.1016/j.buildenv.2017.10.032
   Besir AB, 2018, RENEW SUST ENERG REV, V82, P915, DOI 10.1016/j.rser.2017.09.106
   Bianchini F, 2012, BUILD ENVIRON, V58, P152, DOI 10.1016/j.buildenv.2012.07.005
   Bianchini F, 2012, BUILD ENVIRON, V48, P57, DOI 10.1016/j.buildenv.2011.08.019
   Brudermann T, 2017, URBAN FOR URBAN GREE, V21, P224, DOI 10.1016/j.ufug.2016.12.008
   Castleton HF, 2010, ENERG BUILDINGS, V42, P1582, DOI 10.1016/j.enbuild.2010.05.004
   Chemisana D, 2014, APPL ENERG, V119, P246, DOI 10.1016/j.apenergy.2013.12.027
   Costanzo V, 2016, ENERG BUILDINGS, V114, P247, DOI 10.1016/j.enbuild.2015.04.053
   Enright C., 2013, GREEN ROOFS ARE GROW
   EPA, 2008, RED URB HEAT ISL COM
   Ercan T, 2017, J CLEAN PROD, V142, P1789, DOI 10.1016/j.jclepro.2016.11.109
   Flynn Hilary, 2010, Sustainability, V2, P13, DOI 10.3390/su2092746
   Fong WK, 2009, BUILD ENVIRON, V44, P1528, DOI 10.1016/j.buildenv.2008.07.010
   Forschungsgesellschaft Landschaftsentwicklung Landschaftsbau (FLL), 2002, GUID PLANN EX UPK GR
   Gagliano A, 2015, BUILD ENVIRON, V90, P71, DOI 10.1016/j.buildenv.2015.02.043
   Hsu CW, 2012, APPL ENERG, V100, P205, DOI 10.1016/j.apenergy.2012.02.039
   Hui S.C.M., 2011, P JT S 2011 INT BUIL, P12
   Jaffal I, 2012, RENEW ENERG, V43, P157, DOI 10.1016/j.renene.2011.12.004
   Jean J, 2015, ENERG ENVIRON SCI, V8, P1200, DOI 10.1039/c4ee04073b
   Korol E, 2016, PROCEDIA ENGINEER, V161, P1820, DOI 10.1016/j.proeng.2016.08.673
   Lamnatou C, 2014, J CLEAN PROD, V72, P57, DOI 10.1016/j.jclepro.2014.03.006
   Li D., 2014, ENVIRON RES LETT, V9, DOI [10.1088/1748-9326/9/5/055002/pdf, DOI 10.1088/1748-9326/9/5/055002/PDF]
   Morakinyo TE, 2017, ENERG BUILDINGS, V145, P226, DOI 10.1016/j.enbuild.2017.03.066
   Movilla S, 2013, ENERG POLICY, V60, P142, DOI 10.1016/j.enpol.2013.04.072
   Odeh S, 2018, ENERGIES, V11, DOI 10.3390/en11071879
   Onat NC, 2015, INTEGRATED SUSTAINAB
   Onat NC, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9050706
   Onat NC, 2014, BUILD ENVIRON, V78, P68, DOI 10.1016/j.buildenv.2014.03.030
   Phillips R, 2017, ENERG BUILDINGS, V146, P295, DOI 10.1016/j.enbuild.2017.04.009
   Razzaghmanesh M, 2016, URBAN FOR URBAN GREE, V15, P89, DOI 10.1016/j.ufug.2015.11.013
   Refahi AH, 2015, RENEW ENERG, V80, P595, DOI 10.1016/j.renene.2015.02.030
   Rowe DB, 2011, ENVIRON POLLUT, V159, P2100, DOI 10.1016/j.envpol.2010.10.029
   Saiz S, 2006, ENVIRON SCI TECHNOL, V40, P4312, DOI 10.1021/es0517522
   Santamouris M, 2018, ENERG BUILDINGS, V166, P154, DOI 10.1016/j.enbuild.2018.02.007
   Scherba A, 2011, BUILD ENVIRON, V46, P2542, DOI 10.1016/j.buildenv.2011.06.012
   Schindler BY, 2016, ISR J ECOL EVOL, V62, P68, DOI 10.1080/15659801.2015.1048617
   Shafique M, 2018, RENEW SUST ENERG REV, V90, P757, DOI 10.1016/j.rser.2018.04.006
   Sharma A., 2016, ENVIRON RES LETT, V11, DOI [10.1088/1748-9326/11/6/064004/ampdf, DOI 10.1088/1748-9326/11/6/064004/AMPDF]
   Singh PK, 2013, WATER RESOUR MANAG, V27, P2001, DOI 10.1007/s11269-013-0267-6
   Solcerova A, 2017, BUILD ENVIRON, V111, P249, DOI 10.1016/j.buildenv.2016.10.021
   Sonne J, 2006, ASHRAE J, V48, P59
   Speak AF, 2013, SCI TOTAL ENVIRON, V461, P28, DOI 10.1016/j.scitotenv.2013.04.085
   Sproul J, 2014, ENERG BUILDINGS, V71, P20, DOI 10.1016/j.enbuild.2013.11.058
   Susca T, 2011, ENVIRON POLLUT, V159, P2119, DOI 10.1016/j.envpol.2011.03.007
   Thompson BP, 2010, BUILD ENVIRON, V45, P1006, DOI 10.1016/j.buildenv.2009.10.008
   Van Lith A.P., 2018, J CONSTR ENG MANAG I, V1, P1
   VanWoert ND, 2005, J ENVIRON QUAL, V34, P1036, DOI 10.2134/jeq2004.0364
   Yan H, 2019, J MATERN-FETAL NEO M, V32, P2961, DOI 10.1080/14767058.2018.1452903
   Ziogou I, 2018, SUSTAIN CITIES SOC, V40, P233, DOI 10.1016/j.scs.2018.04.007
NR 58
TC 0
Z9 0
U1 23
U2 23
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104556
DI 10.1016/j.resconrec.2019.104556
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200022
DA 2020-05-12
ER

PT J
AU Kou, ZY
   Wang, X
   Chiu, SF
   Cai, H
AF Kou, Zhaoyu
   Wang, Xi
   Chiu, Shun Fung (Anthony)
   Cai, Hua
TI Quantifying greenhouse gas emissions reduction from bike share systems:
   a model considering real-world trips and transportation mode choice
   patterns
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Bike share; Environmental benefit; Mode replacement; Greenhouse gas
   reduction; Shared economy
ID OPTIMIZATION APPROACH; STATIONS; IMPACT
AB The emerging bike share systems provide convenient mobility to short-distance travelers for both leisure and commuting purposes. Many cities are rolling out bike share programs. However, few studies have evaluated how bike share systems (BSS) are used to quantify their sustainability impacts. This study proposes a Bike Share Emission Reduction Estimation Model (BS-EREM) to quantify the environmental benefits from bike share trips and compare the greenhouse gas (GHG) emission reductions from BSS in eight cities in the United States, including New York, Chicago, Boston, Philadelphia, Washington D.C., Los Angeles, San Francisco, and Seattle. The BS-EREM model stochastically estimates the transportation modes substituted by bike share trips, considering factors such as trip distance, trip purpose, trip start time, the accessibility of public transits, and historical distributions of transportation mode choices. Based on average life cycle emission factors of different transportation modes, our analysis reveals that the annual GHG emission reductions contributed by the eight BSSs in year 2016 range from 41 tons of CO2-eq (Seattle) to 5417 tons of CO2-eq (New York City), while the emission reductions per trip range from 283 to 581 g CO2-eq. The total annual emission reduction is linearly correlated to the number of trips, bikes, and docks. The bike share stations located in the center of a city contributed to more total GHG emission reductions due to the high trip volumes, while the stations that are further away have higher emission reductions on a per trip basis due to longer trips and higher car substitution rate.
C1 [Kou, Zhaoyu; Cai, Hua] Purdue Univ, Sch Ind Engn, W Lafayette, IN 47907 USA.
   [Wang, Xi] IHS Markit, Southfield, MI 48076 USA.
   [Chiu, Shun Fung (Anthony)] De La Salle Univ, Ind & Syst Engn Dept, Manila, Philippines.
   [Chiu, Shun Fung (Anthony)] Asia Univ, Inst Innovat & Circular Econ, Taichung, Taiwan.
   [Cai, Hua] Purdue Univ, Environm & Ecol Engn, W Lafayette, IN 47907 USA.
RP Cai, H (reprint author), 315N Grant St, W Lafayette, IN 47907 USA.
EM huacai@purdue.edu
RI Cai, Hua/B-2011-2014; Kou, Zhaoyu/G-2064-2018
OI Cai, Hua/0000-0002-5895-1664; Chiu, Anthony Shun
   Fung/0000-0003-2411-7302; Kou, Zhaoyu/0000-0002-3993-5335
FU Hugh W. and Edna M. Donnan Fellowship; Environmental and Ecological
   Engineering at Purdue University
FX Z.K. thanks the support from the Hugh W. and Edna M. Donnan Fellowship
   and the Summer Exploratory Research Grant from Environmental and
   Ecological Engineering at Purdue University. The authors are also
   immensely grateful to the anonymous reviewers for their comments and
   suggestions which greatly helped improve the research.
CR Alter L., 2008, TREEHUGGER
   Alvarez-Valdes R, 2016, OMEGA-INT J MANAGE S, V62, P163, DOI 10.1016/j.omega.2015.09.007
   Anderson N.A., 2015, PORTLAND BICYCLE SHA
   [Anonymous], 2015, 2015 SAN FRANCISCO G
   [Anonymous], 2012, DISTRICT COLUMBIA GR
   [Anonymous], 2017, CITY CHICAGO GREENHO
   Borecki N., 2012, VIRGINIA TECH CAPITA
   Boston G., 2014, GHG CHANGE 2012 2013
   Buehler R, 2015, TRANSPORT RES REC, P100, DOI [10.3141/2520-12, 10.1080/01441647.2015.1069908]
   Bullock C, 2017, SUSTAIN CITIES SOC, V28, P76, DOI 10.1016/j.scs.2016.08.024
   Garcia-Palomares JC, 2012, APPL GEOGR, V35, P235, DOI 10.1016/j.apgeog.2012.07.002
   Chiariotti F, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18020512
   Cohen A., 2018, PLANNING SHARED MOBI, DOI [10.7922/G2NV9GDD, DOI 10.7922/G2NV9GDD]
   Dave M, 2010, ENV DES GUIDE, P1
   Drynda P., 2014, CENT E EUR J MANAG E, V2, P199
   Faghih-Imani A, 2017, TRANSPORT RES A-POL, V101, P11, DOI 10.1016/j.tra.2017.05.006
   Fishman E, 2014, TRANSPORT RES D-TR E, V31, P13, DOI 10.1016/j.trd.2014.05.013
   Fuller D, 2013, AM J PUBLIC HEALTH, V103, pE85, DOI 10.2105/AJPH.2012.300917
   Gold M., 2015, 2015 ENV REPORT CARD, P99
   Gonzalez MC, 2008, NATURE, V453, P779, DOI 10.1038/nature06958
   Hamilton TL, 2018, J ENVIRON ECON MANAG, V87, P72, DOI 10.1016/j.jeem.2017.03.007
   Jappinen S, 2013, APPL GEOGR, V43, P13, DOI 10.1016/j.apgeog.2013.05.010
   Kevin T., 2014, 2012 SEATTLE COMMUNI
   Kou ZY, 2019, PHYSICA A, V515, P785, DOI 10.1016/j.physa.2018.09.123
   LDA Consulting, 2016, MEMB SURV REP 2016
   Lobo A., 2013, BIKES ARE FASTER DOO
   Luo H, 2019, RESOUR CONSERV RECY, V146, P180, DOI 10.1016/j.resconrec.2019.03.003
   Martin EW, 2014, J TRANSP GEOGR, V41, P315, DOI 10.1016/j.jtrangeo.2014.06.026
   NACTO, 2017, BIK SHAR US 2017
   Nair R., 2013, LARGE SCALE VEHICLE, DOI [10.1080/15568318.2012.660115.8318, DOI 10.1080/15568318.2012.660115.8318]
   Pan L., 2018, REBALANCING DOCKLESS, P1
   Park C, 2017, TRANSPORT RES A-POL, V105, P154, DOI 10.1016/j.tra.2017.08.019
   Pasion C., 2017, INVENTORY NEW YORK C, P1
   Rhee I, 2011, IEEE ACM T NETWORK, V19, P630, DOI 10.1109/TNET.2011.2120618
   Romero JP, 2012, PROCD SOC BEHV, V54, P646, DOI 10.1016/j.sbspro.2012.09.782
   Shaheen SA, 2013, INT J TRANSP, V1, P35, DOI 10.14257/ijt.2013.1.1.03
   Shaheen SA, 2010, TRANSPORT RES REC, P159, DOI 10.3141/2143-20
   Spring P., 2015, PHILADELPHIA CITYWID
   Susan S., 2014, PUBLIC BIKESHARING N
   Thompson J., 2016, TIGER LINE SHAPEFILE
   U.S.DOT, 2017, 2017 NAT HOUS TRAV S
   United Nations Environment Programme (UNEP), 2018, WEIGHT CIT RES REQ F
   USDOT, 2009, SUMM TRAV TREND 2009
   Zhang YP, 2018, APPL ENERG, V220, P296, DOI 10.1016/j.apenergy.2018.03.101
NR 44
TC 1
Z9 1
U1 26
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104534
DI 10.1016/j.resconrec.2019.104534
PG 17
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200002
DA 2020-05-12
ER

PT J
AU Lai, MKW
   Ho, APY
AF Lai, Michael K. W.
   Ho, Amy P. Y.
TI Unravelling potentials and limitations of sharing economy in reducing
   unnecessary consumption: A social science perspective
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Sharing economy; Social transformation; Hong Kong; Mindful consumption;
   Real utopia
ID FOOD WASTE; MINE; SUSTAINABILITY; COMMUNITY; PATHWAY; YOURS; RISE
AB Hyper-consumption in capitalist economies has had a severe impact on the environment that no one can escape. In recent year, there has been a high degree of optimism in sharing economy with regard to coping with the environmental problems caused by consumption. However, most of the current literature focuses on business perspectives in which a sharing economy is portrayed as a new business model, but not as a way to curb environmental degradation. This paper, based on a social science perspective, investigates the potentials and limitations of the strategies adopted in sharing economy projects towards social transformation (especially coping with environmental degradation and hyper-consumption), with the adoption of Erik Olin Wright's concept of real utopia. A case study approach has been adopted in terms of a sharing economy project named 'Waste-no-mall (Yuen Long)' in Hong Kong. The project founder embraces ideological-led strategies based on collective responsibility, self-determination and reflexivity, encouraging the participants to reflect on their consumption behaviours, and thus increasing the level of awareness of the need to reduce unnecessary consumption. However, it is a double-edge sword that limits its impact to those who are active participants, without spreading to others the need for change. It is also limited for their interstitial strategies within the project, and is unable to call for a concrete symbiotic transformation when it comes to policy. The significance of this paper is two-fold. First, it adopts a social science perspective that centres on exploring the proclaimed social implications of sharing economy, an aspect which is under-studied given that most of current studies are from a business perspective; second, it extends Wright's concept to an operational level by showing an important pathway aiming to solve environmental problems through the simultaneous achievement of both horizontal and vertical balancing strategies, based on Wright's concept of real utopia.
C1 [Lai, Michael K. W.] Univ St Joseph, Fac Social Sci, Macau, Peoples R China.
   [Ho, Amy P. Y.] Hong Kong Polytech Univ, Dept Appl Social Sci, Hung Hom, Kowloon, Hong Kong, Peoples R China.
RP Lai, MKW (reprint author), Univ St Joseph, Fac Social Sci, Macau, Peoples R China.
EM michael.lai@usj.edu.mo; po-ying.amy.ho@polyu.edu.hk
OI Lai, Michael K.W./0000-0002-7609-6171
FU Hong Kong Polytechnic UniversityHong Kong Polytechnic University
FX Thanks to Dr. David IP and Dr. Kaxton Siu for their valuable comments on
   this paper. Also, the authors acknowledge the financial support from
   Research Studentships by the Hong Kong Polytechnic University.
CR Acquier A, 2017, TECHNOL FORECAST SOC, V125, P1, DOI 10.1016/j.techfore.2017.07.006
   Akbar P, 2018, J CLEAN PROD, V201, P416, DOI 10.1016/j.jclepro.2018.08.010
   Albinsson PA, 2012, J CONSUM BEHAV, V11, P303, DOI 10.1002/cb.1389
   Archer M. S., 1995, REALIST SOCIAL THEOR
   ARENDT H., 1958, HUMAN CONDITION
   Ashley L.D., 2017, RES METHODS METHODOL, P114
   Balan C., 2016, CALITATEA, V17, P103
   Bardhi F, 2012, J CONSUM RES, V39, P881, DOI 10.1086/666376
   Baudrillard J, 1970, CONSUMER SOC MYTHS S
   Bauman Z., 2005, WORK CONSUMERISM NEW, P131
   Beck U., 2001, J CONSUM CULT, V1, P261, DOI DOI 10.1177/146954050100100209
   Belk R, 2007, ANN AM ACAD POLIT SS, V611, P126, DOI 10.1177/0002716206298483
   Belk R, 2014, J BUS RES, V67, P1595, DOI 10.1016/j.jbusres.2013.10.001
   Belk R, 2010, J CONSUM RES, V36, P715, DOI 10.1086/612649
   Benkler Y, 2004, YALE LAW J, V114, P273, DOI 10.2307/4135731
   Blal I, 2018, INT J HOSP MANAG, V73, P85, DOI 10.1016/j.ijhm.2018.02.006
   Bocken NMP, 2014, J CLEAN PROD, V65, P42, DOI 10.1016/j.jclepro.2013.11.039
   Bocker L, 2017, ENVIRON INNOV SOC TR, V23, P28, DOI 10.1016/j.eist,2016.09,004
   Botsman R., 2013, SHARING EC LACKS SHA
   Botsman Rachel, 2010, WHATS MINE IS YOURS
   Bryman A, 2016, SOCIAL RES METHODS
   Bucher E, 2016, COMPUT HUM BEHAV, V62, P316, DOI 10.1016/j.chb.2016.04.002
   Clark J, 2018, RESOUR CONSERV RECY, V130, P20, DOI 10.1016/j.resconrec.2017.11.005
   Codagnone C., 2016, SCOPING SHARING EC O
   Cohen A.P., 1985, SYMOLIC CONSTRUCTION
   Corrigan P., 1997, SOCIOLOGY CONSUMPTIO
   Crate S. A., 2016, ANTHR CLIMATE CHANGE
   de Souza Marcela Fernanda da Paz, 2017, INTERACOES-CAMPO GRA, V18, P183, DOI [10.20435/inter.v18i3.1448, DOI 10.20435/INTER.V18I3.1448]
   DEBOTTON A, 2004, STATUS ANXIETY
   Decrop A, 2018, J TRAVEL TOUR MARK, V35, P57, DOI 10.1080/10548408.2017.1307159
   Alonso-Almeida MD, 2020, J RETAIL CONSUM SERV, V52, DOI 10.1016/j.jretconser.2019.101900
   Dogru T, 2019, TOURISM MANAGE, V72, P27, DOI 10.1016/j.tourman.2018.11.008
   Dudley G, 2017, POLIT QUART, V88, P492, DOI 10.1111/1467-923X.12373
   Edwards T., 2000, CONTRADICTIONS CONSU
   Fabo B, 2017, TRANSFER-LONDON, V23, P163, DOI 10.1177/1024258916688861
   Featherstone M., 2007, CONSUMER CULTURE POS
   Ferrari MZ, 2016, EUR J RISK REGUL, V7, P664, DOI 10.1017/S1867299X00010102
   Flick U., 2015, INTRO RES METHODOLOG
   Flyvbjerg B, 2006, QUAL INQ, V12, P219, DOI 10.1177/1077800405284363
   Fraccascia L, 2018, RESOUR CONSERV RECY, V136, P473, DOI 10.1016/j.resconrec.2018.03.009
   Frenken K, 2017, ENVIRON INNOV SOC TR, V23, P3, DOI 10.1016/j.eist.2017.01.003
   Frenken K, 2017, PHILOS T R SOC A, V375, DOI 10.1098/rsta.2016.0367
   Fuentes-Bracamontes R., 2016, ELECT J, V29, DOI [10.1016/j.jcsr.2013.08.006, DOI 10.1016/J.JCSR.2013.08.006]
   Gaustad G, 2018, RESOUR CONSERV RECY, V135, P24, DOI 10.1016/j.resconrec.2017.08.002
   George A.L., 2005, CASE STUDIES THEORY
   Gerring J., 2017, CASE STUDY RES PRINC
   Ginindza S, 2019, CURR ISSUES TOUR, V22, P1975, DOI 10.1080/13683500.2017.1408061
   Goe WR, 2007, 21 CENTURY SOCIOLOGY, V1, P455
   Gusfield J.R., 1975, COMMUNITY CRITICAL R
   Guttentag D, 2015, CURR ISSUES TOUR, V18, P1192, DOI 10.1080/13683500.2013.827159
   Hahnel Robin, 2016, ALTERNATIVES CAPITAL
   Hamari J, 2016, J ASSOC INF SCI TECH, V67, P2047, DOI 10.1002/asi.23552
   Hamilton K, 2009, INT J SOCIOL SOC POL, V29, P543, DOI 10.1108/01443330910986315
   Hartl B, 2016, J BUS RES, V69, P2756, DOI 10.1016/j.jbusres.2015.11.011
   Heinrichs H, 2013, GAIA, V22, P228, DOI 10.14512/gaia.22.4.5
   Henten A. H., 2016, INFO, V18, P1, DOI DOI 10.1108/info-09-2015-0044
   Herweg N, 2017, THEORIES POLICY PROC, P17
   Hesse-Biber S. N., 2017, PRACTICE QUALITATIVE
   Hira A, 2017, J DEV SOC, V33, P175, DOI 10.1177/0169796X17710071
   Hu JY, 2019, RESOUR CONSERV RECY, V149, P177, DOI 10.1016/j.resconrec.2019.05.042
   Hwang JY, 2017, J CONSUM MARK, V34, P132, DOI 10.1108/JCM-10-2015-1560
   Jiang BJ, 2018, MANAGE SCI, V64, P1171, DOI 10.1287/mnsc.2016.2647
   Kingdon J. W., 1984, AGENDAS ALTERNATIVES
   Koutsobinas T., 2014, POLITICAL EC STATUS
   Lamberton CP, 2012, J MARKETING, V76, P109, DOI 10.1509/jm.10.0368
   Leonard A., 2010, STORY STUFF OUR OBSE
   Levitas R, 2013, UTOPIA AS METHOD: THE IMAGINARY RECONSTITUTION OF SOCIETY, P1, DOI 10.1057/9781137314253
   Li YZ, 2019, SOIL TILL RES, V195, DOI 10.1016/j.still.2019.104409
   Lipovetsky G, 2011, ROUT INTERP MARK RES, V13, P25
   MACPHERSON I, 2000, INT J SOC RES METHOD, V3, P49, DOI DOI 10.1080/136455700294923
   Martin CJ, 2016, J CLEAN PROD, V134, P204, DOI 10.1016/j.jclepro.2015.04.062
   Martin CJ, 2016, ECOL ECON, V121, P149, DOI 10.1016/j.ecolecon.2015.11.027
   Marx K., 1988, EC PHILOS MANUSCRIPT, V1844
   Masoud N, 2017, TRANSPORT RES B-METH, V99, P1, DOI 10.1016/j.trb.2017.01.004
   McArthur E, 2015, CONSUMP MARK CULT, V18, P239, DOI 10.1080/10253866.2014.987083
   Muller SC, 2018, ENERG POLICY, V118, P492, DOI 10.1016/j.enpol.2018.03.064
   Munkoe M. M., 2017, Intereconomics, V52, P38, DOI 10.1007/s10272-017-0641-3
   Pathak Vibha, 2013, Perspect Clin Res, V4, P192, DOI 10.4103/2229-3485.115389
   Perren R., 2015, INT ENCY SOCIAL BEHA, V4, P139, DOI DOI 10.1016/6978-0-08-097086-8.64143-0
   Quelch John A., 2007, GREATER GOOD GOOD MA
   Retamal M, 2019, J CLEAN PROD, V222, P143, DOI 10.1016/j.jclepro.2019.02.267
   Rifkin J., 2014, ZERO MARGINAL COST S
   Ritzer G., 2012, DEBTOR WORLD INTERDI
   RITZER G., 2001, HDB SOCIAL THEORY, P410, DOI [DOI 10.4135/9781848608351.N31, 10.4135/9781848608351.n31]
   Roos D, 2017, J BUS RES, V77, P113, DOI 10.1016/j.jbusres.2017.04.011
   Russell SV, 2017, RESOUR CONSERV RECY, V125, P107, DOI 10.1016/j.resconrec.2017.06.007
   Sacchetto D., 2017, COMMUNICATION
   Saintier S, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9081325
   Sandes FS, 2019, INT J CONSUM STUD, V43, P446, DOI 10.1111/ijcs.12524
   Santoso A.S., 2018, INT J BUS GLOB, V21, P408, DOI [10.1504/IJBG.2018.095505, DOI 10.1504/IJBG.2018.095505]
   Schor JB, 2017, SOCIOL COMPASS, V11, DOI 10.1111/soc4.12493
   Seegebarth B, 2016, J CONSUM AFF, V50, P68, DOI 10.1111/joca.12077
   Sheikh A, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003737
   Sheth JN, 2011, J ACAD MARKET SCI, V39, P21, DOI 10.1007/s11747-010-0216-3
   Si HY, 2020, RESOUR CONSERV RECY, V152, DOI 10.1016/j.resconrec.2019.104513
   Slee Tom, 2015, WHATS YOURS IS MINE
   Stephany A., 2015, THE BUSINESS OF SHAR
   Stillerman J., 2015, SOCIOLOGY CONSUMPTIO
   Sturken Marita, 2009, PRACTICES LOOKING IN
   ter Huurne M, 2017, J CONSUM BEHAV, V16, P485, DOI 10.1002/cb.1667
   Teubner T, 2015, BUS INFORM SYST ENG+, V57, P311, DOI 10.1007/s12599-015-0396-y
   Tian Z, 2016, HOTMOBILE'16: PROCEEDINGS OF THE 17TH INTERNATIONAL WORKSHOP ON MOBILE COMPUTING SYSTEMS AND APPLICATIONS, P33, DOI 10.1145/2873587.2873598
   Verboven H., 2016, UWF, V24, P303, DOI DOI 10.1007/S00550-016-0410-Y
   Walsh B., 2011, TIME
   Wang YB, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9081400
   Warde A, 2015, ANNU REV SOCIOL, V41, P117, DOI 10.1146/annurev-soc-071913-043208
   Wright E. O., 2011, CONTEXTS, V10, P36, DOI [10.1177/1536504211408884, DOI 10.1177/1536504211408884]
   Wright E.O., 1994, INTERROGATING INEQUA
   Wright E. O., 2007, SOUNDINGS, V36, P26
   Wright E.O., 2017, BE ANTICAPITALIST 21
   Wright E.O., 2011, AM SOC IT REALLY WOR
   Wright EO, 2010, ENVISIONING REAL UTO
   Wright EO, 2006, NEW LEFT REV, P93
   Wright EO, 2013, AM SOCIOL REV, V78, P1, DOI 10.1177/0003122412468882
   Yin R. K., 2014, CASE STUDY RES DESIG
   Yin RK, 2013, EVALUATION-US, V19, P321, DOI 10.1177/1356389013497081
   Young W, 2017, RESOUR CONSERV RECY, V117, P195, DOI 10.1016/j.resconrec.2016.10.016
   Zahariadis N., 2014, THEORIES POLICY PROC, P25
NR 118
TC 1
Z9 1
U1 37
U2 37
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104546
DI 10.1016/j.resconrec.2019.104546
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200003
DA 2020-05-12
ER

PT J
AU Li, Y
   Lim, MK
   Tan, YS
   Lee, SY
   Tseng, ML
AF Li, Yan
   Lim, Ming K.
   Tan, Yingshuang
   Lee, Sir Yee
   Tseng, Ming-Lang
TI Sharing economy to improve routing for urban logistics distribution
   using electric vehicles
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Urban logistics; Sharing economy; Carbon tax; Electric vehicle routing;
   Ant colony algorithm
ID ANT-COLONY; TIME WINDOW; CARBON TAX; CONSUMPTION; ALGORITHM; EMISSIONS;
   MODEL; TRANSPORTATION; OPTIMIZATION; PERFORMANCE
AB With the increasing concern on global warming, companies begin to use electric vehicles for urban distribution. Owing to battery capacity limitations, electric vehicles may need recharging during delivery process. Hence, the traditional vehicle routing methodologies, which were designed for fossil fuel-powered vehicles, are not feasible for electric vehicles. For this reason, this paper studies the urban logistics distribution routing problem of electric vehicles in the context of sharing economy with the consideration of carbon taxes (taxes on CO2 emissions) and time-of-use electricity prices (time-varying electricity prices), and proposes an optimization model of the electric vehicle routing problem in view of sharing economy. The proposed optimization model aims to minimize the total cost, which includes the operation, penalty, queuing (waiting at the charging stations), electricity and environment costs. An ant colony algorithm is developed for optimization purposes in the model. In this study, simulations are conducted based on a case study with actual locations. The first simulated scenario indicates that adopting distribution sharing is able to reduce travelling distances as well as the total cost in comparison to having separate distribution systems. The second simulated scenario is conducted under different time electricity prices; the results show that lower time-of-use electricity prices alleviate traffic congestion and reduce the total cost. In the third simulated scenario, the effects of different carbon taxes are analysed. The results show that the CO2 emissions will decrease when the carbon tax rate is increased. Finally, the limitations and future research directions of this paper are also discussed.
C1 [Li, Yan; Lim, Ming K.] Chongqing Univ, Coll Mech Engn, Chongqing, Peoples R China.
   [Lim, Ming K.; Lee, Sir Yee] Coventry Univ, Ctr Business Soc, Coventry, W Midlands, England.
   [Tan, Yingshuang] Chongqing Univ, Coll Math & Stat, Chongqing, Peoples R China.
   [Tseng, Ming-Lang] Asia Univ, Inst Innovat & Circular Econ, Taichung, Taiwan.
RP Lim, MK (reprint author), Chongqing Univ, Coll Mech Engn, Chongqing, Peoples R China.; Lim, MK (reprint author), Coventry Univ, Ctr Business Soc, Coventry, W Midlands, England.
EM ming.lim@cqu.edu.cn
RI Lim, Ming K/D-1476-2017; Tseng, Ming Lang/M-9051-2014
OI Lim, Ming K/0000-0003-0809-9431; Tseng, Ming Lang/0000-0002-2702-3590
FU Chongqing Science and Technology CommissionNatural Science Foundation
   Project of CQ CSTC [cstc2019jscx-msxmX0189]
FX This research is funded by the Chongqing Science and Technology
   Commission (Project no. cstc2019jscx-msxmX0189).
CR Abedi-Varaki M, 2017, MOD PHYS LETT B, V31, DOI 10.1142/S0217984917502104
   Adelzadeh M, 2014, INT J ADV MANUF TECH, V75, P793, DOI 10.1007/s00170-014-6141-8
   Alinaghian M, 2017, NETW SPAT ECON, V17, P1185, DOI 10.1007/s11067-017-9364-z
   [Anonymous], 2019, NEWS SOHU
   Assaf R, 2017, CIV ENVIRON ENG REP, V26, P43, DOI 10.1515/ceer-2017-0034
   Bachnik K., 2016, RES PAPERS WROCLAW U, V423, P35
   Balezentis T, 2019, RESOUR CONSERV RECY, V142, P37, DOI 10.1016/j.resconrec.2018.11.013
   Che A, 2017, J CLEAN PROD, V156, P688, DOI 10.1016/j.jclepro.2017.04.018
   Chen SH, 2017, COMPLEXITY, DOI 10.1155/2017/3295436
   Cheng M, 2017, HABITAT INT, V70, P91, DOI 10.1016/j.habitatint.2017.10.008
   Cimen M, 2017, TRANSPORT RES D-TR E, V54, P82, DOI 10.1016/j.trd.2017.04.016
   Conrad R., 2011, 61 ANN IIE C EXP P R
   Craig MT, 2018, ENVIRON RES LETT, V13, DOI 10.1088/1748-9326/aa9a78
   Dai J., 2019, CHONGQING DAILY
   Desaulniers G, 2016, OPER RES, V64, P1388, DOI 10.1287/opre.2016.1535
   Diabat A, 2016, ANN OPER RES, V242, P373, DOI 10.1007/s10479-014-1640-4
   Dorigo M, 2002, IEEE T EVOLUT COMPUT, V6, P317, DOI 10.1109/TEVC.2002.802446
   Erdogan S, 2012, TRANSPORT RES E-LOG, V48, P100, DOI 10.1016/j.tre.2011.08.001
   Fan YC, 2019, RESOUR CONSERV RECY, V151, DOI 10.1016/j.resconrec.2019.104490
   Felipe A, 2014, TRANSPORT RES E-LOG, V71, P111, DOI 10.1016/j.tre.2014.09.003
   Fu JY, 2018, ENG STRUCT, V156, P460, DOI 10.1016/j.engstruct.2017.11.041
   Goeke D, 2015, EUR J OPER RES, V245, P81, DOI 10.1016/j.ejor.2015.01.049
   Goel R, 2018, J COMPUT SCI-NETH, V25, P28, DOI 10.1016/j.jocs.2017.12.012
   Hiermann G, 2016, EUR J OPER RES, V252, P995, DOI 10.1016/j.ejor.2016.01.038
   Hirsch MJ, 2014, J COMB OPTIM, V28, P38, DOI 10.1007/s10878-014-9732-2
   Hu JY, 2019, RESOUR CONSERV RECY, V149, P177, DOI 10.1016/j.resconrec.2019.05.042
   Kannan D, 2012, RESOUR CONSERV RECY, V67, P75, DOI 10.1016/j.resconrec.2012.03.005
   Ke WW, 2017, APPL ENERG, V188, P367, DOI 10.1016/j.apenergy.2016.12.011
   Keskin M, 2016, TRANSPORT RES C-EMER, V65, P111, DOI 10.1016/j.trc.2016.01.013
   Klimenko A. V., 2017, Thermal Engineering, V64, P422, DOI 10.1134/S0040601517060015
   Kondrat'eva O. E., 2017, Thermal Engineering, V64, P437, DOI 10.1134/S0040601517060027
   Lei X., 2016, 2016 INT C LOG INF S
   Li HQ, 2016, TRANSPORT RES B-METH, V94, P169, DOI 10.1016/j.trb.2016.09.012
   Luo JP, 2014, EXPERT SYST APPL, V41, P2535, DOI 10.1016/j.eswa.2013.10.001
   Melo S, 2017, EUR TRANSP RES REV, V9, DOI 10.1007/s12544-017-0246-8
   Meng Ying, 2013, Applied Mechanics and Materials, V392, P837, DOI 10.4028/www.scientific.net/AMM.392.837
   Ming K., 2017, 29 CHIN CONTR DEC C
   Miranda DM, 2018, APPL SOFT COMPUT, V70, P66, DOI 10.1016/j.asoc.2018.05.026
   Mohammed MA, 2017, J COMPUT SCI-NETH, V21, P255, DOI 10.1016/j.jocs.2017.04.003
   Montoya A, 2017, TRANSPORT RES B-METH, V103, P87, DOI 10.1016/j.trb.2017.02.004
   Moro A, 2018, TRANSPORT RES D-TR E, V64, P5, DOI 10.1016/j.trd.2017.07.012
   Munari P, 2018, TOP, V26, P437, DOI 10.1007/s11750-018-0481-8
   Nica E., 2015, EC MANAGEMENT FINANC, V1, P69
   Ocicka B, 2017, LOGFORUM, V13, P183, DOI 10.17270/J.LOG.2017.2.6
   Osorio C, 2017, TRANSPORT RES B-METH, V95, P305, DOI 10.1016/j.trb.2016.07.013
   Pecin D, 2017, OPER RES LETT, V45, P206, DOI 10.1016/j.orl.2017.02.006
   Plotz P, 2018, J IND ECOL, V22, P773, DOI 10.1111/jiec.12623
   Pradhan D, 2019, J SYST SOFTWARE, V153, P86, DOI 10.1016/j.jss.2019.03.064
   Raimundo DR, 2018, RESOUR CONSERV RECY, V137, P270, DOI 10.1016/j.resconrec.2018.06.020
   Sharma A, 2017, ENERGY, V133, P1132, DOI 10.1016/j.energy.2017.04.160
   Shen L, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15092025
   Shen PH, 2017, ENERGY, V123, P89, DOI 10.1016/j.energy.2017.01.120
   Song JN, 2018, J CLEAN PROD, V178, P688, DOI 10.1016/j.jclepro.2018.01.062
   Dinh T, 2018, MATH PROGRAM, V172, P105, DOI 10.1007/s10107-017-1151-6
   Tu XJ, 2018, INT J CLIMATOL, V38, pE290, DOI 10.1002/joc.5368
   Vahed A. R., 2013, J HEURISTICS, V19, P497
   Wang C, 2019, J CLEAN PROD, V206, P741, DOI 10.1016/j.jclepro.2018.09.172
   Wang HZ, 2018, INT J BIOL MACROMOL, V112, P473, DOI 10.1016/j.ijbiomac.2018.02.003
   Wang JX, 2019, J CLEAN PROD, V211, P146, DOI 10.1016/j.jclepro.2018.11.123
   Wang Y, 2017, APPL SOFT COMPUT, V56, P143, DOI 10.1016/j.asoc.2017.02.025
   Wang Y, 2017, J CLEAN PROD, V144, P203, DOI 10.1016/j.jclepro.2017.01.001
   Xia Y., 2018, CELLS NANOMED BIOTEC, P1
   Yang J, 2016, RESOUR CONSERV RECY, V113, P140, DOI 10.1016/j.resconrec.2016.06.016
   Yang J, 2015, COMPUT OPER RES, V55, P217, DOI 10.1016/j.cor.2014.07.003
   Yang YK, 2018, J CLEAN PROD, V199, P1066, DOI 10.1016/j.jclepro.2018.06.181
   Yang Z., 2010, COMPUT-AIDED CIV INF, V22, P44
   Ye K, 2017, INFORM SCIENCES, V406, P29, DOI 10.1016/j.ins.2017.04.016
   Zare-Reisabadi E, 2015, COMPUT IND ENG, V90, P177, DOI 10.1016/j.cie.2015.09.002
   Zhang LL, 2019, RESOUR CONSERV RECY, V142, P113, DOI 10.1016/j.resconrec.2018.11.019
   Zhang N, 2015, RENEW SUST ENERG REV, V41, P584, DOI 10.1016/j.rser.2014.08.076
   Zhang S, 2018, INT J PROD ECON, V203, P404, DOI 10.1016/j.ijpe.2018.07.016
   Zhang Z, 2017, J CLEAN PROD, V142, P2060, DOI 10.1016/j.jclepro.2016.11.078
   Zhang ZZ, 2015, TRANSPORT RES B-METH, V82, P20, DOI 10.1016/j.trb.2015.10.001
   Zhou YX, 2018, RESOUR CONSERV RECY, V139, P307, DOI 10.1016/j.resconrec.2018.08.015
NR 74
TC 0
Z9 0
U1 54
U2 54
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104585
DI 10.1016/j.resconrec.2019.104585
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200020
DA 2020-05-12
ER

PT J
AU Li, YY
   Filimonau, V
   Wang, LE
   Cheng, SK
AF Li, Yunyun
   Filimonau, Viachaslau
   Wang, Ling-en
   Cheng, Shengkui
TI Tourist food consumption and its arable land requirements in a popular
   tourist destination
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Tourism; Food consumption; Natural resource intensity; Carrying
   capacity; Arable land requirements; Tibet; China
ID LOCAL FOOD; CONSEQUENCES; WASTE; MODEL
AB Determining the resource intensity and environmental impacts of tourist food consumption is important for the design of sustainable development strategies for tourist destinations. Yet, studies aiming to accurately quantify the environmental repercussions of tourist food consumption for specific destinations are rare and take limited account of temporal changes in food consumption patterns among tourists. This study contributes to knowledge by calculating the impact of temporal changes in tourist food consumption on arable land requirements (ALR) in a popular tourist destination of Lhasa, Tibet. It finds that tourist food consumption per meal has increased by 8% within the period of 2013-15 which translates into over 50% increase in ALR. The study further pinpoints that 84% of the ALR increase is attributed to the animal-based food consumption of tourist. Lastly, the study shows that, in 2015, nearly 62% of the arable land area of the Lhasa region was required to meet the growing tourist demand for food.
C1 [Li, Yunyun; Wang, Ling-en; Cheng, Shengkui] Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, 11A Datun Rd, Beijing 100101, Peoples R China.
   [Li, Yunyun] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China.
   [Filimonau, Viachaslau] Bournemouth Univ, Fac Management, Talbot Campus, Poole BH12 5BB, Dorset, England.
RP Wang, LE (reprint author), Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, 11A Datun Rd, Beijing 100101, Peoples R China.
EM wangle@igsnrr.ac.cn
RI Li, Yunyun/K-9199-2016
OI Li, Yunyun/0000-0003-2945-1908; Filimonau,
   Viachaslau/0000-0001-7353-5696; wang, lingen/0000-0002-1743-4353
FU National Key Research and Development Plan of China [2016YFE0113100];
   National Youth Science Foundation [41701620]; Chinese Academy of
   Sciences Key Deployment [KJZDEW-G20]; Second Tibetan Plateau Scientific
   Expedition and Research Program (STEP) [2019QZKK1002]; Industrial Fusion
   Technology Demonstration Base for Rural Revitalization [SCKJ004]
FX This work was supported by the National Key Research and Development
   Plan of China under Grant number 2016YFE0113100; National Youth Science
   Foundation under Grant number 41701620; Chinese Academy of Sciences Key
   Deployment under Grant number KJZDEW-G20; Industrial Fusion Technology
   Demonstration Base for Rural Revitalization under Grant number SCKJ004;
   and the Second Tibetan Plateau Scientific Expedition and Research
   Program (STEP) under Grant number 2019QZKK1002.
CR [Anonymous], 2014, IB STAT YB 2014
   Arbulu I, 2017, J IND ECOL, V21, P272, DOI 10.1111/jiec.12420
   BELISLE FJ, 1983, ANN TOURISM RES, V10, P497, DOI 10.1016/0160-7383(83)90005-1
   [蔡运龙 Cai Yunlong], 2002, [地理学报, Acta Geographica Sinica], V57, P127
   CHAPPELL GM, 1954, BRIT J NUTR, V8, P325, DOI 10.1079/BJN19540050
   Chen J, 2007, CATENA, V69, P1, DOI 10.1016/j.catena.2006.04.019
   Chen X., 2017, RES CHINAS AGR SUPPL
   Cohen E, 2004, ANN TOURISM RES, V31, P755, DOI 10.1016/j.annals.2004.02.003
   Coles T, 2008, TOURISM INT BUSINESS
   de Ruiter HR, 2015, P NUTR SOC, V74, pE119, DOI 10.1017/S0029665115001342
   Du W., 2014, DYNAMICS EATING AWAY
   Filimonau V, 2011, J SUSTAIN TOUR, V19, P301, DOI 10.1080/09669582.2010.527345
   Frisvoll S, 2016, SCAND J HOSP TOUR, V16, P76, DOI 10.1080/15022250.2015.1066918
   [高利伟 Gao Liwei], 2017, [自然资源学报, Journal of Natural Resources], V32, P12
   Gerbens-Leenes PW, 2002, AGR ECOSYST ENVIRON, V90, P47, DOI 10.1016/S0167-8809(01)00169-4
   Gossling S, 2002, GLOBAL ENVIRON CHANG, V12, P283, DOI 10.1016/S0959-3780(02)00044-4
   Gustaysson J., 2011, GLOBAL FOOD LOSSES F
   Hall C.M., 2003, CONSUMPTION EXPERIEN
   Halldorsdottir P.O., 2016, ENVIRON RES LETT, V11, P125
   Jiang L, 2015, CHINA AGR ECON REV, V7, P240, DOI 10.1108/CAER-11-2013-0150
   Kastner T, 2012, P NATL ACAD SCI USA, V109, P6868, DOI 10.1073/pnas.1117054109
   Kastner T, 2010, LAND USE POLICY, V27, P853, DOI 10.1016/j.landusepol.2009.11.004
   Kaya Y., 1990, IPCC EN IND SUBGR RE
   Large and Medium City Food Development Research Group, 1990, AGR EC ISSUES, V11, P35
   Lhasa City Statistics Bureau, 2016, STAT COMM 2015 NAT E
   Li Y H, 2012, HENAN SCI, V30, P127
   [李云云 Li Yunyun], 2019, [资源科学, Resources Science], V41, P494
   [李云云 Li Yunyun], 2018, [自然资源学报, Journal of Natural Resources], V33, P978
   [李哲敏 LI Zhemin], 2007, [资源科学, Resources science], V29, P27
   [刘春霞 Liu Chunxia], 2018, [中国生态农业学报, Chinese Journal of Eco-Agriculture], V26, P1227
   Luan YB, 2014, S AFR J SCI, V110, P83, DOI 10.1590/sajs.2014/20120088
   Mak AHN, 2012, INT J HOSP MANAG, V31, P928, DOI 10.1016/j.ijhm.2011.10.012
   Mak AHN, 2012, ANN TOURISM RES, V39, P171, DOI 10.1016/j.annals.2011.05.010
   Mangmeechai Aweewan, 2016, International Journal of Environmental Studies, V73, P778, DOI 10.1080/00207233.2016.1166815
   National Tourism Administration of the Peoples Republic, 2014, YB CHINA TOURISM STA
   National Tourism Administration of the Peoples Republic, 2016, YB CHINA TOURISM STA
   OECD/FAO, 2016, OECD FAO AGR OUTL 20
   Penning D.V.F.W.T., 1995, NATURAL RESOURCES LI, P65
   Peters CJ, 2007, RENEW AGR FOOD SYST, V22, P145, DOI 10.1017/S1742170507001767
   Raj R., 2017, CONFLICTS RELIG CULT
   Rutty M., 2015, ROUTLEDGE HDB TOURIS
   Schonhart M, 2009, OUTLOOK AGR, V38, P175, DOI 10.5367/000000009788632313
   Scialabba N.E.-H., 2013, FOOD WASTAGE FOOTPRI
   Sheng L.Y., 2014, CHIN STAT YB 2014
   Sheng L.Y., 2016, CHINA STAT YB 2016
   Sims R, 2009, J SUSTAIN TOUR, V17, P321, DOI 10.1080/09669580802359293
   Tassou SA, 2009, APPL THERM ENG, V29, P1467, DOI 10.1016/j.applthermaleng.2008.06.027
   Telfer D. J., 2000, Tourism Geographies, V2, P421, DOI 10.1080/146166800750035521
   Tian Tian, 2017, Acta Prataculturae Sinica, V26, P53
   Torres R, 2003, ANN TOURISM RES, V30, P546, DOI 10.1016/S0160-7383(02)00103-2
   USDA, 1992, AGR HDB, V697
   Wakeland W., 2012, FOOD ENG SERIES
   Wang E. H, 2007, CONSUMER EC, V23, P53
   Wang LE, 2017, WASTE MANAGE, V66, P3, DOI 10.1016/j.wasman.2017.04.007
   Wang LG, 2018, RESOUR CONSERV RECY, V136, P1, DOI 10.1016/j.resconrec.2018.04.001
   [王灵恩 Wang Lingen], 2016, [自然资源学报, Journal of Natural Resources], V31, P215
   Xiong J., 2017, FOOD NUTR CHINA, V23, P49
   Zhai Feng-ying, 2005, Zhonghua Liu Xing Bing Xue Za Zhi, V26, P485
   Zhao YY, 2014, CHIN POPUL RESOUR EN, V24, P54
   Zhen L, 2010, ECOL ECON, V69, P1443, DOI 10.1016/j.ecolecon.2008.12.008
NR 60
TC 1
Z9 1
U1 9
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104587
DI 10.1016/j.resconrec.2019.104587
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200025
DA 2020-05-12
ER

PT J
AU Liu, GT
   Wang, B
   Cheng, ZX
   Zhang, N
AF Liu, Guangtian
   Wang, Bing
   Cheng, Zhenxing
   Zhang, Ning
TI The drivers of China's regional green productivity, 1999-2013
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Green growth; Biennial weight modified Russell model; Biennial bounded
   adjusted model; China; Green technology
ID DIRECTIONAL DISTANCE FUNCTIONS; ENVIRONMENTAL-REGULATION; TECHNICAL
   EFFICIENCY; ENERGY-CONSERVATION; UNDESIRABLE OUTPUTS; PORTER HYPOTHESIS;
   MALMQUIST INDEX; CO2 EMISSIONS; GROWTH; REGULATIONS
AB This paper investigates the tendencies of China's green total-factor productivity (TFP) and its factors for regional green growth. We strengthen the robustness by constructing three different DEA models. For this purpose, we develop and compare three new measures, i.e. the biennial weight modified Russell model (BWMRM), the biennial bounded adjusted model (BBAM), and the biennial range adjusted model (BRAM). We further propose a related Luenberger productivity indicator and decompose green growth with two different methods, namely, the tradition-decomposition view (TDV) and the factors-decomposition view (FDV). We apply the proposed methodology to China's provincial data between 1999 and 2013. The main findings are as follows: First, China's green productivity has exhibited measurable improvements between 1999 and 2013, and technological progress is the main driving force, while efficiency deterioration has a weak negative effect. Second, the energy conservation and emission reduction performance arc also the critical drivers of green productivity. Specifically, the performance of emission reduction is larger than that of energy conservation. Third, energy conservation and emission reduction improve the green productivity through promoting technical progress, which supports the Porter hypothesis. Fourth, the East and Central areas achieved win-win situation and the effect attained in the East is more remarkable, while the West encountered the "double deterioration" effect.
C1 [Liu, Guangtian; Wang, Bing; Cheng, Zhenxing; Zhang, Ning] Jinan Univ, Coll Econ, Guangzhou 510632, Guangdong, Peoples R China.
   [Liu, Guangtian] PCI Suntek Technol Co Ltd, Guangzhou 510653, Guangdong, Peoples R China.
RP Zhang, N (reprint author), Jinan Univ, Coll Econ, Guangzhou 510632, Guangdong, Peoples R China.
EM zn928@naver.com
FU National Key R&D Program of China [2018YFCO213600]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [71822402, 91746112]; Philosophy and Social Sciences Research of
   Ministry of Education of China [17JZD013]
FX This paper was supported by the National Key R&D Program of China
   (2018YFCO213600), the National Natural Science Foundation of China
   (71822402, 91746112) and Philosophy and Social Sciences Research of
   Ministry of Education of China (17JZD013).
CR Alpay E, 2002, AM J AGR ECON, V84, P887, DOI 10.1111/1467-8276.00041
   Ambec S, 2002, ECON LETT, V75, P355, DOI 10.1016/S0165-1765(02)00005-8
   Ambec S, 2013, REV ENV ECON POLICY, V7, P2, DOI 10.1093/reep/res016
   BARBERA AJ, 1990, J ENVIRON ECON MANAG, V18, P50, DOI 10.1016/0095-0696(90)90051-Y
   Barros CP, 2012, OMEGA-INT J MANAGE S, V40, P1, DOI 10.1016/j.omega.2011.02.005
   Beede D.N., 1992, MEASURING EXPL UNPUB
   Berman E, 2001, REV ECON STAT, V83, P498, DOI 10.1162/00346530152480144
   Bokusheva R, 2012, INT J PROD ECON, V136, P93, DOI 10.1016/j.ijpe.2011.09.017
   Boyd GA, 2002, ENVIRON RESOUR ECON, V23, P29, DOI 10.1023/A:1020236517937
   Boyd GA, 1999, J ENVIRON ECON MANAG, V38, P121, DOI 10.1006/jeem.1999.1082
   Cerin P, 2006, ECOL ECON, V56, P209, DOI 10.1016/j.ecolecon.2005.01.016
   Chang TP, 2012, J BANK FINANC, V36, P1997, DOI 10.1016/j.jbankfin.2012.03.003
   Chen CM., 2012, WORKING PAPER
   Chen P.C., 2011, NONRADIAL DIRECTIONA
   Chen S.Y., 2010, EC RES J, P129
   Chung YH, 1997, J ENVIRON MANAGE, V51, P229, DOI 10.1006/jema.1997.0146
   Cooper WW, 2011, J PROD ANAL, V35, P85, DOI 10.1007/s11123-010-0190-2
   Cooper WW, 1999, J PROD ANAL, V11, P5, DOI 10.1023/A:1007701304281
   Cooper WW, 2007, DATA ENVELOPMENT ANA
   Domazlicky BR, 2004, ENVIRON RESOUR ECON, V28, P301, DOI 10.1023/B:EARE.0000031056.93333.3a
   Fare R, 2010, EUR J OPER RES, V200, P320, DOI 10.1016/j.ejor.2009.01.031
   Fujii H., 2014, DECOMPOSITION PRODUC
   Fujii H, 2015, GLOBAL ENVIRON CHANG, V35, P505, DOI 10.1016/j.gloenvcha.2015.06.005
   Fujii H, 2014, J BANK FINANC, V38, P41, DOI 10.1016/j.jbankfin.2013.09.022
   GOLLOP FM, 1983, J POLIT ECON, V91, P654, DOI 10.1086/261170
   GRAY WB, 1987, AM ECON REV, V77, P998
   Gray WB, 2003, J ENVIRON ECON MANAG, V46, P384, DOI 10.1016/S0095-0696(03)00031-7
   Guan D, 2008, GLOBAL ENVIRON CHANG, V18, P626, DOI 10.1016/j.gloenvcha.2008.08.001
   Hamamoto M, 2006, RESOUR ENERGY ECON, V28, P299, DOI 10.1016/j.reseneeco.2005.11.001
   Hu JL, 2005, INT J SUST DEV WORLD, V12, P429, DOI 10.1080/13504500509469652
   JORGENSON DW, 1990, RAND J ECON, V21, P314, DOI 10.2307/2555426
   Kuosmanen T, 2009, ECOL ECON, V68, P1633, DOI 10.1016/j.ecolecon.2008.07.012
   Lanoie P, 2008, J PROD ANAL, V30, P121, DOI 10.1007/s11123-008-0108-4
   Lanoie P, 2011, J ECON MANAGE STRAT, V20, P803, DOI 10.1111/j.1530-9134.2011.00301.x
   Li K, 2016, APPL ENERG, V168, P351, DOI 10.1016/j.apenergy.2016.01.104
   Liu GT, 2016, ECON SYST, V40, P481, DOI 10.1016/j.ecosys.2015.12.004
   Liu W, 2018, RESOUR CONSERV RECY, V139, P50, DOI 10.1016/j.resconrec.2018.07.017
   Liu X, 2017, J AIR TRANSP MANAG, V65, P99, DOI 10.1016/j.jairtraman.2017.09.009
   Liu Y, 2019, RESOUR CONSERV RECY, V147, P201, DOI 10.1016/j.resconrec.2019.04.013
   Mahlberg B, 2011, INT J PROD ECON, V131, P721, DOI 10.1016/j.ijpe.2011.02.021
   Managi S, 2005, LAND ECON, V81, P303, DOI 10.3368/le.81.2.303
   Mohr RD, 2002, J ENVIRON ECON MANAG, V43, P158, DOI 10.1006/jeem.2000.1166
   Pastor J. T., 2011, SOCIO-ECON PLAN SCI, V45, P10, DOI DOI 10.1016/J.SEPS.2010.09.001
   Picazo-Tadeo AJ, 2005, RESOUR ENERGY ECON, V27, P131, DOI 10.1016/j.reseneeco.2004.07.001
   PORTER ME, 1995, J ECON PERSPECT, V9, P97, DOI 10.1257/jep.9.4.97
   PORTER ME, 1991, SCI AM, V264, P168, DOI 10.1038/scientificamerican0491-168
   PORTER ME, 1995, HARVARD BUS REV, V73, P120
   Rubashkina Y, 2015, ENERG POLICY, V83, P288, DOI 10.1016/j.enpol.2015.02.014
   Sen S, 2015, EUR ECON REV, V80, P36, DOI 10.1016/j.euroecorev.2015.08.004
   Sueyoshi T, 2012, ENERG ECON, V34, P686, DOI 10.1016/j.eneco.2011.10.018
   Wang H, 2013, ENERG ECON, V40, P795, DOI 10.1016/j.eneco.2013.09.030
   Wang QW, 2018, ENERG ECON, V70, P12, DOI 10.1016/j.eneco.2017.12.014
   Yang CH, 2012, RESOUR ENERGY ECON, V34, P514, DOI 10.1016/j.reseneeco.2012.05.001
   Yue SJ, 2019, RESOUR CONSERV RECY, V146, P475, DOI 10.1016/j.resconrec.2019.03.035
   Zhang YB, 2015, ECOL INDIC, V51, P215, DOI 10.1016/j.ecolind.2014.06.042
   Zhao X, 2016, J CLEAN PROD, V112, P1528, DOI 10.1016/j.jclepro.2015.05.029
   Zheng JH, 1998, J COMP ECON, V26, P465, DOI 10.1006/jcec.1998.1540
   Zhou DQ, 2016, APPL ENERG, V166, P201, DOI 10.1016/j.apenergy.2015.09.081
NR 58
TC 0
Z9 0
U1 32
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104561
DI 10.1016/j.resconrec.2019.104561
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200026
DA 2020-05-12
ER

PT J
AU Morseletto, P
AF Morseletto, Piero
TI Targets for a circular economy
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Targets; Circular economy targets; Circular economy governance; Circular
   economy strategies; Resource efficiency
ID LIFE-CYCLE ASSESSMENT; POLICIES; DESIGN; WASTE; LOOP; IMPLEMENTATION;
   CHALLENGES; STRATEGIES; RECOVERY; CHINA
AB The transition to a circular economy requires actions and policies. In the praxis of governance, a common way to steer the transition to a different state proceeds through the setting of targets. Thus far, no study has investigated circular economy targets in a systematic way. To bridge this gap, this study examines which targets can facilitate the transition towards a circular economy. The analysis focuses both on existing and new targets; the latter complement existing targets which are limited to a few discrete cases addressing only partially the goal of a more circular economy. A framework based on 10 common circular economy strategies (i.e. recover, recycling, repurpose, remanufacture, refurbish, repair, re-use, reduce, rethink, refuse) is applied to scrutinise the selected targets. The study clarifies that existing targets for recovery and recycling do not necessarily promote a circular economy, though they are the most commonly applied targets so far. Because of lack of efficacy of recovery and recycling, targets should instead favour other more powerful circular economy strategies. In relation to these, the study looks into new and existing targets showing how they can reduce waste, increase efficiency, close production loops, and maximise retention of the economic value of materials and products. In particular, the study proposes an expanded set of brand new targets for the transition to a circular economy together with a fresh view on targets aimed at scholars and decision-makers alike.
C1 [Morseletto, Piero] Vrije Univ Amsterdam, Fac Earth & Life Sci, Inst Environm Studies IVM, Boelelaan 1087, Amsterdam, Netherlands.
RP Morseletto, P (reprint author), Vrije Univ Amsterdam, Fac Earth & Life Sci, Inst Environm Studies IVM, Boelelaan 1087, Amsterdam, Netherlands.
EM piero.morseletto@vu.nl
RI Morseletto, Piero/N-2142-2019
OI Morseletto, Piero/0000-0002-5921-4471
CR ADEME, 2009, ASS RES REUS REC PAC
   Akenji L, 2016, J CLEAN PROD, V132, P1, DOI 10.1016/j.jclepro.2016.03.071
   Allwood J.M., 2014, HDB RECYCLING STATE, V30, P445, DOI DOI 10.1016/B978-0-12-396459-5.00030-1
   Allwood J. M., 2012, SUSTAINABLE MAT BOTH, P384
   Allwood JM, 2011, RESOUR CONSERV RECY, V55, P362, DOI 10.1016/j.resconrec.2010.11.002
   Andrews D, 2015, LOCAL ECON, V30, P305, DOI 10.1177/0269094215578226
   [Anonymous], 2010, HDB GEN GUID LIF CYC
   Astrup TF, 2015, WASTE MANAGE, V37, P104, DOI 10.1016/j.wasman.2014.06.011
   Babbitt CW, 2018, RESOUR CONSERV RECY, V135, P1, DOI 10.1016/j.resconrec.2018.04.012
   Bahn-Walkowiak B, 2015, RESOURCES-BASEL, V4, P597, DOI 10.3390/resources4030597
   Bakker C., 2014, PRODUCTS LAST PRODUC
   Becker J., 2013, PROCESS MANAGEMENT G
   Bevan G, 2006, PUBLIC ADMIN, V84, P517, DOI 10.1111/j.1467-9299.2006.00600.x
   BioIS-Bio-Intelligence Service, 2013, STUD INCR MECH REC T
   Bird L, 2014, OPENING REMARKS CARP
   Bjorn A, 2017, J CLEAN PROD, V163, P106, DOI 10.1016/j.jclepro.2015.12.095
   Blichert-Toft J., 2017, FUTURE GLOB MINER RE, V6, P1
   Boswell C, 2015, PUBLIC ADMIN, V93, P490, DOI 10.1111/padm.12134
   Bressanelli G, 2019, INT J PROD RES, V57, P7395, DOI 10.1080/00207543.2018.1542176
   Burns B., 2010, LONGER LASTING PRODU, p39e60
   Chapman Jonathan, 2017, ROUTLEDGE HDB SUSTAI
   Charter M., 2007, REMANUFACTURING PROD
   Clark JH, 2016, GREEN CHEM, V18, P3914, DOI 10.1039/c6gc00501b
   Clift R, 2011, CHEM ENG, V837, P30
   Cooper DR, 2017, J IND ECOL, V21, P38, DOI 10.1111/jiec.12388
   Cooper T, 2005, J IND ECOL, V9, P51, DOI 10.1162/1088198054084671
   Crano WD, 2010, SYD SYM SOC PSYCHOL, P3
   Cullen JM, 2017, J IND ECOL, V21, P483, DOI 10.1111/jiec.12599
   de Jesus A, 2018, ECOL ECON, V145, P75, DOI 10.1016/j.ecolecon.2017.08.001
   De los Rios IC, 2017, J CLEAN PROD, V160, P109, DOI 10.1016/j.jclepro.2016.10.130
   Demirbas A, 2009, ENERG CONVERS MANAGE, V50, P2239, DOI 10.1016/j.enconman.2009.05.010
   den Hollander MC, 2017, J IND ECOL, V21, P517, DOI 10.1111/jiec.12610
   Despeisse M, 2017, TECHNOL FORECAST SOC, V115, P75, DOI 10.1016/j.techfore.2016.09.021
   EC [European Commission], 2015, CLOS LOOP EU ACT PLA
   EEA-European Environment Agency, 2016, 2015 OV POL INSTR TA
   Elia V, 2017, J CLEAN PROD, V142, P2741, DOI 10.1016/j.jclepro.2016.10.196
   EMF, 2013, CIRCULAR EC
   EPRS, 2017, CIRC EC WAST MAN EU
   Ferguson M, 2010, SUPPLY CHAIN INTEGR, P1
   Geyer R, 2016, J IND ECOL, V20, P1010, DOI 10.1111/jiec.12355
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Gregson N, 2015, ECON SOC, V44, P218, DOI 10.1080/03085147.2015.1013353
   Guide VDR, 2000, J OPER MANAG, V18, P467, DOI 10.1016/S0272-6963(00)00034-6
   Haas W, 2015, J IND ECOL, V19, P765, DOI 10.1111/jiec.12244
   Haupt M, 2017, INT J LIFE CYCLE ASS, V22, P832, DOI 10.1007/s11367-017-1267-1
   Haupt M, 2017, J IND ECOL, V21, P391, DOI 10.1111/jiec.12439
   Hofmann F, 2019, J CLEAN PROD, V224, P361, DOI 10.1016/j.jclepro.2019.03.115
   Hogg D., 2014, IMPACT ASSESSMENT OP
   Homrich AS, 2018, J CLEAN PROD, V175, P525, DOI 10.1016/j.jclepro.2017.11.064
   Hood Christopher, 2006, POLITICS PUBLIC SERV
   Jani Y, 2014, J ENVIRON CHEM ENG, V2, P1767, DOI 10.1016/j.jece.2014.03.016
   Jawahir IS, 2007, P 1 INT C SUST MAN S, P1
   Jayaraman V, 2006, INT J PROD RES, V44, P981, DOI 10.1080/00207540500250507
   Jensen PD, 2011, RESOUR CONSERV RECY, V55, P703, DOI 10.1016/j.resconrec.2011.02.003
   Kalmykova Y, 2018, RESOUR CONSERV RECY, V135, P190, DOI 10.1016/j.resconrec.2017.10.034
   Karvonen Iris, 2017, Journal of Remanufacturing, V7, P159, DOI 10.1007/s13243-017-0038-2
   King AM, 2006, SUSTAIN DEV, V14, P257, DOI 10.1002/sd.271
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Kristensen DK, 2016, J AGR ENVIRON ETHIC, V29, P749, DOI 10.1007/s10806-016-9632-9
   Lafferty W. M., 2000, IMPLEMENTING SUSTAIN, P337
   Lauber V., 2000, VOLUNTARY APPROACH E, P104
   Laurenti R, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10072129
   Leising E, 2018, J CLEAN PROD, V176, P976, DOI 10.1016/j.jclepro.2017.12.010
   Leslie HA, 2016, ENVIRON INT, V94, P230, DOI 10.1016/j.envint.2016.05.012
   Lester S., 2009, 0909 EPRG U CAMBR
   Lewandowski M, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8010043
   Lewis H, 2010, PACKAG TECHNOL SCI, V23, P145, DOI 10.1002/pts.886
   Lieder M, 2016, J CLEAN PROD, V115, P36, DOI 10.1016/j.jclepro.2015.12.042
   Linder M, 2017, J IND ECOL, V21, P545, DOI 10.1111/jiec.12552
   Linder M, 2017, GREEN CHEM LETT REV, V10, P428, DOI 10.1080/17518253.2017.1392618
   Ludeke-Freund F, 2019, J IND ECOL, V23, P36, DOI 10.1111/jiec.12763
   Lund R., 1998, P 5 INT C ENV CONSC
   Manninen K, 2018, J CLEAN PROD, V171, P413, DOI 10.1016/j.jclepro.2017.10.003
   Masi D, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9091602
   Mayer A, 2019, J IND ECOL, V23, P62, DOI 10.1111/jiec.12809
   McDowall W, 2017, J IND ECOL, V21, P651, DOI 10.1111/jiec.12597
   McDowell J., 2016, SPAIN BECOMES 1 EU C
   Milios L., 2016, POLICIES RESOURCE EF
   Milios L, 2018, SUSTAIN SCI, V13, P861, DOI 10.1007/s11625-017-0502-9
   Mobley R.K., 2002, INTRO PREDICTIVE MAI
   Moreau V, 2017, J IND ECOL, V21, P497, DOI 10.1111/jiec.12598
   Morseletto P., J IND ECOL
   Morseletto P, 2017, INT ENVIRON AGREEM-P, V17, P655, DOI 10.1007/s10784-016-9336-7
   Murray A, 2017, J BUS ETHICS, V140, P369, DOI 10.1007/s10551-015-2693-2
   NELSON RR, 1991, STRATEGIC MANAGE J, V12, P61, DOI 10.1002/smj.4250121006
   Niero M, 2016, RESOUR CONSERV RECY, V114, P18, DOI 10.1016/j.resconrec.2016.06.023
   Nussholz JLK, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9101810
   Otto F., 2005, NATURAL DESIGN
   Pacheco-Torgal F, 2013, WOOD PUBL SER CIVIL, P1, DOI 10.1533/9780857096906.1
   Parida A, 2006, J QUAL MAINT ENG, V12, P239, DOI 10.1108/13552510610685084
   Parris TM, 2003, ANNU REV ENV RESOUR, V28, P559, DOI 10.1146/annurev.energy.28.050302.105551
   Potting J, 2017, CIRCULAR EC MEASURIN
   Prieto-Sandoval V, 2018, J CLEAN PROD, V179, P605, DOI 10.1016/j.jclepro.2017.12.224
   Qi J., 2016, DEV CIRCULAR EC CHIN
   Ranta V, 2018, RESOUR CONSERV RECY, V135, P70, DOI 10.1016/j.resconrec.2017.08.017
   Reike D, 2018, RESOUR CONSERV RECY, V135, P246, DOI 10.1016/j.resconrec.2017.08.027
   Repo P, 2018, EUR J SUSTAIN DEV, V7, P249, DOI 10.14207/ejsd.2018.v7n1p249
   Romero A, 2014, IFIP ADV INF COMM TE, V442, P159
   Rotmans J., 2001, FORESIGHT, V3, P15, DOI DOI 10.1108/14636680110803003
   Sakai S, 2011, J MATER CYCLES WASTE, V13, P86, DOI 10.1007/s10163-011-0009-x
   Santini A, 2010, RESOUR CONSERV RECY, V54, P1128, DOI 10.1016/j.resconrec.2010.03.006
   Sihvonen S, 2017, J CLEAN PROD, V143, P769, DOI 10.1016/j.jclepro.2016.12.047
   Sihvonen S, 2015, PROC CIRP, V29, P639, DOI 10.1016/j.procir.2015.01.026
   Singh J, 2016, J CLEAN PROD, V134, P342, DOI 10.1016/j.jclepro.2015.12.020
   Smol M, 2015, J CLEAN PROD, V95, P45, DOI 10.1016/j.jclepro.2015.02.051
   Sousa-Zomer TT, 2018, RESOUR CONSERV RECY, V135, P3, DOI 10.1016/j.resconrec.2017.10.033
   Su B, 2013, J CLEAN PROD, V42, P215, DOI 10.1016/j.jclepro.2012.11.020
   Tecchio P, 2017, J CLEAN PROD, V168, P1533, DOI 10.1016/j.jclepro.2017.05.198
   Tukker A, 2015, J CLEAN PROD, V97, P76, DOI 10.1016/j.jclepro.2013.11.049
   Tuominen A, 2007, TRANSPORT POLICY, V14, P388, DOI 10.1016/j.tranpol.2007.04.002
   Turner R.K., 1994, EC INCENTIVES ENV PO, P251
   Vedung E., 2010, CARROTS STICKS SERMO, P21
   Vezzoli C., 2008, DESIGN ENV SUSTAINAB
   Voss JP, 2006, REFLEXIVE GOVERNANCE FOR SUSTAINABLE DEVELOPMENT, P1
   Wang L, 2013, J CLEAN PROD, V44, P168, DOI 10.1016/j.jclepro.2012.11.036
   Weide P., 2010, OECD IEA SERIES
   Wheelen T.L., 2004, STRATEGIC MANAGEMENT
   Wieser H, 2016, GAIA, V25, P156, DOI 10.14512/gaia.25.3.5
   Willskytt S., 2016, ECOBALANCE C 2016
   Worrell E., 2014, RECYCLING CONTEXT HD, P1
   Zaman AU, 2015, J CLEAN PROD, V91, P12, DOI 10.1016/j.jclepro.2014.12.013
   ZeroWIN, 2010, ZER WAST IND NETW
   Zhu QH, 2010, J ENVIRON MANAGE, V91, P1324, DOI 10.1016/j.jenvman.2010.02.013
   Zink T, 2017, J IND ECOL, V21, P593, DOI 10.1111/jiec.12545
NR 124
TC 4
Z9 4
U1 28
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104553
DI 10.1016/j.resconrec.2019.104553
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200007
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Pinto, JTM
   Diemer, A
AF Pinto, Julian T. M.
   Diemer, Arnaud
TI Supply chain integration strategies and circularity in the European
   steel industry
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Steel; Europe; Supply chain integration; Circular economy; Closed loop
   supply chains
ID LIFE-CYCLE ASSESSMENT; REVERSE LOGISTICS; EMISSION REDUCTION; ECONOMY;
   IRON; SYSTEMS; REUSE; COMPETITIVENESS; TECHNOLOGIES; STEELMAKING
AB As the environmental mindset became increasingly present in the steel industry, so did the concerns with the developments of its market. In an attempt to address both sides of this challenge, this article aimed at identifying how the implementation of different Supply Chain Integration strategies oriented towards raw material self-sufficiency and resource ownership retention could affect circularity. The European steel industry was used as case study and the effects of closing material loops via Supply Chain Integration were tested by running simulations on an integrated Life Cycle Assessment and System Dynamics model. The results brought to light that different approaches can be environmentally and strategically promising, as well as able to drive improvements in raw material self-sufficiency and in resource ownership retention. Noteworthy were the adoption of vertical hedging strategies on the supply side, and of horizontal hedging strategies on end-of-life for either recycling, refurbishing or repair and maintenance services.
C1 [Pinto, Julian T. M.; Diemer, Arnaud] AdaptEconII Project, Marie Sklodowska Curie Fellowship Act Excellent R, European Commiss Horizon Programme 2020, Clermont Ferrand, France.
   [Pinto, Julian T. M.; Diemer, Arnaud] Univ Clermont Auvergne, CERDI, Clermont Ferrand, France.
   [Pinto, Julian T. M.] Univ Iceland, Dept Ind Engn, Reykjavik, Iceland.
RP Pinto, JTM (reprint author), 26 Ave Leon Blum, F-63000 Clermont Ferrand, France.
EM julian.torres@live.it
OI Pinto, Julian Torres de Miranda/0000-0002-5856-9166
FU European Commission's Horizon 2020 Programme through a Marie Sklodowska
   Curie Fellowship Action in Excellent Research [675153, 4]
FX This article is part of a series of publications aimed at helping to
   improve environmentally-oriented policy-and decision-making in the
   European steel industry, focusing on sustainable resource management. It
   derives from AdaptEconll's project #4, which has received funding from
   the European Commission's Horizon 2020 Programme through a Marie
   Sklodowska Curie Fellowship Action in Excellent Research (Grant
   Agreement no. 675153).
CR Adegoloye G, 2016, CONSTR BUILD MATER, V115, P171, DOI 10.1016/j.conbuildmat.2016.04.036
   [Anonymous], 2017, STUD REV LIST CRIT R
   [Anonymous], 2006, 14044 ISO
   Arik E, 2014, RESOUR POLICY, V42, P10, DOI 10.1016/j.resourpol.2014.08.002
   Beddows R., 2014, STEEL 2050 STEEL TRA
   Bir, 2015, WORLD STEEL REC FIG
   Bjorkman B., 2014, HDB RECYCLING
   Bovea MD, 2016, WASTE MANAGE, V53, P204, DOI 10.1016/j.wasman.2016.03.038
   Bowersox D.J., 1999, 21 CENTURY LOGISTICS
   Braz AC, 2018, J CLEAN PROD, V202, P376, DOI 10.1016/j.jclepro.2018.08.042
   Bringas J.E., 2004, HDB COMP WORLD STEEL
   Burchart-Korol D, 2015, METALURGIJA, V54, P276
   Cannella S, 2016, INT J PROD ECON, V175, P35, DOI 10.1016/j.ijpe.2016.01.012
   Cardoso SR, 2013, EUR J OPER RES, V226, P436, DOI 10.1016/j.ejor.2012.11.035
   CEDED, 2017, MAT FLOWS HOM APPL I
   Chevalier J., 1995, EC IND STRATEGIES EN
   Cooper DR, 2014, RESOUR CONSERV RECY, V84, P24, DOI 10.1016/j.resconrec.2013.11.014
   Cullen JM, 2012, ENVIRON SCI TECHNOL, V46, P13048, DOI 10.1021/es302433p
   Dcosta A.P., 1999, GLOBAL RESTRUCTURING
   Demailly D, 2008, ENERG ECON, V30, P2009, DOI 10.1016/j.eneco.2007.01.020
   Dindarian A., 2011, SUST SYST TECHN C, DOI [10.1109/Issst.2011.5936867, DOI 10.1109/ISSST.2011.5936867]
   Eckelman MJ, 2014, J CLEAN PROD, V80, P38, DOI 10.1016/j.jclepro.2014.05.039
   Ellen Mcarthur Foundation, 2015, DEL CIRC EC TOOLK PO
   Ellen Mcarthur Foundation, 2017, CIRC EC WEALTH FLOWS
   Ellen Mcarthur Foundation, 2014, NEW DYNAMIC EFFECTIV
   Ellen Mcarthur Foundation, 2012, CIRC EC EC BUS RAT A
   Ellen Mcarthur Foundation, 2014, CIRC EC ACC SCAL UP
   Ellen Mcarthur Foundation, 2013, CIRCULAR EC OPPORTUN
   Ellen Mcarthur Foundation, 2015, GROWTH CIRC EC VIS C
   Ellen Mcarthur Foundation, 2016, INT ASS UNL CIRC EC
   Ernst & Young, 2014, GLOB STEEL 2014 PLAN
   Ernst & Young, 2015, GLOB STEEL 2015 16 G
   Ernst & Young, 2017, RIS THREAT SUBST MIN
   Eurofer, 2017, EUR STEEL FIG
   Eurofer, 2017, STEEL BACKB SUST EUR
   European Commission, 2010, ILCD HDB GEN GUID LI
   European Commission, 2012, MAN RES EFF EUR
   European Union, 2011, IMPR EAF PROC CONTR
   EUROSLAG, 2018, EUR ASS MET SLAG PRO
   EUROSTAT, 2018, DAT REP QUANT HAZ SH
   Ferreira H, 2015, J CLEAN PROD, V108, P1081, DOI 10.1016/j.jclepro.2015.05.140
   Gardner DT, 1999, IEEE T ENG MANAGE, V46, P177, DOI 10.1109/17.759146
   Gaur J, 2017, J CLEAN PROD, V167, P1415, DOI 10.1016/j.jclepro.2016.12.098
   Geissdoerfer M, 2017, J CLEAN PROD, V143, P757, DOI 10.1016/j.jclepro.2016.12.048
   Golroudbary SR, 2015, SIMUL MODEL PRACT TH, V53, P88, DOI 10.1016/j.simpat.2015.02.001
   Govindan K, 2017, J CLEAN PROD, V142, P371, DOI 10.1016/j.jclepro.2016.03.126
   Gregson N, 2015, ECON SOC, V44, P218, DOI 10.1080/03085147.2015.1013353
   Gunasekaran A, 2004, EUR J OPER RES, V159, P269, DOI 10.1016/j.ejor.2003.08.016
   Haas W, 2015, J IND ECOL, V19, P765, DOI 10.1111/jiec.12244
   He YJ, 2017, INT J PROD ECON, V183, P39, DOI 10.1016/j.ijpe.2016.10.012
   Heiser D. R., 2006, J SUPPLY CHAIN MANAG, V42, P4, DOI DOI 10.1111/J.1745-493X.2006.00018.X
   Hosoda T, 2018, EUR J OPER RES, V269, P313, DOI 10.1016/j.ejor.2017.07.020
   Islam MT, 2018, RESOUR CONSERV RECY, V137, P48, DOI 10.1016/j.resconrec.2018.05.026
   Jayaram J, 2010, INT J PROD ECON, V125, P262, DOI 10.1016/j.ijpe.2010.02.014
   Johnson J, 2008, ENERG POLICY, V36, P181, DOI 10.1016/j.enpol.2007.08.028
   JRC, 2012, PRODUCT ENV FOOTPRIN
   Kahle L.R., 2014, COMMUNICATING SUSTAI
   Kissling R, 2013, RESOUR CONSERV RECY, V80, P21, DOI 10.1016/j.resconrec.2013.07.009
   Korhonen J, 2004, J CLEAN PROD, V12, P809, DOI 10.1016/j.jelepro.2004.02.026
   Lewandowski M, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8010043
   Liao WJ, 2012, ECOL MODEL, V228, P76, DOI 10.1016/j.ecolmodel.2012.01.004
   Lii P, 2016, INT J PROD ECON, V174, P142, DOI 10.1016/j.ijpe.2016.01.018
   Madias J., 2013, TREATISE PROCESS MET
   Meixell MJ, 2005, TRANSPORT RES E-LOG, V41, P531, DOI 10.1016/j.tre.2005.06.003
   Miao ZW, 2017, OMEGA-INT J MANAGE S, V66, P308, DOI 10.1016/j.omega.2015.11.001
   NFDC, 2012, REC REUS SURV
   Niero M, 2019, RESOUR CONSERV RECY, V140, P305, DOI 10.1016/j.resconrec.2018.10.002
   NRC, 2000, SURV SUPPL CHAIN INT
   Nuss P, 2018, SCI TOTAL ENVIRON, V613, P569, DOI 10.1016/j.scitotenv.2017.09.117
   Panasiyk D, 2016, PROC CIRP, V48, P348, DOI 10.1016/j.procir.2016.04.084
   Park J, 2010, J CLEAN PROD, V18, P1494, DOI 10.1016/j.jclepro.2010.06.001
   Pauliuk S, 2018, RESOUR CONSERV RECY, V129, P81, DOI 10.1016/j.resconrec.2017.10.019
   Pauliuk S, 2017, RESOUR CONSERV RECY, V116, P84, DOI 10.1016/j.resconrec.2016.09.029
   Pauliuk S, 2013, RESOUR CONSERV RECY, V71, P22, DOI 10.1016/j.resconrec.2012.11.008
   PEARCE D, 1989, EC NATURAL RESOURCES
   Pinto Julian T.M., 2019, ENV SYST RES, P8, DOI [10.1186/S40068-019-0144-2, DOI 10.1186/S40068-019-0144-2]
   Prosman EJ, 2017, J IND ECOL, V21, P641, DOI 10.1111/jiec.12535
   Ramirez-Santos AA, 2018, SEP PURIF TECHNOL, V194, P425, DOI 10.1016/j.seppur.2017.11.063
   Reppelin-Hill V, 1999, J ENVIRON ECON MANAG, V38, P283, DOI 10.1006/jeem.1999.1085
   RREUSE, 2012, CHALL BOOST REUS RAT
   Schenkel M, 2015, J MANUF SYST, V37, P729, DOI 10.1016/j.jmsy.2015.04.009
   Schubert E.S., 2011, COGENERATION CHALLEN
   Schultmann F, 2006, EUR J OPER RES, V171, P1033, DOI 10.1016/j.ejor.2005.01.016
   Seager TP, 2002, J CLEAN PROD, V10, P225, DOI 10.1016/S0959-6526(01)00040-3
   Shamsuddin M., 2016, PHYS CHEM METALLURGI
   Shankar R, 2018, INT J PROD ECON, V195, P273, DOI 10.1016/j.ijpe.2017.10.005
   Shou YY, 2018, J PURCH SUPPLY MANAG, V24, P352, DOI 10.1016/j.pursup.2017.11.004
   Su B, 2013, J CLEAN PROD, V42, P215, DOI 10.1016/j.jclepro.2012.11.020
   Sverdrup H., 2014, GEOCHEMICAL PERSPECT, DOI [10.7185/Geochempersp.3.2, DOI 10.7185/GEOCHEMPERSP.3.2]
   Swierczek A, 2014, INT J PROD ECON, V157, P89, DOI 10.1016/j.ijpe.2013.08.010
   Ter fide F., 2006, STAINLESS STEEL RECY
   Truttmann N, 2006, RESOUR CONSERV RECY, V48, P249, DOI 10.1016/j.resconrec.2006.02.003
   Tukker A, 2015, J CLEAN PROD, V97, P76, DOI 10.1016/j.jclepro.2013.11.049
   United Nations Environmental Programme (UNEP), 2011, GREEN EC PATHW SUST
   Uribe-Soto W, 2017, RENEW SUST ENERG REV, V74, P809, DOI 10.1016/j.rser.2017.03.008
   Vaclav S., 2016, STILL IRON AGE
   van der Vaart T, 2004, INT J PROD ECON, V92, P21, DOI 10.1016/j.ijpe.2003.10.002
   van der Vaart T, 2008, INT J PROD ECON, V111, P42, DOI 10.1016/j.ijpe.2006.10.011
   Vickery SK, 2003, J OPER MANAG, V21, P523, DOI 10.1016/j.jom.2003.02.002
   Wang NM, 2019, INT J PROD ECON, V217, P246, DOI 10.1016/j.ijpe.2018.01.002
   Warrian P., 2012, PROFILE STEEL IND GL
   Wiengarten F, 2016, INT J PROD ECON, V171, P361, DOI 10.1016/j.ijpe.2015.03.020
   Winans K, 2017, RENEW SUST ENERG REV, V68, P825, DOI 10.1016/j.rser.2016.09.123
   Worldsteel Association, 2012, SUST STEEL COR GREEN
   Worldsteel Association, 2015, STEEL CIRC EC LIF CY
   Worldsteel Association, 2015, WAT MAN STEEL IND
   Worldsteel Association, 2017, WORLD STEEL FIGURES
   Worldsteel Association, 2012, WHIT BOOK STEEL
   Worldsteel Association, 2017, METH REP LIF CYCL IN
   Worldsteel Association, 2017, STEEL MARK
   Worldsteel Association, 2013, SUST STEEL POL IND 2
   WSSTP, 2013, RES TECHN DEV NEEDS
   Xu L, 2018, RESOUR CONSERV RECY, V131, P297, DOI 10.1016/j.resconrec.2017.10.012
   Yellishetty M., 2012, IRON RESOURCES PRODU
   Yellishetty M, 2011, ENVIRON SCI POLICY, V14, P650, DOI 10.1016/j.envsci.2011.04.008
   Yellishetty M, 2011, J CLEAN PROD, V19, P78, DOI 10.1016/j.jclepro.2010.08.020
   Yildirim IZ, 2011, ADV CIV ENG, DOI 10.1155/2011/463638
   Zore Z, 2018, J CLEAN PROD, V201, P1138, DOI 10.1016/j.jclepro.2018.07.150
NR 118
TC 0
Z9 0
U1 26
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104517
DI 10.1016/j.resconrec.2019.104517
PG 16
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200018
DA 2020-05-12
ER

PT J
AU Rebello, RZ
   Lima, MTWDC
   Yamane, LH
   Siman, RR
AF Rebello, Rafaela Zamprogno
   Dias Carneiro Lima, Maria Tereza Weitzel
   Yamane, Luciana Harue
   Siman, Renato Ribeiro
TI Characterization of end-of-life LED lamps for the recovery of precious
   metals and rare earth elements
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE LED lamps; Characterization; WEEE; Precious metals; Rare earth elements
ID POTENTIAL ENVIRONMENTAL IMPACTS; PRINTED-CIRCUIT BOARDS; E-WASTE;
   GENERATION; MANAGEMENT; GOLD
AB LED (Light Emitting Diode) lamps have been replacing conventional light bulbs (fluorescent and incandescent) due to their lifetime, luminescence power, and energy saving, and thus, the generation of end-of-life LED lamps is increasing. Unpublished data on their composition, focusing in the precious metals and rare earth elements, is presented and is extremely important for future studies involving recycling processes. From samples comminuted in ring mills, loss-on-ignition as well as digestion in aqua regia and nitric acid were used. The results showed that LED lamps had 8 wt.% and 14 wt.% of inorganics, 34 wt.% and 36 wt.% of polymers, and 50 wt.% and 58 wt.% of metals when leached by aqua regia and nitric acid, respectively. Two traditional e-waste leaching agents were used for comparison purposes, and although aqua regia was reported as efficient for the leaching of precious metals, rare earth elements were only verified for leaching with nitric acid. Antimony, silver, aluminum, and copper presented statistically significant differences between the two leaching agents used. The characterization also allowed for identifying the presence of arsenic, which is considered a harmful substance to health. Compared to other types of lamps (fluorescent and incandescent), only LED lamps contain gold, which makes them economically attractive. In this sense, it was concluded that LED lamps must be recycled both from the environmental point of view, regarding the presence of arsenic and the increasing waste generation, and the economic point of view, due to the presence of critical metals and recovery potential.
C1 [Rebello, Rafaela Zamprogno; Yamane, Luciana Harue; Siman, Renato Ribeiro] Univ Fed Espirito Santo, Dept Environm Engn, Av Fernando Ferrari 514, BR-29075910 Vitoria, ES, Brazil.
   [Dias Carneiro Lima, Maria Tereza Weitzel] Univ Fed Espirito Santo, Dept Chem, Av Fernando Ferrari 514, BR-29075910 Vitoria, ES, Brazil.
RP Siman, RR (reprint author), Univ Fed Espirito Santo, Dept Environm Engn, Av Fernando Ferrari 514, BR-29075910 Vitoria, ES, Brazil.
EM rafaelazrebello@gmail.com; mariacarneiro@hotmail.com;
   luciana.yamane@ufes.br; renato.siman@ufes.br
OI Siman, Renato/0000-0003-2939-7403
FU Fundacao de Amparo a Pesquisa e Inovacao do Espirito Santo (FAPES),
   Espirito Santo, Brazil [68781369/2014]
FX This research was supported by the Fundacao de Amparo a Pesquisa e
   Inovacao do Espirito Santo (FAPES), Espirito Santo, Brazil (Process n
   68781369/2014).
CR Berlin U., 2012, C EL GOES GREEN
   Bi XY, 2011, SCI TOTAL ENVIRON, V409, P5126, DOI 10.1016/j.scitotenv.2011.08.009
   Binnemans K, 2014, J RARE EARTH, V32, P195, DOI 10.1016/S1002-0721(14)60051-X
   Chatterjee D, 2018, MUTAT RES-GEN TOX EN, V836, P82, DOI 10.1016/j.mrgentox.2018.06.012
   Cyganowski P, 2017, J SAUDI CHEM SOC, V21, P741, DOI 10.1016/j.jscs.2017.03.007
   De Santi C, 2015, MICROELECTRON RELIAB, V55, P1765, DOI 10.1016/j.microrel.2015.06.080
   dos Santos TS, 2015, ENG SANIT AMBIENT, V20, P595, DOI 10.1590/S1413-41522015020040125106
   Elomaa H., 2017, RECYCLING, V2, P14, DOI [10.3390/recycling2030014, DOI 10.3390/RECYCLING2030014]
   European Lamp Companies Federation, 2009, ENV ASP LAMPS
   Fang S, 2018, J CLEAN PROD, V182, P624, DOI 10.1016/j.jclepro.2018.01.260
   Gil-de-Castro A, 2017, ELECTR POW SYST RES, V146, P107, DOI 10.1016/j.epsr.2017.01.026
   Grandell L, 2016, RENEW ENERG, V95, P53, DOI 10.1016/j.renene.2016.03.102
   Guamieri P., 2016, J CLEAN PROD, DOI [10.1016/j.jdcpro.2016.06.025, DOI 10.1016/J.JDCPRO.2016.06.025]
   Hu SH, 2015, ENVIRON PROG SUSTAIN, V34, P471, DOI 10.1002/ep.12019
   Isildar A, 2018, RESOUR CONSERV RECY, V135, P296, DOI 10.1016/j.resconrec.2017.07.031
   Kumar A, 2019, RESOUR CONSERV RECY, V146, P329, DOI 10.1016/j.resconrec.2019.04.006
   Kumar A, 2017, RESOUR CONSERV RECY, V122, P32, DOI 10.1016/j.resconrec.2017.01.018
   Lim SR, 2013, ENVIRON SCI TECHNOL, V47, P1040, DOI 10.1021/es302886m
   Lim SR, 2011, ENVIRON SCI TECHNOL, V45, P320, DOI 10.1021/es101052q
   Machacek E., 2015, RESOUR CONSERV RECY, DOI [10.1016/j.resconrec.2015.09, DOI 10.1016/J.RESCONREC.2015.09]
   Park S.H., 2016, MICROELECTRON RELIAB, DOI [10.1016/j.microre1.2015.12.006, DOI 10.1016/J.MICRORE1.2015.12.006]
   Park YJ, 2009, J HAZARD MATER, V164, P1152, DOI 10.1016/j.jhazmat.2008.09.043
   Rahman SMM, 2017, RESOUR CONSERV RECY, V127, P256, DOI 10.1016/j.resconrec.2017.04.013
   Sangwan KS, 2014, PROC CIRP, V15, P467, DOI 10.1016/j.procir.2014.06.017
   Sheng PP, 2007, WASTE MANAGE RES, V25, P380, DOI 10.1177/0734242X07076946
   Syed S, 2012, HYDROMETALLURGY, V115, P30, DOI 10.1016/j.hydromet.2011.12.012
   Tunsu C., 2014, HYDROMETALLURGY, DOI [10.1016/j.hydromet2014.01.019, DOI 10.1016/J.HYDROMET2014.01.019]
   Vasilyev F, 2015, HYDROMETALLURGY, V153, P121, DOI 10.1016/j.hydromet.2015.02.004
   Vats MC, 2015, WASTE MANAGE, V45, P280, DOI 10.1016/j.wasman.2015.06.002
   Veit Hugo Marcelo, 2014, Rem: Rev. Esc. Minas, V67, P73, DOI 10.1590/S0370-44672014000100011
   Wakolbinger T, 2014, INT J PROD ECON, V154, P263, DOI 10.1016/j.ijpe.2014.04.025
   Yamane LH, 2011, WASTE MANAGE, V31, P2553, DOI 10.1016/j.wasman.2011.07.006
   Zepf V., 2013, RARE EARTH ELEMENTS, P11, DOI [10.1007/978-3-642-35458-8_2, DOI 10.1007/978-3-642-35458-8_2, 10.1007/978-3-642-35458-8]
   Zhan L., 2015, J HAZARD MATER, DOI [10.1016/j.jhazmat2015.06.029, DOI 10.1016/J.JHAZMAT2015.06.029]
   Zhang SG, 2017, WASTE MANAGE, V65, P113, DOI 10.1016/j.wasman.2017.04.003
NR 35
TC 0
Z9 0
U1 18
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104557
DI 10.1016/j.resconrec.2019.104557
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200011
DA 2020-05-12
ER

PT J
AU Salem, M
   Raab, K
   Wagner, R
AF Salem, Mohammed
   Raab, Katharina
   Wagner, Ralf
TI Solid waste management: The disposal behavior of poor people living in
   Gaza Strip refugee camps
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Gaza Strip camps; Solid waste management; Disposal behavior; recycling;
   Reuse; Emotional outcomes
ID ENVIRONMENTAL BEHAVIOR; QUALITATIVE RESEARCH; PLANNED BEHAVIOR; HUMAN
   HEALTH; ATTITUDES; INTERVIEWS; GENERATION; UNIVERSITY; CONTEXT; IMPACT
AB Solid waste management (SWM) services present a challenge in the Gaza Strip (GS), where the infrastructure is inadequate and currently operating landfills are overloaded. This paper examines the solid waste disposal behavior of poor people living in GS refugee camps. A total of 180 semi-structured, face-to-face interviews were conducted in the eight camps to collect primary data relevant to SWM and to provide a novel account of the routine events, decisions, emotions, and cognitions related to the disposal of basic household items. A majority of the interviewees (88%) perceive a link between their wellbeing and proper waste disposal behavior. The respondents are aware of the adverse impact of improper waste disposal on their health and the surrounding environment, and, despite their limited financial resources, they expressed a willingness to pay for proper SWM services. Current waste disposal practices do not involve separating waste, and heads of households are not keen on encouraging their family members to do so. Only a small fraction of the interviewees (23%) are aware of any environmental initiatives although all confirmed their concern about the underlying environmental and health issues. All interviewees expressed their substantial dissatisfaction with current disposal practices, and the findings reveal that the interviewees who engage in pro-environmental behavior are more content. Poor people living in camps tend to dispose of their possessions in three main ways: giving away, throwing away, and selling their items. These methods should be further investigated to assess their feasibility with regard to overcoming the current SWM challenge.
C1 [Salem, Mohammed] Univ Coll Appl Sci, POB 1415, Remal, Gaza, Palestine.
   [Raab, Katharina; Wagner, Ralf] Univ Kassel, Monchebergstr 1, D-34125 Kassel, Germany.
RP Salem, M (reprint author), Univ Coll Appl Sci, POB 1415, Remal, Gaza, Palestine.
EM mrdd_salem@hotmail.com; raab.katharina@googlemail.com;
   rwagner@wirtschaft.uni-kassel.de
RI Salem, Mohammed/AAB-7026-2020
CR Adeniran AE, 2017, WASTE MANAGE, V67, P3, DOI 10.1016/j.wasman.2017.05.002
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Al-Khatib IA, 2007, WASTE MANAGE, V27, P1910, DOI 10.1016/j.wasman.2006.11.006
   Alhouti S, 2016, J BUS RES, V69, P1242, DOI 10.1016/j.jbusres.2015.09.007
   Ayob SF, 2017, FACILITIES, V35, P696, DOI 10.1108/F-06-2016-0065
   Bamberg S, 2007, J ENVIRON PSYCHOL, V27, P190, DOI 10.1016/j.jenvp.2007.04.001
   BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251
   Caniato M, 2015, WASTE MANAGE, V35, P255, DOI 10.1016/j.wasman.2014.09.018
   De Feo G, 2019, SCI TOTAL ENVIRON, V651, P2380, DOI 10.1016/j.scitotenv.2018.10.161
   De Voir J., 2009, TRACKING EXTERNAL DO
   [EC European Commission Science for Environment Policy], 2011, PLAST WAST EC HUM HL
   Gkargkavouzi A, 2019, RESOUR CONSERV RECY, V148, P145, DOI 10.1016/j.resconrec.2019.01.039
   Goyal Sandeep, 2014, International Journal of Business and Globalisation, V12, P413, DOI 10.1504/IJBG.2014.062843
   Graham-Rowe E, 2014, RESOUR CONSERV RECY, V84, P15, DOI 10.1016/j.resconrec.2013.12.005
   GROB A, 1995, J ENVIRON PSYCHOL, V15, P209, DOI 10.1016/0272-4944(95)90004-7
   GRUNERT KG, 1995, INT J RES MARK, V12, P209, DOI DOI 10.1016/0167-8116(95)00022-T
   Guerrero LA, 2013, WASTE MANAGE, V33, P220, DOI 10.1016/j.wasman.2012.09.008
   Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903
   Ifegbesan AP, 2017, INT J SUST HIGHER ED, V18, P1244, DOI 10.1108/IJSHE-03-2016-0057
   JACOBY J, 1977, J MARKETING, V41, P22, DOI 10.2307/1250630
   Kolk A, 2014, BUS SOC, V53, P338, DOI 10.1177/0007650312474928
   Li D, 2019, RESOUR CONSERV RECY, V146, P28, DOI 10.1016/j.resconrec.2019.03.024
   Liese S., 2018, THESIS
   MADDEN TJ, 1992, PERS SOC PSYCHOL B, V18, P3, DOI 10.1177/0146167292181001
   Marshall RE, 2013, WASTE MANAGE, V33, P988, DOI 10.1016/j.wasman.2012.12.023
   Mattar L, 2018, J CLEAN PROD, V198, P1219, DOI 10.1016/j.jclepro.2018.07.085
   McCarty JA, 2001, J PUBLIC POLICY MARK, V20, P93, DOI 10.1509/jppm.20.1.93.17291
   Ouda O. K. M., 2013, CURR WORLD ENVIRON, V8, P355
   PCBS-Palestinian Central Bureau of Statistics, 2018, PREL RES POP HOUS ES
   Raab K., 2017, EMAC EUR MARK AC C 2
   Saunders SG, 2010, ADV CONSUM RES, V37, P440
   Shearer L, 2017, WASTE MANAGE, V60, P164, DOI 10.1016/j.wasman.2016.09.036
   Shehada W., 2011, THESIS
   Sim J, 2018, INT J SOC RES METHOD, V21, P619, DOI 10.1080/13645579.2018.1454643
   Sourvinou A, 2018, J SUSTAIN TOUR, V26, P649, DOI 10.1080/09669582.2017.1377721
   Tabash MI, 2016, PUBLIC HEALTH, V138, P127, DOI 10.1016/j.puhe.2016.04.001
   Teo M. M. M., 2001, CONSTRUCTION MANAGEM, V19, P741, DOI DOI 10.1080/01446190110067037
   Tolotti G., 2018, DISPOSAL BEHAV UNPUB
   Van der Werff E, 2019, RESOUR CONSERV RECY, V144, P256, DOI 10.1016/j.resconrec.2019.01.032
   VINING JA, 1992, ENVIRON BEHAV, V24, P3, DOI 10.1177/0013916592241001
   Wacker JG, 1998, J OPER MANAG, V16, P361, DOI 10.1016/S0272-6963(98)00019-9
   Wagner R., 2017, GSSI GLOB SAL SCI I
   Webb D, 2013, J ENVIRON PSYCHOL, V35, P59, DOI 10.1016/j.jenvp.2013.04.003
   Wilson D.C., 2015, GLOBAL WASTE MANAGEM
   Woon KS, 2016, RESOUR CONSERV RECY, V107, P104, DOI 10.1016/j.resconrec.2015.11.020
   World Bank, 2018, EC MON REP AD HOC LI
   Yassin MM, 2006, PUBLIC HEALTH, V120, P1177, DOI 10.1016/j.puhe.2006.07.026
   Zulauf K, 2015, PROC EUR CONF ENTREP, P749
NR 48
TC 0
Z9 0
U1 21
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104550
DI 10.1016/j.resconrec.2019.104550
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200028
DA 2020-05-12
ER

PT J
AU Wang, C
   Zhao, LF
   Lim, MK
   Chen, WQ
   Sutherland, JW
AF Wang, Chao
   Zhao, Longfeng
   Lim, Ming K.
   Chen, Wei-Qiang
   Sutherland, John W.
TI Structure of the global plastic waste trade network and the impact of
   China's import Ban
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Plastic waste; International trade; Complex networks; Geo-visualization;
   China's import ban; Percolation theory
ID INTERNATIONAL-TRADE; EVOLUTION; FLOW; PERSPECTIVES; PERCOLATION;
   COUNTRIES; PATTERNS; FEATURES; BELT
AB Millions of tonnes (teragrams) of plastic waste are traded around the world every year, which plays an important role in partially substituting virgin plastics as a source of raw materials in plastic product manufacturing. In this paper, global plastic waste trade networks (GPWTNs) from 1988 to 2017 are established using the UN-Comtrade database. The spatiotemporal evolution of the GPWTNs is analyzed. Attention is given to the country ranks, inter- and intra-continental trade flows, and geo-visual communities in the GPWTNs. We also evaluate the direct and indirect impacts of China's plastic waste import ban on the GPWTNs. The results show that the GPWTNs have small-world and scale-free properties and a core-periphery structure. The geography of the plastic waste trade is structured by Asia as the dominant importer and North America and Europe as the largest sources of plastic waste. China is the unrivaled colossus in the global plastic waste trade. After China's import ban, the plastic waste trade flows have been largely redirected to Southeast Asian countries. Compared with import countries, export countries are more important for the robustness of GPWTNs. Clearly, developed countries will not announce bans on plastic waste exports; these countries have strong motivation to continue to shift plastic waste to poorer countries. However, the import bans from developing countries will compel developed countries to build new disposal facilities and deal with their plastic waste domestically.
C1 [Wang, Chao] Beijing Univ Technol, Coll Econ & Management, Res Base Beijing Modern Mfg Dev, Beijing, Peoples R China.
   [Zhao, Longfeng] Northwestern Polytech Univ, Sch Management, Xian 710021, Shaanxi, Peoples R China.
   [Zhao, Longfeng] Xian Polytech Univ, Sch Management, Xian, Shaanxi, Peoples R China.
   [Lim, Ming K.] Chongqing Univ, Coll Mech Engn, Chongqing, Peoples R China.
   [Lim, Ming K.] Coventry Univ, Ctr Business Soc, Coventry, W Midlands, England.
   [Chen, Wei-Qiang] Chinese Acad Sci, Inst Urban Environm, Key Lab Urban Environm & Hlth, Xiamen, Fujian, Peoples R China.
   [Sutherland, John W.] Purdue Univ, Environm & Ecol Engn, W Lafayette, IN 47907 USA.
RP Zhao, LF (reprint author), Northwestern Polytech Univ, Sch Management, Xian 710021, Shaanxi, Peoples R China.
EM zlfccnu@mails.ccnu.edu.cn
RI Lim, Ming K/D-1476-2017
OI Lim, Ming K/0000-0003-0809-9431; Wang, Chao/0000-0003-2076-9493; Zhao,
   Longfeng/0000-0002-0642-3798
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [61603011, 71901171, 41671523]; CAS Pioneer
   Hundred-Talent Program
FX This work has been supported in part by the National Natural Science
   Foundation of China (61603011,71901171, and 41671523). Wei-Qiang Chen
   acknowledges the financial support from the CAS Pioneer Hundred-Talent
   Program. We gratefully acknowledge the discussions with and the support
   of Professor H. Eugene Stanley from Boston University.
CR Alam O, 2018, RESOUR CONSERV RECY, V132, P121, DOI 10.1016/j.resconrec.2018.01.037
   An HZ, 2014, ENERGY, V74, P254, DOI 10.1016/j.energy.2014.06.095
   [Anonymous], 2018, GUARDIAN
   Barabasi AL, 2003, SCI AM, V288, P60, DOI 10.1038/scientificamerican0503-60
   Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509
   Barigozzi M, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.046104
   Bastian M., 2009, 3 INT AAAI C WEBL SO
   Bing XY, 2015, J CLEAN PROD, V103, P28, DOI 10.1016/j.jclepro.2015.02.019
   Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008
   Botticello J, 2012, TEXTILE, V10, P164, DOI 10.2752/175183512X13315695424356
   Brooks A., 2015, CLOTHING POVERTY HID
   Brooks AL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat0131
   Brooks A, 2013, GEOFORUM, V44, P10, DOI 10.1016/j.geoforum.2012.06.004
   Caschili S, 2015, NETW SPAT ECON, V15, P313, DOI 10.1007/s11067-014-9274-2
   China Federation of Logistics and Purchasing, 2013, NEW REG PLAST WAST T
   Chinese General Administration of Customs, 2017, CHIN GEN ADM CUST LA
   Dilkes-Hoffman LS, 2019, RESOUR CONSERV RECY, V147, P227, DOI 10.1016/j.resconrec.2019.05.005
   Estrada E, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.066102
   Faraca G, 2019, RESOUR CONSERV RECY, V143, P299, DOI 10.1016/j.resconrec.2019.01.014
   Gao CX, 2015, APPL ENERG, V156, P542, DOI 10.1016/j.apenergy.2015.07.054
   Garlaschelli D, 2005, PHYSICA A, V355, P138, DOI 10.1016/j.physa.2005.02.075
   Garlaschelli D, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.188701
   Ge JP, 2016, RESOUR POLICY, V50, P119, DOI 10.1016/j.resourpol.2016.09.002
   Geng Y, 2019, NATURE, V565, P153, DOI 10.1038/d41586-019-00017-z
   Gereffi G., 2014, MANUFACTURING MIRACL
   Geyer R, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700782
   Gibbs C, 2010, CRIMINOL PUBLIC POL, V9, P543, DOI 10.1111/j.1745-9133.2010.00649.x
   GRID-Arendal, 2018, GRID AR STOR MAP TRA
   Hao XQ, 2016, APPL ENERG, V162, P1515, DOI 10.1016/j.apenergy.2015.04.032
   Havlin S, 2015, CHAOS SOLITON FRACT, V72, P4, DOI 10.1016/j.chaos.2014.09.006
   Hojman DA, 2008, J ECON THEORY, V139, P295, DOI 10.1016/j.jet.2007.07.007
   Hu X., 2019, J CLEAN PROD
   Javorsek M., 2016, ARTNET WORKING PAPER
   Ji L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160869
   Ji Q, 2014, ENERG CONVERS MANAGE, V85, P856, DOI 10.1016/j.enconman.2013.12.072
   Kellenberg D, 2015, ANNU REV RESOUR ECON, V7, P109, DOI 10.1146/annurev-resource-100913-012639
   Keller W, 2011, WORLD ECON, V34, P853, DOI 10.1111/j.1467-9701.2011.01358.x
   Kitt Jennifer R., 1994, GEORGETOWN INT ENV L, V7, P485
   kohli Atul, 2012, Rev. Econ. Polit., V32, P531, DOI 10.1590/S0101-31572012000400001
   Lee KT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016356
   Lepawsky J, 2015, GEOGR J, V181, P147, DOI 10.1111/geoj.12077
   Lepawsky J, 2010, CAN GEOGR-GEOGR CAN, V54, P177, DOI 10.1111/j.1541-0064.2009.00279.x
   Liu D, 2019, RESOUR CONSERV RECY, V142, P122, DOI 10.1016/j.resconrec.2018.11.025
   Liu Z, 2018, RESOUR CONSERV RECY, V136, P22, DOI 10.1016/j.resconrec.2018.04.005
   Liu ZG, 2018, J GEOGR SCI, V28, P1233, DOI 10.1007/s11442-018-1522-9
   Pu Y, 2019, RESOUR CONSERV RECY, V151, DOI 10.1016/j.resconrec.2019.104445
   Qu S, 2019, RESOUR CONSERV RECY, V144, P252, DOI 10.1016/j.resconrec.2019.01.004
   Resource Recycling Inc, 2018, THAIL BANS SCRAP PLA
   Saberi AA, 2015, PHYS REP, V578, P1, DOI 10.1016/j.physrep.2015.03.003
   Serrano MA, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.015101
   Shinkuma T, 2009, ENVIRON IMPACT ASSES, V29, P25, DOI 10.1016/j.eiar.2008.04.004
   Siddique R, 2008, WASTE MANAGE, V28, P1835, DOI 10.1016/j.wasman.2007.09.011
   SINGH JB, 1989, J BUS ETHICS, V8, P889, DOI 10.1007/BF00384533
   Song ZY, 2018, J GEOGR SCI, V28, P1249, DOI 10.1007/s11442-018-1523-8
   Soskolne C.L., 2001, GLOB BIOETH, V14, P3
   Velis C., 2014, GLOBAL RECYCLING MAR, P1
   Wang C, 2019, J CLEAN PROD, V206, P741, DOI 10.1016/j.jclepro.2018.09.172
   Wang XB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154575
   Wang ZH, 2016, NATURE, V536, P23, DOI 10.1038/536023a
   Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918
   Weiss J., 2004, OXFORD DEV STUDIES, V32, P283
   Widmer R, 2005, ENVIRON IMPACT ASSES, V25, P436, DOI 10.1016/j.eiar.2005.04.001
   Wilhite A., 2001, Computational Economics, V18, P49, DOI 10.1023/A:1013814511151
   Xu YF, 2019, RESOUR CONSERV RECY, V149, P343, DOI 10.1016/j.resconrec.2019.05.040
   Yang Y, 2015, ENERGY, V93, P534, DOI 10.1016/j.energy.2015.09.079
   Zhong WQ, 2018, RESOUR CONSERV RECY, V136, P345, DOI 10.1016/j.resconrec.2018.05.006
   Zhong WQ, 2014, PHYSICA A, V413, P42, DOI 10.1016/j.physa.2014.06.055
NR 67
TC 2
Z9 2
U1 63
U2 63
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD FEB
PY 2020
VL 153
AR 104591
DI 10.1016/j.resconrec.2019.104591
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA JU0XT
UT WOS:000501403200027
DA 2020-05-12
ER

PT J
AU Miao, SH
   Chen, Y
   Hu, XX
   Zhou, RS
   Ma, Y
AF Miao, Suhua
   Chen, Ying
   Hu, Xinxin
   Zhou, Rongsong
   Ma, Yu
TI An Intraoperative Multibranch Abnormal Muscle Response Monitoring Method
   During Microvascular Decompression for Hemifacial Spasm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Abnormal muscle response; Detection rate; Hemifacial spasm; Lateral
   spread response; Microvascular decompression
ID LATERAL SPREAD RESPONSE; NEUROVASCULAR COMPRESSION; EPHAPTIC
   TRANSMISSION; VASCULAR COMPRESSION; CRANIAL NERVE
AB BACKGROUND: Intraoperative abnormal muscle response (AMR) is widely used as an indicator during microvascular decompression surgery for hemifacial spasm. Usually only 1 muscle is recorded, and not all patients show a response, leaving the surgery somewhat blinded. We propose an improved method to record from multiple muscles innervated by multiple branches of the facial nerve to increase the positive AMR detection rate.
   METHODS: Retrospective analysis was performed of 1604 patients with hemifacial spasm undergoing microvascular decompression at a single center. All patients were monitored for AMR by stimulating the zygomatic branch of the facial nerve. Only mentalis was recorded in 158 cases (single-branch AMR). Orbicularis oris, frontalis, and mentalis were simultaneously monitored in 148 cases (3-branch AMR), and platysma was further added in the remaining 1298 cases (4-branch AMR). Positive AMR detection rates were compared across the groups.
   RESULTS: Total positive AMR detection rates significantly increased as more muscles were included in monitoring and were 74.1% for single-branch AMR, 86.5% for 3-branch AMR, and 98.4% for 4-branch AMR. Detection rates from single muscles were not significantly different across the groups. For all available cases, rates were 73.5% from mentalis, 47.2% from frontalis, 64.1% from orbicularis oris, and 40.8% from platysma.
   CONCLUSIONS: This new multibranch AMR monitoring method can effectively increase the positive detection rate to as high as 98.4%. It is expected to better assist surgery.
C1 [Miao, Suhua; Chen, Ying; Hu, Xinxin; Zhou, Rongsong; Ma, Yu] Tsinghua Univ, Neuromodulat Ctr, YuQuan Hosp, Beijing, Peoples R China.
RP Ma, Y (reprint author), Tsinghua Univ, Neuromodulat Ctr, YuQuan Hosp, Beijing, Peoples R China.
EM mayu@tsinghua.edu.cn
FU Beijing Science and Technology Program [Z181100001718167]; National Key
   Research and Development Program of China [2016YFC0105904YQM]
FX This work was supported by the Beijing Science and Technology Program
   (grant number Z181100001718167) and National Key Research and
   Development Program of China (grant number 2016YFC0105904YQM).
CR Campos-Benitez M, 2008, J NEUROSURG, V109, P416, DOI 10.3171/JNS/2008/109/9/0416
   GARDNER WJ, 1962, J NEUROSURG, V19, P947, DOI 10.3171/jns.1962.19.11.0947
   Heuser K, 2007, EUR J NEUROL, V14, P335, DOI 10.1111/j.1468-1331.2006.01670.x
   Hyun SJ, 2010, NEUROSURG REV, V33, P325, DOI 10.1007/s10143-010-0254-9
   JANNETTA PJ, 1980, ANN SURG, V192, P518, DOI 10.1097/00000658-198010000-00010
   Lee S, 2018, CLIN NEUROPHYSIOL, V129, P1490, DOI 10.1016/j.clinph.2018.03.006
   Li JP, 2012, J CLIN NEUROSCI, V19, P44, DOI 10.1016/j.jocn.2011.04.023
   Misawa S, 2006, J NEUROL NEUROSUR PS, V77, P216, DOI 10.1136/jnnp.2005.073833
   MOLLER AR, 1987, J NEUROSURG, V66, P681, DOI 10.3171/jns.1987.66.5.0681
   MOLLER AR, 1985, NEUROLOGY, V35, P969, DOI 10.1212/WNL.35.7.969
   MOLLER AR, 1991, ACTA NEUROCHIR, V113, P24, DOI 10.1007/BF01402110
   Moller AR, 1999, NEUROL RES, V21, P439
   MOLLER AR, 1987, EXP NEUROL, V98, P110, DOI 10.1016/0014-4886(87)90076-8
   NIELSEN VK, 1984, NEUROLOGY, V34, P418, DOI 10.1212/WNL.34.4.418
   Sekula RF, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09142
   Thirumala PD, 2015, BRIT J NEUROSURG, V29, P818, DOI 10.3109/02688697.2015.1054351
   Tobishima H, 2014, NEUROL MED-CHIR, V54, P474, DOI 10.2176/nmc.oa2012-0204
   Wei YX, 2018, J NEUROSURG, V128, P885, DOI 10.3171/2016.11.JNS162148
   Yamashita S, 2002, MUSCLE NERVE, V25, P845, DOI 10.1002/mus.10123
   Ying TT, 2011, INT J SURG, V9, P347, DOI 10.1016/j.ijsu.2011.02.010
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 1
EP 5
DI 10.1016/j.wneu.2019.10.073
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200134
PM 31639503
DA 2020-05-12
ER

PT J
AU Ding, HQ
   Quan, XY
   Liao, S
   Liu, SJ
   Liu, L
AF Ding, Huaqiang
   Quan, Xingyun
   Liao, Shuai
   Liu, Shengjie
   Liu, Liang
TI Recurrent Acute Subdural Hematoma Due to Middle Meningeal Artery
   Bleeding Treated by Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute subdural hematoma; Embolization; Middle meningeal artery; Minimal
   invasive
ID HEMORRHAGE; ANEURYSM
AB BACKGROUND: Recurrent acute subdural hematomas (ASDHs) are a common complication of neurosurgical operations. However, ASDHs associated with middle meningeal artery (MMA) injury are extremely rare. We encountered a rare case of recurrent ASDH due to MMA bleeding after craniotomy for a non-traumatic ASDH and successfully performed MMA embolization for treatment of it.
   CASE DESCRIPTION: A 56-year-old woman was admitted to our department with progressively worsening headache and vomiting approximately 1 week. She had no history of head trauma and illness. A head computed tomography (CT) scan revealed an ASDH on the right hemisphere. The patient underwent a right-sided craniotomy for evacuation of the hematoma. Two days later, she exhibited impaired consciousness and a repeat CT scan showed a recurrent ASDH. To clarify the cause, we performed cerebral digital subtraction angiography for the patient. Obvious contrast extravasation from the anterior branch of the right MMA was noticed. It was considered to be related to the recurrent ASDH. Embolization of the MMA was performed using Onyx 18 (Micro Therapeutics, Inc., Irvine, California, USA). Follow-up CT scans showed progressive resolution of the ASDH and no recurrence. The patient was discharged without any neurologic deficits.
   CONCLUSIONS: In our case, the relationship between the recurrent ASDH and MMA was observed via angiography and MMA embolization was successfully performed to avoid surgery for reevacuation, suggesting that active bleeding of MMA may be a cause of recurrent ASDH after neurosurgical operations and endovascular exploration, and possible treatment is necessary for an unexplained ASDH.
C1 [Ding, Huaqiang; Quan, Xingyun; Liao, Shuai; Liu, Shengjie; Liu, Liang] Southwest Med Univ, Dept Neurosurg, Affiliated Hosp, Luzhou, Sichuan, Peoples R China.
   [Liu, Liang] Neurosurg Clin Med Res Ctr Sichuan Prov, Luzhou, Sichuan, Peoples R China.
   [Liu, Liang] Academician Expert Workstn Sichuan Prov, Luzhou, Sichuan, Peoples R China.
RP Liu, L (reprint author), Southwest Med Univ, Dept Neurosurg, Affiliated Hosp, Luzhou, Sichuan, Peoples R China.; Liu, L (reprint author), Neurosurg Clin Med Res Ctr Sichuan Prov, Luzhou, Sichuan, Peoples R China.; Liu, L (reprint author), Academician Expert Workstn Sichuan Prov, Luzhou, Sichuan, Peoples R China.
EM liulst@163.com
OI Ding, Huaqiang/0000-0001-9101-4632
CR AOKI N, 1992, SURG NEUROL, V37, P59, DOI 10.1016/0090-3019(92)90068-X
   Ban SP, 2018, RADIOLOGY, V286, P909, DOI 10.1148/radiol.2017170053
   Chrastina J, 2020, EUR J TRAUMA EMERG S, V46, P347, DOI 10.1007/s00068-019-01077-6
   de Andrade AF, 2008, NEUROSURGERY, V62, P416, DOI 10.1227/01.neu.0000316008.11388.f2
   Desai VR, 2016, CUREUS, V8, DOI 10.7759/cureus.616
   Gerosa A, 2019, WORLD NEUROSURG, V128, P225, DOI 10.1016/j.wneu.2019.05.030
   Kohyama S, 2009, MINIM INVAS NEUROSUR, V52, P36, DOI 10.1055/s-0028-1085456
   Kohyama S, 2014, J STROKE CEREBROVASC, V23, pE433, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.014
   KOROSUE K, 1988, NEUROSURGERY, V22, P411, DOI 10.1227/00006123-198802000-00024
   Link TW, NEUROSURGERY, DOI 10.1093/neuros/nyy521
   Marion DW, 2006, NEUROSURGERY, V58, P655
   Hernandez-Diaz ZM, 2019, BEHAV SCI-BASEL, V9, DOI 10.3390/bs9060063
   Mulcahy MJ, 2018, WORLD NEUROSURG, V110, P403, DOI 10.1016/j.wneu.2017.11.152
   Peres CMA, 2018, J NEUROSURG, V128, P1044, DOI 10.3171/2016.11.JNS161398
   Saito A, 2014, CASE REP NEUROL, V6, P122, DOI 10.1159/000362116
   Suyama Y, 2018, BMJ CASE REP, V2018
   Suzuki Masanori, 2014, NMC Case Rep J, V1, P6, DOI 10.2176/nmccrj.2013-0318
   Suzuki S, 2004, AM J NEURORADIOL, V25, P1177
   Vega RA, 2017, NEUROSURG CLIN N AM, V28, P247, DOI 10.1016/j.nec.2016.11.007
   Waqas M, 2019, WORLD NEUROSURG, V126, P228, DOI 10.1016/j.wneu.2019.02.208
   Zussman BM, 2019, WORLD NEUROSURG, V128, P284, DOI 10.1016/j.wneu.2019.05.084
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 6
EP 9
DI 10.1016/j.wneu.2019.10.028
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200135
PM 31622681
DA 2020-05-12
ER

PT J
AU Yanagihara, W
   Beppu, T
   Ogasawara, Y
   Ito, S
   Sato, Y
   Sugai, T
   Ogasawara, K
AF Yanagihara, Wataru
   Beppu, Takaaki
   Ogasawara, Yasushi
   Ito, Shigeki
   Sato, Yuichi
   Sugai, Tamotsu
   Ogasawara, Kuniaki
TI Primary Plasmacytoma in the Cerebellum: A Case Report and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intracranial plasmacytoma; Neuroimaging; Prognosis; Therapy
ID MULTIPLE-MYELOMA; EXTRAMEDULLARY PLASMACYTOMA; SOLITARY PLASMACYTOMA;
   INTRACRANIAL PLASMACYTOMA; BONE; INVOLVEMENT; GUIDELINES; MANAGEMENT;
   SURVIVAL; FEATURES
AB BACKGROUND: Most plasmacytomas arise in the bone marrow (intramedullary), as part of multiple myeloma (MM). In contrast, extramedullary plasmacytoma without MM is rare, and plasmacytoma primarily occurring in the brain parenchyma is extremely rare. Clinical behaviors of primary plasmacytoma in the brain have remained unclear. We report a case of primary plasmacytoma in the cerebellum and review the literature.
   CASE DESCRIPTION: The patient was a 33-year-old woman, displaying vertigo and peripheral facial nerve palsy. A tumor was identified in the subcortical white matter of the middle-upper cerebellum. Magnetic resonance imaging showed no specific findings for this lesion. Tumor was surgically resected because of aggressive tumor growth. Pathologic diagnosis of the tumor was plasmacytoma. The patient was treated with irradiation to the tumor bed after surgery. Although histology of the bone marrow showed a few atypical plasma cells (1%-2%), below the threshold of the diagnostic criterion for MM, we started chemotherapy to prevent occurrence of MM. Neither tumor recurrence nor development of MM was found for 16 months after surgery.
   CONCLUSIONS: Histology is essential for diagnosis of primary plasmacytoma in the brain because of the lack of specific findings on neuroimaging. A finding of a few atypical plasma cells in the bone marrow might support the assumption that extramedullary plasmacytoma represents a harbinger of subsequent development of MM. In addition to appropriate therapies combining maximum tumor removal and radiotherapy to the brain, rigorous hematological management might have contributed to favorable outcomes.
C1 [Yanagihara, Wataru; Beppu, Takaaki; Ogasawara, Yasushi; Sato, Yuichi; Ogasawara, Kuniaki] Iwate Med Univ, Dept Neurosurg, Morioka, Iwate, Japan.
   [Ito, Shigeki] Iwate Med Univ, Dept Internal Med, Hematol & Oncol, Morioka, Iwate, Japan.
   [Sugai, Tamotsu] Iwate Med Univ, Dept Mol Diagnost Pathol, Morioka, Iwate, Japan.
RP Yanagihara, W (reprint author), Iwate Med Univ, Dept Neurosurg, Morioka, Iwate, Japan.
EM wataru.yanagihara.ns@gmail.com
OI Yanagihara, Wataru/0000-0001-6120-0952
CR BINDAL AK, 1995, J NEUROSURG, V83, P218, DOI 10.3171/jns.1995.83.2.0218
   Carneiro FP, 2009, WORLD J GASTROENTERO, V15, P3565, DOI 10.3748/wjg.15.3565
   Cerase A, 2008, NEURORADIOLOGY, V50, P665, DOI 10.1007/s00234-008-0390-x
   Dores GM, 2009, BRIT J HAEMATOL, V144, P86, DOI 10.1111/j.1365-2141.2008.07421.x
   Eum JHD, 2009, J NEUROSURG, V110, P737, DOI 10.3171/2008.2.17652
   KANIE N, 1981, Neurologia Medico-Chirurgica, V21, P337
   Katodritou E, 2014, AM J HEMATOL, V89, P803, DOI 10.1002/ajh.23745
   KRUMHOLZ A, 1982, ANN NEUROL, V11, P529, DOI 10.1002/ana.410110514
   Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432
   Mihaljevic B, 1997, ONCOL REP, V4, P439
   Schwartz TH, 2001, NEUROSURGERY, V49, P1039, DOI 10.1097/00006123-200111000-00002
   SHIH LY, 1995, BRIT J CANCER, V71, P128, DOI 10.1038/bjc.1995.26
   Soutar R, 2004, BRIT J HAEMATOL, V124, P717, DOI 10.1111/j.1365-2141.2004.04834.x
   Tsang RW, 2018, INT J RADIAT ONCOL, V101, P794, DOI 10.1016/j.ijrobp.2018.05.009
   Vallario A, 1999, BRIT J HAEMATOL, V105, P441, DOI 10.1111/j.1365-2141.1999.01321.x
   Vujovic O, 1998, J NEURO-ONCOL, V39, P47, DOI 10.1023/A:1005987120570
   Wilberger AC, 2016, AM J CLIN PATHOL, V146, P156, DOI [10.1093/AJCP/AQW058, 10.1093/ajcp/aqw058]
   WILTSHAW E, 1976, MEDICINE, V55, P217, DOI 10.1097/00005792-197605000-00002
   WISNIEWSKI T, 1990, NEUROSURGERY, V27, P826, DOI 10.1227/00006123-199011000-00026
   Wisniewski T, 2018, NEUROL NEUROCHIR POL, V52, P543, DOI 10.1016/j.pjnns.2018.06.005
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 10
EP 13
DI 10.1016/j.wneu.2019.10.036
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200136
PM 31629133
DA 2020-05-12
ER

PT J
AU Cofano, F
   Marengo, N
   Ajello, M
   Penner, F
   Mammi, M
   Petrone, S
   Lavorato, A
   Zenga, F
   Garbossa, D
AF Cofano, Fabio
   Marengo, Nicola
   Ajello, Marco
   Penner, Federica
   Mammi, Marco
   Petrone, Salvatore
   Lavorato, Andrea
   Zenga, Francesco
   Garbossa, Diego
TI The Era of Cortical Bone Trajectory Screws in Spine Surgery: A
   Qualitative Review with Rating of Evidence
SO WORLD NEUROSURGERY
LA English
DT Review
DE Biomechanics; Cortical bone trajectory; Cortical screws; Posterior
   fixation; Spine surgery; Surgical technique
ID LUMBAR INTERBODY FUSION; CONVENTIONAL PEDICLE SCREW; FIXATION STRENGTH;
   BIOMECHANICAL EVALUATION; CLINICAL-OUTCOMES; MORPHOMETRIC MEASUREMENT;
   RADIOLOGICAL EVALUATION; PARS INTERARTICULARIS; MINERAL DENSITY;
   SPONDYLOLISTHESIS
AB The use of cortical bone trajectory (CBT) pedicle screws for posterior fixation and fusion seems to constitute a viable alternative for spinal procedures, with the potential to mitigate risks, be minimally invasive, and cause less tissue damage than the traditional technique. This review analyzes the literature regarding CBT according to the rate of evidence of articles and their main focus. CBT has proved to be a safe and viable option for screw fixation in spine sup gery. Given the denser bone interception, high-quality biomechanics studies show equal or even better properties compared with classic pedicle screw fixation, depending on several factors such as screw size and length. Through the years, surgical technique has improved to gain a longer and safer trajectory than first described, Level 2 and 3 clinical studies suggest equal clinical and radiologic outcomes compared with pedicle trajectory fixation, but high-quality, level 1, randomized controlled trials are needed to confirm these results.
C1 [Cofano, Fabio; Marengo, Nicola; Ajello, Marco; Penner, Federica; Mammi, Marco; Petrone, Salvatore; Lavorato, Andrea; Zenga, Francesco; Garbossa, Diego] Univ Turin, Dept Neurosci Rita Levi Montalcini, Neurosurg Unit, Turin, Italy.
RP Cofano, F (reprint author), Univ Turin, Dept Neurosci Rita Levi Montalcini, Neurosurg Unit, Turin, Italy.
EM fabio.cofano@gmail.com
FU Ministero dell'Istruzione, dell'Universita e della Ricercae -MIUR
   project "Dipartimenti di eccellenza 2018-2022"
FX This study was supported by Ministero dell'Istruzione, dell'Universita e
   della Ricercae -MIUR project "Dipartimenti di eccellenza 2018-2022".
CR Akpolat YT, 2016, SPINE, V41, pE335, DOI 10.1097/BRS.0000000000001233
   Asamoto S, 2018, J NEUROL SURG PART A, V79, P464, DOI 10.1055/s-0038-1641147
   Ashayeri K, 2018, CLIN SPINE SURG, V31, pE391, DOI 10.1097/BSD.0000000000000676
   Ashayeri K, 2016, EUR SPINE J, V25, P3760, DOI 10.1007/s00586-016-4561-x
   Baluch DA, 2014, SPINE, V39, pE1297, DOI 10.1097/BRS.0000000000000553
   Bielecki M, 2016, VIDEOSURGERY MINIINV, V11, P156, DOI 10.5114/wiitm.2016.62289
   Bohl MA, 2018, WORLD NEUROSURG, V113, pE480, DOI 10.1016/j.wneu.2018.02.060
   Bruzzo Mattia, 2017, J Neurosurg Sci, DOI 10.23736/S0390-5616.17.03976-5
   Chen CH, 2018, J CLIN NEUROSCI, V48, P224, DOI 10.1016/j.jocn.2017.11.008
   Chen YR, 2016, CUREUS, V8, DOI 10.7759/cureus.714
   Chen YR, 2018, CUREUS, V10, DOI 10.7759/cureus.3462
   Cheng WK, 2018, J CLIN NEUROSCI, V47, P304, DOI 10.1016/j.jocn.2017.09.012
   Cheng WK, 2016, SPINE J, V16, pE59, DOI 10.1016/j.spinee.2015.09.046
   Cheng WK, 2015, INT J SPINE SURG, V9, DOI 10.14444/2046
   Chin KR, 2017, CLIN SPINE SURG, V30, pE791, DOI 10.1097/BSD.0000000000000436
   Cofano F, 2019, NEUROSURG REV, V42, P297, DOI 10.1007/s10143-017-0939-4
   Dabbous B, 2016, ACTA NEUROCHIR, V158, P1413, DOI 10.1007/s00701-016-2810-8
   Dayani F, 2019, J CLIN NEUROSCI, V61, P106, DOI 10.1016/j.jocn.2018.10.131
   Delgado-Fernandez J, 2017, ASIAN SPINE J, V11, P817, DOI 10.4184/asj.2017.11.5.817
   Elmekaty M, 2018, ASIAN SPINE J, V12, P870, DOI 10.31616/asj.2018.12.5.870
   Feng ZH, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017227
   Gao H, 2018, CLIN SPINE SURG, V31, pE329, DOI 10.1097/BSD.0000000000000651
   Gautschi OP, 2017, J NEUROSURG SCI, V61, P335, DOI 10.23736/S0390-5616.16.03230-6
   Glennie RA, 2015, J CLIN NEUROSCI, V22, P972, DOI 10.1016/j.jocn.2015.01.010
   Goel A, 2018, J NEUROSURG-SPINE, V29, P121, DOI 10.3171/2017.12.SPINE171338
   Goldstein MJ, 2016, SPINE, V41, pE1421, DOI 10.1097/BRS.0000000000001652
   Grigoryan G, 2019, OPER NEUROSURG, V17, P396, DOI 10.1093/ons/opy388
   Hayashi K, 2018, J CLIN NEUROSCI, V57, P79, DOI 10.1016/j.jocn.2018.08.032
   Hoffman H, 2019, INT J SPINE SURG, V13, P33, DOI 10.14444/6005
   Huang HM, 2018, J CLIN NEUROSCI, V55, P103, DOI 10.1016/j.jocn.2018.06.033
   Hung CW, 2016, CLIN NEUROL NEUROSUR, V145, P41, DOI 10.1016/j.clineuro.2016.03.005
   Hussain I, 2018, WORLD NEUROSURG, V110, pE504, DOI 10.1016/j.wneu.2017.11.034
   Iwatsuki K, 2014, ORTHOP SURG, V6, P244, DOI 10.1111/os.12122
   Kaito T, 2018, J ORTHOP SCI, V23, P865, DOI 10.1016/j.jos.2018.06.005
   Karsy M, 2017, CUREUS, V9, DOI 10.7759/cureus.1419
   Kasukawa Y, 2015, ASIAN SPINE J, V9, P440, DOI 10.4184/asj.2015.9.3.440
   Kaye ID, 2017, JBJS REV, V5, DOI 10.2106/JBJS.RVW.16.00120
   Keorochana G, 2017, WORLD NEUROSURG, V102, P340, DOI 10.1016/j.wneu.2017.03.010
   Khanna N, 2016, SPINE, V41, pS90, DOI 10.1097/BRS.0000000000001475
   Kim SB, 2018, TECH ORTHOP, V33, P246, DOI 10.1097/BTO.0000000000000285
   Kojima K, 2015, ACTA NEUROCHIR, V157, P1173, DOI 10.1007/s00701-015-2432-6
   Kotheeranurak V, 2019, WORLD NEUROSURG, V122, P469, DOI 10.1016/j.wneu.2018.10.029
   Le XF, 2018, WORLD NEUROSURG, V120, pE745, DOI 10.1016/j.wneu.2018.08.157
   Lee GW, 2018, WORLD NEUROSURG, V117, pE154, DOI 10.1016/j.wneu.2018.05.218
   Lee GW, 2018, WORLD NEUROSURG, V109, pE194, DOI 10.1016/j.wneu.2017.09.137
   Lee GW, 2015, SPINE J, V15, P1519, DOI 10.1016/j.spinee.2015.02.038
   Li HM, 2018, WORLD NEUROSURG, V119, pE717, DOI 10.1016/j.wneu.2018.07.253
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Mai HT, 2016, SPINE J, V16, P835, DOI 10.1016/j.spinee.2015.11.034
   Marengo N, 2019, WORLD NEUROSURG, V130, pE98, DOI 10.1016/j.wneu.2019.05.241
   Marengo N, 2018, EUR SPINE J, V27, P213, DOI 10.1007/s00586-018-5599-8
   Marengo N, 2018, BIOMED RES INT, DOI 10.1155/2018/7424568
   Matsukawa K, 2018, ACTA NEUROCHIR, V160, P405, DOI 10.1007/s00701-017-3424-5
   Matsukawa K, 2017, CLIN SPINE SURG, V30, P301, DOI 10.1097/BSD.0000000000000258
   Matsukawa K, 2017, CLIN SPINE SURG, V30, pE497, DOI 10.1097/BSD.0000000000000130
   Matsukawa K, 2016, SPINE, V41, pE851, DOI 10.1097/BRS.0000000000001459
   Matsukawa K, 2016, J NEUROSURG-SPINE, V24, P910, DOI 10.3171/2015.11.SPINE15926
   Matsukawa K, 2016, ACTA NEUROCHIR, V158, P465, DOI 10.1007/s00701-016-2705-8
   Matsukawa K, 2015, ORTHOP SURG, V7, P317, DOI 10.1111/os.12212
   Matsukawa K, 2015, J NEUROSURG-SPINE, V23, P471, DOI 10.3171/2015.1.SPINE141103
   Matsukawa K, 2015, SPINE, V40, pE873, DOI 10.1097/BRS.0000000000000983
   Matsukawa K, 2014, J NEUROSURG-SPINE, V21, P203, DOI 10.3171/2014.3.SPINE13665
   Matsukawa K, 2014, SPINE, V39, pE240, DOI 10.1097/BRS.0000000000000116
   Matsukawa K, 2013, J SPINAL DISORD TECH, V26, pE248, DOI 10.1097/BSD.0b013e318288ac39
   Mendenhall S, 2019, J NEUROSURG-PEDIATR, V23, P1, DOI 10.3171/2018.10.PEDS18327
   Miyakoshi N, 2018, CASE REP ORTHOP, V2018
   Mizuno M, 2014, NEUROL MED-CHIR, V54, P716, DOI 10.2176/nmc.st.2013-0395
   Mobbs RJ, 2016, SPINE J, V16, P842, DOI 10.1016/j.spinee.2016.02.041
   Mobbs RJ, 2013, ORTHOP SURG, V5, P56, DOI 10.1111/os.12027
   Mori K, 2016, ASIAN SPINE J, V10, P238, DOI 10.4184/asj.2016.10.2.238
   Mullin JP, 2016, J NEUROSURG-SPINE, V25, P727, DOI 10.3171/2016.4.SPINE151483
   Ninomiya K, 2016, ASIAN SPINE J, V10, P901, DOI 10.4184/asj.2016.10.5.901
   Ninomiya K, 2016, ASIAN SPINE J, V10, P251, DOI 10.4184/asj.2016.10.2.251
   Ninomiya K, 2015, ASIAN SPINE J, V9, P884, DOI 10.4184/asj.2015.9.6.884
   Ohkawa T, 2015, ORTHOP SURG, V7, P232, DOI 10.1111/os.12189
   Orita S, 2016, J NEUROL SURG PART A, V77, P531, DOI 10.1055/s-0035-1566118
   Oshino H, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018-015-0270-0
   Pacione D, 2015, J CLIN NEUROSCI, V22, P899, DOI 10.1016/j.jocn.2014.09.025
   Patel SS, 2016, J CLIN NEUROSCI, V24, P63, DOI 10.1016/j.jocn.2015.07.018
   Penner F, 2019, WORLD NEUROSURG, V126, pE1468, DOI 10.1016/j.wneu.2019.03.121
   Perez-Orribo L, 2013, SPINE, V38, P635, DOI 10.1097/BRS.0b013e318279a95e
   Phan K, 2018, WORLD NEUROSURG, V110, P502, DOI 10.1016/j.wneu.2017.09.042
   Phan Kevin, 2017, J Spine Surg, V3, P679, DOI 10.21037/jss.2017.11.03
   Phan K, 2015, ORTHOP SURG, V7, P213, DOI 10.1111/os.12185
   Rexiti P, 2018, AM J TRANSL RES, V10, P2413
   Rodriguez A, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13521
   Sakaura H, 2019, ASIAN SPINE J, V13, P248, DOI 10.31616/asj.2018.0169
   Sakaura H, 2018, J NEUROSURG-SPINE, V28, P57, DOI 10.3171/2017.5.SPINE161154
   Sakaura H, 2016, J NEUROSURG-SPINE, V25, P591, DOI 10.3171/2016.3.SPINE151525
   Sakaura H, 2016, ASIAN SPINE J, V10, P639, DOI 10.4184/asj.2016.10.4.639
   Sansur CA, 2016, J NEUROSURG-SPINE, V25, P467, DOI 10.3171/2016.2.SPINE151046
   Santoni BG, 2009, SPINE J, V9, P366, DOI 10.1016/j.spinee.2008.07.008
   Sellin JN, 2018, J NEUROSURG-PEDIATR, V21, P190, DOI 10.3171/2017.7.PEDS17240
   Senoglu M, 2017, WORLD NEUROSURG, V103, P694, DOI 10.1016/j.wneu.2017.03.137
   Sheng SR, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004676
   Shi SY, 2018, WORLD NEUROSURG, V117, pE82, DOI 10.1016/j.wneu.2018.05.168
   Snyder LA, 2016, WORLD NEUROSURG, V88, P205, DOI 10.1016/j.wneu.2015.12.065
   Song TF, 2014, CHINESE MED J-PEKING, V127, P3808, DOI 10.3760/cma.j.issn.0366-6999.20141887
   Takata Y, 2014, J MED INVESTIG, V61, P388, DOI 10.2152/jmi.61.388
   Takenaka S, 2017, CLIN SPINE SURG, V30, pE1411, DOI 10.1097/BSD.0000000000000514
   Tortolani PJ, 2016, J AM ACAD ORTHOP SUR, V24, P755, DOI 10.5435/JAAOS-D-15-00597
   Tschugg A, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2504-z
   Ueno M, 2015, J NEUROSURG-SPINE, V22, P416, DOI 10.3171/2014.9.SPINE1484
   Ueno M, 2013, J NEUROSURG-SPINE, V19, P600, DOI 10.3171/2013.7.SPINE13191
   Wang JZ, 2019, EUR SPINE J, V28, P1678, DOI 10.1007/s00586-019-05999-y
   Wang K, 2019, WORLD NEUROSURG, V125, pE348, DOI 10.1016/j.wneu.2019.01.076
   Wochna JC, 2018, CUREUS, V10, DOI 10.7759/cureus.2891
   Wray S, 2015, J NEUROSURG-SPINE, V22, P503, DOI 10.3171/2014.10.SPINE14205
   Wright JG, 2003, J BONE JOINT SURG AM, V85A, P1, DOI 10.2106/00004623-200301000-00001
   Xuan J, 2018, WORLD NEUROSURG, V116, pE1023, DOI 10.1016/j.wneu.2018.05.152
   Xuan J, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005852
   Xuan J, 2016, EUR SPINE J, V25, P4199, DOI 10.1007/s00586-016-4730-y
   Zhang H, 2016, EUR SPINE J, V25, P870, DOI 10.1007/s00586-015-4224-3
   Zhang RJ, 2019, J NEUROSURG-SPINE, V30, P759, DOI 10.3171/2018.12.SPINE18970
NR 114
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 14
EP 24
DI 10.1016/j.wneu.2019.10.079
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200137
PM 31639506
DA 2020-05-12
ER

PT J
AU Chagoya, G
   Hardigan, AA
   Fox, BM
   Laskay, N
   Salehani, AA
   Rotman, LE
   Elsayed, GA
   Bernstock, JD
   Omar, NB
   Tabibian, BE
   Ilyas, A
   Hackney, J
   Fisher, WS
AF Chagoya, Gustavo
   Hardigan, Andrew A.
   Fox, Brandon M.
   Laskay, Nicholas
   Salehani, Arsalaan A.
   Rotman, Lauren E.
   Elsayed, Galal A.
   Bernstock, Joshua D.
   Omar, Nidal B.
   Tabibian, B. Ethan
   Ilyas, Adeel
   Hackney, James
   Fisher, Winfield S., III
TI Cerebellar Arteriovenous Malformation Rupture Despite Apparent
   Angiographic Obliteration
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiographic obliteration; Arteriovenous malformation; Cerebellar
   hemorrhage; Intracerebral hemorrhage
ID GAMMA-KNIFE; HEMORRHAGE RATES; RADIOSURGERY; RISK; ADULT
AB BACKGROUND: Arteriovenous malformations (AVMs) can occur in all regions of the brain and spinal cord, with clinical consequences and risks varying by location. Delayed AVM rupture despite digital subtraction angiography- confirmed obliteration post-radiation is exceedingly rare.
   CASE DESCRIPTION: To our knowledge, we present the first documented of delayed hemorrhage associated with a cerebellar AVM 5 years after linear accelerator-based radiation in a man aged 31 years despite apparent anoiographic obliteration.
   CONCLUSIONS: Intracranial hemorrhage after radiosurgery in digital subtraction angiography-confirmed obliterated AVMs is rare, with limited understanding of risk factors, appropriate preventative management, and mechanisms of occurrence. This case serves to demonstrate the need for greater awareness of this rare complication, as well as the need for appropriate surveillance and management strategies.
C1 [Chagoya, Gustavo; Hardigan, Andrew A.; Fox, Brandon M.; Laskay, Nicholas; Salehani, Arsalaan A.; Rotman, Lauren E.; Elsayed, Galal A.; Omar, Nidal B.; Tabibian, B. Ethan; Ilyas, Adeel; Fisher, Winfield S., III] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
   [Hardigan, Andrew A.; Fox, Brandon M.] Univ Alabama Birmingham, Dept Med Scientist Training Program, Birmingham, AL USA.
   [Hackney, James] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Bernstock, Joshua D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
RP Chagoya, G (reprint author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
EM gchagoya@uabmc.edu
OI Chagoya, Gustavo/0000-0002-8337-4467
FU University of Alabama at Birmingham Medical Scientist Training Program
FX D.B. has positions/equity in CITC Ltd. and Avidea Technologies. All
   other authors declare that they have no competing interests. This work
   was accomplished with the support from the University of Alabama at
   Birmingham Medical Scientist Training Program to A.A.H. and B.M.F.
CR ABE M, 1989, J NEUROL NEUROSUR PS, V52, P167, DOI 10.1136/jnnp.52.2.167
   Abla AA, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14211
   Aboukais R, 2017, J NEUROSURG, V126, P1088, DOI 10.3171/2016.3.JNS152846
   Antico J, 2003, INTERV NEURORADIOL, V9, P113, DOI 10.1177/15910199030090S222
   Beijnum J van, 2014, JAMA-J AM MED ASSOC, V306, P2011
   Bostrom JP, 2016, WORLD NEUROSURG, V94, P328, DOI 10.1016/j.wneu.2016.07.016
   Bowden G, 2014, J NEUROSURG, V120, P583, DOI 10.3171/2013.9.JNS131022
   Bradac O, 2010, CENT EUR NEUROSURG, V71, P92, DOI 10.1055/s-0029-1220937
   Codd PJ, 2008, J NEUROSURG, V109, P486, DOI 10.3171/JNS/2008/109/9/0486
   da Costa L, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.1.E6
   Flickinger JC, 2013, PROG NEUROL SURG, V27, P49, DOI 10.1159/000341623
   Grady C, 2017, J NEUROSURG, V126, P1899, DOI 10.3171/2016.4.JNS152320
   Heron DE, 2018, STEREOTACTIC RADIOSU
   Heros RC, 2005, J NEUROSURG, V102, P829, DOI 10.3171/jns.2005.102.5.0829
   Hino A, 1999, SURG NEUROL, V52, P156, DOI 10.1016/S0090-3019(99)00060-9
   Karlsson B, 1997, NEUROSURGERY, V40, P425, DOI 10.1097/00006123-199703000-00001
   Maruyama K, 2005, NEW ENGL J MED, V352, P146, DOI 10.1056/NEJMoa040907
   NAGATA S, 1991, Neurologia Medico-Chirurgica, V31, P406, DOI 10.2176/nmc.31.406
   Orio P, 2006, J NEUROSURG, V105, P58, DOI 10.3171/sup.2006.105.7.58
   Parkhutik V, 2012, STROKE, V43, P1247, DOI 10.1161/STROKEAHA.111.635789
   Pellettieri L, 1997, ACTA RADIOL, V38, P2
   Prat R, 2009, SURG NEUROL, V71, P211, DOI 10.1016/j.surneu.2007.07.046
   Rodriguez-Hernandez A, 2012, NEUROSURGERY, V71, P1111, DOI 10.1227/NEU.0b013e318271c081
   Rutledge WC, 2014, TRANSL STROKE RES, V5, P538, DOI 10.1007/s12975-014-0351-0
   Shin M, 2005, J NEUROSURG, V102, P842, DOI 10.3171/jns.2005.102.5.0842
   Sorenson TJ, 2018, WORLD NEUROSURG, V116, pE856, DOI 10.1016/j.wneu.2018.05.117
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Stapf C, 2002, J NEUROL NEUROSUR PS, V73, P294, DOI 10.1136/jnnp.73.3.294
   Torne R, 2015, CLIN NEUROL NEUROSUR, V134, P37, DOI 10.1016/j.clineuro.2015.04.003
   Whitehead KJ, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a006635
   Yahya S, 2017, J CLIN NEUROSCI, V38, P91, DOI 10.1016/j.jocn.2016.12.015
   Yang WY, 2019, WORLD NEUROSURG, V122, pE1615, DOI 10.1016/j.wneu.2018.11.193
   Yen CP, 2007, J NEUROSURG, V106, P361, DOI 10.3171/jns.2007.106.3.361
   Yen CP, 2011, STROKE, V42, P1691, DOI 10.1161/STROKEAHA.110.602706
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 25
EP 32
DI 10.1016/j.wneu.2019.10.067
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200138
PM 31629928
DA 2020-05-12
ER

PT J
AU Arganaraz, R
   Saenz, A
   Linares, JM
   Martinez, P
   Bailez, M
   Mantese, B
AF Arganaraz, Romina
   Saenz, Amparo
   Manuel Linares, Juan
   Martinez, Patricia
   Bailez, Marcela
   Mantese, Beatriz
TI New Simulator for Neuroendoscopy: A Realistic and Attainable Model
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biological models; Neuroendoscopy; Neurosurgical education; Simulation;
   Surgical training
ID ANEURYSM
AB OBJECTIVE: To present an attainable and realistic model for neuroendoscopic simulation which replicates exercises of tissue biopsy and coagulation and membrane fenestration.
   METHODS: We presented a stepwise method to create a neuroendoscopic simulation model using bovine brain and membrane units made by a soda cup covered by an amniotic membrane inside an expanded polystyrene spherical container. We used face validation for preliminary evaluation. We also rated the students before and after training with the NEVAT global rating scale (GRS) and recorded the time required to complete all 3 procedures (third ventriculostomy, tissue biopsy, and coagulation). The total cost of the model was $5.
   RESULTS: The experts consider this new model as capable of reproducing real surgical situations with great similarity to the human brain. We tested the model in 20 trainees. The median GRS score before the training was 9 (range, 7-12). After repeated training and performance feedback, the final median GRS score was 41 (range, 37.5-45; P < 0.0001). The time needed to finish the exercises before training was 33 minutes (range, 30.5-42.5 minutes), and after using the model the final median time was 20 minutes (range, 17.5-22 minutes; P < 0.0001).
   CONCLUSIONS: Simulators for neuroendoscopy described so far are reliable, but they entail a high cost. Models with live animals, although of lower cost, are questioned from an ethical point of view. In the current work, we describe a high fidelity ventricular neuroendoscopic simulator model that, because of its low cost, can be replicated in any training center that has a neuroendoscope.
C1 [Arganaraz, Romina; Saenz, Amparo; Manuel Linares, Juan; Mantese, Beatriz] Pediat Hosp Prof Dr Juan P Garrahan, Neurosurg Dept, Buenos Aires, DF, Argentina.
   [Manuel Linares, Juan; Martinez, Patricia; Bailez, Marcela] Pediat Hosp Prof Dr Juan P Garrahan, Simulat Dept, Buenos Aires, DF, Argentina.
RP Saenz, A (reprint author), Pediat Hosp Prof Dr Juan P Garrahan, Neurosurg Dept, Buenos Aires, DF, Argentina.
EM amparo_saenz@hotmail.com
CR Bjerrum F, 2018, MED TEACH, V40, P668, DOI 10.1080/0142159X.2018.1472754
   Bout HJ, 2014, LAB ANIMAL, V43, P411, DOI 10.1038/laban.572
   Breimer GE, 2015, CHILD NERV SYST, V31, P1247, DOI 10.1007/s00381-015-2716-4
   Coelho G, 2015, CHILD NERV SYST, V31, P213, DOI 10.1007/s00381-014-2538-9
   Coelho G, 2014, CHILD NERV SYST, V30, P1997, DOI 10.1007/s00381-014-2548-7
   Di Ieva A, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.09.005
   Ferreira CD, 2014, CHILD NERV SYST, V30, P1209, DOI 10.1007/s00381-013-2346-7
   Filho Francisco Vaz Guimaraes, 2011, Neurosurg Focus, V30, pE17, DOI 10.3171/2011.2.FOCUS10321
   Horowitz M, 2001, NEUROSURGERY, V49, P1461, DOI 10.1097/00006123-200112000-00031
   Jaimovich SG, 2016, CHILD NERV SYST, V32, P345, DOI 10.1007/s00381-015-2936-7
   Louhimies S, 2002, ATLA-ALTERN LAB ANIM, V30, P217, DOI 10.1177/026119290203002S36
   Sastry RA, 2018, J NEUROSURG-PEDIATR, V21, P90, DOI 10.3171/2017.7.PEDS17235
   Sugden C, 2010, SURG CLIN N AM, V90, P519, DOI 10.1016/j.suc.2010.02.009
   Winer JL, 2015, J NEUROSURG, V123, P1316, DOI 10.3171/2014.10.JNS1497
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 33
EP 38
DI 10.1016/j.wneu.2019.10.092
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200139
PM 31655233
DA 2020-05-12
ER

PT J
AU Chen, LZ
   Jiang, Y
   Hu, FY
   He, L
   Zheng, HB
AF Chen, Lizhang
   Jiang, Yi
   Hu, Fayun
   He, Li
   Zheng, Hongbo
TI Endovascular Revascularization of Nonacute Symptomatic Proximal
   Extracranial Vertebral Artery Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular revascularization; Nonacute; Occlusion; Symptomatic;
   Vertebral artery
ID STUMP; RECANALIZATION; ANGIOPLASTY; PREDICTION; REGISTRY; BYPASS; OSTIUM
AB OBJECTIVE: To evaluate the feasibility, success rate, and safety of endovascular revascularization of nonacute symptomatic proximal extracranial vertebral artery occlusion (PEVAO).
   METHODS: In a retrospective, single-center study, we analyzed clinical and imaging data from consecutive patients with PEVAO who underwent endovascular revascularization from June 2011 to March 2018.
   RESULTS: The study enrolled 23 patients (mean age, 59 years; range, 42-77 years; 17 men). The rate of successful technical revascularization was 91.3% (n = 21), and the rate of complications was 4.3% (n = 1). At 3-month follow-up, the patients with successful endovascular revascularization of nonacute symptomatic PEVAO did not present any neurologic symptoms and computed tomography angiography did not show restenosis of the stent.
   CONCLUSIONS: Endovascular revascularization of non acute symptomatic PEVAO is feasible and associated with a high rate of procedural success and low rate of procedural complications. A large, multicenter, randomized study is warranted to confirm the findings.
C1 [Chen, Lizhang; Jiang, Yi; Hu, Fayun; He, Li; Zheng, Hongbo] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China.
RP Zheng, HB (reprint author), Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China.
EM drzhenghb@126.com
OI Chen, Lizhang/0000-0002-8170-8494
CR Chambers CE, 2011, CATHETER CARDIO INTE, V77, P546, DOI 10.1002/ccd.22867
   Chen L, 2019, NEW ZEAL J CROP HORT, V47, P155, DOI 10.1080/01140671.2019.1616569
   Chen YH, 2016, JACC-CARDIOVASC INTE, V9, P1825, DOI 10.1016/j.jcin.2016.06.015
   da Costa LB, 2006, ARQ NEURO-PSIQUIAT, V64, P664, DOI 10.1590/S0004-282X2006000400028
   Dementovych N, 2012, J NEUROINTERV SURG, V4, P110, DOI 10.1136/jnis.2011.004689
   DIAZ FG, 1984, J NEUROSURG, V61, P874, DOI 10.3171/jns.1984.61.5.0874
   Duan HZ, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2018.11.FOCUS18360
   Glass TA, 2002, ARCH NEUROL-CHICAGO, V59, P369, DOI 10.1001/archneur.59.3.369
   Gupta R, 2011, J NEUROINTERV SURG, V3, P54, DOI 10.1136/jnis.2009.002139
   Iwata T, 2012, NEUROSURGERY, V70, P82, DOI 10.1227/NEU.0b013e31822e074c
   Iwata T, 2009, NEUROSURGERY, V65, P378, DOI 10.1227/01.NEU.0000348293.01482.0F
   Kakino S, 2008, SURG NEUROL, V69, P164, DOI 10.1016/j.surneu.2007.07.073
   Kawano H, 2013, J NEUROL SCI, V324, P74, DOI 10.1016/j.jns.2012.10.005
   Laskey WK, 2007, J AM COLL CARDIOL, V50, P584, DOI 10.1016/j.jacc.2007.03.058
   Low PA, 2015, J CLIN NEUROL, V11, P220, DOI 10.3988/jcn.2015.11.3.220
   Morino Y, 2011, JACC-CARDIOVASC INTE, V4, P213, DOI 10.1016/j.jcin.2010.09.024
   Nguyen TN, 2008, J NEUROL NEUROSUR PS, V79, P91, DOI 10.1136/jnnp.2007.124826
   Nii K, 2013, NEUROL MED-CHIR, V53, P422, DOI 10.2176/nmc.53.422
   Noorian AR, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/neurintsurg-2011-010139
   Opolski MP, 2015, JACC-CARDIOVASC INTE, V8, P257, DOI 10.1016/j.jcin.2014.07.031
   Park S, 2014, AM J NEURORADIOL, V35, P367, DOI 10.3174/ajnr.A3681
   Suzuki M, 2018, INTERNAL MED, V57, P733, DOI 10.2169/internalmedicine.9317-17
   Tempaku A, 2017, J GEN FAM MED, V18, P462, DOI 10.1002/jgf2.114
   Xu G, 2009, INTERV NEURORADIOL, V15, P462, DOI 10.1177/159101990901500416
NR 24
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 39
EP 44
DI 10.1016/j.wneu.2019.10.059
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200140
PM 31629152
DA 2020-05-12
ER

PT J
AU O'Neill, BE
   Uluc, K
   Wood, MD
   Jaboin, J
   Cetas, JS
   Ciporen, J
   Dogan, A
AF O'Neill, Brannan E.
   Uluc, Kutluay
   Wood, Matthew D.
   Jaboin, Jerry
   Cetas, Justin S.
   Ciporen, Jeremy
   Dogan, Aclan
TI Arteriovenous Malformation Presenting as Symptomatic, Enlarging and
   Contrast-Enhancing Mass 12 Years After Being Treated with Embolization
   and Radiotherapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Avascular; AVM; Pathology
ID RESECTION; NECROSIS; OUTCOMES; SURGERY
AB BACKGROUND: Gross total resection of arteriovenous malformations (AVMs) of the central nervous system confirmed by formal angiography is accepted as a cure for patients. In some cases, this may not be possible. Even though in these cases other treatment modalities such as endovascular embolization and radiotherapy can be used, long-term follow-up is lacking in the literature.
   CASE DESCRIPTION: Here we report a case of a 57-year-old woman with history of a right-sided parieto-occipital/periatrial AVM, initially treated with a combination of endovascular embolization and radiotherapy.
   CONCLUSIONS: The patient subsequently presented (12 years later) with a symptomatic, enlarging, contrast-enhancing mass at the same location that was angiographically occult but ultimately proven to be an AVM on a background of reactive changes on pathology.
C1 [O'Neill, Brannan E.; Uluc, Kutluay; Cetas, Justin S.; Ciporen, Jeremy; Dogan, Aclan] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
   [Wood, Matthew D.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA.
   [Jaboin, Jerry] Oregon Hlth & Sci Univ, Dept Radiat Oncol, Portland, OR 97201 USA.
RP Dogan, A (reprint author), Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
EM dogana@ohsu.edu
RI Dogan, Aclan/AAF-8305-2019
CR Chen HI, 2006, J NEUROSURG, V105, P455, DOI 10.3171/jns.2006.105.3.455
   Codd PJ, 2008, J NEUROSURG, V109, P486, DOI 10.3171/JNS/2008/109/9/0486
   Dillon WP, 1997, AM J NEURORADIOL, V18, P1839
   Drake C G, 1979, Clin Neurosurg, V26, P145
   Foroughi M, 2010, ACTA NEUROCHIR, V152, P803, DOI 10.1007/s00701-009-0581-1
   Jimenez JE, 2017, J NEUROSURG-PEDIATR, V19, P149, DOI 10.3171/2016.9.PEDS16235
   Klimo P, 2007, CHILD NERV SYST, V23, P31, DOI 10.1007/s00381-006-0245-x
   Leblanc GG, 2009, STROKE, V40, pE694, DOI 10.1161/STROKEAHA.109.563692
   Massengale JL, 2006, NEUROSURGERY, V59, P553, DOI 10.1227/01.NEU.0000227476.95859.F1
   Mazal PR, 2006, PATHOLOGY, V38, P28, DOI 10.1080/00313020500455795
   Oyoshi T, 2010, NEUROL MED-CHIR, V50, P62, DOI 10.2176/nmc.50.62
   Patel TR, 2014, WORLD NEUROSURG, V81, P594, DOI 10.1016/j.wneu.2013.10.043
   Plasencia Andres R, 2012, Surg Neurol Int, V3, pS90, DOI 10.4103/2152-7806.95420
   Pollock BE, 2003, NEUROSURGERY, V52, P1291, DOI 10.1227/01.NEU.0000064800.26214.FE
   REDEKOP GJ, 1993, J NEUROSURG, V78, P413, DOI 10.3171/jns.1993.78.3.0413
   Sorenson TJ, 2018, WORLD NEUROSURG, V116, pE856, DOI 10.1016/j.wneu.2018.05.117
   Tsuji Atsushi, 2016, Acta Neurochir Suppl, V123, P135, DOI 10.1007/978-3-319-29887-0_19
   WAKAI S, 1992, J NEUROSURG, V76, P231, DOI 10.3171/jns.1992.76.2.0231
   Xhumari A, 2015, ACTA NEUROCHIR, V157, P889, DOI 10.1007/s00701-015-2377-9
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 45
EP 49
DI 10.1016/j.wneu.2019.10.055
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200141
PM 31629146
DA 2020-05-12
ER

PT J
AU Soldozy, S
   Sharifi, KA
   Desai, B
   Giraldo, D
   Yeghyayan, M
   Liu, L
   Norat, P
   Sokolowski, JD
   Yagmurlu, K
   Park, MS
   Tvrdik, P
   Kalani, MYS
AF Soldozy, Sauson
   Sharifi, Khadijeh A.
   Desai, Bhargav
   Giraldo, Daniel
   Yeghyayan, Michelle
   Liu, Lei
   Norat, Pedro
   Sokolowski, Jennifer D.
   Yagmurlu, Kaan
   Park, Min S.
   Tvrdik, Petr
   Kalani, M. Yashar S.
TI Cortical Spreading Depression in the Setting of Traumatic Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Review
DE Astrocytes; Calcium signaling; Cortical spreading depression; Microglia;
   Spreading depolarization; Traumatic brain injury
ID ANOXIC DEPOLARIZATION; NITRIC-OXIDE; IN-VIVO; PERSPECTIVES; TRIGGERS;
   LACTATE; TARGETS; GLUCOSE; STROKE; DAMAGE
AB Cortical spreading depression (CSD) is a pathophysiologic phenomenon that describes an expanding wave of depolarization within the cortical gray matter. Originally described over 70 years ago, this spreading depression disrupts neuronal and glial ionic equilibrium, leading to increased energy demands that can cause a metabolic crisis. This results in secondary insult, further perpetuating brain injury and neuronal death. Initially not thought to be of clinical significance, the view of CSD was modified with the advent of intracranial electroencephalography, or electrocorticography. With these improved monitoring techniques, CSD has been identified as a major mechanism by which traumatic brain injury (TBI) imparts its negative sequalae. TBI is a heterogenous disease process that runs the gamut of clinical presentations. This includes concussion, epidural and subdural hematoma, diffuse axonal injury, and subarachnoid hemorrhage. Nonetheless, CSD appears to be frequently occurring among the various types of TBI, thus allowing for the potential development of targeted therapies in an otherwise ill-fated patient cohort. Although a complete understanding of the interplay between CSD and TBI has not yet been achieved, the authors recount the efforts that have been employed over the last several decades in an effort to bridge this gap. In addition, our current understanding of the role neuroimmune cells play in CSD is discussed in the context of TBI. Finally, current therapeutic strategies using CSD as a pharmacologic target are explored with respect to their clinical use in patients with TBI.
C1 [Soldozy, Sauson; Sharifi, Khadijeh A.; Desai, Bhargav; Giraldo, Daniel; Yeghyayan, Michelle; Liu, Lei; Norat, Pedro; Sokolowski, Jennifer D.; Yagmurlu, Kaan; Park, Min S.; Tvrdik, Petr; Kalani, M. Yashar S.] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22903 USA.
   [Sharifi, Khadijeh A.; Liu, Lei; Tvrdik, Petr; Kalani, M. Yashar S.] Univ Virginia Hlth Syst, Dept Neurosci, Charlottesville, VA 22903 USA.
RP Kalani, MYS (reprint author), Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA 22903 USA.; Kalani, MYS (reprint author), Univ Virginia Hlth Syst, Dept Neurosci, Charlottesville, VA 22903 USA.
EM Stemcelldoctor@kalanimed.com
CR Bouley J, 2019, J NEUROTRAUM, V36, P1008, DOI 10.1089/neu.2018.5844
   Bowman R, 2013, ROT, RIOT, AND REBELLION: MR. JEFFERSON'S STRUGGLE TO SAVE THE UNIVERSITY THAT CHANGED AMERICA, P93
   Brawek B, 2013, CELL CALCIUM, V53, P159, DOI 10.1016/j.ceca.2012.12.003
   Carlson AP, 2019, J NEUROSURG, V130, P1513, DOI 10.3171/2017.12.JNS171665
   Chen SP, 2017, HEADACHE, V57, P1340, DOI 10.1111/head.13154
   Chen SP, 2016, PAIN, V157, P797, DOI 10.1097/j.pain.0000000000000437
   Cheyuo C, 2011, J CEREBR BLOOD F MET, V31, P1187, DOI 10.1038/jcbfm.2011.24
   Chuquet J, 2007, J NEUROSCI, V27, P4036, DOI 10.1523/JNEUROSCI.0721-07.2007
   Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277
   Costa C, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-62
   Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333
   Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010
   Enger R, 2015, CEREB CORTEX, V25, P4469, DOI 10.1093/cercor/bhv054
   Eriksen N, 2019, NEUROCRIT CARE, V30, P557, DOI 10.1007/s12028-019-00692-w
   FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056
   Galgano M, 2017, CELL TRANSPLANT, V26, P1118, DOI 10.1177/0963689717714102
   Garza Ivan, 2010, Curr Neurol Neurosci Rep, V10, P7, DOI 10.1007/s11910-009-0083-9
   GORELOVA NA, 1987, ELECTROEN CLIN NEURO, V66, P440, DOI 10.1016/0013-4694(87)90213-6
   Gorji A, 2001, BRAIN RES REV, V38, P33, DOI 10.1016/S0165-0173(01)00081-9
   GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154
   Grinberg YY, 2013, J NEUROCHEM, V126, P662, DOI 10.1111/jnc.12267
   Grinberg YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019294
   Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5
   Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]
   HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0
   Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152
   Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050
   Hosseini-Zare MS, 2017, EXP NEUROL, V295, P155, DOI 10.1016/j.expneurol.2017.05.002
   Kurauchi Y, 2017, J PHARMACOL SCI, V133, P146, DOI 10.1016/j.jphs.2017.02.004
   Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191
   Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391
   Leao AAP, 1944, J NEUROPHYSIOL, V7, P359
   LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409
   Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018
   MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7
   Martins-Ferreira H, 2000, BRAIN RES REV, V32, P215, DOI 10.1016/S0165-0173(99)00083-1
   MATSUURA T, 1971, EXP BRAIN RES, V12, P238, DOI 10.1007/BF00237916
   Mizuma A, 2019, J NEUROTRAUM, V36, P996, DOI 10.1089/neu.2018.5856
   Pietrobon D, 2014, NAT REV NEUROSCI, V15, P379, DOI 10.1038/nrn3770
   Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111
   Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22
   Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586
   Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303
   Schneider U, 2015, ACTA NEUROPATHOL, V130, P215, DOI 10.1007/s00401-015-1440-1
   Stauderman KA, 2018, CELL CALCIUM, V74, P147, DOI 10.1016/j.ceca.2018.07.005
   Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09
   Torrente D, 2014, NEUROSCI LETT, V565, P2, DOI 10.1016/j.neulet.2013.12.058
   Torrente D, 2014, NEUROSCI LETT, V558, P87, DOI 10.1016/j.neulet.2013.11.004
   Toth P, 2016, AM J PHYSIOL-HEART C, V311, pH1118, DOI 10.1152/ajpheart.00267.2016
   Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095
   Tvrdik P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112366
   Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF
   von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30
   VYSKOCIL F, 1972, BRAIN RES, V39, P255, DOI 10.1016/0006-8993(72)90802-5
   Witcher KG, 2018, GLIA, V66, P2719, DOI 10.1002/glia.23523
   Zhang FY, 2002, J NEUROSURG, V97, P963, DOI 10.3171/jns.2002.97.4.0963
   Zhou N, 2010, CEREB CORTEX, V20, P2614, DOI 10.1093/cercor/bhq018
NR 57
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 50
EP 57
DI 10.1016/j.wneu.2019.10.048
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200142
PM 31655239
DA 2020-05-12
ER

PT J
AU Chen, Y
   Chen, F
   Yin, D
   Shao, Q
   Hu, F
   Chen, J
   Xiong, YB
AF Chen, Yang
   Chen, Fan
   Yin, Du
   Shao, Qiang
   Hu, Fei
   Chen, Jun
   Xiong, Yubo
TI Two Internal Carotid Aneurysms After a Car Accident in a Young Man
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysms; Internal carotid artery; Intravascular surgery; Subarachnoid
   hemorrhage; Traumatic
ID TRAUMATIC INTRACRANIAL ANEURYSM; ENDOVASCULAR TREATMENT; ARTERY
   ANEURYSM; IRREGULAR SHAPE; PSEUDOANEURYSMS; SIZE
AB BACKGROUND: Posttraumatic internal carotid aneurysms are rare. Two posttraumatic aneurysms occurring at the same time are even more rare. Two pseudoaneurysms located in different segments of the ipsilateral internal carotid artery have not been found in the literature. We provide the results of angio-graphic images of traumatic aneurysms over time.
   CASE DESCRIPTION: We report a young man aged 17 years with multiple aneurysms of the internal carotid artery following head injury. Head computed tomography examination was performed in our hospital showing a small amount of subarachnoid hemorrhage, nodular high-density shadow on the left side of the sellar region, casting a high-density shadow on the suprasellar cistern and left sulcus approximately 1 x 1 cm in size, and subarachnoid hemorrhage. Digital subtraction angiography was performed on the sixth day of admission: the C5 and C6 segments of the left internal carotid artery had 2 x 4 mm mound processes and 7 x 7 nun saccular processes, respectively. Interventional surgery was performed immediately. Due to aneurysm enlargement, intravascular surgery was performed for coiling of the corresponding aneurysms. The left internal carotid artery occlusion test showed that the right internal carotid artery was well compensated by the left side via the anterior communicating artery. The ophthalmic artery aneurysm of the left internal carotid artery and the clinoid segment pseudoaneurysms were embolized. Follow-up for 1 year showed no obvious sequelae and a good recovery.
   CONCLUSIONS: This case suggests that patients with posttraumatic subarachnoid hemorrhage should be considered for the possibility of traumatic aneurysms. If this occurs, an aggressive operation would achieve a good outcome.
C1 [Chen, Yang; Chen, Fan; Yin, Du; Shao, Qiang; Hu, Fei; Chen, Jun; Xiong, Yubo] Gen Hosp Yangtze River Shipping, Dept Neurosurg, Wuhan, Peoples R China.
   [Chen, Fan] Univ Med Greifswald, Dept Neurosurg, Greifswald, Germany.
RP Chen, F (reprint author), Gen Hosp Yangtze River Shipping, Dept Neurosurg, Wuhan, Peoples R China.; Chen, F (reprint author), Univ Med Greifswald, Dept Neurosurg, Greifswald, Germany.
EM professorchen@foxmail.com
OI Chen, Fan/0000-0002-5739-2776; chen, yang/0000-0002-5420-504X
CR Arai Nobuhiko, 2017, NMC Case Rep J, V4, P33, DOI 10.2176/nmccrj.cr.2016-0139
   Bjorkman J, 2017, STROKE, V48, P1986, DOI 10.1161/STROKEAHA.117.017147
   Buchanan IA, 2019, WORLD NEUROSURG, V121, P117, DOI 10.1016/j.wneu.2018.08.220
   BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022
   Cirillo M, 2013, EUR J RADIOL, V82, pE853, DOI 10.1016/j.ejrad.2013.08.052
   Cox MW, 2007, J VASC SURG, V46, P1227, DOI 10.1016/j.jvs.2007.08.021
   Dubey A, 2008, J CLIN NEUROSCI, V15, P609, DOI 10.1016/j.jocn.2007.11.006
   Ellamushi HE, 2001, J NEUROSURG, V94, P728, DOI 10.3171/jns.2001.94.5.0728
   Feng X, 2017, WORLD NEUROSURG, V107, P255, DOI 10.1016/j.wneu.2017.07.063
   Garg K, 2016, TURK NEUROSURG, V26, P357, DOI 10.5137/1019-5149.JTN.12598-14.1
   Gunes S, 2017, J CRANIOFAC SURG, V28, pE74, DOI 10.1097/SCS.0000000000003237
   Kasinathan Sudhakar, 2019, Asian J Neurosurg, V14, P28, DOI 10.4103/ajns.AJNS_198_18
   Konakondla S, 2017, NEUROSURGERY, V80, P778, DOI 10.1093/neuros/nyw115
   Laissaoui Y, 2014, ANN VASC SURG, V28, DOI 10.1016/j.avsg.2012.06.032
   Li TF, 2018, TURK NEUROSURG, V28, P43, DOI 10.5137/1019-5149.JTN.18186-16.1
   Mehrotra A, 2016, WORLD NEUROSURG, V92, P126, DOI 10.1016/j.wneu.2016.04.124
   Morton RP, 2016, ANN SURG, V263, P821, DOI 10.1097/SLA.0000000000001158
   Orz Yasser, 2015, Asian J Neurosurg, V10, P26, DOI 10.4103/1793-5482.144159
   RINNE J, 1994, NEUROSURGERY, V35, P803, DOI 10.1227/00006123-199411000-00001
   Saito Kiyoshi, 1995, Neurologia Medico-Chirurgica, V35, P886, DOI 10.2176/nmc.35.886
   Shen X, 2014, INTERV NEURORADIOL, V20, P442, DOI 10.15274/NRJ-2014-10037
   Spanos K, 2016, INJURY, V47, P307, DOI 10.1016/j.injury.2015.09.015
   Yamaguchi J, 2016, NEUROL MED-CHIR, V56, P89, DOI 10.2176/nmc.cr.2015-0206
   Yi J, 2016, J STROKE CEREBROVASC, V25, P1244, DOI 10.1016/j.jstrokecerebrovasdis.2016.01.031
   Zangbar B, 2015, BRAIN INJURY, V29, P601, DOI 10.3109/02699052.2015.1004559
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 58
EP 61
DI 10.1016/j.wneu.2019.10.066
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200143
PM 31629926
DA 2020-05-12
ER

PT J
AU Lebovitz, J
   Storey, C
   Sweid, A
   Tjoumakaris, S
   Gooch, MR
   Rosenwasser, R
   Jabbour, P
AF Lebovitz, Jonathon
   Storey, Christopher
   Sweid, Ahmad
   Tjoumakaris, Stavropoula
   Gooch, M. Reid
   Rosenwasser, Robert
   Jabbour, Pascal
TI Onyx Embolization of Spinal Arteriovenous Fistula via Scepter Balloon
SO WORLD NEUROSURGERY
LA English
DT Article
DE Embolization; Scepter balloon; Spinal arteriovenous fistula
AB BACKGROUND: Spinal arteriovenous fistulas (AVFs) are a rare entity that can have devastating neurologic outcomes. Currently, these lesions are treated via open microsurgical resection or transarterial embolization with good success. However, some patients cannot be treated with a minimally invasive endovascular technique secondary to difficulty catheterizing their vascular anatomy. Our aim is to present a case of balloon-assisted Onyx embolization of a spinal AVF.
   CASE DESCRIPTION: We present the case of a 59-year-old male with progressive lower back pain with lower-extremity weakness. We performed a spinal angiogram where an AVF was identified with very torturous anatomy. The patient was originally treated with open microsurgical resection; however, approximate to 6 weeks later the fistula and symptoms returned. At that time, we were able to treat the lesion with the Scepter-C balloon.
   CONCLUSIONS: We present a challenging case in which normal embolization microcatheters were unable to navigate difficult anatomy, but we were able to gain access and obliterate the fistula by using a balloon catheter.
C1 [Lebovitz, Jonathon; Storey, Christopher; Sweid, Ahmad; Tjoumakaris, Stavropoula; Gooch, M. Reid; Rosenwasser, Robert; Jabbour, Pascal] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
   Jefferson Hosp Neurosci, Philadelphia, PA USA.
RP Jabbour, P (reprint author), Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
EM pascal.jabbour@jefferson.edu
OI Sweid, Ahmad/0000-0002-2652-2451
CR McTaggart RA, 2017, J NEUROINTERV SURG, V9, P316, DOI 10.1136/neurintsurg-2015-011984
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 62
EP 66
DI 10.1016/j.wneu.2019.10.112
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200144
PM 31669689
DA 2020-05-12
ER

PT J
AU Prasad, GL
AF Prasad, G. Lakshmi
TI Cranial Melioidosis Presenting as Osteomyelitis and/or Extra-Axial
   Abscess: Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Burkholderia pseudomallei; Cerebral melioidosis; Cranial melioidosis;
   India; Melioidosis; Osteomyelitis
ID NEUROLOGICAL MELIOIDOSIS; SYSTEM
AB BACKGROUND: Central nervous system (CNS) melioidosis is rare. Clinical presentations depend on the region of endemicity. Despite treatment, neurologic disease has relatively high mortality rates. Less than 80 cases of CNS involvement have been reported.
   METHODS: A literature review was performed by searching online databases for melioidosis presenting as osteomyelitis or scalp/extra-axial abscess (OSEAA). In addition, 3 similar cases managed at my institute have been presented.
   RESULTS: Including this report of 3 cases, 20 additional cases have been reported. Of these, 12 cases (60%) were from India. The mean age of patients was 45.5 years (range, 29-74 years), and none were in the pediatric age group. Patients in the fifth to sixth decades were most frequently affected. The male to female ratio was 5.3:1. Eleven patients had predisposing factors. Fever, headache, and scalp swelling were the most common features. Five cases had history of previous melioid infection. Seven cases had systemic disease. Debridement was performed in 11 cases. The average intensive phase treatment duration was 4.6 weeks (range, 2-8 weeks) and 5.5 months (range, 3-12 months) for the maintenance phase. Mean follow-up duration was 13.5 months (range, 2 weeks-40 months). Two deaths (10%) were reported, and 1 case of residual frontal abscess had relapse.
   CONCLUSIONS: Cranial melioidosis presenting as OSEAA is associated with good outcome, in contrast with other neurologic presentations. Intensive phase for at least 2-3 weeks followed by maintenance phase for 3-6 months is the standard treatment, similar to other melioid presentations. A high degree of suspicion and accurate identification of the organism is crucial. Patients need to be monitored for recurrences, both clinically and radiologically.
C1 [Prasad, G. Lakshmi] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Neurosurg, Manipal, India.
RP Prasad, GL (reprint author), Manipal Acad Higher Educ, Kasturba Med Coll, Dept Neurosurg, Manipal, India.
EM lakshmi.prasad@manipal.edu
CR Antony B, 2010, SE ASIAN J TROP MED, V41, P169
   Balaji V, 2008, Indian J Med Sci, V62, P456, DOI 10.4103/0019-5359.48457
   Bommakanti K, 2010, NEUROL INDIA, V58, P801, DOI [10.4103/0028-3886.72188, 10.4103/0028-3886.73738]
   Chadwick DR, 2002, T ROY SOC TROP MED H, V96, P72, DOI 10.1016/S0035-9203(02)90248-8
   Chetchotisakd P, 2014, LANCET, V383, P807, DOI 10.1016/S0140-6736(13)61951-0
   Currie B, 2014, NT DIS CONTROL B, V21, P4
   Currie Bart J, 2008, Trans R Soc Trop Med Hyg, V102 Suppl 1, pS1, DOI 10.1016/S0035-9203(08)70002-6
   Currie BJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000900
   Currie BJ, 2000, ACTA TROP, V74, P145, DOI 10.1016/S0001-706X(99)00064-9
   Dance D, 2014, INT J ANTIMICROB AG, V43, P310, DOI 10.1016/j.ijantimicag.2014.01.005
   Deuble M, 2013, AM J TROP MED HYG, V89, P535, DOI 10.4269/ajtmh.12-0559
   Fong SL, 2017, NEUROL ASIA, V22, P25
   Garg G, 2015, J Assoc Physicians India, V63, P82
   Gilligan PH, 1999, MANUAL CLIN MICROBIO, P526
   Hsu CCT, 2016, J NEUROIMAGING, V26, P75, DOI 10.1111/jon.12282
   John TJ, 2004, INDIAN J MED RES, V119, pVI
   John TJ, 1996, INDIAN J MED RES, V103, P62
   Koszyca B, 2004, CLIN NEUROPATHOL, V23, P195
   Kumar GSS, 2008, J NEUROSURG, V108, P243, DOI 10.3171/JNS/2008/108/2/0243
   Lau SKP, 2015, EXP BIOL MED, V240, P742, DOI 10.1177/1535370215583801
   Liang CC, 2016, WORLD NEUROSURG, V89, DOI 10.1016/j.wneu.2016.01.093
   Limmathurotsakul D, 2007, AM J TROP MED HYG, V77, P118, DOI 10.4269/ajtmh.2007.77.118
   Limmathurotsakul D, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2015.8, 10.1038/nmicrobiol.2015.8]
   Lipsitz Rebecca, 2012, Emerg Infect Dis, V18, pe2, DOI 10.3201/eid1812.120638
   Madi D, 2016, INDIAN J PATHOL MICR, V59, P417, DOI 10.4103/0377-4929.188118
   Miksic NG, 2007, EMERG INFECT DIS, V13, P1257, DOI 10.3201/eid1308.070479
   Muthusamy KA, 2007, J CLIN NEUROSCI, V14, P1213, DOI 10.1016/j.jocn.2006.03.022
   Naha K, 2012, AUSTRALAS MED J, V5, P455, DOI 10.4066/AMJ.2012.1374
   Novak RT, 2006, J CLIN MICROBIOL, V44, P85, DOI 10.1128/JCM.44.1.85-90.2006
   PIT S, 1988, POSTGRAD MED J, V64, P140, DOI 10.1136/pgmj.64.748.140
   Pitman MC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003586
   Prasad GL, 2017, NEUROL INDIA, V65, P1423, DOI 10.4103/0028-3886.217952
   Prasad GL, 2017, CHILD NERV SYST, V33, P915, DOI 10.1007/s00381-017-3422-1
   Raja N S, 2005, J Postgrad Med, V51, P140
   Saipan Penchan, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P856
   Shaw T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194595
   Shetty HS, 2015, BMJ CASE REP, V2015
   Vachvanichsanong P, 2002, INFECT DIS CLIN PRAC, V11, P211
   Vidyalakshmi K, 2007, Indian J Med Microbiol, V25, P245
   Vidyalakshmi K, 2008, INT J TUBERC LUNG D, V12, P1209
   WHITE NJ, 1989, LANCET, V2, P697, DOI 10.1016/S0140-6736(89)90768-X
   Wiersinga WJ, 2012, NEW ENGL J MED, V367, P1035, DOI 10.1056/NEJMra1204699
   WOODS ML, 1992, CLIN INFECT DIS, V15, P163, DOI 10.1093/clinids/15.1.163
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 67
EP 75
DI 10.1016/j.wneu.2019.10.058
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200145
PM 31629141
DA 2020-05-12
ER

PT J
AU Horvat, D
   Lovell, J
   Boulter, J
   Sabersky, A
   Brown, J
AF Horvat, David
   Lovell, John
   Boulter, Jason
   Sabersky, Abraham
   Brown, Joseph
TI Case of Vagal Nerve Stimulator-Induced Stridor After Anterior Cervical
   Diskectomy and Fusion-Induced Vocal Cord Paralysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical diskectomy and fusion; Complications; Stridor; Vagal
   nerve stimulator
ID OBSTRUCTIVE SLEEP-APNEA; PARTIAL SEIZURES
AB BACKGROUND: Vagal nerve stimulation is a generally safe adjunctive treatment for medically refractory epilepsy. Nevertheless, reports of vocal cord dysfunction during stimulation can be found in the literature. When vagal nerve stimulation-induced vocal cord dysfunction is compounded with contralateral dysfunction, such as that which can occur after anterior cervical diskectomy and fusion, serious pulmonary complications can occur.
   CASE DESCRIPTION: A 56-year-old female presented to the emergency department 3 weeks postoperatively from a cervical 7- thoracic 2 anterior cervical diskectomy and fusion through a right-sided approach with new-onset, intermittent stridor. otorhinolaryngology conducted a fiberoptic laryngoscopy and determined that the patient had a right vocal cord paralysis and intermittent left vocal cord paresis that coincided with activation of the patient's vagal nerve stimulator. The stimulator was shut off, and the patient's stridor disappeared.
   CONCLUSIONS: Vagal nerve stimulation - induced vocal cord paralysis is a but known complication. Given this potential for vocal cord dysfunction, neurosurgeons should plan further anterior cervical diskectomy and fusions accordingly to ensure that patients do not develop dysfunction of bilateral vocal cords. Should this develop, however, cessation of vagal nerve stimulation can improve or treat the pulmonologic complication that develops.
C1 [Horvat, David; Lovell, John; Brown, Joseph] Walter Reed Natl Mil Med Ctr, Dept Neurol, Bethesda, MD 20889 USA.
   [Boulter, Jason; Sabersky, Abraham] Walter Reed Natl Mil Med Ctr, Div Neurosurg, Bethesda, MD USA.
RP Horvat, D (reprint author), Walter Reed Natl Mil Med Ctr, Dept Neurol, Bethesda, MD 20889 USA.
EM david.e.horvat.mil@mail.mil
CR Abdul-Hamid A, 2017, BMJ CASE REP, V2017
   Aron M, 2012, J PEDIATR-US, V160, P868, DOI 10.1016/j.jpeds.2012.01.045
   BENMENACHEM E, 1994, EPILEPSIA, V35, P616, DOI 10.1111/j.1528-1157.1994.tb02482.x
   Bhatt YM, 2010, J LARYNGOL OTOL, V124, P557, DOI 10.1017/S0022215109991307
   Charous SJ, 2001, LARYNGOSCOPE, V111, P2028, DOI 10.1097/00005537-200111000-00030
   Chen CC, 2014, EUR SPINE J, V23, P622, DOI 10.1007/s00586-013-3084-y
   GEORGE R, 1995, NEUROLOGY, V45, P224, DOI 10.1212/wnl.45.2.224
   Handforth A, 1998, NEUROLOGY, V51, P48, DOI 10.1212/WNL.51.1.48
   Kelts G, 2015, INT J PEDIATR OTORHI, V79, P251, DOI 10.1016/j.ijporl.2014.10.037
   Louis EKS, 2010, EPILEPTIC DISORD, V12, P76, DOI 10.1684/epd.2010.0294
   Parhizgar F, 2011, J CLIN SLEEP MED, V7, P401, DOI 10.5664/JCSM.1204
   RAMSAY RE, 1994, EPILEPSIA, V35, P627, DOI 10.1111/j.1528-1157.1994.tb02483.x
   Serdaroglu A, 2016, CHILD NERV SYST, V32, P641, DOI 10.1007/s00381-015-3004-z
   Tan TP, 2014, SPINE J, V14, P1332, DOI 10.1016/j.spinee.2014.02.017
   Van Lierde K, 2015, J VOICE, V29, DOI 10.1016/j.jvoice.2015.01.010
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 76
EP 78
DI 10.1016/j.wneu.2019.10.132
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200146
PM 31678441
DA 2020-05-12
ER

PT J
AU Tanaka, K
   Fujiwara, M
   Okuda, Y
   Ishida, F
   Suzuki, H
AF Tanaka, Katsuhiro
   Fujiwara, Masaya
   Okuda, Yasuyuki
   Ishida, Fujimaro
   Suzuki, Hidenori
TI A Ruptured Blood Blister-Like Aneurysm Associated with Intraperitoneal
   Hemorrhage due to Segmental Arterial Mediolysis: A Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Blood blister-like aneurysm; Dissection aneurysm; Segmental arterial
   mediolysis
ID SUBARACHNOID HEMORRHAGE; WALL
AB BACKGROUND: Segmental arterial mediolysis (SAM) is a rare non-atherosclerotic,noninflammatory vascular disease, characterized by mediolysis.We report an extremely rare case of subarachnoid hemorrhage (SAH) due to a ruptured blood blister-like aneurysm (BBA) of the internal carotid artery associated with SAM-related arteriopathy.
   CASE DESCRIPTION: We experienced a case of SAH followed by intraperitoneal hemorrhage that occurred 12 days after the SAH onset. SAH was caused by a ruptured BBA of the internal carotid artery, which was treated by trapping with high-flow bypass. Intraperitoneal hemorrhage was caused by a rupture of a posterior inferior pancreaticoduodenal artery (PIPDA) aneurysm, which induced hypovolemic shock resulting in death in spite of endovascular internal trapping. Postmortem pathologic examination revealed that the PIPDA pseudoaneurysm was due to SAM.
   CONCLUSIONS: We should pay attention to the association of SAM, which is a potentially life-threatening pathology when treating cerebral BBAs.
C1 [Tanaka, Katsuhiro; Ishida, Fujimaro] NHO Mie Chuo Med Ctr, Dept Neurosurg, Tsu, Mie, Japan.
   [Fujiwara, Masaya] NHO Mie Chuo Med Ctr, Dept Pathol, Tsu, Mie, Japan.
   [Okuda, Yasuyuki] NHO Mie Chuo Med Ctr, Dept Radiol, Tsu, Mie, Japan.
   [Suzuki, Hidenori] Mie Univ, Dept Neurosurg, Grad Sch Med, Tsu, Mie, Japan.
RP Tanaka, K (reprint author), NHO Mie Chuo Med Ctr, Dept Neurosurg, Tsu, Mie, Japan.
EM tk_0303_ns@yahoo.co.jp
OI Suzuki, Hidenori/0000-0002-8555-5448; Tanaka,
   Katsuhiro/0000-0002-5222-0019
CR Cooke DL, 2013, J NEUROINTERV SURG, V5, P478, DOI 10.1136/neurintsurg-2012-010323
   Fuse T, 1996, SURG NEUROL, V46, P258, DOI 10.1016/0090-3019(96)00217-0
   Hayashi Satoru, 2018, Surg Neurol Int, V9, P175, DOI 10.4103/sni.sni_129_18
   Hellstern V, 2018, CLIN NEURORADIOL, V28, P445, DOI 10.1007/s00062-017-0641-5
   Horsley-Silva JL, 2014, J PANCREAS, V15, P72, DOI 10.6092/1590-8577/2036
   Inazuka Mayuko, 2019, No Shinkei Geka, V47, P543, DOI 10.11477/mf.1436203979
   Isaji T, 2018, WORLD NEUROSURG, V116, P44, DOI 10.1016/j.wneu.2018.05.043
   Ishikawa T, 1997, NEUROSURGERY, V40, P403, DOI 10.1097/00006123-199702000-00038
   Kim HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161182
   MASAOKA H, 1989, LANCET, V2, P1402
   Matsuda R, 2012, J NEUROSURG, V116, P948, DOI 10.3171/2012.1.JNS111967
   Naidu SG, 2018, AM J ROENTGENOL, V210, P899, DOI 10.2214/AJR.17.18309
   NAKAGAWA F, 1986, J NEUROSURG, V65, P303, DOI 10.3171/jns.1986.65.3.0303
   Ohara Jiro, 2019, No Shinkei Geka, V47, P97, DOI 10.11477/mf.1436203902
   Peschillo S, 2016, AM J NEURORADIOL, V37, P856, DOI 10.3174/ajnr.A4606
   Pillai AK, 2014, CARDIOVASC INTER RAD, V37, P604, DOI 10.1007/s00270-014-0859-4
   Ro A, 2010, CARDIOVASC PATHOL, V19, P248, DOI 10.1016/j.carpath.2009.02.002
   Sakata N, 2002, PATHOL RES PRACT, V198, P493, DOI 10.1078/0344-0338-00290
   Shinoda N, 2016, WORLD NEUROSURG, V88, DOI 10.1016/j.wneu.2015.12.058
   SLAVIN RE, 1976, LAB INVEST, V35, P23
   Slavin RE, 2007, INT J SURG PATHOL, V15, P121, DOI 10.1177/1066896906297684
   Stetler WR, 2012, NEUROCRIT CARE, V16, P154, DOI 10.1007/s12028-011-9590-z
   Welch BT, 2017, INTERV NEURORADIOL, V23, P378, DOI 10.1177/1591019917703074
   YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 79
EP 85
DI 10.1016/j.wneu.2019.10.096
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200147
PM 31669242
DA 2020-05-12
ER

PT J
AU Soni, P
   Koech, H
   Silva, D
   Das, P
   Sindwani, R
   Dobri, G
   Recinos, PF
AF Soni, Pranay
   Koech, Hilary
   Silva, Danilo
   Das, Paramita
   Sindwani, Raj
   Dobri, Georgiana
   Recinos, Pablo F.
TI Cerebral Venous Sinus Thrombosis After Transsphenoidal Resection: A Rare
   Complication of Cushing Disease-Associated Hypercoagulability
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral venous sinus thrombosis; Cushing disease; Cushing syndrome;
   Hypercoagulable; Venous thromboembolism
ID STATE; PATIENT; FIBRINOLYSIS; COAGULATION; SURGERY
AB BACKGROUND: Venous thromboembolism is a well-known complication of Cushing syndrome. Deep vein thrombosis and pulmonary embolic events have been widely reported in patients with Cushing syndrome, but cerebral venous sinus thrombosis remains a much less common finding in these patients.
   CASE DESCRIPTION: We report one of the first cases of cerebral venous sinus thrombosis in a patient with Cushing disease. An 18-year-old man presented to our clinic with accelerated weight gain despite an active lifestyle and unchanged diet. Workup revealed adrenocorticotrophic hormone-dependent hypercortisolism, and magnetic resonance imaging demonstrated a 6-mm pituitary microadenoma, consistent with Cushing disease. He underwent endoscopic transsphenoidal resection and achieved the desired postoperative adrenal insufficiency. The patient was discharged home, but presented again in a delayed fashion with profound cerebral venous sinus thrombosis requiring a prolonged hospitalization.
   CONCLUSIONS: Previous studies have suggested that the coagulation profile of patients with Cushing syndrome normalizes when measured 12 months after correction of hypercortisolism, but these patients may remain hypercoagulable for an undefined period postoperatively, despite becoming adrenally insufficient. Although there have been scarce reports of cerebral venous sinus thrombosis in non-adrenocorticotrophic hormone-dependent Cushing syndrome, we report the first case of cerebral venous sinus thrombosis postoperatively in a patient with Cushing disease in remission.
C1 [Soni, Pranay; Koech, Hilary; Recinos, Pablo F.] Cleveland Clin, Dept Neurosurg, Neurol Inst, Cleveland, OH 44106 USA.
   [Soni, Pranay; Sindwani, Raj; Recinos, Pablo F.] Cleveland Clin, Minimally Invas Cranial Base & Pituitary Surg, Rosa Ella Burkhardt Brain Tumor & Neurooncol Ctr, Cleveland, OH 44106 USA.
   [Sindwani, Raj; Recinos, Pablo F.] Cleveland Clin, Sect Rhinol Sinus & Skull Base Surg, Head & Neck Inst, Cleveland, OH 44106 USA.
   [Silva, Danilo] Lenox Hill Hosp, Dept Neurosurg, Northwall Hlth, New York, NY 10021 USA.
   [Das, Paramita] UChicago Med, Dept Neurosurg, Chicago, IL USA.
   [Dobri, Georgiana] Weill Cornell Med, Dept Neurosurg, New York, NY USA.
   [Dobri, Georgiana] Weill Cornell Med, Div Endocrinol Diabet & Metab, Dept Med, New York, NY USA.
RP Recinos, PF (reprint author), Cleveland Clin, Dept Neurosurg, Neurol Inst, Cleveland, OH 44106 USA.; Recinos, PF (reprint author), Cleveland Clin, Minimally Invas Cranial Base & Pituitary Surg, Rosa Ella Burkhardt Brain Tumor & Neurooncol Ctr, Cleveland, OH 44106 USA.; Recinos, PF (reprint author), Cleveland Clin, Sect Rhinol Sinus & Skull Base Surg, Head & Neck Inst, Cleveland, OH 44106 USA.
EM recinop@ccf.org
OI Soni, Pranay/0000-0003-0270-6915; Recinos, Pablo/0000-0002-9748-2784
CR Al-Khalaf AH, 2016, NEUROSCIENCES, V21, P75, DOI 10.17712/nsj.2016.1.20150534
   Appenzeller S, 2005, CLIN NEUROL NEUROSUR, V107, P371, DOI 10.1016/j.clineuro.2004.10.004
   Boscaro M, 2002, J CLIN ENDOCR METAB, V87, P3662, DOI 10.1210/jc.87.8.3662
   Boscaro M, 2009, J CLIN ENDOCR METAB, V94, P3121, DOI 10.1210/jc.2009-0612
   Casonato A, 1999, BLOOD COAGUL FIBRIN, V10, P145, DOI 10.1097/00001721-199904000-00006
   Crassard I, 2005, REV NEUROL-FRANCE, V161, P706
   Fallo F, 2009, CLIN ENDOCRINOL, V71, P768, DOI 10.1111/j.1365-2265.2009.03610.x
   Fatti LM, 2000, J ENDOCRINOL INVEST, V23, P145, DOI 10.1007/BF03343697
   Feelders RA, 2012, EUR J ENDOCRINOL, V167, P311, DOI 10.1530/EJE-11-1095
   Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26
   HUANG LQ, 1995, BLOOD COAGUL FIBRIN, V6, P438, DOI 10.1097/00001721-199507000-00011
   Kastelan D, 2009, ENDOCRINE, V36, P70, DOI 10.1007/s12020-009-9186-y
   Khealani BA, 2008, STROKE, V39, P2707, DOI 10.1161/STROKEAHA.107.512814
   Lacroix A, 2015, LANCET, V386, P913, DOI 10.1016/S0140-6736(14)61375-1
   Manetti L, 2010, EUR J ENDOCRINOL, V163, P783, DOI 10.1530/EJE-10-0583
   Miao ZZ, 2018, WORLD NEUROSURG, V110, P101, DOI 10.1016/j.wneu.2017.10.163
   PATRASSI GM, 1985, THROMB HAEMOSTASIS, V54, P518
   PATRASSI GM, 1992, BLOOD COAGUL FIBRIN, V3, P789, DOI 10.1097/00001721-199212000-00013
   Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364
   van der Pas R, 2013, CLIN ENDOCRINOL, V78, P481, DOI 10.1111/cen.12094
   van der Pas R, 2012, J CLIN ENDOCR METAB, V97, P1303, DOI 10.1210/jc.2011-2753
   Van Zaane B, 2009, J CLIN ENDOCR METAB, V94, P2743, DOI 10.1210/jc.2009-0290
   Waheed Waqar, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-216584
   Witek P, 2013, ENDOKRYNOL POL, V64, P30
   Yoshimura S, 2005, J NEUROL NEUROSUR PS, V76, P1182, DOI 10.1136/jnnp.2004.057315
NR 25
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 86
EP 89
DI 10.1016/j.wneu.2019.10.077
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200148
PM 31639504
DA 2020-05-12
ER

PT J
AU Miura, I
   Kubota, M
   Momosaki, O
   Nyui, M
   Takebayashi, K
   Kawamata, T
   Yuzurihara, M
AF Miura, Isamu
   Kubota, Motoo
   Momosaki, Oji
   Nyui, Miki
   Takebayashi, Kento
   Kawamata, Takakazu
   Yuzurihara, Masahito
TI A Rapidly Growing Cervical Meningeal Melanocytoma with a Dumbbell-Shaped
   Extension
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dumbbell tumor; FDG; Melanocytoma; Positron emission tomography; Tumor
   growth rate
ID SERIES; TUMORS
AB BACKGROUND: Meningeal melanocytoma is a rare benign lesion found in central nervous system. Preoperative diagnosis of meningeal melanocytoma is often a diagnostic challenge, as the clinical and neurologic features are often nonspecific. Various characteristics, including the natural course of this tumor, remain poorly understood. We report a case of a rapidly growing dumbbell-shaped melanocytoma compressing the spinal cord that manifested 2 years after a tumor was identified at the right C2-C3 foramen.
   CASE DESCRIPTION: A 40-year-old, right-handed man presented with a 2-month history of right palm and left leg numbness. Magnetic resonance imaging of the cervical spine showed a dumbbell-shaped tumor at the right C2-C3 foramen with extension into the central canal. The lesion was hyperintense on T1-weighted images and hypointense to isointense on T2-weighted images. Contrast enhancement was not visualized clearly. Fluorodeoxyglucose-positron emission tomography with computed tomography showed intense uptake in the lesion. The patient's history included a small lesion that had been localized at the right C2-C3 foramen 2 years before admission. The pathologic findings were consistent with melanocytoma.
   CONCLUSIONS: It is important to include meningeal melanocytoma in the differential diagnosis of dumbbell tumors, as meningeal melanocytomas may show rapid progression.
C1 [Miura, Isamu; Kubota, Motoo; Momosaki, Oji; Yuzurihara, Masahito] Kameda Med Ctr, Dept Spinal Surg, Chiba, Japan.
   [Nyui, Miki] Kameda Med Ctr, Dept Pathol, Chiba, Japan.
   [Miura, Isamu; Momosaki, Oji; Takebayashi, Kento; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
RP Miura, I (reprint author), Kameda Med Ctr, Dept Spinal Surg, Chiba, Japan.; Miura, I (reprint author), Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
EM isamu2345@yahoo.co.jp
OI oji, momosaki/0000-0001-7054-7472; Miura, Isamu/0000-0001-5231-5862
CR Ahluwalia S, 2003, BRIT J NEUROSURG, V17, P347, DOI 10.1080/02688690310001601243
   Beaulieu S, 2004, AM J ROENTGENOL, V182, P971, DOI 10.2214/ajr.182.4.1820971
   Brat DJ, 1999, AM J SURG PATHOL, V23, P745, DOI 10.1097/00000478-199907000-00001
   Eden K, 1941, BRIT J SURG, V28, P549, DOI 10.1002/bjs.18002811205
   GEORGE B, 1995, J NEUROSURG, V82, P917, DOI 10.3171/jns.1995.82.6.0917
   Goyal A, 2003, SPINE, V28, pE140, DOI 10.1097/00007632-200304010-00025
   Ozawa H, 2007, J NEUROSURG-SPINE, V7, P587, DOI 10.3171/SPI-07/12/587
   Smith AB, 2009, RADIOGRAPHICS, V29, P1503, DOI 10.1148/rg.295095109
   Srirama Jayamma S, 2015, CASE REP RADIOL, V2015
   Turhan T, 2004, J NEUROSURG, V100, P287, DOI 10.3171/spi.2004.100.3.0287
   Yang CL, 2016, J NEURO-ONCOL, V127, P279, DOI 10.1007/s11060-015-2006-8
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 90
EP 93
DI 10.1016/j.wneu.2019.10.150
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200149
PM 31678313
DA 2020-05-12
ER

PT J
AU Gutierrez-Avila, O
   Moroi, J
   Ishikawa, T
AF Gutierrez-Avila, Oscar
   Moroi, Junta
   Ishikawa, Tatsuya
TI Dissection of the Superficial Temporal Artery: Significance and
   Performance with Bipolar Forceps
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bipolar dissection; Cerebral bypass; External carotid artery;
   Superficial temporal artery
ID ANATOMY; BYPASS
AB BACKGROUND: Adequate bypass harvesting of the superficial temporal artery (STA) is a standard procedure for every neurosurgeon, so mastery of techniques for its management and care is mandatory.
   METHODS: Here, we report the effectiveness of using the bipolar forceps as a novel procedure.
   RESULTS: This procedure improves safety, efficiency, and bleeding compared to the usual dissection.
   CONCLUSIONS: In cases requiring an STA donor, this technique may be as useful as the traditional method and could become part of the neurosurgeon's armamentarium.
C1 [Gutierrez-Avila, Oscar; Moroi, Junta; Ishikawa, Tatsuya] Inst Brain & Blood Vessels Akita, Dept Surg Neurol Res, Akita, Japan.
RP Gutierrez-Avila, O (reprint author), Inst Brain & Blood Vessels Akita, Dept Surg Neurol Res, Akita, Japan.
EM oscar.gtvl@gmail.com
OI Gutierrez-Avila, Oscar/0000-0001-5046-6712
CR Ahn JY, 2017, J KOREAN NEUROSURG S, V60, P8, DOI 10.3340/jkns.2016.0707.004
   Charbel Fady T, 2005, Neurosurgery, V56, P186
   CHATER N, 1973, CALIF MED, V119, P9
   DONAGHY RMP, 1972, SURG GYNECOL OBSTETR, V134, P269
   Grand W, 2015, VASCULATURE BRAIN CR
   ITO Z, 1985, MICROSURGERY CEREBRA
   Johnson MH, 2009, NEUROSURG CLIN N AM, V20, P239, DOI 10.1016/j.nec.2009.07.001
   Kalani MYS, 2015, WORLD NEUROSURG, V83, P345, DOI 10.1016/j.wneu.2014.10.013
   Kalani MYS, 2014, NEUROSURGERY, V74, P482, DOI 10.1227/NEU.0000000000000312
   Kim Byung Soo, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P145, DOI 10.7461/jcen.2013.15.3.145
   Lawton MT, 2018, 7 BYPASSES
   Li X, 2017, AGING DIS, V8, P384, DOI 10.14336/AD.2016.1115
   MARANO SR, 1985, NEUROSURGERY, V16, P786, DOI 10.1227/00006123-198506000-00008
   Matsumoto M, 2014, OKAJIMAS FOLIA ANAT, V63, P37
   McLaughlin N, 2013, J NEUROSURG, V118, P309, DOI 10.3171/2012.10.JNS12161
   Meguro Toshinari, 2013, No Shinkei Geka, V41, P401
   Nathal Edgar, 2005, Neurosurgery, V56, P178
   Newell DW, 2004, NEUROSURGERY, V54, P1441, DOI 10.1227/01.NEU.0000124754.84425.48
   Pinar YA, 2006, SURG RADIOL ANAT, V28, P248, DOI 10.1007/s00276-006-0094-z
   Prevost R, 2018, J VISC SURG, V155, P341, DOI 10.1016/j.jviscsurg.2018.06.0091878
   Rubio RR, 2018, WORLD NEUROSURG, V110, pE79, DOI 10.1016/j.wneu.2017.10.100
   Schirmer CM, 2013, NEUROSURGERY, V72, P6, DOI 10.1227/NEU.0b013e318273a5f2
   Takemoto Yushin, 2016, Surg Neurol Int, V7, pS247, DOI 10.4103/2152-7806.179586
   Tamura Y, 2011, ACTA NEUROCHIR, V153, P1645, DOI 10.1007/s00701-011-1035-0
   Thanapal Sengottuvel, 2018, Asian J Neurosurg, V13, P9, DOI 10.4103/ajns.AJNS_76_17
   Tokugawa J, 2018, OPER NEUROSURG, V14, P16, DOI 10.1093/ons/opx086
   Wanebo JE, 2004, NEUROSURGERY, V55, P395, DOI 10.1227/01.NEU.0000129549.99061.94
   Winkler EA, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2018.11.FOCUS18530
   Yasargil MG, 1969, DIAGNOSIS INDICATION
   Zipfel GJ, 2005, SKULL BASE-INTERD AP, V15, P27, DOI 10.1055/s-2005-868161
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 94
EP 97
DI 10.1016/j.wneu.2019.10.145
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200150
PM 31678315
DA 2020-05-12
ER

PT J
AU Caras, A
   Mugge, L
   Miller, WK
   Mansour, TR
   Schroeder, J
   Medhkour, A
AF Caras, Andrew
   Mugge, Luke
   Miller, William Kyle
   Mansour, Tarek R.
   Schroeder, Jason
   Medhkour, Azedine
TI Usefulness and Impact of Intraoperative Imaging for Glioma Resection on
   Patient Outcome and Extent of Resection: A Systematic Review and
   Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Extent of resection; Glioma resection; Intraoperative imaging; Quality
   of life
ID LOW-GRADE GLIOMA; BRAIN-TUMOR; FUNCTIONAL NEURONAVIGATION; PRELIMINARY
   EXPERIENCE; SURGICAL RESECTION; LANGUAGE DEFICITS; AWAKE CRANIOTOMY;
   INSULAR GLIOMAS; SINGLE-CENTER; SURGERY
AB BACKGROUND: Diffusion tensor imaging (DTI), functional magnetic resonance imaging (fMRI), and intraoperative magnetic resonance imaging (iMRI) permit greater visualization and more accurate presurgical planning. Meta-analysis of these techniques for maximizing resection, postoperative functionality, and survival may further validate purported strengths of these techniques compared with standard neuronavigation.
   METHODS: A systematic search of the PubMed database was conducted in line with the PRISMA guidelines for meta-analysis with the following keywords: "Diffusion tensor imaging" OR "intraoperative MRI" OR "functional MRI" AND "glioma surgery resection outcome." Articles found to meet inclusion criteria were segregated and analyzed and resulting data were compared with standard neuronavigation (control cohort).
   RESULTS: A total of 435 articles were identified, with 29 distinct studies meeting inclusion criteria, including DTI (n = 3), fMRI (n = 5), and iMRI (n = 21). Nine studies directly compared results with standard navigation. Mean gross total resection (GTR) rates were not different among cases using DTI, fMRI, iMRI, or traditional neuronavigation (P = 0136). On controlling for covariates, more patients received GTR in the advanced imaging cohort, although statistically insignificant (46.5% [95% confidence interval, 38.0%-55.0%] vs. 30.4% [95% confidence interval, 11.6%-49.1%]; P = 0127; partial eta(2) = 0.217). Patients undergoing advanced imaging showed attenuated incidence of postsurgical permanent neurologic deficits, although also statistically insignificant (11.3% vs. 13.8%; P = 0.838).
   CONCLUSIONS: Current data are overall insufficient to support the notion that advanced imaging techniques are superior, either as a combined cohort or individually, in achieving GTR, improved symptom resolution, or survival compared with traditional neuronavigation.
C1 [Caras, Andrew; Miller, William Kyle; Schroeder, Jason; Medhkour, Azedine] Univ Toledo, Dept Surg, Div Neurosurg, Med Ctr, 2801 W Bancroft St, Toledo, OH 43606 USA.
   [Mugge, Luke] Inova Neurosci & Spine Inst, Dept Neurosurg, Fairfax, VA USA.
   [Mansour, Tarek R.] Henry Ford Hlth Syst, Dept Neurol Surg, Detroit, MI USA.
RP Caras, A (reprint author), Univ Toledo, Dept Surg, Div Neurosurg, Med Ctr, 2801 W Bancroft St, Toledo, OH 43606 USA.
EM andrew.caras@rockets.utoledo.edu
OI Caras, Andrew/0000-0001-6379-8089; Miller, William/0000-0003-4533-6993
CR Ahmadi R, 2016, BRIT J NEUROSURG, V30, P397, DOI 10.3109/02688697.2016.1161726
   Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011
   Bai SC, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0690-7
   Bailey PD, 2015, J NEUROIMAGING, V25, P776, DOI 10.1111/jon.12273
   Bekelis K, 2016, WORLD NEUROSURG, V94, P551, DOI 10.1016/j.wneu.2016.07.077
   Bisdas S, 2015, CLIN NEURORADIOL, V25, P237, DOI 10.1007/s00062-015-0443-6
   Black PM, 1997, NEUROSURGERY, V41, P831, DOI 10.1097/00006123-199710000-00013
   Brell M, 2000, ACTA NEUROCHIR, V142, P739, DOI 10.1007/s007010070088
   Brennan Nicole Petrovich, 2016, Top Magn Reson Imaging, V25, P1, DOI 10.1097/RMR.0000000000000074
   Castellano A, 2012, NEURO-ONCOLOGY, V14, P192, DOI 10.1093/neuonc/nor188
   Chen LF, 2017, TURK NEUROSURG, V27, P696, DOI 10.5137/1019-5149.JTN.18346-16.1
   Claus EB, 2005, CANCER-AM CANCER SOC, V103, P1227, DOI 10.1002/cncr.20867
   Coburger J, 2017, J NEUROSURG SCI, V61, P233, DOI 10.23736/S0390-5616.16.03284-7
   Coburger J, 2016, NEUROSURGERY, V78, P775, DOI 10.1227/NEU.0000000000001081
   D'Andrea G, 2016, WORLD NEUROSURG, V87, P627, DOI 10.1016/j.wneu.2015.10.076
   Eljamel MS, 2016, PHOTODIAGN PHOTODYN, V16, P35, DOI 10.1016/j.pdpdt.2016.07.012
   Ginat DT, 2014, J MAGN RESON IMAGING, V39, P1357, DOI 10.1002/jmri.24380
   Gulati S, 2009, MINIM INVAS NEUROSUR, V52, P17, DOI 10.1055/s-0028-1104566
   Hall WA, 2003, ACT NEUR S, V85, P137
   Hall Walter A, 2009, Top Magn Reson Imaging, V19, P205, DOI 10.1097/RMR.0b013e3181934a09
   HANCOCK C, 2014, OPEN J RADIOL, V4, P260
   Huang M, 2016, WORLD NEUROSURG, V89, DOI 10.1016/j.wneu.2015.12.071
   Incekara F, 2016, J NEUROL SURG PART A, V77, P79, DOI 10.1055/s-0035-1551830
   Kiris T, 2011, ACTA NEUROCHIR SUPPL, V109, P55, DOI 10.1007/978-3-211-99651-5_9
   Kuhnt D, 2012, NEUROSURGERY, V70, P911, DOI 10.1227/NEU.0b013e318237a807
   Leuthardt EC, 2011, NEUROSURGERY, V69, P194, DOI 10.1227/NEU.0b013e31821d0e4c
   Lu JF, 2013, J CLIN NEUROSCI, V20, P1280, DOI 10.1016/j.jocn.2012.10.042
   Majchrzak K, 2011, NEUROL NEUROCHIR POL, V45, P351
   Makary M, 2011, J MAGN RESON IMAGING, V34, P1022, DOI 10.1002/jmri.22739
   Maldaun MVC, 2014, J NEUROSURG, V121, P810, DOI 10.3171/2014.6.JNS132285
   McGirt MJ, 2009, NEUROSURGERY, V65, P463, DOI 10.1227/01.NEU.0000349763.42238.E9
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Motomura K, 2017, J NEUROSURG, V127, P790, DOI 10.3171/2016.9.JNS16152
   Muragaki Y, 2006, ACTA NEUROCHIR SUPPL, V98, P67
   Nadkarni TN, 2015, NEUROIMAGE-CLIN, V7, P415, DOI 10.1016/j.nicl.2014.12.014
   Nimsky C, 2003, ACT NEUR S, V88, P21
   O'Donnell LJ, 2011, NEUROSURG CLIN N AM, V22, P185, DOI 10.1016/j.nec.2010.12.004
   Ohue S, 2015, NEUROSURG REV, V38, P293, DOI 10.1007/s10143-014-0593-z
   Olubiyi OI, 2015, WORLD NEUROSURG, V84, P528, DOI 10.1016/j.wneu.2015.04.044
   Panigrahi M, 2017, WORLD NEUROSURG, V98, P587, DOI 10.1016/j.wneu.2016.11.001
   Peus D, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-72
   Potgieser ARE, 2014, CLIN NEUROL NEUROSUR, V124, P51, DOI 10.1016/j.clineuro.2014.06.009
   Schneider JP, 2005, NEURORADIOLOGY, V47, P489, DOI 10.1007/s00234-005-1397-1
   Schulder Michael, 2003, Cancer Control, V10, P115
   Senft C, 2008, NEUROSURGERY, V63, P257, DOI 10.1227/01.NEU.0000313624.77452.3C
   Senft C, 2011, LANCET ONCOL, V12, P997, DOI 10.1016/S1470-2045(11)70196-6
   Senft C, 2010, TECHNOL CANCER RES T, V9, P339, DOI 10.1177/153303461000900404
   Senft C, 2010, CLIN NEUROL NEUROSUR, V112, P237, DOI 10.1016/j.clineuro.2009.12.003
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Wood JM, 2011, AM J NEURORADIOL, V32, P1420, DOI 10.3174/ajnr.A2679
   Wu JS, 2007, NEUROSURGERY, V61, P935, DOI 10.1227/01.neu.0000303189.80049.ab
   Yousem DM, 2014, NEUROIMAG CLIN N AM, V24, P717, DOI 10.1016/j.nic.2014.07.007
   Zhang JS, 2015, NEUROSURG REV, V38, P319, DOI 10.1007/s10143-014-0585-z
   Zhang ZZ, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00175
   Zheng X, 2016, WORLD NEUROSURG, V89, P434, DOI 10.1016/j.wneu.2016.01.092
   Zhuang DX, 2016, WORLD NEUROSURG, V89, P84, DOI 10.1016/j.wneu.2016.01.067
NR 56
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 98
EP 110
DI 10.1016/j.wneu.2019.10.072
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200151
PM 31639502
DA 2020-05-12
ER

PT J
AU Barchetti, G
   Cagnazzo, F
   Raz, E
   Barbagallo, G
   Toccaceli, G
   Peschillo, S
AF Barchetti, Giovanni
   Cagnazzo, Federico
   Raz, Eytan
   Barbagallo, Giuseppe
   Toccaceli, Giada
   Peschillo, Simone
TI Mechanical Thrombectomy of Distal Occlusions Using a Direct Aspiration
   First Pass Technique Compared with New Generation of Mini-0.017
   Microcatheter Compatible-Stent Retrievers: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE ADAPT; Meta-analysis; Stent retrievers; Stroke; Thrombectomy
ID ACUTE ISCHEMIC-STROKE; MIDDLE CEREBRAL-ARTERY; M2 OCCLUSION;
   ENDOVASCULAR TREATMENT; BABY TREVO; GUIDELINES; ADAPT
AB BACKGROUND: There are no current evidence-based recommendations on mechanical thrombectomy (MT) in M2 or other distal occlusions. The objective of this paper was to investigate clinical and radiologic outcomes of MT in distal locations using the new generation of mini-0.017 microcatheter compatible-stent retrievers (SRs) compared with a direct aspiration first pass technique (ADAPT) MT.
   METHODS: A systematic search was performed for studies published from January 2016 to March 2019. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we included studies that reported clinical and radiologic outcomes of patients undergoing MT using new generation of SRs or ADAPT in distal locations. The cumulative prevalence was estimated for each outcome. Heterogeneity of the data was assessed by the Higgins index (I-2), and a random-effects model was applied.
   RESULTS: Fifteen studies and 494 patients were included; 7 studies reported on patients treated with a new SR and 8 studies analyzed patients treated with ADAPT. The rate of thrombolysis in cerebral infarction score 2b-3 after MT for distal occlusions was 80.6% (383 of 494; 95% confidence interval [CI]. 74.8%-86.3%; I-2 = 64.4%). Successful recanalization was comparable after SR use with low-profile devices and ADAPT (176 of 226; 82%; 95% CI, 72.6%-1.5%; I-2 = 70.5% vs. 207 of 268; 79.4%; 95% CI, 71.8%-86.9%; I-2 = 60.8%, respectively; P = 0.4). The rate of the modified Rankin scale score of 0-2 at 3 months was higher in the ADAPT group (160 of 251; 68.9%; 95% CI, 51.8%-85.9%; I-2 = 92.2%) than the SR group (92 of 177; 58.7%; 95% CI, 37.3%-80%; I-2 = 58.7%; P = 0.01). The mortality rate was lower among the ADAPT group (20 of 251; 5.4%; 95% CI, 1.4%-9%; I-2 = 63%) than the SR group (16 of 108; 13%; 95% CI, 6%-19%; I-2 = 13%; P = 0.008).
   CONCLUSIONS: MT in distal locations using the new generation of SR yields comparable results compared with ADAPT in terms of recanalization; however, the use of SR is associated with lower functional independence and higher mortality rate.
C1 [Barchetti, Giovanni] Sapienza Univ Rome, Intervent Neuroradiol, Rome, Italy.
   [Cagnazzo, Federico] CHU Montpellier, Univ Hosp Gui de Chauliac, Neuroradiol Dept, Montpellier, France.
   [Raz, Eytan] NYU Langone Hlth, Dept Radiol, New York, NY USA.
   [Toccaceli, Giada; Peschillo, Simone] Univ Catania, Dept Neurol Surg, Endovasc Neurosurg, Catania, Italy.
   [Barbagallo, Giuseppe] Univ Catania, Dept Neurol Surg, Catania, Italy.
RP Peschillo, S (reprint author), Univ Catania, Dept Neurol Surg, Endovasc Neurosurg, Catania, Italy.
EM simone.peschillo@gmail.com
OI Peschillo, Simone/0000-0002-3920-8517
CR Altenbernd J, 2018, J NEUROINTERV SURG, V10, P434, DOI 10.1136/neurintsurg-2017-013233
   Arnold M, 2015, EUR NEUROL, V74, P315, DOI 10.1159/000441445
   Bhogal P, 2017, INTERV NEUROL, V6, P191, DOI 10.1159/000475535
   Bourcier R, 2019, J NEUROINTERV SURG, V11, P625, DOI 10.1136/neurintsurg-2018-014380
   Cerejo R, 2016, J NEUROINTERV SURG, V8, P1178, DOI 10.1136/neurintsurg-2015-012078
   Coutinho JM, 2016, AM J NEURORADIOL, V37, P667, DOI 10.3174/ajnr.A4591
   Dobrocky T, 2020, CLIN NEURORADIOL, V30, P51, DOI 10.1007/s00062-018-0739-4
   Dorn F, 2015, J STROKE CEREBROVASC, V24, P1465, DOI 10.1016/j.jstrokecerebrovasdis.2015.04.013
   Flores A, 2015, J NEUROINTERV SURG, V7, P234, DOI 10.1136/neurintsurg-2014-011100
   Gory B, 2018, STROKE, V49, P461, DOI 10.1161/STROKEAHA.117.019598
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Grieb D, 2019, J NEURORADIOLOGY, V46, P231, DOI 10.1016/j.neurad.2019.01.096
   Haussen DC, 2016, J NEUROINTERV SURG, V8, P295, DOI 10.1136/neurintsurg-2014-011613
   Hofmeister J, 2018, J NEURORADIOLOGY, V45, P305, DOI 10.1016/j.neurad.2018.01.051
   Kim YW, 2017, J NEUROINTERV SURG, V9, P626, DOI 10.1136/neurintsurg-2016-012466
   Kuhn AL, 2017, J NEUROINTERV SURG, V9, P541, DOI 10.1136/neurintsurg-2016-012454
   Kurre W, 2017, CLIN NEURORADIOL, V27, P351, DOI 10.1007/s00062-016-0497-0
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Mokin M, 2017, NEUROSURGERY, V81, P795, DOI 10.1093/neuros/nyx060
   Muller-Eschner M, 2019, CARDIOVASC INTER RAD, V42, P101, DOI 10.1007/s00270-018-2039-4
   Navia P, 2016, J NEUROINTERV SURG, V8, P787, DOI 10.1136/neurintsurg-2015-011798
   Park JS, 2016, J KOREAN NEUROSURG S, V59, P352, DOI 10.3340/jkns.2016.59.4.352
   Peschillo S, 2017, J NEUROINTERV SURG, V9, P743, DOI 10.1136/neurintsurg-2016-012533
   Peschillo S, 2018, INTERV NEUROL, V7, P501, DOI 10.1159/000491028
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Premat K, 2018, CLIN NEURORADIOL, V28, P553, DOI 10.1007/s00062-017-0594-8
   Saber H, 2018, J NEUROINTERV SURG, V10, P620, DOI 10.1136/neurintsurg-2017-013515
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Turc G, 2019, EUR STROKE J, V4, P6, DOI 10.1177/2396987319832140
   Yamaguchi S, 2018, WORLD NEUROSURG, V118, P203, DOI 10.1016/j.wneu.2018.07.118
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 111
EP 119
DI 10.1016/j.wneu.2019.10.030
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200152
PM 31627000
DA 2020-05-12
ER

PT J
AU Ma, YH
   Sun, D
   Chen, SG
   Chen, XJ
AF Ma, Yihui
   Sun, Dong
   Chen, Shuguang
   Chen, Xinjun
TI Hybrid Surgical Rescue of Failed Stent Retrieval with Acute Middle
   Cerebral Artery Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute middle cerebral artery occlusion; Carotid artery stenting; Carotid
   endarterectomy; Failed stent retrieval; Hybrid operation; Thrombectomy
C1 [Ma, Yihui; Chen, Shuguang; Chen, Xinjun] Wuhan Univ, Zhongnan Hosp, Dept Neurosurg, Wuhan, Peoples R China.
   [Sun, Dong] Wuhan Univ, Zhongnan Hosp, Dept Neurol, Wuhan, Peoples R China.
RP Chen, XJ (reprint author), Wuhan Univ, Zhongnan Hosp, Dept Neurosurg, Wuhan, Peoples R China.
EM chenxjwhu@126.com
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 120
EP 120
DI 10.1016/j.wneu.2019.10.127
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200153
PM 31698128
DA 2020-05-12
ER

PT J
AU Sanchez, JAS
   Solis, SS
   Rangel, JAIR
AF Soriano Sanchez, Jose Antonio
   Soriano Solis, Sergio
   Israel Romero Rangel, Jose Alberto
TI Role of the Checklist in Neurosurgery, a Realistic Perspective to "The
   Need for Surgical Safety Checklists in Neurosurgery Now and in the
   Future - a Systematic Review"
SO WORLD NEUROSURGERY
LA English
DT Review
DE Neurosurgery; Patient safety; Surgical checklist; Systematic review
C1 [Soriano Sanchez, Jose Antonio; Soriano Solis, Sergio; Israel Romero Rangel, Jose Alberto] Amer British Cowdray Med Ctr IAP, Cdmx, Mexico.
RP Sanchez, JAS (reprint author), Amer British Cowdray Med Ctr IAP, Cdmx, Mexico.
EM neurojass1@hotmail.com
OI Romero-Rangel, Jose Alberto Israel/0000-0002-5405-4907
CR Elsamadicy AA, 2018, NEUROSURGERY, V83, P997, DOI 10.1093/neuros/nyx565
   Ford KE, 2018, SURG-J R COLL SURG E, V16, P27, DOI 10.1016/j.surge.2016.03.009
   Ghannad M, 2019, J CLIN EPIDEMIOL, V116, P9, DOI 10.1016/j.jclinepi.2019.07.011
   Han SJ, 2015, NEUROSURG CLIN N AM, V26, P143, DOI 10.1016/j.nec.2014.11.007
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Lyons MK, 2010, AM J MED QUAL, V25, P285, DOI 10.1177/1062860610363305
   Mirza SK, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-53
   Mishra A, 2009, QUAL SAF HEALTH CARE, V18, P104, DOI 10.1136/qshc.2007.024760
   Taylor CL, 2016, WORLD NEUROSURG, V93, P159, DOI 10.1016/j.wneu.2016.06.017
   Westman M, 2020, WORLD NEUROSURG, V134, P614, DOI 10.1016/j.wneu.2019.09.140
   White MC, 2018, BMJ GLOB HEALTH, V3, P1
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 121
EP 122
DI 10.1016/j.wneu.2019.09.140
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200154
PM 31678319
DA 2020-05-12
ER

PT J
AU Noureldine, MHA
   Saikali, I
   Nassif, A
   Chahinian, R
   Sweid, A
   Kikano, R
   Mawad, M
AF Noureldine, Mohammad Hassan A.
   Saikali, Ibrahim
   Nassif, Anis
   Chahinian, Rita
   Sweid, Ahmad
   Kikano, Raghid
   Mawad, Michel
TI Pediatric Moyamoya Presenting as a Subarachnoid Hemorrhage from a
   Ruptured Anterior Cerebral Artery Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Anterior cerebral artery; Pediatric Moyamoya; Subarachnoid
   hemorrhage
ID DISEASE; REVASCULARIZATION; CHILDREN
AB BACKGROUND: The incidence of Moyamoya disease (MMD)-associated intracranial aneurysms ranges from 3% to 14% in adult patients, whereas this complication has rarely been reported in children.
   CASE DESCRIPTION: We herein report the first case, to our knowledge, of an extremely rare subarachnoid hemorrhage presentation of a child with a ruptured anterior cerebral artery dissecting aneurysm secondary to a newly discovered, unilateral Moyamoya-like pathology.
   CONCLUSIONS: MMD-associated aneurysms are extremely rare in children, hemorrhage may be the initial presentation of the disease. Prompt intervention is essential to exclude the ruptured aneurysm that is at risk of rebleeding because of persistent hemodynamic stress.
C1 [Noureldine, Mohammad Hassan A.] Johns Hopkins Univ, Sch Med, Inst Brain Protect Sci, Johns Hopkins All Childrens Hosp,Dept Neurosurg, St Petersburg, FL USA.
   [Saikali, Ibrahim] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Div Neurosurg, Beirut, Lebanon.
   [Nassif, Anis; Chahinian, Rita; Kikano, Raghid; Mawad, Michel] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Dept Radiol, Beirut, Lebanon.
   [Sweid, Ahmad] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA.
RP Saikali, I (reprint author), Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Div Neurosurg, Beirut, Lebanon.
EM ibrahim.saikali@lau.edu.lb
OI Sweid, Ahmad/0000-0002-2652-2451
CR Baaj AA, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.01.FOCUS08293
   Burke GM, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.1.FOCUS08310
   Fukui M, 1997, CLIN NEUROL NEUROSUR, V99, pS238
   Fung LWE, 2005, CHILD NERV SYST, V21, P358, DOI 10.1007/s00381-004-1118-9
   HAMADA J, 1994, J NEUROSURG, V80, P328, DOI 10.3171/jns.1994.80.2.0328
   Iwama T, 1997, CLIN NEUROL NEUROSUR, V99, pS187, DOI 10.1016/S0303-8467(97)00081-4
   Kawaguchi S, 1996, ACTA NEUROCHIR, V138, P1287, DOI 10.1007/BF01411057
   Leveque M, 2011, J NEUROSURG, V114, P116, DOI 10.3171/2009.9.JNS081659
   Liu P, 2016, WORLD NEUROSURG, V94, P513, DOI 10.1016/j.wneu.2016.05.039
   Miyake H, 2000, NEUROL MED-CHIR, V40, P55, DOI 10.2176/nmc.40.55
   Narayan P, 2004, J NEUROSURG, V100, P340, DOI 10.3171/jns.2004.100.2.0340
   Pandey P, 2011, STROKE, V42, P3304, DOI 10.1161/STROKEAHA.110.598565
   Park YS, 2010, J NEUROSURG, V113, P749, DOI 10.3171/2009.11.JNS09895
   Scott RM, 2004, J NEUROSURG, V100, P142, DOI 10.3171/ped.2004.100.2.0142
   Takahashi JC, 2010, NEUROL MED-CHIR, V50, P824, DOI 10.2176/nmc.50.824
   YUASA H, 1982, J NEUROSURG, V56, P131, DOI 10.3171/jns.1982.56.1.0131
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 123
EP 127
DI 10.1016/j.wneu.2019.10.157
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200155
PM 31689569
DA 2020-05-12
ER

PT J
AU Noureldine, MHA
   Jha, RT
   Peto, I
   Malafronte, PJ
   Allen, K
   Agazzi, S
AF Noureldine, Mohammad Hassan A.
   Jha, R. Tushar
   Peto, Ivo
   Malafronte, Patrick J.
   Allen, Kyle
   Agazzi, Siviero
TI Facial Nerve Schwannoma Complicated by Acute Hemorrhage After Treatment
   with Stereotactic Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE CyberKnife; Facial nerve neuroma; Facial nerve palsy; Facial nerve
   schwannoma; Intratumoral hemorrhage; Microsurgery; Radiotherapy;
   Stereotactic radiosurgery
ID GAMMA-KNIFE SURGERY
AB BACKGROUND: Facial nerve schwannomas (FNSs) are rare benign tumors that arise from Schwann cells of the facial nerve. FNSs are similar to vestibular schwannomas in many aspects, yet their infiltrative nature into the facial nerve fascicles warrants a more conservative management approach. In the last decade, stereotactic radiosurgery (SRS) has shown promise in stabilizing or shrinking FNSs.
   CASE DESCRIPTION: A 71-year-old woman presented with mild facial paresis. Tumor growth after a period of watchful waiting warranted treatment with SRS, which was complicated by an acute posterior fossa hemorrhage and brainstem compression, necessitating microsurgical hematoma evacuation, tumor resection, and facial nerve substitution.
   CONCLUSIONS: SRS has led to better facial nerve function and outcomes and currently considered a reasonable alternative to microsurgical resection in patients with FNSs. This is the first report to our knowledge of an acute, life-threatening hemorrhage after SRS in a patient with FNS.
C1 [Noureldine, Mohammad Hassan A.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Inst Brain Protect Sci,Johns Hopkins All Children, St Petersburg, FL USA.
   [Jha, R. Tushar] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA.
   [Jha, R. Tushar] Boston Med Ctr, Boston, MA USA.
   [Peto, Ivo; Allen, Kyle; Agazzi, Siviero] Univ S Florida, Dept Neurosurg, Morsani Coll Med, Tampa Gen Hosp, Tampa, FL 33620 USA.
   [Malafronte, Patrick J.] Ruffolo Hooper & Associates MD PA, Tampa, FL USA.
   [Allen, Kyle] Tampa Bay Hearing & Balance Ctr, Tampa, FL USA.
RP Agazzi, S (reprint author), Univ S Florida, Dept Neurosurg, Morsani Coll Med, Tampa Gen Hosp, Tampa, FL 33620 USA.
EM sagazzi@usf.edu
OI Agazzi, Siviero/0000-0001-5760-0187
CR Bartindale M, 2019, J NEUROL SURG PART B, V80, P458, DOI 10.1055/s-0038-1675590
   Carlson ML, 2017, LARYNGOSCOPE, V127, P1420, DOI 10.1002/lary.26193
   Carlson ML, 2016, MAYO CLIN PROC, V91, P1563, DOI 10.1016/j.mayocp.2016.07.007
   Comps JN, 2018, ACTA NEUROCHIR, V160, P987, DOI 10.1007/s00701-018-3503-2
   Eshraghi AA, 2019, J NEUROL SURG PART B, V80, P352, DOI 10.1055/s-0038-1670687
   Hajjaj M, 1996, J LARYNGOL OTOL, V110, P632, DOI 10.1017/S0022215100134474
   Hasegawa T, 2016, J NEUROSURG, V124, P403, DOI 10.3171/2015.3.JNS142677
   McMonagle B, 2008, J LARYNGOL OTOL, V122, P1139, DOI 10.1017/S0022215107000667
   McRackan TR, 2015, OTOL NEUROTOL, V36, P393, DOI 10.1097/MAO.0000000000000708
   McRackan TR, 2012, OTOL NEUROTOL, V33, P78, DOI 10.1097/MAO.0b013e31823c8ef1
   Moon JH, 2014, J NEUROSURG, V121, P116, DOI 10.3171/2014.8.GKS141504
   Niknafs YS, 2014, WORLD NEUROSURG, V82, P751, DOI 10.1016/j.wneu.2013.02.069
   Nikolopoulos TP, 2010, OTOL NEUROTOL, V31, P478, DOI 10.1097/MAO.0b013e3181d279a3
   Quesnel AM, 2018, OTOLARYNG CLIN N AM, V51, P1179, DOI 10.1016/j.otc.2018.07.013
   Sheehan JP, 2015, J NEUROSURG, V123, P387, DOI 10.3171/2014.11.JNS141160
   Wiggins RH, 2006, AM J NEURORADIOL, V27, P694
   Xu F, 2017, WORLD NEUROSURG, V100, P444, DOI 10.1016/j.wneu.2016.09.082
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 128
EP 132
DI 10.1016/j.wneu.2019.10.161
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200156
PM 31689568
DA 2020-05-12
ER

PT J
AU Ko, Y
   Takeshima, Y
   Nakagawa, I
   Motoyama, Y
   Park, YS
   Nakase, H
AF Ko, Yumi
   Takeshima, Yasuhiro
   Nakagawa, Ichiro
   Motoyama, Yasushi
   Park, Young-Su
   Nakase, Hiroyuki
TI Overshunting-Associated Myelopathy Treated with Endoscopic Third
   Ventriculostomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid shunt; Complication; Hydrocephalus; Myelopathy;
   Overdrainage; Paravertebral venous plexus; Ventriculoperitoneal shunt
ID CERVICAL MYELOPATHY; COMPLICATION; PRESSURE
AB BACKGROUND: Overshunting-associated myelopathy (OSAM) is a rare of cerebrospinal fluid shunt placement. Previous reports have recommended removal or ligation of the shunt and use or revision of a pressure programmable valve to treat OSAM. We present a rare case of OSAM successfully treated with endoscopic third ventriculostomy (ETV).
   CASE DESCRIPTION: A 67-year-old female who had undergone ventriculoperitoneal shunting with a constant pressure valve for long-standing overt ventriculomegaly in adults 42 years ago presented to our department with bilateral hand numbness. Magnetic resonance imaging of the cervical spine showed spinal canal stenosis and dilatation of the paravertebral venous plexus with spinal cord compression. Cervical laminoplasty was temporarily effective, but her symptoms reoccurred and worsened. ETV was performed, and a programmable shunt valve adjusted to maximum pressure was also interposed as a safety device. Her symptoms immediately improved after this operation. Cervical magnetic resonance imaging and computed tomography showed that the cervical paravertebral venous dilatation had also resolved immediately. Clinical improvement was maintained with no recurrence of hydrocephalus or paravertebral venous dilatation for 2 years postoperatively.
   CONCLUSIONS: This is the first case of OSAM treated with ETV. ETV might be a useful treatment option for OSAM after treatment for obstructive hydrocephalus.
C1 [Ko, Yumi; Takeshima, Yasuhiro; Nakagawa, Ichiro; Motoyama, Yasushi; Park, Young-Su; Nakase, Hiroyuki] Nara Med Univ, Dept Neurosurg, Sch Med, Kashihara, Nara, Japan.
RP Takeshima, Y (reprint author), Nara Med Univ, Dept Neurosurg, Sch Med, Kashihara, Nara, Japan.
EM takeshim@naramed-u.ac.jp
CR Adib SD, 2018, WORLD NEUROSURG, V116, P274, DOI 10.1016/j.wneu.2018.05.175
   Amano E, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010082
   Ho JMK, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.7.FOCUS16179
   Kovacs A, 2018, WORLD NEUROSURG, V116, P29, DOI 10.1016/j.wneu.2018.05.032
   Miyazaki T, 1998, NEUROLOGY, V50, P1864, DOI 10.1212/WNL.50.6.1864
   Mokri B, 2003, CURR OPIN NEUROL, V16, P319, DOI 10.1097/00019052-200306000-00011
   Ros B, 2018, NEUROSURG REV, V41, P969, DOI 10.1007/s10143-017-0849-5
   Wolfe SQ, 2007, J NEUROSURG, V106, P227, DOI 10.3171/ped.2007.106.3.227
NR 8
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 133
EP 136
DI 10.1016/j.wneu.2019.10.183
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200157
PM 31704357
DA 2020-05-12
ER

PT J
AU Yoon, SG
   Kim, MS
   Kwon, SC
   Lyo, IU
   Sim, HB
AF Yoon, Sun Geon
   Kim, Min Su
   Kwon, Soon Chan
   Lyo, In Uk
   Sim, Hong Bo
TI Delayed Ureter Stricture and Kidney Atrophy After Oblique Lumbar
   Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Kidney; Oblique lumbar interbody fusion; Ureter
ID SURGICAL APPROACH; COMPLICATIONS; SURGERY; ANATOMY
AB BACKGROUND: Oblique lumbar interbody fusion (OLIF) is a surgical techique for lumbar interbody fusion that allows surgeons to use a large cage while preserving the spine muscles. The surgical corridor of OLIF is close to the ureter in the retroperitoneal space and therefore entails a potential for injury to this organ. Although there are some published cases of ureteral injury that were identified during OLIF, to our knowledge, there have been no reports about delayed ureteral strictures and kidney atrophy after OLIF We report a case of ureter stricture and ipsilateral kidney atrophy that was incidentally identified a few months postoperatively without signs of ureter injury during the operation.
   CASE DESCRIPTION: A 49-year-old woman presented with low back and leg pain. On lumbar magnetic resonance imaging, a Meyerding grade 1 spondylolisthesis of L4 on L5 with L4 nerve root encroachment was confirmed. The patient underwent L4/L5 OLIF and was discharged on the 10th day after surgery with improved symptoms. Three months later, an abdominopelvic computed tomography performed for an unrelated condition showed left kidney atrophy. A retrograde ureteropyelogram confirmed a stricture near the operation site. A ureter stent was successfully inserted to overcome the stricture, but renal atrophy was not reversed.
   CONCLUSIONS: Ureter injury may be observed with several months' delay after OLIF in patients without symptoms or laboratory abnormalities, even if no direct injury was noted during the procedure.
C1 [Yoon, Sun Geon; Kim, Min Su; Kwon, Soon Chan; Lyo, In Uk; Sim, Hong Bo] Univ Ulsan, Ulsan Univ Hosp, Dept Neurosurg, Coll Med, Ulsan, South Korea.
RP Sim, HB (reprint author), Univ Ulsan, Ulsan Univ Hosp, Dept Neurosurg, Coll Med, Ulsan, South Korea.
EM nssim01@gmail.com
OI Yoon, Sun Geon/0000-0002-1013-936X; Kim, Min Soo/0000-0002-8901-7241
CR Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Ebata S, 2018, SPINE SURG RELAT RES, V2, P140, DOI 10.22603/ssrr.2017-0036
   Fujibayashi S, 2017, SPINE, V42, P1478, DOI 10.1097/BRS.0000000000002139
   Fujibayashi S, 2017, J ORTHOP SCI, V22, P420, DOI 10.1016/j.jos.2017.01.009
   Guerin P, 2012, SURG RADIOL ANAT, V34, P151, DOI 10.1007/s00276-011-0881-z
   Information NCfB, 2019, GOS AC
   Kepler CK, 2011, EUR SPINE J, V20, P550, DOI 10.1007/s00586-010-1593-5
   Kubota Go, 2017, BMC Res Notes, V10, P193, DOI 10.1186/s13104-017-2509-9
   Lee HJ, 2017, WORLD NEUROSURG, V102, DOI 10.1016/j.wneu.2017.04.038
   Li JXJ, 2017, WORLD NEUROSURG, V98, P113, DOI 10.1016/j.wneu.2016.10.074
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Ouchida J, 2019, EUR SPINE J, V28, P835, DOI 10.1007/s00586-018-5803-x
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Quillo-Olvera J, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.22
   Voin V, 2017, WORLD NEUROSURG, V104, P674, DOI 10.1016/j.wneu.2017.05.062
   Xiao L, 2019, WORLD NEUROSURG, V123, pE717, DOI 10.1016/j.wneu.2018.12.011
   Zeng ZY, 2018, ORTHOP SURG, V10, P98, DOI 10.1111/os.12380
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 137
EP 140
DI 10.1016/j.wneu.2019.10.171
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200158
PM 31698121
DA 2020-05-12
ER

PT J
AU Raper, DMS
   Rutledge, WC
   Winkler, E
   Abla, AA
AF Raper, Daniel M. S.
   Rutledge, W. Caleb
   Winkler, Ethan
   Abla, Adib A.
TI Spontaneous Perforation of Anterior Choroidal Artery with Resultant
   Pseudoaneurysm Formation: Unusual Cause of Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Microsurgery; Pseudoaneurysm; Subarachnoid hemorrhage; Surgical
   technique
ID ANEURYSM; RUPTURE
AB BACKGROUND: Subarachnoid hemorrhage resulting from spontaneous perforation of a small intracranial vessel, with resultant pseudoaneurysm formation, has not been widely reported in the literature.
   CASE DESCRIPTION: We present the case of a 71-year-old patient with repture of a small aneurysm of a duplicated left anterior choroidal artery causing an acute third nerve palsy. The aneurysm was not able to be treated endo-vascularly without sacrifice of the parent vessel. At surgery, a pseudoaneurysm was seen completely separate from the parent vessel, which was actively bleeding through a hole in the vessel. The pseudoaneurysm was indenting the oculomotor nerve. After confirmation of adequate collateral flow, the abnormal segment of vessel was trapped and the pseudoaneurysm removed with surrounding clot. The patient's cranial nerve palsy resolved.
   CONCLUSIONS: This case illustrates an unusual sequela of subarachnoid hemorrhage presenting a unique challenge in surgical management.
C1 [Raper, Daniel M. S.; Rutledge, W. Caleb; Winkler, Ethan; Abla, Adib A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94117 USA.
RP Abla, AA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94117 USA.
EM Adib.abla@ucsf.edu
CR Mori K, 2004, NEUROSURG REV, V27, P289, DOI 10.1007/s10143-004-0336-7
   Nomura M, 2000, J NEUROSURG, V93, P998, DOI 10.3171/jns.2000.93.6.0998
   Nomura M, 2015, SURG J-NY, V1, pE47, DOI 10.1055/s-0035-1567877
   Nomura M, 2017, NEURORADIOL J, V30, DOI 10.1177/1971400916684667
   Tanoue S, 2004, J NEUROSURG, V101, P159, DOI 10.3171/jns.2004.101.1.0159
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 141
EP 144
DI 10.1016/j.wneu.2019.10.174
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200159
PM 31698118
DA 2020-05-12
ER

PT J
AU Chiba, R
   Akiyama, Y
   Kimura, Y
   Yokoyama, R
   Mikuni, N
AF Chiba, Ryohei
   Akiyama, Yukinori
   Kimura, Yusuke
   Yokoyama, Rintaro
   Mikuni, Nobuhiro
TI Diagnosis of a Rare Intraventricular Schwannoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraventricular schwannoma; Pathogenesis
ID VENTRICULAR SCHWANNOMA; SPINAL-CORD; SOLITARY; DISEASE; TUMOR
AB BACKGROUND: Intraventricular schwannoma is extremely rare, with only 35 cases reported to date in the literature. Consequently, its etiology and pathogenesis are still unclear, and therefore require further investigations. Here, we report on and discuss a rare case of intraventricular schwannoma to elucidate on this matter.
   CASE DESCRIPTION: A 26-year-old man was admitted to our institution with a 1-month history of headaches and left hemianopsia. At diagnosis, magnetic resonance imaging of the brain revealed a well-demarcated mass with surrounding edema in the right lateral ventricle. Total resection of the tumor was performed by a transsulcal approach through the right parietal lobe. In surgery, it was observed that the tumor was attached to the choroid plexus without invading the wall of the right lateral ventricle. The respective histologic examination confirmed the diagnosis of intraventricular schwannoma. Six months after the surgery, there was no recurrence. Additionally, during this follow-up period, the patient did not develop any neurologic deficit, including visual field narrowing or parietal symptoms, such as acalculia and right-left, finger, and space agnosias.
   CONCLUSIONS: Although intraventricular schwannomas are rare, 35 cases have already been reported to date. We emphasize the importance of diagnosing such cases correctly to increase knowledge on the origin and pathogenesis of intraventricular tumors, which would facilitate disease management.
C1 [Chiba, Ryohei; Akiyama, Yukinori; Kimura, Yusuke; Yokoyama, Rintaro; Mikuni, Nobuhiro] Sapporo Med Univ, Dept Neurosurg, Sch Med, Sapporo, Hokkaido, Japan.
RP Akiyama, Y (reprint author), Sapporo Med Univ, Dept Neurosurg, Sch Med, Sapporo, Hokkaido, Japan.
EM akiyuki@sapmed.ac.jp
CR Abdolhosseinpour H, 2016, CHILD NERV SYST, V32, P1135, DOI 10.1007/s00381-015-2986-x
   Alberione F, 2013, NEUROCIRUGIA, V24, P272, DOI 10.1016/j.neucir.2012.02.007
   ARYANPUR J, 1988, J NEUROSURG, V69, P446, DOI 10.3171/jns.1988.69.3.0446
   Barbosa MD, 2001, NEUROCIRUGIA, V12, P56
   Benedict WJ, 2008, CHILD NERV SYST, V24, P529, DOI 10.1007/s00381-007-0556-6
   BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3
   Curran-Melendez SM, 2015, J NEUROL SURG REP, V76, P32, DOI 10.1055/s-0034-1395493
   DAVID M, 1965, NEUROCHIRURGIE, V11, P578
   Dow GR, 2004, BRIT J NEUROSURG, V18, P561, DOI 10.1080/02688690400012632
   Erdogan E, 2003, MINIM INVAS NEUROSUR, V46, P50, DOI 10.1055/s-2003-37969
   FEIGIN I, 1971, ACTA NEUROPATHOL, V17, P188, DOI 10.1007/BF00685053
   Ghatak N R, 1975, Surg Neurol, V3, P45
   Glikstein R, 2015, NEURORADIOL J, V28, P46, DOI 10.15274/NRJ-2014-10104
   Hodges TR, 2011, CASE REP MED, DOI 10.1155/2011/165954
   Jaimovich R, 2013, CHILD NERV SYST, V29, P499, DOI 10.1007/s00381-012-1977-4
   JUNG JM, 1995, J NEUROSURG, V82, P121, DOI 10.3171/jns.1995.82.1.0121
   Kachhara Rajneesh, 2012, Asian J Neurosurg, V7, P151, DOI 10.4103/1793-5482.103728
   Kouitcheu R, 2018, NEUROCHIRURGIE, V64, P310, DOI 10.1016/j.neuchi.2018.01.010
   Leveque M, 2007, NEUROCHIRURGIE, V53, P383, DOI 10.1016/j.neuchi.2007.06.005
   Li M, 2015, J CLIN NEUROSCI, V22, P919, DOI 10.1016/j.jocn.2014.11.003
   Luo W, 2013, CLIN NEUROL NEUROSUR, V115, P1052, DOI 10.1016/j.clineuro.2012.10.029
   Marchand Koechlin P, 1957, ANN MED PSYCHOL PARI, V115, P6
   Martin Smrcka, 2010, Asian J Neurosurg, V5, P83
   Messing-Junger A Martina, 2006, Brain Pathol, V16, P87
   Oertel MF, 2009, CLIN NEUROL NEUROSUR, V111, P768, DOI 10.1016/j.clineuro.2009.06.009
   OST AH, 1990, AM J NEURORADIOL, V11, P1262
   PARDATSCHER K, 1979, J NEUROSURG, V50, P817, DOI 10.3171/jns.1979.50.6.0817
   PIMENTEL J, 1988, CHILD NERV SYST, V4, P373, DOI 10.1007/BF00270615
   RAMAMURTHI B, 1958, J NEUROL NEUROSUR PS, V21, P92, DOI 10.1136/jnnp.21.2.92
   REDEKOP G, 1990, J NEUROSURG, V73, P777, DOI 10.3171/jns.1990.73.5.0777
   RIGGS HE, 1957, J NEUROPATH EXP NEUR, V16, P332, DOI 10.1097/00005072-195707000-00004
   Russell Rubinstein LJDS, 1977, PATHOLOGY TUMOURS NE
   VANRENSBURG MJ, 1975, J NEUROL NEUROSUR PS, V38, P703
   WEINER HL, 1993, J NEURO-ONCOL, V15, P37, DOI 10.1007/BF01050261
   Zhu TM, 2018, WORLD NEUROSURG, V117, P357, DOI 10.1016/j.wneu.2018.06.025
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 145
EP 149
DI 10.1016/j.wneu.2019.09.137
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200160
PM 31589985
DA 2020-05-12
ER

PT J
AU Armocida, D
   Marzetti, F
   Pesce, A
   Caporlingua, A
   D'Angelo, L
   Santoro, A
AF Armocida, Daniele
   Marzetti, Francesco
   Pesce, Alessandro
   Caporlingua, Alessandro
   D'Angelo, Luca
   Santoro, Antonio
TI Purely Meningeal Intracranial Relapse of Melanoma Brain Metastases After
   Surgical Resection and Immunotherapy as a Unique Disease Progression
   Pattern: Our Experience and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain metastasis; Melanoma; Meningeal metastases; MRI; Subdural hematoma
ID MALIGNANT-MELANOMA; CEREBRAL METASTASES; THERAPY; SURGERY
AB BACKGROUND: We present a case of 72-year-old man with a history of melanoma diagnosed in 2015 presenting a stable disease in treatment with dabrafenib.
   CASE DESCRIPTION: The patient had been surgically treated for a presumed intracranial parietooccipital metastasis. He presented 1 month later with a meningeal lesion associated with a subdural hematoma. A second surgical treatment confirmed the diagnosis of meningeal recurrence of metastatic melanoma.
   CONCLUSIONS: The most recent literature lacks studies defining the clinical phenomena or an early recurrence of intracranial melanoma with de novo involvement of dural compartment in patients in treatment with a target immunotherapy. The aim of this present study is to report a case of early recurrence of intracranial melanoma metastases with evidence of fast immunohistochemical and macroscopical mutation of pathologic elements, with an analysis of literature that shows the lack of well-described occurrences.
C1 [Armocida, Daniele; Marzetti, Francesco; Caporlingua, Alessandro; D'Angelo, Luca; Santoro, Antonio] Sapienza Univ, Azienda Osped Univ Policlin Umberto I, Human Neurosci Dept, Neurosurg Div, Rome, Italy.
   [Pesce, Alessandro] Sapienza Univ, Rome NESMOS Dept, St Andrea Neurosurg Div, Rome, Italy.
RP Armocida, D (reprint author), Sapienza Univ, Azienda Osped Univ Policlin Umberto I, Human Neurosci Dept, Neurosurg Div, Rome, Italy.
EM danielearmocida@yahoo.it
CR AMER MH, 1978, CANCER, V42, P660, DOI 10.1002/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO;2-E
   Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105
   Caruso R, 2017, WORLD NEUROSURG, V106, DOI 10.1016/J.WNEU.2017.07.059
   D'Andrea G, 2017, WORLD NEUROSURG, V97, P169, DOI 10.1016/j.wneu.2016.09.054
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Frati A, 2018, WORLD NEUROSURG, V114, pE565, DOI 10.1016/j.wneu.2018.03.034
   Hoz SS, 2018, SAO PAULO MED J, V136, P372, DOI 10.1590/1516-3180.2017.0003090317
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Long GV, 2012, LANCET ONCOL, V13, P1087, DOI 10.1016/S1470-2045(12)70431-X
   Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327
   Maxwell R, 2017, INT J CANCER, V140, P2716, DOI 10.1002/ijc.30241
   Miller D, 2013, CLIN NEUROL NEUROSUR, V115, P1721, DOI 10.1016/j.clineuro.2013.03.019
   Oliva IG, 2017, CANCER J, V23, P68, DOI 10.1097/PPO.0000000000000237
   Panagiotou IE, 2005, NEOPLASMA, V52, P150
   PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802
   Pessina F, 2017, WORLD NEUROSURG, V105, P184, DOI [10.1016/j.wneu.2017.05.131, 10.1016/j.wneu.2017.05.13]
   Pessina F, 2016, WORLD NEUROSURG, V94, P6, DOI 10.1016/j.wneu.2016.06.098
   Peuvrel L, 2014, J NEURO-ONCOL, V120, P147, DOI 10.1007/s11060-014-1533-z
   Ramakrishna Naren, 2013, Am Soc Clin Oncol Educ Book, P399, DOI 10.1200/EdBook_AM.2013.33.399
   Renfrow JJ, 2013, CURR TREAT OPTION ON, V14, P514, DOI 10.1007/s11864-013-0248-2
   Salvati M, 2012, NEUROSURG REV, V35, P211, DOI 10.1007/s10143-011-0348-z
   Samlowski WE, 2007, CANCER, V109, P1855, DOI 10.1002/cncr.22605
   Sampson JH, 1998, J NEUROSURG, V88, P11, DOI 10.3171/jns.1998.88.1.0011
   Schwartz H, 2016, CANCER RES, V76, P4359, DOI 10.1158/0008-5472.CAN-16-0485
   Simard JL, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0722-x
   Skibber JM, 1996, ANN SURG ONCOL, V3, P118, DOI 10.1007/BF02305789
   Tanei T, 2012, NAGOYA J MED SCI, V74, P173
   Wronski M, 2000, J NEUROSURG, V93, P9, DOI 10.3171/jns.2000.93.1.0009
   Zacest AC, 2002, J NEUROSURG, V96, P552, DOI 10.3171/jns.2002.96.3.0552
NR 29
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 150
EP 154
DI 10.1016/j.wneu.2019.10.101
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200161
PM 31751613
DA 2020-05-12
ER

PT J
AU Mansour, S
   Echeverry, N
   Shapiro, S
   Snelling, B
AF Mansour, Samuel
   Echeverry, Nikolas
   Shapiro, Stephen
   Snelling, Brian
TI The Use of BrainPath Tubular Retractors in the Management of Deep Brain
   Lesions: A Review of Current Studies
SO WORLD NEUROSURGERY
LA English
DT Review
DE BrainPath; Intracranial; Retraction injury; Tubular retractor
ID RESECTION; SYSTEM; REMOVAL; SURGERY
AB BACKGROUND: Traditional retraction to access deep intraparenchymal brain lesions results in vascular disruption. Tubular retractors such as the BrainPath tubular retractor system were developed to reduce retractor-related force injuries via radial dispersion of force. Our study seeks to assess the indications, benefits, and complications associated with BrainPath retractors.
   METHODS: A literature search of PubMed MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Cochrane Database of Systematic Reviews was performed. The search terminology used was "BrainPath OR Brain-Path." The BrainPath Web site was also examined. Postoperative morbidity and mortality were analyzed to estimate complications linked to using the retractor.
   RESULTS: Twenty-nine articles (n = 289 patients) met the inclusion criteria. BrainPath was used primarily for tumor resections and hematoma evacuations. These cases were subdivided into groups based on lesion location, size, and resection volume for further analysis. Gross total resection was achieved in 79% of tumor excisions and subtotal resection in 21%. Hematoma evacuation >90% of original hematoma volume was achieved in 651% of cases, 75%-90% of original volume in 21.7%, and <75% in the remaining 13.2%. The complication rate attributed to retractor use was 8.3%.
   CONCLUSIONS: This report is the first formal assessment of the BrainPath tubular retraction system, highlighting technical considerations of the retractor from the surgeon's perspective, patient outcomes, and complications. The retractor is a safe, efficacious system that can be used for tumor resection or biopsy and hematoma evacuation. However, further randomized controlled trials are indicated to accurately assess complication rates and outcomes.
C1 [Mansour, Samuel; Echeverry, Nikolas; Shapiro, Stephen; Snelling, Brian] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
   [Snelling, Brian] Boca Raton Reg Hosp, Marcus Neurosci Inst, Boca Raton, FL USA.
RP Mansour, S (reprint author), Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
EM smansour2012@health.fau.edu
CR Agarwal V, 2017, CUREUS, V9, DOI 10.7759/cureus.1722
   Akbari SHA, 2019, OPER NEUROSURG, V16, P292, DOI 10.1093/ons/opy108
   Amenta PS, 2016, INTERDISCIP NEUROSUR, V5, P12, DOI 10.1016/j.inat.2016.03.006
   ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052
   Assina R, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13564
   Bakhsheshian J, 2019, OPER NEUROSURG, V16, P159, DOI 10.1093/ons/opy079
   Bander ED, 2019, J NEURO-ONCOL, V141, P121, DOI 10.1007/s11060-018-03014-w
   Bauer AM, 2017, OPER NEUROSURG, V13, P69, DOI 10.1227/NEU.0000000000001258
   Bernardo A, 2015, WORLD NEUROSURG, V84, P132, DOI 10.1016/j.wneu.2015.02.042
   Chakravarthi SS, 2016, INTERDISCIP NEUROSUR, V6, P55, DOI 10.1016/j.inat.2016.07.004
   Chen CJ, 2016, CASE REP NEUROL MED, DOI 10.1155/2016/8654262
   Chen YN, 2017, ACTA NEUROCHIR, V159, P1589, DOI 10.1007/s00701-017-3260-7
   Day JD, 2017, NEUROSURGERY, V64, P151, DOI 10.1093/neuros/nyx324
   Ding Dale, 2017, J Cerebrovasc Endovasc Neurosurg, V19, P101, DOI 10.7461/jcen.2017.19.2.101
   Ding D, 2015, J CLIN NEUROSCI, V22, P1816, DOI 10.1016/j.jocn.2015.03.052
   Ding DL, 2015, J CLIN NEUROSCI, V22, P1025, DOI 10.1016/j.jocn.2015.01.004
   Eichberg DG, 2019, OPER NEUROSURG, V16, P571, DOI 10.1093/ons/opy249
   Eichberg DG, 2018, WORLD NEUROSURG, V112, pE50, DOI 10.1016/j.wneu.2017.12.023
   Eliyas JK, 2016, WORLD NEUROSURG, V90, P556, DOI 10.1016/j.wneu.2015.12.100
   Gassie K, 2019, J NEUROL SURG PART A, V80, P198, DOI 10.1055/s-0038-1676575
   Goren O, OPER NEUROSURG, DOI 10.1093/ons/opy389
   GREENBERG IM, 1981, NEUROSURGERY, V8, P205, DOI 10.1227/00006123-198102000-00009
   Greenfield JP, 2008, NEUROSURGERY, V63, P334, DOI [10.1227/01.NEU.0000334741.61745.72, 10.1227/01.neu.0000334741.61745.72]
   Griessenauer C, 2018, CUREUS, V10, DOI 10.7759/cureus.3569
   Habboub G, 2017, J CLIN NEUROSCI, V35, P117, DOI 10.1016/j.jocn.2016.09.020
   Harris AE, 2008, NEUROSURGERY, V62, P622, DOI [10.1227/01.NEU.0000146227.75138.08, 10.1227/01.neu.0000316266.97714.da]
   Herrera Sebastian R, 2010, Surg Technol Int, V19, P47
   Hinman A, 2008, J ARTHROPLASTY, V23, P9, DOI 10.1016/j.arth.2008.05.010
   Iyer R, 2018, J NEUROL SURG PART A, V79, P330, DOI 10.1055/s-0038-1641738
   Jackson C, 2017, J NEUROL SURG PART A, V78, P588, DOI 10.1055/s-0037-1602698
   KELLY PJ, 1988, J NEUROSURG, V69, P301, DOI 10.3171/jns.1988.69.2.0301
   Labib MA, 2016, NEUROSURGERY, V80, P1
   Mampre D, 2018, WORLD NEUROSURG, V119, pE1016, DOI 10.1016/j.wneu.2018.08.049
   NICO Corporation, BRAINPATH GALL
   Pena C., NICO BRAINPATH ACCES
   Przybylowski CJ, 2015, J CLIN NEUROSCI, V22, P1727, DOI 10.1016/j.jocn.2015.05.015
   Ratre S, 2016, J NEUROL SURG PART A, V77, P312, DOI 10.1055/s-0036-1580595
   Raza SM, 2011, MINIM INVAS NEUROSUR, V54, P5, DOI 10.1055/s-0031-1273734
   Ritsma B, 2014, CASE REP NEUROL MED, DOI 10.1155/2014/102307
   Scranton RA, 2016, J NEUROSURG, V125, P1360, DOI 10.3171/2015.12.JNS152185
   Witek AM, 2018, OPER NEUROSURG, V15, P32, DOI 10.1093/ons/opx186
   Zammar SG, 2019, CUREUS, V11, DOI 10.7759/cureus.4272
   Zhong J, 2003, NEUROL RES, V25, P831, DOI 10.1179/016164103771953925
NR 43
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 155
EP 163
DI 10.1016/j.wneu.2019.08.218
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200162
PM 31513954
DA 2020-05-12
ER

PT J
AU Afonso, AM
   Alles, JVD
   Gutierrez, AM
   Quarante, LHG
   Leal, RG
   Lebiedziejewski, JAGD
   Vendrell, ES
AF Montalvo Afonso, Antonio
   Darriba Alles, Juan Vicente
   Moreno Gutierrez, Angela
   Gonzalez Quarante, Lain Hermes
   Garcia Leal, Roberto
   de Villoria Lebiedziejewski, Juan Adan Guzman
   Sola Vendrell, Emma
TI Imaging and Radiologic-Pathologic Correlation in Granular Cell
   Astrocytomas: Report of 2 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gemistocytic astrocytoma; Granular cell astrocytoma; Lymphocytes; MRI;
   Perivascular cuffing
ID TUMOR-INFILTRATING LYMPHOCYTES; CENTRAL-NERVOUS-SYSTEM; CD8(+)
   LYMPHOCYTES; SURVIVAL; FEATURES; PERFUSION
AB BACKGROUND: Granular cell astrocytoma is a rare and aggressive subtype of astrocytoma that is histopathologically well defined in the literature. It is formed by polygonal cells with granular cytoplasm mixed with neoplastic astrocytes and usually a perivascular infiltrate of lymphocytes. Despite its unusual histologic appearance, relevant radiologic features have not yet been described.
   CASE DESCRIPTION: We report 2 middle-aged patients with neurologic symptoms secondary to a newly diagnosed brain tumor. The absence of central tumor necrosis as well as the presence of an atypical pattern of enhancement and areas of intense diffusion restriction on magnetic resonance imaging in both cases led to the diagnosis of primary central nervous system lymphoma. Histopathologic findings in both tumors showed an aggressive astrocytoma with a prominent granular cell population and perivascular lymphocytic cuffing in tissue, corresponding to a granular cell astrocytoma. Despite the favorable prognostic factors, including World Health Organization grades II and III astrocytomas and IDH mutations, the outcome was poor.
   CONCLUSIONS: Granular cell astrocytomas can show unusual aggressive radiologic features that do not correspond to their histopathologic grade of malignancy. The presence of perivascular lymphocytic infiltrate may alter the typical radiologic appearance of common astrocytomas.
C1 [Montalvo Afonso, Antonio; Darriba Alles, Juan Vicente; Moreno Gutierrez, Angela; Gonzalez Quarante, Lain Hermes; Garcia Leal, Roberto] Hosp Gen Univ Gregorio Maranon, Dept Neurosurg, Madrid, Spain.
   [de Villoria Lebiedziejewski, Juan Adan Guzman] Hosp Gen Univ Gregorio Maranon, Dept Neuroradiol, Madrid, Spain.
   [Sola Vendrell, Emma] Hosp Gen Univ Gregorio Maranon, Dept Neuropathol, Madrid, Spain.
RP Afonso, AM (reprint author), Hosp Gen Univ Gregorio Maranon, Dept Neurosurg, Madrid, Spain.
EM anmontal90@gmail.com
CR Vizcaino MA, 2019, BRAIN PATHOL, V29, P193, DOI 10.1111/bpa.12657
   Al-Okaili RN, 2006, RADIOGRAPHICS, V26, pS173, DOI 10.1148/rg.26si065513
   Brat DJ, 2002, AM J SURG PATHOL, V26, P750, DOI 10.1097/00000478-200206000-00008
   Calli C, 2006, EUR J RADIOL, V58, P394, DOI 10.1016/j.ejrad.2005.12.032
   Campbell RN, 2014, J CLIN NEUROSCI, V21, P1457, DOI 10.1016/j.jocn.2013.10.037
   Caporalini C, 2016, CLIN NEUROPATHOL, V35, P186, DOI 10.5414/NP300952
   Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
   Cohen-Gadol AA, 2003, MAYO CLIN PROC, V78, P567, DOI 10.4065/78.5.567
   DICKSON DW, 1986, J NEUROPATH EXP NEUR, V45, P304, DOI 10.1097/00005072-198605000-00013
   Dunn Gavin P, 2007, Cancer Immun, V7, P12
   El Asri AC, 2015, J NEUROSURG-PEDIATR, V15, P506, DOI 10.3171/2014.10.PEDS13388
   George AA, 2013, HISTOPATHOLOGY, V63, P883, DOI 10.1111/his.12236
   Godefroy A, 2012, J NEURORADIOLOGY, V39, P190, DOI 10.1016/j.neurad.2011.09.003
   Guo AC, 2002, RADIOLOGY, V224, P177, DOI 10.1148/radiol.2241010637
   Gupta R, 2018, HUM PATHOL CASE REP, V14, P4
   Haldorsen IS, 2011, AM J NEURORADIOL, V32, P984, DOI 10.3174/ajnr.A2171
   Han S, 2014, BRIT J CANCER, V110, P2560, DOI 10.1038/bjc.2014.162
   Heo YJ, 2017, EUR RADIOL, V27, P3022, DOI 10.1007/s00330-016-4649-z
   HORI A, 1985, ACTA NEUROCHIR, V74, P49, DOI 10.1007/BF01413277
   Imitola J, 2015, J NEURO-ONCOL, V124, P147, DOI 10.1007/s11060-015-1811-4
   Kang M, 2012, ACTA CYTOL, V56, P571, DOI 10.1159/000338392
   KROUWER HGJ, 1991, J NEUROSURG, V74, P399, DOI 10.3171/jns.1991.74.3.0399
   Li P, 2016, BRIT J NEUROSURG, V30, P611, DOI 10.1080/02688697.2016.1181152
   Liao WH, 2009, ACTA RADIOL, V50, P217, DOI 10.1080/02841850802616752
   LIPPER MH, 1993, AM J NEURORADIOL, V14, P1397
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   MARKESBERY WR, 1973, J NEUROPATH EXP NEUR, V32, P92, DOI 10.1097/00005072-197301000-00006
   McGirt MJ, 2009, J NEUROSURG, V110, P156, DOI 10.3171/2008.4.17536
   Baena RR, 2007, NEUROSURG REV, V30, P339, DOI 10.1007/s10143-007-0079-3
   Rutledge WC, 2013, CLIN CANCER RES, V19, P4951, DOI 10.1158/1078-0432.CCR-13-0551
   Saad A, 2006, AM J CLIN PATHOL, V126, P602, DOI 10.1309/M67J9YF5K43AQ5KC
   Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102
   Sayour EJ, 2015, CANCER IMMUNOL IMMUN, V64, P419, DOI 10.1007/s00262-014-1651-7
   Simkin PM, 2016, J MED IMAG RADIAT ON, V60, P733, DOI 10.1111/1754-9485.12550
   Tay KL, 2011, NEURORADIOLOGY, V53, P405, DOI 10.1007/s00234-010-0741-2
   Voellger B, 2015, J NEUROL SURG PART A, V76, P30, DOI 10.1055/s-0034-1382781
   Wierzba-Bobrowicz T, 2008, FOLIA NEUROPATHOL, V46, P286
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 164
EP 169
DI 10.1016/j.wneu.2019.10.169
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200163
PM 31698124
DA 2020-05-12
ER

PT J
AU Kulanthaivelu, K
   Prasad, C
   Reddy, YVK
   Mahadevan, A
AF Kulanthaivelu, Karthik
   Prasad, Chandrajit
   Reddy, Yerasi Varun Kumar
   Mahadevan, Anita
TI Holohemispheric Invasive Aspergillus Granulomatous Cerebritis of the
   Brain
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebritis; Fungal; Granuloma; Hematogenous; Holohemispheric; Invasive
ID CENTRAL-NERVOUS-SYSTEM; FUNGAL-INFECTIONS; IMMUNOCOMPROMISED PATIENTS;
   FUMIGATUS; MR
AB BACKGROUND: Invasive aspergillosis of the central nervous system, a saprophytic infection with a unique vascular tropism, carries the burden of increased morbidity and mortality. Early clinical and imaging findings can masquerade as an innocuous condition before a secondary inexorable progression. We highlight the clinical and imaging phenotype of a patient with fatal invasive granulomatous aspergillosis.
   CASE DESCRIPTION: A 39-year-old man presented with progressive weakness of the left upper and lower limb for 4 months. Imaging demonstrated right holohemispheric extensive, numerous, confluent, ill-defined, T2 hypointense foci with moderate perilesional edema. Numerous foci of microhemorrhages with cortical asymmetric mineralization were seen. Post-contrast heterogeneous, variegate, punctiform enhancement of the lesions was observed extending to the ventricular margins. Volume loss of the left cerebral peduncle and ipsilateral long white matter descending tracts was noted. Histopathologic examination of a stereotactic biopsy specimen from the frontal region lesion showed dense inflammatory infiltrate with granulomas, a few in a perivascular distribution and branching septate hyphae resembling Aspergillus. The patient was initiated on antifungal therapy and in the following week, he had progressive drowsiness. The patient succumbed the next day.
   CONCLUSIONS: Diffuse holohemispheric, progressive presentation of a granulomatous form of invasive aspergillosis is a rare entity. The miliary pattern of heterogenous enhancement, holohemispheric conglomerate T2 hypointensities, interspersed hemorrhage, juxtacortical punctate T2 hyperintense foci, low perfusion, and the relative absence of diffusion abnormality are distinctive features. Early diagnosis of this atypical imaging phenotype of Aspergillus infection and appropriate treatment is critical for better prognosis.
C1 [Kulanthaivelu, Karthik; Prasad, Chandrajit] Natl Inst Mental Hlth & Neurosci, Dept Neuroimaging & Intervent Radiol, Bengaluru, India.
   [Reddy, Yerasi Varun Kumar] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bengaluru, India.
   [Mahadevan, Anita] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bengaluru, India.
RP Prasad, C (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neuroimaging & Intervent Radiol, Bengaluru, India.
EM chandrajitt2@gmail.com
CR Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335
   ASHDOWN BC, 1994, AM J ROENTGENOL, V162, P155, DOI 10.2214/ajr.162.1.8273655
   BEAL MF, 1982, NEUROLOGY, V32, P473, DOI 10.1212/WNL.32.5.473
   Boes B, 1994, J Neuroimaging, V4, P123
   Challa S, 2007, NEUROL INDIA, V55, P289, DOI 10.4103/0028-3886.35691
   Dagenais TRT, 2009, CLIN MICROBIOL REV, V22, P447, DOI 10.1128/CMR.00055-08
   Goralska K, 2018, INFECTION, V46, P443, DOI 10.1007/s15010-018-1152-2
   Hurst RW, 2001, AM J NEURORADIOL, V22, P858
   Jain KK, 2007, NEUROL INDIA, V55, P241
   Kastrup Oliver, 2005, NeuroRx, V2, P324, DOI 10.1602/neurorx.2.2.324
   Kourkoumpetis TK, 2012, MEDICINE, V91, P328, DOI 10.1097/MD.0b013e318274cd77
   Koutsouras GW, 2017, VIRULENCE, V8, P705, DOI 10.1080/21505594.2016.1261789
   Mathur M, 2012, NEUROIMAG CLIN N AM, V22, P609, DOI 10.1016/j.nic.2012.04.004
   MIAUX Y, 1995, AM J NEURORADIOL, V16, P555
   Murthy J M K, 2014, Handb Clin Neurol, V121, P1383, DOI 10.1016/B978-0-7020-4088-7.00095-X
   Murthy JMK, 2001, MYCOSES, V44, P141, DOI 10.1046/j.1439-0507.2001.00643.x
   Nadkarni T., 2005, Journal of Postgraduate Medicine, V51, P37
   OSTROW TD, 1994, TOP MAGN RESON IMAG, V6, P22
   Panackal Anil A, 2015, Continuum (Minneap Minn), V21, P1662, DOI 10.1212/CON.0000000000000241
   Panda PK, 2017, MYCOPATHOLOGIA, V182, P527, DOI 10.1007/s11046-016-0106-4
   Patterson TF, 2016, CLIN INFECT DIS, V63, pE1, DOI 10.1093/cid/ciw326
   Payot A., 1999, Clin Microbiol Infect, V5, P573, DOI 10.1111/j.1469-0691.1999.tb00438.x
   Rauchway AC, 2010, NEUROL CLIN, V28, P293, DOI 10.1016/j.ncl.2009.09.013
   Saini J, 2010, WORLD NEUROSURG, V74, P661, DOI 10.1016/j.wneu.2010.06.017
   Schwartz S, 2011, INFECTION, V39, P201, DOI 10.1007/s15010-011-0108-6
   Shankar SK, 2007, NEUROL INDIA, V55, P198, DOI 10.4103/0028-3886.35680
   Sharma BS, 1997, SURG NEUROL, V47, P489, DOI 10.1016/S0090-3019(96)00209-1
   Tempkin AD, 2006, RADIOGRAPHICS, V26, P1239, DOI 10.1148/rg.264055152
   Truzzi GD, 2017, CLIN CASE REP, V5, P218, DOI 10.1002/ccr3.798
   Turgut M, 2008, SURG NEUROL, V69, P169, DOI 10.1016/j.surneu.2006.12.049
   WALSH TJ, 1985, ANN NEUROL, V18, P574, DOI 10.1002/ana.410180511
   Yamada K, 2001, NEURORADIOLOGY, V43, P559, DOI 10.1007/s002340000535
   YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002
   YOUNG RF, 1985, J NEUROSURG, V63, P371, DOI 10.3171/jns.1985.63.3.0371
NR 34
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 170
EP 175
DI 10.1016/j.wneu.2019.09.100
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200164
PM 31562969
DA 2020-05-12
ER

PT J
AU Yamagami, K
   Maeda, Y
   Iihara, K
AF Yamagami, Keitaro
   Maeda, Yoshihisa
   Iihara, Koji
TI Variant Type of Posterior Reversible Encephalopathy Syndrome Associated
   with Deep Brain Hemorrhage: Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Antihypertensive treatment; Deep brain hemorrhage; Hypertension;
   Intraparenchymal hemorrhage; Posterior reversible encephalopathy
   syndrome; Vasogenic edema
ID PATHOPHYSIOLOGY
AB BACKGROUND: Various radiologic patterns of posterior reversible encephalopathy syndrome (PRES) have been reported. Among them, PRES involving brainstem, thalamus, or deep white matter and lacking parieto-occipital edema is rare. Although PRES in general has a benign course, PRES-related intracranial hemorrhage has been associated with a poor prognosis. We report a case of variant type of PRES associated with deep brain hemorrhage and discuss the characteristics of PRES-related intracranial hemorrhage via a literature review.
   CASE DESCRIPTION: A woman aged 41 years with a history of untreated hypertension presented to our hospital complaining of severe headache and with an elevated blood pressure of 237/142 mmHg. Computed tomography revealed a hemorrhage in the left thalamus and basal ganglia. Magnetic resonance imaging revealed remarkable hyperintensity in the left cerebellum, pons, bilateral temporal lobes, bilateral basal ganglia, and bilateral cerebral white matter on fluid-attenuated inversion recovery imaging, which represented vasogenic edema. The parieto-occipital regions were unremarkable. Given this clinical presentation, PRES associated with deep brain hemorrhage was suspected. The patient received strict blood pressure control treatment, which resulted in gradual symptom improvement. Magnetic resonance images obtained 1 month after admission demonstrated an almost complete resolution of the edema.
   CONCLUSIONS: Although hemorrhage in the thalamus, basal ganglia, or brainstem is uncommon in patients with PRES, it may occur in patients with variant type of PRES involving these lesions. It is important to recognize the presence of variant patterns of clinical features and radiologic findings of PRES to allow for early identification and appropriate treatment.
C1 [Yamagami, Keitaro; Maeda, Yoshihisa] Hachisuga Hosp, Dept Neurosurg, Munakata, Japan.
   [Yamagami, Keitaro; Iihara, Koji] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Japan.
RP Yamagami, K (reprint author), Hachisuga Hosp, Dept Neurosurg, Munakata, Japan.; Yamagami, K (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Japan.
EM yamagami.keitaro.twins@gmail.com
CR Aranas RM, 2009, NEUROCRIT CARE, V10, P306, DOI 10.1007/s12028-009-9200-5
   Bartynski WS, 2008, AM J NEURORADIOL, V29, P1043, DOI 10.3174/ajnr.A0929
   Fugate JE, 2015, LANCET NEUROL, V14, P914, DOI 10.1016/S1474-4422(15)00111-8
   Gauiran DTV, 2018, CASE REP MED, DOI 10.1155/2018/4238676
   Hefzy HM, 2009, AM J NEURORADIOL, V30, P1371, DOI 10.3174/ajnr.A1588
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Kawanabe T, 2011, NEUROL MED-CHIR, V51, P582, DOI 10.2176/nmc.51.582
   Lee WJ, 2015, J CEREBROVASC ENDOVA, V3, P239
   Loar RW, 2013, PEDIATR TRANSPLANT, V17, pE67, DOI 10.1111/petr.12039
   McKinney AM, 2007, AM J ROENTGENOL, V189, P904, DOI 10.2214/AJR.07.2024
   Miller-Patterson C, 2017, BMJ CASE REP, V2017
   Ou SC, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00843
   Pilato F, 2019, CLIN NEUROL NEUROSUR, V185, DOI 10.1016/j.clineuro.2019.105459
   Schweitzer AD, 2017, NEURORADIOLOGY, V59, P379, DOI 10.1007/s00234-017-1815-1
   Sharma A, 2010, NEURORADIOLOGY, V52, P855, DOI 10.1007/s00234-009-0632-6
   Tetsuka S, 2019, J NEUROL SCI, V404, P72, DOI 10.1016/j.jns.2019.07.018
   Yamashita T, 2012, NEUROL MED-CHIR, V52, P640, DOI 10.2176/nmc.52.640
   Zhang YX, 2016, J STROKE CEREBROVASC, V25, pE233, DOI 10.1016/j.jstrokecerebrovasdis.2016.09.033
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 176
EP 181
DI 10.1016/j.wneu.2019.10.196
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200165
PM 31712110
DA 2020-05-12
ER

PT J
AU Senturk, S
   Unsal, UU
AF Senturk, Salim
   Unsal, Ulkun Unlu
TI Percutaneous Endoscopic Interlaminar Decompression of Hypervascular
   Spinal Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Interlaminar decompression; Spinal metastases
ID CORD COMPRESSION; EMBOLIZATION; MANAGEMENT; LUMBAR; TUMORS
AB BACKGROUND: Percutaneous endoscopic surgery is a common technique used for the treatment of disk herniation and spinal stenosis. In this report, we present a patient who underwent percutaneous endoscopic decompression due to spinal metastasis.
   CASE DESCRIPTION: A 72-year-old female patient with a known diagnosis of lung cancer presented to our clinic with a 10-day history of severe pain in the left leg and a 5-day history of muscle weakness in the left thigh. The patient had a history of multiple organ metastasis and multiple spinal metastasis. On neurologic examination, left hip flexion and extension were graded 2/5. Radiologic workup revealed compression on the left L3 nerve root caused by vertebral metastasis. The patient was planned for a percutaneous full-endoscopic interlaminar decompression due to her clinical condition. The tumor surrounding the left L3 nerve root was removed via endoscopic punch, which resulted in rapid relief of her back pain postoperatively. Adjunct physical therapy was recommended after discharge.
   CONCLUSIONS: Percutaneous full-endoscopic interlaminar decompression can be an alternative minimally invasive treatment option in selected patients with radicular pain and neurologic deficit caused by spinal metastasis.
C1 [Senturk, Salim; Unsal, Ulkun Unlu] Koc Univ Hosp, Dept Neurosurg, Istanbul, Turkey.
RP Unsal, UU (reprint author), Koc Univ Hosp, Dept Neurosurg, Istanbul, Turkey.
EM ulkununlu@hotmail.com
RI Unsal, Ulkun Unlu/B-9861-2016
OI Unsal, Ulkun Unlu/0000-0001-5194-3138
CR Bernard F, 2017, J NEUROSURG-SPINE, V26, P725, DOI 10.3171/2016.9.SPINE16597
   COBB CA, 1977, J NEUROSURG, V47, P653, DOI 10.3171/jns.1977.47.5.0653
   Cole JS, 2008, LANCET NEUROL, V7, P459, DOI 10.1016/S1474-4422(08)70089-9
   FELDMAN F, 1975, AM J ROENTGENOL, V123, P130, DOI 10.2214/ajr.123.1.130
   Frank E, 1998, SURG NEUROL, V50, P333, DOI 10.1016/S0090-3019(98)00016-0
   Harel R, 2010, EUR J CANCER, V46, P2696, DOI 10.1016/j.ejca.2010.04.025
   Helweg-Larsen S, 2000, INT J RADIAT ONCOL, V46, P1163, DOI 10.1016/S0360-3016(99)00333-8
   HELWEGLARSEN S, 1994, EUR J CANCER, V30A, P396, DOI 10.1016/0959-8049(94)90263-1
   HILAL SK, 1975, J NEUROSURG, V43, P275, DOI 10.3171/jns.1975.43.3.0275
   Klimo P, 2004, ONCOLOGIST, V9, P188, DOI 10.1634/theoncologist.9-2-188
   Kumar N, 2017, EJSO-EUR J SURG ONC, V43, P1784, DOI 10.1016/j.ejso.2017.05.006
   Manke C, 2001, AM J NEURORADIOL, V22, P997
   Nair S, 2013, INTERV NEURORADIOL, V19, P377, DOI 10.1177/159101991301900317
   OLERUD C, 1993, ACTA ORTHOP SCAND, V64, P9, DOI 10.3109/17453679308994517
   Parihar VS, 2017, J NEUROL SURG PART A, V78, P219, DOI 10.1055/s-0036-1594014
   Ruetten S, 2006, MINIM INVAS NEUROSUR, V49, P80, DOI 10.1055/s-2006-932172
   Song DQ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000013987
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   WONG DA, 1990, SPINE, V15, P1, DOI 10.1097/00007632-199001000-00001
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 182
EP 186
DI 10.1016/j.wneu.2019.10.175
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200166
PM 31698126
DA 2020-05-12
ER

PT J
AU Cho, A
   Cho, SS
   Buch, VP
   Buch, LY
   Lee, JYK
AF Cho, Anna
   Cho, Steve S.
   Buch, Vivek P.
   Buch, Love Y.
   Lee, John Y. K.
TI Second Window Indocyanine Green (SWIG) Near Infrared Fluorescent
   Transventricular Biopsy of Pineal Tumor
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fluorescent imaging; Indocyanine green; Pineocytoma; Tumor visualization
ID GUIDED SURGERY
AB BACKGROUND: Second Window Indocyanine Green (SWIG) is a novel technique for real-time, intraoperative tumor visualization using a high-dose infusion of indocyanine green (ICG) 24 hours before surgery. Due to pathologic diversity found in the pineal region, tissue diagnosis in patients with pineal region mass is essential to optimize further clinical management.
   CASE DESCRIPTION: We present the case of a 75-year-old woman with -min pineal region mass for 18 years, who presented with progressive classic signs and symptoms of obstructive hydrocephalus over the past 6 months. Preoperative imaging confirmed a contrast-enhancing pineal region tumor, which appeared to be obstructing the aqueduct of Sylvius, causing proximal obstructive hydrocephalus. We delivered 5 mg/kg of ICG intravenously 24 hours before the surgery. The patient underwent an endoscopic third ventriculostomy and a biopsy of the pineal lesion. The tumor demonstrated clear near-infrared fluorescence, which was distinct from surrounding third ventricle floor and ependyma. The signal-to-background ratio was 2.9. The final pathology report revealed a World Health Organization grade I pineocytoma.
   CONCLUSIONS: We report on a novel application of near-infrared fluorescence for tumor identification of pineal region tumors, using the "SWIG technique."
C1 [Cho, Anna; Cho, Steve S.; Buch, Vivek P.; Buch, Love Y.; Lee, John Y. K.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Cho, Anna] Med Univ Vienna, Dept Neurosurg, Vienna, Austria.
RP Lee, JYK (reprint author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
EM leejohn@uphs.upenn.edu
OI Cho, Anna/0000-0002-5211-382X
CR Ahmed AI, 2015, WORLD NEUROSURG, V83, P543, DOI 10.1016/j.wneu.2014.11.013
   BRUCE JN, 1995, ACTA NEUROCHIR, V134, P130, DOI 10.1007/BF01417679
   Cho SS, 2018, MOL IMAGING BIOL, V20, P213, DOI 10.1007/s11307-017-1107-5
   Hitti FL, 2018, OPER NEUROSURG, V15, pE53, DOI 10.1093/ons/opy053
   Jeon JW, 2019, OPER NEUROSURG, V17, P32, DOI 10.1093/ons/opy213
   Konovalov AN, 2003, SURG NEUROL, V59, P250, DOI 10.1016/S0090-3019(03)00080-6
   Lee JYK, 2018, J NEUROSURG, V128, P380, DOI 10.3171/2016.10.JNS161636
   Lee JYK, 2017, WORLD NEUROSURG, V106, P120, DOI [10.1016/j.wneu.2017.06.128, 10.1016/j.WNEU.2017.06.128]
   Litvack ZN, 2012, J NEUROSURG, V116, P935, DOI 10.3171/2012.1.JNS11601
   Raabe A, 2003, NEUROSURGERY, V52, P132, DOI 10.1097/00006123-200301000-00017
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Takeda J, 2017, J NEURO-ONCOL, V134, P119, DOI 10.1007/s11060-017-2494-9
   Widhalm G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076988
   Zeh R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182034
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 196
EP 200
DI 10.1016/j.wneu.2019.10.113
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200170
PM 31669685
DA 2020-05-12
ER

PT J
AU Yolcu, YU
   Lehman, VT
   Bhatti, AUR
   Goyal, A
   Alvi, MA
   Bydon, M
AF Yolcu, Yagiz Ugur
   Lehman, Vance T.
   Bhatti, Atiq Ur Rehman
   Goyal, Anshit
   Alvi, Mohammed Ali
   Bydon, Mohamad
TI Use of Hybrid Imaging Techniques in Diagnosis of Facet Joint
   Arthropathy: A Narrative Review of Three Modalities
SO WORLD NEUROSURGERY
LA English
DT Review
DE Diagnosis; Facet arthropathy; Facet joint; PET/CT; PET/MRI; SPECT/CT;
   Spine surgery
ID LOW-BACK-PAIN; COMPUTED TOMOGRAPHY/COMPUTED TOMOGRAPHY; TC-99M-MDP
   SPECT/CT; CLINICAL-FEATURES; PET; MANAGEMENT; CT; SCINTIGRAPHY;
   ELEMENTS; PET/MRI
AB Facet joint osteoarthritis/arthropathy of the spine is a common cause of back and neck pain that frequently overlaps clinically with other diseases of the spine. Because of the possible overlap, it is crucial to have an accurate diagnostic strategy, especially when determining the management approach. Various strategies have been suggested and adopted, with several these still being used in clinics. Over the years, because of the disadvantages of single-modality imaging methods (computed tomography, magnetic resonance imaging, single-photon emission computed tomography), the interest in radiologic examination started to move toward hybrid imaging techniques. Although the data are mixed, many initial studies have shown promise. However, there are relatively few data with comparative medial branch blocks, and further investigation is needed. Given the advantages and disadvantages of these new techniques, the imaging results have to be interpreted within clinical context and with consideration of the current state of knowledge in the decision-making process.
C1 [Yolcu, Yagiz Ugur; Bhatti, Atiq Ur Rehman; Goyal, Anshit; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Neuroinformat Lab, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Yolcu, Yagiz Ugur; Bhatti, Atiq Ur Rehman; Goyal, Anshit; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Lehman, Vance T.] Mayo Clin, Dept Radiol, Rochester, MN USA.
RP Bydon, M (reprint author), Mayo Clin, Neuroinformat Lab, Dept Neurol Surg, Rochester, MN 55905 USA.; Bydon, M (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM Bydon.mohamad@mayo.edu
CR Bogduk N., 2013, PRACTICE GUIDELINES
   Cipriano PW, 2018, J NUCL MED, V59, P967, DOI 10.2967/jnumed.117.198259
   Cohen SP, 2007, ANESTHESIOLOGY, V106, P591, DOI 10.1097/00000542-200703000-00024
   Cohen SP, 2007, CLIN J PAIN, V23, P45, DOI 10.1097/01.ajp.0000210941.04182.ea
   Czervionke LF, 2008, PAIN MED, V9, P400, DOI 10.1111/j.1526-4637.2007.00313.x
   D'Aprile Paola, 2018, Acta Biomed, V89, P208, DOI 10.23750/abm.v89i1-S.7024
   DePalma MJ, 2011, PAIN MED, V12, P224, DOI 10.1111/j.1526-4637.2010.01045.x
   Dolan AL, 1996, BRIT J RHEUMATOL, V35, P1269
   Fosse Pacome, 2018, Eur J Hybrid Imaging, V2, P6, DOI 10.1186/s41824-017-0022-y
   Freiermuth D, 2015, PAIN MED, V16, P1916, DOI 10.1111/pme.12841
   Gamie S, 2008, NUCL MED REV, V11, P17
   Ghormley RK, 1933, J AMER MED ASSOC, V101, P1773, DOI 10.1001/jama.1933.02740480005002
   GLANTZ MJ, 1991, ANN NEUROL, V29, P347, DOI 10.1002/ana.410290403
   Grant FD, 2008, J NUCL MED, V49, P68, DOI 10.2967/jnumed.106.037200
   Groheux D, 2016, DIAGN INTERV IMAG, V97, P1003, DOI 10.1016/j.diii.2016.06.020
   Guezennec C, 2017, CANCER IMAGING, V17, DOI 10.1186/s40644-017-0118-4
   Harisankar CNB, 2012, INDIAN J NUCL MED, V27, P156, DOI 10.4103/0972-3919.112720
   HOLDER LE, 1995, J NUCL MED, V36, P37
   Holland C, 2012, DTSCH ARZTEBL INT, V109, P425, DOI 10.3238/arztebl.2012.0425
   Horger M, 2006, SEMIN NUCL MED, V36, P286, DOI 10.1053/j.semnuclmed.2006.05.001
   Jain A, 2015, CLIN J PAIN, V31, P1054, DOI 10.1097/AJP.0000000000000212
   Jenkins NW, 2017, AM J NEURORADIOL, V38, P2028, DOI 10.3174/ajnr.A5348
   Kang B, 2016, AM J ROENTGENOL, V206, pW10, DOI 10.2214/AJR.14.13818
   King W, 2007, SPINE J, V7, P22, DOI 10.1016/j.spinee.2006.07.009
   Kitajima K, 2017, NAGOYA J MED SCI, V79, P527, DOI 10.18999/nagjms.79.4.527
   Lalkadamyali H, 2008, AM J ROENTGENOL, V191, P973, DOI 10.2214/AJR.07.2829
   Lehman VT, 2014, AM J NEURORADIOL, V35, P609, DOI 10.3174/ajnr.A3731
   Lehman VT, 2016, DIAGN INTERV RADIOL, V22, P277, DOI 10.5152/dir.2015.15203
   Lehman VT, 2013, NUCL MED COMMUN, V34, P1097, DOI 10.1097/MNM.0b013e328364bfa6
   LEWINNEK GE, 1986, CLIN ORTHOP RELAT R, P216
   Lim R, 2007, J PEDIATR ORTHOPED, V27, P277, DOI 10.1097/BPO.0b013e31803409ba
   Mabray Marc C, 2016, World J Nucl Med, V15, P85, DOI 10.4103/1450-1147.174698
   Matar HE, 2013, INT ORTHOP, V37, P865, DOI 10.1007/s00264-013-1811-y
   MCCALL IW, 1979, SPINE, V4, P441, DOI 10.1097/00007632-197909000-00009
   McDonald M, 2007, NEUROSURG FOCUS, V22, P1
   Nguyen BJ, 2018, NUCL MED COMMUN, V39, P699, DOI 10.1097/MNM.0000000000000858
   Pneumaticos SG, 2006, RADIOLOGY, V238, P693, DOI 10.1148/radiol.2382041930
   Rager O, 2017, BIOMED RES INT, DOI 10.1155/2017/7039406
   Ravindra VM, 2016, WORLD NEUROSURG, V96, P390, DOI 10.1016/j.wneu.2016.09.012
   Rosen RS, 2006, J NUCL MED, V47, P1274
   Ruf J, 2007, NUCL MED COMMUN, V28, P782, DOI 10.1097/MNM.0b013e3282efa1a9
   Russo VM, 2017, WORLD NEUROSURG, V107, P732, DOI 10.1016/j.wneu.2017.08.092
   Sawicki LM, 2017, J MED IMAG RADIAT ON, V61, P327, DOI 10.1111/1754-9485.12565
   SCHWARZER AC, 1994, SPINE, V19, P1132, DOI 10.1097/00007632-199405001-00006
   SCHWARZER AC, 1995, ANN RHEUM DIS, V54, P100, DOI 10.1136/ard.54.2.100
   Strobel K, 2007, AM J ROENTGENOL, V188, pW467, DOI 10.2214/AJR.06.1215
   Utsunomiya D, 2006, RADIOLOGY, V238, P264, DOI 10.1148/radiol.2373041358
   van Eerd M, 2010, PAIN PRACT, V10, P113, DOI 10.1111/j.1533-2500.2009.00346.x
   Verdoorn JT, 2015, DIAGN INTERV RADIOL, V21, P342, DOI 10.5152/dir.2015.14400
   Woods AM, 2017, NUCL MED COMMUN, V38, P1047, DOI 10.1097/MNM.0000000000000765
   Wu CX, 2013, THERANOSTICS, V3, P448, DOI 10.7150/thno.6592
NR 51
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 201
EP 210
DI 10.1016/j.wneu.2019.10.082
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200171
PM 31655232
DA 2020-05-12
ER

PT J
AU Ghorbani, M
   Griessenauer, CJ
   Wipplinger, C
   Abdolhoseinpour, H
   Bahrami, R
   Asaadi, S
   Mortazavi, A
AF Ghorbani, Mohammad
   Griessenauer, Christoph J.
   Wipplinger, Christoph
   Abdolhoseinpour, Hesam
   Bahrami, Reza
   Asaadi, Sina
   Mortazavi, Abolghasem
TI Combined Endovascular and Endoscopic Approach for Treatment of
   Concomitant Sphenoid Sinus Giant Traumatic Aneurysm and Direct Carotid
   Cavernous Fistulae
SO WORLD NEUROSURGERY
LA English
DT Article
DE Direct carotid cavernous fistulas; Endoscopic; Endovascular; Sphenoid
   sinus traumatic aneurysm
AB BACKGROUND: Direct carotid cavernous fistulas (CCFs) and sphenoid sinus traumatic aneurysms are well-known pathologies that can present concomitantly in rare cases. Patients with both lesions are usually symptomatic from both the CCF and the traumatic aneurysm. Symptoms include proptosis, chemosis, bruit, epistaxis, visual field defects, and loss of vision. Surgical treatment can be challenging, and for most cases an endovascular approach is the treatment of choice.
   CASE DESCRIPTION: We present an unusual case of a direct CCF with an associated large traumatic aneurysm in the sphenoid sinus due to a history of trauma presenting with unusual symptoms that was treated by a combined endoscopic and endovascular approach.
   CONCLUSIONS: Concurrent occurrence of a traumatic CCF and traumatic aneurysm of the cavernous segment is extremely rare. Early diagnosis and treatment of these lesions are important considering their high mortality rate. Complete occlusion of the fistula and aneurysm while preserving the patency of the carotid artery via an endovascular approach is the treatment of choice for these lesions.
C1 [Ghorbani, Mohammad; Bahrami, Reza; Asaadi, Sina; Mortazavi, Abolghasem] Univ Med Sci, Div Vasc & Endovasc Neurosurg, Firoozgar Hosp, Tehran, Iran.
   [Griessenauer, Christoph J.] Geisinger Hlth Syst, Dept Neurosurg, Danville, PA USA.
   [Abdolhoseinpour, Hesam] Islamic Azad Univ, Tehran Med Branch, Tehran, Iran.
   [Wipplinger, Christoph] Med Univ Innsbruck, Innsbruck, Austria.
RP Mortazavi, A (reprint author), Univ Med Sci, Div Vasc & Endovasc Neurosurg, Firoozgar Hosp, Tehran, Iran.
EM sgmortazavi@gmail.com
RI Ghorbani, Mohammad/N-8636-2018
OI Ghorbani, Mohammad/0000-0002-7709-3095; Griessenauer,
   Christoph/0000-0002-2952-3812
CR BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   Barry RC, 2011, J CLIN NEUROSCI, V18, P1072, DOI 10.1016/j.jocn.2010.12.026
   Ducruet AF, 2013, WORLD NEUROSURG, V80, P538, DOI 10.1016/j.wneu.2013.02.033
   Iampreechakul P, 2019, INTERV NEURORADIOL, V25, P71, DOI 10.1177/1591019918800220
   Karanam LSP, 2014, J CLIN IMAG SCI, V4, DOI 10.4103/2156-7514.127961
   Klevtsova E, 2015, J EMERG MED, V48, P186, DOI 10.1016/j.jemermed.2014.09.043
   Luo CB, 2004, AM J NEURORADIOL, V25, P501
   Menon G, 2018, CUREUS, V10, DOI 10.7759/cureus.3002
   Miley Jefferson T, 2008, J Vasc Interv Neurol, V1, P79
   Narayan Dange Nitin, 2018, Asian J Neurosurg, V13, P1244, DOI 10.4103/ajns.AJNS_161_17
   Rajagopal R, 2016, POL J RADIOL, V81, P483, DOI 10.12659/PJR.898414
   Zhao P, 2012, NEURORADIOL J, V25, P231, DOI 10.1177/197140091202500214
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 211
EP 214
DI 10.1016/j.wneu.2019.10.131
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200172
PM 31678447
DA 2020-05-12
ER

PT J
AU Cambruzzi, E
AF Cambruzzi, Eduardo
TI Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent
   Patients: Clinical Impact of Molecular Analysis and Histogenetic
   Evaluation
SO WORLD NEUROSURGERY
LA English
DT Review
DE Central nervous system; Diffuse large B-cell lymphoma; Immunocompetent
   patient; Immunohistochemistry; Lymphoid neoplasia; Pathology
ID CENTRAL-NERVOUS-SYSTEM; HEALTH-ORGANIZATION CLASSIFICATION; PRIMARY CNS
   LYMPHOMA; IMMUNOHISTOCHEMICAL PROFILE; PROGNOSTIC-SIGNIFICANCE; R-CHOP;
   EXPRESSION; EPIDEMIOLOGY; INFILTRATION; INDIVIDUALS
AB Primary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) represents less than 1% of non-Hodgkin lymphomas and 2%-3% of brain tumors. Primary CNS DLBCL occurs sporadically in healthy patients. Tumor development and progression have been associated with reduced/absent expression of human leukocyte antigen class I and II proteins; increased expression of CXCR4, CXCL12, CXCR5, and CCR7; mutations of VH4/34, BC16, MYC, and PAX5 genes; and rearrangement of immunoglobulin heavy and light chain genes. Generally, DLBCL is a single supratentorial lesion (60%-70%), and stereotactic biopsy and intraoperative examination are the main diagnostic methods. Distinctive histo-logic features are a diffuse growth pattern and angioinvasiveness. Most neoplastic cells resemble centroblasts and exhibit positive CD20, CD22, PAX5, CD79a, and MUM1 expression. The prognosis of primary CNS DLBCL is less favorable than that of nodal DLBCL, and DLBCL subtype, strong FOXP1 immunoreactivity, MYC and BCL2 overexpression, and BCL6 translocations are associated with poor prognosis.
C1 [Cambruzzi, Eduardo] Univ Fed Rio Grande do Sul, Dept Pathol, Porto Alegre, RS, Brazil.
   [Cambruzzi, Eduardo] Complexo Hosp Santa Casa, Dept Pathol, Porto Alegre, RS, Brazil.
   [Cambruzzi, Eduardo] Hosp N Sra Conceicao, Porto Alegre, RS, Brazil.
   [Cambruzzi, Eduardo] Univ Luterana Brasil, Dept Pathol, Canoas, RS, Brazil.
   [Cambruzzi, Eduardo] Fundacao Univ Cardiol, Inst Cardiol, Porto Alegre, RS, Brazil.
RP Cambruzzi, E (reprint author), Univ Fed Rio Grande do Sul, Dept Pathol, Porto Alegre, RS, Brazil.; Cambruzzi, E (reprint author), Complexo Hosp Santa Casa, Dept Pathol, Porto Alegre, RS, Brazil.; Cambruzzi, E (reprint author), Hosp N Sra Conceicao, Porto Alegre, RS, Brazil.; Cambruzzi, E (reprint author), Univ Luterana Brasil, Dept Pathol, Canoas, RS, Brazil.; Cambruzzi, E (reprint author), Fundacao Univ Cardiol, Inst Cardiol, Porto Alegre, RS, Brazil.
EM dudacambruzzi@yahoo.com.br
CR Abramson JS, 2017, NEW ENGL J MED, V377, P783, DOI 10.1056/NEJMc1704610
   Aki H, 2013, INT J CLIN EXP PATHO, V6, P1068
   Alvarez R, 2012, ANN ONCOL, V23, P1274, DOI 10.1093/annonc/mdr436
   Bataille B, 2000, J NEUROSURG, V92, P261, DOI 10.3171/jns.2000.92.2.0261
   Birsen Rudy, 2018, Oncotarget, V9, P16822, DOI 10.18632/oncotarget.24706
   Booman M, 2008, J PATHOL, V216, P209, DOI 10.1002/path.2399
   Braggio E, 2015, CLIN CANCER RES, V21, P3986, DOI 10.1158/1078-0432.CCR-14-2116
   Brunn A, 2013, ACTA NEUROPATHOL, V126, P603, DOI 10.1007/s00401-013-1169-7
   Cambruzzi E, 2018, CHILD NERV SYST, V34, P809, DOI 10.1007/s00381-018-3765-2
   Chang C, 2015, HISTOPATHOLOGY, V67, P625, DOI 10.1111/his.12706
   Chapuy B, 2016, BLOOD, V127, P869, DOI 10.1182/blood-2015-10-673236
   Correa DD, 2007, ANN ONCOL, V18, P1145, DOI 10.1093/annonc/mdl464
   DeWitt JC, 2017, CURR OPIN NEUROL, V30, P643, DOI 10.1097/WCO.0000000000000490
   Ekstein D, 2006, J NEUROL SCI, V247, P39, DOI 10.1016/j.jns.2006.03.012
   Ferreri AJM, 2019, BLOOD, V134, P252, DOI 10.1182/blood.2019000633
   Ferreri AJM, 2016, LANCET HAEMATOL, V3, pE217, DOI 10.1016/S2352-3026(16)00036-3
   Four M, 2017, HEMATOL ONCOL, V35, P487, DOI 10.1002/hon.2375
   Fox CP, 2019, BRIT J HAEMATOL, V184, P348, DOI 10.1111/bjh.15661
   Giannini C, 2014, J NEUROPATH EXP NEUR, V73, P478, DOI 10.1097/NEN.0000000000000076
   Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545
   Harley B, 2018, J CLIN NEUROSCI, V57, P177, DOI 10.1016/j.jocn.2018.08.022
   Hattab EM, 2010, MODERN PATHOL, V23, P235, DOI 10.1038/modpathol.2009.164
   Hayashi Y, 2001, J NEURO-ONCOL, V55, P51, DOI 10.1023/A:1012946812930
   He MX, 2013, NEURO-ONCOLOGY, V15, P727, DOI 10.1093/neuonc/not012
   Ichiki A, 2017, J CLIN EXP HEMATOP, V57, P54, DOI 10.3960/jslrt.17029
   Kim S, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1626653
   Kluin PM, 2017, WHO CLASSIFICATION T, P300
   Kurzwelly D, 2010, J NEURO-ONCOL, V97, P389, DOI 10.1007/s11060-009-0032-0
   Langner-Lemervier S, 2016, NEURO-ONCOLOGY, V18
   Liu J, 2017, ONCOL LETT, V14, P5505, DOI 10.3892/ol.2017.6893
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lukas RV, 2018, ONCOLOGY-NY, V32, pE11
   Lukas RV, 2018, ONCOLOGY-NY, V32, P17
   Montesinos-Rongen M, 2015, J IMMUNOL, V195, P1312, DOI 10.4049/jimmunol.1402341
   Nguyen-Them L, 2016, EUR J CANCER, V61, P69, DOI 10.1016/j.ejca.2016.03.080
   Nomura M, 2013, MOL CLIN ONCOL, V1, P655, DOI 10.3892/mco.2013.110
   Nowakowski GS, 2011, LEUKEMIA, V25, P1877, DOI 10.1038/leu.2011.165
   Offner F, 2015, BLOOD, V126, P1893, DOI 10.1182/blood-2015-03-632430
   Olson JE, 2002, CANCER, V95, P1504, DOI 10.1002/cncr.10851
   Otani R, 2019, J CLIN NEUROSCI, V69, P26, DOI 10.1016/j.jocn.2019.08.083
   Plasswilm L, 2002, ANN HEMATOL, V81, P415, DOI 10.1007/s00277-002-0498-8
   Preusser M, 2010, PATHOLOGY, V42, P547, DOI 10.3109/00313025.2010.508786
   Puligundla CK, 2017, INDIAN J MED PAEDIAT, V38, P478, DOI 10.4103/ijmpo.ijmpo_202_16
   Rae AI, 2019, NEUROSURGERY, V84, P935, DOI 10.1093/neuros/nyy096
   Raoux D, 2010, NEUROPATHOLOGY, V30, P232, DOI 10.1111/j.1440-1789.2009.01074.x
   Rudresha AH, 2017, SOUTH ASIAN J CANCER, V6, P165, DOI 10.4103/2278-330X.221341
   Sharma MC, 2016, INDIAN J MED RES, V143, P605, DOI 10.4103/0971-5916.187109
   Song MK, 2011, J NEURO-ONCOL, V104, P825, DOI 10.1007/s11060-011-0555-z
   Sugita Y, 2016, NEUROPATHOLOGY, V36, P313, DOI 10.1111/neup.12276
   Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569
   Venetz D, 2010, INT J CANCER, V127, P2300, DOI 10.1002/ijc.25236
   Zahid MF, 2016, EUR J HAEMATOL, V97, P108, DOI 10.1111/ejh.12763
   Zhang XM, 2013, J CLIN NEUROSCI, V20, P75, DOI 10.1016/j.jocn.2012.05.021
NR 53
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 215
EP 220
DI 10.1016/j.wneu.2019.09.158
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200173
PM 31605845
DA 2020-05-12
ER

PT J
AU Cossu, G
   Al-Taha, K
   Hajdu, SD
   Daniel, RT
   Messerer, M
AF Cossu, Giulia
   Al-Taha, Khalid
   Hajdu, Steven D.
   Daniel, Roy T.
   Messerer, Mahmoud
TI Carotid-Cavernous Fistula After Transsphenoidal Surgery: A Rare but
   Challenging Complication
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid artery injury; Carotid-cavernous fistula; Coiling; Embolization;
   Endoscopy; Endovascular treatment; Transsphenoidal surgery
ID ENDOVASCULAR MANAGEMENT; PITUITARY-ADENOMA; ARTERY LACERATION;
   STENT-GRAFT; EMBOLIZATION; ANEURYSM; INJURIES
AB BACKGROUND: Carotid-cavernous fistula (CCF) is a rare complication after transsphenoidal surgery.
   METHODS: The aim of this article is to report a case of CCF after the endoscopic resection of a growth hormone secreting pituitary microadenoma, and to discuss and review all the cases of CCF secondary to transsphenoidal procedures described in literature.
   RESULTS: A patient aged 74 years was operated for a growth hormone pituitary microadenoma through an endoscopic transsphenoidal surgery. During the procedure, a copious bleeding from the left cavernous sinus was managed with hemostatic material. A direct CCF was diagnosed and managed with transvenous and transarterial coiling. A complete exclusion of the fistula was possible, and the patency of the internal carotid artery was maintained. A total of 9 other cases have been reported. A transsphenoidal approach was performed for sellar tumors in 6 cases, and for chronic sinusitis in 2 cases. In 7 cases, intraoperative hemorrhage was reported, which could be controlled in 5 cases. The postoperative diagnosis of CCF was immediate in 5 cases. Patients presented with persistent bleeding after nasal unpacking or later with chemosis and proptosis. Cerebral angiography was the gold standard for the diagnosis. Eight cases were successfully treated through endovascular techniques with no recurrence observed at follow-up (mean of 15 months). No major neurologic complications were observed.
   CONCLUSIONS: CCF should be suspected with every abnormal bleeding after transsphenoidal surgeries, even when the symptoms are mild. Diagnostic arteriography and endovascular treatment represent the mainstay of the management, and an early diagnosis strongly improves the prognosis.
C1 [Cossu, Giulia; Al-Taha, Khalid; Daniel, Roy T.; Messerer, Mahmoud] Lausanne Univ Hosp, Dept Neurosurg, Lausanne, Switzerland.
   [Hajdu, Steven D.] Lausanne Univ Hosp, Dept Diagnost & Intervent Radiol, Lausanne, Switzerland.
RP Cossu, G (reprint author), Lausanne Univ Hosp, Dept Neurosurg, Lausanne, Switzerland.
EM giulia.cossu@chuv.ch
CR AHUJA A, 1992, NEUROSURGERY, V31, P774
   Berker M, 2012, PITUITARY, V15, P288, DOI 10.1007/s11102-011-0368-2
   Bink A, 2010, AM J NEURORADIOL, V31, P1216, DOI 10.3174/ajnr.A2040
   Ciceri EFM, 2006, NEUROL SCI, V27, P317, DOI 10.1007/s10072-006-0703-y
   Cinar C, 2013, INTERV NEURORADIOL, V19, P102, DOI 10.1177/159101991301900116
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   Dolenc VV, 1999, BRIT J NEUROSURG, V13, P185, DOI 10.1080/02688699943961
   Ducruet AF, 2013, WORLD NEUROSURG, V80, P538, DOI 10.1016/j.wneu.2013.02.033
   Gardner PA, 2013, NEUROSURGERY, V73, P261, DOI 10.1227/01.neu.0000430821.71267.f2
   Giustina A, 2010, J CLIN ENDOCR METAB, V95, P3141, DOI 10.1210/jc.2009-2670
   GUGLIELMI G, 1992, NEUROSURGERY, V31, P591, DOI 10.1227/00006123-199209000-00026
   HALBACH VV, 1989, AM J NEURORADIOL, V10, P377
   HIGASHIDA RT, 1989, AM J ROENTGENOL, V153, P577, DOI 10.2214/ajr.153.3.577
   Kalia JS, 2009, J NEUROINTERV SURG, V1, P142, DOI 10.1136/jnis.2009.001040
   Karaman E, 2009, J CRANIOFAC SURG, V20, P556, DOI 10.1097/SCS.0b013e31819ba1e8
   Kocer N, 2002, AM J NEURORADIOL, V23, P442
   Koitschev A, 2006, ACTA OTO-LARYNGOL, V126, P730, DOI 10.1080/00016480500469578
   Laws E R Jr, 1999, Pituitary, V2, P163
   LEWIS AI, 1995, NEUROSURGERY, V36, P239, DOI 10.1227/00006123-199502000-00001
   Nadarajah M, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/neurintsurg-2011-010000
   Nossek E, 2015, ACTA NEUROCHIR, V157, P1125, DOI 10.1007/s00701-015-2446-0
   Patel PD, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1742
   Pigott TJD, 1989, BRIT J NEUROSURG, V3, P613, DOI 10.3109/02688698909002855
   Pradeep N, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011786.rep
   Raymond J, 1997, AM J NEURORADIOL, V18, P655
   RENN WH, 1975, J NEUROSURG, V43, P288, DOI 10.3171/jns.1975.43.3.0288
   Ringer AJ, 2005, NEUROSURG CLIN N AM, V16, P279, DOI 10.1016/j.nec.2004.08.004
   Sylvester PT, 2016, J NEUROSURG, V125, P1256, DOI 10.3171/2015.6.JNS142483
   TAKAHASHM, 1969, J NEUROSURG, V30, P498, DOI DOI 10.3171/jns.1969.30.4.0498
   Wendl CM, 2017, CLIN NEURORADIOL, V27, P493, DOI 10.1007/s00062-016-0511-6
NR 30
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 221
EP 227
DI 10.1016/j.wneu.2019.10.194
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200174
PM 31712112
DA 2020-05-12
ER

PT J
AU Ogul, H
AF Ogul, Hayri
TI Ophthalmic Arteries Arising from the Bilateral Anterior Cerebral
   Arteries Diagnosed by Three-Dimensional Time-of-Flight Magnetic
   Resonance Angiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE MRA; Ophthalmic artery; Vascular anomaly
ID ORIGIN
AB BACKGROUND: The ophthalmic artery (OA) is a very important branch of the supraclinoid segment of the internal carotid artery. Origination of the OA from the anterior cerebral artery is an extremely rare condition. Being unaware of the origin anomalies of OAs can lead to unfavorable results, especially in cases in which craniofacial surgery or cerebral therapeutic angiography is planned.
   CASE DESCRIPTION: An anomalous origin of the ipsilateral OAs from the A1 segments of the bilateral anterior cerebral arteries was detected by three-dimensional time-of-flight magnetic resonance angiography.
   CONCLUSIONS: Anomalous origin of the OA from the anterior cerebral artery may be explained by a failure in the caudal migration of the ventral OA. Because of high soft tissue resolution and absence of radiation, three-dimensional time-of-flight magnetic resonance angiography is preferred for detection of orbital and cerebral vascular anomalies.
C1 [Ogul, Hayri] Ataturk Univ, Med Fac, Dept Radiol, Erzurum, Turkey.
RP Ogul, H (reprint author), Ataturk Univ, Med Fac, Dept Radiol, Erzurum, Turkey.
EM drhogul@gmail.com
OI Ogul, Hayri/0000-0001-5989-3729
CR Belotti F, 2016, NEUROSURG REV, V39, P483, DOI 10.1007/s10143-016-0715-x
   HASSLER W, 1989, NEURORADIOLOGY, V31, P85
   Hayreh S S, 1962, Br J Ophthalmol, V46, P65, DOI 10.1136/bjo.46.2.65
   ISLAK C, 1994, J NEURORADIOLOGY, V21, P46
   JIMENEZCASTELLANOS J, 1995, SURG RADIOL ANAT, V17, P139, DOI 10.1007/BF01627574
   Lasjaunias P, 1992, FUNCTIONAL VASCULAR, V3, P15
   Li YH, 2011, NEUROL MED-CHIR, V51, P579, DOI 10.2176/nmc.51.579
   Padget Dorcas Hager, 1948, CONTRIBUTIONS TO EMBRYOLOGY [CARNEGIE INST OF WASHINGTON PUBL], V32, P205
   Tsutsumi S, 2012, SURG RADIOL ANAT, V34, P833, DOI 10.1007/s00276-012-0965-4
   Uchino A, 2015, SURG RADIOL ANAT, V37, P1009, DOI 10.1007/s00276-015-1441-8
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 228
EP 230
DI 10.1016/j.wneu.2019.11.008
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200175
PM 31715401
DA 2020-05-12
ER

PT J
AU Splavski, B
   Rotim, K
   Boop, FA
   Gienapp, AJ
   Arnautovic, KI
AF Splavski, Bruno
   Rotim, Kresimir
   Boop, Frederick A.
   Gienapp, Andrew J.
   Arnautovic, Kenan, I
TI Ambroise Pare: His Contribution to the Future Advancement of
   Neurosurgery and the Hardships of His Times Affecting His Life and
   Brilliant Career
SO WORLD NEUROSURGERY
LA English
DT Article
DE 16th century France; Ambroise Pare; History; Neurosurgery
ID HENRY-II; FRANCE; DEATH; PARE,AMBROISE; LOCALIZATION; KING
AB Ambroise Pare was celebrated surgeon of the 16th century whose practical accomplishments, books, and ideas transformed surgery and was a precursor for the later development of neurosurgery. He developed many surgical innovations related to wound management, arterial ligation for the prevention of hemorrhage during limb amputations, and the treatment of war-related head and spine injuries. He maintained that a surgeon should operate gently to reduce pain and improve outcome, and he dedicated his career to the wounded, sick, and poor. He also served 4 consecutive French monarchs-Henri II and his 3 sons Francois II, Charles IX, and Henri III. As a Huguenot (a Reformed Protestant) by faith, he lived in an environment dominated by Catholicism. Hence, his practice and life were sometimes hindered by political circumstances and religious prejudice. In this historical vignette, we will discuss the professional accomplishments of Ambroise Pare that influenced the future development of neurosurgery, including his descriptions of phantom-limb pain and peripheral nerve injury, his innovations in neurotraumatology, and the saws he invented for use in skull surgery. We will also highlight Pare's broad neurosurgical contributions to the field. Finally, we will discuss his personal life during the difficult and dangerous political circumstances of 16th century France.
C1 [Splavski, Bruno; Rotim, Kresimir] Sisters Mercy Univ Hosp Ctr, Dept Neurosurg, Zagreb, Croatia.
   [Splavski, Bruno; Rotim, Kresimir] Osijek Univ, Sch Med, Osijek, Croatia.
   [Splavski, Bruno] Osijek Univ, Sch Dent Med & Hlth, Osijek, Croatia.
   [Rotim, Kresimir] Univ Appl Hlth Sci, Zagreb, Croatia.
   [Boop, Frederick A.; Gienapp, Andrew J.; Arnautovic, Kenan, I] Semmes Murphey Clin, Memphis, TN 38120 USA.
   [Boop, Frederick A.; Arnautovic, Kenan, I] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA.
   [Boop, Frederick A.; Gienapp, Andrew J.] Le Bonheur Childrens Hosp, Neurosci Inst, Memphis, TN USA.
RP Arnautovic, KI (reprint author), Semmes Murphey Clin, Memphis, TN 38120 USA.; Arnautovic, KI (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA.
EM kenanarnaut@yahoo.com
RI Arnautovic, Kenan/AAI-6898-2020; Splavski, Bruno/AAM-1579-2020
OI Arnautovic, Kenan/0000-0003-3745-288X; 
CR Bagwell CE, 2005, ANN SURG, V241, P872, DOI 10.1097/01.sla.0000165185.88634.d0
   Banerjee AD, 2011, BRIT J NEUROSURG, V25, P193, DOI 10.3109/02688697.2010.544786
   Donaldson IML, 2015, J ROY SOC MED, V108, P457, DOI 10.1177/0141076815612639
   Dowling KA, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.4.FOCUS15119
   Drucker Charles B, 2008, Yale J Biol Med, V81, P199
   DUNN PM, 1994, ARCH DIS CHILD-FETAL, V71, pF231, DOI 10.1136/fn.71.3.F231
   FARIA MA, 1992, J NEUROSURG, V77, P964, DOI 10.3171/jns.1992.77.6.0964
   Friedman SG, 2018, J VASC SURG, V68, P646, DOI 10.1016/j.jvs.2018.04.053
   Fullerton Joseph B, 2009, Clin Cardiol, V32, pE82, DOI 10.1002/clc.20388
   Gfrerer L, 2018, PLAST RECONSTR SURG, V142, P1036, DOI 10.1097/PRS.0000000000004795
   Goodrich J T, 1985, Med Herit, V1, P280
   Haas L F, 1991, J Neurol Neurosurg Psychiatry, V54, P287, DOI 10.1136/jnnp.54.4.287
   Hernigou P, 2013, INT ORTHOP, V37, P975, DOI 10.1007/s00264-013-1872-y
   Hernigou P, 2013, INT ORTHOP, V37, P769, DOI 10.1007/s00264-013-1857-x
   Hernigou P, 2013, INT ORTHOP, V37, P543, DOI 10.1007/s00264-013-1797-5
   KING LS, 1973, AM J PATHOL, V73, P514
   LISTON SL, 1994, AM J SURG, V167, P440, DOI 10.1016/0002-9610(94)90132-5
   Manzoni T, 1998, ARCH ITAL BIOL, V136, P103
   Markatos K, 2017, WORLD NEUROSURG, V106, P442, DOI 10.1016/j.wneu.2017.07.039
   Martin G, 2001, AUST NZ J SURG, V71, P318, DOI 10.1046/j.1440-1622.2001.02102.x
   NORWICH I, 1991, S AFR MED J, V80, P245
   Paget S., AMBROISE PARE HIS TI, P1510
   Pare A., 1952, APOLOGIE TREATISE AM
   Pearce JMS, 2008, EUR NEUROL, V59, P113, DOI 10.1159/000111872
   Popa CC, 2018, ROM J MORPHOL EMBRYO, V59, P637
   Rose FC, 2009, J HIST NEUROSCI, V18, P239, DOI 10.1080/09647040802025052
   Shen JT, 2014, AM SURGEON, V80, P536
   Singer DW, 1924, SELECTIONS WORKS AMB
   Splayski B, 2019, WORLD NEUROSURG, V129, P202, DOI 10.1016/j.wneu.2019.06.008
   Vinchon M, 2009, CHILD NERV SYST, V25, P639, DOI 10.1007/s00381-008-0775-5
   Zanello M, 2015, ACTA NEUROCHIR, V157, P145, DOI 10.1007/s00701-014-2280-9
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 233
EP 239
DI 10.1016/j.wneu.2019.10.187
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200177
PM 31706970
DA 2020-05-12
ER

PT J
AU Turgut, M
   Akhaddar, A
   Turgut, AT
AF Turgut, Mehmet
   Akhaddar, Ali
   Turgut, Ahmet T.
TI Calcified or Ossified Chronic Subdural Hematoma: A Systematic Review of
   114 Cases Reported During Last Century with a Demonstrative Case Report
SO WORLD NEUROSURGERY
LA English
DT Review
DE Armored or armoured brain; Calcified subdural hematoma; Chronic subdural
   hematoma; Complication; Craniotomy; Head trauma; Ossified subdural
   hematoma; Shunting; Surgical treatment
ID ARMORED BRAIN; TENSION PNEUMOCEPHALUS; COMPUTED-TOMOGRAPHY; SHUNT;
   MANAGEMENT; PATIENT; SURGERY; CALCIFICATIONS; MEMBRANECTOMY;
   HYDROCEPHALUS
AB OBJECTIVE: Calcified or ossified chronic subdural hematoma (CSDH), characterized by slowly progressing neurologic symptoms, is a rarely seen entity that may remain asymptomatic for many years. Management of CSDH has improved dramatically in recent years as a result of advances in diagnostic tools, but there is still some controversy regarding the optimal treatment strategy.
   METHODS: In this systematic review, PRISMA guidelines were followed to query existing online databases between January 1930 and December 2018. We found a total of 88 articles containing 114 cases of calcified or ossified CSDH, comprising 83 patients operated on and 31 not operated on.
   RESULTS: In this study, there were 78 males and 29 females (7 with unreported gender) from 25 countries, ages ranging from 4 months to 86 years (mean, 33.7 years), with CSDH caused by head trauma in 33.3%, shunting for hydrocephalus in 27.2%, or after cranial surgery in 4.4%. The duration of symptoms ranged from acute onset to 20 years, with a mean of 24.1 months. Imaging techniques such as radiography, computed tomography, and magnetic resonance imaging were used, with pathologic confirmation of CSDH and complete recovery in 56.4% of patients.
   CONCLUSIONS: Incidence of calcified or ossified CSDH is high in certain countries, including the United States, Japan, and Turkey, with a steady increase in recent years. The therapy of choice is surgery in these patients and it should be considered in the differential diagnosis at presentation because of its infrequency and variable clinical manifestation, after shunting in children or head trauma in adults.
C1 [Turgut, Mehmet] Adnan Menderes Univ, Dept Neurosurg, Fac Med, Aydin, Turkey.
   [Akhaddar, Ali] Mohammed V Univ Rabat, Avicenne Mil Hosp Marrakech, Dept Neurosurg, Rabat, Morocco.
   [Turgut, Ahmet T.] Istinye Univ, Dept Radiol, Fac Med, Istanbul, Turkey.
RP Turgut, M (reprint author), Adnan Menderes Univ, Dept Neurosurg, Fac Med, Aydin, Turkey.
EM drmturgut@yahoo.com
OI Akhaddar, Ali/0000-0001-5743-2777
CR AFRA D, 1961, J NEUROSURG, V18, P393, DOI 10.3171/jns.1961.18.3.0393
   Akhaddar A, 2011, HEADACHE, V51, P1440, DOI 10.1111/j.1526-4610.2011.01865.x
   Akmil MU, 2015, HASEKI TIP BUL, V53, P168, DOI 10.4274/haseki.2292
   Al Wohaibi M, 2003, CAN MED ASSOC J, V169, P46
   Allen AM, 1940, NEW ENGL J MED, V223, P324, DOI 10.1056/NEJM194008292230903
   Amr R, 2008, PEDIATR NEUROSURG, V44, P88, DOI 10.1159/000110672
   ANEGAWA S, 1987, Neurological Surgery, V15, P1249
   AOKI N, 1993, ACTA NEUROCHIR, V120, P44, DOI 10.1007/BF02001468
   Aran-Echabe E, 2014, REV NEUROLOGIA, V58, P420, DOI 10.33588/rn.5809.2014007
   ARBIT E, 1991, J NEUROSURG, V74, P139, DOI 10.3171/jns.1991.74.1.0139
   ARSENI C, 1970, J NEUROL NEUROSUR PS, V33, P205, DOI 10.1136/jnnp.33.2.205
   Asghar M, 2002, J ROY SOC MED, V95, P290, DOI 10.1258/jrsm.95.6.290
   Balevi Mustafa, 2017, Asian J Neurosurg, V12, P598, DOI 10.4103/ajns.AJNS_8_15
   Bankole OB, 2010, AFR J NEUROL SCI, V29, P66
   BARMEIR EP, 1985, EUR J RADIOL, V5, P186
   Bold DA, 1943, J NERV MENT DIS, V98, P609
   Borkar SA, 2013, PAN ARAB J NEUROSURG, V17, P1
   BREMER AM, 1982, NEUROSURGERY, V11, P284, DOI 10.1227/00006123-198208000-00017
   Bull JWD, 1940, P ROY SOC MED, V33, P203
   Cai J, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-110
   Celik H, 2014, J NEUROL SCI-TURK, V31, P361
   Chan ZW, 2018, BMJ CASE REP, V2018
   CHUSID JG, 1953, J NEUROSURG, V10, P430, DOI 10.3171/jns.1953.10.4.0430
   Costello E, 2008, RANDOM HOUSE WEBSTER
   Cote DJ, 2016, J CLIN NEUROSCI, V31, P106, DOI 10.1016/j.jocn.2016.02.014
   Critchley M, 1933, P ROY SOC MED, V26, P306
   CUSICK JF, 1972, J NEUROSURG, V37, P731, DOI 10.3171/jns.1972.37.6.0731
   Dammers R, 2007, J NEUROL NEUROSUR PS, V78, P542, DOI 10.1136/jnnp.2006.108662
   de Araujo Silva Danilo Otavio, 2012, Surg Neurol Int, V3, P150, DOI 10.4103/2152-7806.104744
   DEBOIS V, 1980, SURG NEUROL, V14, P455
   Dimogerontas G, 2006, BRIT J NEUROSURG, V20, P435, DOI 10.1080/02688690601101796
   Dinc C, 2006, TURK NOROSIRURJI DER, V16, P126
   Djoubairou BO, 2015, NEUROL INDIA, V63, P282, DOI 10.4103/0028-3886.156316
   Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y
   Dyke CG, 1938, B NEUROL I NY, V7, P119
   Endo S H, 1976, No Shinkei Geka, V4, P1193
   Evans SJ, 2007, NEUROLOGY, V68, P1954, DOI 10.1212/01.wnl.0000265518.75600.e8
   Fang JC, 2019, WORLD NEUROSURG, V126, P613, DOI 10.1016/j.wneu.2019.03.144
   Galldiks N, 2010, NEUROCRIT CARE, V12, P272, DOI 10.1007/s12028-009-9303-z
   Gandolfi A, 1983, Acta Neurol (Napoli), V5, P130
   Garg K, 2013, NEUROL INDIA, V61, P548, DOI 10.4103/0028-3886.121950
   Gezercan Y, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3621-3
   Goldhahn R, 1930, DTSCH Z CHIR, V224
   Gotoh M, 2001, NEUROL SURG TOKYO, V29, P259
   Gould CE, 1940, B VANCOUVER MED ASS, V18, P21
   Goyal Puneet Kumar, 2013, Asian J Neurosurg, V8, P165, DOI 10.4103/1793-5482.121695
   GRANATA F, 1977, Acta Neurologica (Naples), V32, P340
   GRIPONISSIOTIS B, 1955, J NEUROSURG, V12, P419, DOI 10.3171/jns.1955.12.4.0419
   Gul S, 2008, TURK KLIN J NEUR, V3, P145
   Gupta SK, 2015, SAUDI J ANAESTH, V9, P89, DOI 10.4103/1658-354X.146323
   Haciyakupoglu E, 2017, INT J CLIN EXP MED, V10, P14856
   Harwood-Nash D, 1973, CURR PROBL RADIOL, V3, P1
   He XS, 2005, J NEUROL NEUROSUR PS, V76, P367, DOI 10.1136/jnnp.2004.043174
   HIRAKAWA T, 1989, SURG NEUROL, V32, P51, DOI 10.1016/0090-3019(89)90035-9
   Hong HJ, 2009, SURG NEUROL, V71, P161, DOI 10.1016/j.surneu.2008.01.023
   Howng S L, 1986, Gaoxiong Yi Xue Ke Xue Za Zhi, V2, P465
   Ianovici Monica N, 1980, Neurol Psychiatr (Bucur), V18, P15
   Ide Mitsunobu, 1993, Neurologia Medico-Chirurgica, V33, P559, DOI 10.2176/nmc.33.559
   Imaizumi S, 2001, NEUROL MED-CHIR, V41, P19, DOI 10.2176/nmc.41.19
   Ingraham FD, 1944, J PEDIATR-US, V24, P1, DOI 10.1016/S0022-3476(44)80138-X
   IPLIKCIOGLU AC, 1991, J TRAUMA, V31, P272
   Isobe N, 2008, NEUROL SURG TOKYO, V36, P1115
   Isu T, 1977, No Shinkei Geka, V5, P1279
   ITO H, 1987, J NEUROSURG, V66, P862, DOI 10.3171/jns.1987.66.6.0862
   Ito Miiko, 2014, No Shinkei Geka, V42, P717
   JACKSON FE, 1965, J AMER MED ASSOC, V191, P598, DOI 10.1001/jama.1965.03080070082018
   Juan WS, 2012, ACTA NEUROCHIR, V154, P707, DOI 10.1007/s00701-011-1234-8
   Kannuki S, 2009, NEUROL SURG TOKYO, V37, P567
   Kanu OO, 2012, ROMANIAN NEUROSURGER, VXIX, P1
   Kaplan M, 2008, TURK NEUROSURG, V18, P420
   Karvounis P C, 1987, Acta Neurol (Napoli), V9, P212
   Kaspera W, 2005, NEUROPATHOLOGY, V25, P99, DOI 10.1111/j.1440-1789.2004.00592.x
   Kavcic A, 2006, NEUROLOGY, V66, P758, DOI 10.1212/01.wnl.0000200960.84140.d9
   Keser N, 2017, J SURG CASE REP, DOI 10.1093/jscr/rjx048
   Kim JH, 2011, J KOREAN NEUROSURG S, V50, P103, DOI 10.3340/jkns.2011.50.2.103
   King JEJ, 1943, AM J SURG, V59, P248
   Kobayashi H, 1988, Zentralbl Neurochir, V49, P119
   KONDOH T, 1989, SURG NEUROL, V32, P471, DOI 10.1016/0090-3019(89)90014-1
   Kotwica Z, 1987, Neurol Psychiatr (Bucur), V25, P257
   Kpelao E, 2018, OPEN J MODERN NEUROS, V8, P72
   Lampugnani E, 1973, Riv Neurobiol, V19, P255
   Lang E, 1943, ZBL NEUROCHIR, V7, P193
   Lega BC, 2010, J NEUROSURG, V113, P615, DOI 10.3171/2009.9.JNS08825
   Li H, 2017, WORLD NEUROSURG, V108, DOI 10.1016/j.wneu.2017.09.023
   Li X, 2015, NEUROSURG QUART, V25, P167
   Loh Joon-Khim, 1997, Kaohsiung Journal of Medical Sciences, V13, P272
   LUDWIG B, 1983, NEURORADIOLOGY, V25, P39, DOI 10.1007/BF00327479
   MACLEAN JA, 1955, NEUROLOGY, V5, P520, DOI 10.1212/WNL.5.7.520
   Marcikic M, 2010, ACTA CLIN CROAT, V49, P331
   Matsumura M, 1984, Neurol Med Chir (Tokyo), V24, P504, DOI 10.2176/nmc.24.504
   MCLAURIN R L, 1956, Am Surg, V22, P736
   MCLAURIN RL, 1966, J NEUROSURG, V24, P648, DOI 10.3171/jns.1966.24.3.0648
   Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Moon HG, 2003, YONSEI MED J, V44, P915, DOI 10.3349/ymj.2003.44.5.915
   Moon KS, 2007, J CLIN NEUROSCI, V14, P283, DOI 10.1016/j.jocn.2005.11.016
   MORI N, 1982, Neurological Surgery, V10, P1203
   MOSBERG WH, 1952, J NERV MENT DIS, V115, P163
   Moskala M, 2007, MICROSC MICROANAL, V13, P211, DOI 10.1017/S1431927607070286
   Munro D, 1942, NEW ENGL J MED, V227, P87, DOI 10.1056/NEJM194207162270301
   Munro D., 1938, CRANIO CEREBRAL INJU
   NAGATA K, 1984, Neurological Surgery, V12, P1093
   Narsinghani Umesh, 2002, J Ark Med Soc, V98, P300
   NIWA J, 1988, SURG NEUROL, V30, P135, DOI 10.1016/0090-3019(88)90099-7
   Norman C H Jr, 1971, J Natl Med Assoc, V63, P3
   Oda Shinri, 2010, Tokai J Exp Clin Med, V35, P85
   Ovallath S, 2012, CASE REP MED, DOI 10.1155/2012/982198
   Papanikolaou PG, 2008, J NEUROSURG, V108, P401, DOI 10.3171/JNS/2008/108/2/0401
   Pappamikail Lia, 2013, Surg Neurol Int, V4, P21, DOI 10.4103/2152-7806.107548
   Park JS, 2003, J KOREAN NEUROSURG S, V34, P177
   Per H, 2006, BRAIN DEV-JPN, V28, P607, DOI 10.1016/j.braindev.2006.03.012
   Perria C, 1966, Minerva Neurochir, V10, P42
   Petraglia Anthony L, 2011, Surg Neurol Int, V2, P120, DOI 10.4103/2152-7806.84391
   Porta M, 1974, Acta Neurol (Napoli), V29, P275
   PORTUGAL J R, 1963, Zentralbl Neurochir, V24, P74
   Pruna V, 2010, ROMAN NEUROSURG, V15, P22
   Rao ZX, 2010, BRIT J NEUROSURG, V24, P722, DOI 10.3109/02688697.2010.520763
   Richards PG, 2006, ARCH DIS CHILD, V91, P205, DOI 10.1136/adc.2005.090761
   Rocchi G, 2007, SURG NEUROL, V67, P374, DOI 10.1016/j.surneu.2006.08.066
   SAINTMARTIN J, 1992, ARCH FR PEDIATR, V49, P203
   Sakamoto T, 2000, JPN J NEUROSURG TOKY, V9, P541
   Salunke P, 2013, BRIT J NEUROSURG, V27, P524, DOI 10.3109/02688697.2013.769043
   Samson M, 1945, LAVAL MED, V7, P297
   Sandhu K, 2004, INDIAN J ANAESTH, V48, P439
   Santarius Thomas, 2010, Clin Neurosurg, V57, P112
   Saritas A, 2013, DUZCE MED J, V15
   Sato K, 2005, NEUROL SURG TOKYO, V33, P805
   Satyarthee Guru Dutta, 2018, Asian J Neurosurg, V13, P1175, DOI 10.4103/ajns.AJNS_263_16
   Schuller A., 1935, ROFO FORTSCHR RONTG, V51, P119
   Selcuklu A, 1990, ERCIYES MED J, V12, P576
   Senol N, 2015, J NEUROL SCI-TURK, V32, P208
   Sgaramella E, 2002, J Neurosurg Sci, V46, P28
   Shaikh Nissar, 2010, Surg Neurol Int, V1, DOI 10.4103/2152-7806.65185
   Sharma RR, 1999, PEDIATR NEUROSURG, V31, P150, DOI 10.1159/000028851
   Shim YS, 2007, YONSEI MED J, V48, P210, DOI 10.3349/ymj.2007.48.2.210
   Shimizu Y, 1988, Neurol Med Chir (Tokyo), V28, P190, DOI 10.2176/nmc.28.190
   Siddiqui SA, 2017, WORLD NEUROSURG, V98, P520, DOI 10.1016/j.wneu.2016.11.031
   Sikahall-Meneses Edna, 2008, Cir Cir, V76, P199
   SPADARO A, 1986, SURG NEUROL, V26, P487, DOI 10.1016/0090-3019(86)90262-4
   Spadaro A, 1987, J Neurosurg Sci, V31, P49
   Stanisic M, 2012, ACTA NEUROCHIR, V154, P113, DOI 10.1007/s00701-011-1203-2
   Surme MB, 2017, TURKIYE KLIN J NEUR, V12
   Taha MM, 2012, TURK NEUROSURG, V22, P407, DOI 10.5137/1019-5149.JTN.4782-11.1
   Tandon V, 2013, TURK NEUROSURG, V23, P815, DOI 10.5137/1019-5149.JTN.6189-12.1
   Tatli M, 2006, PEDIATR NEUROSURG, V42, P122, DOI 10.1159/000090468
   Turgut M, 2010, CENT EUR NEUROSURG, V71, P146, DOI 10.1055/s-0030-1253346
   Turgut M, 1997, CHILD NERV SYST, V13, P415, DOI 10.1007/s003810050111
   Turgut M, 2019, J NEUROL SURG REP, V80, pE44, DOI 10.1055/s-0039-1694738
   TVETE S, 1978, FORTSCHR RONTG NEUEN, V129, P506
   TYSON G, 1980, J NEUROSURG, V52, P776, DOI 10.3171/jns.1980.52.6.0776
   Viozzi I, 2017, ACTA NEUROCHIR, V159, P81, DOI 10.1007/s00701-016-2991-1
   WAGA S, 1979, SURG NEUROL, V11, P51
   Waga S, 1970, No To Shinkei, V22, P325
   Wakamoto H, 2003, NEUROL SURG TOKYO, V31, P269
   Watts C, 1976, Surg Neurol, V6, P247
   Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937
   White M, 2010, BRIT J NEUROSURG, V24, P257, DOI 10.3109/02688691003675218
   Xiao ZY, 2017, TRANSL NEUROSCI CLIN, V3, P220
   YAMADA K, 1992, ACTA NEUROCHIR, V114, P151, DOI 10.1007/BF01400606
   YAMASHIMA T, 1987, NEUROCHIRURGIA, V30, P95
   Yan H J, 1998, Changgeng Yi Xue Za Zhi, V21, P521
   Yang HZ, 2004, TZU CHI MED J, V16, P261
   Yang X, 2015, J CRANIOFAC SURG, V26, pE550, DOI 10.1097/SCS.0000000000002025
   Yokoyama K, 2008, AM J NEURORADIOL, V29, P1159, DOI 10.3174/ajnr.A1001
   Zarkou S, 2009, NEUROLOGIST, V15, P299, DOI 10.1097/NRL.0b013e3181b65558
   Zhang S, 2018, MOL PAIN, V14, DOI 10.1177/1744806918767512
   조혁래, 2005, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V37, P386
NR 167
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 240
EP 263
DI 10.1016/j.wneu.2019.10.153
PG 24
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200178
PM 31682989
DA 2020-05-12
ER

PT J
AU Park, BJ
   Starks, R
   Kirby, P
   Menezes, AH
   Dlouhy, BJ
AF Park, Brian J.
   Starks, Rachel
   Kirby, Patricia
   Menezes, Arnold H.
   Dlouhy, Brian J.
TI IgG4-Related Disease of the Craniovertebral Junction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone; Craniovertebral junction; IgG4-related disease; Spine
ID IMMUNOGLOBULIN G4-RELATED DISEASE; HYPERTROPHIC PACHYMENINGITIS;
   SCLEROSING DISEASE; MIMICKING; FEATURES; PATIENT
AB BACKGROUND: The majority of the abnormalities and diseases that affect the craniovertebral junction (CVJ) have already been reported, and therefore it is exceedingly rare to identify new pathology that affects the CVJ. Immunoglobulin G4-related disease (IgG4-RD) is an immune mediated process treated with immunosuppressive medications. To our knowledge, this is the first reported case of IgG4-RD affecting the CVJ.
   CASE DESCRIPTION: The authors report the case of a woman aged 71 years IgG4-RD of the CVJ. She presented with intractable left occipital pain and limited flexion, extension, and rotation of the neck. Computed tomography and magnetic resonance imaging revealed a lytic enhancing lesion of the left occipital condyle, left C1 lateral mass, and left C1 anterior arch resulting in cranial settling, basilar invagination, and CVJ instability. An open biopsy, subtotal resection, and occiput to C2 fusion was performed. Pathology revealed IgG4-RD. The patient was subsequently placed on rituximab immunotherapy with complete resolution of enhancement on magnetic resonance imaging and bone growth at the previous site of the lytic IgG4-RD lesion.
   CONCLUSIONS: To our knowledge, this case describes the first case of IgG4-RD affecting the CVJ, which mimicked a tumor-like process. When IgG4-RD affects the CVJ, stability must be accounted for, especially in the cases of osteolytic destruction. The combination of medical therapy to target the underlying inflammatory process and surgery to provide structural stability was successful.
C1 [Park, Brian J.; Menezes, Arnold H.; Dlouhy, Brian J.] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Starks, Rachel; Kirby, Patricia] Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA.
   [Dlouhy, Brian J.] Univ Iowa, Carver Coll Med, Pappajohn Biomed Inst, Iowa City, IA 52242 USA.
   [Dlouhy, Brian J.] Univ Iowa, Iowa Neurosci Inst, Carver Coll Med, Iowa City, IA 52242 USA.
RP Dlouhy, BJ (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.; Dlouhy, BJ (reprint author), Univ Iowa, Carver Coll Med, Pappajohn Biomed Inst, Iowa City, IA 52242 USA.; Dlouhy, BJ (reprint author), Univ Iowa, Iowa Neurosci Inst, Carver Coll Med, Iowa City, IA 52242 USA.
EM brian-dlouhy@uiowa.edu
CR Bridges KJ, 2019, BRIT J NEUROSURG, V33, P570, DOI 10.1080/02688697.2017.1384793
   Caso F, 2014, JOINT BONE SPINE, V81, P190, DOI 10.1016/j.jbspin.2013.07.011
   Chan SK, 2009, AM J SURG PATHOL, V33, P1249, DOI 10.1097/PAS.0b013e3181abdfc2
   Choi SH, 2010, NEUROLOGY, V75, P1388, DOI 10.1212/WNL.0b013e3181f73614
   Chuang T, 2016, MEDICINE, V95, P37
   Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72
   Dlouhy BJ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14837
   Ezzeldin M, 2014, J NEUROL SCI, V347, P398, DOI 10.1016/j.jns.2014.10.012
   Ferreira Nuno Ribeiro, 2016, J Med Case Rep, V10, P61, DOI 10.1186/s13256-016-0838-2
   Gu R, 2016, EUR SPINE J, V25, pS147, DOI 10.1007/s00586-015-4251-0
   Horger M, 2012, AM J ROENTGENOL, V199, pW276, DOI 10.2214/AJR.11.8321
   Kamisawa T, 2015, LANCET, V385, P1460, DOI 10.1016/S0140-6736(14)60720-0
   Kim SH, 2014, ANN REHABIL MED-ARM, V38, P856, DOI 10.5535/arm.2014.38.6.856
   Li LL, 2017, ANN OTO RHINOL LARYN, V126, P236, DOI 10.1177/0003489416672476
   Lin F, 2014, NATL MED J CHINA, V94, P3262
   Lindstrom KM, 2010, ACTA NEUROPATHOL, V120, P765, DOI 10.1007/s00401-010-0746-2
   Lopez AJ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14807
   Lu LX, 2014, JAMA NEUROL, V71, P785, DOI 10.1001/jamaneurol.2014.243
   Lu Z, 2016, CLIN RHEUMATOL, V35, P1549, DOI 10.1007/s10067-015-3104-x
   Maher M, 2017, CLIN IMAG, V46, P108, DOI 10.1016/j.clinimag.2017.07.012
   Majumder S, 2018, CLIN GASTROENTEROL H, V16, P1947, DOI 10.1016/j.cgh.2018.02.049
   Menezes A H, 1997, Semin Pediatr Neurol, V4, P209, DOI 10.1016/S1071-9091(97)80038-1
   Miloushev VZ, 2014, CLIN NUCL MED, V39, P537, DOI 10.1097/RLU.0000000000000437
   Palazzo E, 2014, JOINT BONE SPINE, V81, P27, DOI 10.1016/j.jbspin.2013.06.001
   Radotra BD, 2016, J NEUROSURG-SPINE, V25, P790, DOI 10.3171/2016.4.SPINE1674
   Rumalla K, 2017, J NEUROSURG-SPINE, V26, P688, DOI 10.3171/2016.11.SPINE16924
   Sato M, 2015, INTERNAL MED, V54, P2267, DOI 10.2169/internalmedicine.54.3230
   Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650
   Takahashi H, 2014, JOINT BONE SPINE, V81, P331, DOI 10.1016/j.jbspin.2014.01.010
   Tang SH, 2017, BRIT J HAEMATOL, V177, P673, DOI 10.1111/bjh.14651
   Wallace ZS, 2019, ANN RHEUM DIS, V78, P406, DOI 10.1136/annrheumdis-2018-214603
   Wallace ZS, 2013, MEDICINE, V92, P206, DOI 10.1097/MD.0b013e31829cce35
   Wang LW, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1567-2
   Williams MM, 2017, J NEUROSURG-SPINE, V26, P76, DOI 10.3171/2016.5.SPINE16119
   Winkel Maia, 2018, Surg Neurol Int, V9, P209, DOI 10.4103/sni.sni_156_18
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 264
EP 271
DI 10.1016/j.wneu.2019.10.195
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200179
PM 31712115
DA 2020-05-12
ER

PT J
AU Iunes, EA
   Barletta, EA
   Belsuzarri, TAB
   Onishi, FJ
   Cavalheiro, S
   Joaquim, AF
AF Iunes, Eduardo Augusto
   Barletta, Enrico Affonso
   Barba Belsuzarri, Telmo Augusto
   Onishi, Franz Jooji
   Cavalheiro, Sergio
   Joaquim, Andrei Fernandes
TI Correlation Between Different Interbody Grafts and Pseudarthrosis After
   Anterior Cervical Discectomy and Fusion Compared with Control Group:
   Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anterior cervical discectomy and fusion; Failure and degenerative disc
   disease; Outcome; Pseudarthrosis
ID ADJACENT-LEVEL OSSIFICATION; FOLLOW-UP; ZERO-PROFILE; RISK-FACTORS;
   BONE-GRAFT; DEGENERATIVE DISEASE; SAGITTAL ALIGNMENT; CLINICAL-OUTCOMES;
   PLATE FIXATION; SPINE SURGERY
AB BACKGROUND: Cervical spine degenerative disease is one of the main causes of myelopathy. Anterior cervical discectomy and fusion (ACDF) is the most common surgical procedure used to treat cervical myelopathy. Therefore, it is important to study pseudarthrosis rates after ACDF and correlate them with the graft used.
   METHODS: We performed a systematic review to evaluate the relationship between pseudarthrosis after ACDF and the interbody graft used.
   RESULTS: A total of 3732 patients were evaluated in 46 studies. The mean age of the included patients was 51.5 +/- 4.18 years (range, 42-59.6 years). ACDF is most often perforemd as single-level surgery and the level most impaired is C5-C6. The use of titanium cages, zero profile, recombinant human bone morphogenetic protein 2, and carbon cages was seen as a protective factor for pseudarthrosis compared with the autograft group (control group); with an odds ratio of 0.29, 0.51, 0.03, and 0.3, respectively; the results were statistically relevant. The use of polyetheretherketone, poly(methyl methacrylate), and trabecular metal was a risk factor for development of pseudarthrosis compared with the control group, with an odds ratio of 1.7, 8.7, and 6.8, respectively; the results were statistically relevant. Radiologic follow-up was an important factor for the pseudarthrosis rate; paradoxically, a short follow-up (<1 year) had lower rates of pseudarthrosis and follow-up >2 years increased the chance of finding pseudarthrosis.
   CONCLUSIONS: Different types of grafts lead to a significant difference in pseudarthrosis rates. Follow-up time is also an important factor that affects the rate of pseudarthrosis after ACDF.
C1 [Iunes, Eduardo Augusto] Fed Univ Sao Paulo Unifesp, Dept Neurosurg, Sao Paulo, Brazil.
   [Barletta, Enrico Affonso] Pontifical Catholic Univ Campinas, Sao Paulo, Brazil.
   [Barba Belsuzarri, Telmo Augusto] Pontifical Catholic Univ Campinas, Dept Neurosurg, Campinas, SP, Brazil.
   [Barba Belsuzarri, Telmo Augusto] Pontifical Catholic Univ Campinas, Postgrad Program, Masters Hlth Sci, Campinas, SP, Brazil.
   [Onishi, Franz Jooji; Cavalheiro, Sergio] Univ Fed Sao Paulo, Med Sch, Dept Neurosurg, Sao Paulo, Brazil.
   [Joaquim, Andrei Fernandes] Univ Estadual Campinas, Dept Neurosurg, UNICAMP, Campinas, Brazil.
RP Barletta, EA (reprint author), Pontifical Catholic Univ Campinas, Sao Paulo, Brazil.
EM enrico.barletta333@gmail.com
OI onishi, franz/0000-0002-5641-5104
CR Adams MA, 2006, SPINE, V31, P2151, DOI 10.1097/01.brs.0000231761.73859.2c
   Ahn SS, 2016, WORLD NEUROSURG, V89, P42, DOI [10.1016/J.WNEU.2016.01.013, 10.1016/j.wneu.2016.01.013]
   Albanese V, 2017, WORLD NEUROSURG, V106, P724, DOI 10.1016/j.wneu.2017.06.051
   Fernandez-Nino JA, 2018, SSM-POPUL HLTH, V6, P1, DOI 10.1016/j.ssmph.2018.07.008
   Alonso F, 2017, WORLD NEUROSURG, V108, P676, DOI 10.1016/j.wneu.2017.09.071
   Arnold PM, 2016, J NEUROSURG-SPINE, V25, P292, DOI 10.3171/2016.1.SPINE15798
   Azab W, 2012, TURK NEUROSURG, V22, P611, DOI 10.5137/1019-5149.JTN.5646-11.2
   Ba ZY, 2012, SPINE, V37, pE1260, DOI 10.1097/BRS.0b013e318265df75
   BABA H, 1993, SPINE, V18, P2167, DOI 10.1097/00007632-199311000-00004
   Barbagallo GMV, 2013, EUR SPINE J, V22, pS868, DOI 10.1007/s00586-013-3005-0
   Bazaz R, 2002, SPINE, V27, P2453, DOI 10.1097/00007632-200211150-00007
   Beaman FD, 2006, RADIOGRAPHICS, V26, P373, DOI 10.1148/rg.262055039
   Benneker LM, 2005, SPINE, V30, P167, DOI 10.1097/01.brs.0000150833.93248.09
   Boos N, 2002, SPINE, V27, P2631, DOI 10.1097/00007632-200212010-00002
   Bruneau M, 2001, Neurosurg Focus, V10, pE8, DOI 10.3171/foc.2001.10.4.9
   Buser Z, 2016, J NEUROSURG-SPINE, V25, P509, DOI 10.3171/2016.1.SPINE151005
   Buttermann GR, 2018, SPINE, V43, P207, DOI 10.1097/BRS.0000000000002273
   Chau AMT, 2009, EUR SPINE J, V18, P449, DOI 10.1007/s00586-008-0878-4
   Chen MC, 2016, J NEUROSURG-SPINE, V25, P205, DOI 10.3171/2016.1.SPINE15807
   Cho DY, 2004, SURG NEUROL, V62, P378, DOI 10.1016/j.surneu.2004.01.021
   Choi SH, 2017, SPINE, V42, P1772, DOI 10.1097/BRS.0000000000002219
   CLARKE E, 1956, BRAIN, V79, P483, DOI 10.1093/brain/79.3.483
   Emery S E, 2001, J Am Acad Orthop Surg, V9, P376
   Epstein NE, 2000, J SPINAL DISORD, V13, P1, DOI 10.1097/00002517-200002000-00001
   Faldini C, 2011, J ORTHOP TRAUMATOL, V12, P201, DOI 10.1007/s10195-011-0169-4
   Fernandez-Fairen M, 2019, WORLD NEUROSURG, V122, pE156, DOI 10.1016/j.wneu.2018.09.160
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Frempong-Boadu A, 2002, J SPINAL DISORD TECH, V15, P362, DOI 10.1097/00024720-200210000-00004
   Fujibayashi S, 2000, SPINE, V25, P2258, DOI 10.1097/00007632-200009010-00018
   Fujibayashi S, 2008, J CLIN NEUROSCI, V15, P1017, DOI 10.1016/j.jocn.2007.05.011
   Gornet MF, 2017, J NEUROSURG-SPINE, V26, P653, DOI 10.3171/2016.10.SPINE16264
   Grob D, 1998, SPINE, V23, P2674, DOI 10.1097/00007632-199812150-00005
   Gupta U, 2016, OPTOELECTRON ADV MAT, V10, P5
   Hillard Virany H, 2006, Spine J, V6, p242S, DOI 10.1016/j.spinee.2006.05.005
   Huppert J, 2011, EUR SPINE J, V20, P1417, DOI 10.1007/s00586-011-1722-9
   Jagannathan J, 2008, J NEUROSURG-SPINE, V8, P420, DOI 10.3171/SPI/2008/8/5/420
   Ji GY, 2015, J SPINAL DISORD TECH, V28, pE433, DOI 10.1097/BSD.0b013e3182a355ad
   Kaiser MG, 2002, NEUROSURGERY, V50, P229, DOI 10.1097/00006123-200202000-00001
   Kani KK, 2018, SKELETAL RADIOL, V47, P7, DOI 10.1007/s00256-017-2798-z
   Kao FC, 2005, CLIN ORTHOP RELAT R, P108, DOI 10.1097/01.blo.0000142626.90278.9e
   Kasliwal MK, 2014, J CLIN NEUROSCI, V21, P217, DOI 10.1016/j.jocn.2013.03.018
   Kim HJ, 2012, SPINE, V37, pS65, DOI 10.1097/BRS.0b013e31826cb8f5
   Kim JT, 2009, J KOREAN NEUROSURG S, V45, P312, DOI 10.3340/jkns.2009.45.5.312
   Kim SJ, 2014, J KOREAN NEUROSURG S, V55, P12, DOI 10.3340/jkns.2014.55.1.12
   Klingler JH, 2014, SCI WORLD J, DOI 10.1155/2014/398396
   Lane PD, 2015, INT J SPINE SURG, V9, DOI 10.14444/2039
   Lawson LY, 2017, WIRES DEV BIOL, V6, DOI 10.1002/wdev.283
   Lee DH, 2018, SPINE, V43, P97, DOI 10.1097/BRS.0000000000002271
   Lee JC, 2019, ASIAN SPINE J, V13, P258, DOI 10.31616/asj.2018.0174
   Lee MJ, 2005, J SPINAL DISORD TECH, V18, P406, DOI 10.1097/01.bsd.0000177211.44960.71
   Leven D, 2016, ASIAN SPINE J, V10, P776, DOI 10.4184/asj.2016.10.4.776
   Li ZH, 2017, EUR SPINE J, V26, P1129, DOI 10.1007/s00586-016-4739-2
   Lin QS, 2012, EUR SPINE J, V21, P474, DOI 10.1007/s00586-011-1961-9
   Lofgren H, 2010, EUR SPINE J, V19, P464, DOI 10.1007/s00586-009-1161-z
   Lonjon N, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014097
   Lowery GL, 1998, SPINE, V23, P181, DOI 10.1097/00007632-199801150-00006
   Lu DC, 2013, J NEUROSURG-SPINE, V18, P43, DOI 10.3171/2012.10.SPINE10231
   Luo Jiaquan, 2015, Eur J Orthop Surg Traumatol, V25 Suppl 1, pS147, DOI 10.1007/s00590-015-1613-6
   McCormack BM, 1996, WESTERN J MED, V165, P43
   Mobbs RJ, 2007, J CLIN NEUROSCI, V14, P639, DOI 10.1016/j.jocn.2006.04.003
   Moon HJ, 2011, ACTA NEUROCHIR, V153, P559, DOI 10.1007/s00701-010-0879-z
   Oni P, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120469
   Park JB, 2005, J BONE JOINT SURG AM, V87A, P558, DOI 10.2106/JBJS.C.01555
   Peppers TA, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018-017-0564-5
   Phillips FM, 1997, SPINE, V22, P1585, DOI 10.1097/00007632-199707150-00012
   Pitzen TR, 2009, SPINE, V34, P641, DOI 10.1097/BRS.0b013e318198ce10
   Richter H, 2016, J NEUROL SURG PART A, V77, P300, DOI 10.1055/s-0035-1567861
   Riley LH, 2005, SPINE, V30, P2564, DOI 10.1097/01.brs.0000186317.86379.02
   ROBINSON RA, 1955, B JOHNS HOPKINS HOSP, V96, P223
   Robinson RA, 2010, SAS J, V4, P34, DOI [10.1016/j.esas.2010.01.003, DOI 10.1016/J.ESAS.2010.01.003]
   Roth D, 2009, DM-DIS MON, V55, P737, DOI 10.1016/j.disamonth.2009.06.004
   Ryken TC, 2009, J NEUROSURG-SPINE, V11, P203, DOI 10.3171/2009.2.SPINE08723
   Samartzis Dino, 2003, Spine J, V3, P451, DOI 10.1016/S1529-9430(03)00173-6
   Scholz M, 2011, CLIN ORTHOP RELAT R, V469, P666, DOI 10.1007/s11999-010-1597-9
   SENTER HJ, 1989, NEUROSURGERY, V25, P39, DOI 10.1227/00006123-198907000-00007
   Sharma V, 2018, J NEUROSCI RURAL PRA, V9, P14, DOI 10.4103/jnrp.jnrp_366_17
   Shiban E, 2018, ACTA NEUROCHIR, V160, P845, DOI 10.1007/s00701-018-3495-y
   Shiban E, 2016, ACTA NEUROCHIR, V158, P349, DOI 10.1007/s00701-015-2630-2
   Shriver MF, 2015, SPINE J, V15, P2016, DOI 10.1016/j.spinee.2015.05.010
   Silber JS, 2003, SPINE, V28, P134, DOI 10.1097/00007632-200301150-00008
   Simmons EH, 1969, BONE JOINT J, V51, P225
   Smith-Hammond CA, 2004, SPINE, V29, P1441, DOI 10.1097/01.BRS.0000129100.59913.EA
   Song KJ, 2009, SPINE, V34, P2886, DOI 10.1097/BRS.0b013e3181b64f2c
   Sugawara T, 2009, ACTA NEUROCHIR, V151, P303, DOI 10.1007/s00701-009-0217-5
   Takagi I, 2011, DM-DIS MON, V57, P583, DOI 10.1016/j.disamonth.2011.08.024
   Tetreault L, 2015, NEUROSURGERY, V24, P77
   Tome-Bermejo F, 2017, CLIN SPINE SURG, V30, pE648, DOI 10.1097/BSD.0000000000000293
   TRACY BM, 1984, J BIOMED MATER RES, V18, P719, DOI 10.1002/jbm.820180702
   Traynelis VC, 2017, GLOB SPINE J, V7, P1035, DOI 10.1177/2192568216688184
   Ugokwe KT, 2008, J NEUROSURG-SPINE, V9, P175, DOI 10.3171/SPI/2008/9/8/175
   van Limbeek J, 2000, EUR SPINE J, V9, P129, DOI 10.1007/s005860050223
   Vanichkachorn J, 2016, EUR SPINE J, V25, P2233, DOI 10.1007/s00586-016-4414-7
   Wu WJ, 2012, EUR SPINE J, V21, P1374, DOI 10.1007/s00586-011-2131-9
   Yang JJ, 2011, CLIN ORTHOP SURG, V3, P16, DOI 10.4055/cios.2011.3.1.16
   Yoo Minwook, 2014, Korean J Spine, V11, P127, DOI 10.14245/kjs.2014.11.3.127
   Yue WM, 2005, SPINE, V30, P2138, DOI 10.1097/01.brs.0000180479.63092.17
   Zeng JF, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009724
   Zevgaridis Dimitris, 2002, Neurosurg Focus, V12, pE2
   Zhu D, 2019, MED SCI MONITOR, V25, P547, DOI 10.12659/MSM.911234
NR 99
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 272
EP 279
DI 10.1016/j.wneu.2019.10.100
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200180
PM 31669245
DA 2020-05-12
ER

PT J
AU Khansuheb, MZ
   Kouznetsov, E
   Manchak, M
   Durrani, Q
   Drofa, A
AF Khansuheb, Mahammed Zia
   Kouznetsov, Evgueni
   Manchak, Michael
   Durrani, Qasim
   Drofa, Alexander
TI Vertebral Artery Sacrifice: Novel Strategy in Treatment of Vertebral
   Artery Loop
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical; Dolichoectasia; Endovascular; Radiculopathy; Spine
ID CERVICAL RADICULOPATHY
AB BACKGROUND: We report a case of cervical radiculopathy caused by an anomalous vertebral artery (VA) and the efficacy of endovascular vertebral artery sacrifice.
   CASE DESCRIPTION: A 62-year-old woman was referred to neurosurgery because of an 8- to 9-year history of progressive left C6-7 radiculopathy refractory to other forms of treatment. Radiologic evaluation showed an abnormally tortuous loop of VA at V2 causing direct neurovascular compression at the C6-7 level. Initial attempts at microvascular decompression with posterior for-aminotomy were unsuccessful due to strong adhesion between the VA and C7 nerve root. This was followed by an endovascular VA sacrifice relieving the patient's symptoms.
   CONCLUSIONS: Cervical root compression by an aberrant or anomalous extracranial VA is a rare cause of radiculopathy. Endovascular VA sacrifice provided symptom relief in our patient, when other options failed. To our knowledge, this is the first report of endovascular VA sacrifice for management of cervical radiculopathy due to VA loop.
C1 [Khansuheb, Mahammed Zia; Kouznetsov, Evgueni; Manchak, Michael; Durrani, Qasim; Drofa, Alexander] Sanford Med Ctr Fargo, Dept Neurovasc Surg, Fargo, ND 58104 USA.
   [Khansuheb, Mahammed Zia; Drofa, Alexander] Univ North Dakota, Grand Forks, ND USA.
RP Kouznetsov, E (reprint author), Sanford Med Ctr Fargo, Dept Neurovasc Surg, Fargo, ND 58104 USA.
EM evgueni.kouznetsov@sanfordhealth.org
CR Bruneau M, 2006, NEUROSURGERY, V59, P20, DOI 10.1227/01.NEU.0000219931.64378.B5
   Chibbaro S, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.12.002
   Detwiler PW, 1998, J NEUROSURG, V89, P485, DOI 10.3171/jns.1998.89.3.0485
   Doweidar A, 2014, J RADIOL CASE REP, V8, P35, DOI 10.3941/jrcr.v8i5.1407
   Eksi MS, 2016, EUR SPINE J, V25, P4171, DOI 10.1007/s00586-016-4691-1
   Hage ZA, 2012, J NEUROSURG-SPINE, V17, P337, DOI 10.3171/2012.7.SPINE123
   Korinth MC, 2007, SURG NEUROL, V67, P172, DOI 10.1016/j.surneu.2006.03.047
   Park SB, 2012, J KOREAN NEUROSURG S, V52, P513, DOI 10.3340/jkns.2012.52.6.513
   Sakaida H, 2001, J NEUROSURG, V94, P145, DOI 10.3171/spi.2001.94.1.0145
   Tandon A, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.6.FOCUS1339
   Wood L, 2017, Eur Spine J, DOI 10.1007/s00586-017-5123-6
NR 11
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 280
EP 283
DI 10.1016/j.wneu.2019.10.068
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200181
PM 31634622
DA 2020-05-12
ER

PT J
AU Neulen, A
   Stein, M
   Pantel, T
   Berres, M
   Brockmann, C
   Giese, A
   Kantelhardt, SR
AF Neulen, Axel
   Stein, Maximilian
   Pantel, Tobias
   Berres, Manfred
   Brockmann, Carolin
   Giese, Alf
   Kantelhardt, Sven R.
TI Image-Guided Transcranial Doppler Ultrasound for Monitoring
   Posthemorrhagic Vasospasms of Infratentorial Arteries: A Feasibility
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed cerebral ischemia; Image guidance; Subarachnoid hemorrhage;
   Transcranial Doppler sonography; Vasospasm
ID VELOCITY-MEASUREMENTS; CEREBRAL VASOSPASM; GUIDANCE; SONOGRAPHY;
   MANAGEMENT; DIAGNOSIS; ISCHEMIA
AB BACKGROUND: A considerable number of patients with subarachnoid hemorrhage (SAH) develop vasospasms of the infratentorial arteries. Transcranial Doppler sonography (TCD) is used to screen for vasospasm. In this study, we used a technical modification that combines TCD with an image guidance device that the operator can use to navigate to the ultrasonic window and to predefined intracranial vascular targets. Our aim was to analyze the feasibility, spatial precision, and spatial reproducibility of serial image-guided TCD of infratentorial and-for comparison-supratentorial arteries in the clinical setting of monitoring for vasospasm after SAH.
   METHODS: The study included 10 SAH patients, who each received 5 serial image-guided TCD examinations. Using computed tomography angiography data, trajectories to the infratentorial and supratentorial cerebral arteries were planned and loaded into an image guidance device tracking the Doppler probe. As a measure of spatial precision and spatial reproducibility, we analyzed the distances between the positions of preplanned vascular targets and optimal Doppler signals.
   RESULTS: The mean distance between preplanned and optimal target points was 4.8 +/- 2.1 mm (first exam), indicating high spatial precision. The spatial precision decreased with increasing depth of the vascular target. In all patients, image-guided TCD detected all predefined supratentorial and infratentorial vascular segments. There were no significant changes in spatial precision in serial exams, indicating high reproducibility.
   CONCLUSIONS: Image-guided TCD is feasible for supratentorial and infratentorial arteries. It shows high spatial precision and reproducibility. This study provides a basis for future clinical studies on image-guided TCD for post-SAH vasospasm screening.
C1 [Neulen, Axel; Stein, Maximilian; Pantel, Tobias; Giese, Alf; Kantelhardt, Sven R.] Johannes Gutenberg Univ Mainz, Dept Neurosurg, Univ Med Ctr, Mainz, Germany.
   [Berres, Manfred] Johannes Gutenberg Univ Mainz, Inst Med Biometry Epidemiol & Informat, Univ Med Ctr, Mainz, Germany.
   [Berres, Manfred] Univ Appl Sci Koblenz, Dept Math & Technol, Remagen, Germany.
   [Brockmann, Carolin] Johannes Gutenberg Univ Mainz, Dept Neuroradiol, Univ Med Ctr, Mainz, Germany.
   [Giese, Alf] Orthoctr Hamburg, Hamburg, Germany.
RP Kantelhardt, SR (reprint author), Johannes Gutenberg Univ Mainz, Dept Neurosurg, Univ Med Ctr, Mainz, Germany.
EM sven.kantelhardt@unimedizin-mainz.de
OI Neulen, Axel/0000-0003-3547-1630
CR Burch CM, 1996, J NEUROIMAGING, V6, P8, DOI 10.1111/jon1996618
   Chartrain AG, 2018, J NEUROINTERV SURG, V10, P66, DOI 10.1136/neurintsurg-2017-013091
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Manoel ALD, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00292
   Dinc N, 2019, NEUROSURG REV, V42, P983, DOI 10.1007/s10143-018-1015-4
   Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9
   Francoeur CL, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1447-6
   Greke Christian, 2013, J Neurosurg Anesthesiol, V25, P55, DOI 10.1097/ANA.0b013e31826b3d55
   Kantelhardt SR, 2015, OPER NEUROSURG, V11, P504, DOI 10.1227/NEU.0000000000000921
   Kantelhardt SR, 2011, NEUROSURGERY, V68, P257, DOI 10.1227/NEU.0b013e31821553b2
   Keric N, 2013, ACTA NEUROCHIR, V155, P1781, DOI 10.1007/s00701-013-1789-7
   Keric N, 2013, J NEUROSURG ANESTH, V25, P317, DOI 10.1097/ANA.0b013e31828cb27e
   Lawton MT, 2017, NEW ENGL J MED, V377, P257, DOI 10.1056/NEJMcp1605827
   Lewis PM, 2010, BRIT J NEUROSURG, V24, P303, DOI 10.3109/02688691003632854
   Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7
   Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246
   McMahon CJ, 2007, BRIT J NEUROSURG, V21, P21, DOI 10.1080/02688690701210539
   Neulen A, 2016, CLIN NEUROL NEUROSUR, V145, P14, DOI 10.1016/j.clineuro.2016.03.012
   Neulen A, 2019, INT J COMPUT ASS RAD, V14, P157, DOI 10.1007/s11548-018-1844-1
   Neulen A, 2013, CLIN NEUROL NEUROSUR, V115, P1382, DOI 10.1016/j.clineuro.2012.12.025
   Rahme R, 2013, ACTA NEUROCHIR SUPPL, V115, P107, DOI 10.1007/978-3-7091-1192-5_23
   Sabri M, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/394036
   SLOAN MA, 1989, NEUROLOGY, V39, P1514, DOI 10.1212/WNL.39.11.1514
   Soustiel JF, 2002, STROKE, V33, P72, DOI 10.1161/hs0102.100484
   Sviri GE, 2006, STROKE, V37, P2738, DOI 10.1161/01.STR.0000244765.29502.85
   Sviri GE, 2006, NEUROSURGERY, V59, P360, DOI 10.1227/01.NEU.0000223502.93013.6E
   Washington CW, 2011, NEUROCRIT CARE, V15, P312, DOI 10.1007/s12028-011-9594-8
   Westermaier T, 2014, NEUROCRIT CARE, V20, P406, DOI 10.1007/s12028-013-9896-0
   Wozniak MA, 1996, J NEUROIMAGING, V6, P87, DOI 10.1111/jon19966287
NR 29
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 284
EP 291
DI 10.1016/j.wneu.2019.10.144
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200182
PM 31678314
DA 2020-05-12
ER

PT J
AU Bortolotti, C
   Bertolini, G
   Sorenson, TJ
   Cirillo, L
   Lanzino, G
   Sturiale, C
AF Bortolotti, Carlo
   Bertolini, Giacomo
   Sorenson, Thomas J.
   Cirillo, Luigi
   Lanzino, Giuseppe
   Sturiale, Carmelo
TI Multimodal Approach for Treatment of Hemorrhaged Mesencephalic
   Arteriovenous Malformation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Arteriovenous malformation; Brainstem; Endovascular;
   Hemorrhage; Microsurgery
C1 [Bortolotti, Carlo; Bertolini, Giacomo; Sturiale, Carmelo] Inst Neurol Sci Bologna, Dept Neurol Surg, Bologna, Italy.
   [Cirillo, Luigi] Inst Neurol Sci Bologna, Dept Neuroradiol, Bologna, Italy.
   [Sorenson, Thomas J.; Lanzino, Giuseppe] Mayo Clin, Dept Neurol Surg, Rochester, MN USA.
   [Lanzino, Giuseppe] Mayo Clin, Dept Radiol, Rochester, MN USA.
   [Sorenson, Thomas J.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
RP Bertolini, G (reprint author), Inst Neurol Sci Bologna, Dept Neurol Surg, Bologna, Italy.
EM giacomo.bertolini@studio.unibo.it
OI Bertolini, Giacomo/0000-0002-0840-9535
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 292
EP 292
DI 10.1016/j.wneu.2019.09.028
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200183
PM 31521752
DA 2020-05-12
ER

PT J
AU Nakamura, T
   Ogiwara, T
   Goto, T
   Fujii, Y
   Miyaoka, Y
   Hanaoka, Y
   Horiuchi, T
   Hongo, K
AF Nakamura, Takuya
   Ogiwara, Toshihiro
   Goto, Tetsuya
   Fujii, Yu
   Miyaoka, Yoshinari
   Hanaoka, Yoshiki
   Horiuchi, Tetsuyoshi
   Hongo, Kazuhiro
TI Clinical Experience of Endoscopic Endonasal Approach in the Innovative,
   Newly Developed Operating Room "Smart Cyber Operating Theater (SCOT)"
SO WORLD NEUROSURGERY
LA English
DT Article
DE Education; Endoscopic endonasal approach; Pituitary; Smart cyber
   operating theater
AB BACKGROUND: When medical devices and equipment in an operating room are connected to a network, vast amounts of data concerning the progress of the operation and the patient's condition can be comprehensively processed to improve the precision and safety of the surgical procedure. To make this possible, a next-generation networked operating room, "Smart Cyber Operating Theater" (SCOT), has been developed with medical-engineer cooperation. SCOT integrates stand-alone medical devices using the "OPeLiNK" communication interface. Using OPeLiNK, medical devices are connected and various data, such as intraoperative magnetic resonance imaging, neuromonitoring, biochemical monitoring, and navigation system, are integrated and displayed in the same timeline.
   CASE DESCRIPTION: The authors succeeded in clinical tumor resection via the endoscopic endonasal approach using the SCOT system in a 79-year-old man with a large nonfunctioning pituitary adenoma. The surgeons performed the operation while sharing information in real time between all staff in the operating room and supervising expert surgeons at the surgical strategy desk. Any decisions, such as intraoperative surgical procedures, were made with discussion between the operating room and the surgical strategy desk. The patient's postoperative course was uneventful.
   CONCLUSIONS: This is the first case report of endoscopic endonasal approach performed successfully in the SCOT. Further developments in this technology may lead to innovations in not only microscopic neurosurgery but also endoscopic neurosurgery.
C1 [Nakamura, Takuya; Ogiwara, Toshihiro; Goto, Tetsuya; Fujii, Yu; Miyaoka, Yoshinari; Hanaoka, Yoshiki; Horiuchi, Tetsuyoshi; Hongo, Kazuhiro] Shinshu Univ, Dept Neurosurg, Sch Med, Matsumoto, Nagano, Japan.
RP Ogiwara, T (reprint author), Shinshu Univ, Dept Neurosurg, Sch Med, Matsumoto, Nagano, Japan.
EM togiwara@shinshu-u.ac.jp
CR Ashour R, 2016, WORLD NEUROSURG, V93, P183, DOI 10.1016/j.wneu.2016.06.045
   Berkmann S, 2012, ACTA NEUROCHIR, V154, P639, DOI 10.1007/s00701-012-1285-5
   Ogiwara T, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS16498
   Okamoto J, 2018, BIOMED ENG-BIOMED TE, V63, P31, DOI 10.1515/bmt-2017-0006
   Okuda T, 2010, ACTA NEUROCHIR, V152, P1801, DOI 10.1007/s00701-010-0728-0
   Tamura M, 2015, NEUROL MED-CHIR, V55, P383, DOI 10.2176/nmc.ra.2014-0415
NR 6
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 293
EP 296
DI 10.1016/j.wneu.2019.11.021
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200184
PM 31715411
DA 2020-05-12
ER

EF